biochemical.chemicalFormula	biochemical.clearance	biochemical.halfLife	biochemical.molecularWeight	biochemical.smiles	biochemical.state	biochemical.volumeOfDistribution	enzymes.PIds	enzymes.genes	enzymes.names	externalLinks	externalLinks.BindingDB	externalLinks.ChEBI	externalLinks.ChEMBL	externalLinks.ChemSpider	externalLinks.Drugs.com	externalLinks.Guide to Pharmacology	externalLinks.Human Metabolome Database	externalLinks.KEGG Compound	externalLinks.KEGG Drug	externalLinks.PDBe Ligand	externalLinks.PDRhealth	externalLinks.PharmGKB	externalLinks.PubChem Compound	externalLinks.PubChem Substance	externalLinks.RxList	externalLinks.RxNav	externalLinks.Therapeutic Targets Database	externalLinks.Wikipedia	externalLinks.ZINC	general.brandNames	general.genericName	general.groups	general.id	general.inChI	general.inChIKey	general.maxPhase	general.summary	general.toxicity	general.type	pathways.links	pathways.names	propertiesAdmet	propertiesAdmet.Ames test	propertiesAdmet.Biodegradation	propertiesAdmet.Blood Brain Barrier	propertiesAdmet.CYP450 1A2 substrate	propertiesAdmet.CYP450 2C19 inhibitor	propertiesAdmet.CYP450 2C9 inhibitor	propertiesAdmet.CYP450 2C9 substrate	propertiesAdmet.CYP450 2D6 inhibitor	propertiesAdmet.CYP450 2D6 substrate	propertiesAdmet.CYP450 3A4 inhibitor	propertiesAdmet.CYP450 3A4 substrate	propertiesAdmet.CYP450 inhibitory promiscuity	propertiesAdmet.Caco-2 permeable	propertiesAdmet.Carcinogenicity	propertiesAdmet.Human Intestinal Absorption	propertiesAdmet.P-glycoprotein inhibitor I	propertiesAdmet.P-glycoprotein inhibitor II	propertiesAdmet.P-glycoprotein substrate	propertiesAdmet.Rat acute toxicity	propertiesAdmet.Renal organic cation transporter	propertiesAdmet.hERG inhibition (predictor I)	propertiesAdmet.hERG inhibition (predictor II)	propertiesExperimental	propertiesExperimental.Caco2 permeability	propertiesExperimental.Radioactivity (mCi/mL)	propertiesExperimental.boiling point (°C)	propertiesExperimental.logP	propertiesExperimental.logS	propertiesExperimental.melting point (°C)	propertiesExperimental.pKa	propertiesExperimental.water solubility	propertiesPredicted.Bioavailability	propertiesPredicted.Ghose Filter	propertiesPredicted.Hydrogen Acceptor Count	propertiesPredicted.Hydrogen Donor Count	propertiesPredicted.MDDR-like Rule	propertiesPredicted.Number of Rings	propertiesPredicted.Physiological Charge	propertiesPredicted.Polar Surface Area	propertiesPredicted.Polarizability	propertiesPredicted.Refractivity	propertiesPredicted.Rotatable Bond Count	propertiesPredicted.Rule of Five	propertiesPredicted.Veber's Rule	propertiesPredicted.Water Solubility	propertiesPredicted.logP	propertiesPredicted.logS	propertiesPredicted.pKa (Strongest Acidic)	propertiesPredicted.pKa (Strongest Basic)	targets.PIds	targets.genes	targets.names
C23H27N5O7S	32 - 41 mL/min/1.73 m2124 - 160 mL/min/1.73 m2 [older pediatric patients]	36-72 minutes	517.555	[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=CC=C1)C(O)=O	Solid	101 mL/kg [intravenous administration of 50 mg/kg (5-minute infusion) in neonates]					50240426	8232	CHEMBL702	39798	Drugs.com Drug Page		HMDB0014464	C14034	D00466	WPP		PA450975	43672	46504757	RxList Drug Page	1546000	DAP001164	Piperacillin	ZINC000003913937	Pipracil, Zosyn	Piperacillin	Approved	DB00319	InChI=1S/C23H27N5O7S/c1-4-26-10-11-27(19(32)18(26)31)22(35)25-13(12-8-6-5-7-9-12)16(29)24-14-17(30)28-15(21(33)34)23(2,3)36-20(14)28/h5-9,13-15,20H,4,10-11H2,1-3H3,(H,24,29)(H,25,35)(H,33,34)/t13-,14-,15+,20-/m1/s1	IVBHGBMCVLDMKU-GXNBUGAJSA-N	4	Piperacillin is a penicillin antibiotic combined with tazobactam to treat piperacillin-resistant, piperacillin/tazobactam­ susceptible, β-lactamase generating strains of several bacteria.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.3925 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor					0.3					1	No	7	3	Yes	4	-1	156.43 Å2	51.77 Å3	126.3 m3·mol-1	6	No	No	0.119 mg/mL	-0.26	-3.6	3.49	-4.3	Q75Y35;!P0A3M6;!Q8DNB6;!Q7CRA4	pbp3;!penA;!pbp2a;!pbp1b	1. Penicillin-binding protein 3;!2. Penicillin-binding protein 2B;!3. Penicillin-binding protein 2a;!4. Penicillin-binding protein 1b
C20H23N5O6S	Not Available	Mean elimination half-life is 1.3 to 1.5 hours. Longer in neonates, and 2 to 6 hours in patients with renal impairment.	461.492	[H][C@](NC(=O)N1CCNC1=O)(C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@]12[H])C1=CC=CC=C1	Solid	Not Available						2956	CHEMBL1537	4980416			HMDB0015194	C06839	D02339			PA164749135	6479523	46506654		1266	DAP001169	Azlocillin	ZINC000003830261		Azlocillin	Approved	DB01061	InChI=1S/C20H23N5O6S/c1-20(2)13(17(28)29)25-15(27)12(16(25)32-20)22-14(26)11(10-6-4-3-5-7-10)23-19(31)24-9-8-21-18(24)30/h3-7,11-13,16H,8-9H2,1-2H3,(H,21,30)(H,22,26)(H,23,31)(H,28,29)/t11-,12-,13+,16-/m1/s1	JTWOMNBEOCYFNV-NFFDBFGFSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.1838 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					0.2				Sodium salt is soluble in water (50 mg/ml)	1	Yes	6	4	No	4	-1	148.15 Å2	44.97 Å3	111.71 m3·mol-1	5	Yes	No	0.233 mg/mL	-0.33	-3.3	3.49	-5.9	Q8XJ01	pbpA	1. Penicillin-binding protein 1A
C35H36FN3O9	Not Available	Not Available	661.6734	COC(=O)C1=C(C=CC(C[C@H](NC(C)=O)C(=O)N[C@H]2CCCCN(CC3=CC=C(C=C3)C3=CC=CC=C3)C2=O)=C1)C(F)(C(O)=O)C(O)=O	Solid	Not Available					14692		CHEMBL357488	394585						903			447522	46506689					ZINC000024662085		RU90395	Experimental	DB02432	InChI=1S/C35H36FN3O9/c1-21(40)37-29(19-23-13-16-27(26(18-23)32(43)48-2)35(36,33(44)45)34(46)47)30(41)38-28-10-6-7-17-39(31(28)42)20-22-11-14-25(15-12-22)24-8-4-3-5-9-24/h3-5,8-9,11-16,18,28-29H,6-7,10,17,19-20H2,1-2H3,(H,37,40)(H,38,41)(H,44,45)(H,46,47)/t28-,29-/m0/s1	RLLAUERCSKPFGD-VMPREFPWSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Inhibitor	Inhibitor	Substrate	2.6625 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										0	No	8	4	Yes	4	-2	179.41 Å2	65.9 Å3	169.79 m3·mol-1	13	No	No		3.54		2.25	-1.9	P12931	SRC	1. Proto-oncogene tyrosine-protein kinase Src
C20H19ClN4O4S	Not Available	Not Available	446.907	[H][C@@]1(CC2=C(C=CC=C2)N(CC(=O)NCCO)C1=O)NC(=O)C1=CC2=C(N1)SC(Cl)=C2	Solid	Not Available								10160347						FRX			11987874	99444263					ZINC000028818268		(S)-2-CHLORO-N-(1-(2-(2-HYDROXYETHYLAMINO)-2-OXOETHYL)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL)-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE	Experimental	DB07792	InChI=1S/C20H19ClN4O4S/c21-16-9-12-8-13(24-19(12)30-16)18(28)23-14-7-11-3-1-2-4-15(11)25(20(14)29)10-17(27)22-5-6-26/h1-4,8-9,14,24,26H,5-7,10H2,(H,22,27)(H,23,28)/t14-/m0/s1	VUKPNWLGSLOHIF-AWEZNQCLSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.2973 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	4	4	Yes	4	0	114.53 Å2	45.48 Å3	110.62 m3·mol-1	6	Yes	No	0.00712 mg/mL	1.2	-4.8	10.94	-1.8	P11217	PYGM	1. Glycogen phosphorylase, muscle form
C22H20F5N3O3	Not Available	Not Available	469.412	CC(C)(C(=O)NCC(F)(F)C(F)(F)F)C(=O)N[C@H]1C2=CC=CC=C2C2=CC=CC=C2NC1=O	Not Available	Not Available						86474		25027400									49867930	347828207				RO4929097	ZINC000043208642		RG-4733	Investigational	DB11870	InChI=1S/C22H20F5N3O3/c1-20(2,18(32)28-11-21(23,24)22(25,26)27)19(33)30-16-14-9-4-3-7-12(14)13-8-5-6-10-15(13)29-17(16)31/h3-10,16H,11H2,1-2H3,(H,28,32)(H,29,31)(H,30,33)/t16-/m0/s1	OJPLJFIFUQPSJR-INIZCTEOSA-N	2		Not Available	Small Molecule																																			1	Yes	3	3	Yes	3	0	87.3 Å2	41.16 Å3	109.42 m3·mol-1	6	Yes	No	0.00228 mg/mL	3.78	-5.3	10.85	-4.5			
C22H23F3N4O4	Not Available	Not Available	464.445	C[C@H](NC(=O)CCC(F)(F)F)C(=O)N[C@H]1C2=CC=CC=C2C2=CC=CN=C2N(CCO)C1=O	Not Available	Not Available							CHEMBL2338397	29315056									71236992	347828361					ZINC000095586643		LY-3039478	Investigational	DB12050	InChI=1S/C22H23F3N4O4/c1-13(27-17(31)8-9-22(23,24)25)20(32)28-18-15-6-3-2-5-14(15)16-7-4-10-26-19(16)29(11-12-30)21(18)33/h2-7,10,13,18,30H,8-9,11-12H2,1H3,(H,27,31)(H,28,32)/t13-,18-/m0/s1	YCBAQKQAINQRFW-UGSOOPFHSA-N	2		Not Available	Small Molecule																																			1	Yes	5	3	Yes	3	0	111.63 Å2	43.07 Å3	112.03 m3·mol-1	8	Yes	No	0.0994 mg/mL	1.07	-3.7	11.41	2.24			
C26H27F5N6O3	Not Available	Not Available	566.523	FC1=C(F)C(=CC=C1)[C@@H]1CC[C@@H](NC(=O)N2CCC(CC2)N2C(=O)NC3=C2C=CC=N3)C(=O)N(CC(F)(F)F)C1	Not Available	Not Available					50224431		CHEMBL236593	9494017						N7R			11319053	347828507				Telcagepant	ZINC000028827350		Telcagepant	Investigational	DB12228	InChI=1S/C26H27F5N6O3/c27-18-4-1-3-17(21(18)28)15-6-7-19(23(38)36(13-15)14-26(29,30)31)33-24(39)35-11-8-16(9-12-35)37-20-5-2-10-32-22(20)34-25(37)40/h1-5,10,15-16,19H,6-9,11-14H2,(H,33,39)(H,32,34,40)/t15-,19-/m1/s1	CGDZXLJGHVKVIE-DNVCBOLYSA-N	3		Not Available	Small Molecule																																			1	No	4	2	No	5	0	97.88 Å2	52.43 Å3	134.6 m3·mol-1	5	No	No	0.0936 mg/mL	2.63	-3.8	10.69	3.16	Q16602;!P06881;!P10092	CALCRL;!CALCA;!CALCB	1. Calcitonin gene-related peptide type 1 receptor;!2. Calcitonin gene-related peptide 1;!3. Calcitonin gene-related peptide 2
C28H30N6O3	Not Available	Not Available	498.587	CNC1=CC(NC(=O)N[C@@H]2N=C(C3=CC=CC=N3)C3=CC=CC=C3N(CC(=O)C(C)(C)C)C2=O)=CC=C1	Not Available	Not Available					50056102		CHEMBL324547	8046211									9870520	347828609					ZINC000003810905		Netazepide	Investigational	DB12355	InChI=1S/C28H30N6O3/c1-28(2,3)23(35)17-34-22-14-6-5-12-20(22)24(21-13-7-8-15-30-21)32-25(26(34)36)33-27(37)31-19-11-9-10-18(16-19)29-4/h5-16,25,29H,17H2,1-4H3,(H2,31,33,37)/t25-/m0/s1	YDZYKNJZCVIKPP-VWLOTQADSA-N	2		Not Available	Small Molecule																																			1	No	6	3	Yes	4	0	115.79 Å2	52.73 Å3	143.44 m3·mol-1	7	Yes	No	0.00452 mg/mL	4.05	-5	13.24	4.31			
C24H16F4N4O2	Not Available	Not Available	468.412	FC1=CC=C(NC(=O)[C@@H]2[C@H](N(CC(F)(F)F)C(=O)C3=CC=CC=C23)C2=CC=CN=C2)C=C1C#N	Not Available	Not Available								52084616									89508529	347828863							SJ-733	Investigational	DB12659	InChI=1S/C24H16F4N4O2/c25-19-8-7-16(10-15(19)11-29)31-22(33)20-17-5-1-2-6-18(17)23(34)32(13-24(26,27)28)21(20)14-4-3-9-30-12-14/h1-10,12,20-21H,13H2,(H,31,33)/t20-,21+/m0/s1	VKCPFWKTFZAOTO-LEWJYISDSA-N	1		Not Available	Small Molecule																																			1	Yes	4	1	No	4	0	86.09 Å2	42.36 Å3	116.12 m3·mol-1	5	Yes	No	0.00532 mg/mL	3.64	-4.9	13.64	4.78			
C28H22ClF3N6O3	The apparent clearance at steady state is 5.6 L/h in patients with relapsed or refractory AML, 4.6 L/h in patients with newly diagnosed AML who were also treated with azacitidine, and 6.1 L/h in patients with cholangiocarcinoma.9	The terminal half-life at steady state is 58 hours in patients with relapsed or refractory AML, 98 hours in patients with newly diagnosed AML who were also treated with azacitidine, and 129 hours in patients with cholangiocarcinoma.9	582.97	[H][C@@](N(C(=O)[C@]1([H])CCC(=O)N1C1=NC=CC(=C1)C#N)C1=CC(F)=CN=C1)(C(=O)NC1CC(F)(F)C1)C1=C(Cl)C=CC=C1	Solid	The apparent volume of distribution at steady state is 403 L in patients with relapsed or refractory AML, 504 L in patients with newly diagnosed AML who were also treated with azacitidine, and 706 L in patients with cholangiocarcinoma.9	P08684;!P20813;!P11712;!P10632	CYP3A4;!CYP2B6;!CYP2C9;!CYP2C8	1. Cytochrome P450 3A4;!2. Cytochrome P450 2B6;!3. Cytochrome P450 2C9;!4. Cytochrome P450 2C8		363689	145430	CHEMBL3989958	38772333												2049873		Ivosidenib	ZINC000205136523	Tibsovo	Ivosidenib	Approved, Investigational	DB14568	InChI=1S/C28H22ClF3N6O3/c29-21-4-2-1-3-20(21)25(26(40)36-18-11-28(31,32)12-18)37(19-10-17(30)14-34-15-19)27(41)22-5-6-24(39)38(22)23-9-16(13-33)7-8-35-23/h1-4,7-10,14-15,18,22,25H,5-6,11-12H2,(H,36,40)/t22-,25-/m0/s1	WIJZXSAJMHAVGX-DHLKQENFSA-N	3	Ivosidenib is an isocitrate dehydrogenase-1 inhibitor used to treat acute myeloid leukemia and cholangiocarcinoma in adults with a susceptible IDH1 mutation.	There is limited information regarding the LD50 or overdose of ivosidenib. Ivosidenib is associated with a risk of differentiation syndrome, Guillain-Barre syndrome, and embryo-fetal toxicity.6,9	Small Molecule																																		<1 mg/mL	1	No	6	1	Yes	5	0	119.29 Å2	53.42 Å3	139.33 m3·mol-1	7	No	No	0.0208 mg/mL	3.01	-4.4	12.14	1.81	O75874	IDH1	1. Isocitrate dehydrogenase [NADP] cytoplasmic
C26H37N5O2	renal cl=0,008 L/minnonrenal cl=3.2 L/min	The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.	451.6043	[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4		50426497	3286	CHEMBL1201087	49452	Drugs.com Drug Page	GtP Drug Page	HMDB0014393	C08187	D00987			PA448708	54746	46508571	RxList Drug Page	47579	DAP000251	Cabergoline	ZINC000003800008	Dostinex	Cabergoline	Approved	DB00248	InChI=1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1	KORNTPPJEAJQIU-KJXAQDMKSA-N	4	Cabergoline is a dopamine receptor agonist used for the treatment of hyperprolactinemic conditions due to various causes.	Overdosage might be expected to produce nasal congestion, syncope, or hallucinations.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.8786 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.6		102-104 °C		Insoluble	1	No	4	2	Yes	4	2	71.68 Å2	52.5 Å3	133.5 m3·mol-1	8	Yes	No	0.064 mg/mL	2.58	-3.8	15.25	9.32	P14416;!P41595;!P35462;!P28223;!P18089;!P28221;!P21917;!P08913;!P08908;!P18825;!P21918;!P21728;!P28222;!P28335;!P34969;!P35348;!P35368;!P25100;!P08588;!P07550;!BE0004889	DRD2;!HTR2B;!DRD3;!HTR2A;!ADRA2B;!HTR1D;!DRD4;!ADRA2A;!HTR1A;!ADRA2C;!DRD5;!DRD1;!HTR1B;!HTR2C;!HTR7;!ADRA1A;!ADRA1B;!ADRA1D;!ADRB1;!ADRB2;!	1. Dopamine D2 receptor;!2. 5-hydroxytryptamine receptor 2B;!3. Dopamine D3 receptor;!4. 5-hydroxytryptamine receptor 2A;!5. Alpha-2B adrenergic receptor;!6. 5-hydroxytryptamine receptor 1D;!7. Dopamine D4 receptor;!8. Alpha-2A adrenergic receptor;!9. 5-hydroxytryptamine receptor 1A;!10. Alpha-2C adrenergic receptor;!11. Dopamine D5 receptor;!12. Dopamine D1 receptor;!13. 5-hydroxytryptamine receptor 1B;!14. 5-hydroxytryptamine receptor 2C;!15. 5-hydroxytryptamine receptor 7;!16. Alpha-1A adrenergic receptor;!17. Alpha-1B adrenergic receptor;!18. Alpha-1D adrenergic receptor;!19. Beta-1 adrenergic receptor;!20. Beta-2 adrenergic receptor;!21. D(1) dopamine receptor (Protein Group)
C19H24N2O	160 +/- 35 mL/h/kg	Approximately 40 hours	296.414	[H][C@]12CCCC3=C1C(=CC=C3)C(=O)N(C2)[C@@H]1CN2CCC1CC2	Solid	8.3 ± 2.5 L/kg	P10635;!P08684;!P05177	CYP2D6;!CYP3A4;!CYP1A2	1. Cytochrome P450 2D6;!2. Cytochrome P450 3A4;!3. Cytochrome P450 1A2		50417287	85161	CHEMBL1189679	4892289	Drugs.com Drug Page				D07175	O7B		PA10352	6337614	46508530	RxList Drug Page	70561	DAP000367	Palonosetron	ZINC000003795819	Akynzeo, Aloxi	Palonosetron	Approved, Investigational	DB00377	InChI=1S/C19H24N2O/c22-19-16-6-2-4-14-3-1-5-15(18(14)16)11-21(19)17-12-20-9-7-13(17)8-10-20/h2,4,6,13,15,17H,1,3,5,7-12H2/t15-,17-/m1/s1	CPZBLNMUGSZIPR-NVXWUHKLSA-N	4	Palonosetron is a serotonin antagonist used in the prophylaxis or management of vomiting that results from emetogenic chemotherapy, and for the management of postoperative nausea and vomiting.	A single intravenous dose of palonosetron at 30 mg/kg (947 and 474 times the human dose for rats and mice, respectively, based on body surface area) was lethal to rats and mice. The major signs of toxicity were convulsions, gasping, pallor, cyanosis and collapse.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.7383 LD50, mol/kg	Inhibitor	Weak inhibitor	Inhibitor					2.7					1	Yes	2	0	No	5	1	23.55 Å2	33.9 Å3	88.52 m3·mol-1	1	Yes	Yes	0.464 mg/mL	2.55	-2.8		7.97	P46098	HTR3A	1. 5-hydroxytryptamine receptor 3A
C19H21N5O4	In patients with congestive heart failure, the clearance of this drug is decreased. Impairment of renal function does not have relevant effects on elimination 8.	The plasma half-life is about 2-3 hours Label.	383.4011	COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1	Solid	About 0.6 L/kg 11.					29568	8364	CHEMBL2	4724	Drugs.com Drug Page	GtP Drug Page	HMDB0014600	C07368	D08411	XRA		PA451093	4893	46508594	RxList Drug Page	8629	DAP000300	Prazosin	ZINC000095616601	Minipress, Minizide	Prazosin	Approved	DB00457	InChI=1S/C19H21N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h3-4,9-11H,5-8H2,1-2H3,(H2,20,21,22)	IENZQIKPVFGBNW-UHFFFAOYSA-N	4	Prazosin is an alpha-blocker that causes a decrease in total peripheral resistance and is used to treat hypertension.	TDLO, LD50: Oral TDLO (human): 285 μg/kg; Oral TDLO (woman): 10 μg/kg MSDS.Oral LD50 (rat): 1950 mg/kg; Intraperitoneal LD50 (rat): 102 mg/kg MSDS.Overdose informationAccidental ingestion of at least 50 mg of prazosin by a two-year-old child led to severe drowsiness with depressed reflexes. There was no fall in blood pressure, and the child recovered without complication Label. Use in pregnancyThere are no adequate and well-controlled studies determining the safety of prazosin use during pregnancy. It is considered a pregnancy category C drug. Prazosin should be used during pregnancy only in cases where the benefit outweighs the possible risk to the mother and fetus Label. In specific cases where blood pressure control was emergent during pregnancy, prazosin has been used and no effects on the fetus or neonate were reported Label. Use in nursingThis drug is found excreted in small concentrations in human milk. This drug should be used with caution when used during nursing Label.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3304 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor				638.366	1.3		277-280	6.54	1.4 mg/mL	1	Yes	7	1	No	4	1	106.95 Å2	40.51 Å3	104.5 m3·mol-1	4	Yes	No	0.693 mg/mL	1.65	-2.7		7.24			
C23H25N5O5	The clearance of doxazosin is low and ranges from approximately 1-2 ml/min/kg.4,11	The terminal elimination half-life of doxazosin has been estimated at 9-12 hours according to some resources.4,7 The FDA label indicates the elimination half-life of doxazosin is 22 hours.19	451.4751	COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=CC=CC=C2O1	Solid	The volume of distribution of doxazosin is 1.0-1.9 L/kg.7,11 In a study of radiolabeled doxazosin administered to pregnant rats, doxazosin was found to cross the placenta.19	P08684;!P33261;!P11712;!P10635	CYP3A4;!CYP2C19;!CYP2C9;!CYP2D6	1. Cytochrome P450 3A4;!2. Cytochrome P450 2C19;!3. Cytochrome P450 2C9;!4. Cytochrome P450 2D6		86731	4708	CHEMBL707	3045	Drugs.com Drug Page		HMDB0014728	C06970	D07874		PDRhealth Drug Page	PA449407	3157	46506825	RxList Drug Page	49276	DAP000381	Doxazosin		Cardura	Doxazosin	Approved	DB00590	InChI=1S/C23H25N5O5/c1-30-18-11-14-15(12-19(18)31-2)25-23(26-21(14)24)28-9-7-27(8-10-28)22(29)20-13-32-16-5-3-4-6-17(16)33-20/h3-6,11-12,20H,7-10,13H2,1-2H3,(H2,24,25,26)	RUZYUOTYCVRMRZ-UHFFFAOYSA-N	4	Doxazosin is an alpha-1 adrenergic receptor used to treat mild to moderate hypertension and urinary obstruction due to benign prostatic hyperplasia.	LD50 informationThe oral LD50 of doxazosin in mice is >1000 mg/kg.21Overdose informationSymptoms of overdose include hypotension, changes in heart rate, and drowsiness.10 Administer supportive treatment in case of an overdose with doxazosin. Remove unabsorbed doxazosin from the gastrointestinal tract, correct hypotension, and closely monitor vital signs.10	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1954 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor				718	2.1		275-277	6.52	0.8%	1	Yes	9	1	No	5	1	112.27 Å2	47.17 Å3	121.64 m3·mol-1	4	Yes	No	0.79 mg/mL	2.14	-2.8	12.67	7.24			
C22H28N6O3S	Not Available	5.8 hours	456.561	CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2	Solid	Not Available	P08684;!P10635;!P20815;!P24462;!P11712;!P33261	CYP3A4;!CYP2D6;!CYP3A5;!CYP3A7;!CYP2C9;!CYP2C19	1. Cytochrome P450 3A4;!2. Cytochrome P450 2D6;!3. Cytochrome P450 3A5;!4. Cytochrome P450 3A7;!5. Cytochrome P450 2C9;!6. Cytochrome P450 2C19		1944	119573	CHEMBL593	5423	Drugs.com Drug Page		HMDB0014843	C06941		SPP		PA449223	5625	46508878		83816	DAP000183	Delavirdine	ZINC000018516586		Delavirdine	Approved	DB00705	InChI=1S/C22H28N6O3S/c1-15(2)24-19-5-4-8-23-21(19)27-9-11-28(12-10-27)22(29)20-14-16-13-17(26-32(3,30)31)6-7-18(16)25-20/h4-8,13-15,24-26H,9-12H2,1-3H3	WHBIGIKBNXZKFE-UHFFFAOYSA-N	3	Delavirdine is a non-nucleoside reverse transcriptase inhibitor used to treat HIV infection.	Major toxicity of delavirdine is rash and should be advised to promptly notify their physician should rash occur. The majority of rashes associated with delavirdine occur within 1 to 3 weeks after initiating treatment with delavirdine. The rash normally resolves in 3 to 14 days and may be treated symptomatically while therapy with delavirdine is continued. Any patient experiencing severe rash or rash accompanied by symptoms such as fever, blistering, oral lesions, conjunctivitis, swelling, muscle or joint aches should discontinue medication and consult a physician.	Small Molecule	http://smpdb.ca/view/SMP0000738?highlight[compounds][]=DB00705&highlight[proteins][]=DB00705	Delavirdine Action Pathway		Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.5840 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor					2.8		226-228 °C			1	Yes	6	3	No	4	0	110.43 Å2	49.99 Å3	126.64 m3·mol-1	5	Yes	No	0.086 mg/mL	1.02	-3.7	9.39	6.82	Q72547	pol	1. Reverse transcriptase/RNaseH
C19H25N5O4	Plasma clearance is 80mL/min and renal clearance is 10mL/min1.	Terazosin has a mean half life 12 hours though this can be as high as 14 hours in patients over 70 years and as low as 11.4 hours in patients 20 to 39 years oldLabel1.	387.4329	COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1CCCO1	Solid	25L to 30L1.					50033111	9445	CHEMBL611	5208	Drugs.com Drug Page		HMDB0015293	C07127	D08569			PA451612	5401	46509129	RxList Drug Page	37798	DAP000371	Terazosin			Terazosin	Approved	DB01162	InChI=1S/C19H25N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22)	VCKUSRYTPJJLNI-UHFFFAOYSA-N	4	Terazosin is an alpha-1 adrenergic antagonist used in the treatment of symptomatic benign prostatic hyperplasia and management of hypertension.	In the event of an overdose, patients may experience hypotensionLabel. Blood pressure and heart rate should be controlled by having the patient lie down or by treating with volume expanders or if necessary vasopressorsLabel. Patients should be monitored for renal functionLabel. Because terazosin is highly protein bound, dialysis is unlikely to provide benefit to overdosing patientsLabel.The oral LD50 in mice is 5500mg/kgMSDS.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.2262 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor							271-274			1	Yes	8	1	No	4	1	103.04 Å2	41.28 Å3	105.18 m3·mol-1	4	Yes	No	1.5 mg/mL	1.18	-2.4	19.93	7.24			
C31H42N6O4	Not Available	Not Available	562.703	COC1=C(OCCCN2CCCCC2)C=C2N=CN=C(N3CCN(CC3)C(=O)NC3=CC=C(OC(C)C)C=C3)C2=C1	Solid	Not Available					13535	90237	CHEMBL124660	2302085									3038522	175427013					ZINC000003966243		Tandutinib	Investigational	DB05465	InChI=1S/C31H42N6O4/c1-23(2)41-25-10-8-24(9-11-25)34-31(38)37-17-15-36(16-18-37)30-26-20-28(39-3)29(21-27(26)32-22-33-30)40-19-7-14-35-12-5-4-6-13-35/h8-11,20-23H,4-7,12-19H2,1-3H3,(H,34,38)	UXXQOJXBIDBUAC-UHFFFAOYSA-N	2		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.2288 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	No	8	1	Yes	5	1	92.29 Å2	64.1 Å3	162.58 m3·mol-1	10	No	No	0.0753 mg/mL	4.34	-3.9	14.01	9.03			
C22H22N4O5	Not Available	Not Available	422.441	COC1=C2C(NC=C2C(=O)C(=O)N2CCN(CC2)C(=O)C2=CC=CC=C2)=C(OC)N=C1	Solid	Not Available					50228465		CHEMBL238103	443361															ZINC000028826898		BMS-488043	Investigational	DB05532	InChI=1S/C22H22N4O5/c1-30-16-13-24-20(31-2)18-17(16)15(12-23-18)19(27)22(29)26-10-8-25(9-11-26)21(28)14-6-4-3-5-7-14/h3-7,12-13,23H,8-11H2,1-2H3	DBPMWRYLTBNCCE-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	Yes	6	1	No	4	0	104.83 Å2	43.35 Å3	113.03 m3·mol-1	5	Yes	No	0.0992 mg/mL	1.22	-3.6	8.6	2.35	Q5NUL3	FFAR4	1. Free fatty acid receptor 4
C22H31FN6O2	Not Available	Not Available	430.5189	[H][C@@](N)(C(=O)N1CC[C@]([H])(F)C1)[C@@]([H])(C(=O)N(C)C)[C@@]1([H])CC[C@@]([H])(CC1)C1=CC=CC2=NC=NN12	Solid	Not Available					50221979		CHEMBL400841	24684686						524			11495704	99443606					ZINC000100071163		(2S,3S)-3-AMINO-4-[(3S)-3-FLUOROPYRROLIDIN-1-YL]-N,N-DIMETHYL-4-OXO-2-(TRANS-4-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-5-YLCYCLOHEXYL)BUTANAMIDE	Experimental	DB07135	InChI=1S/C22H31FN6O2/c1-27(2)21(30)19(20(24)22(31)28-11-10-16(23)12-28)15-8-6-14(7-9-15)17-4-3-5-18-25-13-26-29(17)18/h3-5,13-16,19-20H,6-12,24H2,1-2H3/t14-,15-,16-,19-,20-/m0/s1	ZPWDKZWKUOYOHA-UKSSEWCLSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.6631 LD50, mol/kg	Inhibitor	Weak inhibitor	Inhibitor										1	Yes	5	1	No	4	1	96.83 Å2	45.69 Å3	125.95 m3·mol-1	5	Yes	No	0.152 mg/mL	0.81	-3.4	18.94	7.39			
C21H27N7O	Not Available	Not Available	393.4854	C1CCC(CC1)NC1=NC(NC2=CC=C(C=C2)N2CCOCC2)=NC2=C1N=CN2	Solid	Not Available					50170831	70723	CHEMBL188343	182286						AD5			210332	99443811				Reversine	ZINC000003620786		Reversine	Experimental	DB07340	InChI=1S/C21H27N7O/c1-2-4-15(5-3-1)24-20-18-19(23-14-22-18)26-21(27-20)25-16-6-8-17(9-7-16)28-10-12-29-13-11-28/h6-9,14-15H,1-5,10-13H2,(H3,22,23,24,25,26,27)	ZFLJHSQHILSNCM-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3133 LD50, mol/kg	Non-inhibitor	Strong inhibitor	Inhibitor										1	Yes	7	3	No	5	0	90.99 Å2	43.91 Å3	115.04 m3·mol-1	5	Yes	No	0.0355 mg/mL	3.58	-4	9.71	4.37	Q96GD4;!Q9NQS7	AURKB;!INCENP	1. Aurora kinase B;!2. Inner centromere protein
C12H11ClN6	Not Available	Not Available	274.709	ClC1=CNC2=C1C(=NC=N2)N1CCC2=C(C1)N=CN2	Solid	Not Available					24845	90625	CHEMBL259833	22376891						CQW			24798742	99444056					ZINC000016052800		5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine	Experimental	DB07585	InChI=1S/C12H11ClN6/c13-7-3-14-11-10(7)12(18-6-17-11)19-2-1-8-9(4-19)16-5-15-8/h3,5-6H,1-2,4H2,(H,15,16)(H,14,17,18)	YFFJXGRXFASBDL-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	2.8092 LD50, mol/kg	Inhibitor	Weak inhibitor	Inhibitor										1	Yes	4	2	No	4	0	73.49 Å2	26.86 Å3	73.65 m3·mol-1	1	Yes	No	0.117 mg/mL	1.24	-3.4	12.01	6.65	P31749;!P49841	AKT1;!GSK3B	1. RAC-alpha serine/threonine-protein kinase;!2. Glycogen synthase kinase-3 beta
C18H20ClN5	Not Available	Not Available	341.838	NCC1(CCN(CC1)C1=C2C=CNC2=NC=N1)C1=CC=C(Cl)C=C1	Solid	Not Available					50376063		CHEMBL406863	22377580						M03			24762195	99444619					ZINC000016052627		1-[4-(4-chlorophenyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine	Experimental	DB08148	InChI=1S/C18H20ClN5/c19-14-3-1-13(2-4-14)18(11-20)6-9-24(10-7-18)17-15-5-8-21-16(15)22-12-23-17/h1-5,8,12H,6-7,9-11,20H2,(H,21,22,23)	QOZMRRGNAZNWDN-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	2.9019 LD50, mol/kg	Inhibitor	Weak inhibitor	Inhibitor										1	Yes	4	2	No	4	2	70.83 Å2	37.12 Å3	98 m3·mol-1	3	Yes	No	0.0518 mg/mL	3.01	-3.8	13.57	9.45	P17612;!P61925	PRKACA;!PKIA	1. cAMP-dependent protein kinase catalytic subunit alpha;!2. cAMP-dependent protein kinase inhibitor alpha
C19H22ClN5	Not Available	Not Available	355.864	NCC1(CC2=CC=C(Cl)C=C2)CCN(CC1)C1=C2C=CNC2=NC=N1	Solid	Not Available					50376067		CHEMBL260000	9870838						M04			11696113	99444620					ZINC000016052628		1-[4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine	Experimental	DB08149	InChI=1S/C19H22ClN5/c20-15-3-1-14(2-4-15)11-19(12-21)6-9-25(10-7-19)18-16-5-8-22-17(16)23-13-24-18/h1-5,8,13H,6-7,9-12,21H2,(H,22,23,24)	KCWPSUKJCKZEAO-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	2.9019 LD50, mol/kg	Inhibitor	Weak inhibitor	Inhibitor										1	Yes	4	2	No	4	2	70.83 Å2	38.49 Å3	102.6 m3·mol-1	4	Yes	No	0.0263 mg/mL	3.45	-4.1	13.58	9.72	P17612;!P61925	PRKACA;!PKIA	1. cAMP-dependent protein kinase catalytic subunit alpha;!2. cAMP-dependent protein kinase inhibitor alpha
C18H21ClN5	Not Available	Not Available	342.846	[NH3+]C1(CC2=CC=C(Cl)C=C2)CCN(CC1)C1=C2C=CNC2=NC=N1	Solid	Not Available								22377581						M05			42627562	99444621							4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-aminium	Experimental	DB08150	InChI=1S/C18H20ClN5/c19-14-3-1-13(2-4-14)11-18(20)6-9-24(10-7-18)17-15-5-8-21-16(15)22-12-23-17/h1-5,8,12H,6-7,9-11,20H2,(H,21,22,23)/p+1	RZIDZIGAXXNODG-UHFFFAOYSA-O			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	2.8687 LD50, mol/kg	Inhibitor	Weak inhibitor	Inhibitor										1	Yes	3	2	No	4	2	72.45 Å2	36.96 Å3	109.24 m3·mol-1	3	Yes	No	0.00715 mg/mL	2.97	-4.7	13.59	9.85	P17612;!P61925	PRKACA;!PKIA	1. cAMP-dependent protein kinase catalytic subunit alpha;!2. cAMP-dependent protein kinase inhibitor alpha
C22H25FN6O2	Not Available	Not Available	424.4713	[H][C@@](N)(C(=O)N1CC[C@]([H])(F)C1)[C@@]([H])(C(=O)N(C)C)C1=CC=C(C=C1)C1=CN2N=CN=C2C=C1	Solid	Not Available					50221972		CHEMBL237337	8495608						S14			10320144	99444975					ZINC000014947659		6-(4-{(1S,2S)-2-AMINO-1-[(DIMETHYLAMINO)CARBONYL]-3-[(3S)-3-FLUOROPYRROLIDIN-1-YL]-3-OXOPROPYL}PHENYL)-1H-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-4-IUM	Experimental	DB08504	InChI=1S/C22H25FN6O2/c1-27(2)21(30)19(20(24)22(31)28-10-9-17(23)12-28)15-5-3-14(4-6-15)16-7-8-18-25-13-26-29(18)11-16/h3-8,11,13,17,19-20H,9-10,12,24H2,1-2H3/t17-,19-,20-/m0/s1	ZNHVIJAGMFQGMS-IHPCNDPISA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.6436 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	5	1	No	4	0	96.83 Å2	44.19 Å3	125.43 m3·mol-1	5	Yes	No	0.109 mg/mL	0.73	-3.6	18.09	6.94			
C16H20N6O	Not Available	~3 hours	312.3696	C[C@@H]1CCN(C[C@@H]1N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N	Solid	Vd= 87L after intravenous administration. Distribution is equal between red blood cells and plasma.					50193995	71200	CHEMBL221959	8102425	Drugs.com Drug Page				D09970	MI1	PDRhealth Drug Page		9926791	347827811	RxList Drug Page	1357536		Tofacitinib	ZINC000003818808	Xeljanz	Tofacitinib	Approved, Investigational	DB08895	InChI=1S/C16H20N6O/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20)/t11-,13+/m1/s1	UJLAWZDWDVHWOW-YPMHNXCESA-N	4	Tofacitinib is a Janus kinase (JAK) inhibitor used to treat rheumatic conditions, such as rheumatoid arthritis and ankylosing spondylitis, and ulcerative colitis.	Minimum lethal dose in rat: 500 mg/kg.Maximum asymptomatic dose in non human primate: 40 mg/kg. Lymphatic, immune system, bone marrow and erythroid cell toxicity was seen in animal studies involving rate and monkeys. Doses used in these studies ranged from 1mg/kg/day to 10mg/kg/day, over a duration of 6 weeks to 6 months. Lymphopenia, neutropenia, and anemia is seen in human subjects and may call for an interruption or discontinuation of therapy if severe. Reduced female fertility in rats was seen at exposures 17 times the maximum recommended human dose. Fertility may be impaired in human females and harm may be caused to unborn child.Carcinogenic potential is seen, however evidence for dose dependency is lacking.Because the janus kinase pathway plays a role in stimulating the production of red blood cells and is involved in immune cell function, inhibition of this pathway leads to increased risk of anemia, neutropenia, lymphopenia, cancer and infection. Lymphopenia, neutropenia, and anemia in human subjects may call for an interruption or discontinuation of therapy if severe. Role of JAK inhibition in the development of gastrointestinal perforation is not known.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.7249 LD50, mol/kg	Inhibitor	Weak inhibitor	Inhibitor					1.808					1	Yes	5	1	No	3	1	88.91 Å2	32.38 Å3	87.8 m3·mol-1	3	Yes	No	0.299 mg/mL	1.24	-3	9.15	6.44			
C25H24N6O2	In patients with normal renal function, the clearance rate is in the range of 112-159 ml/min.3	The elimination half-life of ibrutinib is of approximately 4-6 hours.11	440.507	NC1=NC=NC2=C1C(=NN2[C@@H]1CCCN(C1)C(=O)C=C)C1=CC=C(OC2=CC=CC=C2)C=C1	Solid	The volume of distribution at steady-state of ibrutinib is in approximately 10,000 L.11	P08684;!P20815;!P10635	CYP3A4;!CYP3A5;!CYP2D6	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5;!3. Cytochrome P450 2D6		50357312	76612	CHEMBL1873475	26637187	Drugs.com Drug Page				D10223	1E8		PA166121346	24821094	310264995		1442981		Ibrutinib	ZINC000035328014	Imbruvica	Ibrutinib	Approved	DB09053	InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1	XYFPWWZEPKGCCK-GOSISDBHSA-N		Ibrutinib is an antineoplastic agent used to treat chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's Macroglobulinemia.	Ibrutinib was not showed to present a mutagenic potential in bacterial assays, nor clastogenic in chromosome aberration assays in mammalian cells or in bone marrow micronucleus assays in mice. Carcinogenicity or effects on fertility have not been determined.16	Small Molecule																														3.97		149-158ºC	3.74	0.003 mg/ml	1	No	5	1	No	5	0	99.16 Å2	47.84 Å3	138.07 m3·mol-1	5	Yes	No	0.0203 mg/mL	3.63	-4.3	19.7	6.58	Q06187	BTK	1. Tyrosine-protein kinase BTK
C24H32N2O5	Not Available	Not Available	428.529	[H][C@]12C[C@H](OC)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=C3C=CC(OC)=C1)C2	Not Available	Not Available							CHEMBL2110987	59636															ZINC000004213849		Metoserpate	Vet approved	DB11530	InChI=1S/C24H32N2O5/c1-28-14-5-6-15-16-7-8-26-12-13-9-20(29-2)23(30-3)21(24(27)31-4)17(13)11-19(26)22(16)25-18(15)10-14/h5-6,10,13,17,19-21,23,25H,7-9,11-12H2,1-4H3/t13-,17+,19-,20+,21+,23+/m1/s1	FPGCYQVKNKEGRQ-SXLQGMKLSA-N			Not Available	Small Molecule																																			1	Yes	5	1	No	5	0	73.02 Å2	48.29 Å3	116.96 m3·mol-1	5	Yes	No	0.155 mg/mL	2.15	-3.4	16.29	6.99			
C24H32ClN5O2	Not Available	Not Available	457.996	[H][C@](CNC(C)C)(C(=O)N1CCN(CC1)C1=NC=NC2=C1[C@]([H])(C)C[C@@]2([H])O)C1=CC=C(Cl)C=C1	Not Available	Not Available					50398379	95089	CHEMBL2177390	28189084						0RF			24788740	347828101				Ipatasertib	ZINC000068250459		Ipatasertib	Investigational	DB11743	InChI=1S/C24H32ClN5O2/c1-15(2)26-13-19(17-4-6-18(25)7-5-17)24(32)30-10-8-29(9-11-30)23-21-16(3)12-20(31)22(21)27-14-28-23/h4-7,14-16,19-20,26,31H,8-13H2,1-3H3/t16-,19-,20-/m1/s1	GRZXWCHAXNAUHY-NSISKUIASA-N	2		Not Available	Small Molecule																																			1	Yes	6	2	Yes	4	1	81.59 Å2	50.29 Å3	127.76 m3·mol-1	6	Yes	No	0.0516 mg/mL	2.92	-4	13.68	9.49			
C25H30N6O3	Not Available	Not Available	462.554	CNC(=O)C1=CC(=CC=C1)C1=CC=C2C(N=C(N=C2N2CCOC[C@@H]2C)N2CCOC[C@@H]2C)=N1	Not Available	Not Available					50429701		CHEMBL2336325	28294977									25262792	347828256					ZINC000059258964		Vistusertib	Investigational	DB11925	InChI=1S/C25H30N6O3/c1-16-14-33-11-9-30(16)23-20-7-8-21(18-5-4-6-19(13-18)24(32)26-3)27-22(20)28-25(29-23)31-10-12-34-15-17(31)2/h4-8,13,16-17H,9-12,14-15H2,1-3H3,(H,26,32)/t16-,17-/m0/s1	JUSFANSTBFGBAF-IRXDYDNUSA-N	2		Not Available	Small Molecule																																			1	No	8	1	No	5	0	92.71 Å2	51.35 Å3	133.06 m3·mol-1	4	Yes	No	0.0692 mg/mL	3.53	-3.8	14.84	2			
C21H25ClN6O2	Not Available	Not Available	428.915	NC1(CCN(CC1)C1=C2C=CNC2=NC=N1)C(=O)N[C@@H](CCO)C1=CC=C(Cl)C=C1	Not Available	Not Available					50427349		CHEMBL2325741	28189073						0XZ			25227436	347828497					ZINC000043204023		Capivasertib	Investigational	DB12218	InChI=1S/C21H25ClN6O2/c22-15-3-1-14(2-4-15)17(6-12-29)27-20(30)21(23)7-10-28(11-8-21)19-16-5-9-24-18(16)25-13-26-19/h1-5,9,13,17,29H,6-8,10-12,23H2,(H,27,30)(H,24,25,26)/t17-/m0/s1	JDUBGYFRJFOXQC-KRWDZBQOSA-N	2		Not Available	Small Molecule																																			1	Yes	6	4	Yes	4	2	120.16 Å2	44.79 Å3	116.97 m3·mol-1	6	Yes	No		1.31		13.03	8.33			
C19H27N5O3	Not Available	Not Available	373.457	CCCC(=O)N1CCCN(CC1)C1=NC(N)=C2C=C(OC)C(OC)=CC2=N1	Not Available	Not Available					50088386	135576	CHEMBL188185	2378									2472	347828509		19850		Bunazosin	ZINC000000601249		Bunazosin	Investigational	DB12230	InChI=1S/C19H27N5O3/c1-4-6-17(25)23-7-5-8-24(10-9-23)19-21-14-12-16(27-3)15(26-2)11-13(14)18(20)22-19/h11-12H,4-10H2,1-3H3,(H2,20,21,22)	RHLJLALHBZGAFM-UHFFFAOYSA-N	4		Not Available	Small Molecule																																			1	Yes	7	1	No	3	1	93.81 Å2	40.08 Å3	105.53 m3·mol-1	5	Yes	No	0.584 mg/mL	1.94	-2.8		7.26			
C21H25N5O2	Not Available	Not Available	379.464	CCNC1=CC=CN=C1N1CCN(CC1)C(=O)C1=CC2=CC(OC)=CC=C2N1	Not Available	Not Available					1437		CHEMBL280527	54835									60848	347828536				Atevirdine	ZINC000000597817		Atevirdine	Investigational	DB12264	InChI=1S/C21H25N5O2/c1-3-22-18-5-4-8-23-20(18)25-9-11-26(12-10-25)21(27)19-14-15-13-16(28-2)6-7-17(15)24-19/h4-8,13-14,22,24H,3,9-12H2,1-2H3	UCPOMLWZWRTIAA-UHFFFAOYSA-N	2		Not Available	Small Molecule																																			1	Yes	5	2	No	4	1	73.49 Å2	42.8 Å3	112 m3·mol-1	5	Yes	No	0.0382 mg/mL	2.08	-4	14.5	6.88			
C15H17N3O2S	Not Available	Not Available	303.38	O=C(N[C@H]1CN2CCC1CC2)C1=CNC2=C(SC=C2)C1=O	Not Available	Not Available					50334438		CHEMBL1643880	135810									154104	347828648					ZINC000000016869		Pumosetrag	Investigational	DB12402	InChI=1S/C15H17N3O2S/c19-13-10(7-16-11-3-6-21-14(11)13)15(20)17-12-8-18-4-1-9(12)2-5-18/h3,6-7,9,12H,1-2,4-5,8H2,(H,16,19)(H,17,20)/t12-/m0/s1	AFUWQWYPPZFWCO-LBPRGKRZSA-N	2		Not Available	Small Molecule																																			1	Yes	4	2	No	4	0	61.44 Å2	31.71 Å3	82.67 m3·mol-1	2	Yes	No	0.0902 mg/mL	0.34	-3.5	6.64	7.45			
C21H19F4N7	Not Available	Not Available	445.426	CN1C=C(N=C1C1CCN(CC1)C1=C2C=NNC2=NC=N1)C1=CC=C(F)C(=C1)C(F)(F)F	Not Available	Not Available							CHEMBL3545076	25069691									25118925	347828891					ZINC000043204100		LY-2584702	Investigational	DB12690	InChI=1S/C21H19F4N7/c1-31-10-17(13-2-3-16(22)15(8-13)21(23,24)25)29-19(31)12-4-6-32(7-5-12)20-14-9-28-30-18(14)26-11-27-20/h2-3,8-12H,4-7H2,1H3,(H,26,27,28,30)	FYXRSVDHGLUMHB-UHFFFAOYSA-N	1		Not Available	Small Molecule																																			1	Yes	5	1	No	5	0	75.52 Å2	42.25 Å3	112.47 m3·mol-1	4	Yes	No	0.01 mg/mL	3.99	-4.6	9.16	5.92			
C22H22ClN7O2	Not Available	Not Available	451.92	COC1=CC(=CC=C1Cl)N1CCN(CC1)C(=O)CN1N=C(C2=NC=CN2)C2=CC=CN=C12	Not Available	Not Available								25069703									25016615	347829103							CCX-354	Investigational	DB12963	InChI=1S/C22H22ClN7O2/c1-32-18-13-15(4-5-17(18)23)28-9-11-29(12-10-28)19(31)14-30-22-16(3-2-6-26-22)20(27-30)21-24-7-8-25-21/h2-8,13H,9-12,14H2,1H3,(H,24,25)	ZIMLRKWQDLVPEK-UHFFFAOYSA-N	2		Not Available	Small Molecule																																			1	No	6	1	No	5	0	92.17 Å2	47.61 Å3	142.29 m3·mol-1	5	Yes	No	0.114 mg/mL	2.16	-3.6	11.15	5.05			
C24H23N7O4	Not Available	Not Available	473.493	COC1=CN=C(N2C=NC(C)=N2)C2=C1C(=CN2)C(=O)C(=O)N1CCN(CC1)C(=O)C1=CC=CC=C1	Not Available	Not Available					50236759		CHEMBL3301620	9492405						83J									ZINC000034815611		Temsavir	Investigational	DB14675	InChI=1S/C24H23N7O4/c1-15-27-14-31(28-15)22-20-19(18(35-2)13-26-22)17(12-25-20)21(32)24(34)30-10-8-29(9-11-30)23(33)16-6-4-3-5-7-16/h3-7,12-14,25H,8-11H2,1-2H3	QRPZBKAMSFHVRW-UHFFFAOYSA-N	1		Not Available	Small Molecule																																			1	Yes	7	1	No	5	0	126.31 Å2	48.67 Å3	128.73 m3·mol-1	5	Yes	No	0.147 mg/mL	1.01	-3.5	9.07	1.25			
C22H23ClFN5O3	Not Available	Not Available	459.91	COC1=C(OC(=O)N2CCN(C)C[C@H]2C)C=C2C(NC3=C(F)C(Cl)=CC=C3)=NC=NC2=C1	Not Available	Not Available					50123453		CHEMBL3623290	38772332															ZINC000221149242		AZD-3759	Investigational	DB14795	InChI=1S/C22H23ClFN5O3/c1-13-11-28(2)7-8-29(13)22(30)32-19-9-14-17(10-18(19)31-3)25-12-26-21(14)27-16-6-4-5-15(23)20(16)24/h4-6,9-10,12-13H,7-8,11H2,1-3H3,(H,25,26,27)/t13-/m1/s1	MXDSJQHFFDGFDK-CYBMUJFWSA-N	1		Not Available	Small Molecule																																			1	Yes	6	1	No	4	1	79.82 Å2	46.54 Å3	119.16 m3·mol-1	5	Yes	No	0.0696 mg/mL	4.03	-3.8	13.81	7.1			
C20H21FN6O	Not Available	Not Available	380.427	C[C@@H]1CCC2=C(C=C(F)C=N2)[C@H]2CCCN2C2=NC3=C(C=NN3C=C2)C(=O)N1	Not Available	Not Available								64853862																	Selitrectinib	Investigational	DB14896	InChI=1S/C20H21FN6O/c1-12-4-5-16-14(9-13(21)10-22-16)17-3-2-7-26(17)18-6-8-27-19(25-18)15(11-23-27)20(28)24-12/h6,8-12,17H,2-5,7H2,1H3,(H,24,28)/t12-,17-/m1/s1	OEBIHOVSAMBXIB-SJKOYZFVSA-N	1		Not Available	Small Molecule																																			1	Yes	5	1	No	5	0	75.42 Å2	38.66 Å3	114.28 m3·mol-1	0	Yes	No	0.0815 mg/mL	2.32	-3.7	12.88	1.84			
C20H24N6O2S	Not Available	Not Available	412.51	C[C@@H]1COCCN1C1=NC(=NC(=C1)C1(CC1)[S@](C)(=N)=O)C1=CN=CC2=C1C=CN2	Not Available	Not Available								58828171																	Ceralasertib	Investigational	DB14917	InChI=1S/C20H24N6O2S/c1-13-12-28-8-7-26(13)18-9-17(20(4-5-20)29(2,21)27)24-19(25-18)15-10-22-11-16-14(15)3-6-23-16/h3,6,9-11,13,21,23H,4-5,7-8,12H2,1-2H3/t13-,29-/m1/s1	DTTJKLNXNZAVSM-JYCIKRDWSA-N	2		Not Available	Small Molecule																																			1	Yes	7	2	No	5	0	107.85 Å2	43.1 Å3	121.99 m3·mol-1	4	Yes	No	0.127 mg/mL	1.91	-3.5	13.76	4.5	Q13535	ATR	1. Serine/threonine-protein kinase ATR
C15H19N5O	Not Available	Not Available	285.351	C[C@H]1CC[C@H](CN1C(=O)C=C)NC1=NC=NC2=C1C=CN2	Not Available	Not Available					209866		CHEMBL4085457	59718512															ZINC000526061581		PF-06651600	Investigational	DB14924	InChI=1S/C15H19N5O/c1-3-13(21)20-8-11(5-4-10(20)2)19-15-12-6-7-16-14(12)17-9-18-15/h3,6-7,9-11H,1,4-5,8H2,2H3,(H2,16,17,18,19)/t10-,11+/m0/s1	CBRJPFGIXUFMTM-WDEREUQCSA-N	3		Not Available	Small Molecule																																			1	Yes	4	2	No	3	1	73.91 Å2	29.95 Å3	82.84 m3·mol-1	3	Yes	No	0.457 mg/mL	1.47	-2.8	13.59	6.6			
C25H36F3N5O3	Not Available	Not Available	511.59	CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@](C1)(C(C)C)C(=O)N1C[C@@H]2C[C@H]1CN2C1=NC=NC(=C1)C(F)(F)F	Not Available	Not Available								58828233															ZINC000068207369		PF-04634817	Investigational	DB14955	InChI=1S/C25H36F3N5O3/c1-15(2)24(6-4-16(10-24)31-19-5-7-36-13-20(19)35-3)23(34)33-12-17-8-18(33)11-32(17)22-9-21(25(26,27)28)29-14-30-22/h9,14-20,31H,4-8,10-13H2,1-3H3/t16-,17+,18+,19+,20-,24+/m1/s1	MCRWZBYTLVCCJJ-DKALBXGISA-N	2		Not Available	Small Molecule																																			1	No	7	1	Yes	5	1	79.82 Å2	51.84 Å3	128.3 m3·mol-1	7	No	No	0.0706 mg/mL	2.91	-3.9		9.98			
C22H28N2O3	Not Available	Not Available	368.477	COCC[C@H]1C[C@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@](C2)([C@H]13)C(=O)OC	Not Available	Not Available								24721799														18-Methoxycoronaridine	ZINC000013522281		18-methoxycoronaridine	Investigational	DB15096	InChI=1S/C22H28N2O3/c1-26-10-8-15-11-14-12-22(21(25)27-2)19-17(7-9-24(13-14)20(15)22)16-5-3-4-6-18(16)23-19/h3-6,14-15,20,23H,7-13H2,1-2H3/t14-,15+,20+,22-/m1/s1	DTJQBBHYRQYDEG-SVBQBFEESA-N			Not Available	Small Molecule																																			1	Yes	3	1	No	5	1	54.56 Å2	41.9 Å3	104.62 m3·mol-1	5	Yes	No	0.0396 mg/mL	2.73	-4	16.38	8.39			
C22H22N6O3	Not Available	Not Available	418.457	COC1=CC(=CC(OC)=C1)C#CC1=NN([C@H]2CCN(C2)C(=O)C=C)C2=C1C(N)=NC=N2	Not Available	Not Available					161389		CHEMBL3701238	58877816						TZ0									ZINC000207800318		Futibatinib	Investigational	DB15149	InChI=1S/C22H22N6O3/c1-4-19(29)27-8-7-15(12-27)28-22-20(21(23)24-13-25-22)18(26-28)6-5-14-9-16(30-2)11-17(10-14)31-3/h4,9-11,13,15H,1,7-8,12H2,2-3H3,(H2,23,24,25)/t15-/m0/s1	KEIPNCCJPRMIAX-HNNXBMFYSA-N			Not Available	Small Molecule																																			1	Yes	7	1	Yes	4	0	108.39 Å2	45.57 Å3	122.82 m3·mol-1	6	Yes	No	0.0398 mg/mL	1.77	-4	19.22	2.58			
C25H22N6O3	Not Available	Not Available	454.49	CC#CC(=O)N1CC[C@H](C1)N1C(=O)N(C2=C(N)N=CN=C12)C1=CC=C(OC2=CC=CC=C2)C=C1	Not Available	Not Available					194087		CHEMBL4071161	58171734															ZINC000072318699		Tirabrutinib	Investigational	DB15227	InChI=1S/C25H22N6O3/c1-2-6-21(32)29-14-13-18(15-29)31-24-22(23(26)27-16-28-24)30(25(31)33)17-9-11-20(12-10-17)34-19-7-4-3-5-8-19/h3-5,7-12,16,18H,13-15H2,1H3,(H2,26,27,28)/t18-/m1/s1	SEJLPXCPMNSRAM-GOSISDBHSA-N	2		Not Available	Small Molecule																																			1	Yes	5	1	No	5	0	104.89 Å2	48.25 Å3	127.73 m3·mol-1	5	Yes	No	0.0267 mg/mL	3.27	-4.2	18.57	3.33	Q06187	BTK	1. Tyrosine-protein kinase BTK
C20H23FN4O2	Not Available	Not Available	370.428	CC#CC(=O)N[C@H]1CCCN(C1)C1=C2C(C)=C(C)NC2=C(C=C1F)C(N)=O	Not Available	Not Available					164638			64835069																	Branebrutinib	Investigational	DB15347	InChI=1S/C20H23FN4O2/c1-4-6-16(26)24-13-7-5-8-25(10-13)19-15(21)9-14(20(22)27)18-17(19)11(2)12(3)23-18/h9,13,23H,5,7-8,10H2,1-3H3,(H2,22,27)(H,24,26)/t13-/m0/s1	VJPPLCNBDLZIFG-ZDUSSCGKSA-N	1		Not Available	Small Molecule																																			1	Yes	3	3	No	3	0	91.22 Å2	39.78 Å3	104.3 m3·mol-1	4	Yes	No	0.00971 mg/mL	2.62	-4.6	14.12	0.25	Q06187	BTK	1. Tyrosine-protein kinase BTK
C30H30F2N6O3	Sotorasib has an apparent clearance at steady state of 26.2 L/h.6	Sotorasib has a terminal elimination half life of 5.5 ± 1.8 hours.5,6	560.606	CC(C)C1=NC=CC(C)=C1N1C(=O)N=C(N2CCN(C[C@@H]2C)C(=O)C=C)C2=CC(F)=C(N=C12)C1=C(O)C=CC=C1F	Solid	The volume of distribution of sotorasib is 211 L.6	BE0004866;!P10632;!P11712;!P20813	;!CYP2C8;!CYP2C9;!CYP2B6	1. Cytochrome P450 3A Subfamily (Protein Group);!2. Cytochrome P450 2C8;!3. Cytochrome P450 2C9;!4. Cytochrome P450 2B6		50514402		CHEMBL4535757	72380148					D12055							2550714		Sotorasib		Lumakras	Sotorasib	Approved, Investigational	DB15569	InChI=1S/C30H30F2N6O3/c1-6-23(40)36-12-13-37(18(5)15-36)28-19-14-21(32)26(24-20(31)8-7-9-22(24)39)34-29(19)38(30(41)35-28)27-17(4)10-11-33-25(27)16(2)3/h6-11,14,16,18,39H,1,12-13,15H2,2-5H3/t18-/m0/s1	NXQKSXLFSAEQCZ-SFHVURJKSA-N	1	Sotorasib is an experimental KRAS inhibitor being investigated for the treatment of KRAS G12C mutant non small cell lung cancer, colorectal cancer, and appendix cancer.	Data regarding overdoses of sotorasib are not readily available. However, in clinical trials, signs of dose limiting toxicity were not found.5 Patients experiencing an overdose may experience and increased risk and severity of adverse effects such as diarrhea, nausea, vomiting, fatigue, and elevated aminotransferase.5	Small Molecule																																	8.06, 4.56	1.3 mg/mL at pH 1.2, 0.03 mg/mL at pH 6.8	1	No	7	1	No	5	-1	102.23 Å2	57.21 Å3	150.12 m3·mol-1	3	No	No	0.0185 mg/mL	4.74	-4.5	6.98	4.74	P01116	KRAS	1. GTPase KRas
C23H29N7O3	Not Available	Not Available	451.531	CN(C)C(=O)OC1=CC(NC(=O)C2(CN)CCN(CC2)C2=C3C(C)=CNC3=NC=N2)=CC=C1	Not Available	Not Available					50044004		CHEMBL3356433	35308210															ZINC000142095785		LX-7101	Investigational	DB16009	InChI=1S/C23H29N7O3/c1-15-12-25-19-18(15)20(27-14-26-19)30-9-7-23(13-24,8-10-30)21(31)28-16-5-4-6-17(11-16)33-22(32)29(2)3/h4-6,11-12,14H,7-10,13,24H2,1-3H3,(H,28,31)(H,25,26,27)	PWPNYABQEOGNNC-UHFFFAOYSA-N	2		Not Available	Small Molecule																																			1	Yes	6	3	Yes	4	2	129.47 Å2	47.86 Å3	127.74 m3·mol-1	6	Yes	No	0.0761 mg/mL	2.13	-3.8	13.35	9.16			
C28H39N7O3	Not Available	Not Available	521.666	CC[C@H]1N(C2CCCC2)C2=NC(NC3=CC=C(C=C3OC)C(=O)NC3CCN(C)CC3)=NC=C2N(C)C1=O	Not Available	Not Available							CHEMBL513909	9539348						R78									ZINC000013986815		BI 2536	Investigational	DB16107	InChI=1S/C28H39N7O3/c1-5-22-27(37)34(3)23-17-29-28(32-25(23)35(22)20-8-6-7-9-20)31-21-11-10-18(16-24(21)38-4)26(36)30-19-12-14-33(2)15-13-19/h10-11,16-17,19-20,22H,5-9,12-15H2,1-4H3,(H,30,36)(H,29,31,32)/t22-/m1/s1	XQVVPGYIWAGRNI-JOCHJYFZSA-N	2		Not Available	Small Molecule																																			1	No	8	2	Yes	5	1	102.93 Å2	58.88 Å3	148.64 m3·mol-1	7	No	No	0.0198 mg/mL	3.06	-4.4	12.25	8.57			
C16H18N6O	Not Available	Not Available	310.361	C[C@H]1CN(C(=O)CC#N)[C@]11CCN(C1)C1=C2C=CNC2=NC=N1	Not Available	Not Available							CHEMBL4297507	59718502						FHX									ZINC000117625213		Delgocitinib	Investigational	DB16133	InChI=1S/C16H18N6O/c1-11-8-22(13(23)2-5-17)16(11)4-7-21(9-16)15-12-3-6-18-14(12)19-10-20-15/h3,6,10-11H,2,4,7-9H2,1H3,(H,18,19,20)/t11-,16-/m0/s1	LOWWYYZBZNSPDT-ZBEGNZNMSA-N	2		Not Available	Small Molecule																																			1	Yes	5	1	No	4	1	88.91 Å2	32.56 Å3	85.89 m3·mol-1	2	Yes	No	0.552 mg/mL	0.65	-2.8	9.14	6.43			
C21H25F3N6O2	Not Available	Not Available	450.466	CCC(=O)N1CC[C@@H](C1)NC1=C2CN(CCC2=NC=N1)C1=CN=C(OC)C(=C1)C(F)(F)F	Not Available	Not Available							CHEMBL3643413	52083264						9NQ											Leniolisib	Investigational	DB16217	InChI=1S/C21H25F3N6O2/c1-3-18(31)30-6-4-13(10-30)28-19-15-11-29(7-5-17(15)26-12-27-19)14-8-16(21(22,23)24)20(32-2)25-9-14/h8-9,12-13H,3-7,10-11H2,1-2H3,(H,26,27,28)/t13-/m0/s1	MWKYMZXCGYXLPL-ZDUSSCGKSA-N	3		Not Available	Small Molecule																																			1	Yes	7	1	Yes	4	0	83.48 Å2	43.46 Å3	115.08 m3·mol-1	6	Yes	No	0.0658 mg/mL	2.01	-3.8	18.21	5.43			
C25H40N8O2	Not Available	Not Available	484.649	CC(=O)N[C@@H]1C[C@@H](CC[C@@H]1N1CC[C@H](NC2=NC=NC3=CC(=NN23)C(C)(C)C)C1=O)NC(C)(C)C	Not Available	Not Available								71061479																	BMS-813160	Investigational	DB16240	InChI=1S/C25H40N8O2/c1-15(34)28-18-12-16(30-25(5,6)7)8-9-19(18)32-11-10-17(22(32)35)29-23-27-14-26-21-13-20(24(2,3)4)31-33(21)23/h13-14,16-19,30H,8-12H2,1-7H3,(H,28,34)(H,26,27,29)/t16-,17+,18-,19+/m1/s1	CMVHFGNTABZQJU-HCXYKTFWSA-N	1		Not Available	Small Molecule																																			1	No	7	3	Yes	4	1	116.55 Å2	53.99 Å3	146.59 m3·mol-1	7	Yes	No	0.0178 mg/mL	1.63	-4.4	13.82	10.39			
C26H31ClN6O2	Not Available	Not Available	495.02	CN(C)C\C=C\C(=O)N1CCCC[C@H](C1)N1C(NC(=O)C2=CC=NC(C)=C2)=NC2=C1C(Cl)=CC=C2	Not Available	Not Available							CHEMBL3787344	35308229															ZINC000210610738		Nazartinib	Investigational	DB16250	InChI=1S/C26H31ClN6O2/c1-18-16-19(12-13-28-18)25(35)30-26-29-22-10-6-9-21(27)24(22)33(26)20-8-4-5-15-32(17-20)23(34)11-7-14-31(2)3/h6-7,9-13,16,20H,4-5,8,14-15,17H2,1-3H3,(H,29,30,35)/b11-7+/t20-/m1/s1	IOMMMLWIABWRKL-WUTDNEBXSA-N	1		Not Available	Small Molecule																																			1	No	5	1	Yes	4	1	83.36 Å2	54.2 Å3	140.04 m3·mol-1	6	Yes	No	0.02 mg/mL	3.5	-4.4	13.62	8.81			
C22H26N8	Not Available	Not Available	402.506	CC1=CC(NC2=NC(N[C@H]3C[C@@H]4CC[C@H](C3)N4CCC#N)=C3C=CC=NC3=C2)=NN1	Not Available	Not Available								75536963																	Izencitinib	Investigational	DB16660	InChI=1S/C22H26N8/c1-14-10-21(29-28-14)26-20-13-19-18(4-2-8-24-19)22(27-20)25-15-11-16-5-6-17(12-15)30(16)9-3-7-23/h2,4,8,10,13,15-17H,3,5-6,9,11-12H2,1H3,(H3,25,26,27,28,29)/t15-,16-,17+	DADAEARVGOQWHV-OSYLJGHBSA-N	1		Not Available	Small Molecule																																			1	Yes	7	3	Yes	5	1	105.55 Å2	44.79 Å3	118.38 m3·mol-1	6	Yes	No	0.061 mg/mL	2.44	-3.8	13.25	7.3			
C18H22O4	Not Available	Not Available	302.3649	C[C@@H](CC1=CC(O)=C(O)C=C1)[C@H](C)CC1=CC(O)=C(O)C=C1	Solid	Not Available					22372	73468	CHEMBL313972	64490		GtP Drug Page	HMDB0014325	C10719	D04862			PA164746493	71398	46508042		227239	DNC001037	Masoprocol	ZINC000000012342		Masoprocol	Approved, Investigational	DB00179	InChI=1S/C18H22O4/c1-11(7-13-3-5-15(19)17(21)9-13)12(2)8-14-4-6-16(20)18(22)10-14/h3-6,9-12,19-22H,7-8H2,1-2H3/t11-,12+	HCZKYJDFEPMADG-TXEJJXNPSA-N	2		Symptoms of overdose or allergic reaction include bluish coloration of skin, dizziness, severe, or feeling faint, wheezing or trouble in breathing.	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1491 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					5.8		185.5 °C			1	Yes	4	4	No	2	0	80.92 Å2	33.63 Å3	86.62 m3·mol-1	5	Yes	No	0.0136 mg/mL	4.76	-4.4	9.21	-6.3			
C12H18N2O4	Renal cl=385 mL/minute	The metabolites display a half-life of about 3 to 4 hours.	254.2823	COC1=CC(C(O)CNC(=O)CN)=C(OC)C=C1	Solid	Not Available	P10635	CYP2D6	1. Cytochrome P450 2D6			6933	CHEMBL1201212	4050	Drugs.com Drug Page		HMDB0014356	C07890	D08220			PA164749381	4195	46507373	RxList Drug Page	6963	DAP000229	Midodrine		Proamatine	Midodrine	Approved	DB00211	InChI=1S/C12H18N2O4/c1-17-8-3-4-11(18-2)9(5-8)10(15)7-14-12(16)6-13/h3-5,10,15H,6-7,13H2,1-2H3,(H,14,16)	PTKSEFOSCHHMPD-UHFFFAOYSA-N	4	Midodrine is an alpha-adrenergic agonist used to treat orthostatic hypotension.	Symptoms of overdose could include hypertension, piloerection (goosebumps), a sensation of coldness and urinary retention. The single doses that would be associated with symptoms of overdosage or would be potentially life- threatening are unknown. The oral LD50 is approximately 30 to 50 mg/kg in rats, 675 mg/kg in mice, and 125 to 160 mg/kg in dogs. Desglymidodrine is dialyzable.	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3137 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					-0.5		200 to 203°C	7.8	Soluble	1	No	5	3	No	1	1	93.81 Å2	26.65 Å3	66.22 m3·mol-1	6	Yes	No	4.45 mg/mL	-0.95	-1.8	13.77	8.14	P35348;!P35368;!P25100	ADRA1A;!ADRA1B;!ADRA1D	1. Alpha-1A adrenergic receptor;!2. Alpha-1B adrenergic receptor;!3. Alpha-1D adrenergic receptor
C18H20O2	Not Available	Not Available	268.356	CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1	Solid	Not Available	P08684;!P10632;!P11712;!P05181;!P21964;!P11511	CYP3A4;!CYP2C8;!CYP2C9;!CYP2E1;!COMT;!CYP19A1	1. Cytochrome P450 3A4;!2. Cytochrome P450 2C8;!3. Cytochrome P450 2C9;!4. Cytochrome P450 2E1;!5. Catechol O-methyltransferase;!6. Cytochrome P450 19A1		20625	41922	CHEMBL411	395306				C07620	D00577	DES		PA449307	3054	46507453		3390	DAP001011	Diethylstilbestrol	ZINC000000001290		Diethylstilbestrol	Approved, Investigational	DB00255	InChI=1S/C18H20O2/c1-3-17(13-5-9-15(19)10-6-13)18(4-2)14-7-11-16(20)12-8-14/h5-12,19-20H,3-4H2,1-2H3/b18-17+	RGLYKWWBQGJZGM-ISLYRVAYSA-N	3		Symptoms of overdose include nausea and vomiting, and withdrawal bleeding may occur in females.	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.9462 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					5.07	-4.35	172		12 mg/L (at 25 °C)	1	Yes	2	2	No	2	0	40.46 Å2	30.69 Å3	83.24 m3·mol-1	4	No	No	0.0109 mg/mL	5.19	-4.4	8.63	-6.5			
C14H11NO5	7 L/h	2-3.5 hours	273.2408	CC1=CC=C(C=C1)C(=O)C1=CC(=C(O)C(O)=C1)[N+]([O-])=O	Solid	9 L	P11712	CYP2C9	1. Cytochrome P450 2C9		50108877	63630	CHEMBL1324	3848682	Drugs.com Drug Page		HMDB0014468	C07949	D00786	TCW	PDRhealth Drug Page	PA451720	4659569	46504932	RxList Drug Page	72937	DAP000607	Tolcapone	ZINC000035342789	Tasmar	Tolcapone	Approved, Withdrawn	DB00323	InChI=1S/C14H11NO5/c1-8-2-4-9(5-3-8)13(17)10-6-11(15(19)20)14(18)12(16)7-10/h2-7,16,18H,1H3	MIQPIUSUKVNLNT-UHFFFAOYSA-N	4	Tolcapone is a catechol-O-methyltransferase (COMT) inhibitor used as adjunct therapy in the symptomatic management of idiopathic Parkinson's disease.	LD50 = 1600 mg/kg (Orally in rats)	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.2574 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					4					1	Yes	5	2	No	2	-1	100.67 Å2	26.89 Å3	71.96 m3·mol-1	3	Yes	No	0.0569 mg/mL	3.28	-3.7	5.59	-6.5	P21964	COMT	1. Catechol O-methyltransferase
C15H16O2	6-MNA has an apparent steady-state clearance of 20 - 30 mL/min.Label	6-MNA has a mean half-life of 24 hours with a range of 19-36 hours.Label	228.2863	COC1=CC2=C(C=C1)C=C(CCC(C)=O)C=C2	Solid	The Vd of 6-MNA reported after administration of a single dose is 0.1-0.2 L/kg or approximately 5-10 L.1 Vdss reported in official product labeling is approximately 53 L.Label,10	P05164;!P05177;!P11712;!P28845;!Q04828;!P52895;!P17516	MPO;!CYP1A2;!CYP2C9;!HSD11B1;!AKR1C1;!AKR1C2;!AKR1C4	1. Myeloperoxidase;!2. Cytochrome P450 1A2;!3. Cytochrome P450 2C9;!4. Corticosteroid 11-beta-dehydrogenase isozyme 1;!5. Aldo-keto reductase family 1 member C1;!6. Aldo-keto reductase family 1 member C2;!7. Aldo-keto reductase family 1 member C4		40128	7443	CHEMBL1070	4256	Drugs.com Drug Page		HMDB0014604		D00425	NBO	PDRhealth Drug Page	PA450572	4409	46507729	RxList Drug Page	31448	DAP000735	Nabumetone	ZINC000000020221	Relafen	Nabumetone	Approved	DB00461	InChI=1S/C15H16O2/c1-11(16)3-4-12-5-6-14-10-15(17-2)8-7-13(14)9-12/h5-10H,3-4H2,1-2H3	BLXXJMDCKKHMKV-UHFFFAOYSA-N	4	Nabumetone is an NSAID used to treat osteoarthritis and rheumatoid arthritis.	LD50 ValuesMouse: 4290 mg/kg (Oral), 2380 mg/kg (IP)11Rat: 3880 mg/kg (Oral), 1520 mg/kg (IP), >10 g/kg (SC)11Monkey: 3200 mg/kg (Oral)11OverdoseSigns and symptoms of nabumetone overdose include lethargy, drowsiness, nausea, vomiting, and epigastric pain.Label These are considered reversible with supportive care. GI bleeding, hypertension, acute kidney injury, respiratory depression, and coma are rare but can occur. No antidote exists for nabumetone overdose although administration of activated charcoal and/or induction of emesis can reduce absorption if the nabumetone dose was taken less than 4 hours prior.Label,10 6-MNA is cannot be cleared by dialysis.Carcinogenicity & MutagenicityNabumetone was not significantly carcinogenic in rats or mice studied over 2 years.Label Neither the Ames test nor mouse micronucleus test showed nabumetone or it's active metabolite, 6-MNA, to be mutagenic. Chromosomal abberation has been observed in cultured lymphocytes exposed to concentrations of 80 mcg/mL and higher of nabumetone or 6-MNA equivalent to the maximum recommended human dose.Reproductive ToxicityNo adverse effects on fertility have been observed in male and female rats at doses of 320 mg/kg/day.Label,10] No teratogenicity has been observed in pregnant rabbits or rats. Dystocia and delayed parturition have been noted in rats resulting in reduced survival of offspring. This has been attributed to the role of prostaglandins in uterine contraction. NSAIDs can also cause premature closure of the ductus ateriosus.Lactation6-MNA has been detected in the milk of lactating rats.Label,10 While no data is available in humans, 6-MNA is both highly protein bound and exists in its anionic form in circulation. For these reasons partitioning into breast milk is expected to be limited.	Small Molecule	http://smpdb.ca/view/SMP0000114?highlight[compounds][]=DB00461&highlight[proteins][]=DB00461	Nabumetone Action Pathway		Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	1.7384 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2400		78-82		Practically insoluble	1	Yes	2	0	No	2	0	26.3 Å2	26.17 Å3	68.43 m3·mol-1	4	Yes	Yes	0.00193 mg/mL	3.22	-5.1	19.59	-4.8			
C21H28N2O5	Not Available	The mean elimination half-life of trimethobenzamide is 7 to 9 hours.	388.4574	COC1=CC(=CC(OC)=C1OC)C(=O)NCC1=CC=C(OCCN(C)C)C=C1	Solid	Not Available						27796	CHEMBL1201256	5375	Drugs.com Drug Page		HMDB0014800	C07178	D08643		PDRhealth Drug Page	PA164764516	5577	46507787	RxList Drug Page	38685		Trimethobenzamide	ZINC000000538509	Tigan	Trimethobenzamide	Approved, Investigational	DB00662	InChI=1S/C21H28N2O5/c1-23(2)10-11-28-17-8-6-15(7-9-17)14-22-21(24)16-12-18(25-3)20(27-5)19(13-16)26-4/h6-9,12-13H,10-11,14H2,1-5H3,(H,22,24)	FEZBIKUBAYAZIU-UHFFFAOYSA-N	4	Trimethobenzamide is an antiemetic used to treat postoperative nausea and vomiting and nausea associated with gastroenteritis.	Oral LD50 in mice is 1600 mg/kg.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.3338 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.29		188.7 °C	8.78	40 mg/L	1	Yes	6	1	No	2	1	69.26 Å2	43.19 Å3	108.52 m3·mol-1	10	Yes	No	0.0398 mg/mL	2.16	-4	14.68	8.77			
C18H18O2	Not Available	Not Available	266.34	[H]\C(C)=C(/C(=C(\[H])C)/C1=CC=C(O)C=C1)\C1=CC=C(O)C=C1	Solid	Not Available					40491	4518	CHEMBL1018	580857				C08090	D00898			PA164745534	667476	46504661	RxList Drug Page	3368	DAP001015	Dienestrol	ZINC000000001283		Dienestrol	Approved, Investigational	DB00890	InChI=1S/C18H18O2/c1-3-17(13-5-9-15(19)10-6-13)18(4-2)14-7-11-16(20)12-8-14/h3-12,19-20H,1-2H3/b17-3+,18-4+	NFDFQCUYFHCNBW-SCGPFSFSSA-N		Dienestrol is a non steroidal estrogen used to treat atrophic vaginitis and kraurosis vulvae.	Symptoms of overdose include nausea and vomiting, and withdrawal bleeding may occur in females.	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.8229 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					5.9	-4.95	233-234		3 mg/L (at 37 °C)	1	Yes	2	2	No	2	0	40.46 Å2	30.27 Å3	84.36 m3·mol-1	3	Yes	No	0.0123 mg/mL	4.83	-4.3	9.1	-6	P03372;!P04278	ESR1;!SHBG	1. Estrogen receptor alpha;!2. Sex hormone-binding globulin
C28H31NO5	Not Available	Not Available	461.5494	CC1=CC=C(C=C1)C(=O)OC1=C(OC(=O)C2=CC=C(C)C=C2)C=C(C=C1)C(O)CNC(C)(C)C	Solid	Not Available						3133	CHEMBL1201295	32525	Drugs.com Drug Page			C06853	D07534			PA448644	35330	46506895		19499		Bitolterol			Bitolterol	Withdrawn	DB00901	InChI=1S/C28H31NO5/c1-18-6-10-20(11-7-18)26(31)33-24-15-14-22(23(30)17-29-28(3,4)5)16-25(24)34-27(32)21-12-8-19(2)9-13-21/h6-16,23,29-30H,17H2,1-5H3	FZGVEKPRDOIXJY-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.3906 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					5.8					1	No	4	2	Yes	3	1	84.86 Å2	52.07 Å3	132.76 m3·mol-1	10	No	No	0.00048 mg/mL	6.3	-6	14	9.59	P07550	ADRB2	1. Beta-2 adrenergic receptor
C20H21ClO4	The oral clearance of fenofibrate is 1.1L/h in young adults and 1.2L/h in the elderly.11,12	Fenofibric acid, the active metabolite of fenofibrate, has a half life of 23 hours.11,12 Fenofibrate has a half life of 19-27 hours in healthy subjects and up to 143 hours in patients with renal failure.3	360.831	CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1	Solid	The volume of distribution of fenofibrate is 0.89L/kg,4 and can be as high as 60L.3	O60656;!P23141;!P16152;!P10632;!P33261;!P11509;!Q04828;!P52895;!P42330;!P15121;!P11712	UGT1A9;!CES1;!CBR1;!CYP2C8;!CYP2C19;!CYP2A6;!AKR1C1;!AKR1C2;!AKR1C3;!AKR1B1;!CYP2C9	1. UDP-glucuronosyltransferase 1-9;!2. Liver carboxylesterase 1;!3. Carbonyl reductase [NADPH] 1;!4. Cytochrome P450 2C8;!5. Cytochrome P450 2C19;!6. Cytochrome P450 2A6;!7. Aldo-keto reductase family 1 member C1;!8. Aldo-keto reductase family 1 member C2;!9. Aldo-keto reductase family 1 member C3;!10. Aldose reductase;!11. Cytochrome P450 2C9		50085042	5001	CHEMBL672	3222	Drugs.com Drug Page		HMDB0015173	C07586	D00565		PDRhealth Drug Page	PA449594	3339	46507371	RxList Drug Page	8703	DAP000270	Fenofibrate	ZINC000000584092	Antara, Cholib, Fenoglide, Fenomax, Lipidil Supra, Lipofen, Tricor, Triglide	Fenofibrate	Approved	DB01039	InChI=1S/C20H21ClO4/c1-13(2)24-19(23)20(3,4)25-17-11-7-15(8-12-17)18(22)14-5-9-16(21)10-6-14/h5-13H,1-4H3	YMTINGFKWWXKFG-UHFFFAOYSA-N	4	Fenofibrate is a peroxisome proliferator receptor alpha activator used to lower LDL-C, total-C, triglycerides, and Apo B, while increasing HDL-C in hypercholesterolemia, dyslipidemia, and hypertriglyceridemia.	The oral LD50 in rats is >2g/kg and in mice is 1600mg/kg.13 The oral TDLO in rats is 9mg/kg.13Treat patients with supportive care including monitoring of vital signs and observing clinical status.11,12 Recent overdose may be treated with inducing vomiting or gastric lavage.11,12 Due to fenofibrate's extensive protein binding, hemodialysis is not expected to be useful.2,11,12	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.2250 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					5.2		79-82			1	Yes	3	0	No	2	0	52.6 Å2	38.15 Å3	97.13 m3·mol-1	7	No	No	0.000707 mg/mL	5.28	-5.7		-4.9			
C16H14O6	Not Available	Not Available	302.2788	COC1=C(O)C=C(C=C1)[C@@H]1CC(=O)C2=C(O)C=C(O)C=C2O1	Solid	Not Available					23418	28230	CHEMBL399121	65234			HMDB0005782	C01709		6JP	PDRhealth Drug Page	PA164742902	72281	46507998		1314255	DAP001306	Hesperetin	ZINC000000039092		Hesperetin	Experimental	DB01094	InChI=1S/C16H14O6/c1-21-13-3-2-8(4-10(13)18)14-7-12(20)16-11(19)5-9(17)6-15(16)22-14/h2-6,14,17-19H,7H2,1H3/t14-/m0/s1	AIONOLUJZLIMTK-AWEZNQCLSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Inhibitor	Non-substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	3.1455 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.60		227.5 °C		273 mg/L	1	Yes	6	3	No	3	0	96.22 Å2	29.3 Å3	77.75 m3·mol-1	2	Yes	No	0.138 mg/mL	2.68	-3.3	7.86	-4.6	P55157;!P35610;!P04278;!O75908	MTTP;!SOAT1;!SHBG;!SOAT2	1. Microsomal triglyceride transfer protein large subunit;!2. Sterol O-acyltransferase 1;!3. Sex hormone-binding globulin;!4. Sterol O-acyltransferase 2
C20H21NO4	Not Available	0.5-2 hours	339.385	COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1	Solid	Not Available					14754	28241	CHEMBL19224	4518	Drugs.com Drug Page		HMDB0015245	C06533	D07425	EV1		PA164745550	4680	46508003	RxList Drug Page	7895	DAP000959	Papaverine	ZINC000000056555		Papaverine	Approved, Investigational	DB01113	InChI=1S/C20H21NO4/c1-22-17-6-5-13(10-18(17)23-2)9-16-15-12-20(25-4)19(24-3)11-14(15)7-8-21-16/h5-8,10-12H,9H2,1-4H3	XQYZDYMELSJDRZ-UHFFFAOYSA-N	4	Papaverine is an alkaloid used to treat many types of smooth muscle spasms such as "vascular spasms" associated with acute myocardial infarction and angina pectoris, as well as "visceral spasms".	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.9877 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3		226 (dec) °C			1	Yes	5	0	Yes	3	0	49.81 Å2	36.57 Å3	95.52 m3·mol-1	6	Yes	No	0.0129 mg/mL	3.08	-4.4		6.03			
C17H21NO4	Not Available	Not Available	303.3529	CC(CC1=CC=C(O)C=C1)NCC(O)C1=CC(O)=CC(O)=C1	Solid	Not Available					50131281	149226	CHEMBL32800	3226		GtP Drug Page	HMDB0015405		D04157			PA10079	3343	46509099		4333	DAP000946	Fenoterol			Fenoterol	Approved, Investigational	DB01288	InChI=1S/C17H21NO4/c1-11(6-12-2-4-14(19)5-3-12)18-10-17(22)13-7-15(20)9-16(21)8-13/h2-5,7-9,11,17-22H,6,10H2,1H3	LSLYOANBFKQKPT-UHFFFAOYSA-N	4	Fenoterol is a beta-2 adrenergic agonist and bronchodilator used for the symptomatic treatment of asthma.	Symptoms of overdose include angina (chest pain), dizziness, dry mouth, fatigue, flu-like symptoms, headache, heart irregularities, high or low blood pressure, high blood sugar, insomnia, muscle cramps, nausea, nervousness, rapid heartbeat, seizures, and tremor.	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1550 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							222-223			1	Yes	5	5	No	2	1	92.95 Å2	31.75 Å3	85 m3·mol-1	6	Yes	No	0.162 mg/mL	1.47	-3.3	8.85	9.63			
C20H27NO4	Not Available	Not Available	345.4327	COC1=C(OC)C=C(CCNCC(O)COC2=CC=CC(C)=C2)C=C1	Solid	Not Available	P10635	CYP2D6	1. Cytochrome P450 2D6			238698	CHEMBL314010	2282			HMDB0015409					PA164743236	2372	46506014			DAP000897	Bevantolol			Bevantolol	Experimental	DB01295	InChI=1S/C20H27NO4/c1-15-5-4-6-18(11-15)25-14-17(22)13-21-10-9-16-7-8-19(23-2)20(12-16)24-3/h4-8,11-12,17,21-22H,9-10,13-14H2,1-3H3	HXLAFSUPPDYFEO-UHFFFAOYSA-N			Not Available	Small Molecule	http://smpdb.ca/view/SMP0000668?highlight[compounds][]=DB01295&highlight[proteins][]=DB01295	Bevantolol Action Pathway		Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.0966 LD50, mol/kg	Non-inhibitor	Strong inhibitor	Inhibitor					3.00		137-138 °C			1	Yes	5	2	No	2	1	59.95 Å2	39.75 Å3	98.54 m3·mol-1	10	Yes	No	0.0137 mg/mL	3.03	-4.4	14.09	9.31	P08588;!P07550;!P35348	ADRB1;!ADRB2;!ADRA1A	1. Beta-1 adrenergic receptor;!2. Beta-2 adrenergic receptor;!3. Alpha-1A adrenergic receptor
C14H12O3	Not Available	Not Available	228.2433	COC1=CC(O)=C(C=C1)C(=O)C1=CC=CC=C1	Solid	Not Available					50253134	34283	CHEMBL1625	4471			HMDB0015497	C14285	D05309			PA164742933	4632	46508419		32673		Oxybenzone	ZINC000000136138	Meijer	Oxybenzone	Approved, Investigational	DB01428	InChI=1S/C14H12O3/c1-17-11-7-8-12(13(15)9-11)14(16)10-5-3-2-4-6-10/h2-9,15H,1H3	DXGLGDHPHMLXJC-UHFFFAOYSA-N	4	Oxybenzone is a sunscreen agent found in sunscreens that absorbs UV rays.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.6986 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				155 °C at 5.00E+00 mm Hg	3.79		65.5 °C			1	Yes	3	1	No	2	-1	46.53 Å2	23.96 Å3	65.08 m3·mol-1	3	Yes	No	0.128 mg/mL	3.62	-3.2	7.07	-4.8	P06401;!P10275;!P03372;!Q92731	PGR;!AR;!ESR1;!ESR2	1. Progesterone receptor;!2. Androgen receptor;!3. Estrogen receptor alpha;!4. Estrogen receptor beta
C21H16FNO7	Not Available	Not Available	413.3526	COC(=O)C1=C(O)C=CC=C1OC\C=C\C1=CC(C2=CC(=NO2)C(O)=O)=C(F)C=C1	Solid	Not Available					13990		CHEMBL117869	394932						234			447994	46506116					ZINC000002047375		5-(2-Fluoro-5-{(1E)-3-[3-hydroxy-2-(methoxycarbonyl)phenoxy]-1-propen-1-yl}phenyl)-1,2-oxazole-3-carboxylic acid	Experimental	DB02014	InChI=1S/C21H16FNO7/c1-28-21(27)19-16(24)5-2-6-17(19)29-9-3-4-12-7-8-14(22)13(10-12)18-11-15(20(25)26)23-30-18/h2-8,10-11,24H,9H2,1H3,(H,25,26)/b4-3+	QKHWJUMLYAYZFS-ONEGZZNKSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.4032 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	6	2	Yes	3	-1	119.09 Å2	40.09 Å3	105.01 m3·mol-1	8	Yes	No	0.0337 mg/mL	4.62	-4.1	3.9	-3.2			
C18H17NO4	Not Available	Not Available	311.3319	COC1=CC(OC)=C(\C=C2\C(=O)NC3=CC=CC=C23)C(OC)=C1	Solid	Not Available					50263829		CHEMBL489156	4450729						IC1			5288600	46509166					ZINC000000136945		IC261	Experimental	DB03083	InChI=1S/C18H17NO4/c1-21-11-8-16(22-2)14(17(9-11)23-3)10-13-12-6-4-5-7-15(12)19-18(13)20/h4-10H,1-3H3,(H,19,20)/b13-10+	JBJYTZXCZDNOJW-JLHYYAGUSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.7309 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	1	No	3	0	56.79 Å2	32.57 Å3	89.12 m3·mol-1	4	Yes	No	0.0104 mg/mL	2.79	-4.5	11.31	-2	P78368	CSNK1G2	1. Casein kinase I isoform gamma-2
C15H12O4	Not Available	Not Available	256.2534	OC1=CC=C(\C=C\C(=O)C2=C(O)C=C(O)C=C2)C=C1	Solid	Not Available					50042944	310312	CHEMBL129795	553829			HMDB0037316	C08650		HCC			638278	46506198				Isoliquiritigenin	ZINC000003869608		Isoliquiritigenin	Experimental	DB03285	InChI=1S/C15H12O4/c16-11-4-1-10(2-5-11)3-8-14(18)13-7-6-12(17)9-15(13)19/h1-9,16-17,19H/b8-3+	DXDRHHKMWQZJHT-FPYGCLRLSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.0091 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	3	No	2	-1	77.76 Å2	26.66 Å3	72.82 m3·mol-1	3	Yes	No	0.0551 mg/mL	3.63	-3.7	7.11	-6.4			
C9H10O2	Not Available	Not Available	150.1745	COC1=C(O)C=CC(C=C)=C1	Solid	Not Available						42438	CHEMBL1232595	325			HMDB0013744	C17883		4M4			332	46506755				2-Methoxy-4-vinylphenol	ZINC000001849800		4-Vinylguaiacol	Experimental	DB03514	InChI=1S/C9H10O2/c1-3-7-4-5-8(10)9(6-7)11-2/h3-6,10H,1H2,2H3	YOMSJEATGXXYPX-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.0980 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	2	1	No	1	0	29.46 Å2	15.99 Å3	44.19 m3·mol-1	2	Yes	Yes	7.42 mg/mL	2.25	-1.3	10.03	-4.9			
C24H24O4	Not Available	Not Available	376.445	CC1=CC(OCC(O)=O)=CC(C)=C1CC1=CC=C(O)C(CC2=CC=CC=C2)=C1	Solid	Not Available								394946						G24			448011	46504743							GC-24	Experimental	DB03788	InChI=1S/C24H24O4/c1-16-10-21(28-15-24(26)27)11-17(2)22(16)14-19-8-9-23(25)20(13-19)12-18-6-4-3-5-7-18/h3-11,13,25H,12,14-15H2,1-2H3,(H,26,27)	JYHIGYLGYNCMGI-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1148 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	2	Yes	3	-1	66.76 Å2	41.06 Å3	110.14 m3·mol-1	7	No	No	0.000404 mg/mL	6.2	-6	3.92	-4.9	P10828	THRB	1. Thyroid hormone receptor beta
C20H22O6	Not Available	Not Available	358.3851	[H][C@]1(CC2=CC=C(O)C(OC)=C2)COC(=O)[C@]1([H])CC1=CC=C(O)C(OC)=C1	Solid	Not Available					50240921	6698	CHEMBL425148	106491			HMDB0035698	C10682		MAX			119205	46507098				Matairesinol	ZINC000001595957		Matairesinol	Experimental	DB04200	InChI=1S/C20H22O6/c1-24-18-9-12(3-5-16(18)21)7-14-11-26-20(23)15(14)8-13-4-6-17(22)19(10-13)25-2/h3-6,9-10,14-15,21-22H,7-8,11H2,1-2H3/t14-,15+/m0/s1	MATGKVZWFZHCLI-LSDHHAIUSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	2.4961 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	2	Yes	3	0	85.22 Å2	36.86 Å3	95.63 m3·mol-1	6	Yes	No	0.0121 mg/mL	3.29	-4.5	9.64	-4.6	Q6PKH6	DHRS4L2	1. Dehydrogenase/reductase SDR family member 4-like 2
C10H12O5	Not Available	Not Available	212.1993	COC1=CC(\C=C\C(O)O)=CC(O)=C1O	Solid	Not Available								4450689						HFL			5288545	46506497					ZINC000008206678		5-(3,3-Dihydroxypropeny)-3-Methoxy-Benzene-1,2-Diol	Experimental	DB04449	InChI=1S/C10H12O5/c1-15-8-5-6(2-3-9(12)13)4-7(11)10(8)14/h2-5,9,11-14H,1H3/b3-2+	QQVLKPZAOPJJCB-NSCUHMNNSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.9800 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	4	No	1	0	90.15 Å2	21.07 Å3	54.65 m3·mol-1	3	Yes	No	2.54 mg/mL	0.69	-1.9	9.46	-3.9			
C15H12O3	Not Available	Not Available	240.254	OC1=CC=C(C=C1)C1=CC2=C(OC1)C=C(O)C=C2	Solid	Not Available					50419932		CHEMBL1957038	189918									219100	175426901					ZINC000001491943		Idronoxil	Investigational	DB04915	InChI=1S/C15H12O3/c16-13-4-1-10(2-5-13)12-7-11-3-6-14(17)8-15(11)18-9-12/h1-8,16-17H,9H2	ZZUBHVMHNVYXRR-UHFFFAOYSA-N	3		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.9655 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	2	No	3	0	49.69 Å2	25.76 Å3	69.73 m3·mol-1	1	Yes	No	0.0693 mg/mL	3.09	-3.5	8.63	-4.9	Q16206	ENOX2	1. Ecto-NOX disulfide-thiol exchanger 2
C20H26N2O4	Not Available	Not Available	358.4314	COC1=CC=C(C=C1OC)C(=O)NCC1=CC=C(OCCN(C)C)C=C1	Solid	Not Available						94809	CHEMBL2107457	3660								PA152432599	3792	175426905				Itopride	ZINC000000537874		Itopride	Investigational	DB04924	InChI=1S/C20H26N2O4/c1-22(2)11-12-26-17-8-5-15(6-9-17)14-21-20(23)16-7-10-18(24-3)19(13-16)25-4/h5-10,13H,11-12,14H2,1-4H3,(H,21,23)	QQQIECGTIMUVDS-UHFFFAOYSA-N	4	Itopride is an acetylcholine esterase inhibitor and dopamine D2 receptor antagonist used to treat symptoms of functional dyspepsia such as nausea and vomiting.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.3307 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	1	No	2	1	60.03 Å2	40.58 Å3	102.05 m3·mol-1	9	Yes	No	0.0261 mg/mL	2.32	-4.1	14.71	8.77	P14416;!P22303	DRD2;!ACHE	1. Dopamine D2 receptor;!2. Acetylcholinesterase
C18H22O12P2	Not Available	Not Available	492.31	[H]\C(=C(/[H])C1=C(OP(O)(O)=O)C(OP(O)(O)=O)=C(OC)C=C1)C1=CC(OC)=C(OC)C(OC)=C1	Solid	Not Available					50236033		CHEMBL1205402	5293743									6918546	175426952					ZINC000003994214		OXI-4503	Investigational	DB05143	InChI=1S/C18H22O12P2/c1-25-13-8-7-12(16(29-31(19,20)21)18(13)30-32(22,23)24)6-5-11-9-14(26-2)17(28-4)15(10-11)27-3/h5-10H,1-4H3,(H2,19,20,21)(H2,22,23,24)/b6-5-	GSOXMQLWUDQTNT-WAYWQWQTSA-N	1		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Non-substrate	2.6950 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	10	4	No	2	-4	170.44 Å2	43.31 Å3	113.07 m3·mol-1	10	Yes	No	0.0268 mg/mL	1.77	-4.3	1.31	-4.3			
C22H24O4S	Not Available	Not Available	384.49	CSC1=CC=C(C=C1)C(=O)\C=C\C1=CC(C)=C(OC(C)(C)C(O)=O)C(C)=C1	Solid	Not Available							CHEMBL3707395	8040573									9864881	347827716				Elafibranor	ZINC000114643710		Elafibranor	Investigational	DB05187	InChI=1S/C22H24O4S/c1-14-12-16(13-15(2)20(14)26-22(3,4)21(24)25)6-11-19(23)17-7-9-18(27-5)10-8-17/h6-13H,1-5H3,(H,24,25)/b11-6+	AFLFKFHDSCQHOL-IZZDOVSWSA-N	2		Not Available	Small Molecule																																			1	No	4	1	No	2	-1	63.6 Å2	43.14 Å3	111.47 m3·mol-1	7	No	No	0.000228 mg/mL	5.87	-6.2	4	-4.9	Q07869;!Q03181;!P37231	PPARA;!PPARD;!PPARG	1. Peroxisome proliferator-activated receptor alpha;!2. Peroxisome proliferator-activated receptor delta;!3. Peroxisome proliferator-activated receptor gamma
C27H30O6	Not Available	Not Available	450.5235	CC(C)=CCOC1=CC=C(\C=C\C(=O)C2=C(OCC(O)=O)C=C(OCC=C(C)C)C=C2)C=C1	Solid	Not Available	P16152	CBR1	1. Carbonyl reductase [NADPH] 1				CHEMBL1441961	4445402			HMDB0042013						5282219	175426956				Sofalcone	ZINC000003831462		Sofalcone	Investigational	DB05197	InChI=1S/C27H30O6/c1-19(2)13-15-31-22-8-5-21(6-9-22)7-12-25(28)24-11-10-23(32-16-14-20(3)4)17-26(24)33-18-27(29)30/h5-14,17H,15-16,18H2,1-4H3,(H,29,30)/b12-7+	GFWRVVCDTLRWPK-KPKJPENVSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.6850 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	6	1	No	2	-1	82.06 Å2	51.22 Å3	130.59 m3·mol-1	12	No	No	0.000674 mg/mL	5.62	-5.8	3.22	-4.4			
C18H22O6	Not Available	Not Available	334.3637	COC1=CC(=CC(OC)=C1OC)[C@@H](O)CC1=CC(O)=C(OC)C=C1	Solid	Not Available								90508									100154	175426964				Combretastatin			CA4P	Investigational	DB05284	InChI=1S/C18H22O6/c1-21-15-6-5-11(8-14(15)20)7-13(19)12-9-16(22-2)18(24-4)17(10-12)23-3/h5-6,8-10,13,19-20H,7H2,1-4H3/t13-/m0/s1	LGZKGOGODCLQHG-ZDUSSCGKSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	2.5923 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	6	2	No	2	0	77.38 Å2	34.48 Å3	89.75 m3·mol-1	7	Yes	No	0.0545 mg/mL	2.34	-3.8	9.99	-3.1	P07437	TUBB	1. Tubulin beta chain
C23H24O6	Not Available	Not Available	396.439	COC1=CC=C(\C=C\C(\O)=C\C(=O)\C=C\C2=CC(OC)=C(OC)C=C2)C=C1OC	Solid	Not Available							CHEMBL128748	4978553														Dimethylcurcumin	ZINC000100007120		Dimethylcurcumin	Investigational	DB06133	InChI=1S/C23H24O6/c1-26-20-11-7-16(13-22(20)28-3)5-9-18(24)15-19(25)10-6-17-8-12-21(27-2)23(14-17)29-4/h5-15,24H,1-4H3/b9-5+,10-6+,18-15-	ZMGUKFHHNQMKJI-CIOHCNBKSA-N	2		Not Available	Small Molecule																																			1	Yes	6	1	No	2	0	74.22 Å2	44.04 Å3	115.09 m3·mol-1	9	Yes	No	0.00141 mg/mL	4.05	-5.4	9.04	-4.3	P10275	AR	1. Androgen receptor
C29H30O8	Not Available	Not Available	506.551	CCCOC1=CC=C2[C@@H]([C@H]([C@@H](C2=C1)C1=CC=C(OC)C=C1OCCO)C(O)=O)C1=CC=C2OCOC2=C1	Solid	Not Available					50061077		CHEMBL431651	155044															ZINC000003825437		Enrasentan	Investigational	DB06460	InChI=1S/C29H30O8/c1-3-11-34-19-6-7-20-22(14-19)27(21-8-5-18(33-2)15-24(21)35-12-10-30)28(29(31)32)26(20)17-4-9-23-25(13-17)37-16-36-23/h4-9,13-15,26-28,30H,3,10-12,16H2,1-2H3,(H,31,32)/t26-,27+,28+/m0/s1	GLCKXJLCYIJMRB-UPRLRBBYSA-N			Not Available	Small Molecule																																			1	No	8	2	Yes	5	-1	103.68 Å2	53.64 Å3	135.19 m3·mol-1	10	No	No	0.00434 mg/mL	4.38	-5.1	3.71	-2.8	P25101;!P24530	EDNRA;!EDNRB	1. Endothelin-1 receptor;!2. Endothelin B receptor
C22H20O4	Not Available	Not Available	348.398	COC1=CC=C(C=C1)[C@@H]1[C@@H](COC2=CC(O)=CC=C12)C1=CC=C(O)C=C1	Solid	Not Available								32698072																	Triphendiol	Investigational	DB06588	InChI=1S/C22H20O4/c1-25-18-9-4-15(5-10-18)22-19-11-8-17(24)12-21(19)26-13-20(22)14-2-6-16(23)7-3-14/h2-12,20,22-24H,13H2,1H3/t20-,22-/m0/s1	KQCJZAUNKSGEFM-UNMCSNQZSA-N			Not Available	Small Molecule																																			1	Yes	4	2	No	4	0	58.92 Å2	36.72 Å3	100.07 m3·mol-1	3	Yes	No	0.0071 mg/mL	4.45	-4.7	9.5	-4.5			
C18H27NO3	Not Available	Following oral ingestion of equipotent dose of 26.6 mg of pure capsaicin, the half life was approximately 24.9 ± 5.0 min 4. Following topical application of 3% solution of capsaicin, the half-life of capsaicin was approximately 24 h 4. The mean population elimination half-life was 1.64 h following application of a topical patch containing 179 mg of capsaicin 4.	305.4119	COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1	Solid	Not Available	P08684;!P35354;!P05164;!P05177;!P05181;!P21397;!P09172;!P15104;!P06276	CYP3A4;!PTGS2;!MPO;!CYP1A2;!CYP2E1;!MAOA;!DBH;!GLUL;!BCHE	1. Cytochrome P450 3A4;!2. Prostaglandin G/H synthase 2;!3. Myeloperoxidase;!4. Cytochrome P450 1A2;!5. Cytochrome P450 2E1;!6. Amine oxidase [flavin-containing] A;!7. Dopamine beta-hydroxylase;!8. Glutamine synthetase;!9. Cholinesterase		20461	3374	CHEMBL294199	1265957	Drugs.com Drug Page		HMDB0002227	C06866	D00250	4DY			1548943	347827793	RxList Drug Page	1992		Capsaicin	ZINC000001530575	Capzasin Quick Relief, Capzasin-HP, Castiva Warming, Dendracin Neurodendraxcin, Lidopro, Medi-derm, Medi-derm With Lidocaine, Medrox, Qutenza, Rematex, Xoten-C, Zostrix	Capsaicin	Approved	DB06774	InChI=1S/C18H27NO3/c1-14(2)8-6-4-5-7-9-18(21)19-13-15-10-11-16(20)17(12-15)22-3/h6,8,10-12,14,20H,4-5,7,9,13H2,1-3H3,(H,19,21)/b8-6+	YKPUWZUDDOIDPM-SOFGYWHQSA-N	4	Capsaicin is a topical analgesic agent used for the symptomatic relief of neuropathic pain associated with post-herpetic neuralgia, as well as other muscle and joint pain.	Acute oral LD50 and dermal LD50 in mouse are 47.2 mg/kg and >512 mg/kg, respectively MSDS. Capsaicin is shown to be mutagenic for bacteria and yeast MSDS.Capsaicin can cause serious irritation, conjunctivitis and lacrimation via contact with eyes. It induces a burning sensation and pain in case of contact with eyes and skin. As it is also irritating to the respiratory system, it causes lung irritation and coughing as well as bronchoconstriction. Other respiratory effects include laryngospasm, swelling of the larynx and lungs, chemical pneumonitis,respiratory arrest and central nervous system effects such as convulsions and excitement 5. In case of ingestion, gastrointestinal tract irritation may be observed along with a sensation of warmth or painful burning MSDS. Symptoms of systemic toxicity include disorientation, fear, loss of body motor control including diminished hand-eye coordination, hyperventilation, tachycardia, and pulmonary oedema 5. Careful early decontamination is recommended and medical intervention should be initiated for any life-threatening symptoms. In case of contact, individual must be removed from the source of exposure and the contacted skin and mucous membranes should be thoroughly washed with copious amounts of water 5.	Small Molecule																													210-220			65		Insoluble in cold water	1	Yes	3	2	No	1	0	58.56 Å2	36.32 Å3	90.32 m3·mol-1	9	Yes	No		3.75		9.93	-1.4			
C15H12Br2N2O4	Not Available	Not Available	444.075	COC1=CC=C(C=C1)C(=O)N\N=C\C1=CC(Br)=C(O)C(Br)=C1O	Solid	Not Available					31931		CHEMBL492514	21824324						2RB			16475583	99443449					ZINC000009190152		N'-[(1E)-(3,5-dibromo-2,4-dihydroxyphenyl)methylidene]-4-methoxybenzohydrazide	Experimental	DB06978	InChI=1S/C15H12Br2N2O4/c1-23-10-4-2-8(3-5-10)15(22)19-18-7-9-6-11(16)14(21)12(17)13(9)20/h2-7,20-21H,1H3,(H,19,22)/b18-7+	BMGXNERTVNWBJG-CNHKJKLMSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.4245 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	3	No	2	-1	91.15 Å2	36.36 Å3	93.91 m3·mol-1	4	Yes	No	0.0251 mg/mL	3.74	-4.2	6.44	0.011	Q5G940	fabZ	1. 3-hydroxyacyl-[acyl-carrier-protein] dehydratase FabZ
C20H16N2O3	Not Available	Not Available	332.3526	COC1=CC(=CC=C1O)C1=CC2=C(C=C1)\C(=C\C1=CC=CN1)C(=O)N2	Solid	Not Available					14649		CHEMBL202930	8301349						43A			10125830	99443549					ZINC000014956244		(3Z)-6-(4-HYDROXY-3-METHOXYPHENYL)-3-(1H-PYRROL-2-YLMETHYLENE)-1,3-DIHYDRO-2H-INDOL-2-ONE	Experimental	DB07078	InChI=1S/C20H16N2O3/c1-25-19-10-13(5-7-18(19)23)12-4-6-15-16(11-14-3-2-8-21-14)20(24)22-17(15)9-12/h2-11,21,23H,1H3,(H,22,24)/b16-11-	AYSXURJZVXBSRV-WJDWOHSUSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	2.8881 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	3	No	4	0	74.35 Å2	36.55 Å3	97.95 m3·mol-1	3	Yes	No	0.0458 mg/mL	3.45	-3.9	9.82	-2.1	O14757	CHEK1	1. Serine/threonine-protein kinase Chk1
C10H10O4	Not Available	Not Available	194.184	COC1=C(O)C=C(\C=C\C(O)=O)C=C1	Solid	Not Available					50241245	27794	CHEMBL233295	643318			HMDB0000955	C10470		4FE			736186	99443580				Isoferulic_acid	ZINC000000156055		Isoferulic acid	Experimental	DB07109	InChI=1S/C10H10O4/c1-14-9-4-2-7(6-8(9)11)3-5-10(12)13/h2-6,11H,1H3,(H,12,13)/b5-3+	QURCVMIEKCOAJU-HWKANZROSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.4314 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	2	No	1	-1	66.76 Å2	19.36 Å3	51.5 m3·mol-1	3	Yes	No	0.871 mg/mL	1.67	-2.4	3.58	-4.9	Q55813	Not Available	1. O-methyltransferase
C17H20O2	Not Available	Not Available	256.3395	CCCCCC1=CC(O)=C(OC2=CC=CC=C2)C=C1	Solid	Not Available					16296		CHEMBL1224745	4439178						5PP			5274976	99443649					ZINC000014961108		5-PENTYL-2-PHENOXYPHENOL	Experimental	DB07178	InChI=1S/C17H20O2/c1-2-3-5-8-14-11-12-17(16(18)13-14)19-15-9-6-4-7-10-15/h4,6-7,9-13,18H,2-3,5,8H2,1H3	OJLYTHOKCYLPMA-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	1.9572 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	1	1	No	2	0	29.46 Å2	29.82 Å3	77.72 m3·mol-1	6	No	Yes	0.0109 mg/mL	5.46	-4.4	8.53	-3.7			
C25H22N2O4	Not Available	Not Available	414.4532	COC1=C(OC)C=C2C(OC3=CC4=CC=CC(C(=O)NC5CC5)=C4C=C3)=CC=NC2=C1	Solid	Not Available					50236856		CHEMBL272198	9616239						887			11441375	99443745					ZINC000016052729		N-cyclopropyl-6-[(6,7-dimethoxyquinolin-4-yl)oxy]naphthalene-1-carboxamide	Experimental	DB07274	InChI=1S/C25H22N2O4/c1-29-23-13-20-21(14-24(23)30-2)26-11-10-22(20)31-17-8-9-18-15(12-17)4-3-5-19(18)25(28)27-16-6-7-16/h3-5,8-14,16H,6-7H2,1-2H3,(H,27,28)	ZATGFXTWDKIEKC-UHFFFAOYSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.4595 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	1	Yes	5	0	69.68 Å2	44.58 Å3	116.78 m3·mol-1	6	Yes	No	0.0018 mg/mL	3.85	-5.4	15.5	5.89			
C20H24O4	Not Available	Not Available	328.4022	CC(C)C1=C(O)C=CC(CC2=C(C)C=C(OCC(O)=O)C=C2C)=C1	Solid	Not Available					50115668	79988	CHEMBL107400	8037944		GtP Drug Page		C15618		B72			9862248	99443896					ZINC000013475083		Sobetirome	Investigational	DB07425	InChI=1S/C20H24O4/c1-12(2)17-9-15(5-6-19(17)21)10-18-13(3)7-16(8-14(18)4)24-11-20(22)23/h5-9,12,21H,10-11H2,1-4H3,(H,22,23)	QNAZTOHXCZPOSA-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1625 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	2	No	2	-1	66.76 Å2	36.4 Å3	94.6 m3·mol-1	6	No	No	0.00261 mg/mL	5.35	-5.1	3.93	-4.9			
C14H15NO2	Not Available	Not Available	229.2744	COC1=C(OCC2=NC=CC=C2)C=C(C)C=C1	Solid	Not Available								25057637						B77			44129642	99443898					ZINC000053683040		2-[(2-methoxy-5-methylphenoxy)methyl]pyridine	Experimental	DB07427	InChI=1S/C14H15NO2/c1-11-6-7-13(16-2)14(9-11)17-10-12-5-3-4-8-15-12/h3-9H,10H2,1-2H3	AVXQTLSOXWQOHO-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.1144 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	0	No	2	0	31.35 Å2	25.32 Å3	65.96 m3·mol-1	4	Yes	Yes	0.892 mg/mL	2.76	-2.4		3.78	P69905;!P68871	HBA1;!HBB	1. Hemoglobin subunit alpha;!2. Hemoglobin subunit beta
C14H15NO2	Not Available	Not Available	229.2744	COC1=CC(OCC2=CC=NC=C2)=C(C)C=C1	Solid	Not Available								25057638						B78			46937073	99443899					ZINC000053683042		4-[(5-methoxy-2-methylphenoxy)methyl]pyridine	Experimental	DB07428	InChI=1S/C14H15NO2/c1-11-3-4-13(16-2)9-14(11)17-10-12-5-7-15-8-6-12/h3-9H,10H2,1-2H3	MBHBRRBLXCXQKV-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.9415 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	0	No	2	0	31.35 Å2	25.1 Å3	66.48 m3·mol-1	4	Yes	Yes	0.69 mg/mL	2.68	-2.5		4.99	P69905;!P68871	HBA1;!HBB	1. Hemoglobin subunit alpha;!2. Hemoglobin subunit beta
C21H22O4	Not Available	Not Available	338.397	COC1=CC(O)=C(C=C1CC=C(C)C)C(=O)\C=C\C1=CC=C(O)C=C1	Solid	Not Available					246523			4479431						BVL			5321765	99443971					ZINC000019816069		(2E)-1-[2-hydroxy-4-methoxy-5-(3-methylbut-2-en-1-yl)phenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one	Experimental	DB07500	InChI=1S/C21H22O4/c1-14(2)4-8-16-12-18(20(24)13-21(16)25-3)19(23)11-7-15-5-9-17(22)10-6-15/h4-7,9-13,22,24H,8H2,1-3H3/b11-7+	ZUGCRBMNFSAUOC-YRNVUSSQSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.2755 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	2	No	2	-1	66.76 Å2	37.26 Å3	101.54 m3·mol-1	6	No	No	0.00322 mg/mL	5.5	-5	7.07	-4.9	Q9NZK7	PLA2G2E	1. Group IIE secretory phospholipase A2
C18H17NO5	Not Available	Not Available	327.3313	COC1=CC=C(\C=C\C(=O)NC2=CC=CC=C2C(O)=O)C=C1OC	Solid	Not Available	P08684;!P11712	CYP3A4;!CYP2C9	1. Cytochrome P450 3A4;!2. Cytochrome P450 2C9		21613	77572	CHEMBL415324	4445411					D02027	D27			5282230	99444086		57330		Tranilast	ZINC000000000797		Tranilast	Investigational	DB07615	InChI=1S/C18H17NO5/c1-23-15-9-7-12(11-16(15)24-2)8-10-17(20)19-14-6-4-3-5-13(14)18(21)22/h3-11H,1-2H3,(H,19,20)(H,21,22)/b10-8+	NZHGWWWHIYHZNX-CSKARUKUSA-N	4		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.4428 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	2	No	2	-1	84.86 Å2	34.2 Å3	91.52 m3·mol-1	6	Yes	No	0.0084 mg/mL	3.56	-4.6	3.55	-2			
C10H10O4	Not Available	Not Available	194.184	COC1=CC(\C=C\C(O)=O)=CC=C1O	Solid	Not Available					50214744	17620	CHEMBL32749	393368			HMDB0000954	C01494		FER			445858	99444238		1368647		Ferulic_acid	ZINC000000058258		Ferulic acid	Experimental	DB07767	InChI=1S/C10H10O4/c1-14-9-6-7(2-4-8(9)11)3-5-10(12)13/h2-6,11H,1H3,(H,12,13)/b5-3+	KSEBMYQBYZTDHS-HWKANZROSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.4314 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	2	No	1	-1	66.76 Å2	19.18 Å3	51.5 m3·mol-1	3	Yes	No	0.906 mg/mL	1.67	-2.3	3.58	-4.9	P51584;!P10478;!D2YW37;!Q55813	xynY;!xynZ;!Not Available;!Not Available	1. Endo-1,4-beta-xylanase Y;!2. Endo-1,4-beta-xylanase Z;!3. Est1e;!4. O-methyltransferase
C15H14O5	Not Available	Not Available	274.2687	OC1=CC=C(CCC(=O)C2=C(O)C=C(O)C=C2O)C=C1	Solid	Not Available					23446	17276	CHEMBL45068	4624		GtP Drug Page	HMDB0003306	C00774		G50			4788	99444281		1368167		Phloretin	ZINC000000047553		Phloretin	Experimental	DB07810	InChI=1S/C15H14O5/c16-10-4-1-9(2-5-10)3-6-12(18)15-13(19)7-11(17)8-14(15)20/h1-2,4-5,7-8,16-17,19-20H,3,6H2	VGEREEWJJVICBM-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.0976 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	4	No	2	0	97.99 Å2	27.75 Å3	73.71 m3·mol-1	4	Yes	No	0.132 mg/mL	3.9	-3.3	7.96	-4.6	Q9AIU0	ttgR	1. HTH-type transcriptional regulator TtgR
C22H18O7	Not Available	Not Available	394.3741	[H][C@]12O[C@]([H])(C(C(=O)OC)=C1C(=O)OC)C(=C2C1=CC=C(O)C=C1)C1=CC=C(O)C=C1	Solid	Not Available							CHEMBL1213270	9706091						HZ3			11531308	99444403					ZINC000016052474		dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate	Experimental	DB07932	InChI=1S/C22H18O7/c1-27-21(25)17-18(22(26)28-2)20-16(12-5-9-14(24)10-6-12)15(19(17)29-20)11-3-7-13(23)8-4-11/h3-10,19-20,23-24H,1-2H3/t19-,20+	CRLQCBACIMUGDZ-BGYRXZFFSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	2.9210 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	2	Yes	4	-1	102.29 Å2	39.94 Å3	103.3 m3·mol-1	6	Yes	No	0.00942 mg/mL	3.01	-4.6	5.87	-4.3	P03372;!Q15596	ESR1;!NCOA2	1. Estrogen receptor alpha;!2. Nuclear receptor coactivator 2
C19H16N2O4	Not Available	Not Available	336.3413	COC1=C(\C=N\NC(=O)C2=CC(O)=C(O)C=C2)C2=CC=CC=C2C=C1	Solid	Not Available					33953			7838983						K05			9562794	99444505					ZINC000000074303		(E)-3,4-DIHYDROXY-N'-[(2-METHOXYNAPHTHALEN-1-YL)METHYLENE]BENZOHYDRAZIDE	Experimental	DB08034	InChI=1S/C19H16N2O4/c1-25-18-9-7-12-4-2-3-5-14(12)15(18)11-20-21-19(24)13-6-8-16(22)17(23)10-13/h2-11,22-23H,1H3,(H,21,24)/b20-11+	TVOPERZEGKBKAY-RGVLZGJSSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	-	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.2049 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	3	No	3	0	91.15 Å2	35.06 Å3	95.11 m3·mol-1	4	Yes	No	0.0136 mg/mL	3.19	-4.4	8.33	0.89	P03366	gag-pol	1. Gag-Pol polyprotein
C16H16O	Not Available	Not Available	224.2976	CC1=CC(\C=C\C2=CC=CC=C2)=CC(C)=C1O	Solid	Not Available					50012798		CHEMBL55960	4896100						LJ1			6365297	99444571					ZINC000029548831		2,6-dimethyl-4-[(E)-2-phenylethenyl]phenol	Experimental	DB08100	InChI=1S/C16H16O/c1-12-10-15(11-13(2)16(12)17)9-8-14-6-4-3-5-7-14/h3-11,17H,1-2H3/b9-8+	PAHKYLUYTGBFNW-CMDGGOBGSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.0605 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	1	1	No	2	0	20.23 Å2	26.85 Å3	73.58 m3·mol-1	2	No	Yes	0.00429 mg/mL	5.04	-4.7	9.72	-6.4			
C15H14N2O5	Not Available	Not Available	302.2821	COC1=CC(=CC(OC)=C1O)\N=N\C1=CC=CC=C1C(O)=O	Solid	Not Available								25058737						MOB			6288148	99444667					ZINC000038311600		2-((3',5'-DIMETHOXY-4'-HYDROXYPHENYL)AZO)BENZOIC ACID	Experimental	DB08196	InChI=1S/C15H14N2O5/c1-21-12-7-9(8-13(22-2)14(12)18)16-17-11-6-4-3-5-10(11)15(19)20/h3-8,18H,1-2H3,(H,19,20)/b17-16+	OUUSCQGLQHBVJX-WUKNDPDISA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.1782 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	7	2	No	2	-1	100.71 Å2	30.19 Å3	82.54 m3·mol-1	5	Yes	No	0.0805 mg/mL	3.42	-3.6	3.36	-0.48	P22629	Not Available	1. Streptavidin
C23H20O10	Not Available	Not Available	456.3989	[H][C@@](CC(O)=O)(OC(=O)\C=C\C1=CC=C(O)C=C1)[C@@]([H])(OC(=O)\C=C\C1=CC=C(O)C=C1)C(O)=O	Solid	Not Available					50430005		CHEMBL1234956	9844429						OFF			11669698	99444793					ZINC000013339564		2-DEOXY-3,4-BIS-O-[3-(4-HYDROXYPHENYL)PROPANOYL]-L-THREO-PENTARIC ACID	Experimental	DB08322	InChI=1S/C23H20O10/c24-16-7-1-14(2-8-16)5-11-20(28)32-18(13-19(26)27)22(23(30)31)33-21(29)12-6-15-3-9-17(25)10-4-15/h1-12,18,22,24-25H,13H2,(H,26,27)(H,30,31)/b11-5+,12-6+/t18-,22+/m0/s1	VJLMRHSHSNLOGC-NOPZTHQXSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.7184 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	8	4	No	2	-2	167.66 Å2	44.3 Å3	113.93 m3·mol-1	12	Yes	No	0.0287 mg/mL	3.72	-4.2	3.17	-6	P11217	PYGM	1. Glycogen phosphorylase, muscle form
C14H12O4	Not Available	Not Available	244.246	OC1=CC(\C=C\C2=CC=C(O)C(O)=C2)=CC(O)=C1	Solid	Not Available					50045936	28814	CHEMBL69863	581006			HMDB0004215	C05901		PIT			667639	99444870				Piceatannol	ZINC000000014036		Piceatannol	Experimental	DB08399	InChI=1S/C14H12O4/c15-11-5-10(6-12(16)8-11)2-1-9-3-4-13(17)14(18)7-9/h1-8,15-18H/b2-1+	CDRPUGZCRXZLFL-OWOJBTEDSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Inhibitor	Non-inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.8860 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	4	No	2	0	80.92 Å2	25.46 Å3	69.44 m3·mol-1	2	Yes	No	0.097 mg/mL	3.1	-3.4	8.41	-6.2	P25705;!P06576;!P36542	ATP5A1;!ATP5B;!ATP5C1	1. ATP synthase subunit alpha, mitochondrial;!2. ATP synthase subunit beta, mitochondrial;!3. ATP synthase subunit gamma, mitochondrial
C20H23NO4	Not Available	Not Available	341.4009	CC1=CC(NC(=O)CC2=CC=C(OC(C)(C)C(O)=O)C=C2)=CC(C)=C1	Solid	Not Available							CHEMBL18901	109085						RQ3			122335	99444957				Efaproxiral	ZINC000001481819		Efaproxiral	Investigational	DB08486	InChI=1S/C20H23NO4/c1-13-9-14(2)11-16(10-13)21-18(22)12-15-5-7-17(8-6-15)25-20(3,4)19(23)24/h5-11H,12H2,1-4H3,(H,21,22)(H,23,24)	BNFRJXLZYUTIII-UHFFFAOYSA-N	3		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3549 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	2	No	2	-1	75.63 Å2	37.38 Å3	97.48 m3·mol-1	6	Yes	No	0.0027 mg/mL	4.39	-5.1	3.56	-4.7	P69905;!P68871	HBA1;!HBB	1. Hemoglobin subunit alpha;!2. Hemoglobin subunit beta
C11H12O5	Not Available	Not Available	224.21	COC1=CC(\C=C\C(O)=O)=CC(OC)=C1O	Solid	Not Available					50341142	15714	CHEMBL109341	553361			HMDB0032616	C00482		SXX			637775	99445058				Sinapinic_acid	ZINC000000153654		Sinapic acid	Experimental	DB08587	InChI=1S/C11H12O5/c1-15-8-5-7(3-4-10(12)13)6-9(16-2)11(8)14/h3-6,14H,1-2H3,(H,12,13)/b4-3+	PCMORTLOPMLEFB-ONEGZZNKSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.2035 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	2	No	1	-1	75.99 Å2	22.32 Å3	57.97 m3·mol-1	4	Yes	No	0.631 mg/mL	1.52	-2.6	3.41	-4.6	P51584	xynY	1. Endo-1,4-beta-xylanase Y
C9H10O4	Not Available	Not Available	182.1733	COC(=O)C1=CC(OC)=C(O)C=C1	Solid	Not Available						46477	CHEMBL486214	18693			HMDB0240266			VXX			19844	99445182				Methyl_group	ZINC000000388238		Methyl vanillate	Experimental	DB08711	InChI=1S/C9H10O4/c1-12-8-5-6(9(11)13-2)3-4-7(8)10/h3-5,10H,1-2H3	BVWTXUYLKBHMOX-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.3185 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	1	No	1	0	55.76 Å2	18.09 Å3	46.53 m3·mol-1	3	Yes	No	3.57 mg/mL	1.52	-1.7	9	-4.9	P51584	xynY	1. Endo-1,4-beta-xylanase Y
C21H21NO5	Not Available	Not Available	367.3951	CC(=O)OC1=CC=C(\C=C\C(=O)NCCC2=CC=CC=C2)C=C1OC(C)=O	Solid	Not Available								10131649						Y12			11957394	99445224					ZINC000016051983		4-{(1E)-3-OXO-3-[(2-PHENYLETHYL)AMINO]PROP-1-EN-1-YL}-1,2-PHENYLENE DIACETATE	Experimental	DB08753	InChI=1S/C21H21NO5/c1-15(23)26-19-10-8-18(14-20(19)27-16(2)24)9-11-21(25)22-13-12-17-6-4-3-5-7-17/h3-11,14H,12-13H2,1-2H3,(H,22,25)/b11-9+	GARHCDOTUULBOQ-PKNBQFBNSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.0392 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	1	No	2	0	81.7 Å2	39.39 Å3	101.41 m3·mol-1	9	Yes	No	0.000717 mg/mL	2.78	-5.7	15.17	-0.39	Q672W7	def	1. Peptide deformylase
C17H17NO4	Not Available	Not Available	299.3212	OC1=CC=C(CCNC(=O)\C=C\C2=CC(O)=C(O)C=C2)C=C1	Solid	Not Available							CHEMBL206646	8170478			HMDB0033026			Y13			9994897	99445225					ZINC000013515185		N-Caffeoyltyramine	Experimental	DB08754	InChI=1S/C17H17NO4/c19-14-5-1-12(2-6-14)9-10-18-17(22)8-4-13-3-7-15(20)16(21)11-13/h1-8,11,19-21H,9-10H2,(H,18,22)/b8-4+	VSHUQLRHTJOKTA-XBXARRHUSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.9665 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	4	No	2	0	89.79 Å2	32.1 Å3	85.09 m3·mol-1	5	Yes	No	0.038 mg/mL	2.66	-3.9	9.04	-0.39	Q672W7	def	1. Peptide deformylase
C10H12O2	Not Available	Not Available	164.2011	COC1=C(O)C=CC(CC=C)=C1	Solid	Not Available					50164168	4917	CHEMBL42710	13876103	Drugs.com Drug Page		HMDB0005809	C10453		EOL			3314	310265013		4186		Eugenol	ZINC000000001411		Eugenol	Approved	DB09086	InChI=1S/C10H12O2/c1-3-4-8-5-6-9(11)10(7-8)12-2/h3,5-7,11H,1,4H2,2H3	RRAFCDWBNXTKKO-UHFFFAOYSA-N		Eugenol is a phenol used for the temporary relief of toothaches.	Not Available	Small Molecule																																			1	Yes	2	1	No	1	0	29.46 Å2	17.9 Å3	48.79 m3·mol-1	3	Yes	Yes	1.44 mg/mL	2.61	-2.1	9.94	-4.9	P03372;!Q92731;!P10275;!Q8NET8	ESR1;!ESR2;!AR;!TRPV3	1. Estrogen receptor alpha;!2. Estrogen receptor beta;!3. Androgen receptor;!4. Transient receptor potential cation channel subfamily V member 3
C18H27NO3	Not Available	In rats, the elimination half life of zucapsaicin and its metabolites is approximately 7 to 11 hours 5.	305.4119	COC1=C(O)C=CC(CNC(=O)CCCC\C=C/C(C)C)=C1	Solid	Not Available	P05177;!P33261;!P11712;!P05181	CYP1A2;!CYP2C19;!CYP2C9;!CYP2E1	1. Cytochrome P450 1A2;!2. Cytochrome P450 2C19;!3. Cytochrome P450 2C9;!4. Cytochrome P450 2E1			135952	CHEMBL313971	1265956									1548942	310265037				Zucapsaicin	ZINC000004468952		Zucapsaicin	Approved, Investigational	DB09120	InChI=1S/C18H27NO3/c1-14(2)8-6-4-5-7-9-18(21)19-13-15-10-11-16(20)17(12-15)22-3/h6,8,10-12,14,20H,4-5,7,9,13H2,1-3H3,(H,19,21)/b8-6-	YKPUWZUDDOIDPM-VURMDHGXSA-N	3	Zucapsaicin is a topical analgesic used as an adjunct to relieve severe pain of osteoarthritis of the knee in selected adult patients.	Most common adverse effects involved application site reactions such as transient burning and warm sensation. Other adverse effects observed in clinical trials are eye irritation, arthralgia, aggravated osteoarthritis, burning sensation, headache, cough and sneezing. Oral LD50 in mouse is >87.5 mg/kg in male and <60 mg/kg in females. Oral LD50 in rats is >90 mg/kg in males and >60 mg/kg in females 5.	Small Molecule																																71.5-74.5		Insoluble	1	Yes	3	2	No	1	0	58.56 Å2	35.34 Å3	90.32 m3·mol-1	9	Yes	No	0.00841 mg/mL	3.75	-4.6	9.93	-1.4	Q8NER1	TRPV1	1. Transient receptor potential cation channel subfamily V member 1
C25H22O10	Not Available	Not Available	482.441	[H][C@@]1(OC2=C(O[C@@H]1CO)C=CC(=C2)[C@@]1([H])OC2=C(C(O)=CC(O)=C2)C(=O)[C@@H]1O)C1=CC(OC)=C(O)C=C1	Solid	Not Available	P22309	UGT1A1	1. UDP-glucuronosyltransferase 1-1		50084982	9144	CHEMBL431701	29263				C07610	D08515			PA166129539	31553	310265190		155067		Silibinin	ZINC000002033589		Silibinin	Experimental, Investigational	DB09298	InChI=1S/C25H22O10/c1-32-17-6-11(2-4-14(17)28)24-20(10-26)33-16-5-3-12(7-18(16)34-24)25-23(31)22(30)21-15(29)8-13(27)9-19(21)35-25/h2-9,20,23-29,31H,10H2,1H3/t20-,23+,24-,25-/m1/s1	SEBFKMXJBCUCAI-HKTJVKLFSA-N	4	Silibinin is a flavonolignan with hepatoprotective effects used to treat toxic liver damage and as an adjunct in the management of chronic conditions such as cirrhosis and hepatitis.	Not Available	Small Molecule																																			1	No	10	5	No	5	0	155.14 Å2	48.41 Å3	120.29 m3·mol-1	4	Yes	No	0.0926 mg/mL	2.63	-3.7	7.75	-3			
C20H22O3	Not Available	Not Available	310.393	COC1=CC=C(C=C1)C(=O)CC(=O)C1=CC=C(C=C1)C(C)(C)C	Not Available	Not Available						134751	CHEMBL1200522	46261									51040	310265226		45045		Avobenzone	ZINC000000000973	Meijer, Sumadan Wash	Avobenzone	Approved, Investigational	DB09495	InChI=1S/C20H22O3/c1-20(2,3)16-9-5-14(6-10-16)18(21)13-19(22)15-7-11-17(23-4)12-8-15/h5-12H,13H2,1-4H3	XNEFYCZVKIDDMS-UHFFFAOYSA-N	4	Avobenzone is a sunscreen agent found in sunscreens that absorbs UV rays.	A minimum toxic dose has not been established. Significant toxicity is not expected	Small Molecule																																			1	Yes	3	0	No	2	0	43.37 Å2	34.86 Å3	91.75 m3·mol-1	6	Yes	No	0.000622 mg/mL	4.56	-5.7	9.88	-4.8			
C14H12O6S	Not Available	Not Available	308.3	COC1=C(C=C(C(=O)C2=CC=CC=C2)C(O)=C1)S(O)(=O)=O	Not Available	Not Available						135312	CHEMBL2059073	18829									19988	347827937		1311567		Sulisobenzone	ZINC000001690324		Sulisobenzone	Experimental	DB11185	InChI=1S/C14H12O6S/c1-20-12-8-11(15)10(7-13(12)21(17,18)19)14(16)9-5-3-2-4-6-9/h2-8,15H,1H3,(H,17,18,19)	CXVGEDCSTKKODG-UHFFFAOYSA-N		Sulisobenzone is an ingredient used in sunscreen to block UVA and UVB radiation.	Acute oral toxicity (LD50): 3530 mg/kg [Rat].This drug can cause skin and eye irritation 6.Drug-induced phototoxicity is a non-immunological inflammatory skin reaction, caused by concurrent topical or systemic exposure to a specific molecule and ultraviolet radiation. Most of the phototoxic compounds absorb energy particularly from UVA light leading to activated derivatives, which can induce cellular damage 5.Benzophenones are ultraviolet light filters that have been documented to cause a variety of adverse skin reactions, including contact and photocontact dermatitis, contact and photocontact urticaria, and anaphylaxis. Recently, they have become especially well known for their ability to induce allergy and photoallergy. Topical sunscreens and other cosmetics are the sources of these allergens in the majority of patients, however reports of reactions secondary to use of industrial products also exist. Benzophenones as a group have been named the American Contact Dermatitis Society's Allergen of the Year for 2014 to raise awareness of both allergy and photoallergy to these ubiquitous agents 3.The liver is the main target organ of benzophenone toxicity in rats and mice, based on elevations n liver weights, hepatocellular hypertrophy, clinical chemistry changes, and induction of liver microsomal cytochrome P450 2B isomer. The kidney was also identified as a target organ of benzophenone toxicity in rats only, which was based on exposure concentration-related increases in kidney weights and microscopic changes 15.	Small Molecule																																145		10 microgram/mL	1	Yes	6	2	No	2	-2	100.9 Å2	29.14 Å3	75.7 m3·mol-1	4	Yes	No	0.214 mg/mL	2.8	-3.2	-2.4	-5			1. Skin epithelial cells
C14H12O4	No pharmacokinetic data available.	No pharmacokinetic data available.	244.246	COC1=CC(O)=C(C=C1)C(=O)C1=CC=CC=C1O	Solid	No pharmacokinetic data available.						34208	CHEMBL1326877	8251				C14283	D03853							23350		Dioxybenzone	ZINC000000037293		Dioxybenzone	Approved	DB11221	InChI=1S/C14H12O4/c1-18-9-6-7-11(13(16)8-9)14(17)10-4-2-3-5-12(10)15/h2-8,15-16H,1H3	MEZZCSHVIGVWFI-UHFFFAOYSA-N		Dioxybenzone is a benzophenone derivative used in sunscreens to block UVB and short-wave UVA radiation.	No toxicokinetic data available.	Small Molecule																													172.5			74			1	Yes	4	2	No	2	-1	66.76 Å2	24.81 Å3	67.06 m3·mol-1	3	Yes	No	0.148 mg/mL	3.97	-3.2	6.78	-4.8	P04278	SHBG	1. Sex hormone-binding globulin
C12H14O4	Not Available	Not Available	222.2372	[H]\C(=C(\[H])C1=CC(OC)=C(O)C=C1)C(=O)OCC	Not Available	Not Available					50297424		CHEMBL286796	643791						ZYC						1420983			ZINC000000160496		Ethyl ferulate	Approved, Experimental	DB11285	InChI=1S/C12H14O4/c1-3-16-12(14)7-5-9-4-6-10(13)11(8-9)15-2/h4-8,13H,3H2,1-2H3/b7-5+	ATJVZXXHKSYELS-FNORWQNLSA-N			Not Available	Small Molecule																																			1	Yes	3	1	No	1	0	55.76 Å2	23.57 Å3	61.02 m3·mol-1	5	Yes	No	0.328 mg/mL	2.41	-2.8	9.87	-4.9			
C12H18O3	Not Available	Not Available	210.2695	CCCCOCC1=CC(OC)=C(O)C=C1	Not Available	Not Available								4260417			HMDB0037642						5084146	347827963		1313189			ZINC000002561203		Vanillyl butyl ether	Approved	DB11299	InChI=1S/C12H18O3/c1-3-4-7-15-9-10-5-6-11(13)12(8-10)14-2/h5-6,8,13H,3-4,7,9H2,1-2H3	VLDFMKOUUQYFGF-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	Yes	3	1	No	1	0	38.69 Å2	24.21 Å3	59.94 m3·mol-1	6	Yes	Yes	0.425 mg/mL	2.71	-2.7	9.91	-4.1			
C17H27NO3	Not Available	About 7 minutes 15.	293.4012	CCCCCCCCC(=O)NCC1=CC(OC)=C(O)C=C1	Not Available	Not Available					50044767	46936	CHEMBL75124	2891			HMDB0029846									31945		Nonivamide	ZINC000001697652		Nonivamide	Investigational	DB11324	InChI=1S/C17H27NO3/c1-3-4-5-6-7-8-9-17(20)18-13-14-10-11-15(19)16(12-14)21-2/h10-12,19H,3-9,13H2,1-2H3,(H,18,20)	RGOVYLWUIBMPGK-UHFFFAOYSA-N	3		Nonivamide appears to be of low acute toxicity, according to the EMA summary report 15. The oral LD50 in rats is reported with 5110 mg/kg and the dermal LD50 in rabbits is greater than 10 000 mg/kg. Administered intraperitoneally, the LD50 in rats was measured to be about 90 mg/kg. In combination with nicoboxil, the acute dermal toxicity of nonivamide was increased. Signs of toxicity (depression, labored respiration, diarrhea) were observed at doses as low as 32 mg/kg body weight of nonivamide combined 200 mg nicoboxil/kg body weight 15.Allergic reactions in humans following administration of capsaicin or capsicum extracts are reported to be rare 15.No information on carcinogenic properties of nonivamide was available. Tumorigenic properties have been reported in literature for Capsaicin or chili 15.	Small Molecule																													492.7			57	9.77	Soluble in water (slightly)	1	Yes	3	2	No	1	0	58.56 Å2	35.07 Å3	84.65 m3·mol-1	10	Yes	No	0.0233 mg/mL	3.82	-4.1	9.93	-1.4	Q8NER1	TRPV1	1. Transient receptor potential cation channel subfamily V member 1
C25H31NO3	Not Available	Not Available	393.527	COC1=CC=C(C=C1OC1CCCC1)[C@H]1CNC(=O)[C@H](CC2=CC(C)=CC=C2)C1	Not Available	Not Available								8041067									9865375	347828021				HT-0712			HT-0712	Investigational	DB11650	InChI=1S/C25H31NO3/c1-17-6-5-7-18(12-17)13-20-14-21(16-26-25(20)27)19-10-11-23(28-2)24(15-19)29-22-8-3-4-9-22/h5-7,10-12,15,20-22H,3-4,8-9,13-14,16H2,1-2H3,(H,26,27)/t20-,21-/m1/s1	ABEJDMOBAFLQNJ-NHCUHLMSSA-N	2		Not Available	Small Molecule																																			1	Yes	3	1	Yes	4	0	47.56 Å2	45.05 Å3	115.08 m3·mol-1	6	No	No	0.000252 mg/mL	5.04	-6.2	14.48	-1.5			
C21H20O6	No pharmacokinetic data available.	No pharmacokinetic data available.	368.3799	COC1=CC(\C=C\C(=O)CC(=O)\C=C\C2=CC(OC)=C(O)C=C2)=CC=C1O	Solid	Following oral administration of radio-labelled curcumin to rats, radioactivity was detected in the liver and kidneys 3.	P11712;!P08684;!P20813;!P05177;!P10635;!P08263;!P09488;!P09211	CYP2C9;!CYP3A4;!CYP2B6;!CYP1A2;!CYP2D6;!GSTA1;!GSTM1;!GSTP1	1. Cytochrome P450 2C9;!2. Cytochrome P450 3A4;!3. Cytochrome P450 2B6;!4. Cytochrome P450 1A2;!5. Cytochrome P450 2D6;!6. Glutathione S-transferase A1;!7. Glutathione S-transferase Mu 1;!8. Glutathione S-transferase P		50140172	3962	CHEMBL140	839564			HMDB0002269			CC9			969516	347828040		2955		Curcumin	ZINC000000899824		Curcumin	Approved, Investigational	DB11672	InChI=1S/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-12,24-25H,13H2,1-2H3/b7-3+,8-4+	VFLDPWHFBUODDF-FCXRPNKRSA-N	4		In an acute oral toxicity study in mouse, LD50 was >2000 mg/kg MSDS. Single oral doses of curcumin at 1-5 g/kg bw induced no toxic effects in rats 3. There has been no cases of overdose reported 3.	Small Molecule																																183		Insoluble in cold water	1	Yes	6	2	No	2	0	93.06 Å2	38.12 Å3	103.81 m3·mol-1	8	Yes	No	0.00575 mg/mL	4.12	-4.8	9.08	-4.4	P37231;!P11473;!O15440;!P16152;!P09211	PPARG;!VDR;!ABCC5;!CBR1;!GSTP1	1. Peroxisome proliferator-activated receptor gamma;!2. Vitamin D3 receptor;!3. Multidrug resistance-associated protein 5;!4. Carbonyl reductase [NADPH] 1;!5. Glutathione S-transferase P
C19H23O10PS	Not Available	Not Available	474.42	COC1=CC(OC)=C(\C=C\S(=O)(=O)CC2=CC=C(OC)C(OP(O)(O)=O)=C2)C(OC)=C1	Not Available	Not Available							CHEMBL1206245	9423523									11248490	347828322					ZINC000028965775		Briciclib	Investigational	DB12004	InChI=1S/C19H23O10PS/c1-25-14-10-17(27-3)15(18(11-14)28-4)7-8-31(23,24)12-13-5-6-16(26-2)19(9-13)29-30(20,21)22/h5-11H,12H2,1-4H3,(H2,20,21,22)/b8-7+	LXENKEWVEVKKGV-BQYQJAHWSA-N			Not Available	Small Molecule																																			1	Yes	9	2	No	2	-2	137.82 Å2	45.06 Å3	113.07 m3·mol-1	10	Yes	No	0.0788 mg/mL	1.32	-3.8	1.62	-4.3			
C21H27NO5	Not Available	Not Available	373.449	C[C@H](NCCC1=C(C)C=C(OCC(O)=O)C(C)=C1)[C@H](O)C1=CC=C(O)C=C1	Not Available	Not Available							CHEMBL2107773	7996631									9820882	347828386					ZINC000072266295		Ritobegron	Investigational	DB12080	InChI=1S/C21H27NO5/c1-13-11-19(27-12-20(24)25)14(2)10-17(13)8-9-22-15(3)21(26)16-4-6-18(23)7-5-16/h4-7,10-11,15,21-23,26H,8-9,12H2,1-3H3,(H,24,25)/t15-,21-/m0/s1	VMMYRRFPMAGXNP-BTYIYWSLSA-N	3		Not Available	Small Molecule																																			1	Yes	6	4	No	2	0	99.02 Å2	41.25 Å3	103.67 m3·mol-1	9	Yes	No	0.0103 mg/mL	0.9	-4.6	3.73	10.01			
C8H10O3	Not Available	Not Available	154.1632	COC1=C(O)C=CC(CO)=C1	Not Available	Not Available						18353		56139			HMDB0032012	C06317					62348	347828393				Vanillyl_alcohol	ZINC000000164388		Vanillyl alcohol	Investigational	DB12087	InChI=1S/C8H10O3/c1-11-8-4-6(5-9)2-3-7(8)10/h2-4,9-10H,5H2,1H3	ZENOXNGFMSCLLL-UHFFFAOYSA-N	2		Not Available	Small Molecule																																			1	No	3	2	No	1	0	49.69 Å2	15.74 Å3	41.32 m3·mol-1	2	Yes	No	29.4 mg/mL	0.74	-0.72	9.92	-2.8			
C21H25NO8S	Not Available	Not Available	451.49	COC1=CC(OC)=C(\C=C\S(=O)(=O)CC2=CC=C(OC)C(NCC(O)=O)=C2)C(OC)=C1	Not Available	Not Available					50060917	145417	CHEMBL1241855	5293927						6FS			6918736	347828442				Rigosertib	ZINC000003942646		Rigosertib	Investigational	DB12146	InChI=1S/C21H25NO8S/c1-27-15-10-19(29-3)16(20(11-15)30-4)7-8-31(25,26)13-14-5-6-18(28-2)17(9-14)22-12-21(23)24/h5-11,22H,12-13H2,1-4H3,(H,23,24)/b8-7+	OWBFCJROIKNMGD-BQYQJAHWSA-N	3		Not Available	Small Molecule																																			1	Yes	9	2	No	2	-1	120.39 Å2	46.32 Å3	116.5 m3·mol-1	11	Yes	No	0.0226 mg/mL	-0.25	-4.3	2.27	5.24			
C20H26O6	Not Available	Not Available	362.4168	COC1=C(O)C=CC(C[C@@H](CO)[C@H](CO)CC2=CC(OC)=C(O)C=C2)=C1	Not Available	Not Available					50240914	65004	CHEMBL368347	58845			HMDB0013692	C18167		GO6			65373	347828466				Secoisolariciresinol	ZINC000002020114		Secoisolariciresinol	Investigational	DB12179	InChI=1S/C20H26O6/c1-25-19-9-13(3-5-17(19)23)7-15(11-21)16(12-22)8-14-4-6-18(24)20(10-14)26-2/h3-6,9-10,15-16,21-24H,7-8,11-12H2,1-2H3/t15-,16-/m0/s1	PUETUDUXMCLALY-HOTGVXAUSA-N	2		Not Available	Small Molecule																																			1	Yes	6	4	No	2	0	99.38 Å2	38.59 Å3	99.29 m3·mol-1	9	Yes	No	0.012 mg/mL	2.33	-4.5	9.96	-2.6			
C22H30O4	Not Available	Not Available	358.478	COC1=CC=C(C[C@H](C)[C@H](C)CC2=CC=C(OC)C(OC)=C2)C=C1OC	Not Available	Not Available							CHEMBL90983	418597									476861	347828505					ZINC000016953163		Terameprocol	Investigational	DB12226	InChI=1S/C22H30O4/c1-15(11-17-7-9-19(23-3)21(13-17)25-5)16(2)12-18-8-10-20(24-4)22(14-18)26-6/h7-10,13-16H,11-12H2,1-6H3/t15-,16+	ORQFDHFZSMXRLM-IYBDPMFKSA-N	2		Not Available	Small Molecule																																			1	Yes	4	0	No	2	0	36.92 Å2	41.9 Å3	104.55 m3·mol-1	9	No	Yes	0.000192 mg/mL	5.34	-6.3		-4.3			
C20H21NO2	Not Available	Not Available	307.393	CCC1=NC(CC2=CC=CC=C2)=C2C=C(OC)C(OC)=CC2=C1	Not Available	Not Available						135307	CHEMBL2105060	64045									70882	347828526		52918		Moxaverine	ZINC000000001754		Moxaverine	Investigational	DB12251	InChI=1S/C20H21NO2/c1-4-16-11-15-12-19(22-2)20(23-3)13-17(15)18(21-16)10-14-8-6-5-7-9-14/h5-9,11-13H,4,10H2,1-3H3	MYCMTMIGRXJNSO-UHFFFAOYSA-N	3		Not Available	Small Molecule																																			1	Yes	3	0	No	3	0	31.35 Å2	35.02 Å3	91.81 m3·mol-1	5	Yes	Yes	0.00102 mg/mL	4.23	-5.5		6.49			
C18H21O8P	Not Available	Not Available	396.332	COC1=CC=C(\C=C/C2=CC(OC)=C(OC)C(OC)=C2)C=C1OP(O)(O)=O	Not Available	Not Available							CHEMBL1206232	4508406									5351387	347828799				Combretastatin_A-4_phosphate	ZINC000001543513		Fosbretabulin	Investigational	DB12577	InChI=1S/C18H21O8P/c1-22-14-8-7-12(9-15(14)26-27(19,20)21)5-6-13-10-16(23-2)18(25-4)17(11-13)24-3/h5-11H,1-4H3,(H2,19,20,21)/b6-5-	WDOGQTQEKVLZIJ-WAYWQWQTSA-N	2		Not Available	Small Molecule																																			1	Yes	7	2	No	2	-2	103.68 Å2	38.29 Å3	100.22 m3·mol-1	8	Yes	No	0.00239 mg/mL	2.72	-5.2	1.62	-4.3			
C18H22O6	Not Available	Not Available	334.368	COC1=CC=C(C[C@@H](O)C2=CC(OC)=C(OC)C(OC)=C2)C=C1O	Not Available	Not Available							CHEMBL246600	8070931									9895264	347828814				Combretastatin	ZINC000001607492		Combretastatin	Investigational	DB12596	InChI=1S/C18H22O6/c1-21-15-6-5-11(8-14(15)20)7-13(19)12-9-16(22-2)18(24-4)17(10-12)23-3/h5-6,8-10,13,19-20H,7H2,1-4H3/t13-/m1/s1	LGZKGOGODCLQHG-CYBMUJFWSA-N	2		Not Available	Small Molecule																																			1	Yes	6	2	No	2	0	77.38 Å2	34.18 Å3	89.75 m3·mol-1	7	Yes	No	0.0545 mg/mL	2.34	-3.8	9.99	-3.1			
C9H10O3	Not Available	Not Available	166.1739	COC1=C(O)C=CC(=C1)C(C)=O	Not Available	Not Available						2781	CHEMBL346919	21106900				C11380		I75			2214	347828831				Apocynin	ZINC000000162515		Apocynin	Investigational	DB12618	InChI=1S/C9H10O3/c1-6(10)7-3-4-8(11)9(5-7)12-2/h3-5,11H,1-2H3	DFYRUELUNQRZTB-UHFFFAOYSA-N	1		Not Available	Small Molecule																																			1	Yes	3	1	No	1	0	46.53 Å2	16.94 Å3	44.9 m3·mol-1	2	Yes	No	3.04 mg/mL	1.07	-1.7	8.27	-4.9			
C24H22O6	Not Available	Not Available	406.434	COC1=CC=C(COC2=C(OC)C=C3C(OC(=O)C4=CC(=CC=C34)C(C)O)=C2)C=C1	Not Available	Not Available							CHEMBL2141712	10171042									11998575	347828985							Palomid 529	Investigational	DB12812	InChI=1S/C24H22O6/c1-14(25)16-6-9-18-19-11-22(28-3)23(12-21(19)30-24(26)20(18)10-16)29-13-15-4-7-17(27-2)8-5-15/h4-12,14,25H,13H2,1-3H3	YEAHTLOYHVWAKW-UHFFFAOYSA-N	1		Not Available	Small Molecule																																			1	Yes	5	1	Yes	4	0	74.22 Å2	44.23 Å3	112.18 m3·mol-1	6	Yes	No	0.00343 mg/mL	3.83	-5.1	14.59	-3			
C21H26N2O6	Not Available	Not Available	402.447	COC1=CC=C(\C=C/C2=CC(OC)=C(OC)C(OC)=C2)C=C1NC(=O)[C@@H](N)CO	Not Available	Not Available					50147363		CHEMBL572284	5293602									6918405	347829037				Ombrabulin	ZINC000001892617		Ombrabulin	Investigational	DB12882	InChI=1S/C21H26N2O6/c1-26-17-8-7-13(9-16(17)23-21(25)15(22)12-24)5-6-14-10-18(27-2)20(29-4)19(11-14)28-3/h5-11,15,24H,12,22H2,1-4H3,(H,23,25)/b6-5-/t15-/m0/s1	IXWNTLSTOZFSCM-YVACAVLKSA-N	3		Not Available	Small Molecule																																			1	Yes	7	3	No	2	1	112.27 Å2	42.01 Å3	111.63 m3·mol-1	9	Yes	No	0.0214 mg/mL	1.52	-4.3	11.8	7.69			
C26H26O6	Not Available	Not Available	434.488	CCCC1=C(OCC2=CC=C(C=C2)[C@H](O)C2=CC=CC(=C2)C(O)=O)C=CC(C(C)=O)=C1O	Not Available	Not Available								9786555									11611800	347829151							LY-2300559	Investigational	DB13016	InChI=1S/C26H26O6/c1-3-5-22-23(13-12-21(16(2)27)25(22)29)32-15-17-8-10-18(11-9-17)24(28)19-6-4-7-20(14-19)26(30)31/h4,6-14,24,28-29H,3,5,15H2,1-2H3,(H,30,31)/t24-/m0/s1	DWQVYDLTPMGYNE-DEOSSOPVSA-N			Not Available	Small Molecule																																			1	Yes	6	3	Yes	3	-1	104.06 Å2	46.98 Å3	122.12 m3·mol-1	9	No	No	0.00275 mg/mL	5.52	-5.2	4.01	-3.4			
C15H12O5	Not Available	Not Available	272.256	OC(=O)C1=CC=C(COC2=CC=CC(O)=C2C=O)C=C1	Not Available	Not Available							CHEMBL2104482	49868									55223	347829161					ZINC000000010202		Tucaresol	Investigational	DB13027	InChI=1S/C15H12O5/c16-8-12-13(17)2-1-3-14(12)20-9-10-4-6-11(7-5-10)15(18)19/h1-8,17H,9H2,(H,18,19)	XEDONBRPTABQFB-UHFFFAOYSA-N	2		Not Available	Small Molecule																																			1	Yes	5	2	No	2	-1	83.83 Å2	27.14 Å3	72.95 m3·mol-1	5	Yes	No	0.0362 mg/mL	3.26	-3.9	4.06	-4.9			
C18H15NO4	Not Available	Not Available	309.321	CC1=C(OC(=O)C2=CC=C(N)C=C2)C(O)=C2C=CC=CC2=C1O	Not Available	Not Available						135317		76340									84621	347829171		46276			ZINC000005419379		Aminaphthone	Investigational	DB13039	InChI=1S/C18H15NO4/c1-10-15(20)13-4-2-3-5-14(13)16(21)17(10)23-18(22)11-6-8-12(19)9-7-11/h2-9,20-21H,19H2,1H3	YLMPBJUYFTWHKJ-UHFFFAOYSA-N	4	Aminaphthone is a medication that inhibits erythrocyte aggregation in capillaries, improving venous return for the treatment of capillary fragility.	Not Available	Small Molecule																																			1	Yes	4	3	No	3	0	92.78 Å2	31.49 Å3	88.01 m3·mol-1	3	Yes	No	0.0147 mg/mL	4.35	-4.3	9.55	2.54			
C18H22O3	Not Available	Not Available	286.371	CC[C@H](C1=CC=C2C=C(OC)C=CC2=C1)C(C)(C)C(O)=O	Solid	Not Available								34995295									59084697	347829260				Methallenestril	ZINC000000897074		Methallenestril	Experimental	DB13143	InChI=1S/C18H22O3/c1-5-16(18(2,3)17(19)20)14-7-6-13-11-15(21-4)9-8-12(13)10-14/h6-11,16H,5H2,1-4H3,(H,19,20)/t16-/m1/s1	KHLJKRBMZVNZOC-MRXNPFEDSA-N			Not Available	Small Molecule																																			1	Yes	3	1	No	2	-1	46.53 Å2	32.23 Å3	83.11 m3·mol-1	5	Yes	No	0.00102 mg/mL	4.72	-5.4	4.53	-4.8			
C23H24O4	Not Available	Not Available	364.441	CC(=O)OC1=CC=C(C=C1)C(=C1CCCCC1)C1=CC=C(OC(C)=O)C=C1	Not Available	Not Available						31446	CHEMBL141305	2795												2983		Cyclofenil	ZINC000000608288		Cyclofenil	Experimental	DB13472	InChI=1S/C23H24O4/c1-16(24)26-21-12-8-19(9-13-21)23(18-6-4-3-5-7-18)20-10-14-22(15-11-20)27-17(2)25/h8-15H,3-7H2,1-2H3	GVOUFPWUYJWQSK-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	Yes	2	0	Yes	3	0	52.6 Å2	41.08 Å3	113.52 m3·mol-1	6	Yes	No	0.000792 mg/mL	4.86	-5.7		-6.8			
C19H23NO5	Not Available	Not Available	345.395	COC1=CC(C[C@@H]2NCCC3=CC(O)=C(O)C=C23)=CC(OC)=C1OC	Not Available	Not Available					82503	135461	CHEMBL174984	59192														Tretoquinol	ZINC000000000802		Tretoquinol	Experimental	DB13692	InChI=1S/C19H23NO5/c1-23-17-7-11(8-18(24-2)19(17)25-3)6-14-13-10-16(22)15(21)9-12(13)4-5-20-14/h7-10,14,20-22H,4-6H2,1-3H3/t14-/m0/s1	RGVPOXRFEPSFGH-AWEZNQCLSA-N			Not Available	Small Molecule																																			1	Yes	6	3	No	3	1	80.18 Å2	37.16 Å3	95 m3·mol-1	5	Yes	No	0.0986 mg/mL	2.24	-3.5	9.53	8.52			
C15H15NO2	Not Available	Not Available	241.29	COC1=C(O)C(\C=N\C2=CC=C(C)C=C2)=CC=C1	Solid	Not Available								10846266									5476587	347829322					ZINC000004793359		2-Methoxy-6-{(E)-[(4-methylphenyl)imino]methyl}phenol	Experimental	DB13869	InChI=1S/C15H15NO2/c1-11-6-8-13(9-7-11)16-10-12-4-3-5-14(18-2)15(12)17/h3-10,17H,1-2H3/b16-10+	OYEREWRJWMPHMA-MHWRWJLKSA-N			Not Available	Small Molecule																																			1	Yes	3	1	No	2	0	41.82 Å2	27.13 Å3	74.87 m3·mol-1	3	Yes	No	0.0101 mg/mL	3.9	-4.4	9.34	2.14	Q92731;!P03372	ESR2;!ESR1	1. Estrogen receptor beta;!2. Estrogen receptor alpha
C17H15ClO4	In five elderly volunteers aged 77 to 87, the oral clearance of fenofibric acid after a single oral dose of fenofibrate was 1.2 L/h, which compares to 1.1 L/h in young adults Label.	Following once daily dosing, fenofibric acid demonstrates an elimination associated with a half-life of about 20 hours after absorption Label.	318.75	CC(C)(OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1)C(O)=O	Solid	The volume of distribution for fenofibric acid is demonstrated to be 70.9 +/- 27.5 L 2.					28700	83469	CHEMBL981	58457						F5A			64929	347829325		24852		Fenofibrate	ZINC000000001984	Fibricor, Trilipix	Fenofibric acid	Approved	DB13873	InChI=1S/C17H15ClO4/c1-17(2,16(20)21)22-14-9-5-12(6-10-14)15(19)11-3-7-13(18)8-4-11/h3-10H,1-2H3,(H,20,21)	MQOBSOSZFYZQOK-UHFFFAOYSA-N	4	Fenofibric acid is a fibrate used to treat severe hypertriglyceridemia, primary hypercholesterolemia, or mixed dyslipidemia.	Oral LD50 (rat): 1242 mg/kg, Oral LD50 (mouse): 100 mg/kg, lntraperitoneal LD50 (mouse): 500 mg/kg MSDSFenofibric acid is contraindicated for: (a) patients with severe renal impairment, including those receiving dialysis, (b) patients with active liver disease, including those with primary biliary cirrhosis and unexplained persistent liver function abnormalities, (c) patients with preexisting gallbladder disease, (d) patients with known hypersensitivity to fenofibric acid or Fenofibrate, and (e) nursing mothers Label.The relationship between the use of fenofibric acid and risk of mortality and coronary heart disease morbidity has not been formally established Label. However, a number of studies involving fenofibrate and agents that are chemically and pharmacologically similar to fenofibrate demonstrate inconclusive results. In the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, a non-significant 11% (HR 1.11 [0.95, 1.29], p=0.18) and 19% (HR 1.19 [0.90, 1.57], p=0.22) increase in total and coronary heart disease mortality, respectively, with Fenofibrate as compared to placebo Label. For the Coronary Drug Project, a large study of post myocardial infarction of patients treated for 5 years with clofibrate, there was a difference in the rate of cholelithiasis and cholecystitis requiring surgery between the clofibrate and placebo groups of 3.0% vs. 1.8%, respectively Label. The World Health Organization (WHO) also conducted a study in which 5000 subjects without known coronary artery disease were treated with placebo or clofibrate for 5 years and followed for an additional year Label. The results involved a statistically significant, higher age-adjusted all-cause mortality in the clofibrate group compared with the placebo group (5.70% vs. 3.96%, p<0.01) in which excess mortality was due to a 33% increase in non-cardiovascular causes, including malignancy, post-cholecystectomy complications, and pancreatitis Label. With the Helsinki Heart Study, 4081 middle aged men without a history of coronary artery disease were given either placebo or gemfibrozil for 5 years, with a 3.5 year open extension afterward Label. Although total mortality was numerically higher in the gemfibrozil arm, it was statistically significant (p=0.19, 95% confidence interval for relative risk = 0.91-1.64). Finally, a secondary prevention component of the Helsinki Heart Study observed middle aged men not included in the primary prevention study because they had known or suspected coronary heart disease Label. When these subjects were administered gemfibrozil or placebo therapy for 5 years, cardiac deaths trended higher in the gemfibrozil group but was ultimately not statistically significant (HR 2.2, 95% confidence interval: 0.94-5.05) Label.Fibrates facilitate the risk for myopathy and have been associated with rhabdomyolysis Label. The risk for serious muscle toxicity appears to be increased in elderly patients and in patients with diabetes, renal failure, or hypothyroidism Label. Myopathy should be considered in any patient with diffuse myalgia, muscle tenderness or weakness, and/or marked elevations of creatine phosphokinase levels Label.Fenofibrate administered across a range of doses with the higher dose equivalent to 105 mg fenofibric acid has been associated with increases in serum transaminases like AST (SGOT) and ALT (SGPT) Label. In a pooled analysis of 10 placebo-controlled trials, increases to more than 3 times the upper limit of normal of ALT occurred in 5.3% of patients taking Fenofibrate versus 1.1% of patients treated with placebo Label. If enzyme levels persist above three times the normal limit, therapy is to be discontinued Label. After discontinuing fenofibrate treatment or during continued treatment a return to normal transaminase limits was usually observed Label. The incidence of increases in transaminases observed with fenofibrate therapy appear to be dose related Label. From an 8 week dose-ranging study, the incidence of ALT or AST elevations to at least three times the upper limit of normal was 13% in patients receiving dosages equivalent to 35 mg to 105 mg fenofibric acid per day and was comparatively 0% in those receiving placebo or doses equivalent to 35 mg or less fenofibric acid per day Label. Hepatocellular, chronic active and cholestatic hepatitis associated with Fenofibrate therapy have been reported after exposures of weeks to several years Label. In extremely rare cases, cirrhosis has been reported in associated with chronic active hepatitis Label.Increases in serum creatinine have been reported in patients on Fenofibrate Label. These elevations tend to return to baseline following discontinuation of the drug Label. Although the clinical significance of these observations is unknown, renal monitoring should be considered for patients with renal impairment and for patients at risk for renal insufficiency, perhaps like patients with diabetes or the elderly Label.Fenofibric acid may increase cholesterol excretion into the bile, leading to cholelithiasis Label. If gallstones are found, fenofibric acid should be discontinued Label.Caution must be exercised over the ability of fenofibric acid to potentiate the anticoagulant effects of coumarin anticoagulants, resulting in prolongation of the prothrombin time/International Normalized Ratio (PT/INR) Label.Pancreatitis has also been reported in patients taking Fenofibrate Label. This effect may be caused by the failure of efficacy in patients with severe hypertriglyceridemia, a direct drug effect, or a secondary phenomenon mediated through biliary tract stone or sludge formation with obstruction of the common bile duct Label.Mild to moderate hemoglobin, hematocrit, and white blood cell decreases have been observed in patients following the start of fenofibrate therapy Label. However, although these levels tend to stabilize during long-term administration of the medication Label, thrombocytopenia and agranulocytosis have been observed in patients treated with fenofibrates as well Label. Scheduled monitoring of red and white blood cell counts during the first 12 months of fenofibric acid administration is subsequently recommended Label.Acute hypersensitivity reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis requiring patient hospitalization and treatment with steroids have been reported in patients treated with fenofibrates Label.In the fenofibrate arm during the FIELD trial, occurrences of pulmonary embolus (PE) and deep vein thrombosis (DVT) were recorded at higher rates when compared to the placebo group Label. In particular, the placebo group had N=4900 and the fenofibrate group N=4895 Label. For DVT there were 48 events (1%) in the placebo group and 67 (1%) in the fenofibrate group with p=0.074 Label. While for PE, there were 32 (0.7%) events in the placebo group and 53 (1%) in the fenofibrate group with p=0.022 Label. Likewise, in the Coronary Drug Project, a higher proportion of the clofibrate group reported definite or suspected fatal or nonfatal PE or thrombophlebitis when compared to the placebo group (5.2% vs 3.3% at 5 years with p<0.01) Label.Additionally there have been postmarketing and clinical trial reports of serious paradoxical decreases in HDL cholesterol levels to as low as 2 mg/dL happening in diabetic and non-diabetic patients initiated on fibrate therapy Label. This decrease in HDL-C is accompanied by a decrease in apolipoprotein A1. Such decreases have been reported to occur within 2 weeks to years after initiation of fibrate therapy Label. The HDL-C levels remain depressed until fibrate therapy has been withdrawn; the response to withdrawal of fibrate therapy is in fact rapid and sustained Label. HDL-C levels are recommended to be checked within the first few months after initiation of fibrate therapy. In the case of severely depressed HDL-C levels being detected, fibrate therapy should be withdrawn and HDL-C levels monitored until it has returned to baseline with no intention or plan to re-initiate fibrate therapy Label.Adverse effects associated with the use of fenofibrate and fenofibric acid include abdominal pain, back pain, headache, nausea, constipation, abnormal liver tests, increased AST, increased ALT, increased creatine phosphokinase, respiratory disorder, rhinitis, diarrhea, dyspepsia, nasopharyngitis, sinusitis, upper respiratory tract infection, arthralgia, myalgia, pain in extremity, and/or dizziness Label,4.Adverse effects identified during the post-approval use period of fenofibrate include rhabdomyolysis, panrcreatitis, renal failure, muscle spasms, acute renal failure, hepatitis, cirrhosis, anemia, asthenia, and severely depressed HDL-cholesterol levels 4.As Fenofibric acid has the capability to potentiate the anticoagulant effect of coumarin anticoagulants (and subsequently prolong the PT/INR of patients), caution should be exercised when oral coumarin anticoagulants are given in conjunction with fenofibric acid. Frequent PT/INR determinations are therefore advisable until stabilized PT/INR readings are obtainedLabel,4.Fenofibric acid should be administered to patients at least 1 hour before or 4 to 6 hours after a bile acid resin is given as such drugs may bind other agents being given concurrently and impede their absorption Label,4.Immunosuppressant medications like cyclosporine and tacrolimus can cause nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the main elimination route for fenofibric acid, there exists a risk that an interaction could lead to deterioration of renal function Label,4. As a consequence, the benefits and risks of using fenofibric acid with any other potentially nephrotoxic agents should be carefully considered and the lowest effective dose employed Label,4.Cases of myopathy, including rhabdomyolysis, have been reported with fenofibrates co-administered with colchicine, and caution should be exercised when considering the combination use of fenofibrates with colchicine Label,4.No well controlled studies regarding the use of fenofibric acid in pregnant women have been established Label,4. Since the safety of fenofibric acid in pregnant women has not been formally elucidated, fenofibric acid should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus Label,4.Moreover, fenofibric acid should not be used in nursing mothers. Under the circumstances, a decision should be made between having to discontinue nursing or to discontinue the use of fenofibric acid, taking into perspective the importance of the drug therapy to the mother Label,4.The safety and effectiveness of fenofibric acid in paediatric patients has not been formally established Label,4.Fenofibric acid is predominantly excreted by the kidney system unchanged or as fenofibric acid glucuronide Label,4. The risk of experiencing adverse reactions associated with exposure to fenofibric acid may consequently be greater in patients with impaired renal function Label,4. Subsequently, because elderly patients may have a higher incidence of renal impairment, the dosage of fenofibric acid for geriatric patients should be based upon renal function, with normal renal function requiring no dosage modifications Label,4. Renal function monitoring in elderly patients taking fenofibric acid is recommended Label,4.In patients with severe renal impairment, the use of fenofibric acid is to be avoided while dose reductions is necessary in patients with mild to moderate renal impairment Label,4. Monitoring renal function in patients with renal impairment is recommended Label,4.The use of fenofibric acid has not been evaluated in patients with hepatic impairment Label,4.In a 24 month study, Wistar rats were dosed at various levels of fenofibrate. At a dose of 200mg/kg/day (6 times the maximum recommended human dose [MRHD] based on body surface area comparisons mg/m2), the incidence of liver carcinomas was significantly increased in both sexes of the rats Label,4. At doses of 10 (0.3 times the MRHD) and 200 mg/kg/day, a statistically significant increase in pancreatic carcinomas was observed in males, and an increase in pancreatic adenomas and benign testicular interstitial cell tumours were observed at 200 mg/kg/day in males Label,4. In a second 24 month study on the Sprague-Dawley strain of rats, doses of 10 and 60 mg/kg/day produced significant increases in the incidence of pancreatic acinar adenomas in both sexes of the rats and increases in interstitial cell tumours of the testes at 2 times the MRHD Label,4.In addition, fenofibrate 10 and 60 mg/kg/day, clofibrate 400 mg/kg/day (2 times the MRHD), and gemfibrozil 250 mg/kg/day (2 times the MRHD) are studied in a 117 week study in rats. Fenofibrate increased pancreatic acing adenomas in both sexes of the rats Label,4. Clofibrate increased hepatocellular carcinoma and pancreatic acinar adenomas in males and hepatic neoplastic nodules in females Label,4. And finally, gemfibrozil increased hepatic neoplastic nodules in males and females, while all three drugs increased testicular interstitial cell tumours in males Label,4.In a 21 month study with CF-1 mice, fenofibrate 10, 45, and 200 mg/kg/day (approximately 0.2, 1, and 3 times the MRHD) significantly increased the liver carcinomas in both sexes at 3 times the MRHD Label,4. With a second 18 month study at 10, 60, and 200 mg/kg/day, fenofibrate significantly increased the liver carcinomas in male and female mice 3 times the MRHD Label,4.Changes in peroxisome morphology and numbers have been observed in humans after treatment with other members of the fibrate class when liver biopsies were compared before and after treatment in the same individual Label,4Fenofibrate was shown to be devoid of mutagenic potential in the Ames and micronucleus tests in vivo/rat Label,4. In addition, fenofibric acid, has bee.n demonstrated to be devoid of mutagenic potential in the following tests: Ames, mouse lymphoma, chromosomal aberration and sister chromatid exchange in human lymphocytes, and unscheduled DNA synthesis in primary rat hepatocytes Label,4.In a fertility study, rats were given oral dietary doses of fenofibrate. Males received doses for 61 days prior to mating and females for 15 days prior to mating through weaning, which resulted in no adverse effect on fertility at doses up to 300 mg/kg/day (~10 times the MRHD, based on mg/m2 surface area comparisons) Label,4.	Small Molecule																																			1	Yes	4	1	No	2	-1	63.6 Å2	32.42 Å3	83.19 m3·mol-1	5	Yes	No	0.0051 mg/mL	4.36	-4.8	3.1	-4.9	Q07869;!Q9NPA2;!P37231;!Q03181;!O75469	PPARA;!MMP25;!PPARG;!PPARD;!NR1I2	1. Peroxisome proliferator-activated receptor alpha;!2. Matrix metalloproteinase-25;!3. Peroxisome proliferator-activated receptor gamma;!4. Peroxisome proliferator-activated receptor delta;!5. Nuclear receptor subfamily 1 group I member 2
C18H20N2O3	Not Available	Not Available	312.369	COC1=CC(C#N)=C(OC)C=C1CCNCC1=C(O)C=CC=C1	Solid	Not Available								58191431						U0G								25CN-NBOH	ZINC000098210306		N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine	Experimental	DB13948	InChI=1S/C18H20N2O3/c1-22-17-10-15(11-19)18(23-2)9-13(17)7-8-20-12-14-5-3-4-6-16(14)21/h3-6,9-10,20-21H,7-8,12H2,1-2H3	VWEDZTZAXHMZIL-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	Yes	5	2	No	2	1	74.51 Å2	34.23 Å3	89.3 m3·mol-1	7	Yes	No	0.0197 mg/mL	1.69	-4.2	8.32	10.2	P28223	HTR2A	1. 5-hydroxytryptamine receptor 2A
C16H14O4	Not Available	Not Available	270.284	COC1=C(C(=O)\C=C\C2=CC=CC=C2)C(O)=CC(O)=C1	Not Available	Not Available					50185446		CHEMBL378104	557026			HMDB0132913											Cardamomin	ZINC000004716487		Dihydroxymethoxychalcone	Experimental	DB14122	InChI=1S/C16H14O4/c1-20-15-10-12(17)9-14(19)16(15)13(18)8-7-11-5-3-2-4-6-11/h2-10,17,19H,1H3/b8-7+	NYSZJNUIVUBQMM-BQYQJAHWSA-N			Not Available	Small Molecule																																			1	Yes	4	2	No	2	0	66.76 Å2	28.42 Å3	77.3 m3·mol-1	4	Yes	No	0.0777 mg/mL	3.78	-3.5	7.2	-4.9			
C20H24O4	Not Available	Not Available	328.408	COC1=CC(C[C@H](C)[C@H](C)CC2=CC3=C(OCO3)C=C2)=CC=C1O	Not Available	Not Available					90735	94153	CHEMBL254071	8579683												1872381		Macelignan	ZINC000013108863		Macelignan	Experimental	DB14129	InChI=1S/C20H24O4/c1-13(8-15-4-6-17(21)19(10-15)22-3)14(2)9-16-5-7-18-20(11-16)24-12-23-18/h4-7,10-11,13-14,21H,8-9,12H2,1-3H3/t13-,14+/m0/s1	QDDILOVMGWUNGD-UONOGXRCSA-N			Not Available	Small Molecule																																			1	Yes	4	1	Yes	3	0	47.92 Å2	37.11 Å3	92.91 m3·mol-1	6	No	No	0.00285 mg/mL	5.13	-5.1	10.28	-4.5			
C10H12O2	Not Available	Not Available	164.204	COC1=CC(C=CC)=CC=C1O	Not Available	Not Available						18224	CHEMBL2135887	7061				C10469								1363706		Isoeugenol			Isoeugenol	Approved, Experimental	DB14188	InChI=1S/C10H12O2/c1-3-4-8-5-6-9(11)10(7-8)12-2/h3-7,11H,1-2H3	BJIOGJUNALELMI-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	Yes	2	1	No	1	0	29.46 Å2	18.25 Å3	49.86 m3·mol-1	2	Yes	Yes	1.36 mg/mL	2.64	-2.1	10.01	-4.9			
C21H20O9S	No pharmacokinetic data available.	No pharmacokinetic data available.	448.44	COC1=CC(\C=C\C(=O)CC(=O)\C=C\C2=CC=C(OS(O)(=O)=O)C(OC)=C2)=CC=C1O	Not Available	Following oral administration of radio-labelled curcumin to rats, radioactivity was detected in the liver and kidneys 2.	P33261;!P20813;!BE0009758;!P11712;!P08684;!P20815;!P10635;!P05177;!O75897;!P0DMM9;!P49888;!O43704	CYP2C19;!CYP2B6;!;!CYP2C9;!CYP3A4;!CYP3A5;!CYP2D6;!CYP1A2;!SULT1C4;!SULT1A3;!SULT1E1;!SULT1B1	1. Cytochrome P450 2C19;!2. Cytochrome P450 2B6;!3. UDP-glucuronosyltransferases (UGTs) (Protein Group);!4. Cytochrome P450 2C9;!5. Cytochrome P450 3A4;!6. Cytochrome P450 3A5;!7. Cytochrome P450 2D6;!8. Cytochrome P450 1A2;!9. Sulfotransferase 1C4;!10. Sulfotransferase 1A3/1A4;!11. Estrogen sulfotransferase;!12. Sulfotransferase family cytosolic 1B member 1					34988878															ZINC000011524418		Curcumin sulfate	Experimental	DB14635	InChI=1S/C21H20O9S/c1-28-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(21(12-15)29-2)30-31(25,26)27/h3-12,24H,13H2,1-2H3,(H,25,26,27)/b7-3+,8-4+	NEJVQQBBTRFOHB-FCXRPNKRSA-N			In an acute oral toxicity study in mouse, LD50 was >2000 mg/kg MSDS. Single oral doses of curcumin at 1-5 g/kg bw induced no toxic effects in rats 2. There has been no cases of overdose reported 2.	Small Molecule																																			1	Yes	8	2	No	2	-1	136.43 Å2	43.54 Å3	113.8 m3·mol-1	10	Yes	No	0.00831 mg/mL	3.65	-4.7	-2.2	-4.4	P37231;!P11473;!O15440;!P16152;!P09211	PPARG;!VDR;!ABCC5;!CBR1;!GSTP1	1. Peroxisome proliferator-activated receptor gamma;!2. Vitamin D3 receptor;!3. Multidrug resistance-associated protein 5;!4. Carbonyl reductase [NADPH] 1;!5. Glutathione S-transferase P
C22H22O4	Not Available	Not Available	350.414	C\C=C(\C(=C\C)\C1=CC=C(OC(C)=O)C=C1)/C1=CC=C(OC(C)=O)C=C1	Not Available	Not Available							CHEMBL3188355	4707742														Dienestrol_diacetate	ZINC000000608322		Dienestrol diacetate	Experimental	DB14668	InChI=1S/C22H22O4/c1-5-21(17-7-11-19(12-8-17)25-15(3)23)22(6-2)18-9-13-20(14-10-18)26-16(4)24/h5-14H,1-4H3/b21-5+,22-6+	YWLLGDVBTLPARJ-OXAZHYLESA-N			Not Available	Small Molecule																																			1	Yes	2	0	No	2	0	52.6 Å2	39.01 Å3	102.66 m3·mol-1	7	Yes	No	0.000534 mg/mL	4.65	-5.8		-6.8			
C18H20O5	Not Available	Not Available	316.353	COC1=CC=C(\C=C/C2=CC(OC)=C(OC)C(OC)=C2)C=C1O	Not Available	Not Available					50005480		CHEMBL67	4508364						7BA								Combretastatin_A-4	ZINC000013452167		Combretastatin A4	Experimental	DB14680	InChI=1S/C18H20O5/c1-20-15-8-7-12(9-14(15)19)5-6-13-10-16(21-2)18(23-4)17(11-13)22-3/h5-11,19H,1-4H3/b6-5-	HVXBOLULGPECHP-WAYWQWQTSA-N			Not Available	Small Molecule																																			1	Yes	5	1	No	2	0	57.15 Å2	33.8 Å3	89.35 m3·mol-1	6	Yes	No	0.00977 mg/mL	3.38	-4.5	9.84	-4.3			
C14H11NO5	Not Available	Not Available	273.244	OC1=C(O)C(=CC(=C1)C(=O)CC1=CC=CC=C1)[N+]([O-])=O	Not Available	Not Available					50108878		CHEMBL160038	8014109															ZINC000000008750		Nebicapone	Investigational	DB14849	InChI=1S/C14H11NO5/c16-12(6-9-4-2-1-3-5-9)10-7-11(15(19)20)14(18)13(17)8-10/h1-5,7-8,17-18H,6H2	MRFOLGFFTUGAEB-UHFFFAOYSA-N	2		Not Available	Small Molecule																																			1	Yes	5	2	No	2	-1	100.67 Å2	26.52 Å3	71.46 m3·mol-1	4	Yes	No	0.075 mg/mL	2.7	-3.6	5.5	-6.5			
C26H22O10	Not Available	Not Available	494.452	OC(=O)[C@@H](CC1=CC(O)=C(O)C=C1)OC(=O)\C=C\C1=C(/C=C/C2=CC(O)=C(O)C=C2)C(O)=C(O)C=C1	Not Available	Not Available					50414250	9017	CHEMBL457077	4445105				C10492											ZINC000004098737		Salvianolic acid A	Investigational	DB15246	InChI=1S/C26H22O10/c27-18-7-2-14(11-21(18)30)1-6-17-16(4-9-20(29)25(17)33)5-10-24(32)36-23(26(34)35)13-15-3-8-19(28)22(31)12-15/h1-12,23,27-31,33H,13H2,(H,34,35)/b6-1+,10-5+/t23-/m1/s1	YMGFTDKNIWPMGF-UCPJVGPRSA-N			Not Available	Small Molecule																																			1	No	9	7	Yes	3	-1	184.98 Å2	48.67 Å3	130.37 m3·mol-1	9	No	No	0.00867 mg/mL	4.74	-4.8	3.14	-6.3			
C21H22O5	Not Available	Not Available	354.3964	COC1=C(C(=O)\C=C\C2=CC=C(O)C=C2)C(O)=C(CC=C(C)C)C(O)=C1	Not Available	Not Available					50384998	66331	CHEMBL253896	555077			HMDB0037479	C16417										Xanthohumol	ZINC000005158937		Xanthohumol	Investigational	DB15359	InChI=1S/C21H22O5/c1-13(2)4-10-16-18(24)12-19(26-3)20(21(16)25)17(23)11-7-14-5-8-15(22)9-6-14/h4-9,11-12,22,24-25H,10H2,1-3H3/b11-7+	ORXQGKIUCDPEAJ-YRNVUSSQSA-N	1		Not Available	Small Molecule																																			1	Yes	5	3	No	2	-1	86.99 Å2	38.52 Å3	103.53 m3·mol-1	6	No	No	0.00556 mg/mL	5.2	-4.8	7.01	-4.9			
C21H19NO3S	Not Available	Not Available	365.45	COC1=CC2=CC=C(C=C2C=C1)C(C)C(=O)OC1=CC=C(C=C1)C(N)=S	Not Available	Not Available								32490194																	ATB-346	Investigational	DB15377	InChI=1S/C21H19NO3S/c1-13(21(23)25-18-8-5-14(6-9-18)20(22)26)15-3-4-17-12-19(24-2)10-7-16(17)11-15/h3-13H,1-2H3,(H2,22,26)	YCNMAPLPQYQJFC-UHFFFAOYSA-N	1		Not Available	Small Molecule																																			1	Yes	2	1	Yes	3	0	61.55 Å2	37.75 Å3	106.47 m3·mol-1	6	Yes	No	0.000368 mg/mL	4.53	-6	12.45	-4.8			
C18H28O4	Not Available	Not Available	308.4125	COC1=C(O)C=CC(COC(=O)CCCCCCC(C)C)=C1	Not Available	Not Available								8049443			HMDB0034781												ZINC000013481841		Dihydrocapsiate	Investigational	DB15398	InChI=1S/C18H28O4/c1-14(2)8-6-4-5-7-9-18(20)22-13-15-10-11-16(19)17(12-15)21-3/h10-12,14,19H,4-9,13H2,1-3H3	RBCYRZPENADQGZ-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	Yes	3	1	No	1	0	55.76 Å2	36.52 Å3	87.25 m3·mol-1	11	Yes	No	0.0129 mg/mL	4.84	-4.4	9.91	-4.9			
C11H14O3	Not Available	Not Available	194.2271	COC1=CC(CCC(C)=O)=CC=C1O	Not Available	Not Available					50304073	68657	CHEMBL25894	28952			HMDB0032590	C17497								2199325		Zingerone	ZINC000000526834		Zingerone	Experimental	DB15589	InChI=1S/C11H14O3/c1-8(12)3-4-9-5-6-10(13)11(7-9)14-2/h5-7,13H,3-4H2,1-2H3	OJYLAHXKWMRDGS-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	Yes	3	1	No	1	0	46.53 Å2	20.95 Å3	53.96 m3·mol-1	4	Yes	No	0.567 mg/mL	1.92	-2.5	9.95	-4.9			
C19H17NO5S	Not Available	Not Available	371.41	COC1=CC=CC(=C1)C(=O)COC1=CC=C(CC2SC(=O)NC2=O)C=C1	Not Available	Not Available					50466687		CHEMBL4291468	32698412																	Azemiglitazone	Investigational	DB16028	InChI=1S/C19H17NO5S/c1-24-15-4-2-3-13(10-15)16(21)11-25-14-7-5-12(6-8-14)9-17-18(22)20-19(23)26-17/h2-8,10,17H,9,11H2,1H3,(H,20,22,23)	YAUMOGALQJYOJQ-UHFFFAOYSA-N	2		Not Available	Small Molecule																																			1	Yes	5	1	Yes	3	-1	81.7 Å2	37.96 Å3	97.48 m3·mol-1	7	Yes	No	0.00411 mg/mL	2.86	-5	6.61	-4.6			
C22H28FNO3	Not Available	Not Available	373.468	COC1=C(OC)C(=CC=C1)[C@H](O)C1CCN(CCC2=CC=C(F)C=C2)CC1	Not Available	Not Available							CHEMBL74355	4470782														Volinanserin	ZINC000000598040		Volinanserin	Investigational	DB16351	InChI=1S/C22H28FNO3/c1-26-20-5-3-4-19(22(20)27-2)21(25)17-11-14-24(15-12-17)13-10-16-6-8-18(23)9-7-16/h3-9,17,21,25H,10-15H2,1-2H3/t21-/m1/s1	HXTGXYRHXAGCFP-OAQYLSRUSA-N	3		Not Available	Small Molecule																																			1	Yes	4	1	Yes	3	1	41.93 Å2	40.13 Å3	105.32 m3·mol-1	7	Yes	No	0.0211 mg/mL	3.59	-4.2	13.95	8.75	P28223	HTR2A	1. 5-hydroxytryptamine receptor 2A
C27H44O3	The metabolic clearance rate was 23.5±4.34 ml/min in healthy male volunteers and 10.1±1.35 ml/min in male patients with uraemia 8. In the pediatric patients undergoing peritoneal dialysis receiving dose of 10.2 ng/kg (SD 5.5 ng/kg) for 2 months, the clearance rate was 15.3 mL/hr/kg Label.	After administration of single oral doses, the elimination half life was 5-8 hours Label.	416.6365	C[C@H](CCCC(C)(C)O)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	Solid	Upon intravenous administration, the volume of distribution of calcitriol was 0.49±0.14 L/kg in healthy male volunteers and 0.27±0.06 l/kg in uraemic male patients participating in a pharmacokinetic study 8. There is some evidence that calcitriol is transferred into human milk at low levels (ie, 2.2±0.1 pg/mL) in mothers Label. Calcitriol from maternal circulation may also enter the fetal circulation Label.	Q07973;!P08684	CYP24A1;!CYP3A4	1. 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial;!2. Cytochrome P450 3A4		50200182	17823	CHEMBL846	4444108	Drugs.com Drug Page	GtP Drug Page	HMDB0001903	C01673	D00129	VDX	PDRhealth Drug Page	PA448717	5280453	46508162	RxList Drug Page	1894	DAP000289	Calcitriol	ZINC000100015048	Rocaltrol, Vectical	Calcitriol	Approved, Nutraceutical	DB00136	InChI=1S/C27H44O3/c1-18(8-6-14-26(3,4)30)23-12-13-24-20(9-7-15-27(23,24)5)10-11-21-16-22(28)17-25(29)19(21)2/h10-11,18,22-25,28-30H,2,6-9,12-17H2,1,3-5H3/b20-10+,21-11-/t18-,22-,23-,24+,25+,27-/m1/s1	GMRQFYUYWCNGIN-NKMMMXOESA-N	4	Calcitriol is an active metabolite of vitamin D that is used to treat hyperparathyroidism and is also used in dialysis patients to combat hypocalcemia.	LD50 (oral, rat) = 620 μg/kg; LD50 (intraperitoneal, rat) > 5 mg/kg MSDS.Symptoms of calcitriol toxicity mirrors the early and late signs and symptoms of vitamin D intoxication associated with hypercalcemia 10. Early signs include weakness, headache, somnolence, nausea, vomiting, dry mouth, constipation, muscle pain, bone pain and metallic taste. Late signs are characterized by polyuria, polydipsia, anorexia, weight loss, nocturia, conjunctivitis (calcific), pancreatitis, photophobia, rhinorrhea, pruritus, hyperthermia, decreased libido, elevated BUN, albuminuria, hypercholesterolemia, elevated SGOT and SGPT, ectopic calcification, hypertension, cardiac arrhythmias and, rarely, overt psychosis 10.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	5.1352 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					5		113-114		Insoluble	1	No	3	3	Yes	3	0	60.69 Å2	51.13 Å3	126.53 m3·mol-1	6	Yes	No	0.00667 mg/mL	4.35	-4.8	14.39	-1.3			
C27H44O2	Not Available	288 hours	400.6371	C[C@H](CCCC(C)(C)O)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C	Solid	Not Available	O15528;!Q07973	CYP27B1;!CYP24A1	1. 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial;!2. 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial		50521013	17933	CHEMBL1040	4446820			HMDB0003550	C01561		VDY	PDRhealth Drug Page	PA164745614	5283731	46505690		1855064	DAP000290	Calcifediol	ZINC000004474414	Rayaldee	Calcifediol	Approved, Nutraceutical	DB00146	InChI=1S/C27H44O2/c1-19-10-13-23(28)18-22(19)12-11-21-9-7-17-27(5)24(14-15-25(21)27)20(2)8-6-16-26(3,4)29/h11-12,20,23-25,28-29H,1,6-10,13-18H2,2-5H3/b21-11+,22-12-/t20-,23+,24-,25+,27-/m1/s1	JWUBBDSIWDLEOM-DTOXIADCSA-N	4	Calcifediol is an active metabolite of vitamin D used to treat hyperparathyroidism as well as to combat hypocalcemia in dialysis patients.	Bone pain, constipation (especially in children or adolescents), diarrhea, drowsiness, dryness of mouth; headache (continuing), increased thirst, increase in frequency of urination, especially at night, or in amount of urine, irregular heartbeat, itching skin, loss of appetite, metallic taste, muscle pain, nausea or vomiting (especially in children or adolescents), unusual tiredness or weakness.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	4.1429 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					6				Insoluble	1	No	2	2	Yes	3	0	40.46 Å2	50.38 Å3	125.06 m3·mol-1	6	No	No	0.0022 mg/mL	5.65	-5.3	18.38	-0.98	P11473	VDR	1. Vitamin D3 receptor
C28H44O	There are no formal reports regarding the clearance rate of ergocalciferol. Due to the structural similarity, it is recommended to consult this parameter with cholecalciferol. On the other hand, the proposed renal clearance of calcitriol is of 31 ml/min.8	Ergocalciferol can be found circulation for 1-2 days. This quick turnover is presented due to hepatic conversion and uptake by fat and muscle cells where it is transformed to the active form.6	396.6484	CC(C)[C@@H](C)\C=C\[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C	Solid	The amount of circulating ergocalciferol is very limited as this compound is rapidly stored in fat tissue such as adipose tissue, liver and muscle. This is very obvious in reports that indicate that circulating ergocalciferol is significantly reduced in obese patients.6	Q96AT9;!P05108;!Q07973;!O15528;!Q02318;!Q6VVX0	RPE;!CYP11A1;!CYP24A1;!CYP27B1;!CYP27A1;!CYP2R1	1. Ribulose-phosphate 3-epimerase;!2. Cholesterol side-chain cleavage enzyme, mitochondrial;!3. 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial;!4. 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial;!5. Sterol 26-hydroxylase, mitochondrial;!6. Vitamin D 25-hydroxylase		50247883	28934	CHEMBL1536	4444351	Drugs.com Drug Page		HMDB0000900	C05441	D00187	D2V	PDRhealth Drug Page	PA449484	5280793	46505053	RxList Drug Page	4018	DAP000291	Ergocalciferol	ZINC000004629876	Drisdol, Mvi Pediatric	Ergocalciferol	Approved, Nutraceutical	DB00153	InChI=1S/C28H44O/c1-19(2)20(3)9-10-22(5)26-15-16-27-23(8-7-17-28(26,27)6)12-13-24-18-25(29)14-11-21(24)4/h9-10,12-13,19-20,22,25-27,29H,4,7-8,11,14-18H2,1-3,5-6H3/b10-9+,23-12+,24-13-/t20-,22+,25-,26+,27-,28+/m0/s1	MECHNRXZTMCUDQ-RKHKHRCZSA-N	4	Ergocalciferol is a vitamin found in many supplement products.	The reported LD50 for orally administered ergocalciferol in the rat is of 10 mg/kg.MSDS Overdosage with this agent is reported to produce hypervitaminosis characterized by hypercalcemia, renal impairment, calcification of soft tissues, a decline in the rate of linear growth and increase in bone mineralization.15Once an overdose state is registered, immediate withdrawal of vitamin D is required along with a calcium diet, generous intake of fluids and symptomatic treatment. The administration of loop diuretics is an option to increase renal calcium excretion. On the other hand, dialysis and administration of citrates, sulfates, phosphates, corticosteroids, EDTA and mithramycin are recommended.15There haven't been long term studies analyzing the carcinogenic and mutagenic potential of ergocalciferol or its effects in fertility.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	3.6931 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				Decomposes	8.89		115-117°C	6.35	Insoluble	1	No	1	1	No	3	0	20.23 Å2	50.72 Å3	128.89 m3·mol-1	5	No	Yes	0.000433 mg/mL	7.05	-6	18.38	-1.3	P11473;!BE0004902	VDR;!	1. Vitamin D3 receptor;!2. Voltage-dependent calcium channel (Protein Group)
C20H30O	Not Available	1.9 hours	286.4516	C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C	Solid	Not Available	O43174	CYP26A1	1. Cytochrome P450 26A1		50092056	17336	CHEMBL986	393012	Drugs.com Drug Page		HMDB0000305	C17276	D00069	RTL	PDRhealth Drug Page	PA451884	445354	46508191	RxList Drug Page	11246	DNC001498	Vitamin_A	ZINC000003831417	Aquasol A, Infuvite, Infuvite Pediatric, Mvc-fluoride, Mvi Pediatric, Vitafol-one	Vitamin A	Approved, Nutraceutical, Vet approved	DB00162	InChI=1S/C20H30O/c1-16(8-6-9-17(2)13-15-21)11-12-19-18(3)10-7-14-20(19,4)5/h6,8-9,11-13,21H,7,10,14-15H2,1-5H3/b9-6+,12-11+,16-8+,17-13+	FPIPGXGPPPQFEQ-OVSJKPMPSA-N	4	Vitamin A is a vitamin important for retinal function that is used clinically to correct vitamin A deficiency.	Acute toxicity to vitamin A can occur when adults or children ingest >100x or >20x the RDA, respectively, over a period of hours or a few days.2 The RDA for vitamin A differs depending on age and sex and can range from 300 - 900 μg retinol activity equivalents (RAE) per day.4 Symptoms of acute systemic toxicity generally include mucocutaneous involvement (e.g. xerosis, cheilitis, skin peeling) and may involve mental status changes.3 Children are typically more susceptible to acute vitamin A toxicity - daily intakes of as little as 1500 IU/kg have been observed to result in toxicity.2Chronic vitamin A toxicity can develop following the long-term ingestion of high vitamin A doses. While there is a wide variation in the lowest toxic vitamin A dose, the ingestion of >25 000 IU daily for 6 years or 100,000 IU daily for 6 months is considered to be toxic.2 Chronic vitamin A toxicity can affect many organ systems and can lead to the development of osteoporosis and CNS effects (e.g. headaches).3	Small Molecule	http://smpdb.ca/view/SMP0000074?highlight[compounds][]=DB00162&highlight[proteins][]=DB00162;!http://smpdb.ca/view/SMP0000336?highlight[compounds][]=DB00162&highlight[proteins][]=DB00162	Retinol Metabolism;!Vitamin A Deficiency		AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.1249 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					5.68		63.5 °C		0.671 mg/L	1	Yes	1	1	No	1	0	20.23 Å2	36.54 Å3	97.92 m3·mol-1	5	Yes	Yes	0.00758 mg/mL	4.69	-4.6	16.44	-2.2	P05090;!P41222;!Q96NR8;!Q92781;!Q8NBN7;!O94788;!P00352;!O95237;!O75911;!P47895;!Q6NUM9;!Q8TC12;!Q9BTZ2;!Q9HBH5;!Q9NYR8	APOD;!PTGDS;!RDH12;!RDH5;!RDH13;!ALDH1A2;!ALDH1A1;!LRAT;!DHRS3;!ALDH1A3;!RETSAT;!RDH11;!DHRS4;!RDH14;!RDH8	1. Apolipoprotein D;!2. Prostaglandin-H2 D-isomerase;!3. Retinol dehydrogenase 12;!4. 11-cis retinol dehydrogenase;!5. Retinol dehydrogenase 13;!6. Retinal dehydrogenase 2;!7. Retinal dehydrogenase 1;!8. Lecithin retinol acyltransferase;!9. Short-chain dehydrogenase/reductase 3;!10. Aldehyde dehydrogenase family 1 member A3;!11. All-trans-retinol 13,14-reductase;!12. Retinol dehydrogenase 11;!13. Dehydrogenase/reductase SDR family member 4;!14. Retinol dehydrogenase 14;!15. Retinol dehydrogenase 8
C27H44O	Studies have determined that the mean clearance value of administered cholecalciferol supplementation in a group of 49 kidney transplant patients was approximately 2.5 L/day 5.	At this time, there have been resources that document the half-life of cholecalciferol as being about 50 days 8 while other sources have noted that the half-life of calcitriol (1,25-dihydroxyvitamin D3) is approximately 15 hours while that of calcidiol (25-hydroxyvitamin D3) is about 15 days 10.Moreover, it appears that the half-lives of any particular administration of vitamin d can vary due to variations in vitamin d binding protein concentrations and genotype in particular individuals 6.	384.6377	CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C	Solid	Studies have determined that the mean central volume of distribution of administered cholecalciferol supplementation in a group of 49 kidney transplant patients was approximately 237 L 5.	Q6VVX0;!Q02318;!P51589;!P08684;!P05108;!P04798;!P10632	CYP2R1;!CYP27A1;!CYP2J2;!CYP3A4;!CYP11A1;!CYP1A1;!CYP2C8	1. Vitamin D 25-hydroxylase;!2. Sterol 26-hydroxylase, mitochondrial;!3. Cytochrome P450 2J2;!4. Cytochrome P450 3A4;!5. Cholesterol side-chain cleavage enzyme, mitochondrial;!6. Cytochrome P450 1A1;!7. Cytochrome P450 2C8		50030475	28940	CHEMBL1042	4444353	Drugs.com Drug Page		HMDB0000876	C05443	D00188	VD3	PDRhealth Drug Page	PA164748138	5280795	46506365		1244014	DAP001273	Cholecalciferol	ZINC000004474460	Adrovance, Animi-3 With Vitamin D, Citranatal B-calm Kit, Citranatal Harmony, Fosamax Plus D, Fosavance, Infuvite, Infuvite Pediatric, Mvc-fluoride, Natafort, Pregvit, Vidextra	CholecalciferolCommonly known or available as Vitamin D3	Approved, Nutraceutical	DB00169	InChI=1S/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h12-13,19,21,24-26,28H,3,6-11,14-18H2,1-2,4-5H3/b22-12+,23-13-/t21-,24+,25-,26+,27-/m1/s1	QYSXJUFSXHHAJI-YRZJJWOYSA-N	4	Vitamin D3 is a form of Vitamin D used in the treatment of specific medical conditions such as refractory rickets, hypoparathyroidism, and familial hypophosphatemia, as well as osteoporosis and chronic kidney disease.	Chronic or acute administration of excessive doses of cholecalciferol may lead to hypervitaminosis D, manifested by hypercalcemia and its sequelae 12,13,14. Early symptoms of hypercalcemia may include weakness, fatigue, somnolence, headache, anorexia, dry mouth, metallic taste, nausea, vomiting, vertigo, tinnitus, ataxia, and hypotonia 12,13,14. Later and possibly more serious manifestation include nephrocalcinosis, renal dysfunction, osteoporosis in adults, impaired growth in children, anemia, metastatic calcification, pancreatitis, generalized vascular calcification, and seizures 12,13,14.Safety of doses in excess of 400 IU (10mcg) of vitamin D3 daily during pregnancy has not been established 12,13,14. Maternal hypercalcemia, possibly caused by excessive vitamin D intake during pregnancy, has been associated with hypercalcemia in neonates, which may lead to supravalvular aortic stenosis syndrome, the features of which may include retinopathy, mental or growth retardation, strabismus, and other effects 12,13,14. Hypercalcemia during pregnancy may also lead to suppression of parathyroid hormone release in the neonate, resulting in hypocalcemia, tetany, and seizures 12,13,14.Vitamin D is deficient in maternal milk; therefore, breastfed infants may require supplementation. Use of excessive amounts of Vitamin D in nursing mothers may result in hypercalcemia in infants. Doses of Vitamin D3 in excess of 10 µg daily should not be administered daily to nursing women.	Small Molecule	http://smpdb.ca/view/SMP0000099?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000111?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000209?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000388?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000389?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000510?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000082?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000089?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000092?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000107?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000117?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000119?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000319?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000508?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000023?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000079?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000095?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000112?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000131?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000386?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000387?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000509?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000511?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169	Lovastatin Action Pathway;!Cerivastatin Action Pathway;!Hypercholesterolemia;!Chondrodysplasia Punctata II, X-Linked Dominant (CDPX2);!Smith-Lemli-Opitz Syndrome (SLOS);!Mevalonic Aciduria;!Simvastatin Action Pathway;!Pravastatin Action Pathway;!Rosuvastatin Action Pathway;!Zoledronate Action Pathway;!Pamidronate Action Pathway;!Fluvastatin Action Pathway;!Lysosomal Acid Lipase Deficiency (Wolman Disease);!Cholesteryl Ester Storage Disease;!Steroid Biosynthesis;!Ibandronate Action Pathway;!Alendronate Action Pathway;!Risedronate Action Pathway;!Atorvastatin Action Pathway;!Desmosterolosis;!CHILD Syndrome;!Hyper-IgD Syndrome;!Wolman Disease		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	3.9310 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					7.5		84.5 °C		Insoluble	1	No	1	1	Yes	3	0	20.23 Å2	49.63 Å3	123.22 m3·mol-1	6	No	Yes	0.00038 mg/mL	7.13	-6	18.38	-1.3	P11473	VDR	1. Vitamin D3 receptor
C22H32O3	Not Available	Not Available	344.4877	[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)CC[C@]12C	Solid	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5			34829	CHEMBL1201173	216968	Drugs.com Drug Page		HMDB0014398	C14643	D02289			PA450346	247839	46506584	RxList Drug Page	29439	DAP001048	Medrysone	ZINC000003977945	Hms	Medrysone	Approved	DB00253	InChI=1S/C22H32O3/c1-12-9-15-17-6-5-16(13(2)23)22(17,4)11-19(25)20(15)21(3)8-7-14(24)10-18(12)21/h10,12,15-17,19-20,25H,5-9,11H2,1-4H3/t12-,15-,16+,17-,19-,20+,21-,22+/m0/s1	GZENKSODFLBBHQ-ILSZZQPISA-N		Medrysone is a topical glucocorticoid applied ophthalmically for the treatment of various ocular inflammatory or allergic conditions.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.3015 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.2		156.5 °C			1	Yes	3	1	No	4	0	54.37 Å2	39.94 Å3	98.85 m3·mol-1	1	Yes	No	0.0337 mg/mL	3.13	-4	18.37	-0.26	P04150	NR3C1	1. Glucocorticoid receptor
C21H28O2	Not Available	Dydrogesterone: 5-7 hours, 20-dihydrodydrogesterone (DHD) metabolite: 14-17 hours	312.4458	[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]2([H])C=CC2=CC(=O)CC[C@@]12C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			31527	CHEMBL1200853	8699		GtP Drug Page	HMDB0014522		D01217			PA164745443	9051	46506195		3706	DAP001205	Dydrogesterone	ZINC000003875998		Dydrogesterone	Approved, Investigational, Withdrawn	DB00378	InChI=1S/C21H28O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h4-5,12,16-19H,6-11H2,1-3H3/t16-,17+,18-,19+,20+,21+/m0/s1	JGMOKGBVKVMRFX-HQZYFCCVSA-N	4	Dydrogesterone is a synthetic progesterone for menstrual cycle regulation, infertility treatment, prevention of miscarriage, and other conditions.	No serious or unexpected toxicity has been observed with dydrogesterone. In acute toxicity studies, the LD50 doses in rats exceeded 4,640mg/kg for the oral route.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	1.8041 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.4		168-169			1	Yes	2	0	No	4	0	34.14 Å2	36.39 Å3	93.82 m3·mol-1	1	Yes	Yes	0.00486 mg/mL	3.79	-4.8	19.4	-4.8	P06401	PGR	1. Progesterone receptor
C21H30O2	Apparent clearance1367 ± 348 (50mg of progesterone administered by vaginal insert once daily) 11.106 ± 15 L/h (50mg/mL IM injection once daily) 11.	Absorption half-life is approximately 25-50 hours and an elimination half-life of 5-20 minutes (progesterone gel) 20. Progesterone, administered orally, has a short serum half-life (approximately 5 minutes). It is rapidly metabolized to 17-hydroxyprogesterone during its first pass through the liver 11.	314.4617	[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	When administered vaginally, progesterone is well absorbed by uterine endometrial tissue, and a small percentage is distributed into the systemic circulation.The amount of progesterone in the systemic circulation appears to be of minimal importance, especially when implantation, pregnancy, and live birth outcomes appear similar for intramuscular and vaginal administration of progesterone 11.					8903	17026	CHEMBL103	5773	Drugs.com Drug Page		HMDB0001830	C00410	D00066	STR	PDRhealth Drug Page	PA451123	5994	46508968	RxList Drug Page	8727	DAP000549	Progesterone	ZINC000004428529	Bijuva, Crinone, Endometrin, Prochieve, Prometrium	Progesterone	Approved, Vet approved	DB00396	InChI=1S/C21H30O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h12,16-19H,4-11H2,1-3H3/t16-,17+,18-,19-,20-,21+/m0/s1	RJKFOVLPORLFTN-LEKSSAKUSA-N	4	Progesterone is a hormone used for a variety of functions, including contraception, control of abnormal uterine bleeding, maintenance of pregnancy, and prevention of endometrial hyperplasia.	Intraperitoneal LD50 (rat): 327 mg/kg MSDS. Use in pregnancyOnly forms of progesterone that are indicated on product labeling for pregnancy should be used. Some forms of progesterone should not be used in pregnancy Label, 22. Refer to individual product monographs for information regarding use in pregnancy. Many studies have found no effects on fetal development associated with long-term use of contraceptive doses of oral progestins. Studies of infant growth and development that have been conducted have not demonstrated significant adverse effects, however, these studies are few in number. It is therefore advisable to rule out suspected pregnancy before starting any hormonal contraceptive 22. Effects on fertilityProgesterone at high doses is an antifertility drug and high doses would be expected to impair fertility until cessation 25. The progesterone contraceptive should not be used during pregnancy. CarcinogenicityProgesterone has been shown to induce or promote the formation of ovarian, uterine, mammary, and genital tract tumors in animals. The clinical relevance of these findings is unknown 24. Certain epidemiological studies of patients using oral contraceptives have reported an increased relative risk of developing breast cancer, especially at a younger age and associated with a longer duration of use. These studies have mainly involved combined oral contraceptives, and therefore, it is unknown whether this risk is attributable to progestins, estrogens, or a combination of both. At this time, there is insufficient data to determine whether the use of progestin-only contraceptives increases the risk in a similar way to combined contraceptives. A meta-analysis of 54 studies showed a small increase in the frequency of breast cancer diagnosis for women who were currently using combined oral contraceptives, or had used them within the past 10 years. There was no increase in the frequency of having breast cancer diagnosed ten or more years after cessation of hormone use. Women with breast cancer should not use oral contraceptives, as there is no sufficient data to fully establish or negate the risk of cancer with hormonal contraceptive use 22. Use in breastfeedingProgesterone has been detected in the milk of nursing mothers 21, 22. No adverse effects, in general, have been found on breastfeeding ability or on the health, growth, or development of the growing infant. Despite this, isolated post-marketing cases of decreased milk production have been reported 22.	Small Molecule	http://smpdb.ca/view/SMP0000371?highlight[compounds][]=DB00396&highlight[proteins][]=DB00396;!http://smpdb.ca/view/SMP0000575?highlight[compounds][]=DB00396&highlight[proteins][]=DB00396;!http://smpdb.ca/view/SMP0000717?highlight[compounds][]=DB00396&highlight[proteins][]=DB00396;!http://smpdb.ca/view/SMP0000372?highlight[compounds][]=DB00396&highlight[proteins][]=DB00396;!http://smpdb.ca/view/SMP0000577?highlight[compounds][]=DB00396&highlight[proteins][]=DB00396;!http://smpdb.ca/view/SMP0000718?highlight[compounds][]=DB00396&highlight[proteins][]=DB00396;!http://smpdb.ca/view/SMP0000130?highlight[compounds][]=DB00396&highlight[proteins][]=DB00396;!http://smpdb.ca/view/SMP0000373?highlight[compounds][]=DB00396&highlight[proteins][]=DB00396;!http://smpdb.ca/view/SMP0000566?highlight[compounds][]=DB00396&highlight[proteins][]=DB00396;!http://smpdb.ca/view/SMP0000576?highlight[compounds][]=DB00396&highlight[proteins][]=DB00396;!http://smpdb.ca/view/SMP0000578?highlight[compounds][]=DB00396&highlight[proteins][]=DB00396	Congenital Lipoid Adrenal Hyperplasia (CLAH) or Lipoid CAH;!11-beta-Hydroxylase Deficiency (CYP11B1);!Apparent Mineralocorticoid Excess Syndrome;!Adrenal Hyperplasia Type 5 or Congenital Adrenal Hyperplasia Due to 17 alpha-Hydroxylase Deficiency;!Corticosterone Methyl Oxidase I Deficiency (CMO I);!3-beta-Hydroxysteroid Dehydrogenase Deficiency;!Steroidogenesis;!Adrenal Hyperplasia Type 3 or Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency;!17-alpha-Hydroxylase Deficiency (CYP17);!21-Hydroxylase Deficiency (CYP21);!Corticosterone Methyl Oxidase II Deficiency (CMO II)		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	1.8041 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				394.13°C (rough estimate)	3.87	-4.43	128-132	Strongest acidic: , Strongest basic: 18.92, -4.8	<0.1 g/100 mL at 19 ºC	1	Yes	2	0	No	4	0	34.14 Å2	37.26 Å3	92.71 m3·mol-1	1	Yes	Yes	0.00546 mg/mL	4.15	-4.8	18.47	-4.8			
C20H28O2	Not Available	Not Available	300.4351	C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O	Solid	Not Available					31892	50648	CHEMBL705	395778	Drugs.com Drug Page		HMDB0002369	C15493	D02815	9CR		PA164746900	449171	46507356	RxList Drug Page	81864	DAP000275	Alitretinoin	ZINC000012661824	Panretin, Toctino	Alitretinoin	Approved, Investigational	DB00523	InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8-,16-14+	SHGAZHPCJJPHSC-ZVCIMWCZSA-N	3	Alitretinoin is a vitamin A derivative used to treat Kaposi's sarcoma and used off label to treat chronic hand eczema and psoriasis.	Not Available	Small Molecule	http://smpdb.ca/view/SMP0000074?highlight[compounds][]=DB00523&highlight[proteins][]=DB00523;!http://smpdb.ca/view/SMP0000336?highlight[compounds][]=DB00523&highlight[proteins][]=DB00523	Retinol Metabolism;!Vitamin A Deficiency		Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.1455 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					4.2		189-190 °C		0.6 mg/L	1	Yes	2	1	No	1	-1	37.3 Å2	35.89 Å3	97.79 m3·mol-1	5	No	Yes	0.00477 mg/mL	5.01	-4.8	4.76		P10276;!P19793;!P10826;!P28702;!P13631;!P48443;!P17936;!Q15238;!Q6V0L0	RARA;!RXRA;!RARB;!RXRB;!RARG;!RXRG;!IGFBP3;!PSG5;!CYP26C1	1. Retinoic acid receptor alpha;!2. Retinoic acid receptor RXR-alpha;!3. Retinoic acid receptor beta;!4. Retinoic acid receptor RXR-beta;!5. Retinoic acid receptor gamma;!6. Retinoic acid receptor RXR-gamma;!7. Insulin-like growth factor-binding protein 3;!8. Pregnancy-specific beta-1-glycoprotein 5;!9. Cytochrome P450 26C1
C20H26O2	The plasma clearance of norethisterone has been estimated as 0.4 L/hr/kg,4,19 and the intrinsic clearance is approximately 73-81 L/h.9	The half-life of norethisterone has been variably estimated as 8-10 hours.4,3,8,14,18	298.4192	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	Solid	The volume of distribution of norethisterone is approximately 4 L/kg.4,19 Sulfated metabolites of norethisterone, as well as small quantities of parent drug, have been shown to distribute into breast milk.11	P08684;!P17516;!P26439;!BE0004887;!P51857;!P33261;!P05177;!P11509	CYP3A4;!AKR1C4;!HSD3B2;!;!AKR1D1;!CYP2C19;!CYP1A2;!CYP2A6	1. Cytochrome P450 3A4;!2. Aldo-keto reductase family 1 member C4;!3. 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2;!4. 3-oxo-5-alpha-steroid 4-dehydrogenase (Protein Group);!5. 3-oxo-5-beta-steroid 4-dehydrogenase;!6. Cytochrome P450 2C19;!7. Cytochrome P450 1A2;!8. Cytochrome P450 2A6		50148732	7627	CHEMBL1162	5994	Drugs.com Drug Page		HMDB0014855	C05028	D00182	NDR	PDRhealth Drug Page	PA450651	6230	46504816	RxList Drug Page	7514	DAP001212	Norethisterone	ZINC000085205451	Activella 1/0.5 28 Day, Activelle, Alyacen 1/35, Alyacen 7/7/7, Amabelz 0.5/0.1 28 Day, Aranelle 28, Aurovela, Aurovela Fe, Aygestin, Balziva 28 Day, Blisovi 21 Fe 1.5/30 28 Day Pack, Blisovi 24 Fe 1/20 28 Day, Brevicon, Briellyn 28 Day, Camila 28 Day, Charlotte 24 Fe Chewable 28 Day, Combipatch, Cyclafem 1/35 28 Day, Cyclafem 7/7/7 28 Day, Cyonanz 28 Day, Dasetta 1/35 28 Day, Dasetta 7/7/7 28 Day, Deblitane 28 Day, Errin 28 Day, Estalis, Estrostep Fe 28 Day, Femcon Fe 28 Day, Femhrt 0.5/2.5 28 Day, Fyavolv, Gemmily 28 Day, Generess Fe 28, Hailey 1.5/30 21 Day, Hailey 24 Fe 28 Day, Hailey Fe 1.5/30 28 Day, Hailey Fe 1/20 28 Day, Heather 28 Day, Incassia, Jencycla 28 Day, Jinteli, Junel 1.5/30 21 Day, Junel 1/20 21 Day, Junel Fe 1.5/30 28 Day, Junel Fe 1/20 28 Day, Junel Fe 24 1/20 28 Day, Kaitlib Fe 28 Day, Larin 1.5/30, Larin 1/20, Larin 24 Fe 1/20, Larin Fe 1.5/30, Larin Fe 1/20, Layolis Fe 28, Leena 28 Day, Lo Loestrin Fe 28 Day, Loestrin 1.5/30 21 Day, Loestrin 24 Fe 28 Day, Loestrin Fe 1/20 28 Day, Lolo, Lomedia 24 Fe, Lopreeza 1/0.5 28 Day, Lupaneta Pack 1-month, Lyleq 28 Day, Lyza, Melodetta 24 Fe Chewable 28 Day, Merzee 28 Day, Microgestin 1.5/30 21 Day, Microgestin 1/20 21 Day, Microgestin 24 Fe 28 Day, Microgestin Fe 1.5/30 28 Day, Microgestin Fe 1/20 28 Day, Mimvey, Minastrin 24 Fe Chewable 28 Day, Myfembree, Necon 0.5/35 28 Day, Necon 1/35 28 Day, Necon 7/7/7 28 Day, Nexesta Fe 28 Day, Nora-BE 28 Day, Norlutate, Norlyda 28 Day, Norlyroc 28 Day, Nortrel 1/35 21 Day, Nortrel 1/35 28 Day, Nortrel 7/7/7 28 Day, Nylia 1/35 28 Day, Nylia 7/7/7 28 Day, Oriahnn 28 Day Kit, Ortho Micronor, Ortho Micronor 28 Day, Ortho-novum 7/7/7 28 Day, Philith 28 Day, Pirmella 1/35 28 Day, Pirmella 7/7/7 28 Day, Select, Sharobel 28 Day, Synphasic, Tarina 24 Fe 1/20 28 Day, Tarina Fe 1/20 28 Day, Taysofy 28 Day, Taytulla 28 Day, Tilia Fe, Tri-legest 28 Day, Tulana 28 Day, Vyfemla 28 Day, Wera 28 Day, Wymzya Fe 28 Day, Zenchent	Norethisterone	Approved	DB00717	InChI=1S/C20H26O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,12,15-18,22H,4-11H2,2H3/t15-,16+,17+,18-,19-,20-/m0/s1	VIKNJXKGJWUCNN-XGXHKTLJSA-N	4	Norethisterone is a synthetic second-generation progestin used for contraception, prevention of endometrial hyperplasia in hormone replacement therapy, and in the treatment of other hormone-mediated illnesses such as endometriosis.	The oral LD50 in mice 6 g/kg and the TDLo in human women is 42 mg/kg.20 There have been no reports of serious ill effects following overdose of oral contraceptives, including following ingestion by children.19,18 Symptoms of overdosage are likely to be consistent with the adverse effect profile of the contraceptive and may, therefore, include significant nausea and/or vomiting.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.8788 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							202-208C			1	Yes	2	1	No	4	0	37.3 Å2	34.59 Å3	87.42 m3·mol-1	0	Yes	Yes	0.00668 mg/mL	3.22	-4.6	17.59	-1.7			
C20H28O2	Not Available	0.5-2 hours	300.442	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O	Solid	Not Available	P24462;!P20813;!P10632;!P11712;!P08684;!P20815;!P11509;!P33260;!P04798;!Q02928	CYP3A7;!CYP2B6;!CYP2C8;!CYP2C9;!CYP3A4;!CYP3A5;!CYP2A6;!CYP2C18;!CYP1A1;!CYP4A11	1. Cytochrome P450 3A7;!2. Cytochrome P450 2B6;!3. Cytochrome P450 2C8;!4. Cytochrome P450 2C9;!5. Cytochrome P450 3A4;!6. Cytochrome P450 3A5;!7. Cytochrome P450 2A6;!8. Cytochrome P450 2C18;!9. Cytochrome P450 1A1;!10. Cytochrome P450 4A11		31883	15367	CHEMBL38	392618	Drugs.com Drug Page		HMDB0001852	C00777	D00094	REA		PA164746900	5538	46504843	RxList Drug Page	10753	DNC000117	Tretinoin	ZINC000012358651	Altreno, Atralin, Avita, Biacna, Refissa, Renova, Retin-A, Stieva-A, Tri-luma, Twyneo, Veltin, Vesanoid, Ziana	Tretinoin	Approved, Investigational, Nutraceutical	DB00755	InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14+	SHGAZHPCJJPHSC-YCNIQYBTSA-N	4	Tretinoin is a vitamin A derivative used to treat acne vulgaris, certain types of promyelocytic leukemia, and fine wrinkles.	Not Available	Small Molecule	http://smpdb.ca/view/SMP0000074?highlight[compounds][]=DB00755&highlight[proteins][]=DB00755;!http://smpdb.ca/view/SMP0000336?highlight[compounds][]=DB00755&highlight[proteins][]=DB00755	Retinol Metabolism;!Vitamin A Deficiency		Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.1455 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					6.30		181 °C		<0.1 g/100 mL	1	Yes	2	1	No	1	-1	37.3 Å2	36.85 Å3	97.79 m3·mol-1	5	No	Yes	0.00477 mg/mL	5.01	-4.8	4.76				
C19H24O3	Not Available	Not Available	300.3921	[H][C@@]12CCC3=CC(=O)C=C[C@]3(C)[C@@]1([H])CC[C@]1(C)OC(=O)CC[C@@]21[H]	Solid	Not Available					50367848	9460	CHEMBL1571	13172	Drugs.com Drug Page		HMDB0015031	C02197	D00153			PA164743056	13769	46508076	RxList Drug Page	10378	DAP000624	Testolactone	ZINC000004081771		Testolactone	Approved, Investigational	DB00894	InChI=1S/C19H24O3/c1-18-9-7-13(20)11-12(18)3-4-14-15(18)8-10-19(2)16(14)5-6-17(21)22-19/h7,9,11,14-16H,3-6,8,10H2,1-2H3/t14-,15+,16+,18+,19+/m1/s1	BPEWUONYVDABNZ-DZBHQSCQSA-N	4	Testolactone is a medication used to treat advanced breast cancer.	Oral LD50s in mouse and dog are 1630 mg/kg and 593-926 mg/kg, respectively.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.7356 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.7		218.5 °C		Slightly soluble (27.4 mg/L)	1	Yes	2	0	No	4	0	43.37 Å2	33.42 Å3	85.79 m3·mol-1	0	Yes	No	0.023 mg/mL	3.23	-4.1	18.37	-5			
C20H28O2	The clearance of isotretinoin is 15.9L/h in pediatric patients with neuroblastoma.6 Clearance is also 21.3mL/min/kg in guinea pigs and 7.2mL/min/kg in obese rats.5	The half life ranges from 7-39 hours13 with a mean elimination half life of 20 hours.1 The half life of 4-oxo-13-cis-retinoic acid ranges from 17-50 hours with a mean elimination half life of 25 hours.13	300.4351	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O	Solid	The volume of distribution in humans is unknown because there is no intravenous preparation.13 In a study of pediatric patients with neuroblastoma the volume of distribution was found to be 85L.6 The volume of distribution was also found to be 2432mL/kg in guinea pigs and 1716mL/kg in obese rats.5	P08684	CYP3A4	1. Cytochrome P450 3A4		50031459	6067	CHEMBL547	4445539	Drugs.com Drug Page		HMDB0006219		D00348			PA450128	5282379	46508729	RxList Drug Page	6064	DAP000009	Isotretinoin	ZINC000003792789	Absorica, Accutane, Amnesteem, Claravis, Clarus, Epuris, Myorisan, Sotret, Zenatane	Isotretinoin	Approved	DB00982	InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14-	SHGAZHPCJJPHSC-XFYACQKRSA-N	4	Isotretinoin is a retinoid used to treat severe recalcitrant acne.	Patients experiencing an overdose may present with vomiting, facial flushing, cheilosis, abdominal pain, headache, dizziness, and ataxia.Label These symptoms may rapidly resolve.Label Generally no treatment is required for these overdoses.7The oral lowest dose causing toxic effect (TDLO) for children is 30mg/kg/21W, oral TDLO for men is 24mg/kg/4W, oral TDLO for women is 56mg/kg/8W.14 The intraperitoneal LD50 for rats is 901mg/kg, oral LD50 for mice is 3389mg/kg, oral LD50 for rats is >4000mg/kg.14Isotretinoin is associated with major congenital malformations, spontaneous abortion, and premature birth.Label It is unknown if isotretinoin is expressed in breast milk but due to the associated hazards a decision should be made to either stop nursing or stop taking isotretinoin.LabelIn animal studies, isotretinoin was associated with an increased risk of pheochromocytoma and adrenal medullary hyperplasia at doses above the recommended clinical dose.Label Isotretinoin was negative for the Ames test of mutagenicity once and weakly positive a second time.Label It has not been shown to be clastogenic.Label A study in dogs noted testicular atrophy after doses of 10-30 times the recommended clinical dose for 30 weeks.Label In trials with men there were no effects seen on sperm count, motility, morphology, ejaculate volume, and seminal plasma fructose.Label	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.1455 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				462.8	5.66		189-190	~4	0.00477mg/mL	1	Yes	2	1	No	1	-1	37.3 Å2	36.15 Å3	97.79 m3·mol-1	5	No	Yes	0.00477 mg/mL	5.01	-4.8	4.76		P13631;!P10276	RARG;!RARA	1. Retinoic acid receptor gamma;!2. Retinoic acid receptor alpha
C27H34O3	Not Available	The elimination half-life from plasma is very short.	406.5571	[H][C@@]12CC[C@H](OC(=O)CCC3=CC=CC=C3)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	Solid	Not Available						7468	CHEMBL1200412	199761	Drugs.com Drug Page		HMDB0015119	C08155	D00956			PA164746281	229455	46506276		31495	DAP000903	Nandrolone	ZINC000003881613		Nandrolone phenpropionate	Approved, Illicit, Investigational	DB00984	InChI=1S/C27H34O3/c1-27-16-15-22-21-11-9-20(28)17-19(21)8-10-23(22)24(27)12-13-25(27)30-26(29)14-7-18-5-3-2-4-6-18/h2-6,17,21-25H,7-16H2,1H3/t21-,22+,23+,24-,25-,27-/m0/s1	UBWXUGDQUBIEIZ-QNTYDACNSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	1.8785 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							118 °C		3090 mg/L (at 25 °C)	1	No	2	0	No	5	0	43.37 Å2	47.83 Å3	118.43 m3·mol-1	5	No	No	0.000458 mg/mL	5.79	-6	18.25	-4.7	P10275	AR	1. Androgen receptor
C20H24O2	Not Available	24 hours	296.4034	[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC(=C)C2=CC(=O)C=C[C@]12C	Solid	Not Available	P11511;!P08684	CYP19A1;!CYP3A4	1. Cytochrome P450 19A1;!2. Cytochrome P450 3A4		50398447	4953	CHEMBL1200374	54278	Drugs.com Drug Page		HMDB0015125	C08162	D00963	EXM		PA449563	60198	46508243	RxList Drug Page	258494	DAP000625	Exemestane	ZINC000003973334	Aromasin	Exemestane	Approved, Investigational	DB00990	InChI=1S/C20H24O2/c1-12-10-14-15-4-5-18(22)20(15,3)9-7-16(14)19(2)8-6-13(21)11-17(12)19/h6,8,11,14-16H,1,4-5,7,9-10H2,2-3H3/t14-,15-,16-,19+,20-/m0/s1	BFYIZQONLCFLEV-DAELLWKTSA-N	4	Exemestane is an aromatase inhibitor used to treat breast cancer in postmenopausal women after treatment with tamoxifen.	Convulsions	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.7582 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.7		155.13 °C		Non-soluble	1	Yes	2	0	No	4	0	34.14 Å2	33.72 Å3	89.03 m3·mol-1	0	Yes	Yes	0.00683 mg/mL	3.87	-4.6		-5			
C26H38O4	Not Available	Not Available	414.586	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)C(=O)COC(=O)C(C)(C)C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			50782	CHEMBL1200592	10050591								PA449245	11876263	46506381		22537	DAP001106	Desoxycorticosterone_pivalate	ZINC000004082455		Desoxycorticosterone pivalate	Experimental, Vet approved	DB01134	InChI=1S/C26H38O4/c1-24(2,3)23(29)30-15-22(28)21-9-8-19-18-7-6-16-14-17(27)10-12-25(16,4)20(18)11-13-26(19,21)5/h14,18-21H,6-13,15H2,1-5H3/t18-,19-,20-,21+,25-,26-/m0/s1	VVOIQBFMTVCINR-WWMZEODYSA-N			Symptoms of overdose include polyuria, polydipsia, increased blood volume, edema, and cardiac enlargement.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	1.7883 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					4				Insoluble	1	Yes	3	0	No	4	0	60.44 Å2	48.3 Å3	117.26 m3·mol-1	5	No	No	0.00141 mg/mL	5.57	-5.5	17.19	-4.8	P08235	NR3C2	1. Mineralocorticoid receptor
C23H30O6	Data regarding the clearance of cortisone acetate is not readily available.8	Not Available	402.4807	[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5		50455157	3897	CHEMBL1650	5543	Drugs.com Drug Page		HMDB0015459	C08173	D00973			PA449130	5745	46508852	RxList Drug Page	21655		Cortisone_acetate	ZINC000003875334		Cortisone acetate	Approved, Investigational	DB01380	InChI=1S/C23H30O6/c1-13(24)29-12-19(27)23(28)9-7-17-16-5-4-14-10-15(25)6-8-21(14,2)20(16)18(26)11-22(17,23)3/h10,16-17,20,28H,4-9,11-12H2,1-3H3/t16-,17-,20+,21-,22-,23-/m0/s1	ITRJWOMZKQRYTA-RFZYENFJSA-N	4	Cortisone acetate is a steroid hormone used for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses and endocrine disorders associated with inadequate production of steroid hormones.	Data regarding acute overdoses of glucocorticoids are rare.8 Chronic high doses of glucocorticoids can lead to the development of cataract, glaucoma, hypertension, water retention, hyperlipidemia, peptic ulcer, pancreatitis, myopathy, osteoporosis, mood changes, psychosis, dermal atrophy, allergy, acne, hypertrichosis, immune suppression, decreased resistance to infection, moon face, hyperglycemia, hypocalcemia, hypophosphatemia, metabolic acidosis, growth suppression, and secondary adrenal insufficiency.6 Overdose may be treated by adjusting the dose or stopping the corticosteroid as well as initiating symptomatic and supportive treatment.6	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.1280 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.10		227-229		20 mg/L (at 25 °C)	1	Yes	5	1	No	4	0	97.74 Å2	43.06 Å3	105.63 m3·mol-1	4	Yes	No	0.0278 mg/mL	2.1	-4.2	12.6	-3.8	P04150;!P04083	NR3C1;!ANXA1	1. Glucocorticoid receptor;!2. Annexin A1
C21H32O	Not Available	Not Available	300.4782	[H][C@@]12CC[C@@](O)(CC=C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCCC=C3CC[C@@]21[H]	Solid	Not Available						31189	CHEMBL3185133	205855			HMDB0015500	C12811	D01374			PA164745307	235905	46506946		525	DPR000085	Allylestrenol	ZINC000004214767		Allylestrenol	Experimental	DB01431	InChI=1S/C21H32O/c1-3-12-21(22)14-11-19-18-9-8-15-6-4-5-7-16(15)17(18)10-13-20(19,21)2/h3,6,16-19,22H,1,4-5,7-14H2,2H3/t16-,17+,18+,19-,20-,21-/m0/s1	ATXHVCQZZJYMCF-XUDSTZEESA-N		Allylestrenol is a steroid used to prevent premature labour in pregnant women.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.4200 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							80 °C			1	Yes	1	1	No	4	0	20.23 Å2	37.18 Å3	93.14 m3·mol-1	2	Yes	Yes	0.000558 mg/mL	4.83	-5.7		-0.17	P06401;!P03372	PGR;!ESR1	1. Progesterone receptor;!2. Estrogen receptor alpha
C18H24O2	Not Available	Not Available	272.382	[H][C@@]12CCC(=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	Solid	Not Available						34187		83803				C14500			PDRhealth Drug Page		92834	46505377				19-Norandrostenedione	ZINC000004428372		19-norandrostenedione	Experimental, Illicit	DB01434	InChI=1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h10,13-16H,2-9H2,1H3/t13-,14+,15+,16-,18-/m0/s1	JRIZOGLBRPZBLQ-QXUSFIETSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.6104 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	0	No	4	0	34.14 Å2	31.56 Å3	79.13 m3·mol-1	0	Yes	Yes	0.0454 mg/mL	3.63	-3.8	18.25	-4.7			
C27H44O2	Not Available	The half-life of alfacalcidol ranges from three to four hours.9,12	400.6371	CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	Solid	Not Available						31186	CHEMBL1601669	4445376			HMDB0015504		D01518	M9B		PA164746469	5282181	46505115		12062		Alfacalcidol	ZINC000012484965	One-alpha	Alfacalcidol	Approved, Nutraceutical	DB01436	InChI=1S/C27H44O2/c1-18(2)8-6-9-19(3)24-13-14-25-21(10-7-15-27(24,25)5)11-12-22-16-23(28)17-26(29)20(22)4/h11-12,18-19,23-26,28-29H,4,6-10,13-17H2,1-3,5H3/b21-11+,22-12-/t19-,23-,24-,25+,26+,27-/m1/s1	OFHCOWSQAMBJIW-AVJTYSNKSA-N	4	Alfacalcidol is a vitamin D analogue used for the management of hypocalcemia, secondary hyperparathyroidism, and osteodystrophy in patients with chronic renal failure, as well as some types of rickets and osteomalacia.	There is a discrepancy across a number of reported LD50 values for alfacalcidol, which can be attributed to differences in the procedures used in laboratories. Oral LD50 in mice ranges from 440 to 490 mcg/kg. Intravenous in mice was 290 mcg/kg; however, another source presented 56 mcg/kg in female mice and 71 mcg/kg in male mice. Oral LD50 in rats ranges from 340 to 720 mcg/kg.9In case of an acute accidental overdose following oral administration, emesis or gastric lavage can be induced to prevent further drug absorption. Mineral oil may be used to promote fecal drug elimination in instances where the drug was already absorbed in the stomach.9 Alfacalcidol overdose can lead to hypercalcemia, hypercalciuria, and hyperphosphatemia. Similarly, a high intake of calcium and phosphate concurrently with a therapeutic dose of alfacalcidol can result in those conditions.9 Hypercalcemia most commonly presents with headache, weakness, hypertension, somnolence, dizziness, sweating, anorexia, nausea, vomiting, diarrhea, constipation, polyuria, polydipsia and muscle and bone pain, and metallic taste.12 Hypercalcemia should be responded to with discontinuation of alfacalcidol, a low calcium diet and withdrawal of calcium supplements.9 Prolonged hypercalcemia can lead to nephrocalcinosis, nephrolithiasis, and reduced kidney function. In cases of severe hypercalcemia, general supportive measures are recommended, which may include forced diuresis and close monitoring of renal function, electrolytes, and electrocardiographs. Monitoring for abnormalities is especially critical in patients receiving digitalis glycosides. Management with glucocorticosteroids, loop diuretics, bisphosphonates, and calcitonin, as well as hemodialysis with low calcium content, may be considered.12	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	4.6023 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							136 °C		<1 mg/mL	1	No	2	2	Yes	3	0	40.46 Å2	50.56 Å3	124.7 m3·mol-1	6	No	No	0.00163 mg/mL	5.82	-5.4	14.39	-2.8	P11473;!O15528;!P19793	VDR;!CYP27B1;!RXRA	1. Vitamin D3 receptor;!2. 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial;!3. Retinoic acid receptor RXR-alpha
C18H24O2	Not Available	Not Available	272.388	[H][C@@]12CCC(=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)CC3=CC[C@@]21[H]	Solid	Not Available								18612511									18633059	46508864				19-Nor-5-androstenedione			19-Nor-5-androstenedione	Experimental, Illicit	DB01443	InChI=1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h2,13-16H,3-10H2,1H3/t13-,14+,15+,16-,18-/m0/s1	WELNRNVZXWUOGT-QXUSFIETSA-N			Because 19-Nor-5-androstenedione is metabolically related toother controlled anabolic steroids, it is likely to have similar adverse health effects such as liver, heart and skin problems, hormonal disruptions, stunted growth,and psychological effects such as rage and depression.	Small Molecule																																			1	Yes	2	0	No	4	0	34.14 Å2	31.58 Å3	79.16 m3·mol-1	0	Yes	Yes	0.0621 mg/mL	3.27	-3.6	16.25	-7.2			
C18H28O2	Not Available	Not Available	276.4137	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CC[C@H](O)CC3=CC[C@@]21[H]	Solid	Not Available					50423550		CHEMBL259126	8075901			HMDB0004590						9900246	46507256				19-Nor-5-androstenediol	ZINC000012496354		19-Nor-5-androstenediol	Experimental, Illicit	DB01455	InChI=1S/C18H28O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h2,12-17,19-20H,3-10H2,1H3/t12-,13-,14+,15+,16-,17-,18-/m0/s1	VVUQRXPUVKXAIO-XFUVECHXSA-N			Not Available	Small Molecule																																			1	Yes	2	2	No	4	0	40.46 Å2	33.21 Å3	81.01 m3·mol-1	0	Yes	No	0.0645 mg/mL	2.5	-3.6	18.23	-0.77			
C27H35NO5	Not Available	Not Available	453.579	[H][C@@]12OC3=C(OC(C)=O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@@]11C[C@]([H])([C@](C)(O)CCC)[C@]2(OC)C=C1	Solid	Not Available							CHEMBL3989451	16736130									20055090	46506577				Acetorphine	ZINC000072266292		Acetorphine	Experimental, Illicit	DB01469	InChI=1S/C27H35NO5/c1-6-9-24(3,30)19-15-25-10-11-27(19,31-5)23-26(25)12-13-28(4)20(25)14-17-7-8-18(32-16(2)29)22(33-23)21(17)26/h7-8,10-11,19-20,23,30H,6,9,12-15H2,1-5H3/t19-,20-,23-,24-,25-,26+,27-/m1/s1	LFYBMMHFJIAKFE-PMEKXCSPSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	3.3149 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	1	Yes	6	1	68.23 Å2	49.84 Å3	125.67 m3·mol-1	6	Yes	No	0.0197 mg/mL	2.66	-4.4	14.68	8.97			
C19H28O3	Clearance is via the urine. Excretion studies were performed using 200mg of 4-hydroxytestosterone administered to healthy male volunteers. Urine samples were then analyzed for metabolic products using conventional gas chromatography-mass spectrometry approaches.One metabolite, 3-beta,4-alpha-dihydroxy-5alpha-androstan-17-one was identified as a long term metabolite which can be detected for 90 hours. Longer detection times are possible with the use of alternative monitoring technique in sports drug testing.	Not Available	304.43	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=C(O)C(=O)CC[C@]12C	Solid	Not Available							CHEMBL2431525	141138									160615	46508337				4-Hydroxytestosterone	ZINC000031460450		4-Hydroxytestosterone	Experimental, Illicit	DB01485	InChI=1S/C19H28O3/c1-18-10-8-15(20)17(22)14(18)4-3-11-12-5-6-16(21)19(12,2)9-7-13(11)18/h11-13,16,21-22H,3-10H2,1-2H3/t11-,12-,13-,16-,18+,19-/m0/s1	BQOIJSIMMIDHMO-FBPKJDBXSA-N			Excessive doses of anabolic steroids can induce harmful changes in cholesterol, acne, hypertension, liver damage, and damage to the heart. Hormonal imbalances caused by the use of anabolic steriods may result in gynecomastia and testicular atrophy.Anabolic steroids are known to increase harmful LDL, while decreasing beneficial HDL cholesterol. Their ability to stimulate sebaceous glands may increase acne. Additionally, the elevation in blood pressure caused by anabolic steroids, is particularly pronounced and harmful in those with pre-existing hypertension.	Small Molecule																																			1	Yes	3	2	No	4	0	57.53 Å2	34.73 Å3	86.4 m3·mol-1	0	Yes	No	0.068 mg/mL	2.85	-3.6	9.28	-0.88			
C18H26O3	Not Available	Not Available	290.403	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C(O)=C3CC[C@@]21[H]	Solid	Not Available						135210		16736429									20055236	46508722				Oxabolone			Oxabolone	Experimental, Illicit	DB01500	InChI=1S/C18H26O3/c1-18-9-8-11-10-4-6-15(19)17(21)13(10)3-2-12(11)14(18)5-7-16(18)20/h10-12,14,16,20-21H,2-9H2,1H3/t10-,11-,12-,14+,16+,18+/m1/s1	GXHBCWCMYVTJOW-YGRHGMIBSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.8869 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							189 °C			1	Yes	3	2	No	4	0	57.53 Å2	33.23 Å3	81.92 m3·mol-1	0	Yes	No	0.0883 mg/mL	2.55	-3.5	9.3	-0.88			
C19H27ClO2	Not Available	Not Available	322.869	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=C(Cl)C(=O)CC[C@]12C	Solid	Not Available						135372	CHEMBL2106571	62171					D07731				68947	46505505		61686		Clostebol	ZINC000004025021		Clostebol	Experimental, Illicit	DB01521	InChI=1S/C19H27ClO2/c1-18-10-8-15(21)17(20)14(18)4-3-11-12-5-6-16(22)19(12,2)9-7-13(11)18/h11-13,16,22H,3-10H2,1-2H3/t11-,12-,13-,16-,18+,19-/m0/s1	KCZCIYZKSLLNNH-FBPKJDBXSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.7601 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							189 °C			1	Yes	2	1	No	4	0	37.3 Å2	36.02 Å3	89.22 m3·mol-1	0	Yes	Yes	0.0153 mg/mL	3.75	-4.3	19.38	-0.88			
C19H28O3	Not Available	Not Available	304.43	[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C(O)=C3CC[C@@]21[H]	Solid	Not Available								42759157									69249407	46504925					ZINC000263614121		17alpha-methyl-4-hydroxynandrolone	Illicit	DB01540	InChI=1S/C19H28O3/c1-18-9-7-12-11-5-6-16(20)17(21)14(11)4-3-13(12)15(18)8-10-19(18,2)22/h11-13,15,21-22H,3-10H2,1-2H3/t11-,12-,13-,15+,18+,19+/m1/s1	CLNUZOCYKSHICX-FAHHUNKHSA-N			Not Available	Small Molecule																																			1	Yes	3	2	No	4	0	57.53 Å2	35.02 Å3	86.56 m3·mol-1	0	Yes	No	0.0575 mg/mL	2.83	-3.7	9.33	-0.53			
C19H26O2	Not Available	14 days	286.4085	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	Not Available					91719	34584	CHEMBL209073	12744				C14502	D07536				13308	46505583		2289408		Boldenone	ZINC000004215042		Boldenone	Illicit, Vet approved	DB01541	InChI=1S/C19H26O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h7,9,11,14-17,21H,3-6,8,10H2,1-2H3/t14-,15-,16-,17-,18-,19-/m0/s1	RSIHSRDYCUFFLA-DYKIIFRCSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.6259 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							165 °C			1	Yes	2	1	No	4	0	37.3 Å2	33.11 Å3	85.52 m3·mol-1	0	Yes	Yes	0.0259 mg/mL	3.36	-4	18.39	-0.88	P10275	AR	1. Androgen receptor
C18H28O2	Not Available	Not Available	276.42	C[C@]12CC[C@H]3[C@@H](CCC4=C[C@@H](O)CC[C@H]34)[C@@H]1CC[C@@H]2O	Solid	Not Available						145661	CHEMBL307500	8011024									9835303	46505759				Bolandiol	ZINC000026375797		Bolandiol	Experimental, Illicit	DB01554	InChI=1S/C18H28O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h10,12-17,19-20H,2-9H2,1H3/t12-,13-,14+,15+,16-,17-,18-/m0/s1	CMXKUJNZWYTFJN-XFUVECHXSA-N			Not Available	Small Molecule																																			1	Yes	2	2	No	4	0	40.46 Å2	33.3 Å3	80.85 m3·mol-1	0	Yes	No	0.0566 mg/mL	2.65	-3.7	17.52	-0.82			
C21H28O4	Not Available	Not Available	344.4446	[H][C@@]12CC[C@](C)(O)[C@@]1(C)C[C@@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C(C=O)=C[C@]12C	Solid	Not Available						135456	CHEMBL2107419	16234			HMDB0004631						17150	46508967				Formebolone	ZINC000004216332		Formebolone	Experimental, Illicit	DB01569	InChI=1S/C21H28O4/c1-19-9-12(11-22)16(23)8-13(19)4-5-14-15-6-7-21(3,25)20(15,2)10-17(24)18(14)19/h8-9,11,14-15,17-18,24-25H,4-7,10H2,1-3H3/t14-,15-,17+,18+,19-,20-,21-/m0/s1	AMVODTGMYSRMNP-GNIMZFFESA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	3.2193 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				543.6 °C			210.5 °C			1	Yes	4	2	No	4	0	74.6 Å2	38.13 Å3	96.9 m3·mol-1	1	Yes	No	0.0605 mg/mL	1.76	-3.8	14.39	-2.9	P80365	HSD11B2	1. Corticosteroid 11-beta-dehydrogenase isozyme 2
C18H20O2	Not Available	Not Available	268.3502	[H][C@@]12CCC(=O)[C@@]1(C)CC[C@]1([H])C3=C(CC=C21)C=C(O)C=C3	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4		50423544	42309	CHEMBL323533	193995				C14392	D04041	EQI			223368	46506633				Equilin	ZINC000100031739		Equilin	Experimental	DB02187	InChI=1S/C18H20O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3-5,10,14,16,19H,2,6-9H2,1H3/t14-,16+,18+/m1/s1	WKRLQDKEXYKHJB-HFTRVMKXSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.8021 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							239 °C		1.41 mg/L (at 25 °C)	1	Yes	2	1	No	4	0	37.3 Å2	30.52 Å3	79.93 m3·mol-1	0	Yes	Yes	0.0133 mg/mL	3.9	-4.3	9.41	-6	P03372;!P14061	ESR1;!HSD17B1	1. Estrogen receptor alpha;!2. Estradiol 17-beta-dehydrogenase 1
C27H40O3	Not Available	Not Available	412.6047	O[C@H](\C=C\[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C)C1CC1	Solid	Not Available	P05164;!Q07973	MPO;!CYP24A1	1. Myeloperoxidase;!2. 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial		50369964	50749	CHEMBL1200666	4450880		GtP Drug Page	HMDB0015567		D01125	MC9		PA448714	5288783	46507122	RxList Drug Page	29365	DAP000292	Calcipotriol	ZINC000003921872	Calcitrene, Dovobet, Dovonex, Enstilar, Sorilux, Taclonex, Wynzora	Calcipotriol	Approved	DB02300	InChI=1S/C27H40O3/c1-17(6-13-25(29)20-8-9-20)23-11-12-24-19(5-4-14-27(23,24)3)7-10-21-15-22(28)16-26(30)18(21)2/h6-7,10,13,17,20,22-26,28-30H,2,4-5,8-9,11-12,14-16H2,1,3H3/b13-6+,19-7+,21-10-/t17-,22-,23-,24+,25-,26+,27-/m1/s1	LWQQLNNNIPYSNX-UROSTWAQSA-N	4	Calcipotriol is a topical synthetic vitamin D2 derivative used in the treatment of plaque psoriasis.	Topically applied calcipotriene can be absorbed in sufficient amounts to produce systemic effects. Elevated serum calcium has been observed with excessive use of calcipotriene.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	3.9699 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	3	No	4	0	60.69 Å2	49.59 Å3	125.45 m3·mol-1	5	Yes	No	0.0135 mg/mL	3.84	-4.5	14.39	-1.6			
C20H28O2	Not Available	Not Available	300.4351	C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)C(=O)CCC1(C)C	Solid	Not Available						44597		4451124			HMDB0012329	C16683		OXR			5289090	46506951					ZINC000012502479		4-Oxoretinol	Experimental	DB02699	InChI=1S/C20H28O2/c1-15(7-6-8-16(2)12-14-21)9-10-18-17(3)19(22)11-13-20(18,4)5/h6-10,12,21H,11,13-14H2,1-5H3/b8-6+,10-9+,15-7+,16-12+	PLIUCYCUYQIBDZ-RMWYGNQTSA-N			Not Available	Small Molecule	http://smpdb.ca/view/SMP0000074?highlight[compounds][]=DB02699&highlight[proteins][]=DB02699;!http://smpdb.ca/view/SMP0000336?highlight[compounds][]=DB02699&highlight[proteins][]=DB02699	Retinol Metabolism;!Vitamin A Deficiency		Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.7980 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	1	No	1	0	37.3 Å2	36.68 Å3	98.62 m3·mol-1	5	Yes	Yes	0.0121 mg/mL	4.03	-4.4	16.44	-2.2			
C21H32O2	Not Available	Not Available	316.4776	[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4		50375319	16581	CHEMBL253363	8611			HMDB0000253	C01953	D00143	PLO			8955	46506718		114052	DNC001147	Pregnenolone	ZINC000003861150		Pregnenolone	Approved, Experimental	DB02789	InChI=1S/C21H32O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h4,15-19,23H,5-12H2,1-3H3/t15-,16-,17+,18-,19-,20-,21+/m0/s1	ORNBQBCIOKFOEO-QGVNFLHTSA-N	4		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.9852 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	1	No	4	0	37.3 Å2	38.09 Å3	93.76 m3·mol-1	1	Yes	Yes	0.0136 mg/mL	3.58	-4.4	18.2	-1.4	O75469;!O00204	NR1I2;!SULT2B1	1. Nuclear receptor subfamily 1 group I member 2;!2. Sulfotransferase family cytosolic 2B member 1
C19H24O2	Not Available	Not Available	284.3927	[H][C@@]12CC[C@](C)(O)[C@@]1(C)C=CC1=C3CCC(=O)C=C3CC[C@@]21[H]	Solid	Not Available					50367916	379896	CHEMBL166444	229099		GtP Drug Page		C14257		R18			261000	46505539				Metribolone	ZINC000003814420		Metribolone	Experimental	DB02998	InChI=1S/C19H24O2/c1-18-9-7-15-14-6-4-13(20)11-12(14)3-5-16(15)17(18)8-10-19(18,2)21/h7,9,11,16-17,21H,3-6,8,10H2,1-2H3/t16-,17+,18+,19+/m1/s1	CCCIJQPRIXGQOE-XWSJACJDSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.6259 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	1	No	4	0	37.3 Å2	33.01 Å3	86.29 m3·mol-1	0	Yes	Yes	0.0332 mg/mL	2.53	-3.9	18.4	-0.53			
C29H48O4	Not Available	Not Available	460.689	[H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C)[C@@H](C)OCCCC(O)(CC)CC	Solid	Not Available							CHEMBL432600	4450786						KH1			73896915	46505581					ZINC000004474609		Lexacalcitol	Experimental	DB03451	InChI=1S/C29H48O4/c1-6-29(32,7-2)16-9-17-33-21(4)25-13-14-26-22(10-8-15-28(25,26)5)11-12-23-18-24(30)19-27(31)20(23)3/h11-12,21,24-27,30-32H,3,6-10,13-19H2,1-2,4-5H3/b22-11+,23-12-/t21-,24-,25-,26+,27+,28-/m1/s1	KLZOTDOJMRMLDX-YBBVPDDNSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	3.4928 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	3	Yes	3	0	69.92 Å2	55.8 Å3	137.52 m3·mol-1	9	Yes	No	0.00632 mg/mL	4.36	-4.9	14.25	-2.8	P11473	VDR	1. Vitamin D3 receptor
C23H34O5	Not Available	Not Available	390.5131	[H][C@@]1(CC[C@]2(O)[C@]3([H])CC[C@]4([H])C[C@@H](O)CC[C@]4(C)[C@@]3([H])C[C@@H](O)[C@]12C)C1=CC(=O)OC1	Solid	Not Available					225707	42098	CHEMBL1153	14728						DOG			15478	46509019				Digoxigenin	ZINC000003982471		Digoxigenin	Experimental	DB03671	InChI=1S/C23H34O5/c1-21-7-5-15(24)10-14(21)3-4-17-18(21)11-19(25)22(2)16(6-8-23(17,22)27)13-9-20(26)28-12-13/h9,14-19,24-25,27H,3-8,10-12H2,1-2H3/t14-,15+,16-,17-,18+,19-,21+,22+,23+/m1/s1	SHIBSTMRCDJXLN-KCZCNTNESA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	3.4699 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	4	3	No	5	0	86.99 Å2	42.7 Å3	105.16 m3·mol-1	1	Yes	No	0.0632 mg/mL	1.84	-3.8	7.15	-1.4			
C28H44O	Not Available	Not Available	396.659	CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	Solid	Not Available					50378884	16933	CHEMBL1232562	392539				C01694		ERG			444679	46505947				Ergosterol	ZINC000004084618		Ergosterol	Approved, Experimental	DB04038	InChI=1S/C28H44O/c1-18(2)19(3)7-8-20(4)24-11-12-25-23-10-9-21-17-22(29)13-15-27(21,5)26(23)14-16-28(24,25)6/h7-10,18-20,22,24-26,29H,11-17H2,1-6H3/b8-7+/t19-,20+,22-,24+,25-,26-,27-,28+/m0/s1	DNVPQKQSNYMLRS-APGDWVJJSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.6528 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							170 °C			1	No	1	1	No	4	0	20.23 Å2	51.01 Å3	127.13 m3·mol-1	4	No	Yes	0.000156 mg/mL	6.63	-6.4	18.27	-1.4			
C23H34O4	Not Available	Not Available	374.5137	[H][C@]12CC[C@]3([H])[C@]([H])(CC[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@H](O)C2	Solid	Not Available					66977	42219	CHEMBL1453	3571902						DTX			4369270	46508220				Digitoxigenin	ZINC000003875959		Digitoxigenin	Experimental	DB04177	InChI=1S/C23H34O4/c1-21-8-5-16(24)12-15(21)3-4-19-18(21)6-9-22(2)17(7-10-23(19,22)26)14-11-20(25)27-13-14/h11,15-19,24,26H,3-10,12-13H2,1-2H3/t15-,16+,17-,18+,19-,21+,22-,23+/m1/s1	XZTUSOXSLKTKJQ-CESUGQOBSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.9314 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	3	2	No	5	-1	66.76 Å2	42.57 Å3	103.64 m3·mol-1	1	Yes	No	0.0244 mg/mL	3.07	-4.2	7.18	0.25			
C21H28O5	Not Available	Not Available	360.444	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)CC[C@]4(C)[C@@]3([H])[C@@H](O)C[C@]12C=O)C(=O)CO	Solid	Not Available	P15538;!P19099;!P05093;!P08684	CYP11B1;!CYP11B2;!CYP17A1;!CYP3A4	1. Cytochrome P450 11B1, mitochondrial;!2. Cytochrome P450 11B2, mitochondrial;!3. Steroid 17-alpha-hydroxylase/17,20 lyase;!4. Cytochrome P450 3A4		19214	27584	CHEMBL273453	5633				C01780		AS4		PA164924487	5839	46505770		1312358	DAP001344	Aldosterone	ZINC000003833824		Aldosterone	Experimental, Investigational	DB04630	InChI=1S/C21H28O5/c1-20-7-6-13(24)8-12(20)2-3-14-15-4-5-16(18(26)10-22)21(15,11-23)9-17(25)19(14)20/h8,11,14-17,19,22,25H,2-7,9-10H2,1H3/t14-,15-,16+,17-,19+,20-,21+/m0/s1	PQSUYGKTWSAVDQ-ZVIOFETBSA-N	4		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.5456 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					1.08		166.5 °C		51.2 mg/L (at 37 °C)	1	Yes	5	2	No	4	0	91.67 Å2	38.82 Å3	96.79 m3·mol-1	3	Yes	No	0.148 mg/mL	1.06	-3.4	13.82	-2.9			
C21H30O4	Not Available	Not Available	346.4605	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)CC[C@]4(C)[C@@]3([H])[C@@]([H])(O)C[C@]12C)C(=O)CO	Solid	Not Available	P08684;!P28845;!P80365	CYP3A4;!HSD11B1;!HSD11B2	1. Cytochrome P450 3A4;!2. Corticosteroid 11-beta-dehydrogenase isozyme 1;!3. Corticosteroid 11-beta-dehydrogenase isozyme 2		50170653	16827	CHEMBL110739	5550			HMDB0001547	C02140		C0R			5753	46504547				Corticosterone	ZINC000013513592		Corticosterone	Experimental	DB04652	InChI=1S/C21H30O4/c1-20-8-7-13(23)9-12(20)3-4-14-15-5-6-16(18(25)11-22)21(15,2)10-17(24)19(14)20/h9,14-17,19,22,24H,3-8,10-11H2,1-2H3/t14-,15-,16+,17-,19+,20-,21-/m0/s1	OMFXVFTZEKFJBZ-HJTSIMOOSA-N			Not Available	Small Molecule	http://smpdb.ca/view/SMP0000371?highlight[compounds][]=DB04652&highlight[proteins][]=DB04652;!http://smpdb.ca/view/SMP0000575?highlight[compounds][]=DB04652&highlight[proteins][]=DB04652;!http://smpdb.ca/view/SMP0000717?highlight[compounds][]=DB04652&highlight[proteins][]=DB04652;!http://smpdb.ca/view/SMP0000372?highlight[compounds][]=DB04652&highlight[proteins][]=DB04652;!http://smpdb.ca/view/SMP0000577?highlight[compounds][]=DB04652&highlight[proteins][]=DB04652;!http://smpdb.ca/view/SMP0000718?highlight[compounds][]=DB04652&highlight[proteins][]=DB04652;!http://smpdb.ca/view/SMP0000130?highlight[compounds][]=DB04652&highlight[proteins][]=DB04652;!http://smpdb.ca/view/SMP0000373?highlight[compounds][]=DB04652&highlight[proteins][]=DB04652;!http://smpdb.ca/view/SMP0000566?highlight[compounds][]=DB04652&highlight[proteins][]=DB04652;!http://smpdb.ca/view/SMP0000576?highlight[compounds][]=DB04652&highlight[proteins][]=DB04652;!http://smpdb.ca/view/SMP0000578?highlight[compounds][]=DB04652&highlight[proteins][]=DB04652	Congenital Lipoid Adrenal Hyperplasia (CLAH) or Lipoid CAH;!11-beta-Hydroxylase Deficiency (CYP11B1);!Apparent Mineralocorticoid Excess Syndrome;!Adrenal Hyperplasia Type 5 or Congenital Adrenal Hyperplasia Due to 17 alpha-Hydroxylase Deficiency;!Corticosterone Methyl Oxidase I Deficiency (CMO I);!3-beta-Hydroxysteroid Dehydrogenase Deficiency;!Steroidogenesis;!Adrenal Hyperplasia Type 3 or Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency;!17-alpha-Hydroxylase Deficiency (CYP17);!21-Hydroxylase Deficiency (CYP21);!Corticosterone Methyl Oxidase II Deficiency (CMO II)		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.5110 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	2	No	4	0	74.6 Å2	38.83 Å3	96 m3·mol-1	2	Yes	No	0.046 mg/mL	2.02	-3.9	13.86	-0.26	P28845;!Q15788;!P08235	HSD11B1;!NCOA1;!NR3C2	1. Corticosteroid 11-beta-dehydrogenase isozyme 1;!2. Nuclear receptor coactivator 1;!3. Mineralocorticoid receptor
C23H36O2	Not Available	Not Available	344.5307	CC[C@@](C)([H])[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1/C[C@](O)([H])C(=C)[C@]([H])(O)C1	Solid	Not Available							CHEMBL2104955	4451487						VD1			5289547	175426893					ZINC000013975113		Becocalcidiol	Investigational	DB04891	InChI=1S/C23H36O2/c1-5-15(2)19-10-11-20-18(7-6-12-23(19,20)4)9-8-17-13-21(24)16(3)22(25)14-17/h8-9,15,19-22,24-25H,3,5-7,10-14H2,1-2,4H3/b18-9+/t15-,19+,20-,21+,22+,23+/m0/s1	QSLUXQQUPXBIHH-YHSKWIAJSA-N	2		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	3.9749 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	2	No	3	0	40.46 Å2	42.79 Å3	106.23 m3·mol-1	3	Yes	No	0.0097 mg/mL	4.43	-4.6	14.19	-3	Q15648;!P11473	MED1;!VDR	1. Mediator of RNA polymerase II transcription subunit 1;!2. Vitamin D3 receptor
C20H30O5	Not Available	Not Available	350.455	[H][C@]12CCC(=C)[C@@H](C\C=C3/[C@H](O)COC3=O)[C@]1(C)CC[C@@H](O)[C@@]2(C)CO	Solid	Not Available					50084419	65408	CHEMBL186141	4477067									5318517	347827741				Andrographolide	ZINC000003881797		Andrographolide	Investigational	DB05767	InChI=1S/C20H30O5/c1-12-4-7-16-19(2,9-8-17(23)20(16,3)11-21)14(12)6-5-13-15(22)10-25-18(13)24/h5,14-17,21-23H,1,4,6-11H2,2-3H3/b13-5+/t14-,15-,16+,17-,19+,20+/m1/s1	BOJKULTULYSRAS-OTESTREVSA-N	2		Not Available	Small Molecule																																			1	Yes	4	3	No	3	0	86.99 Å2	38.27 Å3	94.93 m3·mol-1	3	Yes	No	0.284 mg/mL	1.66	-3.1	13.48	-2.8	P01375;!P01584;!P05231;!Q00653;!P19838	TNF;!IL1B;!IL6;!NFKB2;!NFKB1	1. Tumor necrosis factor;!2. Interleukin-1 beta;!3. Interleukin-6;!4. Nuclear factor NF-kappa-B p100 subunit;!5. Nuclear factor NF-kappa-B p105 subunit
C15H18O3	Not Available	Not Available	246.3016	CC1=C(CO)C2=C(C)C3(CC3)[C@@](C)(O)C(=O)C2=C1	Solid	Not Available					50410835	135002	CHEMBL118218	130640									148189	175427030				Irofulven	ZINC000003916310		Irofulven	Investigational	DB05786	InChI=1S/C15H18O3/c1-8-6-10-12(11(8)7-16)9(2)15(4-5-15)14(3,18)13(10)17/h6,16,18H,4-5,7H2,1-3H3/t14-/m0/s1	NICJCIQSJJKZAH-AWEZNQCLSA-N	3		Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.0258 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	2	No	3	0	57.53 Å2	27.33 Å3	70.91 m3·mol-1	1	Yes	No	0.52 mg/mL	0.67	-2.7	12.77	-1.7	Q96AE4	FUBP1	1. Far upstream element-binding protein 1
C19H28O2	Not Available	Not Available	288.431	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3C[C@@H](C)[C@@]21[H]	Solid	Not Available								8014619									19582	175427041				Trestolone	ZINC000004217690		Trestolone	Investigational	DB05830	InChI=1S/C19H28O2/c1-11-9-12-10-13(20)3-4-14(12)15-7-8-19(2)16(18(11)15)5-6-17(19)21/h10-11,14-18,21H,3-9H2,1-2H3/t11-,14+,15-,16+,17+,18-,19+/m1/s1	YSGQGNQWBLYHPE-CFUSNLFHSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.6259 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	1	No	4	0	37.3 Å2	33.92 Å3	84.5 m3·mol-1	0	Yes	Yes	0.0391 mg/mL	3.35	-3.9	18.34	-0.88			
C32H43NO4	Not Available	Not Available	505.699	COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2	Solid	Not Available					217379		CHEMBL1762621	355161														Bardoxolone_methyl	ZINC000003982151		Bardoxolone methyl	Investigational	DB05983	InChI=1S/C32H43NO4/c1-27(2)11-13-32(26(36)37-8)14-12-31(7)24(20(32)17-27)21(34)15-23-29(5)16-19(18-33)25(35)28(3,4)22(29)9-10-30(23,31)6/h15-16,20,22,24H,9-14,17H2,1-8H3/t20-,22-,24-,29-,30+,31+,32-/m0/s1	WPTTVJLTNAWYAO-KPOXMGGZSA-N	2		Not Available	Small Molecule																																			0	No	4	0	No	5	0	84.23 Å2	58.23 Å3	144.36 m3·mol-1	2	No	No	0.00294 mg/mL	6.55	-5.2		-5.3	P25963	NFKBIA	1. NF-kappa-B inhibitor alpha
C26H42O4	Not Available	Not Available	418.6093	[H]\C(\C(\[H])=C1/CCC[C@@]2(C)[C@@]1([H])CC[C@]2([H])[C@]([H])(C)OCCC(C)(C)O)=C1/C[C@@]([H])(O)C[C@]([H])(O)C1=C	Solid	Not Available					50124417	31801	CHEMBL333950	4911262						MCZ									ZINC000004474617		Maxacalcitol	Investigational	DB06272	InChI=1S/C26H42O4/c1-17-20(15-21(27)16-24(17)28)9-8-19-7-6-12-26(5)22(10-11-23(19)26)18(2)30-14-13-25(3,4)29/h8-9,18,21-24,27-29H,1,6-7,10-16H2,2-5H3/b19-8+,20-9-/t18-,21+,22+,23-,24-,26+/m0/s1	DTXXSJZBSTYZKE-ZDQKKZTESA-N	3		Not Available	Small Molecule																																			1	No	4	3	Yes	3	0	69.92 Å2	50.09 Å3	123.83 m3·mol-1	6	Yes	No	0.015 mg/mL	2.79	-4.4	14.34	-2.7			
C28H44O2	Not Available	32 to 37 hours.	412.6478	[H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C)[C@H](C)\C=C\[C@H](C)C(C)C	Solid	Not Available	Q02318	CYP27A1	1. Sterol 26-hydroxylase, mitochondrial			4712	CHEMBL1200810	4444554	Drugs.com Drug Page			C08211	D01009	V2H	PDRhealth Drug Page		46705423	347827769	RxList Drug Page	11516		Doxercalciferol	ZINC000004641374	Hectorol	Doxercalciferol	Approved	DB06410	InChI=1S/C28H44O2/c1-18(2)19(3)9-10-20(4)25-13-14-26-22(8-7-15-28(25,26)6)11-12-23-16-24(29)17-27(30)21(23)5/h9-12,18-20,24-27,29-30H,5,7-8,13-17H2,1-4,6H3/b10-9+,22-11+,23-12-/t19-,20+,24+,25+,26-,27-,28+/m0/s1	HKXBNHCUPKIYDM-CGMHZMFXSA-N	4	Doxercalciferol is a synthetic vitamin D2 analog used to treat secondary hyperparathyroidism in patients with chronic kidney disease with or without therapy of dialysis.	Not Available	Small Molecule																																		Relatively insoluble	1	No	2	2	No	3	0	40.46 Å2	51.58 Å3	130.36 m3·mol-1	5	No	No	0.00168 mg/mL	5.75	-5.4	14.39	-2.8	P11473	VDR	1. Vitamin D3 receptor
C25H38O3	Not Available	Not Available	386.576	CCCCCCC(C)(C)C1=CC(O)=C2[C@H]3CC(CO)=CC[C@@H]3C(C)(C)OC2=C1	Solid	Not Available					50067498		CHEMBL334533	96934									107778	347827772				Dexanabinol	ZINC000003799010		Dexanabinol	Investigational	DB06444	InChI=1S/C25H38O3/c1-6-7-8-9-12-24(2,3)18-14-21(27)23-19-13-17(16-26)10-11-20(19)25(4,5)28-22(23)15-18/h10,14-15,19-20,26-27H,6-9,11-13,16H2,1-5H3/t19-,20-/m0/s1	SSQJFGMEZBFMNV-PMACEKPBSA-N	3		Not Available	Small Molecule																																			1	No	3	2	Yes	3	0	49.69 Å2	47.4 Å3	116.73 m3·mol-1	7	No	No	0.00148 mg/mL	6.14	-5.4	9.98	-2.7	P01375	TNF	1. Tumor necrosis factor
C23H32O4	Not Available	Not Available	372.505	[H][C@@]12CC[C@H](C(=O)COC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			34671	CHEMBL1200542	5737				C14554	D03698							258333		Desoxycorticosterone_acetate	ZINC000004428527		Desoxycorticosterone acetate	Approved	DB06780	InChI=1S/C23H32O4/c1-14(24)27-13-21(26)20-7-6-18-17-5-4-15-12-16(25)8-10-22(15,2)19(17)9-11-23(18,20)3/h12,17-20H,4-11,13H2,1-3H3/t17-,18-,19-,20+,22-,23-/m0/s1	VPGRYOFKCNULNK-ACXQXYJUSA-N			Not Available	Small Molecule																																			1	Yes	3	0	No	4	0	60.44 Å2	42.13 Å3	103.56 m3·mol-1	4	Yes	No	0.00502 mg/mL	3.77	-4.9	17.17	-4.8	P08235	NR3C2	1. Mineralocorticoid receptor
C21H28O2	Not Available	Not Available	312.4458	[H][C@@]12CC[C@@](O)(CC)[C@@]1(CC)C=CC1=C3CCC(=O)C=C3CC[C@@]21[H]	Solid	Not Available								5257020			HMDB0004626			17H			6857686	99443341				Tetrahydrogestrinone	ZINC000012496366		Tetrahydrogestrinone	Experimental	DB06870	InChI=1S/C21H28O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h9,11,13,18-19,23H,3-8,10,12H2,1-2H3/t18-,19+,20+,21+/m1/s1	OXHNQTSIKGHVBH-ANULTFPQSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.6006 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	1	No	4	0	37.3 Å2	37.03 Å3	95.42 m3·mol-1	2	Yes	Yes	0.0199 mg/mL	3.5	-4.2	18.4	-0.14	P10275	AR	1. Androgen receptor
C19H24O2	Not Available	Not Available	284.3927	[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	Not Available					91718	40799	CHEMBL1078534	12893			HMDB0003422			ANB			13472	99443844				Boldione	ZINC000003881421		Boldione	Experimental	DB07373	InChI=1S/C19H24O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h7,9,11,14-16H,3-6,8,10H2,1-2H3/t14-,15-,16-,18-,19-/m0/s1	LUJVUUWNAPIQQI-QAGGRKNESA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.5360 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	0	No	4	0	34.14 Å2	32.45 Å3	84.7 m3·mol-1	0	Yes	Yes	0.0169 mg/mL	3.93	-4.2	18.39	-5	P71278	onr	1. Pentaerythritol tetranitrate reductase
C19H24O5	Not Available	Not Available	332.3909	[H][C@@]12C[C@]3(CC1=C)[C@@H](C(O)=O)[C@]1([H])[C@@]4(C)[C@@H](O)CC[C@@]1(OC4=O)[C@]3([H])CC2	Solid	Not Available						32902		10222155				C11864		GA4			92109	99444286					ZINC000004102247		Gibberellin A4	Experimental	DB07815	InChI=1S/C19H24O5/c1-9-7-18-8-10(9)3-4-11(18)19-6-5-12(20)17(2,16(23)24-19)14(19)13(18)15(21)22/h10-14,20H,1,3-8H2,2H3,(H,21,22)/t10-,11-,12+,13-,14-,17-,18+,19-/m1/s1	RSQSQJNRHICNNH-NFMPGMCNSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.2992 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	2	No	5	-1	83.83 Å2	34.58 Å3	84.08 m3·mol-1	1	Yes	No	1.19 mg/mL	1.56	-2.4	4.29	-3	Q6P093	AADACL2	1. Arylacetamide deacetylase-like 2
C23H24O8	Not Available	Not Available	428.4319	[H][C@@]12CCC(=O)[C@@]1(C)C[C@@H](OC(C)=O)C1=C2C(=O)C2=C3C(=CO2)C(=O)O[C@H](COC)[C@]13C	Solid	Not Available					15234	52289	CHEMBL428496	276037				C15181		KWT			312145	99444530				Wortmannin	ZINC000001619592		Wortmannin	Experimental	DB08059	InChI=1S/C23H24O8/c1-10(24)30-13-7-22(2)12(5-6-14(22)25)16-18(13)23(3)15(9-28-4)31-21(27)11-8-29-20(17(11)23)19(16)26/h8,12-13,15H,5-7,9H2,1-4H3/t12-,13+,15+,22-,23-/m0/s1	QDLHCMPXEPAAMD-QAIWCSMKSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	4.0908 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	0	No	5	0	109.11 Å2	42.98 Å3	106.86 m3·mol-1	4	Yes	No	0.121 mg/mL	1.44	-3.6		-3.2			
C27H32O4	Not Available	Not Available	420.5406	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC=C4C=C(CC[C@]4(C)[C@@]3([H])CC[C@]12C)C(O)=O)C(=O)C1=CC=C(O)C=C1	Solid	Not Available								8020773						MUF			9845059	99444691					ZINC000003803450		(8alpha,10alpha,13alpha,17beta)-17-[(4-hydroxyphenyl)carbonyl]androsta-3,5-diene-3-carboxylic acid	Experimental	DB08220	InChI=1S/C27H32O4/c1-26-13-11-17(25(30)31)15-18(26)5-8-20-21-9-10-23(27(21,2)14-12-22(20)26)24(29)16-3-6-19(28)7-4-16/h3-7,15,20-23,28H,8-14H2,1-2H3,(H,30,31)/t20-,21-,22-,23+,26-,27-/m0/s1	RPNNXCYIESWDSC-JRZBRKEGSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.6597 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	2	No	5	-1	74.6 Å2	47.84 Å3	121.45 m3·mol-1	3	No	No	0.00264 mg/mL	5.16	-5.2	4.35	-6.9	Q15788;!Q96RI1	NCOA1;!NR1H4	1. Nuclear receptor coactivator 1;!2. Bile acid receptor
C22H30O5	Not Available	Not Available	374.4706	[H][C@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)CC[C@]4([H])[C@@]3([H])CC[C@]12C)OC(=O)CCC(O)=O	Solid	Not Available								4451095						NTH			5289054	99444779					ZINC000033821445		SUCCINIC ACID MONO-(13-METHYL-3-OXO-2,3,6,7,8,9,10,11,12,13,14,15,16,17-TETRADECAHYDRO-1H-CYCLOPENTA[A]PHENANTHREN-17-YL) ESTER	Experimental	DB08308	InChI=1S/C22H30O5/c1-22-11-10-16-15-5-3-14(23)12-13(15)2-4-17(16)18(22)6-7-19(22)27-21(26)9-8-20(24)25/h12,15-19H,2-11H2,1H3,(H,24,25)/t15-,16+,17+,18-,19+,22-/m0/s1	IRQUJNVGEAJGSD-KIEDKLRZSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.0592 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	1	No	4	-1	80.67 Å2	41.7 Å3	100 m3·mol-1	5	Yes	No	0.0108 mg/mL	3.33	-4.5	4.31	-4.7	P00947	ksi	1. Steroid Delta-isomerase
C24H27NO7	Not Available	Not Available	441.4737	[H][C@]12C[C@@H]3O[C@@]1(C)C[C@@]1(C2)C=CC(=O)[C@@](C)(CCC(=O)NC2=C(O)C(=CC=C2O)C(O)=O)[C@]31[H]	Solid	Not Available						68236	CHEMBL411278	5257055						PMN			6857724	99444878				Platensimycin	ZINC000029050726		Platensimycin	Experimental	DB08407	InChI=1S/C24H27NO7/c1-22(7-6-17(28)25-18-14(26)4-3-13(19(18)29)21(30)31)16(27)5-8-24-10-12-9-15(20(22)24)32-23(12,2)11-24/h3-5,8,12,15,20,26,29H,6-7,9-11H2,1-2H3,(H,25,28)(H,30,31)/t12-,15+,20+,22-,23+,24+/m1/s1	CSOMAHTTWTVBFL-OFBLZTNGSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	3.0222 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	7	4	No	5	-1	133.16 Å2	44.81 Å3	116.81 m3·mol-1	5	Yes	No	0.0139 mg/mL	3.24	-4.5	2.96	-3.4	P0AAI5	fabF	1. 3-oxoacyl-[acyl-carrier-protein] synthase 2
C20H28O2	Not Available	Not Available	300.4351	O=C(O)\C=C(/C)\C=C\C[C@]1(C)CC2=C(CCCC2(C)C)C1=C	Solid	Not Available								4451273						RE9			5289278	99444938					ZINC000015475858		6-(2,3,4,5,6,7-HEXAHYDRO-2,4,4-TRIMETHYL-1-METYLENEINDEN-2-YL)-3-METHYLHEXA-2,4-DIENOIC ACID	Experimental	DB08467	InChI=1S/C20H28O2/c1-14(12-18(21)22)8-6-11-20(5)13-17-16(15(20)2)9-7-10-19(17,3)4/h6,8,12H,2,7,9-11,13H2,1,3-5H3,(H,21,22)/b8-6+,14-12+/t20-/m1/s1	HEVXQLBAMFMFKU-IAZPEVBMSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Non-substrate	2.1458 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	1	No	2	-1	37.3 Å2	34.61 Å3	93.62 m3·mol-1	4	Yes	Yes	0.00892 mg/mL	4.67	-4.5	4.54				
C25H34O6	Not Available	Not Available	430.5339	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)CC[C@]4(C)[C@@]3([H])[C@@]([H])(C[C@]12C)OC(=O)CCC(O)=O)C(C)=O	Solid	Not Available						45496		4451359						SIH			5289373	99445018					ZINC000013512622		PROGESTERONE-11-ALPHA-OL-HEMISUCCINATE	Experimental	DB08547	InChI=1S/C25H34O6/c1-14(26)18-6-7-19-17-5-4-15-12-16(27)10-11-24(15,2)23(17)20(13-25(18,19)3)31-22(30)9-8-21(28)29/h12,17-20,23H,4-11,13H2,1-3H3,(H,28,29)/t17-,18+,19-,20+,23+,24-,25+/m0/s1	JBBNFGYRYNBDIH-DBGGZKJISA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.3116 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	1	Yes	4	-1	97.74 Å2	46.96 Å3	114.34 m3·mol-1	6	Yes	No	0.0085 mg/mL	3.11	-4.7	4.22	-4.8	P01859	IGHG2	1. Ig gamma-2 chain C region
C28H44O3	50 mg, 100 mg, and 150 mg doses of nadrolone decanoate had mean apparent clearances of 80.0 L/h, 74.3 L/h, and 76.2 L/h respectively.1	Nandrolone decanoate has an absorption half life of 6 days and an elimination half life of 4.3 hours.13 Alternate studies have shown that nandrolone decanoate has a terminal half life of 7.1, 11.7, and 11.8 hours for doses of 50, 100, and 150 mg respectively.1	428.6472	[H][C@@]12CC[C@H](OC(=O)CCCCCCCCC)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	Solid	Not Available	P11511;!P27338;!P21397;!P16662;!P22310;!P06133;!P35503;!P22309;!Q9HAW8	CYP19A1;!MAOB;!MAOA;!UGT2B7;!UGT1A4;!UGT2B4;!UGT1A3;!UGT1A1;!UGT1A10	1. Cytochrome P450 19A1;!2. Amine oxidase [flavin-containing] B;!3. Amine oxidase [flavin-containing] A;!4. UDP-glucuronosyltransferase 2B7;!5. UDP-glucuronosyltransferase 1-4;!6. UDP-glucuronosyltransferase 2B4;!7. UDP-glucuronosyltransferase 1-3;!8. UDP-glucuronosyltransferase 1-1;!9. UDP-glucuronosyltransferase 1-10			7467	CHEMBL1200946	9296	Drugs.com Drug Page		HMDB0015694	C08154	D00955			PA165958423	9677	99445274		31494	DAP000903	Nandrolone_decanoate	ZINC000008214619		Nandrolone decanoate	Approved, Illicit	DB08804	InChI=1S/C28H44O3/c1-3-4-5-6-7-8-9-10-27(30)31-26-16-15-25-24-13-11-20-19-21(29)12-14-22(20)23(24)17-18-28(25,26)2/h19,22-26H,3-18H2,1-2H3/t22-,23+,24+,25-,26-,28-/m0/s1	JKWKMORAXJQQSR-MOPIKTETSA-N	2	Nandrolone decanoate is an anabolic steroid indicated for the management of the anemia of renal insufficiency by increasing hemoglobin and red cell mass.	Data regarding acute overdose of nandrolone decanoate are not readily available.13 However, patients experiencing a chronic overdose of anabolic steroids may experience adverse effects including suppression of testosterone and spermatogenesis, shrinking of testicles, decreased libido, and erectile dysfunction in men; and suppressed estrogen, progesterone, and ovulation, amenorrhea, and clitoromegaly in women.8 Patients may also experience neuropsychiatric, cardiovascular, and hepatic adverse effects.8 Alkylated anabolic steroids such as nandrolone decanoate are more likely to cause hepatic adverse effects.8 Treat patients with symptomatic and supportive measures.The intraperitoneal LD50 in mice is >566 mg/kg.14	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	1.8804 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							32-35		3.09 mg/mL at 25 °C	1	No	2	0	Yes	4	0	43.37 Å2	53.64 Å3	125.94 m3·mol-1	10	No	No	0.000157 mg/mL	7.32	-6.4	18.25	-4.7	P10275;!P01100;!BE0004881;!P28222;!P08069;!BE0009376	AR;!FOS;!;!HTR1B;!IGF1R;!	1. Androgen receptor;!2. Proto-oncogene c-Fos;!3. 5-hydroxytryptamine 2 receptor (Protein Group);!4. 5-hydroxytryptamine receptor 1B;!5. Insulin-like growth factor 1 receptor;!6. Dopamine receptor (Protein Group)
C19H26O3	Plasma clearance is approximately 4.2 L/(h kg), when delivered intravenously. In women, following a 500mg dose of formestane, 20% was excreted as glucuronide within the first 24 hours. [1]One long term metabolite (3beta,4alpha-dihydroxy-5alpha-androstan-17-one) can be detected for 90 hours. A longer detection time is possible with more sensitive technology, which may be of utility in sports drug testing. [1]	Terminal plasma elimination half life of 18 minutes, when delivered intravenously. [2]	302.4079	[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=C(O)C(=O)CC[C@]12C	Solid	Vd = 1.8 L/kg; widely distributed to organs and tissues when delivered intravenously. [2]	P08684	CYP3A4	1. Cytochrome P450 3A4		225704	75172	CHEMBL132530	10799	Drugs.com Drug Page				D07260				11273	175427144		15070		Formestane	ZINC000003919580		Formestane	Approved, Investigational, Withdrawn	DB08905	InChI=1S/C19H26O3/c1-18-10-8-15(20)17(22)14(18)4-3-11-12-5-6-16(21)19(12,2)9-7-13(11)18/h11-13,22H,3-10H2,1-2H3/t11-,12-,13-,18+,19-/m0/s1	OSVMTWJCGUFAOD-KZQROQTASA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.6135 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.66		199 - 202	9.31	Insoluble	1	Yes	3	1	No	4	0	54.37 Å2	34.05 Å3	85.57 m3·mol-1	0	Yes	No	0.0578 mg/mL	3.41	-3.7	9.21	-3.7			
C21H28O2	Elimination of tibolone is not dependent renal function 14.	The elimination half-life is approximately 45 h 4.	312.453	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC(=O)CC3)C[C@@]([H])(C)[C@@]21[H]	Solid	Not Available	P08842;!P14060;!P26439;!P50225	STS;!HSD3B1;!HSD3B2;!SULT1A1	1. Steryl-sulfatase;!2. 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1;!3. 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2;!4. Sulfotransferase 1A1			32223	CHEMBL2103774	392038					D01639				444008	347827821		38260		Tibolone	ZINC000003812889		Tibolone	Approved, Investigational	DB09070	InChI=1S/C21H28O2/c1-4-21(23)10-8-18-19-13(2)11-14-12-15(22)5-6-16(14)17(19)7-9-20(18,21)3/h1,13,17-19,23H,5-12H2,2-3H3/t13-,17-,18+,19-,20+,21+/m1/s1	WZDGZWOAQTVYBX-XOINTXKNSA-N	4		>2000 mg/kg MSDSThe Million Women Study (MWS), which had a prospective observational design, studied the use of hormone replacement therapy. The results indicated that the increase in the incidence of breast cancer with estrogen and progestogen (compared to estrogen alone) was greater than the reduction in occurrence of endometrial cancer associated with adding progestogen to estrogen therapy. The MWS also reported a marked increase in the incidence of breast cancer with tibolone and with implanted and transdermal estrogen-only preparations 6.Tibolone treatment in rodent studies showed an increased association with the development of a range of tumors in long-term oral carcinogenicity studies. These tumors included pituitary adenomas, mammary carcinomas and fibroadenomas, hepatic adenomas, uterine carcinoma, stromal polyps and stromal sarcoma, and carcinomas of the urinary bladder and testes. Tibolone failed to show any evidence of genotoxicity in studies for gene mutations, chromosomal damage as well as DNA damage 9.Other adverse effects these include dizziness, headache, nausea, abdominal pain, rashes, pruritus, weight gain, edema, and migraine 16.	Small Molecule																																		<0.1 g/L	1	Yes	2	1	No	4	0	37.3 Å2	36.77 Å3	91.73 m3·mol-1	0	Yes	Yes	0.00722 mg/mL	3.1	-4.6	16.27	-1.7	P03372	ESR1	1. Estrogen receptor alpha
C20H25NO2	The metabolic clearance rate from serum (Cl/F) is 64 mL/min 5.	Elimination half-life of dienogest is around 9-10 hours. The half-life of urinary metabolites excretion is 14 hours 5.	311.425	[H][C@@]12CC[C@@](O)(CC#N)[C@@]1(C)CCC1=C3CCC(=O)C=C3CC[C@@]21[H]	Solid	The apparent volume of distribution (Vd/F) of dienogest is 40 L 5.	P08684	CYP3A4	1. Cytochrome P450 3A4			70708	CHEMBL1201864	62093									68861	310265039		22968		Dienogest	ZINC000004215629	Natazia, Visanne	Dienogest	Approved	DB09123	InChI=1S/C20H25NO2/c1-19-8-6-16-15-5-3-14(22)12-13(15)2-4-17(16)18(19)7-9-20(19,23)10-11-21/h12,17-18,23H,2-10H2,1H3/t17-,18+,19+,20-/m1/s1	AZFLJNIPTRTECV-FUMNGEBKSA-N	4	Dienogest is an oral progestin used for the treatment of endometriosis as monotherapy or contraception in combination with ethinylestradiol.	Oral LD50 in mouse is 4 mg/kg MSDS. In a long-term carcinogenicity study involving rats and mice, exposure of 10 times the dose of maximum recommended clinical dose of dienogest resulted in increased incidences of pituitary adenomas, fibroepithelial mammary tumours, stromal polyps of the uterus and malignant lymphoma 6. These tumors are thought to arise from marked species differences in the optimal oestrogen:progestogen ratio for reproductive function. In rat liver foci assay, dienogest did not induce tumor promotion activity 6. Dienogest does not display genotoxic potential.	Small Molecule																																210-218		Practically insoluble	1	Yes	3	1	No	4	0	61.09 Å2	35.4 Å3	90.19 m3·mol-1	1	Yes	No	0.0761 mg/mL	2.31	-3.6	13.78	-3.3	P06401;!P10275	PGR;!AR	1. Progesterone receptor;!2. Androgen receptor
C20H26O2	Not Available	Not Available	298.426	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])CC(=O)CC3	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4		50410507	34895	CHEMBL1387	5995				C14249	D05207							7515		Norethynodrel	ZINC000118913164		Norethynodrel	Approved	DB09371	InChI=1S/C20H26O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,16-18,22H,4-12H2,2H3/t16-,17-,18+,19+,20+/m1/s1	ICTXHFFSOAJUMG-SLHNCBLASA-N			Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	34.79 Å3	87.18 m3·mol-1	0	Yes	Yes	0.00982 mg/mL	2.81	-4.5	16.21	-1.7	P03372;!P10275;!P04278	ESR1;!AR;!SHBG	1. Estrogen receptor alpha;!2. Androgen receptor;!3. Sex hormone-binding globulin
C21H26O2	Not Available	Not Available	310.437	[H][C@@]12CC[C@@](O)(CC=C)[C@@]1(C)C=CC1=C3CCC(=O)C=C3CC[C@@]21[H]	Not Available	Not Available							CHEMBL1315492	8216634					D02840							1314612		Altrenogest	ZINC000004214784		Altrenogest	Vet approved	DB11372	InChI=1S/C21H26O2/c1-3-10-21(23)12-9-19-18-6-4-14-13-15(22)5-7-16(14)17(18)8-11-20(19,21)2/h3,8,11,13,18-19,23H,1,4-7,9-10,12H2,2H3/t18-,19+,20+,21+/m1/s1	VWAUPFMBXBWEQY-ANULTFPQSA-N			Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	36.06 Å3	95.46 m3·mol-1	2	Yes	Yes	0.0301 mg/mL	3.2	-4	18.4	-0.18			
C20H30O2	Not Available	Not Available	302.458	[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3C[C@@H](C)[C@@]21[H]	Not Available	Not Available					26258	34849	CHEMBL425863	220460				C14255	D05025									Mibolerone	ZINC000004216936		Mibolerone	Vet approved	DB11429	InChI=1S/C20H30O2/c1-12-10-13-11-14(21)4-5-15(13)16-6-8-19(2)17(18(12)16)7-9-20(19,3)22/h11-12,15-18,22H,4-10H2,1-3H3/t12-,15+,16-,17+,18-,19+,20+/m1/s1	PTQMMNYJKCSPET-OMHQDGTGSA-N			Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	35.86 Å3	89.14 m3·mol-1	0	Yes	Yes	0.0194 mg/mL	3.63	-4.2	18.34	-0.53	P10275	AR	1. Androgen receptor
C18H22O2	Not Available	Not Available	270.372	[H][C@@]12CC[C@H](O)[C@@]1(C)C=CC1=C3CCC(=O)C=C3CC[C@@]21[H]	Not Available	Not Available						35018	CHEMBL3182355	23383				C14261	D08627							1484278		Trenbolone	ZINC000003814429		Trenbolone	Vet approved	DB11551	InChI=1S/C18H22O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h8-10,15-17,20H,2-7H2,1H3/t15-,16+,17+,18+/m1/s1	MEHHPFQKXOUFFV-OWSLCNJRSA-N			Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	31.26 Å3	81.65 m3·mol-1	0	Yes	Yes	0.0586 mg/mL	2.25	-3.7	18.4	-0.89			
C21H24O2	Renal Excretion accounts for < 1 % 6.	Plasma half-life is 24 hr 6.	308.4141	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)C=CC1=C3CCC(=O)C=C3CC[C@@]21[H]	Solid	67 L 11	P08684	CYP3A4	1. Cytochrome P450 3A4		50423515	89642	CHEMBL1868702	25877			HMDB0002720		D04317				27812	347828012		4792		Gestrinone	ZINC000003938633		Gestrinone	Approved	DB11619	InChI=1S/C21H24O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,9,11,13,18-19,23H,3,5-8,10,12H2,1H3/t18-,19+,20+,21+/m1/s1	BJJXHLWLUDYTGC-ANULTFPQSA-N			Many of gestrinone's adverse effects occur due to its androgenic activity. These effects include acne, seborrhea, hirsutism, weight gain and deepening of the voice. Most patients develop at least one adverse event while taking this drug. This is because the drug is embryotoxic in some animals and may also cause masculinization of a female fetus. Gestrinone significantly reduces HDL concentrations 8.It is advisable to monitor liver transaminases and cholesterol levels in hyperlipidemic patients, as well as glucose in diabetic patients. Gestrinone has shown to decrease in the concentration of thyroid-binding globulin. Therefore, a decrease in serum total thyroxine levels is commonly observed. This is without clinical significance as free thyroxine levels and thyroid-stimulating hormone levels remain within the normal reference range 11.	Small Molecule																													507.638			150-152			1	Yes	2	1	No	4	0	37.3 Å2	35.55 Å3	93.73 m3·mol-1	1	Yes	Yes	0.00969 mg/mL	2.85	-4.5	17.88	-1.5	P04278;!P06401;!P04150;!P10275;!P30968;!P03372	SHBG;!PGR;!NR3C1;!AR;!GNRHR;!ESR1	1. Sex hormone-binding globulin;!2. Progesterone receptor;!3. Glucocorticoid receptor;!4. Androgen receptor;!5. Gonadotropin-releasing hormone receptor;!6. Estrogen receptor alpha
C20H24O6	Not Available	Not Available	360.406	CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O	Not Available	Not Available					50241049	9747	CHEMBL463763	97099				C09204					107985	347828340				Triptolide	ZINC000008234271		Triptolide	Investigational	DB12025	InChI=1S/C20H24O6/c1-8(2)18-13(25-18)14-20(26-14)17(3)5-4-9-10(7-23-15(9)21)11(17)6-12-19(20,24-12)16(18)22/h8,11-14,16,22H,4-7H2,1-3H3/t11-,12-,13-,14-,16+,17-,18-,19+,20+/m0/s1	DFBIRQPKNDILPW-CIVMWXNOSA-N	3		Not Available	Small Molecule																																			1	Yes	5	1	No	7	0	84.12 Å2	37.14 Å3	87.26 m3·mol-1	1	Yes	No	0.886 mg/mL	1.33	-2.6	12.54	-3.8			
C22H32O2	Not Available	Not Available	328.4883	CC(=O)OC\C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C	Not Available	Not Available								8421459			HMDB0035185						10245972	347828413					ZINC000014685555		Zuretinol acetate	Investigational	DB12112	InChI=1S/C22H32O2/c1-17(9-7-10-18(2)14-16-24-20(4)23)12-13-21-19(3)11-8-15-22(21,5)6/h7,9-10,12-14H,8,11,15-16H2,1-6H3/b10-7+,13-12+,17-9-,18-14+	QGNJRVVDBSJHIZ-AQDFTDIISA-N	2		Not Available	Small Molecule																																			1	Yes	1	0	No	1	0	26.3 Å2	40.5 Å3	107.07 m3·mol-1	7	No	Yes	0.00238 mg/mL	5.14	-5.1		-7			
C22H26N2O2	Not Available	Not Available	350.462	[H][C@]12N3CCC[C@@]1(CC)C=C(N1C4=CC=CC=C4C(CC3)=C21)C(=O)OCC	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4		50059033	32297	CHEMBL71752	392007									443955	347828430		24506		Vinpocetine	ZINC000019796031		Vinpocetine	Investigational	DB12131	InChI=1S/C22H26N2O2/c1-3-22-11-7-12-23-13-10-16-15-8-5-6-9-17(15)24(19(16)20(22)23)18(14-22)21(25)26-4-2/h5-6,8-9,14,20H,3-4,7,10-13H2,1-2H3/t20-,22+/m1/s1	DDNCQMVWWZOMLN-IRLDBZIGSA-N	3	Vinpocetine is a synthetic derivative of a vinca alkaloid used to treat neurological symptoms of cerebrovascular disease.	Not Available	Small Molecule																																			1	Yes	2	0	No	5	1	34.47 Å2	40.31 Å3	104.24 m3·mol-1	4	Yes	Yes	0.0254 mg/mL	4.07	-4.1		6.94			
C29H35NO8	Not Available	Not Available	525.598	COC[C@H]1OC(=O)\C(=C\N(CC=C)CC=C)C2=C(O)C(=O)C3=C([C@@H](C[C@@]4(C)[C@H]3CCC4=O)OC(C)=O)[C@@]12C	Not Available	Not Available						65345	CHEMBL411907	8025448									9849735	347828818					ZINC000029134545		Sonolisib	Investigational	DB12601	InChI=1S/C29H35NO8/c1-7-11-30(12-8-2)14-17-23-26(34)25(33)22-18-9-10-20(32)28(18,4)13-19(37-16(3)31)24(22)29(23,5)21(15-36-6)38-27(17)35/h7-8,14,18-19,21,34H,1-2,9-13,15H2,3-6H3/b17-14+/t18-,19+,21+,28-,29-/m0/s1	QIUASFSNWYMDFS-NILGECQDSA-N	2		Not Available	Small Molecule																																			1	No	7	1	Yes	4	0	119.44 Å2	54.57 Å3	141.15 m3·mol-1	9	No	No	0.0267 mg/mL	2.51	-4.3	8.49	-2.8			
C29H39NO3	Not Available	Not Available	449.635	CN(C)C1=CC=C(C=C1)[C@H]1C[C@]2(C)[C@@H](CC[C@]2(O)CCCO)[C@@H]2CCC3=CC(=O)CCC3=C12	Not Available	Not Available					50366558		CHEMBL1908373	4470982									5311505	347828846				Onapristone	ZINC000003831947		Onapristone	Investigational	DB12637	InChI=1S/C29H39NO3/c1-28-18-25(19-5-8-21(9-6-19)30(2)3)27-23-12-10-22(32)17-20(23)7-11-24(27)26(28)13-15-29(28,33)14-4-16-31/h5-6,8-9,17,24-26,31,33H,4,7,10-16,18H2,1-3H3/t24-,25+,26-,28+,29+/m0/s1	IEXUMDBQLIVNHZ-YOUGDJEHSA-N			Not Available	Small Molecule																																			1	No	4	2	No	5	0	60.77 Å2	52.99 Å3	135.3 m3·mol-1	5	Yes	No	0.00759 mg/mL	3.96	-4.8	14.34	4.89	P04150;!Q6QNK2	NR3C1;!ADGRD1	1. Glucocorticoid receptor;!2. Probable G-protein coupled receptor 133
C20H30O2	Not Available	Not Available	302.458	CC[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C	Not Available	Not Available						135282	CHEMBL1697845	5649									5858	347828967		7513		Norethandrolone	ZINC000003875356		Norethandrolone	Investigational	DB12787	InChI=1S/C20H30O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h12,15-18,22H,3-11H2,1-2H3/t15-,16+,17+,18-,19-,20-/m0/s1	ZDHCJEIGTNNEMY-XGXHKTLJSA-N	3		Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	36.28 Å3	89.12 m3·mol-1	1	Yes	Yes	0.0174 mg/mL	3.87	-4.2	19.28	-0.27			
C29H48O2	Not Available	Not Available	428.701	CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C)C(C)C	Not Available	Not Available								8201186									10025615	347829221							1alpha-Hydroxyvitamin D5	Investigational	DB13097	InChI=1S/C29H48O2/c1-7-22(19(2)3)11-10-20(4)26-14-15-27-23(9-8-16-29(26,27)6)12-13-24-17-25(30)18-28(31)21(24)5/h12-13,19-20,22,25-28,30-31H,5,7-11,14-18H2,1-4,6H3/b23-12+,24-13-/t20-,22-,25-,26-,27+,28+,29-/m1/s1	NWFOBODUYTUMNC-VPSCEVSQSA-N	1		Not Available	Small Molecule																																			1	No	2	2	Yes	3	0	40.46 Å2	54.09 Å3	133.85 m3·mol-1	7	No	No	0.000923 mg/mL	6.55	-5.7	14.39	-2.8			
C22H30O3	Not Available	Not Available	342.479	C[C@H](O)C(=O)[C@@]1(C)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3CC[C@]12C	Not Available	Not Available						136027	CHEMBL2104765	62152									68926	347829250				Trimegestone	ZINC000004217604		Trimegestone	Investigational	DB13129	InChI=1S/C22H30O3/c1-13(23)20(25)22(3)11-9-19-18-6-4-14-12-15(24)5-7-16(14)17(18)8-10-21(19,22)2/h12-13,18-19,23H,4-11H2,1-3H3/t13-,18+,19-,21-,22+/m0/s1	JUNDJWOLDSCTFK-MTZCLOFQSA-N	4		Not Available	Small Molecule																																			1	Yes	3	1	No	4	0	54.37 Å2	39.44 Å3	99.51 m3·mol-1	2	Yes	No	0.0188 mg/mL	3.71	-4.3	13.7	-3.4			
C18H26O2	Not Available	Not Available	274.3978	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	Solid	Not Available					50080092	7466	CHEMBL757	9520			HMDB0002725	C07254		6VW		PA164746281	9904	347829275		7244		Nandrolone	ZINC000003814379		Nandrolone	Experimental, Investigational	DB13169	InChI=1S/C18H26O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h10,13-17,20H,2-9H2,1H3/t13-,14+,15+,16-,17-,18-/m0/s1	NPAGDVCDWIYMMC-IZPLOLCNSA-N	3	Nandrolone is an anabolic steroid indicated to increase bone density and muscle mass in patients with osteoporosis.	Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	32.27 Å3	79.95 m3·mol-1	0	Yes	Yes	0.0561 mg/mL	3.07	-3.7	18.25	-0.88			
C26H38O4	The elimination on the first day following intravenous injection of oxabolone cipionate is slow and reaches a rapid excretion phase with the maximum urinary level in the fifth day of administration 2.	Not Available	414.586	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=C(O)C(=O)CC[C@]4([H])[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1	Solid	Not Available						31940	CHEMBL2105318	62175									68952	347829285				Oxabolone_cipionate	ZINC000026892649		Oxabolone cipionate	Experimental	DB13185	InChI=1S/C26H38O4/c1-26-15-14-18-17-9-11-22(27)25(29)20(17)8-7-19(18)21(26)10-12-23(26)30-24(28)13-6-16-4-2-3-5-16/h16-19,21,23,29H,2-15H2,1H3/t17-,18-,19-,21+,23+,26+/m1/s1	KHKDIUPVDIEHAH-KXLSUQFWSA-N			Not Available	Small Molecule																																			1	Yes	3	1	No	5	0	63.6 Å2	48.9 Å3	116.85 m3·mol-1	5	No	No	0.00377 mg/mL	5.29	-5	9.23	-3.7			
C20H28O3	Not Available	Not Available	316.441	[H][C@@]12CC[C@](O)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	Not Available	Not Available						135991	CHEMBL3707212	92341												4793		Gestronol	ZINC000005167250		Gestonorone	Experimental	DB13230	InChI=1S/C20H28O3/c1-12(21)20(23)10-8-18-17-5-3-13-11-14(22)4-6-15(13)16(17)7-9-19(18,20)2/h11,15-18,23H,3-10H2,1-2H3/t15-,16+,17+,18-,19-,20-/m0/s1	GTFUITFQDGVJSK-XGXHKTLJSA-N			Not Available	Small Molecule																																			1	Yes	3	1	No	4	0	54.37 Å2	36.34 Å3	89.63 m3·mol-1	1	Yes	No	0.0213 mg/mL	3.1	-4.2	12.7	-3.8			
C21H26N2O3	Not Available	Not Available	354.45	[H][C@]12N3CCC[C@@]1(CC)C[C@@](O)(N1C4=CC=CC=C4C(CC3)=C21)C(=O)OC	Not Available	Not Available						9985	CHEMBL1165342	14635				C09251					15376	347829295		11201		Vincamine	ZINC000001069082		Vincamine	Experimental	DB13374	InChI=1S/C21H26N2O3/c1-3-20-10-6-11-22-12-9-15-14-7-4-5-8-16(14)23(17(15)18(20)22)21(25,13-20)19(24)26-2/h4-5,7-8,18,25H,3,6,9-13H2,1-2H3/t18-,20+,21+/m1/s1	RXPRRQLKFXBCSJ-GIVPXCGWSA-N			Not Available	Small Molecule																																			1	Yes	3	1	No	5	0	54.7 Å2	39.39 Å3	99.57 m3·mol-1	3	Yes	No	0.216 mg/mL	3.39	-3.2	10.52	6.7			
C20H23NO4	Not Available	Not Available	341.407	COC1=CC=C2C[C@@H]3[C@@H]4CC=C(OC(C)=O)[C@@H]5OC1=C2[C@]45CCN3C	Not Available	Not Available						135449	CHEMBL2104751	9683173														Thebacon			Thebacon	Experimental	DB13458	InChI=1S/C20H23NO4/c1-11(22)24-16-7-5-13-14-10-12-4-6-15(23-3)18-17(12)20(13,19(16)25-18)8-9-21(14)2/h4,6-7,13-14,19H,5,8-10H2,1-3H3/t13-,14+,19-,20-/m0/s1	RRJQTGHQFYTZOW-ILWKUFEGSA-N			Not Available	Small Molecule																																			1	Yes	4	0	No	5	1	48 Å2	36.36 Å3	94.29 m3·mol-1	3	Yes	No	0.179 mg/mL	1.66	-3.3		9.36			
C24H32O2	Not Available	Not Available	352.518	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2OC1=CCCC1	Not Available	Not Available						135488	CHEMBL2106999	8536132														Quinbolone	ZINC000004217390		Quinbolone	Experimental	DB13484	InChI=1S/C24H32O2/c1-23-13-11-17(25)15-16(23)7-8-19-20-9-10-22(26-18-5-3-4-6-18)24(20,2)14-12-21(19)23/h5,11,13,15,19-22H,3-4,6-10,12,14H2,1-2H3/t19-,20-,21-,22-,23-,24-/m0/s1	IUVKMZGDUIUOCP-BTNSXGMBSA-N			Not Available	Small Molecule																																			1	Yes	2	0	No	5	0	26.3 Å2	42.19 Å3	108.18 m3·mol-1	2	No	Yes	0.001 mg/mL	5.03	-5.6	18.86	-4.6			
C19H28O2	Not Available	Not Available	288.431	C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C	Not Available	Not Available						34896	CHEMBL2106801	4447645				C14491										Normethandrone	ZINC000004217180		Methylestrenolone	Experimental	DB13533	InChI=1S/C19H28O2/c1-18-9-7-15-14-6-4-13(20)11-12(14)3-5-16(15)17(18)8-10-19(18,2)21/h11,14-17,21H,3-10H2,1-2H3/t14-,15+,16+,17-,18-,19-/m0/s1	ZXSWTMLNIIZPET-ZOFHRBRSSA-N			Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	34.21 Å3	84.59 m3·mol-1	0	Yes	Yes	0.0302 mg/mL	3.35	-4	19.28	-0.53			
C20H22O2	Not Available	Not Available	294.394	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)C=CC1=C3CCC(=O)C=C3CC[C@@]21[H]	Not Available	Not Available						135231	CHEMBL1908319	12749												7519		Norgestrienone	ZINC000004217177		Norgestrienone	Experimental	DB13563	InChI=1S/C20H22O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,8,10,12,17-18,22H,4-7,9,11H2,2H3/t17-,18+,19+,20+/m1/s1	GVDMJXQHPUYPHP-FYQPLNBISA-N			Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	33.61 Å3	89.12 m3·mol-1	0	Yes	Yes	0.0113 mg/mL	2.41	-4.4	17.57	-1.7			
C20H28O2	Not Available	Not Available	300.4351	[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Not Available	Not Available						6810	CHEMBL1418176	6061			HMDB0041925									6818		Metandienone	ZINC000003875469		Metandienone	Experimental	DB13586	InChI=1S/C20H28O2/c1-18-9-6-14(21)12-13(18)4-5-15-16(18)7-10-19(2)17(15)8-11-20(19,3)22/h6,9,12,15-17,22H,4-5,7-8,10-11H2,1-3H3/t15-,16+,17+,18+,19+,20+/m1/s1	XWALNWXLMVGSFR-HLXURNFRSA-N		Metandienone is an anabolic steroid indicated for appetite stimulation in patients with anorexia.	Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	35.09 Å3	90.16 m3·mol-1	0	Yes	Yes	0.0161 mg/mL	3.64	-4.3	18.39	-0.53			
C22H30O2	Not Available	Not Available	326.48	CCC(=O)[C@@]1(C)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3CC[C@]12C	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4		18660	73390	CHEMBL196003	33716				C14208								8744		Promegestone	ZINC000003814408		Promegestone	Experimental	DB13602	InChI=1S/C22H30O2/c1-4-20(24)22(3)12-10-19-18-7-5-14-13-15(23)6-8-16(14)17(18)9-11-21(19,22)2/h13,18-19H,4-12H2,1-3H3/t18-,19+,21+,22-/m1/s1	QFFCYTLOTYIJMR-XMGTWHOFSA-N			Not Available	Small Molecule																																			1	Yes	2	0	No	4	0	34.14 Å2	38.7 Å3	97.94 m3·mol-1	2	Yes	Yes	0.00772 mg/mL	4.66	-4.6	19	-4.7			
C27H44O3	Not Available	Not Available	416.646	CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	Not Available	Not Available					50441892		CHEMBL2105611	4446823												291204		Tacalcitol	ZINC000004474668		Tacalcitol	Experimental, Investigational	DB13689	InChI=1S/C27H44O3/c1-17(2)25(29)13-8-18(3)23-11-12-24-20(7-6-14-27(23,24)5)9-10-21-15-22(28)16-26(30)19(21)4/h9-10,17-18,22-26,28-30H,4,6-8,11-16H2,1-3,5H3/b20-9+,21-10-/t18-,22-,23-,24+,25-,26+,27-/m1/s1	BJYLYJCXYAMOFT-RSFVBTMBSA-N	3	Tacalcitol is a vitamin D analog indicated in the treatment of mild to moderate plaque psoriasis.	Not Available	Small Molecule																																			1	No	3	3	Yes	3	0	60.69 Å2	51.11 Å3	126.29 m3·mol-1	6	Yes	No	0.0105 mg/mL	4.51	-4.6	14.39	-1.1			
C20H30O2	Not Available	Not Available	302.451	[H][C@]1(O)CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])CC(=O)C=C(C)[C@]4(C)[C@@]3([H])CC[C@]12C	Not Available	Not Available						135283		2301378			HMDB0041928									6833		Metenolone	ZINC000005497532		Metenolone	Experimental	DB13710	InChI=1S/C20H30O2/c1-12-10-14(21)11-13-4-5-15-16-6-7-18(22)19(16,2)9-8-17(15)20(12,13)3/h10,13,15-18,22H,4-9,11H2,1-3H3/t13-,15-,16-,17-,18-,19-,20-/m0/s1	ANJQEDFWRSLVBR-VHUDCFPWSA-N		Metenolone is an anabolic steroid indicated in the treatment and prevention of muscle wasting due to diseases, drug treatments, or other catabolic processes.	Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	35.88 Å3	88.98 m3·mol-1	0	Yes	Yes	0.022 mg/mL	3.65	-4.1	19.38	-0.88			
C19H25NO4	Not Available	Not Available	331.4061	CC(C)=CC1C(C(=O)OCN2C(=O)C3=C(CCCC3)C2=O)C1(C)C	Not Available	Not Available						39397	CHEMBL1788386	75773				C18373										Tetramethrin			Tetramethrin	Experimental	DB13752	InChI=1S/C19H25NO4/c1-11(2)9-14-15(19(14,3)4)18(23)24-10-20-16(21)12-7-5-6-8-13(12)17(20)22/h9,14-15H,5-8,10H2,1-4H3	CXBMCYHAMVGWJQ-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	Yes	3	0	No	3	0	63.68 Å2	36.73 Å3	90.19 m3·mol-1	5	Yes	No	0.0754 mg/mL	3.09	-3.6		-4.1			
C21H28O2	Not Available	Not Available	312.4458	[H][C@@]12CC[C@](C)(C(C)=O)[C@@]1(C)CCC1=C3CCC(=O)C=C3CC[C@@]21[H]	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			135339	CHEMBL2104231	84009					D07223							22483		Demegestone	ZINC000004215548		Demegestone	Experimental	DB13857	InChI=1S/C21H28O2/c1-13(22)20(2)11-9-19-18-6-4-14-12-15(23)5-7-16(14)17(18)8-10-21(19,20)3/h12,18-19H,4-11H2,1-3H3/t18-,19+,20-,21+/m1/s1	JWAHBTQSSMYISL-MHTWAQMVSA-N			Not Available	Small Molecule																																			1	Yes	2	0	No	4	0	34.14 Å2	36.71 Å3	93.31 m3·mol-1	1	Yes	Yes	0.0111 mg/mL	3.96	-4.4	18.42	-4.7	P06401	PGR	1. Progesterone receptor
C21H30O3	Not Available	Not Available	330.468	[H][C@@]12CC[C@H](OC(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3C[C@@H](C)[C@@]21[H]	Solid	Not Available							CHEMBL452329	8421572														Trestolone_acetate			Trestolone acetate	Experimental	DB13958	InChI=1S/C21H30O3/c1-12-10-14-11-15(23)4-5-16(14)17-8-9-21(3)18(20(12)17)6-7-19(21)24-13(2)22/h11-12,16-20H,4-10H2,1-3H3/t12-,16+,17-,18+,19+,20-,21+/m1/s1	IVCRCPJOLWECJU-XQVQQVTHSA-N			Not Available	Small Molecule																																			1	Yes	2	0	No	4	0	43.37 Å2	38.59 Å3	93.65 m3·mol-1	2	Yes	No	0.00582 mg/mL	3.79	-4.8	18.34	-4.7			
C23H30O4	No pharmacokinetic data available.	The mean (SD) half life of segesterone acetate is 4.5 (3.4) hours Label.	370.489	[H][C@@]12CC(=C)[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	Solid	The volume of distribution of segesterone acetate is 19.6 L/kg Label.	P08684	CYP3A4	1. Cytochrome P450 3A4			135563	CHEMBL3707377	97161												2055977		Segesterone_acetate	ZINC000005167230	Annovera	Segesterone acetate	Approved, Experimental, Investigational	DB14583	InChI=1S/C23H30O4/c1-13-11-21-20-7-5-16-12-17(26)6-8-18(16)19(20)9-10-22(21,4)23(13,14(2)24)27-15(3)25/h12,18-21H,1,5-11H2,2-4H3/t18-,19+,20+,21-,22-,23-/m0/s1	CKFBRGLGTWAVLG-GOMYTPFNSA-N	3		There have been no reports of serious ill effects from overdose of combination hormonal contraceptive use. Overdosage may cause withdrawal bleeding in females and nausea. In case of suspected overdose, all vaginal systems containing segesterone acetate should be removed and symptomatic treatment should be initiated Label.In a 2-year carcinogenicity study in rats receiving segesterone acetate via subdermal implants, there was no drug-related increase in tumor incidence. In a 2-year intravaginal carcinogenicity study in mice, segesterone acetate gel produced an increased incidence of adenocarcinoma and lobular hyperplasia in the breast at a supratherapeutic dose of 30 mg/kg/day. Segesterone acetate was not shown to be mutagenic or clastogenic Label.	Small Molecule																																173-177		Insoluble	1	Yes	3	0	No	4	0	60.44 Å2	41.79 Å3	102.95 m3·mol-1	3	Yes	No	0.00231 mg/mL	3.64	-5.2	17.46	-4.7	P06401;!P10275;!P04150	PGR;!AR;!NR3C1	1. Progesterone receptor;!2. Androgen receptor;!3. Glucocorticoid receptor
C21H28O3	Not Available	Not Available	328.452	[H][C@@]12CC(=C)[C@](O)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	Not Available	Not Available							CHEMBL2107778	9998301												2055978		Segesterone			Segesterone	Experimental	DB14584	InChI=1S/C21H28O3/c1-12-10-19-18-6-4-14-11-15(23)5-7-16(14)17(18)8-9-20(19,3)21(12,24)13(2)22/h11,16-19,24H,1,4-10H2,2-3H3/t16-,17+,18+,19-,20-,21-/m0/s1	SFLXYFZGKSGFKA-XUDSTZEESA-N			Not Available	Small Molecule																																			1	Yes	3	1	No	4	0	54.37 Å2	37.67 Å3	93.8 m3·mol-1	1	Yes	No	0.0241 mg/mL	3.2	-4.1	12.21	-4			
C18H26O5S	Not Available	Not Available	354.46	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@H]2OS(O)(=O)=O	Not Available	Not Available								2342153															ZINC000038604628		Nandrolone hydrogen sulfate	Experimental, Investigational	DB14624	InChI=1S/C18H26O5S/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)23-24(20,21)22/h10,13-17H,2-9H2,1H3,(H,20,21,22)/t13-,14+,15+,16-,17-,18-/m0/s1	SKZMVWBZTQNCKW-IZPLOLCNSA-N			Not Available	Small Molecule																																			1	Yes	4	1	No	4	-1	80.67 Å2	38.16 Å3	89.95 m3·mol-1	2	Yes	No	0.018 mg/mL	3.12	-4.3	-1.3	-4.7			
C23H34O3	Not Available	Not Available	358.522	[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@H](CC[C@]12C)OC(C)=O	Not Available	Not Available						34930	CHEMBL1892286	2005918				C14658										Pregnenolone_acetate	ZINC000003860692		Pregnenolone acetate	Investigational	DB14626	InChI=1S/C23H34O3/c1-14(24)19-7-8-20-18-6-5-16-13-17(26-15(2)25)9-11-22(16,3)21(18)10-12-23(19,20)4/h5,17-21H,6-13H2,1-4H3/t17-,18-,19+,20-,21-,22-,23+/m0/s1	CRRKVZVYZQXICQ-RJJCNJEVSA-N			Not Available	Small Molecule																																			1	Yes	2	0	No	4	0	43.37 Å2	42.51 Å3	102.91 m3·mol-1	3	Yes	No	0.00188 mg/mL	4.02	-5.3	19.4	-6.8			
C30H44O3	Not Available	14 days	452.679	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2OC(=O)CCCCCCCCC=C	Not Available	Not Available							CHEMBL2106059	10128605														Boldenone_undecylenate	ZINC000004215044		Boldenone undecylenate	Illicit, Vet approved	DB14639	InChI=1S/C30H44O3/c1-4-5-6-7-8-9-10-11-12-28(32)33-27-16-15-25-24-14-13-22-21-23(31)17-19-29(22,2)26(24)18-20-30(25,27)3/h4,17,19,21,24-27H,1,5-16,18,20H2,2-3H3/t24-,25-,26-,27-,29-,30-/m0/s1	AHMMSNQYOPMLSX-CNQKSJKFSA-N			Not Available	Small Molecule																																			0	No	2	0	Yes	4	0	43.37 Å2	56.18 Å3	136.15 m3·mol-1	11	No	No	5.54e-05 mg/mL	7.76	-6.9	18.39	-5	P10275	AR	1. Androgen receptor
C20H24O3	Not Available	Not Available	312.409	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)CCC4=C3C=C[C@]12C)OC(C)=O	Not Available	Not Available					50190646		CHEMBL1698011	59737														Trenbolone_acetate	ZINC000004083873		Trenbolone acetate	Vet approved	DB14660	InChI=1S/C20H24O3/c1-12(21)23-19-8-7-18-17-5-3-13-11-14(22)4-6-15(13)16(17)9-10-20(18,19)2/h9-11,17-19H,3-8H2,1-2H3/t17-,18+,19+,20+/m1/s1	CMRJPMODSSEAPL-FYQPLNBISA-N			Not Available	Small Molecule																																			1	Yes	2	0	No	4	0	43.37 Å2	35.53 Å3	90.81 m3·mol-1	2	Yes	No	0.00758 mg/mL	2.7	-4.6	18.4	-4.8			
C26H38O4	Not Available	Not Available	414.586	[H][C@@]12CC[C@](OC(=O)CCCCC)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	Not Available	Not Available						31650	CHEMBL2107389	391969												4791		Gestonorone_caproate	ZINC000004216396		Gestonorone caproate	Approved	DB14677	InChI=1S/C26H38O4/c1-4-5-6-7-24(29)30-26(17(2)27)15-13-23-22-10-8-18-16-19(28)9-11-20(18)21(22)12-14-25(23,26)3/h16,20-23H,4-15H2,1-3H3/t20-,21+,22+,23-,25-,26-/m0/s1	XURCMZMFZXXQDJ-UKNJCJGYSA-N			Not Available	Small Molecule																																			1	Yes	3	0	Yes	4	0	60.44 Å2	48.55 Å3	117.21 m3·mol-1	7	No	No	0.00141 mg/mL	5.58	-5.5	17.69	-4.7			
C27H38O3	Not Available	Not Available	410.598	[H][C@@]12CC[C@@](OC(=O)CCCCCC)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			34894	CHEMBL3187229	199613				C14486								31984		Norethisterone_enanthate	ZINC000004217172		Norethindrone enanthate	Experimental	DB14678	InChI=1S/C27H38O3/c1-4-6-7-8-9-25(29)30-27(5-2)17-15-24-23-12-10-19-18-20(28)11-13-21(19)22(23)14-16-26(24,27)3/h2,18,21-24H,4,6-17H2,1,3H3/t21-,22+,23+,24-,26-,27-/m0/s1	APTGJECXMIKIET-WOSSHHRXSA-N	4	Norethindrone enanthate is a synthetic progestogen indicated for contraceptive therapy.	Not Available	Small Molecule																																			1	No	2	0	Yes	4	0	43.37 Å2	49.66 Å3	119.61 m3·mol-1	7	No	No	0.00148 mg/mL	6.14	-5.4	18.25	-4.7			
C21H28O5	Not Available	Not Available	360.444	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Not Available	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5		13739	16962	CHEMBL1499	193441			HMDB0002802	C00762	D07749							2878		Cortisone	ZINC000004083557		Cortisone	Experimental	DB14681	InChI=1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h9,14-15,18,22,26H,3-8,10-11H2,1-2H3/t14-,15-,18+,19-,20-,21-/m0/s1	MFYSYFVPBJMHGN-ZPOLXVRWSA-N	4		Not Available	Small Molecule																																			1	Yes	5	2	No	4	0	91.67 Å2	38.95 Å3	96.47 m3·mol-1	2	Yes	No	0.136 mg/mL	1.66	-3.4	12.58	-3.3			
C27H44O	Not Available	Not Available	384.648	[H][C@@]1(CC[C@@]2([H])C(\C=C/C3=C(C)CC[C@H](O)C3)=CCC[C@]12C)[C@H](C)CCCC(C)C	Not Available	Not Available						8403		4444516				C07711											ZINC000016343334		Previtamin D(3)	Experimental	DB15614	InChI=1S/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h10,12-13,19,21,24-26,28H,6-9,11,14-18H2,1-5H3/b13-12-/t21-,24+,25-,26+,27-/m1/s1	YUGCAAVRZWBXEQ-WHTXLNIXSA-N			Not Available	Small Molecule																																			1	No	1	1	Yes	3	0	20.23 Å2	49.02 Å3	124.3 m3·mol-1	7	No	Yes	0.000374 mg/mL	7.07	-6	18.31	-1.3			
C21H29ClO3	Not Available	Not Available	364.91	[H][C@@]12CC[C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=C(Cl)C(=O)CC[C@]12C	Not Available	Not Available						81712	CHEMBL519327	12762				C18374								236522		Clostebol_acetate	ZINC000003881980		Clostebol acetate	Experimental	DB15984	InChI=1S/C21H29ClO3/c1-12(23)25-18-7-6-14-13-4-5-16-19(22)17(24)9-11-20(16,2)15(13)8-10-21(14,18)3/h13-15,18H,4-11H2,1-3H3/t13-,14-,15-,18-,20+,21-/m0/s1	XYGMEFJSKQEBTO-KUJXMBTLSA-N		Clostebol acetate is a steroid combined with neomycin in topical formulations for the treatment of minor skin wounds.	Not Available	Small Molecule																																			1	Yes	2	0	No	4	0	43.37 Å2	40.68 Å3	98.37 m3·mol-1	2	Yes	No	0.00309 mg/mL	4.2	-5.1		-6.2			
C17H14F3N3O2S	Apparent clearance (CL/F), single oral 200 mg dose, healthy subjects = 27.7 L/hr.31 Clearance may be decreased by about 47% in patients with chronic renal insufficiency, according to a pharmacokinetic study. Studies have not been performed in patients with severe renal impairment.31	The effective half-life of celecoxib is approximately 11 hours when a single 200 mg dose is given to healthy subjects.25,31 The terminal half-life of celecoxib varies because of its low solubility, which prolongs absorption.31	381.372	CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F	Solid	The apparent volume of distribution of celecoxib at steady state (Vss/F) is about 429 L25, which suggests wide distribution into various tissues. Celecoxib is not preferentially bound to red blood cells.31 Another resource reports a volume of distribution of 455 ± 166L.12					11639	41423	CHEMBL118	2562	Drugs.com Drug Page		HMDB0005014	C07589	D00567	CEL		PA448871	2662	46505596	RxList Drug Page	140587	DAP000737	Celecoxib	ZINC000002570895	Celebrex, Consensi, Elyxyb, Seglentis	Celecoxib	Approved, Investigational	DB00482	InChI=1S/C17H14F3N3O2S/c1-11-2-4-12(5-3-11)15-10-16(17(18,19)20)22-23(15)13-6-8-14(9-7-13)26(21,24)25/h2-10H,1H3,(H2,21,24,25)	RZEKVGVHFLEQIL-UHFFFAOYSA-N	4	Celecoxib is an NSAID used to treat osteoarthritis, rheumatoid arthritis, acute pain, menstrual symptoms, and to reduce polyps is familial adenomatous polyposis.	The oral TDLo in humans 5.71 mg/kg.29It is not advisable to administer celecoxib in patients with renal impairment or advanced hepatic impairment, as this may lead to increased serum concentrations, causing toxicity.31 Symptoms of overdose may include breathing difficulties, coma, drowsiness, gastrointestinal bleeding, high blood pressure, kidney failure, nausea, sluggishness, stomach pain, and vomiting.23 Because serious gastrointestinal tract ulceration and bleeding can occur without preceding symptoms, patients should be monitored for signs/symptoms of gastrointestinal bleeding. Symptomatic and supportive measures should be taken in a celecoxib overdose. The induction of emesis or administration of active charcoal should take place if the patient is seen within 4 hours of celecoxib ingestion. Diuresis, urinary alkalinization, hemodialysis, or hemoperfusion may not be useful in a celecoxib overdose due to its high level of protein binding.31	Small Molecule	http://smpdb.ca/view/SMP0000096?highlight[compounds][]=DB00482&highlight[proteins][]=DB00482;!http://smpdb.ca/view/SMP0000644?highlight[compounds][]=DB00482&highlight[proteins][]=DB00482	Celecoxib Action Pathway;!Celecoxib Metabolism Pathway		Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.3719 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor		13		529.0±60.0	3.53		157-159	11.1	Poorly soluble	1	Yes	3	1	No	3	0	77.98 Å2	35.2 Å3	92.23 m3·mol-1	4	Yes	No	0.00503 mg/mL	4.01	-4.9	10.6	-0.41			
C20H21ClN4O	Not Available	Not Available	368.87	CC(C)(C)C1=NN(C(NC(=O)NC2=CC=C(Cl)C=C2)=C1)C1=CC=CC=C1	Solid	Not Available					13354		CHEMBL85860	571189						L10			656949	46508963					ZINC000013474619		N-[(3Z)-5-Tert-butyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-ylidene]-N'-(4-chlorophenyl)urea	Experimental	DB01807	InChI=1S/C20H21ClN4O/c1-20(2,3)17-13-18(25(24-17)16-7-5-4-6-8-16)23-19(26)22-15-11-9-14(21)10-12-15/h4-13H,1-3H3,(H2,22,23,26)	XIWRCSVXKPGGAJ-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Inhibitor	Non-substrate	2.5352 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	2	2	No	3	0	58.95 Å2	38.29 Å3	106.77 m3·mol-1	4	No	No		5.83		11.37	1.9	Q16539	MAPK14	1. Mitogen-activated protein kinase 14
C16H19N5	Not Available	Not Available	281.3556	CC1=CC=C(C=C1)C1=NN(C2=C1C(N)=NC=N2)C(C)(C)C	Solid	Not Available					25116		CHEMBL306380	1357						PP1			1400	46508473					ZINC000002047275		1-Ter-Butyl-3-P-Tolyl-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine	Experimental	DB01809	InChI=1S/C16H19N5/c1-10-5-7-11(8-6-10)13-12-14(17)18-9-19-15(12)21(20-13)16(2,3)4/h5-9H,1-4H3,(H2,17,18,19)	ZVPDNRVYHLRXLX-UHFFFAOYSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Non-substrate	2.3339 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	1	No	3	0	69.62 Å2	31.75 Å3	96.53 m3·mol-1	2	Yes	No	0.0953 mg/mL	3.23	-3.5	19.66	3.71	P07949;!P08631	RET;!HCK	1. Proto-oncogene tyrosine-protein kinase receptor Ret;!2. Tyrosine-protein kinase HCK
C14H17N3O2	Not Available	Not Available	259.3037	CCOC(=O)C1=C(C)N(N=C1C)C1=CC=C(N)C=C1	Solid	Not Available					14796			571202						5DE			656966	46508369					ZINC000000109947		1-(4-Aminophenyl)-3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester	Experimental	DB03183	InChI=1S/C14H17N3O2/c1-4-19-14(18)13-9(2)16-17(10(13)3)12-7-5-11(15)6-8-12/h5-8H,4,15H2,1-3H3	FIEYZIRYXYDMSK-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.6300 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	1	No	2	0	70.14 Å2	28.71 Å3	75.64 m3·mol-1	4	Yes	No	0.448 mg/mL	1.92	-2.8		4.29	Q08499	PDE4D	1. cAMP-specific 3',5'-cyclic phosphodiesterase 4D
C16H11BrF3N3O2S	Not Available	Not Available	446.242	NS(=O)(=O)C1=CC=C(C=C1)N1N=C(C=C1C1=CC=C(Br)C=C1)C(F)(F)F	Solid	Not Available							CHEMBL1235806	1353						S58			1396	46508683					ZINC000002047040		1-Phenylsulfonamide-3-Trifluoromethyl-5-Parabromophenylpyrazole	Experimental	DB03477	InChI=1S/C16H11BrF3N3O2S/c17-11-3-1-10(2-4-11)14-9-15(16(18,19)20)22-23(14)12-5-7-13(8-6-12)26(21,24)25/h1-9H,(H2,21,24,25)	OYZKFVIVPRQRQQ-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.4702 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	1	No	3	0	77.98 Å2	36.43 Å3	94.82 m3·mol-1	4	Yes	No	0.00251 mg/mL	4.26	-5.2	10.6	-0.44	P35354	PTGS2	1. Prostaglandin G/H synthase 2
C17H15ClN4O5S	Not Available	Not Available	422.843	NS(=O)(=O)C1=CC=C(CNC(=O)C2=C(NN=C2)C2=CC(Cl)=C(O)C=C2O)C=C1	Solid	Not Available					15399		CHEMBL200255	20120291						2DD			5327104	46506992					ZINC000014958419		N-[4-(AMINOSULFONYL)BENZYL]-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE	Experimental	DB04588	InChI=1S/C17H15ClN4O5S/c18-13-5-11(14(23)6-15(13)24)16-12(8-21-22-16)17(25)20-7-9-1-3-10(4-2-9)28(19,26)27/h1-6,8,23-24H,7H2,(H,20,25)(H,21,22)(H2,19,26,27)	OOHYJGNSESWEFT-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	-	Carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.1838 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	6	5	No	3	0	158.4 Å2	40.16 Å3	104.27 m3·mol-1	5	Yes	No	0.0473 mg/mL	1.25	-4	7.68	1.54	P07900	HSP90AA1	1. Heat shock protein HSP 90-alpha
C16H13ClFN3O3S	Not Available	Not Available	381.809	COC1=C(F)C=C(C=C1)C1=C(Cl)N=CN1C1=CC=C(C=C1)S(N)(=O)=O	Solid	Not Available	P35354	PTGS2	1. Prostaglandin G/H synthase 2		50131593	76127	CHEMBL435381	184745									213053	175426942				Cimicoxib	ZINC000001494105		Cimicoxib	Investigational	DB05095	InChI=1S/C16H13ClFN3O3S/c1-24-14-7-2-10(8-13(14)18)15-16(17)20-9-21(15)11-3-5-12(6-4-11)25(19,22)23/h2-9H,1H3,(H2,19,22,23)	KYXDNECMRLFQMZ-UHFFFAOYSA-N	2		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.4869 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	1	No	3	0	87.21 Å2	35.53 Å3	103.72 m3·mol-1	4	Yes	No	0.018 mg/mL	2.72	-4.3	10.69	3.32			
C25H30F3N5O4	Not Available	Not Available	521.541	CC1(C)CC2=C(C(=NN2C2=CC(N[C@H]3CC[C@@H](CC3)OC(=O)CN)=C(C=C2)C(N)=O)C(F)(F)F)C(=O)C1	Solid	Not Available							CHEMBL1195136	25060921									44195571	347827754							SNX-5422	Investigational	DB06070	InChI=1S/C25H30F3N5O4/c1-24(2)10-18-21(19(34)11-24)22(25(26,27)28)32-33(18)14-5-8-16(23(30)36)17(9-14)31-13-3-6-15(7-4-13)37-20(35)12-29/h5,8-9,13,15,31H,3-4,6-7,10-12,29H2,1-2H3,(H2,30,36)/t13-,15-	AVDSOVJPJZVBTC-CTYIDZIISA-N	1		Not Available	Small Molecule																																			1	No	6	3	Yes	4	0	142.33 Å2	51.66 Å3	131.81 m3·mol-1	8	No	No	0.00924 mg/mL	2.88	-4.8	15.08	7.09	P07900;!P08238	HSP90AA1;!HSP90AB1	1. Heat shock protein HSP 90-alpha;!2. Heat shock protein HSP 90-beta
C22H21Cl3N4O	Not Available	6 to 9 days with normal BMI and 16 days if BMI is greater than 30	463.787	CC1=C(N(N=C1C(=O)NN1CCCCC1)C1=C(Cl)C=C(Cl)C=C1)C1=CC=C(Cl)C=C1	Solid	Not Available					21278	34967	CHEMBL111	94641	Drugs.com Drug Page	GtP Drug Page	HMDB0015623	C14319	D05731	AY6		PA152407999	104850	99443236			DNC001371	Rimonabant	ZINC000001540228		Rimonabant	Approved, Investigational	DB06155	InChI=1S/C22H21Cl3N4O/c1-14-20(22(30)27-28-11-3-2-4-12-28)26-29(19-10-9-17(24)13-18(19)25)21(14)15-5-7-16(23)8-6-15/h5-10,13H,2-4,11-12H2,1H3,(H,27,30)	JZCPYUJPEARBJL-UHFFFAOYSA-N	3		Almost twice as many people discontinued rimonabant compared with placebo because of adverse events (13.8% vs. 7.2%). These consistently involved psychiatric disorders (8.5% vs. 3.2%), including depression and anxiety. Other common side effects included insomnia, nausea, vomiting, diarrhoea and fatigue.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Inhibitor	Non-substrate	Inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.5418 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	No	3	1	No	4	0	50.16 Å2	47.96 Å3	122.83 m3·mol-1	4	No	No	0.002 mg/mL	5.91	-5.4	10.8	1.68			
C15H14N4O2S	Not Available	Not Available	314.362	NC1=CC=C(C=C1)S(=O)(=O)NC1=CC=NN1C1=CC=CC=C1	Solid	Not Available					50090677	77780	CHEMBL1109	5144	Drugs.com Drug Page		HMDB0015667		D01954			PA130231310	5335	99443275				Sulfaphenazole	ZINC000000057490		Sulfaphenazole	Approved	DB06729	InChI=1S/C15H14N4O2S/c16-12-6-8-14(9-7-12)22(20,21)18-15-10-11-17-19(15)13-4-2-1-3-5-13/h1-11,18H,16H2	QWCJHSGMANYXCW-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.1884 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					1.52		181 °C		1500 mg/L (at 25 °C)	1	Yes	4	2	No	3	-1	90.01 Å2	31.82 Å3	85.21 m3·mol-1	3	Yes	No	0.278 mg/mL	1.81	-3	6.82	2.44	P0AC13	folP	1. Dihydropteroate synthase
C24H25N5O	Not Available	Not Available	399.4882	CC(C)(C)C1=NN(C(NC(=O)NC2=C3C=CC=CC3=CC=C2)=C1)C1=CC=CC(N)=C1	Solid	Not Available					31825		CHEMBL522387	24604865						1AU			25174101	99443353					ZINC000039715801		1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea	Experimental	DB06882	InChI=1S/C24H25N5O/c1-24(2,3)21-15-22(29(28-21)18-11-7-10-17(25)14-18)27-23(30)26-20-13-6-9-16-8-4-5-12-19(16)20/h4-15H,25H2,1-3H3,(H2,26,27,30)	HJWMLCDGRWWLAQ-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Inhibitor	Non-substrate	2.6740 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	3	No	4	0	84.97 Å2	43.68 Å3	123.11 m3·mol-1	4	No	No	0.00528 mg/mL	5.39	-4.9	11.14	4.24			
C20H23N5O	Not Available	Not Available	349.4295	CC(C)(C)C1=NN(C(NC(=O)NC2=CC=CC=C2)=C1)C1=CC=CC(N)=C1	Solid	Not Available					50115216		CHEMBL87580	9090317						1AW			10915062	99443354					ZINC000013474626		1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea	Experimental	DB06883	InChI=1S/C20H23N5O/c1-20(2,3)17-13-18(23-19(26)22-15-9-5-4-6-10-15)25(24-17)16-11-7-8-14(21)12-16/h4-13H,21H2,1-3H3,(H2,22,23,26)	DHNYNLNKNQJSHF-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.5634 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	3	No	3	0	84.97 Å2	37.77 Å3	106.66 m3·mol-1	4	Yes	No	0.0198 mg/mL	4.4	-4.2	11.38	4.21	P12931	SRC	1. Proto-oncogene tyrosine-protein kinase Src
C21H15F3N4O	Not Available	Not Available	396.3652	CC1=C(C2=CC3=C(C=C2)N=C(N)N=C3)C(=O)N(C=C1)C1=CC(=CC=C1)C(F)(F)F	Solid	Not Available					50260917		CHEMBL504805	22376730						C52			24812719	99443999					ZINC000016052721		3-(2-aminoquinazolin-6-yl)-4-methyl-1-[3-(trifluoromethyl)phenyl]pyridin-2(1H)-one	Experimental	DB07528	InChI=1S/C21H15F3N4O/c1-12-7-8-28(16-4-2-3-15(10-16)21(22,23)24)19(29)18(12)13-5-6-17-14(9-13)11-26-20(25)27-17/h2-11H,1H3,(H2,25,26,27)	HXUZQEYFKAZBPX-UHFFFAOYSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.7418 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	4	1	No	4	0	72.11 Å2	38.35 Å3	104.82 m3·mol-1	3	Yes	No	0.00584 mg/mL	3.99	-4.8	16.46	3.93			
C17H17N3O2S	Not Available	Not Available	327.401	CN(C1=CC=NN1C1=CC=CC=C1)S(=O)(=O)C1=CC=C(C)C=C1	Solid	Not Available					50105824		CHEMBL332958	394432						DMZ			447297	99444141							N,4-Dimethyl-N-(1-phenyl-1H-pyrazol-5-yl)benzenesulfonamide	Experimental	DB07670	InChI=1S/C17H17N3O2S/c1-14-8-10-16(11-9-14)23(21,22)19(2)17-12-13-18-20(17)15-6-4-3-5-7-15/h3-13H,1-2H3	KRHPBWNETCEFGS-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.5863 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	0	No	3	0	55.2 Å2	34.16 Å3	90.44 m3·mol-1	3	Yes	No	0.187 mg/mL	3.37	-3.2		2.09			
C17H13F3N2O2	Not Available	Not Available	334.2925	OC1=CC(O)=C(C=C1)C1=NN(CC=C)C2=C1C=CC=C2C(F)(F)F	Solid	Not Available					50157493		CHEMBL222501	23281343						KN1			46870043	99444518							4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol	Experimental	DB08047	InChI=1S/C17H13F3N2O2/c1-2-8-22-16-12(4-3-5-13(16)17(18,19)20)15(21-22)11-7-6-10(23)9-14(11)24/h2-7,9,23-24H,1,8H2	ZDUDMCQPFKPISO-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Inhibitor	Non-substrate	2.5366 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	2	No	3	0	58.28 Å2	30.82 Å3	95.15 m3·mol-1	4	Yes	No	0.00829 mg/mL	4.46	-4.6	8.41	1.21			
C20H18N6O	Not Available	Not Available	358.3965	CNC(=O)C1=CC(NC2=C3C=NN(C3=NC=N2)C2=CC=CC=C2)=C(C)C=C1	Solid	Not Available					50331619		CHEMBL410668	19686042						N4D			23400214	99444713					ZINC000003926710		N,4-dimethyl-3-[(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino]benzamide	Experimental	DB08242	InChI=1S/C20H18N6O/c1-13-8-9-14(20(27)21-2)10-17(13)25-18-16-11-24-26(19(16)23-12-22-18)15-6-4-3-5-7-15/h3-12H,1-2H3,(H,21,27)(H,22,23,25)	OYTBZXSFNNAVKU-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Non-substrate	2.6414 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	2	No	4	0	84.73 Å2	38.88 Å3	105.18 m3·mol-1	4	Yes	No	0.0295 mg/mL	3.14	-4.1	14.34	2.01			
C19H18N2O4S	Not Available	22 minutes (parecoxib); 8 hours (valdecoxib)	370.422	CCC(=O)NS(=O)(=O)C1=CC=C(C=C1)C1=C(C)ON=C1C1=CC=CC=C1	Solid	Not Available	P08684;!P11712	CYP3A4;!CYP2C9	1. Cytochrome P450 3A4;!2. Cytochrome P450 2C9			73038	CHEMBL1206690	106990					D02709	PXB		PA166049193	119828	99444910		279950		Parecoxib	ZINC000005761797	Dynastat	Parecoxib	Approved	DB08439	InChI=1S/C19H18N2O4S/c1-3-17(22)21-26(23,24)16-11-9-14(10-12-16)18-13(2)25-20-19(18)15-7-5-4-6-8-15/h4-12H,3H2,1-2H3,(H,21,22)	TZRHLKRLEZJVIJ-UHFFFAOYSA-N	4	Parecoxib is a selective COX-2 inhibitor and NSAID used for the short-term management of perioperative pain.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	-	Carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.2665 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	1	No	3	-1	89.27 Å2	38 Å3	98.9 m3·mol-1	4	Yes	No	0.0162 mg/mL	3.51	-4.4	4.24	0.42	P35354;!P02788	PTGS2;!LTF	1. Prostaglandin G/H synthase 2;!2. Lactotransferrin
C15H12N6O3S	Not Available	Not Available	356.359	NC(=O)C1=NN(C2=C1C=CC1=C2C=NN1)C1=CC=C(C=C1)S(N)(=O)=O	Solid	Not Available					7167		CHEMBL360520	20120330						SBC			5331010	99444998					ZINC000014945777		1-[4-(AMINOSULFONYL)PHENYL]-1,6-DIHYDROPYRAZOLO[3,4-E]INDAZOLE-3-CARBOXAMIDE	Experimental	DB08527	InChI=1S/C15H12N6O3S/c16-15(22)13-10-5-6-12-11(7-18-19-12)14(10)21(20-13)8-1-3-9(4-2-8)25(17,23)24/h1-7H,(H2,16,22)(H,18,19)(H2,17,23,24)	HGAKLLFPOGATII-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.1452 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	3	No	4	0	149.75 Å2	34.41 Å3	91.63 m3·mol-1	3	Yes	No	0.261 mg/mL	0.24	-3.1	10.52	1.39			
C19H13F2N3O2S2	Not Available	Not Available	417.452	FC1=CC=C(C=C1)N1N=C(C=C1NS(=O)(=O)C1=CC=CC(F)=C1)C1=CC=CS1	Solid	Not Available					50185943		CHEMBL378160	2024280						SP0			2742752	99445031					ZINC000001047087		3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE	Experimental	DB08560	InChI=1S/C19H13F2N3O2S2/c20-13-6-8-15(9-7-13)24-19(12-17(22-24)18-5-2-10-27-18)23-28(25,26)16-4-1-3-14(21)11-16/h1-12,23H	GULUFDCOGAXLEP-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.7619 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	1	No	4	-1	63.99 Å2	39.62 Å3	102.59 m3·mol-1	4	Yes	No	0.00728 mg/mL	4.73	-4.8	6.25	1.44			
C17H14F3N3O3S	Not Available	Not Available	397.37	COC1=C(F)C=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)F	Not Available	Not Available					50057583	73032	CHEMBL28636	2319853					D03689							356834		Deracoxib	ZINC000000607803		Deracoxib	Vet approved	DB11395	InChI=1S/C17H14F3N3O3S/c1-26-16-7-2-10(8-13(16)18)15-9-14(17(19)20)22-23(15)11-3-5-12(6-4-11)27(21,24)25/h2-9,17H,1H3,(H2,21,24,25)	WAZQAZKAZLXFMK-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	Yes	4	1	No	3	0	87.21 Å2	35.83 Å3	93 m3·mol-1	5	Yes	No	0.0104 mg/mL	2.76	-4.6	10.7	0.68			
C24H25N5O3S	Not Available	Not Available	463.56	CNCC1=CC=C(C=C1)C1=NOC(=C1)C1=NC(=CN=C1N)C1=CC=C(C=C1)S(=O)(=O)C(C)C	Not Available	Not Available					350085	131166	CHEMBL3989870	30773968									59472121	347828143					ZINC000096170459		Berzosertib	Investigational	DB11794	InChI=1S/C24H25N5O3S/c1-15(2)33(30,31)19-10-8-18(9-11-19)21-14-27-24(25)23(28-21)22-12-20(29-32-22)17-6-4-16(5-7-17)13-26-3/h4-12,14-15,26H,13H2,1-3H3,(H2,25,27)	JZCWLJDSIRUGIN-UHFFFAOYSA-N	2		Not Available	Small Molecule																																			1	Yes	7	2	Yes	4	1	124 Å2	50.76 Å3	128.62 m3·mol-1	7	Yes	No	0.0401 mg/mL	3.16	-4.1	16.52	9.22			
C25H22F3N5O4S	Not Available	Not Available	545.54	CN1N=CC=C1C1=C(C)N(C2=CC=CC(=C2)C(F)(F)F)C(=O)C(=C1)C(=O)NCC1=NC=C(C=C1)S(C)(=O)=O	Not Available	Not Available					50120430		CHEMBL3617964	30687100									71587812	347828201					ZINC000072316197		Alvelestat	Investigational	DB11863	InChI=1S/C25H22F3N5O4S/c1-15-20(22-9-10-31-32(22)2)12-21(23(34)30-13-17-7-8-19(14-29-17)38(3,36)37)24(35)33(15)18-6-4-5-16(11-18)25(26,27)28/h4-12,14H,13H2,1-3H3,(H,30,34)	QNQZWEGMKJBHEM-UHFFFAOYSA-N	2		Not Available	Small Molecule																																			1	No	6	1	Yes	4	0	114.26 Å2	52.25 Å3	146.4 m3·mol-1	7	No	No	0.00275 mg/mL	1.27	-5.3	12.17	2			
C21H11F6N5	Not Available	Not Available	447.344	NC1=CC=C(C=N1)C#CC1=C2N=C(C=C(N2N=C1)C(F)(F)F)C1=CC=C(C=C1)C(F)(F)F	Not Available	Not Available							CHEMBL3301593	32695160									71533696	347828254				Decoglurant	ZINC000115922684		Decoglurant	Investigational	DB11923	InChI=1S/C21H11F6N5/c22-20(23,24)15-6-4-13(5-7-15)16-9-17(21(25,26)27)32-19(31-16)14(11-30-32)3-1-12-2-8-18(28)29-10-12/h2,4-11H,(H2,28,29)	DMJHZVARRXJSEG-UHFFFAOYSA-N	2		Not Available	Small Molecule																																			1	Yes	4	1	No	4	0	69.1 Å2	39.33 Å3	111.06 m3·mol-1	5	No	No	0.0023 mg/mL	5.03	-5.3		4.54			
C21H19N3O3S	Not Available	Not Available	393.46	CCOC1=CC=C(C=C1)C1=NN2N=CC=CC2=C1C1=CC=C(C=C1)S(C)(=O)=O	Not Available	Not Available					50153982		CHEMBL364804	8008415									9832687	347828327					ZINC000000583671		GW-406381	Investigational	DB12009	InChI=1S/C21H19N3O3S/c1-3-27-17-10-6-16(7-11-17)21-20(19-5-4-14-22-24(19)23-21)15-8-12-18(13-9-15)28(2,25)26/h4-14H,3H2,1-2H3	NXMZBNYLCVTRGB-UHFFFAOYSA-N	3		Not Available	Small Molecule																																			1	Yes	5	0	No	4	0	73.56 Å2	41.88 Å3	120.02 m3·mol-1	5	Yes	No	0.00249 mg/mL	3.45	-5.2	19.69	0.98			
C19H17F3N2O4S	Not Available	Not Available	426.41	CC1=C(CC(O)=O)C2=CC=CN=C2N1CC1=CC=C(C=C1C(F)(F)F)S(C)(=O)=O	Not Available	Not Available					50233520		CHEMBL3137332	32701918						FSY			23582412	347828329				Fevipiprant	ZINC000043101772		Fevipiprant	Investigational	DB12011	InChI=1S/C19H17F3N2O4S/c1-11-15(9-17(25)26)14-4-3-7-23-18(14)24(11)10-12-5-6-13(29(2,27)28)8-16(12)19(20,21)22/h3-8H,9-10H2,1-2H3,(H,25,26)	GFPPXZDRVCSVNR-UHFFFAOYSA-N	3		Not Available	Small Molecule																																			1	Yes	5	1	Yes	3	-1	89.26 Å2	38.66 Å3	100.88 m3·mol-1	6	Yes	No	0.00857 mg/mL	2.27	-4.7	4.39	3.73			
C19H20N2O3S	Not Available	Not Available	356.44	CCOC1=CC=C(C=C1)C1=CC(C)=CN1C1=CC=C(C=C1)S(N)(=O)=O	Not Available	Not Available							CHEMBL1835207	7995822									9820073	347828626				Apricoxib			Apricoxib	Investigational	DB12378	InChI=1S/C19H20N2O3S/c1-3-24-17-8-4-15(5-9-17)19-12-14(2)13-21(19)16-6-10-18(11-7-16)25(20,22)23/h4-13H,3H2,1-2H3,(H2,20,22,23)	JTMITOKKUMVWRT-UHFFFAOYSA-N	2		Not Available	Small Molecule																																			1	Yes	3	1	No	3	0	74.32 Å2	38.33 Å3	109.24 m3·mol-1	5	Yes	No	0.0191 mg/mL	3.82	-4.3	10.87	-4.8			
C20H16N4O2S	Not Available	Not Available	376.43	CN(C(C)=O)C1=CC=CC(=C1)C1=CC=NC2=C(C=NN12)C(=O)C1=CC=CS1	Not Available	Not Available					86522		CHEMBL262075	4953363									6450813	347828809				Indiplon	ZINC000000538650		Indiplon	Investigational	DB12590	InChI=1S/C20H16N4O2S/c1-13(25)23(2)15-6-3-5-14(11-15)17-8-9-21-20-16(12-22-24(17)20)19(26)18-7-4-10-27-18/h3-12H,1-2H3	CBIAWPMZSFFRGN-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	Yes	4	0	No	4	0	67.57 Å2	39.66 Å3	114.23 m3·mol-1	4	Yes	No	0.00449 mg/mL	2.69	-4.9		0.96			
C20H16N6O	Not Available	Not Available	356.389	CC1=NC2=CC=C(C=C2N1)N1N=CC(C(=O)C2=CC3=CC=CC=C3N2)=C1N	Not Available	Not Available					50197683		CHEMBL3907479	34450878						LWJ			66555680	347829055					ZINC000098209140		DEBIO-1347	Investigational	DB12903	InChI=1S/C20H16N6O/c1-11-23-16-7-6-13(9-17(16)24-11)26-20(21)14(10-22-26)19(27)18-8-12-4-2-3-5-15(12)25-18/h2-10,25H,21H2,1H3,(H,23,24)	BEMNJULZEQTDJY-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	Yes	4	3	No	5	1	105.38 Å2	39.62 Å3	103.26 m3·mol-1	3	Yes	No	0.0172 mg/mL	2.86	-4.3	12.18	6.83			
C17H13ClN2O2	Not Available	Not Available	312.75	OC(=O)CC1=CN(N=C1C1=CC=C(Cl)C=C1)C1=CC=CC=C1	Not Available	Not Available						76164	CHEMBL1334692	61957												28876		Lonazolac	ZINC000000001631		Lonazolac	Experimental	DB13432	InChI=1S/C17H13ClN2O2/c18-14-8-6-12(7-9-14)17-13(10-16(21)22)11-20(19-17)15-4-2-1-3-5-15/h1-9,11H,10H2,(H,21,22)	XVUQHFRQHBLHQD-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	Yes	3	1	No	3	-1	55.12 Å2	32.25 Å3	85.3 m3·mol-1	4	Yes	No	0.00937 mg/mL	4.33	-4.5	4.31	1.89			
C16H11ClF3N3O2S	Not Available	Long plasma half-life 6.	401.79	NS(=O)(=O)C1=CC=C(C=C1)N1N=C(C=C1C1=CC=C(Cl)C=C1)C(F)(F)F	Solid	Not Available					50057527		CHEMBL282093	8041499															ZINC000000600558		SC-236	Experimental, Investigational	DB14059	InChI=1S/C16H11ClF3N3O2S/c17-11-3-1-10(2-4-11)14-9-15(16(18,19)20)22-23(14)12-5-7-13(8-6-12)26(21,24)25/h1-9H,(H2,21,24,25)	NSQNZEUFHPTJME-UHFFFAOYSA-N			Not Available	Small Molecule																																		insoluble	1	Yes	3	1	No	3	0	77.98 Å2	35.2 Å3	92 m3·mol-1	4	Yes	No	0.004 mg/mL	4.1	-5	10.6	-0.44	Q8SPQ9;!BE0009554	PTGS2;!	1. Cyclooxygenase 2;!2. Nuclear factor NF-kappa-B complex (Protein Group)
C27H22F4N6O3S	Not Available	Not Available	586.57	CN1C=C(C=N1)S(=O)(=O)N1CCC2=CC3=C(C[C@@]2(C1)C(=O)C1=CC(=CC=N1)C(F)(F)F)C=NN3C1=CC=C(F)C=C1	Not Available	Not Available							CHEMBL4068611	57617720														Relacorilant	ZINC000141949519		Relacorilant	Investigational	DB14976	InChI=1S/C27H22F4N6O3S/c1-35-15-22(14-33-35)41(39,40)36-9-7-18-11-24-17(13-34-37(24)21-4-2-20(28)3-5-21)12-26(18,16-36)25(38)23-10-19(6-8-32-23)27(29,30)31/h2-6,8,10-11,13-15H,7,9,12,16H2,1H3/t26-/m0/s1	WANIDIGFXJFFEL-SANMLTNESA-N	2		Not Available	Small Molecule																																			1	No	6	0	No	6	0	102.98 Å2	54.45 Å3	154.09 m3·mol-1	5	No	No	0.0164 mg/mL	3.34	-4.6		2.37			
C22H21F3N2O4S	Not Available	Not Available	466.48	CC1=C(N(CCO)C=C1C(=O)NC1=CC=C(C=C1)S(C)(=O)=O)C1=C(C=CC=C1)C(F)(F)F	Not Available	Not Available					50398059		CHEMBL2181932	28666733						E6R								Esaxerenone	ZINC000043200720		Esaxerenone	Investigational	DB15207	InChI=1S/C22H21F3N2O4S/c1-14-18(21(29)26-15-7-9-16(10-8-15)32(2,30)31)13-27(11-12-28)20(14)17-5-3-4-6-19(17)22(23,24)25/h3-10,13,28H,11-12H2,1-2H3,(H,26,29)	NOSNHVJANRODGR-UHFFFAOYSA-N	3		Not Available	Small Molecule																																			1	Yes	4	2	Yes	3	0	88.4 Å2	45.47 Å3	117.57 m3·mol-1	6	Yes	No	0.00475 mg/mL	3.48	-5	14.97	-2.6			
C22H19N5O2	Not Available	Not Available	385.427	CC1=CC=C(C=C1N1N=CC(C(=O)C2=CC=CC(=C2)C#N)=C1N)C(=O)NC1CC1	Not Available	Not Available								9513071															ZINC000116024237		Acumapimod	Investigational	DB15448	InChI=1S/C22H19N5O2/c1-13-5-6-16(22(29)26-17-7-8-17)10-19(13)27-21(24)18(12-25-27)20(28)15-4-2-3-14(9-15)11-23/h2-6,9-10,12,17H,7-8,24H2,1H3,(H,26,29)	VGUSQKZDZHAAEE-UHFFFAOYSA-N	1		Not Available	Small Molecule																																			1	Yes	5	2	No	4	0	113.8 Å2	41.43 Å3	110.9 m3·mol-1	5	Yes	No	0.0366 mg/mL	3.34	-4	15.42	2.18			
C20H13ClF3N5O3S	Not Available	Not Available	495.86	CC1=CC(NS(=O)(=O)C2=CC=C(Cl)C(=C2)C(F)(F)F)=C(N=C1)C(=O)C1=C2C=CNC2=NC=N1	Not Available	Not Available					50398343		CHEMBL2178573	28669931															ZINC000043204193		CCX-140	Investigational	DB16066	InChI=1S/C20H13ClF3N5O3S/c1-10-6-15(29-33(31,32)11-2-3-14(21)13(7-11)20(22,23)24)17(26-8-10)18(30)16-12-4-5-25-19(12)28-9-27-16/h2-9,29H,1H3,(H,25,27,28)	LUUMLYXKTPBTQR-UHFFFAOYSA-N	2		Not Available	Small Molecule																																			1	No	6	2	No	4	-1	117.7 Å2	44.57 Å3	114.09 m3·mol-1	5	Yes	No	0.00564 mg/mL	4.01	-4.9	6.61	2.19			
C19H17F3N2O3S	Not Available	Not Available	410.41	CNCC1=CN(C(=C1OC)C1=C(F)C=C(F)C=C1)S(=O)(=O)C1=CC(F)=CC=C1	Not Available	Not Available								68006985																	Abeprazan	Investigational	DB16078	InChI=1S/C19H17F3N2O3S/c1-23-10-12-11-24(28(25,26)15-5-3-4-13(20)8-15)18(19(12)27-2)16-7-6-14(21)9-17(16)22/h3-9,11,23H,10H2,1-2H3	OUNXGNDVWVPCOL-UHFFFAOYSA-N	3		Not Available	Small Molecule																																			1	Yes	4	1	No	3	1	60.33 Å2	37.88 Å3	99.21 m3·mol-1	4	Yes	No	0.00997 mg/mL	3.38	-4.6		8.32			
C26H23F4N7O3S	Not Available	Not Available	589.57	[H][C@@]12CCN(C[C@]1(CC1=C(C2)N(N=C1)C1=CC=C(F)C=C1)C(=O)C1=CC(=CC=N1)C(F)(F)F)S(=O)(=O)C1=NN(C)N=C1	Not Available	Not Available					50265794		CHEMBL4089731	75533847																	Exicorilant	Investigational	DB16162	InChI=1S/C26H23F4N7O3S/c1-35-32-14-23(34-35)41(39,40)36-9-7-17-11-22-16(13-33-37(22)20-4-2-19(27)3-5-20)12-25(17,15-36)24(38)21-10-18(6-8-31-21)26(28,29)30/h2-6,8,10,13-14,17H,7,9,11-12,15H2,1H3/t17-,25-/m0/s1	HWJYJKAURRIWJM-GKVSMKOHSA-N	1		Not Available	Small Molecule																																			1	No	7	0	No	6	0	115.87 Å2	53.41 Å3	152.64 m3·mol-1	5	No	No	0.017 mg/mL	3.42	-4.5		2.38			
C21H19F3N2O4S	Not Available	Not Available	452.45	CCOC(=O)CN1N=C(C=C1C1=CC=C(C=C1)C1=CC(=CC=C1)S(C)(=O)=O)C(F)(F)F	Not Available	Not Available							CHEMBL4297218	59718525																	Rovazolac	Investigational	DB16320	InChI=1S/C21H19F3N2O4S/c1-3-30-20(27)13-26-18(12-19(25-26)21(22,23)24)15-9-7-14(8-10-15)16-5-4-6-17(11-16)31(2,28)29/h4-12H,3,13H2,1-2H3	ZUMNJDGBYXHASJ-UHFFFAOYSA-N	2		Not Available	Small Molecule																																			1	Yes	4	0	Yes	3	0	78.26 Å2	43.2 Å3	120.32 m3·mol-1	8	Yes	No	0.00147 mg/mL	3.7	-5.5	16.19	0.31			
C33H40N2O9	Not Available	Not Available	608.6787	[H][C@]12C[C@@H](OC(=O)C3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=C3C=CC(OC)=C1)C2	Solid	Not Available	P20815	CYP3A5	1. Cytochrome P450 3A5		50017712	28487	CHEMBL772	5566	Drugs.com Drug Page		HMDB0014351	C06539	D00197			PA451236	5770	46505863		9260	DAP000755	Reserpine	ZINC000003938746	Renese-R	Reserpine	Approved, Investigational	DB00206	InChI=1S/C33H40N2O9/c1-38-19-7-8-20-21-9-10-35-16-18-13-27(44-32(36)17-11-25(39-2)30(41-4)26(12-17)40-3)31(42-5)28(33(37)43-6)22(18)15-24(35)29(21)34-23(20)14-19/h7-8,11-12,14,18,22,24,27-28,31,34H,9-10,13,15-16H2,1-6H3/t18-,22+,24-,27-,28+,31+/m1/s1	QEVHRUUCFGRFIF-MDEJGZGSSA-N	3		Possible human carcinogen. May cause reproductive harm. ORL-RAT LD50 420 mg/kg; IPR-RAT LD50 44 mg/kg; IVN-RAT LD50 15 mg/kg; ORL-MUS LD50 200 mg/kg; SCU-MUS LD50 52 mg/kg; IPR-RBT LD50 7 mg/kg	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	3.1297 LD50, mol/kg	Inhibitor	Weak inhibitor	Non-inhibitor					3.2		264.5 °C	6.6	73 mg/L (at 30 °C)	1	No	8	1	Yes	6	1	117.78 Å2	66.06 Å3	161.42 m3·mol-1	10	No	No	0.0113 mg/mL	3.53	-4.7	16.29	7.39	Q05940;!P54219;!O15392	SLC18A2;!SLC18A1;!BIRC5	1. Synaptic vesicular amine transporter;!2. Chromaffin granule amine transporter;!3. Baculoviral IAP repeat-containing protein 5
C19H16ClNO4	In a clinical pharmacokinetic study, the plasma clearance of indometacin was reported to range from 1 to 2.5 mL/kg/min following oral administration.2	Indometacin disposition from the plasma is reported to be biphasic, with a half-life of 1 hour during the initial phase and 2.6–11.2 hours during the second phase.6 Interindividual and intraindividual variations are possible due to the extensive and sporadic nature of the enterohepatic recycling and biliary discharge of the drug.2,6The mean half-life of oral indomethacin is estimated to be about 4.5 hours.13 The disposition of intravenous indometacin in preterm neonates was shown to vary across premature infants. In neonates older than 7 days, the mean plasma half-life of intravenous indometacin was approximately 20 hours, ranging from 15 hours in infants weighing more than 1000 g and 21 hours in infants weighing less than 1000 g.14	357.788	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	Solid	The volume of distribution ranged from 0.34 to 1.57 L/kg following oral, intravenous, or rectal administration of single and multiple doses of indometacin in healthy individuals.7 Indometacin is distributed into the synovial fluid 2 and is extensively bound to tissues 6. It has been detected in human breast milk 2 and placenta.13 Although indometacin has been shown to cross the blood-brain barrier (BBB)13, its extensive plasma protein binding allows only the small fraction of free or unbound indometacin to diffuse across the BBB.6	P33261;!P11712;!P23141;!O60656;!P22309;!P16662	CYP2C19;!CYP2C9;!CES1;!UGT1A9;!UGT1A1;!UGT2B7	1. Cytochrome P450 2C19;!2. Cytochrome P450 2C9;!3. Liver carboxylesterase 1;!4. UDP-glucuronosyltransferase 1-9;!5. UDP-glucuronosyltransferase 1-1;!6. UDP-glucuronosyltransferase 2B7		17638	49662	CHEMBL6	3584	Drugs.com Drug Page	GtP Drug Page	HMDB0014473	C01926	D00141	IMN		PA449982	3715	46508291	RxList Drug Page	5781	DAP000617	Indometacin	ZINC000000601283	Indocin, Tivorbex	Indomethacin	Approved, Investigational	DB00328	InChI=1S/C19H16ClNO4/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12/h3-9H,10H2,1-2H3,(H,22,23)	CGIGDMFJXJATDK-UHFFFAOYSA-N	4	Indomethacin is a nonsteroidal anti-inflammatory (NSAID) used for symptomatic management of chronic musculoskeletal pain conditions and to induce closure of a hemodynamically significant patent ductus arteriosus in premature infants.	Acute oral LD50 is 2.42 mg/kg in rats and 13 mg/kg in mice.MSDS The oral LD50 of indomethacin in mice and rats (based on 14-day mortality response) was 50 and 12 mg/kg, respectively.13 Symptoms of overdose may be characterized by nausea, vomiting, intense headache, dizziness, mental confusion, disorientation, or lethargy. In addition, there have been reports of paresthesias, numbness, and convulsions. In case of an overdose, the patient should receive symptomatic and supportive treatment with stomach emptying through induced vomiting or gastric lavage.13 The patient should then be closely monitored for any signs of gastrointestinal ulceration and hemorrhage. Antacids may be useful.13	Small Molecule	http://smpdb.ca/view/SMP0000104?highlight[compounds][]=DB00328&highlight[proteins][]=DB00328	Indomethacin Action Pathway		Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	4.0722 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor		-4.69			4.27	-4.62	151	4.5	0.937 mg/L (at 25 °C)	1	Yes	4	1	No	3	-1	68.53 Å2	36.64 Å3	94.81 m3·mol-1	4	Yes	No	0.0024 mg/mL	3.53	-5.2	3.79	-2.9			
C29H32O13	Total body clearance = 33 - 48 mL/min [IV administration, adults]Mean renal clearance = 7 - 10 mL/min/m^2	4-11 hours	588.5566	[H][C@]12COC(=O)[C@]1([H])[C@H](C1=CC(OC)=C(O)C(OC)=C1)C1=CC3=C(OCO3)C=C1[C@H]2O[C@@H]1O[C@]2([H])CO[C@@H](C)O[C@@]2([H])[C@H](O)[C@H]1O	Solid	The disposition of etoposide is a biphasic process with a distribution half-life of 1.5 hours. It does not cross into cerebrospinal fluid well.Volume of distribution, steady state = 18 - 29 L.					50127140	4911	CHEMBL44657	33510	Drugs.com Drug Page		HMDB0014911	C01576	D00125	EVP		PA449552	36462	46505434	RxList Drug Page	4179	DAP000786	Etoposide	ZINC000003938684	Etopophos, Toposar, Vepesid	Etoposide	Approved	DB00773	InChI=1S/C29H32O13/c1-11-36-9-20-27(40-11)24(31)25(32)29(41-20)42-26-14-7-17-16(38-10-39-17)6-13(14)21(22-15(26)8-37-28(22)33)12-4-18(34-2)23(30)19(5-12)35-3/h4-7,11,15,20-22,24-27,29-32H,8-10H2,1-3H3/t11-,15+,20-,21-,22+,24-,25-,26-,27-,29+/m1/s1	VJJPUSNTGOMMGY-MRVIYFEKSA-N	4	Etoposide is a podophyllotoxin derivative used to treat testicular and small cell lung tumors.	Side effects include alopecia, constipation, diarrhea, nausea and vomiting and secondary malignancies (leukemia).	Small Molecule	http://smpdb.ca/view/SMP0000601?highlight[compounds][]=DB00773&highlight[proteins][]=DB00773;!http://smpdb.ca/view/SMP0000442?highlight[compounds][]=DB00773&highlight[proteins][]=DB00773	Etoposide Metabolism Pathway;!Etoposide Action Pathway		Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.9588 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					0.60		236-251 °C		Sparingly soluble	0	No	12	3	No	7	0	160.83 Å2	57.95 Å3	139.02 m3·mol-1	5	No	No	0.978 mg/mL	1.16	-2.8	9.33	-3.7			
C22H19N3O4	The mean apparent oral clearance of tadalafil is 2.5-3.4L/h in healthy adults.1,7,8 The mean apparent oral clearance in adults with PAH is reported as 3.5L/h	The mean half-life of elimination of tadalafil is 15-17.5h in healthy adults.1,7,8 The mean half-life of elimination in adults with PAH is reported as 35h.8	389.404	[H][C@]12CC3=C(NC4=CC=CC=C34)[C@H](N1C(=O)CN(C)C2=O)C1=CC2=C(OCO2)C=C1	Solid	Tadalafil has a mean apparent volume of distribution of 63L in healthy adults.1,7 The mean apparent volume of distribution is reported as 77L in adults with PAH.8	P08684	CYP3A4	1. Cytochrome P450 3A4		14777	71940	CHEMBL779	99301	Drugs.com Drug Page		HMDB0014958		D02008	CIA	PDRhealth Drug Page	PA10333	110635	46507646	RxList Drug Page	358263	DAP000615	Tadalafil	ZINC000003993855	Adcirca, Alyq, Cialis, Entadfi	Tadalafil	Approved, Investigational	DB00820	InChI=1S/C22H19N3O4/c1-24-10-19(26)25-16(22(24)27)9-14-13-4-2-3-5-15(13)23-20(14)21(25)12-6-7-17-18(8-12)29-11-28-17/h2-8,16,21,23H,9-11H2,1H3/t16-,21-/m1/s1	WOXKDUGGOYFFRN-IIBYNOLFSA-N	4	Tadalafil is a phosphodiesterase 5 inhibitor used to treat erectile dysfunction, benign prostatic hyperplasia, and pulmonary arterial hypertension.	Symptoms of overdose are expected to be similar to typical adverse effects which may include headache, dyspepsia, back pain, myalgia, nasopharyngitis, and dizziness.7,8 Standard supportive care is recommended. Hemodialysis is not expected to contribute significantly to tadalafil clearance.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.6521 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.89		301-302 °C		Practically insoluble in water	1	Yes	4	1	No	6	0	74.87 Å2	40.92 Å3	104.08 m3·mol-1	1	Yes	No	0.25 mg/mL	1.64	-3.2	15.17	-4.2			
C12H10N2O5	Not Available	While the mean serum half-life is 1.5 hours, the half-life may exceed 10 hours in case of renal impairment.	262.2182	CCN1N=C(C(O)=O)C(=O)C2=CC3=C(OCO3)C=C12	Solid	Not Available	P05177	CYP1A2	1. Cytochrome P450 1A2		39350	3716	CHEMBL1208	2660	Drugs.com Drug Page		HMDB0014965	C08052	D00872			PA449007	2762	46507547	RxList Drug Page	2550	DAP000999	Cinoxacin	ZINC000000032350		Cinoxacin	Approved, Investigational, Withdrawn	DB00827	InChI=1S/C12H10N2O5/c1-2-14-7-4-9-8(18-5-19-9)3-6(7)11(15)10(13-14)12(16)17/h3-4H,2,5H2,1H3,(H,16,17)	VDUWPHTZYNWKRN-UHFFFAOYSA-N			Oral, subcutaneous, and intravenous LD50 in the rat is 3610 mg/kg, 1380 mg/kg, and 860 mg/kg, respectively. Oral, subcutaneous, and intravenous LD50 in the mouse is 2330 mg/kg, 900 mg/kg, and 850 mg/kg, respectively. Symptoms following an overdose of cinoxacin may include gastrointestinal effects such as anorexia, nausea, vomiting, epigastric distress, and diarrhea; the severity of the epigastric distress and diarrhea are dose-related. Headache, dizziness, insomnia, photophobia, tinnitus, and a tingling sensation have also been reported in some patients.	Small Molecule				AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.8922 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					1.5		261-262			1	Yes	7	1	No	3	-1	88.43 Å2	24.72 Å3	73.6 m3·mol-1	2	Yes	No	0.961 mg/mL	1.72	-2.4	4.93	-4.7	P43700;!BSEQ0052171	gyrA;!	1. DNA gyrase subunit A;!2. DNA
C32H38N2O8	Not Available	Not Available	578.6527	[H][C@]12C[C@@H](OC(=O)C3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=CC=CC=C31)C2	Solid	Not Available						27478	CHEMBL1200515	8232			HMDB0015221	C06541	D08194			PA164742966	8550	46505311		62174	DAP000909	Deserpidine	ZINC000004097186		Deserpidine	Approved	DB01089	InChI=1S/C32H38N2O8/c1-37-24-12-17(13-25(38-2)29(24)39-3)31(35)42-26-14-18-16-34-11-10-20-19-8-6-7-9-22(19)33-28(20)23(34)15-21(18)27(30(26)40-4)32(36)41-5/h6-9,12-13,18,21,23,26-27,30,33H,10-11,14-16H2,1-5H3/t18-,21+,23-,26-,27+,30+/m1/s1	CVBMAZKKCSYWQR-WCGOZPBSSA-N		Deserpidine is an alkaloid that has been used to manage hypertension.	Symptoms of overdose include dizziness or drowsiness (severe), flushing of skin, pinpoint pupils of eyes and slowed pulse.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	3.0921 LD50, mol/kg	Inhibitor	Weak inhibitor	Non-inhibitor					3.3		228-232			1	No	7	1	Yes	6	1	108.55 Å2	62.6 Å3	154.96 m3·mol-1	9	No	No	0.0111 mg/mL	3.69	-4.7	16.37	7.4	Q05940	SLC18A2	1. Synaptic vesicular amine transporter
C19H16N2O6	Not Available	Not Available	368.3401	CCC1=C(O)C=C(O)C(=C1)C1=NNC(C(O)=O)=C1C1=CC=C2OCOC2=C1	Solid	Not Available					50161650		CHEMBL178130	13007150						4BC			5326934	46509084					ZINC000008466460		4-(1,3-Benzodioxol-5-Yl)-5-(5-Ethyl-2,4-Dihydroxyphenyl)-2h-Pyrazole-3-Carboxylic Acid	Experimental	DB02840	InChI=1S/C19H16N2O6/c1-2-9-5-11(13(23)7-12(9)22)17-16(18(19(24)25)21-20-17)10-3-4-14-15(6-10)27-8-26-14/h3-7,22-23H,2,8H2,1H3,(H,20,21)(H,24,25)	LCTWZJKHOGKNMX-UHFFFAOYSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	-	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.2870 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	7	4	No	4	-1	124.9 Å2	36.38 Å3	96.15 m3·mol-1	4	Yes	No	0.16 mg/mL	3.51	-3.4	3.47	0.78			
C20H18NO4	Not Available	Not Available	336.3612	COC1=CC=C2C=C3C4=CC5=C(OCO5)C=C4CC[N+]3=CC2=C1OC	Solid	Not Available					50203126	16118	CHEMBL295124	2263			HMDB0003409	C00757	D00092	BER		PA165860812	2353	46506051		1437	DNC000385	Berberine	ZINC000003779067		Berberine	Approved, Investigational	DB04115	InChI=1S/C20H18NO4/c1-22-17-4-3-12-7-16-14-9-19-18(24-11-25-19)8-13(14)5-6-21(16)10-15(12)20(17)23-2/h3-4,7-10H,5-6,11H2,1-2H3/q+1	YBHILYKTIRIUTE-UHFFFAOYSA-N	4		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.7834 LD50, mol/kg	Inhibitor	Weak inhibitor	Non-inhibitor							145 °C			1	No	4	0	No	5	1	40.8 Å2	36.92 Å3	93.52 m3·mol-1	2	Yes	No	0.000354 mg/mL	-1.3	-6		-4.4	O15392;!P0A0N5	BIRC5;!qacR	1. Baculoviral IAP repeat-containing protein 5;!2. HTH-type transcriptional regulator QacR
C23H20F2N2O4	Not Available	Not Available	426.42	C[C@H]1NCC2=CC(=CC=C12)C1=CC=C2C(=O)C(=CN(C3CC3)C2=C1OC(F)F)C(O)=O	Solid	Not Available	P05177	CYP1A2	1. Cytochrome P450 1A2			131716	CHEMBL215303	110579														Garenoxacin	ZINC000003585048		Garenoxacin	Investigational	DB06160	InChI=1S/C23H20F2N2O4/c1-11-15-5-2-12(8-13(15)9-26-11)16-6-7-17-19(21(16)31-23(24)25)27(14-3-4-14)10-18(20(17)28)22(29)30/h2,5-8,10-11,14,23,26H,3-4,9H2,1H3,(H,29,30)/t11-/m1/s1	NJDRXTDGYFKORP-LLVKDONJSA-N			Not Available	Small Molecule																																			1	Yes	6	2	No	5	0	78.87 Å2	42.39 Å3	110.37 m3·mol-1	5	Yes	No	0.0232 mg/mL	1.62	-4.3	6.05	8.88			
C22H23NO7	Not Available	Not Available	413.4205	[H][C@@]1(OC(=O)C2=C1C=CC(OC)=C2OC)[C@]1([H])N(C)CCC2=CC3=C(OCO3)C(OC)=C12	Solid	Not Available	P11712;!P08684	CYP2C9;!CYP3A4	1. Cytochrome P450 2C9;!2. Cytochrome P450 3A4		50424716	73237	CHEMBL364713	242139			HMDB0033439	C09592								7533		Noscapine	ZINC000019418974		Noscapine	Approved, Investigational	DB06174	InChI=1S/C22H23NO7/c1-23-8-7-11-9-14-20(29-10-28-14)21(27-4)15(11)17(23)18-12-5-6-13(25-2)19(26-3)16(12)22(24)30-18/h5-6,9,17-18H,7-8,10H2,1-4H3/t17-,18+/m1/s1	AKNNEGZIBPJZJG-MSOLQXFVSA-N		Noscapine is a non-sedating isoquinoline alkaloid used primarily for its antitussive properties.	Not Available	Small Molecule																																			1	Yes	7	0	No	5	1	75.69 Å2	42.17 Å3	107.08 m3·mol-1	4	Yes	No	0.181 mg/mL	2.58	-3.4	13.07	7.14	Q99720	SIGMAR1	1. Sigma non-opioid intracellular receptor 1
C22H25N5O	Not Available	Not Available	375.4668	CCC1=NC(N)=NC(N)=C1C1=CC2=C(C=C1)C1=CC=CC=C1N2CCCOC	Solid	Not Available					18039			5290506						2IG			6914626	99443438					ZINC000014966601		6-ETHYL-5-[9-(3-METHOXYPROPYL)-9H-CARBAZOL-2-YL]PYRIMIDINE-2,4-DIAMINE	Experimental	DB06967	InChI=1S/C22H25N5O/c1-3-17-20(21(23)26-22(24)25-17)14-9-10-16-15-7-4-5-8-18(15)27(19(16)13-14)11-6-12-28-2/h4-5,7-10,13H,3,6,11-12H2,1-2H3,(H4,23,24,25,26)	MLSVRCGEBXIIQO-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.6757 LD50, mol/kg	Inhibitor	Weak inhibitor	Inhibitor										1	Yes	5	2	Yes	4	1	91.98 Å2	43.18 Å3	114.96 m3·mol-1	6	Yes	No	0.0158 mg/mL	3.5	-4.4	17.18	7.76	P00797	REN	1. Renin
C24H20N2O5	Not Available	Not Available	416.426	COC1=CC=CC=C1C1=CC2=C(C3=C(C=CC(O)=C3)N2CCCO)C2=C1C(=O)NC2=O	Solid	Not Available					50245497		CHEMBL512341	8540034						330			10364585	99443477					ZINC000016052181		9-HYDROXY-6-(3-HYDROXYPROPYL)-4-(2-METHOXYPHENYL)PYRROLO[3,4-C]CARBAZOLE-1,3(2H,6H)-DIONE	Experimental	DB07006	InChI=1S/C24H20N2O5/c1-31-19-6-3-2-5-14(19)15-12-18-20(22-21(15)23(29)25-24(22)30)16-11-13(28)7-8-17(16)26(18)9-4-10-27/h2-3,5-8,11-12,27-28H,4,9-10H2,1H3,(H,25,29,30)	AOGOZJCRIFBTTN-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	2.1625 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	5	3	No	5	0	100.79 Å2	44.07 Å3	116.36 m3·mol-1	5	Yes	No	0.019 mg/mL	2.59	-4.3	8.1	-2.4			
C19H16NO4	Not Available	Not Available	322.3346	COC1=C(OC)C=C2C3=C([NH+]=CC2=C1)C1=C(C3)C=C2OCOC2=C1	Solid	Not Available								4449976						AI3			5287652	99443825							2,3-DIMETHOXY-12H-[1,3]DIOXOLO[5,6]INDENO[1,2-C]ISOQUINOLIN-6-IUM	Experimental	DB07354	InChI=1S/C19H15NO4/c1-21-15-5-11-8-20-19-13-7-18-17(23-9-24-18)4-10(13)3-14(19)12(11)6-16(15)22-2/h4-8H,3,9H2,1-2H3/p+1	LXDREMZQGAILJU-UHFFFAOYSA-O			Not Available	Small Molecule				AMES toxic	Ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.5745 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	1	No	5	0	51.06 Å2	35.29 Å3	89 m3·mol-1	2	Yes	No	0.00126 mg/mL	3.2	-5.4	11.22	5.44	P11387	TOP1	1. DNA topoisomerase 1
C22H20ClN3O4S	Not Available	Not Available	457.93	[H][C@](C)(OC1=C(SC(=C1)N1C=NC2=CC(OC)=C(OC)C=C12)C(N)=O)C1=CC=CC=C1Cl	Solid	Not Available					28206		CHEMBL222419	10131669						BLZ			11957417	99443942					ZINC000016052682		5-[5,6-BIS(METHYLOXY)-1H-BENZIMIDAZOL-1-YL]-3-{[1-(2-CHLOROPHENYL)ETHYL]OXY}-2-THIOPHENECARBOXAMIDE	Experimental	DB07471	InChI=1S/C22H20ClN3O4S/c1-12(13-6-4-5-7-14(13)23)30-19-10-20(31-21(19)22(24)27)26-11-25-15-8-17(28-2)18(29-3)9-16(15)26/h4-12H,1-3H3,(H2,24,27)/t12-/m1/s1	UHCHLTQBLNUYRT-GFCCVEGCSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.2926 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	5	1	Yes	4	0	88.6 Å2	46.75 Å3	128.32 m3·mol-1	7	Yes	No	0.0104 mg/mL	4.34	-4.6	13.94	5.56	P20248;!P24941	CCNA2;!CDK2	1. Cyclin-A2;!2. Cyclin-dependent kinase 2
C20H20N2O4	Not Available	Not Available	352.3838	CCC1=C(O)C=C(O)C(=C1)C1=C(C(C)=NN1)C1=CC2=C(OCCO2)C=C1	Solid	Not Available					15362	41656	CHEMBL399530	10392116						CT5			5327091	99444065					ZINC000008536348		CCT-018159	Experimental	DB07594	InChI=1S/C20H20N2O4/c1-3-12-8-14(16(24)10-15(12)23)20-19(11(2)21-22-20)13-4-5-17-18(9-13)26-7-6-25-17/h4-5,8-10,23-24H,3,6-7H2,1-2H3,(H,21,22)	OWPMENVYXDJDOW-UHFFFAOYSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.3374 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	3	No	4	0	87.6 Å2	37.26 Å3	99.05 m3·mol-1	3	Yes	No	0.104 mg/mL	3.49	-3.5	9.21	3.07	P08238;!P07900	HSP90AB1;!HSP90AA1	1. Heat shock protein HSP 90-beta;!2. Heat shock protein HSP 90-alpha
C19H16INO4	Not Available	Not Available	449.2391	COC1=CC=C2N(C(=O)C3=CC=C(I)C=C3)C(C)=C(CC(O)=O)C2=C1	Solid	Not Available					50308511		CHEMBL590284	394813						IMM			447835	99444454					ZINC000002047442		1-(4-IODOBENZOYL)-5-METHOXY-2-METHYL INDOLE-3-ACETIC ACID	Experimental	DB07983	InChI=1S/C19H16INO4/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12/h3-9H,10H2,1-2H3,(H,22,23)	CXBFZYKAVCAPSV-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	3.6058 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	1	No	3	-1	68.53 Å2	40.05 Å3	103.37 m3·mol-1	4	Yes	No	0.00512 mg/mL	3.85	-4.9	3.83	-2.9	P23219	PTGS1	1. Prostaglandin G/H synthase 1
C17H19N5O2	Not Available	Not Available	325.3651	COC1=C(OC)C=C(C=C1)C1=NN(C2CCC2)C2=NC=NC(N)=C12	Solid	Not Available					36408		CHEMBL1233881	24605308						KS4			24905153	99444524					ZINC000008581973		1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine	Experimental	DB08053	InChI=1S/C17H19N5O2/c1-23-12-7-6-10(8-13(12)24-2)15-14-16(18)19-9-20-17(14)22(21-15)11-4-3-5-11/h6-9,11H,3-5H2,1-2H3,(H2,18,19,20)	ITOYZJGFTNTKKR-UHFFFAOYSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.4905 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	6	1	No	4	0	88.08 Å2	35.03 Å3	102.42 m3·mol-1	4	Yes	No	0.161 mg/mL	2.26	-3.3	19.66	3.73	P12931	SRC	1. Proto-oncogene tyrosine-protein kinase Src
C27H24N2O3	Not Available	Not Available	424.4911	CC(C)OC1=CC=C2C(CCC3=C2C2=C(C=NC2=O)C2=C3N(CCO)C3=CC=CC=C23)=C1	Solid	Not Available								25060609						VIN			25203955	99445174					ZINC000039143289		12-(2-hydroxyethyl)-2-(1-methylethoxy)-13,14-dihydronaphtho[2,1-a]pyrrolo[3,4-c]carbazol-5(12H)-one	Experimental	DB08703	InChI=1S/C27H24N2O3/c1-15(2)32-17-8-10-18-16(13-17)7-9-20-23(18)25-21(14-28-27(25)31)24-19-5-3-4-6-22(19)29(11-12-30)26(20)24/h3-6,8,10,13-15,30H,7,9,11-12H2,1-2H3	FGKKIHITEICGMN-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	2.2947 LD50, mol/kg	Inhibitor	Weak inhibitor	Inhibitor										1	Yes	4	1	No	6	0	63.82 Å2	48.26 Å3	126.33 m3·mol-1	4	Yes	No	0.00579 mg/mL	4.59	-4.9	15.45	0.48	P80192	MAP3K9	1. Mitogen-activated protein kinase kinase kinase 9
C23H23ClFNO5	Not Available	The median terminal plasma half-life following administration of elvitegravir and ritonavir was approximately 8.7 hours.	447.884	[H][C@@](CO)(C(C)C)N1C=C(C(O)=O)C(=O)C2=C1C=C(OC)C(CC1=C(F)C(Cl)=CC=C1)=C2	Solid	Not Available	P08684;!P22309	CYP3A4;!UGT1A1	1. Cytochrome P450 3A4;!2. UDP-glucuronosyltransferase 1-1		50183273	72289	CHEMBL204656	4441060						ELV			5277135	310265026	RxList Drug Page	1306286		Elvitegravir	ZINC000013682481	Genvoya, Stribild	Elvitegravir	Approved	DB09101	InChI=1S/C23H23ClFNO5/c1-12(2)19(11-27)26-10-16(23(29)30)22(28)15-8-14(20(31-3)9-18(15)26)7-13-5-4-6-17(24)21(13)25/h4-6,8-10,12,19,27H,7,11H2,1-3H3,(H,29,30)/t19-/m1/s1	JUZYLCPPVHEVSV-LJQANCHMSA-N	4	Elvitegravir is an antiretroviral agent used in combination with other antiretrovirals for the treatment of HIV-1 infection in antiretroviral treatment-experienced adults.	The most common adverse reactions reported for elvitegravir use during clinical trials include nausea, vomiting, and diarrhea. Less common side effects occurring in <2% of patients, include abdominal pain, dyspepsia, fatigue, insomnia, rash, depression, suicidal ideation, and suicidal attempt.	Small Molecule																																		<0.3 mcg/mL	1	Yes	6	2	Yes	3	-1	87.07 Å2	44.8 Å3	116.26 m3·mol-1	7	Yes	No	0.00652 mg/mL	4.67	-4.8	5.97	-0.53	Q7ZJM1	pol	1. Integrase
C23H22O6	Not Available	Not Available	394.4172	[H][C@@]12COC3=C(C=C(OC)C(OC)=C3)[C@]1([H])C(=O)C1=CC=C3O[C@H](CC3=C1O2)C(C)=C	Not Available	Not Available					50135527	28201	CHEMBL429023	6500			HMDB0034436	C07593		970			6758	347827979		1366666		Rotenone	ZINC000003860715		Rotenone	Vet approved	DB11457	InChI=1S/C23H22O6/c1-11(2)16-8-14-15(28-16)6-5-12-22(24)21-13-7-18(25-3)19(26-4)9-17(13)27-10-20(21)29-23(12)14/h5-7,9,16,20-21H,1,8,10H2,2-4H3/t16-,20-,21+/m1/s1	JUVIOZPCNVVQFO-HBGVWJBISA-N			Not Available	Small Molecule																																			1	Yes	6	0	No	5	0	63.22 Å2	42.07 Å3	105.71 m3·mol-1	3	Yes	No	0.0129 mg/mL	3.32	-4.5	13.99	-4.2			
C20H17NO6	Not Available	Not Available	367.3521	[H][C@]1(OC(=O)C2=C1C=CC1=C2OCO1)[C@@]1([H])N(C)CCC2=CC3=C(OCO3)C=C12	Solid	Not Available					50000693	3092	CHEMBL417990	9820				C09364		H0Z			10237	347827985				Bicuculline	ZINC000019899011		Bicuculline	Experimental	DB11562	InChI=1S/C20H17NO6/c1-21-5-4-10-6-14-15(25-8-24-14)7-12(10)17(21)18-11-2-3-13-19(26-9-23-13)16(11)20(22)27-18/h2-3,6-7,17-18H,4-5,8-9H2,1H3/t17-,18+/m0/s1	IYGYMKDQCDOMRE-ZWKOTPCHSA-N			Not Available	Small Molecule																																			1	Yes	6	0	No	6	0	66.46 Å2	37.3 Å3	93.45 m3·mol-1	1	Yes	No	0.361 mg/mL	2.68	-3	13.1	6.67			
C21H19N3O5	Not Available	Not Available	393.399	CNC(=O)C1=C(C)OC2=CC(OC3=NC=NC4=CC(OC)=C(OC)C=C34)=CC=C12	Not Available	Not Available								39625837									44480399	347828047					ZINC000114898570		Fruquintinib	Investigational	DB11679	InChI=1S/C21H19N3O5/c1-11-19(20(25)22-2)13-6-5-12(7-16(13)28-11)29-21-14-8-17(26-3)18(27-4)9-15(14)23-10-24-21/h5-10H,1-4H3,(H,22,25)	BALLNEJQLSTPIO-UHFFFAOYSA-N	3		Not Available	Small Molecule																																			1	Yes	5	1	No	4	0	95.71 Å2	40.64 Å3	106.25 m3·mol-1	5	Yes	No	0.0803 mg/mL	2.64	-3.7	14.99	2.57			
C22H14F3NO5	Not Available	Not Available	429.351	FC(F)(F)C1=CC=C(CN2C(=O)[C@@]3(COC4=C3C=C3OCOC3=C4)C3=CC=CC=C23)O1	Not Available	Not Available					206760		CHEMBL3707218	34500834									49836093	347828122				Funapide	ZINC000113473392		Funapide	Investigational	DB11769	InChI=1S/C22H14F3NO5/c23-22(24,25)19-6-5-12(31-19)9-26-15-4-2-1-3-13(15)21(20(26)27)10-28-16-8-18-17(7-14(16)21)29-11-30-18/h1-8H,9-11H2/t21-/m0/s1	NEBUOXBYNAHKFV-NRFANRHFSA-N	2		Not Available	Small Molecule																																			1	Yes	4	0	No	6	0	61.14 Å2	38.49 Å3	100.35 m3·mol-1	3	Yes	No	0.0341 mg/mL	3.45	-4.1		-3.1			
C19H21N5O3	Not Available	Not Available	367.409	COC1=CC=C2NC3=C4C(=CC=C3[N+]([O-])=O)N(CCCN(C)C)N=C4C2=C1	Not Available	Not Available							CHEMBL118841	10664646									5351360	347828774					ZINC000003778885		Pyrazoloacridine	Investigational	DB12549	InChI=1S/C19H21N5O3/c1-22(2)9-4-10-23-15-7-8-16(24(25)26)19-17(15)18(21-23)13-11-12(27-3)5-6-14(13)20-19/h5-8,11,20H,4,9-10H2,1-3H3	HZCWPKGYTCJSEB-UHFFFAOYSA-N	2		Not Available	Small Molecule																																			1	No	5	1	Yes	4	0	89.22 Å2	39.72 Å3	114 m3·mol-1	6	Yes	No	0.159 mg/mL	-0.71	-3.4	4.9	9.66			
C32H37NO6	Not Available	Not Available	531.649	COCCOC1=CC(OCCOC)=CC(CN2C3=CC=CC=C3C(=C2C(O)=O)C2=CC=C(C=C2)C(C)(C)C)=C1	Not Available	Not Available								32698223									24946920	347828859							GSK-376501	Investigational	DB12654	InChI=1S/C32H37NO6/c1-32(2,3)24-12-10-23(11-13-24)29-27-8-6-7-9-28(27)33(30(29)31(34)35)21-22-18-25(38-16-14-36-4)20-26(19-22)39-17-15-37-5/h6-13,18-20H,14-17,21H2,1-5H3,(H,34,35)	OIDYMQICWGYEDR-UHFFFAOYSA-N	1		Not Available	Small Molecule																																			0	No	6	1	Yes	4	-1	79.15 Å2	59.87 Å3	152.6 m3·mol-1	13	No	No	0.000129 mg/mL	6.38	-6.6	4.69	-3.7			
C39H53N3O9	Not Available	Not Available	707.865	CCN(CC)CCN1C2=CC(OC)=CC=C2C2=C1[C@H]1C[C@H]3[C@H](C[C@@H](OC(=O)C4=CC(OC)=C(OC)C(OC)=C4)[C@H](OC)[C@H]3C(=O)OC)CN1CC2	Not Available	Not Available						125518	CHEMBL3989595	16735698														Bietaserpine	ZINC000095628218		Bietaserpine	Experimental	DB13575	InChI=1S/C39H53N3O9/c1-9-40(10-2)15-16-42-29-20-25(45-3)11-12-26(29)27-13-14-41-22-24-19-33(37(49-7)34(39(44)50-8)28(24)21-30(41)35(27)42)51-38(43)23-17-31(46-4)36(48-6)32(18-23)47-5/h11-12,17-18,20,24,28,30,33-34,37H,9-10,13-16,19,21-22H2,1-8H3/t24-,28+,30-,33-,34+,37+/m1/s1	WFTSRDISOMSAQC-ZNFOTRSXSA-N			Not Available	Small Molecule																																			0	No	9	0	Yes	6	2	110.16 Å2	79.12 Å3	193.83 m3·mol-1	15	No	No	0.00677 mg/mL	4.49	-5		9.81			
C13H11NO5	Not Available	Not Available	261.2301	CCN1C=C(C(O)=O)C(=O)C2=CC3=C(OCO3)C=C12	Not Available	Not Available						138856	CHEMBL416755	4467				C11342	D02301	OXI						7798		Oxolinic_acid	ZINC000000001875		Oxolinic acid	Experimental	DB13627	InChI=1S/C13H11NO5/c1-2-14-5-8(13(16)17)12(15)7-3-10-11(4-9(7)14)19-6-18-10/h3-5H,2,6H2,1H3,(H,16,17)	KYGZCKSPAKDVKC-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	Yes	6	1	No	3	-1	76.07 Å2	25.52 Å3	65.84 m3·mol-1	2	Yes	No	1.91 mg/mL	1.35	-2.1	5.39	-4.3			
C33H40N2O9	Not Available	Not Available	608.688	CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C(NC5=CC=C(OC)C=C45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)C1=CC(OC)=C(OC)C(OC)=C1	Not Available	Not Available						135848	CHEMBL3989541	64824												235829		Methoserpidine	ZINC000056898766		Methoserpidine	Experimental	DB13631	InChI=1S/C33H40N2O9/c1-38-19-7-8-23-22(14-19)20-9-10-35-16-18-13-27(44-32(36)17-11-25(39-2)30(41-4)26(12-17)40-3)31(42-5)28(33(37)43-6)21(18)15-24(35)29(20)34-23/h7-8,11-12,14,18,21,24,27-28,31,34H,9-10,13,15-16H2,1-6H3/t18-,21+,24-,27-,28+,31+/m1/s1	ULBNWNUHGJLQHO-VKMIBBQISA-N			Not Available	Small Molecule																																			1	No	8	1	Yes	6	1	117.78 Å2	66.18 Å3	161.42 m3·mol-1	10	No	No	0.0113 mg/mL	3.53	-4.7	16.65	7.03			
C26H32N2O8	Not Available	Not Available	500.548	CCOC1=C(OCC)C(OCC)=C(N)C2=C1C(OC2=O)C1N(C)CCC2=CC3=C(OCO3)C(OC)=C12	Not Available	Not Available						135802	CHEMBL2104445	65119			HMDB0240249									38810		Tritoqualine			Tritoqualine	Approved	DB13711	InChI=1S/C26H32N2O8/c1-6-31-23-17-16(18(27)24(32-7-2)25(23)33-8-3)26(29)36-21(17)19-15-13(9-10-28(19)4)11-14-20(22(15)30-5)35-12-34-14/h11,19,21H,6-10,12,27H2,1-5H3	IRGJVQIJENCTQF-UHFFFAOYSA-N			Not Available	Small Molecule	http://smpdb.ca/view/SMP0062895?highlight[compounds][]=DB13711&highlight[proteins][]=DB13711	Tritoqualine H1-Antihistamine Action																																	1	No	9	1	Yes	5	1	110.94 Å2	52.8 Å3	132.49 m3·mol-1	8	No	No	0.204 mg/mL	3.31	-3.4	13.29	7.06			
C21H18ClNO6	Intravenous administration of acemetacin in healthy subjects reported a clearance rate of 4.59 ml min/kg.5	The elimination half-life of acemetacin after steady-state is 4.5 hours.4	415.83	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(=O)OCC(O)=O	Solid	The apparent volume of distribution of acemetacin is in a range of 0.5-0.7 L/kg.9	P16662	UGT2B7	1. UDP-glucuronosyltransferase 2B7		50336272	31162	CHEMBL189171	1904					D01582			PA166049184	1981	347829316		16695		Acemetacin	ZINC000000601272		Acemetacin	Approved, Investigational	DB13783	InChI=1S/C21H18ClNO6/c1-12-16(10-20(26)29-11-19(24)25)17-9-15(28-2)7-8-18(17)23(12)21(27)13-3-5-14(22)6-4-13/h3-9H,10-11H2,1-2H3,(H,24,25)	FSQKKOOTNAMONP-UHFFFAOYSA-N		Acemetacin is a NSAID indicated in the treatment of pain and inflammation.	The pharmacological activity of acemetacin causes blockage of prostaglandin synthesis. Prostaglandin is one of the mediators of renal blood flow and glomerular filtration thus, acemetacin causes a decreased renal function, transient renal insufficiency, interstitial nephritis and papillary necrosis especially in elderly patients, patients with congestive heart failure, hepatic cirrhosis and impaired renal function.9	Small Molecule																													637ºC	4.49		151.5ºC	2.6	Slightly soluble	1	Yes	5	1	Yes	3	-1	94.83 Å2	41.23 Å3	105.66 m3·mol-1	7	Yes	No	0.00229 mg/mL	3.15	-5.3	3.26	-2.3	P23219;!P35354	PTGS1;!PTGS2	1. Prostaglandin G/H synthase 1;!2. Prostaglandin G/H synthase 2
C28H24F3NO6	Not Available	Not Available	527.496	CC[C@@H](OC1=CC(=CC=C1)N1C(C)=C(C(=O)C2=CC=C(OC)C=C2)C2=CC=C(OC(F)(F)F)C=C12)C(O)=O	Not Available	Not Available					50267991		CHEMBL490029	9853263															ZINC000049878561		MK-0533	Investigational	DB15242	InChI=1S/C28H24F3NO6/c1-4-24(27(34)35)37-20-7-5-6-18(14-20)32-16(2)25(26(33)17-8-10-19(36-3)11-9-17)22-13-12-21(15-23(22)32)38-28(29,30)31/h5-15,24H,4H2,1-3H3,(H,34,35)/t24-/m1/s1	STWITCBWQHTJFJ-XMMPIXPASA-N			Not Available	Small Molecule																																			0	No	6	1	Yes	4	-1	86.99 Å2	51.64 Å3	138.96 m3·mol-1	10	No	No	0.000378 mg/mL	7.3	-6.1	3.78	-4.5			
C19H18O9	Not Available	Not Available	390.344	COC(=O)C1=C(C2=C(OCO2)C(OC)=C1)C1=C(CO)C=C(OC)C2=C1OCO2	Not Available	Not Available							CHEMBL482035	7997503															ZINC000002012988		Bicyclol	Investigational	DB16014	InChI=1S/C19H18O9/c1-22-11-4-9(6-20)13(17-15(11)25-7-27-17)14-10(19(21)24-3)5-12(23-2)16-18(14)28-8-26-16/h4-5,20H,6-8H2,1-3H3	KXMTXZACPVCDMH-UHFFFAOYSA-N	2		Not Available	Small Molecule																																			1	Yes	8	1	No	4	0	101.91 Å2	38.06 Å3	94.5 m3·mol-1	5	Yes	No	0.271 mg/mL	1.79	-3.2	15.03	-2.8			
C22H13FN2O5	Not Available	Not Available	404.353	CN1C=C(C2=C1C=C1OCOC1=C2)C1=C(C(=O)NC1=O)C1=COC2=CC=C(F)C=C12	Not Available	Not Available					50267716		CHEMBL483465	24701488															ZINC000040413912		9-ING-41	Investigational	DB16047	InChI=1S/C22H13FN2O5/c1-25-7-13(11-5-17-18(6-15(11)25)30-9-29-17)19-20(22(27)24-21(19)26)14-8-28-16-3-2-10(23)4-12(14)16/h2-8H,9H2,1H3,(H,24,26,27)	FARXPFGGGGLENU-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	Yes	4	1	No	6	0	82.7 Å2	39.41 Å3	103.06 m3·mol-1	2	Yes	No	0.0352 mg/mL	2.95	-4.1	9.86	-3			
C26H31N5O4	Not Available	Not Available	477.565	COC1=C(OC)C=C2C(CCN3C(=O)N(CCNC(N)=O)\C(C=C23)=N\C2=C(C)C=C(C)C=C2C)=C1	Not Available	Not Available								8110374															ZINC000000602859		Ensifentrine	Investigational	DB16157	InChI=1S/C26H31N5O4/c1-15-10-16(2)24(17(3)11-15)29-23-14-20-19-13-22(35-5)21(34-4)12-18(19)6-8-30(20)26(33)31(23)9-7-28-25(27)32/h10-14H,6-9H2,1-5H3,(H3,27,28,32)/b29-23+	CSOBIBXVIYAXFM-BYNJWEBRSA-N	2		Not Available	Small Molecule																																			1	No	5	2	Yes	4	0	109.49 Å2	52.81 Å3	137.62 m3·mol-1	6	Yes	No	0.0218 mg/mL	3.27	-4.3	14.74	5.23			
C17H22NO3	Not Available	Not Available	288.366	COC1=CC=CC2=C1[N+](C)=C1O[C@H](CC1=C2OC)C(C)C	Not Available	Not Available								16735880															ZINC000001596423		Lunasine	Investigational	DB16223	InChI=1S/C17H22NO3/c1-10(2)14-9-12-16(20-5)11-7-6-8-13(19-4)15(11)18(3)17(12)21-14/h6-8,10,14H,9H2,1-5H3/q+1/t14-/m1/s1	GUIBZZYABLMRRD-CQSZACIVSA-N	2		Not Available	Small Molecule																																			1	No	3	0	No	3	1	31.57 Å2	32.08 Å3	81.75 m3·mol-1	3	Yes	Yes	0.000151 mg/mL	-1.2	-6.3		-4.5			
C32H26N4O2	Not Available	5 hours	498.5744	CC1=NC2=C(CCN(C(=O)C3=CC=C(NC(=O)C4=CC=CC=C4C4=CC=CC=C4)C=C3)C3=CC=CC=C23)N1	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4		85095	681850	CHEMBL1755	133239	Drugs.com Drug Page	GtP Drug Page	HMDB0015010		D07748			PA164742939	151171	46504533		302285	DNC001525	Conivaptan	ZINC000012503187	Vaprisol	Conivaptan	Approved, Investigational	DB00872	InChI=1S/C32H26N4O2/c1-21-33-28-19-20-36(29-14-8-7-13-27(29)30(28)34-21)32(38)23-15-17-24(18-16-23)35-31(37)26-12-6-5-11-25(26)22-9-3-2-4-10-22/h2-18H,19-20H2,1H3,(H,33,34)(H,35,37)	IKENVDNFQMCRTR-UHFFFAOYSA-N	4	Conivaptan is an antidiuretic hormone inhibitor used to raise serum sodium levels.	Although no data on overdosage in humans are available, conivaptan has been administered as a 20 mg loading dose on Day 1 followed by continuous infusion of 80 mg/day for 4 days in hyponatremia patients and up to 120 mg/day for 2 days in CHF patients. No new toxicities were identified at these higher doses, but adverse events related to the pharmacologic activity of conivaptan, e.g. hypotension and thirst, occurred more frequently at these higher doses.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.5446 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor					6.3				Very slightly soluble (0.15 mg/mL at 23 °C)	1	No	3	2	No	6	0	78.09 Å2	55.51 Å3	150.83 m3·mol-1	4	No	No	0.00175 mg/mL	5.44	-5.5	13.53	6.23			
C33H30N4O2	>800 mL/min	Bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.	514.6169	CCCC1=NC2=C(C=C(C=C2C)C2=NC3=CC=CC=C3N2C)N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=O	Solid	500 L	P33261;!P35503	CYP2C19;!UGT1A3	1. Cytochrome P450 2C19;!2. UDP-glucuronosyltransferase 1-3		50043280	9434	CHEMBL1017	59391	Drugs.com Drug Page	GtP Drug Page	HMDB0015101	C07710	D00627	TLS	PDRhealth Drug Page	PA451605	65999	46505370	RxList Drug Page	73494	DAP000766	Telmisartan	ZINC000001530886	Actelsar Hct, Micardis, Micardis-hct, Pritor, Twynsta	Telmisartan	Approved, Investigational	DB00966	InChI=1S/C33H30N4O2/c1-4-9-30-35-31-21(2)18-24(32-34-27-12-7-8-13-28(27)36(32)3)19-29(31)37(30)20-22-14-16-23(17-15-22)25-10-5-6-11-26(25)33(38)39/h5-8,10-19H,4,9,20H2,1-3H3,(H,38,39)	RMMXLENWKUUMAY-UHFFFAOYSA-N	4	Telmisartan is an ARB used to treat hypertension, diabetic nephropathy, and congestive heart failure.	Intravenous LD50 in rats is 150-200 mg/kg in males and 200 to 250 mg/kg in females. Acute oral toxicity is low: no deaths and no changes occurred in rats or dogs at 2000 mg/kg, the highest dose tested. Limited data are available with regard to overdosage in humans. The most likely manifestations of overdosage with telmisartan would be hypotension, dizziness and tachycardia; bradycardia could occur from parasympathetic (vagal) stimulation.	Small Molecule	http://smpdb.ca/view/SMP0000164?highlight[compounds][]=DB00966&highlight[proteins][]=DB00966	Telmisartan Action Pathway		Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	2.8075 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor		-4.82			7.7		261-263 °C		Practically insoluble	0	No	4	1	Yes	6	-1	72.94 Å2	58.61 Å3	164.49 m3·mol-1	7	No	No	0.0035 mg/mL	6.13	-5.2	3.62	5.86			
C30H26F6N4O2	Not Available	Not Available	588.5435	FC(F)(F)C1=CC(=CC=C1)N1CCN(CCOC(=O)C2=CC=CC=C2NC2=C3C=CC(=CC3=NC=C2)C(F)(F)F)CC1	Solid	Not Available						135841	CHEMBL345524	61973			HMDB0015488					PA164784000	68723	46507354				Antrafenine	ZINC000053073961		Antrafenine	Approved	DB01419	InChI=1S/C30H26F6N4O2/c31-29(32,33)20-4-3-5-22(18-20)40-14-12-39(13-15-40)16-17-42-28(41)24-6-1-2-7-25(24)38-26-10-11-37-27-19-21(30(34,35)36)8-9-23(26)27/h1-11,18-19H,12-17H2,(H,37,38)	NWGGKKGAFZIVBJ-UHFFFAOYSA-N			Not Available	Small Molecule	http://smpdb.ca/view/SMP0000693?highlight[compounds][]=DB01419&highlight[proteins][]=DB01419	Antrafenine Action Pathway		Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.7506 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor							88-90			0	No	5	1	Yes	5	0	57.7 Å2	55.48 Å3	147.01 m3·mol-1	10	No	No	0.00284 mg/mL	8.39	-5.3	16.69	7.04	P23219;!P35354	PTGS1;!PTGS2	1. Prostaglandin G/H synthase 1;!2. Prostaglandin G/H synthase 2
C28H29F3N6	Not Available	Not Available	506.5653	C[C@H](NC1=NC(=CC=N1)C1=C(N=C(C2CCNCC2)N1C)C1=CC=CC(=C1)C(F)(F)F)C1=CC=CC=C1	Solid	Not Available					15240		CHEMBL305178	394736						084			447721	46506130					ZINC000021289776		4-[5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1-methyl-4-(3-trifluoromethylphenyl)-1H-imidazol-2-yl]-piperidine	Experimental	DB01761	InChI=1S/C28H29F3N6/c1-18(19-7-4-3-5-8-19)34-27-33-16-13-23(35-27)25-24(21-9-6-10-22(17-21)28(29,30)31)36-26(37(25)2)20-11-14-32-15-12-20/h3-10,13,16-18,20,32H,11-12,14-15H2,1-2H3,(H,33,34,35)/t18-/m0/s1	QICPQLFMWYQJGX-SFHVURJKSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.7156 LD50, mol/kg	Inhibitor	Weak inhibitor	Inhibitor										0	No	5	2	Yes	5	1	67.66 Å2	53.39 Å3	140 m3·mol-1	7	No	No	0.00438 mg/mL	5.54	-5.1	14.11	10			
C30H27N5	Not Available	Not Available	457.5689	C([C@H]1CN(CCN1)C1=NN=C(C2=CC3=CC=CC=C3C=C2)C(=C1)C1=CC=NC=C1)C1=CC=CC=C1	Solid	Not Available								3571958						6NP			4369379	46506846					ZINC000012501440		6((S)-3-Benzylpiperazin-1-Yl)-3-(Naphthalen-2-Yl)-4-(Pyridin-4-Yl)Pyrazine	Experimental	DB01988	InChI=1S/C30H27N5/c1-2-6-22(7-3-1)18-27-21-35(17-16-32-27)29-20-28(24-12-14-31-15-13-24)30(34-33-29)26-11-10-23-8-4-5-9-25(23)19-26/h1-15,19-20,27,32H,16-18,21H2/t27-/m0/s1	WFSFNKVFXLIZIY-MHZLTWQESA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.6339 LD50, mol/kg	Inhibitor	Strong inhibitor	Inhibitor										1	No	5	1	No	6	1	53.94 Å2	52.09 Å3	142.49 m3·mol-1	5	No	No	0.00157 mg/mL	5.47	-5.5		8.87	Q16539	MAPK14	1. Mitogen-activated protein kinase 14
C42H45N8	Not Available	Not Available	661.8603	NC1=CC2=C(C=C1)C1=CC=C(N)C=C1C(C1=CC=CC=C1)=[N+]2CCCCCCC1=CN(CCNC2=C3CCCCC3=NC3=C2C=CC=C3)N=N1	Solid	Not Available					50377920		CHEMBL455333	4451459						TZ4			5289507	46505020					ZINC000038377621		3,8-Diamino-6-Phenyl-5-[6-[1-[2-[(1,2,3,4-Tetrahydro-9-Acridinyl)Amino]Ethyl]-1h-1,2,3-Triazol-4-Yl]Hexyl]-Phenanthridinium	Experimental	DB02226	InChI=1S/C42H44N8/c43-30-19-21-33-34-22-20-31(44)27-40(34)50(42(37(33)26-30)29-12-4-3-5-13-29)24-11-2-1-6-14-32-28-49(48-47-32)25-23-45-41-35-15-7-9-17-38(35)46-39-18-10-8-16-36(39)41/h3-5,7,9,12-13,15,17,19-22,26-28,44H,1-2,6,8,10-11,14,16,18,23-25,43H2,(H,45,46)/p+1	NAARZDJZGYBXKL-UHFFFAOYSA-O			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	2.6865 LD50, mol/kg	Inhibitor	Weak inhibitor	Inhibitor										0	No	6	3	Yes	8	2	111.55 Å2	77.75 Å3	217.12 m3·mol-1	12	No	No	0.000297 mg/mL	3.2	-6.4		8.89	P22303	ACHE	1. Acetylcholinesterase
C24H20Cl2F2N4O	Not Available	Not Available	489.345	FC1=CC=C(C(F)=C1)C1=C2CNC(=O)N(C2=CC(=C1)N1CCNCC1)C1=C(Cl)C=CC=C1Cl	Solid	Not Available					15241		CHEMBL94417	3821414						DQO			4630909	46509163					ZINC000012502758		1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperazin-1-Yl-3,4-Dihydroquinazolin-2(1h)-One	Experimental	DB02873	InChI=1S/C24H20Cl2F2N4O/c25-19-2-1-3-20(26)23(19)32-22-12-15(31-8-6-29-7-9-31)11-17(18(22)13-30-24(32)33)16-5-4-14(27)10-21(16)28/h1-5,10-12,29H,6-9,13H2,(H,30,33)	YAWZIQKDHQIHOS-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.4396 LD50, mol/kg	Non-inhibitor	Strong inhibitor	Inhibitor										1	No	3	2	No	5	1	47.61 Å2	47.25 Å3	126.31 m3·mol-1	3	No	No	0.00592 mg/mL	5.09	-4.9	15.38	8.86			
C42H45N8	Not Available	Not Available	661.8603	NC1=CC2=C(C=C1)C1=CC=C(N)C=C1C(C1=CC=CC=C1)=[N+]2CCCCCCC1=CN=NN1CCNC1=C2CCCCC2=NC2=C1C=CC=C2	Solid	Not Available					50149201		CHEMBL117651	4451460						TZ5			5289508	46507327					ZINC000027091884		3,8-Diamino-6-Phenyl-5-[6-[1-[2-[(1,2,3,4-Tetrahydro-9-Acridinyl)Amino]Ethyl]-1h-1,2,3-Triazol-5-Yl]Hexyl]-Phenanthridinium	Experimental	DB03005	InChI=1S/C42H44N8/c43-30-19-21-33-34-22-20-31(44)27-40(34)49(42(37(33)26-30)29-12-4-3-5-13-29)24-11-2-1-6-14-32-28-46-48-50(32)25-23-45-41-35-15-7-9-17-38(35)47-39-18-10-8-16-36(39)41/h3-5,7,9,12-13,15,17,19-22,26-28,44H,1-2,6,8,10-11,14,16,18,23-25,43H2,(H,45,47)/p+1	ISUOMOOYAOQQPZ-UHFFFAOYSA-O			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	2.6865 LD50, mol/kg	Inhibitor	Weak inhibitor	Inhibitor										0	No	6	3	Yes	8	2	111.55 Å2	77.08 Å3	217.57 m3·mol-1	12	No	No	0.000296 mg/mL	3.09	-6.4		8.89	P22303	ACHE	1. Acetylcholinesterase
C22H26ClN7	Not Available	Not Available	423.942	CC1=C(Cl)C=C(NC2=NC(=CC=N2)C2=CC(=NC=C2)N2CCN(CCN)CC2)C=C1	Solid	Not Available							CHEMBL1161626	571203						WAI			656967	46505237					ZINC000022921405		4-{2-[4-(2-Aminoethyl)Piperazin-1-Yl]Pyridin-4-Yl}-N-(3-Chloro-4-Methylphenyl)Pyrimidin-2-Amine	Experimental	DB03916	InChI=1S/C22H26ClN7/c1-16-2-3-18(15-19(16)23)27-22-26-8-5-20(28-22)17-4-7-25-21(14-17)30-12-10-29(9-6-24)11-13-30/h2-5,7-8,14-15H,6,9-13,24H2,1H3,(H,26,27,28)	RHOOHUMOHVIXEF-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.6311 LD50, mol/kg	Inhibitor	Strong inhibitor	Inhibitor										1	Yes	7	2	Yes	4	1	83.2 Å2	46.71 Å3	122.35 m3·mol-1	6	Yes	No	0.0447 mg/mL	3.85	-4	13.29	9.37	P77173;!Q83QN9	zipA;!zipA	1. Cell division protein ZipA;!2. Cell division protein ZipA homolog
C27H29N7	Not Available	Not Available	451.5661	CN(C)C1=CC=C(C=C1)C1=NC2=C(N1)C=CC(=C2)C1=NC2=C(N1)C=C(C=C2)N1CCN(C)CC1	Solid	Not Available								395077						BBZ			448202	46508638					ZINC000002047210		2'-(4-Dimethylaminophenyl)-5-(4-Methyl-1-Piperazinyl)-2,5'-Bi-Benzimidazole	Experimental	DB04011	InChI=1S/C27H29N7/c1-32(2)20-7-4-18(5-8-20)26-28-22-10-6-19(16-24(22)30-26)27-29-23-11-9-21(17-25(23)31-27)34-14-12-33(3)13-15-34/h4-11,16-17H,12-15H2,1-3H3,(H,28,30)(H,29,31)	VMCOQLKKSNQANE-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	2.6542 LD50, mol/kg	Inhibitor	Weak inhibitor	Inhibitor										1	No	5	2	No	6	1	67.08 Å2	54.88 Å3	158.99 m3·mol-1	4	Yes	No	0.025 mg/mL	4.66	-4.3	11.3	7.87			
C20H17N5O	Not Available	Not Available	343.3819	CN(C(C)=O)C1=CC=CC(=C1)C1=NN=C2C=CC(=NN12)C1=CC=CC=C1	Solid	Not Available					50162321		CHEMBL369180	4450203						CL3			5287936	46504540					ZINC000012504169		N-Methyl-N-[3-(6-Phenyl[1,2,4]Triazolo[4,3-B]Pyridazin-3-Yl)Phenyl]Acetamide	Experimental	DB04154	InChI=1S/C20H17N5O/c1-14(26)24(2)17-10-6-9-16(13-17)20-22-21-19-12-11-18(23-25(19)20)15-7-4-3-5-8-15/h3-13H,1-2H3	ALBWBHNFOJJMCV-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.4826 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	0	No	4	0	63.39 Å2	36.51 Å3	121.83 m3·mol-1	3	Yes	No	0.0245 mg/mL	2.85	-4.2		1.07	P77173;!Q83QN9	zipA;!zipA	1. Cell division protein ZipA;!2. Cell division protein ZipA homolog
C18H16FN3	Not Available	Not Available	293.3381	CC1=NC(=CC=C1)C1=NN2CCCC2=C1C1=CC=C(F)C=C1	Solid	Not Available					50148669		CHEMBL121790	4449885						580			5287525	46504872					ZINC000012504364		3-(4-Fluorophenyl)-2-(6-Methylpyridin-2-Yl)-5,6-Dihydro-4h-Pyrrolo[1,2-B]Pyrazole	Experimental	DB04480	InChI=1S/C18H16FN3/c1-12-4-2-5-15(20-12)18-17(13-7-9-14(19)10-8-13)16-6-3-11-22(16)21-18/h2,4-5,7-10H,3,6,11H2,1H3	NBDZLUOYAAVYHF-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.4420 LD50, mol/kg	Inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	0	No	4	0	30.71 Å2	31.57 Å3	95.08 m3·mol-1	2	Yes	Yes	0.00869 mg/mL	3.77	-4.5		1.86			
C24H23N3O2	Not Available	Not Available	385.4583	O=C1NC2=C(O1)C(=CC=C2)N1CCN(CC2=CC(=CC=C2)C2=CC=CC=C2)CC1	Solid	Not Available					50241119		CHEMBL218166	181044									208951	175426891				Bifeprunox	ZINC000052971454		Bifeprunox	Investigational	DB04888	InChI=1S/C24H23N3O2/c28-24-25-21-10-5-11-22(23(21)29-24)27-14-12-26(13-15-27)17-18-6-4-9-20(16-18)19-7-2-1-3-8-19/h1-11,16H,12-15,17H2,(H,25,28)	CYGODHVAJQTCBG-UHFFFAOYSA-N	3		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.5436 LD50, mol/kg	Inhibitor	Strong inhibitor	Inhibitor										1	Yes	4	1	No	5	1	44.81 Å2	43.09 Å3	116.49 m3·mol-1	4	Yes	No	0.0197 mg/mL	4.51	-4.3	9.47	7.75			
C33H30ClN5O3	Not Available	Not Available	580.09	CC1=C2N=C(NC3=CC=C(OCCN4CCCC4)C=C3)N=NC2=CC(=C1)C1=CC(OC(=O)C2=CC=CC=C2)=CC=C1Cl	Solid	Not Available					97971		CHEMBL403989	10147091									11973736	347827709					ZINC000029136020		TG-100801	Investigational	DB05075	InChI=1S/C33H30ClN5O3/c1-22-19-24(28-21-27(13-14-29(28)34)42-32(40)23-7-3-2-4-8-23)20-30-31(22)36-33(38-37-30)35-25-9-11-26(12-10-25)41-18-17-39-15-5-6-16-39/h2-4,7-14,19-21H,5-6,15-18H2,1H3,(H,35,36,38)	JMGXJHWTVBGOKG-UHFFFAOYSA-N	1		Not Available	Small Molecule																																			0	No	7	1	Yes	6	1	89.47 Å2	63.93 Å3	165.53 m3·mol-1	10	No	No	0.00167 mg/mL	7.64	-5.5	13.33	9.03	P17948;!P35968;!P35916;!P41240	FLT1;!KDR;!FLT4;!CSK	1. Vascular endothelial growth factor receptor 1;!2. Vascular endothelial growth factor receptor 2;!3. Vascular endothelial growth factor receptor 3;!4. Tyrosine-protein kinase CSK
C17H20ClFN4OS	Not Available	Not Available	382.88	O.Cl.CC1=CC2=C(N=C(N=C2S1)N1CCNCC1)C1=CC=CC=C1F	Solid	Not Available								5293405																	DDP-225	Investigational	DB05642	InChI=1S/C17H17FN4S.ClH.H2O/c1-11-10-13-15(12-4-2-3-5-14(12)18)20-17(21-16(13)23-11)22-8-6-19-7-9-22;;/h2-5,10,19H,6-9H2,1H3;1H;1H2	SAURKKOJWIFYSR-UHFFFAOYSA-N	2		Not Available	Small Molecule																																			1	Yes	4	1	No	4	1	41.05 Å2	34.88 Å3	91.18 m3·mol-1	2	Yes	No	0.014 mg/mL	4.37	-4.4		8.68	P46098;!P23975	HTR3A;!SLC6A2	1. 5-hydroxytryptamine receptor 3A;!2. Sodium-dependent noradrenaline transporter
C21H21FN6O	Not Available	Not Available	392.438	CN1CCN(CC1)C1=CC=C2N=C(NC2=C1)C1=C(N)C2=C(NC1=O)C=CC=C2F	Solid	Not Available	P04798;!P05177;!P35503;!P16662;!P33261;!P08684	CYP1A1;!CYP1A2;!UGT1A3;!UGT2B7;!CYP2C19;!CYP3A4	1. Cytochrome P450 1A1;!2. Cytochrome P450 1A2;!3. UDP-glucuronosyltransferase 1-3;!4. UDP-glucuronosyltransferase 2B7;!5. Cytochrome P450 2C19;!6. Cytochrome P450 3A4		25118		CHEMBL522892	11530944						38O			9977819	347827750				Fibroblast_growth_factor_receptor_1	ZINC000003816310		Dovitinib	Investigational	DB05928	InChI=1S/C21H21FN6O/c1-27-7-9-28(10-8-27)12-5-6-14-16(11-12)25-20(24-14)18-19(23)17-13(22)3-2-4-15(17)26-21(18)29/h2-6,11H,7-10H2,1H3,(H,24,25)(H3,23,26,29)	PIQCTGMSNWUMAF-UHFFFAOYSA-N	3		Not Available	Small Molecule																																			1	Yes	5	3	No	5	1	90.28 Å2	42.46 Å3	112.36 m3·mol-1	2	Yes	No	0.137 mg/mL	1.35	-3.5	8.56	7.87	O75469	NR1I2	1. Nuclear receptor subfamily 1 group I member 2
C26H23N5O	Not Available	Not Available	421.504	C[C@@]1(O)C[C@@H](C1)C1=NC(=C2N1C=CN=C2N)C1=CC=C2C=CC(=NC2=C1)C1=CC=CC=C1	Solid	Not Available					50315887		CHEMBL1091644															Linsitinib	ZINC000100071817		Linsitinib	Investigational	DB06075	InChI=1S/C26H23N5O/c1-26(32)14-19(15-26)25-30-22(23-24(27)28-11-12-31(23)25)18-8-7-17-9-10-20(29-21(17)13-18)16-5-3-2-4-6-16/h2-13,19,32H,14-15H2,1H3,(H2,27,28)/t19-,26+	PKCDDUHJAFVJJB-VLZXCDOPSA-N	3		Not Available	Small Molecule																																			1	Yes	5	2	No	6	0	89.33 Å2	48.04 Å3	125.39 m3·mol-1	3	Yes	No	0.0027 mg/mL	3.42	-5.2	15.23	5.66	P06213;!P08069	INSR;!IGF1R	1. Insulin receptor;!2. Insulin-like growth factor 1 receptor
C18H13N7S	Not Available	Not Available	359.408	CN1C=C(C=N1)C1=NN2C(SC3=CC=C4N=CC=CC4=C3)=NN=C2C=C1	Solid	Not Available					60589	90624	CHEMBL1236107	24608644						SX8									ZINC000039129916		SGX-523	Investigational	DB06314	InChI=1S/C18H13N7S/c1-24-11-13(10-20-24)16-6-7-17-21-22-18(25(17)23-16)26-14-4-5-15-12(9-14)3-2-8-19-15/h2-11H,1H3	BCZUAADEACICHN-UHFFFAOYSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.3146 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	0	No	5	0	73.79 Å2	36.6 Å3	123.74 m3·mol-1	3	Yes	No	0.0177 mg/mL	3.18	-4.3		4.26	P08581	MET	1. Hepatocyte growth factor receptor
C17H11N5O	Not Available	Not Available	301.309	O=C(C1=C2N=CC=C(N2N=C1)C1=CC=NC=C1)C1=CC=CC=N1	Solid	Not Available							CHEMBL2105199	187602														Ocinaplon	ZINC000000005014		Ocinaplon	Investigational	DB06529	InChI=1S/C17H11N5O/c23-16(14-3-1-2-7-19-14)13-11-21-22-15(6-10-20-17(13)22)12-4-8-18-9-5-12/h1-11H	OQJFBUOFGHPMSR-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	Yes	5	0	No	4	0	73.04 Å2	30.99 Å3	94.68 m3·mol-1	3	Yes	No	0.0833 mg/mL	1.63	-3.6		4.5			
C24H24N6O	Not Available	Not Available	412.487	CN1CCN(CC1)C1=CC=C(C=C1)C1=CC2=C(NC=C2NC(=O)C2=CN=CC=C2)N=C1	Solid	Not Available						39634		5290452						199			6914568	99443347					ZINC000016051756		N-{5-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-1H-PYRROLO[2,3-B]PYRIDIN-3-YL}NICOTINAMIDE	Experimental	DB06876	InChI=1S/C24H24N6O/c1-29-9-11-30(12-10-29)20-6-4-17(5-7-20)19-13-21-22(16-27-23(21)26-15-19)28-24(31)18-3-2-8-25-14-18/h2-8,13-16H,9-12H2,1H3,(H,26,27)(H,28,31)	YJWJKKXGAPWLGT-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.6372 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	5	2	No	5	1	77.15 Å2	46.59 Å3	123.93 m3·mol-1	4	Yes	No	0.0439 mg/mL	2.7	-4	14.62	7.88	O14757	CHEK1	1. Serine/threonine-protein kinase Chk1
C19H17N5O	Not Available	Not Available	331.3712	OCC1=C2N=C(C=C(NCC3=CN=CC=C3)N2N=C1)C1=CC=CC=C1	Solid	Not Available							CHEMBL400520	19872882						2SC			21066379	99443454					ZINC000028958754		(5-phenyl-7-(pyridin-3-ylmethylamino)pyrazolo[1,5-a]pyrimidin-3-yl)methanol	Experimental	DB06983	InChI=1S/C19H17N5O/c25-13-16-12-22-24-18(21-11-14-5-4-8-20-10-14)9-17(23-19(16)24)15-6-2-1-3-7-15/h1-10,12,21,25H,11,13H2	RBLKWWBHDUBPFN-UHFFFAOYSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Inhibitor	Non-substrate	2.4350 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	2	No	4	0	75.34 Å2	36.33 Å3	107.26 m3·mol-1	5	Yes	No	0.0308 mg/mL	1.99	-4	14.54	4.82	P24941	CDK2	1. Cyclin-dependent kinase 2
C19H12Cl2N6S	Not Available	Not Available	427.31	ClC1=C(Cl)C(=CC=C1)C1=NC2=C(SC#N)C=NN2C(NCC2=CC=NC=C2)=C1	Solid	Not Available								22376271						3SC			44629555	99443536					ZINC000033295963		5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)-3-thiocyanatopyrazolo[1,5-a]pyrimidin-7-amine	Experimental	DB07065	InChI=1S/C19H12Cl2N6S/c20-14-3-1-2-13(18(14)21)15-8-17(24-9-12-4-6-23-7-5-12)27-19(26-15)16(10-25-27)28-11-22/h1-8,10,24H,9H2	AHPKUZJCNHGFQA-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Non-substrate	2.2334 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	1	No	4	0	78.9 Å2	42.17 Å3	123.92 m3·mol-1	5	Yes	No	0.0076 mg/mL	4.26	-4.8		5.02	P24941	CDK2	1. Cyclin-dependent kinase 2
C25H26N4O	Not Available	Not Available	398.5001	C(CN1CCNCC1)NC1=CC=NC2=C1C(=C(O2)C1=CC=CC=C1)C1=CC=CC=C1	Solid	Not Available					17716		CHEMBL392990	9727836						547			11553058	99443617					ZINC000023359504		2,3-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-B]PYRIDIN-4-AMINE	Experimental	DB07146	InChI=1S/C25H26N4O/c1-3-7-19(8-4-1)22-23-21(27-15-18-29-16-13-26-14-17-29)11-12-28-25(23)30-24(22)20-9-5-2-6-10-20/h1-12,26H,13-18H2,(H,27,28)	QUIQCYFSBGOBKE-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Inhibitor	Substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.4814 LD50, mol/kg	Inhibitor	Weak inhibitor	Inhibitor										1	Yes	4	2	Yes	5	1	53.33 Å2	45.24 Å3	121.81 m3·mol-1	6	Yes	No	0.0341 mg/mL	3.45	-4.1		9.24	P06239	LCK	1. Tyrosine-protein kinase Lck
C19H16BrN5O	Not Available	Not Available	410.267	CC1=C(C=CC=C1)C1=NC2=C(Br)C=NN2C(NCC2=C[N+]([O-])=CC=C2)=C1	Solid	Not Available							CHEMBL249334	9479388						5SC			11304412	99443650					ZINC000024931709		3-((3-bromo-5-o-tolylpyrazolo[1,5-a]pyrimidin-7-ylamino)methyl)pyridine 1-oxide	Experimental	DB07179	InChI=1S/C19H16BrN5O/c1-13-5-2-3-7-15(13)17-9-18(25-19(23-17)16(20)11-22-25)21-10-14-6-4-8-24(26)12-14/h2-9,11-12,21H,10H2,1H3	DXUJQXZHHGJMFM-UHFFFAOYSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Non-substrate	2.5089 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	1	No	4	0	69.16 Å2	39.56 Å3	116.42 m3·mol-1	4	Yes	No	0.00318 mg/mL	2.78	-5.1		1.19	P24941	CDK2	1. Cyclin-dependent kinase 2
C23H24N6O2S	Not Available	Not Available	448.541	CN1CCN(CC1)C1=CC=C(C=C1)C(=O)NC1=NNC2=CN(C=C12)C(=O)CC1=CC=CS1	Solid	Not Available								10137725						626			11963557	99443657					ZINC000016052328		4-(4-METHYLPIPERAZIN-1-YL)-N-[5-(2-THIENYLACETYL)-1,5-DIHYDROPYRROLO[3,4-C]PYRAZOL-3-YL]BENZAMIDE	Experimental	DB07186	InChI=1S/C23H24N6O2S/c1-27-8-10-28(11-9-27)17-6-4-16(5-7-17)23(31)24-22-19-14-29(15-20(19)25-26-22)21(30)13-18-3-2-12-32-18/h2-7,12,14-15,25H,8-11,13H2,1H3,(H,24,26,31)	TYYNSDQVFIOSFH-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.5855 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	5	2	No	5	1	86.26 Å2	49.88 Å3	128.04 m3·mol-1	5	Yes	No	0.101 mg/mL	3.08	-3.6	10.47	7.74	O14965;!P53350	AURKA;!PLK1	1. Aurora kinase A;!2. Serine/threonine-protein kinase PLK1
C18H14BrN5	Not Available	Not Available	380.241	BrC1=C2N=C(C=C(NCC3=CC=NC=C3)N2N=C1)C1=CC=CC=C1	Solid	Not Available					105234		CHEMBL401377	8515169						6SC			10339710	99443681					ZINC000028957141		3-bromo-5-phenyl-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine	Experimental	DB07210	InChI=1S/C18H14BrN5/c19-15-12-22-24-17(21-11-13-6-8-20-9-7-13)10-16(23-18(15)24)14-4-2-1-3-5-14/h1-10,12,21H,11H2	JECHSYMSTXETFI-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Non-substrate	2.3801 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	1	No	4	0	55.11 Å2	36.6 Å3	108.06 m3·mol-1	4	Yes	No	0.00781 mg/mL	3.52	-4.7		5.02	P24941	CDK2	1. Cyclin-dependent kinase 2
C23H24N6O	Not Available	Not Available	400.4763	CN(C)C1=CC=C(C=C1)C1=C(N=CN=C1N)C#CC1=CC=C(N=C1)N1CCOCC1	Solid	Not Available					14488		CHEMBL216697	10160341						89I			11987868	99443751					ZINC000020149029		5-[4-(DIMETHYLAMINO)PHENYL]-6-[(6-MORPHOLIN-4-YLPYRIDIN-3-YL)ETHYNYL]PYRIMIDIN-4-AMINE	Experimental	DB07280	InChI=1S/C23H24N6O/c1-28(2)19-7-5-18(6-8-19)22-20(26-16-27-23(22)24)9-3-17-4-10-21(25-15-17)29-11-13-30-14-12-29/h4-8,10,15-16H,11-14H2,1-2H3,(H2,24,26,27)	AINVOEOJEKKMKB-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.4310 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	7	1	No	4	0	80.4 Å2	44.37 Å3	116.43 m3·mol-1	5	Yes	No	0.0176 mg/mL	3.34	-4.4		4.92			
C24H25N5O	Not Available	Not Available	399.4882	C(CN1CCNCC1)NC1=C2C(OC(=C2C2=CC=CC=C2)C2=CC=CC=C2)=NC=N1	Solid	Not Available					17714	40432	CHEMBL247272	21865411						979			17756743	99443768					ZINC000023359501		5,6-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-D]PYRIMIDIN-4-AMINE	Experimental	DB07297	InChI=1S/C24H25N5O/c1-3-7-18(8-4-1)20-21-23(26-13-16-29-14-11-25-12-15-29)27-17-28-24(21)30-22(20)19-9-5-2-6-10-19/h1-10,17,25H,11-16H2,(H,26,27,28)	PTILEOLOGGMFCS-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.4788 LD50, mol/kg	Inhibitor	Weak inhibitor	Inhibitor										1	Yes	5	2	Yes	5	1	66.22 Å2	44.64 Å3	120.95 m3·mol-1	6	Yes	No	0.0636 mg/mL	3.34	-3.8	17.79	9.23			
C20H18N4O	Not Available	Not Available	330.3831	OCCNC1=NC=NC2=C1C(=C(N2)C1=CC=CC=C1)C1=CC=CC=C1	Solid	Not Available					14803		CHEMBL366312	3571995						DFZ			4369433	99444126					ZINC000006475919		3-AMINO-3-BENZYL-[4.3.0]BICYCLO-1,6-DIAZANONAN-2-ONE	Experimental	DB07655	InChI=1S/C20H18N4O/c25-12-11-21-19-17-16(14-7-3-1-4-8-14)18(15-9-5-2-6-10-15)24-20(17)23-13-22-19/h1-10,13,25H,11-12H2,(H2,21,22,23,24)	MPJYGQHMIFDQIN-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	2.5274 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	4	3	No	4	1	73.83 Å2	35.66 Å3	100.71 m3·mol-1	5	Yes	No	0.00947 mg/mL	3.11	-4.5	12.28	6.31	O14757	CHEK1	1. Serine/threonine-protein kinase Chk1
C18H14ClN5	Not Available	Not Available	335.79	NC1=CC=CC(=C1)C1=C2N=C(NC3=CC=CC(Cl)=C3)C=CN2N=C1	Solid	Not Available								4925420						DZO			6419789	99444169					ZINC000033943533		3-(3-aminophenyl)-N-(3-chlorophenyl)pyrazolo[1,5-a]pyrimidin-5-amine	Experimental	DB07698	InChI=1S/C18H14ClN5/c19-13-4-2-6-15(10-13)22-17-7-8-24-18(23-17)16(11-21-24)12-3-1-5-14(20)9-12/h1-11H,20H2,(H,22,23)	JDNMRPIWJIDDAY-UHFFFAOYSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.5385 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	2	No	4	0	68.24 Å2	34.52 Å3	107.21 m3·mol-1	3	Yes	No	0.00512 mg/mL	4.11	-4.8	14.88	3.7	Q8TF76	GSG2	1. Serine/threonine-protein kinase haspin
C18H13N7	Not Available	Not Available	327.3427	NC1=NNC2=C1C=C(N=N2)C1=C2C=CC=CN2N=C1C1=CC=CC=C1	Solid	Not Available					50229978	91383	CHEMBL259551	9668404						FRZ			11493598	99444265					ZINC000028565323		5-(2-PHENYLPYRAZOLO[1,5-A]PYRIDIN-3-YL)-1H-PYRAZOLO[3,4-C]PYRIDAZIN-3-AMINE	Experimental	DB07794	InChI=1S/C18H13N7/c19-17-12-10-13(20-22-18(12)23-21-17)15-14-8-4-5-9-25(14)24-16(15)11-6-2-1-3-7-11/h1-10H,(H3,19,21,22,23)	XVECMUKVOMUNLE-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.5144 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	2	No	5	0	97.78 Å2	33.93 Å3	108.19 m3·mol-1	2	Yes	No	0.0431 mg/mL	2.83	-3.9	12.77	3.09			
C20H19F3N4O	Not Available	Not Available	388.3863	CN1CCN(CC1)C1=NC2=C(C=C(C=C2N=C1)C(F)(F)F)C1=CC(O)=CC=C1	Solid	Not Available					50265838		CHEMBL462712	24692249						IHX			25113181	99444440					ZINC000040873944		3-[3-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)quinoxalin-5-yl]phenol	Experimental	DB07969	InChI=1S/C20H19F3N4O/c1-26-5-7-27(8-6-26)18-12-24-17-11-14(20(21,22)23)10-16(19(17)25-18)13-3-2-4-15(28)9-13/h2-4,9-12,28H,5-8H2,1H3	QNCYYRHIUFGGJX-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	2.7688 LD50, mol/kg	Inhibitor	Weak inhibitor	Inhibitor										1	Yes	5	1	No	4	1	52.49 Å2	37.84 Å3	101.33 m3·mol-1	3	Yes	No	0.113 mg/mL	4.07	-3.5	9.75	7.48			
C23H29N7O2	Not Available	Not Available	435.5221	CC(C)N1C(C)=NC=C1C1=NC(NC2=CC=C(C=C2)N2CCN(CC2)C(=O)CO)=NC=C1	Solid	Not Available					50263070		CHEMBL477786	9445509						IM9			11270500	99444453					ZINC000038994180		2-{4-[4-({4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-yl}amino)phenyl]piperazin-1-yl}-2-oxoethanol	Experimental	DB07982	InChI=1S/C23H29N7O2/c1-16(2)30-17(3)25-14-21(30)20-8-9-24-23(27-20)26-18-4-6-19(7-5-18)28-10-12-29(13-11-28)22(32)15-31/h4-9,14,16,31H,10-13,15H2,1-3H3,(H,24,26,27)	PVTKDXZNSUHUMO-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.4662 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	7	2	Yes	4	0	99.41 Å2	47.99 Å3	123.71 m3·mol-1	6	Yes	No	0.401 mg/mL	1.49	-3	13.58	6.01			
C26H23N5O	Not Available	Not Available	421.4937	NC1=NC=CC=C1NCC1=C(OCC2=NC=CC=C2)C=CC(=C1)C1=CC2=C(C=CN2)C=C1	Solid	Not Available					15787		CHEMBL220428	9807912						IP7			11633167	99444465					ZINC000011726159		N~3~-[5-(1H-INDOL-6-YL)-2-(PYRIDIN-2-YLMETHOXY)BENZYL]PYRIDINE-2,3-DIAMINE	Experimental	DB07994	InChI=1S/C26H23N5O/c27-26-23(5-3-12-30-26)31-16-21-14-19(20-7-6-18-10-13-29-24(18)15-20)8-9-25(21)32-17-22-4-1-2-11-28-22/h1-15,29,31H,16-17H2,(H2,27,30)	KMBPJSHPAXOXBT-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	2.5762 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	5	3	Yes	5	1	88.85 Å2	47.19 Å3	128.34 m3·mol-1	7	Yes	No	0.000865 mg/mL	3.89	-5.7	16.3	7.1	P56817	BACE1	1. Beta-secretase 1
C17H16N6	Not Available	Not Available	304.3491	CC(C)N1N=C(C2=C(N)N=CN=C12)C1=CC2=CC=CN=C2C=C1	Solid	Not Available					36407		CHEMBL1233882	24605261						KS5			24905152	99444525					ZINC000020148983		1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine	Experimental	DB08054	InChI=1S/C17H16N6/c1-10(2)23-17-14(16(18)20-9-21-17)15(22-23)12-5-6-13-11(8-12)4-3-7-19-13/h3-10H,1-2H3,(H2,18,20,21)	GEZALMMCQYDFML-UHFFFAOYSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.2311 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	1	No	4	0	82.51 Å2	33.07 Å3	100.77 m3·mol-1	2	Yes	No	0.0616 mg/mL	2.59	-3.7	19.66	4.38	P12931	SRC	1. Proto-oncogene tyrosine-protein kinase Src
C22H23ClN6	Not Available	Not Available	406.911	[H][C@]1(C)CN(CCN1)C1=CC=C2N=C(NC3=C(C)C=CC=C3Cl)C3=CN=CN3C2=C1	Solid	Not Available								25061091						KSM			46937119	99444528					ZINC000039033598		N-(2-chloro-6-methylphenyl)-8-[(3S)-3-methylpiperazin-1-yl]imidazo[1,5-a]quinoxalin-4-amine	Experimental	DB08057	InChI=1S/C22H23ClN6/c1-14-4-3-5-17(23)21(14)27-22-20-11-24-13-29(20)19-10-16(6-7-18(19)26-22)28-9-8-25-15(2)12-28/h3-7,10-11,13,15,25H,8-9,12H2,1-2H3,(H,26,27)/t15-/m0/s1	VWJPPYCULHDHBB-HNNXBMFYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	2.7828 LD50, mol/kg	Inhibitor	Weak inhibitor	Inhibitor										1	Yes	5	2	No	5	2	57.49 Å2	44.48 Å3	118.38 m3·mol-1	3	Yes	No	0.00657 mg/mL	3.74	-4.8	14.32	8.96	P06239	LCK	1. Tyrosine-protein kinase Lck
C16H13N5	Not Available	Not Available	275.3079	CN1N=C(C2=C(N)N=CN=C12)C1=CC2=CC=CC=C2C=C1	Solid	Not Available					123756		CHEMBL1234815	24605315						NPZ			24905144	99444771					ZINC000020149030		1-methyl-3-naphthalen-2-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine	Experimental	DB08300	InChI=1S/C16H13N5/c1-21-16-13(15(17)18-9-19-16)14(20-21)12-7-6-10-4-2-3-5-11(10)8-12/h2-9H,1H3,(H2,17,18,19)	UOKGZPYGRJDACN-UHFFFAOYSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.3214 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	1	No	4	0	69.62 Å2	29.74 Å3	94.13 m3·mol-1	1	Yes	No	0.0494 mg/mL	2.65	-3.8	19.68	3.81	P48736	PIK3CG	1. Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform
C22H25FN6O2	Not Available	Not Available	424.4713	[H][C@@](N)(C(=O)N1CC[C@]([H])(F)C1)[C@@]([H])(C(=O)N(C)C)C1=CC=C(C=C1)C1=CN2N=CN=C2C=C1	Solid	Not Available					50221972		CHEMBL237337	8495608						S14			10320144	99444975					ZINC000014947659		6-(4-{(1S,2S)-2-AMINO-1-[(DIMETHYLAMINO)CARBONYL]-3-[(3S)-3-FLUOROPYRROLIDIN-1-YL]-3-OXOPROPYL}PHENYL)-1H-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-4-IUM	Experimental	DB08504	InChI=1S/C22H25FN6O2/c1-27(2)21(30)19(20(24)22(31)28-10-9-17(23)12-28)15-5-3-14(4-6-15)16-7-8-18-25-13-26-29(18)11-16/h3-8,11,13,17,19-20H,9-10,12,24H2,1-2H3/t17-,19-,20-/m0/s1	ZNHVIJAGMFQGMS-IHPCNDPISA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.6436 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	5	1	No	4	0	96.83 Å2	44.19 Å3	125.43 m3·mol-1	5	Yes	No	0.109 mg/mL	0.73	-3.6	18.09	6.94			
C18H14BrN5	Not Available	Not Available	380.241	BrC1=C2N=C(C=C(NCC3=CC=CN=C3)N2N=C1)C1=CC=CC=C1	Solid	Not Available					50223586		CHEMBL249530	8424667						SCJ			10249180	99445006					ZINC000028958699		3-bromo-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine	Experimental	DB08535	InChI=1S/C18H14BrN5/c19-15-12-22-24-17(21-11-13-5-4-8-20-10-13)9-16(23-18(15)24)14-6-2-1-3-7-14/h1-10,12,21H,11H2	SMIZFGZXFDGISG-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Non-substrate	2.3801 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	1	No	4	0	55.11 Å2	36.64 Å3	108.06 m3·mol-1	4	Yes	No	0.00787 mg/mL	3.52	-4.7		4.82	P24941	CDK2	1. Cyclin-dependent kinase 2
C18H14BrN5	Not Available	Not Available	380.241	BrC1=CN=C2N1C=C(C=C2NCC1=CN=CN=C1)C1=CC=CC=C1	Solid	Not Available								8424669						SCW			10249182	99445008					ZINC000003820146		3-bromo-6-phenyl-N-(pyrimidin-5-ylmethyl)imidazo[1,2-a]pyridin-8-amine	Experimental	DB08537	InChI=1S/C18H14BrN5/c19-17-10-23-18-16(22-9-13-7-20-12-21-8-13)6-15(11-24(17)18)14-4-2-1-3-5-14/h1-8,10-12,22H,9H2	LZLKFNBMXXLTLX-UHFFFAOYSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Inhibitor	Non-substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Non-substrate	2.5455 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	4	1	No	4	0	55.11 Å2	36.57 Å3	99.95 m3·mol-1	4	Yes	No	0.00634 mg/mL	2.15	-4.8		5.55	P24941	CDK2	1. Cyclin-dependent kinase 2
C21H22N6O	Not Available	Not Available	374.439	CCN1N=CC=C1C1=CNC2=NC=C(C=C12)C1=CC(C(=O)N(C)C)=C(N)C=C1	Solid	Not Available								21437058						SX7			46937162	99445054					ZINC000044459878		2-amino-5-[3-(1-ethyl-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,N-dimethylbenzamide	Experimental	DB08583	InChI=1S/C21H22N6O/c1-4-27-19(7-8-25-27)17-12-24-20-15(17)10-14(11-23-20)13-5-6-18(22)16(9-13)21(28)26(2)3/h5-12H,4,22H2,1-3H3,(H,23,24)	INAGORZAOFUKOZ-UHFFFAOYSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.7682 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	4	2	No	4	0	92.83 Å2	40.76 Å3	122.31 m3·mol-1	4	Yes	No	0.0381 mg/mL	2.34	-4	14.68	3.08	P00519	ABL1	1. Tyrosine-protein kinase ABL1
C24H25N5O	Not Available	Not Available	399.4882	C(CN1CCCCC1)OC1=CC=C(C=C1)C1=CN2N=CC(=C2N=C1)C1=CC=NC=C1	Solid	Not Available					50262685	78510	CHEMBL478629	9698930						TAK			11524144	99445068					ZINC000013829435		Dorsomorphin	Experimental	DB08597	InChI=1S/C24H25N5O/c1-2-12-28(13-3-1)14-15-30-22-6-4-19(5-7-22)21-16-26-24-23(17-27-29(24)18-21)20-8-10-25-11-9-20/h4-11,16-18H,1-3,12-15H2	XHBVYDAKJHETMP-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.4667 LD50, mol/kg	Inhibitor	Strong inhibitor	Inhibitor										1	Yes	5	0	Yes	5	1	55.55 Å2	45.75 Å3	128.51 m3·mol-1	6	Yes	No	0.0148 mg/mL	3.44	-4.4		8.81	Q04771;!P62942	ACVR1;!FKBP1A	1. Activin receptor type-1;!2. Peptidyl-prolyl cis-trans isomerase FKBP1A
C17H19N5O	Not Available	Not Available	309.3657	[H][C@]1(CN)CN(CCO1)C1=C(C=NC2=C1C=NN2)C1=CC=CC=C1	Solid	Not Available					33217		CHEMBL562314	24627049						ZY6			44129608	99445245					ZINC000039001862		1-[(2S)-4-(5-phenyl-1H-pyrazolo[3,4-b]pyridin-4-yl)morpholin-2-yl]methanamine	Experimental	DB08774	InChI=1S/C17H19N5O/c18-8-13-11-22(6-7-23-13)16-14(12-4-2-1-3-5-12)9-19-17-15(16)10-20-21-17/h1-5,9-10,13H,6-8,11,18H2,(H,19,20,21)/t13-/m0/s1	YBRZCAKSBYWZTC-ZDUSSCGKSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	2.6302 LD50, mol/kg	Inhibitor	Strong inhibitor	Inhibitor										1	Yes	5	2	No	4	1	80.06 Å2	32.89 Å3	90.13 m3·mol-1	3	Yes	No	0.581 mg/mL	0.96	-2.7	10.17	9.05	O14757	CHEK1	1. Serine/threonine-protein kinase Chk1
C25H24N6O2	In patients with normal renal function, the clearance rate is in the range of 112-159 ml/min.3	The elimination half-life of ibrutinib is of approximately 4-6 hours.11	440.507	NC1=NC=NC2=C1C(=NN2[C@@H]1CCCN(C1)C(=O)C=C)C1=CC=C(OC2=CC=CC=C2)C=C1	Solid	The volume of distribution at steady-state of ibrutinib is in approximately 10,000 L.11	P08684;!P20815;!P10635	CYP3A4;!CYP3A5;!CYP2D6	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5;!3. Cytochrome P450 2D6		50357312	76612	CHEMBL1873475	26637187	Drugs.com Drug Page				D10223	1E8		PA166121346	24821094	310264995		1442981		Ibrutinib	ZINC000035328014	Imbruvica	Ibrutinib	Approved	DB09053	InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1	XYFPWWZEPKGCCK-GOSISDBHSA-N		Ibrutinib is an antineoplastic agent used to treat chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's Macroglobulinemia.	Ibrutinib was not showed to present a mutagenic potential in bacterial assays, nor clastogenic in chromosome aberration assays in mammalian cells or in bone marrow micronucleus assays in mice. Carcinogenicity or effects on fertility have not been determined.16	Small Molecule																														3.97		149-158ºC	3.74	0.003 mg/ml	1	No	5	1	No	5	0	99.16 Å2	47.84 Å3	138.07 m3·mol-1	5	Yes	No	0.0203 mg/mL	3.63	-4.3	19.7	6.58	Q06187	BTK	1. Tyrosine-protein kinase BTK
C24H29N7O2	The mean apparent oral clearance of palbociclib is of 63.1 L/h.3	The mean plasma elimination half-life of palbociclib is 29 hours.3	447.5328	CC(=O)C1=C(C)C2=CN=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2N(C2CCCC2)C1=O	Solid	The mean apparent distribution of palbociclib is 2583 L which suggests that palbociclib penetrates extensively into peripheral tissues.11	P08684;!Q06520	CYP3A4;!SULT2A1	1. Cytochrome P450 3A4;!2. Bile salt sulfotransferase		6309	85993	CHEMBL189963	4487437	Drugs.com Drug Page				D10372	LQQ		PA166153469	5330286	310265004	RxList Drug Page	1601374		Palbociclib	ZINC000003938686	Ibrance	Palbociclib	Approved, Investigational	DB09073	InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)	AHJRHEGDXFFMBM-UHFFFAOYSA-N	4	Palbociclib is an endocrine-based chemotherapeutic agent used in combination with other antineoplastic agents to treat HER2-negative and HR-positive advanced or metastatic breast cancer.	The reported oral Ld50 is of 100 mg/kg.MSDS In cases of overdosage, only supportive measures are considered.LabelPalbociclib was showed to present clastogenic activities in in vitro and in vivo assays. As well, it has been reported to produce fetal harm due to its mechanism of action.3 Lastly, it was shown to increase the incidence of microglial cell tumors in the central nervous system at high doses.Label	Small Molecule																													711.5 ºC	0.99		263-266 ºC	7.4 (the secondary piperazine nitrogen) and 3.9 (the pyridine nitrogen)	10 mg/ml (isethionate form)	1	Yes	8	2	No	5	1	103.35 Å2	49.69 Å3	127.47 m3·mol-1	5	Yes	No	0.0174 mg/mL	2.77	-4.4	11.34	8.86	P11802;!Q00534	CDK4;!CDK6	1. Cyclin-dependent kinase 4;!2. Cyclin-dependent kinase 6
C25H27N3O2S	19.8mL/h/kg	Brexpiprazole and its major metabolite, DM-3411 have half lives of 91 and 96 hours respectively.	433.57	O=C1NC2=CC(OCCCCN3CCN(CC3)C3=C4C=CSC4=CC=C3)=CC=C2C=C1	Solid	Intravenous volume of distribution is 1.56L/kg.	P10635;!P08684	CYP2D6;!CYP3A4	1. Cytochrome P450 2D6;!2. Cytochrome P450 3A4		194780	134716	CHEMBL2105760	10152155	Drugs.com Drug Page				D10309			PA166160053	11978813	310265043	RxList Drug Page	1658314		Brexpiprazole	ZINC000084758479	Rexulti	Brexpiprazole	Approved, Investigational	DB09128	InChI=1S/C25H27N3O2S/c29-25-9-7-19-6-8-20(18-22(19)26-25)30-16-2-1-11-27-12-14-28(15-13-27)23-4-3-5-24-21(23)10-17-31-24/h3-10,17-18H,1-2,11-16H2,(H,26,29)	ZKIAIYBUSXZPLP-UHFFFAOYSA-N	4	Brexpiprazole is a serotonin–dopamine activity modulator used in the treatment of major depressive disorder as an adjunct and schizophrenia.	The most commonly observed adverse effects include: weight increase, akathisia, somnolence, tremor and nasopharyngitis. Neonates are at risk for extrapyramidal and/or withdrawal symptoms if exposed to an antipsychotic drug during the third trimester of development.	Small Molecule																																			1	Yes	4	1	Yes	5	1	44.81 Å2	49.48 Å3	129.16 m3·mol-1	7	Yes	No	0.00227 mg/mL	4.65	-5.3	13.56	8.4	P08908;!P14416;!P28223;!P18825;!P35368	HTR1A;!DRD2;!HTR2A;!ADRA2C;!ADRA1B	1. 5-hydroxytryptamine receptor 1A;!2. Dopamine D2 receptor;!3. 5-hydroxytryptamine receptor 2A;!4. Alpha-2C adrenergic receptor;!5. Alpha-1B adrenergic receptor
C20H17F2N3O3	Not Available	Not Available	385.3641	OC(=O)C1=CN(C2=CC=C(F)C=C2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O	Solid	Not Available	P05177	CYP1A2	1. Cytochrome P450 1A2			94493	CHEMBL37858	50727			HMDB0039526						56208	347827981				Sarafloxacin	ZINC000000538330		Sarafloxacin	Vet approved, Withdrawn	DB11491	InChI=1S/C20H17F2N3O3/c21-12-1-3-13(4-2-12)25-11-15(20(27)28)19(26)14-9-16(22)18(10-17(14)25)24-7-5-23-6-8-24/h1-4,9-11,23H,5-8H2,(H,27,28)	XBHBWNFJWIASRO-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	Yes	6	2	No	4	0	72.88 Å2	37.15 Å3	99.9 m3·mol-1	3	Yes	No	0.105 mg/mL	0.52	-3.6	5.55	8.76			
C25H21FN6O2S	Not Available	Not Available	488.54	NC1=C2C(SC=C2C2=CC=C(NC(=O)NC3=CC(F)=CC=C3)C=C2)=C(C=N1)C1=CN(CCO)N=C1	Not Available	Not Available					50381716		CHEMBL1980297	24809095									46207586	347828059					ZINC000063298074		Ilorasertib	Investigational	DB11694	InChI=1S/C25H21FN6O2S/c26-17-2-1-3-19(10-17)31-25(34)30-18-6-4-15(5-7-18)21-14-35-23-20(12-28-24(27)22(21)23)16-11-29-32(13-16)8-9-33/h1-7,10-14,33H,8-9H2,(H2,27,28)(H2,30,31,34)	WPHKIQPVPYJNAX-UHFFFAOYSA-N	1		Not Available	Small Molecule																																			1	No	5	4	Yes	5	0	118.09 Å2	50.11 Å3	147.93 m3·mol-1	6	Yes	No	0.00695 mg/mL	3.72	-4.8	11.28	4.96			
C26H23N7O2	Acalabrutinib's mean apparent oral clearance (CL/F) is observed to be 159 L/hr with similar PK between patients and healthy subjects, based on population PK analysis.6	After administering a single oral dose of 100 mg acalabrutinib, the median terminal elimination half-life of the drug was found to be 0.9 (with a range of 0.6 to 2.8) hours.6The half-life of the active metabolite, ACP-5862, is about 6.9 hours.6	465.517	CC#CC(=O)N1CCC[C@H]1C1=NC(=C2N1C=CN=C2N)C1=CC=C(C=C1)C(=O)NC1=CC=CC=N1	Solid	The mean steady-state volume of distribution is approximately 34 L.6	P08684;!P20815;!BE0004866	CYP3A4;!CYP3A5;!	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5;!3. Cytochrome P450 3A Subfamily (Protein Group)		50175583		CHEMBL3707348	36764951									71226662	347828068		1986808		Acalabrutinib	ZINC000208774715	Calquence	Acalabrutinib	Approved, Investigational	DB11703	InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1	WDENQIQQYWYTPO-IBGZPJMESA-N		Acalabrutinib is a Bruton tyrosine kinase inhibitor used to treat mantle cell lymphoma, chronic lymphocytic leukemia, and small lymphocytic lymphoma.	Data regarding the toxicity of acalabrutinib is not readily available.6	Small Molecule																														0.49				Freely soluble in water at pH values below 3 but is practically insoluble in water at pH values above 6	1	No	6	2	No	5	0	118.51 Å2	51 Å3	135.72 m3·mol-1	5	Yes	No	0.0109 mg/mL	2.56	-4.6	12.34	5	Q06187	BTK	1. Tyrosine-protein kinase BTK
C23H30N8O	Not Available	32.6 hours	434.548	CN(C)C(=O)C1=CC2=CN=C(NC3=CC=C(C=N3)N3CCNCC3)N=C2N1C1CCCC1	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4		148264		CHEMBL3545110	30798107					D10883	6ZZ		PA166153470	44631912	347828089		1873916		Ribociclib	ZINC000072316335	Kisqali 200 Mg Daily Dose Carton, Kisqali Femara Co-pack	Ribociclib	Approved, Investigational	DB11730	InChI=1S/C23H30N8O/c1-29(2)22(32)19-13-16-14-26-23(28-21(16)31(19)17-5-3-4-6-17)27-20-8-7-18(15-25-20)30-11-9-24-10-12-30/h7-8,13-15,17,24H,3-6,9-12H2,1-2H3,(H,25,26,27,28)	RHXHGRAEPCAFML-UHFFFAOYSA-N	3	Ribociclib is a kinase inhibitor used to treat HR+, HER2- advanced or metastatic breast cancer.	Not Available	Small Molecule																																			1	Yes	7	2	No	5	1	91.21 Å2	49.13 Å3	125.59 m3·mol-1	5	Yes	No	0.231 mg/mL	2.38	-3.3	11.59	8.87	P11802;!Q00534	CDK4;!CDK6	1. Cyclin-dependent kinase 4;!2. Cyclin-dependent kinase 6
C27H32N8O2	Not Available	Not Available	500.607	CN1CCN(CC1)C1=CC=C(NC2=NC=C3C(=O)N(CC=C)N(C3=N2)C2=NC(=CC=C2)C(C)(C)O)C=C1	Not Available	Not Available					50240826	91414	CHEMBL1976040	24808590						8X7			24856436	347828098				Adavosertib	ZINC000063539231		MK-1775	Investigational	DB11740	InChI=1S/C27H32N8O2/c1-5-13-34-25(36)21-18-28-26(29-19-9-11-20(12-10-19)33-16-14-32(4)15-17-33)31-24(21)35(34)23-8-6-7-22(30-23)27(2,3)37/h5-12,18,37H,1,13-17H2,2-4H3,(H,28,29,31)	BKWJAKQVGHWELA-UHFFFAOYSA-N	2		Not Available	Small Molecule																																			1	No	9	2	Yes	5	1	100.96 Å2	54.19 Å3	155.95 m3·mol-1	7	No	No	0.0625 mg/mL	3.17	-3.9	13.69	7.96	P30291	WEE1	1. Wee1-like protein kinase
C25H25Cl2N7O	Not Available	Not Available	510.42	CCNC1(CCN(CC1)C1=C2N=C(N(C2=NC=N1)C1=CC=C(Cl)C=C1)C1=CC=CC=C1Cl)C(N)=O	Not Available	Not Available					27337		CHEMBL562668	8227602									10052040	347828103				Otenabant	ZINC000003948997		Otenabant	Investigational	DB11745	InChI=1S/C25H25Cl2N7O/c1-2-31-25(24(28)35)11-13-33(14-12-25)22-20-23(30-15-29-22)34(17-9-7-16(26)8-10-17)21(32-20)18-5-3-4-6-19(18)27/h3-10,15,31H,2,11-14H2,1H3,(H2,28,35)	UNAZAADNBYXMIV-UHFFFAOYSA-N	3		Not Available	Small Molecule																																			1	No	6	2	Yes	5	1	101.96 Å2	53.2 Å3	158.88 m3·mol-1	6	No	No	0.0107 mg/mL	4.42	-4.7	15.89	8.97	P21554	CNR1	1. Cannabinoid receptor 1
C26H29N5O2	Not Available	Not Available	443.551	CC1(COC2=CC=C3N(C=NC3=C2)C2=CC=C3C=CC=C(N4CCC(N)CC4)C3=N2)COC1	Not Available	Not Available					185149	145365	CHEMBL2105728	8541584						6T2			10366136	347828178				Crenolanib	ZINC000003820043		Crenolanib	Investigational	DB11832	InChI=1S/C26H29N5O2/c1-26(14-32-15-26)16-33-20-6-7-22-21(13-20)28-17-31(22)24-8-5-18-3-2-4-23(25(18)29-24)30-11-9-19(27)10-12-30/h2-8,13,17,19H,9-12,14-16,27H2,1H3	DYNHJHQFHQTFTP-UHFFFAOYSA-N	2		Not Available	Small Molecule																																			1	No	6	1	No	6	1	78.43 Å2	49.86 Å3	138.65 m3·mol-1	5	Yes	No	0.0129 mg/mL	3.28	-4.5		10.03			
C25H29N9O3	Not Available	Not Available	503.567	COCCOC1=CC=C(C=C1)N1CCN(CCN2N=CC3=C2N=C(N)N2N=C(N=C32)C2=CC=CO2)CC1	Not Available	Not Available					50202986		CHEMBL240624	8293510									10117987	347828202				Preladenant	ZINC000053006885		Preladenant	Investigational	DB11864	InChI=1S/C25H29N9O3/c1-35-15-16-36-19-6-4-18(5-7-19)32-11-8-31(9-12-32)10-13-33-23-20(17-27-33)24-28-22(21-3-2-14-37-21)30-34(24)25(26)29-23/h2-7,14,17H,8-13,15-16H2,1H3,(H2,26,29)	DTYWJKSSUANMHD-UHFFFAOYSA-N	3		Not Available	Small Molecule																																			1	No	9	1	Yes	6	1	125 Å2	56.43 Å3	172.18 m3·mol-1	9	No	No	0.218 mg/mL	2.72	-3.4		7.95			
C22H19N5O	Not Available	Not Available	369.428	CC1=CC=CC(=N1)C1=NN2CCCC2=C1C1=C2C=C(C=CC2=NC=C1)C(N)=O	Not Available	Not Available					50015640	137064	CHEMBL2364611	8266022									10090485	347828243				Galunisertib	ZINC000003959536		Galunisertib	Investigational	DB11911	InChI=1S/C22H19N5O/c1-13-4-2-5-18(25-13)21-20(19-6-3-11-27(19)26-21)15-9-10-24-17-8-7-14(22(23)28)12-16(15)17/h2,4-5,7-10,12H,3,6,11H2,1H3,(H2,23,28)	IVRXNBXKWIJUQB-UHFFFAOYSA-N	3		Not Available	Small Molecule																																			1	Yes	4	1	No	5	0	86.69 Å2	39.5 Å3	117.87 m3·mol-1	2	Yes	No	0.0112 mg/mL	2.64	-4.5	14.58	3.36			
C21H11F6N5	Not Available	Not Available	447.344	NC1=CC=C(C=N1)C#CC1=C2N=C(C=C(N2N=C1)C(F)(F)F)C1=CC=C(C=C1)C(F)(F)F	Not Available	Not Available							CHEMBL3301593	32695160									71533696	347828254				Decoglurant	ZINC000115922684		Decoglurant	Investigational	DB11923	InChI=1S/C21H11F6N5/c22-20(23,24)15-6-4-13(5-7-15)16-9-17(21(25,26)27)32-19(31-16)14(11-30-32)3-1-12-2-8-18(28)29-10-12/h2,4-11H,(H2,28,29)	DMJHZVARRXJSEG-UHFFFAOYSA-N	2		Not Available	Small Molecule																																			1	Yes	4	1	No	4	0	69.1 Å2	39.33 Å3	111.06 m3·mol-1	5	No	No	0.0023 mg/mL	5.03	-5.3		4.54			
C23H21N7O	Not Available	Not Available	411.4591	C1CN(CCO1)C1=CC=C(NC2=NC(=CN3C=CN=C23)C2=CC3=C(C=NN3)C=C2)C=C1	Not Available	Not Available					50015448		CHEMBL3265032	31042596						CG9			59473233	347828420				Syk	ZINC000098208742		Entospletinib	Investigational	DB12121	InChI=1S/C23H21N7O/c1-2-17-14-25-28-20(17)13-16(1)21-15-30-8-7-24-23(30)22(27-21)26-18-3-5-19(6-4-18)29-9-11-31-12-10-29/h1-8,13-15H,9-12H2,(H,25,28)(H,26,27)	XSMSNFMDVXXHGJ-UHFFFAOYSA-N	2		Not Available	Small Molecule																																			1	Yes	6	2	No	6	0	83.37 Å2	44.44 Å3	120.86 m3·mol-1	4	Yes	No		2.82		11.74	3.74	P43405	SYK	1. Tyrosine-protein kinase SYK
C27H27FN8O3	Not Available	Not Available	530.564	CC1=C2N(C=C1NC(=O)OC[C@@H]1COCCN1)N=CN=C2NC1=CC=C2N(CC3=CC=CC(F)=C3)N=CC2=C1	Not Available	Not Available					50333373		CHEMBL1645462	8612442									10437018	347828581					ZINC000006717782		BMS-599626	Investigational	DB12318	InChI=1S/C27H27FN8O3/c1-17-23(34-27(37)39-15-22-14-38-8-7-29-22)13-36-25(17)26(30-16-32-36)33-21-5-6-24-19(10-21)11-31-35(24)12-18-3-2-4-20(28)9-18/h2-6,9-11,13,16,22,29H,7-8,12,14-15H2,1H3,(H,34,37)(H,30,32,33)/t22-/m0/s1	LUJZZYWHBDHDQX-QFIPXVFZSA-N	1		Not Available	Small Molecule																																			1	No	8	3	Yes	6	1	119.63 Å2	55.74 Å3	166.66 m3·mol-1	8	No	No	0.0129 mg/mL	3.99	-4.6	12.24	7.49			
C22H24N6O	Not Available	Not Available	388.475	C(CN1CCCCC1)OC1=CC=CC(=C1)C1=NNC2=CC=C(C=C12)C1=NNC=N1	Not Available	Not Available						91437	CHEMBL1614713	8605788									10430360	347828674					ZINC000038836256		CC-401	Investigational	DB12432	InChI=1S/C22H24N6O/c1-2-9-28(10-3-1)11-12-29-18-6-4-5-16(13-18)21-19-14-17(22-23-15-24-27-22)7-8-20(19)25-26-21/h4-8,13-15H,1-3,9-12H2,(H,25,26)(H,23,24,27)	XDJCLCLBSGGNKS-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	Yes	5	2	Yes	5	1	82.72 Å2	43.39 Å3	125.73 m3·mol-1	6	Yes	No	0.0295 mg/mL	3.81	-4.1	10.58	8.82			
C26H24F4N6O	Not Available	Not Available	512.502	CN(C1CCN(CC1)C1=NN=C(C2=CC=NN2C)C2=CC=CC=C12)C(=O)C1=C(C=C(F)C=C1)C(F)(F)F	Not Available	Not Available							CHEMBL2142592	26323626						1KS			49848070	347828775					ZINC000068247898		Taladegib	Investigational	DB12550	InChI=1S/C26H24F4N6O/c1-34(25(37)20-8-7-16(27)15-21(20)26(28,29)30)17-10-13-36(14-11-17)24-19-6-4-3-5-18(19)23(32-33-24)22-9-12-31-35(22)2/h3-9,12,15,17H,10-11,13-14H2,1-2H3	SZBGQDXLNMELTB-UHFFFAOYSA-N	2		Not Available	Small Molecule																																			1	No	5	0	No	5	0	67.15 Å2	49.2 Å3	145.08 m3·mol-1	5	No	No	0.0033 mg/mL	3.98	-5.2		3.68			
C20H16N4O2S	Not Available	Not Available	376.43	CN(C(C)=O)C1=CC=CC(=C1)C1=CC=NC2=C(C=NN12)C(=O)C1=CC=CS1	Not Available	Not Available					86522		CHEMBL262075	4953363									6450813	347828809				Indiplon	ZINC000000538650		Indiplon	Investigational	DB12590	InChI=1S/C20H16N4O2S/c1-13(25)23(2)15-6-3-5-14(11-15)17-8-9-21-20-16(12-22-24(17)20)19(26)18-7-4-10-27-18/h3-12H,1-2H3	CBIAWPMZSFFRGN-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	Yes	4	0	No	4	0	67.57 Å2	39.66 Å3	114.23 m3·mol-1	4	Yes	No	0.00449 mg/mL	2.69	-4.9		0.96			
C19H23N5O2	Not Available	Not Available	353.426	COCCC1=CC=C(C=N1)C1=C(C)N=C2N1N=CC=C2N1CCOCC1	Not Available	Not Available					50397991		CHEMBL2180408	28424205									51352628	347828861					ZINC000068268153		JNJ-42396302	Investigational	DB12657	InChI=1S/C19H23N5O2/c1-14-18(15-3-4-16(20-13-15)6-10-25-2)24-19(22-14)17(5-7-21-24)23-8-11-26-12-9-23/h3-5,7,13H,6,8-12H2,1-2H3	BPLVDYJDAVYLRQ-UHFFFAOYSA-N	1		Not Available	Small Molecule																																			1	Yes	6	0	No	4	0	64.78 Å2	39.66 Å3	110.47 m3·mol-1	5	Yes	No	0.112 mg/mL	1.22	-3.5		4.5			
C19H19N3O2S	Not Available	Not Available	353.44	O=S(=O)(C1=CC=CC=C1)C1=CN=C2C(C=CC=C2N2CCNCC2)=C1	Not Available	Not Available					50318633		CHEMBL1083390	9431746									11256720	347828884				Intepirdine	ZINC000043199965		Intepirdine	Investigational	DB12680	InChI=1S/C19H19N3O2S/c23-25(24,16-6-2-1-3-7-16)17-13-15-5-4-8-18(19(15)21-14-17)22-11-9-20-10-12-22/h1-8,13-14,20H,9-12H2	JJZFWROHYSMCMU-UHFFFAOYSA-N	3		Not Available	Small Molecule																																			1	Yes	5	1	No	4	1	62.3 Å2	37.33 Å3	98.7 m3·mol-1	3	Yes	No	0.057 mg/mL	2.66	-3.8		8.61			
C23H21N5O3S	Not Available	Not Available	447.51	S=C(NCC1=CC=C2OCOC2=C1)N1CCN(CC1)C1=NC=NC2=C1OC1=C2C=CC=C1	Not Available	Not Available					50172081	91389	CHEMBL2103851	9457280									11282283	347828932					ZINC000034951302		Amuvatinib	Investigational	DB12742	InChI=1S/C23H21N5O3S/c32-23(24-12-15-5-6-18-19(11-15)30-14-29-18)28-9-7-27(8-10-28)22-21-20(25-13-26-22)16-3-1-2-4-17(16)31-21/h1-6,11,13H,7-10,12,14H2,(H,24,32)	FOFDIMHVKGYHRU-UHFFFAOYSA-N	2		Not Available	Small Molecule																																			1	Yes	5	1	No	6	0	75.89 Å2	47.82 Å3	124.53 m3·mol-1	3	Yes	No	0.0741 mg/mL	3.52	-3.8	14.11	1.37	P10721;!P08581;!P07949;!P16234;!P36888;!Q06609	KIT;!MET;!RET;!PDGFRA;!FLT3;!RAD51	1. Mast/stem cell growth factor receptor Kit;!2. Hepatocyte growth factor receptor;!3. Proto-oncogene tyrosine-protein kinase receptor Ret;!4. Platelet-derived growth factor receptor alpha;!5. Receptor-type tyrosine-protein kinase FLT3;!6. DNA repair protein RAD51 homolog 1
C37H36N4O3	Not Available	Not Available	584.72	COC(=O)C1=CN=C2N1CCC1=CC=CC=C1C2=C1CCN(CCC2=CC=C(OCC3=CC=C4C=CC=CC4=N3)C=C2)CC1	Not Available	Not Available							CHEMBL539378	4953357									6450806	347828975				Laniquidar	ZINC000003937143		Laniquidar	Investigational	DB12799	InChI=1S/C37H36N4O3/c1-43-37(42)34-24-38-36-35(32-8-4-2-6-27(32)19-23-41(34)36)29-17-21-40(22-18-29)20-16-26-10-14-31(15-11-26)44-25-30-13-12-28-7-3-5-9-33(28)39-30/h2-15,24H,16-23,25H2,1H3	TULGGJGJQXESOO-UHFFFAOYSA-N	2		Not Available	Small Molecule																																			0	No	5	0	Yes	7	1	69.48 Å2	67.99 Å3	182.16 m3·mol-1	8	No	No	0.000453 mg/mL	6.28	-6.1		8.11			
C19H16N8O	Not Available	Not Available	372.392	OCCN1C=C(C=N1)C1=CN=C2N=NN(CC3=CC4=CC=CN=C4C=C3)C2=N1	Not Available	Not Available					50396934	91425	CHEMBL2001019	21437054						KRW			17754438	347829009					ZINC000043195316		PF-04217903	Investigational	DB12848	InChI=1S/C19H16N8O/c28-7-6-26-12-15(9-22-26)17-10-21-18-19(23-17)27(25-24-18)11-13-3-4-16-14(8-13)2-1-5-20-16/h1-5,8-10,12,28H,6-7,11H2	PDMUGYOXRHVNMO-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	Yes	7	1	No	5	0	107.43 Å2	38.44 Å3	124.98 m3·mol-1	5	Yes	No	0.224 mg/mL	1.34	-3.2	15.39	4.5			
C23H21N7	Not Available	Not Available	395.47	C1CN(CCN1C1=NC=CC=N1)C1=C(C=C(N=N1)C1=CC=CC=C1)C1=CC=NC=C1	Not Available	Not Available								28561746									54576073	347829051							TT-301	Investigational	DB12899	InChI=1S/C23H21N7/c1-2-5-19(6-3-1)21-17-20(18-7-11-24-12-8-18)22(28-27-21)29-13-15-30(16-14-29)23-25-9-4-10-26-23/h1-12,17H,13-16H2	ZPJGUEPHFXPAQF-UHFFFAOYSA-N	1		Not Available	Small Molecule																																			1	Yes	7	0	No	5	0	70.93 Å2	43.25 Å3	119.41 m3·mol-1	4	Yes	No	0.0726 mg/mL	3.43	-3.7		4.56			
C22H22ClN7O2	Not Available	Not Available	451.92	COC1=CC(=CC=C1Cl)N1CCN(CC1)C(=O)CN1N=C(C2=NC=CN2)C2=CC=CN=C12	Not Available	Not Available								25069703									25016615	347829103							CCX-354	Investigational	DB12963	InChI=1S/C22H22ClN7O2/c1-32-18-13-15(4-5-17(18)23)28-9-11-29(12-10-28)19(31)14-30-22-16(3-2-6-26-22)20(27-30)21-24-7-8-25-21/h2-8,13H,9-12,14H2,1H3,(H,24,25)	ZIMLRKWQDLVPEK-UHFFFAOYSA-N	2		Not Available	Small Molecule																																			1	No	6	1	No	5	0	92.17 Å2	47.61 Å3	142.29 m3·mol-1	5	Yes	No	0.114 mg/mL	2.16	-3.6	11.15	5.05			
C19H13F2N7	Not Available	Not Available	377.359	CN1C=C(C=N1)C1=NN2C(C=C1)=NN=C2C(F)(F)C1=CC=C2N=CC=CC2=C1	Not Available	Not Available					163243	91417	CHEMBL2133806	21437051									46911863	347829236					ZINC000043170515		JNJ-38877605	Investigational	DB13113	InChI=1S/C19H13F2N7/c1-27-11-13(10-23-27)16-6-7-17-24-25-18(28(17)26-16)19(20,21)14-4-5-15-12(9-14)3-2-8-22-15/h2-11H,1H3	JRWCBEOAFGHNNU-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	Yes	5	0	No	5	0	73.79 Å2	35.86 Å3	120.86 m3·mol-1	3	Yes	No	0.0115 mg/mL	3.04	-4.5		4.41			
C29H32Cl2N6	The mean apparent total clearance has been observed to be 1.12 L/h/kg in adult malaria patients 4.	The terminal elimination half-life was observed to be 576h or 24 days 4. This is thought to be due to the extensive distribution of piperaquine.	535.52	ClC1=CC2=C(C=C1)C(=CC=N2)N1CCN(CCCN2CCN(CC2)C2=CC=NC3=C2C=CC(Cl)=C3)CC1	Solid	Piperaquine is thought to distribute into a central compartment with an apparent volume of 26.7 L/kg, and two peripheral compartments with apparent volumes of 76.8 L/kg and 617 L/kg 4. These combine for a total volume of distribution of 720.5 L/kg.	P08684;!P33261;!P11712;!P20813;!P05181	CYP3A4;!CYP2C19;!CYP2C9;!CYP2B6;!CYP2E1	1. Cytochrome P450 3A4;!2. Cytochrome P450 2C19;!3. Cytochrome P450 2C9;!4. Cytochrome P450 2B6;!5. Cytochrome P450 2E1			91231	CHEMBL303933	109031								PA166104279						Piperaquine	ZINC000026251015		Piperaquine	Approved, Experimental, Investigational	DB13941	InChI=1S/C29H32Cl2N6/c30-22-2-4-24-26(20-22)32-8-6-28(24)36-16-12-34(13-17-36)10-1-11-35-14-18-37(19-15-35)29-7-9-33-27-21-23(31)3-5-25(27)29/h2-9,20-21H,1,10-19H2	UCRHFBCYFMIWHC-UHFFFAOYSA-N	4		Studies of piperaquine in monkeys and dogs have shown some hepatotoxicity and reversible depression in white blood cells and neutrophils Label. Additional observations include infiltration of macrophages with intracytoplasmic basophilic granular material consistent with phospholipidosis and degenerative lesions in numerous organs and tissues. These effects were seen at exposure levels similar to clinical dosing in humans. At high doses, piperaquine can interfere with cardiac conduction and produce effects on blood pressure. Mild phototoxicity has been observed with piperaquine in rats exposed to UV light.	Small Molecule																																			0	No	6	0	Yes	6	3	38.74 Å2	59.56 Å3	153.42 m3·mol-1	6	No	Yes	0.0167 mg/mL	5.27	-4.5		8.47			
C25H26N8O	Not Available	Not Available	454.538	CCC1=CC(=CC=C1N1N=C(C(C)C)C2=C1N=CC=C2N1C=NC(=C1)C1=CN(C)N=C1)C(N)=O	Not Available	Not Available					126083		CHEMBL3661115	58796458															ZINC000169703510		TAS-116	Investigational	DB14876	InChI=1S/C25H26N8O/c1-5-16-10-17(24(26)34)6-7-20(16)33-25-22(23(30-33)15(2)3)21(8-9-27-25)32-13-19(28-14-32)18-11-29-31(4)12-18/h6-15H,5H2,1-4H3,(H2,26,34)	NVVPMZUGELHVMH-UHFFFAOYSA-N	1		Not Available	Small Molecule																																			1	No	5	1	Yes	5	0	109.44 Å2	50.36 Å3	152.67 m3·mol-1	6	Yes	No	0.106 mg/mL	3.64	-3.6	14.82	4.88			
C29H29FN4O	Not Available	Not Available	468.576	COCCNCCC1=CC(NC2=NC=C3C[C@@H](C4=CC=CC=C4F)C4=CC=CC=C4C3=N2)=CC=C1	Not Available	Not Available								59718644																	Derazantinib	Investigational	DB14889	InChI=1S/C29H29FN4O/c1-35-16-15-31-14-13-20-7-6-8-22(17-20)33-29-32-19-21-18-26(24-10-4-5-12-27(24)30)23-9-2-3-11-25(23)28(21)34-29/h2-12,17,19,26,31H,13-16,18H2,1H3,(H,32,33,34)/t26-/m1/s1	KPJDVVCDVBFRMU-AREMUKBSSA-N	2		Not Available	Small Molecule																																			1	No	5	2	Yes	5	1	59.07 Å2	51.26 Å3	138.11 m3·mol-1	9	No	No	0.00106 mg/mL	6.13	-5.6	13.8	9.53			
C19H17N5O3	Not Available	Not Available	363.377	NC1=NC2=CC(=CC=C2O1)C1=CN2C(C=C1)=NC=C2C(=O)N1CCOCC1	Not Available	Not Available					119531		CHEMBL3935857	35143228															ZINC000146965425		Serabelisib	Investigational	DB14935	InChI=1S/C19H17N5O3/c20-19-22-14-9-12(1-3-16(14)27-19)13-2-4-17-21-10-15(24(17)11-13)18(25)23-5-7-26-8-6-23/h1-4,9-11H,5-8H2,(H2,20,22)	BLGWHBSBBJNKJO-UHFFFAOYSA-N	2		Not Available	Small Molecule																																			1	Yes	5	1	No	5	0	98.89 Å2	38.71 Å3	99.74 m3·mol-1	2	Yes	No	0.288 mg/mL	0.61	-3.1	13.86	4.58			
C27H24N6	Not Available	Not Available	432.531	NC1=NC=CC=C1C1=NC2=CC=C(N=C2N1C1=CC=C(C=C1)C1(N)CCC1)C1=CC=CC=C1	Not Available	Not Available								57251282						6S1									ZINC000072315647		Miransertib	Investigational	DB14982	InChI=1S/C27H24N6/c28-24-21(8-4-17-30-24)25-32-23-14-13-22(18-6-2-1-3-7-18)31-26(23)33(25)20-11-9-19(10-12-20)27(29)15-5-16-27/h1-4,6-14,17H,5,15-16,29H2,(H2,28,30)	HNFMVVHMKGFCMB-UHFFFAOYSA-N	1		Not Available	Small Molecule																																			1	No	5	2	No	6	1	95.64 Å2	48.66 Å3	150.66 m3·mol-1	4	Yes	No	0.00313 mg/mL	4.86	-5.1		9.65			
C22H23FN6OS	Not Available	Not Available	438.53	COC1=CC(F)=CC=C1C1=C(C)SC2=CN=C(NC3=CN(N=C3)C3CCNCC3)N=C12	Not Available	Not Available								68007018																	MAX-40279	Investigational	DB15191	InChI=1S/C22H23FN6OS/c1-13-20(17-4-3-14(23)9-18(17)30-2)21-19(31-13)11-25-22(28-21)27-15-10-26-29(12-15)16-5-7-24-8-6-16/h3-4,9-12,16,24H,5-8H2,1-2H3,(H,25,27,28)	AVIOBQFPAGEICQ-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	No	6	2	No	5	1	76.89 Å2	46.45 Å3	130.05 m3·mol-1	4	Yes	No	0.0183 mg/mL	3.26	-4.4	10.65	9.89			
C23H24N4O	Not Available	Not Available	372.472	CN1C[C@H]2CCN([C@H]2C1)C1=CC=C(C=C1)C1=CC=C(C=C1)N1N=CC=CC1=O	Not Available	Not Available								34980744															ZINC000118827084		ABT-288	Investigational	DB15192	InChI=1S/C23H24N4O/c1-25-15-19-12-14-26(22(19)16-25)20-8-4-17(5-9-20)18-6-10-21(11-7-18)27-23(28)3-2-13-24-27/h2-11,13,19,22H,12,14-16H2,1H3/t19-,22+/m1/s1	GNIRITULTPTAQW-KNQAVFIVSA-N	2		Not Available	Small Molecule																																			1	Yes	4	0	No	5	1	39.15 Å2	42.52 Å3	113.47 m3·mol-1	3	Yes	Yes	0.0438 mg/mL	3.06	-3.9		9.19			
C26H27FN10	The mean apparent oral clearance of avapritinib is 19.5L/h.4	The half life of avapritinib is 32-57h.4	498.57	CN1C=C(C=N1)C1=CN2N=CN=C(N3CCN(CC3)C3=NC=C(C=N3)[C@@](C)(N)C3=CC=C(F)C=C3)C2=C1	Solid	The mean apparent volume of distribution is 1200L.4	P08684;!P11712	CYP3A4;!CYP2C9	1. Cytochrome P450 3A4;!2. Cytochrome P450 2C9		469269		CHEMBL4204794	58828673												2272107		Avapritinib		Ayvakit	Avapritinib	Approved, Investigational	DB15233	InChI=1S/C26H27FN10/c1-26(28,20-3-5-22(27)6-4-20)21-13-29-25(30-14-21)36-9-7-35(8-10-36)24-23-11-18(16-37(23)33-17-31-24)19-12-32-34(2)15-19/h3-6,11-17H,7-10,28H2,1-2H3/t26-/m0/s1	DWYRIWUZIJHQKQ-SANMLTNESA-N	3	Avapritinib is a selective tyrosine kinase inhibitor being investigated for the treatment of multidrug resistant gastrointestinal tumors.	Data regarding overdoses of avapritinib are not readily available.4	Small Molecule																																			1	No	8	1	No	6	1	106.29 Å2	52.99 Å3	164.55 m3·mol-1	5	Yes	No	0.0301 mg/mL	3.26	-4.2		8.52	;!P10721	;!KIT	1. Platelet derived growth factor receptor alpha;!2. Mast/stem cell growth factor receptor Kit
C28H27FN6O2	Not Available	Not Available	498.562	CN1C(C)=CC(=C1C(=O)C(=O)NC1=CC=C(C=C1)N1CCN(CC1)C1=NC=C(F)C=N1)C1=CC=CC=C1	Not Available	Not Available								58828130																	Olorofim	Investigational	DB15245	InChI=1S/C28H27FN6O2/c1-19-16-24(20-6-4-3-5-7-20)25(33(19)2)26(36)27(37)32-22-8-10-23(11-9-22)34-12-14-35(15-13-34)28-30-17-21(29)18-31-28/h3-11,16-18H,12-15H2,1-2H3,(H,32,37)	SUFPWYYDCOKDLL-UHFFFAOYSA-N	1		Not Available	Small Molecule																																			1	No	6	1	Yes	5	0	83.36 Å2	52.99 Å3	144.16 m3·mol-1	6	Yes	No	0.0142 mg/mL	4.74	-4.6	12.29	2.66			
C22H18FN7	Not Available	Not Available	399.433	CC1=NC(=CC=C1)C1=C(N=C(CNC2=C(F)C=CC=C2)N1)C1=CN2N=CN=C2C=C1	Not Available	Not Available					50015639		CHEMBL3260567	32813335															ZINC000113391423		Vactosertib	Investigational	DB15310	InChI=1S/C22H18FN7/c1-14-5-4-8-18(27-14)22-21(15-9-10-20-25-13-26-30(20)12-15)28-19(29-22)11-24-17-7-3-2-6-16(17)23/h2-10,12-13,24H,11H2,1H3,(H,28,29)	FJCDSQATIJKQKA-UHFFFAOYSA-N	1		Not Available	Small Molecule																																			1	Yes	5	2	No	5	0	83.79 Å2	42.5 Å3	123.9 m3·mol-1	5	Yes	No	0.00936 mg/mL	3.36	-4.6	10.77	4.59			
C26H26FN7O2	Not Available	Not Available	487.539	CN1CCN(CC1)C1=C(F)C=C(NC2=NC(OC3=CC=CC(NC(=O)C=C)=C3)=C3C=CNC3=N2)C=C1	Not Available	Not Available					294480		CHEMBL4297865	57490375															ZINC000142081723		Abivertinib	Investigational	DB15327	InChI=1S/C26H26FN7O2/c1-3-23(35)29-17-5-4-6-19(15-17)36-25-20-9-10-28-24(20)31-26(32-25)30-18-7-8-22(21(27)16-18)34-13-11-33(2)12-14-34/h3-10,15-16H,1,11-14H2,2H3,(H,29,35)(H2,28,30,31,32)	UOFYSRZSLXWIQB-UHFFFAOYSA-N	2		Not Available	Small Molecule																																			1	No	6	3	Yes	5	1	98.41 Å2	52.34 Å3	138.95 m3·mol-1	7	Yes	No	0.0276 mg/mL	4.82	-4.2	12.6	7.25	P00533;!Q06187	EGFR;!BTK	1. Epidermal growth factor receptor;!2. Tyrosine-protein kinase BTK
C30H33N5O2	Not Available	Not Available	495.627	CN1N=NC(C)=C1C1=CC2=C(N=C1)C1=C(C=C(C=C1)C(C)(C)O)N2[C@@H](C1CCOCC1)C1=CC=CC=C1	Not Available	Not Available					297146			58828664						YWA											BMS-986158	Investigational	DB15435	InChI=1S/C30H33N5O2/c1-19-28(34(4)33-32-19)22-16-26-27(31-18-22)24-11-10-23(30(2,3)36)17-25(24)35(26)29(20-8-6-5-7-9-20)21-12-14-37-15-13-21/h5-11,16-18,21,29,36H,12-15H2,1-4H3/t29-/m1/s1	KGERZPVQIRYWRK-GDLZYMKVSA-N	2		Not Available	Small Molecule																																			1	No	5	1	No	6	0	77.99 Å2	55.94 Å3	156.15 m3·mol-1	5	Yes	No	0.00819 mg/mL	4.36	-4.8	14.53	1.96			
C26H26N6O3	Not Available	Not Available	470.533	COC1=CC=C(COC2=CC=C(CN3C(N)=NC4=C3N=CC(=C4)C3=CN(C)N=C3)C=C2OC)C=C1	Not Available	Not Available					164901		CHEMBL3673452	58937169															ZINC000473215300		GZ-389988	Investigational	DB16056	InChI=1S/C26H26N6O3/c1-31-15-20(13-29-31)19-11-22-25(28-12-19)32(26(27)30-22)14-18-6-9-23(24(10-18)34-3)35-16-17-4-7-21(33-2)8-5-17/h4-13,15H,14,16H2,1-3H3,(H2,27,30)	HVRWZFQFSQUILC-UHFFFAOYSA-N	2		Not Available	Small Molecule																																			1	No	7	1	Yes	5	0	102.24 Å2	51.5 Å3	144.49 m3·mol-1	8	Yes	No	0.0275 mg/mL	3.54	-4.2		4.11			
C30H34N8O3	Not Available	Not Available	554.655	COC1=C(NC2=NC=CC(=N2)N2C=C(CN(C)C)C(=N2)C2=CC=CC=C2)C=C(NC(=O)C=C)C(=C1)N1CCOCC1	Not Available	Not Available								64835231																	Lazertinib	Investigational	DB16216	InChI=1S/C30H34N8O3/c1-5-28(39)32-23-17-24(26(40-4)18-25(23)37-13-15-41-16-14-37)33-30-31-12-11-27(34-30)38-20-22(19-36(2)3)29(35-38)21-9-7-6-8-10-21/h5-12,17-18,20H,1,13-16,19H2,2-4H3,(H,32,39)(H,31,33,34)	RRMJMHOQSALEJJ-UHFFFAOYSA-N	1		Not Available	Small Molecule																																			1	No	9	2	Yes	5	1	109.67 Å2	59.53 Å3	162.61 m3·mol-1	10	No	No	0.025 mg/mL	4.55	-4.4	13.65	8.35			
C24H21ClFN5O3	Not Available	Not Available	481.91	COC1=NN=C(C=C1)[C@@H](O)C1=C(Cl)C=C(F)C(=C1)C1=NC=NC2=C1C=CC(=C2)N1CCOCC1	Not Available	Not Available							CHEMBL4297629	67896524						1IX											Nedisertib	Investigational	DB16252	InChI=1S/C24H21ClFN5O3/c1-33-22-5-4-20(29-30-22)24(32)16-11-17(19(26)12-18(16)25)23-15-3-2-14(10-21(15)27-13-28-23)31-6-8-34-9-7-31/h2-5,10-13,24,32H,6-9H2,1H3/t24-/m0/s1	MOWXJLUYGFNTAL-DEOSSOPVSA-N	1		Not Available	Small Molecule																																			1	No	8	1	No	5	0	93.49 Å2	47.89 Å3	127.22 m3·mol-1	5	Yes	No	0.031 mg/mL	3.58	-4.2	12.6	3.08			
C26H28N6O	Not Available	Not Available	440.551	CC(C)N1CCN(CC2=CN=C(O2)C2=CC(=CC3=C2C=NN3)C2=CC=CC3=C2C=CN3)CC1	Not Available	Not Available					50004529		CHEMBL2216859	28651123						VVX									ZINC000095564436		Nemiralisib	Investigational	DB16253	InChI=1S/C26H28N6O/c1-17(2)32-10-8-31(9-11-32)16-19-14-28-26(33-19)22-12-18(13-25-23(22)15-29-30-25)20-4-3-5-24-21(20)6-7-27-24/h3-7,12-15,17,27H,8-11,16H2,1-2H3,(H,29,30)	MCIDWGZGWVSZMK-UHFFFAOYSA-N	2		Not Available	Small Molecule																																			1	No	4	2	No	6	1	76.98 Å2	50.16 Å3	141.74 m3·mol-1	5	Yes	No	0.0571 mg/mL	3.49	-3.9	11.32	7.82			
C11H8O2	Not Available	Not Available	172.18	CC1=CC(=O)C2=CC=CC=C2C1=O	Solid	Not Available					24778	28869	CHEMBL590	3915		GtP Drug Page	HMDB0001892	C05377	D02335	VK3	PDRhealth Drug Page	PA450358	4055	46505447		6728	DNC001501	Menadione	ZINC000000001677		Menadione	Approved, Nutraceutical	DB00170	InChI=1S/C11H8O2/c1-7-6-10(12)8-4-2-3-5-9(8)11(7)13/h2-6H,1H3	MJVAVZPDRWSRRC-UHFFFAOYSA-N	1		Menadione (vitamin K3), which is not used as a nutritional supplemental form of vitamin K for humans, has been reported to cause adverse reactions, including hemolytic anemia. Large doses have also been reported to cause brain damage.	Small Molecule				AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Non-substrate	2.7195 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.20	-3.03	107 °C		160 mg/L (at 30 °C)	1	Yes	2	0	No	2	0	34.14 Å2	17.64 Å3	50.54 m3·mol-1	0	Yes	Yes	0.504 mg/mL	1.89	-2.5		-7.2	P38435;!Q9BQB6;!Q8N0U8;!P00734;!P00740;!P04070;!P07225;!P16083;!P15559;!P02818	GGCX;!VKORC1;!VKORC1L1;!F2;!F9;!PROC;!PROS1;!NQO2;!NQO1;!BGLAP	1. Vitamin K-dependent gamma-carboxylase;!2. Vitamin K epoxide reductase complex subunit 1;!3. Vitamin K epoxide reductase complex subunit 1-like protein 1;!4. Prothrombin;!5. Coagulation factor IX;!6. Vitamin K-dependent protein C;!7. Vitamin K-dependent protein S;!8. Ribosyldihydronicotinamide dehydrogenase [quinone];!9. NAD(P)H dehydrogenase [quinone] 1;!10. Osteocalcin
C15H16O2	6-MNA has an apparent steady-state clearance of 20 - 30 mL/min.Label	6-MNA has a mean half-life of 24 hours with a range of 19-36 hours.Label	228.2863	COC1=CC2=C(C=C1)C=C(CCC(C)=O)C=C2	Solid	The Vd of 6-MNA reported after administration of a single dose is 0.1-0.2 L/kg or approximately 5-10 L.1 Vdss reported in official product labeling is approximately 53 L.Label,10	P05164;!P05177;!P11712;!P28845;!Q04828;!P52895;!P17516	MPO;!CYP1A2;!CYP2C9;!HSD11B1;!AKR1C1;!AKR1C2;!AKR1C4	1. Myeloperoxidase;!2. Cytochrome P450 1A2;!3. Cytochrome P450 2C9;!4. Corticosteroid 11-beta-dehydrogenase isozyme 1;!5. Aldo-keto reductase family 1 member C1;!6. Aldo-keto reductase family 1 member C2;!7. Aldo-keto reductase family 1 member C4		40128	7443	CHEMBL1070	4256	Drugs.com Drug Page		HMDB0014604		D00425	NBO	PDRhealth Drug Page	PA450572	4409	46507729	RxList Drug Page	31448	DAP000735	Nabumetone	ZINC000000020221	Relafen	Nabumetone	Approved	DB00461	InChI=1S/C15H16O2/c1-11(16)3-4-12-5-6-14-10-15(17-2)8-7-13(14)9-12/h5-10H,3-4H2,1-2H3	BLXXJMDCKKHMKV-UHFFFAOYSA-N	4	Nabumetone is an NSAID used to treat osteoarthritis and rheumatoid arthritis.	LD50 ValuesMouse: 4290 mg/kg (Oral), 2380 mg/kg (IP)11Rat: 3880 mg/kg (Oral), 1520 mg/kg (IP), >10 g/kg (SC)11Monkey: 3200 mg/kg (Oral)11OverdoseSigns and symptoms of nabumetone overdose include lethargy, drowsiness, nausea, vomiting, and epigastric pain.Label These are considered reversible with supportive care. GI bleeding, hypertension, acute kidney injury, respiratory depression, and coma are rare but can occur. No antidote exists for nabumetone overdose although administration of activated charcoal and/or induction of emesis can reduce absorption if the nabumetone dose was taken less than 4 hours prior.Label,10 6-MNA is cannot be cleared by dialysis.Carcinogenicity & MutagenicityNabumetone was not significantly carcinogenic in rats or mice studied over 2 years.Label Neither the Ames test nor mouse micronucleus test showed nabumetone or it's active metabolite, 6-MNA, to be mutagenic. Chromosomal abberation has been observed in cultured lymphocytes exposed to concentrations of 80 mcg/mL and higher of nabumetone or 6-MNA equivalent to the maximum recommended human dose.Reproductive ToxicityNo adverse effects on fertility have been observed in male and female rats at doses of 320 mg/kg/day.Label,10] No teratogenicity has been observed in pregnant rabbits or rats. Dystocia and delayed parturition have been noted in rats resulting in reduced survival of offspring. This has been attributed to the role of prostaglandins in uterine contraction. NSAIDs can also cause premature closure of the ductus ateriosus.Lactation6-MNA has been detected in the milk of lactating rats.Label,10 While no data is available in humans, 6-MNA is both highly protein bound and exists in its anionic form in circulation. For these reasons partitioning into breast milk is expected to be limited.	Small Molecule	http://smpdb.ca/view/SMP0000114?highlight[compounds][]=DB00461&highlight[proteins][]=DB00461	Nabumetone Action Pathway		Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	1.7384 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2400		78-82		Practically insoluble	1	Yes	2	0	No	2	0	26.3 Å2	26.17 Å3	68.43 m3·mol-1	4	Yes	Yes	0.00193 mg/mL	3.22	-5.1	19.59	-4.8			
C20H12O5	renal cl=1.75 mL/min/kg [After IV administration]hepatic cl=1.50 mL/min/kg [After IV administration]	Not Available	332.3063	OC1=CC=C2C(OC3=CC(O)=CC=C3C22OC(=O)C3=C2C=CC=C3)=C1	Solid	0.5 L/kg					50237588	31624	CHEMBL1057	15968			HMDB0014831		D01261	FLU		PA164746009	16850	46504703	RxList Drug Page	25138		Fluorescein	ZINC000003860453	Ak-fluor, Altafluor, Diofluor, Fluorescite, Fluress	Fluorescein	Approved	DB00693	InChI=1S/C20H12O5/c21-11-5-7-15-17(9-11)24-18-10-12(22)6-8-16(18)20(15)14-4-2-1-3-13(14)19(23)25-20/h1-10,21-22H	GNBHRKFJIUUOQI-UHFFFAOYSA-N	4	Fluorescein is a dye used in angiography or angioscopy of the iris and retina.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.7602 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.4		315 dec °C		600 mg/mL (sodium salt)	1	Yes	3	2	No	5	0	75.99 Å2	33.14 Å3	91.22 m3·mol-1	0	Yes	No	0.0255 mg/mL	3.88	-4.1	8.72	-3.7	P06310;!BSEQ0052171	Not Available;!	1. Ig kappa chain V-II region RPMI 6410;!2. DNA
C14H14O3	Naproxen is cleared at a rate of 0.13 mL/min/kg.1213	The elimination half-life of naproxen is reported to be 12-17 hours.313	230.2592	COC1=CC2=C(C=C1)C=C(C=C2)[C@H](C)C(O)=O	Solid	Naproxen has a volume of distribution of 0.16 L/kg.1213	P10632;!P16662;!P35503;!P19224;!Q9HAW7;!Q9HAW9;!O60656;!Q9HAW8;!P11712;!P05177	CYP2C8;!UGT2B7;!UGT1A3;!UGT1A6;!UGT1A7;!UGT1A8;!UGT1A9;!UGT1A10;!CYP2C9;!CYP1A2	1. Cytochrome P450 2C8;!2. UDP-glucuronosyltransferase 2B7;!3. UDP-glucuronosyltransferase 1-3;!4. UDP-glucuronosyltransferase 1-6;!5. UDP-glucuronosyltransferase 1-7;!6. UDP-glucuronosyltransferase 1-8;!7. UDP-glucuronosyltransferase 1-9;!8. UDP-glucuronosyltransferase 1-10;!9. Cytochrome P450 2C9;!10. Cytochrome P450 1A2		50339185	7476	CHEMBL154	137720	Drugs.com Drug Page		HMDB0001923	C01517	D00118	NPS	PDRhealth Drug Page	PA450595	156391	46505508	RxList Drug Page	7258	DAP000968	Naproxen	ZINC000000105216	Aleve, Aleve PM, Aleve-D, Anaprox, EC-Naprosyn, Naprelan, Naprosyn, Sallus, Sudafed Sinus & Pain, Treximet, Vimovo	Naproxen	Approved, Vet approved	DB00788	InChI=1S/C14H14O3/c1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10/h3-9H,1-2H3,(H,15,16)/t9-/m0/s1	CMWTZPSULFXXJA-VIFPVBQESA-N	4	Naproxen is an NSAID used to treat rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, tendinitis, bursitis, acute gout, primary dysmenorrhea, and mild to moderate pain.	Although the over-the-counter (OTC) availability of naproxen provides convenience to patients, it also increases the likelihood of overdose.3 Thankfully, the extent of overdose is typically mild with adverse effects normally limited to drowsiness, lethargy, epigastric pain, nausea and vomiting.31213 Although there is no antidote for naproxen overdose, symptoms will typically subside with appropriate supportive care.12133Naproxen is classified as Category B during the first 2 trimesters of pregnancy, and as Category D during the third trimester.14 Naproxen is contraindicated in the 3rd trimester since it increases the risk of premature closure of the fetal ductus arteriosus and should be avoided in pregnant women starting at 30 weeks gestation.1213	Small Molecule	http://smpdb.ca/view/SMP0000120?highlight[compounds][]=DB00788&highlight[proteins][]=DB00788	Naproxen Action Pathway		AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.4579 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor		-4.83			3.18	-4.16	152°C	4.15	15.9 mg/L (at 25 °C)	1	Yes	3	1	No	2	-1	46.53 Å2	24.81 Å3	64.85 m3·mol-1	3	Yes	No	0.0511 mg/mL	2.99	-3.6	4.19	-4.8			
C18H18O2	Not Available	Not Available	266.34	[H]\C(C)=C(/C(=C(\[H])C)/C1=CC=C(O)C=C1)\C1=CC=C(O)C=C1	Solid	Not Available					40491	4518	CHEMBL1018	580857				C08090	D00898			PA164745534	667476	46504661	RxList Drug Page	3368	DAP001015	Dienestrol	ZINC000000001283		Dienestrol	Approved, Investigational	DB00890	InChI=1S/C18H18O2/c1-3-17(13-5-9-15(19)10-6-13)18(4-2)14-7-11-16(20)12-8-14/h3-12,19-20H,1-2H3/b17-3+,18-4+	NFDFQCUYFHCNBW-SCGPFSFSSA-N		Dienestrol is a non steroidal estrogen used to treat atrophic vaginitis and kraurosis vulvae.	Symptoms of overdose include nausea and vomiting, and withdrawal bleeding may occur in females.	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.8229 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					5.9	-4.95	233-234		3 mg/L (at 37 °C)	1	Yes	2	2	No	2	0	40.46 Å2	30.27 Å3	84.36 m3·mol-1	3	Yes	No	0.0123 mg/mL	4.83	-4.3	9.1	-6	P03372;!P04278	ESR1;!SHBG	1. Estrogen receptor alpha;!2. Sex hormone-binding globulin
C16H14O6	Not Available	Not Available	302.2788	COC1=C(O)C=C(C=C1)[C@@H]1CC(=O)C2=C(O)C=C(O)C=C2O1	Solid	Not Available					23418	28230	CHEMBL399121	65234			HMDB0005782	C01709		6JP	PDRhealth Drug Page	PA164742902	72281	46507998		1314255	DAP001306	Hesperetin	ZINC000000039092		Hesperetin	Experimental	DB01094	InChI=1S/C16H14O6/c1-21-13-3-2-8(4-10(13)18)14-7-12(20)16-11(19)5-9(17)6-15(16)22-14/h2-6,14,17-19H,7H2,1H3/t14-/m0/s1	AIONOLUJZLIMTK-AWEZNQCLSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Inhibitor	Non-substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	3.1455 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.60		227.5 °C		273 mg/L	1	Yes	6	3	No	3	0	96.22 Å2	29.3 Å3	77.75 m3·mol-1	2	Yes	No	0.138 mg/mL	2.68	-3.3	7.86	-4.6	P55157;!P35610;!P04278;!O75908	MTTP;!SOAT1;!SHBG;!SOAT2	1. Microsomal triglyceride transfer protein large subunit;!2. Sterol O-acyltransferase 1;!3. Sex hormone-binding globulin;!4. Sterol O-acyltransferase 2
C16H12O3	Not Available	Not Known	252.2647	COC1=CC=C(C=C1)C1C(=O)C2=CC=CC=C2C1=O	Solid	Not Available					50280155	133809	CHEMBL712	2112	Drugs.com Drug Page		HMDB0015257		D07457		PDRhealth Drug Page	PA164746467	2197	46504660	RxList Drug Page	17941	DAP001274	Anisindione	ZINC000100015486		Anisindione	Approved	DB01125	InChI=1S/C16H12O3/c1-19-11-8-6-10(7-9-11)14-15(17)12-4-2-3-5-13(12)16(14)18/h2-9,14H,1H3	XRCFXMGQEVUZFC-UHFFFAOYSA-N			An overdose is likely to cause abnormal bleeding, for which the symptoms include: bleeding from gums or nose, blood in urine or stools, excessive bleeding from minor cuts, patches of discoloration or bruises on the skin.	Small Molecule				AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Non-substrate	2.4052 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.88		155-156		79.8 mg/L	1	Yes	3	0	No	3	-1	43.37 Å2	26.3 Å3	71.7 m3·mol-1	2	Yes	No	0.0128 mg/mL	2.72	-4.3	4.55	-4.8	P38435	GGCX	1. Vitamin K-dependent gamma-carboxylase
C14H10MgO6	Not Available	Not Available	298.531	[Mg++].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O	Solid	Not Available						6640	CHEMBL2106755	58278			HMDB0015469	C07995				PA450300	54684589	46508713		52364		Magnesium_salicylate		Diurex, Doans	Magnesium salicylate	Experimental	DB01397	InChI=1S/2C7H6O3.Mg/c2*8-6-4-2-1-3-5(6)7(9)10;/h2*1-4,8H,(H,9,10);/q;;+2/p-2	MQHWFIOJQSCFNM-UHFFFAOYSA-L		Magnesium salicylate is an NSAID analgesic used in the symptomatic relief of mild to moderate muscular pain.	Not Available	Small Molecule	http://smpdb.ca/view/SMP0000698?highlight[compounds][]=DB01397&highlight[proteins][]=DB01397	Magnesium Salicylate Action Pathway		Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.3552 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	1	No	2	-1	60.36 Å2	12.38 Å3	46.13 m3·mol-1	2	Yes	No	0.0686 mg/mL	1.98	-3.6	2.79	-6.3	P35354;!P23219	PTGS2;!PTGS1	1. Prostaglandin G/H synthase 2;!2. Prostaglandin G/H synthase 1
C14H10O5	Not Available	The parent compound has an elimination half-life of about 1 hour. Salicylic acid (the active metabolite) biotransformation is saturated at anti-inflammatory doses of salsalate. Such capacity limited biotransformation results in an increase in the half-life of salicylic acid from 3.5 to 16 or more hours.	258.2262	OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O	Solid	Not Available					85244	9014	CHEMBL154111	4977	Drugs.com Drug Page		HMDB0015471		D00428		PDRhealth Drug Page	PA164745462	5161	46506882	RxList Drug Page	36108	DAP000734	Salsalate	ZINC000000002062		Salsalate	Approved	DB01399	InChI=1S/C14H10O5/c15-11-7-3-1-5-9(11)14(18)19-12-8-4-2-6-10(12)13(16)17/h1-8,15H,(H,16,17)	WVYADZUPLLSGPU-UHFFFAOYSA-N	4	Salsalate is a nonsteroidal anti-inflammatory agent used in the symptomatic relief of rheumatoid arthritis, osteoarthritis and related rheumatic disorders.	Death has followed ingestion of 10 to 30 g of salicylates in adults, but much larger amounts have been ingested without fatal outcome.	Small Molecule	http://smpdb.ca/view/SMP0000707?highlight[compounds][]=DB01399&highlight[proteins][]=DB01399	Salsalate Action Pathway		Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.4607 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							147 °C			1	Yes	4	2	No	2	-1	83.83 Å2	24.93 Å3	67.1 m3·mol-1	4	Yes	No	0.246 mg/mL	3.64	-3	3.4	-4.3			
C14H12O3	Not Available	Not Available	228.2433	COC1=CC(O)=C(C=C1)C(=O)C1=CC=CC=C1	Solid	Not Available					50253134	34283	CHEMBL1625	4471			HMDB0015497	C14285	D05309			PA164742933	4632	46508419		32673		Oxybenzone	ZINC000000136138	Meijer	Oxybenzone	Approved, Investigational	DB01428	InChI=1S/C14H12O3/c1-17-11-7-8-12(13(15)9-11)14(16)10-5-3-2-4-6-10/h2-9,15H,1H3	DXGLGDHPHMLXJC-UHFFFAOYSA-N	4	Oxybenzone is a sunscreen agent found in sunscreens that absorbs UV rays.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.6986 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				155 °C at 5.00E+00 mm Hg	3.79		65.5 °C			1	Yes	3	1	No	2	-1	46.53 Å2	23.96 Å3	65.08 m3·mol-1	3	Yes	No	0.128 mg/mL	3.62	-3.2	7.07	-4.8	P06401;!P10275;!P03372;!Q92731	PGR;!AR;!ESR1;!ESR2	1. Progesterone receptor;!2. Androgen receptor;!3. Estrogen receptor alpha;!4. Estrogen receptor beta
C9H8O4	Not Available	Not Available	180.1574	OC(=O)\C=C\C1=C(O)C=C(O)C=C1	Solid	Not Available							CHEMBL1235981	393925			HMDB0126377			SN1			446611	46504653					ZINC000002043461		2,4-Dihydroxy-Trans Cinnamic Acid	Experimental	DB01704	InChI=1S/C9H8O4/c10-7-3-1-6(8(11)5-7)2-4-9(12)13/h1-5,10-11H,(H,12,13)/b4-2+	HGEFWFBFQKWVMY-DUXPYHPUSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.0077 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	3	No	1	-1	77.76 Å2	17.11 Å3	47.02 m3·mol-1	2	Yes	No	1.59 mg/mL	1.53	-2	3.64	-5.6	P17538	CTRB1	1. Chymotrypsinogen B
C22H16BrNO4	Not Available	Not Available	438.271	[H]N(\C(=C/C1=CC=C(OC2=CC=CC=C2Br)C=C1)C(O)=O)C(=O)C1=CC=CC=C1	Solid	Not Available					50166405		CHEMBL188442	571325						PH7			657131	46508533							(2Z)-2-(Benzoylamino)-3-[4-(2-bromophenoxy)phenyl]acrylic acid	Experimental	DB01720	InChI=1S/C22H16BrNO4/c23-18-8-4-5-9-20(18)28-17-12-10-15(11-13-17)14-19(22(26)27)24-21(25)16-6-2-1-3-7-16/h1-14H,(H,24,25)(H,26,27)/b19-14-	WLPJLQNKCJWAFL-RGEXLXHISA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.2503 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	2	Yes	3	-1	75.63 Å2	40.22 Å3	110.66 m3·mol-1	6	Yes	No	0.000356 mg/mL	4.92	-6.1	3.05	-3.7	P26662	Not Available	1. Genome polyprotein
C21H16FNO7	Not Available	Not Available	413.3526	COC(=O)C1=C(O)C=CC=C1OC\C=C\C1=CC(C2=CC(=NO2)C(O)=O)=C(F)C=C1	Solid	Not Available					13990		CHEMBL117869	394932						234			447994	46506116					ZINC000002047375		5-(2-Fluoro-5-{(1E)-3-[3-hydroxy-2-(methoxycarbonyl)phenoxy]-1-propen-1-yl}phenyl)-1,2-oxazole-3-carboxylic acid	Experimental	DB02014	InChI=1S/C21H16FNO7/c1-28-21(27)19-16(24)5-2-6-17(19)29-9-3-4-12-7-8-14(22)13(10-12)18-11-15(20(25)26)23-30-18/h2-8,10-11,24H,9H2,1H3,(H,25,26)/b4-3+	QKHWJUMLYAYZFS-ONEGZZNKSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.4032 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	6	2	Yes	3	-1	119.09 Å2	40.09 Å3	105.01 m3·mol-1	8	Yes	No	0.0337 mg/mL	4.62	-4.1	3.9	-3.2			
C15H12O7	Not Available	Not Available	304.2516	O[C@@H]1[C@H](OC2=CC(O)=CC(O)=C2C1=O)C1=CC=C(O)C(O)=C1	Solid	Not Available					212435	17948	CHEMBL66	388626				C01617		DQH			439533	46508033				Taxifolin	ZINC000100018343		Taxifolin	Experimental	DB02224	InChI=1S/C15H12O7/c16-7-4-10(19)12-11(5-7)22-15(14(21)13(12)20)6-1-2-8(17)9(18)3-6/h1-5,14-19,21H/t14-,15+/m0/s1	CXQWRCVTCMQVQX-LSDHHAIUSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	3.0200 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					0.95					1	Yes	7	5	No	3	0	127.45 Å2	29.03 Å3	74.61 m3·mol-1	1	Yes	No	1.16 mg/mL	1.82	-2.4	7.74	-4			
C10H6O5	Not Available	Not Available	206.1516	OC1=CC2=C(C(O)=C1)C(=O)C=C(O)C2=O	Solid	Not Available						42646	CHEMBL1232770	14346744				C18012		FLV			160478	46505645							Flaviolin	Experimental	DB02521	InChI=1S/C10H6O5/c11-4-1-5-9(6(12)2-4)7(13)3-8(14)10(5)15/h1-3,11-12,14H	RROPNRTUMVVUED-UHFFFAOYSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	-	Inhibitor	Non-inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.5615 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	3	No	2	-1	94.83 Å2	18.31 Å3	52.11 m3·mol-1	0	Yes	No	2.4 mg/mL	1.02	-1.9	4.78	-5.6	Q4R2T2;!Q9FCA6	Not Available;!cyp158a2	1. Prenyltransferase;!2. Putative cytochrome P450
C14H12O3	Not Available	Not Available	228.2433	OC1=CC=C(\C=C\C2=CC(O)=CC(O)=C2)C=C1	Solid	Not Available					23926	45713	CHEMBL165	392875			HMDB0003747	C03582		STL		PA165291838	445154	46504705		1000492	DNC001205	Resveratrol	ZINC000000006787		Resveratrol	Investigational	DB02709	InChI=1S/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1+	LUKBXSAWLPMMSZ-OWOJBTEDSA-N	4		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.6791 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							254 °C			1	Yes	3	3	No	2	0	60.69 Å2	24.55 Å3	67.46 m3·mol-1	2	Yes	No	0.0688 mg/mL	3.4	-3.5	8.49	-6.2			
C14H16BNO4	Not Available	Not Available	273.092	CCOC1=C(C(=O)NCB(O)O)C2=C(C=CC=C2)C=C1	Solid	Not Available					39812		CHEMBL1234635	4451044						NBF			5288987	46508531					ZINC000169748477		[(2-Ethoxy-1-Naphthoyl)Amino]Methylboronic Acid	Experimental	DB02841	InChI=1S/C14H16BNO4/c1-2-20-12-8-7-10-5-3-4-6-11(10)13(12)14(17)16-9-15(18)19/h3-8,18-19H,2,9H2,1H3,(H,16,17)	VGXJNGVFESCMME-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3963 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	3	No	2	0	78.79 Å2	28.92 Å3	71.55 m3·mol-1	5	Yes	No	0.0815 mg/mL	2.21	-3.5	8.68	-1.4	P62593;!P62594;!Q9L5C8	bla;!bla;!blaCTX-M-9a	1. Beta-lactamase TEM;!2. Beta-lactamase TEM;!3. Beta-lactamase
C15H13BrFNO2	Not Available	Not Available	338.172	[H]N([C@H](C)C1=CC=C(Br)C=C1)C(=O)C1=C(O)C=CC(F)=C1	Solid	Not Available					50078284		CHEMBL38912	4593573						BFS			5496910	46508661							N-[(1R)-1-(4-Bromophenyl)ethyl]-5-fluoro-2-hydroxybenzamide	Experimental	DB02880	InChI=1S/C15H13BrFNO2/c1-9(10-2-4-11(16)5-3-10)18-15(20)13-8-12(17)6-7-14(13)19/h2-9,19H,1H3,(H,18,20)/t9-/m1/s1	KFTNEILVDDUXGR-SECBINFHSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.8741 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	2	No	2	0	49.33 Å2	30.16 Å3	78.88 m3·mol-1	3	Yes	No	0.0106 mg/mL	4.45	-4.5	7.93	-1.7			
C8H9NO2	Not Available	Not Available	151.1626	COC1=CC(=CC=C1)C(N)=O	Solid	Not Available					50106188		CHEMBL123978	88942						3MB			98487	46508871					ZINC000004521662		3-Methoxybenzamide	Experimental	DB03073	InChI=1S/C8H9NO2/c1-11-7-4-2-3-6(5-7)8(9)10/h2-5H,1H3,(H2,9,10)	VKPLPDIMEREJJF-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.1222 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	2	1	No	1	0	52.32 Å2	15.33 Å3	41.6 m3·mol-1	2	Yes	No	4.58 mg/mL	0.67	-1.5	14.16	-0.48			
C18H17NO4	Not Available	Not Available	311.3319	COC1=CC(OC)=C(\C=C2\C(=O)NC3=CC=CC=C23)C(OC)=C1	Solid	Not Available					50263829		CHEMBL489156	4450729						IC1			5288600	46509166					ZINC000000136945		IC261	Experimental	DB03083	InChI=1S/C18H17NO4/c1-21-11-8-16(22-2)14(17(9-11)23-3)10-13-12-6-4-5-7-15(12)19-18(13)20/h4-10H,1-3H3,(H,19,20)/b13-10+	JBJYTZXCZDNOJW-JLHYYAGUSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.7309 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	1	No	3	0	56.79 Å2	32.57 Å3	89.12 m3·mol-1	4	Yes	No	0.0104 mg/mL	2.79	-4.5	11.31	-2	P78368	CSNK1G2	1. Casein kinase I isoform gamma-2
C15H12O4	Not Available	Not Available	256.2534	OC1=CC=C(\C=C\C(=O)C2=C(O)C=C(O)C=C2)C=C1	Solid	Not Available					50042944	310312	CHEMBL129795	553829			HMDB0037316	C08650		HCC			638278	46506198				Isoliquiritigenin	ZINC000003869608		Isoliquiritigenin	Experimental	DB03285	InChI=1S/C15H12O4/c16-11-4-1-10(2-5-11)3-8-14(18)13-7-6-12(17)9-15(13)19/h1-9,16-17,19H/b8-3+	DXDRHHKMWQZJHT-FPYGCLRLSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.0091 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	3	No	2	-1	77.76 Å2	26.66 Å3	72.82 m3·mol-1	3	Yes	No	0.0551 mg/mL	3.63	-3.7	7.11	-6.4			
C15H12O5	Not Available	Not Available	272.2528	[H][C@]1(CC(=O)C2=C(O1)C=C(O)C=C2O)C1=CC=C(O)C=C1	Solid	Not Available					23419	17846	CHEMBL9352	388383			HMDB0002670	C00509		NAR		PA151958361	439246	46508043		1368173		Naringenin	ZINC000000156701		Naringenin	Experimental	DB03467	InChI=1S/C15H12O5/c16-9-3-1-8(2-4-9)13-7-12(19)15-11(18)5-10(17)6-14(15)20-13/h1-6,13,16-18H,7H2/t13-/m0/s1	FTVWIRXFELQLPI-ZDUSSCGKSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	3.5110 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.52		251 °C			1	Yes	5	3	No	3	0	86.99 Å2	27.31 Å3	71.29 m3·mol-1	1	Yes	No	0.214 mg/mL	2.84	-3.1	7.86	-5			
C9H10O2	Not Available	Not Available	150.1745	COC1=C(O)C=CC(C=C)=C1	Solid	Not Available						42438	CHEMBL1232595	325			HMDB0013744	C17883		4M4			332	46506755				2-Methoxy-4-vinylphenol	ZINC000001849800		4-Vinylguaiacol	Experimental	DB03514	InChI=1S/C9H10O2/c1-3-7-4-5-8(10)9(6-7)11-2/h3-6,10H,1H2,2H3	YOMSJEATGXXYPX-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.0980 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	2	1	No	1	0	29.46 Å2	15.99 Å3	44.19 m3·mol-1	2	Yes	Yes	7.42 mg/mL	2.25	-1.3	10.03	-4.9			
C15H12O4	Not Available	Not Available	256.2534	OC1=CC=C(C=C1)[C@@H]1CC(=O)C2=CC=C(O)C=C2O1	Solid	Not Available					50241408	28777	CHEMBL252642	102790				C09762		DFV			114829	46505285					ZINC000000985403		5-deoxyflavanone	Experimental	DB03601	InChI=1S/C15H12O4/c16-10-3-1-9(2-4-10)14-8-13(18)12-6-5-11(17)7-15(12)19-14/h1-7,14,16-17H,8H2/t14-/m0/s1	FURUXTVZLHCCNA-AWEZNQCLSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	3.1675 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	2	No	3	0	66.76 Å2	26.41 Å3	69.31 m3·mol-1	1	Yes	No	0.133 mg/mL	2.49	-3.3	7.79	-4.9			
C24H24O4	Not Available	Not Available	376.445	CC1=CC(OCC(O)=O)=CC(C)=C1CC1=CC=C(O)C(CC2=CC=CC=C2)=C1	Solid	Not Available								394946						G24			448011	46504743							GC-24	Experimental	DB03788	InChI=1S/C24H24O4/c1-16-10-21(28-15-24(26)27)11-17(2)22(16)14-19-8-9-23(25)20(13-19)12-18-6-4-3-5-7-18/h3-11,13,25H,12,14-15H2,1-2H3,(H,26,27)	JYHIGYLGYNCMGI-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1148 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	2	Yes	3	-1	66.76 Å2	41.06 Å3	110.14 m3·mol-1	7	No	No	0.000404 mg/mL	6.2	-6	3.92	-4.9	P10828	THRB	1. Thyroid hormone receptor beta
C15H12O3	Not Available	Not Available	240.254	OC1=CC2=C(C=C1)C(=O)C[C@H](O2)C1=CC=CC=C1	Solid	Not Available						41888	CHEMBL402744	600255						DDC			688857	46507009					ZINC000000057920		(2S)-7-hydroxyflavanone	Experimental	DB04274	InChI=1S/C15H12O3/c16-11-6-7-12-13(17)9-14(18-15(12)8-11)10-4-2-1-3-5-10/h1-8,14,16H,9H2/t14-/m0/s1	SWAJPHCXKPCPQZ-AWEZNQCLSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.8753 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	1	No	3	0	46.53 Å2	25.37 Å3	67.33 m3·mol-1	1	Yes	No	0.111 mg/mL	2.79	-3.3	7.8	-4.9			
C15H12O3	Not Available	Not Available	240.254	OC1=CC=C(C=C1)[C@@H]1CC(=O)C2=CC=CC=C2O1	Solid	Not Available						41965		600257						DFL			688859	46508379					ZINC000000057922		4'-Hydroxyflavanone	Experimental	DB04429	InChI=1S/C15H12O3/c16-11-7-5-10(6-8-11)15-9-13(17)12-3-1-2-4-14(12)18-15/h1-8,15-16H,9H2/t15-/m0/s1	ZLHVIYHWWQYJID-HNNXBMFYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.8753 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	1	No	3	0	46.53 Å2	25.37 Å3	67.33 m3·mol-1	1	Yes	No	0.0992 mg/mL	2.79	-3.4	9.47	-4.9	P04278	SHBG	1. Sex hormone-binding globulin
C10H12O5	Not Available	Not Available	212.1993	COC1=CC(\C=C\C(O)O)=CC(O)=C1O	Solid	Not Available								4450689						HFL			5288545	46506497					ZINC000008206678		5-(3,3-Dihydroxypropeny)-3-Methoxy-Benzene-1,2-Diol	Experimental	DB04449	InChI=1S/C10H12O5/c1-15-8-5-6(2-3-9(12)13)4-7(11)10(8)14/h2-5,9,11-14H,1H3/b3-2+	QQVLKPZAOPJJCB-NSCUHMNNSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.9800 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	4	No	1	0	90.15 Å2	21.07 Å3	54.65 m3·mol-1	3	Yes	No	2.54 mg/mL	0.69	-1.9	9.46	-3.9			
C10H6O3	Not Available	Not Available	174.1528	OC1=CC(=O)C2=CC=CC=C2C1=O	Solid	Not Available					50049066	44401	CHEMBL240963	10430995				C10368		NQ			6755	46509125				Lawsone	ZINC000004632115		Lawsone	Experimental	DB04744	InChI=1S/C10H6O3/c11-8-5-9(12)10(13)7-4-2-1-3-6(7)8/h1-5,12H	CSFWPUWCSPOLJW-UHFFFAOYSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Non-substrate	3.0215 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	3	1	No	2	-1	54.37 Å2	16.42 Å3	48.15 m3·mol-1	0	Yes	No	1.8 mg/mL	0.98	-2	5.32	-5.4			
C22H24O4S	Not Available	Not Available	384.49	CSC1=CC=C(C=C1)C(=O)\C=C\C1=CC(C)=C(OC(C)(C)C(O)=O)C(C)=C1	Solid	Not Available							CHEMBL3707395	8040573									9864881	347827716				Elafibranor	ZINC000114643710		Elafibranor	Investigational	DB05187	InChI=1S/C22H24O4S/c1-14-12-16(13-15(2)20(14)26-22(3,4)21(24)25)6-11-19(23)17-7-9-18(27-5)10-8-17/h6-13H,1-5H3,(H,24,25)/b11-6+	AFLFKFHDSCQHOL-IZZDOVSWSA-N	2		Not Available	Small Molecule																																			1	No	4	1	No	2	-1	63.6 Å2	43.14 Å3	111.47 m3·mol-1	7	No	No	0.000228 mg/mL	5.87	-6.2	4	-4.9	Q07869;!Q03181;!P37231	PPARA;!PPARD;!PPARG	1. Peroxisome proliferator-activated receptor alpha;!2. Peroxisome proliferator-activated receptor delta;!3. Peroxisome proliferator-activated receptor gamma
C27H30O6	Not Available	Not Available	450.5235	CC(C)=CCOC1=CC=C(\C=C\C(=O)C2=C(OCC(O)=O)C=C(OCC=C(C)C)C=C2)C=C1	Solid	Not Available	P16152	CBR1	1. Carbonyl reductase [NADPH] 1				CHEMBL1441961	4445402			HMDB0042013						5282219	175426956				Sofalcone	ZINC000003831462		Sofalcone	Investigational	DB05197	InChI=1S/C27H30O6/c1-19(2)13-15-31-22-8-5-21(6-9-22)7-12-25(28)24-11-10-23(32-16-14-20(3)4)17-26(24)33-18-27(29)30/h5-14,17H,15-16,18H2,1-4H3,(H,29,30)/b12-7+	GFWRVVCDTLRWPK-KPKJPENVSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.6850 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	6	1	No	2	-1	82.06 Å2	51.22 Å3	130.59 m3·mol-1	12	No	No	0.000674 mg/mL	5.62	-5.8	3.22	-4.4			
C18H22O6	Not Available	Not Available	334.3637	COC1=CC(=CC(OC)=C1OC)[C@@H](O)CC1=CC(O)=C(OC)C=C1	Solid	Not Available								90508									100154	175426964				Combretastatin			CA4P	Investigational	DB05284	InChI=1S/C18H22O6/c1-21-15-6-5-11(8-14(15)20)7-13(19)12-9-16(22-2)18(24-4)17(10-12)23-3/h5-6,8-10,13,19-20H,7H2,1-4H3/t13-/m0/s1	LGZKGOGODCLQHG-ZDUSSCGKSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	2.5923 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	6	2	No	2	0	77.38 Å2	34.48 Å3	89.75 m3·mol-1	7	Yes	No	0.0545 mg/mL	2.34	-3.8	9.99	-3.1	P07437	TUBB	1. Tubulin beta chain
C19H20N2O2	Not Available	Not Available	308.3743	[H]\C(=C1\CCCN=C1C1=CN=CC=C1)C1=C(OC)C=C(OC)C=C1	Solid	Not Available	P05177;!P05181	CYP1A2;!CYP2E1	1. Cytochrome P450 1A2;!2. Cytochrome P450 2E1		50061564		CHEMBL134713	4470526						ZY7			5310985	175427027				GTS-21	ZINC000000000860		GTS-21	Investigational	DB05708	InChI=1S/C19H20N2O2/c1-22-17-8-7-14(18(12-17)23-2)11-15-5-4-10-21-19(15)16-6-3-9-20-13-16/h3,6-9,11-13H,4-5,10H2,1-2H3/b15-11+	RPYWXZCFYPVCNQ-RVDMUPIBSA-N	2		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	2.5296 LD50, mol/kg	Inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	0	No	3	0	43.71 Å2	33.96 Å3	91.83 m3·mol-1	4	Yes	No	0.00683 mg/mL	2.96	-4.6		4.46	P36544	CHRNA7	1. Neuronal acetylcholine receptor subunit alpha-7
C20H17F3N2O4	Not Available	Not Available	406.361	COC1=CC=CC2=C1C(O)=C(C(=O)N(C)C1=CC=C(C=C1)C(F)(F)F)C(=O)N2C	Solid	Not Available							CHEMBL2107784	11444963									54682876	175427045				Tasquinimod	ZINC000000602397		Tasquinimod	Investigational	DB05861	InChI=1S/C20H17F3N2O4/c1-24(12-9-7-11(8-10-12)20(21,22)23)18(27)16-17(26)15-13(25(2)19(16)28)5-4-6-14(15)29-3/h4-10,26H,1-3H3	ONDYALNGTUAJDX-UHFFFAOYSA-N	3		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.7663 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	1	No	3	-1	70.08 Å2	36.89 Å3	100.19 m3·mol-1	4	Yes	No	0.00911 mg/mL	2.31	-4.6	4.73	-2.4			
C17H18O2	Not Available	Due to the insufficient data about the elimination phase, the terminal half-life of tapinarof cannot be determined.3	254.329	CC(C)C1=C(O)C=C(\C=C\C2=CC=CC=C2)C=C1O	Solid	The Vss of tapinarof is estimated to be from 1270 to 1500 mL/kg.3	P05177;!P08684;!P11712;!P33261;!P10635	CYP1A2;!CYP3A4;!CYP2C9;!CYP2C19;!CYP2D6	1. Cytochrome P450 1A2;!2. Cytochrome P450 3A4;!3. Cytochrome P450 2C9;!4. Cytochrome P450 2C19;!5. Cytochrome P450 2D6				CHEMBL259571	4943924														3,5-Dihydroxy-4-isopropyl-trans-stilbene	ZINC000005761533		Tapinarof	Approved, Investigational	DB06083	InChI=1S/C17H18O2/c1-12(2)17-15(18)10-14(11-16(17)19)9-8-13-6-4-3-5-7-13/h3-12,18-19H,1-2H3/b9-8+	ZISJNXNHJRQYJO-CMDGGOBGSA-N	3	Tapinarof is a therapeutic aryl hydrocarbon receptor-modulating agent (TAMA) indicated for the treatment of adult psoriasis.	Long-term carcinogenicity studies were conducted in mice (daily topical administration at doses of 0.5, 1.5, and 3% tapinarof cream) and in rats (subcutaneous administration at doses of 0.1, 0.3, and 1 mg/kg/day tapinarof). No drug-related neoplasms were noted in mice after 98 (females) to 102 (males) weeks of daily topical administration at doses up to 3% tapinarof cream (44 times the MRHD based on AUC comparisons). No drug-related neoplasms were noted in female rats after 83 weeks of daily subcutaneous administration at up to 1 mg/kg/day tapinarof (9 times the MRHD based on AUC comparisons).11Tapinarof revealed no evidence of mutagenicity or clastogenicity in an Ames assay, an in vitro mammalian chromosomal aberration assay, an in vitro mouse lymphoma assay, and two in vivo micronucleus assays in mice and rats.11Tapinarof did not impair female fertility at subcutaneous doses up to 30 mg/kg/day (268 times the MRHD based on AUC comparisons).11	Small Molecule																																			1	Yes	2	2	No	2	0	40.46 Å2	29.58 Å3	79.67 m3·mol-1	3	Yes	No	0.0339 mg/mL	4.95	-3.9	9.19	-5.9	P35869	AHR	1. Aryl hydrocarbon receptor
C23H24O6	Not Available	Not Available	396.439	COC1=CC=C(\C=C\C(\O)=C\C(=O)\C=C\C2=CC(OC)=C(OC)C=C2)C=C1OC	Solid	Not Available							CHEMBL128748	4978553														Dimethylcurcumin	ZINC000100007120		Dimethylcurcumin	Investigational	DB06133	InChI=1S/C23H24O6/c1-26-20-11-7-16(13-22(20)28-3)5-9-18(24)15-19(25)10-6-17-8-12-21(27-2)23(14-17)29-4/h5-15,24H,1-4H3/b9-5+,10-6+,18-15-	ZMGUKFHHNQMKJI-CIOHCNBKSA-N	2		Not Available	Small Molecule																																			1	Yes	6	1	No	2	0	74.22 Å2	44.04 Å3	115.09 m3·mol-1	9	Yes	No	0.00141 mg/mL	4.05	-5.4	9.04	-4.3	P10275	AR	1. Androgen receptor
C13H11NO3	Not Available	Not Available	229.235	NC1=CC(O)=C(C=C1)C(=O)OC1=CC=CC=C1	Solid	Not Available						114203	CHEMBL1200868	8290															ZINC000000119905		Phenyl aminosalicylate	Approved	DB06807	InChI=1S/C13H11NO3/c14-9-6-7-11(12(15)8-9)13(16)17-10-4-2-1-3-5-10/h1-8,15H,14H2	DNVVZWSVACQWJE-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	Yes	3	2	No	2	0	72.55 Å2	23.52 Å3	64.54 m3·mol-1	3	Yes	No	0.173 mg/mL	3.15	-3.1	9.87	2.32			
C18H12Br2N2O3	Not Available	Not Available	464.107	OC1=C(Br)C=C(\C=N\NC(=O)C2=CC=C3C=CC=CC3=C2)C(O)=C1Br	Solid	Not Available					31930		CHEMBL492513	24705308						2BC			46937037	99443420					ZINC000040422706		N'-[(1E)-(3,5-dibromo-2,4-dihydroxyphenyl)methylidene]naphthalene-2-carbohydrazide	Experimental	DB06949	InChI=1S/C18H12Br2N2O3/c19-14-8-13(16(23)15(20)17(14)24)9-21-22-18(25)12-6-5-10-3-1-2-4-11(10)7-12/h1-9,23-24H,(H,22,25)/b21-9+	LVLHTGJPIBVDTM-ZVBGSRNCSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.4085 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	3	No	3	-1	81.92 Å2	39.33 Å3	103.89 m3·mol-1	3	Yes	No	0.00463 mg/mL	4.88	-5	6.44	0.33	Q5G940	fabZ	1. 3-hydroxyacyl-[acyl-carrier-protein] dehydratase FabZ
C18H14ClN3O4	Not Available	Not Available	371.774	CC(=O)C1=CC=C(NC(=O)C2=C(NN=C2)C2=CC(Cl)=C(O)C=C2O)C=C1	Solid	Not Available					15393		CHEMBL200469	20120290						2D7			5327103	99443427					ZINC000016051845		N-(4-ACETYLPHENYL)-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE	Experimental	DB06956	InChI=1S/C18H14ClN3O4/c1-9(23)10-2-4-11(5-3-10)21-18(26)13-8-20-22-17(13)12-6-14(19)16(25)7-15(12)24/h2-8,24-25H,1H3,(H,20,22)(H,21,26)	BTTFXKUTBNGQTP-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.9926 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	4	No	3	-1	115.31 Å2	35.85 Å3	99.46 m3·mol-1	4	Yes	No	0.0286 mg/mL	2.49	-4.1	7.53	1.51	P07900	HSP90AA1	1. Heat shock protein HSP 90-alpha
C15H12Br2N2O4	Not Available	Not Available	444.075	COC1=CC=C(C=C1)C(=O)N\N=C\C1=CC(Br)=C(O)C(Br)=C1O	Solid	Not Available					31931		CHEMBL492514	21824324						2RB			16475583	99443449					ZINC000009190152		N'-[(1E)-(3,5-dibromo-2,4-dihydroxyphenyl)methylidene]-4-methoxybenzohydrazide	Experimental	DB06978	InChI=1S/C15H12Br2N2O4/c1-23-10-4-2-8(3-5-10)15(22)19-18-7-9-6-11(16)14(21)12(17)13(9)20/h2-7,20-21H,1H3,(H,19,22)/b18-7+	BMGXNERTVNWBJG-CNHKJKLMSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.4245 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	3	No	2	-1	91.15 Å2	36.36 Å3	93.91 m3·mol-1	4	Yes	No	0.0251 mg/mL	3.74	-4.2	6.44	0.011	Q5G940	fabZ	1. 3-hydroxyacyl-[acyl-carrier-protein] dehydratase FabZ
C14H9Br3N2O3	Not Available	Not Available	492.945	OC1=C(Br)C=C(\C=N\NC(=O)C2=CC=CC(Br)=C2)C(O)=C1Br	Solid	Not Available					31928		CHEMBL522157	21824400						3BE			16478818	99443515					ZINC000009668311		3-bromo-N'-[(1E)-(3,5-dibromo-2,4-dihydroxyphenyl)methylidene]benzohydrazide	Experimental	DB07044	InChI=1S/C14H9Br3N2O3/c15-9-3-1-2-7(4-9)14(22)19-18-6-8-5-10(16)13(21)11(17)12(8)20/h1-6,20-21H,(H,19,22)/b18-6+	VOWXAXNVAGLOGM-NGYBGAFCSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.4135 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	3	No	2	-1	81.92 Å2	36.75 Å3	95.07 m3·mol-1	3	Yes	No	0.00844 mg/mL	4.66	-4.8	6.44	-0.21	Q5G940	fabZ	1. 3-hydroxyacyl-[acyl-carrier-protein] dehydratase FabZ
C20H16N2O3	Not Available	Not Available	332.3526	COC1=CC(=CC=C1O)C1=CC2=C(C=C1)\C(=C\C1=CC=CN1)C(=O)N2	Solid	Not Available					14649		CHEMBL202930	8301349						43A			10125830	99443549					ZINC000014956244		(3Z)-6-(4-HYDROXY-3-METHOXYPHENYL)-3-(1H-PYRROL-2-YLMETHYLENE)-1,3-DIHYDRO-2H-INDOL-2-ONE	Experimental	DB07078	InChI=1S/C20H16N2O3/c1-25-19-10-13(5-7-18(19)23)12-4-6-15-16(11-14-3-2-8-21-14)20(24)22-17(15)9-12/h2-11,21,23H,1H3,(H,22,24)/b16-11-	AYSXURJZVXBSRV-WJDWOHSUSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	2.8881 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	3	No	4	0	74.35 Å2	36.55 Å3	97.95 m3·mol-1	3	Yes	No	0.0458 mg/mL	3.45	-3.9	9.82	-2.1	O14757	CHEK1	1. Serine/threonine-protein kinase Chk1
C10H10O4	Not Available	Not Available	194.184	COC1=C(O)C=C(\C=C\C(O)=O)C=C1	Solid	Not Available					50241245	27794	CHEMBL233295	643318			HMDB0000955	C10470		4FE			736186	99443580				Isoferulic_acid	ZINC000000156055		Isoferulic acid	Experimental	DB07109	InChI=1S/C10H10O4/c1-14-9-4-2-7(6-8(9)11)3-5-10(12)13/h2-6,11H,1H3,(H,12,13)/b5-3+	QURCVMIEKCOAJU-HWKANZROSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.4314 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	2	No	1	-1	66.76 Å2	19.36 Å3	51.5 m3·mol-1	3	Yes	No	0.871 mg/mL	1.67	-2.4	3.58	-4.9	Q55813	Not Available	1. O-methyltransferase
C15H9BrO3	Not Available	Not Available	317.134	OC1=CC=C(C=C1)C1=C(Br)C2=C(C=C(O)C=C2)C1=O	Solid	Not Available					50166754		CHEMBL190467	8461931						789			10286462	99443701					ZINC000016051727		3-BROMO-6-HYDROXY-2-(4-HYDROXYPHENYL)-1H-INDEN-1-ONE	Experimental	DB07230	InChI=1S/C15H9BrO3/c16-14-11-6-5-10(18)7-12(11)15(19)13(14)8-1-3-9(17)4-2-8/h1-7,17-18H	DHPCBFMFERFZLR-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.6950 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	2	No	3	0	57.53 Å2	28.43 Å3	76.77 m3·mol-1	1	Yes	No	0.0266 mg/mL	3.3	-4.1	7.55	-6.5			
C21H22O4	Not Available	Not Available	338.397	COC1=CC(O)=C(C=C1CC=C(C)C)C(=O)\C=C\C1=CC=C(O)C=C1	Solid	Not Available					246523			4479431						BVL			5321765	99443971					ZINC000019816069		(2E)-1-[2-hydroxy-4-methoxy-5-(3-methylbut-2-en-1-yl)phenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one	Experimental	DB07500	InChI=1S/C21H22O4/c1-14(2)4-8-16-12-18(20(24)13-21(16)25-3)19(23)11-7-15-5-9-17(22)10-6-15/h4-7,9-13,22,24H,8H2,1-3H3/b11-7+	ZUGCRBMNFSAUOC-YRNVUSSQSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.2755 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	2	No	2	-1	66.76 Å2	37.26 Å3	101.54 m3·mol-1	6	No	No	0.00322 mg/mL	5.5	-5	7.07	-4.9	Q9NZK7	PLA2G2E	1. Group IIE secretory phospholipase A2
C18H17NO5	Not Available	Not Available	327.3313	COC1=CC=C(\C=C\C(=O)NC2=CC=CC=C2C(O)=O)C=C1OC	Solid	Not Available	P08684;!P11712	CYP3A4;!CYP2C9	1. Cytochrome P450 3A4;!2. Cytochrome P450 2C9		21613	77572	CHEMBL415324	4445411					D02027	D27			5282230	99444086		57330		Tranilast	ZINC000000000797		Tranilast	Investigational	DB07615	InChI=1S/C18H17NO5/c1-23-15-9-7-12(11-16(15)24-2)8-10-17(20)19-14-6-4-3-5-13(14)18(21)22/h3-11H,1-2H3,(H,19,20)(H,21,22)/b10-8+	NZHGWWWHIYHZNX-CSKARUKUSA-N	4		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.4428 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	2	No	2	-1	84.86 Å2	34.2 Å3	91.52 m3·mol-1	6	Yes	No	0.0084 mg/mL	3.56	-4.6	3.55	-2			
C15H10O5	Not Available	Not Available	270.2369	CC1=CC(O)=C2C(=O)C3=C(C=C(O)C=C3O)C(=O)C2=C1	Solid	Not Available					11318	42223	CHEMBL289277	3107			HMDB0035214	C10343		EMO			3220	99444186				Emodin	ZINC000003824868		Emodin	Investigational	DB07715	InChI=1S/C15H10O5/c1-6-2-8-12(10(17)3-6)15(20)13-9(14(8)19)4-7(16)5-11(13)18/h2-5,16-18H,1H3	RHMXXJGYXNZAPX-UHFFFAOYSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.5826 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	3	No	3	-1	94.83 Å2	26.58 Å3	72.13 m3·mol-1	0	Yes	No	0.222 mg/mL	3.82	-3.1	7.29	-5.4			
C20H14O5	Not Available	Not Available	334.3222	OC(=O)C1=C(C=CC=C1)C1C2=CC=C(O)C=C2OC2=CC(O)=CC=C12	Solid	Not Available						42492	CHEMBL1232699	61512						FDS			68205	99444235				Fluorescein	ZINC000005847030		Fluorescin	Experimental	DB07764	InChI=1S/C20H14O5/c21-11-5-7-15-17(9-11)25-18-10-12(22)6-8-16(18)19(15)13-3-1-2-4-14(13)20(23)24/h1-10,19,21-22H,(H,23,24)	MURGITYSBWUQTI-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	3.6405 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	3	No	4	-1	86.99 Å2	33.88 Å3	91.84 m3·mol-1	2	Yes	No	0.0159 mg/mL	4.06	-4.3	3.89	-3.7	P01857	IGHG1	1. Ig gamma-1 chain C region
C10H10O4	Not Available	Not Available	194.184	COC1=CC(\C=C\C(O)=O)=CC=C1O	Solid	Not Available					50214744	17620	CHEMBL32749	393368			HMDB0000954	C01494		FER			445858	99444238		1368647		Ferulic_acid	ZINC000000058258		Ferulic acid	Experimental	DB07767	InChI=1S/C10H10O4/c1-14-9-6-7(2-4-8(9)11)3-5-10(12)13/h2-6,11H,1H3,(H,12,13)/b5-3+	KSEBMYQBYZTDHS-HWKANZROSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.4314 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	2	No	1	-1	66.76 Å2	19.18 Å3	51.5 m3·mol-1	3	Yes	No	0.906 mg/mL	1.67	-2.3	3.58	-4.9	P51584;!P10478;!D2YW37;!Q55813	xynY;!xynZ;!Not Available;!Not Available	1. Endo-1,4-beta-xylanase Y;!2. Endo-1,4-beta-xylanase Z;!3. Est1e;!4. O-methyltransferase
C15H14O5	Not Available	Not Available	274.2687	OC1=CC=C(CCC(=O)C2=C(O)C=C(O)C=C2O)C=C1	Solid	Not Available					23446	17276	CHEMBL45068	4624		GtP Drug Page	HMDB0003306	C00774		G50			4788	99444281		1368167		Phloretin	ZINC000000047553		Phloretin	Experimental	DB07810	InChI=1S/C15H14O5/c16-10-4-1-9(2-5-10)3-6-12(18)15-13(19)7-11(17)8-14(15)20/h1-2,4-5,7-8,16-17,19-20H,3,6H2	VGEREEWJJVICBM-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.0976 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	4	No	2	0	97.99 Å2	27.75 Å3	73.71 m3·mol-1	4	Yes	No	0.132 mg/mL	3.9	-3.3	7.96	-4.6	Q9AIU0	ttgR	1. HTH-type transcriptional regulator TtgR
C17H18O3	Not Available	Not Available	270.323	[H][C@@](CC1=CC=CC=C1)(OC1=CC=C(CC)C=C1)C(O)=O	Solid	Not Available					50171895		CHEMBL191060	9325014						GRR			11149906	99444313					ZINC000013671697		(2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid	Experimental	DB07842	InChI=1S/C17H18O3/c1-2-13-8-10-15(11-9-13)20-16(17(18)19)12-14-6-4-3-5-7-14/h3-11,16H,2,12H2,1H3,(H,18,19)/t16-/m0/s1	CJMVTSLLWMPEKQ-INIZCTEOSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.7751 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	1	No	2	-1	46.53 Å2	29.37 Å3	77.36 m3·mol-1	6	Yes	No	0.0133 mg/mL	4.48	-4.3	4.06	-4.9			
C22H19NO8	Not Available	Not Available	425.3882	COC(=O)C1=C(O)C=CC=C1OC\C=C\C1=CC(=CC=C1)C1=C(CO)C(=NO1)C(O)=O	Solid	Not Available					13997		CHEMBL184444	395769						IX1			449162	99444472					ZINC000014954269		5-(3-{3-[3-HYDROXY-2-(METHOXYCARBONYL)PHENOXY]PROPENYL}PHENYL)-4-(HYDROXYMETHYL)ISOXAZOLE-3-CARBOXYLIC ACID	Experimental	DB08001	InChI=1S/C22H19NO8/c1-29-22(28)18-16(25)8-3-9-17(18)30-10-4-6-13-5-2-7-14(11-13)20-15(12-24)19(21(26)27)23-31-20/h2-9,11,24-25H,10,12H2,1H3,(H,26,27)/b6-4+	DQSRCEFDWMQCCV-GQCTYLIASA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Inhibitor	Non-substrate	2.3650 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	7	3	Yes	3	-1	139.32 Å2	42.57 Å3	111.61 m3·mol-1	9	Yes	No	0.0662 mg/mL	3.71	-3.8	3.86	-3.1	P18031	PTPN1	1. Tyrosine-protein phosphatase non-receptor type 1
C19H16N2O4	Not Available	Not Available	336.3413	COC1=C(\C=N\NC(=O)C2=CC(O)=C(O)C=C2)C2=CC=CC=C2C=C1	Solid	Not Available					33953			7838983						K05			9562794	99444505					ZINC000000074303		(E)-3,4-DIHYDROXY-N'-[(2-METHOXYNAPHTHALEN-1-YL)METHYLENE]BENZOHYDRAZIDE	Experimental	DB08034	InChI=1S/C19H16N2O4/c1-25-18-9-7-12-4-2-3-5-14(12)15(18)11-20-21-19(24)13-6-8-16(22)17(23)10-13/h2-11,22-23H,1H3,(H,21,24)/b20-11+	TVOPERZEGKBKAY-RGVLZGJSSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	-	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.2049 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	3	No	3	0	91.15 Å2	35.06 Å3	95.11 m3·mol-1	4	Yes	No	0.0136 mg/mL	3.19	-4.4	8.33	0.89	P03366	gag-pol	1. Gag-Pol polyprotein
C16H16O	Not Available	Not Available	224.2976	CC1=CC(\C=C\C2=CC=CC=C2)=CC(C)=C1O	Solid	Not Available					50012798		CHEMBL55960	4896100						LJ1			6365297	99444571					ZINC000029548831		2,6-dimethyl-4-[(E)-2-phenylethenyl]phenol	Experimental	DB08100	InChI=1S/C16H16O/c1-12-10-15(11-13(2)16(12)17)9-8-14-6-4-3-5-7-14/h3-11,17H,1-2H3/b9-8+	PAHKYLUYTGBFNW-CMDGGOBGSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.0605 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	1	1	No	2	0	20.23 Å2	26.85 Å3	73.58 m3·mol-1	2	No	Yes	0.00429 mg/mL	5.04	-4.7	9.72	-6.4			
C16H16O6	Not Available	Not Available	304.2946	COC(=O)C1=C(C)C=C(OC2=C(O)C(O)=CC(C)=C2)C=C1O	Solid	Not Available								9954468						MGI			11779786	99444650					ZINC000036430941		methyl 4-(2,3-dihydroxy-5-methylphenoxy)-2-hydroxy-6-methylbenzoate	Experimental	DB08179	InChI=1S/C16H16O6/c1-8-4-12(18)15(19)13(5-8)22-10-6-9(2)14(11(17)7-10)16(20)21-3/h4-7,17-19H,1-3H3	BLXSEOJIXHWXQJ-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.5983 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	3	No	2	0	96.22 Å2	30.84 Å3	80.35 m3·mol-1	4	Yes	No	0.0515 mg/mL	4.24	-3.8	8.79	-3.8	Q04760	GLO1	1. Lactoylglutathione lyase
C15H14N2O5	Not Available	Not Available	302.2821	COC1=CC(=CC(OC)=C1O)\N=N\C1=CC=CC=C1C(O)=O	Solid	Not Available								25058737						MOB			6288148	99444667					ZINC000038311600		2-((3',5'-DIMETHOXY-4'-HYDROXYPHENYL)AZO)BENZOIC ACID	Experimental	DB08196	InChI=1S/C15H14N2O5/c1-21-12-7-9(8-13(22-2)14(12)18)16-17-11-6-4-3-5-10(11)15(19)20/h3-8,18H,1-2H3,(H,19,20)/b17-16+	OUUSCQGLQHBVJX-WUKNDPDISA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.1782 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	7	2	No	2	-1	100.71 Å2	30.19 Å3	82.54 m3·mol-1	5	Yes	No	0.0805 mg/mL	3.42	-3.6	3.36	-0.48	P22629	Not Available	1. Streptavidin
C18H18O6	Not Available	Not Available	330.3319	[H][C@]1(O)C=C[C@@]([H])(O)[C@]1([H])OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12	Solid	Not Available							CHEMBL291386							NCZ			446415	99444732					ZINC000100036551		2-hydroxy-7-methoxy-5-methyl-naphthalene-1-carboxylic acid meso-2,5-dihydroxy-cyclopent-3-enyl ester	Experimental	DB08261	InChI=1S/C18H18O6/c1-9-7-10(23-2)8-12-11(9)3-4-13(19)16(12)18(22)24-17-14(20)5-6-15(17)21/h3-8,14-15,17,19-21H,1-2H3/t14-,15+,17+	XILHLKXLRFUQFI-QLPKVWCKSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Inhibitor	Non-inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.6533 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	3	No	3	0	96.22 Å2	33.73 Å3	87.96 m3·mol-1	4	Yes	No	0.337 mg/mL	2.82	-3	9.5	-3.4	P0A3R9	ncsA	1. Neocarzinostatin
C14H12O4	Not Available	Not Available	244.246	OC1=CC(\C=C\C2=CC=C(O)C(O)=C2)=CC(O)=C1	Solid	Not Available					50045936	28814	CHEMBL69863	581006			HMDB0004215	C05901		PIT			667639	99444870				Piceatannol	ZINC000000014036		Piceatannol	Experimental	DB08399	InChI=1S/C14H12O4/c15-11-5-10(6-12(16)8-11)2-1-9-3-4-13(17)14(18)7-9/h1-8,15-18H/b2-1+	CDRPUGZCRXZLFL-OWOJBTEDSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Inhibitor	Non-inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.8860 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	4	No	2	0	80.92 Å2	25.46 Å3	69.44 m3·mol-1	2	Yes	No	0.097 mg/mL	3.1	-3.4	8.41	-6.2	P25705;!P06576;!P36542	ATP5A1;!ATP5B;!ATP5C1	1. ATP synthase subunit alpha, mitochondrial;!2. ATP synthase subunit beta, mitochondrial;!3. ATP synthase subunit gamma, mitochondrial
C18H19NO3	Not Available	Not Available	297.3484	[H][C@@]1(CCCN1C(=O)C1=C(O)C=C(O)C=C1)C1=CC=CC=C1C	Solid	Not Available							CHEMBL470365	24694529						PY9			25058141	99444913							4-{[(2R)-2-(2-methylphenyl)pyrrolidin-1-yl]carbonyl}benzene-1,3-diol	Experimental	DB08442	InChI=1S/C18H19NO3/c1-12-5-2-3-6-14(12)16-7-4-10-19(16)18(22)15-9-8-13(20)11-17(15)21/h2-3,5-6,8-9,11,16,20-21H,4,7,10H2,1H3/t16-/m1/s1	TWODFUZHWYZBHZ-MRXNPFEDSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.6117 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	3	2	No	3	0	60.77 Å2	30.73 Å3	85.76 m3·mol-1	2	Yes	No	0.0769 mg/mL	4.02	-3.6	8.02	-1.5	P07900	HSP90AA1	1. Heat shock protein HSP 90-alpha
C11H9NO4	Not Available	Not Available	219.1935	OC1=CC(O)=C(C(=O)N2C=CC=C2)C(O)=C1	Solid	Not Available							CHEMBL513225	9335407						PYU			11160307	99444914					ZINC000096006136		2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol	Experimental	DB08443	InChI=1S/C11H9NO4/c13-7-5-8(14)10(9(15)6-7)11(16)12-3-1-2-4-12/h1-6,13-15H	RYGSNHBTZDYVSS-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.3467 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	3	No	2	0	82.69 Å2	20.8 Å3	56.7 m3·mol-1	1	Yes	No	3.24 mg/mL	1.32	-1.8	7.65	-4.3	P07900	HSP90AA1	1. Heat shock protein HSP 90-alpha
C18H18ClNO8	Not Available	Not Available	411.79	COC(=O)C1=C(CCC(=O)NC2=C(O)C=C(OC)C(O)=C2)C(Cl)=C(O)C=C1O	Solid	Not Available								9548187						RDA			11373270	99444935					ZINC000024798681		METHYL 3-CHLORO-2-{3-[(2,5-DIHYDROXY-4-METHOXYPHENYL)AMINO]-3-OXOPROPYL}-4,6-DIHYDROXYBENZOATE	Experimental	DB08464	InChI=1S/C18H18ClNO8/c1-27-14-7-10(21)9(5-11(14)22)20-15(25)4-3-8-16(18(26)28-2)12(23)6-13(24)17(8)19/h5-7,21-24H,3-4H2,1-2H3,(H,20,25)	GUVWEHNRWHNDRF-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.5249 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	7	5	No	2	-1	145.55 Å2	39.28 Å3	101.46 m3·mol-1	7	Yes	No	0.0399 mg/mL	3.38	-4	7.04	-4.1	P08238;!P14625	HSP90AB1;!HSP90B1	1. Heat shock protein HSP 90-beta;!2. Endoplasmin
C18H20ClNO7	Not Available	Not Available	397.807	COC1=CC(N)=C(OC)C(CCOC(=O)C2=C(O)C=C(O)C(Cl)=C2)=C1OC	Solid	Not Available								10015480						RDE			11840979	99444936					ZINC000036470929		2-(3-AMINO-2,5,6-TRIMETHOXYPHENYL)ETHYL 5-CHLORO-2,4-DIHYDROXYBENZOATE	Experimental	DB08465	InChI=1S/C18H20ClNO7/c1-24-15-7-12(20)16(25-2)9(17(15)26-3)4-5-27-18(23)10-6-11(19)14(22)8-13(10)21/h6-8,21-22H,4-5,20H2,1-3H3	DFYGLJKFZQGYPA-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Inhibitor	Non-substrate	2.1856 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	7	3	No	2	-1	120.47 Å2	39.21 Å3	100.31 m3·mol-1	8	Yes	No	0.0412 mg/mL	3.33	-4	7.08	4.35	P08238;!P14625	HSP90AB1;!HSP90B1	1. Heat shock protein HSP 90-beta;!2. Endoplasmin
C14H14O3	Not Available	Not Available	230.2592	OC1=CC=C(CCC2=CC(O)=CC(O)=C2)C=C1	Solid	Not Available					50085531	4582	CHEMBL111234	161607				C10255		RE2			185914	99444937					ZINC000000899123		5-[2-(4-hydroxyphenyl)ethyl]benzene-1,3-diol	Experimental	DB08466	InChI=1S/C14H14O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h3-9,15-17H,1-2H2	HITJFUSPLYBJPE-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.6999 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	3	No	2	0	60.69 Å2	24.87 Å3	66.34 m3·mol-1	3	Yes	No	0.0812 mg/mL	3.6	-3.4	9.3	-5.4			
C16H14O5	Not Available	Not Available	286.2794	COC1=CC(O)=C2C(=O)C[C@H](OC2=C1)C1=CC=C(O)C=C1	Solid	Not Available					50312648	28927	CHEMBL448297	66249			HMDB0030090	C09833		SAK			73571	99444988		2263158		Sakuranetin	ZINC000000338284		Sakuranetin	Experimental	DB08517	InChI=1S/C16H14O5/c1-20-11-6-12(18)16-13(19)8-14(21-15(16)7-11)9-2-4-10(17)5-3-9/h2-7,14,17-18H,8H2,1H3/t14-/m0/s1	DJOJDHGQRNZXQQ-AWEZNQCLSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Inhibitor	Non-substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	3.3571 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	2	No	3	0	75.99 Å2	29.41 Å3	75.77 m3·mol-1	2	Yes	No	0.0883 mg/mL	2.98	-3.5	8.62	-4.6	Q5G940	fabZ	1. 3-hydroxyacyl-[acyl-carrier-protein] dehydratase FabZ
C11H10O4	Not Available	Not Available	206.1947	[H]\C(=C(/[H])C1=CC=CC=C1OC)C(=O)C(O)=O	Solid	Not Available								26329127						TOM			131704311	99445108					ZINC000053683259		4-(2-METHOXYPHENYL)-2-OXOBUT-3-ENOIC ACID	Experimental	DB08637	InChI=1S/C11H10O4/c1-15-10-5-3-2-4-8(10)6-7-9(12)11(13)14/h2-7H,1H3,(H,13,14)/b7-6-	QGTBUESLYPYXRT-SREVYHEPSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.7217 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	1	No	1	-1	63.6 Å2	19.98 Å3	54.87 m3·mol-1	4	Yes	No	0.284 mg/mL	2.27	-2.9	2.94	-4.8	Q51948	nahD	1. 2-hydroxychromene-2-carboxylate isomerase
C19H18O4	Not Available	Not Available	310.3438	[H][C@](CC)(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=C(OC)C=C2	Solid	Not Available								25058337						U03			54736485	99445134					ZINC000100036950		4-HYDROXY-7-METHOXY-3-(1-PHENYL-PROPYL)-CHROMEN-2-ONE	Experimental	DB08663	InChI=1S/C19H18O4/c1-3-14(12-7-5-4-6-8-12)17-18(20)15-10-9-13(22-2)11-16(15)23-19(17)21/h4-11,14,20H,3H2,1-2H3/t14-/m0/s1	CCPGCKQLIHGSCJ-AWEZNQCLSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	3.6423 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	1	No	3	-1	55.76 Å2	33.2 Å3	88.11 m3·mol-1	4	Yes	No	0.0296 mg/mL	3.58	-4	5.62	-4.8	P04584	gag-pol	1. Gag-Pol polyprotein
C9H10O4	Not Available	Not Available	182.1733	COC(=O)C1=CC(OC)=C(O)C=C1	Solid	Not Available						46477	CHEMBL486214	18693			HMDB0240266			VXX			19844	99445182				Methyl_group	ZINC000000388238		Methyl vanillate	Experimental	DB08711	InChI=1S/C9H10O4/c1-12-8-5-6(9(11)13-2)3-4-7(8)10/h3-5,10H,1-2H3	BVWTXUYLKBHMOX-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.3185 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	1	No	1	0	55.76 Å2	18.09 Å3	46.53 m3·mol-1	3	Yes	No	3.57 mg/mL	1.52	-1.7	9	-4.9	P51584	xynY	1. Endo-1,4-beta-xylanase Y
C17H17NO4	Not Available	Not Available	299.3212	OC1=CC=C(CCNC(=O)\C=C\C2=CC(O)=C(O)C=C2)C=C1	Solid	Not Available							CHEMBL206646	8170478			HMDB0033026			Y13			9994897	99445225					ZINC000013515185		N-Caffeoyltyramine	Experimental	DB08754	InChI=1S/C17H17NO4/c19-14-5-1-12(2-6-14)9-10-18-17(22)8-4-13-3-7-15(20)16(21)11-13/h1-8,11,19-21H,9-10H2,(H,18,22)/b8-4+	VSHUQLRHTJOKTA-XBXARRHUSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.9665 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	4	No	2	0	89.79 Å2	32.1 Å3	85.09 m3·mol-1	5	Yes	No	0.038 mg/mL	2.66	-3.9	9.04	-0.39	Q672W7	def	1. Peptide deformylase
C25H22O10	Not Available	Not Available	482.441	[H][C@@]1(OC2=C(O[C@@H]1CO)C=CC(=C2)[C@@]1([H])OC2=C(C(O)=CC(O)=C2)C(=O)[C@@H]1O)C1=CC(OC)=C(O)C=C1	Solid	Not Available	P22309	UGT1A1	1. UDP-glucuronosyltransferase 1-1		50084982	9144	CHEMBL431701	29263				C07610	D08515			PA166129539	31553	310265190		155067		Silibinin	ZINC000002033589		Silibinin	Experimental, Investigational	DB09298	InChI=1S/C25H22O10/c1-32-17-6-11(2-4-14(17)28)24-20(10-26)33-16-5-3-12(7-18(16)34-24)25-23(31)22(30)21-15(29)8-13(27)9-19(21)35-25/h2-9,20,23-29,31H,10H2,1H3/t20-,23+,24-,25-/m1/s1	SEBFKMXJBCUCAI-HKTJVKLFSA-N	4	Silibinin is a flavonolignan with hepatoprotective effects used to treat toxic liver damage and as an adjunct in the management of chronic conditions such as cirrhosis and hepatitis.	Not Available	Small Molecule																																			1	No	10	5	No	5	0	155.14 Å2	48.41 Å3	120.29 m3·mol-1	4	Yes	No	0.0926 mg/mL	2.63	-3.7	7.75	-3			
C8H8O3	Not Available	The plasma half-life for salicylate is 2 to 3 hr in low doses and about 12 hr at usual anti-inflammatory doses. The half-life of salicylate may be as long as 15 to 30 hr at high therapeutic doses or when there is intoxication.	152.1473	COC(=O)C1=CC=CC=C1O	Liquid	After absorption, methyl salicylate is distributed throughout most body tissues and most transcellular fluids, primarily by pH dependent passive processes. Salicylate is actively transported by a low-capacity, saturable system out of the CSF across the choroid plexus. The drug readily crosses the placental barrier.						31832	CHEMBL108545	13848808	Drugs.com Drug Page		HMDB0034172	C12305	D01087				4133	347827876		29787		Methyl_salicylate	ZINC000000000490	Dendracin Neurodendraxcin, Flexall Ultra Plus, Lidopro, Listerine Antiseptic, Medi-derm, Medi-derm With Lidocaine, Medrox, Mentholatum, Rematex, Salonpas Pain Relieving Patch, Tiger Balm, Xoten-C	Methyl salicylate	Approved, Vet approved	DB09543	InChI=1S/C8H8O3/c1-11-8(10)6-4-2-3-5-7(6)9/h2-5,9H,1H3	OSWPMRLSEDHDFF-UHFFFAOYSA-N	4	Methyl salicylate is a topical counter-irritant used for the symptomatic relief of acute musculoskeletal pain in the muscles, joints, and tendons.	Oral LD50 values (mg/kg) for mouse, rat and rabbit are 1110, 887 and 1300, respectively. Oral LD50 values for child and adult human (mg/kg) are 228 and 506, respectively. Although systemic toxicity from topical administration is rare, methyl salicylate can be absorbed in intract skin to cause stimulation of the central nervous system respiratory center, disturbance of lipid and carbohydrate metabolism, and disturbance of intracellular respiration. Severe toxicity can result in acute lung injury, lethargy, coma, seizures, cerebral edema, and death. In case of salicylate poisoning, the treatment consists of general supportive care, gastrointestinal decontamination with activated charcoal in cases of salicylate ingestion, and monitoring of serum salicylate concentrations. Bicarbonate infusions or hemodialysis can be used to achieve enhanced salicylate elimination 7.	Small Molecule																													220-224	2.5		-8.6		Slightly soluble	1	No	2	1	No	1	0	46.53 Å2	14.98 Å3	40.06 m3·mol-1	2	Yes	No	5.73 mg/mL	2.32	-1.4	9.72	-4.3			
C13H10O3	Please refer to Aspirin for more information.	Mean half-life of 1.1 h 15.	214.2167	OC1=CC=CC=C1C(=O)OC1=CC=CC=C1	Solid	Steady-state plasma salicylate concentrations increase more than proportionally with increasing dosages; the time required to reach steady state increases with increasing daily dose. Dosage intervals of 8-12 h are sufficient to maintain plasma salicylate concentrations in the normal therapeutic anti-inflammatory concentration range 10.						34918	CHEMBL1339216	8058			HMDB0032018	C14163					8361	347827884		36122		Phenyl_salicylate	ZINC000000038545	Hyophen, Phosphasal, Urelle, Uribel, Urimar Reformulated Oct 2013, Urin DS, Ustell, Utira	Phenyl salicylate	Approved	DB11071	InChI=1S/C13H10O3/c14-12-9-5-4-8-11(12)13(15)16-10-6-2-1-3-7-10/h1-9,14H	ZQBAKBUEJOMQEX-UHFFFAOYSA-N			Oral LD50 in the rat is 3000 mg/kg 13Adverse effects can be divided into several categories 4, 12:Eyes: irritation 12Skin: skin irritation 12Cardiovascular: rapid pulse, flushing 4Central Nervous System —blurred vision, dizziness 4Respiratory —shortness of breath or troubled breathing 4, irritation of respiratory system 12Genitourinary —difficult micturition, acute urinary retention 4Gastrointestinal —dry mouth, nausea/vomiting 4Overdosage may be managed by inducing emesis or gastric lavage. Slow intravenous administration of physostigmine in doses of 1 to 4 mg (0.5 to 1 mg in children) repeated as needed in 1-2 h to relieve severe antimuscarinic symptoms. Administration of small doses of diazepam to control excitement and seizures may be warranted. Artificial respiration with oxygen can be used if needed for respiratory depression. Adequate hydration is important, as well as symptomatic treatment, provided as necessary 4.	Small Molecule																													172-173			41-43		insoluble	1	Yes	2	1	No	2	0	46.53 Å2	21.96 Å3	59.84 m3·mol-1	3	Yes	No	0.216 mg/mL	3.98	-3	9.67	-4.3	P23219;!P35354	PTGS1;!PTGS2	1. Prostaglandin G/H synthase 1;!2. Prostaglandin G/H synthase 2
C14H10O3	Not Available	Not Available	226.231	OC1=CC=CC2=C1C(=O)C1=C(O)C=CC=C1C2	Solid	Not Available					50041802	37510	CHEMBL46469	2117				C06831					2202	347827926		873		Dithranol	ZINC000000001322	Drithocreme, Zithranol, Zithranol-RR	Anthralin	Approved	DB11157	InChI=1S/C14H10O3/c15-10-5-1-3-8-7-9-4-2-6-11(16)13(9)14(17)12(8)10/h1-6,15-16H,7H2	NUZWLKWWNNJHPT-UHFFFAOYSA-N	4	Anthralin is an anthracene used to treat stable plaque psoriasis.	Some mild adverse effects include alterations in nail coloring, hair coloring, increase in photosensitivity, and skin irritation 8.The most common side effects of anthralin are skin irritation and staining of nearby skin, nails, clothing, and other objects that come in contact with the treated patient. The incidence of irritation of psoriatic/surrounding healthy skin is higher in patients who leave anthralin on the skin without rinsing than in those who use short-contact therapy of 2 hours or less, followed by rinsing 12.If the psoriatic plaques are well circumscribed, the surrounding normal skin may be protected by the use of a coating agent such as zinc oxide ointment. Anthralin should be applied cautiously to the face and intertriginous areas due to the risk of severe skin irritation 13.There is no current evidence of any long-term anthralin toxicity related either to skin exposure or to systemic issues 12.Some long-term studies in mice have demonstrated anthralin to be tumorigenic in mouse skin. This carcinogenic potential has not been thoroughly evaluated. Tumorigenic and carcinogenic effects of anthralin have not been observed in humans at this time 7. Anthralin is classified as FDA pregnancy risk category C drug 13. It is not known if anthralin can cause fetal harm when administered during gestation. Because of the lack of evidential human data, anthralin should be used during pregnancy only when clearly required 8.	Small Molecule																																178-182 °C		not soluble in water	1	Yes	3	2	No	3	0	57.53 Å2	23.12 Å3	64.27 m3·mol-1	0	Yes	No	0.184 mg/mL	4.24	-3.1	8.47	-5.6	P35908;!Q99456;!Q9UQF2	KRT2;!KRT12;!MAPK8IP1	1. Keratin, type II cytoskeletal 2 epidermal;!2. Keratin, type I cytoskeletal 12;!3. C-Jun-amino-terminal kinase-interacting protein 1
C14H12O6S	Not Available	Not Available	308.3	COC1=C(C=C(C(=O)C2=CC=CC=C2)C(O)=C1)S(O)(=O)=O	Not Available	Not Available						135312	CHEMBL2059073	18829									19988	347827937		1311567		Sulisobenzone	ZINC000001690324		Sulisobenzone	Experimental	DB11185	InChI=1S/C14H12O6S/c1-20-12-8-11(15)10(7-13(12)21(17,18)19)14(16)9-5-3-2-4-6-9/h2-8,15H,1H3,(H,17,18,19)	CXVGEDCSTKKODG-UHFFFAOYSA-N		Sulisobenzone is an ingredient used in sunscreen to block UVA and UVB radiation.	Acute oral toxicity (LD50): 3530 mg/kg [Rat].This drug can cause skin and eye irritation 6.Drug-induced phototoxicity is a non-immunological inflammatory skin reaction, caused by concurrent topical or systemic exposure to a specific molecule and ultraviolet radiation. Most of the phototoxic compounds absorb energy particularly from UVA light leading to activated derivatives, which can induce cellular damage 5.Benzophenones are ultraviolet light filters that have been documented to cause a variety of adverse skin reactions, including contact and photocontact dermatitis, contact and photocontact urticaria, and anaphylaxis. Recently, they have become especially well known for their ability to induce allergy and photoallergy. Topical sunscreens and other cosmetics are the sources of these allergens in the majority of patients, however reports of reactions secondary to use of industrial products also exist. Benzophenones as a group have been named the American Contact Dermatitis Society's Allergen of the Year for 2014 to raise awareness of both allergy and photoallergy to these ubiquitous agents 3.The liver is the main target organ of benzophenone toxicity in rats and mice, based on elevations n liver weights, hepatocellular hypertrophy, clinical chemistry changes, and induction of liver microsomal cytochrome P450 2B isomer. The kidney was also identified as a target organ of benzophenone toxicity in rats only, which was based on exposure concentration-related increases in kidney weights and microscopic changes 15.	Small Molecule																																145		10 microgram/mL	1	Yes	6	2	No	2	-2	100.9 Å2	29.14 Å3	75.7 m3·mol-1	4	Yes	No	0.214 mg/mL	2.8	-3.2	-2.4	-5			1. Skin epithelial cells
C14H12O4	No pharmacokinetic data available.	No pharmacokinetic data available.	244.246	COC1=CC(O)=C(C=C1)C(=O)C1=CC=CC=C1O	Solid	No pharmacokinetic data available.						34208	CHEMBL1326877	8251				C14283	D03853							23350		Dioxybenzone	ZINC000000037293		Dioxybenzone	Approved	DB11221	InChI=1S/C14H12O4/c1-18-9-6-7-11(13(16)8-9)14(17)10-4-2-3-5-12(10)15/h2-8,15-16H,1H3	MEZZCSHVIGVWFI-UHFFFAOYSA-N		Dioxybenzone is a benzophenone derivative used in sunscreens to block UVB and short-wave UVA radiation.	No toxicokinetic data available.	Small Molecule																													172.5			74			1	Yes	4	2	No	2	-1	66.76 Å2	24.81 Å3	67.06 m3·mol-1	3	Yes	No	0.148 mg/mL	3.97	-3.2	6.78	-4.8	P04278	SHBG	1. Sex hormone-binding globulin
C12H14O4	Not Available	Not Available	222.2372	[H]\C(=C(\[H])C1=CC(OC)=C(O)C=C1)C(=O)OCC	Not Available	Not Available					50297424		CHEMBL286796	643791						ZYC						1420983			ZINC000000160496		Ethyl ferulate	Approved, Experimental	DB11285	InChI=1S/C12H14O4/c1-3-16-12(14)7-5-9-4-6-10(13)11(8-9)15-2/h4-8,13H,3H2,1-2H3/b7-5+	ATJVZXXHKSYELS-FNORWQNLSA-N			Not Available	Small Molecule																																			1	Yes	3	1	No	1	0	55.76 Å2	23.57 Å3	61.02 m3·mol-1	5	Yes	No	0.328 mg/mL	2.41	-2.8	9.87	-4.9			
C22H23NO4	Not Available	Not Available	365.4223	CCCCC1=CC2=C(NC=C(C(=O)OC)C2=O)C=C1OCC1=CC=CC=C1	Not Available	Not Available							CHEMBL2104807	24579			HMDB0031754		D05144										ZINC000100033029		Nequinate	Vet approved	DB11433	InChI=1S/C22H23NO4/c1-3-4-10-16-11-17-19(23-13-18(21(17)24)22(25)26-2)12-20(16)27-14-15-8-6-5-7-9-15/h5-9,11-13H,3-4,10,14H2,1-2H3,(H,23,24)	NNOPDLNHPOLRRE-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	Yes	4	1	Yes	3	0	64.63 Å2	41.02 Å3	105.78 m3·mol-1	8	No	No	0.000763 mg/mL	5.33	-5.7	10.15	-1.8			
C21H20O6	No pharmacokinetic data available.	No pharmacokinetic data available.	368.3799	COC1=CC(\C=C\C(=O)CC(=O)\C=C\C2=CC(OC)=C(O)C=C2)=CC=C1O	Solid	Following oral administration of radio-labelled curcumin to rats, radioactivity was detected in the liver and kidneys 3.	P11712;!P08684;!P20813;!P05177;!P10635;!P08263;!P09488;!P09211	CYP2C9;!CYP3A4;!CYP2B6;!CYP1A2;!CYP2D6;!GSTA1;!GSTM1;!GSTP1	1. Cytochrome P450 2C9;!2. Cytochrome P450 3A4;!3. Cytochrome P450 2B6;!4. Cytochrome P450 1A2;!5. Cytochrome P450 2D6;!6. Glutathione S-transferase A1;!7. Glutathione S-transferase Mu 1;!8. Glutathione S-transferase P		50140172	3962	CHEMBL140	839564			HMDB0002269			CC9			969516	347828040		2955		Curcumin	ZINC000000899824		Curcumin	Approved, Investigational	DB11672	InChI=1S/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-12,24-25H,13H2,1-2H3/b7-3+,8-4+	VFLDPWHFBUODDF-FCXRPNKRSA-N	4		In an acute oral toxicity study in mouse, LD50 was >2000 mg/kg MSDS. Single oral doses of curcumin at 1-5 g/kg bw induced no toxic effects in rats 3. There has been no cases of overdose reported 3.	Small Molecule																																183		Insoluble in cold water	1	Yes	6	2	No	2	0	93.06 Å2	38.12 Å3	103.81 m3·mol-1	8	Yes	No	0.00575 mg/mL	4.12	-4.8	9.08	-4.4	P37231;!P11473;!O15440;!P16152;!P09211	PPARG;!VDR;!ABCC5;!CBR1;!GSTP1	1. Peroxisome proliferator-activated receptor gamma;!2. Vitamin D3 receptor;!3. Multidrug resistance-associated protein 5;!4. Carbonyl reductase [NADPH] 1;!5. Glutathione S-transferase P
C15H14O3	Not Available	Not Available	242.2699	OC1=CC=C(C=C1)[C@H]1COC2=C(C1)C=CC(O)=C2	Not Available	Not Available					50410528	34741	CHEMBL198877	82594			HMDB0002209	C14131					91469	347828042		1803717		Equol	ZINC000000388661		Equol	Investigational	DB11674	InChI=1S/C15H14O3/c16-13-4-1-10(2-5-13)12-7-11-3-6-14(17)8-15(11)18-9-12/h1-6,8,12,16-17H,7,9H2/t12-/m1/s1	ADFCQWZHKCXPAJ-GFCCVEGCSA-N	2		Not Available	Small Molecule																																			1	Yes	3	2	No	3	0	49.69 Å2	25.81 Å3	68.96 m3·mol-1	1	Yes	No	0.0445 mg/mL	3.19	-3.7	9.63	-4.9	Q92731;!P04278	ESR2;!SHBG	1. Estrogen receptor beta;!2. Sex hormone-binding globulin
C15H14O6	Not Available	Not Available	290.2681	O[C@@H]1CC2=C(O)C=C(O)C=C2O[C@@H]1C1=CC(O)=C(O)C=C1	Not Available	Not Available					23417	90	CHEMBL583912	65230			HMDB0001871	C09727		28E			72276	347828350				Catechin	ZINC000000119988		Epicatechin	Investigational	DB12039	InChI=1S/C15H14O6/c16-8-4-11(18)9-6-13(20)15(21-14(9)5-8)7-1-2-10(17)12(19)3-7/h1-5,13,15-20H,6H2/t13-,15-/m1/s1	PFTAWBLQPZVEMU-UKRRQHHQSA-N	2		Not Available	Small Molecule																																			1	Yes	6	5	No	3	0	110.38 Å2	28.13 Å3	74 m3·mol-1	1	Yes	No	0.645 mg/mL	1.8	-2.6	9	-3.3			
C16H13NO7	Not Available	Not Available	331.28	CC(=O)OC1=CC=CC=C1C(=O)OC1=CC=CC(CO[N+]([O-])=O)=C1	Not Available	Not Available						125482	CHEMBL374385	106359									119032	347828686					ZINC000000022315		Nitroaspirin	Investigational	DB12445	InChI=1S/C16H13NO7/c1-11(18)23-15-8-3-2-7-14(15)16(19)24-13-6-4-5-12(9-13)10-22-17(20)21/h2-9H,10H2,1H3	IOJUJUOXKXMJNF-UHFFFAOYSA-N	2		Not Available	Small Molecule																																			1	Yes	5	0	No	2	0	104.97 Å2	31.6 Å3	81.5 m3·mol-1	8	Yes	No	0.00402 mg/mL	3.17	-4.9		-6	P23219	PTGS1	1. Prostaglandin G/H synthase 1
C18H21O8P	Not Available	Not Available	396.332	COC1=CC=C(\C=C/C2=CC(OC)=C(OC)C(OC)=C2)C=C1OP(O)(O)=O	Not Available	Not Available							CHEMBL1206232	4508406									5351387	347828799				Combretastatin_A-4_phosphate	ZINC000001543513		Fosbretabulin	Investigational	DB12577	InChI=1S/C18H21O8P/c1-22-14-8-7-12(9-15(14)26-27(19,20)21)5-6-13-10-16(23-2)18(25-4)17(11-13)24-3/h5-11H,1-4H3,(H2,19,20,21)/b6-5-	WDOGQTQEKVLZIJ-WAYWQWQTSA-N	2		Not Available	Small Molecule																																			1	Yes	7	2	No	2	-2	103.68 Å2	38.29 Å3	100.22 m3·mol-1	8	Yes	No	0.00239 mg/mL	2.72	-5.2	1.62	-4.3			
C18H22O6	Not Available	Not Available	334.368	COC1=CC=C(C[C@@H](O)C2=CC(OC)=C(OC)C(OC)=C2)C=C1O	Not Available	Not Available							CHEMBL246600	8070931									9895264	347828814				Combretastatin	ZINC000001607492		Combretastatin	Investigational	DB12596	InChI=1S/C18H22O6/c1-21-15-6-5-11(8-14(15)20)7-13(19)12-9-16(22-2)18(24-4)17(10-12)23-3/h5-6,8-10,13,19-20H,7H2,1-4H3/t13-/m1/s1	LGZKGOGODCLQHG-CYBMUJFWSA-N	2		Not Available	Small Molecule																																			1	Yes	6	2	No	2	0	77.38 Å2	34.18 Å3	89.75 m3·mol-1	7	Yes	No	0.0545 mg/mL	2.34	-3.8	9.99	-3.1			
C9H10O3	Not Available	Not Available	166.1739	COC1=C(O)C=CC(=C1)C(C)=O	Not Available	Not Available						2781	CHEMBL346919	21106900				C11380		I75			2214	347828831				Apocynin	ZINC000000162515		Apocynin	Investigational	DB12618	InChI=1S/C9H10O3/c1-6(10)7-3-4-8(11)9(5-7)12-2/h3-5,11H,1-2H3	DFYRUELUNQRZTB-UHFFFAOYSA-N	1		Not Available	Small Molecule																																			1	Yes	3	1	No	1	0	46.53 Å2	16.94 Å3	44.9 m3·mol-1	2	Yes	No	3.04 mg/mL	1.07	-1.7	8.27	-4.9			
C21H20O6	Not Available	Not Available	368.385	COC1=CC=C(C=C1)C1=C(O)C(=O)C2=C(O)C=C(O)C(CC=C(C)C)=C2O1	Not Available	Not Available					50272527		CHEMBL498485	4477409			HMDB0139407						5318980	347828876					ZINC000014762797		Icaritin	Investigational	DB12672	InChI=1S/C21H20O6/c1-11(2)4-9-14-15(22)10-16(23)17-18(24)19(25)20(27-21(14)17)12-5-7-13(26-3)8-6-12/h4-8,10,22-23,25H,9H2,1-3H3	TUUXBSASAQJECY-UHFFFAOYSA-N	2		Not Available	Small Molecule																																			1	Yes	6	3	No	3	-1	96.22 Å2	38.77 Å3	103.61 m3·mol-1	4	Yes	No	0.00821 mg/mL	4.33	-4.6	6.22	-3.8			
C15H12O5	Not Available	Not Available	272.256	OC(=O)C1=CC=C(COC2=CC=CC(O)=C2C=O)C=C1	Not Available	Not Available							CHEMBL2104482	49868									55223	347829161					ZINC000000010202		Tucaresol	Investigational	DB13027	InChI=1S/C15H12O5/c16-8-12-13(17)2-1-3-14(12)20-9-10-4-6-11(7-5-10)15(18)19/h1-8,17H,9H2,(H,18,19)	XEDONBRPTABQFB-UHFFFAOYSA-N	2		Not Available	Small Molecule																																			1	Yes	5	2	No	2	-1	83.83 Å2	27.14 Å3	72.95 m3·mol-1	5	Yes	No	0.0362 mg/mL	3.26	-3.9	4.06	-4.9			
C18H15NO4	Not Available	Not Available	309.321	CC1=C(OC(=O)C2=CC=C(N)C=C2)C(O)=C2C=CC=CC2=C1O	Not Available	Not Available						135317		76340									84621	347829171		46276			ZINC000005419379		Aminaphthone	Investigational	DB13039	InChI=1S/C18H15NO4/c1-10-15(20)13-4-2-3-5-14(13)16(21)17(10)23-18(22)11-6-8-12(19)9-7-11/h2-9,20-21H,19H2,1H3	YLMPBJUYFTWHKJ-UHFFFAOYSA-N	4	Aminaphthone is a medication that inhibits erythrocyte aggregation in capillaries, improving venous return for the treatment of capillary fragility.	Not Available	Small Molecule																																			1	Yes	4	3	No	3	0	92.78 Å2	31.49 Å3	88.01 m3·mol-1	3	Yes	No	0.0147 mg/mL	4.35	-4.3	9.55	2.54			
C15H10O5	Not Available	Not Available	270.2369	OC(=O)C1=CC(O)=C2C(CC3=C(C(O)=CC=C3)C2=O)=C1	Solid	Not Available					50060855		CHEMBL421615	106641			HMDB0039449						119396	347829279					ZINC000001636654		Rheinanthrone	Experimental	DB13175	InChI=1S/C15H10O5/c16-10-3-1-2-7-4-8-5-9(15(19)20)6-11(17)13(8)14(18)12(7)10/h1-3,5-6,16-17H,4H2,(H,19,20)	OZFQHULMMDWMIV-UHFFFAOYSA-N			Not Available	Small Molecule																																250-280			1	Yes	5	3	No	3	-1	94.83 Å2	26.56 Å3	71.53 m3·mol-1	1	Yes	No	0.122 mg/mL	3.9	-3.4	3.54	-5.6			
C21H20N4O3	Not Available	Not Available	376.416	COC1=CC=C(C=C1C(=O)NCC1=CC=CN=C1)C(=O)NCC1=CC=CN=C1	Not Available	Not Available					50103507	93175	CHEMBL1257015	4649														Picotamide	ZINC000000538174		Picotamide	Experimental	DB13327	InChI=1S/C21H20N4O3/c1-28-19-7-6-17(20(26)24-13-15-4-2-8-22-11-15)10-18(19)21(27)25-14-16-5-3-9-23-12-16/h2-12H,13-14H2,1H3,(H,24,26)(H,25,27)	KYWCWBXGRWWINE-UHFFFAOYSA-N		Picotamide is a platelet aggregation inhibitor indicated in the treatment of myocardial infarction, thrombosis, cerebrovascular disorders, pulmonary emboli, and atherosclerosis.	Not Available	Small Molecule																																			1	Yes	5	2	Yes	3	0	93.21 Å2	39.26 Å3	105.38 m3·mol-1	7	Yes	No	0.0168 mg/mL	0.98	-4.4	13.44	5.12			
C20H21NO3	Not Available	Not Available	323.392	COC1=CC=C2C(=O)C(C)=C(OC2=C1CN(C)C)C1=CC=CC=C1	Not Available	Not Available						135374	CHEMBL519364	2969														Dimefline	ZINC000000000223		Dimefline	Experimental	DB13482	InChI=1S/C20H21NO3/c1-13-18(22)15-10-11-17(23-4)16(12-21(2)3)20(15)24-19(13)14-8-6-5-7-9-14/h5-11H,12H2,1-4H3	ZXFQRFXLFWWKLX-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	Yes	4	0	No	3	0	38.77 Å2	35.86 Å3	96.33 m3·mol-1	4	Yes	Yes	0.0373 mg/mL	3.15	-3.9		6.24			
C16H14O5	Not Available	Not Available	286.283	COC1=CC=CC=C1OC(=O)C1=CC=CC=C1OC(C)=O	Not Available	Not Available						135185	CHEMBL2105097	61994														Guacetisal	ZINC000000000348		Guacetisal	Experimental	DB13538	InChI=1S/C16H14O5/c1-11(17)20-13-8-4-3-7-12(13)16(18)21-15-10-6-5-9-14(15)19-2/h3-10H,1-2H3	HSJFYRYGGKLQBT-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	Yes	3	0	No	2	0	61.83 Å2	28.79 Å3	75.46 m3·mol-1	6	Yes	No	0.0169 mg/mL	3.08	-4.2		-4.9			
C20H21NO3	Not Available	Not Available	323.392	COC1=CC=C2C(=O)C3=CC=CC=C3OC2=C1CN1CCCCC1	Not Available	Not Available						135373	CHEMBL2104462	59116														Mepixanox	ZINC000004216861		Mepixanox	Experimental	DB13579	InChI=1S/C20H21NO3/c1-23-17-10-9-15-19(22)14-7-3-4-8-18(14)24-20(15)16(17)13-21-11-5-2-6-12-21/h3-4,7-10H,2,5-6,11-13H2,1H3	PYSOHOOUXFWCFF-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	Yes	3	0	No	4	1	38.77 Å2	35.62 Å3	93.96 m3·mol-1	3	Yes	Yes	0.0796 mg/mL	3.59	-3.6		7.25			
C17H15NO5	Not Available	Not Available	313.309	CC(=O)NC1=CC=C(OC(=O)C2=CC=CC=C2OC(C)=O)C=C1	Not Available	Not Available						135340	CHEMBL162036	19846												1372		Benorilate	ZINC000000001003		Benorilate	Approved	DB13657	InChI=1S/C17H15NO5/c1-11(19)18-13-7-9-14(10-8-13)23-17(21)15-5-3-4-6-16(15)22-12(2)20/h3-10H,1-2H3,(H,18,19)	FEJKLNWAOXSSNR-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	Yes	3	1	No	2	0	81.7 Å2	31.93 Å3	83.86 m3·mol-1	6	Yes	No	0.0141 mg/mL	2.48	-4.4	14.66	-4.4			
C13H9BrClNO2	Not Available	Not Available	326.57	OC1=CC=C(Br)C=C1C(=O)NC1=CC=C(Cl)C=C1	Not Available	Not Available						135394	CHEMBL153192	69679														Bromochlorosalicylanilide	ZINC000000001178		Bromochlorosalicylanilide	Experimental	DB13696	InChI=1S/C13H9BrClNO2/c14-8-1-6-12(17)11(7-8)13(18)16-10-4-2-9(15)3-5-10/h1-7,17H,(H,16,18)	QBSGXIBYUQJHMJ-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	Yes	2	2	No	2	0	49.33 Å2	27.4 Å3	76 m3·mol-1	2	Yes	No	0.0168 mg/mL	4.13	-4.3	7.49	-4.3			
C19H23NO3	Not Available	Not Available	313.397	CCN(CC)CCOC(=O)C1=CC=CC(=C1O)C1=CC=CC=C1	Not Available	Not Available						135341	CHEMBL2110895	20415															ZINC000001999340		Xenysalate	Experimental	DB13815	InChI=1S/C19H23NO3/c1-3-20(4-2)13-14-23-19(22)17-12-8-11-16(18(17)21)15-9-6-5-7-10-15/h5-12,21H,3-4,13-14H2,1-2H3	HLDCSYXMVXILQC-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	Yes	3	1	No	2	1	49.77 Å2	36.06 Å3	92.72 m3·mol-1	8	Yes	No	0.244 mg/mL	4.3	-3.1	9.58	8.84			
C15H15NO2	Not Available	Not Available	241.29	COC1=C(O)C(\C=N\C2=CC=C(C)C=C2)=CC=C1	Solid	Not Available								10846266									5476587	347829322					ZINC000004793359		2-Methoxy-6-{(E)-[(4-methylphenyl)imino]methyl}phenol	Experimental	DB13869	InChI=1S/C15H15NO2/c1-11-6-8-13(9-7-11)16-10-12-4-3-5-14(18-2)15(12)17/h3-10,17H,1-2H3/b16-10+	OYEREWRJWMPHMA-MHWRWJLKSA-N			Not Available	Small Molecule																																			1	Yes	3	1	No	2	0	41.82 Å2	27.13 Å3	74.87 m3·mol-1	3	Yes	No	0.0101 mg/mL	3.9	-4.4	9.34	2.14	Q92731;!P03372	ESR2;!ESR1	1. Estrogen receptor beta;!2. Estrogen receptor alpha
C15H14O6	Not Available	Not Available	290.2681	O[C@H]1CC2=C(O)C=C(O)C=C2O[C@@H]1C1=CC=C(O)C(O)=C1	Solid	Not Available					60836	15600	CHEMBL311498	8711			HMDB0002780	C06562		KXN						1367177		Catechin	ZINC000000119983		Cianidanol	Approved, Withdrawn	DB14086	InChI=1S/C15H14O6/c16-8-4-11(18)9-6-13(20)15(21-14(9)5-8)7-1-2-10(17)12(19)3-7/h1-5,13,15-20H,6H2/t13-,15+/m0/s1	PFTAWBLQPZVEMU-DZGCQCFKSA-N	2		Not Available	Small Molecule																																			1	Yes	6	5	No	3	0	110.38 Å2	27.89 Å3	74 m3·mol-1	1	Yes	No	0.645 mg/mL	1.8	-2.6	9	-3.3			
C14H14O2	Not Available	Not Available	214.264	CC(C1=CC=CC=C1)C1=CC=C(O)C=C1O	Solid	Not Available					240731		CHEMBL3961037	9346995												1313724					Phenylethyl resorcinol	Approved, Experimental	DB14120	InChI=1S/C14H14O2/c1-10(11-5-3-2-4-6-11)13-8-7-12(15)9-14(13)16/h2-10,15-16H,1H3	PQSXNIMHIHYFEE-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	Yes	2	2	No	2	0	40.46 Å2	23.25 Å3	64.31 m3·mol-1	2	Yes	No	0.159 mg/mL	3.74	-3.1	9.46	-5.4			
C16H14O4	Not Available	Not Available	270.284	COC1=C(C(=O)\C=C\C2=CC=CC=C2)C(O)=CC(O)=C1	Not Available	Not Available					50185446		CHEMBL378104	557026			HMDB0132913											Cardamomin	ZINC000004716487		Dihydroxymethoxychalcone	Experimental	DB14122	InChI=1S/C16H14O4/c1-20-15-10-12(17)9-14(19)16(15)13(18)8-7-11-5-3-2-4-6-11/h2-10,17,19H,1H3/b8-7+	NYSZJNUIVUBQMM-BQYQJAHWSA-N			Not Available	Small Molecule																																			1	Yes	4	2	No	2	0	66.76 Å2	28.42 Å3	77.3 m3·mol-1	4	Yes	No	0.0777 mg/mL	3.78	-3.5	7.2	-4.9			
C10H12O2	Not Available	Not Available	164.204	COC1=CC(C=CC)=CC=C1O	Not Available	Not Available						18224	CHEMBL2135887	7061				C10469								1363706		Isoeugenol			Isoeugenol	Approved, Experimental	DB14188	InChI=1S/C10H12O2/c1-3-4-8-5-6-9(11)10(7-8)12-2/h3-7,11H,1-2H3	BJIOGJUNALELMI-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	Yes	2	1	No	1	0	29.46 Å2	18.25 Å3	49.86 m3·mol-1	2	Yes	Yes	1.36 mg/mL	2.64	-2.1	10.01	-4.9			
C21H20O9S	No pharmacokinetic data available.	No pharmacokinetic data available.	448.44	COC1=CC(\C=C\C(=O)CC(=O)\C=C\C2=CC=C(OS(O)(=O)=O)C(OC)=C2)=CC=C1O	Not Available	Following oral administration of radio-labelled curcumin to rats, radioactivity was detected in the liver and kidneys 2.	P33261;!P20813;!BE0009758;!P11712;!P08684;!P20815;!P10635;!P05177;!O75897;!P0DMM9;!P49888;!O43704	CYP2C19;!CYP2B6;!;!CYP2C9;!CYP3A4;!CYP3A5;!CYP2D6;!CYP1A2;!SULT1C4;!SULT1A3;!SULT1E1;!SULT1B1	1. Cytochrome P450 2C19;!2. Cytochrome P450 2B6;!3. UDP-glucuronosyltransferases (UGTs) (Protein Group);!4. Cytochrome P450 2C9;!5. Cytochrome P450 3A4;!6. Cytochrome P450 3A5;!7. Cytochrome P450 2D6;!8. Cytochrome P450 1A2;!9. Sulfotransferase 1C4;!10. Sulfotransferase 1A3/1A4;!11. Estrogen sulfotransferase;!12. Sulfotransferase family cytosolic 1B member 1					34988878															ZINC000011524418		Curcumin sulfate	Experimental	DB14635	InChI=1S/C21H20O9S/c1-28-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(21(12-15)29-2)30-31(25,26)27/h3-12,24H,13H2,1-2H3,(H,25,26,27)/b7-3+,8-4+	NEJVQQBBTRFOHB-FCXRPNKRSA-N			In an acute oral toxicity study in mouse, LD50 was >2000 mg/kg MSDS. Single oral doses of curcumin at 1-5 g/kg bw induced no toxic effects in rats 2. There has been no cases of overdose reported 2.	Small Molecule																																			1	Yes	8	2	No	2	-1	136.43 Å2	43.54 Å3	113.8 m3·mol-1	10	Yes	No	0.00831 mg/mL	3.65	-4.7	-2.2	-4.4	P37231;!P11473;!O15440;!P16152;!P09211	PPARG;!VDR;!ABCC5;!CBR1;!GSTP1	1. Peroxisome proliferator-activated receptor gamma;!2. Vitamin D3 receptor;!3. Multidrug resistance-associated protein 5;!4. Carbonyl reductase [NADPH] 1;!5. Glutathione S-transferase P
C18H20O5	Not Available	Not Available	316.353	COC1=CC=C(\C=C/C2=CC(OC)=C(OC)C(OC)=C2)C=C1O	Not Available	Not Available					50005480		CHEMBL67	4508364						7BA								Combretastatin_A-4	ZINC000013452167		Combretastatin A4	Experimental	DB14680	InChI=1S/C18H20O5/c1-20-15-8-7-12(9-14(15)19)5-6-13-10-16(21-2)18(23-4)17(11-13)22-3/h5-11,19H,1-4H3/b6-5-	HVXBOLULGPECHP-WAYWQWQTSA-N			Not Available	Small Molecule																																			1	Yes	5	1	No	2	0	57.15 Å2	33.8 Å3	89.35 m3·mol-1	6	Yes	No	0.00977 mg/mL	3.38	-4.5	9.84	-4.3			
C16H16N4O	Not Available	Not Available	280.331	NC(=N)C1=CC=C(\C=C\C2=C(O)C=C(C=C2)C(N)=N)C=C1	Not Available	Not Available							CHEMBL1301	10612853			HMDB0240284					PA164745514						Hydroxystilbamidine	ZINC000000001547		Hydroxystilbamidine	Approved	DB14753	InChI=1S/C16H16N4O/c17-15(18)12-5-2-10(3-6-12)1-4-11-7-8-13(16(19)20)9-14(11)21/h1-9,21H,(H3,17,18)(H3,19,20)/b4-1+	TUESWZZJYCLFNL-DAFODLJHSA-N			Not Available	Small Molecule																																			1	Yes	5	5	No	2	2	119.97 Å2	30.99 Å3	106.84 m3·mol-1	4	Yes	No	0.0644 mg/mL	1.24	-3.6	8.22	12.14	BSEQ0052171		1. DNA
C14H11NO5	Not Available	Not Available	273.244	OC1=C(O)C(=CC(=C1)C(=O)CC1=CC=CC=C1)[N+]([O-])=O	Not Available	Not Available					50108878		CHEMBL160038	8014109															ZINC000000008750		Nebicapone	Investigational	DB14849	InChI=1S/C14H11NO5/c16-12(6-9-4-2-1-3-5-9)10-7-11(15(19)20)14(18)13(17)8-10/h1-5,7-8,17-18H,6H2	MRFOLGFFTUGAEB-UHFFFAOYSA-N	2		Not Available	Small Molecule																																			1	Yes	5	2	No	2	-1	100.67 Å2	26.52 Å3	71.46 m3·mol-1	4	Yes	No	0.075 mg/mL	2.7	-3.6	5.5	-6.5			
C26H22O10	Not Available	Not Available	494.452	OC(=O)[C@@H](CC1=CC(O)=C(O)C=C1)OC(=O)\C=C\C1=C(/C=C/C2=CC(O)=C(O)C=C2)C(O)=C(O)C=C1	Not Available	Not Available					50414250	9017	CHEMBL457077	4445105				C10492											ZINC000004098737		Salvianolic acid A	Investigational	DB15246	InChI=1S/C26H22O10/c27-18-7-2-14(11-21(18)30)1-6-17-16(4-9-20(29)25(17)33)5-10-24(32)36-23(26(34)35)13-15-3-8-19(28)22(31)12-15/h1-12,23,27-31,33H,13H2,(H,34,35)/b6-1+,10-5+/t23-/m1/s1	YMGFTDKNIWPMGF-UCPJVGPRSA-N			Not Available	Small Molecule																																			1	No	9	7	Yes	3	-1	184.98 Å2	48.67 Å3	130.37 m3·mol-1	9	No	No	0.00867 mg/mL	4.74	-4.8	3.14	-6.3			
C21H22O5	Not Available	Not Available	354.3964	COC1=C(C(=O)\C=C\C2=CC=C(O)C=C2)C(O)=C(CC=C(C)C)C(O)=C1	Not Available	Not Available					50384998	66331	CHEMBL253896	555077			HMDB0037479	C16417										Xanthohumol	ZINC000005158937		Xanthohumol	Investigational	DB15359	InChI=1S/C21H22O5/c1-13(2)4-10-16-18(24)12-19(26-3)20(21(16)25)17(23)11-7-14-5-8-15(22)9-6-14/h4-9,11-12,22,24-25H,10H2,1-3H3/b11-7+	ORXQGKIUCDPEAJ-YRNVUSSQSA-N	1		Not Available	Small Molecule																																			1	Yes	5	3	No	2	-1	86.99 Å2	38.52 Å3	103.53 m3·mol-1	6	No	No	0.00556 mg/mL	5.2	-4.8	7.01	-4.9			
C27H27NO7	Not Available	Not Available	477.513	COC1=CC=C(C=C1)[C@@]12OC3=CC(OC)=CC(OC)=C3[C@]1(O)[C@H](O)[C@@H]([C@H]2C1=CC=CC=C1)C(N)=O	Not Available	Not Available							CHEMBL583207	352511															ZINC000006009986		Didesmethylrocaglamide	Experimental	DB15496	InChI=1S/C27H27NO7/c1-32-17-11-9-16(10-12-17)27-22(15-7-5-4-6-8-15)21(25(28)30)24(29)26(27,31)23-19(34-3)13-18(33-2)14-20(23)35-27/h4-14,21-22,24,29,31H,1-3H3,(H2,28,30)/t21-,22-,24-,26+,27+/m1/s1	RMNPQEWLGQURNX-PXIJUOARSA-N			Not Available	Small Molecule																																			1	Yes	7	3	Yes	5	0	120.47 Å2	49.24 Å3	126.47 m3·mol-1	6	Yes	No	0.0179 mg/mL	1.94	-4.4	11.63	-2.2	P35232;!Q99623	PHB;!PHB2	1. Prohibitin;!2. Prohibitin-2
C18H14N2O4	Not Available	Not Available	322.32	OC1=CC=C(\C=N\NC(=O)C2=CC3=C(C=CC=C3)C=C2O)C=C1O	Not Available	Not Available					50323460	132754	CHEMBL1209885	12549134															ZINC000000096084		Dynasore	Experimental	DB15964	InChI=1S/C18H14N2O4/c21-15-6-5-11(7-17(15)23)10-19-20-18(24)14-8-12-3-1-2-4-13(12)9-16(14)22/h1-10,21-23H,(H,20,24)/b19-10+	SYNDQCRDGGCQRZ-VXLYETTFSA-N			Not Available	Small Molecule																																			1	Yes	5	4	No	3	0	102.15 Å2	33.34 Å3	90.63 m3·mol-1	3	Yes	No	0.0322 mg/mL	3.69	-4	7.77	1.47			
C22H18O10	Not Available	Not Available	442.376	OC1=CC2=C(C[C@H](OC(=O)C3=CC(O)=C(O)C(O)=C3)[C@H](O2)C2=CC(O)=C(O)C=C2)C(O)=C1	Not Available	Not Available					50487717	76132	CHEMBL483083	4440417						XEG									ZINC000004534390		Epigallo Catechin Gallate	Investigational	DB16120	InChI=1S/C22H18O10/c23-11-6-14(25)12-8-19(32-22(30)10-4-16(27)20(29)17(28)5-10)21(31-18(12)7-11)9-1-2-13(24)15(26)3-9/h1-7,19,21,23-29H,8H2/t19-,21+/m0/s1	LSHVYAFMTMFKBA-PZJWPPBQSA-N	3		Not Available	Small Molecule																																			1	Yes	9	7	No	4	0	177.14 Å2	42.06 Å3	109.76 m3·mol-1	4	No	No	0.0443 mg/mL	3.38	-4	8.03	-4.9			
C13H11NO3	Not Available	Not Available	229.235	OC1=CC=C(NC(=O)C2=CC=CC=C2O)C=C1	Not Available	Not Available						31938	CHEMBL389507	4441															ZINC000000001856		Osalmid	Investigational	DB16273	InChI=1S/C13H11NO3/c15-10-7-5-9(6-8-10)14-13(17)11-3-1-2-4-12(11)16/h1-8,15-16H,(H,14,17)	LGCMKPRGGJRYGM-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	Yes	3	3	No	2	0	69.56 Å2	22.57 Å3	65.55 m3·mol-1	2	Yes	No	0.409 mg/mL	2.46	-2.8	7.92	-4.2			
C22H19ClO3	10.4 +/- 5.5 ml/min [HIV-infected patients receiving IV administration]	2.2 to 3.2 days	366.837	OC1=C([C@H]2CC[C@@H](CC2)C2=CC=C(Cl)C=C2)C(=O)C2=CC=CC=C2C1=O	Solid	0.60 ± 0.17 L/kg	P11712;!P08684	CYP2C9;!CYP3A4	1. Cytochrome P450 2C9;!2. Cytochrome P450 3A4		16301	575568	CHEMBL1450	10482034	Drugs.com Drug Page		HMDB0015249	C06835	D00236	AOQ		PA448502	74989	46507298	RxList Drug Page	60212	DAP000156	Atovaquone	ZINC000116473771	Malarone, Mepron	Atovaquone	Approved	DB01117	InChI=1S/C22H19ClO3/c23-16-11-9-14(10-12-16)13-5-7-15(8-6-13)19-20(24)17-3-1-2-4-18(17)21(25)22(19)26/h1-4,9-13,15,26H,5-8H2/t13-,15-	KUCQYCKVKVOKAY-CTYIDZIISA-N	4	Atovaquone is an antimicrobial indicated for the prevention and treatment of Pneumocystis jirovecii pneumonia (PCP) and for the prevention and treatment of Plasmodium falciparum malaria.	The median lethal dose is higher than the maximum oral dose tested in mice and rats (1825 mg/kg per day). Overdoses up to 31,500 mg of atovaquone have been reported. In one such patient who also took an unspecified dose of dapsone, methemoglobinemia occurred. Rash has also been reported after overdose.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.8010 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					5.8				Practically insoluble	1	Yes	3	1	No	4	-1	54.37 Å2	39.64 Å3	103.11 m3·mol-1	2	Yes	No	0.000796 mg/mL	5	-5.7	5.53	-5.3			
C16H12O6	Not Available	Not Available	300.2629	[H][C@]12CC(=O)O[C@]1([H])C1=C(C(=O)C3=C(C=CC=C3O)C1=O)[C@]([H])(C)O2	Solid	Not Available								4883427						NOM			6323454	46507615					ZINC000004983927		Nanaomycin D	Experimental	DB01668	InChI=1S/C16H12O6/c1-6-11-13(16-9(21-6)5-10(18)22-16)14(19)7-3-2-4-8(17)12(7)15(11)20/h2-4,6,9,16-17H,5H2,1H3/t6-,9-,16-/m0/s1	XUWPJKDMEZSVTP-UOSCCXBLSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	3.3215 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	1	No	4	0	89.9 Å2	29.01 Å3	74.26 m3·mol-1	0	Yes	No	1.94 mg/mL	1.46	-2.2	8.21	-4.2	Q53908	actVA 6	1. ActVA 6 protein
C18H17NO4	Not Available	Not Available	311.3319	COC1=CC(=O)C2=C(C(COC3=CC=CC=C3)=C(C)N2C)C1=O	Solid	Not Available							CHEMBL94277	3668219						340			4469805	46505527					ZINC000006469947		5-Methoxy-1,2-Dimethyl-3-(Phenoxymethyl)Indole-4,7-Dione	Experimental	DB03626	InChI=1S/C18H17NO4/c1-11-13(10-23-12-7-5-4-6-8-12)16-17(19(11)2)14(20)9-15(22-3)18(16)21/h4-9H,10H2,1-3H3	JRPJCFILHCLEJI-UHFFFAOYSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Non-substrate	2.7743 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	0	No	3	0	57.53 Å2	33.16 Å3	88.66 m3·mol-1	4	Yes	No	0.0646 mg/mL	2.08	-3.7		-4.6	P15559	NQO1	1. NAD(P)H dehydrogenase [quinone] 1
C21H14O7	Not Available	Not Available	378.3317	COC(=O)C1=C(C)CC(=O)C2=C(O)C3=C(C=C12)C(=O)C1=CC=CC(O)=C1C3=O	Solid	Not Available								4451078						NGV			5289026	46505354					ZINC000012504118		Nogalaviketone	Experimental	DB04064	InChI=1S/C21H14O7/c1-8-6-13(23)16-10(14(8)21(27)28-2)7-11-17(20(16)26)19(25)15-9(18(11)24)4-3-5-12(15)22/h3-5,7,22,26H,6H2,1-2H3	QHNJNOBWURJIEK-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Inhibitor	Non-inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	3.2140 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	6	2	No	4	-1	117.97 Å2	37.73 Å3	99.55 m3·mol-1	2	Yes	No	0.0233 mg/mL	4.4	-4.2	6.96	-5.3	Q9RN59	snoaL	1. Nogalonic acid methyl ester cyclase
C20H24O3	Not Available	Not Available	312.409	CC(C)(C)C1CCC(CC1)C1=C(O)C(=O)C2=CC=CC=C2C1=O	Solid	Not Available								13749867									146797	347827788					ZINC000005114256		BW-A 58C	Experimental	DB06740	InChI=1S/C20H24O3/c1-20(2,3)13-10-8-12(9-11-13)16-17(21)14-6-4-5-7-15(14)18(22)19(16)23/h4-7,12-13,23H,8-11H2,1-3H3	NWCVRXADYNRXCT-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	Yes	3	1	No	3	-1	54.37 Å2	35.62 Å3	91.83 m3·mol-1	2	Yes	No	0.0115 mg/mL	4.29	-4.4	5.95	-5.1			
C19H18N2O3	Not Available	Not Available	322.3578	[H][C@@]1(C)C[N@@]1C1=CC(=O)C2=C(C(CO)=C(N2C)C2=CC=CC=C2)C1=O	Solid	Not Available								26326179						ARH			5287703	99443856							3-(HYDROXYMETHYL)-1-METHYL-5-(2-METHYLAZIRIDIN-1-YL)-2-PHENYL-1H-INDOLE-4,7-DIONE	Experimental	DB07385	InChI=1S/C19H18N2O3/c1-11-9-21(11)14-8-15(23)18-16(19(14)24)13(10-22)17(20(18)2)12-6-4-3-5-7-12/h3-8,11,22H,9-10H2,1-2H3/t11-,21+/m1/s1	RQFCSAVLOHDQNB-FIKIJFGZSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	2.6962 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	1	No	4	0	62.31 Å2	34.78 Å3	93.69 m3·mol-1	3	Yes	No	0.744 mg/mL	1.42	-2.6	14.74	-2.9	P15559	NQO1	1. NAD(P)H dehydrogenase [quinone] 1
C20H20N2O3	Not Available	Not Available	336.3844	[H][C@@]12CC3=C4C(NC=C4[C@]1([H])[C@]1([H])N(C(O)=C(C(C)=O)C1=O)C2(C)C)=CC=C3	Solid	Not Available								58753						CZA			54682463	99444075							(6AR,11AS,11BR)-10-ACETYL-9-HYDROXY-7,7-DIMETHYL-2,6,6A,7,11A,11B-HEXAHYDRO-11H-PYRROLO[1',2':2,3]ISOINDOLO[4,5,6-CD]INDOL-11-ONE	Experimental	DB07604	InChI=1S/C20H20N2O3/c1-9(23)14-18(24)17-16-11-8-21-13-6-4-5-10(15(11)13)7-12(16)20(2,3)22(17)19(14)25/h4-6,8,12,16-17,21,25H,7H2,1-3H3/t12-,16+,17+/m1/s1	RLOAZVAJNNPPDI-DQYPLSBCSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	-	Inhibitor	Non-inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	3.6118 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	2	No	5	-1	73.4 Å2	36.18 Å3	104 m3·mol-1	1	Yes	No	0.169 mg/mL	3.23	-3.3	3.37	-1.8	O14983	ATP2A1	1. Sarcoplasmic/endoplasmic reticulum calcium ATPase 1
C22H18O7	Not Available	Not Available	394.3741	[H][C@]12O[C@]([H])(C(C(=O)OC)=C1C(=O)OC)C(=C2C1=CC=C(O)C=C1)C1=CC=C(O)C=C1	Solid	Not Available							CHEMBL1213270	9706091						HZ3			11531308	99444403					ZINC000016052474		dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate	Experimental	DB07932	InChI=1S/C22H18O7/c1-27-21(25)17-18(22(26)28-2)20-16(12-5-9-14(24)10-6-12)15(19(17)29-20)11-3-7-13(23)8-4-11/h3-10,19-20,23-24H,1-2H3/t19-,20+	CRLQCBACIMUGDZ-BGYRXZFFSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	2.9210 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	2	Yes	4	-1	102.29 Å2	39.94 Å3	103.3 m3·mol-1	6	Yes	No	0.00942 mg/mL	3.01	-4.6	5.87	-4.3	P03372;!Q15596	ESR1;!NCOA2	1. Estrogen receptor alpha;!2. Nuclear receptor coactivator 2
C16H14O5	Not Available	Not Available	286.2794	[H][C@@]1(CC(O)=O)CC2=CC3=C(C(O)=CC=C3)C(=O)C2=C(C)O1	Solid	Not Available						31034		25058731				C12434		SDN			443833	99445012					ZINC000024960091		[(3S)-9-hydroxy-1-methyl-10-oxo-4,10-dihydro-3H-benzo[g]isochromen-3-yl]acetic acid	Experimental	DB08541	InChI=1S/C16H14O5/c1-8-14-10(6-11(21-8)7-13(18)19)5-9-3-2-4-12(17)15(9)16(14)20/h2-5,11,17H,6-7H2,1H3,(H,18,19)/t11-/m0/s1	HHXSOTFPYPQSBU-NSHDSACASA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	3.5183 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	2	No	3	-1	83.83 Å2	29.26 Å3	77.35 m3·mol-1	2	Yes	No	0.13 mg/mL	1.94	-3.3	3.73	-4.8	Q53901	actII	1. ActII protein
C15H14O3	Not Available	Not Available	242.274	CC1(C)CCC2=C(O1)C1=CC=CC=C1C(=O)C2=O	Not Available	Not Available					81348	10429	CHEMBL15192	3748				C10367					3885	347828274					ZINC000001531790		Lapachone	Investigational	DB11948	InChI=1S/C15H14O3/c1-15(2)8-7-11-13(17)12(16)9-5-3-4-6-10(9)14(11)18-15/h3-6H,7-8H2,1-2H3	QZPQTZZNNJUOLS-UHFFFAOYSA-N	2		Not Available	Small Molecule																																			1	Yes	3	0	No	3	0	43.37 Å2	25.65 Å3	69.09 m3·mol-1	0	Yes	No	0.0563 mg/mL	2.63	-3.6		-4.9	P10745	RBP3	1. Retinol-binding protein 3
C20H13NO3	Not Available	Not Available	315.328	CN1C2C3=C(C1C1=CC=CC=C1C2=O)C(=O)C1=CC=CC=C1C3=O	Not Available	Not Available								32700482									72942015	347828706							TU-100	Investigational	DB12467	InChI=1S/C20H13NO3/c1-21-16-10-6-2-3-7-11(10)20(24)17(21)15-14(16)18(22)12-8-4-5-9-13(12)19(15)23/h2-9,16-17H,1H3	KAYRGFYBCCETPE-UHFFFAOYSA-N	2		Not Available	Small Molecule																																			1	Yes	4	0	No	5	0	54.45 Å2	32.1 Å3	89.78 m3·mol-1	0	Yes	No	0.131 mg/mL	2.21	-3.4	11.8	3.87			
C25H24F2N2O3	Not Available	Not Available	438.4665	CC(C)OC(=O)C1=CN(CC(C)(C)C2=C1NC1=CC=CC=C21)C(=O)C1=CC(F)=C(F)C=C1	Not Available	Not Available					28542		CHEMBL454138	8201699						33Y			10026128	347828916					ZINC000040848320		Turofexorate isopropyl	Investigational	DB12719	InChI=1S/C25H24F2N2O3/c1-14(2)32-24(31)17-12-29(23(30)15-9-10-18(26)19(27)11-15)13-25(3,4)21-16-7-5-6-8-20(16)28-22(17)21/h5-12,14,28H,13H2,1-4H3	INASOKQDNHHMRE-UHFFFAOYSA-N	1		Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	62.4 Å2	45.62 Å3	117.9 m3·mol-1	4	No	No	0.00135 mg/mL	5.11	-5.5	13.58	-4.5			
C19H20O3	Not Available	Not Available	296.366	C[C@H]1COC2=C1C(=O)C(=O)C1=C2C=CC2=C1CCCC2(C)C	Not Available	Not Available					57938		CHEMBL187460	140851															ZINC000002109876		Cryptotanshinone	Experimental	DB15579	InChI=1S/C19H20O3/c1-10-9-22-18-12-6-7-13-11(5-4-8-19(13,2)3)15(12)17(21)16(20)14(10)18/h6-7,10H,4-5,8-9H2,1-3H3/t10-/m0/s1	GVKKJJOMQCNPGB-JTQLQIEISA-N			Not Available	Small Molecule																																			1	Yes	3	0	No	4	0	43.37 Å2	33.26 Å3	86.41 m3·mol-1	0	Yes	No	0.00976 mg/mL	3.89	-4.5		-4.9			
C27H44O3	The metabolic clearance rate was 23.5±4.34 ml/min in healthy male volunteers and 10.1±1.35 ml/min in male patients with uraemia 8. In the pediatric patients undergoing peritoneal dialysis receiving dose of 10.2 ng/kg (SD 5.5 ng/kg) for 2 months, the clearance rate was 15.3 mL/hr/kg Label.	After administration of single oral doses, the elimination half life was 5-8 hours Label.	416.6365	C[C@H](CCCC(C)(C)O)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	Solid	Upon intravenous administration, the volume of distribution of calcitriol was 0.49±0.14 L/kg in healthy male volunteers and 0.27±0.06 l/kg in uraemic male patients participating in a pharmacokinetic study 8. There is some evidence that calcitriol is transferred into human milk at low levels (ie, 2.2±0.1 pg/mL) in mothers Label. Calcitriol from maternal circulation may also enter the fetal circulation Label.	Q07973;!P08684	CYP24A1;!CYP3A4	1. 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial;!2. Cytochrome P450 3A4		50200182	17823	CHEMBL846	4444108	Drugs.com Drug Page	GtP Drug Page	HMDB0001903	C01673	D00129	VDX	PDRhealth Drug Page	PA448717	5280453	46508162	RxList Drug Page	1894	DAP000289	Calcitriol	ZINC000100015048	Rocaltrol, Vectical	Calcitriol	Approved, Nutraceutical	DB00136	InChI=1S/C27H44O3/c1-18(8-6-14-26(3,4)30)23-12-13-24-20(9-7-15-27(23,24)5)10-11-21-16-22(28)17-25(29)19(21)2/h10-11,18,22-25,28-30H,2,6-9,12-17H2,1,3-5H3/b20-10+,21-11-/t18-,22-,23-,24+,25+,27-/m1/s1	GMRQFYUYWCNGIN-NKMMMXOESA-N	4	Calcitriol is an active metabolite of vitamin D that is used to treat hyperparathyroidism and is also used in dialysis patients to combat hypocalcemia.	LD50 (oral, rat) = 620 μg/kg; LD50 (intraperitoneal, rat) > 5 mg/kg MSDS.Symptoms of calcitriol toxicity mirrors the early and late signs and symptoms of vitamin D intoxication associated with hypercalcemia 10. Early signs include weakness, headache, somnolence, nausea, vomiting, dry mouth, constipation, muscle pain, bone pain and metallic taste. Late signs are characterized by polyuria, polydipsia, anorexia, weight loss, nocturia, conjunctivitis (calcific), pancreatitis, photophobia, rhinorrhea, pruritus, hyperthermia, decreased libido, elevated BUN, albuminuria, hypercholesterolemia, elevated SGOT and SGPT, ectopic calcification, hypertension, cardiac arrhythmias and, rarely, overt psychosis 10.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	5.1352 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					5		113-114		Insoluble	1	No	3	3	Yes	3	0	60.69 Å2	51.13 Å3	126.53 m3·mol-1	6	Yes	No	0.00667 mg/mL	4.35	-4.8	14.39	-1.3			
C27H44O2	Not Available	288 hours	400.6371	C[C@H](CCCC(C)(C)O)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C	Solid	Not Available	O15528;!Q07973	CYP27B1;!CYP24A1	1. 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial;!2. 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial		50521013	17933	CHEMBL1040	4446820			HMDB0003550	C01561		VDY	PDRhealth Drug Page	PA164745614	5283731	46505690		1855064	DAP000290	Calcifediol	ZINC000004474414	Rayaldee	Calcifediol	Approved, Nutraceutical	DB00146	InChI=1S/C27H44O2/c1-19-10-13-23(28)18-22(19)12-11-21-9-7-17-27(5)24(14-15-25(21)27)20(2)8-6-16-26(3,4)29/h11-12,20,23-25,28-29H,1,6-10,13-18H2,2-5H3/b21-11+,22-12-/t20-,23+,24-,25+,27-/m1/s1	JWUBBDSIWDLEOM-DTOXIADCSA-N	4	Calcifediol is an active metabolite of vitamin D used to treat hyperparathyroidism as well as to combat hypocalcemia in dialysis patients.	Bone pain, constipation (especially in children or adolescents), diarrhea, drowsiness, dryness of mouth; headache (continuing), increased thirst, increase in frequency of urination, especially at night, or in amount of urine, irregular heartbeat, itching skin, loss of appetite, metallic taste, muscle pain, nausea or vomiting (especially in children or adolescents), unusual tiredness or weakness.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	4.1429 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					6				Insoluble	1	No	2	2	Yes	3	0	40.46 Å2	50.38 Å3	125.06 m3·mol-1	6	No	No	0.0022 mg/mL	5.65	-5.3	18.38	-0.98	P11473	VDR	1. Vitamin D3 receptor
C23H36O7	The reported clearance rate of pravastatin ranges from 6.3-13.5 ml.min/kg in adults9 while in children it has been reported to be of 4-11 L/min.8	The reported elimination half-life of pravastatin is reported to be of 1.8 hours.2	424.5277	[H][C@]12[C@H](C[C@H](O)C=C1C=C[C@H](C)[C@@H]2CC[C@@H](O)C[C@@H](O)CC(O)=O)OC(=O)[C@@H](C)CC	Solid	The reported steady-state volume of distribution of pravastatin is reported to be of 0.5 L/kg.9 This pharmacokinetic parameter in children was found to range from 31-37 ml/kg.8					20688	63618	CHEMBL1144	49398	Drugs.com Drug Page		HMDB0005022	C01844	D08410			PA451089	54687	46504851	RxList Drug Page	42463	DAP000550	Pravastatin	ZINC000003798763		Pravastatin	Approved	DB00175	InChI=1S/C23H36O7/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28)/t13-,14-,16+,17+,18+,19-,20-,22-/m0/s1	TUZYXOIXSAXUGO-PZAWKZKUSA-N	4	Pravastatin is an HMG-CoA reductase inhibitor used to lower lipid levels and to reduce the risk of cardiovascular events, including myocardial infarction and stroke.	The reported oral LD50 of pravastatin in mice is of 8939 mg/kg.MSDS There haven't been significant overdosage reports however, in the case of overdosage, symptomatic treatment is recommended along with laboratory monitoring and supportive measures.LabelIn carcinogenic studies, high dose administration of pravastatin has been reported to increase the incidence of hepatocellular carcinomas in males and lung carcinomas in females. There is no evidence relating the administration of pravastatin with mutagenicity in different assays not to produce effects in fertility or reproductive potential.Label	Small Molecule	http://smpdb.ca/view/SMP0000089?highlight[compounds][]=DB00175&highlight[proteins][]=DB00175	Pravastatin Action Pathway																											>600 ºC at 760 mmHg	0.59		171.2 - 173°C	4.2	10 mg/ml	1	Yes	6	4	No	2	-1	124.29 Å2	46.17 Å3	113.6 m3·mol-1	11	Yes	No	0.242 mg/mL	1.65	-3.2	4.21	-2.7	P04035;!Q92769	HMGCR;!HDAC2	1. 3-hydroxy-3-methylglutaryl-coenzyme A reductase;!2. Histone deacetylase 2
C37H67NO13	The clearance of erythromycin in healthy subjects was 0.53 ± 0.13 l/h/kg after a 125mg intravenous dose.11 In a clinical study of healthy patients and patients with liver cirrhosis, clearance of erythromycin was significantly reduced in those with severe liver cirrhosis.17 The clearance in cirrhotic patients was 42.2 ± 10.1 l h–1 versus 113.2 ± 44.2 l h-1 in healthy patients.17	The elimination half-life of oral erythromycin was 3.5 hours according to one study6 and ranged between 2.4-3.1 hours in another study.15 Repetitive dosing of erythromycin leads to increased elimination half-life.16	733.9268	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O	Solid	Erythromycin is found in most body fluids and accumulates in leucocytes and inflammatory liquid.21,5,19 Spinal fluid concentrations of erythromycin are low, however, the diffusion of erythromycin through the blood-brain barrier increases in meningitis, likely due to the presence of inflamed tissues which are easily penetrated.22 Erythromycin crosses the placenta.21					50344942	42355	CHEMBL532	12041	Drugs.com Drug Page		HMDB0014344	C01912	D00140	ERY	PDRhealth Drug Page	PA449493	12560	46508487	RxList Drug Page	4053	DAP000111	Erythromycin	ZINC000085534336	Aktipak, Apo-Erythro-S, Benzamycin, E.E.S., Ery, Ery-tab, Eryc, Erygel, Eryped, Erythro, Erythrocin, Erythrocin Stearate	Erythromycin	Approved, Investigational, Vet approved	DB00199	InChI=1S/C37H67NO13/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30-,31+,32-,34+,35-,36-,37-/m1/s1	ULGZDMOVFRHVEP-RWJQBGPGSA-N	4	Erythromycin is a macrolide antibiotic used to treat and prevent a variety of bacterial infections.	LD50The oral LD50 of erythromycin in rats is 9272 mg/kg.23Overdose informationSymptoms of overdose may include diarrhea, nausea, stomach cramps, and vomiting. Erythromycin should immediately be discontinued in cases of overdose. Rapid elimination of unabsorbed drug should be attempted. Supportive measures should be initiated. Erythromycin is not adequately removed by peritoneal dialysis or hemodialysis.21	Small Molecule	http://smpdb.ca/view/SMP0000250?highlight[compounds][]=DB00199&highlight[proteins][]=DB00199	Erythromycin Action Pathway		Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.2296 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				719.69	2.6	-3.2	133-135	8.88	Soluble in water at 2mg/ml	0	No	13	5	Yes	3	1	193.91 Å2	78.51 Å3	186.04 m3·mol-1	7	No	No	0.459 mg/mL	2.6	-3.2	12.45	9			
C38H72N2O12	Mean apparent plasma cl=630 mL/min (following single 500 mg oral and i.v. dose) Label	Terminal elimination half-life: 68 hours Label	748.9845	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O	Solid	After oral administration, azithromycin is widely distributed in tissues with an apparent steady-state volume of distribution of 31.1 L/kg Label. Significantly greater azithromycin concentrations have been measured in the tissues rather than in plasma or serum Label, 3. The lung, tonsils and prostate are organs have shown a particularly high rate of azithromycin uptake 3.This drug is concentrated within macrophages and polymorphonucleocytes, allowing for effective activity against Chlamydia trachomatis 4. In addition, azithromycin is found to be concentrated in phagocytes and fibroblasts, shown by in vitro incubation techniques. In vivo studies demonstrate that concentration in phagocytes may contribute to azithromycin distribution to inflamed tissues Label.					50373918	2955	CHEMBL529	10482163	Drugs.com Drug Page		HMDB0014352	C06838		ZIT		PA448519	447043	46507743	RxList Drug Page	1299904	DNC001539	Azithromycin	ZINC000085537026	Azasite, Zithromax, Zmax	Azithromycin	Approved	DB00207	InChI=1S/C38H72N2O12/c1-15-27-38(10,46)31(42)24(6)40(13)19-20(2)17-36(8,45)33(52-35-29(41)26(39(11)12)16-21(3)48-35)22(4)30(23(5)34(44)50-27)51-28-18-37(9,47-14)32(43)25(7)49-28/h20-33,35,41-43,45-46H,15-19H2,1-14H3/t20-,21-,22+,23-,24-,25+,26+,27-,28+,29-,30+,31-,32+,33-,35+,36-,37-,38-/m1/s1	MQTOSJVFKKJCRP-BICOPXKESA-N	4	Azithromycin is a macrolide antibiotic used to treat a variety of bacterial infections.	Rat Oral LD50: >2000 mk/kg MSDSPossible major adverse effects include cardiovascular arrhythmias and hearing loss. Macrolide resistance is also an ongoing issue.3 Hepatotoxicity has been observed in rare cases.4A note on the risk of liver toxicity:Due to the act that azithromycin is mainly eliminated by the liver, caution should be observed when azithromycin is given to patients with decreased hepatic function Label. A note on potential renal toxicity:Because limited data in patients with renal GFR <10 mL/min, caution should be exercised when prescribing azithromycin to these patients Label.Use in Pregnancy:This drug is categorized as a pregnancy category B drug. Reproduction studies have been done in rats and mice at doses up to moderately maternally toxic doses (for example, 200 mg/kg/day). These doses, based on a mg/m2 basis, are approximately 4 and 2 times, respectively, the human daily dose of 500 mg. In the animal studies, no harmful effects to the fetus due to azithromycin were observed. There are, at this time, no conclusive and well-controlled studies that have been done in pregnant women. Because animal reproduction studies do not always predict human response, azithromycin should be used during pregnancy only if clearly needed Label.Nursing Mothers: It is unknown at this time whether azithromycin is excreted in human milk. Because many other drugs are excreted in human milk, caution should be observed when azithromycin is given to a nursing woman Label.Carcinogenesis, Mutagenesis, Impairment of Fertility: Long-term studies in animals have not been performed to study carcinogenic potential. Azithromycin has demonstrated no potential to be mutagenic in standard laboratory tests. No evidence of negative effects on fertility due to azithromycin was found Label.	Small Molecule	http://smpdb.ca/view/SMP0000247?highlight[compounds][]=DB00207&highlight[proteins][]=DB00207	Azithromycin Action Pathway		Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Inhibitor	Non-inhibitor	Substrate	2.5423 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.03		126	8.5	soluble in ethanol and DSMO, minimally soluble in water	0	No	13	5	Yes	3	2	180.08 Å2	82.93 Å3	194.11 m3·mol-1	7	No	No	0.514 mg/mL	2.44	-3.2	12.43	9.57			
C24H36O5	Not Available	Lovastatin half-life is reported to be of 13.37 hours.44 The elimination half-life of the hydroxy acid form of lovastatin is reported to be of 0.7-3 hours.6	404.5396	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC	Solid	Lovastatin is able to cross the blood-brain barrier and placenta.44	P08684;!Q15166;!P10632;!P22309;!P35503;!P16662;!P33261	CYP3A4;!PON3;!CYP2C8;!UGT1A1;!UGT1A3;!UGT2B7;!CYP2C19	1. Cytochrome P450 3A4;!2. Serum paraoxonase/lactonase 3;!3. Cytochrome P450 2C8;!4. UDP-glucuronosyltransferase 1-1;!5. UDP-glucuronosyltransferase 1-3;!6. UDP-glucuronosyltransferase 2B7;!7. Cytochrome P450 2C19		34168	40303	CHEMBL503	48085	Drugs.com Drug Page	GtP Drug Page	HMDB0014372	C07074	D00359	803		PA450272	53232	46508223	RxList Drug Page	6472	DAP000551	Lovastatin	ZINC000003812841	Advicor, Altoprev	Lovastatin	Approved, Investigational	DB00227	InChI=1S/C24H36O5/c1-5-15(3)24(27)29-21-11-14(2)10-17-7-6-16(4)20(23(17)21)9-8-19-12-18(25)13-22(26)28-19/h6-7,10,14-16,18-21,23,25H,5,8-9,11-13H2,1-4H3/t14-,15-,16-,18+,19+,20-,21-,23-/m0/s1	PCZOHLXUXFIOCF-BXMDZJJMSA-N	4	Lovastatin is an HMG-CoA reductase inhibitor used to lower LDL cholesterol and reduce the risk of cardiovascular disease and associated conditions, including myocardial infarction and stroke.	The median lethal dose of lovastatin is higher than 15 g/m2. Five healthy human volunteers have received up to 200 mg of lovastatin as a single dose without clinically significant adverse experiences. A few cases of accidental overdosage have been reported; no patients had any specific symptoms, and all patients recovered without sequelae. The maximum dose taken was 5 to 6 g.43In carcinogenic studies, there is an increase in the incidence of hepatocellular carcinomas and adenomas, pulmonary adenomas, papilloma in non-glandular mucose in stomach and thyroid neoplasms. However, with respect to effects on fertility, lovastatin has been reported to present testicular atrophy, decreased spermatogenesis, spermatocytic degeneration and giant cell formation which derived into decreased fertility in males. Lastly, there is no evidence of mutagenicity induced by lovastatin.43	Small Molecule	http://smpdb.ca/view/SMP0000099?highlight[compounds][]=DB00227&highlight[proteins][]=DB00227	Lovastatin Action Pathway		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.0554 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				559.2 ºC at 760 mmHg	4.08		174.5 °C	13.49	0.0004 mg/mL	1	Yes	3	1	Yes	3	0	72.83 Å2	46.06 Å3	113.18 m3·mol-1	7	Yes	No	0.0243 mg/mL	3.9	-4.2	14.91	-2.8			
C22H32O3	Not Available	Not Available	344.4877	[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)CC[C@]12C	Solid	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5			34829	CHEMBL1201173	216968	Drugs.com Drug Page		HMDB0014398	C14643	D02289			PA450346	247839	46506584	RxList Drug Page	29439	DAP001048	Medrysone	ZINC000003977945	Hms	Medrysone	Approved	DB00253	InChI=1S/C22H32O3/c1-12-9-15-17-6-5-16(13(2)23)22(17,4)11-19(25)20(15)21(3)8-7-14(24)10-18(12)21/h10,12,15-17,19-20,25H,5-9,11H2,1-4H3/t12-,15-,16+,17-,19-,20+,21-,22+/m0/s1	GZENKSODFLBBHQ-ILSZZQPISA-N		Medrysone is a topical glucocorticoid applied ophthalmically for the treatment of various ocular inflammatory or allergic conditions.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.3015 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.2		156.5 °C			1	Yes	3	1	No	4	0	54.37 Å2	39.94 Å3	98.85 m3·mol-1	1	Yes	No	0.0337 mg/mL	3.13	-4	18.37	-0.26	P04150	NR3C1	1. Glucocorticoid receptor
C26H35F3O6	Data regarding the clearance of travoprost is not readily available or accessible.	The terminal elimination half-life of travoprost free acid is determined to be approximately 45 minutes, although studies demonstrated half-life values that ranged from 17 to 86 minutes 10,11.	500.5477	CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(=C1)C(F)(F)F	Liquid	Given the data currently available, it has been recorded that travoprost free acid is moderately distributed into body tissues with a volume of distribution of 2.6 L/kg in rats 11.						746859	CHEMBL1200799	4445407	Drugs.com Drug Page		HMDB0014432		D01964		PDRhealth Drug Page	PA164781371	5282226	46507637	RxList Drug Page	283809	DAP000274	Travoprost	ZINC000004474682	Duotrav, Izba, Travatan	Travoprost	Approved	DB00287	InChI=1S/C26H35F3O6/c1-17(2)35-25(33)11-6-4-3-5-10-21-22(24(32)15-23(21)31)13-12-19(30)16-34-20-9-7-8-18(14-20)26(27,28)29/h3,5,7-9,12-14,17,19,21-24,30-32H,4,6,10-11,15-16H2,1-2H3/b5-3-,13-12+/t19-,21-,22-,23+,24-/m1/s1	MKPLKVHSHYCHOC-AHTXBMBWSA-N	4	Travoprost is a prostaglandin analog used in the treatment of elevated intraocular pressure due to open angle glaucoma or ocular hypertension.	No cases of overdose have been reported for travoprost 6. A topical overdose is not likely to occur or to be associated with toxicity 6. A topical overdose of travoprost may be flushed from the eye(s) with lukewarm water 6. Treatment of a suspected oral ingestion is symptomatic and supportive 6.Travoprost has harmful pharmacological effects on pregnancy and/or the fetus/new-born child. Travoprost should not be used during pregnancy unless clearly necessary 6. The medication subsequently must not be used in women of childbearing age/potential unless adequate contraceptive measures are in place 6.It is unknown whether travoprost from the eye drops is excreted in human breast milk. Animal studies have shown excretion of travoprost and metabolites in breast milk 10,11,6. The use of travoprost by breast-feeding mothers is not recommended 6.There are no data on the effects of TRAVATAN on human fertility 10,11,6. Animal studies showed no effect of travoprost on fertility at doses more than 250 times the maximum recommended human ocular dose 6.Use in patients below the age of 16 years is not recommended because of potential safety concerns related to increased pigmentation following long-term chronic use 10,11.No overall clinical differences in safety or effectiveness have been observed between elderly and other adult patients 10,11.Travoprost has been studied in patients with mild to severe hepatic impairment and in patients with mild to severe renal impairment (creatinine clearance as low as 14 ml/min) 6. No dosage adjustment is necessary for these patients 6.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	3.5280 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					4.6				>16 mg/ml at 25.0°C	0	No	5	3	No	2	0	96.22 Å2	50.93 Å3	127.86 m3·mol-1	14	No	No	0.00759 mg/mL	3.84	-4.8	13.95	-2.9	P43088	PTGFR	1. Prostaglandin F2-alpha receptor
C43H68ClNO11	Not Available	Not Available	810.46	[H][C@]1(CC[C@H](Cl)[C@@H](C1)OC)\C=C(/C)[C@@]1([H])OC(=O)[C@]2([H])CCCCN2C(=O)C(=O)[C@]2(O)O[C@@]([H])([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC)C(=O)C[C@H](O)[C@H]1C)OC	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			135888	CHEMBL1200686	21111755	Drugs.com Drug Page						PDRhealth Drug Page	PA164783790	6509979	46505748	RxList Drug Page	321952	DAP000594	Pimecrolimus	ZINC000085536990	Elidel	Pimecrolimus	Approved, Investigational	DB00337	InChI=1S/C43H68ClNO11/c1-10-30-18-24(2)17-25(3)19-36(53-8)39-37(54-9)21-27(5)43(51,56-39)40(48)41(49)45-16-12-11-13-32(45)42(50)55-38(28(6)33(46)23-34(30)47)26(4)20-29-14-15-31(44)35(22-29)52-7/h18,20,25,27-33,35-39,46,51H,10-17,19,21-23H2,1-9H3/b24-18+,26-20+/t25-,27+,28+,29-,30+,31-,32-,33-,35+,36-,37-,38+,39+,43+/m0/s1	KASDHRXLYQOAKZ-XDSKOBMDSA-N	4	Pimecrolimus is a topical calcineurin inhibitor used in the treatment of mild-moderate atopic dermatitis who are not candidates for other types of therapy due to previous lack of response or other reasons.	Side effects include burning sensation, irritation, pruritus, erythema, and skin infections, at the application site.	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.6919 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					4.4					0	No	10	2	Yes	4	0	158.13 Å2	87.79 Å3	214.03 m3·mol-1	6	No	No	0.00152 mg/mL	6.81	-5.7	9.96	-2.9	P42345;!P62942	MTOR;!FKBP1A	1. Serine/threonine-protein kinase mTOR;!2. Peptidyl-prolyl cis-trans isomerase FKBP1A
C21H28O2	Not Available	Dydrogesterone: 5-7 hours, 20-dihydrodydrogesterone (DHD) metabolite: 14-17 hours	312.4458	[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]2([H])C=CC2=CC(=O)CC[C@@]12C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			31527	CHEMBL1200853	8699		GtP Drug Page	HMDB0014522		D01217			PA164745443	9051	46506195		3706	DAP001205	Dydrogesterone	ZINC000003875998		Dydrogesterone	Approved, Investigational, Withdrawn	DB00378	InChI=1S/C21H28O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h4-5,12,16-19H,6-11H2,1-3H3/t16-,17+,18-,19+,20+,21+/m0/s1	JGMOKGBVKVMRFX-HQZYFCCVSA-N	4	Dydrogesterone is a synthetic progesterone for menstrual cycle regulation, infertility treatment, prevention of miscarriage, and other conditions.	No serious or unexpected toxicity has been observed with dydrogesterone. In acute toxicity studies, the LD50 doses in rats exceeded 4,640mg/kg for the oral route.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	1.8041 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.4		168-169			1	Yes	2	0	No	4	0	34.14 Å2	36.39 Å3	93.82 m3·mol-1	1	Yes	Yes	0.00486 mg/mL	3.79	-4.8	19.4	-4.8	P06401	PGR	1. Progesterone receptor
C24H34O4	The mean clearance of medroxyprogesterone acetate (MPA) is 1668±146L/day or 21.9±4.3L/kg/day.5 Due to the high inter patient variability in MPA pharmacokinetics, clearance has been reported to be 1600-4000L/day.15	Oral medroxyprogesterone acetate (MPA) has an absorption half life of 15-30min and a biological half life of 40-60 hours.2 Intramuscular MPA has an absorption half life of 0.86±0.30 days and an elimination half life of 24.03±21.74 days.3 Subcutaneous MPA has an absorption half life of 1.05±0.56 days and an elimination half life of 30.90±15.11 days.3	386.5244	[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)CC[C@]12C	Solid	The volume of distribution of medroxyprogesterone acetate is 20±3L.15	P08684;!P10632;!P26439;!P11712;!P04800	CYP3A4;!CYP2C8;!HSD3B2;!CYP2C9;!Cyp3a1	1. Cytochrome P450 3A4;!2. Cytochrome P450 2C8;!3. 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2;!4. Cytochrome P450 2C9;!5. Cytochrome P450 3A1		50067678	6716	CHEMBL717	6043	Drugs.com Drug Page	GtP Drug Page		C08150	D00951			PA450344	6279	46508895	RxList Drug Page	1000112	DAP001211	Medroxyprogesterone	ZINC000005029557	Depo-provera, Depo-subq Provera, Premphase 28 Day, Prempro 0.625/2.5 28 Day, Provera	Medroxyprogesterone acetate	Approved, Investigational	DB00603	InChI=1S/C24H34O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h13-14,18-20H,6-12H2,1-5H3/t14-,18+,19-,20-,22+,23-,24-/m0/s1	PSGAAPLEWMOORI-PEINSRQWSA-N	4	Medroxyprogesterone acetate is a progestin used as a contraceptive and in the treatment of secondary amenorrhea, abnormal uterine bleeding, pain from endometriosis, endometrial and renal carcinomas, paraphilia in males, and GnRH-dependent precocious puberty.	The oral LD50 in rats is >6400mg/kg and in mice is >16g/kg.16 The intraperitoneal LD50 in rats is >900mg/kg and in mice is >1500mg/kg.16 The subcutaneous LD50 in rats is >900mg/kg and in mice is>1500mg/kg.16Patients experiencing and overdose or oral medroxyprogesterone acetate (MPA) may present with nausea, vomiting, breast tenderness, dizziness, abdominal pain, drowsiness, fatigue, and withdrawal bleeding.10,11 Treat patients by stopping MPA and beginning symptomatic treatment.10,11 Patients who have been given too much of a MPA depo injection should contact a healthcare professional, hospital emergency department, or local poison control immediately.15	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	1.8121 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							205-209		10mM	1	Yes	3	0	No	4	0	60.44 Å2	44.06 Å3	107.81 m3·mol-1	3	Yes	No	0.00221 mg/mL	4.13	-5.2	17.73	-4.9			
C21H26O5	Data regarding the clearance of prednisone is not readily available.9A 5.5µg/h/kg infusion of prednisolone has an average clearance of 0.066±0.12L/h/kg, while a 0.15±0.03L/h/kg infusion has an average clearance of 0.15L/h/kg.3	Prednisone and its active metabolite prednisolone have half lives of 2-3 hours from both immediate and delayed release preparations.9	358.4281	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	Data regarding the volume of distribution for prednisone is not readily available.9 However, a 0.15mg/kg dose of prednisolone has a volume of distribution of 29.3L, while a 0.30mg/kg dose has a volume of distribution of 44.2L.6	P33261;!P20815;!BE0004866;!P11509;!Q16678;!P20813;!P10632;!P11712;!P28845;!P08684	CYP2C19;!CYP3A5;!;!CYP2A6;!CYP1B1;!CYP2B6;!CYP2C8;!CYP2C9;!HSD11B1;!CYP3A4	1. Cytochrome P450 2C19;!2. Cytochrome P450 3A5;!3. Cytochrome P450 3A Subfamily (Protein Group);!4. Cytochrome P450 2A6;!5. Cytochrome P450 1B1;!6. Cytochrome P450 2B6;!7. Cytochrome P450 2C8;!8. Cytochrome P450 2C9;!9. Corticosteroid 11-beta-dehydrogenase isozyme 1;!10. Cytochrome P450 3A4			8382	CHEMBL635	5656	Drugs.com Drug Page		HMDB0014773	C07370	D00473	PDN		PA451100	5865	46508166	RxList Drug Page	8640	DAP001041	Prednisone	ZINC000003875357	Deltasone, Rayos, Winpred	Prednisone	Approved, Vet approved	DB00635	InChI=1S/C21H26O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-15,18,22,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,18+,19-,20-,21-/m0/s1	XOFYZVNMUHMLCC-ZPOLXVRWSA-N		Prednisone is a corticosteroid used to treat inflammation or immune-mediated reactions and to treat endocrine or neoplastic diseases.	Data regarding acute overdoses of prednisone are rare but prolonged high doses of prednisone can lead to a higher incidence and severity of adverse effects such as mental symptoms, moon face, abnormal fat deposits, fluid retention, excessive appetite, weight gain, hypertrichosis, acne, striae, ecchymosis, increased sweating, pigmentation, dry scaly skin, thinning scalp hair, increased blood pressure, tachycardia, thrombophlebitis, decreased resistance to infection, negative nitrogen balance with delayed bone and wound healing, headache, weakness, menstrual disorders, accentuated menopausal symptoms, neuropathy, fractures, osteoporosis, peptic ulcer, decreased glucose tolerance, hypokalemia, and adrenal insufficiency.9	Small Molecule	http://smpdb.ca/view/SMP0000440?highlight[compounds][]=DB00635&highlight[proteins][]=DB00635;!http://smpdb.ca/view/SMP0000631?highlight[compounds][]=DB00635&highlight[proteins][]=DB00635	Prednisone Action Pathway;!Prednisone Metabolism Pathway		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.8914 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					1.46		230 - 235 °C (decomposes)		Very slightly soluble	1	Yes	5	2	No	4	0	91.67 Å2	38.2 Å3	97.57 m3·mol-1	2	Yes	No		1.66		12.58	-3.3	P04150	NR3C1	1. Glucocorticoid receptor
C25H38O5	Not Available	4.85 hours19	418.5662	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC	Solid	Rat studies indicate that when radiolabeled simvastatin was administered, simvastatin-derived radioactivity crossed the blood-brain barrier.29	P08684;!P20815;!P10632;!P11712;!P10635;!P20813;!P22309;!P35503;!P16662;!P33261;!O00748;!P23141	CYP3A4;!CYP3A5;!CYP2C8;!CYP2C9;!CYP2D6;!CYP2B6;!UGT1A1;!UGT1A3;!UGT2B7;!CYP2C19;!CES2;!CES1	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5;!3. Cytochrome P450 2C8;!4. Cytochrome P450 2C9;!5. Cytochrome P450 2D6;!6. Cytochrome P450 2B6;!7. UDP-glucuronosyltransferase 1-1;!8. UDP-glucuronosyltransferase 1-3;!9. UDP-glucuronosyltransferase 2B7;!10. Cytochrome P450 2C19;!11. Cocaine esterase;!12. Liver carboxylesterase 1		50139181	9150	CHEMBL1064	49179	Drugs.com Drug Page		HMDB0005007		D00434		PDRhealth Drug Page	PA451363	54454	46508654	RxList Drug Page	36567	DAP001519	Simvastatin	ZINC000003780893	Cholib, FloLipid, Simcor, Vytorin, Zocor	Simvastatin	Approved	DB00641	InChI=1S/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1	RYMZZMVNJRMUDD-HGQWONQESA-N	4	Simvastatin is an HMG-CoA reductase inhibitor used to lower lipid levels and reduce the risk of cardiovascular events including myocardial infarction and stroke.	Not Available	Small Molecule	http://smpdb.ca/view/SMP0000082?highlight[compounds][]=DB00641&highlight[proteins][]=DB00641	Simvastatin Action Pathway		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.0061 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					4.68		135-138 °C		Insoluble	1	Yes	3	1	Yes	3	0	72.83 Å2	47.88 Å3	117.68 m3·mol-1	7	Yes	No	0.0122 mg/mL	4.46	-4.5	14.91	-2.8			
C26H40O5	The systemic clearance of latanoprost is 7 mL/min/kg.6	The elimination half-life of latanoprost from the plasma is about 17 minutes.3,6 The elimination half-life of latanoprost from the eye is estimated at 2–3 hours.3	432.5928	CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1	Liquid	The volume of distribution of latanoprost is 0.16 ± 0.02 L/kg. The activated acid form of latanoprost can be measured in aqueous humor in the initial 4 hours post-administration, and it is measured in the plasma only for 1 hour following ophthalmic administration.6 This drug is more lipophilic than its parent prostaglandin and easily penetrates the cornea.2 It has been shown to cross the placenta in rats.11			1. Corneal esterases		50240648	6384	CHEMBL1051	4470740	Drugs.com Drug Page		HMDB0014792		D00356		PDRhealth Drug Page	PA164774763	5311221	46506279	RxList Drug Page	43611	DAP001216	Latanoprost	ZINC000012468792	Rocklatan, Xalacom, Xalatan, Xelpros	Latanoprost	Approved, Investigational	DB00654	InChI=1S/C26H40O5/c1-19(2)31-26(30)13-9-4-3-8-12-22-23(25(29)18-24(22)28)17-16-21(27)15-14-20-10-6-5-7-11-20/h3,5-8,10-11,19,21-25,27-29H,4,9,12-18H2,1-2H3/b8-3-/t21-,22+,23+,24-,25+/m0/s1	GGXICVAJURFBLW-CEYXHVGTSA-N	4	Latanoprost is an isopropyl ester prodrug used to treat increased intraocular pressure.	The oral LD50 in the rat is > 50 mg/kg.7An overdose of latanoprost is not expected to result in dangerous patient outcomes, however, conjunctival or episcleral hyperemia may occur.6,8An intravenous infusion of 3 μg/kg of latanoprost in healthy volunteers led to mean plasma concentrations of 200 times higher than a normally administered therapeutic dose and no adverse effects were noted.6 One study suggested that an overdose of latanoprost lead to cystoid macular edema after a large, unintended overdose. This resolved within 4 weeks after 4 weeks following treatment with nepafenac 0.3% eye drops in addition to oral acetazolamide.4 Contact the local poison control center for updated guidance on the management of a latanoprost overdose.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	4.3748 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				583.8	3.98			4.88		1	No	4	3	No	2	0	86.99 Å2	50.9 Å3	124.34 m3·mol-1	14	Yes	No	0.0129 mg/mL	3.98	-4.5	14.47	-2.7			
C47H73NO17	39 +/- 22 mL/hr/kg [febrile neutropenic cancer and bone marrow transplant patients receiving infusion of 1 mg/kg/day at Day 1]17 +/- 6 mL/hr/kg [febrile neutropenic cancer and bone marrow transplant patients receiving infusion of 1 mg/kg/day 3-20 days later]51 +/- 44 mL/hr/kg [febrile neutropenic cancer and bone marrow transplant patients receiving infusion of 2.5 mg/kg/day at Day 1]22 +/- 15 mL/hr/kg [febrile neutropenic cancer and bone marrow transplant patients receiving infusion of 2.5 mg/kg/day 3-20 days later]21 +/- 14 mL/hr/kg [febrile neutropenic cancer and bone marrow transplant patients receiving infusion of 5 mg/kg/day at Day 1]11 +/- 6 mL/hr/kg [febrile neutropenic cancer and bone marrow transplant patients receiving infusion of 5 mg/kg/day 3-20 days later]	An elimination half-life of approximately 15 days follows an initial plasma half-life of about 24 hours.	924.079	[H][C@]12C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](N)[C@@H]3O)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]1C(O)=O)O2	Solid	Not Available					50457967	2682	CHEMBL267345	10237579	Drugs.com Drug Page		HMDB0014819	C06573	D00203			PA448415	5280965	46505473	RxList Drug Page	236594	DAP001322	Amphotericin_B	ZINC000253387843	Abelcet, Ambisome, Amphotec, Fungizone	Amphotericin B	Approved, Investigational	DB00681	InChI=1S/C47H73NO17/c1-27-17-15-13-11-9-7-5-6-8-10-12-14-16-18-34(64-46-44(58)41(48)43(57)30(4)63-46)24-38-40(45(59)60)37(54)26-47(61,65-38)25-33(51)22-36(53)35(52)20-19-31(49)21-32(50)23-39(55)62-29(3)28(2)42(27)56/h5-18,27-38,40-44,46,49-54,56-58,61H,19-26,48H2,1-4H3,(H,59,60)/b6-5+,9-7+,10-8+,13-11+,14-12+,17-15+,18-16+/t27-,28-,29-,30+,31+,32+,33-,34-,35+,36+,37-,38-,40+,41-,42+,43+,44-,46-,47+/m0/s1	APKFDSVGJQXUKY-INPOYWNPSA-N	4	Amphotericin B is an antifungal used to treat fungal infections in neutropenic patients, cryptococcal meningitis in HIV infection, fungal infections, and leishmaniasis.	Oral, rat: LD50 = >5 gm/kg. Amphotericin B overdoses can result in cardio-respiratory arrest.	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.2357 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					0.8		170.0 °C		750 mg/L (at 28 °C)	0	No	17	12	No	3	0	319.61 Å2	99.4 Å3	244.67 m3·mol-1	3	No	No	0.0819 mg/mL	-2.3	-4	3.58	9.11	BMOL0000004		1. Ergosterol
C32H53N2O4	0.25 L/kg/hr [Adults (Ages 27 to 58 years)]0.21 L/kg/hr [Geriatrics (>=65 yrs)]0.16 L/kg/hr [Normal ewnal and hepatice function]0.13 L/kg/hr [Renal transplant patients]0.13 L/kg/hr [Hepatic dysfunction patients]0.35 +/- 0.08 L/kg/hr [Pediatric Patients 3 to <12 mos]0.32 +/- 0.07 L/kg/hr [Pediatric Patients 1 to 3 yrs]0.44 +/- 0.16 L/kg/hr [Pediatric Patients 3 to 8 yrs]	The rapid distribution half-life is 1-2 minutes and the slower distribution half-life is 14-18 minutes. Renal impairment has no net effect on half-life, however, half-life is almost doubled in patients with impaired liver function.	529.7742	[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](O)[C@H](C[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1	Solid	0.3 L/kg [3 to <12 mos]0.26 L/kg [1 to <3 yrs]0.21 L/kg [3 to <8 yrs]						8884	CHEMBL1201244	390053	Drugs.com Drug Page	GtP Drug Page	HMDB0014866	C07556	D00765			PA164754992	441290	46506855	RxList Drug Page	68139	DAP000349	Rocuronium_bromide	ZINC000053229445		Rocuronium	Approved	DB00728	InChI=1S/C32H53N2O4/c1-5-14-34(15-6-7-16-34)28-20-26-24-9-8-23-19-29(36)27(33-12-17-37-18-13-33)21-32(23,4)25(24)10-11-31(26,3)30(28)38-22(2)35/h5,23-30,36H,1,6-21H2,2-4H3/q+1/t23-,24+,25-,26-,27-,28-,29-,30-,31-,32-/m0/s1	YXRDKMPIGHSVRX-OOJCLDBCSA-N	4	Rocuronium is a vecuronium analog used to facilitate tracheal intubation and to relax skeletal muscles during surgery.	No cases of significant accidental or intentional overdose have been reported. Overdosage with neuromuscular blocking agents may result in neuromuscular block beyond the time needed for surgery and anesthesia.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Inhibitor	Inhibitor	Substrate	2.9310 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor									Complete	1	No	4	1	Yes	6	2	59 Å2	62.78 Å3	161.65 m3·mol-1	6	No	No	2.84e-05 mg/mL	-0.33	-7.3	14.59	7.96	Q15822;!P08172;!P46098	CHRNA2;!CHRM2;!HTR3A	1. Neuronal acetylcholine receptor subunit alpha-2;!2. Muscarinic acetylcholine receptor M2;!3. 5-hydroxytryptamine receptor 3A
C20H34O5	Not Available	5 to 10 minutes (after a single dose), in healthy adults and neonates.	354.487	CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O	Solid	Not Available					50101853	15544	CHEMBL495	4444306	Drugs.com Drug Page	GtP Drug Page	HMDB0001442	C04741	D00180	XPG	PDRhealth Drug Page	PA448334	149351	46508029	RxList Drug Page	598	DAP001490	Prostaglandin_E1	ZINC000003813088	Caverject, Edex, Muse, Prostin Vr	Alprostadil	Approved, Investigational	DB00770	InChI=1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h12-13,15-17,19,21,23H,2-11,14H2,1H3,(H,24,25)/b13-12+/t15-,16+,17+,19+/m0/s1	GMVPRGQOIOIIMI-DWKJAMRDSA-N	4	Alprostadil is a medication used to treat erectile dysfunction.	Oral, mouse: LD50 = 186 mg/kg; Oral, rat: LD50 = 228 mg/kg. Apnea, bradycardia, pyrexia, hypotension, and flushing may be signs of drug overdosage.	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.9631 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.20		115-116 °C	4.85 (at 25 °C)	26.7 mg/L	1	Yes	5	3	No	1	-1	94.83 Å2	42.13 Å3	98.32 m3·mol-1	13	Yes	No	0.0788 mg/mL	3.59	-3.6	4.35	-1.6	P43116;!P34995;!Q9Y5Y4	PTGER2;!PTGER1;!PTGDR2	1. Prostaglandin E2 receptor EP2 subtype;!2. Prostaglandin E2 receptor EP1 subtype;!3. Prostaglandin D2 receptor 2
C41H76N2O15	Not Available	12 hours	837.0465	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	Solid	Not Available	P20813;!P08684	CYP2B6;!CYP3A4	1. Cytochrome P450 2B6;!2. Cytochrome P450 3A4			48935	CHEMBL1214185	5291557				C13173	D01710	ROX		PA164750505	6915744	46507676		9478	DAP000885	Roxithromycin	ZINC000096006016		Roxithromycin	Approved, Investigational, Withdrawn	DB00778	InChI=1S/C41H76N2O15/c1-15-29-41(10,49)34(45)24(4)31(42-53-21-52-17-16-50-13)22(2)19-39(8,48)36(58-38-32(44)28(43(11)12)18-23(3)54-38)25(5)33(26(6)37(47)56-29)57-30-20-40(9,51-14)35(46)27(7)55-30/h22-30,32-36,38,44-46,48-49H,15-21H2,1-14H3/b42-31+/t22-,23-,24+,25+,26-,27+,28+,29-,30+,32-,33+,34-,35+,36-,38+,39-,40-,41-/m1/s1	RXZBMPWDPOLZGW-XMRMVWPWSA-N	4	Roxithromycin is an antibiotic used to treat a variety of susceptible bacterial infections.	Roxithromycin primarily causes gastrointestinal adverse events, such as diarrhoea, nausea, abdominal pain and vomiting. Less common adverse events include headaches, rashes, abnormal liver function values and alteration in senses of smell and taste.	Small Molecule	http://smpdb.ca/view/SMP0000251?highlight[compounds][]=DB00778&highlight[proteins][]=DB00778	Roxithromycin Action Pathway		Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Inhibitor	Inhibitor	Substrate	2.9728 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor					1.7				0.0189 mg/L at 25 °C (SRC PhysProp estimated -- MEYLAN,WM et al. (1996))	0	No	16	5	Yes	3	1	216.89 Å2	91.83 Å3	211.24 m3·mol-1	13	No	No	0.187 mg/mL	3	-3.6	12.45	9.08	P0A7J6;!P08183	rplJ;!ABCB1	1. 50S ribosomal protein L10;!2. P-glycoprotein 1
C24H32O4	Not Available	Not Available	384.5085	[H][C@@]12CC[C@@](OC(C)=O)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CC[C@H](OC(C)=O)C=C3CC[C@@]21[H]	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4		50237627	31580	CHEMBL1200624	8913			HMDB0014961	C12724	D01294			PA164749157	9270	46506993	RxList Drug Page	4170	DAP000856	Etynodiol_diacetate	ZINC000003876023	Kelnor 1/35 28 Day, Kelnor 1/50 28 Day, Zovia 1/35e 28 Day, Zovia 1/50e 28 Day	Ethynodiol diacetate	Approved	DB00823	InChI=1S/C24H32O4/c1-5-24(28-16(3)26)13-11-22-21-8-6-17-14-18(27-15(2)25)7-9-19(17)20(21)10-12-23(22,24)4/h1,14,18-22H,6-13H2,2-4H3/t18-,19-,20+,21+,22-,23-,24-/m0/s1	ONKUMRGIYFNPJW-KIEAKMPYSA-N	1	Ethynodiol diacetate is an oral contraceptive used to prevent pregnancy.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.1783 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					5		126-127			1	Yes	2	0	No	4	0	52.6 Å2	44.13 Å3	106.62 m3·mol-1	4	Yes	No	0.00397 mg/mL	3.69	-5		-6.7	P06401;!P03372	PGR;!ESR1	1. Progesterone receptor;!2. Estrogen receptor alpha
C33H47NO13	Not Available	Not Available	665.733	[H][C@@]12C[C@H](O)C[C@]3(O)C[C@H](O)[C@@H](C(O)=O)[C@]([H])(C[C@@H](O[C@]4([H])O[C@H](C)[C@@H](O)[C@H](N)[C@@H]4O)\C=C\C=C\C=C\C=C\C[C@@H](C)OC(=O)\C=C\[C@@]1([H])O2)O3	Solid	Not Available					50370755		CHEMBL1200656	10468784	Drugs.com Drug Page			C08073	D00884			PA164744325	5284447	46509171	RxList Drug Page	7268	DAP001331	Natamycin	ZINC000008220909	Natacyn	Natamycin	Approved	DB00826	InChI=1S/C33H47NO13/c1-18-10-8-6-4-3-5-7-9-11-21(45-32-30(39)28(34)29(38)19(2)44-32)15-25-27(31(40)41)22(36)17-33(42,47-25)16-20(35)14-24-23(46-24)12-13-26(37)43-18/h3-9,11-13,18-25,27-30,32,35-36,38-39,42H,10,14-17,34H2,1-2H3,(H,40,41)/b4-3+,7-5+,8-6+,11-9+,13-12+/t18-,19-,20+,21+,22+,23-,24-,25+,27-,28+,29-,30+,32+,33-/m1/s1	NCXMLFZGDNKEPB-FFPOYIOWSA-N	3	Natamycin is a macrolide antifungal used to treat fungal infections of the eye.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.4181 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					1.1	-3.21	290 dec °C		4100 mg/L (at 21 °C)	0	No	13	7	No	4	0	230.99 Å2	68.58 Å3	169.88 m3·mol-1	3	No	No	0.278 mg/mL	-1.7	-3.4	3.58	9.11	BMOL0000004		1. Ergosterol
C21H28O5	A 0.15mg/kg dose of prednisolone has a clearance of 0.09L/kg/h, while a 0.30mg/kg dose has a clearance of 0.12L/kg/h.1	Prednisolone has a plasma half life of 2.1-3.5 hours.1 This half life is shorter in children and longer in those with liver disease.1	360.444	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	A 0.15mg/kg dose of prednisolone has a volume of distribution of 29.3L, while a 0.30mg/kg dose has a volume of distribution of 44.2L.1	P08684	CYP3A4	1. Cytochrome P450 3A4		19190	8378	CHEMBL131	5552	Drugs.com Drug Page	GtP Drug Page	HMDB0014998	C07369	D00472	TUA		PA451096	5755	46504847	RxList Drug Page	8638	DAP000419	Prednisolone	ZINC000003833821	Millipred Dp 6 Day	Prednisolone	Approved, Vet approved	DB00860	InChI=1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-16,18,22,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1	OIGNJSKKLXVSLS-VWUMJDOOSA-N	4	Prednisolone is a glucocorticoid used to treat adrenocortical insufficiency, inflammatory conditions, and some cancers.	The intraperitoneal LD50 in rats is 2g/kg and 65mg/kg in mice.8 The subcutaneous LD50 in rats is 147mg/kg and >3500mg/kg in mice.8 The oral LD50 in mice is 1680mg/kg.8 In humans, the oral TDLO in men is 9mg/kg/2W and in women is 14mg/kg/13D.8Patients experiencing an overdose of prednisolone may present with gastrointestinal disturbances, insomnia, and restlessness.5 Overdose of oral prednisolone may be treated by gastric lavage or inducing vomiting if the overdose was recent, as well as supportive and symptomatic therapy.9 Chronic overdosage may be treated by dose reduction or treating patients on alternate days.9 An overdose by the ophthalmic route is not expected to cause problems.9	Small Molecule	http://smpdb.ca/view/SMP0000440?highlight[compounds][]=DB00860&highlight[proteins][]=DB00860;!http://smpdb.ca/view/SMP0000441?highlight[compounds][]=DB00860&highlight[proteins][]=DB00860;!http://smpdb.ca/view/SMP0000631?highlight[compounds][]=DB00860&highlight[proteins][]=DB00860;!http://smpdb.ca/view/SMP0000632?highlight[compounds][]=DB00860&highlight[proteins][]=DB00860	Prednisone Action Pathway;!Prednisolone Action Pathway;!Prednisone Metabolism Pathway;!Prednisolone Metabolism Pathway		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.8914 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					1.62	-3.21	235 °C		223 mg/L (at 25 °C)	1	Yes	5	3	No	4	0	94.83 Å2	38.69 Å3	98.49 m3·mol-1	2	Yes	No	0.239 mg/mL	1.27	-3.2	12.59	-2.9			
C44H69NO12	0.040 L/hr/kg [healthy subjects, IV]0.172 ± 0.088 L/hr/kg [healthy subjects, oral]0.083 L/hr/kg [adult kidney transplant patients, IV]0.053 L/hr/kg [adult liver transplant patients, IV]0.051 L/hr/kg [adult heart transplant patients, IV]0.138 ± 0.071 L/hr/kg [pediatric liver transplant patients]0.12 ± 0.04 (range 0.06-0.17) L/hr/kg [pediatric kidney transplant patients] 0.038 ± 0.014 L/hr/kg [patients with renal impairment, 0.02 mg/kg/4 hr dose, IV]0.042 ± 0.02 L/hr/kg [Mild Hepatic Impairment, 0.02 mg/kg/4 hr dose, IV]0.034 ± 0.019 L/hr/kg [Mild Hepatic Impairment, 7.7 mg dose, PO]0.017 ± 0.013 L/hr/kg [Severe hepatic impairment, 0.02 mg/kg/4 hr dose, IV]0.016 ± 0.011 L/hr/kg [Severe hepatic impairment, 8 mg dose, PO]	The elimination half life in adult healthy volunteers, kidney transplant patients, liver transplants patients, and heart transplant patients are approximately 35, 19, 12, 24 hours, respectively. The elimination half life in pediatric liver transplant patients was 11.5±3.8 hours, in pediatric kidney transplant patients was 10.2±5.0 (range 3.4-25) hours.	804.0182	CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC	Solid	2.6 ± 2.1 L/kg [pediatric liver transplant patients]1.07 ± 0.20 L/kg [patients with renal impairment, 0.02 mg/kg/4 hr dose, IV]3.1 ± 1.6 L/kg [Mild Hepatic Impairment, 0.02 mg/kg/4 hr dose, IV]3.7 ± 4.7 L/kg [Mild Hepatic Impairment, 7.7 mg dose, PO]3.9 ± 1.0 L/kg [Severe hepatic impairment, 0.02 mg/kg/4 hr dose, IV]3.1 ± 3.4 L/kg [Severe hepatic impairment, 8 mg dose, PO]	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5		50079777	61049	CHEMBL269732	393220	Drugs.com Drug Page		HMDB15002	C01375	D00107	FK5		PA451578	445643	46506004	RxList Drug Page	235991	DAP000162	Tacrolimus	ZINC000169289411	Advagraf, Astagraf, Envarsus, Modigraf, Prograf, Protopic	Tacrolimus	Approved, Investigational	DB00864	InChI=1S/C44H69NO12/c1-10-13-31-19-25(2)18-26(3)20-37(54-8)40-38(55-9)22-28(5)44(52,57-40)41(49)42(50)45-17-12-11-14-32(45)43(51)56-39(29(6)34(47)24-35(31)48)27(4)21-30-15-16-33(46)36(23-30)53-7/h10,19,21,26,28-34,36-40,46-47,52H,1,11-18,20,22-24H2,2-9H3/b25-19+,27-21+/t26-,28+,29+,30-,31+,32-,33+,34-,36+,37-,38-,39+,40+,44+/m0/s1	QJJXYPPXXYFBGM-LFZNUXCKSA-N	4	Tacrolimus is a calcineurin inhibitor used to prevent organ transplant rejection and to treat moderate to severe atopic dermatitis.	Side effects can be severe and include blurred vision, liver and kidney problems (it is nephrotoxic), seizures, tremors, hypertension, hypomagnesemia, diabetes mellitus, hyperkalemia, itching, insomnia, confusion. LD50=134-194 mg/kg (rat).	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Inhibitor	Inhibitor	Substrate	2.7541 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.3		126 °C		Insoluble	0	No	11	3	Yes	4	0	178.36 Å2	87.9 Å3	215.62 m3·mol-1	7	No	No	0.00402 mg/mL	5.59	-5.3	9.96	-2.9			
C21H27ClO5	Not Available	Not Available	394.889	[H][C@@]12CC[C@](O)(C(=O)OCCl)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Not Available	Not Available						50848		8041134												237027		Loteprednol	ZINC000030691679	Alrex, Lotemax, Zylet	Loteprednol	Approved, Experimental	DB00873	InChI=1S/C21H27ClO5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,18(25)27-11-22)20(15,2)10-16(24)17(14)19/h5,7,9,14-17,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,17+,19-,20-,21-/m0/s1	YPZVAYHNBBHPTO-MXRBDKCISA-N		Loteprednol is a corticosteroid indicated in the treatment of pain and inflammation after cataract surgery.	Not Available	Small Molecule																																			1	Yes	4	2	No	4	0	83.83 Å2	41.29 Å3	102.65 m3·mol-1	3	Yes	No	0.0336 mg/mL	2.52	-4.1	12.01	-2.9			
C51H79NO13	In adult renal transplant patients with low- to moderate-immunologic risk, oral administration of 2 mg sirolimus led to oral clearance of 173 ± 50 mL/h/kg for oral solution and 139 ± 63 mL/h/kg for oral tablets.8	The mean ± SD terminal elimination half-life (t½) of sirolimus after multiple dosing in stable renal transplant patients was estimated to be about 62 ± 16 hours.8	914.187	[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC	Solid	The mean (± SD) blood-to-plasma ratio of sirolimus was 36 ± 18 L in stable renal allograft patients, indicating that sirolimus is extensively partitioned into formed blood elements. The mean volume of distribution (Vss/F) of sirolimus is 12 ± 8 L/kg.8	P08684;!P20815;!P24462	CYP3A4;!CYP3A5;!CYP3A7	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5;!3. Cytochrome P450 3A7		36609	9168	CHEMBL413	10482078	Drugs.com Drug Page		HMDB15015	C07909	D00753	RAP		PA451365	5284616	46505675	RxList Drug Page	35302	DNC001197	Sirolimus	ZINC000169289388	Fyarro, Hyftor, Rapamune	Sirolimus	Approved, Investigational	DB00877	InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1	QFJCIRLUMZQUOT-HPLJOQBZSA-N	4	Sirolimus is an mTOR inhibitor immunosuppressant used to prevent organ transplant rejections, treat lymphangioleiomyomatosis, and treat adults with perivascular epithelioid cell tumors.	Oral LD50 of sirolimus is 800 mg/kg in rats and 2500 mg/kg in mouse.12Sirolimus is a narrow therapeutic index drug.5 Although there are reports of overdose with sirolimus, there is limited information on overdose in the clinical setting. Symptoms of overdose are consistent with the adverse effects of sirolimus. General supportive measures are recommended in the event of an overdose. Because sirolimus has low aqueous solubility and high erythrocyte and plasma protein binding, it is not expected to be dialyzable to any significant extent.8	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Inhibitor	Inhibitor	Substrate	2.8689 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				183-185	4.63					0	No	12	3	Yes	4	0	195.43 Å2	101.74 Å3	250.66 m3·mol-1	6	No	No	0.00173 mg/mL	7.45	-5.7	9.96	-3	P42345	MTOR	1. Serine/threonine-protein kinase mTOR
C24H34O3	Not Available	The serum half-life of rimexolone could not be reliably estimated due to the large number of samples below the quantitation limit of the assay (80 pg/mL). However, based on the time required to reach steady-state, the half-life appears to be short (1-2 hours).	370.533	[H][C@@]12C[C@@H](C)[C@](C)(C(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5		50103606	135566	CHEMBL1200617	4470902	Drugs.com Drug Page				D05729			PA164752251	5311412	46504820	RxList Drug Page	55681	DAP000420	Rimexolone	ZINC000003945984		Rimexolone	Approved	DB00896	InChI=1S/C24H34O3/c1-6-20(27)24(5)14(2)11-18-17-8-7-15-12-16(25)9-10-22(15,3)21(17)19(26)13-23(18,24)4/h9-10,12,14,17-19,21,26H,6-8,11,13H2,1-5H3/t14-,17+,18+,19+,21-,22+,23+,24-/m1/s1	QTTRZHGPGKRAFB-OOKHYKNYSA-N	4	Rimexolone is a glucocorticoid used to treat inflammation of the eye.	Symptoms of overdose include retinal toxicity, glaucoma, and subcapsular cataract.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.1317 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					4.2				Insoluble	1	Yes	3	1	No	4	0	54.37 Å2	42.91 Å3	109.07 m3·mol-1	2	Yes	No	0.0121 mg/mL	4.38	-4.5	18.76	-0.21	P04150	NR3C1	1. Glucocorticoid receptor
C27H44O3	1.49 +/- 0.60 L/h [chronic kidney disease Stage 5 with hemodialysis]1.54 +/- 0.95 L/h [chronic kidney disease Stage 5with peritoneal dialysis]	4 to 6 hours	416.6365	[H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1C[C@@H](O)C[C@H](O)C1)[C@H](C)\C=C\[C@H](C)C(C)(C)O	Solid	30.8 ± 7.5 L [CKD Stage 5-HD]34.9 ± 9.5 L [CKD Stage 5-PD]23.8 L [healthy subjects]	Q07973;!P08684;!P22310	CYP24A1;!CYP3A4;!UGT1A4	1. 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial;!2. Cytochrome P450 3A4;!3. UDP-glucuronosyltransferase 1-4		233195	7931	CHEMBL1200622	4444552	Drugs.com Drug Page		HMDB0015046	C08127	D00930			PA450798	5281104	46505780	RxList Drug Page	73710	DAP000211	Paricalcitol	ZINC000013911941	Zemplar	Paricalcitol	Approved, Investigational	DB00910	InChI=1S/C27H44O3/c1-18(8-9-19(2)26(3,4)30)24-12-13-25-21(7-6-14-27(24,25)5)11-10-20-15-22(28)17-23(29)16-20/h8-11,18-19,22-25,28-30H,6-7,12-17H2,1-5H3/b9-8+,21-11+/t18-,19+,22-,23-,24-,25+,27-/m1/s1	BPKAHTKRCLCHEA-UBFJEZKGSA-N	4	Paricalcitol is a vitamin D analog used to treat hyperparathyroidism associated with stage 3 or greater chronic kidney disease.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	4.4277 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					4.5					1	No	3	3	No	3	0	60.69 Å2	51.06 Å3	127.95 m3·mol-1	5	Yes	No	0.0068 mg/mL	4.26	-4.8	14.81	-1	P11473	VDR	1. Vitamin D3 receptor
C22H38O5	Because of the rapid de-esterification of misoprostol before or during absorption, it is usually undetectable in plasma.8 Misoprostol's active metabolite, misoprostol acid, has a total body clearance of 0.286L/kg/min.8 Subjects with mild renal impairment had a total body clearance of 0.226±0.073L/kg/min, subjects with moderate renal impairment had a total body clearance of 0.270±0.103L/kg/min, and subjects with end stage renal disease had a total body clearance of 0.105±0.052L/kg/min.8	The half life of an 800µg oral dose is 1.0401±0.5090h, for a sublingual dose is 0.8542±0.1170h, and for a buccal dose is 0.8365±0.1346h.5	382.5341	CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC	Liquid	Data regarding the volume of distribution of misoprostol is scarce.The apparent volume of distribution of the active metabolite of misoprostol was in subjects with normal renal function was 13.6±8.0L/kg, with mild renal impairment was 17.3±23.0L/kg, with moderate renal impairment was 14.3±6.8L/kg, and with end stage renal disease was 11.0±9.6L/kg.8					85606	63610	CHEMBL606	4445541	Drugs.com Drug Page		HMDB0015064		D00419			PA450523	5282381	46505041	RxList Drug Page	42331	DAP000358	Misoprostol		Arthrotec, Cytotec, Mifegymiso	Misoprostol	Approved	DB00929	InChI=1S/C22H38O5/c1-4-5-14-22(2,26)15-10-12-18-17(19(23)16-20(18)24)11-8-6-7-9-13-21(25)27-3/h10,12,17-18,20,24,26H,4-9,11,13-16H2,1-3H3/b12-10+/t17-,18-,20-,22?/m1/s1	OJLOPKGSLYJEMD-URPKTTJQSA-N	4	Misoprostol is a prostaglandin E1 analogue used to reduce the risk of NSAID-induced gastric ulcers.	The oral LD50 in rats is 81mg/kg and in mice is 27mg/kg.12 The intraperitoneal LD50 in rats is 40mg/kg and in mice is 70mg/kg.12Patients experiencing an overdose may present with sedation, tremor, convulsions, dyspnea, abdominal pain, diarrhea, fever, palpitations, hypotension, and bradycardia.11,13,14 Hemodialysis is not expected to be useful in the treatment of misoprostol overdose13 but oral activated charcoal may help reduce absorption.14 In the event of an overdose, treat symptoms with supportive therapy.13 This may include removal of undissolved tablets from the vagina or buccal cavity, intravenous fluid replacement, acetaminophen, diazepam, haloperidol, or intramuscular diclofenac depending on the symptoms that present.11	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	3.7051 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							261-263		1.6mg/mL	1	Yes	4	2	No	1	0	83.83 Å2	45.44 Å3	107.88 m3·mol-1	14	Yes	No	0.0164 mg/mL	3.86	-4.4	14.69	-0.95			
C42H78N2O14	Not Available	The mean plasma half-life of erythromycylamine was estimated to be about 8 h (2 to 36 h), with a mean urinary terminal elimination half-life of about 44 h (16 to 65 h) in patients with normal renal function.	835.086	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4		59397	474014	CHEMBL1237072	4976073	Drugs.com Drug Page				D03865	DI0	PDRhealth Drug Page	PA449368	6473883	46509156	RxList Drug Page	23437	DAP000888	Dirithromycin	ZINC000096095661		Dirithromycin	Experimental	DB00954	InChI=1S/C42H78N2O14/c1-15-29-42(10,49)37-24(4)32(43-30(56-37)21-52-17-16-50-13)22(2)19-40(8,48)36(58-39-33(45)28(44(11)12)18-23(3)53-39)25(5)34(26(6)38(47)55-29)57-31-20-41(9,51-14)35(46)27(7)54-31/h22-37,39,43,45-46,48-49H,15-21H2,1-14H3/t22-,23-,24+,25+,26-,27+,28+,29-,30-,31+,32+,33-,34+,35+,36-,37-,39+,40-,41-,42-/m1/s1	WLOHNSSYAXHWNR-DWIOZXRMSA-N	1	Dirithromycin is an antibiotic used to treat a variety of respiratory, skin, and other infections.	The toxic symptoms following an overdose of a macrolide antibiotic may include nausea, vomiting, epigastric distress, and diarrhea.	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.7997 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					1.6				Poor	0	No	15	5	Yes	4	2	196.33 Å2	90.75 Å3	212.95 m3·mol-1	12	No	No	0.23 mg/mL	2.95	-3.6	12.49	9.13	BSEQ0052173		1. 23S ribosomal RNA
C22H30O5	The average plasma clearance of methylprednisolone is 336mL/h/kg.1	Methylprednisolone has a half life of 2.3h.1,6	374.4706	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C	Solid	The average volume of distribution of methylprednisolone is 1.38L/kg.1	BE0009795;!BE0009796;!P08684;!BE0004866;!P11509;!Q16678;!P20813;!P10632;!P33261;!P11712	;!;!CYP3A4;!;!CYP2A6;!CYP1B1;!CYP2B6;!CYP2C8;!CYP2C19;!CYP2C9	1. 20-ketosteroid reductase (20-hydroxysteroid dehydrogenase) (Protein Group);!2. 11beta-hydroxysteroid dehydrogenase (Protein Group);!3. Cytochrome P450 3A4;!4. Cytochrome P450 3A Subfamily (Protein Group);!5. Cytochrome P450 2A6;!6. Cytochrome P450 1B1;!7. Cytochrome P450 2B6;!8. Cytochrome P450 2C8;!9. Cytochrome P450 2C19;!10. Cytochrome P450 2C9		50103616	6888	CHEMBL650	6485	Drugs.com Drug Page		HMDB0015094		D00407			PA450466	6741	46504885	RxList Drug Page	6902	DAP001040	Methylprednisolone	ZINC000003875560	Depo-medrol, Depo-medrol With Lidocaine, Hybrisil, Medrol, Medroloan Suik, Readysharp-p40, Readysharp-p80	Methylprednisolone	Approved, Vet approved	DB00959	InChI=1S/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,17-,19+,20-,21-,22-/m0/s1	VHRSUDSXCMQTMA-PJHHCJLFSA-N	4	Methylprednisolone is a corticosteroid used to treat inflammation or immune reactions across a variety of organ systems, endocrine conditions, and neoplastic diseases.	The oral LD50 in rats is >4g/kg.14 The intraperitoneal LD50 in mice is 2292mg/kg and in rats is 100mg/kg.14Data regarding acute overdoses of glucocorticoids are rare.12,13 Chronic high doses of glucocorticoids can lead to the development of cataract, glaucoma, hypertension, water retention, hyperlipidemia, peptic ulcer, pancreatitis, myopathy, osteoporosis, mood changes, psychosis, dermal atrophy, allergy, acne, hypertrichosis, immune suppression, decreased resistance to infection, moon face, hyperglycemia, hypocalcemia, hypophosphatemia, metabolic acidosis, growth suppression, and secondary adrenal insufficiency.8 Treat acute overdoses with symptomatic and supportive therapy, while chronic overdoses will require temporarily reduced dosages.8,13	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.0025 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					1.525	-2.99	232.5 °C		120 mg/L (at 25 °C)	1	Yes	5	3	No	4	0	94.83 Å2	40.77 Å3	103.04 m3·mol-1	2	Yes	No	0.109 mg/mL	1.56	-3.5	12.59	-2.9	P04150;!P04083	NR3C1;!ANXA1	1. Glucocorticoid receptor;!2. Annexin A1
C27H34O3	Not Available	The elimination half-life from plasma is very short.	406.5571	[H][C@@]12CC[C@H](OC(=O)CCC3=CC=CC=C3)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	Solid	Not Available						7468	CHEMBL1200412	199761	Drugs.com Drug Page		HMDB0015119	C08155	D00956			PA164746281	229455	46506276		31495	DAP000903	Nandrolone	ZINC000003881613		Nandrolone phenpropionate	Approved, Illicit, Investigational	DB00984	InChI=1S/C27H34O3/c1-27-16-15-22-21-11-9-20(28)17-19(21)8-10-23(22)24(27)12-13-25(27)30-26(29)14-7-18-5-3-2-4-6-18/h2-6,17,21-25H,7-16H2,1H3/t21-,22+,23+,24-,25-,27-/m0/s1	UBWXUGDQUBIEIZ-QNTYDACNSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	1.8785 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							118 °C		3090 mg/L (at 25 °C)	1	No	2	0	No	5	0	43.37 Å2	47.83 Å3	118.43 m3·mol-1	5	No	No	0.000458 mg/mL	5.79	-6	18.25	-4.7	P10275	AR	1. Androgen receptor
C20H24O2	Not Available	24 hours	296.4034	[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC(=C)C2=CC(=O)C=C[C@]12C	Solid	Not Available	P11511;!P08684	CYP19A1;!CYP3A4	1. Cytochrome P450 19A1;!2. Cytochrome P450 3A4		50398447	4953	CHEMBL1200374	54278	Drugs.com Drug Page		HMDB0015125	C08162	D00963	EXM		PA449563	60198	46508243	RxList Drug Page	258494	DAP000625	Exemestane	ZINC000003973334	Aromasin	Exemestane	Approved, Investigational	DB00990	InChI=1S/C20H24O2/c1-12-10-14-15-4-5-18(22)20(15,3)9-7-16(14)19(2)8-6-13(21)11-17(12)19/h6,8,11,14-16H,1,4-5,7,9-10H2,2-3H3/t14-,15-,16-,19+,20-/m0/s1	BFYIZQONLCFLEV-DAELLWKTSA-N	4	Exemestane is an aromatase inhibitor used to treat breast cancer in postmenopausal women after treatment with tamoxifen.	Convulsions	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.7582 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.7		155.13 °C		Non-soluble	1	Yes	2	0	No	4	0	34.14 Å2	33.72 Å3	89.03 m3·mol-1	0	Yes	Yes	0.00683 mg/mL	3.87	-4.6		-5			
C22H32O4	20 mL/min/kg [Normal subjects]	20-30 minutes	360.494	[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)C(C)CC#CC)[C@@]1([H])C\C(C2)=C\CCCC(O)=O	Solid	0.7 to 0.8 L/kg					23954	63916	CHEMBL494	4470703	Drugs.com Drug Page							PA164746843	5311181	46507818	RxList Drug Page	40138	DAP000273	Iloprost		Ventavis	Iloprost	Approved, Investigational	DB01088	InChI=1S/C22H32O4/c1-3-4-7-15(2)20(23)11-10-18-19-13-16(8-5-6-9-22(25)26)12-17(19)14-21(18)24/h8,10-11,15,17-21,23-24H,5-7,9,12-14H2,1-2H3,(H,25,26)/b11-10+,16-8+/t15?,17-,18+,19-,20+,21+/m0/s1	HIFJCPQKFCZDDL-ACWOEMLNSA-N	4	Iloprost is a synthetic prostacyclin analog indicated to treat pulmonary arterial hypertension (PAH).	Overdoses can lead to hypotension, headache, flushing, nausea, vomiting, and diarrhea.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.7260 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					4.8				Very slightly soluble	1	Yes	4	3	No	2	-1	77.76 Å2	42.68 Å3	105.18 m3·mol-1	9	Yes	No	0.00874 mg/mL	3.56	-4.6	4.66	-0.87	P43119;!P34995;!P27815;!Q07343;!Q08493;!Q08499;!P00750;!Q9Y5Y4	PTGIR;!PTGER1;!PDE4A;!PDE4B;!PDE4C;!PDE4D;!PLAT;!PTGDR2	1. Prostacyclin receptor;!2. Prostaglandin E2 receptor EP1 subtype;!3. cAMP-specific 3',5'-cyclic phosphodiesterase 4A;!4. cAMP-specific 3',5'-cyclic phosphodiesterase 4B;!5. cAMP-specific 3',5'-cyclic phosphodiesterase 4C;!6. cAMP-specific 3',5'-cyclic phosphodiesterase 4D;!7. Tissue-type plasminogen activator;!8. Prostaglandin D2 receptor 2
C29H44O12	Not Available	Not Available	584.6525	[H][C@@]12CC[C@]3(O)C[C@H](C[C@@H](O)[C@]3(CO)[C@@]1([H])[C@H](O)C[C@]1(C)[C@H](CC[C@]21O)C1=CC(=O)OC1)O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O	Solid	Not Available					50286739	472805	CHEMBL222863	388599			HMDB0015224	C01443	D00112	OBN		PA163522138	439501	46505479		7762	DAP000465	Ouabain	ZINC000008143614		Ouabain	Approved	DB01092	InChI=1S/C29H44O12/c1-13-22(34)23(35)24(36)25(40-13)41-15-8-19(32)28(12-30)21-17(3-5-27(28,37)9-15)29(38)6-4-16(14-7-20(33)39-11-14)26(29,2)10-18(21)31/h7,13,15-19,21-25,30-32,34-38H,3-6,8-12H2,1-2H3/t13-,15-,16+,17+,18+,19+,21+,22-,23+,24+,25-,26+,27-,28+,29-/m0/s1	LPMXVESGRSUGHW-HBYQJFLCSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	4.7797 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor					-2.00		200 °C		1.03E+004 mg/L	0	No	11	8	No	6	-1	206.6 Å2	59.92 Å3	140.83 m3·mol-1	4	No	No	4.61 mg/mL	-2.8	-2.1	7.18	-2.9	P05023;!P50993;!P13637	ATP1A1;!ATP1A2;!ATP1A3	1. Sodium/potassium-transporting ATPase subunit alpha-1;!2. Sodium/potassium-transporting ATPase subunit alpha-2;!3. Sodium/potassium-transporting ATPase subunit alpha-3
C26H38O4	Not Available	Not Available	414.586	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)C(=O)COC(=O)C(C)(C)C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			50782	CHEMBL1200592	10050591								PA449245	11876263	46506381		22537	DAP001106	Desoxycorticosterone_pivalate	ZINC000004082455		Desoxycorticosterone pivalate	Experimental, Vet approved	DB01134	InChI=1S/C26H38O4/c1-24(2,3)23(29)30-15-22(28)21-9-8-19-18-7-6-16-14-17(27)10-12-25(16,4)20(18)11-13-26(19,21)5/h14,18-21H,6-13,15H2,1-5H3/t18-,19-,20-,21+,25-,26-/m0/s1	VVOIQBFMTVCINR-WWMZEODYSA-N			Symptoms of overdose include polyuria, polydipsia, increased blood volume, edema, and cardiac enlargement.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	1.7883 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					4				Insoluble	1	Yes	3	0	No	4	0	60.44 Å2	48.3 Å3	117.26 m3·mol-1	5	No	No	0.00141 mg/mL	5.57	-5.5	17.19	-4.8	P08235	NR3C2	1. Mineralocorticoid receptor
C38H69NO13	Not Available	3-4 hours	747.9534	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC	Solid	Not Available					50404044	3732	CHEMBL1741	10342604	Drugs.com Drug Page		HMDB0015342	C06912	D00276	CTY		PA449028	84029	46506489	RxList Drug Page	21212	DAP000410	Clarithromycin	ZINC000085534098	Biaxin, Biaxin Bid, Omeclamox, Prevpac	Clarithromycin	Approved	DB01211	InChI=1S/C38H69NO13/c1-15-26-38(10,45)31(42)21(4)28(40)19(2)17-37(9,47-14)33(52-35-29(41)25(39(11)12)16-20(3)48-35)22(5)30(23(6)34(44)50-26)51-27-18-36(8,46-13)32(43)24(7)49-27/h19-27,29-33,35,41-43,45H,15-18H2,1-14H3/t19-,20-,21+,22+,23-,24+,25+,26-,27+,29-,30+,31-,32+,33-,35+,36-,37-,38-/m1/s1	AGOYDEPGAOXOCK-KCBOHYOISA-N	4	Clarithromycin is a macrolide antibiotic used for the treatment of a wide variety of bacterial infections such as acute otitis, pharyngitis, tonsillitis, respiratory tract infections, uncomplicated skin infections, and helicobacter pylori infection.	Symptoms of toxicity include diarrhea, nausea, abnormal taste, dyspepsia, and abdominal discomfort. Transient hearing loss with high doses has been observed. Pseudomembraneous colitis has been reported with clarithromycin use. Allergic reactions ranging from urticaria and mild skin eruptions to rare cases of anaphylaxis and Stevens-Johnson syndrome have also occurred. Rare cases of severe hepatic dysfunctions also have been reported. Hepatic failure is usually reversible, but fatalities have been reported. Clarithromycin may also cause tooth decolouration which may be removed by dental cleaning. Fetal abnormalities, such as cardiovascular defects, cleft palate and fetal growth retardation, have been observed in animals. Clarithromycin may cause QT prolongation.	Small Molecule	http://smpdb.ca/view/SMP0000248?highlight[compounds][]=DB01211&highlight[proteins][]=DB01211	Clarithromycin Action Pathway		Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Inhibitor	Non-inhibitor	Substrate	2.7236 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.16		220 dec °C	8.99 (at 25 °C)	0.33 mg/L	0	No	13	4	Yes	3	1	182.91 Å2	82.03 Å3	190.79 m3·mol-1	8	No	No	0.217 mg/mL	3.24	-3.5	12.46	9			
C25H34O6	Budesonide has a plasma clearance of 0.9-1.8L/min.9,10,15,16 The 22R form has a clearance of 1.4L/min while the 22S form has a clearance of 1.0L/min.11 The clearance in asthmatic children 4-6 years old is 0.5L/min.12,14	Budesonide has a plasma elimination half life of 2-3.6h.9,10,11,15 The terminal elimination half life in asthmatic children 4-6 years old is 2.3h.12	430.5339	[H][C@@]12C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	The volume of distribution of budesonide is 2.2-3.9L/kg.9,10,11,12,15,16	P20815;!BE0004866;!P11509;!Q16678;!P20813;!P10632;!P11712;!P33261;!P08684	CYP3A5;!;!CYP2A6;!CYP1B1;!CYP2B6;!CYP2C8;!CYP2C9;!CYP2C19;!CYP3A4	1. Cytochrome P450 3A5;!2. Cytochrome P450 3A Subfamily (Protein Group);!3. Cytochrome P450 2A6;!4. Cytochrome P450 1B1;!5. Cytochrome P450 2B6;!6. Cytochrome P450 2C8;!7. Cytochrome P450 2C9;!8. Cytochrome P450 2C19;!9. Cytochrome P450 3A4		50354850	3207	CHEMBL1370	4444479	Drugs.com Drug Page		HMDB0015353		D00246		PDRhealth Drug Page	PA448681	5281004	46504869	RxList Drug Page	19831	DAP000320	Budesonide		Breyna, Breztri, Cortiment, Entocort, Ortikos, Pulmicort, Pulmicort Turbuhaler, Rhinocort, Symbicort, Tarpeyo, Uceris	Budesonide	Approved	DB01222	InChI=1S/C25H34O6/c1-4-5-21-30-20-11-17-16-7-6-14-10-15(27)8-9-23(14,2)22(16)18(28)12-24(17,3)25(20,31-21)19(29)13-26/h8-10,16-18,20-22,26,28H,4-7,11-13H2,1-3H3/t16-,17-,18-,20+,21?,22+,23-,24-,25+/m0/s1	VOVIALXJUBGFJZ-KWVAZRHASA-N	4	Budesonide is a corticosteroid used to treat Crohn's disease, asthma, COPD, hay fever and allergies, and ulcerative colitis.	Acute overdose of corticosteroids is rare, however prolonged high dosing of corticosteroids can lead to hypercorticism and adrenal axis suppression.9,10,11,12,14,15,16 In the case of overdose, reduce the dosage of corticosteroids temporarily.9,10,11,12,14,15,16A 200mg oral dose is lethal to female mice while a 400mg oral dose is lethal to male mice.9,10,15	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1601 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				599.7	1.914		226°C			1	Yes	6	2	No	5	0	93.06 Å2	46.88 Å3	116.11 m3·mol-1	4	Yes	No	0.0457 mg/mL	2.73	-4	13.75	-2.9			
C20H32O5	Not Available	The in vitro half-life of epoprostenol in human blood at 37°C and pH 7.4 is approximately 6 minutes; the in vivo half-life of epoprostenol in humans is therefore expected to be no greater than 6 minutes.	352.4651	[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)CCCCC)[C@@]1([H])C\C(O2)=C\CCCC(O)=O	Solid	357 mL/kg						15552	CHEMBL1139	4445566	Drugs.com Drug Page		HMDB0001335	C01312	D00106			PA449479	5280427	46507362	RxList Drug Page	8814	DAP001213	Prostacyclin	ZINC000003813078	Flolan, Veletri	Epoprostenol	Approved	DB01240	InChI=1S/C20H32O5/c1-2-3-4-7-14(21)10-11-16-17-12-15(8-5-6-9-20(23)24)25-19(17)13-18(16)22/h8,10-11,14,16-19,21-22H,2-7,9,12-13H2,1H3,(H,23,24)/b11-10+,15-8-/t14-,16+,17+,18+,19-/m0/s1	KAQKFAOMNZTLHT-OZUDYXHBSA-N	4	Epoprostenol is a vasodilator and platelet aggregation inhibitor used for the management of primary pulmonary hypertension and pulmonary hypertension in patients with heart failure.	Symptoms of overdose are extensions of its dose-limiting pharmacologic effects and include flushing, headache, hypotension, nausea, vomiting, and diarrhea. Most events were self-limiting and resolved with reduction or withholding of epoprostenol. Single intravenous doses at 10 and 50 mg/kg (2703 and 27,027 times the recommended acute phase human dose based on body surface area) were lethal to mice and rats, respectively. Symptoms of acute toxicity were hypoactivity, ataxia, loss of righting reflex, deep slow breathing, and hypothermia.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.6928 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3					1	Yes	5	3	No	2	-1	86.99 Å2	41.09 Å3	99.01 m3·mol-1	10	Yes	No	0.136 mg/mL	2.42	-3.4	4.43	-1.6	Q16647;!Q9H244;!P43119	PTGIS;!P2RY12;!PTGIR	1. Prostacyclin synthase;!2. P2Y purinoceptor 12;!3. Prostacyclin receptor
C43H53NO14	21 L/h/m2 [Total body clearance, cancer patients after IV administration of 20–115 mg/m2]	Dose-dependent. Doses of 70 mg per square meter of body surface area (mg/m 2 ) or higher produce a triphasic elimination profile. With lower doses, assay limitations precluded detection of the terminal elimination phase. The half-life of the alpha, beta, and gamma phase are 4 minutes, 36 minutes, and 11.1 hours, respectively.	807.8792	[H][C@@]1(C[C@@]2(O)[C@@H](OC(=O)C3=CC=CC=C3)[C@]3([H])[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C(=C1C)C2(C)C)OC(C)=O)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1	Solid	The initial rapid decline represents distribution to the peripheral compartments and the late (terminal) phase is due, in part, to a relatively slow efflux of docetaxel from the peripheral compartment.* 113 L	P08684;!P20815;!P24462;!Q16678	CYP3A4;!CYP3A5;!CYP3A7;!CYP1B1	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5;!3. Cytochrome P450 3A7;!4. Cytochrome P450 1B1		36351	4672	CHEMBL92	130581	Drugs.com Drug Page		HMDB0015378	C11231	D02165	TXL		PA449383	148124	46506766	RxList Drug Page	1299922	DAP000590	Docetaxel	ZINC000085537053	Taxotere	Docetaxel	Approved, Investigational	DB01248	InChI=1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1	ZDZOTLJHXYCWBA-VCVYQWHSSA-N	4	Docetaxel is a taxoid antineoplastic agent used in the treatment of various cancers, such as locally advanced or metastatic breast cancer, metastatic prostate cancer, gastric adenocarcinoma, and head and neck cancer.	Oral LD50 in rat is >2000 mg/kg. Anticipated complications of overdosage include: bone marrow suppression, peripheral neurotoxicity, and mucositis. In two reports of overdose, one patient received 150 mg/m2 and the other received 200 mg/m2 as 1-hour infusions. Both patients experienced severe neutropenia, mild asthenia, cutaneous reactions, and mild paresthesia, and recovered without incident.	Small Molecule	http://smpdb.ca/view/SMP0000435?highlight[compounds][]=DB01248&highlight[proteins][]=DB01248	Docetaxel Action Pathway		Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.5741 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.4		232 °C		Insoluble	0	No	10	5	Yes	6	0	224.45 Å2	82.15 Å3	203.9 m3·mol-1	13	No	No	0.0127 mg/mL	2.92	-4.8	11.9	-3	Q9H4B7;!P11137;!P27816;!P10636;!P10415;!O75469	TUBB1;!MAP2;!MAP4;!MAPT;!BCL2;!NR1I2	1. Tubulin beta-1 chain;!2. Microtubule-associated protein 2;!3. Microtubule-associated protein 4;!4. Microtubule-associated protein tau;!5. Apoptosis regulator Bcl-2;!6. Nuclear receptor subfamily 1 group I member 2
C24H32O6	Not Available	Not Available	416.5073	[H][C@@]12C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			204734	CHEMBL1201109	4470603	Drugs.com Drug Page		HMDB0015389		D03696		PDRhealth Drug Page	PA164776996	5311066	46506186	RxList Drug Page	3254	DAP001188	Desonide	ZINC000004212851	Desonate, Desowen, Desrx, Lokara, Tridesilon, Verdeso	Desonide	Approved, Investigational	DB01260	InChI=1S/C24H32O6/c1-21(2)29-19-10-16-15-6-5-13-9-14(26)7-8-22(13,3)20(15)17(27)11-23(16,4)24(19,30-21)18(28)12-25/h7-9,15-17,19-20,25,27H,5-6,10-12H2,1-4H3/t15-,16-,17-,19+,20+,22-,23-,24+/m0/s1	WBGKWQHBNHJJPZ-LECWWXJVSA-N	4	Desonide is a topical corticosteroid used for the symptomatic treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	2.5316 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					1.4		257-260		Practically insoluble	1	Yes	6	2	No	5	0	93.06 Å2	44.59 Å3	112.06 m3·mol-1	2	Yes	No	0.0594 mg/mL	1.9	-3.8	13.75	-2.9	P04150	NR3C1	1. Glucocorticoid receptor
C42H69NO15	Not Available	Not Available	827.995	CO[C@H]1[C@@H](CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@@H]1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C)OC(C)=O	Solid	Not Available						31739	CHEMBL224436	4445361			HMDB0015418	C12662	D01235			PA164749133	5282165	46505431		6084	DAP000887	Josamycin	ZINC000096006021		Josamycin	Investigational	DB01321	InChI=1S/C42H69NO15/c1-23(2)19-32(47)56-40-27(6)53-34(22-42(40,8)50)57-37-26(5)54-41(36(49)35(37)43(9)10)58-38-29(17-18-44)20-24(3)30(46)16-14-12-13-15-25(4)52-33(48)21-31(39(38)51-11)55-28(7)45/h12-14,16,18,23-27,29-31,34-41,46,49-50H,15,17,19-22H2,1-11H3/b13-12+,16-14+/t24-,25-,26-,27+,29+,30+,31-,34+,35-,36-,37-,38+,39+,40+,41+,42-/m1/s1	XJSFLOJWULLJQS-NGVXBBESSA-N	3	Josamycin is a macrolide antibiotic used for the treatment of various susceptible bacterial infections.	Not Available	Small Molecule	http://smpdb.ca/view/SMP0000731?highlight[compounds][]=DB01321&highlight[proteins][]=DB01321	Josamycin Action Pathway		Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	1.8513 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							131.5 °C			0	No	13	3	Yes	3	1	206.05 Å2	87.66 Å3	211.03 m3·mol-1	14	No	No	0.0535 mg/mL	3.22	-4.2	12.71	7.9	P44345	rplD	1. 50S ribosomal protein L4
C24H30O3	Drospirenone is rapidly cleared, typically within 2-3 days of administration of the last active tablet.14 The rate of clearance of drospirenone calculated in the serum ranges from 1.2-1.5 ml/min/kg, however, this value can vary by up to 25% according to the patient.23	The serum half-life of drospirenone is estimated to be 30 hours.13 The half-life of drospirenone metabolite excretion in the urine and feces is approximately 40 hours.23	366.4932	[H][C@@]12C[C@]1([H])[C@@]1([H])[C@]3([H])[C@]4([H])C[C@]4([H])[C@@]4(CCC(=O)O4)[C@@]3(C)CC[C@]1([H])[C@@]1(C)CCC(=O)C=C21	Solid	The volume of distribution of drospirenone is estimated to be 4 L/kg, according to the FDA label for Yaz.19 Prescribing information from a combination of estradiol and drospirenone estimates the volume of distribution to range from 3.7- 4.2 L/kg.23	P35354;!P27169;!P08684	PTGS2;!PON1;!CYP3A4	1. Prostaglandin G/H synthase 2;!2. Serum paraoxonase/arylesterase 1;!3. Cytochrome P450 3A4		150275	50838	CHEMBL1509	62105	Drugs.com Drug Page		HMDB0015467		D03917			PA164749409	68873	46507653	RxList Drug Page	11636	DAP001206	Drospirenone	ZINC000003927200	Angeliq 0.25/0.5 28 Day, Beyaz 28 Day, Gianvi 28-day, Jasmiel 28 Day, Lo-zumandimine 28 Day, Loryna, Nextstellis 28 Day, Nikki 28 Day, Ocella 28 Day, Safyral 28 Day, Slynd, Syeda 28 Day, Vestura, Yasmin, Yasmin 28 Day, Yaz 28 Day, Yaz Plus, Zarah, Zumandimine 28 Day	Drospirenone	Approved	DB01395	InChI=1S/C24H30O3/c1-22-6-3-12(25)9-17(22)13-10-14(13)20-16(22)4-7-23(2)21(20)15-11-18(15)24(23)8-5-19(26)27-24/h9,13-16,18,20-21H,3-8,10-11H2,1-2H3/t13-,14+,15-,16+,18+,20-,21+,22-,23+,24+/m1/s1	METQSPRSQINEEU-HXCATZOESA-N	4	Drospirenone is a progestin used in oral contraceptive pills for the prevention of pregnancy and other conditions.	The oral LD50 of drospirenone in rats is >2000 mg/kg.22Overdose informationAn overdose of drospirenone, like other oral contraceptives, may lead to cause nausea or withdrawal bleeding. For drospirenone in particular, as an analog of spironolactone, may affect the levels of serum sodium and potassium. Their concentrations should be monitored in cases of overdose in addition to monitoring from metabolic acidosis and hyperkalemia, which may also result.15,19	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.9430 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				552.2	3.08	-5.2	196-200	-5		1	Yes	2	0	No	7	0	43.37 Å2	41.81 Å3	101.68 m3·mol-1	0	Yes	No	0.00225 mg/mL	3.37	-5.2	18.52	-5	P08235;!P10275;!P06401;!P04150	NR3C2;!AR;!PGR;!NR3C1	1. Mineralocorticoid receptor;!2. Androgen receptor;!3. Progesterone receptor;!4. Glucocorticoid receptor
C32H44O7	152 L/hr [Following IV administration of 800 mcg of ciclesonide]	Not Available	540.697	[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(O[C@@H](O2)C1CCCCC1)C(=O)COC(=O)C(C)C	Solid	Not Available	P23141;!P08684;!P10635	CES1;!CYP3A4;!CYP2D6	1. Liver carboxylesterase 1;!2. Cytochrome P450 3A4;!3. Cytochrome P450 2D6		50247997	31397	CHEMBL2040682	5293368	Drugs.com Drug Page				D01703			PA164781399	6918155	46508553	RxList Drug Page	274964	DAP000423	Ciclesonide	ZINC000003915154	Alvesco, Omnaris, Zetonna	Ciclesonide	Approved, Investigational	DB01410	InChI=1S/C32H44O7/c1-18(2)28(36)37-17-25(35)32-26(38-29(39-32)19-8-6-5-7-9-19)15-23-22-11-10-20-14-21(33)12-13-30(20,3)27(22)24(34)16-31(23,32)4/h12-14,18-19,22-24,26-27,29,34H,5-11,15-17H2,1-4H3/t22-,23-,24-,26+,27+,29+,30-,31-,32+/m0/s1	LUKZNWIVRBCLON-GXOBDPJESA-N	4	Ciclesonide is a glucocorticoid used in the symptomatic relief of nasal symptoms associated with seasonal and perennial allergic rhinitis in adults and adolescents.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	3.5547 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	6	1	Yes	6	0	99.13 Å2	60.18 Å3	146.28 m3·mol-1	6	No	No	0.00157 mg/mL	5.32	-5.5	14.78	-2.9	P04150	NR3C1	1. Glucocorticoid receptor
C22H32O3	Testosterone propionate has a reduced clearance rate compared to testosterone.5 The reported clearance rate is of approximately 2000 ml/min.1	Testosterone propionate possesses a relatively short half-life compared with other testosterone esters at approximately 4.5 days.	344.4877	[H][C@@]12CC[C@H](OC(=O)CC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	The registered volume of distribution for testosterone propionate is in the range of 75-120 L/kg.1	P21964;!P22309;!BE0004887;!P08684	COMT;!UGT1A1;!;!CYP3A4	1. Catechol O-methyltransferase;!2. UDP-glucuronosyltransferase 1-1;!3. 3-oxo-5-alpha-steroid 4-dehydrogenase (Protein Group);!4. Cytochrome P450 3A4		50215709	9466	CHEMBL1170	5774	Drugs.com Drug Page		HMDB0015489	C08158	D00959			PA164751373	5995	46508693		10382		Testosterone_propionate	ZINC000000490791		Testosterone propionate	Approved, Investigational, Vet approved, Withdrawn	DB01420	InChI=1S/C22H32O3/c1-4-20(24)25-19-8-7-17-16-6-5-14-13-15(23)9-11-21(14,2)18(16)10-12-22(17,19)3/h13,16-19H,4-12H2,1-3H3/t16-,17-,18-,19-,21-,22-/m0/s1	PDMMFKSKQVNJMI-BLQWBTBKSA-N	4	Testosterone propionate is a slow-release anabolic steroid no longer used commonly for the treatment of androgen deficiency or promotion of anabolic effects on muscles.	Reports have showed a potential stimulation of cancerous tissue growth. The potential testosterone propionate accumulation in the body produces a high risk of edema secondaryh to water and sodium retention.5	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.0463 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor						-5.37	118-123 °C		1.48 mg/L (at 25ºC)	1	Yes	2	0	No	4	0	43.37 Å2	40.45 Å3	98.21 m3·mol-1	3	Yes	No	0.00502 mg/mL	4.51	-4.8	18.52	-4.8			
C27H44O2	Not Available	The half-life of alfacalcidol ranges from three to four hours.9,12	400.6371	CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	Solid	Not Available						31186	CHEMBL1601669	4445376			HMDB0015504		D01518	M9B		PA164746469	5282181	46505115		12062		Alfacalcidol	ZINC000012484965	One-alpha	Alfacalcidol	Approved, Nutraceutical	DB01436	InChI=1S/C27H44O2/c1-18(2)8-6-9-19(3)24-13-14-25-21(10-7-15-27(24,25)5)11-12-22-16-23(28)17-26(29)20(22)4/h11-12,18-19,23-26,28-29H,4,6-10,13-17H2,1-3,5H3/b21-11+,22-12-/t19-,23-,24-,25+,26+,27-/m1/s1	OFHCOWSQAMBJIW-AVJTYSNKSA-N	4	Alfacalcidol is a vitamin D analogue used for the management of hypocalcemia, secondary hyperparathyroidism, and osteodystrophy in patients with chronic renal failure, as well as some types of rickets and osteomalacia.	There is a discrepancy across a number of reported LD50 values for alfacalcidol, which can be attributed to differences in the procedures used in laboratories. Oral LD50 in mice ranges from 440 to 490 mcg/kg. Intravenous in mice was 290 mcg/kg; however, another source presented 56 mcg/kg in female mice and 71 mcg/kg in male mice. Oral LD50 in rats ranges from 340 to 720 mcg/kg.9In case of an acute accidental overdose following oral administration, emesis or gastric lavage can be induced to prevent further drug absorption. Mineral oil may be used to promote fecal drug elimination in instances where the drug was already absorbed in the stomach.9 Alfacalcidol overdose can lead to hypercalcemia, hypercalciuria, and hyperphosphatemia. Similarly, a high intake of calcium and phosphate concurrently with a therapeutic dose of alfacalcidol can result in those conditions.9 Hypercalcemia most commonly presents with headache, weakness, hypertension, somnolence, dizziness, sweating, anorexia, nausea, vomiting, diarrhea, constipation, polyuria, polydipsia and muscle and bone pain, and metallic taste.12 Hypercalcemia should be responded to with discontinuation of alfacalcidol, a low calcium diet and withdrawal of calcium supplements.9 Prolonged hypercalcemia can lead to nephrocalcinosis, nephrolithiasis, and reduced kidney function. In cases of severe hypercalcemia, general supportive measures are recommended, which may include forced diuresis and close monitoring of renal function, electrolytes, and electrocardiographs. Monitoring for abnormalities is especially critical in patients receiving digitalis glycosides. Management with glucocorticosteroids, loop diuretics, bisphosphonates, and calcitonin, as well as hemodialysis with low calcium content, may be considered.12	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	4.6023 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							136 °C		<1 mg/mL	1	No	2	2	Yes	3	0	40.46 Å2	50.56 Å3	124.7 m3·mol-1	6	No	No	0.00163 mg/mL	5.82	-5.4	14.39	-2.8	P11473;!O15528;!P19793	VDR;!CYP27B1;!RXRA	1. Vitamin D3 receptor;!2. 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial;!3. Retinoic acid receptor RXR-alpha
C19H28O2	Not Available	Not Available	288.4244	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)C=C[C@]12C	Solid	Not Available						59714		206590				C15377					236666	46507716				1-Testosterone	ZINC000004791927		1-Testosterone	Experimental, Illicit, Investigational	DB01481	InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h7,9,12,14-17,21H,3-6,8,10-11H2,1-2H3/t12-,14-,15-,16-,17-,18-,19-/m0/s1	OKJCFMUGMSVJBG-ABEVXSGRSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.0714 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	1	No	4	0	37.3 Å2	33.91 Å3	84.7 m3·mol-1	0	Yes	Yes	0.0128 mg/mL	3.41	-4.4	19.38	-0.88	P10275	AR	1. Androgen receptor
C19H26O2	Not Available	14 days	286.4085	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	Not Available					91719	34584	CHEMBL209073	12744				C14502	D07536				13308	46505583		2289408		Boldenone	ZINC000004215042		Boldenone	Illicit, Vet approved	DB01541	InChI=1S/C19H26O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h7,9,11,14-17,21H,3-6,8,10H2,1-2H3/t14-,15-,16-,17-,18-,19-/m0/s1	RSIHSRDYCUFFLA-DYKIIFRCSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.6259 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							165 °C			1	Yes	2	1	No	4	0	37.3 Å2	33.11 Å3	85.52 m3·mol-1	0	Yes	Yes	0.0259 mg/mL	3.36	-4	18.39	-0.88	P10275	AR	1. Androgen receptor
C19H28O2	Not Available	Not Available	288.431	[H][C@@]12CC[C@H](O)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	Solid	Not Available								8215338									10039774	46507237					ZINC000005955127		18-methyl-19-nortestosterone	Experimental, Illicit	DB01543	InChI=1S/C19H28O2/c1-2-19-10-9-15-14-6-4-13(20)11-12(14)3-5-16(15)17(19)7-8-18(19)21/h11,14-18,21H,2-10H2,1H3/t14-,15+,16+,17-,18-,19-/m0/s1	FBYZQDCRLYHHHP-ZOFHRBRSSA-N			Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	34.36 Å3	84.56 m3·mol-1	1	Yes	Yes	0.0302 mg/mL	3.51	-4	18.25	-0.75			
C20H30O2	Not Available	Not Available	302.458	[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)C=C[C@]12C	Solid	Not Available								5442174										46506576				Methyl-1-testosterone	ZINC000004081584		Methyl-1-testosterone	Experimental, Illicit	DB01572	InChI=1S/C20H30O2/c1-18-9-6-14(21)12-13(18)4-5-15-16(18)7-10-19(2)17(15)8-11-20(19,3)22/h6,9,13,15-17,22H,4-5,7-8,10-12H2,1-3H3/t13-,15+,16-,17-,18-,19-,20-/m0/s1	JRNSSSJKIGAFCT-YDSAWKJFSA-N			Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	35.73 Å3	89.33 m3·mol-1	0	Yes	Yes	0.00401 mg/mL	3.69	-4.9		-0.53			
C53H83NO14	Following a 3 mg radiolabeled dose of everolimus, 80% of the radioactivity was recovered from the feces, while 5% was excreted in the urine.	~30 hours.	958.24	[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC	Solid	The blood-to-plasma ratio of everolimus is 17% to 73%.	P10635;!P08684	CYP2D6;!CYP3A4	1. Cytochrome P450 2D6;!2. Cytochrome P450 3A4		50088378	68478	CHEMBL1908360	21106307	Drugs.com Drug Page				D02714			PA164746311	6442177	46505248	RxList Drug Page	141704	DAP001223	Everolimus	ZINC000169677008	Afinitor, Votubia, Zortress	Everolimus	Approved	DB01590	InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1	HKVAMNSJSFKALM-GKUWKFKPSA-N	4	Everolimus is a mammalian target of rapamycin (mTOR) kinase inhibitor used to treat various types of malignancies.	IC50 of 0.63 nM.	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Inhibitor	Inhibitor	Substrate	2.7442 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	13	3	Yes	4	0	204.66 Å2	106.61 Å3	261.71 m3·mol-1	9	No	No	0.00163 mg/mL	7.4	-5.8	9.96	-2.7	P42345	MTOR	1. Serine/threonine-protein kinase mTOR
C19H28O2	Not Available	12 hours	288.4244	[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C	Solid	Not Available	P24462;!P14061;!Q06520;!O00204;!P14060;!P22637;!P05093	CYP3A7;!HSD17B1;!SULT2A1;!SULT2B1;!HSD3B1;!choB;!CYP17A1	1. Cytochrome P450 3A7;!2. Estradiol 17-beta-dehydrogenase 1;!3. Bile salt sulfotransferase;!4. Sulfotransferase family cytosolic 2B member 1;!5. 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1;!6. Cholesterol oxidase;!7. Steroid 17-alpha-hydroxylase/17,20 lyase		50223368	28689	CHEMBL90593	5670		GtP Drug Page	HMDB0000077	C01227	D08409	AND		PA451993	5881	46508824		3143	DNC001146	Dehydroepiandrosterone	ZINC000003807917	Intrarosa	Prasterone	Approved, Investigational, Nutraceutical	DB01708	InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h3,13-16,20H,4-11H2,1-2H3/t13-,14-,15-,16-,18-,19-/m0/s1	FMGSKLZLMKYGDP-USOAJAOKSA-N	4	Prasterone is a steroid formulated as a vaginal insert indicated for the treatment of moderate to severe dyspareunia associated with menopausal vulvar and vaginal atrophy.	Acute oral toxicity (LD50): >10000 mg/kg [Rat]. Lowest Published Toxic Dose (TDL) [Man] - Route: Oral; Dose: 10 mg/kg/2W intermittent.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.5214 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.23		140-141 °C		63.5 mg/L (at 25 °C)	1	Yes	2	1	No	4	0	37.3 Å2	34.1 Å3	84.66 m3·mol-1	0	Yes	Yes	0.0438 mg/mL	3.36	-3.8	18.2	-1.4	P03372;!Q92731;!BE0004797;!BE0004956;!P10275;!Q07869;!Q99720;!O75469;!Q14994	ESR1;!ESR2;!;!;!AR;!PPARA;!SIGMAR1;!NR1I2;!NR1I3	1. Estrogen receptor alpha;!2. Estrogen receptor beta;!3. GABA(A) Receptor (Protein Group);!4. NMDA receptor (Protein Group);!5. Androgen receptor;!6. Peroxisome proliferator-activated receptor alpha;!7. Sigma non-opioid intracellular receptor 1;!8. Nuclear receptor subfamily 1 group I member 2;!9. Nuclear receptor subfamily 1 group I member 3
C36H56O12	Not Available	Not Available	680.8226	[H]\C1=C2/[C@@]([H])(COC)CC[C@@]2([H])[C@@]([H])(C)[C@@]([H])(O)[C@]([H])(O[C@@]2([H])O[C@]([H])(COC(C)(C)C=C)[C@@]([H])(O)[C@]([H])(OC(C)=O)[C@@]2([H])O)C2=C(C[C@]([H])(O)[C@]12C)[C@]([H])(C)COC(C)=O	Solid	Not Available						51015	CHEMBL4244843	394625						FSC			447573	46508360				Fusicoccin			Fusicoccin	Experimental	DB01780	InChI=1S/C36H56O12/c1-10-35(6,7)45-17-26-30(41)33(46-21(5)38)31(42)34(47-26)48-32-28-24(18(2)15-44-20(4)37)13-27(39)36(28,8)14-25-22(16-43-9)11-12-23(25)19(3)29(32)40/h10,14,18-19,22-23,26-27,29-34,39-42H,1,11-13,15-17H2,2-9H3/b25-14-/t18-,19-,22-,23+,26-,27+,29-,30-,31-,32-,33+,34-,36+/m1/s1	KXTYBXCEQOANSX-WYKQKOHHSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	3.4297 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	10	4	Yes	4	0	170.44 Å2	72.71 Å3	175.76 m3·mol-1	14	No	No	0.0849 mg/mL	1.35	-3.9	12.24	-3	P62258	YWHAE	1. 14-3-3 protein epsilon
C27H41NO5S	Not Available	Not Available	491.683	[H][C@]1(C\C=C(C)/CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)C(\C)=C\C1=CSC(C)=N1	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			29579	CHEMBL96172	9400674				C12039		EPD			447865	46508361				Epothilone	ZINC000003951739		Epothilone D	Investigational	DB01873	InChI=1S/C27H41NO5S/c1-16-9-8-10-17(2)25(31)19(4)26(32)27(6,7)23(29)14-24(30)33-22(12-11-16)18(3)13-21-15-34-20(5)28-21/h11,13,15,17,19,22-23,25,29,31H,8-10,12,14H2,1-7H3/b16-11-,18-13+/t17-,19+,22-,23-,25-/m0/s1	XOZIUKBZLSUILX-GIQCAXHBSA-N	2		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.8243 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	5	2	No	2	0	96.72 Å2	55.62 Å3	136.04 m3·mol-1	2	No	No	0.00246 mg/mL	5.1	-5.3	14.09	2.73	Q13748;!P07437;!Q9H4B7;!P68371;!P04350;!P68366;!Q13509;!Q9BQE3;!Q9NY65;!P68363;!Q71U36	TUBA3C;!TUBB;!TUBB1;!TUBB4B;!TUBB4A;!TUBA4A;!TUBB3;!TUBA1C;!TUBA8;!TUBA1B;!TUBA1A	1. Tubulin alpha-3C/D chain;!2. Tubulin beta chain;!3. Tubulin beta-1 chain;!4. Tubulin beta-4B chain;!5. Tubulin beta-4A chain;!6. Tubulin alpha-4A chain;!7. Tubulin beta-3 chain;!8. Tubulin alpha-1C chain;!9. Tubulin alpha-8 chain;!10. Tubulin alpha-1B chain;!11. Tubulin alpha-1A chain
C27H46O4S	Not Available	Not Available	466.717	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC=C4C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)OS(O)(=O)=O)[C@H](C)CCCC(C)C	Solid	Not Available						41321	CHEMBL1231592	58586			HMDB0000653	C18043		C3S			65076	46507419				Cholesterol_sulfate	ZINC000012494196		Cholesterol sulfate	Experimental	DB01990	InChI=1S/C27H46O4S/c1-18(2)7-6-8-19(3)23-11-12-24-22-10-9-20-17-21(31-32(28,29)30)13-15-26(20,4)25(22)14-16-27(23,24)5/h9,18-19,21-25H,6-8,10-17H2,1-5H3,(H,28,29,30)/t19-,21+,22+,23-,24+,25+,26+,27-/m1/s1	BHYOQNUELFTYRT-DPAQBDIFSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.4505 LD50, mol/kg	Non-inhibitor	Strong inhibitor	Non-inhibitor										1	No	3	1	Yes	4	-1	63.6 Å2	56.55 Å3	130.61 m3·mol-1	7	No	No	7.48e-05 mg/mL	7.17	-6.8	-1.4		P35398	RORA	1. Nuclear receptor ROR-alpha
C20H32O5	Not Available	Not Available	352.4651	[H][C@](O)(CCCCC)\C=C\[C@@]1([H])C(=O)C[C@]([H])(O)[C@]1([H])C\C=C/CCCC(O)=O	Solid	Not Available					21544	15555	CHEMBL1235252	395250			HMDB0001403	C00696		PG2			448457	46504574				Prostaglandin_D2	ZINC000085994848		Prostaglandin D2	Investigational	DB02056	InChI=1S/C20H32O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-18,21-22H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/b7-4-,13-12+/t15-,16+,17+,18-/m0/s1	BHMBVRSPMRCCGG-OUTUXVNYSA-N			Not Available	Small Molecule	http://smpdb.ca/view/SMP0000077?highlight[compounds][]=DB02056&highlight[proteins][]=DB02056;!http://smpdb.ca/view/SMP0000087?highlight[compounds][]=DB02056&highlight[proteins][]=DB02056;!http://smpdb.ca/view/SMP0000093?highlight[compounds][]=DB02056&highlight[proteins][]=DB02056;!http://smpdb.ca/view/SMP0000094?highlight[compounds][]=DB02056&highlight[proteins][]=DB02056;!http://smpdb.ca/view/SMP0000114?highlight[compounds][]=DB02056&highlight[proteins][]=DB02056;!http://smpdb.ca/view/SMP0000116?highlight[compounds][]=DB02056&highlight[proteins][]=DB02056;!http://smpdb.ca/view/SMP0000692?highlight[compounds][]=DB02056&highlight[proteins][]=DB02056;!http://smpdb.ca/view/SMP0000697?highlight[compounds][]=DB02056&highlight[proteins][]=DB02056;!http://smpdb.ca/view/SMP0000702?highlight[compounds][]=DB02056&highlight[proteins][]=DB02056;!http://smpdb.ca/view/SMP0000084?highlight[compounds][]=DB02056&highlight[proteins][]=DB02056;!http://smpdb.ca/view/SMP0000085?highlight[compounds][]=DB02056&highlight[proteins][]=DB02056;!http://smpdb.ca/view/SMP0000086?highlight[compounds][]=DB02056&highlight[proteins][]=DB02056;!http://smpdb.ca/view/SMP0000096?highlight[compounds][]=DB02056&highlight[proteins][]=DB02056;!http://smpdb.ca/view/SMP0000101?highlight[compounds][]=DB02056&highlight[proteins][]=DB02056;!http://smpdb.ca/view/SMP0000104?highlight[compounds][]=DB02056&highlight[proteins][]=DB02056;!http://smpdb.ca/view/SMP0000289?highlight[compounds][]=DB02056&highlight[proteins][]=DB02056;!http://smpdb.ca/view/SMP0000353?highlight[compounds][]=DB02056&highlight[proteins][]=DB02056;!http://smpdb.ca/view/SMP0000693?highlight[compounds][]=DB02056&highlight[proteins][]=DB02056;!http://smpdb.ca/view/SMP0000696?highlight[compounds][]=DB02056&highlight[proteins][]=DB02056;!http://smpdb.ca/view/SMP0000698?highlight[compounds][]=DB02056&highlight[proteins][]=DB02056;!http://smpdb.ca/view/SMP0000700?highlight[compounds][]=DB02056&highlight[proteins][]=DB02056;!http://smpdb.ca/view/SMP0000703?highlight[compounds][]=DB02056&highlight[proteins][]=DB02056;!http://smpdb.ca/view/SMP0000704?highlight[compounds][]=DB02056&highlight[proteins][]=DB02056;!http://smpdb.ca/view/SMP0000705?highlight[compounds][]=DB02056&highlight[proteins][]=DB02056;!http://smpdb.ca/view/SMP0000706?highlight[compounds][]=DB02056&highlight[proteins][]=DB02056;!http://smpdb.ca/view/SMP0000709?highlight[compounds][]=DB02056&highlight[proteins][]=DB02056;!http://smpdb.ca/view/SMP0000075?highlight[compounds][]=DB02056&highlight[proteins][]=DB02056;!http://smpdb.ca/view/SMP0000083?highlight[compounds][]=DB02056&highlight[proteins][]=DB02056;!http://smpdb.ca/view/SMP0000098?highlight[compounds][]=DB02056&highlight[proteins][]=DB02056;!http://smpdb.ca/view/SMP0000102?highlight[compounds][]=DB02056&highlight[proteins][]=DB02056	Piroxicam Action Pathway;!Rofecoxib Action Pathway;!Diclofenac Action Pathway;!Sulindac Action Pathway;!Nabumetone Action Pathway;!Valdecoxib Action Pathway;!Antipyrine Action Pathway;!Flurbiprofen Action Pathway;!Nepafenac Action Pathway;!Etodolac Action Pathway;!Ketoprofen Action Pathway;!Ibuprofen Action Pathway;!Celecoxib Action Pathway;!Suprofen Action Pathway;!Indomethacin Action Pathway;!Diflunisal Action Pathway;!Leukotriene C4 Synthesis Deficiency;!Antrafenine Action Pathway;!Fenoprofen Action Pathway;!Magnesium Salicylate Action Pathway;!Lornoxicam Action Pathway;!Trisalicylate-Choline Action Pathway;!Tolmetin Action Pathway;!Tiaprofenic Acid Action Pathway;!Tenoxicam Action Pathway;!Salicylic Acid Action Pathway;!Arachidonic Acid Metabolism;!Acetylsalicylic Acid Action Pathway;!Ketorolac Action Pathway;!Bromfenac Action Pathway		Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.9631 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	3	No	1	-1	94.83 Å2	40.78 Å3	99.44 m3·mol-1	12	Yes	No	0.086 mg/mL	3.23	-3.6	4.4	-1.6	Q9Y5Y4;!P42330	PTGDR2;!AKR1C3	1. Prostaglandin D2 receptor 2;!2. Aldo-keto reductase family 1 member C3
C29H40N2O9	Not Available	Not Available	560.6359	CO[C@H]1C[C@H](C)CC2=C(OC)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O	Solid	Not Available					50008059	5292	CHEMBL278315	10272739				C11222		GDM		PA152031327	5288382	46505674			DCL000325	Geldanamycin	ZINC000100064834		Geldanamycin	Experimental, Investigational	DB02424	InChI=1S/C29H40N2O9/c1-15-11-19-25(34)20(14-21(32)27(19)39-7)31-28(35)16(2)9-8-10-22(37-5)26(40-29(30)36)18(4)13-17(3)24(33)23(12-15)38-6/h8-10,13-15,17,22-24,26,33H,11-12H2,1-7H3,(H2,30,36)(H,31,35)/b10-8-,16-9+,18-13+/t15-,17+,22+,23+,24-,26+/m1/s1	QTQAWLPCGQOSGP-KSRBKZBZSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.3822 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	8	3	No	2	0	163.48 Å2	58.64 Å3	152.68 m3·mol-1	5	No	No	0.00634 mg/mL	2.15	-5	12.77	-3.3	P14625;!P07900;!P08238	HSP90B1;!HSP90AA1;!HSP90AB1	1. Endoplasmin;!2. Heat shock protein HSP 90-alpha;!3. Heat shock protein HSP 90-beta
C22H31NO5S	Not Available	Not Available	421.55	[H][C@]1(CSC(=O)N1)[C@@]1(O)C[C@H]2C[C@@H](CC[C@H](C)\C=C/C=C/CC\C(C)=C/C(=O)O2)O1	Solid	Not Available					65515	69136	CHEMBL404116	393069						LAR			6437378	46508901				Latrunculin	ZINC000005766575		Latrunculin A	Experimental	DB02621	InChI=1S/C22H31NO5S/c1-15-7-5-3-4-6-8-16(2)11-20(24)27-18-12-17(10-9-15)28-22(26,13-18)19-14-29-21(25)23-19/h3-5,7,11,15,17-19,26H,6,8-10,12-14H2,1-2H3,(H,23,25)/b4-3+,7-5-,16-11-/t15-,17-,18-,19+,22-/m1/s1	DDVBPZROPPMBLW-IZGXTMSKSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.6858 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	2	No	3	0	84.86 Å2	44.76 Å3	115.96 m3·mol-1	1	Yes	No	0.0204 mg/mL	4.31	-4.3	11.36	-4.4	P68133;!P06396;!Q46220	ACTA1;!GSN;!Not Available	1. Actin, alpha skeletal muscle;!2. Gelsolin;!3. Iota toxin component Ia
C31H48O6	Not Available	Approximately 5 to 6 hours in adults.	516.7092	[H][C@@]12C[C@@H](O)[C@@]3([H])[C@@]4(C)CC[C@@H](O)[C@@H](C)[C@]4([H])CC[C@]3(C)[C@@]1(C)C[C@H](OC(C)=O)\C2=C(\CCC=C(C)C)C(O)=O	Solid	Not Available	P10635;!P08684;!P22309	CYP2D6;!CYP3A4;!UGT1A1	1. Cytochrome P450 2D6;!2. Cytochrome P450 3A4;!3. UDP-glucuronosyltransferase 1-1		58924	29013	CHEMBL374975	2271900			HMDB0015570	C06694	D04281	FUA		PA164749648	3000226	46505364		113608	DAP001008	Fusidic_acid	ZINC000008143796	Fucibet, Fucidin, Fucithalmic	Fusidic acid	Approved, Investigational	DB02703	InChI=1S/C31H48O6/c1-17(2)9-8-10-20(28(35)36)26-22-15-24(34)27-29(5)13-12-23(33)18(3)21(29)11-14-30(27,6)31(22,7)16-25(26)37-19(4)32/h9,18,21-25,27,33-34H,8,10-16H2,1-7H3,(H,35,36)/b26-20-/t18-,21-,22-,23+,24+,25-,27-,29-,30-,31-/m0/s1	IECPWNUMDGFDKC-MZJAQBGESA-N	4	Fusidic acid is a topical antibacterial agent used to prevent and treat mild to moderate skin infections caused by susceptible bacteria.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	3.5929 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							192.5 °C	5.35		1	No	5	3	Yes	4	-1	104.06 Å2	59.76 Å3	144.12 m3·mol-1	6	No	No	0.00521 mg/mL	4.42	-5	4.46	-0.2	P13551;!P62580;!P00484	fusA;!cat;!cat3	1. Elongation factor G;!2. Chloramphenicol acetyltransferase;!3. Chloramphenicol acetyltransferase 3
C21H32O2	Not Available	Not Available	316.4776	[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4		50375319	16581	CHEMBL253363	8611			HMDB0000253	C01953	D00143	PLO			8955	46506718		114052	DNC001147	Pregnenolone	ZINC000003861150		Pregnenolone	Approved, Experimental	DB02789	InChI=1S/C21H32O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h4,15-19,23H,5-12H2,1-3H3/t15-,16-,17+,18-,19-,20-,21+/m0/s1	ORNBQBCIOKFOEO-QGVNFLHTSA-N	4		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.9852 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	1	No	4	0	37.3 Å2	38.09 Å3	93.76 m3·mol-1	1	Yes	Yes	0.0136 mg/mL	3.58	-4.4	18.2	-1.4	O75469;!O00204	NR1I2;!SULT2B1	1. Nuclear receptor subfamily 1 group I member 2;!2. Sulfotransferase family cytosolic 2B member 1
C29H44O8	Not Available	Not Available	520.6549	[H]\C1=C([H])/[C@@]([H])(OC)[C@]([H])(CCCC[C@]([H])(OC(=O)[C@@]([H])(C)[C@@]2(O)O[C@]([H])([C@@]([H])(C)[C@]([H])(O)[C@@]2([H])OC)[C@@]1([H])C)C1=CC=CC=C1)OC	Solid	Not Available						9200	CHEMBL1235782	4943557				C11300		S1A			5281897	46505293							Soraphen A	Experimental	DB02859	InChI=1S/C29H44O8/c1-18-16-17-24(34-5)23(33-4)15-11-10-14-22(21-12-8-7-9-13-21)36-28(31)20(3)29(32)27(35-6)25(30)19(2)26(18)37-29/h7-9,12-13,16-20,22-27,30,32H,10-11,14-15H2,1-6H3/b17-16+/t18-,19-,20+,22-,23-,24+,25-,26-,27+,29+/m0/s1	WPMGNXPRKGXGBO-OFQQMTDKSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	3.0223 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	2	No	3	0	103.68 Å2	57.92 Å3	139.94 m3·mol-1	4	No	No	0.00916 mg/mL	4.49	-4.8	10.6	-3.4	O00763	ACACB	1. Acetyl-CoA carboxylase 2
C27H41NO6S	Not Available	Not Available	507.683	[H]\C(=C(\C)[C@]1([H])C[C@]2([H])O[C@]2(C)CCC[C@]([H])(C)[C@]([H])(O)[C@@]([H])(C)C(=O)C(C)(C)[C@@]([H])(O)CC(=O)O1)C1=CSC(C)=N1	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4		50103627	31550	CHEMBL94657	10213816				C12154		EPB			448013	46505629			DNC000616		ZINC000003951737		Patupilone	Experimental, Investigational	DB03010	InChI=1S/C27H41NO6S/c1-15-9-8-10-27(7)22(34-27)12-20(16(2)11-19-14-35-18(4)28-19)33-23(30)13-21(29)26(5,6)25(32)17(3)24(15)31/h11,14-15,17,20-22,24,29,31H,8-10,12-13H2,1-7H3/b16-11+/t15-,17+,20-,21-,22-,24-,27+/m0/s1	QXRSDHAAWVKZLJ-PVYNADRNSA-N	3		Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.7983 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	2	No	3	0	109.25 Å2	56.11 Å3	134.76 m3·mol-1	2	No	No	0.00342 mg/mL	4.12	-5.2	14.09	2.73	Q13748;!P07437;!Q9H4B7;!P68371;!P04350;!P68366;!Q13509;!Q9BQE3;!Q9NY65;!P68363;!Q71U36	TUBA3C;!TUBB;!TUBB1;!TUBB4B;!TUBB4A;!TUBA4A;!TUBB3;!TUBA1C;!TUBA8;!TUBA1B;!TUBA1A	1. Tubulin alpha-3C/D chain;!2. Tubulin beta chain;!3. Tubulin beta-1 chain;!4. Tubulin beta-4B chain;!5. Tubulin beta-4A chain;!6. Tubulin alpha-4A chain;!7. Tubulin beta-3 chain;!8. Tubulin alpha-1C chain;!9. Tubulin alpha-8 chain;!10. Tubulin alpha-1B chain;!11. Tubulin alpha-1A chain
C29H48O4	Not Available	Not Available	460.689	[H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C)[C@@H](C)OCCCC(O)(CC)CC	Solid	Not Available							CHEMBL432600	4450786						KH1			73896915	46505581					ZINC000004474609		Lexacalcitol	Experimental	DB03451	InChI=1S/C29H48O4/c1-6-29(32,7-2)16-9-17-33-21(4)25-13-14-26-22(10-8-15-28(25,26)5)11-12-23-18-24(30)19-27(31)20(23)3/h11-12,21,24-27,30-32H,3,6-10,13-19H2,1-2,4-5H3/b22-11+,23-12-/t21-,24-,25-,26+,27+,28-/m1/s1	KLZOTDOJMRMLDX-YBBVPDDNSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	3.4928 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	3	Yes	3	0	69.92 Å2	55.8 Å3	137.52 m3·mol-1	9	Yes	No	0.00632 mg/mL	4.36	-4.9	14.25	-2.8	P11473	VDR	1. Vitamin D3 receptor
C52H76N2O13	Not Available	Not Available	937.1654	[H]\C(=C(\C)[C@@]1([H])OC(=O)[C@]2([H])CCCCN2C(=O)C(=O)[C@]2(O)O[C@@]([H])([C@]([H])(C[C@@]2([H])C)OC)[C@]([H])(C[C@@]([H])(C)[C@]([H])(O)\C(C)=C([H])\[C@@]([H])(CC)C(=O)C[C@]([H])(O)[C@@]1([H])C)OC)[C@]1([H])CC[C@@]([H])(OC2=CC=C3N(C)C=CC3=C2)[C@@]([H])(C1)OC	Solid	Not Available								16743789						587			5496872	46504459					ZINC000169290591		L-709,587	Experimental	DB03621	InChI=1S/C52H76N2O13/c1-11-35-23-29(2)46(57)30(3)24-44(63-9)48-45(64-10)25-32(5)52(61,67-48)49(58)50(59)54-20-13-12-14-39(54)51(60)66-47(33(6)40(55)28-41(35)56)31(4)22-34-15-18-42(43(26-34)62-8)65-37-16-17-38-36(27-37)19-21-53(38)7/h16-17,19,21-23,27,30,32-35,39-40,42-48,55,57,61H,11-15,18,20,24-26,28H2,1-10H3/b29-23+,31-22+/t30-,32-,33-,34+,35-,39+,40+,42-,43-,44+,45+,46-,47-,48-,52-/m1/s1	APSPCHLQXFEUHG-CPBVNLROSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	3.0335 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	12	3	Yes	6	0	192.52 Å2	104.27 Å3	252.66 m3·mol-1	8	No	No	0.00455 mg/mL	6.96	-5.3	9.96	-2.9	P62942	FKBP1A	1. Peptidyl-prolyl cis-trans isomerase FKBP1A
C23H34O5	Not Available	Not Available	390.5131	[H][C@@]1(CC[C@]2(O)[C@]3([H])CC[C@]4([H])C[C@@H](O)CC[C@]4(C)[C@@]3([H])C[C@@H](O)[C@]12C)C1=CC(=O)OC1	Solid	Not Available					225707	42098	CHEMBL1153	14728						DOG			15478	46509019				Digoxigenin	ZINC000003982471		Digoxigenin	Experimental	DB03671	InChI=1S/C23H34O5/c1-21-7-5-15(24)10-14(21)3-4-17-18(21)11-19(25)22(2)16(6-8-23(17,22)27)13-9-20(26)28-12-13/h9,14-19,24-25,27H,3-8,10-12H2,1-2H3/t14-,15+,16-,17-,18+,19-,21+,22+,23+/m1/s1	SHIBSTMRCDJXLN-KCZCNTNESA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	3.4699 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	4	3	No	5	0	86.99 Å2	42.7 Å3	105.16 m3·mol-1	1	Yes	No	0.0632 mg/mL	1.84	-3.8	7.15	-1.4			
C24H38O6	Not Available	Not Available	422.5549	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H](O)C[C@@H](O)CC(O)=O)OC(=O)[C@@H](C)CC	Solid	Not Available					50406681	82985	CHEMBL1201373	58269						LVA			64727	46506686					ZINC000004134473		Mevinolinic acid	Experimental	DB03785	InChI=1S/C24H38O6/c1-5-15(3)24(29)30-21-11-14(2)10-17-7-6-16(4)20(23(17)21)9-8-18(25)12-19(26)13-22(27)28/h6-7,10,14-16,18-21,23,25-26H,5,8-9,11-13H2,1-4H3,(H,27,28)/t14-,15-,16-,18+,19+,20-,21-,23-/m0/s1	QLJODMDSTUBWDW-BXMDZJJMSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	2.6058 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	3	No	2	-1	104.06 Å2	47.54 Å3	116.67 m3·mol-1	11	Yes	No	0.0641 mg/mL	3.24	-3.8	4.21	-2.7	P13702	mvaA	1. 3-hydroxy-3-methylglutaryl-coenzyme A reductase
C37H49NO6	Not Available	Not Available	603.7881	[H][C@](C)(CC)C(=O)O[C@@]1([H])C[C@@]([H])(C)C=C2C=C[C@]([H])(C)[C@]([H])(CC[C@@]3([H])C[C@@]([H])(O)CC(=O)N3CC3=CC4=C(C=C3)C(CO)=C(OC)C=C4)[C@@]12[H]	Solid	Not Available								395776						AAY			449169	46504607					ZINC000003993474		LFA703	Experimental	DB03932	InChI=1S/C37H49NO6/c1-6-23(3)37(42)44-34-16-22(2)15-27-9-7-24(4)30(36(27)34)13-11-28-18-29(40)19-35(41)38(28)20-25-8-12-31-26(17-25)10-14-33(43-5)32(31)21-39/h7-10,12,14-15,17,22-24,28-30,34,36,39-40H,6,11,13,16,18-21H2,1-5H3/t22-,23-,24-,28-,29+,30-,34-,36-/m0/s1	WPVRNXUYVXQXPY-YFAYRSKXSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	2.7841 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										0	No	5	2	Yes	5	0	96.3 Å2	68.05 Å3	174.37 m3·mol-1	11	No	No	0.00152 mg/mL	5.19	-5.6	14.62	-1.5	P20701	ITGAL	1. Integrin alpha-L
C28H44O	Not Available	Not Available	396.659	CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	Solid	Not Available					50378884	16933	CHEMBL1232562	392539				C01694		ERG			444679	46505947				Ergosterol	ZINC000004084618		Ergosterol	Approved, Experimental	DB04038	InChI=1S/C28H44O/c1-18(2)19(3)7-8-20(4)24-11-12-25-23-10-9-21-17-22(29)13-15-27(21,5)26(23)14-16-28(24,25)6/h7-10,18-20,22,24-26,29H,11-17H2,1-6H3/b8-7+/t19-,20+,22-,24+,25-,26-,27-,28+/m0/s1	DNVPQKQSNYMLRS-APGDWVJJSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.6528 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							170 °C			1	No	1	1	No	4	0	20.23 Å2	51.01 Å3	127.13 m3·mol-1	4	No	Yes	0.000156 mg/mL	6.63	-6.4	18.27	-1.4			
C21H38O6	Not Available	Not Available	386.5228	[H][C@@]1(C)C[C@]([H])(C)[C@]([H])(O)[C@@]([H])(C)[C@]([H])(O)[C@@]([H])(C)C(=O)O[C@]([H])(CC)[C@]([H])(C)[C@]([H])(O)[C@@]([H])(C)C1=O	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			16089		108752				C03240		DEB			121904	46508714					ZINC000004096057		6-Deoxyerythronolide B	Experimental	DB04070	InChI=1S/C21H38O6/c1-8-16-12(4)19(24)13(5)17(22)10(2)9-11(3)18(23)14(6)20(25)15(7)21(26)27-16/h10-16,18-20,23-25H,8-9H2,1-7H3/t10-,11+,12+,13+,14-,15-,16-,18+,19+,20+/m1/s1	HQZOLNNEQAKEHT-IBBGRPSASA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.6539 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	3	No	1	0	104.06 Å2	42.94 Å3	102.94 m3·mol-1	1	Yes	No	1.12 mg/mL	2.87	-2.5	14	-3	Q00441	eryF	1. 6-deoxyerythronolide B hydroxylase
C23H34O4	Not Available	Not Available	374.5137	[H][C@]12CC[C@]3([H])[C@]([H])(CC[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@H](O)C2	Solid	Not Available					66977	42219	CHEMBL1453	3571902						DTX			4369270	46508220				Digitoxigenin	ZINC000003875959		Digitoxigenin	Experimental	DB04177	InChI=1S/C23H34O4/c1-21-8-5-16(24)12-15(21)3-4-19-18(21)6-9-22(2)17(7-10-23(19,22)26)14-11-20(25)27-13-14/h11,15-19,24,26H,3-10,12-13H2,1-2H3/t15-,16+,17-,18+,19-,21+,22-,23+/m1/s1	XZTUSOXSLKTKJQ-CESUGQOBSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.9314 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	3	2	No	5	-1	66.76 Å2	42.57 Å3	103.64 m3·mol-1	1	Yes	No	0.0244 mg/mL	3.07	-4.2	7.18	0.25			
C49H65N3O15	Not Available	Not Available	936.065	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(=O)CC(=O)OCC3CCCN(C)C3)[C@@H]1C)=C(N1CCOCC1)C2=O	Solid	Not Available								58828244						RIF			131704272	46506912							CGP 4832	Experimental	DB04220	InChI=1S/C49H65N3O15/c1-25-12-10-13-26(2)48(61)50-38-39(52-17-20-63-21-18-52)44(59)35-36(43(38)58)42(57)30(6)46-37(35)47(60)49(7,67-46)65-19-15-32(62-9)27(3)45(29(5)41(56)28(4)40(25)55)66-34(54)22-33(53)64-24-31-14-11-16-51(8)23-31/h10,12-13,15,19,25,27-29,31-32,40-41,45,55-57H,11,14,16-18,20-24H2,1-9H3,(H,50,61)/b12-10+,19-15+,26-13-/t25-,27+,28+,29+,31?,32-,40-,41+,45+,49-/m0/s1	FRCBXOTYSDSELT-DUULCSDKSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Inhibitor	Inhibitor	Substrate	2.7871 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										0	No	15	4	Yes	6	0	237 Å2	97.82 Å3	249.77 m3·mol-1	9	No	No	0.016 mg/mL	2.13	-4.8	6.78	9.13	P06971	fhuA	1. Ferrichrome-iron receptor
C30H46O3	Not Available	Not Available	454.6844	[H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C)[C@H](C)\C=C\C=C\C(O)(CC)CC	Solid	Not Available							CHEMBL1908376	4450374						EB1			20055510	46507218					ZINC000003925433		Seocalcitol	Investigational	DB04258	InChI=1S/C30H46O3/c1-6-30(33,7-2)18-9-8-11-21(3)26-15-16-27-23(12-10-17-29(26,27)5)13-14-24-19-25(31)20-28(32)22(24)4/h8-9,11,13-14,18,21,25-28,31-33H,4,6-7,10,12,15-17,19-20H2,1-3,5H3/b11-8+,18-9+,23-13+,24-14-/t21-,25-,26-,27+,28+,29-/m1/s1	LVLLALCJVJNGQQ-SEODYNFXSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	4.2195 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	3	3	Yes	3	0	60.69 Å2	56.19 Å3	142.26 m3·mol-1	7	No	No	0.00382 mg/mL	5.27	-5.1	14.39	-1	P11473	VDR	1. Vitamin D3 receptor
C27H46O	Not Available	Not Available	386.6535	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC=C4C[C@@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCCC(C)C	Solid	Not Available					20192	16113	CHEMBL112570	5775			HMDB0000067	C00187	D00040	CLR			5997	46508234		2438		Cholesterol	ZINC000003875383		Cholesterol	Approved, Investigational	DB04540	InChI=1S/C27H46O/c1-18(2)7-6-8-19(3)23-11-12-24-22-10-9-20-17-21(28)13-15-26(20,4)25(22)14-16-27(23,24)5/h9,18-19,21-25,28H,6-8,10-17H2,1-5H3/t19-,21+,22+,23-,24+,25+,26+,27-/m1/s1	HVYWMOMLDIMFJA-DPAQBDIFSA-N	4		Not Available	Small Molecule	http://smpdb.ca/view/SMP0000099?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000111?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000209?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000316?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000372?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000388?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000389?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000510?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000577?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000718?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000082?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000089?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000092?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000107?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000117?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000119?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000314?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000319?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000371?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000508?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000575?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000717?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000720?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000023?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000035?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000079?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000095?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000112?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000130?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000131?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540	Lovastatin Action Pathway;!Cerivastatin Action Pathway;!Hypercholesterolemia;!Zellweger Syndrome;!Adrenal Hyperplasia Type 5 or Congenital Adrenal Hyperplasia Due to 17 alpha-Hydroxylase Deficiency;!Chondrodysplasia Punctata II, X-Linked Dominant (CDPX2);!Smith-Lemli-Opitz Syndrome (SLOS);!Mevalonic Aciduria;!Corticosterone Methyl Oxidase I Deficiency (CMO I);!3-beta-Hydroxysteroid Dehydrogenase Deficiency;!Simvastatin Action Pathway;!Pravastatin Action Pathway;!Rosuvastatin Action Pathway;!Zoledronate Action Pathway;!Pamidronate Action Pathway;!Fluvastatin Action Pathway;!Congenital Bile Acid Synthesis Defect Type II;!Lysosomal Acid Lipase Deficiency (Wolman Disease);!Congenital Lipoid Adrenal Hyperplasia (CLAH) or Lipoid CAH;!Cholesteryl Ester Storage Disease;!11-beta-Hydroxylase Deficiency (CYP11B1);!Apparent Mineralocorticoid Excess Syndrome;!27-Hydroxylase Deficiency;!Steroid Biosynthesis;!Bile Acid Biosynthesis;!Ibandronate Action Pathway;!Alendronate Action Pathway;!Risedronate Action Pathway;!Steroidogenesis;!Atorvastatin Action Pathway		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.8078 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				360 °C			148.5 °C		0.095 mg/L (at 30 °C)	1	No	1	1	No	4	0	20.23 Å2	50.64 Å3	120.62 m3·mol-1	5	No	Yes	2.79e-05 mg/mL	7.11	-7.1	18.2	-1.4	Q14994;!P11473;!Q9ULY5;!P35398	NR1I3;!VDR;!CLEC4E;!RORA	1. Nuclear receptor subfamily 1 group I member 3;!2. Vitamin D3 receptor;!3. C-type lectin domain family 4 member E;!4. Nuclear receptor ROR-alpha
C27H46O2	Not Available	Not Available	402.6529	CC(C)CCC[C@@](C)(O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	Solid	Not Available					50035884		CHEMBL1233249	389586			HMDB0006283			HC2			440711	46508206					ZINC000004096811		20-hydroxycholesterol	Experimental	DB04704	InChI=1S/C27H46O2/c1-18(2)7-6-14-27(5,29)24-11-10-22-21-9-8-19-17-20(28)12-15-25(19,3)23(21)13-16-26(22,24)4/h8,18,20-24,28-29H,6-7,9-17H2,1-5H3/t20-,21-,22-,23-,24-,25-,26-,27+/m0/s1	MCKLJFJEQRYRQT-MGNSQDQZSA-N			Not Available	Small Molecule	http://smpdb.ca/view/SMP0000371?highlight[compounds][]=DB04704&highlight[proteins][]=DB04704;!http://smpdb.ca/view/SMP0000575?highlight[compounds][]=DB04704&highlight[proteins][]=DB04704;!http://smpdb.ca/view/SMP0000717?highlight[compounds][]=DB04704&highlight[proteins][]=DB04704;!http://smpdb.ca/view/SMP0000372?highlight[compounds][]=DB04704&highlight[proteins][]=DB04704;!http://smpdb.ca/view/SMP0000577?highlight[compounds][]=DB04704&highlight[proteins][]=DB04704;!http://smpdb.ca/view/SMP0000718?highlight[compounds][]=DB04704&highlight[proteins][]=DB04704;!http://smpdb.ca/view/SMP0000130?highlight[compounds][]=DB04704&highlight[proteins][]=DB04704;!http://smpdb.ca/view/SMP0000373?highlight[compounds][]=DB04704&highlight[proteins][]=DB04704;!http://smpdb.ca/view/SMP0000566?highlight[compounds][]=DB04704&highlight[proteins][]=DB04704;!http://smpdb.ca/view/SMP0000576?highlight[compounds][]=DB04704&highlight[proteins][]=DB04704;!http://smpdb.ca/view/SMP0000578?highlight[compounds][]=DB04704&highlight[proteins][]=DB04704	Congenital Lipoid Adrenal Hyperplasia (CLAH) or Lipoid CAH;!11-beta-Hydroxylase Deficiency (CYP11B1);!Apparent Mineralocorticoid Excess Syndrome;!Adrenal Hyperplasia Type 5 or Congenital Adrenal Hyperplasia Due to 17 alpha-Hydroxylase Deficiency;!Corticosterone Methyl Oxidase I Deficiency (CMO I);!3-beta-Hydroxysteroid Dehydrogenase Deficiency;!Steroidogenesis;!Adrenal Hyperplasia Type 3 or Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency;!17-alpha-Hydroxylase Deficiency (CYP17);!21-Hydroxylase Deficiency (CYP21);!Corticosterone Methyl Oxidase II Deficiency (CMO II)		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	3.0155 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	2	2	No	4	0	40.46 Å2	50.57 Å3	122.3 m3·mol-1	5	No	No	0.000571 mg/mL	5.8	-5.8	18.2	-0.26			
C27H46O2	Not Available	Not Available	402.6529	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC=C4C[C@@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCCC(C)(C)O	Solid	Not Available					20182	42977	CHEMBL169046	58604				C15519		HC3			65094	46506794					ZINC000005751264		25-Hydroxycholesterol	Experimental	DB04705	InChI=1S/C27H46O2/c1-18(7-6-14-25(2,3)29)22-10-11-23-21-9-8-19-17-20(28)12-15-26(19,4)24(21)13-16-27(22,23)5/h8,18,20-24,28-29H,6-7,9-17H2,1-5H3/t18-,20+,21+,22-,23+,24+,26+,27-/m1/s1	INBGSXNNRGWLJU-ZHHJOTBYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	3.0155 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	2	2	No	4	0	40.46 Å2	51.11 Å3	122.45 m3·mol-1	5	No	No	0.000244 mg/mL	5.64	-6.2	18.2	-1			
C27H46O2	Not Available	Not Available	402.6529	[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@@H](O)C=C4C[C@@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCCC(C)C	Solid	Not Available					50045545	42989	CHEMBL497834	415508			HMDB0006119			HCR			473141	46505045					ZINC000005758832		7beta-hydroxycholesterol	Experimental	DB04706	InChI=1S/C27H46O2/c1-17(2)7-6-8-18(3)21-9-10-22-25-23(12-14-27(21,22)5)26(4)13-11-20(28)15-19(26)16-24(25)29/h16-18,20-25,28-29H,6-15H2,1-5H3/t18-,20+,21-,22+,23+,24+,25+,26+,27-/m1/s1	OYXZMSRRJOYLLO-KGZHIOMZSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	3.0155 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	2	2	No	4	0	40.46 Å2	51.12 Å3	122.06 m3·mol-1	5	No	No	0.000476 mg/mL	5.96	-5.9	18.2	-0.83			
C32H44N2O9	Not Available	Not Available	600.6998	[H][C@@]1([C@H](C)C(=O)NC)N([C@@H]2CC[C@H](O)[C@H](C)O2)C(=O)\C(=C(\O)/C=C/C(/C)=C/[C@@H](C)[C@@]2([H])O[C@@]3(C)O[C@H](C=C[C@@]33CO3)[C@@H]2C)C1=O	Solid	Not Available						45773	CHEMBL1236068	21270076						STD			54708748	46505558				Streptolydigin	ZINC000169363256		Streptolydigin	Experimental	DB04785	InChI=1S/C32H44N2O9/c1-16(14-17(2)28-18(3)23-12-13-32(15-40-32)31(6,42-23)43-28)8-9-22(36)25-27(37)26(19(4)29(38)33-7)34(30(25)39)24-11-10-21(35)20(5)41-24/h8-9,12-14,17-21,23-24,26,28,35-36H,10-11,15H2,1-7H3,(H,33,38)/b9-8+,16-14+,25-22+/t17-,18+,19+,20+,21+,23-,24+,26+,28-,31-,32-/m1/s1	KVTPRMVXYZKLIG-NCAOFHFGSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.8753 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	9	3	Yes	5	-1	147.16 Å2	63.96 Å3	160.29 m3·mol-1	7	No	No	0.0386 mg/mL	2.09	-4.2	5.29	-0.48			
C26H40O3	Not Available	Not Available	400.603	[H][C@@]1(CC[C@]2([H])\C(CCC[C@]12C)=C\C=C1C[C@@H](O)C[C@H](O)C1)[C@H](C)CC#CC(C)(C)O	Solid	Not Available							CHEMBL2105107	5291648						TX5			6915835	46504586					ZINC000012504514		Inecalcitol	Investigational	DB04796	InChI=1S/C26H40O3/c1-18(7-5-13-25(2,3)29)23-11-12-24-20(8-6-14-26(23,24)4)10-9-19-15-21(27)17-22(28)16-19/h9-10,18,21-24,27-29H,6-8,11-12,14-17H2,1-4H3/b20-10+/t18-,21-,22-,23-,24-,26-/m1/s1	HHGRMHMXKPQNGF-WNSNRMDMSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	4.7066 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	3	No	3	0	60.69 Å2	48.7 Å3	121.57 m3·mol-1	5	Yes	No	0.00221 mg/mL	4	-5.3	14.67	-2.7	P11473	VDR	1. Vitamin D3 receptor
C37H61N2O4	Not Available	141 minutes (mean)	597.904	[H][C@@]12C[C@@H]([C@H](OC(=O)CC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)N1CCCCC1)[N+]1(CC=C)CCCCC1	Solid	Not Available						135845	CHEMBL1201352	4470890								PA451227	5311399	46506932	RxList Drug Page	262100		Rapacuronium	ZINC000003943562		Rapacuronium	Approved, Withdrawn	DB04834	InChI=1S/C37H61N2O4/c1-6-20-39(21-12-9-13-22-39)32-24-30-28-15-14-27-23-33(42-26(3)40)31(38-18-10-8-11-19-38)25-37(27,5)29(28)16-17-36(30,4)35(32)43-34(41)7-2/h6,27-33,35H,1,7-25H2,2-5H3/q+1/t27-,28+,29-,30-,31-,32-,33-,35-,36-,37-/m0/s1	HTIKWNNIPGXLGM-YLINKJIISA-N		Rapacuronium is a nondepolarizing neuromuscular blocking agent used as an adjunct to general anesthesia to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgical procedures.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	-	Inhibitor	Inhibitor	Substrate	2.6637 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	3	0	Yes	6	2	55.84 Å2	72.25 Å3	183.1 m3·mol-1	9	No	No	4.64e-06 mg/mL	2.32	-8.1		9.65	P08172	CHRM2	1. Muscarinic acetylcholine receptor M2
C24H29ClO4	Not Available	Elimination Following oral or intramuscular administration, the plasma half-life is 38 and 96 hours, respectively.	416.938	[H][C@@]12C[C@]1([H])[C@@]1(C)C(=CC2=O)C(Cl)=C[C@@]2([H])[C@]3([H])CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CC[C@]12[H]	Solid	Not Available	P08684;!P11511	CYP3A4;!CYP19A1	1. Cytochrome P450 3A4;!2. Cytochrome P450 19A1		50094569	50743	CHEMBL139835	9496					D01368	CA4		PA10049	9880	46506931		22054	DAP000906	Cyproterone_acetate	ZINC000003814423	Androcur, Cléo -35, Cyestra-35, Diane	Cyproterone acetate	Approved, Investigational	DB04839	InChI=1S/C24H29ClO4/c1-12(26)24(29-13(2)27)8-6-16-14-10-20(25)19-11-21(28)15-9-18(15)23(19,4)17(14)5-7-22(16,24)3/h10-11,14-18H,5-9H2,1-4H3/t14-,15+,16-,17-,18-,22-,23-,24-/m0/s1	UWFYSQMTEOIJJG-FDTZYFLXSA-N	4	Cyproterone acetate is a steroid used in combination with ethinyl estradiol to treat women with severe acne and symptoms of androgenization. Also used alone at much higher doses for palliative treatment of patients with prostate cancer	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.8261 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							200-201			1	Yes	3	0	No	5	0	60.44 Å2	44.64 Å3	111.81 m3·mol-1	3	Yes	No	0.00152 mg/mL	3.64	-5.4	17.83	-5.6	P10275;!P07288	AR;!KLK3	1. Androgen receptor;!2. Prostate-specific antigen
C27H42N2O5S	Not Available	52 hours	506.7	[H][C@]12C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC[C@@]1(C)O2)C(\C)=C\C1=CSC(C)=N1	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			63605	CHEMBL1201752	20145579					D04645	GZX		PA165958343	6445540	99443224		337523		Ixabepilone	ZINC000003993846	Ixempra	Ixabepilone	Approved, Investigational	DB04845	InChI=1S/C27H42N2O5S/c1-15-9-8-10-27(7)22(34-27)12-20(16(2)11-19-14-35-18(4)28-19)29-23(31)13-21(30)26(5,6)25(33)17(3)24(15)32/h11,14-15,17,20-22,24,30,32H,8-10,12-13H2,1-7H3,(H,29,31)/b16-11+/t15-,17+,20-,21-,22-,24-,27+/m0/s1	FABUFPQFXZVHFB-PVYNADRNSA-N	3	Ixabepilone is a microtubule inhibitor administered in combination with capecitabine or alone in the treatment of metastatic or locally advanced breast cancer that has shown inadequate response to taxanes and anthracyclines.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.6638 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	3	No	3	0	112.05 Å2	56.86 Å3	136.71 m3·mol-1	2	No	No	0.00352 mg/mL	3.39	-5.2	13.85	2.73	Q13509	TUBB3	1. Tubulin beta-3 chain
C29H39NO9	Clearance for homoharringtonine was not quantified.	Homoharringtonine has a half life of about 6 hours after subcutaneous administration.	545.6213	[H][C@@]1(OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)C(OC)=C[C@]23CCCN2CCC2=CC4=C(OCO4)C=C2[C@]13[H]	Solid	Homoharringtonine has a steady state Vd of 141 ± 93.4 L.						71019	CHEMBL46286	251215	Drugs.com Drug Page				D08956	HMT			285033	175426874	RxList Drug Page	27100		Omacetaxine_mepesuccinate	ZINC000026011099	Synribo	Omacetaxine mepesuccinate	Approved, Investigational	DB04865	InChI=1S/C29H39NO9/c1-27(2,33)8-5-10-29(34,16-23(31)36-4)26(32)39-25-22(35-3)15-28-9-6-11-30(28)12-7-18-13-20-21(38-17-37-20)14-19(18)24(25)28/h13-15,24-25,33-34H,5-12,16-17H2,1-4H3/t24-,25-,28+,29-/m1/s1	HYFHYPWGAURHIV-JFIAXGOJSA-N	2	Omacetaxine mepesuccinate is a cephalotaxine used in the treatment of Chronic Myeloid Leukemia (CML) that is intolerant to or resistant to two or more tyrosine kinase inhibitors.	The most severe adverse effects after homoharringtonine administration are myelosuppression, bleeding, hyperglycemia, and fetal harm.	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	3.1592 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	8	2	Yes	5	1	123.99 Å2	57.62 Å3	142.07 m3·mol-1	11	No	No	0.108 mg/mL	1.88	-3.7	12.09	9.42	P20276;!P39023	rpl2;!RPL3	1. 50S ribosomal protein L2;!2. 60S ribosomal protein L3
C33H52O4	Not Available	Not Available	512.775	[H][C@]12C[C@@]3([H])[C@]4([H])CC=C5C[C@H](CC[C@]5(C)[C@@]4([H])CC[C@]3(C)[C@@]1([H])[C@H](C)[C@@]1(CC[C@@H](C)CO1)O2)OC(=O)CCCCC	Solid	Not Available								17460070									16394575	347827721					ZINC000097971833		Caprospinol	Investigational	DB05263	InChI=1S/C33H52O4/c1-6-7-8-9-29(34)36-24-13-15-31(4)23(18-24)10-11-25-26(31)14-16-32(5)27(25)19-28-30(32)22(3)33(37-28)17-12-21(2)20-35-33/h10,21-22,24-28,30H,6-9,11-20H2,1-5H3/t21-,22+,24+,25-,26+,27+,28+,30+,31+,32+,33-/m1/s1	VMOZFSWFUBLCNN-AAPULDEBSA-N			Not Available	Small Molecule																																			0	No	3	0	Yes	6	0	44.76 Å2	64.08 Å3	147.85 m3·mol-1	6	No	No	1.55e-05 mg/mL	7.4	-7.5		-4			
C30H50O5	Not Available	Not Available	490.725	[H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)[C@@H](OCCCO)[C@H](O)C1=C)[C@H](C)CCCC(C)(C)O	Solid	Not Available						73927		5293354						ED9			6918141	175426970				Eldecalcitol	ZINC000003934328		Eldecalcitol	Investigational	DB05295	InChI=1S/C30H50O5/c1-20(9-6-15-29(3,4)34)24-13-14-25-22(10-7-16-30(24,25)5)11-12-23-19-26(32)28(27(33)21(23)2)35-18-8-17-31/h11-12,20,24-28,31-34H,2,6-10,13-19H2,1,3-5H3/b22-11+,23-12-/t20-,24-,25+,26-,27-,28-,30-/m1/s1	FZEXGDDBXLBRTD-AYIMTCTASA-N	3		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	3.3673 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	5	4	Yes	3	0	90.15 Å2	59.7 Å3	143.54 m3·mol-1	10	Yes	No	0.0105 mg/mL	3.67	-4.7	13.38	-1.3	P11473	VDR	1. Vitamin D3 receptor
C24H30Cl2O6	Not Available	Not Available	485.4	[H][C@@]12CC[C@](OC(=O)C(Cl)Cl)(C(=O)OCC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	Not Available						135783	CHEMBL2107614	8110701									9935073	175427004					ZINC000003979944		Etiprednol dicloacetate	Investigational	DB05442	InChI=1S/C24H30Cl2O6/c1-4-31-21(30)24(32-20(29)19(25)26)10-8-16-15-6-5-13-11-14(27)7-9-22(13,2)18(15)17(28)12-23(16,24)3/h7,9,11,15-19,28H,4-6,8,10,12H2,1-3H3/t15-,16-,17-,18+,22-,23-,24-/m0/s1	QAIOVDNCIZSSSF-RFAJLIJZSA-N	2		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.9813 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	1	Yes	4	0	89.9 Å2	49.4 Å3	121.88 m3·mol-1	6	Yes	No	0.00235 mg/mL	3.99	-5.3	14.88	-2.9	P01584	IL1B	1. Interleukin-1 beta
C27H44O3	Not Available	Not Available	416.6365	[H][C@]12C[C@@]3([H])[C@]4([H])CC[C@]5([H])C[C@@H](O)CC[C@]5(C)[C@@]4([H])CC[C@]3(C)[C@@]1([H])[C@H](C)[C@@]1(CC[C@@H](C)CO1)O2	Solid	Not Available						28933		82568			HMDB0030048	C08913						347910146					ZINC000008234226		Smilagenin	Investigational	DB05450	InChI=1S/C27H44O3/c1-16-7-12-27(29-15-16)17(2)24-23(30-27)14-22-20-6-5-18-13-19(28)8-10-25(18,3)21(20)9-11-26(22,24)4/h16-24,28H,5-15H2,1-4H3/t16-,17+,18-,19+,20-,21+,22+,23+,24+,25+,26+,27-/m1/s1	GMBQZIIUCVWOCD-UQHLGXRBSA-N	2		Trials showed that the drug has a good clinical safety profile and is well-tolerated.	Small Molecule																																			1	No	3	1	No	6	0	38.69 Å2	51.43 Å3	119.42 m3·mol-1	0	No	Yes	3.28e-05 mg/mL	5.33	-7.1	18.3	-1.4			
C21H34F2O5	Not Available	Not Available	404.495	CC[C@H](C)CC(F)(F)[C@@]1(O)CC[C@H]2[C@@H](CC(=O)[C@@H]2CCCCCCC(O)=O)O1	Solid	Not Available							CHEMBL2103799	28529307																	Cobiprostone	Investigational	DB05514	InChI=1S/C21H34F2O5/c1-3-14(2)13-20(22,23)21(27)11-10-16-15(17(24)12-18(16)28-21)8-6-4-5-7-9-19(25)26/h14-16,18,27H,3-13H2,1-2H3,(H,25,26)/t14-,15+,16+,18+,21+/m0/s1	SDDSJMXGJNWMJY-BRHAQHMBSA-N	2		Not Available	Small Molecule																																			1	Yes	5	2	No	2	-1	83.83 Å2	44.14 Å3	100.15 m3·mol-1	11	Yes	No	0.0158 mg/mL	4.85	-4.4	4.3	-4.4	P51788	CLCN2	1. Chloride channel protein 2
C19H28O2	Not Available	Not Available	288.431	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3C[C@@H](C)[C@@]21[H]	Solid	Not Available								8014619									19582	175427041				Trestolone	ZINC000004217690		Trestolone	Investigational	DB05830	InChI=1S/C19H28O2/c1-11-9-12-10-13(20)3-4-14(12)15-7-8-19(2)16(18(11)15)5-6-17(19)21/h10-11,14-18,21H,3-9H2,1-2H3/t11-,14+,15-,16+,17+,18-,19+/m1/s1	YSGQGNQWBLYHPE-CFUSNLFHSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.6259 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	1	No	4	0	37.3 Å2	33.92 Å3	84.5 m3·mol-1	0	Yes	Yes	0.0391 mg/mL	3.35	-3.9	18.34	-0.88			
C22H36N2O6	Not Available	Not Available	424.531	[H][C@@]1([C@H](OC)[C@@H](CC[C@]11CO1)OC(=O)N[C@H](C(C)C)C(N)=O)[C@@]1(C)O[C@@H]1CC=C(C)C	Solid	Not Available					50088527		CHEMBL3527358	5293846									6918653	175427046							PPI-2458	Investigational	DB05864	InChI=1S/C22H36N2O6/c1-12(2)7-8-15-21(5,30-15)18-17(27-6)14(9-10-22(18)11-28-22)29-20(26)24-16(13(3)4)19(23)25/h7,13-18H,8-11H2,1-6H3,(H2,23,25)(H,24,26)/t14-,15-,16-,17-,18-,21+,22+/m1/s1	QBDVVYNLLXGUGN-XGTBZJOHSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.7785 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	2	Yes	3	0	115.71 Å2	46.27 Å3	110.43 m3·mol-1	9	Yes	No	0.0439 mg/mL	2.07	-4	13.45	-3.6	P50579	METAP2	1. Methionine aminopeptidase 2
C27H39NO5S	Not Available	Not Available	489.67	C[C@H]1\C=C\C\C(C)=C/C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\C1=CSC(C)=N1	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4					5294026									6918835	347827748					ZINC000100657972		KOS-1584	Investigational	DB05903	InChI=1S/C27H39NO5S/c1-16-9-8-10-17(2)25(31)19(4)26(32)27(6,7)23(29)14-24(30)33-22(12-11-16)18(3)13-21-15-34-20(5)28-21/h8,10-11,13,15,17,19,22-23,25,29,31H,9,12,14H2,1-7H3/b10-8+,16-11-,18-13+/t17-,19+,22-,23-,25-/m0/s1	XAYAKDZVINDZGB-BMVMHAJPSA-N	2		Not Available	Small Molecule																																			1	No	5	2	No	2	0	96.72 Å2	54.41 Å3	137.16 m3·mol-1	2	Yes	No	0.00256 mg/mL	4.73	-5.3	14.07	2.73			
C28H44O3	Not Available	Not Available	428.657	CC(C)[C@](C)(O)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	Solid	Not Available								7826201												1536458			ZINC000004791507		1alpha,24S-Dihydroxyvitamin D2	Investigational	DB06117	InChI=1S/C28H44O3/c1-18(2)28(6,31)15-13-19(3)24-11-12-25-21(8-7-14-27(24,25)5)9-10-22-16-23(29)17-26(30)20(22)4/h9-10,13,15,18-19,23-26,29-31H,4,7-8,11-12,14,16-17H2,1-3,5-6H3/b15-13+,21-9+,22-10-/t19-,23-,24-,25+,26+,27-,28-/m1/s1	ODZFJAXAEXQSKL-WRJREGAQSA-N			Not Available	Small Molecule																																			1	No	3	3	No	3	0	60.69 Å2	52.29 Å3	131.89 m3·mol-1	5	Yes	No	0.00726 mg/mL	4.59	-4.8	14.39	-1.1			
C43H74N2O14	80% of the administered dose excreted in the bile, which makes the fecal-biliary route is the most important route of elimination.Enterohepatic recycling could also occur.Only 4 to 14% of an administered dose is eliminated through renal-urinary excretion route.	Intravenous:Young persons (18 to 32 years of age): Approximately 4.5 to 6.2 hours.Elderly persons (73 to 85 years of age): Approximately 9.8 to 13.5 hours. Oral: 5.5-8 hours, Rectal in children: 8 hours	843.065	[H][C@@]1(CC[C@@H]([C@@H](C)O1)N(C)C)O[C@H]1\C=C\C=C\C[C@@H](C)OC(=O)C[C@@H](O)[C@H](OC)[C@@H](O[C@]2([H])O[C@H](C)[C@@H](O[C@@]3([H])C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C)[C@@H](CC=O)C[C@H]1C	Solid	The tissue distribution of spiramycin is extensive. The volume of distribution is in excess of 300 L, and concentrations achieved in bone, muscle, respiratory tract and saliva exceed those found in serum. Spiramycin showed high concentrations in tissues such as: lungs, bronchi, tonsils, and sinuses.						85260	CHEMBL453514	4451378						SPR			6440717	347827756		9991		Spiramycin	ZINC000257373089	Rovamycin	Spiramycin	Approved	DB06145	InChI=1S/C43H74N2O14/c1-24-21-29(19-20-46)39(59-42-37(49)36(45(9)10)38(27(4)56-42)58-35-23-43(6,51)41(50)28(5)55-35)40(52-11)31(47)22-33(48)53-25(2)15-13-12-14-16-32(24)57-34-18-17-30(44(7)8)26(3)54-34/h12-14,16,20,24-32,34-42,47,49-51H,15,17-19,21-23H2,1-11H3/b13-12+,16-14+/t24-,25-,26-,27-,28+,29+,30+,31-,32+,34+,35+,36-,37-,38-,39+,40+,41+,42+,43-/m1/s1	ACTOXUHEUCPTEW-CEUOBAOPSA-N	3	Spiramycin is a macrolide antimicrobial agent used in the treatment of various bacterial infections.	Cardiac toxicity, specifically QT prolongation (irregular heartbeat; recurrent fainting).Cholestatic hepatitis (abdominal pain; nausea; vomiting; yellow eyes or skin).Gastrointestinal toxicity, specifically acute colitis (abdominal pain and tenderness; bloody stools; fever).Intestinal injury (abdominal pain and tenderness).Ulcerated esophagitis (chest pain; heartburn).	Small Molecule																																			0	No	15	4	Yes	4	2	195.38 Å2	93.01 Å3	219.25 m3·mol-1	11	No	No	0.196 mg/mL	2.5	-3.6	12.53	9.33	Q9A1X4	rplC	1. 50S ribosomal protein L3
C53H84NO14P	Not Available	Not Available	990.222	CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			79700	CHEMBL2103839	24597928				C15183										Deforolimus	ZINC000169677038		Ridaforolimus	Investigational	DB06233	InChI=1S/C53H84NO14P/c1-32-18-14-13-15-19-33(2)44(63-8)30-40-23-21-38(7)53(61,67-40)50(58)51(59)54-25-17-16-20-41(54)52(60)66-45(35(4)28-39-22-24-43(46(29-39)64-9)68-69(11,12)62)31-42(55)34(3)27-37(6)48(57)49(65-10)47(56)36(5)26-32/h13-15,18-19,27,32,34-36,38-41,43-46,48-49,57,61H,16-17,20-26,28-31H2,1-12H3/b15-13+,18-14+,33-19+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1	BUROJSBIWGDYCN-GAUTUEMISA-N	3		Not Available	Small Molecule																																			0	No	12	2	Yes	4	0	201.5 Å2	107.25 Å3	267.98 m3·mol-1	8	No	No	0.000805 mg/mL	7.25	-6.1	9.96	-3	P42345	MTOR	1. Serine/threonine-protein kinase mTOR
C19H30O3	Not Available	Not Available	306.446	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@H](O)C=C2C[C@@H](O)CC[C@]12C	Solid	Not Available								7993774															ZINC000033967857		HE-2200	Investigational	DB06257	InChI=1S/C19H30O3/c1-18-7-5-12(20)9-11(18)10-15(21)17-13-3-4-16(22)19(13,2)8-6-14(17)18/h10,12-17,20-22H,3-9H2,1-2H3/t12-,13-,14-,15-,16-,17-,18-,19-/m0/s1	OEVZKEVBDIDVOI-YSZCXEEOSA-N			Not Available	Small Molecule																																			1	Yes	3	3	No	4	0	60.69 Å2	35.67 Å3	86.92 m3·mol-1	0	Yes	No	0.223 mg/mL	1.65	-3.1	18.2	-0.55			
C26H42O4	Not Available	Not Available	418.6093	[H]\C(\C(\[H])=C1/CCC[C@@]2(C)[C@@]1([H])CC[C@]2([H])[C@]([H])(C)OCCC(C)(C)O)=C1/C[C@@]([H])(O)C[C@]([H])(O)C1=C	Solid	Not Available					50124417	31801	CHEMBL333950	4911262						MCZ									ZINC000004474617		Maxacalcitol	Investigational	DB06272	InChI=1S/C26H42O4/c1-17-20(15-21(27)16-24(17)28)9-8-19-7-6-12-26(5)22(10-11-23(19)26)18(2)30-14-13-25(3,4)29/h8-9,18,21-24,27-29H,1,6-7,10-16H2,2-5H3/b19-8+,20-9-/t18-,21+,22+,23-,24-,26+/m0/s1	DTXXSJZBSTYZKE-ZDQKKZTESA-N	3		Not Available	Small Molecule																																			1	No	4	3	Yes	3	0	69.92 Å2	50.09 Å3	123.83 m3·mol-1	6	Yes	No	0.015 mg/mL	2.79	-4.4	14.34	-2.7			
C56H87NO16	16.2 L/h (22%)	Temsirolimus exhibits a bi-exponential decline in whole blood concentrations and the mean half-lives of temsirolimus and sirolimus were 17.3 hr and 54.6 hr, respectively.	1030.2871	OCC(C)(CO)C(=O)O[C@@H]1CC[C@@H](C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@@H](OC)C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)C[C@H]1OC	Solid	172 L in whole blood of cancer patients; both temsirolimus and sirolimus are extensive distributed partitioned into formed blood elements	P10635;!P08684;!P20815;!P24462	CYP2D6;!CYP3A4;!CYP3A5;!CYP3A7	1. Cytochrome P450 2D6;!2. Cytochrome P450 3A4;!3. Cytochrome P450 3A5;!4. Cytochrome P450 3A7		50343413	79699	CHEMBL1201182	21468899	Drugs.com Drug Page		HMDB0015632	C15182	D06068	A4I		PA164746890	23724530	99443243	RxList Drug Page	657797	DAP001222	Temsirolimus		Torisel	Temsirolimus	Approved	DB06287	InChI=1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1	CBPNZQVSJQDFBE-FUXHJELOSA-N	4	Temsirolimus is a antineoplastic agent used in the treatment of renal cell carcinoma (RCC) that works by inhibiting mTOR.	Temsirolimus has been administered to patients with cancer in phase 1 and 2 trials with repeated intravenous doses as high as 220 mg/m2. The risk of several serious adverse events, including thrombosis, bowel perforation, interstitial lung disease (ILD), seizure, and psychosis, is increased with doses of temsirolimus greater than 25 mg.	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Inhibitor	Inhibitor	Substrate	2.8760 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	14	4	Yes	4	0	241.96 Å2	112.7 Å3	277.07 m3·mol-1	11	No	No	0.00235 mg/mL	7.13	-5.6	9.96	-2.9			
C42H59N3O10	Cethromycin clearance in patients receiving a once-daily oral dose of 300 mg is reported to be approximately 63 L/h.2	Cethromycin given in five oral doses of 150 or 300 mg has a plasma half-life of 4.85 ± 1.10 and 4.94 ± 0.66 hrs, respectively.2 A single oral dose of 150 mg produced a measured half-life of 5.66 ± 0.77 hrs.7	765.945	[H]C(CO[C@]1(C)C[C@@H](C)C(=O)[C@H](C)[C@H]2NC(=O)O[C@]2(C)[C@@H](CC)OC(=O)[C@H](C)C(=O)[C@H](C)[C@H]1O[C@@H]1O[C@H](C)C[C@@H]([C@H]1O)N(C)C)=C([H])C1=CC2=C(C=CC=C2)N=C1	Solid	Cethromycin given in five 150 mg oral doses had an apparent volume of distribution at the terminal elimination phase of 1433 ± 843 L, and an apparent steady-state volume of distribution of 1453 ± 997 L. The corresponding values for a 300 mg dose was 761 ± 293 L and 769 ± 272 L.2 Cethromycin is known to accumulate in the epithelial lining fluid and alveolar cells,2 as well as within polymorphonuclear leukocytes.6	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5			29506	CHEMBL3989904	34991522				C12020	D02391				447451	310264871				Cethromycin			Cethromycin	Investigational	DB06419	InChI=1S/C42H59N3O10/c1-11-32-42(8)36(44-40(50)55-42)25(4)33(46)23(2)21-41(7,51-18-14-15-28-20-29-16-12-13-17-30(29)43-22-28)37(26(5)34(47)27(6)38(49)53-32)54-39-35(48)31(45(9)10)19-24(3)52-39/h12-17,20,22-27,31-32,35-37,39,48H,11,18-19,21H2,1-10H3,(H,44,50)/t23-,24-,25+,26+,27-,31+,32-,35-,36-,37-,39+,41-,42-/m1/s1	PENDGIOBPJLVBT-AMXFZXBBSA-N	3	Cethromycin is a ketolide antibiotic with broad-spectrum activity against Gram-positive, Gram-negative, and atypical bacteria that may be useful for treating several conditions including community-acquired pneumonia, inhalation anthrax, plague, and tularemia.	Toxicity information regarding cethromycin is not readily available. Patients experiencing an overdose are at an increased risk of severe adverse effects such as diarrhea, nausea, vomiting, abdominal pain, and headaches. Symptomatic and supportive measures are recommended.13,1	Small Molecule																																			0	No	10	2	Yes	5	1	162.82 Å2	84.61 Å3	204.58 m3·mol-1	8	No	No	0.00489 mg/mL	5.75	-5.2	9.22	8.61	BSEQ0052173		1. 23S ribosomal RNA
C47H74O15	Not Available	Not Available	879.094	[H][C@@]12CC=C3C[C@H](CC[C@]3(C)[C@@]1([H])C[C@@H](OC(=O)C(\C)=C\C)[C@]1(C)[C@H](CC[C@]21O)C(C)=O)O[C@H]1C[C@H](OC)[C@H](O[C@H]2C[C@H](OC)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](OC)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1	Solid	Not Available								8138385														P57	ZINC000255201631		P-57AS3	Investigational	DB06569	InChI=1S/C47H74O15/c1-12-23(2)43(51)60-35-20-32-31(47(52)18-16-30(24(3)48)46(35,47)8)14-13-28-19-29(15-17-45(28,32)7)59-36-21-33(53-9)40(26(5)56-36)61-37-22-34(54-10)41(27(6)57-37)62-44-39(50)42(55-11)38(49)25(4)58-44/h12-13,25-27,29-42,44,49-50,52H,14-22H2,1-11H3/b23-12+/t25-,26-,27-,29+,30-,31-,32+,33+,34+,35-,36+,37+,38-,39-,40-,41-,42+,44+,45+,46+,47+/m1/s1	CBMQKMMZBOSHHP-VXXSQTRDSA-N			Not Available	Small Molecule																																			0	No	14	3	Yes	7	0	187.13 Å2	97.44 Å3	224.39 m3·mol-1	13	No	No	0.00769 mg/mL	5.04	-5.1	12.29	-3.2			
C36H56O6	Not Available	56.3 to 69.5 hours	584.8262	[H][C@]12[C@@H](CC[C@@]1(CC[C@]1(C)[C@]2([H])CC[C@]2([H])[C@@]3(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@]3([H])CC[C@@]12C)C(O)=O)C(C)=C	Solid	Not Available					50050955	65484	CHEMBL404519	403003									457928	175427073				Bevirimat	ZINC000003936686		Bevirimat	Investigational	DB06581	InChI=1S/C36H56O6/c1-21(2)22-12-17-36(30(40)41)19-18-34(8)23(28(22)36)10-11-25-33(7)15-14-26(42-27(37)20-31(3,4)29(38)39)32(5,6)24(33)13-16-35(25,34)9/h22-26,28H,1,10-20H2,2-9H3,(H,38,39)(H,40,41)/t22-,23+,24-,25+,26-,28+,33-,34+,35+,36-/m0/s1	YJEJKUQEXFSVCJ-WRFMNRASSA-N	2		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	3.5488 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	5	2	Yes	5	-2	100.9 Å2	67.97 Å3	161.75 m3·mol-1	7	No	No	0.000135 mg/mL	8	-6.6	4.16	-7.1	P04585	gag-pol	1. Gag-Pol polyprotein
C40H69NO12	Not Available	Not Available	755.987	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C(C)C)[C@@]2(C)CC(C)=C(O2)[C@H](C)C(=O)[C@]1(C)OC	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4		85390		CHEMBL2110756	5293473														Mitemcinal	ZINC000085537008		Mitemcinal	Investigational	DB06587	InChI=1S/C40H69NO12/c1-16-28-40(12,47-15)33(43)23(6)31-21(4)18-39(11,53-31)35(52-37-30(42)27(17-22(5)48-37)41(13)20(2)3)24(7)32(25(8)36(45)50-28)51-29-19-38(10,46-14)34(44)26(9)49-29/h20,22-30,32,34-35,37,42,44H,16-19H2,1-15H3/t22-,23+,24+,25-,26+,27+,28-,29+,30-,32+,34+,35-,37+,38-,39-,40-/m1/s1	BELMMAAWNYFCGF-PZXAHSFZSA-N	2		Not Available	Small Molecule																																			0	No	12	2	Yes	4	1	151.68 Å2	83.09 Å3	197.85 m3·mol-1	9	No	No	0.038 mg/mL	4.9	-4.3	12.63	9.63	O43193	MLNR	1. Motilin receptor
C23H34O5	Not Available	Not Available	390.52	[H][C@]12[C@H](CCC=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC	Solid	Not Available	P23141	CES1	1. Liver carboxylesterase 1		50011036	34848	CHEMBL54440	58262				C13963		2UO			64715	99443247				Mevastatin	ZINC000003833876		Mevastatin	Experimental	DB06693	InChI=1S/C23H34O5/c1-4-14(2)23(26)28-20-7-5-6-16-9-8-15(3)19(22(16)20)11-10-18-12-17(24)13-21(25)27-18/h6,8-9,14-15,17-20,22,24H,4-5,7,10-13H2,1-3H3/t14-,15-,17+,18+,19-,20-,22-/m0/s1	AJLFOPYRIVGYMJ-INTXDZFKSA-N			Side effects include those of other statins, such as myalgias, abdominal pain, nausea. It also has a higher chance of giving more severe side effects related to myotoxicity (myopathy, myositis, rhabdomyolysis), and hepatotoxicity, than other statins. Due to these major side effects and their enhanced rate of occurance, Mevastatin is not given therapeutically.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	2.6058 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.95		152 °C			1	Yes	3	1	Yes	3	0	72.83 Å2	43.57 Å3	108.63 m3·mol-1	7	Yes	No	0.0321 mg/mL	3.62	-4.1	14.91	-2.8	P04035	HMGCR	1. 3-hydroxy-3-methylglutaryl-coenzyme A reductase
C21H26O2	Not Available	16 to 18 hrs.	310.4299	CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1C=C[C@@]2(O)C#C	Solid	Not Available	P08684;!P33261;!P20815;!P24462	CYP3A4;!CYP2C19;!CYP3A5;!CYP3A7	1. Cytochrome P450 3A4;!2. Cytochrome P450 2C19;!3. Cytochrome P450 3A5;!4. Cytochrome P450 3A7			135323	CHEMBL1213583	2298532			HMDB0015668					PA165958397	3033968	99443276		25734		Gestodene	ZINC000238809420		Gestodene	Investigational	DB06730	InChI=1S/C21H26O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,10,12-13,16-19,23H,3,5-9,11H2,1H3/t16-,17+,18+,19-,20-,21-/m0/s1	SIGSPDASOTUPFS-XUDSTZEESA-N	4		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.7480 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							197.9 °C			1	Yes	2	1	No	4	0	37.3 Å2	35.96 Å3	92.99 m3·mol-1	1	Yes	Yes	0.00581 mg/mL	3.46	-4.7	17.08	-1.9	P06401	PGR	1. Progesterone receptor
C35H58O9	Not Available	Not Available	622.84	CO[C@H]1\C=C\C=C(C)\C[C@H](C)[C@H](O)[C@H](C)\C=C(/C)\C=C(OC)\C(=O)O[C@@H]1[C@@H](C)[C@@H](O)[C@H](C)[C@@]1(O)C[C@@H](O)[C@H](C)[C@H](O1)C(C)C	Solid	Not Available					50064186	22689	CHEMBL290814	4642865									6436223	347827783				Bafilomycin	ZINC000169647947		Bafilomycin A1	Experimental	DB06733	InChI=1S/C35H58O9/c1-19(2)32-24(7)27(36)18-35(40,44-32)26(9)31(38)25(8)33-28(41-10)14-12-13-20(3)15-22(5)30(37)23(6)16-21(4)17-29(42-11)34(39)43-33/h12-14,16-17,19,22-28,30-33,36-38,40H,15,18H2,1-11H3/b14-12+,20-13+,21-16+,29-17-/t22-,23+,24-,25-,26-,27+,28-,30-,31+,32+,33+,35+/m0/s1	XDHNQDDQEHDUTM-JQWOJBOSSA-N			Not Available	Small Molecule																																			0	No	8	4	No	2	0	134.91 Å2	69.33 Å3	174.53 m3·mol-1	7	No	No	0.0155 mg/mL	5.08	-4.6	11.69	-0.73	P38606	ATP6V1A	1. V-type proton ATPase catalytic subunit A
C44H65NO13	Not Available	Not Available	815.998	CO[C@H]1\C=C/C=C(C)\C[C@H](C)[C@H](O)[C@H](C)\C=C(\C)/C=C(OC)\C(=O)OC1[C@@H](C)[C@@H](O)[C@H](C)[C@@]1(O)C[C@@H](OC(=O)\C=C\C(=O)NC2=C(O)CCC2=O)[C@H](C)[C@H](O1)C(C)C	Solid	Not Available								21249786										347910364							Bafilomycin B1	Experimental	DB06734	InChI=1S/C44H65NO13/c1-23(2)41-28(7)35(56-37(49)18-17-36(48)45-38-31(46)15-16-32(38)47)22-44(53,58-41)30(9)40(51)29(8)42-33(54-10)14-12-13-24(3)19-26(5)39(50)27(6)20-25(4)21-34(55-11)43(52)57-42/h12-14,17-18,20-21,23,26-30,33,35,39-42,46,50-51,53H,15-16,19,22H2,1-11H3,(H,45,48)/b14-12-,18-17+,24-13-,25-20-,34-21+/t26-,27+,28-,29-,30-,33-,35+,39-,40+,41+,42?,44+/m0/s1	KFUFLYSBMNNJTF-MZYUNMTESA-N			Not Available	Small Molecule																																			0	No	11	5	Yes	3	-1	207.38 Å2	87.47 Å3	222.85 m3·mol-1	12	No	No	0.00584 mg/mL	5.04	-5.2	4.93	-0.73	P38606	ATP6V1A	1. V-type proton ATPase catalytic subunit A
C16H24O4	Not Available	Not Available	280.3594	[H][C@]1(O)C[C@@]2([H])\C=C\CCC[C@]([H])(C)OC(=O)\C=C\[C@@]([H])(O)[C@]2([H])C1	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4		97307	48080	CHEMBL19980	4449949						AFB			5287620	99443819				Brefeldin_A	ZINC000012371944		Brefeldin A	Experimental	DB07348	InChI=1S/C16H24O4/c1-11-5-3-2-4-6-12-9-13(17)10-14(12)15(18)7-8-16(19)20-11/h4,6-8,11-15,17-18H,2-3,5,9-10H2,1H3/b6-4+,8-7+/t11-,12+,13-,14+,15+/m0/s1	KQNZDYYTLMIZCT-KQPMLPITSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1006 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	2	No	2	0	66.76 Å2	31.04 Å3	78.75 m3·mol-1	0	Yes	No	0.812 mg/mL	2.01	-2.5	14.42	-2.7	Q99418;!P84077	CYTH2;!ARF1	1. Cytohesin-2;!2. ADP-ribosylation factor 1
C17H28O4	Not Available	Not Available	296.4018	[H][C@@]1(C)C[C@]([H])(C)[C@]([H])(O)[C@@]([H])(C)C(=O)O[C@]([H])(CC)[C@]([H])(C)\C=C\C1=O	Solid	Not Available						29461		4445261				C11993		E4H			5282031	99444174							(3R,4S,5S,7R,9E,11R,12R)-12-ETHYL-4-HYDROXY-3,5,7,11-TETRAMETHYLOXACYCLODODEC-9-ENE-2,8-DIONE	Experimental	DB07703	InChI=1S/C17H28O4/c1-6-15-10(2)7-8-14(18)11(3)9-12(4)16(19)13(5)17(20)21-15/h7-8,10-13,15-16,19H,6,9H2,1-5H3/b8-7+/t10-,11-,12+,13-,15-,16+/m1/s1	NZUJVBSYQXETNF-PQWITYJESA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.5797 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	1	No	1	0	63.6 Å2	33.24 Å3	82.8 m3·mol-1	1	Yes	No	0.245 mg/mL	3.6	-3.1	14.45	-3	Q9ZGI2	pikAIV	1. Type I polyketide synthase PikAIV
C22H28O5	Not Available	Not Available	372.4547	[H][C@@]12CC[C@H](OC(=O)CCC(O)=O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3CC[C@@]21[H]	Solid	Not Available							CHEMBL1233274	59813						HE7			66440	99444362				Estradiol_hemisuccinate	ZINC000004026838		Estradiol hemisuccinate	Experimental	DB07891	InChI=1S/C22H28O5/c1-22-11-10-16-15-5-3-14(23)12-13(15)2-4-17(16)18(22)6-7-19(22)27-21(26)9-8-20(24)25/h3,5,12,16-19,23H,2,4,6-11H2,1H3,(H,24,25)/t16-,17-,18+,19+,22+/m1/s1	YJPIDPAGJSWWBE-FNIAAEIWSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3962 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	2	No	4	-1	83.83 Å2	41.88 Å3	99.95 m3·mol-1	5	Yes	No	0.0048 mg/mL	4.01	-4.9	4.31	-5.4			
C20H29NO5S	Not Available	Not Available	395.513	[H][C@]1(CSC(=O)N1)[C@@]1(O)C[C@H]2C[C@@H](CC[C@H](C)\C=C/CC\C(C)=C/C(=O)O2)O1	Solid	Not Available						49703	CHEMBL411879	10192733						LAB			6436219	99444551				Latrunculin	ZINC000005751767		Latrunculin B	Experimental	DB08080	InChI=1S/C20H29NO5S/c1-13-5-3-4-6-14(2)9-18(22)25-16-10-15(8-7-13)26-20(24,11-16)17-12-27-19(23)21-17/h3,5,9,13,15-17,24H,4,6-8,10-12H2,1-2H3,(H,21,23)/b5-3-,14-9-/t13-,15-,16-,17+,20-/m1/s1	NSHPHXHGRHSMIK-JRIKCGFMSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.7374 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	2	No	3	0	84.86 Å2	42.08 Å3	105.64 m3·mol-1	1	Yes	No	0.0713 mg/mL	3.79	-3.7	11.36	-4.4	P68133;!Q969V6;!Q8WWL2	ACTA1;!MKL1;!SPIRE2	1. Actin, alpha skeletal muscle;!2. MKL/myocardin-like protein 1;!3. Protein spire homolog 2
C17H27NO4	Not Available	Not Available	309.4006	[H][C@](CC)(C=O)[C@@]1([H])NC(C(O)=O)=C2[C@@]1([H])CCC[C@@]2([H])OCCCC	Solid	Not Available								25058525						LK5			46937124	99444580					ZINC000100036343		(1S,4R,7AR)-4-BUTOXY-1-[(1R)-1-FORMYLPROPYL]-2,4,5,6,7,7A-HEXAHYDRO-1H-ISOINDOLE-3-CARBOXYLIC ACID	Experimental	DB08109	InChI=1S/C17H27NO4/c1-3-5-9-22-13-8-6-7-12-14(13)16(17(20)21)18-15(12)11(4-2)10-19/h10-13,15,18H,3-9H2,1-2H3,(H,20,21)/t11-,12+,13+,15+/m0/s1	WRBRCIHZCYLBFW-KYEXWDHISA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.4426 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	2	No	2	0	75.63 Å2	34.63 Å3	84.63 m3·mol-1	8	Yes	No	0.206 mg/mL	2.1	-3.2	5.77	1.81	P05364	ampC	1. Beta-lactamase
C18H26O4	Not Available	Not Available	306.3966	[H][C@]1(O)CC(=O)O[C@@]([H])(CC[C@@]2([H])[C@@]([H])(C)C=CC3=CCC[C@]([H])(O)[C@]23[H])C1	Solid	Not Available								3572094						MVB			4369567	99444695					ZINC000006416565		(1S,7S,8S,8AR)-1,2,3,7,8,8A-HEXAHYDRO-7-METHYL-8-[2-[(2R,4R)-TETRAHYDRO-4-HY DROXY-6-OXO-2H-PYRAN-2-YL]ETHYL]-1-NAPHTHALENOL	Experimental	DB08224	InChI=1S/C18H26O4/c1-11-5-6-12-3-2-4-16(20)18(12)15(11)8-7-14-9-13(19)10-17(21)22-14/h3,5-6,11,13-16,18-20H,2,4,7-10H2,1H3/t11-,13+,14-,15-,16-,18-/m0/s1	WWSNTLOVYSRDEL-TVKPWXLESA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.6070 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	2	No	3	0	66.76 Å2	33.96 Å3	85.68 m3·mol-1	3	Yes	No	0.26 mg/mL	1.49	-3.1	14.91	-0.85	P23141	CES1	1. Liver carboxylesterase 1
C22H30O5	Not Available	Not Available	374.4706	[H][C@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)CC[C@]4([H])[C@@]3([H])CC[C@]12C)OC(=O)CCC(O)=O	Solid	Not Available								4451095						NTH			5289054	99444779					ZINC000033821445		SUCCINIC ACID MONO-(13-METHYL-3-OXO-2,3,6,7,8,9,10,11,12,13,14,15,16,17-TETRADECAHYDRO-1H-CYCLOPENTA[A]PHENANTHREN-17-YL) ESTER	Experimental	DB08308	InChI=1S/C22H30O5/c1-22-11-10-16-15-5-3-14(23)12-13(15)2-4-17(16)18(22)6-7-19(22)27-21(26)9-8-20(24)25/h12,15-19H,2-11H2,1H3,(H,24,25)/t15-,16+,17+,18-,19+,22-/m0/s1	IRQUJNVGEAJGSD-KIEDKLRZSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.0592 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	1	No	4	-1	80.67 Å2	41.7 Å3	100 m3·mol-1	5	Yes	No	0.0108 mg/mL	3.33	-4.5	4.31	-4.7	P00947	ksi	1. Steroid Delta-isomerase
C25H38O5	Not Available	Not Available	418.5662	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])C[C@]([H])(CC[C@]4(C)[C@@]3([H])CC[C@]12C)OC(=O)CCC(O)=O)C(C)=O	Solid	Not Available						62043		4451314						S5H			5289324	99444981					ZINC000011422518		5-ALPHA-PREGNANE-3-BETA-OL-HEMISUCCINATE	Experimental	DB08510	InChI=1S/C25H38O5/c1-15(26)19-6-7-20-18-5-4-16-14-17(30-23(29)9-8-22(27)28)10-12-24(16,2)21(18)11-13-25(19,20)3/h16-21H,4-14H2,1-3H3,(H,27,28)/t16-,17-,18-,19+,20-,21-,24-,25+/m0/s1	UVTGFMKBPVLATL-DSOJQRAMSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.1566 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	1	Yes	4	-1	80.67 Å2	48.08 Å3	112.95 m3·mol-1	6	Yes	No	0.00175 mg/mL	4.25	-5.4	4.11	-6.9	P01859	IGHG2	1. Ig gamma-2 chain C region
C25H34O6	Not Available	Not Available	430.5339	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)CC[C@]4(C)[C@@]3([H])[C@@]([H])(C[C@]12C)OC(=O)CCC(O)=O)C(C)=O	Solid	Not Available						45496		4451359						SIH			5289373	99445018					ZINC000013512622		PROGESTERONE-11-ALPHA-OL-HEMISUCCINATE	Experimental	DB08547	InChI=1S/C25H34O6/c1-14(26)18-6-7-19-17-5-4-15-12-16(27)10-11-24(15,2)23(17)20(13-25(18,19)3)31-22(30)9-8-21(28)29/h12,17-20,23H,4-11,13H2,1-3H3,(H,28,29)/t17-,18+,19-,20+,23+,24-,25+/m0/s1	JBBNFGYRYNBDIH-DBGGZKJISA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.3116 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	1	Yes	4	-1	97.74 Å2	46.96 Å3	114.34 m3·mol-1	6	Yes	No	0.0085 mg/mL	3.11	-4.7	4.22	-4.8	P01859	IGHG2	1. Ig gamma-2 chain C region
C23H32O5	Not Available	Not Available	388.4972	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)OC(=O)CCC(O)=O	Solid	Not Available								106489						TH2			119202	99445090					ZINC000004025723		Testosterone succinate	Experimental	DB08619	InChI=1S/C23H32O5/c1-22-11-9-15(24)13-14(22)3-4-16-17-5-6-19(23(17,2)12-10-18(16)22)28-21(27)8-7-20(25)26/h13,16-19H,3-12H2,1-2H3,(H,25,26)/t16-,17-,18-,19-,22-,23-/m0/s1	CJQNBXFUHQZFOE-VYAQIDIUSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.1662 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	1	No	4	-1	80.67 Å2	43.74 Å3	104.47 m3·mol-1	5	Yes	No	0.00844 mg/mL	3.63	-4.7	4.31	-4.8	P0A3R9	ncsA	1. Neocarzinostatin
C19H28ClNO6	Not Available	Not Available	401.882	[H][C@]1(CC=C(C)C)O[C@]1(C)[C@@]1([H])[C@]([H])(OC)[C@@]([H])(CC[C@]11CO1)OC(=O)NC(=O)CCl	Solid	Not Available					17446	90748	CHEMBL424278	328427						TN4			369976	99445104					ZINC000003914617		TNP-470	Investigational	DB08633	InChI=1S/C19H28ClNO6/c1-11(2)5-6-13-18(3,27-13)16-15(24-4)12(7-8-19(16)10-25-19)26-17(23)21-14(22)9-20/h5,12-13,15-16H,6-10H2,1-4H3,(H,21,22,23)/t12-,13-,15-,16-,18+,19+/m1/s1	MSHZHSPISPJWHW-PVDLLORBSA-N	1		Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.8117 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	1	Yes	3	0	89.69 Å2	41.46 Å3	98.45 m3·mol-1	7	Yes	No	0.0234 mg/mL	2.24	-4.2	9.71	-3.7			
C28H44O3	50 mg, 100 mg, and 150 mg doses of nadrolone decanoate had mean apparent clearances of 80.0 L/h, 74.3 L/h, and 76.2 L/h respectively.1	Nandrolone decanoate has an absorption half life of 6 days and an elimination half life of 4.3 hours.13 Alternate studies have shown that nandrolone decanoate has a terminal half life of 7.1, 11.7, and 11.8 hours for doses of 50, 100, and 150 mg respectively.1	428.6472	[H][C@@]12CC[C@H](OC(=O)CCCCCCCCC)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	Solid	Not Available	P11511;!P27338;!P21397;!P16662;!P22310;!P06133;!P35503;!P22309;!Q9HAW8	CYP19A1;!MAOB;!MAOA;!UGT2B7;!UGT1A4;!UGT2B4;!UGT1A3;!UGT1A1;!UGT1A10	1. Cytochrome P450 19A1;!2. Amine oxidase [flavin-containing] B;!3. Amine oxidase [flavin-containing] A;!4. UDP-glucuronosyltransferase 2B7;!5. UDP-glucuronosyltransferase 1-4;!6. UDP-glucuronosyltransferase 2B4;!7. UDP-glucuronosyltransferase 1-3;!8. UDP-glucuronosyltransferase 1-1;!9. UDP-glucuronosyltransferase 1-10			7467	CHEMBL1200946	9296	Drugs.com Drug Page		HMDB0015694	C08154	D00955			PA165958423	9677	99445274		31494	DAP000903	Nandrolone_decanoate	ZINC000008214619		Nandrolone decanoate	Approved, Illicit	DB08804	InChI=1S/C28H44O3/c1-3-4-5-6-7-8-9-10-27(30)31-26-16-15-25-24-13-11-20-19-21(29)12-14-22(20)23(24)17-18-28(25,26)2/h19,22-26H,3-18H2,1-2H3/t22-,23+,24+,25-,26-,28-/m0/s1	JKWKMORAXJQQSR-MOPIKTETSA-N	2	Nandrolone decanoate is an anabolic steroid indicated for the management of the anemia of renal insufficiency by increasing hemoglobin and red cell mass.	Data regarding acute overdose of nandrolone decanoate are not readily available.13 However, patients experiencing a chronic overdose of anabolic steroids may experience adverse effects including suppression of testosterone and spermatogenesis, shrinking of testicles, decreased libido, and erectile dysfunction in men; and suppressed estrogen, progesterone, and ovulation, amenorrhea, and clitoromegaly in women.8 Patients may also experience neuropsychiatric, cardiovascular, and hepatic adverse effects.8 Alkylated anabolic steroids such as nandrolone decanoate are more likely to cause hepatic adverse effects.8 Treat patients with symptomatic and supportive measures.The intraperitoneal LD50 in mice is >566 mg/kg.14	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	1.8804 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							32-35		3.09 mg/mL at 25 °C	1	No	2	0	Yes	4	0	43.37 Å2	53.64 Å3	125.94 m3·mol-1	10	No	No	0.000157 mg/mL	7.32	-6.4	18.25	-4.7	P10275;!P01100;!BE0004881;!P28222;!P08069;!BE0009376	AR;!FOS;!;!HTR1B;!IGF1R;!	1. Androgen receptor;!2. Proto-oncogene c-Fos;!3. 5-hydroxytryptamine 2 receptor (Protein Group);!4. 5-hydroxytryptamine receptor 1B;!5. Insulin-like growth factor 1 receptor;!6. Dopamine receptor (Protein Group)
C25H34F2O5	Not Available	Not Available	452.5313	CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COC1=CC=CC=C1	Liquid	The highest concentration of tafluprost acid was found in the cornea and conjunctiva.	P35354	PTGS2	1. Prostaglandin G/H synthase 2			66899	CHEMBL1963683	8044182	Drugs.com Drug Page		HMDB0015704		D06274		PDRhealth Drug Page	PA165958432	9868491	175427102	RxList Drug Page	1244607		Tafluprost	ZINC000013912394	Zioptan	Tafluprost	Approved	DB08819	InChI=1S/C25H34F2O5/c1-18(2)32-24(30)13-9-4-3-8-12-20-21(23(29)16-22(20)28)14-15-25(26,27)17-31-19-10-6-5-7-11-19/h3,5-8,10-11,14-15,18,20-23,28-29H,4,9,12-13,16-17H2,1-2H3/b8-3-,15-14+/t20-,21-,22+,23-/m1/s1	WSNODXPBBALQOF-VEJSHDCNSA-N	4	Tafluprost is an ophthalmic prostaglandin analog used to lower intraocular pressure in patients with ocular hypertension or open-angle glaucoma.	Most common ocular adverse reaction is conjunctival hyperemia (range 4% – 20%).	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	3.7129 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				100°C	4.05		87.5 °C	5.5-6.7	Insoluble	1	Yes	4	2	No	2	0	75.99 Å2	47.77 Å3	120.59 m3·mol-1	13	Yes	No	0.00528 mg/mL	4.29	-4.9	14.51	-2.9	P43088	PTGFR	1. Prostaglandin F2-alpha receptor
C23H38O5	Not Available	Not Available	394.552	CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(=O)OC	Liquid	Not Available						135626	CHEMBL1908315	4445416					D02073				5282237	310264927		12449		Gemeprost	ZINC000004216393		Gemeprost	Approved, Withdrawn	DB08964	InChI=1S/C23H38O5/c1-5-6-15-23(2,3)21(26)14-13-18-17(19(24)16-20(18)25)11-9-7-8-10-12-22(27)28-4/h10,12-14,17-18,20-21,25-26H,5-9,11,15-16H2,1-4H3/b12-10+,14-13+/t17-,18-,20-,21-/m1/s1	KYBOHGVERHWSSV-VNIVIJDLSA-N	3	Gemeprost is a prostaglandin E1 analogue used for cervical dilation and, in combination with mifepristone, for pregnancy termination.	Serious or life-threatening adverse effects include coronary spasms with subsequent myocardial infarctions and uterine rupture following prolonged uterine hypertonia or abnormal uterine pain. More common adverse effects are nausea, vomiting, loose stools, diarrhea, lower abdominal or back pain, headache, mild pyrexia and flushing. Less common side effects include hypotension, chest pain palpitations, tachycardia, muscle weakness, dyspnea, chills and headache. Oral LD50 is 300 mg/kg in mouse, 980 mg/kg in rat and 3200 mg/kg in rabbit MSDS.	Small Molecule																																			1	Yes	4	2	No	1	0	83.83 Å2	46.3 Å3	113.05 m3·mol-1	13	Yes	No	0.0176 mg/mL	4.71	-4.4	14.68	-1.1	P43115;!P43116	PTGER3;!PTGER2	1. Prostaglandin E2 receptor EP3 subtype;!2. Prostaglandin E2 receptor EP2 subtype
C22H29FO4	Not Available	Not Available	376.4617	[H][C@@]12C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C	Solid	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5			135581	CHEMBL251634	8701									9053	310264934		4463		Fluocortolone	ZINC000004213353		Fluocortolone	Approved, Withdrawn	DB08971	InChI=1S/C22H29FO4/c1-11-6-14-13-8-16(23)15-7-12(25)4-5-21(15,2)20(13)17(26)9-22(14,3)19(11)18(27)10-24/h4-5,7,11,13-14,16-17,19-20,24,26H,6,8-10H2,1-3H3/t11-,13+,14+,16+,17+,19-,20-,21+,22+/m1/s1	GAKMQHDJQHZUTJ-ULHLPKEOSA-N		Fluocortolone is a glucocorticoid used topically for localized skin reactions and also orally for systemic use.	Not Available	Small Molecule																																180-182			1	Yes	4	2	No	4	0	74.6 Å2	40.14 Å3	101.47 m3·mol-1	2	Yes	No	0.0339 mg/mL	1.97	-4	13.84	-0.23			
C22H30O4	Not Available	Not Available	358.478	[H][C@@]12CC[C@@](O)(CCC(O)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=CC2=CC(=O)CC[C@]12C	Solid	Not Available						50156	CHEMBL1616951	570976	Drugs.com Drug Page								656615	310264973		618970		Potassium_canrenoate	ZINC000003938750		Canrenoic acid	Approved, Withdrawn	DB09015	InChI=1S/C22H30O4/c1-20-9-5-15(23)13-14(20)3-4-16-17(20)6-10-21(2)18(16)7-11-22(21,26)12-8-19(24)25/h3-4,13,16-18,26H,5-12H2,1-2H3,(H,24,25)/t16-,17+,18+,20+,21+,22-/m1/s1	PBKZPPIHUVSDNM-WNHSNXHDSA-N	3	Canrenoic acid is an aldosterone antagonist used in primary hyperaldosteronism and other disorders related to aberrant aldosterone levels.	Not Available	Small Molecule																																165			1	Yes	4	2	No	4	-1	74.6 Å2	40.44 Å3	100.98 m3·mol-1	3	Yes	No	0.0442 mg/mL	2.93	-3.9	4.48	-3.1			
C23H32O2	Not Available	The half-life of medrogestone is reported to be of 4 hours.5	340.507	[H][C@@]12CC[C@](C)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			135446	CHEMBL2106825	8125459									9949848	310265040		6690		Medrogestone	ZINC000004216820		Medrogestone	Approved, Withdrawn	DB09124	InChI=1S/C23H32O2/c1-14-12-17-18(21(3)9-6-16(25)13-20(14)21)7-11-23(5)19(17)8-10-22(23,4)15(2)24/h12-13,17-19H,6-11H2,1-5H3/t17-,18+,19+,21-,22-,23+/m1/s1	HCFSGRMEEXUOSS-JXEXPEPMSA-N		Medrogestone is a progestin used as an adjunct to control secondary amenorrhea and dysfunctional bleeding in adolescent and adult females, and treat endometrial shedding in menopausal women.	There were reports of increased urinary flow rates and total micturition volumes as well as sexual dysfunction and hyperglycemia.4	Small Molecule																													467.17ºC at 760 mmHg	4.45		144-146ºC		5.34e-06 mol/L	1	Yes	2	0	No	4	0	34.14 Å2	40.37 Å3	102.6 m3·mol-1	1	Yes	Yes	0.00404 mg/mL	4.59	-4.9	19.18	-4.9	P06401	PGR	1. Progesterone receptor
C22H36O5	Mean total clearance is 1.77 liters per hour 2.	The mean half life of elimination is 1.64 hours 2.	380.525	CCCC[C@H](C)C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(O)=O	Solid	Not Available						135594	CHEMBL2107456	4942859					D02722				6438378	310265118					ZINC000004216741		Limaprost	Investigational	DB09211	InChI=1S/C22H36O5/c1-3-4-9-16(2)14-17(23)12-13-19-18(20(24)15-21(19)25)10-7-5-6-8-11-22(26)27/h8,11-13,16-19,21,23,25H,3-7,9-10,14-15H2,1-2H3,(H,26,27)/b11-8+,13-12+/t16-,17+,18+,19+,21+/m0/s1	OJZYRQPMEIEQFC-UAWLTFRCSA-N	4	Limaprost is an oral prostaglandin E1 analogue used to improve symptoms associated with thromboangiitis obliterans, acquired lumbar spinal canal stenosis, and other ischemic conditions.	The most common adverse effects seen with limaprost are diarrhea, nausea/vomiting, flushing, abdominal discomfort, and headache Label.	Small Molecule																																			1	Yes	5	3	No	1	-1	94.83 Å2	45.22 Å3	108.56 m3·mol-1	13	Yes	No	0.0248 mg/mL	4.32	-4.2	4.44	-1.5	P43116;!P34995;!P43115;!P35408	PTGER2;!PTGER1;!PTGER3;!PTGER4	1. Prostaglandin E2 receptor EP2 subtype;!2. Prostaglandin E2 receptor EP1 subtype;!3. Prostaglandin E2 receptor EP3 subtype;!4. Prostaglandin E2 receptor EP4 subtype
C19H28O8	The clearance of artesunate is 180L/h while the clearance of DHA is 32.3L/h.8	The elimination half life of artesunate is 0.3h with a range of 0.1-1.8h.8 The elimination half life of DHA is 1.3h with a range of 0.9-2.9h.8 Half life after intramuscular administration is 48 min in children and 41 min in adults.7	384.425	[H][C@@]12CC[C@@H](C)[C@]3([H])CC[C@@]4(C)OO[C@@]13[C@]([H])(O[C@@H](OC(=O)CCC(O)=O)[C@@H]2C)O4	Solid	The volume of distribution of artesunate is 68.5L while the volume of distribution of DHA is 59.7L.8	P16662;!O60656;!P11509	UGT2B7;!UGT1A9;!CYP2A6	1. UDP-glucuronosyltransferase 2B7;!2. UDP-glucuronosyltransferase 1-9;!3. Cytochrome P450 2A6			63918	CHEMBL361497	5293084			HMDB0240267		D02482	D95			6917864	310265169		18346		Artesunate	ZINC000014096305		Artesunate	Approved, Investigational	DB09274	InChI=1S/C19H28O8/c1-10-4-5-13-11(2)16(23-15(22)7-6-14(20)21)24-17-19(13)12(10)8-9-18(3,25-17)26-27-19/h10-13,16-17H,4-9H2,1-3H3,(H,20,21)/t10-,11-,12+,13+,16-,17-,18-,19-/m1/s1	FIHJKUPKCHIPAT-AHIGJZGOSA-N	4	Artesunate is artesunate is an artemesinin derivative indicated for the initial treatment of severe malaria.	Data regarding overdoses of artesunate are rare.8 Patients experiencing an overdose may present with pancytopenia, melena, seizures, multiorgan failure, and death.8 Treat overdose with symptomatic and supportive measures.8	Small Molecule																																131-135			1	Yes	7	1	No	4	-1	100.52 Å2	39.46 Å3	89.95 m3·mol-1	5	Yes	No	0.678 mg/mL	3.1	-2.8	3.77	-4.2	P04926	EXP-1	1. Malaria protein EXP-1
C40H67NO14	Not Available	Not Available	785.969	CO[C@H]1[C@H](O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@@H]1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			34812	CHEMBL2106399	4445491	Drugs.com Drug Page			C14056					5282322	310265197				Kitasamycin	ZINC000085537070		Kitasamycin	Experimental	DB09309	InChI=1S/C40H67NO14/c1-22(2)18-30(45)53-38-26(6)51-32(21-40(38,7)48)54-35-25(5)52-39(34(47)33(35)41(8)9)55-36-27(16-17-42)19-23(3)28(43)15-13-11-12-14-24(4)50-31(46)20-29(44)37(36)49-10/h11-13,15,17,22-29,32-39,43-44,47-48H,14,16,18-21H2,1-10H3/b12-11+,15-13+/t23-,24-,25-,26+,27+,28+,29-,32+,33-,34-,35-,36+,37+,38+,39+,40-/m1/s1	IEMDOFXTVAPVLX-YWQHLDGFSA-N			Not Available	Small Molecule																																			0	No	13	4	Yes	3	1	199.98 Å2	83.98 Å3	201.88 m3·mol-1	12	No	No	0.131 mg/mL	2.78	-3.8	12.68	7.9			
C21H27FO5	Not Available	Not Available	378.44	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			34474	CHEMBL1200774	5665				C14618	D04227							4497		Fluprednisolone	ZINC000003875362		Fluprednisolone	Approved	DB09378	InChI=1S/C21H27FO5/c1-19-5-3-11(24)7-14(19)15(22)8-12-13-4-6-21(27,17(26)10-23)20(13,2)9-16(25)18(12)19/h3,5,7,12-13,15-16,18,23,25,27H,4,6,8-10H2,1-2H3/t12-,13-,15-,16-,18+,19-,20-,21-/m0/s1	MYYIMZRZXIQBGI-HVIRSNARSA-N			Not Available	Small Molecule																																			1	Yes	5	3	No	4	0	94.83 Å2	38.9 Å3	98.32 m3·mol-1	2	Yes	No	0.261 mg/mL	0.93	-3.2	12.58	-2.9			
C22H28O5	Not Available	Not Available	372.461	[H][C@]1(C)C[C@@]2([H])[C@]3([H])CCC4=CC(=O)C=C[C@]4(C)[C@@]3([H])C(=O)C[C@]2(C)[C@@]1(O)C(=O)CO	Not Available	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5			135573	CHEMBL1201148	4447637												29523		Meprednisone	ZINC000004216862		Meprednisone	Approved, Investigational	DB09383	InChI=1S/C22H28O5/c1-12-8-16-15-5-4-13-9-14(24)6-7-20(13,2)19(15)17(25)10-21(16,3)22(12,27)18(26)11-23/h6-7,9,12,15-16,19,23,27H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,19+,20-,21-,22-/m0/s1	PIDANAQULIKBQS-RNUIGHNZSA-N	2		Not Available	Small Molecule																																			1	Yes	5	2	No	4	0	91.67 Å2	40.19 Å3	102.04 m3·mol-1	2	Yes	No	0.0711 mg/mL	2.02	-3.7	12.44	-3.3			
C31H38O7	Not Available	Not Available	522.638	C[C@H]1C[C@@]2(OC(C)=O)[C@H]([C@H]1OC(=O)C1=CC=CC=C1)[C@@H](OC(C)=O)C(=C)CC[C@H]1[C@@H](\C=C(C)\C2=O)C1(C)C	Not Available	Not Available						136008	CHEMBL552128	8753322									10577938	347827957		1426391			ZINC000096903163		Diacetyl benzoyl lathyrol	Approved	DB11260	InChI=1S/C31H38O7/c1-17-13-14-23-24(30(23,6)7)15-18(2)28(34)31(38-21(5)33)16-19(3)27(25(31)26(17)36-20(4)32)37-29(35)22-11-9-8-10-12-22/h8-12,15,19,23-27H,1,13-14,16H2,2-7H3/b18-15+/t19-,23-,24+,25-,26-,27-,31+/m0/s1	JPYYWXPAHJBKJX-VWSFRBHVSA-N			Not Available	Small Molecule																																			0	No	4	0	Yes	4	0	95.97 Å2	55.46 Å3	141.47 m3·mol-1	7	No	No	0.000363 mg/mL	5.71	-6.2		-5.5			
C42H67NO16	Not Available	Not Available	841.9785	[H][C@@]1(C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O1)O[C@@H]1[C@@H](C)O[C@@]([H])(O[C@H]2[C@@H](CC=O)C[C@@H](C)C(=O)\C=C\[C@@H]3O[C@H]3C[C@@H](C)OC(=O)C[C@@H](OC(C)=O)[C@@H]2OC)[C@H](O)[C@H]1N(C)C	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4				CHEMBL1231649	4450165						CAI								Carbomycin			Carbomycin	Vet approved	DB11383	InChI=1S/C42H67NO16/c1-21(2)16-32(47)57-40-25(6)53-34(20-42(40,8)50)58-37-24(5)54-41(36(49)35(37)43(9)10)59-38-27(14-15-44)17-22(3)28(46)12-13-29-30(56-29)18-23(4)52-33(48)19-31(39(38)51-11)55-26(7)45/h12-13,15,21-25,27,29-31,34-41,49-50H,14,16-20H2,1-11H3/b13-12+/t22-,23-,24-,25+,27+,29+,30+,31-,34+,35-,36-,37-,38+,39+,40+,41+,42-/m1/s1	FQVHOULQCKDUCY-OGHXVOSASA-N			Not Available	Small Molecule																																			0	No	14	2	Yes	4	1	215.42 Å2	87.69 Å3	208.45 m3·mol-1	14	No	No	0.115 mg/mL	2.95	-3.9	12.71	8.43			
C50H74O14	Not Available	Not Available	899.128	[H][C@@]12OC\C3=C/C=C/[C@H](C)[C@H](O[C@@]4([H])C[C@H](OC)[C@@H](O[C@@]5([H])C[C@H](OC)[C@@H](O)[C@H](C)O5)[C@H](C)O4)\C(C)=C\C[C@@H]4C[C@@H](C[C@]5(O4)O[C@H](C4CCCCC4)[C@@H](C)C=C5)OC(=O)[C@]([H])(C=C(C)[C@H]1O)[C@@]23O	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4				CHEMBL2361641	8008478												73455		Doramectin	ZINC000245253793		Doramectin	Vet approved	DB11400	InChI=1S/C50H74O14/c1-27-13-12-16-34-26-57-47-42(51)30(4)21-37(50(34,47)54)48(53)60-36-22-35(63-49(25-36)20-19-29(3)45(64-49)33-14-10-9-11-15-33)18-17-28(2)44(27)61-41-24-39(56-8)46(32(6)59-41)62-40-23-38(55-7)43(52)31(5)58-40/h12-13,16-17,19-21,27,29,31-33,35-47,51-52,54H,9-11,14-15,18,22-26H2,1-8H3/b13-12+,28-17+,34-16+/t27-,29-,31-,32-,35+,36-,37-,38-,39-,40-,41-,42+,43-,44-,45-,46-,47+,49+,50+/m0/s1	QLFZZSKTJWDQOS-YDBLARSUSA-N			Not Available	Small Molecule																																			0	No	13	3	Yes	8	0	170.06 Å2	87.69 Å3	238.58 m3·mol-1	7	No	No	0.00599 mg/mL	6.27	-5.2	12.47	-3.4			
C49H73NO14	Not Available	Not Available	900.116	[H]O[C@@H]1C(C)=C[C@@]2([H])C(=O)O[C@@]3([H])C[C@@]([H])(C\C=C(C)/[C@@H](O[C@H]4C[C@H](OC)[C@H](O[C@H]5C[C@@H](OC)[C@H](N([H])C(C)=O)[C@H](C)O5)[C@H](C)O4)[C@@H](C)\C=C/C=C4/CO[C@@]1([H])[C@]24O[H])O[C@@]1(C3)O[C@H](C(C)C)[C@@H](C)C=C1	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4					4953133					D04037							1006619		Eprinomectin	ZINC000306122586		Eprinomectin	Vet approved	DB11405	InChI=1S/C49H73NO14/c1-25(2)43-28(5)17-18-48(64-43)23-35-20-34(63-48)16-15-27(4)44(26(3)13-12-14-33-24-57-46-42(52)29(6)19-36(47(53)60-35)49(33,46)54)61-40-22-38(56-11)45(31(8)59-40)62-39-21-37(55-10)41(30(7)58-39)50-32(9)51/h12-15,17-19,25-26,28,30-31,34-46,52,54H,16,20-24H2,1-11H3,(H,50,51)/b13-12-,27-15-,33-14-/t26-,28-,30-,31-,34+,35-,36-,37+,38-,39-,40-,41+,42+,43+,44-,45+,46+,48+,49+/m0/s1	WPNHOHPRXXCPRA-TVXIRPTOSA-N			Not Available	Small Molecule																																			0	No	13	3	Yes	7	0	178.93 Å2	98.77 Å3	237.68 m3·mol-1	8	No	No	0.00747 mg/mL	5.12	-5.1	12.49	-1.3			
C40H76N2O12	Not Available	Not Available	777.05	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)N(CCC)C[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C	Not Available	Not Available							CHEMBL2107342	28530824												1113697			ZINC000169292837		Gamithromycin	Vet approved	DB11416	InChI=1S/C40H76N2O12/c1-15-17-42-21-22(3)33(44)40(11,48)29(16-2)52-36(46)26(7)32(53-30-20-39(10,49-14)34(45)27(8)51-30)25(6)35(38(9,47)19-23(42)4)54-37-31(43)28(41(12)13)18-24(5)50-37/h22-35,37,43-45,47-48H,15-21H2,1-14H3/t22-,23+,24+,25-,26+,27-,28-,29+,30-,31+,32-,33+,34-,35+,37-,38+,39+,40+/m0/s1	VWAMTBXLZPEDQO-UZSBJOJWSA-N			Not Available	Small Molecule																																			0	No	13	5	Yes	3	2	180.08 Å2	86.24 Å3	203.55 m3·mol-1	9	No	No	0.294 mg/mL	2.98	-3.4	12.46	9.95			
C20H30O2	Not Available	Not Available	302.458	[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3C[C@@H](C)[C@@]21[H]	Not Available	Not Available					26258	34849	CHEMBL425863	220460				C14255	D05025									Mibolerone	ZINC000004216936		Mibolerone	Vet approved	DB11429	InChI=1S/C20H30O2/c1-12-10-13-11-14(21)4-5-15(13)16-6-8-19(2)17(18(12)16)7-9-20(19,3)22/h11-12,15-18,22H,4-10H2,1-3H3/t12-,15+,16-,17+,18-,19+,20+/m1/s1	PTQMMNYJKCSPET-OMHQDGTGSA-N			Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	35.86 Å3	89.14 m3·mol-1	0	Yes	Yes	0.0194 mg/mL	3.63	-4.2	18.34	-0.53	P10275	AR	1. Androgen receptor
C36H62O11	Not Available	Not Available	670.881	[H][C@@]1(C[C@H](C)[C@@]([H])(O1)[C@]1(CC)CC[C@@]([H])(O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@]([H])(O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)[C@@]1([H])O[C@@](O)(CO)[C@H](C)C[C@@H]1C	Not Available	Not Available						27617	CHEMBL256105	389937				C06693	D08228							1368208		Monensin	ZINC000008143466		Monensin	Experimental, Vet approved	DB11430	InChI=1S/C36H62O11/c1-10-34(31-20(3)16-26(43-31)28-19(2)15-21(4)36(41,18-37)46-28)12-11-27(44-34)33(8)13-14-35(47-33)17-25(38)22(5)30(45-35)23(6)29(42-9)24(7)32(39)40/h19-31,37-38,41H,10-18H2,1-9H3,(H,39,40)/t19-,20-,21+,22+,23-,24-,25-,26+,27+,28-,29+,30-,31+,33-,34-,35+,36-/m0/s1	GAOZTHIDHYLHMS-KEOBGNEYSA-N			Not Available	Small Molecule																																			0	No	11	4	Yes	5	-1	153.37 Å2	73.59 Å3	172.38 m3·mol-1	10	No	No	0.00633 mg/mL	4.82	-5	4.24	-2.9			
C37H53NO8	The apparent clearance of moxidectin is 3.5 L/hour.4	Moxidectin reporter terminal half-life is 20.2 days.3	639.83	[H][C@@]12OC\C3=C/C=C/[C@H](C)C\C(C)=C\C[C@]4([H])C[C@@]([H])(C[C@]5(C\C(=N/OC)[C@H](C)[C@H](O5)C(\C)=C\C(C)C)O4)OC(=O)[C@]([H])(C=C(C)[C@H]1O)[C@@]23O	Solid	Moxidectin presents a larger volume of distribution and mean residence time when compared to ivermectin. The reported volume of distribution is of 1.2 l/kg.3	Q14097	CYP2B	1. CYP2B protein				CHEMBL2104415	22901017					D05084							1047072		Moxidectin	ZINC000169649308		Moxidectin	Approved, Investigational, Vet approved	DB11431	InChI=1S/C37H53NO8/c1-21(2)14-25(6)33-26(7)31(38-42-8)19-36(46-33)18-29-17-28(45-36)13-12-23(4)15-22(3)10-9-11-27-20-43-34-32(39)24(5)16-30(35(40)44-29)37(27,34)41/h9-12,14,16,21-22,26,28-30,32-34,39,41H,13,15,17-20H2,1-8H3/b10-9+,23-12+,25-14+,27-11+,38-31+/t22-,26-,28+,29-,30-,32+,33+,34+,36-,37+/m0/s1	YZBLFMPOMVTDJY-LSGXYNIPSA-N	3		Moxidectin is reported to be safe as it is reported to be a poor substrate of P-glycoprotein.1 The reported LD50in mice are in the range of 70-131 micromol/kg.2 Carcinogenicity studies have not been performed. Moxidectin was shown to present no effects in genotoxicity, mutagenicity and fertility.Label The reports of overdose there are related to the presence of transient and self-limiting neurological signs including the presence of convulsions.11	Small Molecule																													When found in oily form it is expected to boil at 160 ºC	6		145-154 ºC	12.8	Insoluble	0	No	8	2	No	5	0	116.04 Å2	71.02 Å3	179.22 m3·mol-1	3	No	No	0.0052 mg/mL	5.67	-5.1	12.55	2.81	Q25634;!;!	GluClX;!;!	1. Glutamate-gated chloride channel;!2. GABA-A gated chloride channel;!3. ABC transporters
C43H72O11	Not Available	Not Available	765.038	[H][C@@]1(CC[C@](O)(CC)[C@H](C)O1)[C@]1(C)CC[C@]2(O1)O[C@@]1(O[C@]([H])([C@@H](CC)C(=O)[C@@H](C)[C@@H](O)[C@H](C)[C@]3([H])O[C@@]([H])([C@@H](CC)C(O)=O)[C@@H](C)C[C@@H]3C)[C@@H](C)C[C@H]1C)C=C[C@H]2O	Not Available	Not Available							CHEMBL2104423	58911					D05122							1314370		Narasin	ZINC000085540282		Narasin	Experimental, Vet approved	DB11432	InChI=1S/C43H72O11/c1-12-30(35(46)27(8)34(45)28(9)36-23(4)21-24(5)37(51-36)31(13-2)39(47)48)38-25(6)22-26(7)42(52-38)18-15-32(44)43(54-42)20-19-40(11,53-43)33-16-17-41(49,14-3)29(10)50-33/h15,18,23-34,36-38,44-45,49H,12-14,16-17,19-22H2,1-11H3,(H,47,48)/t23-,24-,25-,26+,27-,28-,29-,30-,31+,32+,33+,34+,36+,37+,38-,40-,41+,42-,43-/m0/s1	VHKXXVVRRDYCIK-CWCPJSEDSA-N			Not Available	Small Molecule																																			0	No	11	4	Yes	5	-1	161.21 Å2	85.69 Å3	204.54 m3·mol-1	12	No	No	0.00241 mg/mL	7.88	-5.5	4.5	-3			
C23H32O4	Not Available	Not Available	372.505	[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)C[C@H](C)[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	Not Available	Not Available							CHEMBL2104744	7996587					D05210									Norgestomet	ZINC000004217176		Norgestomet	Vet approved	DB11440	InChI=1S/C23H32O4/c1-13-12-22(4)20(9-10-23(22,14(2)24)27-15(3)25)19-7-5-16-11-17(26)6-8-18(16)21(13)19/h11,13,18-21H,5-10,12H2,1-4H3/t13-,18-,19-,20-,21+,22-,23-/m0/s1	IWSXBCZCPVUWHT-VIFKTUCRSA-N			Not Available	Small Molecule																																			1	Yes	3	0	No	4	0	60.44 Å2	42.06 Å3	103.33 m3·mol-1	3	Yes	No	0.00489 mg/mL	3.83	-4.9	17.68	-4.7			
C35H61NO12	Not Available	Not Available	687.868	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1O	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4		234401	16869	CHEMBL606258	10190754				C01946								7629		Oleandomycin	ZINC000085432018		Oleandomycin	Vet approved	DB11442	InChI=1S/C35H61NO12/c1-16-14-35(15-43-35)32(40)19(4)27(37)18(3)22(7)46-33(41)21(6)31(47-26-13-25(42-11)28(38)23(8)45-26)20(5)30(16)48-34-29(39)24(36(9)10)12-17(2)44-34/h16-31,34,37-39H,12-15H2,1-11H3/t16-,17+,18-,19+,20+,21+,22+,23-,24-,25-,26-,27-,28-,29+,30-,31-,34-,35+/m0/s1	RZPAKFUAFGMUPI-QESOVKLGSA-N			Not Available	Small Molecule																																			0	No	12	3	Yes	4	1	162.68 Å2	73.87 Å3	173.69 m3·mol-1	6	No	No	0.407 mg/mL	2.98	-3.2	12.67	9			
C22H36O5	Not Available	Not Available	380.525	CCCCC[C@@](C)(O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=C=CCCC(=O)OC	Not Available	Not Available								4940711					D05642										ZINC000005513458		Prostalene	Vet approved	DB11454	InChI=1S/C22H36O5/c1-4-5-10-14-22(2,26)15-13-18-17(19(23)16-20(18)24)11-8-6-7-9-12-21(25)27-3/h7-8,13,15,17-20,23-24,26H,4-5,9-12,14,16H2,1-3H3/b15-13+/t6?,17-,18-,19+,20-,22-/m1/s1	GNIYHUSSKSFYBD-MFZPGRHISA-N			Not Available	Small Molecule																																			1	Yes	4	3	No	1	0	86.99 Å2	44.39 Å3	109.56 m3·mol-1	12	Yes	No	0.0288 mg/mL	2.83	-4.1	14.51	-1.3			
C43H63NO11	Not Available	Not Available	769.973	[H][C@@]12OC\C3=C/C=C/[C@H](C)[C@H](O[C@@]4([H])C[C@H](OC)[C@@H](O)[C@H](C)O4)\C(C)=C\C[C@]4([H])C[C@@]([H])(C[C@]5(CC[C@H](C)[C@]([H])(O5)C5CCCCC5)O4)OC(=O)[C@]([H])(C=C(C)\C1=N\O)[C@@]23O	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4				CHEMBL1908325	16738655												1044269		Selamectin	ZINC000169677006		Selamectin	Vet approved	DB11459	InChI=1S/C43H63NO11/c1-24-11-10-14-30-23-50-40-36(44-48)27(4)19-33(43(30,40)47)41(46)52-32-20-31(16-15-25(2)38(24)53-35-21-34(49-6)37(45)28(5)51-35)54-42(22-32)18-17-26(3)39(55-42)29-12-8-7-9-13-29/h10-11,14-15,19,24,26,28-29,31-35,37-40,45,47-48H,7-9,12-13,16-18,20-23H2,1-6H3/b11-10+,25-15+,30-14+,44-36-/t24-,26-,28-,31+,32-,33-,34-,35-,37-,38-,39-,40+,42+,43+/m0/s1	AFJYYKSVHJGXSN-XHKIUTQPSA-N			Not Available	Small Molecule																																			0	No	11	3	No	7	0	154.73 Å2	39.7 Å3	206.75 m3·mol-1	4	No	No	0.00425 mg/mL	6.21	-5.3	9.58	-3.6			
C41H71N3O8	Not Available	Not Available	734.032	[H][C@@]1(O[C@H]2[C@@H](CCN3CCCCC3)C[C@@H](C)C(=O)\C=C\C(\C)=C\[C@H](CN3CCCCC3)[C@@H](CC)OC(=O)C[C@@H](O)[C@@H]2C)O[C@H](C)[C@@H](O)[C@@H]([C@H]1O)N(C)C	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4				CHEMBL3039509	30790722												1306059			ZINC000096941865		Tildipirosin	Vet approved	DB11470	InChI=1S/C41H71N3O8/c1-8-35-32(26-44-20-13-10-14-21-44)23-27(2)15-16-33(45)28(3)24-31(17-22-43-18-11-9-12-19-43)40(29(4)34(46)25-36(47)51-35)52-41-39(49)37(42(6)7)38(48)30(5)50-41/h15-16,23,28-32,34-35,37-41,46,48-49H,8-14,17-22,24-26H2,1-7H3/b16-15+,27-23+/t28-,29+,30-,31+,32-,34-,35-,37+,38-,39-,40-,41+/m1/s1	HNDXPZPJZGTJLJ-UEJFNEDBSA-N			Not Available	Small Molecule																																			1	No	10	3	Yes	4	3	132.24 Å2	83.58 Å3	206.76 m3·mol-1	9	No	No	0.0548 mg/mL	4.46	-4.1	12.68	10.05			
C46H80N2O13	Not Available	Not Available	869.147	CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H]([C@H]2O)N(C)C)[C@@H](CCN2C[C@@H](C)C[C@@H](C)C2)C[C@@H](C)C(=O)\C=C\C(\C)=C\[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC	Not Available	Not Available							CHEMBL1908333	4445656					D02492							38278		Tilmicosin	ZINC000245204941		Tilmicosin	Investigational, Vet approved	DB11471	InChI=1S/C46H80N2O13/c1-13-36-33(24-57-46-44(56-12)43(55-11)40(53)31(8)59-46)19-25(2)14-15-34(49)28(5)20-32(16-17-48-22-26(3)18-27(4)23-48)42(29(6)35(50)21-37(51)60-36)61-45-41(54)38(47(9)10)39(52)30(7)58-45/h14-15,19,26-33,35-36,38-46,50,52-54H,13,16-18,20-24H2,1-12H3/b15-14+,25-19+/t26-,27+,28-,29+,30-,31-,32+,33-,35-,36-,38+,39-,40-,41-,42-,43-,44-,45+,46-/m1/s1	JTSDBFGMPLKDCD-XVFHVFLVSA-N			Not Available	Small Molecule																																			0	No	14	4	Yes	4	2	186.15 Å2	95.79 Å3	232.21 m3·mol-1	12	No	No	0.0484 mg/mL	4.19	-4.2	12.55	10.16			
C41H79N3O12	Not Available	Not Available	806.092	[H][C@@]1(C[C@@](C)(OC)[C@](O)(CNCCC)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C	Not Available	Not Available								8008030												1309314		Tulathromycin	ZINC000094313254		Tulathromycin A	Vet approved	DB11474	InChI=1S/C41H79N3O12/c1-15-17-42-22-41(50)28(8)53-31(20-39(41,10)51-14)55-33-25(5)35(56-37-32(45)29(44(12)13)18-24(4)52-37)38(9,48)19-23(3)21-43-27(7)34(46)40(11,49)30(16-2)54-36(47)26(33)6/h23-35,37,42-43,45-46,48-50H,15-22H2,1-14H3/t23-,24-,25+,26-,27-,28+,29+,30-,31+,32-,33+,34-,35-,37+,38-,39-,40-,41+/m1/s1	GUARTUJKFNAVIK-QPTWMBCESA-N			Not Available	Small Molecule																																			0	No	14	7	Yes	3	3	200.9 Å2	90.92 Å3	210.7 m3·mol-1	11	No	No	0.184 mg/mL	2.5	-3.6	12.2	10.21			
C46H77NO17	Not Available	Not Available	916.1001	CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C)[C@@H](CC=O)C[C@@H](C)C(=O)\C=C\C(\C)=C\[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC	Not Available	Not Available						17658	CHEMBL42743	4444097				C01457	D02490	TYK						995505		Tylosin	ZINC000252441679		Tylosin	Vet approved	DB11475	InChI=1S/C46H77NO17/c1-13-33-30(22-58-45-42(57-12)41(56-11)37(52)26(5)60-45)18-23(2)14-15-31(49)24(3)19-29(16-17-48)39(25(4)32(50)20-34(51)62-33)64-44-38(53)36(47(9)10)40(27(6)61-44)63-35-21-46(8,55)43(54)28(7)59-35/h14-15,17-18,24-30,32-33,35-45,50,52-55H,13,16,19-22H2,1-12H3/b15-14+,23-18+/t24-,25+,26-,27-,28+,29+,30-,32-,33-,35+,36-,37-,38-,39-,40-,41-,42-,43+,44+,45-,46-/m1/s1	WBPYTXDJUQJLPQ-VMXQISHHSA-N			Not Available	Small Molecule																																			0	No	17	5	Yes	4	1	238.67 Å2	98.12 Å3	232.21 m3·mol-1	13	No	No	0.211 mg/mL	2.32	-3.6	12.45	7.2			
C42H70O11	Not Available	Not Available	751.011	[H][C@@](C)(C(=O)[C@]([H])(CC)[C@@]1([H])O[C@@]2(O[C@@]3(CC[C@](C)(O3)[C@@]3([H])CC[C@](O)(CC)[C@]([H])(C)O3)[C@]([H])(O)C=C2)[C@]([H])(C)C[C@]1([H])C)[C@@]([H])(O)[C@]([H])(C)[C@]1([H])O[C@]([H])(CC[C@]1([H])C)[C@@]([H])(CC)C(O)=O	Not Available	Not Available						80025	CHEMBL1208572	2342058				C15690	D08502							1311566		Salinomycin	ZINC000085540254		Salinomycin	Vet approved	DB11544	InChI=1S/C42H70O11/c1-11-29(38(46)47)31-15-14-23(4)36(50-31)27(8)34(44)26(7)35(45)30(12-2)37-24(5)22-25(6)41(51-37)19-16-32(43)42(53-41)21-20-39(10,52-42)33-17-18-40(48,13-3)28(9)49-33/h16,19,23-34,36-37,43-44,48H,11-15,17-18,20-22H2,1-10H3,(H,46,47)/t23-,24-,25+,26-,27-,28-,29+,30-,31+,32+,33+,34+,36+,37-,39-,40+,41-,42-/m0/s1	KQXDHUJYNAXLNZ-XQSDOZFQSA-N			Not Available	Small Molecule																																			0	No	11	4	Yes	5	-1	161.21 Å2	81.82 Å3	200.07 m3·mol-1	12	No	No	0.00297 mg/mL	7.51	-5.4	4.45	-3			
C53H87NO19	Not Available	Not Available	1042.267	CC[C@H]1OC(=O)C[C@@H](OC(C)=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C)[C@@H](CC=O)C[C@@H](C)C(=O)\C=C\C(\C)=C\[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC	Not Available	Not Available							CHEMBL2103834	4945313												1368469					Tylvalosin	Vet approved	DB11554	InChI=1S/C53H87NO19/c1-16-38-36(26-65-52-49(64-15)48(63-14)44(60)31(7)67-52)22-28(4)17-18-37(57)29(5)23-35(19-20-55)46(30(6)39(69-34(10)56)24-41(59)70-38)73-51-45(61)43(54(12)13)47(32(8)68-51)72-42-25-53(11,62)50(33(9)66-42)71-40(58)21-27(2)3/h17-18,20,22,27,29-33,35-36,38-39,42-52,60-62H,16,19,21,23-26H2,1-15H3/b18-17+,28-22+/t29-,30+,31-,32-,33+,35+,36-,38-,39-,42+,43-,44-,45-,46-,47-,48-,49-,50+,51+,52-,53-/m1/s1	KCJJINQANFZSAM-HZDSEHBESA-N			Not Available	Small Molecule																																			0	No	17	3	Yes	4	1	250.81 Å2	111.37 Å3	264.29 m3·mol-1	19	No	No	0.0361 mg/mL	4.63	-4.5	12.57	8.43			
C21H28O3	Not Available	Not Available	328.452	CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			135993	CHEMBL2105722	62024					D07222							31930		Nomegestrol	ZINC000004217164		Nomegestrol	Approved	DB11636	InChI=1S/C21H28O3/c1-12-10-18-16(15-5-4-14(23)11-17(12)15)6-8-20(3)19(18)7-9-21(20,24)13(2)22/h10-11,15-16,18-19,24H,4-9H2,1-3H3/t15-,16-,18-,19+,20+,21+/m1/s1	KZUIYQJTUIACIG-YBZCJVABSA-N			Not Available	Small Molecule																																			1	Yes	3	1	No	4	0	54.37 Å2	37.69 Å3	95.03 m3·mol-1	1	Yes	No	0.0122 mg/mL	2.98	-4.4	12.7	-3.8			
C44H57NO17	Not Available	Not Available	871.93	CC(C)C[C@H](NC(=O)OC(C)(C)C)[C@@H](O)C(=O)O[C@H]1[C@@H]2OC(=O)O[C@@]22[C@@H](OC(=O)C3=CC=CC=C3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O	Not Available	Not Available							CHEMBL382300	5293609									6918412	347828037				Ortataxel	ZINC000169362007		Ortataxel	Investigational	DB11669	InChI=1S/C44H57NO17/c1-20(2)17-25(45-38(53)61-40(6,7)8)29(49)37(52)57-30-21(3)28-31(56-22(4)46)33(50)42(11)26(48)18-27-43(19-55-27,60-23(5)47)32(42)35(58-36(51)24-15-13-12-14-16-24)44(41(28,9)10)34(30)59-39(54)62-44/h12-16,20,25-27,29-32,34-35,48-49H,17-19H2,1-11H3,(H,45,53)/t25-,26-,27+,29+,30+,31+,32-,34-,35-,42+,43-,44+/m0/s1	BWKDAMBGCPRVPI-ZQRPHVBESA-N	2		Not Available	Small Molecule																																			0	No	11	3	Yes	6	0	245.82 Å2	87.2 Å3	210.47 m3·mol-1	16	No	No	0.0218 mg/mL	4.13	-4.6	11.03	-3			
C47H68O17	Not Available	Not Available	905.044	[H][C@]12C[C@H](OC(C)=O)C(C)(C)[C@](O)(C[C@]3([H])C\C(C[C@@]([H])(O3)\C=C\C(C)(C)[C@]3(O)O[C@@]([H])(C\C(=C/C(=O)OC)[C@@H]3OC(=O)\C=C\C=C\CCC)C[C@@]([H])(OC(=O)C[C@H](O)C1)[C@@H](C)O)=C\C(=O)OC)O2	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			88353	CHEMBL449158	10196541									22524140	347828109				Bryostatin	ZINC000169357315		Bryostatin 1	Investigational	DB11752	InChI=1S/C47H68O17/c1-10-11-12-13-14-15-39(51)62-43-31(22-41(53)58-9)21-34-25-37(28(2)48)61-42(54)24-32(50)23-35-26-38(59-29(3)49)45(6,7)46(55,63-35)27-36-19-30(20-40(52)57-8)18-33(60-36)16-17-44(4,5)47(43,56)64-34/h12-17,20,22,28,32-38,43,48,50,55-56H,10-11,18-19,21,23-27H2,1-9H3/b13-12+,15-14+,17-16+,30-20+,31-22+/t28-,32-,33+,34+,35-,36+,37-,38+,43+,46+,47-/m1/s1	MJQUEDHRCUIRLF-TVIXENOKSA-N	2		Not Available	Small Molecule																																			0	No	12	4	Yes	4	0	240.11 Å2	95.4 Å3	233.05 m3·mol-1	13	No	No	0.00595 mg/mL	5.04	-5.2	10.59	-2.8	P17252;!Q02156;!Q14790;!Q15139;!P42081;!P35354;!P24385;!P01375;!Q9Z1N9	PRKCA;!PRKCE;!CASP8;!PRKD1;!CD86;!PTGS2;!CCND1;!TNF;!Unc13b	1. Protein kinase C alpha type;!2. Protein kinase C epsilon type;!3. Caspase-8;!4. Serine/threonine-protein kinase D1;!5. T-lymphocyte activation antigen CD86;!6. Prostaglandin G/H synthase 2;!7. G1/S-specific cyclin-D1;!8. Tumor necrosis factor;!9. Protein unc-13 homolog B
C25H31NO6	114 ±27 L/h, according to one noncompartmental pharmacokinetic study.1The clearance of corticosteroids is enhanced in hypothyroid patients and increased in patients with hyperthyroidism. Dosing adjustments may be considered according to thyroid status.Label A study of corticosteroid clearance was performed in patients with a creatinine clearance of 15 mL/min or less, and determined that the active metabolite of deflazacort, 21-deflazacort was similar to that in patients with normal renal clearance.Label	The half-life of deflazacort ranges from 1.1 to 1.9 h 1,16	441.524	[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@]([H])(O)C[C@]3(C)[C@@]1(N=C(C)O2)C(=O)COC(C)=O	Solid	One study determined the volume of distribution to be 204 ± 84 L.1	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5			135720	CHEMBL1201891	164861					D03671				189821	347828252		22396		Deflazacort	ZINC000004212809	Emflaza	Deflazacort	Approved, Investigational	DB11921	InChI=1S/C25H31NO6/c1-13-26-25(20(30)12-31-14(2)27)21(32-13)10-18-17-6-5-15-9-16(28)7-8-23(15,3)22(17)19(29)11-24(18,25)4/h7-9,17-19,21-22,29H,5-6,10-12H2,1-4H3/t17-,18-,19-,21+,22+,23-,24-,25+/m0/s1	FBHSPRKOSMHSIF-GRMWVWQJSA-N	4	Deflazacort is a corticosteroid used to treat Duchenne muscular dystrophy.	The LD50 for the oral dose is 5200 mg/kg (mouse); Oral TDLO (woman): 0.12 mg/kgMSDSA note on altered endocrine function and immunosuppressionDeflazacort, as a steroid prodrug used over a long-term period, can cause hormone imbalance leading to diseases such as Cushing's Syndrome and hypothalamic-pituitary-adrenal axis suppression. It can also predispose to infection, as it promotes immunosuppression.10 It is important to monitor for hormonal imbalance and infection and provide necessary treatment if they occur.LabelMutagenicity/carcinogenicityMutagenicity assays were negative in various laboratory and in vivo assays performed on rats.Label,16 Chronic use in mice for 2 years in one study resulted in a higher rate of osteoma and osteosarcomas in mice receiving 0.06, 0.12, 0.25, 0.50, or 1.0 mg/kg of deflazacort daily.LabelUse in pregnancyThere are no sufficient data to support the administration of deflazacort during pregnancy. Corticosteroid drugs such as deflazacort should only be used during pregnancy only if the benefits of therapy outweigh the potential risks.Label,16Use in lactationCorticosteroids, when administered systemically, are excreted in the breastmilk. Exposure may lead to disturbances in bone development and growth and endocrine disturbances in the exposed infant.Label,16	Small Molecule																														2.4		>215 C	5.52	108 μg/mL	1	Yes	5	1	No	5	0	102.26 Å2	46.79 Å3	117.12 m3·mol-1	4	Yes	No	0.0175 mg/mL	1.8	-4.4	14.74	0.48	P04150	NR3C1	1. Glucocorticoid receptor
C26H36F2O6	Not Available	Not Available	482.565	CC(C)OC(=O)CCC[C@H]1CC[C@H]2[C@H](C[C@@H](O)[C@@H]2\C=C\[C@@H](O)COC2=CC(F)=CC=C2F)OC1	Not Available	Not Available								32698273									50902259	347828354							Sepetaprost	Investigational	DB12043	InChI=1S/C26H36F2O6/c1-16(2)34-26(31)5-3-4-17-6-9-21-20(23(30)13-24(21)32-14-17)10-8-19(29)15-33-25-12-18(27)7-11-22(25)28/h7-8,10-12,16-17,19-21,23-24,29-30H,3-6,9,13-15H2,1-2H3/b10-8+/t17-,19+,20+,21+,23+,24-/m0/s1	BKVUSNOUTQMSBE-XCMGCKIWSA-N	2		Not Available	Small Molecule																																			1	No	5	2	Yes	3	0	85.22 Å2	51.45 Å3	124.09 m3·mol-1	11	Yes	No	0.00652 mg/mL	3.7	-4.9	14.01	-2.9			
C22H28O3	Not Available	Not Available	340.4559	[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=CC2=CC(=O)CC[C@]12C	Not Available	Not Available						135445	CHEMBL1463345	13192			HMDB0003033						13789	347828500		1982		Canrenone	ZINC000003881648		Canrenone	Investigational	DB12221	InChI=1S/C22H28O3/c1-20-9-5-15(23)13-14(20)3-4-16-17(20)6-10-21(2)18(16)7-11-22(21)12-8-19(24)25-22/h3-4,13,16-18H,5-12H2,1-2H3/t16-,17+,18+,20+,21+,22-/m1/s1	UJVLDDZCTMKXJK-WNHSNXHDSA-N	4	Canrenone is an antimineralocorticoid and active metabolite of spironolactone used in the treatment of primary hyperaldosteronism and edematous states caused by secondary hyperaldosteronism (e.g. heart failure).	Not Available	Small Molecule																																			1	Yes	2	0	No	5	0	43.37 Å2	38.67 Å3	97.48 m3·mol-1	0	Yes	No	0.0042 mg/mL	3.6	-4.9		-4.8			
C23H28O8	Not Available	Not Available	432.469	COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@@H](C[C@]21C)C1=COC=C1	Not Available	Not Available					50159165	67900	CHEMBL445332	113947									128563	347828589				Salvinorin_A	ZINC000013607514		Salvinorin A	Investigational	DB12327	InChI=1S/C23H28O8/c1-12(24)30-16-9-15(20(26)28-4)22(2)7-5-14-21(27)31-17(13-6-8-29-11-13)10-23(14,3)19(22)18(16)25/h6,8,11,14-17,19H,5,7,9-10H2,1-4H3/t14-,15-,16-,17-,19-,22-,23-/m0/s1	OBSYBRPAKCASQB-AGQYDFLVSA-N	2		Not Available	Small Molecule																																			1	Yes	4	0	No	4	0	109.11 Å2	44.17 Å3	106 m3·mol-1	5	Yes	No	0.08 mg/mL	2.39	-3.7	16.45	-2.9			
C44H55NO16	Not Available	Not Available	853.915	CCC(=O)O[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]2[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C4=CC=CO4)C(C)=C([C@@H](O)C(=O)[C@]12C)C3(C)C	Not Available	Not Available								5293786									6918589	347828594				Milataxel			Milataxel	Investigational	DB12334	InChI=1S/C44H55NO16/c1-10-29(47)58-27-19-28-43(21-56-28,60-23(3)46)34-36(59-37(51)24-15-12-11-13-16-24)44(54)20-26(22(2)30(41(44,7)8)32(48)35(50)42(27,34)9)57-38(52)33(49)31(25-17-14-18-55-25)45-39(53)61-40(4,5)6/h11-18,26-28,31-34,36,48-49,54H,10,19-21H2,1-9H3,(H,45,53)/t26-,27-,28+,31-,32+,33+,34-,36-,42+,43-,44+/m0/s1	XIVMHSNIQAICTR-UQYHODNASA-N	2		Not Available	Small Molecule																																			0	No	10	4	Yes	6	0	243.66 Å2	86.24 Å3	210.07 m3·mol-1	16	No	No	0.0672 mg/mL	3.12	-4.1	11.42	-2.9	Q9H4B7;!P07437	TUBB1;!TUBB	1. Tubulin beta-1 chain;!2. Tubulin beta chain
C30H41NO6S	Not Available	Not Available	543.72	C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](CC=C)[C@H]1O)C1=CC=C2SC(C)=NC2=C1	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4				CHEMBL2304041	9459163									11284169	347828638					ZINC000003964449		Sagopilone	Investigational	DB12391	InChI=1S/C30H41NO6S/c1-7-9-20-27(34)17(2)10-8-13-30(6)25(37-30)15-22(19-11-12-23-21(14-19)31-18(3)38-23)36-26(33)16-24(32)29(4,5)28(20)35/h7,11-12,14,17,20,22,24-25,27,32,34H,1,8-10,13,15-16H2,2-6H3/t17-,20+,22-,24-,25-,27-,30+/m0/s1	BFZKMNSQCNVFGM-UCEYFQQTSA-N	2		Not Available	Small Molecule																																			0	No	6	2	No	4	0	109.25 Å2	59.69 Å3	145.71 m3·mol-1	3	No	No	0.0024 mg/mL	5.1	-5.4	14.08	2.88			
C32H48N4O8	The mean clearance is 18.9 L/hr at the dose of 80mg/m^2.	The half-life across all dose levels ranged from 9.9 to 54.1 h (median, 18.2 h) 5.	616.7455	CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O	Solid	At the maximum tolerated dose of 80mg/m^2, the mean Vd value is 385 L.					50005781	65324	CHEMBL383824	16744073						KOS			5288674	347828683				17-Dimethylaminoethylamino-17-demethoxygeldanamycin	ZINC000100030312		Alvespimycin	Investigational	DB12442	InChI=1S/C32H48N4O8/c1-18-14-22-27(34-12-13-36(5)6)24(37)17-23(29(22)39)35-31(40)19(2)10-9-11-25(42-7)30(44-32(33)41)21(4)16-20(3)28(38)26(15-18)43-8/h9-11,16-18,20,25-26,28,30,34,38H,12-15H2,1-8H3,(H2,33,41)(H,35,40)/b11-9-,19-10+,21-16+/t18-,20+,25+,26+,28-,30+/m1/s1	KUFRQPKVAWMTJO-LMZWQJSESA-N	1		Alvespimycin exhibits a dose-limiting toxicity where most toxic effects were experienced at ≥ 80mg/m^2 in Phase I clinical trials. Common adverse effects include nausea, vomiting, fatigue, hematologic toxicity, liver enzyme disturbances and ocular disturbances including blurred vision and keratitis. They are reported to be generally reversible. The doses lower than 80mg/m^2 are well-tolerated. The dose-limiting	Small Molecule																																		Soluble	1	No	9	4	No	2	1	169.52 Å2	66.39 Å3	172.38 m3·mol-1	8	No	No	0.0211 mg/mL	1.85	-4.5	12.78	8.56	P07900	HSP90AA1	1. Heat shock protein HSP 90-alpha
C40H66N2O9	Not Available	Not Available	718.973	CC[C@H](O)[C@@H](C)[C@H]1O[C@@H]1C[C@@](C)(O)\C=C\C=C(/C)[C@H]1OC(=O)C[C@H](O)CC[C@@](C)(O)[C@@H](OC(=O)N2CCN(CC2)C2CCCCCC2)\C=C\[C@@H]1C	Not Available	Not Available					36359			17330478						9B0			16202132	347828739					ZINC000096179269		E7107	Investigational	DB12508	InChI=1S/C40H66N2O9/c1-7-32(44)29(4)37-33(49-37)26-39(5,47)19-12-13-27(2)36-28(3)16-17-34(40(6,48)20-18-31(43)25-35(45)51-36)50-38(46)42-23-21-41(22-24-42)30-14-10-8-9-11-15-30/h12-13,16-17,19,28-34,36-37,43-44,47-48H,7-11,14-15,18,20-26H2,1-6H3/b17-16+,19-12+,27-13+/t28-,29+,31+,32-,33+,34-,36+,37+,39-,40+/m0/s1	MNOMBFWMICHMKG-MGYWSNOQSA-N			Not Available	Small Molecule																																			0	No	8	4	Yes	4	1	152.53 Å2	83.35 Å3	199.41 m3·mol-1	11	No	No	0.0275 mg/mL	4.41	-4.4	13.8	8.29			
C29H41NO6	Not Available	Not Available	499.648	CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)\C=C\C1=CC=C(OCCN(C)C)C=C1	Not Available	Not Available					148430			5293699									6918502	347828875				Beloranib	ZINC000003982162		Beloranib	Investigational	DB12671	InChI=1S/C29H41NO6/c1-20(2)7-13-24-28(3,36-24)27-26(32-6)23(15-16-29(27)19-34-29)35-25(31)14-10-21-8-11-22(12-9-21)33-18-17-30(4)5/h7-12,14,23-24,26-27H,13,15-19H2,1-6H3/b14-10+/t23-,24-,26-,27-,28+,29+/m1/s1	ZEZFKUBILQRZCK-MJSCXXSSSA-N	2		Not Available	Small Molecule																																			1	No	6	0	Yes	4	1	73.06 Å2	57.66 Å3	140.35 m3·mol-1	12	Yes	No	0.00264 mg/mL	4.5	-5.3		8.77			
C28H45NO5S	The total body clearance of lefamulin has been determined to range from 2.94 to 30.0 L/h after an injected dose.11	The average elimination half-life of lefamulin is about 8 hours in patients diagnosed with community-acquired bacterial pneumonia.11 One pharmacokinetic study of healthy volunteers revealed a mean half-life of 13.2 hours after an intravenous infusion of lefamulin.7	507.73	[H][C@@]12C(=O)CC[C@]11CCC(C)[C@@]2(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]1C)OC(=O)CS[C@@H]1CC[C@@H](N)C[C@H]1O	Solid	The average volume of distribution of lefamulin is 86.1 L in patients with community-acquired bacterial pneumonia, but can range from 34.2 to 153 L.11 During clinical studies, lefamulin has been shown to significantly concentrate in the lung tissue, likely increasing its effectiveness in treating pneumonia.3 After lefamulin is administered, penetration into various tissues is observed, and is about 6 times greater in concentration in the fluid of the pulmonary epithelium, when compared with concentrations in the plasma.8 Animal studies demonstrate that lefamulin crosses the placenta.11	P08684	CYP3A4	1. Cytochrome P450 3A4		50019649		CHEMBL3291398							62B			25185057	347828993		2198944		Lefamulin		Xenleta	Lefamulin	Approved, Investigational	DB12825	InChI=1S/C28H45NO5S/c1-6-26(4)14-22(34-23(32)15-35-21-8-7-18(29)13-20(21)31)27(5)16(2)9-11-28(17(3)25(26)33)12-10-19(30)24(27)28/h6,16-18,20-22,24-25,31,33H,1,7-15,29H2,2-5H3/t16?,17-,18+,20+,21+,22+,24-,25-,26+,27-,28-/m0/s1	KPVIXBKIJXZQJX-CSOZIWFHSA-N	3	Lefamulin is a pleuromutilin antibacterial used to treat community-acquired bacterial pneumonia (CABP).	In the case of overdose with lefamulin, the patient should be monitored closely and provided with supportive treatment, according to symptoms and signs. This drug and its active metabolite are not removable by dialysis.11	Small Molecule																													618.6±55.0	3.72			9.41		1	No	5	3	Yes	4	1	109.85 Å2	57.34 Å3	138.86 m3·mol-1	6	No	No	0.00494 mg/mL	2.9	-5	14.19	10.08	P61182	rplV	1. 50S ribosomal protein L22
C32H48O9	Not Available	Not Available	576.727	CO[C@H]1C[C@H](O[C@H]2CC[C@@]3(C)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H]([C@H](C[C@]43O)OC(C)=O)C3=CC(=O)OC3)C2)O[C@@H](C)[C@@H]1O	Not Available	Not Available						59030	CHEMBL1075789	9716290									11541511	347829006				Oleandrin	ZINC000008214621		Oleandrin	Experimental, Investigational	DB12843	InChI=1S/C32H48O9/c1-17-29(35)24(37-5)14-27(39-17)41-21-8-10-30(3)20(13-21)6-7-23-22(30)9-11-31(4)28(19-12-26(34)38-16-19)25(40-18(2)33)15-32(23,31)36/h12,17,20-25,27-29,35-36H,6-11,13-16H2,1-5H3/t17-,20+,21-,22-,23+,24-,25-,27-,28-,29-,30-,31+,32-/m0/s1	JLPDBLFIVFSOCC-XYXFTTADSA-N			Not Available	Small Molecule																																			1	No	7	2	Yes	6	-1	120.75 Å2	63.2 Å3	148.45 m3·mol-1	6	No	No	0.00299 mg/mL	2.95	-5.3	6.82	-3.2			
C22H28O5	Not Available	Not Available	372.461	C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)CC(=O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4					110996									124653	347829094					ZINC000004744090		Methylprednisone	Approved, Investigational	DB12952	InChI=1S/C22H28O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,19,23,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,19+,20-,21-,22-/m0/s1	SVYCRJXQZUCUND-PQXSVQADSA-N	4		Not Available	Small Molecule																																			1	Yes	5	2	No	4	0	91.67 Å2	40.27 Å3	102.12 m3·mol-1	2	Yes	No	0.0587 mg/mL	1.95	-3.8	12.58	-3.3			
C45H53NO14	Not Available	Not Available	831.912	CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C3=CC=CC=C3)[C@H]3[C@]4(C[C@H]4C[C@H]4OC[C@@]34OC(C)=O)C1=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1	Not Available	Not Available								5293466									6918260	347829123				Larotaxel	ZINC000095627892		Larotaxel	Investigational	DB12984	InChI=1S/C45H53NO14/c1-23-29(57-39(52)33(49)32(26-15-11-9-12-16-26)46-40(53)60-41(4,5)6)21-45(54)37(58-38(51)27-17-13-10-14-18-27)35-43(36(50)34(56-24(2)47)31(23)42(45,7)8)20-28(43)19-30-44(35,22-55-30)59-25(3)48/h9-18,28-30,32-35,37,49,54H,19-22H2,1-8H3,(H,46,53)/t28-,29+,30-,32+,33-,34-,35+,37+,43-,44+,45-/m1/s1	DXOJIXGRFSHVKA-BZVZGCBYSA-N	3		Not Available	Small Molecule																																			0	No	9	3	Yes	7	0	210.29 Å2	84.72 Å3	209.73 m3·mol-1	15	No	No	0.00567 mg/mL	4.04	-5.2	11.26	-3.6			
C27H39NO6	Not Available	Not Available	473.61	C[C@H]1\C=C/C\C(C)=C/C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\C1=NOC(C)=C1	Not Available	Not Available								34986490									71587784	347829205							KOSN-1724	Investigational	DB13078	InChI=1S/C27H39NO6/c1-16-9-8-10-17(2)25(31)20(5)26(32)27(6,7)23(29)15-24(30)33-22(12-11-16)18(3)13-21-14-19(4)34-28-21/h8,10-11,13-14,17,20,22-23,25,29,31H,9,12,15H2,1-7H3/b10-8-,16-11-,18-13+/t17-,20+,22-,23-,25-/m0/s1	JAYGOFBXDFAXBW-CYEKYUJNSA-N			Not Available	Small Molecule																																			1	No	5	2	No	2	0	109.86 Å2	52.7 Å3	134.1 m3·mol-1	2	Yes	No	0.0286 mg/mL	4.52	-4.2	14.06	0.8			
C29H48O2	Not Available	Not Available	428.701	CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C)C(C)C	Not Available	Not Available								8201186									10025615	347829221							1alpha-Hydroxyvitamin D5	Investigational	DB13097	InChI=1S/C29H48O2/c1-7-22(19(2)3)11-10-20(4)26-14-15-27-23(9-8-16-29(26,27)6)12-13-24-17-25(30)18-28(31)21(24)5/h12-13,19-20,22,25-28,30-31H,5,7-11,14-18H2,1-4,6H3/b23-12+,24-13-/t20-,22-,25-,26-,27+,28+,29-/m1/s1	NWFOBODUYTUMNC-VPSCEVSQSA-N	1		Not Available	Small Molecule																																			1	No	2	2	Yes	3	0	40.46 Å2	54.09 Å3	133.85 m3·mol-1	7	No	No	0.000923 mg/mL	6.55	-5.7	14.39	-2.8			
C41H67NO15	Not Available	Not Available	813.9684	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O	Solid	Not Available					50370258	45735	CHEMBL564085	16707	Drugs.com Drug Page		HMDB0015448	C12753	D01322	TAO		PA127840611	202225	347829281	RxList Drug Page	10864	DAP000411	Troleandomycin	ZINC000169307271		Troleandomycin	Approved	DB13179	InChI=1S/C41H67NO15/c1-19-17-41(18-49-41)38(46)23(5)34(53-27(9)43)21(3)25(7)52-39(47)24(6)35(56-32-16-31(48-14)36(26(8)51-32)54-28(10)44)22(4)33(19)57-40-37(55-29(11)45)30(42(12)13)15-20(2)50-40/h19-26,30-37,40H,15-18H2,1-14H3/t19-,20+,21-,22+,23+,24+,25+,26-,30-,31-,32-,33-,34-,35-,36-,37+,40-,41+/m0/s1	LQCLVBQBTUVCEQ-QTFUVMRISA-N			Troleandomycin inhibits clearance of theophylline and can increase the likelyhood of toxicity in patients recieving theophylline therapy 1.	Small Molecule				AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.2177 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							812.49			0	No	12	0	Yes	4	1	184.19 Å2	86.05 Å3	201.15 m3·mol-1	12	No	No	0.0192 mg/mL	4.3	-4.6	19.62	7.87	P49228;!P60723;!O75469	rpmF;!rplD;!NR1I2	1. 50S ribosomal protein L32;!2. 50S ribosomal protein L4;!3. Nuclear receptor subfamily 1 group I member 2
C26H38O4	The elimination on the first day following intravenous injection of oxabolone cipionate is slow and reaches a rapid excretion phase with the maximum urinary level in the fifth day of administration 2.	Not Available	414.586	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=C(O)C(=O)CC[C@]4([H])[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1	Solid	Not Available						31940	CHEMBL2105318	62175									68952	347829285				Oxabolone_cipionate	ZINC000026892649		Oxabolone cipionate	Experimental	DB13185	InChI=1S/C26H38O4/c1-26-15-14-18-17-9-11-22(27)25(29)20(17)8-7-19(18)21(26)10-12-23(26)30-24(28)13-6-16-4-2-3-5-16/h16-19,21,23,29H,2-15H2,1H3/t17-,18-,19-,21+,23+,26+/m1/s1	KHKDIUPVDIEHAH-KXLSUQFWSA-N			Not Available	Small Molecule																																			1	Yes	3	1	No	5	0	63.6 Å2	48.9 Å3	116.85 m3·mol-1	5	No	No	0.00377 mg/mL	5.29	-5	9.23	-3.7			
C22H27FO5	Not Available	Not Available	390.451	C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]2(C)[C@H]1C(=O)C(O)=O	Not Available	Not Available								18865233					D07972									Fluocortin	ZINC000006031566		Fluocortin	Experimental	DB13223	InChI=1S/C22H27FO5/c1-10-6-13-12-8-15(23)14-7-11(24)4-5-21(14,2)18(12)16(25)9-22(13,3)17(10)19(26)20(27)28/h4-5,7,10,12-13,15-18,25H,6,8-9H2,1-3H3,(H,27,28)/t10-,12+,13+,15+,16+,17-,18-,21+,22+/m1/s1	PUWHHWCHAVXSIG-NCLPIGKXSA-N			Not Available	Small Molecule																																			1	Yes	5	2	No	4	-1	91.67 Å2	40.21 Å3	101.56 m3·mol-1	2	Yes	No	0.0302 mg/mL	2.74	-4.1	3.73	-0.23			
C20H28O3	Not Available	Not Available	316.441	[H][C@@]12CC[C@](O)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	Not Available	Not Available						135991	CHEMBL3707212	92341												4793		Gestronol	ZINC000005167250		Gestonorone	Experimental	DB13230	InChI=1S/C20H28O3/c1-12(21)20(23)10-8-18-17-5-3-13-11-14(22)4-6-15(13)16(17)7-9-19(18,20)2/h11,15-18,23H,3-10H2,1-2H3/t15-,16+,17+,18-,19-,20-/m0/s1	GTFUITFQDGVJSK-XGXHKTLJSA-N			Not Available	Small Molecule																																			1	Yes	3	1	No	4	0	54.37 Å2	36.34 Å3	89.63 m3·mol-1	1	Yes	No	0.0213 mg/mL	3.1	-4.2	12.7	-3.8			
C30H44O9	Not Available	Not Available	548.673	[H][C@@]1(CC[C@]2(O)[C@]3([H])CC[C@]4(O)C[C@H](CC[C@]4(C=O)[C@@]3([H])CC[C@]12C)O[C@H]1C[C@H](OC)[C@H](O)[C@@H](C)O1)C1=CC(=O)OC1	Not Available	Not Available						4037	CHEMBL1075788	390429				C08859										Cymarin	ZINC000008214527		Cymarin	Experimental	DB13240	InChI=1S/C30H44O9/c1-17-26(33)23(36-3)13-25(38-17)39-19-4-9-28(16-31)21-5-8-27(2)20(18-12-24(32)37-15-18)7-11-30(27,35)22(21)6-10-29(28,34)14-19/h12,16-17,19-23,25-26,33-35H,4-11,13-15H2,1-3H3/t17-,19+,20-,21+,22-,23+,25+,26-,27-,28+,29+,30+/m1/s1	XQCGNURMLWFQJR-ZNDDOCHDSA-N			Not Available	Small Molecule																																			1	No	8	3	No	6	0	131.75 Å2	58.62 Å3	140.03 m3·mol-1	5	No	No	0.0804 mg/mL	1.69	-3.8	7.18	0.27			
C30H42O8	Not Available	Not Available	530.658	[H][C@@]1(CC[C@]2(O)[C@]3([H])CCC4=C[C@]([H])(CC[C@]4(C)[C@@]3([H])CC[C@]12C)O[C@]1([H])O[C@@]([H])(C)[C@]([H])(O)[C@@]([H])(O)[C@@]1([H])O)C1=COC(=O)C=C1	Not Available	Not Available						32065	CHEMBL600325	4447658									5284613	347829292		8795		Proscillaridin	ZINC000008214665		Proscillaridin	Experimental	DB13307	InChI=1S/C30H42O8/c1-16-24(32)25(33)26(34)27(37-16)38-19-8-11-28(2)18(14-19)5-6-22-21(28)9-12-29(3)20(10-13-30(22,29)35)17-4-7-23(31)36-15-17/h4,7,14-16,19-22,24-27,32-35H,5-6,8-13H2,1-3H3/t16-,19-,20+,21-,22+,24-,25+,26+,27-,28-,29+,30-/m0/s1	MYEJFUXQJGHEQK-ALRJYLEOSA-N			Not Available	Small Molecule																																			1	No	7	4	No	6	0	125.68 Å2	58.26 Å3	140.05 m3·mol-1	3	No	No	0.0427 mg/mL	2.3	-4.1	12.22	0.3			
C37H66FNO13	Not Available	Not Available	751.927	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@](C)(F)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			131719	CHEMBL2106403	64388														Flurithromycin	ZINC000085540108		Flurithromycin	Experimental	DB13338	InChI=1S/C37H66FNO13/c1-14-24-37(10,46)29(42)21(5)28(41)34(7,38)17-35(8,45)31(52-33-26(40)23(39(11)12)15-18(2)48-33)19(3)27(20(4)32(44)50-24)51-25-16-36(9,47-13)30(43)22(6)49-25/h18-27,29-31,33,40,42-43,45-46H,14-17H2,1-13H3/t18-,19+,20-,21+,22+,23+,24-,25+,26-,27+,29-,30+,31-,33+,34+,35-,36-,37-/m1/s1	XOEUHCONYHZURQ-HNUBZJOYSA-N			Not Available	Small Molecule																																			0	No	13	5	Yes	3	1	193.91 Å2	79.53 Å3	185.93 m3·mol-1	7	No	No	0.355 mg/mL	2.43	-3.3	11.82	8.38			
C42H69NO15	Not Available	Not Available	828.006	CCCC(=O)O[C@H]1[C@H](C)O[C@H](C[C@@]1(C)OC(=O)CC)O[C@@H]1[C@@H](C)O[C@@H](O[C@H]2[C@@H](CC=O)C[C@@H](C)[C@@H](O)\C=C\C=C\C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]2OC)[C@H](O)[C@H]1N(C)C	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			32103	CHEMBL1908350	4445397														Rokitamycin	ZINC000169676935		Rokitamycin	Experimental	DB13409	InChI=1S/C42H69NO15/c1-11-16-32(48)55-40-27(6)53-34(23-42(40,7)58-31(47)12-2)56-37-26(5)54-41(36(50)35(37)43(8)9)57-38-28(19-20-44)21-24(3)29(45)18-15-13-14-17-25(4)52-33(49)22-30(46)39(38)51-10/h13-15,18,20,24-30,34-41,45-46,50H,11-12,16-17,19,21-23H2,1-10H3/b14-13+,18-15+/t24-,25-,26-,27+,28+,29+,30-,34+,35-,36-,37-,38+,39+,40+,41+,42-/m1/s1	VYWWNRMSAPEJLS-MDWYKHENSA-N			Not Available	Small Molecule																																			0	No	13	3	Yes	3	1	206.05 Å2	89.06 Å3	211.11 m3·mol-1	15	No	No	0.061 mg/mL	3.63	-4.1	12.71	7.9			
C41H67NO15	Midecamycin presentas a low renal clearance value.3	The half-life of midecamycin is longer than the first macrolide antibiotics.3 after intravenous administration, the half-life reported is of 54 minutes.4	813.979	[H][C@@]1(C[C@@](C)(O)[C@@H](OC(=O)CC)[C@H](C)O1)O[C@@H]1[C@@H](C)O[C@@]([H])(O[C@H]2[C@@H](CC=O)C[C@@H](C)[C@@H](O)\C=C\C=C\C[C@@H](C)OC(=O)C[C@@]([H])(OC(=O)CC)[C@@H]2OC)[C@H](O)[C@H]1N(C)C	Solid	The reported apparent volume of distribution of midecamycin is 7.7 L/kg.4	P08684	CYP3A4	1. Cytochrome P450 3A4			31845	CHEMBL444963	4445365					D01339							30005		Midecamycin	ZINC000169368401		Midecamycin	Experimental	DB13456	InChI=1S/C41H67NO15/c1-11-30(45)54-29-21-32(47)51-24(4)16-14-13-15-17-28(44)23(3)20-27(18-19-43)37(38(29)50-10)57-40-35(48)34(42(8)9)36(25(5)53-40)56-33-22-41(7,49)39(26(6)52-33)55-31(46)12-2/h13-15,17,19,23-29,33-40,44,48-49H,11-12,16,18,20-22H2,1-10H3/b14-13+,17-15+/t23-,24-,25-,26+,27+,28+,29-,33+,34-,35-,36-,37+,38+,39+,40+,41-/m1/s1	DMUAPQTXSSNEDD-QALJCMCCSA-N		Midecamycin is a macrolide antibiotic used to treat a variety of infections caused by susceptible bacteria.	Not Available	Small Molecule																													874 ºC	2.22		155 ºC	6.9	Insoluble	0	No	13	3	Yes	3	1	206.05 Å2	85.96 Å3	206.51 m3·mol-1	14	No	No	0.0935 mg/mL	3.19	-3.9	12.71	7.9			
C27H45IO	Not Available	Not Available	516.562	CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3C[C@@H](C[131I])C4=C(CC[C@H](O)C4)[C@H]3CC[C@]12C	Not Available	Not Available						34893	CHEMBL2106905	571011				C13547											ZINC000118913163		Iodine (131I) norcholesterol	Experimental	DB13487	InChI=1S/C27H45IO/c1-17(2)6-5-7-18(3)25-10-11-26-24-14-19(16-28)23-15-20(29)8-9-21(23)22(24)12-13-27(25,26)4/h17-20,22,24-26,29H,5-16H2,1-4H3/t18-,19+,20+,22-,24-,25-,26+,27-/m1/s1/i28+4	QJHZPCLORSPENH-DRTKWHMQSA-N		Iodine (131I) norcholesterol is a radioiodine-labeled cholesterol analogue that accumulates in areas where steroid hormones are produced and is used in certain diagnostic procedures.	Not Available	Small Molecule																																			0	No	1	1	Yes	4	0	20.23 Å2	55.61 Å3	133.56 m3·mol-1	6	No	Yes	0.000117 mg/mL	7.67	-6.6	18.19	-1.4			
C35H58O12	Not Available	Not Available	670.837	CCCCC[C@@H](O)[C@@H]1[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)[C@@H](O)[C@H](O)\C(C)=C\C=C\C=C\C=C\C=C\[C@H](O)[C@@H](C)OC1=O	Not Available	Not Available						31639	CHEMBL2272031	4445390				C13299										Pentamycin	ZINC000060183177		Pentamycin	Experimental	DB13571	InChI=1S/C35H58O12/c1-4-5-11-16-29(41)32-30(42)20-26(38)18-24(36)17-25(37)19-27(39)21-31(43)34(45)33(44)22(2)14-12-9-7-6-8-10-13-15-28(40)23(3)47-35(32)46/h6-10,12-15,23-34,36-45H,4-5,11,16-21H2,1-3H3/b7-6+,10-8+,12-9+,15-13+,22-14+/t23-,24+,25-,26+,27-,28+,29-,30+,31-,32-,33-,34-/m1/s1	AGJUUQSLGVCRQA-SWOUQTJZSA-N			Not Available	Small Molecule																																			0	No	11	10	No	1	0	228.6 Å2	74.3 Å3	182.93 m3·mol-1	5	No	No	0.209 mg/mL	-0.68	-3.5	12.89	-2.8			
C28H48OSe	Not Available	Not Available	475.614	C[75Se]C[C@@H]1C[C@H]2[C@@H]3CC[C@H]([C@H](C)CCCC(C)C)[C@@]3(C)CC[C@@H]2C2=C1C[C@@H](O)CC2	Not Available	Not Available								108863																	Selenium (75Se) norcholesterol	Experimental	DB13622	InChI=1S/C28H48OSe/c1-18(2)7-6-8-19(3)26-11-12-27-25-15-20(17-30-5)24-16-21(29)9-10-22(24)23(25)13-14-28(26,27)4/h18-21,23,25-27,29H,6-17H2,1-5H3/t19-,20+,21+,23-,25-,26-,27+,28-/m1/s1/i30-4	AEVGUKVBCBHBNF-MJMUOCKJSA-N		Selenium (75Se) norcholesterol is a radiopharmaceutical indicated in nuclear imaging studies of the digestive system.	Not Available	Small Molecule																																			1	No	2	1	Yes	4	0	20.23 Å2	54.58 Å3	138.28 m3·mol-1	7	No	Yes	0.000337 mg/mL	6.31	-6.2	18.19	-1.4			
C27H44O3	Not Available	Not Available	416.646	CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	Not Available	Not Available					50441892		CHEMBL2105611	4446823												291204		Tacalcitol	ZINC000004474668		Tacalcitol	Experimental, Investigational	DB13689	InChI=1S/C27H44O3/c1-17(2)25(29)13-8-18(3)23-11-12-24-20(7-6-14-27(23,24)5)9-10-21-15-22(28)16-26(30)19(21)4/h9-10,17-18,22-26,28-30H,4,6-8,11-16H2,1-3,5H3/b20-9+,21-10-/t18-,22-,23-,24+,25-,26+,27-/m1/s1	BJYLYJCXYAMOFT-RSFVBTMBSA-N	3	Tacalcitol is a vitamin D analog indicated in the treatment of mild to moderate plaque psoriasis.	Not Available	Small Molecule																																			1	No	3	3	Yes	3	0	60.69 Å2	51.11 Å3	126.29 m3·mol-1	6	Yes	No	0.0105 mg/mL	4.51	-4.6	14.39	-1.1			
C20H30O2	Not Available	Not Available	302.451	[H][C@]1(O)CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])CC(=O)C=C(C)[C@]4(C)[C@@]3([H])CC[C@]12C	Not Available	Not Available						135283		2301378			HMDB0041928									6833		Metenolone	ZINC000005497532		Metenolone	Experimental	DB13710	InChI=1S/C20H30O2/c1-12-10-14(21)11-13-4-5-15-16-6-7-18(22)19(16,2)9-8-17(15)20(12,13)3/h10,13,15-18,22H,4-9,11H2,1-3H3/t13-,15-,16-,17-,18-,19-,20-/m0/s1	ANJQEDFWRSLVBR-VHUDCFPWSA-N		Metenolone is an anabolic steroid indicated in the treatment and prevention of muscle wasting due to diseases, drug treatments, or other catabolic processes.	Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	35.88 Å3	88.98 m3·mol-1	0	Yes	Yes	0.022 mg/mL	3.65	-4.1	19.38	-0.88			
C30H44O9	Not Available	Not Available	548.673	CO[C@@H]1[C@@H](O)[C@H](C)O[C@@H](O[C@H]2CC[C@@]3(C=O)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H](CC[C@]43O)C3=CC(=O)OC3)C2)[C@H]1O	Not Available	Not Available						135825	CHEMBL1075790	16498835														Peruvoside			Peruvoside	Experimental	DB13756	InChI=1S/C30H44O9/c1-16-24(33)26(36-3)25(34)27(38-16)39-19-6-10-29(15-31)18(13-19)4-5-22-21(29)7-9-28(2)20(8-11-30(22,28)35)17-12-23(32)37-14-17/h12,15-16,18-22,24-27,33-35H,4-11,13-14H2,1-3H3/t16-,18+,19-,20+,21-,22+,24-,25-,26+,27-,28+,29+,30-/m0/s1	PMTSPAGBAFCORP-HBUONDEYSA-N			Not Available	Small Molecule																																			1	No	8	3	No	6	0	131.75 Å2	58.9 Å3	140.05 m3·mol-1	5	No	No	0.0791 mg/mL	2.02	-3.8	7.18	0.27			
C27H45IO	Not Available	Not Available	516.562	CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C[131I])[C@H]3CC[C@]12C	Not Available	Not Available						135998	CHEMBL2105011	396792														Iodocholesterol	ZINC000118913216		Iodocholesterol (131I)	Experimental	DB13797	InChI=1S/C27H45IO/c1-18(2)6-5-7-19(3)23-10-11-24-22-9-8-20-16-21(29)12-15-27(20,17-28)25(22)13-14-26(23,24)4/h8,18-19,21-25,29H,5-7,9-17H2,1-4H3/t19-,21+,22+,23-,24+,25+,26-,27-/m1/s1/i28+4	FIOAEFCJGZJUPW-ODFYUTSGSA-N			Not Available	Small Molecule																																			0	No	1	1	Yes	4	0	20.23 Å2	55.14 Å3	133.67 m3·mol-1	6	No	Yes	3.97e-05 mg/mL	7.8	-7.1	18.2	-1.4			
C23H28O6	Not Available	Not Available	400.471	COC(=O)CCC=C=CC[C@H]1[C@H](\C=C\[C@H](O)COC2=CC=CC=C2)[C@@H](O)CC1=O	Not Available	Not Available						31538		8153928														Enprostil			Enprostil	Experimental	DB13824	InChI=1S/C23H28O6/c1-28-23(27)12-8-3-2-7-11-19-20(22(26)15-21(19)25)14-13-17(24)16-29-18-9-5-4-6-10-18/h3-7,9-10,13-14,17,19-20,22,24,26H,8,11-12,15-16H2,1H3/b14-13+/t2?,17-,19-,20-,22-/m0/s1	PTOJVMZPWPAXER-FPXSIRDUSA-N			Not Available	Small Molecule																																			1	Yes	5	2	No	2	0	93.06 Å2	43.51 Å3	111.36 m3·mol-1	11	Yes	No	0.0149 mg/mL	2.59	-4.4	13.99	-2.9			
C21H25ClO5	Not Available	Not Available	392.88	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@]([H])(O)[C@@]1([H])[C@@]2([H])C=C(Cl)C2=CC(=O)C=C[C@]12C	Not Available	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5			135619	CHEMBL1697832	4447592					D03561							21285		Cloprednol	ZINC000004215431		Cloprednol	Experimental	DB13843	InChI=1S/C21H25ClO5/c1-19-5-3-11(24)7-14(19)15(22)8-12-13-4-6-21(27,17(26)10-23)20(13,2)9-16(25)18(12)19/h3,5,7-8,12-13,16,18,23,25,27H,4,6,9-10H2,1-2H3/t12-,13-,16-,18+,19-,20-,21-/m0/s1	YTJIBEDMAQUYSZ-FDNPDPBUSA-N		Cloprednol is a glucocorticoid indicated in the treatment of arthritis and asthma.	Not Available	Small Molecule																																			1	Yes	5	3	No	4	0	94.83 Å2	40.42 Å3	104.33 m3·mol-1	2	Yes	No	0.099 mg/mL	1.15	-3.6	12.58	-2.9			
C27H40O3	Testosterone cypionate presents a lower clearance rate after intramuscular administration compared to other analogs of testosterone.	The half-life of testosterone cypionate is one of the longest, being approximately of 8 days.5	412.614	[H][C@@]12CC[C@H](OC(=O)CCC3CCCC3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	The volume of distribution following intravenous administration of testosterone is of approximately 1 L/kg.7	P08684;!P21397;!P05108;!P20815;!P24462;!P04798;!Q16696;!P20813;!P33261;!P10632;!P11712;!Q9HB55;!BE0004887;!P11511	CYP3A4;!MAOA;!CYP11A1;!CYP3A5;!CYP3A7;!CYP1A1;!CYP2A13;!CYP2B6;!CYP2C19;!CYP2C8;!CYP2C9;!CYP3A43;!;!CYP19A1	1. Cytochrome P450 3A4;!2. Amine oxidase [flavin-containing] A;!3. Cholesterol side-chain cleavage enzyme, mitochondrial;!4. Cytochrome P450 3A5;!5. Cytochrome P450 3A7;!6. Cytochrome P450 1A1;!7. Cytochrome P450 2A13;!8. Cytochrome P450 2B6;!9. Cytochrome P450 2C19;!10. Cytochrome P450 2C8;!11. Cytochrome P450 2C9;!12. Cytochrome P450 3A43;!13. 3-oxo-5-alpha-steroid 4-dehydrogenase (Protein Group);!14. Cytochrome P450 19A1			9463	CHEMBL1201101	390140				C08156	D00957									Testosterone_cypionate	ZINC000004097468	Depo-testosterone	Testosterone cypionate	Approved	DB13943	InChI=1S/C27H40O3/c1-26-15-13-20(28)17-19(26)8-9-21-22-10-11-24(27(22,2)16-14-23(21)26)30-25(29)12-7-18-5-3-4-6-18/h17-18,21-24H,3-16H2,1-2H3/t21-,22-,23-,24-,26-,27-/m0/s1	HPFVBGJFAYZEBE-ZLQWOROUSA-N	4	Testosterone cypionate is an androgen used to treat low or absent testosterone.	Preclinical studies with testosterone implants induced cervical-uterine tumors in mice which metastasized in some cases. Some reports indicate that administration of testosterone cypionate in females can augment the susceptibility to hepatoma as well as increase the number of tumors. Clinical studies have reported cases of hepatocellular carcinoma in long-term high-dose therapy.6	Small Molecule																																98-104ºC		Insoluble	1	No	2	0	No	5	0	43.37 Å2	49.84 Å3	119.36 m3·mol-1	5	No	No	0.000437 mg/mL	6.11	-6	18.52	-4.8	P10275;!P03372;!P08235	AR;!ESR1;!NR3C2	1. Androgen receptor;!2. Estrogen receptor alpha;!3. Mineralocorticoid receptor
C26H40O3	Not Available	Testosterone enanthate presents a long half-life in the range of 7-9 days.3	400.594	[H][C@@]12CC[C@H](OC(=O)CCCCCC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	The volume of distribution following intravenous administration of testosterone is of approximately 1 L/kg.8	P08684;!P21397;!P05108;!P20815;!P24462;!P04798;!Q16696;!P20813;!P33261;!P10632;!P11712;!Q9HB55;!BE0004887;!P11511	CYP3A4;!MAOA;!CYP11A1;!CYP3A5;!CYP3A7;!CYP1A1;!CYP2A13;!CYP2B6;!CYP2C19;!CYP2C8;!CYP2C9;!CYP3A43;!;!CYP19A1	1. Cytochrome P450 3A4;!2. Amine oxidase [flavin-containing] A;!3. Cholesterol side-chain cleavage enzyme, mitochondrial;!4. Cytochrome P450 3A5;!5. Cytochrome P450 3A7;!6. Cytochrome P450 1A1;!7. Cytochrome P450 2A13;!8. Cytochrome P450 2B6;!9. Cytochrome P450 2C19;!10. Cytochrome P450 2C8;!11. Cytochrome P450 2C9;!12. Cytochrome P450 3A43;!13. 3-oxo-5-alpha-steroid 4-dehydrogenase (Protein Group);!14. Cytochrome P450 19A1			9464	CHEMBL1200335	9045			HMDB0005814	C08157										Testosterone_enanthate	ZINC000003876080	Delatestryl, Xyosted	Testosterone enanthate	Approved	DB13944	InChI=1S/C26H40O3/c1-4-5-6-7-8-24(28)29-23-12-11-21-20-10-9-18-17-19(27)13-15-25(18,2)22(20)14-16-26(21,23)3/h17,20-23H,4-16H2,1-3H3/t20-,21-,22-,23-,25-,26-/m0/s1	VOCBWIIFXDYGNZ-IXKNJLPQSA-N	4	Testosterone enanthate is an androgen used to treat low or absent testosterone.	Testosterone enanthate has been tested in preclinical carcinogenesis trials. In this studies, it is suggested that the exposure to this drug may increase the susceptibility to hematoma as well as the number of tumors and decrease the degree of differentiation of chemically induced carcinomas of the liver.LabelTestosterone enanthate is not indicated for use in females and is contraindicated in pregnant women. Testosterone is teratogenic and may cause fetal harm when administered to a pregnant woman based on data from animal studies and its mechanism of action. 11During treatment with large doses of exogenous androgens, including testosterone enanthate, spermatogenesis may be suppressed through feedback inhibition of the hypothalamic-pituitary-testicular axis 11. Reduced fertility is observed in some men taking testosterone replacement therapy and the impact on fertility may be irreversible 11.Safety and effectiveness of testosterone enanthate in pediatric patients less than 18 years old have not been established 11. Improper use may result in the acceleration of bone age and premature closure of epiphyses 11.Geriatric patients treated with androgens may also be at risk for worsening of signs and symptoms of Benign Prostatic Hyperplasia 11.	Small Molecule																														3.58		34-39ºC		Insoluble	1	No	2	0	Yes	4	0	43.37 Å2	49.18 Å3	116.61 m3·mol-1	7	No	No	0.000463 mg/mL	6.29	-5.9	18.52	-4.8	P10275;!P03372;!P08235	AR;!ESR1;!NR3C2	1. Androgen receptor;!2. Estrogen receptor alpha;!3. Mineralocorticoid receptor
C30H48O3	While there is limited information available, an earlier study reports a metabolic clearance rate of 24.5 mL/min/kg for testosterone following oral administration of 25 mg testosterone and 40 mg testosterone undecanoate in women.5	The elimination half-life of testosterone undecanoate is approximately two hours. Once testosterone is formed from testosterone undecanoate, the half life of testosterone can vary and the reported values in the literature remain inconsistent, ranging from 10 to to 100 minutes.6,8 Testosterone undecanoate in castor oil for intramuscular injection had a half life of 33.9 days, allowing it to maintain serum levels in the normal range for over 6 weeks.[A176954]	456.711	CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C	Solid	There is no information available.	P08684;!P21397;!P05108;!P20815;!P24462;!P04798;!Q16678;!Q16696;!P20813;!P33261;!P10632;!P11712;!Q9HB55;!BE0004887;!P11511	CYP3A4;!MAOA;!CYP11A1;!CYP3A5;!CYP3A7;!CYP1A1;!CYP1B1;!CYP2A13;!CYP2B6;!CYP2C19;!CYP2C8;!CYP2C9;!CYP3A43;!;!CYP19A1	1. Cytochrome P450 3A4;!2. Amine oxidase [flavin-containing] A;!3. Cholesterol side-chain cleavage enzyme, mitochondrial;!4. Cytochrome P450 3A5;!5. Cytochrome P450 3A7;!6. Cytochrome P450 1A1;!7. Cytochrome P450 1B1;!8. Cytochrome P450 2A13;!9. Cytochrome P450 2B6;!10. Cytochrome P450 2C19;!11. Cytochrome P450 2C8;!12. Cytochrome P450 2C9;!13. Cytochrome P450 3A43;!14. 3-oxo-5-alpha-steroid 4-dehydrogenase (Protein Group);!15. Cytochrome P450 19A1			135741	CHEMBL2107067	58664														Testosterone_undecanoate	ZINC000008214690	Aveed, Jatenzo, Tlando	Testosterone undecanoate	Approved, Investigational	DB13946	InChI=1S/C30H48O3/c1-4-5-6-7-8-9-10-11-12-28(32)33-27-16-15-25-24-14-13-22-21-23(31)17-19-29(22,2)26(24)18-20-30(25,27)3/h21,24-27H,4-20H2,1-3H3/t24-,25-,26-,27-,29-,30-/m0/s1	UDSFVOAUHKGBEK-CNQKSJKFSA-N	4	Testosterone undecanoate is an androgen indicated for testosterone replacement therapy in adult males with primary hypogonadism and hypogonadotropic hypogonadism.	The oral LD50 is 4000 mg/kg in mice and rats. The subcutaneous LD50 is 2880 mg/kg in mice and rats.9There is limited information on testosterone undecanoate overdose. There was one report of acute overdose from an approved injectable testosterone product, which resulted in increased serum testosterone levels of up to 11,400 ng/dL with a cerebrovascular accident.6 There was one case of overdose following administration of oral testosterone undecanoate capsules: this patient inadvertently took a 20% higher dose than the maximum recommended dose but did not report any adverse reactions.7 Overdose should be managed with discontinuation of the drug in combination with appropriate symptomatic and supportive care.6The abuse of anabolic androgenic steroids can result in serious adverse reactions, such as cardiac arrest, myocardial infarction, hypertrophic cardiomyopathy, congestive heart failure, cerebrovascular accident, hepatotoxicity, and psychiatric manifestations, including major depression, mania, paranoia, psychosis, delusions, hallucinations, hostility, and aggression. Men receiving testosterone have experienced transient ischemic attacks, convulsions, hypomania, irritability, dyslipidemias, testicular atrophy, subfertility, and infertility.6	Small Molecule																																		<1 mg/mL	0	No	2	0	Yes	4	0	43.37 Å2	57.8 Å3	135.02 m3·mol-1	11	No	No	7.4e-05 mg/mL	8.06	-6.8	18.52	-4.8	P10275	AR	1. Androgen receptor
C40H52N2O4	Not Available	Not Available	624.866	[H]N(N=C1CC[C@@]2(C)C(CC[C@@]3([H])[C@]4([H])CC[C@H](OC(=O)CCCCCC)[C@@]4(C)CC[C@]23[H])=C1)C(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1	Not Available	Not Available								34995240														Testosterone_enantate_benzilic_acid_hydrazone	ZINC000299888598		Testosterone enantate benzilic acid hydrazone	Approved, Experimental	DB13947	InChI=1S/C40H52N2O4/c1-4-5-6-13-18-36(43)46-35-22-21-33-32-20-19-30-27-31(23-25-38(30,2)34(32)24-26-39(33,35)3)41-42-37(44)40(45,28-14-9-7-10-15-28)29-16-11-8-12-17-29/h7-12,14-17,27,32-35,45H,4-6,13,18-26H2,1-3H3,(H,42,44)/t32-,33-,34-,35-,38-,39-/m0/s1	PTVXYACXDYZNID-JKXGKYMWSA-N			Not Available	Small Molecule																																			0	No	4	2	Yes	6	0	87.99 Å2	74.51 Å3	182.37 m3·mol-1	11	No	No	0.000122 mg/mL	8.49	-6.7	11.09	2.14			
C21H32O3	Not Available	Not Available	332.484	[H][C@@]12CC[C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)CC[C@]12C	Not Available	Not Available							CHEMBL3275971	9984405														Dihydrotestosterone_acetate	ZINC000002557145		Stanolone acetate	Experimental	DB13951	InChI=1S/C21H32O3/c1-13(22)24-19-7-6-17-16-5-4-14-12-15(23)8-10-20(14,2)18(16)9-11-21(17,19)3/h14,16-19H,4-12H2,1-3H3/t14-,16-,17-,18-,19-,20-,21-/m0/s1	ILCTUFVQFCIIDS-NGFSFWIMSA-N			Not Available	Small Molecule																																			1	Yes	2	0	No	4	0	43.37 Å2	39.03 Å3	92.75 m3·mol-1	2	Yes	No	0.00115 mg/mL	3.85	-5.5		-6.8	P10275;!P14061;!P03372;!P08235	AR;!HSD17B1;!ESR1;!NR3C2	1. Androgen receptor;!2. Estradiol 17-beta-dehydrogenase 1;!3. Estrogen receptor alpha;!4. Mineralocorticoid receptor
C26H36O3	Not Available	Not Available	396.5622	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1	Not Available	The distribution of exogenous estrogens is similar to that of endogenous estrogens. Estrogens are widely distributed in the body and are generally found in higher concentrations in the sex hormone target organs Label.	P05177;!P22309;!P08684;!P20815;!P24462;!P04798;!Q16678;!P33261;!P10632;!P11712	CYP1A2;!UGT1A1;!CYP3A4;!CYP3A5;!CYP3A7;!CYP1A1;!CYP1B1;!CYP2C19;!CYP2C8;!CYP2C9	1. Cytochrome P450 1A2;!2. UDP-glucuronosyltransferase 1-1;!3. Cytochrome P450 3A4;!4. Cytochrome P450 3A5;!5. Cytochrome P450 3A7;!6. Cytochrome P450 1A1;!7. Cytochrome P450 1B1;!8. Cytochrome P450 2C19;!9. Cytochrome P450 2C8;!10. Cytochrome P450 2C9			34745	CHEMBL1200973	9033				C14640	D04063				9403					Estradiol_cypionate	ZINC000003876078	Depo-estradiol	Estradiol cypionate	Approved, Investigational, Vet approved	DB13954	InChI=1S/C26H36O3/c1-26-15-14-21-20-10-8-19(27)16-18(20)7-9-22(21)23(26)11-12-24(26)29-25(28)13-6-17-4-2-3-5-17/h8,10,16-17,21-24,27H,2-7,9,11-15H2,1H3/t21-,22-,23+,24+,26+/m1/s1	UOACKFBJUYNSLK-XRKIENNPSA-N	2	Estradiol cypionate is an estradiol prodrug used to treat vasomotor symptoms and hypoestrogenisms from hypogonadism.	Not Available	Small Molecule																																			1	No	2	1	No	5	0	46.53 Å2	47.77 Å3	114.83 m3·mol-1	5	No	No	0.000118 mg/mL	6.49	-6.5	10.33	-5.4	P03372;!Q92731;!O75469;!P43681;!Q15596;!Q99527;!P00846;!Q14457;!P37059;!P62508	ESR1;!ESR2;!NR1I2;!CHRNA4;!NCOA2;!GPER1;!MT-ATP6;!BECN1;!HSD17B2;!ESRRG	1. Estrogen receptor alpha;!2. Estrogen receptor beta;!3. Nuclear receptor subfamily 1 group I member 2;!4. Neuronal acetylcholine receptor subunit alpha-4;!5. Nuclear receptor coactivator 2;!6. G-protein coupled estrogen receptor 1;!7. ATP synthase subunit a;!8. Beclin-1;!9. Estradiol 17-beta-dehydrogenase 2;!10. Estrogen-related receptor gamma
C32H48O4	Not Available	Not Available	496.732	CCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(OC(=O)CCCCCC)=CC=C4[C@H]3CC[C@]12C	Not Available	Not Available	P05177;!P22309;!P08684;!P20815;!P24462;!P04798;!Q16678;!P33261;!P10632;!P11712	CYP1A2;!UGT1A1;!CYP3A4;!CYP3A5;!CYP3A7;!CYP1A1;!CYP1B1;!CYP2C19;!CYP2C8;!CYP2C9	1. Cytochrome P450 1A2;!2. UDP-glucuronosyltransferase 1-1;!3. Cytochrome P450 3A4;!4. Cytochrome P450 3A5;!5. Cytochrome P450 3A7;!6. Cytochrome P450 1A1;!7. Cytochrome P450 1B1;!8. Cytochrome P450 2C19;!9. Cytochrome P450 2C8;!10. Cytochrome P450 2C9					145199														Estradiol_dienantate	ZINC000031476880		Estradiol dienanthate	Approved, Investigational, Vet approved	DB13955	InChI=1S/C32H48O4/c1-4-6-8-10-12-30(33)35-24-15-17-25-23(22-24)14-16-27-26(25)20-21-32(3)28(27)18-19-29(32)36-31(34)13-11-9-7-5-2/h15,17,22,26-29H,4-14,16,18-21H2,1-3H3/t26-,27-,28+,29+,32+/m1/s1	OVAHZPTYWMWNKO-CAHAWPIUSA-N		Estradiol dienanthate is an estrogen used in some combined hormonal oral contraceptives.	Not Available	Small Molecule																																			0	No	2	0	Yes	4	0	52.6 Å2	61.85 Å3	144.27 m3·mol-1	14	No	No	1.16e-05 mg/mL	9.06	-7.6		-6.8	P03372;!Q92731;!O75469;!P43681;!Q15596;!Q99527;!P00846;!Q14457;!P37059;!P62508	ESR1;!ESR2;!NR1I2;!CHRNA4;!NCOA2;!GPER1;!MT-ATP6;!BECN1;!HSD17B2;!ESRRG	1. Estrogen receptor alpha;!2. Estrogen receptor beta;!3. Nuclear receptor subfamily 1 group I member 2;!4. Neuronal acetylcholine receptor subunit alpha-4;!5. Nuclear receptor coactivator 2;!6. G-protein coupled estrogen receptor 1;!7. ATP synthase subunit a;!8. Beclin-1;!9. Estradiol 17-beta-dehydrogenase 2;!10. Estrogen-related receptor gamma
C23H32O3	Not Available	Not Available	356.4984	[H][C@@]12CC[C@H](OC(=O)CCCC)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	Not Available	Not Available	P05177;!P22309;!P08684;!P20815;!P24462;!P04798;!Q16678;!P33261;!P10632;!P11712	CYP1A2;!UGT1A1;!CYP3A4;!CYP3A5;!CYP3A7;!CYP1A1;!CYP1B1;!CYP2C19;!CYP2C8;!CYP2C9	1. Cytochrome P450 1A2;!2. UDP-glucuronosyltransferase 1-1;!3. Cytochrome P450 3A4;!4. Cytochrome P450 3A5;!5. Cytochrome P450 3A7;!6. Cytochrome P450 1A1;!7. Cytochrome P450 1B1;!8. Cytochrome P450 2C19;!9. Cytochrome P450 2C8;!10. Cytochrome P450 2C9			31561	CHEMBL1511	13194				C12859					13791		RxList Drug Page			Estradiol_valerate	ZINC000003881556	Delestrogen, Natazia	Estradiol valerate	Approved, Investigational, Vet approved	DB13956	InChI=1S/C23H32O3/c1-3-4-5-22(25)26-21-11-10-20-19-8-6-15-14-16(24)7-9-17(15)18(19)12-13-23(20,21)2/h7,9,14,18-21,24H,3-6,8,10-13H2,1-2H3/t18-,19-,20+,21+,23+/m1/s1	RSEPBGGWRJCQGY-RBRWEJTLSA-N	4	Estradiol valerate is an estradiol prodrug used to treat some effects of menopause, hypoestrogenism, androgen dependant carcinoma of the prostate, and in combination products for endometriosis and contraception.	Not Available	Small Molecule																																			1	No	2	1	No	4	0	46.53 Å2	42.57 Å3	102.89 m3·mol-1	5	No	No	0.000617 mg/mL	5.78	-5.8	10.33	-5.4	P03372;!Q92731;!O75469;!P43681;!Q15596;!Q99527;!P00846;!Q14457;!P37059;!P62508	ESR1;!ESR2;!NR1I2;!CHRNA4;!NCOA2;!GPER1;!MT-ATP6;!BECN1;!HSD17B2;!ESRRG	1. Estrogen receptor alpha;!2. Estrogen receptor beta;!3. Nuclear receptor subfamily 1 group I member 2;!4. Neuronal acetylcholine receptor subunit alpha-4;!5. Nuclear receptor coactivator 2;!6. G-protein coupled estrogen receptor 1;!7. ATP synthase subunit a;!8. Beclin-1;!9. Estradiol 17-beta-dehydrogenase 2;!10. Estrogen-related receptor gamma
C21H30O3	Not Available	Not Available	330.468	[H][C@@]12CC[C@H](OC(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3C[C@@H](C)[C@@]21[H]	Solid	Not Available							CHEMBL452329	8421572														Trestolone_acetate			Trestolone acetate	Experimental	DB13958	InChI=1S/C21H30O3/c1-12-10-14-11-15(23)4-5-16(14)17-8-9-21(3)18(20(12)17)6-7-19(21)24-13(2)22/h11-12,16-20H,4-10H2,1-3H3/t12-,16+,17-,18+,19+,20-,21+/m1/s1	IVCRCPJOLWECJU-XQVQQVTHSA-N			Not Available	Small Molecule																																			1	Yes	2	0	No	4	0	43.37 Å2	38.59 Å3	93.65 m3·mol-1	2	Yes	No	0.00582 mg/mL	3.79	-4.8	18.34	-4.7			
C23H30O4	Not Available	Not Available	370.489	[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3C(C)=C[C@@]21[H]	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			135564	CHEMBL1476022	82771					D08281							53744		Nomegestrol_acetate	ZINC000003938628		Nomegestrol acetate	Approved, Investigational	DB13981	InChI=1S/C23H30O4/c1-13-11-20-18(17-6-5-16(26)12-19(13)17)7-9-22(4)21(20)8-10-23(22,14(2)24)27-15(3)25/h11-12,17-18,20-21H,5-10H2,1-4H3/t17-,18-,20-,21+,22+,23+/m1/s1	IIVBFTNIGYRNQY-YQLZSBIMSA-N	4		Not Available	Small Molecule																																			1	Yes	3	0	No	4	0	60.44 Å2	41.78 Å3	104.18 m3·mol-1	3	Yes	No	0.00415 mg/mL	3.42	-5	17.72	-4.8			
C31H45N3O6	Not Available	Not Available	555.716	C[C@H](\C=C\C=C(/C)[C@H]1OC(=O)C[C@H](O)CC[C@@](C)(O)[C@@H](OC(=O)N2CCN(C)CC2)\C=C\[C@@H]1C)C1=CC=CC=N1	Solid	Not Available								71360838																	H3B-8800	Investigational	DB14017	InChI=1S/C31H45N3O6/c1-22(26-11-6-7-16-32-26)9-8-10-23(2)29-24(3)12-13-27(39-30(37)34-19-17-33(5)18-20-34)31(4,38)15-14-25(35)21-28(36)40-29/h6-13,16,22,24-25,27,29,35,38H,14-15,17-21H2,1-5H3/b9-8+,13-12+,23-10+/t22-,24+,25-,27+,29-,31-/m1/s1	YOIQWBAHJZGRFW-WVRLKXNASA-N			Not Available	Small Molecule																																			1	No	6	2	Yes	3	1	112.43 Å2	62.34 Å3	156.6 m3·mol-1	6	No	No	0.153 mg/mL	3.14	-3.6	13.92	6.89	O75533	SF3B1	1. Splicing factor 3B subunit 1
C29H50O	Not Available	Not Available	414.718	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC=C4C[C@@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CC[C@@H](CC)C(C)C	Solid	Not Available					50218197	27693	CHEMBL221542	192962			HMDB0000852	C01753	D08518							47070		Beta-Sitosterol	ZINC000004095717		beta-Sitosterol	Experimental	DB14038	InChI=1S/C29H50O/c1-7-21(19(2)3)9-8-20(4)25-12-13-26-24-11-10-22-18-23(30)14-16-28(22,5)27(24)15-17-29(25,26)6/h10,19-21,23-27,30H,7-9,11-18H2,1-6H3/t20-,21-,23+,24+,25-,26+,27+,28+,29-/m1/s1	KZJWDPNRJALLNS-VJSFXXLFSA-N	2		Not Available	Small Molecule																																			1	No	1	1	Yes	4	0	20.23 Å2	54.21 Å3	129.77 m3·mol-1	6	No	Yes	1.84e-05 mg/mL	7.84	-7.4	18.2	-1.4			
C40H68O11	Not Available	Not Available	724.973	[H][C@@]1(C[C@H](C)[C@@]([H])(O1)[C@]1(C)CC[C@@]([H])(O1)[C@]1(C)C[C@@H](C)[C@]2(O1)O[C@]([H])(C[C@@]1([H])CC[C@H](C)[C@@]([H])(O1)[C@@H](C)C(O)=O)C[C@@H](OC)[C@H]2C)[C@@]1([H])O[C@@](O)(CO)[C@H](C)C[C@@H]1C	Solid	Not Available						7569	CHEMBL405862	10196461				C11609										Nigericin	ZINC000085552063		Nigericin	Experimental	DB14056	InChI=1S/C40H68O11/c1-21-11-12-28(46-33(21)26(6)36(42)43)17-29-18-30(45-10)27(7)40(48-29)25(5)19-38(9,51-40)32-13-14-37(8,49-32)35-23(3)16-31(47-35)34-22(2)15-24(4)39(44,20-41)50-34/h21-35,41,44H,11-20H2,1-10H3,(H,42,43)/t21-,22-,23-,24+,25+,26+,27+,28+,29+,30+,31+,32+,33+,34-,35+,37-,38-,39-,40+/m0/s1	DANUORFCFTYTSZ-SJSJOXFOSA-N			Not Available	Small Molecule																																			0	No	11	3	Yes	6	-1	142.37 Å2	81.84 Å3	189.1 m3·mol-1	9	No	No	0.00137 mg/mL	6.11	-5.7	4.07	-3.4			
C46H75NO14	Not Available	Not Available	866.099	[H][C@@]1(OC(=O)\C(OC)=C\C(\C)=C\[C@@H](C)[C@@H](O)[C@@H](CC)[C@@H](O)[C@H](C)C\C(C)=C\C=C\[C@@H]1OC)[C@@H](C)[C@@H](O)[C@H](C)[C@@]1(O)C[C@@H](O[C@H]2C[C@@H](O)[C@H](OC(N)=O)[C@@H](C)O2)[C@H](C)[C@H](O1)\C=C\C	Solid	Not Available						73167	CHEMBL1241239	4942642															ZINC000254286797		Concanamycin A	Experimental	DB14062	InChI=1S/C46H75NO14/c1-13-16-34-28(7)37(58-38-22-33(48)43(31(10)57-38)60-45(47)53)23-46(54,61-34)30(9)41(51)29(8)42-35(55-11)18-15-17-24(3)19-26(5)39(49)32(14-2)40(50)27(6)20-25(4)21-36(56-12)44(52)59-42/h13,15-18,20-21,26-35,37-43,48-51,54H,14,19,22-23H2,1-12H3,(H2,47,53)/b16-13+,18-15+,24-17+,25-20+,36-21-/t26-,27-,28-,29+,30+,31-,32+,33-,34-,35+,37-,38+,39+,40-,41-,42-,43-,46-/m1/s1	DJZCTUVALDDONK-HQMSUKCRSA-N			Not Available	Small Molecule																																			0	No	12	6	Yes	3	0	225.92 Å2	93.53 Å3	232.65 m3·mol-1	12	No	No	0.0128 mg/mL	5.59	-4.8	11.68	-3	P08183	ABCB1	1. P-glycoprotein 1
C23H30O4	No pharmacokinetic data available.	The mean (SD) half life of segesterone acetate is 4.5 (3.4) hours Label.	370.489	[H][C@@]12CC(=C)[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	Solid	The volume of distribution of segesterone acetate is 19.6 L/kg Label.	P08684	CYP3A4	1. Cytochrome P450 3A4			135563	CHEMBL3707377	97161												2055977		Segesterone_acetate	ZINC000005167230	Annovera	Segesterone acetate	Approved, Experimental, Investigational	DB14583	InChI=1S/C23H30O4/c1-13-11-21-20-7-5-16-12-17(26)6-8-18(16)19(20)9-10-22(21,4)23(13,14(2)24)27-15(3)25/h12,18-21H,1,5-11H2,2-4H3/t18-,19+,20+,21-,22-,23-/m0/s1	CKFBRGLGTWAVLG-GOMYTPFNSA-N	3		There have been no reports of serious ill effects from overdose of combination hormonal contraceptive use. Overdosage may cause withdrawal bleeding in females and nausea. In case of suspected overdose, all vaginal systems containing segesterone acetate should be removed and symptomatic treatment should be initiated Label.In a 2-year carcinogenicity study in rats receiving segesterone acetate via subdermal implants, there was no drug-related increase in tumor incidence. In a 2-year intravaginal carcinogenicity study in mice, segesterone acetate gel produced an increased incidence of adenocarcinoma and lobular hyperplasia in the breast at a supratherapeutic dose of 30 mg/kg/day. Segesterone acetate was not shown to be mutagenic or clastogenic Label.	Small Molecule																																173-177		Insoluble	1	Yes	3	0	No	4	0	60.44 Å2	41.79 Å3	102.95 m3·mol-1	3	Yes	No	0.00231 mg/mL	3.64	-5.2	17.46	-4.7	P06401;!P10275;!P04150	PGR;!AR;!NR3C1	1. Progesterone receptor;!2. Androgen receptor;!3. Glucocorticoid receptor
C21H28O3	Not Available	Not Available	328.452	[H][C@@]12CC(=C)[C@](O)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	Not Available	Not Available							CHEMBL2107778	9998301												2055978		Segesterone			Segesterone	Experimental	DB14584	InChI=1S/C21H28O3/c1-12-10-19-18-6-4-14-11-15(23)5-7-16(14)17(18)8-9-20(19,3)21(12,24)13(2)22/h11,16-19,24H,1,4-10H2,2-3H3/t16-,17+,18+,19-,20-,21-/m0/s1	SFLXYFZGKSGFKA-XUDSTZEESA-N			Not Available	Small Molecule																																			1	Yes	3	1	No	4	0	54.37 Å2	37.67 Å3	93.8 m3·mol-1	1	Yes	No	0.0241 mg/mL	3.2	-4.1	12.21	-4			
C24H31ClO7	Loteprednol etabonate was slowly hydrolyzed in liver at clearance rates of 0.21 +/- 0.04 and 2.41 +/- 0.13 ml/h/kg in the liver and plasma, respectively 2.	The terminal half-life of loteprednol etabonate as determined when administered intravenously at a dose of 5 mg/kg in the dog animal model is 2.8 hours 3.	466.96	[H][C@@]12CC[C@](OC(=O)OCC)(C(=O)OCCl)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	The only data available regarding the volume of distribution of loteprednol etabonate (LE) is the volume of distribution the agent demonstrated when administered to dogs - a value of 3.7 L/kg 3. It has been shown, however, that the topical ocular administration of LE distributes preferentially into the cellular components of blood 8.	P08684;!P27169	CYP3A4;!PON1	1. Cytochrome P450 3A4;!2. Serum paraoxonase/arylesterase 1			31784	CHEMBL1200865	392049	Drugs.com Drug Page		HMDB0015011		D01689			PA164764569	9865442	46504713	RxList Drug Page		DAP001045	Loteprednol	ZINC000003920673	Eysuvis, Inveltys, Lotemax	Loteprednol etabonate	Approved	DB14596	InChI=1S/C24H31ClO7/c1-4-30-21(29)32-24(20(28)31-13-25)10-8-17-16-6-5-14-11-15(26)7-9-22(14,2)19(16)18(27)12-23(17,24)3/h7,9,11,16-19,27H,4-6,8,10,12-13H2,1-3H3/t16-,17-,18-,19+,22-,23-,24-/m0/s1	DMKSVUSAATWOCU-HROMYWEYSA-N	4	Loteprednol etabonate is a corticosteroid used to treat allergic conjunctivitis as well as inflammation and pain after ocular surgery.	The most common adverse drug reactions reported during clinical trials for the medication were eye pain and posterior capsular opacification, both of which may also be the consequence of the very surgical procedures performed on the eye(s) Label.The agent is not absorbed systemically following topical ophthalmic administration and maternal use is not expected to result in fetal exposure to the drug Label.The medication is not absorbed systemically by the mother following topical ophthalmic administration, and breastfeeding is not expected to result in exposure of the child to the agent Label.Long-term animal studies have not been conducted to evaluate the carcinogenic potential of loteprednol etabonate. Loteprednol etabonate was not genotoxic in vitro in the Ames test, the mouse lymphoma thymidine kinase (tk) assay, or in a chromosome aberration test in human lymphocytes, or in vivo in the single dose mouse micronucleus assay Label.Overdose is not expected to be likely to occur after ocular administration 8.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.2305 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.4		220-224 °C		5 mg/mL	1	Yes	5	1	Yes	4	0	99.13 Å2	48.43 Å3	118.17 m3·mol-1	7	Yes	No	0.00693 mg/mL	3.94	-4.8	14.88	-2.9	P04150	NR3C1	1. Glucocorticoid receptor
C24H30O6	Not Available	Not Available	414.498	C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3C(=O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O	Not Available	Not Available								92124															ZINC000006066697		Meprednisone acetate	Experimental	DB14625	InChI=1S/C24H30O6/c1-13-9-18-17-6-5-15-10-16(26)7-8-22(15,3)21(17)19(27)11-23(18,4)24(13,29)20(28)12-30-14(2)25/h7-8,10,13,17-18,21,29H,5-6,9,11-12H2,1-4H3/t13-,17-,18-,21+,22-,23-,24-/m0/s1	RZAMUHXEOMZXET-ABQXZQTJSA-N			Not Available	Small Molecule																																			1	Yes	5	1	No	4	0	97.74 Å2	44.17 Å3	111.19 m3·mol-1	4	Yes	No	0.0168 mg/mL	2.46	-4.4	12.46	-3.9			
C23H34O3	Not Available	Not Available	358.522	[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@H](CC[C@]12C)OC(C)=O	Not Available	Not Available						34930	CHEMBL1892286	2005918				C14658										Pregnenolone_acetate	ZINC000003860692		Pregnenolone acetate	Investigational	DB14626	InChI=1S/C23H34O3/c1-14(24)19-7-8-20-18-6-5-16-13-17(26-15(2)25)9-11-22(16,3)21(18)10-12-23(19,20)4/h5,17-21H,6-13H2,1-4H3/t17-,18-,19+,20-,21-,22-,23+/m0/s1	CRRKVZVYZQXICQ-RJJCNJEVSA-N			Not Available	Small Molecule																																			1	Yes	2	0	No	4	0	43.37 Å2	42.51 Å3	102.91 m3·mol-1	3	Yes	No	0.00188 mg/mL	4.02	-5.3	19.4	-6.8			
C21H29O8P	Not Available	The half life of prednisolone is 2-4 hours.6	440.429	[H][C@@]12CC[C@](O)(C(=O)COP(O)(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	The volume of distribution of prednisolone phosphate has been reported as 0.22-0.7L/kg.7	P08684;!P20815;!BE0004866;!P11509;!Q16678;!P20813;!P10632;!P11712;!P33261;!P80365;!P28845	CYP3A4;!CYP3A5;!;!CYP2A6;!CYP1B1;!CYP2B6;!CYP2C8;!CYP2C9;!CYP2C19;!HSD11B2;!HSD11B1	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5;!3. Cytochrome P450 3A Subfamily (Protein Group);!4. Cytochrome P450 2A6;!5. Cytochrome P450 1B1;!6. Cytochrome P450 2B6;!7. Cytochrome P450 2C8;!8. Cytochrome P450 2C9;!9. Cytochrome P450 2C19;!10. Corticosteroid 11-beta-dehydrogenase isozyme 2;!11. Corticosteroid 11-beta-dehydrogenase isozyme 1			145705	CHEMBL1201231	65064														Prednisolone_sodium_phosphate	ZINC000004097473	Orapred, Pediapred	Prednisolone phosphate	Approved, Vet approved	DB14631	InChI=1S/C21H29O8P/c1-19-7-5-13(22)9-12(19)3-4-14-15-6-8-21(25,17(24)11-29-30(26,27)28)20(15,2)10-16(23)18(14)19/h5,7,9,14-16,18,23,25H,3-4,6,8,10-11H2,1-2H3,(H2,26,27,28)/t14-,15-,16-,18+,19-,20-,21-/m0/s1	JDOZJEUDSLGTLU-VWUMJDOOSA-N	3	Prednisolone phosphate is a corticosteroid used to treat inflammation, immune reactions, as well as endocrine or neoplastic conditions.	Data regarding acute overdose is not readily available.6 However, patients experiencing chronic overdose may present with mental symptoms, moon face, abnormal fat deposits, and fluid retention.6 Acute oral overdose may be treated with immediate gastric lavage or emesis followed by symptomatic and supportive treatment.6 Chronic overdosage can be managed by temporary dose reduction or alternate day treatment.6	Small Molecule																																			1	Yes	7	4	No	4	-2	141.36 Å2	43.42 Å3	109.37 m3·mol-1	4	Yes	No	0.432 mg/mL	1.15	-3	1.18	-2.9	P04150;!P04083	NR3C1;!ANXA1	1. Glucocorticoid receptor;!2. Annexin A1
C27H38O6	Not Available	Not Available	458.587	[H][C@@]12CC[C@](O)(C(=O)COC(=O)CC(C)(C)C)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Not Available	Not Available						8381	CHEMBL1200909	84007				C08182	D00982				93055					Prednisolone_tebutate	ZINC000004097474		Prednisolone tebutate	Approved, Vet approved	DB14632	InChI=1S/C27H38O6/c1-24(2,3)14-22(31)33-15-21(30)27(32)11-9-19-18-7-6-16-12-17(28)8-10-25(16,4)23(18)20(29)13-26(19,27)5/h8,10,12,18-20,23,29,32H,6-7,9,11,13-15H2,1-5H3/t18-,19-,20-,23+,25-,26-,27-/m0/s1	HUMXXHTVHHLNRO-KAJVQRHHSA-N			Not Available	Small Molecule																																			1	No	5	2	Yes	4	0	100.9 Å2	51.06 Å3	125.9 m3·mol-1	6	Yes	No	0.00929 mg/mL	3.45	-4.7	12.61	-2.9			
C25H32O8	Not Available	Not Available	460.523	[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Not Available	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5			135745	CHEMBL485659	571099														Prednisolone	ZINC000003881478		Prednisolone hemisuccinate	Experimental	DB14633	InChI=1S/C25H32O8/c1-23-9-7-15(26)11-14(23)3-4-16-17-8-10-25(32,24(17,2)12-18(27)22(16)23)19(28)13-33-21(31)6-5-20(29)30/h7,9,11,16-18,22,27,32H,3-6,8,10,12-13H2,1-2H3,(H,29,30)/t16-,17-,18-,22+,23-,24-,25-/m0/s1	APGDTXUMTIZLCJ-CGVGKPPMSA-N		Prednisolone hemisuccinate is a corticosteroid indicated in the treatment of anaphylaxis, asthma, edema, organ rejection, and other indications.	Not Available	Small Molecule																																			1	Yes	7	3	Yes	4	-1	138.2 Å2	47.52 Å3	118.54 m3·mol-1	7	Yes	No	0.0483 mg/mL	1.54	-4	3.66	-2.9			
C23H29FO6	Not Available	Not Available	420.477	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4					91954															ZINC000005161248		Fluprednisolone acetate	Experimental	DB14637	InChI=1S/C23H29FO6/c1-12(25)30-11-19(28)23(29)7-5-15-14-9-17(24)16-8-13(26)4-6-21(16,2)20(14)18(27)10-22(15,23)3/h4,6,8,14-15,17-18,20,27,29H,5,7,9-11H2,1-3H3/t14-,15-,17-,18-,20+,21-,22-,23-/m0/s1	CYMBAKFTWRNHPS-APRQOCPKSA-N			Not Available	Small Molecule																																			1	Yes	5	2	No	4	0	100.9 Å2	42.94 Å3	107.47 m3·mol-1	4	Yes	No	0.0414 mg/mL	1.37	-4	12.61	-2.9			
C30H44O3	Not Available	14 days	452.679	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2OC(=O)CCCCCCCCC=C	Not Available	Not Available							CHEMBL2106059	10128605														Boldenone_undecylenate	ZINC000004215044		Boldenone undecylenate	Illicit, Vet approved	DB14639	InChI=1S/C30H44O3/c1-4-5-6-7-8-9-10-11-12-28(32)33-27-16-15-25-24-14-13-22-21-23(31)17-19-29(22,2)26(24)18-20-30(25,27)3/h4,17,19,21,24-27H,1,5-16,18,20H2,2-3H3/t24-,25-,26-,27-,29-,30-/m0/s1	AHMMSNQYOPMLSX-CNQKSJKFSA-N			Not Available	Small Molecule																																			0	No	2	0	Yes	4	0	43.37 Å2	56.18 Å3	136.15 m3·mol-1	11	No	No	5.54e-05 mg/mL	7.76	-6.9	18.39	-5	P10275	AR	1. Androgen receptor
C27H36O6	Not Available	Not Available	456.5711	[H][C@]1(C[C@@]2([H])[C@]3([H])CCC4=CC(OC(=O)CC)=CC=C4[C@@]3([H])CC[C@]2(C)[C@@]1([H])OC(=O)CC)OC(=O)CC	Not Available	Not Available							CHEMBL3559901	92362									102232					Estriol_tripropionate	ZINC000030690586		Estriol tripropionate	Experimental	DB14641	InChI=1S/C27H36O6/c1-5-23(28)31-17-9-11-18-16(14-17)8-10-20-19(18)12-13-27(4)21(20)15-22(32-24(29)6-2)26(27)33-25(30)7-3/h9,11,14,19-22,26H,5-8,10,12-13,15H2,1-4H3/t19-,20-,21+,22-,26+,27+/m1/s1	ONMZMZJEZHMWQL-REUUDLSRSA-N			ORAL (LD50): Acute: >2000 mg/kg [Rat].	Small Molecule																																			1	Yes	3	0	Yes	4	0	78.9 Å2	52.33 Å3	122.6 m3·mol-1	9	No	No	0.000438 mg/mL	5.57	-6		-6.6	P03372;!Q92731;!P04278	ESR1;!ESR2;!SHBG	1. Estrogen receptor alpha;!2. Estrogen receptor beta;!3. Sex hormone-binding globulin
C27H36O7	Not Available	Not Available	472.578	[H][C@@]12CC[C@](OC(=O)CC)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C	Not Available	Not Available						135762	CHEMBL1697782	56717														Methylprednisolone_aceponate	ZINC000004213828		Methylprednisolone aceponate	Approved, Vet approved	DB14643	InChI=1S/C27H36O7/c1-6-23(32)34-27(22(31)14-33-16(3)28)10-8-19-18-11-15(2)20-12-17(29)7-9-25(20,4)24(18)21(30)13-26(19,27)5/h7,9,12,15,18-19,21,24,30H,6,8,10-11,13-14H2,1-5H3/t15-,18-,19-,21-,24+,25-,26-,27-/m0/s1	DALKLAYLIPSCQL-YPYQNWSCSA-N	4	Methylprednisolone aceponate is a corticosteroid indicated in the treatment of corticosteroid-responsive dermatoses.	Not Available	Small Molecule																																			1	Yes	5	1	Yes	4	0	106.97 Å2	50.86 Å3	125.97 m3·mol-1	7	Yes	No	0.00637 mg/mL	3.14	-4.9	14.8	-2.9			
C26H34O8	Not Available	Not Available	474.55	[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C	Not Available	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5			135765	CHEMBL1201265	16034														Methylprednisolone	ZINC000003977781	Solu-medrol	Methylprednisolone hemisuccinate	Approved	DB14644	InChI=1S/C26H34O8/c1-14-10-16-17-7-9-26(33,20(29)13-34-22(32)5-4-21(30)31)25(17,3)12-19(28)23(16)24(2)8-6-15(27)11-18(14)24/h6,8,11,14,16-17,19,23,28,33H,4-5,7,9-10,12-13H2,1-3H3,(H,30,31)/t14-,16-,17-,19-,23+,24-,25-,26-/m0/s1	IMBXEJJVJRTNOW-XYMSELFBSA-N	4	Methylprednisolone hemisuccinate is a water soluble corticosteroid used to treat severe allergic reactions, dermatologic diseases, endocrine disorders, gastrointestinal diseases, hematological disorders, neoplastic diseases, nervous system conditions, ophthalmic diseases, renal diseases, respiratory diseases, and rheumatic disorders.	Not Available	Small Molecule																																			1	Yes	7	3	Yes	4	-1	138.2 Å2	49.87 Å3	123.09 m3·mol-1	7	Yes	No	0.0264 mg/mL	1.83	-4.2	3.66	-2.9			
C23H28O6	Not Available	Not Available	400.471	[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Not Available	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5			34655	CHEMBL1507567	82567				C14668	D08416										ZINC000003881638		Prednisone acetate	Approved, Experimental, Investigational	DB14646	InChI=1S/C23H28O6/c1-13(24)29-12-19(27)23(28)9-7-17-16-5-4-14-10-15(25)6-8-21(14,2)20(16)18(26)11-22(17,23)3/h6,8,10,16-17,20,28H,4-5,7,9,11-12H2,1-3H3/t16-,17-,20+,21-,22-,23-/m0/s1	MOVRKLZUVNCBIP-RFZYENFJSA-N	4		Not Available	Small Molecule																																			1	Yes	5	1	No	4	0	97.74 Å2	42.51 Å3	106.72 m3·mol-1	4	Yes	No	0.0235 mg/mL	2.1	-4.2	12.6	-3.8			
C27H40O6	Not Available	Not Available	460.611	CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@H](CC(=O)O3)OC(C)=O)[C@@H]12	Not Available	Not Available								9987219															ZINC000036454924		Acetyl simvastatin	Experimental	DB14648	InChI=1S/C27H40O6/c1-7-27(5,6)26(30)33-23-13-16(2)12-19-9-8-17(3)22(25(19)23)11-10-20-14-21(31-18(4)28)15-24(29)32-20/h8-9,12,16-17,20-23,25H,7,10-11,13-15H2,1-6H3/t16-,17-,20+,21+,22-,23-,25-/m0/s1	OHVWRJDVJRNCPE-BIKFJBPRSA-N			Not Available	Small Molecule																																			1	No	3	0	Yes	3	0	78.9 Å2	50.83 Å3	126.83 m3·mol-1	9	Yes	No	0.0021 mg/mL	4.9	-5.3		-6.6			
C23H36O3	Not Available	Not Available	360.538	[H][C@@]12CC[C@H](OC(=O)CC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)[C@H](C)C[C@]12C	Not Available	Not Available						31523	CHEMBL1201048	194604					D01534			PA164760855						Drostanolone_propionate	ZINC000004213057		Drostanolone propionate	Approved, Illicit	DB14655	InChI=1S/C23H36O3/c1-5-21(25)26-20-9-8-17-16-7-6-15-12-19(24)14(2)13-23(15,4)18(16)10-11-22(17,20)3/h14-18,20H,5-13H2,1-4H3/t14-,15+,16+,17+,18+,20+,22+,23+/m1/s1	NOTIQUSPUUHHEH-UXOVVSIBSA-N			Side effects include virilization (masculine traits in women), acne, fluid retention, and hypercalcemia.	Small Molecule																																			1	Yes	2	0	No	4	0	43.37 Å2	43.19 Å3	101.96 m3·mol-1	3	No	No	0.000631 mg/mL	5.1	-5.8		-6.9			
C20H24O3	Not Available	Not Available	312.409	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)CCC4=C3C=C[C@]12C)OC(C)=O	Not Available	Not Available					50190646		CHEMBL1698011	59737														Trenbolone_acetate	ZINC000004083873		Trenbolone acetate	Vet approved	DB14660	InChI=1S/C20H24O3/c1-12(21)23-19-8-7-18-17-5-3-13-11-14(22)4-6-15(13)16(17)9-10-20(18,19)2/h9-11,17-19H,3-8H2,1-2H3/t17-,18+,19+,20+/m1/s1	CMRJPMODSSEAPL-FYQPLNBISA-N			Not Available	Small Molecule																																			1	Yes	2	0	No	4	0	43.37 Å2	35.53 Å3	90.81 m3·mol-1	2	Yes	No	0.00758 mg/mL	2.7	-4.6	18.4	-4.8			
C27H36F2O5	Not Available	Not Available	478.577	[H][C@@]12C[C@@H](C)[C@H](C(=O)COC(=O)C(C)(C)C)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C	Not Available	Not Available							CHEMBL2106277	59756																	Difluocortolone pivalate	Experimental	DB14664	InChI=1S/C27H36F2O5/c1-14-9-16-17-11-19(28)18-10-15(30)7-8-26(18,6)27(17,29)21(32)12-25(16,5)22(14)20(31)13-34-23(33)24(2,3)4/h7-8,10,14,16-17,19,21-22,32H,9,11-13H2,1-6H3/t14-,16+,17+,19+,21+,22-,25+,26+,27+/m1/s1	UWGRWFCLGQWKPR-GSTUPEFVSA-N			Not Available	Small Molecule																																			1	Yes	4	1	No	4	0	80.67 Å2	50.61 Å3	123.85 m3·mol-1	5	Yes	No	0.00492 mg/mL	4.25	-5	13.61	-3.4			
C26H38O4	Not Available	Not Available	414.586	[H][C@@]12CC[C@](OC(=O)CCCCC)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	Not Available	Not Available						31650	CHEMBL2107389	391969												4791		Gestonorone_caproate	ZINC000004216396		Gestonorone caproate	Approved	DB14677	InChI=1S/C26H38O4/c1-4-5-6-7-24(29)30-26(17(2)27)15-13-23-22-10-8-18-16-19(28)9-11-20(18)21(22)12-14-25(23,26)3/h16,20-23H,4-15H2,1-3H3/t20-,21+,22+,23-,25-,26-/m0/s1	XURCMZMFZXXQDJ-UKNJCJGYSA-N			Not Available	Small Molecule																																			1	Yes	3	0	Yes	4	0	60.44 Å2	48.55 Å3	117.21 m3·mol-1	7	No	No	0.00141 mg/mL	5.58	-5.5	17.69	-4.7			
C27H38O3	Not Available	Not Available	410.598	[H][C@@]12CC[C@@](OC(=O)CCCCCC)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			34894	CHEMBL3187229	199613				C14486								31984		Norethisterone_enanthate	ZINC000004217172		Norethindrone enanthate	Experimental	DB14678	InChI=1S/C27H38O3/c1-4-6-7-8-9-25(29)30-27(5-2)17-15-24-23-12-10-19-18-20(28)11-13-21(19)22(23)14-16-26(24,27)3/h2,18,21-24H,4,6-17H2,1,3H3/t21-,22+,23+,24-,26-,27-/m0/s1	APTGJECXMIKIET-WOSSHHRXSA-N	4	Norethindrone enanthate is a synthetic progestogen indicated for contraceptive therapy.	Not Available	Small Molecule																																			1	No	2	0	Yes	4	0	43.37 Å2	49.66 Å3	119.61 m3·mol-1	7	No	No	0.00148 mg/mL	6.14	-5.4	18.25	-4.7			
C25H40O6	Not Available	Not Available	436.5815	[H][C@@](O)(CC[C@@]1([H])[C@@H](C)C=CC2=C[C@H](C)C[C@H](OC(=O)C(C)(C)CC)[C@]12[H])C[C@@H](O)CC(O)=O	Not Available	Not Available					18375		CHEMBL1201391	58263			HMDB0061047			SIM									ZINC000003833877		Tenivastatin	Experimental	DB14714	InChI=1S/C25H40O6/c1-6-25(4,5)24(30)31-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-18(26)13-19(27)14-22(28)29/h7-8,11,15-16,18-21,23,26-27H,6,9-10,12-14H2,1-5H3,(H,28,29)/t15-,16-,18+,19+,20-,21-,23-/m0/s1	XWLXKKNPFMNSFA-HGQWONQESA-N			Not Available	Small Molecule																																			1	No	5	3	No	2	-1	104.06 Å2	49.23 Å3	121.18 m3·mol-1	11	Yes	No	0.0402 mg/mL	3.79	-4	4.21	-2.7			
C39H68N2O8	Not Available	Not Available	692.979	CO[C@@]1(C[C@H](O)[C@@H](NC(C)=O)[C@@H](O1)[C@H](O)[C@H](O)CO)C(=O)N[C@@H]1CC[C@@]2(C)[C@@H](CC[C@H]3[C@@H]4CC[C@H]([C@H](C)CCCC(C)C)[C@@]4(C)CC[C@H]23)C1	Not Available	Not Available							CHEMBL2105634	28529003															ZINC000085540178		Coleneuramide	Investigational	DB14932	InChI=1S/C39H68N2O8/c1-22(2)9-8-10-23(3)28-13-14-29-27-12-11-25-19-26(15-17-37(25,5)30(27)16-18-38(28,29)6)41-36(47)39(48-7)20-31(44)33(40-24(4)43)35(49-39)34(46)32(45)21-42/h22-23,25-35,42,44-46H,8-21H2,1-7H3,(H,40,43)(H,41,47)/t23-,25+,26-,27+,28-,29+,30+,31+,32-,33-,34-,35-,37+,38-,39-/m1/s1	CHMRTBYTCBDIRG-JQZMMWJVSA-N	2		Not Available	Small Molecule																																			0	No	8	6	Yes	5	0	157.58 Å2	81.47 Å3	186.76 m3·mol-1	12	No	No	0.00153 mg/mL	4.53	-5.7	12.63	-1.3			
C35H48Cl5NO4	Not Available	Not Available	724.02	COC1=C(Cl)C(OC(=O)O[C@H]2CC[C@]3(C)[C@H]4CC[C@]5(C)[C@H](CC[C@H]5[C@@H]4CC=C3C2)[C@H](C)CCCC(C)C)=C(Cl)C(=N1)C(Cl)(Cl)Cl	Not Available	Not Available								17283754																	4-demethyl-4-cholesteryloxycarbonylpenclomedine	Investigational	DB15075	InChI=1S/C35H48Cl5NO4/c1-19(2)8-7-9-20(3)24-12-13-25-23-11-10-21-18-22(14-16-33(21,4)26(23)15-17-34(24,25)5)44-32(42)45-29-27(36)30(35(38,39)40)41-31(43-6)28(29)37/h10,19-20,22-26H,7-9,11-18H2,1-6H3/t20-,22+,23+,24-,25+,26+,33+,34-/m1/s1	ZJUUIXYKTPSIOH-LEZJFEBPSA-N	2		Not Available	Small Molecule																																			0	No	4	0	Yes	5	0	57.65 Å2	78.79 Å3	185.5 m3·mol-1	11	No	No	1.26e-06 mg/mL	12.14	-8.8		-1.2			
C25H29FO5	Not Available	Not Available	427.503	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1C[C@H]1O[C@H](O[C@@]21C(=O)C[18F])C1=CC=CO1	Not Available	Not Available								58828602																	Fluorofuranylnorprogesterone F-18	Investigational	DB15282	InChI=1S/C25H29FO5/c1-24-9-8-17-16-7-5-15(27)11-14(16)4-6-18(17)19(24)12-22-25(24,21(28)13-26)31-23(30-22)20-3-2-10-29-20/h2-3,10-11,16-19,22-23H,4-9,12-13H2,1H3/t16-,17+,18+,19-,22+,23+,24-,25+/m0/s1/i26-1	VJKRBRUNEOHPBS-JQKUZGBFSA-N	2		Not Available	Small Molecule																																			1	Yes	4	0	No	6	0	65.74 Å2	45.2 Å3	110.28 m3·mol-1	3	Yes	No	0.0251 mg/mL	4.33	-4.2	14.61	-2.9			
C57H86N2O14	Not Available	Not Available	1023.315	CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)/[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)[C@@H]3CC[C@@H](ON3C3=CC=CC=C3)\C=C(C)/[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O	Not Available	Not Available								75531297																	ILS-920	Investigational	DB15422	InChI=1S/C57H86N2O14/c1-33-26-37(5)51(62)53(70-10)52(63)38(6)27-34(2)47(61)32-49(35(3)28-40-20-24-46(60)50(30-40)69-9)71-56(66)45-18-14-15-25-58(45)55(65)54(64)57(67)39(7)19-21-42(72-57)31-48(68-8)36(4)29-43-22-23-44(33)59(73-43)41-16-12-11-13-17-41/h11-13,16-17,27,29,33-35,37,39-40,42-46,48-50,52-53,60,63,67H,14-15,18-26,28,30-32H2,1-10H3/b36-29-,38-27-/t33-,34+,35+,37+,39+,40-,42-,43+,44-,45-,46+,48-,49-,50+,52+,53-,57+/m0/s1	WZFNBQBUDJACCD-AYNOCWQQSA-N	1		Not Available	Small Molecule																																			0	No	14	3	Yes	6	0	207.9 Å2	111.78 Å3	286.35 m3·mol-1	7	No	No	0.00237 mg/mL	8.76	-5.6	9.96	-1.2			
C55H87NO14	Not Available	Not Available	986.294	[H][C@@]12CC[C@@H](C)[C@@](O)(O1)C(=O)C(=O)N1CCCC[C@@]1([H])C(=O)O[C@@]([H])(CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C2)OC)[C@H](C)C[C@@H]1CC[C@@H](OCCOCC)[C@@H](C1)OC	Not Available	Not Available							CHEMBL2107380	24582455												1942479		Umirolimus	ZINC000169677041		Umirolimus	Experimental	DB15527	InChI=1S/C55H87NO14/c1-12-67-26-27-68-45-24-22-41(31-48(45)65-10)30-37(5)47-33-44(57)36(4)29-39(7)50(59)51(66-11)49(58)38(6)28-34(2)18-14-13-15-19-35(3)46(64-9)32-42-23-21-40(8)55(63,70-42)52(60)53(61)56-25-17-16-20-43(56)54(62)69-47/h13-15,18-19,29,34,36-38,40-43,45-48,50-51,59,63H,12,16-17,20-28,30-33H2,1-11H3/b15-13+,18-14+,35-19+,39-29+/t34-,36-,37-,38-,40-,41+,42+,43+,45-,46+,47+,48-,50-,51+,55-/m1/s1	YYSFXUWWPNHNAZ-PKJQJFMNSA-N			Not Available	Small Molecule																																			0	No	13	2	Yes	4	0	193.66 Å2	110.83 Å3	271.21 m3·mol-1	11	No	No	0.000763 mg/mL	8.4	-6.1	9.96	-3			
C28H46O3	Not Available	Not Available	430.673	[H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C)[C@H](C)CCCCC(C)(C)O	Not Available	Not Available								7826421												1423458			ZINC000038791777		24-Homo-1,25-dihydroxyvitamin D3	Experimental	DB15557	InChI=1S/C28H46O3/c1-19(9-6-7-15-27(3,4)31)24-13-14-25-21(10-8-16-28(24,25)5)11-12-22-17-23(29)18-26(30)20(22)2/h11-12,19,23-26,29-31H,2,6-10,13-18H2,1,3-5H3/b21-11+,22-12-/t19-,23-,24-,25+,26+,28-/m1/s1	WKTIGYIYJKESCJ-JJWMBMNSSA-N			Not Available	Small Molecule																																			1	No	3	3	Yes	3	0	60.69 Å2	53.36 Å3	131.13 m3·mol-1	7	Yes	No	0.00475 mg/mL	4.8	-5	14.39	-1.3			
C23H30O6	Data regarding the clearance of prednisolone acetate is not readily available.6,7,8	Oral prednisolone acetate has a plasma half life of 2-3 hours.5	402.4807	[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@]([H])(O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	The volume of distribution of the active metabolite, prednisolone, is 0.22/0.7L/kg.5	P08684	CYP3A4	1. Cytochrome P450 3A4			8380	CHEMBL1152	5629				C08180					5834					Prednisolone_acetate	ZINC000003875348	Blephamide, Econopred Plus, Flo-pred, Pred Forte, Pred Mild, Pred-G	Prednisolone acetate	Approved, Vet approved	DB15566	InChI=1S/C23H30O6/c1-13(24)29-12-19(27)23(28)9-7-17-16-5-4-14-10-15(25)6-8-21(14,2)20(16)18(26)11-22(17,23)3/h6,8,10,16-18,20,26,28H,4-5,7,9,11-12H2,1-3H3/t16-,17-,18-,20+,21-,22-,23-/m0/s1	LRJOMUJRLNCICJ-JZYPGELDSA-N	4	Prednisolone acetate is a glucocorticoid used to treat a wide variety of endocrine, inflammatory, and immune conditions as well as for palliation of neoplastic conditions.	The oral LD50 of prednisolone acetate in mice is 1680 mg/kg.8 Patients experiencing an overdose of oral prednisolone acetate may experience an increased severity in the adverse effects of corticosteroids.5 Overdose of oral prednisolone acetate may be treated by gastric lavage or inducing vomiting if the overdose was recent, as well as supportive and symptomatic therapy.5 Chronic overdosage may be treated by dose reduction or treating patients on alternate days.5 An overdose by the ophthalmic route is not expected to cause problems.5	Small Molecule																														1.332		238			1	Yes	5	2	No	4	0	100.9 Å2	42.93 Å3	107.64 m3·mol-1	4	Yes	No	0.0417 mg/mL	1.71	-4	12.61	-2.9	P04150	NR3C1	1. Glucocorticoid receptor
C27H44O	Not Available	Not Available	384.648	[H][C@@]1(CC[C@@]2([H])C(\C=C/C3=C(C)CC[C@H](O)C3)=CCC[C@]12C)[C@H](C)CCCC(C)C	Not Available	Not Available						8403		4444516				C07711											ZINC000016343334		Previtamin D(3)	Experimental	DB15614	InChI=1S/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h10,12-13,19,21,24-26,28H,6-9,11,14-18H2,1-5H3/b13-12-/t21-,24+,25-,26+,27-/m1/s1	YUGCAAVRZWBXEQ-WHTXLNIXSA-N			Not Available	Small Molecule																																			1	No	1	1	Yes	3	0	20.23 Å2	49.02 Å3	124.3 m3·mol-1	7	No	Yes	0.000374 mg/mL	7.07	-6	18.31	-1.3			
C27H37FO5	Not Available	Not Available	460.586	[H][C@@]12C[C@@H](C)[C@H](C(=O)COC(=O)C(C)(C)C)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C	Not Available	Not Available								107027												4465			ZINC000030691645		Fluocortolone pivalate	Experimental	DB15777	InChI=1S/C27H37FO5/c1-14-9-17-16-11-19(28)18-10-15(29)7-8-26(18,5)23(16)20(30)12-27(17,6)22(14)21(31)13-33-24(32)25(2,3)4/h7-8,10,14,16-17,19-20,22-23,30H,9,11-13H2,1-6H3/t14-,16+,17+,19+,20+,22-,23-,26+,27+/m1/s1	XZBJVIQXJHGUBE-HZMVJJPJSA-N		Fluocortolone pivalate is a corticosteroid used to treat corticosteroid-responsive dermatoses and hemorrhoids.	Not Available	Small Molecule																																			1	Yes	4	1	No	4	0	80.67 Å2	50.5 Å3	124.32 m3·mol-1	5	Yes	No	0.0022 mg/mL	4.21	-5.3	15.15	-0.23			
C28H39FO5	Not Available	Not Available	474.613	[H][C@@]12C[C@@H](C)[C@H](C(=O)COC(=O)CCCCC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C	Not Available	Not Available							CHEMBL2107415	16735815												4464			ZINC000004213356		Fluocortolone caproate	Experimental	DB15821	InChI=1S/C28H39FO5/c1-5-6-7-8-24(33)34-15-23(32)25-16(2)11-19-18-13-21(29)20-12-17(30)9-10-27(20,3)26(18)22(31)14-28(19,25)4/h9-10,12,16,18-19,21-22,25-26,31H,5-8,11,13-15H2,1-4H3/t16-,18+,19+,21+,22+,25-,26-,27+,28+/m1/s1	WHZRCUIISKRTJL-YTZKRAOUSA-N		Fluocortolone caproate is a corticosteroid indicated in the treatment of hemorrhoids, anal fissures, and corticosteroid-responsive dermatoses.	Not Available	Small Molecule																																			1	No	4	1	Yes	4	0	80.67 Å2	52.93 Å3	129.05 m3·mol-1	8	Yes	No	0.0017 mg/mL	4.44	-5.4	15.15	-0.23			
C27H42O4	Not Available	Not Available	430.629	[H][C@]12C[C@@]3([H])[C@]4([H])CC=C5C[C@@H](O)C[C@@H](O)[C@]5(C)[C@@]4([H])CC[C@]3(C)[C@@]1([H])[C@H](C)[C@@]1(CC[C@@H](C)CO1)O2	Not Available	Not Available						8913	CHEMBL1169820	390469				C08909	D08498							35890			ZINC000008234225		Ruscogenin	Experimental	DB15830	InChI=1S/C27H42O4/c1-15-7-10-27(30-14-15)16(2)24-22(31-27)13-21-19-6-5-17-11-18(28)12-23(29)26(17,4)20(19)8-9-25(21,24)3/h5,15-16,18-24,28-29H,6-14H2,1-4H3/t15-,16+,18-,19-,20+,21+,22+,23-,24+,25+,26+,27-/m1/s1	QMQIQBOGXYYATH-IDABPMKMSA-N		Ruscogenin is an anti-inflammatory steroid used in combination with local anesthetics for the treatment of hemorrhoids and for local anesthesia.	Not Available	Small Molecule																																			1	No	4	2	No	6	0	58.92 Å2	51.73 Å3	121.74 m3·mol-1	0	Yes	No	0.00821 mg/mL	3.62	-4.7	14.45	-2.8			
C24H31Na2O9P	Not Available	Not Available	540.456	[Na+].[Na+].[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)COP([O-])([O-])=O	Not Available	Not Available								34996341																	Desonide sodium phosphate	Experimental	DB15835	InChI=1S/C24H33O9P.2Na/c1-21(2)32-19-10-16-15-6-5-13-9-14(25)7-8-22(13,3)20(15)17(26)11-23(16,4)24(19,33-21)18(27)12-31-34(28,29)30;;/h7-9,15-17,19-20,26H,5-6,10-12H2,1-4H3,(H2,28,29,30);;/q;2*+1/p-2/t15-,16-,17-,19+,20+,22-,23-,24+;;/m0../s1	IHTZFPUWMRSEMG-PXQDNWDYSA-L		Desonide sodium phosphate is a medication indicated in the treatment of external eye inflammation.	Not Available	Small Molecule																																			1	No	8	1	No	5	-2	145.25 Å2	48.69 Å3	120.69 m3·mol-1	4	No	No	0.958 mg/mL	1.78	-2.8	1.17	-2.9			
C21H25ClO5	Not Available	Not Available	392.88	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])C[C@H](Cl)C2=CC(=O)C=C[C@]12C	Not Available	Not Available						135618		2298578														Chloroprednisone	ZINC000033650036		Chloroprednisone	Experimental	DB15970	InChI=1S/C21H25ClO5/c1-19-5-3-11(24)7-14(19)15(22)8-12-13-4-6-21(27,17(26)10-23)20(13,2)9-16(25)18(12)19/h3,5,7,12-13,15,18,23,27H,4,6,8-10H2,1-2H3/t12-,13-,15-,18+,19-,20-,21-/m0/s1	NPSLCOWKFFNQKK-ZPSUVKRCSA-N			Not Available	Small Molecule																																			1	Yes	5	2	No	4	0	91.67 Å2	40.51 Å3	102.13 m3·mol-1	2	Yes	No	0.0395 mg/mL	1.78	-4	12.58	-3.3			
C45H73NO16	Not Available	Not Available	884.07	[H][C@@]1(O[C@H]2[C@@H](CC=O)C[C@@H](C)[C@@H](OC(=O)CC)\C=C\C=C\C[C@@H](C)OC(=O)C[C@@H](OC(C)=O)[C@@H]2OC)O[C@H](C)[C@@]([H])(O[C@H]2C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C	Not Available	Not Available							CHEMBL3251862	30791857												28069			ZINC000169320743		Josamycin propionate	Experimental	DB15981	InChI=1S/C45H73NO16/c1-13-34(49)59-32-18-16-14-15-17-27(5)55-36(51)23-33(58-30(8)48)42(54-12)41(31(19-20-47)22-26(32)4)62-44-39(52)38(46(10)11)40(28(6)57-44)61-37-24-45(9,53)43(29(7)56-37)60-35(50)21-25(2)3/h14-16,18,20,25-29,31-33,37-44,52-53H,13,17,19,21-24H2,1-12H3/b15-14+,18-16+/t26-,27-,28-,29+,31+,32+,33-,37+,38-,39-,40-,41+,42+,43+,44+,45-/m1/s1	NVBREHSOJSEKBQ-ZQMZUEOGSA-N			Not Available	Small Molecule																																			0	No	13	2	Yes	3	1	212.12 Å2	95.19 Å3	224.81 m3·mol-1	17	No	No	0.0238 mg/mL	4.36	-4.6	12.71	8.51			
C14H26O3	Not Available	Not Available	242.359	CCOCC(=O)O[C@@H]1C[C@H](C)CC[C@H]1C(C)C	Not Available	Not Available							CHEMBL3989469	62157															ZINC000004213769		Menglytate	Experimental	DB15983	InChI=1S/C14H26O3/c1-5-16-9-14(15)17-13-8-11(4)6-7-12(13)10(2)3/h10-13H,5-9H2,1-4H3/t11-,12+,13-/m1/s1	DXGZIMYAPNIRHS-FRRDWIJNSA-N		Menglytate is an ingredient in products used to treat a cough and throat irritation.	Not Available	Small Molecule																																			1	Yes	2	0	No	1	0	35.53 Å2	28.47 Å3	67.8 m3·mol-1	6	Yes	Yes	0.045 mg/mL	3.29	-3.7		-4.2			
C21H29ClO3	Not Available	Not Available	364.91	[H][C@@]12CC[C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=C(Cl)C(=O)CC[C@]12C	Not Available	Not Available						81712	CHEMBL519327	12762				C18374								236522		Clostebol_acetate	ZINC000003881980		Clostebol acetate	Experimental	DB15984	InChI=1S/C21H29ClO3/c1-12(23)25-18-7-6-14-13-4-5-16-19(22)17(24)9-11-20(16,2)15(13)8-10-21(14,18)3/h13-15,18H,4-11H2,1-3H3/t13-,14-,15-,18-,20+,21-/m0/s1	XYGMEFJSKQEBTO-KUJXMBTLSA-N		Clostebol acetate is a steroid combined with neomycin in topical formulations for the treatment of minor skin wounds.	Not Available	Small Molecule																																			1	Yes	2	0	No	4	0	43.37 Å2	40.68 Å3	98.37 m3·mol-1	2	Yes	No	0.00309 mg/mL	4.2	-5.1		-6.2			
C27H38O6	Not Available	Not Available	458.595	[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCCCC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Not Available	Not Available								136723																	Prednisolone caproate	Experimental	DB15999	InChI=1S/C27H38O6/c1-4-5-6-7-23(31)33-16-22(30)27(32)13-11-20-19-9-8-17-14-18(28)10-12-25(17,2)24(19)21(29)15-26(20,27)3/h10,12,14,19-21,24,29,32H,4-9,11,13,15-16H2,1-3H3/t19-,20-,21-,24+,25-,26-,27-/m0/s1	DNSAKUGJOSFARZ-FOMYWIRZSA-N		Prednisolone caproate is a corticosteroid indicated to treat hemorrhoids, anal fissures, and proctitis.	Not Available	Small Molecule																																			1	No	5	2	Yes	4	0	100.9 Å2	51.73 Å3	126.07 m3·mol-1	8	Yes	No	0.0065 mg/mL	3.75	-4.8	12.61	-2.9			
C29H46O3	Not Available	Not Available	442.684	[H][C@@]12CC[C@H](OC(=O)CCCCCCCCC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Not Available	Not Available						35000	CHEMBL1473654	136680				C14607								37858		Testosterone_decanoate	ZINC000019685816		Testosterone decanoate	Experimental	DB16001	InChI=1S/C29H46O3/c1-4-5-6-7-8-9-10-11-27(31)32-26-15-14-24-23-13-12-21-20-22(30)16-18-28(21,2)25(23)17-19-29(24,26)3/h20,23-26H,4-19H2,1-3H3/t23-,24-,25-,26-,28-,29-/m0/s1	LBERVHLCXUMDOT-MPZZESAYSA-N		Testosterone decanoate is a steroid indicated for testosterone replacement therapy in sterilization, missing testicle, hypopituitarism, and osteoporosis.	Not Available	Small Molecule																																			1	No	2	0	Yes	4	0	43.37 Å2	54.86 Å3	130.42 m3·mol-1	10	No	No	0.000114 mg/mL	7.62	-6.6	18.52	-4.8			
C25H38O3	Not Available	Not Available	386.576	[H][C@@]12CC[C@H](OC(=O)CCC(C)C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Not Available	Not Available					50103618	35001	CHEMBL3189011	201317				C14663								75806		Testosterone_isocaproate	ZINC000004538407		Testosterone isocaproate	Experimental	DB16002	InChI=1S/C25H38O3/c1-16(2)5-10-23(27)28-22-9-8-20-19-7-6-17-15-18(26)11-13-24(17,3)21(19)12-14-25(20,22)4/h15-16,19-22H,5-14H2,1-4H3/t19-,20-,21-,22-,24-,25-/m0/s1	PPYHLSBUTAPNGT-BKWLFHPQSA-N		Testosterone isocaproate is a steroid indicated for testosterone replacement therapy in sterilization, missing testicle, hypopituitarism, and osteoporosis.	Not Available	Small Molecule																																			1	No	2	0	No	4	0	43.37 Å2	46.61 Å3	111.96 m3·mol-1	5	No	No	0.000955 mg/mL	5.68	-5.6	18.52	-4.8			
C28H36O3	Not Available	Not Available	420.593	[H][C@@]12CC[C@H](OC(=O)CCC3=CC=CC=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Not Available	Not Available						35002	CHEMBL2356993	14062				C14667								37855		Testosterone_phenylpropionate	ZINC000003881605		Testosterone phenylpropionate	Experimental	DB16003	InChI=1S/C28H36O3/c1-27-16-14-21(29)18-20(27)9-10-22-23-11-12-25(28(23,2)17-15-24(22)27)31-26(30)13-8-19-6-4-3-5-7-19/h3-7,18,22-25H,8-17H2,1-2H3/t22-,23-,24-,25-,27-,28-/m0/s1	HHSXYDOROIURIP-FEZCWRLCSA-N		Testosterone phenylpropionate is a steroid indicated for testosterone replacement therapy in sterilization, missing testicle, hypopituitarism, and osteoporosis.	Not Available	Small Molecule																																			1	No	2	0	No	5	0	43.37 Å2	49.36 Å3	122.9 m3·mol-1	5	No	No	0.000283 mg/mL	6.09	-6.2	18.52	-4.8			
C26H42N2O6	Not Available	Not Available	478.63	[H][C@@]1([C@H](OC)[C@@H](CC[C@]11CO1)OC(=O)N1CC(CCN2CCOCC2)C1)[C@@]1(C)O[C@@H]1CC=C(C)C	Not Available	Not Available							CHEMBL4297651	81368488																	Aclimostat	Investigational	DB16079	InChI=1S/C26H42N2O6/c1-18(2)5-6-21-25(3,34-21)23-22(30-4)20(7-9-26(23)17-32-26)33-24(29)28-15-19(16-28)8-10-27-11-13-31-14-12-27/h5,19-23H,6-17H2,1-4H3/t20-,21-,22-,23-,25+,26+/m1/s1	QJWJPMLDQYEPPW-AUKZVGPFSA-N	2		Not Available	Small Molecule																																			1	No	6	0	Yes	5	1	76.3 Å2	54.23 Å3	128.57 m3·mol-1	9	Yes	No	0.152 mg/mL	2.03	-3.5		7.57			
C31H50O3	Not Available	Not Available	470.738	[H][C@@]12CC[C@H](OC(=O)CCCCCCCCCC)[C@@]1(C)C[C@H](C)[C@]1([H])[C@@]3([H])CCC(=O)C=C3C[C@@H](C)[C@@]21[H]	Not Available	Not Available								68025242																	Dimethandrolone Undecanoate	Investigational	DB16141	InChI=1S/C31H50O3/c1-5-6-7-8-9-10-11-12-13-28(33)34-27-17-16-26-30-21(2)18-23-19-24(32)14-15-25(23)29(30)22(3)20-31(26,27)4/h19,21-22,25-27,29-30H,5-18,20H2,1-4H3/t21-,22+,25+,26+,27+,29-,30+,31+/m1/s1	FVICENFBEMJOCE-RTFNQGFNSA-N	1		Not Available	Small Molecule																																			0	No	2	0	Yes	4	0	43.37 Å2	59.02 Å3	139.64 m3·mol-1	11	No	No	4.39e-05 mg/mL	8.34	-7	18.3	-4.7			
C24H34O6S	Not Available	Not Available	450.59	COCC1=CC=CC(C[C@H](O)\C=C\[C@H]2[C@H](O)CC(=O)[C@@H]2CCSCCCC(=O)OC)=C1	Not Available	Not Available							CHEMBL303960	7979588															ZINC000003940680		Rivenprost	Investigational	DB16315	InChI=1S/C24H34O6S/c1-29-16-18-6-3-5-17(13-18)14-19(25)8-9-20-21(23(27)15-22(20)26)10-12-31-11-4-7-24(28)30-2/h3,5-6,8-9,13,19-22,25-26H,4,7,10-12,14-16H2,1-2H3/b9-8+/t19-,20-,21-,22-/m1/s1	FBQUXLIJKPWCAO-AZIFJQEOSA-N			Not Available	Small Molecule																																			1	Yes	5	2	No	2	0	93.06 Å2	51.52 Å3	124.47 m3·mol-1	14	Yes	No	0.00814 mg/mL	2.61	-4.7	14.43	-2.9	P35408;!BE0010100	PTGER4;!	1. Prostaglandin E2 receptor EP4 subtype;!2. Prostaglandin E2 Receptors (Protein Group)
C26H40O3	Not Available	Not Available	400.603	[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@H](CC[C@]12C)OC(=O)CCCCCC	Not Available	Not Available								143333														Prasterone_enanthate	ZINC000005820240		Prasterone enantate	Approved	DB16625	InChI=1S/C26H40O3/c1-4-5-6-7-8-24(28)29-19-13-15-25(2)18(17-19)9-10-20-21-11-12-23(27)26(21,3)16-14-22(20)25/h9,19-22H,4-8,10-17H2,1-3H3/t19-,20-,21-,22-,25-,26-/m0/s1	HHENOUDBWKNPAB-BNCSLUSBSA-N		Prasterone enantate is an estrogen indicated for hormone replacement therapy in postmenopausal women.	Not Available	Small Molecule																																			1	No	2	0	Yes	4	0	43.37 Å2	48.28 Å3	116.84 m3·mol-1	7	No	No		6.28			-6.9			
C18H22O4	Not Available	Not Available	302.3649	C[C@@H](CC1=CC(O)=C(O)C=C1)[C@H](C)CC1=CC(O)=C(O)C=C1	Solid	Not Available					22372	73468	CHEMBL313972	64490		GtP Drug Page	HMDB0014325	C10719	D04862			PA164746493	71398	46508042		227239	DNC001037	Masoprocol	ZINC000000012342		Masoprocol	Approved, Investigational	DB00179	InChI=1S/C18H22O4/c1-11(7-13-3-5-15(19)17(21)9-13)12(2)8-14-4-6-16(20)18(22)10-14/h3-6,9-12,19-22H,7-8H2,1-2H3/t11-,12+	HCZKYJDFEPMADG-TXEJJXNPSA-N	2		Symptoms of overdose or allergic reaction include bluish coloration of skin, dizziness, severe, or feeling faint, wheezing or trouble in breathing.	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1491 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					5.8		185.5 °C			1	Yes	4	4	No	2	0	80.92 Å2	33.63 Å3	86.62 m3·mol-1	5	Yes	No	0.0136 mg/mL	4.76	-4.4	9.21	-6.3			
C15H16O2	6-MNA has an apparent steady-state clearance of 20 - 30 mL/min.Label	6-MNA has a mean half-life of 24 hours with a range of 19-36 hours.Label	228.2863	COC1=CC2=C(C=C1)C=C(CCC(C)=O)C=C2	Solid	The Vd of 6-MNA reported after administration of a single dose is 0.1-0.2 L/kg or approximately 5-10 L.1 Vdss reported in official product labeling is approximately 53 L.Label,10	P05164;!P05177;!P11712;!P28845;!Q04828;!P52895;!P17516	MPO;!CYP1A2;!CYP2C9;!HSD11B1;!AKR1C1;!AKR1C2;!AKR1C4	1. Myeloperoxidase;!2. Cytochrome P450 1A2;!3. Cytochrome P450 2C9;!4. Corticosteroid 11-beta-dehydrogenase isozyme 1;!5. Aldo-keto reductase family 1 member C1;!6. Aldo-keto reductase family 1 member C2;!7. Aldo-keto reductase family 1 member C4		40128	7443	CHEMBL1070	4256	Drugs.com Drug Page		HMDB0014604		D00425	NBO	PDRhealth Drug Page	PA450572	4409	46507729	RxList Drug Page	31448	DAP000735	Nabumetone	ZINC000000020221	Relafen	Nabumetone	Approved	DB00461	InChI=1S/C15H16O2/c1-11(16)3-4-12-5-6-14-10-15(17-2)8-7-13(14)9-12/h5-10H,3-4H2,1-2H3	BLXXJMDCKKHMKV-UHFFFAOYSA-N	4	Nabumetone is an NSAID used to treat osteoarthritis and rheumatoid arthritis.	LD50 ValuesMouse: 4290 mg/kg (Oral), 2380 mg/kg (IP)11Rat: 3880 mg/kg (Oral), 1520 mg/kg (IP), >10 g/kg (SC)11Monkey: 3200 mg/kg (Oral)11OverdoseSigns and symptoms of nabumetone overdose include lethargy, drowsiness, nausea, vomiting, and epigastric pain.Label These are considered reversible with supportive care. GI bleeding, hypertension, acute kidney injury, respiratory depression, and coma are rare but can occur. No antidote exists for nabumetone overdose although administration of activated charcoal and/or induction of emesis can reduce absorption if the nabumetone dose was taken less than 4 hours prior.Label,10 6-MNA is cannot be cleared by dialysis.Carcinogenicity & MutagenicityNabumetone was not significantly carcinogenic in rats or mice studied over 2 years.Label Neither the Ames test nor mouse micronucleus test showed nabumetone or it's active metabolite, 6-MNA, to be mutagenic. Chromosomal abberation has been observed in cultured lymphocytes exposed to concentrations of 80 mcg/mL and higher of nabumetone or 6-MNA equivalent to the maximum recommended human dose.Reproductive ToxicityNo adverse effects on fertility have been observed in male and female rats at doses of 320 mg/kg/day.Label,10] No teratogenicity has been observed in pregnant rabbits or rats. Dystocia and delayed parturition have been noted in rats resulting in reduced survival of offspring. This has been attributed to the role of prostaglandins in uterine contraction. NSAIDs can also cause premature closure of the ductus ateriosus.Lactation6-MNA has been detected in the milk of lactating rats.Label,10 While no data is available in humans, 6-MNA is both highly protein bound and exists in its anionic form in circulation. For these reasons partitioning into breast milk is expected to be limited.	Small Molecule	http://smpdb.ca/view/SMP0000114?highlight[compounds][]=DB00461&highlight[proteins][]=DB00461	Nabumetone Action Pathway		Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	1.7384 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2400		78-82		Practically insoluble	1	Yes	2	0	No	2	0	26.3 Å2	26.17 Å3	68.43 m3·mol-1	4	Yes	Yes	0.00193 mg/mL	3.22	-5.1	19.59	-4.8			
C15H14O3	Not Available	Plasma half-life is approximately 3 hours.	242.2699	CC(C(O)=O)C1=CC(OC2=CC=CC=C2)=CC=C1	Solid	Not Available					54705	5004	CHEMBL1297	3225	Drugs.com Drug Page		HMDB0014713	C06997	D00968			PA449597	3342	46504597	RxList Drug Page	4331	DAP000619	Fenoprofen		Fenortho, Nalfon	Fenoprofen	Approved	DB00573	InChI=1S/C15H14O3/c1-11(15(16)17)12-6-5-9-14(10-12)18-13-7-3-2-4-8-13/h2-11H,1H3,(H,16,17)	RDJGLLICXDHJDY-UHFFFAOYSA-N		Fenoprofen is an anti-inflammatory analgesic used to treat mild to moderate pain in addition to the signs and symptoms of rheumatoid arthritis and osteoarthritis.	Symptoms of overdose appear within several hours and generally involve the gastrointestinal and central nervous systems. They include dyspepsia, nausea, vomiting, abdominal pain, dizziness, headache, ataxia, tinnitus, tremor, drowsiness, and confusion. Hyperpyrexia, tachycardia, hypotension, and acute renal failure may occur rarely following overdose. Respiratory depression and metabolic acidosis have also been reported following overdose with certain NSAIDs.	Small Molecule	http://smpdb.ca/view/SMP0000696?highlight[compounds][]=DB00573&highlight[proteins][]=DB00573	Fenoprofen Action Pathway		Non AMES toxic	Ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.9985 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.1		168-171	4.5	Slight (calcium salt)	1	Yes	2	1	No	2	-1	46.53 Å2	25.3 Å3	68.18 m3·mol-1	4	Yes	No	0.0811 mg/mL	3.65	-3.5	3.96	-3.7			
C19H24N2O3	Labetalol has a plasma clearance of approximately 1500mL/min and a whole blood clearance of 1100mL/min.2	Labetalol has a half life of 1.7-6.1 hours.2	328.4055	CC(CCC1=CC=CC=C1)NCC(O)C1=CC(C(N)=O)=C(O)C=C1	Solid	In normotensive patients, the volume of distribution is 805L.2 In hypertensive patients, the volume of distribution is between 188-747L with an average of 392L.2	P10635;!P33261;!P22309;!P16662;!O60656	CYP2D6;!CYP2C19;!UGT1A1;!UGT2B7;!UGT1A9	1. Cytochrome P450 2D6;!2. Cytochrome P450 2C19;!3. UDP-glucuronosyltransferase 1-1;!4. UDP-glucuronosyltransferase 2B7;!5. UDP-glucuronosyltransferase 1-9		25758	6343	CHEMBL429	3734	Drugs.com Drug Page		HMDB0014736	C07063	D08106		PDRhealth Drug Page	PA164743150	3869	46505511	RxList Drug Page	6185	DAP000038	Labetalol		Trandate	Labetalol	Approved	DB00598	InChI=1S/C19H24N2O3/c1-13(7-8-14-5-3-2-4-6-14)21-12-18(23)15-9-10-17(22)16(11-15)19(20)24/h2-6,9-11,13,18,21-23H,7-8,12H2,1H3,(H2,20,24)	SGUAFYQXFOLMHL-UHFFFAOYSA-N	4	Labetalol is an alpha and beta adrenergic antagonist used to treat hypertension, angina, and sympathetic overactivity syndrome.	The oral LD50 in mice is 600mg/kg and in rats is >2g/kg.7,8 The intravenous LD50 in mice and rats is 50-60mg/kg.7,8Patients experiencing an overdose may present with excessive hypotension and bradycardia.7,8 Patients should be placed on their back with their legs raised to maintain perfusion of the brain.7,8 Oral overdoses may be treated with gastric lavage or emesis, bradycardia may be treated with atropine or epinephrine, cardiac failure may be treated with digitalis and a diuretic, hypotension may be treated with vasopressors, bronchospasms may be treated with epinephrine or a beta2 agonist, and seizures may be treated with diazepam.7,8	Small Molecule	http://smpdb.ca/view/SMP0000368?highlight[compounds][]=DB00598&highlight[proteins][]=DB00598	Labetalol Action Pathway		Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1174 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				552.7			188 °C	9.3		1	Yes	4	4	No	2	1	95.58 Å2	36.83 Å3	94.72 m3·mol-1	8	Yes	No	0.00578 mg/mL	1.89	-4.8	8.05	9.8			
C18H23NO3	Not Available	2 minutes	301.3801	CC(CCC1=CC=C(O)C=C1)NCCC1=CC(O)=C(O)C=C1	Solid	Not Available	P21964	COMT	1. Catechol O-methyltransferase		50325274	4670	CHEMBL926	33786	Drugs.com Drug Page	GtP Drug Page	HMDB0014979	C06967	D03879			PA449381	36811	46505241	RxList Drug Page	3616	DAP000245	Dobutamine			Dobutamine	Approved	DB00841	InChI=1S/C18H23NO3/c1-13(2-3-14-4-7-16(20)8-5-14)19-11-10-15-6-9-17(21)18(22)12-15/h4-9,12-13,19-22H,2-3,10-11H2,1H3	JRWZLRBJNMZMFE-UHFFFAOYSA-N	4	Dobutamine is a beta-1 agonist used to treat cardiac decompensation in patients with organic heart disease or from cardiac surgery.	Not Available	Small Molecule	http://smpdb.ca/view/SMP0000662?highlight[compounds][]=DB00841&highlight[proteins][]=DB00841	Dobutamine Action Pathway		Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.2261 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor					3.6		184-186			1	Yes	4	4	No	2	1	72.72 Å2	34.44 Å3	88.39 m3·mol-1	7	Yes	No	0.0137 mg/mL	2.62	-4.3	10.14	9.27	BE0004863;!P08588;!P07550;!P03372	;!ADRB1;!ADRB2;!ESR1	1. Alpha-1 adrenergic receptors (Protein Group);!2. Beta-1 adrenergic receptor;!3. Beta-2 adrenergic receptor;!4. Estrogen receptor alpha
C10H13NO4	The renal clearance is about 130 mL/min in normal subjects and is decreased in patients with renal insufficiency.11	The plasma half-life of methyldopa is 105 minutes.11 Following intravenous injection, the plasma half-life of methyldopa ranges from 90 to 127 minutes.13	211.2145	C[C@](N)(CC1=CC=C(O)C(O)=C1)C(O)=O	Solid	The apparent volume of distribution ranges between 0.19 and 0.32L/kg and the total volume of distribution ranges from 0.41 to 0.72L/kg. Since methyldopa is lipid-soluble 4, it crosses the placental barrier, appears in cord blood, and appears in breast milk.11	P21964;!P20711;!BE0009567;!P09172;!P11086	COMT;!DDC;!;!DBH;!PNMT	1. Catechol O-methyltransferase;!2. Aromatic-L-amino-acid decarboxylase;!3. Sulfotransferase (Protein Group);!4. Dopamine beta-hydroxylase;!5. Phenylethanolamine N-methyltransferase		48449	61058	CHEMBL459	35562	Drugs.com Drug Page		HMDB0011754	C07194	D08205		PDRhealth Drug Page	PA450453	38853	46508535	RxList Drug Page	1545996	DAP000226	Methyldopa	ZINC000000020255		Methyldopa	Approved	DB00968	InChI=1S/C10H13NO4/c1-10(11,9(14)15)5-6-2-3-7(12)8(13)4-6/h2-4,12-13H,5,11H2,1H3,(H,14,15)/t10-/m0/s1	CJCSPKMFHVPWAR-JTQLQIEISA-N	4	Methyldopa is a centrally-acting alpha-2 adrenergic agonist used to manage hypertension alone or in combination with hydrochlorothiazide, and to treat hypertensive crises.	The lowest published toxic dose via oral route is 44 gm/kg/3Y (intermittent) in a female. Oral LD50 is 5000 mg/kg in rats and 5300 mg/kg in mice. Intraperitoneal LD50 is 300 mg/kg in rats and 150 mg/kg in mice.14Acute overdosage is characterized by acute hypotension and other presentations attributed to the brain and gastrointestinal dysfunction, such as excessive sedation, weakness, bradycardia, dizziness, light-headedness, constipation, distention, flatus, diarrhea, nausea, and vomiting. Symptomatic and supportive measures should be initiated in the event of methyldopa overdose. Overdosage following recent oral ingestion can be managed by gastric lavage or emesis, as well as infusions to limit further drug absorption. Cardiac rate and output, blood volume, electrolyte balance, paralytic ileus, urinary function and cerebral activity should be closely monitored. The use of sympathomimetic drugs such as levarterenol, epinephrine, and metaraminol bitartrate, or dialysis may be considered.11	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.6281 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							>300		1E+004 mg/L (at 25 °C)	1	No	5	4	No	1	0	103.78 Å2	20.73 Å3	53.79 m3·mol-1	3	Yes	No	2.26 mg/mL	-1.4	-2	1.73	9.85	P20711;!P08913	DDC;!ADRA2A	1. Aromatic-L-amino-acid decarboxylase;!2. Alpha-2A adrenergic receptor
C18H23NO4	Not Available	Elimination half-life is approximately 8 minutes.	317.3795	O[C@@H](CNCCCCC1=CC=C(O)C=C1)C1=CC(O)=C(O)C=C1	Solid	Not Available						50580	CHEMBL1201251	54785			HMDB0015234		D02976			PA164747979	60789	46509010		61609	DAP000936	Arbutamine			Arbutamine	Approved	DB01102	InChI=1S/C18H23NO4/c20-15-7-4-13(5-8-15)3-1-2-10-19-12-18(23)14-6-9-16(21)17(22)11-14/h4-9,11,18-23H,1-3,10,12H2/t18-/m0/s1	IIRWWTKISYTTBL-SFHVURJKSA-N			Not Available	Small Molecule	http://smpdb.ca/view/SMP0000664?highlight[compounds][]=DB01102&highlight[proteins][]=DB01102	Arbutamine Action Pathway		Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.9867 LD50, mol/kg	Non-inhibitor	Strong inhibitor	Inhibitor					2.9					1	Yes	5	5	No	2	1	92.95 Å2	35.54 Å3	89.78 m3·mol-1	8	Yes	No	0.0842 mg/mL	2	-3.6	8.97	9.76	P08588;!P07550;!P13945	ADRB1;!ADRB2;!ADRB3	1. Beta-1 adrenergic receptor;!2. Beta-2 adrenergic receptor;!3. Beta-3 adrenergic receptor
C21H27NO3	Not Available	2-10 hours	341.444	CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1	Solid	252 L	P10635;!P08684;!P05177	CYP2D6;!CYP3A4;!CYP1A2	1. Cytochrome P450 2D6;!2. Cytochrome P450 3A4;!3. Cytochrome P450 1A2		50067133	63619	CHEMBL631	4763	Drugs.com Drug Page	GtP Drug Page	HMDB0015313	C07381	D08435		PDRhealth Drug Page	PA451131	4932	46504529	RxList Drug Page	8754	DAP000497	Propafenone		Rythmol	Propafenone	Approved	DB01182	InChI=1S/C21H27NO3/c1-2-14-22-15-18(23)16-25-21-11-7-6-10-19(21)20(24)13-12-17-8-4-3-5-9-17/h3-11,18,22-23H,2,12-16H2,1H3	JWHAUXFOSRPERK-UHFFFAOYSA-N	4	Propafenone is a Class 1C antiarrhythmic agent used in the management of paroxysmal atrial fibrillation/flutter and ventricular arrhythmias.	Symptoms of propafenone overdose (usually most severe within the first 3 hours) may include convulsions (rarely), heartbeat irregularities, low blood pressure, and sleepiness.	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.3795 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor					3.2				Slightly soluble	1	Yes	4	2	No	2	1	58.56 Å2	39.75 Å3	100.21 m3·mol-1	11	Yes	No	0.00758 mg/mL	3.54	-4.6	14.09	9.63			
C9H11NO4	Intravenously administered levodopa is cleared at a rate of 14.2mL/min/kg in elderly patients and 23.4mL/min/kg in younger patients4. When given carbidopa, the clearance of levodopa was 5.8mL/min/kg in elderyly patients and 9.3mL/min/kg in younger patients4.	2.3 hours for orally inhaled levodopaLabel. Oral levodopa has a half life of 50 minutes but when combined with a peripheral dopa decarboxylase inhibitor, the half life is increased to 1.5 hours8.	197.1879	N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O	Solid	168L for orally inhaled levodopaLabel.	P20711	DDC	1. Aromatic-L-amino-acid decarboxylase		60928	15765	CHEMBL1009	5824	Drugs.com Drug Page	GtP Drug Page	HMDB0000181	C00355	D00059	DAH		PA450213	6047	46508120	RxList Drug Page	6375	DAP000209	Levodopa	ZINC000000895199	Dhivy, Duodopa, Duopa, Inbrija, Parcopa, Prolopa, Rytary, Sinemet, Stalevo	Levodopa	Approved	DB01235	InChI=1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1	WTDRDQBEARUVNC-LURJTMIESA-N	4	Levodopa is a dopamine precursor used in the management of Parkinson's disease, often in combination with carbidopa, as well as other conditions associated with parkinsonism.	There is no readily available data for the use of levodopa in pregnancyLabel. Rabbits treated with levodopa and carbidopa produced smaller litters and their offspring developed visceral and skeletal deformitiesLabel. Levodopa may lower prolactin and interfere with lactation but there is limited human data to demonstrate this effectLabel. Levodopa is present in human breast milk and so the potential effects of nursing while taking levodopa should be considered before prescribing levodopa to nursing mothersLabel. There is currently a lack of data on the safety and effectiveness of using levodopa in pediatric patientsLabel. Patients over 65 years of age are more likely to experience adverse effects associated with taking levodopa, however this generally is not sufficient to exclude this patient group from treatmentLabel.	Small Molecule	http://smpdb.ca/view/SMP0000170?highlight[compounds][]=DB01235&highlight[proteins][]=DB01235;!http://smpdb.ca/view/SMP0000006?highlight[compounds][]=DB01235&highlight[proteins][]=DB01235;!http://smpdb.ca/view/SMP0000012?highlight[compounds][]=DB01235&highlight[proteins][]=DB01235;!http://smpdb.ca/view/SMP0000218?highlight[compounds][]=DB01235&highlight[proteins][]=DB01235;!http://smpdb.ca/view/SMP0000429?highlight[compounds][]=DB01235&highlight[proteins][]=DB01235;!http://smpdb.ca/view/SMP0000169?highlight[compounds][]=DB01235&highlight[proteins][]=DB01235;!http://smpdb.ca/view/SMP0000190?highlight[compounds][]=DB01235&highlight[proteins][]=DB01235;!http://smpdb.ca/view/SMP0000494?highlight[compounds][]=DB01235&highlight[proteins][]=DB01235;!http://smpdb.ca/view/SMP0000497?highlight[compounds][]=DB01235&highlight[proteins][]=DB01235;!http://smpdb.ca/view/SMP0000498?highlight[compounds][]=DB01235&highlight[proteins][]=DB01235;!http://smpdb.ca/view/SMP0000533?highlight[compounds][]=DB01235&highlight[proteins][]=DB01235	Aromatic L-Aminoacid Decarboxylase Deficiency;!Tyrosine Metabolism;!Catecholamine Biosynthesis;!Tyrosinemia Type I;!Disulfiram Action Pathway;!Alkaptonuria;!Hawkinsinuria;!Tyrosinemia, Transient, of the Newborn;!Tyrosine Hydroxylase Deficiency;!Dopamine beta-Hydroxylase Deficiency;!Monoamine Oxidase-A Deficiency (MAO-A)		AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.0131 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				448.4	0.05		295		5mM	1	No	5	4	No	1	0	103.78 Å2	18.91 Å3	49.08 m3·mol-1	3	Yes	No	3.3 mg/mL	-1.8	-1.8	1.65	9.06	P21728;!P21918;!P14416;!P35462;!P21917	DRD1;!DRD5;!DRD2;!DRD3;!DRD4	1. Dopamine D1 receptor;!2. Dopamine D5 receptor;!3. Dopamine D2 receptor;!4. Dopamine D3 receptor;!5. Dopamine D4 receptor
C19H20ClNO4	Not Available	1-2 hours	361.819	CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O	Solid	Not Available	P04798;!P10632;!P08684	CYP1A1;!CYP2C8;!CYP3A4	1. Cytochrome P450 1A1;!2. Cytochrome P450 2C8;!3. Cytochrome P450 3A4		28701	47612	CHEMBL264374	35728		GtP Drug Page	HMDB0015465		D01366	PEM		PA162364313	39042	46509188		1525	DAP001182	Bezafibrate	ZINC000003956919	Bezalip	Bezafibrate	Approved, Investigational	DB01393	InChI=1S/C19H20ClNO4/c1-19(2,18(23)24)25-16-9-3-13(4-10-16)11-12-21-17(22)14-5-7-15(20)8-6-14/h3-10H,11-12H2,1-2H3,(H,21,22)(H,23,24)	IIBYAHWJQTYFKB-UHFFFAOYSA-N	4	Bezafibrate is a lipid-lowering fibrate used in the management of primary and secondary hyperlipidaemia, when there is a lack of clinical improvement following lifestyle modifications or correction of the underlying disorder.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.4927 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							186 °C			1	Yes	4	2	No	2	-1	75.63 Å2	37.53 Å3	95.96 m3·mol-1	7	Yes	No	0.00155 mg/mL	3.99	-5.4	3.83	-0.84			
C14H12O3	Not Available	Not Available	228.2433	COC1=CC(O)=C(C=C1)C(=O)C1=CC=CC=C1	Solid	Not Available					50253134	34283	CHEMBL1625	4471			HMDB0015497	C14285	D05309			PA164742933	4632	46508419		32673		Oxybenzone	ZINC000000136138	Meijer	Oxybenzone	Approved, Investigational	DB01428	InChI=1S/C14H12O3/c1-17-11-7-8-12(13(15)9-11)14(16)10-5-3-2-4-6-10/h2-9,15H,1H3	DXGLGDHPHMLXJC-UHFFFAOYSA-N	4	Oxybenzone is a sunscreen agent found in sunscreens that absorbs UV rays.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.6986 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				155 °C at 5.00E+00 mm Hg	3.79		65.5 °C			1	Yes	3	1	No	2	-1	46.53 Å2	23.96 Å3	65.08 m3·mol-1	3	Yes	No	0.128 mg/mL	3.62	-3.2	7.07	-4.8	P06401;!P10275;!P03372;!Q92731	PGR;!AR;!ESR1;!ESR2	1. Progesterone receptor;!2. Androgen receptor;!3. Estrogen receptor alpha;!4. Estrogen receptor beta
C22H16BrNO4	Not Available	Not Available	438.271	[H]N(\C(=C/C1=CC=C(OC2=CC=CC=C2Br)C=C1)C(O)=O)C(=O)C1=CC=CC=C1	Solid	Not Available					50166405		CHEMBL188442	571325						PH7			657131	46508533							(2Z)-2-(Benzoylamino)-3-[4-(2-bromophenoxy)phenyl]acrylic acid	Experimental	DB01720	InChI=1S/C22H16BrNO4/c23-18-8-4-5-9-20(18)28-17-12-10-15(11-13-17)14-19(22(26)27)24-21(25)16-6-2-1-3-7-16/h1-14H,(H,24,25)(H,26,27)/b19-14-	WLPJLQNKCJWAFL-RGEXLXHISA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.2503 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	2	Yes	3	-1	75.63 Å2	40.22 Å3	110.66 m3·mol-1	6	Yes	No	0.000356 mg/mL	4.92	-6.1	3.05	-3.7	P26662	Not Available	1. Genome polyprotein
C9H8O4	Not Available	Not Available	180.1574	OC(=O)\C=C\C1=CC(O)=C(O)C=C1	Solid	Not Available					4375	16433	CHEMBL145	600426			HMDB0003501	C01481		DHC			689043	46504491			DNC000378		ZINC000000058172		3,4-Dihydroxycinnamic Acid	Experimental, Investigational	DB01880	InChI=1S/C9H8O4/c10-7-3-1-6(5-8(7)11)2-4-9(12)13/h1-5,10-11H,(H,12,13)/b4-2+	QAIPRVGONGVQAS-DUXPYHPUSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.4041 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					1.15		225 dec °C	4.62 (at 25 °C)		1	Yes	4	3	No	1	-1	77.76 Å2	17.34 Å3	47.02 m3·mol-1	2	Yes	No	1.61 mg/mL	1.53	-2	3.45	-6.3	Q3IWB0;!P14174;!P16113	hutH;!MIF;!pyp	1. Histidine ammonia-lyase;!2. Macrophage migration inhibitory factor;!3. Photoactive yellow protein
C23H23Br2NO5	Not Available	Not Available	553.24	OC(O)CC1=CC(Br)=C(OC2=CC(C(O)NCCC3=CC=CC=C3)=C(O)C=C2)C(Br)=C1	Solid	Not Available								4449873						442			5287509	46505732							[3,5-Dibromo-4-(4-Hydroxy-3-Phenethylcarbamoyl-Phenoxy)-Phenyl]-Acetic Acid	Experimental	DB02106	InChI=1S/C23H23Br2NO5/c24-18-10-15(12-21(28)29)11-19(25)22(18)31-16-6-7-20(27)17(13-16)23(30)26-9-8-14-4-2-1-3-5-14/h1-7,10-11,13,21,23,26-30H,8-9,12H2	KIRQJXNQGZAKGR-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.4108 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	5	5	Yes	3	1	102.18 Å2	49.22 Å3	125.88 m3·mol-1	9	No	No	0.00816 mg/mL	4.44	-4.8	9.6	8.54	P10828	THRB	1. Thyroid hormone receptor beta
C19H18O6	Not Available	Not Available	342.3426	[H][C@@](CC1=CC=CC=C1)(C(O)=O)[C@]([H])(CC1=CC2=C(OCO2)C=C1)C(O)=O	Solid	Not Available							CHEMBL1231535	4593419						BYS			5496627	46508466					ZINC000012080868		2-Benzo[1,3]Dioxol-5-Ylmethyl-3-Benzyl-Succinic Acid	Experimental	DB02450	InChI=1S/C19H18O6/c20-18(21)14(8-12-4-2-1-3-5-12)15(19(22)23)9-13-6-7-16-17(10-13)25-11-24-16/h1-7,10,14-15H,8-9,11H2,(H,20,21)(H,22,23)/t14-,15-/m0/s1	ASEJDWRSZYAIOT-GJZGRUSLSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.5271 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	6	2	Yes	3	-2	93.06 Å2	34.75 Å3	87.84 m3·mol-1	7	Yes	No	0.156 mg/mL	3.47	-3.3	3.62	-4.7	Q79MP6;!P52699	blaIMP-1;!Not Available	1. Beta-lactamase;!2. Beta-lactamase IMP-1
C23H22N2O6	Not Available	Not Available	422.4306	[H][C@](N)(CC1=C(O)C=C(O)C(N\C(COC2=CC=C3C=CC=CC3=C2)=C\C=O)=C1)C(O)=O	Solid	Not Available								26329750						NBQ			17754104	46507750					ZINC000012502206		2-Hydroxy-5-({1-[(2-Naphthyloxy)Methyl]-3-Oxoprop-1-Enyl}Amino)Tyrosine	Experimental	DB02511	InChI=1S/C23H22N2O6/c24-19(23(29)30)10-16-11-20(22(28)12-21(16)27)25-17(7-8-26)13-31-18-6-5-14-3-1-2-4-15(14)9-18/h1-9,11-12,19,25,27-28H,10,13,24H2,(H,29,30)/b17-7+/t19-/m0/s1	PZWMZAFFUAWVDN-CQXYXCHQSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	-	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.2396 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	8	5	Yes	3	0	142.11 Å2	43.81 Å3	117.43 m3·mol-1	9	Yes	No	0.00714 mg/mL	-0.2	-4.8	1.69	8.98	P46881	Not Available	1. Phenylethylamine oxidase
C20H22N2O6	Not Available	Not Available	386.3985	[H]\C(C=O)=C(\COC1=CC=C(C)C=C1)NC1=C(O)C=C(O)C(C[C@]([H])(N)C(O)=O)=C1	Solid	Not Available								26354103						MBQ			52941757	46509095					ZINC000103549492		2-Hydroxy-5-({1-[(4-Methylphenoxy)Methyl]-3-Oxoprop-1-Enyl}Amino)-L-Tyrosine	Experimental	DB02537	InChI=1S/C20H22N2O6/c1-12-2-4-15(5-3-12)28-11-14(6-7-23)22-17-9-13(8-16(21)20(26)27)18(24)10-19(17)25/h2-7,9-10,16,22,24-25H,8,11,21H2,1H3,(H,26,27)/b14-6+/t16-/m0/s1	FSNBWEOGSXUNGF-CQMBDMNQSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.0591 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	8	5	No	2	0	142.11 Å2	39.15 Å3	106.02 m3·mol-1	9	Yes	No	0.0342 mg/mL	-0.67	-4	1.69	8.98	P46881	Not Available	1. Phenylethylamine oxidase
C14H12O3	Not Available	Not Available	228.2433	OC1=CC=C(\C=C\C2=CC(O)=CC(O)=C2)C=C1	Solid	Not Available					23926	45713	CHEMBL165	392875			HMDB0003747	C03582		STL		PA165291838	445154	46504705		1000492	DNC001205	Resveratrol	ZINC000000006787		Resveratrol	Investigational	DB02709	InChI=1S/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1+	LUKBXSAWLPMMSZ-OWOJBTEDSA-N	4		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.6791 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							254 °C			1	Yes	3	3	No	2	0	60.69 Å2	24.55 Å3	67.46 m3·mol-1	2	Yes	No	0.0688 mg/mL	3.4	-3.5	8.49	-6.2			
C15H12O4	Not Available	Not Available	256.2534	OC1=CC=C(\C=C\C(=O)C2=C(O)C=C(O)C=C2)C=C1	Solid	Not Available					50042944	310312	CHEMBL129795	553829			HMDB0037316	C08650		HCC			638278	46506198				Isoliquiritigenin	ZINC000003869608		Isoliquiritigenin	Experimental	DB03285	InChI=1S/C15H12O4/c16-11-4-1-10(2-5-11)3-8-14(18)13-7-6-12(17)9-15(13)19/h1-9,16-17,19H/b8-3+	DXDRHHKMWQZJHT-FPYGCLRLSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.0091 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	3	No	2	-1	77.76 Å2	26.66 Å3	72.82 m3·mol-1	3	Yes	No	0.0551 mg/mL	3.63	-3.7	7.11	-6.4			
C24H24O4	Not Available	Not Available	376.445	CC1=CC(OCC(O)=O)=CC(C)=C1CC1=CC=C(O)C(CC2=CC=CC=C2)=C1	Solid	Not Available								394946						G24			448011	46504743							GC-24	Experimental	DB03788	InChI=1S/C24H24O4/c1-16-10-21(28-15-24(26)27)11-17(2)22(16)14-19-8-9-23(25)20(13-19)12-18-6-4-3-5-7-18/h3-11,13,25H,12,14-15H2,1-2H3,(H,26,27)	JYHIGYLGYNCMGI-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1148 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	2	Yes	3	-1	66.76 Å2	41.06 Å3	110.14 m3·mol-1	7	No	No	0.000404 mg/mL	6.2	-6	3.92	-4.9	P10828	THRB	1. Thyroid hormone receptor beta
C20H22O6	Not Available	Not Available	358.3851	[H][C@]1(CC2=CC=C(O)C(OC)=C2)COC(=O)[C@]1([H])CC1=CC=C(O)C(OC)=C1	Solid	Not Available					50240921	6698	CHEMBL425148	106491			HMDB0035698	C10682		MAX			119205	46507098				Matairesinol	ZINC000001595957		Matairesinol	Experimental	DB04200	InChI=1S/C20H22O6/c1-24-18-9-12(3-5-16(18)21)7-14-11-26-20(23)15(14)8-13-4-6-17(22)19(10-13)25-2/h3-6,9-10,14-15,21-22H,7-8,11H2,1-2H3/t14-,15+/m0/s1	MATGKVZWFZHCLI-LSDHHAIUSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	2.4961 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	2	Yes	3	0	85.22 Å2	36.86 Å3	95.63 m3·mol-1	6	Yes	No	0.0121 mg/mL	3.29	-4.5	9.64	-4.6	Q6PKH6	DHRS4L2	1. Dehydrogenase/reductase SDR family member 4-like 2
C24H23ClO2	Total body clearance = 9.16 L/hr.	Terminal half-life = 26 hours .	378.891	OCCOC1=CC=C(C=C1)C(=C(\CCCl)C1=CC=CC=C1)\C1=CC=CC=C1	Solid	448 L	P08684;!P11712;!P33261;!P20813;!P10635	CYP3A4;!CYP2C9;!CYP2C19;!CYP2B6;!CYP2D6	1. Cytochrome P450 3A4;!2. Cytochrome P450 2C9;!3. Cytochrome P450 2C19;!4. Cytochrome P450 2B6;!5. Cytochrome P450 2D6			73275	CHEMBL2105395	2300501	Drugs.com Drug Page				D08958				3036505	175426911	RxList Drug Page	1370971		Ospemifene	ZINC000001550766	Osphena	Ospemifene	Approved, Investigational	DB04938	InChI=1S/C24H23ClO2/c25-16-15-23(19-7-3-1-4-8-19)24(20-9-5-2-6-10-20)21-11-13-22(14-12-21)27-18-17-26/h1-14,26H,15-18H2/b24-23-	LUMKNAVTFCDUIE-VHXPQNKSSA-N	4	Ospemifene is a non-hormonal estrogen receptor modulator (SERM) used to treat moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.	Adverse reactions (≥1 percent) include: hot flush, vaginal discharge, muscle spasms, genital discharge, hyperhidrosis.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Non-substrate	2.3083 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor									Insoluble	1	Yes	2	1	Yes	3	0	29.46 Å2	41.97 Å3	121.68 m3·mol-1	8	No	Yes	0.000526 mg/mL	5.56	-5.9	15.1	-2.8	P03372	ESR1	1. Estrogen receptor alpha
C11H15NO4	Not Available	Not Available	225.244	CCOC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1	Solid	Not Available						135971	CHEMBL1823681	148944												1421444		Etilevodopa	ZINC000056897596		Etilevodopa	Investigational	DB06535	InChI=1S/C11H15NO4/c1-2-16-11(15)8(12)5-7-3-4-9(13)10(14)6-7/h3-4,6,8,13-14H,2,5,12H2,1H3/t8-/m0/s1	NULMGOSOSZBEQL-QMMMGPOBSA-N			Not Available	Small Molecule																																			1	Yes	4	3	No	1	1	92.78 Å2	23.27 Å3	58.6 m3·mol-1	5	Yes	No	1.78 mg/mL	0.97	-2.1	9.29	6.97			
C26H37NO3	5-HMT, healthy subjects: 14.4 L/h5-HMT is also secreted into the nephron.	7-8 hours for the active metabolite 5-hydroxymethyl tolterodine	411.5769	CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(OC(=O)C(C)C)C=CC(CO)=C1)C(C)C	Solid	IV, 5-HMT: 169 L	P10635;!P08684	CYP2D6;!CYP3A4	1. Cytochrome P450 2D6;!2. Cytochrome P450 3A4			135920	CHEMBL1201764	5293755	Drugs.com Drug Page		HMDB0015648		D07226			PA165958376	6918558	99443256	RxList Drug Page	797195		Fesoterodine	ZINC000001552908	Toviaz	Fesoterodine	Approved	DB06702	InChI=1S/C26H37NO3/c1-18(2)26(29)30-25-13-12-21(17-28)16-24(25)23(22-10-8-7-9-11-22)14-15-27(19(3)4)20(5)6/h7-13,16,18-20,23,28H,14-15,17H2,1-6H3/t23-/m1/s1	DCCSDBARQIPTGU-HSZRJFAPSA-N	4	Fesoterodine is an antimuscarinic agent used in the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.	Rat, Oral, LD50: ~ 681 mg/kgMouse, Oral, LD50: ~ 316 mg/kgRat, Intravenous, NOAEL: 10 mg/kgMouse, Intravenous, NOAEL: 10 mg/kg	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.4003 LD50, mol/kg	Inhibitor	Weak inhibitor	Inhibitor									Highly soluble	0	No	3	1	No	2	1	49.77 Å2	48.29 Å3	124.08 m3·mol-1	11	No	No	0.00205 mg/mL	5.7	-5.3	14.98	10.64	P20309;!P08173;!P11229;!P08172;!P08912	CHRM3;!CHRM4;!CHRM1;!CHRM2;!CHRM5	1. Muscarinic acetylcholine receptor M3;!2. Muscarinic acetylcholine receptor M4;!3. Muscarinic acetylcholine receptor M1;!4. Muscarinic acetylcholine receptor M2;!5. Muscarinic acetylcholine receptor M5
C18H21NO5	Not Available	Not Available	331.368	CC(CC1=CC=C2OCOC2=C1)NCC(O)C1=CC=C(O)C(O)=C1	Solid	Not Available						135413	CHEMBL1201273	4798														Protokylol			Protokylol	Approved, Vet approved	DB06814	InChI=1S/C18H21NO5/c1-11(6-12-2-5-17-18(7-12)24-10-23-17)19-9-16(22)13-3-4-14(20)15(21)8-13/h2-5,7-8,11,16,19-22H,6,9-10H2,1H3	LUMAEVHDZXIGEP-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	Yes	6	4	Yes	3	1	91.18 Å2	35.44 Å3	88.78 m3·mol-1	6	Yes	No	0.236 mg/mL	1.48	-3.2	9.86	8.98	P07550	ADRB2	1. Beta-2 adrenergic receptor
C17H18N2O4	Not Available	Not Available	314.3358	[H][C@](N)(CC1=CC(\N=C\CC2=CC=CC=C2)=C(O)C=C1O)C(O)=O	Solid	Not Available						39866		25057256						2TY			46937041	99443459					ZINC000053683758		2-HYDROXY-5-{[(1E)-2-PHENYLETHYLIDENE]AMINO}-L-TYROSINE	Experimental	DB06988	InChI=1S/C17H18N2O4/c18-13(17(22)23)8-12-9-14(16(21)10-15(12)20)19-7-6-11-4-2-1-3-5-11/h1-5,7,9-10,13,20-21H,6,8,18H2,(H,22,23)/b19-7+/t13-/m0/s1	BSKROLLIUIDPDT-KUJOXMSCSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.0410 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	6	4	No	2	0	116.14 Å2	32.53 Å3	88.21 m3·mol-1	6	Yes	No	0.0792 mg/mL	-0.16	-3.6	1.46	9.09	P46881	Not Available	1. Phenylethylamine oxidase
C17H20O2	Not Available	Not Available	256.3395	CCCCCC1=CC(O)=C(OC2=CC=CC=C2)C=C1	Solid	Not Available					16296		CHEMBL1224745	4439178						5PP			5274976	99443649					ZINC000014961108		5-PENTYL-2-PHENOXYPHENOL	Experimental	DB07178	InChI=1S/C17H20O2/c1-2-3-5-8-14-11-12-17(16(18)13-14)19-15-9-6-4-7-10-15/h4,6-7,9-13,18H,2-3,5,8H2,1H3	OJLYTHOKCYLPMA-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	1.9572 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	1	1	No	2	0	29.46 Å2	29.82 Å3	77.72 m3·mol-1	6	No	Yes	0.0109 mg/mL	5.46	-4.4	8.53	-3.7			
C21H22O4	Not Available	Not Available	338.397	COC1=CC(O)=C(C=C1CC=C(C)C)C(=O)\C=C\C1=CC=C(O)C=C1	Solid	Not Available					246523			4479431						BVL			5321765	99443971					ZINC000019816069		(2E)-1-[2-hydroxy-4-methoxy-5-(3-methylbut-2-en-1-yl)phenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one	Experimental	DB07500	InChI=1S/C21H22O4/c1-14(2)4-8-16-12-18(20(24)13-21(16)25-3)19(23)11-7-15-5-9-17(22)10-6-15/h4-7,9-13,22,24H,8H2,1-3H3/b11-7+	ZUGCRBMNFSAUOC-YRNVUSSQSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.2755 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	2	No	2	-1	66.76 Å2	37.26 Å3	101.54 m3·mol-1	6	No	No	0.00322 mg/mL	5.5	-5	7.07	-4.9	Q9NZK7	PLA2G2E	1. Group IIE secretory phospholipase A2
C18H17NO5	Not Available	Not Available	327.3313	COC1=CC=C(\C=C\C(=O)NC2=CC=CC=C2C(O)=O)C=C1OC	Solid	Not Available	P08684;!P11712	CYP3A4;!CYP2C9	1. Cytochrome P450 3A4;!2. Cytochrome P450 2C9		21613	77572	CHEMBL415324	4445411					D02027	D27			5282230	99444086		57330		Tranilast	ZINC000000000797		Tranilast	Investigational	DB07615	InChI=1S/C18H17NO5/c1-23-15-9-7-12(11-16(15)24-2)8-10-17(20)19-14-6-4-3-5-13(14)18(21)22/h3-11H,1-2H3,(H,19,20)(H,21,22)/b10-8+	NZHGWWWHIYHZNX-CSKARUKUSA-N	4		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.4428 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	2	No	2	-1	84.86 Å2	34.2 Å3	91.52 m3·mol-1	6	Yes	No	0.0084 mg/mL	3.56	-4.6	3.55	-2			
C15H14O5	Not Available	Not Available	274.2687	OC1=CC=C(CCC(=O)C2=C(O)C=C(O)C=C2O)C=C1	Solid	Not Available					23446	17276	CHEMBL45068	4624		GtP Drug Page	HMDB0003306	C00774		G50			4788	99444281		1368167		Phloretin	ZINC000000047553		Phloretin	Experimental	DB07810	InChI=1S/C15H14O5/c16-10-4-1-9(2-5-10)3-6-12(18)15-13(19)7-11(17)8-14(15)20/h1-2,4-5,7-8,16-17,19-20H,3,6H2	VGEREEWJJVICBM-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.0976 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	4	No	2	0	97.99 Å2	27.75 Å3	73.71 m3·mol-1	4	Yes	No	0.132 mg/mL	3.9	-3.3	7.96	-4.6	Q9AIU0	ttgR	1. HTH-type transcriptional regulator TtgR
C17H18O3	Not Available	Not Available	270.323	[H][C@@](CC1=CC=CC=C1)(OC1=CC=C(CC)C=C1)C(O)=O	Solid	Not Available					50171895		CHEMBL191060	9325014						GRR			11149906	99444313					ZINC000013671697		(2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid	Experimental	DB07842	InChI=1S/C17H18O3/c1-2-13-8-10-15(11-9-13)20-16(17(18)19)12-14-6-4-3-5-7-14/h3-11,16H,2,12H2,1H3,(H,18,19)/t16-/m0/s1	CJMVTSLLWMPEKQ-INIZCTEOSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.7751 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	1	No	2	-1	46.53 Å2	29.37 Å3	77.36 m3·mol-1	6	Yes	No	0.0133 mg/mL	4.48	-4.3	4.06	-4.9			
C12H10O4	Not Available	Not Available	218.2054	OC(=O)C(\O)=C\C=C\C(=O)C1=CC=CC=C1	Solid	Not Available								20126668						HPX				99444385							2-hydroxy-6-oxo-6-phenyl-2,4-hexadienoic acid	Experimental	DB07914	InChI=1S/C12H10O4/c13-10(9-5-2-1-3-6-9)7-4-8-11(14)12(15)16/h1-8,14H,(H,15,16)/b7-4+,11-8-	RDRDHXDYMGUCKE-KXBBGWRGSA-N			Not Available	Small Molecule																																			1	Yes	4	2	No	1	-1	74.6 Å2	21.85 Å3	60.71 m3·mol-1	4	Yes	No	0.359 mg/mL	1.72	-2.8	3.25	-6.1	Q59721;!Q0S9X1	bphK;!Not Available	1. Glutathione S-transferase;!2. Catechol 2,3-dioxygenase
C12H10O4	Not Available	Not Available	218.2054	OC(=O)C(\O)=C/C=C/C(=O)C1=CC=CC=C1	Solid	Not Available								16188846						HPZ				99444386					ZINC000100036081		(2E,4E)-2-Hydroxy-6-oxo-6-phenyl-2,4-hexadienoic acid	Experimental	DB07915	InChI=1S/C12H10O4/c13-10(9-5-2-1-3-6-9)7-4-8-11(14)12(15)16/h1-8,14H,(H,15,16)/b7-4+,11-8+	RDRDHXDYMGUCKE-VCABWLAWSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.4253 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	2	No	1	-1	74.6 Å2	21.7 Å3	60.71 m3·mol-1	4	Yes	No	0.359 mg/mL	1.72	-2.8	3.25	-6.1	P47229	bphD	1. 2-hydroxy-6-oxo-6-phenylhexa-2,4-dienoate hydrolase
C9H9NO4	Not Available	Not Available	195.1721	[H]N=C(CC1=CC(O)=C(O)C=C1)C(O)=O	Solid	Not Available														IM3			46937113	99444450							(2E)-3-(3,4-DIHYDROXYPHENYL)-2-IMINOPROPANOIC ACID	Experimental	DB07979	InChI=1S/C9H9NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,10-12H,3H2,(H,13,14)/b10-6-	VFINRVRRNHRWEQ-POHAHGRESA-N			Not Available	Small Molecule				AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3100 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	4	No	1	0	101.61 Å2	18.07 Å3	59.15 m3·mol-1	3	Yes	No	0.533 mg/mL	0.82	-2.6	3.62	2.6	P14920	DAO	1. D-amino-acid oxidase
C11H12O3	Not Available	Not Available	192.2112	OC(=O)C(=O)CCCC1=CC=CC=C1	Solid	Not Available								11384294						KPV			13294447	99444521							5-phenyl-2-keto-valeric acid	Experimental	DB08050	InChI=1S/C11H12O3/c12-10(11(13)14)8-4-7-9-5-2-1-3-6-9/h1-3,5-6H,4,7-8H2,(H,13,14)	MJXXAPORLGKVLB-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.6802 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	1	No	1	-1	54.37 Å2	19.97 Å3	51.91 m3·mol-1	5	Yes	No	0.18 mg/mL	2.79	-3	3.56	-9.7	P51852	ipdC	1. Indole-3-pyruvate decarboxylase
C14H12O4	Not Available	Not Available	244.246	OC1=CC(\C=C\C2=CC=C(O)C(O)=C2)=CC(O)=C1	Solid	Not Available					50045936	28814	CHEMBL69863	581006			HMDB0004215	C05901		PIT			667639	99444870				Piceatannol	ZINC000000014036		Piceatannol	Experimental	DB08399	InChI=1S/C14H12O4/c15-11-5-10(6-12(16)8-11)2-1-9-3-4-13(17)14(18)7-9/h1-8,15-18H/b2-1+	CDRPUGZCRXZLFL-OWOJBTEDSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Inhibitor	Non-inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.8860 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	4	No	2	0	80.92 Å2	25.46 Å3	69.44 m3·mol-1	2	Yes	No	0.097 mg/mL	3.1	-3.4	8.41	-6.2	P25705;!P06576;!P36542	ATP5A1;!ATP5B;!ATP5C1	1. ATP synthase subunit alpha, mitochondrial;!2. ATP synthase subunit beta, mitochondrial;!3. ATP synthase subunit gamma, mitochondrial
C14H14O3	Not Available	Not Available	230.2592	OC1=CC=C(CCC2=CC(O)=CC(O)=C2)C=C1	Solid	Not Available					50085531	4582	CHEMBL111234	161607				C10255		RE2			185914	99444937					ZINC000000899123		5-[2-(4-hydroxyphenyl)ethyl]benzene-1,3-diol	Experimental	DB08466	InChI=1S/C14H14O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h3-9,15-17H,1-2H2	HITJFUSPLYBJPE-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.6999 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	3	No	2	0	60.69 Å2	24.87 Å3	66.34 m3·mol-1	3	Yes	No	0.0812 mg/mL	3.6	-3.4	9.3	-5.4			
C16H15NO4	Not Available	Not Available	285.2946	ON(CCOC1=CC=CC(=C1)C(=O)C1=CC=CC=C1)C=O	Solid	Not Available					21684			4451320						SB8			5289330	99444995					ZINC000014976917		2-(3-BENZOYLPHENOXY)ETHYL(HYDROXY)FORMAMIDE	Experimental	DB08524	InChI=1S/C16H15NO4/c18-12-17(20)9-10-21-15-8-4-7-14(11-15)16(19)13-5-2-1-3-6-13/h1-8,11-12,20H,9-10H2	ZHFKBNAHHTUQBH-UHFFFAOYSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Non-substrate	2.1700 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	1	No	2	0	66.84 Å2	29.06 Å3	77.76 m3·mol-1	6	Yes	No	0.0417 mg/mL	2.24	-3.8	8.27	-4.9			
C10H8O4	Not Available	Not Available	192.1681	OC(=O)C(=O)\C=C\C1=CC=CC=C1O	Solid	Not Available						59354		4444428				C06203		TOH			5280911	99445107							2-Hydroxybenzalpyruvate	Experimental	DB08636	InChI=1S/C10H8O4/c11-8-4-2-1-3-7(8)5-6-9(12)10(13)14/h1-6,11H,(H,13,14)/b6-5+	HMXOGGUFCBUALL-AATRIKPKSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.5021 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	2	No	1	-1	74.6 Å2	18.3 Å3	50.39 m3·mol-1	3	Yes	No	0.623 mg/mL	2.12	-2.5	2.84	-6.4	Q51948	nahD	1. 2-hydroxychromene-2-carboxylate isomerase
C21H21NO5	Not Available	Not Available	367.3951	CC(=O)OC1=CC=C(\C=C\C(=O)NCCC2=CC=CC=C2)C=C1OC(C)=O	Solid	Not Available								10131649						Y12			11957394	99445224					ZINC000016051983		4-{(1E)-3-OXO-3-[(2-PHENYLETHYL)AMINO]PROP-1-EN-1-YL}-1,2-PHENYLENE DIACETATE	Experimental	DB08753	InChI=1S/C21H21NO5/c1-15(23)26-19-10-8-18(14-20(19)27-16(2)24)9-11-21(25)22-13-12-17-6-4-3-5-7-17/h3-11,14H,12-13H2,1-2H3,(H,22,25)/b11-9+	GARHCDOTUULBOQ-PKNBQFBNSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.0392 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	1	No	2	0	81.7 Å2	39.39 Å3	101.41 m3·mol-1	9	Yes	No	0.000717 mg/mL	2.78	-5.7	15.17	-0.39	Q672W7	def	1. Peptide deformylase
C17H17NO4	Not Available	Not Available	299.3212	OC1=CC=C(CCNC(=O)\C=C\C2=CC(O)=C(O)C=C2)C=C1	Solid	Not Available							CHEMBL206646	8170478			HMDB0033026			Y13			9994897	99445225					ZINC000013515185		N-Caffeoyltyramine	Experimental	DB08754	InChI=1S/C17H17NO4/c19-14-5-1-12(2-6-14)9-10-18-17(22)8-4-13-3-7-15(20)16(21)11-13/h1-8,11,19-21H,9-10H2,(H,18,22)/b8-4+	VSHUQLRHTJOKTA-XBXARRHUSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.9665 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	4	No	2	0	89.79 Å2	32.1 Å3	85.09 m3·mol-1	5	Yes	No	0.038 mg/mL	2.66	-3.9	9.04	-0.39	Q672W7	def	1. Peptide deformylase
C15H13ClO3	Not Available	Not Available	276.715	[H][C@@](CC1=CC=CC=C1)(OC1=CC=C(Cl)C=C1)C(O)=O	Solid	Not Available					50171897		CHEMBL364748	9634928						YRG			11460087	99445231					ZINC000013671687		(2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid	Experimental	DB08760	InChI=1S/C15H13ClO3/c16-12-6-8-13(9-7-12)19-14(15(17)18)10-11-4-2-1-3-5-11/h1-9,14H,10H2,(H,17,18)/t14-/m0/s1	CPBLTMSKPQDJPW-AWEZNQCLSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.4534 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	1	No	2	-1	46.53 Å2	27.69 Å3	72.52 m3·mol-1	5	Yes	No	0.0299 mg/mL	4.12	-4	3.66	-4.9			
C21H23FN2O5	Not Available	Not Available	402.4161	C[C@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)OCC1=CC=CC=C1)C(=O)CF	Solid	Not Available							CHEMBL68828	23161386						ZYA			15118984	99445246					ZINC000026272137		Benzoyl-tyrosine-alanine-fluoro-methyl ketone	Experimental	DB08775	InChI=1S/C21H23FN2O5/c1-14(19(26)12-22)23-20(27)18(11-15-7-9-17(25)10-8-15)24-21(28)29-13-16-5-3-2-4-6-16/h2-10,14,18,25H,11-13H2,1H3,(H,23,27)(H,24,28)/t14-,18-/m0/s1	RYABQRLJLIHDIP-KSSFIOAISA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.2664 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	3	No	2	0	104.73 Å2	40.51 Å3	103.64 m3·mol-1	10	Yes	No	0.0217 mg/mL	2.8	-4.3	9.5	-4.5	Q9UBX1	CTSF	1. Cathepsin F
C15H20O3	No pharmacokinetic data available.	No pharmacokinetic data available.	248.322	COC1=CC=C(\C=C\C(=O)OCCC(C)C)C=C1	Liquid	No pharmacokinetic data available.							CHEMBL1476782	1266578												1426854		Amiloxate	ZINC000001600509		Amiloxate	Approved	DB11207	InChI=1S/C15H20O3/c1-12(2)10-11-18-15(16)9-6-13-4-7-14(17-3)8-5-13/h4-9,12H,10-11H2,1-3H3/b9-6+	UBNYRXMKIIGMKK-RMKNXTFCSA-N	-Infinity		Oral LD50 in rat is 9600 mg/kg MSDS.	Small Molecule																													170			< -30		Insoluble	1	Yes	2	0	No	1	0	35.53 Å2	28.33 Å3	72.71 m3·mol-1	7	Yes	Yes	0.00738 mg/mL	3.97	-4.5		-4.8			
C14H12O4	No pharmacokinetic data available.	No pharmacokinetic data available.	244.246	COC1=CC(O)=C(C=C1)C(=O)C1=CC=CC=C1O	Solid	No pharmacokinetic data available.						34208	CHEMBL1326877	8251				C14283	D03853							23350		Dioxybenzone	ZINC000000037293		Dioxybenzone	Approved	DB11221	InChI=1S/C14H12O4/c1-18-9-6-7-11(13(16)8-9)14(17)10-4-2-3-5-12(10)15/h2-8,15-16H,1H3	MEZZCSHVIGVWFI-UHFFFAOYSA-N		Dioxybenzone is a benzophenone derivative used in sunscreens to block UVB and short-wave UVA radiation.	No toxicokinetic data available.	Small Molecule																													172.5			74			1	Yes	4	2	No	2	-1	66.76 Å2	24.81 Å3	67.06 m3·mol-1	3	Yes	No	0.148 mg/mL	3.97	-3.2	6.78	-4.8	P04278	SHBG	1. Sex hormone-binding globulin
C12H14O4	Not Available	Not Available	222.2372	[H]\C(=C(\[H])C1=CC(OC)=C(O)C=C1)C(=O)OCC	Not Available	Not Available					50297424		CHEMBL286796	643791						ZYC						1420983			ZINC000000160496		Ethyl ferulate	Approved, Experimental	DB11285	InChI=1S/C12H14O4/c1-3-16-12(14)7-5-9-4-6-10(13)11(8-9)15-2/h4-8,13H,3H2,1-2H3/b7-5+	ATJVZXXHKSYELS-FNORWQNLSA-N			Not Available	Small Molecule																																			1	Yes	3	1	No	1	0	55.76 Å2	23.57 Å3	61.02 m3·mol-1	5	Yes	No	0.328 mg/mL	2.41	-2.8	9.87	-4.9			
C9H10O4	Not Available	The serum half-life of Aspirin, a similar salicylate, is 20 min 20.	182.175	OCCOC(=O)C1=CC=CC=C1O	Liquid	Not Available						86541	CHEMBL173562	6616									6880	347827966		26051			ZINC000001698306	Salonpas Gel-patch	Glycol salicylate	Approved	DB11323	InChI=1S/C9H10O4/c10-5-6-13-9(12)7-3-1-2-4-8(7)11/h1-4,10-11H,5-6H2	LVYLCBNXHHHPSB-UHFFFAOYSA-N		Glycol salicylate is a salicylate used to treat mild to moderate muscle pain.	Acute ingestion of > 150 mg/kg of salicylates may result in severe toxicity. Salicylate tablets may form stomach bezoars, prolonging absorption of the drug and toxicity. Chronic toxicity can occur after several days or more of high therapeutic doses; it is common, often undiagnosed, and often more serious than acute toxicity. Chronic toxicity is likely to occur in elderly patients 15.Treatment for salicylate poisoning consists of activated charcoal and alkaline diuresis with extra KCl 15.Unless contraindicated (eg, by altered mental status), activated charcoal is administered as soon as possible and, if bowel sounds are active and there is adequate gastrointestinal motility, may be repeated every 4 hours until charcoal appears in the stool 15.After volume and electrolyte abnormalities are corrected and maintained, alkaline diuresis can be used to increase urine pH, ideally to ≥ 8. Alkaline diuresis is advised for patients with any symptoms of poisoning and should not be delayed until salicylate levels are determined. This process is usually safe and greatly increases the rate of salicylate excretion. Because hypokalemia can interfere with alkaline diuresis, patients are often given a solution composed of 1 L of 5% D/W, 3 50-mEq ampules of NaHCO3, and 40 mEq of KCl at 1.5 to 2 times the maintenance IV fluid rate. Serum potassium levels are monitored. Due to the fact that fluid overload can lead to the occurrence of pulmonary edema, patients are monitored for respiratory findings 15.Drugs that increase urinary HCO3 (eg, acetazolamide) must be avoided because they worsen metabolic acidosis and decrease blood pH. Drugs that decrease respiratory drive should be avoided when possible because they may impair hyperventilation and respiratory alkalosis, decreasing blood pH 16.	Small Molecule																													166			25		13.1 g/L	1	Yes	3	2	No	1	0	66.76 Å2	18.04 Å3	46.36 m3·mol-1	4	Yes	No	3.8 mg/mL	1.63	-1.7	9.72	-2.8	P23219;!P35354	PTGS1;!PTGS2	1. Prostaglandin G/H synthase 1;!2. Prostaglandin G/H synthase 2
C13H10Cl2O2	Not Available	Not Available	269.12	OC1=CC=C(Cl)C=C1CC1=CC(Cl)=CC=C1O	Not Available	Not Available					50303912	34689	CHEMBL33845	2929				C14292		JAL						3351		Dichlorophen	ZINC000000056435		Dichlorophen	Experimental, Vet approved	DB11396	InChI=1S/C13H10Cl2O2/c14-10-1-3-12(16)8(6-10)5-9-7-11(15)2-4-13(9)17/h1-4,6-7,16-17H,5H2	MDNWOSOZYLHTCG-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	Yes	2	2	No	2	0	40.46 Å2	25.61 Å3	69.37 m3·mol-1	2	Yes	No	0.0309 mg/mL	4.67	-3.9	7.22	-6.3			
C21H20O6	No pharmacokinetic data available.	No pharmacokinetic data available.	368.3799	COC1=CC(\C=C\C(=O)CC(=O)\C=C\C2=CC(OC)=C(O)C=C2)=CC=C1O	Solid	Following oral administration of radio-labelled curcumin to rats, radioactivity was detected in the liver and kidneys 3.	P11712;!P08684;!P20813;!P05177;!P10635;!P08263;!P09488;!P09211	CYP2C9;!CYP3A4;!CYP2B6;!CYP1A2;!CYP2D6;!GSTA1;!GSTM1;!GSTP1	1. Cytochrome P450 2C9;!2. Cytochrome P450 3A4;!3. Cytochrome P450 2B6;!4. Cytochrome P450 1A2;!5. Cytochrome P450 2D6;!6. Glutathione S-transferase A1;!7. Glutathione S-transferase Mu 1;!8. Glutathione S-transferase P		50140172	3962	CHEMBL140	839564			HMDB0002269			CC9			969516	347828040		2955		Curcumin	ZINC000000899824		Curcumin	Approved, Investigational	DB11672	InChI=1S/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-12,24-25H,13H2,1-2H3/b7-3+,8-4+	VFLDPWHFBUODDF-FCXRPNKRSA-N	4		In an acute oral toxicity study in mouse, LD50 was >2000 mg/kg MSDS. Single oral doses of curcumin at 1-5 g/kg bw induced no toxic effects in rats 3. There has been no cases of overdose reported 3.	Small Molecule																																183		Insoluble in cold water	1	Yes	6	2	No	2	0	93.06 Å2	38.12 Å3	103.81 m3·mol-1	8	Yes	No	0.00575 mg/mL	4.12	-4.8	9.08	-4.4	P37231;!P11473;!O15440;!P16152;!P09211	PPARG;!VDR;!ABCC5;!CBR1;!GSTP1	1. Peroxisome proliferator-activated receptor gamma;!2. Vitamin D3 receptor;!3. Multidrug resistance-associated protein 5;!4. Carbonyl reductase [NADPH] 1;!5. Glutathione S-transferase P
C16H18O9	Not Available	Not Available	354.3087	O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\C2=CC(O)=C(O)C=C2)[C@@H]1O)C(O)=O	Not Available	Not Available					50327036	16112	CHEMBL284616	1405788			HMDB0003164	C00852					1794427	347828344		1311387			ZINC000002138728		Chlorogenic Acid	Investigational	DB12029	InChI=1S/C16H18O9/c17-9-3-1-8(5-10(9)18)2-4-13(20)25-12-7-16(24,15(22)23)6-11(19)14(12)21/h1-5,11-12,14,17-19,21,24H,6-7H2,(H,22,23)/b4-2+/t11-,12-,14-,16+/m1/s1	CWVRJTMFETXNAD-JUHZACGLSA-N	2		Not Available	Small Molecule																																			1	Yes	8	6	No	2	-1	164.75 Å2	33.42 Å3	83.23 m3·mol-1	5	No	No	3.44 mg/mL	-0.27	-2	3.33	-3.2			
C20H26O6	Not Available	Not Available	362.4168	COC1=C(O)C=CC(C[C@@H](CO)[C@H](CO)CC2=CC(OC)=C(O)C=C2)=C1	Not Available	Not Available					50240914	65004	CHEMBL368347	58845			HMDB0013692	C18167		GO6			65373	347828466				Secoisolariciresinol	ZINC000002020114		Secoisolariciresinol	Investigational	DB12179	InChI=1S/C20H26O6/c1-25-19-9-13(3-5-17(19)23)7-15(11-21)16(12-22)8-14-4-6-18(24)20(10-14)26-2/h3-6,9-10,15-16,21-24H,7-8,11-12H2,1-2H3/t15-,16-/m0/s1	PUETUDUXMCLALY-HOTGVXAUSA-N	2		Not Available	Small Molecule																																			1	Yes	6	4	No	2	0	99.38 Å2	38.59 Å3	99.29 m3·mol-1	9	Yes	No	0.012 mg/mL	2.33	-4.5	9.96	-2.6			
C21H26O4	Not Available	Not Available	342.435	CC(C)(C)C1=CC=C(CCC(O)COC2=CC=C(C=C2)C(O)=O)C=C1	Not Available	Not Available							CHEMBL2105019	51499									57112	347828689							Lifibrol	Investigational	DB12448	InChI=1S/C21H26O4/c1-21(2,3)17-9-4-15(5-10-17)6-11-18(22)14-25-19-12-7-16(8-13-19)20(23)24/h4-5,7-10,12-13,18,22H,6,11,14H2,1-3H3,(H,23,24)	LNXBEIZREVRNTF-UHFFFAOYSA-N	3		Not Available	Small Molecule																																			1	Yes	4	2	No	2	-1	66.76 Å2	39.33 Å3	98.37 m3·mol-1	8	Yes	No	0.00586 mg/mL	4.85	-4.8	4.36	-3			
C16H17NO3	Not Available	Not Available	271.3111	OC1=CC=C(CC2NCCC3=C2C=C(O)C(O)=C3)C=C1	Not Available	Not Available						18418	CHEMBL19344	102800			HMDB0033103	C06346					114840	347828960				Higenamine			Higenamine	Investigational	DB12779	InChI=1S/C16H17NO3/c18-12-3-1-10(2-4-12)7-14-13-9-16(20)15(19)8-11(13)5-6-17-14/h1-4,8-9,14,17-20H,5-7H2	WZRCQWQRFZITDX-UHFFFAOYSA-N	1		Not Available	Small Molecule																																			1	Yes	4	4	No	3	1	72.72 Å2	29.25 Å3	77.6 m3·mol-1	2	Yes	No	0.236 mg/mL	2.36	-3.1	8.56	9.47			
C10H13NO4	Not Available	Not Available	211.217	COC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1	Not Available	Not Available						134880	CHEMBL1328898	21968														Melevodopa	ZINC000019861870		Melevodopa	Experimental	DB13313	InChI=1S/C10H13NO4/c1-15-10(14)7(11)4-6-2-3-8(12)9(13)5-6/h2-3,5,7,12-13H,4,11H2,1H3/t7-/m0/s1	XBBDACCLCFWBSI-ZETCQYMHSA-N		Melevodopa is a methyl ester of levodopa indicated in combination with carbidopa for the treatment of Parkinson's disease.	Not Available	Small Molecule																																			1	Yes	4	3	No	1	1	92.78 Å2	21.25 Å3	53.85 m3·mol-1	4	Yes	No	2.15 mg/mL	0.62	-2	9.29	6.97			
C19H23NO3	Not Available	Not Available	313.397	COC1=CC(=CC=C1)C(=O)CCN[C@@H](C)[C@H](O)C1=CC=CC=C1	Not Available	Not Available						135343	CHEMBL1651913	4590049												7805		Oxyfedrine	ZINC000002018339		Oxyfedrine	Experimental	DB13398	InChI=1S/C19H23NO3/c1-14(19(22)15-7-4-3-5-8-15)20-12-11-18(21)16-9-6-10-17(13-16)23-2/h3-10,13-14,19-20,22H,11-12H2,1-2H3/t14-,19-/m0/s1	GDYUVHBMFVMBAF-LIRRHRJNSA-N			Not Available	Small Molecule																																			1	Yes	4	2	No	2	1	58.56 Å2	34.91 Å3	90.75 m3·mol-1	8	Yes	No	0.0217 mg/mL	2.63	-4.2	13.88	9.06			
C21H27NO2	Not Available	Not Available	325.452	CCN(CC)CCOC1=CC=CC=C1C(=O)CCC1=CC=CC=C1	Not Available	Not Available						135389	CHEMBL1736151	3160					D01440									Etafenone	ZINC000000001376		Etafenone	Experimental	DB13845	InChI=1S/C21H27NO2/c1-3-22(4-2)16-17-24-21-13-9-8-12-19(21)20(23)15-14-18-10-6-5-7-11-18/h5-13H,3-4,14-17H2,1-2H3	OEGDFSLNGABBKJ-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	Yes	3	0	No	2	1	29.54 Å2	38.46 Å3	99.76 m3·mol-1	10	Yes	Yes	0.0111 mg/mL	4.38	-4.5	16.33	8.53			
C11H14O3	Not Available	Not Available	194.2271	CCCCOC(=O)C1=CC=C(O)C=C1	Solid	Not Available					23448	88542	CHEMBL459008	6916			HMDB0032575		D01420	27K						1306937		Butylparaben	ZINC000001586769		Butylparaben	Approved, Experimental	DB14084	InChI=1S/C11H14O3/c1-2-3-8-14-11(13)9-4-6-10(12)7-5-9/h4-7,12H,2-3,8H2,1H3	QFOHBWFCKVYLES-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	Yes	2	1	No	1	0	46.53 Å2	21.45 Å3	53.94 m3·mol-1	5	Yes	No	0.466 mg/mL	3	-2.6	8.5	-6.1			
C16H14O4	Not Available	Not Available	270.284	COC1=C(C(=O)\C=C\C2=CC=CC=C2)C(O)=CC(O)=C1	Not Available	Not Available					50185446		CHEMBL378104	557026			HMDB0132913											Cardamomin	ZINC000004716487		Dihydroxymethoxychalcone	Experimental	DB14122	InChI=1S/C16H14O4/c1-20-15-10-12(17)9-14(19)16(15)13(18)8-7-11-5-3-2-4-6-11/h2-10,17,19H,1H3/b8-7+	NYSZJNUIVUBQMM-BQYQJAHWSA-N			Not Available	Small Molecule																																			1	Yes	4	2	No	2	0	66.76 Å2	28.42 Å3	77.3 m3·mol-1	4	Yes	No	0.0777 mg/mL	3.78	-3.5	7.2	-4.9			
C14H12O3	Not Available	Not Available	228.247	OC1=CC=C(C=C1)C(=O)OCC1=CC=CC=C1	Not Available	Not Available						34571	CHEMBL447861	6912				C14393	D07518							19075		Paraben	ZINC000000388756		Benzylparaben	Approved, Experimental	DB14176	InChI=1S/C14H12O3/c15-13-8-6-12(7-9-13)14(16)17-10-11-4-2-1-3-5-11/h1-9,15H,10H2	MOZDKDIOPSPTBH-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	Yes	2	1	No	2	0	46.53 Å2	24.13 Å3	64.68 m3·mol-1	4	Yes	No	0.135 mg/mL	3.4	-3.2	8.5	-6.1			
C10H12O3	Not Available	Not Available	180.2005	CCCOC(=O)C1=CC=C(O)C=C1	Not Available	Not Available					70190	32063	CHEMBL194014	6907			HMDB0032574		D01422	36M						34706		Propylparaben	ZINC000001586788		Propylparaben	Approved, Experimental	DB14177	InChI=1S/C10H12O3/c1-2-7-13-10(12)8-3-5-9(11)6-4-8/h3-6,11H,2,7H2,1H3	QELSKZZBTMNZEB-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	Yes	2	1	No	1	0	46.53 Å2	19.35 Å3	49.34 m3·mol-1	4	Yes	No	0.96 mg/mL	2.55	-2.3	8.5	-6.1			
C21H20O9S	No pharmacokinetic data available.	No pharmacokinetic data available.	448.44	COC1=CC(\C=C\C(=O)CC(=O)\C=C\C2=CC=C(OS(O)(=O)=O)C(OC)=C2)=CC=C1O	Not Available	Following oral administration of radio-labelled curcumin to rats, radioactivity was detected in the liver and kidneys 2.	P33261;!P20813;!BE0009758;!P11712;!P08684;!P20815;!P10635;!P05177;!O75897;!P0DMM9;!P49888;!O43704	CYP2C19;!CYP2B6;!;!CYP2C9;!CYP3A4;!CYP3A5;!CYP2D6;!CYP1A2;!SULT1C4;!SULT1A3;!SULT1E1;!SULT1B1	1. Cytochrome P450 2C19;!2. Cytochrome P450 2B6;!3. UDP-glucuronosyltransferases (UGTs) (Protein Group);!4. Cytochrome P450 2C9;!5. Cytochrome P450 3A4;!6. Cytochrome P450 3A5;!7. Cytochrome P450 2D6;!8. Cytochrome P450 1A2;!9. Sulfotransferase 1C4;!10. Sulfotransferase 1A3/1A4;!11. Estrogen sulfotransferase;!12. Sulfotransferase family cytosolic 1B member 1					34988878															ZINC000011524418		Curcumin sulfate	Experimental	DB14635	InChI=1S/C21H20O9S/c1-28-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(21(12-15)29-2)30-31(25,26)27/h3-12,24H,13H2,1-2H3,(H,25,26,27)/b7-3+,8-4+	NEJVQQBBTRFOHB-FCXRPNKRSA-N			In an acute oral toxicity study in mouse, LD50 was >2000 mg/kg MSDS. Single oral doses of curcumin at 1-5 g/kg bw induced no toxic effects in rats 2. There has been no cases of overdose reported 2.	Small Molecule																																			1	Yes	8	2	No	2	-1	136.43 Å2	43.54 Å3	113.8 m3·mol-1	10	Yes	No	0.00831 mg/mL	3.65	-4.7	-2.2	-4.4	P37231;!P11473;!O15440;!P16152;!P09211	PPARG;!VDR;!ABCC5;!CBR1;!GSTP1	1. Peroxisome proliferator-activated receptor gamma;!2. Vitamin D3 receptor;!3. Multidrug resistance-associated protein 5;!4. Carbonyl reductase [NADPH] 1;!5. Glutathione S-transferase P
C14H11NO5	Not Available	Not Available	273.244	OC1=C(O)C(=CC(=C1)C(=O)CC1=CC=CC=C1)[N+]([O-])=O	Not Available	Not Available					50108878		CHEMBL160038	8014109															ZINC000000008750		Nebicapone	Investigational	DB14849	InChI=1S/C14H11NO5/c16-12(6-9-4-2-1-3-5-9)10-7-11(15(19)20)14(18)13(17)8-10/h1-5,7-8,17-18H,6H2	MRFOLGFFTUGAEB-UHFFFAOYSA-N	2		Not Available	Small Molecule																																			1	Yes	5	2	No	2	-1	100.67 Å2	26.52 Å3	71.46 m3·mol-1	4	Yes	No	0.075 mg/mL	2.7	-3.6	5.5	-6.5			
C26H22O10	Not Available	Not Available	494.452	OC(=O)[C@@H](CC1=CC(O)=C(O)C=C1)OC(=O)\C=C\C1=C(/C=C/C2=CC(O)=C(O)C=C2)C(O)=C(O)C=C1	Not Available	Not Available					50414250	9017	CHEMBL457077	4445105				C10492											ZINC000004098737		Salvianolic acid A	Investigational	DB15246	InChI=1S/C26H22O10/c27-18-7-2-14(11-21(18)30)1-6-17-16(4-9-20(29)25(17)33)5-10-24(32)36-23(26(34)35)13-15-3-8-19(28)22(31)12-15/h1-12,23,27-31,33H,13H2,(H,34,35)/b6-1+,10-5+/t23-/m1/s1	YMGFTDKNIWPMGF-UCPJVGPRSA-N			Not Available	Small Molecule																																			1	No	9	7	Yes	3	-1	184.98 Å2	48.67 Å3	130.37 m3·mol-1	9	No	No	0.00867 mg/mL	4.74	-4.8	3.14	-6.3			
C21H22O5	Not Available	Not Available	354.3964	COC1=C(C(=O)\C=C\C2=CC=C(O)C=C2)C(O)=C(CC=C(C)C)C(O)=C1	Not Available	Not Available					50384998	66331	CHEMBL253896	555077			HMDB0037479	C16417										Xanthohumol	ZINC000005158937		Xanthohumol	Investigational	DB15359	InChI=1S/C21H22O5/c1-13(2)4-10-16-18(24)12-19(26-3)20(21(16)25)17(23)11-7-14-5-8-15(22)9-6-14/h4-9,11-12,22,24-25H,10H2,1-3H3/b11-7+	ORXQGKIUCDPEAJ-YRNVUSSQSA-N	1		Not Available	Small Molecule																																			1	Yes	5	3	No	2	-1	86.99 Å2	38.52 Å3	103.53 m3·mol-1	6	No	No	0.00556 mg/mL	5.2	-4.8	7.01	-4.9			
C21H27NO3	Not Available	Not Available	341.451	CCCNC[C@H](O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1	Not Available	Not Available							CHEMBL1322675	160687															ZINC000001530759		(S)-Propafenone	Investigational	DB15410	InChI=1S/C21H27NO3/c1-2-14-22-15-18(23)16-25-21-11-7-6-10-19(21)20(24)13-12-17-8-4-3-5-9-17/h3-11,18,22-23H,2,12-16H2,1H3/t18-/m0/s1	JWHAUXFOSRPERK-SFHVURJKSA-N			Not Available	Small Molecule																																			1	Yes	4	2	No	2	1	58.56 Å2	39.58 Å3	100.21 m3·mol-1	11	Yes	No	0.00758 mg/mL	3.54	-4.6	14.09	9.72			
C14H18O4	Not Available	Not Available	250.294	CCOCCOC(=O)\C=C\C1=CC=C(OC)C=C1	Not Available	Not Available							CHEMBL2104045	4523729												288262		Cinoxate	ZINC000002041136		Cinoxate	Approved	DB15467	InChI=1S/C14H18O4/c1-3-17-10-11-18-14(15)9-6-12-4-7-13(16-2)8-5-12/h4-9H,3,10-11H2,1-2H3/b9-6+	CMDKPGRTAQVGFQ-RMKNXTFCSA-N			Not Available	Small Molecule																																			1	Yes	3	0	No	1	0	44.76 Å2	27.39 Å3	70.08 m3·mol-1	8	Yes	No	0.0451 mg/mL	2.67	-3.7		-4.1			
C12H14O3	Not Available	Not Available	206.241	CCOC(=O)\C=C\C1=CC=C(OC)C=C1	Not Available	Not Available					50486903		CHEMBL95956	4445096			HMDB0030762	C10476								2468050			ZINC000000899863		Ethyl methoxycinnamate	Experimental	DB16440	InChI=1S/C12H14O3/c1-3-15-12(13)9-6-10-4-7-11(14-2)8-5-10/h4-9H,3H2,1-2H3/b9-6+	DHNGCHLFKUPGPX-RMKNXTFCSA-N			Not Available	Small Molecule																																			1	Yes	2	0	No	1	0	35.53 Å2	22.78 Å3	59.04 m3·mol-1	5	Yes	Yes		2.71			-4.8			
C6H9N3O2	Not Available	Not Available	155.1546	N[C@@H](CC1=CNC=N1)C(O)=O	Solid	Not Available					7953	15971	CHEMBL17962	6038		GtP Drug Page	HMDB0000177	C00135	D00032	HIS	PDRhealth Drug Page	PA449882	6274	46507001		5340		Histidine	ZINC000006661227	Aminosyn II 7 %, Sulfite-free, Aminosyn-PF 7%, Clinimix 2.75/5, Clinimix E 2.75/5, Clinisol 15, Freamine 6.9, Freamine III 10, Hepatamine 8, Nephramine, Olimel, Periolimel, Plenamine, Premasol, Primene, Procalamine 3, Prosol, Travasol 10, Trophamine 10 %	Histidine	Investigational, Nutraceutical	DB00117	InChI=1S/C6H9N3O2/c7-5(6(10)11)1-4-2-8-3-9-4/h2-3,5H,1,7H2,(H,8,9)(H,10,11)/t5-/m0/s1	HNDVDQJCIGZPNO-YFKPBYRVSA-N	3	Histidine is an amino acid commonly found as a component of total parenteral nutrition.	ORL-RAT LD50 > 15000 mg/kg, IPR-RAT LD50 > 8000 mg/kg, ORL-MUS LD50 > 15000 mg/kg, IVN-MUS LD50 > 2000 mg/kg; Mild gastrointestinal side effects.	Small Molecule	http://smpdb.ca/view/SMP0000247?highlight[compounds][]=DB00117&highlight[proteins][]=DB00117;!http://smpdb.ca/view/SMP0000249?highlight[compounds][]=DB00117&highlight[proteins][]=DB00117;!http://smpdb.ca/view/SMP0000250?highlight[compounds][]=DB00117&highlight[proteins][]=DB00117;!http://smpdb.ca/view/SMP0000255?highlight[compounds][]=DB00117&highlight[proteins][]=DB00117;!http://smpdb.ca/view/SMP0000256?highlight[compounds][]=DB00117&highlight[proteins][]=DB00117;!http://smpdb.ca/view/SMP0000257?highlight[compounds][]=DB00117&highlight[proteins][]=DB00117;!http://smpdb.ca/view/SMP0000259?highlight[compounds][]=DB00117&highlight[proteins][]=DB00117;!http://smpdb.ca/view/SMP0000262?highlight[compounds][]=DB00117&highlight[proteins][]=DB00117;!http://smpdb.ca/view/SMP0000493?highlight[compounds][]=DB00117&highlight[proteins][]=DB00117;!http://smpdb.ca/view/SMP0000711?highlight[compounds][]=DB00117&highlight[proteins][]=DB00117;!http://smpdb.ca/view/SMP0000726?highlight[compounds][]=DB00117&highlight[proteins][]=DB00117;!http://smpdb.ca/view/SMP0000009?highlight[compounds][]=DB00117&highlight[proteins][]=DB00117;!http://smpdb.ca/view/SMP0000044?highlight[compounds][]=DB00117&highlight[proteins][]=DB00117;!http://smpdb.ca/view/SMP0000191?highlight[compounds][]=DB00117&highlight[proteins][]=DB00117;!http://smpdb.ca/view/SMP0000248?highlight[compounds][]=DB00117&highlight[proteins][]=DB00117;!http://smpdb.ca/view/SMP0000251?highlight[compounds][]=DB00117&highlight[proteins][]=DB00117;!http://smpdb.ca/view/SMP0000254?highlight[compounds][]=DB00117&highlight[proteins][]=DB00117;!http://smpdb.ca/view/SMP0000293?highlight[compounds][]=DB00117&highlight[proteins][]=DB00117;!http://smpdb.ca/view/SMP0000294?highlight[compounds][]=DB00117&highlight[proteins][]=DB00117;!http://smpdb.ca/view/SMP0000713?highlight[compounds][]=DB00117&highlight[proteins][]=DB00117;!http://smpdb.ca/view/SMP0000715?highlight[compounds][]=DB00117&highlight[proteins][]=DB00117;!http://smpdb.ca/view/SMP0000730?highlight[compounds][]=DB00117&highlight[proteins][]=DB00117;!http://smpdb.ca/view/SMP0000731?highlight[compounds][]=DB00117&highlight[proteins][]=DB00117;!http://smpdb.ca/view/SMP0000007?highlight[compounds][]=DB00117&highlight[proteins][]=DB00117;!http://smpdb.ca/view/SMP0000252?highlight[compounds][]=DB00117&highlight[proteins][]=DB00117;!http://smpdb.ca/view/SMP0000253?highlight[compounds][]=DB00117&highlight[proteins][]=DB00117;!http://smpdb.ca/view/SMP0000258?highlight[compounds][]=DB00117&highlight[proteins][]=DB00117;!http://smpdb.ca/view/SMP0000290?highlight[compounds][]=DB00117&highlight[proteins][]=DB00117;!http://smpdb.ca/view/SMP0000291?highlight[compounds][]=DB00117&highlight[proteins][]=DB00117;!http://smpdb.ca/view/SMP0000292?highlight[compounds][]=DB00117&highlight[proteins][]=DB00117	Azithromycin Action Pathway;!Clindamycin Action Pathway;!Erythromycin Action Pathway;!Kanamycin Action Pathway;!Neomycin Action Pathway;!Netilmicin Action Pathway;!Streptomycin Action Pathway;!Clomocycline Action Pathway;!Carnosinuria, Carnosinemia;!Tobramycin Action Pathway;!Rolitetracycline Action Pathway;!Ammonia Recycling;!Histidine Metabolism;!Histidinemia;!Clarithromycin Action Pathway;!Roxithromycin Action Pathway;!Gentamicin Action Pathway;!Oxytetracycline Action Pathway;!Tetracycline Action Pathway;!Arbekacin Action Pathway;!Methylhistidine Metabolism;!Troleandomycin Action Pathway;!Josamycin Action Pathway;!beta-Alanine Metabolism;!Telithromycin Action Pathway;!Amikacin Action Pathway;!Spectinomycin Action Pathway;!Demeclocycline Action Pathway;!Doxycycline Action Pathway;!Minocycline Action Pathway		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.7719 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					-3.32	-0.53	287 dec °C	2.76 (at 0 °C)	4.56E+004 mg/L (at 25 °C)	1	No	4	3	No	1	0	92 Å2	14.67 Å3	38.06 m3·mol-1	3	Yes	No	71.3 mg/mL	-3.6	-0.34	1.85	9.44	P19113;!P12081;!Q99624;!P42357	HDC;!HARS;!SLC38A3;!HAL	1. Histidine decarboxylase;!2. Histidine--tRNA ligase, cytoplasmic;!3. Sodium-coupled neutral amino acid transporter 3;!4. Histidine ammonia-lyase
C9H11NO2	Not Available	Not Available	165.1891	N[C@@H](CC1=CC=CC=C1)C(O)=O	Solid	Not Available					18073	17295	CHEMBL301523	5910		GtP Drug Page	HMDB0000159	C00079	D00021	PHE	PDRhealth Drug Page	PA450931	6140	46505708		8156	DAP000807	Phenylalanine	ZINC000000105196	Aminosyn II 7 %, Sulfite-free, Aminosyn-PF 7%, Clinimix 2.75/5, Clinimix E 2.75/5, Clinisol 15, Freamine 6.9, Freamine III 10, Hepatamine 8, Nephramine, Olimel, Periolimel, Plenamine, Premasol, Primene, Procalamine 3, Prosol, Travasol 10, Trophamine 10 %	Phenylalanine	Approved, Investigational, Nutraceutical	DB00120	InChI=1S/C9H11NO2/c10-8(9(11)12)6-7-4-2-1-3-5-7/h1-5,8H,6,10H2,(H,11,12)/t8-/m0/s1	COLNVLDHVKWLRT-QMMMGPOBSA-N	3	Phenylalanine is an amino acid commonly found as a component of total parenteral nutrition.	L-phenylalanine will exacerbate symptoms of phenylketonuria if used by phenylketonurics. L-phenylalanine was reported to exacerbate tardive dyskinesia when used by some with schizophrenia.	Small Molecule	http://smpdb.ca/view/SMP0000370?highlight[compounds][]=DB00120&highlight[proteins][]=DB00120;!http://smpdb.ca/view/SMP0000206?highlight[compounds][]=DB00120&highlight[proteins][]=DB00120;!http://smpdb.ca/view/SMP0000008?highlight[compounds][]=DB00120&highlight[proteins][]=DB00120;!http://smpdb.ca/view/SMP0000369?highlight[compounds][]=DB00120&highlight[proteins][]=DB00120	Tyrosinemia Type 3 (TYRO3);!Phenylketonuria;!Phenylalanine and Tyrosine Metabolism;!Tyrosinemia Type 2 (or Richner-Hanhart Syndrome)		Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.9053 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					-1.38		283 dec °C	1.24 (at 25 °C)	2.69E+004 mg/L (at 25 °C)	1	No	3	2	No	1	0	63.32 Å2	17.03 Å3	45.12 m3·mol-1	3	Yes	No	4.14 mg/mL	-1.2	-1.6	2.47	9.45	P17735;!Q9UHI5;!Q9Y285;!P00439;!O95363;!Q9NSD9;!P07101	TAT;!SLC7A8;!FARSA;!PAH;!FARS2;!FARSB;!TH	1. Tyrosine aminotransferase;!2. Large neutral amino acids transporter small subunit 2;!3. Phenylalanine--tRNA ligase alpha subunit;!4. Phenylalanine-4-hydroxylase;!5. Phenylalanine--tRNA ligase, mitochondrial;!6. Phenylalanine--tRNA ligase beta subunit;!7. Tyrosine 3-monooxygenase
C6H14N2O2	Not Available	Not Available	146.1876	NCCCC[C@H](N)C(O)=O	Solid	Not Available					217367	18019	CHEMBL8085	5747			HMDB0003405	C00047	D02304	LYS	PDRhealth Drug Page	PA450280	5962	46504770		6536		Lysine	ZINC000001532522	Aminosyn II 7 %, Sulfite-free, Aminosyn-PF 7%, Clinimix 2.75/5, Clinimix E 2.75/5, Clinisol 15, Freamine 6.9, Freamine III 10, Hepatamine 8, Nephramine, Olimel, Periolimel, Plenamine, Premasol, Primene, Procalamine 3, Prosol, Travasol 10, Trophamine 10 %	Lysine	Approved, Nutraceutical	DB00123	InChI=1S/C6H14N2O2/c7-4-2-1-3-5(8)6(9)10/h5H,1-4,7-8H2,(H,9,10)/t5-/m0/s1	KDXKERNSBIXSRK-YFKPBYRVSA-N	3	Lysine is an amino acid commonly found as a component of total parenteral nutrition.	Not Available	Small Molecule	http://smpdb.ca/view/SMP0000066?highlight[compounds][]=DB00123&highlight[proteins][]=DB00123;!http://smpdb.ca/view/SMP0000719?highlight[compounds][]=DB00123&highlight[proteins][]=DB00123;!http://smpdb.ca/view/SMP0000037?highlight[compounds][]=DB00123&highlight[proteins][]=DB00123;!http://smpdb.ca/view/SMP0000528?highlight[compounds][]=DB00123&highlight[proteins][]=DB00123;!http://smpdb.ca/view/SMP0000564?highlight[compounds][]=DB00123&highlight[proteins][]=DB00123;!http://smpdb.ca/view/SMP0000571?highlight[compounds][]=DB00123&highlight[proteins][]=DB00123;!http://smpdb.ca/view/SMP0000174?highlight[compounds][]=DB00123&highlight[proteins][]=DB00123;!http://smpdb.ca/view/SMP0000186?highlight[compounds][]=DB00123&highlight[proteins][]=DB00123;!http://smpdb.ca/view/SMP0000239?highlight[compounds][]=DB00123&highlight[proteins][]=DB00123;!http://smpdb.ca/view/SMP0000465?highlight[compounds][]=DB00123&highlight[proteins][]=DB00123;!http://smpdb.ca/view/SMP0000527?highlight[compounds][]=DB00123&highlight[proteins][]=DB00123	Biotin Metabolism;!2-Aminoadipic 2-Oxoadipic Aciduria;!Lysine Degradation;!Hyperlysinemia II or Saccharopinuria;!Multiple Carboxylase Deficiency, Neonatal or Early Onset Form;!Pyridoxine Dependency with Seizures;!Biotinidase Deficiency;!Glutaric Aciduria Type I;!Saccharopinuria/Hyperlysinemia II;!Carnitine Synthesis;!Hyperlysinemia I, Familial																												-3.05		224.5 dec °C	3.12 (at 0 °C)	1E+006 mg/L (at 20 °C)	1	No	4	3	No	0	1	89.34 Å2	15.84 Å3	37.81 m3·mol-1	5	Yes	No	105.0 mg/mL	-3.2	-0.14	2.74	10.29	P30825;!O43246;!Q8WY07;!P52569;!Q15046	SLC7A1;!SLC7A4;!SLC7A3;!SLC7A2;!KARS	1. High affinity cationic amino acid transporter 1;!2. Cationic amino acid transporter 4;!3. Cationic amino acid transporter 3;!4. Low affinity cationic amino acid transporter 2;!5. Lysine--tRNA ligase
C6H14N4O2	Not Available	Not Available	174.201	N[C@@H](CCCNC(N)=N)C(O)=O	Solid	Not Available					21959	16467	CHEMBL1485	6082	Drugs.com Drug Page	GtP Drug Page	HMDB0000517	C00062	D02982	ARG	PDRhealth Drug Page	PA448478	6322	46507180		1091		Arginine	ZINC000001532525	Aminosyn II 7 %, Sulfite-free, Aminosyn-PF 7%, Clinimix 2.75/5, Clinimix E 2.75/5, Clinisol 15, Freamine 6.9, Freamine III 10, Hepatamine 8, Olimel, Periolimel, Plenamine, Premasol, Primene, Procalamine 3, Prosol, R-gene, Travasol 10, Trophamine 10 %	Arginine	Investigational, Nutraceutical	DB00125	InChI=1S/C6H14N4O2/c7-4(5(11)12)2-1-3-10-6(8)9/h4H,1-3,7H2,(H,11,12)(H4,8,9,10)/t4-/m0/s1	ODKSFYDXXFIFQN-BYPYZUCNSA-N	4	Arginine is an amino acid commonly found as a component of total parenteral nutrition.	Oral supplementation with L-arginine at doses up to 15 grams daily are generally well tolerated. The most common adverse reactions of higher doses from 15 to 30 grams daily are nausea, abdominal cramps and diarrhea. Some may experience these symptoms at lower doses.	Small Molecule	http://smpdb.ca/view/SMP0000002?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000003?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000004?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000020?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000188?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000360?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000361?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000507?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000179?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000242?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000362?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000484?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000485?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000504?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000505?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000721?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000001?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000059?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000067?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000175?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000192?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000205?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000207?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000208?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000223?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000244?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000357?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000363?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000506?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0063777?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125	Carbamoyl Phosphate Synthetase Deficiency;!Argininosuccinic Aciduria;!Glycine and Serine Metabolism;!Arginine and Proline Metabolism;!Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency);!Hyperprolinemia Type II;!Hyperprolinemia Type I;!L-Arginine:Glycine Amidinotransferase Deficiency;!Dihydropyrimidine Dehydrogenase Deficiency (DHPD);!Dimethylglycine Dehydrogenase Deficiency;!Arginine: Glycine Amidinotransferase Deficiency (AGAT Deficiency);!Dimethylglycine Dehydrogenase Deficiency;!Hyperglycinemia, Non-Ketotic;!Creatine Deficiency, Guanidinoacetate Methyltransferase Deficiency;!Hyperornithinemia with Gyrate Atrophy (HOGA);!3-Phosphoglycerate Dehydrogenase Deficiency;!Citrullinemia Type I;!Urea Cycle;!Aspartate Metabolism;!Canavan Disease;!Hypoacetylaspartia;!Ornithine Transcarbamylase Deficiency (OTC Deficiency);!Prolidase Deficiency (PD);!Prolinemia Type II;!Non-Ketotic Hyperglycinemia;!Sarcosinemia;!Argininemia;!Ornithine Aminotransferase Deficiency (OAT Deficiency);!Hyperornithinemia-Hyperammonemia-Homocitrullinuria [HHH-syndrome];!Nitric Oxide Signaling Pathway		AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.4851 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					-4.20		244 dec °C	2.24 (at 0 °C)	1.82E+005 mg/L (at 25 °C)	1	No	6	5	No	0	1	125.22 Å2	17.8 Å3	53.92 m3·mol-1	5	Yes	No	2.28 mg/mL	-3.2	-1.9	2.41	12.41			
C4H7NO4	Not Available	Not Available	133.1027	N[C@@H](CC(O)=O)C(O)=O	Solid	Not Available	P27708	CAD	1. CAD protein		18125	17053	CHEMBL274323	5745		GtP Drug Page	HMDB0000191	C00049	D00013	IAS	PDRhealth Drug Page	PA448494	5960	46507997		1169		Aspartic_acid	ZINC000000895032	Aminosyn II 7 %, Sulfite-free, Aminosyn-PF 7%, Clinisol 15, Olimel, Periolimel, Plenamine, Premasol, Primene, Prosol, Trophamine 10 %	Aspartic acid	Approved, Nutraceutical	DB00128	InChI=1S/C4H7NO4/c5-2(4(8)9)1-3(6)7/h2H,1,5H2,(H,6,7)(H,8,9)/t2-/m0/s1	CKLJMWTZIZZHCS-REOHCLBHSA-N	3	Aspartic acid is an amino acid commonly found as a component in total parenteral nutrition.	Mild gastrointestinal side effects including diarrhea. LD50 (rat) > 5,000 mg/kg.	Small Molecule	http://smpdb.ca/view/SMP0000129?highlight[compounds][]=DB00128&highlight[proteins][]=DB00128;!http://smpdb.ca/view/SMP0000167?highlight[compounds][]=DB00128&highlight[proteins][]=DB00128;!http://smpdb.ca/view/SMP0000220?highlight[compounds][]=DB00128&highlight[proteins][]=DB00128;!http://smpdb.ca/view/SMP0000362?highlight[compounds][]=DB00128&highlight[proteins][]=DB00128;!http://smpdb.ca/view/SMP0000385?highlight[compounds][]=DB00128&highlight[proteins][]=DB00128;!http://smpdb.ca/view/SMP0000493?highlight[compounds][]=DB00128&highlight[proteins][]=DB00128;!http://smpdb.ca/view/SMP0000504?highlight[compounds][]=DB00128&highlight[proteins][]=DB00128;!http://smpdb.ca/view/SMP0000505?highlight[compounds][]=DB00128&highlight[proteins][]=DB00128;!http://smpdb.ca/view/SMP0000512?highlight[compounds][]=DB00128&highlight[proteins][]=DB00128;!http://smpdb.ca/view/SMP0000536?highlight[compounds][]=DB00128&highlight[proteins][]=DB00128;!http://smpdb.ca/view/SMP0000537?highlight[compounds][]=DB00128&highlight[proteins][]=DB00128;!http://smpdb.ca/view/SMP0000002?highlight[compounds][]=DB00128&highlight[proteins][]=DB00128;!http://smpdb.ca/view/SMP0000003?highlight[compounds][]=DB00128&highlight[proteins][]=DB00128;!http://smpdb.ca/view/SMP0000006?highlight[compounds][]=DB00128&highlight[proteins][]=DB00128;!http://smpdb.ca/view/SMP0000009?highlight[compounds][]=DB00128&highlight[proteins][]=DB00128;!http://smpdb.ca/view/SMP0000020?highlight[compounds][]=DB00128&highlight[proteins][]=DB00128;!http://smpdb.ca/view/SMP0000050?highlight[compounds][]=DB00128&highlight[proteins][]=DB00128;!http://smpdb.ca/view/SMP0000072?highlight[compounds][]=DB00128&highlight[proteins][]=DB00128;!http://smpdb.ca/view/SMP0000188?highlight[compounds][]=DB00128&highlight[proteins][]=DB00128;!http://smpdb.ca/view/SMP0000210?highlight[compounds][]=DB00128&highlight[proteins][]=DB00128;!http://smpdb.ca/view/SMP0000218?highlight[compounds][]=DB00128&highlight[proteins][]=DB00128;!http://smpdb.ca/view/SMP0000339?highlight[compounds][]=DB00128&highlight[proteins][]=DB00128;!http://smpdb.ca/view/SMP0000360?highlight[compounds][]=DB00128&highlight[proteins][]=DB00128;!http://smpdb.ca/view/SMP0000361?highlight[compounds][]=DB00128&highlight[proteins][]=DB00128;!http://smpdb.ca/view/SMP0000364?highlight[compounds][]=DB00128&highlight[proteins][]=DB00128;!http://smpdb.ca/view/SMP0000365?highlight[compounds][]=DB00128&highlight[proteins][]=DB00128;!http://smpdb.ca/view/SMP0000428?highlight[compounds][]=DB00128&highlight[proteins][]=DB00128;!http://smpdb.ca/view/SMP0000429?highlight[compounds][]=DB00128&highlight[proteins][]=DB00128;!http://smpdb.ca/view/SMP0000507?highlight[compounds][]=DB00128&highlight[proteins][]=DB00128;!http://smpdb.ca/view/SMP0000535?highlight[compounds][]=DB00128&highlight[proteins][]=DB00128	Malate-Aspartate Shuttle;!Adenylosuccinate Lyase Deficiency;!Xanthine Dehydrogenase Deficiency (Xanthinuria);!Arginine: Glycine Amidinotransferase Deficiency (AGAT Deficiency);!Homocarnosinosis;!Carnosinuria, Carnosinemia;!Creatine Deficiency, Guanidinoacetate Methyltransferase Deficiency;!Hyperornithinemia with Gyrate Atrophy (HOGA);!Xanthinuria Type I;!Mitochondrial DNA Depletion Syndrome;!Myoadenylate Deaminase Deficiency;!Carbamoyl Phosphate Synthetase Deficiency;!Argininosuccinic Aciduria;!Tyrosine Metabolism;!Ammonia Recycling;!Arginine and Proline Metabolism;!Purine Metabolism;!Glutamate Metabolism;!Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency);!Purine Nucleoside Phosphorylase Deficiency;!Tyrosinemia Type I;!Hyperinsulinism-Hyperammonemia Syndrome;!Hyperprolinemia Type II;!Hyperprolinemia Type I;!Lesch-Nyhan Syndrome (LNS);!Gout or Kelley-Seegmiller Syndrome;!Mercaptopurine Action Pathway;!Disulfiram Action Pathway;!L-Arginine:Glycine Amidinotransferase Deficiency;!Adenine Phosphoribosyltransferase Deficiency (APRT)		Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.1037 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					-3.89		270 °C	2.01 (at 0 °C)	5390 mg/L (at 25 °C)	1	No	5	3	No	0	-1	100.62 Å2	11.28 Å3	26.53 m3·mol-1	3	Yes	No	142.0 mg/mL	-3.5	0.03	1.7	9.61	BE0009692;!Q9UJS0;!P17174;!P45381;!P08243;!P00966;!Q03154;!P00505;!P14868;!O75746;!Q12797;!P22234;!P30520;!P43005;!Q5T6L4;!Q6PI48;!Q7L266;!P07998;!P61626	;!SLC25A13;!GOT1;!ASPA;!ASNS;!ASS1;!ACY1;!GOT2;!DARS;!SLC25A12;!ASPH;!PAICS;!ADSS;!SLC1A1;!ASS;!DARS2;!ASRGL1;!RNASE1;!LYZ	1. Adenylosuccinate Synthetases (Protein Group);!2. Calcium-binding mitochondrial carrier protein Aralar2;!3. Aspartate aminotransferase, cytoplasmic;!4. Aspartoacylase;!5. Asparagine synthetase [glutamine-hydrolyzing];!6. Argininosuccinate synthase;!7. Aminoacylase-1;!8. Aspartate aminotransferase, mitochondrial;!9. Aspartate--tRNA ligase, cytoplasmic;!10. Calcium-binding mitochondrial carrier protein Aralar1;!11. Aspartyl/asparaginyl beta-hydroxylase;!12. Multifunctional protein ADE2;!13. Adenylosuccinate synthetase isozyme 2;!14. Excitatory amino acid transporter 3;!15. Argininosuccinate synthetase, isoform CRA_a;!16. Aspartate--tRNA ligase, mitochondrial;!17. Isoaspartyl peptidase/L-asparaginase;!18. Ribonuclease pancreatic;!19. Lysozyme C
C5H12N2O2	Not Available	Not Available	132.161	NCCC[C@H](N)C(O)=O	Solid	Not Available					50487430	15729	CHEMBL446143	6026		GtP Drug Page	HMDB0000214	C00077		ORN	PDRhealth Drug Page	PA164783814	6262	46505239		7704		Ornithine	ZINC000001532530	Primene	Ornithine	Approved, Nutraceutical	DB00129	InChI=1S/C5H12N2O2/c6-3-1-2-4(7)5(8)9/h4H,1-3,6-7H2,(H,8,9)/t4-/m0/s1	AHLPHDHHMVZTML-BYPYZUCNSA-N	4	Ornithine is an amino acid commonly found as a component in total parenteral nutrition.	Oral, rat LD50 = 10000 mg/kg	Small Molecule	http://smpdb.ca/view/SMP0000362?highlight[compounds][]=DB00129&highlight[proteins][]=DB00129;!http://smpdb.ca/view/SMP0000504?highlight[compounds][]=DB00129&highlight[proteins][]=DB00129;!http://smpdb.ca/view/SMP0000505?highlight[compounds][]=DB00129&highlight[proteins][]=DB00129;!http://smpdb.ca/view/SMP0000002?highlight[compounds][]=DB00129&highlight[proteins][]=DB00129;!http://smpdb.ca/view/SMP0000003?highlight[compounds][]=DB00129&highlight[proteins][]=DB00129;!http://smpdb.ca/view/SMP0000020?highlight[compounds][]=DB00129&highlight[proteins][]=DB00129;!http://smpdb.ca/view/SMP0000188?highlight[compounds][]=DB00129&highlight[proteins][]=DB00129;!http://smpdb.ca/view/SMP0000360?highlight[compounds][]=DB00129&highlight[proteins][]=DB00129;!http://smpdb.ca/view/SMP0000361?highlight[compounds][]=DB00129&highlight[proteins][]=DB00129;!http://smpdb.ca/view/SMP0000507?highlight[compounds][]=DB00129&highlight[proteins][]=DB00129;!http://smpdb.ca/view/SMP0000001?highlight[compounds][]=DB00129&highlight[proteins][]=DB00129;!http://smpdb.ca/view/SMP0000059?highlight[compounds][]=DB00129&highlight[proteins][]=DB00129;!http://smpdb.ca/view/SMP0000205?highlight[compounds][]=DB00129&highlight[proteins][]=DB00129;!http://smpdb.ca/view/SMP0000207?highlight[compounds][]=DB00129&highlight[proteins][]=DB00129;!http://smpdb.ca/view/SMP0000208?highlight[compounds][]=DB00129&highlight[proteins][]=DB00129;!http://smpdb.ca/view/SMP0000357?highlight[compounds][]=DB00129&highlight[proteins][]=DB00129;!http://smpdb.ca/view/SMP0000363?highlight[compounds][]=DB00129&highlight[proteins][]=DB00129;!http://smpdb.ca/view/SMP0000445?highlight[compounds][]=DB00129&highlight[proteins][]=DB00129;!http://smpdb.ca/view/SMP0000506?highlight[compounds][]=DB00129&highlight[proteins][]=DB00129	Arginine: Glycine Amidinotransferase Deficiency (AGAT Deficiency);!Creatine Deficiency, Guanidinoacetate Methyltransferase Deficiency;!Hyperornithinemia with Gyrate Atrophy (HOGA);!Carbamoyl Phosphate Synthetase Deficiency;!Argininosuccinic Aciduria;!Arginine and Proline Metabolism;!Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency);!Hyperprolinemia Type II;!Hyperprolinemia Type I;!L-Arginine:Glycine Amidinotransferase Deficiency;!Citrullinemia Type I;!Urea Cycle;!Ornithine Transcarbamylase Deficiency (OTC Deficiency);!Prolidase Deficiency (PD);!Prolinemia Type II;!Argininemia;!Ornithine Aminotransferase Deficiency (OAT Deficiency);!Spermidine and Spermine Biosynthesis;!Hyperornithinemia-Hyperammonemia-Homocitrullinuria [HHH-syndrome]		AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.0540 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					-4.22		140 °C	1.94 (at 25 °C)	Appreciable	1	No	4	3	No	0	1	89.34 Å2	13.85 Å3	33.21 m3·mol-1	4	Yes	No	172.0 mg/mL	-3.7	0.11	2.67	10.29	P04181;!P00480;!P05089;!P54368;!P30825;!P52569;!Q9BXI2;!P78540;!Q9Y619;!P50440	OAT;!OTC;!ARG1;!OAZ1;!SLC7A1;!SLC7A2;!SLC25A2;!ARG2;!SLC25A15;!GATM	1. Ornithine aminotransferase, mitochondrial;!2. Ornithine carbamoyltransferase, mitochondrial;!3. Arginase-1;!4. Ornithine decarboxylase antizyme 1;!5. High affinity cationic amino acid transporter 1;!6. Low affinity cationic amino acid transporter 2;!7. Mitochondrial ornithine transporter 2;!8. Arginase-2, mitochondrial;!9. Mitochondrial ornithine transporter 1;!10. Glycine amidinotransferase, mitochondrial
C5H10N2O3	Not Available	The half life of elimination is 1 h Label.	146.1445	N[C@@H](CCC(N)=O)C(O)=O	Solid	Volume of distribution is 200 mL/kg after intravenous bolus dose Label.	P00488;!O94925;!Q9UI32;!P21980;!O43548;!O95932;!P22735;!P49221;!Q08188;!Q96PF1;!P49915;!P08243;!Q16773;!O15067;!O75879;!O94808;!P27708;!P47897;!Q6IA69	F13A1;!GLS;!GLS2;!TGM2;!TGM5;!TGM6;!TGM1;!TGM4;!TGM3;!TGM7;!GMPS;!ASNS;!CCBL1;!PFAS;!GATB;!GFPT2;!CAD;!QARS;!NADSYN1	1. Coagulation factor XIII A chain;!2. Glutaminase kidney isoform, mitochondrial;!3. Glutaminase liver isoform, mitochondrial;!4. Protein-glutamine gamma-glutamyltransferase 2;!5. Protein-glutamine gamma-glutamyltransferase 5;!6. Protein-glutamine gamma-glutamyltransferase 6;!7. Protein-glutamine gamma-glutamyltransferase K;!8. Protein-glutamine gamma-glutamyltransferase 4;!9. Protein-glutamine gamma-glutamyltransferase E;!10. Protein-glutamine gamma-glutamyltransferase Z;!11. GMP synthase [glutamine-hydrolyzing];!12. Asparagine synthetase [glutamine-hydrolyzing];!13. Kynurenine--oxoglutarate transaminase 1;!14. Phosphoribosylformylglycinamidine synthase;!15. Glutamyl-tRNA(Gln) amidotransferase subunit B, mitochondrial;!16. Glutamine--fructose-6-phosphate aminotransferase [isomerizing] 2;!17. CAD protein;!18. Glutamine--tRNA ligase;!19. Glutamine-dependent NAD(+) synthetase		18121	58359	CHEMBL930	5746		GtP Drug Page	HMDB0000641	C00064	D00015	GLN	PDRhealth Drug Page	PA10090	5961	46505866		4885		Glutamine	ZINC000001532526	Endari	L-Glutamine	Approved, Investigational, Nutraceutical	DB00130	InChI=1S/C5H10N2O3/c6-3(5(9)10)1-2-4(7)8/h3H,1-2,6H2,(H2,7,8)(H,9,10)/t3-/m0/s1	ZDXPYRJPNDTMRX-VKHMYHEASA-N	4	L-Glutamine is an amino acid commonly found as a component in total parenteral nutrition.	Doses of L-glutamine up to 21 grams daily appear to be well tolerated. Reported adverse reactions are mainly gastrointestinal and not common. They include constipation and bloating. There is one older report of two hypomanic patients whose manic symptoms were exacerbated following the use of 2 to 4 grams daily of L-glutamine. The symptoms resolved when the L-glutamine was stopped. These patients were not rechallenged, nor are there any other reports of this nature.The most common adverse effects observed in clinical trials of Endari were constipation (21%), nausea (19%), headache (18%), abdominal pain (17%), cough (16%), extremity pain (13%), back pain (12%), and chest pain (12%) Label.	Small Molecule	http://smpdb.ca/view/SMP0000045?highlight[compounds][]=DB00130&highlight[proteins][]=DB00130;!http://smpdb.ca/view/SMP0000126?highlight[compounds][]=DB00130&highlight[proteins][]=DB00130;!http://smpdb.ca/view/SMP0000167?highlight[compounds][]=DB00130&highlight[proteins][]=DB00130;!http://smpdb.ca/view/SMP0000220?highlight[compounds][]=DB00130&highlight[proteins][]=DB00130;!http://smpdb.ca/view/SMP0000385?highlight[compounds][]=DB00130&highlight[proteins][]=DB00130;!http://smpdb.ca/view/SMP0000512?highlight[compounds][]=DB00130&highlight[proteins][]=DB00130;!http://smpdb.ca/view/SMP0000534?highlight[compounds][]=DB00130&highlight[proteins][]=DB00130;!http://smpdb.ca/view/SMP0000536?highlight[compounds][]=DB00130&highlight[proteins][]=DB00130;!http://smpdb.ca/view/SMP0000537?highlight[compounds][]=DB00130&highlight[proteins][]=DB00130;!http://smpdb.ca/view/SMP0002358?highlight[compounds][]=DB00130&highlight[proteins][]=DB00130;!http://smpdb.ca/view/SMP0000002?highlight[compounds][]=DB00130&highlight[proteins][]=DB00130;!http://smpdb.ca/view/SMP0000003?highlight[compounds][]=DB00130&highlight[proteins][]=DB00130;!http://smpdb.ca/view/SMP0000009?highlight[compounds][]=DB00130&highlight[proteins][]=DB00130;!http://smpdb.ca/view/SMP0000046?highlight[compounds][]=DB00130&highlight[proteins][]=DB00130;!http://smpdb.ca/view/SMP0000050?highlight[compounds][]=DB00130&highlight[proteins][]=DB00130;!http://smpdb.ca/view/SMP0000072?highlight[compounds][]=DB00130&highlight[proteins][]=DB00130;!http://smpdb.ca/view/SMP0000202?highlight[compounds][]=DB00130&highlight[proteins][]=DB00130;!http://smpdb.ca/view/SMP0000210?highlight[compounds][]=DB00130&highlight[proteins][]=DB00130;!http://smpdb.ca/view/SMP0000216?highlight[compounds][]=DB00130&highlight[proteins][]=DB00130;!http://smpdb.ca/view/SMP0000217?highlight[compounds][]=DB00130&highlight[proteins][]=DB00130;!http://smpdb.ca/view/SMP0000240?highlight[compounds][]=DB00130&highlight[proteins][]=DB00130;!http://smpdb.ca/view/SMP0000339?highlight[compounds][]=DB00130&highlight[proteins][]=DB00130;!http://smpdb.ca/view/SMP0000364?highlight[compounds][]=DB00130&highlight[proteins][]=DB00130;!http://smpdb.ca/view/SMP0000365?highlight[compounds][]=DB00130&highlight[proteins][]=DB00130;!http://smpdb.ca/view/SMP0000390?highlight[compounds][]=DB00130&highlight[proteins][]=DB00130;!http://smpdb.ca/view/SMP0000428?highlight[compounds][]=DB00130&highlight[proteins][]=DB00130;!http://smpdb.ca/view/SMP0000535?highlight[compounds][]=DB00130&highlight[proteins][]=DB00130;!http://smpdb.ca/view/SMP0002298?highlight[compounds][]=DB00130&highlight[proteins][]=DB00130;!http://smpdb.ca/view/SMP0002359?highlight[compounds][]=DB00130&highlight[proteins][]=DB00130;!http://smpdb.ca/view/SMP0000001?highlight[compounds][]=DB00130&highlight[proteins][]=DB00130	Amino Sugar Metabolism;!Phenylacetate Metabolism;!Adenylosuccinate Lyase Deficiency;!Xanthine Dehydrogenase Deficiency (Xanthinuria);!Homocarnosinosis;!Xanthinuria Type I;!G(M2)-Gangliosidosis: Variant B, Tay-Sachs Disease;!Mitochondrial DNA Depletion Syndrome;!Myoadenylate Deaminase Deficiency;!The Oncogenic Action of L-2-Hydroxyglutarate in Hydroxygluaricaciduria;!Carbamoyl Phosphate Synthetase Deficiency;!Argininosuccinic Aciduria;!Ammonia Recycling;!Pyrimidine Metabolism;!Purine Metabolism;!Glutamate Metabolism;!MNGIE (Mitochondrial Neurogastrointestinal Encephalopathy);!Purine Nucleoside Phosphorylase Deficiency;!Sialuria or French Type Sialuria;!Sialuria or French Type Sialuria;!Salla Disease/Infantile Sialic Acid Storage Disease;!Hyperinsulinism-Hyperammonemia Syndrome;!Lesch-Nyhan Syndrome (LNS);!Gout or Kelley-Seegmiller Syndrome;!Tay-Sachs Disease;!Mercaptopurine Action Pathway;!Adenine Phosphoribosyltransferase Deficiency (APRT);!Glutaminolysis and Cancer;!The Oncogenic Action of D-2-Hydroxyglutarate in Hydroxygluaricaciduria;!Citrullinemia Type I		Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.2587 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					-3.64	-0.55	185.5 dec °C	2.17	4.13E+004 mg/L (at 25 °C)	1	No	4	3	No	0	0	106.41 Å2	13.87 Å3	33.11 m3·mol-1	4	Yes	No	97.8 mg/mL	-4	-0.17	2.15	9.31	P17812;!Q06203;!P15104	CTPS1;!PPAT;!GLUL	1. CTP synthase 1;!2. Amidophosphoribosyltransferase;!3. Glutamine synthetase
C3H7NO3	Not Available	Not Available	105.0926	N[C@@H](CO)C(O)=O	Solid	Not Available					50357212	33384	CHEMBL11298	5736		GtP Drug Page	HMDB0000187	C00065	D00016	SER		PA451330	5951	46506450		9671		Serine	ZINC000000895034	Aminosyn II 7 %, Sulfite-free, Aminosyn-PF 7%, Clinimix 2.75/5, Clinimix E 2.75/5, Clinisol 15, Freamine 6.9, Freamine III 10, Hepatamine 8, Olimel, Periolimel, Plenamine, Premasol, Primene, Procalamine 3, Prosol, Travasol 10, Trophamine 10 %	Serine	Investigational, Nutraceutical	DB00133	InChI=1S/C3H7NO3/c4-2(1-5)3(6)7/h2,5H,1,4H2,(H,6,7)/t2-/m0/s1	MTCFGRXMJLQNBG-REOHCLBHSA-N	3	Serine is an amino acid commonly found as a component in total parenteral nutrition.	Not Available	Small Molecule	http://smpdb.ca/view/SMP0000004?highlight[compounds][]=DB00133&highlight[proteins][]=DB00133;!http://smpdb.ca/view/SMP0000009?highlight[compounds][]=DB00133&highlight[proteins][]=DB00133;!http://smpdb.ca/view/SMP0000029?highlight[compounds][]=DB00133&highlight[proteins][]=DB00133;!http://smpdb.ca/view/SMP0000177?highlight[compounds][]=DB00133&highlight[proteins][]=DB00133;!http://smpdb.ca/view/SMP0000348?highlight[compounds][]=DB00133&highlight[proteins][]=DB00133;!http://smpdb.ca/view/SMP0002313?highlight[compounds][]=DB00133&highlight[proteins][]=DB00133;!http://smpdb.ca/view/SMP0015056?highlight[compounds][]=DB00133&highlight[proteins][]=DB00133;!http://smpdb.ca/view/SMP0015057?highlight[compounds][]=DB00133&highlight[proteins][]=DB00133;!http://smpdb.ca/view/SMP0015058?highlight[compounds][]=DB00133&highlight[proteins][]=DB00133;!http://smpdb.ca/view/SMP0015062?highlight[compounds][]=DB00133&highlight[proteins][]=DB00133;!http://smpdb.ca/view/SMP0015063?highlight[compounds][]=DB00133&highlight[proteins][]=DB00133;!http://smpdb.ca/view/SMP0015074?highlight[compounds][]=DB00133&highlight[proteins][]=DB00133;!http://smpdb.ca/view/SMP0015077?highlight[compounds][]=DB00133&highlight[proteins][]=DB00133;!http://smpdb.ca/view/SMP0015078?highlight[compounds][]=DB00133&highlight[proteins][]=DB00133;!http://smpdb.ca/view/SMP0015084?highlight[compounds][]=DB00133&highlight[proteins][]=DB00133;!http://smpdb.ca/view/SMP0015086?highlight[compounds][]=DB00133&highlight[proteins][]=DB00133;!http://smpdb.ca/view/SMP0015092?highlight[compounds][]=DB00133&highlight[proteins][]=DB00133;!http://smpdb.ca/view/SMP0015094?highlight[compounds][]=DB00133&highlight[proteins][]=DB00133;!http://smpdb.ca/view/SMP0015095?highlight[compounds][]=DB00133&highlight[proteins][]=DB00133;!http://smpdb.ca/view/SMP0015097?highlight[compounds][]=DB00133&highlight[proteins][]=DB00133;!http://smpdb.ca/view/SMP0015101?highlight[compounds][]=DB00133&highlight[proteins][]=DB00133;!http://smpdb.ca/view/SMP0015103?highlight[compounds][]=DB00133&highlight[proteins][]=DB00133;!http://smpdb.ca/view/SMP0015109?highlight[compounds][]=DB00133&highlight[proteins][]=DB00133;!http://smpdb.ca/view/SMP0015112?highlight[compounds][]=DB00133&highlight[proteins][]=DB00133;!http://smpdb.ca/view/SMP0015114?highlight[compounds][]=DB00133&highlight[proteins][]=DB00133;!http://smpdb.ca/view/SMP0015116?highlight[compounds][]=DB00133&highlight[proteins][]=DB00133;!http://smpdb.ca/view/SMP0015117?highlight[compounds][]=DB00133&highlight[proteins][]=DB00133;!http://smpdb.ca/view/SMP0015119?highlight[compounds][]=DB00133&highlight[proteins][]=DB00133;!http://smpdb.ca/view/SMP0015120?highlight[compounds][]=DB00133&highlight[proteins][]=DB00133;!http://smpdb.ca/view/SMP0015121?highlight[compounds][]=DB00133&highlight[proteins][]=DB00133	Glycine and Serine Metabolism;!Ammonia Recycling;!Selenoamino Acid Metabolism;!Cystathionine beta-Synthase Deficiency;!Globoid Cell Leukodystrophy;!Sarcosine Oncometabolite Pathway;!Phosphatidylethanolamine Biosynthesis PE(14:0/14:0);!Phosphatidylethanolamine Biosynthesis PE(14:0/14:1(9Z));!Phosphatidylethanolamine Biosynthesis PE(14:0/15:0);!Phosphatidylethanolamine Biosynthesis PE(14:0/18:1(11Z));!Phosphatidylethanolamine Biosynthesis PE(14:0/18:1(9Z));!Phosphatidylethanolamine Biosynthesis PE(14:0/20:4(8Z,11Z,14Z,17Z));!Phosphatidylethanolamine Biosynthesis PE(14:0/22:1(13Z));!Phosphatidylethanolamine Biosynthesis PE(14:0/22:2(13Z,16Z));!Phosphatidylethanolamine Biosynthesis PE(14:0/24:1(15Z));!Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/14:1(9Z));!Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/18:1(9Z));!Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/18:3(6Z,9Z,12Z));!Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/18:3(9Z,12Z,15Z));!Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/20:0);!Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/20:3(8Z,11Z,14Z));!Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/20:4(8Z,11Z,14Z,17Z));!Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z));!Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/24:0);!Phosphatidylethanolamine Biosynthesis PE(15:0/14:0);!Phosphatidylethanolamine Biosynthesis PE(15:0/15:0);!Phosphatidylethanolamine Biosynthesis PE(15:0/16:0);!Phosphatidylethanolamine Biosynthesis PE(15:0/18:0);!Phosphatidylethanolamine Biosynthesis PE(15:0/18:1(11Z));!Phosphatidylethanolamine Biosynthesis PE(15:0/18:1(9Z))		Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.2700 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					-3.07		228 dec °C	2.21 (at 25 °C)	4.25E+005 mg/L (at 25 °C)	1	No	4	3	No	0	0	83.55 Å2	9.39 Å3	22.04 m3·mol-1	2	Yes	No	480.0 mg/mL	-3.9	0.66	2.03	8.93	P35520;!P20132;!Q9GZT4;!O15270;!O15269;!P49591;!P21549	CBS;!SDS;!SRR;!SPTLC2;!SPTLC1;!SARS;!AGXT	1. Cystathionine beta-synthase;!2. L-serine dehydratase/L-threonine deaminase;!3. Serine racemase;!4. Serine palmitoyltransferase 2;!5. Serine palmitoyltransferase 1;!6. Serine--tRNA ligase, cytoplasmic;!7. Serine--pyruvate aminotransferase
C5H11NO2S	Not Available	Not Available	149.211	CSCC[C@H](N)C(O)=O	Solid	Not Available	P31153;!Q9Y3D2;!Q00266;!Q9NZV6;!Q9UJ68;!P56192;!Q96GW9;!Q9NZL9;!Q9H2M3;!P15104;!P42898	MAT2A;!MSRB2;!MAT1A;!MSRB1;!MSRA;!MARS;!MARS2;!MAT2B;!BHMT2;!GLUL;!MTHFR	1. S-adenosylmethionine synthase isoform type-2;!2. Methionine-R-sulfoxide reductase B2, mitochondrial;!3. S-adenosylmethionine synthase isoform type-1;!4. Methionine-R-sulfoxide reductase B1;!5. Mitochondrial peptide methionine sulfoxide reductase;!6. Methionine--tRNA ligase, cytoplasmic;!7. Methionine--tRNA ligase, mitochondrial;!8. Methionine adenosyltransferase 2 subunit beta;!9. S-methylmethionine--homocysteine S-methyltransferase BHMT2;!10. Glutamine synthetase;!11. Methylenetetrahydrofolate reductase		50142500	16643	CHEMBL42336	5907			HMDB0000696	C00073	D00019	MET	PDRhealth Drug Page	PA450423	6137	46505750		6837		Methionine	ZINC000001532529	Aminosyn II 7 %, Sulfite-free, Aminosyn-PF 7%, Clinimix 2.75/5, Clinimix E 2.75/5, Clinisol 15, Freamine 6.9, Freamine III 10, Hepatamine 8, Nephramine, Olimel, Periolimel, Plenamine, Premasol, Primene, Procalamine 3, Prosol, Travasol 10, Trophamine 10 %	Methionine	Approved, Nutraceutical	DB00134	InChI=1S/C5H11NO2S/c1-9-3-2-4(6)5(7)8/h4H,2-3,6H2,1H3,(H,7,8)/t4-/m0/s1	FFEARJCKVFRZRR-BYPYZUCNSA-N	4	Methionine is an amino acid commonly found as a component in total parenteral nutrition.	Doses of L-methionine of up to 250 mg daily are generally well tolerated. Higher doses may cause nausea, vomiting and headache. Healthy adults taking 8 grams of L-methionine daily for four days were found to have reduced serum folate levels and leucocytosis. Healthy adults taking 13.9 grams of L-methionine daily for five days were found to have changes in serum pH and potassium and increased urinary calcium excretion. Schizophrenic patients given 10 to 20 grams of L-methionine daily for two weeks developed functional psychoses. Single doses of 8 grams precipitated encephalopathy in patients with cirrhosis.	Small Molecule	http://smpdb.ca/view/SMP0000004?highlight[compounds][]=DB00134&highlight[proteins][]=DB00134;!http://smpdb.ca/view/SMP0000123?highlight[compounds][]=DB00134&highlight[proteins][]=DB00134;!http://smpdb.ca/view/SMP0000177?highlight[compounds][]=DB00134&highlight[proteins][]=DB00134;!http://smpdb.ca/view/SMP0000248?highlight[compounds][]=DB00134&highlight[proteins][]=DB00134;!http://smpdb.ca/view/SMP0000251?highlight[compounds][]=DB00134&highlight[proteins][]=DB00134;!http://smpdb.ca/view/SMP0000254?highlight[compounds][]=DB00134&highlight[proteins][]=DB00134;!http://smpdb.ca/view/SMP0000293?highlight[compounds][]=DB00134&highlight[proteins][]=DB00134;!http://smpdb.ca/view/SMP0000294?highlight[compounds][]=DB00134&highlight[proteins][]=DB00134;!http://smpdb.ca/view/SMP0000713?highlight[compounds][]=DB00134&highlight[proteins][]=DB00134;!http://smpdb.ca/view/SMP0000730?highlight[compounds][]=DB00134&highlight[proteins][]=DB00134;!http://smpdb.ca/view/SMP0000731?highlight[compounds][]=DB00134&highlight[proteins][]=DB00134;!http://smpdb.ca/view/SMP0002313?highlight[compounds][]=DB00134&highlight[proteins][]=DB00134;!http://smpdb.ca/view/SMP0000033?highlight[compounds][]=DB00134&highlight[proteins][]=DB00134;!http://smpdb.ca/view/SMP0000221?highlight[compounds][]=DB00134&highlight[proteins][]=DB00134;!http://smpdb.ca/view/SMP0000223?highlight[compounds][]=DB00134&highlight[proteins][]=DB00134;!http://smpdb.ca/view/SMP0000244?highlight[compounds][]=DB00134&highlight[proteins][]=DB00134;!http://smpdb.ca/view/SMP0000252?highlight[compounds][]=DB00134&highlight[proteins][]=DB00134;!http://smpdb.ca/view/SMP0000253?highlight[compounds][]=DB00134&highlight[proteins][]=DB00134;!http://smpdb.ca/view/SMP0000258?highlight[compounds][]=DB00134&highlight[proteins][]=DB00134;!http://smpdb.ca/view/SMP0000290?highlight[compounds][]=DB00134&highlight[proteins][]=DB00134;!http://smpdb.ca/view/SMP0000291?highlight[compounds][]=DB00134&highlight[proteins][]=DB00134;!http://smpdb.ca/view/SMP0000292?highlight[compounds][]=DB00134&highlight[proteins][]=DB00134;!http://smpdb.ca/view/SMP0000295?highlight[compounds][]=DB00134&highlight[proteins][]=DB00134;!http://smpdb.ca/view/SMP0000445?highlight[compounds][]=DB00134&highlight[proteins][]=DB00134;!http://smpdb.ca/view/SMP0000712?highlight[compounds][]=DB00134&highlight[proteins][]=DB00134;!http://smpdb.ca/view/SMP0000714?highlight[compounds][]=DB00134&highlight[proteins][]=DB00134;!http://smpdb.ca/view/SMP0000727?highlight[compounds][]=DB00134&highlight[proteins][]=DB00134;!http://smpdb.ca/view/SMP0000728?highlight[compounds][]=DB00134&highlight[proteins][]=DB00134;!http://smpdb.ca/view/SMP0000729?highlight[compounds][]=DB00134&highlight[proteins][]=DB00134;!http://smpdb.ca/view/SMP0000179?highlight[compounds][]=DB00134&highlight[proteins][]=DB00134	Glycine and Serine Metabolism;!Betaine Metabolism;!Cystathionine beta-Synthase Deficiency;!Clarithromycin Action Pathway;!Roxithromycin Action Pathway;!Gentamicin Action Pathway;!Oxytetracycline Action Pathway;!Tetracycline Action Pathway;!Arbekacin Action Pathway;!Troleandomycin Action Pathway;!Josamycin Action Pathway;!Sarcosine Oncometabolite Pathway;!Methionine Metabolism;!Methionine Adenosyltransferase Deficiency;!Non-Ketotic Hyperglycinemia;!Sarcosinemia;!Telithromycin Action Pathway;!Amikacin Action Pathway;!Spectinomycin Action Pathway;!Demeclocycline Action Pathway;!Doxycycline Action Pathway;!Minocycline Action Pathway;!Lymecycline Action Pathway;!Spermidine and Spermine Biosynthesis;!Tigecycline Action Pathway;!Paromomycin Action Pathway;!Methacycline Action Pathway;!Lincomycin Action Pathway;!Chloramphenicol Action Pathway;!Dihydropyrimidine Dehydrogenase Deficiency (DHPD)		Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	0.6483 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					-1.87	-0.42	283 dec °C	2.28 (at 25 °C)	5.66E+004 mg/L (at 25 °C)	1	No	3	2	No	0	0	63.32 Å2	15.5 Å3	37.59 m3·mol-1	4	Yes	No	23.9 mg/mL	-2.2	-0.8	2.53	9.5	Q9UBK8;!Q99707;!P50579;!Q93088;!Q9H2M3	MTRR;!MTR;!METAP2;!BHMT;!BHMT2	1. Methionine synthase reductase;!2. Methionine synthase;!3. Methionine aminopeptidase 2;!4. Betaine--homocysteine S-methyltransferase 1;!5. S-methylmethionine--homocysteine S-methyltransferase BHMT2
C9H11NO3	Not Available	Not Available	181.1885	N[C@@H](CC1=CC=C(O)C=C1)C(O)=O	Solid	Not Available					18129	58315	CHEMBL925	5833			HMDB0000158	C00082	D00022	TYR	PDRhealth Drug Page	PA451822	6057	46507885		10962	DAP000808	Tyrosine	ZINC000000266964	Aminosyn-PF 7%, Clinimix 2.75/5, Clinimix E 2.75/5, Clinisol 15, Olimel, Periolimel, Plenamine, Premasol, Primene, Prosol, Travasol 10, Trophamine 10 %	Tyrosine	Approved, Investigational, Nutraceutical	DB00135	InChI=1S/C9H11NO3/c10-8(9(12)13)5-6-1-3-7(11)4-2-6/h1-4,8,11H,5,10H2,(H,12,13)/t8-/m0/s1	OUYCCCASQSFEME-QMMMGPOBSA-N	3	Tyrosine is an amino acid commonly found as a component in total parenteral nutrition.	L-Tyrosine has very low toxicity. There have been very few reports of toxicity. LD50 (oral, rat) > 5110 mg/kg.	Small Molecule	http://smpdb.ca/view/SMP0000170?highlight[compounds][]=DB00135&highlight[proteins][]=DB00135;!http://smpdb.ca/view/SMP0000206?highlight[compounds][]=DB00135&highlight[proteins][]=DB00135;!http://smpdb.ca/view/SMP0000006?highlight[compounds][]=DB00135&highlight[proteins][]=DB00135;!http://smpdb.ca/view/SMP0000012?highlight[compounds][]=DB00135&highlight[proteins][]=DB00135;!http://smpdb.ca/view/SMP0000218?highlight[compounds][]=DB00135&highlight[proteins][]=DB00135;!http://smpdb.ca/view/SMP0000370?highlight[compounds][]=DB00135&highlight[proteins][]=DB00135;!http://smpdb.ca/view/SMP0000429?highlight[compounds][]=DB00135&highlight[proteins][]=DB00135;!http://smpdb.ca/view/SMP0000008?highlight[compounds][]=DB00135&highlight[proteins][]=DB00135;!http://smpdb.ca/view/SMP0000169?highlight[compounds][]=DB00135&highlight[proteins][]=DB00135;!http://smpdb.ca/view/SMP0000190?highlight[compounds][]=DB00135&highlight[proteins][]=DB00135;!http://smpdb.ca/view/SMP0000369?highlight[compounds][]=DB00135&highlight[proteins][]=DB00135;!http://smpdb.ca/view/SMP0000494?highlight[compounds][]=DB00135&highlight[proteins][]=DB00135;!http://smpdb.ca/view/SMP0000497?highlight[compounds][]=DB00135&highlight[proteins][]=DB00135;!http://smpdb.ca/view/SMP0000498?highlight[compounds][]=DB00135&highlight[proteins][]=DB00135;!http://smpdb.ca/view/SMP0000533?highlight[compounds][]=DB00135&highlight[proteins][]=DB00135;!http://smpdb.ca/view/SMP0000716?highlight[compounds][]=DB00135&highlight[proteins][]=DB00135	Aromatic L-Aminoacid Decarboxylase Deficiency;!Phenylketonuria;!Tyrosine Metabolism;!Catecholamine Biosynthesis;!Tyrosinemia Type I;!Tyrosinemia Type 3 (TYRO3);!Disulfiram Action Pathway;!Phenylalanine and Tyrosine Metabolism;!Alkaptonuria;!Hawkinsinuria;!Tyrosinemia Type 2 (or Richner-Hanhart Syndrome);!Tyrosinemia, Transient, of the Newborn;!Tyrosine Hydroxylase Deficiency;!Dopamine beta-Hydroxylase Deficiency;!Monoamine Oxidase-A Deficiency (MAO-A);!Thyroid Hormone Synthesis																												-2.26	-2.57	343 dec °C	2.2 (at 25 °C)	479 mg/L (at 25 °C)	1	No	4	3	No	1	0	83.55 Å2	18.12 Å3	47.1 m3·mol-1	3	Yes	No	7.67 mg/mL	-1.5	-1.4	2	9.19	P07101;!Q9Y2Z4;!P54577;!P17735	TH;!YARS2;!YARS;!TAT	1. Tyrosine 3-monooxygenase;!2. Tyrosine--tRNA ligase, mitochondrial;!3. Tyrosine--tRNA ligase, cytoplasmic;!4. Tyrosine aminotransferase
C6H12N2O4S2	Not Available	Not Available	240.3	N[C@@H](CSSC[C@H](N)C(O)=O)C(O)=O	Solid	Not Available						16283	CHEMBL590540	60997			HMDB0000192	C00491	D03636		PDRhealth Drug Page	PA449176	67678	46506670		3036		Cystine	ZINC000001532673		Cystine	Approved, Nutraceutical	DB00138	InChI=1S/C6H12N2O4S2/c7-3(5(9)10)1-13-14-2-4(8)6(11)12/h3-4H,1-2,7-8H2,(H,9,10)(H,11,12)/t3-,4-/m0/s1	LEVWYRKDKASIDU-IMJSIDKUSA-N	3	Cystine is an oxidated derivative of the amino acid cysteine found in various nutritional products, acne treatments, and creams to treat cervical injury or inflammation.	With typical doses of 1 to 1.5 grams daily, the most commonly reported side effects have been gastrointestinal, such as nausea. There are rare reports of cystine renal stone formation, Single injections of L-cysteine (0.6-1.5 g/kg) into 4-day-old pups resulted in massive damage to cortical neurons, permanent retinal dystrophy, atrophy of the brain and hyperactivity.	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.0474 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					-5.08		260.5 dec °C	1	190 mg/L (at 20 °C)	1	No	6	4	No	0	0	126.64 Å2	22.77 Å3	54.87 m3·mol-1	7	Yes	No	16.8 mg/mL	-5.9	-1.2	1.56	9.34	Q9UPY5;!O60931	SLC7A11;!CTNS	1. Cystine/glutamate transporter;!2. Cystinosin
C5H9NO4	Not Available	Not Available	147.1293	N[C@@H](CCC(O)=O)C(O)=O	Solid	Not Available					17657	16015	CHEMBL575060	30572		GtP Drug Page	HMDB0000148	C00025	D00007	GGL		PA449776	33032	46505816		25916	DAP000015	Glutamic_acid	ZINC000001482113	Aminosyn II 7 %, Sulfite-free, Aminosyn-PF 7%, Clinisol 15, Olimel, Periolimel, Plenamine, Premasol, Primene, Prosol, Trophamine 10 %	Glutamic acid	Approved, Nutraceutical	DB00142	InChI=1S/C5H9NO4/c6-3(5(9)10)1-2-4(7)8/h3H,1-2,6H2,(H,7,8)(H,9,10)/t3-/m0/s1	WHUUTDBJXJRKMK-VKHMYHEASA-N	3	Glutamic acid is an amino acid commonly found as a component in total parenteral nutrition.	Glutamate causes neuronal damage and eventual cell death, particularly when NMDA receptors are activated, High dosages of glutamic acid may include symptoms such as headaches and neurological problems.	Small Molecule	http://smpdb.ca/view/SMP0000002?highlight[compounds][]=DB00142&highlight[proteins][]=DB00142;!http://smpdb.ca/view/SMP0000003?highlight[compounds][]=DB00142&highlight[proteins][]=DB00142;!http://smpdb.ca/view/SMP0000004?highlight[compounds][]=DB00142&highlight[proteins][]=DB00142;!http://smpdb.ca/view/SMP0000006?highlight[compounds][]=DB00142&highlight[proteins][]=DB00142;!http://smpdb.ca/view/SMP0000009?highlight[compounds][]=DB00142&highlight[proteins][]=DB00142;!http://smpdb.ca/view/SMP0000016?highlight[compounds][]=DB00142&highlight[proteins][]=DB00142;!http://smpdb.ca/view/SMP0000020?highlight[compounds][]=DB00142&highlight[proteins][]=DB00142;!http://smpdb.ca/view/SMP0000044?highlight[compounds][]=DB00142&highlight[proteins][]=DB00142;!http://smpdb.ca/view/SMP0000050?highlight[compounds][]=DB00142&highlight[proteins][]=DB00142;!http://smpdb.ca/view/SMP0000072?highlight[compounds][]=DB00142&highlight[proteins][]=DB00142;!http://smpdb.ca/view/SMP0000084?highlight[compounds][]=DB00142&highlight[proteins][]=DB00142;!http://smpdb.ca/view/SMP0000085?highlight[compounds][]=DB00142&highlight[proteins][]=DB00142;!http://smpdb.ca/view/SMP0000086?highlight[compounds][]=DB00142&highlight[proteins][]=DB00142;!http://smpdb.ca/view/SMP0000096?highlight[compounds][]=DB00142&highlight[proteins][]=DB00142;!http://smpdb.ca/view/SMP0000101?highlight[compounds][]=DB00142&highlight[proteins][]=DB00142;!http://smpdb.ca/view/SMP0000104?highlight[compounds][]=DB00142&highlight[proteins][]=DB00142;!http://smpdb.ca/view/SMP0000137?highlight[compounds][]=DB00142&highlight[proteins][]=DB00142;!http://smpdb.ca/view/SMP0000139?highlight[compounds][]=DB00142&highlight[proteins][]=DB00142;!http://smpdb.ca/view/SMP0000173?highlight[compounds][]=DB00142&highlight[proteins][]=DB00142;!http://smpdb.ca/view/SMP0000186?highlight[compounds][]=DB00142&highlight[proteins][]=DB00142;!http://smpdb.ca/view/SMP0000188?highlight[compounds][]=DB00142&highlight[proteins][]=DB00142;!http://smpdb.ca/view/SMP0000191?highlight[compounds][]=DB00142&highlight[proteins][]=DB00142;!http://smpdb.ca/view/SMP0000210?highlight[compounds][]=DB00142&highlight[proteins][]=DB00142;!http://smpdb.ca/view/SMP0000216?highlight[compounds][]=DB00142&highlight[proteins][]=DB00142;!http://smpdb.ca/view/SMP0000217?highlight[compounds][]=DB00142&highlight[proteins][]=DB00142;!http://smpdb.ca/view/SMP0000218?highlight[compounds][]=DB00142&highlight[proteins][]=DB00142;!http://smpdb.ca/view/SMP0000239?highlight[compounds][]=DB00142&highlight[proteins][]=DB00142;!http://smpdb.ca/view/SMP0000240?highlight[compounds][]=DB00142&highlight[proteins][]=DB00142;!http://smpdb.ca/view/SMP0000289?highlight[compounds][]=DB00142&highlight[proteins][]=DB00142;!http://smpdb.ca/view/SMP0000339?highlight[compounds][]=DB00142&highlight[proteins][]=DB00142	Carbamoyl Phosphate Synthetase Deficiency;!Argininosuccinic Aciduria;!Glycine and Serine Metabolism;!Tyrosine Metabolism;!Ammonia Recycling;!Propanoate Metabolism;!Arginine and Proline Metabolism;!Histidine Metabolism;!Purine Metabolism;!Glutamate Metabolism;!Etodolac Action Pathway;!Ketoprofen Action Pathway;!Ibuprofen Action Pathway;!Celecoxib Action Pathway;!Suprofen Action Pathway;!Indomethacin Action Pathway;!2-Methyl-3-hydroxybutryl-CoA Dehydrogenase Deficiency;!3-Methylglutaconic Aciduria Type I;!beta-Ketothiolase Deficiency;!Glutaric Aciduria Type I;!Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency);!Histidinemia;!Purine Nucleoside Phosphorylase Deficiency;!Sialuria or French Type Sialuria;!Sialuria or French Type Sialuria;!Tyrosinemia Type I;!Saccharopinuria/Hyperlysinemia II;!Salla Disease/Infantile Sialic Acid Storage Disease;!Diflunisal Action Pathway;!Hyperinsulinism-Hyperammonemia Syndrome																												-3.69		224 dec °C	2.23 (at 0 °C)	8570 mg/L (at 25 °C)	1	No	5	3	No	0	-1	100.62 Å2	13.32 Å3	31.29 m3·mol-1	4	Yes	No	80.6 mg/mL	-3.2	-0.26	1.88	9.54	Q13255;!Q14833;!Q16099;!Q16478;!Q14831;!O00222;!O00341;!O14841;!O15067;!O15382;!O15399;!O94925;!P00505;!P07814;!P08243;!P15104;!P17174;!P17735;!P24298;!P38435;!P43003;!P43004;!P43005;!P48506;!P48664;!P49448;!P49915;!P54687;!P80404;!Q05586;!Q05932;!Q07075;!Q12879;!Q13224;!Q14957;!Q2TU84;!Q5JPH6;!Q6IA69;!Q8N159;!Q8N5Z0;!Q8TCU5;!Q8TD30;!Q9UDR5;!Q9UI32;!Q9ULA0;!Q9UPY5;!Q9Y646;!Q9Y617;!P00367;!P39086;!P42261;!P48507;!Q04609;!Q05329;!Q99259;!O95954;!P42262;!P42263;!P48058;!P54886;!Q13002;!Q13003	GRM1;!GRM4;!GRIK4;!GRIK5;!GRM7;!GRM8;!SLC1A7;!OPLAH;!PFAS;!BCAT2;!GRIN2D;!GLS;!GOT2;!EPRS;!ASNS;!GLUL;!GOT1;!TAT;!GPT;!GGCX;!SLC1A3;!SLC1A2;!SLC1A1;!GCLC;!SLC1A6;!GLUD2;!GMPS;!BCAT1;!ABAT;!GRIN1;!FPGS;!ENPEP;!GRIN2A;!GRIN2B;!GRIN2C;!GIG18;!EARS2;!NADSYN1;!NAGS;!AADAT;!GRIN3A;!GPT2;!AASS;!GLS2;!DNPEP;!SLC7A11;!CPQ;!PSAT1;!GLUD1;!GRIK1;!GRIA1;!GCLM;!FOLH1;!GAD2;!GAD1;!FTCD;!GRIA2;!GRIA3;!GRIA4;!ALDH18A1;!GRIK2;!GRIK3	1. Metabotropic glutamate receptor 1;!2. Metabotropic glutamate receptor 4;!3. Glutamate receptor ionotropic, kainate 4;!4. Glutamate receptor ionotropic, kainate 5;!5. Metabotropic glutamate receptor 7;!6. Metabotropic glutamate receptor 8;!7. Excitatory amino acid transporter 5;!8. 5-oxoprolinase;!9. Phosphoribosylformylglycinamidine synthase;!10. Branched-chain-amino-acid aminotransferase, mitochondrial;!11. Glutamate receptor ionotropic, NMDA 2D;!12. Glutaminase kidney isoform, mitochondrial;!13. Aspartate aminotransferase, mitochondrial;!14. Bifunctional glutamate/proline--tRNA ligase;!15. Asparagine synthetase [glutamine-hydrolyzing];!16. Glutamine synthetase;!17. Aspartate aminotransferase, cytoplasmic;!18. Tyrosine aminotransferase;!19. Alanine aminotransferase 1;!20. Vitamin K-dependent gamma-carboxylase;!21. Excitatory amino acid transporter 1;!22. Excitatory amino acid transporter 2;!23. Excitatory amino acid transporter 3;!24. Glutamate--cysteine ligase catalytic subunit;!25. Excitatory amino acid transporter 4;!26. Glutamate dehydrogenase 2, mitochondrial;!27. GMP synthase [glutamine-hydrolyzing];!28. Branched-chain-amino-acid aminotransferase, cytosolic;!29. 4-aminobutyrate aminotransferase, mitochondrial;!30. Glutamate receptor ionotropic, NMDA 1;!31. Folylpolyglutamate synthase, mitochondrial;!32. Glutamyl aminopeptidase;!33. Glutamate receptor ionotropic, NMDA 2A;!34. Glutamate receptor ionotropic, NMDA 2B;!35. Glutamate receptor ionotropic, NMDA 2C;!36. Aspartate aminotransferase;!37. Probable glutamate--tRNA ligase, mitochondrial;!38. Glutamine-dependent NAD(+) synthetase;!39. N-acetylglutamate synthase, mitochondrial;!40. Kynurenine/alpha-aminoadipate aminotransferase, mitochondrial;!41. Glutamate receptor ionotropic, NMDA 3A;!42. Alanine aminotransferase 2;!43. Alpha-aminoadipic semialdehyde synthase, mitochondrial;!44. Glutaminase liver isoform, mitochondrial;!45. Aspartyl aminopeptidase;!46. Cystine/glutamate transporter;!47. Carboxypeptidase Q;!48. Phosphoserine aminotransferase;!49. Glutamate dehydrogenase 1, mitochondrial;!50. Glutamate receptor ionotropic, kainate 1;!51. Glutamate receptor 1;!52. Glutamate--cysteine ligase regulatory subunit;!53. Glutamate carboxypeptidase 2;!54. Glutamate decarboxylase 2;!55. Glutamate decarboxylase 1;!56. Formimidoyltransferase-cyclodeaminase;!57. Glutamate receptor 2;!58. Glutamate receptor 3;!59. Glutamate receptor 4;!60. Delta-1-pyrroline-5-carboxylate synthase;!61. Glutamate receptor ionotropic, kainate 2;!62. Glutamate receptor ionotropic, kainate 3
C10H17N3O6S	Not Available	Not Available	307.323	N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O	Solid	Not Available	P09210;!P08263	GSTA2;!GSTA1	1. Glutathione S-transferase A2;!2. Glutathione S-transferase A1		50422268	16856	CHEMBL1543	111188			HMDB0000125	C02471	D00014	GSH	PDRhealth Drug Page	PA449780	124886	46504598		4890		Glutathione	ZINC000003830891		Glutathione	Approved, Investigational, Nutraceutical	DB00143	InChI=1S/C10H17N3O6S/c11-5(10(18)19)1-2-7(14)13-6(4-20)9(17)12-3-8(15)16/h5-6,20H,1-4,11H2,(H,12,17)(H,13,14)(H,15,16)(H,18,19)/t5-,6-/m0/s1	RWSXRVCMGQZWBV-WDSKDSINSA-N	3		ORL-MUS LD50 5000 mg/kg, IPR-MUS LD50 4020 mg/kg, SCU-MUS LD50 5000 mg/kg, IVN-RBT LD50 > 2000 mg/kg, IMS-MUS LD50 4000 mg/kg	Small Molecule	http://smpdb.ca/view/SMP0000077?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000087?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000093?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000094?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000114?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000116?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000136?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000183?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000243?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000500?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000567?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000692?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000697?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000702?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000015?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000075?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000083?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000098?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000102?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000106?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000109?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000113?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000120?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000143?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000337?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000385?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000447?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000559?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000604?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000640?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143	Piroxicam Action Pathway;!Rofecoxib Action Pathway;!Diclofenac Action Pathway;!Sulindac Action Pathway;!Nabumetone Action Pathway;!Valdecoxib Action Pathway;!2-Hydroxyglutric Aciduria (D and L Form);!gamma-Glutamyltransferase Deficiency;!4-Hydroxybutyric Aciduria/Succinic Semialdehyde Dehydrogenase Deficiency;!5-Oxoprolinase Deficiency;!Succinic Semialdehyde Dehydrogenase Deficiency;!Antipyrine Action Pathway;!Flurbiprofen Action Pathway;!Nepafenac Action Pathway;!Glutathione Metabolism;!Arachidonic Acid Metabolism;!Acetylsalicylic Acid Action Pathway;!Ketorolac Action Pathway;!Bromfenac Action Pathway;!Meloxicam Action Pathway;!Mefenamic Acid Action Pathway;!Oxaprozin Action Pathway;!Naproxen Action Pathway;!5-Oxoprolinuria;!Glutathione Synthetase Deficiency;!Homocarnosinosis;!Cyclophosphamide Action Pathway;!Pyruvate Kinase Deficiency;!Cyclophosphamide Metabolism Pathway;!Acetaminophen Metabolism Pathway		AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.7842 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					-6.4		195 °C			1	No	7	6	No	0	-1	158.82 Å2	29.3 Å3	69.11 m3·mol-1	9	No	No		-4.9		1.94	9.22			
C6H13NO2	Not Available	Not Available	131.1729	CC(C)C[C@H](N)C(O)=O	Solid	Not Available					50219348	57427	CHEMBL291962	5880			HMDB0000687	C00123	D00030	LEU	PDRhealth Drug Page	PA450197	6106	46507163		6308		Leucine	ZINC000003645145	Aminosyn II 7 %, Sulfite-free, Aminosyn-PF 7%, Clinimix 2.75/5, Clinimix E 2.75/5, Clinisol 15, Freamine 6.9, Freamine III 10, Hepatamine 8, Nephramine, Olimel, Periolimel, Plenamine, Premasol, Primene, Procalamine 3, Prosol, Travasol 10, Trophamine 10 %	Leucine	Investigational, Nutraceutical	DB00149	InChI=1S/C6H13NO2/c1-4(2)3-5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)/t5-/m0/s1	ROHFNLRQFUQHCH-YFKPBYRVSA-N	3	Leucine is an amino acid commonly found as a component of total parenteral nutrition.	Not Available	Small Molecule	http://smpdb.ca/view/SMP0000137?highlight[compounds][]=DB00149&highlight[proteins][]=DB00149;!http://smpdb.ca/view/SMP0000139?highlight[compounds][]=DB00149&highlight[proteins][]=DB00149;!http://smpdb.ca/view/SMP0000173?highlight[compounds][]=DB00149&highlight[proteins][]=DB00149;!http://smpdb.ca/view/SMP0000248?highlight[compounds][]=DB00149&highlight[proteins][]=DB00149;!http://smpdb.ca/view/SMP0000251?highlight[compounds][]=DB00149&highlight[proteins][]=DB00149;!http://smpdb.ca/view/SMP0000254?highlight[compounds][]=DB00149&highlight[proteins][]=DB00149;!http://smpdb.ca/view/SMP0000293?highlight[compounds][]=DB00149&highlight[proteins][]=DB00149;!http://smpdb.ca/view/SMP0000294?highlight[compounds][]=DB00149&highlight[proteins][]=DB00149;!http://smpdb.ca/view/SMP0000524?highlight[compounds][]=DB00149&highlight[proteins][]=DB00149;!http://smpdb.ca/view/SMP0000713?highlight[compounds][]=DB00149&highlight[proteins][]=DB00149;!http://smpdb.ca/view/SMP0000730?highlight[compounds][]=DB00149&highlight[proteins][]=DB00149;!http://smpdb.ca/view/SMP0000731?highlight[compounds][]=DB00149&highlight[proteins][]=DB00149;!http://smpdb.ca/view/SMP0002298?highlight[compounds][]=DB00149&highlight[proteins][]=DB00149;!http://smpdb.ca/view/SMP0000138?highlight[compounds][]=DB00149&highlight[proteins][]=DB00149;!http://smpdb.ca/view/SMP0000200?highlight[compounds][]=DB00149&highlight[proteins][]=DB00149;!http://smpdb.ca/view/SMP0000252?highlight[compounds][]=DB00149&highlight[proteins][]=DB00149;!http://smpdb.ca/view/SMP0000253?highlight[compounds][]=DB00149&highlight[proteins][]=DB00149;!http://smpdb.ca/view/SMP0000258?highlight[compounds][]=DB00149&highlight[proteins][]=DB00149;!http://smpdb.ca/view/SMP0000290?highlight[compounds][]=DB00149&highlight[proteins][]=DB00149;!http://smpdb.ca/view/SMP0000291?highlight[compounds][]=DB00149&highlight[proteins][]=DB00149;!http://smpdb.ca/view/SMP0000292?highlight[compounds][]=DB00149&highlight[proteins][]=DB00149;!http://smpdb.ca/view/SMP0000295?highlight[compounds][]=DB00149&highlight[proteins][]=DB00149;!http://smpdb.ca/view/SMP0000523?highlight[compounds][]=DB00149&highlight[proteins][]=DB00149;!http://smpdb.ca/view/SMP0000712?highlight[compounds][]=DB00149&highlight[proteins][]=DB00149;!http://smpdb.ca/view/SMP0000714?highlight[compounds][]=DB00149&highlight[proteins][]=DB00149;!http://smpdb.ca/view/SMP0000727?highlight[compounds][]=DB00149&highlight[proteins][]=DB00149;!http://smpdb.ca/view/SMP0000728?highlight[compounds][]=DB00149&highlight[proteins][]=DB00149;!http://smpdb.ca/view/SMP0000729?highlight[compounds][]=DB00149&highlight[proteins][]=DB00149;!http://smpdb.ca/view/SMP0000032?highlight[compounds][]=DB00149&highlight[proteins][]=DB00149;!http://smpdb.ca/view/SMP0000140?highlight[compounds][]=DB00149&highlight[proteins][]=DB00149	2-Methyl-3-hydroxybutryl-CoA Dehydrogenase Deficiency;!3-Methylglutaconic Aciduria Type I;!beta-Ketothiolase Deficiency;!Clarithromycin Action Pathway;!Roxithromycin Action Pathway;!Gentamicin Action Pathway;!Oxytetracycline Action Pathway;!Tetracycline Action Pathway;!Isovaleric Acidemia;!Arbekacin Action Pathway;!Troleandomycin Action Pathway;!Josamycin Action Pathway;!Glutaminolysis and Cancer;!3-Hydroxy-3-methylglutaryl-CoA Lyase Deficiency;!Methylmalonic Aciduria;!Telithromycin Action Pathway;!Amikacin Action Pathway;!Spectinomycin Action Pathway;!Demeclocycline Action Pathway;!Doxycycline Action Pathway;!Minocycline Action Pathway;!Lymecycline Action Pathway;!Isobutyryl-CoA Dehydrogenase Deficiency;!Tigecycline Action Pathway;!Paromomycin Action Pathway;!Methacycline Action Pathway;!Lincomycin Action Pathway;!Chloramphenicol Action Pathway;!Valine, Leucine, and Isoleucine Degradation;!3-Methylglutaconic Aciduria Type III																												-1.52		293 °C	2.35 (at 13 °C)	2.15E+004 mg/L (at 25 °C)	1	No	3	2	No	0	0	63.32 Å2	14.16 Å3	34.17 m3·mol-1	3	Yes	No	69.8 mg/mL	-1.6	-0.27	2.79	9.52	Q15031;!O60294;!Q9UIC8;!Q9P2J5;!O15382;!P54687	LARS2;!LCMT2;!LCMT1;!LARS;!BCAT2;!BCAT1	1. Probable leucine--tRNA ligase, mitochondrial;!2. Leucine carboxyl methyltransferase 2;!3. Leucine carboxyl methyltransferase 1;!4. Leucine--tRNA ligase, cytoplasmic;!5. Branched-chain-amino-acid aminotransferase, mitochondrial;!6. Branched-chain-amino-acid aminotransferase, cytosolic
C3H7NO2S	Not Available	Not Available	121.158	N[C@@H](CS)C(O)=O	Solid	Not Available					50109609	17561	CHEMBL863	5653			HMDB0000574	C00097	D00026	CYS		PA449173	5862	46506553		3024		Cysteine	ZINC000000895042	Elcys, Freamine 6.9, Freamine III 10, Hepatamine 8, Nephramine, Nouress, Premasol, Primene, Procalamine 3, Trophamine 10 %	Cysteine	Approved, Nutraceutical	DB00151	InChI=1S/C3H7NO2S/c4-2(1-7)3(5)6/h2,7H,1,4H2,(H,5,6)/t2-/m0/s1	XUJNEKJLAYXESH-REOHCLBHSA-N	4	Cysteine is an amino acid commonly found as a component of total parenteral nutrition and used as an antidote for acetaminophen overdose.	Not Available	Small Molecule	http://smpdb.ca/view/SMP0000004?highlight[compounds][]=DB00151&highlight[proteins][]=DB00151;!http://smpdb.ca/view/SMP0000021?highlight[compounds][]=DB00151&highlight[proteins][]=DB00151;!http://smpdb.ca/view/SMP0000072?highlight[compounds][]=DB00151&highlight[proteins][]=DB00151;!http://smpdb.ca/view/SMP0000080?highlight[compounds][]=DB00151&highlight[proteins][]=DB00151;!http://smpdb.ca/view/SMP0000088?highlight[compounds][]=DB00151&highlight[proteins][]=DB00151;!http://smpdb.ca/view/SMP0000091?highlight[compounds][]=DB00151&highlight[proteins][]=DB00151;!http://smpdb.ca/view/SMP0000110?highlight[compounds][]=DB00151&highlight[proteins][]=DB00151;!http://smpdb.ca/view/SMP0000121?highlight[compounds][]=DB00151&highlight[proteins][]=DB00151;!http://smpdb.ca/view/SMP0000134?highlight[compounds][]=DB00151&highlight[proteins][]=DB00151;!http://smpdb.ca/view/SMP0000135?highlight[compounds][]=DB00151&highlight[proteins][]=DB00151;!http://smpdb.ca/view/SMP0000177?highlight[compounds][]=DB00151&highlight[proteins][]=DB00151;!http://smpdb.ca/view/SMP0000339?highlight[compounds][]=DB00151&highlight[proteins][]=DB00151;!http://smpdb.ca/view/SMP0000501?highlight[compounds][]=DB00151&highlight[proteins][]=DB00151;!http://smpdb.ca/view/SMP0000027?highlight[compounds][]=DB00151&highlight[proteins][]=DB00151;!http://smpdb.ca/view/SMP0000033?highlight[compounds][]=DB00151&highlight[proteins][]=DB00151;!http://smpdb.ca/view/SMP0000078?highlight[compounds][]=DB00151&highlight[proteins][]=DB00151;!http://smpdb.ca/view/SMP0000090?highlight[compounds][]=DB00151&highlight[proteins][]=DB00151;!http://smpdb.ca/view/SMP0000097?highlight[compounds][]=DB00151&highlight[proteins][]=DB00151;!http://smpdb.ca/view/SMP0000103?highlight[compounds][]=DB00151&highlight[proteins][]=DB00151;!http://smpdb.ca/view/SMP0000108?highlight[compounds][]=DB00151&highlight[proteins][]=DB00151;!http://smpdb.ca/view/SMP0000122?highlight[compounds][]=DB00151&highlight[proteins][]=DB00151;!http://smpdb.ca/view/SMP0000133?highlight[compounds][]=DB00151&highlight[proteins][]=DB00151;!http://smpdb.ca/view/SMP0000136?highlight[compounds][]=DB00151&highlight[proteins][]=DB00151;!http://smpdb.ca/view/SMP0000183?highlight[compounds][]=DB00151&highlight[proteins][]=DB00151;!http://smpdb.ca/view/SMP0000184?highlight[compounds][]=DB00151&highlight[proteins][]=DB00151;!http://smpdb.ca/view/SMP0000193?highlight[compounds][]=DB00151&highlight[proteins][]=DB00151;!http://smpdb.ca/view/SMP0000221?highlight[compounds][]=DB00151&highlight[proteins][]=DB00151;!http://smpdb.ca/view/SMP0000223?highlight[compounds][]=DB00151&highlight[proteins][]=DB00151;!http://smpdb.ca/view/SMP0000243?highlight[compounds][]=DB00151&highlight[proteins][]=DB00151;!http://smpdb.ca/view/SMP0000244?highlight[compounds][]=DB00151&highlight[proteins][]=DB00151	Glycine and Serine Metabolism;!Taurine and Hypotaurine Metabolism;!Glutamate Metabolism;!Polythiazide Action Pathway;!Bumetanide Action Pathway;!Quinethazone Action Pathway;!Indapamide Action Pathway;!Trichlormethiazide Action Pathway;!Spironolactone Action Pathway;!Eplerenone Action Pathway;!Cystathionine beta-Synthase Deficiency;!Hyperinsulinism-Hyperammonemia Syndrome;!gamma-Glutamyltranspeptidase Deficiency;!Pantothenate and CoA Biosynthesis;!Methionine Metabolism;!Chlorothiazide Action Pathway;!Bendroflumethiazide Action Pathway;!Ethacrynic Acid Action Pathway;!Cyclothiazide Action Pathway;!Hydroflumethiazide Action Pathway;!Chlorthalidone Action Pathway;!Amiloride Action Pathway;!2-Hydroxyglutric Aciduria (D and L Form);!gamma-Glutamyltransferase Deficiency;!Glucose Transporter Defect (SGLT2);!Iminoglycinuria;!Methionine Adenosyltransferase Deficiency;!Non-Ketotic Hyperglycinemia;!4-Hydroxybutyric Aciduria/Succinic Semialdehyde Dehydrogenase Deficiency;!Sarcosinemia		AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.7757 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					-2.49		240 dec °C	1.71	2.77E+005 mg/L (at 25 °C)	1	No	3	3	No	0	0	63.32 Å2	11.41 Å3	28.22 m3·mol-1	2	Yes	No	23.1 mg/mL	-2.8	-0.72	2.35	9.05	P48507;!P48506;!P17174;!P00505;!P32929;!P35520;!P49589;!P16455;!P48637;!Q9HA77;!Q9Y600;!Q9Y697;!Q16878	GCLM;!GCLC;!GOT1;!GOT2;!CTH;!CBS;!CARS;!MGMT;!GSS;!CARS2;!CSAD;!NFS1;!CDO1	1. Glutamate--cysteine ligase regulatory subunit;!2. Glutamate--cysteine ligase catalytic subunit;!3. Aspartate aminotransferase, cytoplasmic;!4. Aspartate aminotransferase, mitochondrial;!5. Cystathionine gamma-lyase;!6. Cystathionine beta-synthase;!7. Cysteine--tRNA ligase, cytoplasmic;!8. Methylated-DNA--protein-cysteine methyltransferase;!9. Glutathione synthetase;!10. Probable cysteine--tRNA ligase, mitochondrial;!11. Cysteine sulfinic acid decarboxylase;!12. Cysteine desulfurase, mitochondrial;!13. Cysteine dioxygenase type 1
C6H13N3O3	Not Available	Not Available	175.1857	N[C@@H](CCCNC(N)=O)C(O)=O	Solid	Not Available					92903	16349	CHEMBL444814	9367		GtP Drug Page	HMDB0000904	C00327	D07706	CIR		PA164747225	9750	46506583		2567		Citrulline	ZINC000001532614		Citrulline	Investigational, Nutraceutical	DB00155	InChI=1S/C6H13N3O3/c7-4(5(10)11)2-1-3-9-6(8)12/h4H,1-3,7H2,(H,10,11)(H3,8,9,12)/t4-/m0/s1	RHGKLRLOHDJJDR-BYPYZUCNSA-N	3		Not Available	Small Molecule	http://smpdb.ca/view/SMP0000362?highlight[compounds][]=DB00155&highlight[proteins][]=DB00155;!http://smpdb.ca/view/SMP0000504?highlight[compounds][]=DB00155&highlight[proteins][]=DB00155;!http://smpdb.ca/view/SMP0000505?highlight[compounds][]=DB00155&highlight[proteins][]=DB00155;!http://smpdb.ca/view/SMP0000002?highlight[compounds][]=DB00155&highlight[proteins][]=DB00155;!http://smpdb.ca/view/SMP0000003?highlight[compounds][]=DB00155&highlight[proteins][]=DB00155;!http://smpdb.ca/view/SMP0000020?highlight[compounds][]=DB00155&highlight[proteins][]=DB00155;!http://smpdb.ca/view/SMP0000188?highlight[compounds][]=DB00155&highlight[proteins][]=DB00155;!http://smpdb.ca/view/SMP0000360?highlight[compounds][]=DB00155&highlight[proteins][]=DB00155;!http://smpdb.ca/view/SMP0000361?highlight[compounds][]=DB00155&highlight[proteins][]=DB00155;!http://smpdb.ca/view/SMP0000507?highlight[compounds][]=DB00155&highlight[proteins][]=DB00155;!http://smpdb.ca/view/SMP0000001?highlight[compounds][]=DB00155&highlight[proteins][]=DB00155;!http://smpdb.ca/view/SMP0000059?highlight[compounds][]=DB00155&highlight[proteins][]=DB00155;!http://smpdb.ca/view/SMP0000067?highlight[compounds][]=DB00155&highlight[proteins][]=DB00155;!http://smpdb.ca/view/SMP0000175?highlight[compounds][]=DB00155&highlight[proteins][]=DB00155;!http://smpdb.ca/view/SMP0000192?highlight[compounds][]=DB00155&highlight[proteins][]=DB00155;!http://smpdb.ca/view/SMP0000205?highlight[compounds][]=DB00155&highlight[proteins][]=DB00155;!http://smpdb.ca/view/SMP0000207?highlight[compounds][]=DB00155&highlight[proteins][]=DB00155;!http://smpdb.ca/view/SMP0000208?highlight[compounds][]=DB00155&highlight[proteins][]=DB00155;!http://smpdb.ca/view/SMP0000357?highlight[compounds][]=DB00155&highlight[proteins][]=DB00155;!http://smpdb.ca/view/SMP0000363?highlight[compounds][]=DB00155&highlight[proteins][]=DB00155;!http://smpdb.ca/view/SMP0000506?highlight[compounds][]=DB00155&highlight[proteins][]=DB00155;!http://smpdb.ca/view/SMP0063777?highlight[compounds][]=DB00155&highlight[proteins][]=DB00155	Arginine: Glycine Amidinotransferase Deficiency (AGAT Deficiency);!Creatine Deficiency, Guanidinoacetate Methyltransferase Deficiency;!Hyperornithinemia with Gyrate Atrophy (HOGA);!Carbamoyl Phosphate Synthetase Deficiency;!Argininosuccinic Aciduria;!Arginine and Proline Metabolism;!Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency);!Hyperprolinemia Type II;!Hyperprolinemia Type I;!L-Arginine:Glycine Amidinotransferase Deficiency;!Citrullinemia Type I;!Urea Cycle;!Aspartate Metabolism;!Canavan Disease;!Hypoacetylaspartia;!Ornithine Transcarbamylase Deficiency (OTC Deficiency);!Prolidase Deficiency (PD);!Prolinemia Type II;!Argininemia;!Ornithine Aminotransferase Deficiency (OAT Deficiency);!Hyperornithinemia-Hyperammonemia-Homocitrullinuria [HHH-syndrome];!Nitric Oxide Signaling Pathway		Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.3397 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					-3.19		235.5 °C	2.43 (at 25 °C)	200 g/L (at 20 °C)	1	No	4	4	No	0	0	118.44 Å2	17.35 Å3	41.33 m3·mol-1	5	Yes	No	21.8 mg/mL	-3.9	-0.9	2.27	9.23			
C3H7NO2	Not Available	Not Available	89.0932	C[C@H](N)C(O)=O	Solid	Not Available					50000099	16977	CHEMBL279597	5735		GtP Drug Page	HMDB0000161	C00041	D00012	ALA		PA448055	5950	46504866		426	DAP000805	Alanine	ZINC000004658553	Aminosyn II 7 %, Sulfite-free, Aminosyn-PF 7%, Clinimix 2.75/5, Clinimix E 2.75/5, Clinisol 15, Freamine 6.9, Freamine III 10, Hepatamine 8, Olimel, Periolimel, Plenamine, Premasol, Primene, Procalamine 3, Prosol, Travasol 10, Trophamine 10 %	Alanine	Nutraceutical	DB00160	InChI=1S/C3H7NO2/c1-2(4)3(5)6/h2H,4H2,1H3,(H,5,6)/t2-/m0/s1	QNAYBMKLOCPYGJ-REOHCLBHSA-N	3	Alanine is an amino acid commonly found as a component of total parenteral nutrition.	Not Available	Small Molecule	http://smpdb.ca/view/SMP0000002?highlight[compounds][]=DB00160&highlight[proteins][]=DB00160;!http://smpdb.ca/view/SMP0000003?highlight[compounds][]=DB00160&highlight[proteins][]=DB00160;!http://smpdb.ca/view/SMP0000004?highlight[compounds][]=DB00160&highlight[proteins][]=DB00160;!http://smpdb.ca/view/SMP0000029?highlight[compounds][]=DB00160&highlight[proteins][]=DB00160;!http://smpdb.ca/view/SMP0000072?highlight[compounds][]=DB00160&highlight[proteins][]=DB00160;!http://smpdb.ca/view/SMP0000248?highlight[compounds][]=DB00160&highlight[proteins][]=DB00160;!http://smpdb.ca/view/SMP0000251?highlight[compounds][]=DB00160&highlight[proteins][]=DB00160;!http://smpdb.ca/view/SMP0000254?highlight[compounds][]=DB00160&highlight[proteins][]=DB00160;!http://smpdb.ca/view/SMP0000293?highlight[compounds][]=DB00160&highlight[proteins][]=DB00160;!http://smpdb.ca/view/SMP0000294?highlight[compounds][]=DB00160&highlight[proteins][]=DB00160;!http://smpdb.ca/view/SMP0000339?highlight[compounds][]=DB00160&highlight[proteins][]=DB00160;!http://smpdb.ca/view/SMP0000501?highlight[compounds][]=DB00160&highlight[proteins][]=DB00160;!http://smpdb.ca/view/SMP0000713?highlight[compounds][]=DB00160&highlight[proteins][]=DB00160;!http://smpdb.ca/view/SMP0000730?highlight[compounds][]=DB00160&highlight[proteins][]=DB00160;!http://smpdb.ca/view/SMP0000731?highlight[compounds][]=DB00160&highlight[proteins][]=DB00160;!http://smpdb.ca/view/SMP0002298?highlight[compounds][]=DB00160&highlight[proteins][]=DB00160;!http://smpdb.ca/view/SMP0000015?highlight[compounds][]=DB00160&highlight[proteins][]=DB00160;!http://smpdb.ca/view/SMP0000055?highlight[compounds][]=DB00160&highlight[proteins][]=DB00160;!http://smpdb.ca/view/SMP0000063?highlight[compounds][]=DB00160&highlight[proteins][]=DB00160;!http://smpdb.ca/view/SMP0000143?highlight[compounds][]=DB00160&highlight[proteins][]=DB00160;!http://smpdb.ca/view/SMP0000179?highlight[compounds][]=DB00160&highlight[proteins][]=DB00160;!http://smpdb.ca/view/SMP0000242?highlight[compounds][]=DB00160&highlight[proteins][]=DB00160;!http://smpdb.ca/view/SMP0000247?highlight[compounds][]=DB00160&highlight[proteins][]=DB00160;!http://smpdb.ca/view/SMP0000249?highlight[compounds][]=DB00160&highlight[proteins][]=DB00160;!http://smpdb.ca/view/SMP0000250?highlight[compounds][]=DB00160&highlight[proteins][]=DB00160;!http://smpdb.ca/view/SMP0000255?highlight[compounds][]=DB00160&highlight[proteins][]=DB00160;!http://smpdb.ca/view/SMP0000256?highlight[compounds][]=DB00160&highlight[proteins][]=DB00160;!http://smpdb.ca/view/SMP0000257?highlight[compounds][]=DB00160&highlight[proteins][]=DB00160;!http://smpdb.ca/view/SMP0000259?highlight[compounds][]=DB00160&highlight[proteins][]=DB00160;!http://smpdb.ca/view/SMP0000262?highlight[compounds][]=DB00160&highlight[proteins][]=DB00160	Carbamoyl Phosphate Synthetase Deficiency;!Argininosuccinic Aciduria;!Glycine and Serine Metabolism;!Selenoamino Acid Metabolism;!Glutamate Metabolism;!Clarithromycin Action Pathway;!Roxithromycin Action Pathway;!Gentamicin Action Pathway;!Oxytetracycline Action Pathway;!Tetracycline Action Pathway;!Hyperinsulinism-Hyperammonemia Syndrome;!gamma-Glutamyltranspeptidase Deficiency;!Arbekacin Action Pathway;!Troleandomycin Action Pathway;!Josamycin Action Pathway;!Glutaminolysis and Cancer;!Glutathione Metabolism;!Alanine Metabolism;!Tryptophan Metabolism;!5-Oxoprolinuria;!Dihydropyrimidine Dehydrogenase Deficiency (DHPD);!Dimethylglycine Dehydrogenase Deficiency;!Azithromycin Action Pathway;!Clindamycin Action Pathway;!Erythromycin Action Pathway;!Kanamycin Action Pathway;!Neomycin Action Pathway;!Netilmicin Action Pathway;!Streptomycin Action Pathway;!Clomocycline Action Pathway																												-2.85		300 dec °C	2.34 (at 25 °C)	1.64E+005 mg/L (at 25 °C)	1	No	3	2	No	0	0	63.32 Å2	8.49 Å3	20.5 m3·mol-1	1	Yes	No	447.0 mg/mL	-2.8	0.7	2.47	9.48	P21549;!P24298;!Q9Y697;!Q7Z2H8;!Q9UHI5;!Q9BYV1;!P49588;!P43007;!P80404;!Q16719;!Q5JTZ9;!Q8IUZ5;!Q8TD30	AGXT;!GPT;!NFS1;!SLC36A1;!SLC7A8;!AGXT2;!AARS;!SLC1A4;!ABAT;!KYNU;!AARS2;!PHYKPL;!GPT2	1. Serine--pyruvate aminotransferase;!2. Alanine aminotransferase 1;!3. Cysteine desulfurase, mitochondrial;!4. Proton-coupled amino acid transporter 1;!5. Large neutral amino acids transporter small subunit 2;!6. Alanine--glyoxylate aminotransferase 2, mitochondrial;!7. Alanine--tRNA ligase, cytoplasmic;!8. Neutral amino acid transporter A;!9. 4-aminobutyrate aminotransferase, mitochondrial;!10. Kynureninase;!11. Alanine--tRNA ligase, mitochondrial;!12. 5-phosphohydroxy-L-lysine phospho-lyase;!13. Alanine aminotransferase 2
C5H11NO2	Not Available	Not Available	117.1463	CC(C)[C@H](N)C(O)=O	Solid	Not Available	P26640;!P05166;!P54687	VARS;!PCCB;!BCAT1	1. Valine--tRNA ligase;!2. Propionyl-CoA carboxylase beta chain, mitochondrial;!3. Branched-chain-amino-acid aminotransferase, cytosolic		50463208	16414	CHEMBL43068	6050			HMDB0000883	C00183	D00039	VAL	PDRhealth Drug Page	PA451843	6287	46504886		11115		Valine	ZINC000000895099	Aminosyn II 7 %, Sulfite-free, Aminosyn-PF 7%, Clinimix 2.75/5, Clinimix E 2.75/5, Clinisol 15, Freamine 6.9, Freamine III 10, Hepatamine 8, Nephramine, Olimel, Periolimel, Plenamine, Premasol, Primene, Procalamine 3, Prosol, Travasol 10, Trophamine 10 %	Valine	Approved, Nutraceutical	DB00161	InChI=1S/C5H11NO2/c1-3(2)4(6)5(7)8/h3-4H,6H2,1-2H3,(H,7,8)/t4-/m0/s1	KZSNJWFQEVHDMF-BYPYZUCNSA-N	3	Valine is an amino acid commonly found as a component of total parenteral nutrition.	Symptoms of hypoglycemia, increased mortality in ALS patients taking large doses of BCAAs.	Small Molecule	http://smpdb.ca/view/SMP0000016?highlight[compounds][]=DB00161&highlight[proteins][]=DB00161;!http://smpdb.ca/view/SMP0000137?highlight[compounds][]=DB00161&highlight[proteins][]=DB00161;!http://smpdb.ca/view/SMP0000139?highlight[compounds][]=DB00161&highlight[proteins][]=DB00161;!http://smpdb.ca/view/SMP0000173?highlight[compounds][]=DB00161&highlight[proteins][]=DB00161;!http://smpdb.ca/view/SMP0000248?highlight[compounds][]=DB00161&highlight[proteins][]=DB00161;!http://smpdb.ca/view/SMP0000251?highlight[compounds][]=DB00161&highlight[proteins][]=DB00161;!http://smpdb.ca/view/SMP0000254?highlight[compounds][]=DB00161&highlight[proteins][]=DB00161;!http://smpdb.ca/view/SMP0000293?highlight[compounds][]=DB00161&highlight[proteins][]=DB00161;!http://smpdb.ca/view/SMP0000294?highlight[compounds][]=DB00161&highlight[proteins][]=DB00161;!http://smpdb.ca/view/SMP0000524?highlight[compounds][]=DB00161&highlight[proteins][]=DB00161;!http://smpdb.ca/view/SMP0000713?highlight[compounds][]=DB00161&highlight[proteins][]=DB00161;!http://smpdb.ca/view/SMP0000730?highlight[compounds][]=DB00161&highlight[proteins][]=DB00161;!http://smpdb.ca/view/SMP0000731?highlight[compounds][]=DB00161&highlight[proteins][]=DB00161;!http://smpdb.ca/view/SMP0000138?highlight[compounds][]=DB00161&highlight[proteins][]=DB00161;!http://smpdb.ca/view/SMP0000198?highlight[compounds][]=DB00161&highlight[proteins][]=DB00161;!http://smpdb.ca/view/SMP0000200?highlight[compounds][]=DB00161&highlight[proteins][]=DB00161;!http://smpdb.ca/view/SMP0000252?highlight[compounds][]=DB00161&highlight[proteins][]=DB00161;!http://smpdb.ca/view/SMP0000253?highlight[compounds][]=DB00161&highlight[proteins][]=DB00161;!http://smpdb.ca/view/SMP0000258?highlight[compounds][]=DB00161&highlight[proteins][]=DB00161;!http://smpdb.ca/view/SMP0000290?highlight[compounds][]=DB00161&highlight[proteins][]=DB00161;!http://smpdb.ca/view/SMP0000291?highlight[compounds][]=DB00161&highlight[proteins][]=DB00161;!http://smpdb.ca/view/SMP0000292?highlight[compounds][]=DB00161&highlight[proteins][]=DB00161;!http://smpdb.ca/view/SMP0000295?highlight[compounds][]=DB00161&highlight[proteins][]=DB00161;!http://smpdb.ca/view/SMP0000523?highlight[compounds][]=DB00161&highlight[proteins][]=DB00161;!http://smpdb.ca/view/SMP0000712?highlight[compounds][]=DB00161&highlight[proteins][]=DB00161;!http://smpdb.ca/view/SMP0000714?highlight[compounds][]=DB00161&highlight[proteins][]=DB00161;!http://smpdb.ca/view/SMP0000727?highlight[compounds][]=DB00161&highlight[proteins][]=DB00161;!http://smpdb.ca/view/SMP0000728?highlight[compounds][]=DB00161&highlight[proteins][]=DB00161;!http://smpdb.ca/view/SMP0000729?highlight[compounds][]=DB00161&highlight[proteins][]=DB00161;!http://smpdb.ca/view/SMP0000032?highlight[compounds][]=DB00161&highlight[proteins][]=DB00161	Propanoate Metabolism;!2-Methyl-3-hydroxybutryl-CoA Dehydrogenase Deficiency;!3-Methylglutaconic Aciduria Type I;!beta-Ketothiolase Deficiency;!Clarithromycin Action Pathway;!Roxithromycin Action Pathway;!Gentamicin Action Pathway;!Oxytetracycline Action Pathway;!Tetracycline Action Pathway;!Isovaleric Acidemia;!Arbekacin Action Pathway;!Troleandomycin Action Pathway;!Josamycin Action Pathway;!3-Hydroxy-3-methylglutaryl-CoA Lyase Deficiency;!Malonic Aciduria;!Methylmalonic Aciduria;!Telithromycin Action Pathway;!Amikacin Action Pathway;!Spectinomycin Action Pathway;!Demeclocycline Action Pathway;!Doxycycline Action Pathway;!Minocycline Action Pathway;!Lymecycline Action Pathway;!Isobutyryl-CoA Dehydrogenase Deficiency;!Tigecycline Action Pathway;!Paromomycin Action Pathway;!Methacycline Action Pathway;!Lincomycin Action Pathway;!Chloramphenicol Action Pathway;!Valine, Leucine, and Isoleucine Degradation		Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.4765 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					-2.26		315 °C	2.3 (at 13 °C)	5.85E+004 mg/L (at 25 °C)	1	No	3	2	No	0	0	63.32 Å2	12.19 Å3	29.49 m3·mol-1	2	Yes	No	214.0 mg/mL	-2	0.26	2.72	9.6	P05166;!P54687;!P26640	PCCB;!BCAT1;!VARS	1. Propionyl-CoA carboxylase beta chain, mitochondrial;!2. Branched-chain-amino-acid aminotransferase, cytosolic;!3. Valine--tRNA ligase
C6H13NO2	Not Available	Not Available	131.1729	CC[C@H](C)[C@H](N)C(O)=O	Solid	Not Available					18140	58045	CHEMBL1233584	6067		GtP Drug Page	HMDB0000172	C00407	D00065	ILE	PDRhealth Drug Page	PA164750430	6306	46506864		6033		Isoleucine	ZINC000003581355	Aminosyn II 7 %, Sulfite-free, Aminosyn-PF 7%, Clinimix 2.75/5, Clinimix E 2.75/5, Clinisol 15, Freamine 6.9, Freamine III 10, Hepatamine 8, Nephramine, Olimel, Periolimel, Plenamine, Premasol, Primene, Procalamine 3, Prosol, Travasol 10, Trophamine 10 %	Isoleucine	Investigational, Nutraceutical	DB00167	InChI=1S/C6H13NO2/c1-3-4(2)5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)/t4-,5-/m0/s1	AGPKZVBTJJNPAG-WHFBIAKZSA-N	3	Isoleucine is an amino acid commonly found as a component of total parenteral nutrition.	Symptoms of hypoglycemia, increased mortality in ALS patients taking large doses of BCAAs	Small Molecule	http://smpdb.ca/view/SMP0000137?highlight[compounds][]=DB00167&highlight[proteins][]=DB00167;!http://smpdb.ca/view/SMP0000139?highlight[compounds][]=DB00167&highlight[proteins][]=DB00167;!http://smpdb.ca/view/SMP0000173?highlight[compounds][]=DB00167&highlight[proteins][]=DB00167;!http://smpdb.ca/view/SMP0000248?highlight[compounds][]=DB00167&highlight[proteins][]=DB00167;!http://smpdb.ca/view/SMP0000251?highlight[compounds][]=DB00167&highlight[proteins][]=DB00167;!http://smpdb.ca/view/SMP0000254?highlight[compounds][]=DB00167&highlight[proteins][]=DB00167;!http://smpdb.ca/view/SMP0000293?highlight[compounds][]=DB00167&highlight[proteins][]=DB00167;!http://smpdb.ca/view/SMP0000294?highlight[compounds][]=DB00167&highlight[proteins][]=DB00167;!http://smpdb.ca/view/SMP0000524?highlight[compounds][]=DB00167&highlight[proteins][]=DB00167;!http://smpdb.ca/view/SMP0000713?highlight[compounds][]=DB00167&highlight[proteins][]=DB00167;!http://smpdb.ca/view/SMP0000730?highlight[compounds][]=DB00167&highlight[proteins][]=DB00167;!http://smpdb.ca/view/SMP0000731?highlight[compounds][]=DB00167&highlight[proteins][]=DB00167;!http://smpdb.ca/view/SMP0000138?highlight[compounds][]=DB00167&highlight[proteins][]=DB00167;!http://smpdb.ca/view/SMP0000200?highlight[compounds][]=DB00167&highlight[proteins][]=DB00167;!http://smpdb.ca/view/SMP0000252?highlight[compounds][]=DB00167&highlight[proteins][]=DB00167;!http://smpdb.ca/view/SMP0000253?highlight[compounds][]=DB00167&highlight[proteins][]=DB00167;!http://smpdb.ca/view/SMP0000258?highlight[compounds][]=DB00167&highlight[proteins][]=DB00167;!http://smpdb.ca/view/SMP0000290?highlight[compounds][]=DB00167&highlight[proteins][]=DB00167;!http://smpdb.ca/view/SMP0000291?highlight[compounds][]=DB00167&highlight[proteins][]=DB00167;!http://smpdb.ca/view/SMP0000292?highlight[compounds][]=DB00167&highlight[proteins][]=DB00167;!http://smpdb.ca/view/SMP0000295?highlight[compounds][]=DB00167&highlight[proteins][]=DB00167;!http://smpdb.ca/view/SMP0000523?highlight[compounds][]=DB00167&highlight[proteins][]=DB00167;!http://smpdb.ca/view/SMP0000712?highlight[compounds][]=DB00167&highlight[proteins][]=DB00167;!http://smpdb.ca/view/SMP0000714?highlight[compounds][]=DB00167&highlight[proteins][]=DB00167;!http://smpdb.ca/view/SMP0000727?highlight[compounds][]=DB00167&highlight[proteins][]=DB00167;!http://smpdb.ca/view/SMP0000728?highlight[compounds][]=DB00167&highlight[proteins][]=DB00167;!http://smpdb.ca/view/SMP0000729?highlight[compounds][]=DB00167&highlight[proteins][]=DB00167;!http://smpdb.ca/view/SMP0000032?highlight[compounds][]=DB00167&highlight[proteins][]=DB00167;!http://smpdb.ca/view/SMP0000140?highlight[compounds][]=DB00167&highlight[proteins][]=DB00167;!http://smpdb.ca/view/SMP0000141?highlight[compounds][]=DB00167&highlight[proteins][]=DB00167	2-Methyl-3-hydroxybutryl-CoA Dehydrogenase Deficiency;!3-Methylglutaconic Aciduria Type I;!beta-Ketothiolase Deficiency;!Clarithromycin Action Pathway;!Roxithromycin Action Pathway;!Gentamicin Action Pathway;!Oxytetracycline Action Pathway;!Tetracycline Action Pathway;!Isovaleric Acidemia;!Arbekacin Action Pathway;!Troleandomycin Action Pathway;!Josamycin Action Pathway;!3-Hydroxy-3-methylglutaryl-CoA Lyase Deficiency;!Methylmalonic Aciduria;!Telithromycin Action Pathway;!Amikacin Action Pathway;!Spectinomycin Action Pathway;!Demeclocycline Action Pathway;!Doxycycline Action Pathway;!Minocycline Action Pathway;!Lymecycline Action Pathway;!Isobutyryl-CoA Dehydrogenase Deficiency;!Tigecycline Action Pathway;!Paromomycin Action Pathway;!Methacycline Action Pathway;!Lincomycin Action Pathway;!Chloramphenicol Action Pathway;!Valine, Leucine, and Isoleucine Degradation;!3-Methylglutaconic Aciduria Type III;!3-Methylglutaconic Aciduria Type IV		Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.5846 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					-1.70		285.5 dec °C	2.37 (at 0 °C)	3.44E+004 mg/L (at 25 °C)	1	No	3	2	No	0	0	63.32 Å2	14.11 Å3	34.09 m3·mol-1	3	Yes	No	114.0 mg/mL	-1.5	-0.06	2.79	9.59	P45954;!P54687;!O15382;!P41252;!Q9NSE4	ACADSB;!BCAT1;!BCAT2;!IARS;!IARS2	1. Short/branched chain specific acyl-CoA dehydrogenase, mitochondrial;!2. Branched-chain-amino-acid aminotransferase, cytosolic;!3. Branched-chain-amino-acid aminotransferase, mitochondrial;!4. Isoleucine--tRNA ligase, cytoplasmic;!5. Isoleucine--tRNA ligase, mitochondrial
C4H8N2O3	Not Available	Not Available	132.1179	N[C@@H](CC(N)=O)C(O)=O	Solid	Not Available					181137	58048	CHEMBL58832	6031			HMDB0000168	C00152		41Q		PA164776968	6267	46507804		1157		Asparagine	ZINC000001532556		Asparagine	Approved, Investigational, Nutraceutical	DB00174	InChI=1S/C4H8N2O3/c5-2(4(8)9)1-3(6)7/h2H,1,5H2,(H2,6,7)(H,8,9)/t2-/m0/s1	DCXYFEDJOCDNAF-REOHCLBHSA-N			Not Available	Small Molecule	http://smpdb.ca/view/SMP0000009?highlight[compounds][]=DB00174&highlight[proteins][]=DB00174;!http://smpdb.ca/view/SMP0000248?highlight[compounds][]=DB00174&highlight[proteins][]=DB00174;!http://smpdb.ca/view/SMP0000251?highlight[compounds][]=DB00174&highlight[proteins][]=DB00174;!http://smpdb.ca/view/SMP0000254?highlight[compounds][]=DB00174&highlight[proteins][]=DB00174;!http://smpdb.ca/view/SMP0000293?highlight[compounds][]=DB00174&highlight[proteins][]=DB00174;!http://smpdb.ca/view/SMP0000294?highlight[compounds][]=DB00174&highlight[proteins][]=DB00174;!http://smpdb.ca/view/SMP0000713?highlight[compounds][]=DB00174&highlight[proteins][]=DB00174;!http://smpdb.ca/view/SMP0000730?highlight[compounds][]=DB00174&highlight[proteins][]=DB00174;!http://smpdb.ca/view/SMP0000731?highlight[compounds][]=DB00174&highlight[proteins][]=DB00174;!http://smpdb.ca/view/SMP0000247?highlight[compounds][]=DB00174&highlight[proteins][]=DB00174;!http://smpdb.ca/view/SMP0000249?highlight[compounds][]=DB00174&highlight[proteins][]=DB00174;!http://smpdb.ca/view/SMP0000250?highlight[compounds][]=DB00174&highlight[proteins][]=DB00174;!http://smpdb.ca/view/SMP0000255?highlight[compounds][]=DB00174&highlight[proteins][]=DB00174;!http://smpdb.ca/view/SMP0000256?highlight[compounds][]=DB00174&highlight[proteins][]=DB00174;!http://smpdb.ca/view/SMP0000257?highlight[compounds][]=DB00174&highlight[proteins][]=DB00174;!http://smpdb.ca/view/SMP0000259?highlight[compounds][]=DB00174&highlight[proteins][]=DB00174;!http://smpdb.ca/view/SMP0000262?highlight[compounds][]=DB00174&highlight[proteins][]=DB00174;!http://smpdb.ca/view/SMP0000711?highlight[compounds][]=DB00174&highlight[proteins][]=DB00174;!http://smpdb.ca/view/SMP0000726?highlight[compounds][]=DB00174&highlight[proteins][]=DB00174;!http://smpdb.ca/view/SMP0000067?highlight[compounds][]=DB00174&highlight[proteins][]=DB00174;!http://smpdb.ca/view/SMP0000175?highlight[compounds][]=DB00174&highlight[proteins][]=DB00174;!http://smpdb.ca/view/SMP0000192?highlight[compounds][]=DB00174&highlight[proteins][]=DB00174;!http://smpdb.ca/view/SMP0000252?highlight[compounds][]=DB00174&highlight[proteins][]=DB00174;!http://smpdb.ca/view/SMP0000253?highlight[compounds][]=DB00174&highlight[proteins][]=DB00174;!http://smpdb.ca/view/SMP0000258?highlight[compounds][]=DB00174&highlight[proteins][]=DB00174;!http://smpdb.ca/view/SMP0000290?highlight[compounds][]=DB00174&highlight[proteins][]=DB00174;!http://smpdb.ca/view/SMP0000291?highlight[compounds][]=DB00174&highlight[proteins][]=DB00174;!http://smpdb.ca/view/SMP0000292?highlight[compounds][]=DB00174&highlight[proteins][]=DB00174;!http://smpdb.ca/view/SMP0000295?highlight[compounds][]=DB00174&highlight[proteins][]=DB00174;!http://smpdb.ca/view/SMP0000712?highlight[compounds][]=DB00174&highlight[proteins][]=DB00174	Ammonia Recycling;!Clarithromycin Action Pathway;!Roxithromycin Action Pathway;!Gentamicin Action Pathway;!Oxytetracycline Action Pathway;!Tetracycline Action Pathway;!Arbekacin Action Pathway;!Troleandomycin Action Pathway;!Josamycin Action Pathway;!Azithromycin Action Pathway;!Clindamycin Action Pathway;!Erythromycin Action Pathway;!Kanamycin Action Pathway;!Neomycin Action Pathway;!Netilmicin Action Pathway;!Streptomycin Action Pathway;!Clomocycline Action Pathway;!Tobramycin Action Pathway;!Rolitetracycline Action Pathway;!Aspartate Metabolism;!Canavan Disease;!Hypoacetylaspartia;!Telithromycin Action Pathway;!Amikacin Action Pathway;!Spectinomycin Action Pathway;!Demeclocycline Action Pathway;!Doxycycline Action Pathway;!Minocycline Action Pathway;!Lymecycline Action Pathway;!Tigecycline Action Pathway		Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.4003 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					-3.82	-0.74	234-235 °C	8.82 (at 18 °C)	2.94E+004 mg/L (at 25 °C)	1	No	4	3	No	0	0	106.41 Å2	11.68 Å3	28.35 m3·mol-1	3	Yes	No	168.0 mg/mL	-4.3	0.1	2	8.43	BE0009976;!Q15758;!P08243;!O43776;!Q7L266;!Q96I59	;!SLC1A5;!ASNS;!NARS;!ASRGL1;!NARS2	1. Sodium-coupled neutral amino acid transporters (Protein Group);!2. Neutral amino acid transporter B(0);!3. Asparagine synthetase [glutamine-hydrolyzing];!4. Asparagine--tRNA ligase, cytoplasmic;!5. Isoaspartyl peptidase/L-asparaginase;!6. Probable asparagine--tRNA ligase, mitochondrial
C21H31N3O5	A 30kg child has a typical clearance of 10L/h, which increases with renal function.8,9 The mean renal clearance of lisinopril in healthy adult males is 121mL/min.2	Lisinopril has an effective half life of accumulation of 12.6h2,8,9,10 and a terminal half life of 46.7h.2	405.4879	NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O	Solid	The apparent volume of distribution of lisinopril is 124L.3					66979	43755	CHEMBL1237	4514933	Drugs.com Drug Page		HMDB0001938		D00362	LPR	PDRhealth Drug Page	PA450242	5362119	46504893	RxList Drug Page	1546022	DAP000587	Lisinopril	ZINC000003812863	Prinivil, Qbrelis, Zestoretic, Zestril	Lisinopril	Approved, Investigational	DB00722	InChI=1S/C21H31N3O5/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29)/t16-,17-,18-/m0/s1	RLAWWYSOJDYHDC-BZSNNMDCSA-N	4	Lisinopril is an ACE inhibitor used to treat hypertension, heart failure, and acute myocardial infarction.	The oral and subcutaneous LD50 in rats is >8500mg/kg and in mice is >9100mg/kg.11 The oral LDLO in women is 1200µg/kg/16D and in men is 43mg/kg/43W.11Patients experiencing an overdose of lisinopril may present with hypotension.8,9,10 Patients should be treated with intravenous saline to restore blood pressure.8,9,10 Lisinopril can be removed from the blood by hemodialysis due to it not being protein bound.8,9,10	Small Molecule	http://smpdb.ca/view/SMP0000150?highlight[compounds][]=DB00722&highlight[proteins][]=DB00722	Lisinopril Action Pathway		Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.8723 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					-1.01		148	2.5 (at 25 °C)	9.7E+004 mg/L	1	No	7	4	No	2	0	132.96 Å2	43.64 Å3	107.37 m3·mol-1	12	Yes	No	0.216 mg/mL	-3.1	-3.3	3.17	10.21			
C6H11NO2	The oral clearance of vigabatrin is 2.4 L/h for infants (5m - 2y), 5.1 L/h for children (3y - 9y), 5.8 L/h for adolescents (10y - 16y), and 7 L/h for adults.7	The terminal half-life of vigabatrin is approximately 5.7 hours for infants (5m - 2y), 6.8 hours for children (3y - 9y), 9.5 hours for adolescents (10y - 16y), and 10.5 h for adults.7	129.157	NC(CCC(O)=O)C=C	Solid	Vigabatrin is widely distributed throughout the body with a mean steady-state volume of distribution of 1.1 L/kg.7	P11712	CYP2C9	1. Cytochrome P450 2C9		50118886	63638	CHEMBL89598	5463	Drugs.com Drug Page		HMDB0015212	C07500	D00535			PA10231	5665	46507052	RxList Drug Page	14851	DAP000557	Vigabatrin		Sabril, Vigadrone	Vigabatrin	Approved	DB01080	InChI=1S/C6H11NO2/c1-2-5(7)3-4-6(8)9/h2,5H,1,3-4,7H2,(H,8,9)	PJDFLNIOAUIZSL-UHFFFAOYSA-N	4	Vigabatrin is an irreversible GABA transaminase inhibitor used as an adjunct therapy to treat refractory complex partial seizures in patients ≥2 years unresponsive to alternatives. May also be used as monotherapy to treat infantile spasms in infants 1 month to 2 years.	The oral LD50 of vigabatrin in mice and rats is 2830 mg/kg and 3100 mg/kg, respectively.8 Symptoms of overdose tend to involve significant CNS depression - e.g. coma, unconsciousness, and/or drowsiness - with less common symptoms including neurologic disorders (e.g. seizure activity, speech disorder, headache) and psychiatric sequelae (e.g. psychosis, agitation, abnormal behaviour, confusion).7 In cases of overdose, symptoms generally resolve with symptomatic and supportive care. Standard measures to remove unabsorbed drug may be employed (e.g. gastric lavage), although an in vitro study found that activated charcoal did not significantly absorb vigabatrin.7 Although vigabatrin is not protein-bound, the effectiveness of hemodialysis in drug removal during overdose is unknown - isolated reports of patients in renal failure undergoing hemodialysis who were receiving therapeutic doses of vigabatrin note a reduction in vigabatrin plasma concentrations of 40-60% following dialysis.7	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.6656 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					-1.96		171-176C	4 and 9.7	55.1 mg/mL	1	No	3	2	No	0	0	63.32 Å2	13.64 Å3	34.29 m3·mol-1	4	Yes	No	96.6 mg/mL	-2.1	-0.13	4.61	9.91			
C9H11NO4	Intravenously administered levodopa is cleared at a rate of 14.2mL/min/kg in elderly patients and 23.4mL/min/kg in younger patients4. When given carbidopa, the clearance of levodopa was 5.8mL/min/kg in elderyly patients and 9.3mL/min/kg in younger patients4.	2.3 hours for orally inhaled levodopaLabel. Oral levodopa has a half life of 50 minutes but when combined with a peripheral dopa decarboxylase inhibitor, the half life is increased to 1.5 hours8.	197.1879	N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O	Solid	168L for orally inhaled levodopaLabel.	P20711	DDC	1. Aromatic-L-amino-acid decarboxylase		60928	15765	CHEMBL1009	5824	Drugs.com Drug Page	GtP Drug Page	HMDB0000181	C00355	D00059	DAH		PA450213	6047	46508120	RxList Drug Page	6375	DAP000209	Levodopa	ZINC000000895199	Dhivy, Duodopa, Duopa, Inbrija, Parcopa, Prolopa, Rytary, Sinemet, Stalevo	Levodopa	Approved	DB01235	InChI=1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1	WTDRDQBEARUVNC-LURJTMIESA-N	4	Levodopa is a dopamine precursor used in the management of Parkinson's disease, often in combination with carbidopa, as well as other conditions associated with parkinsonism.	There is no readily available data for the use of levodopa in pregnancyLabel. Rabbits treated with levodopa and carbidopa produced smaller litters and their offspring developed visceral and skeletal deformitiesLabel. Levodopa may lower prolactin and interfere with lactation but there is limited human data to demonstrate this effectLabel. Levodopa is present in human breast milk and so the potential effects of nursing while taking levodopa should be considered before prescribing levodopa to nursing mothersLabel. There is currently a lack of data on the safety and effectiveness of using levodopa in pediatric patientsLabel. Patients over 65 years of age are more likely to experience adverse effects associated with taking levodopa, however this generally is not sufficient to exclude this patient group from treatmentLabel.	Small Molecule	http://smpdb.ca/view/SMP0000170?highlight[compounds][]=DB01235&highlight[proteins][]=DB01235;!http://smpdb.ca/view/SMP0000006?highlight[compounds][]=DB01235&highlight[proteins][]=DB01235;!http://smpdb.ca/view/SMP0000012?highlight[compounds][]=DB01235&highlight[proteins][]=DB01235;!http://smpdb.ca/view/SMP0000218?highlight[compounds][]=DB01235&highlight[proteins][]=DB01235;!http://smpdb.ca/view/SMP0000429?highlight[compounds][]=DB01235&highlight[proteins][]=DB01235;!http://smpdb.ca/view/SMP0000169?highlight[compounds][]=DB01235&highlight[proteins][]=DB01235;!http://smpdb.ca/view/SMP0000190?highlight[compounds][]=DB01235&highlight[proteins][]=DB01235;!http://smpdb.ca/view/SMP0000494?highlight[compounds][]=DB01235&highlight[proteins][]=DB01235;!http://smpdb.ca/view/SMP0000497?highlight[compounds][]=DB01235&highlight[proteins][]=DB01235;!http://smpdb.ca/view/SMP0000498?highlight[compounds][]=DB01235&highlight[proteins][]=DB01235;!http://smpdb.ca/view/SMP0000533?highlight[compounds][]=DB01235&highlight[proteins][]=DB01235	Aromatic L-Aminoacid Decarboxylase Deficiency;!Tyrosine Metabolism;!Catecholamine Biosynthesis;!Tyrosinemia Type I;!Disulfiram Action Pathway;!Alkaptonuria;!Hawkinsinuria;!Tyrosinemia, Transient, of the Newborn;!Tyrosine Hydroxylase Deficiency;!Dopamine beta-Hydroxylase Deficiency;!Monoamine Oxidase-A Deficiency (MAO-A)		AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.0131 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				448.4	0.05		295		5mM	1	No	5	4	No	1	0	103.78 Å2	18.91 Å3	49.08 m3·mol-1	3	Yes	No	3.3 mg/mL	-1.8	-1.8	1.65	9.06	P21728;!P21918;!P14416;!P35462;!P21917	DRD1;!DRD5;!DRD2;!DRD3;!DRD4	1. Dopamine D1 receptor;!2. Dopamine D5 receptor;!3. Dopamine D2 receptor;!4. Dopamine D3 receptor;!5. Dopamine D4 receptor
C7H13NO3S	Not Available	Not Available	191.248	CSCC[C@H](NC(C)=O)C(O)=O	Solid	Not Available						21557		395338				C02712		AME			448580	46506781		1426463			ZINC000001529501		N-Acetylmethionine	Experimental	DB01646	InChI=1S/C7H13NO3S/c1-5(9)8-6(7(10)11)3-4-12-2/h6H,3-4H2,1-2H3,(H,8,9)(H,10,11)/t6-/m0/s1	XUYPXLNMDZIRQH-LURJTMIESA-N		N-Acetylmethionine is an amino acid used as a peritoneal dialysis treatment in patients with renal failure and nutritional therapy in patients with nutritional deficiency or post-infection weakness.	Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.5530 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							105.5 °C		3.07E+005 mg/L (at 25 °C)	1	Yes	3	2	No	0	-1	66.4 Å2	19.59 Å3	47.03 m3·mol-1	5	Yes	No	6.84 mg/mL	-0.11	-1.4	4.02	-1.8	P08100;!Q44244	RHO;!Aaar	1. Rhodopsin;!2. N-acylamino acid racemase
C8H18N4O2	Not Available	Not Available	202.2541	N[C@@H](CCC\N=C(/N)N(C)C)C(O)=O	Solid	Not Available					92901	17929	CHEMBL457530	110375			HMDB0001539	C03626		DA2			123831	46508091				Asymmetric_dimethylarginine	ZINC000001529718		N,N-dimethylarginine	Experimental	DB01686	InChI=1S/C8H18N4O2/c1-12(2)8(10)11-5-3-4-6(9)7(13)14/h6H,3-5,9H2,1-2H3,(H2,10,11)(H,13,14)/t6-/m0/s1	YDGMGEXADBMOMJ-LURJTMIESA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.0460 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	3	No	0	1	104.94 Å2	22.19 Å3	53.7 m3·mol-1	5	Yes	No	6.77 mg/mL	-2.7	-1.5	2.54	12.34	P35228;!P29474	NOS2;!NOS3	1. Nitric oxide synthase, inducible;!2. Nitric oxide synthase, endothelial
C7H16N2O2	Not Available	Not Available	160.2141	CNCCCC[C@H](N)C(O)=O	Solid	Not Available						17604		144469			HMDB0002038	C02728		MLZ			164795	46506725					ZINC000001529511		Epsilon-N-methyllysine	Experimental	DB01714	InChI=1S/C7H16N2O2/c1-9-5-3-2-4-6(8)7(10)11/h6,9H,2-5,8H2,1H3,(H,10,11)/t6-/m0/s1	PQNASZJZHFPQLE-LURJTMIESA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.2640 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	3	No	0	1	75.35 Å2	18.04 Å3	42.58 m3·mol-1	6	Yes	No	51.5 mg/mL	-2.9	-0.49	2.8	10.58			
C9H20N2O2	Not Available	Not Available	188.2673	C[C@H](N)[C@H](N)CCCCCC(O)=O	Solid	Not Available						42085		392785						DNN			445025	46508244					ZINC000019364244		7,8-Diamino-Nonanoic Acid	Experimental	DB01715	InChI=1S/C9H20N2O2/c1-7(10)8(11)5-3-2-4-6-9(12)13/h7-8H,2-6,10-11H2,1H3,(H,12,13)/t7-,8+/m0/s1	KCEGBPIYGIWCDH-JGVFFNPUSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.5127 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	3	No	0	1	89.34 Å2	21.85 Å3	51.3 m3·mol-1	7	Yes	No	4.94 mg/mL	-1.9	-1.6	4.73	9.97	P13000	bioD1	1. ATP-dependent dethiobiotin synthetase BioD 1
C6H13NO2	Not Available	Not Available	131.1729	CC[C@@H](C)[C@H](N)C(O)=O	Solid	Not Available						85338	CHEMBL56053	89698			HMDB0000557			IIL			99288	46504618					ZINC000000388312		L-alloisoleucine	Experimental	DB01739	InChI=1S/C6H13NO2/c1-3-4(2)5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)/t4-,5+/m1/s1	AGPKZVBTJJNPAG-UHNVWZDZSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.5846 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	3	2	No	0	0	63.32 Å2	14.23 Å3	34.09 m3·mol-1	3	Yes	No	114.0 mg/mL	-1.5	-0.06	2.79	9.59			
C6H13NO2	Not Available	Not Available	131.1729	CC(C)C[C@@H](N)C(O)=O	Solid	Not Available						28225	CHEMBL1232258	388617		GtP Drug Page	HMDB0013773	C01570		DLE			439524	46507999					ZINC000000388396		D-Leucine	Experimental	DB01746	InChI=1S/C6H13NO2/c1-4(2)3-5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)/t5-/m1/s1	ROHFNLRQFUQHCH-RXMQYKEDSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.5061 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							293 °C			1	No	3	2	No	0	0	63.32 Å2	14.25 Å3	34.17 m3·mol-1	3	Yes	No	69.8 mg/mL	-1.6	-0.27	2.79	9.52			
C13H13NO2	Not Available	Not Available	215.2478	[H][C@](N)(CC1=CC=C2C=CC=CC2=C1)C(O)=O	Solid	Not Available							CHEMBL1234619	161608						NAL			185915	46506480					ZINC000000128256		Beta-(2-Naphthyl)-Alanine	Experimental	DB01766	InChI=1S/C13H13NO2/c14-12(13(15)16)8-9-5-6-10-3-1-2-4-11(10)7-9/h1-7,12H,8,14H2,(H,15,16)/t12-/m0/s1	JPZXHKDZASGCLU-LBPRGKRZSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.0648 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	2	No	2	0	63.32 Å2	23.17 Å3	61.57 m3·mol-1	3	Yes	No	0.201 mg/mL	-0.19	-3	2.61	9.44	P54577;!Q13526;!P00734	YARS;!PIN1;!F2	1. Tyrosine--tRNA ligase, cytoplasmic;!2. Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1;!3. Prothrombin
C3H7NO2	Not Available	Not Available	89.0932	C[C@@H](N)C(O)=O	Solid	Not Available					50000109	15570	CHEMBL66693	64234		GtP Drug Page	HMDB0001310	C00133		DAL			71080	46508779					ZINC000004658556		D-Alanine	Experimental	DB01786	InChI=1S/C3H7NO2/c1-2(4)3(5)6/h2H,4H2,1H3,(H,5,6)/t2-/m1/s1	QNAYBMKLOCPYGJ-UWTATZPHSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.0339 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							292 °C		1.65E+005 mg/L (at 25 °C)	1	No	3	2	No	0	0	63.32 Å2	8.54 Å3	20.5 m3·mol-1	1	Yes	No	447.0 mg/mL	-2.8	0.7	2.47	9.48	P43133;!P15555	nprS;!Not Available	1. Thermolysin;!2. D-alanyl-D-alanine carboxypeptidase
C6H14NO6P	Not Available	Not Available	227.1522	[H][C@](N)(COP(O)(=O)OC(C)C)C(O)=O	Solid	Not Available								16744105						MIS			17754078	46504829					ZINC000006364759		Monoisopropylphosphorylserine	Experimental	DB01805	InChI=1S/C6H14NO6P/c1-4(2)13-14(10,11)12-3-5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)(H,10,11)/t5-/m0/s1	DALHHSOTZKMXMV-YFKPBYRVSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.1841 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	5	3	No	0	-1	119.08 Å2	19.86 Å3	46.56 m3·mol-1	6	Yes	No	26.8 mg/mL	-2.1	-0.93	1.67	9.38	P07478;!P00782;!P07477;!P22303	PRSS2;!apr;!PRSS1;!ACHE	1. Trypsin-2;!2. Subtilisin BPN';!3. Trypsin-1;!4. Acetylcholinesterase
C3H8AsNO3S	Not Available	Not Available	213.087	N[C@@H](CS[AsH]O)C(O)=O	Solid	Not Available														CZZ			17753936	46505856							Thiarsahydroxy-Cysteine	Experimental	DB01808	InChI=1S/C3H8AsNO3S/c5-2(3(6)7)1-9-4-8/h2,4,8H,1,5H2,(H,6,7)/t2-/m0/s1	SHJQITKLZDPXCU-REOHCLBHSA-N			Not Available	Small Molecule				AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.0524 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	3	No	0	0	83.55 Å2	15.65 Å3	30.8 m3·mol-1	4	Yes	No	33.7 mg/mL	-3.6	-0.8	1.47	8.79	P08692	arsC	1. Arsenate reductase
C9H16N2O6	Not Available	Not Available	248.2331	N[C@@H](CCCCNC(C(O)=O)C(O)=O)C(O)=O	Solid	Not Available								16744089						LLY			17754065	46504965					ZINC000006360448		Nz-(Dicarboxymethyl)Lysine	Experimental	DB01815	InChI=1S/C9H16N2O6/c10-5(7(12)13)3-1-2-4-11-6(8(14)15)9(16)17/h5-6,11H,1-4,10H2,(H,12,13)(H,14,15)(H,16,17)/t5-/m0/s1	XINFXVVRMYBFMI-YFKPBYRVSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.3212 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	8	5	No	0	-1	149.95 Å2	24.04 Å3	54.65 m3·mol-1	9	Yes	No	6.37 mg/mL	-5.6	-1.6	1.04	10.41	P0A872	talB	1. Transaldolase B
C8H16N2O6	Not Available	Not Available	236.2224	[H][C@](N)(C[C@]([H])(O)O[C@]([H])(C)[C@]([H])(N)C(O)=O)C(O)=O	Solid	Not Available								16743823						AEI			17753823	46508943					ZINC000058632161		Threonine-Aspartic Ester	Experimental	DB01817	InChI=1S/C8H16N2O6/c1-3(6(10)8(14)15)16-5(11)2-4(9)7(12)13/h3-6,11H,2,9-10H2,1H3,(H,12,13)(H,14,15)/t3-,4+,5-,6+/m1/s1	VCAYFLVMRCFGDV-MOJAZDJTSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.6638 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	8	5	No	0	0	156.1 Å2	21.94 Å3	50.47 m3·mol-1	7	Yes	No	28.1 mg/mL	-6.3	-0.92	1.62	9.2	P00805	ansB	1. L-asparaginase 2
C10H22N8O4	Not Available	Not Available	318.3329	NCC[C@H](NC(=O)[C@@H](N)CCCNC(=N)N[N+]([O-])=O)C(N)=O	Solid	Not Available					22030		CHEMBL44833	571159						DP1			656910	46509184					ZINC000012501145		L-N(omega)-Nitroarginine-2,4-L-diaminobutyric amide	Experimental	DB01821	InChI=1S/C10H22N8O4/c11-4-3-7(8(13)19)16-9(20)6(12)2-1-5-15-10(14)17-18(21)22/h6-7H,1-5,11-12H2,(H2,13,19)(H,16,20)(H3,14,15,17)/t6-,7-/m0/s1	KUZKVXUOMSVPOA-BQBZGAKWSA-N			Not Available	Small Molecule				AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.5862 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	9	7	No	0	3	215.28 Å2	31.28 Å3	87.09 m3·mol-1	10	No	No		-4		10.9	9.54			
C5H12N4O3	Not Available	Not Available	176.1738	N[C@@H](CCONC(N)=N)C(O)=O	Solid	Not Available					50370459	609827	CHEMBL443732	388342			HMDB0002706	C00308		GGB			439202	46507101				Canavanine	ZINC000003869452		Canavanine	Experimental	DB01833	InChI=1S/C5H12N4O3/c6-3(4(10)11)1-2-12-9-5(7)8/h3H,1-2,6H2,(H,10,11)(H4,7,8,9)/t3-/m0/s1	FSBIGDSBMBYOPN-VKHMYHEASA-N			Not Available	Small Molecule				AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.1576 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	5	No	0	1	134.45 Å2	17.02 Å3	61.24 m3·mol-1	5	Yes	No		-3.7		2.1	10.34	P29474	NOS3	1. Nitric oxide synthase, endothelial
C8H16FN3O2	Not Available	Not Available	205.233	[H]N([H])[C@@H](C[C@@H](F)CC\N=C(/C)N([H])[H])C(O)=O	Solid	Not Available														I58			448269	46508853							4R-Fluoro-N6-ethanimidoyl-L-lysine	Experimental	DB01835	InChI=1S/C8H16FN3O2/c1-5(10)12-3-2-6(9)4-7(11)8(13)14/h6-7H,2-4,11H2,1H3,(H2,10,12)(H,13,14)/t6-,7-/m0/s1	LTCJJIZTKXNFGK-BQBZGAKWSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3046 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	5	3	No	0	1	101.7 Å2	20.47 Å3	49.32 m3·mol-1	6	Yes	No	1.31 mg/mL	-3.2	-2.2	2.54	11.84	P35228	NOS2	1. Nitric oxide synthase, inducible
C5H9NO4	Not Available	Not Available	147.1293	CC(=O)OC[C@H](N)C(O)=O	Solid	Not Available						17981	CHEMBL1234916	89874			HMDB0003011	C00979		OAS			99478	46507422				O-Acetylserine	ZINC000000895446		O-acetyl-L-serine	Experimental	DB01837	InChI=1S/C5H9NO4/c1-3(7)10-2-4(6)5(8)9/h4H,2,6H2,1H3,(H,8,9)/t4-/m0/s1	VZXPDPZARILFQX-BYPYZUCNSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.5968 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	2	No	0	0	89.62 Å2	13.44 Å3	31.19 m3·mol-1	4	Yes	No	174.0 mg/mL	-3.4	0.07	1.86	8.6	P23219	PTGS1	1. Prostaglandin G/H synthase 1
C4H8NO7P	Not Available	Not Available	213.0826	N[C@@H](CC(=O)OP(O)(O)=O)C(O)=O	Solid	Not Available						15836		134354				C03082		PHD			152441	46506289							Phosphoaspartate	Experimental	DB01857	InChI=1S/C4H8NO7P/c5-2(4(7)8)1-3(6)12-13(9,10)11/h2H,1,5H2,(H,7,8)(H2,9,10,11)/t2-/m0/s1	IXZNKTPIYKDIGG-REOHCLBHSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.8475 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	4	No	0	-2	147.15 Å2	16.08 Å3	37.69 m3·mol-1	5	Yes	No	13.2 mg/mL	-3.4	-1.2	1.08	8.6	P71447;!P41789	pgmB;!glnG	1. Beta-phosphoglucomutase;!2. Nitrogen regulation protein NR(I)
C11H21N3O7P	Not Available	Not Available	338.2741	[H][C@](C)(N=C([O-])CCCC[C@]([H])(N=C(O)CN)C(O)=O)P(O)(O)=O	Solid	Not Available								25059144						RE1			131704183	46507667							Glycyl-L-a-Aminopimelyl-E-(D-2-Aminoethyl)Phosphonate	Experimental	DB01868	InChI=1S/C11H22N3O7P/c1-7(22(19,20)21)13-9(15)5-3-2-4-8(11(17)18)14-10(16)6-12/h7-8H,2-6,12H2,1H3,(H,13,15)(H,14,16)(H,17,18)(H2,19,20,21)/p-1/t7-,8-/m0/s1	DREJXTKPUGMERN-YUMQZZPRSA-M			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.1436 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	10	5	No	0	-2	188.86 Å2	30.82 Å3	86.93 m3·mol-1	10	Yes	No	5.52 mg/mL	-2.1	-1.8	1.58	9.36	P15555	Not Available	1. D-alanyl-D-alanine carboxypeptidase
C6H11NO4	Not Available	Not Available	161.1558	[H][C@](C)(CC(O)=O)[C@]([H])(N)C(O)=O	Solid	Not Available							CHEMBL38885	8074565						MEG			9898908	46508849					ZINC000001672628		(2S,3S)-2-azanyl-3-methyl-pentanedioic acid	Experimental	DB01898	InChI=1S/C6H11NO4/c1-3(2-4(8)9)5(7)6(10)11/h3,5H,2,7H2,1H3,(H,8,9)(H,10,11)/t3-,5-/m0/s1	FHJNAFIJPFGZRI-UCORVYFPSA-N			Not Available	Small Molecule																																			1	No	5	3	No	0	-1	100.62 Å2	14.93 Å3	35.76 m3·mol-1	4	Yes	No	38.1 mg/mL	-2.9	-0.63	2.02	9.6			
C3H7NO3S	Not Available	Not Available	137.158	N[C@@H](CSO)C(O)=O	Solid	Not Available						41710		144942						CSO			165339	46507482							S-Hydroxycysteine	Experimental	DB01915	InChI=1S/C3H7NO3S/c4-2(1-8-7)3(5)6/h2,7H,1,4H2,(H,5,6)/t2-/m0/s1	FXIRVRPOOYSARH-REOHCLBHSA-N			Not Available	Small Molecule				AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.9007 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	3	No	0	0	83.55 Å2	12.41 Å3	30 m3·mol-1	3	Yes	No	342.0 mg/mL	-3.2	0.4	1.87	8.69	P01024;!P00282;!P09211;!Q9BWD1;!P08263;!P02689;!P07097;!P00782	C3;!azu;!GSTP1;!ACAT2;!GSTA1;!PMP2;!phbA;!apr	1. Complement C3;!2. Azurin;!3. Glutathione S-transferase P;!4. Acetyl-CoA acetyltransferase, cytosolic;!5. Glutathione S-transferase A1;!6. Myelin P2 protein;!7. Acetyl-CoA acetyltransferase;!8. Subtilisin BPN'
C9H12NO6P	Not Available	Not Available	261.1684	N[C@@H](CC1=CC=C(OP(O)(O)=O)C=C1)C(O)=O	Solid	Not Available					22597	37788	CHEMBL286939	28593			HMDB0006049	C06501		PTR			30819	46507690					ZINC000001530464		Phosphonotyrosine	Experimental	DB01962	InChI=1S/C9H12NO6P/c10-8(9(11)12)5-6-1-3-7(4-2-6)16-17(13,14)15/h1-4,8H,5,10H2,(H,11,12)(H2,13,14,15)/t8-/m0/s1	DCWXELXMIBXGTH-QMMMGPOBSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.0836 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	4	No	1	-2	130.08 Å2	22.88 Å3	57.97 m3·mol-1	5	Yes	No	1.93 mg/mL	-1.5	-2.1	1.38	9.46	P08631;!P12931;!P10721	HCK;!SRC;!KIT	1. Tyrosine-protein kinase HCK;!2. Proto-oncogene tyrosine-protein kinase Src;!3. Mast/stem cell growth factor receptor Kit
C6H15BNO5	Not Available	Not Available	191.998	N[C@@H](CCCC[B-](O)(O)O)C(O)=O	Solid	Not Available						40520		392738						ABH			444965	46506382					ZINC000169748469		2(S)-Amino-6-Boronohexanoic Acid	Experimental	DB01983	InChI=1S/C6H15BNO5/c8-5(6(9)10)3-1-2-4-7(11,12)13/h5,11-13H,1-4,8H2,(H,9,10)/q-1/t5-/m0/s1	BLVGFZFOWWBCCZ-YFKPBYRVSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.7509 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	5	No	0	-1	124.01 Å2	19.64 Å3	40.88 m3·mol-1	6	Yes	No	2.83 mg/mL	-5	-1.9	1.9	9.53	P05089	ARG1	1. Arginase-1
C8H16N4O3	Not Available	Not Available	216.2376	CC(=O)N[C@@H](CCCNC(N)=N)C(O)=O	Solid	Not Available						40521		60752			HMDB0004620			AAG			67427	46508435					ZINC000001847640		N-acetyl-L-arginine	Experimental	DB01985	InChI=1S/C8H16N4O3/c1-5(13)12-6(7(14)15)3-2-4-11-8(9)10/h6H,2-4H2,1H3,(H,12,13)(H,14,15)(H4,9,10,11)/t6-/m0/s1	SNEIUMQYRCDYCH-LURJTMIESA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.8562 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	5	No	0	0	128.3 Å2	22.03 Å3	63.37 m3·mol-1	6	Yes	No	0.767 mg/mL	-3.3	-2.4	3.59	12.24	Q05581	cs1	1. Clavaminate synthase 1
C7H15N2O6P	Not Available	Not Available	254.1776	N[C@@H](CCCNC(=O)CP(O)(O)=O)C(O)=O	Solid	Not Available							CHEMBL1160567	111277						PAO			124992	46505486							N-(Phosphonoacetyl)-L-Ornithine	Experimental	DB02011	InChI=1S/C7H15N2O6P/c8-5(7(11)12)2-1-3-9-6(10)4-16(13,14)15/h5H,1-4,8H2,(H,9,10)(H,11,12)(H2,13,14,15)/t5-/m0/s1	FCIHAQFHXJOLIF-YFKPBYRVSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.9953 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	5	No	0	-1	149.95 Å2	22.61 Å3	53.64 m3·mol-1	7	Yes	No	5.85 mg/mL	-4.3	-1.6	1.48	9.28			
C14H25N3O6S	Not Available	Not Available	363.43	CC(C)[C@@H](NC(=O)[C@H](CS)NC(=O)CCC[C@H](N)C(O)=O)C(O)=O	Solid	Not Available						28496	CHEMBL70421	395032				C05556		ACV			448130	46506598		1551571			ZINC000003873037		ACV tripeptide	Experimental	DB02025	InChI=1S/C14H25N3O6S/c1-7(2)11(14(22)23)17-12(19)9(6-24)16-10(18)5-3-4-8(15)13(20)21/h7-9,11,24H,3-6,15H2,1-2H3,(H,16,18)(H,17,19)(H,20,21)(H,22,23)/t8-,9-,11+/m0/s1	BYEIJZFKOAXBBV-ATZCPNFKSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.8780 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	7	6	No	0	-1	158.82 Å2	36.7 Å3	87.21 m3·mol-1	11	No	No	0.478 mg/mL	-3	-2.9	1.94	9.15			
C8H21N7O2	Not Available	Not Available	247.298	NCCNC[C@@H](N)CCCNC(=N)N[N+]([O-])=O	Solid	Not Available					21960		CHEMBL227937	571160						DP3			656911	46504827					ZINC000001662969		N-{(4S)-4-Amino-5-[(2-aminoethyl)amino]pentyl}-N'-nitroguanidine	Experimental	DB02027	InChI=1S/C8H21N7O2/c9-3-5-12-6-7(10)2-1-4-13-8(11)14-15(16)17/h7,12H,1-6,9-10H2,(H3,11,13,14)/t7-/m0/s1	RMSWBHUVFNFNIZ-ZETCQYMHSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.4278 LD50, mol/kg	Non-inhibitor	Strong inhibitor	Non-inhibitor										1	No	8	6	No	0	2	155.12 Å2	25.97 Å3	74.42 m3·mol-1	9	No	No	0.338 mg/mL	-2.5	-2.9	10.98	9.94			
C5H9NO3S	Not Available	Not Available	163.195	[H][C@](N)(CSC(C)=O)C(O)=O	Solid	Not Available								8305638						SCY			10130120	46505017							S-Acetyl-Cysteine	Experimental	DB02039	InChI=1S/C5H9NO3S/c1-3(7)10-2-4(6)5(8)9/h4H,2,6H2,1H3,(H,8,9)/t4-/m0/s1	XCIRMLHOFVDUDP-BYPYZUCNSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.6062 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	2	No	0	0	80.39 Å2	15.46 Å3	37.69 m3·mol-1	4	Yes	No	23.2 mg/mL	-2.9	-0.85	1.89	8.29	Q92993;!P07097;!P0A6R0;!A0A0H3K1U2	KAT5;!phbA;!fabH;!mvaS	1. Histone acetyltransferase KAT5;!2. Acetyl-CoA acetyltransferase;!3. 3-oxoacyl-[acyl-carrier-protein] synthase 3;!4. 3-hydroxy-3-methylglutaryl CoA synthase
C10H12N2O3	Not Available	Not Available	208.2139	N[C@@H](CC(=O)C1=CC=CC=C1N)C(O)=O	Solid	Not Available					31880	57959	CHEMBL498416	141580			HMDB0000684	C00328		KYN			161166	46507622				Kynurenine	ZINC000000895186		Kynurenine	Experimental	DB02070	InChI=1S/C10H12N2O3/c11-7-4-2-1-3-6(7)9(13)5-8(12)10(14)15/h1-4,8H,5,11-12H2,(H,14,15)/t8-/m0/s1	YGPSJZOEDVAXAB-QMMMGPOBSA-N	1		Not Available	Small Molecule	http://smpdb.ca/view/SMP0000063?highlight[compounds][]=DB02070&highlight[proteins][]=DB02070	Tryptophan Metabolism		Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.8739 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	5	3	No	1	0	106.41 Å2	20.59 Å3	55.05 m3·mol-1	4	Yes	No	1.67 mg/mL	-1.9	-2.1	1.19	8.96			
C18H30N8O6S	Not Available	Not Available	486.546	CCNC1=NC(SC[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)NCC(O)=O)=NC(NC(C)C)=N1	Solid	Not Available								4450024						ATA			5287712	46506861					ZINC000012501645		Glutathione S-atrazine	Experimental	DB02146	InChI=1S/C18H30N8O6S/c1-4-20-16-24-17(22-9(2)3)26-18(25-16)33-8-11(14(30)21-7-13(28)29)23-12(27)6-5-10(19)15(31)32/h9-11H,4-8,19H2,1-3H3,(H,21,30)(H,23,27)(H,28,29)(H,31,32)(H2,20,22,24,25,26)/t10-,11-/m0/s1	WDLCRTLULMGVMR-QWRGUYRKSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.4883 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	12	7	No	1	-1	221.55 Å2	49.47 Å3	124.3 m3·mol-1	15	No	No	0.189 mg/mL	-6.6	-3.4	-6.9	9.31			
C7H13NO3S	Not Available	Not Available	191.248	[H][C@](N)(CSC(=O)CCC)C(O)=O	Solid	Not Available								16743928						CY4			17753929	46506003					ZINC000006777921		S-Butyryl-Cystein	Experimental	DB02160	InChI=1S/C7H13NO3S/c1-2-3-6(9)12-4-5(8)7(10)11/h5H,2-4,8H2,1H3,(H,10,11)/t5-/m0/s1	QARMATOLSBVIJD-YFKPBYRVSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.6794 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	2	No	0	0	80.39 Å2	19.33 Å3	46.92 m3·mol-1	6	Yes	No	12.1 mg/mL	-1.8	-1.2	2.13	8.28	P07097	phbA	1. Acetyl-CoA acetyltransferase
C5H10N2O3	Not Available	Not Available	146.1445	N[C@H](CCC(N)=O)C(O)=O	Solid	Not Available					181129	17061	CHEMBL1232207	128633		GtP Drug Page	HMDB0003423	C00819		DGN			145815	46508385					ZINC000001532609		D-Glutamine	Experimental	DB02174	InChI=1S/C5H10N2O3/c6-3(5(9)10)1-2-4(7)8/h3H,1-2,6H2,(H2,7,8)(H,9,10)/t3-/m1/s1	ZDXPYRJPNDTMRX-GSVOUGTGSA-N			Not Available	Small Molecule																																			1	No	4	3	No	0	0	106.41 Å2	13.59 Å3	33.11 m3·mol-1	4	Yes	No	97.8 mg/mL	-4	-0.17	2.15	9.31	P56868	murI	1. Glutamate racemase
C4H9NO2S	Not Available	Not Available	135.185	CSC[C@H](N)C(O)=O	Solid	Not Available					50213729	45658	CHEMBL394875	22826			HMDB0002108			SMC			24417	46506571				S-Methylcysteine	ZINC000003861771		S-Methylcysteine	Experimental	DB02216	InChI=1S/C4H9NO2S/c1-8-2-3(5)4(6)7/h3H,2,5H2,1H3,(H,6,7)/t3-/m0/s1	IDIDJDIHTAOVLG-VKHMYHEASA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.2908 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	3	2	No	0	0	63.32 Å2	13.56 Å3	32.87 m3·mol-1	3	Yes	No	65.8 mg/mL	-2.4	-0.31	2.44	9.15	P07339;!P16455	CTSD;!MGMT	1. Cathepsin D;!2. Methylated-DNA--protein-cysteine methyltransferase
C6H13NO3	Not Available	Not Available	147.1723	[H][C@@](N)(CCCCO)C(O)=O	Solid	Not Available								4450282						DDO			5288041	46506578					ZINC000002035148		6-hydroxy-D-norleucine	Experimental	DB02233	InChI=1S/C6H13NO3/c7-5(6(9)10)3-1-2-4-8/h5,8H,1-4,7H2,(H,9,10)/t5-/m1/s1	OLUWXTFAPJJWPL-RXMQYKEDSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.1183 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	3	No	0	0	83.55 Å2	15.46 Å3	36.15 m3·mol-1	5	Yes	No	101.0 mg/mL	-2.9	-0.16	2.46	9.53	P06608	ansB	1. L-asparaginase
C5H11NO3S	Not Available	Not Available	165.211	C[S@@](=O)CC[C@H](N)C(O)=O	Solid	Not Available						58773		8238279				C15998		SME			10062737	46504569					ZINC000001529567		L-methionine (R)-S-oxide	Experimental	DB02235	InChI=1S/C5H11NO3S/c1-10(9)3-2-4(6)5(7)8/h4H,2-3,6H2,1H3,(H,7,8)/t4-,10+/m0/s1	QEFRNWWLZKMPFJ-ZXPFJRLXSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.7066 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	2	No	0	0	80.39 Å2	16.08 Å3	39.34 m3·mol-1	4	Yes	No	54.0 mg/mL	-4.6	-0.49	1.74	9.11	P29422;!Q93UV9;!P05067	katA;!PROF;!APP	1. Catalase;!2. Protease;!3. Amyloid beta A4 protein
C10H18N4O6	Not Available	Not Available	290.2731	N[C@@H](CCC\N=C(/N)N[C@H](CC(O)=O)C(O)=O)C(O)=O	Solid	Not Available								395433						AS1			448718	46504554				Argininosuccinic_acid			Argininosuccinate	Experimental	DB02267	InChI=1S/C10H18N4O6/c11-5(8(17)18)2-1-3-13-10(12)14-6(9(19)20)4-7(15)16/h5-6H,1-4,11H2,(H,15,16)(H,17,18)(H,19,20)(H3,12,13,14)/t5-,6+/m0/s1	KDZOASGQNOPSCU-NTSWFWBYSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.6366 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	10	6	No	0	-1	188.33 Å2	27.55 Å3	65.02 m3·mol-1	9	No	No	1.37 mg/mL	-5.9	-2.3	2.14	11.92	P04424;!P59846	ASL;!argG	1. Argininosuccinate lyase;!2. Argininosuccinate synthase
C9H17NO3	Not Available	Not Available	187.2362	[H][C@@](C)(N)C(=O)CCCCCC(O)=O	Solid	Not Available						149468		395028						KAP			448124	46507728					ZINC000001532843		7-Keto-8-Aminopelargonic Acid	Experimental	DB02274	InChI=1S/C9H17NO3/c1-7(10)8(11)5-3-2-4-6-9(12)13/h7H,2-6,10H2,1H3,(H,12,13)/t7-/m0/s1	GUAHPAJOXVYFON-ZETCQYMHSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.6111 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	2	No	0	0	80.39 Å2	20.48 Å3	48.74 m3·mol-1	7	Yes	No	3.84 mg/mL	-1.3	-1.7	4.45	8.08	P12995	bioA	1. Adenosylmethionine-8-amino-7-oxononanoate aminotransferase
C6H16N5O	Not Available	Not Available	174.2241	N[C@@H](CCCNC(N)=[NH2+])C(N)=O	Solid	Not Available						40477		392789						AAR			445032	46505098							Arginineamide	Experimental	DB02299	InChI=1S/C6H15N5O/c7-4(5(8)12)2-1-3-11-6(9)10/h4H,1-3,7H2,(H2,8,12)(H4,9,10,11)/p+1/t4-/m0/s1	ULEBESPCVWBNIF-BYPYZUCNSA-O			Not Available	Small Molecule				AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.2751 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	5	No	0	2	132.75 Å2	18.75 Å3	56.55 m3·mol-1	5	Yes	No	24.1 mg/mL	-2.3	-0.94	16.31	12.4	P22459	KCNA4	1. Potassium voltage-gated channel subfamily A member 4
C8H18N4O2	Not Available	Not Available	202.2541	CN\C(NCCC[C@H](N)C(O)=O)=N\C	Solid	Not Available						61914		147942			HMDB0003334			2MR			169148	46506150					ZINC000005965908		Symmetric dimethylarginine	Experimental	DB02302	InChI=1S/C8H18N4O2/c1-10-8(11-2)12-5-3-4-6(9)7(13)14/h6H,3-5,9H2,1-2H3,(H,13,14)(H2,10,11,12)/t6-/m0/s1	HVPFXCBJHIIJGS-LURJTMIESA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.7566 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	4	No	0	1	99.74 Å2	21.78 Å3	53.18 m3·mol-1	5	Yes	No	1.56 mg/mL	-2.7	-2.1	2.54	12.4	P51698	linB	1. Haloalkane dehalogenase
C9H17NO6S	Not Available	Not Available	267.299	N[C@@H](CCSC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O)C(O)=O	Solid	Not Available						90364		389052				C03539		RHC			440041	46506348					ZINC000004096144		5-(3-Amino-4,4-Dihyroxy-Butylsulfanylmethyl)-Tetrahydro-Furan-2,3,4-Triol	Experimental	DB02321	InChI=1S/C9H17NO6S/c10-4(8(13)14)1-2-17-3-5-6(11)7(12)9(15)16-5/h4-7,9,11-12,15H,1-3,10H2,(H,13,14)/t4-,5+,6+,7+,9+/m0/s1	IQFWYNFDWRYSRA-OEQWSMLSSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.8207 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	5	No	1	0	133.24 Å2	26.33 Å3	59.49 m3·mol-1	6	Yes	No	41.0 mg/mL	-4.2	-0.81	1.8	9.5	O34667	luxS	1. S-ribosylhomocysteine lyase
C9H17NO4S	Not Available	Not Available	235.301	N[C@@H](CCSCCCCC(O)=O)C(O)=O	Solid	Not Available								394210						CBH			446994	46505551					ZINC000002047772		S-(D-Carboxybutyl)-L-Homocysteine	Experimental	DB02337	InChI=1S/C9H17NO4S/c10-7(9(13)14)4-6-15-5-2-1-3-8(11)12/h7H,1-6,10H2,(H,11,12)(H,13,14)/t7-/m0/s1	BMONDXDFXRPNKQ-ZETCQYMHSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.4813 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	5	3	No	0	-1	100.62 Å2	25.23 Å3	57.78 m3·mol-1	9	Yes	No	1.98 mg/mL	-1.9	-2.1	2.55	9.5			
C5H9NO4	Not Available	Not Available	147.1293	CC(=O)N[C@@H](CO)C(O)=O	Solid	Not Available						45441		58744			HMDB0002931			SAC			65249	46504512					ZINC000000158173		N-Acetyl-Serine	Experimental	DB02340	InChI=1S/C5H9NO4/c1-3(8)6-4(2-7)5(9)10/h4,7H,2H2,1H3,(H,6,8)(H,9,10)/t4-/m0/s1	JJIHLJJYMXLCOY-BYPYZUCNSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.5161 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	3	No	0	-1	86.63 Å2	13.43 Å3	31.48 m3·mol-1	3	Yes	No	84.6 mg/mL	-1.8	-0.24	3.61	-2	P00488	F13A1	1. Coagulation factor XIII A chain
C3H7NO2Se	Not Available	Not Available	168.05	N[C@@H](C[SeH])C(O)=O	Solid	Not Available						16633	CHEMBL109962	23436			HMDB0003288	C05688		SEC			6326983	46508133		1549332		Selenocysteine			Selenocysteine	Experimental	DB02345	InChI=1S/C3H7NO2Se/c4-2(1-7)3(5)6/h2,7H,1,4H2,(H,5,6)/t2-/m0/s1	ZKZBPNGNEQAJSX-REOHCLBHSA-N			Not Available	Small Molecule	http://smpdb.ca/view/SMP0000029?highlight[compounds][]=DB02345&highlight[proteins][]=DB02345	Selenoamino Acid Metabolism		AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.5769 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							143-146 °C		3.92E+005 mg/L (at 0 °C)	1	No	4	3	No	0	0	63.32 Å2	10.67 Å3	33.45 m3·mol-1	2	Yes	No	325.0 mg/mL	-4.1	0.29	1.27	8.4	P49913;!P15531;!P07658;!P77444	CAMP;!NME1;!fdhF;!sufS	1. Cathelicidin antimicrobial peptide;!2. Nucleoside diphosphate kinase A;!3. Formate dehydrogenase H;!4. Cysteine desulfurase
C4H9NO2S2	Not Available	Not Available	167.25	[H][C@](N)(CSSC)C(O)=O	Solid	Not Available								2338507						SCH			3080775	46507768							S-Methyl Thiocysteine Group	Experimental	DB02361	InChI=1S/C4H9NO2S2/c1-8-9-2-3(5)4(6)7/h3H,2,5H2,1H3,(H,6,7)/t3-/m0/s1	PYFNLWPQPNXHCS-VKHMYHEASA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.8720 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	3	2	No	0	0	63.32 Å2	16.09 Å3	41.01 m3·mol-1	4	Yes	No	19.3 mg/mL	-2.3	-0.94	2.15	9.04	P37700	celCCG	1. Endoglucanase G
C7H16NO6P	Not Available	Not Available	241.1788	[H][C@](N)(COP(=O)(OCC)OCC)C(O)=O	Solid	Not Available								16744195						SDP			17754161	46508316					ZINC000006595392		2-Amino-3-(Diethoxy-Phosphoryloxy)-Propionic Acid	Experimental	DB02364	InChI=1S/C7H16NO6P/c1-3-12-15(11,13-4-2)14-5-6(8)7(9)10/h6H,3-5,8H2,1-2H3,(H,9,10)/t6-/m0/s1	MOFCKRBDMJNCOC-LURJTMIESA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.4076 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	2	No	0	0	108.08 Å2	21.98 Å3	51.38 m3·mol-1	8	Yes	No	35.0 mg/mL	-2.5	-0.84	2.19	9.34	P0ADA1	tesA	1. Acyl-CoA thioesterase I
C8H15N3O4	Not Available	Not Available	217.2224	CC(=O)N[C@@H](CCCNC(N)=O)C(O)=O	Solid	Not Available						49002		571213				C15532		OLN			656979	46506512					ZINC000012494450		N-Acetyl-L-Citrulline	Experimental	DB02368	InChI=1S/C8H15N3O4/c1-5(12)11-6(7(13)14)3-2-4-10-8(9)15/h6H,2-4H2,1H3,(H,11,12)(H,13,14)(H3,9,10,15)/t6-/m0/s1	WMQMIOYQXNRROC-LURJTMIESA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.6137 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	4	No	0	-1	121.52 Å2	21.49 Å3	50.77 m3·mol-1	6	Yes	No	3.57 mg/mL	-1.9	-1.8	3.87	-1.5	Q8P8J2	argF'	1. N-acetylornithine carbamoyltransferase
C9H18N2O4	Not Available	Not Available	218.2502	C[C@@H](NCCCC[C@H](N)C(O)=O)C(O)=O	Solid	Not Available								16744100						RF9			17754073	46507581					ZINC000012501967		Nz-(1-Carboxyethyl)-Lysine	Experimental	DB02370	InChI=1S/C9H18N2O4/c1-6(8(12)13)11-5-3-2-4-7(10)9(14)15/h6-7,11H,2-5,10H2,1H3,(H,12,13)(H,14,15)/t6-,7+/m1/s1	XCYPSOHOIAZISD-RQJHMYQMSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.3371 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	4	No	0	0	112.65 Å2	23 Å3	53.16 m3·mol-1	8	Yes	No	14.3 mg/mL	-5	-1.2	1.66	10.68	Q9X1K9	dapA	1. 4-hydroxy-tetrahydrodipicolinate synthase
C5H12N4O3	Not Available	Not Available	176.1738	N[C@@H](CCNC(=N)NO)C(O)=O	Solid	Not Available					50008099		CHEMBL1234777	393563						NNH			446124	46505343					ZINC000002244322		nor-NOHA	Investigational	DB02381	InChI=1S/C5H12N4O3/c6-3(4(10)11)1-2-8-5(7)9-12/h3,12H,1-2,6H2,(H,10,11)(H3,7,8,9)/t3-/m0/s1	KOBHCUDVWOTEKO-VKHMYHEASA-N	1		Not Available	Small Molecule				AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.1334 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	6	No	0	1	131.46 Å2	16.73 Å3	61.54 m3·mol-1	4	No	No	2.24 mg/mL	-3.7	-1.9	2.08	10.56	P05089	ARG1	1. Arginase-1
C5H11NO3S	Not Available	Not Available	165.211	N[C@@H](CSCCO)C(O)=O	Solid	Not Available								106509						OCY			119224	46508617					ZINC000002525397		Hydroxyethylcysteine	Experimental	DB02413	InChI=1S/C5H11NO3S/c6-4(5(8)9)3-10-2-1-7/h4,7H,1-3,6H2,(H,8,9)/t4-/m0/s1	MWFRVMDVLYIXJF-BYPYZUCNSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.4680 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	3	No	0	0	83.55 Å2	16.72 Å3	39.37 m3·mol-1	5	Yes	No	38.3 mg/mL	-3.4	-0.63	2.26	9.14	Q04095	gag-pro-pol	1. Gag-Pro-Pol polyprotein
C7H16N2O3	Not Available	Not Available	176.2135	N[C@H](CO)CCCCNC(O)=O	Solid	Not Available								16744081									17754062	46504643					ZINC000034940874		(5r)-5-Amino-6-Hydroxyhexylcarbamic Acid	Experimental	DB02437	InChI=1S/C7H16N2O3/c8-6(5-10)3-1-2-4-9-7(11)12/h6,9-10H,1-5,8H2,(H,11,12)/t6-/m0/s1	XHKWPAAHPLALGC-LURJTMIESA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.5932 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	4	No	0	0	95.58 Å2	19.06 Å3	44.24 m3·mol-1	6	Yes	No	26.3 mg/mL	-3	-0.83	4.13	9.83	P0A433;!P08192;!P39377	opd;!folC;!iadA	1. Parathion hydrolase;!2. Bifunctional protein FolC;!3. Isoaspartyl dipeptidase
C3H7NO4Se	Not Available	Not Available	200.05	[H][C@](N)(C[SeH](=O)=O)C(O)=O	Solid	Not Available								25057802						SOC			17754171	46506335							Dioxyselenocysteine	Experimental	DB02442	InChI=1S/C3H7NO4Se/c4-2(3(5)6)1-9(7)8/h2,9H,1,4H2,(H,5,6)/t2-/m0/s1	LQMXQNUAKTVFAG-REOHCLBHSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.6160 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	3	No	0	-1	97.46 Å2	12.78 Å3	36.03 m3·mol-1	3	Yes	No	215.0 mg/mL	-4.8	0.03	1.15	8.05	P00782	apr	1. Subtilisin BPN'
C5H10N2O4	Not Available	Not Available	162.1439	N[C@@H](CCC(=O)NO)C(O)=O	Solid	Not Available					50129196	75305	CHEMBL63893	395780						HGA			449178	46506511					ZINC000002522574		Glutamine hydroxamate	Experimental	DB02446	InChI=1S/C5H10N2O4/c6-3(5(9)10)1-2-4(8)7-11/h3,11H,1-2,6H2,(H,7,8)(H,9,10)/t3-/m0/s1	YVGZXTQJQNXIAU-VKHMYHEASA-N			Not Available	Small Molecule				AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.8275 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	5	4	No	0	0	112.65 Å2	14.79 Å3	34.87 m3·mol-1	4	Yes	No	55.0 mg/mL	-4	-0.47	1.93	9.46	P17169	glmS	1. Glutamine--fructose-6-phosphate aminotransferase [isomerizing]
C16H19N5O10S	Not Available	Not Available	473.415	[H][C@](N)(CCC(=O)N[C@@]([H])(CSC1=C(C=C(C=C1)N(=O)=O)N(=O)=O)C(=O)NCC(O)=O)C(O)=O	Solid	Not Available					50391004	8927	CHEMBL1232997	88032			HMDB0062528	C11175		GDN			97535	46504887					ZINC000003870210		S-(2,4-dinitrophenyl)glutathione	Experimental	DB02458	InChI=1S/C16H19N5O10S/c17-9(16(26)27)2-4-13(22)19-10(15(25)18-6-14(23)24)7-32-12-3-1-8(20(28)29)5-11(12)21(30)31/h1,3,5,9-10H,2,4,6-7,17H2,(H,18,25)(H,19,22)(H,23,24)(H,26,27)/t9-,10-/m0/s1	FXEUKVKGTKDDIQ-UWVGGRQHSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.5332 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	11	5	No	1	-1	250.46 Å2	42.88 Å3	108.34 m3·mol-1	13	No	No	0.0319 mg/mL	-3.3	-4.2	1.59	9.31	P09488;!P28161	GSTM1;!GSTM2	1. Glutathione S-transferase Mu 1;!2. Glutathione S-transferase Mu 2
C4H10NO5PS	Not Available	Not Available	215.165	N[C@@H](CSCP(O)(O)=O)C(O)=O	Solid	Not Available							CHEMBL175970	167125						CYQ			192579	46508988							S-Methyl Phosphocysteine	Experimental	DB02461	InChI=1S/C4H10NO5PS/c5-3(4(6)7)1-12-2-11(8,9)10/h3H,1-2,5H2,(H,6,7)(H2,8,9,10)/t3-/m0/s1	IIALWEPLPCANHU-VKHMYHEASA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.8587 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	4	No	0	-1	120.85 Å2	18.23 Å3	43.35 m3·mol-1	5	Yes	No	27.6 mg/mL	-3.2	-0.89	1.49	9.2	P0AE67	cheY	1. Chemotaxis protein CheY
C5H11NO3S	Not Available	Not Available	165.211	[H]C([H])([H])[S@](=O)C([H])([H])C([H])([H])[C@@]([H])(C([O-])=O)[N+]([H])([H])[H]	Solid	Not Available						49031		9085165				C15999		MHO			10909908	46508428					ZINC000003861729		L-methionine (S)-S-oxide	Experimental	DB02467	InChI=1S/C5H11NO3S/c1-10(9)3-2-4(6)5(7)8/h4H,2-3,6H2,1H3,(H,7,8)/t4-,10-/m0/s1	QEFRNWWLZKMPFJ-MFXDVPHUSA-N			Not Available	Small Molecule																																			1	No	3	1	No	0	0	84.84 Å2	16.12 Å3	61.47 m3·mol-1	4	Yes	No	54.0 mg/mL	-4.6	-0.49	1.74	9.11	P0A884;!Q79G13;!P20339;!Q54331;!P22364;!P80561	thyA;!celA1;!RAB5A;!celB;!mauC;!Not Available	1. Thymidylate synthase;!2. Possible cellulase CelA1 (Endoglucanase) (Endo-1,4-beta-glucanase) (FI-cmcase) (Carboxymethyl cellulase);!3. Ras-related protein Rab-5A;!4. Cellulase B;!5. Amicyanin;!6. Aminopeptidase S
C9H16N4O3	Not Available	Not Available	228.2483	NC(=N)NCCC[C@H](N1CCC1=O)C(O)=O	Solid	Not Available						15426		389919				C06656		PCX			441123	46508834					ZINC000001530512		Deoxyamidinoproclavaminic acid	Experimental	DB02475	InChI=1S/C9H16N4O3/c10-9(11)12-4-1-2-6(8(15)16)13-5-3-7(13)14/h6H,1-5H2,(H,15,16)(H4,10,11,12)/t6-/m0/s1	UYADDEKIZFRINK-LURJTMIESA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1298 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	4	No	1	0	119.51 Å2	23.31 Å3	66.4 m3·mol-1	6	Yes	No	1.38 mg/mL	-3.2	-2.2	3.51	12.23	Q05581	cs1	1. Clavaminate synthase 1
C6H14NO8P	Not Available	Not Available	259.151	[H][C@@](O)(CO)COP(O)(=O)OC[C@]([H])(N)C(O)=O	Solid	Not Available						64945		392176						GSE			444182	46505969							L-Alpha-Glycerophosphorylserine	Experimental	DB02497	InChI=1S/C6H14NO8P/c7-5(6(10)11)3-15-16(12,13)14-2-4(9)1-8/h4-5,8-9H,1-3,7H2,(H,10,11)(H,12,13)/t4-,5+/m1/s1	ZWZWYGMENQVNFU-UHNVWZDZSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.9841 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	5	No	0	-1	159.54 Å2	21.42 Å3	49.65 m3·mol-1	8	Yes	No	19.6 mg/mL	-4.3	-1.1	1.51	9.38	P08758	ANXA5	1. Annexin A5
C4H10N4O3	Not Available	Not Available	162.1472	N[C@@H](C\N=C(/N)NO)C(O)=O	Solid	Not Available								571292						DIR			657087	46506971							Dinor-N(Omega)-Hydroxy-L-Arginine	Experimental	DB02499	InChI=1S/C4H10N4O3/c5-2(3(9)10)1-7-4(6)8-11/h2,11H,1,5H2,(H,9,10)(H3,6,7,8)/t2-/m0/s1	RPHCSGPGZUWMRV-REOHCLBHSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.1849 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	5	No	0	0	133.96 Å2	14.94 Å3	46.38 m3·mol-1	3	Yes	No	11.7 mg/mL	-3.7	-1.1	1.82	10.05	P05089	ARG1	1. Arginase-1
C10H18N4O5	Not Available	Not Available	274.2737	NC(=N)NCCC[C@H](NC(=O)CCC(O)=O)C(O)=O	Solid	Not Available						17705		388993				C03296		SUG			439968	46507643					ZINC000001529628		N(2)-succinyl-L-arginine	Experimental	DB02501	InChI=1S/C10H18N4O5/c11-10(12)13-5-1-2-6(9(18)19)14-7(15)3-4-8(16)17/h6H,1-5H2,(H,14,15)(H,16,17)(H,18,19)(H4,11,12,13)/t6-/m0/s1	UMOXFSXIFQOWTD-LURJTMIESA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.8561 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	9	6	No	0	-1	169.09 Å2	26.29 Å3	74.78 m3·mol-1	9	No	No	0.41 mg/mL	-3	-2.8	3.23	12.16	P76216	astB	1. N-succinylarginine dihydrolase
C5H9NO4	Not Available	Not Available	147.1293	N[C@H](CCC(O)=O)C(O)=O	Solid	Not Available					26431	15966	CHEMBL76232	21814		GtP Drug Page	HMDB0003339	C00217		DGL			23327	46508281		1428878			ZINC000000895124		D-Glutamic Acid	Experimental	DB02517	InChI=1S/C5H9NO4/c6-3(5(9)10)1-2-4(7)8/h3H,1-2,6H2,(H,7,8)(H,9,10)/t3-/m1/s1	WHUUTDBJXJRKMK-GSVOUGTGSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	0.7222 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							201 °C		8880 mg/L (at 25 °C)	1	No	5	3	No	0	-1	100.62 Å2	13.19 Å3	31.29 m3·mol-1	4	Yes	No	80.6 mg/mL	-3.2	-0.26	1.88	9.54	P43133	nprS	1. Thermolysin
C6H12FNO2	Not Available	Not Available	149.1634	C[C@H](CF)C[C@H](N)C(O)=O	Solid	Not Available								16744083						LEF			15227560	46506320							(4s)-5-Fluoro-L-Leucine	Experimental	DB02542	InChI=1S/C6H12FNO2/c1-4(3-7)2-5(8)6(9)10/h4-5H,2-3,8H2,1H3,(H,9,10)/t4-,5-/m0/s1	FHOARJRQRXAPOF-WHFBIAKZSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.0938 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	3	2	No	0	0	63.32 Å2	14.42 Å3	34.33 m3·mol-1	4	Yes	No	62.0 mg/mL	-2.1	-0.38	2.52	9.52	P0CG47	UBB	1. Polyubiquitin-B
C9H11NO2	Not Available	Not Available	165.1891	N[C@H](CC1=CC=CC=C1)C(O)=O	Solid	Not Available						57981	CHEMBL379630	64639				C02265		DPN			71567	46505758				Phenylalanine	ZINC000000001927		D-Phenylalanine	Experimental	DB02556	InChI=1S/C9H11NO2/c10-8(9(11)12)6-7-4-2-1-3-5-7/h1-5,8H,6,10H2,(H,11,12)/t8-/m1/s1	COLNVLDHVKWLRT-MRVPVSSYSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.9053 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor									2.82E+004 mg/L (at 16 °C)	1	No	3	2	No	1	0	63.32 Å2	17.13 Å3	45.12 m3·mol-1	3	Yes	No	4.14 mg/mL	-1.2	-1.6	2.47	9.45	Q16773;!P06850	CCBL1;!CRH	1. Kynurenine--oxoglutarate transaminase 1;!2. Corticoliberin
C6H11NO3	Not Available	Not Available	145.1564	[H]C(=O)CCC[C@H](N)C(O)=O	Solid	Not Available						58321		141126			HMDB0059595	C04076		DO2			160603	46505195				Allysine	ZINC000001529204		Allysine	Experimental	DB02571	InChI=1S/C6H11NO3/c7-5(6(9)10)3-1-2-4-8/h4-5H,1-3,7H2,(H,9,10)/t5-/m0/s1	GFXYTQPNNXGICT-YFKPBYRVSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	0.7661 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	2	No	0	0	80.39 Å2	14.58 Å3	34.96 m3·mol-1	5	Yes	No	49.4 mg/mL	-2.9	-0.47	2.25	9.49	Q88K39	ansB	1. Glutaminase-asparaginase
C15H26N4O7	Not Available	Not Available	374.3895	[H]N([H])CC(=O)N([H])[C@@H](CCCCC(=O)N([H])[C@H](C)C(=O)N([H])[C@H](C)C(O)=O)C(O)=O	Solid	Not Available								393699						REX			446306	46508348					ZINC000015599994		N-[(6S)-6-Carboxy-6-(glycylamino)hexanoyl]-D-alanyl-D-alanine	Experimental	DB02578	InChI=1S/C15H26N4O7/c1-8(13(22)18-9(2)14(23)24)17-11(20)6-4-3-5-10(15(25)26)19-12(21)7-16/h8-10H,3-7,16H2,1-2H3,(H,17,20)(H,18,22)(H,19,21)(H,23,24)(H,25,26)/t8-,9-,10+/m1/s1	RALBRZJHHGWNNU-BBBLOLIVSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	1.8059 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	8	6	No	0	-1	187.92 Å2	37.69 Å3	87.89 m3·mol-1	12	No	No	1.07 mg/mL	-4.9	-2.5	3.2	8.14	P15555	Not Available	1. D-alanyl-D-alanine carboxypeptidase
C14H23N3O6S	Not Available	Not Available	361.414	[H][C@@](N=C(O)C(CS)N=C(O)CCCC(N)C(O)=O)(C(C)=C)C(O)=O	Solid	Not Available								64873359						CDH			131704210	46506795							(6Z)-6-{[(1Z)-1-{[(1R)-1-Carboxy-2-methyl-2-propen-1-yl]imino}-1-hydroxy-3-sulfanyl-2-propanyl]imino}-6-hydroxynorleucine	Experimental	DB02582	InChI=1S/C14H23N3O6S/c1-7(2)11(14(22)23)17-12(19)9(6-24)16-10(18)5-3-4-8(15)13(20)21/h8-9,11,24H,1,3-6,15H2,2H3,(H,16,18)(H,17,19)(H,20,21)(H,22,23)/t8?,9?,11-/m1/s1	BGZJEMYSINIAHS-NWGYLPEXSA-N			Not Available	Small Molecule				AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.1072 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	9	6	No	0	-1	165.8 Å2	36.4 Å3	87.95 m3·mol-1	11	No	No	0.075 mg/mL	-1.7	-3.7	2.06	9.42			
C4H10NO7P	Not Available	Not Available	215.0985	N[C@@H]([C@H](O)COP(O)(O)=O)C(O)=O	Solid	Not Available						18336		389731			HMDB0006802	C06055		4TP			440901	46505076							4-Hydroxy-L-Threonine-5-Monophosphate	Experimental	DB02609	InChI=1S/C4H10NO7P/c5-3(4(7)8)2(6)1-12-13(9,10)11/h2-3,6H,1,5H2,(H,7,8)(H2,9,10,11)/t2-,3+/m1/s1	FKHAKIJOKDGEII-GBXIJSLDSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.9003 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	5	No	0	-2	150.31 Å2	16.6 Å3	38.88 m3·mol-1	5	Yes	No	22.7 mg/mL	-3.9	-0.98	1.31	8.93	P19624	pdxA	1. 4-hydroxythreonine-4-phosphate dehydrogenase
C9H21N4O2	Not Available	Not Available	217.2886	[H]N([H])[C@@H](CCCN([H])C(\N([H])[H])=[N+](/[H])CCC)C(O)=O	Solid	Not Available								4449861						3AR			5287494	46507586							N-omega-propyl-L-arginine	Experimental	DB02644	InChI=1S/C9H20N4O2/c1-2-5-12-9(11)13-6-3-4-7(10)8(14)15/h7H,2-6,10H2,1H3,(H,14,15)(H3,11,12,13)/p+1/t7-/m0/s1	AOMXURITGZJPKB-ZETCQYMHSA-O			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Inhibitor	Inhibitor	Non-substrate	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.9779 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	5	5	No	0	1	115.34 Å2	24.44 Å3	68.89 m3·mol-1	7	Yes	No	6.25 mg/mL	-2.1	-1.6	2.29	12.26	P35228;!P29475	NOS2;!NOS1	1. Nitric oxide synthase, inducible;!2. Nitric oxide synthase, brain
C4H7NO4	Not Available	Not Available	133.1027	N[C@H](CC(O)=O)C(O)=O	Solid	Not Available					31174	17364	CHEMBL29757	75697			HMDB0006483	C00402		DAS			83887	46504502					ZINC000000895218		D-Aspartic Acid	Experimental	DB02655	InChI=1S/C4H7NO4/c5-2(4(8)9)1-3(6)7/h2H,1,5H2,(H,6,7)(H,8,9)/t2-/m1/s1	CKLJMWTZIZZHCS-UWTATZPHSA-N			Not Available	Small Molecule	http://smpdb.ca/view/SMP0000067?highlight[compounds][]=DB02655&highlight[proteins][]=DB02655;!http://smpdb.ca/view/SMP0000175?highlight[compounds][]=DB02655&highlight[proteins][]=DB02655;!http://smpdb.ca/view/SMP0000192?highlight[compounds][]=DB02655&highlight[proteins][]=DB02655	Aspartate Metabolism;!Canavan Disease;!Hypoacetylaspartia		Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.1037 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	5	3	No	0	-1	100.62 Å2	11.35 Å3	26.53 m3·mol-1	3	Yes	No	142.0 mg/mL	-3.5	0.03	1.7	9.61	P43133;!P06608	nprS;!ansB	1. Thermolysin;!2. L-asparaginase
C5H12NO4P	Not Available	Not Available	181.1268	C[P@@](O)(=O)CC[C@@H](N)C(O)=O	Solid	Not Available					50220010	142854		5342158				C05042		PPQ			6971307	46506119					ZINC000000902215		2-Amino-4-(Hydroxymethyl-Phosphinyl)Butanoic Acid	Experimental	DB02663	InChI=1S/C5H12NO4P/c1-11(9,10)3-2-4(6)5(7)8/h4H,2-3,6H2,1H3,(H,7,8)(H,9,10)/t4-/m1/s1	IAJOBQBIJHVGMQ-SCSAIBSYSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	1.5749 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							230 dec °C			1	No	5	3	No	0	-1	100.62 Å2	16.03 Å3	39.66 m3·mol-1	4	Yes	No	46.3 mg/mL	-3.5	-0.59	1.86	9.53	P0A1P6	glnA	1. Glutamine synthetase
C10H13NO2	Not Available	Not Available	179.2157	CC1=CC=CC(C[C@H](N)C(O)=O)=C1	Solid	Not Available							CHEMBL1231013	2042224						APD			2761494	46505706					ZINC000001652106		3-Methylphenylalanine	Experimental	DB02685	InChI=1S/C10H13NO2/c1-7-3-2-4-8(5-7)6-9(11)10(12)13/h2-5,9H,6,11H2,1H3,(H,12,13)/t9-/m0/s1	JZRBSTONIYRNRI-VIFPVBQESA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.8692 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	3	2	No	1	0	63.32 Å2	19.34 Å3	50.16 m3·mol-1	3	Yes	No	1.99 mg/mL	-0.67	-2	2.58	9.45	P07858	CTSB	1. Cathepsin B
C5H12N2O4S2	Not Available	Not Available	228.29	[H][C@](N)(CSCCS(N)(=O)=O)C(O)=O	Solid	Not Available								395112						SDC			448254	46507249					ZINC000005828870		S-{2-[Amino(Dihydroxy)-Lambda~4~-Sulfanyl]Ethyl}-D-Cysteine	Experimental	DB02689	InChI=1S/C5H12N2O4S2/c6-4(5(8)9)3-12-1-2-13(7,10)11/h4H,1-3,6H2,(H,8,9)(H2,7,10,11)/t4-/m0/s1	ZRCBQBJBRHIRRG-BYPYZUCNSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.1874 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	5	3	No	0	0	123.48 Å2	21.54 Å3	49.3 m3·mol-1	6	Yes	No	28.7 mg/mL	-4.2	-0.9	1.64	9.14	P05089	ARG1	1. Arginase-1
C10H16N2O2	Not Available	Not Available	196.2462	[H][C@](N)(CC[C@@]1([H])C=CC([H])(N)C=C1)C(O)=O	Solid	Not Available								26329193						ACZ			99594	46505792							2-Amino-4-(4-Amino-Cyclohexa-2,5-Dienyl)-Butyric Acid	Experimental	DB02725	InChI=1S/C10H16N2O2/c11-8-4-1-7(2-5-8)3-6-9(12)10(13)14/h1-2,4-5,7-9H,3,6,11-12H2,(H,13,14)/t7-,8?,9-/m0/s1	LAJWZJCOWPUSOA-SMOXQLQSSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.7801 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	3	No	1	1	89.34 Å2	20.59 Å3	56.02 m3·mol-1	4	Yes	No	4.0 mg/mL	-2.6	-1.7	2.63	9.74	P12995	bioA	1. Adenosylmethionine-8-amino-7-oxononanoate aminotransferase
C25H35N6O4	Not Available	Not Available	483.5832	[H]N([H])C(N([H])[H])=[N+]([H])CCC[C@H](N([H])C(=O)[C@H](CCC1=CC=CC=C1)N([H])[C@H](C)C(O)=O)C(=O)N([H])C1=CC=CC=C1	Solid	Not Available								4450760						8MI			5288637	46507423							Diamino-N-[(4S)-5-anilino-4-{[(2S)-2-{[(1R)-1-carboxyethyl]amino}-4-phenylbutanoyl]amino}-5-oxopentyl]methaniminium	Experimental	DB02747	InChI=1S/C25H34N6O4/c1-17(24(34)35)29-21(15-14-18-9-4-2-5-10-18)23(33)31-20(13-8-16-28-25(26)27)22(32)30-19-11-6-3-7-12-19/h2-7,9-12,17,20-21,29H,8,13-16H2,1H3,(H,30,32)(H,31,33)(H,34,35)(H4,26,27,28)/p+1/t17-,20+,21+/m1/s1	HDGWGGCPTVXRNA-QMMLZNLJSA-O			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.3141 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	7	7	No	2	1	173.54 Å2	51.92 Å3	144.99 m3·mol-1	14	No	No	0.00483 mg/mL	0.27	-5	7.46	10.87			
C4H9HgNO2S	Not Available	Not Available	335.77	C[Hg]SC[C@@H](N)C(O)=O	Solid	Not Available								26329810						CMH			46936479	46505119							S-(Methylmercury)-L-Cysteine	Experimental	DB02750	InChI=1S/C3H7NO2S.CH3.Hg/c4-2(1-7)3(5)6;;/h2,7H,1,4H2,(H,5,6);1H3;/q;;+1/p-1/t2-;;/m1../s1	OMYFBIZVJYGJJA-YBBRRFGFSA-M			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.8783 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	3	2	No	0	0	63.32 Å2	15.59 Å3	33.22 m3·mol-1	4	Yes	No	20.2 mg/mL	-3.4	-1.2	1.76	9.21	Q7Z2Z2	EFTUD1	1. Elongation factor Tu GTP-binding domain-containing protein 1
C3H7NO2S2	Not Available	Not Available	153.223	N[C@@H](CSS)C(O)=O	Solid	Not Available						58591		144934				C01962		CSS			165331	46505635							S-Mercaptocysteine	Experimental	DB02761	InChI=1S/C3H7NO2S2/c4-2(1-8-7)3(5)6/h2,7H,1,4H2,(H,5,6)/t2-/m0/s1	XBKONSCREBSMCS-REOHCLBHSA-N			Not Available	Small Molecule				AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.0402 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	3	3	No	0	0	63.32 Å2	14.3 Å3	33.99 m3·mol-1	3	Yes	No	14.3 mg/mL	-2.4	-1	2.04	8.9	P77444;!P0A6V7;!Q01770;!Q7K9G0;!Q9ZHG9;!P31142;!P31101;!Q16762;!Q5SJI0	sufS;!glpE;!hcp;!MST;!c-des;!sseA;!hcp;!TST;!Not Available	1. Cysteine desulfurase;!2. Thiosulfate sulfurtransferase GlpE;!3. Hydroxylamine reductase;!4. 3-mercaptopyruvate sulfurtransferase;!5. L-cysteine/cystine lyase C-DES;!6. 3-mercaptopyruvate sulfurtransferase;!7. Hydroxylamine reductase;!8. Thiosulfate sulfurtransferase;!9. Sulfurtransferase
C4H10N2O3	Not Available	Not Available	134.1338	NOCC[C@H](N)C(O)=O	Solid	Not Available						145769	CHEMBL1231652	390176			HMDB0012251	C08270		CAN			441443	46506663			DNC000866	Canaline	ZINC000001531042		Canaline	Experimental	DB02821	InChI=1S/C4H10N2O3/c5-3(4(7)8)1-2-9-6/h3H,1-2,5-6H2,(H,7,8)/t3-/m0/s1	FQPGMQABJNQLLF-VKHMYHEASA-N			Not Available	Small Molecule				AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.8781 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	5	3	No	0	0	98.57 Å2	12.91 Å3	30.98 m3·mol-1	4	Yes	No	308.0 mg/mL	-3.7	0.36	2.24	9.46	P04181	OAT	1. Ornithine aminotransferase, mitochondrial
C9H17NO2	Not Available	Not Available	171.2368	N[C@@H](CC1CCCCC1)C(O)=O	Solid	Not Available					50179725		CHEMBL383208	621428						ALC			712421	46509087					ZINC000012368795		3-Cyclohexyl-L-alanine	Experimental	DB02884	InChI=1S/C9H17NO2/c10-8(9(11)12)6-7-4-2-1-3-5-7/h7-8H,1-6,10H2,(H,11,12)/t8-/m0/s1	ORQXBVXKBGUSBA-QMMMGPOBSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.8217 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	3	2	No	1	0	63.32 Å2	19.36 Å3	46.17 m3·mol-1	3	Yes	No	2.52 mg/mL	-0.72	-1.8	2.73	9.52	P08048	ZFY	1. Zinc finger Y-chromosomal protein
C8H13NO4	Not Available	Not Available	187.1931	N[C@@H](CCCC(=C)C(O)=O)C(O)=O	Solid	Not Available								393109						2NP			445478	46508095					ZINC000002046788		L-2-Amino-6-Methylene-Pimelic Acid	Experimental	DB02892	InChI=1S/C8H13NO4/c1-5(7(10)11)3-2-4-6(9)8(12)13/h6H,1-4,9H2,(H,10,11)(H,12,13)/t6-/m0/s1	SGAIRWMSXVAPOO-LURJTMIESA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.7492 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	5	3	No	0	-1	100.62 Å2	18.62 Å3	44.87 m3·mol-1	6	Yes	No	22.0 mg/mL	-1.9	-0.93	2.16	9.53	P04964	ddh	1. Meso-diaminopimelate D-dehydrogenase
C5H11NO2S	Not Available	Not Available	149.211	CSCC[C@@H](N)C(O)=O	Solid	Not Available						57932	CHEMBL1234268	76512				C00855		MED			84815	46505884					ZINC000001532766	Prosol	D-Methionine	Approved, Experimental, Investigational	DB02893	InChI=1S/C5H11NO2S/c1-9-3-2-4(6)5(7)8/h4H,2-3,6H2,1H3,(H,7,8)/t4-/m1/s1	FFEARJCKVFRZRR-SCSAIBSYSA-N		D-Methionine is an amino acid found in mixture products used for nutrient supplementation.	Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	0.6483 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							213 dec °C			1	No	3	2	No	0	0	63.32 Å2	15.46 Å3	37.59 m3·mol-1	4	Yes	No	23.9 mg/mL	-2.2	-0.8	2.53	9.5	P50579;!Q9KQN0	METAP2;!Not Available	1. Methionine aminopeptidase 2;!2. Transcriptional regulator, HTH_3 family
C6H11NO4S	Not Available	Not Available	193.221	[H][C@@](CCSC)(NC(O)=O)C(O)=O	Solid	Not Available						41696		16743925						CXM			17753927	46508277					ZINC000035264110		N-Carboxymethionine	Experimental	DB02899	InChI=1S/C6H11NO4S/c1-12-3-2-4(5(8)9)7-6(10)11/h4,7H,2-3H2,1H3,(H,8,9)(H,10,11)/t4-/m0/s1	LWQBAQJPCYBWJQ-BYPYZUCNSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.6656 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	3	No	0	-2	86.63 Å2	18.44 Å3	43.88 m3·mol-1	5	Yes	No	7.08 mg/mL	0.36	-1.4	3.48		P41020;!P41021;!P41022;!P26789;!P26790;!Q5SII2;!P0A884	ureC;!ureB;!ureA;!Not Available;!Not Available;!rsmF;!thyA	1. Urease subunit alpha;!2. Urease subunit beta;!3. Urease subunit gamma;!4. Light-harvesting protein B-800/850 alpha chain;!5. Light-harvesting protein B-800/850 beta chain;!6. Probable rRNA methylase;!7. Thymidylate synthase
C4H9NO3	Not Available	Not Available	119.1192	[H][C@](CN)(CO)C(O)=O	Solid	Not Available								16743752						BSE			17753872	46508484					ZINC000012502811		Beta-3-Serine	Experimental	DB02904	InChI=1S/C4H9NO3/c5-1-3(2-6)4(7)8/h3,6H,1-2,5H2,(H,7,8)/t3-/m0/s1	UHLNJPIGFDWGTP-VKHMYHEASA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.1831 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	3	No	0	0	83.55 Å2	11.36 Å3	27.05 m3·mol-1	3	Yes	No	465.0 mg/mL	-3.9	0.59	3.75	9.95	P12488	env	1. Envelope glycoprotein gp160
C5H11NO3Se	Not Available	Not Available	212.11	[H][C@](N)(CC[Se](C)=O)C(O)=O	Solid	Not Available												C05708		MSO			17754089	46505728							Selenomethionine Selenoxide	Experimental	DB02958	InChI=1S/C5H11NO3Se/c1-10(9)3-2-4(6)5(7)8/h4H,2-3,6H2,1H3,(H,7,8)/t4-,10?/m0/s1	KGXZPWNBFWCDRF-YGVKFDHGSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.3577 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	5	2	No	0	0	80.39 Å2	15.95 Å3	44.74 m3·mol-1	4	Yes	No	105.0 mg/mL	-4	-0.31	1.6	9.11			
C5H15N4O6PS	Not Available	Not Available	290.235	[H][C@](N)(CCCN[P@@](N)(=O)NS(O)(=O)=O)C(O)=O	Solid	Not Available								7822395						PSQ			9543429	46508926							Ndelta-(N'-Sulphodiaminophosphinyl)-L-Ornithine	Experimental	DB02965	InChI=1S/C5H15N4O6PS/c6-4(5(10)11)2-1-3-8-16(7,12)9-17(13,14)15/h4H,1-3,6H2,(H,10,11)(H,13,14,15)(H4,7,8,9,12)/t4-,16+/m0/s1	MDGVOXPIIICZEK-FOIQGAMDSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.2250 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	9	6	No	0	-1	184.84 Å2	24.72 Å3	57.85 m3·mol-1	7	No	No	5.55 mg/mL	-4.5	-1.7	-1	9.5	P04391	argI	1. Ornithine carbamoyltransferase chain I
C6H14N2O3	Not Available	Not Available	162.187	[H][C@](N)(CCOCCN)C(O)=O	Solid	Not Available								393659						AVG			446250	46508365					ZINC000003581194		2-Amino-4-(2-Amino-Ethoxy)-Butyric Acid	Experimental	DB02971	InChI=1S/C6H14N2O3/c7-2-4-11-3-1-5(8)6(9)10/h5H,1-4,7-8H2,(H,9,10)/t5-/m0/s1	FDDYPVBIHWFLOI-YFKPBYRVSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	-	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.5801 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	5	3	No	0	1	98.57 Å2	17.03 Å3	39.61 m3·mol-1	6	Yes	No	159.0 mg/mL	-4.4	-0.01	2.45	9.75			
C5H10N2O3S	Not Available	Not Available	178.21	N[C@@H](CSCC(N)=O)C(O)=O	Solid	Not Available								16744260						YCM			17754220	46509176					ZINC000001596714		Cysteine-S-acetamide	Experimental	DB02987	InChI=1S/C5H10N2O3S/c6-3(5(9)10)1-11-2-4(7)8/h3H,1-2,6H2,(H2,7,8)(H,9,10)/t3-/m0/s1	VFKYKPOTSJWPIU-VKHMYHEASA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.7667 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	3	No	0	0	106.41 Å2	17.1 Å3	40.93 m3·mol-1	5	Yes	No	21.5 mg/mL	-4	-0.92	2.07	8.83	P07998;!P00973	RNASE1;!OAS1	1. Ribonuclease pancreatic;!2. 2'-5'-oligoadenylate synthase 1
C10H17N3O9S	Not Available	Not Available	355.322	[H]N([H])[C@@H](CCC(=O)N([H])[C@@H](CS(O)(=O)=O)C(=O)N([H])CC(O)=O)C(O)=O	Solid	Not Available								392112						GTS			444104	46504962					ZINC000001616624		Glutathione sulfonic acid	Experimental	DB03003	InChI=1S/C10H17N3O9S/c11-5(10(18)19)1-2-7(14)13-6(4-23(20,21)22)9(17)12-3-8(15)16/h5-6H,1-4,11H2,(H,12,17)(H,13,14)(H,15,16)(H,18,19)(H,20,21,22)/t5-,6-/m0/s1	QGWRMTHFAZVWAM-WDSKDSINSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.1180 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	10	6	No	0	-2	213.19 Å2	31.34 Å3	71.33 m3·mol-1	10	No	No	3.0 mg/mL	-5	-2.1	-1.2	9.31	Q03013;!P08263;!P09211;!P0A9D2	GSTM4;!GSTA1;!GSTP1;!gstA	1. Glutathione S-transferase Mu 4;!2. Glutathione S-transferase A1;!3. Glutathione S-transferase P;!4. Glutathione S-transferase GstA
C18H33N3O6S	Not Available	Not Available	419.536	CCCCCCCCSC[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)NCC(O)=O	Solid	Not Available								391395				C11302		GTY			443115	46508495					ZINC000008234408		S-octylglutathione	Experimental	DB03032	InChI=1S/C18H33N3O6S/c1-2-3-4-5-6-7-10-28-12-14(17(25)20-11-16(23)24)21-15(22)9-8-13(19)18(26)27/h13-14H,2-12,19H2,1H3,(H,20,25)(H,21,22)(H,23,24)(H,26,27)/t13-,14-/m0/s1	MJWCZWAVSJZQNL-KBPBESRZSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1495 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	5	No	0	-1	158.82 Å2	45.91 Å3	106.09 m3·mol-1	17	Yes	No	0.0341 mg/mL	-1.5	-4.1	1.81	9.31	Q03013	GSTM4	1. Glutathione S-transferase Mu 4
C3H7NO2SSe	Not Available	Not Available	200.12	N[C@@H](CS[SeH])C(O)=O	Solid	Not Available								19687052						CSZ			17753926	46506767							S-Selanyl Cysteine	Experimental	DB03049	InChI=1S/C3H7NO2SSe/c4-2(1-7-8)3(5)6/h2,8H,1,4H2,(H,5,6)/t2-/m0/s1	KRUPEGHZMWTFPP-REOHCLBHSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.0546 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	3	No	0	0	63.32 Å2	14 Å3	41.35 m3·mol-1	3	Yes	No	57.5 mg/mL	-3.7	-0.54	1.17	8.9	P77444	sufS	1. Cysteine desulfurase
C5H10N2O3	Not Available	Not Available	146.1445	N[C@@H](CCC(O)=O)C(N)=O	Solid	Not Available								393382						GMA			445883	46506385				Isoglutamine	ZINC000002508203		Isoglutamine	Experimental	DB03091	InChI=1S/C5H10N2O3/c6-3(5(7)10)1-2-4(8)9/h3H,1-2,6H2,(H2,7,10)(H,8,9)/t3-/m0/s1	AEFLONBTGZFSGQ-VKHMYHEASA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.4063 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	3	No	0	0	106.41 Å2	13.9 Å3	33.11 m3·mol-1	4	Yes	No	79.7 mg/mL	-4	-0.26	4.06	8.46	P0ABA0	atpF	1. ATP synthase subunit b
C5H11NO3	Not Available	Not Available	133.1457	N[C@@H](CCCO)C(O)=O	Solid	Not Available							CHEMBL495224	4449920						AA4			5287587	46505812					ZINC000001571334		L-Pentahomoserine	Experimental	DB03105	InChI=1S/C5H11NO3/c6-4(5(8)9)2-1-3-7/h4,7H,1-3,6H2,(H,8,9)/t4-/m0/s1	CZWARROQQFCFJB-BYPYZUCNSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	0.8559 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	3	No	0	0	83.55 Å2	13.48 Å3	31.55 m3·mol-1	4	Yes	No	268.0 mg/mL	-3.3	0.3	2.36	9.22			
C7H13NO4	Not Available	Not Available	175.1824	N[C@@H](CCCCC(O)=O)C(O)=O	Solid	Not Available						44387		394004						NPI			446719	46509145					ZINC000001594926		L-2-aminopimelic acid	Experimental	DB03134	InChI=1S/C7H13NO4/c8-5(7(11)12)3-1-2-4-6(9)10/h5H,1-4,8H2,(H,9,10)(H,11,12)/t5-/m0/s1	JUQLUIFNNFIIKC-YFKPBYRVSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	0.9984 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	5	3	No	0	-1	100.62 Å2	17.63 Å3	40.49 m3·mol-1	6	Yes	No	12.6 mg/mL	-2.4	-1.1	2.13	9.53	P56220	dapD	1. 2,3,4,5-tetrahydropyridine-2,6-dicarboxylate N-succinyltransferase
C6H14N4O3	Not Available	Not Available	190.2004	N[C@@H](CCCNC(=N)NO)C(O)=O	Solid	Not Available					50230418	43088	CHEMBL260629	110427			HMDB0004224			HAR			123895	46506099					ZINC000004096974		N(5)-[(hydroxyamino)(imino)methyl]-L-ornithine	Experimental	DB03144	InChI=1S/C6H14N4O3/c7-4(5(11)12)2-1-3-9-6(8)10-13/h4,13H,1-3,7H2,(H,11,12)(H3,8,9,10)/t4-/m0/s1	FQWRAVYMZULPNK-BYPYZUCNSA-N			Not Available	Small Molecule	http://smpdb.ca/view/SMP0000362?highlight[compounds][]=DB03144&highlight[proteins][]=DB03144;!http://smpdb.ca/view/SMP0000504?highlight[compounds][]=DB03144&highlight[proteins][]=DB03144;!http://smpdb.ca/view/SMP0000505?highlight[compounds][]=DB03144&highlight[proteins][]=DB03144;!http://smpdb.ca/view/SMP0000207?highlight[compounds][]=DB03144&highlight[proteins][]=DB03144;!http://smpdb.ca/view/SMP0000208?highlight[compounds][]=DB03144&highlight[proteins][]=DB03144;!http://smpdb.ca/view/SMP0000363?highlight[compounds][]=DB03144&highlight[proteins][]=DB03144;!http://smpdb.ca/view/SMP0000506?highlight[compounds][]=DB03144&highlight[proteins][]=DB03144;!http://smpdb.ca/view/SMP0000020?highlight[compounds][]=DB03144&highlight[proteins][]=DB03144;!http://smpdb.ca/view/SMP0000188?highlight[compounds][]=DB03144&highlight[proteins][]=DB03144;!http://smpdb.ca/view/SMP0000360?highlight[compounds][]=DB03144&highlight[proteins][]=DB03144;!http://smpdb.ca/view/SMP0000361?highlight[compounds][]=DB03144&highlight[proteins][]=DB03144;!http://smpdb.ca/view/SMP0000507?highlight[compounds][]=DB03144&highlight[proteins][]=DB03144	Arginine: Glycine Amidinotransferase Deficiency (AGAT Deficiency);!Creatine Deficiency, Guanidinoacetate Methyltransferase Deficiency;!Hyperornithinemia with Gyrate Atrophy (HOGA);!Prolidase Deficiency (PD);!Prolinemia Type II;!Ornithine Aminotransferase Deficiency (OAT Deficiency);!Hyperornithinemia-Hyperammonemia-Homocitrullinuria [HHH-syndrome];!Arginine and Proline Metabolism;!Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency);!Hyperprolinemia Type II;!Hyperprolinemia Type I;!L-Arginine:Glycine Amidinotransferase Deficiency		AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.0835 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	6	No	0	1	131.46 Å2	19.04 Å3	66.18 m3·mol-1	5	No	No	1.49 mg/mL	-3.3	-2.1	2.2	10.48	P29474;!O34453;!P35228;!P05089;!P29475	NOS3;!nos;!NOS2;!ARG1;!NOS1	1. Nitric oxide synthase, endothelial;!2. Nitric oxide synthase oxygenase;!3. Nitric oxide synthase, inducible;!4. Arginase-1;!5. Nitric oxide synthase, brain
C5H9NO3	Not Available	Not Available	131.1299	[H][C@](N)(C[C@@]1([H])CO1)C(O)=O	Solid	Not Available					85447			394622						LIS			447569	46505024							3-Oxiran-2ylalanine	Experimental	DB03191	InChI=1S/C5H9NO3/c6-4(5(7)8)1-3-2-9-3/h3-4H,1-2,6H2,(H,7,8)/t3-,4-/m0/s1	HKPCHCJYQVJLIZ-IMJSIDKUSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.0861 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	2	No	1	0	75.85 Å2	12.44 Å3	29.36 m3·mol-1	3	Yes	No	457.0 mg/mL	-3.3	0.54	2.08	9.45	Q00266	MAT1A	1. S-adenosylmethionine synthase isoform type-1
C3H7NO2S	Not Available	Not Available	121.158	N[C@H](CS)C(O)=O	Solid	Not Available					50109584	35236	CHEMBL171281	83819			HMDB0003417	C00793		DCY			92851	46505834					ZINC000000895347		D-Cysteine	Experimental	DB03201	InChI=1S/C3H7NO2S/c4-2(1-7)3(5)6/h2,7H,1,4H2,(H,5,6)/t2-/m1/s1	XUJNEKJLAYXESH-UWTATZPHSA-N			Not Available	Small Molecule																																			1	No	3	3	No	0	0	63.32 Å2	11.4 Å3	28.22 m3·mol-1	2	Yes	No	23.1 mg/mL	-2.8	-0.72	2.35	9.05	P15085	CPA1	1. Carboxypeptidase A1
C4H7NO2	Not Available	Not Available	101.1039	N[C@@H](C=C)C(O)=O	Solid	Not Available						43858		137492						LVG			156126	46506124					ZINC000001566185		Vinylglycine	Experimental	DB03214	InChI=1S/C4H7NO2/c1-2-3(5)4(6)7/h2-3H,1,5H2,(H,6,7)/t3-/m0/s1	RQVLGLPAZTUBKX-VKHMYHEASA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.6609 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	3	2	No	0	0	63.32 Å2	9.65 Å3	24.91 m3·mol-1	2	Yes	No	250.0 mg/mL	-2.5	0.39	2.42	8.95	Q96RQ9;!Q96QU6	IL4I1;!ACCS	1. L-amino-acid oxidase;!2. 1-aminocyclopropane-1-carboxylate synthase-like protein 1
C7H15N3O3	Not Available	Not Available	189.2123	NCCC(=O)NCC[C@H](N)C(O)=O	Solid	Not Available								25057781						193			46936619	46506230					ZINC000012503315		(2s)-4-(Beta-Alanylamino)-2-Aminobutanoic Acid	Experimental	DB03236	InChI=1S/C7H15N3O3/c8-3-1-6(11)10-4-2-5(9)7(12)13/h5H,1-4,8-9H2,(H,10,11)(H,12,13)/t5-/m0/s1	ZTTQHTAQUGLWNQ-YFKPBYRVSA-N			Not Available	Small Molecule				AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.6861 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	5	4	No	0	1	118.44 Å2	19.52 Å3	46.07 m3·mol-1	6	Yes	No	28.3 mg/mL	-5.1	-0.83	2.35	9.41			
C6H13NO	Not Available	Not Available	115.1735	[H][C@](N)(CCCC)C=O	Solid	Not Available								4450819									5288719	46507443							1-Amino-1-Carbonyl Pentane	Experimental	DB03241	InChI=1S/C6H13NO/c1-2-3-4-6(7)5-8/h5-6H,2-4,7H2,1H3/t6-/m0/s1	TZJGKUCHNFFHGN-LURJTMIESA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.3410 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	2	1	No	0	1	43.09 Å2	13.5 Å3	33.3 m3·mol-1	4	Yes	No	43.6 mg/mL	0.67	-0.42		8.09	P0DJ06	SAP2	1. Candidapepsin-2
C6H14N2O2	Not Available	Not Available	146.1876	[H][C@@](N)(CCCCN)C(O)=O	Solid	Not Available					217368	16855	CHEMBL319497	51793				C00739		DLY			57449	46506741					ZINC000001532731		D-Lysine	Experimental	DB03252	InChI=1S/C6H14N2O2/c7-4-2-1-3-5(8)6(9)10/h5H,1-4,7-8H2,(H,9,10)/t5-/m1/s1	KDXKERNSBIXSRK-RXMQYKEDSA-N			Not Available	Small Molecule				AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.3190 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	3	No	0	1	89.34 Å2	15.91 Å3	37.81 m3·mol-1	5	Yes	No	105.0 mg/mL	-3.2	-0.14	2.74	10.29	Q9HTQ2;!P00861	dadX;!lysA	1. Alanine racemase, catabolic;!2. Diaminopimelate decarboxylase
C3H8N2OS	Not Available	Not Available	120.173	N[C@@H](CS)C(N)=O	Solid	Not Available								5022653						CY3			6540253	46508809							Cysteinamide	Experimental	DB03275	InChI=1S/C3H8N2OS/c4-2(1-7)3(5)6/h2,7H,1,4H2,(H2,5,6)/t2-/m0/s1	YEDNBEGNKOANMB-REOHCLBHSA-N	2		Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.0646 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	2	3	No	0	1	69.11 Å2	11.81 Å3	30.05 m3·mol-1	2	Yes	No		-1.4		9.98	8.08			
C3H8AsNO4S	Not Available	Not Available	229.087	[H][C@](N)(CS[As](O)O)C(O)=O	Solid	Not Available								25057221						CZ2			49866861	46504867							Thiarsa Dihydroxy Cysteine	Experimental	DB03289	InChI=1S/C3H8AsNO4S/c5-2(3(6)7)1-10-4(8)9/h2,8-9H,1,5H2,(H,6,7)/t2-/m0/s1	FZFDBYKEUGDOOP-REOHCLBHSA-N			Not Available	Small Molecule																																			1	No	5	4	No	0	-1	103.78 Å2	16.36 Å3	32.57 m3·mol-1	4	Yes	No	37.5 mg/mL	-3.8	-0.79	1.29	8.56	P08692	arsC	1. Arsenate reductase
C3H8NO5P	Not Available	Not Available	169.0731	[H][C@@](N)(CP(O)(O)=O)C(O)=O	Solid	Not Available							CHEMBL1231023	394116						APO			446873	46506843					ZINC000003873029		3-Phosphono-D-alanine	Experimental	DB03292	InChI=1S/C3H8NO5P/c4-2(3(5)6)1-10(7,8)9/h2H,1,4H2,(H,5,6)(H2,7,8,9)/t2-/m1/s1	LBTABPSJONFLPO-UWTATZPHSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.6183 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	4	No	0	-1	120.85 Å2	12.86 Å3	31.08 m3·mol-1	3	Yes	No	34.7 mg/mL	-3.8	-0.69	1.4	9.83	P78330	PSPH	1. Phosphoserine phosphatase
C17H34N6O5S	Not Available	Not Available	434.554	NCCCCNCCCNC(=O)CNC(=O)[C@H](CS)NC(=O)CC[C@H](N)C(O)=O	Solid	Not Available						16613		389641				C05730		TS5			440772	46505567					ZINC000003869959		Glutathionylspermidine	Experimental	DB03295	InChI=1S/C17H34N6O5S/c18-6-1-2-7-20-8-3-9-21-15(25)10-22-16(26)13(11-29)23-14(24)5-4-12(19)17(27)28/h12-13,20,29H,1-11,18-19H2,(H,21,25)(H,22,26)(H,23,24)(H,27,28)/t12-,13-/m0/s1	NEDQLXHBVHSKNV-STQMWFEESA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	1.9668 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	11	8	No	0	2	199.14 Å2	47.62 Å3	112.45 m3·mol-1	17	No	No		-8.3		1.87	10.89			
C7H15N3O2	Not Available	Not Available	173.2129	CC(=N)NCCC[C@H](N)C(O)=O	Solid	Not Available					50072297		CHEMBL11471	97098						ILO			107984	46507343					ZINC000001886324		N(G)-Iminoethylornithine	Experimental	DB03305	InChI=1S/C7H15N3O2/c1-5(8)10-4-2-3-6(9)7(11)12/h6H,2-4,9H2,1H3,(H2,8,10)(H,11,12)/t6-/m0/s1	UYZFAUAYFLEHRC-LURJTMIESA-N			Not Available	Small Molecule				AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.6674 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	5	4	No	0	1	99.2 Å2	18.49 Å3	55.12 m3·mol-1	5	Yes	No		-2.9		2.53	12.82			
C3H9N2O2	Not Available	Not Available	105.1158	N[C@@H](C[NH3+])C(O)=O	Solid	Not Available						84374		5341970						DNP			17753953	46506291							3-Amino-Alanine	Experimental	DB03320	InChI=1S/C3H8N2O2/c4-1-2(5)3(6)7/h2H,1,4-5H2,(H,6,7)/p+1/t2-/m0/s1	PECYZEOJVXMISF-REOHCLBHSA-O			Not Available	Small Molecule				AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.4611 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	3	3	No	0	0	90.96 Å2	10.22 Å3	34.99 m3·mol-1	2	Yes	No	177.0 mg/mL	-4	0.1	2.1	9.57	P12488	env	1. Envelope glycoprotein gp160
C17H23IN4O8S	Not Available	Not Available	570.356	N[C@@H](CCC(=O)N[C@@H](CS[C@@H](O)N(O)C1=CC=C(I)C=C1)C(=O)NCC(O)=O)C(O)=O	Solid	Not Available								16743995						GIP			17753999	46505523					ZINC000014880713		S-(N-hydroxy-N-iodophenylcarbamoyl)glutathione	Experimental	DB03330	InChI=1S/C17H23IN4O8S/c18-9-1-3-10(4-2-9)22(30)17(29)31-8-12(15(26)20-7-14(24)25)21-13(23)6-5-11(19)16(27)28/h1-4,11-12,17,29-30H,5-8,19H2,(H,20,26)(H,21,23)(H,24,25)(H,27,28)/t11-,12-,17+/m0/s1	SCHAHXXLASZJCD-NVGCLXPQSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.5014 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	10	7	No	1	-1	202.52 Å2	48.57 Å3	128.66 m3·mol-1	13	No	No	0.163 mg/mL	-1.9	-3.5	1.77	9.31	Q04760	GLO1	1. Lactoylglutathione lyase
C3H8AsNO5S	Not Available	Not Available	245.086	N[C@@H](CS[As](O)(O)=O)C(O)=O	Solid	Not Available								25057131						CSR			17753924	46508550							S-Arsonocysteine	Experimental	DB03352	InChI=1S/C3H8AsNO5S/c5-2(3(6)7)1-11-4(8,9)10/h2H,1,5H2,(H,6,7)(H2,8,9,10)/t2-/m0/s1	XSWAJYRRDHPZDP-REOHCLBHSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.0653 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	4	No	0	-2	120.85 Å2	17.38 Å3	34.01 m3·mol-1	4	Yes	No	40.4 mg/mL	-4.1	-0.78	1.1	9.22	P08692;!P0A006;!Q7K9G0	arsC;!arsC;!MST	1. Arsenate reductase;!2. Protein ArsC;!3. 3-mercaptopyruvate sulfurtransferase
C8H18N2O2	Not Available	Not Available	174.2407	[H][C@](N)(CCCCN(C)C)C(O)=O	Solid	Not Available						43997		167778						MLY			193344	46508331					ZINC000002579066		N-Dimethyl-Lysine	Experimental	DB03362	InChI=1S/C8H18N2O2/c1-10(2)6-4-3-5-7(9)8(11)12/h7H,3-6,9H2,1-2H3,(H,11,12)/t7-/m0/s1	XXEWFEBMSGLYBY-ZETCQYMHSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.7865 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	2	No	0	1	66.56 Å2	19.87 Å3	47.88 m3·mol-1	6	Yes	No	170.0 mg/mL	-2.7	-0.01	2.84	9.98			
C6H12N2O3S	Not Available	Not Available	192.236	CSCC[C@@H](NC(N)=O)C(O)=O	Solid	Not Available						137948		395543						CDT			448878	46506719					ZINC000002087309		N-Carbamyl-D-Methionine	Experimental	DB03364	InChI=1S/C6H12N2O3S/c1-12-3-2-4(5(9)10)8-6(7)11/h4H,2-3H2,1H3,(H,9,10)(H3,7,8,11)/t4-/m1/s1	DEWDMTSMCKXBNP-SCSAIBSYSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.5964 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	3	3	No	0	-1	92.42 Å2	18.78 Å3	45.71 m3·mol-1	5	Yes	No	12.8 mg/mL	-0.44	-1.2	3.94	-2.3	P60327	Not Available	1. N-carbamoyl-D-amino acid hydrolase
C3H7NO3S	Not Available	Not Available	137.158	[H][C@](N)(CS=O)C(O)=O	Solid	Not Available						41630		16743742						CSX			49866839	46509121							S-oxy-L-cysteine	Experimental	DB03382	InChI=1S/C3H7NO3S/c4-2(1-8-7)3(5)6/h2,8H,1,4H2,(H,5,6)/t2-/m0/s1	BHLMCOCHAVMHLD-REOHCLBHSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.8982 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	3	No	0	-1	80.39 Å2	12.09 Å3	27.64 m3·mol-1	3	Yes	No	470.0 mg/mL	-4.3	0.54	1.4	8.82	P0A793;!P48147;!O67040;!O53240;!P9WG35;!P00441;!P37062	panD;!PREP;!ppx;!Not Available;!tpx;!SOD1;!npr	1. Aspartate 1-decarboxylase;!2. Prolyl endopeptidase;!3. Exopolyphosphatase;!4. Conserved protein;!5. Probable thiol peroxidase;!6. Superoxide dismutase [Cu-Zn];!7. NADH peroxidase
C8H14N2O5S	Not Available	Not Available	250.272	N[C@@H](CCC(=O)N[C@@H](CS)C(O)=O)C(O)=O	Solid	Not Available						17515	CHEMBL460831	110467			HMDB0001049	C00669		3GC			123938	46506032				Gamma-Glutamylcysteine	ZINC000003870040		gamma-Glutamylcysteine	Experimental	DB03408	InChI=1S/C8H14N2O5S/c9-4(7(12)13)1-2-6(11)10-5(3-16)8(14)15/h4-5,16H,1-3,9H2,(H,10,11)(H,12,13)(H,14,15)/t4-,5-/m0/s1	RITKHVBHSGLULN-WHFBIAKZSA-N			Not Available	Small Molecule	http://smpdb.ca/view/SMP0000072?highlight[compounds][]=DB03408&highlight[proteins][]=DB03408;!http://smpdb.ca/view/SMP0000339?highlight[compounds][]=DB03408&highlight[proteins][]=DB03408;!http://smpdb.ca/view/SMP0000501?highlight[compounds][]=DB03408&highlight[proteins][]=DB03408;!http://smpdb.ca/view/SMP0000136?highlight[compounds][]=DB03408&highlight[proteins][]=DB03408;!http://smpdb.ca/view/SMP0000183?highlight[compounds][]=DB03408&highlight[proteins][]=DB03408;!http://smpdb.ca/view/SMP0000243?highlight[compounds][]=DB03408&highlight[proteins][]=DB03408;!http://smpdb.ca/view/SMP0000499?highlight[compounds][]=DB03408&highlight[proteins][]=DB03408;!http://smpdb.ca/view/SMP0000500?highlight[compounds][]=DB03408&highlight[proteins][]=DB03408;!http://smpdb.ca/view/SMP0000567?highlight[compounds][]=DB03408&highlight[proteins][]=DB03408;!http://smpdb.ca/view/SMP0000013?highlight[compounds][]=DB03408&highlight[proteins][]=DB03408;!http://smpdb.ca/view/SMP0000015?highlight[compounds][]=DB03408&highlight[proteins][]=DB03408;!http://smpdb.ca/view/SMP0000143?highlight[compounds][]=DB03408&highlight[proteins][]=DB03408;!http://smpdb.ca/view/SMP0000337?highlight[compounds][]=DB03408&highlight[proteins][]=DB03408;!http://smpdb.ca/view/SMP0000385?highlight[compounds][]=DB03408&highlight[proteins][]=DB03408;!http://smpdb.ca/view/SMP0000722?highlight[compounds][]=DB03408&highlight[proteins][]=DB03408	Glutamate Metabolism;!Hyperinsulinism-Hyperammonemia Syndrome;!gamma-Glutamyltranspeptidase Deficiency;!2-Hydroxyglutric Aciduria (D and L Form);!gamma-Glutamyltransferase Deficiency;!4-Hydroxybutyric Aciduria/Succinic Semialdehyde Dehydrogenase Deficiency;!beta-Mercaptolactate-Cysteine Disulfiduria;!5-Oxoprolinase Deficiency;!Succinic Semialdehyde Dehydrogenase Deficiency;!Cysteine Metabolism;!Glutathione Metabolism;!5-Oxoprolinuria;!Glutathione Synthetase Deficiency;!Homocarnosinosis;!Cystinosis, Ocular Nonnephropathic		AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.5829 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	5	No	0	-1	129.72 Å2	23.36 Å3	56.31 m3·mol-1	7	Yes	No	2.62 mg/mL	-3.8	-2	1.91	9.24	P48637	GSS	1. Glutathione synthetase
C6H13NO3	Not Available	Not Available	147.1723	N[C@@H](CCCCO)C(O)=O	Solid	Not Available							CHEMBL1233976	88202						LDO			97725	46508093					ZINC000001747033		6-hydroxynorleucine	Experimental	DB03412	InChI=1S/C6H13NO3/c7-5(6(9)10)3-1-2-4-8/h5,8H,1-4,7H2,(H,9,10)/t5-/m0/s1	OLUWXTFAPJJWPL-YFKPBYRVSA-N			Not Available	Small Molecule																																			1	No	4	3	No	0	0	83.55 Å2	15.55 Å3	36.15 m3·mol-1	5	Yes	No	101.0 mg/mL	-2.9	-0.16	2.46	9.53	P06608	ansB	1. L-asparaginase
C16H24N2O4	Not Available	Not Available	308.3728	CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1)C(O)=O	Solid	Not Available	P16444	DPEP1	1. Dipeptidase 1		50367209		CHEMBL29292	65145						BES			72172	46505598				Ubenimex	ZINC000001542895		Ubenimex	Investigational	DB03424	InChI=1S/C16H24N2O4/c1-10(2)8-13(16(21)22)18-15(20)14(19)12(17)9-11-6-4-3-5-7-11/h3-7,10,12-14,19H,8-9,17H2,1-2H3,(H,18,20)(H,21,22)/t12-,13+,14+/m1/s1	VGGGPCQERPFHOB-RDBSUJKOSA-N	3		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.8987 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	5	4	No	1	0	112.65 Å2	33.09 Å3	82.05 m3·mol-1	8	Yes	No	1.29 mg/mL	-1.1	-2.4	3.73	8.35			
C6H10NO4	Not Available	Not Available	160.1479	[H][C@@](C)(C[C@]([H])(N)C(O)=O)C([O-])=O	Solid	Not Available								5341968						SYM			131704245	46508238							2s,4r-4-Methylglutamate	Experimental	DB03425	InChI=1S/C6H11NO4/c1-3(5(8)9)2-4(7)6(10)11/h3-4H,2,7H2,1H3,(H,8,9)(H,10,11)/p-1/t3-,4+/m1/s1	KRKRAOXTGDJWNI-DMTCNVIQSA-M			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.3539 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	5	2	No	0	-1	103.45 Å2	14.73 Å3	46.7 m3·mol-1	4	Yes	No	267.0 mg/mL	-2.7	0.18	2.01	9.53	Q13002	GRIK2	1. Glutamate receptor ionotropic, kainate 2
C13H21N3O6S	Not Available	Not Available	347.387	[H]N([H])[C@@H](CCCC(=O)N([H])[C@@H](CS)C(=O)N([H])[C@H](C=C)C(O)=O)C(O)=O	Solid	Not Available								4911105						ASV			6398414	46508704					ZINC000006363128		delta-(L-alpha-Aminoadipoyl)-L-cysteinyl-D-vinylglycine	Experimental	DB03427	InChI=1S/C13H21N3O6S/c1-2-8(13(21)22)16-11(18)9(6-23)15-10(17)5-3-4-7(14)12(19)20/h2,7-9,23H,1,3-6,14H2,(H,15,17)(H,16,18)(H,19,20)(H,21,22)/t7-,8+,9-/m0/s1	JJJCGQKXGIRXKN-YIZRAAEISA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.9995 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	7	6	No	0	-1	158.82 Å2	33.47 Å3	82.62 m3·mol-1	11	No	No	0.905 mg/mL	-3.5	-2.6	1.94	9.15			
C6H10NO8P	Not Available	Not Available	255.1193	[H]N([C@@H](CC(O)=O)C(O)=O)C(=O)CP(O)(O)=O	Solid	Not Available							CHEMBL504802	36554						PAL			39981	46507931			DNC000976		ZINC000001563934		Sparfosic acid	Experimental	DB03459	InChI=1S/C6H10NO8P/c8-4(2-16(13,14)15)7-3(6(11)12)1-5(9)10/h3H,1-2H2,(H,7,8)(H,9,10)(H,11,12)(H2,13,14,15)/t3-/m0/s1	ZZKNRXZVGOYGJT-VKHMYHEASA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.0339 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	8	5	No	0	-3	161.23 Å2	19.82 Å3	46.97 m3·mol-1	6	Yes	No	6.73 mg/mL	-2.7	-1.6	1.65		P0A789;!P27708	pyrB;!CAD	1. Aspartate carbamoyltransferase catalytic chain;!2. CAD protein
C6H12N2O3	Not Available	Not Available	160.1711	CNC(=O)CC[C@H](N)C(O)=O	Solid	Not Available						58200		388957				C03153		MEQ			439925	46505841					ZINC000001529600		N5-Methylglutamine	Experimental	DB03473	InChI=1S/C6H12N2O3/c1-8-5(9)3-2-4(7)6(10)11/h4H,2-3,7H2,1H3,(H,8,9)(H,10,11)/t4-/m0/s1	ONXPDKGXOOORHB-BYPYZUCNSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.4834 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	3	No	0	0	92.42 Å2	15.86 Å3	38.01 m3·mol-1	4	Yes	No	56.5 mg/mL	-3.8	-0.45	2.26	9.31	Q9WYV8	prmC	1. Release factor glutamine methyltransferase
C7H14N2O5S	Not Available	Not Available	238.261	[H][C@](O)(C[C@]([H])(N)C(O)=O)SC[C@]([H])(N)C(O)=O	Solid	Not Available								25057192						HTI			49867129	46505542					ZINC000058632347		(4s)-4-{[(2s)-2-Amino-3-Oxopropyl]Sulfanyl}-L-Homoserinate	Experimental	DB03502	InChI=1S/C7H14N2O5S/c8-3(6(11)12)1-5(10)15-2-4(9)7(13)14/h3-5,10H,1-2,8-9H2,(H,11,12)(H,13,14)/t3-,4-,5+/m0/s1	ZGWOKDWPXPPFGS-VAYJURFESA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.8043 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	5	No	0	0	146.87 Å2	22.41 Å3	52.38 m3·mol-1	7	Yes	No	24.1 mg/mL	-6.3	-1	1.62	9.29	P44801	asd	1. Aspartate-semialdehyde dehydrogenase
C6H9NO6	Not Available	Not Available	191.1388	N[C@@H](CC(=O)OCC(O)=O)C(O)=O	Solid	Not Available								16743844						ASB			17753844	46505968					ZINC000006360489		Aspartic Acid-4-Carboxymethyl Ester	Experimental	DB03522	InChI=1S/C6H9NO6/c7-3(6(11)12)1-5(10)13-2-4(8)9/h3H,1-2,7H2,(H,8,9)(H,11,12)/t3-/m0/s1	VYJCBTPDYBSANG-VKHMYHEASA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.7645 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	3	No	0	-1	126.92 Å2	16.43 Å3	37.39 m3·mol-1	6	Yes	No	20.9 mg/mL	-4	-0.96	1.51	8.6	Q60099	dhlB	1. (S)-2-haloacid dehalogenase
C3H8NO5PS	Not Available	Not Available	201.138	N[C@@H](CSP(O)(O)=O)C(O)=O	Solid	Not Available						22066		2340106						CSP			3082729	46505488							S-Phosphocysteine	Experimental	DB03544	InChI=1S/C3H8NO5PS/c4-2(3(5)6)1-11-10(7,8)9/h2H,1,4H2,(H,5,6)(H2,7,8,9)/t2-/m0/s1	MNEMQJJMDDZXRO-REOHCLBHSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.1025 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	4	No	0	-2	120.85 Å2	16.25 Å3	39.52 m3·mol-1	4	Yes	No	42.9 mg/mL	-3	-0.67	1.5	9.9	P69795;!P0AF93	chbB;!ridA	1. N,N'-diacetylchitobiose-specific phosphotransferase enzyme IIB component;!2. Enamine/imine deaminase
C9H11NO3	Not Available	Not Available	181.1885	N[C@@H](CC1=CC=CC(O)=C1)C(O)=O	Solid	Not Available					50463214	44303	CHEMBL1232501	5323512			HMDB0059720			MTY			6950578	46507251					ZINC000000392006		3-Tyrosine	Experimental	DB03552	InChI=1S/C9H11NO3/c10-8(9(12)13)5-6-2-1-3-7(11)4-6/h1-4,8,11H,5,10H2,(H,12,13)/t8-/m0/s1	JZKXXXDKRQWDET-QMMMGPOBSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.3005 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							268 °C			1	No	4	3	No	1	0	83.55 Å2	18.06 Å3	47.1 m3·mol-1	3	Yes	No	5.13 mg/mL	-1.5	-1.6	2	9.14	P07101	TH	1. Tyrosine 3-monooxygenase
C7H19N3	Not Available	Not Available	145.2459	NCCCCNCCCN	Solid	Not Available					50009353	16610	CHEMBL19612	1071		GtP Drug Page	HMDB0001257	C00315		SPD			1102	46506086		1483262		Spermidine	ZINC000001532612		Spermidine	Experimental	DB03566	InChI=1S/C7H19N3/c8-4-1-2-6-10-7-3-5-9/h10H,1-9H2	ATHGHQPFGPMSJY-UHFFFAOYSA-N			Not Available	Small Molecule	http://smpdb.ca/view/SMP0000177?highlight[compounds][]=DB03566&highlight[proteins][]=DB03566;!http://smpdb.ca/view/SMP0000033?highlight[compounds][]=DB03566&highlight[proteins][]=DB03566;!http://smpdb.ca/view/SMP0000221?highlight[compounds][]=DB03566&highlight[proteins][]=DB03566;!http://smpdb.ca/view/SMP0000445?highlight[compounds][]=DB03566&highlight[proteins][]=DB03566;!http://smpdb.ca/view/SMP0000214?highlight[compounds][]=DB03566&highlight[proteins][]=DB03566;!http://smpdb.ca/view/SMP0000222?highlight[compounds][]=DB03566&highlight[proteins][]=DB03566;!http://smpdb.ca/view/SMP0000340?highlight[compounds][]=DB03566&highlight[proteins][]=DB03566;!http://smpdb.ca/view/SMP0000341?highlight[compounds][]=DB03566&highlight[proteins][]=DB03566;!http://smpdb.ca/view/SMP0000570?highlight[compounds][]=DB03566&highlight[proteins][]=DB03566	Cystathionine beta-Synthase Deficiency;!Methionine Metabolism;!Methionine Adenosyltransferase Deficiency;!Spermidine and Spermine Biosynthesis;!S-Adenosylhomocysteine (SAH) Hydrolase Deficiency;!Glycine N-Methyltransferase Deficiency;!Methylenetetrahydrofolate Reductase Deficiency (MTHFRD);!Hypermethioninemia;!Homocystinuria-Megaloblastic Anemia Due to Defect in Cobalamin Metabolism, cblG Complementation Type		Non AMES toxic	Ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.4561 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				129 °C at 1.40E+01 mm Hg			< 25 °C			1	No	3	3	No	0	3	64.07 Å2	18.8 Å3	44.97 m3·mol-1	7	Yes	No	32.7 mg/mL	-1.1	-0.65		10.68	P08588;!P07550;!Q16881;!P23181;!P0AFK9	ADRB1;!ADRB2;!TXNRD1;!aacC1;!potD	1. Beta-1 adrenergic receptor;!2. Beta-2 adrenergic receptor;!3. Thioredoxin reductase 1, cytoplasmic;!4. Gentamicin 3'-acetyltransferase;!5. Spermidine/putrescine-binding periplasmic protein
C9H16N2O5	Not Available	Not Available	232.2337	NCCC[C@H](NC(=O)CCC(O)=O)C(O)=O	Solid	Not Available						27574		113025			HMDB0001199	C03415		SUO			127370	46507657							N~2~-Succinylornithine	Experimental	DB03582	InChI=1S/C9H16N2O5/c10-5-1-2-6(9(15)16)11-7(12)3-4-8(13)14/h6H,1-5,10H2,(H,11,12)(H,13,14)(H,15,16)/t6-/m0/s1	VWXQFHJBQHTHMK-LURJTMIESA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.2995 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	4	No	0	-1	129.72 Å2	22.77 Å3	53.55 m3·mol-1	8	Yes	No	19.3 mg/mL	-4.1	-1.1	3.32	9.9	P76216	astB	1. N-succinylarginine dihydrolase
C7H14N2O4	Not Available	Not Available	190.1971	N[C@@H](CCC[C@H](N)C(O)=O)C(O)=O	Solid	Not Available						57609		388416			HMDB0001370	C00666		API			439283	46506904					ZINC000001532712		2,6-Diaminopimelic Acid	Experimental	DB03590	InChI=1S/C7H14N2O4/c8-4(6(10)11)2-1-3-5(9)7(12)13/h4-5H,1-3,8-9H2,(H,10,11)(H,12,13)/t4-,5-/m0/s1	GMKMEZVLHJARHF-WHFBIAKZSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	0.9661 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	4	No	0	0	126.64 Å2	18.93 Å3	43.64 m3·mol-1	6	Yes	No	14.1 mg/mL	-5.5	-1.1	1.85	9.83	P22188;!P04964	murE;!ddh	1. UDP-N-acetylmuramoyl-L-alanyl-D-glutamate--2,6-diaminopimelate ligase;!2. Meso-diaminopimelate D-dehydrogenase
C17H22IN3O6S	Not Available	Not Available	523.343	[H]N([H])[C@@H](CCC(=O)N([H])[C@@H](CSCC1=CC=CC=C1I)C(=O)N([H])CC(O)=O)C(O)=O	Solid	Not Available								394293						IBG			447108	46508001					ZINC000014880825		gamma-Glutamyl[S-(2-iodobenzyl)cysteinyl]glycine	Experimental	DB03597	InChI=1S/C17H22IN3O6S/c18-11-4-2-1-3-10(11)8-28-9-13(16(25)20-7-15(23)24)21-14(22)6-5-12(19)17(26)27/h1-4,12-13H,5-9,19H2,(H,20,25)(H,21,22)(H,23,24)(H,26,27)/t12-,13-/m0/s1	QFYJAEOZTBVJQM-STQMWFEESA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.2538 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	7	5	No	1	-1	158.82 Å2	45.41 Å3	111.79 m3·mol-1	12	No	No	0.0301 mg/mL	-2	-4.2	1.81	9.31	O76074;!Q03013;!O76083	PDE5A;!GSTM4;!PDE9A	1. cGMP-specific 3',5'-cyclic phosphodiesterase;!2. Glutathione S-transferase Mu 4;!3. High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A
C17H23N3O6S	Not Available	Not Available	397.446	[H]N([H])[C@@H](CCC(=O)N([H])[C@@H](CSCC1=CC=CC=C1)C(=O)N([H])CC(O)=O)C(O)=O	Solid	Not Available	P08263	GSTA1	1. Glutathione S-transferase A1					393264						GSB			445707	46507389					ZINC000003874918		S-benzylglutathione	Experimental	DB03602	InChI=1S/C17H23N3O6S/c18-12(17(25)26)6-7-14(21)20-13(16(24)19-8-15(22)23)10-27-9-11-4-2-1-3-5-11/h1-5,12-13H,6-10,18H2,(H,19,24)(H,20,21)(H,22,23)(H,25,26)/t12-,13-/m0/s1	XYJWEQWNNKNSFU-STQMWFEESA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.8241 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	5	No	1	-1	158.82 Å2	40.51 Å3	98.43 m3·mol-1	12	Yes	No	0.116 mg/mL	-2.9	-3.5	1.81	9.31	Q04760;!P08263	GLO1;!GSTA1	1. Lactoylglutathione lyase;!2. Glutathione S-transferase A1
C9H10N2O4	Not Available	Not Available	210.1867	[H]N=C1C=C(C[C@H](N)C(O)=O)C(=O)C=C1O	Solid	Not Available								16744243						TYY			17754209	46505253							3-(4-hydroxy-3-imino-6-oxo-cyclohexa-1,4-dienyl)-alanine	Experimental	DB03631	InChI=1S/C9H10N2O4/c10-5-1-4(2-6(11)9(14)15)7(12)3-8(5)13/h1,3,6,10,13H,2,11H2,(H,14,15)/b10-5-/t6-/m0/s1	FKLZKBKFGLLJJV-HPWAZMHGSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.1675 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	4	No	1	0	124.47 Å2	19.5 Å3	63.84 m3·mol-1	3	Yes	No	0.82 mg/mL	-5.3	-2.4	1.74	9.17	P46883	tynA	1. Primary amine oxidase
C7H9NO2S	Not Available	Not Available	171.217	N[C@@H](CC1=CC=CS1)C(O)=O	Solid	Not Available							CHEMBL1236302	129413						TIH			146719	46504951					ZINC000004141711		beta-2-Thienyl-L-alanine	Experimental	DB03673	InChI=1S/C7H9NO2S/c8-6(7(9)10)4-5-2-1-3-11-5/h1-3,6H,4,8H2,(H,9,10)/t6-/m0/s1	WTOFYLAWDLQMBZ-LURJTMIESA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.0284 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	3	2	No	1	0	63.32 Å2	16.88 Å3	42.12 m3·mol-1	3	Yes	No	1.61 mg/mL	-1.3	-2	2.6	9.27	P00439	PAH	1. Phenylalanine-4-hydroxylase
C17H22N4O8S	Not Available	Not Available	442.444	N[C@@H](CCC(=O)N[C@@H](CSCC1=CC=C(C=C1)[N+]([O-])=O)C(=O)NCC(O)=O)C(O)=O	Solid	Not Available						87407		88035						GTB			97538	46508527					ZINC000003874914		S-(4-nitrobenzyl)glutathione	Experimental	DB03686	InChI=1S/C17H22N4O8S/c18-12(17(26)27)5-6-14(22)20-13(16(25)19-7-15(23)24)9-30-8-10-1-3-11(4-2-10)21(28)29/h1-4,12-13H,5-9,18H2,(H,19,25)(H,20,22)(H,23,24)(H,26,27)/t12-,13-/m0/s1	OAWORKDPTSAMBZ-STQMWFEESA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.5268 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	9	5	No	1	-1	201.96 Å2	43 Å3	104.75 m3·mol-1	13	Yes	No		-3		1.81	9.31	P09211	GSTP1	1. Glutathione S-transferase P
C9H20N3O2	Not Available	Not Available	202.274	CCC\C(N)=N/CCC[C@H]([NH3+])C(O)=O	Solid	Not Available								4451493						VIO			131704256	46504611							[(1S)-4-(1-Aminobutylideneamino)-1-carboxybutyl]azanium	Experimental	DB03710	InChI=1S/C9H19N3O2/c1-2-4-8(11)12-6-3-5-7(10)9(13)14/h7H,2-6,10H2,1H3,(H2,11,12)(H,13,14)/p+1/t7-/m0/s1	KRILJVOCVSUPMA-ZETCQYMHSA-O			Not Available	Small Molecule				AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.0856 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	3	No	0	1	103.32 Å2	22.69 Å3	65.35 m3·mol-1	7	Yes	No		-1.8		2.39	11.81	P29475	NOS1	1. Nitric oxide synthase, brain
C5H13BNO5S	Not Available	Not Available	210.036	[H][C@](N)(CSCC[B-](O)(O)O)C(O)=O	Solid	Not Available								393561						S2C			446122	46504906					ZINC000195757320		S-2-(Boronoethyl)-L-Cysteine	Experimental	DB03731	InChI=1S/C5H13BNO5S/c7-4(5(8)9)3-13-2-1-6(10,11)12/h4,10-12H,1-3,7H2,(H,8,9)/q-1/t4-/m0/s1	XLVRIIJULVQAMP-BYPYZUCNSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.8303 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	5	No	0	-1	124.01 Å2	20.53 Å3	44.1 m3·mol-1	6	Yes	No	1.46 mg/mL	-5.4	-2.2	1.78	9.14	P05089;!P78540	ARG1;!ARG2	1. Arginase-1;!2. Arginase-2, mitochondrial
C8H16O2S2	Not Available	Not Available	208.341	[H][C@](S)(CCS)CCCCC(O)=O	Solid	Not Available					16436	45230	CHEMBL1235647	8010019				C02147		RED			9834298	46508127					ZINC000003869601		Dihydrolipoic Acid	Experimental	DB03760	InChI=1S/C8H16O2S2/c9-8(10)4-2-1-3-7(12)5-6-11/h7,11-12H,1-6H2,(H,9,10)/t7-/m1/s1	IZFHEQBZOYJLPK-SSDOTTSWSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.2957 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	3	No	0	-1	37.3 Å2	23.27 Å3	55.94 m3·mol-1	7	Yes	Yes	0.103 mg/mL	2.2	-3.3	4.91		P23434;!P10515;!Q15120;!Q9WY54	GCSH;!DLAT;!PDK3;!gcvT	1. Glycine cleavage system H protein, mitochondrial;!2. Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial;!3. [Pyruvate dehydrogenase [lipoamide]] kinase isozyme 3, mitochondrial;!4. Aminomethyltransferase
C5H10NO3	Not Available	Not Available	132.1378	[NH3+][C@@H](CCC=O)C(O)=O	Solid	Not Available								4450747									5288620	46506024							Glutamyl Group	Experimental	DB03774	InChI=1S/C5H9NO3/c6-4(5(8)9)2-1-3-7/h3-4H,1-2,6H2,(H,8,9)/p+1/t4-/m0/s1	KABXUUFDPUOJMW-BYPYZUCNSA-O			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.2151 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	3	2	No	0	0	82.01 Å2	12.87 Å3	41.66 m3·mol-1	4	Yes	No	23.7 mg/mL	-3.4	-0.85	2.12	9.11			
C5H11NO4S	Not Available	Not Available	181.21	CS(=O)(=O)CC[C@H](N)C(O)=O	Solid	Not Available						87824	CHEMBL442720	392966						OMT			445282	46507503					ZINC000001691392		L-methionine sulfone	Experimental	DB03790	InChI=1S/C5H11NO4S/c1-11(9,10)3-2-4(6)5(7)8/h4H,2-3,6H2,1H3,(H,7,8)/t4-/m0/s1	UCUNFLYVYCGDHP-BYPYZUCNSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.8765 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	5	2	No	0	0	97.46 Å2	16.88 Å3	39.1 m3·mol-1	4	Yes	No	43.9 mg/mL	-4.5	-0.62	1.55	8.69	P42321	katA	1. Catalase
C3H4F3NO2	Not Available	Not Available	143.0646	[H][C@](N)(C(O)=O)C(F)(F)F	Solid	Not Available								78589						FLA			87123	46504500					ZINC000002047325		Trifluoroalanine	Experimental	DB03794	InChI=1S/C3H4F3NO2/c4-3(5,6)1(7)2(8)9/h1H,7H2,(H,8,9)/t1-/m0/s1	HMJQKIDUCWWIBW-SFOWXEAESA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.1353 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	3	2	No	0	-1	63.32 Å2	8.77 Å3	21.2 m3·mol-1	2	Yes	No	17.6 mg/mL	-1.7	-0.91	1.02	4.73			
C5H8F3NO2S	Not Available	Not Available	203.183	N[C@@H](CCSC(F)(F)F)C(O)=O	Solid	Not Available						43978		144820						MF3			165196	46507751			DNC001467		ZINC000001698833		Trifluoromethionine	Experimental	DB03799	InChI=1S/C5H8F3NO2S/c6-5(7,8)12-2-1-3(9)4(10)11/h3H,1-2,9H2,(H,10,11)/t3-/m0/s1	YLJLTSVBCXYTQK-VKHMYHEASA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.4381 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	3	2	No	0	0	63.32 Å2	15.85 Å3	37.81 m3·mol-1	5	Yes	No	12.8 mg/mL	-0.85	-1.2	1.59	9.5	P00959;!P0AE18	metG;!map	1. Methionine--tRNA ligase;!2. Methionine aminopeptidase
C7H14N2O4	Not Available	Not Available	190.1971	N[C@@H](CCCCNC(O)=O)C(O)=O	Solid	Not Available						43575		16744071						KCX			17754054	46507407					ZINC000006753301		Lysine Nz-Carboxylic Acid	Experimental	DB03801	InChI=1S/C7H14N2O4/c8-5(6(10)11)3-1-2-4-9-7(12)13/h5,9H,1-4,8H2,(H,10,11)(H,12,13)/t5-/m0/s1	PWIKLEYMFKCERQ-YFKPBYRVSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.5244 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	5	4	No	0	-1	112.65 Å2	19.15 Å3	44.11 m3·mol-1	6	Yes	No	13.5 mg/mL	-2.8	-1.2	2.14	9.53	P14489;!P14900;!P10724;!P22188;!P0A433;!P15925;!P05020;!P24941;!Q8VTT5;!P13661;!P81006;!Q45515;!Q70AC7;!P39377;!P0A1V8;!Q9HTQ2;!O25323;!Q7SIE9;!Q9WYE2	bla;!murD;!alr;!murE;!opd;!fgs;!pyrC;!CDK2;!hyuA;!bla;!lhyD;!Not Available;!Not Available;!iadA;!bla;!dadX;!Not Available;!Not Available;!Not Available	1. Beta-lactamase OXA-10;!2. UDP-N-acetylmuramoylalanine--D-glutamate ligase;!3. Alanine racemase;!4. UDP-N-acetylmuramoyl-L-alanyl-D-glutamate--2,6-diaminopimelate ligase;!5. Parathion hydrolase;!6. Folylpolyglutamate synthase;!7. Dihydroorotase;!8. Cyclin-dependent kinase 2;!9. D-hydantoinase;!10. Beta-lactamase OXA-1;!11. L-hydantoinase;!12. D-hydantoinase;!13. Methylmalonyl-CoA carboxyltransferase 5S subunit;!14. Isoaspartyl dipeptidase;!15. Beta-lactamase OXA-2;!16. Alanine racemase, catabolic;!17. Endonuclease III;!18. Hydrolase;!19. Alpha-L-fucosidase, putative
C6H11NO4	Not Available	Not Available	161.1558	[H][C@@](C)(CC(O)=O)[C@]([H])(N)C(O)=O	Solid	Not Available							CHEMBL290744	9587427						LME			11412540	46506110					ZINC000001672629		3-Methylglutamic acid	Experimental	DB03810	InChI=1S/C6H11NO4/c1-3(2-4(8)9)5(7)6(10)11/h3,5H,2,7H2,1H3,(H,8,9)(H,10,11)/t3-,5+/m1/s1	FHJNAFIJPFGZRI-WUJLRWPWSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.1921 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	5	3	No	0	-1	100.62 Å2	14.98 Å3	35.76 m3·mol-1	4	Yes	No	38.1 mg/mL	-2.9	-0.63	2.02	9.6			
C5H9F2NO2S	Not Available	Not Available	185.192	N[C@@H](CCSC(F)F)C(O)=O	Solid	Not Available								394805						2FM			447827	46506881							Difluoromethionine	Experimental	DB03816	InChI=1S/C5H9F2NO2S/c6-5(7)11-2-1-3(8)4(9)10/h3,5H,1-2,8H2,(H,9,10)/t3-/m0/s1	YHBNXKYHZMAFED-VKHMYHEASA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.3926 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	3	2	No	0	0	63.32 Å2	15.77 Å3	37.76 m3·mol-1	5	Yes	No	21.6 mg/mL	-1.1	-0.93	1.95	9.5	P00959	metG	1. Methionine--tRNA ligase
C4H10N2O2	Not Available	Not Available	118.1344	NCC[C@H](N)C(O)=O	Solid	Not Available					92987	48950	CHEMBL321357	118548			HMDB0006284	C03283		DAB			134490	46508539					ZINC000052986906		L-2,4-diaminobutyric acid	Experimental	DB03817	InChI=1S/C4H10N2O2/c5-2-1-3(6)4(7)8/h3H,1-2,5-6H2,(H,7,8)/t3-/m0/s1	OGNSCSPNOLGXSM-VKHMYHEASA-N			Not Available	Small Molecule				AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.2524 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	3	No	0	1	89.34 Å2	11.89 Å3	28.56 m3·mol-1	3	Yes	No	270.0 mg/mL	-4	0.36	2.55	9.95	P12488	env	1. Envelope glycoprotein gp160
C9H11NO3	Not Available	Not Available	181.1885	N[C@H](CC1=CC=C(O)C=C1)C(O)=O	Solid	Not Available						58570	CHEMBL1076637	64252				C06420		DTY			71098	46504669					ZINC000000002234		D-Tyrosine	Experimental	DB03839	InChI=1S/C9H11NO3/c10-8(9(12)13)5-6-1-3-7(11)4-2-6/h1-4,8,11H,5,10H2,(H,12,13)/t8-/m1/s1	OUYCCCASQSFEME-MRVPVSSYSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.2474 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor									453 mg/L (at 25 °C)	1	No	4	3	No	1	0	83.55 Å2	18.06 Å3	47.1 m3·mol-1	3	Yes	No	7.67 mg/mL	-1.5	-1.4	2	9.19			
C6H9NO6	Not Available	Not Available	191.1388	N[C@@H](CC(C(O)=O)C(O)=O)C(O)=O	Solid	Not Available					50076390	61936	CHEMBL38397	94455						CGU			104625	46505246					ZINC000002004603		gamma-carboxy-L-glutamic acid	Experimental	DB03847	InChI=1S/C6H9NO6/c7-3(6(12)13)1-2(4(8)9)5(10)11/h2-3H,1,7H2,(H,8,9)(H,10,11)(H,12,13)/t3-/m0/s1	UHBYWPGGCSDKFX-VKHMYHEASA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.2544 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	4	No	0	-2	137.92 Å2	16.24 Å3	37.58 m3·mol-1	5	Yes	No	22.5 mg/mL	-3.6	-0.93	1.48	9.54	P00734;!P02818;!P00742	F2;!BGLAP;!F10	1. Prothrombin;!2. Osteocalcin;!3. Coagulation factor X
C6H11NO3S	Not Available	Not Available	177.221	CC(=O)CSC[C@H](N)C(O)=O	Solid	Not Available								16743921						CSA			17753922	46505338					ZINC000006761318		S-Acetonylcysteine	Experimental	DB03858	InChI=1S/C6H11NO3S/c1-4(8)2-11-3-5(7)6(9)10/h5H,2-3,7H2,1H3,(H,9,10)/t5-/m0/s1	BYMSHHJFWDLNBG-YFKPBYRVSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.5592 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	2	No	0	0	80.39 Å2	17.76 Å3	42.66 m3·mol-1	5	Yes	No	14.9 mg/mL	-2.9	-1.1	2.16	9.09			
C21H25N3O6S	Not Available	Not Available	447.505	[H]N([H])[C@@H](CCC(=O)N([H])[C@@H](CSCC1=CC=CC2=CC=CC=C12)C(=O)N([H])CC(O)=O)C(O)=O	Solid	Not Available								395998						GGC			449471	46505686					ZINC000012504001		L-gamma-glutamyl-S-(naphthalen-1-ylmethyl)-L-cysteinylglycine	Experimental	DB03885	InChI=1S/C21H25N3O6S/c22-16(21(29)30)8-9-18(25)24-17(20(28)23-10-19(26)27)12-31-11-14-6-3-5-13-4-1-2-7-15(13)14/h1-7,16-17H,8-12,22H2,(H,23,28)(H,24,25)(H,26,27)(H,29,30)/t16-,17-/m0/s1	IHZCIRSQSFPOLH-IRXDYDNUSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.0967 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	5	No	2	-1	158.82 Å2	46.15 Å3	114.88 m3·mol-1	12	Yes	No		-1.9		1.81	9.31			
C17H23BrN4O8S	Not Available	Not Available	523.356	N[C@@H](CCC(=O)N[C@@H](CS[C@H](O)N(O)C1=CC=C(Br)C=C1)C(=O)NCC(O)=O)C(O)=O	Solid	Not Available								25060414						GBP			17753992	46506985					ZINC000058660391		S-(N-hydroxy-N-bromophenylcarbamoyl)glutathione	Experimental	DB03889	InChI=1S/C17H23BrN4O8S/c18-9-1-3-10(4-2-9)22(30)17(29)31-8-12(15(26)20-7-14(24)25)21-13(23)6-5-11(19)16(27)28/h1-4,11-12,17,29-30H,5-8,19H2,(H,20,26)(H,21,23)(H,24,25)(H,27,28)/t11-,12-,17-/m0/s1	OGZMPQOWGQBWAV-PRXAMGSTSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.5080 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	10	7	No	1	-1	202.52 Å2	46.93 Å3	122.92 m3·mol-1	13	No	No		-2		1.77	9.31	Q16775	HAGH	1. Hydroxyacylglutathione hydrolase, mitochondrial
C9H19N4O2	Not Available	Not Available	215.2728	N[C@@H](CCC\[NH+]=C(/N)NCC=C)C(O)=O	Solid	Not Available								4450018						ARV			5287706	46508041							5-N-Allyl-arginine	Experimental	DB03892	InChI=1S/C9H18N4O2/c1-2-5-12-9(11)13-6-3-4-7(10)8(14)15/h2,7H,1,3-6,10H2,(H,14,15)(H3,11,12,13)/p+1/t7-/m0/s1	ZPQWZDPOLXVMOU-ZETCQYMHSA-O			Not Available	Small Molecule				AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.0378 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	5	5	No	0	1	115.34 Å2	23.68 Å3	68.78 m3·mol-1	7	Yes	No		-2.2		2.34	12.02	P29475	NOS1	1. Nitric oxide synthase, brain
C12H21N3O6	Not Available	Not Available	303.3116	[H]N([H])CC(=O)N([H])[C@@H](CCCCC(=O)N([H])[C@H](C)C(O)=O)C(O)=O	Solid	Not Available								393700						REY			446307	46506012					ZINC000003581164		Glycyl-L-alpha-amino-epsilon-pimelyl-D-alanine	Experimental	DB03927	InChI=1S/C12H21N3O6/c1-7(11(18)19)14-9(16)5-3-2-4-8(12(20)21)15-10(17)6-13/h7-8H,2-6,13H2,1H3,(H,14,16)(H,15,17)(H,18,19)(H,20,21)/t7-,8+/m1/s1	ZMQJQOKNTYQVHO-SFYZADRCSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	1.7329 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	5	No	0	-1	158.82 Å2	30.14 Å3	70.59 m3·mol-1	10	Yes	No		-4.3		3.28	8.14	P15555	Not Available	1. D-alanyl-D-alanine carboxypeptidase
C3H7NO3	Not Available	Not Available	105.0926	N[C@H](CO)C(O)=O	Solid	Not Available					23167	16523	CHEMBL285123	64231			HMDB0003406	C00740		DSN			71077	46508200		1742747	DCL000784	Serine	ZINC000000895342		D-Serine	Approved, Experimental	DB03929	InChI=1S/C3H7NO3/c4-2(1-5)3(6)7/h2,5H,1,4H2,(H,6,7)/t2-/m1/s1	MTCFGRXMJLQNBG-UWTATZPHSA-N	4		Not Available	Small Molecule	http://smpdb.ca/view/SMP0000004?highlight[compounds][]=DB03929&highlight[proteins][]=DB03929;!http://smpdb.ca/view/SMP0000248?highlight[compounds][]=DB03929&highlight[proteins][]=DB03929;!http://smpdb.ca/view/SMP0000251?highlight[compounds][]=DB03929&highlight[proteins][]=DB03929;!http://smpdb.ca/view/SMP0000254?highlight[compounds][]=DB03929&highlight[proteins][]=DB03929;!http://smpdb.ca/view/SMP0000293?highlight[compounds][]=DB03929&highlight[proteins][]=DB03929;!http://smpdb.ca/view/SMP0000294?highlight[compounds][]=DB03929&highlight[proteins][]=DB03929;!http://smpdb.ca/view/SMP0000713?highlight[compounds][]=DB03929&highlight[proteins][]=DB03929;!http://smpdb.ca/view/SMP0000730?highlight[compounds][]=DB03929&highlight[proteins][]=DB03929;!http://smpdb.ca/view/SMP0000731?highlight[compounds][]=DB03929&highlight[proteins][]=DB03929;!http://smpdb.ca/view/SMP0000223?highlight[compounds][]=DB03929&highlight[proteins][]=DB03929;!http://smpdb.ca/view/SMP0000244?highlight[compounds][]=DB03929&highlight[proteins][]=DB03929;!http://smpdb.ca/view/SMP0000252?highlight[compounds][]=DB03929&highlight[proteins][]=DB03929;!http://smpdb.ca/view/SMP0000253?highlight[compounds][]=DB03929&highlight[proteins][]=DB03929;!http://smpdb.ca/view/SMP0000258?highlight[compounds][]=DB03929&highlight[proteins][]=DB03929;!http://smpdb.ca/view/SMP0000290?highlight[compounds][]=DB03929&highlight[proteins][]=DB03929;!http://smpdb.ca/view/SMP0000291?highlight[compounds][]=DB03929&highlight[proteins][]=DB03929;!http://smpdb.ca/view/SMP0000292?highlight[compounds][]=DB03929&highlight[proteins][]=DB03929;!http://smpdb.ca/view/SMP0000295?highlight[compounds][]=DB03929&highlight[proteins][]=DB03929;!http://smpdb.ca/view/SMP0000712?highlight[compounds][]=DB03929&highlight[proteins][]=DB03929;!http://smpdb.ca/view/SMP0000714?highlight[compounds][]=DB03929&highlight[proteins][]=DB03929;!http://smpdb.ca/view/SMP0000727?highlight[compounds][]=DB03929&highlight[proteins][]=DB03929;!http://smpdb.ca/view/SMP0000728?highlight[compounds][]=DB03929&highlight[proteins][]=DB03929;!http://smpdb.ca/view/SMP0000729?highlight[compounds][]=DB03929&highlight[proteins][]=DB03929;!http://smpdb.ca/view/SMP0000179?highlight[compounds][]=DB03929&highlight[proteins][]=DB03929;!http://smpdb.ca/view/SMP0000242?highlight[compounds][]=DB03929&highlight[proteins][]=DB03929;!http://smpdb.ca/view/SMP0000247?highlight[compounds][]=DB03929&highlight[proteins][]=DB03929;!http://smpdb.ca/view/SMP0000249?highlight[compounds][]=DB03929&highlight[proteins][]=DB03929;!http://smpdb.ca/view/SMP0000250?highlight[compounds][]=DB03929&highlight[proteins][]=DB03929;!http://smpdb.ca/view/SMP0000255?highlight[compounds][]=DB03929&highlight[proteins][]=DB03929;!http://smpdb.ca/view/SMP0000256?highlight[compounds][]=DB03929&highlight[proteins][]=DB03929	Glycine and Serine Metabolism;!Clarithromycin Action Pathway;!Roxithromycin Action Pathway;!Gentamicin Action Pathway;!Oxytetracycline Action Pathway;!Tetracycline Action Pathway;!Arbekacin Action Pathway;!Troleandomycin Action Pathway;!Josamycin Action Pathway;!Non-Ketotic Hyperglycinemia;!Sarcosinemia;!Telithromycin Action Pathway;!Amikacin Action Pathway;!Spectinomycin Action Pathway;!Demeclocycline Action Pathway;!Doxycycline Action Pathway;!Minocycline Action Pathway;!Lymecycline Action Pathway;!Tigecycline Action Pathway;!Paromomycin Action Pathway;!Methacycline Action Pathway;!Lincomycin Action Pathway;!Chloramphenicol Action Pathway;!Dihydropyrimidine Dehydrogenase Deficiency (DHPD);!Dimethylglycine Dehydrogenase Deficiency;!Azithromycin Action Pathway;!Clindamycin Action Pathway;!Erythromycin Action Pathway;!Kanamycin Action Pathway;!Neomycin Action Pathway		Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.2700 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							229 dec °C		3.64E+005 mg/L (at 20 °C)	1	No	4	3	No	0	0	83.55 Å2	9.39 Å3	22.04 m3·mol-1	2	Yes	No	480.0 mg/mL	-3.9	0.66	2.03	8.93	Q05586;!P23415;!P29508;!P36275	GRIN1;!GLRA1;!SERPINB3;!shp	1. Glutamate receptor ionotropic, NMDA 1;!2. Glycine receptor subunit alpha-1;!3. Serpin B3;!4. Head decoration protein
C4H8N2O3	Not Available	Not Available	132.1179	N[C@H](CC(N)=O)C(O)=O	Solid	Not Available						74337	CHEMBL1232369	388679			HMDB0033780	C01905		DSG			439600	46507204					ZINC000001529313		D-Asparagine	Experimental	DB03943	InChI=1S/C4H8N2O3/c5-2(4(8)9)1-3(6)7/h2H,1,5H2,(H2,6,7)(H,8,9)/t2-/m1/s1	DCXYFEDJOCDNAF-UWTATZPHSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.4003 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	3	No	0	0	106.41 Å2	11.77 Å3	28.35 m3·mol-1	3	Yes	No	168.0 mg/mL	-4.3	0.1	2	8.43			
C6H13N3O2S	Not Available	Not Available	191.251	[H]N([H])[C@@H](CCCN([H])C(=S)N([H])[H])C(O)=O	Solid	Not Available					50095201		CHEMBL93247	2015302						SCI			2733514	46505566					ZINC000003873047		Thiocitrulline	Experimental	DB03953	InChI=1S/C6H13N3O2S/c7-4(5(10)11)2-1-3-9-6(8)12/h4H,1-3,7H2,(H,10,11)(H3,8,9,12)/t4-/m0/s1	BKGWACHYAMTLAF-BYPYZUCNSA-N			Not Available	Small Molecule				AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.9652 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	3	4	No	0	0	101.37 Å2	19.42 Å3	49.32 m3·mol-1	5	Yes	No	3.51 mg/mL	-3	-1.7	2.69	9.23	P35228	NOS2	1. Nitric oxide synthase, inducible
C5H12AsNO2S	Not Available	Not Available	225.141	[H][C@](N)(CS[As](C)C)C(O)=O	Solid	Not Available								25057289						CAS			17753880	46508261							S-(Dimethylarsenic)Cysteine	Experimental	DB03963	InChI=1S/C5H12AsNO2S/c1-6(2)10-3-4(7)5(8)9/h4H,3,7H2,1-2H3,(H,8,9)/t4-/m0/s1	UKLXSOVDMSQHMM-BYPYZUCNSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.1104 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	3	2	No	0	0	63.32 Å2	18.61 Å3	39 m3·mol-1	4	Yes	No	7.58 mg/mL	-2.3	-1.5	1.95	9.14	O60603;!P16753;!P12497;!P29474;!Q9Y678;!P03300;!Q13426;!P0A745	TLR2;!UL80;!gag-pol;!NOS3;!COPG1;!Not Available;!XRCC4;!msrA	1. Toll-like receptor 2;!2. Capsid scaffolding protein;!3. Gag-Pol polyprotein;!4. Nitric oxide synthase, endothelial;!5. Coatomer subunit gamma-1;!6. Genome polyprotein;!7. DNA repair protein XRCC4;!8. Peptide methionine sulfoxide reductase MsrA
C7H16N4O2	Not Available	Not Available	188.2275	N[C@@H](CCCCNC(N)=N)C(O)=O	Solid	Not Available					50309588	27747	CHEMBL589752	8732			HMDB0000670	C01924		HRG			9085	46506308					ZINC000001529320		L-homoarginine	Experimental	DB03974	InChI=1S/C7H16N4O2/c8-5(6(12)13)3-1-2-4-11-7(9)10/h5H,1-4,8H2,(H,12,13)(H4,9,10,11)/t5-/m0/s1	QUOGESRFPZDMMT-YFKPBYRVSA-N			Not Available	Small Molecule				AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	1.7827 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	5	No	0	1	125.22 Å2	20.04 Å3	58.52 m3·mol-1	6	Yes	No	1.58 mg/mL	-2.7	-2.1	2.49	12.3	P29474	NOS3	1. Nitric oxide synthase, endothelial
C9H21N2O2	Not Available	Not Available	189.2752	C[N+](C)(C)CCCC[C@H](N)C(O)=O	Solid	Not Available						17311	CHEMBL1234168	389121						M3L			440121	46505213					ZINC000001529747		Trimethyllysine	Experimental	DB03977	InChI=1S/C9H20N2O2/c1-11(2,3)7-5-4-6-8(10)9(12)13/h8H,4-7,10H2,1-3H3/p+1/t8-/m0/s1	MXNRLFUSFKVQSK-QMMMGPOBSA-O			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.0601 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	3	2	No	0	1	63.32 Å2	21.97 Å3	63.79 m3·mol-1	6	Yes	No	0.233 mg/mL	-6.2	-3	2.41	9.53	P99999;!P0DP23	CYCS;!CALM1	1. Cytochrome c;!2. Calmodulin
C6H16N3O	Not Available	Not Available	146.2107	N[C@@H](CCCC[NH3+])C(N)=O	Solid	Not Available								16744093						LYN			17754068	46506171							2,6-Diamino-Hexanoic Acid Amide	Experimental	DB03988	InChI=1S/C6H15N3O/c7-4-2-1-3-5(8)6(9)10/h5H,1-4,7-8H2,(H2,9,10)/p+1/t5-/m0/s1	HKXLAGBDJVHRQG-YFKPBYRVSA-O			Not Available	Small Molecule				AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.9876 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	2	3	No	0	2	96.75 Å2	16.72 Å3	50.92 m3·mol-1	5	Yes	No	10.4 mg/mL	-1.5	-1.2	16.63	10.21	P18509	ADCYAP1	1. Pituitary adenylate cyclase-activating polypeptide
C10H12N2O3	Not Available	Not Available	208.2139	N[C@@H](CNC(=O)C1=CC=CC=C1)C(O)=O	Solid	Not Available								25056933						DBZ			14233317	46506481							3-(Benzoylamino)-L-Alanine	Experimental	DB03992	InChI=1S/C10H12N2O3/c11-8(10(14)15)6-12-9(13)7-4-2-1-3-5-7/h1-5,8H,6,11H2,(H,12,13)(H,14,15)/t8-/m0/s1	BMHTVISVLHMFTC-QMMMGPOBSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.5247 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	3	No	1	0	92.42 Å2	21.04 Å3	53.81 m3·mol-1	4	Yes	No	2.95 mg/mL	-2.3	-1.8	1.91	8.5			
C6H14N4O2	Not Available	Not Available	174.201	N[C@H](CCCNC(N)=N)C(O)=O	Solid	Not Available						15816	CHEMBL212301	64224			HMDB0003416	C00792		DAR			71070	46506552		1742746		Arginine	ZINC000001532749		D-arginine	Experimental	DB04027	InChI=1S/C6H14N4O2/c7-4(5(11)12)2-1-3-10-6(8)9/h4H,1-3,7H2,(H,11,12)(H4,8,9,10)/t4-/m1/s1	ODKSFYDXXFIFQN-SCSAIBSYSA-N			Not Available	Small Molecule				AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.6259 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	5	No	0	1	125.22 Å2	18.04 Å3	53.92 m3·mol-1	5	Yes	No	2.28 mg/mL	-3.2	-1.9	2.41	12.41	P06732	CKM	1. Creatine kinase M-type
C3H7NO7V	Not Available	Not Available	220.0317	N[C@@H](CO[V](O)([O-])([O-])[O-])C(O)=O	Solid	Not Available								16744213						SVA			17754186	46506158							Serine vanadate	Experimental	DB04031	InChI=1S/C3H6NO3.H2O.3O.V/c4-2(1-5)3(6)7;;;;;/h2H,1,4H2,(H,6,7);1H2;;;;/q-1;;3*-1;+2/p-1/t2-;;;;;/m0...../s1	SYKYEBJDHHGBFL-PUAMRSTPSA-M			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.9914 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	8	3	No	0	0	161.96 Å2	15.65 Å3	27.72 m3·mol-1	4	Yes	No	32.5 mg/mL	-5.8	-0.92	1.25	7.68	P00634	phoA	1. Alkaline phosphatase
C11H13NO2	Not Available	Not Available	191.2264	[H][C@@](N)(C1CC2=CC=CC=C2C1)C(O)=O	Solid	Not Available					50220455		CHEMBL434785	16744052						IGL			12192007	46508579					ZINC000006117201		Alpha-Amino-2-Indanacetic Acid	Experimental	DB04061	InChI=1S/C11H13NO2/c12-10(11(13)14)9-5-7-3-1-2-4-8(7)6-9/h1-4,9-10H,5-6,12H2,(H,13,14)/t10-/m1/s1	GUDHMDVRURNAHL-SNVBAGLBSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.1661 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	3	2	No	2	0	63.32 Å2	20.52 Å3	52.83 m3·mol-1	2	Yes	No	1.9 mg/mL	-0.77	-2	2.4	9.56			
C7H11NO5	Not Available	Not Available	189.1659	CC(=O)N[C@@H](CCC(O)=O)C(O)=O	Solid	Not Available					50151383	17533	CHEMBL1234751	64077				C00624		NLG			70914	46507366					ZINC000001532704		N-Acetyl-L-Glutamate	Experimental	DB04075	InChI=1S/C7H11NO5/c1-4(9)8-5(7(12)13)2-3-6(10)11/h5H,2-3H2,1H3,(H,8,9)(H,10,11)(H,12,13)/t5-/m0/s1	RFMMMVDNIPUKGG-YFKPBYRVSA-N		N-Acetyl-L-Glutamate is a glutamate derivate used to prevent allergic conjunctivitis.	Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.4388 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							199 °C			1	No	5	3	No	0	-2	103.7 Å2	17.44 Å3	40.73 m3·mol-1	5	Yes	No	18.6 mg/mL	-1.1	-1	3.43	-1.8	P0A6C8;!Q9HTN2	argB;!argB	1. Acetylglutamate kinase;!2. Acetylglutamate kinase
C15H28N2O5	Not Available	Not Available	316.3932	[H][C@](O)(CC(O)=O)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCCC(C)C	Solid	Not Available								4450373						E6C			5288147	46505427					ZINC000003874327		N-[1-Hydroxycarboxyethyl-Carbonyl]Leucylamino-2-Methyl-Butane	Experimental	DB04126	InChI=1S/C15H28N2O5/c1-9(2)5-6-16-14(21)11(7-10(3)4)17-15(22)12(18)8-13(19)20/h9-12,18H,5-8H2,1-4H3,(H,16,21)(H,17,22)(H,19,20)/t11-,12-/m0/s1	KBIWEWPGBHKYML-RYUDHWBXSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.0096 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	4	No	0	-1	115.73 Å2	34.67 Å3	80.99 m3·mol-1	10	Yes	No	2.42 mg/mL	0.63	-2.1	4.25	-2.8	P07858;!P09668	CTSB;!CTSH	1. Cathepsin B;!2. Pro-cathepsin H
C16H29N3O6S	Not Available	Not Available	391.483	CCCCCCSC[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)NCC(O)=O	Solid	Not Available	P08263	GSTA1	1. Glutathione S-transferase A1		50095998	27704	CHEMBL345292	88033				C02886		LEE			97536	46505872			DNC001323		ZINC000003874923		S-Hexylglutathione	Experimental	DB04132	InChI=1S/C16H29N3O6S/c1-2-3-4-5-8-26-10-12(15(23)18-9-14(21)22)19-13(20)7-6-11(17)16(24)25/h11-12H,2-10,17H2,1H3,(H,18,23)(H,19,20)(H,21,22)(H,24,25)/t11-,12-/m0/s1	HXJDWCWJDCOHDG-RYUDHWBXSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.1333 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	5	No	0	-1	158.82 Å2	42.03 Å3	96.89 m3·mol-1	15	Yes	No	0.146 mg/mL	-2.4	-3.4	1.81	9.31	Q04760;!Q03013;!P09211;!Q8MU52;!P08263;!P0CG29	GLO1;!GSTM4;!GSTP1;!GST;!GSTA1;!GSTT2	1. Lactoylglutathione lyase;!2. Glutathione S-transferase Mu 4;!3. Glutathione S-transferase P;!4. Glutathione S-transferase;!5. Glutathione S-transferase A1;!6. Glutathione S-transferase theta-2
C11H19N3O7S	Not Available	Not Available	337.349	N[C@@H](CCC(=O)N[C@@H](CSCO)C(=O)NCC(O)=O)C(O)=O	Solid	Not Available						48926		394301			HMDB0004662	C14180		AHE			447123	46507088					ZINC000003870218		S-Hydroxymethyl Glutathione	Experimental	DB04153	InChI=1S/C11H19N3O7S/c12-6(11(20)21)1-2-8(16)14-7(4-22-5-15)10(19)13-3-9(17)18/h6-7,15H,1-5,12H2,(H,13,19)(H,14,16)(H,17,18)(H,20,21)/t6-,7-/m0/s1	PIUSLWSYOYFRFR-BQBZGAKWSA-N			Not Available	Small Molecule				AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.9135 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	8	6	No	0	-1	179.05 Å2	32.23 Å3	75.2 m3·mol-1	11	No	No	5.27 mg/mL	-5.5	-1.8	1.79	9.31	P11766	ADH5	1. Alcohol dehydrogenase class-3
C7H12N2O4	Not Available	Not Available	188.1812	CC(=O)N[C@@H](CCC(N)=O)C(O)=O	Solid	Not Available						21553		158492						NLQ			182230	46508739		1426379		Aceglutamide	ZINC000002019886		Aceglutamide	Experimental	DB04167	InChI=1S/C7H12N2O4/c1-4(10)9-5(7(12)13)2-3-6(8)11/h5H,2-3H2,1H3,(H2,8,11)(H,9,10)(H,12,13)/t5-/m0/s1	KSMRODHGGIIXDV-YFKPBYRVSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.4053 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	3	No	0	-1	109.49 Å2	17.82 Å3	42.55 m3·mol-1	5	Yes	No	21.9 mg/mL	-1.9	-0.93	3.76	-1.4	Q9RYA6	menC	1. N-acylamino acid racemase
C9H17NO6S	Not Available	Not Available	267.299	[H][C@](N)(CCSC[C@@]([H])(O)[C@@]([H])(O)C(=O)CO)C(O)=O	Solid	Not Available								4450788						KRI			5288675	46508110					ZINC000012504198		(S)-2-Amino-4-[(2s,3r)-2,3,5-Trihydroxy-4-Oxo-Pentyl]Mercapto-Butyric Acid	Experimental	DB04182	InChI=1S/C9H17NO6S/c10-5(9(15)16)1-2-17-4-7(13)8(14)6(12)3-11/h5,7-8,11,13-14H,1-4,10H2,(H,15,16)/t5-,7+,8-/m0/s1	QFXXRJSDEMCBPH-ARDNSNSESA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.7225 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	5	No	0	0	141.08 Å2	26.08 Å3	61.13 m3·mol-1	9	Yes	No	21.3 mg/mL	-4.6	-1.1	1.87	9.48	O34667	luxS	1. S-ribosylhomocysteine lyase
C5H11NO2	Not Available	Not Available	117.1463	CCC[C@H](N)C(O)=O	Solid	Not Available					50357215	18314	CHEMBL55612	58608				C01826		NVA			65098	46507762				Norvaline	ZINC000000391821		Norvaline	Experimental	DB04185	InChI=1S/C5H11NO2/c1-2-3-4(6)5(7)8/h4H,2-3,6H2,1H3,(H,7,8)/t4-/m0/s1	SNDPXSYFESPGGJ-BYPYZUCNSA-N		Norvaline is a drug used to treat vaginal inflammation with betamethasone and tyrothricin.	Not Available	Small Molecule																																			1	No	3	2	No	0	0	63.32 Å2	12.51 Å3	29.62 m3·mol-1	3	Yes	No	212.0 mg/mL	-1.9	0.26	2.71	9.53	P50440;!P00480	GATM;!OTC	1. Glycine amidinotransferase, mitochondrial;!2. Ornithine carbamoyltransferase, mitochondrial
C9H18N4O4	Not Available	Not Available	246.2636	NC(=N)NCCC[C@H](NCCC(O)=O)C(O)=O	Solid	Not Available						57304		393816				C06655		CMA			446475	46505010					ZINC000001530510		N(2)-(2-carboxyethyl)-L-arginine	Experimental	DB04189	InChI=1S/C9H18N4O4/c10-9(11)13-4-1-2-6(8(16)17)12-5-3-7(14)15/h6,12H,1-5H2,(H,14,15)(H,16,17)(H4,10,11,13)/t6-/m0/s1	OHWCFZJEIHZWMN-LURJTMIESA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	1.8580 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	8	6	No	0	0	148.53 Å2	25.05 Å3	69.48 m3·mol-1	9	No	No	0.658 mg/mL	-5.5	-2.6	1.72	12.15			
C4H9NO3	Not Available	Not Available	119.1192	N[C@@H](CCO)C(O)=O	Solid	Not Available						15699	CHEMBL11722	12126			HMDB0000719	C00263		HSE			12647	46504898					ZINC000000895146		L-Homoserine	Experimental	DB04193	InChI=1S/C4H9NO3/c5-3(1-2-6)4(7)8/h3,6H,1-2,5H2,(H,7,8)/t3-/m0/s1	UKAUYVFTDYCKQA-VKHMYHEASA-N			Not Available	Small Molecule	http://smpdb.ca/view/SMP0000177?highlight[compounds][]=DB04193&highlight[proteins][]=DB04193;!http://smpdb.ca/view/SMP0000033?highlight[compounds][]=DB04193&highlight[proteins][]=DB04193;!http://smpdb.ca/view/SMP0000221?highlight[compounds][]=DB04193&highlight[proteins][]=DB04193;!http://smpdb.ca/view/SMP0000214?highlight[compounds][]=DB04193&highlight[proteins][]=DB04193;!http://smpdb.ca/view/SMP0000222?highlight[compounds][]=DB04193&highlight[proteins][]=DB04193;!http://smpdb.ca/view/SMP0000340?highlight[compounds][]=DB04193&highlight[proteins][]=DB04193;!http://smpdb.ca/view/SMP0000341?highlight[compounds][]=DB04193&highlight[proteins][]=DB04193;!http://smpdb.ca/view/SMP0000570?highlight[compounds][]=DB04193&highlight[proteins][]=DB04193	Cystathionine beta-Synthase Deficiency;!Methionine Metabolism;!Methionine Adenosyltransferase Deficiency;!S-Adenosylhomocysteine (SAH) Hydrolase Deficiency;!Glycine N-Methyltransferase Deficiency;!Methylenetetrahydrofolate Reductase Deficiency (MTHFRD);!Hypermethioninemia;!Homocystinuria-Megaloblastic Anemia Due to Defect in Cobalamin Metabolism, cblG Complementation Type		Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	0.9205 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							203 dec °C		1E+006 mg/L (at 30 °C)	1	No	4	3	No	0	0	83.55 Å2	11.44 Å3	26.91 m3·mol-1	3	Yes	No	423.0 mg/mL	-3.8	0.55	2.22	9.16			
C11H20N2O6	Not Available	Not Available	276.2863	N[C@@H](CCCCN[C@@H](CCC(O)=O)C(O)=O)C(O)=O	Solid	Not Available						16927		141086			HMDB0000279	C00449		SHR			160556	46505056				Saccharopine	ZINC000001532666		L-Saccharopine	Experimental	DB04207	InChI=1S/C11H20N2O6/c12-7(10(16)17)3-1-2-6-13-8(11(18)19)4-5-9(14)15/h7-8,13H,1-6,12H2,(H,14,15)(H,16,17)(H,18,19)/t7-,8-/m0/s1	ZDGJAHTZVHVLOT-YUMQZZPRSA-N			Not Available	Small Molecule	http://smpdb.ca/view/SMP0000719?highlight[compounds][]=DB04207&highlight[proteins][]=DB04207;!http://smpdb.ca/view/SMP0000186?highlight[compounds][]=DB04207&highlight[proteins][]=DB04207;!http://smpdb.ca/view/SMP0000239?highlight[compounds][]=DB04207&highlight[proteins][]=DB04207;!http://smpdb.ca/view/SMP0000527?highlight[compounds][]=DB04207&highlight[proteins][]=DB04207;!http://smpdb.ca/view/SMP0000037?highlight[compounds][]=DB04207&highlight[proteins][]=DB04207;!http://smpdb.ca/view/SMP0000528?highlight[compounds][]=DB04207&highlight[proteins][]=DB04207;!http://smpdb.ca/view/SMP0000571?highlight[compounds][]=DB04207&highlight[proteins][]=DB04207	2-Aminoadipic 2-Oxoadipic Aciduria;!Glutaric Aciduria Type I;!Saccharopinuria/Hyperlysinemia II;!Hyperlysinemia I, Familial;!Lysine Degradation;!Hyperlysinemia II or Saccharopinuria;!Pyridoxine Dependency with Seizures		Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.1770 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	8	5	No	0	-1	149.95 Å2	28.14 Å3	63.95 m3·mol-1	11	Yes	No	5.25 mg/mL	-5.4	-1.7	1.44	10.89	Q9UDR5	AASS	1. Alpha-aminoadipic semialdehyde synthase, mitochondrial
C4H5NO2	Not Available	Not Available	99.088	N[C@@H](C#C)C(O)=O	Solid	Not Available								152908						LPG			175496	46505992							L-2-amino-3-butynoic acid	Experimental	DB04217	InChI=1S/C4H5NO2/c1-2-3(5)4(6)7/h1,3H,5H2,(H,6,7)/t3-/m0/s1	DSUAJFIEKRKPEE-VKHMYHEASA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.3292 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	3	2	No	0	0	63.32 Å2	9.09 Å3	23.33 m3·mol-1	1	Yes	No	1.5 mg/mL	-3	-1.8	1.66	8.3	P77444;!P32929	sufS;!CTH	1. Cysteine desulfurase;!2. Cystathionine gamma-lyase
C6H13N5O4	Not Available	Not Available	219.1985	N[C@@H](CCCNC(=N)N[N+]([O-])=O)C(O)=O	Solid	Not Available					50225106	27960	CHEMBL227744	389023				C03417		NRG			440005	46508354				Nitroarginine	ZINC000019796052		Nitroarginine	Experimental, Investigational	DB04223	InChI=1S/C6H13N5O4/c7-4(5(12)13)2-1-3-9-6(8)10-11(14)15/h4H,1-3,7H2,(H,12,13)(H3,8,9,10)/t4-/m0/s1	MRAUNPAHJZDYCK-BYPYZUCNSA-N			Not Available	Small Molecule				AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.3722 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	8	5	No	0	1	154.37 Å2	20.19 Å3	59.91 m3·mol-1	6	Yes	No	0.874 mg/mL	-3.8	-2.4	1.9	9.22			
C6H13NO2	Not Available	Not Available	131.1729	[H][C@@](N)(CC)CCC(O)=O	Solid	Not Available								4451492						VIG			5289553	46506258					ZINC000005925575		4-Amino Hexanoic Acid	Experimental	DB04235	InChI=1S/C6H13NO2/c1-2-5(7)3-4-6(8)9/h5H,2-4,7H2,1H3,(H,8,9)/t5-/m1/s1	ROFNJLCLYMMXCT-RXMQYKEDSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.4915 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	3	2	No	0	0	63.32 Å2	14.51 Å3	34.4 m3·mol-1	4	Yes	No	105.0 mg/mL	-1.9	-0.09	4.7	10.47	P80404	ABAT	1. 4-aminobutyrate aminotransferase, mitochondrial
C15H30N5O5	Not Available	Not Available	360.4292	CC(C)C[C@H](NC(=O)[C@@H](O)CC(O)=O)C(=O)NCCCC[NH+]=C(N)N	Solid	Not Available						30270		4450371						E64			5288145	46505123							4-[[(2S)-2-[[(2S)-3-Carboxy-2-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]butyl-(diaminomethylidene)azanium	Experimental	DB04276	InChI=1S/C15H29N5O5/c1-9(2)7-10(20-14(25)11(21)8-12(22)23)13(24)18-5-3-4-6-19-15(16)17/h9-11,21H,3-8H2,1-2H3,(H,18,24)(H,20,25)(H,22,23)(H4,16,17,19)/p+1/t10-,11-/m0/s1	QPQNJAXBPHVASB-QWRGUYRKSA-O			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.4411 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	7	7	No	0	0	181.74 Å2	38.57 Å3	101.66 m3·mol-1	12	No	No	0.52 mg/mL	-3.2	-2.9	3.95	11.28	A0A0H3JWX6;!P07384	srtB;!CAPN1	1. NPQTN specific sortase B;!2. Calpain-1 catalytic subunit
C6H11NO3	Not Available	Not Available	145.1564	[H][C@](N)(CCC(C)=O)C(O)=O	Solid	Not Available								4451108						ONL			5289072	46509131					ZINC000000895890		5-Oxo-L-Norleucine	Experimental	DB04296	InChI=1S/C6H11NO3/c1-4(8)2-3-5(7)6(9)10/h5H,2-3,7H2,1H3,(H,9,10)/t5-/m0/s1	KSIJECNNZVKMJG-YFKPBYRVSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.1688 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	2	No	0	0	80.39 Å2	14.41 Å3	34.84 m3·mol-1	4	Yes	No	91.6 mg/mL	-2.9	-0.2	2.25	9.11	P0AG16	purF	1. Amidophosphoribosyltransferase
C9H9NO5	Not Available	Not Available	211.1715	N[C@@H](CC1=CC(=O)C(O)=CC1=O)C(O)=O	Solid	Not Available						36076		16744234						TPQ			123871	46505126							6-hydroxydopa quinone	Experimental	DB04334	InChI=1S/C9H9NO5/c10-5(9(14)15)1-4-2-7(12)8(13)3-6(4)11/h2-3,5,13H,1,10H2,(H,14,15)/t5-/m0/s1	AGMJSPIGDFKRRO-YFKPBYRVSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.9074 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	3	No	1	-1	117.69 Å2	19.03 Å3	51.37 m3·mol-1	3	Yes	No	2.01 mg/mL	-2.8	-2	1.73	9.03	Q16853;!P46883;!P46881	AOC3;!tynA;!Not Available	1. Membrane primary amine oxidase;!2. Primary amine oxidase;!3. Phenylethylamine oxidase
C5H9NO4S	Clearance information for carbocisteine is not readily available in the literature.	The plasma half-life of carbicostine is 1.33 hours.2	179.194	N[C@@H](CSCC(O)=O)C(O)=O	Solid	Carbocisteine penetrates well into the lung and bronchial secretions.2	Q16878;!P00439;!Q9UNP4	CDO1;!PAH;!ST3GAL5	1. Cysteine dioxygenase type 1;!2. Phenylalanine-4-hydroxylase;!3. Lactosylceramide alpha-2,3-sialyltransferase		50213735	16163	CHEMBL396416	168055				C03727	D00175	CCS			193653	46507988		2023		Carbocisteine	ZINC000001529732		Carbocisteine	Approved, Investigational	DB04339	InChI=1S/C5H9NO4S/c6-3(5(9)10)1-11-2-4(7)8/h3H,1-2,6H2,(H,7,8)(H,9,10)/t3-/m0/s1	GBFLZEXEOZUWRN-VKHMYHEASA-N	4	Carbocisteine is a expectorant mucolytic used in the relief of respiratory of COPD and other conditions associated with increased mucus viscosity.	The oral LD50 of carbocisteine in rats is >15000 mg/kg.15 An overdose with carbocisteine is likely to result in gastrointestinal discomfort with nausea and vomiting.14	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.5786 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				417.3 ± 45.0	-4.24		185-187	1.84	1.6g/L	1	No	5	3	No	0	-1	100.62 Å2	16.69 Å3	39.11 m3·mol-1	5	Yes	No	21.6 mg/mL	-3.3	-0.92	1.84	9.14	Q63HM9;!Q9UNP4	PLCXD3;!ST3GAL5	1. PI-PLC X domain-containing protein 3;!2. Lactosylceramide alpha-2,3-sialyltransferase
C17H22IN3O6S	Not Available	Not Available	523.343	[H]N([H])[C@@H](CCC(=O)N([H])[C@@H](CSCC1=CC(I)=CC=C1)C(=O)N([H])CC(O)=O)C(O)=O	Solid	Not Available								395901						GBI			449342	46508698					ZINC000014881179		S-(3-Iodobenzyl)glutathione	Experimental	DB04341	InChI=1S/C17H22IN3O6S/c18-11-3-1-2-10(6-11)8-28-9-13(16(25)20-7-15(23)24)21-14(22)5-4-12(19)17(26)27/h1-3,6,12-13H,4-5,7-9,19H2,(H,20,25)(H,21,22)(H,23,24)(H,26,27)/t12-,13-/m0/s1	AHWSFXKKIDTZBI-STQMWFEESA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.2179 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	7	5	No	1	-1	158.82 Å2	46.1 Å3	111.79 m3·mol-1	12	No	No	0.03 mg/mL	-2	-4.2	1.81	9.31			
C5H9NO3	Not Available	Not Available	131.1299	N[C@@H](CCC=O)C(O)=O	Solid	Not Available						58066		167744			HMDB0002104	C01165		CAB			193305	46507715					ZINC000001532877		4-Carboxy-4-Aminobutanal	Experimental	DB04388	InChI=1S/C5H9NO3/c6-4(5(8)9)2-1-3-7/h3-4H,1-2,6H2,(H,8,9)/t4-/m0/s1	KABXUUFDPUOJMW-BYPYZUCNSA-N			Not Available	Small Molecule	http://smpdb.ca/view/SMP0000362?highlight[compounds][]=DB04388&highlight[proteins][]=DB04388;!http://smpdb.ca/view/SMP0000504?highlight[compounds][]=DB04388&highlight[proteins][]=DB04388;!http://smpdb.ca/view/SMP0000505?highlight[compounds][]=DB04388&highlight[proteins][]=DB04388;!http://smpdb.ca/view/SMP0000207?highlight[compounds][]=DB04388&highlight[proteins][]=DB04388;!http://smpdb.ca/view/SMP0000208?highlight[compounds][]=DB04388&highlight[proteins][]=DB04388;!http://smpdb.ca/view/SMP0000363?highlight[compounds][]=DB04388&highlight[proteins][]=DB04388;!http://smpdb.ca/view/SMP0000506?highlight[compounds][]=DB04388&highlight[proteins][]=DB04388;!http://smpdb.ca/view/SMP0000020?highlight[compounds][]=DB04388&highlight[proteins][]=DB04388;!http://smpdb.ca/view/SMP0000188?highlight[compounds][]=DB04388&highlight[proteins][]=DB04388;!http://smpdb.ca/view/SMP0000360?highlight[compounds][]=DB04388&highlight[proteins][]=DB04388;!http://smpdb.ca/view/SMP0000361?highlight[compounds][]=DB04388&highlight[proteins][]=DB04388;!http://smpdb.ca/view/SMP0000507?highlight[compounds][]=DB04388&highlight[proteins][]=DB04388	Arginine: Glycine Amidinotransferase Deficiency (AGAT Deficiency);!Creatine Deficiency, Guanidinoacetate Methyltransferase Deficiency;!Hyperornithinemia with Gyrate Atrophy (HOGA);!Prolidase Deficiency (PD);!Prolinemia Type II;!Ornithine Aminotransferase Deficiency (OAT Deficiency);!Hyperornithinemia-Hyperammonemia-Homocitrullinuria [HHH-syndrome];!Arginine and Proline Metabolism;!Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency);!Hyperprolinemia Type II;!Hyperprolinemia Type I;!L-Arginine:Glycine Amidinotransferase Deficiency		Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	0.7661 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	2	No	0	0	80.39 Å2	12.56 Å3	30.36 m3·mol-1	4	Yes	No	144.0 mg/mL	-3.4	0.04	2.12	9.11	Q88K39	ansB	1. Glutaminase-asparaginase
C6H13NO2	Not Available	Not Available	131.1729	CCCC[C@@H](N)C(O)=O	Solid	Not Available						42101		401917						DNE			456468	46507238					ZINC000002034415		D-norleucine	Experimental	DB04419	InChI=1S/C6H13NO2/c1-2-3-4-5(7)6(8)9/h5H,2-4,7H2,1H3,(H,8,9)/t5-/m1/s1	LRQKBLKVPFOOQJ-RXMQYKEDSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.2754 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	3	2	No	0	0	63.32 Å2	14.43 Å3	34.22 m3·mol-1	4	Yes	No	89.2 mg/mL	-1.4	-0.17	2.79	9.53	P00439;!P01270;!P20823	PAH;!PTH;!HNF1A	1. Phenylalanine-4-hydroxylase;!2. Parathyroid hormone;!3. Hepatocyte nuclear factor 1-alpha
C4H9NO2S	Not Available	Not Available	135.185	N[C@@H](CCS)C(O)=O	Solid	Not Available					50242405	58199	CHEMBL469662	82666				C00155		HCS			91552	46507349				Homocysteine	ZINC000000895077		Homocysteine	Experimental	DB04422	InChI=1S/C4H9NO2S/c5-3(1-2-8)4(6)7/h3,8H,1-2,5H2,(H,6,7)/t3-/m0/s1	FFFHZYDWPBMWHY-VKHMYHEASA-N			Not Available	Small Molecule				AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.4790 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	3	3	No	0	0	63.32 Å2	13.54 Å3	32.94 m3·mol-1	3	Yes	No	14.8 mg/mL	-2.6	-0.96	2.46	9.41	O34667;!Q9X112;!Q9WYA5	luxS;!metE;!Not Available	1. S-ribosylhomocysteine lyase;!2. 5-methyltetrahydropteroyltriglutamate--homocysteine methyltransferase;!3. 5-methyltetrahydrofolate S-homocysteine methyltransferase
C11H19N5O2	Not Available	Not Available	253.3009	[H][C@@]12CCCN1C(=O)[C@H](CCCNC(N)=N)NC2=O	Solid	Not Available								395718						ALJ			449095	46505787					ZINC000013584769		Verpacamide A	Experimental	DB04433	InChI=1S/C11H19N5O2/c12-11(13)14-5-1-3-7-10(18)16-6-2-4-8(16)9(17)15-7/h7-8H,1-6H2,(H,15,17)(H4,12,13,14)/t7-,8-/m0/s1	ZRJHYOXNWCMGMW-YUMQZZPRSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.5631 LD50, mol/kg	Inhibitor	Weak inhibitor	Non-inhibitor										1	No	5	4	No	2	1	111.31 Å2	26.68 Å3	75.71 m3·mol-1	4	Yes	No	1.6 mg/mL	-2.1	-2.2	11.27	12.17	P11797	chiB	1. Chitinase B
C4H9NO2	Not Available	Not Available	103.1198	CC[C@@H](N)C(O)=O	Solid	Not Available						28797	CHEMBL553426	388757			HMDB0000650	C02261		DBB			439691	46505337					ZINC000000901329		Alpha-Aminobutyric Acid	Experimental	DB04454	InChI=1S/C4H9NO2/c1-2-3(5)4(6)7/h3H,2,5H2,1H3,(H,6,7)/t3-/m1/s1	QWCKQJZIFLGMSD-GSVOUGTGSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.3782 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	3	2	No	0	0	63.32 Å2	10.38 Å3	25.02 m3·mol-1	2	Yes	No	358.0 mg/mL	-2.3	0.54	2.62	9.53	P50440;!P03369;!P01133;!P43683	GATM;!gag-pol;!EGF;!mrsA	1. Glycine amidinotransferase, mitochondrial;!2. Gag-Pol polyprotein;!3. Pro-epidermal growth factor;!4. Lantibiotic mersacidin
C6H11NO3S	Not Available	Not Available	177.221	[H]C(=O)N[C@@H](CCSC)C(O)=O	Solid	Not Available						16552		388809				C03145		FME			439750	46505840				N-Formylmethionine	ZINC000001529464		N-Formylmethionine	Experimental	DB04464	InChI=1S/C6H11NO3S/c1-11-3-2-5(6(9)10)7-4-8/h4-5H,2-3H2,1H3,(H,7,8)(H,9,10)/t5-/m0/s1	PYUSHNKNPOHWEZ-YFKPBYRVSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.2614 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	2	No	0	-1	66.4 Å2	17.27 Å3	42.54 m3·mol-1	5	Yes	No	9.75 mg/mL	-0.16	-1.3	3.93	-1.4	Q92696;!P53611;!P07173;!P06008;!P06009;!P06010;!P35089;!P35094;!P26789;!P26790;!P01008;!P61769;!P03886;!P01889;!P09152;!P11349;!P11350;!P29377;!P00269;!P13073;!P00395;!P00403;!P00414;!P20674;!P10606;!P09669;!P24311;!P15954;!P10176;!Q02221;!P14854;!P24310;!P23882;!P22629;!P04271;!P0C1V1;!P0CG48;!A5HEI4;!P39300;!P19909;!P0A6W9;!P07998;!Q16740	RABGGTA;!RABGGTB;!pufC;!puhA;!pufL;!pufM;!Not Available;!Not Available;!Not Available;!Not Available;!SERPINC1;!B2M;!MT-ND1;!HLA-B;!narG;!narH;!narI;!S100G;!rub;!COX4I1;!MT-CO1;!MT-CO2;!MT-CO3;!COX5A;!COX5B;!COX6C;!COX7B;!COX7C;!COX8A;!COX6A2;!COX6B1;!COX7A1;!fmt;!Not Available;!S100B;!hld;!UBC;!atpH;!ulaG;!spg;!gshA;!RNASE1;!CLPP	1. Geranylgeranyl transferase type-2 subunit alpha;!2. Geranylgeranyl transferase type-2 subunit beta;!3. Photosynthetic reaction center cytochrome c subunit;!4. Reaction center protein H chain;!5. Reaction center protein L chain;!6. Reaction center protein M chain;!7. Light-harvesting protein B-800/820 alpha chain;!8. Light-harvesting protein B-800/820 beta chain;!9. Light-harvesting protein B-800/850 alpha chain;!10. Light-harvesting protein B-800/850 beta chain;!11. Antithrombin-III;!12. Beta-2-microglobulin;!13. NADH-ubiquinone oxidoreductase chain 1;!14. HLA class I histocompatibility antigen, B-27 alpha chain;!15. Respiratory nitrate reductase 1 alpha chain;!16. Respiratory nitrate reductase 1 beta chain;!17. Respiratory nitrate reductase 1 gamma chain;!18. Protein S100-G;!19. Rubredoxin;!20. Cytochrome c oxidase subunit 4 isoform 1, mitochondrial;!21. Cytochrome c oxidase subunit 1;!22. Cytochrome c oxidase subunit 2;!23. Cytochrome c oxidase subunit 3;!24. Cytochrome c oxidase subunit 5A, mitochondrial;!25. Cytochrome c oxidase subunit 5B, mitochondrial;!26. Cytochrome c oxidase subunit 6C;!27. Cytochrome c oxidase subunit 7B, mitochondrial;!28. Cytochrome c oxidase subunit 7C, mitochondrial;!29. Cytochrome c oxidase subunit 8A, mitochondrial;!30. Cytochrome c oxidase subunit 6A2, mitochondrial;!31. Cytochrome c oxidase subunit 6B1;!32. Cytochrome c oxidase subunit 7A1, mitochondrial;!33. Methionyl-tRNA formyltransferase;!34. Streptavidin;!35. Protein S100-B;!36. Delta-hemolysin;!37. Polyubiquitin-C;!38. AtpH;!39. Probable L-ascorbate-6-phosphate lactonase UlaG;!40. Immunoglobulin G-binding protein G;!41. Glutamate--cysteine ligase;!42. Ribonuclease pancreatic;!43. Putative ATP-dependent Clp protease proteolytic subunit, mitochondrial
C8H18N2O2	Not Available	Not Available	174.2407	NCCCCCC[C@H](N)C(O)=O	Solid	Not Available								25056746						HHK			46936985	46507117					ZINC000012504366		(2s)-2,8-Diaminooctanoic Acid	Experimental	DB04486	InChI=1S/C8H18N2O2/c9-6-4-2-1-3-5-7(10)8(11)12/h7H,1-6,9-10H2,(H,11,12)/t7-/m0/s1	KMPBBRFCAYFTMR-ZETCQYMHSA-N			Not Available	Small Molecule				AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.3627 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	3	No	0	1	89.34 Å2	20.19 Å3	47.01 m3·mol-1	7	Yes	No	11.0 mg/mL	-2.3	-1.2	2.84	10.29			
C7H15NO2	Not Available	Not Available	145.1995	CN[C@H](CC(C)C)C(O)=O	Solid	Not Available								5324040						MLU			6951123	46504834					ZINC000000403026		N-Methylleucine	Experimental	DB04487	InChI=1S/C7H15NO2/c1-5(2)4-6(8-3)7(9)10/h5-6,8H,4H2,1-3H3,(H,9,10)/t6-/m1/s1	XJODGRWDFZVTKW-ZCFIWIBFSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.8401 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	3	2	No	0	0	49.33 Å2	16.09 Å3	38.95 m3·mol-1	4	Yes	No	35.0 mg/mL	-1.4	-0.62	2.42	10.58	P02778	CXCL10	1. C-X-C motif chemokine 10
C7H13N3O4S	Not Available	Not Available	235.261	[H]N([H])C(=NCCS[C@@H](CC(O)=O)C(O)=O)N([H])[H]	Solid	Not Available								393491						GEM			446018	46506328					ZINC000002384679		Guanidinoethylmercaptosuccinic acid	Experimental	DB04489	InChI=1S/C7H13N3O4S/c8-7(9)10-1-2-15-4(6(13)14)3-5(11)12/h4H,1-3H2,(H,11,12)(H,13,14)(H4,8,9,10)/t4-/m0/s1	VKVCLXDFOQQABP-BYPYZUCNSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.9899 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	4	No	0	-1	139 Å2	22.84 Å3	54.23 m3·mol-1	7	Yes	No	2.42 mg/mL	-2.9	-2	3.61	11.65	O75976	CPD	1. Carboxypeptidase D
C4H7NO3	Not Available	Not Available	117.1033	[H][C@@](N)(CC=O)C(O)=O	Solid	Not Available														AS2			49866644	46505846					ZINC000003870023		Aspartate Semialdehyde	Experimental	DB04498	InChI=1S/C4H7NO3/c5-3(1-2-6)4(7)8/h2-3H,1,5H2,(H,7,8)/t3-/m1/s1	HOSWPDPVFBCLSY-GSVOUGTGSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.1351 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	2	No	0	0	80.39 Å2	10.51 Å3	25.61 m3·mol-1	3	Yes	No	225.0 mg/mL	-3.6	0.28	1.95	8.98	P44801	asd	1. Aspartate-semialdehyde dehydrogenase
C9H15NO5S	Not Available	Not Available	249.284	[H][C@](CCSC)(NC(=O)CCC(O)=O)C(O)=O	Solid	Not Available								395339						SMG			448581	46504882					ZINC000002043758		N-Succinyl Methionine	Experimental	DB04511	InChI=1S/C9H15NO5S/c1-16-5-4-6(9(14)15)10-7(11)2-3-8(12)13/h6H,2-5H2,1H3,(H,10,11)(H,12,13)(H,14,15)/t6-/m1/s1	CZFFMUMOBDIXJU-ZCFIWIBFSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.6438 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	3	No	0	-2	103.7 Å2	24.65 Å3	57.92 m3·mol-1	8	Yes	No	2.31 mg/mL	-0.28	-2	3.54	-2	Q44244	Aaar	1. N-acylamino acid racemase
C19H33N3O8S	Not Available	Not Available	463.546	[H]N([H])[C@@H](CCC(=O)N([H])[C@@H](CS[C@@]1([H])C[C@H](O)O[C@@H]1CCCCC)C(=O)N([H])CC(O)=O)C(O)=O	Solid	Not Available								392385						HAG			444455	46506521					ZINC000031976570		4-S-Glutathionyl-5-pentyl-tetrahydro-furan-2-ol	Experimental	DB04521	InChI=1S/C19H33N3O8S/c1-2-3-4-5-13-14(8-17(26)30-13)31-10-12(18(27)21-9-16(24)25)22-15(23)7-6-11(20)19(28)29/h11-14,17,26H,2-10,20H2,1H3,(H,21,27)(H,22,23)(H,24,25)(H,28,29)/t11-,12-,13+,14-,17+/m0/s1	ICRIFHIWWXQBPY-JEJJNBGPSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3527 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	9	6	No	1	-1	188.28 Å2	48.67 Å3	110.91 m3·mol-1	15	No	No	0.594 mg/mL	-2.8	-2.9	1.8	9.31	Q16772	GSTA3	1. Glutathione S-transferase A3
C3H8NO6P	Not Available	Not Available	185.0725	N[C@@H](COP(O)(O)=O)C(O)=O	Solid	Not Available					17664	15811	CHEMBL284377	62074		GtP Drug Page	HMDB0000272	C01005		SEP			68841	46505297					ZINC000003869280		Dexfosfoserine	Experimental	DB04522	InChI=1S/C3H8NO6P/c4-2(3(5)6)1-10-11(7,8)9/h2H,1,4H2,(H,5,6)(H2,7,8,9)/t2-/m0/s1	BZQFBWGGLXLEPQ-REOHCLBHSA-N		Dexfosfoserine is an amino acid used for nutritional supplementation therapy in over-fatigue states.	Not Available	Small Molecule	http://smpdb.ca/view/SMP0000004?highlight[compounds][]=DB04522&highlight[proteins][]=DB04522;!http://smpdb.ca/view/SMP0000223?highlight[compounds][]=DB04522&highlight[proteins][]=DB04522;!http://smpdb.ca/view/SMP0000244?highlight[compounds][]=DB04522&highlight[proteins][]=DB04522;!http://smpdb.ca/view/SMP0000179?highlight[compounds][]=DB04522&highlight[proteins][]=DB04522;!http://smpdb.ca/view/SMP0000242?highlight[compounds][]=DB04522&highlight[proteins][]=DB04522;!http://smpdb.ca/view/SMP0000484?highlight[compounds][]=DB04522&highlight[proteins][]=DB04522;!http://smpdb.ca/view/SMP0000485?highlight[compounds][]=DB04522&highlight[proteins][]=DB04522;!http://smpdb.ca/view/SMP0000721?highlight[compounds][]=DB04522&highlight[proteins][]=DB04522	Glycine and Serine Metabolism;!Non-Ketotic Hyperglycinemia;!Sarcosinemia;!Dihydropyrimidine Dehydrogenase Deficiency (DHPD);!Dimethylglycine Dehydrogenase Deficiency;!Dimethylglycine Dehydrogenase Deficiency;!Hyperglycinemia, Non-Ketotic;!3-Phosphoglycerate Dehydrogenase Deficiency		Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.8397 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	4	No	0	-2	130.08 Å2	13.97 Å3	32.91 m3·mol-1	4	Yes	No	19.9 mg/mL	-3.2	-0.97	1.2	9.39	O15530;!P11309;!Q04759;!P06737;!P26276;!P11217;!P17612;!O32723;!P02974;!P00634;!P08100;!P29508;!P51584;!Q9UL54;!Q03721;!P05451;!Q15796;!O31465;!P25924;!P07515;!P13569	PDPK1;!PIM1;!PRKCQ;!PYGL;!algC;!PYGM;!PRKACA;!spoIIAA;!pilE1;!phoA;!RHO;!SERPINB3;!xynY;!TAOK2;!KCNC4;!REG1A;!SMAD2;!glsA1;!cysG;!ptsH;!CFTR	1. 3-phosphoinositide-dependent protein kinase 1;!2. Serine/threonine-protein kinase pim-1;!3. Protein kinase C theta type;!4. Glycogen phosphorylase, liver form;!5. Phosphomannomutase/phosphoglucomutase;!6. Glycogen phosphorylase, muscle form;!7. cAMP-dependent protein kinase catalytic subunit alpha;!8. Anti-sigma F factor antagonist;!9. Fimbrial protein;!10. Alkaline phosphatase;!11. Rhodopsin;!12. Serpin B3;!13. Endo-1,4-beta-xylanase Y;!14. Serine/threonine-protein kinase TAO2;!15. Potassium voltage-gated channel subfamily C member 4;!16. Lithostathine-1-alpha;!17. Mothers against decapentaplegic homolog 2;!18. Glutaminase 1;!19. Siroheme synthase;!20. Phosphocarrier protein HPr;!21. Cystic fibrosis transmembrane conductance regulator
C5H11NO3S2	Not Available	Not Available	197.276	N[C@@H](CSSCCO)C(O)=O	Solid	Not Available						74104		148678						CME			170018	46504681							S,S-(2-Hydroxyethyl)Thiocysteine	Experimental	DB04530	InChI=1S/C5H11NO3S2/c6-4(5(8)9)3-11-10-2-1-7/h4,7H,1-3,6H2,(H,8,9)/t4-/m0/s1	YPUBRSXDQSFQBA-BYPYZUCNSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.9468 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	3	No	0	0	83.55 Å2	19.35 Å3	47.38 m3·mol-1	6	Yes	No	36.0 mg/mL	-3.2	-0.74	2.04	9.04	P0A884;!Q07343;!P04818;!P17612;!P11309;!P05089;!P00722;!P39126;!P36952;!P0AEX9;!P0ACB2;!P9WH11;!Q01064;!O60493;!P39805;!Q99418	thyA;!PDE4B;!TYMS;!PRKACA;!PIM1;!ARG1;!lacZ;!icd;!SERPINB5;!malE;!hemB;!rmlC;!PDE1B;!SNX3;!licT;!CYTH2	1. Thymidylate synthase;!2. cAMP-specific 3',5'-cyclic phosphodiesterase 4B;!3. Thymidylate synthase;!4. cAMP-dependent protein kinase catalytic subunit alpha;!5. Serine/threonine-protein kinase pim-1;!6. Arginase-1;!7. Beta-galactosidase;!8. Isocitrate dehydrogenase [NADP];!9. Serpin B5;!10. Maltose-binding periplasmic protein;!11. Delta-aminolevulinic acid dehydratase;!12. dTDP-4-dehydrorhamnose 3,5-epimerase;!13. Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B;!14. Sorting nexin-3;!15. Transcription antiterminator LicT;!16. Cytohesin-2
C10H13NO2S	Not Available	Not Available	211.281	N[C@@H](CSCC1=CC=CC=C1)C(O)=O	Solid	Not Available					50213728	145803	CHEMBL63130	168022						BCS			193613	46508797					ZINC000000404298		S-Benzylcysteine	Experimental	DB04531	InChI=1S/C10H13NO2S/c11-9(10(12)13)7-14-6-8-4-2-1-3-5-8/h1-5,9H,6-7,11H2,(H,12,13)/t9-/m0/s1	GHBAYRBVXCRIHT-VIFPVBQESA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.1261 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	3	2	No	1	0	63.32 Å2	22.67 Å3	57.54 m3·mol-1	5	Yes	No	1.07 mg/mL	-0.78	-2.3	2.42	9.14	P16455	MGMT	1. Methylated-DNA--protein-cysteine methyltransferase
C6H13BNO5	Not Available	Not Available	189.982	N[C@@H](CC\C=C\[B-](O)(O)O)C(O)=O	Solid	Not Available								571290						2BH			657085	46507630					ZINC000169748487		DEHYDRO-2(S)-AMINO-6-BORONOHEXANOIC ACID	Experimental	DB04585	InChI=1S/C6H13BNO5/c8-5(6(9)10)3-1-2-4-7(11,12)13/h2,4-5,11-13H,1,3,8H2,(H,9,10)/q-1/b4-2+/t5-/m0/s1	CCCYGXMAMSUXAV-FYTLMZHYSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.9085 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	5	No	0	-1	124.01 Å2	19 Å3	41.47 m3·mol-1	5	Yes	No	1.17 mg/mL	-5	-2.2	1.84	9.52	P05089	ARG1	1. Arginase-1
C9H18N2O3	Not Available	Not Available	202.2508	CC(C)(C)OC(=O)[C@@H](N)CCC(N)=O	Solid	Not Available								4450081						BGT			5287779	46505589					ZINC000053683597		Glutamine t-butyl ester	Experimental	DB04636	InChI=1S/C9H18N2O3/c1-9(2,3)14-8(13)6(10)4-5-7(11)12/h6H,4-5,10H2,1-3H3,(H2,11,12)/t6-/m0/s1	VVOPSEUXHSUTJS-LURJTMIESA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.1233 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	3	2	No	0	1	95.41 Å2	21.46 Å3	51.68 m3·mol-1	6	Yes	No	14.4 mg/mL	-0.54	-1.2	16.46	7.18	Q16769	QPCT	1. Glutaminyl-peptide cyclotransferase
C9H19N4O4S	Not Available	Not Available	279.337	N[C@@H](CS\C(N)=N\CCC[C@H]([NH3+])C(O)=O)C(O)=O	Solid	Not Available								25057775						CYR			131704288	46505175							[(1S)-4-[[Amino-[(2R)-2-amino-2-carboxyethyl]sulfanylmethylidene]amino]-1-carboxybutyl]azanium	Experimental	DB04671	InChI=1S/C9H18N4O4S/c10-5(7(14)15)2-1-3-13-9(12)18-4-6(11)8(16)17/h5-6H,1-4,10-11H2,(H2,12,13)(H,14,15)(H,16,17)/p+1/t5-,6-/m0/s1	FBDBZWJNHYXEKT-WDSKDSINSA-O			Not Available	Small Molecule																																			1	No	7	5	No	0	1	166.64 Å2	28.41 Å3	78.03 m3·mol-1	9	Yes	No	0.535 mg/mL	-5.5	-2.8	1.86	9.73	P13981	arcA	1. Arginine deiminase
C10H17N3O8S	Not Available	Not Available	339.322	N[C@@H](CCC(=O)N[C@@H](C[S@](O)=O)C(=O)NCC(O)=O)C(O)=O	Solid	Not Available								4484237						GSF			5326960	46506088					ZINC000012504471		GLUTATHIONE SULFINATE	Experimental	DB04700	InChI=1S/C10H17N3O8S/c11-5(10(18)19)1-2-7(14)13-6(4-22(20)21)9(17)12-3-8(15)16/h5-6H,1-4,11H2,(H,12,17)(H,13,14)(H,15,16)(H,18,19)(H,20,21)/t5-,6-/m0/s1	DMAPAHUEYHXRFI-WDSKDSINSA-N			Not Available	Small Molecule				AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.2108 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	9	6	No	0	-2	196.12 Å2	30.78 Å3	69.88 m3·mol-1	10	No	No	16.3 mg/mL	-5.9	-1.3	1.31	9.31	Q9Y2Q3	GSTK1	1. Glutathione S-transferase kappa 1
C11H19N3O6S	Not Available	Not Available	321.35	CSC[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)NCC(O)=O	Solid	Not Available					225232	141473	CHEMBL1233129	103128				C11347		GSM			115260	46507560					ZINC000001532230		S-Methyl glutathione	Experimental	DB04701	InChI=1S/C11H19N3O6S/c1-21-5-7(10(18)13-4-9(16)17)14-8(15)3-2-6(12)11(19)20/h6-7H,2-5,12H2,1H3,(H,13,18)(H,14,15)(H,16,17)(H,19,20)/t6-,7-/m0/s1	QTQDDTSVRVWHMO-BQBZGAKWSA-N			Not Available	Small Molecule	http://smpdb.ca/view/SMP0000501?highlight[compounds][]=DB04701&highlight[proteins][]=DB04701;!http://smpdb.ca/view/SMP0000183?highlight[compounds][]=DB04701&highlight[proteins][]=DB04701;!http://smpdb.ca/view/SMP0000500?highlight[compounds][]=DB04701&highlight[proteins][]=DB04701;!http://smpdb.ca/view/SMP0000015?highlight[compounds][]=DB04701&highlight[proteins][]=DB04701;!http://smpdb.ca/view/SMP0000143?highlight[compounds][]=DB04701&highlight[proteins][]=DB04701;!http://smpdb.ca/view/SMP0000337?highlight[compounds][]=DB04701&highlight[proteins][]=DB04701	gamma-Glutamyltranspeptidase Deficiency;!gamma-Glutamyltransferase Deficiency;!5-Oxoprolinase Deficiency;!Glutathione Metabolism;!5-Oxoprolinuria;!Glutathione Synthetase Deficiency		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.7868 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	5	No	0	-1	158.82 Å2	31.25 Å3	73.77 m3·mol-1	10	Yes	No	2.61 mg/mL	-4.5	-2.1	1.81	9.31	P28161	GSTM2	1. Glutathione S-transferase Mu 2
C4H10N2O2	Not Available	Not Available	118.1344	C[C@@H](N)[C@@H](N)C(O)=O	Solid	Not Available								25059111						VDL			14221359	46504536					ZINC000095483612		D-Erythro-2,3-diaminobutyric acid	Experimental	DB04802	InChI=1S/C4H10N2O2/c1-2(5)3(6)4(7)8/h2-3H,5-6H2,1H3,(H,7,8)/t2-,3-/m1/s1	SXGMVGOVILIERA-PWNYCUMCSA-N			Not Available	Small Molecule																																			1	No	4	3	No	0	0	89.34 Å2	11.48 Å3	28.12 m3·mol-1	2	Yes	No	289.0 mg/mL	-3.6	0.39	2.22	9.78			
C4H10N2O2	Not Available	Not Available	118.1344	C[C@@H](N)[C@H](N)C(O)=O	Solid	Not Available								9248543						VLL			11073394	46508875					ZINC000095483610		(2S)-2,3-Diaminobutanoic acid	Experimental	DB04804	InChI=1S/C4H10N2O2/c1-2(5)3(6)4(7)8/h2-3H,5-6H2,1H3,(H,7,8)/t2-,3+/m1/s1	SXGMVGOVILIERA-GBXIJSLDSA-N			Not Available	Small Molecule																																			1	No	4	3	No	0	0	89.34 Å2	11.64 Å3	28.12 m3·mol-1	2	Yes	No	289.0 mg/mL	-3.6	0.39	2.22	9.78			
C11H19N3O7S	Not Available	Not Available	337.349	NC(CCC(=O)NC(CSCO)C(=O)NCC(O)=O)C(O)=O	Solid	Not Available								1052									1082	175427006							LJP 1082	Investigational	DB05446	InChI=1S/C11H19N3O7S/c12-6(11(20)21)1-2-8(16)14-7(4-22-5-15)10(19)13-3-9(17)18/h6-7,15H,1-5,12H2,(H,13,19)(H,14,16)(H,17,18)(H,20,21)	PIUSLWSYOYFRFR-UHFFFAOYSA-N			Not Available	Small Molecule				AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.9135 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	8	6	No	0	-1	179.05 Å2	32.24 Å3	75.2 m3·mol-1	11	No	No	5.27 mg/mL	-5.5	-1.8	1.79	9.31	P02749	APOH	1. Beta-2-glycoprotein 1
C16H19N3O5	Not Available	Not Available	333.3392	N[C@H](CCC(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(O)=O)C(O)=O	Solid	Not Available							CHEMBL2103812	5360288									6992140	175427014		2367440			ZINC000001549362		Golotimod	Investigational	DB05475	InChI=1S/C16H19N3O5/c17-11(15(21)22)5-6-14(20)19-13(16(23)24)7-9-8-18-12-4-2-1-3-10(9)12/h1-4,8,11,13,18H,5-7,17H2,(H,19,20)(H,21,22)(H,23,24)/t11-,13+/m1/s1	CATMPQFFVNKDEY-YPMHNXCESA-N	2		No adverse effects were observed in any patients participating in clinical trials.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.6624 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	5	No	2	-1	145.51 Å2	33.36 Å3	84.29 m3·mol-1	8	Yes	No	0.347 mg/mL	-2	-3	1.98	9.31	O60603;!O00206;!Q9NYK1;!Q9NR96	TLR2;!TLR4;!TLR7;!TLR9	1. Toll-like receptor 2;!2. Toll-like receptor 4;!3. Toll-like receptor 7;!4. Toll-like receptor 9
C3H7N3O4	Not Available	Not Available	149.1054	N[C@@H](CN(O)N=O)C(O)=O	Solid	Not Available							CHEMBL452715	20787						AL0			22128	8166290				Alanosine	ZINC000004214744		Alanosine	Investigational	DB05540	InChI=1S/C3H7N3O4/c4-2(3(7)8)1-6(10)5-9/h2,10H,1,4H2,(H,7,8)/t2-/m0/s1	MLFKVJCWGUZWNV-REOHCLBHSA-N	2		Not Available	Small Molecule				AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.1600 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	3	No	0	0	116.22 Å2	11.94 Å3	30.7 m3·mol-1	4	Yes	No		-3.6		1.5	8.67	P0A786;!P30520;!Q8N142	pyrB;!ADSS;!ADSSL1	1. Aspartate carbamoyltransferase catalytic chain;!2. Adenylosuccinate synthetase isozyme 2;!3. Adenylosuccinate synthetase isozyme 1
C12H19N3O6	Not Available	Not Available	301.299	[H]N([H])CC(=O)N1CCC[C@H]1C(=O)N([H])[C@@H](CCC(O)=O)C(O)=O	Solid	Not Available							CHEMBL371315	2338502															ZINC000003776571		Glypromate	Investigational	DB05633	InChI=1S/C12H19N3O6/c13-6-9(16)15-5-1-2-8(15)11(19)14-7(12(20)21)3-4-10(17)18/h7-8H,1-6,13H2,(H,14,19)(H,17,18)(H,20,21)/t7-,8-/m0/s1	JJGBXTYGTKWGAT-YUMQZZPRSA-N			Not Available	Small Molecule																																			1	No	7	4	No	1	-1	150.03 Å2	28.23 Å3	69.08 m3·mol-1	7	Yes	No	14.7 mg/mL	-4.9	-1.3	3.2	7.83			
C13H21N3O6	Not Available	Not Available	315.326	C[C@]1(CCCN1C(=O)CN)C(=O)N[C@@H](CCC(O)=O)C(O)=O	Solid	Not Available							CHEMBL197084	9493869														Trofinetide			Trofinetide	Investigational	DB06045	InChI=1S/C13H21N3O6/c1-13(5-2-6-16(13)9(17)7-14)12(22)15-8(11(20)21)3-4-10(18)19/h8H,2-7,14H2,1H3,(H,15,22)(H,18,19)(H,20,21)/t8-,13-/m0/s1	BUSXWGRAOZQTEY-SDBXPKJASA-N	3		Not Available	Small Molecule																																			1	No	7	4	No	1	-1	150.03 Å2	30.95 Å3	73.79 m3·mol-1	7	Yes	No	10.4 mg/mL	-4.5	-1.5	3.27	7.83			
C5H9NO3S	Acetylcysteine has a mean clearance of 0.11 L/hr/kg.15	The mean terminal half life of acetylcysteine in adults is 5.6 hours15 and in pre-term neonates is 11 hours.2	163.195	CC(=O)N[C@@H](CS)C(O)=O	Solid	The volume of distribution of acetylcysteine is 0.47 L/kg.15	Q03154	ACY1	1. Aminoacylase-1		50420190	28939	CHEMBL600	11540	Drugs.com Drug Page		HMDB0001890	C06809	D00221	SC2		PA448033	12035	99443235	RxList Drug Page	197	DNC000981	Acetylcysteine	ZINC000003589203	Acetadote	Acetylcysteine	Approved, Investigational	DB06151	InChI=1S/C5H9NO3S/c1-3(7)6-4(2-10)5(8)9/h4,10H,2H2,1H3,(H,6,7)(H,8,9)/t4-/m0/s1	PWKSKIMOESPYIA-BYPYZUCNSA-N	4	Acetylcysteine is a medication that can be used as a mucolytic in patients with certain lung conditions and as an antidote for acetaminophen overdose.	Patients experiencing an overdose may present with vomiting, nausea, bronchospasm, periorbital angioedema, and hypotension.3 Treat patients with symptomatic and supportive measures.15 Hemodialysis may remove some acetylcysteine from circulation as it is somewhat protein bound.15	Small Molecule																																109-110	9.52 (at 25 °C)		1	No	3	3	No	0	-1	66.4 Å2	15.34 Å3	37.67 m3·mol-1	3	Yes	No	5.09 mg/mL	-0.71	-1.5	3.82	-2	P48637;!Q9UPY5;!BMOL0000027;!Q03154;!O14920;!O15111;!Q13224;!Q05586;!Q12879;!O15399;!Q8TCU5	GSS;!SLC7A11;!;!ACY1;!IKBKB;!CHUK;!GRIN2B;!GRIN1;!GRIN2A;!GRIN2D;!GRIN3A	1. Glutathione synthetase;!2. Cystine/glutamate transporter;!3. NAPQI (N-acetyl-p-benzoquinone imine);!4. Aminoacylase-1;!5. Inhibitor of nuclear factor kappa-B kinase subunit beta;!6. Inhibitor of nuclear factor kappa-B kinase subunit alpha;!7. Glutamate receptor ionotropic, NMDA 2B;!8. Glutamate receptor ionotropic, NMDA 1;!9. Glutamate receptor ionotropic, NMDA 2A;!10. Glutamate receptor ionotropic, NMDA 2D;!11. Glutamate receptor ionotropic, NMDA 3A
C12H22AsN3O6S	Not Available	Not Available	411.3	C[As](C)SC[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)NCC(O)=O	Solid	Not Available						94295	CHEMBL3247378	9857733																	Darinaparsin	Investigational	DB06179	InChI=1S/C12H22AsN3O6S/c1-13(2)23-6-8(11(20)15-5-10(18)19)16-9(17)4-3-7(14)12(21)22/h7-8H,3-6,14H2,1-2H3,(H,15,20)(H,16,17)(H,18,19)(H,21,22)/t7-,8-/m0/s1	JGDXFQORBMPJGR-YUMQZZPRSA-N	2		Not Available	Small Molecule																																			1	No	7	5	No	0	-1	158.82 Å2	36.38 Å3	79.89 m3·mol-1	11	Yes	No	1.4 mg/mL	-4.4	-2.5	1.5	9.31			
C6H10N2O5	The apparent total clearance was 5.7 L/min (range 3.0-9.7), the renal clearance was 290 mL/min (range 204-445), and the 24-hour urinary excretion was 4.5 % of the dose (range 3.5-7.5).	Median values for the terminal half-life was 5.6 hours (range 4.3-9.5).	190.154	NC(=O)N[C@@H](CCC(O)=O)C(O)=O	Solid	The apparent volume of distribution was 2657 L (range: 1616-5797).						71028	CHEMBL1201780	108351	Drugs.com Drug Page		HMDB0015673	C05829	D07130			PA165958402	121396	99443290	RxList Drug Page	401713		Carglumic_acid	ZINC000001530283	Carbaglu	Carglumic acid	Approved	DB06775	InChI=1S/C6H10N2O5/c7-6(13)8-3(5(11)12)1-2-4(9)10/h3H,1-2H2,(H,9,10)(H,11,12)(H3,7,8,13)/t3-/m0/s1	LCQLHJZYVOQKHU-VKHMYHEASA-N	3	Carglumic acid is an analog of N-acetylglutamate (NAG) used for the treatment of acute and chronic hyperammonemia in patients with N-acetylglutamate synthase (NAGS) deficiency.	LD50, oral, mouse: >1000 mg/kg	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.3576 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					-1.097					1	No	5	4	No	0	-2	129.72 Å2	16.79 Å3	39.41 m3·mol-1	5	Yes	No	19.1 mg/mL	-1.4	-1	3.36	-2.3	P31327	CPS1	1. Carbamoyl-phosphate synthase [ammonia], mitochondrial
C9H17NO4	Not Available	Not Available	203.2356	[H][C@@](CC(C)C)(NC(=O)OCC)C(O)=O	Solid	Not Available								8807335						0AG			10631973	99443310							N-(ethoxycarbonyl)-L-leucine	Experimental	DB06839	InChI=1S/C9H17NO4/c1-4-14-9(13)10-7(8(11)12)5-6(2)3/h6-7H,4-5H2,1-3H3,(H,10,13)(H,11,12)/t7-/m0/s1	WJYLMMNPQWEDQG-ZETCQYMHSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.9782 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	2	No	0	-1	75.63 Å2	21.35 Å3	49.99 m3·mol-1	6	Yes	No	12.6 mg/mL	1.47	-1.2	4.07				
C18H20N2O4	Not Available	Not Available	328.3624	[H][C@](N)(CCC(=O)NC1=CC=C(OCC2=CC=CC=C2)C=C1)C(O)=O	Solid	Not Available					24256		CHEMBL478381	24699373						4BQ			24768560	99443573					ZINC000024975367		(2S)-2-amino-5-oxo-5-[(4-phenylmethoxyphenyl)amino]pentanoic acid	Experimental	DB07102	InChI=1S/C18H20N2O4/c19-16(18(22)23)10-11-17(21)20-14-6-8-15(9-7-14)24-12-13-4-2-1-3-5-13/h1-9,16H,10-12,19H2,(H,20,21)(H,22,23)/t16-/m0/s1	BYSBXIPCDJNEBG-INIZCTEOSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.9744 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	3	No	2	0	101.65 Å2	34.76 Å3	90.64 m3·mol-1	8	Yes	No	0.0094 mg/mL	-0.19	-4.5	1.86	9.31			
C13H13NO2	Not Available	Not Available	215.2478	N[C@@H](CC1=CC=CC2=C1C=CC=C2)C(O)=O	Solid	Not Available								2006998						ALN			2724883	99443836					ZINC000000391807		1-Naphthyl-L-alanine	Experimental	DB07365	InChI=1S/C13H13NO2/c14-12(13(15)16)8-10-6-3-5-9-4-1-2-7-11(9)10/h1-7,12H,8,14H2,(H,15,16)/t12-/m0/s1	OFYAYGJCPXRNBL-LBPRGKRZSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.0648 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	2	No	2	0	63.32 Å2	22.6 Å3	61.57 m3·mol-1	3	Yes	No	0.221 mg/mL	-0.19	-3	2.61	9.42	P06202;!P16088	oppA;!pol	1. Periplasmic oligopeptide-binding protein;!2. Pol polyprotein
C10H19NO4	Not Available	Not Available	217.2622	[H][C@@](CCO)(NC(=O)CCCCC)C(O)=O	Solid	Not Available								24778570						C6L			24860535	99444003							N-hexanoyl-L-homoserine	Experimental	DB07532	InChI=1S/C10H19NO4/c1-2-3-4-5-9(13)11-8(6-7-12)10(14)15/h8,12H,2-7H2,1H3,(H,11,13)(H,14,15)/t8-/m0/s1	BJLILZXVIKTHKQ-QMMMGPOBSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.8852 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	3	No	0	-1	86.63 Å2	23.71 Å3	54.78 m3·mol-1	8	Yes	No	11.2 mg/mL	0.29	-1.3	4.14	-1.3			
C16H31NO3	Not Available	Not Available	285.4222	[H]N([H])[C@@H](CC1CCCCC1)[C@@H](O)C[C@@H](CC(C)C)C(O)=O	Solid	Not Available								4883334						CAL			6323244	99444013					ZINC000033626079		5-Amino-6-cyclohexyl-4-hydroxy-2-isobutyl-hexanoic acid	Experimental	DB07542	InChI=1S/C16H31NO3/c1-11(2)8-13(16(19)20)10-15(18)14(17)9-12-6-4-3-5-7-12/h11-15,18H,3-10,17H2,1-2H3,(H,19,20)/t13-,14+,15+/m1/s1	INCRGCAIRMMQQJ-ILXRZTDVSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.9636 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	3	No	1	0	83.55 Å2	33.72 Å3	79.84 m3·mol-1	8	Yes	No	0.198 mg/mL	0.74	-3.2	4.56	9.87	P07339	CTSD	1. Cathepsin D
C15H29NO3	Not Available	Not Available	271.3957	[H][C@](N)(CC1CCCCC1)[C@@]([H])(O)C[C@@]([H])(C(C)C)C(O)=O	Solid	Not Available								4450227						CPV			5287976	99444052					ZINC000033821259		5-AMINO-6-CYCLOHEXYL-4-HYDROXY-2-ISOPROPYL-HEXANOIC ACID	Experimental	DB07581	InChI=1S/C15H29NO3/c1-10(2)12(15(18)19)9-14(17)13(16)8-11-6-4-3-5-7-11/h10-14,17H,3-9,16H2,1-2H3,(H,18,19)/t12-,13-,14-/m0/s1	SRFUYEFGHOTBHV-IHRRRGAJSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.9466 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	3	No	1	0	83.55 Å2	31.84 Å3	75.24 m3·mol-1	7	Yes	No	0.389 mg/mL	0.3	-2.8	4.52	9.87	P04584	gag-pol	1. Gag-Pol polyprotein
C10H19NO3S	Not Available	Not Available	233.328	[H][C@@](CCS)(NC(=O)CCCCC)C(O)=O	Solid	Not Available								25057702						CYK			24860536	99444074					ZINC000053683103		N-hexanoyl-L-homocysteine	Experimental	DB07603	InChI=1S/C10H19NO3S/c1-2-3-4-5-9(12)11-8(6-7-15)10(13)14/h8,15H,2-7H2,1H3,(H,11,12)(H,13,14)/t8-/m0/s1	HAUWXQBEWNVHPD-QMMMGPOBSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.9169 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	3	No	0	-1	66.4 Å2	25.63 Å3	60.81 m3·mol-1	8	Yes	No	1.15 mg/mL	1.54	-2.3	4.25	-1.3			
C12H25NO2S	Not Available	Not Available	247.397	[H][C@](N)(CSCCCCCCCCC)C(O)=O	Solid	Not Available								25057718						GT9			46937099	99444320							S-NONYL-CYSTEINE	Experimental	DB07849	InChI=1S/C12H25NO2S/c1-2-3-4-5-6-7-8-9-16-10-11(13)12(14)15/h11H,2-10,13H2,1H3,(H,14,15)/t11-/m0/s1	NYQGIUKEPYHDNY-NSHDSACASA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.5770 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	2	No	0	0	63.32 Å2	30.63 Å3	69.8 m3·mol-1	11	Yes	No	0.0263 mg/mL	1.04	-4	2.51	9.14	P09211	GSTP1	1. Glutathione S-transferase P
C8H17NOS2	Not Available	Not Available	207.357	[H][C@](S)(CCS)CCCCC(N)=O	Solid	Not Available						43711		392881						LPM			445160	99444591					ZINC000003869863		6,8-DIMERCAPTO-OCTANOIC ACID AMIDE	Experimental	DB08120	InChI=1S/C8H17NOS2/c9-8(10)4-2-1-3-7(12)5-6-11/h7,11-12H,1-6H2,(H2,9,10)/t7-/m1/s1	VLYUGYAKYZETRF-SSDOTTSWSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.3238 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	1	3	No	0	0	43.09 Å2	23.64 Å3	57.76 m3·mol-1	7	Yes	No	0.0753 mg/mL	1.4	-3.4	9.82	-1.4	P10802	Not Available	1. Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex
C11H20N2O3	Not Available	Not Available	228.2881	OC(=O)CCCNC(=O)NC1CCCCC1	Solid	Not Available					50192936		CHEMBL219695	4925684						NC4			6420119	99444728					ZINC000008754389		4-{[(CYCLOHEXYLAMINO)CARBONYL]AMINO}BUTANOIC ACID	Experimental	DB08257	InChI=1S/C11H20N2O3/c14-10(15)7-4-8-12-11(16)13-9-5-2-1-3-6-9/h9H,1-8H2,(H,14,15)(H2,12,13,16)	WSVFRGGLURJIMG-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.5478 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	3	No	1	-1	78.43 Å2	25.23 Å3	59.49 m3·mol-1	5	Yes	No	0.809 mg/mL	0.89	-2.4	4.32	-0.62			
C13H24N2O3	Not Available	Not Available	256.3413	OC(=O)CCCCCNC(=O)NC1CCCCC1	Solid	Not Available					50192966		CHEMBL434374	4925685						NC6			6420120	99444729					ZINC000013493677		6-{[(CYCLOHEXYLAMINO)CARBONYL]AMINO}HEXANOIC ACID	Experimental	DB08258	InChI=1S/C13H24N2O3/c16-12(17)9-5-2-6-10-14-13(18)15-11-7-3-1-4-8-11/h11H,1-10H2,(H,16,17)(H2,14,15,18)	KFTVEPYSUSWBRD-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.5478 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	3	No	1	-1	78.43 Å2	29.51 Å3	68.69 m3·mol-1	7	Yes	No	0.574 mg/mL	1.78	-2.6	4.39	-0.62			
C14H26N2O3	Not Available	Not Available	270.3678	OC(=O)CCCCCCNC(=O)NC1CCCCC1	Solid	Not Available								4925686						NC7			6420121	99444730					ZINC000013493757		7-{[(CYCLOHEXYLAMINO)CARBONYL]AMINO}HEPTANOIC ACID	Experimental	DB08259	InChI=1S/C14H26N2O3/c17-13(18)10-6-1-2-7-11-15-14(19)16-12-8-4-3-5-9-12/h12H,1-11H2,(H,17,18)(H2,15,16,19)	GYTIWWDVOFXKPF-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.5478 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	3	No	1	-1	78.43 Å2	31.61 Å3	73.29 m3·mol-1	8	Yes	No	0.231 mg/mL	2.22	-3.1	4.49	-0.62	P34913	EPHX2	1. Bifunctional epoxide hydrolase 2
C16H17NO4	Not Available	Not Available	287.3105	[H][C@@](N)(C[C@]([H])(CC1=CC2=CC=CC=C2C=C1)C(O)=O)C(O)=O	Solid	Not Available					50118891		CHEMBL435982	7993122						NHL			9817372	99444743					ZINC000013491561		(4S)-4-(2-NAPHTHYLMETHYL)-D-GLUTAMIC ACID	Experimental	DB08272	InChI=1S/C16H17NO4/c17-14(16(20)21)9-13(15(18)19)8-10-5-6-11-3-1-2-4-12(11)7-10/h1-7,13-14H,8-9,17H2,(H,18,19)(H,20,21)/t13-,14+/m0/s1	YDWIUFASTTZKNI-UONOGXRCSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.8397 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	3	No	2	-1	100.62 Å2	30 Å3	77.01 m3·mol-1	6	Yes	No	0.0901 mg/mL	-0.14	-3.5	2.19	9.53	Q9A1B7	murI	1. Glutamate racemase
C10H12BrNO2S	Not Available	Not Available	290.177	[H][C@](N)(CSCC1=CC=C(Br)C=C1)C(O)=O	Solid	Not Available								4451141						PBB			5289112	99444841							S-(4-BROMOBENZYL)CYSTEINE	Experimental	DB08370	InChI=1S/C10H12BrNO2S/c11-8-3-1-7(2-4-8)5-15-6-9(12)10(13)14/h1-4,9H,5-6,12H2,(H,13,14)/t9-/m0/s1	QZGWXEMBSFZEBK-VIFPVBQESA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.4896 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	2	No	1	0	63.32 Å2	26.15 Å3	65.16 m3·mol-1	5	Yes	No	0.0533 mg/mL	-0.016	-3.7	1.46	9.14	P09211	GSTP1	1. Glutathione S-transferase P
C9H15NO5	Not Available	Not Available	217.2191	[H][C@@](CCC)(NC(=O)CCC(O)=O)C(O)=O	Solid	Not Available								5254643						SN0			6852189	99445025							N-(3-carboxypropanoyl)-L-norvaline	Experimental	DB08554	InChI=1S/C9H15NO5/c1-2-3-6(9(14)15)10-7(11)4-5-8(12)13/h6H,2-5H2,1H3,(H,10,11)(H,12,13)(H,14,15)/t6-/m0/s1	HRAPDLBXHOBAKA-LURJTMIESA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.7519 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	3	No	0	-2	103.7 Å2	21.3 Å3	49.96 m3·mol-1	7	Yes	No	9.55 mg/mL	0.032	-1.4	3.64	-2	Q5LI27;!Q8P8J2	Not Available;!argF'	1. Putative ornithine carbamoyltransferase;!2. N-acetylornithine carbamoyltransferase
C13H17N5OS	Not Available	Not Available	291.372	N[C@@H](CCCNC(N)=N)C(=O)C1=NC2=CC=CC=C2S1	Solid	Not Available					50420340	45993	CHEMBL2089125	26330359						THZ			46937165	99445095					ZINC000053683253		1-[(4S)-4-amino-5-(1,3-benzothiazol-2-yl)-5-oxopentyl]guanidine	Experimental	DB08624	InChI=1S/C13H17N5OS/c14-8(4-3-7-17-13(15)16)11(19)12-18-9-5-1-2-6-10(9)20-12/h1-2,5-6,8H,3-4,7,14H2,(H4,15,16,17)/t8-/m0/s1	MAJHCCQPIDXPAN-QMMMGPOBSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	2.5910 LD50, mol/kg	Inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	6	4	No	2	2	117.88 Å2	30.44 Å3	88.29 m3·mol-1	6	Yes	No	0.13 mg/mL	0.78	-3.4	17.79	12	P00734;!P35869	F2;!AHR	1. Prothrombin;!2. Aryl hydrocarbon receptor
C11H16N2O8	Not Available	Not Available	304.255	CC(=O)N[C@@H](CC(=O)N[C@@H](CCC(O)=O)C(O)=O)C(O)=O	Solid	Not Available						135289	CHEMBL2105616	182277	Drugs.com Drug Page				D07374				210320	175427113				N-Acetylaspartylglutamic_acid	ZINC000002504638		Spaglumic acid	Experimental	DB08835	InChI=1S/C11H16N2O8/c1-5(14)12-7(11(20)21)4-8(15)13-6(10(18)19)2-3-9(16)17/h6-7H,2-4H2,1H3,(H,12,14)(H,13,15)(H,16,17)(H,18,19)(H,20,21)/t6-,7-/m0/s1	GUCKKCMJTSNWCU-BQBZGAKWSA-N	4	Spaglumic acid is the β-aspartyl isoform of N-Acetyl-l-aspartylglutamate, a naturally occurring neurotransmitter, used in allergic eye conditions due to its ability to stabilize mast cells.	Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.7395 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	8	5	No	0	-3	170.1 Å2	27.37 Å3	64.06 m3·mol-1	9	Yes	No	3.22 mg/mL	-2.3	-2	3.01	-2	Q04609	FOLH1	1. Glutamate carboxypeptidase 2
C5H14N4	Not Available	Not Available	130.1915	NCCCCNC(N)=N	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4		85213	17431	CHEMBL58343	194			HMDB0001432	C00179		AG2			199	175427116				Agmatine	ZINC000001532560		Agmatine	Experimental	DB08838	InChI=1S/C5H14N4/c6-3-1-2-4-9-5(7)8/h1-4,6H2,(H4,7,8,9)	QYPPJABKJHAVHS-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.7458 LD50, mol/kg	Inhibitor	Weak inhibitor	Non-inhibitor							234-238 degress Celcius			1	No	4	4	No	0	2	87.92 Å2	15.01 Å3	48.09 m3·mol-1	4	Yes	No	3.61 mg/mL	-1.2	-1.6		12.61	P18825;!Q9Y2I1;!P02708;!Q05586;!P48048;!Q00975;!Q9UHC3	ADRA2C;!NISCH;!CHRNA1;!GRIN1;!KCNJ1;!CACNA1B;!ASIC3	1. Alpha-2C adrenergic receptor;!2. Nischarin;!3. Acetylcholine receptor subunit alpha;!4. Glutamate receptor ionotropic, NMDA 1;!5. ATP-sensitive inward rectifier potassium channel 1;!6. Voltage-dependent N-type calcium channel subunit alpha-1B;!7. Acid-sensing ion channel 3
C5H11NO2Se	Not Available	Not Available	192.071	C[75Se]CC[C@H](N)C(O)=O	Not Available	Not Available							CHEMBL1201054	59637												9133					Selenomethionine Se-75	Approved	DB09400	InChI=1S/C5H11NO2Se/c1-9-3-2-4(6)5(7)8/h4H,2-3,6H2,1H3,(H,7,8)/t4-/m0/s1/i9-4	RJFAYQIBOAGBLC-ZEMBQCNESA-N			Not Available	Small Molecule																																			1	No	4	2	No	0	0	63.32 Å2	14.64 Å3	42.91 m3·mol-1	4	Yes	No	109.0 mg/mL	-3.3	-0.25	1.56	9.5			
C18H24N2O5	The disposition of enalaprilat in patients with renal insufficiency is similar to that in patients with normal renal function until the glomerular filtration rate is 30 mL/min or less. Renal clearance was 158 ± 47 ml/min.	11 hr	348.3936	[H][C@@](C)(N[C@@]([H])(CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@@]1([H])C(O)=O	Not Available	Not Available					50367254	4786	CHEMBL577	4575429			HMDB0041886	C11720	D03769	EAL			5462501	347827859	RxList Drug Page	3829		Enalaprilat	ZINC000003812851		Enalaprilat	Approved	DB09477	InChI=1S/C18H24N2O5/c1-12(16(21)20-11-5-8-15(20)18(24)25)19-14(17(22)23)10-9-13-6-3-2-4-7-13/h2-4,6-7,12,14-15,19H,5,8-11H2,1H3,(H,22,23)(H,24,25)/t12-,14-,15-/m0/s1	LZFZMUMEGBBDTC-QEJZJMRPSA-N	4	Enalaprilat is an antihypertensive agent used for the management of hypertension when oral therapy is not practical.	Adverse experiences occurring in 0.5 to 1.0 percent of patients in controlled clinical trials included: myocardial infarction, fatigue, dizziness, fever, rash and constipation.Angioedema has also been reported in patients receiving enalaprilat, with an incidence higher in black than in non-black patients. Angioedema associated with laryngeal edema may be fatal. If angioedema of the face, extremities, lips, tongue, glottis and/or larynx occurs, treatment with enalaprilat should be discontinued and appropriate therapy instituted immediately . Rarer adverse effects that are less likely, but should be monitored for, include development of anaphylaxis, hypotension, agranulocytosis, hepatic failure, hyperkalemia, and persistent cough. Furthermore, ACE inhibitors should be avoided during pregnancy as they can cause fetal and neonatal morbidity and death. When pregnancy is detected, ACE inhibitors should be discontinued as soon as possible. Use during the second and third trimesters of pregnancy has been associated with fetal and neonatal injury, including hypotension, neonatal skull hypoplasia, anuria, reversible or irreversible renal failure, and death.	Small Molecule																																			1	No	6	3	No	2	-1	106.94 Å2	35.82 Å3	90.06 m3·mol-1	8	Yes	No	0.876 mg/mL	-1.1	-2.6	3.13	7.83	P12821;!P46663	ACE;!BDKRB1	1. Angiotensin-converting enzyme;!2. B1 bradykinin receptor
C5H11NO2Se	Not Available	Not Available	196.11	C[Se]CC[C@H](N)C(O)=O	Not Available	Not Available						62621	CHEMBL113178	94765				C05335		MSE			105024	347827917		9644		Selenomethionine			Selenomethionine	Approved, Investigational	DB11142	InChI=1S/C5H11NO2Se/c1-9-3-2-4(6)5(7)8/h4H,2-3,6H2,1H3,(H,7,8)/t4-/m0/s1	RJFAYQIBOAGBLC-BYPYZUCNSA-N	3		Not Available	Small Molecule																																			1	No	4	2	No	0	0	63.32 Å2	14.64 Å3	42.91 m3·mol-1	4	Yes	No	109.0 mg/mL	-3.3	-0.25	1.56	9.5			
C8H17FeN3O6S2	Not Available	Not Available	371.2	[Fe++].NCC(O)=O.[H][C@](N)(CS)C(O)=O.[H][C@](N)(C[S-])C([O-])=O	Not Available	Not Available								34987810												1490797				EnBrace HR, EnLyte	Ferrous cysteine glycinate	Approved	DB11197	InChI=1S/2C3H7NO2S.C2H5NO2.Fe/c2*4-2(1-7)3(5)6;3-1-2(4)5;/h2*2,7H,1,4H2,(H,5,6);1,3H2,(H,4,5);/q;;;+2/p-2/t2*2-;;/m00../s1	NIBOCUPOPAKNJE-NVKWYWNSSA-L		Ferrous cysteine glycinate is an ingredient found in a variety of supplements and vitamins.	Not Available	Small Molecule																																			1	No	3	1	No	0	0	66.15 Å2	10.67 Å3	39.8 m3·mol-1	5	Yes	No	23.1 mg/mL	-2.8	-0.72	2.35	9.05			
C14H24N6O4	Not Available	Prezatide is rapidly eliminated within minutes 5.	340.384	NCCCC[C@H](NC(=O)[C@H](CC1=CNC=N1)NC(=O)CN)C(O)=O	Solid	Not Available					50350478	75430	CHEMBL1814493	66263									73587	347827962		1368533			ZINC000013507674		Prezatide	Experimental	DB11296	InChI=1S/C14H24N6O4/c15-4-2-1-3-10(14(23)24)20-13(22)11(19-12(21)6-16)5-9-7-17-8-18-9/h7-8,10-11H,1-6,15-16H2,(H,17,18)(H,19,21)(H,20,22)(H,23,24)/t10-,11-/m0/s1	MVORZMQFXBLMHM-QWRGUYRKSA-N			Not Available	Small Molecule																																			0	No	7	6	No	1	1	176.22 Å2	34.52 Å3	84.91 m3·mol-1	11	No	No	3.14 mg/mL	-5.1	-2	3.46	10.2			
C7H16N4O2	Not Available	Not Available	188.2275	CNC(=N)NCCC[C@H](N)C(O)=O	Not Available	Not Available					92900	60257	CHEMBL256147	117259			HMDB0029416	C03884		NMM			132862	347828162				Methylarginine	ZINC000001529776		Tilarginine	Approved, Investigational	DB11815	InChI=1S/C7H16N4O2/c1-10-7(9)11-4-2-3-5(8)6(12)13/h5H,2-4,8H2,1H3,(H,12,13)(H3,9,10,11)/t5-/m0/s1	NTNWOCRCBQPEKQ-YFKPBYRVSA-N	4		Not Available	Small Molecule																																			1	No	6	5	No	0	1	111.23 Å2	19.79 Å3	58.7 m3·mol-1	5	Yes	No	1.45 mg/mL	-2.9	-2.1	2.48	12.64			
C8H15N3O4	Not Available	Not Available	217.225	C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(O)=O	Not Available	Not Available						74387	CHEMBL3707366	110464									123935	347828213		1359422			ZINC000002504612		Alanyl glutamine	Investigational	DB11876	InChI=1S/C8H15N3O4/c1-4(9)7(13)11-5(8(14)15)2-3-6(10)12/h4-5H,2-3,9H2,1H3,(H2,10,12)(H,11,13)(H,14,15)/t4-,5-/m0/s1	HJCMDXDYPOUFDY-WHFBIAKZSA-N	4	Alanyl glutamine is a dipeptide consisting of alanine and glutamine used for supplementation.	Not Available	Small Molecule																																			1	No	5	4	No	0	0	135.51 Å2	20.97 Å3	50.41 m3·mol-1	6	Yes	No	12.7 mg/mL	-4.5	-1.2	3.57	8.39			
C25H47N9O5	Not Available	Not Available	553.709	CC[C@H](C)C(NC(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(N)=O	Not Available	Not Available							CHEMBL3545314										71722017	347828216							Dusquetide	Investigational	DB11879	InChI=1S/C25H47N9O5/c1-6-14(4)19(33-21(36)16(26)9-7-11-30-25(28)29)23(38)32-18(13(2)3)24(39)34-12-8-10-17(34)22(37)31-15(5)20(27)35/h13-19H,6-12,26H2,1-5H3,(H2,27,35)(H,31,37)(H,32,38)(H,33,36)(H4,28,29,30)/t14-,15-,16-,17-,18-,19?/m0/s1	ZUJBBVJXXYRPFS-OUROWQTJSA-N	2		Not Available	Small Molecule																																			0	No	9	8	No	1	2	238.62 Å2	59.37 Å3	155.22 m3·mol-1	15	No	No	0.0992 mg/mL	-2.4	-3.8	12.21	11.74			
C7H13NO3S2	Not Available	Not Available	223.31	CC(C)(S)C(=O)N[C@@H](CS)C(O)=O	Not Available	Not Available					50406934	31312	CHEMBL80830	570965								PA166123566	656604	347828452				Bucillamine	ZINC000000020222		Bucillamine	Investigational	DB12160	InChI=1S/C7H13NO3S2/c1-7(2,13)6(11)8-4(3-12)5(9)10/h4,12-13H,3H2,1-2H3,(H,8,11)(H,9,10)/t4-/m0/s1	VUAFHZCUKUDDBC-BYPYZUCNSA-N	3		Not Available	Small Molecule																																			1	Yes	3	4	No	0	-1	66.4 Å2	22.09 Å3	54.7 m3·mol-1	4	Yes	No		0.52		3.97	-3.8			
C8H17N3O2S	Not Available	Not Available	219.3	CC(=N)NCCSCC[C@H](N)C(O)=O	Not Available	Not Available					50086467		CHEMBL114551	7972783									9797017	347828516					ZINC000002004483		GW-274150	Investigational	DB12237	InChI=1S/C8H17N3O2S/c1-6(9)11-3-5-14-4-2-7(10)8(12)13/h7H,2-5,10H2,1H3,(H2,9,11)(H,12,13)/t7-/m0/s1	MOLOJNHYNHBPCW-ZETCQYMHSA-N	2		Not Available	Small Molecule																																			1	No	5	4	No	0	1	99.2 Å2	24.11 Å3	67.65 m3·mol-1	7	Yes	No	1.55 mg/mL	-2.7	-2.2	2.15	12.6			
C7H14N2O3	Not Available	Not Available	174.1977	CCNC(=O)CC[C@H](N)C(O)=O	Not Available	Not Available						58128	CHEMBL3039113	388498			HMDB0034365	C01047		85G			439378	347828685		38022		Theanine	ZINC000001532828		Theanine	Investigational	DB12444	InChI=1S/C7H14N2O3/c1-2-9-6(10)4-3-5(8)7(11)12/h5H,2-4,8H2,1H3,(H,9,10)(H,11,12)/t5-/m0/s1	DATAGRPVKZEWHA-YFKPBYRVSA-N	2		Not Available	Small Molecule																																			1	No	4	3	No	0	0	92.42 Å2	17.85 Å3	42.76 m3·mol-1	5	Yes	No	48.3 mg/mL	-3.4	-0.56	2.35	9.31			
C17H37N7O3	Not Available	Not Available	387.529	NCCCNCCCCNC(=O)C(O)NC(=O)CCCCCCNC(N)=N	Not Available	Not Available						135609	CHEMBL406117	49995									55362	347828893				Gusperimus			Gusperimus	Investigational	DB12692	InChI=1S/C17H37N7O3/c18-9-7-11-21-10-5-6-12-22-15(26)16(27)24-14(25)8-3-1-2-4-13-23-17(19)20/h16,21,27H,1-13,18H2,(H,22,26)(H,24,25)(H4,19,20,23)	IDINUJSAMVOPCM-UHFFFAOYSA-N	2		Not Available	Small Molecule																																			0	No	8	8	No	0	3	178.38 Å2	44.43 Å3	115.75 m3·mol-1	17	No	No	0.129 mg/mL	-3.1	-3.5	11.37	12.28			
C4H9NO2Se	Not Available	Not Available	182.08	C[Se]C[C@H](N)C(O)=O	Not Available	Not Available						27812	CHEMBL62382	129633			HMDB0004113	C05689					147004	347828898				Methylselenocysteine			Methylselenocysteine	Investigational	DB12697	InChI=1S/C4H9NO2Se/c1-8-2-3(5)4(6)7/h3H,2,5H2,1H3,(H,6,7)/t3-/m0/s1	XDSSPSLGNGIIHP-VKHMYHEASA-N	1		Not Available	Small Molecule																																			1	No	4	2	No	0	0	63.32 Å2	12.89 Å3	38.2 m3·mol-1	3	Yes	No	156.0 mg/mL	-3.5	-0.07	1.46	8.4			
C7H15N5O4	Not Available	Not Available	233.228	COC(=O)[C@@H](N)CCCNC(=N)N[N+]([O-])=O	Not Available	Not Available					50098937	7549	CHEMBL7890	36427				C04337					39836	347828939					ZINC000015987659		N-omega-nitro-L-arginine methyl ester	Investigational	DB12750	InChI=1S/C7H15N5O4/c1-16-6(13)5(8)3-2-4-10-7(9)11-12(14)15/h5H,2-4,8H2,1H3,(H3,9,10,11)/t5-/m0/s1	KCWZGJVSDFYRIX-YFKPBYRVSA-N	2		Not Available	Small Molecule																																			1	No	7	4	No	0	1	143.37 Å2	22.35 Å3	64.67 m3·mol-1	7	Yes	No	0.698 mg/mL	-1.2	-2.5	10.95	8.03			
C16H23N3O4	Not Available	Not Available	321.377	CCOC(=O)C1=CC=C(OC(=O)CCCCCNC(N)=N)C=C1	Solid	Not Available	P07477;!P09871;!P00736	PRSS1;!C1S;!C1R	1. Trypsin-1;!2. Complement C1s subcomponent;!3. Complement C1r subcomponent		50104435	93036	CHEMBL87563	3329									3447	347828997				Gabexate	ZINC000002002226		Gabexate	Investigational	DB12831	InChI=1S/C16H23N3O4/c1-2-22-15(21)12-7-9-13(10-8-12)23-14(20)6-4-3-5-11-19-16(17)18/h7-10H,2-6,11H2,1H3,(H4,17,18,19)	YKGYIDJEEQRWQH-UHFFFAOYSA-N		Gabexate is a protease inhibitor indicated in the treatment of acute pancreatitis.	LD50 of 6480mg/kg observed in rats.MSDS	Small Molecule																																			1	Yes	5	3	No	1	1	114.5 Å2	35.67 Å3	96.7 m3·mol-1	11	Yes	No	0.109 mg/mL	2.1	-3.5		12.13	P03952;!P00734;!P00747	KLKB1;!F2;!PLG	1. Plasma kallikrein;!2. Prothrombin;!3. Plasminogen
C15H30N2O5	At steady state following once-daily subcutaneous administration of 20 mg and 40 mg pegvaliase, the mean ± SD (range) apparent clearance was 0.39 ± 0.87 L/h and 1.25 ± 2.46 L/h, respectively Label.	Following once-daily subcutaneous administration of 20 mg and 40 mg pegvaliase, the mean ± SD (range) half-life at steady state was 47 ± 42 (14 to 132) hours and 60 ± 45 (14 to 127) hours, respectively Label.	318.414	COCCOCCCCCC(=O)NCCCC[C@H](N)C(O)=O	Solid	The mean ± SD (range) apparent volume of distribution at steady state was 26.4 ± 64.8 (1.8 to 241) L and 22.2 ± 19.7 (3.1 to 49.5) L after once-daily subcutaneous administration of 20 mg and 40 mg pegvaliase, respectively Label.								58172730									86278362	347829004		2046360		Pegvaliase		Palynziq	Pegvaliase	Approved, Investigational	DB12839	InChI=1S/C15H30N2O5/c1-21-11-12-22-10-6-2-3-8-14(18)17-9-5-4-7-13(16)15(19)20/h13H,2-12,16H2,1H3,(H,17,18)(H,19,20)/t13-/m0/s1	NPOCDVAOUKODSQ-ZDUSSCGKSA-N	3	Pegvaliase is an enzyme used to treat phenylketonuria in patients with phenylalanine levels that are too high on current treatment.	No LD50 value has been reported for pegvaliase. A subcutaneous dose of 20 mg/kg/day of pegvaliase-pqpz produced impaired fertility in female rats leading to decreases in corpora lutea, implantations, and litter size, in association with toxic effects including decreased weight, ovarian weight, and food consumption Label. The carcinogenic and genototoxic potential have not been studied.	Small Molecule																																			1	No	6	3	No	0	0	110.88 Å2	36.89 Å3	83.41 m3·mol-1	15	Yes	No	0.63 mg/mL	-2	-2.7	2.24	9.53			
C8H18N2O3S	Not Available	Not Available	222.3	CCCCS(=N)(=O)CCC(N)C(O)=O	Not Available	Not Available						28714	CHEMBL1256575	19896				C04543					21157	347829028				Buthionine_sulfoximine			Buthionine sulfoximine	Investigational	DB12870	InChI=1S/C8H18N2O3S/c1-2-3-5-14(10,13)6-4-7(9)8(11)12/h7,10H,2-6,9H2,1H3,(H,11,12)	KJQFBVYMGADDTQ-UHFFFAOYSA-N	1		Not Available	Small Molecule																																			1	No	5	3	No	0	0	104.24 Å2	23.65 Å3	54.01 m3·mol-1	7	Yes	No	2.2 mg/mL	-3	-2	2.18	9.09			
C9H17NO3	Not Available	Not Available	187.239	CC(C)(C)C(=O)NCCCC(O)=O	Not Available	Not Available						134834	CHEMBL1870796	62118									68888	347829093				Pivagabine	ZINC000001545856		Pivagabine	Investigational	DB12951	InChI=1S/C9H17NO3/c1-9(2,3)8(13)10-6-4-5-7(11)12/h4-6H2,1-3H3,(H,10,13)(H,11,12)	SRPNQDXRVRCTNK-UHFFFAOYSA-N	1		Not Available	Small Molecule																																			1	Yes	3	2	No	0	-1	66.4 Å2	20.5 Å3	48.6 m3·mol-1	5	Yes	No	4.14 mg/mL	1	-1.7	4.75	-0.86			
C17H37N7O3	Not Available	Not Available	387.529	NCCCNCCCCNC(=O)[C@H](O)NC(=O)CCCCCCNC(N)=N	Not Available	Not Available							CHEMBL1172736	82420									91272	347829130					ZINC000004215557		Deoxyspergualin	Investigational	DB12991	InChI=1S/C17H37N7O3/c18-9-7-11-21-10-5-6-12-22-15(26)16(27)24-14(25)8-3-1-2-4-13-23-17(19)20/h16,21,27H,1-13,18H2,(H,22,26)(H,24,25)(H4,19,20,23)/t16-/m0/s1	IDINUJSAMVOPCM-INIZCTEOSA-N	2		Not Available	Small Molecule																																			0	No	8	8	No	0	3	178.38 Å2	44.84 Å3	115.75 m3·mol-1	17	No	No	0.129 mg/mL	-3.1	-3.5	11.37	12.28			
C11H23N5O6	Not Available	Not Available	321.334	N[C@@H](CCC(O)=O)C(O)=O.N[C@@H](CCCNC(N)=N)C(O)=O	Not Available	Not Available						31234	CHEMBL2104514	144883					D02397							114464		Arginine_glutamate			Arginine glutamate	Investigational	DB13207	InChI=1S/C6H14N4O2.C5H9NO4/c7-4(5(11)12)2-1-3-10-6(8)9;6-3(5(9)10)1-2-4(7)8/h4H,1-3,7H2,(H,11,12)(H4,8,9,10);3H,1-2,6H2,(H,7,8)(H,9,10)/t4-;3-/m00/s1	RVEWUBJVAHOGKA-WOYAITHZSA-N		Arginine glutamate is two amino acids indicated in the treatment of hyperammonemia and in combination for total parenteral nutrition.	Not Available	Small Molecule																																			1	No	6	5	No	0	1	125.22 Å2	17.86 Å3	53.92 m3·mol-1	9	Yes	No	2.28 mg/mL	-3.2	-1.9	2.41	12.41			
C10H13N3O2	Not Available	Not Available	207.233	NC(=N)NCC1COC2=C(O1)C=CC=C2	Not Available	Not Available						134871	CHEMBL76725	15704														Guanoxan			Guanoxan	Approved	DB13211	InChI=1S/C10H13N3O2/c11-10(12)13-5-7-6-14-8-3-1-2-4-9(8)15-7/h1-4,7H,5-6H2,(H4,11,12,13)	HIUVKVDQFXDZHU-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	Yes	5	3	No	2	1	80.36 Å2	21.58 Å3	65.35 m3·mol-1	2	Yes	No	1.33 mg/mL	0.42	-2.2		11.99			
C8H15NO3	Not Available	Not Available	173.212	CC(C)CC(NC(C)=O)C(O)=O	Not Available	Not Available							CHEMBL1875805	1918														Acetylleucine			Acetylleucine	Experimental	DB13226	InChI=1S/C8H15NO3/c1-5(2)4-7(8(11)12)9-6(3)10/h5,7H,4H2,1-3H3,(H,9,10)(H,11,12)	WXNXCEHXYPACJF-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	Yes	3	2	No	0	-1	66.4 Å2	18.29 Å3	43.61 m3·mol-1	4	Yes	No	10.9 mg/mL	0.49	-1.2	4.2	-1.8			
C6H14ClNO2S	Not Available	Not Available	199.69	[Cl-].C[S+](C)CC[C@H](N)C(O)=O	Not Available	Not Available						6884	CHEMBL1797128	16736395				C04078													Methylmethionine chloride	Experimental	DB13250	InChI=1S/C6H13NO2S.ClH/c1-10(2)4-3-5(7)6(8)9;/h5H,3-4,7H2,1-2H3;1H/t5-;/m0./s1	MYGVPKMVGSXPCQ-JEDNCBNOSA-N			Not Available	Small Molecule																																			1	No	3	2	No	0	1	63.32 Å2	17.52 Å3	41.1 m3·mol-1	4	Yes	No	9.2 mg/mL	-3.3	-1.3	2.24	9.41			
C8H20MgN2O12	Not Available	Not Available	360.555	O.O.O.O.[Mg++].N[C@@H](CC(O)=O)C([O-])=O.N[C@@H](CC(O)=O)C([O-])=O	Not Available	Not Available								34993538										347911448		142131		Magnesium_aspartate			Magnesium aspartate	Experimental	DB13359	InChI=1S/2C4H7NO4.Mg.4H2O/c2*5-2(4(8)9)1-3(6)7;;;;;/h2*2H,1,5H2,(H,6,7)(H,8,9);;4*1H2/q;;+2;;;;/p-2/t2*2-;;;;;/m00...../s1	CRSJYWPXKKSOCQ-CBAPHJFVSA-L			Not Available	Small Molecule																																			1	No	5	2	No	0	-1	103.45 Å2	10.99 Å3	37.37 m3·mol-1	6	Yes	No	2.98 mg/mL	-3.5	-2	1.7	9.61			
C9H20N4	Not Available	Not Available	184.287	NC(=N)NCC1CCCCCCN1	Not Available	Not Available						134828	CHEMBL2008565	33166														Guanazodine			Guanazodine	Experimental	DB13604	InChI=1S/C9H20N4/c10-9(11)13-7-8-5-3-1-2-4-6-12-8/h8,12H,1-7H2,(H4,10,11,13)	ZCVAIGPGEINFCX-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	Yes	4	4	No	1	2	73.93 Å2	21.88 Å3	64.37 m3·mol-1	2	Yes	No	0.961 mg/mL	0.48	-2.3		12.4			
C11H21N5O6S	Not Available	Not Available	351.38	OC(=O)C1CSC(N1)C(O)=O.N[C@@H](CCCNC(N)=N)C(O)=O	Not Available	Not Available							CHEMBL3707384	142008														Tidiacic			Tidiacic arginine	Experimental	DB13748	InChI=1S/C6H14N4O2.C5H7NO4S/c7-4(5(11)12)2-1-3-10-6(8)9;7-4(8)2-1-11-3(6-2)5(9)10/h4H,1-3,7H2,(H,11,12)(H4,8,9,10);2-3,6H,1H2,(H,7,8)(H,9,10)/t4-;/m0./s1	LUCWYYXUZVULSK-WCCKRBBISA-N			Not Available	Small Molecule																																			1	No	6	5	No	1	1	125.22 Å2	17.79 Å3	53.92 m3·mol-1	7	Yes	No	20.6 mg/mL	-3.2	-0.93	2.41	12.41			
C5H11NO2S	Not Available	Not Available	149.211	CSCCC(N)C(O)=O	Solid	Not Available					86195	16811	CHEMBL274119	853			HMDB0033951	C01733	D04983							9100		Methionine			Racemethionine	Approved, Experimental	DB13972	InChI=1S/C5H11NO2S/c1-9-3-2-4(6)5(7)8/h4H,2-3,6H2,1H3,(H,7,8)	FFEARJCKVFRZRR-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	No	3	2	No	0	0	63.32 Å2	15.61 Å3	37.59 m3·mol-1	4	Yes	No	23.9 mg/mL	-2.2	-0.8	2.53	9.5			
C10H19NO5	Not Available	Not Available	233.264	CC(C)(CO)[C@@H](O)C(=O)NCCCC(O)=O	Solid	Not Available						134949	CHEMBL2110783	26309					D08042									Hopantenic_acid	ZINC000002017228		Hopantenic acid	Experimental	DB14044	InChI=1S/C10H19NO5/c1-10(2,6-12)8(15)9(16)11-5-3-4-7(13)14/h8,12,15H,3-6H2,1-2H3,(H,11,16)(H,13,14)/t8-/m0/s1	SBBDHANTMHIRGW-QMMMGPOBSA-N			Not Available	Small Molecule																																			1	No	5	4	No	0	-1	106.86 Å2	23.92 Å3	56.27 m3·mol-1	7	Yes	No	40.1 mg/mL	-1.1	-0.77	4.37	-2.8			
C5H12N2O3S	Not Available	Not Available	180.22	CS(=N)(=O)CC[C@H](N)C(O)=O	Not Available	Not Available						87826	CHEMBL143324	80339				C03510		MSL						1722382		Methionine_sulfoximine			Methionine sulfoximine	Experimental	DB14103	InChI=1S/C5H12N2O3S/c1-11(7,10)3-2-4(6)5(8)9/h4,7H,2-3,6H2,1H3,(H,8,9)/t4-,11?/m0/s1	SXTAYKAGBXMACB-DPVSGNNYSA-N			Not Available	Small Molecule																																			1	No	5	3	No	0	0	104.24 Å2	17.19 Å3	40.22 m3·mol-1	4	Yes	No	7.39 mg/mL	-4.4	-1.4	1.89	9.09			
C8H14FNO4	Not Available	Not Available	206.204	N[C@@H](C[C@H](CCC[18F])C(O)=O)C(O)=O	Not Available	Not Available								32698684																	Florilglutamic acid F-18	Investigational	DB15041	InChI=1S/C8H14FNO4/c9-3-1-2-5(7(11)12)4-6(10)8(13)14/h5-6H,1-4,10H2,(H,11,12)(H,13,14)/t5-,6-/m0/s1/i9-1	MKDNDKMECWBLOF-XUCPOOORSA-N	2		Not Available	Small Molecule																																			1	No	5	3	No	0	-1	100.62 Å2	19.38 Å3	45.3 m3·mol-1	7	Yes	No	19.2 mg/mL	-2.4	-1	2.22	9.53			
C22H48N12O2	Not Available	Not Available	512.708	N[C@@H](CCCNC(N)=N)C(=O)NCCCN1CCN(CCCNC(=O)[C@@H](N)CCCNC(N)=N)CC1	Not Available	Not Available							CHEMBL3544919	33427375														Ciraparantag			Ciraparantag	Investigational	DB15199	InChI=1S/C22H48N12O2/c23-17(5-1-7-31-21(25)26)19(35)29-9-3-11-33-13-15-34(16-14-33)12-4-10-30-20(36)18(24)6-2-8-32-22(27)28/h17-18H,1-16,23-24H2,(H,29,35)(H,30,36)(H4,25,26,31)(H4,27,28,32)/t17-,18-/m0/s1	HRDUUSCYRPOMSO-ROUUACIJSA-N	2		Not Available	Small Molecule																																			0	No	12	10	No	1	5	240.52 Å2	59.7 Å3	163.12 m3·mol-1	18	No	No	0.19 mg/mL	-4.3	-3.4		12.51			
C10H12FNO3	Not Available	Not Available	212.211	N[C@H](CC1=CC=C(OC[18F])C=C1)C(O)=O	Not Available	Not Available								9754145																	D-fluoromethyltyrosine F-18	Investigational	DB15296	InChI=1S/C10H12FNO3/c11-6-15-8-3-1-7(2-4-8)5-9(12)10(13)14/h1-4,9H,5-6,12H2,(H,13,14)/t9-/m1/s1/i11-1	GEBHVOHKNWLITQ-DEVVULMSSA-N	1		Not Available	Small Molecule																																			1	No	4	2	No	1	0	72.55 Å2	20.29 Å3	51.3 m3·mol-1	5	Yes	No	2.63 mg/mL	-1.2	-1.9	2.06	9.47			
C11H14FNO3	Not Available	Not Available	226.238	N[C@@H](CC1=CC=C(OCC[18F])C=C1)C(O)=O	Not Available	Not Available							CHEMBL477278	8010200															ZINC000101627026		FET F-18	Investigational	DB15405	InChI=1S/C11H14FNO3/c12-5-6-16-9-3-1-8(2-4-9)7-10(13)11(14)15/h1-4,10H,5-7,13H2,(H,14,15)/t10-/m0/s1/i12-1	QZZYPHBVOQMBAT-LRAGLOQXSA-N	2		Not Available	Small Molecule																																			1	No	4	2	No	1	0	72.55 Å2	22.52 Å3	56.18 m3·mol-1	6	Yes	No	2.47 mg/mL	-1.1	-2	1.93	9.47			
C6H13NO2	Not Available	Not Available	131.1729	CCCC[C@H](N)C(O)=O	Not Available	Not Available						18347	CHEMBL292439	19964			HMDB0001645	C01933		NLE								Norleucine	ZINC000001529322		Norleucine	Investigational	DB15458	InChI=1S/C6H13NO2/c1-2-3-4-5(7)6(8)9/h5H,2-4,7H2,1H3,(H,8,9)/t5-/m0/s1	LRQKBLKVPFOOQJ-YFKPBYRVSA-N	2		Not Available	Small Molecule																																			1	No	3	2	No	0	0	63.32 Å2	14.46 Å3	34.22 m3·mol-1	4	Yes	No	89.2 mg/mL	-1.4	-0.17	2.79	9.53			
C7H13N3O4	Not Available	Not Available	203.198	NCC(=O)N[C@@H](CCC(N)=O)C(O)=O	Not Available	Not Available						74392	CHEMBL330038	110444															ZINC000002555108		Glycylglutamine	Experimental	DB15990	InChI=1S/C7H13N3O4/c8-3-6(12)10-4(7(13)14)1-2-5(9)11/h4H,1-3,8H2,(H2,9,11)(H,10,12)(H,13,14)/t4-/m0/s1	PNMUAGGSDZXTHX-BYPYZUCNSA-N		Glycylglutamine is an ingredient in amino acid solutions for parenteral nutrition.	Not Available	Small Molecule																																			1	No	5	4	No	0	0	135.51 Å2	19.22 Å3	45.91 m3·mol-1	6	Yes	No	17.4 mg/mL	-5.1	-1.1	3.48	8.14			
C10H21N5O6	Not Available	Not Available	307.307	N[C@@H](CC(O)=O)C(O)=O.N[C@@H](CCCNC(N)=N)C(O)=O	Not Available	Not Available								9675306												18254					Arginine aspartate	Experimental	DB15993	InChI=1S/C6H14N4O2.C4H7NO4/c7-4(5(11)12)2-1-3-10-6(8)9;5-2(4(8)9)1-3(6)7/h4H,1-3,7H2,(H,11,12)(H4,8,9,10);2H,1,5H2,(H,6,7)(H,8,9)/t4-;2-/m00/s1	SUUWYOYAXFUOLX-ZBRNBAAYSA-N	3	Arginine aspartate is an ingredient in products indicated to treat exhaustion during stress, endurance sports, or in the elderly.	Not Available	Small Molecule																																			1	No	6	5	No	0	1	125.22 Å2	17.93 Å3	53.92 m3·mol-1	8	Yes	No	2.28 mg/mL	-3.2	-1.9	2.41	12.41			
C4H6KNO4	Not Available	Not Available	171.193	[K+].NC(CC([O-])=O)C(O)=O	Not Available	Not Available								19957263																	Potassium hydrogen DL-aspartate	Experimental	DB15998	InChI=1S/C4H7NO4.K/c5-2(4(8)9)1-3(6)7;/h2H,1,5H2,(H,6,7)(H,8,9);/q;+1/p-1	TXXVQZSTAVIHFD-UHFFFAOYSA-M		Potassium hydrogen DL-aspartate is a medication indicated to treat combined potassium-magnesium deficiency with subsequent arrhythmia.	Not Available	Small Molecule																																			1	No	5	2	No	0	-1	103.45 Å2	10.99 Å3	37.37 m3·mol-1	3	Yes	No	515.0 mg/mL	-3.5	0.48	1.7	9.61			
C11H21N5O5	Not Available	Not Available	303.319	OC(=O)[C@@H]1CCC(=O)N1.N[C@@H](CCCNC(N)=N)C(O)=O	Not Available	Not Available								171679												1482633					Arginine PCA	Experimental	DB16025	InChI=1S/C6H14N4O2.C5H7NO3/c7-4(5(11)12)2-1-3-10-6(8)9;7-4-2-1-3(6-4)5(8)9/h4H,1-3,7H2,(H,11,12)(H4,8,9,10);3H,1-2H2,(H,6,7)(H,8,9)/t4-;3-/m00/s1	UYCAGRPOUWSBIQ-WOYAITHZSA-N			Not Available	Small Molecule																																			1	No	6	5	No	1	1	125.22 Å2	18.04 Å3	53.92 m3·mol-1	6	Yes	No	2.28 mg/mL	-3.2	-1.9	2.41	12.41			
C16H27N3O6	Not Available	Not Available	357.407	N[C@H](CC1CCCCC1)C(=O)N[C@H](CCC(O)=O)C(=O)NCC(O)=O	Not Available	Not Available								8301633															ZINC000034269848		AIM-102	Investigational	DB16176	InChI=1S/C16H27N3O6/c17-11(8-10-4-2-1-3-5-10)15(24)19-12(6-7-13(20)21)16(25)18-9-14(22)23/h10-12H,1-9,17H2,(H,18,25)(H,19,24)(H,20,21)(H,22,23)/t11-,12-/m1/s1	CNDMSQXUUIBFPE-VXGBXAGGSA-N	2		Not Available	Small Molecule																																			1	No	7	5	No	1	-1	158.82 Å2	36.94 Å3	87.06 m3·mol-1	10	Yes	No	0.812 mg/mL	-3.1	-2.6	3.16	8.13			
C9H12NO7P	Not Available	Not Available	277.169	N[C@@H](CC1=CC=C(OP(O)(O)=O)C(O)=C1)C(O)=O	Not Available	Not Available								113330																	Foslevodopa	Investigational	DB16683	InChI=1S/C9H12NO7P/c10-6(9(12)13)3-5-1-2-8(7(11)4-5)17-18(14,15)16/h1-2,4,6,11H,3,10H2,(H,12,13)(H2,14,15,16)/t6-/m0/s1	YNDMEEULGSTYJT-LURJTMIESA-N	3		Not Available	Small Molecule																																			1	No	7	5	No	1	-2	150.31 Å2	23.74 Å3	59.95 m3·mol-1	5	Yes	No	1.66 mg/mL	-1.3	-2.2	1.26	9.41			
C27H44O3	The metabolic clearance rate was 23.5±4.34 ml/min in healthy male volunteers and 10.1±1.35 ml/min in male patients with uraemia 8. In the pediatric patients undergoing peritoneal dialysis receiving dose of 10.2 ng/kg (SD 5.5 ng/kg) for 2 months, the clearance rate was 15.3 mL/hr/kg Label.	After administration of single oral doses, the elimination half life was 5-8 hours Label.	416.6365	C[C@H](CCCC(C)(C)O)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	Solid	Upon intravenous administration, the volume of distribution of calcitriol was 0.49±0.14 L/kg in healthy male volunteers and 0.27±0.06 l/kg in uraemic male patients participating in a pharmacokinetic study 8. There is some evidence that calcitriol is transferred into human milk at low levels (ie, 2.2±0.1 pg/mL) in mothers Label. Calcitriol from maternal circulation may also enter the fetal circulation Label.	Q07973;!P08684	CYP24A1;!CYP3A4	1. 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial;!2. Cytochrome P450 3A4		50200182	17823	CHEMBL846	4444108	Drugs.com Drug Page	GtP Drug Page	HMDB0001903	C01673	D00129	VDX	PDRhealth Drug Page	PA448717	5280453	46508162	RxList Drug Page	1894	DAP000289	Calcitriol	ZINC000100015048	Rocaltrol, Vectical	Calcitriol	Approved, Nutraceutical	DB00136	InChI=1S/C27H44O3/c1-18(8-6-14-26(3,4)30)23-12-13-24-20(9-7-15-27(23,24)5)10-11-21-16-22(28)17-25(29)19(21)2/h10-11,18,22-25,28-30H,2,6-9,12-17H2,1,3-5H3/b20-10+,21-11-/t18-,22-,23-,24+,25+,27-/m1/s1	GMRQFYUYWCNGIN-NKMMMXOESA-N	4	Calcitriol is an active metabolite of vitamin D that is used to treat hyperparathyroidism and is also used in dialysis patients to combat hypocalcemia.	LD50 (oral, rat) = 620 μg/kg; LD50 (intraperitoneal, rat) > 5 mg/kg MSDS.Symptoms of calcitriol toxicity mirrors the early and late signs and symptoms of vitamin D intoxication associated with hypercalcemia 10. Early signs include weakness, headache, somnolence, nausea, vomiting, dry mouth, constipation, muscle pain, bone pain and metallic taste. Late signs are characterized by polyuria, polydipsia, anorexia, weight loss, nocturia, conjunctivitis (calcific), pancreatitis, photophobia, rhinorrhea, pruritus, hyperthermia, decreased libido, elevated BUN, albuminuria, hypercholesterolemia, elevated SGOT and SGPT, ectopic calcification, hypertension, cardiac arrhythmias and, rarely, overt psychosis 10.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	5.1352 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					5		113-114		Insoluble	1	No	3	3	Yes	3	0	60.69 Å2	51.13 Å3	126.53 m3·mol-1	6	Yes	No	0.00667 mg/mL	4.35	-4.8	14.39	-1.3			
C27H44O2	Not Available	288 hours	400.6371	C[C@H](CCCC(C)(C)O)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C	Solid	Not Available	O15528;!Q07973	CYP27B1;!CYP24A1	1. 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial;!2. 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial		50521013	17933	CHEMBL1040	4446820			HMDB0003550	C01561		VDY	PDRhealth Drug Page	PA164745614	5283731	46505690		1855064	DAP000290	Calcifediol	ZINC000004474414	Rayaldee	Calcifediol	Approved, Nutraceutical	DB00146	InChI=1S/C27H44O2/c1-19-10-13-23(28)18-22(19)12-11-21-9-7-17-27(5)24(14-15-25(21)27)20(2)8-6-16-26(3,4)29/h11-12,20,23-25,28-29H,1,6-10,13-18H2,2-5H3/b21-11+,22-12-/t20-,23+,24-,25+,27-/m1/s1	JWUBBDSIWDLEOM-DTOXIADCSA-N	4	Calcifediol is an active metabolite of vitamin D used to treat hyperparathyroidism as well as to combat hypocalcemia in dialysis patients.	Bone pain, constipation (especially in children or adolescents), diarrhea, drowsiness, dryness of mouth; headache (continuing), increased thirst, increase in frequency of urination, especially at night, or in amount of urine, irregular heartbeat, itching skin, loss of appetite, metallic taste, muscle pain, nausea or vomiting (especially in children or adolescents), unusual tiredness or weakness.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	4.1429 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					6				Insoluble	1	No	2	2	Yes	3	0	40.46 Å2	50.38 Å3	125.06 m3·mol-1	6	No	No	0.0022 mg/mL	5.65	-5.3	18.38	-0.98	P11473	VDR	1. Vitamin D3 receptor
C28H44O	There are no formal reports regarding the clearance rate of ergocalciferol. Due to the structural similarity, it is recommended to consult this parameter with cholecalciferol. On the other hand, the proposed renal clearance of calcitriol is of 31 ml/min.8	Ergocalciferol can be found circulation for 1-2 days. This quick turnover is presented due to hepatic conversion and uptake by fat and muscle cells where it is transformed to the active form.6	396.6484	CC(C)[C@@H](C)\C=C\[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C	Solid	The amount of circulating ergocalciferol is very limited as this compound is rapidly stored in fat tissue such as adipose tissue, liver and muscle. This is very obvious in reports that indicate that circulating ergocalciferol is significantly reduced in obese patients.6	Q96AT9;!P05108;!Q07973;!O15528;!Q02318;!Q6VVX0	RPE;!CYP11A1;!CYP24A1;!CYP27B1;!CYP27A1;!CYP2R1	1. Ribulose-phosphate 3-epimerase;!2. Cholesterol side-chain cleavage enzyme, mitochondrial;!3. 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial;!4. 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial;!5. Sterol 26-hydroxylase, mitochondrial;!6. Vitamin D 25-hydroxylase		50247883	28934	CHEMBL1536	4444351	Drugs.com Drug Page		HMDB0000900	C05441	D00187	D2V	PDRhealth Drug Page	PA449484	5280793	46505053	RxList Drug Page	4018	DAP000291	Ergocalciferol	ZINC000004629876	Drisdol, Mvi Pediatric	Ergocalciferol	Approved, Nutraceutical	DB00153	InChI=1S/C28H44O/c1-19(2)20(3)9-10-22(5)26-15-16-27-23(8-7-17-28(26,27)6)12-13-24-18-25(29)14-11-21(24)4/h9-10,12-13,19-20,22,25-27,29H,4,7-8,11,14-18H2,1-3,5-6H3/b10-9+,23-12+,24-13-/t20-,22+,25-,26+,27-,28+/m0/s1	MECHNRXZTMCUDQ-RKHKHRCZSA-N	4	Ergocalciferol is a vitamin found in many supplement products.	The reported LD50 for orally administered ergocalciferol in the rat is of 10 mg/kg.MSDS Overdosage with this agent is reported to produce hypervitaminosis characterized by hypercalcemia, renal impairment, calcification of soft tissues, a decline in the rate of linear growth and increase in bone mineralization.15Once an overdose state is registered, immediate withdrawal of vitamin D is required along with a calcium diet, generous intake of fluids and symptomatic treatment. The administration of loop diuretics is an option to increase renal calcium excretion. On the other hand, dialysis and administration of citrates, sulfates, phosphates, corticosteroids, EDTA and mithramycin are recommended.15There haven't been long term studies analyzing the carcinogenic and mutagenic potential of ergocalciferol or its effects in fertility.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	3.6931 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				Decomposes	8.89		115-117°C	6.35	Insoluble	1	No	1	1	No	3	0	20.23 Å2	50.72 Å3	128.89 m3·mol-1	5	No	Yes	0.000433 mg/mL	7.05	-6	18.38	-1.3	P11473;!BE0004902	VDR;!	1. Vitamin D3 receptor;!2. Voltage-dependent calcium channel (Protein Group)
C27H44O	Studies have determined that the mean clearance value of administered cholecalciferol supplementation in a group of 49 kidney transplant patients was approximately 2.5 L/day 5.	At this time, there have been resources that document the half-life of cholecalciferol as being about 50 days 8 while other sources have noted that the half-life of calcitriol (1,25-dihydroxyvitamin D3) is approximately 15 hours while that of calcidiol (25-hydroxyvitamin D3) is about 15 days 10.Moreover, it appears that the half-lives of any particular administration of vitamin d can vary due to variations in vitamin d binding protein concentrations and genotype in particular individuals 6.	384.6377	CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C	Solid	Studies have determined that the mean central volume of distribution of administered cholecalciferol supplementation in a group of 49 kidney transplant patients was approximately 237 L 5.	Q6VVX0;!Q02318;!P51589;!P08684;!P05108;!P04798;!P10632	CYP2R1;!CYP27A1;!CYP2J2;!CYP3A4;!CYP11A1;!CYP1A1;!CYP2C8	1. Vitamin D 25-hydroxylase;!2. Sterol 26-hydroxylase, mitochondrial;!3. Cytochrome P450 2J2;!4. Cytochrome P450 3A4;!5. Cholesterol side-chain cleavage enzyme, mitochondrial;!6. Cytochrome P450 1A1;!7. Cytochrome P450 2C8		50030475	28940	CHEMBL1042	4444353	Drugs.com Drug Page		HMDB0000876	C05443	D00188	VD3	PDRhealth Drug Page	PA164748138	5280795	46506365		1244014	DAP001273	Cholecalciferol	ZINC000004474460	Adrovance, Animi-3 With Vitamin D, Citranatal B-calm Kit, Citranatal Harmony, Fosamax Plus D, Fosavance, Infuvite, Infuvite Pediatric, Mvc-fluoride, Natafort, Pregvit, Vidextra	CholecalciferolCommonly known or available as Vitamin D3	Approved, Nutraceutical	DB00169	InChI=1S/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h12-13,19,21,24-26,28H,3,6-11,14-18H2,1-2,4-5H3/b22-12+,23-13-/t21-,24+,25-,26+,27-/m1/s1	QYSXJUFSXHHAJI-YRZJJWOYSA-N	4	Vitamin D3 is a form of Vitamin D used in the treatment of specific medical conditions such as refractory rickets, hypoparathyroidism, and familial hypophosphatemia, as well as osteoporosis and chronic kidney disease.	Chronic or acute administration of excessive doses of cholecalciferol may lead to hypervitaminosis D, manifested by hypercalcemia and its sequelae 12,13,14. Early symptoms of hypercalcemia may include weakness, fatigue, somnolence, headache, anorexia, dry mouth, metallic taste, nausea, vomiting, vertigo, tinnitus, ataxia, and hypotonia 12,13,14. Later and possibly more serious manifestation include nephrocalcinosis, renal dysfunction, osteoporosis in adults, impaired growth in children, anemia, metastatic calcification, pancreatitis, generalized vascular calcification, and seizures 12,13,14.Safety of doses in excess of 400 IU (10mcg) of vitamin D3 daily during pregnancy has not been established 12,13,14. Maternal hypercalcemia, possibly caused by excessive vitamin D intake during pregnancy, has been associated with hypercalcemia in neonates, which may lead to supravalvular aortic stenosis syndrome, the features of which may include retinopathy, mental or growth retardation, strabismus, and other effects 12,13,14. Hypercalcemia during pregnancy may also lead to suppression of parathyroid hormone release in the neonate, resulting in hypocalcemia, tetany, and seizures 12,13,14.Vitamin D is deficient in maternal milk; therefore, breastfed infants may require supplementation. Use of excessive amounts of Vitamin D in nursing mothers may result in hypercalcemia in infants. Doses of Vitamin D3 in excess of 10 µg daily should not be administered daily to nursing women.	Small Molecule	http://smpdb.ca/view/SMP0000099?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000111?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000209?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000388?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000389?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000510?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000082?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000089?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000092?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000107?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000117?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000119?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000319?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000508?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000023?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000079?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000095?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000112?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000131?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000386?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000387?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000509?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000511?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169	Lovastatin Action Pathway;!Cerivastatin Action Pathway;!Hypercholesterolemia;!Chondrodysplasia Punctata II, X-Linked Dominant (CDPX2);!Smith-Lemli-Opitz Syndrome (SLOS);!Mevalonic Aciduria;!Simvastatin Action Pathway;!Pravastatin Action Pathway;!Rosuvastatin Action Pathway;!Zoledronate Action Pathway;!Pamidronate Action Pathway;!Fluvastatin Action Pathway;!Lysosomal Acid Lipase Deficiency (Wolman Disease);!Cholesteryl Ester Storage Disease;!Steroid Biosynthesis;!Ibandronate Action Pathway;!Alendronate Action Pathway;!Risedronate Action Pathway;!Atorvastatin Action Pathway;!Desmosterolosis;!CHILD Syndrome;!Hyper-IgD Syndrome;!Wolman Disease		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	3.9310 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					7.5		84.5 °C		Insoluble	1	No	1	1	Yes	3	0	20.23 Å2	49.63 Å3	123.22 m3·mol-1	6	No	Yes	0.00038 mg/mL	7.13	-6	18.38	-1.3	P11473	VDR	1. Vitamin D3 receptor
C22H28F2O5	Not Available	Not Available	410.4515	[H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C	Solid	Not Available						59750	CHEMBL1201380	64505	Drugs.com Drug Page		HMDB0014368		D07827			PA164749408	71415	46504519	RxList Drug Page	91311	DAP001184	Diflorasone	ZINC000005752191	Apexicon, Florone, Psorcon	Diflorasone	Approved	DB00223	InChI=1S/C22H28F2O5/c1-11-6-13-14-8-16(23)15-7-12(26)4-5-19(15,2)21(14,24)17(27)9-20(13,3)22(11,29)18(28)10-25/h4-5,7,11,13-14,16-17,25,27,29H,6,8-10H2,1-3H3/t11-,13-,14-,16-,17-,19-,20-,21-,22-/m0/s1	WXURHACBFYSXBI-XHIJKXOTSA-N		Diflorasone is a topical corticosteroid used to treat the symptoms of various inflammatory skin conditions that cause erythema, pruritus, and discomfort.	Topically applied diflorasone can be absorbed in sufficient amounts to produce systemic effects. Symptoms of overdose include thinning of skin and suppression of adrenal cortex (decreased ability to respond to stress).	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3293 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.1					1	Yes	5	3	No	4	0	94.83 Å2	40.92 Å3	102.32 m3·mol-1	2	Yes	No	0.0853 mg/mL	1.34	-3.7	12.42	-3.3	P04150	NR3C1	1. Glucocorticoid receptor
C22H32O3	Not Available	Not Available	344.4877	[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)CC[C@]12C	Solid	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5			34829	CHEMBL1201173	216968	Drugs.com Drug Page		HMDB0014398	C14643	D02289			PA450346	247839	46506584	RxList Drug Page	29439	DAP001048	Medrysone	ZINC000003977945	Hms	Medrysone	Approved	DB00253	InChI=1S/C22H32O3/c1-12-9-15-17-6-5-16(13(2)23)22(17,4)11-19(25)20(15)21(3)8-7-14(24)10-18(12)21/h10,12,15-17,19-20,25H,5-9,11H2,1-4H3/t12-,15-,16+,17-,19-,20+,21-,22+/m0/s1	GZENKSODFLBBHQ-ILSZZQPISA-N		Medrysone is a topical glucocorticoid applied ophthalmically for the treatment of various ocular inflammatory or allergic conditions.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.3015 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.2		156.5 °C			1	Yes	3	1	No	4	0	54.37 Å2	39.94 Å3	98.85 m3·mol-1	1	Yes	No	0.0337 mg/mL	3.13	-4	18.37	-0.26	P04150	NR3C1	1. Glucocorticoid receptor
C28H35FO7	Not Available	Not Available	502.5717	[H][C@@]12C[C@H]3OC4(CCCC4)O[C@@]3(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5			31199	CHEMBL1200732	392009	Drugs.com Drug Page		HMDB0014433		D01387		PDRhealth Drug Page	PA164746074	443958	46506705	RxList Drug Page	17652	DAP001044	Amcinonide	ZINC000003977777		Amcinonide	Approved	DB00288	InChI=1S/C28H35FO7/c1-16(30)34-15-22(33)28-23(35-26(36-28)9-4-5-10-26)13-20-19-7-6-17-12-18(31)8-11-24(17,2)27(19,29)21(32)14-25(20,28)3/h8,11-12,19-21,23,32H,4-7,9-10,13-15H2,1-3H3/t19-,20-,21-,23+,24-,25-,27-,28+/m0/s1	ILKJAFIWWBXGDU-MOGDOJJUSA-N		Amcinonide is a topical corticosteroid used in the treatment of inflammation and pruritus due to a variety of dermatoses.	Results from acute toxicity studies do not indicate that any risk of acute intoxication is to be expected following a single dermal application of an overdose (application over a large area under conditions favorable to absorption) or inadvertent oral ingestion.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.4315 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.3					1	No	6	1	No	6	0	99.13 Å2	52.38 Å3	127.88 m3·mol-1	4	No	No	0.00774 mg/mL	3.2	-4.8	13.63	-3.4	P04150;!P04083	NR3C1;!ANXA1	1. Glucocorticoid receptor;!2. Annexin A1
C22H28O2	The clearance rate of etonogestrel is reported to be of 7.5 L/h.3	The elimination half-life of etonogestrel is reported to be of 25 hours which indicates a reversible contraceptive effect.7	324.4565	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	Solid	The apparent volume of distribution of etonogestrel is of around 201 L.3	P08684	CYP3A4	1. Cytochrome P450 3A4		50423516	50777	CHEMBL1531	5292944	Drugs.com Drug Page		HMDB0014439				PDRhealth Drug Page	PA164771231	6917715	46505321		14584	DAP000855	Etonogestrel	ZINC000011680067	Eluryng, Implanon, Nexplanon, Nuvaring	Etonogestrel	Approved, Investigational	DB00294	InChI=1S/C22H28O2/c1-4-21-13-14(3)20-17-9-7-16(23)12-15(17)6-8-18(20)19(21)10-11-22(21,24)5-2/h2,12,17-20,24H,3-4,6-11,13H2,1H3/t17-,18-,19-,20+,21-,22-/m0/s1	GCKFUYQCUCGESZ-BPIQYHPVSA-N	4	Etonogestrel is a long-acting synthetic derived progestin contraceptive used in various devices such as contraceptive rings and intradermal implants.	The reported LD50 of oral etonogestrel in the rat is reported to be higher than 2000 mg/kg.MSDS Overdosage can only happen when more than one implant is inserted. In cases of overdose, removal of the implant is recommended.LabelThere aren't reports relating etonogestrel with carcinogenesis, mutagenesis or impaired fertility.Label	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.1164 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				473.1ºC at 760 mmHg	3.32		196-200ºC	10.4	Insoluble	1	Yes	2	1	No	4	0	37.3 Å2	37.83 Å3	96.35 m3·mol-1	1	Yes	Yes	0.00737 mg/mL	3.6	-4.6	17.99	-1.5	P06401	PGR	1. Progesterone receptor
C22H30O	The metabolic clearance rate of desogestrel is reported to be of about 2 ml/min/kg.14	The terminal half-life of desogestrel is determined to be of 30 hours.14	310.473	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCCC=C3CC[C@@]21[H]	Solid	The apparent volume of distribution of desogestrel is of 1.5 L/kg.14	P08684;!P11712;!P22309	CYP3A4;!CYP2C9;!UGT1A1	1. Cytochrome P450 3A4;!2. Cytochrome P450 2C9;!3. UDP-glucuronosyltransferase 1-1		50423510	4453	CHEMBL1533	37400			HMDB0014449	C07629	D02367			PA449238	40973	46505739	RxList Drug Page	22656	DAP001209	Desogestrel	ZINC000004097416	Apri 28 Day, Azurette 28 Day, Bekyree 28 Day, Caziant 28 Day, Cesia 28 Day, Cyred 28 Day, Emoquette, Enskyce 28 Day, Freya, Isibloom 28 Day, Juleber 28 Day, Kalliga, Kariva 28 Day, Linessa, Marvelon, Mircette 28 Day, Pimtrea Pack, Reclipsen, Simliya, Velivet 28 Day, Viorele 28 Day, Volnea 28 Day	Desogestrel	Approved	DB00304	InChI=1S/C22H30O/c1-4-21-14-15(3)20-17-9-7-6-8-16(17)10-11-18(20)19(21)12-13-22(21,23)5-2/h2,8,17-20,23H,3-4,6-7,9-14H2,1H3/t17-,18-,19-,20+,21-,22-/m0/s1	RPLCPCMSCLEKRS-BPIQYHPVSA-N	4	Desogestrel is a synthetic progestin used in contraception, often in combination with ethinyl estradiol.	Administration of large quantities of desogestrel has been shown to produce strong hormonal effects but to lack chronic toxicity. The reported LD50 in rats after oral administration of desogestrel is higher than 2000 mg/kg.10 Overdose hasn't reported serious effects but only symptoms of nausea and withdrawal of bleeding.LabelMost reports haven't linked the administration of desogestrel with the increased risk of breast cancer. The increased risk has been reported to be related to the duration of use. However, several reports indicate a desogestrel-driven increased risk in cervical intra-epithelial neoplasia but the results are still not conclusive.Label	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.3315 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				428ºC	5.65		109-110ºC	13.04	<1 mg/ml	1	Yes	1	1	No	4	0	20.23 Å2	37.51 Å3	95.73 m3·mol-1	1	Yes	Yes	0.00301 mg/mL	4.42	-5	17.99	-1.5	P06401;!P03372	PGR;!ESR1	1. Progesterone receptor;!2. Estrogen receptor alpha
C22H29FO4	Not Available	Not Available	376.4617	[H][C@@]12CC[C@](O)(C(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C	Solid	Not Available	P20815;!P08684	CYP3A5;!CYP3A4	1. Cytochrome P450 3A5;!2. Cytochrome P450 3A4		50103631	31625	CHEMBL1200600	9494	Drugs.com Drug Page		HMDB0014469		D01367		PDRhealth Drug Page	PA164781355	9878	46505984	RxList Drug Page	4491	DAP001047	Fluorometholone	ZINC000118912517	FML, FML Forte Liquifilm, FML-S, Flarex, Fluor-OP	Fluorometholone	Approved, Investigational	DB00324	InChI=1S/C22H29FO4/c1-12-9-17-15-6-8-21(27,13(2)24)20(15,4)11-18(26)22(17,23)19(3)7-5-14(25)10-16(12)19/h5,7,10,12,15,17-18,26-27H,6,8-9,11H2,1-4H3/t12-,15-,17-,18-,19-,20-,21-,22-/m0/s1	FAOZLTXFLGPHNG-KNAQIMQKSA-N	4	Fluorometholone is an ophthalmic corticosteroid used for the relief of inflammation located in both the palpebral and bulbar conjunctiva, the cornea, and the anterior segment of the globe of the eye.	Side effects may include acute anterior uveitis and perforation of the globe. Keratitis, conjunctivitis, corneal ulcers, mydriasis, conjunctival hyperemia, loss of accommodation and ptosis have occasionally been reported following local use of corticosteroids. LD50 = 234 mg/kg (rats)	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3393 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.00	-4.1	292-303		30 mg/L (at 25 °C)	1	Yes	4	2	No	4	0	74.6 Å2	39.94 Å3	100.87 m3·mol-1	1	Yes	No	0.0166 mg/mL	2.42	-4.4	12.65	-3.4	P04150	NR3C1	1. Glucocorticoid receptor
C24H32O4	Not Available	34 hours	384.516	[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4		50238674	6723	CHEMBL1201139	11192	Drugs.com Drug Page			C08151	D00952			PA450351	11683	46505827	RxList Drug Page	29451	DAP000861	Megestrol	ZINC000004097467	Megace	Megestrol acetate	Approved, Investigational, Vet approved	DB00351	InChI=1S/C24H32O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h12-13,18-20H,6-11H2,1-5H3/t18-,19+,20+,22-,23+,24+/m1/s1	RQZAXGRLVPAYTJ-GQFGMJRRSA-N	4	Megestrol acetate is a progestin that is administered orally to treat anorexia and cachexia or serious unexplained weight loss and is also used as an antineoplastic agent to treat certain types of malignancy.	No serious unexpected side effects have resulted from studies involving megestrol acetate oral suspension administered in dosages as high as 1200 mg/day. Treatment with megestrol acetate, an orexigenic agent, has also resulted in iatrogenic adrenal suppression. The mechanism is presumably related to the glucocorticoid properties of megestrol acetate [PMID: 12872362].	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	1.8121 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.2		218.0-220.0 °C		2 µg/mL (at 37 °C for the acetate salt)	1	Yes	3	0	No	4	0	60.44 Å2	43.51 Å3	108.66 m3·mol-1	3	Yes	No	0.00336 mg/mL	3.72	-5.1	17.83	-4.9	P06401;!P04150	PGR;!NR3C1	1. Progesterone receptor;!2. Glucocorticoid receptor
C21H28O2	Clearance was found to 4.8 L/h in healthy female volunteers with a normal BMI, and 7.70-8.51 L/h in obese patients after a single 1.5 mg dose.6 After a 0.75 mg dose of levonorgestrel in 16 patients in another pharmacokinetic study, mean clearance was calculated at 7.06 L/h.4 Following levonorgestrel implant removal, the serum concentration falls below 100 pg/mL within the first 96 hours and further falls below the sensitivity of detection within the range of 5 days to 2 weeks.29	The elimination half-life of a 0.75 mg dose of 1.5 mg of levonorgestrel ranges between 20-60 hours post-administration.3 A pharmacokinetic study of women with a normal BMI and BMI over revealed an elimination half-life of 29.7 h and 41.0-46.4 hours, respectively.6 Another pharmacokinetic study revealed a mean elimination half-life of 24.4 hours after a 0.75 mg dose of levonorgestrel was administered to 16 patients.4	312.4458	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	Solid	One pharmacokinetic study determined a mean steady-state volume of distribution of 1.5 mg of levonorgestrel to be 162.2 L in those with normal BMI and in the range of 404.7 L to 466.4 L in obese patients with a body mass index of at least 30.6 Mean volume of distribution in 16 patients receiving 0.75 mg of levonorgestrel in another pharmacokinetic study was 260 L.4 The Plan B one-step FDA label reports an apparent volume of distribution of 1.8 L/kg.19	P20815;!P08684	CYP3A5;!CYP3A4	1. Cytochrome P450 3A5;!2. Cytochrome P450 3A4		50410522	6443	CHEMBL1389	12560	Drugs.com Drug Page	GtP Drug Page	HMDB0014511	C08153	D00950	NOG	PDRhealth Drug Page	PA450218	13109	46508082	RxList Drug Page	6373	DAP001207	Levonorgestrel	ZINC000003814395	Afirmelle 28 Day, Aftera, Alesse, Altavera 28 Day, Amethia 91 Day, Amethyst, Ashlyna 91 Day, Aubra 28 Day, Aviane 28, Ayuna 28 Day Pack, Balcoltra 28 Day, Bionafem, Camrese 91 Day, Camreselo 91 Day, Chateal 28 Day, Climara Pro, Daysee 91 Day, Delyla 28 Day, Dolishale 28 Day, Econtra, Enpresse 28 Day, Fallback Solo, Falmina 28 Day, Fayosim 91 Day, Iclevia 91 Day, Indayo, Introvale 91 Day, Jaimiess 91 Day, Jolessa 91 Day, Kurvelo, Kyleena, Larissia 28 Day Pack, Levonest 28 Day, Levora 0.15/30 28 Day, Liletta, Lillow 28 Day, Lo Simpesse, LoJaimiess, Loseasonique, Lutera 28 Day, Marlissa 28 Day, Min-ovral, Mirena, Morning After, My Choice, My Way, Myzilra 28 Day, New Day, Next Choice, Next Choice One Dose, Opcicon One-step, Option 2, Orsythia 28 Day, Plan B, Plan B One-step, Portia 28 Day, Preventeza, Quartette 91 Day Pack, React, Rivelsa 91 Day, Seasonale, Seasonique, Setlakin 91 Day, Simpesse, Skyla, Sronyx 28 Day, Take Action, Triquilar, Trivora 28 Day, Twirla 3 Count Weekly Patch, Tyblume 28 Day, Vienva 28 Day	Levonorgestrel	Approved, Investigational	DB00367	InChI=1S/C21H28O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,13,16-19,23H,3,5-12H2,1H3/t16-,17+,18+,19-,20-,21-/m0/s1	WWYNJERNGUHSAO-XUDSTZEESA-N	4	Levonorgestrel is a progestin found in oral and IUD contraceptives and at higher doses in emergency contraceptives.	The oral LD50 in rats is greater than 5000 mg/kg.24An overdose of this drug, like other contraceptives, may cause nausea and withdrawal bleeding. Provide symptomatic treatment in the case of a levonorgestrel overdose and contact the local poison control center. There is no specific antidote for a levonorgestrel overdose.19,25,26	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.8264 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				459.1	3.8	-4.7	240 °C	17.91,-1.5	0.0058 g/L	1	Yes	2	1	No	4	0	37.3 Å2	36.75 Å3	92.03 m3·mol-1	1	Yes	Yes	0.00583 mg/mL	3.66	-4.7	17.91	-1.5			
C21H28O2	Not Available	Dydrogesterone: 5-7 hours, 20-dihydrodydrogesterone (DHD) metabolite: 14-17 hours	312.4458	[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]2([H])C=CC2=CC(=O)CC[C@@]12C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			31527	CHEMBL1200853	8699		GtP Drug Page	HMDB0014522		D01217			PA164745443	9051	46506195		3706	DAP001205	Dydrogesterone	ZINC000003875998		Dydrogesterone	Approved, Investigational, Withdrawn	DB00378	InChI=1S/C21H28O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h4-5,12,16-19H,6-11H2,1-3H3/t16-,17+,18-,19+,20+,21+/m0/s1	JGMOKGBVKVMRFX-HQZYFCCVSA-N	4	Dydrogesterone is a synthetic progesterone for menstrual cycle regulation, infertility treatment, prevention of miscarriage, and other conditions.	No serious or unexpected toxicity has been observed with dydrogesterone. In acute toxicity studies, the LD50 doses in rats exceeded 4,640mg/kg for the oral route.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	1.8041 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.4		168-169			1	Yes	2	0	No	4	0	34.14 Å2	36.39 Å3	93.82 m3·mol-1	1	Yes	Yes	0.00486 mg/mL	3.79	-4.8	19.4	-4.8	P06401	PGR	1. Progesterone receptor
C28H37ClO7	Following intravenous administration, the clearance of beclomethasone dipropionate and 17-BMP were 150 L/h and 120 L/h, respectively.1	Following intravenous administration, the half life of beclomethasone dipropionate was 0.5 hours while the half life of the active metabolite 17-BMP was 2.7 hours. Following oral and intranasal administration, the half life of 17-BMP was 8.8 and 5.7 hours, respectively.1	521.042	[H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	Following intravenous administration, the steady-state volume of distribution was 20 L for beclomethasone dipropionate and 424 L for the active metabolite, beclomethasone-17-monopropionate.1	P20815;!P08684	CYP3A5;!CYP3A4	1. Cytochrome P450 3A5;!2. Cytochrome P450 3A4			3002	CHEMBL1200500	20396	Drugs.com Drug Page		HMDB0014538	C07813	D07495			PA448547	21700	46509195	RxList Drug Page	1348	DAP000416	Beclometasone	ZINC000003938744	Alanase, Beconase, Propaderm, Qnasl, Qvar, Rivanase AQ	Beclomethasone dipropionate	Approved, Investigational	DB00394	InChI=1S/C28H37ClO7/c1-6-23(33)35-15-22(32)28(36-24(34)7-2)16(3)12-20-19-9-8-17-13-18(30)10-11-25(17,4)27(19,29)21(31)14-26(20,28)5/h10-11,13,16,19-21,31H,6-9,12,14-15H2,1-5H3/t16-,19-,20-,21-,25-,26-,27-,28-/m0/s1	KUVIULQEHSCUHY-XYWKZLDCSA-N	4	Beclomethasone dipropionate is an inhaled corticosteroid used as maintenance treatment in the prophylaxis of asthma attacks.	The oral LD50 in rats is >3750 mg/kg.MSDS The acute toxicity of beclometasone dipropionate is low. The only harmful effect that follows inhalation of large amounts of the drug over a short period of time is suppression of hypothalamic-pituitary-adrenal (HPA) function. Chronic: The excessive use of beclometasone dipropionate over a long period could lead to adrenal suppression.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.1115 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.49		208-210			1	No	5	1	Yes	4	0	106.97 Å2	54.46 Å3	134.79 m3·mol-1	8	No	No	0.00208 mg/mL	4.43	-5.4	13.85	-3.3	P04150	NR3C1	1. Glucocorticoid receptor
C21H30O2	Apparent clearance1367 ± 348 (50mg of progesterone administered by vaginal insert once daily) 11.106 ± 15 L/h (50mg/mL IM injection once daily) 11.	Absorption half-life is approximately 25-50 hours and an elimination half-life of 5-20 minutes (progesterone gel) 20. Progesterone, administered orally, has a short serum half-life (approximately 5 minutes). It is rapidly metabolized to 17-hydroxyprogesterone during its first pass through the liver 11.	314.4617	[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	When administered vaginally, progesterone is well absorbed by uterine endometrial tissue, and a small percentage is distributed into the systemic circulation.The amount of progesterone in the systemic circulation appears to be of minimal importance, especially when implantation, pregnancy, and live birth outcomes appear similar for intramuscular and vaginal administration of progesterone 11.					8903	17026	CHEMBL103	5773	Drugs.com Drug Page		HMDB0001830	C00410	D00066	STR	PDRhealth Drug Page	PA451123	5994	46508968	RxList Drug Page	8727	DAP000549	Progesterone	ZINC000004428529	Bijuva, Crinone, Endometrin, Prochieve, Prometrium	Progesterone	Approved, Vet approved	DB00396	InChI=1S/C21H30O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h12,16-19H,4-11H2,1-3H3/t16-,17+,18-,19-,20-,21+/m0/s1	RJKFOVLPORLFTN-LEKSSAKUSA-N	4	Progesterone is a hormone used for a variety of functions, including contraception, control of abnormal uterine bleeding, maintenance of pregnancy, and prevention of endometrial hyperplasia.	Intraperitoneal LD50 (rat): 327 mg/kg MSDS. Use in pregnancyOnly forms of progesterone that are indicated on product labeling for pregnancy should be used. Some forms of progesterone should not be used in pregnancy Label, 22. Refer to individual product monographs for information regarding use in pregnancy. Many studies have found no effects on fetal development associated with long-term use of contraceptive doses of oral progestins. Studies of infant growth and development that have been conducted have not demonstrated significant adverse effects, however, these studies are few in number. It is therefore advisable to rule out suspected pregnancy before starting any hormonal contraceptive 22. Effects on fertilityProgesterone at high doses is an antifertility drug and high doses would be expected to impair fertility until cessation 25. The progesterone contraceptive should not be used during pregnancy. CarcinogenicityProgesterone has been shown to induce or promote the formation of ovarian, uterine, mammary, and genital tract tumors in animals. The clinical relevance of these findings is unknown 24. Certain epidemiological studies of patients using oral contraceptives have reported an increased relative risk of developing breast cancer, especially at a younger age and associated with a longer duration of use. These studies have mainly involved combined oral contraceptives, and therefore, it is unknown whether this risk is attributable to progestins, estrogens, or a combination of both. At this time, there is insufficient data to determine whether the use of progestin-only contraceptives increases the risk in a similar way to combined contraceptives. A meta-analysis of 54 studies showed a small increase in the frequency of breast cancer diagnosis for women who were currently using combined oral contraceptives, or had used them within the past 10 years. There was no increase in the frequency of having breast cancer diagnosed ten or more years after cessation of hormone use. Women with breast cancer should not use oral contraceptives, as there is no sufficient data to fully establish or negate the risk of cancer with hormonal contraceptive use 22. Use in breastfeedingProgesterone has been detected in the milk of nursing mothers 21, 22. No adverse effects, in general, have been found on breastfeeding ability or on the health, growth, or development of the growing infant. Despite this, isolated post-marketing cases of decreased milk production have been reported 22.	Small Molecule	http://smpdb.ca/view/SMP0000371?highlight[compounds][]=DB00396&highlight[proteins][]=DB00396;!http://smpdb.ca/view/SMP0000575?highlight[compounds][]=DB00396&highlight[proteins][]=DB00396;!http://smpdb.ca/view/SMP0000717?highlight[compounds][]=DB00396&highlight[proteins][]=DB00396;!http://smpdb.ca/view/SMP0000372?highlight[compounds][]=DB00396&highlight[proteins][]=DB00396;!http://smpdb.ca/view/SMP0000577?highlight[compounds][]=DB00396&highlight[proteins][]=DB00396;!http://smpdb.ca/view/SMP0000718?highlight[compounds][]=DB00396&highlight[proteins][]=DB00396;!http://smpdb.ca/view/SMP0000130?highlight[compounds][]=DB00396&highlight[proteins][]=DB00396;!http://smpdb.ca/view/SMP0000373?highlight[compounds][]=DB00396&highlight[proteins][]=DB00396;!http://smpdb.ca/view/SMP0000566?highlight[compounds][]=DB00396&highlight[proteins][]=DB00396;!http://smpdb.ca/view/SMP0000576?highlight[compounds][]=DB00396&highlight[proteins][]=DB00396;!http://smpdb.ca/view/SMP0000578?highlight[compounds][]=DB00396&highlight[proteins][]=DB00396	Congenital Lipoid Adrenal Hyperplasia (CLAH) or Lipoid CAH;!11-beta-Hydroxylase Deficiency (CYP11B1);!Apparent Mineralocorticoid Excess Syndrome;!Adrenal Hyperplasia Type 5 or Congenital Adrenal Hyperplasia Due to 17 alpha-Hydroxylase Deficiency;!Corticosterone Methyl Oxidase I Deficiency (CMO I);!3-beta-Hydroxysteroid Dehydrogenase Deficiency;!Steroidogenesis;!Adrenal Hyperplasia Type 3 or Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency;!17-alpha-Hydroxylase Deficiency (CYP17);!21-Hydroxylase Deficiency (CYP21);!Corticosterone Methyl Oxidase II Deficiency (CMO II)		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	1.8041 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				394.13°C (rough estimate)	3.87	-4.43	128-132	Strongest acidic: , Strongest basic: 18.92, -4.8	<0.1 g/100 mL at 19 ºC	1	Yes	2	0	No	4	0	34.14 Å2	37.26 Å3	92.71 m3·mol-1	1	Yes	Yes	0.00546 mg/mL	4.15	-4.8	18.47	-4.8			
C24H32O4S	Clearance data is not readily available.Label,7	1.4 hours.Label,7Canrenone has a half life of 16.5 hours, 7-α-thiomethylspirolactone has a half life of 13.8 hours, and 6-ß-hydroxy-7-α-thiomethylspirolactone has a half life of 15 hours.Label,7	416.573	[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O	Solid	Volume of distribution data is not readily available.Label,7	P15538;!P10632	CYP11B1;!CYP2C8	1. Cytochrome P450 11B1, mitochondrial;!2. Cytochrome P450 2C8		50228080	9241	CHEMBL1393	5628	Drugs.com Drug Page	GtP Drug Page	HMDB0014565	C07310	D00443	SNL	PDRhealth Drug Page	PA451483	5833	46508525	RxList Drug Page	9997	DAP000297	Spironolactone	ZINC000003861599	Aldactazide, Aldactone, Carospir	Spironolactone	Approved	DB00421	InChI=1S/C24H32O4S/c1-14(25)29-19-13-15-12-16(26)4-8-22(15,2)17-5-9-23(3)18(21(17)19)6-10-24(23)11-7-20(27)28-24/h12,17-19,21H,4-11,13H2,1-3H3/t17-,18-,19+,21+,22-,23-,24+/m0/s1	LXMSZDCAJNLERA-ZHYRCANASA-N	4	Spironolactone is an aldosterone receptor antagonist used for the treatment of hypertension, hyperaldosteronism, edema due to various conditions, hirsutism (off-label) and hypokalemia.	Patients experiencing an overdose may present with drowsiness, mental confusion, maculopapular or erythematous rash, nausea, vomiting, dizziness, or diarrhea. Vomiting is generally induced or a gastric lavage is performed.Label Supportive treatment involves maintining hydration, electrolyte balance, and vital functionsLabel.The oral LD50 in mice, rats, and rabbits is >1g/kg.LabelSpironolactone should be avoided in pregnancy due to reports of feminization of male fetuses in animal studies.Label Active metabolites of spironolactone are present in breast milk and levels that are likely inconsequential, though the long term effects have not been studied.LabelIn animal studies, spironolactone slowed follicle development, ovulation, and implantation.Label Spironolactone increased the incidence of benign adenomas in the testes of male rats, benign uterine endometrial stromal polyps in female rats, and thyroid follicular cell adenomas in both sexes of rats.Label Spironolactone and canrenone are generally not considered to be mutagenic in tests but canrenone occasionally tests positive for mutagenicity with metabolic activation and spironolactone has occasionally tested inconclusive though slightly positive for mutagenicity.Label	Small Molecule	http://smpdb.ca/view/SMP0000134?highlight[compounds][]=DB00421&highlight[proteins][]=DB00421	Spironolactone Action Pathway		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.0150 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				201	2.78		134.5 °C			1	Yes	3	0	No	5	0	60.44 Å2	46.03 Å3	113.5 m3·mol-1	2	Yes	No	0.00198 mg/mL	3.64	-5.3	17.89	-4.9			
C22H29FO5	In a study that included Indian women of reproductive age, the CL/F following a single intramuscular dose of betamethasone phosphate was 6,466 ± 805 mL/hour.9	In a study that included Indian women of reproductive age, the half-life following a single intramuscular dose of betamethasone phosphate was 10.2 ± 2.5 hours.9	392.4611	[H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	In a study that included Indian women of reproductive age, the volume of distribution following a single intramuscular dose of betamethasone phosphate was 94,584±23,539 mL(s).9	P11511;!P20815;!P24462;!P11509;!Q16678;!P20813;!P10632;!P11712;!P33261;!P08684	CYP19A1;!CYP3A5;!CYP3A7;!CYP2A6;!CYP1B1;!CYP2B6;!CYP2C8;!CYP2C9;!CYP2C19;!CYP3A4	1. Cytochrome P450 19A1;!2. Cytochrome P450 3A5;!3. Cytochrome P450 3A7;!4. Cytochrome P450 2A6;!5. Cytochrome P450 1B1;!6. Cytochrome P450 2B6;!7. Cytochrome P450 2C8;!8. Cytochrome P450 2C9;!9. Cytochrome P450 2C19;!10. Cytochrome P450 3A4		73823	3077	CHEMBL632	9399	Drugs.com Drug Page		HMDB0014586		D00244			PA164754818	9782	46505155	RxList Drug Page	1514	DAP001043	Betamethasone	ZINC000003876136	Betaderm, Betaloan Suik, Beteflam, Betnesol, Celestoderm, Celestone Soluspan, Dermacinrx Therazole Pak, Diprolene, Diprosalic, Diprosone, Dovobet, Enstilar, Fucibet, Lotriderm, Lotrisone, Luxiq, Marbeta, Rivasone, Rolene, Rosone, Sernivo, Taclonex, Valisone-G, Wynzora	Betamethasone	Approved, Vet approved	DB00443	InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,17-,19-,20-,21-,22-/m0/s1	UREBDLICKHMUKA-DVTGEIKXSA-N	4	Betamethasone is a systemic corticosteroid used to relieve inflammation in various conditions, including but not limited to allergic states, dermatologic disorders, gastrointestinal diseases, and hematological disorders.	Chronic high doses of glucocorticoids can lead to the development of cataracts, glaucoma, hypertension, water retention, hyperlipidemia, peptic ulcer, pancreatitis, myopathy, osteoporosis, mood changes, psychosis, dermal atrophy, allergy, acne, hypertrichosis, immune suppression, decreased resistance to infection, moon face, hyperglycemia, hypocalcemia, hypophosphatemia, metabolic acidosis, growth suppression, and secondary adrenal insufficiency.6 Overdose may be treated by adjusting the dose or stopping the corticosteroid as well as initiating symptomatic and supportive treatment.6	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1482 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor				568.2°C	1.138	-3.77	178°C		66.5 mg/L (at 25 °C)	1	Yes	5	3	No	4	0	94.83 Å2	40.81 Å3	102.49 m3·mol-1	2	Yes	No	0.0505 mg/mL	1.68	-3.9	12.42	-3.3	P04150	NR3C1	1. Glucocorticoid receptor
C22H29FO4	Not Available	The half-life of the material was 15 ± 2 hours (for urine) and 17 ± 2 hours (for feces) between the third and fifth trial day.	376.4617	[H][C@@]12C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	Not Available					50103622	691037	CHEMBL1766	4470604	Drugs.com Drug Page		HMDB0014687				PDRhealth Drug Page	PA164746011	5311067	46506793	RxList Drug Page	3255	DAP001185	Desoximetasone	ZINC000004212854	Desoxi, Topicort	Desoximetasone	Approved	DB00547	InChI=1S/C22H29FO4/c1-12-8-16-15-5-4-13-9-14(25)6-7-21(13,3)22(15,23)18(27)10-20(16,2)19(12)17(26)11-24/h6-7,9,12,15-16,18-19,24,27H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,18+,19-,20+,21+,22+/m1/s1	VWVSBHGCDBMOOT-IIEHVVJPSA-N	4	Desoximetasone is a glucocorticoid used to treat inflammatory and pruritic corticosteroid-responsive dermatoses.	Topically applied desoximetasone can be absorbed in sufficient amounts to produce systemic effects. Symptoms of overdose include thinning of skin and suppression of adrenal cortex (decreased ability to respond to stress).	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.6856 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor					2.35		217 °C		42.1 mg/L	1	Yes	4	2	No	4	0	74.6 Å2	40.12 Å3	101.17 m3·mol-1	2	Yes	No	0.031 mg/mL	2.35	-4.1	13.44	-3.3	P04150	NR3C1	1. Glucocorticoid receptor
C25H31F3O5S	1093mL/min for fluticasone propionate10. A study of 24 healthy Caucasian males showed a clearance of 63.9L/h following intravenous administration1.	7.8 hours for intravenous fluticasone propionate10Label. A study of 24 healthy Caucasian males shows a half life of 14.0 hours following intravenous administration and 10.8 hours following inhalation1.	500.571	[H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C	Solid	The volume of distribution of intravenous fluticasone propionate is 4.2L/kg10Label. A study of 24 healthy Caucasian males showed a volume of distribution at steady state of 577L following intravenous administration1.	P20815;!P24462;!P10632;!P08684	CYP3A5;!CYP3A7;!CYP2C8;!CYP3A4	1. Cytochrome P450 3A5;!2. Cytochrome P450 3A7;!3. Cytochrome P450 2C8;!4. Cytochrome P450 3A4		50354849	31441	CHEMBL1473	392059	Drugs.com Drug Page		HMDB0005036		D01708			PA449686	444036	46506140	RxList Drug Page	50121	DAP001039	Fluticasone_propionate	ZINC000003920027	Advair, Airduo, Airduo Respiclick, Aller-flo, Armonair, Beser, Cutivate, Dymista, Flonase, Flovent, Fluticare, Ticanase, Wixela, Xhance	Fluticasone propionate	Approved	DB00588	InChI=1S/C25H31F3O5S/c1-5-20(31)33-25(21(32)34-12-26)13(2)8-15-16-10-18(27)17-9-14(29)6-7-22(17,3)24(16,28)19(30)11-23(15,25)4/h6-7,9,13,15-16,18-19,30H,5,8,10-12H2,1-4H3/t13-,15+,16+,18+,19+,22+,23+,24+,25+/m1/s1	WMWTYOKRWGGJOA-CENSZEJFSA-N	4	Fluticasone propionate is a glucocorticoid used to treat asthma, inflammatory pruritic dermatoses, and nonallergic rhinitis.	Fluticasone propionate's use in specific populations has not been well studied10. Fluticasone propionate is not carcinogenic, mutagenic, or clastogenic, nor did it affect fertility in animal studies10Label. Subcutaneous fluticasone propionate has been shown to produce teratogenic effects in rats though oral administration does not9Label. Generally, there are no reported adverse effects with fluticasone in pregnancy6. Fluticasone propionate in human milk may cause growth suppression, effects on endogenous corticosteroid production, or other effects9,2. Pediatric patients treated with fluticasone propionate ointment experienced adrenal suppression9. Geriatric patients treated with fluticasone propionate did not show any difference in safety or efficacy compared to other patient groups, though older patients may be more sensitive to adverse effects9. There is no difference in the clearance of fluticasone propionate across genders or raceLabel. Patients with hepatic impairment should be closely monitored due to the elimination mechanismLabel5.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.3753 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.78		261-273 °C		Insoluble	1	No	4	1	Yes	4	0	80.67 Å2	49.29 Å3	121.65 m3·mol-1	6	No	No	0.0114 mg/mL	3.72	-4.6	13.61	-3.4			
C24H30F2O6	This pharmacokinetic parameter is not relevant as the systemic absorption of fluocinolone acetonide is very minimal and the concentration in urine is lower than the minimum quantitation limit.10	The reported half-life of fluocinolone acetonide ranges between 1.3-1.7 hours.7	452.4882	[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO	Solid	This pharmacokinetic parameter is not relevant as the systemic absorption of fluocinolone acetonide is very minimal.	P08684	CYP3A4	1. Cytochrome P450 3A4			31623	CHEMBL989	5980	Drugs.com Drug Page		HMDB0014729		D01825			PA164754912	6215	46506244	RxList Drug Page	4461	DAP000813	Fluocinolone_acetonide	ZINC000003977981	Capex, Derma-Smoothe/FS, Derma-smoothe FS, Dermotic, Flac, Iluvien, Neo-synalar, Otixal, Otovel, Retisert, Synalar, Tri-luma, Yutiq	Fluocinolone acetonide	Approved, Investigational, Vet approved	DB00591	InChI=1S/C24H30F2O6/c1-20(2)31-19-9-13-14-8-16(25)15-7-12(28)5-6-21(15,3)23(14,26)17(29)10-22(13,4)24(19,32-20)18(30)11-27/h5-7,13-14,16-17,19,27,29H,8-11H2,1-4H3/t13-,14-,16-,17-,19+,21-,22-,23-,24+/m0/s1	FEBLZLNTKCEFIT-VSXGLTOVSA-N	4	Fluocinolone acetonide is a corticosteroid used to treat skin conditions, eczematous otitis externa, diabetic macular edema, and non-infectious uveitis of the posterior segment of the eye.	Studies to determine the carcinogenic and its effect in fertility have not been performed. It is important to consider that several corticosteroids have been shown to present genotoxic potential but fluocinolone acetonide was shown to not be genotoxic in the Ames test and mouse lymphoma TK assay.19	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.7033 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.48		266-268	13.9	Insoluble	1	Yes	6	2	No	5	0	93.06 Å2	44.84 Å3	111.41 m3·mol-1	2	Yes	No	0.0547 mg/mL	1.6	-3.9	13.38	-3.3	P04150;!P04083;!P07355;!P12429;!P09525;!P08758	NR3C1;!ANXA1;!ANXA2;!ANXA3;!ANXA4;!ANXA5	1. Glucocorticoid receptor;!2. Annexin A1;!3. Annexin A2;!4. Annexin A3;!5. Annexin A4;!6. Annexin A5
C22H27ClF2O4	Not Available	In vitro experiments show halobetasol propionate, a derivative of ulobetasol, has a half life of 33 minutes.9	428.9	[H][C@@]12C[C@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C	Solid	Not Available							CHEMBL1201360	4470691	Drugs.com Drug Page						PDRhealth Drug Page	PA164768832	5311167	46506187	RxList Drug Page	41208	DAP001186	Ulobetasol	ZINC000004214603	Bryhali, Duobrii, Lexette, Ultravate, Ultravate X Ointment	Ulobetasol	Approved	DB00596	InChI=1S/C22H27ClF2O4/c1-11-6-13-14-8-16(24)15-7-12(26)4-5-19(15,2)21(14,25)17(27)9-20(13,3)22(11,29)18(28)10-23/h4-5,7,11,13-14,16-17,27,29H,6,8-10H2,1-3H3/t11-,13-,14-,16-,17-,19-,20-,21-,22-/m0/s1	LEHFPXVYPMWYQD-XHIJKXOTSA-N	4	Ulobetasol is a lipocortin corticosteroid used to treat inflammatory and pruritic corticosteroid-responsive dermatoses.	Data regarding acute overdoses of glucocorticoids are rare.7,8 Chronic high doses of glucocorticoids can lead to the development of cataract, glaucoma, hypertension, water retention, hyperlipidemia, peptic ulcer, pancreatitis, myopathy, osteoporosis, mood changes, psychosis, dermal atrophy, allergy, acne, hypertrichosis, immune suppression, decreased resistance to infection, moon face, hyperglycemia, hypocalcemia, hypophosphatemia, metabolic acidosis, growth suppression, and secondary adrenal insufficiency.5 Overdose may be treated by adjusting the dose or stopping the corticosteroid as well as initiating symptomatic and supportive treatment.5,10	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.3204 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							200-216		Practically insoluble	1	Yes	4	2	No	4	0	74.6 Å2	42.07 Å3	105.37 m3·mol-1	2	Yes	No	0.022 mg/mL	2.7	-4.3	12.46	-3.4	P04150	NR3C1	1. Glucocorticoid receptor
C24H34O4	The mean clearance of medroxyprogesterone acetate (MPA) is 1668±146L/day or 21.9±4.3L/kg/day.5 Due to the high inter patient variability in MPA pharmacokinetics, clearance has been reported to be 1600-4000L/day.15	Oral medroxyprogesterone acetate (MPA) has an absorption half life of 15-30min and a biological half life of 40-60 hours.2 Intramuscular MPA has an absorption half life of 0.86±0.30 days and an elimination half life of 24.03±21.74 days.3 Subcutaneous MPA has an absorption half life of 1.05±0.56 days and an elimination half life of 30.90±15.11 days.3	386.5244	[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)CC[C@]12C	Solid	The volume of distribution of medroxyprogesterone acetate is 20±3L.15	P08684;!P10632;!P26439;!P11712;!P04800	CYP3A4;!CYP2C8;!HSD3B2;!CYP2C9;!Cyp3a1	1. Cytochrome P450 3A4;!2. Cytochrome P450 2C8;!3. 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2;!4. Cytochrome P450 2C9;!5. Cytochrome P450 3A1		50067678	6716	CHEMBL717	6043	Drugs.com Drug Page	GtP Drug Page		C08150	D00951			PA450344	6279	46508895	RxList Drug Page	1000112	DAP001211	Medroxyprogesterone	ZINC000005029557	Depo-provera, Depo-subq Provera, Premphase 28 Day, Prempro 0.625/2.5 28 Day, Provera	Medroxyprogesterone acetate	Approved, Investigational	DB00603	InChI=1S/C24H34O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h13-14,18-20H,6-12H2,1-5H3/t14-,18+,19-,20-,22+,23-,24-/m0/s1	PSGAAPLEWMOORI-PEINSRQWSA-N	4	Medroxyprogesterone acetate is a progestin used as a contraceptive and in the treatment of secondary amenorrhea, abnormal uterine bleeding, pain from endometriosis, endometrial and renal carcinomas, paraphilia in males, and GnRH-dependent precocious puberty.	The oral LD50 in rats is >6400mg/kg and in mice is >16g/kg.16 The intraperitoneal LD50 in rats is >900mg/kg and in mice is >1500mg/kg.16 The subcutaneous LD50 in rats is >900mg/kg and in mice is>1500mg/kg.16Patients experiencing and overdose or oral medroxyprogesterone acetate (MPA) may present with nausea, vomiting, breast tenderness, dizziness, abdominal pain, drowsiness, fatigue, and withdrawal bleeding.10,11 Treat patients by stopping MPA and beginning symptomatic treatment.10,11 Patients who have been given too much of a MPA depo injection should contact a healthcare professional, hospital emergency department, or local poison control immediately.15	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	1.8121 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							205-209		10mM	1	Yes	3	0	No	4	0	60.44 Å2	44.06 Å3	107.81 m3·mol-1	3	Yes	No	0.00221 mg/mL	4.13	-5.2	17.73	-4.9			
C21H27FO6	The clearance of triamcinolone is 28.6±5.6L/h.4 The mean total body clearance of triamcinolone acetonide is 0.57L/h.2 The clearance of triamcinolone diacetate is 34.4±10.6L/h.4	The half life of triamcinolone is 2.7h.4 The mean terminal elimination half life following an inhaled dose of triamcinolone acetonide is 2.4h.2 The half life of triamcinolone diacetate is 2.8h.4	394.4339	[H][C@@]12C[C@@H](O)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	The apparent volume of distribution of triamcinolone is 115.2±10L.4 The mean apparent volume of distribution of triamcinolone acetonide is 1.96L/kg.2 The apparent volume of distribution of triamcinolone diacetate is 119.7±33.14L.4	P08684;!P35354;!P06276;!P20815;!P24462	CYP3A4;!PTGS2;!BCHE;!CYP3A5;!CYP3A7	1. Cytochrome P450 3A4;!2. Prostaglandin G/H synthase 2;!3. Cholinesterase;!4. Cytochrome P450 3A5;!5. Cytochrome P450 3A7		41132	9667	CHEMBL1451	29046	Drugs.com Drug Page	GtP Drug Page	HMDB0014758		D00385		PDRhealth Drug Page	PA451749	31307	46507950	RxList Drug Page	10759	DAP000417	Triamcinolone	ZINC000003882036	Aller-cort, Allernaze, Aristocort, Aristocort R, Juulissa Pharmapak, Kenalog, Marcaine, Nasacort, Oracort, Oralone, Pediaderm Ta, Triaderm, Trianex, Triderm, Triesence, Triloan Suik, Tritocin, Viaderm Kc, Xipere, Zilretta	Triamcinolone	Approved, Vet approved	DB00620	InChI=1S/C21H27FO6/c1-18-6-5-12(24)7-11(18)3-4-13-14-8-15(25)21(28,17(27)10-23)19(14,2)9-16(26)20(13,18)22/h5-7,13-16,23,25-26,28H,3-4,8-10H2,1-2H3/t13-,14-,15+,16-,18-,19-,20-,21-/m0/s1	GFNANZIMVAIWHM-OBYCQNJPSA-N	4	Triamcinolone is a glucocorticoid used to treat a wide variety of inflammatory conditions of organ systems and tissues.	The subcutaneous LD50 of triamcinolone acetonide in rats is 13,100µg/kg and in mice is 132mg/kg.17 The oral LD50 in rats is 1451mg/kg and in mice is 2168mg/kg.[LD50] The intraperitoneal LD50 in mice is 105mg/kg.[LD50]Patients experiencing an overdose may develop Cushing's syndrome.6 This overdose may be treated with supportive therapy and mifepristone for its antiglucocorticoid activity.6	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3369 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor							270			1	Yes	6	4	No	4	0	115.06 Å2	39.8 Å3	99.38 m3·mol-1	2	Yes	No	0.847 mg/mL	0.24	-2.7	11.75	-3.3	P04150	NR3C1	1. Glucocorticoid receptor
C19H30O3	Not Available	0.55 hours (1st phage), 9 hours (2nd phase)	306.4397	[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)OC[C@]12C	Solid	Not Available	P11712	CYP2C9	1. Cytochrome P450 2C9			7820	CHEMBL1200436	5667	Drugs.com Drug Page		HMDB0014759	C07346	D00462			PA164749395	5878	46509027	RxList Drug Page	7779	DAP000905	Oxandrolone	ZINC000003813047	Oxandrin	Oxandrolone	Approved, Investigational	DB00621	InChI=1S/C19H30O3/c1-17-11-22-16(20)10-12(17)4-5-13-14(17)6-8-18(2)15(13)7-9-19(18,3)21/h12-15,21H,4-11H2,1-3H3/t12-,13+,14-,15-,17-,18-,19-/m0/s1	QSLJIVKCVHQPLV-PEMPUTJUSA-N	4	Oxandrolone is an androgenic hormone used to treat muscle loss from prolonged corticosteroid treatment and to treat bone pain associated with osteoporosis.	The oral LD50 of oxandrolone in mice and dogs is greater than 5,000 mg/kg.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.5177 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					4.2		236.5 °C			1	Yes	2	1	No	4	0	46.53 Å2	35.4 Å3	84.75 m3·mol-1	0	Yes	No	0.014 mg/mL	2.95	-4.3		-0.53	P10275	AR	1. Androgen receptor
C19H28O2	The mean metabolic clearance in middle aged men is 812±64L/day.3	The half life of testosterone is highly variable, ranging from 10-100 minutes.14,15,16,17,18,19,20	288.4244	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	The volume of distribution of testosterone in elderly men is 80.36±24.51L.2					8885	17347	CHEMBL386630	5791		GtP Drug Page	HMDB0000234	C00535	D00075	TES	PDRhealth Drug Page	PA451627	6013	46505691	RxList Drug Page	10379	DAP000841	Testosterone	ZINC000118912393	Androderm, Androgel, Axiron, Fortesta, Natesto, Striant, Testim, Testopel, Vogelxo	Testosterone	Approved, Investigational	DB00624	InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-17,21H,3-10H2,1-2H3/t14-,15-,16-,17-,18-,19-/m0/s1	MUMGGOZAMZWBJJ-DYKIIFRCSA-N	4	Testosterone is a hormone used to treat hypogonadism, breast carcinoma in women, or the vasomotor symptoms of menopause.	Data regarding an overdose with a topical testosterone product is not readily available.14,15,16,17,18,19,20 In the case of overdose with an injectable product, patients may present with a cerebrovascular event.14,15,16,17,18,19,20 Treat overdoses by stopping testosterone products, washing off any topical products with soap and water, and initiating symptomatic and supportive treatments.14,15,16,17,18,19,20	Small Molecule	http://smpdb.ca/view/SMP0000356?highlight[compounds][]=DB00624&highlight[proteins][]=DB00624;!http://smpdb.ca/view/SMP0030406?highlight[compounds][]=DB00624&highlight[proteins][]=DB00624;!http://smpdb.ca/view/SMP0000068?highlight[compounds][]=DB00624&highlight[proteins][]=DB00624;!http://smpdb.ca/view/SMP0000565?highlight[compounds][]=DB00624&highlight[proteins][]=DB00624	17-beta Hydroxysteroid Dehydrogenase III Deficiency;!Androstenedione Metabolism;!Androgen and Estrogen Metabolism;!Aromatase Deficiency		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.6259 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor		-4.34			3.32		155 °C		23.4 mg/L (at 25 °C)	1	Yes	2	1	No	4	0	37.3 Å2	33.88 Å3	84.43 m3·mol-1	0	Yes	Yes	0.0333 mg/mL	3.37	-3.9	18.52	-0.88			
C21H26O5	Data regarding the clearance of prednisone is not readily available.9A 5.5µg/h/kg infusion of prednisolone has an average clearance of 0.066±0.12L/h/kg, while a 0.15±0.03L/h/kg infusion has an average clearance of 0.15L/h/kg.3	Prednisone and its active metabolite prednisolone have half lives of 2-3 hours from both immediate and delayed release preparations.9	358.4281	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	Data regarding the volume of distribution for prednisone is not readily available.9 However, a 0.15mg/kg dose of prednisolone has a volume of distribution of 29.3L, while a 0.30mg/kg dose has a volume of distribution of 44.2L.6	P33261;!P20815;!BE0004866;!P11509;!Q16678;!P20813;!P10632;!P11712;!P28845;!P08684	CYP2C19;!CYP3A5;!;!CYP2A6;!CYP1B1;!CYP2B6;!CYP2C8;!CYP2C9;!HSD11B1;!CYP3A4	1. Cytochrome P450 2C19;!2. Cytochrome P450 3A5;!3. Cytochrome P450 3A Subfamily (Protein Group);!4. Cytochrome P450 2A6;!5. Cytochrome P450 1B1;!6. Cytochrome P450 2B6;!7. Cytochrome P450 2C8;!8. Cytochrome P450 2C9;!9. Corticosteroid 11-beta-dehydrogenase isozyme 1;!10. Cytochrome P450 3A4			8382	CHEMBL635	5656	Drugs.com Drug Page		HMDB0014773	C07370	D00473	PDN		PA451100	5865	46508166	RxList Drug Page	8640	DAP001041	Prednisone	ZINC000003875357	Deltasone, Rayos, Winpred	Prednisone	Approved, Vet approved	DB00635	InChI=1S/C21H26O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-15,18,22,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,18+,19-,20-,21-/m0/s1	XOFYZVNMUHMLCC-ZPOLXVRWSA-N		Prednisone is a corticosteroid used to treat inflammation or immune-mediated reactions and to treat endocrine or neoplastic diseases.	Data regarding acute overdoses of prednisone are rare but prolonged high doses of prednisone can lead to a higher incidence and severity of adverse effects such as mental symptoms, moon face, abnormal fat deposits, fluid retention, excessive appetite, weight gain, hypertrichosis, acne, striae, ecchymosis, increased sweating, pigmentation, dry scaly skin, thinning scalp hair, increased blood pressure, tachycardia, thrombophlebitis, decreased resistance to infection, negative nitrogen balance with delayed bone and wound healing, headache, weakness, menstrual disorders, accentuated menopausal symptoms, neuropathy, fractures, osteoporosis, peptic ulcer, decreased glucose tolerance, hypokalemia, and adrenal insufficiency.9	Small Molecule	http://smpdb.ca/view/SMP0000440?highlight[compounds][]=DB00635&highlight[proteins][]=DB00635;!http://smpdb.ca/view/SMP0000631?highlight[compounds][]=DB00635&highlight[proteins][]=DB00635	Prednisone Action Pathway;!Prednisone Metabolism Pathway		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.8914 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					1.46		230 - 235 °C (decomposes)		Very slightly soluble	1	Yes	5	2	No	4	0	91.67 Å2	38.2 Å3	97.57 m3·mol-1	2	Yes	No		1.66		12.58	-3.3	P04150	NR3C1	1. Glucocorticoid receptor
C22H28F2O5	Not Available	Not Available	410.458	[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4		50240002	34764	CHEMBL1201392	15632				C14479	D04208			PA164749388	16490	46505121		4458	DAP000814	Flumetasone	ZINC000003983936	Locacorten Vioform	Flumethasone	Approved, Vet approved	DB00663	InChI=1S/C22H28F2O5/c1-11-6-13-14-8-16(23)15-7-12(26)4-5-19(15,2)21(14,24)17(27)9-20(13,3)22(11,29)18(28)10-25/h4-5,7,11,13-14,16-17,25,27,29H,6,8-10H2,1-3H3/t11-,13+,14+,16+,17+,19+,20+,21+,22+/m1/s1	WXURHACBFYSXBI-GQKYHHCASA-N		Flumethasone is a corticosteroid used to treat contact dermatitis, atopic dermatitis, eczema, psoriasis, diaper rash, and other skin conditions.	Can lead to signs of irritation such as burning sensation, itching or skin rash at the site of application; hypersensitivity reactions.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.4249 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.86		219 °C (base only)		0.392 mg/L	1	Yes	5	3	No	4	0	94.83 Å2	41.25 Å3	102.32 m3·mol-1	2	Yes	No	0.0853 mg/mL	1.34	-3.7	12.42	-3.3	P04150	NR3C1	1. Glucocorticoid receptor
C21H29FO5	Population pharmacokinetics have estimated the plasma clearance of fludrocortisone to be 40.8 L/h.9	The plasma half-life of fludrocortisone has been variably reported to be between 1-3.5 hours,6,9,10 though prescribing information gives an approximate half-life of 18-36 hours.15	380.4504	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	The apparent volume of distribution of fludrocortisone is 80-85 L.9,6 Distribution into CSF appears minimal - the observed ratio of CSF drug concentration versus plasma drug concentration is 1:6.16	P08684;!P80365;!P28845	CYP3A4;!HSD11B2;!HSD11B1	1. Cytochrome P450 3A4;!2. Corticosteroid 11-beta-dehydrogenase isozyme 2;!3. Corticosteroid 11-beta-dehydrogenase isozyme 1			50885	CHEMBL1201388	29111	Drugs.com Drug Page	GtP Drug Page	HMDB0014825	C07004	D07967	ZK5		PA164743961	31378	46508616	RxList Drug Page	4452	DAP001105	Fludrocortisone	ZINC000004097304	Florinef	Fludrocortisone	Approved, Investigational	DB00687	InChI=1S/C21H29FO5/c1-18-7-5-13(24)9-12(18)3-4-15-14-6-8-20(27,17(26)11-23)19(14,2)10-16(25)21(15,18)22/h9,14-16,23,25,27H,3-8,10-11H2,1-2H3/t14-,15-,16-,18-,19-,20-,21-/m0/s1	AAXVEMMRQDVLJB-BULBTXNYSA-N	4	Fludrocortisone is a mineralocorticoid used to treat adrenocortical insufficiency and salt-losing adrenogenital syndrome.	The oral LD50 of fludrocortisone in rats is >1g/kg.17 Acute overdosage of fludrocortisone is likely to result in symptoms consistent with its adverse effect profile. Patients receiving a single large dose should be treated with plenty of water by mouth and should undergo monitoring of serum electrolytes, particularly potassium and sodium, and be treated appropriately for any developing imbalances.15,16	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1686 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	5	3	No	4	0	94.83 Å2	39.53 Å3	96.93 m3·mol-1	2	Yes	No	0.224 mg/mL	1.32	-3.2	12.55	-3.3	P08235;!P04150	NR3C2;!NR3C1	1. Mineralocorticoid receptor;!2. Glucocorticoid receptor
C24H30O6	Apparent plasma cl=10 L/hr	4-6 hours	414.4914	[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)C[C@H]1O[C@@]11[C@@]2([H])[C@@H](CC2=CC(=O)CC[C@]12C)C(=O)OC	Solid	43 to 90 L	P19099;!P08684;!P20815	CYP11B2;!CYP3A4;!CYP3A5	1. Cytochrome P450 11B2, mitochondrial;!2. Cytochrome P450 3A4;!3. Cytochrome P450 3A5		50318300	31547	CHEMBL1095097	10203511	Drugs.com Drug Page	GtP Drug Page	HMDB0014838	C12512	D01115	YNU	PDRhealth Drug Page	PA164749044	443872	46509053	RxList Drug Page	298869	DAP000085	Eplerenone	ZINC000003985982	Inspra	Eplerenone	Approved	DB00700	InChI=1S/C24H30O6/c1-21-7-4-14(25)10-13(21)11-15(20(27)28-3)19-16-5-8-23(9-6-18(26)30-23)22(16,2)12-17-24(19,21)29-17/h10,15-17,19H,4-9,11-12H2,1-3H3/t15-,16+,17-,19+,21+,22+,23-,24-/m1/s1	JUKPWJGBANNWMW-VWBFHTRKSA-N	4	Eplerenone is an aldosterone receptor antagonist used to improve survival of patients with symptomatic heart failure and to reduce blood pressure.	The most likely symptoms of human overdosage would be anticipated to be hypotension or hyperkalemia. However, no cases of human overdosage with eplerenone have been reported.	Small Molecule	http://smpdb.ca/view/SMP0000135?highlight[compounds][]=DB00700&highlight[proteins][]=DB00700	Eplerenone Action Pathway		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.4761 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					1.3				Slightly soluble	1	Yes	4	0	No	6	0	82.2 Å2	43.94 Å3	106.68 m3·mol-1	2	Yes	No	0.00903 mg/mL	2.33	-4.7	16.44	-4.2			
C20H26O2	The plasma clearance of norethisterone has been estimated as 0.4 L/hr/kg,4,19 and the intrinsic clearance is approximately 73-81 L/h.9	The half-life of norethisterone has been variably estimated as 8-10 hours.4,3,8,14,18	298.4192	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	Solid	The volume of distribution of norethisterone is approximately 4 L/kg.4,19 Sulfated metabolites of norethisterone, as well as small quantities of parent drug, have been shown to distribute into breast milk.11	P08684;!P17516;!P26439;!BE0004887;!P51857;!P33261;!P05177;!P11509	CYP3A4;!AKR1C4;!HSD3B2;!;!AKR1D1;!CYP2C19;!CYP1A2;!CYP2A6	1. Cytochrome P450 3A4;!2. Aldo-keto reductase family 1 member C4;!3. 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2;!4. 3-oxo-5-alpha-steroid 4-dehydrogenase (Protein Group);!5. 3-oxo-5-beta-steroid 4-dehydrogenase;!6. Cytochrome P450 2C19;!7. Cytochrome P450 1A2;!8. Cytochrome P450 2A6		50148732	7627	CHEMBL1162	5994	Drugs.com Drug Page		HMDB0014855	C05028	D00182	NDR	PDRhealth Drug Page	PA450651	6230	46504816	RxList Drug Page	7514	DAP001212	Norethisterone	ZINC000085205451	Activella 1/0.5 28 Day, Activelle, Alyacen 1/35, Alyacen 7/7/7, Amabelz 0.5/0.1 28 Day, Aranelle 28, Aurovela, Aurovela Fe, Aygestin, Balziva 28 Day, Blisovi 21 Fe 1.5/30 28 Day Pack, Blisovi 24 Fe 1/20 28 Day, Brevicon, Briellyn 28 Day, Camila 28 Day, Charlotte 24 Fe Chewable 28 Day, Combipatch, Cyclafem 1/35 28 Day, Cyclafem 7/7/7 28 Day, Cyonanz 28 Day, Dasetta 1/35 28 Day, Dasetta 7/7/7 28 Day, Deblitane 28 Day, Errin 28 Day, Estalis, Estrostep Fe 28 Day, Femcon Fe 28 Day, Femhrt 0.5/2.5 28 Day, Fyavolv, Gemmily 28 Day, Generess Fe 28, Hailey 1.5/30 21 Day, Hailey 24 Fe 28 Day, Hailey Fe 1.5/30 28 Day, Hailey Fe 1/20 28 Day, Heather 28 Day, Incassia, Jencycla 28 Day, Jinteli, Junel 1.5/30 21 Day, Junel 1/20 21 Day, Junel Fe 1.5/30 28 Day, Junel Fe 1/20 28 Day, Junel Fe 24 1/20 28 Day, Kaitlib Fe 28 Day, Larin 1.5/30, Larin 1/20, Larin 24 Fe 1/20, Larin Fe 1.5/30, Larin Fe 1/20, Layolis Fe 28, Leena 28 Day, Lo Loestrin Fe 28 Day, Loestrin 1.5/30 21 Day, Loestrin 24 Fe 28 Day, Loestrin Fe 1/20 28 Day, Lolo, Lomedia 24 Fe, Lopreeza 1/0.5 28 Day, Lupaneta Pack 1-month, Lyleq 28 Day, Lyza, Melodetta 24 Fe Chewable 28 Day, Merzee 28 Day, Microgestin 1.5/30 21 Day, Microgestin 1/20 21 Day, Microgestin 24 Fe 28 Day, Microgestin Fe 1.5/30 28 Day, Microgestin Fe 1/20 28 Day, Mimvey, Minastrin 24 Fe Chewable 28 Day, Myfembree, Necon 0.5/35 28 Day, Necon 1/35 28 Day, Necon 7/7/7 28 Day, Nexesta Fe 28 Day, Nora-BE 28 Day, Norlutate, Norlyda 28 Day, Norlyroc 28 Day, Nortrel 1/35 21 Day, Nortrel 1/35 28 Day, Nortrel 7/7/7 28 Day, Nylia 1/35 28 Day, Nylia 7/7/7 28 Day, Oriahnn 28 Day Kit, Ortho Micronor, Ortho Micronor 28 Day, Ortho-novum 7/7/7 28 Day, Philith 28 Day, Pirmella 1/35 28 Day, Pirmella 7/7/7 28 Day, Select, Sharobel 28 Day, Synphasic, Tarina 24 Fe 1/20 28 Day, Tarina Fe 1/20 28 Day, Taysofy 28 Day, Taytulla 28 Day, Tilia Fe, Tri-legest 28 Day, Tulana 28 Day, Vyfemla 28 Day, Wera 28 Day, Wymzya Fe 28 Day, Zenchent	Norethisterone	Approved	DB00717	InChI=1S/C20H26O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,12,15-18,22H,4-11H2,2H3/t15-,16+,17+,18-,19-,20-/m0/s1	VIKNJXKGJWUCNN-XGXHKTLJSA-N	4	Norethisterone is a synthetic second-generation progestin used for contraception, prevention of endometrial hyperplasia in hormone replacement therapy, and in the treatment of other hormone-mediated illnesses such as endometriosis.	The oral LD50 in mice 6 g/kg and the TDLo in human women is 42 mg/kg.20 There have been no reports of serious ill effects following overdose of oral contraceptives, including following ingestion by children.19,18 Symptoms of overdosage are likely to be consistent with the adverse effect profile of the contraceptive and may, therefore, include significant nausea and/or vomiting.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.8788 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							202-208C			1	Yes	2	1	No	4	0	37.3 Å2	34.59 Å3	87.42 m3·mol-1	0	Yes	Yes	0.00668 mg/mL	3.22	-4.6	17.59	-1.7			
C32H53N2O4	0.25 L/kg/hr [Adults (Ages 27 to 58 years)]0.21 L/kg/hr [Geriatrics (>=65 yrs)]0.16 L/kg/hr [Normal ewnal and hepatice function]0.13 L/kg/hr [Renal transplant patients]0.13 L/kg/hr [Hepatic dysfunction patients]0.35 +/- 0.08 L/kg/hr [Pediatric Patients 3 to <12 mos]0.32 +/- 0.07 L/kg/hr [Pediatric Patients 1 to 3 yrs]0.44 +/- 0.16 L/kg/hr [Pediatric Patients 3 to 8 yrs]	The rapid distribution half-life is 1-2 minutes and the slower distribution half-life is 14-18 minutes. Renal impairment has no net effect on half-life, however, half-life is almost doubled in patients with impaired liver function.	529.7742	[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](O)[C@H](C[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1	Solid	0.3 L/kg [3 to <12 mos]0.26 L/kg [1 to <3 yrs]0.21 L/kg [3 to <8 yrs]						8884	CHEMBL1201244	390053	Drugs.com Drug Page	GtP Drug Page	HMDB0014866	C07556	D00765			PA164754992	441290	46506855	RxList Drug Page	68139	DAP000349	Rocuronium_bromide	ZINC000053229445		Rocuronium	Approved	DB00728	InChI=1S/C32H53N2O4/c1-5-14-34(15-6-7-16-34)28-20-26-24-9-8-23-19-29(36)27(33-12-17-37-18-13-33)21-32(23,4)25(24)10-11-31(26,3)30(28)38-22(2)35/h5,23-30,36H,1,6-21H2,2-4H3/q+1/t23-,24+,25-,26-,27-,28-,29-,30-,31-,32-/m0/s1	YXRDKMPIGHSVRX-OOJCLDBCSA-N	4	Rocuronium is a vecuronium analog used to facilitate tracheal intubation and to relax skeletal muscles during surgery.	No cases of significant accidental or intentional overdose have been reported. Overdosage with neuromuscular blocking agents may result in neuromuscular block beyond the time needed for surgery and anesthesia.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Inhibitor	Inhibitor	Substrate	2.9310 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor									Complete	1	No	4	1	Yes	6	2	59 Å2	62.78 Å3	161.65 m3·mol-1	6	No	No	2.84e-05 mg/mL	-0.33	-7.3	14.59	7.96	Q15822;!P08172;!P46098	CHRNA2;!CHRM2;!HTR3A	1. Neuronal acetylcholine receptor subunit alpha-2;!2. Muscarinic acetylcholine receptor M2;!3. 5-hydroxytryptamine receptor 3A
C21H30O5	Total hydrocortisone by the oral route has a mean clearance of 12.85L/h, while the free fraction has a mean clearance of 235.78L/h.1 A 20mg IV dose of hydrocortisone has a clearance of 18.2±4.2L/h.6	Total hydrocortisone via the oral route has a half life of 2.15h while the free fraction has a half life of 1.39h.1 A 20mg IV dose of hydrocortisone has a terminal half life of 1.9±0.4h.6	362.4599	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	Total hydrocortisone has a volume of distribution of 39.82L, while the free fraction has a volume of distribution of 474.38L.1					13775	17650	CHEMBL389621	5551	Drugs.com Drug Page	GtP Drug Page	HMDB0000063	C00735	D00088	HCY	PDRhealth Drug Page	PA449905	5754	46505089	RxList Drug Page	5492	DAP000718	Hydrocortisone	ZINC000013540519	Ala-cort, Ala-scalp, Alcortin, Alkindi, Anusol HC, Aquanil HC, Casporyn HC, Cipro, Cipro HC, Colocort, Cortaid, Cortane-B, Cortef, Cortenema, Cortisporin, Cortizone-10, Dermacort, Dermarest Eczema, Dermazene, Home Papkit, Hydroskin, Monistat Itch Relief, Neosporin Eczema, Preparation H Hydrocortisone, Procto-med, Procto-pak, Proctocort, Proctol, Proctosedyl, Proctosol, Proctozone HC, Scalpicin Itch Relief, Texacort, Vanoxide-HC, Xerese	Hydrocortisone	Approved, Vet approved	DB00741	InChI=1S/C21H30O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h9,14-16,18,22,24,26H,3-8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1	JYGXADMDTFJGBT-VWUMJDOOSA-N	4	Hydrocortisone is a glucocorticoid used to treat corticosteroid-responsive dermatoses, endocrine disorders, immune conditions, and allergic disorders.	Data regarding acute overdoses of glucocorticoids are rare.14,15,16,17,18,19 Chronic high doses of glucocorticoids can lead to the development of cataract, glaucoma, hypertension, water retention, hyperlipidemia, peptic ulcer, pancreatitis, myopathy, osteoporosis, mood changes, psychosis, dermal atrophy, allergy, acne, hypertrichosis, immune suppression, decreased resistance to infection, moon face, hyperglycemia, hypocalcemia, hypophosphatemia, metabolic acidosis, growth suppression, and secondary adrenal insufficiency.8 Overdose may be treated by adjusting the dose or stopping the corticosteroid as well as initiating symptomatic and supportive treatment.8	Small Molecule	http://smpdb.ca/view/SMP0000372?highlight[compounds][]=DB00741&highlight[proteins][]=DB00741;!http://smpdb.ca/view/SMP0000577?highlight[compounds][]=DB00741&highlight[proteins][]=DB00741;!http://smpdb.ca/view/SMP0000718?highlight[compounds][]=DB00741&highlight[proteins][]=DB00741;!http://smpdb.ca/view/SMP0000310?highlight[compounds][]=DB00741&highlight[proteins][]=DB00741;!http://smpdb.ca/view/SMP0000371?highlight[compounds][]=DB00741&highlight[proteins][]=DB00741;!http://smpdb.ca/view/SMP0000575?highlight[compounds][]=DB00741&highlight[proteins][]=DB00741;!http://smpdb.ca/view/SMP0000717?highlight[compounds][]=DB00741&highlight[proteins][]=DB00741;!http://smpdb.ca/view/SMP0000130?highlight[compounds][]=DB00741&highlight[proteins][]=DB00741;!http://smpdb.ca/view/SMP0000373?highlight[compounds][]=DB00741&highlight[proteins][]=DB00741;!http://smpdb.ca/view/SMP0000566?highlight[compounds][]=DB00741&highlight[proteins][]=DB00741;!http://smpdb.ca/view/SMP0000576?highlight[compounds][]=DB00741&highlight[proteins][]=DB00741;!http://smpdb.ca/view/SMP0000578?highlight[compounds][]=DB00741&highlight[proteins][]=DB00741	Adrenal Hyperplasia Type 5 or Congenital Adrenal Hyperplasia Due to 17 alpha-Hydroxylase Deficiency;!Corticosterone Methyl Oxidase I Deficiency (CMO I);!3-beta-Hydroxysteroid Dehydrogenase Deficiency;!Corticotropin Activation of Cortisol Production;!Congenital Lipoid Adrenal Hyperplasia (CLAH) or Lipoid CAH;!11-beta-Hydroxylase Deficiency (CYP11B1);!Apparent Mineralocorticoid Excess Syndrome;!Steroidogenesis;!Adrenal Hyperplasia Type 3 or Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency;!17-alpha-Hydroxylase Deficiency (CYP17);!21-Hydroxylase Deficiency (CYP21);!Corticosterone Methyl Oxidase II Deficiency (CMO II)		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.8914 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor		-4.66			1.61	-2.97	220 °C		320 mg/L (at 25 °C)	1	Yes	5	3	No	4	0	94.83 Å2	39.45 Å3	97.4 m3·mol-1	2	Yes	No	0.199 mg/mL	1.28	-3.3	12.59	-2.8			
C22H28Cl2O4	Not Available	5.8 hours	427.361	[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	Not Available	P10632;!P08684;!P20815	CYP2C8;!CYP3A4;!CYP3A5	1. Cytochrome P450 2C8;!2. Cytochrome P450 3A4;!3. Cytochrome P450 3A5		50237628	6970	CHEMBL1201404	390090	Drugs.com Drug Page		HMDB0014902	C07816	D08227		PDRhealth Drug Page	PA450541	441335	46505288	RxList Drug Page	108118	DAP001042	Mometasone	ZINC000004097440		Mometasone	Experimental	DB00764	InChI=1S/C22H28Cl2O4/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,24)17(26)10-20(16,3)22(12,28)18(27)11-23/h6-7,9,12,15-17,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1	QLIIKPVHVRXHRI-CXSFZGCWSA-N	4	Mometasone is a corticosteroid with no indications.	The potential for acute toxic effects following overdose with the mometasone inhaler is low. However, habitual overuse of the product can cause symptoms of steroid overload, including menstrual irregularities, acne, obesity, and muscle weakness. Single oral doses up to 8000 µg have been studied on human volunteers with no adverse events reported.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.9124 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.1		218-220 °C		Practically insoluble.	1	Yes	4	2	No	4	0	74.6 Å2	43.82 Å3	110.29 m3·mol-1	2	Yes	No	0.00523 mg/mL	3.5	-4.9	12.49	-3.3	P04150;!P06401	NR3C1;!PGR	1. Glucocorticoid receptor;!2. Progesterone receptor
C27H41NO6	Not Available	Not Available	475.6175	[H][C@@]12CC[C@](O)(C(=O)COC(=O)CN(CC)CC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			50851	CHEMBL1201263	75860			HMDB0014907					PA164745515	84088	46509076			DAP001187	Hydrocortamate	ZINC000004213506		Hydrocortamate	Approved	DB00769	InChI=1S/C27H41NO6/c1-5-28(6-2)15-23(32)34-16-22(31)27(33)12-10-20-19-8-7-17-13-18(29)9-11-25(17,3)24(19)21(30)14-26(20,27)4/h13,19-21,24,30,33H,5-12,14-16H2,1-4H3/t19-,20-,21-,24+,25-,26-,27-/m0/s1	FWFVLWGEFDIZMJ-FOMYWIRZSA-N			Side effects include burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, miliaria.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.9454 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					1.2		162-163			1	No	6	2	Yes	4	0	104.14 Å2	53.53 Å3	129.48 m3·mol-1	8	Yes	No	0.0855 mg/mL	2.32	-3.8	12.61	6.99	P04150	NR3C1	1. Glucocorticoid receptor
C18H24O2	In one pharmacokinetic study, the clearance of orally administered micronized estradiol in postmenopausal women was 29.9±15.5 mL/min/kg.10 Another study revealed a clearance of intravenously administered estradiol was 1.3 mL/min/kg.23	The terminal half-lives for various estrogen products post oral or intravenous administration has been reported to range from 1-12 hours.10 One pharmacokinetic study of oral estradiol valerate administration in postmenopausal women revealed a terminal elimination half-life of 16.9 ± 6.0 h.22 A pharmacokinetic study of intravenous estradiol administration in postmenopausal women showed an elimination half-life of 27.45 ± 5.65 minutes.23 The half-life of estradiol appears to vary by route of administration.	272.382	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	Solid	Estrogens administered exogenously distribute in a similar fashion to endogenous estrogens. They can be found throughout the body, especially in the sex hormone target organs, such as the breast, ovaries and uterus.10,21,27	P08684;!P05177;!P20815;!P24462;!P22309;!P04798;!Q16678;!P33261;!P10632;!P11712;!P54855;!P21964;!BE0009758;!P11511	CYP3A4;!CYP1A2;!CYP3A5;!CYP3A7;!UGT1A1;!CYP1A1;!CYP1B1;!CYP2C19;!CYP2C8;!CYP2C9;!UGT2B15;!COMT;!;!CYP19A1	1. Cytochrome P450 3A4;!2. Cytochrome P450 1A2;!3. Cytochrome P450 3A5;!4. Cytochrome P450 3A7;!5. UDP-glucuronosyltransferase 1-1;!6. Cytochrome P450 1A1;!7. Cytochrome P450 1B1;!8. Cytochrome P450 2C19;!9. Cytochrome P450 2C8;!10. Cytochrome P450 2C9;!11. UDP-glucuronosyltransferase 2B15;!12. Catechol O-methyltransferase;!13. UDP-glucuronosyltransferases (UGTs) (Protein Group);!14. Cytochrome P450 19A1		17292	16469	CHEMBL135	5554	Drugs.com Drug Page	GtP Drug Page	HMDB0000151	C00951	D00105	EST		PA449503	5757	46508115	RxList Drug Page	4083	DAP000854	Estradiol_(medication)	ZINC000013520815	Activella 1/0.5 28 Day, Activelle, Alora, Amabelz 0.5/0.1 28 Day, Angeliq 0.25/0.5 28 Day, Bijuva, Climara, Climara Pro, Combipatch, Divigel, Dotti, Elestrin, Estalis, Estrace, Estradot, Estring, Estrogel, Evamist, Imvexxy 4 Mcg Starter Pack, Lopreeza 1/0.5 28 Day, Lyllana, Menostar, Mimvey, Minivelle, Myfembree, Oesclim, Oriahnn 28 Day Kit, Prefest 30 Day, Vagifem, Vivelle, Yuvafem	Estradiol	Approved, Investigational, Vet approved	DB00783	InChI=1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-17,19-20H,2,4,6-9H2,1H3/t14-,15-,16+,17+,18+/m1/s1	VOXZDWNPVJITMN-ZBRFXRBCSA-N	4	Estradiol is an estrogenic steroid used to treat vasomotor symptoms of vulvar and vaginal atrophy in menopause, hypoestrogenism, prevention of postmenopausal osteoporosis, treatment of breast cancer, and advanced androgen-dependent carcinoma of the prostate.	The NOAEL (no-observed-adverse-effect-level) oral toxicity of estradiol after 90 day in rats was 0.003 mg/kg/day for blood, female reproductive, and male reproductive, endocrine, and liver toxicity.36 Oral TDLO of ethinyl estradiol is 21 mg/kg/21D intermittent, woman) with an oral LD50 of 960 mg/kg in the rat.37 There is limited information in the literature regarding estrogen overdose. Estradiol overdose likely leads to the occurrence of estrogen-associated adverse effects, including nausea, vomiting, abdominal pain, breast tenderness, venous thrombosis, and vaginal bleeding.35 It is generally recommend to discontinue estradiol treatment and offer supportive care in the case of an overdose.30	Small Molecule	http://smpdb.ca/view/SMP0030880?highlight[compounds][]=DB00783&highlight[proteins][]=DB00783;!http://smpdb.ca/view/SMP0000356?highlight[compounds][]=DB00783&highlight[proteins][]=DB00783;!http://smpdb.ca/view/SMP0000068?highlight[compounds][]=DB00783&highlight[proteins][]=DB00783;!http://smpdb.ca/view/SMP0000565?highlight[compounds][]=DB00783&highlight[proteins][]=DB00783	Estrone Metabolism;!17-beta Hydroxysteroid Dehydrogenase III Deficiency;!Androgen and Estrogen Metabolism;!Aromatase Deficiency		Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.2272 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor		-4.77		445.9±45.0	4.01		173	10.46±0.03	3.6 mg/L (at 27 °C)	1	Yes	2	2	No	4	0	40.46 Å2	32.12 Å3	79.9 m3·mol-1	0	Yes	No	0.0213 mg/mL	3.75	-4.1	10.33	-0.88			
C24H32O4	Not Available	Not Available	384.5085	[H][C@@]12CC[C@@](OC(C)=O)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CC[C@H](OC(C)=O)C=C3CC[C@@]21[H]	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4		50237627	31580	CHEMBL1200624	8913			HMDB0014961	C12724	D01294			PA164749157	9270	46506993	RxList Drug Page	4170	DAP000856	Etynodiol_diacetate	ZINC000003876023	Kelnor 1/35 28 Day, Kelnor 1/50 28 Day, Zovia 1/35e 28 Day, Zovia 1/50e 28 Day	Ethynodiol diacetate	Approved	DB00823	InChI=1S/C24H32O4/c1-5-24(28-16(3)26)13-11-22-21-8-6-17-14-18(27-15(2)25)7-9-19(17)20(21)10-12-23(22,24)4/h1,14,18-22H,6-13H2,2-4H3/t18-,19-,20+,21+,22-,23-,24-/m0/s1	ONKUMRGIYFNPJW-KIEAKMPYSA-N	1	Ethynodiol diacetate is an oral contraceptive used to prevent pregnancy.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.1783 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					5		126-127			1	Yes	2	0	No	4	0	52.6 Å2	44.13 Å3	106.62 m3·mol-1	4	Yes	No	0.00397 mg/mL	3.69	-5		-6.7	P06401;!P03372	PGR;!ESR1	1. Progesterone receptor;!2. Estrogen receptor alpha
C29H35NO2	Not Available	18 hours	429.5937	[H][C@@]12CC[C@@](O)(C#CC)[C@@]1(C)C[C@H](C1=CC=C(C=C1)N(C)C)C1=C3CCC(=O)C=C3CC[C@@]21[H]	Solid	Not Available					50072024	50692	CHEMBL1276308	49889	Drugs.com Drug Page	GtP Drug Page	HMDB0014972	C07652	D00585	486		PA450500	55245	46505795	RxList Drug Page	6964	DAP000090	Mifepristone	ZINC000003831128	Korlym, Mifegymiso	Mifepristone	Approved, Investigational	DB00834	InChI=1S/C29H35NO2/c1-5-15-29(32)16-14-26-24-12-8-20-17-22(31)11-13-23(20)27(24)25(18-28(26,29)2)19-6-9-21(10-7-19)30(3)4/h6-7,9-10,17,24-26,32H,8,11-14,16,18H2,1-4H3/t24-,25+,26-,28-,29-/m0/s1	VKHAHZOOUSRJNA-GCNJZUOMSA-N	4	Mifepristone is a cortisol receptor blocker used to treat Cushing's syndrome, and to terminate pregnancies up to 70 days gestation.	Nearly all of the women who receive mifepristone will report adverse reactions, and many can be expected to report more than one such reaction. About 90% of patients report adverse reactions following administration of misoprostol on day three of the treatment procedure. Side effects include more heavy bleeding than a heavy menstrual period, abdominal pain, uterine cramping, nausea, vomiting, and diarrhea.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.7705 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					4.5		191-196 °C		Poorly soluble	1	No	3	1	No	5	0	40.54 Å2	50.69 Å3	132.58 m3·mol-1	3	No	No	0.00336 mg/mL	5.13	-5.1	12.87	4.89			
C22H28ClFO4	Not Available	Not Available	410.907	[H][C@@]12C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C	Solid	Not Available						59582		4470589	Drugs.com Drug Page		HMDB0014976		D07719			PA164744013	5311052	46505290	RxList Drug Page	21249	DAP001190	Clocortolone	ZINC000021981454	Cloderm	Clocortolone	Approved	DB00838	InChI=1S/C22H28ClFO4/c1-11-6-13-14-8-16(24)15-7-12(26)4-5-21(15,3)22(14,23)18(28)9-20(13,2)19(11)17(27)10-25/h4-5,7,11,13-14,16,18-19,25,28H,6,8-10H2,1-3H3/t11-,13+,14+,16+,18+,19-,20+,21+,22+/m1/s1	YMTMADLUXIRMGX-RFPWEZLHSA-N	1	Clocortolone is a corticosteroid used to treat inflammatory and pruritic dermatoses of the scalp.	Topically applied clocortolone can be absorbed in sufficient amounts to produce systemic effects. Symptoms of overdose include thinning of skin and suppression of adrenal cortex (decreased ability to respond to stress).	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.9732 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.8					1	Yes	4	2	No	4	0	74.6 Å2	41.8 Å3	105.74 m3·mol-1	2	Yes	No	0.015 mg/mL	2.47	-4.4	13.54	-3.3	P04150	NR3C1	1. Glucocorticoid receptor
C24H33FO6	Not Available	Not Available	436.5136	CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4		50240003	5127	CHEMBL1201012	14475	Drugs.com Drug Page		HMDB0014984		D00328			PA164750513	15209	46505159	RxList Drug Page	4500	DAP000418	Fludroxycortide	ZINC000004097308	Cordran, Nolix	Flurandrenolide	Approved	DB00846	InChI=1S/C24H33FO6/c1-21(2)30-19-9-14-13-8-16(25)15-7-12(27)5-6-22(15,3)20(13)17(28)10-23(14,4)24(19,31-21)18(29)11-26/h7,13-14,16-17,19-20,26,28H,5-6,8-11H2,1-4H3/t13-,14-,16-,17-,19+,20+,22-,23-,24+/m0/s1	POPFMWWJOGLOIF-XWCQMRHXSA-N	3	Flurandrenolide is a corticosteroid used to treat corticosteroid-responsive dermatoses.	Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary- adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.2002 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					0.6		251 °C		Insoluble	1	Yes	6	2	No	5	0	93.06 Å2	45.51 Å3	110.79 m3·mol-1	2	Yes	No	0.0578 mg/mL	1.56	-3.9	13.74	-2.8	P04150	NR3C1	1. Glucocorticoid receptor
C20H32O2	Not Available	Not Available	304.4669	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)[C@H](C)C[C@]12C	Solid	Not Available	P11511	CYP19A1	1. Cytochrome P450 19A1			34838	CHEMBL1582	5789			HMDB0014996	C14605				PA164760855	6011	46508724		23678	DAP000840	Drostanolone	ZINC000003875387		Drostanolone	Illicit	DB00858	InChI=1S/C20H32O2/c1-12-11-20(3)13(10-17(12)21)4-5-14-15-6-7-18(22)19(15,2)9-8-16(14)20/h12-16,18,22H,4-11H2,1-3H3/t12-,13+,14+,15+,16+,18+,19+,20+/m1/s1	IKXILDNPCZPPRV-RFMGOVQKSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.2244 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.99		151 °C			1	Yes	2	1	No	4	0	37.3 Å2	36.63 Å3	88.18 m3·mol-1	0	Yes	Yes	0.00605 mg/mL	3.95	-4.7	19.38	-0.88	P10275	AR	1. Androgen receptor
C21H28O5	A 0.15mg/kg dose of prednisolone has a clearance of 0.09L/kg/h, while a 0.30mg/kg dose has a clearance of 0.12L/kg/h.1	Prednisolone has a plasma half life of 2.1-3.5 hours.1 This half life is shorter in children and longer in those with liver disease.1	360.444	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	A 0.15mg/kg dose of prednisolone has a volume of distribution of 29.3L, while a 0.30mg/kg dose has a volume of distribution of 44.2L.1	P08684	CYP3A4	1. Cytochrome P450 3A4		19190	8378	CHEMBL131	5552	Drugs.com Drug Page	GtP Drug Page	HMDB0014998	C07369	D00472	TUA		PA451096	5755	46504847	RxList Drug Page	8638	DAP000419	Prednisolone	ZINC000003833821	Millipred Dp 6 Day	Prednisolone	Approved, Vet approved	DB00860	InChI=1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-16,18,22,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1	OIGNJSKKLXVSLS-VWUMJDOOSA-N	4	Prednisolone is a glucocorticoid used to treat adrenocortical insufficiency, inflammatory conditions, and some cancers.	The intraperitoneal LD50 in rats is 2g/kg and 65mg/kg in mice.8 The subcutaneous LD50 in rats is 147mg/kg and >3500mg/kg in mice.8 The oral LD50 in mice is 1680mg/kg.8 In humans, the oral TDLO in men is 9mg/kg/2W and in women is 14mg/kg/13D.8Patients experiencing an overdose of prednisolone may present with gastrointestinal disturbances, insomnia, and restlessness.5 Overdose of oral prednisolone may be treated by gastric lavage or inducing vomiting if the overdose was recent, as well as supportive and symptomatic therapy.9 Chronic overdosage may be treated by dose reduction or treating patients on alternate days.9 An overdose by the ophthalmic route is not expected to cause problems.9	Small Molecule	http://smpdb.ca/view/SMP0000440?highlight[compounds][]=DB00860&highlight[proteins][]=DB00860;!http://smpdb.ca/view/SMP0000441?highlight[compounds][]=DB00860&highlight[proteins][]=DB00860;!http://smpdb.ca/view/SMP0000631?highlight[compounds][]=DB00860&highlight[proteins][]=DB00860;!http://smpdb.ca/view/SMP0000632?highlight[compounds][]=DB00860&highlight[proteins][]=DB00860	Prednisone Action Pathway;!Prednisolone Action Pathway;!Prednisone Metabolism Pathway;!Prednisolone Metabolism Pathway		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.8914 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					1.62	-3.21	235 °C		223 mg/L (at 25 °C)	1	Yes	5	3	No	4	0	94.83 Å2	38.69 Å3	98.49 m3·mol-1	2	Yes	No	0.239 mg/mL	1.27	-3.2	12.59	-2.9			
C21H27ClO5	Not Available	Not Available	394.889	[H][C@@]12CC[C@](O)(C(=O)OCCl)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Not Available	Not Available						50848		8041134												237027		Loteprednol	ZINC000030691679	Alrex, Lotemax, Zylet	Loteprednol	Approved, Experimental	DB00873	InChI=1S/C21H27ClO5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,18(25)27-11-22)20(15,2)10-16(24)17(14)19/h5,7,9,14-17,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,17+,19-,20-,21-/m0/s1	YPZVAYHNBBHPTO-MXRBDKCISA-N		Loteprednol is a corticosteroid indicated in the treatment of pain and inflammation after cataract surgery.	Not Available	Small Molecule																																			1	Yes	4	2	No	4	0	83.83 Å2	41.29 Å3	102.65 m3·mol-1	3	Yes	No	0.0336 mg/mL	2.52	-4.1	12.01	-2.9			
C19H24O3	Not Available	Not Available	300.3921	[H][C@@]12CCC3=CC(=O)C=C[C@]3(C)[C@@]1([H])CC[C@]1(C)OC(=O)CC[C@@]21[H]	Solid	Not Available					50367848	9460	CHEMBL1571	13172	Drugs.com Drug Page		HMDB0015031	C02197	D00153			PA164743056	13769	46508076	RxList Drug Page	10378	DAP000624	Testolactone	ZINC000004081771		Testolactone	Approved, Investigational	DB00894	InChI=1S/C19H24O3/c1-18-9-7-13(20)11-12(18)3-4-14-15(18)8-10-19(2)16(14)5-6-17(21)22-19/h7,9,11,14-16H,3-6,8,10H2,1-2H3/t14-,15+,16+,18+,19+/m1/s1	BPEWUONYVDABNZ-DZBHQSCQSA-N	4	Testolactone is a medication used to treat advanced breast cancer.	Oral LD50s in mouse and dog are 1630 mg/kg and 593-926 mg/kg, respectively.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.7356 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.7		218.5 °C		Slightly soluble (27.4 mg/L)	1	Yes	2	0	No	4	0	43.37 Å2	33.42 Å3	85.79 m3·mol-1	0	Yes	No	0.023 mg/mL	3.23	-4.1	18.37	-5			
C27H44O3	1.49 +/- 0.60 L/h [chronic kidney disease Stage 5 with hemodialysis]1.54 +/- 0.95 L/h [chronic kidney disease Stage 5with peritoneal dialysis]	4 to 6 hours	416.6365	[H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1C[C@@H](O)C[C@H](O)C1)[C@H](C)\C=C\[C@H](C)C(C)(C)O	Solid	30.8 ± 7.5 L [CKD Stage 5-HD]34.9 ± 9.5 L [CKD Stage 5-PD]23.8 L [healthy subjects]	Q07973;!P08684;!P22310	CYP24A1;!CYP3A4;!UGT1A4	1. 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial;!2. Cytochrome P450 3A4;!3. UDP-glucuronosyltransferase 1-4		233195	7931	CHEMBL1200622	4444552	Drugs.com Drug Page		HMDB0015046	C08127	D00930			PA450798	5281104	46505780	RxList Drug Page	73710	DAP000211	Paricalcitol	ZINC000013911941	Zemplar	Paricalcitol	Approved, Investigational	DB00910	InChI=1S/C27H44O3/c1-18(8-9-19(2)26(3,4)30)24-12-13-25-21(7-6-14-27(24,25)5)11-10-20-15-22(28)17-23(29)16-20/h8-11,18-19,22-25,28-30H,6-7,12-17H2,1-5H3/b9-8+,21-11+/t18-,19+,22-,23-,24-,25+,27-/m1/s1	BPKAHTKRCLCHEA-UBFJEZKGSA-N	4	Paricalcitol is a vitamin D analog used to treat hyperparathyroidism associated with stage 3 or greater chronic kidney disease.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	4.4277 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					4.5					1	No	3	3	No	3	0	60.69 Å2	51.06 Å3	127.95 m3·mol-1	5	Yes	No	0.0068 mg/mL	4.26	-4.8	14.81	-1	P11473	VDR	1. Vitamin D3 receptor
C29H41NO4	Clearance may be higher in children than in adults.Plasma clearance rate, IV administration, anaesthetized patients = 901.2 ± 39.7 mL/min;Plasma clearance rate, IV administration, healthy subjects = 1042 - 1280 mL/min.	Buprenorphine demonstrates slow dissociation kinetics (~166 min), which contributes to its long duration of action and allows for once-daily or even every-second-day dosing.18 In clinical trial studies, the half-life of sublingually administered buprenorphine/naloxone 2mg/0.5mg was found to be 30.75 hours.19,20	467.6401	CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4	Solid	Buprenorphine is highly lipophilic, and therefore extensively distributed, with rapid penetration through the blood-brain barrier. The estimated volume of distribution is 188 - 335 L when given intravenously. It is able to cross into the placenta and breast milk.	P08684;!P20815;!P11712;!P10632;!P24462;!P10635;!P33260;!P33261	CYP3A4;!CYP3A5;!CYP2C9;!CYP2C8;!CYP3A7;!CYP2D6;!CYP2C18;!CYP2C19	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5;!3. Cytochrome P450 2C9;!4. Cytochrome P450 2C8;!5. Cytochrome P450 3A7;!6. Cytochrome P450 2D6;!7. Cytochrome P450 2C18;!8. Cytochrome P450 2C19		50026603	3216	CHEMBL560511	559124	Drugs.com Drug Page		HMDB0015057	C08007	D07132			PA448685	644073	46505782	RxList Drug Page	1819	DAP001353	Buprenorphine	ZINC000001319780	Belbuca, Buprenex, Buprenorphine, Butrans, Probuphine, Sublocade, Suboxone, Subutex, Zubsolv	Buprenorphine	Approved, Illicit, Investigational, Vet approved	DB00921	InChI=1S/C29H41NO4/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3/t20-,21-,24-,26+,27-,28+,29-/m1/s1	RMRJXGBAOAMLHD-IHFGGWKQSA-N	4	Buprenorphine is a partial opioid agonist used for management of severe pain that is not responsive to alternative treatments. Also used for maintenance treatment of opioid addiction.	Manifestations of acute overdose include pinpoint pupils, sedation, hypotension, respiratory depression and death.	Small Molecule	http://smpdb.ca/view/SMP0000684?highlight[compounds][]=DB00921&highlight[proteins][]=DB00921	Buprenorphine Action Pathway		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	3.1511 LD50, mol/kg	Inhibitor	Weak inhibitor	Non-inhibitor					4.98			8.31 (at 25 °C)		1	No	5	2	No	7	1	62.16 Å2	53.03 Å3	131.76 m3·mol-1	5	Yes	No	0.0168 mg/mL	3.55	-4.4	10.42	9.63			
C32H47F5O3S	Not Available	40 days	606.78	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@@]21[H]	Solid	3 to 5 L/kg	P08684;!P22309	CYP3A4;!UGT1A1	1. Cytochrome P450 3A4;!2. UDP-glucuronosyltransferase 1-1		50238741	31638	CHEMBL1358	94553	Drugs.com Drug Page	GtP Drug Page	HMDB0015082		D01161			PA164747170	17756771	46508664	RxList Drug Page	282357	DAP000319	Fulvestrant		Faslodex	Fulvestrant	Approved, Investigational	DB00947	InChI=1S/C32H47F5O3S/c1-30-17-15-26-25-12-11-24(38)21-23(25)20-22(29(26)27(30)13-14-28(30)39)10-7-5-3-2-4-6-8-18-41(40)19-9-16-31(33,34)32(35,36)37/h11-12,21-22,26-29,38-39H,2-10,13-20H2,1H3/t22-,26-,27+,28+,29-,30+,41?/m1/s1	VWUXBMIQPBEWFH-WCCTWKNTSA-N	4	Fulvestrant is an estrogen receptor antagonist used to treat HR+ breast cancer that may also be HER2-.	There is no clinical experience with overdosage in humans.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.6310 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor					8.9					0	No	3	2	Yes	4	0	57.53 Å2	65.88 Å3	155.34 m3·mol-1	15	No	No	0.00672 mg/mL	7.57	-5	10.32	-0.88			
C23H31NO3	Data regarding the clearance of norgestimate is not readily available.10,11	Norgestimate is rapidly deacetylated.1,2 The active metabolites of norgestimate, 17-desacetyl norgestimate, has a half life of 12-30h,1 while norgestrel has a half life of 36.4±10.2h.11	369.4971	[H][C@@]12CC[C@@](OC(C)=O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CC\C(C=C3CC[C@@]21[H])=N/O	Solid	Data regarding the volume of distribution of norgestimate are not readily available.10,11	P08684;!P20813;!P11712;!P22309	CYP3A4;!CYP2B6;!CYP2C9;!UGT1A1	1. Cytochrome P450 3A4;!2. Cytochrome P450 2B6;!3. Cytochrome P450 2C9;!4. UDP-glucuronosyltransferase 1-1			50815	CHEMBL1200934	5022837			HMDB0015092		D05209			PA164744346	6540478	46507381	RxList Drug Page	31994	DAP001210	Norgestimate	ZINC000003938695	Estarylla 28 Day, Femynor 28 Day, Mili 28 Day, Mono-linyah 28 Day, Mononessa 28 Day, Nymyo 28 Day, Ortho Tri-cyclen 28 Day, Ortho Tri-cyclen Lo 28 Day, Prefest 30 Day, Previfem 28 Day, Sprintec 28 Day, Tri Femynor 28 Day, Tri-LO- Estarylla 28 Day, Tri-LO-marzia 28-day, Tri-LO-mili, Tri-Lo-Sprintec, Tri-estarylla 28 Day, Tri-linyah, Tri-mili 28 Day, Tri-nymyo 28 Day Pack, Tri-previfem 28 Day, Tri-sprintec 28 Day, Tri-vylibra 28 Day, Tri-vylibra Lo 28 Day, Trinessa 28 Day, Trinessa Lo 28 Day, Vylibra 28 Day	Norgestimate	Approved, Investigational	DB00957	InChI=1S/C23H31NO3/c1-4-22-12-10-19-18-9-7-17(24-26)14-16(18)6-8-20(19)21(22)11-13-23(22,5-2)27-15(3)25/h2,14,18-21,26H,4,6-13H2,1,3H3/b24-17+/t18-,19+,20+,21-,22-,23-/m0/s1	KIQQMECNKUGGKA-NMYWJIRASA-N	4	Norgestimate is a progesterone used as a contraceptive and to treat acne vulgaris.	Data regarding overdoses of norgestimate are rare.10,11 However, the majority of patients overdosing on oral contraceptives do not become seriously ill.6 Treat overdoses with symptomatic and supportive care.6,10,11	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.4561 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							216 °C			1	Yes	3	1	No	4	0	58.89 Å2	42.79 Å3	105 m3·mol-1	3	Yes	No	0.00531 mg/mL	4.11	-4.8	11.47	3.11	P06401;!P03372;!P10275	PGR;!ESR1;!AR	1. Progesterone receptor;!2. Estrogen receptor alpha;!3. Androgen receptor
C22H30O5	The average plasma clearance of methylprednisolone is 336mL/h/kg.1	Methylprednisolone has a half life of 2.3h.1,6	374.4706	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C	Solid	The average volume of distribution of methylprednisolone is 1.38L/kg.1	BE0009795;!BE0009796;!P08684;!BE0004866;!P11509;!Q16678;!P20813;!P10632;!P33261;!P11712	;!;!CYP3A4;!;!CYP2A6;!CYP1B1;!CYP2B6;!CYP2C8;!CYP2C19;!CYP2C9	1. 20-ketosteroid reductase (20-hydroxysteroid dehydrogenase) (Protein Group);!2. 11beta-hydroxysteroid dehydrogenase (Protein Group);!3. Cytochrome P450 3A4;!4. Cytochrome P450 3A Subfamily (Protein Group);!5. Cytochrome P450 2A6;!6. Cytochrome P450 1B1;!7. Cytochrome P450 2B6;!8. Cytochrome P450 2C8;!9. Cytochrome P450 2C19;!10. Cytochrome P450 2C9		50103616	6888	CHEMBL650	6485	Drugs.com Drug Page		HMDB0015094		D00407			PA450466	6741	46504885	RxList Drug Page	6902	DAP001040	Methylprednisolone	ZINC000003875560	Depo-medrol, Depo-medrol With Lidocaine, Hybrisil, Medrol, Medroloan Suik, Readysharp-p40, Readysharp-p80	Methylprednisolone	Approved, Vet approved	DB00959	InChI=1S/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,17-,19+,20-,21-,22-/m0/s1	VHRSUDSXCMQTMA-PJHHCJLFSA-N	4	Methylprednisolone is a corticosteroid used to treat inflammation or immune reactions across a variety of organ systems, endocrine conditions, and neoplastic diseases.	The oral LD50 in rats is >4g/kg.14 The intraperitoneal LD50 in mice is 2292mg/kg and in rats is 100mg/kg.14Data regarding acute overdoses of glucocorticoids are rare.12,13 Chronic high doses of glucocorticoids can lead to the development of cataract, glaucoma, hypertension, water retention, hyperlipidemia, peptic ulcer, pancreatitis, myopathy, osteoporosis, mood changes, psychosis, dermal atrophy, allergy, acne, hypertrichosis, immune suppression, decreased resistance to infection, moon face, hyperglycemia, hypocalcemia, hypophosphatemia, metabolic acidosis, growth suppression, and secondary adrenal insufficiency.8 Treat acute overdoses with symptomatic and supportive therapy, while chronic overdoses will require temporarily reduced dosages.8,13	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.0025 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					1.525	-2.99	232.5 °C		120 mg/L (at 25 °C)	1	Yes	5	3	No	4	0	94.83 Å2	40.77 Å3	103.04 m3·mol-1	2	Yes	No	0.109 mg/mL	1.56	-3.5	12.59	-2.9	P04150;!P04083	NR3C1;!ANXA1	1. Glucocorticoid receptor;!2. Annexin A1
C20H24O2	Ethinylestradiol has an intravenous clearance of 16.47L/h, and an estimated renal clearance of approximately 2.1L/h.4 A 30µg oral dose has a clearance of 58.0±19.8L/h and a 1.2mg topical dose has a clearance of 303.5±100.5L/h.10	A 30µg oral dose has a half life of 8.4±4.8h and a 1.2mg topical dose has a half life of 27.7±34.2h.10	296.4034	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	Solid	A 30µg oral dose has an apparent volume of distribution of 625.3±228.7L and a 1.2mg topical dose has an apparent volume of distribution of 11745.3±15934.8L.10					50187243	4903	CHEMBL691	5770			HMDB0001926	C07534	D00554	3WF		PA449527	5991	46508618	RxList Drug Page	4124	DAP001018	Ethinylestradiol	ZINC000003812897	Afirmelle 28 Day, Alesse, Altavera 28 Day, Alyacen 1/35, Alyacen 7/7/7, Amethia 91 Day, Amethyst, Annovera, Apri 28 Day, Aranelle 28, Ashlyna 91 Day, Aubra 28 Day, Aurovela, Aurovela Fe, Aviane 28, Ayuna 28 Day Pack, Azurette 28 Day, Balcoltra 28 Day, Balziva 28 Day, Bekyree 28 Day, Beyaz 28 Day, Blisovi 21 Fe 1.5/30 28 Day Pack, Blisovi 24 Fe 1/20 28 Day, Brevicon, Briellyn 28 Day, Camrese 91 Day, Camreselo 91 Day, Caziant 28 Day, Cesia 28 Day, Charlotte 24 Fe Chewable 28 Day, Chateal 28 Day, Cléo -35, Cryselle 28, Cyclafem 1/35 28 Day, Cyclafem 7/7/7 28 Day, Cyestra-35, Cyonanz 28 Day, Cyred 28 Day, Dasetta 1/35 28 Day, Dasetta 7/7/7 28 Day, Daysee 91 Day, Delyla 28 Day, Diane, Dolishale 28 Day, Elinest 28 Day, Eluryng, Emoquette, Enpresse 28 Day, Enskyce 28 Day, Estarylla 28 Day, Estrostep Fe 28 Day, Evra, Falmina 28 Day, Fayosim 91 Day, Femcon Fe 28 Day, Femhrt 0.5/2.5 28 Day, Femynor 28 Day, Freya, Fyavolv, Gemmily 28 Day, Generess Fe 28, Gianvi 28-day, Hailey 1.5/30 21 Day, Hailey 24 Fe 28 Day, Hailey Fe 1.5/30 28 Day, Hailey Fe 1/20 28 Day, Iclevia 91 Day, Indayo, Introvale 91 Day, Isibloom 28 Day, Jaimiess 91 Day, Jasmiel 28 Day, Jinteli, Jolessa 91 Day, Juleber 28 Day, Junel 1.5/30 21 Day, Junel 1/20 21 Day, Junel Fe 1.5/30 28 Day, Junel Fe 1/20 28 Day, Junel Fe 24 1/20 28 Day, Kaitlib Fe 28 Day, Kalliga, Kariva 28 Day, Kelnor 1/35 28 Day, Kelnor 1/50 28 Day, Kurvelo, Larin 1.5/30, Larin 1/20, Larin 24 Fe 1/20, Larin Fe 1.5/30, Larin Fe 1/20, Larissia 28 Day Pack, Layolis Fe 28, Leena 28 Day, Levonest 28 Day, Levora 0.15/30 28 Day, Lillow 28 Day, Linessa, Lo Loestrin Fe 28 Day, Lo Simpesse, Lo-zumandimine 28 Day, Lo/ovral 28 Day, LoJaimiess, Loestrin 1.5/30 21 Day, Loestrin 24 Fe 28 Day, Loestrin Fe 1/20 28 Day, Lolo, Lomedia 24 Fe, Loryna, Loseasonique, Low-ogestrel 28 Day, Lutera 28 Day, Marlissa 28 Day, Marvelon, Melodetta 24 Fe Chewable 28 Day, Merzee 28 Day, Microgestin 1.5/30 21 Day, Microgestin 1/20 21 Day, Microgestin 24 Fe 28 Day, Microgestin Fe 1.5/30 28 Day, Microgestin Fe 1/20 28 Day, Mili 28 Day, Min-ovral, Minastrin 24 Fe Chewable 28 Day, Mircette 28 Day, Mono-linyah 28 Day, Mononessa 28 Day, Myzilra 28 Day, Necon 0.5/35 28 Day, Necon 1/35 28 Day, Necon 7/7/7 28 Day, Nexesta Fe 28 Day, Nikki 28 Day, Nortrel 1/35 21 Day, Nortrel 1/35 28 Day, Nortrel 7/7/7 28 Day, Nuvaring, Nylia 1/35 28 Day, Nylia 7/7/7 28 Day, Nymyo 28 Day, Ocella 28 Day, Orsythia 28 Day, Ortho Tri-cyclen 28 Day, Ortho Tri-cyclen Lo 28 Day, Ortho-novum 7/7/7 28 Day, Philith 28 Day, Pimtrea Pack, Pirmella 1/35 28 Day, Pirmella 7/7/7 28 Day, Portia 28 Day, Previfem 28 Day, Quartette 91 Day Pack, Reclipsen, Rivelsa 91 Day, Safyral 28 Day, Seasonale, Seasonique, Select, Setlakin 91 Day, Simliya, Simpesse, Sprintec 28 Day, Sronyx 28 Day, Syeda 28 Day, Synphasic, Tarina 24 Fe 1/20 28 Day, Tarina Fe 1/20 28 Day, Taysofy 28 Day, Taytulla 28 Day, Tilia Fe, Tri Femynor 28 Day, Tri-LO- Estarylla 28 Day, Tri-LO-marzia 28-day, Tri-LO-mili, Tri-Lo-Sprintec, Tri-estarylla 28 Day, Tri-legest 28 Day, Tri-linyah, Tri-mili 28 Day, Tri-nymyo 28 Day Pack, Tri-previfem 28 Day, Tri-sprintec 28 Day, Tri-vylibra 28 Day, Tri-vylibra Lo 28 Day, Trinessa 28 Day, Trinessa Lo 28 Day, Triquilar, Trivora 28 Day, Twirla 3 Count Weekly Patch, Tyblume 28 Day, Velivet 28 Day, Vestura, Vienva 28 Day, Viorele 28 Day, Volnea 28 Day, Vyfemla 28 Day, Vylibra 28 Day, Wera 28 Day, Wymzya Fe 28 Day, Xulane, Yasmin, Yasmin 28 Day, Yaz 28 Day, Yaz Plus, Zafemy, Zarah, Zenchent, Zovia 1/35e 28 Day, Zovia 1/50e 28 Day, Zumandimine 28 Day	Ethinylestradiol	Approved	DB00977	InChI=1S/C20H24O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,5,7,12,16-18,21-22H,4,6,8-11H2,2H3/t16-,17-,18+,19+,20+/m1/s1	BFPYWIDHMRZLRN-SLHNCBLASA-N	4	Ethinylestradiol is an estradiol used as a contraceptive.	Female patients experiencing and overdose may present with withdrawal bleeding, nausea, vomiting, breast tenderness, abdominal pain, drowsiness, and fatigue.15,25,16,17,24,18,19,20,21,22,23 Overdose should be treated with symptomatic and supportive care including monitoring for potassium concentrations, sodium concentrations, and signs of metabolic acidosis.15,25,16,17,24,18,19,20,21,22,23	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.4584 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor					3.67	-4.3	142-144		11.3 mg/L (at 27 °C)	1	Yes	2	2	No	4	0	40.46 Å2	34.53 Å3	87.37 m3·mol-1	0	Yes	No	0.00677 mg/mL	3.9	-4.6	10.33	-1.7			
C27H34O3	Not Available	The elimination half-life from plasma is very short.	406.5571	[H][C@@]12CC[C@H](OC(=O)CCC3=CC=CC=C3)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	Solid	Not Available						7468	CHEMBL1200412	199761	Drugs.com Drug Page		HMDB0015119	C08155	D00956			PA164746281	229455	46506276		31495	DAP000903	Nandrolone	ZINC000003881613		Nandrolone phenpropionate	Approved, Illicit, Investigational	DB00984	InChI=1S/C27H34O3/c1-27-16-15-22-21-11-9-20(28)17-19(21)8-10-23(22)24(27)12-13-25(27)30-26(29)14-7-18-5-3-2-4-6-18/h2-6,17,21-25H,7-16H2,1H3/t21-,22+,23+,24-,25-,27-/m0/s1	UBWXUGDQUBIEIZ-QNTYDACNSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	1.8785 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							118 °C		3090 mg/L (at 25 °C)	1	No	2	0	No	5	0	43.37 Å2	47.83 Å3	118.43 m3·mol-1	5	No	No	0.000458 mg/mL	5.79	-6	18.25	-4.7	P10275	AR	1. Androgen receptor
C20H24O2	Not Available	24 hours	296.4034	[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC(=C)C2=CC(=O)C=C[C@]12C	Solid	Not Available	P11511;!P08684	CYP19A1;!CYP3A4	1. Cytochrome P450 19A1;!2. Cytochrome P450 3A4		50398447	4953	CHEMBL1200374	54278	Drugs.com Drug Page		HMDB0015125	C08162	D00963	EXM		PA449563	60198	46508243	RxList Drug Page	258494	DAP000625	Exemestane	ZINC000003973334	Aromasin	Exemestane	Approved, Investigational	DB00990	InChI=1S/C20H24O2/c1-12-10-14-15-4-5-18(22)20(15,3)9-7-16(14)19(2)8-6-13(21)11-17(12)19/h6,8,11,14-16H,1,4-5,7,9-10H2,2-3H3/t14-,15-,16-,19+,20-/m0/s1	BFYIZQONLCFLEV-DAELLWKTSA-N	4	Exemestane is an aromatase inhibitor used to treat breast cancer in postmenopausal women after treatment with tamoxifen.	Convulsions	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.7582 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.7		155.13 °C		Non-soluble	1	Yes	2	0	No	4	0	34.14 Å2	33.72 Å3	89.03 m3·mol-1	0	Yes	Yes	0.00683 mg/mL	3.87	-4.6		-5			
C25H32ClFO5	Data regarding the clearance of clobetasol propionate are not readily available.3	Data regarding the half life of clobetasol propionate are not readily available.3	466.97	[H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	Data regarding the volume of distribution of clobetasole propionate are not readily available.10,11,12,13,14,15	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5		39347	31414	CHEMBL1159650	30399	Drugs.com Drug Page				D01272	XRD	PDRhealth Drug Page	PA164744375	32798	46505670	RxList Drug Page	21245	DAP001183	Clobetasol_propionate	ZINC000003977767	Clobex, Clodan, Dermovate, Impeklo, Impoyz, Olux, Temovate, Tovet	Clobetasol propionate	Approved	DB01013	InChI=1S/C25H32ClFO5/c1-5-21(31)32-25(20(30)13-26)14(2)10-18-17-7-6-15-11-16(28)8-9-22(15,3)24(17,27)19(29)12-23(18,25)4/h8-9,11,14,17-19,29H,5-7,10,12-13H2,1-4H3/t14-,17-,18-,19-,22-,23-,24-,25-/m0/s1	CBGUOGMQLZIXBE-XGQKBEPLSA-N	4	Clobetasol propionate is a corticosteroid used to treat corticosteroid-responsive dermatoses and plaque psoriasis.	Data regarding acute overdoses of glucocorticoids are rare.10,11,12 Overdoses of clobetasol propionate can lead to reversible HPA axis suppression and glucocorticoid insufficiency.15 Chronic high doses of glucocorticoids can lead to the development of cataract, glaucoma, hypertension, water retention, hyperlipidemia, peptic ulcer, pancreatitis, myopathy, osteoporosis, mood changes, psychosis, dermal atrophy, allergy, acne, hypertrichosis, immune suppression, decreased resistance to infection, moon face, hyperglycemia, hypocalcemia, hypophosphatemia, metabolic acidosis, growth suppression, and secondary adrenal insufficiency.8 Overdose may be treated by adjusting the dose or stopping the corticosteroid as well as initiating symptomatic and supportive treatment.8	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1435 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.50		196			1	Yes	4	1	No	4	0	80.67 Å2	48.27 Å3	119.32 m3·mol-1	5	Yes	No	0.00413 mg/mL	4.18	-5	13.63	-3.4	P04150;!P04083;!P08235	NR3C1;!ANXA1;!NR3C2	1. Glucocorticoid receptor;!2. Annexin A1;!3. Mineralocorticoid receptor
C26H32F2O7	Not Available	Not Available	494.5249	[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)COC(C)=O	Solid	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5			5109	CHEMBL1501	9265	Drugs.com Drug Page		HMDB0015181		D00325		PDRhealth Drug Page	PA449664	9642	46504523	RxList Drug Page	4462	DAP000421	Fluocinonide	ZINC000003977978	Lidemol, Lidex, Lyderm, Tiamol, Vanos	Fluocinonide	Approved, Investigational	DB01047	InChI=1S/C26H32F2O7/c1-13(29)33-12-20(32)26-21(34-22(2,3)35-26)10-15-16-9-18(27)17-8-14(30)6-7-23(17,4)25(16,28)19(31)11-24(15,26)5/h6-8,15-16,18-19,21,31H,9-12H2,1-5H3/t15-,16-,18-,19-,21+,23-,24-,25-,26+/m0/s1	WJOHZNCJWYWUJD-IUGZLZTKSA-N	4	Fluocinonide is a high potency corticosteroid commonly used topically for a number of inflammatory skin conditions.	Side effects may include acne-like eruptions, burning, dryness, excessive hair growth, infection of the skin, irritation, itching, lack of skin colour, prickly heat, skin inflammation, skin loss or softening, stretch marks.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	3.1492 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.19		309 °C		4.74 mg/L	1	No	6	1	No	5	0	99.13 Å2	48.97 Å3	120.56 m3·mol-1	4	Yes	No	0.0168 mg/mL	2.05	-4.5	13.6	-3.4	P04150;!Q99835	NR3C1;!SMO	1. Glucocorticoid receptor;!2. Smoothened homolog
C28H46O	Not Available	Not Available	398.6642	CC(C)[C@@H](C)\C=C\[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1/C[C@@H](O)CC[C@@H]1C	Solid	Not Available						4591	CHEMBL2356023	4470607	Drugs.com Drug Page		HMDB0015203	C06957	D00299			PA164744345	5311071	46507699	RxList Drug Page	3429	DAP000365	Dihydrotachysterol	ZINC000004212953		Dihydrotachysterol	Approved	DB01070	InChI=1S/C28H46O/c1-19(2)20(3)9-10-22(5)26-15-16-27-23(8-7-17-28(26,27)6)12-13-24-18-25(29)14-11-21(24)4/h9-10,12-13,19-22,25-27,29H,7-8,11,14-18H2,1-6H3/b10-9+,23-12+,24-13+/t20-,21-,22+,25-,26+,27-,28+/m0/s1	ILYCWAKSDCYMBB-OPCMSESCSA-N	2	Dihydrotachysterol is a synthetic analog of vitamin D that does not require renal activation like vitamin D2 or Vitamin D3.	Toxicity associated with dihydrotachysterol is similar to that seen with large doses of vitamin D.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	3.1244 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					7.5					1	No	1	1	No	3	0	20.23 Å2	51.77 Å3	129.11 m3·mol-1	5	No	Yes	0.000125 mg/mL	7.4	-6.5	18.3	-1.4	P11473	VDR	1. Vitamin D3 receptor
C29H44O12	Not Available	Not Available	584.6525	[H][C@@]12CC[C@]3(O)C[C@H](C[C@@H](O)[C@]3(CO)[C@@]1([H])[C@H](O)C[C@]1(C)[C@H](CC[C@]21O)C1=CC(=O)OC1)O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O	Solid	Not Available					50286739	472805	CHEMBL222863	388599			HMDB0015224	C01443	D00112	OBN		PA163522138	439501	46505479		7762	DAP000465	Ouabain	ZINC000008143614		Ouabain	Approved	DB01092	InChI=1S/C29H44O12/c1-13-22(34)23(35)24(36)25(40-13)41-15-8-19(32)28(12-30)21-17(3-5-27(28,37)9-15)29(38)6-4-16(14-7-20(33)39-11-14)26(29,2)10-18(21)31/h7,13,15-19,21-25,30-32,34-38H,3-6,8-12H2,1-2H3/t13-,15-,16+,17+,18+,19+,21+,22-,23+,24+,25-,26+,27-,28+,29-/m0/s1	LPMXVESGRSUGHW-HBYQJFLCSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	4.7797 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor					-2.00		200 °C		1.03E+004 mg/L	0	No	11	8	No	6	-1	206.6 Å2	59.92 Å3	140.83 m3·mol-1	4	No	No	4.61 mg/mL	-2.8	-2.1	7.18	-2.9	P05023;!P50993;!P13637	ATP1A1;!ATP1A2;!ATP1A3	1. Sodium/potassium-transporting ATPase subunit alpha-1;!2. Sodium/potassium-transporting ATPase subunit alpha-2;!3. Sodium/potassium-transporting ATPase subunit alpha-3
C20H27NO3	Not Available	8 hours.	329.4333	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N	Solid	Not Available						32260	CHEMBL1200907	570949			HMDB0015240	C12580	D01180			PA164748507	656583	46507062		38668	DAP000148	Trilostane	ZINC000100038546		Trilostane	Approved, Investigational, Vet approved, Withdrawn	DB01108	InChI=1S/C20H27NO3/c1-18-7-6-14-12(13(18)3-4-15(18)22)5-8-20-17(24-20)16(23)11(10-21)9-19(14,20)2/h12-15,17,22-23H,3-9H2,1-2H3/t12-,13-,14-,15-,17+,18-,19+,20+/m0/s1	KVJXBPDAXMEYOA-CXANFOAXSA-N	2		Symptoms of overdose include darkening of skin, drowsiness or tiredness, loss of appetite, mental depression, skin rash, and/or vomiting.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.3725 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3		264 dec °C			1	Yes	4	2	No	5	-1	76.78 Å2	36.81 Å3	90.17 m3·mol-1	0	Yes	No	0.0592 mg/mL	2.3	-3.8	5.23	-0.88	P14060;!P26439;!P03372;!Q92731	HSD3B1;!HSD3B2;!ESR1;!ESR2	1. 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1;!2. 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2;!3. Estrogen receptor alpha;!4. Estrogen receptor beta
C27H36O8	Not Available	Not Available	488.577	[H][C@@]12CC[C@](OC(=O)OCC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			135791	CHEMBL1200386	5145991	Drugs.com Drug Page							PA164749394	6714002	46506799	RxList Drug Page	34369	DAP001189	Prednicarbate	ZINC000003938652	Dermatop	Prednicarbate	Approved, Investigational	DB01130	InChI=1S/C27H36O8/c1-5-22(31)34-15-21(30)27(35-24(32)33-6-2)12-10-19-18-8-7-16-13-17(28)9-11-25(16,3)23(18)20(29)14-26(19,27)4/h9,11,13,18-20,23,29H,5-8,10,12,14-15H2,1-4H3/t18-,19-,20-,23+,25-,26-,27-/m0/s1	FNPXMHRZILFCKX-KAJVQRHHSA-N	2	Prednicarbate is a medium potency topical corticosteroid used to manage pruritus and inflammation associated with responsive skin conditions.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.4426 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.9					1	No	6	1	Yes	4	0	116.2 Å2	52.43 Å3	127.8 m3·mol-1	9	Yes	No	0.00562 mg/mL	3.83	-4.9	14.83	-2.9	P04150	NR3C1	1. Glucocorticoid receptor
C26H38O4	Not Available	Not Available	414.586	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)C(=O)COC(=O)C(C)(C)C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			50782	CHEMBL1200592	10050591								PA449245	11876263	46506381		22537	DAP001106	Desoxycorticosterone_pivalate	ZINC000004082455		Desoxycorticosterone pivalate	Experimental, Vet approved	DB01134	InChI=1S/C26H38O4/c1-24(2,3)23(29)30-15-22(28)21-9-8-19-18-7-6-16-14-17(27)10-12-25(16,4)20(18)11-13-26(19,21)5/h14,18-21H,6-13,15H2,1-5H3/t18-,19-,20-,21+,25-,26-/m0/s1	VVOIQBFMTVCINR-WWMZEODYSA-N			Symptoms of overdose include polyuria, polydipsia, increased blood volume, edema, and cardiac enlargement.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	1.7883 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					4				Insoluble	1	Yes	3	0	No	4	0	60.44 Å2	48.3 Å3	117.26 m3·mol-1	5	No	No	0.00141 mg/mL	5.57	-5.5	17.19	-4.8	P08235	NR3C2	1. Mineralocorticoid receptor
C20H29FO3	Not Available	9.2 hours	336.4409	[H][C@@]12CC[C@](C)(O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	Not Available					18189	5120	CHEMBL1445	6205	Drugs.com Drug Page	GtP Drug Page	HMDB0015316		D00327			PA164744518	6446	46508867	RxList Drug Page	4494	DAP000904	Fluoxymesterone	ZINC000003875484	Androxy, Halotestin	Fluoxymesterone	Approved, Illicit	DB01185	InChI=1S/C20H29FO3/c1-17-8-6-13(22)10-12(17)4-5-15-14-7-9-19(3,24)18(14,2)11-16(23)20(15,17)21/h10,14-16,23-24H,4-9,11H2,1-3H3/t14-,15-,16-,17-,18-,19-,20-/m0/s1	YLRFCQOZQXIBAB-RBZZARIASA-N		Fluoxymesterone is a synthetic androgenic anabolic steroid that used in the treatment of hypogonadism and delayed puberty in males, as well as breast neoplasms in women.	Side effects include virilization (masculine traits in women), acne, fluid retention, and hypercalcemia.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.7028 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.38		265		67.5 mg/L	1	Yes	3	2	No	4	0	57.53 Å2	36.65 Å3	90.19 m3·mol-1	0	Yes	No	0.0452 mg/mL	2.38	-3.9	13.6	-3			
C23H31Cl2NO3	Not Available	20 hours	440.403	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(OC(=O)N(CCCl)CCCl)C=C3CC[C@@]21[H]	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4		50333646	4868	CHEMBL1575	227635	Drugs.com Drug Page		HMDB0015327	C11228	D04066			PA449507	259331	46508765	RxList Drug Page	4089	DAP001307	Estramustine	ZINC000004099032	Emcyt	Estramustine	Approved, Investigational	DB01196	InChI=1S/C23H31Cl2NO3/c1-23-9-8-18-17-5-3-16(29-22(28)26(12-10-24)13-11-25)14-15(17)2-4-19(18)20(23)6-7-21(23)27/h3,5,14,18-21,27H,2,4,6-13H2,1H3/t18-,19-,20+,21+,23+/m1/s1	FRPJXPJMRWBBIH-RBRWEJTLSA-N	3	Estramustine is an antineoplastic agent used for the management of metastatic and/or progressive prostate cancer in palliative setting.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.7844 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					5.7		155			1	Yes	2	1	Yes	4	0	49.77 Å2	47.96 Å3	116.21 m3·mol-1	6	No	No	0.000385 mg/mL	5.1	-6.1	19.38	-0.88	Q92731;!P03372;!P11137;!P78559	ESR2;!ESR1;!MAP2;!MAP1A	1. Estrogen receptor beta;!2. Estrogen receptor alpha;!3. Microtubule-associated protein 2;!4. Microtubule-associated protein 1A
C22H29FO5	A 20mg oral tablet has a clearance of 15.7L/h.16 A 1.5mg oral dose of dexamethasone has a clearance of 15.6±4.9L/h while a 3.0mg intramuscular dose has a clearance of 9.9±1.4L/h.5	The mean terminal half life of a 20mg oral tablet is 4 hours.16 A 1.5mg oral dose of dexamethasone has a half life of 6.6±4.3h, while a 3mg intramuscular dose has a half life of 4.2±1.2h.5	392.4611	[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	A 1.5mg oral dose of dexamethasone has a volume of distribution of 51.0L, while a 3mg intramuscular dose has a volume of distribution of 96.0L.5					18207	41879	CHEMBL384467	5541	Drugs.com Drug Page	GtP Drug Page	HMDB0015364	C15643	D00292	DEX	PDRhealth Drug Page	PA449247	5743	46508930	RxList Drug Page	3264	DAP000007	Dexamethasone	ZINC000003875332	Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper	Dexamethasone	Approved, Investigational, Vet approved	DB01234	InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1	UREBDLICKHMUKA-CXSFZGCWSA-N		Dexamethasone is a glucocorticoid available in various modes of administration that is used for the treatment of various inflammatory conditions, including bronchial asthma, as well as endocrine and rheumatic disorders.	The oral LD50 in female mice was 6.5g/kg and 794mg/kg via the intravenous route.13Overdoses are not expected with otic formulations.12 Chronic high doses of glucocorticoids can lead to the development of cataract, glaucoma, hypertension, water retention, hyperlipidemia, peptic ulcer, pancreatitis, myopathy, osteoporosis, mood changes, psychosis, dermal atrophy, allergy, acne, hypertrichosis, immune suppression, decreased resistance to infection, moon face, hyperglycemia, hypocalcemia, hypophosphatemia, metabolic acidosis, growth suppression, and secondary adrenal insufficiency.2 Overdose may be treated by adjusting the dose or stopping the corticosteroid as well as initiating symptomatic and supportive treatment.2	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1482 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor		-4.75			1.83	-3.64	260-264		89 mg/L (at 25 °C)	1	Yes	5	3	No	4	0	94.83 Å2	40.71 Å3	102.49 m3·mol-1	2	Yes	No	0.0505 mg/mL	1.68	-3.9	12.42	-3.3			
C30H47NO4S	Not Available	Not Available	517.763	[H][C@@]12C(=O)CC[C@]11CC[C@@H](C)[C@@]2(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]1C)OC(=O)CS[C@H]1C[C@@H]2CC[C@H](C1)N2C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4				CHEMBL1658	25064484	Drugs.com Drug Page					G34		PA164749341	6918462	46509062	RxList Drug Page	642274	DAP000886	Retapamulin	ZINC000100013500	Altabax	Retapamulin	Approved	DB01256	InChI=1S/C30H47NO4S/c1-7-28(4)16-24(35-25(33)17-36-22-14-20-8-9-21(15-22)31(20)6)29(5)18(2)10-12-30(19(3)27(28)34)13-11-23(32)26(29)30/h7,18-22,24,26-27,34H,1,8-17H2,2-6H3/t18-,19+,20-,21+,22-,24-,26+,27+,28-,29+,30+/m1/s1	STZYTFJPGGDRJD-NHUWBDDWSA-N	4	Retapamulin is a topical antibiotic agent used for the treatment of impetigo caused by methicillin-susceptible Staphylococcus aureus or Streptococcus pyogenes.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.7920 LD50, mol/kg	Inhibitor	Weak inhibitor	Non-inhibitor					5					1	No	4	1	Yes	5	1	66.84 Å2	59.82 Å3	145.45 m3·mol-1	6	No	No	0.000394 mg/mL	4.37	-6.1	14.43	9.69	Q9A1X4	rplC	1. 50S ribosomal protein L3
C21H26O2	Not Available	Not Available	310.4299	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(OC)C=C3	Solid	Not Available	P08684;!P10632;!P11712	CYP3A4;!CYP2C8;!CYP2C9	1. Cytochrome P450 3A4;!2. Cytochrome P450 2C8;!3. Cytochrome P450 2C9			6784	CHEMBL1201151	6054			HMDB0015446	C07618	D00575			PA450388	6291	46507679		6782	DAP001014	Mestranol	ZINC000003815424		Mestranol	Approved	DB01357	InChI=1S/C21H26O2/c1-4-21(22)12-10-19-18-7-5-14-13-15(23-3)6-8-16(14)17(18)9-11-20(19,21)2/h1,6,8,13,17-19,22H,5,7,9-12H2,2-3H3/t17-,18-,19+,20+,21+/m1/s1	IMSSROKUHAOUJS-MJCUULBUSA-N	3	Mestranol is a synthetic estradiol found in oral contraceptive pills for contraception and the treatment of other conditions in the female reproductive system, such as dysmenorrhea and dysfunctional uterine bleeding.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.5234 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor							150.5 °C			1	Yes	2	1	No	4	0	29.46 Å2	36.7 Å3	91.86 m3·mol-1	1	Yes	Yes	0.00377 mg/mL	4.04	-4.9	17.59	-1.7	P03372	ESR1	1. Estrogen receptor alpha
C23H30O6	Data regarding the clearance of cortisone acetate is not readily available.8	Not Available	402.4807	[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5		50455157	3897	CHEMBL1650	5543	Drugs.com Drug Page		HMDB0015459	C08173	D00973			PA449130	5745	46508852	RxList Drug Page	21655		Cortisone_acetate	ZINC000003875334		Cortisone acetate	Approved, Investigational	DB01380	InChI=1S/C23H30O6/c1-13(24)29-12-19(27)23(28)9-7-17-16-5-4-14-10-15(25)6-8-21(14,2)20(16)18(26)11-22(17,23)3/h10,16-17,20,28H,4-9,11-12H2,1-3H3/t16-,17-,20+,21-,22-,23-/m0/s1	ITRJWOMZKQRYTA-RFZYENFJSA-N	4	Cortisone acetate is a steroid hormone used for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses and endocrine disorders associated with inadequate production of steroid hormones.	Data regarding acute overdoses of glucocorticoids are rare.8 Chronic high doses of glucocorticoids can lead to the development of cataract, glaucoma, hypertension, water retention, hyperlipidemia, peptic ulcer, pancreatitis, myopathy, osteoporosis, mood changes, psychosis, dermal atrophy, allergy, acne, hypertrichosis, immune suppression, decreased resistance to infection, moon face, hyperglycemia, hypocalcemia, hypophosphatemia, metabolic acidosis, growth suppression, and secondary adrenal insufficiency.6 Overdose may be treated by adjusting the dose or stopping the corticosteroid as well as initiating symptomatic and supportive treatment.6	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.1280 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.10		227-229		20 mg/L (at 25 °C)	1	Yes	5	1	No	4	0	97.74 Å2	43.06 Å3	105.63 m3·mol-1	4	Yes	No	0.0278 mg/mL	2.1	-4.2	12.6	-3.8	P04150;!P04083	NR3C1;!ANXA1	1. Glucocorticoid receptor;!2. Annexin A1
C24H30O3	Drospirenone is rapidly cleared, typically within 2-3 days of administration of the last active tablet.14 The rate of clearance of drospirenone calculated in the serum ranges from 1.2-1.5 ml/min/kg, however, this value can vary by up to 25% according to the patient.23	The serum half-life of drospirenone is estimated to be 30 hours.13 The half-life of drospirenone metabolite excretion in the urine and feces is approximately 40 hours.23	366.4932	[H][C@@]12C[C@]1([H])[C@@]1([H])[C@]3([H])[C@]4([H])C[C@]4([H])[C@@]4(CCC(=O)O4)[C@@]3(C)CC[C@]1([H])[C@@]1(C)CCC(=O)C=C21	Solid	The volume of distribution of drospirenone is estimated to be 4 L/kg, according to the FDA label for Yaz.19 Prescribing information from a combination of estradiol and drospirenone estimates the volume of distribution to range from 3.7- 4.2 L/kg.23	P35354;!P27169;!P08684	PTGS2;!PON1;!CYP3A4	1. Prostaglandin G/H synthase 2;!2. Serum paraoxonase/arylesterase 1;!3. Cytochrome P450 3A4		150275	50838	CHEMBL1509	62105	Drugs.com Drug Page		HMDB0015467		D03917			PA164749409	68873	46507653	RxList Drug Page	11636	DAP001206	Drospirenone	ZINC000003927200	Angeliq 0.25/0.5 28 Day, Beyaz 28 Day, Gianvi 28-day, Jasmiel 28 Day, Lo-zumandimine 28 Day, Loryna, Nextstellis 28 Day, Nikki 28 Day, Ocella 28 Day, Safyral 28 Day, Slynd, Syeda 28 Day, Vestura, Yasmin, Yasmin 28 Day, Yaz 28 Day, Yaz Plus, Zarah, Zumandimine 28 Day	Drospirenone	Approved	DB01395	InChI=1S/C24H30O3/c1-22-6-3-12(25)9-17(22)13-10-14(13)20-16(22)4-7-23(2)21(20)15-11-18(15)24(23)8-5-19(26)27-24/h9,13-16,18,20-21H,3-8,10-11H2,1-2H3/t13-,14+,15-,16+,18+,20-,21+,22-,23+,24+/m1/s1	METQSPRSQINEEU-HXCATZOESA-N	4	Drospirenone is a progestin used in oral contraceptive pills for the prevention of pregnancy and other conditions.	The oral LD50 of drospirenone in rats is >2000 mg/kg.22Overdose informationAn overdose of drospirenone, like other oral contraceptives, may lead to cause nausea or withdrawal bleeding. For drospirenone in particular, as an analog of spironolactone, may affect the levels of serum sodium and potassium. Their concentrations should be monitored in cases of overdose in addition to monitoring from metabolic acidosis and hyperkalemia, which may also result.15,19	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.9430 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				552.2	3.08	-5.2	196-200	-5		1	Yes	2	0	No	7	0	43.37 Å2	41.81 Å3	101.68 m3·mol-1	0	Yes	No	0.00225 mg/mL	3.37	-5.2	18.52	-5	P08235;!P10275;!P06401;!P04150	NR3C2;!AR;!PGR;!NR3C1	1. Mineralocorticoid receptor;!2. Androgen receptor;!3. Progesterone receptor;!4. Glucocorticoid receptor
C22H27NO2	Not Available	Approximately 24 hours.	337.4553	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC3=C(C[C@]12C)C=NO3	Solid	Not Available	P08684;!P11511	CYP3A4;!CYP19A1	1. Cytochrome P450 3A4;!2. Cytochrome P450 19A1		50423541	4315	CHEMBL1479	26436	Drugs.com Drug Page		HMDB0002835		D00289	QA1		PA164749056	28417	46506475	RxList Drug Page	3102	DAP001017	Danazol	ZINC000003881958	Cyclomen	Danazol	Approved	DB01406	InChI=1S/C22H27NO2/c1-4-22(24)10-8-18-16-6-5-15-11-19-14(13-23-25-19)12-20(15,2)17(16)7-9-21(18,22)3/h1,11,13,16-18,24H,5-10,12H2,2-3H3/t16-,17+,18+,20+,21+,22+/m1/s1	POZRVZJJTULAOH-LHZXLZLDSA-N	4	Danazol is a synthetic steroid and pituitary gonadotropin inhibitor used in the treatment of endometriosis and symptomatic treatment of severe pain and tenderness associated with benign fibrocystic breasts.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.3291 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					0.51		224.2-226.8			1	Yes	2	1	No	5	0	46.26 Å2	38.44 Å3	98.54 m3·mol-1	0	Yes	No	0.0176 mg/mL	3.46	-4.3	17.59	0.25	P03372;!P10275;!P06401;!P30968;!Q96P88;!P13500	ESR1;!AR;!PGR;!GNRHR;!GNRHR2;!CCL2	1. Estrogen receptor alpha;!2. Androgen receptor;!3. Progesterone receptor;!4. Gonadotropin-releasing hormone receptor;!5. Putative gonadotropin-releasing hormone II receptor;!6. C-C motif chemokine 2
C22H32O3	Testosterone propionate has a reduced clearance rate compared to testosterone.5 The reported clearance rate is of approximately 2000 ml/min.1	Testosterone propionate possesses a relatively short half-life compared with other testosterone esters at approximately 4.5 days.	344.4877	[H][C@@]12CC[C@H](OC(=O)CC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	The registered volume of distribution for testosterone propionate is in the range of 75-120 L/kg.1	P21964;!P22309;!BE0004887;!P08684	COMT;!UGT1A1;!;!CYP3A4	1. Catechol O-methyltransferase;!2. UDP-glucuronosyltransferase 1-1;!3. 3-oxo-5-alpha-steroid 4-dehydrogenase (Protein Group);!4. Cytochrome P450 3A4		50215709	9466	CHEMBL1170	5774	Drugs.com Drug Page		HMDB0015489	C08158	D00959			PA164751373	5995	46508693		10382		Testosterone_propionate	ZINC000000490791		Testosterone propionate	Approved, Investigational, Vet approved, Withdrawn	DB01420	InChI=1S/C22H32O3/c1-4-20(24)25-19-8-7-17-16-6-5-14-13-15(23)9-11-21(14,2)18(16)10-12-22(17,19)3/h13,16-19H,4-12H2,1-3H3/t16-,17-,18-,19-,21-,22-/m0/s1	PDMMFKSKQVNJMI-BLQWBTBKSA-N	4	Testosterone propionate is a slow-release anabolic steroid no longer used commonly for the treatment of androgen deficiency or promotion of anabolic effects on muscles.	Reports have showed a potential stimulation of cancerous tissue growth. The potential testosterone propionate accumulation in the body produces a high risk of edema secondaryh to water and sodium retention.5	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.0463 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor						-5.37	118-123 °C		1.48 mg/L (at 25ºC)	1	Yes	2	0	No	4	0	43.37 Å2	40.45 Å3	98.21 m3·mol-1	3	Yes	No	0.00502 mg/mL	4.51	-4.8	18.52	-4.8			
C21H32O	Not Available	Not Available	300.4782	[H][C@@]12CC[C@@](O)(CC=C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCCC=C3CC[C@@]21[H]	Solid	Not Available						31189	CHEMBL3185133	205855			HMDB0015500	C12811	D01374			PA164745307	235905	46506946		525	DPR000085	Allylestrenol	ZINC000004214767		Allylestrenol	Experimental	DB01431	InChI=1S/C21H32O/c1-3-12-21(22)14-11-19-18-9-8-15-6-4-5-7-16(15)17(18)10-13-20(19,21)2/h3,6,16-19,22H,1,4-5,7-14H2,2H3/t16-,17+,18+,19-,20-,21-/m0/s1	ATXHVCQZZJYMCF-XUDSTZEESA-N		Allylestrenol is a steroid used to prevent premature labour in pregnant women.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.4200 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							80 °C			1	Yes	1	1	No	4	0	20.23 Å2	37.18 Å3	93.14 m3·mol-1	2	Yes	Yes	0.000558 mg/mL	4.83	-5.7		-0.17	P06401;!P03372	PGR;!ESR1	1. Progesterone receptor;!2. Estrogen receptor alpha
C18H24O2	Not Available	Not Available	272.382	[H][C@@]12CCC(=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	Solid	Not Available						34187		83803				C14500			PDRhealth Drug Page		92834	46505377				19-Norandrostenedione	ZINC000004428372		19-norandrostenedione	Experimental, Illicit	DB01434	InChI=1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h10,13-16H,2-9H2,1H3/t13-,14+,15+,16-,18-/m0/s1	JRIZOGLBRPZBLQ-QXUSFIETSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.6104 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	0	No	4	0	34.14 Å2	31.56 Å3	79.13 m3·mol-1	0	Yes	Yes	0.0454 mg/mL	3.63	-3.8	18.25	-4.7			
C27H44O2	Not Available	The half-life of alfacalcidol ranges from three to four hours.9,12	400.6371	CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	Solid	Not Available						31186	CHEMBL1601669	4445376			HMDB0015504		D01518	M9B		PA164746469	5282181	46505115		12062		Alfacalcidol	ZINC000012484965	One-alpha	Alfacalcidol	Approved, Nutraceutical	DB01436	InChI=1S/C27H44O2/c1-18(2)8-6-9-19(3)24-13-14-25-21(10-7-15-27(24,25)5)11-12-22-16-23(28)17-26(29)20(22)4/h11-12,18-19,23-26,28-29H,4,6-10,13-17H2,1-3,5H3/b21-11+,22-12-/t19-,23-,24-,25+,26+,27-/m1/s1	OFHCOWSQAMBJIW-AVJTYSNKSA-N	4	Alfacalcidol is a vitamin D analogue used for the management of hypocalcemia, secondary hyperparathyroidism, and osteodystrophy in patients with chronic renal failure, as well as some types of rickets and osteomalacia.	There is a discrepancy across a number of reported LD50 values for alfacalcidol, which can be attributed to differences in the procedures used in laboratories. Oral LD50 in mice ranges from 440 to 490 mcg/kg. Intravenous in mice was 290 mcg/kg; however, another source presented 56 mcg/kg in female mice and 71 mcg/kg in male mice. Oral LD50 in rats ranges from 340 to 720 mcg/kg.9In case of an acute accidental overdose following oral administration, emesis or gastric lavage can be induced to prevent further drug absorption. Mineral oil may be used to promote fecal drug elimination in instances where the drug was already absorbed in the stomach.9 Alfacalcidol overdose can lead to hypercalcemia, hypercalciuria, and hyperphosphatemia. Similarly, a high intake of calcium and phosphate concurrently with a therapeutic dose of alfacalcidol can result in those conditions.9 Hypercalcemia most commonly presents with headache, weakness, hypertension, somnolence, dizziness, sweating, anorexia, nausea, vomiting, diarrhea, constipation, polyuria, polydipsia and muscle and bone pain, and metallic taste.12 Hypercalcemia should be responded to with discontinuation of alfacalcidol, a low calcium diet and withdrawal of calcium supplements.9 Prolonged hypercalcemia can lead to nephrocalcinosis, nephrolithiasis, and reduced kidney function. In cases of severe hypercalcemia, general supportive measures are recommended, which may include forced diuresis and close monitoring of renal function, electrolytes, and electrocardiographs. Monitoring for abnormalities is especially critical in patients receiving digitalis glycosides. Management with glucocorticosteroids, loop diuretics, bisphosphonates, and calcitonin, as well as hemodialysis with low calcium content, may be considered.12	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	4.6023 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							136 °C		<1 mg/mL	1	No	2	2	Yes	3	0	40.46 Å2	50.56 Å3	124.7 m3·mol-1	6	No	No	0.00163 mg/mL	5.82	-5.4	14.39	-2.8	P11473;!O15528;!P19793	VDR;!CYP27B1;!RXRA	1. Vitamin D3 receptor;!2. 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial;!3. Retinoic acid receptor RXR-alpha
C18H24O2	Not Available	Not Available	272.388	[H][C@@]12CCC(=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)CC3=CC[C@@]21[H]	Solid	Not Available								18612511									18633059	46508864				19-Nor-5-androstenedione			19-Nor-5-androstenedione	Experimental, Illicit	DB01443	InChI=1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h2,13-16H,3-10H2,1H3/t13-,14+,15+,16-,18-/m0/s1	WELNRNVZXWUOGT-QXUSFIETSA-N			Because 19-Nor-5-androstenedione is metabolically related toother controlled anabolic steroids, it is likely to have similar adverse health effects such as liver, heart and skin problems, hormonal disruptions, stunted growth,and psychological effects such as rage and depression.	Small Molecule																																			1	Yes	2	0	No	4	0	34.14 Å2	31.58 Å3	79.16 m3·mol-1	0	Yes	Yes	0.0621 mg/mL	3.27	-3.6	16.25	-7.2			
C25H35NO4	Not Available	Not Available	413.5497	[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]11CC[C@@]2(OC)[C@]([H])(C1)[C@](C)(O)CCC	Solid	Not Available								96924									107765	46507682				Dihydroetorphine	ZINC000005843973		Dihydroetorphine	Experimental, Illicit	DB01450	InChI=1S/C25H35NO4/c1-5-8-22(2,28)17-14-23-9-10-25(17,29-4)21-24(23)11-12-26(3)18(23)13-15-6-7-16(27)20(30-21)19(15)24/h6-7,17-18,21,27-28H,5,8-14H2,1-4H3/t17-,18-,21-,22-,23-,24+,25-/m1/s1	BRTSNYPDACNMIP-FAWZKKEFSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	3.4494 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	2	No	6	1	62.16 Å2	46.35 Å3	115.55 m3·mol-1	4	Yes	No	0.114 mg/mL	2.66	-3.6	10.24	9.13			
C19H26O2	Not Available	Not Available	286.415	[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)C=C[C@]12C	Solid	Not Available						133930		9372004									11196935	46504446				1-Androstenedione	ZINC000013512012		1-Androstenedione	Experimental, Illicit	DB01451	InChI=1S/C19H26O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h7,9,12,14-16H,3-6,8,10-11H2,1-2H3/t12-,14-,15-,16-,18-,19-/m0/s1	WJIQCDPCDVWDDE-WZNAKSSCSA-N			Not Available	Small Molecule																																			1	Yes	2	0	No	4	0	34.14 Å2	33.2 Å3	83.87 m3·mol-1	0	Yes	Yes	0.0051 mg/mL	3.97	-4.8		-4.9			
C18H28O2	Not Available	Not Available	276.4137	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CC[C@H](O)CC3=CC[C@@]21[H]	Solid	Not Available					50423550		CHEMBL259126	8075901			HMDB0004590						9900246	46507256				19-Nor-5-androstenediol	ZINC000012496354		19-Nor-5-androstenediol	Experimental, Illicit	DB01455	InChI=1S/C18H28O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h2,12-17,19-20H,3-10H2,1H3/t12-,13-,14+,15+,16-,17-,18-/m0/s1	VVUQRXPUVKXAIO-XFUVECHXSA-N			Not Available	Small Molecule																																			1	Yes	2	2	No	4	0	40.46 Å2	33.21 Å3	81.01 m3·mol-1	0	Yes	No	0.0645 mg/mL	2.5	-3.6	18.23	-0.77			
C19H26O2	Not Available	Not Available	286.415	[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2CC(=O)CC[C@]12C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			83865	CHEMBL1743203	141063			HMDB0062415	C20252					160531	46507159				5-Androstenedione	ZINC000100041759		5-androstenedione	Experimental, Illicit	DB01456	InChI=1S/C19H26O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h3,14-16H,4-11H2,1-2H3/t14-,15-,16-,18-,19-/m0/s1	SQGZFRITSMYKRH-QAGGRKNESA-N			Not Available	Small Molecule																																			1	Yes	2	0	No	4	0	34.14 Å2	33.23 Å3	83.63 m3·mol-1	0	Yes	Yes	0.0366 mg/mL	3.57	-3.9	16.23	-7.2			
C27H35NO5	Not Available	Not Available	453.579	[H][C@@]12OC3=C(OC(C)=O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@@]11C[C@]([H])([C@](C)(O)CCC)[C@]2(OC)C=C1	Solid	Not Available							CHEMBL3989451	16736130									20055090	46506577				Acetorphine	ZINC000072266292		Acetorphine	Experimental, Illicit	DB01469	InChI=1S/C27H35NO5/c1-6-9-24(3,30)19-15-25-10-11-27(19,31-5)23-26(25)12-13-28(4)20(25)14-17-7-8-18(32-16(2)29)22(33-23)21(17)26/h7-8,10-11,19-20,23,30H,6,9,12-15H2,1-5H3/t19-,20-,23-,24-,25-,26+,27-/m1/s1	LFYBMMHFJIAKFE-PMEKXCSPSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	3.3149 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	1	Yes	6	1	68.23 Å2	49.84 Å3	125.67 m3·mol-1	6	Yes	No	0.0197 mg/mL	2.66	-4.4	14.68	8.97			
C21H32O2	Not Available	Not Available	316.4776	[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@H](C)CC2=CC(=O)CC[C@]12C	Solid	Not Available					50423546	34583	CHEMBL259548	92280			HMDB0006048	C14475	D03144				102146	46504950				Bolasterone	ZINC000004215039		Bolasterone	Experimental, Illicit	DB01471	InChI=1S/C21H32O2/c1-13-11-14-12-15(22)5-8-19(14,2)16-6-9-20(3)17(18(13)16)7-10-21(20,4)23/h12-13,16-18,23H,5-11H2,1-4H3/t13-,16+,17+,18-,19+,20+,21+/m1/s1	IVFYLRMMHVYGJH-VLOLGRDOSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.0516 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							164 °C			1	Yes	2	1	No	4	0	37.3 Å2	37.53 Å3	93.62 m3·mol-1	0	Yes	Yes	0.0112 mg/mL	3.93	-4.4	18.8	-0.53			
C20H32O2	Not Available	Not Available	304.474	C[C@]1(O)CC[C@H]2[C@@H]3CCC4=C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	Solid	Not Available								24734384									69259387	46505852							17alpha-methyl-3beta,17beta-dihydroxyandrost-4-ene	Experimental, Illicit	DB01474	InChI=1S/C20H32O2/c1-18-9-6-14(21)12-13(18)4-5-15-16(18)7-10-19(2)17(15)8-11-20(19,3)22/h12,14-17,21-22H,4-11H2,1-3H3/t14-,15+,16-,17-,18-,19-,20-/m0/s1	BNUOCVTVOYWNJC-DTMQFJJTSA-N			Not Available	Small Molecule																																			1	Yes	2	2	No	4	0	40.46 Å2	36.14 Å3	89.97 m3·mol-1	0	Yes	No	0.0339 mg/mL	3.23	-4	17.5	-0.5			
C20H34O2	Not Available	Not Available	306.49	C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	Solid	Not Available						79878	CHEMBL3544564	211980				C15376					242493	46506370					ZINC000004073945		BA-2664	Experimental, Illicit	DB01479	InChI=1S/C20H34O2/c1-18-9-6-14(21)12-13(18)4-5-15-16(18)7-10-19(2)17(15)8-11-20(19,3)22/h13-17,21-22H,4-12H2,1-3H3/t13-,14+,15+,16-,17-,18-,19-,20-/m0/s1	QGKQXZFZOIQFBI-XSWYFRFISA-N			Not Available	Small Molecule																																			1	Yes	2	2	No	4	0	40.46 Å2	37.06 Å3	89.27 m3·mol-1	0	Yes	No	0.00469 mg/mL	3.48	-4.8	18.3	-0.47			
C26H33NO4	Not Available	Not Available	423.553	[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@@]11C[C@]([H])(C(C)(C)O)[C@]2(OC)C=C1	Solid	Not Available							CHEMBL2110789	16735758									20054882	46506801				Cyprenorphine	ZINC000004215495		Cyprenorphine	Experimental, Illicit	DB01480	InChI=1S/C26H33NO4/c1-23(2,29)18-13-24-8-9-26(18,30-3)22-25(24)10-11-27(14-15-4-5-15)19(24)12-16-6-7-17(28)21(31-22)20(16)25/h6-9,15,18-19,22,28-29H,4-5,10-14H2,1-3H3/t18-,19-,22-,24-,25+,26-/m1/s1	VSKIOMHXEUHYSI-KNLIIKEYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	3.0389 LD50, mol/kg	Inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	2	No	7	1	62.16 Å2	46.88 Å3	119.33 m3·mol-1	4	Yes	No	0.0582 mg/mL	2.13	-3.9	10.35	9.54			
C19H28O2	Not Available	Not Available	288.4244	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)C=C[C@]12C	Solid	Not Available						59714		206590				C15377					236666	46507716				1-Testosterone	ZINC000004791927		1-Testosterone	Experimental, Illicit, Investigational	DB01481	InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h7,9,12,14-17,21H,3-6,8,10-11H2,1-2H3/t12-,14-,15-,16-,17-,18-,19-/m0/s1	OKJCFMUGMSVJBG-ABEVXSGRSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.0714 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	1	No	4	0	37.3 Å2	33.91 Å3	84.7 m3·mol-1	0	Yes	Yes	0.0128 mg/mL	3.41	-4.4	19.38	-0.88	P10275	AR	1. Androgen receptor
C19H28O3	Clearance is via the urine. Excretion studies were performed using 200mg of 4-hydroxytestosterone administered to healthy male volunteers. Urine samples were then analyzed for metabolic products using conventional gas chromatography-mass spectrometry approaches.One metabolite, 3-beta,4-alpha-dihydroxy-5alpha-androstan-17-one was identified as a long term metabolite which can be detected for 90 hours. Longer detection times are possible with the use of alternative monitoring technique in sports drug testing.	Not Available	304.43	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=C(O)C(=O)CC[C@]12C	Solid	Not Available							CHEMBL2431525	141138									160615	46508337				4-Hydroxytestosterone	ZINC000031460450		4-Hydroxytestosterone	Experimental, Illicit	DB01485	InChI=1S/C19H28O3/c1-18-10-8-15(20)17(22)14(18)4-3-11-12-5-6-16(21)19(12,2)9-7-13(11)18/h11-13,16,21-22H,3-10H2,1-2H3/t11-,12-,13-,16-,18+,19-/m0/s1	BQOIJSIMMIDHMO-FBPKJDBXSA-N			Excessive doses of anabolic steroids can induce harmful changes in cholesterol, acne, hypertension, liver damage, and damage to the heart. Hormonal imbalances caused by the use of anabolic steriods may result in gynecomastia and testicular atrophy.Anabolic steroids are known to increase harmful LDL, while decreasing beneficial HDL cholesterol. Their ability to stimulate sebaceous glands may increase acne. Additionally, the elevation in blood pressure caused by anabolic steroids, is particularly pronounced and harmful in those with pre-existing hypertension.	Small Molecule																																			1	Yes	3	2	No	4	0	57.53 Å2	34.73 Å3	86.4 m3·mol-1	0	Yes	No	0.068 mg/mL	2.85	-3.6	9.28	-0.88			
C20H32O	Not Available	Not Available	288.4675	[H][C@@]12CC[C@@](O)(CC)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCCC=C3CC[C@@]21[H]	Solid	Not Available						31578	CHEMBL1200623	13168								PA449539	13765	46505460		4162		Ethylestrenol	ZINC000004215863		Ethylestrenol	Withdrawn	DB01493	InChI=1S/C20H32O/c1-3-20(21)13-11-18-17-9-8-14-6-4-5-7-15(14)16(17)10-12-19(18,20)2/h6,15-18,21H,3-5,7-13H2,1-2H3/t15-,16+,17+,18-,19-,20-/m0/s1	AOXRBFRFYPMWLR-XGXHKTLJSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.8534 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							about 50			1	Yes	1	1	No	4	0	20.23 Å2	35.94 Å3	88.5 m3·mol-1	1	Yes	Yes	0.00086 mg/mL	4.69	-5.5		-0.27			
C25H33NO4	Not Available	Not Available	411.5338	[H][C@]12CC3=C4C(OC5[C@@]4(CCN1C)[C@]21CC(C(C)(O)CCC)C5(OC)C=C1)=C(O)C=C3	Solid	Not Available						4912		24895				C11793					26721	46505591			DNC000631	Etorphine			Etorphine	Illicit, Vet approved	DB01497	InChI=1S/C25H33NO4/c1-5-8-22(2,28)17-14-23-9-10-25(17,29-4)21-24(23)11-12-26(3)18(23)13-15-6-7-16(27)20(30-21)19(15)24/h6-7,9-10,17-18,21,27-28H,5,8,11-14H2,1-4H3/t17?,18-,21?,22?,23-,24+,25?/m1/s1	CAHCBJPUTCKATP-HBDRVVKHSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	3.2955 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.79		214-217 °C			1	Yes	5	2	No	6	1	62.16 Å2	45.54 Å3	116.51 m3·mol-1	4	Yes	No	0.112 mg/mL	2.47	-3.6	10.21	8.99	P35372;!P41143;!P41145;!P41146;!O60858;!P01189	OPRM1;!OPRD1;!OPRK1;!OPRL1;!TRIM13;!POMC	1. Mu-type opioid receptor;!2. Delta-type opioid receptor;!3. Kappa-type opioid receptor;!4. Nociceptin receptor;!5. E3 ubiquitin-protein ligase TRIM13;!6. Pro-opiomelanocortin
C18H26O3	Not Available	Not Available	290.403	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C(O)=C3CC[C@@]21[H]	Solid	Not Available						135210		16736429									20055236	46508722				Oxabolone			Oxabolone	Experimental, Illicit	DB01500	InChI=1S/C18H26O3/c1-18-9-8-11-10-4-6-15(19)17(21)13(10)3-2-12(11)14(18)5-7-16(18)20/h10-12,14,16,20-21H,2-9H2,1H3/t10-,11-,12-,14+,16+,18+/m1/s1	GXHBCWCMYVTJOW-YGRHGMIBSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.8869 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							189 °C			1	Yes	3	2	No	4	0	57.53 Å2	33.23 Å3	81.92 m3·mol-1	0	Yes	No	0.0883 mg/mL	2.55	-3.5	9.3	-0.88			
C19H30O2	Not Available	Not Available	290.447	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@@H](O)C=C[C@]12C	Solid	Not Available								9475742									11300765	46508681				1-Androstenediol	ZINC000055160979		1-Androstenediol	Experimental, Illicit	DB01503	InChI=1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h7,9,12-17,20-21H,3-6,8,10-11H2,1-2H3/t12-,13-,14-,15-,16-,17-,18-,19-/m0/s1	RZFGPAMUAXASRE-YSZCXEEOSA-N			Not Available	Small Molecule																																			1	Yes	2	2	No	4	0	40.46 Å2	34.68 Å3	85.59 m3·mol-1	0	Yes	No	0.0348 mg/mL	3	-3.9	17.5	-0.82			
C20H34O2	Not Available	Not Available	306.49	C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	Solid	Not Available								91994									101819	46507785					ZINC000005223451		17Alpha-methyl-3beta,17beta-dihydroxy-5alpha-androstane	Experimental, Illicit	DB01513	InChI=1S/C20H34O2/c1-18-9-6-14(21)12-13(18)4-5-15-16(18)7-10-19(2)17(15)8-11-20(19,3)22/h13-17,21-22H,4-12H2,1-3H3/t13-,14-,15+,16-,17-,18-,19-,20-/m0/s1	QGKQXZFZOIQFBI-UYEYMFBJSA-N			Not Available	Small Molecule																																			1	Yes	2	2	No	4	0	40.46 Å2	37.21 Å3	89.27 m3·mol-1	0	Yes	No	0.00469 mg/mL	3.48	-4.8	18.3	-0.47			
C19H27ClO2	Not Available	Not Available	322.869	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=C(Cl)C(=O)CC[C@]12C	Solid	Not Available						135372	CHEMBL2106571	62171					D07731				68947	46505505		61686		Clostebol	ZINC000004025021		Clostebol	Experimental, Illicit	DB01521	InChI=1S/C19H27ClO2/c1-18-10-8-15(21)17(20)14(18)4-3-11-12-5-6-16(22)19(12,2)9-7-13(11)18/h11-13,16,22H,3-10H2,1-2H3/t11-,12-,13-,16-,18+,19-/m0/s1	KCZCIYZKSLLNNH-FBPKJDBXSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.7601 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							189 °C			1	Yes	2	1	No	4	0	37.3 Å2	36.02 Å3	89.22 m3·mol-1	0	Yes	Yes	0.0153 mg/mL	3.75	-4.3	19.38	-0.88			
C19H30O2	Not Available	Not Available	290.4403	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C	Solid	Not Available					50223237	2710	CHEMBL440283	10188			HMDB0003818	C04295	D00179	B81			10634	46507476				5-Androstenediol	ZINC000003814414		Androstenediol	Experimental, Illicit	DB01524	InChI=1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h3,13-17,20-21H,4-11H2,1-2H3/t13-,14-,15-,16-,17-,18-,19-/m0/s1	QADHLRWLCPCEKT-LOVVWNRFSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.2291 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	2	No	4	0	40.46 Å2	34.87 Å3	85.48 m3·mol-1	0	Yes	No	0.055 mg/mL	2.8	-3.7	18.2	-0.77			
C19H30O2	Not Available	Not Available	290.4403	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=C[C@@H](O)CC[C@]12C	Solid	Not Available					50410526	34386	CHEMBL195836	120071			HMDB0005849	C14210					136297	46507648				4-Androstenediol	ZINC000003814413		4-Androstenediol	Experimental, Illicit	DB01526	InChI=1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,13-17,20-21H,3-10H2,1-2H3/t13-,14-,15-,16-,17-,18-,19-/m0/s1	BTTWKVFKBPAFDK-LOVVWNRFSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.2291 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	2	No	4	0	40.46 Å2	34.38 Å3	85.33 m3·mol-1	0	Yes	No	0.0481 mg/mL	2.95	-3.8	17.5	-0.82			
C19H32O2	Not Available	Not Available	292.4562	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](O)CC[C@]12C	Solid	Not Available	O75881	CYP7B1	1. Cytochrome P450 7B1		50093445	36713	CHEMBL335062	15039			HMDB0000554						15818	46505144					ZINC000003814411		5alpha-androstane-3alpha,17beta-diol	Experimental, Illicit	DB01530	InChI=1S/C19H32O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12-17,20-21H,3-11H2,1-2H3/t12-,13+,14-,15-,16-,17-,18-,19-/m0/s1	CBMYJHIOYJEBSB-KHOSGYARSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3334 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	2	2	No	4	0	40.46 Å2	35.25 Å3	84.63 m3·mol-1	0	Yes	No	0.0193 mg/mL	3.2	-4.2	18.3	-0.76			
C19H26O2	Not Available	Not Available	286.4085	[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	Not Available	P08684;!P42330	CYP3A4;!AKR1C3	1. Cytochrome P450 3A4;!2. Aldo-keto reductase family 1 member C3		91713	16422	CHEMBL274826	5898			HMDB0000053	C00280	D00051	ASD			6128	46508011		784		Androstenedione	ZINC000004428526		Androstenedione	Experimental, Illicit	DB01536	InChI=1S/C19H26O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-16H,3-10H2,1-2H3/t14-,15-,16-,18-,19-/m0/s1	AEMFNILZOJDQLW-QAGGRKNESA-N			Not Available	Small Molecule	http://smpdb.ca/view/SMP0000356?highlight[compounds][]=DB01536&highlight[proteins][]=DB01536;!http://smpdb.ca/view/SMP0030406?highlight[compounds][]=DB01536&highlight[proteins][]=DB01536;!http://smpdb.ca/view/SMP0000068?highlight[compounds][]=DB01536&highlight[proteins][]=DB01536;!http://smpdb.ca/view/SMP0000565?highlight[compounds][]=DB01536&highlight[proteins][]=DB01536	17-beta Hydroxysteroid Dehydrogenase III Deficiency;!Androstenedione Metabolism;!Androgen and Estrogen Metabolism;!Aromatase Deficiency		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.5360 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.75	-3.69	158 °C		57.8 mg/L (at 25 °C)	1	Yes	2	0	No	4	0	34.14 Å2	33.21 Å3	83.61 m3·mol-1	0	Yes	Yes	0.027 mg/mL	3.93	-4	18.52	-4.8	P14061;!P14060;!Q00441;!P42330	HSD17B1;!HSD3B1;!eryF;!AKR1C3	1. Estradiol 17-beta-dehydrogenase 1;!2. 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1;!3. 6-deoxyerythronolide B hydroxylase;!4. Aldo-keto reductase family 1 member C3
C19H28O3	Not Available	Not Available	304.43	[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C(O)=C3CC[C@@]21[H]	Solid	Not Available								42759157									69249407	46504925					ZINC000263614121		17alpha-methyl-4-hydroxynandrolone	Illicit	DB01540	InChI=1S/C19H28O3/c1-18-9-7-12-11-5-6-16(20)17(21)14(11)4-3-13(12)15(18)8-10-19(18,2)22/h11-13,15,21-22H,3-10H2,1-2H3/t11-,12-,13-,15+,18+,19+/m1/s1	CLNUZOCYKSHICX-FAHHUNKHSA-N			Not Available	Small Molecule																																			1	Yes	3	2	No	4	0	57.53 Å2	35.02 Å3	86.56 m3·mol-1	0	Yes	No	0.0575 mg/mL	2.83	-3.7	9.33	-0.53			
C19H26O2	Not Available	14 days	286.4085	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	Not Available					91719	34584	CHEMBL209073	12744				C14502	D07536				13308	46505583		2289408		Boldenone	ZINC000004215042		Boldenone	Illicit, Vet approved	DB01541	InChI=1S/C19H26O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h7,9,11,14-17,21H,3-6,8,10H2,1-2H3/t14-,15-,16-,17-,18-,19-/m0/s1	RSIHSRDYCUFFLA-DYKIIFRCSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.6259 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							165 °C			1	Yes	2	1	No	4	0	37.3 Å2	33.11 Å3	85.52 m3·mol-1	0	Yes	Yes	0.0259 mg/mL	3.36	-4	18.39	-0.88	P10275	AR	1. Androgen receptor
C19H28O2	Not Available	Not Available	288.431	[H][C@@]12CC[C@H](O)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	Solid	Not Available								8215338									10039774	46507237					ZINC000005955127		18-methyl-19-nortestosterone	Experimental, Illicit	DB01543	InChI=1S/C19H28O2/c1-2-19-10-9-15-14-6-4-13(20)11-12(14)3-5-16(15)17(19)7-8-18(19)21/h11,14-18,21H,2-10H2,1H3/t14-,15+,16+,17-,18-,19-/m0/s1	FBYZQDCRLYHHHP-ZOFHRBRSSA-N			Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	34.36 Å3	84.56 m3·mol-1	1	Yes	Yes	0.0302 mg/mL	3.51	-4	18.25	-0.75			
C26H35NO4	Not Available	Not Available	425.569	[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@]11CC[C@@]2(OC)[C@H](C1)C(C)(C)O	Solid	Not Available					50001714	4650	CHEMBL281786	391634		GtP Drug Page		C11794					443408	46506559				Diprenorphine	ZINC000004102215		Diprenorphine	Illicit, Vet approved	DB01548	InChI=1S/C26H35NO4/c1-23(2,29)18-13-24-8-9-26(18,30-3)22-25(24)10-11-27(14-15-4-5-15)19(24)12-16-6-7-17(28)21(31-22)20(16)25/h6-7,15,18-19,22,28-29H,4-5,8-14H2,1-3H3/t18-,19-,22-,24-,25+,26-/m1/s1	OIJXLIIMXHRJJH-KNLIIKEYSA-N	-Infinity		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	3.1511 LD50, mol/kg	Inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	2	No	7	1	62.16 Å2	47.86 Å3	118.37 m3·mol-1	4	Yes	No	0.104 mg/mL	2.28	-3.6	10.42	9.63			
C18H28O2	Not Available	Not Available	276.42	C[C@]12CC[C@H]3[C@@H](CCC4=C[C@@H](O)CC[C@H]34)[C@@H]1CC[C@@H]2O	Solid	Not Available						145661	CHEMBL307500	8011024									9835303	46505759				Bolandiol	ZINC000026375797		Bolandiol	Experimental, Illicit	DB01554	InChI=1S/C18H28O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h10,12-17,19-20H,2-9H2,1H3/t12-,13-,14+,15+,16-,17-,18-/m0/s1	CMXKUJNZWYTFJN-XFUVECHXSA-N			Not Available	Small Molecule																																			1	Yes	2	2	No	4	0	40.46 Å2	33.3 Å3	80.85 m3·mol-1	0	Yes	No	0.0566 mg/mL	2.65	-3.7	17.52	-0.82			
C21H32O2	Not Available	Not Available	316.4776	[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@H](C)CC2=CC(=O)CC[C@]12C	Solid	Not Available						135356	CHEMBL455706	26239			HMDB0004627						28204	46507441				Calusterone	ZINC000004215173		Calusterone	Experimental, Illicit	DB01564	InChI=1S/C21H32O2/c1-13-11-14-12-15(22)5-8-19(14,2)16-6-9-20(3)17(18(13)16)7-10-21(20,4)23/h12-13,16-18,23H,5-11H2,1-4H3/t13-,16-,17-,18+,19-,20-,21-/m0/s1	IVFYLRMMHVYGJH-PVPPCFLZSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.0516 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							128 °C			1	Yes	2	1	No	4	0	37.3 Å2	37.77 Å3	93.62 m3·mol-1	0	Yes	Yes	0.0112 mg/mL	3.93	-4.4	18.8	-0.53	P10275	AR	1. Androgen receptor
C21H28O4	Not Available	Not Available	344.4446	[H][C@@]12CC[C@](C)(O)[C@@]1(C)C[C@@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C(C=O)=C[C@]12C	Solid	Not Available						135456	CHEMBL2107419	16234			HMDB0004631						17150	46508967				Formebolone	ZINC000004216332		Formebolone	Experimental, Illicit	DB01569	InChI=1S/C21H28O4/c1-19-9-12(11-22)16(23)8-13(19)4-5-14-15-6-7-21(3,25)20(15,2)10-17(24)18(14)19/h8-9,11,14-15,17-18,24-25H,4-7,10H2,1-3H3/t14-,15-,17+,18+,19-,20-,21-/m0/s1	AMVODTGMYSRMNP-GNIMZFFESA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	3.2193 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				543.6 °C			210.5 °C			1	Yes	4	2	No	4	0	74.6 Å2	38.13 Å3	96.9 m3·mol-1	1	Yes	No	0.0605 mg/mL	1.76	-3.8	14.39	-2.9	P80365	HSD11B2	1. Corticosteroid 11-beta-dehydrogenase isozyme 2
C20H30O2	Not Available	Not Available	302.458	[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)C=C[C@]12C	Solid	Not Available								5442174										46506576				Methyl-1-testosterone	ZINC000004081584		Methyl-1-testosterone	Experimental, Illicit	DB01572	InChI=1S/C20H30O2/c1-18-9-6-14(21)12-13(18)4-5-15-16(18)7-10-19(2)17(15)8-11-20(19,3)22/h6,9,13,15-17,22H,4-5,7-8,10-12H2,1-3H3/t13-,15+,16-,17-,18-,19-,20-/m0/s1	JRNSSSJKIGAFCT-YDSAWKJFSA-N			Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	35.73 Å3	89.33 m3·mol-1	0	Yes	Yes	0.00401 mg/mL	3.69	-4.9		-0.53			
C24H40O4	Not Available	Not Available	392.572	[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O	Solid	Not Available	BE0004866		1. Cytochrome P450 3A Subfamily (Protein Group)		53721	9907	CHEMBL1551	29131			HMDB0000946	C07880	D00734	IU5		PA451837	31401	46508795		11065	DNC000420	Ursodeoxycholic_acid	ZINC000003914809	Reltone, Urso, Urso Forte	Ursodeoxycholic acid	Approved, Investigational	DB01586	InChI=1S/C24H40O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15+,16-,17-,18+,19+,20+,22+,23+,24-/m1/s1	RUDATBOHQWOJDD-UZVSRGJWSA-N	4	Ursodeoxycholic acid is a bile acid used for the treatment of primary biliary cirrhosis (PBC), dissolution of radiolucent gallstones in patients with a functioning gallbladder, and treatment of hepatobiliary disorders associated with cystic fibrosis in pediatric patients.	Neither accidental nor intentional overdosing with ursodeoxycholic acid has been reported. Doses of ursodeoxycholic acid in the range of 16-20 mg/kg/day have been tolerated for 6-37 months without symptoms by 7 patients. The LD50 for ursodeoxycholic acid in rats is over 5000 mg/kg given over 7-10 days and over 7500 mg/kg for mice. The most likely manifestation of severe overdose with ursodeoxycholic acid would probably be diarrhea, which should be treated symptomatically.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	2.5624 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.00		203 °C		20 mg/L (at 20 °C)	1	Yes	4	3	No	4	-1	77.76 Å2	46.42 Å3	109.27 m3·mol-1	4	Yes	No	0.0197 mg/mL	3.71	-4.3	4.6	-0.54			
C19H28O2	Not Available	12 hours	288.4244	[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C	Solid	Not Available	P24462;!P14061;!Q06520;!O00204;!P14060;!P22637;!P05093	CYP3A7;!HSD17B1;!SULT2A1;!SULT2B1;!HSD3B1;!choB;!CYP17A1	1. Cytochrome P450 3A7;!2. Estradiol 17-beta-dehydrogenase 1;!3. Bile salt sulfotransferase;!4. Sulfotransferase family cytosolic 2B member 1;!5. 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1;!6. Cholesterol oxidase;!7. Steroid 17-alpha-hydroxylase/17,20 lyase		50223368	28689	CHEMBL90593	5670		GtP Drug Page	HMDB0000077	C01227	D08409	AND		PA451993	5881	46508824		3143	DNC001146	Dehydroepiandrosterone	ZINC000003807917	Intrarosa	Prasterone	Approved, Investigational, Nutraceutical	DB01708	InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h3,13-16,20H,4-11H2,1-2H3/t13-,14-,15-,16-,18-,19-/m0/s1	FMGSKLZLMKYGDP-USOAJAOKSA-N	4	Prasterone is a steroid formulated as a vaginal insert indicated for the treatment of moderate to severe dyspareunia associated with menopausal vulvar and vaginal atrophy.	Acute oral toxicity (LD50): >10000 mg/kg [Rat]. Lowest Published Toxic Dose (TDL) [Man] - Route: Oral; Dose: 10 mg/kg/2W intermittent.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.5214 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.23		140-141 °C		63.5 mg/L (at 25 °C)	1	Yes	2	1	No	4	0	37.3 Å2	34.1 Å3	84.66 m3·mol-1	0	Yes	Yes	0.0438 mg/mL	3.36	-3.8	18.2	-1.4	P03372;!Q92731;!BE0004797;!BE0004956;!P10275;!Q07869;!Q99720;!O75469;!Q14994	ESR1;!ESR2;!;!;!AR;!PPARA;!SIGMAR1;!NR1I2;!NR1I3	1. Estrogen receptor alpha;!2. Estrogen receptor beta;!3. GABA(A) Receptor (Protein Group);!4. NMDA receptor (Protein Group);!5. Androgen receptor;!6. Peroxisome proliferator-activated receptor alpha;!7. Sigma non-opioid intracellular receptor 1;!8. Nuclear receptor subfamily 1 group I member 2;!9. Nuclear receptor subfamily 1 group I member 3
C36H56O12	Not Available	Not Available	680.8226	[H]\C1=C2/[C@@]([H])(COC)CC[C@@]2([H])[C@@]([H])(C)[C@@]([H])(O)[C@]([H])(O[C@@]2([H])O[C@]([H])(COC(C)(C)C=C)[C@@]([H])(O)[C@]([H])(OC(C)=O)[C@@]2([H])O)C2=C(C[C@]([H])(O)[C@]12C)[C@]([H])(C)COC(C)=O	Solid	Not Available						51015	CHEMBL4244843	394625						FSC			447573	46508360				Fusicoccin			Fusicoccin	Experimental	DB01780	InChI=1S/C36H56O12/c1-10-35(6,7)45-17-26-30(41)33(46-21(5)38)31(42)34(47-26)48-32-28-24(18(2)15-44-20(4)37)13-27(39)36(28,8)14-25-22(16-43-9)11-12-23(25)19(3)29(32)40/h10,14,18-19,22-23,26-27,29-34,39-42H,1,11-13,15-17H2,2-9H3/b25-14-/t18-,19-,22-,23+,26-,27+,29-,30-,31-,32-,33+,34-,36+/m1/s1	KXTYBXCEQOANSX-WYKQKOHHSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	3.4297 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	10	4	Yes	4	0	170.44 Å2	72.71 Å3	175.76 m3·mol-1	14	No	No	0.0849 mg/mL	1.35	-3.9	12.24	-3	P62258	YWHAE	1. 14-3-3 protein epsilon
C27H41NO5S	Not Available	Not Available	491.683	[H][C@]1(C\C=C(C)/CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)C(\C)=C\C1=CSC(C)=N1	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			29579	CHEMBL96172	9400674				C12039		EPD			447865	46508361				Epothilone	ZINC000003951739		Epothilone D	Investigational	DB01873	InChI=1S/C27H41NO5S/c1-16-9-8-10-17(2)25(31)19(4)26(32)27(6,7)23(29)14-24(30)33-22(12-11-16)18(3)13-21-15-34-20(5)28-21/h11,13,15,17,19,22-23,25,29,31H,8-10,12,14H2,1-7H3/b16-11-,18-13+/t17-,19+,22-,23-,25-/m0/s1	XOZIUKBZLSUILX-GIQCAXHBSA-N	2		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.8243 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	5	2	No	2	0	96.72 Å2	55.62 Å3	136.04 m3·mol-1	2	No	No	0.00246 mg/mL	5.1	-5.3	14.09	2.73	Q13748;!P07437;!Q9H4B7;!P68371;!P04350;!P68366;!Q13509;!Q9BQE3;!Q9NY65;!P68363;!Q71U36	TUBA3C;!TUBB;!TUBB1;!TUBB4B;!TUBB4A;!TUBA4A;!TUBB3;!TUBA1C;!TUBA8;!TUBA1B;!TUBA1A	1. Tubulin alpha-3C/D chain;!2. Tubulin beta chain;!3. Tubulin beta-1 chain;!4. Tubulin beta-4B chain;!5. Tubulin beta-4A chain;!6. Tubulin alpha-4A chain;!7. Tubulin beta-3 chain;!8. Tubulin alpha-1C chain;!9. Tubulin alpha-8 chain;!10. Tubulin alpha-1B chain;!11. Tubulin alpha-1A chain
C19H30O	Not Available	Not Available	274.4409	[H][C@@]12CC=C[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@]([H])(O)CC[C@]12C	Solid	Not Available					50134722	40933	CHEMBL142348	92136			HMDB0005935			ATE			101989	46505452					ZINC000004352598		16,17-Androstene-3-Ol	Experimental	DB01889	InChI=1S/C19H30O/c1-18-9-3-4-16(18)15-6-5-13-12-14(20)7-11-19(13,2)17(15)8-10-18/h3,9,13-17,20H,4-8,10-12H2,1-2H3/t13-,14+,15-,16-,17-,18-,19-/m0/s1	KRVXMNNRSSQZJP-PHFHYRSDSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.8749 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	1	1	No	4	0	20.23 Å2	33.67 Å3	84.23 m3·mol-1	0	Yes	Yes	0.000355 mg/mL	4.07	-5.9	18.3	-1.4	Q14994	NR1I3	1. Nuclear receptor subfamily 1 group I member 3
C26H43NO5	Not Available	Not Available	449.6233	C[C@H](CCC(=O)NCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	Solid	Not Available					50375590	36274	CHEMBL1552	12027				C05466		CHO			12544	46506300					ZINC000003914812		Glycochenodeoxycholic Acid	Experimental	DB02123	InChI=1S/C26H43NO5/c1-15(4-7-22(30)27-14-23(31)32)18-5-6-19-24-20(9-11-26(18,19)3)25(2)10-8-17(28)12-16(25)13-21(24)29/h15-21,24,28-29H,4-14H2,1-3H3,(H,27,30)(H,31,32)/t15-,16+,17-,18-,19+,20+,21-,24+,25+,26-/m1/s1	GHCZAUBVMUEKKP-GYPHWSFCSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.5186 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.12				3.15 mg/L (at 20 °C)	1	No	5	4	Yes	4	-1	106.86 Å2	52.05 Å3	122.08 m3·mol-1	6	Yes	No	0.00793 mg/mL	2.61	-4.8	3.77	-0.49	P0AET8	hdhA	1. 7-alpha-hydroxysteroid dehydrogenase
C18H20O2	Not Available	Not Available	268.3502	[H][C@@]12CCC(=O)[C@@]1(C)CC[C@]1([H])C3=C(CC=C21)C=C(O)C=C3	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4		50423544	42309	CHEMBL323533	193995				C14392	D04041	EQI			223368	46506633				Equilin	ZINC000100031739		Equilin	Experimental	DB02187	InChI=1S/C18H20O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3-5,10,14,16,19H,2,6-9H2,1H3/t14-,16+,18+/m1/s1	WKRLQDKEXYKHJB-HFTRVMKXSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.8021 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							239 °C		1.41 mg/L (at 25 °C)	1	Yes	2	1	No	4	0	37.3 Å2	30.52 Å3	79.93 m3·mol-1	0	Yes	Yes	0.0133 mg/mL	3.9	-4.3	9.41	-6	P03372;!P14061	ESR1;!HSD17B1	1. Estrogen receptor alpha;!2. Estradiol 17-beta-dehydrogenase 1
C27H40O3	Not Available	Not Available	412.6047	O[C@H](\C=C\[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C)C1CC1	Solid	Not Available	P05164;!Q07973	MPO;!CYP24A1	1. Myeloperoxidase;!2. 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial		50369964	50749	CHEMBL1200666	4450880		GtP Drug Page	HMDB0015567		D01125	MC9		PA448714	5288783	46507122	RxList Drug Page	29365	DAP000292	Calcipotriol	ZINC000003921872	Calcitrene, Dovobet, Dovonex, Enstilar, Sorilux, Taclonex, Wynzora	Calcipotriol	Approved	DB02300	InChI=1S/C27H40O3/c1-17(6-13-25(29)20-8-9-20)23-11-12-24-19(5-4-14-27(23,24)3)7-10-21-15-22(28)16-26(30)18(21)2/h6-7,10,13,17,20,22-26,28-30H,2,4-5,8-9,11-12,14-16H2,1,3H3/b13-6+,19-7+,21-10-/t17-,22-,23-,24+,25-,26+,27-/m1/s1	LWQQLNNNIPYSNX-UROSTWAQSA-N	4	Calcipotriol is a topical synthetic vitamin D2 derivative used in the treatment of plaque psoriasis.	Topically applied calcipotriene can be absorbed in sufficient amounts to produce systemic effects. Elevated serum calcium has been observed with excessive use of calcipotriene.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	3.9699 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	3	No	4	0	60.69 Å2	49.59 Å3	125.45 m3·mol-1	5	Yes	No	0.0135 mg/mL	3.84	-4.5	14.39	-1.6			
C34H50O7	Not Available	Not Available	570.7566	[H][C@@]1(CC[C@@]2(C)[C@@]([H])(CC[C@]3(C)[C@]2([H])C(=O)C=C2[C@]4([H])C[C@](C)(CC[C@]4(C)CC[C@@]32C)C(O)=O)C1(C)C)OC(=O)CCC(O)=O	Solid	Not Available					50247012		CHEMBL499915	552190						CBO			636403	46508820		2017	DNC000388	Carbenoxolone	ZINC000003977823		Carbenoxolone	Experimental	DB02329	InChI=1S/C34H50O7/c1-29(2)23-10-13-34(7)27(32(23,5)12-11-24(29)41-26(38)9-8-25(36)37)22(35)18-20-21-19-31(4,28(39)40)15-14-30(21,3)16-17-33(20,34)6/h18,21,23-24,27H,8-17,19H2,1-7H3,(H,36,37)(H,39,40)/t21-,23-,24-,27+,30+,31-,32-,33+,34+/m0/s1	OBZHEBDUNPOCJG-WBXJDKIVSA-N		Carbenoxolone is a drug used to symptomatically treat lip sores and mouth ulcers.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	2.3981 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							292.5 °C			0	No	6	2	Yes	5	-2	117.97 Å2	64.99 Å3	154.31 m3·mol-1	6	No	No	0.000738 mg/mL	6.3	-5.9	4.04	-5.1			
C19H26O3	Not Available	Not Available	302.4079	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C(OC)=C3	Solid	Not Available					50060957	28955	CHEMBL299613	59788			HMDB0000405	C05302		ESM		PA13496724	16760554	175426854				2-Methoxyestradiol	ZINC000003818826		2-Methoxyestradiol	Investigational	DB02342	InChI=1S/C19H26O3/c1-19-8-7-12-13(15(19)5-6-18(19)21)4-3-11-9-16(20)17(22-2)10-14(11)12/h9-10,12-13,15,18,20-21H,3-8H2,1-2H3/t12-,13+,15-,18-,19-/m0/s1	CQOQDQWUFQDJMK-SSTWWWIQSA-N	2		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.8598 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	3	2	No	4	0	49.69 Å2	35.2 Å3	86.37 m3·mol-1	1	Yes	No	0.00968 mg/mL	3.59	-4.5	10.29	-0.88	P21964;!P04798;!Q16678;!P11511;!Q16665	COMT;!CYP1A1;!CYP1B1;!CYP19A1;!HIF1A	1. Catechol O-methyltransferase;!2. Cytochrome P450 1A1;!3. Cytochrome P450 1B1;!4. Cytochrome P450 19A1;!5. Hypoxia-inducible factor 1-alpha
C31H46O19S2	Not Available	Not Available	786.816	CC(C)CC(=O)O[C@H]1[C@@H](O[C@@H]2C[C@]3(C)[C@H]4CC[C@@H]5C[C@@]4(CC[C@H]3C(C2)(C(O)=O)C(O)=O)[C@@H](O)C5=C)O[C@@H](COO)[C@H](OS(O)(=O)=O)[C@@H]1OS(O)(=O)=O	Solid	Not Available								26329724						CXT			46936378	46505904				Carboxyatractyloside	ZINC000096006053		Carboxyatractyloside	Experimental	DB02426	InChI=1S/C31H46O19S2/c1-14(2)9-21(32)48-24-23(50-52(42,43)44)22(49-51(39,40)41)18(13-45-38)47-26(24)46-17-11-29(4)19-6-5-16-10-30(19,25(33)15(16)3)8-7-20(29)31(12-17,27(34)35)28(36)37/h14,16-20,22-26,33,38H,3,5-13H2,1-2,4H3,(H,34,35)(H,36,37)(H,39,40,41)(H,42,43,44)/t16-,17-,18+,19-,20-,22+,23+,24-,25+,26+,29-,30-/m1/s1	CYBVQIBJEFQVPD-GWDNDVLHSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.7066 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										0	No	16	6	Yes	5	-4	296.25 Å2	75.05 Å3	168.79 m3·mol-1	14	No	No	2.17 mg/mL	-1.5	-2.6	-2.3	-0.69	P12235	SLC25A4	1. ADP/ATP translocase 1
C22H34O7	Not Available	Not Available	410.5012	[H][C@]1(O)CCC(C)(C)[C@]2([H])[C@]([H])(O)[C@]([H])(OC(C)=O)[C@@]3(C)O[C@](C)(CC(=O)[C@]3(O)[C@@]12C)C=C	Solid	Not Available					50010261	42471	CHEMBL52606	43607	Drugs.com Drug Page			C09076	D03584	FOK		PA146096022	47936	46509044				Forskolin	ZINC000003977779		Colforsin	Experimental, Investigational	DB02587	InChI=1S/C22H34O7/c1-8-19(5)11-14(25)22(27)20(6)13(24)9-10-18(3,4)16(20)15(26)17(28-12(2)23)21(22,7)29-19/h8,13,15-17,24,26-27H,1,9-11H2,2-7H3/t13-,15-,16-,17-,19-,20-,21+,22-/m0/s1	OHCQJHSOBUTRHG-KGGHGJDLSA-N	-Infinity		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.2384 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	6	3	No	3	0	113.29 Å2	43.32 Å3	104.47 m3·mol-1	3	Yes	No	1.1 mg/mL	1.36	-2.6	11.57	-3	Q08462;!P63092;!O95622;!P13569	ADCY2;!GNAS;!ADCY5;!CFTR	1. Adenylate cyclase type 2;!2. Guanine nucleotide-binding protein G(s) subunit alpha isoforms short;!3. Adenylate cyclase type 5;!4. Cystic fibrosis transmembrane conductance regulator
C26H34O7	Not Available	Not Available	458.551	CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O	Solid	Not Available					50113436	48635	CHEMBL32838	5292885				C09668		FUG			6917655	46505331			DNC000664	Fumagillin	ZINC000004098264		Fumagillin	Experimental	DB02640	InChI=1S/C26H34O7/c1-18(2)13-14-20-25(3,33-20)24-23(30-4)19(15-16-26(24)17-31-26)32-22(29)12-10-8-6-5-7-9-11-21(27)28/h5-13,19-20,23-24H,14-17H2,1-4H3,(H,27,28)/b7-5+,8-6+,11-9+,12-10+/t19-,20-,23-,24-,25+,26+/m1/s1	NGGMYCMLYOUNGM-CSDLUJIJSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.7268 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							190-192			1	Yes	6	1	Yes	3	-1	97.89 Å2	51.13 Å3	128.37 m3·mol-1	11	Yes	No	0.0033 mg/mL	4.05	-5.1	4.88	-3.7	P50579	METAP2	1. Methionine aminopeptidase 2
C24H40O5	Not Available	Not Available	408.5714	[H][C@@](C)(CCC(O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])[C@]([H])(O)C[C@]4([H])C[C@]([H])(O)CC[C@]4(C)[C@@]3([H])C[C@]([H])(O)[C@]12C	Solid	Not Available					21680	16359	CHEMBL205596	192176	Drugs.com Drug Page		HMDB0000619	C00695	D10699	CHD		PA166160055	221493	46507063		1440856			ZINC000006858022	Cholbam, Orphacol	Cholic Acid	Approved	DB02659	InChI=1S/C24H40O5/c1-13(4-7-21(28)29)16-5-6-17-22-18(12-20(27)24(16,17)3)23(2)9-8-15(25)10-14(23)11-19(22)26/h13-20,22,25-27H,4-12H2,1-3H3,(H,28,29)/t13-,14+,15-,16-,17+,18+,19-,20+,22+,23+,24-/m1/s1	BHQCQFFYRZLCQQ-OELDTZBJSA-N	3	Cholic Acid is a bile acid used for the treatment of bile acid synthesis disorders due to single enzyme defects and as an adjunctive treatment of peroxisomal disorders with disrupted liver function.	Not Available	Small Molecule	http://smpdb.ca/view/SMP0000316?highlight[compounds][]=DB02659&highlight[proteins][]=DB02659;!http://smpdb.ca/view/SMP0000314?highlight[compounds][]=DB02659&highlight[proteins][]=DB02659;!http://smpdb.ca/view/SMP0000720?highlight[compounds][]=DB02659&highlight[proteins][]=DB02659;!http://smpdb.ca/view/SMP0000035?highlight[compounds][]=DB02659&highlight[proteins][]=DB02659;!http://smpdb.ca/view/SMP0000315?highlight[compounds][]=DB02659&highlight[proteins][]=DB02659;!http://smpdb.ca/view/SMP0000317?highlight[compounds][]=DB02659&highlight[proteins][]=DB02659;!http://smpdb.ca/view/SMP0000318?highlight[compounds][]=DB02659&highlight[proteins][]=DB02659	Zellweger Syndrome;!Congenital Bile Acid Synthesis Defect Type II;!27-Hydroxylase Deficiency;!Bile Acid Biosynthesis;!Cerebrotendinous Xanthomatosis (CTX);!Familial Hypercholanemia (FHCA);!Congenital Bile Acid Synthesis Defect Type III		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	2.5624 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.02	-3.37	198 °C	4.98 (at 20 °C)	175 mg/L (at 20 °C)	1	Yes	5	4	No	4	-1	97.99 Å2	47.05 Å3	110.79 m3·mol-1	4	Yes	No	0.0738 mg/mL	2.48	-3.7	4.48	-0.16			
C26H42NO6	Not Available	Not Available	464.624	[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])C[C@H](O)[C@]12C)[C@H](C)CCC(=O)NCC([O-])=O	Solid	Not Available					50420252	29746		4573891				C01921		GCH			5460316	46507924		1426482		Glycocholic_acid			Glycocholic acid	Experimental, Investigational	DB02691	InChI=1S/C26H43NO6/c1-14(4-7-22(31)27-13-23(32)33)17-5-6-18-24-19(12-21(30)26(17,18)3)25(2)9-8-16(28)10-15(25)11-20(24)29/h14-21,24,28-30H,4-13H2,1-3H3,(H,27,31)(H,32,33)/p-1/t14-,15+,16-,17-,18+,19+,20-,21+,24+,25+,26-/m1/s1	RFDAIACWWDREDC-FRVQLJSFSA-M	3		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.5186 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					1.65	-5.15	166.5 °C		3.3 mg/L (at 20 °C)	1	No	6	4	Yes	4	-1	129.92 Å2	52.37 Å3	134.43 m3·mol-1	6	Yes	No	0.0214 mg/mL	1.38	-4.4	3.77	-0.14	P51161	FABP6	1. Gastrotropin
C31H48O6	Not Available	Approximately 5 to 6 hours in adults.	516.7092	[H][C@@]12C[C@@H](O)[C@@]3([H])[C@@]4(C)CC[C@@H](O)[C@@H](C)[C@]4([H])CC[C@]3(C)[C@@]1(C)C[C@H](OC(C)=O)\C2=C(\CCC=C(C)C)C(O)=O	Solid	Not Available	P10635;!P08684;!P22309	CYP2D6;!CYP3A4;!UGT1A1	1. Cytochrome P450 2D6;!2. Cytochrome P450 3A4;!3. UDP-glucuronosyltransferase 1-1		58924	29013	CHEMBL374975	2271900			HMDB0015570	C06694	D04281	FUA		PA164749648	3000226	46505364		113608	DAP001008	Fusidic_acid	ZINC000008143796	Fucibet, Fucidin, Fucithalmic	Fusidic acid	Approved, Investigational	DB02703	InChI=1S/C31H48O6/c1-17(2)9-8-10-20(28(35)36)26-22-15-24(34)27-29(5)13-12-23(33)18(3)21(29)11-14-30(27,6)31(22,7)16-25(26)37-19(4)32/h9,18,21-25,27,33-34H,8,10-16H2,1-7H3,(H,35,36)/b26-20-/t18-,21-,22-,23+,24+,25-,27-,29-,30-,31-/m0/s1	IECPWNUMDGFDKC-MZJAQBGESA-N	4	Fusidic acid is a topical antibacterial agent used to prevent and treat mild to moderate skin infections caused by susceptible bacteria.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	3.5929 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							192.5 °C	5.35		1	No	5	3	Yes	4	-1	104.06 Å2	59.76 Å3	144.12 m3·mol-1	6	No	No	0.00521 mg/mL	4.42	-5	4.46	-0.2	P13551;!P62580;!P00484	fusA;!cat;!cat3	1. Elongation factor G;!2. Chloramphenicol acetyltransferase;!3. Chloramphenicol acetyltransferase 3
C21H32O2	Not Available	Not Available	316.4776	[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4		50375319	16581	CHEMBL253363	8611			HMDB0000253	C01953	D00143	PLO			8955	46506718		114052	DNC001147	Pregnenolone	ZINC000003861150		Pregnenolone	Approved, Experimental	DB02789	InChI=1S/C21H32O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h4,15-19,23H,5-12H2,1-3H3/t15-,16-,17+,18-,19-,20-,21+/m0/s1	ORNBQBCIOKFOEO-QGVNFLHTSA-N	4		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.9852 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	1	No	4	0	37.3 Å2	38.09 Å3	93.76 m3·mol-1	1	Yes	Yes	0.0136 mg/mL	3.58	-4.4	18.2	-1.4	O75469;!O00204	NR1I2;!SULT2B1	1. Nuclear receptor subfamily 1 group I member 2;!2. Sulfotransferase family cytosolic 2B member 1
C19H30O2	Not Available	Not Available	290.4403	[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@]2([H])C[C@]([H])(O)CC[C@]12C	Solid	Not Available					50191348	28195	CHEMBL85799	5669			HMDB0000490	C04373		AE2			5880	46507911				Etiocholanolone	ZINC000003875364		Aetiocholanolone	Experimental	DB02854	InChI=1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12-16,20H,3-11H2,1-2H3/t12-,13-,14+,15+,16+,18+,19+/m1/s1	QGXBDMJGAMFCBF-BNSUEQOYSA-N			Not Available	Small Molecule	http://smpdb.ca/view/SMP0030406?highlight[compounds][]=DB02854&highlight[proteins][]=DB02854	Androstenedione Metabolism		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.9757 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	1	No	4	0	37.3 Å2	34.36 Å3	83.81 m3·mol-1	0	Yes	Yes	0.00637 mg/mL	3.77	-4.7	18.3	-1.4	P01859;!Q06520;!P9WGT1;!Q8NBQ5	IGHG2;!SULT2A1;!fabG3;!HSD17B11	1. Ig gamma-2 chain C region;!2. Bile salt sulfotransferase;!3. 3-alpha-(or 20-beta)-hydroxysteroid dehydrogenase;!4. Estradiol 17-beta-dehydrogenase 11
C19H30O2	Not Available	Not Available	290.4403	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)CC[C@]12C	Solid	Not Available					18161	16330	CHEMBL27769	10189			HMDB0002961	C03917	D07456	DHT			10635	46506828				Dihydrotestosterone	ZINC000003814360		Stanolone	Illicit, Investigational	DB02901	InChI=1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12,14-17,21H,3-11H2,1-2H3/t12-,14-,15-,16-,17-,18-,19-/m0/s1	NVKAWKQGWWIWPM-ABEVXSGRSA-N	2		Oral LD50 in rat is 7060 mg/kg. Oral LD50 in mouse is 3450 mg/kg.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.9757 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.55		181 °C		525 mg/mL (at 25 °C)	1	Yes	2	1	No	4	0	37.3 Å2	34.54 Å3	83.6 m3·mol-1	0	Yes	Yes	0.00998 mg/mL	3.41	-4.5	19.38	-0.88			
C19H24O2	Not Available	Not Available	284.3927	[H][C@@]12CC[C@](C)(O)[C@@]1(C)C=CC1=C3CCC(=O)C=C3CC[C@@]21[H]	Solid	Not Available					50367916	379896	CHEMBL166444	229099		GtP Drug Page		C14257		R18			261000	46505539				Metribolone	ZINC000003814420		Metribolone	Experimental	DB02998	InChI=1S/C19H24O2/c1-18-9-7-15-14-6-4-13(20)11-12(14)3-5-16(15)17(18)8-10-19(18,2)21/h7,9,11,16-17,21H,3-6,8,10H2,1-2H3/t16-,17+,18+,19+/m1/s1	CCCIJQPRIXGQOE-XWSJACJDSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.6259 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	1	No	4	0	37.3 Å2	33.01 Å3	86.29 m3·mol-1	0	Yes	Yes	0.0332 mg/mL	2.53	-3.9	18.4	-0.53			
C27H41NO6S	Not Available	Not Available	507.683	[H]\C(=C(\C)[C@]1([H])C[C@]2([H])O[C@]2(C)CCC[C@]([H])(C)[C@]([H])(O)[C@@]([H])(C)C(=O)C(C)(C)[C@@]([H])(O)CC(=O)O1)C1=CSC(C)=N1	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4		50103627	31550	CHEMBL94657	10213816				C12154		EPB			448013	46505629			DNC000616		ZINC000003951737		Patupilone	Experimental, Investigational	DB03010	InChI=1S/C27H41NO6S/c1-15-9-8-10-27(7)22(34-27)12-20(16(2)11-19-14-35-18(4)28-19)33-23(30)13-21(29)26(5,6)25(32)17(3)24(15)31/h11,14-15,17,20-22,24,29,31H,8-10,12-13H2,1-7H3/b16-11+/t15-,17+,20-,21-,22-,24-,27+/m0/s1	QXRSDHAAWVKZLJ-PVYNADRNSA-N	3		Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.7983 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	2	No	3	0	109.25 Å2	56.11 Å3	134.76 m3·mol-1	2	No	No	0.00342 mg/mL	4.12	-5.2	14.09	2.73	Q13748;!P07437;!Q9H4B7;!P68371;!P04350;!P68366;!Q13509;!Q9BQE3;!Q9NY65;!P68363;!Q71U36	TUBA3C;!TUBB;!TUBB1;!TUBB4B;!TUBB4A;!TUBA4A;!TUBB3;!TUBA1C;!TUBA8;!TUBA1B;!TUBA1A	1. Tubulin alpha-3C/D chain;!2. Tubulin beta chain;!3. Tubulin beta-1 chain;!4. Tubulin beta-4B chain;!5. Tubulin beta-4A chain;!6. Tubulin alpha-4A chain;!7. Tubulin beta-3 chain;!8. Tubulin alpha-1C chain;!9. Tubulin alpha-8 chain;!10. Tubulin alpha-1B chain;!11. Tubulin alpha-1A chain
C29H48O4	Not Available	Not Available	460.689	[H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C)[C@@H](C)OCCCC(O)(CC)CC	Solid	Not Available							CHEMBL432600	4450786						KH1			73896915	46505581					ZINC000004474609		Lexacalcitol	Experimental	DB03451	InChI=1S/C29H48O4/c1-6-29(32,7-2)16-9-17-33-21(4)25-13-14-26-22(10-8-15-28(25,26)5)11-12-23-18-24(30)19-27(31)20(23)3/h11-12,21,24-27,30-32H,3,6-10,13-19H2,1-2,4-5H3/b22-11+,23-12-/t21-,24-,25-,26+,27+,28-/m1/s1	KLZOTDOJMRMLDX-YBBVPDDNSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	3.4928 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	3	Yes	3	0	69.92 Å2	55.8 Å3	137.52 m3·mol-1	9	Yes	No	0.00632 mg/mL	4.36	-4.9	14.25	-2.8	P11473	VDR	1. Vitamin D3 receptor
C24H40O4	Not Available	Not Available	392.572	[H][C@@]12CC[C@H]([C@H](C)CCC(O)=O)[C@@]1(C)[C@@H](O)C[C@@]1([H])[C@@]2([H])CC[C@]2([H])C[C@H](O)CC[C@]12C	Solid	Not Available					50375599	28834	CHEMBL406393	193196	Drugs.com Drug Page		HMDB0000626	C04483		DXC			222528	46506360		3194		Deoxycholic_acid	ZINC000003914810	Belkyra, Kybella	Deoxycholic acid	Approved	DB03619	InChI=1S/C24H40O4/c1-14(4-9-22(27)28)18-7-8-19-17-6-5-15-12-16(25)10-11-23(15,2)20(17)13-21(26)24(18,19)3/h14-21,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15-,16-,17+,18-,19+,20+,21+,23+,24-/m1/s1	KXGVEGMKQFWNSR-LLQZFEROSA-N	4	Deoxycholic acid is a cytolytic agent injected subcutaneously to improve the appearance submental fat.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	2.5624 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.50	-3.95	177 °C		43.6 mg/L (at 20 °C)	1	Yes	4	3	No	4	-1	77.76 Å2	46.3 Å3	109.2 m3·mol-1	4	Yes	No	0.0173 mg/mL	3.79	-4.4	4.65	-0.35			
C23H34O5	Not Available	Not Available	390.5131	[H][C@@]1(CC[C@]2(O)[C@]3([H])CC[C@]4([H])C[C@@H](O)CC[C@]4(C)[C@@]3([H])C[C@@H](O)[C@]12C)C1=CC(=O)OC1	Solid	Not Available					225707	42098	CHEMBL1153	14728						DOG			15478	46509019				Digoxigenin	ZINC000003982471		Digoxigenin	Experimental	DB03671	InChI=1S/C23H34O5/c1-21-7-5-15(24)10-14(21)3-4-17-18(21)11-19(25)22(2)16(6-8-23(17,22)27)13-9-20(26)28-12-13/h9,14-19,24-25,27H,3-8,10-12H2,1-2H3/t14-,15+,16-,17-,18+,19-,21+,22+,23+/m1/s1	SHIBSTMRCDJXLN-KCZCNTNESA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	3.4699 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	4	3	No	5	0	86.99 Å2	42.7 Å3	105.16 m3·mol-1	1	Yes	No	0.0632 mg/mL	1.84	-3.8	7.15	-1.4			
C30H50O	Not Available	Not Available	426.7174	[H][C@@]1(CC[C@@]2(C)C3=C(CC[C@]12C)[C@@]1(C)CC[C@H](O)C(C)(C)[C@]1([H])CC3)[C@H](C)CCC=C(C)C	Solid	Not Available						16521	CHEMBL225111	216175		GtP Drug Page	HMDB0001251	C01724		LAN			246983	46506323		1442199		Lanosterol	ZINC000003870056		Lanosterol	Experimental	DB03696	InChI=1S/C30H50O/c1-20(2)10-9-11-21(3)22-14-18-30(8)24-12-13-25-27(4,5)26(31)16-17-28(25,6)23(24)15-19-29(22,30)7/h10,21-22,25-26,31H,9,11-19H2,1-8H3/t21-,22-,25+,26+,28-,29-,30+/m1/s1	CAHGCLMLTWQZNJ-BQNIITSRSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.5576 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							140.5 °C			1	No	1	1	No	4	0	20.23 Å2	55.06 Å3	134.54 m3·mol-1	4	No	Yes	0.000376 mg/mL	7.71	-6.1	19.55	-0.81	P48449	LSS	1. Lanosterol synthase
C34H55NO3	Not Available	Not Available	525.8054	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3C[C@@H](CCCCCCCCCCC(=O)N(C)CCCC)[C@@]21[H]	Solid	Not Available							CHEMBL1222035	94580				C14758		AOE			104772	46506133				ICI-164384	ZINC000003917379		ICI-164384	Experimental	DB03860	InChI=1S/C34H55NO3/c1-4-5-22-35(3)32(38)15-13-11-9-7-6-8-10-12-14-25-23-26-24-27(36)16-17-28(26)29-20-21-34(2)30(33(25)29)18-19-31(34)37/h16-17,24-25,29-31,33,36-37H,4-15,18-23H2,1-3H3/t25-,29-,30+,31+,33-,34+/m1/s1	BVVFOLSZMQVDKV-KXQIQQEYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.7601 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										0	No	3	2	Yes	4	0	60.77 Å2	66.78 Å3	157.62 m3·mol-1	14	No	No	0.000143 mg/mL	8.12	-6.6	10.32	-0.56	Q92731	ESR2	1. Estrogen receptor beta
C19H32O2	Not Available	Not Available	292.4562	[H][C@]1(O)CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])C[C@@]([H])(O)CC[C@]4(C)[C@@]3([H])CC[C@]12C	Solid	Not Available						18329	CHEMBL316048	211834			HMDB0000493	C12525		AOM			242332	46508740					ZINC000003814412		5-Alpha-Androstane-3-Beta,17beta-Diol	Experimental	DB03882	InChI=1S/C19H32O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12-17,20-21H,3-11H2,1-2H3/t12-,13-,14-,15-,16-,17-,18-,19-/m0/s1	CBMYJHIOYJEBSB-YSZCXEEOSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3334 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	2	2	No	4	0	40.46 Å2	35.56 Å3	84.63 m3·mol-1	0	Yes	No	0.0193 mg/mL	3.2	-4.2	18.3	-0.76	Q92731	ESR2	1. Estrogen receptor beta
C19H32O2	Not Available	Not Available	292.4562	[H][C@@]12CC[C@@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@@H](O)CC[C@]12C	Solid	Not Available						40836		394165						AON			446934	46505400					ZINC000006500050		5alpha-androstane-3beta,17alpha-diol	Experimental	DB03926	InChI=1S/C19H32O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12-17,20-21H,3-11H2,1-2H3/t12-,13-,14-,15-,16-,17+,18-,19-/m0/s1	CBMYJHIOYJEBSB-MFXFBURESA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3334 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	2	2	No	4	0	40.46 Å2	35.45 Å3	84.63 m3·mol-1	0	Yes	No	0.0193 mg/mL	3.2	-4.2	18.3	-0.76			
C28H44O	Not Available	Not Available	396.659	CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	Solid	Not Available					50378884	16933	CHEMBL1232562	392539				C01694		ERG			444679	46505947				Ergosterol	ZINC000004084618		Ergosterol	Approved, Experimental	DB04038	InChI=1S/C28H44O/c1-18(2)19(3)7-8-20(4)24-11-12-25-23-10-9-21-17-22(29)13-15-27(21,5)26(23)14-16-28(24,25)6/h7-10,18-20,22,24-26,29H,11-17H2,1-6H3/b8-7+/t19-,20+,22-,24+,25-,26-,27-,28+/m0/s1	DNVPQKQSNYMLRS-APGDWVJJSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.6528 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							170 °C			1	No	1	1	No	4	0	20.23 Å2	51.01 Å3	127.13 m3·mol-1	4	No	Yes	0.000156 mg/mL	6.63	-6.4	18.27	-1.4			
C23H34O4	Not Available	Not Available	374.5137	[H][C@]12CC[C@]3([H])[C@]([H])(CC[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@H](O)C2	Solid	Not Available					66977	42219	CHEMBL1453	3571902						DTX			4369270	46508220				Digitoxigenin	ZINC000003875959		Digitoxigenin	Experimental	DB04177	InChI=1S/C23H34O4/c1-21-8-5-16(24)12-15(21)3-4-19-18(21)6-9-22(2)17(7-10-23(19,22)26)14-11-20(25)27-13-14/h11,15-19,24,26H,3-10,12-13H2,1-2H3/t15-,16+,17-,18+,19-,21+,22-,23+/m1/s1	XZTUSOXSLKTKJQ-CESUGQOBSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.9314 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	3	2	No	5	-1	66.76 Å2	42.57 Å3	103.64 m3·mol-1	1	Yes	No	0.0244 mg/mL	3.07	-4.2	7.18	0.25			
C30H46O3	Not Available	Not Available	454.6844	[H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C)[C@H](C)\C=C\C=C\C(O)(CC)CC	Solid	Not Available							CHEMBL1908376	4450374						EB1			20055510	46507218					ZINC000003925433		Seocalcitol	Investigational	DB04258	InChI=1S/C30H46O3/c1-6-30(33,7-2)18-9-8-11-21(3)26-15-16-27-23(12-10-17-29(26,27)5)13-14-24-19-25(31)20-28(32)22(24)4/h8-9,11,13-14,18,21,25-28,31-33H,4,6-7,10,12,15-17,19-20H2,1-3,5H3/b11-8+,18-9+,23-13+,24-14-/t21-,25-,26-,27+,28+,29-/m1/s1	LVLLALCJVJNGQQ-SEODYNFXSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	4.2195 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	3	3	Yes	3	0	60.69 Å2	56.19 Å3	142.26 m3·mol-1	7	No	No	0.00382 mg/mL	5.27	-5.1	14.39	-1	P11473	VDR	1. Vitamin D3 receptor
C16H26O5	Not Available	Not Available	298.3746	[H][C@]1(CC=C(C)C)O[C@]1(C)[C@@]1(O)[C@]([H])(OC)C(=O)CC[C@@]1(C)O	Solid	Not Available								4451121						OVA			5289086	46507847					ZINC000012504299		Ovalicin	Experimental	DB04324	InChI=1S/C16H26O5/c1-10(2)6-7-12-15(4,21-12)16(19)13(20-5)11(17)8-9-14(16,3)18/h6,12-13,18-19H,7-9H2,1-5H3/t12-,13-,14-,15+,16-/m1/s1	UOXVFQCRPDLSFN-DGXTUMSLSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	2.6717 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	2	No	2	0	79.29 Å2	32.21 Å3	78.67 m3·mol-1	4	Yes	No	2.27 mg/mL	1.15	-2.1	11.59	-3.4	P53582;!P50579	METAP1;!METAP2	1. Methionine aminopeptidase 1;!2. Methionine aminopeptidase 2
C22H30O7	Not Available	Not Available	406.4694	[H][C@]12[C@]3([H])C=C(CO)C[C@]4(O)C(=O)C(C)=C[C@@]4([H])[C@@]3(O)[C@]([H])(C)[C@@]([H])(O)[C@@]1(OC(C)=O)C2(C)C	Solid	Not Available						45127	CHEMBL1235429	437370						PRB			499953	46507195					ZINC000013521034		13-Acetylphorbol	Experimental	DB04376	InChI=1S/C22H30O7/c1-10-6-15-20(27,17(10)25)8-13(9-23)7-14-16-19(4,5)22(16,29-12(3)24)18(26)11(2)21(14,15)28/h6-7,11,14-16,18,23,26-28H,8-9H2,1-5H3/t11-,14+,15-,16-,18-,20-,21-,22-/m1/s1	SDSVJYOOAPRSDA-RPCQODIISA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.7826 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	6	4	No	4	0	124.29 Å2	43.1 Å3	104.93 m3·mol-1	3	Yes	No	1.44 mg/mL	-0.34	-2.4	12.54	-2.7	Q05655	PRKCD	1. Protein kinase C delta type
C27H46O	Not Available	Not Available	386.6535	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC=C4C[C@@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCCC(C)C	Solid	Not Available					20192	16113	CHEMBL112570	5775			HMDB0000067	C00187	D00040	CLR			5997	46508234		2438		Cholesterol	ZINC000003875383		Cholesterol	Approved, Investigational	DB04540	InChI=1S/C27H46O/c1-18(2)7-6-8-19(3)23-11-12-24-22-10-9-20-17-21(28)13-15-26(20,4)25(22)14-16-27(23,24)5/h9,18-19,21-25,28H,6-8,10-17H2,1-5H3/t19-,21+,22+,23-,24+,25+,26+,27-/m1/s1	HVYWMOMLDIMFJA-DPAQBDIFSA-N	4		Not Available	Small Molecule	http://smpdb.ca/view/SMP0000099?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000111?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000209?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000316?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000372?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000388?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000389?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000510?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000577?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000718?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000082?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000089?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000092?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000107?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000117?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000119?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000314?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000319?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000371?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000508?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000575?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000717?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000720?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000023?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000035?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000079?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000095?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000112?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000130?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000131?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540	Lovastatin Action Pathway;!Cerivastatin Action Pathway;!Hypercholesterolemia;!Zellweger Syndrome;!Adrenal Hyperplasia Type 5 or Congenital Adrenal Hyperplasia Due to 17 alpha-Hydroxylase Deficiency;!Chondrodysplasia Punctata II, X-Linked Dominant (CDPX2);!Smith-Lemli-Opitz Syndrome (SLOS);!Mevalonic Aciduria;!Corticosterone Methyl Oxidase I Deficiency (CMO I);!3-beta-Hydroxysteroid Dehydrogenase Deficiency;!Simvastatin Action Pathway;!Pravastatin Action Pathway;!Rosuvastatin Action Pathway;!Zoledronate Action Pathway;!Pamidronate Action Pathway;!Fluvastatin Action Pathway;!Congenital Bile Acid Synthesis Defect Type II;!Lysosomal Acid Lipase Deficiency (Wolman Disease);!Congenital Lipoid Adrenal Hyperplasia (CLAH) or Lipoid CAH;!Cholesteryl Ester Storage Disease;!11-beta-Hydroxylase Deficiency (CYP11B1);!Apparent Mineralocorticoid Excess Syndrome;!27-Hydroxylase Deficiency;!Steroid Biosynthesis;!Bile Acid Biosynthesis;!Ibandronate Action Pathway;!Alendronate Action Pathway;!Risedronate Action Pathway;!Steroidogenesis;!Atorvastatin Action Pathway		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.8078 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				360 °C			148.5 °C		0.095 mg/L (at 30 °C)	1	No	1	1	No	4	0	20.23 Å2	50.64 Å3	120.62 m3·mol-1	5	No	Yes	2.79e-05 mg/mL	7.11	-7.1	18.2	-1.4	Q14994;!P11473;!Q9ULY5;!P35398	NR1I3;!VDR;!CLEC4E;!RORA	1. Nuclear receptor subfamily 1 group I member 3;!2. Vitamin D3 receptor;!3. C-type lectin domain family 4 member E;!4. Nuclear receptor ROR-alpha
C18H24O3	Not Available	Not Available	288.3814	[H][C@@]12C[C@@H](O)[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	Solid	Not Available					50410506	27974	CHEMBL193482	5553			HMDB0000153	C05141	D00185	ESL		PA164769104	5756	46505881		4094	DAP001019	Estriol	ZINC000003815418		Estriol	Approved, Investigational, Vet approved	DB04573	InChI=1S/C18H24O3/c1-18-7-6-13-12-5-3-11(19)8-10(12)2-4-14(13)15(18)9-16(20)17(18)21/h3,5,8,13-17,19-21H,2,4,6-7,9H2,1H3/t13-,14-,15+,16-,17+,18+/m1/s1	PROQIPRRNZUXQM-ZXXIGWHRSA-N	4	Estriol is a weak estrogen used to treat vaginal dryness and estrogen deficiency conditions, such as vaginitis and vulvar itching.	ORAL (LD50): Acute: >2000 mg/kg [Rat].	Small Molecule	http://smpdb.ca/view/SMP0030880?highlight[compounds][]=DB04573&highlight[proteins][]=DB04573	Estrone Metabolism		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.9758 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor					2.45		82-86			1	Yes	3	3	No	4	0	60.69 Å2	33.08 Å3	81.27 m3·mol-1	0	Yes	No	0.119 mg/mL	2.67	-3.4	10.33	-3.2			
C25H32O2	Not Available	Not Available	364.5204	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(OC1CCCC1)C=C3	Solid	Not Available						8716	CHEMBL1201165	8694			HMDB0015579	C07619	D00576			PA164749042	9046	46508939		9066	DAP001016	Quinestrol	ZINC000003875993		Quinestrol	Approved	DB04575	InChI=1S/C25H32O2/c1-3-25(26)15-13-23-22-10-8-17-16-19(27-18-6-4-5-7-18)9-11-20(17)21(22)12-14-24(23,25)2/h1,9,11,16,18,21-23,26H,4-8,10,12-15H2,2H3/t21-,22-,23+,24+,25+/m1/s1	PWZUUYSISTUNDW-VAFBSOEGSA-N			Symptoms of overdose include nausea and vomiting, and withdrawal bleeding may occur in females.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.9408 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor							107.5 °C			1	Yes	2	1	No	5	0	29.46 Å2	44.04 Å3	108.27 m3·mol-1	2	No	Yes	0.00157 mg/mL	5.4	-5.4	17.59	-1.7	P03372	ESR1	1. Estrogen receptor alpha
C21H28O5	Not Available	Not Available	360.444	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)CC[C@]4(C)[C@@]3([H])[C@@H](O)C[C@]12C=O)C(=O)CO	Solid	Not Available	P15538;!P19099;!P05093;!P08684	CYP11B1;!CYP11B2;!CYP17A1;!CYP3A4	1. Cytochrome P450 11B1, mitochondrial;!2. Cytochrome P450 11B2, mitochondrial;!3. Steroid 17-alpha-hydroxylase/17,20 lyase;!4. Cytochrome P450 3A4		19214	27584	CHEMBL273453	5633				C01780		AS4		PA164924487	5839	46505770		1312358	DAP001344	Aldosterone	ZINC000003833824		Aldosterone	Experimental, Investigational	DB04630	InChI=1S/C21H28O5/c1-20-7-6-13(24)8-12(20)2-3-14-15-4-5-16(18(26)10-22)21(15,11-23)9-17(25)19(14)20/h8,11,14-17,19,22,25H,2-7,9-10H2,1H3/t14-,15-,16+,17-,19+,20-,21+/m0/s1	PQSUYGKTWSAVDQ-ZVIOFETBSA-N	4		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.5456 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					1.08		166.5 °C		51.2 mg/L (at 37 °C)	1	Yes	5	2	No	4	0	91.67 Å2	38.82 Å3	96.79 m3·mol-1	3	Yes	No	0.148 mg/mL	1.06	-3.4	13.82	-2.9			
C21H30O4	Not Available	Not Available	346.4605	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)CC[C@]4(C)[C@@]3([H])[C@@]([H])(O)C[C@]12C)C(=O)CO	Solid	Not Available	P08684;!P28845;!P80365	CYP3A4;!HSD11B1;!HSD11B2	1. Cytochrome P450 3A4;!2. Corticosteroid 11-beta-dehydrogenase isozyme 1;!3. Corticosteroid 11-beta-dehydrogenase isozyme 2		50170653	16827	CHEMBL110739	5550			HMDB0001547	C02140		C0R			5753	46504547				Corticosterone	ZINC000013513592		Corticosterone	Experimental	DB04652	InChI=1S/C21H30O4/c1-20-8-7-13(23)9-12(20)3-4-14-15-5-6-16(18(25)11-22)21(15,2)10-17(24)19(14)20/h9,14-17,19,22,24H,3-8,10-11H2,1-2H3/t14-,15-,16+,17-,19+,20-,21-/m0/s1	OMFXVFTZEKFJBZ-HJTSIMOOSA-N			Not Available	Small Molecule	http://smpdb.ca/view/SMP0000371?highlight[compounds][]=DB04652&highlight[proteins][]=DB04652;!http://smpdb.ca/view/SMP0000575?highlight[compounds][]=DB04652&highlight[proteins][]=DB04652;!http://smpdb.ca/view/SMP0000717?highlight[compounds][]=DB04652&highlight[proteins][]=DB04652;!http://smpdb.ca/view/SMP0000372?highlight[compounds][]=DB04652&highlight[proteins][]=DB04652;!http://smpdb.ca/view/SMP0000577?highlight[compounds][]=DB04652&highlight[proteins][]=DB04652;!http://smpdb.ca/view/SMP0000718?highlight[compounds][]=DB04652&highlight[proteins][]=DB04652;!http://smpdb.ca/view/SMP0000130?highlight[compounds][]=DB04652&highlight[proteins][]=DB04652;!http://smpdb.ca/view/SMP0000373?highlight[compounds][]=DB04652&highlight[proteins][]=DB04652;!http://smpdb.ca/view/SMP0000566?highlight[compounds][]=DB04652&highlight[proteins][]=DB04652;!http://smpdb.ca/view/SMP0000576?highlight[compounds][]=DB04652&highlight[proteins][]=DB04652;!http://smpdb.ca/view/SMP0000578?highlight[compounds][]=DB04652&highlight[proteins][]=DB04652	Congenital Lipoid Adrenal Hyperplasia (CLAH) or Lipoid CAH;!11-beta-Hydroxylase Deficiency (CYP11B1);!Apparent Mineralocorticoid Excess Syndrome;!Adrenal Hyperplasia Type 5 or Congenital Adrenal Hyperplasia Due to 17 alpha-Hydroxylase Deficiency;!Corticosterone Methyl Oxidase I Deficiency (CMO I);!3-beta-Hydroxysteroid Dehydrogenase Deficiency;!Steroidogenesis;!Adrenal Hyperplasia Type 3 or Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency;!17-alpha-Hydroxylase Deficiency (CYP17);!21-Hydroxylase Deficiency (CYP21);!Corticosterone Methyl Oxidase II Deficiency (CMO II)		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.5110 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	2	No	4	0	74.6 Å2	38.83 Å3	96 m3·mol-1	2	Yes	No	0.046 mg/mL	2.02	-3.9	13.86	-0.26	P28845;!Q15788;!P08235	HSD11B1;!NCOA1;!NR3C2	1. Corticosteroid 11-beta-dehydrogenase isozyme 1;!2. Nuclear receptor coactivator 1;!3. Mineralocorticoid receptor
C27H46O2	Not Available	Not Available	402.6529	CC(C)CCC[C@@](C)(O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	Solid	Not Available					50035884		CHEMBL1233249	389586			HMDB0006283			HC2			440711	46508206					ZINC000004096811		20-hydroxycholesterol	Experimental	DB04704	InChI=1S/C27H46O2/c1-18(2)7-6-14-27(5,29)24-11-10-22-21-9-8-19-17-20(28)12-15-25(19,3)23(21)13-16-26(22,24)4/h8,18,20-24,28-29H,6-7,9-17H2,1-5H3/t20-,21-,22-,23-,24-,25-,26-,27+/m0/s1	MCKLJFJEQRYRQT-MGNSQDQZSA-N			Not Available	Small Molecule	http://smpdb.ca/view/SMP0000371?highlight[compounds][]=DB04704&highlight[proteins][]=DB04704;!http://smpdb.ca/view/SMP0000575?highlight[compounds][]=DB04704&highlight[proteins][]=DB04704;!http://smpdb.ca/view/SMP0000717?highlight[compounds][]=DB04704&highlight[proteins][]=DB04704;!http://smpdb.ca/view/SMP0000372?highlight[compounds][]=DB04704&highlight[proteins][]=DB04704;!http://smpdb.ca/view/SMP0000577?highlight[compounds][]=DB04704&highlight[proteins][]=DB04704;!http://smpdb.ca/view/SMP0000718?highlight[compounds][]=DB04704&highlight[proteins][]=DB04704;!http://smpdb.ca/view/SMP0000130?highlight[compounds][]=DB04704&highlight[proteins][]=DB04704;!http://smpdb.ca/view/SMP0000373?highlight[compounds][]=DB04704&highlight[proteins][]=DB04704;!http://smpdb.ca/view/SMP0000566?highlight[compounds][]=DB04704&highlight[proteins][]=DB04704;!http://smpdb.ca/view/SMP0000576?highlight[compounds][]=DB04704&highlight[proteins][]=DB04704;!http://smpdb.ca/view/SMP0000578?highlight[compounds][]=DB04704&highlight[proteins][]=DB04704	Congenital Lipoid Adrenal Hyperplasia (CLAH) or Lipoid CAH;!11-beta-Hydroxylase Deficiency (CYP11B1);!Apparent Mineralocorticoid Excess Syndrome;!Adrenal Hyperplasia Type 5 or Congenital Adrenal Hyperplasia Due to 17 alpha-Hydroxylase Deficiency;!Corticosterone Methyl Oxidase I Deficiency (CMO I);!3-beta-Hydroxysteroid Dehydrogenase Deficiency;!Steroidogenesis;!Adrenal Hyperplasia Type 3 or Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency;!17-alpha-Hydroxylase Deficiency (CYP17);!21-Hydroxylase Deficiency (CYP21);!Corticosterone Methyl Oxidase II Deficiency (CMO II)		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	3.0155 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	2	2	No	4	0	40.46 Å2	50.57 Å3	122.3 m3·mol-1	5	No	No	0.000571 mg/mL	5.8	-5.8	18.2	-0.26			
C27H46O2	Not Available	Not Available	402.6529	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC=C4C[C@@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCCC(C)(C)O	Solid	Not Available					20182	42977	CHEMBL169046	58604				C15519		HC3			65094	46506794					ZINC000005751264		25-Hydroxycholesterol	Experimental	DB04705	InChI=1S/C27H46O2/c1-18(7-6-14-25(2,3)29)22-10-11-23-21-9-8-19-17-20(28)12-15-26(19,4)24(21)13-16-27(22,23)5/h8,18,20-24,28-29H,6-7,9-17H2,1-5H3/t18-,20+,21+,22-,23+,24+,26+,27-/m1/s1	INBGSXNNRGWLJU-ZHHJOTBYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	3.0155 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	2	2	No	4	0	40.46 Å2	51.11 Å3	122.45 m3·mol-1	5	No	No	0.000244 mg/mL	5.64	-6.2	18.2	-1			
C27H46O2	Not Available	Not Available	402.6529	[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@@H](O)C=C4C[C@@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCCC(C)C	Solid	Not Available					50045545	42989	CHEMBL497834	415508			HMDB0006119			HCR			473141	46505045					ZINC000005758832		7beta-hydroxycholesterol	Experimental	DB04706	InChI=1S/C27H46O2/c1-17(2)7-6-8-18(3)21-9-10-22-25-23(12-14-27(21,22)5)26(4)13-11-20(28)15-19(26)16-24(25)29/h16-18,20-25,28-29H,6-15H2,1-5H3/t18-,20+,21-,22+,23+,24+,25+,26+,27-/m1/s1	OYXZMSRRJOYLLO-KGZHIOMZSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	3.0155 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	2	2	No	4	0	40.46 Å2	51.12 Å3	122.06 m3·mol-1	5	No	No	0.000476 mg/mL	5.96	-5.9	18.2	-0.83			
C26H40O3	Not Available	Not Available	400.603	[H][C@@]1(CC[C@]2([H])\C(CCC[C@]12C)=C\C=C1C[C@@H](O)C[C@H](O)C1)[C@H](C)CC#CC(C)(C)O	Solid	Not Available							CHEMBL2105107	5291648						TX5			6915835	46504586					ZINC000012504514		Inecalcitol	Investigational	DB04796	InChI=1S/C26H40O3/c1-18(7-5-13-25(2,3)29)23-11-12-24-20(8-6-14-26(23,24)4)10-9-19-15-21(27)17-22(28)16-19/h9-10,18,21-24,27-29H,6-8,11-12,14-17H2,1-4H3/b20-10+/t18-,21-,22-,23-,24-,26-/m1/s1	HHGRMHMXKPQNGF-WNSNRMDMSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	4.7066 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	3	No	3	0	60.69 Å2	48.7 Å3	121.57 m3·mol-1	5	Yes	No	0.00221 mg/mL	4	-5.3	14.67	-2.7	P11473	VDR	1. Vitamin D3 receptor
C24H29ClO4	Not Available	Elimination Following oral or intramuscular administration, the plasma half-life is 38 and 96 hours, respectively.	416.938	[H][C@@]12C[C@]1([H])[C@@]1(C)C(=CC2=O)C(Cl)=C[C@@]2([H])[C@]3([H])CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CC[C@]12[H]	Solid	Not Available	P08684;!P11511	CYP3A4;!CYP19A1	1. Cytochrome P450 3A4;!2. Cytochrome P450 19A1		50094569	50743	CHEMBL139835	9496					D01368	CA4		PA10049	9880	46506931		22054	DAP000906	Cyproterone_acetate	ZINC000003814423	Androcur, Cléo -35, Cyestra-35, Diane	Cyproterone acetate	Approved, Investigational	DB04839	InChI=1S/C24H29ClO4/c1-12(26)24(29-13(2)27)8-6-16-14-10-20(25)19-11-21(28)15-9-18(15)23(19,4)17(14)5-7-22(16,24)3/h10-11,14-18H,5-9H2,1-4H3/t14-,15+,16-,17-,18-,22-,23-,24-/m0/s1	UWFYSQMTEOIJJG-FDTZYFLXSA-N	4	Cyproterone acetate is a steroid used in combination with ethinyl estradiol to treat women with severe acne and symptoms of androgenization. Also used alone at much higher doses for palliative treatment of patients with prostate cancer	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.8261 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							200-201			1	Yes	3	0	No	5	0	60.44 Å2	44.64 Å3	111.81 m3·mol-1	3	Yes	No	0.00152 mg/mL	3.64	-5.4	17.83	-5.6	P10275;!P07288	AR;!KLK3	1. Androgen receptor;!2. Prostate-specific antigen
C27H42N2O5S	Not Available	52 hours	506.7	[H][C@]12C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC[C@@]1(C)O2)C(\C)=C\C1=CSC(C)=N1	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			63605	CHEMBL1201752	20145579					D04645	GZX		PA165958343	6445540	99443224		337523		Ixabepilone	ZINC000003993846	Ixempra	Ixabepilone	Approved, Investigational	DB04845	InChI=1S/C27H42N2O5S/c1-15-9-8-10-27(7)22(34-27)12-20(16(2)11-19-14-35-18(4)28-19)29-23(31)13-21(30)26(5,6)25(33)17(3)24(15)32/h11,14-15,17,20-22,24,30,32H,8-10,12-13H2,1-7H3,(H,29,31)/b16-11+/t15-,17+,20-,21-,22-,24-,27+/m0/s1	FABUFPQFXZVHFB-PVYNADRNSA-N	3	Ixabepilone is a microtubule inhibitor administered in combination with capecitabine or alone in the treatment of metastatic or locally advanced breast cancer that has shown inadequate response to taxanes and anthracyclines.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.6638 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	3	No	3	0	112.05 Å2	56.86 Å3	136.71 m3·mol-1	2	No	No	0.00352 mg/mL	3.39	-5.2	13.85	2.73	Q13509	TUBB3	1. Tubulin beta-3 chain
C23H36O2	Not Available	Not Available	344.5307	CC[C@@](C)([H])[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1/C[C@](O)([H])C(=C)[C@]([H])(O)C1	Solid	Not Available							CHEMBL2104955	4451487						VD1			5289547	175426893					ZINC000013975113		Becocalcidiol	Investigational	DB04891	InChI=1S/C23H36O2/c1-5-15(2)19-10-11-20-18(7-6-12-23(19,20)4)9-8-17-13-21(24)16(3)22(25)14-17/h8-9,15,19-22,24-25H,3,5-7,10-14H2,1-2,4H3/b18-9+/t15-,19+,20-,21+,22+,23+/m0/s1	QSLUXQQUPXBIHH-YHSKWIAJSA-N	2		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	3.9749 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	2	No	3	0	40.46 Å2	42.79 Å3	106.23 m3·mol-1	3	Yes	No	0.0097 mg/mL	4.43	-4.6	14.19	-3	Q15648;!P11473	MED1;!VDR	1. Mediator of RNA polymerase II transcription subunit 1;!2. Vitamin D3 receptor
C25H34O6	There is no clearance quantity since ingenol mebutate is a topical treatment.	There is no half-life quantity since ingenol mebutate is a topical treatment.	430.541	[H][C@@]12C[C@@H](C)[C@]34C=C(C)[C@H](OC(=O)C(\C)=C/C)[C@@]3(O)[C@H](O)C(CO)=C[C@@]([H])(C4=O)[C@]1([H])C2(C)C	Solid	There is no volume of distribution quantity since ingenol mebutate is a topical treatment.						66913	CHEMBL1863513	28533061	Drugs.com Drug Page				D09393				6918670	175426930	RxList Drug Page	1242806		Ingenol_mebutate	ZINC000056898854	Picato	Ingenol mebutate	Approved	DB05013	InChI=1S/C25H34O6/c1-7-12(2)22(29)31-21-13(3)10-24-14(4)8-17-18(23(17,5)6)16(20(24)28)9-15(11-26)19(27)25(21,24)30/h7,9-10,14,16-19,21,26-27,30H,8,11H2,1-6H3/b12-7-/t14-,16-,17-,18+,19-,21+,24+,25+/m1/s1	VDJHFHXMUKFKET-UXMMOKKRSA-N	4	Ingenol mebutate is a topical agent used for the treatment of actinic keratosis.	The most common adverse reactions are local skin reactions at the application site, headache, periorbital edema,and nasopharyngitis.	Small Molecule				AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.7836 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	3	No	4	0	104.06 Å2	47.14 Å3	117.86 m3·mol-1	4	Yes	No	0.279 mg/mL	2.51	-3.2	12.13	-2.8	Q05655;!P17252	PRKCD;!PRKCA	1. Protein kinase C delta type;!2. Protein kinase C alpha type
C21H30O3	Not Available	Not Available	330.468	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@H](O)C=C2C[C@@H](O)CC[C@]12C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4					20571043									16739648	347827717							HE3286	Investigational	DB05212	InChI=1S/C21H30O3/c1-4-21(24)10-7-16-18-15(6-9-20(16,21)3)19(2)8-5-14(22)11-13(19)12-17(18)23/h1,12,14-18,22-24H,5-11H2,2-3H3/t14-,15-,16-,17-,18+,19-,20-,21-/m0/s1	JJKOQZHWYLMASZ-FJWDNACWSA-N	2		Not Available	Small Molecule																																			1	Yes	3	3	No	4	0	60.69 Å2	38.17 Å3	94.39 m3·mol-1	0	Yes	No	0.017 mg/mL	1.8	-4.3	17.59	-0.77	P19838;!Q00653	NFKB1;!NFKB2	1. Nuclear factor NF-kappa-B p105 subunit;!2. Nuclear factor NF-kappa-B p100 subunit
C31H39NO5	Not Available	Not Available	505.655	[H][C@@]12CC[C@](OC(C)=O)(C(=O)COC)[C@@]1(C)C[C@H](C1=CC=C(C=C1)N(C)C)C1=C3CCC(=O)C=C3CC[C@@]21[H]	Solid	Not Available							CHEMBL2105694	7981950										347910049				Proellex			Telapristone acetate	Investigational	DB05253	InChI=1S/C31H39NO5/c1-19(33)37-31(28(35)18-36-5)15-14-27-25-12-8-21-16-23(34)11-13-24(21)29(25)26(17-30(27,31)2)20-6-9-22(10-7-20)32(3)4/h6-7,9-10,16,25-27H,8,11-15,17-18H2,1-5H3/t25-,26+,27-,30-,31-/m0/s1	JVBGZFRPTRKSBB-MJBQOYBXSA-N	2		Not Available	Small Molecule																																			1	No	5	0	Yes	5	0	72.91 Å2	56.9 Å3	144.89 m3·mol-1	7	No	No	0.00556 mg/mL	4.45	-5	18.42	4.89	P06401	PGR	1. Progesterone receptor
C33H52O4	Not Available	Not Available	512.775	[H][C@]12C[C@@]3([H])[C@]4([H])CC=C5C[C@H](CC[C@]5(C)[C@@]4([H])CC[C@]3(C)[C@@]1([H])[C@H](C)[C@@]1(CC[C@@H](C)CO1)O2)OC(=O)CCCCC	Solid	Not Available								17460070									16394575	347827721					ZINC000097971833		Caprospinol	Investigational	DB05263	InChI=1S/C33H52O4/c1-6-7-8-9-29(34)36-24-13-15-31(4)23(18-24)10-11-25-26(31)14-16-32(5)27(25)19-28-30(32)22(3)33(37-28)17-12-21(2)20-35-33/h10,21-22,24-28,30H,6-9,11-20H2,1-5H3/t21-,22+,24+,25-,26+,27+,28+,30+,31+,32+,33-/m1/s1	VMOZFSWFUBLCNN-AAPULDEBSA-N			Not Available	Small Molecule																																			0	No	3	0	Yes	6	0	44.76 Å2	64.08 Å3	147.85 m3·mol-1	6	No	No	1.55e-05 mg/mL	7.4	-7.5		-4			
C23H30O5	Not Available	Not Available	386.4813	[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)CC=C1[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	Not Available						31215	CHEMBL2106613	99892					D01733				111332	175426966				Anecortave	ZINC000003931050		Anecortave acetate	Investigational	DB05288	InChI=1S/C23H30O5/c1-14(24)28-13-20(26)23(27)11-8-19-17-5-4-15-12-16(25)6-9-21(15,2)18(17)7-10-22(19,23)3/h7,12,17,19,27H,4-6,8-11,13H2,1-3H3/t17-,19+,21+,22+,23+/m1/s1	YUWPMEXLKGOSBF-GACAOOTBSA-N	3		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.1280 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	1	No	4	0	80.67 Å2	42.64 Å3	105.81 m3·mol-1	4	Yes	No	0.0113 mg/mL	2.62	-4.5	12.61	-3.8			
C30H50O5	Not Available	Not Available	490.725	[H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)[C@@H](OCCCO)[C@H](O)C1=C)[C@H](C)CCCC(C)(C)O	Solid	Not Available						73927		5293354						ED9			6918141	175426970				Eldecalcitol	ZINC000003934328		Eldecalcitol	Investigational	DB05295	InChI=1S/C30H50O5/c1-20(9-6-15-29(3,4)34)24-13-14-25-22(10-7-16-30(24,25)5)11-12-23-19-26(32)28(27(33)21(23)2)35-18-8-17-31/h11-12,20,24-28,31-34H,2,6-10,13-19H2,1,3-5H3/b22-11+,23-12-/t20-,24-,25+,26-,27-,28-,30-/m1/s1	FZEXGDDBXLBRTD-AYIMTCTASA-N	3		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	3.3673 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	5	4	Yes	3	0	90.15 Å2	59.7 Å3	143.54 m3·mol-1	10	Yes	No	0.0105 mg/mL	3.67	-4.7	13.38	-1.3	P11473	VDR	1. Vitamin D3 receptor
C28H31NaO9S	Not Available	Not Available	566.595	[Na+].CC12CC(O)C3C(CCC4=CC(=O)C=CC34C)C1CCC2(O)C(=O)COC(=O)C1=CC(=CC=C1)S([O-])(=O)=O	Solid	Not Available								11914									23691973	175426980							ATL-2502	Investigational	DB05340	InChI=1S/C28H32O9S.Na/c1-26-10-8-18(29)13-17(26)6-7-20-21-9-11-28(33,27(21,2)14-22(30)24(20)26)23(31)15-37-25(32)16-4-3-5-19(12-16)38(34,35)36;/h3-5,8,10,12-13,20-22,24,30,33H,6-7,9,11,14-15H2,1-2H3,(H,34,35,36);/q;+1/p-1	RWFZSORKWFPGNE-UHFFFAOYSA-M	3		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.4859 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	8	2	Yes	5	-1	158.1 Å2	55.75 Å3	137.82 m3·mol-1	6	No	No	0.0249 mg/mL	0.81	-4.4	-2.5	-2.9			
C29H35NO9	Not Available	Not Available	541.597	CC12CC(O)C3C(CCC4=CC(=O)CCC34C)C1CCC2(O)C(=O)COC(=O)C1=CC=CC(CON(=O)=O)=C1	Solid	Not Available																		347910124							NCX 1022	Investigational	DB05410	InChI=1S/C29H35NO9/c1-27-10-8-20(31)13-19(27)6-7-21-22-9-11-29(35,28(22,2)14-23(32)25(21)27)24(33)16-38-26(34)18-5-3-4-17(12-18)15-39-30(36)37/h3-5,12-13,21-23,25,32,35H,6-11,14-16H2,1-2H3	MBODWAULVMWNDB-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	No	8	2	Yes	5	0	155.95 Å2	56.82 Å3	140.73 m3·mol-1	8	No	No	0.00244 mg/mL	3.93	-5.4	12.61	-2.8			
C28H30O4	Not Available	Not Available	430.544	[H][C@@]12CC[C@@](O)(C#CC)[C@@]1(C)C[C@H](C1=CC=C3OCOC3=C1)C1=C3CCC(=O)C=C3CC[C@@]21[H]	Solid	Not Available								8043052									9867361	347827730					ZINC000003951570		ORG-34517	Investigational	DB05423	InChI=1S/C28H30O4/c1-3-11-28(30)12-10-23-21-7-4-17-13-19(29)6-8-20(17)26(21)22(15-27(23,28)2)18-5-9-24-25(14-18)32-16-31-24/h5,9,13-14,21-23,30H,4,6-8,10,12,15-16H2,1-2H3/t21-,22+,23-,27-,28-/m0/s1	DFELGYQKEOCHOA-BZAFBGKRSA-N	2		Not Available	Small Molecule																																			1	Yes	4	1	No	6	0	55.76 Å2	48.36 Å3	123.92 m3·mol-1	2	Yes	No	0.00337 mg/mL	4.65	-5.1	12.87	-3.7	P04150	NR3C1	1. Glucocorticoid receptor
C24H30Cl2O6	Not Available	Not Available	485.4	[H][C@@]12CC[C@](OC(=O)C(Cl)Cl)(C(=O)OCC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	Not Available						135783	CHEMBL2107614	8110701									9935073	175427004					ZINC000003979944		Etiprednol dicloacetate	Investigational	DB05442	InChI=1S/C24H30Cl2O6/c1-4-31-21(30)24(32-20(29)19(25)26)10-8-16-15-6-5-13-11-14(27)7-9-22(13,2)18(15)17(28)12-23(16,24)3/h7,9,11,15-19,28H,4-6,8,10,12H2,1-3H3/t15-,16-,17-,18+,22-,23-,24-/m0/s1	QAIOVDNCIZSSSF-RFAJLIJZSA-N	2		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.9813 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	1	Yes	4	0	89.9 Å2	49.4 Å3	121.88 m3·mol-1	6	Yes	No	0.00235 mg/mL	3.99	-5.3	14.88	-2.9	P01584	IL1B	1. Interleukin-1 beta
C27H44O3	Not Available	Not Available	416.6365	[H][C@]12C[C@@]3([H])[C@]4([H])CC[C@]5([H])C[C@@H](O)CC[C@]5(C)[C@@]4([H])CC[C@]3(C)[C@@]1([H])[C@H](C)[C@@]1(CC[C@@H](C)CO1)O2	Solid	Not Available						28933		82568			HMDB0030048	C08913						347910146					ZINC000008234226		Smilagenin	Investigational	DB05450	InChI=1S/C27H44O3/c1-16-7-12-27(29-15-16)17(2)24-23(30-27)14-22-20-6-5-18-13-19(28)8-10-25(18,3)21(20)9-11-26(22,24)4/h16-24,28H,5-15H2,1-4H3/t16-,17+,18-,19+,20-,21+,22+,23+,24+,25+,26+,27-/m1/s1	GMBQZIIUCVWOCD-UQHLGXRBSA-N	2		Trials showed that the drug has a good clinical safety profile and is well-tolerated.	Small Molecule																																			1	No	3	1	No	6	0	38.69 Å2	51.43 Å3	119.42 m3·mol-1	0	No	Yes	3.28e-05 mg/mL	5.33	-7.1	18.3	-1.4			
C20H30O5	Not Available	Not Available	350.455	[H][C@]12CCC(=C)[C@@H](C\C=C3/[C@H](O)COC3=O)[C@]1(C)CC[C@@H](O)[C@@]2(C)CO	Solid	Not Available					50084419	65408	CHEMBL186141	4477067									5318517	347827741				Andrographolide	ZINC000003881797		Andrographolide	Investigational	DB05767	InChI=1S/C20H30O5/c1-12-4-7-16-19(2,9-8-17(23)20(16,3)11-21)14(12)6-5-13-15(22)10-25-18(13)24/h5,14-17,21-23H,1,4,6-11H2,2-3H3/b13-5+/t14-,15-,16+,17-,19+,20+/m1/s1	BOJKULTULYSRAS-OTESTREVSA-N	2		Not Available	Small Molecule																																			1	Yes	4	3	No	3	0	86.99 Å2	38.27 Å3	94.93 m3·mol-1	3	Yes	No	0.284 mg/mL	1.66	-3.1	13.48	-2.8	P01375;!P01584;!P05231;!Q00653;!P19838	TNF;!IL1B;!IL6;!NFKB2;!NFKB1	1. Tumor necrosis factor;!2. Interleukin-1 beta;!3. Interleukin-6;!4. Nuclear factor NF-kappa-B p100 subunit;!5. Nuclear factor NF-kappa-B p105 subunit
C24H31NO	Not Available	Terminal elimination half-life = 5-14 hours	349.509	[H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C	Solid	Vdss= 19,669 ± 13,358 L					25458	68642	CHEMBL254328	117349	Drugs.com Drug Page				D09701	AER		PA166123407	132971	175427038	RxList Drug Page	1100072		Abiraterone_acetate	ZINC000003797541	Yonsa, Zytiga	Abiraterone	Approved	DB05812	InChI=1S/C24H31NO/c1-23-11-9-18(26)14-17(23)5-6-19-21-8-7-20(16-4-3-13-25-15-16)24(21,2)12-10-22(19)23/h3-5,7,13,15,18-19,21-22,26H,6,8-12,14H2,1-2H3/t18-,19-,21-,22-,23-,24+/m0/s1	GZOSMCIZMLWJML-VJLLXTKPSA-N	4	Abiraterone is an antiandrogen used in the treatment of prostate cancer.	Toxicity is related to the blockade of 17α-hydroxylase activity. Blockade results in the accumulation of upstream mineralocorticoids like 11-deoxycorticosterone leading to secondary hyperaldosteronism. Signs of hydroaldosteronism include fluid retention and hypokalemia. Mineralocorticoid receptor antagonists may be used to treat signs and symptoms.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.4407 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	1	No	5	0	33.12 Å2	42.03 Å3	107.3 m3·mol-1	1	Yes	Yes	0.00305 mg/mL	3.97	-5.1	18.2	4.81			
C19H28O2	Not Available	Not Available	288.431	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3C[C@@H](C)[C@@]21[H]	Solid	Not Available								8014619									19582	175427041				Trestolone	ZINC000004217690		Trestolone	Investigational	DB05830	InChI=1S/C19H28O2/c1-11-9-12-10-13(20)3-4-14(12)15-7-8-19(2)16(18(11)15)5-6-17(19)21/h10-11,14-18,21H,3-9H2,1-2H3/t11-,14+,15-,16+,17+,18-,19+/m1/s1	YSGQGNQWBLYHPE-CFUSNLFHSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.6259 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	1	No	4	0	37.3 Å2	33.92 Å3	84.5 m3·mol-1	0	Yes	Yes	0.0391 mg/mL	3.35	-3.9	18.34	-0.88			
C22H36N2O6	Not Available	Not Available	424.531	[H][C@@]1([C@H](OC)[C@@H](CC[C@]11CO1)OC(=O)N[C@H](C(C)C)C(N)=O)[C@@]1(C)O[C@@H]1CC=C(C)C	Solid	Not Available					50088527		CHEMBL3527358	5293846									6918653	175427046							PPI-2458	Investigational	DB05864	InChI=1S/C22H36N2O6/c1-12(2)7-8-15-21(5,30-15)18-17(27-6)14(9-10-22(18)11-28-22)29-20(26)24-16(13(3)4)19(23)25/h7,13-18H,8-11H2,1-6H3,(H2,23,25)(H,24,26)/t14-,15-,16-,17-,18-,21+,22+/m1/s1	QBDVVYNLLXGUGN-XGTBZJOHSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.7785 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	2	Yes	3	0	115.71 Å2	46.27 Å3	110.43 m3·mol-1	9	Yes	No	0.0439 mg/mL	2.07	-4	13.45	-3.6	P50579	METAP2	1. Methionine aminopeptidase 2
C27H39NO5S	Not Available	Not Available	489.67	C[C@H]1\C=C\C\C(C)=C/C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\C1=CSC(C)=N1	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4					5294026									6918835	347827748					ZINC000100657972		KOS-1584	Investigational	DB05903	InChI=1S/C27H39NO5S/c1-16-9-8-10-17(2)25(31)19(4)26(32)27(6,7)23(29)14-24(30)33-22(12-11-16)18(3)13-21-15-34-20(5)28-21/h8,10-11,13,15,17,19,22-23,25,29,31H,9,12,14H2,1-7H3/b10-8+,16-11-,18-13+/t17-,19+,22-,23-,25-/m0/s1	XAYAKDZVINDZGB-BMVMHAJPSA-N	2		Not Available	Small Molecule																																			1	No	5	2	No	2	0	96.72 Å2	54.41 Å3	137.16 m3·mol-1	2	Yes	No	0.00256 mg/mL	4.73	-5.3	14.07	2.73			
C32H43NO4	Not Available	Not Available	505.699	COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2	Solid	Not Available					217379		CHEMBL1762621	355161														Bardoxolone_methyl	ZINC000003982151		Bardoxolone methyl	Investigational	DB05983	InChI=1S/C32H43NO4/c1-27(2)11-13-32(26(36)37-8)14-12-31(7)24(20(32)17-27)21(34)15-23-29(5)16-19(18-33)25(35)28(3,4)22(29)9-10-30(23,31)6/h15-16,20,22,24H,9-14,17H2,1-8H3/t20-,22-,24-,29-,30+,31+,32-/m0/s1	WPTTVJLTNAWYAO-KPOXMGGZSA-N	2		Not Available	Small Molecule																																			0	No	4	0	No	5	0	84.23 Å2	58.23 Å3	144.36 m3·mol-1	2	No	No	0.00294 mg/mL	6.55	-5.2		-5.3	P25963	NFKBIA	1. NF-kappa-B inhibitor alpha
C26H44O4	Clearance information for obeticholic acid is not readily available in the literature.9,11	The biological half-life of obeticholic acid is reported to be 24 hours.13	420.6252	[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)[C@H](CC)[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O	Solid	The volume of distribution of obeticholic acid is 618 L.9,11	P05177	CYP1A2	1. Cytochrome P450 1A2		21675	43602	CHEMBL566315	394730				C15636	D09360	CHC			447715	347827752		1798288		Obeticholic_acid	ZINC000014164617	Ocaliva	Obeticholic acid	Approved	DB05990	InChI=1S/C26H44O4/c1-5-17-21-14-16(27)10-12-26(21,4)20-11-13-25(3)18(15(2)6-9-22(28)29)7-8-19(25)23(20)24(17)30/h15-21,23-24,27,30H,5-14H2,1-4H3,(H,28,29)/t15-,16-,17-,18-,19+,20+,21+,23+,24-,25-,26-/m1/s1	ZXERDUOLZKYMJM-ZWECCWDJSA-N	3	Obeticholic acid is a bile acid analog and farnesoid X receptor agonist used to treat primary biliary cholangitis in adult patients with inadequate clinical response or intolerance to UDCA.	LD50 information for obeticholic acid is not readily available in the literature.9The maximum documented exposure to obeticholic acid was 500 mg in healthy research volunteers. Doses of 250 mg have been administered to healthy volunteers for 12 consecutive days. Pruritus and reversible transaminase liver elevations were observed. In PBC patients who received 25mg daily to 50mg daily (2.5 to 5 times the maximum recommended dose), dose-dependent transaminase and bilirubin elevations, ascites, primary biliary cholangitis aggravation, and new-onset jaundice were reported.11In the case of an overdose with obeticholic acid, clinical monitoring and supportive care should be offered as they are required.11	Small Molecule																													562.9±25	5.11		108-110	4.76±0.10		1	No	4	3	No	4	-1	77.76 Å2	49.74 Å3	118.35 m3·mol-1	5	Yes	No	0.011 mg/mL	4.52	-4.6	4.6	-0.16	Q96RI1	NR1H4	1. Bile acid receptor
C28H44O3	Not Available	Not Available	428.657	CC(C)[C@](C)(O)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	Solid	Not Available								7826201												1536458			ZINC000004791507		1alpha,24S-Dihydroxyvitamin D2	Investigational	DB06117	InChI=1S/C28H44O3/c1-18(2)28(6,31)15-13-19(3)24-11-12-25-21(8-7-14-27(24,25)5)9-10-22-16-23(29)17-26(30)20(22)4/h9-10,13,15,18-19,23-26,29-31H,4,7-8,11-12,14,16-17H2,1-3,5-6H3/b15-13+,21-9+,22-10-/t19-,23-,24-,25+,26+,27-,28-/m1/s1	ODZFJAXAEXQSKL-WRJREGAQSA-N			Not Available	Small Molecule																																			1	No	3	3	No	3	0	60.69 Å2	52.29 Å3	131.89 m3·mol-1	5	Yes	No	0.00726 mg/mL	4.59	-4.8	14.39	-1.1			
C29H43FO2	Not Available	Not Available	442.6489	CCC(O)(CC)\C=C\C[C@H](C)C1=CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@@](F)([H])C1=C	Solid	Not Available								9571500									11396600						ZINC000004802676		Elocalcitol	Investigational	DB06194	InChI=1S/C29H43FO2/c1-6-29(32,7-2)17-8-10-20(3)25-14-15-26-22(11-9-16-28(25,26)5)12-13-23-18-24(31)19-27(30)21(23)4/h8,12-14,17,20,24,26-27,31-32H,4,6-7,9-11,15-16,18-19H2,1-3,5H3/b17-8+,22-12+,23-13-/t20-,24+,26-,27-,28+/m0/s1	LRLWXBHFPGSUOX-GJQYOBCGSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	3.4000 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	No	2	2	Yes	3	0	40.46 Å2	52.81 Å3	135.7 m3·mol-1	7	No	No	0.00185 mg/mL	5.68	-5.4	15.08	-1.1	P11473	VDR	1. Vitamin D3 receptor
C19H30O3	Not Available	Not Available	306.446	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@H](O)C=C2C[C@@H](O)CC[C@]12C	Solid	Not Available								7993774															ZINC000033967857		HE-2200	Investigational	DB06257	InChI=1S/C19H30O3/c1-18-7-5-12(20)9-11(18)10-15(21)17-13-3-4-16(22)19(13,2)8-6-14(17)18/h10,12-17,20-22H,3-9H2,1-2H3/t12-,13-,14-,15-,16-,17-,18-,19-/m0/s1	OEVZKEVBDIDVOI-YSZCXEEOSA-N			Not Available	Small Molecule																																			1	Yes	3	3	No	4	0	60.69 Å2	35.67 Å3	86.92 m3·mol-1	0	Yes	No	0.223 mg/mL	1.65	-3.1	18.2	-0.55			
C26H42O4	Not Available	Not Available	418.6093	[H]\C(\C(\[H])=C1/CCC[C@@]2(C)[C@@]1([H])CC[C@]2([H])[C@]([H])(C)OCCC(C)(C)O)=C1/C[C@@]([H])(O)C[C@]([H])(O)C1=C	Solid	Not Available					50124417	31801	CHEMBL333950	4911262						MCZ									ZINC000004474617		Maxacalcitol	Investigational	DB06272	InChI=1S/C26H42O4/c1-17-20(15-21(27)16-24(17)28)9-8-19-7-6-12-26(5)22(10-11-23(19)26)18(2)30-14-13-25(3,4)29/h8-9,18,21-24,27-29H,1,6-7,10-16H2,2-5H3/b19-8+,20-9-/t18-,21+,22+,23-,24-,26+/m0/s1	DTXXSJZBSTYZKE-ZDQKKZTESA-N	3		Not Available	Small Molecule																																			1	No	4	3	Yes	3	0	69.92 Å2	50.09 Å3	123.83 m3·mol-1	6	Yes	No	0.015 mg/mL	2.79	-4.4	14.34	-2.7			
C21H32O2	Not Available	Not Available	316.485	C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@H](O)CC[C@]34C)[C@@H]1CC[C@@]2(O)C#C	Solid	Not Available								32698509														Ethynylandrostanediol	ZINC000005921098		Apoptone	Investigational	DB06307	InChI=1S/C21H32O2/c1-4-21(23)12-9-18-16-6-5-14-13-15(22)7-10-19(14,2)17(16)8-11-20(18,21)3/h1,14-18,22-23H,5-13H2,2-3H3/t14-,15+,16+,17-,18-,19-,20-,21-/m0/s1	CKAXZOYFIHQCBN-JRRMKBMNSA-N	2		Not Available	Small Molecule																																			1	Yes	2	2	No	4	0	40.46 Å2	37.66 Å3	92.1 m3·mol-1	0	Yes	No	0.00398 mg/mL	3.36	-4.9	17.59	-1.2	P10415	BCL2	1. Apoptosis regulator Bcl-2
C28H44O2	Not Available	32 to 37 hours.	412.6478	[H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C)[C@H](C)\C=C\[C@H](C)C(C)C	Solid	Not Available	Q02318	CYP27A1	1. Sterol 26-hydroxylase, mitochondrial			4712	CHEMBL1200810	4444554	Drugs.com Drug Page			C08211	D01009	V2H	PDRhealth Drug Page		46705423	347827769	RxList Drug Page	11516		Doxercalciferol	ZINC000004641374	Hectorol	Doxercalciferol	Approved	DB06410	InChI=1S/C28H44O2/c1-18(2)19(3)9-10-20(4)25-13-14-26-22(8-7-15-28(25,26)6)11-12-23-16-24(29)17-27(30)21(23)5/h9-12,18-20,24-27,29-30H,5,7-8,13-17H2,1-4,6H3/b10-9+,22-11+,23-12-/t19-,20+,24+,25+,26-,27-,28+/m0/s1	HKXBNHCUPKIYDM-CGMHZMFXSA-N	4	Doxercalciferol is a synthetic vitamin D2 analog used to treat secondary hyperparathyroidism in patients with chronic kidney disease with or without therapy of dialysis.	Not Available	Small Molecule																																		Relatively insoluble	1	No	2	2	No	3	0	40.46 Å2	51.58 Å3	130.36 m3·mol-1	5	No	No	0.00168 mg/mL	5.75	-5.4	14.39	-2.8	P11473	VDR	1. Vitamin D3 receptor
C21H32O3	Not Available	Not Available	332.484	[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)\C(C[C@]12C)=C/O	Solid	Not Available	P21397;!P10635;!P18405;!P08684;!P20815;!P24462;!Q9HB55	MAOA;!CYP2D6;!SRD5A1;!CYP3A4;!CYP3A5;!CYP3A7;!CYP3A43	1. Amine oxidase [flavin-containing] A;!2. Cytochrome P450 2D6;!3. 3-oxo-5-alpha-steroid 4-dehydrogenase 1;!4. Cytochrome P450 3A4;!5. Cytochrome P450 3A5;!6. Cytochrome P450 3A7;!7. Cytochrome P450 3A43			7864	CHEMBL1200585	4444502	Drugs.com Drug Page			C07393	D00490				5281034	310264869	RxList Drug Page	7813		Oxymetholone	ZINC000118912450	Anadrol-50	Oxymetholone	Approved, Illicit	DB06412	InChI=1S/C21H32O3/c1-19-11-13(12-22)18(23)10-14(19)4-5-15-16(19)6-8-20(2)17(15)7-9-21(20,3)24/h12,14-17,22,24H,4-11H2,1-3H3/b13-12-/t14-,15+,16-,17-,19-,20-,21-/m0/s1	ICMWWNHDUZJFDW-DHODBPELSA-N		Oxymetholone is an anabolic steroid used for the treatment of types of anemia, such as acquired aplastic anemia, congenital aplastic anemia, myelofibrosis, and the hypoplastic anemias.	May cause cancer.The uncontrolled misuse of oxymetholone can lead to a large variety of detrimental effects, the most often reported of which are cardiovascular events.	Small Molecule																																178°C to 180°C		5.21 mg/L	1	Yes	3	2	No	4	0	57.53 Å2	38.84 Å3	94.6 m3·mol-1	0	Yes	No	0.0349 mg/mL	3.55	-4	8.87	-0.53	P10275;!P16860	AR;!NPPB	1. Androgen receptor;!2. Natriuretic peptides B
C25H38O3	Not Available	Not Available	386.576	CCCCCCC(C)(C)C1=CC(O)=C2[C@H]3CC(CO)=CC[C@@H]3C(C)(C)OC2=C1	Solid	Not Available					50067498		CHEMBL334533	96934									107778	347827772				Dexanabinol	ZINC000003799010		Dexanabinol	Investigational	DB06444	InChI=1S/C25H38O3/c1-6-7-8-9-12-24(2,3)18-14-21(27)23-19-13-17(16-26)10-11-20(19)25(4,5)28-22(23)15-18/h10,14-15,19-20,26-27H,6-9,11-13,16H2,1-5H3/t19-,20-/m0/s1	SSQJFGMEZBFMNV-PMACEKPBSA-N	3		Not Available	Small Molecule																																			1	No	3	2	Yes	3	0	49.69 Å2	47.4 Å3	116.73 m3·mol-1	7	No	No	0.00148 mg/mL	6.14	-5.4	9.98	-2.7	P01375	TNF	1. Tumor necrosis factor
C36H56O6	Not Available	56.3 to 69.5 hours	584.8262	[H][C@]12[C@@H](CC[C@@]1(CC[C@]1(C)[C@]2([H])CC[C@]2([H])[C@@]3(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@]3([H])CC[C@@]12C)C(O)=O)C(C)=C	Solid	Not Available					50050955	65484	CHEMBL404519	403003									457928	175427073				Bevirimat	ZINC000003936686		Bevirimat	Investigational	DB06581	InChI=1S/C36H56O6/c1-21(2)22-12-17-36(30(40)41)19-18-34(8)23(28(22)36)10-11-25-33(7)15-14-26(42-27(37)20-31(3,4)29(38)39)32(5,6)24(33)13-16-35(25,34)9/h22-26,28H,1,10-20H2,2-9H3,(H,38,39)(H,40,41)/t22-,23+,24-,25+,26-,28+,33-,34+,35+,36-/m0/s1	YJEJKUQEXFSVCJ-WRFMNRASSA-N	2		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	3.5488 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	5	2	Yes	5	-2	100.9 Å2	67.97 Å3	161.75 m3·mol-1	7	No	No	0.000135 mg/mL	8	-6.6	4.16	-7.1	P04585	gag-pol	1. Gag-Pol polyprotein
C19H30O3	Not Available	Not Available	306.446	[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@H](O)C[C@@]2([H])C[C@@H](O)CC[C@]12C	Solid	Not Available								8011902															ZINC000006067655		7-beta-Hydroxyepiandrosterone	Investigational	DB06622	InChI=1S/C19H30O3/c1-18-7-5-12(20)9-11(18)10-15(21)17-13-3-4-16(22)19(13,2)8-6-14(17)18/h11-15,17,20-21H,3-10H2,1-2H3/t11-,12+,13+,14+,15+,17+,18+,19+/m1/s1	VFPMCLQMAUVEHD-UCPSWNCLSA-N	2		Not Available	Small Molecule																																			1	Yes	3	2	No	4	0	57.53 Å2	35.56 Å3	85.4 m3·mol-1	0	Yes	No	0.102 mg/mL	2.46	-3.5	18.3	-0.51			
C28H35NO4	Not Available	Not Available	449.5818	[H]\C(=N/O)C1=CC=C(C=C1)[C@@]1([H])C[C@@]2(C)[C@@]([H])(CC[C@]2(COC)OC)[C@]2([H])CCC3=CC(=O)CCC3=C12	Solid	Not Available							CHEMBL267431	7851660						AS0								Asoprisnil	ZINC000003936191		Asoprisnil	Investigational	DB06680	InChI=1S/C28H35NO4/c1-27-15-24(19-6-4-18(5-7-19)16-29-31)26-22-11-9-21(30)14-20(22)8-10-23(26)25(27)12-13-28(27,33-3)17-32-2/h4-7,14,16,23-25,31H,8-13,15,17H2,1-3H3/b29-16+/t23-,24+,25-,27-,28+/m0/s1	GJMNAFGEUJBOCE-MEQIQULJSA-N	3		Not Available	Small Molecule																																			1	No	5	1	No	5	-1	68.12 Å2	51.46 Å3	131.27 m3·mol-1	5	Yes	No	0.00211 mg/mL	4.28	-5.3	7.39	2.56	P06401	PGR	1. Progesterone receptor
C20H30O2	Not Available	6-8 hours	302.451	[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	Not Available	P20813;!P08684;!P11511	CYP2B6;!CYP3A4;!CYP19A1	1. Cytochrome P450 2B6;!2. Cytochrome P450 3A4;!3. Cytochrome P450 19A1		50410531	27436	CHEMBL1395	5788			HMDB0015655	C07198	D00408			PA165958383	6010	99443262		6904		Methyltestosterone	ZINC000003814422	Covaryx, Methitest	Methyltestosterone	Approved	DB06710	InChI=1S/C20H30O2/c1-18-9-6-14(21)12-13(18)4-5-15-16(18)7-10-19(2)17(15)8-11-20(19,3)22/h12,15-17,22H,4-11H2,1-3H3/t15-,16+,17+,18+,19+,20+/m1/s1	GCKMFJBGXUYNAG-HLXURNFRSA-N	2	Methyltestosterone is a synthetic anabolic steroid used for the replacement therapy in conditions associated with testosterone deficiencies in males, such as hypogonadism, and treatment of advancing inoperable metastatic breast cancer in females.	Side effects include amnesia, anxiety, discolored hair, dizziness, dry skin, hirsutism, hostility, impaired urination, paresthesia, penis disorder, peripheral edema, sweating, and vasodilation.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.0516 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.36		163 °C		33.9 mg/L (at 25 °C)	1	Yes	2	1	No	4	0	37.3 Å2	35.85 Å3	89.07 m3·mol-1	0	Yes	Yes	0.0139 mg/mL	3.65	-4.3	18.52	-0.53	P10275;!P03372	AR;!ESR1	1. Androgen receptor;!2. Estrogen receptor alpha
C21H26O2	Not Available	16 to 18 hrs.	310.4299	CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1C=C[C@@]2(O)C#C	Solid	Not Available	P08684;!P33261;!P20815;!P24462	CYP3A4;!CYP2C19;!CYP3A5;!CYP3A7	1. Cytochrome P450 3A4;!2. Cytochrome P450 2C19;!3. Cytochrome P450 3A5;!4. Cytochrome P450 3A7			135323	CHEMBL1213583	2298532			HMDB0015668					PA165958397	3033968	99443276		25734		Gestodene	ZINC000238809420		Gestodene	Investigational	DB06730	InChI=1S/C21H26O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,10,12-13,16-19,23H,3,5-9,11H2,1H3/t16-,17+,18+,19-,20-,21-/m0/s1	SIGSPDASOTUPFS-XUDSTZEESA-N	4		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.7480 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							197.9 °C			1	Yes	2	1	No	4	0	37.3 Å2	35.96 Å3	92.99 m3·mol-1	1	Yes	Yes	0.00581 mg/mL	3.46	-4.7	17.08	-1.9	P06401	PGR	1. Progesterone receptor
C20H24O3	Not Available	Not Available	312.409	CC(C)(C)C1CCC(CC1)C1=C(O)C(=O)C2=CC=CC=C2C1=O	Solid	Not Available								13749867									146797	347827788					ZINC000005114256		BW-A 58C	Experimental	DB06740	InChI=1S/C20H24O3/c1-20(2,3)13-10-8-12(9-11-13)16-17(21)14-6-4-5-7-15(14)18(22)19(16)23/h4-7,12-13,23H,8-11H2,1-3H3	NWCVRXADYNRXCT-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	Yes	3	1	No	3	-1	54.37 Å2	35.62 Å3	91.83 m3·mol-1	2	Yes	No	0.0115 mg/mL	4.29	-4.4	5.95	-5.1			
C20H24O9	Not Available	Not Available	408.3992	C[C@@H]1C(=O)O[C@H]2C[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O	Solid	Not Available					50292287	5355	CHEMBL465161	21468875									9909368	99443279					ZINC000004245650		Ginkgolide A	Nutraceutical	DB06743	InChI=1S/C20H24O9/c1-7-12(22)26-10-6-17-9-5-8(16(2,3)4)18(17)11(21)13(23)28-15(18)29-20(17,14(24)27-9)19(7,10)25/h7-11,15,21,25H,5-6H2,1-4H3/t7-,8+,9-,10+,11+,15+,17-,18+,19-,20-/m1/s1	FPUXKXIZEIDQKW-VKMVSBOZSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.8802 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	6	2	No	6	0	128.59 Å2	38.24 Å3	90.17 m3·mol-1	1	Yes	No	3.05 mg/mL	0.34	-2.1	11.77	-4.1			
C20H24O10	Not Available	Not Available	424.3986	C[C@@H]1C(=O)O[C@H]2[C@H](O)[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O	Solid	Not Available					50251276		CHEMBL514432	21105603									6324617	99443280					ZINC000008552017		ginkgolide-B	Nutraceutical	DB06744	InChI=1S/C20H24O10/c1-6-12(23)28-11-9(21)18-8-5-7(16(2,3)4)17(18)10(22)13(24)29-15(17)30-20(18,14(25)27-8)19(6,11)26/h6-11,15,21-22,26H,5H2,1-4H3/t6-,7+,8-,9+,10+,11+,15+,17+,18+,19-,20-/m1/s1	SQOJOAFXDQDRGF-MMQTXUMRSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.4970 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	3	No	6	0	148.82 Å2	39.09 Å3	91.38 m3·mol-1	1	Yes	No	5.21 mg/mL	-0.58	-1.9	11.71	-3.5			
C20H24O11	Not Available	Not Available	440.398	C[C@@H]1C(=O)O[C@H]2[C@H](O)[C@]34[C@@H]5OC(=O)[C@]3(O[C@@H]3OC(=O)[C@H](O)[C@]43[C@@H]([C@H]5O)C(C)(C)C)[C@@]12O	Solid	Not Available								26330340									9867869	99443281					ZINC000028536264		ginkgolide-C	Nutraceutical	DB06745	InChI=1S/C20H24O11/c1-5-12(24)28-11-8(22)18-10-6(21)7(16(2,3)4)17(18)9(23)13(25)30-15(17)31-20(18,14(26)29-10)19(5,11)27/h5-11,15,21-23,27H,1-4H3/t5-,6-,7+,8+,9+,10-,11+,15+,17+,18-,19-,20-/m1/s1	AMOGMTLMADGEOQ-DTDWCABLSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.0556 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	8	4	No	6	0	169.05 Å2	39.81 Å3	92.67 m3·mol-1	1	Yes	No	8.99 mg/mL	-1.6	-1.7	11.7	-3.3			
C20H24O10	Not Available	Not Available	424.3986	C[C@@H]1C(=O)O[C@H]2C[C@]34[C@@H]5OC(=O)[C@]3(O[C@@H]3OC(=O)[C@H](O)[C@]43[C@@H]([C@H]5O)C(C)(C)C)[C@@]12O	Solid	Not Available								26330341									11154476	99443282					ZINC000008552018		ginkgolide-J	Nutraceutical	DB06746	InChI=1S/C20H24O10/c1-6-12(23)27-7-5-17-11-8(21)9(16(2,3)4)18(17)10(22)13(24)29-15(18)30-20(17,14(25)28-11)19(6,7)26/h6-11,15,21-22,26H,5H2,1-4H3/t6-,7+,8-,9+,10+,11-,15+,17-,18+,19-,20-/m1/s1	LMEHVEUFNRJAAV-UKWFQYJJSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.5802 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	3	No	6	0	148.82 Å2	39.01 Å3	91.46 m3·mol-1	1	Yes	No	6.96 mg/mL	-0.66	-1.8	11.76	-3.3			
C42H72O14	Not Available	Not Available	801.024	CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3[C@H](C[C@@]21C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O	Solid	Not Available						67987	CHEMBL501637	390498				C08946					441923	99443286				Ginsenoside_Rg1	ZINC000238809655		Ginsenoside Rg1	Nutraceutical	DB06750	InChI=1S/C42H72O14/c1-20(2)10-9-13-42(8,56-37-34(52)32(50)30(48)25(19-44)55-37)21-11-15-40(6)28(21)22(45)16-26-39(5)14-12-27(46)38(3,4)35(39)23(17-41(26,40)7)53-36-33(51)31(49)29(47)24(18-43)54-36/h10,21-37,43-52H,9,11-19H2,1-8H3/t21-,22+,23-,24+,25+,26+,27-,28-,29+,30+,31-,32-,33+,34+,35-,36+,37-,39+,40+,41+,42-/m0/s1	YURJSTAIMNSZAE-HHNZYBFYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	4.0254 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										0	No	14	10	Yes	6	0	239.22 Å2	88.31 Å3	203.66 m3·mol-1	10	No	No	0.304 mg/mL	0.68	-3.4	11.91	-3	Q9NPD5	SLCO1B3	1. Solute carrier organic anion transporter family member 1B3
C24H40O4	Not Available	Not Available	392.572	[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O	Solid	Not Available	Q02318;!P08684;!P16662	CYP27A1;!CYP3A4;!UGT2B7	1. Sterol 26-hydroxylase, mitochondrial;!2. Cytochrome P450 3A4;!3. UDP-glucuronosyltransferase 2B7		21674	16755	CHEMBL240597	9728	Drugs.com Drug Page		HMDB0000518	C02528	D00163	JN3		PA165958403	10133	99443291		2323		Chenodeoxycholic_acid	ZINC000003914808	Chenodal	Chenodeoxycholic acid	Approved	DB06777	InChI=1S/C24H40O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15+,16-,17-,18+,19+,20-,22+,23+,24-/m1/s1	RUDATBOHQWOJDD-BSWAIDMHSA-N	4	Chenodeoxycholic acid is a bile acid used for the treatment of primary biliary cirrhosis.	Hepatotoxic.	Small Molecule	http://smpdb.ca/view/SMP0000316?highlight[compounds][]=DB06777&highlight[proteins][]=DB06777;!http://smpdb.ca/view/SMP0000314?highlight[compounds][]=DB06777&highlight[proteins][]=DB06777;!http://smpdb.ca/view/SMP0000720?highlight[compounds][]=DB06777&highlight[proteins][]=DB06777;!http://smpdb.ca/view/SMP0000035?highlight[compounds][]=DB06777&highlight[proteins][]=DB06777;!http://smpdb.ca/view/SMP0000315?highlight[compounds][]=DB06777&highlight[proteins][]=DB06777;!http://smpdb.ca/view/SMP0000317?highlight[compounds][]=DB06777&highlight[proteins][]=DB06777;!http://smpdb.ca/view/SMP0000318?highlight[compounds][]=DB06777&highlight[proteins][]=DB06777	Zellweger Syndrome;!Congenital Bile Acid Synthesis Defect Type II;!27-Hydroxylase Deficiency;!Bile Acid Biosynthesis;!Cerebrotendinous Xanthomatosis (CTX);!Familial Hypercholanemia (FHCA);!Congenital Bile Acid Synthesis Defect Type III		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	2.5624 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					4.15		168-171		89.9 mg/L (at 20 °C)	1	Yes	4	3	No	4	-1	77.76 Å2	46.35 Å3	109.27 m3·mol-1	4	Yes	No	0.0197 mg/mL	3.71	-4.3	4.6	-0.54			
C23H32O4	Not Available	Not Available	372.505	[H][C@@]12CC[C@H](C(=O)COC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			34671	CHEMBL1200542	5737				C14554	D03698							258333		Desoxycorticosterone_acetate	ZINC000004428527		Desoxycorticosterone acetate	Approved	DB06780	InChI=1S/C23H32O4/c1-14(24)27-13-21(26)20-7-6-18-17-5-4-15-12-16(25)8-10-22(15,2)19(17)9-11-23(18,20)3/h12,17-20H,4-11,13H2,1-3H3/t17-,18-,19-,20+,22-,23-/m0/s1	VPGRYOFKCNULNK-ACXQXYJUSA-N			Not Available	Small Molecule																																			1	Yes	3	0	No	4	0	60.44 Å2	42.13 Å3	103.56 m3·mol-1	4	Yes	No	0.00502 mg/mL	3.77	-4.9	17.17	-4.8	P08235	NR3C2	1. Mineralocorticoid receptor
C27H34F2O7	Not Available	Not Available	508.5515	[H][C@@]12CC[C@](OC(=O)CCC)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			31485	CHEMBL1201749	391990	Drugs.com Drug Page		HMDB0061149	C12695	D01266		PDRhealth Drug Page	PA165958405	443936	99443292	RxList Drug Page	23043		Difluprednate	ZINC000004212945	Durezol	Difluprednate	Approved	DB06781	InChI=1S/C27H34F2O7/c1-5-6-23(34)36-26(22(33)14-35-15(2)30)10-8-17-18-12-20(28)19-11-16(31)7-9-24(19,3)27(18,29)21(32)13-25(17,26)4/h7,9,11,17-18,20-21,32H,5-6,8,10,12-14H2,1-4H3/t17-,18-,20-,21-,24-,25-,26-,27-/m0/s1	WYQPLTPSGFELIB-JTQPXKBDSA-N	4	Difluprednate is a topical corticosteroid used for the symptomatic treatment of inflammation and pain associated with ocular surgery.	Preclinical pharmacokinetic and toxicity studies have established that difluprednate ophthalmic emulsion 0.05% given 4 times a day is not toxic to the eye.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.1368 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							191-194			1	No	5	1	Yes	4	0	106.97 Å2	51.45 Å3	125.38 m3·mol-1	8	No	No	0.0097 mg/mL	3	-4.7	13.6	-3.4	P04150	NR3C1	1. Glucocorticoid receptor
C24H32ClFO5	Not Available	Not Available	454.96	[H][C@@]12C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Liquid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4		50240097	31663	CHEMBL1200845	391997	Drugs.com Drug Page				D01308		PDRhealth Drug Page		443943	347827796	RxList Drug Page	5084		Halcinonide	ZINC000004213474	Halog	Halcinonide	Approved, Investigational, Withdrawn	DB06786	InChI=1S/C24H32ClFO5/c1-20(2)30-19-10-16-15-6-5-13-9-14(27)7-8-21(13,3)23(15,26)17(28)11-22(16,4)24(19,31-20)18(29)12-25/h9,15-17,19,28H,5-8,10-12H2,1-4H3/t15-,16-,17-,19+,21-,22-,23-,24+/m0/s1	MUQNGPZZQDCDFT-JNQJZLCISA-N		Halcinonide is a corticosteroid used for the management and symptomatic relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.	Systemic absorption of topical corticosteroids has produced reversible hypothalamicpituitary-adrenal (HPA) axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria in some patients. Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings.	Small Molecule																																276-277			1	Yes	5	1	No	5	0	72.83 Å2	46.61 Å3	113.55 m3·mol-1	2	Yes	No	0.0112 mg/mL	3.3	-4.6	13.63	-3.4	Q99835	SMO	1. Smoothened homolog
C27H40O4	Clearance is highly variable from patient to patient. (3)	Half-life = 16 days (±6 days). (3)	428.6041	[H][C@@]12CC[C@](OC(=O)CCCCC)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	Hydroxyprogesterone caproate has a high volume of distribution. (3)	P08684;!P20815;!P33261	CYP3A4;!CYP3A5;!CYP2C19	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5;!3. Cytochrome P450 2C19		70293	5812	CHEMBL1200848	148552	Drugs.com Drug Page			C08148	D00949		PDRhealth Drug Page		169870	310264886	RxList Drug Page	12488		Hydroxyprogesterone_caproate	ZINC000004083606	Makena	Hydroxyprogesterone caproate	Approved, Investigational	DB06789	InChI=1S/C27H40O4/c1-5-6-7-8-24(30)31-27(18(2)28)16-13-23-21-10-9-19-17-20(29)11-14-25(19,3)22(21)12-15-26(23,27)4/h17,21-23H,5-16H2,1-4H3/t21-,22+,23+,25+,26+,27+/m1/s1	DOMWKUIIPQCAJU-LJHIYBGHSA-N	4	Hydroxyprogesterone caproate is a synthetic progestin used for the prevention of spontaneous preterm births in singleton pregnancies in women who have previously had a spontaneous preterm birth.	Injection site pain is the most common adverse effect associated with hydroxyprogesterone caproate. Other commonly reported adverse effects include: injection site swelling, urticaria, pruritus, injection site pruritus, nausea, injection site nodule, and diarrhea. (4)	Small Molecule																																119-121			1	No	3	0	Yes	4	0	60.44 Å2	50.28 Å3	121.69 m3·mol-1	7	No	No	0.000866 mg/mL	5.88	-5.7	17.75	-4.8	P06401	PGR	1. Progesterone receptor
C21H28O2	Not Available	Not Available	312.4458	[H][C@@]12CC[C@@](O)(CC)[C@@]1(CC)C=CC1=C3CCC(=O)C=C3CC[C@@]21[H]	Solid	Not Available								5257020			HMDB0004626			17H			6857686	99443341				Tetrahydrogestrinone	ZINC000012496366		Tetrahydrogestrinone	Experimental	DB06870	InChI=1S/C21H28O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h9,11,13,18-19,23H,3-8,10,12H2,1-2H3/t18-,19+,20+,21+/m1/s1	OXHNQTSIKGHVBH-ANULTFPQSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.6006 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	1	No	4	0	37.3 Å2	37.03 Å3	95.42 m3·mol-1	2	Yes	Yes	0.0199 mg/mL	3.5	-4.2	18.4	-0.14	P10275	AR	1. Androgen receptor
C19H24O2	Not Available	Not Available	284.3927	[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	Not Available					91718	40799	CHEMBL1078534	12893			HMDB0003422			ANB			13472	99443844				Boldione	ZINC000003881421		Boldione	Experimental	DB07373	InChI=1S/C19H24O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h7,9,11,14-16H,3-6,8,10H2,1-2H3/t14-,15-,16-,18-,19-/m0/s1	LUJVUUWNAPIQQI-QAGGRKNESA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.5360 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	0	No	4	0	34.14 Å2	32.45 Å3	84.7 m3·mol-1	0	Yes	Yes	0.0169 mg/mL	3.93	-4.2	18.39	-5	P71278	onr	1. Pentaerythritol tetranitrate reductase
C19H30O2	Not Available	Not Available	290.4403	[H][C@]1(O)CC[C@@]2([H])[C@]3([H])CC[C@]4([H])CC(=O)CC[C@]4(C)[C@@]3([H])CC[C@]12C	Solid	Not Available					50410540	2150	CHEMBL373357	10827			HMDB0006770	C05293		BDT			11302	99443918					ZINC000003814418		5beta-dihydrotestosterone	Experimental	DB07447	InChI=1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12,14-17,21H,3-11H2,1-2H3/t12-,14+,15+,16+,17+,18+,19+/m1/s1	NVKAWKQGWWIWPM-MISPCMORSA-N			Not Available	Small Molecule	http://smpdb.ca/view/SMP0000356?highlight[compounds][]=DB07447&highlight[proteins][]=DB07447;!http://smpdb.ca/view/SMP0000068?highlight[compounds][]=DB07447&highlight[proteins][]=DB07447;!http://smpdb.ca/view/SMP0000565?highlight[compounds][]=DB07447&highlight[proteins][]=DB07447	17-beta Hydroxysteroid Dehydrogenase III Deficiency;!Androgen and Estrogen Metabolism;!Aromatase Deficiency		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.9757 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	1	No	4	0	37.3 Å2	34.62 Å3	83.6 m3·mol-1	0	Yes	Yes	0.00998 mg/mL	3.41	-4.5	19.38	-0.88	P51857	AKR1D1	1. 3-oxo-5-beta-steroid 4-dehydrogenase
C24H32F6O3	Not Available	Not Available	482.4995	[H][C@]1(CC[C@](C)(CCC#CC(O)(C(F)(F)F)C(F)(F)F)C1(C)C)\C=C\C=C1C[C@](O)([H])C[C@@](O)([H])C1	Solid	Not Available								8633358						C5D			10457944	99444001					ZINC000038911928		(1R,3R)-5-[(2E)-3-{(1S,3R)-2,2,3-trimethyl-3-[6,6,6-trifluoro-5-hydroxy-5-(trifluoromethyl)hex-3-yn-1-yl]cyclopentyl}prop-2-en-1-ylidene]cyclohexane-1,3-diol	Experimental	DB07530	InChI=1S/C24H32F6O3/c1-20(2)17(8-6-7-16-13-18(31)15-19(32)14-16)9-12-21(20,3)10-4-5-11-22(33,23(25,26)27)24(28,29)30/h6-8,17-19,31-33H,4,9-10,12-15H2,1-3H3/b8-6+/t17-,18-,19-,21+/m1/s1	PCHUQQNKOFNVDU-OSXMSNBXSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	3.8675 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	3	3	No	2	-1	60.69 Å2	45.59 Å3	115.82 m3·mol-1	8	Yes	No	0.00107 mg/mL	4.98	-5.6	6.43	-2.7	Q15788;!P11473	NCOA1;!VDR	1. Nuclear receptor coactivator 1;!2. Vitamin D3 receptor
C22H30O2	Not Available	Not Available	326.4724	[H]\C(CC)=C(/[H])C1=C(O)C=C2CC[C@@]3([H])[C@]4([H])CC[C@]([H])(O)[C@@]4(C)CC[C@]3([H])C2=C1	Solid	Not Available								26326672						DRQ			42627296	99444149					ZINC000031861332		(9ALPHA,13BETA,17BETA)-2-[(1Z)-BUT-1-EN-1-YL]ESTRA-1,3,5(10)-TRIENE-3,17-DIOL	Experimental	DB07678	InChI=1S/C22H30O2/c1-3-4-5-15-12-18-14(13-20(15)23)6-7-17-16(18)10-11-22(2)19(17)8-9-21(22)24/h4-5,12-13,16-17,19,21,23-24H,3,6-11H2,1-2H3/b5-4-/t16-,17+,19-,21-,22-/m0/s1	ANAMDWGJXBYJEB-OPWFCKQNSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.2449 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	2	2	No	4	0	40.46 Å2	39.6 Å3	99.87 m3·mol-1	2	No	No	0.00126 mg/mL	5.31	-5.4	9.67	-0.88	P03372;!Q15596	ESR1;!NCOA2	1. Estrogen receptor alpha;!2. Nuclear receptor coactivator 2
C18H24O3	Not Available	Not Available	288.3814	[H][C@@]12C[C@@H](O)[C@@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	Solid	Not Available						42156	CHEMBL1232445	225189						E3O			256737	99444173					ZINC000003881360		17alpha-Estriol	Experimental	DB07702	InChI=1S/C18H24O3/c1-18-7-6-13-12-5-3-11(19)8-10(12)2-4-14(13)15(18)9-16(20)17(18)21/h3,5,8,13-17,19-21H,2,4,6-7,9H2,1H3/t13-,14-,15+,16-,17-,18+/m1/s1	PROQIPRRNZUXQM-PNVOZDDCSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.9758 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	3	3	No	4	0	60.69 Å2	32.95 Å3	81.27 m3·mol-1	0	Yes	No	0.119 mg/mL	2.67	-3.4	10.33	-3.2	Q9HCD5;!Q92731	NCOA5;!ESR2	1. Nuclear receptor coactivator 5;!2. Estrogen receptor beta
C18H24O3	Not Available	Not Available	288.3814	[H][C@]1(O)CC[C@@]2([H])[C@]3([H])CCC4=C(C=C(O)C(O)=C4)[C@@]3([H])CC[C@]12C	Solid	Not Available					50262140	28744	CHEMBL467987	216475			HMDB0000338	C05301		ECS			247304	99444177				2-Hydroxyestradiol	ZINC000003815419		2-Hydroxyestradiol	Experimental	DB07706	InChI=1S/C18H24O3/c1-18-7-6-11-12(14(18)4-5-17(18)21)3-2-10-8-15(19)16(20)9-13(10)11/h8-9,11-12,14,17,19-21H,2-7H2,1H3/t11-,12+,14-,17-,18-/m0/s1	DILDHNKDVHLEQB-XSSYPUMDSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.9758 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	3	3	No	4	0	60.69 Å2	33.08 Å3	81.89 m3·mol-1	0	Yes	No	0.0511 mg/mL	3.44	-3.8	9.67	-0.88	O32393	cyaC	1. Adenylate cyclase
C20H28O3	Not Available	Not Available	316.4345	[H][C@]1(O)CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])[C@@]([H])(COC)C[C@]12C	Solid	Not Available								21169213						EED			23728517	99444178					ZINC000013610524		(9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOL	Experimental	DB07707	InChI=1S/C20H28O3/c1-20-10-13(11-23-2)19-15-6-4-14(21)9-12(15)3-5-16(19)17(20)7-8-18(20)22/h4,6,9,13,16-19,21-22H,3,5,7-8,10-11H2,1-2H3/t13-,16+,17+,18+,19-,20+/m1/s1	LEOPSILMAOYZBO-IUTAEKPZSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.0746 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	3	2	No	4	0	49.69 Å2	36.6 Å3	91.06 m3·mol-1	2	Yes	No	0.00706 mg/mL	3.32	-4.6	10.31	-0.89	P03372;!Q15596	ESR1;!NCOA2	1. Estrogen receptor alpha;!2. Nuclear receptor coactivator 2
C27H36F2O3	Not Available	Not Available	446.5697	[H][C@]1(O)CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])CC(=O)CC[C@]4(C)[C@@]3([H])CC[C@]12CCOCC1=CC(F)=CC(F)=C1	Solid	Not Available							CHEMBL485835	20581191						ENM			16750073	99444188					ZINC000016052389		(5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE	Experimental	DB07717	InChI=1S/C27H36F2O3/c1-26-8-6-21(30)14-18(26)2-3-22-23(26)7-9-27(24(22)4-5-25(27)31)10-11-32-16-17-12-19(28)15-20(29)13-17/h12-13,15,18,22-25,31H,2-11,14,16H2,1H3/t18-,22+,23-,24-,25-,26-,27+/m0/s1	AJODXHGZHBERGJ-JLYQOUBASA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.5253 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	3	1	No	5	0	46.53 Å2	48.83 Å3	119.93 m3·mol-1	5	No	No	0.00155 mg/mL	5.07	-5.5	14.69	-2.9	P10275	AR	1. Androgen receptor
C19H28O2	Not Available	Not Available	288.4244	[H][C@@]1(O)CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)CC[C@]4(C)[C@@]3([H])CC[C@]12C	Solid	Not Available					50410492	42534	CHEMBL196228	9789			HMDB0000628			FFA			10204	99444239				Epitestosterone	ZINC000004538008		Epitestosterone	Experimental	DB07768	InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-17,21H,3-10H2,1-2H3/t14-,15-,16-,17+,18-,19-/m0/s1	MUMGGOZAMZWBJJ-KZYORJDKSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.6259 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	1	No	4	0	37.3 Å2	33.93 Å3	84.43 m3·mol-1	0	Yes	Yes	0.0333 mg/mL	3.37	-3.9	18.52	-0.88	Q04828;!P52895	AKR1C1;!AKR1C2	1. Aldo-keto reductase family 1 member C1;!2. Aldo-keto reductase family 1 member C2
C19H22O6	Not Available	Not Available	346.3744	[H][C@@]12CC[C@]3(O)C[C@]1(CC3=C)[C@@H](C(O)=O)[C@]1([H])[C@@]3(C)[C@@H](O)C=C[C@@]21OC3=O	Solid	Not Available						28833	CHEMBL1232952	6223			HMDB0003559	C01699		GA3			439551	99444285				Gibberellic_acid	ZINC000003860467		Gibberellic acid	Experimental	DB07814	InChI=1S/C19H22O6/c1-9-7-17-8-18(9,24)5-3-10(17)19-6-4-11(20)16(2,15(23)25-19)13(19)12(17)14(21)22/h4,6,10-13,20,24H,1,3,5,7-8H2,2H3,(H,21,22)/t10-,11+,12-,13-,16-,17+,18+,19-/m1/s1	IXORZMNAPKEEDV-OBDJNFEBSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.7712 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	3	No	5	-1	104.06 Å2	23.92 Å3	86.42 m3·mol-1	1	Yes	No	1.95 mg/mL	0.35	-2.2	4.16	-0.9	Q6P093	AADACL2	1. Arylacetamide deacetylase-like 2
C19H24O5	Not Available	Not Available	332.3909	[H][C@@]12C[C@]3(CC1=C)[C@@H](C(O)=O)[C@]1([H])[C@@]4(C)[C@@H](O)CC[C@@]1(OC4=O)[C@]3([H])CC2	Solid	Not Available						32902		10222155				C11864		GA4			92109	99444286					ZINC000004102247		Gibberellin A4	Experimental	DB07815	InChI=1S/C19H24O5/c1-9-7-18-8-10(9)3-4-11(18)19-6-5-12(20)17(2,16(23)24-19)14(19)13(18)15(21)22/h10-14,20H,1,3-8H2,2H3,(H,21,22)/t10-,11-,12+,13-,14-,17-,18+,19-/m1/s1	RSQSQJNRHICNNH-NFMPGMCNSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.2992 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	2	No	5	-1	83.83 Å2	34.58 Å3	84.08 m3·mol-1	1	Yes	No	1.19 mg/mL	1.56	-2.4	4.29	-3	Q6P093	AADACL2	1. Arylacetamide deacetylase-like 2
C22H28O5	Not Available	Not Available	372.4547	[H][C@@]12CC[C@H](OC(=O)CCC(O)=O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3CC[C@@]21[H]	Solid	Not Available							CHEMBL1233274	59813						HE7			66440	99444362				Estradiol_hemisuccinate	ZINC000004026838		Estradiol hemisuccinate	Experimental	DB07891	InChI=1S/C22H28O5/c1-22-11-10-16-15-5-3-14(23)12-13(15)2-4-17(16)18(22)6-7-19(22)27-21(26)9-8-20(24)25/h3,5,12,16-19,23H,2,4,6-11H2,1H3,(H,24,25)/t16-,17-,18+,19+,22+/m1/s1	YJPIDPAGJSWWBE-FNIAAEIWSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3962 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	2	No	4	-1	83.83 Å2	41.88 Å3	99.95 m3·mol-1	5	Yes	No	0.0048 mg/mL	4.01	-4.9	4.31	-5.4			
C23H24O8	Not Available	Not Available	428.4319	[H][C@@]12CCC(=O)[C@@]1(C)C[C@@H](OC(C)=O)C1=C2C(=O)C2=C3C(=CO2)C(=O)O[C@H](COC)[C@]13C	Solid	Not Available					15234	52289	CHEMBL428496	276037				C15181		KWT			312145	99444530				Wortmannin	ZINC000001619592		Wortmannin	Experimental	DB08059	InChI=1S/C23H24O8/c1-10(24)30-13-7-22(2)12(5-6-14(22)25)16-18(13)23(3)15(9-28-4)31-21(27)11-8-29-20(17(11)23)19(16)26/h8,12-13,15H,5-7,9H2,1-4H3/t12-,13+,15+,22-,23-/m0/s1	QDLHCMPXEPAAMD-QAIWCSMKSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	4.0908 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	0	No	5	0	109.11 Å2	42.98 Å3	106.86 m3·mol-1	4	Yes	No	0.121 mg/mL	1.44	-3.6		-3.2			
C27H32O4	Not Available	Not Available	420.5406	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC=C4C=C(CC[C@]4(C)[C@@]3([H])CC[C@]12C)C(O)=O)C(=O)C1=CC=C(O)C=C1	Solid	Not Available								8020773						MUF			9845059	99444691					ZINC000003803450		(8alpha,10alpha,13alpha,17beta)-17-[(4-hydroxyphenyl)carbonyl]androsta-3,5-diene-3-carboxylic acid	Experimental	DB08220	InChI=1S/C27H32O4/c1-26-13-11-17(25(30)31)15-18(26)5-8-20-21-9-10-23(27(21,2)14-12-22(20)26)24(29)16-3-6-19(28)7-4-16/h3-7,15,20-23,28H,8-14H2,1-2H3,(H,30,31)/t20-,21-,22-,23+,26-,27-/m0/s1	RPNNXCYIESWDSC-JRZBRKEGSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.6597 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	2	No	5	-1	74.6 Å2	47.84 Å3	121.45 m3·mol-1	3	No	No	0.00264 mg/mL	5.16	-5.2	4.35	-6.9	Q15788;!Q96RI1	NCOA1;!NR1H4	1. Nuclear receptor coactivator 1;!2. Bile acid receptor
C22H30O5	Not Available	Not Available	374.4706	[H][C@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)CC[C@]4([H])[C@@]3([H])CC[C@]12C)OC(=O)CCC(O)=O	Solid	Not Available								4451095						NTH			5289054	99444779					ZINC000033821445		SUCCINIC ACID MONO-(13-METHYL-3-OXO-2,3,6,7,8,9,10,11,12,13,14,15,16,17-TETRADECAHYDRO-1H-CYCLOPENTA[A]PHENANTHREN-17-YL) ESTER	Experimental	DB08308	InChI=1S/C22H30O5/c1-22-11-10-16-15-5-3-14(23)12-13(15)2-4-17(16)18(22)6-7-19(22)27-21(26)9-8-20(24)25/h12,15-19H,2-11H2,1H3,(H,24,25)/t15-,16+,17+,18-,19+,22-/m0/s1	IRQUJNVGEAJGSD-KIEDKLRZSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.0592 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	1	No	4	-1	80.67 Å2	41.7 Å3	100 m3·mol-1	5	Yes	No	0.0108 mg/mL	3.33	-4.5	4.31	-4.7	P00947	ksi	1. Steroid Delta-isomerase
C24H29NO7	Not Available	Not Available	443.4896	[H][C@]12C[C@]3([H])O[C@@]1(C)C[C@@]1(C2)CCC(=O)[C@@](C)(CCC(=O)NC2=C(O)C=CC(C(O)=O)=C2O)[C@]31[H]	Solid	Not Available								17245480						P9A			16086836	99444837					ZINC000035050252		3-({3-[(1S,4aS,6S,7S,9S,9aR)-1,6-dimethyl-2-oxodecahydro-6,9-epoxy-4a,7-methanobenzo[7]annulen-1-yl]propanoyl}amino)-2,4-dihydroxybenzoic acid	Experimental	DB08366	InChI=1S/C24H29NO7/c1-22(7-6-17(28)25-18-14(26)4-3-13(19(18)29)21(30)31)16(27)5-8-24-10-12-9-15(20(22)24)32-23(12,2)11-24/h3-4,12,15,20,26,29H,5-11H2,1-2H3,(H,25,28)(H,30,31)/t12-,15+,20+,22-,23+,24+/m1/s1	XADCWKSMHQPTGH-OFBLZTNGSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.9926 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	7	4	No	5	-1	133.16 Å2	44.69 Å3	115.72 m3·mol-1	5	Yes	No	0.0144 mg/mL	3.24	-4.5	2.96	-3.4	P0AAI5	fabF	1. 3-oxoacyl-[acyl-carrier-protein] synthase 2
C21H27FO4	Not Available	Not Available	362.4351	CC(C)OC1=CC=C(CC[C@]2(CC(O)=CC(=O)O2)C2CCCC2)C=C1F	Solid	Not Available								20153859						PFI			54688400	99444861					ZINC000100036690		(6S)-6-CYCLOPENTYL-6-[2-(3-FLUORO-4-ISOPROPOXYPHENYL)ETHYL]-4-HYDROXY-5,6-DIHYDRO-2H-PYRAN-2-ONE	Experimental	DB08390	InChI=1S/C21H27FO4/c1-14(2)25-19-8-7-15(11-18(19)22)9-10-21(16-5-3-4-6-16)13-17(23)12-20(24)26-21/h7-8,11-12,14,16,23H,3-6,9-10,13H2,1-2H3/t21-/m0/s1	AKNIHFDXRAOPAI-NRFANRHFSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	3.7796 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	1	Yes	3	0	55.76 Å2	39.1 Å3	98.52 m3·mol-1	6	Yes	No	0.00406 mg/mL	4.8	-5	8.32	-4.9	P26663	Not Available	1. Genome polyprotein
C24H27NO7	Not Available	Not Available	441.4737	[H][C@]12C[C@@H]3O[C@@]1(C)C[C@@]1(C2)C=CC(=O)[C@@](C)(CCC(=O)NC2=C(O)C(=CC=C2O)C(O)=O)[C@]31[H]	Solid	Not Available						68236	CHEMBL411278	5257055						PMN			6857724	99444878				Platensimycin	ZINC000029050726		Platensimycin	Experimental	DB08407	InChI=1S/C24H27NO7/c1-22(7-6-17(28)25-18-14(26)4-3-13(19(18)29)21(30)31)16(27)5-8-24-10-12-9-15(20(22)24)32-23(12,2)11-24/h3-5,8,12,15,20,26,29H,6-7,9-11H2,1-2H3,(H,25,28)(H,30,31)/t12-,15+,20+,22-,23+,24+/m1/s1	CSOMAHTTWTVBFL-OFBLZTNGSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	3.0222 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	7	4	No	5	-1	133.16 Å2	44.81 Å3	116.81 m3·mol-1	5	Yes	No	0.0139 mg/mL	3.24	-4.5	2.96	-3.4	P0AAI5	fabF	1. 3-oxoacyl-[acyl-carrier-protein] synthase 2
C25H38O5	Not Available	Not Available	418.5662	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])C[C@]([H])(CC[C@]4(C)[C@@]3([H])CC[C@]12C)OC(=O)CCC(O)=O)C(C)=O	Solid	Not Available						62043		4451314						S5H			5289324	99444981					ZINC000011422518		5-ALPHA-PREGNANE-3-BETA-OL-HEMISUCCINATE	Experimental	DB08510	InChI=1S/C25H38O5/c1-15(26)19-6-7-20-18-5-4-16-14-17(30-23(29)9-8-22(27)28)10-12-24(16,2)21(18)11-13-25(19,20)3/h16-21H,4-14H2,1-3H3,(H,27,28)/t16-,17-,18-,19+,20-,21-,24-,25+/m0/s1	UVTGFMKBPVLATL-DSOJQRAMSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.1566 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	1	Yes	4	-1	80.67 Å2	48.08 Å3	112.95 m3·mol-1	6	Yes	No	0.00175 mg/mL	4.25	-5.4	4.11	-6.9	P01859	IGHG2	1. Ig gamma-2 chain C region
C25H34O6	Not Available	Not Available	430.5339	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)CC[C@]4(C)[C@@]3([H])[C@@]([H])(C[C@]12C)OC(=O)CCC(O)=O)C(C)=O	Solid	Not Available						45496		4451359						SIH			5289373	99445018					ZINC000013512622		PROGESTERONE-11-ALPHA-OL-HEMISUCCINATE	Experimental	DB08547	InChI=1S/C25H34O6/c1-14(26)18-6-7-19-17-5-4-15-12-16(27)10-11-24(15,2)23(17)20(13-25(18,19)3)31-22(30)9-8-21(28)29/h12,17-20,23H,4-11,13H2,1-3H3,(H,28,29)/t17-,18+,19-,20+,23+,24-,25+/m0/s1	JBBNFGYRYNBDIH-DBGGZKJISA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.3116 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	1	Yes	4	-1	97.74 Å2	46.96 Å3	114.34 m3·mol-1	6	Yes	No	0.0085 mg/mL	3.11	-4.7	4.22	-4.8	P01859	IGHG2	1. Ig gamma-2 chain C region
C23H32O5	Not Available	Not Available	388.4972	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)OC(=O)CCC(O)=O	Solid	Not Available								106489						TH2			119202	99445090					ZINC000004025723		Testosterone succinate	Experimental	DB08619	InChI=1S/C23H32O5/c1-22-11-9-15(24)13-14(22)3-4-16-17-5-6-19(23(17,2)12-10-18(16)22)28-21(27)8-7-20(25)26/h13,16-19H,3-12H2,1-2H3,(H,25,26)/t16-,17-,18-,19-,22-,23-/m0/s1	CJQNBXFUHQZFOE-VYAQIDIUSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.1662 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	1	No	4	-1	80.67 Å2	43.74 Å3	104.47 m3·mol-1	5	Yes	No	0.00844 mg/mL	3.63	-4.7	4.31	-4.8	P0A3R9	ncsA	1. Neocarzinostatin
C19H28ClNO6	Not Available	Not Available	401.882	[H][C@]1(CC=C(C)C)O[C@]1(C)[C@@]1([H])[C@]([H])(OC)[C@@]([H])(CC[C@]11CO1)OC(=O)NC(=O)CCl	Solid	Not Available					17446	90748	CHEMBL424278	328427						TN4			369976	99445104					ZINC000003914617		TNP-470	Investigational	DB08633	InChI=1S/C19H28ClNO6/c1-11(2)5-6-13-18(3,27-13)16-15(24-4)12(7-8-19(16)10-25-19)26-17(23)21-14(22)9-20/h5,12-13,15-16H,6-10H2,1-4H3,(H,21,22,23)/t12-,13-,15-,16-,18+,19+/m1/s1	MSHZHSPISPJWHW-PVDLLORBSA-N	1		Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.8117 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	1	Yes	3	0	89.69 Å2	41.46 Å3	98.45 m3·mol-1	7	Yes	No	0.0234 mg/mL	2.24	-4.2	9.71	-3.7			
C26H34O3	Not Available	Not Available	394.5464	C=C1\C(=C/C=C2\CCC[C@]3(C)[C@]([H])(CC[C@@]23[H])C#CC#CC(C)(O)C)C[C@](O)([H])C[C@@]1(O)[H]	Solid	Not Available								9444440						XE4			11269429	99445213					ZINC000058660808		1,3-CYCLOHEXANEDIOL, 4-METHYLENE-5-[(2E)-[(1S,3AS,7AS)-OCTAHYDRO-1-(5-HYDROXY-5-METHYL-1,3-HEXADIYNYL)-7A-METHYL-4H-INDEN-4-YLIDENE]ETHYLIDENE]-, (1R,3S,5Z)	Experimental	DB08742	InChI=1S/C26H34O3/c1-18-20(16-22(27)17-24(18)28)11-10-19-8-7-15-26(4)21(12-13-23(19)26)9-5-6-14-25(2,3)29/h10-11,21-24,27-29H,1,7-8,12-13,15-17H2,2-4H3/b19-10+,20-11-/t21-,22+,23-,24-,26+/m0/s1	CEEUUHVULXTFGS-BQXVGYHGSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	4.6385 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	3	No	3	0	60.69 Å2	46.99 Å3	120.55 m3·mol-1	4	Yes	No	0.00898 mg/mL	3.39	-4.6	14.06	-2.8	Q15788;!P11473	NCOA1;!VDR	1. Nuclear receptor coactivator 1;!2. Vitamin D3 receptor
C28H44O3	50 mg, 100 mg, and 150 mg doses of nadrolone decanoate had mean apparent clearances of 80.0 L/h, 74.3 L/h, and 76.2 L/h respectively.1	Nandrolone decanoate has an absorption half life of 6 days and an elimination half life of 4.3 hours.13 Alternate studies have shown that nandrolone decanoate has a terminal half life of 7.1, 11.7, and 11.8 hours for doses of 50, 100, and 150 mg respectively.1	428.6472	[H][C@@]12CC[C@H](OC(=O)CCCCCCCCC)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	Solid	Not Available	P11511;!P27338;!P21397;!P16662;!P22310;!P06133;!P35503;!P22309;!Q9HAW8	CYP19A1;!MAOB;!MAOA;!UGT2B7;!UGT1A4;!UGT2B4;!UGT1A3;!UGT1A1;!UGT1A10	1. Cytochrome P450 19A1;!2. Amine oxidase [flavin-containing] B;!3. Amine oxidase [flavin-containing] A;!4. UDP-glucuronosyltransferase 2B7;!5. UDP-glucuronosyltransferase 1-4;!6. UDP-glucuronosyltransferase 2B4;!7. UDP-glucuronosyltransferase 1-3;!8. UDP-glucuronosyltransferase 1-1;!9. UDP-glucuronosyltransferase 1-10			7467	CHEMBL1200946	9296	Drugs.com Drug Page		HMDB0015694	C08154	D00955			PA165958423	9677	99445274		31494	DAP000903	Nandrolone_decanoate	ZINC000008214619		Nandrolone decanoate	Approved, Illicit	DB08804	InChI=1S/C28H44O3/c1-3-4-5-6-7-8-9-10-27(30)31-26-16-15-25-24-13-11-20-19-21(29)12-14-22(20)23(24)17-18-28(25,26)2/h19,22-26H,3-18H2,1-2H3/t22-,23+,24+,25-,26-,28-/m0/s1	JKWKMORAXJQQSR-MOPIKTETSA-N	2	Nandrolone decanoate is an anabolic steroid indicated for the management of the anemia of renal insufficiency by increasing hemoglobin and red cell mass.	Data regarding acute overdose of nandrolone decanoate are not readily available.13 However, patients experiencing a chronic overdose of anabolic steroids may experience adverse effects including suppression of testosterone and spermatogenesis, shrinking of testicles, decreased libido, and erectile dysfunction in men; and suppressed estrogen, progesterone, and ovulation, amenorrhea, and clitoromegaly in women.8 Patients may also experience neuropsychiatric, cardiovascular, and hepatic adverse effects.8 Alkylated anabolic steroids such as nandrolone decanoate are more likely to cause hepatic adverse effects.8 Treat patients with symptomatic and supportive measures.The intraperitoneal LD50 in mice is >566 mg/kg.14	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	1.8804 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							32-35		3.09 mg/mL at 25 °C	1	No	2	0	Yes	4	0	43.37 Å2	53.64 Å3	125.94 m3·mol-1	10	No	No	0.000157 mg/mL	7.32	-6.4	18.25	-4.7	P10275;!P01100;!BE0004881;!P28222;!P08069;!BE0009376	AR;!FOS;!;!HTR1B;!IGF1R;!	1. Androgen receptor;!2. Proto-oncogene c-Fos;!3. 5-hydroxytryptamine 2 receptor (Protein Group);!4. 5-hydroxytryptamine receptor 1B;!5. Insulin-like growth factor 1 receptor;!6. Dopamine receptor (Protein Group)
C26H48ClN3O6Pt	Not Available	Not Available	729.22	N.N.Cl.[Pt++].CC(CCC([O-])=NCC([O-])=O)C1CCC2C3C(O)CC4CC(O)CCC4(C)C3CC(O)C12C	Solid	Not Available								135801																	cis-Diamminechlorocholylglycinateplatinum(II)	Experimental	DB08858	InChI=1S/C26H43NO6.ClH.2H3N.Pt/c1-14(4-7-22(31)27-13-23(32)33)17-5-6-18-24-19(12-21(30)26(17,18)3)25(2)9-8-16(28)10-15(25)11-20(24)29;;;;/h14-21,24,28-30H,4-13H2,1-3H3,(H,27,31)(H,32,33);1H;2*1H3;/q;;;;+2/p-2	RUGJYCHQQOPHCW-UHFFFAOYSA-L			Not Available	Small Molecule																																			1	No	7	3	Yes	4	-1	136.24 Å2	52.47 Å3	145.5 m3·mol-1	6	No	No	0.155 mg/mL	2.2	-3.7	3.83	1.83			
C28H35NO3	Mean oral clearance, single oral dose, healthy subject (CL/F) = 76.8 ± 64.0L/h	Mean elimination half-life, single oral dose, healthy subject = 32.4 ± 6.3 hours	433.592	CN(C)C1=CC=C(C=C1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12	Solid	Not Available	P08684;!P05177	CYP3A4;!CYP1A2	1. Cytochrome P450 3A4;!2. Cytochrome P450 1A2			71025	CHEMBL2103846	19349271	Drugs.com Drug Page				D09567				13559281	310264902	RxList Drug Page	1005921		Ulipristal_acetate	ZINC000034089131	Ella, Ellaone, Esmya	Ulipristal	Approved	DB08867	InChI=1S/C28H35NO3/c1-17(30)28(32)14-13-25-23-11-7-19-15-21(31)10-12-22(19)26(23)24(16-27(25,28)2)18-5-8-20(9-6-18)29(3)4/h5-6,8-9,15,23-25,32H,7,10-14,16H2,1-4H3/t23-,24+,25-,27-,28-/m0/s1	HKDLNTKNLJPAIY-WKWWZUSTSA-N	4	Ulipristal is a selective progesterone receptor modulator used for emergency contraception after unprotected intercourse or in a situation where a planned method of contraception has failed.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.6728 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	1	No	5	0	57.61 Å2	49.66 Å3	129.29 m3·mol-1	3	Yes	No	0.00943 mg/mL	4.18	-4.7	12.7	4.89			
C19H26O3	Plasma clearance is approximately 4.2 L/(h kg), when delivered intravenously. In women, following a 500mg dose of formestane, 20% was excreted as glucuronide within the first 24 hours. [1]One long term metabolite (3beta,4alpha-dihydroxy-5alpha-androstan-17-one) can be detected for 90 hours. A longer detection time is possible with more sensitive technology, which may be of utility in sports drug testing. [1]	Terminal plasma elimination half life of 18 minutes, when delivered intravenously. [2]	302.4079	[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=C(O)C(=O)CC[C@]12C	Solid	Vd = 1.8 L/kg; widely distributed to organs and tissues when delivered intravenously. [2]	P08684	CYP3A4	1. Cytochrome P450 3A4		225704	75172	CHEMBL132530	10799	Drugs.com Drug Page				D07260				11273	175427144		15070		Formestane	ZINC000003919580		Formestane	Approved, Investigational, Withdrawn	DB08905	InChI=1S/C19H26O3/c1-18-10-8-15(20)17(22)14(18)4-3-11-12-5-6-16(21)19(12,2)9-7-13(11)18/h11-13,22H,3-10H2,1-2H3/t11-,12-,13-,18+,19-/m0/s1	OSVMTWJCGUFAOD-KZQROQTASA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.6135 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.66		199 - 202	9.31	Insoluble	1	Yes	3	1	No	4	0	54.37 Å2	34.05 Å3	85.57 m3·mol-1	0	Yes	No	0.0578 mg/mL	3.41	-3.7	9.21	-3.7			
C27H29F3O6S	57.8L/h for fluticasone furoateLabel. A study of 24 healthy Caucasian males showed a clearance of 71.8L/h following intravenous administration5.	15.1 hours for intranasal fluticasone furoateLabel and 24 hours for the inhaled formulation12. A study of 24 healthy Caucasian males showed a half life of 13.6 hours following intravenous administration and 17.3-23.9 hours followed inhalation5.	538.576	[H][C@@]12C[C@@H](C)[C@](OC(=O)C3=CC=CO3)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C	Solid	608L at steady state for intravenous administration of fluticasone furoateLabel. Other reports suggest the mean volume of distribution at steady state is 661L12. A study of 24 healthy Caucasian males showed a volume of distribution at steady state of 704L following intravenous administration5.	P08684;!P20815;!P24462;!P10632	CYP3A4;!CYP3A5;!CYP3A7;!CYP2C8	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5;!3. Cytochrome P450 3A7;!4. Cytochrome P450 2C8		50354851	74899	CHEMBL1676	8030195	Drugs.com Drug Page				D06315	GW6			9854489	175427145	RxList Drug Page	705022		Fluticasone_furoate	ZINC000003992105	Arnuity Ellipta, Avamys, Breo Ellipta, Flonase Sensimist, Trelegy Ellipta, Veramyst	Fluticasone furoate	Approved	DB08906	InChI=1S/C27H29F3O6S/c1-14-9-16-17-11-19(29)18-10-15(31)6-7-24(18,2)26(17,30)21(32)12-25(16,3)27(14,23(34)37-13-28)36-22(33)20-5-4-8-35-20/h4-8,10,14,16-17,19,21,32H,9,11-13H2,1-3H3/t14-,16+,17+,19+,21+,24+,25+,26+,27+/m1/s1	XTULMSXFIHGYFS-VLSRWLAYSA-N	4	Fluticasone furoate is an inhaled corticosteroid that can be used as maintenance treatment of asthma and/or chronic obstructive pulmonary disease (COPD) depending on the product. Also available as a nasal spray to manage symptoms of allergic rhinitis.	Fluticasone furoate administered nasally may be associated with adrenal suppression or an increase in QTc interval though the association has not been well demonstrated in studiesLabel6. Fluticasone furoate requires no dosage adjustment in renal impairment but must be used in caution in hepatic impairment due to the elimination mechanismsLabel12. Fluticasone furoate is not associated with carcinogenicity, mutagenicity, or impairment of fertilityLabel. There are no well controlled studies in pregnancy or lactation though animal studies have shown teratogenicity and hypoadrenalism in the offspring of treated mothers and other corticosteroids are known to be excreted in breast milkLabel. Generally, there are no reported adverse effects with fluticasone in pregnancy3. Pediatric patients should be given the lowest possible dose and monitored for reduction in growth velocityLabel6. There is insufficient evidence to determine whether geriatric patients respond differently to other patientsLabel. Systemic exposure may be 27-49% higher in Japanese, Korean, and Chinese patients compared to Caucasian patients12. Caution should be exercised in these patients and the benefit and risk should be assessed before deciding on a treatmentLabel.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.6232 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							250-252		Insoluble	1	No	4	1	Yes	5	0	93.81 Å2	51.56 Å3	130.08 m3·mol-1	6	No	No	0.0434 mg/mL	4.13	-4.1	13.61	-3.1			
C22H27FO5	Not Available	Not Available	390.4452	[H][C@@]12CC(=C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5			135989	CHEMBL2106763	9969413									11794741	310264933		236650		Fluprednidene	ZINC000004213363		Fluprednidene	Experimental	DB08970	InChI=1S/C22H27FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,15-17,24,26,28H,1,4-5,8,10-11H2,2-3H3/t15-,16-,17-,19-,20-,21-,22-/m0/s1	YVHXHNGGPURVOS-SBTDHBFYSA-N			Not Available	Small Molecule																																			1	Yes	5	3	No	4	0	94.83 Å2	40.32 Å3	102.19 m3·mol-1	2	Yes	No	0.117 mg/mL	1.41	-3.5	12.11	-3.3			
C22H29FO4	Not Available	Not Available	376.4617	[H][C@@]12C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C	Solid	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5			135581	CHEMBL251634	8701									9053	310264934		4463		Fluocortolone	ZINC000004213353		Fluocortolone	Approved, Withdrawn	DB08971	InChI=1S/C22H29FO4/c1-11-6-14-13-8-16(23)15-7-12(25)4-5-21(15,2)20(13)17(26)9-22(14,3)19(11)18(27)10-24/h4-5,7,11,13-14,16-17,19-20,24,26H,6,8-10H2,1-3H3/t11-,13+,14+,16+,17+,19-,20-,21+,22+/m1/s1	GAKMQHDJQHZUTJ-ULHLPKEOSA-N		Fluocortolone is a glucocorticoid used topically for localized skin reactions and also orally for systemic use.	Not Available	Small Molecule																																180-182			1	Yes	4	2	No	4	0	74.6 Å2	40.14 Å3	101.47 m3·mol-1	2	Yes	No	0.0339 mg/mL	1.97	-4	13.84	-0.23			
C24H29Cl2FO5	Not Available	Not Available	487.39	[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(Cl)[C@@H](Cl)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO	Solid	Not Available						135787	CHEMBL461332	16735814	Drugs.com Drug Page								20054914	310264936		103447		Fluclorolone_acetonide	ZINC000004213332		Fluclorolone acetonide	Approved, Withdrawn	DB08973	InChI=1S/C24H29Cl2FO5/c1-20(2)31-19-9-13-14-8-16(27)15-7-12(29)5-6-21(15,3)23(14,26)17(25)10-22(13,4)24(19,32-20)18(30)11-28/h5-7,13-14,16-17,19,28H,8-11H2,1-4H3/t13-,14-,16-,17-,19+,21-,22-,23-,24+/m0/s1	NJNWEGFJCGYWQT-VSXGLTOVSA-N			Not Available	Small Molecule																																			1	No	5	1	No	5	0	72.83 Å2	47.44 Å3	119.21 m3·mol-1	2	Yes	No	0.00175 mg/mL	3.42	-5.4	13.73	-3.3			
C22H30O4	Not Available	Not Available	358.478	[H][C@@]12CC[C@@](O)(CCC(O)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=CC2=CC(=O)CC[C@]12C	Solid	Not Available						50156	CHEMBL1616951	570976	Drugs.com Drug Page								656615	310264973		618970		Potassium_canrenoate	ZINC000003938750		Canrenoic acid	Approved, Withdrawn	DB09015	InChI=1S/C22H30O4/c1-20-9-5-15(23)13-14(20)3-4-16-17(20)6-10-21(2)18(16)7-11-22(21,26)12-8-19(24)25/h3-4,13,16-18,26H,5-12H2,1-2H3,(H,24,25)/t16-,17+,18+,20+,21+,22-/m1/s1	PBKZPPIHUVSDNM-WNHSNXHDSA-N	3	Canrenoic acid is an aldosterone antagonist used in primary hyperaldosteronism and other disorders related to aberrant aldosterone levels.	Not Available	Small Molecule																																165			1	Yes	4	2	No	4	-1	74.6 Å2	40.44 Å3	100.98 m3·mol-1	3	Yes	No	0.0442 mg/mL	2.93	-3.9	4.48	-3.1			
C21H28O2	Elimination of tibolone is not dependent renal function 14.	The elimination half-life is approximately 45 h 4.	312.453	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC(=O)CC3)C[C@@]([H])(C)[C@@]21[H]	Solid	Not Available	P08842;!P14060;!P26439;!P50225	STS;!HSD3B1;!HSD3B2;!SULT1A1	1. Steryl-sulfatase;!2. 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1;!3. 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2;!4. Sulfotransferase 1A1			32223	CHEMBL2103774	392038					D01639				444008	347827821		38260		Tibolone	ZINC000003812889		Tibolone	Approved, Investigational	DB09070	InChI=1S/C21H28O2/c1-4-21(23)10-8-18-19-13(2)11-14-12-15(22)5-6-16(14)17(19)7-9-20(18,21)3/h1,13,17-19,23H,5-12H2,2-3H3/t13-,17-,18+,19-,20+,21+/m1/s1	WZDGZWOAQTVYBX-XOINTXKNSA-N	4		>2000 mg/kg MSDSThe Million Women Study (MWS), which had a prospective observational design, studied the use of hormone replacement therapy. The results indicated that the increase in the incidence of breast cancer with estrogen and progestogen (compared to estrogen alone) was greater than the reduction in occurrence of endometrial cancer associated with adding progestogen to estrogen therapy. The MWS also reported a marked increase in the incidence of breast cancer with tibolone and with implanted and transdermal estrogen-only preparations 6.Tibolone treatment in rodent studies showed an increased association with the development of a range of tumors in long-term oral carcinogenicity studies. These tumors included pituitary adenomas, mammary carcinomas and fibroadenomas, hepatic adenomas, uterine carcinoma, stromal polyps and stromal sarcoma, and carcinomas of the urinary bladder and testes. Tibolone failed to show any evidence of genotoxicity in studies for gene mutations, chromosomal damage as well as DNA damage 9.Other adverse effects these include dizziness, headache, nausea, abdominal pain, rashes, pruritus, weight gain, edema, and migraine 16.	Small Molecule																																		<0.1 g/L	1	Yes	2	1	No	4	0	37.3 Å2	36.77 Å3	91.73 m3·mol-1	0	Yes	Yes	0.00722 mg/mL	3.1	-4.6	16.27	-1.7	P03372	ESR1	1. Estrogen receptor alpha
C21H30O4S	Studies have shown that oral or intravenous administration of tixocortol presents a significantly larger clearance rate compared to cortisol of 33.3 L h/kg.4	Tixocortol presents a shorter half-life than cortisol.6	378.53	[H][C@@]12CC[C@](O)(C(=O)CS)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	Studies have shown that oral or intravenous administration of tixocortol presents a significantly larger volume of distribution compared to cortisol of 21.7 L/kg.4						63560		143053									162955	310265018		57257		Tixocortol	ZINC000005138848		Tixocortol	Approved, Withdrawn	DB09091	InChI=1S/C21H30O4S/c1-19-7-5-13(22)9-12(19)3-4-14-15-6-8-21(25,17(24)11-26)20(15,2)10-16(23)18(14)19/h9,14-16,18,23,25-26H,3-8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1	YWDBSCORAARPPF-VWUMJDOOSA-N		Tixocortol is a corticosteroid used for the symptomatic treatment of rhinitis, pharyngitis, and ulcerative colitis.	Diverse studies performed on tixocortol proved that this drug is non-toxic and non-immunosupressive. This low toxicity and abscence of immuno supression gave tixocortol the potential to be a lead for topical or local anti-inflammatory treatments.7 Nevertheless, toxicortol is a potent cutaneous sensitizer, causing a local allergy.3	Small Molecule																													607ºC at 760 mmHg	4.48		50-55ºC		Insoluble	1	Yes	4	3	No	4	0	74.6 Å2	41.96 Å3	103.53 m3·mol-1	2	Yes	No	0.0428 mg/mL	2.32	-4	9.57	-2.8	P04150;!Q92769	NR3C1;!HDAC2	1. Glucocorticoid receptor;!2. Histone deacetylase 2
C22H28F2O4	Diflucortolone gets rapidly eliminated and the metabolites produced are the latest in getting eliminated from the body.6	The half-life of diflucortolone is approximately in the range of 4 to 5 h while the half-life of 3H-diflucortolone valerate is approximately 9 h.2	394.459	[H][C@@]12C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C	Solid	Less of 1% of the administered dose reaches systemic circulation.7 In order to exert its functions, diflucortolone has to distribute into the living epidermis and upper dermis. Reports have shown that the skin absorption of diflucortolone is rapid where the absorption gets significantly increased in damaged skin. Diflucortolone gets percutaneously absorbed and distributed into organs and tissues where it will be metabolized. When diflucortolone in an ointment form is applied in healthy skin 0.7% of the administered dose is percutaneously absorbed after a 7-hour exposure.6	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5			135624	CHEMBL509924	10128664									11954369	310265022		3392		Diflucortolone	ZINC000004212939		Difluocortolone	Approved, Investigational, Withdrawn	DB09095	InChI=1S/C22H28F2O4/c1-11-6-13-14-8-16(23)15-7-12(26)4-5-21(15,3)22(14,24)18(28)9-20(13,2)19(11)17(27)10-25/h4-5,7,11,13-14,16,18-19,25,28H,6,8-10H2,1-3H3/t11-,13+,14+,16+,18+,19-,20+,21+,22+/m1/s1	OGPWIDANBSLJPC-RFPWEZLHSA-N	1	Difluocortolone is a topical corticosteroid used for the symptomatic treatment of inflammatory skin disorders like eczema, seborrheic eczema, lichen planus and psoriasis.	Diflucortolone can cause skin irritation, vesicles or red patches on the skin.4	Small Molecule																													534ºC at 760 mmHg	3.86		220ºC		2.030 mg/L	1	Yes	4	2	No	4	0	74.6 Å2	40.2 Å3	100.99 m3·mol-1	2	Yes	No	0.0446 mg/mL	2.01	-4	13.42	-3.3	P12429;!P04150	ANXA3;!NR3C1	1. Annexin A3;!2. Glucocorticoid receptor
C20H25NO2	The metabolic clearance rate from serum (Cl/F) is 64 mL/min 5.	Elimination half-life of dienogest is around 9-10 hours. The half-life of urinary metabolites excretion is 14 hours 5.	311.425	[H][C@@]12CC[C@@](O)(CC#N)[C@@]1(C)CCC1=C3CCC(=O)C=C3CC[C@@]21[H]	Solid	The apparent volume of distribution (Vd/F) of dienogest is 40 L 5.	P08684	CYP3A4	1. Cytochrome P450 3A4			70708	CHEMBL1201864	62093									68861	310265039		22968		Dienogest	ZINC000004215629	Natazia, Visanne	Dienogest	Approved	DB09123	InChI=1S/C20H25NO2/c1-19-8-6-16-15-5-3-14(22)12-13(15)2-4-17(16)18(19)7-9-20(19,23)10-11-21/h12,17-18,23H,2-10H2,1H3/t17-,18+,19+,20-/m1/s1	AZFLJNIPTRTECV-FUMNGEBKSA-N	4	Dienogest is an oral progestin used for the treatment of endometriosis as monotherapy or contraception in combination with ethinylestradiol.	Oral LD50 in mouse is 4 mg/kg MSDS. In a long-term carcinogenicity study involving rats and mice, exposure of 10 times the dose of maximum recommended clinical dose of dienogest resulted in increased incidences of pituitary adenomas, fibroepithelial mammary tumours, stromal polyps of the uterus and malignant lymphoma 6. These tumors are thought to arise from marked species differences in the optimal oestrogen:progestogen ratio for reproductive function. In rat liver foci assay, dienogest did not induce tumor promotion activity 6. Dienogest does not display genotoxic potential.	Small Molecule																																210-218		Practically insoluble	1	Yes	3	1	No	4	0	61.09 Å2	35.4 Å3	90.19 m3·mol-1	1	Yes	No	0.0761 mg/mL	2.31	-3.6	13.78	-3.3	P06401;!P10275	PGR;!AR	1. Progesterone receptor;!2. Androgen receptor
C23H32O2	Not Available	The half-life of medrogestone is reported to be of 4 hours.5	340.507	[H][C@@]12CC[C@](C)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			135446	CHEMBL2106825	8125459									9949848	310265040		6690		Medrogestone	ZINC000004216820		Medrogestone	Approved, Withdrawn	DB09124	InChI=1S/C23H32O2/c1-14-12-17-18(21(3)9-6-16(25)13-20(14)21)7-11-23(5)19(17)8-10-22(23,4)15(2)24/h12-13,17-19H,6-11H2,1-5H3/t17-,18+,19+,21-,22-,23+/m1/s1	HCFSGRMEEXUOSS-JXEXPEPMSA-N		Medrogestone is a progestin used as an adjunct to control secondary amenorrhea and dysfunctional bleeding in adolescent and adult females, and treat endometrial shedding in menopausal women.	There were reports of increased urinary flow rates and total micturition volumes as well as sexual dysfunction and hyperglycemia.4	Small Molecule																													467.17ºC at 760 mmHg	4.45		144-146ºC		5.34e-06 mol/L	1	Yes	2	0	No	4	0	34.14 Å2	40.37 Å3	102.6 m3·mol-1	1	Yes	Yes	0.00404 mg/mL	4.59	-4.9	19.18	-4.9	P06401	PGR	1. Progesterone receptor
C19H28O8	The clearance of artesunate is 180L/h while the clearance of DHA is 32.3L/h.8	The elimination half life of artesunate is 0.3h with a range of 0.1-1.8h.8 The elimination half life of DHA is 1.3h with a range of 0.9-2.9h.8 Half life after intramuscular administration is 48 min in children and 41 min in adults.7	384.425	[H][C@@]12CC[C@@H](C)[C@]3([H])CC[C@@]4(C)OO[C@@]13[C@]([H])(O[C@@H](OC(=O)CCC(O)=O)[C@@H]2C)O4	Solid	The volume of distribution of artesunate is 68.5L while the volume of distribution of DHA is 59.7L.8	P16662;!O60656;!P11509	UGT2B7;!UGT1A9;!CYP2A6	1. UDP-glucuronosyltransferase 2B7;!2. UDP-glucuronosyltransferase 1-9;!3. Cytochrome P450 2A6			63918	CHEMBL361497	5293084			HMDB0240267		D02482	D95			6917864	310265169		18346		Artesunate	ZINC000014096305		Artesunate	Approved, Investigational	DB09274	InChI=1S/C19H28O8/c1-10-4-5-13-11(2)16(23-15(22)7-6-14(20)21)24-17-19(13)12(10)8-9-18(3,25-17)26-27-19/h10-13,16-17H,4-9H2,1-3H3,(H,20,21)/t10-,11-,12+,13+,16-,17-,18-,19-/m1/s1	FIHJKUPKCHIPAT-AHIGJZGOSA-N	4	Artesunate is artesunate is an artemesinin derivative indicated for the initial treatment of severe malaria.	Data regarding overdoses of artesunate are rare.8 Patients experiencing an overdose may present with pancytopenia, melena, seizures, multiorgan failure, and death.8 Treat overdose with symptomatic and supportive measures.8	Small Molecule																																131-135			1	Yes	7	1	No	4	-1	100.52 Å2	39.46 Å3	89.95 m3·mol-1	5	Yes	No	0.678 mg/mL	3.1	-2.8	3.77	-4.2	P04926	EXP-1	1. Malaria protein EXP-1
C20H26O2	Not Available	Not Available	298.426	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])CC(=O)CC3	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4		50410507	34895	CHEMBL1387	5995				C14249	D05207							7515		Norethynodrel	ZINC000118913164		Norethynodrel	Approved	DB09371	InChI=1S/C20H26O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,16-18,22H,4-12H2,2H3/t16-,17-,18+,19+,20+/m1/s1	ICTXHFFSOAJUMG-SLHNCBLASA-N			Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	34.79 Å3	87.18 m3·mol-1	0	Yes	Yes	0.00982 mg/mL	2.81	-4.5	16.21	-1.7	P03372;!P10275;!P04278	ESR1;!AR;!SHBG	1. Estrogen receptor alpha;!2. Androgen receptor;!3. Sex hormone-binding globulin
C21H27FO5	Not Available	Not Available	378.44	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			34474	CHEMBL1200774	5665				C14618	D04227							4497		Fluprednisolone	ZINC000003875362		Fluprednisolone	Approved	DB09378	InChI=1S/C21H27FO5/c1-19-5-3-11(24)7-14(19)15(22)8-12-13-4-6-21(27,17(26)10-23)20(13,2)9-16(25)18(12)19/h3,5,7,12-13,15-16,18,23,25,27H,4,6,8-10H2,1-2H3/t12-,13-,15-,16-,18+,19-,20-,21-/m0/s1	MYYIMZRZXIQBGI-HVIRSNARSA-N			Not Available	Small Molecule																																			1	Yes	5	3	No	4	0	94.83 Å2	38.9 Å3	98.32 m3·mol-1	2	Yes	No	0.261 mg/mL	0.93	-3.2	12.58	-2.9			
C22H28O5	Not Available	Not Available	372.461	[H][C@]1(C)C[C@@]2([H])[C@]3([H])CCC4=CC(=O)C=C[C@]4(C)[C@@]3([H])C(=O)C[C@]2(C)[C@@]1(O)C(=O)CO	Not Available	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5			135573	CHEMBL1201148	4447637												29523		Meprednisone	ZINC000004216862		Meprednisone	Approved, Investigational	DB09383	InChI=1S/C22H28O5/c1-12-8-16-15-5-4-13-9-14(24)6-7-20(13,2)19(15)17(25)10-21(16,3)22(12,27)18(26)11-23/h6-7,9,12,15-16,19,23,27H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,19+,20-,21-,22-/m0/s1	PIDANAQULIKBQS-RNUIGHNZSA-N	2		Not Available	Small Molecule																																			1	Yes	5	2	No	4	0	91.67 Å2	40.19 Å3	102.04 m3·mol-1	2	Yes	No	0.0711 mg/mL	2.02	-3.7	12.44	-3.3			
C21H28O2	Not Available	Not Available	312.453	CCC12CCC3C(CCC4=CC(=O)CCC34)C1CCC2(O)C#C	Not Available	Not Available	P08684;!P11511	CYP3A4;!CYP19A1	1. Cytochrome P450 3A4;!2. Cytochrome P450 19A1			7630	CHEMBL2107797	4383	Drugs.com Drug Page				D00954				4542	347827838	RxList Drug Page	7518		Norgestrel		Cryselle 28, Elinest 28 Day, Lo/ovral 28 Day, Low-ogestrel 28 Day	Norgestrel	Approved	DB09389	InChI=1S/C21H28O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,13,16-19,23H,3,5-12H2,1H3	WWYNJERNGUHSAO-UHFFFAOYSA-N	4	Norgestrel is a progestin used in combination with ethinyl estradiol for oral contraception and prevention of pregnancy in women.	Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	36.83 Å3	92.03 m3·mol-1	1	Yes	Yes	0.00583 mg/mL	3.66	-4.7	17.91	-1.5	P06401;!P18405;!P10275	PGR;!SRD5A1;!AR	1. Progesterone receptor;!2. 3-oxo-5-alpha-steroid 4-dehydrogenase 1;!3. Androgen receptor
C31H38O7	Not Available	Not Available	522.638	C[C@H]1C[C@@]2(OC(C)=O)[C@H]([C@H]1OC(=O)C1=CC=CC=C1)[C@@H](OC(C)=O)C(=C)CC[C@H]1[C@@H](\C=C(C)\C2=O)C1(C)C	Not Available	Not Available						136008	CHEMBL552128	8753322									10577938	347827957		1426391			ZINC000096903163		Diacetyl benzoyl lathyrol	Approved	DB11260	InChI=1S/C31H38O7/c1-17-13-14-23-24(30(23,6)7)15-18(2)28(34)31(38-21(5)33)16-19(3)27(25(31)26(17)36-20(4)32)37-29(35)22-11-9-8-10-12-22/h8-12,15,19,23-27H,1,13-14,16H2,2-7H3/b18-15+/t19-,23-,24+,25-,26-,27-,31+/m0/s1	JPYYWXPAHJBKJX-VWSFRBHVSA-N			Not Available	Small Molecule																																			0	No	4	0	Yes	4	0	95.97 Å2	55.46 Å3	141.47 m3·mol-1	7	No	No	0.000363 mg/mL	5.71	-6.2		-5.5			
C21H26O2	Not Available	Not Available	310.437	[H][C@@]12CC[C@@](O)(CC=C)[C@@]1(C)C=CC1=C3CCC(=O)C=C3CC[C@@]21[H]	Not Available	Not Available							CHEMBL1315492	8216634					D02840							1314612		Altrenogest	ZINC000004214784		Altrenogest	Vet approved	DB11372	InChI=1S/C21H26O2/c1-3-10-21(23)12-9-19-18-6-4-14-13-15(22)5-7-16(14)17(18)8-11-20(19,21)2/h3,8,11,13,18-19,23H,1,4-7,9-10,12H2,2H3/t18-,19+,20+,21+/m1/s1	VWAUPFMBXBWEQY-ANULTFPQSA-N			Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	36.06 Å3	95.46 m3·mol-1	2	Yes	Yes	0.0301 mg/mL	3.2	-4	18.4	-0.18			
C20H30O2	Not Available	Not Available	302.458	[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3C[C@@H](C)[C@@]21[H]	Not Available	Not Available					26258	34849	CHEMBL425863	220460				C14255	D05025									Mibolerone	ZINC000004216936		Mibolerone	Vet approved	DB11429	InChI=1S/C20H30O2/c1-12-10-13-11-14(21)4-5-15(13)16-6-8-19(2)17(18(12)16)7-9-20(19,3)22/h11-12,15-18,22H,4-10H2,1-3H3/t12-,15+,16-,17+,18-,19+,20+/m1/s1	PTQMMNYJKCSPET-OMHQDGTGSA-N			Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	35.86 Å3	89.14 m3·mol-1	0	Yes	Yes	0.0194 mg/mL	3.63	-4.2	18.34	-0.53	P10275	AR	1. Androgen receptor
C23H32O4	Not Available	Not Available	372.505	[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)C[C@H](C)[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	Not Available	Not Available							CHEMBL2104744	7996587					D05210									Norgestomet	ZINC000004217176		Norgestomet	Vet approved	DB11440	InChI=1S/C23H32O4/c1-13-12-22(4)20(9-10-23(22,14(2)24)27-15(3)25)19-7-5-16-11-17(26)6-8-18(16)21(13)19/h11,13,18-21H,5-10,12H2,1-4H3/t13-,18-,19-,20-,21+,22-,23-/m0/s1	IWSXBCZCPVUWHT-VIFKTUCRSA-N			Not Available	Small Molecule																																			1	Yes	3	0	No	4	0	60.44 Å2	42.06 Å3	103.33 m3·mol-1	3	Yes	No	0.00489 mg/mL	3.83	-4.9	17.68	-4.7			
C28H47NO4S	Not Available	Not Available	493.742	[H][C@@]12C(=O)CC[C@]11CC[C@@]([H])(C)[C@@]2(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]1C)OC(=O)CSCCN(CC)CC	Not Available	Not Available						44137	CHEMBL1234521	571196				C12065	D06127	MUL						1546410		Tiamulin	ZINC000004217557		Tiamulin	Vet approved	DB11468	InChI=1S/C28H47NO4S/c1-8-26(6)17-22(33-23(31)18-34-16-15-29(9-2)10-3)27(7)19(4)11-13-28(20(5)25(26)32)14-12-21(30)24(27)28/h8,19-20,22,24-25,32H,1,9-18H2,2-7H3/t19-,20+,22-,24+,25+,26-,27+,28+/m1/s1	UURAUHCOJAIIRQ-QGLSALSOSA-N			Not Available	Small Molecule																																			1	No	4	1	Yes	3	1	66.84 Å2	57.98 Å3	140.74 m3·mol-1	10	Yes	No	0.000524 mg/mL	4.5	-6	14.43	9.51			
C28H32FNO6	Not Available	Not Available	497.563	[H][C@@]12C[C@@H](C)[C@](O)(C(=O)COC(=O)C3=CC=NC=C3)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5				CHEMBL3186453	15881												3265		Dexamethasone_isonicotinate	ZINC000004212878		Dexamethasone isonicotinate	Vet approved	DB11487	InChI=1S/C28H32FNO6/c1-16-12-21-20-5-4-18-13-19(31)6-9-25(18,2)27(20,29)22(32)14-26(21,3)28(16,35)23(33)15-36-24(34)17-7-10-30-11-8-17/h6-11,13,16,20-22,32,35H,4-5,12,14-15H2,1-3H3/t16-,20+,21+,22+,25+,26+,27+,28+/m1/s1	BQTXJHAJMDGOFI-NJLPOHDGSA-N			Not Available	Small Molecule																																			1	No	6	2	No	5	0	113.79 Å2	51.74 Å3	130.16 m3·mol-1	5	Yes	No	0.0254 mg/mL	2.96	-4.3	12.44	3.41			
C21H27FO5	Not Available	Not Available	378.44	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@]([H])(O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Not Available	Not Available						34511		113134				C14484								1546449		Isoflupredone	ZINC000003876095		Isoflupredone	Vet approved	DB11522	InChI=1S/C21H27FO5/c1-18-7-5-13(24)9-12(18)3-4-15-14-6-8-20(27,17(26)11-23)19(14,2)10-16(25)21(15,18)22/h5,7,9,14-16,23,25,27H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,18-,19-,20-,21-/m0/s1	WAIJIHDWAKJCBX-BULBTXNYSA-N			Not Available	Small Molecule																																			1	Yes	5	3	No	4	0	94.83 Å2	38.88 Å3	98.02 m3·mol-1	2	Yes	No	0.0811 mg/mL	1.32	-3.7	12.55	-3.3			
C23H30O3	Not Available	Not Available	354.49	[H][C@@]12CC(=C)[C@](O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4					8082266												1537799		Melengestrol	ZINC000038610965		Melengestrol	Vet approved	DB11529	InChI=1S/C23H30O3/c1-13-10-17-18(21(4)8-6-16(25)12-19(13)21)7-9-22(5)20(17)11-14(2)23(22,26)15(3)24/h10,12,17-18,20,26H,2,6-9,11H2,1,3-5H3/t17-,18+,20+,21-,22+,23+/m1/s1	OKHAOBQKCCIRLO-IBVJIVQJSA-N			Not Available	Small Molecule																																			1	Yes	3	1	No	4	0	54.37 Å2	40.91 Å3	103.68 m3·mol-1	1	Yes	No	0.00748 mg/mL	3.38	-4.7	12.21	-4			
C18H22O2	Not Available	Not Available	270.372	[H][C@@]12CC[C@H](O)[C@@]1(C)C=CC1=C3CCC(=O)C=C3CC[C@@]21[H]	Not Available	Not Available						35018	CHEMBL3182355	23383				C14261	D08627							1484278		Trenbolone	ZINC000003814429		Trenbolone	Vet approved	DB11551	InChI=1S/C18H22O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h8-10,15-17,20H,2-7H2,1H3/t15-,16+,17+,18+/m1/s1	MEHHPFQKXOUFFV-OWSLCNJRSA-N			Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	31.26 Å3	81.65 m3·mol-1	0	Yes	Yes	0.0586 mg/mL	2.25	-3.7	18.4	-0.89			
C21H24O2	Renal Excretion accounts for < 1 % 6.	Plasma half-life is 24 hr 6.	308.4141	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)C=CC1=C3CCC(=O)C=C3CC[C@@]21[H]	Solid	67 L 11	P08684	CYP3A4	1. Cytochrome P450 3A4		50423515	89642	CHEMBL1868702	25877			HMDB0002720		D04317				27812	347828012		4792		Gestrinone	ZINC000003938633		Gestrinone	Approved	DB11619	InChI=1S/C21H24O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,9,11,13,18-19,23H,3,5-8,10,12H2,1H3/t18-,19+,20+,21+/m1/s1	BJJXHLWLUDYTGC-ANULTFPQSA-N			Many of gestrinone's adverse effects occur due to its androgenic activity. These effects include acne, seborrhea, hirsutism, weight gain and deepening of the voice. Most patients develop at least one adverse event while taking this drug. This is because the drug is embryotoxic in some animals and may also cause masculinization of a female fetus. Gestrinone significantly reduces HDL concentrations 8.It is advisable to monitor liver transaminases and cholesterol levels in hyperlipidemic patients, as well as glucose in diabetic patients. Gestrinone has shown to decrease in the concentration of thyroid-binding globulin. Therefore, a decrease in serum total thyroxine levels is commonly observed. This is without clinical significance as free thyroxine levels and thyroid-stimulating hormone levels remain within the normal reference range 11.	Small Molecule																													507.638			150-152			1	Yes	2	1	No	4	0	37.3 Å2	35.55 Å3	93.73 m3·mol-1	1	Yes	Yes	0.00969 mg/mL	2.85	-4.5	17.88	-1.5	P04278;!P06401;!P04150;!P10275;!P30968;!P03372	SHBG;!PGR;!NR3C1;!AR;!GNRHR;!ESR1	1. Sex hormone-binding globulin;!2. Progesterone receptor;!3. Glucocorticoid receptor;!4. Androgen receptor;!5. Gonadotropin-releasing hormone receptor;!6. Estrogen receptor alpha
C21H28O3	Not Available	Not Available	328.452	CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			135993	CHEMBL2105722	62024					D07222							31930		Nomegestrol	ZINC000004217164		Nomegestrol	Approved	DB11636	InChI=1S/C21H28O3/c1-12-10-18-16(15-5-4-14(23)11-17(12)15)6-8-20(3)19(18)7-9-21(20,24)13(2)22/h10-11,15-16,18-19,24H,4-9H2,1-3H3/t15-,16-,18-,19+,20+,21+/m1/s1	KZUIYQJTUIACIG-YBZCJVABSA-N			Not Available	Small Molecule																																			1	Yes	3	1	No	4	0	54.37 Å2	37.69 Å3	95.03 m3·mol-1	1	Yes	No	0.0122 mg/mL	2.98	-4.4	12.7	-3.8			
C22H28ClFO4	Not Available	Not Available	410.907	[H][C@@]12C[C@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Not Available	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5			205919	CHEMBL1201362	4470588			HMDB0015148						5311051	347828107		2590		Clobetasol	ZINC000026892643		Clobetasol	Approved, Experimental, Investigational	DB11750	InChI=1S/C22H28ClFO4/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,24)17(26)10-20(16,3)22(12,28)18(27)11-23/h6-7,9,12,15-17,26,28H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,17-,19-,20-,21-,22-/m0/s1	FCSHDIVRCWTZOX-DVTGEIKXSA-N	3		Not Available	Small Molecule																																			1	Yes	4	2	No	4	0	74.6 Å2	41.95 Å3	105.54 m3·mol-1	2	Yes	No	0.0142 mg/mL	3.04	-4.5	12.47	-3.4			
C26H34F5NO4	Not Available	Not Available	519.553	C[C@H](OCC(=O)NCC(F)(F)C(F)(F)F)C1=CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	Not Available	Not Available							CHEMBL3989862	17279714									16122802	347828136					ZINC000035308284		Pefcalcitol	Investigational	DB11786	InChI=1S/C26H34F5NO4/c1-15-18(11-19(33)12-22(15)34)7-6-17-5-4-10-24(3)20(8-9-21(17)24)16(2)36-13-23(35)32-14-25(27,28)26(29,30)31/h6-8,16,19,21-22,33-34H,1,4-5,9-14H2,2-3H3,(H,32,35)/b17-6+,18-7-/t16-,19+,21-,22-,24+/m0/s1	SVCSMAZYWOQCBW-NVJMFHFGSA-N	3		Not Available	Small Molecule																																			1	No	4	3	Yes	3	0	78.79 Å2	50.63 Å3	127.31 m3·mol-1	8	No	No	0.00253 mg/mL	2.95	-5.3	11.52	-2.8			
C24H40O4	Not Available	Not Available	392.58	[H][C@@]1(CC[C@@]2([H])[C@]3([H])C[C@H](O)[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O	Not Available	Not Available					50375596	52023	CHEMBL272621	4446908									5283820	347828138				Hyodeoxycholic_acid	ZINC000003918159		Hyodeoxycholic Acid	Investigational	DB11789	InChI=1S/C24H40O4/c1-14(4-7-22(27)28)17-5-6-18-16-13-21(26)20-12-15(25)8-10-24(20,3)19(16)9-11-23(17,18)2/h14-21,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15-,16+,17-,18+,19+,20+,21+,23-,24-/m1/s1	DGABKXLVXPYZII-SIBKNCMHSA-N			Not Available	Small Molecule																																			1	Yes	4	3	No	4	-1	77.76 Å2	46.42 Å3	109.27 m3·mol-1	4	Yes	No	0.015 mg/mL	3.71	-4.4	4.79	-2.7			
C21H34O2	The total plasma clearance determined for brexanolone is approximately 1 L/h/kg Label.	The terminal half-life observed for brexanolone is approximately 9 hours Label.	318.4935	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)C(C)=O	Solid	The volume of distribution documented for brexanolone is approximately 3 L/kg, a value which suggests relatively extensive distribution into tissues Label.	P15121	AKR1B1	1. Aldose reductase		50191342	50169	CHEMBL207538	83760			HMDB0001449	C13712					92786	347828198		2121777		Allopregnanolone	ZINC000004081043	Zulresso	Brexanolone	Approved, Investigational	DB11859	InChI=1S/C21H34O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h14-19,23H,4-12H2,1-3H3/t14-,15+,16-,17+,18-,19-,20-,21+/m0/s1	AURFZBICLPNKBZ-SYBPFIFISA-N	3		There is limited clinical trial experience regarding human overdosage with brexanolone Label. In premarketing clinical studies, two cases of accidental overdosage due to infusion pump malfunction resulted in transient loss of consciousness Label. Both patients regained consciousness approximately 15 minutes after discontinuation of the infusion without supportive measures Label. After full resolution of symptoms, both patients subsequently resumed and completed treatment Label. Overdosage may result in excessive sedation, including loss of consciousness, and the potential for accompanying respiratory changes Label.There is no available data on brexanolone use in pregnant women to determine a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes Label. However, based on findings from animal studies of other drugs that enhance GABAergic inhibition, brexanolone may cause fetal harm Label.Available data from a lactation study in 12 women indicate that brexanolone is transferred to breastmilk in nursing mothers Label. However, the relative infant dose (RID) is low, 1% to 2% of the maternal weight-adjusted dosage Label. Also, as brexanolone has low oral bioavailability in adults, infant exposure is expected to be low Label. There were no reports of effects of brexanolone on milk production Label. There are no data on the effects of brexanolone on a breastfed infant Label. Available data on the use of brexanolone during lactation does not suggest a significant risk of adverse reactions to breastfed infants from exposure to brexanolone Label. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for brexanolone and any potential adverse effects on the breastfed child from brexanolone or from the underlying maternal condition Label.Brexanolone was not genotoxic when tested in an in vitro microbial mutagenicity (Ames) assay, an in vitro micronucleus assay in human peripheral blood lymphocytes, and an in vivo rat bone marrow micronucleus assay Label.Treatment of female and male rats with brexanolone at doses equal to and greater than 30 mg/kg/day, which is associated with 2 times the plasma levels at the maximum recommended human dose (MRHD) of 90 mcg/kg/hour, caused impairment of female and male fertility and reproduction Label. In female rats, brexanolone was associated with decreased mating and fertility indices, an increase in number of days to mating, prolonged/irregular estrous cycles, an increase in the number of early resorptions, and post implantation loss Label. Reversal of effects in females was observed following a 28-day recovery period Label. In male rats, brexanolone was associated with decreased mating and fertility indices, decreased conception rate, lower prostate, seminal vesicle, and epididymis weight, as well as decreased sperm numbers. Impaired female and male fertility and reproduction were not observed at 0.8 times the MRHD Label.	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	38.52 Å3	92.91 m3·mol-1	1	Yes	Yes	0.00136 mg/mL	3.99	-5.4	18.3	-1.4	BE0004797		1. GABA(A) Receptor (Protein Group)
C20H24O6	Not Available	Not Available	360.406	CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O	Not Available	Not Available					50241049	9747	CHEMBL463763	97099				C09204					107985	347828340				Triptolide	ZINC000008234271		Triptolide	Investigational	DB12025	InChI=1S/C20H24O6/c1-8(2)18-13(25-18)14-20(26-14)17(3)5-4-9-10(7-23-15(9)21)11(17)6-12-19(20,24-12)16(18)22/h8,11-14,16,22H,4-7H2,1-3H3/t11-,12-,13-,14-,16+,17-,18-,19+,20+/m0/s1	DFBIRQPKNDILPW-CIVMWXNOSA-N	3		Not Available	Small Molecule																																			1	Yes	5	1	No	7	0	84.12 Å2	37.14 Å3	87.26 m3·mol-1	1	Yes	No	0.886 mg/mL	1.33	-2.6	12.54	-3.8			
C26H36F2O6	Not Available	Not Available	482.565	CC(C)OC(=O)CCC[C@H]1CC[C@H]2[C@H](C[C@@H](O)[C@@H]2\C=C\[C@@H](O)COC2=CC(F)=CC=C2F)OC1	Not Available	Not Available								32698273									50902259	347828354							Sepetaprost	Investigational	DB12043	InChI=1S/C26H36F2O6/c1-16(2)34-26(31)5-3-4-17-6-9-21-20(23(30)13-24(21)32-14-17)10-8-19(29)15-33-25-12-18(27)7-11-22(25)28/h7-8,10-12,16-17,19-21,23-24,29-30H,3-6,9,13-15H2,1-2H3/b10-8+/t17-,19+,20+,21+,23+,24-/m0/s1	BKVUSNOUTQMSBE-XCMGCKIWSA-N	2		Not Available	Small Molecule																																			1	No	5	2	Yes	3	0	85.22 Å2	51.45 Å3	124.09 m3·mol-1	11	Yes	No	0.00652 mg/mL	3.7	-4.9	14.01	-2.9			
C21H28O4	Not Available	Not Available	344.451	C[C@]12CC=C3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO	Not Available	Not Available							CHEMBL2348782	5428328									7074810	347828387				Anecortave_acetate	ZINC000003927675		Anecortave	Investigational	DB12081	InChI=1S/C21H28O4/c1-19-8-5-14(23)11-13(19)3-4-15-16(19)6-9-20(2)17(15)7-10-21(20,25)18(24)12-22/h6,11,15,17,22,25H,3-5,7-10,12H2,1-2H3/t15-,17+,19+,20+,21+/m1/s1	BCFCRXOJOFDUMZ-ONKRVSLGSA-N			Not Available	Small Molecule																																			1	Yes	4	2	No	4	0	74.6 Å2	38.24 Å3	96.66 m3·mol-1	2	Yes	No	0.0334 mg/mL	2.18	-4	12.58	-3.3			
C20H26O2	Not Available	Not Available	298.426	CC1=CC(=O)C=C2CC[C@H]3[C@@H]4CCC(=O)[C@@]4(C)CC[C@@H]3[C@@]12C	Not Available	Not Available							CHEMBL2105987	51438									57050	347828479				Atamestane	ZINC000004214890		Atamestane	Investigational	DB12194	InChI=1S/C20H26O2/c1-12-10-14(21)11-13-4-5-15-16-6-7-18(22)19(16,2)9-8-17(15)20(12,13)3/h10-11,15-17H,4-9H2,1-3H3/t15-,16-,17-,19-,20-/m0/s1	PEPMWUSGRKINHX-TXTPUJOMSA-N	3		Not Available	Small Molecule																																			1	Yes	2	0	No	4	0	34.14 Å2	34.42 Å3	88.98 m3·mol-1	0	Yes	Yes	0.0156 mg/mL	4.17	-4.3	18.79	-4.9			
C22H28O3	Not Available	Not Available	340.4559	[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=CC2=CC(=O)CC[C@]12C	Not Available	Not Available						135445	CHEMBL1463345	13192			HMDB0003033						13789	347828500		1982		Canrenone	ZINC000003881648		Canrenone	Investigational	DB12221	InChI=1S/C22H28O3/c1-20-9-5-15(23)13-14(20)3-4-16-17(20)6-10-21(2)18(16)7-11-22(21)12-8-19(24)25-22/h3-4,13,16-18H,5-12H2,1-2H3/t16-,17+,18+,20+,21+,22-/m1/s1	UJVLDDZCTMKXJK-WNHSNXHDSA-N	4	Canrenone is an antimineralocorticoid and active metabolite of spironolactone used in the treatment of primary hyperaldosteronism and edematous states caused by secondary hyperaldosteronism (e.g. heart failure).	Not Available	Small Molecule																																			1	Yes	2	0	No	5	0	43.37 Å2	38.67 Å3	97.48 m3·mol-1	0	Yes	No	0.0042 mg/mL	3.6	-4.9		-4.8			
C18H24O4	Not Available	The elimination half-life of estetrol is approximately 27 hours.13 Half-life may range between 19-40 hours.7	304.3808	[H][C@@]12[C@@H](O)[C@@H](O)[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3CC[C@@]21[H]	Solid	Limited distribution of estetrol into red blood cells has been demonstrated.17	P08684;!P16662	CYP3A4;!UGT2B7	1. Cytochrome P450 3A4;!2. UDP-glucuronosyltransferase 2B7		158505	142773	CHEMBL1230314	25245						4OH			27125	347828514		2539031		Estetrol	ZINC000005764481	Nextstellis 28 Day	Estetrol	Approved, Investigational	DB12235	InChI=1S/C18H24O4/c1-18-7-6-12-11-5-3-10(19)8-9(11)2-4-13(12)14(18)15(20)16(21)17(18)22/h3,5,8,12-17,19-22H,2,4,6-7H2,1H3/t12-,13-,14-,15-,16-,17+,18+/m1/s1	AJIPIJNNOJSSQC-NYLIRDPKSA-N	3	Estetrol is an estrogen used in combination with drospirenone for oral contraception.	LD50 information for estetrol is not readily available in the literature. Subjects receiving a dose of 20 mg, 40 mg or 60 mg of estetrol per day over 12 weeks were tolerated without dose-limiting toxicity.10 Symptoms that may occur in association with overdose, based on existing information on overdosage with oral contraceptives include nausea, vomiting, and vaginal bleeding. In one clinical study, 1 of 32 healthy research subjects receiving a dose of 75 mg of estretol with 15 mg of drospirenone for 10 days experienced deep vein thrombosis of the lower right limb. There is no known antidote to an estretol overdose; conduct laboratory testing for electrolytes and evidence of metabolic acidosis and provide symptomatic treatment.17	Small Molecule																													491.9±45.0	2.62		233-236	10.22±0.70		1	Yes	4	4	No	4	0	80.92 Å2	33.88 Å3	82.55 m3·mol-1	0	Yes	No		1.67		10.33	-3.3	P03372;!Q92731	ESR1;!ESR2	Details1. Estrogen receptor alpha;!2. Estrogen receptor beta
C20H24O7	Not Available	Not Available	376.405	CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@@]3(O)C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O	Not Available	Not Available							CHEMBL3358841	8492847									10317383	347828527					ZINC000043203993		PG-701	Investigational	DB12252	InChI=1S/C20H24O7/c1-8(2)18-12(26-18)13-20(27-13)16(3)5-4-9-10(7-24-14(9)21)17(16,23)6-11-19(20,25-11)15(18)22/h8,11-13,15,22-23H,4-7H2,1-3H3/t11-,12-,13-,15+,16-,17+,18-,19+,20+/m0/s1	OKRSVUYYCJPECG-LFGMFVMYSA-N	2		Not Available	Small Molecule																																			1	Yes	6	2	No	7	0	104.35 Å2	37.8 Å3	88.59 m3·mol-1	1	Yes	No	3.04 mg/mL	0.25	-2.1	12.07	-3.4			
C21H34O2	Not Available	Not Available	318.501	[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@]2([H])C[C@H](O)CC[C@]12C	Not Available	Not Available						1712	CHEMBL210952	29132			HMDB0062782			P9N			31402	347828573				Pregnanolone	ZINC000003800039		Eltanolone	Investigational	DB12308	InChI=1S/C21H34O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h14-19,23H,4-12H2,1-3H3/t14-,15-,16+,17-,18+,19+,20+,21-/m1/s1	AURFZBICLPNKBZ-YZRLXODZSA-N			Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	38.36 Å3	92.91 m3·mol-1	1	Yes	Yes	0.00136 mg/mL	3.99	-5.4	18.3	-1.4			
C31H39F2NO6	Not Available	Not Available	559.651	C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)C1C(C)(C)C1(C)C)C(=O)OCC#N	Not Available	Not Available								9551309									11376392	347828585							GW-870086	Investigational	DB12322	InChI=1S/C31H39F2NO6/c1-16-12-18-19-14-21(32)20-13-17(35)8-9-28(20,6)30(19,33)22(36)15-29(18,7)31(16,25(38)39-11-10-34)40-24(37)23-26(2,3)27(23,4)5/h8-9,13,16,18-19,21-23,36H,11-12,14-15H2,1-7H3/t16-,18+,19+,21+,22+,28+,29+,30+,31+/m1/s1	WUBKGTSFJSEIEM-NSHBDUGJSA-N	2		Not Available	Small Molecule																																			1	No	5	1	Yes	5	0	113.69 Å2	57.69 Å3	141.49 m3·mol-1	6	No	No	0.0084 mg/mL	3.91	-4.8	13.56	-3.4			
C23H28O8	Not Available	Not Available	432.469	COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@@H](C[C@]21C)C1=COC=C1	Not Available	Not Available					50159165	67900	CHEMBL445332	113947									128563	347828589				Salvinorin_A	ZINC000013607514		Salvinorin A	Investigational	DB12327	InChI=1S/C23H28O8/c1-12(24)30-16-9-15(20(26)28-4)22(2)7-5-14-21(27)31-17(13-6-8-29-11-13)10-23(14,3)19(22)18(16)25/h6,8,11,14-17,19H,5,7,9-10H2,1-4H3/t14-,15-,16-,17-,19-,22-,23-/m0/s1	OBSYBRPAKCASQB-AGQYDFLVSA-N	2		Not Available	Small Molecule																																			1	Yes	4	0	No	4	0	109.11 Å2	44.17 Å3	106 m3·mol-1	5	Yes	No	0.08 mg/mL	2.39	-3.7	16.45	-2.9			
C23H34O4	Not Available	Not Available	374.521	C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@]2(O)C1=COC=C1	Not Available	Not Available							CHEMBL2068971	135709						E4R		PA166129554	153976	347828605				Rostafuroxin	ZINC000003802462		Rostafuroxin	Investigational	DB12350	InChI=1S/C23H34O4/c1-20-8-5-17(24)13-15(20)3-4-19-18(20)6-9-21(2)22(25,10-11-23(19,21)26)16-7-12-27-14-16/h7,12,14-15,17-19,24-26H,3-6,8-11,13H2,1-2H3/t15-,17+,18+,19-,20+,21-,22+,23+/m1/s1	AEAPORIZZWBIEX-DTBDINHYSA-N	2		Not Available	Small Molecule																																			1	Yes	3	3	No	5	0	73.83 Å2	41.79 Å3	103.1 m3·mol-1	1	Yes	No	0.0347 mg/mL	2.91	-4	13.22	-1.3			
C30H41NO6S	Not Available	Not Available	543.72	C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](CC=C)[C@H]1O)C1=CC=C2SC(C)=NC2=C1	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4				CHEMBL2304041	9459163									11284169	347828638					ZINC000003964449		Sagopilone	Investigational	DB12391	InChI=1S/C30H41NO6S/c1-7-9-20-27(34)17(2)10-8-13-30(6)25(37-30)15-22(19-11-12-23-21(14-19)31-18(3)38-23)36-26(33)16-24(32)29(4,5)28(20)35/h7,11-12,14,17,20,22,24-25,27,32,34H,1,8-10,13,15-16H2,2-6H3/t17-,20+,22-,24-,25-,27-,30+/m0/s1	BFZKMNSQCNVFGM-UCEYFQQTSA-N	2		Not Available	Small Molecule																																			0	No	6	2	No	4	0	109.25 Å2	59.69 Å3	145.71 m3·mol-1	3	No	No	0.0024 mg/mL	5.1	-5.4	14.08	2.88			
C32H50O13	Not Available	Not Available	642.739	C[C@@]12CCC[C@](C)([C@H]1CC[C@@]13CC(=C)[C@@](C1)(CC[C@@H]23)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C(O)=O	Not Available	Not Available						145030		10209449						JC6			16401639	347828676							Steviolbioside	Approved, Investigational	DB12434	InChI=1S/C32H50O13/c1-15-11-31-9-5-18-29(2,7-4-8-30(18,3)28(40)41)19(31)6-10-32(15,14-31)45-27-25(23(38)21(36)17(13-34)43-27)44-26-24(39)22(37)20(35)16(12-33)42-26/h16-27,33-39H,1,4-14H2,2-3H3,(H,40,41)/t16-,17-,18+,19+,20-,21-,22+,23+,24-,25-,26+,27+,29-,30-,31-,32+/m1/s1	OMHUCGDTACNQEX-OSHKXICASA-N			Not Available	Small Molecule																																			0	No	13	8	Yes	6	-1	215.83 Å2	67.26 Å3	153.72 m3·mol-1	7	No	No	1.37 mg/mL	0.11	-2.7	4.59	-3			
C20H28O	Not Available	Not Available	284.443	C[C@]12CC[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C	Not Available	Not Available	P08684;!P11712;!P33261	CYP3A4;!CYP2C9;!CYP2C19	1. Cytochrome P450 3A4;!2. Cytochrome P450 2C9;!3. Cytochrome P450 2C19			31790	CHEMBL2107431	5648				C13037					5857	347828712		6529		Lynestrenol	ZINC000003875355		Lynestrenol	Approved, Investigational	DB12474	InChI=1S/C20H28O/c1-3-20(21)13-11-18-17-9-8-14-6-4-5-7-15(14)16(17)10-12-19(18,20)2/h1,6,15-18,21H,4-5,7-13H2,2H3/t15-,16+,17+,18-,19-,20-/m0/s1	YNVGQYHLRCDXFQ-XGXHKTLJSA-N	4	Lynestrenol is a progestin used for contraception and in the treatment of menstrual disorders.	Not Available	Small Molecule																																			1	Yes	1	1	No	4	0	20.23 Å2	34.69 Å3	86.81 m3·mol-1	0	Yes	Yes	0.00366 mg/mL	4.04	-4.9	17.59	-1.7			
C30H48O3	Not Available	Not Available	456.711	[H]OC(=O)[C@]12CC[C@@]([H])(C(C)=C)[C@]1([H])[C@@]1([H])CC[C@]3([H])[C@@]4(C)CC[C@]([H])(O[H])C(C)(C)[C@]4([H])CC[C@@]3(C)[C@]1(C)CC2	Not Available	Not Available					23208	3087	CHEMBL269277	58496			HMDB0030094	C08619					64971	347828718					ZINC000004097714		Betulinic Acid	Approved, Investigational	DB12480	InChI=1S/C30H48O3/c1-18(2)19-10-15-30(25(32)33)17-16-28(6)20(24(19)30)8-9-22-27(5)13-12-23(31)26(3,4)21(27)11-14-29(22,28)7/h19-24,31H,1,8-17H2,2-7H3,(H,32,33)/t19-,20+,21-,22+,23-,24+,27-,28+,29+,30-/m0/s1	QGJZLNKBHJESQX-FZFNOLFKSA-N	3		Not Available	Small Molecule																																			1	No	3	2	No	5	-1	57.53 Å2	54.64 Å3	132.63 m3·mol-1	2	No	No	0.000204 mg/mL	6.64	-6.4	4.75	-0.84			
C22H32O2	Not Available	Not Available	328.496	[H][C@@]12CC[C@H](OC)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(OCCC)C=C3	Not Available	Not Available						135402	CHEMBL2105394	8059589										347911337		34625		Promestriene	ZINC000001999256		Promestriene	Investigational	DB12487	InChI=1S/C22H32O2/c1-4-13-24-16-6-8-17-15(14-16)5-7-19-18(17)11-12-22(2)20(19)9-10-21(22)23-3/h6,8,14,18-21H,4-5,7,9-13H2,1-3H3/t18-,19-,20+,21+,22+/m1/s1	IUWKNLFTJBHTSD-AANPDWTMSA-N	4	Promestriene is a synthetic estrogen applied topically for the treatment of vulvovaginal atrophic symptoms and to speed wound healing following vulvovaginal surgery or trauma (e.g. post-partum).	Not Available	Small Molecule																																			1	Yes	2	0	No	4	0	18.46 Å2	40.9 Å3	98.41 m3·mol-1	4	No	Yes	8.81e-06 mg/mL	5.41	-7.6		-4			
C24H34O5	There is limited information on clearance of clascoterone.10	There is limited information on the half life of clascoterone.10	402.531	[H][C@@]12CC[C@](OC(=O)CC)(C(=O)CO)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	There is no information available on the volume of distribution.	P05177;!P20813;!P10632;!P11712;!P33261;!P10635;!P05181;!P08684	CYP1A2;!CYP2B6;!CYP2C8;!CYP2C9;!CYP2C19;!CYP2D6;!CYP2E1;!CYP3A4	1. Cytochrome P450 1A2;!2. Cytochrome P450 2B6;!3. Cytochrome P450 2C8;!4. Cytochrome P450 2C9;!  Details5. Cytochrome P450 2C19;!6. Cytochrome P450 2D6;!7. Cytochrome P450 2E1;!8. Cytochrome P450 3A4				CHEMBL3590187	9924713									11750009	347828732		2474340		Clascoterone	ZINC000006716459	Winlevi	Clascoterone	Approved, Investigational	DB12499	InChI=1S/C24H34O5/c1-4-21(28)29-24(20(27)14-25)12-9-19-17-6-5-15-13-16(26)7-10-22(15,2)18(17)8-11-23(19,24)3/h13,17-19,25H,4-12,14H2,1-3H3/t17-,18+,19+,22+,23+,24+/m1/s1	GPNHMOZDMYNCPO-PDUMRIMRSA-N	3	Clascoterone is an androgen receptor antagonist used for the topical treatment of acne vulgaris in patients 12 years of age and older.	There is no information available on the toxicity profile of clascoterone, such as LD50 and overdose in humans.	Small Molecule																																			1	Yes	4	1	No	4	0	80.67 Å2	44.86 Å3	109.59 m3·mol-1	5	Yes	No	0.00753 mg/mL	3.73	-4.7	13.78	-3.3	P10275	AR	1. Androgen receptor
C21H26F2O6	Not Available	Not Available	412.43	C[C@]12C[C@H](O)[C@@]3(F)[C@@H](C[C@H](F)C4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO	Not Available	Not Available						5108	CHEMBL1201390	82611				C07006					91488	347828777		25126		Fluocinolone	ZINC000004097307		Fluocinolone	Investigational	DB12553	InChI=1S/C21H26F2O6/c1-18-4-3-10(25)5-13(18)14(22)6-12-11-7-15(26)21(29,17(28)9-24)19(11,2)8-16(27)20(12,18)23/h3-5,11-12,14-16,24,26-27,29H,6-9H2,1-2H3/t11-,12-,14-,15+,16-,18-,19-,20-,21-/m0/s1	UUOUOERPONYGOS-CLCRDYEYSA-N	1		Not Available	Small Molecule																																			1	Yes	6	4	No	4	0	115.06 Å2	40.14 Å3	99.21 m3·mol-1	2	Yes	No	0.342 mg/mL	-0.098	-3.1	11.75	-3.3			
C29H35NO8	Not Available	Not Available	525.598	COC[C@H]1OC(=O)\C(=C\N(CC=C)CC=C)C2=C(O)C(=O)C3=C([C@@H](C[C@@]4(C)[C@H]3CCC4=O)OC(C)=O)[C@@]12C	Not Available	Not Available						65345	CHEMBL411907	8025448									9849735	347828818					ZINC000029134545		Sonolisib	Investigational	DB12601	InChI=1S/C29H35NO8/c1-7-11-30(12-8-2)14-17-23-26(34)25(33)22-18-9-10-20(32)28(18,4)13-19(37-16(3)31)24(22)29(23,5)21(15-36-6)38-27(17)35/h7-8,14,18-19,21,34H,1-2,9-13,15H2,3-6H3/b17-14+/t18-,19+,21+,28-,29-/m0/s1	QIUASFSNWYMDFS-NILGECQDSA-N	2		Not Available	Small Molecule																																			1	No	7	1	Yes	4	0	119.44 Å2	54.57 Å3	141.15 m3·mol-1	9	No	No	0.0267 mg/mL	2.51	-4.3	8.49	-2.8			
C30H50O	Not Available	Not Available	426.729	[H][C@]12[C@@H](CC[C@]1(C)CC[C@]1(C)[C@]2([H])CC[C@]2([H])[C@@]3(C)CC[C@H](O)C(C)(C)[C@]3([H])CC[C@@]12C)C(C)=C	Not Available	Not Available					50377927	6570	CHEMBL289191	228079				C08628					259846	347828834				Lupeol	ZINC000004081455		Lupeol	Investigational	DB12622	InChI=1S/C30H50O/c1-19(2)20-11-14-27(5)17-18-29(7)21(25(20)27)9-10-23-28(6)15-13-24(31)26(3,4)22(28)12-16-30(23,29)8/h20-25,31H,1,9-18H2,2-8H3/t20-,21+,22-,23+,24-,25+,27+,28-,29+,30+/m0/s1	MQYXUWHLBZFQQO-QGTGJCAVSA-N	-Infinity		Not Available	Small Molecule																																			1	No	1	1	No	5	0	20.23 Å2	53.79 Å3	130.91 m3·mol-1	1	No	Yes	0.000195 mg/mL	7.45	-6.3	19.49	-0.84			
C29H39NO3	Not Available	Not Available	449.635	CN(C)C1=CC=C(C=C1)[C@H]1C[C@]2(C)[C@@H](CC[C@]2(O)CCCO)[C@@H]2CCC3=CC(=O)CCC3=C12	Not Available	Not Available					50366558		CHEMBL1908373	4470982									5311505	347828846				Onapristone	ZINC000003831947		Onapristone	Investigational	DB12637	InChI=1S/C29H39NO3/c1-28-18-25(19-5-8-21(9-6-19)30(2)3)27-23-12-10-22(32)17-20(23)7-11-24(27)26(28)13-15-29(28,33)14-4-16-31/h5-6,8-9,17,24-26,31,33H,4,7,10-16,18H2,1-3H3/t24-,25+,26-,28+,29+/m0/s1	IEXUMDBQLIVNHZ-YOUGDJEHSA-N			Not Available	Small Molecule																																			1	No	4	2	No	5	0	60.77 Å2	52.99 Å3	135.3 m3·mol-1	5	Yes	No	0.00759 mg/mL	3.96	-4.8	14.34	4.89	P04150;!Q6QNK2	NR3C1;!ADGRD1	1. Glucocorticoid receptor;!2. Probable G-protein coupled receptor 133
C31H41NO4	Not Available	Not Available	491.672	CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O	Not Available	Not Available							CHEMBL1093059	354529									400010	347828858				Bardoxolone_methyl	ZINC000006019135		Bardoxolone	Investigational	DB12651	InChI=1S/C31H41NO4/c1-26(2)10-12-31(25(35)36)13-11-30(7)23(19(31)16-26)20(33)14-22-28(5)15-18(17-32)24(34)27(3,4)21(28)8-9-29(22,30)6/h14-15,19,21,23H,8-13,16H2,1-7H3,(H,35,36)/t19-,21-,23-,28-,29+,30+,31-/m0/s1	TXGZJQLMVSIZEI-UQMAOPSPSA-N			Not Available	Small Molecule																																			1	No	5	1	No	5	-1	95.23 Å2	56.02 Å3	139.59 m3·mol-1	1	No	No	0.00401 mg/mL	6.4	-5.1	4.6	-5.3	Q14790	CASP8	1. Caspase-8
C20H30O2	Not Available	Not Available	302.458	CC[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C	Not Available	Not Available						135282	CHEMBL1697845	5649									5858	347828967		7513		Norethandrolone	ZINC000003875356		Norethandrolone	Investigational	DB12787	InChI=1S/C20H30O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h12,15-18,22H,3-11H2,1-2H3/t15-,16+,17+,18-,19-,20-/m0/s1	ZDHCJEIGTNNEMY-XGXHKTLJSA-N	3		Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	36.28 Å3	89.12 m3·mol-1	1	Yes	Yes	0.0174 mg/mL	3.87	-4.2	19.28	-0.27			
C28H45NO5S	The total body clearance of lefamulin has been determined to range from 2.94 to 30.0 L/h after an injected dose.11	The average elimination half-life of lefamulin is about 8 hours in patients diagnosed with community-acquired bacterial pneumonia.11 One pharmacokinetic study of healthy volunteers revealed a mean half-life of 13.2 hours after an intravenous infusion of lefamulin.7	507.73	[H][C@@]12C(=O)CC[C@]11CCC(C)[C@@]2(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]1C)OC(=O)CS[C@@H]1CC[C@@H](N)C[C@H]1O	Solid	The average volume of distribution of lefamulin is 86.1 L in patients with community-acquired bacterial pneumonia, but can range from 34.2 to 153 L.11 During clinical studies, lefamulin has been shown to significantly concentrate in the lung tissue, likely increasing its effectiveness in treating pneumonia.3 After lefamulin is administered, penetration into various tissues is observed, and is about 6 times greater in concentration in the fluid of the pulmonary epithelium, when compared with concentrations in the plasma.8 Animal studies demonstrate that lefamulin crosses the placenta.11	P08684	CYP3A4	1. Cytochrome P450 3A4		50019649		CHEMBL3291398							62B			25185057	347828993		2198944		Lefamulin		Xenleta	Lefamulin	Approved, Investigational	DB12825	InChI=1S/C28H45NO5S/c1-6-26(4)14-22(34-23(32)15-35-21-8-7-18(29)13-20(21)31)27(5)16(2)9-11-28(17(3)25(26)33)12-10-19(30)24(27)28/h6,16-18,20-22,24-25,31,33H,1,7-15,29H2,2-5H3/t16?,17-,18+,20+,21+,22+,24-,25-,26+,27-,28-/m0/s1	KPVIXBKIJXZQJX-CSOZIWFHSA-N	3	Lefamulin is a pleuromutilin antibacterial used to treat community-acquired bacterial pneumonia (CABP).	In the case of overdose with lefamulin, the patient should be monitored closely and provided with supportive treatment, according to symptoms and signs. This drug and its active metabolite are not removable by dialysis.11	Small Molecule																													618.6±55.0	3.72			9.41		1	No	5	3	Yes	4	1	109.85 Å2	57.34 Å3	138.86 m3·mol-1	6	No	No	0.00494 mg/mL	2.9	-5	14.19	10.08	P61182	rplV	1. 50S ribosomal protein L22
C35H45Cl2NO6	Not Available	Not Available	646.65	[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCCC3=CC=C(C=C3)N(CCCl)CCCl)[C@@]1(C)C[C@]([H])(O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Not Available	Not Available						82524	CHEMBL2103751	31708				C19512					34457	347828998		8637		Prednimustine	ZINC000004214173		Prednimustine	Investigational	DB12832	InChI=1S/C35H45Cl2NO6/c1-33-14-12-26(39)20-24(33)8-11-27-28-13-15-35(43,34(28,2)21-29(40)32(27)33)30(41)22-44-31(42)5-3-4-23-6-9-25(10-7-23)38(18-16-36)19-17-37/h6-7,9-10,12,14,20,27-29,32,40,43H,3-5,8,11,13,15-19,21-22H2,1-2H3/t27-,28-,29-,32+,33-,34-,35-/m0/s1	HFVNWDWLWUCIHC-GUPDPFMOSA-N			Not Available	Small Molecule																																			0	No	6	2	Yes	5	0	104.14 Å2	69.68 Å3	174.68 m3·mol-1	13	No	No	0.000642 mg/mL	5.87	-6	12.61	1.72			
C32H48O9	Not Available	Not Available	576.727	CO[C@H]1C[C@H](O[C@H]2CC[C@@]3(C)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H]([C@H](C[C@]43O)OC(C)=O)C3=CC(=O)OC3)C2)O[C@@H](C)[C@@H]1O	Not Available	Not Available						59030	CHEMBL1075789	9716290									11541511	347829006				Oleandrin	ZINC000008214621		Oleandrin	Experimental, Investigational	DB12843	InChI=1S/C32H48O9/c1-17-29(35)24(37-5)14-27(39-17)41-21-8-10-30(3)20(13-21)6-7-23-22(30)9-11-31(4)28(19-12-26(34)38-16-19)25(40-18(2)33)15-32(23,31)36/h12,17,20-25,27-29,35-36H,6-11,13-16H2,1-5H3/t17-,20+,21-,22-,23+,24-,25-,27-,28-,29-,30-,31+,32-/m0/s1	JLPDBLFIVFSOCC-XYXFTTADSA-N			Not Available	Small Molecule																																			1	No	7	2	Yes	6	-1	120.75 Å2	63.2 Å3	148.45 m3·mol-1	6	No	No	0.00299 mg/mL	2.95	-5.3	6.82	-3.2			
C22H28O5	Not Available	Not Available	372.461	C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)CC(=O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4					110996									124653	347829094					ZINC000004744090		Methylprednisone	Approved, Investigational	DB12952	InChI=1S/C22H28O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,19,23,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,19+,20-,21-,22-/m0/s1	SVYCRJXQZUCUND-PQXSVQADSA-N	4		Not Available	Small Molecule																																			1	Yes	5	2	No	4	0	91.67 Å2	40.27 Å3	102.12 m3·mol-1	2	Yes	No	0.0587 mg/mL	1.95	-3.8	12.58	-3.3			
C21H34O2	Not Available	Not Available	318.4935	[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@@H](O)CC[C@]12C	Not Available	Not Available					50388495	11909	CHEMBL2057301	83761			HMDB0001455	C15484					92787	347829112				Isopregnanolone	ZINC000003833954		Sepranolone	Investigational	DB12972	InChI=1S/C21H34O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h14-19,23H,4-12H2,1-3H3/t14-,15-,16-,17+,18-,19-,20-,21+/m0/s1	AURFZBICLPNKBZ-FZCSVUEKSA-N	2		Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	38.66 Å3	92.91 m3·mol-1	1	Yes	Yes	0.00136 mg/mL	3.99	-5.4	18.3	-1.4			
C20H35NO2	Not Available	Not Available	321.505	C[C@]12CC[C@@H]([C@@H](CN)[C@@H]1CCC2=C)[C@@]1(C)CC[C@H](O)C[C@@H]1CO	Not Available	Not Available							CHEMBL3989954	34986541									76965484	347829148							AQX-1125	Investigational	DB13012	InChI=1S/C20H35NO2/c1-13-4-5-17-16(11-21)18(7-9-19(13,17)2)20(3)8-6-15(23)10-14(20)12-22/h14-18,22-23H,1,4-12,21H2,2-3H3/t14-,15+,16+,17+,18+,19-,20+/m1/s1	MDEJTPWQNNMAQF-BVMLLJBZSA-N	2		Not Available	Small Molecule																																			1	Yes	3	3	No	3	1	66.48 Å2	38.8 Å3	94.6 m3·mol-1	3	Yes	No	0.0202 mg/mL	2.01	-4.2	15.04	10.2			
C15H20O3	Not Available	Not Available	248.3175	C\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1	Not Available	Not Available					50433441		CHEMBL540445	20126246				C07609					6473881	347829191		32941		Parthenolide	ZINC000030726283		Parthenolide	Approved, Investigational	DB13063	InChI=1S/C15H20O3/c1-9-5-4-8-15(3)13(18-15)12-11(7-6-9)10(2)14(16)17-12/h5,11-13H,2,4,6-8H2,1,3H3/b9-5+/t11-,12-,13-,15+/m0/s1	KTEXNACQROZXEV-SLXBATTESA-N	2		Not Available	Small Molecule																																			1	Yes	2	0	No	3	0	38.83 Å2	26.87 Å3	68.55 m3·mol-1	0	Yes	Yes	0.196 mg/mL	3.07	-3.1		-4.2			
C27H39NO6	Not Available	Not Available	473.61	C[C@H]1\C=C/C\C(C)=C/C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\C1=NOC(C)=C1	Not Available	Not Available								34986490									71587784	347829205							KOSN-1724	Investigational	DB13078	InChI=1S/C27H39NO6/c1-16-9-8-10-17(2)25(31)20(5)26(32)27(6,7)23(29)15-24(30)33-22(12-11-16)18(3)13-21-14-19(4)34-28-21/h8,10-11,13-14,17,20,22-23,25,29,31H,9,12,15H2,1-7H3/b10-8-,16-11-,18-13+/t17-,20+,22-,23-,25-/m0/s1	JAYGOFBXDFAXBW-CYEKYUJNSA-N			Not Available	Small Molecule																																			1	No	5	2	No	2	0	109.86 Å2	52.7 Å3	134.1 m3·mol-1	2	Yes	No	0.0286 mg/mL	4.52	-4.2	14.06	0.8			
C30H46O4	Not Available	Not Available	470.694	[H][C@@]12C[C@](C)(CC[C@]1(C)CC[C@]1(C)C2=CC(=O)[C@]2([H])[C@@]3(C)CC[C@H](O)C(C)(C)[C@]3([H])CC[C@@]12C)C(O)=O	Not Available	Not Available					50233538	30853	CHEMBL230006	9710				C02283		CBW			10114	347829213		1311506		Enoxolone	ZINC000019203131		Enoxolone	Investigational	DB13089	InChI=1S/C30H46O4/c1-25(2)21-8-11-30(7)23(28(21,5)10-9-22(25)32)20(31)16-18-19-17-27(4,24(33)34)13-12-26(19,3)14-15-29(18,30)6/h16,19,21-23,32H,8-15,17H2,1-7H3,(H,33,34)/t19-,21-,22-,23+,26+,27-,28-,29+,30+/m0/s1	MPDGHEJMBKOTSU-YKLVYJNSSA-N	3		Not Available	Small Molecule																																			1	No	4	2	No	5	-1	74.6 Å2	55.22 Å3	134.27 m3·mol-1	1	No	No	0.00172 mg/mL	6.03	-5.4	4.44	-0.84			
C29H48O2	Not Available	Not Available	428.701	CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C)C(C)C	Not Available	Not Available								8201186									10025615	347829221							1alpha-Hydroxyvitamin D5	Investigational	DB13097	InChI=1S/C29H48O2/c1-7-22(19(2)3)11-10-20(4)26-14-15-27-23(9-8-16-29(26,27)6)12-13-24-17-25(30)18-28(31)21(24)5/h12-13,19-20,22,25-28,30-31H,5,7-11,14-18H2,1-4,6H3/b23-12+,24-13-/t20-,22-,25-,26-,27+,28+,29-/m1/s1	NWFOBODUYTUMNC-VPSCEVSQSA-N	1		Not Available	Small Molecule																																			1	No	2	2	Yes	3	0	40.46 Å2	54.09 Å3	133.85 m3·mol-1	7	No	No	0.000923 mg/mL	6.55	-5.7	14.39	-2.8			
C22H30O3	Not Available	Not Available	342.479	C[C@H](O)C(=O)[C@@]1(C)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3CC[C@]12C	Not Available	Not Available						136027	CHEMBL2104765	62152									68926	347829250				Trimegestone	ZINC000004217604		Trimegestone	Investigational	DB13129	InChI=1S/C22H30O3/c1-13(23)20(25)22(3)11-9-19-18-6-4-14-12-15(24)5-7-16(14)17(18)8-10-21(19,22)2/h12-13,18-19,23H,4-11H2,1-3H3/t13-,18+,19-,21-,22+/m0/s1	JUNDJWOLDSCTFK-MTZCLOFQSA-N	4		Not Available	Small Molecule																																			1	Yes	3	1	No	4	0	54.37 Å2	39.44 Å3	99.51 m3·mol-1	2	Yes	No	0.0188 mg/mL	3.71	-4.3	13.7	-3.4			
C18H26O2	Not Available	Not Available	274.3978	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	Solid	Not Available					50080092	7466	CHEMBL757	9520			HMDB0002725	C07254		6VW		PA164746281	9904	347829275		7244		Nandrolone	ZINC000003814379		Nandrolone	Experimental, Investigational	DB13169	InChI=1S/C18H26O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h10,13-17,20H,2-9H2,1H3/t13-,14+,15+,16-,17-,18-/m0/s1	NPAGDVCDWIYMMC-IZPLOLCNSA-N	3	Nandrolone is an anabolic steroid indicated to increase bone density and muscle mass in patients with osteoporosis.	Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	32.27 Å3	79.95 m3·mol-1	0	Yes	Yes	0.0561 mg/mL	3.07	-3.7	18.25	-0.88			
C26H38O4	The elimination on the first day following intravenous injection of oxabolone cipionate is slow and reaches a rapid excretion phase with the maximum urinary level in the fifth day of administration 2.	Not Available	414.586	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=C(O)C(=O)CC[C@]4([H])[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1	Solid	Not Available						31940	CHEMBL2105318	62175									68952	347829285				Oxabolone_cipionate	ZINC000026892649		Oxabolone cipionate	Experimental	DB13185	InChI=1S/C26H38O4/c1-26-15-14-18-17-9-11-22(27)25(29)20(17)8-7-19(18)21(26)10-12-23(26)30-24(28)13-6-16-4-2-3-5-16/h16-19,21,23,29H,2-15H2,1H3/t17-,18-,19-,21+,23+,26+/m1/s1	KHKDIUPVDIEHAH-KXLSUQFWSA-N			Not Available	Small Molecule																																			1	Yes	3	1	No	5	0	63.6 Å2	48.9 Å3	116.85 m3·mol-1	5	No	No	0.00377 mg/mL	5.29	-5	9.23	-3.7			
C22H27FO5	Not Available	Not Available	390.451	C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]2(C)[C@H]1C(=O)C(O)=O	Not Available	Not Available								18865233					D07972									Fluocortin	ZINC000006031566		Fluocortin	Experimental	DB13223	InChI=1S/C22H27FO5/c1-10-6-13-12-8-15(23)14-7-11(24)4-5-21(14,2)18(12)16(25)9-22(13,3)17(10)19(26)20(27)28/h4-5,7,10,12-13,15-18,25H,6,8-9H2,1-3H3,(H,27,28)/t10-,12+,13+,15+,16+,17-,18-,21+,22+/m1/s1	PUWHHWCHAVXSIG-NCLPIGKXSA-N			Not Available	Small Molecule																																			1	Yes	5	2	No	4	-1	91.67 Å2	40.21 Å3	101.56 m3·mol-1	2	Yes	No	0.0302 mg/mL	2.74	-4.1	3.73	-0.23			
C20H28O3	Not Available	Not Available	316.441	[H][C@@]12CC[C@](O)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	Not Available	Not Available						135991	CHEMBL3707212	92341												4793		Gestronol	ZINC000005167250		Gestonorone	Experimental	DB13230	InChI=1S/C20H28O3/c1-12(21)20(23)10-8-18-17-5-3-13-11-14(22)4-6-15(13)16(17)7-9-19(18,20)2/h11,15-18,23H,3-10H2,1-2H3/t15-,16+,17+,18-,19-,20-/m0/s1	GTFUITFQDGVJSK-XGXHKTLJSA-N			Not Available	Small Molecule																																			1	Yes	3	1	No	4	0	54.37 Å2	36.34 Å3	89.63 m3·mol-1	1	Yes	No	0.0213 mg/mL	3.1	-4.2	12.7	-3.8			
C30H44O9	Not Available	Not Available	548.673	[H][C@@]1(CC[C@]2(O)[C@]3([H])CC[C@]4(O)C[C@H](CC[C@]4(C=O)[C@@]3([H])CC[C@]12C)O[C@H]1C[C@H](OC)[C@H](O)[C@@H](C)O1)C1=CC(=O)OC1	Not Available	Not Available						4037	CHEMBL1075788	390429				C08859										Cymarin	ZINC000008214527		Cymarin	Experimental	DB13240	InChI=1S/C30H44O9/c1-17-26(33)23(36-3)13-25(38-17)39-19-4-9-28(16-31)21-5-8-27(2)20(18-12-24(32)37-15-18)7-11-30(27,35)22(21)6-10-29(28,34)14-19/h12,16-17,19-23,25-26,33-35H,4-11,13-15H2,1-3H3/t17-,19+,20-,21+,22-,23+,25+,26-,27-,28+,29+,30+/m1/s1	XQCGNURMLWFQJR-ZNDDOCHDSA-N			Not Available	Small Molecule																																			1	No	8	3	No	6	0	131.75 Å2	58.62 Å3	140.03 m3·mol-1	5	No	No	0.0804 mg/mL	1.69	-3.8	7.18	0.27			
C30H42O8	Not Available	Not Available	530.658	[H][C@@]1(CC[C@]2(O)[C@]3([H])CCC4=C[C@]([H])(CC[C@]4(C)[C@@]3([H])CC[C@]12C)O[C@]1([H])O[C@@]([H])(C)[C@]([H])(O)[C@@]([H])(O)[C@@]1([H])O)C1=COC(=O)C=C1	Not Available	Not Available						32065	CHEMBL600325	4447658									5284613	347829292		8795		Proscillaridin	ZINC000008214665		Proscillaridin	Experimental	DB13307	InChI=1S/C30H42O8/c1-16-24(32)25(33)26(34)27(37-16)38-19-8-11-28(2)18(14-19)5-6-22-21(28)9-12-29(3)20(10-13-30(22,29)35)17-4-7-23(31)36-15-17/h4,7,14-16,19-22,24-27,32-35H,5-6,8-13H2,1-3H3/t16-,19-,20+,21-,22+,24-,25+,26+,27-,28-,29+,30-/m0/s1	MYEJFUXQJGHEQK-ALRJYLEOSA-N			Not Available	Small Molecule																																			1	No	7	4	No	6	0	125.68 Å2	58.26 Å3	140.05 m3·mol-1	3	No	No	0.0427 mg/mL	2.3	-4.1	12.22	0.3			
C19H26O3	Not Available	Not Available	302.414	COC1=CC=C2[C@H]3CC[C@]4(C)[C@H](O)[C@H](O)C[C@H]4[C@@H]3CCC2=C1	Not Available	Not Available						34738	CHEMBL2106236	214111				C14593										Epimestrol	ZINC000004215816		Epimestrol	Experimental	DB13386	InChI=1S/C19H26O3/c1-19-8-7-14-13-6-4-12(22-2)9-11(13)3-5-15(14)16(19)10-17(20)18(19)21/h4,6,9,14-18,20-21H,3,5,7-8,10H2,1-2H3/t14-,15-,16+,17-,18-,19+/m1/s1	UHQGCIIQUZBJAE-RRQVMCLOSA-N			Not Available	Small Molecule																																			1	Yes	3	2	No	4	0	49.69 Å2	35.02 Å3	85.75 m3·mol-1	1	Yes	No	0.0143 mg/mL	2.82	-4.3	13.62	-3.2			
C21H26O3	Not Available	Not Available	326.436	CO[C@H]1C[C@@]2(C)[C@@H](CC[C@@]2(O)C#C)[C@@H]2CCC3=CC(O)=CC=C3[C@@H]12	Not Available	Not Available					50218560	34857	CHEMBL1628161	10128336				C14757										Moxestrol	ZINC000003815417		Moxestrol	Experimental	DB13418	InChI=1S/C21H26O3/c1-4-21(23)10-9-17-16-7-5-13-11-14(22)6-8-15(13)19(16)18(24-3)12-20(17,21)2/h1,6,8,11,16-19,22-23H,5,7,9-10,12H2,2-3H3/t16-,17-,18-,19+,20-,21-/m0/s1	MTMZZIPTQITGCY-OLGWUGKESA-N			Not Available	Small Molecule																																			1	Yes	3	2	No	4	0	49.69 Å2	37.06 Å3	93.72 m3·mol-1	1	Yes	No	0.00928 mg/mL	3.23	-4.6	10.21	-3.7			
C24H32O2	Not Available	Not Available	352.518	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2OC1=CCCC1	Not Available	Not Available						135488	CHEMBL2106999	8536132														Quinbolone	ZINC000004217390		Quinbolone	Experimental	DB13484	InChI=1S/C24H32O2/c1-23-13-11-17(25)15-16(23)7-8-19-20-9-10-22(26-18-5-3-4-6-18)24(20,2)14-12-21(19)23/h5,11,13,15,19-22H,3-4,6-10,12,14H2,1-2H3/t19-,20-,21-,22-,23-,24-/m0/s1	IUVKMZGDUIUOCP-BTNSXGMBSA-N			Not Available	Small Molecule																																			1	Yes	2	0	No	5	0	26.3 Å2	42.19 Å3	108.18 m3·mol-1	2	No	Yes	0.001 mg/mL	5.03	-5.6	18.86	-4.6			
C27H45IO	Not Available	Not Available	516.562	CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3C[C@@H](C[131I])C4=C(CC[C@H](O)C4)[C@H]3CC[C@]12C	Not Available	Not Available						34893	CHEMBL2106905	571011				C13547											ZINC000118913163		Iodine (131I) norcholesterol	Experimental	DB13487	InChI=1S/C27H45IO/c1-17(2)6-5-7-18(3)25-10-11-26-24-14-19(16-28)23-15-20(29)8-9-21(23)22(24)12-13-27(25,26)4/h17-20,22,24-26,29H,5-16H2,1-4H3/t18-,19+,20+,22-,24-,25-,26+,27-/m1/s1/i28+4	QJHZPCLORSPENH-DRTKWHMQSA-N		Iodine (131I) norcholesterol is a radioiodine-labeled cholesterol analogue that accumulates in areas where steroid hormones are produced and is used in certain diagnostic procedures.	Not Available	Small Molecule																																			0	No	1	1	Yes	4	0	20.23 Å2	55.61 Å3	133.56 m3·mol-1	6	No	Yes	0.000117 mg/mL	7.67	-6.6	18.19	-1.4			
C22H29FO5	Not Available	Not Available	392.467	C[C@H](O)C(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C	Not Available	Not Available								32700976														Fluperolone			Fluperolone	Experimental	DB13491	InChI=1S/C22H29FO5/c1-12(24)18(27)21(28)9-7-15-16-5-4-13-10-14(25)6-8-19(13,2)22(16,23)17(26)11-20(15,21)3/h6,8,10,12,15-17,24,26,28H,4-5,7,9,11H2,1-3H3/t12-,15-,16-,17-,19-,20-,21-,22-/m0/s1	SLVCCRYLKTYUQP-DVTGEIKXSA-N			Not Available	Small Molecule																																			1	Yes	5	3	No	4	0	94.83 Å2	40.82 Å3	102.52 m3·mol-1	2	Yes	No	0.0579 mg/mL	1.89	-3.8	12.53	-3.4			
C21H27ClO3	Not Available	Not Available	362.89	[H][C@@]12CC[C@](O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(Cl)C2=CC(=O)CC[C@]12C	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4				CHEMBL1697830	4447590												78904		Chlormadinone	ZINC000030691600		Chlormadinone	Experimental	DB13528	InChI=1S/C21H27ClO3/c1-12(23)21(25)9-6-16-14-11-18(22)17-10-13(24)4-7-19(17,2)15(14)5-8-20(16,21)3/h10-11,14-16,25H,4-9H2,1-3H3/t14-,15+,16+,19-,20+,21+/m1/s1	VUHJZBBCZGVNDZ-TTYLFXKOSA-N	1	Chlormadinone is a progestin indicated in combination with an estrogen for oral combined hormonal contraceptive therapy.	Not Available	Small Molecule																																			1	Yes	3	1	No	4	0	54.37 Å2	39.66 Å3	99.94 m3·mol-1	1	Yes	No	0.00677 mg/mL	3.28	-4.7	12.7	-3.8			
C19H28O2	Not Available	Not Available	288.431	C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C	Not Available	Not Available						34896	CHEMBL2106801	4447645				C14491										Normethandrone	ZINC000004217180		Methylestrenolone	Experimental	DB13533	InChI=1S/C19H28O2/c1-18-9-7-15-14-6-4-13(20)11-12(14)3-5-16(15)17(18)8-10-19(18,2)21/h11,14-17,21H,3-10H2,1-2H3/t14-,15+,16+,17-,18-,19-/m0/s1	ZXSWTMLNIIZPET-ZOFHRBRSSA-N			Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	34.21 Å3	84.59 m3·mol-1	0	Yes	Yes	0.0302 mg/mL	3.35	-4	19.28	-0.53			
C20H22O2	Not Available	Not Available	294.394	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)C=CC1=C3CCC(=O)C=C3CC[C@@]21[H]	Not Available	Not Available						135231	CHEMBL1908319	12749												7519		Norgestrienone	ZINC000004217177		Norgestrienone	Experimental	DB13563	InChI=1S/C20H22O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,8,10,12,17-18,22H,4-7,9,11H2,2H3/t17-,18+,19+,20+/m1/s1	GVDMJXQHPUYPHP-FYQPLNBISA-N			Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	33.61 Å3	89.12 m3·mol-1	0	Yes	Yes	0.0113 mg/mL	2.41	-4.4	17.57	-1.7			
C20H37NO3	Not Available	Not Available	339.52	CCN(CC)CC(C)OC(=O)[C@H]1CCCC[C@]1(O)C1CCCCC1	Not Available	Not Available						135440		28534065														Rociverine			Rociverine	Experimental	DB13581	InChI=1S/C20H37NO3/c1-4-21(5-2)15-16(3)24-19(22)18-13-9-10-14-20(18,23)17-11-7-6-8-12-17/h16-18,23H,4-15H2,1-3H3/t16?,18-,20+/m1/s1	XPYLKZZOBVLVHB-QDKIRNHSSA-N		Rociverine is an antispasmodic indicated in the treatment of urinary, gastrointestinal, and biliary tract spasms.	Not Available	Small Molecule																																			1	Yes	3	1	No	2	1	49.77 Å2	40.08 Å3	97.7 m3·mol-1	8	Yes	No	0.0582 mg/mL	3.99	-3.8	14.09	9.2	P11229;!P08172;!P20309;!P08173;!P08912	CHRM1;!CHRM2;!CHRM3;!CHRM4;!CHRM5	1. Muscarinic acetylcholine receptor M1;!2. Muscarinic acetylcholine receptor M2;!3. Muscarinic acetylcholine receptor M3;!4. Muscarinic acetylcholine receptor M4;!5. Muscarinic acetylcholine receptor M5
C20H28O2	Not Available	Not Available	300.4351	[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Not Available	Not Available						6810	CHEMBL1418176	6061			HMDB0041925									6818		Metandienone	ZINC000003875469		Metandienone	Experimental	DB13586	InChI=1S/C20H28O2/c1-18-9-6-14(21)12-13(18)4-5-15-16(18)7-10-19(2)17(15)8-11-20(19,3)22/h6,9,12,15-17,22H,4-5,7-8,10-11H2,1-3H3/t15-,16+,17+,18+,19+,20+/m1/s1	XWALNWXLMVGSFR-HLXURNFRSA-N		Metandienone is an anabolic steroid indicated for appetite stimulation in patients with anorexia.	Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	35.09 Å3	90.16 m3·mol-1	0	Yes	Yes	0.0161 mg/mL	3.64	-4.3	18.39	-0.53			
C20H32O2	Not Available	Not Available	304.4669	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)C[C@H](C)[C@]12C	Not Available	Not Available					50423551	135293	CHEMBL258918	14296			HMDB0006036						15020	347829305		6781		Mesterolone	ZINC000003881977		Mesterolone	Experimental	DB13587	InChI=1S/C20H32O2/c1-12-10-14(21)11-13-4-5-15-16-6-7-18(22)19(16,2)9-8-17(15)20(12,13)3/h12-13,15-18,22H,4-11H2,1-3H3/t12-,13-,15-,16-,17-,18-,19-,20-/m0/s1	UXYRZJKIQKRJCF-TZPFWLJSSA-N		Mesterolone is an anabolic steroid indicated in the treatment of low testosterone, hypogonadism, oligozoospermia, and Leydig cell failure.	Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	36.3 Å3	88.15 m3·mol-1	0	Yes	Yes	0.00641 mg/mL	3.7	-4.7	19.38	-0.88			
C22H30O2	Not Available	Not Available	326.48	CCC(=O)[C@@]1(C)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3CC[C@]12C	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4		18660	73390	CHEMBL196003	33716				C14208								8744		Promegestone	ZINC000003814408		Promegestone	Experimental	DB13602	InChI=1S/C22H30O2/c1-4-20(24)22(3)12-10-19-18-7-5-14-13-15(23)6-8-16(14)17(18)9-11-21(19,22)2/h13,18-19H,4-12H2,1-3H3/t18-,19+,21+,22-/m1/s1	QFFCYTLOTYIJMR-XMGTWHOFSA-N			Not Available	Small Molecule																																			1	Yes	2	0	No	4	0	34.14 Å2	38.7 Å3	97.94 m3·mol-1	2	Yes	Yes	0.00772 mg/mL	4.66	-4.6	19	-4.7			
C22H29F3O3	Not Available	Not Available	398.466	CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@@H](C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(F)(F)F	Not Available	Not Available						135987	CHEMBL2104932	16736667														Flumedroxone			Flumedroxone	Experimental	DB13610	InChI=1S/C22H29F3O3/c1-12(26)21(28)9-6-16-14-11-18(22(23,24)25)17-10-13(27)4-7-19(17,2)15(14)5-8-20(16,21)3/h10,14-16,18,28H,4-9,11H2,1-3H3/t14-,15+,16+,18+,19-,20+,21+/m1/s1	CDZJOBWKHSYNMO-SCUQKFFVSA-N			Not Available	Small Molecule																																			1	Yes	3	1	No	4	0	54.37 Å2	40.24 Å3	99.51 m3·mol-1	2	Yes	No	0.00796 mg/mL	3.97	-4.7	12.38	-3.8			
C28H48OSe	Not Available	Not Available	475.614	C[75Se]C[C@@H]1C[C@H]2[C@@H]3CC[C@H]([C@H](C)CCCC(C)C)[C@@]3(C)CC[C@@H]2C2=C1C[C@@H](O)CC2	Not Available	Not Available								108863																	Selenium (75Se) norcholesterol	Experimental	DB13622	InChI=1S/C28H48OSe/c1-18(2)7-6-8-19(3)26-11-12-27-25-15-20(17-30-5)24-16-21(29)9-10-22(24)23(25)13-14-28(26,27)4/h18-21,23,25-27,29H,6-17H2,1-5H3/t19-,20+,21+,23-,25-,26-,27+,28-/m1/s1/i30-4	AEVGUKVBCBHBNF-MJMUOCKJSA-N		Selenium (75Se) norcholesterol is a radiopharmaceutical indicated in nuclear imaging studies of the digestive system.	Not Available	Small Molecule																																			1	No	2	1	Yes	4	0	20.23 Å2	54.58 Å3	138.28 m3·mol-1	7	No	Yes	0.000337 mg/mL	6.31	-6.2	18.19	-1.4			
C32H48O5	Not Available	Not Available	512.731	CC(=O)O[C@H]1CC[C@@]2(C)[C@@H](CC[C@]3(C)[C@@H]2C(=O)C=C2[C@@H]4C[C@](C)(CC[C@]4(C)CC[C@@]32C)C(O)=O)C1(C)C	Not Available	Not Available					50188385	81306	CHEMBL207413	85123				C17734								16784		Acetoxolone	ZINC000034169081		Acetoxolone	Experimental	DB13640	InChI=1S/C32H48O5/c1-19(33)37-24-10-11-30(6)23(27(24,2)3)9-12-32(8)25(30)22(34)17-20-21-18-29(5,26(35)36)14-13-28(21,4)15-16-31(20,32)7/h17,21,23-25H,9-16,18H2,1-8H3,(H,35,36)/t21-,23-,24-,25+,28+,29-,30-,31+,32+/m0/s1	FTQDJVZNPJRVPG-XWEVEMRCSA-N			Not Available	Small Molecule																																			0	No	4	1	No	5	-1	80.67 Å2	59.68 Å3	143.42 m3·mol-1	3	No	No	0.000555 mg/mL	6.47	-6	4.44	-5.1			
C29H38ClFO8	Not Available	Not Available	569.06	CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3CC(C=O)=C4C=C(CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C)OCCCl	Not Available	Not Available						135834	CHEMBL1989587	254985														Formocortal	ZINC000004216336		Formocortal	Experimental	DB13664	InChI=1S/C29H38ClFO8/c1-16(33)37-15-23(35)29-24(38-25(2,3)39-29)12-20-21-10-17(14-32)19-11-18(36-9-8-30)6-7-26(19,4)28(21,31)22(34)13-27(20,29)5/h11,14,20-22,24,34H,6-10,12-13,15H2,1-5H3/t20-,21-,22-,24+,26-,27-,28-,29+/m0/s1	QNXUUBBKHBYRFW-QWAPGEGQSA-N			Not Available	Small Molecule																																			1	No	7	1	Yes	5	0	108.36 Å2	58.69 Å3	141.36 m3·mol-1	8	No	No	0.00875 mg/mL	2.07	-4.8	13.64	-3.4			
C25H34O2	Not Available	Not Available	366.545	C[C@]12CC[C@H]3[C@@H](CC=C4C=C(CC[C@H]34)OC3CCCC3)[C@@H]1CC[C@@]2(O)C#C	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4					8017842														Quingestanol			Quingestanol	Experimental	DB13685	InChI=1S/C25H34O2/c1-3-25(26)15-13-23-22-10-8-17-16-19(27-18-6-4-5-7-18)9-11-20(17)21(22)12-14-24(23,25)2/h1,8,16,18,20-23,26H,4-7,9-15H2,2H3/t20-,21+,22+,23-,24-,25-/m0/s1	PCJFRMOEZQQSAX-AIOSZGMZSA-N			Not Available	Small Molecule																																			1	Yes	2	1	No	5	0	29.46 Å2	43.67 Å3	111.13 m3·mol-1	2	Yes	Yes	0.00211 mg/mL	4.32	-5.2	17.59	-1.7			
C27H44O3	Not Available	Not Available	416.646	CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	Not Available	Not Available					50441892		CHEMBL2105611	4446823												291204		Tacalcitol	ZINC000004474668		Tacalcitol	Experimental, Investigational	DB13689	InChI=1S/C27H44O3/c1-17(2)25(29)13-8-18(3)23-11-12-24-20(7-6-14-27(23,24)5)9-10-21-15-22(28)16-26(30)19(21)4/h9-10,17-18,22-26,28-30H,4,6-8,11-16H2,1-3,5H3/b20-9+,21-10-/t18-,22-,23-,24+,25-,26+,27-/m1/s1	BJYLYJCXYAMOFT-RSFVBTMBSA-N	3	Tacalcitol is a vitamin D analog indicated in the treatment of mild to moderate plaque psoriasis.	Not Available	Small Molecule																																			1	No	3	3	Yes	3	0	60.69 Å2	51.11 Å3	126.29 m3·mol-1	6	Yes	No	0.0105 mg/mL	4.51	-4.6	14.39	-1.1			
C20H30O2	Not Available	Not Available	302.451	[H][C@]1(O)CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])CC(=O)C=C(C)[C@]4(C)[C@@]3([H])CC[C@]12C	Not Available	Not Available						135283		2301378			HMDB0041928									6833		Metenolone	ZINC000005497532		Metenolone	Experimental	DB13710	InChI=1S/C20H30O2/c1-12-10-14(21)11-13-4-5-15-16-6-7-18(22)19(16,2)9-8-17(15)20(12,13)3/h10,13,15-18,22H,4-9,11H2,1-3H3/t13-,15-,16-,17-,18-,19-,20-/m0/s1	ANJQEDFWRSLVBR-VHUDCFPWSA-N		Metenolone is an anabolic steroid indicated in the treatment and prevention of muscle wasting due to diseases, drug treatments, or other catabolic processes.	Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	35.88 Å3	88.98 m3·mol-1	0	Yes	Yes	0.022 mg/mL	3.65	-4.1	19.38	-0.88			
C22H27ClF2O5	Not Available	Not Available	444.9	C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C(Cl)=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO	Not Available	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5			135724	CHEMBL1587228	8022046												26416		Halometasone	ZINC000003938673		Halometasone	Experimental	DB13728	InChI=1S/C22H27ClF2O5/c1-10-4-11-12-5-15(24)13-6-16(27)14(23)7-19(13,2)21(12,25)17(28)8-20(11,3)22(10,30)18(29)9-26/h6-7,10-12,15,17,26,28,30H,4-5,8-9H2,1-3H3/t10-,11+,12+,15+,17+,19+,20+,21+,22+/m1/s1	GGXMRPUKBWXVHE-MIHLVHIWSA-N	4	Halometasone is a corticosteroid indicated in the treatment of corticosteroid responsive dermatoses.	Not Available	Small Molecule																																			1	Yes	5	3	No	4	0	94.83 Å2	43.35 Å3	107.11 m3·mol-1	2	Yes	No	0.0356 mg/mL	1.73	-4.1	12.42	-3.3			
C42H62O16	The constant reabsorption of glycyrrhetic acid in the duodenum causes a delay in the terminal plasma clearance.3 The reported total body clearance of glycyrrhizic acid is reported to be in the range of 16-25 ml.kg/h.5	Depending on the dose, the second elimination phase in humans has a half-life of 3.5 hours.4	822.942	[H][C@@]12C[C@](C)(CC[C@]1(C)CC[C@]1(C)C2=CC(=O)[C@]2([H])[C@@]3(C)CC[C@H](O[C@H]4O[C@@H]([C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@@H]([C@@H](O)[C@H](O)[C@H]4O)C(O)=O)C(O)=O)C(C)(C)[C@]3([H])CC[C@@]12C)C(O)=O	Solid	The apparent volume of distribution of glycyrrhizic acid either in the central compartment and in steady-state are in the range of 37-64 ml/kg and 59-98 ml/kg, respectively.5					50185127	15939	CHEMBL441687	14263				C02284	D00157							26143		Glycyrrhizin	ZINC000096015174		Glycyrrhizic acid	Approved, Experimental	DB13751	InChI=1S/C42H62O16/c1-37(2)21-8-11-42(7)31(20(43)16-18-19-17-39(4,36(53)54)13-12-38(19,3)14-15-41(18,42)6)40(21,5)10-9-22(37)55-35-30(26(47)25(46)29(57-35)33(51)52)58-34-27(48)23(44)24(45)28(56-34)32(49)50/h16,19,21-31,34-35,44-48H,8-15,17H2,1-7H3,(H,49,50)(H,51,52)(H,53,54)/t19-,21-,22-,23-,24-,25-,26-,27+,28-,29-,30+,31+,34-,35-,38+,39-,40-,41+,42+/m0/s1	LPLVUJXQOOQHMX-QWBHMCJMSA-N			Glycyrrhizic acid is thought to generate inhibition of 11-beta-hydroxysteroid dehydrogenase in the kidney which leads to elevated cortisol levels in the kidney. Intravenous administration of the ammoniated form was shown to produce convulsions and hemolysis.11Preclinical overdose studies have been shown to produce mineralocorticoid excess. The LD50 in preclinical studies was reported to be in the range of 308-12700 mg/kg.11 Glycyrrhizic acid has been proven to not have mutagenic, genotoxic, teratogenic nor carcinogenic effects.11	Small Molecule																													Decomposes at 200 ºC	2.8		220 ºC (Decomposes at 200 ºC)		Easily soluble in hot water	0	No	16	8	Yes	7	-3	267.04 Å2	86.31 Å3	198.83 m3·mol-1	7	No	No	0.0545 mg/mL	3.13	-4.2	2.96	-3.7	P28845;!P01375;!P42574;!BE0004903;!P06858	HSD11B1;!TNF;!CASP3;!;!LPL	1. Corticosteroid 11-beta-dehydrogenase isozyme 1;!2. Tumor necrosis factor;!3. Caspase-3;!4. Nuclear factor NF-kappa-B (Protein Group);!5. Lipoprotein lipase
C30H44O9	Not Available	Not Available	548.673	CO[C@@H]1[C@@H](O)[C@H](C)O[C@@H](O[C@H]2CC[C@@]3(C=O)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H](CC[C@]43O)C3=CC(=O)OC3)C2)[C@H]1O	Not Available	Not Available						135825	CHEMBL1075790	16498835														Peruvoside			Peruvoside	Experimental	DB13756	InChI=1S/C30H44O9/c1-16-24(33)26(36-3)25(34)27(38-16)39-19-6-10-29(15-31)18(13-19)4-5-22-21(29)7-9-28(2)20(8-11-30(22,28)35)17-12-23(32)37-14-17/h12,15-16,18-22,24-27,33-35H,4-11,13-14H2,1-3H3/t16-,18+,19-,20+,21-,22+,24-,25-,26+,27-,28+,29+,30-/m0/s1	PMTSPAGBAFCORP-HBUONDEYSA-N			Not Available	Small Molecule																																			1	No	8	3	No	6	0	131.75 Å2	58.9 Å3	140.05 m3·mol-1	5	No	No	0.0791 mg/mL	2.02	-3.8	7.18	0.27			
C27H45IO	Not Available	Not Available	516.562	CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C[131I])[C@H]3CC[C@]12C	Not Available	Not Available						135998	CHEMBL2105011	396792														Iodocholesterol	ZINC000118913216		Iodocholesterol (131I)	Experimental	DB13797	InChI=1S/C27H45IO/c1-18(2)6-5-7-19(3)23-10-11-24-22-9-8-20-16-21(29)12-15-27(20,17-28)25(22)13-14-26(23,24)4/h8,18-19,21-25,29H,5-7,9-17H2,1-4H3/t19-,21+,22+,23-,24+,25+,26-,27-/m1/s1/i28+4	FIOAEFCJGZJUPW-ODFYUTSGSA-N			Not Available	Small Molecule																																			0	No	1	1	Yes	4	0	20.23 Å2	55.14 Å3	133.67 m3·mol-1	6	No	Yes	3.97e-05 mg/mL	7.8	-7.1	18.2	-1.4			
C21H25Cl2FO5	Not Available	Not Available	447.32	C[C@]12C[C@H](Cl)[C@@]3(Cl)[C@@H](C[C@H](F)C4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO	Not Available	Not Available						135986	CHEMBL3707231	32697416												108091		Fluclorolone	ZINC000031284397		Fluclorolone	Experimental	DB13856	InChI=1S/C21H25Cl2FO5/c1-18-4-3-10(26)5-13(18)14(24)6-12-11-7-16(27)21(29,17(28)9-25)19(11,2)8-15(22)20(12,18)23/h3-5,11-12,14-16,25,27,29H,6-9H2,1-2H3/t11-,12-,14-,15-,16+,18-,19-,20-,21-/m0/s1	VTWKPILBIUBMDS-OTJLYDAYSA-N			Not Available	Small Molecule																																			1	Yes	5	3	No	4	0	94.83 Å2	42.62 Å3	107 m3·mol-1	2	Yes	No	0.0202 mg/mL	1.72	-4.4	11.76	-3.3			
C21H28O2	Not Available	Not Available	312.4458	[H][C@@]12CC[C@](C)(C(C)=O)[C@@]1(C)CCC1=C3CCC(=O)C=C3CC[C@@]21[H]	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			135339	CHEMBL2104231	84009					D07223							22483		Demegestone	ZINC000004215548		Demegestone	Experimental	DB13857	InChI=1S/C21H28O2/c1-13(22)20(2)11-9-19-18-6-4-14-12-15(23)5-7-16(14)17(18)8-10-21(19,20)3/h12,18-19H,4-11H2,1-3H3/t18-,19+,20-,21+/m1/s1	JWAHBTQSSMYISL-MHTWAQMVSA-N			Not Available	Small Molecule																																			1	Yes	2	0	No	4	0	34.14 Å2	36.71 Å3	93.31 m3·mol-1	1	Yes	Yes	0.0111 mg/mL	3.96	-4.4	18.42	-4.7	P06401	PGR	1. Progesterone receptor
C20H28O2	Not Available	Not Available	300.442	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CC[C@H](O)C=C3CC[C@@]21[H]	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			50785	CHEMBL1201406	14017					D07939				14687	347829321		24591		Etynodiol	ZINC000030691629		Etynodiol	Experimental	DB13866	InChI=1S/C20H28O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,12,14-18,21-22H,4-11H2,2H3/t14-,15-,16+,17+,18-,19-,20-/m0/s1	JYILPERKVHXLNF-QMNUTNMBSA-N			Not Available	Small Molecule																																			1	Yes	2	2	No	4	0	40.46 Å2	35.26 Å3	88.32 m3·mol-1	0	Yes	No	0.00785 mg/mL	2.81	-4.6	17.52	-1.4			
C22H27F3O4S	57.8L/h for Fluticasone furoate12. A study of 24 healthy Caucasian males showed a clearance of 71.8L/h following intravenous administration1.1093mL/min for Fluticasone propionate11. A study of 24 healthy Caucasian males showed a clearance of 63.9L/h following intravenous administration1.	15.1 hours for intranasal Fluticasone furoate12 and 24 hours for the inhaled formulation13. A study of 24 healthy Caucasian males showed a half life of 13.6 hours following intravenous administration and 17.3-23.9 hours followed inhalation1.7.8 hours for intravenous Fluticasone propionate11Label. A study of 24 healthy Caucasian males shows a half life of 14.0 hours following intravenous administration and 10.8 hours following inhalation1.	444.51	[H][C@@]12C[C@@H](C)[C@](O)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C	Solid	608L at steady state for intravenous administration of Fluticasone furoate12. Other reports suggest the mean volume of distribution at steady state is 661L13. A study of 24 healthy Caucasian males showed a volume of distribution at steady state of 704L following intravenous administration1.The volume of distribution of intravenous Fluticasone propionate is 4.2L/kg11Label. A study of 24 healthy Caucasian males showed a volume of distribution at steady state of 577L following intravenous administration1.	P08684;!P20815;!P24462;!P10632	CYP3A4;!CYP3A5;!CYP3A7;!CYP2C8	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5;!3. Cytochrome P450 3A7;!4. Cytochrome P450 2C8			5134	CHEMBL1201396	4470631				C07815	D07981							41126		Fluticasone	ZINC000004097438		Fluticasone	Approved, Experimental	DB13867	InChI=1S/C22H27F3O4S/c1-11-6-13-14-8-16(24)15-7-12(26)4-5-19(15,2)21(14,25)17(27)9-20(13,3)22(11,29)18(28)30-10-23/h4-5,7,11,13-14,16-17,27,29H,6,8-10H2,1-3H3/t11-,13+,14+,16+,17+,19+,20+,21+,22+/m1/s1	MGNNYOODZCAHBA-GQKYHHCASA-N	4	Fluticasone is a corticosteroid indicated in the treatment of corticosteroid responsive dermatoses, asthma, and COPD.	Fluticasone furoate administered nasally may be associated with adrenal suppression or an increase in QTc interval though the association has not been well demonstrated in studies12,2. Fluticasone furoate requires no dosage adjustment in renal impairment but must be used in caution in hepatic impairment due to the elimination mechanisms12,13. Fluticasone furoate is not associated with carcinogenicity, mutagenicity, or impairment of fertility12. There are no well controlled studies in pregnancy or lactation though animal studies have shown teratogenicity and hypoadrenalism in the offspring of treated mothers and other corticosteroids are known to be excreted in breast milk12. Generally, there are no reported adverse effects with fluticasone in pregnancy6. Pediatric patients should be given the lowest possible dose and monitored for reduction in growth velocity12,2. There is insufficient evidence to determine whether geriatric patients respond differently to other patients12. Systemic exposure may be 27-49% higher in Japanese, Korean, and Chinese patients compared to Caucasian patients13. Caution should be exercised in these patients and the benefit and risk should be assessed before deciding on a treatment12.Fluticasone propionate's use in specific populations has not been well studied11. Fluticasone propionate is not carcinogenic, mutagenic, or clastogenic, nor did it affect fertility in animal studies11Label. Subcutaneous Fluticasone propionate has been shown to produce teratogenic effects in rats though oral administration does not10Label. Generally, there are no reported adverse effects with fluticasone in pregnancy6. Fluticasone propionate in human milk may cause growth suppression, effects on endogenous corticosteroid production, or other effects10,2. Pediatric patients treated with Fluticasone propionate ointment experienced adrenal suppression10. Geriatric patients treated with Fluticasone propionate did not show any difference in safety or efficacy compared to other patient groups, though older patients may be more sensitive to adverse effects10. There is no difference in the clearance of Fluticasone propionate across genders or raceLabel. Patients with hepatic impairment should be closely monitored due to the elimination mechanismLabel5.	Small Molecule																																			1	Yes	4	2	No	4	0	74.6 Å2	43.32 Å3	107.87 m3·mol-1	3	Yes	No	0.0344 mg/mL	2.58	-4.1	12.19	-3.4	P04150;!P06401;!P47712;!P08235	NR3C1;!PGR;!PLA2G4A;!NR3C2	1. Glucocorticoid receptor;!2. Progesterone receptor;!3. Cytosolic phospholipase A2;!4. Mineralocorticoid receptor
C27H40O3	Testosterone cypionate presents a lower clearance rate after intramuscular administration compared to other analogs of testosterone.	The half-life of testosterone cypionate is one of the longest, being approximately of 8 days.5	412.614	[H][C@@]12CC[C@H](OC(=O)CCC3CCCC3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	The volume of distribution following intravenous administration of testosterone is of approximately 1 L/kg.7	P08684;!P21397;!P05108;!P20815;!P24462;!P04798;!Q16696;!P20813;!P33261;!P10632;!P11712;!Q9HB55;!BE0004887;!P11511	CYP3A4;!MAOA;!CYP11A1;!CYP3A5;!CYP3A7;!CYP1A1;!CYP2A13;!CYP2B6;!CYP2C19;!CYP2C8;!CYP2C9;!CYP3A43;!;!CYP19A1	1. Cytochrome P450 3A4;!2. Amine oxidase [flavin-containing] A;!3. Cholesterol side-chain cleavage enzyme, mitochondrial;!4. Cytochrome P450 3A5;!5. Cytochrome P450 3A7;!6. Cytochrome P450 1A1;!7. Cytochrome P450 2A13;!8. Cytochrome P450 2B6;!9. Cytochrome P450 2C19;!10. Cytochrome P450 2C8;!11. Cytochrome P450 2C9;!12. Cytochrome P450 3A43;!13. 3-oxo-5-alpha-steroid 4-dehydrogenase (Protein Group);!14. Cytochrome P450 19A1			9463	CHEMBL1201101	390140				C08156	D00957									Testosterone_cypionate	ZINC000004097468	Depo-testosterone	Testosterone cypionate	Approved	DB13943	InChI=1S/C27H40O3/c1-26-15-13-20(28)17-19(26)8-9-21-22-10-11-24(27(22,2)16-14-23(21)26)30-25(29)12-7-18-5-3-4-6-18/h17-18,21-24H,3-16H2,1-2H3/t21-,22-,23-,24-,26-,27-/m0/s1	HPFVBGJFAYZEBE-ZLQWOROUSA-N	4	Testosterone cypionate is an androgen used to treat low or absent testosterone.	Preclinical studies with testosterone implants induced cervical-uterine tumors in mice which metastasized in some cases. Some reports indicate that administration of testosterone cypionate in females can augment the susceptibility to hepatoma as well as increase the number of tumors. Clinical studies have reported cases of hepatocellular carcinoma in long-term high-dose therapy.6	Small Molecule																																98-104ºC		Insoluble	1	No	2	0	No	5	0	43.37 Å2	49.84 Å3	119.36 m3·mol-1	5	No	No	0.000437 mg/mL	6.11	-6	18.52	-4.8	P10275;!P03372;!P08235	AR;!ESR1;!NR3C2	1. Androgen receptor;!2. Estrogen receptor alpha;!3. Mineralocorticoid receptor
C26H40O3	Not Available	Testosterone enanthate presents a long half-life in the range of 7-9 days.3	400.594	[H][C@@]12CC[C@H](OC(=O)CCCCCC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	The volume of distribution following intravenous administration of testosterone is of approximately 1 L/kg.8	P08684;!P21397;!P05108;!P20815;!P24462;!P04798;!Q16696;!P20813;!P33261;!P10632;!P11712;!Q9HB55;!BE0004887;!P11511	CYP3A4;!MAOA;!CYP11A1;!CYP3A5;!CYP3A7;!CYP1A1;!CYP2A13;!CYP2B6;!CYP2C19;!CYP2C8;!CYP2C9;!CYP3A43;!;!CYP19A1	1. Cytochrome P450 3A4;!2. Amine oxidase [flavin-containing] A;!3. Cholesterol side-chain cleavage enzyme, mitochondrial;!4. Cytochrome P450 3A5;!5. Cytochrome P450 3A7;!6. Cytochrome P450 1A1;!7. Cytochrome P450 2A13;!8. Cytochrome P450 2B6;!9. Cytochrome P450 2C19;!10. Cytochrome P450 2C8;!11. Cytochrome P450 2C9;!12. Cytochrome P450 3A43;!13. 3-oxo-5-alpha-steroid 4-dehydrogenase (Protein Group);!14. Cytochrome P450 19A1			9464	CHEMBL1200335	9045			HMDB0005814	C08157										Testosterone_enanthate	ZINC000003876080	Delatestryl, Xyosted	Testosterone enanthate	Approved	DB13944	InChI=1S/C26H40O3/c1-4-5-6-7-8-24(28)29-23-12-11-21-20-10-9-18-17-19(27)13-15-25(18,2)22(20)14-16-26(21,23)3/h17,20-23H,4-16H2,1-3H3/t20-,21-,22-,23-,25-,26-/m0/s1	VOCBWIIFXDYGNZ-IXKNJLPQSA-N	4	Testosterone enanthate is an androgen used to treat low or absent testosterone.	Testosterone enanthate has been tested in preclinical carcinogenesis trials. In this studies, it is suggested that the exposure to this drug may increase the susceptibility to hematoma as well as the number of tumors and decrease the degree of differentiation of chemically induced carcinomas of the liver.LabelTestosterone enanthate is not indicated for use in females and is contraindicated in pregnant women. Testosterone is teratogenic and may cause fetal harm when administered to a pregnant woman based on data from animal studies and its mechanism of action. 11During treatment with large doses of exogenous androgens, including testosterone enanthate, spermatogenesis may be suppressed through feedback inhibition of the hypothalamic-pituitary-testicular axis 11. Reduced fertility is observed in some men taking testosterone replacement therapy and the impact on fertility may be irreversible 11.Safety and effectiveness of testosterone enanthate in pediatric patients less than 18 years old have not been established 11. Improper use may result in the acceleration of bone age and premature closure of epiphyses 11.Geriatric patients treated with androgens may also be at risk for worsening of signs and symptoms of Benign Prostatic Hyperplasia 11.	Small Molecule																														3.58		34-39ºC		Insoluble	1	No	2	0	Yes	4	0	43.37 Å2	49.18 Å3	116.61 m3·mol-1	7	No	No	0.000463 mg/mL	6.29	-5.9	18.52	-4.8	P10275;!P03372;!P08235	AR;!ESR1;!NR3C2	1. Androgen receptor;!2. Estrogen receptor alpha;!3. Mineralocorticoid receptor
C30H48O3	While there is limited information available, an earlier study reports a metabolic clearance rate of 24.5 mL/min/kg for testosterone following oral administration of 25 mg testosterone and 40 mg testosterone undecanoate in women.5	The elimination half-life of testosterone undecanoate is approximately two hours. Once testosterone is formed from testosterone undecanoate, the half life of testosterone can vary and the reported values in the literature remain inconsistent, ranging from 10 to to 100 minutes.6,8 Testosterone undecanoate in castor oil for intramuscular injection had a half life of 33.9 days, allowing it to maintain serum levels in the normal range for over 6 weeks.[A176954]	456.711	CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C	Solid	There is no information available.	P08684;!P21397;!P05108;!P20815;!P24462;!P04798;!Q16678;!Q16696;!P20813;!P33261;!P10632;!P11712;!Q9HB55;!BE0004887;!P11511	CYP3A4;!MAOA;!CYP11A1;!CYP3A5;!CYP3A7;!CYP1A1;!CYP1B1;!CYP2A13;!CYP2B6;!CYP2C19;!CYP2C8;!CYP2C9;!CYP3A43;!;!CYP19A1	1. Cytochrome P450 3A4;!2. Amine oxidase [flavin-containing] A;!3. Cholesterol side-chain cleavage enzyme, mitochondrial;!4. Cytochrome P450 3A5;!5. Cytochrome P450 3A7;!6. Cytochrome P450 1A1;!7. Cytochrome P450 1B1;!8. Cytochrome P450 2A13;!9. Cytochrome P450 2B6;!10. Cytochrome P450 2C19;!11. Cytochrome P450 2C8;!12. Cytochrome P450 2C9;!13. Cytochrome P450 3A43;!14. 3-oxo-5-alpha-steroid 4-dehydrogenase (Protein Group);!15. Cytochrome P450 19A1			135741	CHEMBL2107067	58664														Testosterone_undecanoate	ZINC000008214690	Aveed, Jatenzo, Tlando	Testosterone undecanoate	Approved, Investigational	DB13946	InChI=1S/C30H48O3/c1-4-5-6-7-8-9-10-11-12-28(32)33-27-16-15-25-24-14-13-22-21-23(31)17-19-29(22,2)26(24)18-20-30(25,27)3/h21,24-27H,4-20H2,1-3H3/t24-,25-,26-,27-,29-,30-/m0/s1	UDSFVOAUHKGBEK-CNQKSJKFSA-N	4	Testosterone undecanoate is an androgen indicated for testosterone replacement therapy in adult males with primary hypogonadism and hypogonadotropic hypogonadism.	The oral LD50 is 4000 mg/kg in mice and rats. The subcutaneous LD50 is 2880 mg/kg in mice and rats.9There is limited information on testosterone undecanoate overdose. There was one report of acute overdose from an approved injectable testosterone product, which resulted in increased serum testosterone levels of up to 11,400 ng/dL with a cerebrovascular accident.6 There was one case of overdose following administration of oral testosterone undecanoate capsules: this patient inadvertently took a 20% higher dose than the maximum recommended dose but did not report any adverse reactions.7 Overdose should be managed with discontinuation of the drug in combination with appropriate symptomatic and supportive care.6The abuse of anabolic androgenic steroids can result in serious adverse reactions, such as cardiac arrest, myocardial infarction, hypertrophic cardiomyopathy, congestive heart failure, cerebrovascular accident, hepatotoxicity, and psychiatric manifestations, including major depression, mania, paranoia, psychosis, delusions, hallucinations, hostility, and aggression. Men receiving testosterone have experienced transient ischemic attacks, convulsions, hypomania, irritability, dyslipidemias, testicular atrophy, subfertility, and infertility.6	Small Molecule																																		<1 mg/mL	0	No	2	0	Yes	4	0	43.37 Å2	57.8 Å3	135.02 m3·mol-1	11	No	No	7.4e-05 mg/mL	8.06	-6.8	18.52	-4.8	P10275	AR	1. Androgen receptor
C21H32O3	Not Available	Not Available	332.484	[H][C@@]12CC[C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)CC[C@]12C	Not Available	Not Available							CHEMBL3275971	9984405														Dihydrotestosterone_acetate	ZINC000002557145		Stanolone acetate	Experimental	DB13951	InChI=1S/C21H32O3/c1-13(22)24-19-7-6-17-16-5-4-14-12-15(23)8-10-20(14,2)18(16)9-11-21(17,19)3/h14,16-19H,4-12H2,1-3H3/t14-,16-,17-,18-,19-,20-,21-/m0/s1	ILCTUFVQFCIIDS-NGFSFWIMSA-N			Not Available	Small Molecule																																			1	Yes	2	0	No	4	0	43.37 Å2	39.03 Å3	92.75 m3·mol-1	2	Yes	No	0.00115 mg/mL	3.85	-5.5		-6.8	P10275;!P14061;!P03372;!P08235	AR;!HSD17B1;!ESR1;!NR3C2	1. Androgen receptor;!2. Estradiol 17-beta-dehydrogenase 1;!3. Estrogen receptor alpha;!4. Mineralocorticoid receptor
C20H26O3	Not Available	Not Available	314.4186	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(OC(C)=O)C=C3CC[C@@]21[H]	Not Available	The distribution of exogenous estrogens is similar to that of endogenous estrogens. Estrogens are widely distributed in the body and are generally found in higher concentrations in the sex hormone target organs Label.	P05177;!P22309;!P08684;!P20815;!P24462;!P04798;!Q16678;!P33261;!P10632;!P11712	CYP1A2;!UGT1A1;!CYP3A4;!CYP3A5;!CYP3A7;!CYP1A1;!CYP1B1;!CYP2C19;!CYP2C8;!CYP2C9	1. Cytochrome P450 1A2;!2. UDP-glucuronosyltransferase 1-1;!3. Cytochrome P450 3A4;!4. Cytochrome P450 3A5;!5. Cytochrome P450 3A7;!6. Cytochrome P450 1A1;!7. Cytochrome P450 1B1;!8. Cytochrome P450 2C19;!9. Cytochrome P450 2C8;!10. Cytochrome P450 2C9			135981	CHEMBL1200430	7994056	Drugs.com Drug Page				D04061				9818306		RxList Drug Page			Estradiol_acetate		Femring	Estradiol acetate	Approved, Investigational, Vet approved	DB13952	InChI=1S/C20H26O3/c1-12(21)23-14-4-6-15-13(11-14)3-5-17-16(15)9-10-20(2)18(17)7-8-19(20)22/h4,6,11,16-19,22H,3,5,7-10H2,1-2H3/t16-,17-,18+,19+,20+/m1/s1	FHXBMXJMKMWVRG-SLHNCBLASA-N	3	Estradiol acetate is an estrogen used to treat vasomotor symptoms and moderate to severe vulvar and vaginal atrophy from menopause.	Can cause nausea and vomiting, and withdrawal bleeding may occur in females.	Small Molecule																																			1	Yes	2	1	No	4	0	46.53 Å2	36.7 Å3	89.06 m3·mol-1	2	Yes	No	0.00183 mg/mL	3.66	-5.2	19.38	-0.88	P03372;!Q92731;!O75469;!P43681;!Q15596;!Q99527;!P00846;!Q14457;!P37059;!P62508	ESR1;!ESR2;!NR1I2;!CHRNA4;!NCOA2;!GPER1;!MT-ATP6;!BECN1;!HSD17B2;!ESRRG	1. Estrogen receptor alpha;!2. Estrogen receptor beta;!3. Nuclear receptor subfamily 1 group I member 2;!4. Neuronal acetylcholine receptor subunit alpha-4;!5. Nuclear receptor coactivator 2;!6. G-protein coupled estrogen receptor 1;!7. ATP synthase subunit a;!8. Beclin-1;!9. Estradiol 17-beta-dehydrogenase 2;!10. Estrogen-related receptor gamma
C25H28O3	Not Available	Not Available	376.488	[H][C@]1(O)CC[C@@]2([H])[C@]3([H])CCC4=CC(OC(=O)C5=CC=CC=C5)=CC=C4[C@@]3([H])CC[C@]12C	Not Available	Not Available	P05177;!P22309;!P08684;!P20815;!P24462;!P04798;!Q16678;!P33261;!P10632;!P11712	CYP1A2;!UGT1A1;!CYP3A4;!CYP3A5;!CYP3A7;!CYP1A1;!CYP1B1;!CYP2C19;!CYP2C8;!CYP2C9	1. Cytochrome P450 1A2;!2. UDP-glucuronosyltransferase 1-1;!3. Cytochrome P450 3A4;!4. Cytochrome P450 3A5;!5. Cytochrome P450 3A7;!6. Cytochrome P450 1A1;!7. Cytochrome P450 1B1;!8. Cytochrome P450 2C19;!9. Cytochrome P450 2C8;!10. Cytochrome P450 2C9		56905	77006	CHEMBL282575	193412				C13444					222757					Estradiol_benzoate	ZINC000003881345		Estradiol benzoate	Approved, Investigational, Vet approved	DB13953	InChI=1S/C25H28O3/c1-25-14-13-20-19-10-8-18(28-24(27)16-5-3-2-4-6-16)15-17(19)7-9-21(20)22(25)11-12-23(25)26/h2-6,8,10,15,20-23,26H,7,9,11-14H2,1H3/t20-,21-,22+,23+,25+/m1/s1	UYIFTLBWAOGQBI-BZDYCCQFSA-N		Estradiol benzoate is an estrogen indicated in combination with progesterone for the treatment of irregular menstruation.	Not Available	Small Molecule																																			1	No	2	1	No	5	0	46.53 Å2	44.07 Å3	109.73 m3·mol-1	3	No	No	0.000189 mg/mL	5.71	-6.3	19.38	-0.88	P03372;!Q92731;!O75469;!P43681;!Q15596;!Q99527;!P00846;!Q14457;!P37059;!P62508	ESR1;!ESR2;!NR1I2;!CHRNA4;!NCOA2;!GPER1;!MT-ATP6;!BECN1;!HSD17B2;!ESRRG	1. Estrogen receptor alpha;!2. Estrogen receptor beta;!3. Nuclear receptor subfamily 1 group I member 2;!4. Neuronal acetylcholine receptor subunit alpha-4;!5. Nuclear receptor coactivator 2;!6. G-protein coupled estrogen receptor 1;!7. ATP synthase subunit a;!8. Beclin-1;!9. Estradiol 17-beta-dehydrogenase 2;!10. Estrogen-related receptor gamma
C26H36O3	Not Available	Not Available	396.5622	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1	Not Available	The distribution of exogenous estrogens is similar to that of endogenous estrogens. Estrogens are widely distributed in the body and are generally found in higher concentrations in the sex hormone target organs Label.	P05177;!P22309;!P08684;!P20815;!P24462;!P04798;!Q16678;!P33261;!P10632;!P11712	CYP1A2;!UGT1A1;!CYP3A4;!CYP3A5;!CYP3A7;!CYP1A1;!CYP1B1;!CYP2C19;!CYP2C8;!CYP2C9	1. Cytochrome P450 1A2;!2. UDP-glucuronosyltransferase 1-1;!3. Cytochrome P450 3A4;!4. Cytochrome P450 3A5;!5. Cytochrome P450 3A7;!6. Cytochrome P450 1A1;!7. Cytochrome P450 1B1;!8. Cytochrome P450 2C19;!9. Cytochrome P450 2C8;!10. Cytochrome P450 2C9			34745	CHEMBL1200973	9033				C14640	D04063				9403					Estradiol_cypionate	ZINC000003876078	Depo-estradiol	Estradiol cypionate	Approved, Investigational, Vet approved	DB13954	InChI=1S/C26H36O3/c1-26-15-14-21-20-10-8-19(27)16-18(20)7-9-22(21)23(26)11-12-24(26)29-25(28)13-6-17-4-2-3-5-17/h8,10,16-17,21-24,27H,2-7,9,11-15H2,1H3/t21-,22-,23+,24+,26+/m1/s1	UOACKFBJUYNSLK-XRKIENNPSA-N	2	Estradiol cypionate is an estradiol prodrug used to treat vasomotor symptoms and hypoestrogenisms from hypogonadism.	Not Available	Small Molecule																																			1	No	2	1	No	5	0	46.53 Å2	47.77 Å3	114.83 m3·mol-1	5	No	No	0.000118 mg/mL	6.49	-6.5	10.33	-5.4	P03372;!Q92731;!O75469;!P43681;!Q15596;!Q99527;!P00846;!Q14457;!P37059;!P62508	ESR1;!ESR2;!NR1I2;!CHRNA4;!NCOA2;!GPER1;!MT-ATP6;!BECN1;!HSD17B2;!ESRRG	1. Estrogen receptor alpha;!2. Estrogen receptor beta;!3. Nuclear receptor subfamily 1 group I member 2;!4. Neuronal acetylcholine receptor subunit alpha-4;!5. Nuclear receptor coactivator 2;!6. G-protein coupled estrogen receptor 1;!7. ATP synthase subunit a;!8. Beclin-1;!9. Estradiol 17-beta-dehydrogenase 2;!10. Estrogen-related receptor gamma
C32H48O4	Not Available	Not Available	496.732	CCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(OC(=O)CCCCCC)=CC=C4[C@H]3CC[C@]12C	Not Available	Not Available	P05177;!P22309;!P08684;!P20815;!P24462;!P04798;!Q16678;!P33261;!P10632;!P11712	CYP1A2;!UGT1A1;!CYP3A4;!CYP3A5;!CYP3A7;!CYP1A1;!CYP1B1;!CYP2C19;!CYP2C8;!CYP2C9	1. Cytochrome P450 1A2;!2. UDP-glucuronosyltransferase 1-1;!3. Cytochrome P450 3A4;!4. Cytochrome P450 3A5;!5. Cytochrome P450 3A7;!6. Cytochrome P450 1A1;!7. Cytochrome P450 1B1;!8. Cytochrome P450 2C19;!9. Cytochrome P450 2C8;!10. Cytochrome P450 2C9					145199														Estradiol_dienantate	ZINC000031476880		Estradiol dienanthate	Approved, Investigational, Vet approved	DB13955	InChI=1S/C32H48O4/c1-4-6-8-10-12-30(33)35-24-15-17-25-23(22-24)14-16-27-26(25)20-21-32(3)28(27)18-19-29(32)36-31(34)13-11-9-7-5-2/h15,17,22,26-29H,4-14,16,18-21H2,1-3H3/t26-,27-,28+,29+,32+/m1/s1	OVAHZPTYWMWNKO-CAHAWPIUSA-N		Estradiol dienanthate is an estrogen used in some combined hormonal oral contraceptives.	Not Available	Small Molecule																																			0	No	2	0	Yes	4	0	52.6 Å2	61.85 Å3	144.27 m3·mol-1	14	No	No	1.16e-05 mg/mL	9.06	-7.6		-6.8	P03372;!Q92731;!O75469;!P43681;!Q15596;!Q99527;!P00846;!Q14457;!P37059;!P62508	ESR1;!ESR2;!NR1I2;!CHRNA4;!NCOA2;!GPER1;!MT-ATP6;!BECN1;!HSD17B2;!ESRRG	Details1. Estrogen receptor alpha;!2. Estrogen receptor beta;!3. Nuclear receptor subfamily 1 group I member 2;!4. Neuronal acetylcholine receptor subunit alpha-4;!5. Nuclear receptor coactivator 2;!6. G-protein coupled estrogen receptor 1;!7. ATP synthase subunit a;!8. Beclin-1;!9. Estradiol 17-beta-dehydrogenase 2;!10. Estrogen-related receptor gamma
C23H32O3	Not Available	Not Available	356.4984	[H][C@@]12CC[C@H](OC(=O)CCCC)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	Not Available	Not Available	P05177;!P22309;!P08684;!P20815;!P24462;!P04798;!Q16678;!P33261;!P10632;!P11712	CYP1A2;!UGT1A1;!CYP3A4;!CYP3A5;!CYP3A7;!CYP1A1;!CYP1B1;!CYP2C19;!CYP2C8;!CYP2C9	1. Cytochrome P450 1A2;!2. UDP-glucuronosyltransferase 1-1;!3. Cytochrome P450 3A4;!4. Cytochrome P450 3A5;!5. Cytochrome P450 3A7;!6. Cytochrome P450 1A1;!7. Cytochrome P450 1B1;!8. Cytochrome P450 2C19;!9. Cytochrome P450 2C8;!10. Cytochrome P450 2C9			31561	CHEMBL1511	13194				C12859					13791		RxList Drug Page			Estradiol_valerate	ZINC000003881556	Delestrogen, Natazia	Estradiol valerate	Approved, Investigational, Vet approved	DB13956	InChI=1S/C23H32O3/c1-3-4-5-22(25)26-21-11-10-20-19-8-6-15-14-16(24)7-9-17(15)18(19)12-13-23(20,21)2/h7,9,14,18-21,24H,3-6,8,10-13H2,1-2H3/t18-,19-,20+,21+,23+/m1/s1	RSEPBGGWRJCQGY-RBRWEJTLSA-N	4	Estradiol valerate is an estradiol prodrug used to treat some effects of menopause, hypoestrogenism, androgen dependant carcinoma of the prostate, and in combination products for endometriosis and contraception.	Not Available	Small Molecule																																			1	No	2	1	No	4	0	46.53 Å2	42.57 Å3	102.89 m3·mol-1	5	No	No	0.000617 mg/mL	5.78	-5.8	10.33	-5.4	P03372;!Q92731;!O75469;!P43681;!Q15596;!Q99527;!P00846;!Q14457;!P37059;!P62508	ESR1;!ESR2;!NR1I2;!CHRNA4;!NCOA2;!GPER1;!MT-ATP6;!BECN1;!HSD17B2;!ESRRG	1. Estrogen receptor alpha;!2. Estrogen receptor beta;!3. Nuclear receptor subfamily 1 group I member 2;!4. Neuronal acetylcholine receptor subunit alpha-4;!5. Nuclear receptor coactivator 2;!6. G-protein coupled estrogen receptor 1;!7. ATP synthase subunit a;!8. Beclin-1;!9. Estradiol 17-beta-dehydrogenase 2;!10. Estrogen-related receptor gamma
C21H30O3	Not Available	Not Available	330.468	[H][C@@]12CC[C@H](OC(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3C[C@@H](C)[C@@]21[H]	Solid	Not Available							CHEMBL452329	8421572														Trestolone_acetate			Trestolone acetate	Experimental	DB13958	InChI=1S/C21H30O3/c1-12-10-14-11-15(23)4-5-16(14)17-8-9-21(3)18(20(12)17)6-7-19(21)24-13(2)22/h11-12,16-20H,4-10H2,1-3H3/t12-,16+,17-,18+,19+,20-,21+/m1/s1	IVCRCPJOLWECJU-XQVQQVTHSA-N			Not Available	Small Molecule																																			1	Yes	2	0	No	4	0	43.37 Å2	38.59 Å3	93.65 m3·mol-1	2	Yes	No	0.00582 mg/mL	3.79	-4.8	18.34	-4.7			
C23H30O4	Not Available	Not Available	370.489	[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3C(C)=C[C@@]21[H]	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			135564	CHEMBL1476022	82771					D08281							53744		Nomegestrol_acetate	ZINC000003938628		Nomegestrol acetate	Approved, Investigational	DB13981	InChI=1S/C23H30O4/c1-13-11-20-18(17-6-5-16(26)12-19(13)17)7-9-22(4)21(20)8-10-23(22,14(2)24)27-15(3)25/h11-12,17-18,20-21H,5-10H2,1-4H3/t17-,18-,20-,21+,22+,23+/m1/s1	IIVBFTNIGYRNQY-YQLZSBIMSA-N	4		Not Available	Small Molecule																																			1	Yes	3	0	No	4	0	60.44 Å2	41.78 Å3	104.18 m3·mol-1	3	Yes	No	0.00415 mg/mL	3.42	-5	17.72	-4.8			
C31H45N3O6	Not Available	Not Available	555.716	C[C@H](\C=C\C=C(/C)[C@H]1OC(=O)C[C@H](O)CC[C@@](C)(O)[C@@H](OC(=O)N2CCN(C)CC2)\C=C\[C@@H]1C)C1=CC=CC=N1	Solid	Not Available								71360838																	H3B-8800	Investigational	DB14017	InChI=1S/C31H45N3O6/c1-22(26-11-6-7-16-32-26)9-8-10-23(2)29-24(3)12-13-27(39-30(37)34-19-17-33(5)18-20-34)31(4,38)15-14-25(35)21-28(36)40-29/h6-13,16,22,24-25,27,29,35,38H,14-15,17-21H2,1-5H3/b9-8+,13-12+,23-10+/t22-,24+,25-,27+,29-,31-/m1/s1	YOIQWBAHJZGRFW-WVRLKXNASA-N			Not Available	Small Molecule																																			1	No	6	2	Yes	3	1	112.43 Å2	62.34 Å3	156.6 m3·mol-1	6	No	No	0.153 mg/mL	3.14	-3.6	13.92	6.89	O75533	SF3B1	1. Splicing factor 3B subunit 1
C30H48O6	Not Available	Not Available	504.708	[H][C@]12CC=C3[C@]4([H])[C@@H](C)[C@H](C)CC[C@@]4(CC[C@@]3(C)[C@]1(C)C[C@@H](O)[C@@]1([H])[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]21C)C(O)=O	Solid	Not Available					50244879	73058	CHEMBL481854	66126												1551573			ZINC000014243546		Madecassic acid	Experimental	DB14037	InChI=1S/C30H48O6/c1-16-9-10-30(25(35)36)12-11-28(5)18(22(30)17(16)2)7-8-21-26(3)13-20(33)24(34)27(4,15-31)23(26)19(32)14-29(21,28)6/h7,16-17,19-24,31-34H,8-15H2,1-6H3,(H,35,36)/t16-,17+,19-,20-,21-,22+,23-,24+,26-,27+,28-,29-,30+/m1/s1	PRAUVHZJPXOEIF-AOLYGAPISA-N			Not Available	Small Molecule																																			1	No	6	5	No	5	-1	118.22 Å2	57.47 Å3	138.43 m3·mol-1	2	No	No	0.0356 mg/mL	2.92	-4.2	4.64	-2.8			
C29H50O	Not Available	Not Available	414.718	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC=C4C[C@@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CC[C@@H](CC)C(C)C	Solid	Not Available					50218197	27693	CHEMBL221542	192962			HMDB0000852	C01753	D08518							47070		Beta-Sitosterol	ZINC000004095717		beta-Sitosterol	Experimental	DB14038	InChI=1S/C29H50O/c1-7-21(19(2)3)9-8-20(4)25-12-13-26-24-11-10-22-18-23(30)14-16-28(22,5)27(24)15-17-29(25,26)6/h10,19-21,23-27,30H,7-9,11-18H2,1-6H3/t20-,21-,23+,24+,25-,26+,27+,28+,29-/m1/s1	KZJWDPNRJALLNS-VJSFXXLFSA-N	2		Not Available	Small Molecule																																			1	No	1	1	Yes	4	0	20.23 Å2	54.21 Å3	129.77 m3·mol-1	6	No	Yes	1.84e-05 mg/mL	7.84	-7.4	18.2	-1.4			
C30H48O5	Not Available	Not Available	488.6991	[H][C@@]12CC[C@]3(C)[C@]([H])(CC=C4[C@]5([H])[C@@H](C)[C@H](C)CC[C@@]5(CC[C@@]34C)C(O)=O)[C@@]1(C)C[C@@H](O)[C@H](O)[C@@]2(C)CO	Solid	Not Available					50241487	2873	CHEMBL404313	106361				C08617		0AS						1551574			ZINC000008221271		Asiatic acid	Experimental	DB14054	InChI=1S/C30H48O5/c1-17-9-12-30(25(34)35)14-13-28(5)19(23(30)18(17)2)7-8-22-26(3)15-20(32)24(33)27(4,16-31)21(26)10-11-29(22,28)6/h7,17-18,20-24,31-33H,8-16H2,1-6H3,(H,34,35)/t17-,18+,20-,21-,22-,23+,24+,26+,27+,28-,29-,30+/m1/s1	JXSVIVRDWWRQRT-UYDOISQJSA-N			Not Available	Small Molecule																																			1	No	5	4	No	5	-1	97.99 Å2	56.63 Å3	136.83 m3·mol-1	2	Yes	No	0.0114 mg/mL	4.23	-4.6	4.74	-2.8			
C48H78O19	Not Available	Not Available	959.133	[H][C@@]12CC[C@]3(C)[C@]([H])(CC=C4[C@]5([H])[C@@H](C)[C@H](C)CC[C@@]5(CC[C@@]34C)C(=O)O[C@@H]3O[C@H](CO[C@@H]4O[C@H](CO)[C@@H](O[C@@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)[C@@]1(C)C[C@@H](O)[C@H](O)[C@@]2(C)CO	Solid	Not Available					23211	79928	CHEMBL1684590	10128466				C15428	D07576							18405			ZINC000253529453		Asiaticoside	Experimental	DB14081	InChI=1S/C48H78O19/c1-20-10-13-48(15-14-46(6)23(29(48)21(20)2)8-9-28-44(4)16-24(51)39(60)45(5,19-50)27(44)11-12-47(28,46)7)43(61)67-42-36(58)33(55)31(53)26(65-42)18-62-40-37(59)34(56)38(25(17-49)64-40)66-41-35(57)32(54)30(52)22(3)63-41/h8,20-22,24-42,49-60H,9-19H2,1-7H3/t20-,21+,22+,24-,25-,26-,27-,28-,29+,30+,31-,32-,33+,34-,35-,36-,37-,38-,39+,40-,41+,42+,44+,45+,46-,47-,48+/m1/s1	WYQVAPGDARQUBT-FGWHUCSPSA-N			Not Available	Small Molecule																																			0	No	18	12	Yes	8	0	315.21 Å2	102.07 Å3	232.55 m3·mol-1	10	No	No	0.798 mg/mL	-0.54	-3.1	11.75	-3.6			
C19H28O2	Not Available	Not Available	296.463	[3H]C1C([3H])C2=CC(=O)C([3H])C([3H])[C@]2(C)[C@H]2CC[C@]3(C)[C@@H](O)CC[C@H]3[C@H]12	Solid	Not Available								35147838																	(1,2,6,7-3H)Testosterone	Experimental	DB14093	InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-17,21H,3-10H2,1-2H3/t14-,15-,16-,17-,18-,19-/m0/s1/i3T,4T,7T,9T/t3?,4?,7?,9?,14-,15-,16-,17-,18-,19-	MUMGGOZAMZWBJJ-JQSYSRDDSA-N			Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	34.06 Å3	84.43 m3·mol-1	0	Yes	Yes	0.0333 mg/mL	3.37	-3.9	18.52	-0.88			
C30H52O2	Not Available	Not Available	444.744	[H][C@@]1(CC[C@]2(C)C1([H])CC[C@]1([H])[C@@]3(C)CC[C@]([H])(O)C(C)(C)[C@]3([H])CC[C@@]21C)C(C)(O)CCC=C(C)C	Not Available	Not Available								2342730												349656		Ginsenoside			Ginsenosides	Experimental	DB14152	InChI=1S/C30H52O2/c1-20(2)10-9-16-30(8,32)22-13-18-28(6)21(22)11-12-24-27(5)17-15-25(31)26(3,4)23(27)14-19-29(24,28)7/h10,21-25,31-32H,9,11-19H2,1-8H3/t21?,22-,23-,24+,25-,27-,28+,29+,30?/m0/s1	NLHQJXWYMZLQJY-SWIZOJJJSA-N	4		Not Available	Small Molecule																																			1	No	2	2	No	4	0	40.46 Å2	55.91 Å3	135.64 m3·mol-1	4	No	No	0.000182 mg/mL	6.84	-6.4	19.49	-0.26			
C25H33ClO6	Not Available	Not Available	464.98	[H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Not Available	Not Available							CHEMBL2115116	56676												1546384			ZINC000022049777		Beclomethasone 17-monopropionate	Experimental	DB14221	InChI=1S/C25H33ClO6/c1-5-21(31)32-25(20(30)13-27)14(2)10-18-17-7-6-15-11-16(28)8-9-22(15,3)24(17,26)19(29)12-23(18,25)4/h8-9,11,14,17-19,27,29H,5-7,10,12-13H2,1-4H3/t14-,17-,18-,19-,22-,23-,24-,25-/m0/s1	OHYGPBKGZGRQKT-XGQKBEPLSA-N			Not Available	Small Molecule																																			1	Yes	5	2	No	4	0	100.9 Å2	48.36 Å3	121.01 m3·mol-1	5	Yes	No	0.00787 mg/mL	3.29	-4.8	13.52	-3.3			
C27H30Cl2O6	The clearance rate of mometasone furoate is not readily available1, though it may be close to 90L/h2.	The terminal half life of an inhaled dose is approximately 5 hoursLabel though it has been reported as 5.8 hours by other sources11,2.	521.429	[H][C@@]12C[C@@H](C)[C@](OC(=O)C3=CC=CO3)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	Steady state volume of distribution of 152LLabel.	P10632;!P08684;!P20815	CYP2C8;!CYP3A4;!CYP3A5	1. Cytochrome P450 2C8;!2. Cytochrome P450 3A4;!3. Cytochrome P450 3A5		50148733	47564	CHEMBL1161	390091				C07817	D00690	MOF								Mometasone	ZINC000003938677	Asmanex, Dulera, Elocom, Elocon, Nasonex, Sinuva, Zenhale	Mometasone furoate	Approved, Investigational, Vet approved	DB14512	InChI=1S/C27H30Cl2O6/c1-15-11-19-18-7-6-16-12-17(30)8-9-24(16,2)26(18,29)21(31)13-25(19,3)27(15,22(32)14-28)35-23(33)20-5-4-10-34-20/h4-5,8-10,12,15,18-19,21,31H,6-7,11,13-14H2,1-3H3/t15-,18+,19+,21+,24+,25+,26+,27+/m1/s1	WOFMFGQZHJDGCX-ZULDAHANSA-N	4	Mometasone furoate is a corticosteroid used to treat asthma, allergic rhinitis, nasal congestion, nasal polyps, dermatitis, and pruritus.	Overdose with a mometasone furoate inhaler may occur with chronic overuseLabel11. Symptoms of chronic overuse may present as hypercorticism and adrenal suppression, and patients may not require any more treatment than monitoringLabel11.In animal studies of pregnancy, some fetal toxic effects were seen at or above the maximum recommended human dose, though rodents are more sensitive to these effects than humansLabel11,12. The benefits and risks of use should be considered in pregnant patients11,12It is unknown if mometasone furoate is excreted in breast milk but other corticosteroids are and therefore caution should be exercised when administering to nursing mothersLabel11,12.Safety and effectiveness in pediatric populations has been established through clinical trials, though there may be a reduction in expected growth of about 1cm per year depending on the dose and duration of treatmentLabel. Pediatric patients should be titrated to the lowest effective dose for mometasone furoate inhalersLabel.A trial of geriatric patients showed no difference in safety or efficacy compared to younger patients, however patients of an even greater age may still be more sensitive to mometasone furoateLabel11,12.The use of a mometasone furoate inhaler in moderate or severe hepatic impairment rarely leads to detectable plasma concentrations though caution may be prudent with increasing degrees of severityLabel11.The effects of mometasone furoate in renal impairment, and across gender and race have not been studiedLabel11.	Small Molecule																														4.115		215-228		Insoluble	0	No	4	1	No	5	0	93.81 Å2	52.31 Å3	132.5 m3·mol-1	5	No	No	0.0108 mg/mL	5.06	-4.7	13.84	-3.1	P04150;!P06401	NR3C1;!PGR	1. Glucocorticoid receptor;!2. Progesterone receptor
C26H36O7	Not Available	6-8 hours	460.567	[H][C@@]12CC[C@](OC(=O)CC)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Not Available	Not Available	P08684;!P20815;!P24462;!P10632	CYP3A4;!CYP3A5;!CYP3A7;!CYP2C8	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5;!3. Cytochrome P450 3A7;!4. Cytochrome P450 2C8			135746	CHEMBL2106309	62148					D06876									Hydrocortisone_aceponate	ZINC000004213508		Hydrocortisone aceponate	Experimental, Vet approved	DB14538	InChI=1S/C26H36O7/c1-5-22(31)33-26(21(30)14-32-15(2)27)11-9-19-18-7-6-16-12-17(28)8-10-24(16,3)23(18)20(29)13-25(19,26)4/h12,18-20,23,29H,5-11,13-14H2,1-4H3/t18-,19-,20-,23+,24-,25-,26-/m0/s1	MFBMYAOAMQLLPK-FZNHGJLXSA-N			Side effects include inhibition of bone formation, suppression of calcium absorption and delayed wound healing	Small Molecule																																			1	Yes	5	1	Yes	4	0	106.97 Å2	49.74 Å3	120.33 m3·mol-1	7	Yes	No	0.00526 mg/mL	2.86	-4.9	14.81	-2.8	P04083;!P04150;!P80365;!P14060	ANXA1;!NR3C1;!HSD11B2;!HSD3B1	1. Annexin A1;!2. Glucocorticoid receptor;!3. Corticosteroid 11-beta-dehydrogenase isozyme 2;!4. 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1
C23H32O6	Not Available	6-8 hours	404.4966	[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Not Available	Not Available	P08684;!P20815;!P24462;!P15538;!P19099;!P10632	CYP3A4;!CYP3A5;!CYP3A7;!CYP11B1;!CYP11B2;!CYP2C8	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5;!3. Cytochrome P450 3A7;!4. Cytochrome P450 11B1, mitochondrial;!5. Cytochrome P450 11B2, mitochondrial;!6. Cytochrome P450 2C8		50474607	17609	CHEMBL1091	5542				C02821	D00165				5744					Hydrocortisone_acetate	ZINC000003875333	Alcortin A, Analpram HC, Anodan-HC, Anucort-HC, Anusol, Anusol HC, Cortifoam, Cortisporin, Cortisporin-TC, Egozinc, Epifoam, Fucidin, Micort-HC, Neo-polycin HC, Nucort, Pramosone, Procort 1.85/1.15, Proctocort, Proctodan-HC, Proctofoam-HC, Rectacort-HC, Rectogel, Riva-sol HC, U-cort, Vagisil, Vytone	Hydrocortisone acetate	Approved, Vet approved	DB14539	InChI=1S/C23H32O6/c1-13(24)29-12-19(27)23(28)9-7-17-16-5-4-14-10-15(25)6-8-21(14,2)20(16)18(26)11-22(17,23)3/h10,16-18,20,26,28H,4-9,11-12H2,1-3H3/t16-,17-,18-,20+,21-,22-,23-/m0/s1	ALEXXDVDDISNDU-JZYPGELDSA-N	3	Hydrocortisone acetate is a corticosteroid used to treat inflammatory and pruritic corticosteroid-responsive dermatoses and ulcerative colitis.	Side effects include inhibition of bone formation, suppression of calcium absorption and delayed wound healing	Small Molecule																																			1	Yes	5	2	No	4	0	100.9 Å2	43.82 Å3	106.55 m3·mol-1	4	Yes	No	0.0582 mg/mL	1.72	-3.8	12.61	-2.8	P04083;!P04150;!P80365;!P14060	ANXA1;!NR3C1;!HSD11B2;!HSD3B1	1. Annexin A1;!2. Glucocorticoid receptor;!3. Corticosteroid 11-beta-dehydrogenase isozyme 2;!4. 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1
C25H36O6	Not Available	6-8 hours	432.557	[H][C@@]12CC[C@](OC(=O)CCC)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Not Available	Not Available	P08684;!P20815;!P24462;!P15538;!P19099;!P10632	CYP3A4;!CYP3A5;!CYP3A7;!CYP11B1;!CYP11B2;!CYP2C8	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5;!3. Cytochrome P450 3A7;!4. Cytochrome P450 11B1, mitochondrial;!5. Cytochrome P450 11B2, mitochondrial;!6. Cytochrome P450 2C8		323672	31674	CHEMBL1683	24344					D01619									Hydrocortisone_butyrate	ZINC000003977794	Locoid	Hydrocortisone butyrate	Approved, Vet approved	DB14540	InChI=1S/C25H36O6/c1-4-5-21(30)31-25(20(29)14-26)11-9-18-17-7-6-15-12-16(27)8-10-23(15,2)22(17)19(28)13-24(18,25)3/h12,17-19,22,26,28H,4-11,13-14H2,1-3H3/t17-,18-,19-,22+,23-,24-,25-/m0/s1	BMCQMVFGOVHVNG-TUFAYURCSA-N	4	Hydrocortisone butyrate is a corticosteroid used to treat inflammatory and pruritic corticosteroid-responsive dermatoses.	Side effects include inhibition of bone formation, suppression of calcium absorption and delayed wound healing	Small Molecule																																			1	Yes	5	2	Yes	4	0	100.9 Å2	47.74 Å3	115.78 m3·mol-1	6	Yes	No	0.0136 mg/mL	2.86	-4.5	13.75	-2.8	P04083;!P04150;!P80365;!P14060	ANXA1;!NR3C1;!HSD11B2;!HSD3B1	1. Annexin A1;!2. Glucocorticoid receptor;!3. Corticosteroid 11-beta-dehydrogenase isozyme 2;!4. 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1
C29H42O6	Not Available	6-8 hours	486.649	[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC3CCCC3)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Not Available	Not Available	P08684;!P20815;!P24462;!P10632	CYP3A4;!CYP3A5;!CYP3A7;!CYP2C8	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5;!3. Cytochrome P450 3A7;!4. Cytochrome P450 2C8		50371265	5783	CHEMBL1549	193884				C08176	D00976									Hydrocortisone_cypionate	ZINC000004097470		Hydrocortisone cypionate	Approved, Investigational, Vet approved	DB14541	InChI=1S/C29H42O6/c1-27-13-11-20(30)15-19(27)8-9-21-22-12-14-29(34,28(22,2)16-23(31)26(21)27)24(32)17-35-25(33)10-7-18-5-3-4-6-18/h15,18,21-23,26,31,34H,3-14,16-17H2,1-2H3/t21-,22-,23-,26+,27-,28-,29-/m0/s1	DLVOSEUFIRPIRM-KAQKJVHQSA-N			Side effects include inhibition of bone formation, suppression of calcium absorption and delayed wound healing	Small Molecule																																			1	No	5	2	Yes	5	0	100.9 Å2	54.76 Å3	132.33 m3·mol-1	7	Yes	No	0.00326 mg/mL	4.02	-5.2	12.61	-2.8	P04083;!P04150;!P80365;!P14060	ANXA1;!NR3C1;!HSD11B2;!HSD3B1	1. Annexin A1;!2. Glucocorticoid receptor;!3. Corticosteroid 11-beta-dehydrogenase isozyme 2;!4. 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1
C21H31O8P	Not Available	6-8 hours	442.445	[H][C@@]12CC[C@](O)(C(=O)COP(O)(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Not Available	Not Available	P08684;!P20815;!P24462;!P10632	CYP3A4;!CYP3A5;!CYP3A7;!CYP2C8	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5;!3. Cytochrome P450 3A7;!4. Cytochrome P450 2C8			68634	CHEMBL1641	390143														Hydrocortisone_phosphate	ZINC000004097471		Hydrocortisone phosphate	Approved, Vet approved	DB14542	InChI=1S/C21H31O8P/c1-19-7-5-13(22)9-12(19)3-4-14-15-6-8-21(25,17(24)11-29-30(26,27)28)20(15,2)10-16(23)18(14)19/h9,14-16,18,23,25H,3-8,10-11H2,1-2H3,(H2,26,27,28)/t14-,15-,16-,18+,19-,20-,21-/m0/s1	BGSOJVFOEQLVMH-VWUMJDOOSA-N	2	Hydrocortisone phosphate is a corticosteroid used to treat congenital adrenal hyperplasia, for emergency asthma treatment, hypersensitivity, and inflammation.	Side effects include inhibition of bone formation, suppression of calcium absorption and delayed wound healing	Small Molecule																																			1	Yes	7	4	No	4	-2	141.36 Å2	44.37 Å3	108.27 m3·mol-1	4	Yes	No	0.73 mg/mL	1.15	-2.8	1.18	-2.8	P04083;!P04150;!P80365;!P14060	ANXA1;!NR3C1;!HSD11B2;!HSD3B1	1. Annexin A1;!2. Glucocorticoid receptor;!3. Corticosteroid 11-beta-dehydrogenase isozyme 2;!4. 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1
C28H40O7	Not Available	6-8 hours	488.613	[H][C@@]12CC[C@](OC(=O)CCC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Not Available	Not Available	P08684;!P20815;!P24462;!P15538;!P19099;!P10632	CYP3A4;!CYP3A5;!CYP3A7;!CYP11B1;!CYP11B2;!CYP2C8	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5;!3. Cytochrome P450 3A7;!4. Cytochrome P450 11B1, mitochondrial;!5. Cytochrome P450 11B2, mitochondrial;!6. Cytochrome P450 2C8			31675	CHEMBL1200953	552186				C13358	D01886				636398					Hydrocortisone	ZINC000004213519	Pandel	Hydrocortisone probutate	Approved, Vet approved	DB14543	InChI=1S/C28H40O7/c1-5-7-24(33)35-28(22(31)16-34-23(32)6-2)13-11-20-19-9-8-17-14-18(29)10-12-26(17,3)25(19)21(30)15-27(20,28)4/h14,19-21,25,30H,5-13,15-16H2,1-4H3/t19-,20-,21-,25+,26-,27-,28-/m0/s1	FOGXJPFPZOHSQS-AYVLZSQQSA-N	4	Hydrocortisone probutate is a corticosteroid used to treat inflammatory and pruritic corticosteroid-responsive dermatoses.	Side effects include inhibition of bone formation, suppression of calcium absorption and delayed wound healing	Small Molecule																																			1	No	5	1	Yes	4	0	106.97 Å2	53.93 Å3	129.56 m3·mol-1	9	Yes	No	0.00283 mg/mL	4	-5.2	14.81	-2.8	P04083;!P04150;!P80365;!P14060	ANXA1;!NR3C1;!HSD11B2;!HSD3B1	1. Annexin A1;!2. Glucocorticoid receptor;!3. Corticosteroid 11-beta-dehydrogenase isozyme 2;!4. 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1
C26H38O6	Not Available	6-8 hours	446.5763	[H][C@@]12CC[C@](OC(=O)CCCC)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Not Available	Not Available	P08684;!P20815;!P24462;!P15538;!P19099;!P10632	CYP3A4;!CYP3A5;!CYP3A7;!CYP11B1;!CYP11B2;!CYP2C8	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5;!3. Cytochrome P450 3A7;!4. Cytochrome P450 11B1, mitochondrial;!5. Cytochrome P450 11B2, mitochondrial;!6. Cytochrome P450 2C8			50865	CHEMBL1200562	4445635									5282494					Hydrocortisone_valerate	ZINC000004213520	Hydroval	Hydrocortisone valerate	Approved, Vet approved	DB14544	InChI=1S/C26H38O6/c1-4-5-6-22(31)32-26(21(30)15-27)12-10-19-18-8-7-16-13-17(28)9-11-24(16,2)23(18)20(29)14-25(19,26)3/h13,18-20,23,27,29H,4-12,14-15H2,1-3H3/t18-,19-,20-,23+,24-,25-,26-/m0/s1	FZCHYNWYXKICIO-FZNHGJLXSA-N	2	Hydrocortisone valerate is a corticosteroid used to treat inflammatory and pruritic corticosteroid-responsive dermatoses.	Side effects include inhibition of bone formation, suppression of calcium absorption and delayed wound healing	Small Molecule																																			1	Yes	5	2	Yes	4	0	100.9 Å2	50.08 Å3	120.38 m3·mol-1	7	Yes	No	0.00763 mg/mL	3.31	-4.8	13.75	-2.8	P04083;!P04150;!P80365;!P14060	ANXA1;!NR3C1;!HSD11B2;!HSD3B1	1. Annexin A1;!2. Glucocorticoid receptor;!3. Corticosteroid 11-beta-dehydrogenase isozyme 2;!4. 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1
C25H34O8	Not Available	Not Available	462.539	[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Not Available	Not Available	P08684;!P10632;!P15538;!P19099	CYP3A4;!CYP2C8;!CYP11B1;!CYP11B2	1. Cytochrome P450 3A4;!2. Cytochrome P450 2C8;!3. Cytochrome P450 11B1, mitochondrial;!4. Cytochrome P450 11B2, mitochondrial		50016931	31677	CHEMBL977	15760					D01442							21651		Hydrocortisone_hemisuccinate	ZINC000004097472	Solu-cortef	Hydrocortisone succinate	Approved	DB14545	InChI=1S/C25H34O8/c1-23-9-7-15(26)11-14(23)3-4-16-17-8-10-25(32,24(17,2)12-18(27)22(16)23)19(28)13-33-21(31)6-5-20(29)30/h11,16-18,22,27,32H,3-10,12-13H2,1-2H3,(H,29,30)/t16-,17-,18-,22+,23-,24-,25-/m0/s1	VWQWXZAWFPZJDA-CGVGKPPMSA-N	4	Hydrocortisone succinate is a corticosteroid used to treat severe allergic reactions, dermatologic diseases, endocrine disorders, gastrointestinal diseases, hematological disorders, neoplastic diseases, nervous system conditions, ophthalmic diseases, renal diseases, respiratory diseases, and rheumatic disorders.	Not Available	Small Molecule																																			1	Yes	7	3	Yes	4	-1	138.2 Å2	48.68 Å3	117.44 m3·mol-1	7	Yes	No	0.0653 mg/mL	1.54	-3.8	3.66	-2.8			
C30H50O2	Not Available	Not Available	442.728	[H][C@@]12CC[C@]3(C)[C@]([H])(CCC4=C5CC(C)(C)CC[C@]5(C)[C@@H](O)C[C@@]34C)[C@@]1(C)CC[C@H](O)C2(C)C	Not Available	Not Available								4438027												2045735			ZINC000033816140		Ursadiol	Experimental	DB14555	InChI=1S/C30H50O2/c1-25(2)15-16-27(5)20(17-25)19-9-10-22-28(6)13-12-23(31)26(3,4)21(28)11-14-29(22,7)30(19,8)18-24(27)32/h21-24,31-32H,9-18H2,1-8H3/t21-,22+,23-,24-,27-,28-,29+,30+/m0/s1	RTLXJEJRLWILSU-GWNGJUQLSA-N			Not Available	Small Molecule																																			1	No	2	2	No	5	0	40.46 Å2	54.73 Å3	133.16 m3·mol-1	0	No	No	0.00253 mg/mL	6.13	-5.2	19.49	-0.3			
C21H30O3	Not Available	Not Available	330.4611	[H][C@@]12CC[C@](O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4		50423511	17252	CHEMBL1062	6002			HMDB0000374	C01176		3QZ						5542		17%CE%B1-Hydroxyprogesterone	ZINC000005434436		Hydroxyprogesterone	Experimental	DB14570	InChI=1S/C21H30O3/c1-13(22)21(24)11-8-18-16-5-4-14-12-15(23)6-9-19(14,2)17(16)7-10-20(18,21)3/h12,16-18,24H,4-11H2,1-3H3/t16-,17+,18+,19+,20+,21+/m1/s1	DBPWSSGDRRHUNT-CEGNMAFCSA-N	4		Not Available	Small Molecule																																			1	Yes	3	1	No	4	0	54.37 Å2	37.9 Å3	94.11 m3·mol-1	1	Yes	No	0.0293 mg/mL	3.4	-4	12.7	-3.8			
C23H30O4	No pharmacokinetic data available.	The mean (SD) half life of segesterone acetate is 4.5 (3.4) hours Label.	370.489	[H][C@@]12CC(=C)[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	Solid	The volume of distribution of segesterone acetate is 19.6 L/kg Label.	P08684	CYP3A4	1. Cytochrome P450 3A4			135563	CHEMBL3707377	97161												2055977		Segesterone_acetate	ZINC000005167230	Annovera	Segesterone acetate	Approved, Experimental, Investigational	DB14583	InChI=1S/C23H30O4/c1-13-11-21-20-7-5-16-12-17(26)6-8-18(16)19(20)9-10-22(21,4)23(13,14(2)24)27-15(3)25/h12,18-21H,1,5-11H2,2-4H3/t18-,19+,20+,21-,22-,23-/m0/s1	CKFBRGLGTWAVLG-GOMYTPFNSA-N	3		There have been no reports of serious ill effects from overdose of combination hormonal contraceptive use. Overdosage may cause withdrawal bleeding in females and nausea. In case of suspected overdose, all vaginal systems containing segesterone acetate should be removed and symptomatic treatment should be initiated Label.In a 2-year carcinogenicity study in rats receiving segesterone acetate via subdermal implants, there was no drug-related increase in tumor incidence. In a 2-year intravaginal carcinogenicity study in mice, segesterone acetate gel produced an increased incidence of adenocarcinoma and lobular hyperplasia in the breast at a supratherapeutic dose of 30 mg/kg/day. Segesterone acetate was not shown to be mutagenic or clastogenic Label.	Small Molecule																																173-177		Insoluble	1	Yes	3	0	No	4	0	60.44 Å2	41.79 Å3	102.95 m3·mol-1	3	Yes	No	0.00231 mg/mL	3.64	-5.2	17.46	-4.7	P06401;!P10275;!P04150	PGR;!AR;!NR3C1	1. Progesterone receptor;!2. Androgen receptor;!3. Glucocorticoid receptor
C21H28O3	Not Available	Not Available	328.452	[H][C@@]12CC(=C)[C@](O)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	Not Available	Not Available							CHEMBL2107778	9998301												2055978		Segesterone			Segesterone	Experimental	DB14584	InChI=1S/C21H28O3/c1-12-10-19-18-6-4-14-11-15(23)5-7-16(14)17(18)8-9-20(19,3)21(12,24)13(2)22/h11,16-19,24H,1,4-10H2,2-3H3/t16-,17+,18+,19-,20-,21-/m0/s1	SFLXYFZGKSGFKA-XUDSTZEESA-N			Not Available	Small Molecule																																			1	Yes	3	1	No	4	0	54.37 Å2	37.67 Å3	93.8 m3·mol-1	1	Yes	No	0.0241 mg/mL	3.2	-4.1	12.21	-4			
C24H31ClO7	Loteprednol etabonate was slowly hydrolyzed in liver at clearance rates of 0.21 +/- 0.04 and 2.41 +/- 0.13 ml/h/kg in the liver and plasma, respectively 2.	The terminal half-life of loteprednol etabonate as determined when administered intravenously at a dose of 5 mg/kg in the dog animal model is 2.8 hours 3.	466.96	[H][C@@]12CC[C@](OC(=O)OCC)(C(=O)OCCl)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	The only data available regarding the volume of distribution of loteprednol etabonate (LE) is the volume of distribution the agent demonstrated when administered to dogs - a value of 3.7 L/kg 3. It has been shown, however, that the topical ocular administration of LE distributes preferentially into the cellular components of blood 8.	P08684;!P27169	CYP3A4;!PON1	1. Cytochrome P450 3A4;!2. Serum paraoxonase/arylesterase 1			31784	CHEMBL1200865	392049	Drugs.com Drug Page		HMDB0015011		D01689			PA164764569	9865442	46504713	RxList Drug Page		DAP001045	Loteprednol	ZINC000003920673	Eysuvis, Inveltys, Lotemax	Loteprednol etabonate	Approved	DB14596	InChI=1S/C24H31ClO7/c1-4-30-21(29)32-24(20(28)31-13-25)10-8-17-16-6-5-14-11-15(26)7-9-22(14,2)19(16)18(27)12-23(17,24)3/h7,9,11,16-19,27H,4-6,8,10,12-13H2,1-3H3/t16-,17-,18-,19+,22-,23-,24-/m0/s1	DMKSVUSAATWOCU-HROMYWEYSA-N	4	Loteprednol etabonate is a corticosteroid used to treat allergic conjunctivitis as well as inflammation and pain after ocular surgery.	The most common adverse drug reactions reported during clinical trials for the medication were eye pain and posterior capsular opacification, both of which may also be the consequence of the very surgical procedures performed on the eye(s) Label.The agent is not absorbed systemically following topical ophthalmic administration and maternal use is not expected to result in fetal exposure to the drug Label.The medication is not absorbed systemically by the mother following topical ophthalmic administration, and breastfeeding is not expected to result in exposure of the child to the agent Label.Long-term animal studies have not been conducted to evaluate the carcinogenic potential of loteprednol etabonate. Loteprednol etabonate was not genotoxic in vitro in the Ames test, the mouse lymphoma thymidine kinase (tk) assay, or in a chromosome aberration test in human lymphocytes, or in vivo in the single dose mouse micronucleus assay Label.Overdose is not expected to be likely to occur after ocular administration 8.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.2305 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.4		220-224 °C		5 mg/mL	1	Yes	5	1	Yes	4	0	99.13 Å2	48.43 Å3	118.17 m3·mol-1	7	Yes	No	0.00693 mg/mL	3.94	-4.8	14.88	-2.9	P04150	NR3C1	1. Glucocorticoid receptor
C24H30O6	Not Available	Not Available	414.498	C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3C(=O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O	Not Available	Not Available								92124															ZINC000006066697		Meprednisone acetate	Experimental	DB14625	InChI=1S/C24H30O6/c1-13-9-18-17-6-5-15-10-16(26)7-8-22(15,3)21(17)19(27)11-23(18,4)24(13,29)20(28)12-30-14(2)25/h7-8,10,13,17-18,21,29H,5-6,9,11-12H2,1-4H3/t13-,17-,18-,21+,22-,23-,24-/m0/s1	RZAMUHXEOMZXET-ABQXZQTJSA-N			Not Available	Small Molecule																																			1	Yes	5	1	No	4	0	97.74 Å2	44.17 Å3	111.19 m3·mol-1	4	Yes	No	0.0168 mg/mL	2.46	-4.4	12.46	-3.9			
C23H34O3	Not Available	Not Available	358.522	[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@H](CC[C@]12C)OC(C)=O	Not Available	Not Available						34930	CHEMBL1892286	2005918				C14658										Pregnenolone_acetate	ZINC000003860692		Pregnenolone acetate	Investigational	DB14626	InChI=1S/C23H34O3/c1-14(24)19-7-8-20-18-6-5-16-13-17(26-15(2)25)9-11-22(16,3)21(18)10-12-23(19,20)4/h5,17-21H,6-13H2,1-4H3/t17-,18-,19+,20-,21-,22-,23+/m0/s1	CRRKVZVYZQXICQ-RJJCNJEVSA-N			Not Available	Small Molecule																																			1	Yes	2	0	No	4	0	43.37 Å2	42.51 Å3	102.91 m3·mol-1	3	Yes	No	0.00188 mg/mL	4.02	-5.3	19.4	-6.8			
C21H29O8P	Not Available	The half life of prednisolone is 2-4 hours.6	440.429	[H][C@@]12CC[C@](O)(C(=O)COP(O)(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	The volume of distribution of prednisolone phosphate has been reported as 0.22-0.7L/kg.7	P08684;!P20815;!BE0004866;!P11509;!Q16678;!P20813;!P10632;!P11712;!P33261;!P80365;!P28845	CYP3A4;!CYP3A5;!;!CYP2A6;!CYP1B1;!CYP2B6;!CYP2C8;!CYP2C9;!CYP2C19;!HSD11B2;!HSD11B1	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5;!3. Cytochrome P450 3A Subfamily (Protein Group);!4. Cytochrome P450 2A6;!5. Cytochrome P450 1B1;!6. Cytochrome P450 2B6;!7. Cytochrome P450 2C8;!8. Cytochrome P450 2C9;!9. Cytochrome P450 2C19;!10. Corticosteroid 11-beta-dehydrogenase isozyme 2;!11. Corticosteroid 11-beta-dehydrogenase isozyme 1			145705	CHEMBL1201231	65064														Prednisolone_sodium_phosphate	ZINC000004097473	Orapred, Pediapred	Prednisolone phosphate	Approved, Vet approved	DB14631	InChI=1S/C21H29O8P/c1-19-7-5-13(22)9-12(19)3-4-14-15-6-8-21(25,17(24)11-29-30(26,27)28)20(15,2)10-16(23)18(14)19/h5,7,9,14-16,18,23,25H,3-4,6,8,10-11H2,1-2H3,(H2,26,27,28)/t14-,15-,16-,18+,19-,20-,21-/m0/s1	JDOZJEUDSLGTLU-VWUMJDOOSA-N	3	Prednisolone phosphate is a corticosteroid used to treat inflammation, immune reactions, as well as endocrine or neoplastic conditions.	Data regarding acute overdose is not readily available.6 However, patients experiencing chronic overdose may present with mental symptoms, moon face, abnormal fat deposits, and fluid retention.6 Acute oral overdose may be treated with immediate gastric lavage or emesis followed by symptomatic and supportive treatment.6 Chronic overdosage can be managed by temporary dose reduction or alternate day treatment.6	Small Molecule																																			1	Yes	7	4	No	4	-2	141.36 Å2	43.42 Å3	109.37 m3·mol-1	4	Yes	No	0.432 mg/mL	1.15	-3	1.18	-2.9	P04150;!P04083	NR3C1;!ANXA1	1. Glucocorticoid receptor;!2. Annexin A1
C27H38O6	Not Available	Not Available	458.587	[H][C@@]12CC[C@](O)(C(=O)COC(=O)CC(C)(C)C)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Not Available	Not Available						8381	CHEMBL1200909	84007				C08182	D00982				93055					Prednisolone_tebutate	ZINC000004097474		Prednisolone tebutate	Approved, Vet approved	DB14632	InChI=1S/C27H38O6/c1-24(2,3)14-22(31)33-15-21(30)27(32)11-9-19-18-7-6-16-12-17(28)8-10-25(16,4)23(18)20(29)13-26(19,27)5/h8,10,12,18-20,23,29,32H,6-7,9,11,13-15H2,1-5H3/t18-,19-,20-,23+,25-,26-,27-/m0/s1	HUMXXHTVHHLNRO-KAJVQRHHSA-N			Not Available	Small Molecule																																			1	No	5	2	Yes	4	0	100.9 Å2	51.06 Å3	125.9 m3·mol-1	6	Yes	No	0.00929 mg/mL	3.45	-4.7	12.61	-2.9			
C25H32O8	Not Available	Not Available	460.523	[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Not Available	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5			135745	CHEMBL485659	571099														Prednisolone	ZINC000003881478		Prednisolone hemisuccinate	Experimental	DB14633	InChI=1S/C25H32O8/c1-23-9-7-15(26)11-14(23)3-4-16-17-8-10-25(32,24(17,2)12-18(27)22(16)23)19(28)13-33-21(31)6-5-20(29)30/h7,9,11,16-18,22,27,32H,3-6,8,10,12-13H2,1-2H3,(H,29,30)/t16-,17-,18-,22+,23-,24-,25-/m0/s1	APGDTXUMTIZLCJ-CGVGKPPMSA-N		Prednisolone hemisuccinate is a corticosteroid indicated in the treatment of anaphylaxis, asthma, edema, organ rejection, and other indications.	Not Available	Small Molecule																																			1	Yes	7	3	Yes	4	-1	138.2 Å2	47.52 Å3	118.54 m3·mol-1	7	Yes	No	0.0483 mg/mL	1.54	-4	3.66	-2.9			
C24H29FO6	Not Available	Not Available	432.488	[H][C@@]12CC(=C)[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Not Available	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5			135700		8155833														Fluprednidene_acetate	ZINC000030691649		Fluprednidene acetate	Experimental	DB14634	InChI=1S/C24H29FO6/c1-13-9-18-17-6-5-15-10-16(27)7-8-21(15,3)23(17,25)19(28)11-22(18,4)24(13,30)20(29)12-31-14(2)26/h7-8,10,17-19,28,30H,1,5-6,9,11-12H2,2-4H3/t17-,18-,19-,21-,22-,23-,24-/m0/s1	DEFOZIFYUBUHHU-IYQKUMFPSA-N		Fluprednidene acetate is a corticosteroid indicated in the treatment of corticosteroid-responsive dermatoses.	Not Available	Small Molecule																																			1	Yes	5	2	No	4	0	100.9 Å2	44.61 Å3	111.34 m3·mol-1	4	Yes	No	0.0292 mg/mL	1.85	-4.2	12.12	-3.4			
C23H29FO6	Not Available	Not Available	420.477	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4					91954															ZINC000005161248		Fluprednisolone acetate	Experimental	DB14637	InChI=1S/C23H29FO6/c1-12(25)30-11-19(28)23(29)7-5-15-14-9-17(24)16-8-13(26)4-6-21(16,2)20(14)18(27)10-22(15,23)3/h4,6,8,14-15,17-18,20,27,29H,5,7,9-11H2,1-3H3/t14-,15-,17-,18-,20+,21-,22-,23-/m0/s1	CYMBAKFTWRNHPS-APRQOCPKSA-N			Not Available	Small Molecule																																			1	Yes	5	2	No	4	0	100.9 Å2	42.94 Å3	107.47 m3·mol-1	4	Yes	No	0.0414 mg/mL	1.37	-4	12.61	-2.9			
C30H44O3	Not Available	14 days	452.679	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2OC(=O)CCCCCCCCC=C	Not Available	Not Available							CHEMBL2106059	10128605														Boldenone_undecylenate	ZINC000004215044		Boldenone undecylenate	Illicit, Vet approved	DB14639	InChI=1S/C30H44O3/c1-4-5-6-7-8-9-10-11-12-28(32)33-27-16-15-25-24-14-13-22-21-23(31)17-19-29(22,2)26(24)18-20-30(25,27)3/h4,17,19,21,24-27H,1,5-16,18,20H2,2-3H3/t24-,25-,26-,27-,29-,30-/m0/s1	AHMMSNQYOPMLSX-CNQKSJKFSA-N			Not Available	Small Molecule																																			0	No	2	0	Yes	4	0	43.37 Å2	56.18 Å3	136.15 m3·mol-1	11	No	No	5.54e-05 mg/mL	7.76	-6.9	18.39	-5	P10275	AR	1. Androgen receptor
C23H29FO6	Not Available	Not Available	420.477	[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Not Available	Not Available						34517	CHEMBL1608183	194836				C14636	D04627										ZINC000004213604		Isoflupredone acetate	Vet approved	DB14640	InChI=1S/C23H29FO6/c1-13(25)30-12-19(28)22(29)9-7-16-17-5-4-14-10-15(26)6-8-20(14,2)23(17,24)18(27)11-21(16,22)3/h6,8,10,16-18,27,29H,4-5,7,9,11-12H2,1-3H3/t16-,17-,18-,20-,21-,22-,23-/m0/s1	ZOCUOMKMBMEYQV-GSLJADNHSA-N			Not Available	Small Molecule																																			1	Yes	5	2	No	4	0	100.9 Å2	42.89 Å3	107.17 m3·mol-1	4	Yes	No	0.025 mg/mL	1.76	-4.2	12.58	-3.4			
C27H36O6	Not Available	Not Available	456.5711	[H][C@]1(C[C@@]2([H])[C@]3([H])CCC4=CC(OC(=O)CC)=CC=C4[C@@]3([H])CC[C@]2(C)[C@@]1([H])OC(=O)CC)OC(=O)CC	Not Available	Not Available							CHEMBL3559901	92362									102232					Estriol_tripropionate	ZINC000030690586		Estriol tripropionate	Experimental	DB14641	InChI=1S/C27H36O6/c1-5-23(28)31-17-9-11-18-16(14-17)8-10-20-19(18)12-13-27(4)21(20)15-22(32-24(29)6-2)26(27)33-25(30)7-3/h9,11,14,19-22,26H,5-8,10,12-13,15H2,1-4H3/t19-,20-,21+,22-,26+,27+/m1/s1	ONMZMZJEZHMWQL-REUUDLSRSA-N			ORAL (LD50): Acute: >2000 mg/kg [Rat].	Small Molecule																																			1	Yes	3	0	Yes	4	0	78.9 Å2	52.33 Å3	122.6 m3·mol-1	9	No	No	0.000438 mg/mL	5.57	-6		-6.6	P03372;!Q92731;!P04278	ESR1;!ESR2;!SHBG	1. Estrogen receptor alpha;!2. Estrogen receptor beta;!3. Sex hormone-binding globulin
C27H36O7	Not Available	Not Available	472.578	[H][C@@]12CC[C@](OC(=O)CC)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C	Not Available	Not Available						135762	CHEMBL1697782	56717														Methylprednisolone_aceponate	ZINC000004213828		Methylprednisolone aceponate	Approved, Vet approved	DB14643	InChI=1S/C27H36O7/c1-6-23(32)34-27(22(31)14-33-16(3)28)10-8-19-18-11-15(2)20-12-17(29)7-9-25(20,4)24(18)21(30)13-26(19,27)5/h7,9,12,15,18-19,21,24,30H,6,8,10-11,13-14H2,1-5H3/t15-,18-,19-,21-,24+,25-,26-,27-/m0/s1	DALKLAYLIPSCQL-YPYQNWSCSA-N	4	Methylprednisolone aceponate is a corticosteroid indicated in the treatment of corticosteroid-responsive dermatoses.	Not Available	Small Molecule																																			1	Yes	5	1	Yes	4	0	106.97 Å2	50.86 Å3	125.97 m3·mol-1	7	Yes	No	0.00637 mg/mL	3.14	-4.9	14.8	-2.9			
C26H34O8	Not Available	Not Available	474.55	[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C	Not Available	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5			135765	CHEMBL1201265	16034														Methylprednisolone	ZINC000003977781	Solu-medrol	Methylprednisolone hemisuccinate	Approved	DB14644	InChI=1S/C26H34O8/c1-14-10-16-17-7-9-26(33,20(29)13-34-22(32)5-4-21(30)31)25(17,3)12-19(28)23(16)24(2)8-6-15(27)11-18(14)24/h6,8,11,14,16-17,19,23,28,33H,4-5,7,9-10,12-13H2,1-3H3,(H,30,31)/t14-,16-,17-,19-,23+,24-,25-,26-/m0/s1	IMBXEJJVJRTNOW-XYMSELFBSA-N	4	Methylprednisolone hemisuccinate is a water soluble corticosteroid used to treat severe allergic reactions, dermatologic diseases, endocrine disorders, gastrointestinal diseases, hematological disorders, neoplastic diseases, nervous system conditions, ophthalmic diseases, renal diseases, respiratory diseases, and rheumatic disorders.	Not Available	Small Molecule																																			1	Yes	7	3	Yes	4	-1	138.2 Å2	49.87 Å3	123.09 m3·mol-1	7	Yes	No	0.0264 mg/mL	1.83	-4.2	3.66	-2.9			
C23H28O6	Not Available	Not Available	400.471	[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Not Available	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5			34655	CHEMBL1507567	82567				C14668	D08416										ZINC000003881638		Prednisone acetate	Approved, Experimental, Investigational	DB14646	InChI=1S/C23H28O6/c1-13(24)29-12-19(27)23(28)9-7-17-16-5-4-14-10-15(25)6-8-21(14,2)20(16)18(26)11-22(17,23)3/h6,8,10,16-17,20,28H,4-5,7,9,11-12H2,1-3H3/t16-,17-,20+,21-,22-,23-/m0/s1	MOVRKLZUVNCBIP-RFZYENFJSA-N	4		Not Available	Small Molecule																																			1	Yes	5	1	No	4	0	97.74 Å2	42.51 Å3	106.72 m3·mol-1	4	Yes	No	0.0235 mg/mL	2.1	-4.2	12.6	-3.8			
C24H31FO6	Not Available	Not Available	434.4977	[H][C@@]12C[C@@H](C)[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Not Available	Not Available	P08684;!P20815;!P24462;!P05093;!P04798;!P11509;!P20813;!P33261;!P10632;!P05181;!Q9HB55;!Q02928;!P15538;!P80365;!P28845	CYP3A4;!CYP3A5;!CYP3A7;!CYP17A1;!CYP1A1;!CYP2A6;!CYP2B6;!CYP2C19;!CYP2C8;!CYP2E1;!CYP3A43;!CYP4A11;!CYP11B1;!HSD11B2;!HSD11B1	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5;!3. Cytochrome P450 3A7;!4. Steroid 17-alpha-hydroxylase/17,20 lyase;!5. Cytochrome P450 1A1;!6. Cytochrome P450 2A6;!7. Cytochrome P450 2B6;!8. Cytochrome P450 2C19;!9. Cytochrome P450 2C8;!10. Cytochrome P450 2E1;!11. Cytochrome P450 3A43;!12. Cytochrome P450 4A11;!13. Cytochrome P450 11B1, mitochondrial;!14. Corticosteroid 11-beta-dehydrogenase isozyme 2;!15. Corticosteroid 11-beta-dehydrogenase isozyme 1		50103620	4463	CHEMBL1530428	206624				C08174	D07796				236702					Dexamethasone_acetate	ZINC000003882068		Dexamethasone acetate	Approved, Investigational, Vet approved	DB14649	InChI=1S/C24H31FO6/c1-13-9-18-17-6-5-15-10-16(27)7-8-21(15,3)23(17,25)19(28)11-22(18,4)24(13,30)20(29)12-31-14(2)26/h7-8,10,13,17-19,28,30H,5-6,9,11-12H2,1-4H3/t13-,17+,18+,19+,21+,22+,23+,24+/m1/s1	AKUJBENLRBOFTD-RPRRAYFGSA-N	3		Not Available	Small Molecule																																			1	Yes	5	2	No	4	0	100.9 Å2	45.02 Å3	111.64 m3·mol-1	4	Yes	No	0.0164 mg/mL	2.12	-4.4	12.44	-3.4	P04150;!P04083;!P35228;!P51843;!O75469	NR3C1;!ANXA1;!NOS2;!NR0B1;!NR1I2	1. Glucocorticoid receptor;!2. Annexin A1;!3. Nitric oxide synthase, inducible;!4. Nuclear receptor subfamily 0 group B member 1;!5. Nuclear receptor subfamily 1 group I member 2
C24H30ClFO5	Not Available	Not Available	452.95	[H][C@@]12C[C@@H](C)[C@H](C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C	Not Available	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5				CHEMBL2106011	10128648																	Clocortolone acetate	Experimental	DB14652	InChI=1S/C24H30ClFO5/c1-12-7-15-16-9-18(26)17-8-14(28)5-6-23(17,4)24(16,25)20(30)10-22(15,3)21(12)19(29)11-31-13(2)27/h5-6,8,12,15-16,18,20-21,30H,7,9-11H2,1-4H3/t12-,15+,16+,18+,20+,21-,22+,23+,24+/m1/s1	ARPLCFGLEYFDCN-CDACMRRYSA-N			Not Available	Small Molecule																																			1	Yes	4	1	No	4	0	80.67 Å2	46.16 Å3	114.89 m3·mol-1	4	Yes	No	0.00394 mg/mL	2.92	-5.1	13.83	-3.3			
C28H38ClFO5	Not Available	Not Available	509.06	CCCCCC(=O)OCC(=O)[C@H]1[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C	Not Available	Not Available								96796															ZINC000118937942		Clocortolone caproate	Experimental	DB14653	InChI=1S/C28H38ClFO5/c1-5-6-7-8-24(34)35-15-22(32)25-16(2)11-18-19-13-21(30)20-12-17(31)9-10-27(20,4)28(19,29)23(33)14-26(18,25)3/h9-10,12,16,18-19,21,23,25,33H,5-8,11,13-15H2,1-4H3/t16-,18+,19+,21+,23+,25-,26+,27+,28+/m1/s1	MMTRTBFDFNRBQO-ANHDKODLSA-N			Not Available	Small Molecule																																			1	No	4	1	Yes	4	0	80.67 Å2	53.59 Å3	133.32 m3·mol-1	8	No	No	0.00103 mg/mL	4.95	-5.7	13.83	-3.3			
C23H36O3	Not Available	Not Available	360.538	[H][C@@]12CC[C@H](OC(=O)CC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)[C@H](C)C[C@]12C	Not Available	Not Available						31523	CHEMBL1201048	194604					D01534			PA164760855						Drostanolone_propionate	ZINC000004213057		Drostanolone propionate	Approved, Illicit	DB14655	InChI=1S/C23H36O3/c1-5-21(25)26-20-9-8-17-16-7-6-15-12-19(24)14(2)13-23(15,4)18(16)10-11-22(17,20)3/h14-18,20H,5-13H2,1-4H3/t14-,15+,16+,17+,18+,20+,22+,23+/m1/s1	NOTIQUSPUUHHEH-UXOVVSIBSA-N			Side effects include virilization (masculine traits in women), acne, fluid retention, and hypercalcemia.	Small Molecule																																			1	Yes	2	0	No	4	0	43.37 Å2	43.19 Å3	101.96 m3·mol-1	3	No	No	0.000631 mg/mL	5.1	-5.8		-6.9			
C25H32O4	Not Available	Not Available	396.527	[H][C@@]12CC(=C)[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C	Not Available	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5			34831	CHEMBL1328968	219803				C14642	D04900									Melengestrol_acetate	ZINC000004216828		Melengestrol acetate	Experimental	DB14659	InChI=1S/C25H32O4/c1-14-11-19-20(23(5)9-7-18(28)13-21(14)23)8-10-24(6)22(19)12-15(2)25(24,16(3)26)29-17(4)27/h11,13,19-20,22H,2,7-10,12H2,1,3-6H3/t19-,20+,22+,23-,24+,25+/m1/s1	UDKABVSQKJNZBH-DWNQPYOZSA-N			Not Available	Small Molecule																																			1	Yes	3	0	No	4	0	60.44 Å2	44.82 Å3	112.83 m3·mol-1	3	Yes	No	0.00147 mg/mL	3.82	-5.4	17.54	-4.9			
C20H24O3	Not Available	Not Available	312.409	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)CCC4=C3C=C[C@]12C)OC(C)=O	Not Available	Not Available					50190646		CHEMBL1698011	59737														Trenbolone_acetate	ZINC000004083873		Trenbolone acetate	Vet approved	DB14660	InChI=1S/C20H24O3/c1-12(21)23-19-8-7-18-17-5-3-13-11-14(22)4-6-15(13)16(17)9-10-20(18,19)2/h9-11,17-19H,3-8H2,1-2H3/t17-,18+,19+,20+/m1/s1	CMRJPMODSSEAPL-FYQPLNBISA-N			Not Available	Small Molecule																																			1	Yes	2	0	No	4	0	43.37 Å2	35.53 Å3	90.81 m3·mol-1	2	Yes	No	0.00758 mg/mL	2.7	-4.6	18.4	-4.8			
C27H36F2O5	Not Available	Not Available	478.577	[H][C@@]12C[C@@H](C)[C@H](C(=O)COC(=O)C(C)(C)C)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C	Not Available	Not Available							CHEMBL2106277	59756																	Difluocortolone pivalate	Experimental	DB14664	InChI=1S/C27H36F2O5/c1-14-9-16-17-11-19(28)18-10-15(30)7-8-26(18,6)27(17,29)21(32)12-25(16,5)22(14)20(31)13-34-23(33)24(2,3)4/h7-8,10,14,16-17,19,21-22,32H,9,11-13H2,1-6H3/t14-,16+,17+,19+,21+,22-,25+,26+,27+/m1/s1	UWGRWFCLGQWKPR-GSTUPEFVSA-N			Not Available	Small Molecule																																			1	Yes	4	1	No	4	0	80.67 Å2	50.61 Å3	123.85 m3·mol-1	5	Yes	No	0.00492 mg/mL	4.25	-5	13.61	-3.4			
C22H30FO8P	The clearance of betamethasone in an intramuscular injection of 3mg betamethasone acetate and 3mg betamethasone phosphate is 12.62 ± 3.45 L/h.1	The half life of betamethasone in an intramuscular injection of 3mg betamethasone acetate and 3mg betamethasone phosphate is 12.47 ± 1.91 h.1	472.446	[H][C@@]12C[C@H](C)[C@](O)(C(=O)COP(O)(O)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	The volume of distribution of betamethasone in an intramuscular injection of 3mg betamethasone acetate and 3mg betamethasone phosphate is 226.00 ± 61.64 L.1	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5			68603	CHEMBL1201207	96937														Betamethasone_phosphate	ZINC000004097469		Betamethasone phosphate	Approved, Vet approved	DB14669	InChI=1S/C22H30FO8P/c1-12-8-16-15-5-4-13-9-14(24)6-7-19(13,2)21(15,23)17(25)10-20(16,3)22(12,27)18(26)11-31-32(28,29)30/h6-7,9,12,15-17,25,27H,4-5,8,10-11H2,1-3H3,(H2,28,29,30)/t12-,15-,16-,17-,19-,20-,21-,22-/m0/s1	VQODGRNSFPNSQE-DVTGEIKXSA-N		Betamethasone phosphate is a fast acting ester prodrug of a corticosteroid used to treat inflammatory conditions.	Patients experiencing an acute overdose should be treated with symptomatic and supportive treatment.5 Chronic overdoses where patients require continued therapy can be treated through temporary dose reduction or alternate day treatment.5The oral, intraperitoneal, and intravenous LD50 values in rats are 1877 mg/kg, 1179 mg/kg, and 1276 mg/kg, respectively.6	Small Molecule																																			1	Yes	7	4	No	4	-2	141.36 Å2	45.43 Å3	113.37 m3·mol-1	4	Yes	No	2.9 mg/mL	1.56	-2.2	1.18	-3.4	P04150;!P04083	NR3C1;!ANXA1	1. Glucocorticoid receptor;!2. Annexin A1
C26H35FO7	Not Available	Not Available	478.557	CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]21C	Not Available	Not Available								92436																	Flurandrenolide acetate	Experimental	DB14673	InChI=1S/C26H35FO7/c1-13(28)32-12-20(31)26-21(33-23(2,3)34-26)10-16-15-9-18(27)17-8-14(29)6-7-24(17,4)22(15)19(30)11-25(16,26)5/h8,15-16,18-19,21-22,30H,6-7,9-12H2,1-5H3/t15-,16-,18-,19-,21+,22+,24-,25-,26+/m0/s1	AUDPKCCPWYXNEV-XTLNBZDDSA-N			Not Available	Small Molecule																																			1	Yes	6	1	No	5	0	99.13 Å2	49.64 Å3	119.94 m3·mol-1	4	Yes	No	0.0162 mg/mL	2	-4.5	14.67	-2.8			
C26H38O4	Not Available	Not Available	414.586	[H][C@@]12CC[C@](OC(=O)CCCCC)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	Not Available	Not Available						31650	CHEMBL2107389	391969												4791		Gestonorone_caproate	ZINC000004216396		Gestonorone caproate	Approved	DB14677	InChI=1S/C26H38O4/c1-4-5-6-7-24(29)30-26(17(2)27)15-13-23-22-10-8-18-16-19(28)9-11-20(18)21(22)12-14-25(23,26)3/h16,20-23H,4-15H2,1-3H3/t20-,21+,22+,23-,25-,26-/m0/s1	XURCMZMFZXXQDJ-UKNJCJGYSA-N			Not Available	Small Molecule																																			1	Yes	3	0	Yes	4	0	60.44 Å2	48.55 Å3	117.21 m3·mol-1	7	No	No	0.00141 mg/mL	5.58	-5.5	17.69	-4.7			
C27H38O3	Not Available	Not Available	410.598	[H][C@@]12CC[C@@](OC(=O)CCCCCC)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			34894	CHEMBL3187229	199613				C14486								31984		Norethisterone_enanthate	ZINC000004217172		Norethindrone enanthate	Experimental	DB14678	InChI=1S/C27H38O3/c1-4-6-7-8-9-25(29)30-27(5-2)17-15-24-23-12-10-19-18-20(28)11-13-21(19)22(23)14-16-26(24,27)3/h2,18,21-24H,4,6-17H2,1,3H3/t21-,22+,23+,24-,26-,27-/m0/s1	APTGJECXMIKIET-WOSSHHRXSA-N	4	Norethindrone enanthate is a synthetic progestogen indicated for contraceptive therapy.	Not Available	Small Molecule																																			1	No	2	0	Yes	4	0	43.37 Å2	49.66 Å3	119.61 m3·mol-1	7	No	No	0.00148 mg/mL	6.14	-5.4	18.25	-4.7			
C27H36O3	Not Available	Not Available	408.582	[H][C@@]12CC[C@@](OC(C)=O)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(OC4CCCC4)=CC3=CC[C@@]21[H]	Not Available	Not Available						135661	CHEMBL2105291	17136														Quingestanol_acetate			Quingestanol acetate	Experimental	DB14679	InChI=1S/C27H36O3/c1-4-27(30-18(2)28)16-14-25-24-11-9-19-17-21(29-20-7-5-6-8-20)10-12-22(19)23(24)13-15-26(25,27)3/h1,9,17,20,22-25H,5-8,10-16H2,2-3H3/t22-,23+,24+,25-,26-,27-/m0/s1	FLGJKPPXEKYCBY-AKCFYGDASA-N			Not Available	Small Molecule																																			1	Yes	2	0	No	5	0	35.53 Å2	49.19 Å3	120.29 m3·mol-1	4	Yes	Yes	0.00175 mg/mL	4.76	-5.4		-4.8			
C21H28O5	Not Available	Not Available	360.444	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Not Available	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5		13739	16962	CHEMBL1499	193441			HMDB0002802	C00762	D07749							2878		Cortisone	ZINC000004083557		Cortisone	Experimental	DB14681	InChI=1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h9,14-15,18,22,26H,3-8,10-11H2,1-2H3/t14-,15-,18+,19-,20-,21-/m0/s1	MFYSYFVPBJMHGN-ZPOLXVRWSA-N	4		Not Available	Small Molecule																																			1	Yes	5	2	No	4	0	91.67 Å2	38.95 Å3	96.47 m3·mol-1	2	Yes	No	0.136 mg/mL	1.66	-3.4	12.58	-3.3			
C29H33FO9S	Not Available	Not Available	576.63	[H][C@@]12C[C@@H](C)[C@](O)(C(=O)COC(=O)C3=CC=CC(=C3)S(O)(=O)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Not Available	Not Available							CHEMBL3305965	56740															ZINC000004212887	Sofracort	Dexamethasone metasulfobenzoate	Approved, Experimental	DB14703	InChI=1S/C29H33FO9S/c1-16-11-22-21-8-7-18-13-19(31)9-10-26(18,2)28(21,30)23(32)14-27(22,3)29(16,35)24(33)15-39-25(34)17-5-4-6-20(12-17)40(36,37)38/h4-6,9-10,12-13,16,21-23,32,35H,7-8,11,14-15H2,1-3H3,(H,36,37,38)/t16-,21+,22+,23+,26+,27+,28+,29+/m1/s1	TWQWRHIQRAZHPR-XNXCGYEVSA-N		Dexamethasone metasulfobenzoate is an ophthalmic and auricular corticosteroid used with antibiotics for the treatment of otitis externa, blepharitis, and other inflammatory eye conditions.	Not Available	Small Molecule																																			1	No	8	3	Yes	5	-1	155.27 Å2	57.93 Å3	142.94 m3·mol-1	6	No	No	0.0457 mg/mL	1.22	-4.1	-2.5	-3.4			
C48H82O18	Not Available	Not Available	947.166	[H][C@@]1(CC[C@]2(C)[C@]1([H])[C@H](O)C[C@]1([H])[C@@]3(C)CC[C@H](O)C(C)(C)[C@]3([H])[C@H](C[C@@]21C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O)C(C)(CCC=C(C)C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O	Not Available	Not Available					50378779	77148	CHEMBL510095	390496				C08944											ZINC000242620164		Ginsenoside B2	Investigational	DB14815	InChI=1S/C48H82O18/c1-21(2)11-10-14-48(9,66-42-38(60)35(57)32(54)26(19-49)63-42)23-12-16-46(7)30(23)24(51)17-28-45(6)15-13-29(52)44(4,5)40(45)25(18-47(28,46)8)62-43-39(36(58)33(55)27(20-50)64-43)65-41-37(59)34(56)31(53)22(3)61-41/h11,22-43,49-60H,10,12-20H2,1-9H3/t22-,23-,24+,25-,26+,27+,28+,29-,30-,31-,32+,33+,34+,35-,36-,37+,38+,39+,40-,41-,42-,43+,45+,46+,47+,48-/m0/s1	PWAOOJDMFUQOKB-WCZZMFLVSA-N			Not Available	Small Molecule																																			0	No	18	12	Yes	7	0	298.14 Å2	103.38 Å3	234.52 m3·mol-1	12	No	No	0.812 mg/mL	-0.042	-3.1	11.85	-3.6			
C28H37NO7	Not Available	Not Available	499.604	CCC1=C(C(=O)O[C@H]2C(C)=C[C@@]34[C@H](C)C[C@@H]5[C@H]([C@H](C=C(CO)[C@@H](O)[C@]23O)C4=O)C5(C)C)C(CC)=NO1	Not Available	Not Available							CHEMBL3989918	52083803																	Ingenol disoxate	Investigational	DB15109	InChI=1S/C28H37NO7/c1-7-18-20(19(8-2)36-29-18)25(33)35-24-13(3)11-27-14(4)9-17-21(26(17,5)6)16(23(27)32)10-15(12-30)22(31)28(24,27)34/h10-11,14,16-17,21-22,24,30-31,34H,7-9,12H2,1-6H3/t14-,16+,17-,21+,22-,24+,27+,28+/m1/s1	GLIUZQUNUNICGS-XUBYYPQFSA-N	3		Not Available	Small Molecule																																			1	No	6	3	Yes	5	0	130.09 Å2	53.9 Å3	134.18 m3·mol-1	6	Yes	No	0.1 mg/mL	2.71	-3.7	12.13	0.46			
C22H28O4	Not Available	Not Available	356.462	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@@]1(O)C(=O)CO	Not Available	Not Available					50432396		CHEMBL2348780	2299335														Vamorolone	ZINC000033650317		Vamorolone	Investigational	DB15114	InChI=1S/C22H28O4/c1-13-10-18-16-5-4-14-11-15(24)6-8-20(14,2)17(16)7-9-21(18,3)22(13,26)19(25)12-23/h6-8,11,13,16,18,23,26H,4-5,9-10,12H2,1-3H3/t13-,16-,18+,20+,21+,22+/m1/s1	ZYTXTXAMMDTYDQ-DGEXFFLYSA-N	2		Not Available	Small Molecule																																			1	Yes	4	2	No	4	0	74.6 Å2	39.26 Å3	102.22 m3·mol-1	2	Yes	No	0.0246 mg/mL	2.54	-4.2	12.45	-3.3			
C25H29FO5	Not Available	Not Available	427.503	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1C[C@H]1O[C@H](O[C@@]21C(=O)C[18F])C1=CC=CO1	Not Available	Not Available								58828602																	Fluorofuranylnorprogesterone F-18	Investigational	DB15282	InChI=1S/C25H29FO5/c1-24-9-8-17-16-7-5-15(27)11-14(16)4-6-18(17)19(24)12-22-25(24,21(28)13-26)31-23(30-22)20-3-2-10-29-20/h2-3,10-11,16-19,22-23H,4-9,12-13H2,1H3/t16-,17+,18+,19-,22+,23+,24-,25+/m0/s1/i26-1	VJKRBRUNEOHPBS-JQKUZGBFSA-N	2		Not Available	Small Molecule																																			1	Yes	4	0	No	6	0	65.74 Å2	45.2 Å3	110.28 m3·mol-1	3	Yes	No	0.0251 mg/mL	4.33	-4.2	14.61	-2.9			
C48H78O20	Not Available	Not Available	975.132	[H][C@@]1(O[C@@H]2[C@@H](CO)O[C@@H](OC[C@H]3O[C@@H](OC(=O)[C@]45CC[C@@H](C)[C@H](C)[C@@]4([H])C4=CC[C@]6([H])[C@@]7(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@]7([H])[C@H](O)C[C@@]6(C)[C@]4(C)CC5)[C@H](O)[C@@H](O)[C@@H]3O)[C@H](O)[C@H]2O)O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O	Not Available	Not Available					23212	66651		28639016												87855		Centella_asiatica	ZINC000253529433		Madecassoside	Experimental	DB15532	InChI=1S/C48H78O20/c1-19-10-11-48(13-12-46(6)22(28(48)20(19)2)8-9-27-44(4)14-24(52)39(61)45(5,18-50)38(44)23(51)15-47(27,46)7)43(62)68-42-35(59)32(56)30(54)26(66-42)17-63-40-36(60)33(57)37(25(16-49)65-40)67-41-34(58)31(55)29(53)21(3)64-41/h8,19-21,23-42,49-61H,9-18H2,1-7H3/t19-,20+,21+,23-,24-,25-,26-,27-,28+,29+,30-,31-,32+,33-,34-,35-,36-,37-,38-,39+,40-,41+,42+,44-,45+,46-,47-,48+/m1/s1	BNMGUJRJUUDLHW-HCZMHFOYSA-N			Not Available	Small Molecule																																			0	No	19	13	Yes	8	0	335.44 Å2	103.17 Å3	234.14 m3·mol-1	10	No	No	1.71 mg/mL	-1.8	-2.8	11.75	-3.6			
C28H46O3	Not Available	Not Available	430.673	[H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C)[C@H](C)CCCCC(C)(C)O	Not Available	Not Available								7826421												1423458			ZINC000038791777		24-Homo-1,25-dihydroxyvitamin D3	Experimental	DB15557	InChI=1S/C28H46O3/c1-19(9-6-7-15-27(3,4)31)24-13-14-25-21(10-8-16-28(24,25)5)11-12-22-17-23(29)18-26(30)20(22)2/h11-12,19,23-26,29-31H,2,6-10,13-18H2,1,3-5H3/b21-11+,22-12-/t19-,23-,24-,25+,26+,28-/m1/s1	WKTIGYIYJKESCJ-JJWMBMNSSA-N			Not Available	Small Molecule																																			1	No	3	3	Yes	3	0	60.69 Å2	53.36 Å3	131.13 m3·mol-1	7	Yes	No	0.00475 mg/mL	4.8	-5	14.39	-1.3			
C23H30O6	Data regarding the clearance of prednisolone acetate is not readily available.6,7,8	Oral prednisolone acetate has a plasma half life of 2-3 hours.5	402.4807	[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@]([H])(O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	The volume of distribution of the active metabolite, prednisolone, is 0.22/0.7L/kg.5	P08684	CYP3A4	1. Cytochrome P450 3A4			8380	CHEMBL1152	5629				C08180					5834					Prednisolone_acetate	ZINC000003875348	Blephamide, Econopred Plus, Flo-pred, Pred Forte, Pred Mild, Pred-G	Prednisolone acetate	Approved, Vet approved	DB15566	InChI=1S/C23H30O6/c1-13(24)29-12-19(27)23(28)9-7-17-16-5-4-14-10-15(25)6-8-21(14,2)20(16)18(26)11-22(17,23)3/h6,8,10,16-18,20,26,28H,4-5,7,9,11-12H2,1-3H3/t16-,17-,18-,20+,21-,22-,23-/m0/s1	LRJOMUJRLNCICJ-JZYPGELDSA-N	4	Prednisolone acetate is a glucocorticoid used to treat a wide variety of endocrine, inflammatory, and immune conditions as well as for palliation of neoplastic conditions.	The oral LD50 of prednisolone acetate in mice is 1680 mg/kg.8 Patients experiencing an overdose of oral prednisolone acetate may experience an increased severity in the adverse effects of corticosteroids.5 Overdose of oral prednisolone acetate may be treated by gastric lavage or inducing vomiting if the overdose was recent, as well as supportive and symptomatic therapy.5 Chronic overdosage may be treated by dose reduction or treating patients on alternate days.5 An overdose by the ophthalmic route is not expected to cause problems.5	Small Molecule																														1.332		238			1	Yes	5	2	No	4	0	100.9 Å2	42.93 Å3	107.64 m3·mol-1	4	Yes	No	0.0417 mg/mL	1.71	-4	12.61	-2.9	P04150	NR3C1	1. Glucocorticoid receptor
C30H39NO2	Not Available	Not Available	445.647	[H][C@@]12CC[C@@]3(CCCO3)[C@@]1(C)C[C@H](C1=CC=C(C=C1)N(C)C)C1=C3CCC(=O)C=C3[C@H](C)C[C@@]21[H]	Not Available	Not Available							CHEMBL460258	143897															ZINC000003918217		ORG-31710	Experimental	DB15585	InChI=1S/C30H39NO2/c1-19-16-25-27-12-14-30(13-5-15-33-30)29(27,2)18-26(20-6-8-21(9-7-20)31(3)4)28(25)23-11-10-22(32)17-24(19)23/h6-9,17,19,25-27H,5,10-16,18H2,1-4H3/t19-,25+,26-,27+,29+,30+/m1/s1	HFDGABTZPISMDD-IEVXGSBISA-N			Not Available	Small Molecule																																			1	No	3	0	No	6	0	29.54 Å2	52.91 Å3	136.34 m3·mol-1	2	No	Yes	0.00101 mg/mL	5.4	-5.6	18.37	4.89			
C30H48O3	Not Available	Not Available	456.711	[H][C@@]12[C@@H](C)[C@H](C)CC[C@@]1(CC[C@]1(C)C2=CC[C@]2([H])[C@@]3(C)CC[C@H](O)C(C)(C)[C@]3([H])CC[C@@]12C)C(O)=O	Not Available	Not Available					50148911	9908	CHEMBL169	58472			HMDB0002395	C08988		6Q5						1426931		Ursolic_acid	ZINC000003978827		Ursolic acid	Experimental	DB15588	InChI=1S/C30H48O3/c1-18-10-15-30(25(32)33)17-16-28(6)20(24(30)19(18)2)8-9-22-27(5)13-12-23(31)26(3,4)21(27)11-14-29(22,28)7/h8,18-19,21-24,31H,9-17H2,1-7H3,(H,32,33)/t18-,19+,21+,22-,23+,24+,27+,28-,29-,30+/m1/s1	WCGUUGGRBIKTOS-GPOJBZKASA-N	2		Not Available	Small Molecule																																			1	No	3	2	No	5	-1	57.53 Å2	54.51 Å3	133.7 m3·mol-1	1	No	No	0.00059 mg/mL	6.58	-5.9	4.74	-0.84			
C27H44O	Not Available	Not Available	384.648	[H][C@@]1(CC[C@@]2([H])C(\C=C/C3=C(C)CC[C@H](O)C3)=CCC[C@]12C)[C@H](C)CCCC(C)C	Not Available	Not Available						8403		4444516				C07711											ZINC000016343334		Previtamin D(3)	Experimental	DB15614	InChI=1S/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h10,12-13,19,21,24-26,28H,6-9,11,14-18H2,1-5H3/b13-12-/t21-,24+,25-,26+,27-/m1/s1	YUGCAAVRZWBXEQ-WHTXLNIXSA-N			Not Available	Small Molecule																																			1	No	1	1	Yes	3	0	20.23 Å2	49.02 Å3	124.3 m3·mol-1	7	No	Yes	0.000374 mg/mL	7.07	-6	18.31	-1.3			
C29H36O4	Not Available	Not Available	448.603	[H][C@@]12C[C@H]3O[C@](C)(O[C@@]3(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C)C1=CC=CC=C1	Not Available	Not Available						49327	CHEMBL3989742	4447595														Algestone_acetophenide	ZINC000004172334		Algestone acetophenide	Experimental	DB15775	InChI=1S/C29H36O4/c1-18(30)29-25(32-28(4,33-29)19-8-6-5-7-9-19)17-24-22-11-10-20-16-21(31)12-14-26(20,2)23(22)13-15-27(24,29)3/h5-9,16,22-25H,10-15,17H2,1-4H3/t22-,23+,24+,25-,26+,27+,28-,29-/m1/s1	AHBKIEXBQNRDNL-FVCOMRFXSA-N		Algestone acetophenide is a progestin indicated in combination with an estrogen as an injectable contraceptive.	Not Available	Small Molecule																																			1	No	4	0	No	6	0	52.6 Å2	50.33 Å3	127.37 m3·mol-1	2	No	No	0.000357 mg/mL	5.74	-6.1	17.63	-4.1			
C27H37FO5	Not Available	Not Available	460.586	[H][C@@]12C[C@@H](C)[C@H](C(=O)COC(=O)C(C)(C)C)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C	Not Available	Not Available								107027												4465			ZINC000030691645		Fluocortolone pivalate	Experimental	DB15777	InChI=1S/C27H37FO5/c1-14-9-17-16-11-19(28)18-10-15(29)7-8-26(18,5)23(16)20(30)12-27(17,6)22(14)21(31)13-33-24(32)25(2,3)4/h7-8,10,14,16-17,19-20,22-23,30H,9,11-13H2,1-6H3/t14-,16+,17+,19+,20+,22-,23-,26+,27+/m1/s1	XZBJVIQXJHGUBE-HZMVJJPJSA-N		Fluocortolone pivalate is a corticosteroid used to treat corticosteroid-responsive dermatoses and hemorrhoids.	Not Available	Small Molecule																																			1	Yes	4	1	No	4	0	80.67 Å2	50.5 Å3	124.32 m3·mol-1	5	Yes	No	0.0022 mg/mL	4.21	-5.3	15.15	-0.23			
C28H39FO5	Not Available	Not Available	474.613	[H][C@@]12C[C@@H](C)[C@H](C(=O)COC(=O)CCCCC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C	Not Available	Not Available							CHEMBL2107415	16735815												4464			ZINC000004213356		Fluocortolone caproate	Experimental	DB15821	InChI=1S/C28H39FO5/c1-5-6-7-8-24(33)34-15-23(32)25-16(2)11-19-18-13-21(29)20-12-17(30)9-10-27(20,3)26(18)22(31)14-28(19,25)4/h9-10,12,16,18-19,21-22,25-26,31H,5-8,11,13-15H2,1-4H3/t16-,18+,19+,21+,22+,25-,26-,27+,28+/m1/s1	WHZRCUIISKRTJL-YTZKRAOUSA-N		Fluocortolone caproate is a corticosteroid indicated in the treatment of hemorrhoids, anal fissures, and corticosteroid-responsive dermatoses.	Not Available	Small Molecule																																			1	No	4	1	Yes	4	0	80.67 Å2	52.93 Å3	129.05 m3·mol-1	8	Yes	No	0.0017 mg/mL	4.44	-5.4	15.15	-0.23			
C27H42O4	Not Available	Not Available	430.629	[H][C@]12C[C@@]3([H])[C@]4([H])CC=C5C[C@@H](O)C[C@@H](O)[C@]5(C)[C@@]4([H])CC[C@]3(C)[C@@]1([H])[C@H](C)[C@@]1(CC[C@@H](C)CO1)O2	Not Available	Not Available						8913	CHEMBL1169820	390469				C08909	D08498							35890			ZINC000008234225		Ruscogenin	Experimental	DB15830	InChI=1S/C27H42O4/c1-15-7-10-27(30-14-15)16(2)24-22(31-27)13-21-19-6-5-17-11-18(28)12-23(29)26(17,4)20(19)8-9-25(21,24)3/h5,15-16,18-24,28-29H,6-14H2,1-4H3/t15-,16+,18-,19-,20+,21+,22+,23-,24+,25+,26+,27-/m1/s1	QMQIQBOGXYYATH-IDABPMKMSA-N		Ruscogenin is an anti-inflammatory steroid used in combination with local anesthetics for the treatment of hemorrhoids and for local anesthesia.	Not Available	Small Molecule																																			1	No	4	2	No	6	0	58.92 Å2	51.73 Å3	121.74 m3·mol-1	0	Yes	No	0.00821 mg/mL	3.62	-4.7	14.45	-2.8			
C23H29ClO4	Not Available	Not Available	404.93	[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(Cl)C2=CC(=O)CC[C@]12C	Not Available	Not Available						31394	CHEMBL110691	8963				C12729								2369		Chlormadinone_acetate	ZINC000003876041		Chlormadinone acetate	Experimental	DB15903	InChI=1S/C23H29ClO4/c1-13(25)23(28-14(2)26)10-7-18-16-12-20(24)19-11-15(27)5-8-21(19,3)17(16)6-9-22(18,23)4/h11-12,16-18H,5-10H2,1-4H3/t16-,17+,18+,21-,22+,23+/m1/s1	QMBJSIBWORFWQT-DFXBJWIESA-N		Chlormadinone acetate is a progestin indicated in combination with an estrogen for birth control.	Not Available	Small Molecule																																			1	Yes	3	0	No	4	0	60.44 Å2	43.67 Å3	109.09 m3·mol-1	3	Yes	No	0.00158 mg/mL	3.72	-5.4	17.83	-5.5			
C21H25ClO5	Not Available	Not Available	392.88	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])C[C@H](Cl)C2=CC(=O)C=C[C@]12C	Not Available	Not Available						135618		2298578														Chloroprednisone	ZINC000033650036		Chloroprednisone	Experimental	DB15970	InChI=1S/C21H25ClO5/c1-19-5-3-11(24)7-14(19)15(22)8-12-13-4-6-21(27,17(26)10-23)20(13,2)9-16(25)18(12)19/h3,5,7,12-13,15,18,23,27H,4,6,8-10H2,1-2H3/t12-,13-,15-,18+,19-,20-,21-/m0/s1	NPSLCOWKFFNQKK-ZPSUVKRCSA-N			Not Available	Small Molecule																																			1	Yes	5	2	No	4	0	91.67 Å2	40.51 Å3	102.13 m3·mol-1	2	Yes	No	0.0395 mg/mL	1.78	-4	12.58	-3.3			
C21H29ClO3	Not Available	Not Available	364.91	[H][C@@]12CC[C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=C(Cl)C(=O)CC[C@]12C	Not Available	Not Available						81712	CHEMBL519327	12762				C18374								236522		Clostebol_acetate	ZINC000003881980		Clostebol acetate	Experimental	DB15984	InChI=1S/C21H29ClO3/c1-12(23)25-18-7-6-14-13-4-5-16-19(22)17(24)9-11-20(16,2)15(13)8-10-21(14,18)3/h13-15,18H,4-11H2,1-3H3/t13-,14-,15-,18-,20+,21-/m0/s1	XYGMEFJSKQEBTO-KUJXMBTLSA-N		Clostebol acetate is a steroid combined with neomycin in topical formulations for the treatment of minor skin wounds.	Not Available	Small Molecule																																			1	Yes	2	0	No	4	0	43.37 Å2	40.68 Å3	98.37 m3·mol-1	2	Yes	No	0.00309 mg/mL	4.2	-5.1		-6.2			
C27H38O6	Not Available	Not Available	458.595	[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCCCC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Not Available	Not Available								136723																	Prednisolone caproate	Experimental	DB15999	InChI=1S/C27H38O6/c1-4-5-6-7-23(31)33-16-22(30)27(32)13-11-20-19-9-8-17-14-18(28)10-12-25(17,2)24(19)21(29)15-26(20,27)3/h10,12,14,19-21,24,29,32H,4-9,11,13,15-16H2,1-3H3/t19-,20-,21-,24+,25-,26-,27-/m0/s1	DNSAKUGJOSFARZ-FOMYWIRZSA-N		Prednisolone caproate is a corticosteroid indicated to treat hemorrhoids, anal fissures, and proctitis.	Not Available	Small Molecule																																			1	No	5	2	Yes	4	0	100.9 Å2	51.73 Å3	126.07 m3·mol-1	8	Yes	No	0.0065 mg/mL	3.75	-4.8	12.61	-2.9			
C29H46O3	Not Available	Not Available	442.684	[H][C@@]12CC[C@H](OC(=O)CCCCCCCCC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Not Available	Not Available						35000	CHEMBL1473654	136680				C14607								37858		Testosterone_decanoate	ZINC000019685816		Testosterone decanoate	Experimental	DB16001	InChI=1S/C29H46O3/c1-4-5-6-7-8-9-10-11-27(31)32-26-15-14-24-23-13-12-21-20-22(30)16-18-28(21,2)25(23)17-19-29(24,26)3/h20,23-26H,4-19H2,1-3H3/t23-,24-,25-,26-,28-,29-/m0/s1	LBERVHLCXUMDOT-MPZZESAYSA-N		Testosterone decanoate is a steroid indicated for testosterone replacement therapy in sterilization, missing testicle, hypopituitarism, and osteoporosis.	Not Available	Small Molecule																																			1	No	2	0	Yes	4	0	43.37 Å2	54.86 Å3	130.42 m3·mol-1	10	No	No	0.000114 mg/mL	7.62	-6.6	18.52	-4.8			
C25H38O3	Not Available	Not Available	386.576	[H][C@@]12CC[C@H](OC(=O)CCC(C)C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Not Available	Not Available					50103618	35001	CHEMBL3189011	201317				C14663								75806		Testosterone_isocaproate	ZINC000004538407		Testosterone isocaproate	Experimental	DB16002	InChI=1S/C25H38O3/c1-16(2)5-10-23(27)28-22-9-8-20-19-7-6-17-15-18(26)11-13-24(17,3)21(19)12-14-25(20,22)4/h15-16,19-22H,5-14H2,1-4H3/t19-,20-,21-,22-,24-,25-/m0/s1	PPYHLSBUTAPNGT-BKWLFHPQSA-N		Testosterone isocaproate is a steroid indicated for testosterone replacement therapy in sterilization, missing testicle, hypopituitarism, and osteoporosis.	Not Available	Small Molecule																																			1	No	2	0	No	4	0	43.37 Å2	46.61 Å3	111.96 m3·mol-1	5	No	No	0.000955 mg/mL	5.68	-5.6	18.52	-4.8			
C28H36O3	Not Available	Not Available	420.593	[H][C@@]12CC[C@H](OC(=O)CCC3=CC=CC=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Not Available	Not Available						35002	CHEMBL2356993	14062				C14667								37855		Testosterone_phenylpropionate	ZINC000003881605		Testosterone phenylpropionate	Experimental	DB16003	InChI=1S/C28H36O3/c1-27-16-14-21(29)18-20(27)9-10-22-23-11-12-25(28(23,2)17-15-24(22)27)31-26(30)13-8-19-6-4-3-5-7-19/h3-7,18,22-25H,8-17H2,1-2H3/t22-,23-,24-,25-,27-,28-/m0/s1	HHSXYDOROIURIP-FEZCWRLCSA-N		Testosterone phenylpropionate is a steroid indicated for testosterone replacement therapy in sterilization, missing testicle, hypopituitarism, and osteoporosis.	Not Available	Small Molecule																																			1	No	2	0	No	5	0	43.37 Å2	49.36 Å3	122.9 m3·mol-1	5	No	No	0.000283 mg/mL	6.09	-6.2	18.52	-4.8			
C35H49NO7	Not Available	Not Available	595.777	[H][C@@]12OC3=C4C(C[C@H]5N(CC6CC6)CC[C@@]14[C@@]51CC[C@@]2(OC)[C@]([H])(C1)[C@](C)(O)C(C)(C)C)=CC=C3OC(=O)CCCCC(O)=O	Not Available	Not Available								32698730																	Buprenorphine hemiadipate	Investigational	DB16117	InChI=1S/C35H49NO7/c1-31(2,3)32(4,40)24-19-33-14-15-35(24,41-5)30-34(33)16-17-36(20-21-10-11-21)25(33)18-22-12-13-23(29(43-30)28(22)34)42-27(39)9-7-6-8-26(37)38/h12-13,21,24-25,30,40H,6-11,14-20H2,1-5H3,(H,37,38)/t24-,25-,30-,32+,33-,34+,35-/m1/s1	CVIJJOARNCQGON-XYQNZYJMSA-N	2		Not Available	Small Molecule																																			0	No	7	2	Yes	7	0	105.53 Å2	66.1 Å3	161.01 m3·mol-1	12	No	No	0.00288 mg/mL	1.93	-5.3	3.3	9.8			
C31H50O3	Not Available	Not Available	470.738	[H][C@@]12CC[C@H](OC(=O)CCCCCCCCCC)[C@@]1(C)C[C@H](C)[C@]1([H])[C@@]3([H])CCC(=O)C=C3C[C@@H](C)[C@@]21[H]	Not Available	Not Available								68025242																	Dimethandrolone Undecanoate	Investigational	DB16141	InChI=1S/C31H50O3/c1-5-6-7-8-9-10-11-12-13-28(33)34-27-17-16-26-30-21(2)18-23-19-24(32)14-15-25(23)29(30)22(3)20-31(26,27)4/h19,21-22,25-27,29-30H,5-18,20H2,1-4H3/t21-,22+,25+,26+,27+,29-,30+,31+/m1/s1	FVICENFBEMJOCE-RTFNQGFNSA-N	1		Not Available	Small Molecule																																			0	No	2	0	Yes	4	0	43.37 Å2	59.02 Å3	139.64 m3·mol-1	11	No	No	4.39e-05 mg/mL	8.34	-7	18.3	-4.7			
C28H29F5O3	Not Available	Not Available	508.529	[H][C@@]12CC[C@@](O)(C(F)(F)C(F)(F)F)[C@@]1(C)C[C@H](C1=CC=C(C=C1)C(C)=O)C1=C3CCC(=O)C=C3CC[C@@]21[H]	Not Available	Not Available					50409115		CHEMBL146032	5293745														Lonaprisan			Lonaprisan	Investigational	DB16221	InChI=1S/C28H29F5O3/c1-15(34)16-3-5-17(6-4-16)22-14-25(2)23(11-12-26(25,36)27(29,30)28(31,32)33)21-9-7-18-13-19(35)8-10-20(18)24(21)22/h3-6,13,21-23,36H,7-12,14H2,1-2H3/t21-,22+,23-,25-,26-/m0/s1	VHZPUDNSVGRVMB-RXDLHWJPSA-N	2		Not Available	Small Molecule																																			0	No	3	1	No	5	0	54.37 Å2	49.03 Å3	125.59 m3·mol-1	4	No	No	0.00424 mg/mL	5.17	-5.1	11.81	-4.2			
C23H38O4	Not Available	Not Available	378.553	[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CC(O)=O	Not Available	Not Available							CHEMBL1254990	166888															ZINC000031520504		norUrsodeoxycholic acid	Investigational	DB16260	InChI=1S/C23H38O4/c1-13(10-20(26)27)16-4-5-17-21-18(7-9-23(16,17)3)22(2)8-6-15(24)11-14(22)12-19(21)25/h13-19,21,24-25H,4-12H2,1-3H3,(H,26,27)/t13-,14+,15-,16-,17+,18+,19+,21+,22+,23-/m1/s1	QYYDXDSPYPOWRO-JHMCBHKWSA-N			Not Available	Small Molecule																																			1	Yes	4	3	No	4	-1	77.76 Å2	44.49 Å3	104.67 m3·mol-1	3	Yes	No	0.0396 mg/mL	3.27	-4	4.53	-0.54			
C23H28O11	Not Available	Not Available	480.466	[H][C@@]12C[C@@]3(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@]1(COC(=O)C1=CC=CC=C1)[C@@]1([H])O[C@]2(O)C[C@]3(C)O1	Not Available	Not Available						7889	CHEMBL4303209	390957				C09959								2288155		Paeoniflorin	ZINC000008234328		Peoniflorin	Investigational	DB16288	InChI=1S/C23H28O11/c1-20-9-22(29)13-7-23(20,32-18-16(27)15(26)14(25)12(8-24)31-18)21(13,19(33-20)34-22)10-30-17(28)11-5-3-2-4-6-11/h2-6,12-16,18-19,24-27,29H,7-10H2,1H3/t12-,13-,14-,15+,16-,18+,19-,20+,21+,22-,23+/m1/s1	YKRGDOXKVOZESV-WRJNSLSBSA-N			Not Available	Small Molecule																																			1	No	10	5	Yes	6	0	164.37 Å2	0 Å3	109.3 m3·mol-1	7	Yes	No	5.32 mg/mL	-0.39	-2	11.54	-3			
C26H40O3	Not Available	Not Available	400.603	[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@H](CC[C@]12C)OC(=O)CCCCCC	Not Available	Not Available								143333														Prasterone_enanthate	ZINC000005820240		Prasterone enantate	Approved	DB16625	InChI=1S/C26H40O3/c1-4-5-6-7-8-24(28)29-19-13-15-25(2)18(17-19)9-10-20-21-11-12-23(27)26(21,3)16-14-22(20)25/h9,19-22H,4-8,10-17H2,1-3H3/t19-,20-,21-,22-,25-,26-/m0/s1	HHENOUDBWKNPAB-BNCSLUSBSA-N		Prasterone enantate is an estrogen indicated for hormone replacement therapy in postmenopausal women.	Not Available	Small Molecule																																			1	No	2	0	Yes	4	0	43.37 Å2	48.28 Å3	116.84 m3·mol-1	7	No	No		6.28			-6.9			
C10H16N5O13P3	Not Available	Not Available	507.181	NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O	Solid	Not Available	P55263	ADK	1. Adenosine kinase		50366480	15422	CHEMBL14249	5742			HMDB0000538	C00002	D08646	ATP		PA164743471	5957	46507614		318	DNC000262	Adenosine_triphosphate	ZINC000004261765		ATP	Investigational, Nutraceutical	DB00171	InChI=1S/C10H16N5O13P3/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(26-10)1-25-30(21,22)28-31(23,24)27-29(18,19)20/h2-4,6-7,10,16-17H,1H2,(H,21,22)(H,23,24)(H2,11,12,13)(H2,18,19,20)/t4-,6-,7-,10-/m1/s1	ZKHQWZAMYRWXGA-KQYNXXCUSA-N	4		Oral LD50 in rats is > 2 g/kg.	Small Molecule	http://smpdb.ca/view/SMP0000002?highlight[compounds][]=DB00171&highlight[proteins][]=DB00171;!http://smpdb.ca/view/SMP0000003?highlight[compounds][]=DB00171&highlight[proteins][]=DB00171;!http://smpdb.ca/view/SMP0000004?highlight[compounds][]=DB00171&highlight[proteins][]=DB00171;!http://smpdb.ca/view/SMP0000009?highlight[compounds][]=DB00171&highlight[proteins][]=DB00171;!http://smpdb.ca/view/SMP0000011?highlight[compounds][]=DB00171&highlight[proteins][]=DB00171;!http://smpdb.ca/view/SMP0000016?highlight[compounds][]=DB00171&highlight[proteins][]=DB00171;!http://smpdb.ca/view/SMP0000020?highlight[compounds][]=DB00171&highlight[proteins][]=DB00171;!http://smpdb.ca/view/SMP0000029?highlight[compounds][]=DB00171&highlight[proteins][]=DB00171;!http://smpdb.ca/view/SMP0000031?highlight[compounds][]=DB00171&highlight[proteins][]=DB00171;!http://smpdb.ca/view/SMP0000039?highlight[compounds][]=DB00171&highlight[proteins][]=DB00171;!http://smpdb.ca/view/SMP0000043?highlight[compounds][]=DB00171&highlight[proteins][]=DB00171;!http://smpdb.ca/view/SMP0000044?highlight[compounds][]=DB00171&highlight[proteins][]=DB00171;!http://smpdb.ca/view/SMP0000046?highlight[compounds][]=DB00171&highlight[proteins][]=DB00171;!http://smpdb.ca/view/SMP0000050?highlight[compounds][]=DB00171&highlight[proteins][]=DB00171;!http://smpdb.ca/view/SMP0000051?highlight[compounds][]=DB00171&highlight[proteins][]=DB00171;!http://smpdb.ca/view/SMP0000057?highlight[compounds][]=DB00171&highlight[proteins][]=DB00171;!http://smpdb.ca/view/SMP0000058?highlight[compounds][]=DB00171&highlight[proteins][]=DB00171;!http://smpdb.ca/view/SMP0000060?highlight[compounds][]=DB00171&highlight[proteins][]=DB00171;!http://smpdb.ca/view/SMP0000072?highlight[compounds][]=DB00171&highlight[proteins][]=DB00171;!http://smpdb.ca/view/SMP0000073?highlight[compounds][]=DB00171&highlight[proteins][]=DB00171;!http://smpdb.ca/view/SMP0000076?highlight[compounds][]=DB00171&highlight[proteins][]=DB00171;!http://smpdb.ca/view/SMP0000082?highlight[compounds][]=DB00171&highlight[proteins][]=DB00171;!http://smpdb.ca/view/SMP0000089?highlight[compounds][]=DB00171&highlight[proteins][]=DB00171;!http://smpdb.ca/view/SMP0000092?highlight[compounds][]=DB00171&highlight[proteins][]=DB00171;!http://smpdb.ca/view/SMP0000107?highlight[compounds][]=DB00171&highlight[proteins][]=DB00171;!http://smpdb.ca/view/SMP0000117?highlight[compounds][]=DB00171&highlight[proteins][]=DB00171;!http://smpdb.ca/view/SMP0000119?highlight[compounds][]=DB00171&highlight[proteins][]=DB00171;!http://smpdb.ca/view/SMP0000123?highlight[compounds][]=DB00171&highlight[proteins][]=DB00171;!http://smpdb.ca/view/SMP0000128?highlight[compounds][]=DB00171&highlight[proteins][]=DB00171;!http://smpdb.ca/view/SMP0000137?highlight[compounds][]=DB00171&highlight[proteins][]=DB00171	Carbamoyl Phosphate Synthetase Deficiency;!Argininosuccinic Aciduria;!Glycine and Serine Metabolism;!Ammonia Recycling;!Inositol Metabolism;!Propanoate Metabolism;!Arginine and Proline Metabolism;!Selenoamino Acid Metabolism;!Pentose Phosphate Pathway;!Glycerolipid Metabolism;!Galactose Metabolism;!Histidine Metabolism;!Pyrimidine Metabolism;!Purine Metabolism;!Fatty Acid Metabolism;!Citric Acid Cycle;!Starch and Sucrose Metabolism;!Pyruvate Metabolism;!Glutamate Metabolism;!Butyrate Metabolism;!Thiamine Metabolism;!Simvastatin Action Pathway;!Pravastatin Action Pathway;!Rosuvastatin Action Pathway;!Zoledronate Action Pathway;!Pamidronate Action Pathway;!Fluvastatin Action Pathway;!Betaine Metabolism;!Gluconeogenesis;!2-Methyl-3-hydroxybutryl-CoA Dehydrogenase Deficiency		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.5022 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					-5.5		176 °C		1E+006 mg/L	0	No	14	7	Yes	3	-4	279.13 Å2	39.07 Å3	95.81 m3·mol-1	8	No	No	4.49 mg/mL	-5.4	-2	0.9	4.93	O95255;!O15439;!P33527;!P13569;!P42336;!P68400;!P67870;!Q96G91;!P53041;!P42684;!O95477;!Q9NR19;!Q9UM73;!Q13564;!Q13131;!P10398;!P37023;!P33121;!P49902;!O43681;!O60706;!P31749;!P25098;!O14727;!Q9NUB1;!P36896;!Q04771;!O95342;!P08243;!Q96Q40;!P12235;!Q09428;!P00966;!Q9Y4W6;!P35626;!Q16671;!Q07912;!P00519;!Q08828;!P08183;!P45844;!Q92887	ABCC6;!ABCC4;!ABCC1;!CFTR;!PIK3CA;!CSNK2A1;!CSNK2B;!P2RY11;!PPP5C;!ABL2;!ABCA1;!ACSS2;!ALK;!NAE1;!PRKAA1;!ARAF;!ACVRL1;!ACSL1;!NT5C2;!ASNA1;!ABCC9;!AKT1;!ADRBK1;!APAF1;!ACSS1;!ACVR1B;!ACVR1;!ABCB11;!ASNS;!CDK15;!SLC25A4;!ABCC8;!ASS1;!AFG3L2;!ADRBK2;!AMHR2;!TNK2;!ABL1;!ADCY1;!ABCB1;!ABCG1;!ABCC2	1. Multidrug resistance-associated protein 6;!2. Multidrug resistance-associated protein 4;!3. Multidrug resistance-associated protein 1;!4. Cystic fibrosis transmembrane conductance regulator;!5. Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform;!6. Casein kinase II subunit alpha;!7. Casein kinase II subunit beta;!8. P2Y purinoceptor 11;!9. Serine/threonine-protein phosphatase 5;!10. Abelson tyrosine-protein kinase 2;!11. ATP-binding cassette sub-family A member 1;!12. Acetyl-coenzyme A synthetase, cytoplasmic;!13. ALK tyrosine kinase receptor;!14. NEDD8-activating enzyme E1 regulatory subunit;!15. 5'-AMP-activated protein kinase catalytic subunit alpha-1;!16. Serine/threonine-protein kinase A-Raf;!17. Serine/threonine-protein kinase receptor R3;!18. Long-chain-fatty-acid--CoA ligase 1;!19. Cytosolic purine 5'-nucleotidase;!20. ATPase ASNA1;!21. ATP-binding cassette sub-family C member 9;!22. RAC-alpha serine/threonine-protein kinase;!23. Beta-adrenergic receptor kinase 1;!24. Apoptotic protease-activating factor 1;!25. Acetyl-coenzyme A synthetase 2-like, mitochondrial;!26. Activin receptor type-1B;!27. Activin receptor type-1;!28. Bile salt export pump;!29. Asparagine synthetase [glutamine-hydrolyzing];!30. Cyclin-dependent kinase 15;!31. ADP/ATP translocase 1;!32. ATP-binding cassette sub-family C member 8;!33. Argininosuccinate synthase;!34. AFG3-like protein 2;!35. Beta-adrenergic receptor kinase 2;!36. Anti-Muellerian hormone type-2 receptor;!37. Activated CDC42 kinase 1;!38. Tyrosine-protein kinase ABL1;!39. Adenylate cyclase type 1;!40. P-glycoprotein 1;!41. ATP-binding cassette sub-family G member 1;!42. Canalicular multispecific organic anion transporter 1
C12H35Al9O55S8	Sucralfate contains aluminum. The administration of sucralfate in non-dialyzed chronic renal failure patients warrants careful consideration from the treating physician as the excretion of absorbed aluminum may be decreased, causing possible aluminum toxicity 13.In dialyzed patients diagnosed with chronic renal failure, aluminum toxicity related to sucralfate has been observed and reported. The daily amount of aluminum ingestion (including sucralfate) should be carefully examined before administering sucralfate in combination with other drugs also containing aluminum, including various antacids 13.	The half-life is not known. In animals, the elimination half-life of the sucrose component of this drug is from 6-20 h 16.	1558.67	O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@](COS(=O)(=O)O[Al](O)O)(O[C@H]2O[C@H](COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@H]2OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O	Solid	This drug is absorbed in a very small quantity, and normally localizes to inflamed gastrointestinal lesions Label.							CHEMBL2029132	32701653	Drugs.com Drug Page		HMDB0014508	C07314			PDRhealth Drug Page	PA451524	70789197	46508862	RxList Drug Page	10156		Sucralfate		Carafate, Sulcrate	Sucralfate	Approved	DB00364	InChI=1S/C12H22O35S8.9Al.20H2O/c13-48(14,15)37-1-4-6(43-51(22,23)24)8(45-53(28,29)30)9(46-54(31,32)33)11(40-4)42-12(3-39-50(19,20)21)10(47-55(34,35)36)7(44-52(25,26)27)5(41-12)2-38-49(16,17)18;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/h4-11H,1-3H2,(H,13,14,15)(H,16,17,18)(H,19,20,21)(H,22,23,24)(H,25,26,27)(H,28,29,30)(H,31,32,33)(H,34,35,36);;;;;;;;;;20*1H2/q;9*+3;;;;;;;;;;;;;;;;;;;;/p-27/t4-,5-,6-,7-,8+,9-,10+,11-,12+;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/m1............................./s1	IPLJAZDIICJQEL-JTJNLBSYSA-A	4	Sucralfate is a gastro-duodenal protective agent used in the treatment of gastric and duodenal ulcers and to prevent duodenal ulcer recurrence.	OverdoseOverdosage has never been observed with sucralfate 13. It is unlikely, as administering a maximum dose of up to 12 g/kg/body weight in several animal species did not result in death. The lethal dose could not be determined in these studies 13. It is likely that overdose of sucralfate in humans would result in constipation, and supportive treatment would be advised 13.Use in pregnancyThis drug is considered a pregnancy Category B drug. Studies have been performed in rodents and rabbits at doses up to 50 times the recommended human dose. No harm to the fetus has been observed in the abovementioned studies. Sufficient and well-controlled clinical trials have not been performed in pregnant women. Due to the fact that the results of animal studies are not always relevant to human response, sucralfate should be used during pregnancy only if it is deemed essential for the mother's health Label.Use in nursingWhether this drug is excreted in human milk is currently unknown. Many drugs are excreted in breast milk, therefore, if sucralfate is administered to a lactating and nursing woman, caution should be observed Label.Carcinogenesis 24 month toxicity studies were performed in rodents, and the dose of sucralfate reached up to 1 g/kg (equivalent to 12 times the recommended human dose). No signs of sucralfate-related tumors were notedLabel.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.4219 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					-7.087		>220	0.43 to 1.19	Insoluble	0	No	35	16	No	2	0	772.17 Å2	107.19 Å3	180.03 m3·mol-1	37	No	No	0.774 mg/mL	-5.9	-3.3	13.53	-3	P0DJD9;!P09038;!P01133;!	PGA5;!FGF2;!EGF;!	1. Pepsin A-5;!2. Fibroblast growth factor 2;!3. Pro-epidermal growth factor;!4. Fibrinogen
C6H8N2O8	Not Available	1 hour	236.1363	[H][C@]12OC[C@H](O[N+]([O-])=O)[C@@]1([H])OC[C@H]2O[N+]([O-])=O	Solid	2 to 4 L/kg	P05181	CYP2E1	1. Cytochrome P450 2E1			6061	CHEMBL6622	6619	Drugs.com Drug Page		HMDB0015021	C07456	D00516		PDRhealth Drug Page	PA450125	6883	46506412	RxList Drug Page	6058	DAP001057	Isosorbide_dinitrate	ZINC000018089317	Bidil, Dilatrate, Isordil	Isosorbide dinitrate	Approved, Investigational	DB00883	InChI=1S/C6H8N2O8/c9-7(10)15-3-1-13-6-4(16-8(11)12)2-14-5(3)6/h3-6H,1-2H2/t3-,4+,5-,6-/m1/s1	MOYKHGMNXAOIAT-JGWLITMVSA-N	4	Isosorbide dinitrate is a vasodilator used to treat angina in coronary artery disease.	Symptoms of overdose include reduced cardiac output and hypotension.	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.4849 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					1.31	-2.63	70 °C		550 mg/L (at 25 °C)	1	Yes	8	0	No	2	0	123.2 Å2	18.15 Å3	42.76 m3·mol-1	4	Yes	No	0.938 mg/mL	-0.0096	-2.4		-4.2	P16066	NPR1	1. Atrial natriuretic peptide receptor 1
C20H34AuO9PS	Not Available	Not Available	678.484	CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O	Solid	Not Available					50153291	2922	CHEMBL1366	5293650	Drugs.com Drug Page		HMDB0015130		D00237		PDRhealth Drug Page	PA448510	70788951	46507010		1227	DAP000757	Auranofin		Ridaura	Auranofin	Approved, Investigational	DB00995	InChI=1S/C14H20O9S.C6H15P.Au/c1-6(15)19-5-10-11(20-7(2)16)12(21-8(3)17)13(14(24)23-10)22-9(4)18;1-4-7(5-2)6-3;/h10-14,24H,5H2,1-4H3;4-6H2,1-3H3;/q;;+1/p-1/t10-,11-,12+,13-,14+;;/m1../s1	AUJRCFUBUPVWSZ-XTZHGVARSA-M	2	Auranofin is an antirheumatic used to treat active, progressive, or destructive forms of inflammatory arthritis.	Oral, rat: LD50 = > 2000 mg/kg. Symptoms of overdose may include diarrhoea, vomiting, abdominal cramps, and symptoms of hypersensitivity (such as skin rash, hives, itching, and difficulty breathing).	Small Molecule				AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Inhibitor	Non-inhibitor	Non-substrate	3.1438 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							110-111			0	No	5	0	No	1	0	114.43 Å2	50.82 Å3	114.88 m3·mol-1	15	No	No	0.151 mg/mL	-1	-3.6		-4.3	P30044;!O14920	PRDX5;!IKBKB	1. Peroxiredoxin-5, mitochondrial;!2. Inhibitor of nuclear factor kappa-B kinase subunit beta
C5H13O14P3	Not Available	Not Available	390.0696	O[C@H]1[C@@H](O)[C@@H](OP(O)(=O)OP(O)(O)=O)O[C@@H]1COP(O)(O)=O	Solid	Not Available					25315	17111		7062			HMDB0000280	C00119		PRP			7339	46506467					ZINC000008215630		5-O-phosphono-alpha-D-ribofuranosyl diphosphate	Approved, Experimental, Investigational	DB01632	InChI=1S/C5H13O14P3/c6-3-2(1-16-20(8,9)10)17-5(4(3)7)18-22(14,15)19-21(11,12)13/h2-7H,1H2,(H,14,15)(H2,8,9,10)(H2,11,12,13)/t2-,3-,4-,5-/m1/s1	PQGCEDQWHSBAJP-TXICZTDVSA-N			Not Available	Small Molecule	http://smpdb.ca/view/SMP0000167?highlight[compounds][]=DB01632&highlight[proteins][]=DB01632;!http://smpdb.ca/view/SMP0000220?highlight[compounds][]=DB01632&highlight[proteins][]=DB01632;!http://smpdb.ca/view/SMP0000385?highlight[compounds][]=DB01632&highlight[proteins][]=DB01632;!http://smpdb.ca/view/SMP0000512?highlight[compounds][]=DB01632&highlight[proteins][]=DB01632;!http://smpdb.ca/view/SMP0000518?highlight[compounds][]=DB01632&highlight[proteins][]=DB01632;!http://smpdb.ca/view/SMP0000536?highlight[compounds][]=DB01632&highlight[proteins][]=DB01632;!http://smpdb.ca/view/SMP0000537?highlight[compounds][]=DB01632&highlight[proteins][]=DB01632;!http://smpdb.ca/view/SMP0000031?highlight[compounds][]=DB01632&highlight[proteins][]=DB01632;!http://smpdb.ca/view/SMP0000046?highlight[compounds][]=DB01632&highlight[proteins][]=DB01632;!http://smpdb.ca/view/SMP0000050?highlight[compounds][]=DB01632&highlight[proteins][]=DB01632;!http://smpdb.ca/view/SMP0000072?highlight[compounds][]=DB01632&highlight[proteins][]=DB01632;!http://smpdb.ca/view/SMP0000202?highlight[compounds][]=DB01632&highlight[proteins][]=DB01632;!http://smpdb.ca/view/SMP0000210?highlight[compounds][]=DB01632&highlight[proteins][]=DB01632;!http://smpdb.ca/view/SMP0000339?highlight[compounds][]=DB01632&highlight[proteins][]=DB01632;!http://smpdb.ca/view/SMP0000364?highlight[compounds][]=DB01632&highlight[proteins][]=DB01632;!http://smpdb.ca/view/SMP0000365?highlight[compounds][]=DB01632&highlight[proteins][]=DB01632;!http://smpdb.ca/view/SMP0000428?highlight[compounds][]=DB01632&highlight[proteins][]=DB01632;!http://smpdb.ca/view/SMP0000519?highlight[compounds][]=DB01632&highlight[proteins][]=DB01632;!http://smpdb.ca/view/SMP0000535?highlight[compounds][]=DB01632&highlight[proteins][]=DB01632;!http://smpdb.ca/view/SMP0000048?highlight[compounds][]=DB01632&highlight[proteins][]=DB01632;!http://smpdb.ca/view/SMP0000136?highlight[compounds][]=DB01632&highlight[proteins][]=DB01632;!http://smpdb.ca/view/SMP0000144?highlight[compounds][]=DB01632&highlight[proteins][]=DB01632;!http://smpdb.ca/view/SMP0000168?highlight[compounds][]=DB01632&highlight[proteins][]=DB01632;!http://smpdb.ca/view/SMP0000172?highlight[compounds][]=DB01632&highlight[proteins][]=DB01632;!http://smpdb.ca/view/SMP0000178?highlight[compounds][]=DB01632&highlight[proteins][]=DB01632;!http://smpdb.ca/view/SMP0000203?highlight[compounds][]=DB01632&highlight[proteins][]=DB01632;!http://smpdb.ca/view/SMP0000219?highlight[compounds][]=DB01632&highlight[proteins][]=DB01632;!http://smpdb.ca/view/SMP0000243?highlight[compounds][]=DB01632&highlight[proteins][]=DB01632;!http://smpdb.ca/view/SMP0000427?highlight[compounds][]=DB01632&highlight[proteins][]=DB01632;!http://smpdb.ca/view/SMP0000430?highlight[compounds][]=DB01632&highlight[proteins][]=DB01632	Adenylosuccinate Lyase Deficiency;!Xanthine Dehydrogenase Deficiency (Xanthinuria);!Homocarnosinosis;!Xanthinuria Type I;!Glucose-6-phosphate Dehydrogenase Deficiency;!Mitochondrial DNA Depletion Syndrome;!Myoadenylate Deaminase Deficiency;!Pentose Phosphate Pathway;!Pyrimidine Metabolism;!Purine Metabolism;!Glutamate Metabolism;!MNGIE (Mitochondrial Neurogastrointestinal Encephalopathy);!Purine Nucleoside Phosphorylase Deficiency;!Hyperinsulinism-Hyperammonemia Syndrome;!Lesch-Nyhan Syndrome (LNS);!Gout or Kelley-Seegmiller Syndrome;!Mercaptopurine Action Pathway;!Ribose-5-phosphate Isomerase Deficiency;!Adenine Phosphoribosyltransferase Deficiency (APRT);!Nicotinate and Nicotinamide Metabolism;!2-Hydroxyglutric Aciduria (D and L Form);!Adenosine Deaminase Deficiency;!AICA-Ribosiduria;!beta-Ureidopropionase Deficiency;!Dihydropyrimidinase Deficiency;!Molybdenum Cofactor Deficiency;!UMP Synthase Deficiency (Orotic Aciduria);!4-Hydroxybutyric Aciduria/Succinic Semialdehyde Dehydrogenase Deficiency;!Azathioprine Action Pathway;!Thioguanine Action Pathway		Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.0708 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	11	7	No	1	-4	229.74 Å2	27.46 Å3	62.58 m3·mol-1	7	No	No	11.6 mg/mL	-3	-1.5	1.09	-3.7	P00492;!P08870;!Q9NWZ5;!Q27796;!P07741;!Q8VP84	HPRT1;!pyrE;!UCKL1;!HGPRTase;!APRT;!trpD	1. Hypoxanthine-guanine phosphoribosyltransferase;!2. Orotate phosphoribosyltransferase;!3. Uridine-cytidine kinase-like 1;!4. Hypoxanthine-guanine phosphoribosyltransferase;!5. Adenine phosphoribosyltransferase;!6. Anthranilate phosphoribosyltransferase
C21H30N10O17P3	Not Available	Not Available	787.441	CN1C=[N+]([C@@H]2O[C@H](CO[P@](O)(=O)O[P@](O)(=O)O[P@](O)(=O)OC[C@H]3O[C@H]([C@H](O)[C@@H]3O)N3C=NC4=C(N)N=CN=C34)[C@@H](O)[C@H]2O)C2=C1C(=O)N=C(N)N2	Solid	Not Available								393721						GTA			446336	46507224					ZINC000096006025		7-methyl-GpppA	Experimental	DB01649	InChI=1S/C21H29N10O17P3/c1-29-6-31(17-10(29)18(36)28-21(23)27-17)20-14(35)12(33)8(46-20)3-44-50(39,40)48-51(41,42)47-49(37,38)43-2-7-11(32)13(34)19(45-7)30-5-26-9-15(22)24-4-25-16(9)30/h4-8,11-14,19-20,32-35H,2-3H2,1H3,(H7-,22,23,24,25,27,28,36,37,38,39,40,41,42)/p+1/t7-,8-,11-,12-,13-,14-,19-,20-/m1/s1	QQOHNVHGNZYSBP-XPWFQUROSA-O			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.7349 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	20	10	Yes	6	-2	394.11 Å2	66.5 Å3	161.42 m3·mol-1	12	No	No	2.89 mg/mL	-11	-2.4	0.91	4.93	Q96C86;!P06730	DCPS;!EIF4E	1. m7GpppX diphosphatase;!2. Eukaryotic translation initiation factor 4E
C15H25N5O20P4	Not Available	Not Available	719.2755	O[C@@H]1[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]([C@@H]1O)N1C=NC2=C1N=CN(C1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O)C2=N	Solid	Not Available						18263		21864848				C02739		PRT			16019963	46507757							1-(5-phospho-D-ribosyl)-ATP	Experimental	DB01661	InChI=1S/C15H25N5O20P4/c16-12-7-13(18-4-19(12)14-10(23)8(21)5(37-14)1-35-41(25,26)27)20(3-17-7)15-11(24)9(22)6(38-15)2-36-43(31,32)40-44(33,34)39-42(28,29)30/h3-6,8-11,14-16,21-24H,1-2H2,(H,31,32)(H,33,34)(H2,25,26,27)(H2,28,29,30)/t5-,6-,8-,9-,10-,11-,14?,15-/m1/s1	RKNHJBVBFHDXGR-MRUDJCSFSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.3619 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	20	11	Yes	4	-5	383.23 Å2	57.34 Å3	144.29 m3·mol-1	12	No	No	9.92 mg/mL	-5	-1.9	1.1	0.6	P60757	hisG	1. ATP phosphoribosyltransferase
C6H12O24S6	Not Available	Not Available	660.535	[H][C@]1(OS(O)(=O)=O)[C@]([H])(OS(O)(=O)=O)[C@@]([H])(OS(O)(=O)=O)[C@]([H])(OS(O)(=O)=O)[C@]([H])(OS(O)(=O)=O)[C@]1([H])OS(O)(=O)=O	Solid	Not Available					50191320		CHEMBL3945401	18786070						IHS			65302	46508928							D-Myo-Inositol-Hexasulphate	Experimental	DB01666	InChI=1S/C6H12O24S6/c7-31(8,9)25-1-2(26-32(10,11)12)4(28-34(16,17)18)6(30-36(22,23)24)5(29-35(19,20)21)3(1)27-33(13,14)15/h1-6H,(H,7,8,9)(H,10,11,12)(H,13,14,15)(H,16,17,18)(H,19,20,21)(H,22,23,24)/t1-,2-,3-,4+,5-,6-	NBTMNFYXJYCQHQ-GPIVLXJGSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.0402 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	18	6	No	1	-6	381.6 Å2	47.3 Å3	95.73 m3·mol-1	12	No	No	0.394 mg/mL	-3.5	-3.2	-3.5		Q7WUJ1;!P19883	phyA;!FST	1. Myo-inositol hexaphosphate phosphohydrolase;!2. Follistatin
C23H36N4O20P2	Not Available	Not Available	750.4943	C[C@H](NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@H](OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)N2C=CC(=O)NC2=O)[C@@H]1NC(C)=O)C(O)=O	Solid	Not Available						84726		4593506				C01212		UMA			5496796	46507193					ZINC000085545647		Uridine-5'-Diphosphate-N-Acetylmuramoyl-L-Alanine	Experimental	DB01673	InChI=1S/C23H36N4O20P2/c1-8(21(35)36)24-19(34)9(2)43-18-14(25-10(3)29)22(45-11(6-28)16(18)32)46-49(40,41)47-48(38,39)42-7-12-15(31)17(33)20(44-12)27-5-4-13(30)26-23(27)37/h4-5,8-9,11-12,14-18,20,22,28,31-33H,6-7H2,1-3H3,(H,24,34)(H,25,29)(H,35,36)(H,38,39)(H,40,41)(H,26,30,37)/t8-,9+,11+,12+,14+,15+,16+,17+,18+,20+,22+/m0/s1	NTMMCWJNQNKACG-KBKUWGQMSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.4144 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	17	10	Yes	3	-3	355.81 Å2	64.42 Å3	150.18 m3·mol-1	15	No	No	9.58 mg/mL	-5.1	-1.9	1.73	-3.7	P14900;!P45066	murD;!murC	1. UDP-N-acetylmuramoylalanine--D-glutamate ligase;!2. UDP-N-acetylmuramate--L-alanine ligase
C20H27N10O16P3	Not Available	Not Available	756.4071	[H][C@]1(COP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@@]2([H])O[C@@]([H])(N3C=NC4=C(N)N=CN=C34)[C@]([H])(O)[C@]2([H])O)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O	Solid	Not Available					50184368	27775	CHEMBL407938	144977				C06197		BA3			165381	46509170					ZINC000008220358		Bis(Adenosine)-5'-Triphosphate	Experimental	DB01690	InChI=1S/C20H27N10O16P3/c21-15-9-17(25-3-23-15)29(5-27-9)19-13(33)11(31)7(43-19)1-41-47(35,36)45-49(39,40)46-48(37,38)42-2-8-12(32)14(34)20(44-8)30-6-28-10-16(22)24-4-26-18(10)30/h3-8,11-14,19-20,31-34H,1-2H2,(H,35,36)(H,37,38)(H,39,40)(H2,21,23,25)(H2,22,24,26)/t7-,8-,11-,12-,13-,14-,19-,20-/m1/s1	QCICUPZZLIQAPA-XPWFQUROSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.8102 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	20	9	Yes	6	-3	387.44 Å2	62.98 Å3	155.23 m3·mol-1	12	No	No	4.39 mg/mL	-10	-2.2	0.89	5.23	P0A6I9	coaE	1. Dephospho-CoA kinase
C18H32O16	Not Available	Not Available	504.4371	[H][C@@]1(O)O[C@]([H])(CO)[C@@]([H])(O[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O[C@]3([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]3([H])O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]1([H])O	Solid	Not Available						41753		389778				C06219					440950	46507144					ZINC000008220386		beta-cellotriose	Experimental	DB01697	InChI=1S/C18H32O16/c19-1-4-7(22)8(23)12(27)17(31-4)34-15-6(3-21)32-18(13(28)10(15)25)33-14-5(2-20)30-16(29)11(26)9(14)24/h4-29H,1-3H2/t4-,5-,6-,7-,8+,9-,10-,11-,12-,13-,14-,15-,16-,17+,18+/m1/s1	FYGDTMLNYKFZSV-CSHPIKHBSA-N			Not Available	Small Molecule																																			0	No	16	11	Yes	3	0	268.68 Å2	47.52 Å3	100.75 m3·mol-1	7	No	No	554.0 mg/mL	-6.5	0.04	11.22	-3.6			
C14H22N2O16P2	Not Available	Not Available	536.2758	O[C@@H]1[C@@H](COP(O)(=O)OP(O)(=O)O[C@H]2OC[C@@H](O)[C@H](O)[C@H]2O)O[C@H]([C@@H]1O)N1C=CC(=O)NC1=O	Solid	Not Available						16082		18152						UDX			19235	46508749					ZINC000008551129		UDP-alpha-D-xylose	Experimental	DB01713	InChI=1S/C14H22N2O16P2/c17-5-3-28-13(11(22)8(5)19)31-34(26,27)32-33(24,25)29-4-6-9(20)10(21)12(30-6)16-2-1-7(18)15-14(16)23/h1-2,5-6,8-13,17,19-22H,3-4H2,(H,24,25)(H,26,27)(H,15,18,23)/t5-,6-,8+,9-,10-,11-,12-,13-/m1/s1	DQQDLYVHOTZLOR-OCIMBMBZSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.3521 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	13	8	Yes	3	-2	271.31 Å2	42.12 Å3	100.49 m3·mol-1	8	No	No	13.6 mg/mL	-4.4	-1.6	1.73	-3.5	P0C0F4	hasB	1. UDP-glucose 6-dehydrogenase
C20H29N10O22P5	Not Available	Not Available	916.3669	[H][C@]1(COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@@]2([H])O[C@@]([H])(N3C=NC4=C(N)N=CN=C34)[C@]([H])(O)[C@]2([H])O)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O	Solid	Not Available					50435017	28898	CHEMBL437508	389195				C04058		AP5			440210	46505205					ZINC000096085195		Bis(Adenosine)-5'-Pentaphosphate	Experimental	DB01717	InChI=1S/C20H29N10O22P5/c21-15-9-17(25-3-23-15)29(5-27-9)19-13(33)11(31)7(47-19)1-45-53(35,36)49-55(39,40)51-57(43,44)52-56(41,42)50-54(37,38)46-2-8-12(32)14(34)20(48-8)30-6-28-10-16(22)24-4-26-18(10)30/h3-8,11-14,19-20,31-34H,1-2H2,(H,35,36)(H,37,38)(H,39,40)(H,41,42)(H,43,44)(H2,21,23,25)(H2,22,24,26)/t7-,8-,11-,12-,13-,14-,19-,20-/m1/s1	OIMACDRJUANHTJ-XPWFQUROSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.8102 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	24	11	Yes	6	-5	480.5 Å2	72.11 Å3	176.98 m3·mol-1	16	No	No	6.92 mg/mL	-10	-2.1	0.23	4.97	P16304;!P27142;!P84139;!P54819;!Q96MA6;!P69441;!P00568	adk;!adk;!adk;!AK2;!AK8;!adk;!AK1	1. Adenylate kinase;!2. Adenylate kinase;!3. Adenylate kinase;!4. Adenylate kinase 2, mitochondrial;!5. Adenylate kinase 8;!6. Adenylate kinase;!7. Adenylate kinase isoenzyme 1
C6H15O15P3	Not Available	Not Available	420.0956	O[C@@H]1[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@@H](O)[C@H]1OP(O)(O)=O	Solid	Not Available						18228	CHEMBL329137	388561			HMDB0001143	C01243		I3S			439455	46506250					ZINC000004095596		1D-myo-inositol 1,3,4-trisphosphate	Experimental	DB01729	InChI=1S/C6H15O15P3/c7-1-2(8)5(20-23(13,14)15)6(21-24(16,17)18)3(9)4(1)19-22(10,11)12/h1-9H,(H2,10,11,12)(H2,13,14,15)(H2,16,17,18)/t1-,2-,3+,4+,5+,6+/m1/s1	MMWCIQZXVOZEGG-MLQGYMEPSA-N			Not Available	Small Molecule	http://smpdb.ca/view/SMP0000011?highlight[compounds][]=DB01729&highlight[proteins][]=DB01729;!http://smpdb.ca/view/SMP0000462?highlight[compounds][]=DB01729&highlight[proteins][]=DB01729	Inositol Metabolism;!Inositol Phosphate Metabolism		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.1296 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	12	9	No	1	-6	260.97 Å2	29.73 Å3	68.39 m3·mol-1	6	No	No	14.8 mg/mL	-4.2	-1.4	0.54	-3.7			
C21H29N7O18P3	Not Available	Not Available	760.4123	NC(=O)[C@H]1C=[N+](C=CC1=O)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](OP(O)(O)=O)[C@@H]2O)N2C=NC3=C(N)N=CN=C23)[C@@H](O)[C@H]1O	Solid	Not Available								25057817						ODP			49867432	46505149					ZINC000263620886		4-oxo-nicotinamide-adenine dinucleotide phosphate	Experimental	DB01753	InChI=1S/C21H28N7O18P3/c22-17-12-19(25-6-24-17)28(7-26-12)21-16(45-47(34,35)36)14(31)11(44-21)5-42-49(39,40)46-48(37,38)41-4-10-13(30)15(32)20(43-10)27-2-1-9(29)8(3-27)18(23)33/h1-3,6-8,10-11,13-16,20-21,30-32H,4-5H2,(H7-,22,23,24,25,33,34,35,36,37,38,39,40)/p+1/t8-,10+,11+,13+,14+,15+,16+,20+,21+/m0/s1	PIXSDSMVQQICPA-BYJCYCELSA-O			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.8695 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	18	9	Yes	5	-3	380.99 Å2	63.5 Å3	164.89 m3·mol-1	13	No	No		-9.3		0.66	4.87	P9WIQ3	fprA	1. NADPH-ferredoxin reductase FprA
C21H28N7O16P3S	Not Available	Not Available	759.471	[H][C@]1(COP(O)(=O)OP(O)(=O)OC[C@@]2([H])O[C@@]([H])([N+]3=CC=CC(=C3)C([S-])=N)[C@]([H])(O)[C@]2([H])O)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(OP(O)(O)=O)[C@]1([H])O	Solid	Not Available							CHEMBL1236188	4451410						TAP			131704180	46506464							7-thionicotinamide-adenine-dinucleotide phosphate	Experimental	DB01763	InChI=1S/C21H28N7O16P3S/c22-17-12-19(25-7-24-17)28(8-26-12)21-16(43-45(32,33)34)14(30)11(42-21)6-40-47(37,38)44-46(35,36)39-5-10-13(29)15(31)20(41-10)27-3-1-2-9(4-27)18(23)48/h1-4,7-8,10-11,13-16,20-21,29-31H,5-6H2,(H7-,22,23,24,25,32,33,34,35,36,37,38,48)/t10-,11-,13-,14-,15-,16-,20-,21-/m1/s1	OJNFDOAQUXJWED-NNYOXOHSSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.6401 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	17	9	Yes	5	-3	345.55 Å2	64.8 Å3	170.68 m3·mol-1	13	No	No	7.49 mg/mL	-14	-2	0.65	6.13	Q13423	NNT	1. NAD(P) transhydrogenase, mitochondrial
C16H25N5O15P2	Not Available	Not Available	589.3417	NC1=C2N=CN([C@@H]3O[C@H](CO[P@](O)(=O)O[P@](O)(=O)O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@@H](O)[C@H]3O)C2=NC=N1	Solid	Not Available						15751	CHEMBL227552	15642			HMDB0006557	C00498		ADQ			16500	46506026					ZINC000008216005		Adenosine-5'-Monophosphate Glucopyranosyl-Monophosphate Ester	Experimental	DB01774	InChI=1S/C16H25N5O15P2/c17-13-7-14(19-3-18-13)21(4-20-7)15-11(26)9(24)6(33-15)2-32-37(28,29)36-38(30,31)35-16-12(27)10(25)8(23)5(1-22)34-16/h3-6,8-12,15-16,22-27H,1-2H2,(H,28,29)(H,30,31)(H2,17,18,19)/t5-,6-,8-,9-,10+,11-,12-,15-,16-/m1/s1	WFPZSXYXPSUOPY-ROYWQJLOSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	3.0945 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	16	9	Yes	4	-2	311.75 Å2	49.4 Å3	117.09 m3·mol-1	9	No	No	4.84 mg/mL	-6.9	-2.1	1.73	4.93	P67910	hldD	1. ADP-L-glycero-D-manno-heptose-6-epimerase
C10H15N5O10P2	Not Available	Not Available	427.2011	NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H]1O	Solid	Not Available						17985	CHEMBL574817	140102			HMDB0000061	C00054		A3P			159296	46507388					ZINC000004228234		Adenosine 3',5'-diphosphate	Experimental	DB01812	InChI=1S/C10H15N5O10P2/c11-8-5-9(13-2-12-8)15(3-14-5)10-6(16)7(25-27(20,21)22)4(24-10)1-23-26(17,18)19/h2-4,6-7,10,16H,1H2,(H2,11,12,13)(H2,17,18,19)(H2,20,21,22)/t4-,6-,7-,10-/m1/s1	WHTCPDAXWFLDIH-KQYNXXCUSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.2659 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	12	6	Yes	3	-4	232.6 Å2	34.28 Å3	84.94 m3·mol-1	6	No	No	3.33 mg/mL	-5.2	-2.1	0.4	4.86	O14792;!O00204;!P10153;!P50225;!Q9Y663;!P07998;!Q06520;!P49888;!P06612;!P52848;!P0A2W7;!O43704	HS3ST1;!SULT2B1;!RNASE2;!SULT1A1;!HS3ST3A1;!RNASE1;!SULT2A1;!SULT1E1;!topA;!NDST1;!acpS;!SULT1B1	1. Heparan sulfate glucosamine 3-O-sulfotransferase 1;!2. Sulfotransferase family cytosolic 2B member 1;!3. Non-secretory ribonuclease;!4. Sulfotransferase 1A1;!5. Heparan sulfate glucosamine 3-O-sulfotransferase 3A1;!6. Ribonuclease pancreatic;!7. Bile salt sulfotransferase;!8. Estrogen sulfotransferase;!9. DNA topoisomerase 1;!10. Bifunctional heparan sulfate N-deacetylase/N-sulfotransferase 1;!11. Holo-[acyl-carrier-protein] synthase;!12. Sulfotransferase family cytosolic 1B member 1
C10H16N5O13P3	Not Available	Not Available	507.181	[H][C@]1(COP(O)(=O)OP(O)(O)=O)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])OP(O)(O)=O	Solid	Not Available								114207						PAP			128882	46509162					ZINC000013527438		3'-Phosphate-Adenosine-5'-Diphosphate	Experimental	DB01842	InChI=1S/C10H16N5O13P3/c11-8-5-9(13-2-12-8)15(3-14-5)10-6(16)7(27-29(17,18)19)4(26-10)1-25-31(23,24)28-30(20,21)22/h2-4,6-7,10,16H,1H2,(H,23,24)(H2,11,12,13)(H2,17,18,19)(H2,20,21,22)/t4-,6-,7-,10-/m1/s1	GBBWIZKLHXYJOA-KQYNXXCUSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.4823 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	14	7	Yes	3	-5	279.13 Å2	39.07 Å3	95.81 m3·mol-1	8	No	No	4.61 mg/mL	-5.3	-2	0.82	4.88	P07998;!P9WQG9	RNASE1;!aac	1. Ribonuclease pancreatic;!2. Aminoglycoside 2'-N-acetyltransferase
C15H24N2O17P2	Not Available	Not Available	566.3018	OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)N2C=CC(=O)NC2=O)[C@H](O)[C@@H](O)[C@@H]1O	Solid	Not Available					50209659	46229	CHEMBL375951	8308			HMDB0060079	C00029		UPG			8629	46507150				Uridine_diphosphate_glucose	ZINC000008215472		Uridine diphosphate glucose	Experimental	DB01861	InChI=1S/C15H24N2O17P2/c18-3-5-8(20)10(22)12(24)14(32-5)33-36(28,29)34-35(26,27)30-4-6-9(21)11(23)13(31-6)17-2-1-7(19)16-15(17)25/h1-2,5-6,8-14,18,20-24H,3-4H2,(H,26,27)(H,28,29)(H,16,19,25)/t5-,6-,8-,9-,10+,11-,12-,13-,14-/m1/s1	HSCJRCZFDFQWRP-JZMIEXBBSA-N			Not Available	Small Molecule	http://smpdb.ca/view/SMP0000043?highlight[compounds][]=DB01861&highlight[proteins][]=DB01861;!http://smpdb.ca/view/SMP0000058?highlight[compounds][]=DB01861&highlight[proteins][]=DB01861;!http://smpdb.ca/view/SMP0000348?highlight[compounds][]=DB01861&highlight[proteins][]=DB01861;!http://smpdb.ca/view/SMP0000444?highlight[compounds][]=DB01861&highlight[proteins][]=DB01861;!http://smpdb.ca/view/SMP0000552?highlight[compounds][]=DB01861&highlight[proteins][]=DB01861;!http://smpdb.ca/view/SMP0000553?highlight[compounds][]=DB01861&highlight[proteins][]=DB01861;!http://smpdb.ca/view/SMP0000182?highlight[compounds][]=DB01861&highlight[proteins][]=DB01861;!http://smpdb.ca/view/SMP0000347?highlight[compounds][]=DB01861&highlight[proteins][]=DB01861;!http://smpdb.ca/view/SMP0000495?highlight[compounds][]=DB01861&highlight[proteins][]=DB01861;!http://smpdb.ca/view/SMP0000556?highlight[compounds][]=DB01861&highlight[proteins][]=DB01861;!http://smpdb.ca/view/SMP0000557?highlight[compounds][]=DB01861&highlight[proteins][]=DB01861;!http://smpdb.ca/view/SMP0000580?highlight[compounds][]=DB01861&highlight[proteins][]=DB01861;!http://smpdb.ca/view/SMP0000010?highlight[compounds][]=DB01861&highlight[proteins][]=DB01861;!http://smpdb.ca/view/SMP0000034?highlight[compounds][]=DB01861&highlight[proteins][]=DB01861;!http://smpdb.ca/view/SMP0000349?highlight[compounds][]=DB01861&highlight[proteins][]=DB01861;!http://smpdb.ca/view/SMP0000496?highlight[compounds][]=DB01861&highlight[proteins][]=DB01861;!http://smpdb.ca/view/SMP0000525?highlight[compounds][]=DB01861&highlight[proteins][]=DB01861;!http://smpdb.ca/view/SMP0000526?highlight[compounds][]=DB01861&highlight[proteins][]=DB01861;!http://smpdb.ca/view/SMP0000554?highlight[compounds][]=DB01861&highlight[proteins][]=DB01861;!http://smpdb.ca/view/SMP0000555?highlight[compounds][]=DB01861&highlight[proteins][]=DB01861;!http://smpdb.ca/view/SMP0000579?highlight[compounds][]=DB01861&highlight[proteins][]=DB01861	Galactose Metabolism;!Starch and Sucrose Metabolism;!Globoid Cell Leukodystrophy;!Lactose Synthesis;!Glycogen Synthetase Deficiency;!Glycogenosis, Type III. Cori Disease, Debrancher Glycogenosis;!Galactosemia;!Metachromatic Leukodystrophy (MLD);!Galactosemia II (GALK);!Mucopolysaccharidosis VI. Sly Syndrome;!Sucrase-Isomaltase Deficiency;!GLUT-1 Deficiency Syndrome;!Nucleotide Sugars Metabolism;!Sphingolipid Metabolism;!Gaucher Disease;!Galactosemia III;!Fabry Disease;!Krabbe Disease;!Glycogenosis, Type IV. Amylopectinosis, Anderson Disease;!Glycogenosis, Type VI. Hers Disease;!Congenital Disorder of Glycosylation CDG-IId																																	0	No	14	9	Yes	3	-2	291.54 Å2	45.39 Å3	106.46 m3·mol-1	9	No	No	15.0 mg/mL	-5	-1.6	1.73	-3.6	P09148;!Q14376;!P31677;!P26393;!P09147;!P04547;!Q7Z4J2;!Q8KN66;!P46976	galT;!GALE;!otsA;!rmlA;!galE;!bgt;!GLT6D1;!Not Available;!GYG1	1. Galactose-1-phosphate uridylyltransferase;!2. UDP-glucose 4-epimerase;!3. Alpha,alpha-trehalose-phosphate synthase [UDP-forming];!4. Glucose-1-phosphate thymidylyltransferase;!5. UDP-glucose 4-epimerase;!6. DNA beta-glucosyltransferase;!7. Glycosyltransferase 6 domain-containing protein 1;!8. WbpP;!9. Glycogenin-1
C6H16O18P4	Not Available	Not Available	500.0755	O[C@H]1[C@@H](OP(O)(O)=O)[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1OP(O)(O)=O	Solid	Not Available					50075651	16783	CHEMBL23552	17216047				C01272		4IP			107758	46508691					ZINC000012494830		Inositol 1,3,4,5-Tetrakisphosphate	Experimental	DB01863	InChI=1S/C6H16O18P4/c7-1-3(21-25(9,10)11)2(8)5(23-27(15,16)17)6(24-28(18,19)20)4(1)22-26(12,13)14/h1-8H,(H2,9,10,11)(H2,12,13,14)(H2,15,16,17)(H2,18,19,20)/t1-,2-,3-,4+,5-,6-/m0/s1	CIPFCGZLFXVXBG-CNWJWELYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.1645 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	14	10	No	1	-8	307.5 Å2	34.19 Å3	79.27 m3·mol-1	8	No	No	11.5 mg/mL	-4.3	-1.6	0.33		P23677;!Q99418;!O43739;!O15530;!P31749;!Q9H4M7;!Q06187;!Q9UN19	ITPKA;!CYTH2;!CYTH3;!PDPK1;!AKT1;!PLEKHA4;!BTK;!DAPP1	1. Inositol-trisphosphate 3-kinase A;!2. Cytohesin-2;!3. Cytohesin-3;!4. 3-phosphoinositide-dependent protein kinase 1;!5. RAC-alpha serine/threonine-protein kinase;!6. Pleckstrin homology domain-containing family A member 4;!7. Tyrosine-protein kinase BTK;!8. Dual adapter for phosphotyrosine and 3-phosphotyrosine and 3-phosphoinositide
C12H22O35S8	Not Available	Not Available	982.802	OS(=O)(=O)OC[C@H]1O[C@@](COS(O)(=O)=O)(O[C@H]2O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]2OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H]1OS(O)(=O)=O	Solid	Not Available							CHEMBL1235872	392225									444237	46504489					ZINC000169654783		Sucrosofate	Experimental	DB01901	InChI=1S/C12H22O35S8/c13-48(14,15)37-1-4-6(43-51(22,23)24)8(45-53(28,29)30)9(46-54(31,32)33)11(40-4)42-12(3-39-50(19,20)21)10(47-55(34,35)36)7(44-52(25,26)27)5(41-12)2-38-49(16,17)18/h4-11H,1-3H2,(H,13,14,15)(H,16,17,18)(H,19,20,21)(H,22,23,24)(H,25,26,27)(H,28,29,30)(H,31,32,33)(H,34,35,36)/t4-,5-,6-,7-,8+,9-,10+,11-,12+/m1/s1	WEPNHBQBLCNOBB-UGDNZRGBSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Inhibitor	Non-inhibitor	Non-substrate	2.4709 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	27	8	No	2	-8	536.49 Å2	72.47 Å3	148.71 m3·mol-1	21	No	No	1.45 mg/mL	-4.1	-2.8	-3.4		P21802;!P05230	FGFR2;!FGF1	1. Fibroblast growth factor receptor 2;!2. Fibroblast growth factor 1
C9H12N3O9P	Not Available	Not Available	337.18	[H][C@]1(COP(O)([O-])=O)O[C@@]([H])(N2C=NC(C(N)=O)=C2[O-])[C@]([H])(O)[C@]1([H])O	Solid	Not Available								25058867						MZP			131704184	46505797							4-Carbamoyl-1-Beta-D-Ribofuranosyl-Imidazolium-5-Olate-5'-Phosphate	Experimental	DB01945	InChI=1S/C9H14N3O9P/c10-7(15)4-8(16)12(2-11-4)9-6(14)5(13)3(21-9)1-20-22(17,18)19/h2-3,5-6,9,13-14,16H,1H2,(H2,10,15)(H2,17,18,19)/p-2/t3-,5-,6-,9-/m1/s1	KTKAFSMJDTUUAN-UUOKFMHZSA-L			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.5200 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	9	4	No	2	-2	203.25 Å2	27.57 Å3	75.85 m3·mol-1	5	Yes	No	4.66 mg/mL	-3.6	-1.9	1.21	2.78			
C16H25N5O13P2	Not Available	Not Available	557.3429	[H][C@]1(O)O[C@]([H])(COP(O)(=O)CP(O)(=O)OC[C@@]2([H])O[C@@]([H])(N3C=NC4=C(N)N=CN=C34)[C@]([H])(O)[C@]2([H])O)[C@@]([H])(O)[C@@]1([H])O	Solid	Not Available								394008						ADV			446724	46508105					ZINC000015636817		AMPCPR	Experimental	DB01975	InChI=1S/C16H25N5O13P2/c17-13-8-14(19-3-18-13)21(4-20-8)15-11(24)9(22)6(33-15)1-31-35(27,28)5-36(29,30)32-2-7-10(23)12(25)16(26)34-7/h3-4,6-7,9-12,15-16,22-26H,1-2,5H2,(H,27,28)(H,29,30)(H2,17,18,19)/t6-,7-,9-,10-,11-,12-,15-,16+/m1/s1	ZPZRETFSCSWNDT-DBXCYWGHSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.6179 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	15	8	Yes	4	-2	282.29 Å2	47.57 Å3	113.48 m3·mol-1	9	No	No	4.24 mg/mL	-7.6	-2.1	0.6	4.92	P83844;!O33199	nudF;!Not Available	1. ADP-ribose pyrophosphatase;!2. MutT/nudix family protein
C9H19O17P3	Not Available	Not Available	492.1582	OCC(=O)COP(O)(=O)OC1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O	Solid	Not Available								4450728						IBS			5288599	46505118							(1R,2R,3S,4R,6S)-3,4,6-Trihydroxy-5-{[(S)-hydroxy(3-hydroxy-2-oxopropoxy)phosphoryl]oxy}-1,2-cyclohexanediyl bis[dihydrogen (phosphate)]	Experimental	DB02028	InChI=1S/C9H19O17P3/c10-1-3(11)2-23-29(21,22)26-7-4(12)5(13)8(24-27(15,16)17)9(6(7)14)25-28(18,19)20/h4-10,12-14H,1-2H2,(H,21,22)(H2,15,16,17)(H2,18,19,20)/t4-,5+,6+,7?,8-,9-/m1/s1	JBQPYAMQMBKZDT-WKBARDANSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.0261 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	13	9	No	1	-5	287.27 Å2	36.19 Å3	84.21 m3·mol-1	10	No	No	14.3 mg/mL	-4.8	-1.5	0.62	-3.7	P50607	TUB	1. Tubby protein homolog
C15H23N5O14P2	Not Available	Not Available	559.3157	NC1=C2N=CN([C@@H]3O[C@H](CO[P@@](O)(=O)O[P@@](O)(=O)OC[C@H]4O[C@H](O)[C@H](O)[C@@H]4O)[C@@H](O)[C@H]3O)C2=NC=N1	Solid	Not Available								394252						AR6			447048	46508870					ZINC000014880207		Adenosine-5-Diphosphoribose	Experimental	DB02059	InChI=1S/C15H23N5O14P2/c16-12-7-13(18-3-17-12)20(4-19-7)14-10(23)8(21)5(32-14)1-30-35(26,27)34-36(28,29)31-2-6-9(22)11(24)15(25)33-6/h3-6,8-11,14-15,21-25H,1-2H2,(H,26,27)(H,28,29)(H2,16,17,18)/t5-,6-,8-,9-,10-,11-,14-,15+/m1/s1	SRNWOUGRCWSEMX-ZQSHOCFMSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.7259 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	15	8	Yes	4	-2	291.52 Å2	46.29 Å3	111.12 m3·mol-1	9	No	No	3.61 mg/mL	-6.2	-2.2	1.85	4.93	Q9NXA8;!P00438;!P83844;!P26397;!P13639;!P04406;!P0A9S1;!O33199;!P45799;!Q84CU3;!Q9NTG7	SIRT5;!pobA;!nudF;!rfbG;!EEF2;!GAPDH;!fucO;!Not Available;!nudE;!ndx4;!SIRT3	1. NAD-dependent protein deacylase sirtuin-5, mitochondrial;!2. p-hydroxybenzoate hydroxylase;!3. ADP-ribose pyrophosphatase;!4. CDP-glucose 4,6-dehydratase;!5. Elongation factor 2;!6. Glyceraldehyde-3-phosphate dehydrogenase;!7. Lactaldehyde reductase;!8. MutT/nudix family protein;!9. ADP compounds hydrolase NudE;!10. ADP-ribose pyrophosphatase;!11. NAD-dependent protein deacetylase sirtuin-3, mitochondrial
C10H15N5O10P2	Not Available	Not Available	427.2011	[H][C@]1(COP(O)(O)=O)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(OP(O)(O)=O)[C@]1([H])O	Solid	Not Available					11941		CHEMBL1161861	389137				C03850		A2P			440141	46504615					ZINC000004096223		Adenosine-2'-5'-Diphosphate	Experimental	DB02098	InChI=1S/C10H15N5O10P2/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(25-27(20,21)22)6(16)4(24-10)1-23-26(17,18)19/h2-4,6-7,10,16H,1H2,(H2,11,12,13)(H2,17,18,19)(H2,20,21,22)/t4-,6-,7-,10-/m1/s1	AEOBEOJCBAYXBA-KQYNXXCUSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.2875 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	12	6	Yes	3	-4	232.6 Å2	33.92 Å3	84.94 m3·mol-1	6	No	No	3.29 mg/mL	-5.4	-2.1	0.35	4.84	P12724;!P07998;!P10153	RNASE3;!RNASE1;!RNASE2	1. Eosinophil cationic protein;!2. Ribonuclease pancreatic;!3. Non-secretory ribonuclease
C17H27N3O17P2	Not Available	Not Available	607.3537	CC(=O)N[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[P@](O)(=O)O[P@](O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=CC(=O)NC1=O	Solid	Not Available						67168		22161			HMDB0060522			UD2			23700	46508676					ZINC000008551132		Uridine-Diphosphate-N-Acetylgalactosamine	Experimental	DB02196	InChI=1S/C17H27N3O17P2/c1-6(22)18-10-13(26)11(24)7(4-21)35-16(10)36-39(31,32)37-38(29,30)33-5-8-12(25)14(27)15(34-8)20-3-2-9(23)19-17(20)28/h2-3,7-8,10-16,21,24-27H,4-5H2,1H3,(H,18,22)(H,29,30)(H,31,32)(H,19,23,28)/t7-,8-,10-,11+,12-,13-,14-,15-,16-/m1/s1	LFTYTUAZOPRMMI-NESSUJCYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.3962 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	14	9	Yes	3	-2	300.41 Å2	51.05 Å3	117.56 m3·mol-1	10	No	No	11.4 mg/mL	-5.3	-1.7	1.74	-3.5	Q16222;!Q14376;!P27828;!P16442;!P17443;!Q9UBQ6;!Q8KN66	UAP1;!GALE;!wecB;!ABO;!murG;!EXTL2;!Not Available	1. UDP-N-acetylhexosamine pyrophosphorylase;!2. UDP-glucose 4-epimerase;!3. UDP-N-acetylglucosamine 2-epimerase;!4. Histo-blood group ABO system transferase;!5. UDP-N-acetylglucosamine--N-acetylmuramyl-(pentapeptide) pyrophosphoryl-undecaprenol N-acetylglucosamine transferase;!6. Exostosin-like 2;!7. WbpP
C7H15N2O8P	Not Available	Not Available	286.1764	NCC(=O)NC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O	Solid	Not Available						18349		4573646				C03838		GAR			5459918	46504693							Glycinamide Ribonucleotide	Experimental	DB02236	InChI=1S/C7H15N2O8P/c8-1-4(10)9-7-6(12)5(11)3(17-7)2-16-18(13,14)15/h3,5-7,11-12H,1-2,8H2,(H,9,10)(H2,13,14,15)/t3-,5-,6-,7?/m1/s1	OBQMLSFOUZUIOB-HJZCUYRDSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.3510 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	8	6	No	1	-1	171.57 Å2	23.69 Å3	55.29 m3·mol-1	5	No	No	14.6 mg/mL	-4.7	-1.3	1.23	8.14	P33221;!P08179;!P22102	purT;!purN;!GART	1. Phosphoribosylglycinamide formyltransferase 2;!2. Phosphoribosylglycinamide formyltransferase;!3. Trifunctional purine biosynthetic protein adenosine-3
C10H16N5O12P3S	Not Available	Not Available	523.247	[H][C@]1(CO[P@@](O)(=S)OP(O)(=O)OP(O)(O)=O)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O	Solid	Not Available														TAT			6858181	46508000							Adenosine-5'-Rp-Alpha-Thio-Triphosphate	Experimental	DB02355	InChI=1S/C10H16N5O12P3S/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(25-10)1-24-30(23,31)27-29(21,22)26-28(18,19)20/h2-4,6-7,10,16-17H,1H2,(H,21,22)(H,23,31)(H2,11,12,13)(H2,18,19,20)/t4-,6-,7-,10-,30-/m1/s1	ROYJKVPBJVNHCQ-AJBXOXQOSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.5484 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	13	7	Yes	3	-4	262.06 Å2	40.95 Å3	103.81 m3·mol-1	8	No	No	2.03 mg/mL	-4.5	-2.4	0.94	4.92	O32393	cyaC	1. Adenylate cyclase
C10H16N5O13P3	Not Available	Not Available	507.181	[H][C@]1(COP(O)(=O)OP(O)(O)=O)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(OP(O)(O)=O)[C@]1([H])O	Solid	Not Available								144850						ATR			165230	46506433					ZINC000013523101		2'-Monophosphoadenosine-5'-Diphosphate	Experimental	DB02363	InChI=1S/C10H16N5O13P3/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(27-29(17,18)19)6(16)4(26-10)1-25-31(23,24)28-30(20,21)22/h2-4,6-7,10,16H,1H2,(H,23,24)(H2,11,12,13)(H2,17,18,19)(H2,20,21,22)/t4-,6-,7-,10-/m1/s1	YPTPYQSAVGGMFN-KQYNXXCUSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.4771 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	14	7	Yes	3	-5	279.13 Å2	38.64 Å3	95.81 m3·mol-1	8	No	No	4.78 mg/mL	-5.4	-2	0.66	4.86	P43876;!P07998;!P0ABQ4	aroE;!RNASE1;!folA	1. Shikimate dehydrogenase;!2. Ribonuclease pancreatic;!3. Dihydrofolate reductase
C6H14O10P2	Not Available	Not Available	308.1169	[H][C@]1(O)[C@]([H])(O)[C@]([H])(CP(O)(O)=O)O[C@]1([H])COP(O)(O)=O	Solid	Not Available								392591						FDQ			444761	46506678					ZINC000005829950		D-Gluco-2,5-Anhydro-1-Deoxy-1-Phosphonohexitol-6-Phosphate	Experimental	DB02393	InChI=1S/C6H14O10P2/c7-5-3(1-15-18(12,13)14)16-4(6(5)8)2-17(9,10)11/h3-8H,1-2H2,(H2,9,10,11)(H2,12,13,14)/t3-,4+,5-,6-/m1/s1	YBOWGOLYQKBCFB-JGWLITMVSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.1347 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	9	6	No	1	-3	173.98 Å2	23.57 Å3	54.81 m3·mol-1	5	No	No	21.8 mg/mL	-3.5	-1.2	1.12	-3.6	P16118	PFKFB1	1. 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 1
C15H24N2O17P2	Not Available	Not Available	566.3018	[H]N1C(=O)C=CN([C@@H]2O[C@H](COP(O)(=O)OP(O)(=O)O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]3O)[C@@H](O)[C@H]2O)C1=O	Solid	Not Available					50209666		CHEMBL227711	395538						UFM			448873	46508932							Uridine-5'-diphosphate-mannose	Experimental	DB02421	InChI=1S/C15H24N2O17P2/c18-3-5-8(20)10(22)12(24)14(32-5)33-36(28,29)34-35(26,27)30-4-6-9(21)11(23)13(31-6)17-2-1-7(19)16-15(17)25/h1-2,5-6,8-14,18,20-24H,3-4H2,(H,26,27)(H,28,29)(H,16,19,25)/t5-,6-,8-,9-,10+,11-,12+,13-,14-/m1/s1	HSCJRCZFDFQWRP-NYYOCOOHSA-N			Not Available	Small Molecule																																			0	No	14	9	Yes	3	-2	291.54 Å2	46.18 Å3	106.46 m3·mol-1	9	No	No	15.0 mg/mL	-5	-1.6	1.73	-3.6	P09147	galE	1. UDP-glucose 4-epimerase
C31H46O19S2	Not Available	Not Available	786.816	CC(C)CC(=O)O[C@H]1[C@@H](O[C@@H]2C[C@]3(C)[C@H]4CC[C@@H]5C[C@@]4(CC[C@H]3C(C2)(C(O)=O)C(O)=O)[C@@H](O)C5=C)O[C@@H](COO)[C@H](OS(O)(=O)=O)[C@@H]1OS(O)(=O)=O	Solid	Not Available								26329724						CXT			46936378	46505904				Carboxyatractyloside	ZINC000096006053		Carboxyatractyloside	Experimental	DB02426	InChI=1S/C31H46O19S2/c1-14(2)9-21(32)48-24-23(50-52(42,43)44)22(49-51(39,40)41)18(13-45-38)47-26(24)46-17-11-29(4)19-6-5-16-10-30(19,25(33)15(16)3)8-7-20(29)31(12-17,27(34)35)28(36)37/h14,16-20,22-26,33,38H,3,5-13H2,1-2,4H3,(H,34,35)(H,36,37)(H,39,40,41)(H,42,43,44)/t16-,17-,18+,19-,20-,22+,23+,24-,25+,26+,29-,30-/m1/s1	CYBVQIBJEFQVPD-GWDNDVLHSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.7066 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										0	No	16	6	Yes	5	-4	296.25 Å2	75.05 Å3	168.79 m3·mol-1	14	No	No	2.17 mg/mL	-1.5	-2.6	-2.3	-0.69	P12235	SLC25A4	1. ADP/ATP translocase 1
C12H23O14P	Not Available	Not Available	422.2764	OC[C@H]1O[C@H](O[C@H]2O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O	Solid	Not Available						18283		109086			HMDB0001124	C00689					122336	46506650					ZINC000004228300		Trehalose-6-Phosphate	Experimental	DB02430	InChI=1S/C12H23O14P/c13-1-3-5(14)7(16)9(18)11(24-3)26-12-10(19)8(17)6(15)4(25-12)2-23-27(20,21)22/h3-19H,1-2H2,(H2,20,21,22)/t3-,4-,5-,6-,7+,8+,9-,10-,11-,12-/m1/s1	LABSPYBHMPDTEL-LIZSDCNHSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.1596 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	13	9	No	2	-2	236.06 Å2	35.55 Å3	79.21 m3·mol-1	6	No	No	40.6 mg/mL	-4.8	-1	1.22	-3.6	P36673	treR	1. HTH-type transcriptional regulator TreR
C9H16N3O14P3	Not Available	Not Available	483.1563	NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O	Solid	Not Available						17677	CHEMBL223533	5941			HMDB0000082	C00063		CTP			6176	46507556					ZINC000003861746		Cytidine-5'-Triphosphate	Experimental	DB02431	InChI=1S/C9H16N3O14P3/c10-5-1-2-12(9(15)11-5)8-7(14)6(13)4(24-8)3-23-28(19,20)26-29(21,22)25-27(16,17)18/h1-2,4,6-8,13-14H,3H2,(H,19,20)(H,21,22)(H2,10,11,15)(H2,16,17,18)/t4-,6-,7-,8-/m1/s1	PCDQPRRSZKQHHS-XVFCMESISA-N			Not Available	Small Molecule	http://smpdb.ca/view/SMP0000046?highlight[compounds][]=DB02431&highlight[proteins][]=DB02431;!http://smpdb.ca/view/SMP0000202?highlight[compounds][]=DB02431&highlight[proteins][]=DB02431;!http://smpdb.ca/view/SMP0000216?highlight[compounds][]=DB02431&highlight[proteins][]=DB02431;!http://smpdb.ca/view/SMP0000217?highlight[compounds][]=DB02431&highlight[proteins][]=DB02431;!http://smpdb.ca/view/SMP0000240?highlight[compounds][]=DB02431&highlight[proteins][]=DB02431;!http://smpdb.ca/view/SMP0000248?highlight[compounds][]=DB02431&highlight[proteins][]=DB02431;!http://smpdb.ca/view/SMP0000251?highlight[compounds][]=DB02431&highlight[proteins][]=DB02431;!http://smpdb.ca/view/SMP0000254?highlight[compounds][]=DB02431&highlight[proteins][]=DB02431;!http://smpdb.ca/view/SMP0000293?highlight[compounds][]=DB02431&highlight[proteins][]=DB02431;!http://smpdb.ca/view/SMP0000294?highlight[compounds][]=DB02431&highlight[proteins][]=DB02431;!http://smpdb.ca/view/SMP0000390?highlight[compounds][]=DB02431&highlight[proteins][]=DB02431;!http://smpdb.ca/view/SMP0000713?highlight[compounds][]=DB02431&highlight[proteins][]=DB02431;!http://smpdb.ca/view/SMP0000730?highlight[compounds][]=DB02431&highlight[proteins][]=DB02431;!http://smpdb.ca/view/SMP0000731?highlight[compounds][]=DB02431&highlight[proteins][]=DB02431;!http://smpdb.ca/view/SMP0014216?highlight[compounds][]=DB02431&highlight[proteins][]=DB02431;!http://smpdb.ca/view/SMP0014218?highlight[compounds][]=DB02431&highlight[proteins][]=DB02431;!http://smpdb.ca/view/SMP0014220?highlight[compounds][]=DB02431&highlight[proteins][]=DB02431;!http://smpdb.ca/view/SMP0014224?highlight[compounds][]=DB02431&highlight[proteins][]=DB02431;!http://smpdb.ca/view/SMP0014228?highlight[compounds][]=DB02431&highlight[proteins][]=DB02431;!http://smpdb.ca/view/SMP0014229?highlight[compounds][]=DB02431&highlight[proteins][]=DB02431;!http://smpdb.ca/view/SMP0014230?highlight[compounds][]=DB02431&highlight[proteins][]=DB02431;!http://smpdb.ca/view/SMP0014233?highlight[compounds][]=DB02431&highlight[proteins][]=DB02431;!http://smpdb.ca/view/SMP0014235?highlight[compounds][]=DB02431&highlight[proteins][]=DB02431;!http://smpdb.ca/view/SMP0014240?highlight[compounds][]=DB02431&highlight[proteins][]=DB02431;!http://smpdb.ca/view/SMP0014242?highlight[compounds][]=DB02431&highlight[proteins][]=DB02431;!http://smpdb.ca/view/SMP0014245?highlight[compounds][]=DB02431&highlight[proteins][]=DB02431;!http://smpdb.ca/view/SMP0014248?highlight[compounds][]=DB02431&highlight[proteins][]=DB02431;!http://smpdb.ca/view/SMP0014249?highlight[compounds][]=DB02431&highlight[proteins][]=DB02431;!http://smpdb.ca/view/SMP0014255?highlight[compounds][]=DB02431&highlight[proteins][]=DB02431;!http://smpdb.ca/view/SMP0014267?highlight[compounds][]=DB02431&highlight[proteins][]=DB02431	Pyrimidine Metabolism;!MNGIE (Mitochondrial Neurogastrointestinal Encephalopathy);!Sialuria or French Type Sialuria;!Sialuria or French Type Sialuria;!Salla Disease/Infantile Sialic Acid Storage Disease;!Clarithromycin Action Pathway;!Roxithromycin Action Pathway;!Gentamicin Action Pathway;!Oxytetracycline Action Pathway;!Tetracycline Action Pathway;!Tay-Sachs Disease;!Arbekacin Action Pathway;!Troleandomycin Action Pathway;!Josamycin Action Pathway;!Phosphatidylcholine Biosynthesis PC(14:0/14:0);!Phosphatidylcholine Biosynthesis PC(14:0/15:0);!Phosphatidylcholine Biosynthesis PC(14:0/16:1(9Z));!Phosphatidylcholine Biosynthesis PC(14:0/18:2(9Z,12Z));!Phosphatidylcholine Biosynthesis PC(14:0/20:0);!Phosphatidylcholine Biosynthesis PC(14:0/20:1(11Z));!Phosphatidylcholine Biosynthesis PC(14:0/20:2(11Z,14Z));!Phosphatidylcholine Biosynthesis PC(14:0/20:4(5Z,8Z,11Z,14Z));!Phosphatidylcholine Biosynthesis PC(14:0/20:5(5Z,8Z,11Z,14Z,17Z));!Phosphatidylcholine Biosynthesis PC(14:0/22:5(4Z,7Z,10Z,13Z,16Z));!Phosphatidylcholine Biosynthesis PC(14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z));!Phosphatidylcholine Biosynthesis PC(14:1(9Z)/14:0);!Phosphatidylcholine Biosynthesis PC(14:1(9Z)/16:0);!Phosphatidylcholine Biosynthesis PC(14:1(9Z)/16:1(9Z));!Phosphatidylcholine Biosynthesis PC(14:1(9Z)/18:3(9Z,12Z,15Z));!Phosphatidylcholine Biosynthesis PC(14:1(9Z)/22:2(13Z,16Z))		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.2404 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	13	7	No	2	-4	268.2 Å2	35.87 Å3	87.16 m3·mol-1	8	No	No	11.2 mg/mL	-3.9	-1.6	0.89	4.34	P42216;!Q9BZX2;!Q9X1B3;!P27623;!Q46893;!P0ABQ0;!Q7SIB1;!P26396	kpsU;!UCK2;!ispD;!tagD;!ispD;!coaBC;!cca;!rfbF	1. 3-deoxy-manno-octulosonate cytidylyltransferase;!2. Uridine-cytidine kinase 2;!3. 2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase;!4. Glycerol-3-phosphate cytidylyltransferase;!5. 2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase;!6. Coenzyme A biosynthesis bifunctional protein CoaBC;!7. CCA-adding enzyme;!8. Glucose-1-phosphate cytidylyltransferase
C23H27N7O14P2	Not Available	Not Available	687.4465	[H]N([H])C(=O)C1=C[N+](=CC=C1)[C@@H]1O[C@H](COP([O-])(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)N2C=NC3=C2N=CN2C=CN=C32)[C@@H](O)[C@H]1O	Solid	Not Available								148756						ENA			131675359	46505630							Etheno-NAD	Experimental	DB02483	InChI=1S/C23H27N7O14P2/c24-19(35)11-2-1-4-28(6-11)22-17(33)15(31)12(42-22)7-40-45(36,37)44-46(38,39)41-8-13-16(32)18(34)23(43-13)30-10-26-14-20-25-3-5-29(20)9-27-21(14)30/h1-6,9-10,12-13,15-18,22-23,31-34H,7-8H2,(H3-,24,35,36,37,38,39)/t12-,13-,15-,16-,17-,18-,22-,23-/m1/s1	JCDBQDNBEQHDHK-BSLNIGMPSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.4807 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	14	6	Yes	6	-1	299.48 Å2	59.74 Å3	147.27 m3·mol-1	11	No	No	2.17 mg/mL	-10	-2.5	1.86	4.68	Q10588;!P00338	BST1;!LDHA	1. ADP-ribosyl cyclase 2;!2. L-lactate dehydrogenase A chain
C12H21N3O13P2	Not Available	Not Available	477.255	[H]N([H])C1=NC(=O)N(C=C1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@@H](O)CO)[C@@H](O)[C@H]1O	Solid	Not Available								394400						C2G			447253	46505163					ZINC000008551188		Cytidine 5'-diphosphoglycerol	Experimental	DB02484	InChI=1S/C12H21N3O13P2/c13-8-1-2-15(12(20)14-8)11-10(19)9(18)7(27-11)5-26-30(23,24)28-29(21,22)25-4-6(17)3-16/h1-2,6-7,9-11,16-19H,3-5H2,(H,21,22)(H,23,24)(H2,13,14,20)/t6-,7+,9+,10+,11+/m0/s1	HHPOUCCVONEPRK-CNYIRLTGSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.2403 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	12	7	No	2	-2	251.13 Å2	39.59 Å3	93.03 m3·mol-1	10	No	No	12.2 mg/mL	-4.5	-1.6	1.82	4.34	P27623	tagD	1. Glycerol-3-phosphate cytidylyltransferase
C22H30N7O13P2	Not Available	Not Available	662.4602	[H]N([H])C(=O)C1=C[N+](=CC=C1)[C@@H]1C[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)N2C=NC3=C(N=CN=C23)N([H])[H])[C@@H](O)[C@H]1O	Solid	Not Available								143731						CNA			163884	46507626					ZINC000024666703		Carba-nicotinamide-adenine-dinucleotide	Experimental	DB02498	InChI=1S/C22H29N7O13P2/c23-19-14-21(26-8-25-19)29(9-27-14)22-18(33)17(32)13(41-22)7-40-44(37,38)42-43(35,36)39-6-11-4-12(16(31)15(11)30)28-3-1-2-10(5-28)20(24)34/h1-3,5,8-9,11-13,15-18,22,30-33H,4,6-7H2,(H5-,23,24,25,26,34,35,36,37,38)/p+1/t11-,12-,13-,15-,16+,17-,18-,22-/m1/s1	DGPLSUKWXXSBCU-VGXGLJSLSA-O			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.6463 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	14	8	Yes	5	-1	309.03 Å2	59.2 Å3	145.74 m3·mol-1	11	No	No	1.83 mg/mL	-10	-2.6	1.86	4.93	P09874	PARP1	1. Poly [ADP-ribose] polymerase 1
C23H34N3O10P	Not Available	Not Available	543.5039	CC(C)C[C@H](NP(O)(=O)O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(O)=O	Solid	Not Available					50251742	45353	CHEMBL479579	392848				C00563		RDF			445114	46506179			DNC001121	Phosphoramidon	ZINC000004475339		Phosphoramidon	Experimental	DB02557	InChI=1S/C23H34N3O10P/c1-11(2)8-16(26-37(33,34)36-23-20(29)19(28)18(27)12(3)35-23)21(30)25-17(22(31)32)9-13-10-24-15-7-5-4-6-14(13)15/h4-7,10-12,16-20,23-24,27-29H,8-9H2,1-3H3,(H,25,30)(H,31,32)(H2,26,33,34)/t12-,16-,17-,18-,19+,20+,23-/m0/s1	ZPHBZEQOLSRPAK-XLCYBJAPSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.7483 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	9	8	Yes	3	-2	210.67 Å2	53.03 Å3	128.94 m3·mol-1	11	No	No	0.839 mg/mL	0.16	-2.8	2.48	-3.6			
C11H18N5O12P3	Not Available	Not Available	505.2082	NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)CP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O	Solid	Not Available					50118221	35056	CHEMBL132722	82670				C13740		APC			91557	46507991					ZINC000008295117		alpha,beta-Methyleneadenosine 5'-triphosphate	Experimental	DB02596	InChI=1S/C11H18N5O12P3/c12-9-6-10(14-2-13-9)16(3-15-6)11-8(18)7(17)5(27-11)1-26-29(19,20)4-30(21,22)28-31(23,24)25/h2-3,5,7-8,11,17-18H,1,4H2,(H,19,20)(H,21,22)(H2,12,13,14)(H2,23,24,25)/t5-,7-,8-,11-/m1/s1	CAWZRIXWFRFUQB-IOSLPCCCSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.5669 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	14	7	Yes	3	-4	269.9 Å2	39.94 Å3	98.17 m3·mol-1	8	No	No	4.29 mg/mL	-6.2	-2.1	0.97	4.93	P26281;!P9WIL5;!P08164;!Q96T66;!O32393;!Q94M05;!O07732;!Q9XB61	folK;!panC;!nadE;!NMNAT3;!cyaC;!4;!lipJ;!carA	1. 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase;!2. Pantothenate synthetase;!3. NH(3)-dependent NAD(+) synthetase;!4. Nicotinamide mononucleotide adenylyltransferase 3;!5. Adenylate cyclase;!6. NTPase P4;!7. Probable lignin peroxidase LipJ;!8. Carbapenam-3-carboxylate synthase
C10H16N6O10P2	Not Available	Not Available	442.2158	[H]N([H])C1=NC(=O)C2=C(N1[H])N(C=N2)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)N([H])[H])[C@@H](O)[C@H]1O	Solid	Not Available								392146						GNH			444148	46506806							Aminophosphonic acid-guanylate ester	Experimental	DB02623	InChI=1S/C10H16N6O10P2/c11-10-14-7-4(8(19)15-10)13-2-16(7)9-6(18)5(17)3(25-9)1-24-28(22,23)26-27(12,20)21/h2-3,5-6,9,17-18H,1H2,(H,22,23)(H3,12,20,21)(H3,11,14,15,19)/t3-,5-,6-,9-/m1/s1	ZGPDMUBRWRJAQQ-UUOKFMHZSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.4856 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	12	7	Yes	3	-2	254.07 Å2	35.69 Å3	87.47 m3·mol-1	6	No	No	4.17 mg/mL	-3.7	-2	-0.27	2.81	P60953	CDC42	1. Cell division control protein 42 homolog
C10H13N5O12P2V	Not Available	Not Available	508.1255	NC1=NC=NC2=C1N=CN2[C@@H]1O[C@@H](CO[P@](O)(=O)OP(O)(O)=O)[C@H]2O[V](=O)(=O)O[C@H]12	Solid	Not Available								58829626						AV2			46936447	46506868							Adenosine-5'-diphosphate-2',3'-vanadate	Experimental	DB02661	InChI=1S/C10H13N5O10P2.2O.V/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(24-10)1-23-27(21,22)25-26(18,19)20;;;/h2-4,6-7,10H,1H2,(H,21,22)(H2,11,12,13)(H2,18,19,20);;;/q-2;;;+2/t4-,6+,7-,10+;;;/m0.../s1	WUULDHXBMSNFAO-YVAIFPRKSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.5098 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	12	4	Yes	4	-3	244.74 Å2	37.62 Å3	85.4 m3·mol-1	6	No	No	2.91 mg/mL	-4.4	-2.2	1.77	4.93	O43252	PAPSS1	1. Bifunctional 3'-phosphoadenosine 5'-phosphosulfate synthase 1
C11H19N5O14P3	Not Available	Not Available	538.2149	C[N+]1=CN([C@@H]2O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]2O)C2=C1C(=O)NC(N)=N2	Solid	Not Available						50226	CHEMBL1234303	392325						MGP			444378	46507684					ZINC000015601432		7-methyl-guanosine-5'-triphosphate	Experimental	DB02716	InChI=1S/C11H18N5O14P3/c1-15-3-16(8-5(15)9(19)14-11(12)13-8)10-7(18)6(17)4(28-10)2-27-32(23,24)30-33(25,26)29-31(20,21)22/h3-4,6-7,10,17-18H,2H2,1H3,(H6-,12,13,14,19,20,21,22,23,24,25,26)/p+1/t4-,6-,7-,10-/m1/s1	DKVRNHPCAOHRSI-KQYNXXCUSA-O			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.4976 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	13	8	Yes	3	-2	285.8 Å2	42.43 Å3	102.43 m3·mol-1	8	No	No	8.02 mg/mL	-8.1	-1.8	1	0.22			
C24H42O21	Not Available	Not Available	666.5777	[H][C@@]1(O)O[C@]([H])(CO)[C@@]([H])(O[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O[C@]3([H])O[C@]([H])(CO)[C@@]([H])(O[C@]4([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]4([H])O)[C@]([H])(O)[C@@]3([H])O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]1([H])O	Solid	Not Available								4450617				C02013					5288428	46508464					ZINC000085603797		Cellotetraose	Experimental	DB02717	InChI=1S/C24H42O21/c25-1-5-9(29)10(30)15(35)22(40-5)44-19-7(3-27)42-24(17(37)12(19)32)45-20-8(4-28)41-23(16(36)13(20)33)43-18-6(2-26)39-21(38)14(34)11(18)31/h5-38H,1-4H2/t5-,6-,7-,8-,9-,10+,11-,12-,13-,14-,15-,16-,17-,18-,19-,20-,21-,22+,23+,24+/m1/s1	LUEWUZLMQUOBSB-HGDSAIHNSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	1.6776 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	21	14	Yes	4	0	347.83 Å2	61.59 Å3	133.16 m3·mol-1	10	No	No	350.0 mg/mL	-8.2	-0.28	11.19	-3.7	Q59325	cbhA	1. Cellulose 1,4-beta-cellobiosidase
C24H31N7O15P2	Not Available	Not Available	719.4884	[H]N([H])C(=O)C1=C(CC(C)=O)C=C[N+](=C1)[C@@H]1O[C@H](COP([O-])(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)N2C=NC3=C(N=CN=C23)N([H])[H])[C@@H](O)[C@H]1O	Solid	Not Available								4450943						NAE			131704217	46507420							[(2R,3S,4R,5R)-5-(4-acetonyl-3-carbamoyl-pyridin-1-ium-1-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methyl [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methoxy-hydroxy-phosphoryl] phosphate	Experimental	DB02732	InChI=1S/C24H31N7O15P2/c1-10(32)4-11-2-3-30(5-12(11)21(26)37)23-18(35)16(33)13(44-23)6-42-47(38,39)46-48(40,41)43-7-14-17(34)19(36)24(45-14)31-9-29-15-20(25)27-8-28-22(15)31/h2-3,5,8-9,13-14,16-19,23-24,33-36H,4,6-7H2,1H3,(H5-,25,26,27,28,37,38,39,40,41)/t13-,14-,16-,17-,18-,19-,23-,24-/m1/s1	SGHBFOOIAAJJMI-YDKVLQLQSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.5961 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	16	7	Yes	5	-1	338.16 Å2	64.38 Å3	155.73 m3·mol-1	13	No	No	1.7 mg/mL	-10	-2.7	1.85	4.93			
C10H18N5O19P5	Not Available	Not Available	667.1408	NC1=C2N=CN([C@@H]3O[C@H](CO[P@@](O)(=O)O[P@](O)(=O)O[P@@](O)(=O)O[P@@](O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]3O)C2=NC=N1	Solid	Not Available						40096		167906			HMDB0059647			5FA			193491	46506020					ZINC000058632138		Adenosine-5'-Pentaphosphate	Experimental	DB02738	InChI=1S/C10H18N5O19P5/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(30-10)1-29-36(21,22)32-38(25,26)34-39(27,28)33-37(23,24)31-35(18,19)20/h2-4,6-7,10,16-17H,1H2,(H,21,22)(H,23,24)(H,25,26)(H,27,28)(H2,11,12,13)(H2,18,19,20)/t4-,6-,7-,10-/m1/s1	WYJWVZZCMBUPSP-KQYNXXCUSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.5022 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	18	9	Yes	3	-6	372.19 Å2	47.67 Å3	117.56 m3·mol-1	12	No	No	5.58 mg/mL	-6.1	-2.1	0.22	4.93	Q75UV1	ndx1	1. Diadenosine hexaphosphate hydrolase
C18H33O19P	Not Available	Not Available	584.417	[H][C@]1(O)O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O[C@@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O[C@@]3([H])O[C@]([H])(COP(O)(O)=O)[C@@]([H])(O)[C@]([H])(O)[C@]3([H])O)[C@]2([H])O)[C@]1([H])O	Solid	Not Available								392572						P3M			444727	46504702					ZINC000024439790		1-3 Sugar Ring of Pentamannosyl 6-Phosphate	Experimental	DB02755	InChI=1S/C18H33O19P/c19-1-4-8(22)14(12(26)16(28)33-4)36-18-13(27)15(9(23)5(2-20)34-18)37-17-11(25)10(24)7(21)6(35-17)3-32-38(29,30)31/h4-28H,1-3H2,(H2,29,30,31)/t4-,5-,6-,7-,8-,9-,10+,11+,12+,13+,14+,15+,16+,17-,18-/m1/s1	HDQMHAJOIVYOIP-NAVBLJQLSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.1596 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	18	12	Yes	3	-2	315.21 Å2	50.38 Å3	111.62 m3·mol-1	9	No	No	50.8 mg/mL	-6.6	-1.1	1.22	-3.7	P20645	M6PR	1. Cation-dependent mannose-6-phosphate receptor
C6H14O11P2	Not Available	Not Available	324.1163	[H][C@]1(O)[C@]([H])(O)[C@]([H])(COP(O)(O)=O)O[C@]1([H])COP(O)(O)=O	Solid	Not Available								393163						AHG			445555	46509175					ZINC000003870733		2,5-Anhydroglucitol-1,6-Biphosphate	Experimental	DB02778	InChI=1S/C6H14O11P2/c7-5-3(1-15-18(9,10)11)17-4(6(5)8)2-16-19(12,13)14/h3-8H,1-2H2,(H2,9,10,11)(H2,12,13,14)/t3-,4+,5-,6-/m1/s1	WSMBXSQDFPTODV-JGWLITMVSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.2068 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	9	6	No	1	-4	183.21 Å2	24.9 Å3	56.64 m3·mol-1	6	No	No	15.9 mg/mL	-2.8	-1.3	0.93	-3.6	P09467	FBP1	1. Fructose-1,6-bisphosphatase 1
C6H14O12P2	Not Available	Not Available	340.1157	O[C@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H](OP(O)(O)=O)[C@@H]1O	Solid	Not Available						18148		74362			HMDB0003514	C01231		G16			82400	46504846					ZINC000004095589		Alpha-D-Glucose 1,6-Bisphosphate	Experimental	DB02835	InChI=1S/C6H14O12P2/c7-3-2(1-16-19(10,11)12)17-6(5(9)4(3)8)18-20(13,14)15/h2-9H,1H2,(H2,10,11,12)(H2,13,14,15)/t2-,3-,4+,5-,6-/m1/s1	RWHOZGRAXYWRNX-VFUOTHLCSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.2512 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	10	7	No	1	-4	203.44 Å2	24.96 Å3	57.67 m3·mol-1	5	No	No	16.0 mg/mL	-3.2	-1.3	0.89	-3.6	P71447;!P36871	pgmB;!PGM1	1. Beta-phosphoglucomutase;!2. Phosphoglucomutase-1
C10H14N5O13P3	Not Available	Not Available	505.1651	[H]N([H])C1=NC(=O)C2=C(N1[H])N(C=N2)[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@]2([H])O[P@](O)(=O)O[C@@]12[H]	Solid	Not Available								392639						GPX			444825	46508518					ZINC000016051591		Guanosine 5'-diphosphate 2':3'-cyclic monophosphate	Experimental	DB02836	InChI=1S/C10H14N5O13P3/c11-10-13-7-4(8(16)14-10)12-2-15(7)9-6-5(26-31(22,23)27-6)3(25-9)1-24-30(20,21)28-29(17,18)19/h2-3,5-6,9H,1H2,(H,20,21)(H,22,23)(H2,17,18,19)(H3,11,13,14,16)/t3-,5-,6-,9-/m1/s1	NGYWTCOGOZELRS-UUOKFMHZSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.4828 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	13	6	Yes	4	-3	263.58 Å2	38.21 Å3	93.03 m3·mol-1	6	No	No	6.92 mg/mL	-2.7	-1.9	-0.2	2	P0A7D4;!Q54089	purA;!relA	1. Adenylosuccinate synthetase;!2. Bifunctional (p)ppGpp synthase/hydrolase RelA
C10H16N5O12P3S	Not Available	Not Available	523.247	NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=S)[C@@H](O)[C@H]1O	Solid	Not Available					50118217	27575	CHEMBL131890	389291				C13742		AGS			440317	46507118					ZINC000008295128		Adenosine 5'-[gamma-thio]triphosphate	Experimental	DB02930	InChI=1S/C10H16N5O12P3S/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(25-10)1-24-28(18,19)26-29(20,21)27-30(22,23)31/h2-4,6-7,10,16-17H,1H2,(H,18,19)(H,20,21)(H2,11,12,13)(H2,22,23,31)/t4-,6-,7-,10-/m1/s1	NLTUCYMLOPLUHL-KQYNXXCUSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.5484 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	13	7	Yes	3	-4	262.06 Å2	40.87 Å3	103.81 m3·mol-1	8	No	No	2.26 mg/mL	-4.6	-2.4	0.82	4.9	Q10588;!P17600;!O14874;!P16118;!P54278;!P62219;!P42443;!Q59560;!Q56148;!P33221;!P15043;!P06710;!P9WI81;!Q7BK04	BST1;!SYN1;!BCKDK;!PFKFB1;!PMS2;!recA;!recA;!recA;!Not Available;!purT;!recQ;!dnaX;!pknB;!cag-alfa	1. ADP-ribosyl cyclase 2;!2. Synapsin-1;!3. [3-methyl-2-oxobutanoate dehydrogenase [lipoamide]] kinase, mitochondrial;!4. 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 1;!5. Mismatch repair endonuclease PMS2;!6. Protein RecA;!7. Protein RecA;!8. Protein RecA;!9. Chloramphenicol 3-O phosphotransferase;!10. Phosphoribosylglycinamide formyltransferase 2;!11. ATP-dependent DNA helicase RecQ;!12. DNA polymerase III subunit tau;!13. Serine/threonine-protein kinase PknB;!14. Cag alpha
C11H18AsN5O12P2	Not Available	Not Available	549.156	[H][C@]1(COP(O)(=O)OP(O)(=O)C[As](O)(O)=O)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O	Solid	Not Available								26326201						ATS			42626649	46505250							Gamma-Arsono-Beta, Gamma-Methyleneadenosine-5'-Diphosphate	Experimental	DB02937	InChI=1S/C11H18AsN5O12P2/c13-9-6-10(15-3-14-9)17(4-16-6)11-8(19)7(18)5(28-11)1-27-31(25,26)29-30(23,24)2-12(20,21)22/h3-5,7-8,11,18-19H,1-2H2,(H,23,24)(H,25,26)(H2,13,14,15)(H2,20,21,22)/t5-,7-,8-,11-/m1/s1	KHQOAQLQNLUEQN-IOSLPCCCSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.6011 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	14	7	Yes	3	-3	269.9 Å2	41.31 Å3	92.89 m3·mol-1	8	No	No	3.62 mg/mL	-5.8	-2.2	1.85	4.99	P18843;!P0A6F3	nadE;!glpK	1. NH(3)-dependent NAD(+) synthetase;!2. Glycerol kinase
C6H14O12P2	Not Available	Not Available	340.1157	O[C@H]1[C@H](O)[C@@H](OP(O)(O)=O)[C@@H](O)[C@@H](OP(O)(O)=O)[C@@H]1O	Solid	Not Available						18225		16744067			HMDB0006234	C04062		ITP			128419	46506084					ZINC000100016181		Inositol 1,3-Bisphosphate	Experimental	DB02942	InChI=1S/C6H14O12P2/c7-1-2(8)5(17-19(11,12)13)4(10)6(3(1)9)18-20(14,15)16/h1-10H,(H2,11,12,13)(H2,14,15,16)/t1-,2-,3+,4+,5+,6-	PUVHMWJJTITUGO-FICORBCRSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.1296 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	10	8	No	1	-4	214.44 Å2	25.07 Å3	57.52 m3·mol-1	4	No	No	23.9 mg/mL	-4	-1.2	0.86	-3.6	Q15075	EEA1	1. Early endosome antigen 1
C15H23FN2O16P2	Not Available	Not Available	568.2928	[H]N1C(=O)C=CN([C@@H]2O[C@H](COP(O)(=O)OP(O)(=O)O[C@H]3O[C@H](CO)[C@H](O)[C@H](O)[C@@]3([H])F)[C@@H](O)[C@H]2O)C1=O	Solid	Not Available								393327						UPF			445795	46509153					ZINC000015553713		Uridine-5'-diphosphate-2-deoxy-2-fluorogalactose	Experimental	DB02976	InChI=1S/C15H23FN2O16P2/c16-8-11(23)9(21)5(3-19)32-14(8)33-36(28,29)34-35(26,27)30-4-6-10(22)12(24)13(31-6)18-2-1-7(20)17-15(18)25/h1-2,5-6,8-14,19,21-24H,3-4H2,(H,26,27)(H,28,29)(H,17,20,25)/t5-,6-,8-,9+,10-,11-,12-,13-,14-/m1/s1	NGTCPFGWXMBZEP-KBQKSTHMSA-N			Not Available	Small Molecule																																			0	No	13	8	Yes	3	-2	271.31 Å2	45.38 Å3	104.76 m3·mol-1	9	No	No	21.7 mg/mL	-4.1	-1.4	1.73	-3	P96945;!Q93EK7	lgtC;!lgtC	1. Glycosyl transferase;!2. LgtC
C21H27N7O14P2	Not Available	Not Available	663.4251	NC(=O)C1=C[NH+]=CC(=C1)[C@@H]1O[C@H](COP([O-])(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)N2C=NC3=C2N=CN=C3N)[C@@H](O)[C@H]1O	Solid	Not Available							CHEMBL1231859	392204						CND			444215	46506222					ZINC000049771855		5-beta-D-ribofuranosylnicotinamide adenine dinucleotide	Experimental	DB03020	InChI=1S/C21H27N7O14P2/c22-18-12-20(26-6-25-18)28(7-27-12)21-16(32)14(30)11(41-21)5-39-44(36,37)42-43(34,35)38-4-10-13(29)15(31)17(40-10)8-1-9(19(23)33)3-24-2-8/h1-3,6-7,10-11,13-17,21,29-32H,4-5H2,(H2,23,33)(H,34,35)(H,36,37)(H2,22,25,26)/t10-,11-,13-,14-,15-,16-,17+,21-/m1/s1	UINNILASBHZOTM-KMXXXSRASA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.9104 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	15	8	Yes	5	-2	331.35 Å2	55.73 Å3	141.43 m3·mol-1	11	No	No	2.16 mg/mL	-7.6	-2.5	0.87	4.94	P00326	ADH1C	1. Alcohol dehydrogenase 1C
C15H22N2O18P2	Not Available	Not Available	580.2853	O[C@@H]1[C@@H](COP(O)(=O)OP(O)(=O)O[C@H]2O[C@@H]([C@@H](O)[C@H](O)[C@H]2O)C(O)=O)O[C@H]([C@@H]1O)N1C=CC(=O)NC1=O	Solid	Not Available					50209665	17200	CHEMBL228057	16522			HMDB0000935	C00167		UGA			17473	46504863				Uridine_diphosphate_glucuronic_acid	ZINC000008215691		UDP-alpha-D-glucuronic acid	Experimental	DB03041	InChI=1S/C15H22N2O18P2/c18-5-1-2-17(15(26)16-5)12-9(22)6(19)4(32-12)3-31-36(27,28)35-37(29,30)34-14-10(23)7(20)8(21)11(33-14)13(24)25/h1-2,4,6-12,14,19-23H,3H2,(H,24,25)(H,27,28)(H,29,30)(H,16,18,26)/t4-,6-,7+,8+,9-,10-,11+,12-,14-/m1/s1	HDYANYHVCAPMJV-LXQIFKJMSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.3361 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	15	9	Yes	3	-3	308.61 Å2	45.33 Å3	106.32 m3·mol-1	9	No	No	18.1 mg/mL	-4.7	-1.5	1.72	-3.7	Q14376;!O94766;!P0C0F4	GALE;!B3GAT3;!hasB	1. UDP-glucose 4-epimerase;!2. Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 3;!3. UDP-glucose 6-dehydrogenase
C14H23N3O15P2	Not Available	Not Available	535.291	NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)O[C@H]2OC[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H]1O	Solid	Not Available								395758						CXY			449144	46506620					ZINC000016051634		Cytidine-5'-diphospho-beta-D-xylose	Experimental	DB03069	InChI=1S/C14H23N3O15P2/c15-7-1-2-17(14(23)16-7)12-10(21)9(20)6(30-12)4-29-33(24,25)32-34(26,27)31-13-11(22)8(19)5(18)3-28-13/h1-2,5-6,8-13,18-22H,3-4H2,(H,24,25)(H,26,27)(H2,15,16,23)/t5-,6-,8+,9-,10-,11-,12-,13-/m1/s1	NWSKPSPTJOAICE-OCIMBMBZSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.4358 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	14	8	Yes	3	-2	280.59 Å2	43.92 Å3	102.47 m3·mol-1	8	No	No	22.3 mg/mL	-4.9	-1.4	1.7	4.33	P26397	rfbG	1. CDP-glucose 4,6-dehydratase
C19H25N7O14P2Se	Not Available	Not Available	716.35	[H]N([H])C(=O)C1=C[Se]C(=N1)[C@]1([H])O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)N2C=NC3=C(N=CN=C23)N([H])[H])[C@@H](O)[C@H]1O	Solid	Not Available							CHEMBL451855	392381						SAE			444451	46508188							Selenazole-4-carboxyamide-adenine dinucleotide	Experimental	DB03070	InChI=1S/C19H25N7O14P2Se/c20-15-9-17(23-4-22-15)26(5-24-9)19-13(30)11(28)8(39-19)2-37-42(34,35)40-41(32,33)36-1-7-10(27)12(29)14(38-7)18-25-6(3-43-18)16(21)31/h3-5,7-8,10-14,19,27-30H,1-2H2,(H2,21,31)(H,32,33)(H,34,35)(H2,20,22,23)/t7-,8-,10-,11-,12-,13-,14-,19-/m1/s1	SKNBJMQZTZPCPF-QZTLEVGFSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.6879 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	17	8	Yes	5	-2	327.27 Å2	57.84 Å3	145.05 m3·mol-1	11	No	No	7.05 mg/mL	-6.7	-2	1.85	4.93	P12268	IMPDH2	1. Inosine-5'-monophosphate dehydrogenase 2
C10H16O14P2	Not Available	Not Available	422.1732	[H][C@]1(CC(=C[C@@]([H])(OP(O)(O)=O)[C@@]1([H])O)C(O)=O)O[C@@](C)(OP(O)(O)=O)C(O)=O	Solid	Not Available								4451362						SKP			5289376	46505941					ZINC000016052263		5-(1-Carboxy-1-Phosphonooxy-Ethoxyl)-Shikimate-3-Phosphate	Experimental	DB03116	InChI=1S/C10H16O14P2/c1-10(9(14)15,24-26(19,20)21)22-5-2-4(8(12)13)3-6(7(5)11)23-25(16,17)18/h3,5-7,11H,2H2,1H3,(H,12,13)(H,14,15)(H2,16,17,18)(H2,19,20,21)/t5-,6-,7+,10+/m1/s1	QUQKBSPZUVNKIF-JQCUSGDOSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.4515 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	12	7	No	1	-6	237.58 Å2	32.55 Å3	77.74 m3·mol-1	8	No	No	7.87 mg/mL	-1.6	-1.7	0.72	-3.6	P0A6D3	aroA	1. 3-phosphoshikimate 1-carboxyvinyltransferase
C6H14O12P2	Not Available	Not Available	340.1157	O[C@H]1[C@@H](O)[C@@H](OP(O)(O)=O)[C@H](O)[C@@H](O)[C@@H]1OP(O)(O)=O	Solid	Not Available						17816		17216032			HMDB0000968	C01220		2IP			439444	46505669					ZINC000100016166		D-Myo-Inositol-1,4-Bisphosphate	Experimental	DB03158	InChI=1S/C6H14O12P2/c7-1-2(8)6(18-20(14,15)16)4(10)3(9)5(1)17-19(11,12)13/h1-10H,(H2,11,12,13)(H2,14,15,16)/t1-,2-,3-,4+,5+,6+/m1/s1	PELZSPZCXGTUMR-RTPHHQFDSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.1296 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	10	8	No	1	-4	214.44 Å2	25.1 Å3	57.52 m3·mol-1	4	No	No	24.4 mg/mL	-4	-1.1	0.86	-3.7	P32019	INPP5B	1. Type II inositol 1,4,5-trisphosphate 5-phosphatase
C15H24N2O15P2	Not Available	Not Available	534.303	[H]N1C(=O)N(C=C(C)C1=O)[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)O[C@H]2OC[C@@H](O)[C@H](O)[C@H]2O)O1	Solid	Not Available								394560						TDX			447462	46505396					ZINC000015634247		Thymidine-5'-diphospho-beta-D-xylose	Experimental	DB03161	InChI=1S/C15H24N2O15P2/c1-6-3-17(15(23)16-13(6)22)10-2-7(18)9(30-10)5-29-33(24,25)32-34(26,27)31-14-12(21)11(20)8(19)4-28-14/h3,7-12,14,18-21H,2,4-5H2,1H3,(H,24,25)(H,26,27)(H,16,22,23)/t7-,8+,9+,10+,11-,12+,14+/m0/s1	AJUADKZRQSBUAK-KDGZBOQCSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.4709 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										0	No	12	7	Yes	3	-2	251.08 Å2	44.46 Å3	103.34 m3·mol-1	8	No	No	11.3 mg/mL	-3.1	-1.7	1.73	-3.2	P95780;!Q8GIQ0	rmlB;!rmlC	1. dTDP-glucose 4,6-dehydratase;!2. DTDP-4-dehydrorhamnose 3,5-epimerase
C12H19N2O8P	Not Available	Not Available	350.2616	[H][C@]1(COP(O)(O)=O)O[C@@]([H])(N2C=C(C)C(=O)NC2=O)[C@]([H])(OC)[C@]1([H])C	Solid	Not Available								16744216						T23			17754189	46504535					ZINC000058650359		2'-O-Methyl-3'-Methyl-3'-Deoxy-Arabinofuranosyl-Thymine-5'-Phosphate	Experimental	DB03249	InChI=1S/C12H19N2O8P/c1-6-4-14(12(16)13-10(6)15)11-9(20-3)7(2)8(22-11)5-21-23(17,18)19/h4,7-9,11H,5H2,1-3H3,(H,13,15,16)(H2,17,18,19)/t7-,8-,9-,11-/m1/s1	MCXXETKRWYMFCI-TURQNECASA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.4048 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	7	3	No	2	-2	134.63 Å2	31.57 Å3	75.87 m3·mol-1	5	Yes	No	4.89 mg/mL	-0.33	-1.9	1.3	-3.9			
C18H32O16	Not Available	Not Available	504.4371	[H][C@]1(O)O[C@]([H])(CO)[C@@]([H])(O[C@@]2([H])O[C@]([H])(CO)[C@@]([H])(O[C@@]3([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]3([H])O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]1([H])O	Solid	Not Available						27931	CHEMBL1234363	167339				C01835					192826	46507051					ZINC000006920404		alpha-maltotriose	Experimental	DB03277	InChI=1S/C18H32O16/c19-1-4-7(22)8(23)12(27)17(31-4)34-15-6(3-21)32-18(13(28)10(15)25)33-14-5(2-20)30-16(29)11(26)9(14)24/h4-29H,1-3H2/t4-,5-,6-,7-,8+,9-,10-,11-,12-,13-,14-,15-,16+,17-,18-/m1/s1	FYGDTMLNYKFZSV-PXXRMHSHSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.0242 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	16	11	Yes	3	0	268.68 Å2	46.57 Å3	100.75 m3·mol-1	7	No	No	554.0 mg/mL	-6.5	0.04	11.22	-3.6	P19961;!Q9RHZ6	AMY2B;!malE	1. Alpha-amylase 2B;!2. Maltose binding protein
C6H17O21P5	Not Available	Not Available	580.0554	[H][C@]1(O)[C@]([H])(OP(O)(O)=O)[C@@]([H])(OP(O)(O)=O)[C@@]([H])(OP(O)(O)=O)[C@]([H])(OP(O)(O)=O)[C@@]1([H])OP(O)(O)=O	Solid	Not Available								16744046						I5P			17754035	46505565					ZINC000253803467		Inositol-(1,3,4,5,6)-Pentakisphosphate	Experimental	DB03344	InChI=1S/C6H17O21P5/c7-1-2(23-28(8,9)10)4(25-30(14,15)16)6(27-32(20,21)22)5(26-31(17,18)19)3(1)24-29(11,12)13/h1-7H,(H2,8,9,10)(H2,11,12,13)(H2,14,15,16)(H2,17,18,19)(H2,20,21,22)/t1-,2-,3-,4+,5+,6+/m0/s1	CTPQAXVNYGZUAJ-ADOSBGCESA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.2264 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	16	11	No	1	-10	354.03 Å2	38.16 Å3	90.14 m3·mol-1	10	No	No	13.4 mg/mL	-4.4	-1.6	0.19		O43739	CYTH3	1. Cytohesin-3
C22H28N6O14P2	Not Available	Not Available	662.437	[H][C@]1(COP([O-])(=O)OP(O)(=O)OC[C@@]2([H])O[C@@]([H])([N+]3=CC=CC(=C3)C(C)=O)[C@]([H])(O)[C@]2([H])O)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O	Solid	Not Available								110455						A3D			131704240	46506585							3-Acetylpyridine Adenine Dinucleotide	Experimental	DB03363	InChI=1S/C22H28N6O14P2/c1-10(29)11-3-2-4-27(5-11)21-17(32)15(30)12(40-21)6-38-43(34,35)42-44(36,37)39-7-13-16(31)18(33)22(41-13)28-9-26-14-19(23)24-8-25-20(14)28/h2-5,8-9,12-13,15-18,21-22,30-33H,6-7H2,1H3,(H3-,23,24,25,34,35,36,37)/t12-,13-,15-,16-,17-,18-,21-,22-/m1/s1	KPVQNXLUPNWQHM-RBEMOOQDSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.6894 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	15	6	Yes	5	-1	295.07 Å2	58.98 Å3	142.2 m3·mol-1	11	No	No	2.12 mg/mL	-9.3	-2.5	1.85	4.93	P04036	dapB	1. 4-hydroxy-tetrahydrodipicolinate reductase
C17H27N3O17P2	Not Available	Not Available	607.3537	CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=CC(=O)NC1=O	Solid	Not Available						16264	CHEMBL388154	393240			HMDB0000290	C00043		UD1			445675	46506870					ZINC000008551100		Uridine-Diphosphate-N-Acetylglucosamine	Experimental	DB03397	InChI=1S/C17H27N3O17P2/c1-6(22)18-10-13(26)11(24)7(4-21)35-16(10)36-39(31,32)37-38(29,30)33-5-8-12(25)14(27)15(34-8)20-3-2-9(23)19-17(20)28/h2-3,7-8,10-16,21,24-27H,4-5H2,1H3,(H,18,22)(H,29,30)(H,31,32)(H,19,23,28)/t7-,8-,10-,11-,12-,13-,14-,15-,16-/m1/s1	LFTYTUAZOPRMMI-CFRASDGPSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.3962 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	14	9	Yes	3	-2	300.41 Å2	50.39 Å3	117.56 m3·mol-1	10	No	No	11.4 mg/mL	-5.3	-1.7	1.74	-3.5	Q16222;!P0A751;!Q14376;!P09147;!Q9UBQ6;!P26572;!P0ACC7;!Q97R46	UAP1;!murA;!GALE;!galE;!EXTL2;!MGAT1;!glmU;!glmU	1. UDP-N-acetylhexosamine pyrophosphorylase;!2. UDP-N-acetylglucosamine 1-carboxyvinyltransferase;!3. UDP-glucose 4-epimerase;!4. UDP-glucose 4-epimerase;!5. Exostosin-like 2;!6. Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase;!7. Bifunctional protein GlmU;!8. Bifunctional protein GlmU
C6H15O15P3	Not Available	Not Available	420.0956	O[C@@H]1[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H](O)[C@@H]1OP(O)(O)=O	Solid	Not Available					50075183	16595	CHEMBL279107	388562			HMDB0001498	C01245		I3P			439456	46506346					ZINC000004095598		1D-myo-inositol 1,4,5-trisphosphate	Experimental	DB03401	InChI=1S/C6H15O15P3/c7-1-2(8)5(20-23(13,14)15)6(21-24(16,17)18)3(9)4(1)19-22(10,11)12/h1-9H,(H2,10,11,12)(H2,13,14,15)(H2,16,17,18)/t1-,2+,3+,4-,5-,6-/m1/s1	MMWCIQZXVOZEGG-XJTPDSDZSA-N			Not Available	Small Molecule																																			0	No	12	9	No	1	-6	260.97 Å2	29.61 Å3	68.39 m3·mol-1	6	No	No	14.8 mg/mL	-4.2	-1.4	0.54	-3.7	Q99418;!Q9Y6I3;!P51178;!P35241;!Q01082;!Q14643;!P23677	CYTH2;!EPN1;!PLCD1;!RDX;!SPTBN1;!ITPR1;!ITPKA	1. Cytohesin-2;!2. Epsin-1;!3. 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase delta-1;!4. Radixin;!5. Spectrin beta chain, non-erythrocytic 1;!6. Inositol 1,4,5-trisphosphate receptor type 1;!7. Inositol-trisphosphate 3-kinase A
C9H14N2O12P2	Not Available	Not Available	404.1612	O[C@H]1[C@@H](O)[C@@H](O[C@@H]1COP(O)(=O)OP(O)(O)=O)N1C=CC(=O)NC1=O	Solid	Not Available					50403871	17659	CHEMBL130266	5809			HMDB0000295	C00015		UDP			6031	46505736					ZINC000004490939		Uridine-5'-Diphosphate	Experimental	DB03435	InChI=1S/C9H14N2O12P2/c12-5-1-2-11(9(15)10-5)8-7(14)6(13)4(22-8)3-21-25(19,20)23-24(16,17)18/h1-2,4,6-8,13-14H,3H2,(H,19,20)(H,10,12,15)(H2,16,17,18)/t4-,6-,7-,8-/m1/s1	XCCTYIAWTASOJW-XVFCMESISA-N			Not Available	Small Molecule	http://smpdb.ca/view/SMP0000034?highlight[compounds][]=DB03435&highlight[proteins][]=DB03435;!http://smpdb.ca/view/SMP0000045?highlight[compounds][]=DB03435&highlight[proteins][]=DB03435;!http://smpdb.ca/view/SMP0000068?highlight[compounds][]=DB03435&highlight[proteins][]=DB03435;!http://smpdb.ca/view/SMP0000342?highlight[compounds][]=DB03435&highlight[proteins][]=DB03435;!http://smpdb.ca/view/SMP0000345?highlight[compounds][]=DB03435&highlight[proteins][]=DB03435;!http://smpdb.ca/view/SMP0000349?highlight[compounds][]=DB03435&highlight[proteins][]=DB03435;!http://smpdb.ca/view/SMP0000405?highlight[compounds][]=DB03435&highlight[proteins][]=DB03435;!http://smpdb.ca/view/SMP0000442?highlight[compounds][]=DB03435&highlight[proteins][]=DB03435;!http://smpdb.ca/view/SMP0000471?highlight[compounds][]=DB03435&highlight[proteins][]=DB03435;!http://smpdb.ca/view/SMP0000525?highlight[compounds][]=DB03435&highlight[proteins][]=DB03435;!http://smpdb.ca/view/SMP0000526?highlight[compounds][]=DB03435&highlight[proteins][]=DB03435;!http://smpdb.ca/view/SMP0000534?highlight[compounds][]=DB03435&highlight[proteins][]=DB03435;!http://smpdb.ca/view/SMP0000554?highlight[compounds][]=DB03435&highlight[proteins][]=DB03435;!http://smpdb.ca/view/SMP0000555?highlight[compounds][]=DB03435&highlight[proteins][]=DB03435;!http://smpdb.ca/view/SMP0000565?highlight[compounds][]=DB03435&highlight[proteins][]=DB03435;!http://smpdb.ca/view/SMP0000579?highlight[compounds][]=DB03435&highlight[proteins][]=DB03435;!http://smpdb.ca/view/SMP0000635?highlight[compounds][]=DB03435&highlight[proteins][]=DB03435;!http://smpdb.ca/view/SMP0000640?highlight[compounds][]=DB03435&highlight[proteins][]=DB03435;!http://smpdb.ca/view/SMP0000648?highlight[compounds][]=DB03435&highlight[proteins][]=DB03435;!http://smpdb.ca/view/SMP0000649?highlight[compounds][]=DB03435&highlight[proteins][]=DB03435;!http://smpdb.ca/view/SMP0000024?highlight[compounds][]=DB03435&highlight[proteins][]=DB03435;!http://smpdb.ca/view/SMP0000043?highlight[compounds][]=DB03435&highlight[proteins][]=DB03435;!http://smpdb.ca/view/SMP0000046?highlight[compounds][]=DB03435&highlight[proteins][]=DB03435;!http://smpdb.ca/view/SMP0000058?highlight[compounds][]=DB03435&highlight[proteins][]=DB03435;!http://smpdb.ca/view/SMP0000086?highlight[compounds][]=DB03435&highlight[proteins][]=DB03435;!http://smpdb.ca/view/SMP0000096?highlight[compounds][]=DB03435&highlight[proteins][]=DB03435;!http://smpdb.ca/view/SMP0000202?highlight[compounds][]=DB03435&highlight[proteins][]=DB03435;!http://smpdb.ca/view/SMP0000216?highlight[compounds][]=DB03435&highlight[proteins][]=DB03435;!http://smpdb.ca/view/SMP0000217?highlight[compounds][]=DB03435&highlight[proteins][]=DB03435;!http://smpdb.ca/view/SMP0000240?highlight[compounds][]=DB03435&highlight[proteins][]=DB03435	Sphingolipid Metabolism;!Amino Sugar Metabolism;!Androgen and Estrogen Metabolism;!Hereditary Coproporphyria (HCP);!Congenital Erythropoietic Porphyria (CEP) or Gunther Disease;!Gaucher Disease;!Codeine Action Pathway;!Etoposide Action Pathway;!Tamoxifen Action Pathway;!Fabry Disease;!Krabbe Disease;!G(M2)-Gangliosidosis: Variant B, Tay-Sachs Disease;!Glycogenosis, Type IV. Amylopectinosis, Anderson Disease;!Glycogenosis, Type VI. Hers Disease;!Aromatase Deficiency;!Congenital Disorder of Glycosylation CDG-IId;!Valproic Acid Metabolism Pathway;!Acetaminophen Metabolism Pathway;!Sorafenib Metabolism Pathway;!Lamivudine Metabolism Pathway;!Porphyrin Metabolism;!Galactose Metabolism;!Pyrimidine Metabolism;!Starch and Sucrose Metabolism;!Ibuprofen Action Pathway;!Celecoxib Action Pathway;!MNGIE (Mitochondrial Neurogastrointestinal Encephalopathy);!Sialuria or French Type Sialuria;!Sialuria or French Type Sialuria;!Salla Disease/Infantile Sialic Acid Storage Disease		Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.1803 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	10	6	No	2	-3	212.39 Å2	30.43 Å3	74.31 m3·mol-1	6	No	No	8.89 mg/mL	-3	-1.7	1.77	-3.7	P27828;!P16442;!P09148;!P16088;!Q9P2W7;!P31677;!Q9UBQ6;!Q7Z4J2;!P39621;!P30085;!P04547;!P09147;!O94766;!Q8T8E9;!P46976	wecB;!ABO;!galT;!pol;!B3GAT1;!otsA;!EXTL2;!GLT6D1;!spsA;!CMPK1;!bgt;!galE;!B3GAT3;!galE;!GYG1	1. UDP-N-acetylglucosamine 2-epimerase;!2. Histo-blood group ABO system transferase;!3. Galactose-1-phosphate uridylyltransferase;!4. Pol polyprotein;!5. Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1;!6. Alpha,alpha-trehalose-phosphate synthase [UDP-forming];!7. Exostosin-like 2;!8. Glycosyltransferase 6 domain-containing protein 1;!9. Spore coat polysaccharide biosynthesis protein SpsA;!10. UMP-CMP kinase;!11. DNA beta-glucosyltransferase;!12. UDP-glucose 4-epimerase;!13. Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 3;!14. UDP-galactose 4-epimerase;!15. Glycogenin-1
C21H28N7O17P3	Not Available	Not Available	743.405	NC(=O)C1=CC=C[N+](=C1)[C@@H]1O[C@H](COP([O-])(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](OP(O)(O)=O)[C@@H]2O)N2C=NC3=C2N=CN=C3N)[C@@H](O)[C@H]1O	Solid	Not Available					11939	44409	CHEMBL295069	5674						NAP			57525501	46507953				Nicotinamide_adenine_dinucleotide_phosphate			Nicotinamide adenine dinucleotide phosphate	Experimental	DB03461	InChI=1S/C21H28N7O17P3/c22-17-12-19(25-7-24-17)28(8-26-12)21-16(44-46(33,34)35)14(30)11(43-21)6-41-48(38,39)45-47(36,37)40-5-10-13(29)15(31)20(42-10)27-3-1-2-9(4-27)18(23)32/h1-4,7-8,10-11,13-16,20-21,29-31H,5-6H2,(H7-,22,23,24,25,32,33,34,35,36,37,38,39)/t10-,11-,13-,14-,15-,16-,20-,21-/m1/s1	XJLXINKUBYWONI-NNYOXOHSSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.8018 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	17	8	Yes	5	-3	367.62 Å2	62.91 Å3	151.75 m3·mol-1	13	No	No	4.84 mg/mL	-11	-2.2	0.66	4.87			
C17H25N5O15P2	Not Available	Not Available	601.3524	[H][C@]1(O)O[C@]([H])(COP(O)(=O)OP(O)(=O)OC[C@@]2([H])O[C@@]([H])(N3C=NC4=C(N)N=CN=C34)[C@]([H])(O)[C@]2([H])O)[C@@]([H])(O)[C@@]1([H])OC(C)=O	Solid	Not Available								394253						OAD			447049	46505222					ZINC000058638658		2'-O-Acetyl Adenosine-5-Diphosphoribose	Experimental	DB03478	InChI=1S/C17H25N5O15P2/c1-6(23)34-13-11(25)8(36-17(13)27)3-33-39(30,31)37-38(28,29)32-2-7-10(24)12(26)16(35-7)22-5-21-9-14(18)19-4-20-15(9)22/h4-5,7-8,10-13,16-17,24-27H,2-3H2,1H3,(H,28,29)(H,30,31)(H2,18,19,20)/t7-,8-,10-,11-,12-,13-,16-,17+/m1/s1	BFNOPXRXIQJDHO-DLFWLGJNSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.8029 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	15	7	Yes	4	-2	297.59 Å2	50.67 Å3	120.27 m3·mol-1	11	No	No	3.54 mg/mL	-5.7	-2.2	1.85	4.93	Q9NXA8	SIRT5	1. NAD-dependent protein deacylase sirtuin-5, mitochondrial
C15H23FN2O16P2	Not Available	Not Available	568.2928	OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)N2C=CC(=O)NC2=O)[C@H](F)[C@@H](O)[C@@H]1O	Solid	Not Available					50304032		CHEMBL593830	395579						U2F			448923	46506848					ZINC000016051573		Uridine-5'-diphosphate-2-deoxy-2-fluoro-alpha-D-galactose	Experimental	DB03488	InChI=1S/C15H23FN2O16P2/c16-8-11(23)9(21)5(3-19)32-14(8)33-36(28,29)34-35(26,27)30-4-6-10(22)12(24)13(31-6)18-2-1-7(20)17-15(18)25/h1-2,5-6,8-14,19,21-24H,3-4H2,(H,26,27)(H,28,29)(H,17,20,25)/t5-,6-,8-,9-,10-,11-,12-,13-,14-/m1/s1	NGTCPFGWXMBZEP-NQQHDEILSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.5275 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										0	No	13	8	Yes	3	-2	271.31 Å2	45.31 Å3	104.76 m3·mol-1	9	No	No	21.7 mg/mL	-4.1	-1.4	1.73	-3	P31677	otsA	1. Alpha,alpha-trehalose-phosphate synthase [UDP-forming]
C15H24N2O17P2	Not Available	Not Available	566.3018	OC[C@H]1O[C@H](O[P@@](O)(=O)O[P@@](O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)N2C=CC(=O)NC2=O)[C@H](O)[C@@H](O)[C@H]1O	Solid	Not Available					50209668	67119	CHEMBL439009	17069			HMDB0000302	C00052		GDU			18068	46507114					ZINC000008551104		Galactose-uridine-5'-diphosphate	Experimental	DB03501	InChI=1S/C15H24N2O17P2/c18-3-5-8(20)10(22)12(24)14(32-5)33-36(28,29)34-35(26,27)30-4-6-9(21)11(23)13(31-6)17-2-1-7(19)16-15(17)25/h1-2,5-6,8-14,18,20-24H,3-4H2,(H,26,27)(H,28,29)(H,16,19,25)/t5-,6-,8+,9-,10+,11-,12-,13-,14-/m1/s1	HSCJRCZFDFQWRP-ABVWGUQPSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.4144 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	14	9	Yes	3	-2	291.54 Å2	45.93 Å3	106.46 m3·mol-1	9	No	No	15.0 mg/mL	-5	-1.6	1.73	-3.6	P16442;!Q14376;!P15291	ABO;!GALE;!B4GALT1	1. Histo-blood group ABO system transferase;!2. UDP-glucose 4-epimerase;!3. Beta-1,4-galactosyltransferase 1
C20H45NO8P2	Not Available	Not Available	489.5207	[H][C@@](COCCCCCCCC)(COP(O)(=O)OCCN)OP(O)(=O)CCCCCCC	Solid	Not Available					50366475		CHEMBL1159973	114411						GEL			129148	46504601							1-O-Octyl-2-Heptylphosphonyl-Sn-Glycero-3-Phosphoethanolamine	Experimental	DB03565	InChI=1S/C20H45NO8P2/c1-3-5-7-9-10-12-15-26-18-20(19-28-31(24,25)27-16-14-21)29-30(22,23)17-13-11-8-6-4-2/h20H,3-19,21H2,1-2H3,(H,22,23)(H,24,25)/t20-/m1/s1	RCCNUBYROFOKAU-HXUWFJFHSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.2540 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	3	No	0	-1	137.54 Å2	54.04 Å3	122.05 m3·mol-1	23	Yes	No	0.806 mg/mL	2.34	-2.8	0.75	10	P04054	PLA2G1B	1. Phospholipase A2
C9H13N2O10P	Not Available	Not Available	340.1807	O[C@H]1[C@@H](O)[C@@H](O[C@@H]1COP(O)(O)=O)N1C(=O)CC(=O)NC1=O	Solid	Not Available						41150	CHEMBL1231399	392864						BMQ			445132	46504629					ZINC000001559604		6-oxouridine 5'-phosphate	Experimental	DB03668	InChI=1S/C9H13N2O10P/c12-4-1-5(13)11(9(16)10-4)8-7(15)6(14)3(21-8)2-20-22(17,18)19/h3,6-8,14-15H,1-2H2,(H,10,12,16)(H2,17,18,19)/t3-,6-,7-,8-/m1/s1	AODYJUNLDJOADV-YXZULKJRSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.2355 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	9	5	No	2	-3	182.93 Å2	26.96 Å3	63.44 m3·mol-1	4	Yes	No		-3		1.23	-3.7	P08244	pyrF	1. Orotidine 5'-phosphate decarboxylase
C16H26N2O15P2	Not Available	Not Available	548.3296	C[C@@H]1O[C@H](OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H](C[C@@H]2O)N2C=C(C)C(=O)NC2=O)[C@H](O)[C@H](O)[C@H]1O	Solid	Not Available						15774		108806				C03319		TRH			121966	46505764					ZINC000008218444		2'-Deoxy-thymidine-beta-L-rhamnose	Experimental	DB03723	InChI=1S/C16H26N2O15P2/c1-6-4-18(16(24)17-14(6)23)10-3-8(19)9(31-10)5-29-34(25,26)33-35(27,28)32-15-13(22)12(21)11(20)7(2)30-15/h4,7-13,15,19-22H,3,5H2,1-2H3,(H,25,26)(H,27,28)(H,17,23,24)/t7-,8-,9+,10+,11-,12+,13+,15+/m0/s1	ZOSQFDVXNQFKBY-CGAXJHMRSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.4742 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	12	7	Yes	3	-2	251.08 Å2	46.34 Å3	107.76 m3·mol-1	8	No	No	11.6 mg/mL	-2.7	-1.7	1.73	-3.2	P26392;!Q9HU22	rfbD;!rmlA	1. dTDP-4-dehydrorhamnose reductase;!2. Glucose-1-phosphate thymidylyltransferase
C17H24N5O17P3	Not Available	Not Available	663.317	[H][C@@]1(O)O[C@]([H])(COP(O)(=O)OP(O)(=O)OC[C@@]2([H])O[C@@]([H])(N3C=NC4=C3N=CN3C=CN=C43)[C@]([H])(OP(O)(O)=O)[C@]2([H])O)[C@@]([H])(O)[C@@]1([H])O	Solid	Not Available								25057396						ENP			49866945	46506210					ZINC000024631640		Etheno-Nadp	Experimental	DB03732	InChI=1S/C17H24N5O17P3/c23-10-7(37-17(26)12(10)25)3-34-41(30,31)39-42(32,33)35-4-8-11(24)13(38-40(27,28)29)16(36-8)22-6-19-9-14-18-1-2-21(14)5-20-15(9)22/h1-2,5-8,10-13,16-17,23-26H,3-4H2,(H,30,31)(H,32,33)(H2,27,28,29)/t7-,8-,10-,11-,12-,13-,16-,17-/m1/s1	KWEQFQACRLGUSH-QJWJOKBXSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.5184 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	16	8	Yes	5	-4	316.44 Å2	54.45 Å3	128.39 m3·mol-1	11	No	No	5.63 mg/mL	-6	-2.1	0.71	4.64	Q10588	BST1	1. ADP-ribosyl cyclase 2
C16H26N2O16P2	Not Available	Not Available	564.329	CC1=CN([C@H]2C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)O2)C(=O)NC1=O	Solid	Not Available						15700	CHEMBL412989	391476				C00842		DAU			443210	46508412							2'deoxy-Thymidine-5'-Diphospho-Alpha-D-Glucose	Experimental	DB03751	InChI=1S/C16H26N2O16P2/c1-6-3-18(16(25)17-14(6)24)10-2-7(20)9(31-10)5-30-35(26,27)34-36(28,29)33-15-13(23)12(22)11(21)8(4-19)32-15/h3,7-13,15,19-23H,2,4-5H2,1H3,(H,26,27)(H,28,29)(H,17,24,25)/t7-,8+,9+,10+,11+,12-,13+,15+/m0/s1	YSYKRGRSMLTJNL-URARBOGNSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.4660 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										0	No	13	8	Yes	3	-2	271.31 Å2	46.66 Å3	109.3 m3·mol-1	9	No	No	11.2 mg/mL	-3.7	-1.7	1.73	-3	P26391;!Q8GIQ0;!P95780;!Q9HU22;!Q9ZGH3	rfbB;!rmlC;!rmlB;!rmlA;!desIV	1. dTDP-glucose 4,6-dehydratase;!2. DTDP-4-dehydrorhamnose 3,5-epimerase;!3. dTDP-glucose 4,6-dehydratase;!4. Glucose-1-phosphate thymidylyltransferase;!5. dTDP-glucose 4,6-dehydratase
C11H19N5O15P4	Not Available	Not Available	585.1881	[H][C@]1(COP(O)(=O)OP(O)(=O)CP(O)(=O)OP(O)(O)=O)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O	Solid	Not Available								393793						ACQ			446443	46505383					ZINC000048015934		Adenosine-5'-[Beta, Gamma-Methylene]Tetraphosphate	Experimental	DB03755	InChI=1S/C11H19N5O15P4/c12-9-6-10(14-2-13-9)16(3-15-6)11-8(18)7(17)5(29-11)1-28-35(26,27)31-33(21,22)4-32(19,20)30-34(23,24)25/h2-3,5,7-8,11,17-18H,1,4H2,(H,19,20)(H,21,22)(H,26,27)(H2,12,13,14)(H2,23,24,25)/t5-,7-,8-,11-/m1/s1	ARRGHMSEJJFDME-IOSLPCCCSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.5963 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	16	8	Yes	3	-5	316.43 Å2	44.54 Å3	109.04 m3·mol-1	10	No	No	4.81 mg/mL	-6.2	-2.1	1.15	4.94	P15925	fgs	1. Folylpolyglutamate synthase
C21H29N7O13P2	Not Available	Not Available	649.4416	[H][C@]1(COP([O-])(=O)OP(O)(=O)OC[C@@]2([H])O[C@@]([H])([N+]3=CC=CC(CN)=C3)[C@]([H])(O)[C@]2([H])O)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O	Solid	Not Available								4451051						NDA			131704258	46506667							3-Aminomethyl-Pyridinium-Adenine-Dinucleotide	Experimental	DB03797	InChI=1S/C21H29N7O13P2/c22-4-10-2-1-3-27(5-10)20-16(31)14(29)11(39-20)6-37-42(33,34)41-43(35,36)38-7-12-15(30)17(32)21(40-12)28-9-26-13-18(23)24-8-25-19(13)28/h1-3,5,8-9,11-12,14-17,20-21,29-32H,4,6-7,22H2,(H3-,23,24,25,33,34,35,36)/t11-,12-,14-,15-,16-,17-,20-,21-/m1/s1	HMCRLFVYYFBZEZ-PLEFRAQWSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.7479 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	15	7	Yes	5	0	304.02 Å2	58.2 Å3	140.27 m3·mol-1	11	No	No	2.21 mg/mL	-13	-2.5	1.85	8.28			
C21H27N7O13P2S	Not Available	Not Available	679.491	[H][C@]1(COP(O)(=O)OP(O)(=O)OC[C@@]2([H])O[C@@]([H])([N+]3=CC=CC(=C3)C([S-])=N)[C@]([H])(O)[C@]2([H])O)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O	Solid	Not Available								4451367						SND			131704262	46508498							Thionicotinamide-Adenine-Dinucleotide	Experimental	DB03893	InChI=1S/C21H27N7O13P2S/c22-17-12-19(25-7-24-17)28(8-26-12)21-16(32)14(30)11(40-21)6-38-43(35,36)41-42(33,34)37-5-10-13(29)15(31)20(39-10)27-3-1-2-9(4-27)18(23)44/h1-4,7-8,10-11,13-16,20-21,29-32H,5-6H2,(H5-,22,23,24,25,33,34,35,36,44)/t10-,11-,13-,14-,15-,16-,20-,21-/m1/s1	UQYPZLRUJKCREN-NNYOXOHSSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.6079 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	15	8	Yes	5	-1	299.02 Å2	60.19 Å3	159.8 m3·mol-1	11	No	No	4.7 mg/mL	-11	-2.2	1.85	5.92	P04406	GAPDH	1. Glyceraldehyde-3-phosphate dehydrogenase
C11H18N5O12P3	Not Available	Not Available	505.2082	[H][C@]1(COP(O)(=O)OP(O)(=O)CP(O)(O)=O)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O	Solid	Not Available					18135	40532	CHEMBL133463	82651				C13741		ACP			91532	46506243					ZINC000008295124		Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate	Experimental	DB03909	InChI=1S/C11H18N5O12P3/c12-9-6-10(14-2-13-9)16(3-15-6)11-8(18)7(17)5(27-11)1-26-31(24,25)28-30(22,23)4-29(19,20)21/h2-3,5,7-8,11,17-18H,1,4H2,(H,22,23)(H,24,25)(H2,12,13,14)(H2,19,20,21)/t5-,7-,8-,11-/m1/s1	UFZTZBNSLXELAL-IOSLPCCCSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.5963 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	14	7	Yes	3	-3	269.9 Å2	39.97 Å3	98.17 m3·mol-1	8	No	No	4.45 mg/mL	-6	-2.1	1.11	4.93	P15925;!Q56310;!P45066;!P46859;!P33221;!P06213;!O14983;!O00764;!P00558;!P9WI81;!P0A9J6;!Q8ZKR2;!Q9X278;!Q12756	fgs;!cheA;!murC;!gntK;!purT;!INSR;!ATP2A1;!PDXK;!PGK1;!pknB;!rbsK;!Not Available;!buk2;!KIF1A	1. Folylpolyglutamate synthase;!2. Chemotaxis protein CheA;!3. UDP-N-acetylmuramate--L-alanine ligase;!4. Thermoresistant gluconokinase;!5. Phosphoribosylglycinamide formyltransferase 2;!6. Insulin receptor;!7. Sarcoplasmic/endoplasmic reticulum calcium ATPase 1;!8. Pyridoxal kinase;!9. Phosphoglycerate kinase 1;!10. Serine/threonine-protein kinase PknB;!11. Ribokinase;!12. Putative sugar kinase;!13. Probable butyrate kinase 2;!14. Kinesin-like protein KIF1A
C6H15O13P3	Not Available	Not Available	388.0968	[H][C@]1(O)[C@@]([H])(O)[C@]([H])(C[C@]1([H])COP(O)(O)=O)OP(O)(=O)OP(O)(O)=O	Solid	Not Available								392181						PCP			444189	46506729					ZINC000012504044		Carboxylic PRPP	Experimental	DB03942	InChI=1S/C6H15O13P3/c7-5-3(2-17-20(9,10)11)1-4(6(5)8)18-22(15,16)19-21(12,13)14/h3-8H,1-2H2,(H,15,16)(H2,9,10,11)(H2,12,13,14)/t3-,4+,5-,6+/m1/s1	OICBXEWBKALHHB-MOJAZDJTSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.0804 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	10	7	No	1	-5	220.51 Å2	28.35 Å3	66.32 m3·mol-1	7	No	No	13.1 mg/mL	-3	-1.5	1.45	-3.3	P37551;!P0A9M5;!P0AG16	purR;!gpt;!purF	1. Pur operon repressor;!2. Xanthine phosphoribosyltransferase;!3. Amidophosphoribosyltransferase
C8H16NO9P	Not Available	Not Available	301.1877	CC(=O)N[C@H]1C(O)O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O	Solid	Not Available						15784		389821			HMDB0001062	C00357		16G			440996	46506695							N-acetyl-D-glucosamine-6-phosphate	Experimental	DB03951	InChI=1S/C8H16NO9P/c1-3(10)9-5-7(12)6(11)4(18-8(5)13)2-17-19(14,15)16/h4-8,11-13H,2H2,1H3,(H,9,10)(H2,14,15,16)/t4-,5-,6-,7-,8?/m1/s1	BRGMHAYQAZFZDJ-RTRLPJTCSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.3156 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	8	6	No	1	-2	165.78 Å2	25.8 Å3	57.9 m3·mol-1	4	No	No	17.6 mg/mL	-3.3	-1.2	1.22	-1.6	P46926;!P0A759	GNPDA1;!nagB	1. Glucosamine-6-phosphate isomerase 1;!2. Glucosamine-6-phosphate deaminase
C6H15O15P3	Not Available	Not Available	420.0956	O[C@H]1[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H](O)[C@H]1OP(O)(O)=O	Solid	Not Available								108982						I2P			122195	46505397					ZINC000013541740		Inositol 2,4,5-trisphosphate	Experimental	DB03956	InChI=1S/C6H15O15P3/c7-1-2(8)5(20-23(13,14)15)6(21-24(16,17)18)3(9)4(1)19-22(10,11)12/h1-9H,(H2,10,11,12)(H2,13,14,15)(H2,16,17,18)/t1-,2-,3-,4-,5+,6+/m0/s1	MMWCIQZXVOZEGG-LKPKBOIGSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.1296 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	12	9	No	1	-6	260.97 Å2	29.49 Å3	68.39 m3·mol-1	6	No	No	14.8 mg/mL	-4.2	-1.4	0.54	-3.7	P51178	PLCD1	1. 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase delta-1
C21H30N10O18P3	Not Available	Not Available	803.4404	[H]N([H])C1=NC(=O)C2=C(N1[H])N(C=N2)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)[N+]2=CN(C)C3=C2N([H])C(=NC3=O)N([H])[H])[C@@H](O)[C@H]1O	Solid	Not Available								108799						GTG			121959	46504811					ZINC000085547903		7-methyl-guanosine-5'-triphosphate-5'-guanosine	Experimental	DB03958	InChI=1S/C21H29N10O18P3/c1-29-5-31(15-9(29)17(37)28-21(23)26-15)19-13(35)11(33)7(47-19)3-45-51(40,41)49-52(42,43)48-50(38,39)44-2-6-10(32)12(34)18(46-6)30-4-24-8-14(30)25-20(22)27-16(8)36/h4-7,10-13,18-19,32-35H,2-3H2,1H3,(H8-,22,23,25,26,27,28,36,37,38,39,40,41,42,43)/p+1/t6-,7-,10-,11-,12-,13-,18-,19-/m1/s1	FHHZHGZBHYYWTG-INFSMZHSSA-O			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.7349 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	21	11	Yes	6	-3	409.79 Å2	67.4 Å3	162.41 m3·mol-1	12	No	No	4.8 mg/mL	-10	-2.2	0.89	2.24	Q96C86;!P0CK31	DCPS;!L1	1. m7GpppX diphosphatase;!2. RNA-directed RNA polymerase lambda-3
C21H27BrN7O17P3	Not Available	Not Available	822.301	[H]N([H])C(=O)C1=C[N+](=CC=C1)[C@@H]1O[C@H](COP([O-])(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](OP(O)(O)=O)[C@@H]2O)N2C(Br)=NC3=C(N=CN=C23)N([H])[H])[C@@H](O)[C@H]1O	Solid	Not Available								4451046						NBP			131704263	46506551							Nicotinamide 8-bromo-adenine dinucleotide phosphate	Experimental	DB03962	InChI=1S/C21H27BrN7O17P3/c22-21-27-11-16(23)25-7-26-18(11)29(21)20-15(45-47(34,35)36)13(31)10(44-20)6-42-49(39,40)46-48(37,38)41-5-9-12(30)14(32)19(43-9)28-3-1-2-8(4-28)17(24)33/h1-4,7,9-10,12-15,19-20,30-32H,5-6H2,(H7-,23,24,25,26,33,34,35,36,37,38,39,40)/t9-,10-,12-,13-,14-,15-,19-,20-/m1/s1	MDKMTCCUJSRQGW-NAJQWHGHSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.6574 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	17	8	Yes	5	-3	367.62 Å2	63.91 Å3	159.37 m3·mol-1	13	No	No	4.28 mg/mL	-9.2	-2.3	0.65	3.94	P52209	PGD	1. 6-phosphogluconate dehydrogenase, decarboxylating
C9H15N2O15P3	Not Available	Not Available	484.1411	O[C@H]1[C@@H](O)[C@@H](O[C@@H]1COP(O)(=O)OP(O)(=O)OP(O)(O)=O)N1C=CC(=O)NC1=O	Solid	Not Available					50118213	15713	CHEMBL336296	5903			HMDB0000285	C00075		UTP			6133	46507277			DNC001492	Uridine_triphosphate	ZINC000003861755		Uridine 5'-triphosphate	Experimental, Investigational	DB04005	InChI=1S/C9H15N2O15P3/c12-5-1-2-11(9(15)10-5)8-7(14)6(13)4(24-8)3-23-28(19,20)26-29(21,22)25-27(16,17)18/h1-2,4,6-8,13-14H,3H2,(H,19,20)(H,21,22)(H,10,12,15)(H2,16,17,18)/t4-,6-,7-,8-/m1/s1	PGAVKCOVUIYSFO-XVFCMESISA-N	3		Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.1803 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	12	7	No	2	-4	258.92 Å2	35.38 Å3	85.18 m3·mol-1	8	No	No	8.37 mg/mL	-3.4	-1.8	0.9	-3.7	Q9BZX2;!P26662;!P26663	UCK2;!Not Available;!Not Available	1. Uridine-cytidine kinase 2;!2. Genome polyprotein;!3. Genome polyprotein
C10H17N5O17P4	Not Available	Not Available	603.1603	NC1=NC2=C(N=CN2[C@@H]2O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](OP(O)(=O)OP(O)(O)=O)[C@H]2O)C(=O)N1	Solid	Not Available						17633		388557			HMDB0059638	C01228		G4P			439450	46508997				Guanosine_pentaphosphate	ZINC000008217069		Guanosine tetraphosphate	Experimental	DB04022	InChI=1S/C10H17N5O17P4/c11-10-13-7-4(8(17)14-10)12-2-15(7)9-5(16)6(30-36(26,27)32-34(21,22)23)3(29-9)1-28-35(24,25)31-33(18,19)20/h2-3,5-6,9,16H,1H2,(H,24,25)(H,26,27)(H2,18,19,20)(H2,21,22,23)(H3,11,13,14,17)/t3-,5-,6-,9-/m1/s1	BUFLLCUFNHESEH-UUOKFMHZSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.4724 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	17	10	Yes	3	-5	342.33 Å2	44.69 Å3	118.69 m3·mol-1	10	No	No		-4.8		-2	15	P42085;!P20964	xpt;!obg	1. Xanthine phosphoribosyltransferase;!2. GTPase ObgE
C21H27N7O14P2	Not Available	Not Available	663.4251	NC(=O)C1=NC(=CC=C1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)N2C=NC3=C2N=CN=C3N)[C@@H](O)[C@H]1O	Solid	Not Available					50368955		CHEMBL1235132	392166			HMDB0039421			PAD			444170	46507346					ZINC000049771447		Cpad	Experimental	DB04071	InChI=1S/C21H27N7O14P2/c22-18-12-20(25-6-24-18)28(7-26-12)21-16(32)14(30)11(41-21)5-39-44(36,37)42-43(34,35)38-4-10-13(29)15(31)17(40-10)8-2-1-3-9(27-8)19(23)33/h1-3,6-7,10-11,13-17,21,29-32H,4-5H2,(H2,23,33)(H,34,35)(H,36,37)(H2,22,24,25)/t10-,11-,13-,14-,15-,16-,17+,21-/m1/s1	LFERELMXERXKKQ-KMXXXSRASA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.9104 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	16	8	Yes	5	-2	327.27 Å2	56.72 Å3	140.48 m3·mol-1	11	No	No	3.15 mg/mL	-5.8	-2.3	1.85	4.93	P00326	ADH1C	1. Alcohol dehydrogenase 1C
C15H23FN2O16P2	Not Available	Not Available	568.2928	[H]N1C(=O)C=CN([C@@H]2O[C@H](COP(O)(=O)OP(O)(=O)O[C@H]3O[C@H](CO)[C@@]([H])(F)[C@H](O)[C@H]3O)[C@@H](O)[C@H]2O)C1=O	Solid	Not Available					50304034		CHEMBL593125	395537						UFG			448872	46506586					ZINC000016051558		Uridine-5'-diphosphate-4-deoxy-4-fluoro-alpha-D-galactose	Experimental	DB04097	InChI=1S/C15H23FN2O16P2/c16-8-5(3-19)32-14(12(24)10(8)22)33-36(28,29)34-35(26,27)30-4-6-9(21)11(23)13(31-6)18-2-1-7(20)17-15(18)25/h1-2,5-6,8-14,19,21-24H,3-4H2,(H,26,27)(H,28,29)(H,17,20,25)/t5-,6-,8-,9-,10+,11-,12-,13-,14-/m1/s1	OAPPZHVTNHJVAL-JZMIEXBBSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.5275 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										0	No	13	8	Yes	3	-2	271.31 Å2	44.87 Å3	104.76 m3·mol-1	9	No	No	21.3 mg/mL	-4.1	-1.4	1.73	-3	P09147	galE	1. UDP-glucose 4-epimerase
C21H27N6O15P2	Not Available	Not Available	665.4178	NC1=C2N=CN([C@@H]3O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]4O[C@H]([C@H](O)[C@@H]4O)[N+]4=CC=CC(=C4)C(O)=O)[C@@H](O)[C@H]3O)C2=NC=N1	Solid	Not Available						18304		145043			HMDB0001179	C00857		DND			165491	46507165					ZINC000008216447		Deamido-Nad+	Experimental	DB04099	InChI=1S/C21H26N6O15P2/c22-17-12-18(24-7-23-17)27(8-25-12)20-16(31)14(29)11(41-20)6-39-44(36,37)42-43(34,35)38-5-10-13(28)15(30)19(40-10)26-3-1-2-9(4-26)21(32)33/h1-4,7-8,10-11,13-16,19-20,28-31H,5-6H2,(H4-,22,23,24,32,33,34,35,36,37)/p+1/t10-,11-,13-,14-,15-,16-,19-,20-/m1/s1	SENPVEZBRZQVST-HISDBWNOSA-O			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	3.0623 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	16	8	Yes	5	-2	312.47 Å2	58.09 Å3	140.17 m3·mol-1	11	No	No	1.88 mg/mL	-9.4	-2.6	1.71	4.93	P18843;!P08164;!Q9HAN9;!P54455;!Q96T66;!O25096	nadE;!nadE;!NMNAT1;!nadD;!NMNAT3;!nadE	1. NH(3)-dependent NAD(+) synthetase;!2. NH(3)-dependent NAD(+) synthetase;!3. Nicotinamide mononucleotide adenylyltransferase 1;!4. Nicotinate-nucleotide adenylyltransferase;!5. Nicotinamide mononucleotide adenylyltransferase 3;!6. NH(3)-dependent NAD(+) synthetase
C10H16N5O14P3	Not Available	Not Available	523.1804	NC1=NC(=O)C2=C(N1)N(C=N2)[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H]1O	Solid	Not Available								163702						G3D			188347	46507196					ZINC000016051736		Guanosine-3'-monophosphate-5'-diphosphate	Experimental	DB04121	InChI=1S/C10H16N5O14P3/c11-10-13-7-4(8(17)14-10)12-2-15(7)9-5(16)6(28-30(18,19)20)3(27-9)1-26-32(24,25)29-31(21,22)23/h2-3,5-6,9,16H,1H2,(H,24,25)(H2,18,19,20)(H2,21,22,23)(H3,11,13,14,17)/t3-,5-,6-,9-/m1/s1	HEYSFDAMRDTCJM-UUOKFMHZSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.4724 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	15	9	Yes	3	-5	295.8 Å2	40.13 Å3	107.82 m3·mol-1	8	No	No	11.1 mg/mL	-4.4	-1.7	-2	20.4	P84077	ARF1	1. ADP-ribosylation factor 1
C10H16N5O14P3	Not Available	Not Available	523.1804	NC1=NC2=C(N=CN2[C@@H]2O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]2O)C(=O)N1	Solid	Not Available						15996	CHEMBL1233147	6569			HMDB0001273	C00044		GTP			6830	46507835					ZINC000060094177		Guanosine-5'-Triphosphate	Experimental	DB04137	InChI=1S/C10H16N5O14P3/c11-10-13-7-4(8(18)14-10)12-2-15(7)9-6(17)5(16)3(27-9)1-26-31(22,23)29-32(24,25)28-30(19,20)21/h2-3,5-6,9,16-17H,1H2,(H,22,23)(H,24,25)(H2,19,20,21)(H3,11,13,14,18)/t3-,5-,6-,9-/m1/s1	XKMLYUALXHKNFT-UUOKFMHZSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.4879 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	14	8	Yes	3	-4	294.81 Å2	39.81 Å3	97.24 m3·mol-1	8	No	No	10.4 mg/mL	-3.8	-1.7	0.92	-0.38	P11124;!Q9NWZ5;!P01112;!P26663;!P61587;!P19711;!Q15382;!P0A6T8;!P16118;!P20339;!P38424;!Q84424;!P03300;!P84077;!P32173;!P43099;!P00367;!Q8N142;!P10114	P2;!UCKL1;!HRAS;!Not Available;!RND3;!Not Available;!RHEB;!folE;!PFKFB1;!RAB5A;!engB;!Not Available;!Not Available;!ARF1;!mobA;!odcI;!GLUD1;!ADSSL1;!RAP2A	1. RNA-directed RNA polymerase;!2. Uridine-cytidine kinase-like 1;!3. GTPase HRas;!4. Genome polyprotein;!5. Rho-related GTP-binding protein RhoE;!6. Genome polyprotein;!7. GTP-binding protein Rheb;!8. GTP cyclohydrolase 1;!9. 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 1;!10. Ras-related protein Rab-5A;!11. Probable GTP-binding protein EngB;!12. mRNA-capping enzyme;!13. Genome polyprotein;!14. ADP-ribosylation factor 1;!15. Molybdenum cofactor guanylyltransferase;!16. Ornithine decarboxylase, inducible;!17. Glutamate dehydrogenase 1, mitochondrial;!18. Adenylosuccinate synthetase isozyme 1;!19. Ras-related protein Rap-2a
C20H32N3O23P3	Not Available	Not Available	775.3957	[H]N([C@H]1[C@@H](OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)N2C=CC(=O)N([H])C2=O)O[C@H](CO)[C@@H](O)[C@@H]1OC(C)(OP(O)(O)=O)C(O)=O)C(C)=O	Solid	Not Available							CHEMBL1236544	394940						UDA			448003	46509124					ZINC000095543621		3'-1-carboxy-1-phosphonooxy-ethoxy-uridine-diphosphate-N-acetylglucosamine	Experimental	DB04174	InChI=1S/C20H32N3O23P3/c1-7(25)21-11-15(43-20(2,18(30)31)45-47(33,34)35)13(28)8(5-24)42-17(11)44-49(38,39)46-48(36,37)40-6-9-12(27)14(29)16(41-9)23-4-3-10(26)22-19(23)32/h3-4,8-9,11-17,24,27-29H,5-6H2,1-2H3,(H,21,25)(H,30,31)(H,36,37)(H,38,39)(H,22,26,32)(H2,33,34,35)/t8-,9-,11-,12-,13-,14-,15-,16-,17-,20+/m1/s1	NLBIPGBVVPCESQ-BVDGEXFOSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.4553 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	19	11	Yes	3	-5	393.47 Å2	62.08 Å3	145.47 m3·mol-1	15	No	No	13.6 mg/mL	-5.1	-1.8	0.8	-3.8	P33038	murA	1. UDP-N-acetylglucosamine 1-carboxyvinyltransferase
C10H16N2O11P2	Not Available	Not Available	402.1884	[H][C@@]1(C[C@@]([H])(O[C@]1([H])COP(O)(O)=O)N1C=C(C)C(=O)NC1=O)OP(O)(O)=O	Solid	Not Available							CHEMBL1235491	108812						THP			121976	46509069					ZINC000011422512		Thymidine-3',5'-Diphosphate	Experimental	DB04205	InChI=1S/C10H16N2O11P2/c1-5-3-12(10(14)11-9(5)13)8-2-6(23-25(18,19)20)7(22-8)4-21-24(15,16)17/h3,6-8H,2,4H2,1H3,(H,11,13,14)(H2,15,16,17)(H2,18,19,20)/t6-,7+,8+/m0/s1	CSNCBOPUCJOHLS-XLPZGREQSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.3253 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	9	5	No	2	-4	192.16 Å2	32.71 Å3	77.16 m3·mol-1	6	Yes	No	7.73 mg/mL	-1.4	-1.7	0.85	-4.2	P06612;!P00644	topA;!nuc	1. DNA topoisomerase 1;!2. Thermonuclease
C18H32O16	Not Available	Not Available	504.4371	[H][C@@]1(O)O[C@]([H])(CO)[C@]([H])(O[C@]2([H])O[C@]([H])(CO)[C@]([H])(O[C@]3([H])O[C@]([H])(CO)[C@]([H])(O)[C@]([H])(O)[C@@]3([H])O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]1([H])O	Solid	Not Available						40896		395580									448924	46508813					ZINC000016051575		beta-(1->4)-galactotriose	Experimental	DB04248	InChI=1S/C18H32O16/c19-1-4-7(22)8(23)12(27)17(31-4)34-15-6(3-21)32-18(13(28)10(15)25)33-14-5(2-20)30-16(29)11(26)9(14)24/h4-29H,1-3H2/t4-,5-,6-,7+,8+,9-,10-,11-,12-,13-,14+,15+,16-,17+,18+/m1/s1	FYGDTMLNYKFZSV-XJJKTWKOSA-N			Not Available	Small Molecule																																			0	No	16	11	Yes	3	0	268.68 Å2	45.26 Å3	100.75 m3·mol-1	7	No	No	554.0 mg/mL	-6.5	0.04	11.22	-3.6	Q65CX5	ganB	1. Arabinogalactan endo-1,4-beta-galactosidase
C6H15O13P3	Not Available	Not Available	388.0968	[H][C@]1(O)[C@@]([H])(O)[C@@]([H])(OP(O)(=O)CP(O)(O)=O)O[C@]1([H])COP(O)(O)=O	Solid	Not Available								395060						PPC			448176	46507418					ZINC000012504276		5-Phosphoribosyl-1-(Beta-Methylene) Pyrophosphate	Experimental	DB04294	InChI=1S/C6H15O13P3/c7-4-3(1-17-22(14,15)16)18-6(5(4)8)19-21(12,13)2-20(9,10)11/h3-8H,1-2H2,(H,12,13)(H2,9,10,11)(H2,14,15,16)/t3-,4-,5-,6-/m1/s1	JFMKBQDEISBIPL-KVTDHHQDSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.1088 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	11	7	No	1	-4	220.51 Å2	28.15 Å3	64.93 m3·mol-1	7	No	No	18.3 mg/mL	-3.8	-1.3	0.74	-3.7	P9WJJ7	nadC	1. Nicotinate-nucleotide pyrophosphorylase [carboxylating]
C6H16O18P4	Not Available	Not Available	500.0755	O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@@H](O)[C@@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O	Solid	Not Available						16155		17216082			HMDB0001187	C04477		I4P			121969	46506539					ZINC000071789370		(1s,3r,4r,6s)-1,3,4,6-Tetrapkisphosphate	Experimental	DB04300	InChI=1S/C6H16O18P4/c7-1-3(21-25(9,10)11)5(23-27(15,16)17)2(8)6(24-28(18,19)20)4(1)22-26(12,13)14/h1-8H,(H2,9,10,11)(H2,12,13,14)(H2,15,16,17)(H2,18,19,20)/t1-,2+,3-,4+,5-,6+	ZAWIXNGTTZTBKV-JMVOWJSSSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.2264 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	14	10	No	1	-8	307.5 Å2	33.68 Å3	79.27 m3·mol-1	8	No	No	11.5 mg/mL	-4.3	-1.6	0.35				
C10H15N5O11P2	Not Available	Not Available	443.2005	NC1=NC2=C(N=CN2[C@@H]2O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]2O)C(=O)N1	Solid	Not Available					92459	17552	CHEMBL384759	8630			HMDB0001201	C00035		GDP			8977	46508144					ZINC000008215481		Guanosine-5'-Diphosphate	Experimental	DB04315	InChI=1S/C10H15N5O11P2/c11-10-13-7-4(8(18)14-10)12-2-15(7)9-6(17)5(16)3(25-9)1-24-28(22,23)26-27(19,20)21/h2-3,5-6,9,16-17H,1H2,(H,22,23)(H2,19,20,21)(H3,11,13,14,18)/t3-,5-,6-,9-/m1/s1	QGWNDRXFNXRZMB-UUOKFMHZSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.4879 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	12	7	Yes	3	-3	248.28 Å2	35.28 Å3	86.37 m3·mol-1	6	No	No	4.44 mg/mL	-3.4	-2	1.79	0.48			
C10H17N6O12P3	Not Available	Not Available	506.1963	NC1=NC=NC2=C1N=CN2[C@@H]1O[C@@H](CO[P@](O)(=O)O[P@@](O)(=O)NP(O)(O)=O)[C@H](O)[C@H]1O	Solid	Not Available					18134			26326149						A0P			44462678	46507028					ZINC000053683526		Phosphoaminophosphonic Acid-Adenylate Ester	Experimental	DB04395	InChI=1S/C10H17N6O12P3/c11-8-5-9(13-2-12-8)16(3-14-5)10-7(18)6(17)4(27-10)1-26-31(24,25)28-30(22,23)15-29(19,20)21/h2-4,6-7,10,17-18H,1H2,(H,24,25)(H2,11,12,13)(H4,15,19,20,21,22,23)/t4-,6-,7+,10+/m0/s1	PVKSNHVPLWYQGJ-FCIPNVEPSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.5012 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	14	8	Yes	3	-4	281.93 Å2	39.25 Å3	97.76 m3·mol-1	8	No	No	4.17 mg/mL	-6	-2.1	-7.5	3.58	P49841;!P23919;!Q56310;!P08069;!P11309;!P45510;!P0A6I3;!P19367;!P33221;!P06239;!P68400;!P29317;!P59846;!P53779;!P0A820;!P45066;!P23367;!Q99661;!P23677;!Q02880;!P48637;!Q83LD8;!Q16877;!P0A3Y5;!P53355;!P08690;!P68133;!P0A6C8;!P0AES6;!P0AEJ4;!P0A6H7;!P29323;!Q04230;!P13569;!P55072;!Q96QT4;!Q12756;!P49368;!Q9WZ57;!P78362;!P53778;!Q9RA63;!P37093;!P23837;!P20083;!P51570;!P0A7G9;!Q06609;!P03960	GSK3B;!DTYMK;!cheA;!IGF1R;!PIM1;!dhaK;!coaA;!HK1;!purT;!LCK;!CSNK2A1;!EPHA2;!argG;!MAPK10;!metK;!murC;!mutL;!KIF2C;!ITPKA;!TOP2B;!GSS;!ispE;!PFKFB4;!aphA;!DAPK1;!arsA;!ACTA1;!argB;!gyrB;!envZ;!hslU;!EPHB2;!trwB;!CFTR;!VCP;!TRPM7;!KIF1A;!CCT3;!Not Available;!SRPK2;!MAPK12;!clpB;!epsE;!phoQ;!parE;!GALK1;!recA;!RAD51;!kdpB	1. Glycogen synthase kinase-3 beta;!2. Thymidylate kinase;!3. Chemotaxis protein CheA;!4. Insulin-like growth factor 1 receptor;!5. Serine/threonine-protein kinase pim-1;!6. Dihydroxyacetone kinase;!7. Pantothenate kinase;!8. Hexokinase-1;!9. Phosphoribosylglycinamide formyltransferase 2;!10. Tyrosine-protein kinase Lck;!11. Casein kinase II subunit alpha;!12. Ephrin type-A receptor 2;!13. Argininosuccinate synthase;!14. Mitogen-activated protein kinase 10;!15. S-adenosylmethionine synthase;!16. UDP-N-acetylmuramate--L-alanine ligase;!17. DNA mismatch repair protein MutL;!18. Kinesin-like protein KIF2C;!19. Inositol-trisphosphate 3-kinase A;!20. DNA topoisomerase 2-beta;!21. Glutathione synthetase;!22. 4-diphosphocytidyl-2-C-methyl-D-erythritol kinase;!23. 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4;!24. Aminoglycoside 3'-phosphotransferase;!25. Death-associated protein kinase 1;!26. Arsenical pump-driving ATPase;!27. Actin, alpha skeletal muscle;!28. Acetylglutamate kinase;!29. DNA gyrase subunit B;!30. Osmolarity sensor protein EnvZ;!31. ATP-dependent protease ATPase subunit HslU;!32. Ephrin type-B receptor 2;!33. TrwB;!34. Cystic fibrosis transmembrane conductance regulator;!35. Transitional endoplasmic reticulum ATPase;!36. Transient receptor potential cation channel subfamily M member 7;!37. Kinesin-like protein KIF1A;!38. T-complex protein 1 subunit gamma;!39. Rod shape-determining protein MreB;!40. SRSF protein kinase 2;!41. Mitogen-activated protein kinase 12;!42. Chaperone protein ClpB;!43. Type II secretion system protein E;!44. Sensor protein PhoQ;!45. DNA topoisomerase 4 subunit B;!46. Galactokinase;!47. Protein RecA;!48. DNA repair protein RAD51 homolog 1;!49. Potassium-transporting ATPase B chain
C6H13O12PV	Not Available	Not Available	359.0755	O[C@@H]1[C@@H](O)[C@H](CO[V](O)(=O)=O)O[C@H](OP(O)(O)=O)[C@H]1O	Solid	Not Available					50094936			58829632						VG1			46936967	46507742							Alpha-D-Glucose-1-Phosphate-6-Vanadate	Experimental	DB04397	InChI=1S/C6H12O9P.H2O.2O.V/c7-1-2-3(8)4(9)5(10)6(14-2)15-16(11,12)13;;;;/h2-6,8-10H,1H2,(H2,11,12,13);1H2;;;/q-1;;;;+2/p-1/t2-,3-,4+,5-,6+;;;;/m0..../s1	SYRDAPWACIANBN-DPXSRCRQSA-M			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.2511 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	10	6	No	1	-3	200.28 Å2	26.24 Å3	51.03 m3·mol-1	5	No	No	9.16 mg/mL	-5.9	-1.6	-2	-3.6	P36871	PGM1	1. Phosphoglucomutase-1
C17H26N3O15P	Not Available	Not Available	543.3732	NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](COP(O)(=O)O[C@]2(C[C@@H](O)[C@@H](O)[C@H](O2)[C@H](O)CO)C(O)=O)[C@@H](O)[C@H]1O	Solid	Not Available						86284		393385				C04121		CMK			445888	46506999					ZINC000030725157		Cmp-2-Keto-3-Deoxy-Octulosonic Acid	Experimental	DB04482	InChI=1S/C17H26N3O15P/c18-9-1-2-20(16(29)19-9)14-12(26)11(25)8(33-14)5-32-36(30,31)35-17(15(27)28)3-6(22)10(24)13(34-17)7(23)4-21/h1-2,6-8,10-14,21-26H,3-5H2,(H,27,28)(H,30,31)(H2,18,19,29)/t6-,7-,8-,10-,11-,12-,13-,14-,17-/m1/s1	YWWJKULNWGRYAS-UOVSKDHASA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.4753 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	15	9	Yes	3	-2	291.59 Å2	47.04 Å3	108.36 m3·mol-1	9	No	No	49.6 mg/mL	-4.8	-1	1.4	4.14	P42216;!P44490	kpsU;!kdsB	1. 3-deoxy-manno-octulosonate cytidylyltransferase;!2. 3-deoxy-manno-octulosonate cytidylyltransferase
C15H29N5O17P3	Not Available	Not Available	644.3353	[H][C@@]1(O)O[C@]([H])(COP(O)(=O)OP(O)(=O)OC[C@@]2([H])O[C@@]([H])(N3C=NC4=C3NCN[C@@]4([H])[NH3+])[C@]([H])(OP(O)(O)=O)[C@]2([H])O)[C@@]([H])(O)[C@@]1([H])O	Solid	Not Available								25057199						APX			131704284	46508839							2'-Monophosphoadenosine-5'-Diphosphoribose	Experimental	DB04497	InChI=1S/C15H28N5O17P3/c16-12-7-13(18-3-17-12)20(4-19-7)14-11(36-38(25,26)27)9(22)6(34-14)2-33-40(30,31)37-39(28,29)32-1-5-8(21)10(23)15(24)35-5/h4-6,8-12,14-15,17-18,21-24H,1-3,16H2,(H,28,29)(H,30,31)(H2,25,26,27)/p+1/t5-,6-,8-,9-,10-,11-,12-,14-,15-/m1/s1	QHNQLFGTVLWISK-MQSGHBOVSA-O			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.8115 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	16	11	Yes	4	-4	337.95 Å2	53.45 Å3	133.57 m3·mol-1	11	No	No	6.36 mg/mL	-10	-2	0.72	6.85			
C9H15N3O11P2	Not Available	Not Available	403.1764	NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O	Solid	Not Available					50194153	17239	CHEMBL425252	5902			HMDB0001546	C00112		CDP			6132	46508856					ZINC000008215624		Cytidine-5'-Diphosphate	Experimental	DB04555	InChI=1S/C9H15N3O11P2/c10-5-1-2-12(9(15)11-5)8-7(14)6(13)4(22-8)3-21-25(19,20)23-24(16,17)18/h1-2,4,6-8,13-14H,3H2,(H,19,20)(H2,10,11,15)(H2,16,17,18)/t4-,6-,7-,8-/m1/s1	ZWIADYZPOWUWEW-XVFCMESISA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.2404 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	11	6	No	2	-3	221.67 Å2	31.39 Å3	76.29 m3·mol-1	6	No	No	10.1 mg/mL	-3.5	-1.6	1.74	4.33	P62619;!P42216;!Q8RQP5;!P0A0Z8;!P0A6I0;!P14169	ispF;!kpsU;!ispF;!neuA;!cmk;!rfbE	1. 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase;!2. 3-deoxy-manno-octulosonate cytidylyltransferase;!3. 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase;!4. N-acylneuraminate cytidylyltransferase;!5. Cytidylate kinase;!6. CDP-paratose 2-epimerase
C10H20NO9P	Not Available	Not Available	329.2409	[H][C@]1(O[C@H](C[C@H](O)[C@H]1NC(C)=O)P(O)(O)=O)[C@H](O)[C@H](O)CO	Solid	Not Available								392825						AXP			445079	46506811					ZINC000005884104		4-acetamido-2,4-didexoy-D-glycero-beta-D-galacto-octopyranosylphosphonic acid	Experimental	DB04561	InChI=1S/C10H20NO9P/c1-4(13)11-8-5(14)2-7(21(17,18)19)20-10(8)9(16)6(15)3-12/h5-10,12,14-16H,2-3H2,1H3,(H,11,13)(H2,17,18,19)/t5-,6+,7-,8+,9+,10+/m0/s1	QITAGYVZDNZULE-HDBWYCHPSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.2135 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	9	7	No	1	-1	176.78 Å2	29.21 Å3	66.82 m3·mol-1	5	No	No	29.8 mg/mL	-4.4	-1	1.29	-1.3	P29768	nanH	1. Sialidase
C14H23N2O9P	Not Available	Not Available	394.3142	CCCCO[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C=C(C)C(=O)NC1=O	Solid	Not Available								25057502						2BT			49866449	46505132					ZINC000058633308		2'-O-butyl-5-methyluridine	Experimental	DB04587	InChI=1S/C14H23N2O9P/c1-3-4-5-23-11-10(17)9(7-24-26(20,21)22)25-13(11)16-6-8(2)12(18)15-14(16)19/h6,9-11,13,17H,3-5,7H2,1-2H3,(H,15,18,19)(H2,20,21,22)/t9-,10-,11-,13-/m1/s1	WSAMAMLAATZRPR-PRULPYPASA-N			Not Available	Small Molecule																																			1	Yes	8	4	No	2	-2	154.86 Å2	36.53 Å3	86.42 m3·mol-1	8	Yes	No	3.9 mg/mL	-0.18	-2	1.23	-3.7			
C15H22O14	Not Available	Not Available	426.3268	[H][C@@]12CO[C@@](C)(O[C@@]1([H])[C@H](O)[C@H](O)[C@H](O[C@H]1[C@H](O)[C@@H](O)C(O)O[C@@H]1C(O)=O)O2)C(O)=O	Solid	Not Available								4449877						46D			5287514	46509174							4-O-{4,6-O-[(1S)-1-Carboxyethylidene]-β-D-mannopyranosyl}-D-glucopyranuronic acid	Experimental	DB04596	InChI=1S/C15H22O14/c1-15(14(23)24)25-2-3-8(29-15)5(17)7(19)13(26-3)28-9-4(16)6(18)12(22)27-10(9)11(20)21/h3-10,12-13,16-19,22H,2H2,1H3,(H,20,21)(H,23,24)/t3-,4-,5-,6-,7+,8-,9+,10+,12?,13+,15+/m1/s1	GZJXZKGVHLWBOW-AISSFXTFSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.1869 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	14	7	No	3	-2	221.9 Å2	37.94 Å3	81.73 m3·mol-1	4	No	No	94.1 mg/mL	-2.9	-0.66	2.63	-3.7	Q9AQS0	xly	1. Xanthan lyase
C11H17N2O11PS	Not Available	Not Available	416.298	[H]N([H])[C@H]1[C@@H](OC(C)=O)[C@@]2([H])O[C@](CS[C@@]2(O)C(=O)N([H])[H])([C@@H]1OP(O)(O)=O)C(O)=O	Solid	Not Available								4484333						TGT			5327077	46506068				Tagetitoxin	ZINC000012504512		Tagetitoxin	Experimental	DB04788	InChI=1S/C11H17N2O11PS/c1-3(14)22-5-4(12)6(24-25(19,20)21)10(9(16)17)2-26-11(18,8(13)15)7(5)23-10/h4-7,18H,2,12H2,1H3,(H2,13,15)(H,16,17)(H2,19,20,21)/t4-,5+,6+,7+,10+,11+/m0/s1	UVAAUIDYGIWLMB-HGNFPZBQSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.5607 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	10	6	No	2	-2	228.93 Å2	34.21 Å3	80.58 m3·mol-1	6	No	No	37.5 mg/mL	-3.8	-1	0.85	8.72	Q8RQE9;!Q8RQE8	rpoB;!rpoC	1. DNA-directed RNA polymerase subunit beta;!2. DNA-directed RNA polymerase subunit beta'
C12H35Na3O26Sb2	Not Available	Not Available	907.88	O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[H][C@@]1(O[Sb]2(O)(O[Sb]34([O-])O[C@@H](C([O-])=O)[C@@]([H])(O3)[C@]([H])(O4)[C@H](O)CO)O[C@@H](C([O-])=O)[C@@]1([H])O2)[C@H](O)CO	Solid	Not Available						28148	CHEMBL2079699	27471272			HMDB15617		D00582			PA164743129	56927674	99443233		8010	DCL000001	Sodium_stibogluconate			Sodium stibogluconate	Approved, Investigational	DB05630	InChI=1S/2C6H9O7.3Na.10H2O.2O.2Sb/c2*7-1-2(8)3(9)4(10)5(11)6(12)13;;;;;;;;;;;;;;;;;/h2*2-5,7-8H,1H2,(H,12,13);;;;10*1H2;;;;/q2*-3;3*+1;;;;;;;;;;;;-1;+3;+4/p-3/t2*2-,3-,4+,5-;;;;;;;;;;;;;;;;;/m11................./s1	YQDGWZZYGYKDLR-UZVLBLASSA-K	4		The main symptoms of antimony overdosage are gastro-intestinal disturbances (nausea, vomiting and severe diarrhoea). Haemorrhagic nephritis and hepatitis may also occur.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.4267 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	17	5	Yes	4	-2	269.08 Å2	39.78 Å3	96.29 m3·mol-1	8	No	No	68.4 mg/mL	-3.4	-1	2.29	-3	P11387	TOP1	1. DNA topoisomerase 1
C42H30N6O12	Mean clearance rate following intravenous administration of 50mg/kg of inositol nicotinate in rats is 65.4±19 mL/min/kg 2.	Mean elimination half life in healthy human adults is approximately one hour 2.	810.732	O=C(O[C@H]1[C@H](OC(=O)C2=CC=CN=C2)[C@@H](OC(=O)C2=CC=CN=C2)[C@H](OC(=O)C2=CC=CN=C2)[C@H](OC(=O)C2=CC=CN=C2)[C@@H]1OC(=O)C1=CC=CN=C1)C1=CC=CN=C1	Solid	Mean Vd following intravenous administration of 50mg/kg of inositol nicotinate in rats is 1051±250 mL/kg 2.	P06576;!Q96PD7	ATP5B;!DGAT2	1. ATP synthase subunit beta, mitochondrial;!2. Diacylglycerol O-acyltransferase 2			31699	CHEMBL1094982	16736141	Drugs.com Drug Page				D01813				3720	347827813		27604		Inositol_nicotinate	ZINC000150338506		Inositol nicotinate	Approved, Withdrawn	DB08949	InChI=1S/C42H30N6O12/c49-37(25-7-1-13-43-19-25)55-31-32(56-38(50)26-8-2-14-44-20-26)34(58-40(52)28-10-4-16-46-22-28)36(60-42(54)30-12-6-18-48-24-30)35(59-41(53)29-11-5-17-47-23-29)33(31)57-39(51)27-9-3-15-45-21-27/h1-24,31-36H/t31-,32-,33-,34+,35-,36-	MFZCIDXOLLEMOO-GYSGTQPESA-N		Inositol nicotinate is a vasodilator and source of niacin found in dietary supplements.	NOAEL is 4000mg. Inositol nicotinate can cause muscle pain, headache, redness of face, nausea, vomiting, edema and rash.	Small Molecule																																		Insoluble	0	No	12	0	Yes	7	0	235.14 Å2	76.08 Å3	201.77 m3·mol-1	18	No	No	0.0174 mg/mL	3.88	-4.7		4.02	P49019;!Q8TDS4	HCAR3;!HCAR2	1. Hydroxycarboxylic acid receptor 3;!2. Hydroxycarboxylic acid receptor 2
C12H29Fe5Na2O23	Total body clearance is 20.5 ml/min.	6 hours.	866.546	O.O.O.[OH-].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[Na+].[Na+].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O	Solid	Vd is 7.3 L							CHEMBL1200823	32699616									91663255	310265059		1484283		Iron_sucrose		Velphoro, Venofer	Iron sucrose	Approved	DB09146	InChI=1S/C12H22O11.5Fe.2Na.4H2O.8O/c13-1-4-6(16)8(18)9(19)11(21-4)23-12(3-15)10(20)7(17)5(2-14)22-12;;;;;;;;;;;;;;;;;;;/h4-11,13-20H,1-3H2;;;;;;;;4*1H2;;;;;;;;/q;5*+3;2*+1;;;;;8*-2/p-1/t4-,5-,6-,7-,8+,9-,10+,11-,12+;;;;;;;;;;;;;;;;;;;/m1.................../s1	FWZTTZUKDVJDCM-CEJAUHOTSA-M	4	Iron sucrose is an compound used as a source of iron in patients with iron deficiency anemia associated with chronic kidney disease (CKD).	Hypersensitivity reactions, including anaphylactic shock, loss of consciousness, collapse, hypotension, dyspnea, and seizure.Monitor iron toxicity through the periodic evaluation of lab works which monitor the body concentration of iron. Lab monitoring of the following parameters: transferrin saturation, serum ferritin concentrations, hemoglobin, and hematocrit could be helpful to avoid iron overload.Severe allergic symptoms include: rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue; unusual hoarseness); burning or pain at the injection site; burning, numbness, or tingling; chest pain; fainting; loss of consciousness; severe or persistent dizziness, headache, or light-headedness; seizures; shortness of breath; swelling of the hands, ankles, or feet.	Small Molecule																																			0	No	11	8	No	2	0	189.53 Å2	30.97 Å3	68.77 m3·mol-1	5	No	No	9.52 mg/mL	-4.5	-1.8	11.84	-3			
C18H32CaO19	Not Available	Not Available	592.513	OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(=O)O[Ca]OC(=O)[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO	Solid	Primarily in bones, teeth							CHEMBL2219740	58310									131704325	347829259				Calcium_glubionate			Calcium glubionate anhydrousCommonly known or available as Calcium glubionate	Approved	DB13142	InChI=1S/C12H22O12.C6H12O7.Ca/c13-1-3(15)10(7(18)8(19)11(21)22)24-12-9(20)6(17)5(16)4(2-14)23-12;7-1-2(8)3(9)4(10)5(11)6(12)13;/h3-10,12-20H,1-2H2,(H,21,22);2-5,7-11H,1H2,(H,12,13);/q;;+2/p-2/t3-,4-,5+,6+,7-,8-,9-,10-,12+;2-,3-,4+,5-;/m11./s1	YPCRNBPOUVJVMU-LCGAVOCYSA-L		Calcium glubionate is a calcium salt indicated in the treatment of hypocalcemia, hyperkalemia, lead poisoning, and as an adjunct in the treatment of exudative skin conditions.	Assess patient for nausea, vomiting, anorexia, thirst, severe constipation, paralytic ileus, and bradycardia	Small Molecule																																			0	No	17	13	No	1	0	334.05 Å2	50.17 Å3	107.1 m3·mol-1	17	No	No	47.2 mg/mL	-9.6	-1.1	11.32	-3.6			
C10H22O14S4	Not Available	Not Available	494.51	CS(=O)(=O)OC[C@@H](OS(C)(=O)=O)[C@@H](O)[C@H](O)[C@@H](COS(C)(=O)=O)OS(C)(=O)=O	Not Available	Not Available						136005	CHEMBL460282	16736959														Mannosulfan	ZINC000044361935		Mannosulfan	Experimental	DB13334	InChI=1S/C10H22O14S4/c1-25(13,14)21-5-7(23-27(3,17)18)9(11)10(12)8(24-28(4,19)20)6-22-26(2,15)16/h7-12H,5-6H2,1-4H3/t7-,8-,9-,10-/m1/s1	UUVIQYKKKBJYJT-ZYUZMQFOSA-N			Not Available	Small Molecule																																			0	No	10	2	No	0	0	213.94 Å2	42.7 Å3	89.41 m3·mol-1	13	Yes	No	3.62 mg/mL	-4	-2.1	12.7	-3.7			
C28H42O29	Not Available	Not Available	842.615	OCOC(=O)[C@H]1O[C@H](O[C@@H]2[C@H](O)[C@@H](O)[C@@H](O[C@@H]3[C@H](O)[C@@H](O)[C@@H](O[C@@H]4[C@H](O)[C@@H](O)[C@@H](O)O[C@@H]4C(=O)OCO)O[C@@H]3C(=O)OCO)O[C@@H]2C(=O)OCO)[C@H](O)[C@@H](O)[C@H]1O	Not Available	Not Available								32698706														Tetragalacturonic_acid_hydroxymethylester			Tetragalacturonic acid hydroxymethylester	Experimental	DB13621	InChI=1S/C28H42O29/c29-1-47-22(43)17-6(34)5(33)11(39)26(55-17)53-15-8(36)13(41)28(57-19(15)24(45)49-3-31)54-16-9(37)12(40)27(56-20(16)25(46)50-4-32)52-14-7(35)10(38)21(42)51-18(14)23(44)48-2-30/h5-21,26-42H,1-4H2/t5-,6+,7+,8+,9+,10+,11+,12+,13+,14+,15+,16+,17-,18-,19-,20-,21-,26-,27-,28-/m0/s1	PGQMFCVZFGJVNB-LRVJTQDXSA-N			Not Available	Small Molecule																																			0	No	25	14	Yes	4	0	453.03 Å2	72.57 Å3	156.12 m3·mol-1	18	No	No	122.0 mg/mL	-8.7	-0.84	11.18	-3.7			
C21H27N7O14P2	Not Available	Not Available	663.4251	NC(=O)C1=C[N+](=CC=C1)[C@@H]1O[C@H](COP([O-])(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)N2C=NC3=C2N=CN=C3N)[C@@H](O)[C@H]1O	Not Available	Not Available					213227	44215	CHEMBL1234613	5681						NAD						1044975		Nicotinamide_adenine_dinucleotide			Nadide	Experimental	DB14128	InChI=1S/C21H27N7O14P2/c22-17-12-19(25-7-24-17)28(8-26-12)21-16(32)14(30)11(41-21)6-39-44(36,37)42-43(34,35)38-5-10-13(29)15(31)20(40-10)27-3-1-2-9(4-27)18(23)33/h1-4,7-8,10-11,13-16,20-21,29-32H,5-6H2,(H5-,22,23,24,25,33,34,35,36,37)/t10-,11-,13-,14-,15-,16-,20-,21-/m1/s1	BAWFJGJZGIEFAR-NNYOXOHSSA-N			Not Available	Small Molecule																																			0	No	16	8	Yes	5	-1	322.08 Å2	58.5 Å3	151.81 m3·mol-1	11	No	No	2.14 mg/mL	-11	-2.5	1.86	6.4			
C6H18O24P6	Not Available	Not Available	660.0353	OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O	Not Available	Not Available						17401	CHEMBL1233511	16735966				C01204		IHP						8302		Phytic_acid	ZINC000169289809		Phytic acid	Investigational	DB14981	InChI=1S/C6H18O24P6/c7-31(8,9)25-1-2(26-32(10,11)12)4(28-34(16,17)18)6(30-36(22,23)24)5(29-35(19,20)21)3(1)27-33(13,14)15/h1-6H,(H2,7,8,9)(H2,10,11,12)(H2,13,14,15)(H2,16,17,18)(H2,19,20,21)(H2,22,23,24)/t1-,2-,3-,4+,5-,6-	IMQLKJBTEOYOSI-GPIVLXJGSA-N	3		Not Available	Small Molecule																																			0	No	18	12	No	1	-12	400.56 Å2	42.6 Å3	101.01 m3·mol-1	12	No	No	13.7 mg/mL	-4.5	-1.7	0.14				
C12H23NO10S3	Not Available	Not Available	437.49	C[S+]([O-])CCCC\C(S[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)=N/OS(O)(=O)=O	Not Available	Not Available								7827557														Glucoraphanin			Glucoraphanin	Investigational	DB15436	InChI=1S/C12H23NO10S3/c1-25(18)5-3-2-4-8(13-23-26(19,20)21)24-12-11(17)10(16)9(15)7(6-14)22-12/h7,9-12,14-17H,2-6H2,1H3,(H,19,20,21)/b13-8+/t7-,9-,10+,11-,12+,25?/m1/s1	GMMLNKINDDUDCF-RFOBZYEESA-N	2		Not Available	Small Molecule																																			1	No	10	5	No	1	-1	183.18 Å2	41.44 Å3	93.62 m3·mol-1	10	Yes	No	12.4 mg/mL	-4.7	-1.6	-3.7	-0.44			
C18H34FeO16	Intravenous iron is cleared from the plasma.6 Ferric derisomaltose is not eliminated via the kidneys, as the size of the complex is large and cannot be excreted via the nephron.10	The plasma-half live of intravenous iron is about 1-4 days.10	562.297	[Fe+3].OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O	Solid	Ferric derisomaltose or released iron that was released is found in cells of the reticuloendothelial system (RES). It is found to be highly concentrated in the liver and spleen.10 The volume of distribution of other forms of intravenous iron is 3L, on average, in a 70 kg adult.5 Though the specific volume of distribution of ferric derisomaltose is not readily available in the literature, it is likely similar to other intravenous forms of iron.5																				2274394		Ferric_derisomaltose			Ferric derisomaltose	Approved	DB15617	InChI=1S/C18H34O16.Fe/c19-1-5(21)9(23)10(24)6(22)3-31-17-16(30)14(28)12(26)8(34-17)4-32-18-15(29)13(27)11(25)7(2-20)33-18;/h5-30H,1-4H2;/q;+3/t5-,6+,7+,8+,9+,10+,11+,12+,13-,14-,15+,16+,17-,18-;/m0./s1	JTQTXQSGPZRXJF-DOJSGGEQSA-N	3	Ferric derisomaltose is an iron injection used in the treatment of iron deficiency anemia.	LD50 information for ferric derisomaltose is not readily available in the literature, however, the LD50 for iron sucrose (another form of intravenous iron) was 140 mg/kg in male rats.12 An overdose with ferric derisomaltose may lead to accumulation of stored iron, causing hemosiderosis.11 Symptoms may include abdominal pain, weakness, and lethargy, among others.7 Serum ferritin should be monitored. Employ supportive treatment including chelating agents.8,11	Small Molecule																																			0	No	16	12	No	2	0	279.68 Å2	47.86 Å3	103.23 m3·mol-1	11	No	No	284.0 mg/mL	-7.3	-0.25	11.86	-3.6	P69905;!BE0004850	HBA1;!	1. Hemoglobin subunit alpha;!2. Transferrin receptor (Protein Group)
C18H26N4O23P4	Not Available	Not Available	790.306	O[C@H]1[C@@H](O)[C@@H](O[C@@H]1COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=CC(=O)NC1=O)N1C=CC(=O)NC1=O	Not Available	Not Available						27791	CHEMBL221326	130647			HMDB0006796	C06198										Diquafosol	ZINC000008551963		Diquafosol	Experimental	DB15919	InChI=1S/C18H26N4O23P4/c23-9-1-3-21(17(29)19-9)15-13(27)11(25)7(41-15)5-39-46(31,32)43-48(35,36)45-49(37,38)44-47(33,34)40-6-8-12(26)14(28)16(42-8)22-4-2-10(24)20-18(22)30/h1-4,7-8,11-16,25-28H,5-6H2,(H,31,32)(H,33,34)(H,35,36)(H,37,38)(H,19,23,29)(H,20,24,30)/t7-,8-,11-,12-,13-,14-,15-,16-/m1/s1	NMLMACJWHPHKGR-NCOIDOBVSA-N	3	Diquafosol is a medication indicated to treat dry eyes associated with keratoconjunctival disorders.	Not Available	Small Molecule																																			0	No	18	10	Yes	4	-4	393.55 Å2	59.64 Å3	144.84 m3·mol-1	14	No	No	13.9 mg/mL	-5.3	-1.8	0.59	-3.8			
C8H18Fe2O12P2	Not Available	Not Available	479.858	[Fe++].[Fe++].OCC(O)COP([O-])([O-])=O.OCCC(CCO)OP([O-])([O-])=O	Not Available	Not Available								14082																	Ferric glycerophosphate	Approved, Experimental	DB15934	InChI=1S/C5H13O6P.C3H9O6P.2Fe/c6-3-1-5(2-4-7)11-12(8,9)10;4-1-3(5)2-9-10(6,7)8;;/h5-7H,1-4H2,(H2,8,9,10);3-5H,1-2H2,(H2,6,7,8);;/q;;2*+2/p-4	CBEYZWBXIPZYNH-UHFFFAOYSA-J			Not Available	Small Molecule																																			1	No	5	2	No	0	-2	112.88 Å2	16.68 Å3	38.88 m3·mol-1	10	Yes	No	55.5 mg/mL	-1.8	-0.94	1.64	-2.4			
C32H26N4O2	Not Available	5 hours	498.5744	CC1=NC2=C(CCN(C(=O)C3=CC=C(NC(=O)C4=CC=CC=C4C4=CC=CC=C4)C=C3)C3=CC=CC=C23)N1	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4		85095	681850	CHEMBL1755	133239	Drugs.com Drug Page	GtP Drug Page	HMDB0015010		D07748			PA164742939	151171	46504533		302285	DNC001525	Conivaptan	ZINC000012503187	Vaprisol	Conivaptan	Approved, Investigational	DB00872	InChI=1S/C32H26N4O2/c1-21-33-28-19-20-36(29-14-8-7-13-27(29)30(28)34-21)32(38)23-15-17-24(18-16-23)35-31(37)26-12-6-5-11-25(26)22-9-3-2-4-10-22/h2-18H,19-20H2,1H3,(H,33,34)(H,35,37)	IKENVDNFQMCRTR-UHFFFAOYSA-N	4	Conivaptan is an antidiuretic hormone inhibitor used to raise serum sodium levels.	Although no data on overdosage in humans are available, conivaptan has been administered as a 20 mg loading dose on Day 1 followed by continuous infusion of 80 mg/day for 4 days in hyponatremia patients and up to 120 mg/day for 2 days in CHF patients. No new toxicities were identified at these higher doses, but adverse events related to the pharmacologic activity of conivaptan, e.g. hypotension and thirst, occurred more frequently at these higher doses.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.5446 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor					6.3				Very slightly soluble (0.15 mg/mL at 23 °C)	1	No	3	2	No	6	0	78.09 Å2	55.51 Å3	150.83 m3·mol-1	4	No	No	0.00175 mg/mL	5.44	-5.5	13.53	6.23			
C33H35FN2O5	The registered total plasma clearance of atorvastatin is of 625 ml/min.5	The half-life of atorvastatin is 14 hours while the half-life of its metabolites can reach up to 30 hours.41,42	558.6398	CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1	Solid	The reported volume of distribution of atorvastatin is of 380 L.41,42					22164	39548	CHEMBL1487	54810	Drugs.com Drug Page		HMDB0005006	C06834	D07474	117	PDRhealth Drug Page	PA448500	60823	46506188	RxList Drug Page	1483793	DAP000553	Atorvastatin	ZINC000003920719	Caduet, Lipitor	Atorvastatin	Approved	DB01076	InChI=1S/C33H35FN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40)/t26-,27-/m1/s1	XUKUURHRXDUEBC-KAYWLYCHSA-N	4	Atorvastatin is an HMG-CoA reductase inhibitor used to lower lipid levels and reduce the risk of cardiovascular disease including myocardial infarction and stroke.	The reported LD50 of oral atorvastatin in mice is higher than 5000 mg/kg.MSDS In cases of overdose with atorvastatin, there is reported symptoms of complicated breathing, jaundice, liver damage, dark urine, muscle pain, and seizures.38 In case of overdose, symptomatic treatment is recommended and due to the high plasma protein binding, hemodialysis is not expected to generate significant improvement.LabelIn carcinogenic studies with high doses of atorvastatin, evidence of rhabdomyosarcoma, fibrosarcoma, liver adenoma, and liver carcinoma were observed.LabelIn fertility studies with high doses of atorvastatin, there were events of aplasia, aspermia, low testis and epididymal weight, decreased sperm motility, decreased spermatid head concentration and increased abnormal sperm.LabelAtorvastatin was shown to not be mutagenic in diverse mutagenic assays.Label	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.5686 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				722 ºC at 760 mmHg	6.36		176 °C	4.46	Practically insoluble	0	No	5	4	Yes	4	-1	111.79 Å2	59.45 Å3	158.2 m3·mol-1	12	No	No	0.00063 mg/mL	5.39	-6	4.31	-2.7			
C25H26FN5O3	Not Available	Not Available	463.504	CCCCN1C2=C(NC(CC3=CC=C(NC(C)=O)C=C3)=N2)C(=O)N(CC2=CC=CC=C2F)C1=O	Solid	Not Available					50133801		CHEMBL120708	394495						FTB			447371	46504933					ZINC000015804848		1-(2-Fluorobenzyl)-3-Butyl-8-(N-Acetyl-4-Aminobenzyl)-Xanthine	Experimental	DB02008	InChI=1S/C25H26FN5O3/c1-3-4-13-30-23-22(24(33)31(25(30)34)15-18-7-5-6-8-20(18)26)28-21(29-23)14-17-9-11-19(12-10-17)27-16(2)32/h5-12H,3-4,13-15H2,1-2H3,(H,27,32)(H,28,29)	JHSHXKJSPVHPCJ-UHFFFAOYSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.7661 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	4	2	Yes	4	0	98.4 Å2	48.18 Å3	127.66 m3·mol-1	8	Yes	No	0.0277 mg/mL	3.62	-4.2	7.86	-0.69			
C23H22ClNO2	Not Available	Not Available	379.879	CC1(C)CN2C(CC(O)=O)=C(C(=C2C1)C1=CC=CC=C1)C1=CC=C(Cl)C=C1	Solid	Not Available	P11712;!P10632;!P51589;!P35503	CYP2C9;!CYP2C8;!CYP2J2;!UGT1A3	1. Cytochrome P450 2C9;!2. Cytochrome P450 2C8;!3. Cytochrome P450 2J2;!4. UDP-glucuronosyltransferase 1-3		50038649		CHEMBL300982	117391						LCF			133021	175426859				Licofelone	ZINC000003805769		Licofelone	Investigational	DB04725	InChI=1S/C23H22ClNO2/c1-23(2)13-19-22(15-6-4-3-5-7-15)21(16-8-10-17(24)11-9-16)18(12-20(26)27)25(19)14-23/h3-11H,12-14H2,1-2H3,(H,26,27)	UAWXGRJVZSAUSZ-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.6966 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	2	1	No	4	-1	42.23 Å2	41.8 Å3	108.79 m3·mol-1	4	No	No	0.00111 mg/mL	5.72	-5.5	4.8				
C23H16N2O5	Not Available	Not Available	400.3835	OC(=O)CCN1C2=C(C=C(O)C=C2)C2=C1C=C(C1=C2C(=O)NC1=O)C1=CC=CC=C1	Solid	Not Available					50245344		CHEMBL462170	8153904						839			9978312	99443736					ZINC000016052180		3-(9-HYDROXY-1,3-DIOXO-4-PHENYL-2,3-DIHYDROPYRROLO[3,4-C]CARBAZOL-6(1H)-YL)PROPANOIC ACID	Experimental	DB07265	InChI=1S/C23H16N2O5/c26-13-6-7-16-15(10-13)19-17(25(16)9-8-18(27)28)11-14(12-4-2-1-3-5-12)20-21(19)23(30)24-22(20)29/h1-7,10-11,26H,8-9H2,(H,27,28)(H,24,29,30)	JDARUOOLJCFUOY-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.1344 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	3	No	5	-1	108.63 Å2	41.51 Å3	109.53 m3·mol-1	4	Yes	No	0.0172 mg/mL	3.09	-4.4	4.07	-5.6			
C27H30N2O4	Not Available	Not Available	446.5381	OC(=O)C1=CC=C2C(=C1)N(CC(=O)N1CCOCC1)C(=C2C1CCCCC1)C1=CC=CC=C1	Solid	Not Available					50162108		CHEMBL179532	3572069						CMF			4369534	99444041					ZINC000013609946		3-CYCLOHEXYL-1-(2-MORPHOLIN-4-YL-2-OXOETHYL)-2-PHENYL-1H-INDOLE-6-CARBOXYLIC ACID	Experimental	DB07570	InChI=1S/C27H30N2O4/c30-24(28-13-15-33-16-14-28)18-29-23-17-21(27(31)32)11-12-22(23)25(19-7-3-1-4-8-19)26(29)20-9-5-2-6-10-20/h2,5-6,9-12,17,19H,1,3-4,7-8,13-16,18H2,(H,31,32)	ZKEZEXYKYHYIMQ-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.2189 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	1	No	5	-1	71.77 Å2	49.78 Å3	127.28 m3·mol-1	5	Yes	No	0.00133 mg/mL	4.54	-5.5	3.62	-4	P26663	Not Available	1. Genome polyprotein
C40H33F3N4O3	Not Available	Not Available	674.724	CN(CC1=CC=CC=C1)C(=O)[C@@H](NC(=O)C1=CC2=C(C=CC(NC(=O)C3=CC=CC=C3C3=CC=C(C=C3)C(F)(F)F)=C2)N1C)C1=CC=CC=C1	Not Available	Not Available					50204367		CHEMBL410414	8093509					D03867							1592684		Dirlotapide	ZINC000003988502		Dirlotapide	Investigational, Vet approved	DB11399	InChI=1S/C40H33F3N4O3/c1-46(25-26-11-5-3-6-12-26)39(50)36(28-13-7-4-8-14-28)45-38(49)35-24-29-23-31(21-22-34(29)47(35)2)44-37(48)33-16-10-9-15-32(33)27-17-19-30(20-18-27)40(41,42)43/h3-24,36H,25H2,1-2H3,(H,44,48)(H,45,49)/t36-/m0/s1	TUOSYWCFRFNJBS-BHVANESWSA-N			Not Available	Small Molecule																																			0	No	4	2	Yes	6	0	86.93 Å2	69.99 Å3	189.73 m3·mol-1	10	No	No	9.05e-05 mg/mL	8.51	-6.9	8.92	0.85			
C21H20N2O5	Not Available	Not Available	380.4	CCC1=C(C(=O)C(N)=O)C2=C(OCC(O)=O)C=CC=C2N1CC1=CC=CC=C1	Not Available	Not Available					50055366		CHEMBL148674	137248						VRD			155815	347828241				Varespladib	ZINC000001543773		Varespladib	Investigational	DB11909	InChI=1S/C21H20N2O5/c1-2-14-19(20(26)21(22)27)18-15(9-6-10-16(18)28-12-17(24)25)23(14)11-13-7-4-3-5-8-13/h3-10H,2,11-12H2,1H3,(H2,22,27)(H,24,25)	BHLXTPHDSZUFHR-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	Yes	5	2	Yes	3	-1	111.62 Å2	39.03 Å3	102.9 m3·mol-1	8	Yes	No	0.00699 mg/mL	2.77	-4.7	3.63	-3.7			
C32H30F5N3O5	The oral clearance (CL/F) of elagolix is 123 L/hr for a 150 mg once daily regimen and 144 L/hr for a 200 mg twice daily regimen Label.	The terminal phase elimination half-life of elagolix is recorded as being 4 to 6 hours Label.	631.6	COC1=CC=CC(=C1F)C1=C(C)N(CC2=C(C=CC=C2F)C(F)(F)F)C(=O)N(C[C@H](NCCCC(O)=O)C2=CC=CC=C2)C1=O	Solid	The apparent volume of distribution at steady state (Vdss/F) of elagolix is reported to be 1674 for a 150 mg daily regimen and 881 for a 200 mg twice daily regimen Label.	BE0004866;!P10635;!P10632	;!CYP2D6;!CYP2C8	1. Cytochrome P450 3A Subfamily (Protein Group);!2. Cytochrome P450 2D6;!3. Cytochrome P450 2C8				CHEMBL1208155	9425680						F5O			11250647	347828301		2049846		Elagolix	ZINC000049888891	Oriahnn 28 Day Kit, Orilissa	Elagolix	Approved, Investigational	DB11979	InChI=1S/C32H30F5N3O5/c1-19-28(21-11-6-14-26(45-2)29(21)34)30(43)40(18-25(20-9-4-3-5-10-20)38-16-8-15-27(41)42)31(44)39(19)17-22-23(32(35,36)37)12-7-13-24(22)33/h3-7,9-14,25,38H,8,15-18H2,1-2H3,(H,41,42)/t25-/m0/s1	HEAUOKZIVMZVQL-VWLOTQADSA-N	4	Elagolix is a gonadotropin releasing hormone receptor antagonist used to treat moderate to severe pain in endometriosis.	In case of overdose, monitor the patient for any signs or symptoms of adverse reactions and initiate appropriate symptomatic treatment, as needed Label. Common adverse reactions of elagolix include hot flush, headache, nausea, insomnia, mood alterations, amenorrhea, depression, anxiety, arthralgia, bone loss, changes in menstrual bleeding patterns, suicidal ideation and behavior, exacerbation of existing mood disorders, and/or hepatic transaminase elevations Label.The recommended duration of use for elagolix is up to 24 months for the 150 mg once daily dose and up to six months for the 200 mg twice daily dose, as it causes a dose-dependent decrease in bone mineral density (BMD) Label. BMD loss is greater with increasing duration of use and may not be completely reversible after stopping treatment Label. For women with moderate hepatic impairment, the recommended dosage is 150 mg once daily for up to six months Label.	Small Molecule																																		<1 mg/mL	0	No	6	2	Yes	4	0	99.18 Å2	59.44 Å3	156.06 m3·mol-1	12	No	No	0.00243 mg/mL	3.14	-5.4	3.86	9.04	P30968	GNRHR	1. Gonadotropin-releasing hormone receptor
C24H19FN2O3	Not Available	Not Available	402.425	OC(=O)CN1C2=C(CN(CC2)C(=O)C2=CC=CC3=CC=CC=C23)C2=CC(F)=CC=C12	Not Available	Not Available					50434990		CHEMBL2386081	29738718									49843471	347828785				Setipiprant	ZINC000091291806		Setipiprant	Investigational	DB12562	InChI=1S/C24H19FN2O3/c25-16-8-9-21-19(12-16)20-13-26(11-10-22(20)27(21)14-23(28)29)24(30)18-7-3-5-15-4-1-2-6-17(15)18/h1-9,12H,10-11,13-14H2,(H,28,29)	IHAXLPDVOWLUOS-UHFFFAOYSA-N	3		Not Available	Small Molecule																																			1	Yes	3	1	No	5	-1	62.54 Å2	42.33 Å3	111.57 m3·mol-1	3	Yes	No	0.00289 mg/mL	3.66	-5.1	3.93	-1.3			
C22H21F3N2O4S	Not Available	Not Available	466.48	CC1=C(N(CCO)C=C1C(=O)NC1=CC=C(C=C1)S(C)(=O)=O)C1=C(C=CC=C1)C(F)(F)F	Not Available	Not Available					50398059		CHEMBL2181932	28666733						E6R								Esaxerenone	ZINC000043200720		Esaxerenone	Investigational	DB15207	InChI=1S/C22H21F3N2O4S/c1-14-18(21(29)26-15-7-9-16(10-8-15)32(2,30)31)13-27(11-12-28)20(14)17-5-3-4-6-19(17)22(23,24)25/h3-10,13,28H,11-12H2,1-2H3,(H,26,29)	NOSNHVJANRODGR-UHFFFAOYSA-N	3		Not Available	Small Molecule																																			1	Yes	4	2	Yes	3	0	88.4 Å2	45.47 Å3	117.57 m3·mol-1	6	Yes	No	0.00475 mg/mL	3.48	-5	14.97	-2.6			
C28H27FN6O2	Not Available	Not Available	498.562	CN1C(C)=CC(=C1C(=O)C(=O)NC1=CC=C(C=C1)N1CCN(CC1)C1=NC=C(F)C=N1)C1=CC=CC=C1	Not Available	Not Available								58828130																	Olorofim	Investigational	DB15245	InChI=1S/C28H27FN6O2/c1-19-16-24(20-6-4-3-5-7-20)25(33(19)2)26(36)27(37)32-22-8-10-23(11-9-22)34-12-14-35(15-13-34)28-30-17-21(29)18-31-28/h3-11,16-18H,12-15H2,1-2H3,(H,32,37)	SUFPWYYDCOKDLL-UHFFFAOYSA-N	1		Not Available	Small Molecule																																			1	No	6	1	Yes	5	0	83.36 Å2	52.99 Å3	144.16 m3·mol-1	6	Yes	No	0.0142 mg/mL	4.74	-4.6	12.29	2.66			
C31H29FN4O5	Not Available	Not Available	556.594	CN1N(C(=O)C(C(=O)NC2=CC(F)=C(OC3=CC=NC4=C3C=CC(OCC(C)(C)O)=C4)C=C2)=C1C)C1=CC=CC=C1	Not Available	Not Available					180270		CHEMBL3984441	61719564															ZINC000143426755		Ningetinib	Investigational	DB16256	InChI=1S/C31H29FN4O5/c1-19-28(30(38)36(35(19)4)21-8-6-5-7-9-21)29(37)34-20-10-13-27(24(32)16-20)41-26-14-15-33-25-17-22(11-12-23(25)26)40-18-31(2,3)39/h5-17,39H,18H2,1-4H3,(H,34,37)	VQYYQSZNRVQLIS-UHFFFAOYSA-N	1		Not Available	Small Molecule																																			1	No	6	2	Yes	5	0	104.23 Å2	58.81 Å3	152.96 m3·mol-1	8	No	No	0.00408 mg/mL	3.89	-5.1	12.96	5.59			
C33H38N4O6	13.3 L/h/m^2 [Dose of 125 mg/m^2, patients with solid tumours] 13.9 L/h/m^2 [Dose of 340 mg/m^2, patients with solid tumours]	The half life of irinotecan is about 6 - 12 hours. The terminal elimination half-life of the active metabolite, SN-38 is 10 - 20 hours.	586.678	CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12	Solid	The volume of distribution of terminal elimination phase is 110 L/m^2 when a dose of 125 mg/m^2 is given to patients with solid tumours. The volume of distribution of terminal elimination phase is 234 L/m^2 when a dose of 340 mg/m^2 is given to patients with solid tumours.					50128267	80630	CHEMBL481	54825	Drugs.com Drug Page		HMDB0014900	C16641	D08086	CP0		PA450085	60838	46505871	RxList Drug Page	51499	DAP001339	Irinotecan	ZINC000001612996	Camptosar, Onivyde	Irinotecan	Approved, Investigational	DB00762	InChI=1S/C33H38N4O6/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2/h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3/t33-/m0/s1	UWKQSNNFCGGAFS-XIFFEERXSA-N	4	Irinotecan is an antineoplastic enzyme inhibitor used to treat metastatic carcinoma of the colon or rectum.	Gastrointestinal complications, such as nausea, vomiting, abdominal cramping, diarrhea, and infection.	Small Molecule	http://smpdb.ca/view/SMP0000600?highlight[compounds][]=DB00762&highlight[proteins][]=DB00762;!http://smpdb.ca/view/SMP0000433?highlight[compounds][]=DB00762&highlight[proteins][]=DB00762	Irinotecan Metabolism Pathway;!Irinotecan Action Pathway		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.7960 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor					3.2		222-223 °C		Soluble	1	No	6	1	No	7	1	112.51 Å2	65.27 Å3	161.33 m3·mol-1	5	No	No	0.107 mg/mL	2.78	-3.7	11.71	9.47	Q969P6;!P11387	TOP1MT;!TOP1	1. DNA topoisomerase I, mitochondrial;!2. DNA topoisomerase 1
C27H41NO6	Not Available	Not Available	475.6175	[H][C@@]12CC[C@](O)(C(=O)COC(=O)CN(CC)CC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			50851	CHEMBL1201263	75860			HMDB0014907					PA164745515	84088	46509076			DAP001187	Hydrocortamate	ZINC000004213506		Hydrocortamate	Approved	DB00769	InChI=1S/C27H41NO6/c1-5-28(6-2)15-23(32)34-16-22(31)27(33)12-10-20-19-8-7-17-13-18(29)9-11-25(17,3)24(19)21(30)14-26(20,27)4/h13,19-21,24,30,33H,5-12,14-16H2,1-4H3/t19-,20-,21-,24+,25-,26-,27-/m0/s1	FWFVLWGEFDIZMJ-FOMYWIRZSA-N			Side effects include burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, miliaria.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.9454 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					1.2		162-163			1	No	6	2	Yes	4	0	104.14 Å2	53.53 Å3	129.48 m3·mol-1	8	Yes	No	0.0855 mg/mL	2.32	-3.8	12.61	6.99	P04150	NR3C1	1. Glucocorticoid receptor
C29H35NO2	Not Available	18 hours	429.5937	[H][C@@]12CC[C@@](O)(C#CC)[C@@]1(C)C[C@H](C1=CC=C(C=C1)N(C)C)C1=C3CCC(=O)C=C3CC[C@@]21[H]	Solid	Not Available					50072024	50692	CHEMBL1276308	49889	Drugs.com Drug Page	GtP Drug Page	HMDB0014972	C07652	D00585	486		PA450500	55245	46505795	RxList Drug Page	6964	DAP000090	Mifepristone	ZINC000003831128	Korlym, Mifegymiso	Mifepristone	Approved, Investigational	DB00834	InChI=1S/C29H35NO2/c1-5-15-29(32)16-14-26-24-12-8-20-17-22(31)11-13-23(20)27(24)25(18-28(26,29)2)19-6-9-21(10-7-19)30(3)4/h6-7,9-10,17,24-26,32H,8,11-14,16,18H2,1-4H3/t24-,25+,26-,28-,29-/m0/s1	VKHAHZOOUSRJNA-GCNJZUOMSA-N	4	Mifepristone is a cortisol receptor blocker used to treat Cushing's syndrome, and to terminate pregnancies up to 70 days gestation.	Nearly all of the women who receive mifepristone will report adverse reactions, and many can be expected to report more than one such reaction. About 90% of patients report adverse reactions following administration of misoprostol on day three of the treatment procedure. Side effects include more heavy bleeding than a heavy menstrual period, abdominal pain, uterine cramping, nausea, vomiting, and diarrhea.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.7705 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					4.5		191-196 °C		Poorly soluble	1	No	3	1	No	5	0	40.54 Å2	50.69 Å3	132.58 m3·mol-1	3	No	No	0.00336 mg/mL	5.13	-5.1	12.87	4.89			
C37H55ClN8O5	Not Available	Not Available	727.336	[H]N([C@H]1[C@@H](C)CC[C@H]1O)C(=O)[C@@H](C[C@H](O)CN1CCN(C[C@H]1C(=O)N([H])C(C)(C)C)C(=O)C1=CN=C(N2CCN(C)CC2)C(Cl)=N1)CC1=CC=CC=C1	Solid	Not Available								392588						3IN			444756	46508413					ZINC000024447263		(2S)-1-[(2S,4R)-4-Benzyl-2-hydroxy-5-{[(1S,2R,5S)-2-hydroxy-5-methylcyclopentyl]amino}-5-oxopentyl]-4-{[6-chloro-5-(4-methyl-1-piperazinyl)-2-pyrazinyl]carbonyl}-N-(2-methyl-2-propanyl)-2-piperazineca rboxamide	Experimental	DB02785	InChI=1S/C37H55ClN8O5/c1-24-11-12-30(48)31(24)41-34(49)26(19-25-9-7-6-8-10-25)20-27(47)22-45-17-18-46(23-29(45)35(50)42-37(2,3)4)36(51)28-21-39-33(32(38)40-28)44-15-13-43(5)14-16-44/h6-10,21,24,26-27,29-31,47-48H,11-20,22-23H2,1-5H3,(H,41,49)(H,42,50)/t24-,26+,27-,29-,30+,31-/m0/s1	SQZXWXXIPWXBCL-CYTJBAGBSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.7992 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										0	No	10	4	Yes	5	0	154.47 Å2	80.36 Å3	199.04 m3·mol-1	12	No	No	0.104 mg/mL	2.16	-3.8	14.14	6.42	P03366	gag-pol	1. Gag-Pol polyprotein
C31H39NO5	Not Available	Not Available	505.655	[H][C@@]12CC[C@](OC(C)=O)(C(=O)COC)[C@@]1(C)C[C@H](C1=CC=C(C=C1)N(C)C)C1=C3CCC(=O)C=C3CC[C@@]21[H]	Solid	Not Available							CHEMBL2105694	7981950										347910049				Proellex			Telapristone acetate	Investigational	DB05253	InChI=1S/C31H39NO5/c1-19(33)37-31(28(35)18-36-5)15-14-27-25-12-8-21-16-23(34)11-13-24(21)29(25)26(17-30(27,31)2)20-6-9-22(10-7-20)32(3)4/h6-7,9-10,16,25-27H,8,11-15,17-18H2,1-5H3/t25-,26+,27-,30-,31-/m0/s1	JVBGZFRPTRKSBB-MJBQOYBXSA-N	2		Not Available	Small Molecule																																			1	No	5	0	Yes	5	0	72.91 Å2	56.9 Å3	144.89 m3·mol-1	7	No	No	0.00556 mg/mL	4.45	-5	18.42	4.89	P06401	PGR	1. Progesterone receptor
C24H30FN7O	Not Available	Not Available	451.55	[H][C@@]12C[C@@]([H])(C=C1)[C@@H]([C@@H]2NC1=C(F)C=NC(NC2=CC=C(N3CCN(C)CC3)C(C)=C2)=N1)C(N)=O	Solid	Not Available					50389967		CHEMBL1614709	9744737																	Cenisertib	Investigational	DB06347	InChI=1S/C24H30FN7O/c1-14-11-17(5-6-19(14)32-9-7-31(2)8-10-32)28-24-27-13-18(25)23(30-24)29-21-16-4-3-15(12-16)20(21)22(26)33/h3-6,11,13,15-16,20-21H,7-10,12H2,1-2H3,(H2,26,33)(H2,27,28,29,30)/t15-,16+,20+,21-/m1/s1	KSOVGRCOLZZTPF-QMKUDKLTSA-N	1		Not Available	Small Molecule																																			1	No	7	3	Yes	5	1	99.41 Å2	48.42 Å3	130.05 m3·mol-1	6	Yes	No	0.0752 mg/mL	2.6	-3.8	14.79	7.86	O14965	AURKA	1. Aurora kinase A
C28H36N4O2S	3902 mL/min	40 mg dose= 18 hours120 mg - 160 mg dose = 29-37 hours	492.676	[H][C@@]12[C@H]3CC[C@H](C3)[C@]1([H])C(=O)N(C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1=NSC3=CC=CC=C13)C2=O	Solid	6173 L	P08684	CYP3A4	1. Cytochrome P450 3A4		85222	70735	CHEMBL1237021	184739	Drugs.com Drug Page				D04820			PA166129557	213046	175427100	RxList Drug Page	1040028		Lurasidone	ZINC000003927822	Latuda	Lurasidone	Approved, Investigational	DB08815	InChI=1S/C28H36N4O2S/c33-27-24-18-9-10-19(15-18)25(24)28(34)32(27)17-21-6-2-1-5-20(21)16-30-11-13-31(14-12-30)26-22-7-3-4-8-23(22)35-29-26/h3-4,7-8,18-21,24-25H,1-2,5-6,9-17H2/t18-,19+,20-,21-,24+,25-/m0/s1	PQXKDMSYBGKCJA-CVTJIBDQSA-N	4	Lurasidone is an atypical antipsychotic used to treat schizophrenia and depressive episodes associated with bipolar I disorder.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.4051 LD50, mol/kg	Inhibitor	Weak inhibitor	Inhibitor										1	No	5	0	No	7	1	56.75 Å2	56.26 Å3	139.33 m3·mol-1	5	Yes	No	0.00789 mg/mL	4.56	-4.8		8.5	P14416;!P28223;!P34969;!P08908;!P18825;!P08913	DRD2;!HTR2A;!HTR7;!HTR1A;!ADRA2C;!ADRA2A	1. Dopamine D2 receptor;!2. 5-hydroxytryptamine receptor 2A;!3. 5-hydroxytryptamine receptor 7;!4. 5-hydroxytryptamine receptor 1A;!5. Alpha-2C adrenergic receptor;!6. Alpha-2A adrenergic receptor
C28H35NO3	Mean oral clearance, single oral dose, healthy subject (CL/F) = 76.8 ± 64.0L/h	Mean elimination half-life, single oral dose, healthy subject = 32.4 ± 6.3 hours	433.592	CN(C)C1=CC=C(C=C1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12	Solid	Not Available	P08684;!P05177	CYP3A4;!CYP1A2	1. Cytochrome P450 3A4;!2. Cytochrome P450 1A2			71025	CHEMBL2103846	19349271	Drugs.com Drug Page				D09567				13559281	310264902	RxList Drug Page	1005921		Ulipristal_acetate	ZINC000034089131	Ella, Ellaone, Esmya	Ulipristal	Approved	DB08867	InChI=1S/C28H35NO3/c1-17(30)28(32)14-13-25-23-11-7-19-15-21(31)10-12-22(19)26(23)24(16-27(25,28)2)18-5-8-20(9-6-18)29(3)4/h5-6,8-9,15,23-25,32H,7,10-14,16H2,1-4H3/t23-,24+,25-,27-,28-/m0/s1	HKDLNTKNLJPAIY-WKWWZUSTSA-N	4	Ulipristal is a selective progesterone receptor modulator used for emergency contraception after unprotected intercourse or in a situation where a planned method of contraception has failed.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.6728 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	1	No	5	0	57.61 Å2	49.66 Å3	129.29 m3·mol-1	3	Yes	No	0.00943 mg/mL	4.18	-4.7	12.7	4.89			
C34H50N8O3	Not Available	Not Available	618.8126	CC[C@H]1N(C(C)C)C2=NC(NC3=CC=C(C=C3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)=NC=C2N(C)C1=O	Not Available	Not Available					50402023		CHEMBL1233528	26327706						IBI			10461508	347828371				Volasertib			Volasertib	Investigational	DB12062	InChI=1S/C34H50N8O3/c1-6-28-33(44)39(4)29-20-35-34(38-31(29)42(28)22(2)3)37-27-14-9-24(19-30(27)45-5)32(43)36-25-10-12-26(13-11-25)41-17-15-40(16-18-41)21-23-7-8-23/h9,14,19-20,22-23,25-26,28H,6-8,10-13,15-18,21H2,1-5H3,(H,36,43)(H,35,37,38)/t25-,26-,28-/m1/s1	SXNJFOWDRLKDSF-STROYTFGSA-N	3		Not Available	Small Molecule																																			1	No	9	2	Yes	6	1	106.17 Å2	72.64 Å3	178.34 m3·mol-1	10	No	No	0.0664 mg/mL	4.2	-4	12.25	8.7			
C44H67N5O4	Clearance values of 53.6 L/h and 56.1 L/h have been reported.7	The elimination half life of ibrexafungerp is approximately 20 hours.7,9	730.051	[H][C@]12CC[C@@]3([H])[C@@]4(C)COC[C@@]3(C[C@H]([C@@H]4OC[C@](C)(N)C(C)(C)C)N3N=CN=C3C3=CC=NC=C3)C1=CC[C@@]1(C)[C@H](C(O)=O)[C@](C)(CC[C@]21C)[C@H](C)C(C)C	Solid	The volume of distribution at steady state is approximately 600 L.9	P08684;!BE0009758;!BE0009567;!P10632	CYP3A4;!;!;!CYP2C8	1. Cytochrome P450 3A4;!2. UDP-glucuronosyltransferases (UGTs) (Protein Group);!3. Sulfotransferase (Protein Group);!4. Cytochrome P450 2C8				CHEMBL4297513	64873335									46871657	347828709		2560213		Ibrexafungerp		Brexafemme	Ibrexafungerp	Approved, Investigational	DB12471	InChI=1S/C44H67N5O4/c1-27(2)28(3)39(7)18-19-41(9)30-12-13-33-40(8)23-52-25-44(33,31(30)14-17-42(41,10)34(39)37(50)51)22-32(35(40)53-24-43(11,45)38(4,5)6)49-36(47-26-48-49)29-15-20-46-21-16-29/h14-16,20-21,26-28,30,32-35H,12-13,17-19,22-25,45H2,1-11H3,(H,50,51)/t28-,30+,32-,33+,34-,35+,39-,40-,41-,42+,43+,44+/m1/s1	BODYFEUFKHPRCK-ZCZMVWJSSA-N	3	Ibrexafungerp is a triterpene antifungal indicated in the treatment of vulvovaginal candidiasis in post-menarchal patients.	Data regarding overdoses of ibrexafungerp are not readily available, however patients did take higher than recommended doses in clinical trials without significant adverse effects.9 Patients experiencing an overdose of ibrexafungerp may experience and increased risk and severity of adverse effects. Patients should be treated with symptomatic and supportive measures.9	Small Molecule																																	2.4, 5.5, 9.0		1	No	8	2	Yes	7	0	125.38 Å2	84.64 Å3	230.85 m3·mol-1	9	No	No	0.000346 mg/mL	4.9	-6.3	4.39	9.75	P40989;!P06780	GSC2;!RHO1	1. 1,3-beta-glucan synthase component GSC2;!2. GTP-binding protein RHO1
C25H34F3N5O2	Not Available	Not Available	493.575	CC(C)(N1CCN(CC1)C1=NC=C(C=C1)C(F)(F)F)C(=O)N[C@H]1C2CC3CC1C[C@@](C3)(C2)C(N)=O	Not Available	Not Available								58827790									11670435	347828734							ABT-384	Investigational	DB12501	InChI=1S/C25H34F3N5O2/c1-23(2,33-7-5-32(6-8-33)19-4-3-18(14-30-19)25(26,27)28)22(35)31-20-16-9-15-10-17(20)13-24(11-15,12-16)21(29)34/h3-4,14-17,20H,5-13H2,1-2H3,(H2,29,34)(H,31,35)/t15?,16?,17?,20-,24+	CLHMYBJIOZXCEX-MALZWFGSSA-N	2		Not Available	Small Molecule																																			1	No	5	2	Yes	5	0	91.56 Å2	50.12 Å3	126.14 m3·mol-1	6	Yes	No	0.0482 mg/mL	2.94	-4	15.1	6.46			
C29H39NO3	Not Available	Not Available	449.635	CN(C)C1=CC=C(C=C1)[C@H]1C[C@]2(C)[C@@H](CC[C@]2(O)CCCO)[C@@H]2CCC3=CC(=O)CCC3=C12	Not Available	Not Available					50366558		CHEMBL1908373	4470982									5311505	347828846				Onapristone	ZINC000003831947		Onapristone	Investigational	DB12637	InChI=1S/C29H39NO3/c1-28-18-25(19-5-8-21(9-6-19)30(2)3)27-23-12-10-22(32)17-20(23)7-11-24(27)26(28)13-15-29(28,33)14-4-16-31/h5-6,8-9,17,24-26,31,33H,4,7,10-16,18H2,1-3H3/t24-,25+,26-,28+,29+/m0/s1	IEXUMDBQLIVNHZ-YOUGDJEHSA-N			Not Available	Small Molecule																																			1	No	4	2	No	5	0	60.77 Å2	52.99 Å3	135.3 m3·mol-1	5	Yes	No	0.00759 mg/mL	3.96	-4.8	14.34	4.89	P04150;!Q6QNK2	NR3C1;!ADGRD1	1. Glucocorticoid receptor;!2. Probable G-protein coupled receptor 133
C35H45Cl2NO6	Not Available	Not Available	646.65	[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCCC3=CC=C(C=C3)N(CCCl)CCCl)[C@@]1(C)C[C@]([H])(O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Not Available	Not Available						82524	CHEMBL2103751	31708				C19512					34457	347828998		8637		Prednimustine	ZINC000004214173		Prednimustine	Investigational	DB12832	InChI=1S/C35H45Cl2NO6/c1-33-14-12-26(39)20-24(33)8-11-27-28-13-15-35(43,34(28,2)21-29(40)32(27)33)30(41)22-44-31(42)5-3-4-23-6-9-25(10-7-23)38(18-16-36)19-17-37/h6-7,9-10,12,14,20,27-29,32,40,43H,3-5,8,11,13,15-19,21-22H2,1-2H3/t27-,28-,29-,32+,33-,34-,35-/m0/s1	HFVNWDWLWUCIHC-GUPDPFMOSA-N			Not Available	Small Molecule																																			0	No	6	2	Yes	5	0	104.14 Å2	69.68 Å3	174.68 m3·mol-1	13	No	No	0.000642 mg/mL	5.87	-6	12.61	1.72			
C21H29N5O2	Not Available	Not Available	383.496	[H][C@]12CC[C@]([H])(C1)[C@]1([H])C(=O)N(CCCCN3CCN(CC3)C3=NC=CC=N3)C(=O)[C@]21[H]	Not Available	Not Available					50099385	145673	CHEMBL274047	82421									91273	347828999				Tandospirone	ZINC000001545034		Tandospirone	Investigational	DB12833	InChI=1S/C21H29N5O2/c27-19-17-15-4-5-16(14-15)18(17)20(28)26(19)9-2-1-8-24-10-12-25(13-11-24)21-22-6-3-7-23-21/h3,6-7,15-18H,1-2,4-5,8-14H2/t15-,16+,17+,18-	CEIJFEGBUDEYSX-FZDBZEDMSA-N	4		Not Available	Small Molecule																																			1	Yes	6	0	Yes	5	1	69.64 Å2	42.98 Å3	107.11 m3·mol-1	6	Yes	No	1.1 mg/mL	1.5	-2.5		7.62			
C38H52N6O2	Not Available	Not Available	624.874	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@H]1C(=O)CN1CCN(CC1)C1=CC(=NC(=N1)N1CCCC1)N1CCCC1	Not Available	Not Available						135853	CHEMBL1630578	94673									104903	347829179		72467		Tirilazad	ZINC000043133316		Tirilazad	Investigational	DB13050	InChI=1S/C38H52N6O2/c1-26-22-31-29-9-8-27-23-28(45)10-12-37(27,2)30(29)11-13-38(31,3)35(26)32(46)25-41-18-20-43(21-19-41)34-24-33(42-14-4-5-15-42)39-36(40-34)44-16-6-7-17-44/h10-12,23-24,26,29,31,35H,4-9,13-22,25H2,1-3H3/t26-,29-,31+,35-,37+,38+/m1/s1	RBKASMJPSJDQKY-RBFSKHHSSA-N	3		Not Available	Small Molecule																																			0	No	8	0	Yes	8	0	72.88 Å2	73.65 Å3	190.35 m3·mol-1	6	No	No	0.0773 mg/mL	6.63	-3.9	18.26	6.59			
C45H56N6O14S	Not Available	Not Available	937.03	[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)COC1=CC=CC=C1)C(O)=O.[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(=O)NCN1CCN(CCO)CC1)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O	Not Available	Not Available						75258	CHEMBL3833378	12977481					D07233									Penimepicycline			Penimepicycline	Experimental	DB13264	InChI=1S/C29H38N4O9.C16H18N2O5S/c1-28(41)15-5-4-6-18(35)19(15)23(36)20-16(28)13-17-22(31(2)3)24(37)21(26(39)29(17,42)25(20)38)27(40)30-14-33-9-7-32(8-10-33)11-12-34;1-16(2)12(15(21)22)18-13(20)11(14(18)24-16)17-10(19)8-23-9-6-4-3-5-7-9/h4-6,16-17,22,34-35,37-38,41-42H,7-14H2,1-3H3,(H,30,40);3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22)/t16-,17-,22-,28+,29-;11-,12+,14-/m01/s1	MEGKRPMNPGTIIG-VNYBMUHKSA-N			Not Available	Small Molecule																																			0	No	12	7	Yes	8	-1	194.34 Å2	61.87 Å3	154.26 m3·mol-1	11	No	No	8.04 mg/mL	-4.5	-1.9	3.34	9.27			
C57H65F5N10O8	Not Available	The elimination half life (t1/2) is approximately 13 hours Label.	1113.201	CO[C@H](C)[C@H](NC(=O)OC)C(=O)N1CCC[C@H]1C1=NC2=C(N1)C=C(F)C(=C2)[C@H]1CC[C@@H](N1C1=CC(F)=C(N2CCC(CC2)C2=CC=C(F)C=C2)C(F)=C1)C1=CC2=C(NC(=N2)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)OC)[C@@H](C)OC)C=C1F	Solid	Not Available	BE0004866;!P22309	;!UGT1A1	1. Cytochrome P450 3A Subfamily (Protein Group);!2. UDP-glucuronosyltransferase 1-1				CHEMBL3545123	35013016									58031952	347829329		1940636		Pibrentasvir		Maviret, Mavyret	Pibrentasvir	Approved, Investigational	DB13878	InChI=1S/C57H65F5N10O8/c1-29(77-3)49(67-56(75)79-5)54(73)70-19-7-9-47(70)52-63-41-25-35(37(59)27-43(41)65-52)45-15-16-46(72(45)34-23-39(61)51(40(62)24-34)69-21-17-32(18-22-69)31-11-13-33(58)14-12-31)36-26-42-44(28-38(36)60)66-53(64-42)48-10-8-20-71(48)55(74)50(30(2)78-4)68-57(76)80-6/h11-14,23-30,32,45-50H,7-10,15-22H2,1-6H3,(H,63,65)(H,64,66)(H,67,75)(H,68,76)/t29-,30-,45-,46-,47+,48+,49+,50+/m1/s1	VJYSBPDEJWLKKJ-NLIMODCCSA-N	4	Pibrentasvir is a Hepatitis C NS5A inhibitor used to treat Hepatitis C.	Pibrentasvir is not shown to be genotoxic according to in vitro or in vivo studies. It also shows to have no effect on mating, female or male fertility, or early embryonic development in rodent studies. Carcinogenicity studies with pibrentasvir have not been conducted Label.	Small Molecule																																		<0.1 mg/mL	0	No	10	4	Yes	10	0	199.58 Å2	113.13 Å3	284.83 m3·mol-1	17	No	No	0.00557 mg/mL	7.63	-5.3	10.66	5.3	Q5L478	NS5A	1. Nonstructural protein 5A
C28H39N6O8P	Not Available	Not Available	618.628	CCCCOC(=O)N1CCN(CC1)C(=O)[C@H](CP(O)(O)=O)NC(=O)C1=CC(=NC(=N1)C1=CC=CC=C1)N1CC[C@@H](C1)OC	Not Available	Not Available								75531283																	Selatogrel	Investigational	DB15163	InChI=1S/C28H39N6O8P/c1-3-4-16-42-28(37)33-14-12-32(13-15-33)27(36)23(19-43(38,39)40)30-26(35)22-17-24(34-11-10-21(18-34)41-2)31-25(29-22)20-8-6-5-7-9-20/h5-9,17,21,23H,3-4,10-16,18-19H2,1-2H3,(H,30,35)(H2,38,39,40)/t21-,23-/m0/s1	FYXHWMQPCJOJCH-GMAHTHKFSA-N	2		Not Available	Small Molecule																																			0	No	10	3	Yes	4	-1	174.73 Å2	63.93 Å3	168.69 m3·mol-1	12	No	No	0.309 mg/mL	-0.52	-3.3	1.77	3.68	Q9H244	P2RY12	1. P2Y purinoceptor 12
C42H62N2O4S	Not Available	Not Available	691.03	CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC=C(C6=CC=C(C=C6)C(O)=O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)NCCN1CCS(=O)(=O)CC1	Not Available	Not Available							CHEMBL3827379	58922159														BMS-955176	ZINC000653825436		BMS-955176	Investigational	DB15193	InChI=1S/C42H62N2O4S/c1-28(2)31-14-19-42(43-22-23-44-24-26-49(47,48)27-25-44)21-20-40(6)33(36(31)42)12-13-35-39(5)17-15-32(29-8-10-30(11-9-29)37(45)46)38(3,4)34(39)16-18-41(35,40)7/h8-11,15,31,33-36,43H,1,12-14,16-27H2,2-7H3,(H,45,46)/t31-,33+,34-,35+,36+,39-,40+,41+,42-/m0/s1	XDMUFNNPLXHNKA-ZTESCHFWSA-N	2		Not Available	Small Molecule																																			1	No	6	2	Yes	7	0	86.71 Å2	81.48 Å3	199.33 m3·mol-1	7	No	No	8.57e-05 mg/mL	4.49	-6.9	4.1	10.72			
C27H34ClN5O3	Not Available	Not Available	512.05	CN(C)C(=O)C1=CC(NC(=O)[C@H]2CCC(=O)N2C2CCN(CC3=CC=C(Cl)C(C)=C3)CC2)=NC(C)=C1	Not Available	Not Available					123072		CHEMBL3670800	58893108															ZINC000068247095		ALK-4290	Investigational	DB15269	InChI=1S/C27H34ClN5O3/c1-17-13-19(5-6-22(17)28)16-32-11-9-21(10-12-32)33-23(7-8-25(33)34)26(35)30-24-15-20(14-18(2)29-24)27(36)31(3)4/h5-6,13-15,21,23H,7-12,16H2,1-4H3,(H,29,30,35)/t23-/m1/s1	DWKNOLCXIFYNFV-HSZRJFAPSA-N	2		Not Available	Small Molecule																																			1	No	5	1	Yes	4	1	85.85 Å2	54.48 Å3	142.79 m3·mol-1	6	No	No	0.104 mg/mL	2.44	-3.7	11.69	7.71			
C30H33FN8O2S	Not Available	Not Available	588.71	CCC1=C(N(C)C2=NC(=C(S2)C#N)C2=CC=C(F)C=C2)N2C=C(C=C(C)C2=N1)N1CCN(CC(=O)N2CC(O)C2)CC1	Not Available	Not Available					50187686		CHEMBL3828074	58828502						7NB											Ziritaxestat	Investigational	DB15403	InChI=1S/C30H33FN8O2S/c1-4-24-29(35(3)30-34-27(25(14-32)42-30)20-5-7-21(31)8-6-20)39-15-22(13-19(2)28(39)33-24)37-11-9-36(10-12-37)18-26(41)38-16-23(40)17-38/h5-8,13,15,23,40H,4,9-12,16-18H2,1-3H3	REQQVBGILUTQNN-UHFFFAOYSA-N	2		Not Available	Small Molecule																																			1	No	8	1	Yes	6	1	104.24 Å2	63.81 Å3	160.17 m3·mol-1	7	No	No	0.0324 mg/mL	3.64	-4.3	14.76	7.85			
C30H39NO2	Not Available	Not Available	445.647	[H][C@@]12CC[C@@]3(CCCO3)[C@@]1(C)C[C@H](C1=CC=C(C=C1)N(C)C)C1=C3CCC(=O)C=C3[C@H](C)C[C@@]21[H]	Not Available	Not Available							CHEMBL460258	143897															ZINC000003918217		ORG-31710	Experimental	DB15585	InChI=1S/C30H39NO2/c1-19-16-25-27-12-14-30(13-5-15-33-30)29(27,2)18-26(20-6-8-21(9-7-20)31(3)4)28(25)23-11-10-22(32)17-24(19)23/h6-9,17,19,25-27H,5,10-16,18H2,1-4H3/t19-,25+,26-,27+,29+,30+/m1/s1	HFDGABTZPISMDD-IEVXGSBISA-N			Not Available	Small Molecule																																			1	No	3	0	No	6	0	29.54 Å2	52.91 Å3	136.34 m3·mol-1	2	No	Yes	0.00101 mg/mL	5.4	-5.6	18.37	4.89			
C26H34N8O	Not Available	Not Available	474.613	CC(C)N1CCN(CC1)C1=CC=C(NC2=NC=C3C=C4N(C3=N2)C2(CCCCC2)CNC4=O)N=C1	Not Available	Not Available					253941		CHEMBL3904602	68007293																	Lerociclib	Investigational	DB16218	InChI=1S/C26H34N8O/c1-18(2)32-10-12-33(13-11-32)20-6-7-22(27-16-20)30-25-28-15-19-14-21-24(35)29-17-26(8-4-3-5-9-26)34(21)23(19)31-25/h6-7,14-16,18H,3-5,8-13,17H2,1-2H3,(H,29,35)(H,27,28,30,31)	YPJRHEKCFKOVRT-UHFFFAOYSA-N	1		Not Available	Small Molecule																																			1	No	7	2	No	6	1	91.21 Å2	54.61 Å3	137.68 m3·mol-1	4	Yes	No	0.134 mg/mL	3.51	-3.6	11.59	8.19			
C27H34FN5O2	Not Available	Not Available	479.6	[H][C@@]12CC[C@H](C(=O)NCC3=NC4=C(N3)C=CC=N4)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])N(C)C(=O)C(F)=C[C@]12C	Not Available	Not Available							CHEMBL3221237	10125035														MK-0773	ZINC000034272162		MK-0773	Investigational	DB16244	InChI=1S/C27H34FN5O2/c1-26-11-10-17-15(6-9-21-27(17,2)13-19(28)25(35)33(21)3)16(26)7-8-18(26)24(34)30-14-22-31-20-5-4-12-29-23(20)32-22/h4-5,12-13,15-18,21H,6-11,14H2,1-3H3,(H,30,34)(H,29,31,32)/t15-,16-,17-,18+,21+,26-,27+/m0/s1	GBEUKTWTUSPHEE-JWJWXJQQSA-N	2		Not Available	Small Molecule																																			1	No	4	2	No	6	0	90.98 Å2	52.31 Å3	131.76 m3·mol-1	3	Yes	No	0.0079 mg/mL	2.36	-4.8	9.84	2.82			
C19H20N2O4S	Not Available	Not Available	372.438	[H][C@@]1(CN(CC2=CC=CC=C2)C(=O)CO1)C1=CC2=C(C=C1)N(C)S(=O)(=O)C2	Solid	Not Available								395591						CP8			448940	46507727							CP-271485	Experimental	DB02118	InChI=1S/C19H20N2O4S/c1-20-17-8-7-15(9-16(17)13-26(20,23)24)18-11-21(19(22)12-25-18)10-14-5-3-2-4-6-14/h2-9,18H,10-13H2,1H3/t18-/m1/s1	CIUMOGWIMXNXSQ-GOSISDBHSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.5831 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	4	0	No	4	0	66.92 Å2	38.41 Å3	97.9 m3·mol-1	3	Yes	No	0.0892 mg/mL	1.08	-3.6	11.55	-4.2	P39900	MMP12	1. Macrophage metalloelastase
C33H33N3O6	Not Available	Not Available	567.6316	CC(=O)N\C(=C/C1=CC=C(CC(O)=O)C(C=O)=C1)C(=O)N[C@H]1CCCCN(CC2=CC=C(C=C2)C2=CC=CC=C2)C1=O	Solid	Not Available					14698		CHEMBL356002	4449905						821			5287555	46504640					ZINC000014880609		2-[4-[(Z)-2-Acetamido-3-oxo-3-[[(3S)-2-oxo-1-[(4-phenylphenyl)methyl]azepan-3-yl]amino]prop-1-enyl]-2-formylphenyl]acetic acid	Experimental	DB03104	InChI=1S/C33H33N3O6/c1-22(38)34-30(18-24-12-15-27(19-31(39)40)28(17-24)21-37)32(41)35-29-9-5-6-16-36(33(29)42)20-23-10-13-26(14-11-23)25-7-3-2-4-8-25/h2-4,7-8,10-15,17-18,21,29H,5-6,9,16,19-20H2,1H3,(H,34,38)(H,35,41)(H,39,40)/b30-18-/t29-/m0/s1	NKMPOVPTYDXGEC-MNRBYUMSSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.3759 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	No	6	3	Yes	4	-1	132.88 Å2	62.12 Å3	160.08 m3·mol-1	10	No	No	0.000515 mg/mL	3.12	-6	3.71	-0.78	P12931	SRC	1. Proto-oncogene tyrosine-protein kinase Src
C24H18Cl2F3NO3	Not Available	Not Available	496.306	[H][C@@](CC1=CC=CC=C1)(N(CC1=CC(=CC=C1)C(F)(F)F)C(=O)C1=C(Cl)C=C(Cl)C=C1)C(O)=O	Solid	Not Available					50126661		CHEMBL24547	394492						153			447368	46506684					ZINC000001554205		(2s)-2-[(2,4-Dichloro-Benzoyl)-(3-Trifluoromethyl-Benzyl)-Amino]-3-Phenyl-Propionic Acid	Experimental	DB03605	InChI=1S/C24H18Cl2F3NO3/c25-18-9-10-19(20(26)13-18)22(31)30(14-16-7-4-8-17(11-16)24(27,28)29)21(23(32)33)12-15-5-2-1-3-6-15/h1-11,13,21H,12,14H2,(H,32,33)/t21-/m0/s1	LAJJKGIZTCCOHY-NRFANRHFSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.4603 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	3	1	Yes	3	-1	57.61 Å2	44.21 Å3	120.32 m3·mol-1	8	No	No	0.000379 mg/mL	6.78	-6.1	3.59	-2	P26663	Not Available	1. Genome polyprotein
C31H25F3N2O4	Not Available	Not Available	546.546	COC1=CC=CC(C(=O)NC2=CC3=C(CN(CC3)C(=O)OC3=CC=CC=C3)C=C2)=C1C1=CC=C(C=C1)C(F)(F)F	Solid	Not Available								58540436															ZINC000072316409		SLx-4090	Investigational	DB05678	InChI=1S/C31H25F3N2O4/c1-39-27-9-5-8-26(28(27)20-10-13-23(14-11-20)31(32,33)34)29(37)35-24-15-12-22-19-36(17-16-21(22)18-24)30(38)40-25-6-3-2-4-7-25/h2-15,18H,16-17,19H2,1H3,(H,35,37)	AZUIUVJESCFSLJ-UHFFFAOYSA-N	2		Not Available	Small Molecule																																			0	No	3	1	Yes	5	0	67.87 Å2	55.02 Å3	146.69 m3·mol-1	7	No	No	0.000197 mg/mL	6.92	-6.4	15.11	-3.8	P55157	MTTP	1. Microsomal triglyceride transfer protein large subunit
C26H25F9N2O4	Not Available	Not Available	600.4733	CCOC(=O)N1[C@H](CC)C[C@H](N(CC2=CC(=CC(=C2)C(F)(F)F)C(F)(F)F)C(=O)OC)C2=C1C=CC(=C2)C(F)(F)F	Solid	Not Available	P19099	CYP11B2	1. Cytochrome P450 11B2, mitochondrial		50312718	49203	CHEMBL479527	140123						0RP			159325					Torcetrapib	ZINC000008214714		Torcetrapib	Investigational	DB06281	InChI=1S/C26H25F9N2O4/c1-4-18-12-21(19-11-15(24(27,28)29)6-7-20(19)37(18)23(39)41-5-2)36(22(38)40-3)13-14-8-16(25(30,31)32)10-17(9-14)26(33,34)35/h6-11,18,21H,4-5,12-13H2,1-3H3/t18-,21+/m1/s1	CMSGWTNRGKRWGS-NQIIRXRSSA-N	3		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.7449 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										0	No	3	0	Yes	3	0	59.08 Å2	50.67 Å3	128.89 m3·mol-1	10	No	No	0.00589 mg/mL	7.08	-5		-1.7			
C22H15NO6	Not Available	Not Available	389.3576	[H][C@](CC1=CC=CC2=CC=CC=C12)(N1C(=O)C2=CC=C(C=C2C1=O)C(O)=O)C(O)=O	Solid	Not Available					41850	92659	CHEMBL405886	23317723						23C			16752640	99443393							2-[(1R)-1-carboxy-2-naphthalen-1-ylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindole-5-carboxylic acid	Experimental	DB06922	InChI=1S/C22H15NO6/c24-19-16-9-8-14(21(26)27)10-17(16)20(25)23(19)18(22(28)29)11-13-6-3-5-12-4-1-2-7-15(12)13/h1-10,18H,11H2,(H,26,27)(H,28,29)/t18-/m1/s1	CZNPWASYMRBJCX-GOSISDBHSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.3377 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	6	2	No	4	-2	111.98 Å2	39.03 Å3	103.12 m3·mol-1	5	Yes	No	0.00674 mg/mL	3.27	-4.8	3.07	-7	P00811	ampC	1. Beta-lactamase
C22H22F3NO5S	Not Available	Not Available	469.474	[H][C@@]1(C[C@](CC(C)C)(N(C(=O)C2=CC=C(C=C2)C(F)(F)F)[C@@]1([H])C1=CC=CS1)C(O)=O)C(O)=O	Solid	Not Available					50162519		CHEMBL180948	4439526						699			5275422	99443671					ZINC000016052233		(2S,4S,5R)-2-ISOBUTYL-5-(2-THIENYL)-1-[4-(TRIFLUOROMETHYL)BENZOYL]PYRROLIDINE-2,4-DICARBOXYLIC ACID	Experimental	DB07200	InChI=1S/C22H22F3NO5S/c1-12(2)10-21(20(30)31)11-15(19(28)29)17(16-4-3-9-32-16)26(21)18(27)13-5-7-14(8-6-13)22(23,24)25/h3-9,12,15,17H,10-11H2,1-2H3,(H,28,29)(H,30,31)/t15-,17+,21-/m0/s1	ZNCZVHCYBGHCHA-XPIZARPCSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.4526 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	2	Yes	3	-2	94.91 Å2	42.77 Å3	109.92 m3·mol-1	7	No	No	0.00317 mg/mL	5.01	-5.2	4.1	-1.5	P26663;!O39930	Not Available;!NS5b	1. Genome polyprotein;!2. RNA-dependent RNA-polymerase
C19H11BrF2N2O4	Not Available	Not Available	449.202	[H]N1C(=O)C[C@@]2(C1=O)C(=O)N(CC1=C(F)C=C(Br)C=C1)C(=O)C1=C2C=C(F)C=C1	Solid	Not Available					50038843		CHEMBL292963	394897						BFI			447950	99443921					ZINC000000597385		(R)-minalrestat	Experimental	DB07450	InChI=1S/C19H11BrF2N2O4/c20-10-2-1-9(14(22)5-10)8-24-16(26)12-4-3-11(21)6-13(12)19(18(24)28)7-15(25)23-17(19)27/h1-6H,7-8H2,(H,23,25,27)/t19-/m1/s1	BMHZAHGTGIZZCT-LJQANCHMSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Non-substrate	2.4178 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	1	No	4	0	83.55 Å2	36.58 Å3	96.73 m3·mol-1	2	Yes	No	0.012 mg/mL	2.5	-4.6	9.33	-6.2			
C17H15NOS	Not Available	Not Available	281.372	CC1=CC(=CC=C1)[C@]12SCCN1C(=O)C1=CC=CC=C21	Solid	Not Available					1369		CHEMBL430639	392560						BM1			444703	99443943					ZINC000003871749		(R)-(+)9B-(3-METHYL)PHENYL-2,3-DIHYDROTHIAZOLO[2,3-A]ISOINDOL-5(9BH)-ONE	Experimental	DB07472	InChI=1S/C17H15NOS/c1-12-5-4-6-13(11-12)17-15-8-3-2-7-14(15)16(19)18(17)9-10-20-17/h2-8,11H,9-10H2,1H3/t17-/m1/s1	FQVDJZWFSZSGGA-QGZVFWFLSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.4974 LD50, mol/kg	Inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	1	0	No	4	0	20.31 Å2	30.29 Å3	83.29 m3·mol-1	1	Yes	Yes	0.00615 mg/mL	4.13	-4.7		-2.1	P04585	gag-pol	1. Gag-Pol polyprotein
C15H10F3N3O4S2	Not Available	Not Available	417.383	NS(=O)(=O)C1=CC=C(C=C1C(F)(F)F)C1=CC=C(O1)\C=C1/SC(=N)NC1=O	Solid	Not Available					17149		CHEMBL233970	22376747						C94			23647657	99444009					ZINC000014963245		4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}-2-(TRIFLUOROMETHYL)BENZENESULFONAMIDE	Experimental	DB07538	InChI=1S/C15H10F3N3O4S2/c16-15(17,18)9-5-7(1-4-12(9)27(20,23)24)10-3-2-8(25-10)6-11-13(22)21-14(19)26-11/h1-6H,(H2,19,21,22)(H2,20,23,24)/b11-6-	RGVVHQNJKUNSFQ-WDZFZDKYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.4357 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	3	No	3	0	126.25 Å2	36.15 Å3	104.23 m3·mol-1	4	Yes	No	0.0546 mg/mL	1.97	-3.9	8.76	1.47			
C15H10N2O4S	Not Available	Not Available	314.316	OC(=O)C1=CC=C(C=C1)C1=CC=C(O1)\C=C1/SC(=N)NC1=O	Solid	Not Available					17143		CHEMBL233349	4761092						C95			5951796	99444010					ZINC000003029819		4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZOIC ACID	Experimental	DB07539	InChI=1S/C15H10N2O4S/c16-15-17-13(18)12(22-15)7-10-5-6-11(21-10)8-1-3-9(4-2-8)14(19)20/h1-7H,(H,19,20)(H2,16,17,18)/b12-7-	JLRKRQCTYQGDKJ-GHXNOFRVSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.3364 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	3	No	3	-1	103.39 Å2	31.12 Å3	93.35 m3·mol-1	3	Yes	No	0.0808 mg/mL	2.15	-3.6	3.9	1.47			
C18H13NO7	Not Available	Not Available	355.2983	[H][C@](CC1=CC=C(O)C=C1)(N1C(=O)C2=C(C=C(C=C2)C(O)=O)C1=O)C(O)=O	Solid	Not Available							CHEMBL264702	5376302						DK2			7013169	99444134							2-[(1R)-1-CARBOXY-2-(4-HYDROXYPHENYL)ETHYL]-1,3-DIOXOISOINDOLINE-5-CARBOXYLIC ACID	Experimental	DB07663	InChI=1S/C18H13NO7/c20-11-4-1-9(2-5-11)7-14(18(25)26)19-15(21)12-6-3-10(17(23)24)8-13(12)16(19)22/h1-6,8,14,20H,7H2,(H,23,24)(H,25,26)/t14-/m1/s1	QISJEFYTLZTWIQ-CQSZACIVSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.4263 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	7	3	No	3	-2	132.21 Å2	34.32 Å3	88.65 m3·mol-1	5	Yes	No	0.0521 mg/mL	1.97	-3.8	2.79	-6	P00811	ampC	1. Beta-lactamase
C17H12N2O4S2	Not Available	Not Available	372.418	OC1=C(\C=C2/SC(=S)N(CC3=CC=CC=C3)C2=O)C=CC=C1[N+]([O-])=O	Solid	Not Available								4661060						GN8			5726921	99444309					ZINC000016479722		(Z)-3-BENZYL-5-(2-HYDROXY-3-NITROBENZYLIDENE)-2-THIOXOTHIAZOLIDIN-4-ONE	Experimental	DB07838	InChI=1S/C17H12N2O4S2/c20-15-12(7-4-8-13(15)19(22)23)9-14-16(21)18(17(24)25-14)10-11-5-2-1-3-6-11/h1-9,20H,10H2/b14-9-	ZTWBCEZQPRYIGY-ZROIWOOFSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.5714 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	1	No	3	-1	83.68 Å2	36.93 Å3	102.02 m3·mol-1	4	Yes	No	0.00303 mg/mL	4.32	-5.1	6.49	-4.2	O60551	NMT2	1. Glycylpeptide N-tetradecanoyltransferase 2
C22H22N2O3	Not Available	Not Available	362.4217	NC(=O)C1=CC=CC(CN2C3=C(CCCCC3)C3=CC=CC(C(O)=O)=C23)=C1	Solid	Not Available					50248245		CHEMBL516023	8039485						I4A			9863791	99444416					ZINC000003961887		5-(3-carbamoylbenzyl)-5,6,7,8,9,10-hexahydrocyclohepta[b]indole-4-carboxylic acid	Experimental	DB07945	InChI=1S/C22H22N2O3/c23-21(25)15-7-4-6-14(12-15)13-24-19-11-3-1-2-8-16(19)17-9-5-10-18(20(17)24)22(26)27/h4-7,9-10,12H,1-3,8,11,13H2,(H2,23,25)(H,26,27)	GKBQRPKZHUFGOB-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Inhibitor	Non-substrate	2.3354 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	2	No	4	-1	85.32 Å2	39.39 Å3	105.1 m3·mol-1	4	Yes	No	0.00325 mg/mL	4.19	-5	3.53	-0.34			
C25H19FN2O4	Not Available	Not Available	430.4278	O\N=C1/C(=O)N(CC2=C3OCOCC3=CC(F)=C2)C2=CC=CC(\C=C\C3=CC=CC=C3)=C12	Solid	Not Available							CHEMBL561540	24626128						J67			45268539	99444481					ZINC000039261472		(3Z)-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-4-[(E)-2-phenylethenyl]-1H-indole-2,3-dione 3-oxime	Experimental	DB08010	InChI=1S/C25H19FN2O4/c26-20-11-18(24-19(12-20)14-31-15-32-24)13-28-21-8-4-7-17(22(21)23(27-30)25(28)29)10-9-16-5-2-1-3-6-16/h1-12,30H,13-15H2/b10-9+,27-23-	DDHASJXGNUWZTM-ZLEWNXFRSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Inhibitor	Non-substrate	2.5092 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	1	No	5	-1	71.36 Å2	43.7 Å3	118.57 m3·mol-1	4	Yes	No	0.00388 mg/mL	4.69	-5	6.71	-3.7			
C24H20N2O3	Not Available	Not Available	384.4272	COC1=CC=C(NC2=C(C(=O)N(CC3=CC=CC=C3)C2=O)C2=CC=CC=C2)C=C1	Solid	Not Available					20156		CHEMBL189938	4450790						L05			5288679	99444534							1-BENZYL-3-(4-METHOXYPHENYLAMINO)-4-PHENYLPYRROLE-2,5-DIONE	Experimental	DB08063	InChI=1S/C24H20N2O3/c1-29-20-14-12-19(13-15-20)25-22-21(18-10-6-3-7-11-18)23(27)26(24(22)28)16-17-8-4-2-5-9-17/h2-15,25H,16H2,1H3	HLZMYWLMBBLASX-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.5084 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	1	Yes	4	0	58.64 Å2	41.64 Å3	113.73 m3·mol-1	6	Yes	No	0.00138 mg/mL	3.74	-5.4	11.72	-4.1			
C17H12ClNO4S2	Not Available	Not Available	393.864	[H]\C(C1=CC=C(O1)C1=CC=C(Cl)C=C1)=C1/SC(=S)N(CCC(O)=O)C1=O	Solid	Not Available					50304611		CHEMBL593602	1079111						MFM			1286536	99444648					ZINC000002240008		(E)-3-(5((5-(4-CHLOROPHENYL)FURAN-2-YL)METHYLENE)-4-OXO-2-THIOXOTHIAZOLIDIN-3-YL)PROPANOIC ACID	Experimental	DB08177	InChI=1S/C17H12ClNO4S2/c18-11-3-1-10(2-4-11)13-6-5-12(23-13)9-14-16(22)19(17(24)25-14)8-7-15(20)21/h1-6,9H,7-8H2,(H,20,21)/b14-9+	YZLFZFALAZYTCI-NTEUORMPSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.6022 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	1	No	3	-1	70.75 Å2	38.8 Å3	102.1 m3·mol-1	5	Yes	No	0.0126 mg/mL	3.91	-4.5	4.4	-2.9			
C20H19ClN4O3S2	Not Available	Not Available	462.973	NC(=N)C1=CC(CN2CCN(CC2=O)S(=O)(=O)C2=CC3=C(S2)C=C(Cl)C=C3)=CC=C1	Solid	Not Available					12592		CHEMBL351298	394485						RRP			447359	99444958					ZINC000002047642		3-({4-[(6-CHLORO-1-BENZOTHIEN-2-YL)SULFONYL]-2-OXOPIPERAZIN-1-YL}METHYL)BENZENECARBOXIMIDAMIDE	Experimental	DB08487	InChI=1S/C20H19ClN4O3S2/c21-16-5-4-14-9-19(29-17(14)10-16)30(27,28)25-7-6-24(18(26)12-25)11-13-2-1-3-15(8-13)20(22)23/h1-5,8-10H,6-7,11-12H2,(H3,22,23)	PRMSFVUWLBPPLY-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.5381 LD50, mol/kg	Inhibitor	Weak inhibitor	Inhibitor										1	Yes	5	2	No	4	1	107.56 Å2	46.53 Å3	127.33 m3·mol-1	4	Yes	No	0.0106 mg/mL	2.26	-4.6	17.01	11.41			
C24H24N4O5	Not Available	Not Available	448.4712	[H][C@]1(O)C[N@]2[C@@]([H])(C1)[C@]1([H])C(=O)N(CC3=CC=C4OCOC4=C3)C(=O)[C@]1([H])[C@]2([H])C1=CC=C(C=C1)C(N)=N	Solid	Not Available								3572029						SHY			4369485	99445017					ZINC000016051594		4-[(3AS,4R,7R,8AS,8BR)-2-(1,3-BENZODIOXOL-5-YLMETHYL)-7-HYDROXY-1,3-DIOXODECAHYDROPYRROLO[3,4-A]PYRROLIZIN-4-YL]BENZENECARBOXIMIDAMIDE	Experimental	DB08546	InChI=1S/C24H24N4O5/c25-22(26)14-4-2-13(3-5-14)21-20-19(16-8-15(29)10-27(16)21)23(30)28(24(20)31)9-12-1-6-17-18(7-12)33-11-32-17/h1-7,15-16,19-21,29H,8-11H2,(H3,25,26)/t15-,16+,19+,20+,21+/m1/s1	CETLUACQMGBMFH-ZALSBGIRSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3001 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	8	3	No	6	2	129.18 Å2	45.37 Å3	128.21 m3·mol-1	4	Yes	No	0.1 mg/mL	0.35	-3.6	14.83	11.48	P00734	F2	1. Prothrombin
C18H15FN2O4S	Not Available	Not Available	374.386	CCC1=CC=C(O1)\C=C1/SC(N[C@H](C(O)=O)C2=CC=C(F)C=C2)=NC1=O	Solid	Not Available							CHEMBL221245	13178234						VRX			16049839	99445177					ZINC000034947225		(2S)-({(5Z)-5-[(5-Ethyl-2-furyl)methylene]-4-oxo-4,5-dihydro-1,3-thiazol-2-yl}amino)(4-fluorophenyl)acetic acid	Experimental	DB08706	InChI=1S/C18H15FN2O4S/c1-2-12-7-8-13(25-12)9-14-16(22)21-18(26-14)20-15(17(23)24)10-3-5-11(19)6-4-10/h3-9,15H,2H2,1H3,(H,23,24)(H,20,21,22)/b14-9-/t15-/m0/s1	RNEACARJKXYVND-MZLJFPOFSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.5104 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	2	No	3	-1	91.9 Å2	36.62 Å3	95.7 m3·mol-1	5	Yes	No	0.0349 mg/mL	3.08	-4	3.88	-2.3	P26663	Not Available	1. Genome polyprotein
C21H16F4N4O2S	Apparent clearance (CL/F), single oral dose = 0.56 L/h (range of 0.33 - 1.02 L/h)	The mean terminal half-life (t1/2) for enzalutamide in patients after a single oral dose is 5.8 days (range 2.8 to 10.2 days). Following a single 160 mg oral dose of enzalutamide in healthy volunteers, the mean terminal t1/2 for N-desmethyl enzalutamide is approximately 7.8 to 8.6 days.	464.436	CNC(=O)C1=C(F)C=C(C=C1)N1C(=S)N(C(=O)C1(C)C)C1=CC=C(C#N)C(=C1)C(F)(F)F	Solid	Apparent volume of distribution (Vd/F), single oral dose = 110 L	P10632;!P08684;!P11712;!P33261;!P20813;!P20815	CYP2C8;!CYP3A4;!CYP2C9;!CYP2C19;!CYP2B6;!CYP3A5	1. Cytochrome P450 2C8;!2. Cytochrome P450 3A4;!3. Cytochrome P450 2C9;!4. Cytochrome P450 2C19;!5. Cytochrome P450 2B6;!6. Cytochrome P450 3A5		50425732	68534	CHEMBL1082407	13093347	Drugs.com Drug Page				D10218				15951529	175427141	RxList Drug Page	1307298		Enzalutamide	ZINC000034806477	Xtandi	Enzalutamide	Approved	DB08899	InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)	WXCXUHSOUPDCQV-UHFFFAOYSA-N	4	Enzalutamide is an androgen receptor inhibitor used to treat castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer.	The most common adverse reactions (≥ 5%) are asthenia/fatigue, back pain, diarrhea, arthralgia, hot flush, peripheral edema, musculoskeletal pain, headache, upper respiratory infection, muscular weakness, dizziness, insomnia, lower respiratory infection, spinal cord compression and cauda equina syndrome, hematuria, paresthesia, anxiety, and hypertension.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Non-substrate	2.4319 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor									Insoluble	1	Yes	3	1	No	3	0	76.44 Å2	42.69 Å3	113.48 m3·mol-1	4	Yes	No	0.00136 mg/mL	4.16	-5.5	13.05	-1.6			
C40H33F3N4O3	Not Available	Not Available	674.724	CN(CC1=CC=CC=C1)C(=O)[C@@H](NC(=O)C1=CC2=C(C=CC(NC(=O)C3=CC=CC=C3C3=CC=C(C=C3)C(F)(F)F)=C2)N1C)C1=CC=CC=C1	Not Available	Not Available					50204367		CHEMBL410414	8093509					D03867							1592684		Dirlotapide	ZINC000003988502		Dirlotapide	Investigational, Vet approved	DB11399	InChI=1S/C40H33F3N4O3/c1-46(25-26-11-5-3-6-12-26)39(50)36(28-13-7-4-8-14-28)45-38(49)35-24-29-23-31(21-22-34(29)47(35)2)44-37(48)33-16-10-9-15-32(33)27-17-19-30(20-18-27)40(41,42)43/h3-24,36H,25H2,1-2H3,(H,44,48)(H,45,49)/t36-/m0/s1	TUOSYWCFRFNJBS-BHVANESWSA-N			Not Available	Small Molecule																																			0	No	4	2	Yes	6	0	86.93 Å2	69.99 Å3	189.73 m3·mol-1	10	No	No	9.05e-05 mg/mL	8.51	-6.9	8.92	0.85			
C22H14F3NO5	Not Available	Not Available	429.351	FC(F)(F)C1=CC=C(CN2C(=O)[C@@]3(COC4=C3C=C3OCOC3=C4)C3=CC=CC=C23)O1	Not Available	Not Available					206760		CHEMBL3707218	34500834									49836093	347828122				Funapide	ZINC000113473392		Funapide	Investigational	DB11769	InChI=1S/C22H14F3NO5/c23-22(24,25)19-6-5-12(31-19)9-26-15-4-2-1-3-13(15)21(20(26)27)10-28-16-8-18-17(7-14(16)21)29-11-30-18/h1-8H,9-11H2/t21-/m0/s1	NEBUOXBYNAHKFV-NRFANRHFSA-N	2		Not Available	Small Molecule																																			1	Yes	4	0	No	6	0	61.14 Å2	38.49 Å3	100.35 m3·mol-1	3	Yes	No	0.0341 mg/mL	3.45	-4.1		-3.1			
C25H22F3N5O4S	Not Available	Not Available	545.54	CN1N=CC=C1C1=C(C)N(C2=CC=CC(=C2)C(F)(F)F)C(=O)C(=C1)C(=O)NCC1=NC=C(C=C1)S(C)(=O)=O	Not Available	Not Available					50120430		CHEMBL3617964	30687100									71587812	347828201					ZINC000072316197		Alvelestat	Investigational	DB11863	InChI=1S/C25H22F3N5O4S/c1-15-20(22-9-10-31-32(22)2)12-21(23(34)30-13-17-7-8-19(14-29-17)38(3,36)37)24(35)33(15)18-6-4-5-16(11-18)25(26,27)28/h4-12,14H,13H2,1-3H3,(H,30,34)	QNQZWEGMKJBHEM-UHFFFAOYSA-N	2		Not Available	Small Molecule																																			1	No	6	1	Yes	4	0	114.26 Å2	52.25 Å3	146.4 m3·mol-1	7	No	No	0.00275 mg/mL	1.27	-5.3	12.17	2			
C23H25ClN2O4S	The clearance of ponesimod is 3.8 L/h.3	Ponesimod has an elimination half life of 33 hours.3	460.97	CCC\N=C1/S\C(=C/C2=CC=C(OC[C@H](O)CO)C(Cl)=C2)C(=O)N1C1=CC=CC=C1C	Solid	The volume of distribution of ponesimod at steady state is 160 L.3	P51589;!P08684;!P20815;!Q08477;!Q9HCS2;!P22309;!P16662	CYP2J2;!CYP3A4;!CYP3A5;!CYP4F3;!CYP4F12;!UGT1A1;!UGT2B7	1. Cytochrome P450 2J2;!2. Cytochrome P450 3A4;!3. Cytochrome P450 3A5;!4. Cytochrome P450 4F3;!5. Cytochrome P450 4F12;!6. UDP-glucuronosyltransferase 1-1;!7. UDP-glucuronosyltransferase 2B7		50316768		CHEMBL1096146	9538103									11363176	347828333		2532300		Ponesimod	ZINC000034509627	Ponvory	Ponesimod	Approved, Investigational	DB12016	InChI=1S/C23H25ClN2O4S/c1-3-10-25-23-26(19-7-5-4-6-15(19)2)22(29)21(31-23)12-16-8-9-20(18(24)11-16)30-14-17(28)13-27/h4-9,11-12,17,27-28H,3,10,13-14H2,1-2H3/b21-12-,25-23-/t17-/m1/s1	LPAUOXUZGSBGDU-STDDISTJSA-N	3	Ponesimod is a sphingosine 1-phosphate receptor modulator indicated to treat relapsing multiple sclerosis.	Patients experiencing an overdose may present with bradycardia, AV conduction block, and changes in blood pressure.3 Patients should be monitored for pulse rate and blood pressure, as well as ECGs.3 Treat patients with symptomatic and supportive measures, which may include atropine for bradycardia.3 dialysis is not expected to remove a significant amount of drug from blood.3	Small Molecule																																		Insoluble	1	Yes	5	2	Yes	3	0	82.36 Å2	49.67 Å3	125.69 m3·mol-1	8	Yes	No	0.00626 mg/mL	4.49	-4.9	13.62	0.91	P21453	S1PR1	1. Sphingosine 1-phosphate receptor 1
C33H35F4N3O2	Avacopan has an estimated total apparent body clearance (CL/F) of 16.3 L/h.9	A single 30 mg dose of avacopan given with food to healthy subjects resulted in mean elimination half-lives of 97.6 and 55.6 hours for avacopan and its M1 metabolite, respectively.9	581.656	CC1=CC=C(NC(=O)[C@H]2CCCN([C@H]2C2=CC=C(NC3CCCC3)C=C2)C(=O)C2=C(F)C=CC=C2C)C=C1C(F)(F)F	Solid	Avacopan has an apparent volume of distribution of 345 L.9	P08684;!P11712;!P05177;!P20813	CYP3A4;!CYP2C9;!CYP1A2;!CYP2B6	1. Cytochrome P450 3A4;!2. Cytochrome P450 2C9;!3. Cytochrome P450 1A2;!4. Cytochrome P450 2B6				CHEMBL3989871	52083514						EFD						2572100		Avacopan		Tavneos	Avacopan	Approved, Investigational	DB15011	InChI=1S/C33H35F4N3O2/c1-20-12-15-25(19-27(20)33(35,36)37)39-31(41)26-10-6-18-40(32(42)29-21(2)7-5-11-28(29)34)30(26)22-13-16-24(17-14-22)38-23-8-3-4-9-23/h5,7,11-17,19,23,26,30,38H,3-4,6,8-10,18H2,1-2H3,(H,39,41)/t26-,30-/m0/s1	PUKBOVABABRILL-YZNIXAGQSA-N	3	Avacopan is an orally bioavailable complement 5a receptor (C5aR) antagonist for the treatment of severe anti-neutrophil cytoplasmic (auto)antibody (ANCA)-associated vasculitis.	Animal studies have not revealed any mutagenic potential of avacopan and no impairment of fertility at doses up to 1000 mg/kg/day. Avacopan is not mutagenic based on the Ames test.9	Small Molecule																																			0	No	3	2	Yes	5	0	61.44 Å2	58.26 Å3	158.6 m3·mol-1	7	No	No	0.000219 mg/mL	7.59	-6.4	14.05	4.98	P21730	C5AR1	1. C5a anaphylatoxin chemotactic receptor 1
C27H21F3N2O5S	Not Available	Not Available	542.53	OC(=O)C1=CC=C(C=C1)S(=O)(=O)N(CC1=CC=C(OC(F)(F)F)C=C1)C1=NC=C2C=CC=CC2=C1C1CC1	Not Available	Not Available					151677		CHEMBL3682589	58935213															ZINC000203668161		Elismetrep	Investigational	DB15287	InChI=1S/C27H21F3N2O5S/c28-27(29,30)37-21-11-5-17(6-12-21)16-32(38(35,36)22-13-9-19(10-14-22)26(33)34)25-24(18-7-8-18)23-4-2-1-3-20(23)15-31-25/h1-6,9-15,18H,7-8,16H2,(H,33,34)	CWEFDWIKLABKBX-UHFFFAOYSA-N	2		Not Available	Small Molecule																																			0	No	6	1	Yes	5	-1	96.8 Å2	50.95 Å3	129.72 m3·mol-1	8	No	No	0.00101 mg/mL	6.65	-5.7	3.52	0.63			
C15H13NO3S2	Not Available	Not Available	319.39	C\C(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/C1=CC=CC=C1	Not Available	Not Available					50049730	31539	CHEMBL56337	1266086														Epalrestat	ZINC000001533688		Epalrestat	Investigational	DB15293	InChI=1S/C15H13NO3S2/c1-10(7-11-5-3-2-4-6-11)8-12-14(19)16(9-13(17)18)15(20)21-12/h2-8H,9H2,1H3,(H,17,18)/b10-7+,12-8-	CHNUOJQWGUIOLD-NFZZJPOKSA-N			Not Available	Small Molecule																																			1	Yes	3	1	No	2	-1	57.61 Å2	32.37 Å3	89.79 m3·mol-1	4	Yes	No	0.00637 mg/mL	3.21	-4.7	3.7	-6.8			
C41H36ClF3N2O4S	Not Available	Not Available	745.25	OC(=O)C1=CC=C(CCCC2=C(CCNS(=O)(=O)CC3=C(C=CC=C3)C(F)(F)F)N(C(C3=CC=CC=C3)C3=CC=CC=C3)C3=C2C=C(Cl)C=C3)C=C1	Not Available	Not Available							CHEMBL2104969	9896558															ZINC000085537113		Giripladib	Investigational	DB15426	InChI=1S/C41H36ClF3N2O4S/c42-33-22-23-37-35(26-33)34(16-9-10-28-18-20-31(21-19-28)40(48)49)38(47(37)39(29-11-3-1-4-12-29)30-13-5-2-6-14-30)24-25-46-52(50,51)27-32-15-7-8-17-36(32)41(43,44)45/h1-8,11-15,17-23,26,39,46H,9-10,16,24-25,27H2,(H,48,49)	NHHBNHIPCSPSHQ-UHFFFAOYSA-N	1		Not Available	Small Molecule																																			0	No	4	2	Yes	6	-1	88.4 Å2	76.7 Å3	198.91 m3·mol-1	14	No	No	2.49e-05 mg/mL	10.22	-7.5	4.24				
C26H27F3N2O3	Not Available	Not Available	472.508	OC(=O)C1=CC=C(C=C1)C1(CC1)NC(=O)C1CC2(CC2)CCN1CC1=CC=C(C=C1)C(F)(F)F	Not Available	Not Available							CHEMBL3920982	61747700																	CR6086	Investigational	DB16111	InChI=1S/C26H27F3N2O3/c27-26(28,29)20-5-1-17(2-6-20)16-31-14-13-24(9-10-24)15-21(31)22(32)30-25(11-12-25)19-7-3-18(4-8-19)23(33)34/h1-8,21H,9-16H2,(H,30,32)(H,33,34)	CADWTPLFEZSAHM-UHFFFAOYSA-N	2		Not Available	Small Molecule																																			1	Yes	4	2	Yes	5	0	69.64 Å2	46.22 Å3	121.46 m3·mol-1	7	Yes	No	0.00152 mg/mL	1.95	-5.5	3.99	7.76			
C27H22ClN3O4	Not Available	Not Available	487.94	CN1N=C(C(=O)N(CC2=CC=CC=C2)CC2=CC=C(C=C2)C(O)=O)C2=C1C1=C(OC2)C=CC(Cl)=C1	Not Available	Not Available							CHEMBL4297626	57617776															ZINC000584641402		Nidufexor	Investigational	DB16255	InChI=1S/C27H22ClN3O4/c1-30-25-21-13-20(28)11-12-23(21)35-16-22(25)24(29-30)26(32)31(14-17-5-3-2-4-6-17)15-18-7-9-19(10-8-18)27(33)34/h2-13H,14-16H2,1H3,(H,33,34)	JYTIXGYXBIBOMN-UHFFFAOYSA-N	2		Not Available	Small Molecule																																			1	No	5	1	Yes	5	-1	84.66 Å2	51.44 Å3	144.78 m3·mol-1	6	Yes	No	0.00139 mg/mL	4.96	-5.6	4.07	-0.3	Q96RI1	NR1H4	1. Bile acid receptor
C4H9N3O2	Not Available	3 hours	131.1332	CN(CC(O)=O)C(N)=N	Solid	Not Available					50357229	16919	CHEMBL283800	566	Drugs.com Drug Page		HMDB0000064	C00300		CRN	PDRhealth Drug Page	PA164778930	586	46504868		2907		Creatine	ZINC000003861770		Creatine	Approved, Investigational, Nutraceutical	DB00148	InChI=1S/C4H9N3O2/c1-7(4(5)6)2-3(8)9/h2H2,1H3,(H3,5,6)(H,8,9)	CVSVTCORWBXHQV-UHFFFAOYSA-N	4		Not Available	Small Molecule	http://smpdb.ca/view/SMP0000004?highlight[compounds][]=DB00148&highlight[proteins][]=DB00148;!http://smpdb.ca/view/SMP0000020?highlight[compounds][]=DB00148&highlight[proteins][]=DB00148;!http://smpdb.ca/view/SMP0000188?highlight[compounds][]=DB00148&highlight[proteins][]=DB00148;!http://smpdb.ca/view/SMP0000360?highlight[compounds][]=DB00148&highlight[proteins][]=DB00148;!http://smpdb.ca/view/SMP0000361?highlight[compounds][]=DB00148&highlight[proteins][]=DB00148;!http://smpdb.ca/view/SMP0000507?highlight[compounds][]=DB00148&highlight[proteins][]=DB00148;!http://smpdb.ca/view/SMP0000207?highlight[compounds][]=DB00148&highlight[proteins][]=DB00148;!http://smpdb.ca/view/SMP0000208?highlight[compounds][]=DB00148&highlight[proteins][]=DB00148;!http://smpdb.ca/view/SMP0000223?highlight[compounds][]=DB00148&highlight[proteins][]=DB00148;!http://smpdb.ca/view/SMP0000244?highlight[compounds][]=DB00148&highlight[proteins][]=DB00148;!http://smpdb.ca/view/SMP0000363?highlight[compounds][]=DB00148&highlight[proteins][]=DB00148;!http://smpdb.ca/view/SMP0000506?highlight[compounds][]=DB00148&highlight[proteins][]=DB00148;!http://smpdb.ca/view/SMP0000179?highlight[compounds][]=DB00148&highlight[proteins][]=DB00148;!http://smpdb.ca/view/SMP0000242?highlight[compounds][]=DB00148&highlight[proteins][]=DB00148;!http://smpdb.ca/view/SMP0000362?highlight[compounds][]=DB00148&highlight[proteins][]=DB00148;!http://smpdb.ca/view/SMP0000484?highlight[compounds][]=DB00148&highlight[proteins][]=DB00148;!http://smpdb.ca/view/SMP0000485?highlight[compounds][]=DB00148&highlight[proteins][]=DB00148;!http://smpdb.ca/view/SMP0000504?highlight[compounds][]=DB00148&highlight[proteins][]=DB00148;!http://smpdb.ca/view/SMP0000505?highlight[compounds][]=DB00148&highlight[proteins][]=DB00148;!http://smpdb.ca/view/SMP0000721?highlight[compounds][]=DB00148&highlight[proteins][]=DB00148	Glycine and Serine Metabolism;!Arginine and Proline Metabolism;!Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency);!Hyperprolinemia Type II;!Hyperprolinemia Type I;!L-Arginine:Glycine Amidinotransferase Deficiency;!Prolidase Deficiency (PD);!Prolinemia Type II;!Non-Ketotic Hyperglycinemia;!Sarcosinemia;!Ornithine Aminotransferase Deficiency (OAT Deficiency);!Hyperornithinemia-Hyperammonemia-Homocitrullinuria [HHH-syndrome];!Dihydropyrimidine Dehydrogenase Deficiency (DHPD);!Dimethylglycine Dehydrogenase Deficiency;!Arginine: Glycine Amidinotransferase Deficiency (AGAT Deficiency);!Dimethylglycine Dehydrogenase Deficiency;!Hyperglycinemia, Non-Ketotic;!Creatine Deficiency, Guanidinoacetate Methyltransferase Deficiency;!Hyperornithinemia with Gyrate Atrophy (HOGA);!3-Phosphoglycerate Dehydrogenase Deficiency		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.0088 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					-0.2		255 dec °C		1.33E+004 mg/L (at 18 °C)	1	No	5	3	No	0	0	90.41 Å2	12.17 Å3	42.01 m3·mol-1	2	Yes	No	4.11 mg/mL	-2.9	-1.5	3.5	12.43	P06732;!P12532;!P12277;!P17540;!P48029;!Q14353	CKM;!CKMT1A;!CKB;!CKMT2;!SLC6A8;!GAMT	1. Creatine kinase M-type;!2. Creatine kinase U-type, mitochondrial;!3. Creatine kinase B-type;!4. Creatine kinase S-type, mitochondrial;!5. Sodium- and chloride-dependent creatine transporter 1;!6. Guanidinoacetate N-methyltransferase
C4H11N5	Renal clearance is about 3.5 times greater than creatinine clearance, which indicates that tubular secretion is the major route of metformin elimination. Following oral administration, approximately 90% of the absorbed drug is eliminated via the renal route within the first 24 hours.24	The plasma elimination half-life of metformin is 6.2 hours in the plasma.24 The elimination half-life in the blood is approximately 17.6 hours, suggesting that the erythrocyte mass may be a compartment of distribution.24	129.1636	CN(C)C(=N)NC(N)=N	Solid	The apparent volume of distribution (V/F) of metformin after one oral dose of metformin 850 mg averaged at 654 ± 358 L.24					50229665	6801	CHEMBL1431	3949	Drugs.com Drug Page		HMDB0001921	C07151	D04966	MF8		PA450395	4091	46507752	RxList Drug Page	6809	DAP000205	Metformin	ZINC000012859773	Actoplus Met, Avandamet, Fortamet, Glubrava, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo	Metformin	Approved	DB00331	InChI=1S/C4H11N5/c1-9(2)4(7)8-3(5)6/h1-2H3,(H5,5,6,7,8)	XZWYZXLIPXDOLR-UHFFFAOYSA-N	4	Metformin is a biguanide antihyperglycemic used in conjunction with diet and exercise for glycemic control in type 2 diabetes mellitus. It is also used off-label for insulin resistance in polycystic ovary syndrome (PCOS).	Metformin (hydrochloride) toxicity data: Oral LD50 (rat): 1 g/kg; Intraperitoneal LD50 (rat): 500 mg/kg; Subcutaneous LD50 (rat): 300 mg/kg; Oral LD50 (mouse): 1450 mg/kg; Intraperitoneal LD50 (mouse): 420 mg/kg; Subcutaneous LD50 (mouse): 225 mg/kg.34A note on lactic acidosisMetformin decreases liver uptake of lactate, thereby increasing lactate blood levels which may increase the risk of lactic acidosis.24 There have been reported postmarketing cases of metformin-associated lactic acidosis, including some fatal cases. Such cases had a subtle onset and were accompanied by nonspecific symptoms including malaise, myalgias, abdominal pain, respiratory distress, or increased somnolence. In certain cases, hypotension and resistant bradyarrhythmias have occurred with severe lactic acidosis.24 Metformin-associated lactic acidosis was characterized by elevated blood lactate concentrations (>5 mmol/L), anion gap acidosis (without evidence of ketonuria or ketonemia), as well as an increased lactate:pyruvate ratio; metformin plasma levels were generally >5 mcg/mL.24Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g. carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, and hepatic impairment.24A note on renal functionIn patients with decreased renal function, the plasma and blood half-life of metformin is prolonged and the renal clearance is decreased.24Metformin should be avoided in those with severely compromised renal function (creatinine clearance < 30 ml/min), acute/decompensated heart failure, severe liver disease and for 48 hours after the use of iodinated contrast dyes due to the risk of lactic acidosis.24 Lower doses should be used in the elderly and those with decreased renal function. Metformin decreases fasting plasma glucose, postprandial blood glucose and glycosolated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control. Metformin may also have a positive effect on lipid levels. A note on hypoglycemiaWhen used alone, metformin does not cause hypoglycemia, however, it may potentiate the hypoglycemic effects of sulfonylureas and insulin when they are used together.24Use in pregnancy Available data from post-marketing studies have not indicated a clear association of metformin with major birth defects, miscarriage, or adverse maternal or fetal outcomes when metformin was ingested during pregnancy. Despite this, the abovementioned studies cannot definitively establish the absence of any metformin-associated risk due to methodological limitations, including small sample size and inconsistent study groups.24Use in nursingA limited number of published studies indicate that metformin is present in human milk. There is insufficient information to confirm the effects of metformin on the nursing infant and no available data on the effects of metformin on the production of milk. The developmental and health benefits of breastfeeding should be considered as well as the mother’s clinical need for metformin and any possible adverse effects on the nursing child.24	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.7407 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				224.1ºC at 760 mmHg	-2.6		223-226 °C	12.4	Freely soluble	1	No	5	4	No	0	2	88.99 Å2	13.43 Å3	56.64 m3·mol-1	0	Yes	No	1.38 mg/mL	-0.92	-2		12.33	Q16134;!Q9Y478;!P21695	ETFDH;!PRKAB1;!GPD1	1. Electron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial;!2. 5'-AMP-activated protein kinase subunit beta-1;!3. Glycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic
C6H8ClN7O	Not Available	Plasma half-life varies from 6 to 9 hours.	229.627	NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N	Solid	Not Available	P19801;!Q9TRC7	AOC1;!AOC1	1. Amiloride-sensitive amine oxidase [copper-containing];!2. Amiloride-sensitive amine oxidase [copper-containing]		16173	2639	CHEMBL945	15403	Drugs.com Drug Page	GtP Drug Page	HMDB0014732	C06821	D07447	AMR	PDRhealth Drug Page	PA448368	16231	46508156	RxList Drug Page	644	DAP000187	Amiloride	ZINC000004340269	Midamor	Amiloride	Approved	DB00594	InChI=1S/C6H8ClN7O/c7-2-4(9)13-3(8)1(12-2)5(15)14-6(10)11/h(H4,8,9,13)(H4,10,11,14,15)	XSDQTOBWRPYKKA-UHFFFAOYSA-N	4	Amiloride is a pyrizine compound used to treat hypertension and congestive heart failure.	No data are available in regard to overdosage in humans. The oral LD50 of amiloride hydrochloride (calculated as the base) is 56 mg/kg in mice and 36 to 85 mg/kg in rats, depending on the strain. The most likely signs and symptoms to be expected with overdosage are dehydration and electrolyte imbalance.	Small Molecule	http://smpdb.ca/view/SMP0000133?highlight[compounds][]=DB00594&highlight[proteins][]=DB00594	Amiloride Action Pathway		AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.5469 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					-0.3		240.5-241.5	8.7	Slightly soluble	1	No	7	5	No	1	1	156.79 Å2	20 Å3	67.18 m3·mol-1	1	Yes	No	0.616 mg/mL	-0.5	-2.6	11.43	7.35			
C10H15N5	Not Available	Not Available	205.2596	NC(=N)NC(=N)NCCC1=CC=CC=C1	Solid	Not Available					50240908	8064	CHEMBL170988	7953			HMDB0015050	C07673	D08351	8CV		PA1000	8249	46505230		8129	DAP000206	Phenformin	ZINC000005851063		Phenformin	Approved, Investigational, Withdrawn	DB00914	InChI=1S/C10H15N5/c11-9(12)15-10(13)14-7-6-8-4-2-1-3-5-8/h1-5H,6-7H2,(H6,11,12,13,14,15)	ICFJFFQQTFMIBG-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.5305 LD50, mol/kg	Inhibitor	Weak inhibitor	Non-inhibitor					-0.83		176.5 °C		210 mg/mL	1	Yes	5	5	No	1	2	97.78 Å2	22.14 Å3	80.72 m3·mol-1	3	Yes	No	0.232 mg/mL	0.83	-3	19.18	11.97	Q13131;!Q15842	PRKAA1;!KCNJ8	1. 5'-AMP-activated protein kinase catalytic subunit alpha-1;!2. ATP-sensitive inward rectifier potassium channel 8
C9H9Cl2N3O	Guanfacine has a total body cleraance of 360±262mL/min and a renal clearance of 233±245mL/min in patients with normal renal function. Patients with a glomerular filtration rate (GFR) of 10-30mL/min had a total body clearance of 308±274mL/min and a renal clearance of 34±22mL/min.2 Patients with a GFR of <1mL/min had a total body clearance of 257±187mL/min and a renal clearance of 18±15mL/min.2	Guanfacine has a half life of 17 hours, but this may range from 10-30 hours.1 The half life is largely independant of renal function.2	246.093	NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl	Solid	Guanfacine has a volume of distribution of 6.3L/kg.1	P33261;!P08684	CYP2C19;!CYP3A4	1. Cytochrome P450 2C19;!2. Cytochrome P450 3A4		81984	5558	CHEMBL862	3399	Drugs.com Drug Page	GtP Drug Page	HMDB0015153	C07037	D08031		PDRhealth Drug Page	PA449825	3519	46506169	RxList Drug Page	40114	DAP000900	Guanfacine	ZINC000003872738	Intuniv, Tenex	Guanfacine	Approved, Investigational	DB01018	InChI=1S/C9H9Cl2N3O/c10-6-2-1-3-7(11)5(6)4-8(15)14-9(12)13/h1-3H,4H2,(H4,12,13,14,15)	INJOMKTZOLKMBF-UHFFFAOYSA-N	4	Guanfacine is an alpha-2A adrenergic receptor agonist used to treat ADHD.	The oral LD50 in rats is 142mg/kg and 15.3mg/kg in mice.12 The subcutaneous LD50 in rats is 114mg/kg and 46mg/kg in mice.12Patients experiencing and overdose may present with hypotension, drowsiness, lethargy, and bradycardia.11 Overdose should be managed by first calling local poison control. Patients may require intravenous saline to maintain blood pressure.3	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.7408 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					0.857		213-216		1mg/mL	1	Yes	3	3	No	1	1	78.97 Å2	22.44 Å3	69.63 m3·mol-1	2	Yes	No	0.139 mg/mL	1.74	-3.2	11.64	8.65			
C11H16ClN5	Not Available	Approximately 20 hours	253.731	CC(C)NC(=N)NC(=N)NC1=CC=C(Cl)C=C1	Solid	Not Available	P11712;!P33261;!P10635	CYP2C9;!CYP2C19;!CYP2D6	1. Cytochrome P450 2C9;!2. Cytochrome P450 2C19;!3. Cytochrome P450 2D6		50227829	8455	CHEMBL1377	4754	Drugs.com Drug Page		HMDB0015263	C07631				PA451124	4923	46506228		2382	DAP000634	Proguanil	ZINC000095452610	Malarone	Proguanil	Approved	DB01131	InChI=1S/C11H16ClN5/c1-7(2)15-10(13)17-11(14)16-9-5-3-8(12)4-6-9/h3-7H,1-2H3,(H5,13,14,15,16,17)	SSOLNOMRVKKSON-UHFFFAOYSA-N	4	Proguanil is a medication indicated for prophylaxis and treatment of Plasmodium falciparum malaria.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.6787 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.53		129 °C		156 mg/L	1	Yes	5	5	No	1	2	83.79 Å2	26.75 Å3	91.65 m3·mol-1	2	Yes	No	0.116 mg/mL	2.38	-3.3		10.4	P00374;!P13922	DHFR;!Not Available	1. Dihydrofolate reductase;!2. Bifunctional dihydrofolate reductase-thymidylate synthase
C8H9N3O2	Not Available	Not Available	179.176	NC(=N)NC1=CC=C(C=C1)C(O)=O	Solid	Not Available					50014341	125204	CHEMBL20767	140479						GBS			159772	46505393					ZINC000000155851		4-guanidinobenzoic acid	Experimental	DB02459	InChI=1S/C8H9N3O2/c9-8(10)11-6-3-1-5(2-4-6)7(12)13/h1-4H,(H,12,13)(H4,9,10,11)	SXTSBZBQQRIYCU-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.0894 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	5	4	No	1	0	99.2 Å2	17.62 Å3	59.45 m3·mol-1	2	Yes	No	0.92 mg/mL	-1	-2.3	4.02	10.26	P00751	CFB	1. Complement factor B
C12H17N3O3S	Not Available	Not Available	283.35	CC(C)C1=CC=C(C=C1S(C)(=O)=O)C(=O)NC(N)=N	Solid	Not Available	P05164	MPO	1. Myeloperoxidase		50058759		CHEMBL436559	133240						HG0								Cariporide	ZINC000013474734		Cariporide	Investigational	DB06468	InChI=1S/C12H17N3O3S/c1-7(2)9-5-4-8(11(16)15-12(13)14)6-10(9)19(3,17)18/h4-7H,1-3H3,(H4,13,14,15,16)	IWXNYAIICFKCTM-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	Yes	5	3	No	1	1	113.11 Å2	29 Å3	84.17 m3·mol-1	3	Yes	No	0.15 mg/mL	0.63	-3.3	10.27	7.62	P19634	SLC9A1	1. Sodium/hydrogen exchanger 1
C8H11N3O	Not Available	Not Available	165.1924	NC(=N)NC1=CC=C(CO)C=C1	Solid	Not Available								16465530						1JZ			17975425	99443371					ZINC000015555321		1-[4-(hydroxymethyl)phenyl]guanidine	Experimental	DB06900	InChI=1S/C8H11N3O/c9-8(10)11-7-3-1-6(5-12)2-4-7/h1-4,12H,5H2,(H4,9,10,11)	JAFHTIHHRCEJDS-UHFFFAOYSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.2760 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	4	No	1	1	82.13 Å2	17.56 Å3	59.01 m3·mol-1	2	Yes	No	0.858 mg/mL	0.18	-2.3	15.1	10.64	Q16651	PRSS8	1. Prostasin
C10H11F3N4S	Not Available	Not Available	276.281	NC(=N)NC(=N)SCC1=CC=CC(=C1)C(F)(F)F	Solid	Not Available					18052		CHEMBL387262	7822426						817			9543472	99443733							1-{[N-(1-Imino-guanidino-methyl)]sulfanylmethyl}-3-trifluoromethyl-benzene	Experimental	DB07262	InChI=1S/C10H11F3N4S/c11-10(12,13)7-3-1-2-6(4-7)5-18-9(16)17-8(14)15/h1-4H,5H2,(H5,14,15,16,17)	DWJNPCRXBNWCJC-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.9826 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	4	No	1	2	85.75 Å2	24.64 Å3	86.33 m3·mol-1	4	Yes	No	0.0226 mg/mL	2.69	-4.1		10.03	P0ABQ4	folA	1. Dihydrofolate reductase
C10H15N5O2	Not Available	Not Available	237.2584	COC1=CC(OC)=CC(NC(=N)NC(N)=N)=C1	Solid	Not Available							CHEMBL1235693	2012213						RJ6			2730282	99444950					ZINC000015924296		N-(3,5-dimethoxyphenyl)imidodicarbonimidic diamide	Experimental	DB08479	InChI=1S/C10H15N5O2/c1-16-7-3-6(4-8(5-7)17-2)14-10(13)15-9(11)12/h3-5H,1-2H3,(H6,11,12,13,14,15)	VQKIGKHIRBCYNE-UHFFFAOYSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.2313 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	7	5	No	1	2	116.24 Å2	24.6 Å3	85.83 m3·mol-1	3	Yes	No	0.137 mg/mL	0.41	-3.2	19.15	9.96	P04818	TYMS	1. Thymidylate synthase
C5H14N4	Not Available	Not Available	130.1915	NCCCCNC(N)=N	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4		85213	17431	CHEMBL58343	194			HMDB0001432	C00179		AG2			199	175427116				Agmatine	ZINC000001532560		Agmatine	Experimental	DB08838	InChI=1S/C5H14N4/c6-3-1-2-4-9-5(7)8/h1-4,6H2,(H4,7,8,9)	QYPPJABKJHAVHS-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.7458 LD50, mol/kg	Inhibitor	Weak inhibitor	Non-inhibitor							234-238 degress Celcius			1	No	4	4	No	0	2	87.92 Å2	15.01 Å3	48.09 m3·mol-1	4	Yes	No	3.61 mg/mL	-1.2	-1.6		12.61	P18825;!Q9Y2I1;!P02708;!Q05586;!P48048;!Q00975;!Q9UHC3	ADRA2C;!NISCH;!CHRNA1;!GRIN1;!KCNJ1;!CACNA1B;!ASIC3	1. Alpha-2C adrenergic receptor;!2. Nischarin;!3. Acetylcholine receptor subunit alpha;!4. Glutamate receptor ionotropic, NMDA 1;!5. ATP-sensitive inward rectifier potassium channel 1;!6. Voltage-dependent N-type calcium channel subunit alpha-1B;!7. Acid-sensing ion channel 3
C12H13I3N2O2	Not Available	Not Available	597.961	CN(C)C=NC1=C(I)C=C(I)C(CCC(O)=O)=C1I	Solid	Not Available							CHEMBL3306201	20473670									5241	310265212		5976					Iopodic acid	Approved, Investigational, Withdrawn	DB09333	InChI=1S/C12H13I3N2O2/c1-17(2)6-16-12-9(14)5-8(13)7(11(12)15)3-4-10(18)19/h5-6H,3-4H2,1-2H3,(H,18,19)	YQNFBOJPTAXAKV-UHFFFAOYSA-N		Iopodic acid is an iodine containing cholecystography agent.	Iopodic acid is cathegorized as one of the top 10 linked to skin reactions.5	Small Molecule																													579.8ºC at 760 mmHg	3.73		168-169ºC	4.8	Insoluble	1	No	4	1	No	1	-1	52.9 Å2	40.23 Å3	104.91 m3·mol-1	4	No	No	0.00819 mg/mL	3.4	-4.9	1.99	4.16	P55073	DIO3	1. Thyroxine 5-deiodinase
C7H16N4O2	Not Available	Not Available	188.2275	CNC(=N)NCCC[C@H](N)C(O)=O	Not Available	Not Available					92900	60257	CHEMBL256147	117259			HMDB0029416	C03884		NMM			132862	347828162				Methylarginine	ZINC000001529776		Tilarginine	Approved, Investigational	DB11815	InChI=1S/C7H16N4O2/c1-10-7(9)11-4-2-3-5(8)6(12)13/h5H,2-4,8H2,1H3,(H,12,13)(H3,9,10,11)/t5-/m0/s1	NTNWOCRCBQPEKQ-YFKPBYRVSA-N	4		Not Available	Small Molecule																																			1	No	6	5	No	0	1	111.23 Å2	19.79 Å3	58.7 m3·mol-1	5	Yes	No	1.45 mg/mL	-2.9	-2.1	2.48	12.64			
C11H15Cl2N5	Not Available	Not Available	288.18	CC(C)NC(=N)NC(=N)NC1=CC=C(Cl)C(Cl)=C1	Not Available	Not Available						135192	CHEMBL1213553	20950								PA165857067	9571037	347828579				Chlorproguanil	ZINC000000001136		Chlorproguanil	Investigational	DB12314	InChI=1S/C11H15Cl2N5/c1-6(2)16-10(14)18-11(15)17-7-3-4-8(12)9(13)5-7/h3-6H,1-2H3,(H5,14,15,16,17,18)	ISZNZKHCRKXXAU-UHFFFAOYSA-N	4		Not Available	Small Molecule																																			1	Yes	5	5	No	1	2	83.79 Å2	28.87 Å3	96.46 m3·mol-1	2	Yes	No	0.0808 mg/mL	2.99	-3.6		10			
C23H22ClN5O3	Betrixaban presents a minimal renal clearance (being 5-7% of the administered dose) 4.	Betrixaban presents a long half-life of between 19-27 hours 1.	451.91	COC1=CC=C(NC(=O)C2=CC=C(C=C2)C(=N)N(C)C)C(=C1)C(=O)NC1=CC=C(Cl)C=N1	Solid	The apparent volume of distribution os 32 L/kg Label.					50249298	140421	CHEMBL512351	18981107									10275777	347828616		1927851		Betrixaban	ZINC000030691754	BEVYXXA	Betrixaban	Approved, Investigational	DB12364	InChI=1S/C23H22ClN5O3/c1-29(2)21(25)14-4-6-15(7-5-14)22(30)27-19-10-9-17(32-3)12-18(19)23(31)28-20-11-8-16(24)13-26-20/h4-13,25H,1-3H3,(H,27,30)(H,26,28,31)	XHOLNRLADUSQLD-UHFFFAOYSA-N	3	Betrixaban is a Factor Xa inhibitor used for prophylaxis of venous thromboembolism in hospitalized patients.	Betrixaban presents a minimal hepatotoxicity, which is the main adverse effect found in this class of drugs. Some of the major adverse effects of Betrixaban are bleeding or hypersensitivity 4.	Small Molecule																																200-212 ºC		2.5-2.7 mg/ml	1	No	6	3	Yes	3	1	107.41 Å2	47.62 Å3	138.29 m3·mol-1	6	Yes	No	0.0163 mg/mL	3.03	-4.4	11.63	10.91	P00742	F10	1. Coagulation factor X
C11H15N3O5S2	Not Available	Not Available	333.38	CC1=CC(=C(C=C1C(=O)NC(N)=N)S(C)(=O)=O)S(C)(=O)=O	Not Available	Not Available							CHEMBL2107802	7975252									9799487	347829020				Rimeporide	ZINC000003951217		Rimeporide	Investigational	DB12861	InChI=1S/C11H15N3O5S2/c1-6-4-8(20(2,16)17)9(21(3,18)19)5-7(6)10(15)14-11(12)13/h4-5H,1-3H3,(H4,12,13,14,15)	GROMEQPXDKRRIE-UHFFFAOYSA-N	1		Not Available	Small Molecule																																			1	No	7	3	No	1	1	147.25 Å2	31.39 Å3	89.02 m3·mol-1	3	Yes	No	0.157 mg/mL	-1.3	-3.3	10.08	6.98			
C4H12N3O4P	Not Available	Not Available	197.131	CN(CCOP(O)(O)=O)C(N)=N	Not Available	Not Available						134856	CHEMBL2104114	21827									23342	347829199				Creatinolfosfate	ZINC000002029729		Creatinolfosfate	Investigational	DB13071	InChI=1S/C4H12N3O4P/c1-7(4(5)6)2-3-11-12(8,9)10/h2-3H2,1H3,(H3,5,6)(H2,8,9,10)	FOIPWTMKYXWFGC-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	No	6	4	No	0	-1	119.87 Å2	16.96 Å3	53.09 m3·mol-1	4	Yes	No	9.81 mg/mL	-1.9	-1.3	1.48	12.3			
C2H7N5	Not Available	Not Available	101.113	NC(=N)NC(N)=N	Not Available	Not Available						3095		5726				C07672					5939	347829224		1918319		Biguanide	ZINC000004097424		Biguanide	Approved, Investigational	DB13100	InChI=1S/C2H7N5/c3-1(4)7-2(5)6/h(H7,3,4,5,6,7)	XNCOSPRUTUOJCJ-UHFFFAOYSA-N	3		Not Available	Small Molecule																																			1	No	5	5	No	0	2	111.77 Å2	9.4 Å3	46.57 m3·mol-1	0	Yes	No	1.81 mg/mL	-1.5	-1.8	19.2	12.06			
C4H10N3O5P	Not Available	Not Available	211.1131	CN(CC(O)=O)C(=N)NP(O)(O)=O	Solid	Not Available						17287	CHEMBL1204644	567			HMDB0001511	C02305					9548602	347829286				Phosphocreatine	ZINC000003869774		Phosphocreatine	Nutraceutical	DB13191	InChI=1S/C4H10N3O5P/c1-7(2-3(8)9)4(5)6-13(10,11)12/h2H2,1H3,(H,8,9)(H4,5,6,10,11,12)	DRBBFCLWYRJSJZ-UHFFFAOYSA-N	3	Phosphocreatine is a cardioprotective agent indicated for use in cardiac surgery.	Not Available	Small Molecule																													449.1±47.0 °C at 760 mmHg			194-195 °C		3.52 mg/mL	1	No	7	5	No	0	-2	133.95 Å2	16.82 Å3	53.18 m3·mol-1	3	Yes	No	3.52 mg/mL	-2.3	-1.8	-1.1	13.57	Q14353;!P48029;!P06732;!P12532;!P17540;!P12277	GAMT;!SLC6A8;!CKM;!CKMT1A;!CKMT2;!CKB	1. Guanidinoacetate N-methyltransferase;!2. Sodium- and chloride-dependent creatine transporter 1;!3. Creatine kinase M-type;!4. Creatine kinase U-type, mitochondrial;!5. Creatine kinase S-type, mitochondrial;!6. Creatine kinase B-type
C6H13N5O	Not Available	Not Available	171.204	NC(=N)NC(=N)N1CCOCC1	Not Available	Not Available					50227841	94665	CHEMBL1490434	64715												30227		Moroxydine	ZINC000009302211		Moroxydine	Experimental	DB13597	InChI=1S/C6H13N5O/c7-5(8)10-6(9)11-1-3-12-4-2-11/h1-4H2,(H5,7,8,9,10)	KJHOZAZQWVKILO-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	No	6	4	No	1	2	98.22 Å2	17.22 Å3	65.72 m3·mol-1	0	Yes	No	1.41 mg/mL	-1.1	-2.1	19.16	11.85			
C20H24Cl2N10	Not Available	Not Available	475.38	ClC1=CC=C(NC(=N)NC(=N)N2CCN(CC2)C(=N)NC(=N)NC2=CC=C(Cl)C=C2)C=C1	Not Available	Not Available					50210775	135768	CHEMBL2104722	64722														Picloxydine	ZINC000030691566		Picloxydine	Experimental	DB13607	InChI=1S/C20H24Cl2N10/c21-13-1-5-15(6-2-13)27-17(23)29-19(25)31-9-11-32(12-10-31)20(26)30-18(24)28-16-7-3-14(22)4-8-16/h1-8H,9-12H2,(H4,23,25,27,29)(H4,24,26,28,30)	YNCLPFSAZFGQCD-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	No	10	8	No	3	4	150 Å2	47.38 Å3	171.62 m3·mol-1	2	No	No	0.0577 mg/mL	3.4	-3.9		10.07			
C27H44O3	The metabolic clearance rate was 23.5±4.34 ml/min in healthy male volunteers and 10.1±1.35 ml/min in male patients with uraemia 8. In the pediatric patients undergoing peritoneal dialysis receiving dose of 10.2 ng/kg (SD 5.5 ng/kg) for 2 months, the clearance rate was 15.3 mL/hr/kg Label.	After administration of single oral doses, the elimination half life was 5-8 hours Label.	416.6365	C[C@H](CCCC(C)(C)O)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	Solid	Upon intravenous administration, the volume of distribution of calcitriol was 0.49±0.14 L/kg in healthy male volunteers and 0.27±0.06 l/kg in uraemic male patients participating in a pharmacokinetic study 8. There is some evidence that calcitriol is transferred into human milk at low levels (ie, 2.2±0.1 pg/mL) in mothers Label. Calcitriol from maternal circulation may also enter the fetal circulation Label.	Q07973;!P08684	CYP24A1;!CYP3A4	1. 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial;!2. Cytochrome P450 3A4		50200182	17823	CHEMBL846	4444108	Drugs.com Drug Page	GtP Drug Page	HMDB0001903	C01673	D00129	VDX	PDRhealth Drug Page	PA448717	5280453	46508162	RxList Drug Page	1894	DAP000289	Calcitriol	ZINC000100015048	Rocaltrol, Vectical	Calcitriol	Approved, Nutraceutical	DB00136	InChI=1S/C27H44O3/c1-18(8-6-14-26(3,4)30)23-12-13-24-20(9-7-15-27(23,24)5)10-11-21-16-22(28)17-25(29)19(21)2/h10-11,18,22-25,28-30H,2,6-9,12-17H2,1,3-5H3/b20-10+,21-11-/t18-,22-,23-,24+,25+,27-/m1/s1	GMRQFYUYWCNGIN-NKMMMXOESA-N	4	Calcitriol is an active metabolite of vitamin D that is used to treat hyperparathyroidism and is also used in dialysis patients to combat hypocalcemia.	LD50 (oral, rat) = 620 μg/kg; LD50 (intraperitoneal, rat) > 5 mg/kg MSDS.Symptoms of calcitriol toxicity mirrors the early and late signs and symptoms of vitamin D intoxication associated with hypercalcemia 10. Early signs include weakness, headache, somnolence, nausea, vomiting, dry mouth, constipation, muscle pain, bone pain and metallic taste. Late signs are characterized by polyuria, polydipsia, anorexia, weight loss, nocturia, conjunctivitis (calcific), pancreatitis, photophobia, rhinorrhea, pruritus, hyperthermia, decreased libido, elevated BUN, albuminuria, hypercholesterolemia, elevated SGOT and SGPT, ectopic calcification, hypertension, cardiac arrhythmias and, rarely, overt psychosis 10.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	5.1352 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					5		113-114		Insoluble	1	No	3	3	Yes	3	0	60.69 Å2	51.13 Å3	126.53 m3·mol-1	6	Yes	No	0.00667 mg/mL	4.35	-4.8	14.39	-1.3			
C27H44O2	Not Available	288 hours	400.6371	C[C@H](CCCC(C)(C)O)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C	Solid	Not Available	O15528;!Q07973	CYP27B1;!CYP24A1	1. 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial;!2. 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial		50521013	17933	CHEMBL1040	4446820			HMDB0003550	C01561		VDY	PDRhealth Drug Page	PA164745614	5283731	46505690		1855064	DAP000290	Calcifediol	ZINC000004474414	Rayaldee	Calcifediol	Approved, Nutraceutical	DB00146	InChI=1S/C27H44O2/c1-19-10-13-23(28)18-22(19)12-11-21-9-7-17-27(5)24(14-15-25(21)27)20(2)8-6-16-26(3,4)29/h11-12,20,23-25,28-29H,1,6-10,13-18H2,2-5H3/b21-11+,22-12-/t20-,23+,24-,25+,27-/m1/s1	JWUBBDSIWDLEOM-DTOXIADCSA-N	4	Calcifediol is an active metabolite of vitamin D used to treat hyperparathyroidism as well as to combat hypocalcemia in dialysis patients.	Bone pain, constipation (especially in children or adolescents), diarrhea, drowsiness, dryness of mouth; headache (continuing), increased thirst, increase in frequency of urination, especially at night, or in amount of urine, irregular heartbeat, itching skin, loss of appetite, metallic taste, muscle pain, nausea or vomiting (especially in children or adolescents), unusual tiredness or weakness.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	4.1429 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					6				Insoluble	1	No	2	2	Yes	3	0	40.46 Å2	50.38 Å3	125.06 m3·mol-1	6	No	No	0.0022 mg/mL	5.65	-5.3	18.38	-0.98	P11473	VDR	1. Vitamin D3 receptor
C28H44O	There are no formal reports regarding the clearance rate of ergocalciferol. Due to the structural similarity, it is recommended to consult this parameter with cholecalciferol. On the other hand, the proposed renal clearance of calcitriol is of 31 ml/min.8	Ergocalciferol can be found circulation for 1-2 days. This quick turnover is presented due to hepatic conversion and uptake by fat and muscle cells where it is transformed to the active form.6	396.6484	CC(C)[C@@H](C)\C=C\[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C	Solid	The amount of circulating ergocalciferol is very limited as this compound is rapidly stored in fat tissue such as adipose tissue, liver and muscle. This is very obvious in reports that indicate that circulating ergocalciferol is significantly reduced in obese patients.6	Q96AT9;!P05108;!Q07973;!O15528;!Q02318;!Q6VVX0	RPE;!CYP11A1;!CYP24A1;!CYP27B1;!CYP27A1;!CYP2R1	1. Ribulose-phosphate 3-epimerase;!2. Cholesterol side-chain cleavage enzyme, mitochondrial;!3. 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial;!4. 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial;!5. Sterol 26-hydroxylase, mitochondrial;!6. Vitamin D 25-hydroxylase		50247883	28934	CHEMBL1536	4444351	Drugs.com Drug Page		HMDB0000900	C05441	D00187	D2V	PDRhealth Drug Page	PA449484	5280793	46505053	RxList Drug Page	4018	DAP000291	Ergocalciferol	ZINC000004629876	Drisdol, Mvi Pediatric	Ergocalciferol	Approved, Nutraceutical	DB00153	InChI=1S/C28H44O/c1-19(2)20(3)9-10-22(5)26-15-16-27-23(8-7-17-28(26,27)6)12-13-24-18-25(29)14-11-21(24)4/h9-10,12-13,19-20,22,25-27,29H,4,7-8,11,14-18H2,1-3,5-6H3/b10-9+,23-12+,24-13-/t20-,22+,25-,26+,27-,28+/m0/s1	MECHNRXZTMCUDQ-RKHKHRCZSA-N	4	Ergocalciferol is a vitamin found in many supplement products.	The reported LD50 for orally administered ergocalciferol in the rat is of 10 mg/kg.MSDS Overdosage with this agent is reported to produce hypervitaminosis characterized by hypercalcemia, renal impairment, calcification of soft tissues, a decline in the rate of linear growth and increase in bone mineralization.15Once an overdose state is registered, immediate withdrawal of vitamin D is required along with a calcium diet, generous intake of fluids and symptomatic treatment. The administration of loop diuretics is an option to increase renal calcium excretion. On the other hand, dialysis and administration of citrates, sulfates, phosphates, corticosteroids, EDTA and mithramycin are recommended.15There haven't been long term studies analyzing the carcinogenic and mutagenic potential of ergocalciferol or its effects in fertility.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	3.6931 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				Decomposes	8.89		115-117°C	6.35	Insoluble	1	No	1	1	No	3	0	20.23 Å2	50.72 Å3	128.89 m3·mol-1	5	No	Yes	0.000433 mg/mL	7.05	-6	18.38	-1.3	P11473;!BE0004902	VDR;!	1. Vitamin D3 receptor;!2. Voltage-dependent calcium channel (Protein Group)
C27H44O	Studies have determined that the mean clearance value of administered cholecalciferol supplementation in a group of 49 kidney transplant patients was approximately 2.5 L/day 5.	At this time, there have been resources that document the half-life of cholecalciferol as being about 50 days 8 while other sources have noted that the half-life of calcitriol (1,25-dihydroxyvitamin D3) is approximately 15 hours while that of calcidiol (25-hydroxyvitamin D3) is about 15 days 10.Moreover, it appears that the half-lives of any particular administration of vitamin d can vary due to variations in vitamin d binding protein concentrations and genotype in particular individuals 6.	384.6377	CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C	Solid	Studies have determined that the mean central volume of distribution of administered cholecalciferol supplementation in a group of 49 kidney transplant patients was approximately 237 L 5.	Q6VVX0;!Q02318;!P51589;!P08684;!P05108;!P04798;!P10632	CYP2R1;!CYP27A1;!CYP2J2;!CYP3A4;!CYP11A1;!CYP1A1;!CYP2C8	1. Vitamin D 25-hydroxylase;!2. Sterol 26-hydroxylase, mitochondrial;!3. Cytochrome P450 2J2;!4. Cytochrome P450 3A4;!5. Cholesterol side-chain cleavage enzyme, mitochondrial;!6. Cytochrome P450 1A1;!7. Cytochrome P450 2C8		50030475	28940	CHEMBL1042	4444353	Drugs.com Drug Page		HMDB0000876	C05443	D00188	VD3	PDRhealth Drug Page	PA164748138	5280795	46506365		1244014	DAP001273	Cholecalciferol	ZINC000004474460	Adrovance, Animi-3 With Vitamin D, Citranatal B-calm Kit, Citranatal Harmony, Fosamax Plus D, Fosavance, Infuvite, Infuvite Pediatric, Mvc-fluoride, Natafort, Pregvit, Vidextra	CholecalciferolCommonly known or available as Vitamin D3	Approved, Nutraceutical	DB00169	InChI=1S/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h12-13,19,21,24-26,28H,3,6-11,14-18H2,1-2,4-5H3/b22-12+,23-13-/t21-,24+,25-,26+,27-/m1/s1	QYSXJUFSXHHAJI-YRZJJWOYSA-N	4	Vitamin D3 is a form of Vitamin D used in the treatment of specific medical conditions such as refractory rickets, hypoparathyroidism, and familial hypophosphatemia, as well as osteoporosis and chronic kidney disease.	Chronic or acute administration of excessive doses of cholecalciferol may lead to hypervitaminosis D, manifested by hypercalcemia and its sequelae 12,13,14. Early symptoms of hypercalcemia may include weakness, fatigue, somnolence, headache, anorexia, dry mouth, metallic taste, nausea, vomiting, vertigo, tinnitus, ataxia, and hypotonia 12,13,14. Later and possibly more serious manifestation include nephrocalcinosis, renal dysfunction, osteoporosis in adults, impaired growth in children, anemia, metastatic calcification, pancreatitis, generalized vascular calcification, and seizures 12,13,14.Safety of doses in excess of 400 IU (10mcg) of vitamin D3 daily during pregnancy has not been established 12,13,14. Maternal hypercalcemia, possibly caused by excessive vitamin D intake during pregnancy, has been associated with hypercalcemia in neonates, which may lead to supravalvular aortic stenosis syndrome, the features of which may include retinopathy, mental or growth retardation, strabismus, and other effects 12,13,14. Hypercalcemia during pregnancy may also lead to suppression of parathyroid hormone release in the neonate, resulting in hypocalcemia, tetany, and seizures 12,13,14.Vitamin D is deficient in maternal milk; therefore, breastfed infants may require supplementation. Use of excessive amounts of Vitamin D in nursing mothers may result in hypercalcemia in infants. Doses of Vitamin D3 in excess of 10 µg daily should not be administered daily to nursing women.	Small Molecule	http://smpdb.ca/view/SMP0000099?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000111?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000209?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000388?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000389?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000510?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000082?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000089?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000092?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000107?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000117?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000119?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000319?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000508?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000023?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000079?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000095?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000112?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000131?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000386?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000387?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000509?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169;!http://smpdb.ca/view/SMP0000511?highlight[compounds][]=DB00169&highlight[proteins][]=DB00169	Lovastatin Action Pathway;!Cerivastatin Action Pathway;!Hypercholesterolemia;!Chondrodysplasia Punctata II, X-Linked Dominant (CDPX2);!Smith-Lemli-Opitz Syndrome (SLOS);!Mevalonic Aciduria;!Simvastatin Action Pathway;!Pravastatin Action Pathway;!Rosuvastatin Action Pathway;!Zoledronate Action Pathway;!Pamidronate Action Pathway;!Fluvastatin Action Pathway;!Lysosomal Acid Lipase Deficiency (Wolman Disease);!Cholesteryl Ester Storage Disease;!Steroid Biosynthesis;!Ibandronate Action Pathway;!Alendronate Action Pathway;!Risedronate Action Pathway;!Atorvastatin Action Pathway;!Desmosterolosis;!CHILD Syndrome;!Hyper-IgD Syndrome;!Wolman Disease		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	3.9310 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					7.5		84.5 °C		Insoluble	1	No	1	1	Yes	3	0	20.23 Å2	49.63 Å3	123.22 m3·mol-1	6	No	Yes	0.00038 mg/mL	7.13	-6	18.38	-1.3	P11473	VDR	1. Vitamin D3 receptor
C22H28F2O5	Not Available	Not Available	410.4515	[H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C	Solid	Not Available						59750	CHEMBL1201380	64505	Drugs.com Drug Page		HMDB0014368		D07827			PA164749408	71415	46504519	RxList Drug Page	91311	DAP001184	Diflorasone	ZINC000005752191	Apexicon, Florone, Psorcon	Diflorasone	Approved	DB00223	InChI=1S/C22H28F2O5/c1-11-6-13-14-8-16(23)15-7-12(26)4-5-19(15,2)21(14,24)17(27)9-20(13,3)22(11,29)18(28)10-25/h4-5,7,11,13-14,16-17,25,27,29H,6,8-10H2,1-3H3/t11-,13-,14-,16-,17-,19-,20-,21-,22-/m0/s1	WXURHACBFYSXBI-XHIJKXOTSA-N		Diflorasone is a topical corticosteroid used to treat the symptoms of various inflammatory skin conditions that cause erythema, pruritus, and discomfort.	Topically applied diflorasone can be absorbed in sufficient amounts to produce systemic effects. Symptoms of overdose include thinning of skin and suppression of adrenal cortex (decreased ability to respond to stress).	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3293 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.1					1	Yes	5	3	No	4	0	94.83 Å2	40.92 Å3	102.32 m3·mol-1	2	Yes	No	0.0853 mg/mL	1.34	-3.7	12.42	-3.3	P04150	NR3C1	1. Glucocorticoid receptor
C22H32O3	Not Available	Not Available	344.4877	[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)CC[C@]12C	Solid	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5			34829	CHEMBL1201173	216968	Drugs.com Drug Page		HMDB0014398	C14643	D02289			PA450346	247839	46506584	RxList Drug Page	29439	DAP001048	Medrysone	ZINC000003977945	Hms	Medrysone	Approved	DB00253	InChI=1S/C22H32O3/c1-12-9-15-17-6-5-16(13(2)23)22(17,4)11-19(25)20(15)21(3)8-7-14(24)10-18(12)21/h10,12,15-17,19-20,25H,5-9,11H2,1-4H3/t12-,15-,16+,17-,19-,20+,21-,22+/m0/s1	GZENKSODFLBBHQ-ILSZZQPISA-N		Medrysone is a topical glucocorticoid applied ophthalmically for the treatment of various ocular inflammatory or allergic conditions.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.3015 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.2		156.5 °C			1	Yes	3	1	No	4	0	54.37 Å2	39.94 Å3	98.85 m3·mol-1	1	Yes	No	0.0337 mg/mL	3.13	-4	18.37	-0.26	P04150	NR3C1	1. Glucocorticoid receptor
C28H35FO7	Not Available	Not Available	502.5717	[H][C@@]12C[C@H]3OC4(CCCC4)O[C@@]3(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5			31199	CHEMBL1200732	392009	Drugs.com Drug Page		HMDB0014433		D01387		PDRhealth Drug Page	PA164746074	443958	46506705	RxList Drug Page	17652	DAP001044	Amcinonide	ZINC000003977777		Amcinonide	Approved	DB00288	InChI=1S/C28H35FO7/c1-16(30)34-15-22(33)28-23(35-26(36-28)9-4-5-10-26)13-20-19-7-6-17-12-18(31)8-11-24(17,2)27(19,29)21(32)14-25(20,28)3/h8,11-12,19-21,23,32H,4-7,9-10,13-15H2,1-3H3/t19-,20-,21-,23+,24-,25-,27-,28+/m0/s1	ILKJAFIWWBXGDU-MOGDOJJUSA-N		Amcinonide is a topical corticosteroid used in the treatment of inflammation and pruritus due to a variety of dermatoses.	Results from acute toxicity studies do not indicate that any risk of acute intoxication is to be expected following a single dermal application of an overdose (application over a large area under conditions favorable to absorption) or inadvertent oral ingestion.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.4315 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.3					1	No	6	1	No	6	0	99.13 Å2	52.38 Å3	127.88 m3·mol-1	4	No	No	0.00774 mg/mL	3.2	-4.8	13.63	-3.4	P04150;!P04083	NR3C1;!ANXA1	1. Glucocorticoid receptor;!2. Annexin A1
C22H28O2	The clearance rate of etonogestrel is reported to be of 7.5 L/h.3	The elimination half-life of etonogestrel is reported to be of 25 hours which indicates a reversible contraceptive effect.7	324.4565	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	Solid	The apparent volume of distribution of etonogestrel is of around 201 L.3	P08684	CYP3A4	1. Cytochrome P450 3A4		50423516	50777	CHEMBL1531	5292944	Drugs.com Drug Page		HMDB0014439				PDRhealth Drug Page	PA164771231	6917715	46505321		14584	DAP000855	Etonogestrel	ZINC000011680067	Eluryng, Implanon, Nexplanon, Nuvaring	Etonogestrel	Approved, Investigational	DB00294	InChI=1S/C22H28O2/c1-4-21-13-14(3)20-17-9-7-16(23)12-15(17)6-8-18(20)19(21)10-11-22(21,24)5-2/h2,12,17-20,24H,3-4,6-11,13H2,1H3/t17-,18-,19-,20+,21-,22-/m0/s1	GCKFUYQCUCGESZ-BPIQYHPVSA-N	4	Etonogestrel is a long-acting synthetic derived progestin contraceptive used in various devices such as contraceptive rings and intradermal implants.	The reported LD50 of oral etonogestrel in the rat is reported to be higher than 2000 mg/kg.MSDS Overdosage can only happen when more than one implant is inserted. In cases of overdose, removal of the implant is recommended.LabelThere aren't reports relating etonogestrel with carcinogenesis, mutagenesis or impaired fertility.Label	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.1164 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				473.1ºC at 760 mmHg	3.32		196-200ºC	10.4	Insoluble	1	Yes	2	1	No	4	0	37.3 Å2	37.83 Å3	96.35 m3·mol-1	1	Yes	Yes	0.00737 mg/mL	3.6	-4.6	17.99	-1.5	P06401	PGR	1. Progesterone receptor
C22H30O	The metabolic clearance rate of desogestrel is reported to be of about 2 ml/min/kg.14	The terminal half-life of desogestrel is determined to be of 30 hours.14	310.473	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCCC=C3CC[C@@]21[H]	Solid	The apparent volume of distribution of desogestrel is of 1.5 L/kg.14	P08684;!P11712;!P22309	CYP3A4;!CYP2C9;!UGT1A1	1. Cytochrome P450 3A4;!2. Cytochrome P450 2C9;!3. UDP-glucuronosyltransferase 1-1		50423510	4453	CHEMBL1533	37400			HMDB0014449	C07629	D02367			PA449238	40973	46505739	RxList Drug Page	22656	DAP001209	Desogestrel	ZINC000004097416	Apri 28 Day, Azurette 28 Day, Bekyree 28 Day, Caziant 28 Day, Cesia 28 Day, Cyred 28 Day, Emoquette, Enskyce 28 Day, Freya, Isibloom 28 Day, Juleber 28 Day, Kalliga, Kariva 28 Day, Linessa, Marvelon, Mircette 28 Day, Pimtrea Pack, Reclipsen, Simliya, Velivet 28 Day, Viorele 28 Day, Volnea 28 Day	Desogestrel	Approved	DB00304	InChI=1S/C22H30O/c1-4-21-14-15(3)20-17-9-7-6-8-16(17)10-11-18(20)19(21)12-13-22(21,23)5-2/h2,8,17-20,23H,3-4,6-7,9-14H2,1H3/t17-,18-,19-,20+,21-,22-/m0/s1	RPLCPCMSCLEKRS-BPIQYHPVSA-N	4	Desogestrel is a synthetic progestin used in contraception, often in combination with ethinyl estradiol.	Administration of large quantities of desogestrel has been shown to produce strong hormonal effects but to lack chronic toxicity. The reported LD50 in rats after oral administration of desogestrel is higher than 2000 mg/kg.10 Overdose hasn't reported serious effects but only symptoms of nausea and withdrawal of bleeding.LabelMost reports haven't linked the administration of desogestrel with the increased risk of breast cancer. The increased risk has been reported to be related to the duration of use. However, several reports indicate a desogestrel-driven increased risk in cervical intra-epithelial neoplasia but the results are still not conclusive.Label	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.3315 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				428ºC	5.65		109-110ºC	13.04	<1 mg/ml	1	Yes	1	1	No	4	0	20.23 Å2	37.51 Å3	95.73 m3·mol-1	1	Yes	Yes	0.00301 mg/mL	4.42	-5	17.99	-1.5	P06401;!P03372	PGR;!ESR1	1. Progesterone receptor;!2. Estrogen receptor alpha
C22H29FO4	Not Available	Not Available	376.4617	[H][C@@]12CC[C@](O)(C(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C	Solid	Not Available	P20815;!P08684	CYP3A5;!CYP3A4	1. Cytochrome P450 3A5;!2. Cytochrome P450 3A4		50103631	31625	CHEMBL1200600	9494	Drugs.com Drug Page		HMDB0014469		D01367		PDRhealth Drug Page	PA164781355	9878	46505984	RxList Drug Page	4491	DAP001047	Fluorometholone	ZINC000118912517	FML, FML Forte Liquifilm, FML-S, Flarex, Fluor-OP	Fluorometholone	Approved, Investigational	DB00324	InChI=1S/C22H29FO4/c1-12-9-17-15-6-8-21(27,13(2)24)20(15,4)11-18(26)22(17,23)19(3)7-5-14(25)10-16(12)19/h5,7,10,12,15,17-18,26-27H,6,8-9,11H2,1-4H3/t12-,15-,17-,18-,19-,20-,21-,22-/m0/s1	FAOZLTXFLGPHNG-KNAQIMQKSA-N	4	Fluorometholone is an ophthalmic corticosteroid used for the relief of inflammation located in both the palpebral and bulbar conjunctiva, the cornea, and the anterior segment of the globe of the eye.	Side effects may include acute anterior uveitis and perforation of the globe. Keratitis, conjunctivitis, corneal ulcers, mydriasis, conjunctival hyperemia, loss of accommodation and ptosis have occasionally been reported following local use of corticosteroids. LD50 = 234 mg/kg (rats)	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3393 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.00	-4.1	292-303		30 mg/L (at 25 °C)	1	Yes	4	2	No	4	0	74.6 Å2	39.94 Å3	100.87 m3·mol-1	1	Yes	No	0.0166 mg/mL	2.42	-4.4	12.65	-3.4	P04150	NR3C1	1. Glucocorticoid receptor
C24H32O4	Not Available	34 hours	384.516	[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4		50238674	6723	CHEMBL1201139	11192	Drugs.com Drug Page			C08151	D00952			PA450351	11683	46505827	RxList Drug Page	29451	DAP000861	Megestrol	ZINC000004097467	Megace	Megestrol acetate	Approved, Investigational, Vet approved	DB00351	InChI=1S/C24H32O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h12-13,18-20H,6-11H2,1-5H3/t18-,19+,20+,22-,23+,24+/m1/s1	RQZAXGRLVPAYTJ-GQFGMJRRSA-N	4	Megestrol acetate is a progestin that is administered orally to treat anorexia and cachexia or serious unexplained weight loss and is also used as an antineoplastic agent to treat certain types of malignancy.	No serious unexpected side effects have resulted from studies involving megestrol acetate oral suspension administered in dosages as high as 1200 mg/day. Treatment with megestrol acetate, an orexigenic agent, has also resulted in iatrogenic adrenal suppression. The mechanism is presumably related to the glucocorticoid properties of megestrol acetate [PMID: 12872362].	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	1.8121 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.2		218.0-220.0 °C		2 µg/mL (at 37 °C for the acetate salt)	1	Yes	3	0	No	4	0	60.44 Å2	43.51 Å3	108.66 m3·mol-1	3	Yes	No	0.00336 mg/mL	3.72	-5.1	17.83	-4.9	P06401;!P04150	PGR;!NR3C1	1. Progesterone receptor;!2. Glucocorticoid receptor
C21H28O2	Clearance was found to 4.8 L/h in healthy female volunteers with a normal BMI, and 7.70-8.51 L/h in obese patients after a single 1.5 mg dose.6 After a 0.75 mg dose of levonorgestrel in 16 patients in another pharmacokinetic study, mean clearance was calculated at 7.06 L/h.4 Following levonorgestrel implant removal, the serum concentration falls below 100 pg/mL within the first 96 hours and further falls below the sensitivity of detection within the range of 5 days to 2 weeks.29	The elimination half-life of a 0.75 mg dose of 1.5 mg of levonorgestrel ranges between 20-60 hours post-administration.3 A pharmacokinetic study of women with a normal BMI and BMI over revealed an elimination half-life of 29.7 h and 41.0-46.4 hours, respectively.6 Another pharmacokinetic study revealed a mean elimination half-life of 24.4 hours after a 0.75 mg dose of levonorgestrel was administered to 16 patients.4	312.4458	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	Solid	One pharmacokinetic study determined a mean steady-state volume of distribution of 1.5 mg of levonorgestrel to be 162.2 L in those with normal BMI and in the range of 404.7 L to 466.4 L in obese patients with a body mass index of at least 30.6 Mean volume of distribution in 16 patients receiving 0.75 mg of levonorgestrel in another pharmacokinetic study was 260 L.4 The Plan B one-step FDA label reports an apparent volume of distribution of 1.8 L/kg.19	P20815;!P08684	CYP3A5;!CYP3A4	1. Cytochrome P450 3A5;!2. Cytochrome P450 3A4		50410522	6443	CHEMBL1389	12560	Drugs.com Drug Page	GtP Drug Page	HMDB0014511	C08153	D00950	NOG	PDRhealth Drug Page	PA450218	13109	46508082	RxList Drug Page	6373	DAP001207	Levonorgestrel	ZINC000003814395	Afirmelle 28 Day, Aftera, Alesse, Altavera 28 Day, Amethia 91 Day, Amethyst, Ashlyna 91 Day, Aubra 28 Day, Aviane 28, Ayuna 28 Day Pack, Balcoltra 28 Day, Bionafem, Camrese 91 Day, Camreselo 91 Day, Chateal 28 Day, Climara Pro, Daysee 91 Day, Delyla 28 Day, Dolishale 28 Day, Econtra, Enpresse 28 Day, Fallback Solo, Falmina 28 Day, Fayosim 91 Day, Iclevia 91 Day, Indayo, Introvale 91 Day, Jaimiess 91 Day, Jolessa 91 Day, Kurvelo, Kyleena, Larissia 28 Day Pack, Levonest 28 Day, Levora 0.15/30 28 Day, Liletta, Lillow 28 Day, Lo Simpesse, LoJaimiess, Loseasonique, Lutera 28 Day, Marlissa 28 Day, Min-ovral, Mirena, Morning After, My Choice, My Way, Myzilra 28 Day, New Day, Next Choice, Next Choice One Dose, Opcicon One-step, Option 2, Orsythia 28 Day, Plan B, Plan B One-step, Portia 28 Day, Preventeza, Quartette 91 Day Pack, React, Rivelsa 91 Day, Seasonale, Seasonique, Setlakin 91 Day, Simpesse, Skyla, Sronyx 28 Day, Take Action, Triquilar, Trivora 28 Day, Twirla 3 Count Weekly Patch, Tyblume 28 Day, Vienva 28 Day	Levonorgestrel	Approved, Investigational	DB00367	InChI=1S/C21H28O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,13,16-19,23H,3,5-12H2,1H3/t16-,17+,18+,19-,20-,21-/m0/s1	WWYNJERNGUHSAO-XUDSTZEESA-N	4	Levonorgestrel is a progestin found in oral and IUD contraceptives and at higher doses in emergency contraceptives.	The oral LD50 in rats is greater than 5000 mg/kg.24An overdose of this drug, like other contraceptives, may cause nausea and withdrawal bleeding. Provide symptomatic treatment in the case of a levonorgestrel overdose and contact the local poison control center. There is no specific antidote for a levonorgestrel overdose.19,25,26	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.8264 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				459.1	3.8	-4.7	240 °C	17.91,-1.5	0.0058 g/L	1	Yes	2	1	No	4	0	37.3 Å2	36.75 Å3	92.03 m3·mol-1	1	Yes	Yes	0.00583 mg/mL	3.66	-4.7	17.91	-1.5			
C21H28O2	Not Available	Dydrogesterone: 5-7 hours, 20-dihydrodydrogesterone (DHD) metabolite: 14-17 hours	312.4458	[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]2([H])C=CC2=CC(=O)CC[C@@]12C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			31527	CHEMBL1200853	8699		GtP Drug Page	HMDB0014522		D01217			PA164745443	9051	46506195		3706	DAP001205	Dydrogesterone	ZINC000003875998		Dydrogesterone	Approved, Investigational, Withdrawn	DB00378	InChI=1S/C21H28O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h4-5,12,16-19H,6-11H2,1-3H3/t16-,17+,18-,19+,20+,21+/m0/s1	JGMOKGBVKVMRFX-HQZYFCCVSA-N	4	Dydrogesterone is a synthetic progesterone for menstrual cycle regulation, infertility treatment, prevention of miscarriage, and other conditions.	No serious or unexpected toxicity has been observed with dydrogesterone. In acute toxicity studies, the LD50 doses in rats exceeded 4,640mg/kg for the oral route.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	1.8041 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.4		168-169			1	Yes	2	0	No	4	0	34.14 Å2	36.39 Å3	93.82 m3·mol-1	1	Yes	Yes	0.00486 mg/mL	3.79	-4.8	19.4	-4.8	P06401	PGR	1. Progesterone receptor
C28H37ClO7	Following intravenous administration, the clearance of beclomethasone dipropionate and 17-BMP were 150 L/h and 120 L/h, respectively.1	Following intravenous administration, the half life of beclomethasone dipropionate was 0.5 hours while the half life of the active metabolite 17-BMP was 2.7 hours. Following oral and intranasal administration, the half life of 17-BMP was 8.8 and 5.7 hours, respectively.1	521.042	[H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	Following intravenous administration, the steady-state volume of distribution was 20 L for beclomethasone dipropionate and 424 L for the active metabolite, beclomethasone-17-monopropionate.1	P20815;!P08684	CYP3A5;!CYP3A4	1. Cytochrome P450 3A5;!2. Cytochrome P450 3A4			3002	CHEMBL1200500	20396	Drugs.com Drug Page		HMDB0014538	C07813	D07495			PA448547	21700	46509195	RxList Drug Page	1348	DAP000416	Beclometasone	ZINC000003938744	Alanase, Beconase, Propaderm, Qnasl, Qvar, Rivanase AQ	Beclomethasone dipropionate	Approved, Investigational	DB00394	InChI=1S/C28H37ClO7/c1-6-23(33)35-15-22(32)28(36-24(34)7-2)16(3)12-20-19-9-8-17-13-18(30)10-11-25(17,4)27(19,29)21(31)14-26(20,28)5/h10-11,13,16,19-21,31H,6-9,12,14-15H2,1-5H3/t16-,19-,20-,21-,25-,26-,27-,28-/m0/s1	KUVIULQEHSCUHY-XYWKZLDCSA-N	4	Beclomethasone dipropionate is an inhaled corticosteroid used as maintenance treatment in the prophylaxis of asthma attacks.	The oral LD50 in rats is >3750 mg/kg.MSDS The acute toxicity of beclometasone dipropionate is low. The only harmful effect that follows inhalation of large amounts of the drug over a short period of time is suppression of hypothalamic-pituitary-adrenal (HPA) function. Chronic: The excessive use of beclometasone dipropionate over a long period could lead to adrenal suppression.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.1115 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.49		208-210			1	No	5	1	Yes	4	0	106.97 Å2	54.46 Å3	134.79 m3·mol-1	8	No	No	0.00208 mg/mL	4.43	-5.4	13.85	-3.3	P04150	NR3C1	1. Glucocorticoid receptor
C21H30O2	Apparent clearance1367 ± 348 (50mg of progesterone administered by vaginal insert once daily) 11.106 ± 15 L/h (50mg/mL IM injection once daily) 11.	Absorption half-life is approximately 25-50 hours and an elimination half-life of 5-20 minutes (progesterone gel) 20. Progesterone, administered orally, has a short serum half-life (approximately 5 minutes). It is rapidly metabolized to 17-hydroxyprogesterone during its first pass through the liver 11.	314.4617	[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	When administered vaginally, progesterone is well absorbed by uterine endometrial tissue, and a small percentage is distributed into the systemic circulation.The amount of progesterone in the systemic circulation appears to be of minimal importance, especially when implantation, pregnancy, and live birth outcomes appear similar for intramuscular and vaginal administration of progesterone 11.					8903	17026	CHEMBL103	5773	Drugs.com Drug Page		HMDB0001830	C00410	D00066	STR	PDRhealth Drug Page	PA451123	5994	46508968	RxList Drug Page	8727	DAP000549	Progesterone	ZINC000004428529	Bijuva, Crinone, Endometrin, Prochieve, Prometrium	Progesterone	Approved, Vet approved	DB00396	InChI=1S/C21H30O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h12,16-19H,4-11H2,1-3H3/t16-,17+,18-,19-,20-,21+/m0/s1	RJKFOVLPORLFTN-LEKSSAKUSA-N	4	Progesterone is a hormone used for a variety of functions, including contraception, control of abnormal uterine bleeding, maintenance of pregnancy, and prevention of endometrial hyperplasia.	Intraperitoneal LD50 (rat): 327 mg/kg MSDS. Use in pregnancyOnly forms of progesterone that are indicated on product labeling for pregnancy should be used. Some forms of progesterone should not be used in pregnancy Label, 22. Refer to individual product monographs for information regarding use in pregnancy. Many studies have found no effects on fetal development associated with long-term use of contraceptive doses of oral progestins. Studies of infant growth and development that have been conducted have not demonstrated significant adverse effects, however, these studies are few in number. It is therefore advisable to rule out suspected pregnancy before starting any hormonal contraceptive 22. Effects on fertilityProgesterone at high doses is an antifertility drug and high doses would be expected to impair fertility until cessation 25. The progesterone contraceptive should not be used during pregnancy. CarcinogenicityProgesterone has been shown to induce or promote the formation of ovarian, uterine, mammary, and genital tract tumors in animals. The clinical relevance of these findings is unknown 24. Certain epidemiological studies of patients using oral contraceptives have reported an increased relative risk of developing breast cancer, especially at a younger age and associated with a longer duration of use. These studies have mainly involved combined oral contraceptives, and therefore, it is unknown whether this risk is attributable to progestins, estrogens, or a combination of both. At this time, there is insufficient data to determine whether the use of progestin-only contraceptives increases the risk in a similar way to combined contraceptives. A meta-analysis of 54 studies showed a small increase in the frequency of breast cancer diagnosis for women who were currently using combined oral contraceptives, or had used them within the past 10 years. There was no increase in the frequency of having breast cancer diagnosed ten or more years after cessation of hormone use. Women with breast cancer should not use oral contraceptives, as there is no sufficient data to fully establish or negate the risk of cancer with hormonal contraceptive use 22. Use in breastfeedingProgesterone has been detected in the milk of nursing mothers 21, 22. No adverse effects, in general, have been found on breastfeeding ability or on the health, growth, or development of the growing infant. Despite this, isolated post-marketing cases of decreased milk production have been reported 22.	Small Molecule	http://smpdb.ca/view/SMP0000371?highlight[compounds][]=DB00396&highlight[proteins][]=DB00396;!http://smpdb.ca/view/SMP0000575?highlight[compounds][]=DB00396&highlight[proteins][]=DB00396;!http://smpdb.ca/view/SMP0000717?highlight[compounds][]=DB00396&highlight[proteins][]=DB00396;!http://smpdb.ca/view/SMP0000372?highlight[compounds][]=DB00396&highlight[proteins][]=DB00396;!http://smpdb.ca/view/SMP0000577?highlight[compounds][]=DB00396&highlight[proteins][]=DB00396;!http://smpdb.ca/view/SMP0000718?highlight[compounds][]=DB00396&highlight[proteins][]=DB00396;!http://smpdb.ca/view/SMP0000130?highlight[compounds][]=DB00396&highlight[proteins][]=DB00396;!http://smpdb.ca/view/SMP0000373?highlight[compounds][]=DB00396&highlight[proteins][]=DB00396;!http://smpdb.ca/view/SMP0000566?highlight[compounds][]=DB00396&highlight[proteins][]=DB00396;!http://smpdb.ca/view/SMP0000576?highlight[compounds][]=DB00396&highlight[proteins][]=DB00396;!http://smpdb.ca/view/SMP0000578?highlight[compounds][]=DB00396&highlight[proteins][]=DB00396	Congenital Lipoid Adrenal Hyperplasia (CLAH) or Lipoid CAH;!11-beta-Hydroxylase Deficiency (CYP11B1);!Apparent Mineralocorticoid Excess Syndrome;!Adrenal Hyperplasia Type 5 or Congenital Adrenal Hyperplasia Due to 17 alpha-Hydroxylase Deficiency;!Corticosterone Methyl Oxidase I Deficiency (CMO I);!3-beta-Hydroxysteroid Dehydrogenase Deficiency;!Steroidogenesis;!Adrenal Hyperplasia Type 3 or Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency;!17-alpha-Hydroxylase Deficiency (CYP17);!21-Hydroxylase Deficiency (CYP21);!Corticosterone Methyl Oxidase II Deficiency (CMO II)		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	1.8041 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				394.13°C (rough estimate)	3.87	-4.43	128-132	Strongest acidic: , Strongest basic: 18.92, -4.8	<0.1 g/100 mL at 19 ºC	1	Yes	2	0	No	4	0	34.14 Å2	37.26 Å3	92.71 m3·mol-1	1	Yes	Yes	0.00546 mg/mL	4.15	-4.8	18.47	-4.8			
C24H32O4S	Clearance data is not readily available.Label,7	1.4 hours.Label,7Canrenone has a half life of 16.5 hours, 7-α-thiomethylspirolactone has a half life of 13.8 hours, and 6-ß-hydroxy-7-α-thiomethylspirolactone has a half life of 15 hours.Label,7	416.573	[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O	Solid	Volume of distribution data is not readily available.Label,7	P15538;!P10632	CYP11B1;!CYP2C8	1. Cytochrome P450 11B1, mitochondrial;!2. Cytochrome P450 2C8		50228080	9241	CHEMBL1393	5628	Drugs.com Drug Page	GtP Drug Page	HMDB0014565	C07310	D00443	SNL	PDRhealth Drug Page	PA451483	5833	46508525	RxList Drug Page	9997	DAP000297	Spironolactone	ZINC000003861599	Aldactazide, Aldactone, Carospir	Spironolactone	Approved	DB00421	InChI=1S/C24H32O4S/c1-14(25)29-19-13-15-12-16(26)4-8-22(15,2)17-5-9-23(3)18(21(17)19)6-10-24(23)11-7-20(27)28-24/h12,17-19,21H,4-11,13H2,1-3H3/t17-,18-,19+,21+,22-,23-,24+/m0/s1	LXMSZDCAJNLERA-ZHYRCANASA-N	4	Spironolactone is an aldosterone receptor antagonist used for the treatment of hypertension, hyperaldosteronism, edema due to various conditions, hirsutism (off-label) and hypokalemia.	Patients experiencing an overdose may present with drowsiness, mental confusion, maculopapular or erythematous rash, nausea, vomiting, dizziness, or diarrhea. Vomiting is generally induced or a gastric lavage is performed.Label Supportive treatment involves maintining hydration, electrolyte balance, and vital functionsLabel.The oral LD50 in mice, rats, and rabbits is >1g/kg.LabelSpironolactone should be avoided in pregnancy due to reports of feminization of male fetuses in animal studies.Label Active metabolites of spironolactone are present in breast milk and levels that are likely inconsequential, though the long term effects have not been studied.LabelIn animal studies, spironolactone slowed follicle development, ovulation, and implantation.Label Spironolactone increased the incidence of benign adenomas in the testes of male rats, benign uterine endometrial stromal polyps in female rats, and thyroid follicular cell adenomas in both sexes of rats.Label Spironolactone and canrenone are generally not considered to be mutagenic in tests but canrenone occasionally tests positive for mutagenicity with metabolic activation and spironolactone has occasionally tested inconclusive though slightly positive for mutagenicity.Label	Small Molecule	http://smpdb.ca/view/SMP0000134?highlight[compounds][]=DB00421&highlight[proteins][]=DB00421	Spironolactone Action Pathway		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.0150 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				201	2.78		134.5 °C			1	Yes	3	0	No	5	0	60.44 Å2	46.03 Å3	113.5 m3·mol-1	2	Yes	No	0.00198 mg/mL	3.64	-5.3	17.89	-4.9			
C22H29FO5	In a study that included Indian women of reproductive age, the CL/F following a single intramuscular dose of betamethasone phosphate was 6,466 ± 805 mL/hour.9	In a study that included Indian women of reproductive age, the half-life following a single intramuscular dose of betamethasone phosphate was 10.2 ± 2.5 hours.9	392.4611	[H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	In a study that included Indian women of reproductive age, the volume of distribution following a single intramuscular dose of betamethasone phosphate was 94,584±23,539 mL(s).9	P11511;!P20815;!P24462;!P11509;!Q16678;!P20813;!P10632;!P11712;!P33261;!P08684	CYP19A1;!CYP3A5;!CYP3A7;!CYP2A6;!CYP1B1;!CYP2B6;!CYP2C8;!CYP2C9;!CYP2C19;!CYP3A4	1. Cytochrome P450 19A1;!2. Cytochrome P450 3A5;!3. Cytochrome P450 3A7;!4. Cytochrome P450 2A6;!5. Cytochrome P450 1B1;!6. Cytochrome P450 2B6;!7. Cytochrome P450 2C8;!8. Cytochrome P450 2C9;!9. Cytochrome P450 2C19;!10. Cytochrome P450 3A4		73823	3077	CHEMBL632	9399	Drugs.com Drug Page		HMDB0014586		D00244			PA164754818	9782	46505155	RxList Drug Page	1514	DAP001043	Betamethasone	ZINC000003876136	Betaderm, Betaloan Suik, Beteflam, Betnesol, Celestoderm, Celestone Soluspan, Dermacinrx Therazole Pak, Diprolene, Diprosalic, Diprosone, Dovobet, Enstilar, Fucibet, Lotriderm, Lotrisone, Luxiq, Marbeta, Rivasone, Rolene, Rosone, Sernivo, Taclonex, Valisone-G, Wynzora	Betamethasone	Approved, Vet approved	DB00443	InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,17-,19-,20-,21-,22-/m0/s1	UREBDLICKHMUKA-DVTGEIKXSA-N	4	Betamethasone is a systemic corticosteroid used to relieve inflammation in various conditions, including but not limited to allergic states, dermatologic disorders, gastrointestinal diseases, and hematological disorders.	Chronic high doses of glucocorticoids can lead to the development of cataracts, glaucoma, hypertension, water retention, hyperlipidemia, peptic ulcer, pancreatitis, myopathy, osteoporosis, mood changes, psychosis, dermal atrophy, allergy, acne, hypertrichosis, immune suppression, decreased resistance to infection, moon face, hyperglycemia, hypocalcemia, hypophosphatemia, metabolic acidosis, growth suppression, and secondary adrenal insufficiency.6 Overdose may be treated by adjusting the dose or stopping the corticosteroid as well as initiating symptomatic and supportive treatment.6	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1482 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor				568.2°C	1.138	-3.77	178°C		66.5 mg/L (at 25 °C)	1	Yes	5	3	No	4	0	94.83 Å2	40.81 Å3	102.49 m3·mol-1	2	Yes	No	0.0505 mg/mL	1.68	-3.9	12.42	-3.3	P04150	NR3C1	1. Glucocorticoid receptor
C22H29FO4	Not Available	The half-life of the material was 15 ± 2 hours (for urine) and 17 ± 2 hours (for feces) between the third and fifth trial day.	376.4617	[H][C@@]12C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	Not Available					50103622	691037	CHEMBL1766	4470604	Drugs.com Drug Page		HMDB0014687				PDRhealth Drug Page	PA164746011	5311067	46506793	RxList Drug Page	3255	DAP001185	Desoximetasone	ZINC000004212854	Desoxi, Topicort	Desoximetasone	Approved	DB00547	InChI=1S/C22H29FO4/c1-12-8-16-15-5-4-13-9-14(25)6-7-21(13,3)22(15,23)18(27)10-20(16,2)19(12)17(26)11-24/h6-7,9,12,15-16,18-19,24,27H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,18+,19-,20+,21+,22+/m1/s1	VWVSBHGCDBMOOT-IIEHVVJPSA-N	4	Desoximetasone is a glucocorticoid used to treat inflammatory and pruritic corticosteroid-responsive dermatoses.	Topically applied desoximetasone can be absorbed in sufficient amounts to produce systemic effects. Symptoms of overdose include thinning of skin and suppression of adrenal cortex (decreased ability to respond to stress).	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.6856 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor					2.35		217 °C		42.1 mg/L	1	Yes	4	2	No	4	0	74.6 Å2	40.12 Å3	101.17 m3·mol-1	2	Yes	No	0.031 mg/mL	2.35	-4.1	13.44	-3.3	P04150	NR3C1	1. Glucocorticoid receptor
C25H31F3O5S	1093mL/min for fluticasone propionate10. A study of 24 healthy Caucasian males showed a clearance of 63.9L/h following intravenous administration1.	7.8 hours for intravenous fluticasone propionate10Label. A study of 24 healthy Caucasian males shows a half life of 14.0 hours following intravenous administration and 10.8 hours following inhalation1.	500.571	[H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C	Solid	The volume of distribution of intravenous fluticasone propionate is 4.2L/kg10Label. A study of 24 healthy Caucasian males showed a volume of distribution at steady state of 577L following intravenous administration1.	P20815;!P24462;!P10632;!P08684	CYP3A5;!CYP3A7;!CYP2C8;!CYP3A4	1. Cytochrome P450 3A5;!2. Cytochrome P450 3A7;!3. Cytochrome P450 2C8;!4. Cytochrome P450 3A4		50354849	31441	CHEMBL1473	392059	Drugs.com Drug Page		HMDB0005036		D01708			PA449686	444036	46506140	RxList Drug Page	50121	DAP001039	Fluticasone_propionate	ZINC000003920027	Advair, Airduo, Airduo Respiclick, Aller-flo, Armonair, Beser, Cutivate, Dymista, Flonase, Flovent, Fluticare, Ticanase, Wixela, Xhance	Fluticasone propionate	Approved	DB00588	InChI=1S/C25H31F3O5S/c1-5-20(31)33-25(21(32)34-12-26)13(2)8-15-16-10-18(27)17-9-14(29)6-7-22(17,3)24(16,28)19(30)11-23(15,25)4/h6-7,9,13,15-16,18-19,30H,5,8,10-12H2,1-4H3/t13-,15+,16+,18+,19+,22+,23+,24+,25+/m1/s1	WMWTYOKRWGGJOA-CENSZEJFSA-N	4	Fluticasone propionate is a glucocorticoid used to treat asthma, inflammatory pruritic dermatoses, and nonallergic rhinitis.	Fluticasone propionate's use in specific populations has not been well studied10. Fluticasone propionate is not carcinogenic, mutagenic, or clastogenic, nor did it affect fertility in animal studies10Label. Subcutaneous fluticasone propionate has been shown to produce teratogenic effects in rats though oral administration does not9Label. Generally, there are no reported adverse effects with fluticasone in pregnancy6. Fluticasone propionate in human milk may cause growth suppression, effects on endogenous corticosteroid production, or other effects9,2. Pediatric patients treated with fluticasone propionate ointment experienced adrenal suppression9. Geriatric patients treated with fluticasone propionate did not show any difference in safety or efficacy compared to other patient groups, though older patients may be more sensitive to adverse effects9. There is no difference in the clearance of fluticasone propionate across genders or raceLabel. Patients with hepatic impairment should be closely monitored due to the elimination mechanismLabel5.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.3753 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.78		261-273 °C		Insoluble	1	No	4	1	Yes	4	0	80.67 Å2	49.29 Å3	121.65 m3·mol-1	6	No	No	0.0114 mg/mL	3.72	-4.6	13.61	-3.4			
C24H30F2O6	This pharmacokinetic parameter is not relevant as the systemic absorption of fluocinolone acetonide is very minimal and the concentration in urine is lower than the minimum quantitation limit.10	The reported half-life of fluocinolone acetonide ranges between 1.3-1.7 hours.7	452.4882	[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO	Solid	This pharmacokinetic parameter is not relevant as the systemic absorption of fluocinolone acetonide is very minimal.	P08684	CYP3A4	1. Cytochrome P450 3A4			31623	CHEMBL989	5980	Drugs.com Drug Page		HMDB0014729		D01825			PA164754912	6215	46506244	RxList Drug Page	4461	DAP000813	Fluocinolone_acetonide	ZINC000003977981	Capex, Derma-Smoothe/FS, Derma-smoothe FS, Dermotic, Flac, Iluvien, Neo-synalar, Otixal, Otovel, Retisert, Synalar, Tri-luma, Yutiq	Fluocinolone acetonide	Approved, Investigational, Vet approved	DB00591	InChI=1S/C24H30F2O6/c1-20(2)31-19-9-13-14-8-16(25)15-7-12(28)5-6-21(15,3)23(14,26)17(29)10-22(13,4)24(19,32-20)18(30)11-27/h5-7,13-14,16-17,19,27,29H,8-11H2,1-4H3/t13-,14-,16-,17-,19+,21-,22-,23-,24+/m0/s1	FEBLZLNTKCEFIT-VSXGLTOVSA-N	4	Fluocinolone acetonide is a corticosteroid used to treat skin conditions, eczematous otitis externa, diabetic macular edema, and non-infectious uveitis of the posterior segment of the eye.	Studies to determine the carcinogenic and its effect in fertility have not been performed. It is important to consider that several corticosteroids have been shown to present genotoxic potential but fluocinolone acetonide was shown to not be genotoxic in the Ames test and mouse lymphoma TK assay.19	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.7033 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.48		266-268	13.9	Insoluble	1	Yes	6	2	No	5	0	93.06 Å2	44.84 Å3	111.41 m3·mol-1	2	Yes	No	0.0547 mg/mL	1.6	-3.9	13.38	-3.3	P04150;!P04083;!P07355;!P12429;!P09525;!P08758	NR3C1;!ANXA1;!ANXA2;!ANXA3;!ANXA4;!ANXA5	1. Glucocorticoid receptor;!2. Annexin A1;!3. Annexin A2;!4. Annexin A3;!5. Annexin A4;!6. Annexin A5
C22H27ClF2O4	Not Available	In vitro experiments show halobetasol propionate, a derivative of ulobetasol, has a half life of 33 minutes.9	428.9	[H][C@@]12C[C@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C	Solid	Not Available							CHEMBL1201360	4470691	Drugs.com Drug Page						PDRhealth Drug Page	PA164768832	5311167	46506187	RxList Drug Page	41208	DAP001186	Ulobetasol	ZINC000004214603	Bryhali, Duobrii, Lexette, Ultravate, Ultravate X Ointment	Ulobetasol	Approved	DB00596	InChI=1S/C22H27ClF2O4/c1-11-6-13-14-8-16(24)15-7-12(26)4-5-19(15,2)21(14,25)17(27)9-20(13,3)22(11,29)18(28)10-23/h4-5,7,11,13-14,16-17,27,29H,6,8-10H2,1-3H3/t11-,13-,14-,16-,17-,19-,20-,21-,22-/m0/s1	LEHFPXVYPMWYQD-XHIJKXOTSA-N	4	Ulobetasol is a lipocortin corticosteroid used to treat inflammatory and pruritic corticosteroid-responsive dermatoses.	Data regarding acute overdoses of glucocorticoids are rare.7,8 Chronic high doses of glucocorticoids can lead to the development of cataract, glaucoma, hypertension, water retention, hyperlipidemia, peptic ulcer, pancreatitis, myopathy, osteoporosis, mood changes, psychosis, dermal atrophy, allergy, acne, hypertrichosis, immune suppression, decreased resistance to infection, moon face, hyperglycemia, hypocalcemia, hypophosphatemia, metabolic acidosis, growth suppression, and secondary adrenal insufficiency.5 Overdose may be treated by adjusting the dose or stopping the corticosteroid as well as initiating symptomatic and supportive treatment.5,10	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.3204 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							200-216		Practically insoluble	1	Yes	4	2	No	4	0	74.6 Å2	42.07 Å3	105.37 m3·mol-1	2	Yes	No	0.022 mg/mL	2.7	-4.3	12.46	-3.4	P04150	NR3C1	1. Glucocorticoid receptor
C24H34O4	The mean clearance of medroxyprogesterone acetate (MPA) is 1668±146L/day or 21.9±4.3L/kg/day.5 Due to the high inter patient variability in MPA pharmacokinetics, clearance has been reported to be 1600-4000L/day.15	Oral medroxyprogesterone acetate (MPA) has an absorption half life of 15-30min and a biological half life of 40-60 hours.2 Intramuscular MPA has an absorption half life of 0.86±0.30 days and an elimination half life of 24.03±21.74 days.3 Subcutaneous MPA has an absorption half life of 1.05±0.56 days and an elimination half life of 30.90±15.11 days.3	386.5244	[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)CC[C@]12C	Solid	The volume of distribution of medroxyprogesterone acetate is 20±3L.15	P08684;!P10632;!P26439;!P11712;!P04800	CYP3A4;!CYP2C8;!HSD3B2;!CYP2C9;!Cyp3a1	1. Cytochrome P450 3A4;!2. Cytochrome P450 2C8;!3. 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2;!4. Cytochrome P450 2C9;!5. Cytochrome P450 3A1		50067678	6716	CHEMBL717	6043	Drugs.com Drug Page	GtP Drug Page		C08150	D00951			PA450344	6279	46508895	RxList Drug Page	1000112	DAP001211	Medroxyprogesterone	ZINC000005029557	Depo-provera, Depo-subq Provera, Premphase 28 Day, Prempro 0.625/2.5 28 Day, Provera	Medroxyprogesterone acetate	Approved, Investigational	DB00603	InChI=1S/C24H34O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h13-14,18-20H,6-12H2,1-5H3/t14-,18+,19-,20-,22+,23-,24-/m0/s1	PSGAAPLEWMOORI-PEINSRQWSA-N	4	Medroxyprogesterone acetate is a progestin used as a contraceptive and in the treatment of secondary amenorrhea, abnormal uterine bleeding, pain from endometriosis, endometrial and renal carcinomas, paraphilia in males, and GnRH-dependent precocious puberty.	The oral LD50 in rats is >6400mg/kg and in mice is >16g/kg.16 The intraperitoneal LD50 in rats is >900mg/kg and in mice is >1500mg/kg.16 The subcutaneous LD50 in rats is >900mg/kg and in mice is>1500mg/kg.16Patients experiencing and overdose or oral medroxyprogesterone acetate (MPA) may present with nausea, vomiting, breast tenderness, dizziness, abdominal pain, drowsiness, fatigue, and withdrawal bleeding.10,11 Treat patients by stopping MPA and beginning symptomatic treatment.10,11 Patients who have been given too much of a MPA depo injection should contact a healthcare professional, hospital emergency department, or local poison control immediately.15	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	1.8121 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							205-209		10mM	1	Yes	3	0	No	4	0	60.44 Å2	44.06 Å3	107.81 m3·mol-1	3	Yes	No	0.00221 mg/mL	4.13	-5.2	17.73	-4.9			
C21H27FO6	The clearance of triamcinolone is 28.6±5.6L/h.4 The mean total body clearance of triamcinolone acetonide is 0.57L/h.2 The clearance of triamcinolone diacetate is 34.4±10.6L/h.4	The half life of triamcinolone is 2.7h.4 The mean terminal elimination half life following an inhaled dose of triamcinolone acetonide is 2.4h.2 The half life of triamcinolone diacetate is 2.8h.4	394.4339	[H][C@@]12C[C@@H](O)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	The apparent volume of distribution of triamcinolone is 115.2±10L.4 The mean apparent volume of distribution of triamcinolone acetonide is 1.96L/kg.2 The apparent volume of distribution of triamcinolone diacetate is 119.7±33.14L.4	P08684;!P35354;!P06276;!P20815;!P24462	CYP3A4;!PTGS2;!BCHE;!CYP3A5;!CYP3A7	1. Cytochrome P450 3A4;!2. Prostaglandin G/H synthase 2;!3. Cholinesterase;!4. Cytochrome P450 3A5;!5. Cytochrome P450 3A7		41132	9667	CHEMBL1451	29046	Drugs.com Drug Page	GtP Drug Page	HMDB0014758		D00385		PDRhealth Drug Page	PA451749	31307	46507950	RxList Drug Page	10759	DAP000417	Triamcinolone	ZINC000003882036	Aller-cort, Allernaze, Aristocort, Aristocort R, Juulissa Pharmapak, Kenalog, Marcaine, Nasacort, Oracort, Oralone, Pediaderm Ta, Triaderm, Trianex, Triderm, Triesence, Triloan Suik, Tritocin, Viaderm Kc, Xipere, Zilretta	Triamcinolone	Approved, Vet approved	DB00620	InChI=1S/C21H27FO6/c1-18-6-5-12(24)7-11(18)3-4-13-14-8-15(25)21(28,17(27)10-23)19(14,2)9-16(26)20(13,18)22/h5-7,13-16,23,25-26,28H,3-4,8-10H2,1-2H3/t13-,14-,15+,16-,18-,19-,20-,21-/m0/s1	GFNANZIMVAIWHM-OBYCQNJPSA-N	4	Triamcinolone is a glucocorticoid used to treat a wide variety of inflammatory conditions of organ systems and tissues.	The subcutaneous LD50 of triamcinolone acetonide in rats is 13,100µg/kg and in mice is 132mg/kg.17 The oral LD50 in rats is 1451mg/kg and in mice is 2168mg/kg.[LD50] The intraperitoneal LD50 in mice is 105mg/kg.[LD50]Patients experiencing an overdose may develop Cushing's syndrome.6 This overdose may be treated with supportive therapy and mifepristone for its antiglucocorticoid activity.6	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3369 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor							270			1	Yes	6	4	No	4	0	115.06 Å2	39.8 Å3	99.38 m3·mol-1	2	Yes	No	0.847 mg/mL	0.24	-2.7	11.75	-3.3	P04150	NR3C1	1. Glucocorticoid receptor
C19H30O3	Not Available	0.55 hours (1st phage), 9 hours (2nd phase)	306.4397	[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)OC[C@]12C	Solid	Not Available	P11712	CYP2C9	1. Cytochrome P450 2C9			7820	CHEMBL1200436	5667	Drugs.com Drug Page		HMDB0014759	C07346	D00462			PA164749395	5878	46509027	RxList Drug Page	7779	DAP000905	Oxandrolone	ZINC000003813047	Oxandrin	Oxandrolone	Approved, Investigational	DB00621	InChI=1S/C19H30O3/c1-17-11-22-16(20)10-12(17)4-5-13-14(17)6-8-18(2)15(13)7-9-19(18,3)21/h12-15,21H,4-11H2,1-3H3/t12-,13+,14-,15-,17-,18-,19-/m0/s1	QSLJIVKCVHQPLV-PEMPUTJUSA-N	4	Oxandrolone is an androgenic hormone used to treat muscle loss from prolonged corticosteroid treatment and to treat bone pain associated with osteoporosis.	The oral LD50 of oxandrolone in mice and dogs is greater than 5,000 mg/kg.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.5177 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					4.2		236.5 °C			1	Yes	2	1	No	4	0	46.53 Å2	35.4 Å3	84.75 m3·mol-1	0	Yes	No	0.014 mg/mL	2.95	-4.3		-0.53	P10275	AR	1. Androgen receptor
C19H28O2	The mean metabolic clearance in middle aged men is 812±64L/day.3	The half life of testosterone is highly variable, ranging from 10-100 minutes.14,15,16,17,18,19,20	288.4244	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	The volume of distribution of testosterone in elderly men is 80.36±24.51L.2					8885	17347	CHEMBL386630	5791		GtP Drug Page	HMDB0000234	C00535	D00075	TES	PDRhealth Drug Page	PA451627	6013	46505691	RxList Drug Page	10379	DAP000841	Testosterone	ZINC000118912393	Androderm, Androgel, Axiron, Fortesta, Natesto, Striant, Testim, Testopel, Vogelxo	Testosterone	Approved, Investigational	DB00624	InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-17,21H,3-10H2,1-2H3/t14-,15-,16-,17-,18-,19-/m0/s1	MUMGGOZAMZWBJJ-DYKIIFRCSA-N	4	Testosterone is a hormone used to treat hypogonadism, breast carcinoma in women, or the vasomotor symptoms of menopause.	Data regarding an overdose with a topical testosterone product is not readily available.14,15,16,17,18,19,20 In the case of overdose with an injectable product, patients may present with a cerebrovascular event.14,15,16,17,18,19,20 Treat overdoses by stopping testosterone products, washing off any topical products with soap and water, and initiating symptomatic and supportive treatments.14,15,16,17,18,19,20	Small Molecule	http://smpdb.ca/view/SMP0000356?highlight[compounds][]=DB00624&highlight[proteins][]=DB00624;!http://smpdb.ca/view/SMP0030406?highlight[compounds][]=DB00624&highlight[proteins][]=DB00624;!http://smpdb.ca/view/SMP0000068?highlight[compounds][]=DB00624&highlight[proteins][]=DB00624;!http://smpdb.ca/view/SMP0000565?highlight[compounds][]=DB00624&highlight[proteins][]=DB00624	17-beta Hydroxysteroid Dehydrogenase III Deficiency;!Androstenedione Metabolism;!Androgen and Estrogen Metabolism;!Aromatase Deficiency		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.6259 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor		-4.34			3.32		155 °C		23.4 mg/L (at 25 °C)	1	Yes	2	1	No	4	0	37.3 Å2	33.88 Å3	84.43 m3·mol-1	0	Yes	Yes	0.0333 mg/mL	3.37	-3.9	18.52	-0.88			
C21H26O5	Data regarding the clearance of prednisone is not readily available.9A 5.5µg/h/kg infusion of prednisolone has an average clearance of 0.066±0.12L/h/kg, while a 0.15±0.03L/h/kg infusion has an average clearance of 0.15L/h/kg.3	Prednisone and its active metabolite prednisolone have half lives of 2-3 hours from both immediate and delayed release preparations.9	358.4281	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	Data regarding the volume of distribution for prednisone is not readily available.9 However, a 0.15mg/kg dose of prednisolone has a volume of distribution of 29.3L, while a 0.30mg/kg dose has a volume of distribution of 44.2L.6	P33261;!P20815;!BE0004866;!P11509;!Q16678;!P20813;!P10632;!P11712;!P28845;!P08684	CYP2C19;!CYP3A5;!;!CYP2A6;!CYP1B1;!CYP2B6;!CYP2C8;!CYP2C9;!HSD11B1;!CYP3A4	1. Cytochrome P450 2C19;!2. Cytochrome P450 3A5;!3. Cytochrome P450 3A Subfamily (Protein Group);!4. Cytochrome P450 2A6;!5. Cytochrome P450 1B1;!6. Cytochrome P450 2B6;!7. Cytochrome P450 2C8;!8. Cytochrome P450 2C9;!9. Corticosteroid 11-beta-dehydrogenase isozyme 1;!10. Cytochrome P450 3A4			8382	CHEMBL635	5656	Drugs.com Drug Page		HMDB0014773	C07370	D00473	PDN		PA451100	5865	46508166	RxList Drug Page	8640	DAP001041	Prednisone	ZINC000003875357	Deltasone, Rayos, Winpred	Prednisone	Approved, Vet approved	DB00635	InChI=1S/C21H26O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-15,18,22,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,18+,19-,20-,21-/m0/s1	XOFYZVNMUHMLCC-ZPOLXVRWSA-N		Prednisone is a corticosteroid used to treat inflammation or immune-mediated reactions and to treat endocrine or neoplastic diseases.	Data regarding acute overdoses of prednisone are rare but prolonged high doses of prednisone can lead to a higher incidence and severity of adverse effects such as mental symptoms, moon face, abnormal fat deposits, fluid retention, excessive appetite, weight gain, hypertrichosis, acne, striae, ecchymosis, increased sweating, pigmentation, dry scaly skin, thinning scalp hair, increased blood pressure, tachycardia, thrombophlebitis, decreased resistance to infection, negative nitrogen balance with delayed bone and wound healing, headache, weakness, menstrual disorders, accentuated menopausal symptoms, neuropathy, fractures, osteoporosis, peptic ulcer, decreased glucose tolerance, hypokalemia, and adrenal insufficiency.9	Small Molecule	http://smpdb.ca/view/SMP0000440?highlight[compounds][]=DB00635&highlight[proteins][]=DB00635;!http://smpdb.ca/view/SMP0000631?highlight[compounds][]=DB00635&highlight[proteins][]=DB00635	Prednisone Action Pathway;!Prednisone Metabolism Pathway		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.8914 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					1.46		230 - 235 °C (decomposes)		Very slightly soluble	1	Yes	5	2	No	4	0	91.67 Å2	38.2 Å3	97.57 m3·mol-1	2	Yes	No		1.66		12.58	-3.3	P04150	NR3C1	1. Glucocorticoid receptor
C22H28F2O5	Not Available	Not Available	410.458	[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4		50240002	34764	CHEMBL1201392	15632				C14479	D04208			PA164749388	16490	46505121		4458	DAP000814	Flumetasone	ZINC000003983936	Locacorten Vioform	Flumethasone	Approved, Vet approved	DB00663	InChI=1S/C22H28F2O5/c1-11-6-13-14-8-16(23)15-7-12(26)4-5-19(15,2)21(14,24)17(27)9-20(13,3)22(11,29)18(28)10-25/h4-5,7,11,13-14,16-17,25,27,29H,6,8-10H2,1-3H3/t11-,13+,14+,16+,17+,19+,20+,21+,22+/m1/s1	WXURHACBFYSXBI-GQKYHHCASA-N		Flumethasone is a corticosteroid used to treat contact dermatitis, atopic dermatitis, eczema, psoriasis, diaper rash, and other skin conditions.	Can lead to signs of irritation such as burning sensation, itching or skin rash at the site of application; hypersensitivity reactions.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.4249 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.86		219 °C (base only)		0.392 mg/L	1	Yes	5	3	No	4	0	94.83 Å2	41.25 Å3	102.32 m3·mol-1	2	Yes	No	0.0853 mg/mL	1.34	-3.7	12.42	-3.3	P04150	NR3C1	1. Glucocorticoid receptor
C21H29FO5	Population pharmacokinetics have estimated the plasma clearance of fludrocortisone to be 40.8 L/h.9	The plasma half-life of fludrocortisone has been variably reported to be between 1-3.5 hours,6,9,10 though prescribing information gives an approximate half-life of 18-36 hours.15	380.4504	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	The apparent volume of distribution of fludrocortisone is 80-85 L.9,6 Distribution into CSF appears minimal - the observed ratio of CSF drug concentration versus plasma drug concentration is 1:6.16	P08684;!P80365;!P28845	CYP3A4;!HSD11B2;!HSD11B1	1. Cytochrome P450 3A4;!2. Corticosteroid 11-beta-dehydrogenase isozyme 2;!3. Corticosteroid 11-beta-dehydrogenase isozyme 1			50885	CHEMBL1201388	29111	Drugs.com Drug Page	GtP Drug Page	HMDB0014825	C07004	D07967	ZK5		PA164743961	31378	46508616	RxList Drug Page	4452	DAP001105	Fludrocortisone	ZINC000004097304	Florinef	Fludrocortisone	Approved, Investigational	DB00687	InChI=1S/C21H29FO5/c1-18-7-5-13(24)9-12(18)3-4-15-14-6-8-20(27,17(26)11-23)19(14,2)10-16(25)21(15,18)22/h9,14-16,23,25,27H,3-8,10-11H2,1-2H3/t14-,15-,16-,18-,19-,20-,21-/m0/s1	AAXVEMMRQDVLJB-BULBTXNYSA-N	4	Fludrocortisone is a mineralocorticoid used to treat adrenocortical insufficiency and salt-losing adrenogenital syndrome.	The oral LD50 of fludrocortisone in rats is >1g/kg.17 Acute overdosage of fludrocortisone is likely to result in symptoms consistent with its adverse effect profile. Patients receiving a single large dose should be treated with plenty of water by mouth and should undergo monitoring of serum electrolytes, particularly potassium and sodium, and be treated appropriately for any developing imbalances.15,16	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1686 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	5	3	No	4	0	94.83 Å2	39.53 Å3	96.93 m3·mol-1	2	Yes	No	0.224 mg/mL	1.32	-3.2	12.55	-3.3	P08235;!P04150	NR3C2;!NR3C1	1. Mineralocorticoid receptor;!2. Glucocorticoid receptor
C24H30O6	Apparent plasma cl=10 L/hr	4-6 hours	414.4914	[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)C[C@H]1O[C@@]11[C@@]2([H])[C@@H](CC2=CC(=O)CC[C@]12C)C(=O)OC	Solid	43 to 90 L	P19099;!P08684;!P20815	CYP11B2;!CYP3A4;!CYP3A5	1. Cytochrome P450 11B2, mitochondrial;!2. Cytochrome P450 3A4;!3. Cytochrome P450 3A5		50318300	31547	CHEMBL1095097	10203511	Drugs.com Drug Page	GtP Drug Page	HMDB0014838	C12512	D01115	YNU	PDRhealth Drug Page	PA164749044	443872	46509053	RxList Drug Page	298869	DAP000085	Eplerenone	ZINC000003985982	Inspra	Eplerenone	Approved	DB00700	InChI=1S/C24H30O6/c1-21-7-4-14(25)10-13(21)11-15(20(27)28-3)19-16-5-8-23(9-6-18(26)30-23)22(16,2)12-17-24(19,21)29-17/h10,15-17,19H,4-9,11-12H2,1-3H3/t15-,16+,17-,19+,21+,22+,23-,24-/m1/s1	JUKPWJGBANNWMW-VWBFHTRKSA-N	4	Eplerenone is an aldosterone receptor antagonist used to improve survival of patients with symptomatic heart failure and to reduce blood pressure.	The most likely symptoms of human overdosage would be anticipated to be hypotension or hyperkalemia. However, no cases of human overdosage with eplerenone have been reported.	Small Molecule	http://smpdb.ca/view/SMP0000135?highlight[compounds][]=DB00700&highlight[proteins][]=DB00700	Eplerenone Action Pathway		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.4761 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					1.3				Slightly soluble	1	Yes	4	0	No	6	0	82.2 Å2	43.94 Å3	106.68 m3·mol-1	2	Yes	No	0.00903 mg/mL	2.33	-4.7	16.44	-4.2			
C20H26O2	The plasma clearance of norethisterone has been estimated as 0.4 L/hr/kg,4,19 and the intrinsic clearance is approximately 73-81 L/h.9	The half-life of norethisterone has been variably estimated as 8-10 hours.4,3,8,14,18	298.4192	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	Solid	The volume of distribution of norethisterone is approximately 4 L/kg.4,19 Sulfated metabolites of norethisterone, as well as small quantities of parent drug, have been shown to distribute into breast milk.11	P08684;!P17516;!P26439;!BE0004887;!P51857;!P33261;!P05177;!P11509	CYP3A4;!AKR1C4;!HSD3B2;!;!AKR1D1;!CYP2C19;!CYP1A2;!CYP2A6	1. Cytochrome P450 3A4;!2. Aldo-keto reductase family 1 member C4;!3. 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2;!4. 3-oxo-5-alpha-steroid 4-dehydrogenase (Protein Group);!5. 3-oxo-5-beta-steroid 4-dehydrogenase;!6. Cytochrome P450 2C19;!7. Cytochrome P450 1A2;!8. Cytochrome P450 2A6		50148732	7627	CHEMBL1162	5994	Drugs.com Drug Page		HMDB0014855	C05028	D00182	NDR	PDRhealth Drug Page	PA450651	6230	46504816	RxList Drug Page	7514	DAP001212	Norethisterone	ZINC000085205451	Activella 1/0.5 28 Day, Activelle, Alyacen 1/35, Alyacen 7/7/7, Amabelz 0.5/0.1 28 Day, Aranelle 28, Aurovela, Aurovela Fe, Aygestin, Balziva 28 Day, Blisovi 21 Fe 1.5/30 28 Day Pack, Blisovi 24 Fe 1/20 28 Day, Brevicon, Briellyn 28 Day, Camila 28 Day, Charlotte 24 Fe Chewable 28 Day, Combipatch, Cyclafem 1/35 28 Day, Cyclafem 7/7/7 28 Day, Cyonanz 28 Day, Dasetta 1/35 28 Day, Dasetta 7/7/7 28 Day, Deblitane 28 Day, Errin 28 Day, Estalis, Estrostep Fe 28 Day, Femcon Fe 28 Day, Femhrt 0.5/2.5 28 Day, Fyavolv, Gemmily 28 Day, Generess Fe 28, Hailey 1.5/30 21 Day, Hailey 24 Fe 28 Day, Hailey Fe 1.5/30 28 Day, Hailey Fe 1/20 28 Day, Heather 28 Day, Incassia, Jencycla 28 Day, Jinteli, Junel 1.5/30 21 Day, Junel 1/20 21 Day, Junel Fe 1.5/30 28 Day, Junel Fe 1/20 28 Day, Junel Fe 24 1/20 28 Day, Kaitlib Fe 28 Day, Larin 1.5/30, Larin 1/20, Larin 24 Fe 1/20, Larin Fe 1.5/30, Larin Fe 1/20, Layolis Fe 28, Leena 28 Day, Lo Loestrin Fe 28 Day, Loestrin 1.5/30 21 Day, Loestrin 24 Fe 28 Day, Loestrin Fe 1/20 28 Day, Lolo, Lomedia 24 Fe, Lopreeza 1/0.5 28 Day, Lupaneta Pack 1-month, Lyleq 28 Day, Lyza, Melodetta 24 Fe Chewable 28 Day, Merzee 28 Day, Microgestin 1.5/30 21 Day, Microgestin 1/20 21 Day, Microgestin 24 Fe 28 Day, Microgestin Fe 1.5/30 28 Day, Microgestin Fe 1/20 28 Day, Mimvey, Minastrin 24 Fe Chewable 28 Day, Myfembree, Necon 0.5/35 28 Day, Necon 1/35 28 Day, Necon 7/7/7 28 Day, Nexesta Fe 28 Day, Nora-BE 28 Day, Norlutate, Norlyda 28 Day, Norlyroc 28 Day, Nortrel 1/35 21 Day, Nortrel 1/35 28 Day, Nortrel 7/7/7 28 Day, Nylia 1/35 28 Day, Nylia 7/7/7 28 Day, Oriahnn 28 Day Kit, Ortho Micronor, Ortho Micronor 28 Day, Ortho-novum 7/7/7 28 Day, Philith 28 Day, Pirmella 1/35 28 Day, Pirmella 7/7/7 28 Day, Select, Sharobel 28 Day, Synphasic, Tarina 24 Fe 1/20 28 Day, Tarina Fe 1/20 28 Day, Taysofy 28 Day, Taytulla 28 Day, Tilia Fe, Tri-legest 28 Day, Tulana 28 Day, Vyfemla 28 Day, Wera 28 Day, Wymzya Fe 28 Day, Zenchent	Norethisterone	Approved	DB00717	InChI=1S/C20H26O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,12,15-18,22H,4-11H2,2H3/t15-,16+,17+,18-,19-,20-/m0/s1	VIKNJXKGJWUCNN-XGXHKTLJSA-N	4	Norethisterone is a synthetic second-generation progestin used for contraception, prevention of endometrial hyperplasia in hormone replacement therapy, and in the treatment of other hormone-mediated illnesses such as endometriosis.	The oral LD50 in mice 6 g/kg and the TDLo in human women is 42 mg/kg.20 There have been no reports of serious ill effects following overdose of oral contraceptives, including following ingestion by children.19,18 Symptoms of overdosage are likely to be consistent with the adverse effect profile of the contraceptive and may, therefore, include significant nausea and/or vomiting.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.8788 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							202-208C			1	Yes	2	1	No	4	0	37.3 Å2	34.59 Å3	87.42 m3·mol-1	0	Yes	Yes	0.00668 mg/mL	3.22	-4.6	17.59	-1.7			
C32H53N2O4	0.25 L/kg/hr [Adults (Ages 27 to 58 years)]0.21 L/kg/hr [Geriatrics (>=65 yrs)]0.16 L/kg/hr [Normal ewnal and hepatice function]0.13 L/kg/hr [Renal transplant patients]0.13 L/kg/hr [Hepatic dysfunction patients]0.35 +/- 0.08 L/kg/hr [Pediatric Patients 3 to <12 mos]0.32 +/- 0.07 L/kg/hr [Pediatric Patients 1 to 3 yrs]0.44 +/- 0.16 L/kg/hr [Pediatric Patients 3 to 8 yrs]	The rapid distribution half-life is 1-2 minutes and the slower distribution half-life is 14-18 minutes. Renal impairment has no net effect on half-life, however, half-life is almost doubled in patients with impaired liver function.	529.7742	[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](O)[C@H](C[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1	Solid	0.3 L/kg [3 to <12 mos]0.26 L/kg [1 to <3 yrs]0.21 L/kg [3 to <8 yrs]						8884	CHEMBL1201244	390053	Drugs.com Drug Page	GtP Drug Page	HMDB0014866	C07556	D00765			PA164754992	441290	46506855	RxList Drug Page	68139	DAP000349	Rocuronium_bromide	ZINC000053229445		Rocuronium	Approved	DB00728	InChI=1S/C32H53N2O4/c1-5-14-34(15-6-7-16-34)28-20-26-24-9-8-23-19-29(36)27(33-12-17-37-18-13-33)21-32(23,4)25(24)10-11-31(26,3)30(28)38-22(2)35/h5,23-30,36H,1,6-21H2,2-4H3/q+1/t23-,24+,25-,26-,27-,28-,29-,30-,31-,32-/m0/s1	YXRDKMPIGHSVRX-OOJCLDBCSA-N	4	Rocuronium is a vecuronium analog used to facilitate tracheal intubation and to relax skeletal muscles during surgery.	No cases of significant accidental or intentional overdose have been reported. Overdosage with neuromuscular blocking agents may result in neuromuscular block beyond the time needed for surgery and anesthesia.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Inhibitor	Inhibitor	Substrate	2.9310 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor									Complete	1	No	4	1	Yes	6	2	59 Å2	62.78 Å3	161.65 m3·mol-1	6	No	No	2.84e-05 mg/mL	-0.33	-7.3	14.59	7.96	Q15822;!P08172;!P46098	CHRNA2;!CHRM2;!HTR3A	1. Neuronal acetylcholine receptor subunit alpha-2;!2. Muscarinic acetylcholine receptor M2;!3. 5-hydroxytryptamine receptor 3A
C21H30O5	Total hydrocortisone by the oral route has a mean clearance of 12.85L/h, while the free fraction has a mean clearance of 235.78L/h.1 A 20mg IV dose of hydrocortisone has a clearance of 18.2±4.2L/h.6	Total hydrocortisone via the oral route has a half life of 2.15h while the free fraction has a half life of 1.39h.1 A 20mg IV dose of hydrocortisone has a terminal half life of 1.9±0.4h.6	362.4599	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	Total hydrocortisone has a volume of distribution of 39.82L, while the free fraction has a volume of distribution of 474.38L.1					13775	17650	CHEMBL389621	5551	Drugs.com Drug Page	GtP Drug Page	HMDB0000063	C00735	D00088	HCY	PDRhealth Drug Page	PA449905	5754	46505089	RxList Drug Page	5492	DAP000718	Hydrocortisone	ZINC000013540519	Ala-cort, Ala-scalp, Alcortin, Alkindi, Anusol HC, Aquanil HC, Casporyn HC, Cipro, Cipro HC, Colocort, Cortaid, Cortane-B, Cortef, Cortenema, Cortisporin, Cortizone-10, Dermacort, Dermarest Eczema, Dermazene, Home Papkit, Hydroskin, Monistat Itch Relief, Neosporin Eczema, Preparation H Hydrocortisone, Procto-med, Procto-pak, Proctocort, Proctol, Proctosedyl, Proctosol, Proctozone HC, Scalpicin Itch Relief, Texacort, Vanoxide-HC, Xerese	Hydrocortisone	Approved, Vet approved	DB00741	InChI=1S/C21H30O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h9,14-16,18,22,24,26H,3-8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1	JYGXADMDTFJGBT-VWUMJDOOSA-N	4	Hydrocortisone is a glucocorticoid used to treat corticosteroid-responsive dermatoses, endocrine disorders, immune conditions, and allergic disorders.	Data regarding acute overdoses of glucocorticoids are rare.14,15,16,17,18,19 Chronic high doses of glucocorticoids can lead to the development of cataract, glaucoma, hypertension, water retention, hyperlipidemia, peptic ulcer, pancreatitis, myopathy, osteoporosis, mood changes, psychosis, dermal atrophy, allergy, acne, hypertrichosis, immune suppression, decreased resistance to infection, moon face, hyperglycemia, hypocalcemia, hypophosphatemia, metabolic acidosis, growth suppression, and secondary adrenal insufficiency.8 Overdose may be treated by adjusting the dose or stopping the corticosteroid as well as initiating symptomatic and supportive treatment.8	Small Molecule	http://smpdb.ca/view/SMP0000372?highlight[compounds][]=DB00741&highlight[proteins][]=DB00741;!http://smpdb.ca/view/SMP0000577?highlight[compounds][]=DB00741&highlight[proteins][]=DB00741;!http://smpdb.ca/view/SMP0000718?highlight[compounds][]=DB00741&highlight[proteins][]=DB00741;!http://smpdb.ca/view/SMP0000310?highlight[compounds][]=DB00741&highlight[proteins][]=DB00741;!http://smpdb.ca/view/SMP0000371?highlight[compounds][]=DB00741&highlight[proteins][]=DB00741;!http://smpdb.ca/view/SMP0000575?highlight[compounds][]=DB00741&highlight[proteins][]=DB00741;!http://smpdb.ca/view/SMP0000717?highlight[compounds][]=DB00741&highlight[proteins][]=DB00741;!http://smpdb.ca/view/SMP0000130?highlight[compounds][]=DB00741&highlight[proteins][]=DB00741;!http://smpdb.ca/view/SMP0000373?highlight[compounds][]=DB00741&highlight[proteins][]=DB00741;!http://smpdb.ca/view/SMP0000566?highlight[compounds][]=DB00741&highlight[proteins][]=DB00741;!http://smpdb.ca/view/SMP0000576?highlight[compounds][]=DB00741&highlight[proteins][]=DB00741;!http://smpdb.ca/view/SMP0000578?highlight[compounds][]=DB00741&highlight[proteins][]=DB00741	Adrenal Hyperplasia Type 5 or Congenital Adrenal Hyperplasia Due to 17 alpha-Hydroxylase Deficiency;!Corticosterone Methyl Oxidase I Deficiency (CMO I);!3-beta-Hydroxysteroid Dehydrogenase Deficiency;!Corticotropin Activation of Cortisol Production;!Congenital Lipoid Adrenal Hyperplasia (CLAH) or Lipoid CAH;!11-beta-Hydroxylase Deficiency (CYP11B1);!Apparent Mineralocorticoid Excess Syndrome;!Steroidogenesis;!Adrenal Hyperplasia Type 3 or Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency;!17-alpha-Hydroxylase Deficiency (CYP17);!21-Hydroxylase Deficiency (CYP21);!Corticosterone Methyl Oxidase II Deficiency (CMO II)		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.8914 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor		-4.66			1.61	-2.97	220 °C		320 mg/L (at 25 °C)	1	Yes	5	3	No	4	0	94.83 Å2	39.45 Å3	97.4 m3·mol-1	2	Yes	No	0.199 mg/mL	1.28	-3.3	12.59	-2.8			
C22H28Cl2O4	Not Available	5.8 hours	427.361	[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	Not Available	P10632;!P08684;!P20815	CYP2C8;!CYP3A4;!CYP3A5	1. Cytochrome P450 2C8;!2. Cytochrome P450 3A4;!3. Cytochrome P450 3A5		50237628	6970	CHEMBL1201404	390090	Drugs.com Drug Page		HMDB0014902	C07816	D08227		PDRhealth Drug Page	PA450541	441335	46505288	RxList Drug Page	108118	DAP001042	Mometasone	ZINC000004097440		Mometasone	Experimental	DB00764	InChI=1S/C22H28Cl2O4/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,24)17(26)10-20(16,3)22(12,28)18(27)11-23/h6-7,9,12,15-17,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1	QLIIKPVHVRXHRI-CXSFZGCWSA-N	4	Mometasone is a corticosteroid with no indications.	The potential for acute toxic effects following overdose with the mometasone inhaler is low. However, habitual overuse of the product can cause symptoms of steroid overload, including menstrual irregularities, acne, obesity, and muscle weakness. Single oral doses up to 8000 µg have been studied on human volunteers with no adverse events reported.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.9124 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.1		218-220 °C		Practically insoluble.	1	Yes	4	2	No	4	0	74.6 Å2	43.82 Å3	110.29 m3·mol-1	2	Yes	No	0.00523 mg/mL	3.5	-4.9	12.49	-3.3	P04150;!P06401	NR3C1;!PGR	1. Glucocorticoid receptor;!2. Progesterone receptor
C27H41NO6	Not Available	Not Available	475.6175	[H][C@@]12CC[C@](O)(C(=O)COC(=O)CN(CC)CC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			50851	CHEMBL1201263	75860			HMDB0014907					PA164745515	84088	46509076			DAP001187	Hydrocortamate	ZINC000004213506		Hydrocortamate	Approved	DB00769	InChI=1S/C27H41NO6/c1-5-28(6-2)15-23(32)34-16-22(31)27(33)12-10-20-19-8-7-17-13-18(29)9-11-25(17,3)24(19)21(30)14-26(20,27)4/h13,19-21,24,30,33H,5-12,14-16H2,1-4H3/t19-,20-,21-,24+,25-,26-,27-/m0/s1	FWFVLWGEFDIZMJ-FOMYWIRZSA-N			Side effects include burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, miliaria.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.9454 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					1.2		162-163			1	No	6	2	Yes	4	0	104.14 Å2	53.53 Å3	129.48 m3·mol-1	8	Yes	No	0.0855 mg/mL	2.32	-3.8	12.61	6.99	P04150	NR3C1	1. Glucocorticoid receptor
C18H24O2	In one pharmacokinetic study, the clearance of orally administered micronized estradiol in postmenopausal women was 29.9±15.5 mL/min/kg.10 Another study revealed a clearance of intravenously administered estradiol was 1.3 mL/min/kg.23	The terminal half-lives for various estrogen products post oral or intravenous administration has been reported to range from 1-12 hours.10 One pharmacokinetic study of oral estradiol valerate administration in postmenopausal women revealed a terminal elimination half-life of 16.9 ± 6.0 h.22 A pharmacokinetic study of intravenous estradiol administration in postmenopausal women showed an elimination half-life of 27.45 ± 5.65 minutes.23 The half-life of estradiol appears to vary by route of administration.	272.382	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	Solid	Estrogens administered exogenously distribute in a similar fashion to endogenous estrogens. They can be found throughout the body, especially in the sex hormone target organs, such as the breast, ovaries and uterus.10,21,27	P08684;!P05177;!P20815;!P24462;!P22309;!P04798;!Q16678;!P33261;!P10632;!P11712;!P54855;!P21964;!BE0009758;!P11511	CYP3A4;!CYP1A2;!CYP3A5;!CYP3A7;!UGT1A1;!CYP1A1;!CYP1B1;!CYP2C19;!CYP2C8;!CYP2C9;!UGT2B15;!COMT;!;!CYP19A1	1. Cytochrome P450 3A4;!2. Cytochrome P450 1A2;!3. Cytochrome P450 3A5;!4. Cytochrome P450 3A7;!5. UDP-glucuronosyltransferase 1-1;!6. Cytochrome P450 1A1;!7. Cytochrome P450 1B1;!8. Cytochrome P450 2C19;!9. Cytochrome P450 2C8;!10. Cytochrome P450 2C9;!11. UDP-glucuronosyltransferase 2B15;!12. Catechol O-methyltransferase;!13. UDP-glucuronosyltransferases (UGTs) (Protein Group);!14. Cytochrome P450 19A1		17292	16469	CHEMBL135	5554	Drugs.com Drug Page	GtP Drug Page	HMDB0000151	C00951	D00105	EST		PA449503	5757	46508115	RxList Drug Page	4083	DAP000854	Estradiol_(medication)	ZINC000013520815	Activella 1/0.5 28 Day, Activelle, Alora, Amabelz 0.5/0.1 28 Day, Angeliq 0.25/0.5 28 Day, Bijuva, Climara, Climara Pro, Combipatch, Divigel, Dotti, Elestrin, Estalis, Estrace, Estradot, Estring, Estrogel, Evamist, Imvexxy 4 Mcg Starter Pack, Lopreeza 1/0.5 28 Day, Lyllana, Menostar, Mimvey, Minivelle, Myfembree, Oesclim, Oriahnn 28 Day Kit, Prefest 30 Day, Vagifem, Vivelle, Yuvafem	Estradiol	Approved, Investigational, Vet approved	DB00783	InChI=1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-17,19-20H,2,4,6-9H2,1H3/t14-,15-,16+,17+,18+/m1/s1	VOXZDWNPVJITMN-ZBRFXRBCSA-N	4	Estradiol is an estrogenic steroid used to treat vasomotor symptoms of vulvar and vaginal atrophy in menopause, hypoestrogenism, prevention of postmenopausal osteoporosis, treatment of breast cancer, and advanced androgen-dependent carcinoma of the prostate.	The NOAEL (no-observed-adverse-effect-level) oral toxicity of estradiol after 90 day in rats was 0.003 mg/kg/day for blood, female reproductive, and male reproductive, endocrine, and liver toxicity.36 Oral TDLO of ethinyl estradiol is 21 mg/kg/21D intermittent, woman) with an oral LD50 of 960 mg/kg in the rat.37 There is limited information in the literature regarding estrogen overdose. Estradiol overdose likely leads to the occurrence of estrogen-associated adverse effects, including nausea, vomiting, abdominal pain, breast tenderness, venous thrombosis, and vaginal bleeding.35 It is generally recommend to discontinue estradiol treatment and offer supportive care in the case of an overdose.30	Small Molecule	http://smpdb.ca/view/SMP0030880?highlight[compounds][]=DB00783&highlight[proteins][]=DB00783;!http://smpdb.ca/view/SMP0000356?highlight[compounds][]=DB00783&highlight[proteins][]=DB00783;!http://smpdb.ca/view/SMP0000068?highlight[compounds][]=DB00783&highlight[proteins][]=DB00783;!http://smpdb.ca/view/SMP0000565?highlight[compounds][]=DB00783&highlight[proteins][]=DB00783	Estrone Metabolism;!17-beta Hydroxysteroid Dehydrogenase III Deficiency;!Androgen and Estrogen Metabolism;!Aromatase Deficiency		Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.2272 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor		-4.77		445.9±45.0	4.01		173	10.46±0.03	3.6 mg/L (at 27 °C)	1	Yes	2	2	No	4	0	40.46 Å2	32.12 Å3	79.9 m3·mol-1	0	Yes	No	0.0213 mg/mL	3.75	-4.1	10.33	-0.88			
C24H32O4	Not Available	Not Available	384.5085	[H][C@@]12CC[C@@](OC(C)=O)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CC[C@H](OC(C)=O)C=C3CC[C@@]21[H]	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4		50237627	31580	CHEMBL1200624	8913			HMDB0014961	C12724	D01294			PA164749157	9270	46506993	RxList Drug Page	4170	DAP000856	Etynodiol_diacetate	ZINC000003876023	Kelnor 1/35 28 Day, Kelnor 1/50 28 Day, Zovia 1/35e 28 Day, Zovia 1/50e 28 Day	Ethynodiol diacetate	Approved	DB00823	InChI=1S/C24H32O4/c1-5-24(28-16(3)26)13-11-22-21-8-6-17-14-18(27-15(2)25)7-9-19(17)20(21)10-12-23(22,24)4/h1,14,18-22H,6-13H2,2-4H3/t18-,19-,20+,21+,22-,23-,24-/m0/s1	ONKUMRGIYFNPJW-KIEAKMPYSA-N	1	Ethynodiol diacetate is an oral contraceptive used to prevent pregnancy.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.1783 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					5		126-127			1	Yes	2	0	No	4	0	52.6 Å2	44.13 Å3	106.62 m3·mol-1	4	Yes	No	0.00397 mg/mL	3.69	-5		-6.7	P06401;!P03372	PGR;!ESR1	1. Progesterone receptor;!2. Estrogen receptor alpha
C29H35NO2	Not Available	18 hours	429.5937	[H][C@@]12CC[C@@](O)(C#CC)[C@@]1(C)C[C@H](C1=CC=C(C=C1)N(C)C)C1=C3CCC(=O)C=C3CC[C@@]21[H]	Solid	Not Available					50072024	50692	CHEMBL1276308	49889	Drugs.com Drug Page	GtP Drug Page	HMDB0014972	C07652	D00585	486		PA450500	55245	46505795	RxList Drug Page	6964	DAP000090	Mifepristone	ZINC000003831128	Korlym, Mifegymiso	Mifepristone	Approved, Investigational	DB00834	InChI=1S/C29H35NO2/c1-5-15-29(32)16-14-26-24-12-8-20-17-22(31)11-13-23(20)27(24)25(18-28(26,29)2)19-6-9-21(10-7-19)30(3)4/h6-7,9-10,17,24-26,32H,8,11-14,16,18H2,1-4H3/t24-,25+,26-,28-,29-/m0/s1	VKHAHZOOUSRJNA-GCNJZUOMSA-N	4	Mifepristone is a cortisol receptor blocker used to treat Cushing's syndrome, and to terminate pregnancies up to 70 days gestation.	Nearly all of the women who receive mifepristone will report adverse reactions, and many can be expected to report more than one such reaction. About 90% of patients report adverse reactions following administration of misoprostol on day three of the treatment procedure. Side effects include more heavy bleeding than a heavy menstrual period, abdominal pain, uterine cramping, nausea, vomiting, and diarrhea.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.7705 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					4.5		191-196 °C		Poorly soluble	1	No	3	1	No	5	0	40.54 Å2	50.69 Å3	132.58 m3·mol-1	3	No	No	0.00336 mg/mL	5.13	-5.1	12.87	4.89			
C22H28ClFO4	Not Available	Not Available	410.907	[H][C@@]12C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C	Solid	Not Available						59582		4470589	Drugs.com Drug Page		HMDB0014976		D07719			PA164744013	5311052	46505290	RxList Drug Page	21249	DAP001190	Clocortolone	ZINC000021981454	Cloderm	Clocortolone	Approved	DB00838	InChI=1S/C22H28ClFO4/c1-11-6-13-14-8-16(24)15-7-12(26)4-5-21(15,3)22(14,23)18(28)9-20(13,2)19(11)17(27)10-25/h4-5,7,11,13-14,16,18-19,25,28H,6,8-10H2,1-3H3/t11-,13+,14+,16+,18+,19-,20+,21+,22+/m1/s1	YMTMADLUXIRMGX-RFPWEZLHSA-N	1	Clocortolone is a corticosteroid used to treat inflammatory and pruritic dermatoses of the scalp.	Topically applied clocortolone can be absorbed in sufficient amounts to produce systemic effects. Symptoms of overdose include thinning of skin and suppression of adrenal cortex (decreased ability to respond to stress).	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.9732 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.8					1	Yes	4	2	No	4	0	74.6 Å2	41.8 Å3	105.74 m3·mol-1	2	Yes	No	0.015 mg/mL	2.47	-4.4	13.54	-3.3	P04150	NR3C1	1. Glucocorticoid receptor
C24H33FO6	Not Available	Not Available	436.5136	CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4		50240003	5127	CHEMBL1201012	14475	Drugs.com Drug Page		HMDB0014984		D00328			PA164750513	15209	46505159	RxList Drug Page	4500	DAP000418	Fludroxycortide	ZINC000004097308	Cordran, Nolix	Flurandrenolide	Approved	DB00846	InChI=1S/C24H33FO6/c1-21(2)30-19-9-14-13-8-16(25)15-7-12(27)5-6-22(15,3)20(13)17(28)10-23(14,4)24(19,31-21)18(29)11-26/h7,13-14,16-17,19-20,26,28H,5-6,8-11H2,1-4H3/t13-,14-,16-,17-,19+,20+,22-,23-,24+/m0/s1	POPFMWWJOGLOIF-XWCQMRHXSA-N	3	Flurandrenolide is a corticosteroid used to treat corticosteroid-responsive dermatoses.	Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary- adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.2002 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					0.6		251 °C		Insoluble	1	Yes	6	2	No	5	0	93.06 Å2	45.51 Å3	110.79 m3·mol-1	2	Yes	No	0.0578 mg/mL	1.56	-3.9	13.74	-2.8	P04150	NR3C1	1. Glucocorticoid receptor
C20H32O2	Not Available	Not Available	304.4669	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)[C@H](C)C[C@]12C	Solid	Not Available	P11511	CYP19A1	1. Cytochrome P450 19A1			34838	CHEMBL1582	5789			HMDB0014996	C14605				PA164760855	6011	46508724		23678	DAP000840	Drostanolone	ZINC000003875387		Drostanolone	Illicit	DB00858	InChI=1S/C20H32O2/c1-12-11-20(3)13(10-17(12)21)4-5-14-15-6-7-18(22)19(15,2)9-8-16(14)20/h12-16,18,22H,4-11H2,1-3H3/t12-,13+,14+,15+,16+,18+,19+,20+/m1/s1	IKXILDNPCZPPRV-RFMGOVQKSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.2244 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.99		151 °C			1	Yes	2	1	No	4	0	37.3 Å2	36.63 Å3	88.18 m3·mol-1	0	Yes	Yes	0.00605 mg/mL	3.95	-4.7	19.38	-0.88	P10275	AR	1. Androgen receptor
C21H28O5	A 0.15mg/kg dose of prednisolone has a clearance of 0.09L/kg/h, while a 0.30mg/kg dose has a clearance of 0.12L/kg/h.1	Prednisolone has a plasma half life of 2.1-3.5 hours.1 This half life is shorter in children and longer in those with liver disease.1	360.444	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	A 0.15mg/kg dose of prednisolone has a volume of distribution of 29.3L, while a 0.30mg/kg dose has a volume of distribution of 44.2L.1	P08684	CYP3A4	1. Cytochrome P450 3A4		19190	8378	CHEMBL131	5552	Drugs.com Drug Page	GtP Drug Page	HMDB0014998	C07369	D00472	TUA		PA451096	5755	46504847	RxList Drug Page	8638	DAP000419	Prednisolone	ZINC000003833821	Millipred Dp 6 Day	Prednisolone	Approved, Vet approved	DB00860	InChI=1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-16,18,22,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1	OIGNJSKKLXVSLS-VWUMJDOOSA-N	4	Prednisolone is a glucocorticoid used to treat adrenocortical insufficiency, inflammatory conditions, and some cancers.	The intraperitoneal LD50 in rats is 2g/kg and 65mg/kg in mice.8 The subcutaneous LD50 in rats is 147mg/kg and >3500mg/kg in mice.8 The oral LD50 in mice is 1680mg/kg.8 In humans, the oral TDLO in men is 9mg/kg/2W and in women is 14mg/kg/13D.8Patients experiencing an overdose of prednisolone may present with gastrointestinal disturbances, insomnia, and restlessness.5 Overdose of oral prednisolone may be treated by gastric lavage or inducing vomiting if the overdose was recent, as well as supportive and symptomatic therapy.9 Chronic overdosage may be treated by dose reduction or treating patients on alternate days.9 An overdose by the ophthalmic route is not expected to cause problems.9	Small Molecule	http://smpdb.ca/view/SMP0000440?highlight[compounds][]=DB00860&highlight[proteins][]=DB00860;!http://smpdb.ca/view/SMP0000441?highlight[compounds][]=DB00860&highlight[proteins][]=DB00860;!http://smpdb.ca/view/SMP0000631?highlight[compounds][]=DB00860&highlight[proteins][]=DB00860;!http://smpdb.ca/view/SMP0000632?highlight[compounds][]=DB00860&highlight[proteins][]=DB00860	Prednisone Action Pathway;!Prednisolone Action Pathway;!Prednisone Metabolism Pathway;!Prednisolone Metabolism Pathway		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.8914 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					1.62	-3.21	235 °C		223 mg/L (at 25 °C)	1	Yes	5	3	No	4	0	94.83 Å2	38.69 Å3	98.49 m3·mol-1	2	Yes	No	0.239 mg/mL	1.27	-3.2	12.59	-2.9			
C21H27ClO5	Not Available	Not Available	394.889	[H][C@@]12CC[C@](O)(C(=O)OCCl)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Not Available	Not Available						50848		8041134												237027		Loteprednol	ZINC000030691679	Alrex, Lotemax, Zylet	Loteprednol	Approved, Experimental	DB00873	InChI=1S/C21H27ClO5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,18(25)27-11-22)20(15,2)10-16(24)17(14)19/h5,7,9,14-17,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,17+,19-,20-,21-/m0/s1	YPZVAYHNBBHPTO-MXRBDKCISA-N		Loteprednol is a corticosteroid indicated in the treatment of pain and inflammation after cataract surgery.	Not Available	Small Molecule																																			1	Yes	4	2	No	4	0	83.83 Å2	41.29 Å3	102.65 m3·mol-1	3	Yes	No	0.0336 mg/mL	2.52	-4.1	12.01	-2.9			
C19H24O3	Not Available	Not Available	300.3921	[H][C@@]12CCC3=CC(=O)C=C[C@]3(C)[C@@]1([H])CC[C@]1(C)OC(=O)CC[C@@]21[H]	Solid	Not Available					50367848	9460	CHEMBL1571	13172	Drugs.com Drug Page		HMDB0015031	C02197	D00153			PA164743056	13769	46508076	RxList Drug Page	10378	DAP000624	Testolactone	ZINC000004081771		Testolactone	Approved, Investigational	DB00894	InChI=1S/C19H24O3/c1-18-9-7-13(20)11-12(18)3-4-14-15(18)8-10-19(2)16(14)5-6-17(21)22-19/h7,9,11,14-16H,3-6,8,10H2,1-2H3/t14-,15+,16+,18+,19+/m1/s1	BPEWUONYVDABNZ-DZBHQSCQSA-N	4	Testolactone is a medication used to treat advanced breast cancer.	Oral LD50s in mouse and dog are 1630 mg/kg and 593-926 mg/kg, respectively.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.7356 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.7		218.5 °C		Slightly soluble (27.4 mg/L)	1	Yes	2	0	No	4	0	43.37 Å2	33.42 Å3	85.79 m3·mol-1	0	Yes	No	0.023 mg/mL	3.23	-4.1	18.37	-5			
C27H44O3	1.49 +/- 0.60 L/h [chronic kidney disease Stage 5 with hemodialysis]1.54 +/- 0.95 L/h [chronic kidney disease Stage 5with peritoneal dialysis]	4 to 6 hours	416.6365	[H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1C[C@@H](O)C[C@H](O)C1)[C@H](C)\C=C\[C@H](C)C(C)(C)O	Solid	30.8 ± 7.5 L [CKD Stage 5-HD]34.9 ± 9.5 L [CKD Stage 5-PD]23.8 L [healthy subjects]	Q07973;!P08684;!P22310	CYP24A1;!CYP3A4;!UGT1A4	1. 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial;!2. Cytochrome P450 3A4;!3. UDP-glucuronosyltransferase 1-4		233195	7931	CHEMBL1200622	4444552	Drugs.com Drug Page		HMDB0015046	C08127	D00930			PA450798	5281104	46505780	RxList Drug Page	73710	DAP000211	Paricalcitol	ZINC000013911941	Zemplar	Paricalcitol	Approved, Investigational	DB00910	InChI=1S/C27H44O3/c1-18(8-9-19(2)26(3,4)30)24-12-13-25-21(7-6-14-27(24,25)5)11-10-20-15-22(28)17-23(29)16-20/h8-11,18-19,22-25,28-30H,6-7,12-17H2,1-5H3/b9-8+,21-11+/t18-,19+,22-,23-,24-,25+,27-/m1/s1	BPKAHTKRCLCHEA-UBFJEZKGSA-N	4	Paricalcitol is a vitamin D analog used to treat hyperparathyroidism associated with stage 3 or greater chronic kidney disease.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	4.4277 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					4.5					1	No	3	3	No	3	0	60.69 Å2	51.06 Å3	127.95 m3·mol-1	5	Yes	No	0.0068 mg/mL	4.26	-4.8	14.81	-1	P11473	VDR	1. Vitamin D3 receptor
C29H41NO4	Clearance may be higher in children than in adults.Plasma clearance rate, IV administration, anaesthetized patients = 901.2 ± 39.7 mL/min;Plasma clearance rate, IV administration, healthy subjects = 1042 - 1280 mL/min.	Buprenorphine demonstrates slow dissociation kinetics (~166 min), which contributes to its long duration of action and allows for once-daily or even every-second-day dosing.18 In clinical trial studies, the half-life of sublingually administered buprenorphine/naloxone 2mg/0.5mg was found to be 30.75 hours.19,20	467.6401	CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4	Solid	Buprenorphine is highly lipophilic, and therefore extensively distributed, with rapid penetration through the blood-brain barrier. The estimated volume of distribution is 188 - 335 L when given intravenously. It is able to cross into the placenta and breast milk.	P08684;!P20815;!P11712;!P10632;!P24462;!P10635;!P33260;!P33261	CYP3A4;!CYP3A5;!CYP2C9;!CYP2C8;!CYP3A7;!CYP2D6;!CYP2C18;!CYP2C19	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5;!3. Cytochrome P450 2C9;!4. Cytochrome P450 2C8;!5. Cytochrome P450 3A7;!6. Cytochrome P450 2D6;!7. Cytochrome P450 2C18;!8. Cytochrome P450 2C19		50026603	3216	CHEMBL560511	559124	Drugs.com Drug Page		HMDB0015057	C08007	D07132			PA448685	644073	46505782	RxList Drug Page	1819	DAP001353	Buprenorphine	ZINC000001319780	Belbuca, Buprenex, Buprenorphine, Butrans, Probuphine, Sublocade, Suboxone, Subutex, Zubsolv	Buprenorphine	Approved, Illicit, Investigational, Vet approved	DB00921	InChI=1S/C29H41NO4/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3/t20-,21-,24-,26+,27-,28+,29-/m1/s1	RMRJXGBAOAMLHD-IHFGGWKQSA-N	4	Buprenorphine is a partial opioid agonist used for management of severe pain that is not responsive to alternative treatments. Also used for maintenance treatment of opioid addiction.	Manifestations of acute overdose include pinpoint pupils, sedation, hypotension, respiratory depression and death.	Small Molecule	http://smpdb.ca/view/SMP0000684?highlight[compounds][]=DB00921&highlight[proteins][]=DB00921	Buprenorphine Action Pathway		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	3.1511 LD50, mol/kg	Inhibitor	Weak inhibitor	Non-inhibitor					4.98			8.31 (at 25 °C)		1	No	5	2	No	7	1	62.16 Å2	53.03 Å3	131.76 m3·mol-1	5	Yes	No	0.0168 mg/mL	3.55	-4.4	10.42	9.63			
C32H47F5O3S	Not Available	40 days	606.78	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@@]21[H]	Solid	3 to 5 L/kg	P08684;!P22309	CYP3A4;!UGT1A1	1. Cytochrome P450 3A4;!2. UDP-glucuronosyltransferase 1-1		50238741	31638	CHEMBL1358	94553	Drugs.com Drug Page	GtP Drug Page	HMDB0015082		D01161			PA164747170	17756771	46508664	RxList Drug Page	282357	DAP000319	Fulvestrant		Faslodex	Fulvestrant	Approved, Investigational	DB00947	InChI=1S/C32H47F5O3S/c1-30-17-15-26-25-12-11-24(38)21-23(25)20-22(29(26)27(30)13-14-28(30)39)10-7-5-3-2-4-6-8-18-41(40)19-9-16-31(33,34)32(35,36)37/h11-12,21-22,26-29,38-39H,2-10,13-20H2,1H3/t22-,26-,27+,28+,29-,30+,41?/m1/s1	VWUXBMIQPBEWFH-WCCTWKNTSA-N	4	Fulvestrant is an estrogen receptor antagonist used to treat HR+ breast cancer that may also be HER2-.	There is no clinical experience with overdosage in humans.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.6310 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor					8.9					0	No	3	2	Yes	4	0	57.53 Å2	65.88 Å3	155.34 m3·mol-1	15	No	No	0.00672 mg/mL	7.57	-5	10.32	-0.88			
C23H31NO3	Data regarding the clearance of norgestimate is not readily available.10,11	Norgestimate is rapidly deacetylated.1,2 The active metabolites of norgestimate, 17-desacetyl norgestimate, has a half life of 12-30h,1 while norgestrel has a half life of 36.4±10.2h.11	369.4971	[H][C@@]12CC[C@@](OC(C)=O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CC\C(C=C3CC[C@@]21[H])=N/O	Solid	Data regarding the volume of distribution of norgestimate are not readily available.10,11	P08684;!P20813;!P11712;!P22309	CYP3A4;!CYP2B6;!CYP2C9;!UGT1A1	1. Cytochrome P450 3A4;!2. Cytochrome P450 2B6;!3. Cytochrome P450 2C9;!4. UDP-glucuronosyltransferase 1-1			50815	CHEMBL1200934	5022837			HMDB0015092		D05209			PA164744346	6540478	46507381	RxList Drug Page	31994	DAP001210	Norgestimate	ZINC000003938695	Estarylla 28 Day, Femynor 28 Day, Mili 28 Day, Mono-linyah 28 Day, Mononessa 28 Day, Nymyo 28 Day, Ortho Tri-cyclen 28 Day, Ortho Tri-cyclen Lo 28 Day, Prefest 30 Day, Previfem 28 Day, Sprintec 28 Day, Tri Femynor 28 Day, Tri-LO- Estarylla 28 Day, Tri-LO-marzia 28-day, Tri-LO-mili, Tri-Lo-Sprintec, Tri-estarylla 28 Day, Tri-linyah, Tri-mili 28 Day, Tri-nymyo 28 Day Pack, Tri-previfem 28 Day, Tri-sprintec 28 Day, Tri-vylibra 28 Day, Tri-vylibra Lo 28 Day, Trinessa 28 Day, Trinessa Lo 28 Day, Vylibra 28 Day	Norgestimate	Approved, Investigational	DB00957	InChI=1S/C23H31NO3/c1-4-22-12-10-19-18-9-7-17(24-26)14-16(18)6-8-20(19)21(22)11-13-23(22,5-2)27-15(3)25/h2,14,18-21,26H,4,6-13H2,1,3H3/b24-17+/t18-,19+,20+,21-,22-,23-/m0/s1	KIQQMECNKUGGKA-NMYWJIRASA-N	4	Norgestimate is a progesterone used as a contraceptive and to treat acne vulgaris.	Data regarding overdoses of norgestimate are rare.10,11 However, the majority of patients overdosing on oral contraceptives do not become seriously ill.6 Treat overdoses with symptomatic and supportive care.6,10,11	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.4561 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							216 °C			1	Yes	3	1	No	4	0	58.89 Å2	42.79 Å3	105 m3·mol-1	3	Yes	No	0.00531 mg/mL	4.11	-4.8	11.47	3.11	P06401;!P03372;!P10275	PGR;!ESR1;!AR	1. Progesterone receptor;!2. Estrogen receptor alpha;!3. Androgen receptor
C22H30O5	The average plasma clearance of methylprednisolone is 336mL/h/kg.1	Methylprednisolone has a half life of 2.3h.1,6	374.4706	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C	Solid	The average volume of distribution of methylprednisolone is 1.38L/kg.1	BE0009795;!BE0009796;!P08684;!BE0004866;!P11509;!Q16678;!P20813;!P10632;!P33261;!P11712	;!;!CYP3A4;!;!CYP2A6;!CYP1B1;!CYP2B6;!CYP2C8;!CYP2C19;!CYP2C9	1. 20-ketosteroid reductase (20-hydroxysteroid dehydrogenase) (Protein Group);!2. 11beta-hydroxysteroid dehydrogenase (Protein Group);!3. Cytochrome P450 3A4;!4. Cytochrome P450 3A Subfamily (Protein Group);!5. Cytochrome P450 2A6;!6. Cytochrome P450 1B1;!7. Cytochrome P450 2B6;!8. Cytochrome P450 2C8;!9. Cytochrome P450 2C19;!10. Cytochrome P450 2C9		50103616	6888	CHEMBL650	6485	Drugs.com Drug Page		HMDB0015094		D00407			PA450466	6741	46504885	RxList Drug Page	6902	DAP001040	Methylprednisolone	ZINC000003875560	Depo-medrol, Depo-medrol With Lidocaine, Hybrisil, Medrol, Medroloan Suik, Readysharp-p40, Readysharp-p80	Methylprednisolone	Approved, Vet approved	DB00959	InChI=1S/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,17-,19+,20-,21-,22-/m0/s1	VHRSUDSXCMQTMA-PJHHCJLFSA-N	4	Methylprednisolone is a corticosteroid used to treat inflammation or immune reactions across a variety of organ systems, endocrine conditions, and neoplastic diseases.	The oral LD50 in rats is >4g/kg.14 The intraperitoneal LD50 in mice is 2292mg/kg and in rats is 100mg/kg.14Data regarding acute overdoses of glucocorticoids are rare.12,13 Chronic high doses of glucocorticoids can lead to the development of cataract, glaucoma, hypertension, water retention, hyperlipidemia, peptic ulcer, pancreatitis, myopathy, osteoporosis, mood changes, psychosis, dermal atrophy, allergy, acne, hypertrichosis, immune suppression, decreased resistance to infection, moon face, hyperglycemia, hypocalcemia, hypophosphatemia, metabolic acidosis, growth suppression, and secondary adrenal insufficiency.8 Treat acute overdoses with symptomatic and supportive therapy, while chronic overdoses will require temporarily reduced dosages.8,13	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.0025 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					1.525	-2.99	232.5 °C		120 mg/L (at 25 °C)	1	Yes	5	3	No	4	0	94.83 Å2	40.77 Å3	103.04 m3·mol-1	2	Yes	No	0.109 mg/mL	1.56	-3.5	12.59	-2.9	P04150;!P04083	NR3C1;!ANXA1	1. Glucocorticoid receptor;!2. Annexin A1
C20H24O2	Ethinylestradiol has an intravenous clearance of 16.47L/h, and an estimated renal clearance of approximately 2.1L/h.4 A 30µg oral dose has a clearance of 58.0±19.8L/h and a 1.2mg topical dose has a clearance of 303.5±100.5L/h.10	A 30µg oral dose has a half life of 8.4±4.8h and a 1.2mg topical dose has a half life of 27.7±34.2h.10	296.4034	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	Solid	A 30µg oral dose has an apparent volume of distribution of 625.3±228.7L and a 1.2mg topical dose has an apparent volume of distribution of 11745.3±15934.8L.10					50187243	4903	CHEMBL691	5770			HMDB0001926	C07534	D00554	3WF		PA449527	5991	46508618	RxList Drug Page	4124	DAP001018	Ethinylestradiol	ZINC000003812897	Afirmelle 28 Day, Alesse, Altavera 28 Day, Alyacen 1/35, Alyacen 7/7/7, Amethia 91 Day, Amethyst, Annovera, Apri 28 Day, Aranelle 28, Ashlyna 91 Day, Aubra 28 Day, Aurovela, Aurovela Fe, Aviane 28, Ayuna 28 Day Pack, Azurette 28 Day, Balcoltra 28 Day, Balziva 28 Day, Bekyree 28 Day, Beyaz 28 Day, Blisovi 21 Fe 1.5/30 28 Day Pack, Blisovi 24 Fe 1/20 28 Day, Brevicon, Briellyn 28 Day, Camrese 91 Day, Camreselo 91 Day, Caziant 28 Day, Cesia 28 Day, Charlotte 24 Fe Chewable 28 Day, Chateal 28 Day, Cléo -35, Cryselle 28, Cyclafem 1/35 28 Day, Cyclafem 7/7/7 28 Day, Cyestra-35, Cyonanz 28 Day, Cyred 28 Day, Dasetta 1/35 28 Day, Dasetta 7/7/7 28 Day, Daysee 91 Day, Delyla 28 Day, Diane, Dolishale 28 Day, Elinest 28 Day, Eluryng, Emoquette, Enpresse 28 Day, Enskyce 28 Day, Estarylla 28 Day, Estrostep Fe 28 Day, Evra, Falmina 28 Day, Fayosim 91 Day, Femcon Fe 28 Day, Femhrt 0.5/2.5 28 Day, Femynor 28 Day, Freya, Fyavolv, Gemmily 28 Day, Generess Fe 28, Gianvi 28-day, Hailey 1.5/30 21 Day, Hailey 24 Fe 28 Day, Hailey Fe 1.5/30 28 Day, Hailey Fe 1/20 28 Day, Iclevia 91 Day, Indayo, Introvale 91 Day, Isibloom 28 Day, Jaimiess 91 Day, Jasmiel 28 Day, Jinteli, Jolessa 91 Day, Juleber 28 Day, Junel 1.5/30 21 Day, Junel 1/20 21 Day, Junel Fe 1.5/30 28 Day, Junel Fe 1/20 28 Day, Junel Fe 24 1/20 28 Day, Kaitlib Fe 28 Day, Kalliga, Kariva 28 Day, Kelnor 1/35 28 Day, Kelnor 1/50 28 Day, Kurvelo, Larin 1.5/30, Larin 1/20, Larin 24 Fe 1/20, Larin Fe 1.5/30, Larin Fe 1/20, Larissia 28 Day Pack, Layolis Fe 28, Leena 28 Day, Levonest 28 Day, Levora 0.15/30 28 Day, Lillow 28 Day, Linessa, Lo Loestrin Fe 28 Day, Lo Simpesse, Lo-zumandimine 28 Day, Lo/ovral 28 Day, LoJaimiess, Loestrin 1.5/30 21 Day, Loestrin 24 Fe 28 Day, Loestrin Fe 1/20 28 Day, Lolo, Lomedia 24 Fe, Loryna, Loseasonique, Low-ogestrel 28 Day, Lutera 28 Day, Marlissa 28 Day, Marvelon, Melodetta 24 Fe Chewable 28 Day, Merzee 28 Day, Microgestin 1.5/30 21 Day, Microgestin 1/20 21 Day, Microgestin 24 Fe 28 Day, Microgestin Fe 1.5/30 28 Day, Microgestin Fe 1/20 28 Day, Mili 28 Day, Min-ovral, Minastrin 24 Fe Chewable 28 Day, Mircette 28 Day, Mono-linyah 28 Day, Mononessa 28 Day, Myzilra 28 Day, Necon 0.5/35 28 Day, Necon 1/35 28 Day, Necon 7/7/7 28 Day, Nexesta Fe 28 Day, Nikki 28 Day, Nortrel 1/35 21 Day, Nortrel 1/35 28 Day, Nortrel 7/7/7 28 Day, Nuvaring, Nylia 1/35 28 Day, Nylia 7/7/7 28 Day, Nymyo 28 Day, Ocella 28 Day, Orsythia 28 Day, Ortho Tri-cyclen 28 Day, Ortho Tri-cyclen Lo 28 Day, Ortho-novum 7/7/7 28 Day, Philith 28 Day, Pimtrea Pack, Pirmella 1/35 28 Day, Pirmella 7/7/7 28 Day, Portia 28 Day, Previfem 28 Day, Quartette 91 Day Pack, Reclipsen, Rivelsa 91 Day, Safyral 28 Day, Seasonale, Seasonique, Select, Setlakin 91 Day, Simliya, Simpesse, Sprintec 28 Day, Sronyx 28 Day, Syeda 28 Day, Synphasic, Tarina 24 Fe 1/20 28 Day, Tarina Fe 1/20 28 Day, Taysofy 28 Day, Taytulla 28 Day, Tilia Fe, Tri Femynor 28 Day, Tri-LO- Estarylla 28 Day, Tri-LO-marzia 28-day, Tri-LO-mili, Tri-Lo-Sprintec, Tri-estarylla 28 Day, Tri-legest 28 Day, Tri-linyah, Tri-mili 28 Day, Tri-nymyo 28 Day Pack, Tri-previfem 28 Day, Tri-sprintec 28 Day, Tri-vylibra 28 Day, Tri-vylibra Lo 28 Day, Trinessa 28 Day, Trinessa Lo 28 Day, Triquilar, Trivora 28 Day, Twirla 3 Count Weekly Patch, Tyblume 28 Day, Velivet 28 Day, Vestura, Vienva 28 Day, Viorele 28 Day, Volnea 28 Day, Vyfemla 28 Day, Vylibra 28 Day, Wera 28 Day, Wymzya Fe 28 Day, Xulane, Yasmin, Yasmin 28 Day, Yaz 28 Day, Yaz Plus, Zafemy, Zarah, Zenchent, Zovia 1/35e 28 Day, Zovia 1/50e 28 Day, Zumandimine 28 Day	Ethinylestradiol	Approved	DB00977	InChI=1S/C20H24O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,5,7,12,16-18,21-22H,4,6,8-11H2,2H3/t16-,17-,18+,19+,20+/m1/s1	BFPYWIDHMRZLRN-SLHNCBLASA-N	4	Ethinylestradiol is an estradiol used as a contraceptive.	Female patients experiencing and overdose may present with withdrawal bleeding, nausea, vomiting, breast tenderness, abdominal pain, drowsiness, and fatigue.15,25,16,17,24,18,19,20,21,22,23 Overdose should be treated with symptomatic and supportive care including monitoring for potassium concentrations, sodium concentrations, and signs of metabolic acidosis.15,25,16,17,24,18,19,20,21,22,23	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.4584 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor					3.67	-4.3	142-144		11.3 mg/L (at 27 °C)	1	Yes	2	2	No	4	0	40.46 Å2	34.53 Å3	87.37 m3·mol-1	0	Yes	No	0.00677 mg/mL	3.9	-4.6	10.33	-1.7			
C27H34O3	Not Available	The elimination half-life from plasma is very short.	406.5571	[H][C@@]12CC[C@H](OC(=O)CCC3=CC=CC=C3)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	Solid	Not Available						7468	CHEMBL1200412	199761	Drugs.com Drug Page		HMDB0015119	C08155	D00956			PA164746281	229455	46506276		31495	DAP000903	Nandrolone	ZINC000003881613		Nandrolone phenpropionate	Approved, Illicit, Investigational	DB00984	InChI=1S/C27H34O3/c1-27-16-15-22-21-11-9-20(28)17-19(21)8-10-23(22)24(27)12-13-25(27)30-26(29)14-7-18-5-3-2-4-6-18/h2-6,17,21-25H,7-16H2,1H3/t21-,22+,23+,24-,25-,27-/m0/s1	UBWXUGDQUBIEIZ-QNTYDACNSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	1.8785 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							118 °C		3090 mg/L (at 25 °C)	1	No	2	0	No	5	0	43.37 Å2	47.83 Å3	118.43 m3·mol-1	5	No	No	0.000458 mg/mL	5.79	-6	18.25	-4.7	P10275	AR	1. Androgen receptor
C20H24O2	Not Available	24 hours	296.4034	[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC(=C)C2=CC(=O)C=C[C@]12C	Solid	Not Available	P11511;!P08684	CYP19A1;!CYP3A4	1. Cytochrome P450 19A1;!2. Cytochrome P450 3A4		50398447	4953	CHEMBL1200374	54278	Drugs.com Drug Page		HMDB0015125	C08162	D00963	EXM		PA449563	60198	46508243	RxList Drug Page	258494	DAP000625	Exemestane	ZINC000003973334	Aromasin	Exemestane	Approved, Investigational	DB00990	InChI=1S/C20H24O2/c1-12-10-14-15-4-5-18(22)20(15,3)9-7-16(14)19(2)8-6-13(21)11-17(12)19/h6,8,11,14-16H,1,4-5,7,9-10H2,2-3H3/t14-,15-,16-,19+,20-/m0/s1	BFYIZQONLCFLEV-DAELLWKTSA-N	4	Exemestane is an aromatase inhibitor used to treat breast cancer in postmenopausal women after treatment with tamoxifen.	Convulsions	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.7582 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.7		155.13 °C		Non-soluble	1	Yes	2	0	No	4	0	34.14 Å2	33.72 Å3	89.03 m3·mol-1	0	Yes	Yes	0.00683 mg/mL	3.87	-4.6		-5			
C25H32ClFO5	Data regarding the clearance of clobetasol propionate are not readily available.3	Data regarding the half life of clobetasol propionate are not readily available.3	466.97	[H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	Data regarding the volume of distribution of clobetasole propionate are not readily available.10,11,12,13,14,15	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5		39347	31414	CHEMBL1159650	30399	Drugs.com Drug Page				D01272	XRD	PDRhealth Drug Page	PA164744375	32798	46505670	RxList Drug Page	21245	DAP001183	Clobetasol_propionate	ZINC000003977767	Clobex, Clodan, Dermovate, Impeklo, Impoyz, Olux, Temovate, Tovet	Clobetasol propionate	Approved	DB01013	InChI=1S/C25H32ClFO5/c1-5-21(31)32-25(20(30)13-26)14(2)10-18-17-7-6-15-11-16(28)8-9-22(15,3)24(17,27)19(29)12-23(18,25)4/h8-9,11,14,17-19,29H,5-7,10,12-13H2,1-4H3/t14-,17-,18-,19-,22-,23-,24-,25-/m0/s1	CBGUOGMQLZIXBE-XGQKBEPLSA-N	4	Clobetasol propionate is a corticosteroid used to treat corticosteroid-responsive dermatoses and plaque psoriasis.	Data regarding acute overdoses of glucocorticoids are rare.10,11,12 Overdoses of clobetasol propionate can lead to reversible HPA axis suppression and glucocorticoid insufficiency.15 Chronic high doses of glucocorticoids can lead to the development of cataract, glaucoma, hypertension, water retention, hyperlipidemia, peptic ulcer, pancreatitis, myopathy, osteoporosis, mood changes, psychosis, dermal atrophy, allergy, acne, hypertrichosis, immune suppression, decreased resistance to infection, moon face, hyperglycemia, hypocalcemia, hypophosphatemia, metabolic acidosis, growth suppression, and secondary adrenal insufficiency.8 Overdose may be treated by adjusting the dose or stopping the corticosteroid as well as initiating symptomatic and supportive treatment.8	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1435 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.50		196			1	Yes	4	1	No	4	0	80.67 Å2	48.27 Å3	119.32 m3·mol-1	5	Yes	No	0.00413 mg/mL	4.18	-5	13.63	-3.4	P04150;!P04083;!P08235	NR3C1;!ANXA1;!NR3C2	1. Glucocorticoid receptor;!2. Annexin A1;!3. Mineralocorticoid receptor
C26H32F2O7	Not Available	Not Available	494.5249	[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)COC(C)=O	Solid	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5			5109	CHEMBL1501	9265	Drugs.com Drug Page		HMDB0015181		D00325		PDRhealth Drug Page	PA449664	9642	46504523	RxList Drug Page	4462	DAP000421	Fluocinonide	ZINC000003977978	Lidemol, Lidex, Lyderm, Tiamol, Vanos	Fluocinonide	Approved, Investigational	DB01047	InChI=1S/C26H32F2O7/c1-13(29)33-12-20(32)26-21(34-22(2,3)35-26)10-15-16-9-18(27)17-8-14(30)6-7-23(17,4)25(16,28)19(31)11-24(15,26)5/h6-8,15-16,18-19,21,31H,9-12H2,1-5H3/t15-,16-,18-,19-,21+,23-,24-,25-,26+/m0/s1	WJOHZNCJWYWUJD-IUGZLZTKSA-N	4	Fluocinonide is a high potency corticosteroid commonly used topically for a number of inflammatory skin conditions.	Side effects may include acne-like eruptions, burning, dryness, excessive hair growth, infection of the skin, irritation, itching, lack of skin colour, prickly heat, skin inflammation, skin loss or softening, stretch marks.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	3.1492 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.19		309 °C		4.74 mg/L	1	No	6	1	No	5	0	99.13 Å2	48.97 Å3	120.56 m3·mol-1	4	Yes	No	0.0168 mg/mL	2.05	-4.5	13.6	-3.4	P04150;!Q99835	NR3C1;!SMO	1. Glucocorticoid receptor;!2. Smoothened homolog
C28H46O	Not Available	Not Available	398.6642	CC(C)[C@@H](C)\C=C\[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1/C[C@@H](O)CC[C@@H]1C	Solid	Not Available						4591	CHEMBL2356023	4470607	Drugs.com Drug Page		HMDB0015203	C06957	D00299			PA164744345	5311071	46507699	RxList Drug Page	3429	DAP000365	Dihydrotachysterol	ZINC000004212953		Dihydrotachysterol	Approved	DB01070	InChI=1S/C28H46O/c1-19(2)20(3)9-10-22(5)26-15-16-27-23(8-7-17-28(26,27)6)12-13-24-18-25(29)14-11-21(24)4/h9-10,12-13,19-22,25-27,29H,7-8,11,14-18H2,1-6H3/b10-9+,23-12+,24-13+/t20-,21-,22+,25-,26+,27-,28+/m0/s1	ILYCWAKSDCYMBB-OPCMSESCSA-N	2	Dihydrotachysterol is a synthetic analog of vitamin D that does not require renal activation like vitamin D2 or Vitamin D3.	Toxicity associated with dihydrotachysterol is similar to that seen with large doses of vitamin D.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	3.1244 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					7.5					1	No	1	1	No	3	0	20.23 Å2	51.77 Å3	129.11 m3·mol-1	5	No	Yes	0.000125 mg/mL	7.4	-6.5	18.3	-1.4	P11473	VDR	1. Vitamin D3 receptor
C29H44O12	Not Available	Not Available	584.6525	[H][C@@]12CC[C@]3(O)C[C@H](C[C@@H](O)[C@]3(CO)[C@@]1([H])[C@H](O)C[C@]1(C)[C@H](CC[C@]21O)C1=CC(=O)OC1)O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O	Solid	Not Available					50286739	472805	CHEMBL222863	388599			HMDB0015224	C01443	D00112	OBN		PA163522138	439501	46505479		7762	DAP000465	Ouabain	ZINC000008143614		Ouabain	Approved	DB01092	InChI=1S/C29H44O12/c1-13-22(34)23(35)24(36)25(40-13)41-15-8-19(32)28(12-30)21-17(3-5-27(28,37)9-15)29(38)6-4-16(14-7-20(33)39-11-14)26(29,2)10-18(21)31/h7,13,15-19,21-25,30-32,34-38H,3-6,8-12H2,1-2H3/t13-,15-,16+,17+,18+,19+,21+,22-,23+,24+,25-,26+,27-,28+,29-/m0/s1	LPMXVESGRSUGHW-HBYQJFLCSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	4.7797 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor					-2.00		200 °C		1.03E+004 mg/L	0	No	11	8	No	6	-1	206.6 Å2	59.92 Å3	140.83 m3·mol-1	4	No	No	4.61 mg/mL	-2.8	-2.1	7.18	-2.9	P05023;!P50993;!P13637	ATP1A1;!ATP1A2;!ATP1A3	1. Sodium/potassium-transporting ATPase subunit alpha-1;!2. Sodium/potassium-transporting ATPase subunit alpha-2;!3. Sodium/potassium-transporting ATPase subunit alpha-3
C20H27NO3	Not Available	8 hours.	329.4333	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N	Solid	Not Available						32260	CHEMBL1200907	570949			HMDB0015240	C12580	D01180			PA164748507	656583	46507062		38668	DAP000148	Trilostane	ZINC000100038546		Trilostane	Approved, Investigational, Vet approved, Withdrawn	DB01108	InChI=1S/C20H27NO3/c1-18-7-6-14-12(13(18)3-4-15(18)22)5-8-20-17(24-20)16(23)11(10-21)9-19(14,20)2/h12-15,17,22-23H,3-9H2,1-2H3/t12-,13-,14-,15-,17+,18-,19+,20+/m0/s1	KVJXBPDAXMEYOA-CXANFOAXSA-N	2		Symptoms of overdose include darkening of skin, drowsiness or tiredness, loss of appetite, mental depression, skin rash, and/or vomiting.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.3725 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3		264 dec °C			1	Yes	4	2	No	5	-1	76.78 Å2	36.81 Å3	90.17 m3·mol-1	0	Yes	No	0.0592 mg/mL	2.3	-3.8	5.23	-0.88	P14060;!P26439;!P03372;!Q92731	HSD3B1;!HSD3B2;!ESR1;!ESR2	1. 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1;!2. 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2;!3. Estrogen receptor alpha;!4. Estrogen receptor beta
C27H36O8	Not Available	Not Available	488.577	[H][C@@]12CC[C@](OC(=O)OCC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			135791	CHEMBL1200386	5145991	Drugs.com Drug Page							PA164749394	6714002	46506799	RxList Drug Page	34369	DAP001189	Prednicarbate	ZINC000003938652	Dermatop	Prednicarbate	Approved, Investigational	DB01130	InChI=1S/C27H36O8/c1-5-22(31)34-15-21(30)27(35-24(32)33-6-2)12-10-19-18-8-7-16-13-17(28)9-11-25(16,3)23(18)20(29)14-26(19,27)4/h9,11,13,18-20,23,29H,5-8,10,12,14-15H2,1-4H3/t18-,19-,20-,23+,25-,26-,27-/m0/s1	FNPXMHRZILFCKX-KAJVQRHHSA-N	2	Prednicarbate is a medium potency topical corticosteroid used to manage pruritus and inflammation associated with responsive skin conditions.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.4426 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.9					1	No	6	1	Yes	4	0	116.2 Å2	52.43 Å3	127.8 m3·mol-1	9	Yes	No	0.00562 mg/mL	3.83	-4.9	14.83	-2.9	P04150	NR3C1	1. Glucocorticoid receptor
C26H38O4	Not Available	Not Available	414.586	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)C(=O)COC(=O)C(C)(C)C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			50782	CHEMBL1200592	10050591								PA449245	11876263	46506381		22537	DAP001106	Desoxycorticosterone_pivalate	ZINC000004082455		Desoxycorticosterone pivalate	Experimental, Vet approved	DB01134	InChI=1S/C26H38O4/c1-24(2,3)23(29)30-15-22(28)21-9-8-19-18-7-6-16-14-17(27)10-12-25(16,4)20(18)11-13-26(19,21)5/h14,18-21H,6-13,15H2,1-5H3/t18-,19-,20-,21+,25-,26-/m0/s1	VVOIQBFMTVCINR-WWMZEODYSA-N			Symptoms of overdose include polyuria, polydipsia, increased blood volume, edema, and cardiac enlargement.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	1.7883 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					4				Insoluble	1	Yes	3	0	No	4	0	60.44 Å2	48.3 Å3	117.26 m3·mol-1	5	No	No	0.00141 mg/mL	5.57	-5.5	17.19	-4.8	P08235	NR3C2	1. Mineralocorticoid receptor
C20H29FO3	Not Available	9.2 hours	336.4409	[H][C@@]12CC[C@](C)(O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	Not Available					18189	5120	CHEMBL1445	6205	Drugs.com Drug Page	GtP Drug Page	HMDB0015316		D00327			PA164744518	6446	46508867	RxList Drug Page	4494	DAP000904	Fluoxymesterone	ZINC000003875484	Androxy, Halotestin	Fluoxymesterone	Approved, Illicit	DB01185	InChI=1S/C20H29FO3/c1-17-8-6-13(22)10-12(17)4-5-15-14-7-9-19(3,24)18(14,2)11-16(23)20(15,17)21/h10,14-16,23-24H,4-9,11H2,1-3H3/t14-,15-,16-,17-,18-,19-,20-/m0/s1	YLRFCQOZQXIBAB-RBZZARIASA-N		Fluoxymesterone is a synthetic androgenic anabolic steroid that used in the treatment of hypogonadism and delayed puberty in males, as well as breast neoplasms in women.	Side effects include virilization (masculine traits in women), acne, fluid retention, and hypercalcemia.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.7028 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.38		265		67.5 mg/L	1	Yes	3	2	No	4	0	57.53 Å2	36.65 Å3	90.19 m3·mol-1	0	Yes	No	0.0452 mg/mL	2.38	-3.9	13.6	-3			
C23H31Cl2NO3	Not Available	20 hours	440.403	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(OC(=O)N(CCCl)CCCl)C=C3CC[C@@]21[H]	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4		50333646	4868	CHEMBL1575	227635	Drugs.com Drug Page		HMDB0015327	C11228	D04066			PA449507	259331	46508765	RxList Drug Page	4089	DAP001307	Estramustine	ZINC000004099032	Emcyt	Estramustine	Approved, Investigational	DB01196	InChI=1S/C23H31Cl2NO3/c1-23-9-8-18-17-5-3-16(29-22(28)26(12-10-24)13-11-25)14-15(17)2-4-19(18)20(23)6-7-21(23)27/h3,5,14,18-21,27H,2,4,6-13H2,1H3/t18-,19-,20+,21+,23+/m1/s1	FRPJXPJMRWBBIH-RBRWEJTLSA-N	3	Estramustine is an antineoplastic agent used for the management of metastatic and/or progressive prostate cancer in palliative setting.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.7844 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					5.7		155			1	Yes	2	1	Yes	4	0	49.77 Å2	47.96 Å3	116.21 m3·mol-1	6	No	No	0.000385 mg/mL	5.1	-6.1	19.38	-0.88	Q92731;!P03372;!P11137;!P78559	ESR2;!ESR1;!MAP2;!MAP1A	1. Estrogen receptor beta;!2. Estrogen receptor alpha;!3. Microtubule-associated protein 2;!4. Microtubule-associated protein 1A
C22H29FO5	A 20mg oral tablet has a clearance of 15.7L/h.16 A 1.5mg oral dose of dexamethasone has a clearance of 15.6±4.9L/h while a 3.0mg intramuscular dose has a clearance of 9.9±1.4L/h.5	The mean terminal half life of a 20mg oral tablet is 4 hours.16 A 1.5mg oral dose of dexamethasone has a half life of 6.6±4.3h, while a 3mg intramuscular dose has a half life of 4.2±1.2h.5	392.4611	[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	A 1.5mg oral dose of dexamethasone has a volume of distribution of 51.0L, while a 3mg intramuscular dose has a volume of distribution of 96.0L.5					18207	41879	CHEMBL384467	5541	Drugs.com Drug Page	GtP Drug Page	HMDB0015364	C15643	D00292	DEX	PDRhealth Drug Page	PA449247	5743	46508930	RxList Drug Page	3264	DAP000007	Dexamethasone	ZINC000003875332	Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper	Dexamethasone	Approved, Investigational, Vet approved	DB01234	InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1	UREBDLICKHMUKA-CXSFZGCWSA-N		Dexamethasone is a glucocorticoid available in various modes of administration that is used for the treatment of various inflammatory conditions, including bronchial asthma, as well as endocrine and rheumatic disorders.	The oral LD50 in female mice was 6.5g/kg and 794mg/kg via the intravenous route.13Overdoses are not expected with otic formulations.12 Chronic high doses of glucocorticoids can lead to the development of cataract, glaucoma, hypertension, water retention, hyperlipidemia, peptic ulcer, pancreatitis, myopathy, osteoporosis, mood changes, psychosis, dermal atrophy, allergy, acne, hypertrichosis, immune suppression, decreased resistance to infection, moon face, hyperglycemia, hypocalcemia, hypophosphatemia, metabolic acidosis, growth suppression, and secondary adrenal insufficiency.2 Overdose may be treated by adjusting the dose or stopping the corticosteroid as well as initiating symptomatic and supportive treatment.2	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1482 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor		-4.75			1.83	-3.64	260-264		89 mg/L (at 25 °C)	1	Yes	5	3	No	4	0	94.83 Å2	40.71 Å3	102.49 m3·mol-1	2	Yes	No	0.0505 mg/mL	1.68	-3.9	12.42	-3.3			
C30H47NO4S	Not Available	Not Available	517.763	[H][C@@]12C(=O)CC[C@]11CC[C@@H](C)[C@@]2(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]1C)OC(=O)CS[C@H]1C[C@@H]2CC[C@H](C1)N2C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4				CHEMBL1658	25064484	Drugs.com Drug Page					G34		PA164749341	6918462	46509062	RxList Drug Page	642274	DAP000886	Retapamulin	ZINC000100013500	Altabax	Retapamulin	Approved	DB01256	InChI=1S/C30H47NO4S/c1-7-28(4)16-24(35-25(33)17-36-22-14-20-8-9-21(15-22)31(20)6)29(5)18(2)10-12-30(19(3)27(28)34)13-11-23(32)26(29)30/h7,18-22,24,26-27,34H,1,8-17H2,2-6H3/t18-,19+,20-,21+,22-,24-,26+,27+,28-,29+,30+/m1/s1	STZYTFJPGGDRJD-NHUWBDDWSA-N	4	Retapamulin is a topical antibiotic agent used for the treatment of impetigo caused by methicillin-susceptible Staphylococcus aureus or Streptococcus pyogenes.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.7920 LD50, mol/kg	Inhibitor	Weak inhibitor	Non-inhibitor					5					1	No	4	1	Yes	5	1	66.84 Å2	59.82 Å3	145.45 m3·mol-1	6	No	No	0.000394 mg/mL	4.37	-6.1	14.43	9.69	Q9A1X4	rplC	1. 50S ribosomal protein L3
C21H26O2	Not Available	Not Available	310.4299	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(OC)C=C3	Solid	Not Available	P08684;!P10632;!P11712	CYP3A4;!CYP2C8;!CYP2C9	1. Cytochrome P450 3A4;!2. Cytochrome P450 2C8;!3. Cytochrome P450 2C9			6784	CHEMBL1201151	6054			HMDB0015446	C07618	D00575			PA450388	6291	46507679		6782	DAP001014	Mestranol	ZINC000003815424		Mestranol	Approved	DB01357	InChI=1S/C21H26O2/c1-4-21(22)12-10-19-18-7-5-14-13-15(23-3)6-8-16(14)17(18)9-11-20(19,21)2/h1,6,8,13,17-19,22H,5,7,9-12H2,2-3H3/t17-,18-,19+,20+,21+/m1/s1	IMSSROKUHAOUJS-MJCUULBUSA-N	3	Mestranol is a synthetic estradiol found in oral contraceptive pills for contraception and the treatment of other conditions in the female reproductive system, such as dysmenorrhea and dysfunctional uterine bleeding.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.5234 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor							150.5 °C			1	Yes	2	1	No	4	0	29.46 Å2	36.7 Å3	91.86 m3·mol-1	1	Yes	Yes	0.00377 mg/mL	4.04	-4.9	17.59	-1.7	P03372	ESR1	1. Estrogen receptor alpha
C23H30O6	Data regarding the clearance of cortisone acetate is not readily available.8	Not Available	402.4807	[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5		50455157	3897	CHEMBL1650	5543	Drugs.com Drug Page		HMDB0015459	C08173	D00973			PA449130	5745	46508852	RxList Drug Page	21655		Cortisone_acetate	ZINC000003875334		Cortisone acetate	Approved, Investigational	DB01380	InChI=1S/C23H30O6/c1-13(24)29-12-19(27)23(28)9-7-17-16-5-4-14-10-15(25)6-8-21(14,2)20(16)18(26)11-22(17,23)3/h10,16-17,20,28H,4-9,11-12H2,1-3H3/t16-,17-,20+,21-,22-,23-/m0/s1	ITRJWOMZKQRYTA-RFZYENFJSA-N	4	Cortisone acetate is a steroid hormone used for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses and endocrine disorders associated with inadequate production of steroid hormones.	Data regarding acute overdoses of glucocorticoids are rare.8 Chronic high doses of glucocorticoids can lead to the development of cataract, glaucoma, hypertension, water retention, hyperlipidemia, peptic ulcer, pancreatitis, myopathy, osteoporosis, mood changes, psychosis, dermal atrophy, allergy, acne, hypertrichosis, immune suppression, decreased resistance to infection, moon face, hyperglycemia, hypocalcemia, hypophosphatemia, metabolic acidosis, growth suppression, and secondary adrenal insufficiency.6 Overdose may be treated by adjusting the dose or stopping the corticosteroid as well as initiating symptomatic and supportive treatment.6	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.1280 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.10		227-229		20 mg/L (at 25 °C)	1	Yes	5	1	No	4	0	97.74 Å2	43.06 Å3	105.63 m3·mol-1	4	Yes	No	0.0278 mg/mL	2.1	-4.2	12.6	-3.8	P04150;!P04083	NR3C1;!ANXA1	1. Glucocorticoid receptor;!2. Annexin A1
C24H30O3	Drospirenone is rapidly cleared, typically within 2-3 days of administration of the last active tablet.14 The rate of clearance of drospirenone calculated in the serum ranges from 1.2-1.5 ml/min/kg, however, this value can vary by up to 25% according to the patient.23	The serum half-life of drospirenone is estimated to be 30 hours.13 The half-life of drospirenone metabolite excretion in the urine and feces is approximately 40 hours.23	366.4932	[H][C@@]12C[C@]1([H])[C@@]1([H])[C@]3([H])[C@]4([H])C[C@]4([H])[C@@]4(CCC(=O)O4)[C@@]3(C)CC[C@]1([H])[C@@]1(C)CCC(=O)C=C21	Solid	The volume of distribution of drospirenone is estimated to be 4 L/kg, according to the FDA label for Yaz.19 Prescribing information from a combination of estradiol and drospirenone estimates the volume of distribution to range from 3.7- 4.2 L/kg.23	P35354;!P27169;!P08684	PTGS2;!PON1;!CYP3A4	1. Prostaglandin G/H synthase 2;!2. Serum paraoxonase/arylesterase 1;!3. Cytochrome P450 3A4		150275	50838	CHEMBL1509	62105	Drugs.com Drug Page		HMDB0015467		D03917			PA164749409	68873	46507653	RxList Drug Page	11636	DAP001206	Drospirenone	ZINC000003927200	Angeliq 0.25/0.5 28 Day, Beyaz 28 Day, Gianvi 28-day, Jasmiel 28 Day, Lo-zumandimine 28 Day, Loryna, Nextstellis 28 Day, Nikki 28 Day, Ocella 28 Day, Safyral 28 Day, Slynd, Syeda 28 Day, Vestura, Yasmin, Yasmin 28 Day, Yaz 28 Day, Yaz Plus, Zarah, Zumandimine 28 Day	Drospirenone	Approved	DB01395	InChI=1S/C24H30O3/c1-22-6-3-12(25)9-17(22)13-10-14(13)20-16(22)4-7-23(2)21(20)15-11-18(15)24(23)8-5-19(26)27-24/h9,13-16,18,20-21H,3-8,10-11H2,1-2H3/t13-,14+,15-,16+,18+,20-,21+,22-,23+,24+/m1/s1	METQSPRSQINEEU-HXCATZOESA-N	4	Drospirenone is a progestin used in oral contraceptive pills for the prevention of pregnancy and other conditions.	The oral LD50 of drospirenone in rats is >2000 mg/kg.22Overdose informationAn overdose of drospirenone, like other oral contraceptives, may lead to cause nausea or withdrawal bleeding. For drospirenone in particular, as an analog of spironolactone, may affect the levels of serum sodium and potassium. Their concentrations should be monitored in cases of overdose in addition to monitoring from metabolic acidosis and hyperkalemia, which may also result.15,19	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.9430 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				552.2	3.08	-5.2	196-200	-5		1	Yes	2	0	No	7	0	43.37 Å2	41.81 Å3	101.68 m3·mol-1	0	Yes	No	0.00225 mg/mL	3.37	-5.2	18.52	-5	P08235;!P10275;!P06401;!P04150	NR3C2;!AR;!PGR;!NR3C1	1. Mineralocorticoid receptor;!2. Androgen receptor;!3. Progesterone receptor;!4. Glucocorticoid receptor
C22H27NO2	Not Available	Approximately 24 hours.	337.4553	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC3=C(C[C@]12C)C=NO3	Solid	Not Available	P08684;!P11511	CYP3A4;!CYP19A1	1. Cytochrome P450 3A4;!2. Cytochrome P450 19A1		50423541	4315	CHEMBL1479	26436	Drugs.com Drug Page		HMDB0002835		D00289	QA1		PA164749056	28417	46506475	RxList Drug Page	3102	DAP001017	Danazol	ZINC000003881958	Cyclomen	Danazol	Approved	DB01406	InChI=1S/C22H27NO2/c1-4-22(24)10-8-18-16-6-5-15-11-19-14(13-23-25-19)12-20(15,2)17(16)7-9-21(18,22)3/h1,11,13,16-18,24H,5-10,12H2,2-3H3/t16-,17+,18+,20+,21+,22+/m1/s1	POZRVZJJTULAOH-LHZXLZLDSA-N	4	Danazol is a synthetic steroid and pituitary gonadotropin inhibitor used in the treatment of endometriosis and symptomatic treatment of severe pain and tenderness associated with benign fibrocystic breasts.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.3291 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					0.51		224.2-226.8			1	Yes	2	1	No	5	0	46.26 Å2	38.44 Å3	98.54 m3·mol-1	0	Yes	No	0.0176 mg/mL	3.46	-4.3	17.59	0.25	P03372;!P10275;!P06401;!P30968;!Q96P88;!P13500	ESR1;!AR;!PGR;!GNRHR;!GNRHR2;!CCL2	1. Estrogen receptor alpha;!2. Androgen receptor;!3. Progesterone receptor;!4. Gonadotropin-releasing hormone receptor;!5. Putative gonadotropin-releasing hormone II receptor;!6. C-C motif chemokine 2
C22H32O3	Testosterone propionate has a reduced clearance rate compared to testosterone.5 The reported clearance rate is of approximately 2000 ml/min.1	Testosterone propionate possesses a relatively short half-life compared with other testosterone esters at approximately 4.5 days.	344.4877	[H][C@@]12CC[C@H](OC(=O)CC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	The registered volume of distribution for testosterone propionate is in the range of 75-120 L/kg.1	P21964;!P22309;!BE0004887;!P08684	COMT;!UGT1A1;!;!CYP3A4	1. Catechol O-methyltransferase;!2. UDP-glucuronosyltransferase 1-1;!3. 3-oxo-5-alpha-steroid 4-dehydrogenase (Protein Group);!4. Cytochrome P450 3A4		50215709	9466	CHEMBL1170	5774	Drugs.com Drug Page		HMDB0015489	C08158	D00959			PA164751373	5995	46508693		10382		Testosterone_propionate	ZINC000000490791		Testosterone propionate	Approved, Investigational, Vet approved, Withdrawn	DB01420	InChI=1S/C22H32O3/c1-4-20(24)25-19-8-7-17-16-6-5-14-13-15(23)9-11-21(14,2)18(16)10-12-22(17,19)3/h13,16-19H,4-12H2,1-3H3/t16-,17-,18-,19-,21-,22-/m0/s1	PDMMFKSKQVNJMI-BLQWBTBKSA-N	4	Testosterone propionate is a slow-release anabolic steroid no longer used commonly for the treatment of androgen deficiency or promotion of anabolic effects on muscles.	Reports have showed a potential stimulation of cancerous tissue growth. The potential testosterone propionate accumulation in the body produces a high risk of edema secondaryh to water and sodium retention.5	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.0463 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor						-5.37	118-123 °C		1.48 mg/L (at 25ºC)	1	Yes	2	0	No	4	0	43.37 Å2	40.45 Å3	98.21 m3·mol-1	3	Yes	No	0.00502 mg/mL	4.51	-4.8	18.52	-4.8			
C21H32O	Not Available	Not Available	300.4782	[H][C@@]12CC[C@@](O)(CC=C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCCC=C3CC[C@@]21[H]	Solid	Not Available						31189	CHEMBL3185133	205855			HMDB0015500	C12811	D01374			PA164745307	235905	46506946		525	DPR000085	Allylestrenol	ZINC000004214767		Allylestrenol	Experimental	DB01431	InChI=1S/C21H32O/c1-3-12-21(22)14-11-19-18-9-8-15-6-4-5-7-16(15)17(18)10-13-20(19,21)2/h3,6,16-19,22H,1,4-5,7-14H2,2H3/t16-,17+,18+,19-,20-,21-/m0/s1	ATXHVCQZZJYMCF-XUDSTZEESA-N		Allylestrenol is a steroid used to prevent premature labour in pregnant women.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.4200 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							80 °C			1	Yes	1	1	No	4	0	20.23 Å2	37.18 Å3	93.14 m3·mol-1	2	Yes	Yes	0.000558 mg/mL	4.83	-5.7		-0.17	P06401;!P03372	PGR;!ESR1	1. Progesterone receptor;!2. Estrogen receptor alpha
C18H24O2	Not Available	Not Available	272.382	[H][C@@]12CCC(=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	Solid	Not Available						34187		83803				C14500			PDRhealth Drug Page		92834	46505377				19-Norandrostenedione	ZINC000004428372		19-norandrostenedione	Experimental, Illicit	DB01434	InChI=1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h10,13-16H,2-9H2,1H3/t13-,14+,15+,16-,18-/m0/s1	JRIZOGLBRPZBLQ-QXUSFIETSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.6104 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	0	No	4	0	34.14 Å2	31.56 Å3	79.13 m3·mol-1	0	Yes	Yes	0.0454 mg/mL	3.63	-3.8	18.25	-4.7			
C27H44O2	Not Available	The half-life of alfacalcidol ranges from three to four hours.9,12	400.6371	CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	Solid	Not Available						31186	CHEMBL1601669	4445376			HMDB0015504		D01518	M9B		PA164746469	5282181	46505115		12062		Alfacalcidol	ZINC000012484965	One-alpha	Alfacalcidol	Approved, Nutraceutical	DB01436	InChI=1S/C27H44O2/c1-18(2)8-6-9-19(3)24-13-14-25-21(10-7-15-27(24,25)5)11-12-22-16-23(28)17-26(29)20(22)4/h11-12,18-19,23-26,28-29H,4,6-10,13-17H2,1-3,5H3/b21-11+,22-12-/t19-,23-,24-,25+,26+,27-/m1/s1	OFHCOWSQAMBJIW-AVJTYSNKSA-N	4	Alfacalcidol is a vitamin D analogue used for the management of hypocalcemia, secondary hyperparathyroidism, and osteodystrophy in patients with chronic renal failure, as well as some types of rickets and osteomalacia.	There is a discrepancy across a number of reported LD50 values for alfacalcidol, which can be attributed to differences in the procedures used in laboratories. Oral LD50 in mice ranges from 440 to 490 mcg/kg. Intravenous in mice was 290 mcg/kg; however, another source presented 56 mcg/kg in female mice and 71 mcg/kg in male mice. Oral LD50 in rats ranges from 340 to 720 mcg/kg.9In case of an acute accidental overdose following oral administration, emesis or gastric lavage can be induced to prevent further drug absorption. Mineral oil may be used to promote fecal drug elimination in instances where the drug was already absorbed in the stomach.9 Alfacalcidol overdose can lead to hypercalcemia, hypercalciuria, and hyperphosphatemia. Similarly, a high intake of calcium and phosphate concurrently with a therapeutic dose of alfacalcidol can result in those conditions.9 Hypercalcemia most commonly presents with headache, weakness, hypertension, somnolence, dizziness, sweating, anorexia, nausea, vomiting, diarrhea, constipation, polyuria, polydipsia and muscle and bone pain, and metallic taste.12 Hypercalcemia should be responded to with discontinuation of alfacalcidol, a low calcium diet and withdrawal of calcium supplements.9 Prolonged hypercalcemia can lead to nephrocalcinosis, nephrolithiasis, and reduced kidney function. In cases of severe hypercalcemia, general supportive measures are recommended, which may include forced diuresis and close monitoring of renal function, electrolytes, and electrocardiographs. Monitoring for abnormalities is especially critical in patients receiving digitalis glycosides. Management with glucocorticosteroids, loop diuretics, bisphosphonates, and calcitonin, as well as hemodialysis with low calcium content, may be considered.12	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	4.6023 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							136 °C		<1 mg/mL	1	No	2	2	Yes	3	0	40.46 Å2	50.56 Å3	124.7 m3·mol-1	6	No	No	0.00163 mg/mL	5.82	-5.4	14.39	-2.8	P11473;!O15528;!P19793	VDR;!CYP27B1;!RXRA	1. Vitamin D3 receptor;!2. 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial;!3. Retinoic acid receptor RXR-alpha
C18H24O2	Not Available	Not Available	272.388	[H][C@@]12CCC(=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)CC3=CC[C@@]21[H]	Solid	Not Available								18612511									18633059	46508864				19-Nor-5-androstenedione			19-Nor-5-androstenedione	Experimental, Illicit	DB01443	InChI=1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h2,13-16H,3-10H2,1H3/t13-,14+,15+,16-,18-/m0/s1	WELNRNVZXWUOGT-QXUSFIETSA-N			Because 19-Nor-5-androstenedione is metabolically related toother controlled anabolic steroids, it is likely to have similar adverse health effects such as liver, heart and skin problems, hormonal disruptions, stunted growth,and psychological effects such as rage and depression.	Small Molecule																																			1	Yes	2	0	No	4	0	34.14 Å2	31.58 Å3	79.16 m3·mol-1	0	Yes	Yes	0.0621 mg/mL	3.27	-3.6	16.25	-7.2			
C25H35NO4	Not Available	Not Available	413.5497	[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]11CC[C@@]2(OC)[C@]([H])(C1)[C@](C)(O)CCC	Solid	Not Available								96924									107765	46507682				Dihydroetorphine	ZINC000005843973		Dihydroetorphine	Experimental, Illicit	DB01450	InChI=1S/C25H35NO4/c1-5-8-22(2,28)17-14-23-9-10-25(17,29-4)21-24(23)11-12-26(3)18(23)13-15-6-7-16(27)20(30-21)19(15)24/h6-7,17-18,21,27-28H,5,8-14H2,1-4H3/t17-,18-,21-,22-,23-,24+,25-/m1/s1	BRTSNYPDACNMIP-FAWZKKEFSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	3.4494 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	2	No	6	1	62.16 Å2	46.35 Å3	115.55 m3·mol-1	4	Yes	No	0.114 mg/mL	2.66	-3.6	10.24	9.13			
C19H26O2	Not Available	Not Available	286.415	[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)C=C[C@]12C	Solid	Not Available						133930		9372004									11196935	46504446				1-Androstenedione	ZINC000013512012		1-Androstenedione	Experimental, Illicit	DB01451	InChI=1S/C19H26O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h7,9,12,14-16H,3-6,8,10-11H2,1-2H3/t12-,14-,15-,16-,18-,19-/m0/s1	WJIQCDPCDVWDDE-WZNAKSSCSA-N			Not Available	Small Molecule																																			1	Yes	2	0	No	4	0	34.14 Å2	33.2 Å3	83.87 m3·mol-1	0	Yes	Yes	0.0051 mg/mL	3.97	-4.8		-4.9			
C18H28O2	Not Available	Not Available	276.4137	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CC[C@H](O)CC3=CC[C@@]21[H]	Solid	Not Available					50423550		CHEMBL259126	8075901			HMDB0004590						9900246	46507256				19-Nor-5-androstenediol	ZINC000012496354		19-Nor-5-androstenediol	Experimental, Illicit	DB01455	InChI=1S/C18H28O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h2,12-17,19-20H,3-10H2,1H3/t12-,13-,14+,15+,16-,17-,18-/m0/s1	VVUQRXPUVKXAIO-XFUVECHXSA-N			Not Available	Small Molecule																																			1	Yes	2	2	No	4	0	40.46 Å2	33.21 Å3	81.01 m3·mol-1	0	Yes	No	0.0645 mg/mL	2.5	-3.6	18.23	-0.77			
C19H26O2	Not Available	Not Available	286.415	[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2CC(=O)CC[C@]12C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			83865	CHEMBL1743203	141063			HMDB0062415	C20252					160531	46507159				5-Androstenedione	ZINC000100041759		5-androstenedione	Experimental, Illicit	DB01456	InChI=1S/C19H26O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h3,14-16H,4-11H2,1-2H3/t14-,15-,16-,18-,19-/m0/s1	SQGZFRITSMYKRH-QAGGRKNESA-N			Not Available	Small Molecule																																			1	Yes	2	0	No	4	0	34.14 Å2	33.23 Å3	83.63 m3·mol-1	0	Yes	Yes	0.0366 mg/mL	3.57	-3.9	16.23	-7.2			
C27H35NO5	Not Available	Not Available	453.579	[H][C@@]12OC3=C(OC(C)=O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@@]11C[C@]([H])([C@](C)(O)CCC)[C@]2(OC)C=C1	Solid	Not Available							CHEMBL3989451	16736130									20055090	46506577				Acetorphine	ZINC000072266292		Acetorphine	Experimental, Illicit	DB01469	InChI=1S/C27H35NO5/c1-6-9-24(3,30)19-15-25-10-11-27(19,31-5)23-26(25)12-13-28(4)20(25)14-17-7-8-18(32-16(2)29)22(33-23)21(17)26/h7-8,10-11,19-20,23,30H,6,9,12-15H2,1-5H3/t19-,20-,23-,24-,25-,26+,27-/m1/s1	LFYBMMHFJIAKFE-PMEKXCSPSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	3.3149 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	1	Yes	6	1	68.23 Å2	49.84 Å3	125.67 m3·mol-1	6	Yes	No	0.0197 mg/mL	2.66	-4.4	14.68	8.97			
C21H32O2	Not Available	Not Available	316.4776	[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@H](C)CC2=CC(=O)CC[C@]12C	Solid	Not Available					50423546	34583	CHEMBL259548	92280			HMDB0006048	C14475	D03144				102146	46504950				Bolasterone	ZINC000004215039		Bolasterone	Experimental, Illicit	DB01471	InChI=1S/C21H32O2/c1-13-11-14-12-15(22)5-8-19(14,2)16-6-9-20(3)17(18(13)16)7-10-21(20,4)23/h12-13,16-18,23H,5-11H2,1-4H3/t13-,16+,17+,18-,19+,20+,21+/m1/s1	IVFYLRMMHVYGJH-VLOLGRDOSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.0516 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							164 °C			1	Yes	2	1	No	4	0	37.3 Å2	37.53 Å3	93.62 m3·mol-1	0	Yes	Yes	0.0112 mg/mL	3.93	-4.4	18.8	-0.53			
C20H32O2	Not Available	Not Available	304.474	C[C@]1(O)CC[C@H]2[C@@H]3CCC4=C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	Solid	Not Available								24734384									69259387	46505852							17alpha-methyl-3beta,17beta-dihydroxyandrost-4-ene	Experimental, Illicit	DB01474	InChI=1S/C20H32O2/c1-18-9-6-14(21)12-13(18)4-5-15-16(18)7-10-19(2)17(15)8-11-20(19,3)22/h12,14-17,21-22H,4-11H2,1-3H3/t14-,15+,16-,17-,18-,19-,20-/m0/s1	BNUOCVTVOYWNJC-DTMQFJJTSA-N			Not Available	Small Molecule																																			1	Yes	2	2	No	4	0	40.46 Å2	36.14 Å3	89.97 m3·mol-1	0	Yes	No	0.0339 mg/mL	3.23	-4	17.5	-0.5			
C20H34O2	Not Available	Not Available	306.49	C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	Solid	Not Available						79878	CHEMBL3544564	211980				C15376					242493	46506370					ZINC000004073945		BA-2664	Experimental, Illicit	DB01479	InChI=1S/C20H34O2/c1-18-9-6-14(21)12-13(18)4-5-15-16(18)7-10-19(2)17(15)8-11-20(19,3)22/h13-17,21-22H,4-12H2,1-3H3/t13-,14+,15+,16-,17-,18-,19-,20-/m0/s1	QGKQXZFZOIQFBI-XSWYFRFISA-N			Not Available	Small Molecule																																			1	Yes	2	2	No	4	0	40.46 Å2	37.06 Å3	89.27 m3·mol-1	0	Yes	No	0.00469 mg/mL	3.48	-4.8	18.3	-0.47			
C26H33NO4	Not Available	Not Available	423.553	[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@@]11C[C@]([H])(C(C)(C)O)[C@]2(OC)C=C1	Solid	Not Available							CHEMBL2110789	16735758									20054882	46506801				Cyprenorphine	ZINC000004215495		Cyprenorphine	Experimental, Illicit	DB01480	InChI=1S/C26H33NO4/c1-23(2,29)18-13-24-8-9-26(18,30-3)22-25(24)10-11-27(14-15-4-5-15)19(24)12-16-6-7-17(28)21(31-22)20(16)25/h6-9,15,18-19,22,28-29H,4-5,10-14H2,1-3H3/t18-,19-,22-,24-,25+,26-/m1/s1	VSKIOMHXEUHYSI-KNLIIKEYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	3.0389 LD50, mol/kg	Inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	2	No	7	1	62.16 Å2	46.88 Å3	119.33 m3·mol-1	4	Yes	No	0.0582 mg/mL	2.13	-3.9	10.35	9.54			
C19H28O2	Not Available	Not Available	288.4244	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)C=C[C@]12C	Solid	Not Available						59714		206590				C15377					236666	46507716				1-Testosterone	ZINC000004791927		1-Testosterone	Experimental, Illicit, Investigational	DB01481	InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h7,9,12,14-17,21H,3-6,8,10-11H2,1-2H3/t12-,14-,15-,16-,17-,18-,19-/m0/s1	OKJCFMUGMSVJBG-ABEVXSGRSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.0714 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	1	No	4	0	37.3 Å2	33.91 Å3	84.7 m3·mol-1	0	Yes	Yes	0.0128 mg/mL	3.41	-4.4	19.38	-0.88	P10275	AR	1. Androgen receptor
C19H28O3	Clearance is via the urine. Excretion studies were performed using 200mg of 4-hydroxytestosterone administered to healthy male volunteers. Urine samples were then analyzed for metabolic products using conventional gas chromatography-mass spectrometry approaches.One metabolite, 3-beta,4-alpha-dihydroxy-5alpha-androstan-17-one was identified as a long term metabolite which can be detected for 90 hours. Longer detection times are possible with the use of alternative monitoring technique in sports drug testing.	Not Available	304.43	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=C(O)C(=O)CC[C@]12C	Solid	Not Available							CHEMBL2431525	141138									160615	46508337				4-Hydroxytestosterone	ZINC000031460450		4-Hydroxytestosterone	Experimental, Illicit	DB01485	InChI=1S/C19H28O3/c1-18-10-8-15(20)17(22)14(18)4-3-11-12-5-6-16(21)19(12,2)9-7-13(11)18/h11-13,16,21-22H,3-10H2,1-2H3/t11-,12-,13-,16-,18+,19-/m0/s1	BQOIJSIMMIDHMO-FBPKJDBXSA-N			Excessive doses of anabolic steroids can induce harmful changes in cholesterol, acne, hypertension, liver damage, and damage to the heart. Hormonal imbalances caused by the use of anabolic steriods may result in gynecomastia and testicular atrophy.Anabolic steroids are known to increase harmful LDL, while decreasing beneficial HDL cholesterol. Their ability to stimulate sebaceous glands may increase acne. Additionally, the elevation in blood pressure caused by anabolic steroids, is particularly pronounced and harmful in those with pre-existing hypertension.	Small Molecule																																			1	Yes	3	2	No	4	0	57.53 Å2	34.73 Å3	86.4 m3·mol-1	0	Yes	No	0.068 mg/mL	2.85	-3.6	9.28	-0.88			
C20H32O	Not Available	Not Available	288.4675	[H][C@@]12CC[C@@](O)(CC)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCCC=C3CC[C@@]21[H]	Solid	Not Available						31578	CHEMBL1200623	13168								PA449539	13765	46505460		4162		Ethylestrenol	ZINC000004215863		Ethylestrenol	Withdrawn	DB01493	InChI=1S/C20H32O/c1-3-20(21)13-11-18-17-9-8-14-6-4-5-7-15(14)16(17)10-12-19(18,20)2/h6,15-18,21H,3-5,7-13H2,1-2H3/t15-,16+,17+,18-,19-,20-/m0/s1	AOXRBFRFYPMWLR-XGXHKTLJSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.8534 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							about 50			1	Yes	1	1	No	4	0	20.23 Å2	35.94 Å3	88.5 m3·mol-1	1	Yes	Yes	0.00086 mg/mL	4.69	-5.5		-0.27			
C25H33NO4	Not Available	Not Available	411.5338	[H][C@]12CC3=C4C(OC5[C@@]4(CCN1C)[C@]21CC(C(C)(O)CCC)C5(OC)C=C1)=C(O)C=C3	Solid	Not Available						4912		24895				C11793					26721	46505591			DNC000631	Etorphine			Etorphine	Illicit, Vet approved	DB01497	InChI=1S/C25H33NO4/c1-5-8-22(2,28)17-14-23-9-10-25(17,29-4)21-24(23)11-12-26(3)18(23)13-15-6-7-16(27)20(30-21)19(15)24/h6-7,9-10,17-18,21,27-28H,5,8,11-14H2,1-4H3/t17?,18-,21?,22?,23-,24+,25?/m1/s1	CAHCBJPUTCKATP-HBDRVVKHSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	3.2955 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.79		214-217 °C			1	Yes	5	2	No	6	1	62.16 Å2	45.54 Å3	116.51 m3·mol-1	4	Yes	No	0.112 mg/mL	2.47	-3.6	10.21	8.99	P35372;!P41143;!P41145;!P41146;!O60858;!P01189	OPRM1;!OPRD1;!OPRK1;!OPRL1;!TRIM13;!POMC	1. Mu-type opioid receptor;!2. Delta-type opioid receptor;!3. Kappa-type opioid receptor;!4. Nociceptin receptor;!5. E3 ubiquitin-protein ligase TRIM13;!6. Pro-opiomelanocortin
C18H26O3	Not Available	Not Available	290.403	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C(O)=C3CC[C@@]21[H]	Solid	Not Available						135210		16736429									20055236	46508722				Oxabolone			Oxabolone	Experimental, Illicit	DB01500	InChI=1S/C18H26O3/c1-18-9-8-11-10-4-6-15(19)17(21)13(10)3-2-12(11)14(18)5-7-16(18)20/h10-12,14,16,20-21H,2-9H2,1H3/t10-,11-,12-,14+,16+,18+/m1/s1	GXHBCWCMYVTJOW-YGRHGMIBSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.8869 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							189 °C			1	Yes	3	2	No	4	0	57.53 Å2	33.23 Å3	81.92 m3·mol-1	0	Yes	No	0.0883 mg/mL	2.55	-3.5	9.3	-0.88			
C19H30O2	Not Available	Not Available	290.447	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@@H](O)C=C[C@]12C	Solid	Not Available								9475742									11300765	46508681				1-Androstenediol	ZINC000055160979		1-Androstenediol	Experimental, Illicit	DB01503	InChI=1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h7,9,12-17,20-21H,3-6,8,10-11H2,1-2H3/t12-,13-,14-,15-,16-,17-,18-,19-/m0/s1	RZFGPAMUAXASRE-YSZCXEEOSA-N			Not Available	Small Molecule																																			1	Yes	2	2	No	4	0	40.46 Å2	34.68 Å3	85.59 m3·mol-1	0	Yes	No	0.0348 mg/mL	3	-3.9	17.5	-0.82			
C20H34O2	Not Available	Not Available	306.49	C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	Solid	Not Available								91994									101819	46507785					ZINC000005223451		17Alpha-methyl-3beta,17beta-dihydroxy-5alpha-androstane	Experimental, Illicit	DB01513	InChI=1S/C20H34O2/c1-18-9-6-14(21)12-13(18)4-5-15-16(18)7-10-19(2)17(15)8-11-20(19,3)22/h13-17,21-22H,4-12H2,1-3H3/t13-,14-,15+,16-,17-,18-,19-,20-/m0/s1	QGKQXZFZOIQFBI-UYEYMFBJSA-N			Not Available	Small Molecule																																			1	Yes	2	2	No	4	0	40.46 Å2	37.21 Å3	89.27 m3·mol-1	0	Yes	No	0.00469 mg/mL	3.48	-4.8	18.3	-0.47			
C19H27ClO2	Not Available	Not Available	322.869	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=C(Cl)C(=O)CC[C@]12C	Solid	Not Available						135372	CHEMBL2106571	62171					D07731				68947	46505505		61686		Clostebol	ZINC000004025021		Clostebol	Experimental, Illicit	DB01521	InChI=1S/C19H27ClO2/c1-18-10-8-15(21)17(20)14(18)4-3-11-12-5-6-16(22)19(12,2)9-7-13(11)18/h11-13,16,22H,3-10H2,1-2H3/t11-,12-,13-,16-,18+,19-/m0/s1	KCZCIYZKSLLNNH-FBPKJDBXSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.7601 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							189 °C			1	Yes	2	1	No	4	0	37.3 Å2	36.02 Å3	89.22 m3·mol-1	0	Yes	Yes	0.0153 mg/mL	3.75	-4.3	19.38	-0.88			
C19H30O2	Not Available	Not Available	290.4403	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C	Solid	Not Available					50223237	2710	CHEMBL440283	10188			HMDB0003818	C04295	D00179	B81			10634	46507476				5-Androstenediol	ZINC000003814414		Androstenediol	Experimental, Illicit	DB01524	InChI=1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h3,13-17,20-21H,4-11H2,1-2H3/t13-,14-,15-,16-,17-,18-,19-/m0/s1	QADHLRWLCPCEKT-LOVVWNRFSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.2291 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	2	No	4	0	40.46 Å2	34.87 Å3	85.48 m3·mol-1	0	Yes	No	0.055 mg/mL	2.8	-3.7	18.2	-0.77			
C19H30O2	Not Available	Not Available	290.4403	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=C[C@@H](O)CC[C@]12C	Solid	Not Available					50410526	34386	CHEMBL195836	120071			HMDB0005849	C14210					136297	46507648				4-Androstenediol	ZINC000003814413		4-Androstenediol	Experimental, Illicit	DB01526	InChI=1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,13-17,20-21H,3-10H2,1-2H3/t13-,14-,15-,16-,17-,18-,19-/m0/s1	BTTWKVFKBPAFDK-LOVVWNRFSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.2291 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	2	No	4	0	40.46 Å2	34.38 Å3	85.33 m3·mol-1	0	Yes	No	0.0481 mg/mL	2.95	-3.8	17.5	-0.82			
C19H32O2	Not Available	Not Available	292.4562	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](O)CC[C@]12C	Solid	Not Available	O75881	CYP7B1	1. Cytochrome P450 7B1		50093445	36713	CHEMBL335062	15039			HMDB0000554						15818	46505144					ZINC000003814411		5alpha-androstane-3alpha,17beta-diol	Experimental, Illicit	DB01530	InChI=1S/C19H32O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12-17,20-21H,3-11H2,1-2H3/t12-,13+,14-,15-,16-,17-,18-,19-/m0/s1	CBMYJHIOYJEBSB-KHOSGYARSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3334 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	2	2	No	4	0	40.46 Å2	35.25 Å3	84.63 m3·mol-1	0	Yes	No	0.0193 mg/mL	3.2	-4.2	18.3	-0.76			
C19H26O2	Not Available	Not Available	286.4085	[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	Not Available	P08684;!P42330	CYP3A4;!AKR1C3	1. Cytochrome P450 3A4;!2. Aldo-keto reductase family 1 member C3		91713	16422	CHEMBL274826	5898			HMDB0000053	C00280	D00051	ASD			6128	46508011		784		Androstenedione	ZINC000004428526		Androstenedione	Experimental, Illicit	DB01536	InChI=1S/C19H26O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-16H,3-10H2,1-2H3/t14-,15-,16-,18-,19-/m0/s1	AEMFNILZOJDQLW-QAGGRKNESA-N			Not Available	Small Molecule	http://smpdb.ca/view/SMP0000356?highlight[compounds][]=DB01536&highlight[proteins][]=DB01536;!http://smpdb.ca/view/SMP0030406?highlight[compounds][]=DB01536&highlight[proteins][]=DB01536;!http://smpdb.ca/view/SMP0000068?highlight[compounds][]=DB01536&highlight[proteins][]=DB01536;!http://smpdb.ca/view/SMP0000565?highlight[compounds][]=DB01536&highlight[proteins][]=DB01536	17-beta Hydroxysteroid Dehydrogenase III Deficiency;!Androstenedione Metabolism;!Androgen and Estrogen Metabolism;!Aromatase Deficiency		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.5360 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.75	-3.69	158 °C		57.8 mg/L (at 25 °C)	1	Yes	2	0	No	4	0	34.14 Å2	33.21 Å3	83.61 m3·mol-1	0	Yes	Yes	0.027 mg/mL	3.93	-4	18.52	-4.8	P14061;!P14060;!Q00441;!P42330	HSD17B1;!HSD3B1;!eryF;!AKR1C3	1. Estradiol 17-beta-dehydrogenase 1;!2. 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1;!3. 6-deoxyerythronolide B hydroxylase;!4. Aldo-keto reductase family 1 member C3
C19H28O3	Not Available	Not Available	304.43	[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C(O)=C3CC[C@@]21[H]	Solid	Not Available								42759157									69249407	46504925					ZINC000263614121		17alpha-methyl-4-hydroxynandrolone	Illicit	DB01540	InChI=1S/C19H28O3/c1-18-9-7-12-11-5-6-16(20)17(21)14(11)4-3-13(12)15(18)8-10-19(18,2)22/h11-13,15,21-22H,3-10H2,1-2H3/t11-,12-,13-,15+,18+,19+/m1/s1	CLNUZOCYKSHICX-FAHHUNKHSA-N			Not Available	Small Molecule																																			1	Yes	3	2	No	4	0	57.53 Å2	35.02 Å3	86.56 m3·mol-1	0	Yes	No	0.0575 mg/mL	2.83	-3.7	9.33	-0.53			
C19H26O2	Not Available	14 days	286.4085	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	Not Available					91719	34584	CHEMBL209073	12744				C14502	D07536				13308	46505583		2289408		Boldenone	ZINC000004215042		Boldenone	Illicit, Vet approved	DB01541	InChI=1S/C19H26O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h7,9,11,14-17,21H,3-6,8,10H2,1-2H3/t14-,15-,16-,17-,18-,19-/m0/s1	RSIHSRDYCUFFLA-DYKIIFRCSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.6259 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							165 °C			1	Yes	2	1	No	4	0	37.3 Å2	33.11 Å3	85.52 m3·mol-1	0	Yes	Yes	0.0259 mg/mL	3.36	-4	18.39	-0.88	P10275	AR	1. Androgen receptor
C19H28O2	Not Available	Not Available	288.431	[H][C@@]12CC[C@H](O)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	Solid	Not Available								8215338									10039774	46507237					ZINC000005955127		18-methyl-19-nortestosterone	Experimental, Illicit	DB01543	InChI=1S/C19H28O2/c1-2-19-10-9-15-14-6-4-13(20)11-12(14)3-5-16(15)17(19)7-8-18(19)21/h11,14-18,21H,2-10H2,1H3/t14-,15+,16+,17-,18-,19-/m0/s1	FBYZQDCRLYHHHP-ZOFHRBRSSA-N			Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	34.36 Å3	84.56 m3·mol-1	1	Yes	Yes	0.0302 mg/mL	3.51	-4	18.25	-0.75			
C26H35NO4	Not Available	Not Available	425.569	[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@]11CC[C@@]2(OC)[C@H](C1)C(C)(C)O	Solid	Not Available					50001714	4650	CHEMBL281786	391634		GtP Drug Page		C11794					443408	46506559				Diprenorphine	ZINC000004102215		Diprenorphine	Illicit, Vet approved	DB01548	InChI=1S/C26H35NO4/c1-23(2,29)18-13-24-8-9-26(18,30-3)22-25(24)10-11-27(14-15-4-5-15)19(24)12-16-6-7-17(28)21(31-22)20(16)25/h6-7,15,18-19,22,28-29H,4-5,8-14H2,1-3H3/t18-,19-,22-,24-,25+,26-/m1/s1	OIJXLIIMXHRJJH-KNLIIKEYSA-N	-Infinity		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	3.1511 LD50, mol/kg	Inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	2	No	7	1	62.16 Å2	47.86 Å3	118.37 m3·mol-1	4	Yes	No	0.104 mg/mL	2.28	-3.6	10.42	9.63			
C18H28O2	Not Available	Not Available	276.42	C[C@]12CC[C@H]3[C@@H](CCC4=C[C@@H](O)CC[C@H]34)[C@@H]1CC[C@@H]2O	Solid	Not Available						145661	CHEMBL307500	8011024									9835303	46505759				Bolandiol	ZINC000026375797		Bolandiol	Experimental, Illicit	DB01554	InChI=1S/C18H28O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h10,12-17,19-20H,2-9H2,1H3/t12-,13-,14+,15+,16-,17-,18-/m0/s1	CMXKUJNZWYTFJN-XFUVECHXSA-N			Not Available	Small Molecule																																			1	Yes	2	2	No	4	0	40.46 Å2	33.3 Å3	80.85 m3·mol-1	0	Yes	No	0.0566 mg/mL	2.65	-3.7	17.52	-0.82			
C21H32O2	Not Available	Not Available	316.4776	[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@H](C)CC2=CC(=O)CC[C@]12C	Solid	Not Available						135356	CHEMBL455706	26239			HMDB0004627						28204	46507441				Calusterone	ZINC000004215173		Calusterone	Experimental, Illicit	DB01564	InChI=1S/C21H32O2/c1-13-11-14-12-15(22)5-8-19(14,2)16-6-9-20(3)17(18(13)16)7-10-21(20,4)23/h12-13,16-18,23H,5-11H2,1-4H3/t13-,16-,17-,18+,19-,20-,21-/m0/s1	IVFYLRMMHVYGJH-PVPPCFLZSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.0516 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							128 °C			1	Yes	2	1	No	4	0	37.3 Å2	37.77 Å3	93.62 m3·mol-1	0	Yes	Yes	0.0112 mg/mL	3.93	-4.4	18.8	-0.53	P10275	AR	1. Androgen receptor
C21H28O4	Not Available	Not Available	344.4446	[H][C@@]12CC[C@](C)(O)[C@@]1(C)C[C@@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C(C=O)=C[C@]12C	Solid	Not Available						135456	CHEMBL2107419	16234			HMDB0004631						17150	46508967				Formebolone	ZINC000004216332		Formebolone	Experimental, Illicit	DB01569	InChI=1S/C21H28O4/c1-19-9-12(11-22)16(23)8-13(19)4-5-14-15-6-7-21(3,25)20(15,2)10-17(24)18(14)19/h8-9,11,14-15,17-18,24-25H,4-7,10H2,1-3H3/t14-,15-,17+,18+,19-,20-,21-/m0/s1	AMVODTGMYSRMNP-GNIMZFFESA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	3.2193 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				543.6 °C			210.5 °C			1	Yes	4	2	No	4	0	74.6 Å2	38.13 Å3	96.9 m3·mol-1	1	Yes	No	0.0605 mg/mL	1.76	-3.8	14.39	-2.9	P80365	HSD11B2	1. Corticosteroid 11-beta-dehydrogenase isozyme 2
C20H30O2	Not Available	Not Available	302.458	[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)C=C[C@]12C	Solid	Not Available								5442174										46506576				Methyl-1-testosterone	ZINC000004081584		Methyl-1-testosterone	Experimental, Illicit	DB01572	InChI=1S/C20H30O2/c1-18-9-6-14(21)12-13(18)4-5-15-16(18)7-10-19(2)17(15)8-11-20(19,3)22/h6,9,13,15-17,22H,4-5,7-8,10-12H2,1-3H3/t13-,15+,16-,17-,18-,19-,20-/m0/s1	JRNSSSJKIGAFCT-YDSAWKJFSA-N			Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	35.73 Å3	89.33 m3·mol-1	0	Yes	Yes	0.00401 mg/mL	3.69	-4.9		-0.53			
C24H40O4	Not Available	Not Available	392.572	[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O	Solid	Not Available	BE0004866		1. Cytochrome P450 3A Subfamily (Protein Group)		53721	9907	CHEMBL1551	29131			HMDB0000946	C07880	D00734	IU5		PA451837	31401	46508795		11065	DNC000420	Ursodeoxycholic_acid	ZINC000003914809	Reltone, Urso, Urso Forte	Ursodeoxycholic acid	Approved, Investigational	DB01586	InChI=1S/C24H40O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15+,16-,17-,18+,19+,20+,22+,23+,24-/m1/s1	RUDATBOHQWOJDD-UZVSRGJWSA-N	4	Ursodeoxycholic acid is a bile acid used for the treatment of primary biliary cirrhosis (PBC), dissolution of radiolucent gallstones in patients with a functioning gallbladder, and treatment of hepatobiliary disorders associated with cystic fibrosis in pediatric patients.	Neither accidental nor intentional overdosing with ursodeoxycholic acid has been reported. Doses of ursodeoxycholic acid in the range of 16-20 mg/kg/day have been tolerated for 6-37 months without symptoms by 7 patients. The LD50 for ursodeoxycholic acid in rats is over 5000 mg/kg given over 7-10 days and over 7500 mg/kg for mice. The most likely manifestation of severe overdose with ursodeoxycholic acid would probably be diarrhea, which should be treated symptomatically.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	2.5624 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.00		203 °C		20 mg/L (at 20 °C)	1	Yes	4	3	No	4	-1	77.76 Å2	46.42 Å3	109.27 m3·mol-1	4	Yes	No	0.0197 mg/mL	3.71	-4.3	4.6	-0.54			
C19H28O2	Not Available	12 hours	288.4244	[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C	Solid	Not Available	P24462;!P14061;!Q06520;!O00204;!P14060;!P22637;!P05093	CYP3A7;!HSD17B1;!SULT2A1;!SULT2B1;!HSD3B1;!choB;!CYP17A1	1. Cytochrome P450 3A7;!2. Estradiol 17-beta-dehydrogenase 1;!3. Bile salt sulfotransferase;!4. Sulfotransferase family cytosolic 2B member 1;!5. 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1;!6. Cholesterol oxidase;!7. Steroid 17-alpha-hydroxylase/17,20 lyase		50223368	28689	CHEMBL90593	5670		GtP Drug Page	HMDB0000077	C01227	D08409	AND		PA451993	5881	46508824		3143	DNC001146	Dehydroepiandrosterone	ZINC000003807917	Intrarosa	Prasterone	Approved, Investigational, Nutraceutical	DB01708	InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h3,13-16,20H,4-11H2,1-2H3/t13-,14-,15-,16-,18-,19-/m0/s1	FMGSKLZLMKYGDP-USOAJAOKSA-N	4	Prasterone is a steroid formulated as a vaginal insert indicated for the treatment of moderate to severe dyspareunia associated with menopausal vulvar and vaginal atrophy.	Acute oral toxicity (LD50): >10000 mg/kg [Rat]. Lowest Published Toxic Dose (TDL) [Man] - Route: Oral; Dose: 10 mg/kg/2W intermittent.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.5214 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.23		140-141 °C		63.5 mg/L (at 25 °C)	1	Yes	2	1	No	4	0	37.3 Å2	34.1 Å3	84.66 m3·mol-1	0	Yes	Yes	0.0438 mg/mL	3.36	-3.8	18.2	-1.4	P03372;!Q92731;!BE0004797;!BE0004956;!P10275;!Q07869;!Q99720;!O75469;!Q14994	ESR1;!ESR2;!;!;!AR;!PPARA;!SIGMAR1;!NR1I2;!NR1I3	1. Estrogen receptor alpha;!2. Estrogen receptor beta;!3. GABA(A) Receptor (Protein Group);!4. NMDA receptor (Protein Group);!5. Androgen receptor;!6. Peroxisome proliferator-activated receptor alpha;!7. Sigma non-opioid intracellular receptor 1;!8. Nuclear receptor subfamily 1 group I member 2;!9. Nuclear receptor subfamily 1 group I member 3
C36H56O12	Not Available	Not Available	680.8226	[H]\C1=C2/[C@@]([H])(COC)CC[C@@]2([H])[C@@]([H])(C)[C@@]([H])(O)[C@]([H])(O[C@@]2([H])O[C@]([H])(COC(C)(C)C=C)[C@@]([H])(O)[C@]([H])(OC(C)=O)[C@@]2([H])O)C2=C(C[C@]([H])(O)[C@]12C)[C@]([H])(C)COC(C)=O	Solid	Not Available						51015	CHEMBL4244843	394625						FSC			447573	46508360				Fusicoccin			Fusicoccin	Experimental	DB01780	InChI=1S/C36H56O12/c1-10-35(6,7)45-17-26-30(41)33(46-21(5)38)31(42)34(47-26)48-32-28-24(18(2)15-44-20(4)37)13-27(39)36(28,8)14-25-22(16-43-9)11-12-23(25)19(3)29(32)40/h10,14,18-19,22-23,26-27,29-34,39-42H,1,11-13,15-17H2,2-9H3/b25-14-/t18-,19-,22-,23+,26-,27+,29-,30-,31-,32-,33+,34-,36+/m1/s1	KXTYBXCEQOANSX-WYKQKOHHSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	3.4297 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	10	4	Yes	4	0	170.44 Å2	72.71 Å3	175.76 m3·mol-1	14	No	No	0.0849 mg/mL	1.35	-3.9	12.24	-3	P62258	YWHAE	1. 14-3-3 protein epsilon
C27H41NO5S	Not Available	Not Available	491.683	[H][C@]1(C\C=C(C)/CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)C(\C)=C\C1=CSC(C)=N1	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			29579	CHEMBL96172	9400674				C12039		EPD			447865	46508361				Epothilone	ZINC000003951739		Epothilone D	Investigational	DB01873	InChI=1S/C27H41NO5S/c1-16-9-8-10-17(2)25(31)19(4)26(32)27(6,7)23(29)14-24(30)33-22(12-11-16)18(3)13-21-15-34-20(5)28-21/h11,13,15,17,19,22-23,25,29,31H,8-10,12,14H2,1-7H3/b16-11-,18-13+/t17-,19+,22-,23-,25-/m0/s1	XOZIUKBZLSUILX-GIQCAXHBSA-N	2		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.8243 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	5	2	No	2	0	96.72 Å2	55.62 Å3	136.04 m3·mol-1	2	No	No	0.00246 mg/mL	5.1	-5.3	14.09	2.73	Q13748;!P07437;!Q9H4B7;!P68371;!P04350;!P68366;!Q13509;!Q9BQE3;!Q9NY65;!P68363;!Q71U36	TUBA3C;!TUBB;!TUBB1;!TUBB4B;!TUBB4A;!TUBA4A;!TUBB3;!TUBA1C;!TUBA8;!TUBA1B;!TUBA1A	1. Tubulin alpha-3C/D chain;!2. Tubulin beta chain;!3. Tubulin beta-1 chain;!4. Tubulin beta-4B chain;!5. Tubulin beta-4A chain;!6. Tubulin alpha-4A chain;!7. Tubulin beta-3 chain;!8. Tubulin alpha-1C chain;!9. Tubulin alpha-8 chain;!10. Tubulin alpha-1B chain;!11. Tubulin alpha-1A chain
C19H30O	Not Available	Not Available	274.4409	[H][C@@]12CC=C[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@]([H])(O)CC[C@]12C	Solid	Not Available					50134722	40933	CHEMBL142348	92136			HMDB0005935			ATE			101989	46505452					ZINC000004352598		16,17-Androstene-3-Ol	Experimental	DB01889	InChI=1S/C19H30O/c1-18-9-3-4-16(18)15-6-5-13-12-14(20)7-11-19(13,2)17(15)8-10-18/h3,9,13-17,20H,4-8,10-12H2,1-2H3/t13-,14+,15-,16-,17-,18-,19-/m0/s1	KRVXMNNRSSQZJP-PHFHYRSDSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.8749 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	1	1	No	4	0	20.23 Å2	33.67 Å3	84.23 m3·mol-1	0	Yes	Yes	0.000355 mg/mL	4.07	-5.9	18.3	-1.4	Q14994	NR1I3	1. Nuclear receptor subfamily 1 group I member 3
C26H43NO5	Not Available	Not Available	449.6233	C[C@H](CCC(=O)NCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	Solid	Not Available					50375590	36274	CHEMBL1552	12027				C05466		CHO			12544	46506300					ZINC000003914812		Glycochenodeoxycholic Acid	Experimental	DB02123	InChI=1S/C26H43NO5/c1-15(4-7-22(30)27-14-23(31)32)18-5-6-19-24-20(9-11-26(18,19)3)25(2)10-8-17(28)12-16(25)13-21(24)29/h15-21,24,28-29H,4-14H2,1-3H3,(H,27,30)(H,31,32)/t15-,16+,17-,18-,19+,20+,21-,24+,25+,26-/m1/s1	GHCZAUBVMUEKKP-GYPHWSFCSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.5186 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.12				3.15 mg/L (at 20 °C)	1	No	5	4	Yes	4	-1	106.86 Å2	52.05 Å3	122.08 m3·mol-1	6	Yes	No	0.00793 mg/mL	2.61	-4.8	3.77	-0.49	P0AET8	hdhA	1. 7-alpha-hydroxysteroid dehydrogenase
C18H20O2	Not Available	Not Available	268.3502	[H][C@@]12CCC(=O)[C@@]1(C)CC[C@]1([H])C3=C(CC=C21)C=C(O)C=C3	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4		50423544	42309	CHEMBL323533	193995				C14392	D04041	EQI			223368	46506633				Equilin	ZINC000100031739		Equilin	Experimental	DB02187	InChI=1S/C18H20O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3-5,10,14,16,19H,2,6-9H2,1H3/t14-,16+,18+/m1/s1	WKRLQDKEXYKHJB-HFTRVMKXSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.8021 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							239 °C		1.41 mg/L (at 25 °C)	1	Yes	2	1	No	4	0	37.3 Å2	30.52 Å3	79.93 m3·mol-1	0	Yes	Yes	0.0133 mg/mL	3.9	-4.3	9.41	-6	P03372;!P14061	ESR1;!HSD17B1	1. Estrogen receptor alpha;!2. Estradiol 17-beta-dehydrogenase 1
C27H40O3	Not Available	Not Available	412.6047	O[C@H](\C=C\[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C)C1CC1	Solid	Not Available	P05164;!Q07973	MPO;!CYP24A1	1. Myeloperoxidase;!2. 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial		50369964	50749	CHEMBL1200666	4450880		GtP Drug Page	HMDB0015567		D01125	MC9		PA448714	5288783	46507122	RxList Drug Page	29365	DAP000292	Calcipotriol	ZINC000003921872	Calcitrene, Dovobet, Dovonex, Enstilar, Sorilux, Taclonex, Wynzora	Calcipotriol	Approved	DB02300	InChI=1S/C27H40O3/c1-17(6-13-25(29)20-8-9-20)23-11-12-24-19(5-4-14-27(23,24)3)7-10-21-15-22(28)16-26(30)18(21)2/h6-7,10,13,17,20,22-26,28-30H,2,4-5,8-9,11-12,14-16H2,1,3H3/b13-6+,19-7+,21-10-/t17-,22-,23-,24+,25-,26+,27-/m1/s1	LWQQLNNNIPYSNX-UROSTWAQSA-N	4	Calcipotriol is a topical synthetic vitamin D2 derivative used in the treatment of plaque psoriasis.	Topically applied calcipotriene can be absorbed in sufficient amounts to produce systemic effects. Elevated serum calcium has been observed with excessive use of calcipotriene.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	3.9699 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	3	No	4	0	60.69 Å2	49.59 Å3	125.45 m3·mol-1	5	Yes	No	0.0135 mg/mL	3.84	-4.5	14.39	-1.6			
C34H50O7	Not Available	Not Available	570.7566	[H][C@@]1(CC[C@@]2(C)[C@@]([H])(CC[C@]3(C)[C@]2([H])C(=O)C=C2[C@]4([H])C[C@](C)(CC[C@]4(C)CC[C@@]32C)C(O)=O)C1(C)C)OC(=O)CCC(O)=O	Solid	Not Available					50247012		CHEMBL499915	552190						CBO			636403	46508820		2017	DNC000388	Carbenoxolone	ZINC000003977823		Carbenoxolone	Experimental	DB02329	InChI=1S/C34H50O7/c1-29(2)23-10-13-34(7)27(32(23,5)12-11-24(29)41-26(38)9-8-25(36)37)22(35)18-20-21-19-31(4,28(39)40)15-14-30(21,3)16-17-33(20,34)6/h18,21,23-24,27H,8-17,19H2,1-7H3,(H,36,37)(H,39,40)/t21-,23-,24-,27+,30+,31-,32-,33+,34+/m0/s1	OBZHEBDUNPOCJG-WBXJDKIVSA-N		Carbenoxolone is a drug used to symptomatically treat lip sores and mouth ulcers.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	2.3981 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							292.5 °C			0	No	6	2	Yes	5	-2	117.97 Å2	64.99 Å3	154.31 m3·mol-1	6	No	No	0.000738 mg/mL	6.3	-5.9	4.04	-5.1			
C19H26O3	Not Available	Not Available	302.4079	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C(OC)=C3	Solid	Not Available					50060957	28955	CHEMBL299613	59788			HMDB0000405	C05302		ESM		PA13496724	16760554	175426854				2-Methoxyestradiol	ZINC000003818826		2-Methoxyestradiol	Investigational	DB02342	InChI=1S/C19H26O3/c1-19-8-7-12-13(15(19)5-6-18(19)21)4-3-11-9-16(20)17(22-2)10-14(11)12/h9-10,12-13,15,18,20-21H,3-8H2,1-2H3/t12-,13+,15-,18-,19-/m0/s1	CQOQDQWUFQDJMK-SSTWWWIQSA-N	2		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.8598 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	3	2	No	4	0	49.69 Å2	35.2 Å3	86.37 m3·mol-1	1	Yes	No	0.00968 mg/mL	3.59	-4.5	10.29	-0.88	P21964;!P04798;!Q16678;!P11511;!Q16665	COMT;!CYP1A1;!CYP1B1;!CYP19A1;!HIF1A	1. Catechol O-methyltransferase;!2. Cytochrome P450 1A1;!3. Cytochrome P450 1B1;!4. Cytochrome P450 19A1;!5. Hypoxia-inducible factor 1-alpha
C31H46O19S2	Not Available	Not Available	786.816	CC(C)CC(=O)O[C@H]1[C@@H](O[C@@H]2C[C@]3(C)[C@H]4CC[C@@H]5C[C@@]4(CC[C@H]3C(C2)(C(O)=O)C(O)=O)[C@@H](O)C5=C)O[C@@H](COO)[C@H](OS(O)(=O)=O)[C@@H]1OS(O)(=O)=O	Solid	Not Available								26329724						CXT			46936378	46505904				Carboxyatractyloside	ZINC000096006053		Carboxyatractyloside	Experimental	DB02426	InChI=1S/C31H46O19S2/c1-14(2)9-21(32)48-24-23(50-52(42,43)44)22(49-51(39,40)41)18(13-45-38)47-26(24)46-17-11-29(4)19-6-5-16-10-30(19,25(33)15(16)3)8-7-20(29)31(12-17,27(34)35)28(36)37/h14,16-20,22-26,33,38H,3,5-13H2,1-2,4H3,(H,34,35)(H,36,37)(H,39,40,41)(H,42,43,44)/t16-,17-,18+,19-,20-,22+,23+,24-,25+,26+,29-,30-/m1/s1	CYBVQIBJEFQVPD-GWDNDVLHSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.7066 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										0	No	16	6	Yes	5	-4	296.25 Å2	75.05 Å3	168.79 m3·mol-1	14	No	No	2.17 mg/mL	-1.5	-2.6	-2.3	-0.69	P12235	SLC25A4	1. ADP/ATP translocase 1
C22H34O7	Not Available	Not Available	410.5012	[H][C@]1(O)CCC(C)(C)[C@]2([H])[C@]([H])(O)[C@]([H])(OC(C)=O)[C@@]3(C)O[C@](C)(CC(=O)[C@]3(O)[C@@]12C)C=C	Solid	Not Available					50010261	42471	CHEMBL52606	43607	Drugs.com Drug Page			C09076	D03584	FOK		PA146096022	47936	46509044				Forskolin	ZINC000003977779		Colforsin	Experimental, Investigational	DB02587	InChI=1S/C22H34O7/c1-8-19(5)11-14(25)22(27)20(6)13(24)9-10-18(3,4)16(20)15(26)17(28-12(2)23)21(22,7)29-19/h8,13,15-17,24,26-27H,1,9-11H2,2-7H3/t13-,15-,16-,17-,19-,20-,21+,22-/m0/s1	OHCQJHSOBUTRHG-KGGHGJDLSA-N	-Infinity		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.2384 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	6	3	No	3	0	113.29 Å2	43.32 Å3	104.47 m3·mol-1	3	Yes	No	1.1 mg/mL	1.36	-2.6	11.57	-3	Q08462;!P63092;!O95622;!P13569	ADCY2;!GNAS;!ADCY5;!CFTR	1. Adenylate cyclase type 2;!2. Guanine nucleotide-binding protein G(s) subunit alpha isoforms short;!3. Adenylate cyclase type 5;!4. Cystic fibrosis transmembrane conductance regulator
C26H34O7	Not Available	Not Available	458.551	CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O	Solid	Not Available					50113436	48635	CHEMBL32838	5292885				C09668		FUG			6917655	46505331			DNC000664	Fumagillin	ZINC000004098264		Fumagillin	Experimental	DB02640	InChI=1S/C26H34O7/c1-18(2)13-14-20-25(3,33-20)24-23(30-4)19(15-16-26(24)17-31-26)32-22(29)12-10-8-6-5-7-9-11-21(27)28/h5-13,19-20,23-24H,14-17H2,1-4H3,(H,27,28)/b7-5+,8-6+,11-9+,12-10+/t19-,20-,23-,24-,25+,26+/m1/s1	NGGMYCMLYOUNGM-CSDLUJIJSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.7268 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							190-192			1	Yes	6	1	Yes	3	-1	97.89 Å2	51.13 Å3	128.37 m3·mol-1	11	Yes	No	0.0033 mg/mL	4.05	-5.1	4.88	-3.7	P50579	METAP2	1. Methionine aminopeptidase 2
C24H40O5	Not Available	Not Available	408.5714	[H][C@@](C)(CCC(O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])[C@]([H])(O)C[C@]4([H])C[C@]([H])(O)CC[C@]4(C)[C@@]3([H])C[C@]([H])(O)[C@]12C	Solid	Not Available					21680	16359	CHEMBL205596	192176	Drugs.com Drug Page		HMDB0000619	C00695	D10699	CHD		PA166160055	221493	46507063		1440856			ZINC000006858022	Cholbam, Orphacol	Cholic Acid	Approved	DB02659	InChI=1S/C24H40O5/c1-13(4-7-21(28)29)16-5-6-17-22-18(12-20(27)24(16,17)3)23(2)9-8-15(25)10-14(23)11-19(22)26/h13-20,22,25-27H,4-12H2,1-3H3,(H,28,29)/t13-,14+,15-,16-,17+,18+,19-,20+,22+,23+,24-/m1/s1	BHQCQFFYRZLCQQ-OELDTZBJSA-N	3	Cholic Acid is a bile acid used for the treatment of bile acid synthesis disorders due to single enzyme defects and as an adjunctive treatment of peroxisomal disorders with disrupted liver function.	Not Available	Small Molecule	http://smpdb.ca/view/SMP0000316?highlight[compounds][]=DB02659&highlight[proteins][]=DB02659;!http://smpdb.ca/view/SMP0000314?highlight[compounds][]=DB02659&highlight[proteins][]=DB02659;!http://smpdb.ca/view/SMP0000720?highlight[compounds][]=DB02659&highlight[proteins][]=DB02659;!http://smpdb.ca/view/SMP0000035?highlight[compounds][]=DB02659&highlight[proteins][]=DB02659;!http://smpdb.ca/view/SMP0000315?highlight[compounds][]=DB02659&highlight[proteins][]=DB02659;!http://smpdb.ca/view/SMP0000317?highlight[compounds][]=DB02659&highlight[proteins][]=DB02659;!http://smpdb.ca/view/SMP0000318?highlight[compounds][]=DB02659&highlight[proteins][]=DB02659	Zellweger Syndrome;!Congenital Bile Acid Synthesis Defect Type II;!27-Hydroxylase Deficiency;!Bile Acid Biosynthesis;!Cerebrotendinous Xanthomatosis (CTX);!Familial Hypercholanemia (FHCA);!Congenital Bile Acid Synthesis Defect Type III		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	2.5624 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.02	-3.37	198 °C	4.98 (at 20 °C)	175 mg/L (at 20 °C)	1	Yes	5	4	No	4	-1	97.99 Å2	47.05 Å3	110.79 m3·mol-1	4	Yes	No	0.0738 mg/mL	2.48	-3.7	4.48	-0.16			
C26H42NO6	Not Available	Not Available	464.624	[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])C[C@H](O)[C@]12C)[C@H](C)CCC(=O)NCC([O-])=O	Solid	Not Available					50420252	29746		4573891				C01921		GCH			5460316	46507924		1426482		Glycocholic_acid			Glycocholic acid	Experimental, Investigational	DB02691	InChI=1S/C26H43NO6/c1-14(4-7-22(31)27-13-23(32)33)17-5-6-18-24-19(12-21(30)26(17,18)3)25(2)9-8-16(28)10-15(25)11-20(24)29/h14-21,24,28-30H,4-13H2,1-3H3,(H,27,31)(H,32,33)/p-1/t14-,15+,16-,17-,18+,19+,20-,21+,24+,25+,26-/m1/s1	RFDAIACWWDREDC-FRVQLJSFSA-M	3		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.5186 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					1.65	-5.15	166.5 °C		3.3 mg/L (at 20 °C)	1	No	6	4	Yes	4	-1	129.92 Å2	52.37 Å3	134.43 m3·mol-1	6	Yes	No	0.0214 mg/mL	1.38	-4.4	3.77	-0.14	P51161	FABP6	1. Gastrotropin
C31H48O6	Not Available	Approximately 5 to 6 hours in adults.	516.7092	[H][C@@]12C[C@@H](O)[C@@]3([H])[C@@]4(C)CC[C@@H](O)[C@@H](C)[C@]4([H])CC[C@]3(C)[C@@]1(C)C[C@H](OC(C)=O)\C2=C(\CCC=C(C)C)C(O)=O	Solid	Not Available	P10635;!P08684;!P22309	CYP2D6;!CYP3A4;!UGT1A1	1. Cytochrome P450 2D6;!2. Cytochrome P450 3A4;!3. UDP-glucuronosyltransferase 1-1		58924	29013	CHEMBL374975	2271900			HMDB0015570	C06694	D04281	FUA		PA164749648	3000226	46505364		113608	DAP001008	Fusidic_acid	ZINC000008143796	Fucibet, Fucidin, Fucithalmic	Fusidic acid	Approved, Investigational	DB02703	InChI=1S/C31H48O6/c1-17(2)9-8-10-20(28(35)36)26-22-15-24(34)27-29(5)13-12-23(33)18(3)21(29)11-14-30(27,6)31(22,7)16-25(26)37-19(4)32/h9,18,21-25,27,33-34H,8,10-16H2,1-7H3,(H,35,36)/b26-20-/t18-,21-,22-,23+,24+,25-,27-,29-,30-,31-/m0/s1	IECPWNUMDGFDKC-MZJAQBGESA-N	4	Fusidic acid is a topical antibacterial agent used to prevent and treat mild to moderate skin infections caused by susceptible bacteria.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	3.5929 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							192.5 °C	5.35		1	No	5	3	Yes	4	-1	104.06 Å2	59.76 Å3	144.12 m3·mol-1	6	No	No	0.00521 mg/mL	4.42	-5	4.46	-0.2	P13551;!P62580;!P00484	fusA;!cat;!cat3	1. Elongation factor G;!2. Chloramphenicol acetyltransferase;!3. Chloramphenicol acetyltransferase 3
C21H32O2	Not Available	Not Available	316.4776	[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4		50375319	16581	CHEMBL253363	8611			HMDB0000253	C01953	D00143	PLO			8955	46506718		114052	DNC001147	Pregnenolone	ZINC000003861150		Pregnenolone	Approved, Experimental	DB02789	InChI=1S/C21H32O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h4,15-19,23H,5-12H2,1-3H3/t15-,16-,17+,18-,19-,20-,21+/m0/s1	ORNBQBCIOKFOEO-QGVNFLHTSA-N	4		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.9852 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	1	No	4	0	37.3 Å2	38.09 Å3	93.76 m3·mol-1	1	Yes	Yes	0.0136 mg/mL	3.58	-4.4	18.2	-1.4	O75469;!O00204	NR1I2;!SULT2B1	1. Nuclear receptor subfamily 1 group I member 2;!2. Sulfotransferase family cytosolic 2B member 1
C19H30O2	Not Available	Not Available	290.4403	[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@]2([H])C[C@]([H])(O)CC[C@]12C	Solid	Not Available					50191348	28195	CHEMBL85799	5669			HMDB0000490	C04373		AE2			5880	46507911				Etiocholanolone	ZINC000003875364		Aetiocholanolone	Experimental	DB02854	InChI=1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12-16,20H,3-11H2,1-2H3/t12-,13-,14+,15+,16+,18+,19+/m1/s1	QGXBDMJGAMFCBF-BNSUEQOYSA-N			Not Available	Small Molecule	http://smpdb.ca/view/SMP0030406?highlight[compounds][]=DB02854&highlight[proteins][]=DB02854	Androstenedione Metabolism		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.9757 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	1	No	4	0	37.3 Å2	34.36 Å3	83.81 m3·mol-1	0	Yes	Yes	0.00637 mg/mL	3.77	-4.7	18.3	-1.4	P01859;!Q06520;!P9WGT1;!Q8NBQ5	IGHG2;!SULT2A1;!fabG3;!HSD17B11	1. Ig gamma-2 chain C region;!2. Bile salt sulfotransferase;!3. 3-alpha-(or 20-beta)-hydroxysteroid dehydrogenase;!4. Estradiol 17-beta-dehydrogenase 11
C19H30O2	Not Available	Not Available	290.4403	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)CC[C@]12C	Solid	Not Available					18161	16330	CHEMBL27769	10189			HMDB0002961	C03917	D07456	DHT			10635	46506828				Dihydrotestosterone	ZINC000003814360		Stanolone	Illicit, Investigational	DB02901	InChI=1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12,14-17,21H,3-11H2,1-2H3/t12-,14-,15-,16-,17-,18-,19-/m0/s1	NVKAWKQGWWIWPM-ABEVXSGRSA-N	2		Oral LD50 in rat is 7060 mg/kg. Oral LD50 in mouse is 3450 mg/kg.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.9757 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.55		181 °C		525 mg/mL (at 25 °C)	1	Yes	2	1	No	4	0	37.3 Å2	34.54 Å3	83.6 m3·mol-1	0	Yes	Yes	0.00998 mg/mL	3.41	-4.5	19.38	-0.88			
C19H24O2	Not Available	Not Available	284.3927	[H][C@@]12CC[C@](C)(O)[C@@]1(C)C=CC1=C3CCC(=O)C=C3CC[C@@]21[H]	Solid	Not Available					50367916	379896	CHEMBL166444	229099		GtP Drug Page		C14257		R18			261000	46505539				Metribolone	ZINC000003814420		Metribolone	Experimental	DB02998	InChI=1S/C19H24O2/c1-18-9-7-15-14-6-4-13(20)11-12(14)3-5-16(15)17(18)8-10-19(18,2)21/h7,9,11,16-17,21H,3-6,8,10H2,1-2H3/t16-,17+,18+,19+/m1/s1	CCCIJQPRIXGQOE-XWSJACJDSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.6259 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	1	No	4	0	37.3 Å2	33.01 Å3	86.29 m3·mol-1	0	Yes	Yes	0.0332 mg/mL	2.53	-3.9	18.4	-0.53			
C27H41NO6S	Not Available	Not Available	507.683	[H]\C(=C(\C)[C@]1([H])C[C@]2([H])O[C@]2(C)CCC[C@]([H])(C)[C@]([H])(O)[C@@]([H])(C)C(=O)C(C)(C)[C@@]([H])(O)CC(=O)O1)C1=CSC(C)=N1	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4		50103627	31550	CHEMBL94657	10213816				C12154		EPB			448013	46505629			DNC000616		ZINC000003951737		Patupilone	Experimental, Investigational	DB03010	InChI=1S/C27H41NO6S/c1-15-9-8-10-27(7)22(34-27)12-20(16(2)11-19-14-35-18(4)28-19)33-23(30)13-21(29)26(5,6)25(32)17(3)24(15)31/h11,14-15,17,20-22,24,29,31H,8-10,12-13H2,1-7H3/b16-11+/t15-,17+,20-,21-,22-,24-,27+/m0/s1	QXRSDHAAWVKZLJ-PVYNADRNSA-N	3		Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.7983 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	2	No	3	0	109.25 Å2	56.11 Å3	134.76 m3·mol-1	2	No	No	0.00342 mg/mL	4.12	-5.2	14.09	2.73	Q13748;!P07437;!Q9H4B7;!P68371;!P04350;!P68366;!Q13509;!Q9BQE3;!Q9NY65;!P68363;!Q71U36	TUBA3C;!TUBB;!TUBB1;!TUBB4B;!TUBB4A;!TUBA4A;!TUBB3;!TUBA1C;!TUBA8;!TUBA1B;!TUBA1A	1. Tubulin alpha-3C/D chain;!2. Tubulin beta chain;!3. Tubulin beta-1 chain;!4. Tubulin beta-4B chain;!5. Tubulin beta-4A chain;!6. Tubulin alpha-4A chain;!7. Tubulin beta-3 chain;!8. Tubulin alpha-1C chain;!9. Tubulin alpha-8 chain;!10. Tubulin alpha-1B chain;!11. Tubulin alpha-1A chain
C29H48O4	Not Available	Not Available	460.689	[H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C)[C@@H](C)OCCCC(O)(CC)CC	Solid	Not Available							CHEMBL432600	4450786						KH1			73896915	46505581					ZINC000004474609		Lexacalcitol	Experimental	DB03451	InChI=1S/C29H48O4/c1-6-29(32,7-2)16-9-17-33-21(4)25-13-14-26-22(10-8-15-28(25,26)5)11-12-23-18-24(30)19-27(31)20(23)3/h11-12,21,24-27,30-32H,3,6-10,13-19H2,1-2,4-5H3/b22-11+,23-12-/t21-,24-,25-,26+,27+,28-/m1/s1	KLZOTDOJMRMLDX-YBBVPDDNSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	3.4928 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	3	Yes	3	0	69.92 Å2	55.8 Å3	137.52 m3·mol-1	9	Yes	No	0.00632 mg/mL	4.36	-4.9	14.25	-2.8	P11473	VDR	1. Vitamin D3 receptor
C24H40O4	Not Available	Not Available	392.572	[H][C@@]12CC[C@H]([C@H](C)CCC(O)=O)[C@@]1(C)[C@@H](O)C[C@@]1([H])[C@@]2([H])CC[C@]2([H])C[C@H](O)CC[C@]12C	Solid	Not Available					50375599	28834	CHEMBL406393	193196	Drugs.com Drug Page		HMDB0000626	C04483		DXC			222528	46506360		3194		Deoxycholic_acid	ZINC000003914810	Belkyra, Kybella	Deoxycholic acid	Approved	DB03619	InChI=1S/C24H40O4/c1-14(4-9-22(27)28)18-7-8-19-17-6-5-15-12-16(25)10-11-23(15,2)20(17)13-21(26)24(18,19)3/h14-21,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15-,16-,17+,18-,19+,20+,21+,23+,24-/m1/s1	KXGVEGMKQFWNSR-LLQZFEROSA-N	4	Deoxycholic acid is a cytolytic agent injected subcutaneously to improve the appearance submental fat.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	2.5624 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.50	-3.95	177 °C		43.6 mg/L (at 20 °C)	1	Yes	4	3	No	4	-1	77.76 Å2	46.3 Å3	109.2 m3·mol-1	4	Yes	No	0.0173 mg/mL	3.79	-4.4	4.65	-0.35			
C23H34O5	Not Available	Not Available	390.5131	[H][C@@]1(CC[C@]2(O)[C@]3([H])CC[C@]4([H])C[C@@H](O)CC[C@]4(C)[C@@]3([H])C[C@@H](O)[C@]12C)C1=CC(=O)OC1	Solid	Not Available					225707	42098	CHEMBL1153	14728						DOG			15478	46509019				Digoxigenin	ZINC000003982471		Digoxigenin	Experimental	DB03671	InChI=1S/C23H34O5/c1-21-7-5-15(24)10-14(21)3-4-17-18(21)11-19(25)22(2)16(6-8-23(17,22)27)13-9-20(26)28-12-13/h9,14-19,24-25,27H,3-8,10-12H2,1-2H3/t14-,15+,16-,17-,18+,19-,21+,22+,23+/m1/s1	SHIBSTMRCDJXLN-KCZCNTNESA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	3.4699 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	4	3	No	5	0	86.99 Å2	42.7 Å3	105.16 m3·mol-1	1	Yes	No	0.0632 mg/mL	1.84	-3.8	7.15	-1.4			
C30H50O	Not Available	Not Available	426.7174	[H][C@@]1(CC[C@@]2(C)C3=C(CC[C@]12C)[C@@]1(C)CC[C@H](O)C(C)(C)[C@]1([H])CC3)[C@H](C)CCC=C(C)C	Solid	Not Available						16521	CHEMBL225111	216175		GtP Drug Page	HMDB0001251	C01724		LAN			246983	46506323		1442199		Lanosterol	ZINC000003870056		Lanosterol	Experimental	DB03696	InChI=1S/C30H50O/c1-20(2)10-9-11-21(3)22-14-18-30(8)24-12-13-25-27(4,5)26(31)16-17-28(25,6)23(24)15-19-29(22,30)7/h10,21-22,25-26,31H,9,11-19H2,1-8H3/t21-,22-,25+,26+,28-,29-,30+/m1/s1	CAHGCLMLTWQZNJ-BQNIITSRSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.5576 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							140.5 °C			1	No	1	1	No	4	0	20.23 Å2	55.06 Å3	134.54 m3·mol-1	4	No	Yes	0.000376 mg/mL	7.71	-6.1	19.55	-0.81	P48449	LSS	1. Lanosterol synthase
C34H55NO3	Not Available	Not Available	525.8054	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3C[C@@H](CCCCCCCCCCC(=O)N(C)CCCC)[C@@]21[H]	Solid	Not Available							CHEMBL1222035	94580				C14758		AOE			104772	46506133				ICI-164384	ZINC000003917379		ICI-164384	Experimental	DB03860	InChI=1S/C34H55NO3/c1-4-5-22-35(3)32(38)15-13-11-9-7-6-8-10-12-14-25-23-26-24-27(36)16-17-28(26)29-20-21-34(2)30(33(25)29)18-19-31(34)37/h16-17,24-25,29-31,33,36-37H,4-15,18-23H2,1-3H3/t25-,29-,30+,31+,33-,34+/m1/s1	BVVFOLSZMQVDKV-KXQIQQEYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.7601 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										0	No	3	2	Yes	4	0	60.77 Å2	66.78 Å3	157.62 m3·mol-1	14	No	No	0.000143 mg/mL	8.12	-6.6	10.32	-0.56	Q92731	ESR2	1. Estrogen receptor beta
C19H32O2	Not Available	Not Available	292.4562	[H][C@]1(O)CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])C[C@@]([H])(O)CC[C@]4(C)[C@@]3([H])CC[C@]12C	Solid	Not Available						18329	CHEMBL316048	211834			HMDB0000493	C12525		AOM			242332	46508740					ZINC000003814412		5-Alpha-Androstane-3-Beta,17beta-Diol	Experimental	DB03882	InChI=1S/C19H32O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12-17,20-21H,3-11H2,1-2H3/t12-,13-,14-,15-,16-,17-,18-,19-/m0/s1	CBMYJHIOYJEBSB-YSZCXEEOSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3334 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	2	2	No	4	0	40.46 Å2	35.56 Å3	84.63 m3·mol-1	0	Yes	No	0.0193 mg/mL	3.2	-4.2	18.3	-0.76	Q92731	ESR2	1. Estrogen receptor beta
C19H32O2	Not Available	Not Available	292.4562	[H][C@@]12CC[C@@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@@H](O)CC[C@]12C	Solid	Not Available						40836		394165						AON			446934	46505400					ZINC000006500050		5alpha-androstane-3beta,17alpha-diol	Experimental	DB03926	InChI=1S/C19H32O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12-17,20-21H,3-11H2,1-2H3/t12-,13-,14-,15-,16-,17+,18-,19-/m0/s1	CBMYJHIOYJEBSB-MFXFBURESA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3334 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	2	2	No	4	0	40.46 Å2	35.45 Å3	84.63 m3·mol-1	0	Yes	No	0.0193 mg/mL	3.2	-4.2	18.3	-0.76			
C28H44O	Not Available	Not Available	396.659	CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	Solid	Not Available					50378884	16933	CHEMBL1232562	392539				C01694		ERG			444679	46505947				Ergosterol	ZINC000004084618		Ergosterol	Approved, Experimental	DB04038	InChI=1S/C28H44O/c1-18(2)19(3)7-8-20(4)24-11-12-25-23-10-9-21-17-22(29)13-15-27(21,5)26(23)14-16-28(24,25)6/h7-10,18-20,22,24-26,29H,11-17H2,1-6H3/b8-7+/t19-,20+,22-,24+,25-,26-,27-,28+/m0/s1	DNVPQKQSNYMLRS-APGDWVJJSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.6528 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							170 °C			1	No	1	1	No	4	0	20.23 Å2	51.01 Å3	127.13 m3·mol-1	4	No	Yes	0.000156 mg/mL	6.63	-6.4	18.27	-1.4			
C23H34O4	Not Available	Not Available	374.5137	[H][C@]12CC[C@]3([H])[C@]([H])(CC[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@H](O)C2	Solid	Not Available					66977	42219	CHEMBL1453	3571902						DTX			4369270	46508220				Digitoxigenin	ZINC000003875959		Digitoxigenin	Experimental	DB04177	InChI=1S/C23H34O4/c1-21-8-5-16(24)12-15(21)3-4-19-18(21)6-9-22(2)17(7-10-23(19,22)26)14-11-20(25)27-13-14/h11,15-19,24,26H,3-10,12-13H2,1-2H3/t15-,16+,17-,18+,19-,21+,22-,23+/m1/s1	XZTUSOXSLKTKJQ-CESUGQOBSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.9314 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	3	2	No	5	-1	66.76 Å2	42.57 Å3	103.64 m3·mol-1	1	Yes	No	0.0244 mg/mL	3.07	-4.2	7.18	0.25			
C30H46O3	Not Available	Not Available	454.6844	[H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C)[C@H](C)\C=C\C=C\C(O)(CC)CC	Solid	Not Available							CHEMBL1908376	4450374						EB1			20055510	46507218					ZINC000003925433		Seocalcitol	Investigational	DB04258	InChI=1S/C30H46O3/c1-6-30(33,7-2)18-9-8-11-21(3)26-15-16-27-23(12-10-17-29(26,27)5)13-14-24-19-25(31)20-28(32)22(24)4/h8-9,11,13-14,18,21,25-28,31-33H,4,6-7,10,12,15-17,19-20H2,1-3,5H3/b11-8+,18-9+,23-13+,24-14-/t21-,25-,26-,27+,28+,29-/m1/s1	LVLLALCJVJNGQQ-SEODYNFXSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	4.2195 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	3	3	Yes	3	0	60.69 Å2	56.19 Å3	142.26 m3·mol-1	7	No	No	0.00382 mg/mL	5.27	-5.1	14.39	-1	P11473	VDR	1. Vitamin D3 receptor
C16H26O5	Not Available	Not Available	298.3746	[H][C@]1(CC=C(C)C)O[C@]1(C)[C@@]1(O)[C@]([H])(OC)C(=O)CC[C@@]1(C)O	Solid	Not Available								4451121						OVA			5289086	46507847					ZINC000012504299		Ovalicin	Experimental	DB04324	InChI=1S/C16H26O5/c1-10(2)6-7-12-15(4,21-12)16(19)13(20-5)11(17)8-9-14(16,3)18/h6,12-13,18-19H,7-9H2,1-5H3/t12-,13-,14-,15+,16-/m1/s1	UOXVFQCRPDLSFN-DGXTUMSLSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	2.6717 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	2	No	2	0	79.29 Å2	32.21 Å3	78.67 m3·mol-1	4	Yes	No	2.27 mg/mL	1.15	-2.1	11.59	-3.4	P53582;!P50579	METAP1;!METAP2	1. Methionine aminopeptidase 1;!2. Methionine aminopeptidase 2
C22H30O7	Not Available	Not Available	406.4694	[H][C@]12[C@]3([H])C=C(CO)C[C@]4(O)C(=O)C(C)=C[C@@]4([H])[C@@]3(O)[C@]([H])(C)[C@@]([H])(O)[C@@]1(OC(C)=O)C2(C)C	Solid	Not Available						45127	CHEMBL1235429	437370						PRB			499953	46507195					ZINC000013521034		13-Acetylphorbol	Experimental	DB04376	InChI=1S/C22H30O7/c1-10-6-15-20(27,17(10)25)8-13(9-23)7-14-16-19(4,5)22(16,29-12(3)24)18(26)11(2)21(14,15)28/h6-7,11,14-16,18,23,26-28H,8-9H2,1-5H3/t11-,14+,15-,16-,18-,20-,21-,22-/m1/s1	SDSVJYOOAPRSDA-RPCQODIISA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.7826 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	6	4	No	4	0	124.29 Å2	43.1 Å3	104.93 m3·mol-1	3	Yes	No	1.44 mg/mL	-0.34	-2.4	12.54	-2.7	Q05655	PRKCD	1. Protein kinase C delta type
C27H46O	Not Available	Not Available	386.6535	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC=C4C[C@@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCCC(C)C	Solid	Not Available					20192	16113	CHEMBL112570	5775			HMDB0000067	C00187	D00040	CLR			5997	46508234		2438		Cholesterol	ZINC000003875383		Cholesterol	Approved, Investigational	DB04540	InChI=1S/C27H46O/c1-18(2)7-6-8-19(3)23-11-12-24-22-10-9-20-17-21(28)13-15-26(20,4)25(22)14-16-27(23,24)5/h9,18-19,21-25,28H,6-8,10-17H2,1-5H3/t19-,21+,22+,23-,24+,25+,26+,27-/m1/s1	HVYWMOMLDIMFJA-DPAQBDIFSA-N	4		Not Available	Small Molecule	http://smpdb.ca/view/SMP0000099?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000111?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000209?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000316?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000372?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000388?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000389?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000510?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000577?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000718?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000082?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000089?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000092?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000107?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000117?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000119?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000314?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000319?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000371?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000508?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000575?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000717?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000720?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000023?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000035?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000079?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000095?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000112?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000130?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000131?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540	Lovastatin Action Pathway;!Cerivastatin Action Pathway;!Hypercholesterolemia;!Zellweger Syndrome;!Adrenal Hyperplasia Type 5 or Congenital Adrenal Hyperplasia Due to 17 alpha-Hydroxylase Deficiency;!Chondrodysplasia Punctata II, X-Linked Dominant (CDPX2);!Smith-Lemli-Opitz Syndrome (SLOS);!Mevalonic Aciduria;!Corticosterone Methyl Oxidase I Deficiency (CMO I);!3-beta-Hydroxysteroid Dehydrogenase Deficiency;!Simvastatin Action Pathway;!Pravastatin Action Pathway;!Rosuvastatin Action Pathway;!Zoledronate Action Pathway;!Pamidronate Action Pathway;!Fluvastatin Action Pathway;!Congenital Bile Acid Synthesis Defect Type II;!Lysosomal Acid Lipase Deficiency (Wolman Disease);!Congenital Lipoid Adrenal Hyperplasia (CLAH) or Lipoid CAH;!Cholesteryl Ester Storage Disease;!11-beta-Hydroxylase Deficiency (CYP11B1);!Apparent Mineralocorticoid Excess Syndrome;!27-Hydroxylase Deficiency;!Steroid Biosynthesis;!Bile Acid Biosynthesis;!Ibandronate Action Pathway;!Alendronate Action Pathway;!Risedronate Action Pathway;!Steroidogenesis;!Atorvastatin Action Pathway		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.8078 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				360 °C			148.5 °C		0.095 mg/L (at 30 °C)	1	No	1	1	No	4	0	20.23 Å2	50.64 Å3	120.62 m3·mol-1	5	No	Yes	2.79e-05 mg/mL	7.11	-7.1	18.2	-1.4	Q14994;!P11473;!Q9ULY5;!P35398	NR1I3;!VDR;!CLEC4E;!RORA	1. Nuclear receptor subfamily 1 group I member 3;!2. Vitamin D3 receptor;!3. C-type lectin domain family 4 member E;!4. Nuclear receptor ROR-alpha
C18H24O3	Not Available	Not Available	288.3814	[H][C@@]12C[C@@H](O)[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	Solid	Not Available					50410506	27974	CHEMBL193482	5553			HMDB0000153	C05141	D00185	ESL		PA164769104	5756	46505881		4094	DAP001019	Estriol	ZINC000003815418		Estriol	Approved, Investigational, Vet approved	DB04573	InChI=1S/C18H24O3/c1-18-7-6-13-12-5-3-11(19)8-10(12)2-4-14(13)15(18)9-16(20)17(18)21/h3,5,8,13-17,19-21H,2,4,6-7,9H2,1H3/t13-,14-,15+,16-,17+,18+/m1/s1	PROQIPRRNZUXQM-ZXXIGWHRSA-N	4	Estriol is a weak estrogen used to treat vaginal dryness and estrogen deficiency conditions, such as vaginitis and vulvar itching.	ORAL (LD50): Acute: >2000 mg/kg [Rat].	Small Molecule	http://smpdb.ca/view/SMP0030880?highlight[compounds][]=DB04573&highlight[proteins][]=DB04573	Estrone Metabolism		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.9758 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor					2.45		82-86			1	Yes	3	3	No	4	0	60.69 Å2	33.08 Å3	81.27 m3·mol-1	0	Yes	No	0.119 mg/mL	2.67	-3.4	10.33	-3.2			
C25H32O2	Not Available	Not Available	364.5204	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(OC1CCCC1)C=C3	Solid	Not Available						8716	CHEMBL1201165	8694			HMDB0015579	C07619	D00576			PA164749042	9046	46508939		9066	DAP001016	Quinestrol	ZINC000003875993		Quinestrol	Approved	DB04575	InChI=1S/C25H32O2/c1-3-25(26)15-13-23-22-10-8-17-16-19(27-18-6-4-5-7-18)9-11-20(17)21(22)12-14-24(23,25)2/h1,9,11,16,18,21-23,26H,4-8,10,12-15H2,2H3/t21-,22-,23+,24+,25+/m1/s1	PWZUUYSISTUNDW-VAFBSOEGSA-N			Symptoms of overdose include nausea and vomiting, and withdrawal bleeding may occur in females.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.9408 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor							107.5 °C			1	Yes	2	1	No	5	0	29.46 Å2	44.04 Å3	108.27 m3·mol-1	2	No	Yes	0.00157 mg/mL	5.4	-5.4	17.59	-1.7	P03372	ESR1	1. Estrogen receptor alpha
C21H28O5	Not Available	Not Available	360.444	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)CC[C@]4(C)[C@@]3([H])[C@@H](O)C[C@]12C=O)C(=O)CO	Solid	Not Available	P15538;!P19099;!P05093;!P08684	CYP11B1;!CYP11B2;!CYP17A1;!CYP3A4	1. Cytochrome P450 11B1, mitochondrial;!2. Cytochrome P450 11B2, mitochondrial;!3. Steroid 17-alpha-hydroxylase/17,20 lyase;!4. Cytochrome P450 3A4		19214	27584	CHEMBL273453	5633				C01780		AS4		PA164924487	5839	46505770		1312358	DAP001344	Aldosterone	ZINC000003833824		Aldosterone	Experimental, Investigational	DB04630	InChI=1S/C21H28O5/c1-20-7-6-13(24)8-12(20)2-3-14-15-4-5-16(18(26)10-22)21(15,11-23)9-17(25)19(14)20/h8,11,14-17,19,22,25H,2-7,9-10H2,1H3/t14-,15-,16+,17-,19+,20-,21+/m0/s1	PQSUYGKTWSAVDQ-ZVIOFETBSA-N	4		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.5456 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					1.08		166.5 °C		51.2 mg/L (at 37 °C)	1	Yes	5	2	No	4	0	91.67 Å2	38.82 Å3	96.79 m3·mol-1	3	Yes	No	0.148 mg/mL	1.06	-3.4	13.82	-2.9			
C21H30O4	Not Available	Not Available	346.4605	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)CC[C@]4(C)[C@@]3([H])[C@@]([H])(O)C[C@]12C)C(=O)CO	Solid	Not Available	P08684;!P28845;!P80365	CYP3A4;!HSD11B1;!HSD11B2	1. Cytochrome P450 3A4;!2. Corticosteroid 11-beta-dehydrogenase isozyme 1;!3. Corticosteroid 11-beta-dehydrogenase isozyme 2		50170653	16827	CHEMBL110739	5550			HMDB0001547	C02140		C0R			5753	46504547				Corticosterone	ZINC000013513592		Corticosterone	Experimental	DB04652	InChI=1S/C21H30O4/c1-20-8-7-13(23)9-12(20)3-4-14-15-5-6-16(18(25)11-22)21(15,2)10-17(24)19(14)20/h9,14-17,19,22,24H,3-8,10-11H2,1-2H3/t14-,15-,16+,17-,19+,20-,21-/m0/s1	OMFXVFTZEKFJBZ-HJTSIMOOSA-N			Not Available	Small Molecule	http://smpdb.ca/view/SMP0000371?highlight[compounds][]=DB04652&highlight[proteins][]=DB04652;!http://smpdb.ca/view/SMP0000575?highlight[compounds][]=DB04652&highlight[proteins][]=DB04652;!http://smpdb.ca/view/SMP0000717?highlight[compounds][]=DB04652&highlight[proteins][]=DB04652;!http://smpdb.ca/view/SMP0000372?highlight[compounds][]=DB04652&highlight[proteins][]=DB04652;!http://smpdb.ca/view/SMP0000577?highlight[compounds][]=DB04652&highlight[proteins][]=DB04652;!http://smpdb.ca/view/SMP0000718?highlight[compounds][]=DB04652&highlight[proteins][]=DB04652;!http://smpdb.ca/view/SMP0000130?highlight[compounds][]=DB04652&highlight[proteins][]=DB04652;!http://smpdb.ca/view/SMP0000373?highlight[compounds][]=DB04652&highlight[proteins][]=DB04652;!http://smpdb.ca/view/SMP0000566?highlight[compounds][]=DB04652&highlight[proteins][]=DB04652;!http://smpdb.ca/view/SMP0000576?highlight[compounds][]=DB04652&highlight[proteins][]=DB04652;!http://smpdb.ca/view/SMP0000578?highlight[compounds][]=DB04652&highlight[proteins][]=DB04652	Congenital Lipoid Adrenal Hyperplasia (CLAH) or Lipoid CAH;!11-beta-Hydroxylase Deficiency (CYP11B1);!Apparent Mineralocorticoid Excess Syndrome;!Adrenal Hyperplasia Type 5 or Congenital Adrenal Hyperplasia Due to 17 alpha-Hydroxylase Deficiency;!Corticosterone Methyl Oxidase I Deficiency (CMO I);!3-beta-Hydroxysteroid Dehydrogenase Deficiency;!Steroidogenesis;!Adrenal Hyperplasia Type 3 or Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency;!17-alpha-Hydroxylase Deficiency (CYP17);!21-Hydroxylase Deficiency (CYP21);!Corticosterone Methyl Oxidase II Deficiency (CMO II)		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.5110 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	2	No	4	0	74.6 Å2	38.83 Å3	96 m3·mol-1	2	Yes	No	0.046 mg/mL	2.02	-3.9	13.86	-0.26	P28845;!Q15788;!P08235	HSD11B1;!NCOA1;!NR3C2	1. Corticosteroid 11-beta-dehydrogenase isozyme 1;!2. Nuclear receptor coactivator 1;!3. Mineralocorticoid receptor
C27H46O2	Not Available	Not Available	402.6529	CC(C)CCC[C@@](C)(O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	Solid	Not Available					50035884		CHEMBL1233249	389586			HMDB0006283			HC2			440711	46508206					ZINC000004096811		20-hydroxycholesterol	Experimental	DB04704	InChI=1S/C27H46O2/c1-18(2)7-6-14-27(5,29)24-11-10-22-21-9-8-19-17-20(28)12-15-25(19,3)23(21)13-16-26(22,24)4/h8,18,20-24,28-29H,6-7,9-17H2,1-5H3/t20-,21-,22-,23-,24-,25-,26-,27+/m0/s1	MCKLJFJEQRYRQT-MGNSQDQZSA-N			Not Available	Small Molecule	http://smpdb.ca/view/SMP0000371?highlight[compounds][]=DB04704&highlight[proteins][]=DB04704;!http://smpdb.ca/view/SMP0000575?highlight[compounds][]=DB04704&highlight[proteins][]=DB04704;!http://smpdb.ca/view/SMP0000717?highlight[compounds][]=DB04704&highlight[proteins][]=DB04704;!http://smpdb.ca/view/SMP0000372?highlight[compounds][]=DB04704&highlight[proteins][]=DB04704;!http://smpdb.ca/view/SMP0000577?highlight[compounds][]=DB04704&highlight[proteins][]=DB04704;!http://smpdb.ca/view/SMP0000718?highlight[compounds][]=DB04704&highlight[proteins][]=DB04704;!http://smpdb.ca/view/SMP0000130?highlight[compounds][]=DB04704&highlight[proteins][]=DB04704;!http://smpdb.ca/view/SMP0000373?highlight[compounds][]=DB04704&highlight[proteins][]=DB04704;!http://smpdb.ca/view/SMP0000566?highlight[compounds][]=DB04704&highlight[proteins][]=DB04704;!http://smpdb.ca/view/SMP0000576?highlight[compounds][]=DB04704&highlight[proteins][]=DB04704;!http://smpdb.ca/view/SMP0000578?highlight[compounds][]=DB04704&highlight[proteins][]=DB04704	Congenital Lipoid Adrenal Hyperplasia (CLAH) or Lipoid CAH;!11-beta-Hydroxylase Deficiency (CYP11B1);!Apparent Mineralocorticoid Excess Syndrome;!Adrenal Hyperplasia Type 5 or Congenital Adrenal Hyperplasia Due to 17 alpha-Hydroxylase Deficiency;!Corticosterone Methyl Oxidase I Deficiency (CMO I);!3-beta-Hydroxysteroid Dehydrogenase Deficiency;!Steroidogenesis;!Adrenal Hyperplasia Type 3 or Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency;!17-alpha-Hydroxylase Deficiency (CYP17);!21-Hydroxylase Deficiency (CYP21);!Corticosterone Methyl Oxidase II Deficiency (CMO II)		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	3.0155 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	2	2	No	4	0	40.46 Å2	50.57 Å3	122.3 m3·mol-1	5	No	No	0.000571 mg/mL	5.8	-5.8	18.2	-0.26			
C27H46O2	Not Available	Not Available	402.6529	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC=C4C[C@@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCCC(C)(C)O	Solid	Not Available					20182	42977	CHEMBL169046	58604				C15519		HC3			65094	46506794					ZINC000005751264		25-Hydroxycholesterol	Experimental	DB04705	InChI=1S/C27H46O2/c1-18(7-6-14-25(2,3)29)22-10-11-23-21-9-8-19-17-20(28)12-15-26(19,4)24(21)13-16-27(22,23)5/h8,18,20-24,28-29H,6-7,9-17H2,1-5H3/t18-,20+,21+,22-,23+,24+,26+,27-/m1/s1	INBGSXNNRGWLJU-ZHHJOTBYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	3.0155 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	2	2	No	4	0	40.46 Å2	51.11 Å3	122.45 m3·mol-1	5	No	No	0.000244 mg/mL	5.64	-6.2	18.2	-1			
C27H46O2	Not Available	Not Available	402.6529	[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@@H](O)C=C4C[C@@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCCC(C)C	Solid	Not Available					50045545	42989	CHEMBL497834	415508			HMDB0006119			HCR			473141	46505045					ZINC000005758832		7beta-hydroxycholesterol	Experimental	DB04706	InChI=1S/C27H46O2/c1-17(2)7-6-8-18(3)21-9-10-22-25-23(12-14-27(21,22)5)26(4)13-11-20(28)15-19(26)16-24(25)29/h16-18,20-25,28-29H,6-15H2,1-5H3/t18-,20+,21-,22+,23+,24+,25+,26+,27-/m1/s1	OYXZMSRRJOYLLO-KGZHIOMZSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	3.0155 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	2	2	No	4	0	40.46 Å2	51.12 Å3	122.06 m3·mol-1	5	No	No	0.000476 mg/mL	5.96	-5.9	18.2	-0.83			
C26H40O3	Not Available	Not Available	400.603	[H][C@@]1(CC[C@]2([H])\C(CCC[C@]12C)=C\C=C1C[C@@H](O)C[C@H](O)C1)[C@H](C)CC#CC(C)(C)O	Solid	Not Available							CHEMBL2105107	5291648						TX5			6915835	46504586					ZINC000012504514		Inecalcitol	Investigational	DB04796	InChI=1S/C26H40O3/c1-18(7-5-13-25(2,3)29)23-11-12-24-20(8-6-14-26(23,24)4)10-9-19-15-21(27)17-22(28)16-19/h9-10,18,21-24,27-29H,6-8,11-12,14-17H2,1-4H3/b20-10+/t18-,21-,22-,23-,24-,26-/m1/s1	HHGRMHMXKPQNGF-WNSNRMDMSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	4.7066 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	3	No	3	0	60.69 Å2	48.7 Å3	121.57 m3·mol-1	5	Yes	No	0.00221 mg/mL	4	-5.3	14.67	-2.7	P11473	VDR	1. Vitamin D3 receptor
C24H29ClO4	Not Available	Elimination Following oral or intramuscular administration, the plasma half-life is 38 and 96 hours, respectively.	416.938	[H][C@@]12C[C@]1([H])[C@@]1(C)C(=CC2=O)C(Cl)=C[C@@]2([H])[C@]3([H])CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CC[C@]12[H]	Solid	Not Available	P08684;!P11511	CYP3A4;!CYP19A1	1. Cytochrome P450 3A4;!2. Cytochrome P450 19A1		50094569	50743	CHEMBL139835	9496					D01368	CA4		PA10049	9880	46506931		22054	DAP000906	Cyproterone_acetate	ZINC000003814423	Androcur, Cléo -35, Cyestra-35, Diane	Cyproterone acetate	Approved, Investigational	DB04839	InChI=1S/C24H29ClO4/c1-12(26)24(29-13(2)27)8-6-16-14-10-20(25)19-11-21(28)15-9-18(15)23(19,4)17(14)5-7-22(16,24)3/h10-11,14-18H,5-9H2,1-4H3/t14-,15+,16-,17-,18-,22-,23-,24-/m0/s1	UWFYSQMTEOIJJG-FDTZYFLXSA-N	4	Cyproterone acetate is a steroid used in combination with ethinyl estradiol to treat women with severe acne and symptoms of androgenization. Also used alone at much higher doses for palliative treatment of patients with prostate cancer	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.8261 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							200-201			1	Yes	3	0	No	5	0	60.44 Å2	44.64 Å3	111.81 m3·mol-1	3	Yes	No	0.00152 mg/mL	3.64	-5.4	17.83	-5.6	P10275;!P07288	AR;!KLK3	1. Androgen receptor;!2. Prostate-specific antigen
C27H42N2O5S	Not Available	52 hours	506.7	[H][C@]12C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC[C@@]1(C)O2)C(\C)=C\C1=CSC(C)=N1	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			63605	CHEMBL1201752	20145579					D04645	GZX		PA165958343	6445540	99443224		337523		Ixabepilone	ZINC000003993846	Ixempra	Ixabepilone	Approved, Investigational	DB04845	InChI=1S/C27H42N2O5S/c1-15-9-8-10-27(7)22(34-27)12-20(16(2)11-19-14-35-18(4)28-19)29-23(31)13-21(30)26(5,6)25(33)17(3)24(15)32/h11,14-15,17,20-22,24,30,32H,8-10,12-13H2,1-7H3,(H,29,31)/b16-11+/t15-,17+,20-,21-,22-,24-,27+/m0/s1	FABUFPQFXZVHFB-PVYNADRNSA-N	3	Ixabepilone is a microtubule inhibitor administered in combination with capecitabine or alone in the treatment of metastatic or locally advanced breast cancer that has shown inadequate response to taxanes and anthracyclines.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.6638 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	3	No	3	0	112.05 Å2	56.86 Å3	136.71 m3·mol-1	2	No	No	0.00352 mg/mL	3.39	-5.2	13.85	2.73	Q13509	TUBB3	1. Tubulin beta-3 chain
C23H36O2	Not Available	Not Available	344.5307	CC[C@@](C)([H])[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1/C[C@](O)([H])C(=C)[C@]([H])(O)C1	Solid	Not Available							CHEMBL2104955	4451487						VD1			5289547	175426893					ZINC000013975113		Becocalcidiol	Investigational	DB04891	InChI=1S/C23H36O2/c1-5-15(2)19-10-11-20-18(7-6-12-23(19,20)4)9-8-17-13-21(24)16(3)22(25)14-17/h8-9,15,19-22,24-25H,3,5-7,10-14H2,1-2,4H3/b18-9+/t15-,19+,20-,21+,22+,23+/m0/s1	QSLUXQQUPXBIHH-YHSKWIAJSA-N	2		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	3.9749 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	2	No	3	0	40.46 Å2	42.79 Å3	106.23 m3·mol-1	3	Yes	No	0.0097 mg/mL	4.43	-4.6	14.19	-3	Q15648;!P11473	MED1;!VDR	1. Mediator of RNA polymerase II transcription subunit 1;!2. Vitamin D3 receptor
C25H34O6	There is no clearance quantity since ingenol mebutate is a topical treatment.	There is no half-life quantity since ingenol mebutate is a topical treatment.	430.541	[H][C@@]12C[C@@H](C)[C@]34C=C(C)[C@H](OC(=O)C(\C)=C/C)[C@@]3(O)[C@H](O)C(CO)=C[C@@]([H])(C4=O)[C@]1([H])C2(C)C	Solid	There is no volume of distribution quantity since ingenol mebutate is a topical treatment.						66913	CHEMBL1863513	28533061	Drugs.com Drug Page				D09393				6918670	175426930	RxList Drug Page	1242806		Ingenol_mebutate	ZINC000056898854	Picato	Ingenol mebutate	Approved	DB05013	InChI=1S/C25H34O6/c1-7-12(2)22(29)31-21-13(3)10-24-14(4)8-17-18(23(17,5)6)16(20(24)28)9-15(11-26)19(27)25(21,24)30/h7,9-10,14,16-19,21,26-27,30H,8,11H2,1-6H3/b12-7-/t14-,16-,17-,18+,19-,21+,24+,25+/m1/s1	VDJHFHXMUKFKET-UXMMOKKRSA-N	4	Ingenol mebutate is a topical agent used for the treatment of actinic keratosis.	The most common adverse reactions are local skin reactions at the application site, headache, periorbital edema,and nasopharyngitis.	Small Molecule				AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.7836 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	3	No	4	0	104.06 Å2	47.14 Å3	117.86 m3·mol-1	4	Yes	No	0.279 mg/mL	2.51	-3.2	12.13	-2.8	Q05655;!P17252	PRKCD;!PRKCA	1. Protein kinase C delta type;!2. Protein kinase C alpha type
C21H30O3	Not Available	Not Available	330.468	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@H](O)C=C2C[C@@H](O)CC[C@]12C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4					20571043									16739648	347827717							HE3286	Investigational	DB05212	InChI=1S/C21H30O3/c1-4-21(24)10-7-16-18-15(6-9-20(16,21)3)19(2)8-5-14(22)11-13(19)12-17(18)23/h1,12,14-18,22-24H,5-11H2,2-3H3/t14-,15-,16-,17-,18+,19-,20-,21-/m0/s1	JJKOQZHWYLMASZ-FJWDNACWSA-N	2		Not Available	Small Molecule																																			1	Yes	3	3	No	4	0	60.69 Å2	38.17 Å3	94.39 m3·mol-1	0	Yes	No	0.017 mg/mL	1.8	-4.3	17.59	-0.77	P19838;!Q00653	NFKB1;!NFKB2	1. Nuclear factor NF-kappa-B p105 subunit;!2. Nuclear factor NF-kappa-B p100 subunit
C31H39NO5	Not Available	Not Available	505.655	[H][C@@]12CC[C@](OC(C)=O)(C(=O)COC)[C@@]1(C)C[C@H](C1=CC=C(C=C1)N(C)C)C1=C3CCC(=O)C=C3CC[C@@]21[H]	Solid	Not Available							CHEMBL2105694	7981950										347910049				Proellex			Telapristone acetate	Investigational	DB05253	InChI=1S/C31H39NO5/c1-19(33)37-31(28(35)18-36-5)15-14-27-25-12-8-21-16-23(34)11-13-24(21)29(25)26(17-30(27,31)2)20-6-9-22(10-7-20)32(3)4/h6-7,9-10,16,25-27H,8,11-15,17-18H2,1-5H3/t25-,26+,27-,30-,31-/m0/s1	JVBGZFRPTRKSBB-MJBQOYBXSA-N	2		Not Available	Small Molecule																																			1	No	5	0	Yes	5	0	72.91 Å2	56.9 Å3	144.89 m3·mol-1	7	No	No	0.00556 mg/mL	4.45	-5	18.42	4.89	P06401	PGR	1. Progesterone receptor
C33H52O4	Not Available	Not Available	512.775	[H][C@]12C[C@@]3([H])[C@]4([H])CC=C5C[C@H](CC[C@]5(C)[C@@]4([H])CC[C@]3(C)[C@@]1([H])[C@H](C)[C@@]1(CC[C@@H](C)CO1)O2)OC(=O)CCCCC	Solid	Not Available								17460070									16394575	347827721					ZINC000097971833		Caprospinol	Investigational	DB05263	InChI=1S/C33H52O4/c1-6-7-8-9-29(34)36-24-13-15-31(4)23(18-24)10-11-25-26(31)14-16-32(5)27(25)19-28-30(32)22(3)33(37-28)17-12-21(2)20-35-33/h10,21-22,24-28,30H,6-9,11-20H2,1-5H3/t21-,22+,24+,25-,26+,27+,28+,30+,31+,32+,33-/m1/s1	VMOZFSWFUBLCNN-AAPULDEBSA-N			Not Available	Small Molecule																																			0	No	3	0	Yes	6	0	44.76 Å2	64.08 Å3	147.85 m3·mol-1	6	No	No	1.55e-05 mg/mL	7.4	-7.5		-4			
C23H30O5	Not Available	Not Available	386.4813	[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)CC=C1[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	Not Available						31215	CHEMBL2106613	99892					D01733				111332	175426966				Anecortave	ZINC000003931050		Anecortave acetate	Investigational	DB05288	InChI=1S/C23H30O5/c1-14(24)28-13-20(26)23(27)11-8-19-17-5-4-15-12-16(25)6-9-21(15,2)18(17)7-10-22(19,23)3/h7,12,17,19,27H,4-6,8-11,13H2,1-3H3/t17-,19+,21+,22+,23+/m1/s1	YUWPMEXLKGOSBF-GACAOOTBSA-N	3		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.1280 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	1	No	4	0	80.67 Å2	42.64 Å3	105.81 m3·mol-1	4	Yes	No	0.0113 mg/mL	2.62	-4.5	12.61	-3.8			
C30H50O5	Not Available	Not Available	490.725	[H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)[C@@H](OCCCO)[C@H](O)C1=C)[C@H](C)CCCC(C)(C)O	Solid	Not Available						73927		5293354						ED9			6918141	175426970				Eldecalcitol	ZINC000003934328		Eldecalcitol	Investigational	DB05295	InChI=1S/C30H50O5/c1-20(9-6-15-29(3,4)34)24-13-14-25-22(10-7-16-30(24,25)5)11-12-23-19-26(32)28(27(33)21(23)2)35-18-8-17-31/h11-12,20,24-28,31-34H,2,6-10,13-19H2,1,3-5H3/b22-11+,23-12-/t20-,24-,25+,26-,27-,28-,30-/m1/s1	FZEXGDDBXLBRTD-AYIMTCTASA-N	3		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	3.3673 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	5	4	Yes	3	0	90.15 Å2	59.7 Å3	143.54 m3·mol-1	10	Yes	No	0.0105 mg/mL	3.67	-4.7	13.38	-1.3	P11473	VDR	1. Vitamin D3 receptor
C28H31NaO9S	Not Available	Not Available	566.595	[Na+].CC12CC(O)C3C(CCC4=CC(=O)C=CC34C)C1CCC2(O)C(=O)COC(=O)C1=CC(=CC=C1)S([O-])(=O)=O	Solid	Not Available								11914									23691973	175426980							ATL-2502	Investigational	DB05340	InChI=1S/C28H32O9S.Na/c1-26-10-8-18(29)13-17(26)6-7-20-21-9-11-28(33,27(21,2)14-22(30)24(20)26)23(31)15-37-25(32)16-4-3-5-19(12-16)38(34,35)36;/h3-5,8,10,12-13,20-22,24,30,33H,6-7,9,11,14-15H2,1-2H3,(H,34,35,36);/q;+1/p-1	RWFZSORKWFPGNE-UHFFFAOYSA-M	3		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.4859 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	8	2	Yes	5	-1	158.1 Å2	55.75 Å3	137.82 m3·mol-1	6	No	No	0.0249 mg/mL	0.81	-4.4	-2.5	-2.9			
C29H35NO9	Not Available	Not Available	541.597	CC12CC(O)C3C(CCC4=CC(=O)CCC34C)C1CCC2(O)C(=O)COC(=O)C1=CC=CC(CON(=O)=O)=C1	Solid	Not Available																		347910124							NCX 1022	Investigational	DB05410	InChI=1S/C29H35NO9/c1-27-10-8-20(31)13-19(27)6-7-21-22-9-11-29(35,28(22,2)14-23(32)25(21)27)24(33)16-38-26(34)18-5-3-4-17(12-18)15-39-30(36)37/h3-5,12-13,21-23,25,32,35H,6-11,14-16H2,1-2H3	MBODWAULVMWNDB-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	No	8	2	Yes	5	0	155.95 Å2	56.82 Å3	140.73 m3·mol-1	8	No	No	0.00244 mg/mL	3.93	-5.4	12.61	-2.8			
C28H30O4	Not Available	Not Available	430.544	[H][C@@]12CC[C@@](O)(C#CC)[C@@]1(C)C[C@H](C1=CC=C3OCOC3=C1)C1=C3CCC(=O)C=C3CC[C@@]21[H]	Solid	Not Available								8043052									9867361	347827730					ZINC000003951570		ORG-34517	Investigational	DB05423	InChI=1S/C28H30O4/c1-3-11-28(30)12-10-23-21-7-4-17-13-19(29)6-8-20(17)26(21)22(15-27(23,28)2)18-5-9-24-25(14-18)32-16-31-24/h5,9,13-14,21-23,30H,4,6-8,10,12,15-16H2,1-2H3/t21-,22+,23-,27-,28-/m0/s1	DFELGYQKEOCHOA-BZAFBGKRSA-N	2		Not Available	Small Molecule																																			1	Yes	4	1	No	6	0	55.76 Å2	48.36 Å3	123.92 m3·mol-1	2	Yes	No	0.00337 mg/mL	4.65	-5.1	12.87	-3.7	P04150	NR3C1	1. Glucocorticoid receptor
C24H30Cl2O6	Not Available	Not Available	485.4	[H][C@@]12CC[C@](OC(=O)C(Cl)Cl)(C(=O)OCC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	Not Available						135783	CHEMBL2107614	8110701									9935073	175427004					ZINC000003979944		Etiprednol dicloacetate	Investigational	DB05442	InChI=1S/C24H30Cl2O6/c1-4-31-21(30)24(32-20(29)19(25)26)10-8-16-15-6-5-13-11-14(27)7-9-22(13,2)18(15)17(28)12-23(16,24)3/h7,9,11,15-19,28H,4-6,8,10,12H2,1-3H3/t15-,16-,17-,18+,22-,23-,24-/m0/s1	QAIOVDNCIZSSSF-RFAJLIJZSA-N	2		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.9813 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	1	Yes	4	0	89.9 Å2	49.4 Å3	121.88 m3·mol-1	6	Yes	No	0.00235 mg/mL	3.99	-5.3	14.88	-2.9	P01584	IL1B	1. Interleukin-1 beta
C27H44O3	Not Available	Not Available	416.6365	[H][C@]12C[C@@]3([H])[C@]4([H])CC[C@]5([H])C[C@@H](O)CC[C@]5(C)[C@@]4([H])CC[C@]3(C)[C@@]1([H])[C@H](C)[C@@]1(CC[C@@H](C)CO1)O2	Solid	Not Available						28933		82568			HMDB0030048	C08913						347910146					ZINC000008234226		Smilagenin	Investigational	DB05450	InChI=1S/C27H44O3/c1-16-7-12-27(29-15-16)17(2)24-23(30-27)14-22-20-6-5-18-13-19(28)8-10-25(18,3)21(20)9-11-26(22,24)4/h16-24,28H,5-15H2,1-4H3/t16-,17+,18-,19+,20-,21+,22+,23+,24+,25+,26+,27-/m1/s1	GMBQZIIUCVWOCD-UQHLGXRBSA-N	2		Trials showed that the drug has a good clinical safety profile and is well-tolerated.	Small Molecule																																			1	No	3	1	No	6	0	38.69 Å2	51.43 Å3	119.42 m3·mol-1	0	No	Yes	3.28e-05 mg/mL	5.33	-7.1	18.3	-1.4			
C20H30O5	Not Available	Not Available	350.455	[H][C@]12CCC(=C)[C@@H](C\C=C3/[C@H](O)COC3=O)[C@]1(C)CC[C@@H](O)[C@@]2(C)CO	Solid	Not Available					50084419	65408	CHEMBL186141	4477067									5318517	347827741				Andrographolide	ZINC000003881797		Andrographolide	Investigational	DB05767	InChI=1S/C20H30O5/c1-12-4-7-16-19(2,9-8-17(23)20(16,3)11-21)14(12)6-5-13-15(22)10-25-18(13)24/h5,14-17,21-23H,1,4,6-11H2,2-3H3/b13-5+/t14-,15-,16+,17-,19+,20+/m1/s1	BOJKULTULYSRAS-OTESTREVSA-N	2		Not Available	Small Molecule																																			1	Yes	4	3	No	3	0	86.99 Å2	38.27 Å3	94.93 m3·mol-1	3	Yes	No	0.284 mg/mL	1.66	-3.1	13.48	-2.8	P01375;!P01584;!P05231;!Q00653;!P19838	TNF;!IL1B;!IL6;!NFKB2;!NFKB1	1. Tumor necrosis factor;!2. Interleukin-1 beta;!3. Interleukin-6;!4. Nuclear factor NF-kappa-B p100 subunit;!5. Nuclear factor NF-kappa-B p105 subunit
C24H31NO	Not Available	Terminal elimination half-life = 5-14 hours	349.509	[H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C	Solid	Vdss= 19,669 ± 13,358 L					25458	68642	CHEMBL254328	117349	Drugs.com Drug Page				D09701	AER		PA166123407	132971	175427038	RxList Drug Page	1100072		Abiraterone_acetate	ZINC000003797541	Yonsa, Zytiga	Abiraterone	Approved	DB05812	InChI=1S/C24H31NO/c1-23-11-9-18(26)14-17(23)5-6-19-21-8-7-20(16-4-3-13-25-15-16)24(21,2)12-10-22(19)23/h3-5,7,13,15,18-19,21-22,26H,6,8-12,14H2,1-2H3/t18-,19-,21-,22-,23-,24+/m0/s1	GZOSMCIZMLWJML-VJLLXTKPSA-N	4	Abiraterone is an antiandrogen used in the treatment of prostate cancer.	Toxicity is related to the blockade of 17α-hydroxylase activity. Blockade results in the accumulation of upstream mineralocorticoids like 11-deoxycorticosterone leading to secondary hyperaldosteronism. Signs of hydroaldosteronism include fluid retention and hypokalemia. Mineralocorticoid receptor antagonists may be used to treat signs and symptoms.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.4407 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	1	No	5	0	33.12 Å2	42.03 Å3	107.3 m3·mol-1	1	Yes	Yes	0.00305 mg/mL	3.97	-5.1	18.2	4.81			
C19H28O2	Not Available	Not Available	288.431	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3C[C@@H](C)[C@@]21[H]	Solid	Not Available								8014619									19582	175427041				Trestolone	ZINC000004217690		Trestolone	Investigational	DB05830	InChI=1S/C19H28O2/c1-11-9-12-10-13(20)3-4-14(12)15-7-8-19(2)16(18(11)15)5-6-17(19)21/h10-11,14-18,21H,3-9H2,1-2H3/t11-,14+,15-,16+,17+,18-,19+/m1/s1	YSGQGNQWBLYHPE-CFUSNLFHSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.6259 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	1	No	4	0	37.3 Å2	33.92 Å3	84.5 m3·mol-1	0	Yes	Yes	0.0391 mg/mL	3.35	-3.9	18.34	-0.88			
C22H36N2O6	Not Available	Not Available	424.531	[H][C@@]1([C@H](OC)[C@@H](CC[C@]11CO1)OC(=O)N[C@H](C(C)C)C(N)=O)[C@@]1(C)O[C@@H]1CC=C(C)C	Solid	Not Available					50088527		CHEMBL3527358	5293846									6918653	175427046							PPI-2458	Investigational	DB05864	InChI=1S/C22H36N2O6/c1-12(2)7-8-15-21(5,30-15)18-17(27-6)14(9-10-22(18)11-28-22)29-20(26)24-16(13(3)4)19(23)25/h7,13-18H,8-11H2,1-6H3,(H2,23,25)(H,24,26)/t14-,15-,16-,17-,18-,21+,22+/m1/s1	QBDVVYNLLXGUGN-XGTBZJOHSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.7785 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	2	Yes	3	0	115.71 Å2	46.27 Å3	110.43 m3·mol-1	9	Yes	No	0.0439 mg/mL	2.07	-4	13.45	-3.6	P50579	METAP2	1. Methionine aminopeptidase 2
C27H39NO5S	Not Available	Not Available	489.67	C[C@H]1\C=C\C\C(C)=C/C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\C1=CSC(C)=N1	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4					5294026									6918835	347827748					ZINC000100657972		KOS-1584	Investigational	DB05903	InChI=1S/C27H39NO5S/c1-16-9-8-10-17(2)25(31)19(4)26(32)27(6,7)23(29)14-24(30)33-22(12-11-16)18(3)13-21-15-34-20(5)28-21/h8,10-11,13,15,17,19,22-23,25,29,31H,9,12,14H2,1-7H3/b10-8+,16-11-,18-13+/t17-,19+,22-,23-,25-/m0/s1	XAYAKDZVINDZGB-BMVMHAJPSA-N	2		Not Available	Small Molecule																																			1	No	5	2	No	2	0	96.72 Å2	54.41 Å3	137.16 m3·mol-1	2	Yes	No	0.00256 mg/mL	4.73	-5.3	14.07	2.73			
C32H43NO4	Not Available	Not Available	505.699	COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2	Solid	Not Available					217379		CHEMBL1762621	355161														Bardoxolone_methyl	ZINC000003982151		Bardoxolone methyl	Investigational	DB05983	InChI=1S/C32H43NO4/c1-27(2)11-13-32(26(36)37-8)14-12-31(7)24(20(32)17-27)21(34)15-23-29(5)16-19(18-33)25(35)28(3,4)22(29)9-10-30(23,31)6/h15-16,20,22,24H,9-14,17H2,1-8H3/t20-,22-,24-,29-,30+,31+,32-/m0/s1	WPTTVJLTNAWYAO-KPOXMGGZSA-N	2		Not Available	Small Molecule																																			0	No	4	0	No	5	0	84.23 Å2	58.23 Å3	144.36 m3·mol-1	2	No	No	0.00294 mg/mL	6.55	-5.2		-5.3	P25963	NFKBIA	1. NF-kappa-B inhibitor alpha
C26H44O4	Clearance information for obeticholic acid is not readily available in the literature.9,11	The biological half-life of obeticholic acid is reported to be 24 hours.13	420.6252	[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)[C@H](CC)[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O	Solid	The volume of distribution of obeticholic acid is 618 L.9,11	P05177	CYP1A2	1. Cytochrome P450 1A2		21675	43602	CHEMBL566315	394730				C15636	D09360	CHC			447715	347827752		1798288		Obeticholic_acid	ZINC000014164617	Ocaliva	Obeticholic acid	Approved	DB05990	InChI=1S/C26H44O4/c1-5-17-21-14-16(27)10-12-26(21,4)20-11-13-25(3)18(15(2)6-9-22(28)29)7-8-19(25)23(20)24(17)30/h15-21,23-24,27,30H,5-14H2,1-4H3,(H,28,29)/t15-,16-,17-,18-,19+,20+,21+,23+,24-,25-,26-/m1/s1	ZXERDUOLZKYMJM-ZWECCWDJSA-N	3	Obeticholic acid is a bile acid analog and farnesoid X receptor agonist used to treat primary biliary cholangitis in adult patients with inadequate clinical response or intolerance to UDCA.	LD50 information for obeticholic acid is not readily available in the literature.9The maximum documented exposure to obeticholic acid was 500 mg in healthy research volunteers. Doses of 250 mg have been administered to healthy volunteers for 12 consecutive days. Pruritus and reversible transaminase liver elevations were observed. In PBC patients who received 25mg daily to 50mg daily (2.5 to 5 times the maximum recommended dose), dose-dependent transaminase and bilirubin elevations, ascites, primary biliary cholangitis aggravation, and new-onset jaundice were reported.11In the case of an overdose with obeticholic acid, clinical monitoring and supportive care should be offered as they are required.11	Small Molecule																													562.9±25	5.11		108-110	4.76±0.10		1	No	4	3	No	4	-1	77.76 Å2	49.74 Å3	118.35 m3·mol-1	5	Yes	No	0.011 mg/mL	4.52	-4.6	4.6	-0.16	Q96RI1	NR1H4	1. Bile acid receptor
C28H44O3	Not Available	Not Available	428.657	CC(C)[C@](C)(O)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	Solid	Not Available								7826201												1536458			ZINC000004791507		1alpha,24S-Dihydroxyvitamin D2	Investigational	DB06117	InChI=1S/C28H44O3/c1-18(2)28(6,31)15-13-19(3)24-11-12-25-21(8-7-14-27(24,25)5)9-10-22-16-23(29)17-26(30)20(22)4/h9-10,13,15,18-19,23-26,29-31H,4,7-8,11-12,14,16-17H2,1-3,5-6H3/b15-13+,21-9+,22-10-/t19-,23-,24-,25+,26+,27-,28-/m1/s1	ODZFJAXAEXQSKL-WRJREGAQSA-N			Not Available	Small Molecule																																			1	No	3	3	No	3	0	60.69 Å2	52.29 Å3	131.89 m3·mol-1	5	Yes	No	0.00726 mg/mL	4.59	-4.8	14.39	-1.1			
C29H43FO2	Not Available	Not Available	442.6489	CCC(O)(CC)\C=C\C[C@H](C)C1=CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@@](F)([H])C1=C	Solid	Not Available								9571500									11396600						ZINC000004802676		Elocalcitol	Investigational	DB06194	InChI=1S/C29H43FO2/c1-6-29(32,7-2)17-8-10-20(3)25-14-15-26-22(11-9-16-28(25,26)5)12-13-23-18-24(31)19-27(30)21(23)4/h8,12-14,17,20,24,26-27,31-32H,4,6-7,9-11,15-16,18-19H2,1-3,5H3/b17-8+,22-12+,23-13-/t20-,24+,26-,27-,28+/m0/s1	LRLWXBHFPGSUOX-GJQYOBCGSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	3.4000 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	No	2	2	Yes	3	0	40.46 Å2	52.81 Å3	135.7 m3·mol-1	7	No	No	0.00185 mg/mL	5.68	-5.4	15.08	-1.1	P11473	VDR	1. Vitamin D3 receptor
C19H30O3	Not Available	Not Available	306.446	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@H](O)C=C2C[C@@H](O)CC[C@]12C	Solid	Not Available								7993774															ZINC000033967857		HE-2200	Investigational	DB06257	InChI=1S/C19H30O3/c1-18-7-5-12(20)9-11(18)10-15(21)17-13-3-4-16(22)19(13,2)8-6-14(17)18/h10,12-17,20-22H,3-9H2,1-2H3/t12-,13-,14-,15-,16-,17-,18-,19-/m0/s1	OEVZKEVBDIDVOI-YSZCXEEOSA-N			Not Available	Small Molecule																																			1	Yes	3	3	No	4	0	60.69 Å2	35.67 Å3	86.92 m3·mol-1	0	Yes	No	0.223 mg/mL	1.65	-3.1	18.2	-0.55			
C26H42O4	Not Available	Not Available	418.6093	[H]\C(\C(\[H])=C1/CCC[C@@]2(C)[C@@]1([H])CC[C@]2([H])[C@]([H])(C)OCCC(C)(C)O)=C1/C[C@@]([H])(O)C[C@]([H])(O)C1=C	Solid	Not Available					50124417	31801	CHEMBL333950	4911262						MCZ									ZINC000004474617		Maxacalcitol	Investigational	DB06272	InChI=1S/C26H42O4/c1-17-20(15-21(27)16-24(17)28)9-8-19-7-6-12-26(5)22(10-11-23(19)26)18(2)30-14-13-25(3,4)29/h8-9,18,21-24,27-29H,1,6-7,10-16H2,2-5H3/b19-8+,20-9-/t18-,21+,22+,23-,24-,26+/m0/s1	DTXXSJZBSTYZKE-ZDQKKZTESA-N	3		Not Available	Small Molecule																																			1	No	4	3	Yes	3	0	69.92 Å2	50.09 Å3	123.83 m3·mol-1	6	Yes	No	0.015 mg/mL	2.79	-4.4	14.34	-2.7			
C21H32O2	Not Available	Not Available	316.485	C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@H](O)CC[C@]34C)[C@@H]1CC[C@@]2(O)C#C	Solid	Not Available								32698509														Ethynylandrostanediol	ZINC000005921098		Apoptone	Investigational	DB06307	InChI=1S/C21H32O2/c1-4-21(23)12-9-18-16-6-5-14-13-15(22)7-10-19(14,2)17(16)8-11-20(18,21)3/h1,14-18,22-23H,5-13H2,2-3H3/t14-,15+,16+,17-,18-,19-,20-,21-/m0/s1	CKAXZOYFIHQCBN-JRRMKBMNSA-N	2		Not Available	Small Molecule																																			1	Yes	2	2	No	4	0	40.46 Å2	37.66 Å3	92.1 m3·mol-1	0	Yes	No	0.00398 mg/mL	3.36	-4.9	17.59	-1.2	P10415	BCL2	1. Apoptosis regulator Bcl-2
C28H44O2	Not Available	32 to 37 hours.	412.6478	[H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C)[C@H](C)\C=C\[C@H](C)C(C)C	Solid	Not Available	Q02318	CYP27A1	1. Sterol 26-hydroxylase, mitochondrial			4712	CHEMBL1200810	4444554	Drugs.com Drug Page			C08211	D01009	V2H	PDRhealth Drug Page		46705423	347827769	RxList Drug Page	11516		Doxercalciferol	ZINC000004641374	Hectorol	Doxercalciferol	Approved	DB06410	InChI=1S/C28H44O2/c1-18(2)19(3)9-10-20(4)25-13-14-26-22(8-7-15-28(25,26)6)11-12-23-16-24(29)17-27(30)21(23)5/h9-12,18-20,24-27,29-30H,5,7-8,13-17H2,1-4,6H3/b10-9+,22-11+,23-12-/t19-,20+,24+,25+,26-,27-,28+/m0/s1	HKXBNHCUPKIYDM-CGMHZMFXSA-N	4	Doxercalciferol is a synthetic vitamin D2 analog used to treat secondary hyperparathyroidism in patients with chronic kidney disease with or without therapy of dialysis.	Not Available	Small Molecule																																		Relatively insoluble	1	No	2	2	No	3	0	40.46 Å2	51.58 Å3	130.36 m3·mol-1	5	No	No	0.00168 mg/mL	5.75	-5.4	14.39	-2.8	P11473	VDR	1. Vitamin D3 receptor
C21H32O3	Not Available	Not Available	332.484	[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)\C(C[C@]12C)=C/O	Solid	Not Available	P21397;!P10635;!P18405;!P08684;!P20815;!P24462;!Q9HB55	MAOA;!CYP2D6;!SRD5A1;!CYP3A4;!CYP3A5;!CYP3A7;!CYP3A43	1. Amine oxidase [flavin-containing] A;!2. Cytochrome P450 2D6;!3. 3-oxo-5-alpha-steroid 4-dehydrogenase 1;!4. Cytochrome P450 3A4;!5. Cytochrome P450 3A5;!6. Cytochrome P450 3A7;!7. Cytochrome P450 3A43			7864	CHEMBL1200585	4444502	Drugs.com Drug Page			C07393	D00490				5281034	310264869	RxList Drug Page	7813		Oxymetholone	ZINC000118912450	Anadrol-50	Oxymetholone	Approved, Illicit	DB06412	InChI=1S/C21H32O3/c1-19-11-13(12-22)18(23)10-14(19)4-5-15-16(19)6-8-20(2)17(15)7-9-21(20,3)24/h12,14-17,22,24H,4-11H2,1-3H3/b13-12-/t14-,15+,16-,17-,19-,20-,21-/m0/s1	ICMWWNHDUZJFDW-DHODBPELSA-N		Oxymetholone is an anabolic steroid used for the treatment of types of anemia, such as acquired aplastic anemia, congenital aplastic anemia, myelofibrosis, and the hypoplastic anemias.	May cause cancer.The uncontrolled misuse of oxymetholone can lead to a large variety of detrimental effects, the most often reported of which are cardiovascular events.	Small Molecule																																178°C to 180°C		5.21 mg/L	1	Yes	3	2	No	4	0	57.53 Å2	38.84 Å3	94.6 m3·mol-1	0	Yes	No	0.0349 mg/mL	3.55	-4	8.87	-0.53	P10275;!P16860	AR;!NPPB	1. Androgen receptor;!2. Natriuretic peptides B
C25H38O3	Not Available	Not Available	386.576	CCCCCCC(C)(C)C1=CC(O)=C2[C@H]3CC(CO)=CC[C@@H]3C(C)(C)OC2=C1	Solid	Not Available					50067498		CHEMBL334533	96934									107778	347827772				Dexanabinol	ZINC000003799010		Dexanabinol	Investigational	DB06444	InChI=1S/C25H38O3/c1-6-7-8-9-12-24(2,3)18-14-21(27)23-19-13-17(16-26)10-11-20(19)25(4,5)28-22(23)15-18/h10,14-15,19-20,26-27H,6-9,11-13,16H2,1-5H3/t19-,20-/m0/s1	SSQJFGMEZBFMNV-PMACEKPBSA-N	3		Not Available	Small Molecule																																			1	No	3	2	Yes	3	0	49.69 Å2	47.4 Å3	116.73 m3·mol-1	7	No	No	0.00148 mg/mL	6.14	-5.4	9.98	-2.7	P01375	TNF	1. Tumor necrosis factor
C36H56O6	Not Available	56.3 to 69.5 hours	584.8262	[H][C@]12[C@@H](CC[C@@]1(CC[C@]1(C)[C@]2([H])CC[C@]2([H])[C@@]3(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@]3([H])CC[C@@]12C)C(O)=O)C(C)=C	Solid	Not Available					50050955	65484	CHEMBL404519	403003									457928	175427073				Bevirimat	ZINC000003936686		Bevirimat	Investigational	DB06581	InChI=1S/C36H56O6/c1-21(2)22-12-17-36(30(40)41)19-18-34(8)23(28(22)36)10-11-25-33(7)15-14-26(42-27(37)20-31(3,4)29(38)39)32(5,6)24(33)13-16-35(25,34)9/h22-26,28H,1,10-20H2,2-9H3,(H,38,39)(H,40,41)/t22-,23+,24-,25+,26-,28+,33-,34+,35+,36-/m0/s1	YJEJKUQEXFSVCJ-WRFMNRASSA-N	2		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	3.5488 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	5	2	Yes	5	-2	100.9 Å2	67.97 Å3	161.75 m3·mol-1	7	No	No	0.000135 mg/mL	8	-6.6	4.16	-7.1	P04585	gag-pol	1. Gag-Pol polyprotein
C19H30O3	Not Available	Not Available	306.446	[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@H](O)C[C@@]2([H])C[C@@H](O)CC[C@]12C	Solid	Not Available								8011902															ZINC000006067655		7-beta-Hydroxyepiandrosterone	Investigational	DB06622	InChI=1S/C19H30O3/c1-18-7-5-12(20)9-11(18)10-15(21)17-13-3-4-16(22)19(13,2)8-6-14(17)18/h11-15,17,20-21H,3-10H2,1-2H3/t11-,12+,13+,14+,15+,17+,18+,19+/m1/s1	VFPMCLQMAUVEHD-UCPSWNCLSA-N	2		Not Available	Small Molecule																																			1	Yes	3	2	No	4	0	57.53 Å2	35.56 Å3	85.4 m3·mol-1	0	Yes	No	0.102 mg/mL	2.46	-3.5	18.3	-0.51			
C28H35NO4	Not Available	Not Available	449.5818	[H]\C(=N/O)C1=CC=C(C=C1)[C@@]1([H])C[C@@]2(C)[C@@]([H])(CC[C@]2(COC)OC)[C@]2([H])CCC3=CC(=O)CCC3=C12	Solid	Not Available							CHEMBL267431	7851660						AS0								Asoprisnil	ZINC000003936191		Asoprisnil	Investigational	DB06680	InChI=1S/C28H35NO4/c1-27-15-24(19-6-4-18(5-7-19)16-29-31)26-22-11-9-21(30)14-20(22)8-10-23(26)25(27)12-13-28(27,33-3)17-32-2/h4-7,14,16,23-25,31H,8-13,15,17H2,1-3H3/b29-16+/t23-,24+,25-,27-,28+/m0/s1	GJMNAFGEUJBOCE-MEQIQULJSA-N	3		Not Available	Small Molecule																																			1	No	5	1	No	5	-1	68.12 Å2	51.46 Å3	131.27 m3·mol-1	5	Yes	No	0.00211 mg/mL	4.28	-5.3	7.39	2.56	P06401	PGR	1. Progesterone receptor
C20H30O2	Not Available	6-8 hours	302.451	[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	Not Available	P20813;!P08684;!P11511	CYP2B6;!CYP3A4;!CYP19A1	1. Cytochrome P450 2B6;!2. Cytochrome P450 3A4;!3. Cytochrome P450 19A1		50410531	27436	CHEMBL1395	5788			HMDB0015655	C07198	D00408			PA165958383	6010	99443262		6904		Methyltestosterone	ZINC000003814422	Covaryx, Methitest	Methyltestosterone	Approved	DB06710	InChI=1S/C20H30O2/c1-18-9-6-14(21)12-13(18)4-5-15-16(18)7-10-19(2)17(15)8-11-20(19,3)22/h12,15-17,22H,4-11H2,1-3H3/t15-,16+,17+,18+,19+,20+/m1/s1	GCKMFJBGXUYNAG-HLXURNFRSA-N	2	Methyltestosterone is a synthetic anabolic steroid used for the replacement therapy in conditions associated with testosterone deficiencies in males, such as hypogonadism, and treatment of advancing inoperable metastatic breast cancer in females.	Side effects include amnesia, anxiety, discolored hair, dizziness, dry skin, hirsutism, hostility, impaired urination, paresthesia, penis disorder, peripheral edema, sweating, and vasodilation.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.0516 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.36		163 °C		33.9 mg/L (at 25 °C)	1	Yes	2	1	No	4	0	37.3 Å2	35.85 Å3	89.07 m3·mol-1	0	Yes	Yes	0.0139 mg/mL	3.65	-4.3	18.52	-0.53	P10275;!P03372	AR;!ESR1	1. Androgen receptor;!2. Estrogen receptor alpha
C21H26O2	Not Available	16 to 18 hrs.	310.4299	CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1C=C[C@@]2(O)C#C	Solid	Not Available	P08684;!P33261;!P20815;!P24462	CYP3A4;!CYP2C19;!CYP3A5;!CYP3A7	1. Cytochrome P450 3A4;!2. Cytochrome P450 2C19;!3. Cytochrome P450 3A5;!4. Cytochrome P450 3A7			135323	CHEMBL1213583	2298532			HMDB0015668					PA165958397	3033968	99443276		25734		Gestodene	ZINC000238809420		Gestodene	Investigational	DB06730	InChI=1S/C21H26O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,10,12-13,16-19,23H,3,5-9,11H2,1H3/t16-,17+,18+,19-,20-,21-/m0/s1	SIGSPDASOTUPFS-XUDSTZEESA-N	4		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.7480 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							197.9 °C			1	Yes	2	1	No	4	0	37.3 Å2	35.96 Å3	92.99 m3·mol-1	1	Yes	Yes	0.00581 mg/mL	3.46	-4.7	17.08	-1.9	P06401	PGR	1. Progesterone receptor
C20H24O3	Not Available	Not Available	312.409	CC(C)(C)C1CCC(CC1)C1=C(O)C(=O)C2=CC=CC=C2C1=O	Solid	Not Available								13749867									146797	347827788					ZINC000005114256		BW-A 58C	Experimental	DB06740	InChI=1S/C20H24O3/c1-20(2,3)13-10-8-12(9-11-13)16-17(21)14-6-4-5-7-15(14)18(22)19(16)23/h4-7,12-13,23H,8-11H2,1-3H3	NWCVRXADYNRXCT-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	Yes	3	1	No	3	-1	54.37 Å2	35.62 Å3	91.83 m3·mol-1	2	Yes	No	0.0115 mg/mL	4.29	-4.4	5.95	-5.1			
C20H24O9	Not Available	Not Available	408.3992	C[C@@H]1C(=O)O[C@H]2C[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O	Solid	Not Available					50292287	5355	CHEMBL465161	21468875									9909368	99443279					ZINC000004245650		Ginkgolide A	Nutraceutical	DB06743	InChI=1S/C20H24O9/c1-7-12(22)26-10-6-17-9-5-8(16(2,3)4)18(17)11(21)13(23)28-15(18)29-20(17,14(24)27-9)19(7,10)25/h7-11,15,21,25H,5-6H2,1-4H3/t7-,8+,9-,10+,11+,15+,17-,18+,19-,20-/m1/s1	FPUXKXIZEIDQKW-VKMVSBOZSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.8802 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	6	2	No	6	0	128.59 Å2	38.24 Å3	90.17 m3·mol-1	1	Yes	No	3.05 mg/mL	0.34	-2.1	11.77	-4.1			
C20H24O10	Not Available	Not Available	424.3986	C[C@@H]1C(=O)O[C@H]2[C@H](O)[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O	Solid	Not Available					50251276		CHEMBL514432	21105603									6324617	99443280					ZINC000008552017		ginkgolide-B	Nutraceutical	DB06744	InChI=1S/C20H24O10/c1-6-12(23)28-11-9(21)18-8-5-7(16(2,3)4)17(18)10(22)13(24)29-15(17)30-20(18,14(25)27-8)19(6,11)26/h6-11,15,21-22,26H,5H2,1-4H3/t6-,7+,8-,9+,10+,11+,15+,17+,18+,19-,20-/m1/s1	SQOJOAFXDQDRGF-MMQTXUMRSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.4970 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	3	No	6	0	148.82 Å2	39.09 Å3	91.38 m3·mol-1	1	Yes	No	5.21 mg/mL	-0.58	-1.9	11.71	-3.5			
C20H24O11	Not Available	Not Available	440.398	C[C@@H]1C(=O)O[C@H]2[C@H](O)[C@]34[C@@H]5OC(=O)[C@]3(O[C@@H]3OC(=O)[C@H](O)[C@]43[C@@H]([C@H]5O)C(C)(C)C)[C@@]12O	Solid	Not Available								26330340									9867869	99443281					ZINC000028536264		ginkgolide-C	Nutraceutical	DB06745	InChI=1S/C20H24O11/c1-5-12(24)28-11-8(22)18-10-6(21)7(16(2,3)4)17(18)9(23)13(25)30-15(17)31-20(18,14(26)29-10)19(5,11)27/h5-11,15,21-23,27H,1-4H3/t5-,6-,7+,8+,9+,10-,11+,15+,17+,18-,19-,20-/m1/s1	AMOGMTLMADGEOQ-DTDWCABLSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.0556 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	8	4	No	6	0	169.05 Å2	39.81 Å3	92.67 m3·mol-1	1	Yes	No	8.99 mg/mL	-1.6	-1.7	11.7	-3.3			
C20H24O10	Not Available	Not Available	424.3986	C[C@@H]1C(=O)O[C@H]2C[C@]34[C@@H]5OC(=O)[C@]3(O[C@@H]3OC(=O)[C@H](O)[C@]43[C@@H]([C@H]5O)C(C)(C)C)[C@@]12O	Solid	Not Available								26330341									11154476	99443282					ZINC000008552018		ginkgolide-J	Nutraceutical	DB06746	InChI=1S/C20H24O10/c1-6-12(23)27-7-5-17-11-8(21)9(16(2,3)4)18(17)10(22)13(24)29-15(18)30-20(17,14(25)28-11)19(6,7)26/h6-11,15,21-22,26H,5H2,1-4H3/t6-,7+,8-,9+,10+,11-,15+,17-,18+,19-,20-/m1/s1	LMEHVEUFNRJAAV-UKWFQYJJSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.5802 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	3	No	6	0	148.82 Å2	39.01 Å3	91.46 m3·mol-1	1	Yes	No	6.96 mg/mL	-0.66	-1.8	11.76	-3.3			
C42H72O14	Not Available	Not Available	801.024	CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3[C@H](C[C@@]21C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O	Solid	Not Available						67987	CHEMBL501637	390498				C08946					441923	99443286				Ginsenoside_Rg1	ZINC000238809655		Ginsenoside Rg1	Nutraceutical	DB06750	InChI=1S/C42H72O14/c1-20(2)10-9-13-42(8,56-37-34(52)32(50)30(48)25(19-44)55-37)21-11-15-40(6)28(21)22(45)16-26-39(5)14-12-27(46)38(3,4)35(39)23(17-41(26,40)7)53-36-33(51)31(49)29(47)24(18-43)54-36/h10,21-37,43-52H,9,11-19H2,1-8H3/t21-,22+,23-,24+,25+,26+,27-,28-,29+,30+,31-,32-,33+,34+,35-,36+,37-,39+,40+,41+,42-/m0/s1	YURJSTAIMNSZAE-HHNZYBFYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	4.0254 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										0	No	14	10	Yes	6	0	239.22 Å2	88.31 Å3	203.66 m3·mol-1	10	No	No	0.304 mg/mL	0.68	-3.4	11.91	-3	Q9NPD5	SLCO1B3	1. Solute carrier organic anion transporter family member 1B3
C24H40O4	Not Available	Not Available	392.572	[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O	Solid	Not Available	Q02318;!P08684;!P16662	CYP27A1;!CYP3A4;!UGT2B7	1. Sterol 26-hydroxylase, mitochondrial;!2. Cytochrome P450 3A4;!3. UDP-glucuronosyltransferase 2B7		21674	16755	CHEMBL240597	9728	Drugs.com Drug Page		HMDB0000518	C02528	D00163	JN3		PA165958403	10133	99443291		2323		Chenodeoxycholic_acid	ZINC000003914808	Chenodal	Chenodeoxycholic acid	Approved	DB06777	InChI=1S/C24H40O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15+,16-,17-,18+,19+,20-,22+,23+,24-/m1/s1	RUDATBOHQWOJDD-BSWAIDMHSA-N	4	Chenodeoxycholic acid is a bile acid used for the treatment of primary biliary cirrhosis.	Hepatotoxic.	Small Molecule	http://smpdb.ca/view/SMP0000316?highlight[compounds][]=DB06777&highlight[proteins][]=DB06777;!http://smpdb.ca/view/SMP0000314?highlight[compounds][]=DB06777&highlight[proteins][]=DB06777;!http://smpdb.ca/view/SMP0000720?highlight[compounds][]=DB06777&highlight[proteins][]=DB06777;!http://smpdb.ca/view/SMP0000035?highlight[compounds][]=DB06777&highlight[proteins][]=DB06777;!http://smpdb.ca/view/SMP0000315?highlight[compounds][]=DB06777&highlight[proteins][]=DB06777;!http://smpdb.ca/view/SMP0000317?highlight[compounds][]=DB06777&highlight[proteins][]=DB06777;!http://smpdb.ca/view/SMP0000318?highlight[compounds][]=DB06777&highlight[proteins][]=DB06777	Zellweger Syndrome;!Congenital Bile Acid Synthesis Defect Type II;!27-Hydroxylase Deficiency;!Bile Acid Biosynthesis;!Cerebrotendinous Xanthomatosis (CTX);!Familial Hypercholanemia (FHCA);!Congenital Bile Acid Synthesis Defect Type III		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	2.5624 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					4.15		168-171		89.9 mg/L (at 20 °C)	1	Yes	4	3	No	4	-1	77.76 Å2	46.35 Å3	109.27 m3·mol-1	4	Yes	No	0.0197 mg/mL	3.71	-4.3	4.6	-0.54			
C23H32O4	Not Available	Not Available	372.505	[H][C@@]12CC[C@H](C(=O)COC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			34671	CHEMBL1200542	5737				C14554	D03698							258333		Desoxycorticosterone_acetate	ZINC000004428527		Desoxycorticosterone acetate	Approved	DB06780	InChI=1S/C23H32O4/c1-14(24)27-13-21(26)20-7-6-18-17-5-4-15-12-16(25)8-10-22(15,2)19(17)9-11-23(18,20)3/h12,17-20H,4-11,13H2,1-3H3/t17-,18-,19-,20+,22-,23-/m0/s1	VPGRYOFKCNULNK-ACXQXYJUSA-N			Not Available	Small Molecule																																			1	Yes	3	0	No	4	0	60.44 Å2	42.13 Å3	103.56 m3·mol-1	4	Yes	No	0.00502 mg/mL	3.77	-4.9	17.17	-4.8	P08235	NR3C2	1. Mineralocorticoid receptor
C27H34F2O7	Not Available	Not Available	508.5515	[H][C@@]12CC[C@](OC(=O)CCC)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			31485	CHEMBL1201749	391990	Drugs.com Drug Page		HMDB0061149	C12695	D01266		PDRhealth Drug Page	PA165958405	443936	99443292	RxList Drug Page	23043		Difluprednate	ZINC000004212945	Durezol	Difluprednate	Approved	DB06781	InChI=1S/C27H34F2O7/c1-5-6-23(34)36-26(22(33)14-35-15(2)30)10-8-17-18-12-20(28)19-11-16(31)7-9-24(19,3)27(18,29)21(32)13-25(17,26)4/h7,9,11,17-18,20-21,32H,5-6,8,10,12-14H2,1-4H3/t17-,18-,20-,21-,24-,25-,26-,27-/m0/s1	WYQPLTPSGFELIB-JTQPXKBDSA-N	4	Difluprednate is a topical corticosteroid used for the symptomatic treatment of inflammation and pain associated with ocular surgery.	Preclinical pharmacokinetic and toxicity studies have established that difluprednate ophthalmic emulsion 0.05% given 4 times a day is not toxic to the eye.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.1368 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							191-194			1	No	5	1	Yes	4	0	106.97 Å2	51.45 Å3	125.38 m3·mol-1	8	No	No	0.0097 mg/mL	3	-4.7	13.6	-3.4	P04150	NR3C1	1. Glucocorticoid receptor
C24H32ClFO5	Not Available	Not Available	454.96	[H][C@@]12C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Liquid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4		50240097	31663	CHEMBL1200845	391997	Drugs.com Drug Page				D01308		PDRhealth Drug Page		443943	347827796	RxList Drug Page	5084		Halcinonide	ZINC000004213474	Halog	Halcinonide	Approved, Investigational, Withdrawn	DB06786	InChI=1S/C24H32ClFO5/c1-20(2)30-19-10-16-15-6-5-13-9-14(27)7-8-21(13,3)23(15,26)17(28)11-22(16,4)24(19,31-20)18(29)12-25/h9,15-17,19,28H,5-8,10-12H2,1-4H3/t15-,16-,17-,19+,21-,22-,23-,24+/m0/s1	MUQNGPZZQDCDFT-JNQJZLCISA-N		Halcinonide is a corticosteroid used for the management and symptomatic relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.	Systemic absorption of topical corticosteroids has produced reversible hypothalamicpituitary-adrenal (HPA) axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria in some patients. Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings.	Small Molecule																																276-277			1	Yes	5	1	No	5	0	72.83 Å2	46.61 Å3	113.55 m3·mol-1	2	Yes	No	0.0112 mg/mL	3.3	-4.6	13.63	-3.4	Q99835	SMO	1. Smoothened homolog
C27H40O4	Clearance is highly variable from patient to patient. (3)	Half-life = 16 days (±6 days). (3)	428.6041	[H][C@@]12CC[C@](OC(=O)CCCCC)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	Hydroxyprogesterone caproate has a high volume of distribution. (3)	P08684;!P20815;!P33261	CYP3A4;!CYP3A5;!CYP2C19	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5;!3. Cytochrome P450 2C19		70293	5812	CHEMBL1200848	148552	Drugs.com Drug Page			C08148	D00949		PDRhealth Drug Page		169870	310264886	RxList Drug Page	12488		Hydroxyprogesterone_caproate	ZINC000004083606	Makena	Hydroxyprogesterone caproate	Approved, Investigational	DB06789	InChI=1S/C27H40O4/c1-5-6-7-8-24(30)31-27(18(2)28)16-13-23-21-10-9-19-17-20(29)11-14-25(19,3)22(21)12-15-26(23,27)4/h17,21-23H,5-16H2,1-4H3/t21-,22+,23+,25+,26+,27+/m1/s1	DOMWKUIIPQCAJU-LJHIYBGHSA-N	4	Hydroxyprogesterone caproate is a synthetic progestin used for the prevention of spontaneous preterm births in singleton pregnancies in women who have previously had a spontaneous preterm birth.	Injection site pain is the most common adverse effect associated with hydroxyprogesterone caproate. Other commonly reported adverse effects include: injection site swelling, urticaria, pruritus, injection site pruritus, nausea, injection site nodule, and diarrhea. (4)	Small Molecule																																119-121			1	No	3	0	Yes	4	0	60.44 Å2	50.28 Å3	121.69 m3·mol-1	7	No	No	0.000866 mg/mL	5.88	-5.7	17.75	-4.8	P06401	PGR	1. Progesterone receptor
C21H28O2	Not Available	Not Available	312.4458	[H][C@@]12CC[C@@](O)(CC)[C@@]1(CC)C=CC1=C3CCC(=O)C=C3CC[C@@]21[H]	Solid	Not Available								5257020			HMDB0004626			17H			6857686	99443341				Tetrahydrogestrinone	ZINC000012496366		Tetrahydrogestrinone	Experimental	DB06870	InChI=1S/C21H28O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h9,11,13,18-19,23H,3-8,10,12H2,1-2H3/t18-,19+,20+,21+/m1/s1	OXHNQTSIKGHVBH-ANULTFPQSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.6006 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	1	No	4	0	37.3 Å2	37.03 Å3	95.42 m3·mol-1	2	Yes	Yes	0.0199 mg/mL	3.5	-4.2	18.4	-0.14	P10275	AR	1. Androgen receptor
C19H24O2	Not Available	Not Available	284.3927	[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	Not Available					91718	40799	CHEMBL1078534	12893			HMDB0003422			ANB			13472	99443844				Boldione	ZINC000003881421		Boldione	Experimental	DB07373	InChI=1S/C19H24O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h7,9,11,14-16H,3-6,8,10H2,1-2H3/t14-,15-,16-,18-,19-/m0/s1	LUJVUUWNAPIQQI-QAGGRKNESA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.5360 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	0	No	4	0	34.14 Å2	32.45 Å3	84.7 m3·mol-1	0	Yes	Yes	0.0169 mg/mL	3.93	-4.2	18.39	-5	P71278	onr	1. Pentaerythritol tetranitrate reductase
C19H30O2	Not Available	Not Available	290.4403	[H][C@]1(O)CC[C@@]2([H])[C@]3([H])CC[C@]4([H])CC(=O)CC[C@]4(C)[C@@]3([H])CC[C@]12C	Solid	Not Available					50410540	2150	CHEMBL373357	10827			HMDB0006770	C05293		BDT			11302	99443918					ZINC000003814418		5beta-dihydrotestosterone	Experimental	DB07447	InChI=1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12,14-17,21H,3-11H2,1-2H3/t12-,14+,15+,16+,17+,18+,19+/m1/s1	NVKAWKQGWWIWPM-MISPCMORSA-N			Not Available	Small Molecule	http://smpdb.ca/view/SMP0000356?highlight[compounds][]=DB07447&highlight[proteins][]=DB07447;!http://smpdb.ca/view/SMP0000068?highlight[compounds][]=DB07447&highlight[proteins][]=DB07447;!http://smpdb.ca/view/SMP0000565?highlight[compounds][]=DB07447&highlight[proteins][]=DB07447	17-beta Hydroxysteroid Dehydrogenase III Deficiency;!Androgen and Estrogen Metabolism;!Aromatase Deficiency		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.9757 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	1	No	4	0	37.3 Å2	34.62 Å3	83.6 m3·mol-1	0	Yes	Yes	0.00998 mg/mL	3.41	-4.5	19.38	-0.88	P51857	AKR1D1	1. 3-oxo-5-beta-steroid 4-dehydrogenase
C24H32F6O3	Not Available	Not Available	482.4995	[H][C@]1(CC[C@](C)(CCC#CC(O)(C(F)(F)F)C(F)(F)F)C1(C)C)\C=C\C=C1C[C@](O)([H])C[C@@](O)([H])C1	Solid	Not Available								8633358						C5D			10457944	99444001					ZINC000038911928		(1R,3R)-5-[(2E)-3-{(1S,3R)-2,2,3-trimethyl-3-[6,6,6-trifluoro-5-hydroxy-5-(trifluoromethyl)hex-3-yn-1-yl]cyclopentyl}prop-2-en-1-ylidene]cyclohexane-1,3-diol	Experimental	DB07530	InChI=1S/C24H32F6O3/c1-20(2)17(8-6-7-16-13-18(31)15-19(32)14-16)9-12-21(20,3)10-4-5-11-22(33,23(25,26)27)24(28,29)30/h6-8,17-19,31-33H,4,9-10,12-15H2,1-3H3/b8-6+/t17-,18-,19-,21+/m1/s1	PCHUQQNKOFNVDU-OSXMSNBXSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	3.8675 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	3	3	No	2	-1	60.69 Å2	45.59 Å3	115.82 m3·mol-1	8	Yes	No	0.00107 mg/mL	4.98	-5.6	6.43	-2.7	Q15788;!P11473	NCOA1;!VDR	1. Nuclear receptor coactivator 1;!2. Vitamin D3 receptor
C22H30O2	Not Available	Not Available	326.4724	[H]\C(CC)=C(/[H])C1=C(O)C=C2CC[C@@]3([H])[C@]4([H])CC[C@]([H])(O)[C@@]4(C)CC[C@]3([H])C2=C1	Solid	Not Available								26326672						DRQ			42627296	99444149					ZINC000031861332		(9ALPHA,13BETA,17BETA)-2-[(1Z)-BUT-1-EN-1-YL]ESTRA-1,3,5(10)-TRIENE-3,17-DIOL	Experimental	DB07678	InChI=1S/C22H30O2/c1-3-4-5-15-12-18-14(13-20(15)23)6-7-17-16(18)10-11-22(2)19(17)8-9-21(22)24/h4-5,12-13,16-17,19,21,23-24H,3,6-11H2,1-2H3/b5-4-/t16-,17+,19-,21-,22-/m0/s1	ANAMDWGJXBYJEB-OPWFCKQNSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.2449 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	2	2	No	4	0	40.46 Å2	39.6 Å3	99.87 m3·mol-1	2	No	No	0.00126 mg/mL	5.31	-5.4	9.67	-0.88	P03372;!Q15596	ESR1;!NCOA2	1. Estrogen receptor alpha;!2. Nuclear receptor coactivator 2
C18H24O3	Not Available	Not Available	288.3814	[H][C@@]12C[C@@H](O)[C@@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	Solid	Not Available						42156	CHEMBL1232445	225189						E3O			256737	99444173					ZINC000003881360		17alpha-Estriol	Experimental	DB07702	InChI=1S/C18H24O3/c1-18-7-6-13-12-5-3-11(19)8-10(12)2-4-14(13)15(18)9-16(20)17(18)21/h3,5,8,13-17,19-21H,2,4,6-7,9H2,1H3/t13-,14-,15+,16-,17-,18+/m1/s1	PROQIPRRNZUXQM-PNVOZDDCSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.9758 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	3	3	No	4	0	60.69 Å2	32.95 Å3	81.27 m3·mol-1	0	Yes	No	0.119 mg/mL	2.67	-3.4	10.33	-3.2	Q9HCD5;!Q92731	NCOA5;!ESR2	1. Nuclear receptor coactivator 5;!2. Estrogen receptor beta
C18H24O3	Not Available	Not Available	288.3814	[H][C@]1(O)CC[C@@]2([H])[C@]3([H])CCC4=C(C=C(O)C(O)=C4)[C@@]3([H])CC[C@]12C	Solid	Not Available					50262140	28744	CHEMBL467987	216475			HMDB0000338	C05301		ECS			247304	99444177				2-Hydroxyestradiol	ZINC000003815419		2-Hydroxyestradiol	Experimental	DB07706	InChI=1S/C18H24O3/c1-18-7-6-11-12(14(18)4-5-17(18)21)3-2-10-8-15(19)16(20)9-13(10)11/h8-9,11-12,14,17,19-21H,2-7H2,1H3/t11-,12+,14-,17-,18-/m0/s1	DILDHNKDVHLEQB-XSSYPUMDSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.9758 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	3	3	No	4	0	60.69 Å2	33.08 Å3	81.89 m3·mol-1	0	Yes	No	0.0511 mg/mL	3.44	-3.8	9.67	-0.88	O32393	cyaC	1. Adenylate cyclase
C20H28O3	Not Available	Not Available	316.4345	[H][C@]1(O)CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])[C@@]([H])(COC)C[C@]12C	Solid	Not Available								21169213						EED			23728517	99444178					ZINC000013610524		(9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOL	Experimental	DB07707	InChI=1S/C20H28O3/c1-20-10-13(11-23-2)19-15-6-4-14(21)9-12(15)3-5-16(19)17(20)7-8-18(20)22/h4,6,9,13,16-19,21-22H,3,5,7-8,10-11H2,1-2H3/t13-,16+,17+,18+,19-,20+/m1/s1	LEOPSILMAOYZBO-IUTAEKPZSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.0746 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	3	2	No	4	0	49.69 Å2	36.6 Å3	91.06 m3·mol-1	2	Yes	No	0.00706 mg/mL	3.32	-4.6	10.31	-0.89	P03372;!Q15596	ESR1;!NCOA2	1. Estrogen receptor alpha;!2. Nuclear receptor coactivator 2
C27H36F2O3	Not Available	Not Available	446.5697	[H][C@]1(O)CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])CC(=O)CC[C@]4(C)[C@@]3([H])CC[C@]12CCOCC1=CC(F)=CC(F)=C1	Solid	Not Available							CHEMBL485835	20581191						ENM			16750073	99444188					ZINC000016052389		(5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE	Experimental	DB07717	InChI=1S/C27H36F2O3/c1-26-8-6-21(30)14-18(26)2-3-22-23(26)7-9-27(24(22)4-5-25(27)31)10-11-32-16-17-12-19(28)15-20(29)13-17/h12-13,15,18,22-25,31H,2-11,14,16H2,1H3/t18-,22+,23-,24-,25-,26-,27+/m0/s1	AJODXHGZHBERGJ-JLYQOUBASA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.5253 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	3	1	No	5	0	46.53 Å2	48.83 Å3	119.93 m3·mol-1	5	No	No	0.00155 mg/mL	5.07	-5.5	14.69	-2.9	P10275	AR	1. Androgen receptor
C19H28O2	Not Available	Not Available	288.4244	[H][C@@]1(O)CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)CC[C@]4(C)[C@@]3([H])CC[C@]12C	Solid	Not Available					50410492	42534	CHEMBL196228	9789			HMDB0000628			FFA			10204	99444239				Epitestosterone	ZINC000004538008		Epitestosterone	Experimental	DB07768	InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-17,21H,3-10H2,1-2H3/t14-,15-,16-,17+,18-,19-/m0/s1	MUMGGOZAMZWBJJ-KZYORJDKSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.6259 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	1	No	4	0	37.3 Å2	33.93 Å3	84.43 m3·mol-1	0	Yes	Yes	0.0333 mg/mL	3.37	-3.9	18.52	-0.88	Q04828;!P52895	AKR1C1;!AKR1C2	1. Aldo-keto reductase family 1 member C1;!2. Aldo-keto reductase family 1 member C2
C19H22O6	Not Available	Not Available	346.3744	[H][C@@]12CC[C@]3(O)C[C@]1(CC3=C)[C@@H](C(O)=O)[C@]1([H])[C@@]3(C)[C@@H](O)C=C[C@@]21OC3=O	Solid	Not Available						28833	CHEMBL1232952	6223			HMDB0003559	C01699		GA3			439551	99444285				Gibberellic_acid	ZINC000003860467		Gibberellic acid	Experimental	DB07814	InChI=1S/C19H22O6/c1-9-7-17-8-18(9,24)5-3-10(17)19-6-4-11(20)16(2,15(23)25-19)13(19)12(17)14(21)22/h4,6,10-13,20,24H,1,3,5,7-8H2,2H3,(H,21,22)/t10-,11+,12-,13-,16-,17+,18+,19-/m1/s1	IXORZMNAPKEEDV-OBDJNFEBSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.7712 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	3	No	5	-1	104.06 Å2	23.92 Å3	86.42 m3·mol-1	1	Yes	No	1.95 mg/mL	0.35	-2.2	4.16	-0.9	Q6P093	AADACL2	1. Arylacetamide deacetylase-like 2
C19H24O5	Not Available	Not Available	332.3909	[H][C@@]12C[C@]3(CC1=C)[C@@H](C(O)=O)[C@]1([H])[C@@]4(C)[C@@H](O)CC[C@@]1(OC4=O)[C@]3([H])CC2	Solid	Not Available						32902		10222155				C11864		GA4			92109	99444286					ZINC000004102247		Gibberellin A4	Experimental	DB07815	InChI=1S/C19H24O5/c1-9-7-18-8-10(9)3-4-11(18)19-6-5-12(20)17(2,16(23)24-19)14(19)13(18)15(21)22/h10-14,20H,1,3-8H2,2H3,(H,21,22)/t10-,11-,12+,13-,14-,17-,18+,19-/m1/s1	RSQSQJNRHICNNH-NFMPGMCNSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.2992 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	2	No	5	-1	83.83 Å2	34.58 Å3	84.08 m3·mol-1	1	Yes	No	1.19 mg/mL	1.56	-2.4	4.29	-3	Q6P093	AADACL2	1. Arylacetamide deacetylase-like 2
C22H28O5	Not Available	Not Available	372.4547	[H][C@@]12CC[C@H](OC(=O)CCC(O)=O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3CC[C@@]21[H]	Solid	Not Available							CHEMBL1233274	59813						HE7			66440	99444362				Estradiol_hemisuccinate	ZINC000004026838		Estradiol hemisuccinate	Experimental	DB07891	InChI=1S/C22H28O5/c1-22-11-10-16-15-5-3-14(23)12-13(15)2-4-17(16)18(22)6-7-19(22)27-21(26)9-8-20(24)25/h3,5,12,16-19,23H,2,4,6-11H2,1H3,(H,24,25)/t16-,17-,18+,19+,22+/m1/s1	YJPIDPAGJSWWBE-FNIAAEIWSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3962 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	2	No	4	-1	83.83 Å2	41.88 Å3	99.95 m3·mol-1	5	Yes	No	0.0048 mg/mL	4.01	-4.9	4.31	-5.4			
C23H24O8	Not Available	Not Available	428.4319	[H][C@@]12CCC(=O)[C@@]1(C)C[C@@H](OC(C)=O)C1=C2C(=O)C2=C3C(=CO2)C(=O)O[C@H](COC)[C@]13C	Solid	Not Available					15234	52289	CHEMBL428496	276037				C15181		KWT			312145	99444530				Wortmannin	ZINC000001619592		Wortmannin	Experimental	DB08059	InChI=1S/C23H24O8/c1-10(24)30-13-7-22(2)12(5-6-14(22)25)16-18(13)23(3)15(9-28-4)31-21(27)11-8-29-20(17(11)23)19(16)26/h8,12-13,15H,5-7,9H2,1-4H3/t12-,13+,15+,22-,23-/m0/s1	QDLHCMPXEPAAMD-QAIWCSMKSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	4.0908 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	0	No	5	0	109.11 Å2	42.98 Å3	106.86 m3·mol-1	4	Yes	No	0.121 mg/mL	1.44	-3.6		-3.2			
C27H32O4	Not Available	Not Available	420.5406	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC=C4C=C(CC[C@]4(C)[C@@]3([H])CC[C@]12C)C(O)=O)C(=O)C1=CC=C(O)C=C1	Solid	Not Available								8020773						MUF			9845059	99444691					ZINC000003803450		(8alpha,10alpha,13alpha,17beta)-17-[(4-hydroxyphenyl)carbonyl]androsta-3,5-diene-3-carboxylic acid	Experimental	DB08220	InChI=1S/C27H32O4/c1-26-13-11-17(25(30)31)15-18(26)5-8-20-21-9-10-23(27(21,2)14-12-22(20)26)24(29)16-3-6-19(28)7-4-16/h3-7,15,20-23,28H,8-14H2,1-2H3,(H,30,31)/t20-,21-,22-,23+,26-,27-/m0/s1	RPNNXCYIESWDSC-JRZBRKEGSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.6597 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	2	No	5	-1	74.6 Å2	47.84 Å3	121.45 m3·mol-1	3	No	No	0.00264 mg/mL	5.16	-5.2	4.35	-6.9	Q15788;!Q96RI1	NCOA1;!NR1H4	1. Nuclear receptor coactivator 1;!2. Bile acid receptor
C22H30O5	Not Available	Not Available	374.4706	[H][C@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)CC[C@]4([H])[C@@]3([H])CC[C@]12C)OC(=O)CCC(O)=O	Solid	Not Available								4451095						NTH			5289054	99444779					ZINC000033821445		SUCCINIC ACID MONO-(13-METHYL-3-OXO-2,3,6,7,8,9,10,11,12,13,14,15,16,17-TETRADECAHYDRO-1H-CYCLOPENTA[A]PHENANTHREN-17-YL) ESTER	Experimental	DB08308	InChI=1S/C22H30O5/c1-22-11-10-16-15-5-3-14(23)12-13(15)2-4-17(16)18(22)6-7-19(22)27-21(26)9-8-20(24)25/h12,15-19H,2-11H2,1H3,(H,24,25)/t15-,16+,17+,18-,19+,22-/m0/s1	IRQUJNVGEAJGSD-KIEDKLRZSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.0592 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	1	No	4	-1	80.67 Å2	41.7 Å3	100 m3·mol-1	5	Yes	No	0.0108 mg/mL	3.33	-4.5	4.31	-4.7	P00947	ksi	1. Steroid Delta-isomerase
C24H29NO7	Not Available	Not Available	443.4896	[H][C@]12C[C@]3([H])O[C@@]1(C)C[C@@]1(C2)CCC(=O)[C@@](C)(CCC(=O)NC2=C(O)C=CC(C(O)=O)=C2O)[C@]31[H]	Solid	Not Available								17245480						P9A			16086836	99444837					ZINC000035050252		3-({3-[(1S,4aS,6S,7S,9S,9aR)-1,6-dimethyl-2-oxodecahydro-6,9-epoxy-4a,7-methanobenzo[7]annulen-1-yl]propanoyl}amino)-2,4-dihydroxybenzoic acid	Experimental	DB08366	InChI=1S/C24H29NO7/c1-22(7-6-17(28)25-18-14(26)4-3-13(19(18)29)21(30)31)16(27)5-8-24-10-12-9-15(20(22)24)32-23(12,2)11-24/h3-4,12,15,20,26,29H,5-11H2,1-2H3,(H,25,28)(H,30,31)/t12-,15+,20+,22-,23+,24+/m1/s1	XADCWKSMHQPTGH-OFBLZTNGSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.9926 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	7	4	No	5	-1	133.16 Å2	44.69 Å3	115.72 m3·mol-1	5	Yes	No	0.0144 mg/mL	3.24	-4.5	2.96	-3.4	P0AAI5	fabF	1. 3-oxoacyl-[acyl-carrier-protein] synthase 2
C21H27FO4	Not Available	Not Available	362.4351	CC(C)OC1=CC=C(CC[C@]2(CC(O)=CC(=O)O2)C2CCCC2)C=C1F	Solid	Not Available								20153859						PFI			54688400	99444861					ZINC000100036690		(6S)-6-CYCLOPENTYL-6-[2-(3-FLUORO-4-ISOPROPOXYPHENYL)ETHYL]-4-HYDROXY-5,6-DIHYDRO-2H-PYRAN-2-ONE	Experimental	DB08390	InChI=1S/C21H27FO4/c1-14(2)25-19-8-7-15(11-18(19)22)9-10-21(16-5-3-4-6-16)13-17(23)12-20(24)26-21/h7-8,11-12,14,16,23H,3-6,9-10,13H2,1-2H3/t21-/m0/s1	AKNIHFDXRAOPAI-NRFANRHFSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	3.7796 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	1	Yes	3	0	55.76 Å2	39.1 Å3	98.52 m3·mol-1	6	Yes	No	0.00406 mg/mL	4.8	-5	8.32	-4.9	P26663	Not Available	1. Genome polyprotein
C24H27NO7	Not Available	Not Available	441.4737	[H][C@]12C[C@@H]3O[C@@]1(C)C[C@@]1(C2)C=CC(=O)[C@@](C)(CCC(=O)NC2=C(O)C(=CC=C2O)C(O)=O)[C@]31[H]	Solid	Not Available						68236	CHEMBL411278	5257055						PMN			6857724	99444878				Platensimycin	ZINC000029050726		Platensimycin	Experimental	DB08407	InChI=1S/C24H27NO7/c1-22(7-6-17(28)25-18-14(26)4-3-13(19(18)29)21(30)31)16(27)5-8-24-10-12-9-15(20(22)24)32-23(12,2)11-24/h3-5,8,12,15,20,26,29H,6-7,9-11H2,1-2H3,(H,25,28)(H,30,31)/t12-,15+,20+,22-,23+,24+/m1/s1	CSOMAHTTWTVBFL-OFBLZTNGSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	3.0222 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	7	4	No	5	-1	133.16 Å2	44.81 Å3	116.81 m3·mol-1	5	Yes	No	0.0139 mg/mL	3.24	-4.5	2.96	-3.4	P0AAI5	fabF	1. 3-oxoacyl-[acyl-carrier-protein] synthase 2
C25H38O5	Not Available	Not Available	418.5662	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])C[C@]([H])(CC[C@]4(C)[C@@]3([H])CC[C@]12C)OC(=O)CCC(O)=O)C(C)=O	Solid	Not Available						62043		4451314						S5H			5289324	99444981					ZINC000011422518		5-ALPHA-PREGNANE-3-BETA-OL-HEMISUCCINATE	Experimental	DB08510	InChI=1S/C25H38O5/c1-15(26)19-6-7-20-18-5-4-16-14-17(30-23(29)9-8-22(27)28)10-12-24(16,2)21(18)11-13-25(19,20)3/h16-21H,4-14H2,1-3H3,(H,27,28)/t16-,17-,18-,19+,20-,21-,24-,25+/m0/s1	UVTGFMKBPVLATL-DSOJQRAMSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.1566 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	1	Yes	4	-1	80.67 Å2	48.08 Å3	112.95 m3·mol-1	6	Yes	No	0.00175 mg/mL	4.25	-5.4	4.11	-6.9	P01859	IGHG2	1. Ig gamma-2 chain C region
C25H34O6	Not Available	Not Available	430.5339	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)CC[C@]4(C)[C@@]3([H])[C@@]([H])(C[C@]12C)OC(=O)CCC(O)=O)C(C)=O	Solid	Not Available						45496		4451359						SIH			5289373	99445018					ZINC000013512622		PROGESTERONE-11-ALPHA-OL-HEMISUCCINATE	Experimental	DB08547	InChI=1S/C25H34O6/c1-14(26)18-6-7-19-17-5-4-15-12-16(27)10-11-24(15,2)23(17)20(13-25(18,19)3)31-22(30)9-8-21(28)29/h12,17-20,23H,4-11,13H2,1-3H3,(H,28,29)/t17-,18+,19-,20+,23+,24-,25+/m0/s1	JBBNFGYRYNBDIH-DBGGZKJISA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.3116 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	1	Yes	4	-1	97.74 Å2	46.96 Å3	114.34 m3·mol-1	6	Yes	No	0.0085 mg/mL	3.11	-4.7	4.22	-4.8	P01859	IGHG2	1. Ig gamma-2 chain C region
C23H32O5	Not Available	Not Available	388.4972	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)OC(=O)CCC(O)=O	Solid	Not Available								106489						TH2			119202	99445090					ZINC000004025723		Testosterone succinate	Experimental	DB08619	InChI=1S/C23H32O5/c1-22-11-9-15(24)13-14(22)3-4-16-17-5-6-19(23(17,2)12-10-18(16)22)28-21(27)8-7-20(25)26/h13,16-19H,3-12H2,1-2H3,(H,25,26)/t16-,17-,18-,19-,22-,23-/m0/s1	CJQNBXFUHQZFOE-VYAQIDIUSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.1662 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	1	No	4	-1	80.67 Å2	43.74 Å3	104.47 m3·mol-1	5	Yes	No	0.00844 mg/mL	3.63	-4.7	4.31	-4.8	P0A3R9	ncsA	1. Neocarzinostatin
C19H28ClNO6	Not Available	Not Available	401.882	[H][C@]1(CC=C(C)C)O[C@]1(C)[C@@]1([H])[C@]([H])(OC)[C@@]([H])(CC[C@]11CO1)OC(=O)NC(=O)CCl	Solid	Not Available					17446	90748	CHEMBL424278	328427						TN4			369976	99445104					ZINC000003914617		TNP-470	Investigational	DB08633	InChI=1S/C19H28ClNO6/c1-11(2)5-6-13-18(3,27-13)16-15(24-4)12(7-8-19(16)10-25-19)26-17(23)21-14(22)9-20/h5,12-13,15-16H,6-10H2,1-4H3,(H,21,22,23)/t12-,13-,15-,16-,18+,19+/m1/s1	MSHZHSPISPJWHW-PVDLLORBSA-N	1		Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.8117 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	1	Yes	3	0	89.69 Å2	41.46 Å3	98.45 m3·mol-1	7	Yes	No	0.0234 mg/mL	2.24	-4.2	9.71	-3.7			
C26H34O3	Not Available	Not Available	394.5464	C=C1\C(=C/C=C2\CCC[C@]3(C)[C@]([H])(CC[C@@]23[H])C#CC#CC(C)(O)C)C[C@](O)([H])C[C@@]1(O)[H]	Solid	Not Available								9444440						XE4			11269429	99445213					ZINC000058660808		1,3-CYCLOHEXANEDIOL, 4-METHYLENE-5-[(2E)-[(1S,3AS,7AS)-OCTAHYDRO-1-(5-HYDROXY-5-METHYL-1,3-HEXADIYNYL)-7A-METHYL-4H-INDEN-4-YLIDENE]ETHYLIDENE]-, (1R,3S,5Z)	Experimental	DB08742	InChI=1S/C26H34O3/c1-18-20(16-22(27)17-24(18)28)11-10-19-8-7-15-26(4)21(12-13-23(19)26)9-5-6-14-25(2,3)29/h10-11,21-24,27-29H,1,7-8,12-13,15-17H2,2-4H3/b19-10+,20-11-/t21-,22+,23-,24-,26+/m0/s1	CEEUUHVULXTFGS-BQXVGYHGSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	4.6385 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	3	No	3	0	60.69 Å2	46.99 Å3	120.55 m3·mol-1	4	Yes	No	0.00898 mg/mL	3.39	-4.6	14.06	-2.8	Q15788;!P11473	NCOA1;!VDR	1. Nuclear receptor coactivator 1;!2. Vitamin D3 receptor
C28H44O3	50 mg, 100 mg, and 150 mg doses of nadrolone decanoate had mean apparent clearances of 80.0 L/h, 74.3 L/h, and 76.2 L/h respectively.1	Nandrolone decanoate has an absorption half life of 6 days and an elimination half life of 4.3 hours.13 Alternate studies have shown that nandrolone decanoate has a terminal half life of 7.1, 11.7, and 11.8 hours for doses of 50, 100, and 150 mg respectively.1	428.6472	[H][C@@]12CC[C@H](OC(=O)CCCCCCCCC)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	Solid	Not Available	P11511;!P27338;!P21397;!P16662;!P22310;!P06133;!P35503;!P22309;!Q9HAW8	CYP19A1;!MAOB;!MAOA;!UGT2B7;!UGT1A4;!UGT2B4;!UGT1A3;!UGT1A1;!UGT1A10	1. Cytochrome P450 19A1;!2. Amine oxidase [flavin-containing] B;!3. Amine oxidase [flavin-containing] A;!4. UDP-glucuronosyltransferase 2B7;!5. UDP-glucuronosyltransferase 1-4;!6. UDP-glucuronosyltransferase 2B4;!7. UDP-glucuronosyltransferase 1-3;!8. UDP-glucuronosyltransferase 1-1;!9. UDP-glucuronosyltransferase 1-10			7467	CHEMBL1200946	9296	Drugs.com Drug Page		HMDB0015694	C08154	D00955			PA165958423	9677	99445274		31494	DAP000903	Nandrolone_decanoate	ZINC000008214619		Nandrolone decanoate	Approved, Illicit	DB08804	InChI=1S/C28H44O3/c1-3-4-5-6-7-8-9-10-27(30)31-26-16-15-25-24-13-11-20-19-21(29)12-14-22(20)23(24)17-18-28(25,26)2/h19,22-26H,3-18H2,1-2H3/t22-,23+,24+,25-,26-,28-/m0/s1	JKWKMORAXJQQSR-MOPIKTETSA-N	2	Nandrolone decanoate is an anabolic steroid indicated for the management of the anemia of renal insufficiency by increasing hemoglobin and red cell mass.	Data regarding acute overdose of nandrolone decanoate are not readily available.13 However, patients experiencing a chronic overdose of anabolic steroids may experience adverse effects including suppression of testosterone and spermatogenesis, shrinking of testicles, decreased libido, and erectile dysfunction in men; and suppressed estrogen, progesterone, and ovulation, amenorrhea, and clitoromegaly in women.8 Patients may also experience neuropsychiatric, cardiovascular, and hepatic adverse effects.8 Alkylated anabolic steroids such as nandrolone decanoate are more likely to cause hepatic adverse effects.8 Treat patients with symptomatic and supportive measures.The intraperitoneal LD50 in mice is >566 mg/kg.14	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	1.8804 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							32-35		3.09 mg/mL at 25 °C	1	No	2	0	Yes	4	0	43.37 Å2	53.64 Å3	125.94 m3·mol-1	10	No	No	0.000157 mg/mL	7.32	-6.4	18.25	-4.7	P10275;!P01100;!BE0004881;!P28222;!P08069;!BE0009376	AR;!FOS;!;!HTR1B;!IGF1R;!	1. Androgen receptor;!2. Proto-oncogene c-Fos;!3. 5-hydroxytryptamine 2 receptor (Protein Group);!4. 5-hydroxytryptamine receptor 1B;!5. Insulin-like growth factor 1 receptor;!6. Dopamine receptor (Protein Group)
C26H48ClN3O6Pt	Not Available	Not Available	729.22	N.N.Cl.[Pt++].CC(CCC([O-])=NCC([O-])=O)C1CCC2C3C(O)CC4CC(O)CCC4(C)C3CC(O)C12C	Solid	Not Available								135801																	cis-Diamminechlorocholylglycinateplatinum(II)	Experimental	DB08858	InChI=1S/C26H43NO6.ClH.2H3N.Pt/c1-14(4-7-22(31)27-13-23(32)33)17-5-6-18-24-19(12-21(30)26(17,18)3)25(2)9-8-16(28)10-15(25)11-20(24)29;;;;/h14-21,24,28-30H,4-13H2,1-3H3,(H,27,31)(H,32,33);1H;2*1H3;/q;;;;+2/p-2	RUGJYCHQQOPHCW-UHFFFAOYSA-L			Not Available	Small Molecule																																			1	No	7	3	Yes	4	-1	136.24 Å2	52.47 Å3	145.5 m3·mol-1	6	No	No	0.155 mg/mL	2.2	-3.7	3.83	1.83			
C28H35NO3	Mean oral clearance, single oral dose, healthy subject (CL/F) = 76.8 ± 64.0L/h	Mean elimination half-life, single oral dose, healthy subject = 32.4 ± 6.3 hours	433.592	CN(C)C1=CC=C(C=C1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12	Solid	Not Available	P08684;!P05177	CYP3A4;!CYP1A2	1. Cytochrome P450 3A4;!2. Cytochrome P450 1A2			71025	CHEMBL2103846	19349271	Drugs.com Drug Page				D09567				13559281	310264902	RxList Drug Page	1005921		Ulipristal_acetate	ZINC000034089131	Ella, Ellaone, Esmya	Ulipristal	Approved	DB08867	InChI=1S/C28H35NO3/c1-17(30)28(32)14-13-25-23-11-7-19-15-21(31)10-12-22(19)26(23)24(16-27(25,28)2)18-5-8-20(9-6-18)29(3)4/h5-6,8-9,15,23-25,32H,7,10-14,16H2,1-4H3/t23-,24+,25-,27-,28-/m0/s1	HKDLNTKNLJPAIY-WKWWZUSTSA-N	4	Ulipristal is a selective progesterone receptor modulator used for emergency contraception after unprotected intercourse or in a situation where a planned method of contraception has failed.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.6728 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	1	No	5	0	57.61 Å2	49.66 Å3	129.29 m3·mol-1	3	Yes	No	0.00943 mg/mL	4.18	-4.7	12.7	4.89			
C19H26O3	Plasma clearance is approximately 4.2 L/(h kg), when delivered intravenously. In women, following a 500mg dose of formestane, 20% was excreted as glucuronide within the first 24 hours. [1]One long term metabolite (3beta,4alpha-dihydroxy-5alpha-androstan-17-one) can be detected for 90 hours. A longer detection time is possible with more sensitive technology, which may be of utility in sports drug testing. [1]	Terminal plasma elimination half life of 18 minutes, when delivered intravenously. [2]	302.4079	[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=C(O)C(=O)CC[C@]12C	Solid	Vd = 1.8 L/kg; widely distributed to organs and tissues when delivered intravenously. [2]	P08684	CYP3A4	1. Cytochrome P450 3A4		225704	75172	CHEMBL132530	10799	Drugs.com Drug Page				D07260				11273	175427144		15070		Formestane	ZINC000003919580		Formestane	Approved, Investigational, Withdrawn	DB08905	InChI=1S/C19H26O3/c1-18-10-8-15(20)17(22)14(18)4-3-11-12-5-6-16(21)19(12,2)9-7-13(11)18/h11-13,22H,3-10H2,1-2H3/t11-,12-,13-,18+,19-/m0/s1	OSVMTWJCGUFAOD-KZQROQTASA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.6135 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.66		199 - 202	9.31	Insoluble	1	Yes	3	1	No	4	0	54.37 Å2	34.05 Å3	85.57 m3·mol-1	0	Yes	No	0.0578 mg/mL	3.41	-3.7	9.21	-3.7			
C27H29F3O6S	57.8L/h for fluticasone furoateLabel. A study of 24 healthy Caucasian males showed a clearance of 71.8L/h following intravenous administration5.	15.1 hours for intranasal fluticasone furoateLabel and 24 hours for the inhaled formulation12. A study of 24 healthy Caucasian males showed a half life of 13.6 hours following intravenous administration and 17.3-23.9 hours followed inhalation5.	538.576	[H][C@@]12C[C@@H](C)[C@](OC(=O)C3=CC=CO3)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C	Solid	608L at steady state for intravenous administration of fluticasone furoateLabel. Other reports suggest the mean volume of distribution at steady state is 661L12. A study of 24 healthy Caucasian males showed a volume of distribution at steady state of 704L following intravenous administration5.	P08684;!P20815;!P24462;!P10632	CYP3A4;!CYP3A5;!CYP3A7;!CYP2C8	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5;!3. Cytochrome P450 3A7;!4. Cytochrome P450 2C8		50354851	74899	CHEMBL1676	8030195	Drugs.com Drug Page				D06315	GW6			9854489	175427145	RxList Drug Page	705022		Fluticasone_furoate	ZINC000003992105	Arnuity Ellipta, Avamys, Breo Ellipta, Flonase Sensimist, Trelegy Ellipta, Veramyst	Fluticasone furoate	Approved	DB08906	InChI=1S/C27H29F3O6S/c1-14-9-16-17-11-19(29)18-10-15(31)6-7-24(18,2)26(17,30)21(32)12-25(16,3)27(14,23(34)37-13-28)36-22(33)20-5-4-8-35-20/h4-8,10,14,16-17,19,21,32H,9,11-13H2,1-3H3/t14-,16+,17+,19+,21+,24+,25+,26+,27+/m1/s1	XTULMSXFIHGYFS-VLSRWLAYSA-N	4	Fluticasone furoate is an inhaled corticosteroid that can be used as maintenance treatment of asthma and/or chronic obstructive pulmonary disease (COPD) depending on the product. Also available as a nasal spray to manage symptoms of allergic rhinitis.	Fluticasone furoate administered nasally may be associated with adrenal suppression or an increase in QTc interval though the association has not been well demonstrated in studiesLabel6. Fluticasone furoate requires no dosage adjustment in renal impairment but must be used in caution in hepatic impairment due to the elimination mechanismsLabel12. Fluticasone furoate is not associated with carcinogenicity, mutagenicity, or impairment of fertilityLabel. There are no well controlled studies in pregnancy or lactation though animal studies have shown teratogenicity and hypoadrenalism in the offspring of treated mothers and other corticosteroids are known to be excreted in breast milkLabel. Generally, there are no reported adverse effects with fluticasone in pregnancy3. Pediatric patients should be given the lowest possible dose and monitored for reduction in growth velocityLabel6. There is insufficient evidence to determine whether geriatric patients respond differently to other patientsLabel. Systemic exposure may be 27-49% higher in Japanese, Korean, and Chinese patients compared to Caucasian patients12. Caution should be exercised in these patients and the benefit and risk should be assessed before deciding on a treatmentLabel.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.6232 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							250-252		Insoluble	1	No	4	1	Yes	5	0	93.81 Å2	51.56 Å3	130.08 m3·mol-1	6	No	No	0.0434 mg/mL	4.13	-4.1	13.61	-3.1			
C22H27FO5	Not Available	Not Available	390.4452	[H][C@@]12CC(=C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5			135989	CHEMBL2106763	9969413									11794741	310264933		236650		Fluprednidene	ZINC000004213363		Fluprednidene	Experimental	DB08970	InChI=1S/C22H27FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,15-17,24,26,28H,1,4-5,8,10-11H2,2-3H3/t15-,16-,17-,19-,20-,21-,22-/m0/s1	YVHXHNGGPURVOS-SBTDHBFYSA-N			Not Available	Small Molecule																																			1	Yes	5	3	No	4	0	94.83 Å2	40.32 Å3	102.19 m3·mol-1	2	Yes	No	0.117 mg/mL	1.41	-3.5	12.11	-3.3			
C22H29FO4	Not Available	Not Available	376.4617	[H][C@@]12C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C	Solid	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5			135581	CHEMBL251634	8701									9053	310264934		4463		Fluocortolone	ZINC000004213353		Fluocortolone	Approved, Withdrawn	DB08971	InChI=1S/C22H29FO4/c1-11-6-14-13-8-16(23)15-7-12(25)4-5-21(15,2)20(13)17(26)9-22(14,3)19(11)18(27)10-24/h4-5,7,11,13-14,16-17,19-20,24,26H,6,8-10H2,1-3H3/t11-,13+,14+,16+,17+,19-,20-,21+,22+/m1/s1	GAKMQHDJQHZUTJ-ULHLPKEOSA-N		Fluocortolone is a glucocorticoid used topically for localized skin reactions and also orally for systemic use.	Not Available	Small Molecule																																180-182			1	Yes	4	2	No	4	0	74.6 Å2	40.14 Å3	101.47 m3·mol-1	2	Yes	No	0.0339 mg/mL	1.97	-4	13.84	-0.23			
C24H29Cl2FO5	Not Available	Not Available	487.39	[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(Cl)[C@@H](Cl)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO	Solid	Not Available						135787	CHEMBL461332	16735814	Drugs.com Drug Page								20054914	310264936		103447		Fluclorolone_acetonide	ZINC000004213332		Fluclorolone acetonide	Approved, Withdrawn	DB08973	InChI=1S/C24H29Cl2FO5/c1-20(2)31-19-9-13-14-8-16(27)15-7-12(29)5-6-21(15,3)23(14,26)17(25)10-22(13,4)24(19,32-20)18(30)11-28/h5-7,13-14,16-17,19,28H,8-11H2,1-4H3/t13-,14-,16-,17-,19+,21-,22-,23-,24+/m0/s1	NJNWEGFJCGYWQT-VSXGLTOVSA-N			Not Available	Small Molecule																																			1	No	5	1	No	5	0	72.83 Å2	47.44 Å3	119.21 m3·mol-1	2	Yes	No	0.00175 mg/mL	3.42	-5.4	13.73	-3.3			
C22H30O4	Not Available	Not Available	358.478	[H][C@@]12CC[C@@](O)(CCC(O)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=CC2=CC(=O)CC[C@]12C	Solid	Not Available						50156	CHEMBL1616951	570976	Drugs.com Drug Page								656615	310264973		618970		Potassium_canrenoate	ZINC000003938750		Canrenoic acid	Approved, Withdrawn	DB09015	InChI=1S/C22H30O4/c1-20-9-5-15(23)13-14(20)3-4-16-17(20)6-10-21(2)18(16)7-11-22(21,26)12-8-19(24)25/h3-4,13,16-18,26H,5-12H2,1-2H3,(H,24,25)/t16-,17+,18+,20+,21+,22-/m1/s1	PBKZPPIHUVSDNM-WNHSNXHDSA-N	3	Canrenoic acid is an aldosterone antagonist used in primary hyperaldosteronism and other disorders related to aberrant aldosterone levels.	Not Available	Small Molecule																																165			1	Yes	4	2	No	4	-1	74.6 Å2	40.44 Å3	100.98 m3·mol-1	3	Yes	No	0.0442 mg/mL	2.93	-3.9	4.48	-3.1			
C21H28O2	Elimination of tibolone is not dependent renal function 14.	The elimination half-life is approximately 45 h 4.	312.453	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC(=O)CC3)C[C@@]([H])(C)[C@@]21[H]	Solid	Not Available	P08842;!P14060;!P26439;!P50225	STS;!HSD3B1;!HSD3B2;!SULT1A1	1. Steryl-sulfatase;!2. 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1;!3. 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2;!4. Sulfotransferase 1A1			32223	CHEMBL2103774	392038					D01639				444008	347827821		38260		Tibolone	ZINC000003812889		Tibolone	Approved, Investigational	DB09070	InChI=1S/C21H28O2/c1-4-21(23)10-8-18-19-13(2)11-14-12-15(22)5-6-16(14)17(19)7-9-20(18,21)3/h1,13,17-19,23H,5-12H2,2-3H3/t13-,17-,18+,19-,20+,21+/m1/s1	WZDGZWOAQTVYBX-XOINTXKNSA-N	4		>2000 mg/kg MSDSThe Million Women Study (MWS), which had a prospective observational design, studied the use of hormone replacement therapy. The results indicated that the increase in the incidence of breast cancer with estrogen and progestogen (compared to estrogen alone) was greater than the reduction in occurrence of endometrial cancer associated with adding progestogen to estrogen therapy. The MWS also reported a marked increase in the incidence of breast cancer with tibolone and with implanted and transdermal estrogen-only preparations 6.Tibolone treatment in rodent studies showed an increased association with the development of a range of tumors in long-term oral carcinogenicity studies. These tumors included pituitary adenomas, mammary carcinomas and fibroadenomas, hepatic adenomas, uterine carcinoma, stromal polyps and stromal sarcoma, and carcinomas of the urinary bladder and testes. Tibolone failed to show any evidence of genotoxicity in studies for gene mutations, chromosomal damage as well as DNA damage 9.Other adverse effects these include dizziness, headache, nausea, abdominal pain, rashes, pruritus, weight gain, edema, and migraine 16.	Small Molecule																																		<0.1 g/L	1	Yes	2	1	No	4	0	37.3 Å2	36.77 Å3	91.73 m3·mol-1	0	Yes	Yes	0.00722 mg/mL	3.1	-4.6	16.27	-1.7	P03372	ESR1	1. Estrogen receptor alpha
C21H30O4S	Studies have shown that oral or intravenous administration of tixocortol presents a significantly larger clearance rate compared to cortisol of 33.3 L h/kg.4	Tixocortol presents a shorter half-life than cortisol.6	378.53	[H][C@@]12CC[C@](O)(C(=O)CS)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	Studies have shown that oral or intravenous administration of tixocortol presents a significantly larger volume of distribution compared to cortisol of 21.7 L/kg.4						63560		143053									162955	310265018		57257		Tixocortol	ZINC000005138848		Tixocortol	Approved, Withdrawn	DB09091	InChI=1S/C21H30O4S/c1-19-7-5-13(22)9-12(19)3-4-14-15-6-8-21(25,17(24)11-26)20(15,2)10-16(23)18(14)19/h9,14-16,18,23,25-26H,3-8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1	YWDBSCORAARPPF-VWUMJDOOSA-N		Tixocortol is a corticosteroid used for the symptomatic treatment of rhinitis, pharyngitis, and ulcerative colitis.	Diverse studies performed on tixocortol proved that this drug is non-toxic and non-immunosupressive. This low toxicity and abscence of immuno supression gave tixocortol the potential to be a lead for topical or local anti-inflammatory treatments.7 Nevertheless, toxicortol is a potent cutaneous sensitizer, causing a local allergy.3	Small Molecule																													607ºC at 760 mmHg	4.48		50-55ºC		Insoluble	1	Yes	4	3	No	4	0	74.6 Å2	41.96 Å3	103.53 m3·mol-1	2	Yes	No	0.0428 mg/mL	2.32	-4	9.57	-2.8	P04150;!Q92769	NR3C1;!HDAC2	1. Glucocorticoid receptor;!2. Histone deacetylase 2
C22H28F2O4	Diflucortolone gets rapidly eliminated and the metabolites produced are the latest in getting eliminated from the body.6	The half-life of diflucortolone is approximately in the range of 4 to 5 h while the half-life of 3H-diflucortolone valerate is approximately 9 h.2	394.459	[H][C@@]12C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C	Solid	Less of 1% of the administered dose reaches systemic circulation.7 In order to exert its functions, diflucortolone has to distribute into the living epidermis and upper dermis. Reports have shown that the skin absorption of diflucortolone is rapid where the absorption gets significantly increased in damaged skin. Diflucortolone gets percutaneously absorbed and distributed into organs and tissues where it will be metabolized. When diflucortolone in an ointment form is applied in healthy skin 0.7% of the administered dose is percutaneously absorbed after a 7-hour exposure.6	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5			135624	CHEMBL509924	10128664									11954369	310265022		3392		Diflucortolone	ZINC000004212939		Difluocortolone	Approved, Investigational, Withdrawn	DB09095	InChI=1S/C22H28F2O4/c1-11-6-13-14-8-16(23)15-7-12(26)4-5-21(15,3)22(14,24)18(28)9-20(13,2)19(11)17(27)10-25/h4-5,7,11,13-14,16,18-19,25,28H,6,8-10H2,1-3H3/t11-,13+,14+,16+,18+,19-,20+,21+,22+/m1/s1	OGPWIDANBSLJPC-RFPWEZLHSA-N	1	Difluocortolone is a topical corticosteroid used for the symptomatic treatment of inflammatory skin disorders like eczema, seborrheic eczema, lichen planus and psoriasis.	Diflucortolone can cause skin irritation, vesicles or red patches on the skin.4	Small Molecule																													534ºC at 760 mmHg	3.86		220ºC		2.030 mg/L	1	Yes	4	2	No	4	0	74.6 Å2	40.2 Å3	100.99 m3·mol-1	2	Yes	No	0.0446 mg/mL	2.01	-4	13.42	-3.3	P12429;!P04150	ANXA3;!NR3C1	1. Annexin A3;!2. Glucocorticoid receptor
C20H25NO2	The metabolic clearance rate from serum (Cl/F) is 64 mL/min 5.	Elimination half-life of dienogest is around 9-10 hours. The half-life of urinary metabolites excretion is 14 hours 5.	311.425	[H][C@@]12CC[C@@](O)(CC#N)[C@@]1(C)CCC1=C3CCC(=O)C=C3CC[C@@]21[H]	Solid	The apparent volume of distribution (Vd/F) of dienogest is 40 L 5.	P08684	CYP3A4	1. Cytochrome P450 3A4			70708	CHEMBL1201864	62093									68861	310265039		22968		Dienogest	ZINC000004215629	Natazia, Visanne	Dienogest	Approved	DB09123	InChI=1S/C20H25NO2/c1-19-8-6-16-15-5-3-14(22)12-13(15)2-4-17(16)18(19)7-9-20(19,23)10-11-21/h12,17-18,23H,2-10H2,1H3/t17-,18+,19+,20-/m1/s1	AZFLJNIPTRTECV-FUMNGEBKSA-N	4	Dienogest is an oral progestin used for the treatment of endometriosis as monotherapy or contraception in combination with ethinylestradiol.	Oral LD50 in mouse is 4 mg/kg MSDS. In a long-term carcinogenicity study involving rats and mice, exposure of 10 times the dose of maximum recommended clinical dose of dienogest resulted in increased incidences of pituitary adenomas, fibroepithelial mammary tumours, stromal polyps of the uterus and malignant lymphoma 6. These tumors are thought to arise from marked species differences in the optimal oestrogen:progestogen ratio for reproductive function. In rat liver foci assay, dienogest did not induce tumor promotion activity 6. Dienogest does not display genotoxic potential.	Small Molecule																																210-218		Practically insoluble	1	Yes	3	1	No	4	0	61.09 Å2	35.4 Å3	90.19 m3·mol-1	1	Yes	No	0.0761 mg/mL	2.31	-3.6	13.78	-3.3	P06401;!P10275	PGR;!AR	1. Progesterone receptor;!2. Androgen receptor
C23H32O2	Not Available	The half-life of medrogestone is reported to be of 4 hours.5	340.507	[H][C@@]12CC[C@](C)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			135446	CHEMBL2106825	8125459									9949848	310265040		6690		Medrogestone	ZINC000004216820		Medrogestone	Approved, Withdrawn	DB09124	InChI=1S/C23H32O2/c1-14-12-17-18(21(3)9-6-16(25)13-20(14)21)7-11-23(5)19(17)8-10-22(23,4)15(2)24/h12-13,17-19H,6-11H2,1-5H3/t17-,18+,19+,21-,22-,23+/m1/s1	HCFSGRMEEXUOSS-JXEXPEPMSA-N		Medrogestone is a progestin used as an adjunct to control secondary amenorrhea and dysfunctional bleeding in adolescent and adult females, and treat endometrial shedding in menopausal women.	There were reports of increased urinary flow rates and total micturition volumes as well as sexual dysfunction and hyperglycemia.4	Small Molecule																													467.17ºC at 760 mmHg	4.45		144-146ºC		5.34e-06 mol/L	1	Yes	2	0	No	4	0	34.14 Å2	40.37 Å3	102.6 m3·mol-1	1	Yes	Yes	0.00404 mg/mL	4.59	-4.9	19.18	-4.9	P06401	PGR	1. Progesterone receptor
C19H28O8	The clearance of artesunate is 180L/h while the clearance of DHA is 32.3L/h.8	The elimination half life of artesunate is 0.3h with a range of 0.1-1.8h.8 The elimination half life of DHA is 1.3h with a range of 0.9-2.9h.8 Half life after intramuscular administration is 48 min in children and 41 min in adults.7	384.425	[H][C@@]12CC[C@@H](C)[C@]3([H])CC[C@@]4(C)OO[C@@]13[C@]([H])(O[C@@H](OC(=O)CCC(O)=O)[C@@H]2C)O4	Solid	The volume of distribution of artesunate is 68.5L while the volume of distribution of DHA is 59.7L.8	P16662;!O60656;!P11509	UGT2B7;!UGT1A9;!CYP2A6	1. UDP-glucuronosyltransferase 2B7;!2. UDP-glucuronosyltransferase 1-9;!3. Cytochrome P450 2A6			63918	CHEMBL361497	5293084			HMDB0240267		D02482	D95			6917864	310265169		18346		Artesunate	ZINC000014096305		Artesunate	Approved, Investigational	DB09274	InChI=1S/C19H28O8/c1-10-4-5-13-11(2)16(23-15(22)7-6-14(20)21)24-17-19(13)12(10)8-9-18(3,25-17)26-27-19/h10-13,16-17H,4-9H2,1-3H3,(H,20,21)/t10-,11-,12+,13+,16-,17-,18-,19-/m1/s1	FIHJKUPKCHIPAT-AHIGJZGOSA-N	4	Artesunate is artesunate is an artemesinin derivative indicated for the initial treatment of severe malaria.	Data regarding overdoses of artesunate are rare.8 Patients experiencing an overdose may present with pancytopenia, melena, seizures, multiorgan failure, and death.8 Treat overdose with symptomatic and supportive measures.8	Small Molecule																																131-135			1	Yes	7	1	No	4	-1	100.52 Å2	39.46 Å3	89.95 m3·mol-1	5	Yes	No	0.678 mg/mL	3.1	-2.8	3.77	-4.2	P04926	EXP-1	1. Malaria protein EXP-1
C20H26O2	Not Available	Not Available	298.426	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])CC(=O)CC3	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4		50410507	34895	CHEMBL1387	5995				C14249	D05207							7515		Norethynodrel	ZINC000118913164		Norethynodrel	Approved	DB09371	InChI=1S/C20H26O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,16-18,22H,4-12H2,2H3/t16-,17-,18+,19+,20+/m1/s1	ICTXHFFSOAJUMG-SLHNCBLASA-N			Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	34.79 Å3	87.18 m3·mol-1	0	Yes	Yes	0.00982 mg/mL	2.81	-4.5	16.21	-1.7	P03372;!P10275;!P04278	ESR1;!AR;!SHBG	1. Estrogen receptor alpha;!2. Androgen receptor;!3. Sex hormone-binding globulin
C21H27FO5	Not Available	Not Available	378.44	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			34474	CHEMBL1200774	5665				C14618	D04227							4497		Fluprednisolone	ZINC000003875362		Fluprednisolone	Approved	DB09378	InChI=1S/C21H27FO5/c1-19-5-3-11(24)7-14(19)15(22)8-12-13-4-6-21(27,17(26)10-23)20(13,2)9-16(25)18(12)19/h3,5,7,12-13,15-16,18,23,25,27H,4,6,8-10H2,1-2H3/t12-,13-,15-,16-,18+,19-,20-,21-/m0/s1	MYYIMZRZXIQBGI-HVIRSNARSA-N			Not Available	Small Molecule																																			1	Yes	5	3	No	4	0	94.83 Å2	38.9 Å3	98.32 m3·mol-1	2	Yes	No	0.261 mg/mL	0.93	-3.2	12.58	-2.9			
C22H28O5	Not Available	Not Available	372.461	[H][C@]1(C)C[C@@]2([H])[C@]3([H])CCC4=CC(=O)C=C[C@]4(C)[C@@]3([H])C(=O)C[C@]2(C)[C@@]1(O)C(=O)CO	Not Available	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5			135573	CHEMBL1201148	4447637												29523		Meprednisone	ZINC000004216862		Meprednisone	Approved, Investigational	DB09383	InChI=1S/C22H28O5/c1-12-8-16-15-5-4-13-9-14(24)6-7-20(13,2)19(15)17(25)10-21(16,3)22(12,27)18(26)11-23/h6-7,9,12,15-16,19,23,27H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,19+,20-,21-,22-/m0/s1	PIDANAQULIKBQS-RNUIGHNZSA-N	2		Not Available	Small Molecule																																			1	Yes	5	2	No	4	0	91.67 Å2	40.19 Å3	102.04 m3·mol-1	2	Yes	No	0.0711 mg/mL	2.02	-3.7	12.44	-3.3			
C21H28O2	Not Available	Not Available	312.453	CCC12CCC3C(CCC4=CC(=O)CCC34)C1CCC2(O)C#C	Not Available	Not Available	P08684;!P11511	CYP3A4;!CYP19A1	1. Cytochrome P450 3A4;!2. Cytochrome P450 19A1			7630	CHEMBL2107797	4383	Drugs.com Drug Page				D00954				4542	347827838	RxList Drug Page	7518		Norgestrel		Cryselle 28, Elinest 28 Day, Lo/ovral 28 Day, Low-ogestrel 28 Day	Norgestrel	Approved	DB09389	InChI=1S/C21H28O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,13,16-19,23H,3,5-12H2,1H3	WWYNJERNGUHSAO-UHFFFAOYSA-N	4	Norgestrel is a progestin used in combination with ethinyl estradiol for oral contraception and prevention of pregnancy in women.	Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	36.83 Å3	92.03 m3·mol-1	1	Yes	Yes	0.00583 mg/mL	3.66	-4.7	17.91	-1.5	P06401;!P18405;!P10275	PGR;!SRD5A1;!AR	1. Progesterone receptor;!2. 3-oxo-5-alpha-steroid 4-dehydrogenase 1;!3. Androgen receptor
C31H38O7	Not Available	Not Available	522.638	C[C@H]1C[C@@]2(OC(C)=O)[C@H]([C@H]1OC(=O)C1=CC=CC=C1)[C@@H](OC(C)=O)C(=C)CC[C@H]1[C@@H](\C=C(C)\C2=O)C1(C)C	Not Available	Not Available						136008	CHEMBL552128	8753322									10577938	347827957		1426391			ZINC000096903163		Diacetyl benzoyl lathyrol	Approved	DB11260	InChI=1S/C31H38O7/c1-17-13-14-23-24(30(23,6)7)15-18(2)28(34)31(38-21(5)33)16-19(3)27(25(31)26(17)36-20(4)32)37-29(35)22-11-9-8-10-12-22/h8-12,15,19,23-27H,1,13-14,16H2,2-7H3/b18-15+/t19-,23-,24+,25-,26-,27-,31+/m0/s1	JPYYWXPAHJBKJX-VWSFRBHVSA-N			Not Available	Small Molecule																																			0	No	4	0	Yes	4	0	95.97 Å2	55.46 Å3	141.47 m3·mol-1	7	No	No	0.000363 mg/mL	5.71	-6.2		-5.5			
C21H26O2	Not Available	Not Available	310.437	[H][C@@]12CC[C@@](O)(CC=C)[C@@]1(C)C=CC1=C3CCC(=O)C=C3CC[C@@]21[H]	Not Available	Not Available							CHEMBL1315492	8216634					D02840							1314612		Altrenogest	ZINC000004214784		Altrenogest	Vet approved	DB11372	InChI=1S/C21H26O2/c1-3-10-21(23)12-9-19-18-6-4-14-13-15(22)5-7-16(14)17(18)8-11-20(19,21)2/h3,8,11,13,18-19,23H,1,4-7,9-10,12H2,2H3/t18-,19+,20+,21+/m1/s1	VWAUPFMBXBWEQY-ANULTFPQSA-N			Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	36.06 Å3	95.46 m3·mol-1	2	Yes	Yes	0.0301 mg/mL	3.2	-4	18.4	-0.18			
C20H30O2	Not Available	Not Available	302.458	[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3C[C@@H](C)[C@@]21[H]	Not Available	Not Available					26258	34849	CHEMBL425863	220460				C14255	D05025									Mibolerone	ZINC000004216936		Mibolerone	Vet approved	DB11429	InChI=1S/C20H30O2/c1-12-10-13-11-14(21)4-5-15(13)16-6-8-19(2)17(18(12)16)7-9-20(19,3)22/h11-12,15-18,22H,4-10H2,1-3H3/t12-,15+,16-,17+,18-,19+,20+/m1/s1	PTQMMNYJKCSPET-OMHQDGTGSA-N			Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	35.86 Å3	89.14 m3·mol-1	0	Yes	Yes	0.0194 mg/mL	3.63	-4.2	18.34	-0.53	P10275	AR	1. Androgen receptor
C23H32O4	Not Available	Not Available	372.505	[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)C[C@H](C)[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	Not Available	Not Available							CHEMBL2104744	7996587					D05210									Norgestomet	ZINC000004217176		Norgestomet	Vet approved	DB11440	InChI=1S/C23H32O4/c1-13-12-22(4)20(9-10-23(22,14(2)24)27-15(3)25)19-7-5-16-11-17(26)6-8-18(16)21(13)19/h11,13,18-21H,5-10,12H2,1-4H3/t13-,18-,19-,20-,21+,22-,23-/m0/s1	IWSXBCZCPVUWHT-VIFKTUCRSA-N			Not Available	Small Molecule																																			1	Yes	3	0	No	4	0	60.44 Å2	42.06 Å3	103.33 m3·mol-1	3	Yes	No	0.00489 mg/mL	3.83	-4.9	17.68	-4.7			
C28H47NO4S	Not Available	Not Available	493.742	[H][C@@]12C(=O)CC[C@]11CC[C@@]([H])(C)[C@@]2(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]1C)OC(=O)CSCCN(CC)CC	Not Available	Not Available						44137	CHEMBL1234521	571196				C12065	D06127	MUL						1546410		Tiamulin	ZINC000004217557		Tiamulin	Vet approved	DB11468	InChI=1S/C28H47NO4S/c1-8-26(6)17-22(33-23(31)18-34-16-15-29(9-2)10-3)27(7)19(4)11-13-28(20(5)25(26)32)14-12-21(30)24(27)28/h8,19-20,22,24-25,32H,1,9-18H2,2-7H3/t19-,20+,22-,24+,25+,26-,27+,28+/m1/s1	UURAUHCOJAIIRQ-QGLSALSOSA-N			Not Available	Small Molecule																																			1	No	4	1	Yes	3	1	66.84 Å2	57.98 Å3	140.74 m3·mol-1	10	Yes	No	0.000524 mg/mL	4.5	-6	14.43	9.51			
C28H32FNO6	Not Available	Not Available	497.563	[H][C@@]12C[C@@H](C)[C@](O)(C(=O)COC(=O)C3=CC=NC=C3)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5				CHEMBL3186453	15881												3265		Dexamethasone_isonicotinate	ZINC000004212878		Dexamethasone isonicotinate	Vet approved	DB11487	InChI=1S/C28H32FNO6/c1-16-12-21-20-5-4-18-13-19(31)6-9-25(18,2)27(20,29)22(32)14-26(21,3)28(16,35)23(33)15-36-24(34)17-7-10-30-11-8-17/h6-11,13,16,20-22,32,35H,4-5,12,14-15H2,1-3H3/t16-,20+,21+,22+,25+,26+,27+,28+/m1/s1	BQTXJHAJMDGOFI-NJLPOHDGSA-N			Not Available	Small Molecule																																			1	No	6	2	No	5	0	113.79 Å2	51.74 Å3	130.16 m3·mol-1	5	Yes	No	0.0254 mg/mL	2.96	-4.3	12.44	3.41			
C21H27FO5	Not Available	Not Available	378.44	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@]([H])(O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Not Available	Not Available						34511		113134				C14484								1546449		Isoflupredone	ZINC000003876095		Isoflupredone	Vet approved	DB11522	InChI=1S/C21H27FO5/c1-18-7-5-13(24)9-12(18)3-4-15-14-6-8-20(27,17(26)11-23)19(14,2)10-16(25)21(15,18)22/h5,7,9,14-16,23,25,27H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,18-,19-,20-,21-/m0/s1	WAIJIHDWAKJCBX-BULBTXNYSA-N			Not Available	Small Molecule																																			1	Yes	5	3	No	4	0	94.83 Å2	38.88 Å3	98.02 m3·mol-1	2	Yes	No	0.0811 mg/mL	1.32	-3.7	12.55	-3.3			
C23H30O3	Not Available	Not Available	354.49	[H][C@@]12CC(=C)[C@](O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4					8082266												1537799		Melengestrol	ZINC000038610965		Melengestrol	Vet approved	DB11529	InChI=1S/C23H30O3/c1-13-10-17-18(21(4)8-6-16(25)12-19(13)21)7-9-22(5)20(17)11-14(2)23(22,26)15(3)24/h10,12,17-18,20,26H,2,6-9,11H2,1,3-5H3/t17-,18+,20+,21-,22+,23+/m1/s1	OKHAOBQKCCIRLO-IBVJIVQJSA-N			Not Available	Small Molecule																																			1	Yes	3	1	No	4	0	54.37 Å2	40.91 Å3	103.68 m3·mol-1	1	Yes	No	0.00748 mg/mL	3.38	-4.7	12.21	-4			
C18H22O2	Not Available	Not Available	270.372	[H][C@@]12CC[C@H](O)[C@@]1(C)C=CC1=C3CCC(=O)C=C3CC[C@@]21[H]	Not Available	Not Available						35018	CHEMBL3182355	23383				C14261	D08627							1484278		Trenbolone	ZINC000003814429		Trenbolone	Vet approved	DB11551	InChI=1S/C18H22O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h8-10,15-17,20H,2-7H2,1H3/t15-,16+,17+,18+/m1/s1	MEHHPFQKXOUFFV-OWSLCNJRSA-N			Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	31.26 Å3	81.65 m3·mol-1	0	Yes	Yes	0.0586 mg/mL	2.25	-3.7	18.4	-0.89			
C21H24O2	Renal Excretion accounts for < 1 % 6.	Plasma half-life is 24 hr 6.	308.4141	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)C=CC1=C3CCC(=O)C=C3CC[C@@]21[H]	Solid	67 L 11	P08684	CYP3A4	1. Cytochrome P450 3A4		50423515	89642	CHEMBL1868702	25877			HMDB0002720		D04317				27812	347828012		4792		Gestrinone	ZINC000003938633		Gestrinone	Approved	DB11619	InChI=1S/C21H24O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,9,11,13,18-19,23H,3,5-8,10,12H2,1H3/t18-,19+,20+,21+/m1/s1	BJJXHLWLUDYTGC-ANULTFPQSA-N			Many of gestrinone's adverse effects occur due to its androgenic activity. These effects include acne, seborrhea, hirsutism, weight gain and deepening of the voice. Most patients develop at least one adverse event while taking this drug. This is because the drug is embryotoxic in some animals and may also cause masculinization of a female fetus. Gestrinone significantly reduces HDL concentrations 8.It is advisable to monitor liver transaminases and cholesterol levels in hyperlipidemic patients, as well as glucose in diabetic patients. Gestrinone has shown to decrease in the concentration of thyroid-binding globulin. Therefore, a decrease in serum total thyroxine levels is commonly observed. This is without clinical significance as free thyroxine levels and thyroid-stimulating hormone levels remain within the normal reference range 11.	Small Molecule																													507.638			150-152			1	Yes	2	1	No	4	0	37.3 Å2	35.55 Å3	93.73 m3·mol-1	1	Yes	Yes	0.00969 mg/mL	2.85	-4.5	17.88	-1.5	P04278;!P06401;!P04150;!P10275;!P30968;!P03372	SHBG;!PGR;!NR3C1;!AR;!GNRHR;!ESR1	1. Sex hormone-binding globulin;!2. Progesterone receptor;!3. Glucocorticoid receptor;!4. Androgen receptor;!5. Gonadotropin-releasing hormone receptor;!6. Estrogen receptor alpha
C21H28O3	Not Available	Not Available	328.452	CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			135993	CHEMBL2105722	62024					D07222							31930		Nomegestrol	ZINC000004217164		Nomegestrol	Approved	DB11636	InChI=1S/C21H28O3/c1-12-10-18-16(15-5-4-14(23)11-17(12)15)6-8-20(3)19(18)7-9-21(20,24)13(2)22/h10-11,15-16,18-19,24H,4-9H2,1-3H3/t15-,16-,18-,19+,20+,21+/m1/s1	KZUIYQJTUIACIG-YBZCJVABSA-N			Not Available	Small Molecule																																			1	Yes	3	1	No	4	0	54.37 Å2	37.69 Å3	95.03 m3·mol-1	1	Yes	No	0.0122 mg/mL	2.98	-4.4	12.7	-3.8			
C22H28ClFO4	Not Available	Not Available	410.907	[H][C@@]12C[C@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Not Available	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5			205919	CHEMBL1201362	4470588			HMDB0015148						5311051	347828107		2590		Clobetasol	ZINC000026892643		Clobetasol	Approved, Experimental, Investigational	DB11750	InChI=1S/C22H28ClFO4/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,24)17(26)10-20(16,3)22(12,28)18(27)11-23/h6-7,9,12,15-17,26,28H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,17-,19-,20-,21-,22-/m0/s1	FCSHDIVRCWTZOX-DVTGEIKXSA-N	3		Not Available	Small Molecule																																			1	Yes	4	2	No	4	0	74.6 Å2	41.95 Å3	105.54 m3·mol-1	2	Yes	No	0.0142 mg/mL	3.04	-4.5	12.47	-3.4			
C26H34F5NO4	Not Available	Not Available	519.553	C[C@H](OCC(=O)NCC(F)(F)C(F)(F)F)C1=CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	Not Available	Not Available							CHEMBL3989862	17279714									16122802	347828136					ZINC000035308284		Pefcalcitol	Investigational	DB11786	InChI=1S/C26H34F5NO4/c1-15-18(11-19(33)12-22(15)34)7-6-17-5-4-10-24(3)20(8-9-21(17)24)16(2)36-13-23(35)32-14-25(27,28)26(29,30)31/h6-8,16,19,21-22,33-34H,1,4-5,9-14H2,2-3H3,(H,32,35)/b17-6+,18-7-/t16-,19+,21-,22-,24+/m0/s1	SVCSMAZYWOQCBW-NVJMFHFGSA-N	3		Not Available	Small Molecule																																			1	No	4	3	Yes	3	0	78.79 Å2	50.63 Å3	127.31 m3·mol-1	8	No	No	0.00253 mg/mL	2.95	-5.3	11.52	-2.8			
C24H40O4	Not Available	Not Available	392.58	[H][C@@]1(CC[C@@]2([H])[C@]3([H])C[C@H](O)[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O	Not Available	Not Available					50375596	52023	CHEMBL272621	4446908									5283820	347828138				Hyodeoxycholic_acid	ZINC000003918159		Hyodeoxycholic Acid	Investigational	DB11789	InChI=1S/C24H40O4/c1-14(4-7-22(27)28)17-5-6-18-16-13-21(26)20-12-15(25)8-10-24(20,3)19(16)9-11-23(17,18)2/h14-21,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15-,16+,17-,18+,19+,20+,21+,23-,24-/m1/s1	DGABKXLVXPYZII-SIBKNCMHSA-N			Not Available	Small Molecule																																			1	Yes	4	3	No	4	-1	77.76 Å2	46.42 Å3	109.27 m3·mol-1	4	Yes	No	0.015 mg/mL	3.71	-4.4	4.79	-2.7			
C21H34O2	The total plasma clearance determined for brexanolone is approximately 1 L/h/kg Label.	The terminal half-life observed for brexanolone is approximately 9 hours Label.	318.4935	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)C(C)=O	Solid	The volume of distribution documented for brexanolone is approximately 3 L/kg, a value which suggests relatively extensive distribution into tissues Label.	P15121	AKR1B1	1. Aldose reductase		50191342	50169	CHEMBL207538	83760			HMDB0001449	C13712					92786	347828198		2121777		Allopregnanolone	ZINC000004081043	Zulresso	Brexanolone	Approved, Investigational	DB11859	InChI=1S/C21H34O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h14-19,23H,4-12H2,1-3H3/t14-,15+,16-,17+,18-,19-,20-,21+/m0/s1	AURFZBICLPNKBZ-SYBPFIFISA-N	3		There is limited clinical trial experience regarding human overdosage with brexanolone Label. In premarketing clinical studies, two cases of accidental overdosage due to infusion pump malfunction resulted in transient loss of consciousness Label. Both patients regained consciousness approximately 15 minutes after discontinuation of the infusion without supportive measures Label. After full resolution of symptoms, both patients subsequently resumed and completed treatment Label. Overdosage may result in excessive sedation, including loss of consciousness, and the potential for accompanying respiratory changes Label.There is no available data on brexanolone use in pregnant women to determine a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes Label. However, based on findings from animal studies of other drugs that enhance GABAergic inhibition, brexanolone may cause fetal harm Label.Available data from a lactation study in 12 women indicate that brexanolone is transferred to breastmilk in nursing mothers Label. However, the relative infant dose (RID) is low, 1% to 2% of the maternal weight-adjusted dosage Label. Also, as brexanolone has low oral bioavailability in adults, infant exposure is expected to be low Label. There were no reports of effects of brexanolone on milk production Label. There are no data on the effects of brexanolone on a breastfed infant Label. Available data on the use of brexanolone during lactation does not suggest a significant risk of adverse reactions to breastfed infants from exposure to brexanolone Label. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for brexanolone and any potential adverse effects on the breastfed child from brexanolone or from the underlying maternal condition Label.Brexanolone was not genotoxic when tested in an in vitro microbial mutagenicity (Ames) assay, an in vitro micronucleus assay in human peripheral blood lymphocytes, and an in vivo rat bone marrow micronucleus assay Label.Treatment of female and male rats with brexanolone at doses equal to and greater than 30 mg/kg/day, which is associated with 2 times the plasma levels at the maximum recommended human dose (MRHD) of 90 mcg/kg/hour, caused impairment of female and male fertility and reproduction Label. In female rats, brexanolone was associated with decreased mating and fertility indices, an increase in number of days to mating, prolonged/irregular estrous cycles, an increase in the number of early resorptions, and post implantation loss Label. Reversal of effects in females was observed following a 28-day recovery period Label. In male rats, brexanolone was associated with decreased mating and fertility indices, decreased conception rate, lower prostate, seminal vesicle, and epididymis weight, as well as decreased sperm numbers. Impaired female and male fertility and reproduction were not observed at 0.8 times the MRHD Label.	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	38.52 Å3	92.91 m3·mol-1	1	Yes	Yes	0.00136 mg/mL	3.99	-5.4	18.3	-1.4	BE0004797		1. GABA(A) Receptor (Protein Group)
C20H24O6	Not Available	Not Available	360.406	CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O	Not Available	Not Available					50241049	9747	CHEMBL463763	97099				C09204					107985	347828340				Triptolide	ZINC000008234271		Triptolide	Investigational	DB12025	InChI=1S/C20H24O6/c1-8(2)18-13(25-18)14-20(26-14)17(3)5-4-9-10(7-23-15(9)21)11(17)6-12-19(20,24-12)16(18)22/h8,11-14,16,22H,4-7H2,1-3H3/t11-,12-,13-,14-,16+,17-,18-,19+,20+/m0/s1	DFBIRQPKNDILPW-CIVMWXNOSA-N	3		Not Available	Small Molecule																																			1	Yes	5	1	No	7	0	84.12 Å2	37.14 Å3	87.26 m3·mol-1	1	Yes	No	0.886 mg/mL	1.33	-2.6	12.54	-3.8			
C26H36F2O6	Not Available	Not Available	482.565	CC(C)OC(=O)CCC[C@H]1CC[C@H]2[C@H](C[C@@H](O)[C@@H]2\C=C\[C@@H](O)COC2=CC(F)=CC=C2F)OC1	Not Available	Not Available								32698273									50902259	347828354							Sepetaprost	Investigational	DB12043	InChI=1S/C26H36F2O6/c1-16(2)34-26(31)5-3-4-17-6-9-21-20(23(30)13-24(21)32-14-17)10-8-19(29)15-33-25-12-18(27)7-11-22(25)28/h7-8,10-12,16-17,19-21,23-24,29-30H,3-6,9,13-15H2,1-2H3/b10-8+/t17-,19+,20+,21+,23+,24-/m0/s1	BKVUSNOUTQMSBE-XCMGCKIWSA-N	2		Not Available	Small Molecule																																			1	No	5	2	Yes	3	0	85.22 Å2	51.45 Å3	124.09 m3·mol-1	11	Yes	No	0.00652 mg/mL	3.7	-4.9	14.01	-2.9			
C21H28O4	Not Available	Not Available	344.451	C[C@]12CC=C3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO	Not Available	Not Available							CHEMBL2348782	5428328									7074810	347828387				Anecortave_acetate	ZINC000003927675		Anecortave	Investigational	DB12081	InChI=1S/C21H28O4/c1-19-8-5-14(23)11-13(19)3-4-15-16(19)6-9-20(2)17(15)7-10-21(20,25)18(24)12-22/h6,11,15,17,22,25H,3-5,7-10,12H2,1-2H3/t15-,17+,19+,20+,21+/m1/s1	BCFCRXOJOFDUMZ-ONKRVSLGSA-N			Not Available	Small Molecule																																			1	Yes	4	2	No	4	0	74.6 Å2	38.24 Å3	96.66 m3·mol-1	2	Yes	No	0.0334 mg/mL	2.18	-4	12.58	-3.3			
C20H26O2	Not Available	Not Available	298.426	CC1=CC(=O)C=C2CC[C@H]3[C@@H]4CCC(=O)[C@@]4(C)CC[C@@H]3[C@@]12C	Not Available	Not Available							CHEMBL2105987	51438									57050	347828479				Atamestane	ZINC000004214890		Atamestane	Investigational	DB12194	InChI=1S/C20H26O2/c1-12-10-14(21)11-13-4-5-15-16-6-7-18(22)19(16,2)9-8-17(15)20(12,13)3/h10-11,15-17H,4-9H2,1-3H3/t15-,16-,17-,19-,20-/m0/s1	PEPMWUSGRKINHX-TXTPUJOMSA-N	3		Not Available	Small Molecule																																			1	Yes	2	0	No	4	0	34.14 Å2	34.42 Å3	88.98 m3·mol-1	0	Yes	Yes	0.0156 mg/mL	4.17	-4.3	18.79	-4.9			
C22H28O3	Not Available	Not Available	340.4559	[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=CC2=CC(=O)CC[C@]12C	Not Available	Not Available						135445	CHEMBL1463345	13192			HMDB0003033						13789	347828500		1982		Canrenone	ZINC000003881648		Canrenone	Investigational	DB12221	InChI=1S/C22H28O3/c1-20-9-5-15(23)13-14(20)3-4-16-17(20)6-10-21(2)18(16)7-11-22(21)12-8-19(24)25-22/h3-4,13,16-18H,5-12H2,1-2H3/t16-,17+,18+,20+,21+,22-/m1/s1	UJVLDDZCTMKXJK-WNHSNXHDSA-N	4	Canrenone is an antimineralocorticoid and active metabolite of spironolactone used in the treatment of primary hyperaldosteronism and edematous states caused by secondary hyperaldosteronism (e.g. heart failure).	Not Available	Small Molecule																																			1	Yes	2	0	No	5	0	43.37 Å2	38.67 Å3	97.48 m3·mol-1	0	Yes	No	0.0042 mg/mL	3.6	-4.9		-4.8			
C18H24O4	Not Available	The elimination half-life of estetrol is approximately 27 hours.13 Half-life may range between 19-40 hours.7	304.3808	[H][C@@]12[C@@H](O)[C@@H](O)[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3CC[C@@]21[H]	Solid	Limited distribution of estetrol into red blood cells has been demonstrated.17	P08684;!P16662	CYP3A4;!UGT2B7	1. Cytochrome P450 3A4;!2. UDP-glucuronosyltransferase 2B7		158505	142773	CHEMBL1230314	25245						4OH			27125	347828514		2539031		Estetrol	ZINC000005764481	Nextstellis 28 Day	Estetrol	Approved, Investigational	DB12235	InChI=1S/C18H24O4/c1-18-7-6-12-11-5-3-10(19)8-9(11)2-4-13(12)14(18)15(20)16(21)17(18)22/h3,5,8,12-17,19-22H,2,4,6-7H2,1H3/t12-,13-,14-,15-,16-,17+,18+/m1/s1	AJIPIJNNOJSSQC-NYLIRDPKSA-N	3	Estetrol is an estrogen used in combination with drospirenone for oral contraception.	LD50 information for estetrol is not readily available in the literature. Subjects receiving a dose of 20 mg, 40 mg or 60 mg of estetrol per day over 12 weeks were tolerated without dose-limiting toxicity.10 Symptoms that may occur in association with overdose, based on existing information on overdosage with oral contraceptives include nausea, vomiting, and vaginal bleeding. In one clinical study, 1 of 32 healthy research subjects receiving a dose of 75 mg of estretol with 15 mg of drospirenone for 10 days experienced deep vein thrombosis of the lower right limb. There is no known antidote to an estretol overdose; conduct laboratory testing for electrolytes and evidence of metabolic acidosis and provide symptomatic treatment.17	Small Molecule																													491.9±45.0	2.62		233-236	10.22±0.70		1	Yes	4	4	No	4	0	80.92 Å2	33.88 Å3	82.55 m3·mol-1	0	Yes	No		1.67		10.33	-3.3	P03372;!Q92731	ESR1;!ESR2	1. Estrogen receptor alpha;!2. Estrogen receptor beta
C20H24O7	Not Available	Not Available	376.405	CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@@]3(O)C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O	Not Available	Not Available							CHEMBL3358841	8492847									10317383	347828527					ZINC000043203993		PG-701	Investigational	DB12252	InChI=1S/C20H24O7/c1-8(2)18-12(26-18)13-20(27-13)16(3)5-4-9-10(7-24-14(9)21)17(16,23)6-11-19(20,25-11)15(18)22/h8,11-13,15,22-23H,4-7H2,1-3H3/t11-,12-,13-,15+,16-,17+,18-,19+,20+/m0/s1	OKRSVUYYCJPECG-LFGMFVMYSA-N	2		Not Available	Small Molecule																																			1	Yes	6	2	No	7	0	104.35 Å2	37.8 Å3	88.59 m3·mol-1	1	Yes	No	3.04 mg/mL	0.25	-2.1	12.07	-3.4			
C21H34O2	Not Available	Not Available	318.501	[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@]2([H])C[C@H](O)CC[C@]12C	Not Available	Not Available						1712	CHEMBL210952	29132			HMDB0062782			P9N			31402	347828573				Pregnanolone	ZINC000003800039		Eltanolone	Investigational	DB12308	InChI=1S/C21H34O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h14-19,23H,4-12H2,1-3H3/t14-,15-,16+,17-,18+,19+,20+,21-/m1/s1	AURFZBICLPNKBZ-YZRLXODZSA-N			Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	38.36 Å3	92.91 m3·mol-1	1	Yes	Yes	0.00136 mg/mL	3.99	-5.4	18.3	-1.4			
C31H39F2NO6	Not Available	Not Available	559.651	C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)C1C(C)(C)C1(C)C)C(=O)OCC#N	Not Available	Not Available								9551309									11376392	347828585							GW-870086	Investigational	DB12322	InChI=1S/C31H39F2NO6/c1-16-12-18-19-14-21(32)20-13-17(35)8-9-28(20,6)30(19,33)22(36)15-29(18,7)31(16,25(38)39-11-10-34)40-24(37)23-26(2,3)27(23,4)5/h8-9,13,16,18-19,21-23,36H,11-12,14-15H2,1-7H3/t16-,18+,19+,21+,22+,28+,29+,30+,31+/m1/s1	WUBKGTSFJSEIEM-NSHBDUGJSA-N	2		Not Available	Small Molecule																																			1	No	5	1	Yes	5	0	113.69 Å2	57.69 Å3	141.49 m3·mol-1	6	No	No	0.0084 mg/mL	3.91	-4.8	13.56	-3.4			
C23H28O8	Not Available	Not Available	432.469	COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@@H](C[C@]21C)C1=COC=C1	Not Available	Not Available					50159165	67900	CHEMBL445332	113947									128563	347828589				Salvinorin_A	ZINC000013607514		Salvinorin A	Investigational	DB12327	InChI=1S/C23H28O8/c1-12(24)30-16-9-15(20(26)28-4)22(2)7-5-14-21(27)31-17(13-6-8-29-11-13)10-23(14,3)19(22)18(16)25/h6,8,11,14-17,19H,5,7,9-10H2,1-4H3/t14-,15-,16-,17-,19-,22-,23-/m0/s1	OBSYBRPAKCASQB-AGQYDFLVSA-N	2		Not Available	Small Molecule																																			1	Yes	4	0	No	4	0	109.11 Å2	44.17 Å3	106 m3·mol-1	5	Yes	No	0.08 mg/mL	2.39	-3.7	16.45	-2.9			
C23H34O4	Not Available	Not Available	374.521	C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@]2(O)C1=COC=C1	Not Available	Not Available							CHEMBL2068971	135709						E4R		PA166129554	153976	347828605				Rostafuroxin	ZINC000003802462		Rostafuroxin	Investigational	DB12350	InChI=1S/C23H34O4/c1-20-8-5-17(24)13-15(20)3-4-19-18(20)6-9-21(2)22(25,10-11-23(19,21)26)16-7-12-27-14-16/h7,12,14-15,17-19,24-26H,3-6,8-11,13H2,1-2H3/t15-,17+,18+,19-,20+,21-,22+,23+/m1/s1	AEAPORIZZWBIEX-DTBDINHYSA-N	2		Not Available	Small Molecule																																			1	Yes	3	3	No	5	0	73.83 Å2	41.79 Å3	103.1 m3·mol-1	1	Yes	No	0.0347 mg/mL	2.91	-4	13.22	-1.3			
C30H41NO6S	Not Available	Not Available	543.72	C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](CC=C)[C@H]1O)C1=CC=C2SC(C)=NC2=C1	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4				CHEMBL2304041	9459163									11284169	347828638					ZINC000003964449		Sagopilone	Investigational	DB12391	InChI=1S/C30H41NO6S/c1-7-9-20-27(34)17(2)10-8-13-30(6)25(37-30)15-22(19-11-12-23-21(14-19)31-18(3)38-23)36-26(33)16-24(32)29(4,5)28(20)35/h7,11-12,14,17,20,22,24-25,27,32,34H,1,8-10,13,15-16H2,2-6H3/t17-,20+,22-,24-,25-,27-,30+/m0/s1	BFZKMNSQCNVFGM-UCEYFQQTSA-N	2		Not Available	Small Molecule																																			0	No	6	2	No	4	0	109.25 Å2	59.69 Å3	145.71 m3·mol-1	3	No	No	0.0024 mg/mL	5.1	-5.4	14.08	2.88			
C32H50O13	Not Available	Not Available	642.739	C[C@@]12CCC[C@](C)([C@H]1CC[C@@]13CC(=C)[C@@](C1)(CC[C@@H]23)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C(O)=O	Not Available	Not Available						145030		10209449						JC6			16401639	347828676							Steviolbioside	Approved, Investigational	DB12434	InChI=1S/C32H50O13/c1-15-11-31-9-5-18-29(2,7-4-8-30(18,3)28(40)41)19(31)6-10-32(15,14-31)45-27-25(23(38)21(36)17(13-34)43-27)44-26-24(39)22(37)20(35)16(12-33)42-26/h16-27,33-39H,1,4-14H2,2-3H3,(H,40,41)/t16-,17-,18+,19+,20-,21-,22+,23+,24-,25-,26+,27+,29-,30-,31-,32+/m1/s1	OMHUCGDTACNQEX-OSHKXICASA-N			Not Available	Small Molecule																																			0	No	13	8	Yes	6	-1	215.83 Å2	67.26 Å3	153.72 m3·mol-1	7	No	No	1.37 mg/mL	0.11	-2.7	4.59	-3			
C20H28O	Not Available	Not Available	284.443	C[C@]12CC[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C	Not Available	Not Available	P08684;!P11712;!P33261	CYP3A4;!CYP2C9;!CYP2C19	1. Cytochrome P450 3A4;!2. Cytochrome P450 2C9;!3. Cytochrome P450 2C19			31790	CHEMBL2107431	5648				C13037					5857	347828712		6529		Lynestrenol	ZINC000003875355		Lynestrenol	Approved, Investigational	DB12474	InChI=1S/C20H28O/c1-3-20(21)13-11-18-17-9-8-14-6-4-5-7-15(14)16(17)10-12-19(18,20)2/h1,6,15-18,21H,4-5,7-13H2,2H3/t15-,16+,17+,18-,19-,20-/m0/s1	YNVGQYHLRCDXFQ-XGXHKTLJSA-N	4	Lynestrenol is a progestin used for contraception and in the treatment of menstrual disorders.	Not Available	Small Molecule																																			1	Yes	1	1	No	4	0	20.23 Å2	34.69 Å3	86.81 m3·mol-1	0	Yes	Yes	0.00366 mg/mL	4.04	-4.9	17.59	-1.7			
C30H48O3	Not Available	Not Available	456.711	[H]OC(=O)[C@]12CC[C@@]([H])(C(C)=C)[C@]1([H])[C@@]1([H])CC[C@]3([H])[C@@]4(C)CC[C@]([H])(O[H])C(C)(C)[C@]4([H])CC[C@@]3(C)[C@]1(C)CC2	Not Available	Not Available					23208	3087	CHEMBL269277	58496			HMDB0030094	C08619					64971	347828718					ZINC000004097714		Betulinic Acid	Approved, Investigational	DB12480	InChI=1S/C30H48O3/c1-18(2)19-10-15-30(25(32)33)17-16-28(6)20(24(19)30)8-9-22-27(5)13-12-23(31)26(3,4)21(27)11-14-29(22,28)7/h19-24,31H,1,8-17H2,2-7H3,(H,32,33)/t19-,20+,21-,22+,23-,24+,27-,28+,29+,30-/m0/s1	QGJZLNKBHJESQX-FZFNOLFKSA-N	3		Not Available	Small Molecule																																			1	No	3	2	No	5	-1	57.53 Å2	54.64 Å3	132.63 m3·mol-1	2	No	No	0.000204 mg/mL	6.64	-6.4	4.75	-0.84			
C22H32O2	Not Available	Not Available	328.496	[H][C@@]12CC[C@H](OC)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(OCCC)C=C3	Not Available	Not Available						135402	CHEMBL2105394	8059589										347911337		34625		Promestriene	ZINC000001999256		Promestriene	Investigational	DB12487	InChI=1S/C22H32O2/c1-4-13-24-16-6-8-17-15(14-16)5-7-19-18(17)11-12-22(2)20(19)9-10-21(22)23-3/h6,8,14,18-21H,4-5,7,9-13H2,1-3H3/t18-,19-,20+,21+,22+/m1/s1	IUWKNLFTJBHTSD-AANPDWTMSA-N	4	Promestriene is a synthetic estrogen applied topically for the treatment of vulvovaginal atrophic symptoms and to speed wound healing following vulvovaginal surgery or trauma (e.g. post-partum).	Not Available	Small Molecule																																			1	Yes	2	0	No	4	0	18.46 Å2	40.9 Å3	98.41 m3·mol-1	4	No	Yes	8.81e-06 mg/mL	5.41	-7.6		-4			
C24H34O5	There is limited information on clearance of clascoterone.10	There is limited information on the half life of clascoterone.10	402.531	[H][C@@]12CC[C@](OC(=O)CC)(C(=O)CO)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	There is no information available on the volume of distribution.	P05177;!P20813;!P10632;!P11712;!P33261;!P10635;!P05181;!P08684	CYP1A2;!CYP2B6;!CYP2C8;!CYP2C9;!CYP2C19;!CYP2D6;!CYP2E1;!CYP3A4	1. Cytochrome P450 1A2;!2. Cytochrome P450 2B6;!3. Cytochrome P450 2C8;!4. Cytochrome P450 2C9;!5. Cytochrome P450 2C19;!6. Cytochrome P450 2D6;!7. Cytochrome P450 2E1;!8. Cytochrome P450 3A4				CHEMBL3590187	9924713									11750009	347828732		2474340		Clascoterone	ZINC000006716459	Winlevi	Clascoterone	Approved, Investigational	DB12499	InChI=1S/C24H34O5/c1-4-21(28)29-24(20(27)14-25)12-9-19-17-6-5-15-13-16(26)7-10-22(15,2)18(17)8-11-23(19,24)3/h13,17-19,25H,4-12,14H2,1-3H3/t17-,18+,19+,22+,23+,24+/m1/s1	GPNHMOZDMYNCPO-PDUMRIMRSA-N	3	Clascoterone is an androgen receptor antagonist used for the topical treatment of acne vulgaris in patients 12 years of age and older.	There is no information available on the toxicity profile of clascoterone, such as LD50 and overdose in humans.	Small Molecule																																			1	Yes	4	1	No	4	0	80.67 Å2	44.86 Å3	109.59 m3·mol-1	5	Yes	No	0.00753 mg/mL	3.73	-4.7	13.78	-3.3	P10275	AR	1. Androgen receptor
C21H26F2O6	Not Available	Not Available	412.43	C[C@]12C[C@H](O)[C@@]3(F)[C@@H](C[C@H](F)C4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO	Not Available	Not Available						5108	CHEMBL1201390	82611				C07006					91488	347828777		25126		Fluocinolone	ZINC000004097307		Fluocinolone	Investigational	DB12553	InChI=1S/C21H26F2O6/c1-18-4-3-10(25)5-13(18)14(22)6-12-11-7-15(26)21(29,17(28)9-24)19(11,2)8-16(27)20(12,18)23/h3-5,11-12,14-16,24,26-27,29H,6-9H2,1-2H3/t11-,12-,14-,15+,16-,18-,19-,20-,21-/m0/s1	UUOUOERPONYGOS-CLCRDYEYSA-N	1		Not Available	Small Molecule																																			1	Yes	6	4	No	4	0	115.06 Å2	40.14 Å3	99.21 m3·mol-1	2	Yes	No	0.342 mg/mL	-0.098	-3.1	11.75	-3.3			
C29H35NO8	Not Available	Not Available	525.598	COC[C@H]1OC(=O)\C(=C\N(CC=C)CC=C)C2=C(O)C(=O)C3=C([C@@H](C[C@@]4(C)[C@H]3CCC4=O)OC(C)=O)[C@@]12C	Not Available	Not Available						65345	CHEMBL411907	8025448									9849735	347828818					ZINC000029134545		Sonolisib	Investigational	DB12601	InChI=1S/C29H35NO8/c1-7-11-30(12-8-2)14-17-23-26(34)25(33)22-18-9-10-20(32)28(18,4)13-19(37-16(3)31)24(22)29(23,5)21(15-36-6)38-27(17)35/h7-8,14,18-19,21,34H,1-2,9-13,15H2,3-6H3/b17-14+/t18-,19+,21+,28-,29-/m0/s1	QIUASFSNWYMDFS-NILGECQDSA-N	2		Not Available	Small Molecule																																			1	No	7	1	Yes	4	0	119.44 Å2	54.57 Å3	141.15 m3·mol-1	9	No	No	0.0267 mg/mL	2.51	-4.3	8.49	-2.8			
C30H50O	Not Available	Not Available	426.729	[H][C@]12[C@@H](CC[C@]1(C)CC[C@]1(C)[C@]2([H])CC[C@]2([H])[C@@]3(C)CC[C@H](O)C(C)(C)[C@]3([H])CC[C@@]12C)C(C)=C	Not Available	Not Available					50377927	6570	CHEMBL289191	228079				C08628					259846	347828834				Lupeol	ZINC000004081455		Lupeol	Investigational	DB12622	InChI=1S/C30H50O/c1-19(2)20-11-14-27(5)17-18-29(7)21(25(20)27)9-10-23-28(6)15-13-24(31)26(3,4)22(28)12-16-30(23,29)8/h20-25,31H,1,9-18H2,2-8H3/t20-,21+,22-,23+,24-,25+,27+,28-,29+,30+/m0/s1	MQYXUWHLBZFQQO-QGTGJCAVSA-N	-Infinity		Not Available	Small Molecule																																			1	No	1	1	No	5	0	20.23 Å2	53.79 Å3	130.91 m3·mol-1	1	No	Yes	0.000195 mg/mL	7.45	-6.3	19.49	-0.84			
C29H39NO3	Not Available	Not Available	449.635	CN(C)C1=CC=C(C=C1)[C@H]1C[C@]2(C)[C@@H](CC[C@]2(O)CCCO)[C@@H]2CCC3=CC(=O)CCC3=C12	Not Available	Not Available					50366558		CHEMBL1908373	4470982									5311505	347828846				Onapristone	ZINC000003831947		Onapristone	Investigational	DB12637	InChI=1S/C29H39NO3/c1-28-18-25(19-5-8-21(9-6-19)30(2)3)27-23-12-10-22(32)17-20(23)7-11-24(27)26(28)13-15-29(28,33)14-4-16-31/h5-6,8-9,17,24-26,31,33H,4,7,10-16,18H2,1-3H3/t24-,25+,26-,28+,29+/m0/s1	IEXUMDBQLIVNHZ-YOUGDJEHSA-N			Not Available	Small Molecule																																			1	No	4	2	No	5	0	60.77 Å2	52.99 Å3	135.3 m3·mol-1	5	Yes	No	0.00759 mg/mL	3.96	-4.8	14.34	4.89	P04150;!Q6QNK2	NR3C1;!ADGRD1	1. Glucocorticoid receptor;!2. Probable G-protein coupled receptor 133
C31H41NO4	Not Available	Not Available	491.672	CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O	Not Available	Not Available							CHEMBL1093059	354529									400010	347828858				Bardoxolone_methyl	ZINC000006019135		Bardoxolone	Investigational	DB12651	InChI=1S/C31H41NO4/c1-26(2)10-12-31(25(35)36)13-11-30(7)23(19(31)16-26)20(33)14-22-28(5)15-18(17-32)24(34)27(3,4)21(28)8-9-29(22,30)6/h14-15,19,21,23H,8-13,16H2,1-7H3,(H,35,36)/t19-,21-,23-,28-,29+,30+,31-/m0/s1	TXGZJQLMVSIZEI-UQMAOPSPSA-N			Not Available	Small Molecule																																			1	No	5	1	No	5	-1	95.23 Å2	56.02 Å3	139.59 m3·mol-1	1	No	No	0.00401 mg/mL	6.4	-5.1	4.6	-5.3	Q14790	CASP8	1. Caspase-8
C20H30O2	Not Available	Not Available	302.458	CC[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C	Not Available	Not Available						135282	CHEMBL1697845	5649									5858	347828967		7513		Norethandrolone	ZINC000003875356		Norethandrolone	Investigational	DB12787	InChI=1S/C20H30O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h12,15-18,22H,3-11H2,1-2H3/t15-,16+,17+,18-,19-,20-/m0/s1	ZDHCJEIGTNNEMY-XGXHKTLJSA-N	3		Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	36.28 Å3	89.12 m3·mol-1	1	Yes	Yes	0.0174 mg/mL	3.87	-4.2	19.28	-0.27			
C28H45NO5S	The total body clearance of lefamulin has been determined to range from 2.94 to 30.0 L/h after an injected dose.11	The average elimination half-life of lefamulin is about 8 hours in patients diagnosed with community-acquired bacterial pneumonia.11 One pharmacokinetic study of healthy volunteers revealed a mean half-life of 13.2 hours after an intravenous infusion of lefamulin.7	507.73	[H][C@@]12C(=O)CC[C@]11CCC(C)[C@@]2(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]1C)OC(=O)CS[C@@H]1CC[C@@H](N)C[C@H]1O	Solid	The average volume of distribution of lefamulin is 86.1 L in patients with community-acquired bacterial pneumonia, but can range from 34.2 to 153 L.11 During clinical studies, lefamulin has been shown to significantly concentrate in the lung tissue, likely increasing its effectiveness in treating pneumonia.3 After lefamulin is administered, penetration into various tissues is observed, and is about 6 times greater in concentration in the fluid of the pulmonary epithelium, when compared with concentrations in the plasma.8 Animal studies demonstrate that lefamulin crosses the placenta.11	P08684	CYP3A4	1. Cytochrome P450 3A4		50019649		CHEMBL3291398							62B			25185057	347828993		2198944		Lefamulin		Xenleta	Lefamulin	Approved, Investigational	DB12825	InChI=1S/C28H45NO5S/c1-6-26(4)14-22(34-23(32)15-35-21-8-7-18(29)13-20(21)31)27(5)16(2)9-11-28(17(3)25(26)33)12-10-19(30)24(27)28/h6,16-18,20-22,24-25,31,33H,1,7-15,29H2,2-5H3/t16?,17-,18+,20+,21+,22+,24-,25-,26+,27-,28-/m0/s1	KPVIXBKIJXZQJX-CSOZIWFHSA-N	3	Lefamulin is a pleuromutilin antibacterial used to treat community-acquired bacterial pneumonia (CABP).	In the case of overdose with lefamulin, the patient should be monitored closely and provided with supportive treatment, according to symptoms and signs. This drug and its active metabolite are not removable by dialysis.11	Small Molecule																													618.6±55.0	3.72			9.41		1	No	5	3	Yes	4	1	109.85 Å2	57.34 Å3	138.86 m3·mol-1	6	No	No	0.00494 mg/mL	2.9	-5	14.19	10.08	P61182	rplV	1. 50S ribosomal protein L22
C35H45Cl2NO6	Not Available	Not Available	646.65	[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCCC3=CC=C(C=C3)N(CCCl)CCCl)[C@@]1(C)C[C@]([H])(O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Not Available	Not Available						82524	CHEMBL2103751	31708				C19512					34457	347828998		8637		Prednimustine	ZINC000004214173		Prednimustine	Investigational	DB12832	InChI=1S/C35H45Cl2NO6/c1-33-14-12-26(39)20-24(33)8-11-27-28-13-15-35(43,34(28,2)21-29(40)32(27)33)30(41)22-44-31(42)5-3-4-23-6-9-25(10-7-23)38(18-16-36)19-17-37/h6-7,9-10,12,14,20,27-29,32,40,43H,3-5,8,11,13,15-19,21-22H2,1-2H3/t27-,28-,29-,32+,33-,34-,35-/m0/s1	HFVNWDWLWUCIHC-GUPDPFMOSA-N			Not Available	Small Molecule																																			0	No	6	2	Yes	5	0	104.14 Å2	69.68 Å3	174.68 m3·mol-1	13	No	No	0.000642 mg/mL	5.87	-6	12.61	1.72			
C32H48O9	Not Available	Not Available	576.727	CO[C@H]1C[C@H](O[C@H]2CC[C@@]3(C)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H]([C@H](C[C@]43O)OC(C)=O)C3=CC(=O)OC3)C2)O[C@@H](C)[C@@H]1O	Not Available	Not Available						59030	CHEMBL1075789	9716290									11541511	347829006				Oleandrin	ZINC000008214621		Oleandrin	Experimental, Investigational	DB12843	InChI=1S/C32H48O9/c1-17-29(35)24(37-5)14-27(39-17)41-21-8-10-30(3)20(13-21)6-7-23-22(30)9-11-31(4)28(19-12-26(34)38-16-19)25(40-18(2)33)15-32(23,31)36/h12,17,20-25,27-29,35-36H,6-11,13-16H2,1-5H3/t17-,20+,21-,22-,23+,24-,25-,27-,28-,29-,30-,31+,32-/m0/s1	JLPDBLFIVFSOCC-XYXFTTADSA-N			Not Available	Small Molecule																																			1	No	7	2	Yes	6	-1	120.75 Å2	63.2 Å3	148.45 m3·mol-1	6	No	No	0.00299 mg/mL	2.95	-5.3	6.82	-3.2			
C22H28O5	Not Available	Not Available	372.461	C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)CC(=O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4					110996									124653	347829094					ZINC000004744090		Methylprednisone	Approved, Investigational	DB12952	InChI=1S/C22H28O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,19,23,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,19+,20-,21-,22-/m0/s1	SVYCRJXQZUCUND-PQXSVQADSA-N	4		Not Available	Small Molecule																																			1	Yes	5	2	No	4	0	91.67 Å2	40.27 Å3	102.12 m3·mol-1	2	Yes	No	0.0587 mg/mL	1.95	-3.8	12.58	-3.3			
C21H34O2	Not Available	Not Available	318.4935	[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@@H](O)CC[C@]12C	Not Available	Not Available					50388495	11909	CHEMBL2057301	83761			HMDB0001455	C15484					92787	347829112				Isopregnanolone	ZINC000003833954		Sepranolone	Investigational	DB12972	InChI=1S/C21H34O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h14-19,23H,4-12H2,1-3H3/t14-,15-,16-,17+,18-,19-,20-,21+/m0/s1	AURFZBICLPNKBZ-FZCSVUEKSA-N	2		Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	38.66 Å3	92.91 m3·mol-1	1	Yes	Yes	0.00136 mg/mL	3.99	-5.4	18.3	-1.4			
C20H35NO2	Not Available	Not Available	321.505	C[C@]12CC[C@@H]([C@@H](CN)[C@@H]1CCC2=C)[C@@]1(C)CC[C@H](O)C[C@@H]1CO	Not Available	Not Available							CHEMBL3989954	34986541									76965484	347829148							AQX-1125	Investigational	DB13012	InChI=1S/C20H35NO2/c1-13-4-5-17-16(11-21)18(7-9-19(13,17)2)20(3)8-6-15(23)10-14(20)12-22/h14-18,22-23H,1,4-12,21H2,2-3H3/t14-,15+,16+,17+,18+,19-,20+/m1/s1	MDEJTPWQNNMAQF-BVMLLJBZSA-N	2		Not Available	Small Molecule																																			1	Yes	3	3	No	3	1	66.48 Å2	38.8 Å3	94.6 m3·mol-1	3	Yes	No	0.0202 mg/mL	2.01	-4.2	15.04	10.2			
C15H20O3	Not Available	Not Available	248.3175	C\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1	Not Available	Not Available					50433441		CHEMBL540445	20126246				C07609					6473881	347829191		32941		Parthenolide	ZINC000030726283		Parthenolide	Approved, Investigational	DB13063	InChI=1S/C15H20O3/c1-9-5-4-8-15(3)13(18-15)12-11(7-6-9)10(2)14(16)17-12/h5,11-13H,2,4,6-8H2,1,3H3/b9-5+/t11-,12-,13-,15+/m0/s1	KTEXNACQROZXEV-SLXBATTESA-N	2		Not Available	Small Molecule																																			1	Yes	2	0	No	3	0	38.83 Å2	26.87 Å3	68.55 m3·mol-1	0	Yes	Yes	0.196 mg/mL	3.07	-3.1		-4.2			
C27H39NO6	Not Available	Not Available	473.61	C[C@H]1\C=C/C\C(C)=C/C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\C1=NOC(C)=C1	Not Available	Not Available								34986490									71587784	347829205							KOSN-1724	Investigational	DB13078	InChI=1S/C27H39NO6/c1-16-9-8-10-17(2)25(31)20(5)26(32)27(6,7)23(29)15-24(30)33-22(12-11-16)18(3)13-21-14-19(4)34-28-21/h8,10-11,13-14,17,20,22-23,25,29,31H,9,12,15H2,1-7H3/b10-8-,16-11-,18-13+/t17-,20+,22-,23-,25-/m0/s1	JAYGOFBXDFAXBW-CYEKYUJNSA-N			Not Available	Small Molecule																																			1	No	5	2	No	2	0	109.86 Å2	52.7 Å3	134.1 m3·mol-1	2	Yes	No	0.0286 mg/mL	4.52	-4.2	14.06	0.8			
C30H46O4	Not Available	Not Available	470.694	[H][C@@]12C[C@](C)(CC[C@]1(C)CC[C@]1(C)C2=CC(=O)[C@]2([H])[C@@]3(C)CC[C@H](O)C(C)(C)[C@]3([H])CC[C@@]12C)C(O)=O	Not Available	Not Available					50233538	30853	CHEMBL230006	9710				C02283		CBW			10114	347829213		1311506		Enoxolone	ZINC000019203131		Enoxolone	Investigational	DB13089	InChI=1S/C30H46O4/c1-25(2)21-8-11-30(7)23(28(21,5)10-9-22(25)32)20(31)16-18-19-17-27(4,24(33)34)13-12-26(19,3)14-15-29(18,30)6/h16,19,21-23,32H,8-15,17H2,1-7H3,(H,33,34)/t19-,21-,22-,23+,26+,27-,28-,29+,30+/m0/s1	MPDGHEJMBKOTSU-YKLVYJNSSA-N	3		Not Available	Small Molecule																																			1	No	4	2	No	5	-1	74.6 Å2	55.22 Å3	134.27 m3·mol-1	1	No	No	0.00172 mg/mL	6.03	-5.4	4.44	-0.84			
C29H48O2	Not Available	Not Available	428.701	CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C)C(C)C	Not Available	Not Available								8201186									10025615	347829221							1alpha-Hydroxyvitamin D5	Investigational	DB13097	InChI=1S/C29H48O2/c1-7-22(19(2)3)11-10-20(4)26-14-15-27-23(9-8-16-29(26,27)6)12-13-24-17-25(30)18-28(31)21(24)5/h12-13,19-20,22,25-28,30-31H,5,7-11,14-18H2,1-4,6H3/b23-12+,24-13-/t20-,22-,25-,26-,27+,28+,29-/m1/s1	NWFOBODUYTUMNC-VPSCEVSQSA-N	1		Not Available	Small Molecule																																			1	No	2	2	Yes	3	0	40.46 Å2	54.09 Å3	133.85 m3·mol-1	7	No	No	0.000923 mg/mL	6.55	-5.7	14.39	-2.8			
C22H30O3	Not Available	Not Available	342.479	C[C@H](O)C(=O)[C@@]1(C)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3CC[C@]12C	Not Available	Not Available						136027	CHEMBL2104765	62152									68926	347829250				Trimegestone	ZINC000004217604		Trimegestone	Investigational	DB13129	InChI=1S/C22H30O3/c1-13(23)20(25)22(3)11-9-19-18-6-4-14-12-15(24)5-7-16(14)17(18)8-10-21(19,22)2/h12-13,18-19,23H,4-11H2,1-3H3/t13-,18+,19-,21-,22+/m0/s1	JUNDJWOLDSCTFK-MTZCLOFQSA-N	4		Not Available	Small Molecule																																			1	Yes	3	1	No	4	0	54.37 Å2	39.44 Å3	99.51 m3·mol-1	2	Yes	No	0.0188 mg/mL	3.71	-4.3	13.7	-3.4			
C18H26O2	Not Available	Not Available	274.3978	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	Solid	Not Available					50080092	7466	CHEMBL757	9520			HMDB0002725	C07254		6VW		PA164746281	9904	347829275		7244		Nandrolone	ZINC000003814379		Nandrolone	Experimental, Investigational	DB13169	InChI=1S/C18H26O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h10,13-17,20H,2-9H2,1H3/t13-,14+,15+,16-,17-,18-/m0/s1	NPAGDVCDWIYMMC-IZPLOLCNSA-N	3	Nandrolone is an anabolic steroid indicated to increase bone density and muscle mass in patients with osteoporosis.	Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	32.27 Å3	79.95 m3·mol-1	0	Yes	Yes	0.0561 mg/mL	3.07	-3.7	18.25	-0.88			
C26H38O4	The elimination on the first day following intravenous injection of oxabolone cipionate is slow and reaches a rapid excretion phase with the maximum urinary level in the fifth day of administration 2.	Not Available	414.586	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=C(O)C(=O)CC[C@]4([H])[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1	Solid	Not Available						31940	CHEMBL2105318	62175									68952	347829285				Oxabolone_cipionate	ZINC000026892649		Oxabolone cipionate	Experimental	DB13185	InChI=1S/C26H38O4/c1-26-15-14-18-17-9-11-22(27)25(29)20(17)8-7-19(18)21(26)10-12-23(26)30-24(28)13-6-16-4-2-3-5-16/h16-19,21,23,29H,2-15H2,1H3/t17-,18-,19-,21+,23+,26+/m1/s1	KHKDIUPVDIEHAH-KXLSUQFWSA-N			Not Available	Small Molecule																																			1	Yes	3	1	No	5	0	63.6 Å2	48.9 Å3	116.85 m3·mol-1	5	No	No	0.00377 mg/mL	5.29	-5	9.23	-3.7			
C22H27FO5	Not Available	Not Available	390.451	C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]2(C)[C@H]1C(=O)C(O)=O	Not Available	Not Available								18865233					D07972									Fluocortin	ZINC000006031566		Fluocortin	Experimental	DB13223	InChI=1S/C22H27FO5/c1-10-6-13-12-8-15(23)14-7-11(24)4-5-21(14,2)18(12)16(25)9-22(13,3)17(10)19(26)20(27)28/h4-5,7,10,12-13,15-18,25H,6,8-9H2,1-3H3,(H,27,28)/t10-,12+,13+,15+,16+,17-,18-,21+,22+/m1/s1	PUWHHWCHAVXSIG-NCLPIGKXSA-N			Not Available	Small Molecule																																			1	Yes	5	2	No	4	-1	91.67 Å2	40.21 Å3	101.56 m3·mol-1	2	Yes	No	0.0302 mg/mL	2.74	-4.1	3.73	-0.23			
C20H28O3	Not Available	Not Available	316.441	[H][C@@]12CC[C@](O)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	Not Available	Not Available						135991	CHEMBL3707212	92341												4793		Gestronol	ZINC000005167250		Gestonorone	Experimental	DB13230	InChI=1S/C20H28O3/c1-12(21)20(23)10-8-18-17-5-3-13-11-14(22)4-6-15(13)16(17)7-9-19(18,20)2/h11,15-18,23H,3-10H2,1-2H3/t15-,16+,17+,18-,19-,20-/m0/s1	GTFUITFQDGVJSK-XGXHKTLJSA-N			Not Available	Small Molecule																																			1	Yes	3	1	No	4	0	54.37 Å2	36.34 Å3	89.63 m3·mol-1	1	Yes	No	0.0213 mg/mL	3.1	-4.2	12.7	-3.8			
C30H44O9	Not Available	Not Available	548.673	[H][C@@]1(CC[C@]2(O)[C@]3([H])CC[C@]4(O)C[C@H](CC[C@]4(C=O)[C@@]3([H])CC[C@]12C)O[C@H]1C[C@H](OC)[C@H](O)[C@@H](C)O1)C1=CC(=O)OC1	Not Available	Not Available						4037	CHEMBL1075788	390429				C08859										Cymarin	ZINC000008214527		Cymarin	Experimental	DB13240	InChI=1S/C30H44O9/c1-17-26(33)23(36-3)13-25(38-17)39-19-4-9-28(16-31)21-5-8-27(2)20(18-12-24(32)37-15-18)7-11-30(27,35)22(21)6-10-29(28,34)14-19/h12,16-17,19-23,25-26,33-35H,4-11,13-15H2,1-3H3/t17-,19+,20-,21+,22-,23+,25+,26-,27-,28+,29+,30+/m1/s1	XQCGNURMLWFQJR-ZNDDOCHDSA-N			Not Available	Small Molecule																																			1	No	8	3	No	6	0	131.75 Å2	58.62 Å3	140.03 m3·mol-1	5	No	No	0.0804 mg/mL	1.69	-3.8	7.18	0.27			
C30H42O8	Not Available	Not Available	530.658	[H][C@@]1(CC[C@]2(O)[C@]3([H])CCC4=C[C@]([H])(CC[C@]4(C)[C@@]3([H])CC[C@]12C)O[C@]1([H])O[C@@]([H])(C)[C@]([H])(O)[C@@]([H])(O)[C@@]1([H])O)C1=COC(=O)C=C1	Not Available	Not Available						32065	CHEMBL600325	4447658									5284613	347829292		8795		Proscillaridin	ZINC000008214665		Proscillaridin	Experimental	DB13307	InChI=1S/C30H42O8/c1-16-24(32)25(33)26(34)27(37-16)38-19-8-11-28(2)18(14-19)5-6-22-21(28)9-12-29(3)20(10-13-30(22,29)35)17-4-7-23(31)36-15-17/h4,7,14-16,19-22,24-27,32-35H,5-6,8-13H2,1-3H3/t16-,19-,20+,21-,22+,24-,25+,26+,27-,28-,29+,30-/m0/s1	MYEJFUXQJGHEQK-ALRJYLEOSA-N			Not Available	Small Molecule																																			1	No	7	4	No	6	0	125.68 Å2	58.26 Å3	140.05 m3·mol-1	3	No	No	0.0427 mg/mL	2.3	-4.1	12.22	0.3			
C19H26O3	Not Available	Not Available	302.414	COC1=CC=C2[C@H]3CC[C@]4(C)[C@H](O)[C@H](O)C[C@H]4[C@@H]3CCC2=C1	Not Available	Not Available						34738	CHEMBL2106236	214111				C14593										Epimestrol	ZINC000004215816		Epimestrol	Experimental	DB13386	InChI=1S/C19H26O3/c1-19-8-7-14-13-6-4-12(22-2)9-11(13)3-5-15(14)16(19)10-17(20)18(19)21/h4,6,9,14-18,20-21H,3,5,7-8,10H2,1-2H3/t14-,15-,16+,17-,18-,19+/m1/s1	UHQGCIIQUZBJAE-RRQVMCLOSA-N			Not Available	Small Molecule																																			1	Yes	3	2	No	4	0	49.69 Å2	35.02 Å3	85.75 m3·mol-1	1	Yes	No	0.0143 mg/mL	2.82	-4.3	13.62	-3.2			
C21H26O3	Not Available	Not Available	326.436	CO[C@H]1C[C@@]2(C)[C@@H](CC[C@@]2(O)C#C)[C@@H]2CCC3=CC(O)=CC=C3[C@@H]12	Not Available	Not Available					50218560	34857	CHEMBL1628161	10128336				C14757										Moxestrol	ZINC000003815417		Moxestrol	Experimental	DB13418	InChI=1S/C21H26O3/c1-4-21(23)10-9-17-16-7-5-13-11-14(22)6-8-15(13)19(16)18(24-3)12-20(17,21)2/h1,6,8,11,16-19,22-23H,5,7,9-10,12H2,2-3H3/t16-,17-,18-,19+,20-,21-/m0/s1	MTMZZIPTQITGCY-OLGWUGKESA-N			Not Available	Small Molecule																																			1	Yes	3	2	No	4	0	49.69 Å2	37.06 Å3	93.72 m3·mol-1	1	Yes	No	0.00928 mg/mL	3.23	-4.6	10.21	-3.7			
C24H32O2	Not Available	Not Available	352.518	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2OC1=CCCC1	Not Available	Not Available						135488	CHEMBL2106999	8536132														Quinbolone	ZINC000004217390		Quinbolone	Experimental	DB13484	InChI=1S/C24H32O2/c1-23-13-11-17(25)15-16(23)7-8-19-20-9-10-22(26-18-5-3-4-6-18)24(20,2)14-12-21(19)23/h5,11,13,15,19-22H,3-4,6-10,12,14H2,1-2H3/t19-,20-,21-,22-,23-,24-/m0/s1	IUVKMZGDUIUOCP-BTNSXGMBSA-N			Not Available	Small Molecule																																			1	Yes	2	0	No	5	0	26.3 Å2	42.19 Å3	108.18 m3·mol-1	2	No	Yes	0.001 mg/mL	5.03	-5.6	18.86	-4.6			
C27H45IO	Not Available	Not Available	516.562	CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3C[C@@H](C[131I])C4=C(CC[C@H](O)C4)[C@H]3CC[C@]12C	Not Available	Not Available						34893	CHEMBL2106905	571011				C13547											ZINC000118913163		Iodine (131I) norcholesterol	Experimental	DB13487	InChI=1S/C27H45IO/c1-17(2)6-5-7-18(3)25-10-11-26-24-14-19(16-28)23-15-20(29)8-9-21(23)22(24)12-13-27(25,26)4/h17-20,22,24-26,29H,5-16H2,1-4H3/t18-,19+,20+,22-,24-,25-,26+,27-/m1/s1/i28+4	QJHZPCLORSPENH-DRTKWHMQSA-N		Iodine (131I) norcholesterol is a radioiodine-labeled cholesterol analogue that accumulates in areas where steroid hormones are produced and is used in certain diagnostic procedures.	Not Available	Small Molecule																																			0	No	1	1	Yes	4	0	20.23 Å2	55.61 Å3	133.56 m3·mol-1	6	No	Yes	0.000117 mg/mL	7.67	-6.6	18.19	-1.4			
C22H29FO5	Not Available	Not Available	392.467	C[C@H](O)C(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C	Not Available	Not Available								32700976														Fluperolone			Fluperolone	Experimental	DB13491	InChI=1S/C22H29FO5/c1-12(24)18(27)21(28)9-7-15-16-5-4-13-10-14(25)6-8-19(13,2)22(16,23)17(26)11-20(15,21)3/h6,8,10,12,15-17,24,26,28H,4-5,7,9,11H2,1-3H3/t12-,15-,16-,17-,19-,20-,21-,22-/m0/s1	SLVCCRYLKTYUQP-DVTGEIKXSA-N			Not Available	Small Molecule																																			1	Yes	5	3	No	4	0	94.83 Å2	40.82 Å3	102.52 m3·mol-1	2	Yes	No	0.0579 mg/mL	1.89	-3.8	12.53	-3.4			
C21H27ClO3	Not Available	Not Available	362.89	[H][C@@]12CC[C@](O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(Cl)C2=CC(=O)CC[C@]12C	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4				CHEMBL1697830	4447590												78904		Chlormadinone	ZINC000030691600		Chlormadinone	Experimental	DB13528	InChI=1S/C21H27ClO3/c1-12(23)21(25)9-6-16-14-11-18(22)17-10-13(24)4-7-19(17,2)15(14)5-8-20(16,21)3/h10-11,14-16,25H,4-9H2,1-3H3/t14-,15+,16+,19-,20+,21+/m1/s1	VUHJZBBCZGVNDZ-TTYLFXKOSA-N	1	Chlormadinone is a progestin indicated in combination with an estrogen for oral combined hormonal contraceptive therapy.	Not Available	Small Molecule																																			1	Yes	3	1	No	4	0	54.37 Å2	39.66 Å3	99.94 m3·mol-1	1	Yes	No	0.00677 mg/mL	3.28	-4.7	12.7	-3.8			
C19H28O2	Not Available	Not Available	288.431	C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C	Not Available	Not Available						34896	CHEMBL2106801	4447645				C14491										Normethandrone	ZINC000004217180		Methylestrenolone	Experimental	DB13533	InChI=1S/C19H28O2/c1-18-9-7-15-14-6-4-13(20)11-12(14)3-5-16(15)17(18)8-10-19(18,2)21/h11,14-17,21H,3-10H2,1-2H3/t14-,15+,16+,17-,18-,19-/m0/s1	ZXSWTMLNIIZPET-ZOFHRBRSSA-N			Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	34.21 Å3	84.59 m3·mol-1	0	Yes	Yes	0.0302 mg/mL	3.35	-4	19.28	-0.53			
C20H22O2	Not Available	Not Available	294.394	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)C=CC1=C3CCC(=O)C=C3CC[C@@]21[H]	Not Available	Not Available						135231	CHEMBL1908319	12749												7519		Norgestrienone	ZINC000004217177		Norgestrienone	Experimental	DB13563	InChI=1S/C20H22O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,8,10,12,17-18,22H,4-7,9,11H2,2H3/t17-,18+,19+,20+/m1/s1	GVDMJXQHPUYPHP-FYQPLNBISA-N			Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	33.61 Å3	89.12 m3·mol-1	0	Yes	Yes	0.0113 mg/mL	2.41	-4.4	17.57	-1.7			
C20H37NO3	Not Available	Not Available	339.52	CCN(CC)CC(C)OC(=O)[C@H]1CCCC[C@]1(O)C1CCCCC1	Not Available	Not Available						135440		28534065														Rociverine			Rociverine	Experimental	DB13581	InChI=1S/C20H37NO3/c1-4-21(5-2)15-16(3)24-19(22)18-13-9-10-14-20(18,23)17-11-7-6-8-12-17/h16-18,23H,4-15H2,1-3H3/t16?,18-,20+/m1/s1	XPYLKZZOBVLVHB-QDKIRNHSSA-N		Rociverine is an antispasmodic indicated in the treatment of urinary, gastrointestinal, and biliary tract spasms.	Not Available	Small Molecule																																			1	Yes	3	1	No	2	1	49.77 Å2	40.08 Å3	97.7 m3·mol-1	8	Yes	No	0.0582 mg/mL	3.99	-3.8	14.09	9.2	P11229;!P08172;!P20309;!P08173;!P08912	CHRM1;!CHRM2;!CHRM3;!CHRM4;!CHRM5	1. Muscarinic acetylcholine receptor M1;!2. Muscarinic acetylcholine receptor M2;!3. Muscarinic acetylcholine receptor M3;!4. Muscarinic acetylcholine receptor M4;!5. Muscarinic acetylcholine receptor M5
C20H28O2	Not Available	Not Available	300.4351	[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Not Available	Not Available						6810	CHEMBL1418176	6061			HMDB0041925									6818		Metandienone	ZINC000003875469		Metandienone	Experimental	DB13586	InChI=1S/C20H28O2/c1-18-9-6-14(21)12-13(18)4-5-15-16(18)7-10-19(2)17(15)8-11-20(19,3)22/h6,9,12,15-17,22H,4-5,7-8,10-11H2,1-3H3/t15-,16+,17+,18+,19+,20+/m1/s1	XWALNWXLMVGSFR-HLXURNFRSA-N		Metandienone is an anabolic steroid indicated for appetite stimulation in patients with anorexia.	Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	35.09 Å3	90.16 m3·mol-1	0	Yes	Yes	0.0161 mg/mL	3.64	-4.3	18.39	-0.53			
C20H32O2	Not Available	Not Available	304.4669	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)C[C@H](C)[C@]12C	Not Available	Not Available					50423551	135293	CHEMBL258918	14296			HMDB0006036						15020	347829305		6781		Mesterolone	ZINC000003881977		Mesterolone	Experimental	DB13587	InChI=1S/C20H32O2/c1-12-10-14(21)11-13-4-5-15-16-6-7-18(22)19(16,2)9-8-17(15)20(12,13)3/h12-13,15-18,22H,4-11H2,1-3H3/t12-,13-,15-,16-,17-,18-,19-,20-/m0/s1	UXYRZJKIQKRJCF-TZPFWLJSSA-N		Mesterolone is an anabolic steroid indicated in the treatment of low testosterone, hypogonadism, oligozoospermia, and Leydig cell failure.	Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	36.3 Å3	88.15 m3·mol-1	0	Yes	Yes	0.00641 mg/mL	3.7	-4.7	19.38	-0.88			
C22H30O2	Not Available	Not Available	326.48	CCC(=O)[C@@]1(C)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3CC[C@]12C	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4		18660	73390	CHEMBL196003	33716				C14208								8744		Promegestone	ZINC000003814408		Promegestone	Experimental	DB13602	InChI=1S/C22H30O2/c1-4-20(24)22(3)12-10-19-18-7-5-14-13-15(23)6-8-16(14)17(18)9-11-21(19,22)2/h13,18-19H,4-12H2,1-3H3/t18-,19+,21+,22-/m1/s1	QFFCYTLOTYIJMR-XMGTWHOFSA-N			Not Available	Small Molecule																																			1	Yes	2	0	No	4	0	34.14 Å2	38.7 Å3	97.94 m3·mol-1	2	Yes	Yes	0.00772 mg/mL	4.66	-4.6	19	-4.7			
C22H29F3O3	Not Available	Not Available	398.466	CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@@H](C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(F)(F)F	Not Available	Not Available						135987	CHEMBL2104932	16736667														Flumedroxone			Flumedroxone	Experimental	DB13610	InChI=1S/C22H29F3O3/c1-12(26)21(28)9-6-16-14-11-18(22(23,24)25)17-10-13(27)4-7-19(17,2)15(14)5-8-20(16,21)3/h10,14-16,18,28H,4-9,11H2,1-3H3/t14-,15+,16+,18+,19-,20+,21+/m1/s1	CDZJOBWKHSYNMO-SCUQKFFVSA-N			Not Available	Small Molecule																																			1	Yes	3	1	No	4	0	54.37 Å2	40.24 Å3	99.51 m3·mol-1	2	Yes	No	0.00796 mg/mL	3.97	-4.7	12.38	-3.8			
C28H48OSe	Not Available	Not Available	475.614	C[75Se]C[C@@H]1C[C@H]2[C@@H]3CC[C@H]([C@H](C)CCCC(C)C)[C@@]3(C)CC[C@@H]2C2=C1C[C@@H](O)CC2	Not Available	Not Available								108863																	Selenium (75Se) norcholesterol	Experimental	DB13622	InChI=1S/C28H48OSe/c1-18(2)7-6-8-19(3)26-11-12-27-25-15-20(17-30-5)24-16-21(29)9-10-22(24)23(25)13-14-28(26,27)4/h18-21,23,25-27,29H,6-17H2,1-5H3/t19-,20+,21+,23-,25-,26-,27+,28-/m1/s1/i30-4	AEVGUKVBCBHBNF-MJMUOCKJSA-N		Selenium (75Se) norcholesterol is a radiopharmaceutical indicated in nuclear imaging studies of the digestive system.	Not Available	Small Molecule																																			1	No	2	1	Yes	4	0	20.23 Å2	54.58 Å3	138.28 m3·mol-1	7	No	Yes	0.000337 mg/mL	6.31	-6.2	18.19	-1.4			
C32H48O5	Not Available	Not Available	512.731	CC(=O)O[C@H]1CC[C@@]2(C)[C@@H](CC[C@]3(C)[C@@H]2C(=O)C=C2[C@@H]4C[C@](C)(CC[C@]4(C)CC[C@@]32C)C(O)=O)C1(C)C	Not Available	Not Available					50188385	81306	CHEMBL207413	85123				C17734								16784		Acetoxolone	ZINC000034169081		Acetoxolone	Experimental	DB13640	InChI=1S/C32H48O5/c1-19(33)37-24-10-11-30(6)23(27(24,2)3)9-12-32(8)25(30)22(34)17-20-21-18-29(5,26(35)36)14-13-28(21,4)15-16-31(20,32)7/h17,21,23-25H,9-16,18H2,1-8H3,(H,35,36)/t21-,23-,24-,25+,28+,29-,30-,31+,32+/m0/s1	FTQDJVZNPJRVPG-XWEVEMRCSA-N			Not Available	Small Molecule																																			0	No	4	1	No	5	-1	80.67 Å2	59.68 Å3	143.42 m3·mol-1	3	No	No	0.000555 mg/mL	6.47	-6	4.44	-5.1			
C29H38ClFO8	Not Available	Not Available	569.06	CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3CC(C=O)=C4C=C(CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C)OCCCl	Not Available	Not Available						135834	CHEMBL1989587	254985														Formocortal	ZINC000004216336		Formocortal	Experimental	DB13664	InChI=1S/C29H38ClFO8/c1-16(33)37-15-23(35)29-24(38-25(2,3)39-29)12-20-21-10-17(14-32)19-11-18(36-9-8-30)6-7-26(19,4)28(21,31)22(34)13-27(20,29)5/h11,14,20-22,24,34H,6-10,12-13,15H2,1-5H3/t20-,21-,22-,24+,26-,27-,28-,29+/m0/s1	QNXUUBBKHBYRFW-QWAPGEGQSA-N			Not Available	Small Molecule																																			1	No	7	1	Yes	5	0	108.36 Å2	58.69 Å3	141.36 m3·mol-1	8	No	No	0.00875 mg/mL	2.07	-4.8	13.64	-3.4			
C25H34O2	Not Available	Not Available	366.545	C[C@]12CC[C@H]3[C@@H](CC=C4C=C(CC[C@H]34)OC3CCCC3)[C@@H]1CC[C@@]2(O)C#C	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4					8017842														Quingestanol			Quingestanol	Experimental	DB13685	InChI=1S/C25H34O2/c1-3-25(26)15-13-23-22-10-8-17-16-19(27-18-6-4-5-7-18)9-11-20(17)21(22)12-14-24(23,25)2/h1,8,16,18,20-23,26H,4-7,9-15H2,2H3/t20-,21+,22+,23-,24-,25-/m0/s1	PCJFRMOEZQQSAX-AIOSZGMZSA-N			Not Available	Small Molecule																																			1	Yes	2	1	No	5	0	29.46 Å2	43.67 Å3	111.13 m3·mol-1	2	Yes	Yes	0.00211 mg/mL	4.32	-5.2	17.59	-1.7			
C27H44O3	Not Available	Not Available	416.646	CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	Not Available	Not Available					50441892		CHEMBL2105611	4446823												291204		Tacalcitol	ZINC000004474668		Tacalcitol	Experimental, Investigational	DB13689	InChI=1S/C27H44O3/c1-17(2)25(29)13-8-18(3)23-11-12-24-20(7-6-14-27(23,24)5)9-10-21-15-22(28)16-26(30)19(21)4/h9-10,17-18,22-26,28-30H,4,6-8,11-16H2,1-3,5H3/b20-9+,21-10-/t18-,22-,23-,24+,25-,26+,27-/m1/s1	BJYLYJCXYAMOFT-RSFVBTMBSA-N	3	Tacalcitol is a vitamin D analog indicated in the treatment of mild to moderate plaque psoriasis.	Not Available	Small Molecule																																			1	No	3	3	Yes	3	0	60.69 Å2	51.11 Å3	126.29 m3·mol-1	6	Yes	No	0.0105 mg/mL	4.51	-4.6	14.39	-1.1			
C20H30O2	Not Available	Not Available	302.451	[H][C@]1(O)CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])CC(=O)C=C(C)[C@]4(C)[C@@]3([H])CC[C@]12C	Not Available	Not Available						135283		2301378			HMDB0041928									6833		Metenolone	ZINC000005497532		Metenolone	Experimental	DB13710	InChI=1S/C20H30O2/c1-12-10-14(21)11-13-4-5-15-16-6-7-18(22)19(16,2)9-8-17(15)20(12,13)3/h10,13,15-18,22H,4-9,11H2,1-3H3/t13-,15-,16-,17-,18-,19-,20-/m0/s1	ANJQEDFWRSLVBR-VHUDCFPWSA-N		Metenolone is an anabolic steroid indicated in the treatment and prevention of muscle wasting due to diseases, drug treatments, or other catabolic processes.	Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	35.88 Å3	88.98 m3·mol-1	0	Yes	Yes	0.022 mg/mL	3.65	-4.1	19.38	-0.88			
C22H27ClF2O5	Not Available	Not Available	444.9	C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C(Cl)=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO	Not Available	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5			135724	CHEMBL1587228	8022046												26416		Halometasone	ZINC000003938673		Halometasone	Experimental	DB13728	InChI=1S/C22H27ClF2O5/c1-10-4-11-12-5-15(24)13-6-16(27)14(23)7-19(13,2)21(12,25)17(28)8-20(11,3)22(10,30)18(29)9-26/h6-7,10-12,15,17,26,28,30H,4-5,8-9H2,1-3H3/t10-,11+,12+,15+,17+,19+,20+,21+,22+/m1/s1	GGXMRPUKBWXVHE-MIHLVHIWSA-N	4	Halometasone is a corticosteroid indicated in the treatment of corticosteroid responsive dermatoses.	Not Available	Small Molecule																																			1	Yes	5	3	No	4	0	94.83 Å2	43.35 Å3	107.11 m3·mol-1	2	Yes	No	0.0356 mg/mL	1.73	-4.1	12.42	-3.3			
C42H62O16	The constant reabsorption of glycyrrhetic acid in the duodenum causes a delay in the terminal plasma clearance.3 The reported total body clearance of glycyrrhizic acid is reported to be in the range of 16-25 ml.kg/h.5	Depending on the dose, the second elimination phase in humans has a half-life of 3.5 hours.4	822.942	[H][C@@]12C[C@](C)(CC[C@]1(C)CC[C@]1(C)C2=CC(=O)[C@]2([H])[C@@]3(C)CC[C@H](O[C@H]4O[C@@H]([C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@@H]([C@@H](O)[C@H](O)[C@H]4O)C(O)=O)C(O)=O)C(C)(C)[C@]3([H])CC[C@@]12C)C(O)=O	Solid	The apparent volume of distribution of glycyrrhizic acid either in the central compartment and in steady-state are in the range of 37-64 ml/kg and 59-98 ml/kg, respectively.5					50185127	15939	CHEMBL441687	14263				C02284	D00157							26143		Glycyrrhizin	ZINC000096015174		Glycyrrhizic acid	Approved, Experimental	DB13751	InChI=1S/C42H62O16/c1-37(2)21-8-11-42(7)31(20(43)16-18-19-17-39(4,36(53)54)13-12-38(19,3)14-15-41(18,42)6)40(21,5)10-9-22(37)55-35-30(26(47)25(46)29(57-35)33(51)52)58-34-27(48)23(44)24(45)28(56-34)32(49)50/h16,19,21-31,34-35,44-48H,8-15,17H2,1-7H3,(H,49,50)(H,51,52)(H,53,54)/t19-,21-,22-,23-,24-,25-,26-,27+,28-,29-,30+,31+,34-,35-,38+,39-,40-,41+,42+/m0/s1	LPLVUJXQOOQHMX-QWBHMCJMSA-N			Glycyrrhizic acid is thought to generate inhibition of 11-beta-hydroxysteroid dehydrogenase in the kidney which leads to elevated cortisol levels in the kidney. Intravenous administration of the ammoniated form was shown to produce convulsions and hemolysis.11Preclinical overdose studies have been shown to produce mineralocorticoid excess. The LD50 in preclinical studies was reported to be in the range of 308-12700 mg/kg.11 Glycyrrhizic acid has been proven to not have mutagenic, genotoxic, teratogenic nor carcinogenic effects.11	Small Molecule																													Decomposes at 200 ºC	2.8		220 ºC (Decomposes at 200 ºC)		Easily soluble in hot water	0	No	16	8	Yes	7	-3	267.04 Å2	86.31 Å3	198.83 m3·mol-1	7	No	No	0.0545 mg/mL	3.13	-4.2	2.96	-3.7	P28845;!P01375;!P42574;!BE0004903;!P06858	HSD11B1;!TNF;!CASP3;!;!LPL	1. Corticosteroid 11-beta-dehydrogenase isozyme 1;!2. Tumor necrosis factor;!3. Caspase-3;!4. Nuclear factor NF-kappa-B (Protein Group);!5. Lipoprotein lipase
C30H44O9	Not Available	Not Available	548.673	CO[C@@H]1[C@@H](O)[C@H](C)O[C@@H](O[C@H]2CC[C@@]3(C=O)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H](CC[C@]43O)C3=CC(=O)OC3)C2)[C@H]1O	Not Available	Not Available						135825	CHEMBL1075790	16498835														Peruvoside			Peruvoside	Experimental	DB13756	InChI=1S/C30H44O9/c1-16-24(33)26(36-3)25(34)27(38-16)39-19-6-10-29(15-31)18(13-19)4-5-22-21(29)7-9-28(2)20(8-11-30(22,28)35)17-12-23(32)37-14-17/h12,15-16,18-22,24-27,33-35H,4-11,13-14H2,1-3H3/t16-,18+,19-,20+,21-,22+,24-,25-,26+,27-,28+,29+,30-/m0/s1	PMTSPAGBAFCORP-HBUONDEYSA-N			Not Available	Small Molecule																																			1	No	8	3	No	6	0	131.75 Å2	58.9 Å3	140.05 m3·mol-1	5	No	No	0.0791 mg/mL	2.02	-3.8	7.18	0.27			
C27H45IO	Not Available	Not Available	516.562	CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C[131I])[C@H]3CC[C@]12C	Not Available	Not Available						135998	CHEMBL2105011	396792														Iodocholesterol	ZINC000118913216		Iodocholesterol (131I)	Experimental	DB13797	InChI=1S/C27H45IO/c1-18(2)6-5-7-19(3)23-10-11-24-22-9-8-20-16-21(29)12-15-27(20,17-28)25(22)13-14-26(23,24)4/h8,18-19,21-25,29H,5-7,9-17H2,1-4H3/t19-,21+,22+,23-,24+,25+,26-,27-/m1/s1/i28+4	FIOAEFCJGZJUPW-ODFYUTSGSA-N			Not Available	Small Molecule																																			0	No	1	1	Yes	4	0	20.23 Å2	55.14 Å3	133.67 m3·mol-1	6	No	Yes	3.97e-05 mg/mL	7.8	-7.1	18.2	-1.4			
C21H25Cl2FO5	Not Available	Not Available	447.32	C[C@]12C[C@H](Cl)[C@@]3(Cl)[C@@H](C[C@H](F)C4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO	Not Available	Not Available						135986	CHEMBL3707231	32697416												108091		Fluclorolone	ZINC000031284397		Fluclorolone	Experimental	DB13856	InChI=1S/C21H25Cl2FO5/c1-18-4-3-10(26)5-13(18)14(24)6-12-11-7-16(27)21(29,17(28)9-25)19(11,2)8-15(22)20(12,18)23/h3-5,11-12,14-16,25,27,29H,6-9H2,1-2H3/t11-,12-,14-,15-,16+,18-,19-,20-,21-/m0/s1	VTWKPILBIUBMDS-OTJLYDAYSA-N			Not Available	Small Molecule																																			1	Yes	5	3	No	4	0	94.83 Å2	42.62 Å3	107 m3·mol-1	2	Yes	No	0.0202 mg/mL	1.72	-4.4	11.76	-3.3			
C21H28O2	Not Available	Not Available	312.4458	[H][C@@]12CC[C@](C)(C(C)=O)[C@@]1(C)CCC1=C3CCC(=O)C=C3CC[C@@]21[H]	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			135339	CHEMBL2104231	84009					D07223							22483		Demegestone	ZINC000004215548		Demegestone	Experimental	DB13857	InChI=1S/C21H28O2/c1-13(22)20(2)11-9-19-18-6-4-14-12-15(23)5-7-16(14)17(18)8-10-21(19,20)3/h12,18-19H,4-11H2,1-3H3/t18-,19+,20-,21+/m1/s1	JWAHBTQSSMYISL-MHTWAQMVSA-N			Not Available	Small Molecule																																			1	Yes	2	0	No	4	0	34.14 Å2	36.71 Å3	93.31 m3·mol-1	1	Yes	Yes	0.0111 mg/mL	3.96	-4.4	18.42	-4.7	P06401	PGR	1. Progesterone receptor
C20H28O2	Not Available	Not Available	300.442	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CC[C@H](O)C=C3CC[C@@]21[H]	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			50785	CHEMBL1201406	14017					D07939				14687	347829321		24591		Etynodiol	ZINC000030691629		Etynodiol	Experimental	DB13866	InChI=1S/C20H28O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,12,14-18,21-22H,4-11H2,2H3/t14-,15-,16+,17+,18-,19-,20-/m0/s1	JYILPERKVHXLNF-QMNUTNMBSA-N			Not Available	Small Molecule																																			1	Yes	2	2	No	4	0	40.46 Å2	35.26 Å3	88.32 m3·mol-1	0	Yes	No	0.00785 mg/mL	2.81	-4.6	17.52	-1.4			
C22H27F3O4S	57.8L/h for Fluticasone furoate12. A study of 24 healthy Caucasian males showed a clearance of 71.8L/h following intravenous administration1.1093mL/min for Fluticasone propionate11. A study of 24 healthy Caucasian males showed a clearance of 63.9L/h following intravenous administration1.	15.1 hours for intranasal Fluticasone furoate12 and 24 hours for the inhaled formulation13. A study of 24 healthy Caucasian males showed a half life of 13.6 hours following intravenous administration and 17.3-23.9 hours followed inhalation1.7.8 hours for intravenous Fluticasone propionate11Label. A study of 24 healthy Caucasian males shows a half life of 14.0 hours following intravenous administration and 10.8 hours following inhalation1.	444.51	[H][C@@]12C[C@@H](C)[C@](O)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C	Solid	608L at steady state for intravenous administration of Fluticasone furoate12. Other reports suggest the mean volume of distribution at steady state is 661L13. A study of 24 healthy Caucasian males showed a volume of distribution at steady state of 704L following intravenous administration1.The volume of distribution of intravenous Fluticasone propionate is 4.2L/kg11Label. A study of 24 healthy Caucasian males showed a volume of distribution at steady state of 577L following intravenous administration1.	P08684;!P20815;!P24462;!P10632	CYP3A4;!CYP3A5;!CYP3A7;!CYP2C8	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5;!3. Cytochrome P450 3A7;!4. Cytochrome P450 2C8			5134	CHEMBL1201396	4470631				C07815	D07981							41126		Fluticasone	ZINC000004097438		Fluticasone	Approved, Experimental	DB13867	InChI=1S/C22H27F3O4S/c1-11-6-13-14-8-16(24)15-7-12(26)4-5-19(15,2)21(14,25)17(27)9-20(13,3)22(11,29)18(28)30-10-23/h4-5,7,11,13-14,16-17,27,29H,6,8-10H2,1-3H3/t11-,13+,14+,16+,17+,19+,20+,21+,22+/m1/s1	MGNNYOODZCAHBA-GQKYHHCASA-N	4	Fluticasone is a corticosteroid indicated in the treatment of corticosteroid responsive dermatoses, asthma, and COPD.	Fluticasone furoate administered nasally may be associated with adrenal suppression or an increase in QTc interval though the association has not been well demonstrated in studies12,2. Fluticasone furoate requires no dosage adjustment in renal impairment but must be used in caution in hepatic impairment due to the elimination mechanisms12,13. Fluticasone furoate is not associated with carcinogenicity, mutagenicity, or impairment of fertility12. There are no well controlled studies in pregnancy or lactation though animal studies have shown teratogenicity and hypoadrenalism in the offspring of treated mothers and other corticosteroids are known to be excreted in breast milk12. Generally, there are no reported adverse effects with fluticasone in pregnancy6. Pediatric patients should be given the lowest possible dose and monitored for reduction in growth velocity12,2. There is insufficient evidence to determine whether geriatric patients respond differently to other patients12. Systemic exposure may be 27-49% higher in Japanese, Korean, and Chinese patients compared to Caucasian patients13. Caution should be exercised in these patients and the benefit and risk should be assessed before deciding on a treatment12.Fluticasone propionate's use in specific populations has not been well studied11. Fluticasone propionate is not carcinogenic, mutagenic, or clastogenic, nor did it affect fertility in animal studies11Label. Subcutaneous Fluticasone propionate has been shown to produce teratogenic effects in rats though oral administration does not10Label. Generally, there are no reported adverse effects with fluticasone in pregnancy6. Fluticasone propionate in human milk may cause growth suppression, effects on endogenous corticosteroid production, or other effects10,2. Pediatric patients treated with Fluticasone propionate ointment experienced adrenal suppression10. Geriatric patients treated with Fluticasone propionate did not show any difference in safety or efficacy compared to other patient groups, though older patients may be more sensitive to adverse effects10. There is no difference in the clearance of Fluticasone propionate across genders or raceLabel. Patients with hepatic impairment should be closely monitored due to the elimination mechanismLabel5.	Small Molecule																																			1	Yes	4	2	No	4	0	74.6 Å2	43.32 Å3	107.87 m3·mol-1	3	Yes	No	0.0344 mg/mL	2.58	-4.1	12.19	-3.4	P04150;!P06401;!P47712;!P08235	NR3C1;!PGR;!PLA2G4A;!NR3C2	1. Glucocorticoid receptor;!2. Progesterone receptor;!3. Cytosolic phospholipase A2;!4. Mineralocorticoid receptor
C27H40O3	Testosterone cypionate presents a lower clearance rate after intramuscular administration compared to other analogs of testosterone.	The half-life of testosterone cypionate is one of the longest, being approximately of 8 days.5	412.614	[H][C@@]12CC[C@H](OC(=O)CCC3CCCC3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	The volume of distribution following intravenous administration of testosterone is of approximately 1 L/kg.7	P08684;!P21397;!P05108;!P20815;!P24462;!P04798;!Q16696;!P20813;!P33261;!P10632;!P11712;!Q9HB55;!BE0004887;!P11511	CYP3A4;!MAOA;!CYP11A1;!CYP3A5;!CYP3A7;!CYP1A1;!CYP2A13;!CYP2B6;!CYP2C19;!CYP2C8;!CYP2C9;!CYP3A43;!;!CYP19A1	1. Cytochrome P450 3A4;!2. Amine oxidase [flavin-containing] A;!3. Cholesterol side-chain cleavage enzyme, mitochondrial;!4. Cytochrome P450 3A5;!5. Cytochrome P450 3A7;!6. Cytochrome P450 1A1;!7. Cytochrome P450 2A13;!8. Cytochrome P450 2B6;!9. Cytochrome P450 2C19;!10. Cytochrome P450 2C8;!11. Cytochrome P450 2C9;!12. Cytochrome P450 3A43;!13. 3-oxo-5-alpha-steroid 4-dehydrogenase (Protein Group);!14. Cytochrome P450 19A1			9463	CHEMBL1201101	390140				C08156	D00957									Testosterone_cypionate	ZINC000004097468	Depo-testosterone	Testosterone cypionate	Approved	DB13943	InChI=1S/C27H40O3/c1-26-15-13-20(28)17-19(26)8-9-21-22-10-11-24(27(22,2)16-14-23(21)26)30-25(29)12-7-18-5-3-4-6-18/h17-18,21-24H,3-16H2,1-2H3/t21-,22-,23-,24-,26-,27-/m0/s1	HPFVBGJFAYZEBE-ZLQWOROUSA-N	4	Testosterone cypionate is an androgen used to treat low or absent testosterone.	Preclinical studies with testosterone implants induced cervical-uterine tumors in mice which metastasized in some cases. Some reports indicate that administration of testosterone cypionate in females can augment the susceptibility to hepatoma as well as increase the number of tumors. Clinical studies have reported cases of hepatocellular carcinoma in long-term high-dose therapy.6	Small Molecule																																98-104ºC		Insoluble	1	No	2	0	No	5	0	43.37 Å2	49.84 Å3	119.36 m3·mol-1	5	No	No	0.000437 mg/mL	6.11	-6	18.52	-4.8	P10275;!P03372;!P08235	AR;!ESR1;!NR3C2	1. Androgen receptor;!2. Estrogen receptor alpha;!3. Mineralocorticoid receptor
C26H40O3	Not Available	Testosterone enanthate presents a long half-life in the range of 7-9 days.3	400.594	[H][C@@]12CC[C@H](OC(=O)CCCCCC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	The volume of distribution following intravenous administration of testosterone is of approximately 1 L/kg.8	P08684;!P21397;!P05108;!P20815;!P24462;!P04798;!Q16696;!P20813;!P33261;!P10632;!P11712;!Q9HB55;!BE0004887;!P11511	CYP3A4;!MAOA;!CYP11A1;!CYP3A5;!CYP3A7;!CYP1A1;!CYP2A13;!CYP2B6;!CYP2C19;!CYP2C8;!CYP2C9;!CYP3A43;!;!CYP19A1	1. Cytochrome P450 3A4;!2. Amine oxidase [flavin-containing] A;!3. Cholesterol side-chain cleavage enzyme, mitochondrial;!4. Cytochrome P450 3A5;!5. Cytochrome P450 3A7;!6. Cytochrome P450 1A1;!7. Cytochrome P450 2A13;!8. Cytochrome P450 2B6;!9. Cytochrome P450 2C19;!10. Cytochrome P450 2C8;!11. Cytochrome P450 2C9;!12. Cytochrome P450 3A43;!13. 3-oxo-5-alpha-steroid 4-dehydrogenase (Protein Group);!14. Cytochrome P450 19A1			9464	CHEMBL1200335	9045			HMDB0005814	C08157										Testosterone_enanthate	ZINC000003876080	Delatestryl, Xyosted	Testosterone enanthate	Approved	DB13944	InChI=1S/C26H40O3/c1-4-5-6-7-8-24(28)29-23-12-11-21-20-10-9-18-17-19(27)13-15-25(18,2)22(20)14-16-26(21,23)3/h17,20-23H,4-16H2,1-3H3/t20-,21-,22-,23-,25-,26-/m0/s1	VOCBWIIFXDYGNZ-IXKNJLPQSA-N	4	Testosterone enanthate is an androgen used to treat low or absent testosterone.	Testosterone enanthate has been tested in preclinical carcinogenesis trials. In this studies, it is suggested that the exposure to this drug may increase the susceptibility to hematoma as well as the number of tumors and decrease the degree of differentiation of chemically induced carcinomas of the liver.LabelTestosterone enanthate is not indicated for use in females and is contraindicated in pregnant women. Testosterone is teratogenic and may cause fetal harm when administered to a pregnant woman based on data from animal studies and its mechanism of action. 11During treatment with large doses of exogenous androgens, including testosterone enanthate, spermatogenesis may be suppressed through feedback inhibition of the hypothalamic-pituitary-testicular axis 11. Reduced fertility is observed in some men taking testosterone replacement therapy and the impact on fertility may be irreversible 11.Safety and effectiveness of testosterone enanthate in pediatric patients less than 18 years old have not been established 11. Improper use may result in the acceleration of bone age and premature closure of epiphyses 11.Geriatric patients treated with androgens may also be at risk for worsening of signs and symptoms of Benign Prostatic Hyperplasia 11.	Small Molecule																														3.58		34-39ºC		Insoluble	1	No	2	0	Yes	4	0	43.37 Å2	49.18 Å3	116.61 m3·mol-1	7	No	No	0.000463 mg/mL	6.29	-5.9	18.52	-4.8	P10275;!P03372;!P08235	AR;!ESR1;!NR3C2	1. Androgen receptor;!2. Estrogen receptor alpha;!3. Mineralocorticoid receptor
C30H48O3	While there is limited information available, an earlier study reports a metabolic clearance rate of 24.5 mL/min/kg for testosterone following oral administration of 25 mg testosterone and 40 mg testosterone undecanoate in women.5	The elimination half-life of testosterone undecanoate is approximately two hours. Once testosterone is formed from testosterone undecanoate, the half life of testosterone can vary and the reported values in the literature remain inconsistent, ranging from 10 to to 100 minutes.6,8 Testosterone undecanoate in castor oil for intramuscular injection had a half life of 33.9 days, allowing it to maintain serum levels in the normal range for over 6 weeks.[A176954]	456.711	CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C	Solid	There is no information available.	P08684;!P21397;!P05108;!P20815;!P24462;!P04798;!Q16678;!Q16696;!P20813;!P33261;!P10632;!P11712;!Q9HB55;!BE0004887;!P11511	CYP3A4;!MAOA;!CYP11A1;!CYP3A5;!CYP3A7;!CYP1A1;!CYP1B1;!CYP2A13;!CYP2B6;!CYP2C19;!CYP2C8;!CYP2C9;!CYP3A43;!;!CYP19A1	1. Cytochrome P450 3A4;!2. Amine oxidase [flavin-containing] A;!3. Cholesterol side-chain cleavage enzyme, mitochondrial;!4. Cytochrome P450 3A5;!5. Cytochrome P450 3A7;!6. Cytochrome P450 1A1;!7. Cytochrome P450 1B1;!8. Cytochrome P450 2A13;!9. Cytochrome P450 2B6;!10. Cytochrome P450 2C19;!11. Cytochrome P450 2C8;!12. Cytochrome P450 2C9;!13. Cytochrome P450 3A43;!14. 3-oxo-5-alpha-steroid 4-dehydrogenase (Protein Group);!15. Cytochrome P450 19A1			135741	CHEMBL2107067	58664														Testosterone_undecanoate	ZINC000008214690	Aveed, Jatenzo, Tlando	Testosterone undecanoate	Approved, Investigational	DB13946	InChI=1S/C30H48O3/c1-4-5-6-7-8-9-10-11-12-28(32)33-27-16-15-25-24-14-13-22-21-23(31)17-19-29(22,2)26(24)18-20-30(25,27)3/h21,24-27H,4-20H2,1-3H3/t24-,25-,26-,27-,29-,30-/m0/s1	UDSFVOAUHKGBEK-CNQKSJKFSA-N	4	Testosterone undecanoate is an androgen indicated for testosterone replacement therapy in adult males with primary hypogonadism and hypogonadotropic hypogonadism.	The oral LD50 is 4000 mg/kg in mice and rats. The subcutaneous LD50 is 2880 mg/kg in mice and rats.9There is limited information on testosterone undecanoate overdose. There was one report of acute overdose from an approved injectable testosterone product, which resulted in increased serum testosterone levels of up to 11,400 ng/dL with a cerebrovascular accident.6 There was one case of overdose following administration of oral testosterone undecanoate capsules: this patient inadvertently took a 20% higher dose than the maximum recommended dose but did not report any adverse reactions.7 Overdose should be managed with discontinuation of the drug in combination with appropriate symptomatic and supportive care.6The abuse of anabolic androgenic steroids can result in serious adverse reactions, such as cardiac arrest, myocardial infarction, hypertrophic cardiomyopathy, congestive heart failure, cerebrovascular accident, hepatotoxicity, and psychiatric manifestations, including major depression, mania, paranoia, psychosis, delusions, hallucinations, hostility, and aggression. Men receiving testosterone have experienced transient ischemic attacks, convulsions, hypomania, irritability, dyslipidemias, testicular atrophy, subfertility, and infertility.6	Small Molecule																																		<1 mg/mL	0	No	2	0	Yes	4	0	43.37 Å2	57.8 Å3	135.02 m3·mol-1	11	No	No	7.4e-05 mg/mL	8.06	-6.8	18.52	-4.8	P10275	AR	1. Androgen receptor
C21H32O3	Not Available	Not Available	332.484	[H][C@@]12CC[C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)CC[C@]12C	Not Available	Not Available							CHEMBL3275971	9984405														Dihydrotestosterone_acetate	ZINC000002557145		Stanolone acetate	Experimental	DB13951	InChI=1S/C21H32O3/c1-13(22)24-19-7-6-17-16-5-4-14-12-15(23)8-10-20(14,2)18(16)9-11-21(17,19)3/h14,16-19H,4-12H2,1-3H3/t14-,16-,17-,18-,19-,20-,21-/m0/s1	ILCTUFVQFCIIDS-NGFSFWIMSA-N			Not Available	Small Molecule																																			1	Yes	2	0	No	4	0	43.37 Å2	39.03 Å3	92.75 m3·mol-1	2	Yes	No	0.00115 mg/mL	3.85	-5.5		-6.8	P10275;!P14061;!P03372;!P08235	AR;!HSD17B1;!ESR1;!NR3C2	1. Androgen receptor;!2. Estradiol 17-beta-dehydrogenase 1;!3. Estrogen receptor alpha;!4. Mineralocorticoid receptor
C20H26O3	Not Available	Not Available	314.4186	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(OC(C)=O)C=C3CC[C@@]21[H]	Not Available	The distribution of exogenous estrogens is similar to that of endogenous estrogens. Estrogens are widely distributed in the body and are generally found in higher concentrations in the sex hormone target organs Label.	P05177;!P22309;!P08684;!P20815;!P24462;!P04798;!Q16678;!P33261;!P10632;!P11712	CYP1A2;!UGT1A1;!CYP3A4;!CYP3A5;!CYP3A7;!CYP1A1;!CYP1B1;!CYP2C19;!CYP2C8;!CYP2C9	1. Cytochrome P450 1A2;!2. UDP-glucuronosyltransferase 1-1;!3. Cytochrome P450 3A4;!4. Cytochrome P450 3A5;!5. Cytochrome P450 3A7;!6. Cytochrome P450 1A1;!7. Cytochrome P450 1B1;!8. Cytochrome P450 2C19;!9. Cytochrome P450 2C8;!10. Cytochrome P450 2C9			135981	CHEMBL1200430	7994056	Drugs.com Drug Page				D04061				9818306		RxList Drug Page			Estradiol_acetate		Femring	Estradiol acetate	Approved, Investigational, Vet approved	DB13952	InChI=1S/C20H26O3/c1-12(21)23-14-4-6-15-13(11-14)3-5-17-16(15)9-10-20(2)18(17)7-8-19(20)22/h4,6,11,16-19,22H,3,5,7-10H2,1-2H3/t16-,17-,18+,19+,20+/m1/s1	FHXBMXJMKMWVRG-SLHNCBLASA-N	3	Estradiol acetate is an estrogen used to treat vasomotor symptoms and moderate to severe vulvar and vaginal atrophy from menopause.	Can cause nausea and vomiting, and withdrawal bleeding may occur in females.	Small Molecule																																			1	Yes	2	1	No	4	0	46.53 Å2	36.7 Å3	89.06 m3·mol-1	2	Yes	No	0.00183 mg/mL	3.66	-5.2	19.38	-0.88	P03372;!Q92731;!O75469;!P43681;!Q15596;!Q99527;!P00846;!Q14457;!P37059;!P62508	ESR1;!ESR2;!NR1I2;!CHRNA4;!NCOA2;!GPER1;!MT-ATP6;!BECN1;!HSD17B2;!ESRRG	1. Estrogen receptor alpha;!2. Estrogen receptor beta;!3. Nuclear receptor subfamily 1 group I member 2;!4. Neuronal acetylcholine receptor subunit alpha-4;!5. Nuclear receptor coactivator 2;!6. G-protein coupled estrogen receptor 1;!7. ATP synthase subunit a;!8. Beclin-1;!9. Estradiol 17-beta-dehydrogenase 2;!10. Estrogen-related receptor gamma
C25H28O3	Not Available	Not Available	376.488	[H][C@]1(O)CC[C@@]2([H])[C@]3([H])CCC4=CC(OC(=O)C5=CC=CC=C5)=CC=C4[C@@]3([H])CC[C@]12C	Not Available	Not Available	P05177;!P22309;!P08684;!P20815;!P24462;!P04798;!Q16678;!P33261;!P10632;!P11712	CYP1A2;!UGT1A1;!CYP3A4;!CYP3A5;!CYP3A7;!CYP1A1;!CYP1B1;!CYP2C19;!CYP2C8;!CYP2C9	1. Cytochrome P450 1A2;!2. UDP-glucuronosyltransferase 1-1;!3. Cytochrome P450 3A4;!4. Cytochrome P450 3A5;!5. Cytochrome P450 3A7;!6. Cytochrome P450 1A1;!7. Cytochrome P450 1B1;!8. Cytochrome P450 2C19;!9. Cytochrome P450 2C8;!10. Cytochrome P450 2C9		56905	77006	CHEMBL282575	193412				C13444					222757					Estradiol_benzoate	ZINC000003881345		Estradiol benzoate	Approved, Investigational, Vet approved	DB13953	InChI=1S/C25H28O3/c1-25-14-13-20-19-10-8-18(28-24(27)16-5-3-2-4-6-16)15-17(19)7-9-21(20)22(25)11-12-23(25)26/h2-6,8,10,15,20-23,26H,7,9,11-14H2,1H3/t20-,21-,22+,23+,25+/m1/s1	UYIFTLBWAOGQBI-BZDYCCQFSA-N		Estradiol benzoate is an estrogen indicated in combination with progesterone for the treatment of irregular menstruation.	Not Available	Small Molecule																																			1	No	2	1	No	5	0	46.53 Å2	44.07 Å3	109.73 m3·mol-1	3	No	No	0.000189 mg/mL	5.71	-6.3	19.38	-0.88	P03372;!Q92731;!O75469;!P43681;!Q15596;!Q99527;!P00846;!Q14457;!P37059;!P62508	ESR1;!ESR2;!NR1I2;!CHRNA4;!NCOA2;!GPER1;!MT-ATP6;!BECN1;!HSD17B2;!ESRRG	1. Estrogen receptor alpha;!2. Estrogen receptor beta;!3. Nuclear receptor subfamily 1 group I member 2;!4. Neuronal acetylcholine receptor subunit alpha-4;!5. Nuclear receptor coactivator 2;!6. G-protein coupled estrogen receptor 1;!7. ATP synthase subunit a;!8. Beclin-1;!9. Estradiol 17-beta-dehydrogenase 2;!10. Estrogen-related receptor gamma
C26H36O3	Not Available	Not Available	396.5622	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1	Not Available	The distribution of exogenous estrogens is similar to that of endogenous estrogens. Estrogens are widely distributed in the body and are generally found in higher concentrations in the sex hormone target organs Label.	P05177;!P22309;!P08684;!P20815;!P24462;!P04798;!Q16678;!P33261;!P10632;!P11712	CYP1A2;!UGT1A1;!CYP3A4;!CYP3A5;!CYP3A7;!CYP1A1;!CYP1B1;!CYP2C19;!CYP2C8;!CYP2C9	1. Cytochrome P450 1A2;!2. UDP-glucuronosyltransferase 1-1;!3. Cytochrome P450 3A4;!4. Cytochrome P450 3A5;!5. Cytochrome P450 3A7;!6. Cytochrome P450 1A1;!7. Cytochrome P450 1B1;!8. Cytochrome P450 2C19;!9. Cytochrome P450 2C8;!10. Cytochrome P450 2C9			34745	CHEMBL1200973	9033				C14640	D04063				9403					Estradiol_cypionate	ZINC000003876078	Depo-estradiol	Estradiol cypionate	Approved, Investigational, Vet approved	DB13954	InChI=1S/C26H36O3/c1-26-15-14-21-20-10-8-19(27)16-18(20)7-9-22(21)23(26)11-12-24(26)29-25(28)13-6-17-4-2-3-5-17/h8,10,16-17,21-24,27H,2-7,9,11-15H2,1H3/t21-,22-,23+,24+,26+/m1/s1	UOACKFBJUYNSLK-XRKIENNPSA-N	2	Estradiol cypionate is an estradiol prodrug used to treat vasomotor symptoms and hypoestrogenisms from hypogonadism.	Not Available	Small Molecule																																			1	No	2	1	No	5	0	46.53 Å2	47.77 Å3	114.83 m3·mol-1	5	No	No	0.000118 mg/mL	6.49	-6.5	10.33	-5.4	P03372;!Q92731;!O75469;!P43681;!Q15596;!Q99527;!P00846;!Q14457;!P37059;!P62508	ESR1;!ESR2;!NR1I2;!CHRNA4;!NCOA2;!GPER1;!MT-ATP6;!BECN1;!HSD17B2;!ESRRG	1. Estrogen receptor alpha;!2. Estrogen receptor beta;!3. Nuclear receptor subfamily 1 group I member 2;!4. Neuronal acetylcholine receptor subunit alpha-4;!5. Nuclear receptor coactivator 2;!6. G-protein coupled estrogen receptor 1;!7. ATP synthase subunit a;!8. Beclin-1;!9. Estradiol 17-beta-dehydrogenase 2;!10. Estrogen-related receptor gamma
C32H48O4	Not Available	Not Available	496.732	CCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(OC(=O)CCCCCC)=CC=C4[C@H]3CC[C@]12C	Not Available	Not Available	P05177;!P22309;!P08684;!P20815;!P24462;!P04798;!Q16678;!P33261;!P10632;!P11712	CYP1A2;!UGT1A1;!CYP3A4;!CYP3A5;!CYP3A7;!CYP1A1;!CYP1B1;!CYP2C19;!CYP2C8;!CYP2C9	1. Cytochrome P450 1A2;!2. UDP-glucuronosyltransferase 1-1;!3. Cytochrome P450 3A4;!4. Cytochrome P450 3A5;!5. Cytochrome P450 3A7;!6. Cytochrome P450 1A1;!7. Cytochrome P450 1B1;!8. Cytochrome P450 2C19;!9. Cytochrome P450 2C8;!10. Cytochrome P450 2C9					145199														Estradiol_dienantate	ZINC000031476880		Estradiol dienanthate	Approved, Investigational, Vet approved	DB13955	InChI=1S/C32H48O4/c1-4-6-8-10-12-30(33)35-24-15-17-25-23(22-24)14-16-27-26(25)20-21-32(3)28(27)18-19-29(32)36-31(34)13-11-9-7-5-2/h15,17,22,26-29H,4-14,16,18-21H2,1-3H3/t26-,27-,28+,29+,32+/m1/s1	OVAHZPTYWMWNKO-CAHAWPIUSA-N		Estradiol dienanthate is an estrogen used in some combined hormonal oral contraceptives.	Not Available	Small Molecule																																			0	No	2	0	Yes	4	0	52.6 Å2	61.85 Å3	144.27 m3·mol-1	14	No	No	1.16e-05 mg/mL	9.06	-7.6		-6.8	P03372;!Q92731;!O75469;!P43681;!Q15596;!Q99527;!P00846;!Q14457;!P37059;!P62508	ESR1;!ESR2;!NR1I2;!CHRNA4;!NCOA2;!GPER1;!MT-ATP6;!BECN1;!HSD17B2;!ESRRG	1. Estrogen receptor alpha;!2. Estrogen receptor beta;!3. Nuclear receptor subfamily 1 group I member 2;!4. Neuronal acetylcholine receptor subunit alpha-4;!5. Nuclear receptor coactivator 2;!6. G-protein coupled estrogen receptor 1;!7. ATP synthase subunit a;!8. Beclin-1;!9. Estradiol 17-beta-dehydrogenase 2;!10. Estrogen-related receptor gamma
C23H32O3	Not Available	Not Available	356.4984	[H][C@@]12CC[C@H](OC(=O)CCCC)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	Not Available	Not Available	P05177;!P22309;!P08684;!P20815;!P24462;!P04798;!Q16678;!P33261;!P10632;!P11712	CYP1A2;!UGT1A1;!CYP3A4;!CYP3A5;!CYP3A7;!CYP1A1;!CYP1B1;!CYP2C19;!CYP2C8;!CYP2C9	1. Cytochrome P450 1A2;!2. UDP-glucuronosyltransferase 1-1;!3. Cytochrome P450 3A4;!4. Cytochrome P450 3A5;!5. Cytochrome P450 3A7;!6. Cytochrome P450 1A1;!7. Cytochrome P450 1B1;!8. Cytochrome P450 2C19;!9. Cytochrome P450 2C8;!10. Cytochrome P450 2C9			31561	CHEMBL1511	13194				C12859					13791		RxList Drug Page			Estradiol_valerate	ZINC000003881556	Delestrogen, Natazia	Estradiol valerate	Approved, Investigational, Vet approved	DB13956	InChI=1S/C23H32O3/c1-3-4-5-22(25)26-21-11-10-20-19-8-6-15-14-16(24)7-9-17(15)18(19)12-13-23(20,21)2/h7,9,14,18-21,24H,3-6,8,10-13H2,1-2H3/t18-,19-,20+,21+,23+/m1/s1	RSEPBGGWRJCQGY-RBRWEJTLSA-N	4	Estradiol valerate is an estradiol prodrug used to treat some effects of menopause, hypoestrogenism, androgen dependant carcinoma of the prostate, and in combination products for endometriosis and contraception.	Not Available	Small Molecule																																			1	No	2	1	No	4	0	46.53 Å2	42.57 Å3	102.89 m3·mol-1	5	No	No	0.000617 mg/mL	5.78	-5.8	10.33	-5.4	P03372;!Q92731;!O75469;!P43681;!Q15596;!Q99527;!P00846;!Q14457;!P37059;!P62508	ESR1;!ESR2;!NR1I2;!CHRNA4;!NCOA2;!GPER1;!MT-ATP6;!BECN1;!HSD17B2;!ESRRG	1. Estrogen receptor alpha;!2. Estrogen receptor beta;!3. Nuclear receptor subfamily 1 group I member 2;!4. Neuronal acetylcholine receptor subunit alpha-4;!5. Nuclear receptor coactivator 2;!6. G-protein coupled estrogen receptor 1;!7. ATP synthase subunit a;!8. Beclin-1;!9. Estradiol 17-beta-dehydrogenase 2;!10. Estrogen-related receptor gamma
C21H30O3	Not Available	Not Available	330.468	[H][C@@]12CC[C@H](OC(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3C[C@@H](C)[C@@]21[H]	Solid	Not Available							CHEMBL452329	8421572														Trestolone_acetate			Trestolone acetate	Experimental	DB13958	InChI=1S/C21H30O3/c1-12-10-14-11-15(23)4-5-16(14)17-8-9-21(3)18(20(12)17)6-7-19(21)24-13(2)22/h11-12,16-20H,4-10H2,1-3H3/t12-,16+,17-,18+,19+,20-,21+/m1/s1	IVCRCPJOLWECJU-XQVQQVTHSA-N			Not Available	Small Molecule																																			1	Yes	2	0	No	4	0	43.37 Å2	38.59 Å3	93.65 m3·mol-1	2	Yes	No	0.00582 mg/mL	3.79	-4.8	18.34	-4.7			
C23H30O4	Not Available	Not Available	370.489	[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3C(C)=C[C@@]21[H]	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			135564	CHEMBL1476022	82771					D08281							53744		Nomegestrol_acetate	ZINC000003938628		Nomegestrol acetate	Approved, Investigational	DB13981	InChI=1S/C23H30O4/c1-13-11-20-18(17-6-5-16(26)12-19(13)17)7-9-22(4)21(20)8-10-23(22,14(2)24)27-15(3)25/h11-12,17-18,20-21H,5-10H2,1-4H3/t17-,18-,20-,21+,22+,23+/m1/s1	IIVBFTNIGYRNQY-YQLZSBIMSA-N	4		Not Available	Small Molecule																																			1	Yes	3	0	No	4	0	60.44 Å2	41.78 Å3	104.18 m3·mol-1	3	Yes	No	0.00415 mg/mL	3.42	-5	17.72	-4.8			
C31H45N3O6	Not Available	Not Available	555.716	C[C@H](\C=C\C=C(/C)[C@H]1OC(=O)C[C@H](O)CC[C@@](C)(O)[C@@H](OC(=O)N2CCN(C)CC2)\C=C\[C@@H]1C)C1=CC=CC=N1	Solid	Not Available								71360838																	H3B-8800	Investigational	DB14017	InChI=1S/C31H45N3O6/c1-22(26-11-6-7-16-32-26)9-8-10-23(2)29-24(3)12-13-27(39-30(37)34-19-17-33(5)18-20-34)31(4,38)15-14-25(35)21-28(36)40-29/h6-13,16,22,24-25,27,29,35,38H,14-15,17-21H2,1-5H3/b9-8+,13-12+,23-10+/t22-,24+,25-,27+,29-,31-/m1/s1	YOIQWBAHJZGRFW-WVRLKXNASA-N			Not Available	Small Molecule																																			1	No	6	2	Yes	3	1	112.43 Å2	62.34 Å3	156.6 m3·mol-1	6	No	No	0.153 mg/mL	3.14	-3.6	13.92	6.89	O75533	SF3B1	1. Splicing factor 3B subunit 1
C30H48O6	Not Available	Not Available	504.708	[H][C@]12CC=C3[C@]4([H])[C@@H](C)[C@H](C)CC[C@@]4(CC[C@@]3(C)[C@]1(C)C[C@@H](O)[C@@]1([H])[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]21C)C(O)=O	Solid	Not Available					50244879	73058	CHEMBL481854	66126												1551573			ZINC000014243546		Madecassic acid	Experimental	DB14037	InChI=1S/C30H48O6/c1-16-9-10-30(25(35)36)12-11-28(5)18(22(30)17(16)2)7-8-21-26(3)13-20(33)24(34)27(4,15-31)23(26)19(32)14-29(21,28)6/h7,16-17,19-24,31-34H,8-15H2,1-6H3,(H,35,36)/t16-,17+,19-,20-,21-,22+,23-,24+,26-,27+,28-,29-,30+/m1/s1	PRAUVHZJPXOEIF-AOLYGAPISA-N			Not Available	Small Molecule																																			1	No	6	5	No	5	-1	118.22 Å2	57.47 Å3	138.43 m3·mol-1	2	No	No	0.0356 mg/mL	2.92	-4.2	4.64	-2.8			
C29H50O	Not Available	Not Available	414.718	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC=C4C[C@@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CC[C@@H](CC)C(C)C	Solid	Not Available					50218197	27693	CHEMBL221542	192962			HMDB0000852	C01753	D08518							47070		Beta-Sitosterol	ZINC000004095717		beta-Sitosterol	Experimental	DB14038	InChI=1S/C29H50O/c1-7-21(19(2)3)9-8-20(4)25-12-13-26-24-11-10-22-18-23(30)14-16-28(22,5)27(24)15-17-29(25,26)6/h10,19-21,23-27,30H,7-9,11-18H2,1-6H3/t20-,21-,23+,24+,25-,26+,27+,28+,29-/m1/s1	KZJWDPNRJALLNS-VJSFXXLFSA-N	2		Not Available	Small Molecule																																			1	No	1	1	Yes	4	0	20.23 Å2	54.21 Å3	129.77 m3·mol-1	6	No	Yes	1.84e-05 mg/mL	7.84	-7.4	18.2	-1.4			
C30H48O5	Not Available	Not Available	488.6991	[H][C@@]12CC[C@]3(C)[C@]([H])(CC=C4[C@]5([H])[C@@H](C)[C@H](C)CC[C@@]5(CC[C@@]34C)C(O)=O)[C@@]1(C)C[C@@H](O)[C@H](O)[C@@]2(C)CO	Solid	Not Available					50241487	2873	CHEMBL404313	106361				C08617		0AS						1551574			ZINC000008221271		Asiatic acid	Experimental	DB14054	InChI=1S/C30H48O5/c1-17-9-12-30(25(34)35)14-13-28(5)19(23(30)18(17)2)7-8-22-26(3)15-20(32)24(33)27(4,16-31)21(26)10-11-29(22,28)6/h7,17-18,20-24,31-33H,8-16H2,1-6H3,(H,34,35)/t17-,18+,20-,21-,22-,23+,24+,26+,27+,28-,29-,30+/m1/s1	JXSVIVRDWWRQRT-UYDOISQJSA-N			Not Available	Small Molecule																																			1	No	5	4	No	5	-1	97.99 Å2	56.63 Å3	136.83 m3·mol-1	2	Yes	No	0.0114 mg/mL	4.23	-4.6	4.74	-2.8			
C48H78O19	Not Available	Not Available	959.133	[H][C@@]12CC[C@]3(C)[C@]([H])(CC=C4[C@]5([H])[C@@H](C)[C@H](C)CC[C@@]5(CC[C@@]34C)C(=O)O[C@@H]3O[C@H](CO[C@@H]4O[C@H](CO)[C@@H](O[C@@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)[C@@]1(C)C[C@@H](O)[C@H](O)[C@@]2(C)CO	Solid	Not Available					23211	79928	CHEMBL1684590	10128466				C15428	D07576							18405			ZINC000253529453		Asiaticoside	Experimental	DB14081	InChI=1S/C48H78O19/c1-20-10-13-48(15-14-46(6)23(29(48)21(20)2)8-9-28-44(4)16-24(51)39(60)45(5,19-50)27(44)11-12-47(28,46)7)43(61)67-42-36(58)33(55)31(53)26(65-42)18-62-40-37(59)34(56)38(25(17-49)64-40)66-41-35(57)32(54)30(52)22(3)63-41/h8,20-22,24-42,49-60H,9-19H2,1-7H3/t20-,21+,22+,24-,25-,26-,27-,28-,29+,30+,31-,32-,33+,34-,35-,36-,37-,38-,39+,40-,41+,42+,44+,45+,46-,47-,48+/m1/s1	WYQVAPGDARQUBT-FGWHUCSPSA-N			Not Available	Small Molecule																																			0	No	18	12	Yes	8	0	315.21 Å2	102.07 Å3	232.55 m3·mol-1	10	No	No	0.798 mg/mL	-0.54	-3.1	11.75	-3.6			
C19H28O2	Not Available	Not Available	296.463	[3H]C1C([3H])C2=CC(=O)C([3H])C([3H])[C@]2(C)[C@H]2CC[C@]3(C)[C@@H](O)CC[C@H]3[C@H]12	Solid	Not Available								35147838																	(1,2,6,7-3H)Testosterone	Experimental	DB14093	InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-17,21H,3-10H2,1-2H3/t14-,15-,16-,17-,18-,19-/m0/s1/i3T,4T,7T,9T/t3?,4?,7?,9?,14-,15-,16-,17-,18-,19-	MUMGGOZAMZWBJJ-JQSYSRDDSA-N			Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	34.06 Å3	84.43 m3·mol-1	0	Yes	Yes	0.0333 mg/mL	3.37	-3.9	18.52	-0.88			
C30H52O2	Not Available	Not Available	444.744	[H][C@@]1(CC[C@]2(C)C1([H])CC[C@]1([H])[C@@]3(C)CC[C@]([H])(O)C(C)(C)[C@]3([H])CC[C@@]21C)C(C)(O)CCC=C(C)C	Not Available	Not Available								2342730												349656		Ginsenoside			Ginsenosides	Experimental	DB14152	InChI=1S/C30H52O2/c1-20(2)10-9-16-30(8,32)22-13-18-28(6)21(22)11-12-24-27(5)17-15-25(31)26(3,4)23(27)14-19-29(24,28)7/h10,21-25,31-32H,9,11-19H2,1-8H3/t21?,22-,23-,24+,25-,27-,28+,29+,30?/m0/s1	NLHQJXWYMZLQJY-SWIZOJJJSA-N	4		Not Available	Small Molecule																																			1	No	2	2	No	4	0	40.46 Å2	55.91 Å3	135.64 m3·mol-1	4	No	No	0.000182 mg/mL	6.84	-6.4	19.49	-0.26			
C25H33ClO6	Not Available	Not Available	464.98	[H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Not Available	Not Available							CHEMBL2115116	56676												1546384			ZINC000022049777		Beclomethasone 17-monopropionate	Experimental	DB14221	InChI=1S/C25H33ClO6/c1-5-21(31)32-25(20(30)13-27)14(2)10-18-17-7-6-15-11-16(28)8-9-22(15,3)24(17,26)19(29)12-23(18,25)4/h8-9,11,14,17-19,27,29H,5-7,10,12-13H2,1-4H3/t14-,17-,18-,19-,22-,23-,24-,25-/m0/s1	OHYGPBKGZGRQKT-XGQKBEPLSA-N			Not Available	Small Molecule																																			1	Yes	5	2	No	4	0	100.9 Å2	48.36 Å3	121.01 m3·mol-1	5	Yes	No	0.00787 mg/mL	3.29	-4.8	13.52	-3.3			
C27H30Cl2O6	The clearance rate of mometasone furoate is not readily available1, though it may be close to 90L/h2.	The terminal half life of an inhaled dose is approximately 5 hoursLabel though it has been reported as 5.8 hours by other sources11,2.	521.429	[H][C@@]12C[C@@H](C)[C@](OC(=O)C3=CC=CO3)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	Steady state volume of distribution of 152LLabel.	P10632;!P08684;!P20815	CYP2C8;!CYP3A4;!CYP3A5	1. Cytochrome P450 2C8;!2. Cytochrome P450 3A4;!3. Cytochrome P450 3A5		50148733	47564	CHEMBL1161	390091				C07817	D00690	MOF								Mometasone	ZINC000003938677	Asmanex, Dulera, Elocom, Elocon, Nasonex, Sinuva, Zenhale	Mometasone furoate	Approved, Investigational, Vet approved	DB14512	InChI=1S/C27H30Cl2O6/c1-15-11-19-18-7-6-16-12-17(30)8-9-24(16,2)26(18,29)21(31)13-25(19,3)27(15,22(32)14-28)35-23(33)20-5-4-10-34-20/h4-5,8-10,12,15,18-19,21,31H,6-7,11,13-14H2,1-3H3/t15-,18+,19+,21+,24+,25+,26+,27+/m1/s1	WOFMFGQZHJDGCX-ZULDAHANSA-N	4	Mometasone furoate is a corticosteroid used to treat asthma, allergic rhinitis, nasal congestion, nasal polyps, dermatitis, and pruritus.	Overdose with a mometasone furoate inhaler may occur with chronic overuseLabel11. Symptoms of chronic overuse may present as hypercorticism and adrenal suppression, and patients may not require any more treatment than monitoringLabel11.In animal studies of pregnancy, some fetal toxic effects were seen at or above the maximum recommended human dose, though rodents are more sensitive to these effects than humansLabel11,12. The benefits and risks of use should be considered in pregnant patients11,12It is unknown if mometasone furoate is excreted in breast milk but other corticosteroids are and therefore caution should be exercised when administering to nursing mothersLabel11,12.Safety and effectiveness in pediatric populations has been established through clinical trials, though there may be a reduction in expected growth of about 1cm per year depending on the dose and duration of treatmentLabel. Pediatric patients should be titrated to the lowest effective dose for mometasone furoate inhalersLabel.A trial of geriatric patients showed no difference in safety or efficacy compared to younger patients, however patients of an even greater age may still be more sensitive to mometasone furoateLabel11,12.The use of a mometasone furoate inhaler in moderate or severe hepatic impairment rarely leads to detectable plasma concentrations though caution may be prudent with increasing degrees of severityLabel11.The effects of mometasone furoate in renal impairment, and across gender and race have not been studiedLabel11.	Small Molecule																														4.115		215-228		Insoluble	0	No	4	1	No	5	0	93.81 Å2	52.31 Å3	132.5 m3·mol-1	5	No	No	0.0108 mg/mL	5.06	-4.7	13.84	-3.1	P04150;!P06401	NR3C1;!PGR	1. Glucocorticoid receptor;!2. Progesterone receptor
C26H36O7	Not Available	6-8 hours	460.567	[H][C@@]12CC[C@](OC(=O)CC)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Not Available	Not Available	P08684;!P20815;!P24462;!P10632	CYP3A4;!CYP3A5;!CYP3A7;!CYP2C8	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5;!3. Cytochrome P450 3A7;!4. Cytochrome P450 2C8			135746	CHEMBL2106309	62148					D06876									Hydrocortisone_aceponate	ZINC000004213508		Hydrocortisone aceponate	Experimental, Vet approved	DB14538	InChI=1S/C26H36O7/c1-5-22(31)33-26(21(30)14-32-15(2)27)11-9-19-18-7-6-16-12-17(28)8-10-24(16,3)23(18)20(29)13-25(19,26)4/h12,18-20,23,29H,5-11,13-14H2,1-4H3/t18-,19-,20-,23+,24-,25-,26-/m0/s1	MFBMYAOAMQLLPK-FZNHGJLXSA-N			Side effects include inhibition of bone formation, suppression of calcium absorption and delayed wound healing	Small Molecule																																			1	Yes	5	1	Yes	4	0	106.97 Å2	49.74 Å3	120.33 m3·mol-1	7	Yes	No	0.00526 mg/mL	2.86	-4.9	14.81	-2.8	P04083;!P04150;!P80365;!P14060	ANXA1;!NR3C1;!HSD11B2;!HSD3B1	1. Annexin A1;!2. Glucocorticoid receptor;!3. Corticosteroid 11-beta-dehydrogenase isozyme 2;!4. 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1
C23H32O6	Not Available	6-8 hours	404.4966	[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Not Available	Not Available	P08684;!P20815;!P24462;!P15538;!P19099;!P10632	CYP3A4;!CYP3A5;!CYP3A7;!CYP11B1;!CYP11B2;!CYP2C8	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5;!3. Cytochrome P450 3A7;!4. Cytochrome P450 11B1, mitochondrial;!5. Cytochrome P450 11B2, mitochondrial;!6. Cytochrome P450 2C8		50474607	17609	CHEMBL1091	5542				C02821	D00165				5744					Hydrocortisone_acetate	ZINC000003875333	Alcortin A, Analpram HC, Anodan-HC, Anucort-HC, Anusol, Anusol HC, Cortifoam, Cortisporin, Cortisporin-TC, Egozinc, Epifoam, Fucidin, Micort-HC, Neo-polycin HC, Nucort, Pramosone, Procort 1.85/1.15, Proctocort, Proctodan-HC, Proctofoam-HC, Rectacort-HC, Rectogel, Riva-sol HC, U-cort, Vagisil, Vytone	Hydrocortisone acetate	Approved, Vet approved	DB14539	InChI=1S/C23H32O6/c1-13(24)29-12-19(27)23(28)9-7-17-16-5-4-14-10-15(25)6-8-21(14,2)20(16)18(26)11-22(17,23)3/h10,16-18,20,26,28H,4-9,11-12H2,1-3H3/t16-,17-,18-,20+,21-,22-,23-/m0/s1	ALEXXDVDDISNDU-JZYPGELDSA-N	3	Hydrocortisone acetate is a corticosteroid used to treat inflammatory and pruritic corticosteroid-responsive dermatoses and ulcerative colitis.	Side effects include inhibition of bone formation, suppression of calcium absorption and delayed wound healing	Small Molecule																																			1	Yes	5	2	No	4	0	100.9 Å2	43.82 Å3	106.55 m3·mol-1	4	Yes	No	0.0582 mg/mL	1.72	-3.8	12.61	-2.8	P04083;!P04150;!P80365;!P14060	ANXA1;!NR3C1;!HSD11B2;!HSD3B1	1. Annexin A1;!2. Glucocorticoid receptor;!3. Corticosteroid 11-beta-dehydrogenase isozyme 2;!4. 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1
C25H36O6	Not Available	6-8 hours	432.557	[H][C@@]12CC[C@](OC(=O)CCC)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Not Available	Not Available	P08684;!P20815;!P24462;!P15538;!P19099;!P10632	CYP3A4;!CYP3A5;!CYP3A7;!CYP11B1;!CYP11B2;!CYP2C8	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5;!3. Cytochrome P450 3A7;!4. Cytochrome P450 11B1, mitochondrial;!5. Cytochrome P450 11B2, mitochondrial;!6. Cytochrome P450 2C8		323672	31674	CHEMBL1683	24344					D01619									Hydrocortisone_butyrate	ZINC000003977794	Locoid	Hydrocortisone butyrate	Approved, Vet approved	DB14540	InChI=1S/C25H36O6/c1-4-5-21(30)31-25(20(29)14-26)11-9-18-17-7-6-15-12-16(27)8-10-23(15,2)22(17)19(28)13-24(18,25)3/h12,17-19,22,26,28H,4-11,13-14H2,1-3H3/t17-,18-,19-,22+,23-,24-,25-/m0/s1	BMCQMVFGOVHVNG-TUFAYURCSA-N	4	Hydrocortisone butyrate is a corticosteroid used to treat inflammatory and pruritic corticosteroid-responsive dermatoses.	Side effects include inhibition of bone formation, suppression of calcium absorption and delayed wound healing	Small Molecule																																			1	Yes	5	2	Yes	4	0	100.9 Å2	47.74 Å3	115.78 m3·mol-1	6	Yes	No	0.0136 mg/mL	2.86	-4.5	13.75	-2.8	P04083;!P04150;!P80365;!P14060	ANXA1;!NR3C1;!HSD11B2;!HSD3B1	1. Annexin A1;!2. Glucocorticoid receptor;!3. Corticosteroid 11-beta-dehydrogenase isozyme 2;!4. 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1
C29H42O6	Not Available	6-8 hours	486.649	[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC3CCCC3)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Not Available	Not Available	P08684;!P20815;!P24462;!P10632	CYP3A4;!CYP3A5;!CYP3A7;!CYP2C8	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5;!3. Cytochrome P450 3A7;!4. Cytochrome P450 2C8		50371265	5783	CHEMBL1549	193884				C08176	D00976									Hydrocortisone_cypionate	ZINC000004097470		Hydrocortisone cypionate	Approved, Investigational, Vet approved	DB14541	InChI=1S/C29H42O6/c1-27-13-11-20(30)15-19(27)8-9-21-22-12-14-29(34,28(22,2)16-23(31)26(21)27)24(32)17-35-25(33)10-7-18-5-3-4-6-18/h15,18,21-23,26,31,34H,3-14,16-17H2,1-2H3/t21-,22-,23-,26+,27-,28-,29-/m0/s1	DLVOSEUFIRPIRM-KAQKJVHQSA-N			Side effects include inhibition of bone formation, suppression of calcium absorption and delayed wound healing	Small Molecule																																			1	No	5	2	Yes	5	0	100.9 Å2	54.76 Å3	132.33 m3·mol-1	7	Yes	No	0.00326 mg/mL	4.02	-5.2	12.61	-2.8	P04083;!P04150;!P80365;!P14060	ANXA1;!NR3C1;!HSD11B2;!HSD3B1	1. Annexin A1;!2. Glucocorticoid receptor;!3. Corticosteroid 11-beta-dehydrogenase isozyme 2;!4. 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1
C21H31O8P	Not Available	6-8 hours	442.445	[H][C@@]12CC[C@](O)(C(=O)COP(O)(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Not Available	Not Available	P08684;!P20815;!P24462;!P10632	CYP3A4;!CYP3A5;!CYP3A7;!CYP2C8	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5;!3. Cytochrome P450 3A7;!4. Cytochrome P450 2C8			68634	CHEMBL1641	390143														Hydrocortisone_phosphate	ZINC000004097471		Hydrocortisone phosphate	Approved, Vet approved	DB14542	InChI=1S/C21H31O8P/c1-19-7-5-13(22)9-12(19)3-4-14-15-6-8-21(25,17(24)11-29-30(26,27)28)20(15,2)10-16(23)18(14)19/h9,14-16,18,23,25H,3-8,10-11H2,1-2H3,(H2,26,27,28)/t14-,15-,16-,18+,19-,20-,21-/m0/s1	BGSOJVFOEQLVMH-VWUMJDOOSA-N	2	Hydrocortisone phosphate is a corticosteroid used to treat congenital adrenal hyperplasia, for emergency asthma treatment, hypersensitivity, and inflammation.	Side effects include inhibition of bone formation, suppression of calcium absorption and delayed wound healing	Small Molecule																																			1	Yes	7	4	No	4	-2	141.36 Å2	44.37 Å3	108.27 m3·mol-1	4	Yes	No	0.73 mg/mL	1.15	-2.8	1.18	-2.8	P04083;!P04150;!P80365;!P14060	ANXA1;!NR3C1;!HSD11B2;!HSD3B1	1. Annexin A1;!2. Glucocorticoid receptor;!3. Corticosteroid 11-beta-dehydrogenase isozyme 2;!4. 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1
C28H40O7	Not Available	6-8 hours	488.613	[H][C@@]12CC[C@](OC(=O)CCC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Not Available	Not Available	P08684;!P20815;!P24462;!P15538;!P19099;!P10632	CYP3A4;!CYP3A5;!CYP3A7;!CYP11B1;!CYP11B2;!CYP2C8	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5;!3. Cytochrome P450 3A7;!4. Cytochrome P450 11B1, mitochondrial;!5. Cytochrome P450 11B2, mitochondrial;!6. Cytochrome P450 2C8			31675	CHEMBL1200953	552186				C13358	D01886				636398					Hydrocortisone	ZINC000004213519	Pandel	Hydrocortisone probutate	Approved, Vet approved	DB14543	InChI=1S/C28H40O7/c1-5-7-24(33)35-28(22(31)16-34-23(32)6-2)13-11-20-19-9-8-17-14-18(29)10-12-26(17,3)25(19)21(30)15-27(20,28)4/h14,19-21,25,30H,5-13,15-16H2,1-4H3/t19-,20-,21-,25+,26-,27-,28-/m0/s1	FOGXJPFPZOHSQS-AYVLZSQQSA-N	4	Hydrocortisone probutate is a corticosteroid used to treat inflammatory and pruritic corticosteroid-responsive dermatoses.	Side effects include inhibition of bone formation, suppression of calcium absorption and delayed wound healing	Small Molecule																																			1	No	5	1	Yes	4	0	106.97 Å2	53.93 Å3	129.56 m3·mol-1	9	Yes	No	0.00283 mg/mL	4	-5.2	14.81	-2.8	P04083;!P04150;!P80365;!P14060	ANXA1;!NR3C1;!HSD11B2;!HSD3B1	1. Annexin A1;!2. Glucocorticoid receptor;!3. Corticosteroid 11-beta-dehydrogenase isozyme 2;!4. 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1
C26H38O6	Not Available	6-8 hours	446.5763	[H][C@@]12CC[C@](OC(=O)CCCC)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Not Available	Not Available	P08684;!P20815;!P24462;!P15538;!P19099;!P10632	CYP3A4;!CYP3A5;!CYP3A7;!CYP11B1;!CYP11B2;!CYP2C8	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5;!3. Cytochrome P450 3A7;!4. Cytochrome P450 11B1, mitochondrial;!5. Cytochrome P450 11B2, mitochondrial;!6. Cytochrome P450 2C8			50865	CHEMBL1200562	4445635									5282494					Hydrocortisone_valerate	ZINC000004213520	Hydroval	Hydrocortisone valerate	Approved, Vet approved	DB14544	InChI=1S/C26H38O6/c1-4-5-6-22(31)32-26(21(30)15-27)12-10-19-18-8-7-16-13-17(28)9-11-24(16,2)23(18)20(29)14-25(19,26)3/h13,18-20,23,27,29H,4-12,14-15H2,1-3H3/t18-,19-,20-,23+,24-,25-,26-/m0/s1	FZCHYNWYXKICIO-FZNHGJLXSA-N	2	Hydrocortisone valerate is a corticosteroid used to treat inflammatory and pruritic corticosteroid-responsive dermatoses.	Side effects include inhibition of bone formation, suppression of calcium absorption and delayed wound healing	Small Molecule																																			1	Yes	5	2	Yes	4	0	100.9 Å2	50.08 Å3	120.38 m3·mol-1	7	Yes	No	0.00763 mg/mL	3.31	-4.8	13.75	-2.8	P04083;!P04150;!P80365;!P14060	ANXA1;!NR3C1;!HSD11B2;!HSD3B1	1. Annexin A1;!2. Glucocorticoid receptor;!3. Corticosteroid 11-beta-dehydrogenase isozyme 2;!4. 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1
C25H34O8	Not Available	Not Available	462.539	[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Not Available	Not Available	P08684;!P10632;!P15538;!P19099	CYP3A4;!CYP2C8;!CYP11B1;!CYP11B2	1. Cytochrome P450 3A4;!2. Cytochrome P450 2C8;!3. Cytochrome P450 11B1, mitochondrial;!4. Cytochrome P450 11B2, mitochondrial		50016931	31677	CHEMBL977	15760					D01442							21651		Hydrocortisone_hemisuccinate	ZINC000004097472	Solu-cortef	Hydrocortisone succinate	Approved	DB14545	InChI=1S/C25H34O8/c1-23-9-7-15(26)11-14(23)3-4-16-17-8-10-25(32,24(17,2)12-18(27)22(16)23)19(28)13-33-21(31)6-5-20(29)30/h11,16-18,22,27,32H,3-10,12-13H2,1-2H3,(H,29,30)/t16-,17-,18-,22+,23-,24-,25-/m0/s1	VWQWXZAWFPZJDA-CGVGKPPMSA-N	4	Hydrocortisone succinate is a corticosteroid used to treat severe allergic reactions, dermatologic diseases, endocrine disorders, gastrointestinal diseases, hematological disorders, neoplastic diseases, nervous system conditions, ophthalmic diseases, renal diseases, respiratory diseases, and rheumatic disorders.	Not Available	Small Molecule																																			1	Yes	7	3	Yes	4	-1	138.2 Å2	48.68 Å3	117.44 m3·mol-1	7	Yes	No	0.0653 mg/mL	1.54	-3.8	3.66	-2.8			
C30H50O2	Not Available	Not Available	442.728	[H][C@@]12CC[C@]3(C)[C@]([H])(CCC4=C5CC(C)(C)CC[C@]5(C)[C@@H](O)C[C@@]34C)[C@@]1(C)CC[C@H](O)C2(C)C	Not Available	Not Available								4438027												2045735			ZINC000033816140		Ursadiol	Experimental	DB14555	InChI=1S/C30H50O2/c1-25(2)15-16-27(5)20(17-25)19-9-10-22-28(6)13-12-23(31)26(3,4)21(28)11-14-29(22,7)30(19,8)18-24(27)32/h21-24,31-32H,9-18H2,1-8H3/t21-,22+,23-,24-,27-,28-,29+,30+/m0/s1	RTLXJEJRLWILSU-GWNGJUQLSA-N			Not Available	Small Molecule																																			1	No	2	2	No	5	0	40.46 Å2	54.73 Å3	133.16 m3·mol-1	0	No	No	0.00253 mg/mL	6.13	-5.2	19.49	-0.3			
C21H30O3	Not Available	Not Available	330.4611	[H][C@@]12CC[C@](O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4		50423511	17252	CHEMBL1062	6002			HMDB0000374	C01176		3QZ						5542		17%CE%B1-Hydroxyprogesterone	ZINC000005434436		Hydroxyprogesterone	Experimental	DB14570	InChI=1S/C21H30O3/c1-13(22)21(24)11-8-18-16-5-4-14-12-15(23)6-9-19(14,2)17(16)7-10-20(18,21)3/h12,16-18,24H,4-11H2,1-3H3/t16-,17+,18+,19+,20+,21+/m1/s1	DBPWSSGDRRHUNT-CEGNMAFCSA-N	4		Not Available	Small Molecule																																			1	Yes	3	1	No	4	0	54.37 Å2	37.9 Å3	94.11 m3·mol-1	1	Yes	No	0.0293 mg/mL	3.4	-4	12.7	-3.8			
C23H30O4	No pharmacokinetic data available.	The mean (SD) half life of segesterone acetate is 4.5 (3.4) hours Label.	370.489	[H][C@@]12CC(=C)[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	Solid	The volume of distribution of segesterone acetate is 19.6 L/kg Label.	P08684	CYP3A4	1. Cytochrome P450 3A4			135563	CHEMBL3707377	97161												2055977		Segesterone_acetate	ZINC000005167230	Annovera	Segesterone acetate	Approved, Experimental, Investigational	DB14583	InChI=1S/C23H30O4/c1-13-11-21-20-7-5-16-12-17(26)6-8-18(16)19(20)9-10-22(21,4)23(13,14(2)24)27-15(3)25/h12,18-21H,1,5-11H2,2-4H3/t18-,19+,20+,21-,22-,23-/m0/s1	CKFBRGLGTWAVLG-GOMYTPFNSA-N	3		There have been no reports of serious ill effects from overdose of combination hormonal contraceptive use. Overdosage may cause withdrawal bleeding in females and nausea. In case of suspected overdose, all vaginal systems containing segesterone acetate should be removed and symptomatic treatment should be initiated Label.In a 2-year carcinogenicity study in rats receiving segesterone acetate via subdermal implants, there was no drug-related increase in tumor incidence. In a 2-year intravaginal carcinogenicity study in mice, segesterone acetate gel produced an increased incidence of adenocarcinoma and lobular hyperplasia in the breast at a supratherapeutic dose of 30 mg/kg/day. Segesterone acetate was not shown to be mutagenic or clastogenic Label.	Small Molecule																																173-177		Insoluble	1	Yes	3	0	No	4	0	60.44 Å2	41.79 Å3	102.95 m3·mol-1	3	Yes	No	0.00231 mg/mL	3.64	-5.2	17.46	-4.7	P06401;!P10275;!P04150	PGR;!AR;!NR3C1	1. Progesterone receptor;!2. Androgen receptor;!3. Glucocorticoid receptor
C21H28O3	Not Available	Not Available	328.452	[H][C@@]12CC(=C)[C@](O)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	Not Available	Not Available							CHEMBL2107778	9998301												2055978		Segesterone			Segesterone	Experimental	DB14584	InChI=1S/C21H28O3/c1-12-10-19-18-6-4-14-11-15(23)5-7-16(14)17(18)8-9-20(19,3)21(12,24)13(2)22/h11,16-19,24H,1,4-10H2,2-3H3/t16-,17+,18+,19-,20-,21-/m0/s1	SFLXYFZGKSGFKA-XUDSTZEESA-N			Not Available	Small Molecule																																			1	Yes	3	1	No	4	0	54.37 Å2	37.67 Å3	93.8 m3·mol-1	1	Yes	No	0.0241 mg/mL	3.2	-4.1	12.21	-4			
C24H31ClO7	Loteprednol etabonate was slowly hydrolyzed in liver at clearance rates of 0.21 +/- 0.04 and 2.41 +/- 0.13 ml/h/kg in the liver and plasma, respectively 2.	The terminal half-life of loteprednol etabonate as determined when administered intravenously at a dose of 5 mg/kg in the dog animal model is 2.8 hours 3.	466.96	[H][C@@]12CC[C@](OC(=O)OCC)(C(=O)OCCl)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	The only data available regarding the volume of distribution of loteprednol etabonate (LE) is the volume of distribution the agent demonstrated when administered to dogs - a value of 3.7 L/kg 3. It has been shown, however, that the topical ocular administration of LE distributes preferentially into the cellular components of blood 8.	P08684;!P27169	CYP3A4;!PON1	1. Cytochrome P450 3A4;!2. Serum paraoxonase/arylesterase 1			31784	CHEMBL1200865	392049	Drugs.com Drug Page		HMDB0015011		D01689			PA164764569	9865442	46504713	RxList Drug Page		DAP001045	Loteprednol	ZINC000003920673	Eysuvis, Inveltys, Lotemax	Loteprednol etabonate	Approved	DB14596	InChI=1S/C24H31ClO7/c1-4-30-21(29)32-24(20(28)31-13-25)10-8-17-16-6-5-14-11-15(26)7-9-22(14,2)19(16)18(27)12-23(17,24)3/h7,9,11,16-19,27H,4-6,8,10,12-13H2,1-3H3/t16-,17-,18-,19+,22-,23-,24-/m0/s1	DMKSVUSAATWOCU-HROMYWEYSA-N	4	Loteprednol etabonate is a corticosteroid used to treat allergic conjunctivitis as well as inflammation and pain after ocular surgery.	The most common adverse drug reactions reported during clinical trials for the medication were eye pain and posterior capsular opacification, both of which may also be the consequence of the very surgical procedures performed on the eye(s) Label.The agent is not absorbed systemically following topical ophthalmic administration and maternal use is not expected to result in fetal exposure to the drug Label.The medication is not absorbed systemically by the mother following topical ophthalmic administration, and breastfeeding is not expected to result in exposure of the child to the agent Label.Long-term animal studies have not been conducted to evaluate the carcinogenic potential of loteprednol etabonate. Loteprednol etabonate was not genotoxic in vitro in the Ames test, the mouse lymphoma thymidine kinase (tk) assay, or in a chromosome aberration test in human lymphocytes, or in vivo in the single dose mouse micronucleus assay Label.Overdose is not expected to be likely to occur after ocular administration 8.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.2305 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.4		220-224 °C		5 mg/mL	1	Yes	5	1	Yes	4	0	99.13 Å2	48.43 Å3	118.17 m3·mol-1	7	Yes	No	0.00693 mg/mL	3.94	-4.8	14.88	-2.9	P04150	NR3C1	1. Glucocorticoid receptor
C24H30O6	Not Available	Not Available	414.498	C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3C(=O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O	Not Available	Not Available								92124															ZINC000006066697		Meprednisone acetate	Experimental	DB14625	InChI=1S/C24H30O6/c1-13-9-18-17-6-5-15-10-16(26)7-8-22(15,3)21(17)19(27)11-23(18,4)24(13,29)20(28)12-30-14(2)25/h7-8,10,13,17-18,21,29H,5-6,9,11-12H2,1-4H3/t13-,17-,18-,21+,22-,23-,24-/m0/s1	RZAMUHXEOMZXET-ABQXZQTJSA-N			Not Available	Small Molecule																																			1	Yes	5	1	No	4	0	97.74 Å2	44.17 Å3	111.19 m3·mol-1	4	Yes	No	0.0168 mg/mL	2.46	-4.4	12.46	-3.9			
C23H34O3	Not Available	Not Available	358.522	[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@H](CC[C@]12C)OC(C)=O	Not Available	Not Available						34930	CHEMBL1892286	2005918				C14658										Pregnenolone_acetate	ZINC000003860692		Pregnenolone acetate	Investigational	DB14626	InChI=1S/C23H34O3/c1-14(24)19-7-8-20-18-6-5-16-13-17(26-15(2)25)9-11-22(16,3)21(18)10-12-23(19,20)4/h5,17-21H,6-13H2,1-4H3/t17-,18-,19+,20-,21-,22-,23+/m0/s1	CRRKVZVYZQXICQ-RJJCNJEVSA-N			Not Available	Small Molecule																																			1	Yes	2	0	No	4	0	43.37 Å2	42.51 Å3	102.91 m3·mol-1	3	Yes	No	0.00188 mg/mL	4.02	-5.3	19.4	-6.8			
C21H29O8P	Not Available	The half life of prednisolone is 2-4 hours.6	440.429	[H][C@@]12CC[C@](O)(C(=O)COP(O)(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	The volume of distribution of prednisolone phosphate has been reported as 0.22-0.7L/kg.7	P08684;!P20815;!BE0004866;!P11509;!Q16678;!P20813;!P10632;!P11712;!P33261;!P80365;!P28845	CYP3A4;!CYP3A5;!;!CYP2A6;!CYP1B1;!CYP2B6;!CYP2C8;!CYP2C9;!CYP2C19;!HSD11B2;!HSD11B1	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5;!3. Cytochrome P450 3A Subfamily (Protein Group);!4. Cytochrome P450 2A6;!5. Cytochrome P450 1B1;!6. Cytochrome P450 2B6;!7. Cytochrome P450 2C8;!8. Cytochrome P450 2C9;!9. Cytochrome P450 2C19;!10. Corticosteroid 11-beta-dehydrogenase isozyme 2;!11. Corticosteroid 11-beta-dehydrogenase isozyme 1			145705	CHEMBL1201231	65064														Prednisolone_sodium_phosphate	ZINC000004097473	Orapred, Pediapred	Prednisolone phosphate	Approved, Vet approved	DB14631	InChI=1S/C21H29O8P/c1-19-7-5-13(22)9-12(19)3-4-14-15-6-8-21(25,17(24)11-29-30(26,27)28)20(15,2)10-16(23)18(14)19/h5,7,9,14-16,18,23,25H,3-4,6,8,10-11H2,1-2H3,(H2,26,27,28)/t14-,15-,16-,18+,19-,20-,21-/m0/s1	JDOZJEUDSLGTLU-VWUMJDOOSA-N	3	Prednisolone phosphate is a corticosteroid used to treat inflammation, immune reactions, as well as endocrine or neoplastic conditions.	Data regarding acute overdose is not readily available.6 However, patients experiencing chronic overdose may present with mental symptoms, moon face, abnormal fat deposits, and fluid retention.6 Acute oral overdose may be treated with immediate gastric lavage or emesis followed by symptomatic and supportive treatment.6 Chronic overdosage can be managed by temporary dose reduction or alternate day treatment.6	Small Molecule																																			1	Yes	7	4	No	4	-2	141.36 Å2	43.42 Å3	109.37 m3·mol-1	4	Yes	No	0.432 mg/mL	1.15	-3	1.18	-2.9	P04150;!P04083	NR3C1;!ANXA1	1. Glucocorticoid receptor;!2. Annexin A1
C27H38O6	Not Available	Not Available	458.587	[H][C@@]12CC[C@](O)(C(=O)COC(=O)CC(C)(C)C)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Not Available	Not Available						8381	CHEMBL1200909	84007				C08182	D00982				93055					Prednisolone_tebutate	ZINC000004097474		Prednisolone tebutate	Approved, Vet approved	DB14632	InChI=1S/C27H38O6/c1-24(2,3)14-22(31)33-15-21(30)27(32)11-9-19-18-7-6-16-12-17(28)8-10-25(16,4)23(18)20(29)13-26(19,27)5/h8,10,12,18-20,23,29,32H,6-7,9,11,13-15H2,1-5H3/t18-,19-,20-,23+,25-,26-,27-/m0/s1	HUMXXHTVHHLNRO-KAJVQRHHSA-N			Not Available	Small Molecule																																			1	No	5	2	Yes	4	0	100.9 Å2	51.06 Å3	125.9 m3·mol-1	6	Yes	No	0.00929 mg/mL	3.45	-4.7	12.61	-2.9			
C25H32O8	Not Available	Not Available	460.523	[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Not Available	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5			135745	CHEMBL485659	571099														Prednisolone	ZINC000003881478		Prednisolone hemisuccinate	Experimental	DB14633	InChI=1S/C25H32O8/c1-23-9-7-15(26)11-14(23)3-4-16-17-8-10-25(32,24(17,2)12-18(27)22(16)23)19(28)13-33-21(31)6-5-20(29)30/h7,9,11,16-18,22,27,32H,3-6,8,10,12-13H2,1-2H3,(H,29,30)/t16-,17-,18-,22+,23-,24-,25-/m0/s1	APGDTXUMTIZLCJ-CGVGKPPMSA-N		Prednisolone hemisuccinate is a corticosteroid indicated in the treatment of anaphylaxis, asthma, edema, organ rejection, and other indications.	Not Available	Small Molecule																																			1	Yes	7	3	Yes	4	-1	138.2 Å2	47.52 Å3	118.54 m3·mol-1	7	Yes	No	0.0483 mg/mL	1.54	-4	3.66	-2.9			
C24H29FO6	Not Available	Not Available	432.488	[H][C@@]12CC(=C)[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Not Available	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5			135700		8155833														Fluprednidene_acetate	ZINC000030691649		Fluprednidene acetate	Experimental	DB14634	InChI=1S/C24H29FO6/c1-13-9-18-17-6-5-15-10-16(27)7-8-21(15,3)23(17,25)19(28)11-22(18,4)24(13,30)20(29)12-31-14(2)26/h7-8,10,17-19,28,30H,1,5-6,9,11-12H2,2-4H3/t17-,18-,19-,21-,22-,23-,24-/m0/s1	DEFOZIFYUBUHHU-IYQKUMFPSA-N		Fluprednidene acetate is a corticosteroid indicated in the treatment of corticosteroid-responsive dermatoses.	Not Available	Small Molecule																																			1	Yes	5	2	No	4	0	100.9 Å2	44.61 Å3	111.34 m3·mol-1	4	Yes	No	0.0292 mg/mL	1.85	-4.2	12.12	-3.4			
C23H29FO6	Not Available	Not Available	420.477	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4					91954															ZINC000005161248		Fluprednisolone acetate	Experimental	DB14637	InChI=1S/C23H29FO6/c1-12(25)30-11-19(28)23(29)7-5-15-14-9-17(24)16-8-13(26)4-6-21(16,2)20(14)18(27)10-22(15,23)3/h4,6,8,14-15,17-18,20,27,29H,5,7,9-11H2,1-3H3/t14-,15-,17-,18-,20+,21-,22-,23-/m0/s1	CYMBAKFTWRNHPS-APRQOCPKSA-N			Not Available	Small Molecule																																			1	Yes	5	2	No	4	0	100.9 Å2	42.94 Å3	107.47 m3·mol-1	4	Yes	No	0.0414 mg/mL	1.37	-4	12.61	-2.9			
C30H44O3	Not Available	14 days	452.679	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2OC(=O)CCCCCCCCC=C	Not Available	Not Available							CHEMBL2106059	10128605														Boldenone_undecylenate	ZINC000004215044		Boldenone undecylenate	Illicit, Vet approved	DB14639	InChI=1S/C30H44O3/c1-4-5-6-7-8-9-10-11-12-28(32)33-27-16-15-25-24-14-13-22-21-23(31)17-19-29(22,2)26(24)18-20-30(25,27)3/h4,17,19,21,24-27H,1,5-16,18,20H2,2-3H3/t24-,25-,26-,27-,29-,30-/m0/s1	AHMMSNQYOPMLSX-CNQKSJKFSA-N			Not Available	Small Molecule																																			0	No	2	0	Yes	4	0	43.37 Å2	56.18 Å3	136.15 m3·mol-1	11	No	No	5.54e-05 mg/mL	7.76	-6.9	18.39	-5	P10275	AR	1. Androgen receptor
C23H29FO6	Not Available	Not Available	420.477	[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Not Available	Not Available						34517	CHEMBL1608183	194836				C14636	D04627										ZINC000004213604		Isoflupredone acetate	Vet approved	DB14640	InChI=1S/C23H29FO6/c1-13(25)30-12-19(28)22(29)9-7-16-17-5-4-14-10-15(26)6-8-20(14,2)23(17,24)18(27)11-21(16,22)3/h6,8,10,16-18,27,29H,4-5,7,9,11-12H2,1-3H3/t16-,17-,18-,20-,21-,22-,23-/m0/s1	ZOCUOMKMBMEYQV-GSLJADNHSA-N			Not Available	Small Molecule																																			1	Yes	5	2	No	4	0	100.9 Å2	42.89 Å3	107.17 m3·mol-1	4	Yes	No	0.025 mg/mL	1.76	-4.2	12.58	-3.4			
C27H36O6	Not Available	Not Available	456.5711	[H][C@]1(C[C@@]2([H])[C@]3([H])CCC4=CC(OC(=O)CC)=CC=C4[C@@]3([H])CC[C@]2(C)[C@@]1([H])OC(=O)CC)OC(=O)CC	Not Available	Not Available							CHEMBL3559901	92362									102232					Estriol_tripropionate	ZINC000030690586		Estriol tripropionate	Experimental	DB14641	InChI=1S/C27H36O6/c1-5-23(28)31-17-9-11-18-16(14-17)8-10-20-19(18)12-13-27(4)21(20)15-22(32-24(29)6-2)26(27)33-25(30)7-3/h9,11,14,19-22,26H,5-8,10,12-13,15H2,1-4H3/t19-,20-,21+,22-,26+,27+/m1/s1	ONMZMZJEZHMWQL-REUUDLSRSA-N			ORAL (LD50): Acute: >2000 mg/kg [Rat].	Small Molecule																																			1	Yes	3	0	Yes	4	0	78.9 Å2	52.33 Å3	122.6 m3·mol-1	9	No	No	0.000438 mg/mL	5.57	-6		-6.6	P03372;!Q92731;!P04278	ESR1;!ESR2;!SHBG	1. Estrogen receptor alpha;!2. Estrogen receptor beta;!3. Sex hormone-binding globulin
C27H36O7	Not Available	Not Available	472.578	[H][C@@]12CC[C@](OC(=O)CC)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C	Not Available	Not Available						135762	CHEMBL1697782	56717														Methylprednisolone_aceponate	ZINC000004213828		Methylprednisolone aceponate	Approved, Vet approved	DB14643	InChI=1S/C27H36O7/c1-6-23(32)34-27(22(31)14-33-16(3)28)10-8-19-18-11-15(2)20-12-17(29)7-9-25(20,4)24(18)21(30)13-26(19,27)5/h7,9,12,15,18-19,21,24,30H,6,8,10-11,13-14H2,1-5H3/t15-,18-,19-,21-,24+,25-,26-,27-/m0/s1	DALKLAYLIPSCQL-YPYQNWSCSA-N	4	Methylprednisolone aceponate is a corticosteroid indicated in the treatment of corticosteroid-responsive dermatoses.	Not Available	Small Molecule																																			1	Yes	5	1	Yes	4	0	106.97 Å2	50.86 Å3	125.97 m3·mol-1	7	Yes	No	0.00637 mg/mL	3.14	-4.9	14.8	-2.9			
C26H34O8	Not Available	Not Available	474.55	[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C	Not Available	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5			135765	CHEMBL1201265	16034														Methylprednisolone	ZINC000003977781	Solu-medrol	Methylprednisolone hemisuccinate	Approved	DB14644	InChI=1S/C26H34O8/c1-14-10-16-17-7-9-26(33,20(29)13-34-22(32)5-4-21(30)31)25(17,3)12-19(28)23(16)24(2)8-6-15(27)11-18(14)24/h6,8,11,14,16-17,19,23,28,33H,4-5,7,9-10,12-13H2,1-3H3,(H,30,31)/t14-,16-,17-,19-,23+,24-,25-,26-/m0/s1	IMBXEJJVJRTNOW-XYMSELFBSA-N	4	Methylprednisolone hemisuccinate is a water soluble corticosteroid used to treat severe allergic reactions, dermatologic diseases, endocrine disorders, gastrointestinal diseases, hematological disorders, neoplastic diseases, nervous system conditions, ophthalmic diseases, renal diseases, respiratory diseases, and rheumatic disorders.	Not Available	Small Molecule																																			1	Yes	7	3	Yes	4	-1	138.2 Å2	49.87 Å3	123.09 m3·mol-1	7	Yes	No	0.0264 mg/mL	1.83	-4.2	3.66	-2.9			
C23H28O6	Not Available	Not Available	400.471	[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Not Available	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5			34655	CHEMBL1507567	82567				C14668	D08416										ZINC000003881638		Prednisone acetate	Approved, Experimental, Investigational	DB14646	InChI=1S/C23H28O6/c1-13(24)29-12-19(27)23(28)9-7-17-16-5-4-14-10-15(25)6-8-21(14,2)20(16)18(26)11-22(17,23)3/h6,8,10,16-17,20,28H,4-5,7,9,11-12H2,1-3H3/t16-,17-,20+,21-,22-,23-/m0/s1	MOVRKLZUVNCBIP-RFZYENFJSA-N	4		Not Available	Small Molecule																																			1	Yes	5	1	No	4	0	97.74 Å2	42.51 Å3	106.72 m3·mol-1	4	Yes	No	0.0235 mg/mL	2.1	-4.2	12.6	-3.8			
C24H31FO6	Not Available	Not Available	434.4977	[H][C@@]12C[C@@H](C)[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Not Available	Not Available	P08684;!P20815;!P24462;!P05093;!P04798;!P11509;!P20813;!P33261;!P10632;!P05181;!Q9HB55;!Q02928;!P15538;!P80365;!P28845	CYP3A4;!CYP3A5;!CYP3A7;!CYP17A1;!CYP1A1;!CYP2A6;!CYP2B6;!CYP2C19;!CYP2C8;!CYP2E1;!CYP3A43;!CYP4A11;!CYP11B1;!HSD11B2;!HSD11B1	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5;!3. Cytochrome P450 3A7;!4. Steroid 17-alpha-hydroxylase/17,20 lyase;!5. Cytochrome P450 1A1;!6. Cytochrome P450 2A6;!7. Cytochrome P450 2B6;!8. Cytochrome P450 2C19;!9. Cytochrome P450 2C8;!10. Cytochrome P450 2E1;!11. Cytochrome P450 3A43;!12. Cytochrome P450 4A11;!13. Cytochrome P450 11B1, mitochondrial;!14. Corticosteroid 11-beta-dehydrogenase isozyme 2;!15. Corticosteroid 11-beta-dehydrogenase isozyme 1		50103620	4463	CHEMBL1530428	206624				C08174	D07796				236702					Dexamethasone_acetate	ZINC000003882068		Dexamethasone acetate	Approved, Investigational, Vet approved	DB14649	InChI=1S/C24H31FO6/c1-13-9-18-17-6-5-15-10-16(27)7-8-21(15,3)23(17,25)19(28)11-22(18,4)24(13,30)20(29)12-31-14(2)26/h7-8,10,13,17-19,28,30H,5-6,9,11-12H2,1-4H3/t13-,17+,18+,19+,21+,22+,23+,24+/m1/s1	AKUJBENLRBOFTD-RPRRAYFGSA-N	3		Not Available	Small Molecule																																			1	Yes	5	2	No	4	0	100.9 Å2	45.02 Å3	111.64 m3·mol-1	4	Yes	No	0.0164 mg/mL	2.12	-4.4	12.44	-3.4	P04150;!P04083;!P35228;!P51843;!O75469	NR3C1;!ANXA1;!NOS2;!NR0B1;!NR1I2	1. Glucocorticoid receptor;!2. Annexin A1;!3. Nitric oxide synthase, inducible;!4. Nuclear receptor subfamily 0 group B member 1;!5. Nuclear receptor subfamily 1 group I member 2
C24H30ClFO5	Not Available	Not Available	452.95	[H][C@@]12C[C@@H](C)[C@H](C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C	Not Available	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5				CHEMBL2106011	10128648																	Clocortolone acetate	Experimental	DB14652	InChI=1S/C24H30ClFO5/c1-12-7-15-16-9-18(26)17-8-14(28)5-6-23(17,4)24(16,25)20(30)10-22(15,3)21(12)19(29)11-31-13(2)27/h5-6,8,12,15-16,18,20-21,30H,7,9-11H2,1-4H3/t12-,15+,16+,18+,20+,21-,22+,23+,24+/m1/s1	ARPLCFGLEYFDCN-CDACMRRYSA-N			Not Available	Small Molecule																																			1	Yes	4	1	No	4	0	80.67 Å2	46.16 Å3	114.89 m3·mol-1	4	Yes	No	0.00394 mg/mL	2.92	-5.1	13.83	-3.3			
C28H38ClFO5	Not Available	Not Available	509.06	CCCCCC(=O)OCC(=O)[C@H]1[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C	Not Available	Not Available								96796															ZINC000118937942		Clocortolone caproate	Experimental	DB14653	InChI=1S/C28H38ClFO5/c1-5-6-7-8-24(34)35-15-22(32)25-16(2)11-18-19-13-21(30)20-12-17(31)9-10-27(20,4)28(19,29)23(33)14-26(18,25)3/h9-10,12,16,18-19,21,23,25,33H,5-8,11,13-15H2,1-4H3/t16-,18+,19+,21+,23+,25-,26+,27+,28+/m1/s1	MMTRTBFDFNRBQO-ANHDKODLSA-N			Not Available	Small Molecule																																			1	No	4	1	Yes	4	0	80.67 Å2	53.59 Å3	133.32 m3·mol-1	8	No	No	0.00103 mg/mL	4.95	-5.7	13.83	-3.3			
C23H36O3	Not Available	Not Available	360.538	[H][C@@]12CC[C@H](OC(=O)CC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)[C@H](C)C[C@]12C	Not Available	Not Available						31523	CHEMBL1201048	194604					D01534			PA164760855						Drostanolone_propionate	ZINC000004213057		Drostanolone propionate	Approved, Illicit	DB14655	InChI=1S/C23H36O3/c1-5-21(25)26-20-9-8-17-16-7-6-15-12-19(24)14(2)13-23(15,4)18(16)10-11-22(17,20)3/h14-18,20H,5-13H2,1-4H3/t14-,15+,16+,17+,18+,20+,22+,23+/m1/s1	NOTIQUSPUUHHEH-UXOVVSIBSA-N			Side effects include virilization (masculine traits in women), acne, fluid retention, and hypercalcemia.	Small Molecule																																			1	Yes	2	0	No	4	0	43.37 Å2	43.19 Å3	101.96 m3·mol-1	3	No	No	0.000631 mg/mL	5.1	-5.8		-6.9			
C25H32O4	Not Available	Not Available	396.527	[H][C@@]12CC(=C)[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C	Not Available	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5			34831	CHEMBL1328968	219803				C14642	D04900									Melengestrol_acetate	ZINC000004216828		Melengestrol acetate	Experimental	DB14659	InChI=1S/C25H32O4/c1-14-11-19-20(23(5)9-7-18(28)13-21(14)23)8-10-24(6)22(19)12-15(2)25(24,16(3)26)29-17(4)27/h11,13,19-20,22H,2,7-10,12H2,1,3-6H3/t19-,20+,22+,23-,24+,25+/m1/s1	UDKABVSQKJNZBH-DWNQPYOZSA-N			Not Available	Small Molecule																																			1	Yes	3	0	No	4	0	60.44 Å2	44.82 Å3	112.83 m3·mol-1	3	Yes	No	0.00147 mg/mL	3.82	-5.4	17.54	-4.9			
C20H24O3	Not Available	Not Available	312.409	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)CCC4=C3C=C[C@]12C)OC(C)=O	Not Available	Not Available					50190646		CHEMBL1698011	59737														Trenbolone_acetate	ZINC000004083873		Trenbolone acetate	Vet approved	DB14660	InChI=1S/C20H24O3/c1-12(21)23-19-8-7-18-17-5-3-13-11-14(22)4-6-15(13)16(17)9-10-20(18,19)2/h9-11,17-19H,3-8H2,1-2H3/t17-,18+,19+,20+/m1/s1	CMRJPMODSSEAPL-FYQPLNBISA-N			Not Available	Small Molecule																																			1	Yes	2	0	No	4	0	43.37 Å2	35.53 Å3	90.81 m3·mol-1	2	Yes	No	0.00758 mg/mL	2.7	-4.6	18.4	-4.8			
C27H36F2O5	Not Available	Not Available	478.577	[H][C@@]12C[C@@H](C)[C@H](C(=O)COC(=O)C(C)(C)C)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C	Not Available	Not Available							CHEMBL2106277	59756																	Difluocortolone pivalate	Experimental	DB14664	InChI=1S/C27H36F2O5/c1-14-9-16-17-11-19(28)18-10-15(30)7-8-26(18,6)27(17,29)21(32)12-25(16,5)22(14)20(31)13-34-23(33)24(2,3)4/h7-8,10,14,16-17,19,21-22,32H,9,11-13H2,1-6H3/t14-,16+,17+,19+,21+,22-,25+,26+,27+/m1/s1	UWGRWFCLGQWKPR-GSTUPEFVSA-N			Not Available	Small Molecule																																			1	Yes	4	1	No	4	0	80.67 Å2	50.61 Å3	123.85 m3·mol-1	5	Yes	No	0.00492 mg/mL	4.25	-5	13.61	-3.4			
C22H30FO8P	The clearance of betamethasone in an intramuscular injection of 3mg betamethasone acetate and 3mg betamethasone phosphate is 12.62 ± 3.45 L/h.1	The half life of betamethasone in an intramuscular injection of 3mg betamethasone acetate and 3mg betamethasone phosphate is 12.47 ± 1.91 h.1	472.446	[H][C@@]12C[C@H](C)[C@](O)(C(=O)COP(O)(O)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	The volume of distribution of betamethasone in an intramuscular injection of 3mg betamethasone acetate and 3mg betamethasone phosphate is 226.00 ± 61.64 L.1	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5			68603	CHEMBL1201207	96937														Betamethasone_phosphate	ZINC000004097469		Betamethasone phosphate	Approved, Vet approved	DB14669	InChI=1S/C22H30FO8P/c1-12-8-16-15-5-4-13-9-14(24)6-7-19(13,2)21(15,23)17(25)10-20(16,3)22(12,27)18(26)11-31-32(28,29)30/h6-7,9,12,15-17,25,27H,4-5,8,10-11H2,1-3H3,(H2,28,29,30)/t12-,15-,16-,17-,19-,20-,21-,22-/m0/s1	VQODGRNSFPNSQE-DVTGEIKXSA-N		Betamethasone phosphate is a fast acting ester prodrug of a corticosteroid used to treat inflammatory conditions.	Patients experiencing an acute overdose should be treated with symptomatic and supportive treatment.5 Chronic overdoses where patients require continued therapy can be treated through temporary dose reduction or alternate day treatment.5The oral, intraperitoneal, and intravenous LD50 values in rats are 1877 mg/kg, 1179 mg/kg, and 1276 mg/kg, respectively.6	Small Molecule																																			1	Yes	7	4	No	4	-2	141.36 Å2	45.43 Å3	113.37 m3·mol-1	4	Yes	No	2.9 mg/mL	1.56	-2.2	1.18	-3.4	P04150;!P04083	NR3C1;!ANXA1	1. Glucocorticoid receptor;!2. Annexin A1
C26H35FO7	Not Available	Not Available	478.557	CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]21C	Not Available	Not Available								92436																	Flurandrenolide acetate	Experimental	DB14673	InChI=1S/C26H35FO7/c1-13(28)32-12-20(31)26-21(33-23(2,3)34-26)10-16-15-9-18(27)17-8-14(29)6-7-24(17,4)22(15)19(30)11-25(16,26)5/h8,15-16,18-19,21-22,30H,6-7,9-12H2,1-5H3/t15-,16-,18-,19-,21+,22+,24-,25-,26+/m0/s1	AUDPKCCPWYXNEV-XTLNBZDDSA-N			Not Available	Small Molecule																																			1	Yes	6	1	No	5	0	99.13 Å2	49.64 Å3	119.94 m3·mol-1	4	Yes	No	0.0162 mg/mL	2	-4.5	14.67	-2.8			
C26H38O4	Not Available	Not Available	414.586	[H][C@@]12CC[C@](OC(=O)CCCCC)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	Not Available	Not Available						31650	CHEMBL2107389	391969												4791		Gestonorone_caproate	ZINC000004216396		Gestonorone caproate	Approved	DB14677	InChI=1S/C26H38O4/c1-4-5-6-7-24(29)30-26(17(2)27)15-13-23-22-10-8-18-16-19(28)9-11-20(18)21(22)12-14-25(23,26)3/h16,20-23H,4-15H2,1-3H3/t20-,21+,22+,23-,25-,26-/m0/s1	XURCMZMFZXXQDJ-UKNJCJGYSA-N			Not Available	Small Molecule																																			1	Yes	3	0	Yes	4	0	60.44 Å2	48.55 Å3	117.21 m3·mol-1	7	No	No	0.00141 mg/mL	5.58	-5.5	17.69	-4.7			
C27H38O3	Not Available	Not Available	410.598	[H][C@@]12CC[C@@](OC(=O)CCCCCC)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			34894	CHEMBL3187229	199613				C14486								31984		Norethisterone_enanthate	ZINC000004217172		Norethindrone enanthate	Experimental	DB14678	InChI=1S/C27H38O3/c1-4-6-7-8-9-25(29)30-27(5-2)17-15-24-23-12-10-19-18-20(28)11-13-21(19)22(23)14-16-26(24,27)3/h2,18,21-24H,4,6-17H2,1,3H3/t21-,22+,23+,24-,26-,27-/m0/s1	APTGJECXMIKIET-WOSSHHRXSA-N	4	Norethindrone enanthate is a synthetic progestogen indicated for contraceptive therapy.	Not Available	Small Molecule																																			1	No	2	0	Yes	4	0	43.37 Å2	49.66 Å3	119.61 m3·mol-1	7	No	No	0.00148 mg/mL	6.14	-5.4	18.25	-4.7			
C27H36O3	Not Available	Not Available	408.582	[H][C@@]12CC[C@@](OC(C)=O)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(OC4CCCC4)=CC3=CC[C@@]21[H]	Not Available	Not Available						135661	CHEMBL2105291	17136														Quingestanol_acetate			Quingestanol acetate	Experimental	DB14679	InChI=1S/C27H36O3/c1-4-27(30-18(2)28)16-14-25-24-11-9-19-17-21(29-20-7-5-6-8-20)10-12-22(19)23(24)13-15-26(25,27)3/h1,9,17,20,22-25H,5-8,10-16H2,2-3H3/t22-,23+,24+,25-,26-,27-/m0/s1	FLGJKPPXEKYCBY-AKCFYGDASA-N			Not Available	Small Molecule																																			1	Yes	2	0	No	5	0	35.53 Å2	49.19 Å3	120.29 m3·mol-1	4	Yes	Yes	0.00175 mg/mL	4.76	-5.4		-4.8			
C21H28O5	Not Available	Not Available	360.444	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Not Available	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5		13739	16962	CHEMBL1499	193441			HMDB0002802	C00762	D07749							2878		Cortisone	ZINC000004083557		Cortisone	Experimental	DB14681	InChI=1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h9,14-15,18,22,26H,3-8,10-11H2,1-2H3/t14-,15-,18+,19-,20-,21-/m0/s1	MFYSYFVPBJMHGN-ZPOLXVRWSA-N	4		Not Available	Small Molecule																																			1	Yes	5	2	No	4	0	91.67 Å2	38.95 Å3	96.47 m3·mol-1	2	Yes	No	0.136 mg/mL	1.66	-3.4	12.58	-3.3			
C29H33FO9S	Not Available	Not Available	576.63	[H][C@@]12C[C@@H](C)[C@](O)(C(=O)COC(=O)C3=CC=CC(=C3)S(O)(=O)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Not Available	Not Available							CHEMBL3305965	56740															ZINC000004212887	Sofracort	Dexamethasone metasulfobenzoate	Approved, Experimental	DB14703	InChI=1S/C29H33FO9S/c1-16-11-22-21-8-7-18-13-19(31)9-10-26(18,2)28(21,30)23(32)14-27(22,3)29(16,35)24(33)15-39-25(34)17-5-4-6-20(12-17)40(36,37)38/h4-6,9-10,12-13,16,21-23,32,35H,7-8,11,14-15H2,1-3H3,(H,36,37,38)/t16-,21+,22+,23+,26+,27+,28+,29+/m1/s1	TWQWRHIQRAZHPR-XNXCGYEVSA-N		Dexamethasone metasulfobenzoate is an ophthalmic and auricular corticosteroid used with antibiotics for the treatment of otitis externa, blepharitis, and other inflammatory eye conditions.	Not Available	Small Molecule																																			1	No	8	3	Yes	5	-1	155.27 Å2	57.93 Å3	142.94 m3·mol-1	6	No	No	0.0457 mg/mL	1.22	-4.1	-2.5	-3.4			
C48H82O18	Not Available	Not Available	947.166	[H][C@@]1(CC[C@]2(C)[C@]1([H])[C@H](O)C[C@]1([H])[C@@]3(C)CC[C@H](O)C(C)(C)[C@]3([H])[C@H](C[C@@]21C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O)C(C)(CCC=C(C)C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O	Not Available	Not Available					50378779	77148	CHEMBL510095	390496				C08944											ZINC000242620164		Ginsenoside B2	Investigational	DB14815	InChI=1S/C48H82O18/c1-21(2)11-10-14-48(9,66-42-38(60)35(57)32(54)26(19-49)63-42)23-12-16-46(7)30(23)24(51)17-28-45(6)15-13-29(52)44(4,5)40(45)25(18-47(28,46)8)62-43-39(36(58)33(55)27(20-50)64-43)65-41-37(59)34(56)31(53)22(3)61-41/h11,22-43,49-60H,10,12-20H2,1-9H3/t22-,23-,24+,25-,26+,27+,28+,29-,30-,31-,32+,33+,34+,35-,36-,37+,38+,39+,40-,41-,42-,43+,45+,46+,47+,48-/m0/s1	PWAOOJDMFUQOKB-WCZZMFLVSA-N			Not Available	Small Molecule																																			0	No	18	12	Yes	7	0	298.14 Å2	103.38 Å3	234.52 m3·mol-1	12	No	No	0.812 mg/mL	-0.042	-3.1	11.85	-3.6			
C28H37NO7	Not Available	Not Available	499.604	CCC1=C(C(=O)O[C@H]2C(C)=C[C@@]34[C@H](C)C[C@@H]5[C@H]([C@H](C=C(CO)[C@@H](O)[C@]23O)C4=O)C5(C)C)C(CC)=NO1	Not Available	Not Available							CHEMBL3989918	52083803																	Ingenol disoxate	Investigational	DB15109	InChI=1S/C28H37NO7/c1-7-18-20(19(8-2)36-29-18)25(33)35-24-13(3)11-27-14(4)9-17-21(26(17,5)6)16(23(27)32)10-15(12-30)22(31)28(24,27)34/h10-11,14,16-17,21-22,24,30-31,34H,7-9,12H2,1-6H3/t14-,16+,17-,21+,22-,24+,27+,28+/m1/s1	GLIUZQUNUNICGS-XUBYYPQFSA-N	3		Not Available	Small Molecule																																			1	No	6	3	Yes	5	0	130.09 Å2	53.9 Å3	134.18 m3·mol-1	6	Yes	No	0.1 mg/mL	2.71	-3.7	12.13	0.46			
C22H28O4	Not Available	Not Available	356.462	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@@]1(O)C(=O)CO	Not Available	Not Available					50432396		CHEMBL2348780	2299335														Vamorolone	ZINC000033650317		Vamorolone	Investigational	DB15114	InChI=1S/C22H28O4/c1-13-10-18-16-5-4-14-11-15(24)6-8-20(14,2)17(16)7-9-21(18,3)22(13,26)19(25)12-23/h6-8,11,13,16,18,23,26H,4-5,9-10,12H2,1-3H3/t13-,16-,18+,20+,21+,22+/m1/s1	ZYTXTXAMMDTYDQ-DGEXFFLYSA-N	2		Not Available	Small Molecule																																			1	Yes	4	2	No	4	0	74.6 Å2	39.26 Å3	102.22 m3·mol-1	2	Yes	No	0.0246 mg/mL	2.54	-4.2	12.45	-3.3			
C25H29FO5	Not Available	Not Available	427.503	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1C[C@H]1O[C@H](O[C@@]21C(=O)C[18F])C1=CC=CO1	Not Available	Not Available								58828602																	Fluorofuranylnorprogesterone F-18	Investigational	DB15282	InChI=1S/C25H29FO5/c1-24-9-8-17-16-7-5-15(27)11-14(16)4-6-18(17)19(24)12-22-25(24,21(28)13-26)31-23(30-22)20-3-2-10-29-20/h2-3,10-11,16-19,22-23H,4-9,12-13H2,1H3/t16-,17+,18+,19-,22+,23+,24-,25+/m0/s1/i26-1	VJKRBRUNEOHPBS-JQKUZGBFSA-N	2		Not Available	Small Molecule																																			1	Yes	4	0	No	6	0	65.74 Å2	45.2 Å3	110.28 m3·mol-1	3	Yes	No	0.0251 mg/mL	4.33	-4.2	14.61	-2.9			
C48H78O20	Not Available	Not Available	975.132	[H][C@@]1(O[C@@H]2[C@@H](CO)O[C@@H](OC[C@H]3O[C@@H](OC(=O)[C@]45CC[C@@H](C)[C@H](C)[C@@]4([H])C4=CC[C@]6([H])[C@@]7(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@]7([H])[C@H](O)C[C@@]6(C)[C@]4(C)CC5)[C@H](O)[C@@H](O)[C@@H]3O)[C@H](O)[C@H]2O)O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O	Not Available	Not Available					23212	66651		28639016												87855		Centella_asiatica	ZINC000253529433		Madecassoside	Experimental	DB15532	InChI=1S/C48H78O20/c1-19-10-11-48(13-12-46(6)22(28(48)20(19)2)8-9-27-44(4)14-24(52)39(61)45(5,18-50)38(44)23(51)15-47(27,46)7)43(62)68-42-35(59)32(56)30(54)26(66-42)17-63-40-36(60)33(57)37(25(16-49)65-40)67-41-34(58)31(55)29(53)21(3)64-41/h8,19-21,23-42,49-61H,9-18H2,1-7H3/t19-,20+,21+,23-,24-,25-,26-,27-,28+,29+,30-,31-,32+,33-,34-,35-,36-,37-,38-,39+,40-,41+,42+,44-,45+,46-,47-,48+/m1/s1	BNMGUJRJUUDLHW-HCZMHFOYSA-N			Not Available	Small Molecule																																			0	No	19	13	Yes	8	0	335.44 Å2	103.17 Å3	234.14 m3·mol-1	10	No	No	1.71 mg/mL	-1.8	-2.8	11.75	-3.6			
C28H46O3	Not Available	Not Available	430.673	[H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C)[C@H](C)CCCCC(C)(C)O	Not Available	Not Available								7826421												1423458			ZINC000038791777		24-Homo-1,25-dihydroxyvitamin D3	Experimental	DB15557	InChI=1S/C28H46O3/c1-19(9-6-7-15-27(3,4)31)24-13-14-25-21(10-8-16-28(24,25)5)11-12-22-17-23(29)18-26(30)20(22)2/h11-12,19,23-26,29-31H,2,6-10,13-18H2,1,3-5H3/b21-11+,22-12-/t19-,23-,24-,25+,26+,28-/m1/s1	WKTIGYIYJKESCJ-JJWMBMNSSA-N			Not Available	Small Molecule																																			1	No	3	3	Yes	3	0	60.69 Å2	53.36 Å3	131.13 m3·mol-1	7	Yes	No	0.00475 mg/mL	4.8	-5	14.39	-1.3			
C23H30O6	Data regarding the clearance of prednisolone acetate is not readily available.6,7,8	Oral prednisolone acetate has a plasma half life of 2-3 hours.5	402.4807	[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@]([H])(O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	The volume of distribution of the active metabolite, prednisolone, is 0.22/0.7L/kg.5	P08684	CYP3A4	1. Cytochrome P450 3A4			8380	CHEMBL1152	5629				C08180					5834					Prednisolone_acetate	ZINC000003875348	Blephamide, Econopred Plus, Flo-pred, Pred Forte, Pred Mild, Pred-G	Prednisolone acetate	Approved, Vet approved	DB15566	InChI=1S/C23H30O6/c1-13(24)29-12-19(27)23(28)9-7-17-16-5-4-14-10-15(25)6-8-21(14,2)20(16)18(26)11-22(17,23)3/h6,8,10,16-18,20,26,28H,4-5,7,9,11-12H2,1-3H3/t16-,17-,18-,20+,21-,22-,23-/m0/s1	LRJOMUJRLNCICJ-JZYPGELDSA-N	4	Prednisolone acetate is a glucocorticoid used to treat a wide variety of endocrine, inflammatory, and immune conditions as well as for palliation of neoplastic conditions.	The oral LD50 of prednisolone acetate in mice is 1680 mg/kg.8 Patients experiencing an overdose of oral prednisolone acetate may experience an increased severity in the adverse effects of corticosteroids.5 Overdose of oral prednisolone acetate may be treated by gastric lavage or inducing vomiting if the overdose was recent, as well as supportive and symptomatic therapy.5 Chronic overdosage may be treated by dose reduction or treating patients on alternate days.5 An overdose by the ophthalmic route is not expected to cause problems.5	Small Molecule																														1.332		238			1	Yes	5	2	No	4	0	100.9 Å2	42.93 Å3	107.64 m3·mol-1	4	Yes	No	0.0417 mg/mL	1.71	-4	12.61	-2.9	P04150	NR3C1	1. Glucocorticoid receptor
C30H39NO2	Not Available	Not Available	445.647	[H][C@@]12CC[C@@]3(CCCO3)[C@@]1(C)C[C@H](C1=CC=C(C=C1)N(C)C)C1=C3CCC(=O)C=C3[C@H](C)C[C@@]21[H]	Not Available	Not Available							CHEMBL460258	143897															ZINC000003918217		ORG-31710	Experimental	DB15585	InChI=1S/C30H39NO2/c1-19-16-25-27-12-14-30(13-5-15-33-30)29(27,2)18-26(20-6-8-21(9-7-20)31(3)4)28(25)23-11-10-22(32)17-24(19)23/h6-9,17,19,25-27H,5,10-16,18H2,1-4H3/t19-,25+,26-,27+,29+,30+/m1/s1	HFDGABTZPISMDD-IEVXGSBISA-N			Not Available	Small Molecule																																			1	No	3	0	No	6	0	29.54 Å2	52.91 Å3	136.34 m3·mol-1	2	No	Yes	0.00101 mg/mL	5.4	-5.6	18.37	4.89			
C30H48O3	Not Available	Not Available	456.711	[H][C@@]12[C@@H](C)[C@H](C)CC[C@@]1(CC[C@]1(C)C2=CC[C@]2([H])[C@@]3(C)CC[C@H](O)C(C)(C)[C@]3([H])CC[C@@]12C)C(O)=O	Not Available	Not Available					50148911	9908	CHEMBL169	58472			HMDB0002395	C08988		6Q5						1426931		Ursolic_acid	ZINC000003978827		Ursolic acid	Experimental	DB15588	InChI=1S/C30H48O3/c1-18-10-15-30(25(32)33)17-16-28(6)20(24(30)19(18)2)8-9-22-27(5)13-12-23(31)26(3,4)21(27)11-14-29(22,28)7/h8,18-19,21-24,31H,9-17H2,1-7H3,(H,32,33)/t18-,19+,21+,22-,23+,24+,27+,28-,29-,30+/m1/s1	WCGUUGGRBIKTOS-GPOJBZKASA-N	2		Not Available	Small Molecule																																			1	No	3	2	No	5	-1	57.53 Å2	54.51 Å3	133.7 m3·mol-1	1	No	No	0.00059 mg/mL	6.58	-5.9	4.74	-0.84			
C27H44O	Not Available	Not Available	384.648	[H][C@@]1(CC[C@@]2([H])C(\C=C/C3=C(C)CC[C@H](O)C3)=CCC[C@]12C)[C@H](C)CCCC(C)C	Not Available	Not Available						8403		4444516				C07711											ZINC000016343334		Previtamin D(3)	Experimental	DB15614	InChI=1S/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h10,12-13,19,21,24-26,28H,6-9,11,14-18H2,1-5H3/b13-12-/t21-,24+,25-,26+,27-/m1/s1	YUGCAAVRZWBXEQ-WHTXLNIXSA-N			Not Available	Small Molecule																																			1	No	1	1	Yes	3	0	20.23 Å2	49.02 Å3	124.3 m3·mol-1	7	No	Yes	0.000374 mg/mL	7.07	-6	18.31	-1.3			
C29H36O4	Not Available	Not Available	448.603	[H][C@@]12C[C@H]3O[C@](C)(O[C@@]3(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C)C1=CC=CC=C1	Not Available	Not Available						49327	CHEMBL3989742	4447595														Algestone_acetophenide	ZINC000004172334		Algestone acetophenide	Experimental	DB15775	InChI=1S/C29H36O4/c1-18(30)29-25(32-28(4,33-29)19-8-6-5-7-9-19)17-24-22-11-10-20-16-21(31)12-14-26(20,2)23(22)13-15-27(24,29)3/h5-9,16,22-25H,10-15,17H2,1-4H3/t22-,23+,24+,25-,26+,27+,28-,29-/m1/s1	AHBKIEXBQNRDNL-FVCOMRFXSA-N		Algestone acetophenide is a progestin indicated in combination with an estrogen as an injectable contraceptive.	Not Available	Small Molecule																																			1	No	4	0	No	6	0	52.6 Å2	50.33 Å3	127.37 m3·mol-1	2	No	No	0.000357 mg/mL	5.74	-6.1	17.63	-4.1			
C27H37FO5	Not Available	Not Available	460.586	[H][C@@]12C[C@@H](C)[C@H](C(=O)COC(=O)C(C)(C)C)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C	Not Available	Not Available								107027												4465			ZINC000030691645		Fluocortolone pivalate	Experimental	DB15777	InChI=1S/C27H37FO5/c1-14-9-17-16-11-19(28)18-10-15(29)7-8-26(18,5)23(16)20(30)12-27(17,6)22(14)21(31)13-33-24(32)25(2,3)4/h7-8,10,14,16-17,19-20,22-23,30H,9,11-13H2,1-6H3/t14-,16+,17+,19+,20+,22-,23-,26+,27+/m1/s1	XZBJVIQXJHGUBE-HZMVJJPJSA-N		Fluocortolone pivalate is a corticosteroid used to treat corticosteroid-responsive dermatoses and hemorrhoids.	Not Available	Small Molecule																																			1	Yes	4	1	No	4	0	80.67 Å2	50.5 Å3	124.32 m3·mol-1	5	Yes	No	0.0022 mg/mL	4.21	-5.3	15.15	-0.23			
C28H39FO5	Not Available	Not Available	474.613	[H][C@@]12C[C@@H](C)[C@H](C(=O)COC(=O)CCCCC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C	Not Available	Not Available							CHEMBL2107415	16735815												4464			ZINC000004213356		Fluocortolone caproate	Experimental	DB15821	InChI=1S/C28H39FO5/c1-5-6-7-8-24(33)34-15-23(32)25-16(2)11-19-18-13-21(29)20-12-17(30)9-10-27(20,3)26(18)22(31)14-28(19,25)4/h9-10,12,16,18-19,21-22,25-26,31H,5-8,11,13-15H2,1-4H3/t16-,18+,19+,21+,22+,25-,26-,27+,28+/m1/s1	WHZRCUIISKRTJL-YTZKRAOUSA-N		Fluocortolone caproate is a corticosteroid indicated in the treatment of hemorrhoids, anal fissures, and corticosteroid-responsive dermatoses.	Not Available	Small Molecule																																			1	No	4	1	Yes	4	0	80.67 Å2	52.93 Å3	129.05 m3·mol-1	8	Yes	No	0.0017 mg/mL	4.44	-5.4	15.15	-0.23			
C27H42O4	Not Available	Not Available	430.629	[H][C@]12C[C@@]3([H])[C@]4([H])CC=C5C[C@@H](O)C[C@@H](O)[C@]5(C)[C@@]4([H])CC[C@]3(C)[C@@]1([H])[C@H](C)[C@@]1(CC[C@@H](C)CO1)O2	Not Available	Not Available						8913	CHEMBL1169820	390469				C08909	D08498							35890			ZINC000008234225		Ruscogenin	Experimental	DB15830	InChI=1S/C27H42O4/c1-15-7-10-27(30-14-15)16(2)24-22(31-27)13-21-19-6-5-17-11-18(28)12-23(29)26(17,4)20(19)8-9-25(21,24)3/h5,15-16,18-24,28-29H,6-14H2,1-4H3/t15-,16+,18-,19-,20+,21+,22+,23-,24+,25+,26+,27-/m1/s1	QMQIQBOGXYYATH-IDABPMKMSA-N		Ruscogenin is an anti-inflammatory steroid used in combination with local anesthetics for the treatment of hemorrhoids and for local anesthesia.	Not Available	Small Molecule																																			1	No	4	2	No	6	0	58.92 Å2	51.73 Å3	121.74 m3·mol-1	0	Yes	No	0.00821 mg/mL	3.62	-4.7	14.45	-2.8			
C23H29ClO4	Not Available	Not Available	404.93	[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(Cl)C2=CC(=O)CC[C@]12C	Not Available	Not Available						31394	CHEMBL110691	8963				C12729								2369		Chlormadinone_acetate	ZINC000003876041		Chlormadinone acetate	Experimental	DB15903	InChI=1S/C23H29ClO4/c1-13(25)23(28-14(2)26)10-7-18-16-12-20(24)19-11-15(27)5-8-21(19,3)17(16)6-9-22(18,23)4/h11-12,16-18H,5-10H2,1-4H3/t16-,17+,18+,21-,22+,23+/m1/s1	QMBJSIBWORFWQT-DFXBJWIESA-N		Chlormadinone acetate is a progestin indicated in combination with an estrogen for birth control.	Not Available	Small Molecule																																			1	Yes	3	0	No	4	0	60.44 Å2	43.67 Å3	109.09 m3·mol-1	3	Yes	No	0.00158 mg/mL	3.72	-5.4	17.83	-5.5			
C21H25ClO5	Not Available	Not Available	392.88	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])C[C@H](Cl)C2=CC(=O)C=C[C@]12C	Not Available	Not Available						135618		2298578														Chloroprednisone	ZINC000033650036		Chloroprednisone	Experimental	DB15970	InChI=1S/C21H25ClO5/c1-19-5-3-11(24)7-14(19)15(22)8-12-13-4-6-21(27,17(26)10-23)20(13,2)9-16(25)18(12)19/h3,5,7,12-13,15,18,23,27H,4,6,8-10H2,1-2H3/t12-,13-,15-,18+,19-,20-,21-/m0/s1	NPSLCOWKFFNQKK-ZPSUVKRCSA-N			Not Available	Small Molecule																																			1	Yes	5	2	No	4	0	91.67 Å2	40.51 Å3	102.13 m3·mol-1	2	Yes	No	0.0395 mg/mL	1.78	-4	12.58	-3.3			
C21H29ClO3	Not Available	Not Available	364.91	[H][C@@]12CC[C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=C(Cl)C(=O)CC[C@]12C	Not Available	Not Available						81712	CHEMBL519327	12762				C18374								236522		Clostebol_acetate	ZINC000003881980		Clostebol acetate	Experimental	DB15984	InChI=1S/C21H29ClO3/c1-12(23)25-18-7-6-14-13-4-5-16-19(22)17(24)9-11-20(16,2)15(13)8-10-21(14,18)3/h13-15,18H,4-11H2,1-3H3/t13-,14-,15-,18-,20+,21-/m0/s1	XYGMEFJSKQEBTO-KUJXMBTLSA-N		Clostebol acetate is a steroid combined with neomycin in topical formulations for the treatment of minor skin wounds.	Not Available	Small Molecule																																			1	Yes	2	0	No	4	0	43.37 Å2	40.68 Å3	98.37 m3·mol-1	2	Yes	No	0.00309 mg/mL	4.2	-5.1		-6.2			
C27H38O6	Not Available	Not Available	458.595	[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCCCC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Not Available	Not Available								136723																	Prednisolone caproate	Experimental	DB15999	InChI=1S/C27H38O6/c1-4-5-6-7-23(31)33-16-22(30)27(32)13-11-20-19-9-8-17-14-18(28)10-12-25(17,2)24(19)21(29)15-26(20,27)3/h10,12,14,19-21,24,29,32H,4-9,11,13,15-16H2,1-3H3/t19-,20-,21-,24+,25-,26-,27-/m0/s1	DNSAKUGJOSFARZ-FOMYWIRZSA-N		Prednisolone caproate is a corticosteroid indicated to treat hemorrhoids, anal fissures, and proctitis.	Not Available	Small Molecule																																			1	No	5	2	Yes	4	0	100.9 Å2	51.73 Å3	126.07 m3·mol-1	8	Yes	No	0.0065 mg/mL	3.75	-4.8	12.61	-2.9			
C29H46O3	Not Available	Not Available	442.684	[H][C@@]12CC[C@H](OC(=O)CCCCCCCCC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Not Available	Not Available						35000	CHEMBL1473654	136680				C14607								37858		Testosterone_decanoate	ZINC000019685816		Testosterone decanoate	Experimental	DB16001	InChI=1S/C29H46O3/c1-4-5-6-7-8-9-10-11-27(31)32-26-15-14-24-23-13-12-21-20-22(30)16-18-28(21,2)25(23)17-19-29(24,26)3/h20,23-26H,4-19H2,1-3H3/t23-,24-,25-,26-,28-,29-/m0/s1	LBERVHLCXUMDOT-MPZZESAYSA-N		Testosterone decanoate is a steroid indicated for testosterone replacement therapy in sterilization, missing testicle, hypopituitarism, and osteoporosis.	Not Available	Small Molecule																																			1	No	2	0	Yes	4	0	43.37 Å2	54.86 Å3	130.42 m3·mol-1	10	No	No	0.000114 mg/mL	7.62	-6.6	18.52	-4.8			
C25H38O3	Not Available	Not Available	386.576	[H][C@@]12CC[C@H](OC(=O)CCC(C)C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Not Available	Not Available					50103618	35001	CHEMBL3189011	201317				C14663								75806		Testosterone_isocaproate	ZINC000004538407		Testosterone isocaproate	Experimental	DB16002	InChI=1S/C25H38O3/c1-16(2)5-10-23(27)28-22-9-8-20-19-7-6-17-15-18(26)11-13-24(17,3)21(19)12-14-25(20,22)4/h15-16,19-22H,5-14H2,1-4H3/t19-,20-,21-,22-,24-,25-/m0/s1	PPYHLSBUTAPNGT-BKWLFHPQSA-N		Testosterone isocaproate is a steroid indicated for testosterone replacement therapy in sterilization, missing testicle, hypopituitarism, and osteoporosis.	Not Available	Small Molecule																																			1	No	2	0	No	4	0	43.37 Å2	46.61 Å3	111.96 m3·mol-1	5	No	No	0.000955 mg/mL	5.68	-5.6	18.52	-4.8			
C28H36O3	Not Available	Not Available	420.593	[H][C@@]12CC[C@H](OC(=O)CCC3=CC=CC=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Not Available	Not Available						35002	CHEMBL2356993	14062				C14667								37855		Testosterone_phenylpropionate	ZINC000003881605		Testosterone phenylpropionate	Experimental	DB16003	InChI=1S/C28H36O3/c1-27-16-14-21(29)18-20(27)9-10-22-23-11-12-25(28(23,2)17-15-24(22)27)31-26(30)13-8-19-6-4-3-5-7-19/h3-7,18,22-25H,8-17H2,1-2H3/t22-,23-,24-,25-,27-,28-/m0/s1	HHSXYDOROIURIP-FEZCWRLCSA-N		Testosterone phenylpropionate is a steroid indicated for testosterone replacement therapy in sterilization, missing testicle, hypopituitarism, and osteoporosis.	Not Available	Small Molecule																																			1	No	2	0	No	5	0	43.37 Å2	49.36 Å3	122.9 m3·mol-1	5	No	No	0.000283 mg/mL	6.09	-6.2	18.52	-4.8			
C35H49NO7	Not Available	Not Available	595.777	[H][C@@]12OC3=C4C(C[C@H]5N(CC6CC6)CC[C@@]14[C@@]51CC[C@@]2(OC)[C@]([H])(C1)[C@](C)(O)C(C)(C)C)=CC=C3OC(=O)CCCCC(O)=O	Not Available	Not Available								32698730																	Buprenorphine hemiadipate	Investigational	DB16117	InChI=1S/C35H49NO7/c1-31(2,3)32(4,40)24-19-33-14-15-35(24,41-5)30-34(33)16-17-36(20-21-10-11-21)25(33)18-22-12-13-23(29(43-30)28(22)34)42-27(39)9-7-6-8-26(37)38/h12-13,21,24-25,30,40H,6-11,14-20H2,1-5H3,(H,37,38)/t24-,25-,30-,32+,33-,34+,35-/m1/s1	CVIJJOARNCQGON-XYQNZYJMSA-N	2		Not Available	Small Molecule																																			0	No	7	2	Yes	7	0	105.53 Å2	66.1 Å3	161.01 m3·mol-1	12	No	No	0.00288 mg/mL	1.93	-5.3	3.3	9.8			
C31H50O3	Not Available	Not Available	470.738	[H][C@@]12CC[C@H](OC(=O)CCCCCCCCCC)[C@@]1(C)C[C@H](C)[C@]1([H])[C@@]3([H])CCC(=O)C=C3C[C@@H](C)[C@@]21[H]	Not Available	Not Available								68025242																	Dimethandrolone Undecanoate	Investigational	DB16141	InChI=1S/C31H50O3/c1-5-6-7-8-9-10-11-12-13-28(33)34-27-17-16-26-30-21(2)18-23-19-24(32)14-15-25(23)29(30)22(3)20-31(26,27)4/h19,21-22,25-27,29-30H,5-18,20H2,1-4H3/t21-,22+,25+,26+,27+,29-,30+,31+/m1/s1	FVICENFBEMJOCE-RTFNQGFNSA-N	1		Not Available	Small Molecule																																			0	No	2	0	Yes	4	0	43.37 Å2	59.02 Å3	139.64 m3·mol-1	11	No	No	4.39e-05 mg/mL	8.34	-7	18.3	-4.7			
C28H29F5O3	Not Available	Not Available	508.529	[H][C@@]12CC[C@@](O)(C(F)(F)C(F)(F)F)[C@@]1(C)C[C@H](C1=CC=C(C=C1)C(C)=O)C1=C3CCC(=O)C=C3CC[C@@]21[H]	Not Available	Not Available					50409115		CHEMBL146032	5293745														Lonaprisan			Lonaprisan	Investigational	DB16221	InChI=1S/C28H29F5O3/c1-15(34)16-3-5-17(6-4-16)22-14-25(2)23(11-12-26(25,36)27(29,30)28(31,32)33)21-9-7-18-13-19(35)8-10-20(18)24(21)22/h3-6,13,21-23,36H,7-12,14H2,1-2H3/t21-,22+,23-,25-,26-/m0/s1	VHZPUDNSVGRVMB-RXDLHWJPSA-N	2		Not Available	Small Molecule																																			0	No	3	1	No	5	0	54.37 Å2	49.03 Å3	125.59 m3·mol-1	4	No	No	0.00424 mg/mL	5.17	-5.1	11.81	-4.2			
C23H38O4	Not Available	Not Available	378.553	[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CC(O)=O	Not Available	Not Available							CHEMBL1254990	166888															ZINC000031520504		norUrsodeoxycholic acid	Investigational	DB16260	InChI=1S/C23H38O4/c1-13(10-20(26)27)16-4-5-17-21-18(7-9-23(16,17)3)22(2)8-6-15(24)11-14(22)12-19(21)25/h13-19,21,24-25H,4-12H2,1-3H3,(H,26,27)/t13-,14+,15-,16-,17+,18+,19+,21+,22+,23-/m1/s1	QYYDXDSPYPOWRO-JHMCBHKWSA-N			Not Available	Small Molecule																																			1	Yes	4	3	No	4	-1	77.76 Å2	44.49 Å3	104.67 m3·mol-1	3	Yes	No	0.0396 mg/mL	3.27	-4	4.53	-0.54			
C23H28O11	Not Available	Not Available	480.466	[H][C@@]12C[C@@]3(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@]1(COC(=O)C1=CC=CC=C1)[C@@]1([H])O[C@]2(O)C[C@]3(C)O1	Not Available	Not Available						7889	CHEMBL4303209	390957				C09959								2288155		Paeoniflorin	ZINC000008234328		Peoniflorin	Investigational	DB16288	InChI=1S/C23H28O11/c1-20-9-22(29)13-7-23(20,32-18-16(27)15(26)14(25)12(8-24)31-18)21(13,19(33-20)34-22)10-30-17(28)11-5-3-2-4-6-11/h2-6,12-16,18-19,24-27,29H,7-10H2,1H3/t12-,13-,14-,15+,16-,18+,19-,20+,21+,22-,23+/m1/s1	YKRGDOXKVOZESV-WRJNSLSBSA-N			Not Available	Small Molecule																																			1	No	10	5	Yes	6	0	164.37 Å2	0 Å3	109.3 m3·mol-1	7	Yes	No	5.32 mg/mL	-0.39	-2	11.54	-3			
C26H40O3	Not Available	Not Available	400.603	[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@H](CC[C@]12C)OC(=O)CCCCCC	Not Available	Not Available								143333														Prasterone_enanthate	ZINC000005820240		Prasterone enantate	Approved	DB16625	InChI=1S/C26H40O3/c1-4-5-6-7-8-24(28)29-19-13-15-25(2)18(17-19)9-10-20-21-11-12-23(27)26(21,3)16-14-22(20)25/h9,19-22H,4-8,10-17H2,1-3H3/t19-,20-,21-,22-,25-,26-/m0/s1	HHENOUDBWKNPAB-BNCSLUSBSA-N		Prasterone enantate is an estrogen indicated for hormone replacement therapy in postmenopausal women.	Not Available	Small Molecule																																			1	No	2	0	Yes	4	0	43.37 Å2	48.28 Å3	116.84 m3·mol-1	7	No	No		6.28			-6.9			
C22H28F2O5	Not Available	Not Available	410.4515	[H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C	Solid	Not Available						59750	CHEMBL1201380	64505	Drugs.com Drug Page		HMDB0014368		D07827			PA164749408	71415	46504519	RxList Drug Page	91311	DAP001184	Diflorasone	ZINC000005752191	Apexicon, Florone, Psorcon	Diflorasone	Approved	DB00223	InChI=1S/C22H28F2O5/c1-11-6-13-14-8-16(23)15-7-12(26)4-5-19(15,2)21(14,24)17(27)9-20(13,3)22(11,29)18(28)10-25/h4-5,7,11,13-14,16-17,25,27,29H,6,8-10H2,1-3H3/t11-,13-,14-,16-,17-,19-,20-,21-,22-/m0/s1	WXURHACBFYSXBI-XHIJKXOTSA-N		Diflorasone is a topical corticosteroid used to treat the symptoms of various inflammatory skin conditions that cause erythema, pruritus, and discomfort.	Topically applied diflorasone can be absorbed in sufficient amounts to produce systemic effects. Symptoms of overdose include thinning of skin and suppression of adrenal cortex (decreased ability to respond to stress).	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3293 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.1					1	Yes	5	3	No	4	0	94.83 Å2	40.92 Å3	102.32 m3·mol-1	2	Yes	No	0.0853 mg/mL	1.34	-3.7	12.42	-3.3	P04150	NR3C1	1. Glucocorticoid receptor
C29H38N4O10	Lymecycline is partially cleared by the kidneys, like other tetracyclines.7	The half-life of lymecycline is approximately 8 hours.3	602.6328	[H][C@@]12C[C@@]3([H])C(C(=O)C4=C(O)C=CC=C4[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(=O)NCNCCCC[C@H](N)C(O)=O)=C(O)[C@H]2N(C)C	Solid	Lymecycline is lipophilic and easily crosses the cell membrane and passively diffuses through bacterial porin channels.3,5 As a second-generation tetracycline, the concentration in the bile ranges from 10 to 25 times higher than plasma concentration.3,7 In general, the volume of distribution of tetracyclines ranges from 1.3–1.7 L/kg or 100–130 L.3						59040	CHEMBL2103929	20121315			HMDB0014401		D06884			PA164747190	54707177	46505518		6513	DAP000881	Lymecycline	ZINC000053682936		Lymecycline	Approved, Investigational	DB00256	InChI=1S/C29H38N4O10/c1-28(42)13-7-6-9-17(34)18(13)22(35)19-14(28)11-15-21(33(2)3)23(36)20(25(38)29(15,43)24(19)37)26(39)32-12-31-10-5-4-8-16(30)27(40)41/h6-7,9,14-16,21,31,34,36-37,42-43H,4-5,8,10-12,30H2,1-3H3,(H,32,39)(H,40,41)/t14-,15-,16-,21-,28+,29-/m0/s1	AHEVKYYGXVEWNO-UEPZRUIBSA-N	3	Lymecycline is a tetracycline antibiotic used for the treatment of acne vulgaris and other susceptible infections.	The oral LD50 of lymecycline in rats is 3200 mg/kg.10 Overdoses with lymecycline are rare. In the case of an overdose, gastric lavage should be performed immediately. Provide supportive treatment and maintain fluid balance.9	Small Molecule	http://smpdb.ca/view/SMP0000295?highlight[compounds][]=DB00256&highlight[proteins][]=DB00256	Lymecycline Action Pathway		Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.5422 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor				928.1±65.0	-1.70		192.5	2.50±0.24		0	No	13	9	Yes	4	1	242.98 Å2	62.48 Å3	154.51 m3·mol-1	10	No	No	1.31 mg/mL	-7.1	-2.7	2.51	9.77	P0A7V8	rpsD	1. 30S ribosomal protein S4
C28H35FO7	Not Available	Not Available	502.5717	[H][C@@]12C[C@H]3OC4(CCCC4)O[C@@]3(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5			31199	CHEMBL1200732	392009	Drugs.com Drug Page		HMDB0014433		D01387		PDRhealth Drug Page	PA164746074	443958	46506705	RxList Drug Page	17652	DAP001044	Amcinonide	ZINC000003977777		Amcinonide	Approved	DB00288	InChI=1S/C28H35FO7/c1-16(30)34-15-22(33)28-23(35-26(36-28)9-4-5-10-26)13-20-19-7-6-17-12-18(31)8-11-24(17,2)27(19,29)21(32)14-25(20,28)3/h8,11-12,19-21,23,32H,4-7,9-10,13-15H2,1-3H3/t19-,20-,21-,23+,24-,25-,27-,28+/m0/s1	ILKJAFIWWBXGDU-MOGDOJJUSA-N		Amcinonide is a topical corticosteroid used in the treatment of inflammation and pruritus due to a variety of dermatoses.	Results from acute toxicity studies do not indicate that any risk of acute intoxication is to be expected following a single dermal application of an overdose (application over a large area under conditions favorable to absorption) or inadvertent oral ingestion.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.4315 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.3					1	No	6	1	No	6	0	99.13 Å2	52.38 Å3	127.88 m3·mol-1	4	No	No	0.00774 mg/mL	3.2	-4.8	13.63	-3.4	P04150;!P04083	NR3C1;!ANXA1	1. Glucocorticoid receptor;!2. Annexin A1
C22H29FO4	Not Available	Not Available	376.4617	[H][C@@]12CC[C@](O)(C(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C	Solid	Not Available	P20815;!P08684	CYP3A5;!CYP3A4	1. Cytochrome P450 3A5;!2. Cytochrome P450 3A4		50103631	31625	CHEMBL1200600	9494	Drugs.com Drug Page		HMDB0014469		D01367		PDRhealth Drug Page	PA164781355	9878	46505984	RxList Drug Page	4491	DAP001047	Fluorometholone	ZINC000118912517	FML, FML Forte Liquifilm, FML-S, Flarex, Fluor-OP	Fluorometholone	Approved, Investigational	DB00324	InChI=1S/C22H29FO4/c1-12-9-17-15-6-8-21(27,13(2)24)20(15,4)11-18(26)22(17,23)19(3)7-5-14(25)10-16(12)19/h5,7,10,12,15,17-18,26-27H,6,8-9,11H2,1-4H3/t12-,15-,17-,18-,19-,20-,21-,22-/m0/s1	FAOZLTXFLGPHNG-KNAQIMQKSA-N	4	Fluorometholone is an ophthalmic corticosteroid used for the relief of inflammation located in both the palpebral and bulbar conjunctiva, the cornea, and the anterior segment of the globe of the eye.	Side effects may include acute anterior uveitis and perforation of the globe. Keratitis, conjunctivitis, corneal ulcers, mydriasis, conjunctival hyperemia, loss of accommodation and ptosis have occasionally been reported following local use of corticosteroids. LD50 = 234 mg/kg (rats)	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3393 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.00	-4.1	292-303		30 mg/L (at 25 °C)	1	Yes	4	2	No	4	0	74.6 Å2	39.94 Å3	100.87 m3·mol-1	1	Yes	No	0.0166 mg/mL	2.42	-4.4	12.65	-3.4	P04150	NR3C1	1. Glucocorticoid receptor
C24H32O4	Not Available	34 hours	384.516	[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4		50238674	6723	CHEMBL1201139	11192	Drugs.com Drug Page			C08151	D00952			PA450351	11683	46505827	RxList Drug Page	29451	DAP000861	Megestrol	ZINC000004097467	Megace	Megestrol acetate	Approved, Investigational, Vet approved	DB00351	InChI=1S/C24H32O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h12-13,18-20H,6-11H2,1-5H3/t18-,19+,20+,22-,23+,24+/m1/s1	RQZAXGRLVPAYTJ-GQFGMJRRSA-N	4	Megestrol acetate is a progestin that is administered orally to treat anorexia and cachexia or serious unexplained weight loss and is also used as an antineoplastic agent to treat certain types of malignancy.	No serious unexpected side effects have resulted from studies involving megestrol acetate oral suspension administered in dosages as high as 1200 mg/day. Treatment with megestrol acetate, an orexigenic agent, has also resulted in iatrogenic adrenal suppression. The mechanism is presumably related to the glucocorticoid properties of megestrol acetate [PMID: 12872362].	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	1.8121 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.2		218.0-220.0 °C		2 µg/mL (at 37 °C for the acetate salt)	1	Yes	3	0	No	4	0	60.44 Å2	43.51 Å3	108.66 m3·mol-1	3	Yes	No	0.00336 mg/mL	3.72	-5.1	17.83	-4.9	P06401;!P04150	PGR;!NR3C1	1. Progesterone receptor;!2. Glucocorticoid receptor
C21H28O2	Not Available	Dydrogesterone: 5-7 hours, 20-dihydrodydrogesterone (DHD) metabolite: 14-17 hours	312.4458	[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]2([H])C=CC2=CC(=O)CC[C@@]12C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			31527	CHEMBL1200853	8699		GtP Drug Page	HMDB0014522		D01217			PA164745443	9051	46506195		3706	DAP001205	Dydrogesterone	ZINC000003875998		Dydrogesterone	Approved, Investigational, Withdrawn	DB00378	InChI=1S/C21H28O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h4-5,12,16-19H,6-11H2,1-3H3/t16-,17+,18-,19+,20+,21+/m0/s1	JGMOKGBVKVMRFX-HQZYFCCVSA-N	4	Dydrogesterone is a synthetic progesterone for menstrual cycle regulation, infertility treatment, prevention of miscarriage, and other conditions.	No serious or unexpected toxicity has been observed with dydrogesterone. In acute toxicity studies, the LD50 doses in rats exceeded 4,640mg/kg for the oral route.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	1.8041 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.4		168-169			1	Yes	2	0	No	4	0	34.14 Å2	36.39 Å3	93.82 m3·mol-1	1	Yes	Yes	0.00486 mg/mL	3.79	-4.8	19.4	-4.8	P06401	PGR	1. Progesterone receptor
C21H30O2	Apparent clearance1367 ± 348 (50mg of progesterone administered by vaginal insert once daily) 11.106 ± 15 L/h (50mg/mL IM injection once daily) 11.	Absorption half-life is approximately 25-50 hours and an elimination half-life of 5-20 minutes (progesterone gel) 20. Progesterone, administered orally, has a short serum half-life (approximately 5 minutes). It is rapidly metabolized to 17-hydroxyprogesterone during its first pass through the liver 11.	314.4617	[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	When administered vaginally, progesterone is well absorbed by uterine endometrial tissue, and a small percentage is distributed into the systemic circulation.The amount of progesterone in the systemic circulation appears to be of minimal importance, especially when implantation, pregnancy, and live birth outcomes appear similar for intramuscular and vaginal administration of progesterone 11.					8903	17026	CHEMBL103	5773	Drugs.com Drug Page		HMDB0001830	C00410	D00066	STR	PDRhealth Drug Page	PA451123	5994	46508968	RxList Drug Page	8727	DAP000549	Progesterone	ZINC000004428529	Bijuva, Crinone, Endometrin, Prochieve, Prometrium	Progesterone	Approved, Vet approved	DB00396	InChI=1S/C21H30O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h12,16-19H,4-11H2,1-3H3/t16-,17+,18-,19-,20-,21+/m0/s1	RJKFOVLPORLFTN-LEKSSAKUSA-N	4	Progesterone is a hormone used for a variety of functions, including contraception, control of abnormal uterine bleeding, maintenance of pregnancy, and prevention of endometrial hyperplasia.	Intraperitoneal LD50 (rat): 327 mg/kg MSDS. Use in pregnancyOnly forms of progesterone that are indicated on product labeling for pregnancy should be used. Some forms of progesterone should not be used in pregnancy Label, 22. Refer to individual product monographs for information regarding use in pregnancy. Many studies have found no effects on fetal development associated with long-term use of contraceptive doses of oral progestins. Studies of infant growth and development that have been conducted have not demonstrated significant adverse effects, however, these studies are few in number. It is therefore advisable to rule out suspected pregnancy before starting any hormonal contraceptive 22. Effects on fertilityProgesterone at high doses is an antifertility drug and high doses would be expected to impair fertility until cessation 25. The progesterone contraceptive should not be used during pregnancy. CarcinogenicityProgesterone has been shown to induce or promote the formation of ovarian, uterine, mammary, and genital tract tumors in animals. The clinical relevance of these findings is unknown 24. Certain epidemiological studies of patients using oral contraceptives have reported an increased relative risk of developing breast cancer, especially at a younger age and associated with a longer duration of use. These studies have mainly involved combined oral contraceptives, and therefore, it is unknown whether this risk is attributable to progestins, estrogens, or a combination of both. At this time, there is insufficient data to determine whether the use of progestin-only contraceptives increases the risk in a similar way to combined contraceptives. A meta-analysis of 54 studies showed a small increase in the frequency of breast cancer diagnosis for women who were currently using combined oral contraceptives, or had used them within the past 10 years. There was no increase in the frequency of having breast cancer diagnosed ten or more years after cessation of hormone use. Women with breast cancer should not use oral contraceptives, as there is no sufficient data to fully establish or negate the risk of cancer with hormonal contraceptive use 22. Use in breastfeedingProgesterone has been detected in the milk of nursing mothers 21, 22. No adverse effects, in general, have been found on breastfeeding ability or on the health, growth, or development of the growing infant. Despite this, isolated post-marketing cases of decreased milk production have been reported 22.	Small Molecule	http://smpdb.ca/view/SMP0000371?highlight[compounds][]=DB00396&highlight[proteins][]=DB00396;!http://smpdb.ca/view/SMP0000575?highlight[compounds][]=DB00396&highlight[proteins][]=DB00396;!http://smpdb.ca/view/SMP0000717?highlight[compounds][]=DB00396&highlight[proteins][]=DB00396;!http://smpdb.ca/view/SMP0000372?highlight[compounds][]=DB00396&highlight[proteins][]=DB00396;!http://smpdb.ca/view/SMP0000577?highlight[compounds][]=DB00396&highlight[proteins][]=DB00396;!http://smpdb.ca/view/SMP0000718?highlight[compounds][]=DB00396&highlight[proteins][]=DB00396;!http://smpdb.ca/view/SMP0000130?highlight[compounds][]=DB00396&highlight[proteins][]=DB00396;!http://smpdb.ca/view/SMP0000373?highlight[compounds][]=DB00396&highlight[proteins][]=DB00396;!http://smpdb.ca/view/SMP0000566?highlight[compounds][]=DB00396&highlight[proteins][]=DB00396;!http://smpdb.ca/view/SMP0000576?highlight[compounds][]=DB00396&highlight[proteins][]=DB00396;!http://smpdb.ca/view/SMP0000578?highlight[compounds][]=DB00396&highlight[proteins][]=DB00396	Congenital Lipoid Adrenal Hyperplasia (CLAH) or Lipoid CAH;!11-beta-Hydroxylase Deficiency (CYP11B1);!Apparent Mineralocorticoid Excess Syndrome;!Adrenal Hyperplasia Type 5 or Congenital Adrenal Hyperplasia Due to 17 alpha-Hydroxylase Deficiency;!Corticosterone Methyl Oxidase I Deficiency (CMO I);!3-beta-Hydroxysteroid Dehydrogenase Deficiency;!Steroidogenesis;!Adrenal Hyperplasia Type 3 or Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency;!17-alpha-Hydroxylase Deficiency (CYP17);!21-Hydroxylase Deficiency (CYP21);!Corticosterone Methyl Oxidase II Deficiency (CMO II)		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	1.8041 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				394.13°C (rough estimate)	3.87	-4.43	128-132	Strongest acidic: , Strongest basic: 18.92, -4.8	<0.1 g/100 mL at 19 ºC	1	Yes	2	0	No	4	0	34.14 Å2	37.26 Å3	92.71 m3·mol-1	1	Yes	Yes	0.00546 mg/mL	4.15	-4.8	18.47	-4.8			
C24H32O4S	Clearance data is not readily available.Label,7	1.4 hours.Label,7Canrenone has a half life of 16.5 hours, 7-α-thiomethylspirolactone has a half life of 13.8 hours, and 6-ß-hydroxy-7-α-thiomethylspirolactone has a half life of 15 hours.Label,7	416.573	[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O	Solid	Volume of distribution data is not readily available.Label,7	P15538;!P10632	CYP11B1;!CYP2C8	1. Cytochrome P450 11B1, mitochondrial;!2. Cytochrome P450 2C8		50228080	9241	CHEMBL1393	5628	Drugs.com Drug Page	GtP Drug Page	HMDB0014565	C07310	D00443	SNL	PDRhealth Drug Page	PA451483	5833	46508525	RxList Drug Page	9997	DAP000297	Spironolactone	ZINC000003861599	Aldactazide, Aldactone, Carospir	Spironolactone	Approved	DB00421	InChI=1S/C24H32O4S/c1-14(25)29-19-13-15-12-16(26)4-8-22(15,2)17-5-9-23(3)18(21(17)19)6-10-24(23)11-7-20(27)28-24/h12,17-19,21H,4-11,13H2,1-3H3/t17-,18-,19+,21+,22-,23-,24+/m0/s1	LXMSZDCAJNLERA-ZHYRCANASA-N	4	Spironolactone is an aldosterone receptor antagonist used for the treatment of hypertension, hyperaldosteronism, edema due to various conditions, hirsutism (off-label) and hypokalemia.	Patients experiencing an overdose may present with drowsiness, mental confusion, maculopapular or erythematous rash, nausea, vomiting, dizziness, or diarrhea. Vomiting is generally induced or a gastric lavage is performed.Label Supportive treatment involves maintining hydration, electrolyte balance, and vital functionsLabel.The oral LD50 in mice, rats, and rabbits is >1g/kg.LabelSpironolactone should be avoided in pregnancy due to reports of feminization of male fetuses in animal studies.Label Active metabolites of spironolactone are present in breast milk and levels that are likely inconsequential, though the long term effects have not been studied.LabelIn animal studies, spironolactone slowed follicle development, ovulation, and implantation.Label Spironolactone increased the incidence of benign adenomas in the testes of male rats, benign uterine endometrial stromal polyps in female rats, and thyroid follicular cell adenomas in both sexes of rats.Label Spironolactone and canrenone are generally not considered to be mutagenic in tests but canrenone occasionally tests positive for mutagenicity with metabolic activation and spironolactone has occasionally tested inconclusive though slightly positive for mutagenicity.Label	Small Molecule	http://smpdb.ca/view/SMP0000134?highlight[compounds][]=DB00421&highlight[proteins][]=DB00421	Spironolactone Action Pathway		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.0150 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				201	2.78		134.5 °C			1	Yes	3	0	No	5	0	60.44 Å2	46.03 Å3	113.5 m3·mol-1	2	Yes	No	0.00198 mg/mL	3.64	-5.3	17.89	-4.9			
C22H29FO5	In a study that included Indian women of reproductive age, the CL/F following a single intramuscular dose of betamethasone phosphate was 6,466 ± 805 mL/hour.9	In a study that included Indian women of reproductive age, the half-life following a single intramuscular dose of betamethasone phosphate was 10.2 ± 2.5 hours.9	392.4611	[H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	In a study that included Indian women of reproductive age, the volume of distribution following a single intramuscular dose of betamethasone phosphate was 94,584±23,539 mL(s).9	P11511;!P20815;!P24462;!P11509;!Q16678;!P20813;!P10632;!P11712;!P33261;!P08684	CYP19A1;!CYP3A5;!CYP3A7;!CYP2A6;!CYP1B1;!CYP2B6;!CYP2C8;!CYP2C9;!CYP2C19;!CYP3A4	1. Cytochrome P450 19A1;!2. Cytochrome P450 3A5;!3. Cytochrome P450 3A7;!4. Cytochrome P450 2A6;!  Details5. Cytochrome P450 1B1;!6. Cytochrome P450 2B6;!7. Cytochrome P450 2C8;!8. Cytochrome P450 2C9;!9. Cytochrome P450 2C19;!10. Cytochrome P450 3A4		73823	3077	CHEMBL632	9399	Drugs.com Drug Page		HMDB0014586		D00244			PA164754818	9782	46505155	RxList Drug Page	1514	DAP001043	Betamethasone	ZINC000003876136	Betaderm, Betaloan Suik, Beteflam, Betnesol, Celestoderm, Celestone Soluspan, Dermacinrx Therazole Pak, Diprolene, Diprosalic, Diprosone, Dovobet, Enstilar, Fucibet, Lotriderm, Lotrisone, Luxiq, Marbeta, Rivasone, Rolene, Rosone, Sernivo, Taclonex, Valisone-G, Wynzora	Betamethasone	Approved, Vet approved	DB00443	InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,17-,19-,20-,21-,22-/m0/s1	UREBDLICKHMUKA-DVTGEIKXSA-N	4	Betamethasone is a systemic corticosteroid used to relieve inflammation in various conditions, including but not limited to allergic states, dermatologic disorders, gastrointestinal diseases, and hematological disorders.	Chronic high doses of glucocorticoids can lead to the development of cataracts, glaucoma, hypertension, water retention, hyperlipidemia, peptic ulcer, pancreatitis, myopathy, osteoporosis, mood changes, psychosis, dermal atrophy, allergy, acne, hypertrichosis, immune suppression, decreased resistance to infection, moon face, hyperglycemia, hypocalcemia, hypophosphatemia, metabolic acidosis, growth suppression, and secondary adrenal insufficiency.6 Overdose may be treated by adjusting the dose or stopping the corticosteroid as well as initiating symptomatic and supportive treatment.6	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1482 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor				568.2°C	1.138	-3.77	178°C		66.5 mg/L (at 25 °C)	1	Yes	5	3	No	4	0	94.83 Å2	40.81 Å3	102.49 m3·mol-1	2	Yes	No	0.0505 mg/mL	1.68	-3.9	12.42	-3.3	P04150	NR3C1	1. Glucocorticoid receptor
C20H28O2	Not Available	Not Available	300.4351	C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O	Solid	Not Available					31892	50648	CHEMBL705	395778	Drugs.com Drug Page		HMDB0002369	C15493	D02815	9CR		PA164746900	449171	46507356	RxList Drug Page	81864	DAP000275	Alitretinoin	ZINC000012661824	Panretin, Toctino	Alitretinoin	Approved, Investigational	DB00523	InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8-,16-14+	SHGAZHPCJJPHSC-ZVCIMWCZSA-N	3	Alitretinoin is a vitamin A derivative used to treat Kaposi's sarcoma and used off label to treat chronic hand eczema and psoriasis.	Not Available	Small Molecule	http://smpdb.ca/view/SMP0000074?highlight[compounds][]=DB00523&highlight[proteins][]=DB00523;!http://smpdb.ca/view/SMP0000336?highlight[compounds][]=DB00523&highlight[proteins][]=DB00523	Retinol Metabolism;!Vitamin A Deficiency		Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.1455 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					4.2		189-190 °C		0.6 mg/L	1	Yes	2	1	No	1	-1	37.3 Å2	35.89 Å3	97.79 m3·mol-1	5	No	Yes	0.00477 mg/mL	5.01	-4.8	4.76		P10276;!P19793;!P10826;!P28702;!P13631;!P48443;!P17936;!Q15238;!Q6V0L0	RARA;!RXRA;!RARB;!RXRB;!RARG;!RXRG;!IGFBP3;!PSG5;!CYP26C1	1. Retinoic acid receptor alpha;!2. Retinoic acid receptor RXR-alpha;!3. Retinoic acid receptor beta;!4. Retinoic acid receptor RXR-beta;!5. Retinoic acid receptor gamma;!6. Retinoic acid receptor RXR-gamma;!7. Insulin-like growth factor-binding protein 3;!8. Pregnancy-specific beta-1-glycoprotein 5;!9. Cytochrome P450 26C1
C22H27ClF2O4	Not Available	In vitro experiments show halobetasol propionate, a derivative of ulobetasol, has a half life of 33 minutes.9	428.9	[H][C@@]12C[C@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C	Solid	Not Available							CHEMBL1201360	4470691	Drugs.com Drug Page						PDRhealth Drug Page	PA164768832	5311167	46506187	RxList Drug Page	41208	DAP001186	Ulobetasol	ZINC000004214603	Bryhali, Duobrii, Lexette, Ultravate, Ultravate X Ointment	Ulobetasol	Approved	DB00596	InChI=1S/C22H27ClF2O4/c1-11-6-13-14-8-16(24)15-7-12(26)4-5-19(15,2)21(14,25)17(27)9-20(13,3)22(11,29)18(28)10-23/h4-5,7,11,13-14,16-17,27,29H,6,8-10H2,1-3H3/t11-,13-,14-,16-,17-,19-,20-,21-,22-/m0/s1	LEHFPXVYPMWYQD-XHIJKXOTSA-N	4	Ulobetasol is a lipocortin corticosteroid used to treat inflammatory and pruritic corticosteroid-responsive dermatoses.	Data regarding acute overdoses of glucocorticoids are rare.7,8 Chronic high doses of glucocorticoids can lead to the development of cataract, glaucoma, hypertension, water retention, hyperlipidemia, peptic ulcer, pancreatitis, myopathy, osteoporosis, mood changes, psychosis, dermal atrophy, allergy, acne, hypertrichosis, immune suppression, decreased resistance to infection, moon face, hyperglycemia, hypocalcemia, hypophosphatemia, metabolic acidosis, growth suppression, and secondary adrenal insufficiency.5 Overdose may be treated by adjusting the dose or stopping the corticosteroid as well as initiating symptomatic and supportive treatment.5,10	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.3204 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							200-216		Practically insoluble	1	Yes	4	2	No	4	0	74.6 Å2	42.07 Å3	105.37 m3·mol-1	2	Yes	No	0.022 mg/mL	2.7	-4.3	12.46	-3.4	P04150	NR3C1	1. Glucocorticoid receptor
C24H34O4	The mean clearance of medroxyprogesterone acetate (MPA) is 1668±146L/day or 21.9±4.3L/kg/day.5 Due to the high inter patient variability in MPA pharmacokinetics, clearance has been reported to be 1600-4000L/day.15	Oral medroxyprogesterone acetate (MPA) has an absorption half life of 15-30min and a biological half life of 40-60 hours.2 Intramuscular MPA has an absorption half life of 0.86±0.30 days and an elimination half life of 24.03±21.74 days.3 Subcutaneous MPA has an absorption half life of 1.05±0.56 days and an elimination half life of 30.90±15.11 days.3	386.5244	[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)CC[C@]12C	Solid	The volume of distribution of medroxyprogesterone acetate is 20±3L.15	P08684;!P10632;!P26439;!P11712;!P04800	CYP3A4;!CYP2C8;!HSD3B2;!CYP2C9;!Cyp3a1	1. Cytochrome P450 3A4;!2. Cytochrome P450 2C8;!3. 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2;!4. Cytochrome P450 2C9;!5. Cytochrome P450 3A1		50067678	6716	CHEMBL717	6043	Drugs.com Drug Page	GtP Drug Page		C08150	D00951			PA450344	6279	46508895	RxList Drug Page	1000112	DAP001211	Medroxyprogesterone	ZINC000005029557	Depo-provera, Depo-subq Provera, Premphase 28 Day, Prempro 0.625/2.5 28 Day, Provera	Medroxyprogesterone acetate	Approved, Investigational	DB00603	InChI=1S/C24H34O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h13-14,18-20H,6-12H2,1-5H3/t14-,18+,19-,20-,22+,23-,24-/m0/s1	PSGAAPLEWMOORI-PEINSRQWSA-N	4	Medroxyprogesterone acetate is a progestin used as a contraceptive and in the treatment of secondary amenorrhea, abnormal uterine bleeding, pain from endometriosis, endometrial and renal carcinomas, paraphilia in males, and GnRH-dependent precocious puberty.	The oral LD50 in rats is >6400mg/kg and in mice is >16g/kg.16 The intraperitoneal LD50 in rats is >900mg/kg and in mice is >1500mg/kg.16 The subcutaneous LD50 in rats is >900mg/kg and in mice is>1500mg/kg.16Patients experiencing and overdose or oral medroxyprogesterone acetate (MPA) may present with nausea, vomiting, breast tenderness, dizziness, abdominal pain, drowsiness, fatigue, and withdrawal bleeding.10,11 Treat patients by stopping MPA and beginning symptomatic treatment.10,11 Patients who have been given too much of a MPA depo injection should contact a healthcare professional, hospital emergency department, or local poison control immediately.15	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	1.8121 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							205-209		10mM	1	Yes	3	0	No	4	0	60.44 Å2	44.06 Å3	107.81 m3·mol-1	3	Yes	No	0.00221 mg/mL	4.13	-5.2	17.73	-4.9			
C21H27FO6	The clearance of triamcinolone is 28.6±5.6L/h.4 The mean total body clearance of triamcinolone acetonide is 0.57L/h.2 The clearance of triamcinolone diacetate is 34.4±10.6L/h.4	The half life of triamcinolone is 2.7h.4 The mean terminal elimination half life following an inhaled dose of triamcinolone acetonide is 2.4h.2 The half life of triamcinolone diacetate is 2.8h.4	394.4339	[H][C@@]12C[C@@H](O)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	The apparent volume of distribution of triamcinolone is 115.2±10L.4 The mean apparent volume of distribution of triamcinolone acetonide is 1.96L/kg.2 The apparent volume of distribution of triamcinolone diacetate is 119.7±33.14L.4	P08684;!P35354;!P06276;!P20815;!P24462	CYP3A4;!PTGS2;!BCHE;!CYP3A5;!CYP3A7	1. Cytochrome P450 3A4;!2. Prostaglandin G/H synthase 2;!3. Cholinesterase;!4. Cytochrome P450 3A5;!5. Cytochrome P450 3A7		41132	9667	CHEMBL1451	29046	Drugs.com Drug Page	GtP Drug Page	HMDB0014758		D00385		PDRhealth Drug Page	PA451749	31307	46507950	RxList Drug Page	10759	DAP000417	Triamcinolone	ZINC000003882036	Aller-cort, Allernaze, Aristocort, Aristocort R, Juulissa Pharmapak, Kenalog, Marcaine, Nasacort, Oracort, Oralone, Pediaderm Ta, Triaderm, Trianex, Triderm, Triesence, Triloan Suik, Tritocin, Viaderm Kc, Xipere, Zilretta	Triamcinolone	Approved, Vet approved	DB00620	InChI=1S/C21H27FO6/c1-18-6-5-12(24)7-11(18)3-4-13-14-8-15(25)21(28,17(27)10-23)19(14,2)9-16(26)20(13,18)22/h5-7,13-16,23,25-26,28H,3-4,8-10H2,1-2H3/t13-,14-,15+,16-,18-,19-,20-,21-/m0/s1	GFNANZIMVAIWHM-OBYCQNJPSA-N	4	Triamcinolone is a glucocorticoid used to treat a wide variety of inflammatory conditions of organ systems and tissues.	The subcutaneous LD50 of triamcinolone acetonide in rats is 13,100µg/kg and in mice is 132mg/kg.17 The oral LD50 in rats is 1451mg/kg and in mice is 2168mg/kg.[LD50] The intraperitoneal LD50 in mice is 105mg/kg.[LD50]Patients experiencing an overdose may develop Cushing's syndrome.6 This overdose may be treated with supportive therapy and mifepristone for its antiglucocorticoid activity.6	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3369 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor							270			1	Yes	6	4	No	4	0	115.06 Å2	39.8 Å3	99.38 m3·mol-1	2	Yes	No	0.847 mg/mL	0.24	-2.7	11.75	-3.3	P04150	NR3C1	1. Glucocorticoid receptor
C19H28O2	The mean metabolic clearance in middle aged men is 812±64L/day.3	The half life of testosterone is highly variable, ranging from 10-100 minutes.14,15,16,17,18,19,20	288.4244	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	The volume of distribution of testosterone in elderly men is 80.36±24.51L.2					8885	17347	CHEMBL386630	5791		GtP Drug Page	HMDB0000234	C00535	D00075	TES	PDRhealth Drug Page	PA451627	6013	46505691	RxList Drug Page	10379	DAP000841	Testosterone	ZINC000118912393	Androderm, Androgel, Axiron, Fortesta, Natesto, Striant, Testim, Testopel, Vogelxo	Testosterone	Approved, Investigational	DB00624	InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-17,21H,3-10H2,1-2H3/t14-,15-,16-,17-,18-,19-/m0/s1	MUMGGOZAMZWBJJ-DYKIIFRCSA-N	4	Testosterone is a hormone used to treat hypogonadism, breast carcinoma in women, or the vasomotor symptoms of menopause.	Data regarding an overdose with a topical testosterone product is not readily available.14,15,16,17,18,19,20 In the case of overdose with an injectable product, patients may present with a cerebrovascular event.14,15,16,17,18,19,20 Treat overdoses by stopping testosterone products, washing off any topical products with soap and water, and initiating symptomatic and supportive treatments.14,15,16,17,18,19,20	Small Molecule	http://smpdb.ca/view/SMP0000356?highlight[compounds][]=DB00624&highlight[proteins][]=DB00624;!http://smpdb.ca/view/SMP0030406?highlight[compounds][]=DB00624&highlight[proteins][]=DB00624;!http://smpdb.ca/view/SMP0000068?highlight[compounds][]=DB00624&highlight[proteins][]=DB00624;!http://smpdb.ca/view/SMP0000565?highlight[compounds][]=DB00624&highlight[proteins][]=DB00624	17-beta Hydroxysteroid Dehydrogenase III Deficiency;!Androstenedione Metabolism;!Androgen and Estrogen Metabolism;!Aromatase Deficiency		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.6259 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor		-4.34			3.32		155 °C		23.4 mg/L (at 25 °C)	1	Yes	2	1	No	4	0	37.3 Å2	33.88 Å3	84.43 m3·mol-1	0	Yes	Yes	0.0333 mg/mL	3.37	-3.9	18.52	-0.88			
C21H26O5	Data regarding the clearance of prednisone is not readily available.9A 5.5µg/h/kg infusion of prednisolone has an average clearance of 0.066±0.12L/h/kg, while a 0.15±0.03L/h/kg infusion has an average clearance of 0.15L/h/kg.3	Prednisone and its active metabolite prednisolone have half lives of 2-3 hours from both immediate and delayed release preparations.9	358.4281	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	Data regarding the volume of distribution for prednisone is not readily available.9 However, a 0.15mg/kg dose of prednisolone has a volume of distribution of 29.3L, while a 0.30mg/kg dose has a volume of distribution of 44.2L.6	P33261;!P20815;!BE0004866;!P11509;!Q16678;!P20813;!P10632;!P11712;!P28845;!P08684	CYP2C19;!CYP3A5;!;!CYP2A6;!CYP1B1;!CYP2B6;!CYP2C8;!CYP2C9;!HSD11B1;!CYP3A4	1. Cytochrome P450 2C19;!2. Cytochrome P450 3A5;!3. Cytochrome P450 3A Subfamily (Protein Group);!4. Cytochrome P450 2A6;!5. Cytochrome P450 1B1;!6. Cytochrome P450 2B6;!7. Cytochrome P450 2C8;!8. Cytochrome P450 2C9;!9. Corticosteroid 11-beta-dehydrogenase isozyme 1;!10. Cytochrome P450 3A4			8382	CHEMBL635	5656	Drugs.com Drug Page		HMDB0014773	C07370	D00473	PDN		PA451100	5865	46508166	RxList Drug Page	8640	DAP001041	Prednisone	ZINC000003875357	Deltasone, Rayos, Winpred	Prednisone	Approved, Vet approved	DB00635	InChI=1S/C21H26O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-15,18,22,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,18+,19-,20-,21-/m0/s1	XOFYZVNMUHMLCC-ZPOLXVRWSA-N		Prednisone is a corticosteroid used to treat inflammation or immune-mediated reactions and to treat endocrine or neoplastic diseases.	Data regarding acute overdoses of prednisone are rare but prolonged high doses of prednisone can lead to a higher incidence and severity of adverse effects such as mental symptoms, moon face, abnormal fat deposits, fluid retention, excessive appetite, weight gain, hypertrichosis, acne, striae, ecchymosis, increased sweating, pigmentation, dry scaly skin, thinning scalp hair, increased blood pressure, tachycardia, thrombophlebitis, decreased resistance to infection, negative nitrogen balance with delayed bone and wound healing, headache, weakness, menstrual disorders, accentuated menopausal symptoms, neuropathy, fractures, osteoporosis, peptic ulcer, decreased glucose tolerance, hypokalemia, and adrenal insufficiency.9	Small Molecule	http://smpdb.ca/view/SMP0000440?highlight[compounds][]=DB00635&highlight[proteins][]=DB00635;!http://smpdb.ca/view/SMP0000631?highlight[compounds][]=DB00635&highlight[proteins][]=DB00635	Prednisone Action Pathway;!Prednisone Metabolism Pathway		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.8914 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					1.46		230 - 235 °C (decomposes)		Very slightly soluble	1	Yes	5	2	No	4	0	91.67 Å2	38.2 Å3	97.57 m3·mol-1	2	Yes	No		1.66		12.58	-3.3	P04150	NR3C1	1. Glucocorticoid receptor
C22H28F2O5	Not Available	Not Available	410.458	[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4		50240002	34764	CHEMBL1201392	15632				C14479	D04208			PA164749388	16490	46505121		4458	DAP000814	Flumetasone	ZINC000003983936	Locacorten Vioform	Flumethasone	Approved, Vet approved	DB00663	InChI=1S/C22H28F2O5/c1-11-6-13-14-8-16(23)15-7-12(26)4-5-19(15,2)21(14,24)17(27)9-20(13,3)22(11,29)18(28)10-25/h4-5,7,11,13-14,16-17,25,27,29H,6,8-10H2,1-3H3/t11-,13+,14+,16+,17+,19+,20+,21+,22+/m1/s1	WXURHACBFYSXBI-GQKYHHCASA-N		Flumethasone is a corticosteroid used to treat contact dermatitis, atopic dermatitis, eczema, psoriasis, diaper rash, and other skin conditions.	Can lead to signs of irritation such as burning sensation, itching or skin rash at the site of application; hypersensitivity reactions.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.4249 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.86		219 °C (base only)		0.392 mg/L	1	Yes	5	3	No	4	0	94.83 Å2	41.25 Å3	102.32 m3·mol-1	2	Yes	No	0.0853 mg/mL	1.34	-3.7	12.42	-3.3	P04150	NR3C1	1. Glucocorticoid receptor
C21H29FO5	Population pharmacokinetics have estimated the plasma clearance of fludrocortisone to be 40.8 L/h.9	The plasma half-life of fludrocortisone has been variably reported to be between 1-3.5 hours,6,9,10 though prescribing information gives an approximate half-life of 18-36 hours.15	380.4504	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	The apparent volume of distribution of fludrocortisone is 80-85 L.9,6 Distribution into CSF appears minimal - the observed ratio of CSF drug concentration versus plasma drug concentration is 1:6.16	P08684;!P80365;!P28845	CYP3A4;!HSD11B2;!HSD11B1	1. Cytochrome P450 3A4;!2. Corticosteroid 11-beta-dehydrogenase isozyme 2;!3. Corticosteroid 11-beta-dehydrogenase isozyme 1			50885	CHEMBL1201388	29111	Drugs.com Drug Page	GtP Drug Page	HMDB0014825	C07004	D07967	ZK5		PA164743961	31378	46508616	RxList Drug Page	4452	DAP001105	Fludrocortisone	ZINC000004097304	Florinef	Fludrocortisone	Approved, Investigational	DB00687	InChI=1S/C21H29FO5/c1-18-7-5-13(24)9-12(18)3-4-15-14-6-8-20(27,17(26)11-23)19(14,2)10-16(25)21(15,18)22/h9,14-16,23,25,27H,3-8,10-11H2,1-2H3/t14-,15-,16-,18-,19-,20-,21-/m0/s1	AAXVEMMRQDVLJB-BULBTXNYSA-N	4	Fludrocortisone is a mineralocorticoid used to treat adrenocortical insufficiency and salt-losing adrenogenital syndrome.	The oral LD50 of fludrocortisone in rats is >1g/kg.17 Acute overdosage of fludrocortisone is likely to result in symptoms consistent with its adverse effect profile. Patients receiving a single large dose should be treated with plenty of water by mouth and should undergo monitoring of serum electrolytes, particularly potassium and sodium, and be treated appropriately for any developing imbalances.15,16	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1686 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	5	3	No	4	0	94.83 Å2	39.53 Å3	96.93 m3·mol-1	2	Yes	No	0.224 mg/mL	1.32	-3.2	12.55	-3.3	P08235;!P04150	NR3C2;!NR3C1	1. Mineralocorticoid receptor;!2. Glucocorticoid receptor
C24H30O6	Apparent plasma cl=10 L/hr	4-6 hours	414.4914	[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)C[C@H]1O[C@@]11[C@@]2([H])[C@@H](CC2=CC(=O)CC[C@]12C)C(=O)OC	Solid	43 to 90 L	P19099;!P08684;!P20815	CYP11B2;!CYP3A4;!CYP3A5	1. Cytochrome P450 11B2, mitochondrial;!2. Cytochrome P450 3A4;!3. Cytochrome P450 3A5		50318300	31547	CHEMBL1095097	10203511	Drugs.com Drug Page	GtP Drug Page	HMDB0014838	C12512	D01115	YNU	PDRhealth Drug Page	PA164749044	443872	46509053	RxList Drug Page	298869	DAP000085	Eplerenone	ZINC000003985982	Inspra	Eplerenone	Approved	DB00700	InChI=1S/C24H30O6/c1-21-7-4-14(25)10-13(21)11-15(20(27)28-3)19-16-5-8-23(9-6-18(26)30-23)22(16,2)12-17-24(19,21)29-17/h10,15-17,19H,4-9,11-12H2,1-3H3/t15-,16+,17-,19+,21+,22+,23-,24-/m1/s1	JUKPWJGBANNWMW-VWBFHTRKSA-N	4	Eplerenone is an aldosterone receptor antagonist used to improve survival of patients with symptomatic heart failure and to reduce blood pressure.	The most likely symptoms of human overdosage would be anticipated to be hypotension or hyperkalemia. However, no cases of human overdosage with eplerenone have been reported.	Small Molecule	http://smpdb.ca/view/SMP0000135?highlight[compounds][]=DB00700&highlight[proteins][]=DB00700	Eplerenone Action Pathway		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.4761 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					1.3				Slightly soluble	1	Yes	4	0	No	6	0	82.2 Å2	43.94 Å3	106.68 m3·mol-1	2	Yes	No	0.00903 mg/mL	2.33	-4.7	16.44	-4.2			
C21H30O5	Total hydrocortisone by the oral route has a mean clearance of 12.85L/h, while the free fraction has a mean clearance of 235.78L/h.1 A 20mg IV dose of hydrocortisone has a clearance of 18.2±4.2L/h.6	Total hydrocortisone via the oral route has a half life of 2.15h while the free fraction has a half life of 1.39h.1 A 20mg IV dose of hydrocortisone has a terminal half life of 1.9±0.4h.6	362.4599	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	Total hydrocortisone has a volume of distribution of 39.82L, while the free fraction has a volume of distribution of 474.38L.1					13775	17650	CHEMBL389621	5551	Drugs.com Drug Page	GtP Drug Page	HMDB0000063	C00735	D00088	HCY	PDRhealth Drug Page	PA449905	5754	46505089	RxList Drug Page	5492	DAP000718	Hydrocortisone	ZINC000013540519	Ala-cort, Ala-scalp, Alcortin, Alkindi, Anusol HC, Aquanil HC, Casporyn HC, Cipro, Cipro HC, Colocort, Cortaid, Cortane-B, Cortef, Cortenema, Cortisporin, Cortizone-10, Dermacort, Dermarest Eczema, Dermazene, Home Papkit, Hydroskin, Monistat Itch Relief, Neosporin Eczema, Preparation H Hydrocortisone, Procto-med, Procto-pak, Proctocort, Proctol, Proctosedyl, Proctosol, Proctozone HC, Scalpicin Itch Relief, Texacort, Vanoxide-HC, Xerese	Hydrocortisone	Approved, Vet approved	DB00741	InChI=1S/C21H30O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h9,14-16,18,22,24,26H,3-8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1	JYGXADMDTFJGBT-VWUMJDOOSA-N	4	Hydrocortisone is a glucocorticoid used to treat corticosteroid-responsive dermatoses, endocrine disorders, immune conditions, and allergic disorders.	Data regarding acute overdoses of glucocorticoids are rare.14,15,16,17,18,19 Chronic high doses of glucocorticoids can lead to the development of cataract, glaucoma, hypertension, water retention, hyperlipidemia, peptic ulcer, pancreatitis, myopathy, osteoporosis, mood changes, psychosis, dermal atrophy, allergy, acne, hypertrichosis, immune suppression, decreased resistance to infection, moon face, hyperglycemia, hypocalcemia, hypophosphatemia, metabolic acidosis, growth suppression, and secondary adrenal insufficiency.8 Overdose may be treated by adjusting the dose or stopping the corticosteroid as well as initiating symptomatic and supportive treatment.8	Small Molecule	http://smpdb.ca/view/SMP0000372?highlight[compounds][]=DB00741&highlight[proteins][]=DB00741;!http://smpdb.ca/view/SMP0000577?highlight[compounds][]=DB00741&highlight[proteins][]=DB00741;!http://smpdb.ca/view/SMP0000718?highlight[compounds][]=DB00741&highlight[proteins][]=DB00741;!http://smpdb.ca/view/SMP0000310?highlight[compounds][]=DB00741&highlight[proteins][]=DB00741;!http://smpdb.ca/view/SMP0000371?highlight[compounds][]=DB00741&highlight[proteins][]=DB00741;!http://smpdb.ca/view/SMP0000575?highlight[compounds][]=DB00741&highlight[proteins][]=DB00741;!http://smpdb.ca/view/SMP0000717?highlight[compounds][]=DB00741&highlight[proteins][]=DB00741;!http://smpdb.ca/view/SMP0000130?highlight[compounds][]=DB00741&highlight[proteins][]=DB00741;!http://smpdb.ca/view/SMP0000373?highlight[compounds][]=DB00741&highlight[proteins][]=DB00741;!http://smpdb.ca/view/SMP0000566?highlight[compounds][]=DB00741&highlight[proteins][]=DB00741;!http://smpdb.ca/view/SMP0000576?highlight[compounds][]=DB00741&highlight[proteins][]=DB00741;!http://smpdb.ca/view/SMP0000578?highlight[compounds][]=DB00741&highlight[proteins][]=DB00741	Adrenal Hyperplasia Type 5 or Congenital Adrenal Hyperplasia Due to 17 alpha-Hydroxylase Deficiency;!Corticosterone Methyl Oxidase I Deficiency (CMO I);!3-beta-Hydroxysteroid Dehydrogenase Deficiency;!Corticotropin Activation of Cortisol Production;!Congenital Lipoid Adrenal Hyperplasia (CLAH) or Lipoid CAH;!11-beta-Hydroxylase Deficiency (CYP11B1);!Apparent Mineralocorticoid Excess Syndrome;!Steroidogenesis;!Adrenal Hyperplasia Type 3 or Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency;!17-alpha-Hydroxylase Deficiency (CYP17);!21-Hydroxylase Deficiency (CYP21);!Corticosterone Methyl Oxidase II Deficiency (CMO II)		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.8914 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor		-4.66			1.61	-2.97	220 °C		320 mg/L (at 25 °C)	1	Yes	5	3	No	4	0	94.83 Å2	39.45 Å3	97.4 m3·mol-1	2	Yes	No	0.199 mg/mL	1.28	-3.3	12.59	-2.8			
C20H28O2	Not Available	0.5-2 hours	300.442	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O	Solid	Not Available	P24462;!P20813;!P10632;!P11712;!P08684;!P20815;!P11509;!P33260;!P04798;!Q02928	CYP3A7;!CYP2B6;!CYP2C8;!CYP2C9;!CYP3A4;!CYP3A5;!CYP2A6;!CYP2C18;!CYP1A1;!CYP4A11	1. Cytochrome P450 3A7;!2. Cytochrome P450 2B6;!3. Cytochrome P450 2C8;!4. Cytochrome P450 2C9;!5. Cytochrome P450 3A4;!6. Cytochrome P450 3A5;!7. Cytochrome P450 2A6;!8. Cytochrome P450 2C18;!9. Cytochrome P450 1A1;!10. Cytochrome P450 4A11		31883	15367	CHEMBL38	392618	Drugs.com Drug Page		HMDB0001852	C00777	D00094	REA		PA164746900	5538	46504843	RxList Drug Page	10753	DNC000117	Tretinoin	ZINC000012358651	Altreno, Atralin, Avita, Biacna, Refissa, Renova, Retin-A, Stieva-A, Tri-luma, Twyneo, Veltin, Vesanoid, Ziana	Tretinoin	Approved, Investigational, Nutraceutical	DB00755	InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14+	SHGAZHPCJJPHSC-YCNIQYBTSA-N	4	Tretinoin is a vitamin A derivative used to treat acne vulgaris, certain types of promyelocytic leukemia, and fine wrinkles.	Not Available	Small Molecule	http://smpdb.ca/view/SMP0000074?highlight[compounds][]=DB00755&highlight[proteins][]=DB00755;!http://smpdb.ca/view/SMP0000336?highlight[compounds][]=DB00755&highlight[proteins][]=DB00755	Retinol Metabolism;!Vitamin A Deficiency		Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.1455 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					6.30		181 °C		<0.1 g/100 mL	1	Yes	2	1	No	1	-1	37.3 Å2	36.85 Å3	97.79 m3·mol-1	5	No	Yes	0.00477 mg/mL	5.01	-4.8	4.76				
C22H28Cl2O4	Not Available	5.8 hours	427.361	[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	Not Available	P10632;!P08684;!P20815	CYP2C8;!CYP3A4;!CYP3A5	1. Cytochrome P450 2C8;!2. Cytochrome P450 3A4;!3. Cytochrome P450 3A5		50237628	6970	CHEMBL1201404	390090	Drugs.com Drug Page		HMDB0014902	C07816	D08227		PDRhealth Drug Page	PA450541	441335	46505288	RxList Drug Page	108118	DAP001042	Mometasone	ZINC000004097440		Mometasone	Experimental	DB00764	InChI=1S/C22H28Cl2O4/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,24)17(26)10-20(16,3)22(12,28)18(27)11-23/h6-7,9,12,15-17,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1	QLIIKPVHVRXHRI-CXSFZGCWSA-N	4	Mometasone is a corticosteroid with no indications.	The potential for acute toxic effects following overdose with the mometasone inhaler is low. However, habitual overuse of the product can cause symptoms of steroid overload, including menstrual irregularities, acne, obesity, and muscle weakness. Single oral doses up to 8000 µg have been studied on human volunteers with no adverse events reported.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.9124 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.1		218-220 °C		Practically insoluble.	1	Yes	4	2	No	4	0	74.6 Å2	43.82 Å3	110.29 m3·mol-1	2	Yes	No	0.00523 mg/mL	3.5	-4.9	12.49	-3.3	P04150;!P06401	NR3C1;!PGR	1. Glucocorticoid receptor;!2. Progesterone receptor
C27H41NO6	Not Available	Not Available	475.6175	[H][C@@]12CC[C@](O)(C(=O)COC(=O)CN(CC)CC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			50851	CHEMBL1201263	75860			HMDB0014907					PA164745515	84088	46509076			DAP001187	Hydrocortamate	ZINC000004213506		Hydrocortamate	Approved	DB00769	InChI=1S/C27H41NO6/c1-5-28(6-2)15-23(32)34-16-22(31)27(33)12-10-20-19-8-7-17-13-18(29)9-11-25(17,3)24(19)21(30)14-26(20,27)4/h13,19-21,24,30,33H,5-12,14-16H2,1-4H3/t19-,20-,21-,24+,25-,26-,27-/m0/s1	FWFVLWGEFDIZMJ-FOMYWIRZSA-N			Side effects include burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, miliaria.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.9454 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					1.2		162-163			1	No	6	2	Yes	4	0	104.14 Å2	53.53 Å3	129.48 m3·mol-1	8	Yes	No	0.0855 mg/mL	2.32	-3.8	12.61	6.99	P04150	NR3C1	1. Glucocorticoid receptor
C24H33FO6	Not Available	Not Available	436.5136	CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4		50240003	5127	CHEMBL1201012	14475	Drugs.com Drug Page		HMDB0014984		D00328			PA164750513	15209	46505159	RxList Drug Page	4500	DAP000418	Fludroxycortide	ZINC000004097308	Cordran, Nolix	Flurandrenolide	Approved	DB00846	InChI=1S/C24H33FO6/c1-21(2)30-19-9-14-13-8-16(25)15-7-12(27)5-6-22(15,3)20(13)17(28)10-23(14,4)24(19,31-21)18(29)11-26/h7,13-14,16-17,19-20,26,28H,5-6,8-11H2,1-4H3/t13-,14-,16-,17-,19+,20+,22-,23-,24+/m0/s1	POPFMWWJOGLOIF-XWCQMRHXSA-N	3	Flurandrenolide is a corticosteroid used to treat corticosteroid-responsive dermatoses.	Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary- adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.2002 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					0.6		251 °C		Insoluble	1	Yes	6	2	No	5	0	93.06 Å2	45.51 Å3	110.79 m3·mol-1	2	Yes	No	0.0578 mg/mL	1.56	-3.9	13.74	-2.8	P04150	NR3C1	1. Glucocorticoid receptor
C21H28O5	A 0.15mg/kg dose of prednisolone has a clearance of 0.09L/kg/h, while a 0.30mg/kg dose has a clearance of 0.12L/kg/h.1	Prednisolone has a plasma half life of 2.1-3.5 hours.1 This half life is shorter in children and longer in those with liver disease.1	360.444	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	A 0.15mg/kg dose of prednisolone has a volume of distribution of 29.3L, while a 0.30mg/kg dose has a volume of distribution of 44.2L.1	P08684	CYP3A4	1. Cytochrome P450 3A4		19190	8378	CHEMBL131	5552	Drugs.com Drug Page	GtP Drug Page	HMDB0014998	C07369	D00472	TUA		PA451096	5755	46504847	RxList Drug Page	8638	DAP000419	Prednisolone	ZINC000003833821	Millipred Dp 6 Day	Prednisolone	Approved, Vet approved	DB00860	InChI=1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-16,18,22,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1	OIGNJSKKLXVSLS-VWUMJDOOSA-N	4	Prednisolone is a glucocorticoid used to treat adrenocortical insufficiency, inflammatory conditions, and some cancers.	The intraperitoneal LD50 in rats is 2g/kg and 65mg/kg in mice.8 The subcutaneous LD50 in rats is 147mg/kg and >3500mg/kg in mice.8 The oral LD50 in mice is 1680mg/kg.8 In humans, the oral TDLO in men is 9mg/kg/2W and in women is 14mg/kg/13D.8Patients experiencing an overdose of prednisolone may present with gastrointestinal disturbances, insomnia, and restlessness.5 Overdose of oral prednisolone may be treated by gastric lavage or inducing vomiting if the overdose was recent, as well as supportive and symptomatic therapy.9 Chronic overdosage may be treated by dose reduction or treating patients on alternate days.9 An overdose by the ophthalmic route is not expected to cause problems.9	Small Molecule	http://smpdb.ca/view/SMP0000440?highlight[compounds][]=DB00860&highlight[proteins][]=DB00860;!http://smpdb.ca/view/SMP0000441?highlight[compounds][]=DB00860&highlight[proteins][]=DB00860;!http://smpdb.ca/view/SMP0000631?highlight[compounds][]=DB00860&highlight[proteins][]=DB00860;!http://smpdb.ca/view/SMP0000632?highlight[compounds][]=DB00860&highlight[proteins][]=DB00860	Prednisone Action Pathway;!Prednisolone Action Pathway;!Prednisone Metabolism Pathway;!Prednisolone Metabolism Pathway		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.8914 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					1.62	-3.21	235 °C		223 mg/L (at 25 °C)	1	Yes	5	3	No	4	0	94.83 Å2	38.69 Å3	98.49 m3·mol-1	2	Yes	No	0.239 mg/mL	1.27	-3.2	12.59	-2.9			
C21H27ClO5	Not Available	Not Available	394.889	[H][C@@]12CC[C@](O)(C(=O)OCCl)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Not Available	Not Available						50848		8041134												237027		Loteprednol	ZINC000030691679	Alrex, Lotemax, Zylet	Loteprednol	Approved, Experimental	DB00873	InChI=1S/C21H27ClO5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,18(25)27-11-22)20(15,2)10-16(24)17(14)19/h5,7,9,14-17,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,17+,19-,20-,21-/m0/s1	YPZVAYHNBBHPTO-MXRBDKCISA-N		Loteprednol is a corticosteroid indicated in the treatment of pain and inflammation after cataract surgery.	Not Available	Small Molecule																																			1	Yes	4	2	No	4	0	83.83 Å2	41.29 Å3	102.65 m3·mol-1	3	Yes	No	0.0336 mg/mL	2.52	-4.1	12.01	-2.9			
C24H34O3	Not Available	The serum half-life of rimexolone could not be reliably estimated due to the large number of samples below the quantitation limit of the assay (80 pg/mL). However, based on the time required to reach steady-state, the half-life appears to be short (1-2 hours).	370.533	[H][C@@]12C[C@@H](C)[C@](C)(C(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5		50103606	135566	CHEMBL1200617	4470902	Drugs.com Drug Page				D05729			PA164752251	5311412	46504820	RxList Drug Page	55681	DAP000420	Rimexolone	ZINC000003945984		Rimexolone	Approved	DB00896	InChI=1S/C24H34O3/c1-6-20(27)24(5)14(2)11-18-17-8-7-15-12-16(25)9-10-22(15,3)21(17)19(26)13-23(18,24)4/h9-10,12,14,17-19,21,26H,6-8,11,13H2,1-5H3/t14-,17+,18+,19+,21-,22+,23+,24-/m1/s1	QTTRZHGPGKRAFB-OOKHYKNYSA-N	4	Rimexolone is a glucocorticoid used to treat inflammation of the eye.	Symptoms of overdose include retinal toxicity, glaucoma, and subcapsular cataract.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.1317 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					4.2				Insoluble	1	Yes	3	1	No	4	0	54.37 Å2	42.91 Å3	109.07 m3·mol-1	2	Yes	No	0.0121 mg/mL	4.38	-4.5	18.76	-0.21	P04150	NR3C1	1. Glucocorticoid receptor
C29H41NO4	Clearance may be higher in children than in adults.Plasma clearance rate, IV administration, anaesthetized patients = 901.2 ± 39.7 mL/min;Plasma clearance rate, IV administration, healthy subjects = 1042 - 1280 mL/min.	Buprenorphine demonstrates slow dissociation kinetics (~166 min), which contributes to its long duration of action and allows for once-daily or even every-second-day dosing.18 In clinical trial studies, the half-life of sublingually administered buprenorphine/naloxone 2mg/0.5mg was found to be 30.75 hours.19,20	467.6401	CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4	Solid	Buprenorphine is highly lipophilic, and therefore extensively distributed, with rapid penetration through the blood-brain barrier. The estimated volume of distribution is 188 - 335 L when given intravenously. It is able to cross into the placenta and breast milk.	P08684;!P20815;!P11712;!P10632;!P24462;!P10635;!P33260;!P33261	CYP3A4;!CYP3A5;!CYP2C9;!CYP2C8;!CYP3A7;!CYP2D6;!CYP2C18;!CYP2C19	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5;!3. Cytochrome P450 2C9;!4. Cytochrome P450 2C8;!5. Cytochrome P450 3A7;!6. Cytochrome P450 2D6;!7. Cytochrome P450 2C18;!8. Cytochrome P450 2C19		50026603	3216	CHEMBL560511	559124	Drugs.com Drug Page		HMDB0015057	C08007	D07132			PA448685	644073	46505782	RxList Drug Page	1819	DAP001353	Buprenorphine	ZINC000001319780	Belbuca, Buprenex, Buprenorphine, Butrans, Probuphine, Sublocade, Suboxone, Subutex, Zubsolv	Buprenorphine	Approved, Illicit, Investigational, Vet approved	DB00921	InChI=1S/C29H41NO4/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3/t20-,21-,24-,26+,27-,28+,29-/m1/s1	RMRJXGBAOAMLHD-IHFGGWKQSA-N	4	Buprenorphine is a partial opioid agonist used for management of severe pain that is not responsive to alternative treatments. Also used for maintenance treatment of opioid addiction.	Manifestations of acute overdose include pinpoint pupils, sedation, hypotension, respiratory depression and death.	Small Molecule	http://smpdb.ca/view/SMP0000684?highlight[compounds][]=DB00921&highlight[proteins][]=DB00921	Buprenorphine Action Pathway		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	3.1511 LD50, mol/kg	Inhibitor	Weak inhibitor	Non-inhibitor					4.98			8.31 (at 25 °C)		1	No	5	2	No	7	1	62.16 Å2	53.03 Å3	131.76 m3·mol-1	5	Yes	No	0.0168 mg/mL	3.55	-4.4	10.42	9.63			
C22H30O5	The average plasma clearance of methylprednisolone is 336mL/h/kg.1	Methylprednisolone has a half life of 2.3h.1,6	374.4706	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C	Solid	The average volume of distribution of methylprednisolone is 1.38L/kg.1	BE0009795;!BE0009796;!P08684;!BE0004866;!P11509;!Q16678;!P20813;!P10632;!P33261;!P11712	;!;!CYP3A4;!;!CYP2A6;!CYP1B1;!CYP2B6;!CYP2C8;!CYP2C19;!CYP2C9	1. 20-ketosteroid reductase (20-hydroxysteroid dehydrogenase) (Protein Group);!2. 11beta-hydroxysteroid dehydrogenase (Protein Group);!3. Cytochrome P450 3A4;!4. Cytochrome P450 3A Subfamily (Protein Group);!5. Cytochrome P450 2A6;!6. Cytochrome P450 1B1;!7. Cytochrome P450 2B6;!8. Cytochrome P450 2C8;!9. Cytochrome P450 2C19;!10. Cytochrome P450 2C9		50103616	6888	CHEMBL650	6485	Drugs.com Drug Page		HMDB0015094		D00407			PA450466	6741	46504885	RxList Drug Page	6902	DAP001040	Methylprednisolone	ZINC000003875560	Depo-medrol, Depo-medrol With Lidocaine, Hybrisil, Medrol, Medroloan Suik, Readysharp-p40, Readysharp-p80	Methylprednisolone	Approved, Vet approved	DB00959	InChI=1S/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,17-,19+,20-,21-,22-/m0/s1	VHRSUDSXCMQTMA-PJHHCJLFSA-N	4	Methylprednisolone is a corticosteroid used to treat inflammation or immune reactions across a variety of organ systems, endocrine conditions, and neoplastic diseases.	The oral LD50 in rats is >4g/kg.14 The intraperitoneal LD50 in mice is 2292mg/kg and in rats is 100mg/kg.14Data regarding acute overdoses of glucocorticoids are rare.12,13 Chronic high doses of glucocorticoids can lead to the development of cataract, glaucoma, hypertension, water retention, hyperlipidemia, peptic ulcer, pancreatitis, myopathy, osteoporosis, mood changes, psychosis, dermal atrophy, allergy, acne, hypertrichosis, immune suppression, decreased resistance to infection, moon face, hyperglycemia, hypocalcemia, hypophosphatemia, metabolic acidosis, growth suppression, and secondary adrenal insufficiency.8 Treat acute overdoses with symptomatic and supportive therapy, while chronic overdoses will require temporarily reduced dosages.8,13	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.0025 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					1.525	-2.99	232.5 °C		120 mg/L (at 25 °C)	1	Yes	5	3	No	4	0	94.83 Å2	40.77 Å3	103.04 m3·mol-1	2	Yes	No	0.109 mg/mL	1.56	-3.5	12.59	-2.9	P04150;!P04083	NR3C1;!ANXA1	1. Glucocorticoid receptor;!2. Annexin A1
C20H28O2	The clearance of isotretinoin is 15.9L/h in pediatric patients with neuroblastoma.6 Clearance is also 21.3mL/min/kg in guinea pigs and 7.2mL/min/kg in obese rats.5	The half life ranges from 7-39 hours13 with a mean elimination half life of 20 hours.1 The half life of 4-oxo-13-cis-retinoic acid ranges from 17-50 hours with a mean elimination half life of 25 hours.13	300.4351	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O	Solid	The volume of distribution in humans is unknown because there is no intravenous preparation.13 In a study of pediatric patients with neuroblastoma the volume of distribution was found to be 85L.6 The volume of distribution was also found to be 2432mL/kg in guinea pigs and 1716mL/kg in obese rats.5	P08684	CYP3A4	1. Cytochrome P450 3A4		50031459	6067	CHEMBL547	4445539	Drugs.com Drug Page		HMDB0006219		D00348			PA450128	5282379	46508729	RxList Drug Page	6064	DAP000009	Isotretinoin	ZINC000003792789	Absorica, Accutane, Amnesteem, Claravis, Clarus, Epuris, Myorisan, Sotret, Zenatane	Isotretinoin	Approved	DB00982	InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14-	SHGAZHPCJJPHSC-XFYACQKRSA-N	4	Isotretinoin is a retinoid used to treat severe recalcitrant acne.	Patients experiencing an overdose may present with vomiting, facial flushing, cheilosis, abdominal pain, headache, dizziness, and ataxia.Label These symptoms may rapidly resolve.Label Generally no treatment is required for these overdoses.7The oral lowest dose causing toxic effect (TDLO) for children is 30mg/kg/21W, oral TDLO for men is 24mg/kg/4W, oral TDLO for women is 56mg/kg/8W.14 The intraperitoneal LD50 for rats is 901mg/kg, oral LD50 for mice is 3389mg/kg, oral LD50 for rats is >4000mg/kg.14Isotretinoin is associated with major congenital malformations, spontaneous abortion, and premature birth.Label It is unknown if isotretinoin is expressed in breast milk but due to the associated hazards a decision should be made to either stop nursing or stop taking isotretinoin.LabelIn animal studies, isotretinoin was associated with an increased risk of pheochromocytoma and adrenal medullary hyperplasia at doses above the recommended clinical dose.Label Isotretinoin was negative for the Ames test of mutagenicity once and weakly positive a second time.Label It has not been shown to be clastogenic.Label A study in dogs noted testicular atrophy after doses of 10-30 times the recommended clinical dose for 30 weeks.Label In trials with men there were no effects seen on sperm count, motility, morphology, ejaculate volume, and seminal plasma fructose.Label	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.1455 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				462.8	5.66		189-190	~4	0.00477mg/mL	1	Yes	2	1	No	1	-1	37.3 Å2	36.15 Å3	97.79 m3·mol-1	5	No	Yes	0.00477 mg/mL	5.01	-4.8	4.76		P13631;!P10276	RARG;!RARA	1. Retinoic acid receptor gamma;!2. Retinoic acid receptor alpha
C20H24O2	Not Available	24 hours	296.4034	[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC(=C)C2=CC(=O)C=C[C@]12C	Solid	Not Available	P11511;!P08684	CYP19A1;!CYP3A4	1. Cytochrome P450 19A1;!2. Cytochrome P450 3A4		50398447	4953	CHEMBL1200374	54278	Drugs.com Drug Page		HMDB0015125	C08162	D00963	EXM		PA449563	60198	46508243	RxList Drug Page	258494	DAP000625	Exemestane	ZINC000003973334	Aromasin	Exemestane	Approved, Investigational	DB00990	InChI=1S/C20H24O2/c1-12-10-14-15-4-5-18(22)20(15,3)9-7-16(14)19(2)8-6-13(21)11-17(12)19/h6,8,11,14-16H,1,4-5,7,9-10H2,2-3H3/t14-,15-,16-,19+,20-/m0/s1	BFYIZQONLCFLEV-DAELLWKTSA-N	4	Exemestane is an aromatase inhibitor used to treat breast cancer in postmenopausal women after treatment with tamoxifen.	Convulsions	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.7582 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.7		155.13 °C		Non-soluble	1	Yes	2	0	No	4	0	34.14 Å2	33.72 Å3	89.03 m3·mol-1	0	Yes	Yes	0.00683 mg/mL	3.87	-4.6		-5			
C29H44O12	Not Available	Not Available	584.6525	[H][C@@]12CC[C@]3(O)C[C@H](C[C@@H](O)[C@]3(CO)[C@@]1([H])[C@H](O)C[C@]1(C)[C@H](CC[C@]21O)C1=CC(=O)OC1)O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O	Solid	Not Available					50286739	472805	CHEMBL222863	388599			HMDB0015224	C01443	D00112	OBN		PA163522138	439501	46505479		7762	DAP000465	Ouabain	ZINC000008143614		Ouabain	Approved	DB01092	InChI=1S/C29H44O12/c1-13-22(34)23(35)24(36)25(40-13)41-15-8-19(32)28(12-30)21-17(3-5-27(28,37)9-15)29(38)6-4-16(14-7-20(33)39-11-14)26(29,2)10-18(21)31/h7,13,15-19,21-25,30-32,34-38H,3-6,8-12H2,1-2H3/t13-,15-,16+,17+,18+,19+,21+,22-,23+,24+,25-,26+,27-,28+,29-/m0/s1	LPMXVESGRSUGHW-HBYQJFLCSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	4.7797 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor					-2.00		200 °C		1.03E+004 mg/L	0	No	11	8	No	6	-1	206.6 Å2	59.92 Å3	140.83 m3·mol-1	4	No	No	4.61 mg/mL	-2.8	-2.1	7.18	-2.9	P05023;!P50993;!P13637	ATP1A1;!ATP1A2;!ATP1A3	1. Sodium/potassium-transporting ATPase subunit alpha-1;!2. Sodium/potassium-transporting ATPase subunit alpha-2;!3. Sodium/potassium-transporting ATPase subunit alpha-3
C27H36O8	Not Available	Not Available	488.577	[H][C@@]12CC[C@](OC(=O)OCC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			135791	CHEMBL1200386	5145991	Drugs.com Drug Page							PA164749394	6714002	46506799	RxList Drug Page	34369	DAP001189	Prednicarbate	ZINC000003938652	Dermatop	Prednicarbate	Approved, Investigational	DB01130	InChI=1S/C27H36O8/c1-5-22(31)34-15-21(30)27(35-24(32)33-6-2)12-10-19-18-8-7-16-13-17(28)9-11-25(16,3)23(18)20(29)14-26(19,27)4/h9,11,13,18-20,23,29H,5-8,10,12,14-15H2,1-4H3/t18-,19-,20-,23+,25-,26-,27-/m0/s1	FNPXMHRZILFCKX-KAJVQRHHSA-N	2	Prednicarbate is a medium potency topical corticosteroid used to manage pruritus and inflammation associated with responsive skin conditions.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.4426 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.9					1	No	6	1	Yes	4	0	116.2 Å2	52.43 Å3	127.8 m3·mol-1	9	Yes	No	0.00562 mg/mL	3.83	-4.9	14.83	-2.9	P04150	NR3C1	1. Glucocorticoid receptor
C26H38O4	Not Available	Not Available	414.586	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)C(=O)COC(=O)C(C)(C)C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			50782	CHEMBL1200592	10050591								PA449245	11876263	46506381		22537	DAP001106	Desoxycorticosterone_pivalate	ZINC000004082455		Desoxycorticosterone pivalate	Experimental, Vet approved	DB01134	InChI=1S/C26H38O4/c1-24(2,3)23(29)30-15-22(28)21-9-8-19-18-7-6-16-14-17(27)10-12-25(16,4)20(18)11-13-26(19,21)5/h14,18-21H,6-13,15H2,1-5H3/t18-,19-,20-,21+,25-,26-/m0/s1	VVOIQBFMTVCINR-WWMZEODYSA-N			Symptoms of overdose include polyuria, polydipsia, increased blood volume, edema, and cardiac enlargement.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	1.7883 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					4				Insoluble	1	Yes	3	0	No	4	0	60.44 Å2	48.3 Å3	117.26 m3·mol-1	5	No	No	0.00141 mg/mL	5.57	-5.5	17.19	-4.8	P08235	NR3C2	1. Mineralocorticoid receptor
C20H29FO3	Not Available	9.2 hours	336.4409	[H][C@@]12CC[C@](C)(O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	Not Available					18189	5120	CHEMBL1445	6205	Drugs.com Drug Page	GtP Drug Page	HMDB0015316		D00327			PA164744518	6446	46508867	RxList Drug Page	4494	DAP000904	Fluoxymesterone	ZINC000003875484	Androxy, Halotestin	Fluoxymesterone	Approved, Illicit	DB01185	InChI=1S/C20H29FO3/c1-17-8-6-13(22)10-12(17)4-5-15-14-7-9-19(3,24)18(14,2)11-16(23)20(15,17)21/h10,14-16,23-24H,4-9,11H2,1-3H3/t14-,15-,16-,17-,18-,19-,20-/m0/s1	YLRFCQOZQXIBAB-RBZZARIASA-N		Fluoxymesterone is a synthetic androgenic anabolic steroid that used in the treatment of hypogonadism and delayed puberty in males, as well as breast neoplasms in women.	Side effects include virilization (masculine traits in women), acne, fluid retention, and hypercalcemia.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.7028 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.38		265		67.5 mg/L	1	Yes	3	2	No	4	0	57.53 Å2	36.65 Å3	90.19 m3·mol-1	0	Yes	No	0.0452 mg/mL	2.38	-3.9	13.6	-3			
C22H29FO5	A 20mg oral tablet has a clearance of 15.7L/h.16 A 1.5mg oral dose of dexamethasone has a clearance of 15.6±4.9L/h while a 3.0mg intramuscular dose has a clearance of 9.9±1.4L/h.5	The mean terminal half life of a 20mg oral tablet is 4 hours.16 A 1.5mg oral dose of dexamethasone has a half life of 6.6±4.3h, while a 3mg intramuscular dose has a half life of 4.2±1.2h.5	392.4611	[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	A 1.5mg oral dose of dexamethasone has a volume of distribution of 51.0L, while a 3mg intramuscular dose has a volume of distribution of 96.0L.5					18207	41879	CHEMBL384467	5541	Drugs.com Drug Page	GtP Drug Page	HMDB0015364	C15643	D00292	DEX	PDRhealth Drug Page	PA449247	5743	46508930	RxList Drug Page	3264	DAP000007	Dexamethasone	ZINC000003875332	Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper	Dexamethasone	Approved, Investigational, Vet approved	DB01234	InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1	UREBDLICKHMUKA-CXSFZGCWSA-N		Dexamethasone is a glucocorticoid available in various modes of administration that is used for the treatment of various inflammatory conditions, including bronchial asthma, as well as endocrine and rheumatic disorders.	The oral LD50 in female mice was 6.5g/kg and 794mg/kg via the intravenous route.13Overdoses are not expected with otic formulations.12 Chronic high doses of glucocorticoids can lead to the development of cataract, glaucoma, hypertension, water retention, hyperlipidemia, peptic ulcer, pancreatitis, myopathy, osteoporosis, mood changes, psychosis, dermal atrophy, allergy, acne, hypertrichosis, immune suppression, decreased resistance to infection, moon face, hyperglycemia, hypocalcemia, hypophosphatemia, metabolic acidosis, growth suppression, and secondary adrenal insufficiency.2 Overdose may be treated by adjusting the dose or stopping the corticosteroid as well as initiating symptomatic and supportive treatment.2	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1482 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor		-4.75			1.83	-3.64	260-264		89 mg/L (at 25 °C)	1	Yes	5	3	No	4	0	94.83 Å2	40.71 Å3	102.49 m3·mol-1	2	Yes	No	0.0505 mg/mL	1.68	-3.9	12.42	-3.3			
C23H30O6	Data regarding the clearance of cortisone acetate is not readily available.8	Not Available	402.4807	[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5		50455157	3897	CHEMBL1650	5543	Drugs.com Drug Page		HMDB0015459	C08173	D00973			PA449130	5745	46508852	RxList Drug Page	21655		Cortisone_acetate	ZINC000003875334		Cortisone acetate	Approved, Investigational	DB01380	InChI=1S/C23H30O6/c1-13(24)29-12-19(27)23(28)9-7-17-16-5-4-14-10-15(25)6-8-21(14,2)20(16)18(26)11-22(17,23)3/h10,16-17,20,28H,4-9,11-12H2,1-3H3/t16-,17-,20+,21-,22-,23-/m0/s1	ITRJWOMZKQRYTA-RFZYENFJSA-N	4	Cortisone acetate is a steroid hormone used for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses and endocrine disorders associated with inadequate production of steroid hormones.	Data regarding acute overdoses of glucocorticoids are rare.8 Chronic high doses of glucocorticoids can lead to the development of cataract, glaucoma, hypertension, water retention, hyperlipidemia, peptic ulcer, pancreatitis, myopathy, osteoporosis, mood changes, psychosis, dermal atrophy, allergy, acne, hypertrichosis, immune suppression, decreased resistance to infection, moon face, hyperglycemia, hypocalcemia, hypophosphatemia, metabolic acidosis, growth suppression, and secondary adrenal insufficiency.6 Overdose may be treated by adjusting the dose or stopping the corticosteroid as well as initiating symptomatic and supportive treatment.6	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.1280 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.10		227-229		20 mg/L (at 25 °C)	1	Yes	5	1	No	4	0	97.74 Å2	43.06 Å3	105.63 m3·mol-1	4	Yes	No	0.0278 mg/mL	2.1	-4.2	12.6	-3.8	P04150;!P04083	NR3C1;!ANXA1	1. Glucocorticoid receptor;!2. Annexin A1
C24H30O3	Drospirenone is rapidly cleared, typically within 2-3 days of administration of the last active tablet.14 The rate of clearance of drospirenone calculated in the serum ranges from 1.2-1.5 ml/min/kg, however, this value can vary by up to 25% according to the patient.23	The serum half-life of drospirenone is estimated to be 30 hours.13 The half-life of drospirenone metabolite excretion in the urine and feces is approximately 40 hours.23	366.4932	[H][C@@]12C[C@]1([H])[C@@]1([H])[C@]3([H])[C@]4([H])C[C@]4([H])[C@@]4(CCC(=O)O4)[C@@]3(C)CC[C@]1([H])[C@@]1(C)CCC(=O)C=C21	Solid	The volume of distribution of drospirenone is estimated to be 4 L/kg, according to the FDA label for Yaz.19 Prescribing information from a combination of estradiol and drospirenone estimates the volume of distribution to range from 3.7- 4.2 L/kg.23	P35354;!P27169;!P08684	PTGS2;!PON1;!CYP3A4	1. Prostaglandin G/H synthase 2;!2. Serum paraoxonase/arylesterase 1;!3. Cytochrome P450 3A4		150275	50838	CHEMBL1509	62105	Drugs.com Drug Page		HMDB0015467		D03917			PA164749409	68873	46507653	RxList Drug Page	11636	DAP001206	Drospirenone	ZINC000003927200	Angeliq 0.25/0.5 28 Day, Beyaz 28 Day, Gianvi 28-day, Jasmiel 28 Day, Lo-zumandimine 28 Day, Loryna, Nextstellis 28 Day, Nikki 28 Day, Ocella 28 Day, Safyral 28 Day, Slynd, Syeda 28 Day, Vestura, Yasmin, Yasmin 28 Day, Yaz 28 Day, Yaz Plus, Zarah, Zumandimine 28 Day	Drospirenone	Approved	DB01395	InChI=1S/C24H30O3/c1-22-6-3-12(25)9-17(22)13-10-14(13)20-16(22)4-7-23(2)21(20)15-11-18(15)24(23)8-5-19(26)27-24/h9,13-16,18,20-21H,3-8,10-11H2,1-2H3/t13-,14+,15-,16+,18+,20-,21+,22-,23+,24+/m1/s1	METQSPRSQINEEU-HXCATZOESA-N	4	Drospirenone is a progestin used in oral contraceptive pills for the prevention of pregnancy and other conditions.	The oral LD50 of drospirenone in rats is >2000 mg/kg.22Overdose informationAn overdose of drospirenone, like other oral contraceptives, may lead to cause nausea or withdrawal bleeding. For drospirenone in particular, as an analog of spironolactone, may affect the levels of serum sodium and potassium. Their concentrations should be monitored in cases of overdose in addition to monitoring from metabolic acidosis and hyperkalemia, which may also result.15,19	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.9430 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				552.2	3.08	-5.2	196-200	-5		1	Yes	2	0	No	7	0	43.37 Å2	41.81 Å3	101.68 m3·mol-1	0	Yes	No	0.00225 mg/mL	3.37	-5.2	18.52	-5	P08235;!P10275;!P06401;!P04150	NR3C2;!AR;!PGR;!NR3C1	1. Mineralocorticoid receptor;!2. Androgen receptor;!3. Progesterone receptor;!4. Glucocorticoid receptor
C22H27NO2	Not Available	Approximately 24 hours.	337.4553	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC3=C(C[C@]12C)C=NO3	Solid	Not Available	P08684;!P11511	CYP3A4;!CYP19A1	1. Cytochrome P450 3A4;!2. Cytochrome P450 19A1		50423541	4315	CHEMBL1479	26436	Drugs.com Drug Page		HMDB0002835		D00289	QA1		PA164749056	28417	46506475	RxList Drug Page	3102	DAP001017	Danazol	ZINC000003881958	Cyclomen	Danazol	Approved	DB01406	InChI=1S/C22H27NO2/c1-4-22(24)10-8-18-16-6-5-15-11-19-14(13-23-25-19)12-20(15,2)17(16)7-9-21(18,22)3/h1,11,13,16-18,24H,5-10,12H2,2-3H3/t16-,17+,18+,20+,21+,22+/m1/s1	POZRVZJJTULAOH-LHZXLZLDSA-N	4	Danazol is a synthetic steroid and pituitary gonadotropin inhibitor used in the treatment of endometriosis and symptomatic treatment of severe pain and tenderness associated with benign fibrocystic breasts.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.3291 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					0.51		224.2-226.8			1	Yes	2	1	No	5	0	46.26 Å2	38.44 Å3	98.54 m3·mol-1	0	Yes	No	0.0176 mg/mL	3.46	-4.3	17.59	0.25	P03372;!P10275;!P06401;!P30968;!Q96P88;!P13500	ESR1;!AR;!PGR;!GNRHR;!GNRHR2;!CCL2	1. Estrogen receptor alpha;!2. Androgen receptor;!3. Progesterone receptor;!4. Gonadotropin-releasing hormone receptor;!5. Putative gonadotropin-releasing hormone II receptor;!6. C-C motif chemokine 2
C22H32O3	Testosterone propionate has a reduced clearance rate compared to testosterone.5 The reported clearance rate is of approximately 2000 ml/min.1	Testosterone propionate possesses a relatively short half-life compared with other testosterone esters at approximately 4.5 days.	344.4877	[H][C@@]12CC[C@H](OC(=O)CC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	The registered volume of distribution for testosterone propionate is in the range of 75-120 L/kg.1	P21964;!P22309;!BE0004887;!P08684	COMT;!UGT1A1;!;!CYP3A4	1. Catechol O-methyltransferase;!2. UDP-glucuronosyltransferase 1-1;!3. 3-oxo-5-alpha-steroid 4-dehydrogenase (Protein Group);!4. Cytochrome P450 3A4		50215709	9466	CHEMBL1170	5774	Drugs.com Drug Page		HMDB0015489	C08158	D00959			PA164751373	5995	46508693		10382		Testosterone_propionate	ZINC000000490791		Testosterone propionate	Approved, Investigational, Vet approved, Withdrawn	DB01420	InChI=1S/C22H32O3/c1-4-20(24)25-19-8-7-17-16-6-5-14-13-15(23)9-11-21(14,2)18(16)10-12-22(17,19)3/h13,16-19H,4-12H2,1-3H3/t16-,17-,18-,19-,21-,22-/m0/s1	PDMMFKSKQVNJMI-BLQWBTBKSA-N	4	Testosterone propionate is a slow-release anabolic steroid no longer used commonly for the treatment of androgen deficiency or promotion of anabolic effects on muscles.	Reports have showed a potential stimulation of cancerous tissue growth. The potential testosterone propionate accumulation in the body produces a high risk of edema secondaryh to water and sodium retention.5	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.0463 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor						-5.37	118-123 °C		1.48 mg/L (at 25ºC)	1	Yes	2	0	No	4	0	43.37 Å2	40.45 Å3	98.21 m3·mol-1	3	Yes	No	0.00502 mg/mL	4.51	-4.8	18.52	-4.8			
C25H35NO4	Not Available	Not Available	413.5497	[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]11CC[C@@]2(OC)[C@]([H])(C1)[C@](C)(O)CCC	Solid	Not Available								96924									107765	46507682				Dihydroetorphine	ZINC000005843973		Dihydroetorphine	Experimental, Illicit	DB01450	InChI=1S/C25H35NO4/c1-5-8-22(2,28)17-14-23-9-10-25(17,29-4)21-24(23)11-12-26(3)18(23)13-15-6-7-16(27)20(30-21)19(15)24/h6-7,17-18,21,27-28H,5,8-14H2,1-4H3/t17-,18-,21-,22-,23-,24+,25-/m1/s1	BRTSNYPDACNMIP-FAWZKKEFSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	3.4494 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	2	No	6	1	62.16 Å2	46.35 Å3	115.55 m3·mol-1	4	Yes	No	0.114 mg/mL	2.66	-3.6	10.24	9.13			
C19H26O2	Not Available	Not Available	286.415	[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2CC(=O)CC[C@]12C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			83865	CHEMBL1743203	141063			HMDB0062415	C20252					160531	46507159				5-Androstenedione	ZINC000100041759		5-androstenedione	Experimental, Illicit	DB01456	InChI=1S/C19H26O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h3,14-16H,4-11H2,1-2H3/t14-,15-,16-,18-,19-/m0/s1	SQGZFRITSMYKRH-QAGGRKNESA-N			Not Available	Small Molecule																																			1	Yes	2	0	No	4	0	34.14 Å2	33.23 Å3	83.63 m3·mol-1	0	Yes	Yes	0.0366 mg/mL	3.57	-3.9	16.23	-7.2			
C27H35NO5	Not Available	Not Available	453.579	[H][C@@]12OC3=C(OC(C)=O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@@]11C[C@]([H])([C@](C)(O)CCC)[C@]2(OC)C=C1	Solid	Not Available							CHEMBL3989451	16736130									20055090	46506577				Acetorphine	ZINC000072266292		Acetorphine	Experimental, Illicit	DB01469	InChI=1S/C27H35NO5/c1-6-9-24(3,30)19-15-25-10-11-27(19,31-5)23-26(25)12-13-28(4)20(25)14-17-7-8-18(32-16(2)29)22(33-23)21(17)26/h7-8,10-11,19-20,23,30H,6,9,12-15H2,1-5H3/t19-,20-,23-,24-,25-,26+,27-/m1/s1	LFYBMMHFJIAKFE-PMEKXCSPSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	3.3149 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	1	Yes	6	1	68.23 Å2	49.84 Å3	125.67 m3·mol-1	6	Yes	No	0.0197 mg/mL	2.66	-4.4	14.68	8.97			
C21H32O2	Not Available	Not Available	316.4776	[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@H](C)CC2=CC(=O)CC[C@]12C	Solid	Not Available					50423546	34583	CHEMBL259548	92280			HMDB0006048	C14475	D03144				102146	46504950				Bolasterone	ZINC000004215039		Bolasterone	Experimental, Illicit	DB01471	InChI=1S/C21H32O2/c1-13-11-14-12-15(22)5-8-19(14,2)16-6-9-20(3)17(18(13)16)7-10-21(20,4)23/h12-13,16-18,23H,5-11H2,1-4H3/t13-,16+,17+,18-,19+,20+,21+/m1/s1	IVFYLRMMHVYGJH-VLOLGRDOSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.0516 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							164 °C			1	Yes	2	1	No	4	0	37.3 Å2	37.53 Å3	93.62 m3·mol-1	0	Yes	Yes	0.0112 mg/mL	3.93	-4.4	18.8	-0.53			
C20H32O2	Not Available	Not Available	304.474	C[C@]1(O)CC[C@H]2[C@@H]3CCC4=C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	Solid	Not Available								24734384									69259387	46505852							17alpha-methyl-3beta,17beta-dihydroxyandrost-4-ene	Experimental, Illicit	DB01474	InChI=1S/C20H32O2/c1-18-9-6-14(21)12-13(18)4-5-15-16(18)7-10-19(2)17(15)8-11-20(19,3)22/h12,14-17,21-22H,4-11H2,1-3H3/t14-,15+,16-,17-,18-,19-,20-/m0/s1	BNUOCVTVOYWNJC-DTMQFJJTSA-N			Not Available	Small Molecule																																			1	Yes	2	2	No	4	0	40.46 Å2	36.14 Å3	89.97 m3·mol-1	0	Yes	No	0.0339 mg/mL	3.23	-4	17.5	-0.5			
C26H33NO4	Not Available	Not Available	423.553	[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@@]11C[C@]([H])(C(C)(C)O)[C@]2(OC)C=C1	Solid	Not Available							CHEMBL2110789	16735758									20054882	46506801				Cyprenorphine	ZINC000004215495		Cyprenorphine	Experimental, Illicit	DB01480	InChI=1S/C26H33NO4/c1-23(2,29)18-13-24-8-9-26(18,30-3)22-25(24)10-11-27(14-15-4-5-15)19(24)12-16-6-7-17(28)21(31-22)20(16)25/h6-9,15,18-19,22,28-29H,4-5,10-14H2,1-3H3/t18-,19-,22-,24-,25+,26-/m1/s1	VSKIOMHXEUHYSI-KNLIIKEYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	3.0389 LD50, mol/kg	Inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	2	No	7	1	62.16 Å2	46.88 Å3	119.33 m3·mol-1	4	Yes	No	0.0582 mg/mL	2.13	-3.9	10.35	9.54			
C19H28O3	Clearance is via the urine. Excretion studies were performed using 200mg of 4-hydroxytestosterone administered to healthy male volunteers. Urine samples were then analyzed for metabolic products using conventional gas chromatography-mass spectrometry approaches.One metabolite, 3-beta,4-alpha-dihydroxy-5alpha-androstan-17-one was identified as a long term metabolite which can be detected for 90 hours. Longer detection times are possible with the use of alternative monitoring technique in sports drug testing.	Not Available	304.43	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=C(O)C(=O)CC[C@]12C	Solid	Not Available							CHEMBL2431525	141138									160615	46508337				4-Hydroxytestosterone	ZINC000031460450		4-Hydroxytestosterone	Experimental, Illicit	DB01485	InChI=1S/C19H28O3/c1-18-10-8-15(20)17(22)14(18)4-3-11-12-5-6-16(21)19(12,2)9-7-13(11)18/h11-13,16,21-22H,3-10H2,1-2H3/t11-,12-,13-,16-,18+,19-/m0/s1	BQOIJSIMMIDHMO-FBPKJDBXSA-N			Excessive doses of anabolic steroids can induce harmful changes in cholesterol, acne, hypertension, liver damage, and damage to the heart. Hormonal imbalances caused by the use of anabolic steriods may result in gynecomastia and testicular atrophy.Anabolic steroids are known to increase harmful LDL, while decreasing beneficial HDL cholesterol. Their ability to stimulate sebaceous glands may increase acne. Additionally, the elevation in blood pressure caused by anabolic steroids, is particularly pronounced and harmful in those with pre-existing hypertension.	Small Molecule																																			1	Yes	3	2	No	4	0	57.53 Å2	34.73 Å3	86.4 m3·mol-1	0	Yes	No	0.068 mg/mL	2.85	-3.6	9.28	-0.88			
C20H32O	Not Available	Not Available	288.4675	[H][C@@]12CC[C@@](O)(CC)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCCC=C3CC[C@@]21[H]	Solid	Not Available						31578	CHEMBL1200623	13168								PA449539	13765	46505460		4162		Ethylestrenol	ZINC000004215863		Ethylestrenol	Withdrawn	DB01493	InChI=1S/C20H32O/c1-3-20(21)13-11-18-17-9-8-14-6-4-5-7-15(14)16(17)10-12-19(18,20)2/h6,15-18,21H,3-5,7-13H2,1-2H3/t15-,16+,17+,18-,19-,20-/m0/s1	AOXRBFRFYPMWLR-XGXHKTLJSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.8534 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							about 50			1	Yes	1	1	No	4	0	20.23 Å2	35.94 Å3	88.5 m3·mol-1	1	Yes	Yes	0.00086 mg/mL	4.69	-5.5		-0.27			
C19H27ClO2	Not Available	Not Available	322.869	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=C(Cl)C(=O)CC[C@]12C	Solid	Not Available						135372	CHEMBL2106571	62171					D07731				68947	46505505		61686		Clostebol	ZINC000004025021		Clostebol	Experimental, Illicit	DB01521	InChI=1S/C19H27ClO2/c1-18-10-8-15(21)17(20)14(18)4-3-11-12-5-6-16(22)19(12,2)9-7-13(11)18/h11-13,16,22H,3-10H2,1-2H3/t11-,12-,13-,16-,18+,19-/m0/s1	KCZCIYZKSLLNNH-FBPKJDBXSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.7601 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							189 °C			1	Yes	2	1	No	4	0	37.3 Å2	36.02 Å3	89.22 m3·mol-1	0	Yes	Yes	0.0153 mg/mL	3.75	-4.3	19.38	-0.88			
C19H30O2	Not Available	Not Available	290.4403	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C	Solid	Not Available					50223237	2710	CHEMBL440283	10188			HMDB0003818	C04295	D00179	B81			10634	46507476				5-Androstenediol	ZINC000003814414		Androstenediol	Experimental, Illicit	DB01524	InChI=1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h3,13-17,20-21H,4-11H2,1-2H3/t13-,14-,15-,16-,17-,18-,19-/m0/s1	QADHLRWLCPCEKT-LOVVWNRFSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.2291 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	2	No	4	0	40.46 Å2	34.87 Å3	85.48 m3·mol-1	0	Yes	No	0.055 mg/mL	2.8	-3.7	18.2	-0.77			
C19H30O2	Not Available	Not Available	290.4403	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=C[C@@H](O)CC[C@]12C	Solid	Not Available					50410526	34386	CHEMBL195836	120071			HMDB0005849	C14210					136297	46507648				4-Androstenediol	ZINC000003814413		4-Androstenediol	Experimental, Illicit	DB01526	InChI=1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,13-17,20-21H,3-10H2,1-2H3/t13-,14-,15-,16-,17-,18-,19-/m0/s1	BTTWKVFKBPAFDK-LOVVWNRFSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.2291 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	2	No	4	0	40.46 Å2	34.38 Å3	85.33 m3·mol-1	0	Yes	No	0.0481 mg/mL	2.95	-3.8	17.5	-0.82			
C19H26O2	Not Available	Not Available	286.4085	[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	Not Available	P08684;!P42330	CYP3A4;!AKR1C3	1. Cytochrome P450 3A4;!2. Aldo-keto reductase family 1 member C3		91713	16422	CHEMBL274826	5898			HMDB0000053	C00280	D00051	ASD			6128	46508011		784		Androstenedione	ZINC000004428526		Androstenedione	Experimental, Illicit	DB01536	InChI=1S/C19H26O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-16H,3-10H2,1-2H3/t14-,15-,16-,18-,19-/m0/s1	AEMFNILZOJDQLW-QAGGRKNESA-N			Not Available	Small Molecule	http://smpdb.ca/view/SMP0000356?highlight[compounds][]=DB01536&highlight[proteins][]=DB01536;!http://smpdb.ca/view/SMP0030406?highlight[compounds][]=DB01536&highlight[proteins][]=DB01536;!http://smpdb.ca/view/SMP0000068?highlight[compounds][]=DB01536&highlight[proteins][]=DB01536;!http://smpdb.ca/view/SMP0000565?highlight[compounds][]=DB01536&highlight[proteins][]=DB01536	17-beta Hydroxysteroid Dehydrogenase III Deficiency;!Androstenedione Metabolism;!Androgen and Estrogen Metabolism;!Aromatase Deficiency		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.5360 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.75	-3.69	158 °C		57.8 mg/L (at 25 °C)	1	Yes	2	0	No	4	0	34.14 Å2	33.21 Å3	83.61 m3·mol-1	0	Yes	Yes	0.027 mg/mL	3.93	-4	18.52	-4.8	P14061;!P14060;!Q00441;!P42330	HSD17B1;!HSD3B1;!eryF;!AKR1C3	1. Estradiol 17-beta-dehydrogenase 1;!2. 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1;!3. 6-deoxyerythronolide B hydroxylase;!4. Aldo-keto reductase family 1 member C3
C19H28O3	Not Available	Not Available	304.43	[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C(O)=C3CC[C@@]21[H]	Solid	Not Available								42759157									69249407	46504925					ZINC000263614121		17alpha-methyl-4-hydroxynandrolone	Illicit	DB01540	InChI=1S/C19H28O3/c1-18-9-7-12-11-5-6-16(20)17(21)14(11)4-3-13(12)15(18)8-10-19(18,2)22/h11-13,15,21-22H,3-10H2,1-2H3/t11-,12-,13-,15+,18+,19+/m1/s1	CLNUZOCYKSHICX-FAHHUNKHSA-N			Not Available	Small Molecule																																			1	Yes	3	2	No	4	0	57.53 Å2	35.02 Å3	86.56 m3·mol-1	0	Yes	No	0.0575 mg/mL	2.83	-3.7	9.33	-0.53			
C26H35NO4	Not Available	Not Available	425.569	[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@]11CC[C@@]2(OC)[C@H](C1)C(C)(C)O	Solid	Not Available					50001714	4650	CHEMBL281786	391634		GtP Drug Page		C11794					443408	46506559				Diprenorphine	ZINC000004102215		Diprenorphine	Illicit, Vet approved	DB01548	InChI=1S/C26H35NO4/c1-23(2,29)18-13-24-8-9-26(18,30-3)22-25(24)10-11-27(14-15-4-5-15)19(24)12-16-6-7-17(28)21(31-22)20(16)25/h6-7,15,18-19,22,28-29H,4-5,8-14H2,1-3H3/t18-,19-,22-,24-,25+,26-/m1/s1	OIJXLIIMXHRJJH-KNLIIKEYSA-N	-Infinity		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	3.1511 LD50, mol/kg	Inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	2	No	7	1	62.16 Å2	47.86 Å3	118.37 m3·mol-1	4	Yes	No	0.104 mg/mL	2.28	-3.6	10.42	9.63			
C21H32O2	Not Available	Not Available	316.4776	[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@H](C)CC2=CC(=O)CC[C@]12C	Solid	Not Available						135356	CHEMBL455706	26239			HMDB0004627						28204	46507441				Calusterone	ZINC000004215173		Calusterone	Experimental, Illicit	DB01564	InChI=1S/C21H32O2/c1-13-11-14-12-15(22)5-8-19(14,2)16-6-9-20(3)17(18(13)16)7-10-21(20,4)23/h12-13,16-18,23H,5-11H2,1-4H3/t13-,16-,17-,18+,19-,20-,21-/m0/s1	IVFYLRMMHVYGJH-PVPPCFLZSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.0516 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							128 °C			1	Yes	2	1	No	4	0	37.3 Å2	37.77 Å3	93.62 m3·mol-1	0	Yes	Yes	0.0112 mg/mL	3.93	-4.4	18.8	-0.53	P10275	AR	1. Androgen receptor
C21H28O4	Not Available	Not Available	344.4446	[H][C@@]12CC[C@](C)(O)[C@@]1(C)C[C@@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C(C=O)=C[C@]12C	Solid	Not Available						135456	CHEMBL2107419	16234			HMDB0004631						17150	46508967				Formebolone	ZINC000004216332		Formebolone	Experimental, Illicit	DB01569	InChI=1S/C21H28O4/c1-19-9-12(11-22)16(23)8-13(19)4-5-14-15-6-7-21(3,25)20(15,2)10-17(24)18(14)19/h8-9,11,14-15,17-18,24-25H,4-7,10H2,1-3H3/t14-,15-,17+,18+,19-,20-,21-/m0/s1	AMVODTGMYSRMNP-GNIMZFFESA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	3.2193 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				543.6 °C			210.5 °C			1	Yes	4	2	No	4	0	74.6 Å2	38.13 Å3	96.9 m3·mol-1	1	Yes	No	0.0605 mg/mL	1.76	-3.8	14.39	-2.9	P80365	HSD11B2	1. Corticosteroid 11-beta-dehydrogenase isozyme 2
C20H30O2	Not Available	Not Available	302.458	[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)C=C[C@]12C	Solid	Not Available								5442174										46506576				Methyl-1-testosterone	ZINC000004081584		Methyl-1-testosterone	Experimental, Illicit	DB01572	InChI=1S/C20H30O2/c1-18-9-6-14(21)12-13(18)4-5-15-16(18)7-10-19(2)17(15)8-11-20(19,3)22/h6,9,13,15-17,22H,4-5,7-8,10-12H2,1-3H3/t13-,15+,16-,17-,18-,19-,20-/m0/s1	JRNSSSJKIGAFCT-YDSAWKJFSA-N			Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	35.73 Å3	89.33 m3·mol-1	0	Yes	Yes	0.00401 mg/mL	3.69	-4.9		-0.53			
C19H28O2	Not Available	12 hours	288.4244	[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C	Solid	Not Available	P24462;!P14061;!Q06520;!O00204;!P14060;!P22637;!P05093	CYP3A7;!HSD17B1;!SULT2A1;!SULT2B1;!HSD3B1;!choB;!CYP17A1	1. Cytochrome P450 3A7;!2. Estradiol 17-beta-dehydrogenase 1;!3. Bile salt sulfotransferase;!4. Sulfotransferase family cytosolic 2B member 1;!5. 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1;!6. Cholesterol oxidase;!7. Steroid 17-alpha-hydroxylase/17,20 lyase		50223368	28689	CHEMBL90593	5670		GtP Drug Page	HMDB0000077	C01227	D08409	AND		PA451993	5881	46508824		3143	DNC001146	Dehydroepiandrosterone	ZINC000003807917	Intrarosa	Prasterone	Approved, Investigational, Nutraceutical	DB01708	InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h3,13-16,20H,4-11H2,1-2H3/t13-,14-,15-,16-,18-,19-/m0/s1	FMGSKLZLMKYGDP-USOAJAOKSA-N	4	Prasterone is a steroid formulated as a vaginal insert indicated for the treatment of moderate to severe dyspareunia associated with menopausal vulvar and vaginal atrophy.	Acute oral toxicity (LD50): >10000 mg/kg [Rat]. Lowest Published Toxic Dose (TDL) [Man] - Route: Oral; Dose: 10 mg/kg/2W intermittent.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.5214 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.23		140-141 °C		63.5 mg/L (at 25 °C)	1	Yes	2	1	No	4	0	37.3 Å2	34.1 Å3	84.66 m3·mol-1	0	Yes	Yes	0.0438 mg/mL	3.36	-3.8	18.2	-1.4	P03372;!Q92731;!BE0004797;!BE0004956;!P10275;!Q07869;!Q99720;!O75469;!Q14994	ESR1;!ESR2;!;!;!AR;!PPARA;!SIGMAR1;!NR1I2;!NR1I3	1. Estrogen receptor alpha;!2. Estrogen receptor beta;!3. GABA(A) Receptor (Protein Group);!4. NMDA receptor (Protein Group);!5. Androgen receptor;!6. Peroxisome proliferator-activated receptor alpha;!7. Sigma non-opioid intracellular receptor 1;!8. Nuclear receptor subfamily 1 group I member 2;!9. Nuclear receptor subfamily 1 group I member 3
C35H52O4	Not Available	9 hours	536.797	CC(C)C(=O)[C@@]12C(O)=C(CC=C(C)C)C(=O)[C@@](CC=C(C)C)(C[C@H](CC=C(C)C)[C@@]1(C)CCC=C(C)C)C2=O	Solid	Not Available					50193079	5834	CHEMBL1237210	16736597				C07608		HYF			441298	46506104			DNC000759	Hyperforin	ZINC000004097413		Hyperforin	Nutraceutical	DB01892	InChI=1S/C35H52O4/c1-22(2)13-12-19-33(11)27(16-14-23(3)4)21-34(20-18-25(7)8)30(37)28(17-15-24(5)6)31(38)35(33,32(34)39)29(36)26(9)10/h13-15,18,26-27,38H,12,16-17,19-21H2,1-11H3/t27-,33+,34+,35-/m0/s1	IWBJJCOKGLUQIZ-HQKKAZOISA-N			Oral LD50 (rat):5628 mg/kg; Skin LD50 (rabbit): 15800 mg/kg; Subcutaneous LD50 (mouse):9800 mg/kg; Intraperitoneal LD50 (rabbit):1826 mg/kg	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	2.9007 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							70-80			0	No	4	1	No	2	-1	71.44 Å2	63.75 Å3	166.68 m3·mol-1	11	No	No	0.000632 mg/mL	9.67	-5.9	3.62	-7.3	O75469;!P23219;!P09917	NR1I2;!PTGS1;!ALOX5	1. Nuclear receptor subfamily 1 group I member 2;!2. Prostaglandin G/H synthase 1;!3. Arachidonate 5-lipoxygenase
C27H46O4S	Not Available	Not Available	466.717	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC=C4C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)OS(O)(=O)=O)[C@H](C)CCCC(C)C	Solid	Not Available						41321	CHEMBL1231592	58586			HMDB0000653	C18043		C3S			65076	46507419				Cholesterol_sulfate	ZINC000012494196		Cholesterol sulfate	Experimental	DB01990	InChI=1S/C27H46O4S/c1-18(2)7-6-8-19(3)23-11-12-24-22-10-9-20-17-21(31-32(28,29)30)13-15-26(20,4)25(22)14-16-27(23,24)5/h9,18-19,21-25H,6-8,10-17H2,1-5H3,(H,28,29,30)/t19-,21+,22+,23-,24+,25+,26+,27-/m1/s1	BHYOQNUELFTYRT-DPAQBDIFSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.4505 LD50, mol/kg	Non-inhibitor	Strong inhibitor	Non-inhibitor										1	No	3	1	Yes	4	-1	63.6 Å2	56.55 Å3	130.61 m3·mol-1	7	No	No	7.48e-05 mg/mL	7.17	-6.8	-1.4		P35398	RORA	1. Nuclear receptor ROR-alpha
C34H50O7	Not Available	Not Available	570.7566	[H][C@@]1(CC[C@@]2(C)[C@@]([H])(CC[C@]3(C)[C@]2([H])C(=O)C=C2[C@]4([H])C[C@](C)(CC[C@]4(C)CC[C@@]32C)C(O)=O)C1(C)C)OC(=O)CCC(O)=O	Solid	Not Available					50247012		CHEMBL499915	552190						CBO			636403	46508820		2017	DNC000388	Carbenoxolone	ZINC000003977823		Carbenoxolone	Experimental	DB02329	InChI=1S/C34H50O7/c1-29(2)23-10-13-34(7)27(32(23,5)12-11-24(29)41-26(38)9-8-25(36)37)22(35)18-20-21-19-31(4,28(39)40)15-14-30(21,3)16-17-33(20,34)6/h18,21,23-24,27H,8-17,19H2,1-7H3,(H,36,37)(H,39,40)/t21-,23-,24-,27+,30+,31-,32-,33+,34+/m0/s1	OBZHEBDUNPOCJG-WBXJDKIVSA-N		Carbenoxolone is a drug used to symptomatically treat lip sores and mouth ulcers.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	2.3981 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							292.5 °C			0	No	6	2	Yes	5	-2	117.97 Å2	64.99 Å3	154.31 m3·mol-1	6	No	No	0.000738 mg/mL	6.3	-5.9	4.04	-5.1			
C45H60N4O14	Not Available	Not Available	880.989	[H][C@]12N=C(\C(C)=C3/N=C(/C=C4\N=C(\C(\C)=C5/N[C@]1(C)[C@@](C)(CC(O)=O)[C@@H]5CCC(O)=O)[C@@](C)(CC(O)=O)[C@@H]4CCC(O)=O)C(C)(C)[C@@H]3CCC(O)=O)[C@](C)(CCC(O)=O)[C@H]2CC(O)=O	Solid	Not Available						17926		21864840				C06399		COJ			10396076	46506147					ZINC000096077688		Hydrogenobyrinic acid	Experimental	DB02460	InChI=1S/C45H60N4O14/c1-21-36-24(10-13-30(52)53)41(3,4)28(47-36)18-27-23(9-12-29(50)51)43(6,19-34(60)61)39(46-27)22(2)37-25(11-14-31(54)55)44(7,20-35(62)63)45(8,49-37)40-26(17-33(58)59)42(5,38(21)48-40)16-15-32(56)57/h18,23-26,40,49H,9-17,19-20H2,1-8H3,(H,50,51)(H,52,53)(H,54,55)(H,56,57)(H,58,59)(H,60,61)(H,62,63)/b27-18-,36-21-,37-22-/t23-,24-,25-,26+,40-,42-,43+,44+,45+/m1/s1	MYMATQFDUQLSCD-IPUCCYEASA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.6760 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	18	8	Yes	5	-4	310.21 Å2	90.53 Å3	225.65 m3·mol-1	18	No	No	0.0143 mg/mL	0.65	-4.8	3.39	8.71	P21638	cobH	1. Precorrin-8X methylmutase
C20H28O2	Not Available	Not Available	300.4351	C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)C(=O)CCC1(C)C	Solid	Not Available						44597		4451124			HMDB0012329	C16683		OXR			5289090	46506951					ZINC000012502479		4-Oxoretinol	Experimental	DB02699	InChI=1S/C20H28O2/c1-15(7-6-8-16(2)12-14-21)9-10-18-17(3)19(22)11-13-20(18,4)5/h6-10,12,21H,11,13-14H2,1-5H3/b8-6+,10-9+,15-7+,16-12+	PLIUCYCUYQIBDZ-RMWYGNQTSA-N			Not Available	Small Molecule	http://smpdb.ca/view/SMP0000074?highlight[compounds][]=DB02699&highlight[proteins][]=DB02699;!http://smpdb.ca/view/SMP0000336?highlight[compounds][]=DB02699&highlight[proteins][]=DB02699	Retinol Metabolism;!Vitamin A Deficiency		Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.7980 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	1	No	1	0	37.3 Å2	36.68 Å3	98.62 m3·mol-1	5	Yes	Yes	0.0121 mg/mL	4.03	-4.4	16.44	-2.2			
C31H48O6	Not Available	Approximately 5 to 6 hours in adults.	516.7092	[H][C@@]12C[C@@H](O)[C@@]3([H])[C@@]4(C)CC[C@@H](O)[C@@H](C)[C@]4([H])CC[C@]3(C)[C@@]1(C)C[C@H](OC(C)=O)\C2=C(\CCC=C(C)C)C(O)=O	Solid	Not Available	P10635;!P08684;!P22309	CYP2D6;!CYP3A4;!UGT1A1	1. Cytochrome P450 2D6;!2. Cytochrome P450 3A4;!3. UDP-glucuronosyltransferase 1-1		58924	29013	CHEMBL374975	2271900			HMDB0015570	C06694	D04281	FUA		PA164749648	3000226	46505364		113608	DAP001008	Fusidic_acid	ZINC000008143796	Fucibet, Fucidin, Fucithalmic	Fusidic acid	Approved, Investigational	DB02703	InChI=1S/C31H48O6/c1-17(2)9-8-10-20(28(35)36)26-22-15-24(34)27-29(5)13-12-23(33)18(3)21(29)11-14-30(27,6)31(22,7)16-25(26)37-19(4)32/h9,18,21-25,27,33-34H,8,10-16H2,1-7H3,(H,35,36)/b26-20-/t18-,21-,22-,23+,24+,25-,27-,29-,30-,31-/m0/s1	IECPWNUMDGFDKC-MZJAQBGESA-N	4	Fusidic acid is a topical antibacterial agent used to prevent and treat mild to moderate skin infections caused by susceptible bacteria.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	3.5929 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							192.5 °C	5.35		1	No	5	3	Yes	4	-1	104.06 Å2	59.76 Å3	144.12 m3·mol-1	6	No	No	0.00521 mg/mL	4.42	-5	4.46	-0.2	P13551;!P62580;!P00484	fusA;!cat;!cat3	1. Elongation factor G;!2. Chloramphenicol acetyltransferase;!3. Chloramphenicol acetyltransferase 3
C21H32O2	Not Available	Not Available	316.4776	[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4		50375319	16581	CHEMBL253363	8611			HMDB0000253	C01953	D00143	PLO			8955	46506718		114052	DNC001147	Pregnenolone	ZINC000003861150		Pregnenolone	Approved, Experimental	DB02789	InChI=1S/C21H32O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h4,15-19,23H,5-12H2,1-3H3/t15-,16-,17+,18-,19-,20-,21+/m0/s1	ORNBQBCIOKFOEO-QGVNFLHTSA-N	4		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.9852 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	1	No	4	0	37.3 Å2	38.09 Å3	93.76 m3·mol-1	1	Yes	Yes	0.0136 mg/mL	3.58	-4.4	18.2	-1.4	O75469;!O00204	NR1I2;!SULT2B1	1. Nuclear receptor subfamily 1 group I member 2;!2. Sulfotransferase family cytosolic 2B member 1
C19H24O2	Not Available	Not Available	284.3927	[H][C@@]12CC[C@](C)(O)[C@@]1(C)C=CC1=C3CCC(=O)C=C3CC[C@@]21[H]	Solid	Not Available					50367916	379896	CHEMBL166444	229099		GtP Drug Page		C14257		R18			261000	46505539				Metribolone	ZINC000003814420		Metribolone	Experimental	DB02998	InChI=1S/C19H24O2/c1-18-9-7-15-14-6-4-13(20)11-12(14)3-5-16(15)17(18)8-10-19(18,2)21/h7,9,11,16-17,21H,3-6,8,10H2,1-2H3/t16-,17+,18+,19+/m1/s1	CCCIJQPRIXGQOE-XWSJACJDSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.6259 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	1	No	4	0	37.3 Å2	33.01 Å3	86.29 m3·mol-1	0	Yes	Yes	0.0332 mg/mL	2.53	-3.9	18.4	-0.53			
C23H34O5	Not Available	Not Available	390.5131	[H][C@@]1(CC[C@]2(O)[C@]3([H])CC[C@]4([H])C[C@@H](O)CC[C@]4(C)[C@@]3([H])C[C@@H](O)[C@]12C)C1=CC(=O)OC1	Solid	Not Available					225707	42098	CHEMBL1153	14728						DOG			15478	46509019				Digoxigenin	ZINC000003982471		Digoxigenin	Experimental	DB03671	InChI=1S/C23H34O5/c1-21-7-5-15(24)10-14(21)3-4-17-18(21)11-19(25)22(2)16(6-8-23(17,22)27)13-9-20(26)28-12-13/h9,14-19,24-25,27H,3-8,10-12H2,1-2H3/t14-,15+,16-,17-,18+,19-,21+,22+,23+/m1/s1	SHIBSTMRCDJXLN-KCZCNTNESA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	3.4699 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	4	3	No	5	0	86.99 Å2	42.7 Å3	105.16 m3·mol-1	1	Yes	No	0.0632 mg/mL	1.84	-3.8	7.15	-1.4			
C30H50O	Not Available	Not Available	426.7174	[H][C@@]1(CC[C@@]2(C)C3=C(CC[C@]12C)[C@@]1(C)CC[C@H](O)C(C)(C)[C@]1([H])CC3)[C@H](C)CCC=C(C)C	Solid	Not Available						16521	CHEMBL225111	216175		GtP Drug Page	HMDB0001251	C01724		LAN			246983	46506323		1442199		Lanosterol	ZINC000003870056		Lanosterol	Experimental	DB03696	InChI=1S/C30H50O/c1-20(2)10-9-11-21(3)22-14-18-30(8)24-12-13-25-27(4,5)26(31)16-17-28(25,6)23(24)15-19-29(22,30)7/h10,21-22,25-26,31H,9,11-19H2,1-8H3/t21-,22-,25+,26+,28-,29-,30+/m1/s1	CAHGCLMLTWQZNJ-BQNIITSRSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.5576 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							140.5 °C			1	No	1	1	No	4	0	20.23 Å2	55.06 Å3	134.54 m3·mol-1	4	No	Yes	0.000376 mg/mL	7.71	-6.1	19.55	-0.81	P48449	LSS	1. Lanosterol synthase
C28H44O	Not Available	Not Available	396.659	CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	Solid	Not Available					50378884	16933	CHEMBL1232562	392539				C01694		ERG			444679	46505947				Ergosterol	ZINC000004084618		Ergosterol	Approved, Experimental	DB04038	InChI=1S/C28H44O/c1-18(2)19(3)7-8-20(4)24-11-12-25-23-10-9-21-17-22(29)13-15-27(21,5)26(23)14-16-28(24,25)6/h7-10,18-20,22,24-26,29H,11-17H2,1-6H3/b8-7+/t19-,20+,22-,24+,25-,26-,27-,28+/m0/s1	DNVPQKQSNYMLRS-APGDWVJJSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.6528 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							170 °C			1	No	1	1	No	4	0	20.23 Å2	51.01 Å3	127.13 m3·mol-1	4	No	Yes	0.000156 mg/mL	6.63	-6.4	18.27	-1.4			
C23H34O4	Not Available	Not Available	374.5137	[H][C@]12CC[C@]3([H])[C@]([H])(CC[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@H](O)C2	Solid	Not Available					66977	42219	CHEMBL1453	3571902						DTX			4369270	46508220				Digitoxigenin	ZINC000003875959		Digitoxigenin	Experimental	DB04177	InChI=1S/C23H34O4/c1-21-8-5-16(24)12-15(21)3-4-19-18(21)6-9-22(2)17(7-10-23(19,22)26)14-11-20(25)27-13-14/h11,15-19,24,26H,3-10,12-13H2,1-2H3/t15-,16+,17-,18+,19-,21+,22-,23+/m1/s1	XZTUSOXSLKTKJQ-CESUGQOBSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.9314 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	3	2	No	5	-1	66.76 Å2	42.57 Å3	103.64 m3·mol-1	1	Yes	No	0.0244 mg/mL	3.07	-4.2	7.18	0.25			
C27H46O	Not Available	Not Available	386.6535	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC=C4C[C@@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCCC(C)C	Solid	Not Available					20192	16113	CHEMBL112570	5775			HMDB0000067	C00187	D00040	CLR			5997	46508234		2438		Cholesterol	ZINC000003875383		Cholesterol	Approved, Investigational	DB04540	InChI=1S/C27H46O/c1-18(2)7-6-8-19(3)23-11-12-24-22-10-9-20-17-21(28)13-15-26(20,4)25(22)14-16-27(23,24)5/h9,18-19,21-25,28H,6-8,10-17H2,1-5H3/t19-,21+,22+,23-,24+,25+,26+,27-/m1/s1	HVYWMOMLDIMFJA-DPAQBDIFSA-N	4		Not Available	Small Molecule	http://smpdb.ca/view/SMP0000099?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000111?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000209?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000316?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000372?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000388?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000389?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000510?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000577?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000718?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000082?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000089?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000092?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000107?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000117?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000119?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000314?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000319?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000371?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000508?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000575?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000717?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000720?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000023?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000035?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000079?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000095?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000112?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000130?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540;!http://smpdb.ca/view/SMP0000131?highlight[compounds][]=DB04540&highlight[proteins][]=DB04540	Lovastatin Action Pathway;!Cerivastatin Action Pathway;!Hypercholesterolemia;!Zellweger Syndrome;!Adrenal Hyperplasia Type 5 or Congenital Adrenal Hyperplasia Due to 17 alpha-Hydroxylase Deficiency;!Chondrodysplasia Punctata II, X-Linked Dominant (CDPX2);!Smith-Lemli-Opitz Syndrome (SLOS);!Mevalonic Aciduria;!Corticosterone Methyl Oxidase I Deficiency (CMO I);!3-beta-Hydroxysteroid Dehydrogenase Deficiency;!Simvastatin Action Pathway;!Pravastatin Action Pathway;!Rosuvastatin Action Pathway;!Zoledronate Action Pathway;!Pamidronate Action Pathway;!Fluvastatin Action Pathway;!Congenital Bile Acid Synthesis Defect Type II;!Lysosomal Acid Lipase Deficiency (Wolman Disease);!Congenital Lipoid Adrenal Hyperplasia (CLAH) or Lipoid CAH;!Cholesteryl Ester Storage Disease;!11-beta-Hydroxylase Deficiency (CYP11B1);!Apparent Mineralocorticoid Excess Syndrome;!27-Hydroxylase Deficiency;!Steroid Biosynthesis;!Bile Acid Biosynthesis;!Ibandronate Action Pathway;!Alendronate Action Pathway;!Risedronate Action Pathway;!Steroidogenesis;!Atorvastatin Action Pathway		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.8078 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				360 °C			148.5 °C		0.095 mg/L (at 30 °C)	1	No	1	1	No	4	0	20.23 Å2	50.64 Å3	120.62 m3·mol-1	5	No	Yes	2.79e-05 mg/mL	7.11	-7.1	18.2	-1.4	Q14994;!P11473;!Q9ULY5;!P35398	NR1I3;!VDR;!CLEC4E;!RORA	1. Nuclear receptor subfamily 1 group I member 3;!2. Vitamin D3 receptor;!3. C-type lectin domain family 4 member E;!4. Nuclear receptor ROR-alpha
C27H46O2	Not Available	Not Available	402.6529	CC(C)CCC[C@@](C)(O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	Solid	Not Available					50035884		CHEMBL1233249	389586			HMDB0006283			HC2			440711	46508206					ZINC000004096811		20-hydroxycholesterol	Experimental	DB04704	InChI=1S/C27H46O2/c1-18(2)7-6-14-27(5,29)24-11-10-22-21-9-8-19-17-20(28)12-15-25(19,3)23(21)13-16-26(22,24)4/h8,18,20-24,28-29H,6-7,9-17H2,1-5H3/t20-,21-,22-,23-,24-,25-,26-,27+/m0/s1	MCKLJFJEQRYRQT-MGNSQDQZSA-N			Not Available	Small Molecule	http://smpdb.ca/view/SMP0000371?highlight[compounds][]=DB04704&highlight[proteins][]=DB04704;!http://smpdb.ca/view/SMP0000575?highlight[compounds][]=DB04704&highlight[proteins][]=DB04704;!http://smpdb.ca/view/SMP0000717?highlight[compounds][]=DB04704&highlight[proteins][]=DB04704;!http://smpdb.ca/view/SMP0000372?highlight[compounds][]=DB04704&highlight[proteins][]=DB04704;!http://smpdb.ca/view/SMP0000577?highlight[compounds][]=DB04704&highlight[proteins][]=DB04704;!http://smpdb.ca/view/SMP0000718?highlight[compounds][]=DB04704&highlight[proteins][]=DB04704;!http://smpdb.ca/view/SMP0000130?highlight[compounds][]=DB04704&highlight[proteins][]=DB04704;!http://smpdb.ca/view/SMP0000373?highlight[compounds][]=DB04704&highlight[proteins][]=DB04704;!http://smpdb.ca/view/SMP0000566?highlight[compounds][]=DB04704&highlight[proteins][]=DB04704;!http://smpdb.ca/view/SMP0000576?highlight[compounds][]=DB04704&highlight[proteins][]=DB04704;!http://smpdb.ca/view/SMP0000578?highlight[compounds][]=DB04704&highlight[proteins][]=DB04704	Congenital Lipoid Adrenal Hyperplasia (CLAH) or Lipoid CAH;!11-beta-Hydroxylase Deficiency (CYP11B1);!Apparent Mineralocorticoid Excess Syndrome;!Adrenal Hyperplasia Type 5 or Congenital Adrenal Hyperplasia Due to 17 alpha-Hydroxylase Deficiency;!Corticosterone Methyl Oxidase I Deficiency (CMO I);!3-beta-Hydroxysteroid Dehydrogenase Deficiency;!Steroidogenesis;!Adrenal Hyperplasia Type 3 or Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency;!17-alpha-Hydroxylase Deficiency (CYP17);!21-Hydroxylase Deficiency (CYP21);!Corticosterone Methyl Oxidase II Deficiency (CMO II)		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	3.0155 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	2	2	No	4	0	40.46 Å2	50.57 Å3	122.3 m3·mol-1	5	No	No	0.000571 mg/mL	5.8	-5.8	18.2	-0.26			
C27H46O2	Not Available	Not Available	402.6529	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC=C4C[C@@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCCC(C)(C)O	Solid	Not Available					20182	42977	CHEMBL169046	58604				C15519		HC3			65094	46506794					ZINC000005751264		25-Hydroxycholesterol	Experimental	DB04705	InChI=1S/C27H46O2/c1-18(7-6-14-25(2,3)29)22-10-11-23-21-9-8-19-17-20(28)12-15-26(19,4)24(21)13-16-27(22,23)5/h8,18,20-24,28-29H,6-7,9-17H2,1-5H3/t18-,20+,21+,22-,23+,24+,26+,27-/m1/s1	INBGSXNNRGWLJU-ZHHJOTBYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	3.0155 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	2	2	No	4	0	40.46 Å2	51.11 Å3	122.45 m3·mol-1	5	No	No	0.000244 mg/mL	5.64	-6.2	18.2	-1			
C27H46O2	Not Available	Not Available	402.6529	[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@@H](O)C=C4C[C@@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCCC(C)C	Solid	Not Available					50045545	42989	CHEMBL497834	415508			HMDB0006119			HCR			473141	46505045					ZINC000005758832		7beta-hydroxycholesterol	Experimental	DB04706	InChI=1S/C27H46O2/c1-17(2)7-6-8-18(3)21-9-10-22-25-23(12-14-27(21,22)5)26(4)13-11-20(28)15-19(26)16-24(25)29/h16-18,20-25,28-29H,6-15H2,1-5H3/t18-,20+,21-,22+,23+,24+,25+,26+,27-/m1/s1	OYXZMSRRJOYLLO-KGZHIOMZSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	3.0155 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	2	2	No	4	0	40.46 Å2	51.12 Å3	122.06 m3·mol-1	5	No	No	0.000476 mg/mL	5.96	-5.9	18.2	-0.83			
C24H29ClO4	Not Available	Elimination Following oral or intramuscular administration, the plasma half-life is 38 and 96 hours, respectively.	416.938	[H][C@@]12C[C@]1([H])[C@@]1(C)C(=CC2=O)C(Cl)=C[C@@]2([H])[C@]3([H])CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CC[C@]12[H]	Solid	Not Available	P08684;!P11511	CYP3A4;!CYP19A1	1. Cytochrome P450 3A4;!2. Cytochrome P450 19A1		50094569	50743	CHEMBL139835	9496					D01368	CA4		PA10049	9880	46506931		22054	DAP000906	Cyproterone_acetate	ZINC000003814423	Androcur, Cléo -35, Cyestra-35, Diane	Cyproterone acetate	Approved, Investigational	DB04839	InChI=1S/C24H29ClO4/c1-12(26)24(29-13(2)27)8-6-16-14-10-20(25)19-11-21(28)15-9-18(15)23(19,4)17(14)5-7-22(16,24)3/h10-11,14-18H,5-9H2,1-4H3/t14-,15+,16-,17-,18-,22-,23-,24-/m0/s1	UWFYSQMTEOIJJG-FDTZYFLXSA-N	4	Cyproterone acetate is a steroid used in combination with ethinyl estradiol to treat women with severe acne and symptoms of androgenization. Also used alone at much higher doses for palliative treatment of patients with prostate cancer	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.8261 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							200-201			1	Yes	3	0	No	5	0	60.44 Å2	44.64 Å3	111.81 m3·mol-1	3	Yes	No	0.00152 mg/mL	3.64	-5.4	17.83	-5.6	P10275;!P07288	AR;!KLK3	1. Androgen receptor;!2. Prostate-specific antigen
C26H33NO2	Not Available	Not Available	391.5457	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)NC1=CC=C(O)C=C1	Solid	Not Available					50092055	42588	CHEMBL7301	4450416					D04162	FEN			5288209	175426938				Fenretinide	ZINC000003871023		Fenretinide	Investigational	DB05076	InChI=1S/C26H33NO2/c1-19(11-16-24-21(3)10-7-17-26(24,4)5)8-6-9-20(2)18-25(29)27-22-12-14-23(28)15-13-22/h6,8-9,11-16,18,28H,7,10,17H2,1-5H3,(H,27,29)/b9-6+,16-11+,19-8+,20-18+	AKJHMTWEGVYYSE-FXILSDISSA-N	3		"Mechanism of fenretinide (4-HPR)-induced cell death"	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Non-substrate	2.1836 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	2	2	No	2	0	49.33 Å2	47.67 Å3	128.05 m3·mol-1	6	No	No	0.00119 mg/mL	6.15	-5.5	9.45	-1.2			
C31H39NO5	Not Available	Not Available	505.655	[H][C@@]12CC[C@](OC(C)=O)(C(=O)COC)[C@@]1(C)C[C@H](C1=CC=C(C=C1)N(C)C)C1=C3CCC(=O)C=C3CC[C@@]21[H]	Solid	Not Available							CHEMBL2105694	7981950										347910049				Proellex			Telapristone acetate	Investigational	DB05253	InChI=1S/C31H39NO5/c1-19(33)37-31(28(35)18-36-5)15-14-27-25-12-8-21-16-23(34)11-13-24(21)29(25)26(17-30(27,31)2)20-6-9-22(10-7-20)32(3)4/h6-7,9-10,16,25-27H,8,11-15,17-18H2,1-5H3/t25-,26+,27-,30-,31-/m0/s1	JVBGZFRPTRKSBB-MJBQOYBXSA-N	2		Not Available	Small Molecule																																			1	No	5	0	Yes	5	0	72.91 Å2	56.9 Å3	144.89 m3·mol-1	7	No	No	0.00556 mg/mL	4.45	-5	18.42	4.89	P06401	PGR	1. Progesterone receptor
C20H28O5S	Not Available	Not Available	380.498	[H][C@@]12CCC3=CC(C(C)C)=C(C=C3[C@@]1(C)CCC[C@@]2(C)C(O)=O)S(O)(=O)=O	Solid	Not Available						135593	CHEMBL2104585	59201	Drugs.com Drug Page		HMDB0015613		D07885			PA165958350	65781	99443230					ZINC000003779720		Ecabet	Investigational	DB05265	InChI=1S/C20H28O5S/c1-12(2)14-10-13-6-7-17-19(3,8-5-9-20(17,4)18(21)22)15(13)11-16(14)26(23,24)25/h10-12,17H,5-9H2,1-4H3,(H,21,22)(H,23,24,25)/t17-,19-,20-/m1/s1	IWCWQNVIUXZOMJ-MISYRCLQSA-N	3		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3482 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	2	No	3	-2	91.67 Å2	41.24 Å3	100.07 m3·mol-1	3	Yes	No	0.00426 mg/mL	4.93	-5	-1.5		P18314;!Q8NFA2	ureC;!NOXO1	1. Urease subunit alpha;!2. NADPH oxidase organizer 1
C23H30O5	Not Available	Not Available	386.4813	[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)CC=C1[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	Not Available						31215	CHEMBL2106613	99892					D01733				111332	175426966				Anecortave	ZINC000003931050		Anecortave acetate	Investigational	DB05288	InChI=1S/C23H30O5/c1-14(24)28-13-20(26)23(27)11-8-19-17-5-4-15-12-16(25)6-9-21(15,2)18(17)7-10-22(19,23)3/h7,12,17,19,27H,4-6,8-11,13H2,1-3H3/t17-,19+,21+,22+,23+/m1/s1	YUWPMEXLKGOSBF-GACAOOTBSA-N	3		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.1280 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	1	No	4	0	80.67 Å2	42.64 Å3	105.81 m3·mol-1	4	Yes	No	0.0113 mg/mL	2.62	-4.5	12.61	-3.8			
C28H31NaO9S	Not Available	Not Available	566.595	[Na+].CC12CC(O)C3C(CCC4=CC(=O)C=CC34C)C1CCC2(O)C(=O)COC(=O)C1=CC(=CC=C1)S([O-])(=O)=O	Solid	Not Available								11914									23691973	175426980							ATL-2502	Investigational	DB05340	InChI=1S/C28H32O9S.Na/c1-26-10-8-18(29)13-17(26)6-7-20-21-9-11-28(33,27(21,2)14-22(30)24(20)26)23(31)15-37-25(32)16-4-3-5-19(12-16)38(34,35)36;/h3-5,8,10,12-13,20-22,24,30,33H,6-7,9,11,14-15H2,1-2H3,(H,34,35,36);/q;+1/p-1	RWFZSORKWFPGNE-UHFFFAOYSA-M	3		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.4859 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	8	2	Yes	5	-1	158.1 Å2	55.75 Å3	137.82 m3·mol-1	6	No	No	0.0249 mg/mL	0.81	-4.4	-2.5	-2.9			
C29H35NO9	Not Available	Not Available	541.597	CC12CC(O)C3C(CCC4=CC(=O)CCC34C)C1CCC2(O)C(=O)COC(=O)C1=CC=CC(CON(=O)=O)=C1	Solid	Not Available																		347910124							NCX 1022	Investigational	DB05410	InChI=1S/C29H35NO9/c1-27-10-8-20(31)13-19(27)6-7-21-22-9-11-29(35,28(22,2)14-23(32)25(21)27)24(33)16-38-26(34)18-5-3-4-17(12-18)15-39-30(36)37/h3-5,12-13,21-23,25,32,35H,6-11,14-16H2,1-2H3	MBODWAULVMWNDB-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	No	8	2	Yes	5	0	155.95 Å2	56.82 Å3	140.73 m3·mol-1	8	No	No	0.00244 mg/mL	3.93	-5.4	12.61	-2.8			
C28H30O4	Not Available	Not Available	430.544	[H][C@@]12CC[C@@](O)(C#CC)[C@@]1(C)C[C@H](C1=CC=C3OCOC3=C1)C1=C3CCC(=O)C=C3CC[C@@]21[H]	Solid	Not Available								8043052									9867361	347827730					ZINC000003951570		ORG-34517	Investigational	DB05423	InChI=1S/C28H30O4/c1-3-11-28(30)12-10-23-21-7-4-17-13-19(29)6-8-20(17)26(21)22(15-27(23,28)2)18-5-9-24-25(14-18)32-16-31-24/h5,9,13-14,21-23,30H,4,6-8,10,12,15-16H2,1-2H3/t21-,22+,23-,27-,28-/m0/s1	DFELGYQKEOCHOA-BZAFBGKRSA-N	2		Not Available	Small Molecule																																			1	Yes	4	1	No	6	0	55.76 Å2	48.36 Å3	123.92 m3·mol-1	2	Yes	No	0.00337 mg/mL	4.65	-5.1	12.87	-3.7	P04150	NR3C1	1. Glucocorticoid receptor
C24H30Cl2O6	Not Available	Not Available	485.4	[H][C@@]12CC[C@](OC(=O)C(Cl)Cl)(C(=O)OCC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	Not Available						135783	CHEMBL2107614	8110701									9935073	175427004					ZINC000003979944		Etiprednol dicloacetate	Investigational	DB05442	InChI=1S/C24H30Cl2O6/c1-4-31-21(30)24(32-20(29)19(25)26)10-8-16-15-6-5-13-11-14(27)7-9-22(13,2)18(15)17(28)12-23(16,24)3/h7,9,11,15-19,28H,4-6,8,10,12H2,1-3H3/t15-,16-,17-,18+,22-,23-,24-/m0/s1	QAIOVDNCIZSSSF-RFAJLIJZSA-N	2		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.9813 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	1	Yes	4	0	89.9 Å2	49.4 Å3	121.88 m3·mol-1	6	Yes	No	0.00235 mg/mL	3.99	-5.3	14.88	-2.9	P01584	IL1B	1. Interleukin-1 beta
C20H30O5	Not Available	Not Available	350.455	[H][C@]12CCC(=C)[C@@H](C\C=C3/[C@H](O)COC3=O)[C@]1(C)CC[C@@H](O)[C@@]2(C)CO	Solid	Not Available					50084419	65408	CHEMBL186141	4477067									5318517	347827741				Andrographolide	ZINC000003881797		Andrographolide	Investigational	DB05767	InChI=1S/C20H30O5/c1-12-4-7-16-19(2,9-8-17(23)20(16,3)11-21)14(12)6-5-13-15(22)10-25-18(13)24/h5,14-17,21-23H,1,4,6-11H2,2-3H3/b13-5+/t14-,15-,16+,17-,19+,20+/m1/s1	BOJKULTULYSRAS-OTESTREVSA-N	2		Not Available	Small Molecule																																			1	Yes	4	3	No	3	0	86.99 Å2	38.27 Å3	94.93 m3·mol-1	3	Yes	No	0.284 mg/mL	1.66	-3.1	13.48	-2.8	P01375;!P01584;!P05231;!Q00653;!P19838	TNF;!IL1B;!IL6;!NFKB2;!NFKB1	1. Tumor necrosis factor;!2. Interleukin-1 beta;!3. Interleukin-6;!4. Nuclear factor NF-kappa-B p100 subunit;!5. Nuclear factor NF-kappa-B p105 subunit
C15H18O3	Not Available	Not Available	246.3016	CC1=C(CO)C2=C(C)C3(CC3)[C@@](C)(O)C(=O)C2=C1	Solid	Not Available					50410835	135002	CHEMBL118218	130640									148189	175427030				Irofulven	ZINC000003916310		Irofulven	Investigational	DB05786	InChI=1S/C15H18O3/c1-8-6-10-12(11(8)7-16)9(2)15(4-5-15)14(3,18)13(10)17/h6,16,18H,4-5,7H2,1-3H3/t14-/m0/s1	NICJCIQSJJKZAH-AWEZNQCLSA-N	3		Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.0258 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	2	No	3	0	57.53 Å2	27.33 Å3	70.91 m3·mol-1	1	Yes	No	0.52 mg/mL	0.67	-2.7	12.77	-1.7	Q96AE4	FUBP1	1. Far upstream element-binding protein 1
C19H28O5S	Not Available	Not Available	368.488	[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@H](CC[C@]12C)OS(O)(=O)=O	Solid	Not Available	P11511;!P24462;!P35354	CYP19A1;!CYP3A7;!PTGS2	1. Cytochrome P450 19A1;!2. Cytochrome P450 3A7;!3. Prostaglandin G/H synthase 2		50375559	16814	CHEMBL259898	12074			HMDB0001032	C04555					12594	175427036				Dehydroepiandrosterone_sulfate	ZINC000004096458		Prasterone sulfate	Investigational	DB05804	InChI=1S/C19H28O5S/c1-18-9-7-13(24-25(21,22)23)11-12(18)3-4-14-15-5-6-17(20)19(15,2)10-8-16(14)18/h3,13-16H,4-11H2,1-2H3,(H,21,22,23)/t13-,14-,15-,16-,18-,19-/m0/s1	CZWCKYRVOZZJNM-USOAJAOKSA-N			Not Available	Small Molecule	http://smpdb.ca/view/SMP0000356?highlight[compounds][]=DB05804&highlight[proteins][]=DB05804;!http://smpdb.ca/view/SMP0000068?highlight[compounds][]=DB05804&highlight[proteins][]=DB05804;!http://smpdb.ca/view/SMP0000565?highlight[compounds][]=DB05804&highlight[proteins][]=DB05804	17-beta Hydroxysteroid Dehydrogenase III Deficiency;!Androgen and Estrogen Metabolism;!Aromatase Deficiency		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Non-substrate	2.4168 LD50, mol/kg	Non-inhibitor	Strong inhibitor	Inhibitor										1	Yes	4	1	No	4	-1	80.67 Å2	39.85 Å3	94.65 m3·mol-1	2	Yes	No	0.00806 mg/mL	3.42	-4.7	-1.4	-7.5			
C24H31NO	Not Available	Terminal elimination half-life = 5-14 hours	349.509	[H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C	Solid	Vdss= 19,669 ± 13,358 L					25458	68642	CHEMBL254328	117349	Drugs.com Drug Page				D09701	AER		PA166123407	132971	175427038	RxList Drug Page	1100072		Abiraterone_acetate	ZINC000003797541	Yonsa, Zytiga	Abiraterone	Approved	DB05812	InChI=1S/C24H31NO/c1-23-11-9-18(26)14-17(23)5-6-19-21-8-7-20(16-4-3-13-25-15-16)24(21,2)12-10-22(19)23/h3-5,7,13,15,18-19,21-22,26H,6,8-12,14H2,1-2H3/t18-,19-,21-,22-,23-,24+/m0/s1	GZOSMCIZMLWJML-VJLLXTKPSA-N	4	Abiraterone is an antiandrogen used in the treatment of prostate cancer.	Toxicity is related to the blockade of 17α-hydroxylase activity. Blockade results in the accumulation of upstream mineralocorticoids like 11-deoxycorticosterone leading to secondary hyperaldosteronism. Signs of hydroaldosteronism include fluid retention and hypokalemia. Mineralocorticoid receptor antagonists may be used to treat signs and symptoms.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.4407 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	1	No	5	0	33.12 Å2	42.03 Å3	107.3 m3·mol-1	1	Yes	Yes	0.00305 mg/mL	3.97	-5.1	18.2	4.81			
C32H43NO4	Not Available	Not Available	505.699	COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2	Solid	Not Available					217379		CHEMBL1762621	355161														Bardoxolone_methyl	ZINC000003982151		Bardoxolone methyl	Investigational	DB05983	InChI=1S/C32H43NO4/c1-27(2)11-13-32(26(36)37-8)14-12-31(7)24(20(32)17-27)21(34)15-23-29(5)16-19(18-33)25(35)28(3,4)22(29)9-10-30(23,31)6/h15-16,20,22,24H,9-14,17H2,1-8H3/t20-,22-,24-,29-,30+,31+,32-/m0/s1	WPTTVJLTNAWYAO-KPOXMGGZSA-N	2		Not Available	Small Molecule																																			0	No	4	0	No	5	0	84.23 Å2	58.23 Å3	144.36 m3·mol-1	2	No	No	0.00294 mg/mL	6.55	-5.2		-5.3	P25963	NFKBIA	1. NF-kappa-B inhibitor alpha
C19H27FO	Not Available	Not Available	290.422	C[C@]12CC[C@H]3[C@@H](CC=C4CCCC[C@]34C)[C@@H]1C[C@@H](F)C2=O	Solid	Not Available								118130														Fluasterone	ZINC000003778181		Fluasterone	Investigational	DB06250	InChI=1S/C19H27FO/c1-18-9-4-3-5-12(18)6-7-13-14(18)8-10-19(2)15(13)11-16(20)17(19)21/h6,13-16H,3-5,7-11H2,1-2H3/t13-,14+,15+,16-,18+,19+/m1/s1	VHZXNQKVFDBFIK-NBBHSKLNSA-N			Not Available	Small Molecule																																			1	Yes	1	0	No	4	0	17.07 Å2	33.22 Å3	82.79 m3·mol-1	0	Yes	Yes	0.00261 mg/mL	4.77	-5	16.48	-8.2			
C21H32O3	Not Available	Not Available	332.484	[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)\C(C[C@]12C)=C/O	Solid	Not Available	P21397;!P10635;!P18405;!P08684;!P20815;!P24462;!Q9HB55	MAOA;!CYP2D6;!SRD5A1;!CYP3A4;!CYP3A5;!CYP3A7;!CYP3A43	1. Amine oxidase [flavin-containing] A;!2. Cytochrome P450 2D6;!3. 3-oxo-5-alpha-steroid 4-dehydrogenase 1;!4. Cytochrome P450 3A4;!5. Cytochrome P450 3A5;!6. Cytochrome P450 3A7;!7. Cytochrome P450 3A43			7864	CHEMBL1200585	4444502	Drugs.com Drug Page			C07393	D00490				5281034	310264869	RxList Drug Page	7813		Oxymetholone	ZINC000118912450	Anadrol-50	Oxymetholone	Approved, Illicit	DB06412	InChI=1S/C21H32O3/c1-19-11-13(12-22)18(23)10-14(19)4-5-15-16(19)6-8-20(2)17(15)7-9-21(20,3)24/h12,14-17,22,24H,4-11H2,1-3H3/b13-12-/t14-,15+,16-,17-,19-,20-,21-/m0/s1	ICMWWNHDUZJFDW-DHODBPELSA-N		Oxymetholone is an anabolic steroid used for the treatment of types of anemia, such as acquired aplastic anemia, congenital aplastic anemia, myelofibrosis, and the hypoplastic anemias.	May cause cancer.The uncontrolled misuse of oxymetholone can lead to a large variety of detrimental effects, the most often reported of which are cardiovascular events.	Small Molecule																																178°C to 180°C		5.21 mg/L	1	Yes	3	2	No	4	0	57.53 Å2	38.84 Å3	94.6 m3·mol-1	0	Yes	No	0.0349 mg/mL	3.55	-4	8.87	-0.53	P10275;!P16860	AR;!NPPB	1. Androgen receptor;!2. Natriuretic peptides B
C36H56O6	Not Available	56.3 to 69.5 hours	584.8262	[H][C@]12[C@@H](CC[C@@]1(CC[C@]1(C)[C@]2([H])CC[C@]2([H])[C@@]3(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@]3([H])CC[C@@]12C)C(O)=O)C(C)=C	Solid	Not Available					50050955	65484	CHEMBL404519	403003									457928	175427073				Bevirimat	ZINC000003936686		Bevirimat	Investigational	DB06581	InChI=1S/C36H56O6/c1-21(2)22-12-17-36(30(40)41)19-18-34(8)23(28(22)36)10-11-25-33(7)15-14-26(42-27(37)20-31(3,4)29(38)39)32(5,6)24(33)13-16-35(25,34)9/h22-26,28H,1,10-20H2,2-9H3,(H,38,39)(H,40,41)/t22-,23+,24-,25+,26-,28+,33-,34+,35+,36-/m0/s1	YJEJKUQEXFSVCJ-WRFMNRASSA-N	2		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	3.5488 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	5	2	Yes	5	-2	100.9 Å2	67.97 Å3	161.75 m3·mol-1	7	No	No	0.000135 mg/mL	8	-6.6	4.16	-7.1	P04585	gag-pol	1. Gag-Pol polyprotein
C28H35NO4	Not Available	Not Available	449.5818	[H]\C(=N/O)C1=CC=C(C=C1)[C@@]1([H])C[C@@]2(C)[C@@]([H])(CC[C@]2(COC)OC)[C@]2([H])CCC3=CC(=O)CCC3=C12	Solid	Not Available							CHEMBL267431	7851660						AS0								Asoprisnil	ZINC000003936191		Asoprisnil	Investigational	DB06680	InChI=1S/C28H35NO4/c1-27-15-24(19-6-4-18(5-7-19)16-29-31)26-22-11-9-21(30)14-20(22)8-10-23(26)25(27)12-13-28(27,33-3)17-32-2/h4-7,14,16,23-25,31H,8-13,15,17H2,1-3H3/b29-16+/t23-,24+,25-,27-,28+/m0/s1	GJMNAFGEUJBOCE-MEQIQULJSA-N	3		Not Available	Small Molecule																																			1	No	5	1	No	5	-1	68.12 Å2	51.46 Å3	131.27 m3·mol-1	5	Yes	No	0.00211 mg/mL	4.28	-5.3	7.39	2.56	P06401	PGR	1. Progesterone receptor
C20H30O2	Not Available	6-8 hours	302.451	[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	Not Available	P20813;!P08684;!P11511	CYP2B6;!CYP3A4;!CYP19A1	1. Cytochrome P450 2B6;!2. Cytochrome P450 3A4;!3. Cytochrome P450 19A1		50410531	27436	CHEMBL1395	5788			HMDB0015655	C07198	D00408			PA165958383	6010	99443262		6904		Methyltestosterone	ZINC000003814422	Covaryx, Methitest	Methyltestosterone	Approved	DB06710	InChI=1S/C20H30O2/c1-18-9-6-14(21)12-13(18)4-5-15-16(18)7-10-19(2)17(15)8-11-20(19,3)22/h12,15-17,22H,4-11H2,1-3H3/t15-,16+,17+,18+,19+,20+/m1/s1	GCKMFJBGXUYNAG-HLXURNFRSA-N	2	Methyltestosterone is a synthetic anabolic steroid used for the replacement therapy in conditions associated with testosterone deficiencies in males, such as hypogonadism, and treatment of advancing inoperable metastatic breast cancer in females.	Side effects include amnesia, anxiety, discolored hair, dizziness, dry skin, hirsutism, hostility, impaired urination, paresthesia, penis disorder, peripheral edema, sweating, and vasodilation.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.0516 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.36		163 °C		33.9 mg/L (at 25 °C)	1	Yes	2	1	No	4	0	37.3 Å2	35.85 Å3	89.07 m3·mol-1	0	Yes	Yes	0.0139 mg/mL	3.65	-4.3	18.52	-0.53	P10275;!P03372	AR;!ESR1	1. Androgen receptor;!2. Estrogen receptor alpha
C20H24O3	Not Available	Not Available	312.409	CC(C)(C)C1CCC(CC1)C1=C(O)C(=O)C2=CC=CC=C2C1=O	Solid	Not Available								13749867									146797	347827788					ZINC000005114256		BW-A 58C	Experimental	DB06740	InChI=1S/C20H24O3/c1-20(2,3)13-10-8-12(9-11-13)16-17(21)14-6-4-5-7-15(14)18(22)19(16)23/h4-7,12-13,23H,8-11H2,1-3H3	NWCVRXADYNRXCT-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	Yes	3	1	No	3	-1	54.37 Å2	35.62 Å3	91.83 m3·mol-1	2	Yes	No	0.0115 mg/mL	4.29	-4.4	5.95	-5.1			
C23H32O4	Not Available	Not Available	372.505	[H][C@@]12CC[C@H](C(=O)COC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			34671	CHEMBL1200542	5737				C14554	D03698							258333		Desoxycorticosterone_acetate	ZINC000004428527		Desoxycorticosterone acetate	Approved	DB06780	InChI=1S/C23H32O4/c1-14(24)27-13-21(26)20-7-6-18-17-5-4-15-12-16(25)8-10-22(15,2)19(17)9-11-23(18,20)3/h12,17-20H,4-11,13H2,1-3H3/t17-,18-,19-,20+,22-,23-/m0/s1	VPGRYOFKCNULNK-ACXQXYJUSA-N			Not Available	Small Molecule																																			1	Yes	3	0	No	4	0	60.44 Å2	42.13 Å3	103.56 m3·mol-1	4	Yes	No	0.00502 mg/mL	3.77	-4.9	17.17	-4.8	P08235	NR3C2	1. Mineralocorticoid receptor
C27H34F2O7	Not Available	Not Available	508.5515	[H][C@@]12CC[C@](OC(=O)CCC)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			31485	CHEMBL1201749	391990	Drugs.com Drug Page		HMDB0061149	C12695	D01266		PDRhealth Drug Page	PA165958405	443936	99443292	RxList Drug Page	23043		Difluprednate	ZINC000004212945	Durezol	Difluprednate	Approved	DB06781	InChI=1S/C27H34F2O7/c1-5-6-23(34)36-26(22(33)14-35-15(2)30)10-8-17-18-12-20(28)19-11-16(31)7-9-24(19,3)27(18,29)21(32)13-25(17,26)4/h7,9,11,17-18,20-21,32H,5-6,8,10,12-14H2,1-4H3/t17-,18-,20-,21-,24-,25-,26-,27-/m0/s1	WYQPLTPSGFELIB-JTQPXKBDSA-N	4	Difluprednate is a topical corticosteroid used for the symptomatic treatment of inflammation and pain associated with ocular surgery.	Preclinical pharmacokinetic and toxicity studies have established that difluprednate ophthalmic emulsion 0.05% given 4 times a day is not toxic to the eye.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.1368 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							191-194			1	No	5	1	Yes	4	0	106.97 Å2	51.45 Å3	125.38 m3·mol-1	8	No	No	0.0097 mg/mL	3	-4.7	13.6	-3.4	P04150	NR3C1	1. Glucocorticoid receptor
C24H32ClFO5	Not Available	Not Available	454.96	[H][C@@]12C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Liquid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4		50240097	31663	CHEMBL1200845	391997	Drugs.com Drug Page				D01308		PDRhealth Drug Page		443943	347827796	RxList Drug Page	5084		Halcinonide	ZINC000004213474	Halog	Halcinonide	Approved, Investigational, Withdrawn	DB06786	InChI=1S/C24H32ClFO5/c1-20(2)30-19-10-16-15-6-5-13-9-14(27)7-8-21(13,3)23(15,26)17(28)11-22(16,4)24(19,31-20)18(29)12-25/h9,15-17,19,28H,5-8,10-12H2,1-4H3/t15-,16-,17-,19+,21-,22-,23-,24+/m0/s1	MUQNGPZZQDCDFT-JNQJZLCISA-N		Halcinonide is a corticosteroid used for the management and symptomatic relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.	Systemic absorption of topical corticosteroids has produced reversible hypothalamicpituitary-adrenal (HPA) axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria in some patients. Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings.	Small Molecule																																276-277			1	Yes	5	1	No	5	0	72.83 Å2	46.61 Å3	113.55 m3·mol-1	2	Yes	No	0.0112 mg/mL	3.3	-4.6	13.63	-3.4	Q99835	SMO	1. Smoothened homolog
C27H40O4	Clearance is highly variable from patient to patient. (3)	Half-life = 16 days (±6 days). (3)	428.6041	[H][C@@]12CC[C@](OC(=O)CCCCC)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	Hydroxyprogesterone caproate has a high volume of distribution. (3)	P08684;!P20815;!P33261	CYP3A4;!CYP3A5;!CYP2C19	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5;!3. Cytochrome P450 2C19		70293	5812	CHEMBL1200848	148552	Drugs.com Drug Page			C08148	D00949		PDRhealth Drug Page		169870	310264886	RxList Drug Page	12488		Hydroxyprogesterone_caproate	ZINC000004083606	Makena	Hydroxyprogesterone caproate	Approved, Investigational	DB06789	InChI=1S/C27H40O4/c1-5-6-7-8-24(30)31-27(18(2)28)16-13-23-21-10-9-19-17-20(29)11-14-25(19,3)22(21)12-15-26(23,27)4/h17,21-23H,5-16H2,1-4H3/t21-,22+,23+,25+,26+,27+/m1/s1	DOMWKUIIPQCAJU-LJHIYBGHSA-N	4	Hydroxyprogesterone caproate is a synthetic progestin used for the prevention of spontaneous preterm births in singleton pregnancies in women who have previously had a spontaneous preterm birth.	Injection site pain is the most common adverse effect associated with hydroxyprogesterone caproate. Other commonly reported adverse effects include: injection site swelling, urticaria, pruritus, injection site pruritus, nausea, injection site nodule, and diarrhea. (4)	Small Molecule																																119-121			1	No	3	0	Yes	4	0	60.44 Å2	50.28 Å3	121.69 m3·mol-1	7	No	No	0.000866 mg/mL	5.88	-5.7	17.75	-4.8	P06401	PGR	1. Progesterone receptor
C19H28O2	Not Available	Not Available	288.4244	[H][C@@]1(O)CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)CC[C@]4(C)[C@@]3([H])CC[C@]12C	Solid	Not Available					50410492	42534	CHEMBL196228	9789			HMDB0000628			FFA			10204	99444239				Epitestosterone	ZINC000004538008		Epitestosterone	Experimental	DB07768	InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-17,21H,3-10H2,1-2H3/t14-,15-,16-,17+,18-,19-/m0/s1	MUMGGOZAMZWBJJ-KZYORJDKSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.6259 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	1	No	4	0	37.3 Å2	33.93 Å3	84.43 m3·mol-1	0	Yes	Yes	0.0333 mg/mL	3.37	-3.9	18.52	-0.88	Q04828;!P52895	AKR1C1;!AKR1C2	1. Aldo-keto reductase family 1 member C1;!2. Aldo-keto reductase family 1 member C2
C27H32O4	Not Available	Not Available	420.5406	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC=C4C=C(CC[C@]4(C)[C@@]3([H])CC[C@]12C)C(O)=O)C(=O)C1=CC=C(O)C=C1	Solid	Not Available								8020773						MUF			9845059	99444691					ZINC000003803450		(8alpha,10alpha,13alpha,17beta)-17-[(4-hydroxyphenyl)carbonyl]androsta-3,5-diene-3-carboxylic acid	Experimental	DB08220	InChI=1S/C27H32O4/c1-26-13-11-17(25(30)31)15-18(26)5-8-20-21-9-10-23(27(21,2)14-12-22(20)26)24(29)16-3-6-19(28)7-4-16/h3-7,15,20-23,28H,8-14H2,1-2H3,(H,30,31)/t20-,21-,22-,23+,26-,27-/m0/s1	RPNNXCYIESWDSC-JRZBRKEGSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.6597 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	2	No	5	-1	74.6 Å2	47.84 Å3	121.45 m3·mol-1	3	No	No	0.00264 mg/mL	5.16	-5.2	4.35	-6.9	Q15788;!Q96RI1	NCOA1;!NR1H4	1. Nuclear receptor coactivator 1;!2. Bile acid receptor
C24H27NO7	Not Available	Not Available	441.4737	[H][C@]12C[C@@H]3O[C@@]1(C)C[C@@]1(C2)C=CC(=O)[C@@](C)(CCC(=O)NC2=C(O)C(=CC=C2O)C(O)=O)[C@]31[H]	Solid	Not Available						68236	CHEMBL411278	5257055						PMN			6857724	99444878				Platensimycin	ZINC000029050726		Platensimycin	Experimental	DB08407	InChI=1S/C24H27NO7/c1-22(7-6-17(28)25-18-14(26)4-3-13(19(18)29)21(30)31)16(27)5-8-24-10-12-9-15(20(22)24)32-23(12,2)11-24/h3-5,8,12,15,20,26,29H,6-7,9-11H2,1-2H3,(H,25,28)(H,30,31)/t12-,15+,20+,22-,23+,24+/m1/s1	CSOMAHTTWTVBFL-OFBLZTNGSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	3.0222 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	7	4	No	5	-1	133.16 Å2	44.81 Å3	116.81 m3·mol-1	5	Yes	No	0.0139 mg/mL	3.24	-4.5	2.96	-3.4	P0AAI5	fabF	1. 3-oxoacyl-[acyl-carrier-protein] synthase 2
C23H32O5	Not Available	Not Available	388.4972	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)OC(=O)CCC(O)=O	Solid	Not Available								106489						TH2			119202	99445090					ZINC000004025723		Testosterone succinate	Experimental	DB08619	InChI=1S/C23H32O5/c1-22-11-9-15(24)13-14(22)3-4-16-17-5-6-19(23(17,2)12-10-18(16)22)28-21(27)8-7-20(25)26/h13,16-19H,3-12H2,1-2H3,(H,25,26)/t16-,17-,18-,19-,22-,23-/m0/s1	CJQNBXFUHQZFOE-VYAQIDIUSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.1662 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	1	No	4	-1	80.67 Å2	43.74 Å3	104.47 m3·mol-1	5	Yes	No	0.00844 mg/mL	3.63	-4.7	4.31	-4.8	P0A3R9	ncsA	1. Neocarzinostatin
C28H35NO3	Mean oral clearance, single oral dose, healthy subject (CL/F) = 76.8 ± 64.0L/h	Mean elimination half-life, single oral dose, healthy subject = 32.4 ± 6.3 hours	433.592	CN(C)C1=CC=C(C=C1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12	Solid	Not Available	P08684;!P05177	CYP3A4;!CYP1A2	1. Cytochrome P450 3A4;!2. Cytochrome P450 1A2			71025	CHEMBL2103846	19349271	Drugs.com Drug Page				D09567				13559281	310264902	RxList Drug Page	1005921		Ulipristal_acetate	ZINC000034089131	Ella, Ellaone, Esmya	Ulipristal	Approved	DB08867	InChI=1S/C28H35NO3/c1-17(30)28(32)14-13-25-23-11-7-19-15-21(31)10-12-22(19)26(23)24(16-27(25,28)2)18-5-8-20(9-6-18)29(3)4/h5-6,8-9,15,23-25,32H,7,10-14,16H2,1-4H3/t23-,24+,25-,27-,28-/m0/s1	HKDLNTKNLJPAIY-WKWWZUSTSA-N	4	Ulipristal is a selective progesterone receptor modulator used for emergency contraception after unprotected intercourse or in a situation where a planned method of contraception has failed.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.6728 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	1	No	5	0	57.61 Å2	49.66 Å3	129.29 m3·mol-1	3	Yes	No	0.00943 mg/mL	4.18	-4.7	12.7	4.89			
C19H26O3	Plasma clearance is approximately 4.2 L/(h kg), when delivered intravenously. In women, following a 500mg dose of formestane, 20% was excreted as glucuronide within the first 24 hours. [1]One long term metabolite (3beta,4alpha-dihydroxy-5alpha-androstan-17-one) can be detected for 90 hours. A longer detection time is possible with more sensitive technology, which may be of utility in sports drug testing. [1]	Terminal plasma elimination half life of 18 minutes, when delivered intravenously. [2]	302.4079	[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=C(O)C(=O)CC[C@]12C	Solid	Vd = 1.8 L/kg; widely distributed to organs and tissues when delivered intravenously. [2]	P08684	CYP3A4	1. Cytochrome P450 3A4		225704	75172	CHEMBL132530	10799	Drugs.com Drug Page				D07260				11273	175427144		15070		Formestane	ZINC000003919580		Formestane	Approved, Investigational, Withdrawn	DB08905	InChI=1S/C19H26O3/c1-18-10-8-15(20)17(22)14(18)4-3-11-12-5-6-16(21)19(12,2)9-7-13(11)18/h11-13,22H,3-10H2,1-2H3/t11-,12-,13-,18+,19-/m0/s1	OSVMTWJCGUFAOD-KZQROQTASA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.6135 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.66		199 - 202	9.31	Insoluble	1	Yes	3	1	No	4	0	54.37 Å2	34.05 Å3	85.57 m3·mol-1	0	Yes	No	0.0578 mg/mL	3.41	-3.7	9.21	-3.7			
C22H30O4	Not Available	Not Available	358.478	[H][C@@]12CC[C@@](O)(CCC(O)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=CC2=CC(=O)CC[C@]12C	Solid	Not Available						50156	CHEMBL1616951	570976	Drugs.com Drug Page								656615	310264973		618970		Potassium_canrenoate	ZINC000003938750		Canrenoic acid	Approved, Withdrawn	DB09015	InChI=1S/C22H30O4/c1-20-9-5-15(23)13-14(20)3-4-16-17(20)6-10-21(2)18(16)7-11-22(21,26)12-8-19(24)25/h3-4,13,16-18,26H,5-12H2,1-2H3,(H,24,25)/t16-,17+,18+,20+,21+,22-/m1/s1	PBKZPPIHUVSDNM-WNHSNXHDSA-N	3	Canrenoic acid is an aldosterone antagonist used in primary hyperaldosteronism and other disorders related to aberrant aldosterone levels.	Not Available	Small Molecule																																165			1	Yes	4	2	No	4	-1	74.6 Å2	40.44 Å3	100.98 m3·mol-1	3	Yes	No	0.0442 mg/mL	2.93	-3.9	4.48	-3.1			
C21H30O4S	Studies have shown that oral or intravenous administration of tixocortol presents a significantly larger clearance rate compared to cortisol of 33.3 L h/kg.4	Tixocortol presents a shorter half-life than cortisol.6	378.53	[H][C@@]12CC[C@](O)(C(=O)CS)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	Studies have shown that oral or intravenous administration of tixocortol presents a significantly larger volume of distribution compared to cortisol of 21.7 L/kg.4						63560		143053									162955	310265018		57257		Tixocortol	ZINC000005138848		Tixocortol	Approved, Withdrawn	DB09091	InChI=1S/C21H30O4S/c1-19-7-5-13(22)9-12(19)3-4-14-15-6-8-21(25,17(24)11-26)20(15,2)10-16(23)18(14)19/h9,14-16,18,23,25-26H,3-8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1	YWDBSCORAARPPF-VWUMJDOOSA-N		Tixocortol is a corticosteroid used for the symptomatic treatment of rhinitis, pharyngitis, and ulcerative colitis.	Diverse studies performed on tixocortol proved that this drug is non-toxic and non-immunosupressive. This low toxicity and abscence of immuno supression gave tixocortol the potential to be a lead for topical or local anti-inflammatory treatments.7 Nevertheless, toxicortol is a potent cutaneous sensitizer, causing a local allergy.3	Small Molecule																													607ºC at 760 mmHg	4.48		50-55ºC		Insoluble	1	Yes	4	3	No	4	0	74.6 Å2	41.96 Å3	103.53 m3·mol-1	2	Yes	No	0.0428 mg/mL	2.32	-4	9.57	-2.8	P04150;!Q92769	NR3C1;!HDAC2	1. Glucocorticoid receptor;!2. Histone deacetylase 2
C20H25NO2	The metabolic clearance rate from serum (Cl/F) is 64 mL/min 5.	Elimination half-life of dienogest is around 9-10 hours. The half-life of urinary metabolites excretion is 14 hours 5.	311.425	[H][C@@]12CC[C@@](O)(CC#N)[C@@]1(C)CCC1=C3CCC(=O)C=C3CC[C@@]21[H]	Solid	The apparent volume of distribution (Vd/F) of dienogest is 40 L 5.	P08684	CYP3A4	1. Cytochrome P450 3A4			70708	CHEMBL1201864	62093									68861	310265039		22968		Dienogest	ZINC000004215629	Natazia, Visanne	Dienogest	Approved	DB09123	InChI=1S/C20H25NO2/c1-19-8-6-16-15-5-3-14(22)12-13(15)2-4-17(16)18(19)7-9-20(19,23)10-11-21/h12,17-18,23H,2-10H2,1H3/t17-,18+,19+,20-/m1/s1	AZFLJNIPTRTECV-FUMNGEBKSA-N	4	Dienogest is an oral progestin used for the treatment of endometriosis as monotherapy or contraception in combination with ethinylestradiol.	Oral LD50 in mouse is 4 mg/kg MSDS. In a long-term carcinogenicity study involving rats and mice, exposure of 10 times the dose of maximum recommended clinical dose of dienogest resulted in increased incidences of pituitary adenomas, fibroepithelial mammary tumours, stromal polyps of the uterus and malignant lymphoma 6. These tumors are thought to arise from marked species differences in the optimal oestrogen:progestogen ratio for reproductive function. In rat liver foci assay, dienogest did not induce tumor promotion activity 6. Dienogest does not display genotoxic potential.	Small Molecule																																210-218		Practically insoluble	1	Yes	3	1	No	4	0	61.09 Å2	35.4 Å3	90.19 m3·mol-1	1	Yes	No	0.0761 mg/mL	2.31	-3.6	13.78	-3.3	P06401;!P10275	PGR;!AR	1. Progesterone receptor;!2. Androgen receptor
C23H32O2	Not Available	The half-life of medrogestone is reported to be of 4 hours.5	340.507	[H][C@@]12CC[C@](C)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			135446	CHEMBL2106825	8125459									9949848	310265040		6690		Medrogestone	ZINC000004216820		Medrogestone	Approved, Withdrawn	DB09124	InChI=1S/C23H32O2/c1-14-12-17-18(21(3)9-6-16(25)13-20(14)21)7-11-23(5)19(17)8-10-22(23,4)15(2)24/h12-13,17-19H,6-11H2,1-5H3/t17-,18+,19+,21-,22-,23+/m1/s1	HCFSGRMEEXUOSS-JXEXPEPMSA-N		Medrogestone is a progestin used as an adjunct to control secondary amenorrhea and dysfunctional bleeding in adolescent and adult females, and treat endometrial shedding in menopausal women.	There were reports of increased urinary flow rates and total micturition volumes as well as sexual dysfunction and hyperglycemia.4	Small Molecule																													467.17ºC at 760 mmHg	4.45		144-146ºC		5.34e-06 mol/L	1	Yes	2	0	No	4	0	34.14 Å2	40.37 Å3	102.6 m3·mol-1	1	Yes	Yes	0.00404 mg/mL	4.59	-4.9	19.18	-4.9	P06401	PGR	1. Progesterone receptor
C21H27FO5	Not Available	Not Available	378.44	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			34474	CHEMBL1200774	5665				C14618	D04227							4497		Fluprednisolone	ZINC000003875362		Fluprednisolone	Approved	DB09378	InChI=1S/C21H27FO5/c1-19-5-3-11(24)7-14(19)15(22)8-12-13-4-6-21(27,17(26)10-23)20(13,2)9-16(25)18(12)19/h3,5,7,12-13,15-16,18,23,25,27H,4,6,8-10H2,1-2H3/t12-,13-,15-,16-,18+,19-,20-,21-/m0/s1	MYYIMZRZXIQBGI-HVIRSNARSA-N			Not Available	Small Molecule																																			1	Yes	5	3	No	4	0	94.83 Å2	38.9 Å3	98.32 m3·mol-1	2	Yes	No	0.261 mg/mL	0.93	-3.2	12.58	-2.9			
C28H34O8S2	Ecamsule is used topically, it not absorbed or metabolized.	Ecamsule is not absorbed and has no reported half life data.	562.69	CC1(C)C2CCC1(CS(O)(=O)=O)C(=O)C2=CC1=CC=C(C=C2C3CCC(CS(O)(=O)=O)(C2=O)C3(C)C)C=C1	Not Available	Ecamsule is intended for topical application and has no volume of distribution.						135830	CHEMBL3989850	28534218									9915879	347827874		1544124		Ecamsule			Ecamsule	Approved	DB09534	InChI=1S/C28H34O8S2/c1-25(2)21-9-11-27(25,15-37(31,32)33)23(29)19(21)13-17-5-7-18(8-6-17)14-20-22-10-12-28(24(20)30,26(22,3)4)16-38(34,35)36/h5-8,13-14,21-22H,9-12,15-16H2,1-4H3,(H,31,32,33)(H,34,35,36)	HEAHZSUCFKFERC-UHFFFAOYSA-N	4	Ecamsule is a sunscreen agent found in sunscreens that absorbs UV rays.	The most common reactions were dermatitis, dry skin, acne, itching, redness and skin discomfort.	Small Molecule																																			1	No	8	2	Yes	5	-2	142.88 Å2	59.64 Å3	143.56 m3·mol-1	6	No	No	0.00571 mg/mL	4.1	-5	-1	-5			
C21H26O2	Not Available	Not Available	310.437	[H][C@@]12CC[C@@](O)(CC=C)[C@@]1(C)C=CC1=C3CCC(=O)C=C3CC[C@@]21[H]	Not Available	Not Available							CHEMBL1315492	8216634					D02840							1314612		Altrenogest	ZINC000004214784		Altrenogest	Vet approved	DB11372	InChI=1S/C21H26O2/c1-3-10-21(23)12-9-19-18-6-4-14-13-15(22)5-7-16(14)17(18)8-11-20(19,21)2/h3,8,11,13,18-19,23H,1,4-7,9-10,12H2,2H3/t18-,19+,20+,21+/m1/s1	VWAUPFMBXBWEQY-ANULTFPQSA-N			Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	36.06 Å3	95.46 m3·mol-1	2	Yes	Yes	0.0301 mg/mL	3.2	-4	18.4	-0.18			
C20H30O2	Not Available	Not Available	302.458	[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3C[C@@H](C)[C@@]21[H]	Not Available	Not Available					26258	34849	CHEMBL425863	220460				C14255	D05025									Mibolerone	ZINC000004216936		Mibolerone	Vet approved	DB11429	InChI=1S/C20H30O2/c1-12-10-13-11-14(21)4-5-15(13)16-6-8-19(2)17(18(12)16)7-9-20(19,3)22/h11-12,15-18,22H,4-10H2,1-3H3/t12-,15+,16-,17+,18-,19+,20+/m1/s1	PTQMMNYJKCSPET-OMHQDGTGSA-N			Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	35.86 Å3	89.14 m3·mol-1	0	Yes	Yes	0.0194 mg/mL	3.63	-4.2	18.34	-0.53	P10275	AR	1. Androgen receptor
C23H32O4	Not Available	Not Available	372.505	[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)C[C@H](C)[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	Not Available	Not Available							CHEMBL2104744	7996587					D05210									Norgestomet	ZINC000004217176		Norgestomet	Vet approved	DB11440	InChI=1S/C23H32O4/c1-13-12-22(4)20(9-10-23(22,14(2)24)27-15(3)25)19-7-5-16-11-17(26)6-8-18(16)21(13)19/h11,13,18-21H,5-10,12H2,1-4H3/t13-,18-,19-,20-,21+,22-,23-/m0/s1	IWSXBCZCPVUWHT-VIFKTUCRSA-N			Not Available	Small Molecule																																			1	Yes	3	0	No	4	0	60.44 Å2	42.06 Å3	103.33 m3·mol-1	3	Yes	No	0.00489 mg/mL	3.83	-4.9	17.68	-4.7			
C28H32FNO6	Not Available	Not Available	497.563	[H][C@@]12C[C@@H](C)[C@](O)(C(=O)COC(=O)C3=CC=NC=C3)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5				CHEMBL3186453	15881												3265		Dexamethasone_isonicotinate	ZINC000004212878		Dexamethasone isonicotinate	Vet approved	DB11487	InChI=1S/C28H32FNO6/c1-16-12-21-20-5-4-18-13-19(31)6-9-25(18,2)27(20,29)22(32)14-26(21,3)28(16,35)23(33)15-36-24(34)17-7-10-30-11-8-17/h6-11,13,16,20-22,32,35H,4-5,12,14-15H2,1-3H3/t16-,20+,21+,22+,25+,26+,27+,28+/m1/s1	BQTXJHAJMDGOFI-NJLPOHDGSA-N			Not Available	Small Molecule																																			1	No	6	2	No	5	0	113.79 Å2	51.74 Å3	130.16 m3·mol-1	5	Yes	No	0.0254 mg/mL	2.96	-4.3	12.44	3.41			
C21H27FO5	Not Available	Not Available	378.44	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@]([H])(O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Not Available	Not Available						34511		113134				C14484								1546449		Isoflupredone	ZINC000003876095		Isoflupredone	Vet approved	DB11522	InChI=1S/C21H27FO5/c1-18-7-5-13(24)9-12(18)3-4-15-14-6-8-20(27,17(26)11-23)19(14,2)10-16(25)21(15,18)22/h5,7,9,14-16,23,25,27H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,18-,19-,20-,21-/m0/s1	WAIJIHDWAKJCBX-BULBTXNYSA-N			Not Available	Small Molecule																																			1	Yes	5	3	No	4	0	94.83 Å2	38.88 Å3	98.02 m3·mol-1	2	Yes	No	0.0811 mg/mL	1.32	-3.7	12.55	-3.3			
C23H30O3	Not Available	Not Available	354.49	[H][C@@]12CC(=C)[C@](O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4					8082266												1537799		Melengestrol	ZINC000038610965		Melengestrol	Vet approved	DB11529	InChI=1S/C23H30O3/c1-13-10-17-18(21(4)8-6-16(25)12-19(13)21)7-9-22(5)20(17)11-14(2)23(22,26)15(3)24/h10,12,17-18,20,26H,2,6-9,11H2,1,3-5H3/t17-,18+,20+,21-,22+,23+/m1/s1	OKHAOBQKCCIRLO-IBVJIVQJSA-N			Not Available	Small Molecule																																			1	Yes	3	1	No	4	0	54.37 Å2	40.91 Å3	103.68 m3·mol-1	1	Yes	No	0.00748 mg/mL	3.38	-4.7	12.21	-4			
C21H28O3	Not Available	Not Available	328.452	CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			135993	CHEMBL2105722	62024					D07222							31930		Nomegestrol	ZINC000004217164		Nomegestrol	Approved	DB11636	InChI=1S/C21H28O3/c1-12-10-18-16(15-5-4-14(23)11-17(12)15)6-8-20(3)19(18)7-9-21(20,24)13(2)22/h10-11,15-16,18-19,24H,4-9H2,1-3H3/t15-,16-,18-,19+,20+,21+/m1/s1	KZUIYQJTUIACIG-YBZCJVABSA-N			Not Available	Small Molecule																																			1	Yes	3	1	No	4	0	54.37 Å2	37.69 Å3	95.03 m3·mol-1	1	Yes	No	0.0122 mg/mL	2.98	-4.4	12.7	-3.8			
C22H28ClFO4	Not Available	Not Available	410.907	[H][C@@]12C[C@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Not Available	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5			205919	CHEMBL1201362	4470588			HMDB0015148						5311051	347828107		2590		Clobetasol	ZINC000026892643		Clobetasol	Approved, Experimental, Investigational	DB11750	InChI=1S/C22H28ClFO4/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,24)17(26)10-20(16,3)22(12,28)18(27)11-23/h6-7,9,12,15-17,26,28H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,17-,19-,20-,21-,22-/m0/s1	FCSHDIVRCWTZOX-DVTGEIKXSA-N	3		Not Available	Small Molecule																																			1	Yes	4	2	No	4	0	74.6 Å2	41.95 Å3	105.54 m3·mol-1	2	Yes	No	0.0142 mg/mL	3.04	-4.5	12.47	-3.4			
C21H28O4	Not Available	Not Available	344.451	C[C@]12CC=C3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO	Not Available	Not Available							CHEMBL2348782	5428328									7074810	347828387				Anecortave_acetate	ZINC000003927675		Anecortave	Investigational	DB12081	InChI=1S/C21H28O4/c1-19-8-5-14(23)11-13(19)3-4-15-16(19)6-9-20(2)17(15)7-10-21(20,25)18(24)12-22/h6,11,15,17,22,25H,3-5,7-10,12H2,1-2H3/t15-,17+,19+,20+,21+/m1/s1	BCFCRXOJOFDUMZ-ONKRVSLGSA-N			Not Available	Small Molecule																																			1	Yes	4	2	No	4	0	74.6 Å2	38.24 Å3	96.66 m3·mol-1	2	Yes	No	0.0334 mg/mL	2.18	-4	12.58	-3.3			
C22H32O2	Not Available	Not Available	328.4883	CC(=O)OC\C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C	Not Available	Not Available								8421459			HMDB0035185						10245972	347828413					ZINC000014685555		Zuretinol acetate	Investigational	DB12112	InChI=1S/C22H32O2/c1-17(9-7-10-18(2)14-16-24-20(4)23)12-13-21-19(3)11-8-15-22(21,5)6/h7,9-10,12-14H,8,11,15-16H2,1-6H3/b10-7+,13-12+,17-9-,18-14+	QGNJRVVDBSJHIZ-AQDFTDIISA-N	2		Not Available	Small Molecule																																			1	Yes	1	0	No	1	0	26.3 Å2	40.5 Å3	107.07 m3·mol-1	7	No	Yes	0.00238 mg/mL	5.14	-5.1		-7			
C25H36O4	Not Available	Not Available	400.5509	[H][C@@]12CC(=CC[C@@]1([H])C(C)(C)OC1=CC(=CC(O)=C21)C(C)(C)CCCCCC)C(O)=O	Not Available	Not Available					50005920		CHEMBL456341	2340729						AJA			3083542	347828478				Ajulemic_acid	ZINC000001905712		Ajulemic acid	Investigational	DB12193	InChI=1S/C25H36O4/c1-6-7-8-9-12-24(2,3)17-14-20(26)22-18-13-16(23(27)28)10-11-19(18)25(4,5)29-21(22)15-17/h10,14-15,18-19,26H,6-9,11-13H2,1-5H3,(H,27,28)/t18-,19-/m1/s1	YCHYFHOSGQABSW-RTBURBONSA-N	2		Not Available	Small Molecule																																			1	No	4	2	Yes	3	-1	66.76 Å2	47.46 Å3	116.68 m3·mol-1	7	No	No	0.00125 mg/mL	6.61	-5.5	3.88	-4.9			
C20H26O2	Not Available	Not Available	298.426	CC1=CC(=O)C=C2CC[C@H]3[C@@H]4CCC(=O)[C@@]4(C)CC[C@@H]3[C@@]12C	Not Available	Not Available							CHEMBL2105987	51438									57050	347828479				Atamestane	ZINC000004214890		Atamestane	Investigational	DB12194	InChI=1S/C20H26O2/c1-12-10-14(21)11-13-4-5-15-16-6-7-18(22)19(16,2)9-8-17(15)20(12,13)3/h10-11,15-17H,4-9H2,1-3H3/t15-,16-,17-,19-,20-/m0/s1	PEPMWUSGRKINHX-TXTPUJOMSA-N	3		Not Available	Small Molecule																																			1	Yes	2	0	No	4	0	34.14 Å2	34.42 Å3	88.98 m3·mol-1	0	Yes	Yes	0.0156 mg/mL	4.17	-4.3	18.79	-4.9			
C22H28O3	Not Available	Not Available	340.4559	[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=CC2=CC(=O)CC[C@]12C	Not Available	Not Available						135445	CHEMBL1463345	13192			HMDB0003033						13789	347828500		1982		Canrenone	ZINC000003881648		Canrenone	Investigational	DB12221	InChI=1S/C22H28O3/c1-20-9-5-15(23)13-14(20)3-4-16-17(20)6-10-21(2)18(16)7-11-22(21)12-8-19(24)25-22/h3-4,13,16-18H,5-12H2,1-2H3/t16-,17+,18+,20+,21+,22-/m1/s1	UJVLDDZCTMKXJK-WNHSNXHDSA-N	4	Canrenone is an antimineralocorticoid and active metabolite of spironolactone used in the treatment of primary hyperaldosteronism and edematous states caused by secondary hyperaldosteronism (e.g. heart failure).	Not Available	Small Molecule																																			1	Yes	2	0	No	5	0	43.37 Å2	38.67 Å3	97.48 m3·mol-1	0	Yes	No	0.0042 mg/mL	3.6	-4.9		-4.8			
C20H24O7	Not Available	Not Available	376.405	CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@@]3(O)C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O	Not Available	Not Available							CHEMBL3358841	8492847									10317383	347828527					ZINC000043203993		PG-701	Investigational	DB12252	InChI=1S/C20H24O7/c1-8(2)18-12(26-18)13-20(27-13)16(3)5-4-9-10(7-24-14(9)21)17(16,23)6-11-19(20,25-11)15(18)22/h8,11-13,15,22-23H,4-7H2,1-3H3/t11-,12-,13-,15+,16-,17+,18-,19+,20+/m0/s1	OKRSVUYYCJPECG-LFGMFVMYSA-N	2		Not Available	Small Molecule																																			1	Yes	6	2	No	7	0	104.35 Å2	37.8 Å3	88.59 m3·mol-1	1	Yes	No	3.04 mg/mL	0.25	-2.1	12.07	-3.4			
C31H39F2NO6	Not Available	Not Available	559.651	C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)C1C(C)(C)C1(C)C)C(=O)OCC#N	Not Available	Not Available								9551309									11376392	347828585							GW-870086	Investigational	DB12322	InChI=1S/C31H39F2NO6/c1-16-12-18-19-14-21(32)20-13-17(35)8-9-28(20,6)30(19,33)22(36)15-29(18,7)31(16,25(38)39-11-10-34)40-24(37)23-26(2,3)27(23,4)5/h8-9,13,16,18-19,21-23,36H,11-12,14-15H2,1-7H3/t16-,18+,19+,21+,22+,28+,29+,30+,31+/m1/s1	WUBKGTSFJSEIEM-NSHBDUGJSA-N	2		Not Available	Small Molecule																																			1	No	5	1	Yes	5	0	113.69 Å2	57.69 Å3	141.49 m3·mol-1	6	No	No	0.0084 mg/mL	3.91	-4.8	13.56	-3.4			
C26H32N2O	Not Available	Not Available	388.5451	[H][C@@]12CC=C(N3C=NC4=CC=CC=C34)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C	Not Available	Not Available					50435990		CHEMBL2105738	9363493						TOK			11188409	347828659				Galeterone	ZINC000006718442		Galeterone	Investigational	DB12415	InChI=1S/C26H32N2O/c1-25-13-11-18(29)15-17(25)7-8-19-20-9-10-24(26(20,2)14-12-21(19)25)28-16-27-22-5-3-4-6-23(22)28/h3-7,10,16,18-21,29H,8-9,11-15H2,1-2H3/t18-,19-,20-,21-,25-,26-/m0/s1	PAFKTGFSEFKSQG-PAASFTFBSA-N	2		Not Available	Small Molecule																																			1	Yes	2	1	No	6	0	38.05 Å2	46.66 Å3	118.58 m3·mol-1	1	Yes	Yes	0.00219 mg/mL	4.47	-5.2	18.2	4.97			
C44H67N5O4	Clearance values of 53.6 L/h and 56.1 L/h have been reported.7	The elimination half life of ibrexafungerp is approximately 20 hours.7,9	730.051	[H][C@]12CC[C@@]3([H])[C@@]4(C)COC[C@@]3(C[C@H]([C@@H]4OC[C@](C)(N)C(C)(C)C)N3N=CN=C3C3=CC=NC=C3)C1=CC[C@@]1(C)[C@H](C(O)=O)[C@](C)(CC[C@]21C)[C@H](C)C(C)C	Solid	The volume of distribution at steady state is approximately 600 L.9	P08684;!BE0009758;!BE0009567;!P10632	CYP3A4;!;!;!CYP2C8	1. Cytochrome P450 3A4;!2. UDP-glucuronosyltransferases (UGTs) (Protein Group);!3. Sulfotransferase (Protein Group);!4. Cytochrome P450 2C8				CHEMBL4297513	64873335									46871657	347828709		2560213		Ibrexafungerp		Brexafemme	Ibrexafungerp	Approved, Investigational	DB12471	InChI=1S/C44H67N5O4/c1-27(2)28(3)39(7)18-19-41(9)30-12-13-33-40(8)23-52-25-44(33,31(30)14-17-42(41,10)34(39)37(50)51)22-32(35(40)53-24-43(11,45)38(4,5)6)49-36(47-26-48-49)29-15-20-46-21-16-29/h14-16,20-21,26-28,30,32-35H,12-13,17-19,22-25,45H2,1-11H3,(H,50,51)/t28-,30+,32-,33+,34-,35+,39-,40-,41-,42+,43+,44+/m1/s1	BODYFEUFKHPRCK-ZCZMVWJSSA-N	3	Ibrexafungerp is a triterpene antifungal indicated in the treatment of vulvovaginal candidiasis in post-menarchal patients.	Data regarding overdoses of ibrexafungerp are not readily available, however patients did take higher than recommended doses in clinical trials without significant adverse effects.9 Patients experiencing an overdose of ibrexafungerp may experience and increased risk and severity of adverse effects. Patients should be treated with symptomatic and supportive measures.9	Small Molecule																																	2.4, 5.5, 9.0		1	No	8	2	Yes	7	0	125.38 Å2	84.64 Å3	230.85 m3·mol-1	9	No	No	0.000346 mg/mL	4.9	-6.3	4.39	9.75	P40989;!P06780	GSC2;!RHO1	1. 1,3-beta-glucan synthase component GSC2;!2. GTP-binding protein RHO1
C30H48O3	Not Available	Not Available	456.711	[H]OC(=O)[C@]12CC[C@@]([H])(C(C)=C)[C@]1([H])[C@@]1([H])CC[C@]3([H])[C@@]4(C)CC[C@]([H])(O[H])C(C)(C)[C@]4([H])CC[C@@]3(C)[C@]1(C)CC2	Not Available	Not Available					23208	3087	CHEMBL269277	58496			HMDB0030094	C08619					64971	347828718					ZINC000004097714		Betulinic Acid	Approved, Investigational	DB12480	InChI=1S/C30H48O3/c1-18(2)19-10-15-30(25(32)33)17-16-28(6)20(24(19)30)8-9-22-27(5)13-12-23(31)26(3,4)21(27)11-14-29(22,28)7/h19-24,31H,1,8-17H2,2-7H3,(H,32,33)/t19-,20+,21-,22+,23-,24+,27-,28+,29+,30-/m0/s1	QGJZLNKBHJESQX-FZFNOLFKSA-N	3		Not Available	Small Molecule																																			1	No	3	2	No	5	-1	57.53 Å2	54.64 Å3	132.63 m3·mol-1	2	No	No	0.000204 mg/mL	6.64	-6.4	4.75	-0.84			
C24H34O5	There is limited information on clearance of clascoterone.10	There is limited information on the half life of clascoterone.10	402.531	[H][C@@]12CC[C@](OC(=O)CC)(C(=O)CO)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	There is no information available on the volume of distribution.	P05177;!P20813;!P10632;!P11712;!P33261;!P10635;!P05181;!P08684	CYP1A2;!CYP2B6;!CYP2C8;!CYP2C9;!CYP2C19;!CYP2D6;!CYP2E1;!CYP3A4	1. Cytochrome P450 1A2;!2. Cytochrome P450 2B6;!3. Cytochrome P450 2C8;!4. Cytochrome P450 2C9;!5. Cytochrome P450 2C19;!6. Cytochrome P450 2D6;!7. Cytochrome P450 2E1;!8. Cytochrome P450 3A4				CHEMBL3590187	9924713									11750009	347828732		2474340		Clascoterone	ZINC000006716459	Winlevi	Clascoterone	Approved, Investigational	DB12499	InChI=1S/C24H34O5/c1-4-21(28)29-24(20(27)14-25)12-9-19-17-6-5-15-13-16(26)7-10-22(15,2)18(17)8-11-23(19,24)3/h13,17-19,25H,4-12,14H2,1-3H3/t17-,18+,19+,22+,23+,24+/m1/s1	GPNHMOZDMYNCPO-PDUMRIMRSA-N	3	Clascoterone is an androgen receptor antagonist used for the topical treatment of acne vulgaris in patients 12 years of age and older.	There is no information available on the toxicity profile of clascoterone, such as LD50 and overdose in humans.	Small Molecule																																			1	Yes	4	1	No	4	0	80.67 Å2	44.86 Å3	109.59 m3·mol-1	5	Yes	No	0.00753 mg/mL	3.73	-4.7	13.78	-3.3	P10275	AR	1. Androgen receptor
C33H44F2N2O3	Not Available	Not Available	554.723	CC(F)(F)C(=O)N[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2	Not Available	Not Available								34980948									71811910	347828744				Omaveloxolone	ZINC000144682962		Omaveloxolone	Investigational	DB12513	InChI=1S/C33H44F2N2O3/c1-27(2)11-13-33(37-26(40)32(8,34)35)14-12-31(7)24(20(33)17-27)21(38)15-23-29(5)16-19(18-36)25(39)28(3,4)22(29)9-10-30(23,31)6/h15-16,20,22,24H,9-14,17H2,1-8H3,(H,37,40)/t20-,22-,24-,29-,30+,31+,33-/m0/s1	RJCWBNBKOKFWNY-IDPLTSGASA-N	2		Not Available	Small Molecule																																			0	No	4	1	No	5	0	87.03 Å2	60.76 Å3	151.25 m3·mol-1	2	No	No	0.00119 mg/mL	6.28	-5.7	10.11	-5.3			
C21H26F2O6	Not Available	Not Available	412.43	C[C@]12C[C@H](O)[C@@]3(F)[C@@H](C[C@H](F)C4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO	Not Available	Not Available						5108	CHEMBL1201390	82611				C07006					91488	347828777		25126		Fluocinolone	ZINC000004097307		Fluocinolone	Investigational	DB12553	InChI=1S/C21H26F2O6/c1-18-4-3-10(25)5-13(18)14(22)6-12-11-7-15(26)21(29,17(28)9-24)19(11,2)8-16(27)20(12,18)23/h3-5,11-12,14-16,24,26-27,29H,6-9H2,1-2H3/t11-,12-,14-,15+,16-,18-,19-,20-,21-/m0/s1	UUOUOERPONYGOS-CLCRDYEYSA-N	1		Not Available	Small Molecule																																			1	Yes	6	4	No	4	0	115.06 Å2	40.14 Å3	99.21 m3·mol-1	2	Yes	No	0.342 mg/mL	-0.098	-3.1	11.75	-3.3			
C29H35NO8	Not Available	Not Available	525.598	COC[C@H]1OC(=O)\C(=C\N(CC=C)CC=C)C2=C(O)C(=O)C3=C([C@@H](C[C@@]4(C)[C@H]3CCC4=O)OC(C)=O)[C@@]12C	Not Available	Not Available						65345	CHEMBL411907	8025448									9849735	347828818					ZINC000029134545		Sonolisib	Investigational	DB12601	InChI=1S/C29H35NO8/c1-7-11-30(12-8-2)14-17-23-26(34)25(33)22-18-9-10-20(32)28(18,4)13-19(37-16(3)31)24(22)29(23,5)21(15-36-6)38-27(17)35/h7-8,14,18-19,21,34H,1-2,9-13,15H2,3-6H3/b17-14+/t18-,19+,21+,28-,29-/m0/s1	QIUASFSNWYMDFS-NILGECQDSA-N	2		Not Available	Small Molecule																																			1	No	7	1	Yes	4	0	119.44 Å2	54.57 Å3	141.15 m3·mol-1	9	No	No	0.0267 mg/mL	2.51	-4.3	8.49	-2.8			
C29H39NO3	Not Available	Not Available	449.635	CN(C)C1=CC=C(C=C1)[C@H]1C[C@]2(C)[C@@H](CC[C@]2(O)CCCO)[C@@H]2CCC3=CC(=O)CCC3=C12	Not Available	Not Available					50366558		CHEMBL1908373	4470982									5311505	347828846				Onapristone	ZINC000003831947		Onapristone	Investigational	DB12637	InChI=1S/C29H39NO3/c1-28-18-25(19-5-8-21(9-6-19)30(2)3)27-23-12-10-22(32)17-20(23)7-11-24(27)26(28)13-15-29(28,33)14-4-16-31/h5-6,8-9,17,24-26,31,33H,4,7,10-16,18H2,1-3H3/t24-,25+,26-,28+,29+/m0/s1	IEXUMDBQLIVNHZ-YOUGDJEHSA-N			Not Available	Small Molecule																																			1	No	4	2	No	5	0	60.77 Å2	52.99 Å3	135.3 m3·mol-1	5	Yes	No	0.00759 mg/mL	3.96	-4.8	14.34	4.89	P04150;!Q6QNK2	NR3C1;!ADGRD1	1. Glucocorticoid receptor;!2. Probable G-protein coupled receptor 133
C31H41NO4	Not Available	Not Available	491.672	CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O	Not Available	Not Available							CHEMBL1093059	354529									400010	347828858				Bardoxolone_methyl	ZINC000006019135		Bardoxolone	Investigational	DB12651	InChI=1S/C31H41NO4/c1-26(2)10-12-31(25(35)36)13-11-30(7)23(19(31)16-26)20(33)14-22-28(5)15-18(17-32)24(34)27(3,4)21(28)8-9-29(22,30)6/h14-15,19,21,23H,8-13,16H2,1-7H3,(H,35,36)/t19-,21-,23-,28-,29+,30+,31-/m0/s1	TXGZJQLMVSIZEI-UQMAOPSPSA-N			Not Available	Small Molecule																																			1	No	5	1	No	5	-1	95.23 Å2	56.02 Å3	139.59 m3·mol-1	1	No	No	0.00401 mg/mL	6.4	-5.1	4.6	-5.3	Q14790	CASP8	1. Caspase-8
C20H30O2	Not Available	Not Available	302.458	CC[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C	Not Available	Not Available						135282	CHEMBL1697845	5649									5858	347828967		7513		Norethandrolone	ZINC000003875356		Norethandrolone	Investigational	DB12787	InChI=1S/C20H30O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h12,15-18,22H,3-11H2,1-2H3/t15-,16+,17+,18-,19-,20-/m0/s1	ZDHCJEIGTNNEMY-XGXHKTLJSA-N	3		Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	36.28 Å3	89.12 m3·mol-1	1	Yes	Yes	0.0174 mg/mL	3.87	-4.2	19.28	-0.27			
C35H45Cl2NO6	Not Available	Not Available	646.65	[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCCC3=CC=C(C=C3)N(CCCl)CCCl)[C@@]1(C)C[C@]([H])(O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Not Available	Not Available						82524	CHEMBL2103751	31708				C19512					34457	347828998		8637		Prednimustine	ZINC000004214173		Prednimustine	Investigational	DB12832	InChI=1S/C35H45Cl2NO6/c1-33-14-12-26(39)20-24(33)8-11-27-28-13-15-35(43,34(28,2)21-29(40)32(27)33)30(41)22-44-31(42)5-3-4-23-6-9-25(10-7-23)38(18-16-36)19-17-37/h6-7,9-10,12,14,20,27-29,32,40,43H,3-5,8,11,13,15-19,21-22H2,1-2H3/t27-,28-,29-,32+,33-,34-,35-/m0/s1	HFVNWDWLWUCIHC-GUPDPFMOSA-N			Not Available	Small Molecule																																			0	No	6	2	Yes	5	0	104.14 Å2	69.68 Å3	174.68 m3·mol-1	13	No	No	0.000642 mg/mL	5.87	-6	12.61	1.72			
C32H48O9	Not Available	Not Available	576.727	CO[C@H]1C[C@H](O[C@H]2CC[C@@]3(C)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H]([C@H](C[C@]43O)OC(C)=O)C3=CC(=O)OC3)C2)O[C@@H](C)[C@@H]1O	Not Available	Not Available						59030	CHEMBL1075789	9716290									11541511	347829006				Oleandrin	ZINC000008214621		Oleandrin	Experimental, Investigational	DB12843	InChI=1S/C32H48O9/c1-17-29(35)24(37-5)14-27(39-17)41-21-8-10-30(3)20(13-21)6-7-23-22(30)9-11-31(4)28(19-12-26(34)38-16-19)25(40-18(2)33)15-32(23,31)36/h12,17,20-25,27-29,35-36H,6-11,13-16H2,1-5H3/t17-,20+,21-,22-,23+,24-,25-,27-,28-,29-,30-,31+,32-/m0/s1	JLPDBLFIVFSOCC-XYXFTTADSA-N			Not Available	Small Molecule																																			1	No	7	2	Yes	6	-1	120.75 Å2	63.2 Å3	148.45 m3·mol-1	6	No	No	0.00299 mg/mL	2.95	-5.3	6.82	-3.2			
C22H28O5	Not Available	Not Available	372.461	C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)CC(=O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4					110996									124653	347829094					ZINC000004744090		Methylprednisone	Approved, Investigational	DB12952	InChI=1S/C22H28O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,19,23,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,19+,20-,21-,22-/m0/s1	SVYCRJXQZUCUND-PQXSVQADSA-N	4		Not Available	Small Molecule																																			1	Yes	5	2	No	4	0	91.67 Å2	40.27 Å3	102.12 m3·mol-1	2	Yes	No	0.0587 mg/mL	1.95	-3.8	12.58	-3.3			
C32H38N2O5	Not Available	Not Available	530.665	C[C@@H]1C[C@H]2[C@@H]3C=C(C)C4=CC5=C(C[C@]4(C)[C@H]3[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O)C=NN5C1=CC=CC=C1	Not Available	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5			135820	CHEMBL2105842	59633									66249	347829140		21660		Cortivazol	ZINC000004215466		Cortivazol	Investigational	DB13003	InChI=1S/C32H38N2O5/c1-18-11-23-25-12-19(2)32(38,28(37)17-39-20(3)35)31(25,5)15-27(36)29(23)30(4)14-21-16-33-34(26(21)13-24(18)30)22-9-7-6-8-10-22/h6-11,13,16,19,23,25,27,29,36,38H,12,14-15,17H2,1-5H3/t19-,23+,25+,27+,29-,30+,31+,32+/m1/s1	RKHQGWMMUURILY-UHRZLXHJSA-N	3		Not Available	Small Molecule																																			1	No	5	2	No	6	0	101.65 Å2	59.8 Å3	149.98 m3·mol-1	5	No	No	0.0033 mg/mL	3.63	-5.2	12.47	2.05	P04150	NR3C1	1. Glucocorticoid receptor
C30H46O4	Not Available	Not Available	470.694	[H][C@@]12C[C@](C)(CC[C@]1(C)CC[C@]1(C)C2=CC(=O)[C@]2([H])[C@@]3(C)CC[C@H](O)C(C)(C)[C@]3([H])CC[C@@]12C)C(O)=O	Not Available	Not Available					50233538	30853	CHEMBL230006	9710				C02283		CBW			10114	347829213		1311506		Enoxolone	ZINC000019203131		Enoxolone	Investigational	DB13089	InChI=1S/C30H46O4/c1-25(2)21-8-11-30(7)23(28(21,5)10-9-22(25)32)20(31)16-18-19-17-27(4,24(33)34)13-12-26(19,3)14-15-29(18,30)6/h16,19,21-23,32H,8-15,17H2,1-7H3,(H,33,34)/t19-,21-,22-,23+,26+,27-,28-,29+,30+/m0/s1	MPDGHEJMBKOTSU-YKLVYJNSSA-N	3		Not Available	Small Molecule																																			1	No	4	2	No	5	-1	74.6 Å2	55.22 Å3	134.27 m3·mol-1	1	No	No	0.00172 mg/mL	6.03	-5.4	4.44	-0.84			
C22H30O3	Not Available	Not Available	342.479	C[C@H](O)C(=O)[C@@]1(C)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3CC[C@]12C	Not Available	Not Available						136027	CHEMBL2104765	62152									68926	347829250				Trimegestone	ZINC000004217604		Trimegestone	Investigational	DB13129	InChI=1S/C22H30O3/c1-13(23)20(25)22(3)11-9-19-18-6-4-14-12-15(24)5-7-16(14)17(18)8-10-21(19,22)2/h12-13,18-19,23H,4-11H2,1-3H3/t13-,18+,19-,21-,22+/m0/s1	JUNDJWOLDSCTFK-MTZCLOFQSA-N	4		Not Available	Small Molecule																																			1	Yes	3	1	No	4	0	54.37 Å2	39.44 Å3	99.51 m3·mol-1	2	Yes	No	0.0188 mg/mL	3.71	-4.3	13.7	-3.4			
C20H28O3	Not Available	Not Available	316.441	[H][C@@]12CC[C@](O)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	Not Available	Not Available						135991	CHEMBL3707212	92341												4793		Gestronol	ZINC000005167250		Gestonorone	Experimental	DB13230	InChI=1S/C20H28O3/c1-12(21)20(23)10-8-18-17-5-3-13-11-14(22)4-6-15(13)16(17)7-9-19(18,20)2/h11,15-18,23H,3-10H2,1-2H3/t15-,16+,17+,18-,19-,20-/m0/s1	GTFUITFQDGVJSK-XGXHKTLJSA-N			Not Available	Small Molecule																																			1	Yes	3	1	No	4	0	54.37 Å2	36.34 Å3	89.63 m3·mol-1	1	Yes	No	0.0213 mg/mL	3.1	-4.2	12.7	-3.8			
C30H44O9	Not Available	Not Available	548.673	[H][C@@]1(CC[C@]2(O)[C@]3([H])CC[C@]4(O)C[C@H](CC[C@]4(C=O)[C@@]3([H])CC[C@]12C)O[C@H]1C[C@H](OC)[C@H](O)[C@@H](C)O1)C1=CC(=O)OC1	Not Available	Not Available						4037	CHEMBL1075788	390429				C08859										Cymarin	ZINC000008214527		Cymarin	Experimental	DB13240	InChI=1S/C30H44O9/c1-17-26(33)23(36-3)13-25(38-17)39-19-4-9-28(16-31)21-5-8-27(2)20(18-12-24(32)37-15-18)7-11-30(27,35)22(21)6-10-29(28,34)14-19/h12,16-17,19-23,25-26,33-35H,4-11,13-15H2,1-3H3/t17-,19+,20-,21+,22-,23+,25+,26-,27-,28+,29+,30+/m1/s1	XQCGNURMLWFQJR-ZNDDOCHDSA-N			Not Available	Small Molecule																																			1	No	8	3	No	6	0	131.75 Å2	58.62 Å3	140.03 m3·mol-1	5	No	No	0.0804 mg/mL	1.69	-3.8	7.18	0.27			
C30H42O8	Not Available	Not Available	530.658	[H][C@@]1(CC[C@]2(O)[C@]3([H])CCC4=C[C@]([H])(CC[C@]4(C)[C@@]3([H])CC[C@]12C)O[C@]1([H])O[C@@]([H])(C)[C@]([H])(O)[C@@]([H])(O)[C@@]1([H])O)C1=COC(=O)C=C1	Not Available	Not Available						32065	CHEMBL600325	4447658									5284613	347829292		8795		Proscillaridin	ZINC000008214665		Proscillaridin	Experimental	DB13307	InChI=1S/C30H42O8/c1-16-24(32)25(33)26(34)27(37-16)38-19-8-11-28(2)18(14-19)5-6-22-21(28)9-12-29(3)20(10-13-30(22,29)35)17-4-7-23(31)36-15-17/h4,7,14-16,19-22,24-27,32-35H,5-6,8-13H2,1-3H3/t16-,19-,20+,21-,22+,24-,25+,26+,27-,28-,29+,30-/m0/s1	MYEJFUXQJGHEQK-ALRJYLEOSA-N			Not Available	Small Molecule																																			1	No	7	4	No	6	0	125.68 Å2	58.26 Å3	140.05 m3·mol-1	3	No	No	0.0427 mg/mL	2.3	-4.1	12.22	0.3			
C22H29FO5	Not Available	Not Available	392.467	C[C@H](O)C(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C	Not Available	Not Available								32700976														Fluperolone			Fluperolone	Experimental	DB13491	InChI=1S/C22H29FO5/c1-12(24)18(27)21(28)9-7-15-16-5-4-13-10-14(25)6-8-19(13,2)22(16,23)17(26)11-20(15,21)3/h6,8,10,12,15-17,24,26,28H,4-5,7,9,11H2,1-3H3/t12-,15-,16-,17-,19-,20-,21-,22-/m0/s1	SLVCCRYLKTYUQP-DVTGEIKXSA-N			Not Available	Small Molecule																																			1	Yes	5	3	No	4	0	94.83 Å2	40.82 Å3	102.52 m3·mol-1	2	Yes	No	0.0579 mg/mL	1.89	-3.8	12.53	-3.4			
C21H27ClO3	Not Available	Not Available	362.89	[H][C@@]12CC[C@](O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(Cl)C2=CC(=O)CC[C@]12C	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4				CHEMBL1697830	4447590												78904		Chlormadinone	ZINC000030691600		Chlormadinone	Experimental	DB13528	InChI=1S/C21H27ClO3/c1-12(23)21(25)9-6-16-14-11-18(22)17-10-13(24)4-7-19(17,2)15(14)5-8-20(16,21)3/h10-11,14-16,25H,4-9H2,1-3H3/t14-,15+,16+,19-,20+,21+/m1/s1	VUHJZBBCZGVNDZ-TTYLFXKOSA-N	1	Chlormadinone is a progestin indicated in combination with an estrogen for oral combined hormonal contraceptive therapy.	Not Available	Small Molecule																																			1	Yes	3	1	No	4	0	54.37 Å2	39.66 Å3	99.94 m3·mol-1	1	Yes	No	0.00677 mg/mL	3.28	-4.7	12.7	-3.8			
C19H28O2	Not Available	Not Available	288.431	C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C	Not Available	Not Available						34896	CHEMBL2106801	4447645				C14491										Normethandrone	ZINC000004217180		Methylestrenolone	Experimental	DB13533	InChI=1S/C19H28O2/c1-18-9-7-15-14-6-4-13(20)11-12(14)3-5-16(15)17(18)8-10-19(18,2)21/h11,14-17,21H,3-10H2,1-2H3/t14-,15+,16+,17-,18-,19-/m0/s1	ZXSWTMLNIIZPET-ZOFHRBRSSA-N			Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	34.21 Å3	84.59 m3·mol-1	0	Yes	Yes	0.0302 mg/mL	3.35	-4	19.28	-0.53			
C24H30O8	Not Available	Not Available	446.496	CCCC(=O)C1=C(O)C=C(OC)C(CC2=C(O)C(C)(C)C(O)=C(C(=O)CCC)C2=O)=C1O	Not Available	Not Available						135960	CHEMBL2105606	10295071														Desaspidin			Desaspidin	Experimental	DB13567	InChI=1S/C24H30O8/c1-6-8-14(25)18-16(27)11-17(32-5)12(20(18)28)10-13-21(29)19(15(26)9-7-2)23(31)24(3,4)22(13)30/h11,27-28,30-31H,6-10H2,1-5H3	GAHOBHHMYUYJDT-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	Yes	8	4	No	2	-2	141.36 Å2	46.75 Å3	121.2 m3·mol-1	9	No	No	0.0678 mg/mL	5	-3.8	3.46	-4.7			
C20H28O2	Not Available	Not Available	300.4351	[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Not Available	Not Available						6810	CHEMBL1418176	6061			HMDB0041925									6818		Metandienone	ZINC000003875469		Metandienone	Experimental	DB13586	InChI=1S/C20H28O2/c1-18-9-6-14(21)12-13(18)4-5-15-16(18)7-10-19(2)17(15)8-11-20(19,3)22/h6,9,12,15-17,22H,4-5,7-8,10-11H2,1-3H3/t15-,16+,17+,18+,19+,20+/m1/s1	XWALNWXLMVGSFR-HLXURNFRSA-N		Metandienone is an anabolic steroid indicated for appetite stimulation in patients with anorexia.	Not Available	Small Molecule																																			1	Yes	2	1	No	4	0	37.3 Å2	35.09 Å3	90.16 m3·mol-1	0	Yes	Yes	0.0161 mg/mL	3.64	-4.3	18.39	-0.53			
C22H30O2	Not Available	Not Available	326.48	CCC(=O)[C@@]1(C)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3CC[C@]12C	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4		18660	73390	CHEMBL196003	33716				C14208								8744		Promegestone	ZINC000003814408		Promegestone	Experimental	DB13602	InChI=1S/C22H30O2/c1-4-20(24)22(3)12-10-19-18-7-5-14-13-15(23)6-8-16(14)17(18)9-11-21(19,22)2/h13,18-19H,4-12H2,1-3H3/t18-,19+,21+,22-/m1/s1	QFFCYTLOTYIJMR-XMGTWHOFSA-N			Not Available	Small Molecule																																			1	Yes	2	0	No	4	0	34.14 Å2	38.7 Å3	97.94 m3·mol-1	2	Yes	Yes	0.00772 mg/mL	4.66	-4.6	19	-4.7			
C22H29F3O3	Not Available	Not Available	398.466	CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@@H](C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(F)(F)F	Not Available	Not Available						135987	CHEMBL2104932	16736667														Flumedroxone			Flumedroxone	Experimental	DB13610	InChI=1S/C22H29F3O3/c1-12(26)21(28)9-6-16-14-11-18(22(23,24)25)17-10-13(27)4-7-19(17,2)15(14)5-8-20(16,21)3/h10,14-16,18,28H,4-9,11H2,1-3H3/t14-,15+,16+,18+,19-,20+,21+/m1/s1	CDZJOBWKHSYNMO-SCUQKFFVSA-N			Not Available	Small Molecule																																			1	Yes	3	1	No	4	0	54.37 Å2	40.24 Å3	99.51 m3·mol-1	2	Yes	No	0.00796 mg/mL	3.97	-4.7	12.38	-3.8			
C32H48O5	Not Available	Not Available	512.731	CC(=O)O[C@H]1CC[C@@]2(C)[C@@H](CC[C@]3(C)[C@@H]2C(=O)C=C2[C@@H]4C[C@](C)(CC[C@]4(C)CC[C@@]32C)C(O)=O)C1(C)C	Not Available	Not Available					50188385	81306	CHEMBL207413	85123				C17734								16784		Acetoxolone	ZINC000034169081		Acetoxolone	Experimental	DB13640	InChI=1S/C32H48O5/c1-19(33)37-24-10-11-30(6)23(27(24,2)3)9-12-32(8)25(30)22(34)17-20-21-18-29(5,26(35)36)14-13-28(21,4)15-16-31(20,32)7/h17,21,23-25H,9-16,18H2,1-8H3,(H,35,36)/t21-,23-,24-,25+,28+,29-,30-,31+,32+/m0/s1	FTQDJVZNPJRVPG-XWEVEMRCSA-N			Not Available	Small Molecule																																			0	No	4	1	No	5	-1	80.67 Å2	59.68 Å3	143.42 m3·mol-1	3	No	No	0.000555 mg/mL	6.47	-6	4.44	-5.1			
C29H38ClFO8	Not Available	Not Available	569.06	CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3CC(C=O)=C4C=C(CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C)OCCCl	Not Available	Not Available						135834	CHEMBL1989587	254985														Formocortal	ZINC000004216336		Formocortal	Experimental	DB13664	InChI=1S/C29H38ClFO8/c1-16(33)37-15-23(35)29-24(38-25(2,3)39-29)12-20-21-10-17(14-32)19-11-18(36-9-8-30)6-7-26(19,4)28(21,31)22(34)13-27(20,29)5/h11,14,20-22,24,34H,6-10,12-13,15H2,1-5H3/t20-,21-,22-,24+,26-,27-,28-,29+/m0/s1	QNXUUBBKHBYRFW-QWAPGEGQSA-N			Not Available	Small Molecule																																			1	No	7	1	Yes	5	0	108.36 Å2	58.69 Å3	141.36 m3·mol-1	8	No	No	0.00875 mg/mL	2.07	-4.8	13.64	-3.4			
C22H27ClF2O5	Not Available	Not Available	444.9	C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C(Cl)=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO	Not Available	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5			135724	CHEMBL1587228	8022046												26416		Halometasone	ZINC000003938673		Halometasone	Experimental	DB13728	InChI=1S/C22H27ClF2O5/c1-10-4-11-12-5-15(24)13-6-16(27)14(23)7-19(13,2)21(12,25)17(28)8-20(11,3)22(10,30)18(29)9-26/h6-7,10-12,15,17,26,28,30H,4-5,8-9H2,1-3H3/t10-,11+,12+,15+,17+,19+,20+,21+,22+/m1/s1	GGXMRPUKBWXVHE-MIHLVHIWSA-N	4	Halometasone is a corticosteroid indicated in the treatment of corticosteroid responsive dermatoses.	Not Available	Small Molecule																																			1	Yes	5	3	No	4	0	94.83 Å2	43.35 Å3	107.11 m3·mol-1	2	Yes	No	0.0356 mg/mL	1.73	-4.1	12.42	-3.3			
C42H62O16	The constant reabsorption of glycyrrhetic acid in the duodenum causes a delay in the terminal plasma clearance.3 The reported total body clearance of glycyrrhizic acid is reported to be in the range of 16-25 ml.kg/h.5	Depending on the dose, the second elimination phase in humans has a half-life of 3.5 hours.4	822.942	[H][C@@]12C[C@](C)(CC[C@]1(C)CC[C@]1(C)C2=CC(=O)[C@]2([H])[C@@]3(C)CC[C@H](O[C@H]4O[C@@H]([C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@@H]([C@@H](O)[C@H](O)[C@H]4O)C(O)=O)C(O)=O)C(C)(C)[C@]3([H])CC[C@@]12C)C(O)=O	Solid	The apparent volume of distribution of glycyrrhizic acid either in the central compartment and in steady-state are in the range of 37-64 ml/kg and 59-98 ml/kg, respectively.5					50185127	15939	CHEMBL441687	14263				C02284	D00157							26143		Glycyrrhizin	ZINC000096015174		Glycyrrhizic acid	Approved, Experimental	DB13751	InChI=1S/C42H62O16/c1-37(2)21-8-11-42(7)31(20(43)16-18-19-17-39(4,36(53)54)13-12-38(19,3)14-15-41(18,42)6)40(21,5)10-9-22(37)55-35-30(26(47)25(46)29(57-35)33(51)52)58-34-27(48)23(44)24(45)28(56-34)32(49)50/h16,19,21-31,34-35,44-48H,8-15,17H2,1-7H3,(H,49,50)(H,51,52)(H,53,54)/t19-,21-,22-,23-,24-,25-,26-,27+,28-,29-,30+,31+,34-,35-,38+,39-,40-,41+,42+/m0/s1	LPLVUJXQOOQHMX-QWBHMCJMSA-N			Glycyrrhizic acid is thought to generate inhibition of 11-beta-hydroxysteroid dehydrogenase in the kidney which leads to elevated cortisol levels in the kidney. Intravenous administration of the ammoniated form was shown to produce convulsions and hemolysis.11Preclinical overdose studies have been shown to produce mineralocorticoid excess. The LD50 in preclinical studies was reported to be in the range of 308-12700 mg/kg.11 Glycyrrhizic acid has been proven to not have mutagenic, genotoxic, teratogenic nor carcinogenic effects.11	Small Molecule																													Decomposes at 200 ºC	2.8		220 ºC (Decomposes at 200 ºC)		Easily soluble in hot water	0	No	16	8	Yes	7	-3	267.04 Å2	86.31 Å3	198.83 m3·mol-1	7	No	No	0.0545 mg/mL	3.13	-4.2	2.96	-3.7	P28845;!P01375;!P42574;!BE0004903;!P06858	HSD11B1;!TNF;!CASP3;!;!LPL	1. Corticosteroid 11-beta-dehydrogenase isozyme 1;!2. Tumor necrosis factor;!3. Caspase-3;!4. Nuclear factor NF-kappa-B (Protein Group);!5. Lipoprotein lipase
C30H44O9	Not Available	Not Available	548.673	CO[C@@H]1[C@@H](O)[C@H](C)O[C@@H](O[C@H]2CC[C@@]3(C=O)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H](CC[C@]43O)C3=CC(=O)OC3)C2)[C@H]1O	Not Available	Not Available						135825	CHEMBL1075790	16498835														Peruvoside			Peruvoside	Experimental	DB13756	InChI=1S/C30H44O9/c1-16-24(33)26(36-3)25(34)27(38-16)39-19-6-10-29(15-31)18(13-19)4-5-22-21(29)7-9-28(2)20(8-11-30(22,28)35)17-12-23(32)37-14-17/h12,15-16,18-22,24-27,33-35H,4-11,13-14H2,1-3H3/t16-,18+,19-,20+,21-,22+,24-,25-,26+,27-,28+,29+,30-/m0/s1	PMTSPAGBAFCORP-HBUONDEYSA-N			Not Available	Small Molecule																																			1	No	8	3	No	6	0	131.75 Å2	58.9 Å3	140.05 m3·mol-1	5	No	No	0.0791 mg/mL	2.02	-3.8	7.18	0.27			
C21H25ClO5	Not Available	Not Available	392.88	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@]([H])(O)[C@@]1([H])[C@@]2([H])C=C(Cl)C2=CC(=O)C=C[C@]12C	Not Available	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5			135619	CHEMBL1697832	4447592					D03561							21285		Cloprednol	ZINC000004215431		Cloprednol	Experimental	DB13843	InChI=1S/C21H25ClO5/c1-19-5-3-11(24)7-14(19)15(22)8-12-13-4-6-21(27,17(26)10-23)20(13,2)9-16(25)18(12)19/h3,5,7-8,12-13,16,18,23,25,27H,4,6,9-10H2,1-2H3/t12-,13-,16-,18+,19-,20-,21-/m0/s1	YTJIBEDMAQUYSZ-FDNPDPBUSA-N		Cloprednol is a glucocorticoid indicated in the treatment of arthritis and asthma.	Not Available	Small Molecule																																			1	Yes	5	3	No	4	0	94.83 Å2	40.42 Å3	104.33 m3·mol-1	2	Yes	No	0.099 mg/mL	1.15	-3.6	12.58	-2.9			
C21H25Cl2FO5	Not Available	Not Available	447.32	C[C@]12C[C@H](Cl)[C@@]3(Cl)[C@@H](C[C@H](F)C4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO	Not Available	Not Available						135986	CHEMBL3707231	32697416												108091		Fluclorolone	ZINC000031284397		Fluclorolone	Experimental	DB13856	InChI=1S/C21H25Cl2FO5/c1-18-4-3-10(26)5-13(18)14(24)6-12-11-7-16(27)21(29,17(28)9-25)19(11,2)8-15(22)20(12,18)23/h3-5,11-12,14-16,25,27,29H,6-9H2,1-2H3/t11-,12-,14-,15-,16+,18-,19-,20-,21-/m0/s1	VTWKPILBIUBMDS-OTJLYDAYSA-N			Not Available	Small Molecule																																			1	Yes	5	3	No	4	0	94.83 Å2	42.62 Å3	107 m3·mol-1	2	Yes	No	0.0202 mg/mL	1.72	-4.4	11.76	-3.3			
C21H28O2	Not Available	Not Available	312.4458	[H][C@@]12CC[C@](C)(C(C)=O)[C@@]1(C)CCC1=C3CCC(=O)C=C3CC[C@@]21[H]	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			135339	CHEMBL2104231	84009					D07223							22483		Demegestone	ZINC000004215548		Demegestone	Experimental	DB13857	InChI=1S/C21H28O2/c1-13(22)20(2)11-9-19-18-6-4-14-12-15(23)5-7-16(14)17(18)8-10-21(19,20)3/h12,18-19H,4-11H2,1-3H3/t18-,19+,20-,21+/m1/s1	JWAHBTQSSMYISL-MHTWAQMVSA-N			Not Available	Small Molecule																																			1	Yes	2	0	No	4	0	34.14 Å2	36.71 Å3	93.31 m3·mol-1	1	Yes	Yes	0.0111 mg/mL	3.96	-4.4	18.42	-4.7	P06401	PGR	1. Progesterone receptor
C22H27F3O4S	57.8L/h for Fluticasone furoate12. A study of 24 healthy Caucasian males showed a clearance of 71.8L/h following intravenous administration1.1093mL/min for Fluticasone propionate11. A study of 24 healthy Caucasian males showed a clearance of 63.9L/h following intravenous administration1.	15.1 hours for intranasal Fluticasone furoate12 and 24 hours for the inhaled formulation13. A study of 24 healthy Caucasian males showed a half life of 13.6 hours following intravenous administration and 17.3-23.9 hours followed inhalation1.7.8 hours for intravenous Fluticasone propionate11Label. A study of 24 healthy Caucasian males shows a half life of 14.0 hours following intravenous administration and 10.8 hours following inhalation1.	444.51	[H][C@@]12C[C@@H](C)[C@](O)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C	Solid	608L at steady state for intravenous administration of Fluticasone furoate12. Other reports suggest the mean volume of distribution at steady state is 661L13. A study of 24 healthy Caucasian males showed a volume of distribution at steady state of 704L following intravenous administration1.The volume of distribution of intravenous Fluticasone propionate is 4.2L/kg11Label. A study of 24 healthy Caucasian males showed a volume of distribution at steady state of 577L following intravenous administration1.	P08684;!P20815;!P24462;!P10632	CYP3A4;!CYP3A5;!CYP3A7;!CYP2C8	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5;!3. Cytochrome P450 3A7;!4. Cytochrome P450 2C8			5134	CHEMBL1201396	4470631				C07815	D07981							41126		Fluticasone	ZINC000004097438		Fluticasone	Approved, Experimental	DB13867	InChI=1S/C22H27F3O4S/c1-11-6-13-14-8-16(24)15-7-12(26)4-5-19(15,2)21(14,25)17(27)9-20(13,3)22(11,29)18(28)30-10-23/h4-5,7,11,13-14,16-17,27,29H,6,8-10H2,1-3H3/t11-,13+,14+,16+,17+,19+,20+,21+,22+/m1/s1	MGNNYOODZCAHBA-GQKYHHCASA-N	4	Fluticasone is a corticosteroid indicated in the treatment of corticosteroid responsive dermatoses, asthma, and COPD.	Fluticasone furoate administered nasally may be associated with adrenal suppression or an increase in QTc interval though the association has not been well demonstrated in studies12,2. Fluticasone furoate requires no dosage adjustment in renal impairment but must be used in caution in hepatic impairment due to the elimination mechanisms12,13. Fluticasone furoate is not associated with carcinogenicity, mutagenicity, or impairment of fertility12. There are no well controlled studies in pregnancy or lactation though animal studies have shown teratogenicity and hypoadrenalism in the offspring of treated mothers and other corticosteroids are known to be excreted in breast milk12. Generally, there are no reported adverse effects with fluticasone in pregnancy6. Pediatric patients should be given the lowest possible dose and monitored for reduction in growth velocity12,2. There is insufficient evidence to determine whether geriatric patients respond differently to other patients12. Systemic exposure may be 27-49% higher in Japanese, Korean, and Chinese patients compared to Caucasian patients13. Caution should be exercised in these patients and the benefit and risk should be assessed before deciding on a treatment12.Fluticasone propionate's use in specific populations has not been well studied11. Fluticasone propionate is not carcinogenic, mutagenic, or clastogenic, nor did it affect fertility in animal studies11Label. Subcutaneous Fluticasone propionate has been shown to produce teratogenic effects in rats though oral administration does not10Label. Generally, there are no reported adverse effects with fluticasone in pregnancy6. Fluticasone propionate in human milk may cause growth suppression, effects on endogenous corticosteroid production, or other effects10,2. Pediatric patients treated with Fluticasone propionate ointment experienced adrenal suppression10. Geriatric patients treated with Fluticasone propionate did not show any difference in safety or efficacy compared to other patient groups, though older patients may be more sensitive to adverse effects10. There is no difference in the clearance of Fluticasone propionate across genders or raceLabel. Patients with hepatic impairment should be closely monitored due to the elimination mechanismLabel5.	Small Molecule																																			1	Yes	4	2	No	4	0	74.6 Å2	43.32 Å3	107.87 m3·mol-1	3	Yes	No	0.0344 mg/mL	2.58	-4.1	12.19	-3.4	P04150;!P06401;!P47712;!P08235	NR3C1;!PGR;!PLA2G4A;!NR3C2	1. Glucocorticoid receptor;!2. Progesterone receptor;!3. Cytosolic phospholipase A2;!4. Mineralocorticoid receptor
C27H40O3	Testosterone cypionate presents a lower clearance rate after intramuscular administration compared to other analogs of testosterone.	The half-life of testosterone cypionate is one of the longest, being approximately of 8 days.5	412.614	[H][C@@]12CC[C@H](OC(=O)CCC3CCCC3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	The volume of distribution following intravenous administration of testosterone is of approximately 1 L/kg.7	P08684;!P21397;!P05108;!P20815;!P24462;!P04798;!Q16696;!P20813;!P33261;!P10632;!P11712;!Q9HB55;!BE0004887;!P11511	CYP3A4;!MAOA;!CYP11A1;!CYP3A5;!CYP3A7;!CYP1A1;!CYP2A13;!CYP2B6;!CYP2C19;!CYP2C8;!CYP2C9;!CYP3A43;!;!CYP19A1	1. Cytochrome P450 3A4;!2. Amine oxidase [flavin-containing] A;!3. Cholesterol side-chain cleavage enzyme, mitochondrial;!4. Cytochrome P450 3A5;!5. Cytochrome P450 3A7;!6. Cytochrome P450 1A1;!7. Cytochrome P450 2A13;!8. Cytochrome P450 2B6;!9. Cytochrome P450 2C19;!10. Cytochrome P450 2C8;!11. Cytochrome P450 2C9;!12. Cytochrome P450 3A43;!13. 3-oxo-5-alpha-steroid 4-dehydrogenase (Protein Group);!14. Cytochrome P450 19A1			9463	CHEMBL1201101	390140				C08156	D00957									Testosterone_cypionate	ZINC000004097468	Depo-testosterone	Testosterone cypionate	Approved	DB13943	InChI=1S/C27H40O3/c1-26-15-13-20(28)17-19(26)8-9-21-22-10-11-24(27(22,2)16-14-23(21)26)30-25(29)12-7-18-5-3-4-6-18/h17-18,21-24H,3-16H2,1-2H3/t21-,22-,23-,24-,26-,27-/m0/s1	HPFVBGJFAYZEBE-ZLQWOROUSA-N	4	Testosterone cypionate is an androgen used to treat low or absent testosterone.	Preclinical studies with testosterone implants induced cervical-uterine tumors in mice which metastasized in some cases. Some reports indicate that administration of testosterone cypionate in females can augment the susceptibility to hepatoma as well as increase the number of tumors. Clinical studies have reported cases of hepatocellular carcinoma in long-term high-dose therapy.6	Small Molecule																																98-104ºC		Insoluble	1	No	2	0	No	5	0	43.37 Å2	49.84 Å3	119.36 m3·mol-1	5	No	No	0.000437 mg/mL	6.11	-6	18.52	-4.8	P10275;!P03372;!P08235	AR;!ESR1;!NR3C2	1. Androgen receptor;!2. Estrogen receptor alpha;!3. Mineralocorticoid receptor
C26H40O3	Not Available	Testosterone enanthate presents a long half-life in the range of 7-9 days.3	400.594	[H][C@@]12CC[C@H](OC(=O)CCCCCC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Solid	The volume of distribution following intravenous administration of testosterone is of approximately 1 L/kg.8	P08684;!P21397;!P05108;!P20815;!P24462;!P04798;!Q16696;!P20813;!P33261;!P10632;!P11712;!Q9HB55;!BE0004887;!P11511	CYP3A4;!MAOA;!CYP11A1;!CYP3A5;!CYP3A7;!CYP1A1;!CYP2A13;!CYP2B6;!CYP2C19;!CYP2C8;!CYP2C9;!CYP3A43;!;!CYP19A1	1. Cytochrome P450 3A4;!2. Amine oxidase [flavin-containing] A;!3. Cholesterol side-chain cleavage enzyme, mitochondrial;!4. Cytochrome P450 3A5;!5. Cytochrome P450 3A7;!6. Cytochrome P450 1A1;!7. Cytochrome P450 2A13;!8. Cytochrome P450 2B6;!9. Cytochrome P450 2C19;!10. Cytochrome P450 2C8;!11. Cytochrome P450 2C9;!12. Cytochrome P450 3A43;!13. 3-oxo-5-alpha-steroid 4-dehydrogenase (Protein Group);!14. Cytochrome P450 19A1			9464	CHEMBL1200335	9045			HMDB0005814	C08157										Testosterone_enanthate	ZINC000003876080	Delatestryl, Xyosted	Testosterone enanthate	Approved	DB13944	InChI=1S/C26H40O3/c1-4-5-6-7-8-24(28)29-23-12-11-21-20-10-9-18-17-19(27)13-15-25(18,2)22(20)14-16-26(21,23)3/h17,20-23H,4-16H2,1-3H3/t20-,21-,22-,23-,25-,26-/m0/s1	VOCBWIIFXDYGNZ-IXKNJLPQSA-N	4	Testosterone enanthate is an androgen used to treat low or absent testosterone.	Testosterone enanthate has been tested in preclinical carcinogenesis trials. In this studies, it is suggested that the exposure to this drug may increase the susceptibility to hematoma as well as the number of tumors and decrease the degree of differentiation of chemically induced carcinomas of the liver.LabelTestosterone enanthate is not indicated for use in females and is contraindicated in pregnant women. Testosterone is teratogenic and may cause fetal harm when administered to a pregnant woman based on data from animal studies and its mechanism of action. 11During treatment with large doses of exogenous androgens, including testosterone enanthate, spermatogenesis may be suppressed through feedback inhibition of the hypothalamic-pituitary-testicular axis 11. Reduced fertility is observed in some men taking testosterone replacement therapy and the impact on fertility may be irreversible 11.Safety and effectiveness of testosterone enanthate in pediatric patients less than 18 years old have not been established 11. Improper use may result in the acceleration of bone age and premature closure of epiphyses 11.Geriatric patients treated with androgens may also be at risk for worsening of signs and symptoms of Benign Prostatic Hyperplasia 11.	Small Molecule																														3.58		34-39ºC		Insoluble	1	No	2	0	Yes	4	0	43.37 Å2	49.18 Å3	116.61 m3·mol-1	7	No	No	0.000463 mg/mL	6.29	-5.9	18.52	-4.8	P10275;!P03372;!P08235	AR;!ESR1;!NR3C2	1. Androgen receptor;!2. Estrogen receptor alpha;!3. Mineralocorticoid receptor
C30H48O3	While there is limited information available, an earlier study reports a metabolic clearance rate of 24.5 mL/min/kg for testosterone following oral administration of 25 mg testosterone and 40 mg testosterone undecanoate in women.5	The elimination half-life of testosterone undecanoate is approximately two hours. Once testosterone is formed from testosterone undecanoate, the half life of testosterone can vary and the reported values in the literature remain inconsistent, ranging from 10 to to 100 minutes.6,8 Testosterone undecanoate in castor oil for intramuscular injection had a half life of 33.9 days, allowing it to maintain serum levels in the normal range for over 6 weeks.[A176954]	456.711	CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C	Solid	There is no information available.	P08684;!P21397;!P05108;!P20815;!P24462;!P04798;!Q16678;!Q16696;!P20813;!P33261;!P10632;!P11712;!Q9HB55;!BE0004887;!P11511	CYP3A4;!MAOA;!CYP11A1;!CYP3A5;!CYP3A7;!CYP1A1;!CYP1B1;!CYP2A13;!CYP2B6;!CYP2C19;!CYP2C8;!CYP2C9;!CYP3A43;!;!CYP19A1	1. Cytochrome P450 3A4;!2. Amine oxidase [flavin-containing] A;!3. Cholesterol side-chain cleavage enzyme, mitochondrial;!4. Cytochrome P450 3A5;!5. Cytochrome P450 3A7;!6. Cytochrome P450 1A1;!7. Cytochrome P450 1B1;!8. Cytochrome P450 2A13;!9. Cytochrome P450 2B6;!10. Cytochrome P450 2C19;!11. Cytochrome P450 2C8;!12. Cytochrome P450 2C9;!13. Cytochrome P450 3A43;!14. 3-oxo-5-alpha-steroid 4-dehydrogenase (Protein Group);!15. Cytochrome P450 19A1			135741	CHEMBL2107067	58664														Testosterone_undecanoate	ZINC000008214690	Aveed, Jatenzo, Tlando	Testosterone undecanoate	Approved, Investigational	DB13946	InChI=1S/C30H48O3/c1-4-5-6-7-8-9-10-11-12-28(32)33-27-16-15-25-24-14-13-22-21-23(31)17-19-29(22,2)26(24)18-20-30(25,27)3/h21,24-27H,4-20H2,1-3H3/t24-,25-,26-,27-,29-,30-/m0/s1	UDSFVOAUHKGBEK-CNQKSJKFSA-N	4	Testosterone undecanoate is an androgen indicated for testosterone replacement therapy in adult males with primary hypogonadism and hypogonadotropic hypogonadism.	The oral LD50 is 4000 mg/kg in mice and rats. The subcutaneous LD50 is 2880 mg/kg in mice and rats.9There is limited information on testosterone undecanoate overdose. There was one report of acute overdose from an approved injectable testosterone product, which resulted in increased serum testosterone levels of up to 11,400 ng/dL with a cerebrovascular accident.6 There was one case of overdose following administration of oral testosterone undecanoate capsules: this patient inadvertently took a 20% higher dose than the maximum recommended dose but did not report any adverse reactions.7 Overdose should be managed with discontinuation of the drug in combination with appropriate symptomatic and supportive care.6The abuse of anabolic androgenic steroids can result in serious adverse reactions, such as cardiac arrest, myocardial infarction, hypertrophic cardiomyopathy, congestive heart failure, cerebrovascular accident, hepatotoxicity, and psychiatric manifestations, including major depression, mania, paranoia, psychosis, delusions, hallucinations, hostility, and aggression. Men receiving testosterone have experienced transient ischemic attacks, convulsions, hypomania, irritability, dyslipidemias, testicular atrophy, subfertility, and infertility.6	Small Molecule																																		<1 mg/mL	0	No	2	0	Yes	4	0	43.37 Å2	57.8 Å3	135.02 m3·mol-1	11	No	No	7.4e-05 mg/mL	8.06	-6.8	18.52	-4.8	P10275	AR	1. Androgen receptor
C40H52N2O4	Not Available	Not Available	624.866	[H]N(N=C1CC[C@@]2(C)C(CC[C@@]3([H])[C@]4([H])CC[C@H](OC(=O)CCCCCC)[C@@]4(C)CC[C@]23[H])=C1)C(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1	Not Available	Not Available								34995240														Testosterone_enantate_benzilic_acid_hydrazone	ZINC000299888598		Testosterone enantate benzilic acid hydrazone	Approved, Experimental	DB13947	InChI=1S/C40H52N2O4/c1-4-5-6-13-18-36(43)46-35-22-21-33-32-20-19-30-27-31(23-25-38(30,2)34(32)24-26-39(33,35)3)41-42-37(44)40(45,28-14-9-7-10-15-28)29-16-11-8-12-17-29/h7-12,14-17,27,32-35,45H,4-6,13,18-26H2,1-3H3,(H,42,44)/t32-,33-,34-,35-,38-,39-/m0/s1	PTVXYACXDYZNID-JKXGKYMWSA-N			Not Available	Small Molecule																																			0	No	4	2	Yes	6	0	87.99 Å2	74.51 Å3	182.37 m3·mol-1	11	No	No	0.000122 mg/mL	8.49	-6.7	11.09	2.14			
C23H30O4	Not Available	Not Available	370.489	[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3C(C)=C[C@@]21[H]	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			135564	CHEMBL1476022	82771					D08281							53744		Nomegestrol_acetate	ZINC000003938628		Nomegestrol acetate	Approved, Investigational	DB13981	InChI=1S/C23H30O4/c1-13-11-20-18(17-6-5-16(26)12-19(13)17)7-9-22(4)21(20)8-10-23(22,14(2)24)27-15(3)25/h11-12,17-18,20-21H,5-10H2,1-4H3/t17-,18-,20-,21+,22+,23+/m1/s1	IIVBFTNIGYRNQY-YQLZSBIMSA-N	4		Not Available	Small Molecule																																			1	Yes	3	0	No	4	0	60.44 Å2	41.78 Å3	104.18 m3·mol-1	3	Yes	No	0.00415 mg/mL	3.42	-5	17.72	-4.8			
C30H48O6	Not Available	Not Available	504.708	[H][C@]12CC=C3[C@]4([H])[C@@H](C)[C@H](C)CC[C@@]4(CC[C@@]3(C)[C@]1(C)C[C@@H](O)[C@@]1([H])[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]21C)C(O)=O	Solid	Not Available					50244879	73058	CHEMBL481854	66126												1551573			ZINC000014243546		Madecassic acid	Experimental	DB14037	InChI=1S/C30H48O6/c1-16-9-10-30(25(35)36)12-11-28(5)18(22(30)17(16)2)7-8-21-26(3)13-20(33)24(34)27(4,15-31)23(26)19(32)14-29(21,28)6/h7,16-17,19-24,31-34H,8-15H2,1-6H3,(H,35,36)/t16-,17+,19-,20-,21-,22+,23-,24+,26-,27+,28-,29-,30+/m1/s1	PRAUVHZJPXOEIF-AOLYGAPISA-N			Not Available	Small Molecule																																			1	No	6	5	No	5	-1	118.22 Å2	57.47 Å3	138.43 m3·mol-1	2	No	No	0.0356 mg/mL	2.92	-4.2	4.64	-2.8			
C29H50O	Not Available	Not Available	414.718	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC=C4C[C@@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CC[C@@H](CC)C(C)C	Solid	Not Available					50218197	27693	CHEMBL221542	192962			HMDB0000852	C01753	D08518							47070		Beta-Sitosterol	ZINC000004095717		beta-Sitosterol	Experimental	DB14038	InChI=1S/C29H50O/c1-7-21(19(2)3)9-8-20(4)25-12-13-26-24-11-10-22-18-23(30)14-16-28(22,5)27(24)15-17-29(25,26)6/h10,19-21,23-27,30H,7-9,11-18H2,1-6H3/t20-,21-,23+,24+,25-,26+,27+,28+,29-/m1/s1	KZJWDPNRJALLNS-VJSFXXLFSA-N	2		Not Available	Small Molecule																																			1	No	1	1	Yes	4	0	20.23 Å2	54.21 Å3	129.77 m3·mol-1	6	No	Yes	1.84e-05 mg/mL	7.84	-7.4	18.2	-1.4			
C30H48O5	Not Available	Not Available	488.6991	[H][C@@]12CC[C@]3(C)[C@]([H])(CC=C4[C@]5([H])[C@@H](C)[C@H](C)CC[C@@]5(CC[C@@]34C)C(O)=O)[C@@]1(C)C[C@@H](O)[C@H](O)[C@@]2(C)CO	Solid	Not Available					50241487	2873	CHEMBL404313	106361				C08617		0AS						1551574			ZINC000008221271		Asiatic acid	Experimental	DB14054	InChI=1S/C30H48O5/c1-17-9-12-30(25(34)35)14-13-28(5)19(23(30)18(17)2)7-8-22-26(3)15-20(32)24(33)27(4,16-31)21(26)10-11-29(22,28)6/h7,17-18,20-24,31-33H,8-16H2,1-6H3,(H,34,35)/t17-,18+,20-,21-,22-,23+,24+,26+,27+,28-,29-,30+/m1/s1	JXSVIVRDWWRQRT-UYDOISQJSA-N			Not Available	Small Molecule																																			1	No	5	4	No	5	-1	97.99 Å2	56.63 Å3	136.83 m3·mol-1	2	Yes	No	0.0114 mg/mL	4.23	-4.6	4.74	-2.8			
C27H32O4	Not Available	Not Available	420.549	[H]\C(=C(\[H])C1=C(C)CCCC1(C)C)\C(\C)=C(/[H])C([H])=C(\C(C)=C(\[H])C(O)=O)C1=CC(=CC=C1)C(O)=O	Solid	Not Available								4943196																	13-cis-12-(3'-Carboxyphenyl)retinoic acid	Experimental	DB14097	InChI=1S/C27H32O4/c1-18(12-14-24-19(2)8-7-15-27(24,4)5)11-13-23(20(3)16-25(28)29)21-9-6-10-22(17-21)26(30)31/h6,9-14,16-17H,7-8,15H2,1-5H3,(H,28,29)(H,30,31)/b14-12+,18-11+,20-16-,23-13-	XKKDQOHDTASHCE-PAZAWXFKSA-N			Not Available	Small Molecule																																			1	No	4	2	No	2	-2	74.6 Å2	47.45 Å3	129.42 m3·mol-1	7	No	No	0.000946 mg/mL	6.19	-5.6	3.74				
C27H30Cl2O6	The clearance rate of mometasone furoate is not readily available1, though it may be close to 90L/h2.	The terminal half life of an inhaled dose is approximately 5 hoursLabel though it has been reported as 5.8 hours by other sources11,2.	521.429	[H][C@@]12C[C@@H](C)[C@](OC(=O)C3=CC=CO3)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	Steady state volume of distribution of 152LLabel.	P10632;!P08684;!P20815	CYP2C8;!CYP3A4;!CYP3A5	1. Cytochrome P450 2C8;!2. Cytochrome P450 3A4;!3. Cytochrome P450 3A5		50148733	47564	CHEMBL1161	390091				C07817	D00690	MOF								Mometasone	ZINC000003938677	Asmanex, Dulera, Elocom, Elocon, Nasonex, Sinuva, Zenhale	Mometasone furoate	Approved, Investigational, Vet approved	DB14512	InChI=1S/C27H30Cl2O6/c1-15-11-19-18-7-6-16-12-17(30)8-9-24(16,2)26(18,29)21(31)13-25(19,3)27(15,22(32)14-28)35-23(33)20-5-4-10-34-20/h4-5,8-10,12,15,18-19,21,31H,6-7,11,13-14H2,1-3H3/t15-,18+,19+,21+,24+,25+,26+,27+/m1/s1	WOFMFGQZHJDGCX-ZULDAHANSA-N	4	Mometasone furoate is a corticosteroid used to treat asthma, allergic rhinitis, nasal congestion, nasal polyps, dermatitis, and pruritus.	Overdose with a mometasone furoate inhaler may occur with chronic overuseLabel11. Symptoms of chronic overuse may present as hypercorticism and adrenal suppression, and patients may not require any more treatment than monitoringLabel11.In animal studies of pregnancy, some fetal toxic effects were seen at or above the maximum recommended human dose, though rodents are more sensitive to these effects than humansLabel11,12. The benefits and risks of use should be considered in pregnant patients11,12It is unknown if mometasone furoate is excreted in breast milk but other corticosteroids are and therefore caution should be exercised when administering to nursing mothersLabel11,12.Safety and effectiveness in pediatric populations has been established through clinical trials, though there may be a reduction in expected growth of about 1cm per year depending on the dose and duration of treatmentLabel. Pediatric patients should be titrated to the lowest effective dose for mometasone furoate inhalersLabel.A trial of geriatric patients showed no difference in safety or efficacy compared to younger patients, however patients of an even greater age may still be more sensitive to mometasone furoateLabel11,12.The use of a mometasone furoate inhaler in moderate or severe hepatic impairment rarely leads to detectable plasma concentrations though caution may be prudent with increasing degrees of severityLabel11.The effects of mometasone furoate in renal impairment, and across gender and race have not been studiedLabel11.	Small Molecule																														4.115		215-228		Insoluble	0	No	4	1	No	5	0	93.81 Å2	52.31 Å3	132.5 m3·mol-1	5	No	No	0.0108 mg/mL	5.06	-4.7	13.84	-3.1	P04150;!P06401	NR3C1;!PGR	1. Glucocorticoid receptor;!2. Progesterone receptor
C26H36O7	Not Available	6-8 hours	460.567	[H][C@@]12CC[C@](OC(=O)CC)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Not Available	Not Available	P08684;!P20815;!P24462;!P10632	CYP3A4;!CYP3A5;!CYP3A7;!CYP2C8	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5;!3. Cytochrome P450 3A7;!4. Cytochrome P450 2C8			135746	CHEMBL2106309	62148					D06876									Hydrocortisone_aceponate	ZINC000004213508		Hydrocortisone aceponate	Experimental, Vet approved	DB14538	InChI=1S/C26H36O7/c1-5-22(31)33-26(21(30)14-32-15(2)27)11-9-19-18-7-6-16-12-17(28)8-10-24(16,3)23(18)20(29)13-25(19,26)4/h12,18-20,23,29H,5-11,13-14H2,1-4H3/t18-,19-,20-,23+,24-,25-,26-/m0/s1	MFBMYAOAMQLLPK-FZNHGJLXSA-N			Side effects include inhibition of bone formation, suppression of calcium absorption and delayed wound healing	Small Molecule																																			1	Yes	5	1	Yes	4	0	106.97 Å2	49.74 Å3	120.33 m3·mol-1	7	Yes	No	0.00526 mg/mL	2.86	-4.9	14.81	-2.8	P04083;!P04150;!P80365;!P14060	ANXA1;!NR3C1;!HSD11B2;!HSD3B1	1. Annexin A1;!2. Glucocorticoid receptor;!3. Corticosteroid 11-beta-dehydrogenase isozyme 2;!4. 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1
C23H32O6	Not Available	6-8 hours	404.4966	[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Not Available	Not Available	P08684;!P20815;!P24462;!P15538;!P19099;!P10632	CYP3A4;!CYP3A5;!CYP3A7;!CYP11B1;!CYP11B2;!CYP2C8	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5;!3. Cytochrome P450 3A7;!4. Cytochrome P450 11B1, mitochondrial;!5. Cytochrome P450 11B2, mitochondrial;!6. Cytochrome P450 2C8		50474607	17609	CHEMBL1091	5542				C02821	D00165				5744					Hydrocortisone_acetate	ZINC000003875333	Alcortin A, Analpram HC, Anodan-HC, Anucort-HC, Anusol, Anusol HC, Cortifoam, Cortisporin, Cortisporin-TC, Egozinc, Epifoam, Fucidin, Micort-HC, Neo-polycin HC, Nucort, Pramosone, Procort 1.85/1.15, Proctocort, Proctodan-HC, Proctofoam-HC, Rectacort-HC, Rectogel, Riva-sol HC, U-cort, Vagisil, Vytone	Hydrocortisone acetate	Approved, Vet approved	DB14539	InChI=1S/C23H32O6/c1-13(24)29-12-19(27)23(28)9-7-17-16-5-4-14-10-15(25)6-8-21(14,2)20(16)18(26)11-22(17,23)3/h10,16-18,20,26,28H,4-9,11-12H2,1-3H3/t16-,17-,18-,20+,21-,22-,23-/m0/s1	ALEXXDVDDISNDU-JZYPGELDSA-N	3	Hydrocortisone acetate is a corticosteroid used to treat inflammatory and pruritic corticosteroid-responsive dermatoses and ulcerative colitis.	Side effects include inhibition of bone formation, suppression of calcium absorption and delayed wound healing	Small Molecule																																			1	Yes	5	2	No	4	0	100.9 Å2	43.82 Å3	106.55 m3·mol-1	4	Yes	No	0.0582 mg/mL	1.72	-3.8	12.61	-2.8	P04083;!P04150;!P80365;!P14060	ANXA1;!NR3C1;!HSD11B2;!HSD3B1	1. Annexin A1;!2. Glucocorticoid receptor;!3. Corticosteroid 11-beta-dehydrogenase isozyme 2;!4. 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1
C25H36O6	Not Available	6-8 hours	432.557	[H][C@@]12CC[C@](OC(=O)CCC)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Not Available	Not Available	P08684;!P20815;!P24462;!P15538;!P19099;!P10632	CYP3A4;!CYP3A5;!CYP3A7;!CYP11B1;!CYP11B2;!CYP2C8	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5;!3. Cytochrome P450 3A7;!4. Cytochrome P450 11B1, mitochondrial;!5. Cytochrome P450 11B2, mitochondrial;!6. Cytochrome P450 2C8		323672	31674	CHEMBL1683	24344					D01619									Hydrocortisone_butyrate	ZINC000003977794	Locoid	Hydrocortisone butyrate	Approved, Vet approved	DB14540	InChI=1S/C25H36O6/c1-4-5-21(30)31-25(20(29)14-26)11-9-18-17-7-6-15-12-16(27)8-10-23(15,2)22(17)19(28)13-24(18,25)3/h12,17-19,22,26,28H,4-11,13-14H2,1-3H3/t17-,18-,19-,22+,23-,24-,25-/m0/s1	BMCQMVFGOVHVNG-TUFAYURCSA-N	4	Hydrocortisone butyrate is a corticosteroid used to treat inflammatory and pruritic corticosteroid-responsive dermatoses.	Side effects include inhibition of bone formation, suppression of calcium absorption and delayed wound healing	Small Molecule																																			1	Yes	5	2	Yes	4	0	100.9 Å2	47.74 Å3	115.78 m3·mol-1	6	Yes	No	0.0136 mg/mL	2.86	-4.5	13.75	-2.8	P04083;!P04150;!P80365;!P14060	ANXA1;!NR3C1;!HSD11B2;!HSD3B1	1. Annexin A1;!2. Glucocorticoid receptor;!3. Corticosteroid 11-beta-dehydrogenase isozyme 2;!4. 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1
C29H42O6	Not Available	6-8 hours	486.649	[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC3CCCC3)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Not Available	Not Available	P08684;!P20815;!P24462;!P10632	CYP3A4;!CYP3A5;!CYP3A7;!CYP2C8	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5;!3. Cytochrome P450 3A7;!4. Cytochrome P450 2C8		50371265	5783	CHEMBL1549	193884				C08176	D00976									Hydrocortisone_cypionate	ZINC000004097470		Hydrocortisone cypionate	Approved, Investigational, Vet approved	DB14541	InChI=1S/C29H42O6/c1-27-13-11-20(30)15-19(27)8-9-21-22-12-14-29(34,28(22,2)16-23(31)26(21)27)24(32)17-35-25(33)10-7-18-5-3-4-6-18/h15,18,21-23,26,31,34H,3-14,16-17H2,1-2H3/t21-,22-,23-,26+,27-,28-,29-/m0/s1	DLVOSEUFIRPIRM-KAQKJVHQSA-N			Side effects include inhibition of bone formation, suppression of calcium absorption and delayed wound healing	Small Molecule																																			1	No	5	2	Yes	5	0	100.9 Å2	54.76 Å3	132.33 m3·mol-1	7	Yes	No	0.00326 mg/mL	4.02	-5.2	12.61	-2.8	P04083;!P04150;!P80365;!P14060	ANXA1;!NR3C1;!HSD11B2;!HSD3B1	1. Annexin A1;!2. Glucocorticoid receptor;!3. Corticosteroid 11-beta-dehydrogenase isozyme 2;!4. 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1
C21H31O8P	Not Available	6-8 hours	442.445	[H][C@@]12CC[C@](O)(C(=O)COP(O)(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Not Available	Not Available	P08684;!P20815;!P24462;!P10632	CYP3A4;!CYP3A5;!CYP3A7;!CYP2C8	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5;!3. Cytochrome P450 3A7;!4. Cytochrome P450 2C8			68634	CHEMBL1641	390143														Hydrocortisone_phosphate	ZINC000004097471		Hydrocortisone phosphate	Approved, Vet approved	DB14542	InChI=1S/C21H31O8P/c1-19-7-5-13(22)9-12(19)3-4-14-15-6-8-21(25,17(24)11-29-30(26,27)28)20(15,2)10-16(23)18(14)19/h9,14-16,18,23,25H,3-8,10-11H2,1-2H3,(H2,26,27,28)/t14-,15-,16-,18+,19-,20-,21-/m0/s1	BGSOJVFOEQLVMH-VWUMJDOOSA-N	2	Hydrocortisone phosphate is a corticosteroid used to treat congenital adrenal hyperplasia, for emergency asthma treatment, hypersensitivity, and inflammation.	Side effects include inhibition of bone formation, suppression of calcium absorption and delayed wound healing	Small Molecule																																			1	Yes	7	4	No	4	-2	141.36 Å2	44.37 Å3	108.27 m3·mol-1	4	Yes	No	0.73 mg/mL	1.15	-2.8	1.18	-2.8	P04083;!P04150;!P80365;!P14060	ANXA1;!NR3C1;!HSD11B2;!HSD3B1	1. Annexin A1;!2. Glucocorticoid receptor;!3. Corticosteroid 11-beta-dehydrogenase isozyme 2;!4. 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1
C28H40O7	Not Available	6-8 hours	488.613	[H][C@@]12CC[C@](OC(=O)CCC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Not Available	Not Available	P08684;!P20815;!P24462;!P15538;!P19099;!P10632	CYP3A4;!CYP3A5;!CYP3A7;!CYP11B1;!CYP11B2;!CYP2C8	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5;!3. Cytochrome P450 3A7;!4. Cytochrome P450 11B1, mitochondrial;!5. Cytochrome P450 11B2, mitochondrial;!6. Cytochrome P450 2C8			31675	CHEMBL1200953	552186				C13358	D01886				636398					Hydrocortisone	ZINC000004213519	Pandel	Hydrocortisone probutate	Approved, Vet approved	DB14543	InChI=1S/C28H40O7/c1-5-7-24(33)35-28(22(31)16-34-23(32)6-2)13-11-20-19-9-8-17-14-18(29)10-12-26(17,3)25(19)21(30)15-27(20,28)4/h14,19-21,25,30H,5-13,15-16H2,1-4H3/t19-,20-,21-,25+,26-,27-,28-/m0/s1	FOGXJPFPZOHSQS-AYVLZSQQSA-N	4	Hydrocortisone probutate is a corticosteroid used to treat inflammatory and pruritic corticosteroid-responsive dermatoses.	Side effects include inhibition of bone formation, suppression of calcium absorption and delayed wound healing	Small Molecule																																			1	No	5	1	Yes	4	0	106.97 Å2	53.93 Å3	129.56 m3·mol-1	9	Yes	No	0.00283 mg/mL	4	-5.2	14.81	-2.8	P04083;!P04150;!P80365;!P14060	ANXA1;!NR3C1;!HSD11B2;!HSD3B1	1. Annexin A1;!2. Glucocorticoid receptor;!3. Corticosteroid 11-beta-dehydrogenase isozyme 2;!4. 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1
C26H38O6	Not Available	6-8 hours	446.5763	[H][C@@]12CC[C@](OC(=O)CCCC)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Not Available	Not Available	P08684;!P20815;!P24462;!P15538;!P19099;!P10632	CYP3A4;!CYP3A5;!CYP3A7;!CYP11B1;!CYP11B2;!CYP2C8	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5;!3. Cytochrome P450 3A7;!4. Cytochrome P450 11B1, mitochondrial;!5. Cytochrome P450 11B2, mitochondrial;!6. Cytochrome P450 2C8			50865	CHEMBL1200562	4445635									5282494					Hydrocortisone_valerate	ZINC000004213520	Hydroval	Hydrocortisone valerate	Approved, Vet approved	DB14544	InChI=1S/C26H38O6/c1-4-5-6-22(31)32-26(21(30)15-27)12-10-19-18-8-7-16-13-17(28)9-11-24(16,2)23(18)20(29)14-25(19,26)3/h13,18-20,23,27,29H,4-12,14-15H2,1-3H3/t18-,19-,20-,23+,24-,25-,26-/m0/s1	FZCHYNWYXKICIO-FZNHGJLXSA-N	2	Hydrocortisone valerate is a corticosteroid used to treat inflammatory and pruritic corticosteroid-responsive dermatoses.	Side effects include inhibition of bone formation, suppression of calcium absorption and delayed wound healing	Small Molecule																																			1	Yes	5	2	Yes	4	0	100.9 Å2	50.08 Å3	120.38 m3·mol-1	7	Yes	No	0.00763 mg/mL	3.31	-4.8	13.75	-2.8	P04083;!P04150;!P80365;!P14060	ANXA1;!NR3C1;!HSD11B2;!HSD3B1	1. Annexin A1;!2. Glucocorticoid receptor;!3. Corticosteroid 11-beta-dehydrogenase isozyme 2;!4. 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1
C25H34O8	Not Available	Not Available	462.539	[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Not Available	Not Available	P08684;!P10632;!P15538;!P19099	CYP3A4;!CYP2C8;!CYP11B1;!CYP11B2	1. Cytochrome P450 3A4;!2. Cytochrome P450 2C8;!3. Cytochrome P450 11B1, mitochondrial;!4. Cytochrome P450 11B2, mitochondrial		50016931	31677	CHEMBL977	15760					D01442							21651		Hydrocortisone_hemisuccinate	ZINC000004097472	Solu-cortef	Hydrocortisone succinate	Approved	DB14545	InChI=1S/C25H34O8/c1-23-9-7-15(26)11-14(23)3-4-16-17-8-10-25(32,24(17,2)12-18(27)22(16)23)19(28)13-33-21(31)6-5-20(29)30/h11,16-18,22,27,32H,3-10,12-13H2,1-2H3,(H,29,30)/t16-,17-,18-,22+,23-,24-,25-/m0/s1	VWQWXZAWFPZJDA-CGVGKPPMSA-N	4	Hydrocortisone succinate is a corticosteroid used to treat severe allergic reactions, dermatologic diseases, endocrine disorders, gastrointestinal diseases, hematological disorders, neoplastic diseases, nervous system conditions, ophthalmic diseases, renal diseases, respiratory diseases, and rheumatic disorders.	Not Available	Small Molecule																																			1	Yes	7	3	Yes	4	-1	138.2 Å2	48.68 Å3	117.44 m3·mol-1	7	Yes	No	0.0653 mg/mL	1.54	-3.8	3.66	-2.8			
C30H50O2	Not Available	Not Available	442.728	[H][C@@]12CC[C@]3(C)[C@]([H])(CCC4=C5CC(C)(C)CC[C@]5(C)[C@@H](O)C[C@@]34C)[C@@]1(C)CC[C@H](O)C2(C)C	Not Available	Not Available								4438027												2045735			ZINC000033816140		Ursadiol	Experimental	DB14555	InChI=1S/C30H50O2/c1-25(2)15-16-27(5)20(17-25)19-9-10-22-28(6)13-12-23(31)26(3,4)21(28)11-14-29(22,7)30(19,8)18-24(27)32/h21-24,31-32H,9-18H2,1-8H3/t21-,22+,23-,24-,27-,28-,29+,30+/m0/s1	RTLXJEJRLWILSU-GWNGJUQLSA-N			Not Available	Small Molecule																																			1	No	2	2	No	5	0	40.46 Å2	54.73 Å3	133.16 m3·mol-1	0	No	No	0.00253 mg/mL	6.13	-5.2	19.49	-0.3			
C21H30O3	Not Available	Not Available	330.4611	[H][C@@]12CC[C@](O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4		50423511	17252	CHEMBL1062	6002			HMDB0000374	C01176		3QZ						5542		17%CE%B1-Hydroxyprogesterone	ZINC000005434436		Hydroxyprogesterone	Experimental	DB14570	InChI=1S/C21H30O3/c1-13(22)21(24)11-8-18-16-5-4-14-12-15(23)6-9-19(14,2)17(16)7-10-20(18,21)3/h12,16-18,24H,4-11H2,1-3H3/t16-,17+,18+,19+,20+,21+/m1/s1	DBPWSSGDRRHUNT-CEGNMAFCSA-N	4		Not Available	Small Molecule																																			1	Yes	3	1	No	4	0	54.37 Å2	37.9 Å3	94.11 m3·mol-1	1	Yes	No	0.0293 mg/mL	3.4	-4	12.7	-3.8			
C24H31ClO7	Loteprednol etabonate was slowly hydrolyzed in liver at clearance rates of 0.21 +/- 0.04 and 2.41 +/- 0.13 ml/h/kg in the liver and plasma, respectively 2.	The terminal half-life of loteprednol etabonate as determined when administered intravenously at a dose of 5 mg/kg in the dog animal model is 2.8 hours 3.	466.96	[H][C@@]12CC[C@](OC(=O)OCC)(C(=O)OCCl)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	The only data available regarding the volume of distribution of loteprednol etabonate (LE) is the volume of distribution the agent demonstrated when administered to dogs - a value of 3.7 L/kg 3. It has been shown, however, that the topical ocular administration of LE distributes preferentially into the cellular components of blood 8.	P08684;!P27169	CYP3A4;!PON1	1. Cytochrome P450 3A4;!2. Serum paraoxonase/arylesterase 1			31784	CHEMBL1200865	392049	Drugs.com Drug Page		HMDB0015011		D01689			PA164764569	9865442	46504713	RxList Drug Page		DAP001045	Loteprednol	ZINC000003920673	Eysuvis, Inveltys, Lotemax	Loteprednol etabonate	Approved	DB14596	InChI=1S/C24H31ClO7/c1-4-30-21(29)32-24(20(28)31-13-25)10-8-17-16-6-5-14-11-15(26)7-9-22(14,2)19(16)18(27)12-23(17,24)3/h7,9,11,16-19,27H,4-6,8,10,12-13H2,1-3H3/t16-,17-,18-,19+,22-,23-,24-/m0/s1	DMKSVUSAATWOCU-HROMYWEYSA-N	4	Loteprednol etabonate is a corticosteroid used to treat allergic conjunctivitis as well as inflammation and pain after ocular surgery.	The most common adverse drug reactions reported during clinical trials for the medication were eye pain and posterior capsular opacification, both of which may also be the consequence of the very surgical procedures performed on the eye(s) Label.The agent is not absorbed systemically following topical ophthalmic administration and maternal use is not expected to result in fetal exposure to the drug Label.The medication is not absorbed systemically by the mother following topical ophthalmic administration, and breastfeeding is not expected to result in exposure of the child to the agent Label.Long-term animal studies have not been conducted to evaluate the carcinogenic potential of loteprednol etabonate. Loteprednol etabonate was not genotoxic in vitro in the Ames test, the mouse lymphoma thymidine kinase (tk) assay, or in a chromosome aberration test in human lymphocytes, or in vivo in the single dose mouse micronucleus assay Label.Overdose is not expected to be likely to occur after ocular administration 8.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.2305 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.4		220-224 °C		5 mg/mL	1	Yes	5	1	Yes	4	0	99.13 Å2	48.43 Å3	118.17 m3·mol-1	7	Yes	No	0.00693 mg/mL	3.94	-4.8	14.88	-2.9	P04150	NR3C1	1. Glucocorticoid receptor
C23H34O3	Not Available	Not Available	358.522	[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@H](CC[C@]12C)OC(C)=O	Not Available	Not Available						34930	CHEMBL1892286	2005918				C14658										Pregnenolone_acetate	ZINC000003860692		Pregnenolone acetate	Investigational	DB14626	InChI=1S/C23H34O3/c1-14(24)19-7-8-20-18-6-5-16-13-17(26-15(2)25)9-11-22(16,3)21(18)10-12-23(19,20)4/h5,17-21H,6-13H2,1-4H3/t17-,18-,19+,20-,21-,22-,23+/m0/s1	CRRKVZVYZQXICQ-RJJCNJEVSA-N			Not Available	Small Molecule																																			1	Yes	2	0	No	4	0	43.37 Å2	42.51 Å3	102.91 m3·mol-1	3	Yes	No	0.00188 mg/mL	4.02	-5.3	19.4	-6.8			
C21H29O8P	Not Available	The half life of prednisolone is 2-4 hours.6	440.429	[H][C@@]12CC[C@](O)(C(=O)COP(O)(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	The volume of distribution of prednisolone phosphate has been reported as 0.22-0.7L/kg.7	P08684;!P20815;!BE0004866;!P11509;!Q16678;!P20813;!P10632;!P11712;!P33261;!P80365;!P28845	CYP3A4;!CYP3A5;!;!CYP2A6;!CYP1B1;!CYP2B6;!CYP2C8;!CYP2C9;!CYP2C19;!HSD11B2;!HSD11B1	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5;!3. Cytochrome P450 3A Subfamily (Protein Group);!4. Cytochrome P450 2A6;!5. Cytochrome P450 1B1;!6. Cytochrome P450 2B6;!7. Cytochrome P450 2C8;!8. Cytochrome P450 2C9;!9. Cytochrome P450 2C19;!10. Corticosteroid 11-beta-dehydrogenase isozyme 2;!11. Corticosteroid 11-beta-dehydrogenase isozyme 1			145705	CHEMBL1201231	65064														Prednisolone_sodium_phosphate	ZINC000004097473	Orapred, Pediapred	Prednisolone phosphate	Approved, Vet approved	DB14631	InChI=1S/C21H29O8P/c1-19-7-5-13(22)9-12(19)3-4-14-15-6-8-21(25,17(24)11-29-30(26,27)28)20(15,2)10-16(23)18(14)19/h5,7,9,14-16,18,23,25H,3-4,6,8,10-11H2,1-2H3,(H2,26,27,28)/t14-,15-,16-,18+,19-,20-,21-/m0/s1	JDOZJEUDSLGTLU-VWUMJDOOSA-N	3	Prednisolone phosphate is a corticosteroid used to treat inflammation, immune reactions, as well as endocrine or neoplastic conditions.	Data regarding acute overdose is not readily available.6 However, patients experiencing chronic overdose may present with mental symptoms, moon face, abnormal fat deposits, and fluid retention.6 Acute oral overdose may be treated with immediate gastric lavage or emesis followed by symptomatic and supportive treatment.6 Chronic overdosage can be managed by temporary dose reduction or alternate day treatment.6	Small Molecule																																			1	Yes	7	4	No	4	-2	141.36 Å2	43.42 Å3	109.37 m3·mol-1	4	Yes	No	0.432 mg/mL	1.15	-3	1.18	-2.9	P04150;!P04083	NR3C1;!ANXA1	1. Glucocorticoid receptor;!2. Annexin A1
C27H38O6	Not Available	Not Available	458.587	[H][C@@]12CC[C@](O)(C(=O)COC(=O)CC(C)(C)C)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Not Available	Not Available						8381	CHEMBL1200909	84007				C08182	D00982				93055					Prednisolone_tebutate	ZINC000004097474		Prednisolone tebutate	Approved, Vet approved	DB14632	InChI=1S/C27H38O6/c1-24(2,3)14-22(31)33-15-21(30)27(32)11-9-19-18-7-6-16-12-17(28)8-10-25(16,4)23(18)20(29)13-26(19,27)5/h8,10,12,18-20,23,29,32H,6-7,9,11,13-15H2,1-5H3/t18-,19-,20-,23+,25-,26-,27-/m0/s1	HUMXXHTVHHLNRO-KAJVQRHHSA-N			Not Available	Small Molecule																																			1	No	5	2	Yes	4	0	100.9 Å2	51.06 Å3	125.9 m3·mol-1	6	Yes	No	0.00929 mg/mL	3.45	-4.7	12.61	-2.9			
C25H32O8	Not Available	Not Available	460.523	[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Not Available	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5			135745	CHEMBL485659	571099														Prednisolone	ZINC000003881478		Prednisolone hemisuccinate	Experimental	DB14633	InChI=1S/C25H32O8/c1-23-9-7-15(26)11-14(23)3-4-16-17-8-10-25(32,24(17,2)12-18(27)22(16)23)19(28)13-33-21(31)6-5-20(29)30/h7,9,11,16-18,22,27,32H,3-6,8,10,12-13H2,1-2H3,(H,29,30)/t16-,17-,18-,22+,23-,24-,25-/m0/s1	APGDTXUMTIZLCJ-CGVGKPPMSA-N		Prednisolone hemisuccinate is a corticosteroid indicated in the treatment of anaphylaxis, asthma, edema, organ rejection, and other indications.	Not Available	Small Molecule																																			1	Yes	7	3	Yes	4	-1	138.2 Å2	47.52 Å3	118.54 m3·mol-1	7	Yes	No	0.0483 mg/mL	1.54	-4	3.66	-2.9			
C23H29FO6	Not Available	Not Available	420.477	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C	Not Available	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4					91954															ZINC000005161248		Fluprednisolone acetate	Experimental	DB14637	InChI=1S/C23H29FO6/c1-12(25)30-11-19(28)23(29)7-5-15-14-9-17(24)16-8-13(26)4-6-21(16,2)20(14)18(27)10-22(15,23)3/h4,6,8,14-15,17-18,20,27,29H,5,7,9-11H2,1-3H3/t14-,15-,17-,18-,20+,21-,22-,23-/m0/s1	CYMBAKFTWRNHPS-APRQOCPKSA-N			Not Available	Small Molecule																																			1	Yes	5	2	No	4	0	100.9 Å2	42.94 Å3	107.47 m3·mol-1	4	Yes	No	0.0414 mg/mL	1.37	-4	12.61	-2.9			
C23H29FO6	Not Available	Not Available	420.477	[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Not Available	Not Available						34517	CHEMBL1608183	194836				C14636	D04627										ZINC000004213604		Isoflupredone acetate	Vet approved	DB14640	InChI=1S/C23H29FO6/c1-13(25)30-12-19(28)22(29)9-7-16-17-5-4-14-10-15(26)6-8-20(14,2)23(17,24)18(27)11-21(16,22)3/h6,8,10,16-18,27,29H,4-5,7,9,11-12H2,1-3H3/t16-,17-,18-,20-,21-,22-,23-/m0/s1	ZOCUOMKMBMEYQV-GSLJADNHSA-N			Not Available	Small Molecule																																			1	Yes	5	2	No	4	0	100.9 Å2	42.89 Å3	107.17 m3·mol-1	4	Yes	No	0.025 mg/mL	1.76	-4.2	12.58	-3.4			
C27H36O7	Not Available	Not Available	472.578	[H][C@@]12CC[C@](OC(=O)CC)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C	Not Available	Not Available						135762	CHEMBL1697782	56717														Methylprednisolone_aceponate	ZINC000004213828		Methylprednisolone aceponate	Approved, Vet approved	DB14643	InChI=1S/C27H36O7/c1-6-23(32)34-27(22(31)14-33-16(3)28)10-8-19-18-11-15(2)20-12-17(29)7-9-25(20,4)24(18)21(30)13-26(19,27)5/h7,9,12,15,18-19,21,24,30H,6,8,10-11,13-14H2,1-5H3/t15-,18-,19-,21-,24+,25-,26-,27-/m0/s1	DALKLAYLIPSCQL-YPYQNWSCSA-N	4	Methylprednisolone aceponate is a corticosteroid indicated in the treatment of corticosteroid-responsive dermatoses.	Not Available	Small Molecule																																			1	Yes	5	1	Yes	4	0	106.97 Å2	50.86 Å3	125.97 m3·mol-1	7	Yes	No	0.00637 mg/mL	3.14	-4.9	14.8	-2.9			
C26H34O8	Not Available	Not Available	474.55	[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C	Not Available	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5			135765	CHEMBL1201265	16034														Methylprednisolone	ZINC000003977781	Solu-medrol	Methylprednisolone hemisuccinate	Approved	DB14644	InChI=1S/C26H34O8/c1-14-10-16-17-7-9-26(33,20(29)13-34-22(32)5-4-21(30)31)25(17,3)12-19(28)23(16)24(2)8-6-15(27)11-18(14)24/h6,8,11,14,16-17,19,23,28,33H,4-5,7,9-10,12-13H2,1-3H3,(H,30,31)/t14-,16-,17-,19-,23+,24-,25-,26-/m0/s1	IMBXEJJVJRTNOW-XYMSELFBSA-N	4	Methylprednisolone hemisuccinate is a water soluble corticosteroid used to treat severe allergic reactions, dermatologic diseases, endocrine disorders, gastrointestinal diseases, hematological disorders, neoplastic diseases, nervous system conditions, ophthalmic diseases, renal diseases, respiratory diseases, and rheumatic disorders.	Not Available	Small Molecule																																			1	Yes	7	3	Yes	4	-1	138.2 Å2	49.87 Å3	123.09 m3·mol-1	7	Yes	No	0.0264 mg/mL	1.83	-4.2	3.66	-2.9			
C23H28O6	Not Available	Not Available	400.471	[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Not Available	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5			34655	CHEMBL1507567	82567				C14668	D08416										ZINC000003881638		Prednisone acetate	Approved, Experimental, Investigational	DB14646	InChI=1S/C23H28O6/c1-13(24)29-12-19(27)23(28)9-7-17-16-5-4-14-10-15(25)6-8-21(14,2)20(16)18(26)11-22(17,23)3/h6,8,10,16-17,20,28H,4-5,7,9,11-12H2,1-3H3/t16-,17-,20+,21-,22-,23-/m0/s1	MOVRKLZUVNCBIP-RFZYENFJSA-N	4		Not Available	Small Molecule																																			1	Yes	5	1	No	4	0	97.74 Å2	42.51 Å3	106.72 m3·mol-1	4	Yes	No	0.0235 mg/mL	2.1	-4.2	12.6	-3.8			
C24H31FO6	Not Available	Not Available	434.4977	[H][C@@]12C[C@@H](C)[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Not Available	Not Available	P08684;!P20815;!P24462;!P05093;!P04798;!P11509;!P20813;!P33261;!P10632;!P05181;!Q9HB55;!Q02928;!P15538;!P80365;!P28845	CYP3A4;!CYP3A5;!CYP3A7;!CYP17A1;!CYP1A1;!CYP2A6;!CYP2B6;!CYP2C19;!CYP2C8;!CYP2E1;!CYP3A43;!CYP4A11;!CYP11B1;!HSD11B2;!HSD11B1	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5;!3. Cytochrome P450 3A7;!4. Steroid 17-alpha-hydroxylase/17,20 lyase;!5. Cytochrome P450 1A1;!6. Cytochrome P450 2A6;!7. Cytochrome P450 2B6;!8. Cytochrome P450 2C19;!9. Cytochrome P450 2C8;!10. Cytochrome P450 2E1;!11. Cytochrome P450 3A43;!12. Cytochrome P450 4A11;!13. Cytochrome P450 11B1, mitochondrial;!14. Corticosteroid 11-beta-dehydrogenase isozyme 2;!15. Corticosteroid 11-beta-dehydrogenase isozyme 1		50103620	4463	CHEMBL1530428	206624				C08174	D07796				236702					Dexamethasone_acetate	ZINC000003882068		Dexamethasone acetate	Approved, Investigational, Vet approved	DB14649	InChI=1S/C24H31FO6/c1-13-9-18-17-6-5-15-10-16(27)7-8-21(15,3)23(17,25)19(28)11-22(18,4)24(13,30)20(29)12-31-14(2)26/h7-8,10,13,17-19,28,30H,5-6,9,11-12H2,1-4H3/t13-,17+,18+,19+,21+,22+,23+,24+/m1/s1	AKUJBENLRBOFTD-RPRRAYFGSA-N	3		Not Available	Small Molecule																																			1	Yes	5	2	No	4	0	100.9 Å2	45.02 Å3	111.64 m3·mol-1	4	Yes	No	0.0164 mg/mL	2.12	-4.4	12.44	-3.4	P04150;!P04083;!P35228;!P51843;!O75469	NR3C1;!ANXA1;!NOS2;!NR0B1;!NR1I2	1. Glucocorticoid receptor;!2. Annexin A1;!3. Nitric oxide synthase, inducible;!4. Nuclear receptor subfamily 0 group B member 1;!5. Nuclear receptor subfamily 1 group I member 2
C25H32O4	Not Available	Not Available	396.527	[H][C@@]12CC(=C)[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C	Not Available	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5			34831	CHEMBL1328968	219803				C14642	D04900									Melengestrol_acetate	ZINC000004216828		Melengestrol acetate	Experimental	DB14659	InChI=1S/C25H32O4/c1-14-11-19-20(23(5)9-7-18(28)13-21(14)23)8-10-24(6)22(19)12-15(2)25(24,16(3)26)29-17(4)27/h11,13,19-20,22H,2,7-10,12H2,1,3-6H3/t19-,20+,22+,23-,24+,25+/m1/s1	UDKABVSQKJNZBH-DWNQPYOZSA-N			Not Available	Small Molecule																																			1	Yes	3	0	No	4	0	60.44 Å2	44.82 Å3	112.83 m3·mol-1	3	Yes	No	0.00147 mg/mL	3.82	-5.4	17.54	-4.9			
C22H30FO8P	The clearance of betamethasone in an intramuscular injection of 3mg betamethasone acetate and 3mg betamethasone phosphate is 12.62 ± 3.45 L/h.1	The half life of betamethasone in an intramuscular injection of 3mg betamethasone acetate and 3mg betamethasone phosphate is 12.47 ± 1.91 h.1	472.446	[H][C@@]12C[C@H](C)[C@](O)(C(=O)COP(O)(O)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	The volume of distribution of betamethasone in an intramuscular injection of 3mg betamethasone acetate and 3mg betamethasone phosphate is 226.00 ± 61.64 L.1	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5			68603	CHEMBL1201207	96937														Betamethasone_phosphate	ZINC000004097469		Betamethasone phosphate	Approved, Vet approved	DB14669	InChI=1S/C22H30FO8P/c1-12-8-16-15-5-4-13-9-14(24)6-7-19(13,2)21(15,23)17(25)10-20(16,3)22(12,27)18(26)11-31-32(28,29)30/h6-7,9,12,15-17,25,27H,4-5,8,10-11H2,1-3H3,(H2,28,29,30)/t12-,15-,16-,17-,19-,20-,21-,22-/m0/s1	VQODGRNSFPNSQE-DVTGEIKXSA-N		Betamethasone phosphate is a fast acting ester prodrug of a corticosteroid used to treat inflammatory conditions.	Patients experiencing an acute overdose should be treated with symptomatic and supportive treatment.5 Chronic overdoses where patients require continued therapy can be treated through temporary dose reduction or alternate day treatment.5The oral, intraperitoneal, and intravenous LD50 values in rats are 1877 mg/kg, 1179 mg/kg, and 1276 mg/kg, respectively.6	Small Molecule																																			1	Yes	7	4	No	4	-2	141.36 Å2	45.43 Å3	113.37 m3·mol-1	4	Yes	No	2.9 mg/mL	1.56	-2.2	1.18	-3.4	P04150;!P04083	NR3C1;!ANXA1	1. Glucocorticoid receptor;!2. Annexin A1
C26H35FO7	Not Available	Not Available	478.557	CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]21C	Not Available	Not Available								92436																	Flurandrenolide acetate	Experimental	DB14673	InChI=1S/C26H35FO7/c1-13(28)32-12-20(31)26-21(33-23(2,3)34-26)10-16-15-9-18(27)17-8-14(29)6-7-24(17,4)22(15)19(30)11-25(16,26)5/h8,15-16,18-19,21-22,30H,6-7,9-12H2,1-5H3/t15-,16-,18-,19-,21+,22+,24-,25-,26+/m0/s1	AUDPKCCPWYXNEV-XTLNBZDDSA-N			Not Available	Small Molecule																																			1	Yes	6	1	No	5	0	99.13 Å2	49.64 Å3	119.94 m3·mol-1	4	Yes	No	0.0162 mg/mL	2	-4.5	14.67	-2.8			
C26H38O4	Not Available	Not Available	414.586	[H][C@@]12CC[C@](OC(=O)CCCCC)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	Not Available	Not Available						31650	CHEMBL2107389	391969												4791		Gestonorone_caproate	ZINC000004216396		Gestonorone caproate	Approved	DB14677	InChI=1S/C26H38O4/c1-4-5-6-7-24(29)30-26(17(2)27)15-13-23-22-10-8-18-16-19(28)9-11-20(18)21(22)12-14-25(23,26)3/h16,20-23H,4-15H2,1-3H3/t20-,21+,22+,23-,25-,26-/m0/s1	XURCMZMFZXXQDJ-UKNJCJGYSA-N			Not Available	Small Molecule																																			1	Yes	3	0	Yes	4	0	60.44 Å2	48.55 Å3	117.21 m3·mol-1	7	No	No	0.00141 mg/mL	5.58	-5.5	17.69	-4.7			
C21H28O5	Not Available	Not Available	360.444	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Not Available	Not Available	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5		13739	16962	CHEMBL1499	193441			HMDB0002802	C00762	D07749							2878		Cortisone	ZINC000004083557		Cortisone	Experimental	DB14681	InChI=1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h9,14-15,18,22,26H,3-8,10-11H2,1-2H3/t14-,15-,18+,19-,20-,21-/m0/s1	MFYSYFVPBJMHGN-ZPOLXVRWSA-N	4		Not Available	Small Molecule																																			1	Yes	5	2	No	4	0	91.67 Å2	38.95 Å3	96.47 m3·mol-1	2	Yes	No	0.136 mg/mL	1.66	-3.4	12.58	-3.3			
C29H33FO9S	Not Available	Not Available	576.63	[H][C@@]12C[C@@H](C)[C@](O)(C(=O)COC(=O)C3=CC=CC(=C3)S(O)(=O)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Not Available	Not Available							CHEMBL3305965	56740															ZINC000004212887	Sofracort	Dexamethasone metasulfobenzoate	Approved, Experimental	DB14703	InChI=1S/C29H33FO9S/c1-16-11-22-21-8-7-18-13-19(31)9-10-26(18,2)28(21,30)23(32)14-27(22,3)29(16,35)24(33)15-39-25(34)17-5-4-6-20(12-17)40(36,37)38/h4-6,9-10,12-13,16,21-23,32,35H,7-8,11,14-15H2,1-3H3,(H,36,37,38)/t16-,21+,22+,23+,26+,27+,28+,29+/m1/s1	TWQWRHIQRAZHPR-XNXCGYEVSA-N		Dexamethasone metasulfobenzoate is an ophthalmic and auricular corticosteroid used with antibiotics for the treatment of otitis externa, blepharitis, and other inflammatory eye conditions.	Not Available	Small Molecule																																			1	No	8	3	Yes	5	-1	155.27 Å2	57.93 Å3	142.94 m3·mol-1	6	No	No	0.0457 mg/mL	1.22	-4.1	-2.5	-3.4			
C22H28O4	Not Available	Not Available	356.462	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@@]1(O)C(=O)CO	Not Available	Not Available					50432396		CHEMBL2348780	2299335														Vamorolone	ZINC000033650317		Vamorolone	Investigational	DB15114	InChI=1S/C22H28O4/c1-13-10-18-16-5-4-14-11-15(24)6-8-20(14,2)17(16)7-9-21(18,3)22(13,26)19(25)12-23/h6-8,11,13,16,18,23,26H,4-5,9-10,12H2,1-3H3/t13-,16-,18+,20+,21+,22+/m1/s1	ZYTXTXAMMDTYDQ-DGEXFFLYSA-N	2		Not Available	Small Molecule																																			1	Yes	4	2	No	4	0	74.6 Å2	39.26 Å3	102.22 m3·mol-1	2	Yes	No	0.0246 mg/mL	2.54	-4.2	12.45	-3.3			
C23H30O6	Data regarding the clearance of prednisolone acetate is not readily available.6,7,8	Oral prednisolone acetate has a plasma half life of 2-3 hours.5	402.4807	[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@]([H])(O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Solid	The volume of distribution of the active metabolite, prednisolone, is 0.22/0.7L/kg.5	P08684	CYP3A4	1. Cytochrome P450 3A4			8380	CHEMBL1152	5629				C08180					5834					Prednisolone_acetate	ZINC000003875348	Blephamide, Econopred Plus, Flo-pred, Pred Forte, Pred Mild, Pred-G	Prednisolone acetate	Approved, Vet approved	DB15566	InChI=1S/C23H30O6/c1-13(24)29-12-19(27)23(28)9-7-17-16-5-4-14-10-15(25)6-8-21(14,2)20(16)18(26)11-22(17,23)3/h6,8,10,16-18,20,26,28H,4-5,7,9,11-12H2,1-3H3/t16-,17-,18-,20+,21-,22-,23-/m0/s1	LRJOMUJRLNCICJ-JZYPGELDSA-N	4	Prednisolone acetate is a glucocorticoid used to treat a wide variety of endocrine, inflammatory, and immune conditions as well as for palliation of neoplastic conditions.	The oral LD50 of prednisolone acetate in mice is 1680 mg/kg.8 Patients experiencing an overdose of oral prednisolone acetate may experience an increased severity in the adverse effects of corticosteroids.5 Overdose of oral prednisolone acetate may be treated by gastric lavage or inducing vomiting if the overdose was recent, as well as supportive and symptomatic therapy.5 Chronic overdosage may be treated by dose reduction or treating patients on alternate days.5 An overdose by the ophthalmic route is not expected to cause problems.5	Small Molecule																														1.332		238			1	Yes	5	2	No	4	0	100.9 Å2	42.93 Å3	107.64 m3·mol-1	4	Yes	No	0.0417 mg/mL	1.71	-4	12.61	-2.9	P04150	NR3C1	1. Glucocorticoid receptor
C30H39NO2	Not Available	Not Available	445.647	[H][C@@]12CC[C@@]3(CCCO3)[C@@]1(C)C[C@H](C1=CC=C(C=C1)N(C)C)C1=C3CCC(=O)C=C3[C@H](C)C[C@@]21[H]	Not Available	Not Available							CHEMBL460258	143897															ZINC000003918217		ORG-31710	Experimental	DB15585	InChI=1S/C30H39NO2/c1-19-16-25-27-12-14-30(13-5-15-33-30)29(27,2)18-26(20-6-8-21(9-7-20)31(3)4)28(25)23-11-10-22(32)17-24(19)23/h6-9,17,19,25-27H,5,10-16,18H2,1-4H3/t19-,25+,26-,27+,29+,30+/m1/s1	HFDGABTZPISMDD-IEVXGSBISA-N			Not Available	Small Molecule																																			1	No	3	0	No	6	0	29.54 Å2	52.91 Å3	136.34 m3·mol-1	2	No	Yes	0.00101 mg/mL	5.4	-5.6	18.37	4.89			
C30H48O3	Not Available	Not Available	456.711	[H][C@@]12[C@@H](C)[C@H](C)CC[C@@]1(CC[C@]1(C)C2=CC[C@]2([H])[C@@]3(C)CC[C@H](O)C(C)(C)[C@]3([H])CC[C@@]12C)C(O)=O	Not Available	Not Available					50148911	9908	CHEMBL169	58472			HMDB0002395	C08988		6Q5						1426931		Ursolic_acid	ZINC000003978827		Ursolic acid	Experimental	DB15588	InChI=1S/C30H48O3/c1-18-10-15-30(25(32)33)17-16-28(6)20(24(30)19(18)2)8-9-22-27(5)13-12-23(31)26(3,4)21(27)11-14-29(22,28)7/h8,18-19,21-24,31H,9-17H2,1-7H3,(H,32,33)/t18-,19+,21+,22-,23+,24+,27+,28-,29-,30+/m1/s1	WCGUUGGRBIKTOS-GPOJBZKASA-N	2		Not Available	Small Molecule																																			1	No	3	2	No	5	-1	57.53 Å2	54.51 Å3	133.7 m3·mol-1	1	No	No	0.00059 mg/mL	6.58	-5.9	4.74	-0.84			
C29H36O4	Not Available	Not Available	448.603	[H][C@@]12C[C@H]3O[C@](C)(O[C@@]3(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C)C1=CC=CC=C1	Not Available	Not Available						49327	CHEMBL3989742	4447595														Algestone_acetophenide	ZINC000004172334		Algestone acetophenide	Experimental	DB15775	InChI=1S/C29H36O4/c1-18(30)29-25(32-28(4,33-29)19-8-6-5-7-9-19)17-24-22-11-10-20-16-21(31)12-14-26(20,2)23(22)13-15-27(24,29)3/h5-9,16,22-25H,10-15,17H2,1-4H3/t22-,23+,24+,25-,26+,27+,28-,29-/m1/s1	AHBKIEXBQNRDNL-FVCOMRFXSA-N		Algestone acetophenide is a progestin indicated in combination with an estrogen as an injectable contraceptive.	Not Available	Small Molecule																																			1	No	4	0	No	6	0	52.6 Å2	50.33 Å3	127.37 m3·mol-1	2	No	No	0.000357 mg/mL	5.74	-6.1	17.63	-4.1			
C23H29ClO4	Not Available	Not Available	404.93	[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(Cl)C2=CC(=O)CC[C@]12C	Not Available	Not Available						31394	CHEMBL110691	8963				C12729								2369		Chlormadinone_acetate	ZINC000003876041		Chlormadinone acetate	Experimental	DB15903	InChI=1S/C23H29ClO4/c1-13(25)23(28-14(2)26)10-7-18-16-12-20(24)19-11-15(27)5-8-21(19,3)17(16)6-9-22(18,23)4/h11-12,16-18H,5-10H2,1-4H3/t16-,17+,18+,21-,22+,23+/m1/s1	QMBJSIBWORFWQT-DFXBJWIESA-N		Chlormadinone acetate is a progestin indicated in combination with an estrogen for birth control.	Not Available	Small Molecule																																			1	Yes	3	0	No	4	0	60.44 Å2	43.67 Å3	109.09 m3·mol-1	3	Yes	No	0.00158 mg/mL	3.72	-5.4	17.83	-5.5			
C21H25ClO5	Not Available	Not Available	392.88	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])C[C@H](Cl)C2=CC(=O)C=C[C@]12C	Not Available	Not Available						135618		2298578														Chloroprednisone	ZINC000033650036		Chloroprednisone	Experimental	DB15970	InChI=1S/C21H25ClO5/c1-19-5-3-11(24)7-14(19)15(22)8-12-13-4-6-21(27,17(26)10-23)20(13,2)9-16(25)18(12)19/h3,5,7,12-13,15,18,23,27H,4,6,8-10H2,1-2H3/t12-,13-,15-,18+,19-,20-,21-/m0/s1	NPSLCOWKFFNQKK-ZPSUVKRCSA-N			Not Available	Small Molecule																																			1	Yes	5	2	No	4	0	91.67 Å2	40.51 Å3	102.13 m3·mol-1	2	Yes	No	0.0395 mg/mL	1.78	-4	12.58	-3.3			
C21H29ClO3	Not Available	Not Available	364.91	[H][C@@]12CC[C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=C(Cl)C(=O)CC[C@]12C	Not Available	Not Available						81712	CHEMBL519327	12762				C18374								236522		Clostebol_acetate	ZINC000003881980		Clostebol acetate	Experimental	DB15984	InChI=1S/C21H29ClO3/c1-12(23)25-18-7-6-14-13-4-5-16-19(22)17(24)9-11-20(16,2)15(13)8-10-21(14,18)3/h13-15,18H,4-11H2,1-3H3/t13-,14-,15-,18-,20+,21-/m0/s1	XYGMEFJSKQEBTO-KUJXMBTLSA-N		Clostebol acetate is a steroid combined with neomycin in topical formulations for the treatment of minor skin wounds.	Not Available	Small Molecule																																			1	Yes	2	0	No	4	0	43.37 Å2	40.68 Å3	98.37 m3·mol-1	2	Yes	No	0.00309 mg/mL	4.2	-5.1		-6.2			
C27H38O6	Not Available	Not Available	458.595	[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCCCC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	Not Available	Not Available								136723																	Prednisolone caproate	Experimental	DB15999	InChI=1S/C27H38O6/c1-4-5-6-7-23(31)33-16-22(30)27(32)13-11-20-19-9-8-17-14-18(28)10-12-25(17,2)24(19)21(29)15-26(20,27)3/h10,12,14,19-21,24,29,32H,4-9,11,13,15-16H2,1-3H3/t19-,20-,21-,24+,25-,26-,27-/m0/s1	DNSAKUGJOSFARZ-FOMYWIRZSA-N		Prednisolone caproate is a corticosteroid indicated to treat hemorrhoids, anal fissures, and proctitis.	Not Available	Small Molecule																																			1	No	5	2	Yes	4	0	100.9 Å2	51.73 Å3	126.07 m3·mol-1	8	Yes	No	0.0065 mg/mL	3.75	-4.8	12.61	-2.9			
C29H46O3	Not Available	Not Available	442.684	[H][C@@]12CC[C@H](OC(=O)CCCCCCCCC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Not Available	Not Available						35000	CHEMBL1473654	136680				C14607								37858		Testosterone_decanoate	ZINC000019685816		Testosterone decanoate	Experimental	DB16001	InChI=1S/C29H46O3/c1-4-5-6-7-8-9-10-11-27(31)32-26-15-14-24-23-13-12-21-20-22(30)16-18-28(21,2)25(23)17-19-29(24,26)3/h20,23-26H,4-19H2,1-3H3/t23-,24-,25-,26-,28-,29-/m0/s1	LBERVHLCXUMDOT-MPZZESAYSA-N		Testosterone decanoate is a steroid indicated for testosterone replacement therapy in sterilization, missing testicle, hypopituitarism, and osteoporosis.	Not Available	Small Molecule																																			1	No	2	0	Yes	4	0	43.37 Å2	54.86 Å3	130.42 m3·mol-1	10	No	No	0.000114 mg/mL	7.62	-6.6	18.52	-4.8			
C25H38O3	Not Available	Not Available	386.576	[H][C@@]12CC[C@H](OC(=O)CCC(C)C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Not Available	Not Available					50103618	35001	CHEMBL3189011	201317				C14663								75806		Testosterone_isocaproate	ZINC000004538407		Testosterone isocaproate	Experimental	DB16002	InChI=1S/C25H38O3/c1-16(2)5-10-23(27)28-22-9-8-20-19-7-6-17-15-18(26)11-13-24(17,3)21(19)12-14-25(20,22)4/h15-16,19-22H,5-14H2,1-4H3/t19-,20-,21-,22-,24-,25-/m0/s1	PPYHLSBUTAPNGT-BKWLFHPQSA-N		Testosterone isocaproate is a steroid indicated for testosterone replacement therapy in sterilization, missing testicle, hypopituitarism, and osteoporosis.	Not Available	Small Molecule																																			1	No	2	0	No	4	0	43.37 Å2	46.61 Å3	111.96 m3·mol-1	5	No	No	0.000955 mg/mL	5.68	-5.6	18.52	-4.8			
C28H36O3	Not Available	Not Available	420.593	[H][C@@]12CC[C@H](OC(=O)CCC3=CC=CC=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Not Available	Not Available						35002	CHEMBL2356993	14062				C14667								37855		Testosterone_phenylpropionate	ZINC000003881605		Testosterone phenylpropionate	Experimental	DB16003	InChI=1S/C28H36O3/c1-27-16-14-21(29)18-20(27)9-10-22-23-11-12-25(28(23,2)17-15-24(22)27)31-26(30)13-8-19-6-4-3-5-7-19/h3-7,18,22-25H,8-17H2,1-2H3/t22-,23-,24-,25-,27-,28-/m0/s1	HHSXYDOROIURIP-FEZCWRLCSA-N		Testosterone phenylpropionate is a steroid indicated for testosterone replacement therapy in sterilization, missing testicle, hypopituitarism, and osteoporosis.	Not Available	Small Molecule																																			1	No	2	0	No	5	0	43.37 Å2	49.36 Å3	122.9 m3·mol-1	5	No	No	0.000283 mg/mL	6.09	-6.2	18.52	-4.8			
C35H49NO7	Not Available	Not Available	595.777	[H][C@@]12OC3=C4C(C[C@H]5N(CC6CC6)CC[C@@]14[C@@]51CC[C@@]2(OC)[C@]([H])(C1)[C@](C)(O)C(C)(C)C)=CC=C3OC(=O)CCCCC(O)=O	Not Available	Not Available								32698730																	Buprenorphine hemiadipate	Investigational	DB16117	InChI=1S/C35H49NO7/c1-31(2,3)32(4,40)24-19-33-14-15-35(24,41-5)30-34(33)16-17-36(20-21-10-11-21)25(33)18-22-12-13-23(29(43-30)28(22)34)42-27(39)9-7-6-8-26(37)38/h12-13,21,24-25,30,40H,6-11,14-20H2,1-5H3,(H,37,38)/t24-,25-,30-,32+,33-,34+,35-/m1/s1	CVIJJOARNCQGON-XYQNZYJMSA-N	2		Not Available	Small Molecule																																			0	No	7	2	Yes	7	0	105.53 Å2	66.1 Å3	161.01 m3·mol-1	12	No	No	0.00288 mg/mL	1.93	-5.3	3.3	9.8			
C28H29F5O3	Not Available	Not Available	508.529	[H][C@@]12CC[C@@](O)(C(F)(F)C(F)(F)F)[C@@]1(C)C[C@H](C1=CC=C(C=C1)C(C)=O)C1=C3CCC(=O)C=C3CC[C@@]21[H]	Not Available	Not Available					50409115		CHEMBL146032	5293745														Lonaprisan			Lonaprisan	Investigational	DB16221	InChI=1S/C28H29F5O3/c1-15(34)16-3-5-17(6-4-16)22-14-25(2)23(11-12-26(25,36)27(29,30)28(31,32)33)21-9-7-18-13-19(35)8-10-20(18)24(21)22/h3-6,13,21-23,36H,7-12,14H2,1-2H3/t21-,22+,23-,25-,26-/m0/s1	VHZPUDNSVGRVMB-RXDLHWJPSA-N	2		Not Available	Small Molecule																																			0	No	3	1	No	5	0	54.37 Å2	49.03 Å3	125.59 m3·mol-1	4	No	No	0.00424 mg/mL	5.17	-5.1	11.81	-4.2			
C26H40O3	Not Available	Not Available	400.603	[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@H](CC[C@]12C)OC(=O)CCCCCC	Not Available	Not Available								143333														Prasterone_enanthate	ZINC000005820240		Prasterone enantate	Approved	DB16625	InChI=1S/C26H40O3/c1-4-5-6-7-8-24(28)29-19-13-15-25(2)18(17-19)9-10-20-21-11-12-23(27)26(21,3)16-14-22(20)25/h9,19-22H,4-8,10-17H2,1-3H3/t19-,20-,21-,22-,25-,26-/m0/s1	HHENOUDBWKNPAB-BNCSLUSBSA-N		Prasterone enantate is an estrogen indicated for hormone replacement therapy in postmenopausal women.	Not Available	Small Molecule																																			1	No	2	0	Yes	4	0	43.37 Å2	48.28 Å3	116.84 m3·mol-1	7	No	No		6.28			-6.9			
C20H30O	Not Available	1.9 hours	286.4516	C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C	Solid	Not Available	O43174	CYP26A1	1. Cytochrome P450 26A1		50092056	17336	CHEMBL986	393012	Drugs.com Drug Page		HMDB0000305	C17276	D00069	RTL	PDRhealth Drug Page	PA451884	445354	46508191	RxList Drug Page	11246	DNC001498	Vitamin_A	ZINC000003831417	Aquasol A, Infuvite, Infuvite Pediatric, Mvc-fluoride, Mvi Pediatric, Vitafol-one	Vitamin A	Approved, Nutraceutical, Vet approved	DB00162	InChI=1S/C20H30O/c1-16(8-6-9-17(2)13-15-21)11-12-19-18(3)10-7-14-20(19,4)5/h6,8-9,11-13,21H,7,10,14-15H2,1-5H3/b9-6+,12-11+,16-8+,17-13+	FPIPGXGPPPQFEQ-OVSJKPMPSA-N	4	Vitamin A is a vitamin important for retinal function that is used clinically to correct vitamin A deficiency.	Acute toxicity to vitamin A can occur when adults or children ingest >100x or >20x the RDA, respectively, over a period of hours or a few days.2 The RDA for vitamin A differs depending on age and sex and can range from 300 - 900 μg retinol activity equivalents (RAE) per day.4 Symptoms of acute systemic toxicity generally include mucocutaneous involvement (e.g. xerosis, cheilitis, skin peeling) and may involve mental status changes.3 Children are typically more susceptible to acute vitamin A toxicity - daily intakes of as little as 1500 IU/kg have been observed to result in toxicity.2Chronic vitamin A toxicity can develop following the long-term ingestion of high vitamin A doses. While there is a wide variation in the lowest toxic vitamin A dose, the ingestion of >25 000 IU daily for 6 years or 100,000 IU daily for 6 months is considered to be toxic.2 Chronic vitamin A toxicity can affect many organ systems and can lead to the development of osteoporosis and CNS effects (e.g. headaches).3	Small Molecule	http://smpdb.ca/view/SMP0000074?highlight[compounds][]=DB00162&highlight[proteins][]=DB00162;!http://smpdb.ca/view/SMP0000336?highlight[compounds][]=DB00162&highlight[proteins][]=DB00162	Retinol Metabolism;!Vitamin A Deficiency		AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.1249 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					5.68		63.5 °C		0.671 mg/L	1	Yes	1	1	No	1	0	20.23 Å2	36.54 Å3	97.92 m3·mol-1	5	Yes	Yes	0.00758 mg/mL	4.69	-4.6	16.44	-2.2	P05090;!P41222;!Q96NR8;!Q92781;!Q8NBN7;!O94788;!P00352;!O95237;!O75911;!P47895;!Q6NUM9;!Q8TC12;!Q9BTZ2;!Q9HBH5;!Q9NYR8	APOD;!PTGDS;!RDH12;!RDH5;!RDH13;!ALDH1A2;!ALDH1A1;!LRAT;!DHRS3;!ALDH1A3;!RETSAT;!RDH11;!DHRS4;!RDH14;!RDH8	1. Apolipoprotein D;!2. Prostaglandin-H2 D-isomerase;!3. Retinol dehydrogenase 12;!4. 11-cis retinol dehydrogenase;!5. Retinol dehydrogenase 13;!6. Retinal dehydrogenase 2;!7. Retinal dehydrogenase 1;!8. Lecithin retinol acyltransferase;!9. Short-chain dehydrogenase/reductase 3;!10. Aldehyde dehydrogenase family 1 member A3;!11. All-trans-retinol 13,14-reductase;!12. Retinol dehydrogenase 11;!13. Dehydrogenase/reductase SDR family member 4;!14. Retinol dehydrogenase 14;!15. Retinol dehydrogenase 8
C21H26O3	Not Available	49 hours (range 33 to 96 hours)	326.4293	COC1=C(C)C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1	Solid	Not Available					50088429	50173	CHEMBL1131	4447573	Drugs.com Drug Page		HMDB0014602		D02754		PDRhealth Drug Page	PA448039	5284513	46509178	RxList Drug Page	16818	DAP000743	Acitretin	ZINC000003798734	Soriatane	Acitretin	Approved	DB00459	InChI=1S/C21H26O3/c1-14(8-7-9-15(2)12-21(22)23)10-11-19-16(3)13-20(24-6)18(5)17(19)4/h7-13H,1-6H3,(H,22,23)/b9-7+,11-10+,14-8+,15-12+	IHUNBGSDBOWDMA-AQFIFDHZSA-N	4	Acitretin is an oral retinoid used in the treatment of severe psoriasis.	Oral, rat: LD50 = >4000 mg/kg. Symptoms of overdose include headache and vertigo.	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.8804 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					6.40		228-230 °C		0.0729 mg/L	1	Yes	3	1	No	1	-1	46.53 Å2	38.58 Å3	104.17 m3·mol-1	6	No	No	0.000478 mg/mL	5.59	-5.8	4.77	-4.8	P19793;!P10276;!P10826;!P13631;!P28702;!P48443;!P09455;!	RXRA;!RARA;!RARB;!RARG;!RXRB;!RXRG;!RBP1;!	1. Retinoic acid receptor RXR-alpha;!2. Retinoic acid receptor alpha;!3. Retinoic acid receptor beta;!4. Retinoic acid receptor gamma;!5. Retinoic acid receptor RXR-beta;!6. Retinoic acid receptor RXR-gamma;!7. Retinol-binding protein 1;!8. Retinoic acid receptor RXR
C20H28O2	Not Available	Not Available	300.4351	C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O	Solid	Not Available					31892	50648	CHEMBL705	395778	Drugs.com Drug Page		HMDB0002369	C15493	D02815	9CR		PA164746900	449171	46507356	RxList Drug Page	81864	DAP000275	Alitretinoin	ZINC000012661824	Panretin, Toctino	Alitretinoin	Approved, Investigational	DB00523	InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8-,16-14+	SHGAZHPCJJPHSC-ZVCIMWCZSA-N	3	Alitretinoin is a vitamin A derivative used to treat Kaposi's sarcoma and used off label to treat chronic hand eczema and psoriasis.	Not Available	Small Molecule	http://smpdb.ca/view/SMP0000074?highlight[compounds][]=DB00523&highlight[proteins][]=DB00523;!http://smpdb.ca/view/SMP0000336?highlight[compounds][]=DB00523&highlight[proteins][]=DB00523	Retinol Metabolism;!Vitamin A Deficiency		Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.1455 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					4.2		189-190 °C		0.6 mg/L	1	Yes	2	1	No	1	-1	37.3 Å2	35.89 Å3	97.79 m3·mol-1	5	No	Yes	0.00477 mg/mL	5.01	-4.8	4.76		P10276;!P19793;!P10826;!P28702;!P13631;!P48443;!P17936;!Q15238;!Q6V0L0	RARA;!RXRA;!RARB;!RXRB;!RARG;!RXRG;!IGFBP3;!PSG5;!CYP26C1	1. Retinoic acid receptor alpha;!2. Retinoic acid receptor RXR-alpha;!3. Retinoic acid receptor beta;!4. Retinoic acid receptor RXR-beta;!5. Retinoic acid receptor gamma;!6. Retinoic acid receptor RXR-gamma;!7. Insulin-like growth factor-binding protein 3;!8. Pregnancy-specific beta-1-glycoprotein 5;!9. Cytochrome P450 26C1
C20H28O2	Not Available	0.5-2 hours	300.442	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O	Solid	Not Available	P24462;!P20813;!P10632;!P11712;!P08684;!P20815;!P11509;!P33260;!P04798;!Q02928	CYP3A7;!CYP2B6;!CYP2C8;!CYP2C9;!CYP3A4;!CYP3A5;!CYP2A6;!CYP2C18;!CYP1A1;!CYP4A11	1. Cytochrome P450 3A7;!2. Cytochrome P450 2B6;!3. Cytochrome P450 2C8;!4. Cytochrome P450 2C9;!5. Cytochrome P450 3A4;!6. Cytochrome P450 3A5;!7. Cytochrome P450 2A6;!8. Cytochrome P450 2C18;!9. Cytochrome P450 1A1;!10. Cytochrome P450 4A11		31883	15367	CHEMBL38	392618	Drugs.com Drug Page		HMDB0001852	C00777	D00094	REA		PA164746900	5538	46504843	RxList Drug Page	10753	DNC000117	Tretinoin	ZINC000012358651	Altreno, Atralin, Avita, Biacna, Refissa, Renova, Retin-A, Stieva-A, Tri-luma, Twyneo, Veltin, Vesanoid, Ziana	Tretinoin	Approved, Investigational, Nutraceutical	DB00755	InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14+	SHGAZHPCJJPHSC-YCNIQYBTSA-N	4	Tretinoin is a vitamin A derivative used to treat acne vulgaris, certain types of promyelocytic leukemia, and fine wrinkles.	Not Available	Small Molecule	http://smpdb.ca/view/SMP0000074?highlight[compounds][]=DB00755&highlight[proteins][]=DB00755;!http://smpdb.ca/view/SMP0000336?highlight[compounds][]=DB00755&highlight[proteins][]=DB00755	Retinol Metabolism;!Vitamin A Deficiency		Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.1455 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					6.30		181 °C		<0.1 g/100 mL	1	Yes	2	1	No	1	-1	37.3 Å2	36.85 Å3	97.79 m3·mol-1	5	No	Yes	0.00477 mg/mL	5.01	-4.8	4.76				
C23H30O3	Not Available	In one study, the apparent terminal half-life of etretinate after 6 months of therapy was approximately 120 days. In another study of 47 patients who had undergone chronic therapy with etretinate, 5 patients had detectable serum drug concentrations (0.5 to 12 ng/mL) 2.1 to 2.9 years after therapy was completed.	354.4825	CCOC(=O)C=C(C)C=CC=C(C)C=CC1=C(C)C(C)=C(OC)C=C1C	Solid	Not Available	P11511	CYP19A1	1. Cytochrome P450 19A1		50248000	4913	CHEMBL464	4445538					D00316			PA449554	3312	46504486		4182		Etretinate	ZINC000003830820		Etretinate	Withdrawn	DB00926	InChI=1S/C23H30O3/c1-8-26-23(24)14-17(3)11-9-10-16(2)12-13-21-18(4)15-22(25-7)20(6)19(21)5/h9-15H,8H2,1-7H3/b11-9+,13-12+,16-10+,17-14+	HQMNCQVAMBCHCO-DJRRULDNSA-N			Symptoms of overdose include headache and vertigo.	Small Molecule				Non AMES toxic	Ready biodegradable	+	Inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Non-substrate	1.8763 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					6.5		104-105			1	No	2	0	No	1	0	35.53 Å2	42.98 Å3	113.68 m3·mol-1	8	No	Yes	0.000405 mg/mL	6.32	-5.9		-4.8	P10276;!P19793;!P10826;!P48443;!P28702;!P13631	RARA;!RXRA;!RARB;!RXRG;!RXRB;!RARG	1. Retinoic acid receptor alpha;!2. Retinoic acid receptor RXR-alpha;!3. Retinoic acid receptor beta;!4. Retinoic acid receptor RXR-gamma;!5. Retinoic acid receptor RXR-beta;!6. Retinoic acid receptor gamma
C20H28O2	The clearance of isotretinoin is 15.9L/h in pediatric patients with neuroblastoma.6 Clearance is also 21.3mL/min/kg in guinea pigs and 7.2mL/min/kg in obese rats.5	The half life ranges from 7-39 hours13 with a mean elimination half life of 20 hours.1 The half life of 4-oxo-13-cis-retinoic acid ranges from 17-50 hours with a mean elimination half life of 25 hours.13	300.4351	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O	Solid	The volume of distribution in humans is unknown because there is no intravenous preparation.13 In a study of pediatric patients with neuroblastoma the volume of distribution was found to be 85L.6 The volume of distribution was also found to be 2432mL/kg in guinea pigs and 1716mL/kg in obese rats.5	P08684	CYP3A4	1. Cytochrome P450 3A4		50031459	6067	CHEMBL547	4445539	Drugs.com Drug Page		HMDB0006219		D00348			PA450128	5282379	46508729	RxList Drug Page	6064	DAP000009	Isotretinoin	ZINC000003792789	Absorica, Accutane, Amnesteem, Claravis, Clarus, Epuris, Myorisan, Sotret, Zenatane	Isotretinoin	Approved	DB00982	InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14-	SHGAZHPCJJPHSC-XFYACQKRSA-N	4	Isotretinoin is a retinoid used to treat severe recalcitrant acne.	Patients experiencing an overdose may present with vomiting, facial flushing, cheilosis, abdominal pain, headache, dizziness, and ataxia.Label These symptoms may rapidly resolve.Label Generally no treatment is required for these overdoses.7The oral lowest dose causing toxic effect (TDLO) for children is 30mg/kg/21W, oral TDLO for men is 24mg/kg/4W, oral TDLO for women is 56mg/kg/8W.14 The intraperitoneal LD50 for rats is 901mg/kg, oral LD50 for mice is 3389mg/kg, oral LD50 for rats is >4000mg/kg.14Isotretinoin is associated with major congenital malformations, spontaneous abortion, and premature birth.Label It is unknown if isotretinoin is expressed in breast milk but due to the associated hazards a decision should be made to either stop nursing or stop taking isotretinoin.LabelIn animal studies, isotretinoin was associated with an increased risk of pheochromocytoma and adrenal medullary hyperplasia at doses above the recommended clinical dose.Label Isotretinoin was negative for the Ames test of mutagenicity once and weakly positive a second time.Label It has not been shown to be clastogenic.Label A study in dogs noted testicular atrophy after doses of 10-30 times the recommended clinical dose for 30 weeks.Label In trials with men there were no effects seen on sperm count, motility, morphology, ejaculate volume, and seminal plasma fructose.Label	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.1455 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				462.8	5.66		189-190	~4	0.00477mg/mL	1	Yes	2	1	No	1	-1	37.3 Å2	36.15 Å3	97.79 m3·mol-1	5	No	Yes	0.00477 mg/mL	5.01	-4.8	4.76		P13631;!P10276	RARG;!RARA	1. Retinoic acid receptor gamma;!2. Retinoic acid receptor alpha
C31H46O2	Intravenous phylloquinone is 90% cleared in 2 hours, and 99% cleared in 8 hours.1,13 A 10 mg intravenous dose of phylloquinone has a mean clearance of 91 ± 24 mL/min.14	Intravenous phylloquinone has an initial half life of 22 minutes, followed by a half life of 125 minutes.1	450.6957	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC\C(C)=C\CC1=C(C)C(=O)C2=C(C=CC=C2)C1=O	Liquid	The steady state volume of distribution of phylloquinone is 20 ± 6 L in subjects who are also taking phenprocoumon therapy.15	P78329;!Q9Y5Z9;!Q9BQB6	CYP4F2;!UBIAD1;!VKORC1	1. Leukotriene-B(4) omega-hydroxylase 1;!2. UbiA prenyltransferase domain-containing protein 1;!3. Vitamin K epoxide reductase complex subunit 1		24782	18067	CHEMBL1550	4447652	Drugs.com Drug Page		HMDB0015157	C02059	D00148	PQN		PA450961	5284607	46504528	RxList Drug Page	8308	DNC001500	Phytomenadione	ZINC000003831332	Aquamephyton, Infuvite, Infuvite Pediatric, Mephyton, Mvi Pediatric, Phytonadione	PhylloquinoneCommonly known or available as Vitamin K1	Approved, Investigational	DB01022	InChI=1S/C31H46O2/c1-22(2)12-9-13-23(3)14-10-15-24(4)16-11-17-25(5)20-21-27-26(6)30(32)28-18-7-8-19-29(28)31(27)33/h7-8,18-20,22-24H,9-17,21H2,1-6H3/b25-20+/t23-,24-/m1/s1	MBWXNTAXLNYFJB-NKFFZRIASA-N	4	Vitamin K1 is a fat soluble vitamin used to treat hemorrhagic conditions in infants and coumarin overdoses.	High doses of vitamin K1 are not associated with toxicity.6 Intravenous administration has been associated with an increased risk of toxicity.9 These patients should be treated with symptomatic and supportive measures.The intravenous LD50 in mice is 1170 mg/kg and the oral LD50 is >24180 mg/kg.18	Small Molecule	http://smpdb.ca/view/SMP0000272?highlight[compounds][]=DB01022&highlight[proteins][]=DB01022;!http://smpdb.ca/view/SMP0000273?highlight[compounds][]=DB01022&highlight[proteins][]=DB01022;!http://smpdb.ca/view/SMP0000278?highlight[compounds][]=DB01022&highlight[proteins][]=DB01022;!http://smpdb.ca/view/SMP0000280?highlight[compounds][]=DB01022&highlight[proteins][]=DB01022;!http://smpdb.ca/view/SMP0000281?highlight[compounds][]=DB01022&highlight[proteins][]=DB01022;!http://smpdb.ca/view/SMP0000284?highlight[compounds][]=DB01022&highlight[proteins][]=DB01022;!http://smpdb.ca/view/SMP0000655?highlight[compounds][]=DB01022&highlight[proteins][]=DB01022;!http://smpdb.ca/view/SMP0000268?highlight[compounds][]=DB01022&highlight[proteins][]=DB01022;!http://smpdb.ca/view/SMP0000269?highlight[compounds][]=DB01022&highlight[proteins][]=DB01022;!http://smpdb.ca/view/SMP0000270?highlight[compounds][]=DB01022&highlight[proteins][]=DB01022;!http://smpdb.ca/view/SMP0000276?highlight[compounds][]=DB01022&highlight[proteins][]=DB01022;!http://smpdb.ca/view/SMP0000279?highlight[compounds][]=DB01022&highlight[proteins][]=DB01022;!http://smpdb.ca/view/SMP0000283?highlight[compounds][]=DB01022&highlight[proteins][]=DB01022;!http://smpdb.ca/view/SMP0000286?highlight[compounds][]=DB01022&highlight[proteins][]=DB01022;!http://smpdb.ca/view/SMP0000656?highlight[compounds][]=DB01022&highlight[proteins][]=DB01022;!http://smpdb.ca/view/SMP0000271?highlight[compounds][]=DB01022&highlight[proteins][]=DB01022;!http://smpdb.ca/view/SMP0000274?highlight[compounds][]=DB01022&highlight[proteins][]=DB01022;!http://smpdb.ca/view/SMP0000275?highlight[compounds][]=DB01022&highlight[proteins][]=DB01022;!http://smpdb.ca/view/SMP0000277?highlight[compounds][]=DB01022&highlight[proteins][]=DB01022;!http://smpdb.ca/view/SMP0000282?highlight[compounds][]=DB01022&highlight[proteins][]=DB01022;!http://smpdb.ca/view/SMP0000285?highlight[compounds][]=DB01022&highlight[proteins][]=DB01022;!http://smpdb.ca/view/SMP0000287?highlight[compounds][]=DB01022&highlight[proteins][]=DB01022;!http://smpdb.ca/view/SMP0000288?highlight[compounds][]=DB01022&highlight[proteins][]=DB01022;!http://smpdb.ca/view/SMP0000464?highlight[compounds][]=DB01022&highlight[proteins][]=DB01022;!http://smpdb.ca/view/SMP0000586?highlight[compounds][]=DB01022&highlight[proteins][]=DB01022	Enoxaparin Action Pathway;!Fondaparinux Action Pathway;!Lepirudin Action Pathway;!Alteplase Action Pathway;!Anistreplase Action Pathway;!Urokinase Action Pathway;!Phenindione Action Pathway;!Warfarin Action Pathway;!Acenocoumarol Action Pathway;!Dicumarol Action Pathway;!Argatroban Action Pathway;!Ximelagatran Action Pathway;!Tenecteplase Action Pathway;!Aminocaproic Acid Action Pathway;!Dicoumarol Action Pathway;!Phenprocoumon Action Pathway;!Heparin Action Pathway;!Ardeparin Action Pathway;!Bivalirudin Action Pathway;!Streptokinase Action Pathway;!Reteplase Action Pathway;!Tranexamic Acid Action Pathway;!Aprotinin Action Pathway;!Vitamin K Metabolism;!Coagulation		Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	1.1603 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor				142.5 °C at 1.00E-03 mm Hg			-20 °C		Insoluble in water	0	No	2	0	No	2	0	34.14 Å2	55.92 Å3	142.96 m3·mol-1	14	No	No	5.92e-05 mg/mL	9.7	-6.9		-7.2	P38435;!P02818	GGCX;!BGLAP	1. Vitamin K-dependent gamma-carboxylase;!2. Osteocalcin
C14H26N	Not Available	Not Available	208.3629	C[N@H+](CCC=C(C)C)[C@@H]1CCC(C)=CC1	Solid	Not Available								4451316						SAZ			5289326	46508851							S-azabisabolene	Experimental	DB02099	InChI=1S/C14H25N/c1-12(2)6-5-11-15(4)14-9-7-13(3)8-10-14/h6-7,14H,5,8-11H2,1-4H3/p+1/t14-/m0/s1	GGPFTSMJRHEOJG-AWEZNQCLSA-O			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	2.4560 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	0	1	No	1	1	4.44 Å2	27.33 Å3	81.29 m3·mol-1	4	Yes	Yes	0.00228 mg/mL	3.52	-5		10.62			
C30H42O2	Not Available	Not Available	434.6533	OC\C(C)=C\C=C\C(\C)=C/C=C/C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C[C@@H](O)CC1(C)C	Solid	Not Available						39930		4449866						3ON			5287502	46506703					ZINC000012501797		(1r)-4-[(1e,3e,5e,7z,9e,11z,13e,15e)-17-Hydroxy-3,7,12,16-Tetramethylheptadeca-1,3,5,7,9,11,13,15-Octaen-1-Yl]-3,5,5-Trimethylcyclohex-3-En-1-Ol	Experimental	DB02253	InChI=1S/C30H42O2/c1-23(12-8-9-13-24(2)15-11-17-26(4)22-31)14-10-16-25(3)18-19-29-27(5)20-28(32)21-30(29,6)7/h8-19,28,31-32H,20-22H2,1-7H3/b9-8+,14-10+,15-11+,19-18+,23-12-,24-13-,25-16+,26-17+/t28-/m1/s1	FNAJVVMDXCOSFY-VFGOXHQXSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.0310 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	2	2	No	1	0	40.46 Å2	55.26 Å3	149.43 m3·mol-1	9	No	No	0.00157 mg/mL	5.9	-5.4	16.76	-1.1	P74334	Not Available	1. Apocarotenoid-15,15'-oxygenase
C15H26O	Not Available	Not Available	222.3663	CC(C)=CCC\C(C)=C/CC\C(C)=C/CO	Solid	Not Available	P27338	MAOB	1. Amine oxidase [flavin-containing] B		11021	42680		1266073				C01493		FOH			1549107	46508260		1362903		Farnesol	ZINC000013507232		Farnesol	Experimental	DB02509	InChI=1S/C15H26O/c1-13(2)7-5-8-14(3)9-6-10-15(4)11-12-16/h7,9,11,16H,5-6,8,10,12H2,1-4H3/b14-9-,15-11-	CRDAMVZIKSXKFV-FBXUGWQNSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.6146 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				111 °C at 3.50E-01 mm Hg			< 25 °C			1	Yes	1	1	No	0	0	20.23 Å2	28.64 Å3	74.98 m3·mol-1	7	Yes	Yes	0.0587 mg/mL	4.16	-3.6	16.33	-2.2	Q96RI1;!P27338	NR1H4;!MAOB	1. Bile acid receptor;!2. Amine oxidase [flavin-containing] B
C10H20O7P2	Not Available	Not Available	314.2091	CC(C)=CCC\C(C)=C\CO[P@@](=O)(O)OP(=O)(O)O	Solid	Not Available						17211	CHEMBL41342	393471			HMDB0001285	C05847		GPP			445995	46504900					ZINC000008215849		Geranyl Diphosphate	Experimental	DB02552	InChI=1S/C10H20O7P2/c1-9(2)5-4-6-10(3)7-8-16-19(14,15)17-18(11,12)13/h5,7H,4,6,8H2,1-3H3,(H,14,15)(H2,11,12,13)/b10-7+	GVVPGTZRZFNKDS-JXMROGBWSA-N			Not Available	Small Molecule	http://smpdb.ca/view/SMP0000099?highlight[compounds][]=DB02552&highlight[proteins][]=DB02552;!http://smpdb.ca/view/SMP0000111?highlight[compounds][]=DB02552&highlight[proteins][]=DB02552;!http://smpdb.ca/view/SMP0000209?highlight[compounds][]=DB02552&highlight[proteins][]=DB02552;!http://smpdb.ca/view/SMP0000388?highlight[compounds][]=DB02552&highlight[proteins][]=DB02552;!http://smpdb.ca/view/SMP0000389?highlight[compounds][]=DB02552&highlight[proteins][]=DB02552;!http://smpdb.ca/view/SMP0000510?highlight[compounds][]=DB02552&highlight[proteins][]=DB02552;!http://smpdb.ca/view/SMP0000082?highlight[compounds][]=DB02552&highlight[proteins][]=DB02552;!http://smpdb.ca/view/SMP0000089?highlight[compounds][]=DB02552&highlight[proteins][]=DB02552;!http://smpdb.ca/view/SMP0000092?highlight[compounds][]=DB02552&highlight[proteins][]=DB02552;!http://smpdb.ca/view/SMP0000107?highlight[compounds][]=DB02552&highlight[proteins][]=DB02552;!http://smpdb.ca/view/SMP0000117?highlight[compounds][]=DB02552&highlight[proteins][]=DB02552;!http://smpdb.ca/view/SMP0000119?highlight[compounds][]=DB02552&highlight[proteins][]=DB02552;!http://smpdb.ca/view/SMP0000319?highlight[compounds][]=DB02552&highlight[proteins][]=DB02552;!http://smpdb.ca/view/SMP0000508?highlight[compounds][]=DB02552&highlight[proteins][]=DB02552;!http://smpdb.ca/view/SMP0000023?highlight[compounds][]=DB02552&highlight[proteins][]=DB02552;!http://smpdb.ca/view/SMP0000079?highlight[compounds][]=DB02552&highlight[proteins][]=DB02552;!http://smpdb.ca/view/SMP0000095?highlight[compounds][]=DB02552&highlight[proteins][]=DB02552;!http://smpdb.ca/view/SMP0000112?highlight[compounds][]=DB02552&highlight[proteins][]=DB02552;!http://smpdb.ca/view/SMP0000131?highlight[compounds][]=DB02552&highlight[proteins][]=DB02552;!http://smpdb.ca/view/SMP0000386?highlight[compounds][]=DB02552&highlight[proteins][]=DB02552;!http://smpdb.ca/view/SMP0000387?highlight[compounds][]=DB02552&highlight[proteins][]=DB02552;!http://smpdb.ca/view/SMP0000509?highlight[compounds][]=DB02552&highlight[proteins][]=DB02552;!http://smpdb.ca/view/SMP0000511?highlight[compounds][]=DB02552&highlight[proteins][]=DB02552	Lovastatin Action Pathway;!Cerivastatin Action Pathway;!Hypercholesterolemia;!Chondrodysplasia Punctata II, X-Linked Dominant (CDPX2);!Smith-Lemli-Opitz Syndrome (SLOS);!Mevalonic Aciduria;!Simvastatin Action Pathway;!Pravastatin Action Pathway;!Rosuvastatin Action Pathway;!Zoledronate Action Pathway;!Pamidronate Action Pathway;!Fluvastatin Action Pathway;!Lysosomal Acid Lipase Deficiency (Wolman Disease);!Cholesteryl Ester Storage Disease;!Steroid Biosynthesis;!Ibandronate Action Pathway;!Alendronate Action Pathway;!Risedronate Action Pathway;!Atorvastatin Action Pathway;!Desmosterolosis;!CHILD Syndrome;!Hyper-IgD Syndrome;!Wolman Disease		Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.4092 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	3	No	0	-3	113.29 Å2	28.52 Å3	72.93 m3·mol-1	8	Yes	No	0.902 mg/mL	1.96	-2.5	1.77		P62617;!P14324;!Q4R2T2;!O95749;!P9WFF5;!P9WFF7;!P62619;!Q9PM68	ispF;!FDPS;!Not Available;!GGPS1;!Not Available;!uppS;!ispF;!ispDF	1. 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase;!2. Farnesyl pyrophosphate synthase;!3. Prenyltransferase;!4. Geranylgeranyl pyrophosphate synthase;!5. (2Z,6E)-farnesyl diphosphate synthase;!6. Decaprenyl diphosphate synthase;!7. 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase;!8. Bifunctional enzyme IspD/IspF
C20H28O2	Not Available	Not Available	300.4351	C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)C(=O)CCC1(C)C	Solid	Not Available						44597		4451124			HMDB0012329	C16683		OXR			5289090	46506951					ZINC000012502479		4-Oxoretinol	Experimental	DB02699	InChI=1S/C20H28O2/c1-15(7-6-8-16(2)12-14-21)9-10-18-17(3)19(22)11-13-20(18,4)5/h6-10,12,21H,11,13-14H2,1-5H3/b8-6+,10-9+,15-7+,16-12+	PLIUCYCUYQIBDZ-RMWYGNQTSA-N			Not Available	Small Molecule	http://smpdb.ca/view/SMP0000074?highlight[compounds][]=DB02699&highlight[proteins][]=DB02699;!http://smpdb.ca/view/SMP0000336?highlight[compounds][]=DB02699&highlight[proteins][]=DB02699	Retinol Metabolism;!Vitamin A Deficiency		Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.7980 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	1	No	1	0	37.3 Å2	36.68 Å3	98.62 m3·mol-1	5	Yes	Yes	0.0121 mg/mL	4.03	-4.4	16.44	-2.2			
C15H25F3O7P2	Not Available	Not Available	436.2975	CC(C)=CCC\C(C)=C\CC\C(=C\CO[P@@](=O)(O)OP(O)(O)=O)C(F)(F)F	Solid	Not Available								396042						FFF			449547	46504774					ZINC000002047050		Trifluorofurnesyl Diphosphate	Experimental	DB02808	InChI=1S/C15H25F3O7P2/c1-12(2)6-4-7-13(3)8-5-9-14(15(16,17)18)10-11-24-27(22,23)25-26(19,20)21/h6,8,10H,4-5,7,9,11H2,1-3H3,(H,22,23)(H2,19,20,21)/b13-8+,14-10-	PXLMLAFPAPGGKK-GVCYOOEQSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.6916 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	3	No	0	-3	113.29 Å2	38.8 Å3	97.66 m3·mol-1	12	Yes	No	0.0896 mg/mL	3.98	-3.7	1.77				
C20H28	Not Available	Not Available	268.4363	C\C(C=C)=C/C=C/C(/C)=C/C=C1/C(C)=CCCC1(C)C	Solid	Not Available								4449996			HMDB0062447			ANR			5287678	46507241					ZINC000049499553		Anhydrovitamin A	Experimental	DB02914	InChI=1S/C20H28/c1-7-16(2)10-8-11-17(3)13-14-19-18(4)12-9-15-20(19,5)6/h7-8,10-14H,1,9,15H2,2-6H3/b11-8+,16-10+,17-13+,19-14-	FWNRILWHNGFAIN-OYUWDNMLSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.5742 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	0	0	No	1	0	0 Å2	34.33 Å3	96.19 m3·mol-1	4	No	Yes	0.00223 mg/mL	5.67	-5.1					
C46H70O	Not Available	Not Available	639.0474	CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC1=CC=CC=C1O	Solid	Not Available						40407		4444381				C05810		8PP			5280832	46507933					ZINC000004096912		2-[(2e,6e,10e,14e,18e,22e,26e)-3,7,11,15,19,23,27,31-Octamethyldotriaconta-2,6,10,14,18,22,26,30-Octaenyl]Phenol	Experimental	DB03232	InChI=1S/C46H70O/c1-37(2)19-12-20-38(3)21-13-22-39(4)23-14-24-40(5)25-15-26-41(6)27-16-28-42(7)29-17-30-43(8)31-18-32-44(9)35-36-45-33-10-11-34-46(45)47/h10-11,19,21,23,25,27,29,31,33-35,47H,12-18,20,22,24,26,28,30,32,36H2,1-9H3/b38-21+,39-23+,40-25+,41-27+,42-29+,43-31+,44-35+	VUNQJPPPTJIREN-CMAXTTDKSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.9252 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	1	1	No	1	0	20.23 Å2	85.73 Å3	218.9 m3·mol-1	23	No	No	0.000226 mg/mL	15.02	-6.4	9.33	-6	P0A8X2	yceI	1. Protein YceI
C29H51N	Not Available	Not Available	413.7219	CN(C)CCC\C(C)=C\CC\C(C)=C\CC\C=C(/C)CC\C=C(/C)CCC=C(C)C	Solid	Not Available								395566						SQA			448904	46504566					ZINC000005158550		(4e,8e,12z,16z)-N,N,4,8,13,17,21-Heptamethyldocosa-4,8,12,16,20-Pentaen-1-Amine	Experimental	DB03874	InChI=1S/C29H51N/c1-25(2)15-11-18-28(5)21-12-19-26(3)16-9-10-17-27(4)20-13-22-29(6)23-14-24-30(7)8/h15-17,21-22H,9-14,18-20,23-24H2,1-8H3/b26-16+,27-17+,28-21+,29-22+	OBYAAZRQFIVRJS-GUUMBNHASA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.5379 LD50, mol/kg	Inhibitor	Weak inhibitor	Non-inhibitor										0	No	1	0	No	0	1	3.24 Å2	56.36 Å3	143.67 m3·mol-1	16	No	No	0.000891 mg/mL	8.92	-5.7		9.86	P33247	shc	1. Squalene--hopene cyclase
C22H33NO	Not Available	Not Available	327.5035	CCNC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C	Solid	Not Available					50092057		CHEMBL418471	4450394						ETR			5288173	46506461					ZINC000012504028		N-Ethylretinamide	Experimental	DB03917	InChI=1S/C22H33NO/c1-7-23-21(24)16-18(3)11-8-10-17(2)13-14-20-19(4)12-9-15-22(20,5)6/h8,10-11,13-14,16H,7,9,12,15H2,1-6H3,(H,23,24)/b11-8+,14-13+,17-10+,18-16+	WKYDOCGICAMTKE-NBIQJRODSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Non-substrate	2.0384 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	1	1	No	1	0	29.1 Å2	41.35 Å3	109.26 m3·mol-1	6	Yes	Yes	0.00332 mg/mL	4.79	-5	16.31	-0.22			
C14H26N	Not Available	Not Available	208.3629	C[N@@H+](CCC=C(C)C)[C@H]1CCC(C)=CC1	Solid	Not Available								4451267						RAZ			5289266	46509037							R-azabisabolene	Experimental	DB03985	InChI=1S/C14H25N/c1-12(2)6-5-11-15(4)14-9-7-13(3)8-10-14/h6-7,14H,5,8-11H2,1-4H3/p+1/t14-/m1/s1	GGPFTSMJRHEOJG-CQSZACIVSA-O			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	2.4560 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	0	1	No	1	1	4.44 Å2	27.21 Å3	81.29 m3·mol-1	4	Yes	Yes	0.00228 mg/mL	3.52	-5		10.62			
C15H28O6P2S	Not Available	Not Available	398.392	[H]\C(CC\C(C)=C(/[H])CSP(O)(=O)OP(O)(O)=O)=C(\C)CCC=C(C)C	Solid	Not Available								571259						FPS			657041	46506151					ZINC000012504468		Farnesyl thiopyrophosphate	Experimental	DB04695	InChI=1S/C15H28O6P2S/c1-13(2)7-5-8-14(3)9-6-10-15(4)11-12-24-23(19,20)21-22(16,17)18/h7,9,11H,5-6,8,10,12H2,1-4H3,(H,19,20)(H2,16,17,18)/b14-9+,15-11+	MYMLCRQRXFRQGP-YFVJMOTDSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.7904 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	3	No	0	-3	104.06 Å2	40.62 Å3	103.23 m3·mol-1	11	Yes	No	0.138 mg/mL	4.11	-3.5	2.03		O95749;!Q03426;!A9JQL9;!P60472	GGPS1;!MVK;!crtM;!ispU	1. Geranylgeranyl pyrophosphate synthase;!2. Mevalonate kinase;!3. Dehydrosqualene synthase;!4. Ditrans,polycis-undecaprenyl-diphosphate synthase ((2E,6E)-farnesyl-diphosphate specific)
C10H20O6P2S	Not Available	Not Available	330.275	[H]\C(CSP(O)(=O)OP(O)(O)=O)=C(\C)CCC=C(C)C	Solid	Not Available							CHEMBL1233134	4450653						GST			5288476	46507778							S-[(2E)-3,7-DIMETHYLOCTA-2,6-DIENYL] TRIHYDROGENTHIODIPHOSPHATE	Experimental	DB04702	InChI=1S/C10H20O6P2S/c1-9(2)5-4-6-10(3)7-8-19-18(14,15)16-17(11,12)13/h5,7H,4,6,8H2,1-3H3,(H,14,15)(H2,11,12,13)/b10-7+	AKIXWSDUEPPMKM-JXMROGBWSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.7904 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	3	No	0	-3	104.06 Å2	31.15 Å3	79.43 m3·mol-1	8	Yes	No	1.4 mg/mL	2.45	-2.4	2.03		Q4R2T2	Not Available	1. Prenyltransferase
C26H33NO2	Not Available	Not Available	391.5457	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)NC1=CC=C(O)C=C1	Solid	Not Available					50092055	42588	CHEMBL7301	4450416					D04162	FEN			5288209	175426938				Fenretinide	ZINC000003871023		Fenretinide	Investigational	DB05076	InChI=1S/C26H33NO2/c1-19(11-16-24-21(3)10-7-17-26(24,4)5)8-6-9-20(2)18-25(29)27-22-12-14-23(28)15-13-22/h6,8-9,11-16,18,28H,7,10,17H2,1-5H3,(H,27,29)/b9-6+,16-11+,19-8+,20-18+	AKJHMTWEGVYYSE-FXILSDISSA-N	3		"Mechanism of fenretinide (4-HPR)-induced cell death"	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Non-substrate	2.1836 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	2	2	No	2	0	49.33 Å2	47.67 Å3	128.05 m3·mol-1	6	No	No	0.00119 mg/mL	6.15	-5.5	9.45	-1.2			
C23H32O2	Not Available	Not Available	340.507	C\C(\C=C\C=C(/C)C1=CC(=CC(=C1)C(C)(C)C)C(C)(C)C)=C/C(O)=O	Solid	Not Available					50052033		CHEMBL89241	4450017						ARL				347910230							LGD-1550	Investigational	DB05785	InChI=1S/C23H32O2/c1-16(12-21(24)25)10-9-11-17(2)18-13-19(22(3,4)5)15-20(14-18)23(6,7)8/h9-15H,1-8H3,(H,24,25)/b10-9+,16-12+,17-11+	JMPZTWDLOGTBPM-OUQSKUGOSA-N			Not Available	Small Molecule																																			1	No	2	1	No	1	-1	37.3 Å2	41.93 Å3	109.59 m3·mol-1	6	No	Yes	0.000304 mg/mL	6.82	-6	4.57		P10276;!P10826;!P13631;!P05412	RARA;!RARB;!RARG;!JUN	1. Retinoic acid receptor alpha;!2. Retinoic acid receptor beta;!3. Retinoic acid receptor gamma;!4. Transcription factor AP-1
C20H24O4	Not Available	Not Available	328.408	C\C(\C=C\C=C(/C)C(O)=O)=C/C=C/C=C(\C)/C=C/C=C(\C)C(O)=O	Solid	Not Available					50269617	3918	CHEMBL464792	4444644				C08588										Crocetin	ZINC000004097701		Transcrocetinate	Investigational	DB05974	InChI=1S/C20H24O4/c1-15(11-7-13-17(3)19(21)22)9-5-6-10-16(2)12-8-14-18(4)20(23)24/h5-14H,1-4H3,(H,21,22)(H,23,24)/b6-5+,11-7+,12-8+,15-9+,16-10+,17-13+,18-14+	PANKHBYNKQNAHN-MQQNZMFNSA-N	2		Not Available	Small Molecule																																			1	Yes	4	2	No	0	-2	74.6 Å2	38.07 Å3	103.8 m3·mol-1	8	Yes	No	0.00558 mg/mL	4.4	-4.8	4.41				
C40H56	The clearance rate of beta-carotene administered orally is 0.68 nmol/L each hour.3	The apparent half-life of beta-carotene is of 6-11 days after initial administration.2	536.888	C\C(\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)CCCC1(C)C	Solid	No pharmacokinetic studies have been performed regarding the volume of distribution of beta-carotene.	Q9HAY6	BCO1	1. Beta,beta-carotene 15,15'-dioxygenase		54988	17579	CHEMBL1293	4444129			HMDB0000561	C02094	D03101	BCR			5280489	347827791		19143		Beta-Carotene	ZINC000006845076	Pregvit	Beta carotene	Approved, Nutraceutical	DB06755	InChI=1S/C40H56/c1-31(19-13-21-33(3)25-27-37-35(5)23-15-29-39(37,7)8)17-11-12-18-32(2)20-14-22-34(4)26-28-38-36(6)24-16-30-40(38,9)10/h11-14,17-22,25-28H,15-16,23-24,29-30H2,1-10H3/b12-11+,19-13+,20-14+,27-25+,28-26+,31-17+,32-18+,33-21+,34-22+	OENHQHLEOONYIE-JLTXGRSLSA-N	4	Beta carotene is a vitamin A precursor found in various nutritional supplements and health products.	Beta-carotene is not toxic but the high and constant administration of this substance can translate into skin yellow coloration.6 Some reports have indicated that administration of high and periodic doses of beta-carotene are correlated to the increase in cancer incidence. This risk seems to be very elevated in the case of smokers.15 The registered LD50 of beta-carotene is >5000 mg/kg.MSDS	Small Molecule																													633-577ºC	17.62		176-184ºC		0.0006 g/l at 25ºC	0	No	0	0	No	2	0	0 Å2	71.84 Å3	191.61 m3·mol-1	10	No	Yes	0.000391 mg/mL	11.12	-6.1					1. Free radicals
C15H20O4	Not Available	Not Available	264.3169	O=CCCCC=C(CCC=C(CCC=O)C=O)C=O	Solid	Not Available								57541697						220			21363450	99443383							UNDECA-3,7-DIENE-1,3,7,11-TETRACARBALDEHYDE	Experimental	DB06912	InChI=1S/C15H20O4/c16-10-3-1-2-6-14(12-18)7-4-8-15(13-19)9-5-11-17/h6,8,10-13H,1-5,7,9H2	WRPMDTWVLJJHMV-UHFFFAOYSA-N			Not Available	Small Molecule				AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.1919 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	0	No	0	0	68.28 Å2	29.07 Å3	75.48 m3·mol-1	12	Yes	No	0.0166 mg/mL	1.11	-4.2	17.16	-4	P61626	LYZ	1. Lysozyme C
C18H30O5	Not Available	Not Available	326.4278	[H]C(C(O)=O)=C(C)C(\[H])=C(/C)C[C@]([H])(C)CCCC[C@@]([H])(O)[C@@]([H])(CO)C=O	Solid	Not Available								64873353						F24			131704306	99444211							(7R,12R,13R)-13-formyl-12,14-dihydroxy-3,5,7-trimethyltetradeca-2,4-dienoic acid	Experimental	DB07740	InChI=1S/C18H30O5/c1-13(8-14(2)9-15(3)10-18(22)23)6-4-5-7-17(21)16(11-19)12-20/h9-11,13,16-17,20-21H,4-8,12H2,1-3H3,(H,22,23)/b14-9+,15-10?/t13-,16-,17-/m1/s1	CJCDMTWCUXKYGF-QPILVHKNSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.5908 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	3	No	0	-1	94.83 Å2	36.31 Å3	91.81 m3·mol-1	12	Yes	No	0.048 mg/mL	2.33	-3.8	4.86	-2.7	Q01581	HMGCS1	1. Hydroxymethylglutaryl-CoA synthase, cytoplasmic
C17H30NO5P	Not Available	Not Available	359.3976	CC(C)=CCC\C(C)=C\CC\C(C)=C\CONC(=O)CP(O)(O)=O	Solid	Not Available								392777						FII			445015	99444242					ZINC000002046984		[(3,7,11-TRIMETHYL-DODECA-2,6,10-TRIENYLOXYCARBAMOYL)-METHYL]-PHOSPHONIC ACID	Experimental	DB07771	InChI=1S/C17H30NO5P/c1-14(2)7-5-8-15(3)9-6-10-16(4)11-12-23-18-17(19)13-24(20,21)22/h7,9,11H,5-6,8,10,12-13H2,1-4H3,(H,18,19)(H2,20,21,22)/b15-9+,16-11+	JAOBYUCYSAOLHS-XGGJEREUSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.5856 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	3	No	0	-2	95.86 Å2	39.39 Å3	98.43 m3·mol-1	11	Yes	No	0.0044 mg/mL	2.61	-4.9	1.66	-4.6	P01116;!P49354;!P49356	KRAS;!FNTA;!FNTB	1. GTPase KRas;!2. Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha;!3. Protein farnesyltransferase subunit beta
C15H28O7P2	Not Available	Not Available	382.33	CC(C)=CCC\C(C)=C\CC\C(C)=C\COP(O)(=O)OP(O)(O)=O	Solid	Not Available					50366477	17407	CHEMBL69330	393270			HMDB0000961	C00448		FPP			445713	99444251				Farnesyl_pyrophosphate	ZINC000012494625		Farnesyl diphosphate	Experimental	DB07780	InChI=1S/C15H28O7P2/c1-13(2)7-5-8-14(3)9-6-10-15(4)11-12-21-24(19,20)22-23(16,17)18/h7,9,11H,5-6,8,10,12H2,1-4H3,(H,19,20)(H2,16,17,18)/b14-9+,15-11+	VWFJDQUYCIWHTN-YFVJMOTDSA-N			Not Available	Small Molecule	http://smpdb.ca/view/SMP0000099?highlight[compounds][]=DB07780&highlight[proteins][]=DB07780;!http://smpdb.ca/view/SMP0000111?highlight[compounds][]=DB07780&highlight[proteins][]=DB07780;!http://smpdb.ca/view/SMP0000209?highlight[compounds][]=DB07780&highlight[proteins][]=DB07780;!http://smpdb.ca/view/SMP0000342?highlight[compounds][]=DB07780&highlight[proteins][]=DB07780;!http://smpdb.ca/view/SMP0000345?highlight[compounds][]=DB07780&highlight[proteins][]=DB07780;!http://smpdb.ca/view/SMP0000388?highlight[compounds][]=DB07780&highlight[proteins][]=DB07780;!http://smpdb.ca/view/SMP0000389?highlight[compounds][]=DB07780&highlight[proteins][]=DB07780;!http://smpdb.ca/view/SMP0000510?highlight[compounds][]=DB07780&highlight[proteins][]=DB07780;!http://smpdb.ca/view/SMP0000024?highlight[compounds][]=DB07780&highlight[proteins][]=DB07780;!http://smpdb.ca/view/SMP0000082?highlight[compounds][]=DB07780&highlight[proteins][]=DB07780;!http://smpdb.ca/view/SMP0000089?highlight[compounds][]=DB07780&highlight[proteins][]=DB07780;!http://smpdb.ca/view/SMP0000092?highlight[compounds][]=DB07780&highlight[proteins][]=DB07780;!http://smpdb.ca/view/SMP0000107?highlight[compounds][]=DB07780&highlight[proteins][]=DB07780;!http://smpdb.ca/view/SMP0000117?highlight[compounds][]=DB07780&highlight[proteins][]=DB07780;!http://smpdb.ca/view/SMP0000119?highlight[compounds][]=DB07780&highlight[proteins][]=DB07780;!http://smpdb.ca/view/SMP0000319?highlight[compounds][]=DB07780&highlight[proteins][]=DB07780;!http://smpdb.ca/view/SMP0000508?highlight[compounds][]=DB07780&highlight[proteins][]=DB07780;!http://smpdb.ca/view/SMP0000023?highlight[compounds][]=DB07780&highlight[proteins][]=DB07780;!http://smpdb.ca/view/SMP0000079?highlight[compounds][]=DB07780&highlight[proteins][]=DB07780;!http://smpdb.ca/view/SMP0000095?highlight[compounds][]=DB07780&highlight[proteins][]=DB07780;!http://smpdb.ca/view/SMP0000112?highlight[compounds][]=DB07780&highlight[proteins][]=DB07780;!http://smpdb.ca/view/SMP0000131?highlight[compounds][]=DB07780&highlight[proteins][]=DB07780;!http://smpdb.ca/view/SMP0000344?highlight[compounds][]=DB07780&highlight[proteins][]=DB07780;!http://smpdb.ca/view/SMP0000346?highlight[compounds][]=DB07780&highlight[proteins][]=DB07780;!http://smpdb.ca/view/SMP0000386?highlight[compounds][]=DB07780&highlight[proteins][]=DB07780;!http://smpdb.ca/view/SMP0000387?highlight[compounds][]=DB07780&highlight[proteins][]=DB07780;!http://smpdb.ca/view/SMP0000509?highlight[compounds][]=DB07780&highlight[proteins][]=DB07780;!http://smpdb.ca/view/SMP0000511?highlight[compounds][]=DB07780&highlight[proteins][]=DB07780	Lovastatin Action Pathway;!Cerivastatin Action Pathway;!Hypercholesterolemia;!Hereditary Coproporphyria (HCP);!Congenital Erythropoietic Porphyria (CEP) or Gunther Disease;!Chondrodysplasia Punctata II, X-Linked Dominant (CDPX2);!Smith-Lemli-Opitz Syndrome (SLOS);!Mevalonic Aciduria;!Porphyrin Metabolism;!Simvastatin Action Pathway;!Pravastatin Action Pathway;!Rosuvastatin Action Pathway;!Zoledronate Action Pathway;!Pamidronate Action Pathway;!Fluvastatin Action Pathway;!Lysosomal Acid Lipase Deficiency (Wolman Disease);!Cholesteryl Ester Storage Disease;!Steroid Biosynthesis;!Ibandronate Action Pathway;!Alendronate Action Pathway;!Risedronate Action Pathway;!Atorvastatin Action Pathway;!Acute Intermittent Porphyria;!Porphyria Variegata (PV);!Desmosterolosis;!CHILD Syndrome;!Hyper-IgD Syndrome;!Wolman Disease		Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.4092 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	3	No	0	-2	113.29 Å2	37.94 Å3	96.73 m3·mol-1	11	Yes	No	0.0807 mg/mL	3.62	-3.7	1.77		P49354;!P49356;!P01116;!Q8EBR3;!P14324;!P60472;!P29559;!O95749;!P9WFF5;!Q92696;!P53611	FNTA;!FNTB;!KRAS;!ispF;!FDPS;!ispU;!nisZ;!GGPS1;!Not Available;!RABGGTA;!RABGGTB	1. Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha;!2. Protein farnesyltransferase subunit beta;!3. GTPase KRas;!4. 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase;!5. Farnesyl pyrophosphate synthase;!6. Ditrans,polycis-undecaprenyl-diphosphate synthase ((2E,6E)-farnesyl-diphosphate specific);!7. Lantibiotic nisin-Z;!8. Geranylgeranyl pyrophosphate synthase;!9. (2Z,6E)-farnesyl diphosphate synthase;!10. Geranylgeranyl transferase type-2 subunit alpha;!11. Geranylgeranyl transferase type-2 subunit beta
C20H36O7P2	Not Available	Not Available	450.449	CC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCOP(O)(=O)OP(O)(O)=O	Solid	Not Available						15831		715						BUE			447277	99444312				Geranylgeranyl_pyrophosphate			Geranylgeranyl diphosphate	Experimental	DB07841	InChI=1S/C20H36O7P2/c1-17(2)9-6-10-18(3)11-7-12-19(4)13-8-14-20(5)15-16-26-29(24,25)27-28(21,22)23/h9,11,13,15H,6-8,10,12,14,16H2,1-5H3,(H,24,25)(H2,21,22,23)	OINNEUNVOZHBOX-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.4092 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	Yes	5	3	No	0	-2	113.29 Å2	47.24 Å3	120.53 m3·mol-1	14	No	No	0.00463 mg/mL	5.28	-5	1.77		P49354;!P53609;!P49356;!O95749;!P14324;!Q92696;!P53611	FNTA;!PGGT1B;!FNTB;!GGPS1;!FDPS;!RABGGTA;!RABGGTB	1. Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha;!2. Geranylgeranyl transferase type-1 subunit beta;!3. Protein farnesyltransferase subunit beta;!4. Geranylgeranyl pyrophosphate synthase;!5. Farnesyl pyrophosphate synthase;!6. Geranylgeranyl transferase type-2 subunit alpha;!7. Geranylgeranyl transferase type-2 subunit beta
C16H28O3	Not Available	Not Available	268.3917	COC(C)(C)CCC[C@@](C)([H])C\C=C\C(\C)=C\C(O)=O	Solid	Not Available								4450887						MEI			5288795	99444646					ZINC000002244163		(2E,4E)-11-METHOXY-3,7,11-TRIMETHYLDODECA-2,4-DIENOIC ACID	Experimental	DB08175	InChI=1S/C16H28O3/c1-13(10-7-11-16(3,4)19-5)8-6-9-14(2)12-15(17)18/h6,9,12-13H,7-8,10-11H2,1-5H3,(H,17,18)/b9-6+,14-12+/t13-/m1/s1	MNYBEULOKRVZKY-ATCPXPEISA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	1.3231 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	1	No	0	-1	46.53 Å2	32.11 Å3	80.86 m3·mol-1	9	Yes	No	0.00868 mg/mL	4.1	-4.5	4.82	-4.1	Q15596;!P28702;!Q13133	NCOA2;!RXRB;!NR1H3	1. Nuclear receptor coactivator 2;!2. Retinoic acid receptor RXR-beta;!3. Oxysterols receptor LXR-alpha
C19H37NO7P2	Not Available	Not Available	453.4471	CN(CCO[P@@](O)(=O)OP(O)(O)=O)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C	Solid	Not Available					50113289		CHEMBL71360	394419						MGM			447278	99444651							2-[METHYL-(5-GERANYL-4-METHYL-PENT-3-ENYL)-AMINO]-ETHYL-DIPHOSPHATE	Experimental	DB08180	InChI=1S/C19H37NO7P2/c1-17(2)9-6-10-18(3)11-7-12-19(4)13-8-14-20(5)15-16-26-29(24,25)27-28(21,22)23/h9,11,13H,6-8,10,12,14-16H2,1-5H3,(H,24,25)(H2,21,22,23)/b18-11+,19-13+	OEMBPHBKZPOPBN-NWLVNBMCSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Inhibitor	Non-inhibitor	Substrate	2.6813 LD50, mol/kg	Non-inhibitor	Strong inhibitor	Non-inhibitor										1	Yes	6	3	No	0	-2	116.53 Å2	48 Å3	119.5 m3·mol-1	15	Yes	No	0.0198 mg/mL	2.24	-4.4	1.76	9.6	P49354;!P53609	FNTA;!PGGT1B	1. Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha;!2. Geranylgeranyl transferase type-1 subunit beta
C23H31NO6	Not Available	Not Available	417.4953	CCCC\C(C)=C\C=C(/C)C(=O)C1=C(O)C=C(CCC\C=C\NC(=O)OC)OC1=O	Solid	Not Available							CHEMBL184023	23252060						MXP			54699009	99444697					ZINC000028382402		Myxopyronin B	Experimental	DB08226	InChI=1S/C23H31NO6/c1-5-6-10-16(2)12-13-17(3)21(26)20-19(25)15-18(30-22(20)27)11-8-7-9-14-24-23(28)29-4/h9,12-15,25H,5-8,10-11H2,1-4H3,(H,24,28)/b14-9+,16-12+,17-13+	QBIHIGNYQFSBGW-NOTXRLOZSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	2.9016 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	2	No	1	-1	101.93 Å2	47.14 Å3	119.59 m3·mol-1	12	Yes	No	0.00245 mg/mL	4.87	-5.2	6.85	-6.4	Q9Z9H6;!Q8RQE9;!Q8RQE8;!Q8RQE7;!Q5SKW1	rpoA;!rpoB;!rpoC;!rpoZ;!sigA	1. DNA-directed RNA polymerase subunit alpha;!2. DNA-directed RNA polymerase subunit beta;!3. DNA-directed RNA polymerase subunit beta';!4. DNA-directed RNA polymerase subunit omega;!5. RNA polymerase sigma factor
C23H31NO6	Not Available	Not Available	417.4953	[H]\C(CCC[C@@]([H])(C)C1=CC(=O)C([H])(C(=O)C(\C)=C(/[H])\C(\[H])=C(/C)CCC)C(=O)O1)=N/C(=O)OC	Solid	Not Available								26328246						NE6			131704307	99444737							Methyl [(1E,5R)-5-{3-[(2E,4E)-2,5-dimethyl-2,4-octadienoyl]-2,4-dioxo-3,4-dihydro-2H-pyran-6-yl}hexylidene]carbamate	Experimental	DB08266	InChI=1S/C23H31NO6/c1-6-9-15(2)11-12-17(4)21(26)20-18(25)14-19(30-22(20)27)16(3)10-7-8-13-24-23(28)29-5/h11-14,16,20H,6-10H2,1-5H3/b15-11+,17-12+,24-13+/t16-,20?/m1/s1	LTDLIPXLSBMTFP-FSAISGGASA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Non-substrate	2.7220 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	0	No	1	0	99.1 Å2	45.43 Å3	116.4 m3·mol-1	11	Yes	No	0.00173 mg/mL	4.54	-5.4	8.7	-2.5	Q5SHR6;!Q8RQE9;!Q8RQE8;!Q8RQE7;!Q5SKW1	rpoA;!rpoB;!rpoC;!rpoZ;!sigA	1. DNA-directed RNA polymerase subunit alpha;!2. DNA-directed RNA polymerase subunit beta;!3. DNA-directed RNA polymerase subunit beta';!4. DNA-directed RNA polymerase subunit omega;!5. RNA polymerase sigma factor
C20H24O3	Not Available	Not Available	312.4028	[H]/C(=C(/[H])\C(\C)=C(/[H])C(O)=O)/C(/[H])=C(\C)/C(/[H])=C(\[H])C1=C(C)C=C(O)C(C)=C1C	Solid	Not Available								4943051						R12			6438583	99444926							Ro 12-7310	Experimental	DB08455	InChI=1S/C20H24O3/c1-13(7-6-8-14(2)11-20(22)23)9-10-18-15(3)12-19(21)17(5)16(18)4/h6-12,21H,1-5H3,(H,22,23)/b8-6+,10-9+,13-7+,14-11+	CAAFTBWHFUPDGX-OFCLTBKTSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1413 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	2	No	1	-1	57.53 Å2	36.52 Å3	99.68 m3·mol-1	5	No	No	0.00119 mg/mL	5.44	-5.4	4.77	-5.9			
C20H28O2	Not Available	Not Available	300.4351	O=C(O)\C=C(/C)\C=C\C[C@]1(C)CC2=C(CCCC2(C)C)C1=C	Solid	Not Available								4451273						RE9			5289278	99444938					ZINC000015475858		6-(2,3,4,5,6,7-HEXAHYDRO-2,4,4-TRIMETHYL-1-METYLENEINDEN-2-YL)-3-METHYLHEXA-2,4-DIENOIC ACID	Experimental	DB08467	InChI=1S/C20H28O2/c1-14(12-18(21)22)8-6-11-20(5)13-17-16(15(20)2)9-7-10-19(17,3)4/h6,8,12H,2,7,9-11,13H2,1,3-5H3,(H,21,22)/b8-6+,14-12+/t20-/m1/s1	HEVXQLBAMFMFKU-IAZPEVBMSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Non-substrate	2.1458 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	1	No	2	-1	37.3 Å2	34.61 Å3	93.62 m3·mol-1	4	Yes	Yes	0.00892 mg/mL	4.67	-4.5	4.54				
C19H26O4	Not Available	Not Available	318.4073	COC1=C(OC)C(=O)C(C\C=C(/C)CCC=C(C)C)=C(C)C1=O	Solid	Not Available						46372	CHEMBL1236595	4444053			HMDB0006709	C00399		UQ2			5280346	99445161		1423925			ZINC000001532641		Ubiquinone Q2	Experimental	DB08690	InChI=1S/C19H26O4/c1-12(2)8-7-9-13(3)10-11-15-14(4)16(20)18(22-5)19(23-6)17(15)21/h8,10H,7,9,11H2,1-6H3/b13-10+	SQQWBSBBCSFQGC-JLHYYAGUSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.2673 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	0	No	1	0	52.6 Å2	36.45 Å3	96.18 m3·mol-1	7	Yes	No	0.01 mg/mL	3.88	-4.5		-4.7	P0AC41;!P07014;!P69054;!P0AC44;!P08574;!P00156;!P31930;!P22695;!P07919;!O14949;!P47985;!O14957;!P14927;!Q9UDW1;!P07173;!P06008;!P06009;!P06010;!P0A6M2;!Q02761;!Q02762;!Q02760;!P0C0Y8;!P0C0Y9;!P0C0Y7	sdhA;!sdhB;!sdhC;!sdhD;!CYC1;!MT-CYB;!UQCRC1;!UQCRC2;!UQCRH;!UQCRQ;!UQCRFS1;!UQCR11;!UQCRB;!UQCR10;!pufC;!puhA;!pufL;!pufM;!dsbB;!petB;!petA;!petC;!pufL;!pufM;!puhA	1. Succinate dehydrogenase flavoprotein subunit;!2. Succinate dehydrogenase iron-sulfur subunit;!3. Succinate dehydrogenase cytochrome b556 subunit;!4. Succinate dehydrogenase hydrophobic membrane anchor subunit;!5. Cytochrome c1, heme protein, mitochondrial;!6. Cytochrome b;!7. Cytochrome b-c1 complex subunit 1, mitochondrial;!8. Cytochrome b-c1 complex subunit 2, mitochondrial;!9. Cytochrome b-c1 complex subunit 6, mitochondrial;!10. Cytochrome b-c1 complex subunit 8;!11. Cytochrome b-c1 complex subunit Rieske, mitochondrial;!12. Cytochrome b-c1 complex subunit 10;!13. Cytochrome b-c1 complex subunit 7;!14. Cytochrome b-c1 complex subunit 9;!15. Photosynthetic reaction center cytochrome c subunit;!16. Reaction center protein H chain;!17. Reaction center protein L chain;!18. Reaction center protein M chain;!19. Disulfide bond formation protein B;!20. Cytochrome b;!21. Ubiquinol-cytochrome c reductase iron-sulfur subunit;!22. Cytochrome c1;!23. Reaction center protein L chain;!24. Reaction center protein M chain;!25. Reaction center protein H chain
C40H56	Not Available	Not Available	536.888	CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C	Not Available	Not Available						15948	CHEMBL501174	394156			HMDB0003000	C05432		LYC			446925	347827946		29008		Lycopene	ZINC000008214943		Lycopene	Approved, Investigational	DB11231	InChI=1S/C40H56/c1-33(2)19-13-23-37(7)27-17-31-39(9)29-15-25-35(5)21-11-12-22-36(6)26-16-30-40(10)32-18-28-38(8)24-14-20-34(3)4/h11-12,15-22,25-32H,13-14,23-24H2,1-10H3/b12-11+,25-15+,26-16+,31-17+,32-18+,35-21+,36-22+,37-27+,38-28+,39-29+,40-30+	OAIJSZIZWZSQBC-GYZMGTAESA-N	4	Lycopene is an ingredient found in a variety of supplements and vitamins.	Not Available	Small Molecule																																			0	No	0	0	No	0	0	0 Å2	73.69 Å3	197.81 m3·mol-1	16	No	No	0.000397 mg/mL	11.93	-6.1					
C30H50	Not Available	Not Available	410.73	CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C=C(/C)CC\C=C(/C)CCC=C(C)C	Not Available	Not Available						15440	CHEMBL458402	553635				C00751		SQL			638072	347827980		10014		Squalene	ZINC000006845904		Squalene	Approved, Vet approved	DB11460	InChI=1S/C30H50/c1-25(2)15-11-19-29(7)23-13-21-27(5)17-9-10-18-28(6)22-14-24-30(8)20-12-16-26(3)4/h15-18,23-24H,9-14,19-22H2,1-8H3/b27-17+,28-18+,29-23+,30-24+	YYGNTYWPHWGJRM-AAJYLUCBSA-N			Not Available	Small Molecule																																			0	No	0	0	No	0	0	0 Å2	56.17 Å3	144.62 m3·mol-1	15	No	No	0.000502 mg/mL	10.42	-5.9					
C19H34O3	Not Available	Not Available	310.478	[H]\C(C[C@@]([H])(C)CCCC(C)(C)OC)=C(\[H])/C(/C)=C(\[H])C(=O)OC(C)C	Not Available	Not Available						39255	CHEMBL1875086	1361490															ZINC000002005163		(S)-methoprene	Vet approved	DB11495	InChI=1S/C19H34O3/c1-15(2)22-18(20)14-17(4)11-8-10-16(3)12-9-13-19(5,6)21-7/h8,11,14-16H,9-10,12-13H2,1-7H3/b11-8+,17-14+/t16-/m1/s1	NFGXHKASABOEEW-GYMWBFJFSA-N			Not Available	Small Molecule																																			0	Yes	2	0	No	0	0	35.53 Å2	38.25 Å3	94.79 m3·mol-1	11	No	No	0.00307 mg/mL	5.26	-5		-4.1			
C24H32O2	Not Available	Not Available	352.518	C\C(\C=C\[C@@H]1C[C@]1(C)C1=CC=C2C(=C1)C(C)(C)CCC2(C)C)=C/C(O)=O	Not Available	Not Available					50101445		CHEMBL75133	8039037									9863341	347828153					ZINC000001550770		VTP-194204	Investigational	DB11806	InChI=1S/C24H32O2/c1-16(13-21(25)26)7-8-18-15-24(18,6)17-9-10-19-20(14-17)23(4,5)12-11-22(19,2)3/h7-10,13-14,18H,11-12,15H2,1-6H3,(H,25,26)/b8-7+,16-13+/t18-,24-/m1/s1	BOOOLEGQBVUTKC-NVQSDHBMSA-N	2		Not Available	Small Molecule																																			1	No	2	1	No	3	-1	37.3 Å2	41.37 Å3	109.56 m3·mol-1	4	No	Yes	0.000104 mg/mL	6.31	-6.5	4.83				
C29H44O3	Not Available	Not Available	440.668	CC(C)=CCC\C(C)=C\CC\C(C)=C\CC[C@@](C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O	Not Available	Not Available							CHEMBL1812161	26632368									46184405	347828248							Vatiquinone	Investigational	DB11917	InChI=1S/C29H44O3/c1-20(2)12-9-13-21(3)14-10-15-22(4)16-11-18-29(8,32)19-17-26-25(7)27(30)23(5)24(6)28(26)31/h12,14,16,32H,9-11,13,15,17-19H2,1-8H3/b21-14+,22-16+/t29-/m1/s1	LNOVHERIIMJMDG-XZXLULOTSA-N	2		Not Available	Small Molecule																																			0	No	3	1	No	1	0	54.37 Å2	54.59 Å3	139.98 m3·mol-1	12	No	No	0.00125 mg/mL	7.81	-5.6	19.53	-0.82			
C27H44O2	Not Available	Not Available	400.647	[H]\C(CC\C(C)=C(/[H])CCC(=O)OC\C([H])=C(/C)CCC=C(C)C)=C(\C)CCC=C(C)C	Not Available	Not Available						31646	CHEMBL2105085	4445377									5282182	347828385				Gefarnate	ZINC000003872668		Gefarnate	Investigational	DB12079	InChI=1S/C27H44O2/c1-22(2)12-8-14-24(5)16-10-17-25(6)18-11-19-27(28)29-21-20-26(7)15-9-13-23(3)4/h12-13,16,18,20H,8-11,14-15,17,19,21H2,1-7H3/b24-16+,25-18+,26-20+	ZPACYDRSPFRDHO-ROBAGEODSA-N	3		Not Available	Small Molecule																																			0	No	1	0	No	0	0	26.3 Å2	51.47 Å3	131.77 m3·mol-1	15	No	No	0.00102 mg/mL	8.18	-5.6		-7			
C22H32O2	Not Available	Not Available	328.4883	CC(=O)OC\C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C	Not Available	Not Available								8421459			HMDB0035185						10245972	347828413					ZINC000014685555		Zuretinol acetate	Investigational	DB12112	InChI=1S/C22H32O2/c1-17(9-7-10-18(2)14-16-24-20(4)23)12-13-21-19(3)11-8-15-22(21,5)6/h7,9-10,12-14H,8,11,15-16H2,1-6H3/b10-7+,13-12+,17-9-,18-14+	QGNJRVVDBSJHIZ-AQDFTDIISA-N	2		Not Available	Small Molecule																																			1	Yes	1	0	No	1	0	26.3 Å2	40.5 Å3	107.07 m3·mol-1	7	No	Yes	0.00238 mg/mL	5.14	-5.1		-7			
C31H40O2	Not Available	Not Available	444.659	[H]\C(CC\C(C)=C(/[H])CC\C(C)=C(/[H])CC1=C(C)C(=O)C2=CC=CC=C2C1=O)=C(\C)CCC=C(C)C	Not Available	Not Available					50423776	78277	CHEMBL259223	4445530			HMDB0030017			1L3			5282367	347828444		29495		Menatetrenone	ZINC000003874199		Menatetrenone	Investigational	DB12148	InChI=1S/C31H40O2/c1-22(2)12-9-13-23(3)14-10-15-24(4)16-11-17-25(5)20-21-27-26(6)30(32)28-18-7-8-19-29(28)31(27)33/h7-8,12,14,16,18-20H,9-11,13,15,17,21H2,1-6H3/b23-14+,24-16+,25-20+	DKHGMERMDICWDU-GHDNBGIDSA-N	4	Menatetrenone is a form of vitamin K2 which is used in the treatment of osteoporosis to stimulate osteogenesis.	Not Available	Small Molecule																																			0	No	2	0	No	2	0	34.14 Å2	54.92 Å3	145.51 m3·mol-1	11	No	No	0.000489 mg/mL	8.48	-6		-7.2			
C20H22O2	Not Available	Not Available	294.3875	[H]/C(=C(/[H])\C(\C)=C(/[H])C(O)=O)/C(/[H])=C(/C)\C(\[H])=C1/CCCC2=CC=CC=C12	Not Available	Not Available					50445062		CHEMBL3098771	8079857						1O8			9904203	347828580							9CUAB30	Investigational	DB12316	InChI=1S/C20H22O2/c1-15(7-5-8-16(2)14-20(21)22)13-18-11-6-10-17-9-3-4-12-19(17)18/h3-5,7-9,12-14H,6,10-11H2,1-2H3,(H,21,22)/b8-5+,15-7-,16-14+,18-13+	PPGNMFUMZSAZCW-VOYUZAMQSA-N	1		Not Available	Small Molecule																																			1	Yes	2	1	No	2	-1	37.3 Å2	33.81 Å3	94.7 m3·mol-1	4	Yes	Yes	0.00157 mg/mL	5	-5.3	4.54				
C24H38O4	Not Available	Not Available	390.564	COC1=C(OC)C(=O)[C@H](C)[C@@H](C\C=C(/C)CC\C=C(/C)CCC=C(C)C)[C@H]1O	Not Available	Not Available						65415	CHEMBL3235620	28284595									24875259	347828588					ZINC000087529312		Antroquinonol	Investigational	DB12326	InChI=1S/C24H38O4/c1-16(2)10-8-11-17(3)12-9-13-18(4)14-15-20-19(5)21(25)23(27-6)24(28-7)22(20)26/h10,12,14,19-20,22,26H,8-9,11,13,15H2,1-7H3/b17-12+,18-14+/t19-,20-,22-/m1/s1	LJTSIMVOOOLKOL-FNRDIUJOSA-N	2		Not Available	Small Molecule																																			1	Yes	4	1	No	1	0	55.76 Å2	46.93 Å3	120.07 m3·mol-1	10	Yes	No	0.00399 mg/mL	4.73	-5	13.51	-3.4			
C26H38O2	Not Available	Not Available	382.5787	CC(C)=CCC\C(C)=C\CC\C(C)=C\CCC1(C)CCC2=CC(O)=CC=C2O1	Not Available	Not Available							CHEMBL120643	8105532			HMDB0036368						9929901	347828854		578285		Tocotrienol			Tocotrienol	Investigational	DB12647	InChI=1S/C26H38O2/c1-20(2)9-6-10-21(3)11-7-12-22(4)13-8-17-26(5)18-16-23-19-24(27)14-15-25(23)28-26/h9,11,13-15,19,27H,6-8,10,12,16-18H2,1-5H3/b21-11+,22-13+	GJJVAFUKOBZPCB-ZGRPYONQSA-N	2		Not Available	Small Molecule																																			1	No	2	1	No	2	0	29.46 Å2	48.17 Å3	122.8 m3·mol-1	9	No	Yes	0.000793 mg/mL	7.75	-5.7	10.01	-4.9			
C22H30O2S	Not Available	Not Available	358.54	CC(C)=CCC\C(C)=C\CC\C(C)=C\CSC1=CC=CC=C1C(O)=O	Not Available	Not Available					50034278		CHEMBL23293	4579849									5469318	347828885					ZINC000001650377		Salirasib	Investigational	DB12681	InChI=1S/C22H30O2S/c1-17(2)9-7-10-18(3)11-8-12-19(4)15-16-25-21-14-6-5-13-20(21)22(23)24/h5-6,9,11,13-15H,7-8,10,12,16H2,1-4H3,(H,23,24)/b18-11+,19-15+	WUILNKCFCLNXOK-CFBAGHHKSA-N	2		Not Available	Small Molecule																																			1	No	2	1	No	1	-1	37.3 Å2	43.46 Å3	112.85 m3·mol-1	10	No	Yes	0.000659 mg/mL	6.84	-5.7	3.41				
C46H64O2	Not Available	Not Available	648.9992	[H]\C(CC\C(C)=C(/[H])CC\C(C)=C(/[H])CC\C(C)=C(/[H])CC\C(C)=C(/[H])CC\C(C)=C(/[H])CC1=C(C)C(=O)C2=CC=CC=C2C1=O)=C(\C)CCC=C(C)C	Not Available	Not Available						44245		4449904						MQ7			5287554	347829202		2001758			ZINC000058638423		Menaquinone 7	Investigational	DB13075	InChI=1S/C46H64O2/c1-34(2)18-12-19-35(3)20-13-21-36(4)22-14-23-37(5)24-15-25-38(6)26-16-27-39(7)28-17-29-40(8)32-33-42-41(9)45(47)43-30-10-11-31-44(43)46(42)48/h10-11,18,20,22,24,26,28,30-32H,12-17,19,21,23,25,27,29,33H2,1-9H3/b35-20+,36-22+,37-24+,38-26+,39-28+,40-32+	RAKQPZMEYJZGPI-LJWNYQGCSA-N	2		Not Available	Small Molecule																																			0	No	2	0	No	2	0	34.14 Å2	83.24 Å3	216.91 m3·mol-1	20	No	No	0.000229 mg/mL	13.46	-6.4		-7.2			
C15H26O	Not Available	Not Available	222.372	[H][C@@]1(CCC(C)=CC1)[C@@](C)(O)CCC=C(C)C	Solid	To demonstrate the distribution of the substance in the skin a part of this tissue was cutted into horizontal slices by a cryotome. From the slices autoradiograms were produced. The densitometric measuration showed that there was a fast penetration of levomenol into the skin. 5 h after the topical application the substance was displaced from outermost to innermost areas. From these results a fast cutaneous absorption and a long therapeutical effect of the antiphlogistic and spasmolytic levomenol in the skin can be expected.					50382730	125	CHEMBL1096927	390796				C09621					442343	347829263		19461		Bisabolol	ZINC000001849759		Levomenol	Approved, Experimental	DB13153	InChI=1S/C15H26O/c1-12(2)6-5-11-15(4,16)14-9-7-13(3)8-10-14/h6-7,14,16H,5,8-11H2,1-4H3/t14-,15+/m1/s1	RGZSQWQPBWRIAQ-CABCVRRESA-N	1		Not Available	Small Molecule																																			1	Yes	1	1	No	1	0	20.23 Å2	28.29 Å3	72.19 m3·mol-1	4	Yes	Yes	0.0729 mg/mL	3.91	-3.5		-0.47			
C17H25NO3	Not Available	Not Available	291.391	CCCC[C@@H](O)\C=C(/C)\C=C\C=C\C(=O)N1CCCC1=O	Not Available	Not Available					50448688	32289	CHEMBL486174	4445371				C12905										Pecilocin	ZINC000004214101		Pecilocin	Experimental	DB13459	InChI=1S/C17H25NO3/c1-3-4-9-15(19)13-14(2)8-5-6-10-16(20)18-12-7-11-17(18)21/h5-6,8,10,13,15,19H,3-4,7,9,11-12H2,1-2H3/b8-5+,10-6+,14-13+/t15-/m1/s1	ZYPGADGCNXOUJP-CXVPHVKISA-N			Not Available	Small Molecule																																			1	Yes	3	1	No	1	0	57.61 Å2	33.94 Å3	86.98 m3·mol-1	7	Yes	No	0.181 mg/mL	2.4	-3.2	18.09	-1.4			
C27H32O4	Not Available	Not Available	420.549	[H]\C(=C(\[H])C1=C(C)CCCC1(C)C)\C(\C)=C(/[H])C([H])=C(\C(C)=C(\[H])C(O)=O)C1=CC(=CC=C1)C(O)=O	Solid	Not Available								4943196																	13-cis-12-(3'-Carboxyphenyl)retinoic acid	Experimental	DB14097	InChI=1S/C27H32O4/c1-18(12-14-24-19(2)8-7-15-27(24,4)5)11-13-23(20(3)16-25(28)29)21-9-6-10-22(17-21)26(30)31/h6,9-14,16-17H,7-8,15H2,1-5H3,(H,28,29)(H,30,31)/b14-12+,18-11+,20-16-,23-13-	XKKDQOHDTASHCE-PAZAWXFKSA-N			Not Available	Small Molecule																																			1	No	4	2	No	2	-2	74.6 Å2	47.45 Å3	129.42 m3·mol-1	7	No	No	0.000946 mg/mL	6.19	-5.6	3.74				
C10H18O	Not Available	In vitro measurements indicated that geraniol is highly stable in human and rat whole blood, whereas following intravenous administration geraniol is eliminated from the bloodstream with a relatively short half-life (about 12 min), starting from a concentration of about 300 μg/mL 1.	154.253	CC(C)=CCC\C(C)=C\CO	Not Available	Not Available					50037023	17447	CHEMBL25719	13849989			HMDB0035155	C01500		64Z						1368875		Geraniol	ZINC000001529210		Geraniol	Approved, Experimental	DB14183	InChI=1S/C10H18O/c1-9(2)5-4-6-10(3)7-8-11/h5,7,11H,4,6,8H2,1-3H3/b10-7+	GLZPCOQZEFWAFX-JXMROGBWSA-N			Not Available	Small Molecule																																			1	No	1	1	No	0	0	20.23 Å2	19.67 Å3	51.18 m3·mol-1	4	Yes	Yes	1.37 mg/mL	2.5	-2	16.33	-2.2			
C21H32O2	Not Available	Not Available	316.485	CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1	Not Available	Not Available					50318487	69477	CHEMBL497318	4474921												2464938		Cannabigerol	ZINC000004217650		Cannabigerol	Experimental	DB14734	InChI=1S/C21H32O2/c1-5-6-7-11-18-14-20(22)19(21(23)15-18)13-12-17(4)10-8-9-16(2)3/h9,12,14-15,22-23H,5-8,10-11,13H2,1-4H3/b17-12+	QXACEHWTBCFNSA-SFQUDFHCSA-N			Not Available	Small Molecule																																			1	No	2	2	No	1	0	40.46 Å2	39.41 Å3	101.51 m3·mol-1	9	No	No	0.00512 mg/mL	7.05	-4.8	9.16	-5.7			
C21H30O2	Not Available	Not Available	314.469	CCCCCC1=CC2=C(C=CC(C)(CCC=C(C)C)O2)C(O)=C1	Not Available	Not Available					50318486	3357	CHEMBL422704	28064				C08998								2585216		Cannabichromene			Cannabichromene	Experimental	DB14735	InChI=1S/C21H30O2/c1-5-6-7-10-17-14-19(22)18-11-13-21(4,23-20(18)15-17)12-8-9-16(2)3/h9,11,13-15,22H,5-8,10,12H2,1-4H3	UVOLYTDXHDXWJU-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	No	2	1	No	2	0	29.46 Å2	39.01 Å3	99.6 m3·mol-1	7	No	Yes	0.00152 mg/mL	6.6	-5.3	9.47	-4.9			
C41H56O2	Not Available	Not Available	580.8821	CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC1=C(C)C(=O)C2=C(C=CC=C2)C1=O	Not Available	Not Available								4446660												42781			ZINC000072131515		Menaquinone 6	Investigational	DB14936	InChI=1S/C41H56O2/c1-30(2)16-11-17-31(3)18-12-19-32(4)20-13-21-33(5)22-14-23-34(6)24-15-25-35(7)28-29-37-36(8)40(42)38-26-9-10-27-39(38)41(37)43/h9-10,16,18,20,22,24,26-28H,11-15,17,19,21,23,25,29H2,1-8H3/b31-18+,32-20+,33-22+,34-24+,35-28+	PFRQBZFETXBLTP-RCIYGOBDSA-N	4		Not Available	Small Molecule																																			0	No	2	0	No	2	0	34.14 Å2	74.54 Å3	193.11 m3·mol-1	17	No	No	0.000266 mg/mL	11.8	-6.3		-7.2			
C24H28O4	Not Available	Not Available	380.484	C\C(\C=C\C=C(/C)\C=C\C(O)=O)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C(O)=O	Not Available	Not Available						7623	CHEMBL1602127	4444661				C08608										Bixin			Norbixin	Investigational	DB15201	InChI=1S/C24H28O4/c1-19(11-7-13-21(3)15-17-23(25)26)9-5-6-10-20(2)12-8-14-22(4)16-18-24(27)28/h5-18H,1-4H3,(H,25,26)(H,27,28)/b6-5+,11-7+,12-8+,17-15+,18-16+,19-9+,20-10+,21-13+,22-14+	ZVKOASAVGLETCT-UOGKPENDSA-N			Not Available	Small Molecule																																			1	Yes	4	2	No	0	-2	74.6 Å2	45.92 Å3	124.28 m3·mol-1	10	No	No	0.00209 mg/mL	5.15	-5.3	4.47				
C36H48O2	Not Available	Not Available	512.778	CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC1=C(C)C(=O)C2=C(C=CC=C2)C1=O	Not Available	Not Available								32815523														Vitamin_K2	ZINC000065743175		Menaquinone	Investigational	DB15381	InChI=1S/C36H48O2/c1-26(2)14-10-15-27(3)16-11-17-28(4)18-12-19-29(5)20-13-21-30(6)24-25-32-31(7)35(37)33-22-8-9-23-34(33)36(32)38/h8-9,14,16,18,20,22-24H,10-13,15,17,19,21,25H2,1-7H3/b27-16+,28-18+,29-20+,30-24+	HYPYXGZDOYTYDR-HAJWAVTHSA-N	4		Not Available	Small Molecule																																			0	No	2	0	No	2	0	34.14 Å2	64.9 Å3	169.31 m3·mol-1	14	No	No	0.000328 mg/mL	10.14	-6.2		-7.2			
C40H56	Not Available	Not Available	536.888	C\C(\C=C\C=C(/C)\C=C\[C@H]1C(C)=CCCC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)CCCC1(C)C	Not Available	Not Available						35147		4925358														Alpha-Carotene	ZINC000008219947		alpha-Carotene	Experimental	DB15909	InChI=1S/C40H56/c1-31(19-13-21-33(3)25-27-37-35(5)23-15-29-39(37,7)8)17-11-12-18-32(2)20-14-22-34(4)26-28-38-36(6)24-16-30-40(38,9)10/h11-14,17-23,25-28,37H,15-16,24,29-30H2,1-10H3/b12-11+,19-13+,20-14+,27-25+,28-26+,31-17+,32-18+,33-21+,34-22+/t37-/m0/s1	ANVAOWXLWRTKGA-NTXLUARGSA-N			Not Available	Small Molecule																																			0	No	0	0	No	2	0	0 Å2	71.15 Å3	191.88 m3·mol-1	10	No	Yes	0.000307 mg/mL	11.17	-6.2					
C40H56O	Not Available	Not Available	552.887	C\C(\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)C[C@@H](O)CC1(C)C	Not Available	Not Available						10362		4444647				C08591		RRX								Cryptoxanthin	ZINC000004097702		Cryptoxanthin	Experimental	DB15914	InChI=1S/C40H56O/c1-30(18-13-20-32(3)23-25-37-34(5)22-15-27-39(37,7)8)16-11-12-17-31(2)19-14-21-33(4)24-26-38-35(6)28-36(41)29-40(38,9)10/h11-14,16-21,23-26,36,41H,15,22,27-29H2,1-10H3/b12-11+,18-13+,19-14+,25-23+,26-24+,30-16+,31-17+,32-20+,33-21+/t36-/m1/s1	DMASLKHVQRHNES-FKKUPVFPSA-N			Not Available	Small Molecule																																			0	No	1	1	No	2	0	20.23 Å2	72.68 Å3	193.28 m3·mol-1	10	No	Yes	0.000503 mg/mL	9.74	-6	18.91	-1.1			
C23H38O	Not Available	Not Available	330.556	CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CCC(C)=O	Not Available	Not Available							CHEMBL79686	4445389				C13297								1362746		Teprenone	ZINC000001915509		Teprenone	Experimental	DB15955	InChI=1S/C23H38O/c1-19(2)11-7-12-20(3)13-8-14-21(4)15-9-16-22(5)17-10-18-23(6)24/h11,13,15,17H,7-10,12,14,16,18H2,1-6H3/b20-13+,21-15+,22-17+	HUCXKZBETONXFO-NJFMWZAGSA-N	4	Teprenone is a medication indicated in the treatment of acute gastroenteritis, exacerbations of gastric inflammation, and gastric ulcers.	Not Available	Small Molecule																																			0	No	1	0	No	0	0	17.07 Å2	43.45 Å3	111.43 m3·mol-1	12	No	No	0.0016 mg/mL	7	-5.3	19.6	-7.3			
C18H24O	Not Available	Not Available	256.389	CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1	Not Available	Not Available					50478311		CHEMBL262344	4579217												1368134		Bakuchiol	ZINC000001644304		Bakuchiol	Investigational	DB16102	InChI=1S/C18H24O/c1-5-18(4,13-6-7-15(2)3)14-12-16-8-10-17(19)11-9-16/h5,7-12,14,19H,1,6,13H2,2-4H3/b14-12+/t18-/m1/s1	LFYJSSARVMHQJB-QIXNEVBVSA-N			Not Available	Small Molecule																																			1	No	1	1	No	1	0	20.23 Å2	31.52 Å3	85.47 m3·mol-1	6	No	Yes	0.00462 mg/mL	5.62	-4.7	9.53	-5.9			
C20H30O2	Not Available	Not Available	302.458	CC(C)=CCC\C(C)=C\CC\C(C)=C\C=C\C(\C)=C\C(O)=O	Not Available	Not Available								4942358															ZINC000030691356		Peretinoin	Investigational	DB16291	InChI=1S/C20H30O2/c1-16(2)9-6-10-17(3)11-7-12-18(4)13-8-14-19(5)15-20(21)22/h8-9,11,13-15H,6-7,10,12H2,1-5H3,(H,21,22)/b14-8+,17-11+,18-13+,19-15+	UUBHZHZSIKRVIV-KCXSXWJSSA-N	3		Not Available	Small Molecule																																			1	No	2	1	No	0	-1	37.3 Å2	37.93 Å3	99.77 m3·mol-1	9	No	Yes	0.00403 mg/mL	5.78	-4.9	4.81				
C40H56O2	Not Available	Not Available	568.886	C\C(\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)C[C@@H](O)CC1(C)C	Liquid	Not Available						28838	CHEMBL173929	4444655				C08601		LUT	PDRhealth Drug Page	PA164748318	5281243	46508835		11359		Xanthophyll	ZINC000008221225		Lutein	Approved, Investigational, Nutraceutical	DB00137	InChI=1S/C40H56O2/c1-29(17-13-19-31(3)21-23-37-33(5)25-35(41)27-39(37,7)8)15-11-12-16-30(2)18-14-20-32(4)22-24-38-34(6)26-36(42)28-40(38,9)10/h11-25,35-37,41-42H,26-28H2,1-10H3/b12-11+,17-13+,18-14+,23-21+,24-22+,29-15+,30-16+,31-19+,32-20+/t35-,36+,37-/m0/s1	KBPHJBAIARWVSC-RGZFRNHPSA-N	4		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.5006 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					7.9		196 °C		Insoluble	0	No	2	2	No	2	0	40.46 Å2	73.81 Å3	195.06 m3·mol-1	10	No	No	0.000732 mg/mL	8.55	-5.9	18.22	-0.91			
C20H30O	Not Available	1.9 hours	286.4516	C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C	Solid	Not Available	O43174	CYP26A1	1. Cytochrome P450 26A1		50092056	17336	CHEMBL986	393012	Drugs.com Drug Page		HMDB0000305	C17276	D00069	RTL	PDRhealth Drug Page	PA451884	445354	46508191	RxList Drug Page	11246	DNC001498	Vitamin_A	ZINC000003831417	Aquasol A, Infuvite, Infuvite Pediatric, Mvc-fluoride, Mvi Pediatric, Vitafol-one	Vitamin A	Approved, Nutraceutical, Vet approved	DB00162	InChI=1S/C20H30O/c1-16(8-6-9-17(2)13-15-21)11-12-19-18(3)10-7-14-20(19,4)5/h6,8-9,11-13,21H,7,10,14-15H2,1-5H3/b9-6+,12-11+,16-8+,17-13+	FPIPGXGPPPQFEQ-OVSJKPMPSA-N	4	Vitamin A is a vitamin important for retinal function that is used clinically to correct vitamin A deficiency.	Acute toxicity to vitamin A can occur when adults or children ingest >100x or >20x the RDA, respectively, over a period of hours or a few days.2 The RDA for vitamin A differs depending on age and sex and can range from 300 - 900 μg retinol activity equivalents (RAE) per day.4 Symptoms of acute systemic toxicity generally include mucocutaneous involvement (e.g. xerosis, cheilitis, skin peeling) and may involve mental status changes.3 Children are typically more susceptible to acute vitamin A toxicity - daily intakes of as little as 1500 IU/kg have been observed to result in toxicity.2Chronic vitamin A toxicity can develop following the long-term ingestion of high vitamin A doses. While there is a wide variation in the lowest toxic vitamin A dose, the ingestion of >25 000 IU daily for 6 years or 100,000 IU daily for 6 months is considered to be toxic.2 Chronic vitamin A toxicity can affect many organ systems and can lead to the development of osteoporosis and CNS effects (e.g. headaches).3	Small Molecule	http://smpdb.ca/view/SMP0000074?highlight[compounds][]=DB00162&highlight[proteins][]=DB00162;!http://smpdb.ca/view/SMP0000336?highlight[compounds][]=DB00162&highlight[proteins][]=DB00162	Retinol Metabolism;!Vitamin A Deficiency		AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.1249 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					5.68		63.5 °C		0.671 mg/L	1	Yes	1	1	No	1	0	20.23 Å2	36.54 Å3	97.92 m3·mol-1	5	Yes	Yes	0.00758 mg/mL	4.69	-4.6	16.44	-2.2	P05090;!P41222;!Q96NR8;!Q92781;!Q8NBN7;!O94788;!P00352;!O95237;!O75911;!P47895;!Q6NUM9;!Q8TC12;!Q9BTZ2;!Q9HBH5;!Q9NYR8	APOD;!PTGDS;!RDH12;!RDH5;!RDH13;!ALDH1A2;!ALDH1A1;!LRAT;!DHRS3;!ALDH1A3;!RETSAT;!RDH11;!DHRS4;!RDH14;!RDH8	1. Apolipoprotein D;!2. Prostaglandin-H2 D-isomerase;!3. Retinol dehydrogenase 12;!4. 11-cis retinol dehydrogenase;!5. Retinol dehydrogenase 13;!6. Retinal dehydrogenase 2;!7. Retinal dehydrogenase 1;!8. Lecithin retinol acyltransferase;!9. Short-chain dehydrogenase/reductase 3;!10. Aldehyde dehydrogenase family 1 member A3;!11. All-trans-retinol 13,14-reductase;!12. Retinol dehydrogenase 11;!13. Dehydrogenase/reductase SDR family member 4;!14. Retinol dehydrogenase 14;!15. Retinol dehydrogenase 8
C21H28O2	Not Available	Dydrogesterone: 5-7 hours, 20-dihydrodydrogesterone (DHD) metabolite: 14-17 hours	312.4458	[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]2([H])C=CC2=CC(=O)CC[C@@]12C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			31527	CHEMBL1200853	8699		GtP Drug Page	HMDB0014522		D01217			PA164745443	9051	46506195		3706	DAP001205	Dydrogesterone	ZINC000003875998		Dydrogesterone	Approved, Investigational, Withdrawn	DB00378	InChI=1S/C21H28O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h4-5,12,16-19H,6-11H2,1-3H3/t16-,17+,18-,19+,20+,21+/m0/s1	JGMOKGBVKVMRFX-HQZYFCCVSA-N	4	Dydrogesterone is a synthetic progesterone for menstrual cycle regulation, infertility treatment, prevention of miscarriage, and other conditions.	No serious or unexpected toxicity has been observed with dydrogesterone. In acute toxicity studies, the LD50 doses in rats exceeded 4,640mg/kg for the oral route.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	1.8041 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.4		168-169			1	Yes	2	0	No	4	0	34.14 Å2	36.39 Å3	93.82 m3·mol-1	1	Yes	Yes	0.00486 mg/mL	3.79	-4.8	19.4	-4.8	P06401	PGR	1. Progesterone receptor
C21H26O3	Not Available	49 hours (range 33 to 96 hours)	326.4293	COC1=C(C)C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1	Solid	Not Available					50088429	50173	CHEMBL1131	4447573	Drugs.com Drug Page		HMDB0014602		D02754		PDRhealth Drug Page	PA448039	5284513	46509178	RxList Drug Page	16818	DAP000743	Acitretin	ZINC000003798734	Soriatane	Acitretin	Approved	DB00459	InChI=1S/C21H26O3/c1-14(8-7-9-15(2)12-21(22)23)10-11-19-16(3)13-20(24-6)18(5)17(19)4/h7-13H,1-6H3,(H,22,23)/b9-7+,11-10+,14-8+,15-12+	IHUNBGSDBOWDMA-AQFIFDHZSA-N	4	Acitretin is an oral retinoid used in the treatment of severe psoriasis.	Oral, rat: LD50 = >4000 mg/kg. Symptoms of overdose include headache and vertigo.	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.8804 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					6.40		228-230 °C		0.0729 mg/L	1	Yes	3	1	No	1	-1	46.53 Å2	38.58 Å3	104.17 m3·mol-1	6	No	No	0.000478 mg/mL	5.59	-5.8	4.77	-4.8	P19793;!P10276;!P10826;!P13631;!P28702;!P48443;!P09455;!	RXRA;!RARA;!RARB;!RARG;!RXRB;!RXRG;!RBP1;!	1. Retinoic acid receptor RXR-alpha;!2. Retinoic acid receptor alpha;!3. Retinoic acid receptor beta;!4. Retinoic acid receptor gamma;!5. Retinoic acid receptor RXR-beta;!6. Retinoic acid receptor RXR-gamma;!7. Retinol-binding protein 1;!8. Retinoic acid receptor RXR
C20H28O2	Not Available	Not Available	300.4351	C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O	Solid	Not Available					31892	50648	CHEMBL705	395778	Drugs.com Drug Page		HMDB0002369	C15493	D02815	9CR		PA164746900	449171	46507356	RxList Drug Page	81864	DAP000275	Alitretinoin	ZINC000012661824	Panretin, Toctino	Alitretinoin	Approved, Investigational	DB00523	InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8-,16-14+	SHGAZHPCJJPHSC-ZVCIMWCZSA-N	3	Alitretinoin is a vitamin A derivative used to treat Kaposi's sarcoma and used off label to treat chronic hand eczema and psoriasis.	Not Available	Small Molecule	http://smpdb.ca/view/SMP0000074?highlight[compounds][]=DB00523&highlight[proteins][]=DB00523;!http://smpdb.ca/view/SMP0000336?highlight[compounds][]=DB00523&highlight[proteins][]=DB00523	Retinol Metabolism;!Vitamin A Deficiency		Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.1455 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					4.2		189-190 °C		0.6 mg/L	1	Yes	2	1	No	1	-1	37.3 Å2	35.89 Å3	97.79 m3·mol-1	5	No	Yes	0.00477 mg/mL	5.01	-4.8	4.76		P10276;!P19793;!P10826;!P28702;!P13631;!P48443;!P17936;!Q15238;!Q6V0L0	RARA;!RXRA;!RARB;!RXRB;!RARG;!RXRG;!IGFBP3;!PSG5;!CYP26C1	1. Retinoic acid receptor alpha;!2. Retinoic acid receptor RXR-alpha;!3. Retinoic acid receptor beta;!4. Retinoic acid receptor RXR-beta;!5. Retinoic acid receptor gamma;!6. Retinoic acid receptor RXR-gamma;!7. Insulin-like growth factor-binding protein 3;!8. Pregnancy-specific beta-1-glycoprotein 5;!9. Cytochrome P450 26C1
C20H28O2	Not Available	0.5-2 hours	300.442	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O	Solid	Not Available	P24462;!P20813;!P10632;!P11712;!P08684;!P20815;!P11509;!P33260;!P04798;!Q02928	CYP3A7;!CYP2B6;!CYP2C8;!CYP2C9;!CYP3A4;!CYP3A5;!CYP2A6;!CYP2C18;!CYP1A1;!CYP4A11	1. Cytochrome P450 3A7;!2. Cytochrome P450 2B6;!3. Cytochrome P450 2C8;!4. Cytochrome P450 2C9;!5. Cytochrome P450 3A4;!6. Cytochrome P450 3A5;!7. Cytochrome P450 2A6;!8. Cytochrome P450 2C18;!9. Cytochrome P450 1A1;!10. Cytochrome P450 4A11		31883	15367	CHEMBL38	392618	Drugs.com Drug Page		HMDB0001852	C00777	D00094	REA		PA164746900	5538	46504843	RxList Drug Page	10753	DNC000117	Tretinoin	ZINC000012358651	Altreno, Atralin, Avita, Biacna, Refissa, Renova, Retin-A, Stieva-A, Tri-luma, Twyneo, Veltin, Vesanoid, Ziana	Tretinoin	Approved, Investigational, Nutraceutical	DB00755	InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14+	SHGAZHPCJJPHSC-YCNIQYBTSA-N	4	Tretinoin is a vitamin A derivative used to treat acne vulgaris, certain types of promyelocytic leukemia, and fine wrinkles.	Not Available	Small Molecule	http://smpdb.ca/view/SMP0000074?highlight[compounds][]=DB00755&highlight[proteins][]=DB00755;!http://smpdb.ca/view/SMP0000336?highlight[compounds][]=DB00755&highlight[proteins][]=DB00755	Retinol Metabolism;!Vitamin A Deficiency		Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.1455 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					6.30		181 °C		<0.1 g/100 mL	1	Yes	2	1	No	1	-1	37.3 Å2	36.85 Å3	97.79 m3·mol-1	5	No	Yes	0.00477 mg/mL	5.01	-4.8	4.76				
C23H30O3	Not Available	In one study, the apparent terminal half-life of etretinate after 6 months of therapy was approximately 120 days. In another study of 47 patients who had undergone chronic therapy with etretinate, 5 patients had detectable serum drug concentrations (0.5 to 12 ng/mL) 2.1 to 2.9 years after therapy was completed.	354.4825	CCOC(=O)C=C(C)C=CC=C(C)C=CC1=C(C)C(C)=C(OC)C=C1C	Solid	Not Available	P11511	CYP19A1	1. Cytochrome P450 19A1		50248000	4913	CHEMBL464	4445538					D00316			PA449554	3312	46504486		4182		Etretinate	ZINC000003830820		Etretinate	Withdrawn	DB00926	InChI=1S/C23H30O3/c1-8-26-23(24)14-17(3)11-9-10-16(2)12-13-21-18(4)15-22(25-7)20(6)19(21)5/h9-15H,8H2,1-7H3/b11-9+,13-12+,16-10+,17-14+	HQMNCQVAMBCHCO-DJRRULDNSA-N			Symptoms of overdose include headache and vertigo.	Small Molecule				Non AMES toxic	Ready biodegradable	+	Inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Non-substrate	1.8763 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					6.5		104-105			1	No	2	0	No	1	0	35.53 Å2	42.98 Å3	113.68 m3·mol-1	8	No	Yes	0.000405 mg/mL	6.32	-5.9		-4.8	P10276;!P19793;!P10826;!P48443;!P28702;!P13631	RARA;!RXRA;!RARB;!RXRG;!RXRB;!RARG	1. Retinoic acid receptor alpha;!2. Retinoic acid receptor RXR-alpha;!3. Retinoic acid receptor beta;!4. Retinoic acid receptor RXR-gamma;!5. Retinoic acid receptor RXR-beta;!6. Retinoic acid receptor gamma
C20H28O2	The clearance of isotretinoin is 15.9L/h in pediatric patients with neuroblastoma.6 Clearance is also 21.3mL/min/kg in guinea pigs and 7.2mL/min/kg in obese rats.5	The half life ranges from 7-39 hours13 with a mean elimination half life of 20 hours.1 The half life of 4-oxo-13-cis-retinoic acid ranges from 17-50 hours with a mean elimination half life of 25 hours.13	300.4351	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O	Solid	The volume of distribution in humans is unknown because there is no intravenous preparation.13 In a study of pediatric patients with neuroblastoma the volume of distribution was found to be 85L.6 The volume of distribution was also found to be 2432mL/kg in guinea pigs and 1716mL/kg in obese rats.5	P08684	CYP3A4	1. Cytochrome P450 3A4		50031459	6067	CHEMBL547	4445539	Drugs.com Drug Page		HMDB0006219		D00348			PA450128	5282379	46508729	RxList Drug Page	6064	DAP000009	Isotretinoin	ZINC000003792789	Absorica, Accutane, Amnesteem, Claravis, Clarus, Epuris, Myorisan, Sotret, Zenatane	Isotretinoin	Approved	DB00982	InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14-	SHGAZHPCJJPHSC-XFYACQKRSA-N	4	Isotretinoin is a retinoid used to treat severe recalcitrant acne.	Patients experiencing an overdose may present with vomiting, facial flushing, cheilosis, abdominal pain, headache, dizziness, and ataxia.Label These symptoms may rapidly resolve.Label Generally no treatment is required for these overdoses.7The oral lowest dose causing toxic effect (TDLO) for children is 30mg/kg/21W, oral TDLO for men is 24mg/kg/4W, oral TDLO for women is 56mg/kg/8W.14 The intraperitoneal LD50 for rats is 901mg/kg, oral LD50 for mice is 3389mg/kg, oral LD50 for rats is >4000mg/kg.14Isotretinoin is associated with major congenital malformations, spontaneous abortion, and premature birth.Label It is unknown if isotretinoin is expressed in breast milk but due to the associated hazards a decision should be made to either stop nursing or stop taking isotretinoin.LabelIn animal studies, isotretinoin was associated with an increased risk of pheochromocytoma and adrenal medullary hyperplasia at doses above the recommended clinical dose.Label Isotretinoin was negative for the Ames test of mutagenicity once and weakly positive a second time.Label It has not been shown to be clastogenic.Label A study in dogs noted testicular atrophy after doses of 10-30 times the recommended clinical dose for 30 weeks.Label In trials with men there were no effects seen on sperm count, motility, morphology, ejaculate volume, and seminal plasma fructose.Label	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.1455 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				462.8	5.66		189-190	~4	0.00477mg/mL	1	Yes	2	1	No	1	-1	37.3 Å2	36.15 Å3	97.79 m3·mol-1	5	No	Yes	0.00477 mg/mL	5.01	-4.8	4.76		P13631;!P10276	RARG;!RARA	1. Retinoic acid receptor gamma;!2. Retinoic acid receptor alpha
C20H24O2	Not Available	24 hours	296.4034	[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC(=C)C2=CC(=O)C=C[C@]12C	Solid	Not Available	P11511;!P08684	CYP19A1;!CYP3A4	1. Cytochrome P450 19A1;!2. Cytochrome P450 3A4		50398447	4953	CHEMBL1200374	54278	Drugs.com Drug Page		HMDB0015125	C08162	D00963	EXM		PA449563	60198	46508243	RxList Drug Page	258494	DAP000625	Exemestane	ZINC000003973334	Aromasin	Exemestane	Approved, Investigational	DB00990	InChI=1S/C20H24O2/c1-12-10-14-15-4-5-18(22)20(15,3)9-7-16(14)19(2)8-6-13(21)11-17(12)19/h6,8,11,14-16H,1,4-5,7,9-10H2,2-3H3/t14-,15-,16-,19+,20-/m0/s1	BFYIZQONLCFLEV-DAELLWKTSA-N	4	Exemestane is an aromatase inhibitor used to treat breast cancer in postmenopausal women after treatment with tamoxifen.	Convulsions	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.7582 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.7		155.13 °C		Non-soluble	1	Yes	2	0	No	4	0	34.14 Å2	33.72 Å3	89.03 m3·mol-1	0	Yes	Yes	0.00683 mg/mL	3.87	-4.6		-5			
C30H42O2	Not Available	Not Available	434.6533	OC\C(C)=C\C=C\C(\C)=C/C=C/C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C[C@@H](O)CC1(C)C	Solid	Not Available						39930		4449866						3ON			5287502	46506703					ZINC000012501797		(1r)-4-[(1e,3e,5e,7z,9e,11z,13e,15e)-17-Hydroxy-3,7,12,16-Tetramethylheptadeca-1,3,5,7,9,11,13,15-Octaen-1-Yl]-3,5,5-Trimethylcyclohex-3-En-1-Ol	Experimental	DB02253	InChI=1S/C30H42O2/c1-23(12-8-9-13-24(2)15-11-17-26(4)22-31)14-10-16-25(3)18-19-29-27(5)20-28(32)21-30(29,6)7/h8-19,28,31-32H,20-22H2,1-7H3/b9-8+,14-10+,15-11+,19-18+,23-12-,24-13-,25-16+,26-17+/t28-/m1/s1	FNAJVVMDXCOSFY-VFGOXHQXSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.0310 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	2	2	No	1	0	40.46 Å2	55.26 Å3	149.43 m3·mol-1	9	No	No	0.00157 mg/mL	5.9	-5.4	16.76	-1.1	P74334	Not Available	1. Apocarotenoid-15,15'-oxygenase
C20H28O2	Not Available	Not Available	300.4351	C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)C(=O)CCC1(C)C	Solid	Not Available						44597		4451124			HMDB0012329	C16683		OXR			5289090	46506951					ZINC000012502479		4-Oxoretinol	Experimental	DB02699	InChI=1S/C20H28O2/c1-15(7-6-8-16(2)12-14-21)9-10-18-17(3)19(22)11-13-20(18,4)5/h6-10,12,21H,11,13-14H2,1-5H3/b8-6+,10-9+,15-7+,16-12+	PLIUCYCUYQIBDZ-RMWYGNQTSA-N			Not Available	Small Molecule	http://smpdb.ca/view/SMP0000074?highlight[compounds][]=DB02699&highlight[proteins][]=DB02699;!http://smpdb.ca/view/SMP0000336?highlight[compounds][]=DB02699&highlight[proteins][]=DB02699	Retinol Metabolism;!Vitamin A Deficiency		Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.7980 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	1	No	1	0	37.3 Å2	36.68 Å3	98.62 m3·mol-1	5	Yes	Yes	0.0121 mg/mL	4.03	-4.4	16.44	-2.2			
C20H28	Not Available	Not Available	268.4363	C\C(C=C)=C/C=C/C(/C)=C/C=C1/C(C)=CCCC1(C)C	Solid	Not Available								4449996			HMDB0062447			ANR			5287678	46507241					ZINC000049499553		Anhydrovitamin A	Experimental	DB02914	InChI=1S/C20H28/c1-7-16(2)10-8-11-17(3)13-14-19-18(4)12-9-15-20(19,5)6/h7-8,10-14H,1,9,15H2,2-6H3/b11-8+,16-10+,17-13+,19-14-	FWNRILWHNGFAIN-OYUWDNMLSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.5742 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	0	0	No	1	0	0 Å2	34.33 Å3	96.19 m3·mol-1	4	No	Yes	0.00223 mg/mL	5.67	-5.1					
C22H33NO	Not Available	Not Available	327.5035	CCNC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C	Solid	Not Available					50092057		CHEMBL418471	4450394						ETR			5288173	46506461					ZINC000012504028		N-Ethylretinamide	Experimental	DB03917	InChI=1S/C22H33NO/c1-7-23-21(24)16-18(3)11-8-10-17(2)13-14-20-19(4)12-9-15-22(20,5)6/h8,10-11,13-14,16H,7,9,12,15H2,1-6H3,(H,23,24)/b11-8+,14-13+,17-10+,18-16+	WKYDOCGICAMTKE-NBIQJRODSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Non-substrate	2.0384 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	1	1	No	1	0	29.1 Å2	41.35 Å3	109.26 m3·mol-1	6	Yes	Yes	0.00332 mg/mL	4.79	-5	16.31	-0.22			
C28H38O6	Not Available	Not Available	470.606	[H][C@]12C[C@]([H])(C(=O)C[C@@H]1C1=C(O)C=C(C=C1OC(=O)\C=C\C(O)=O)C(C)(C)CCCCCC)C2(C)C	Solid	Not Available					50006254		CHEMBL3234035	8349550									10174045	347827707					ZINC000034377258		Cannabinor	Investigational	DB05048	InChI=1S/C28H38O6/c1-6-7-8-9-12-27(2,3)17-13-22(30)26(23(14-17)34-25(33)11-10-24(31)32)18-15-21(29)20-16-19(18)28(20,4)5/h10-11,13-14,18-20,30H,6-9,12,15-16H2,1-5H3,(H,31,32)/b11-10+/t18-,19-,20+/m0/s1	GSTZHANFXAKPSE-MXTREEOPSA-N			Not Available	Small Molecule																																			0	No	5	2	Yes	3	-1	100.9 Å2	53.09 Å3	131.38 m3·mol-1	11	No	No	0.000675 mg/mL	6.91	-5.8	2.73	-6.1			
C26H33NO2	Not Available	Not Available	391.5457	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)NC1=CC=C(O)C=C1	Solid	Not Available					50092055	42588	CHEMBL7301	4450416					D04162	FEN			5288209	175426938				Fenretinide	ZINC000003871023		Fenretinide	Investigational	DB05076	InChI=1S/C26H33NO2/c1-19(11-16-24-21(3)10-7-17-26(24,4)5)8-6-9-20(2)18-25(29)27-22-12-14-23(28)15-13-22/h6,8-9,11-16,18,28H,7,10,17H2,1-5H3,(H,27,29)/b9-6+,16-11+,19-8+,20-18+	AKJHMTWEGVYYSE-FXILSDISSA-N	3		"Mechanism of fenretinide (4-HPR)-induced cell death"	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Non-substrate	2.1836 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	2	2	No	2	0	49.33 Å2	47.67 Å3	128.05 m3·mol-1	6	No	No	0.00119 mg/mL	6.15	-5.5	9.45	-1.2			
C20H28O5S	Not Available	Not Available	380.498	[H][C@@]12CCC3=CC(C(C)C)=C(C=C3[C@@]1(C)CCC[C@@]2(C)C(O)=O)S(O)(=O)=O	Solid	Not Available						135593	CHEMBL2104585	59201	Drugs.com Drug Page		HMDB0015613		D07885			PA165958350	65781	99443230					ZINC000003779720		Ecabet	Investigational	DB05265	InChI=1S/C20H28O5S/c1-12(2)14-10-13-6-7-17-19(3,8-5-9-20(17,4)18(21)22)15(13)11-16(14)26(23,24)25/h10-12,17H,5-9H2,1-4H3,(H,21,22)(H,23,24,25)/t17-,19-,20-/m1/s1	IWCWQNVIUXZOMJ-MISYRCLQSA-N	3		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3482 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	2	No	3	-2	91.67 Å2	41.24 Å3	100.07 m3·mol-1	3	Yes	No	0.00426 mg/mL	4.93	-5	-1.5		P18314;!Q8NFA2	ureC;!NOXO1	1. Urease subunit alpha;!2. NADPH oxidase organizer 1
C23H32O2	Not Available	Not Available	340.507	C\C(\C=C\C=C(/C)C1=CC(=CC(=C1)C(C)(C)C)C(C)(C)C)=C/C(O)=O	Solid	Not Available					50052033		CHEMBL89241	4450017						ARL				347910230							LGD-1550	Investigational	DB05785	InChI=1S/C23H32O2/c1-16(12-21(24)25)10-9-11-17(2)18-13-19(22(3,4)5)15-20(14-18)23(6,7)8/h9-15H,1-8H3,(H,24,25)/b10-9+,16-12+,17-11+	JMPZTWDLOGTBPM-OUQSKUGOSA-N			Not Available	Small Molecule																																			1	No	2	1	No	1	-1	37.3 Å2	41.93 Å3	109.59 m3·mol-1	6	No	Yes	0.000304 mg/mL	6.82	-6	4.57		P10276;!P10826;!P13631;!P05412	RARA;!RARB;!RARG;!JUN	1. Retinoic acid receptor alpha;!2. Retinoic acid receptor beta;!3. Retinoic acid receptor gamma;!4. Transcription factor AP-1
C20H24O4	Not Available	Not Available	328.408	C\C(\C=C\C=C(/C)C(O)=O)=C/C=C/C=C(\C)/C=C/C=C(\C)C(O)=O	Solid	Not Available					50269617	3918	CHEMBL464792	4444644				C08588										Crocetin	ZINC000004097701		Transcrocetinate	Investigational	DB05974	InChI=1S/C20H24O4/c1-15(11-7-13-17(3)19(21)22)9-5-6-10-16(2)12-8-14-18(4)20(23)24/h5-14H,1-4H3,(H,21,22)(H,23,24)/b6-5+,11-7+,12-8+,15-9+,16-10+,17-13+,18-14+	PANKHBYNKQNAHN-MQQNZMFNSA-N	2		Not Available	Small Molecule																																			1	Yes	4	2	No	0	-2	74.6 Å2	38.07 Å3	103.8 m3·mol-1	8	Yes	No	0.00558 mg/mL	4.4	-4.8	4.41				
C40H52O4	Not Available	Not Available	596.852	C\C(\C=C\C=C(/C)\C=C\C1=C(C)C(=O)[C@@H](O)CC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)C(=O)[C@@H](O)CC1(C)C	Solid	Not Available						40968	CHEMBL1255871	4444636			HMDB0002204	C08580		AXT			5281224	347827776		18451		Astaxanthin	ZINC000100042059		Astaxanthin	Investigational	DB06543	InChI=1S/C40H52O4/c1-27(17-13-19-29(3)21-23-33-31(5)37(43)35(41)25-39(33,7)8)15-11-12-16-28(2)18-14-20-30(4)22-24-34-32(6)38(44)36(42)26-40(34,9)10/h11-24,35-36,41-42H,25-26H2,1-10H3/b12-11+,17-13+,18-14+,23-21+,24-22+,27-15+,28-16+,29-19+,30-20+/t35-,36-/m0/s1	MQZIGYBFDRPAKN-UWFIBFSHSA-N	2		Not Available	Small Molecule																																			0	No	4	2	No	2	0	74.6 Å2	73.77 Å3	195.98 m3·mol-1	10	No	No	0.000667 mg/mL	8.05	-6	13.07	-3.5	P25963	NFKBIA	1. NF-kappa-B inhibitor alpha
C40H56	The clearance rate of beta-carotene administered orally is 0.68 nmol/L each hour.3	The apparent half-life of beta-carotene is of 6-11 days after initial administration.2	536.888	C\C(\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)CCCC1(C)C	Solid	No pharmacokinetic studies have been performed regarding the volume of distribution of beta-carotene.	Q9HAY6	BCO1	1. Beta,beta-carotene 15,15'-dioxygenase		54988	17579	CHEMBL1293	4444129			HMDB0000561	C02094	D03101	BCR			5280489	347827791		19143		Beta-Carotene	ZINC000006845076	Pregvit	Beta carotene	Approved, Nutraceutical	DB06755	InChI=1S/C40H56/c1-31(19-13-21-33(3)25-27-37-35(5)23-15-29-39(37,7)8)17-11-12-18-32(2)20-14-22-34(4)26-28-38-36(6)24-16-30-40(38,9)10/h11-14,17-22,25-28H,15-16,23-24,29-30H2,1-10H3/b12-11+,19-13+,20-14+,27-25+,28-26+,31-17+,32-18+,33-21+,34-22+	OENHQHLEOONYIE-JLTXGRSLSA-N	4	Beta carotene is a vitamin A precursor found in various nutritional supplements and health products.	Beta-carotene is not toxic but the high and constant administration of this substance can translate into skin yellow coloration.6 Some reports have indicated that administration of high and periodic doses of beta-carotene are correlated to the increase in cancer incidence. This risk seems to be very elevated in the case of smokers.15 The registered LD50 of beta-carotene is >5000 mg/kg.MSDS	Small Molecule																													633-577ºC	17.62		176-184ºC		0.0006 g/l at 25ºC	0	No	0	0	No	2	0	0 Å2	71.84 Å3	191.61 m3·mol-1	10	No	Yes	0.000391 mg/mL	11.12	-6.1					1. Free radicals
C15H24	Not Available	Not Available	204.3511	C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C	Solid	Not Available								25058473						LSR			15143646	99444598					ZINC000058639152		1,3,3-trimethyl-2-[(1E,3E)-3-methylpenta-1,3-dien-1-yl]cyclohexene	Experimental	DB08127	InChI=1S/C15H24/c1-6-12(2)9-10-14-13(3)8-7-11-15(14,4)5/h6,9-10H,7-8,11H2,1-5H3/b10-9+,12-6+	KUEVAPFABUUVHS-AYCKBHPDSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.4560 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	0	0	No	1	0	0 Å2	26.78 Å3	71.23 m3·mol-1	2	Yes	Yes	0.0267 mg/mL	4.68	-3.9					
C16H28O3	Not Available	Not Available	268.3917	COC(C)(C)CCC[C@@](C)([H])C\C=C\C(\C)=C\C(O)=O	Solid	Not Available								4450887						MEI			5288795	99444646					ZINC000002244163		(2E,4E)-11-METHOXY-3,7,11-TRIMETHYLDODECA-2,4-DIENOIC ACID	Experimental	DB08175	InChI=1S/C16H28O3/c1-13(10-7-11-16(3,4)19-5)8-6-9-14(2)12-15(17)18/h6,9,12-13H,7-8,10-11H2,1-5H3,(H,17,18)/b9-6+,14-12+/t13-/m1/s1	MNYBEULOKRVZKY-ATCPXPEISA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	1.3231 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	1	No	0	-1	46.53 Å2	32.11 Å3	80.86 m3·mol-1	9	Yes	No	0.00868 mg/mL	4.1	-4.5	4.82	-4.1	Q15596;!P28702;!Q13133	NCOA2;!RXRB;!NR1H3	1. Nuclear receptor coactivator 2;!2. Retinoic acid receptor RXR-beta;!3. Oxysterols receptor LXR-alpha
C27H32O4	Not Available	Not Available	420.5406	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC=C4C=C(CC[C@]4(C)[C@@]3([H])CC[C@]12C)C(O)=O)C(=O)C1=CC=C(O)C=C1	Solid	Not Available								8020773						MUF			9845059	99444691					ZINC000003803450		(8alpha,10alpha,13alpha,17beta)-17-[(4-hydroxyphenyl)carbonyl]androsta-3,5-diene-3-carboxylic acid	Experimental	DB08220	InChI=1S/C27H32O4/c1-26-13-11-17(25(30)31)15-18(26)5-8-20-21-9-10-23(27(21,2)14-12-22(20)26)24(29)16-3-6-19(28)7-4-16/h3-7,15,20-23,28H,8-14H2,1-2H3,(H,30,31)/t20-,21-,22-,23+,26-,27-/m0/s1	RPNNXCYIESWDSC-JRZBRKEGSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.6597 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	2	No	5	-1	74.6 Å2	47.84 Å3	121.45 m3·mol-1	3	No	No	0.00264 mg/mL	5.16	-5.2	4.35	-6.9	Q15788;!Q96RI1	NCOA1;!NR1H4	1. Nuclear receptor coactivator 1;!2. Bile acid receptor
C20H24O3	Not Available	Not Available	312.4028	[H]/C(=C(/[H])\C(\C)=C(/[H])C(O)=O)/C(/[H])=C(\C)/C(/[H])=C(\[H])C1=C(C)C=C(O)C(C)=C1C	Solid	Not Available								4943051						R12			6438583	99444926							Ro 12-7310	Experimental	DB08455	InChI=1S/C20H24O3/c1-13(7-6-8-14(2)11-20(22)23)9-10-18-15(3)12-19(21)17(5)16(18)4/h6-12,21H,1-5H3,(H,22,23)/b8-6+,10-9+,13-7+,14-11+	CAAFTBWHFUPDGX-OFCLTBKTSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1413 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	2	No	1	-1	57.53 Å2	36.52 Å3	99.68 m3·mol-1	5	No	No	0.00119 mg/mL	5.44	-5.4	4.77	-5.9			
C20H28O2	Not Available	Not Available	300.4351	O=C(O)\C=C(/C)\C=C\C[C@]1(C)CC2=C(CCCC2(C)C)C1=C	Solid	Not Available								4451273						RE9			5289278	99444938					ZINC000015475858		6-(2,3,4,5,6,7-HEXAHYDRO-2,4,4-TRIMETHYL-1-METYLENEINDEN-2-YL)-3-METHYLHEXA-2,4-DIENOIC ACID	Experimental	DB08467	InChI=1S/C20H28O2/c1-14(12-18(21)22)8-6-11-20(5)13-17-16(15(20)2)9-7-10-19(17,3)4/h6,8,12H,2,7,9-11,13H2,1,3-5H3,(H,21,22)/b8-6+,14-12+/t20-/m1/s1	HEVXQLBAMFMFKU-IAZPEVBMSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Non-substrate	2.1458 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	1	No	2	-1	37.3 Å2	34.61 Å3	93.62 m3·mol-1	4	Yes	Yes	0.00892 mg/mL	4.67	-4.5	4.54				
C22H30O4	Not Available	Not Available	358.478	[H][C@@]12CC[C@@](O)(CCC(O)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=CC2=CC(=O)CC[C@]12C	Solid	Not Available						50156	CHEMBL1616951	570976	Drugs.com Drug Page								656615	310264973		618970		Potassium_canrenoate	ZINC000003938750		Canrenoic acid	Approved, Withdrawn	DB09015	InChI=1S/C22H30O4/c1-20-9-5-15(23)13-14(20)3-4-16-17(20)6-10-21(2)18(16)7-11-22(21,26)12-8-19(24)25/h3-4,13,16-18,26H,5-12H2,1-2H3,(H,24,25)/t16-,17+,18+,20+,21+,22-/m1/s1	PBKZPPIHUVSDNM-WNHSNXHDSA-N	3	Canrenoic acid is an aldosterone antagonist used in primary hyperaldosteronism and other disorders related to aberrant aldosterone levels.	Not Available	Small Molecule																																165			1	Yes	4	2	No	4	-1	74.6 Å2	40.44 Å3	100.98 m3·mol-1	3	Yes	No	0.0442 mg/mL	2.93	-3.9	4.48	-3.1			
C23H32O2	Not Available	The half-life of medrogestone is reported to be of 4 hours.5	340.507	[H][C@@]12CC[C@](C)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			135446	CHEMBL2106825	8125459									9949848	310265040		6690		Medrogestone	ZINC000004216820		Medrogestone	Approved, Withdrawn	DB09124	InChI=1S/C23H32O2/c1-14-12-17-18(21(3)9-6-16(25)13-20(14)21)7-11-23(5)19(17)8-10-22(23,4)15(2)24/h12-13,17-19H,6-11H2,1-5H3/t17-,18+,19+,21-,22-,23+/m1/s1	HCFSGRMEEXUOSS-JXEXPEPMSA-N		Medrogestone is a progestin used as an adjunct to control secondary amenorrhea and dysfunctional bleeding in adolescent and adult females, and treat endometrial shedding in menopausal women.	There were reports of increased urinary flow rates and total micturition volumes as well as sexual dysfunction and hyperglycemia.4	Small Molecule																													467.17ºC at 760 mmHg	4.45		144-146ºC		5.34e-06 mol/L	1	Yes	2	0	No	4	0	34.14 Å2	40.37 Å3	102.6 m3·mol-1	1	Yes	Yes	0.00404 mg/mL	4.59	-4.9	19.18	-4.9	P06401	PGR	1. Progesterone receptor
C40H56O2	Not Available	Not Available	568.886	C\C(\C=C\C=C(/C)\C=C\C1=C(C)C[C@@H](O)CC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)C[C@@H](O)CC1(C)C	Not Available	Not Available						27547	CHEMBL2359248	4444421			HMDB0002789	C06098					5280899	347827933		39918		Zeaxanthin	ZINC000008220175		Zeaxanthin	Approved, Investigational	DB11176	InChI=1S/C40H56O2/c1-29(17-13-19-31(3)21-23-37-33(5)25-35(41)27-39(37,7)8)15-11-12-16-30(2)18-14-20-32(4)22-24-38-34(6)26-36(42)28-40(38,9)10/h11-24,35-36,41-42H,25-28H2,1-10H3/b12-11+,17-13+,18-14+,23-21+,24-22+,29-15+,30-16+,31-19+,32-20+/t35-,36-/m1/s1	JKQXZKUSFCKOGQ-QAYBQHTQSA-N	3		Not Available	Small Molecule																																			0	No	2	2	No	2	0	40.46 Å2	73.47 Å3	194.95 m3·mol-1	10	No	No	0.000649 mg/mL	8.35	-5.9	18.91	-0.79			
C18H22O	No pharmacokinetic data available.	The half life of enzacamene (4-MBC) and its main metabolite, 3-(4-carboxybenzylidene)camphor, displayed half-lives of approximately 15 h after reaching peak plasma concentrations after oral administration in rats 6.	254.373	CC1=CC=C(\C=C2/C3CCC(C)(C2=O)C3(C)C)C=C1	Solid	No pharmacokinetic data available.					50103609	135937	CHEMBL2104261	4939160									7019255	347827944		1311507		Enzacamene			Enzacamene	Approved	DB11219	InChI=1S/C18H22O/c1-12-5-7-13(8-6-12)11-14-15-9-10-18(4,16(14)19)17(15,2)3/h5-8,11,15H,9-10H2,1-4H3/b14-11+	HEOCBCNFKCOKBX-SDNWHVSQSA-N		Enzacamene is an ingredient used in sunscreen to block UVB radiation.	Oral LD50 and dermal LD50 in rat are reported to be 10,000 mg/kg 7. Oral TDLO in rat is 7 mg/kg MSDS. Oral and subcutaneous TDLO following continuous administration in rat are 476 mg/kg/4D and 4 mg/kg/2D, respectively MSDS. Cases of overdose have not been reported for enzacamene. Enzacamene is reported to be an endocrine disruptor that alters the reproductive axis.	Small Molecule																														5.14		66-69		Poorly soluble	1	Yes	1	0	No	3	0	17.07 Å2	30.58 Å3	79.68 m3·mol-1	1	No	Yes	0.0051 mg/mL	5.12	-4.7		-5.2	P06401;!P10275;!Q92731;!P03372	PGR;!AR;!ESR2;!ESR1	1. Progesterone receptor;!2. Androgen receptor;!3. Estrogen receptor beta;!4. Estrogen receptor alpha
C40H56	Not Available	Not Available	536.888	CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C	Not Available	Not Available						15948	CHEMBL501174	394156			HMDB0003000	C05432		LYC			446925	347827946		29008		Lycopene	ZINC000008214943		Lycopene	Approved, Investigational	DB11231	InChI=1S/C40H56/c1-33(2)19-13-23-37(7)27-17-31-39(9)29-15-25-35(5)21-11-12-22-36(6)26-16-30-40(10)32-18-28-38(8)24-14-20-34(3)4/h11-12,15-22,25-32H,13-14,23-24H2,1-10H3/b12-11+,25-15+,26-16+,31-17+,32-18+,35-21+,36-22+,37-27+,38-28+,39-29+,40-30+	OAIJSZIZWZSQBC-GYZMGTAESA-N	4	Lycopene is an ingredient found in a variety of supplements and vitamins.	Not Available	Small Molecule																																			0	No	0	0	No	0	0	0 Å2	73.69 Å3	197.81 m3·mol-1	16	No	No	0.000397 mg/mL	11.93	-6.1					
C19H34O3	Not Available	Not Available	310.478	[H]\C(C[C@@]([H])(C)CCCC(C)(C)OC)=C(\[H])/C(/C)=C(\[H])C(=O)OC(C)C	Not Available	Not Available						39255	CHEMBL1875086	1361490															ZINC000002005163		(S)-methoprene	Vet approved	DB11495	InChI=1S/C19H34O3/c1-15(2)22-18(20)14-17(4)11-8-10-16(3)12-9-13-19(5,6)21-7/h8,11,14-16H,9-10,12-13H2,1-7H3/b11-8+,17-14+/t16-/m1/s1	NFGXHKASABOEEW-GYMWBFJFSA-N			Not Available	Small Molecule																																			0	Yes	2	0	No	0	0	35.53 Å2	38.25 Å3	94.79 m3·mol-1	11	No	No	0.00307 mg/mL	5.26	-5		-4.1			
C24H32O2	Not Available	Not Available	352.518	C\C(\C=C\[C@@H]1C[C@]1(C)C1=CC=C2C(=C1)C(C)(C)CCC2(C)C)=C/C(O)=O	Not Available	Not Available					50101445		CHEMBL75133	8039037									9863341	347828153					ZINC000001550770		VTP-194204	Investigational	DB11806	InChI=1S/C24H32O2/c1-16(13-21(25)26)7-8-18-15-24(18,6)17-9-10-19-20(14-17)23(4,5)12-11-22(19,2)3/h7-10,13-14,18H,11-12,15H2,1-6H3,(H,25,26)/b8-7+,16-13+/t18-,24-/m1/s1	BOOOLEGQBVUTKC-NVQSDHBMSA-N	2		Not Available	Small Molecule																																			1	No	2	1	No	3	-1	37.3 Å2	41.37 Å3	109.56 m3·mol-1	4	No	Yes	0.000104 mg/mL	6.31	-6.5	4.83				
C22H32O2	Not Available	Not Available	328.4883	CC(=O)OC\C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C	Not Available	Not Available								8421459			HMDB0035185						10245972	347828413					ZINC000014685555		Zuretinol acetate	Investigational	DB12112	InChI=1S/C22H32O2/c1-17(9-7-10-18(2)14-16-24-20(4)23)12-13-21-19(3)11-8-15-22(21,5)6/h7,9-10,12-14H,8,11,15-16H2,1-6H3/b10-7+,13-12+,17-9-,18-14+	QGNJRVVDBSJHIZ-AQDFTDIISA-N	2		Not Available	Small Molecule																																			1	Yes	1	0	No	1	0	26.3 Å2	40.5 Å3	107.07 m3·mol-1	7	No	Yes	0.00238 mg/mL	5.14	-5.1		-7			
C25H36O4	Not Available	Not Available	400.5509	[H][C@@]12CC(=CC[C@@]1([H])C(C)(C)OC1=CC(=CC(O)=C21)C(C)(C)CCCCCC)C(O)=O	Not Available	Not Available					50005920		CHEMBL456341	2340729						AJA			3083542	347828478				Ajulemic_acid	ZINC000001905712		Ajulemic acid	Investigational	DB12193	InChI=1S/C25H36O4/c1-6-7-8-9-12-24(2,3)17-14-20(26)22-18-13-16(23(27)28)10-11-19(18)25(4,5)29-21(22)15-17/h10,14-15,18-19,26H,6-9,11-13H2,1-5H3,(H,27,28)/t18-,19-/m1/s1	YCHYFHOSGQABSW-RTBURBONSA-N	2		Not Available	Small Molecule																																			1	No	4	2	Yes	3	-1	66.76 Å2	47.46 Å3	116.68 m3·mol-1	7	No	No	0.00125 mg/mL	6.61	-5.5	3.88	-4.9			
C22H28O3	Not Available	Not Available	340.4559	[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=CC2=CC(=O)CC[C@]12C	Not Available	Not Available						135445	CHEMBL1463345	13192			HMDB0003033						13789	347828500		1982		Canrenone	ZINC000003881648		Canrenone	Investigational	DB12221	InChI=1S/C22H28O3/c1-20-9-5-15(23)13-14(20)3-4-16-17(20)6-10-21(2)18(16)7-11-22(21)12-8-19(24)25-22/h3-4,13,16-18H,5-12H2,1-2H3/t16-,17+,18+,20+,21+,22-/m1/s1	UJVLDDZCTMKXJK-WNHSNXHDSA-N	4	Canrenone is an antimineralocorticoid and active metabolite of spironolactone used in the treatment of primary hyperaldosteronism and edematous states caused by secondary hyperaldosteronism (e.g. heart failure).	Not Available	Small Molecule																																			1	Yes	2	0	No	5	0	43.37 Å2	38.67 Å3	97.48 m3·mol-1	0	Yes	No	0.0042 mg/mL	3.6	-4.9		-4.8			
C20H22O2	Not Available	Not Available	294.3875	[H]/C(=C(/[H])\C(\C)=C(/[H])C(O)=O)/C(/[H])=C(/C)\C(\[H])=C1/CCCC2=CC=CC=C12	Not Available	Not Available					50445062		CHEMBL3098771	8079857						1O8			9904203	347828580							9CUAB30	Investigational	DB12316	InChI=1S/C20H22O2/c1-15(7-5-8-16(2)14-20(21)22)13-18-11-6-10-17-9-3-4-12-19(17)18/h3-5,7-9,12-14H,6,10-11H2,1-2H3,(H,21,22)/b8-5+,15-7-,16-14+,18-13+	PPGNMFUMZSAZCW-VOYUZAMQSA-N	1		Not Available	Small Molecule																																			1	Yes	2	1	No	2	-1	37.3 Å2	33.81 Å3	94.7 m3·mol-1	4	Yes	Yes	0.00157 mg/mL	5	-5.3	4.54				
C26H38O2	Not Available	Not Available	382.5787	CC(C)=CCC\C(C)=C\CC\C(C)=C\CCC1(C)CCC2=CC(O)=CC=C2O1	Not Available	Not Available							CHEMBL120643	8105532			HMDB0036368						9929901	347828854		578285		Tocotrienol			Tocotrienol	Investigational	DB12647	InChI=1S/C26H38O2/c1-20(2)9-6-10-21(3)11-7-12-22(4)13-8-17-26(5)18-16-23-19-24(27)14-15-25(23)28-26/h9,11,13-15,19,27H,6-8,10,12,16-18H2,1-5H3/b21-11+,22-13+	GJJVAFUKOBZPCB-ZGRPYONQSA-N	2		Not Available	Small Molecule																																			1	No	2	1	No	2	0	29.46 Å2	48.17 Å3	122.8 m3·mol-1	9	No	Yes	0.000793 mg/mL	7.75	-5.7	10.01	-4.9			
C23H32O3	Not Available	Not Available	356.4984	[H][C@@]12CC[C@H](OC(=O)CCCC)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	Not Available	Not Available	P05177;!P22309;!P08684;!P20815;!P24462;!P04798;!Q16678;!P33261;!P10632;!P11712	CYP1A2;!UGT1A1;!CYP3A4;!CYP3A5;!CYP3A7;!CYP1A1;!CYP1B1;!CYP2C19;!CYP2C8;!CYP2C9	1. Cytochrome P450 1A2;!2. UDP-glucuronosyltransferase 1-1;!3. Cytochrome P450 3A4;!4. Cytochrome P450 3A5;!5. Cytochrome P450 3A7;!6. Cytochrome P450 1A1;!7. Cytochrome P450 1B1;!8. Cytochrome P450 2C19;!9. Cytochrome P450 2C8;!10. Cytochrome P450 2C9			31561	CHEMBL1511	13194				C12859					13791		RxList Drug Page			Estradiol_valerate	ZINC000003881556	Delestrogen, Natazia	Estradiol valerate	Approved, Investigational, Vet approved	DB13956	InChI=1S/C23H32O3/c1-3-4-5-22(25)26-21-11-10-20-19-8-6-15-14-16(24)7-9-17(15)18(19)12-13-23(20,21)2/h7,9,14,18-21,24H,3-6,8,10-13H2,1-2H3/t18-,19-,20+,21+,23+/m1/s1	RSEPBGGWRJCQGY-RBRWEJTLSA-N	4	Estradiol valerate is an estradiol prodrug used to treat some effects of menopause, hypoestrogenism, androgen dependant carcinoma of the prostate, and in combination products for endometriosis and contraception.	Not Available	Small Molecule																																			1	No	2	1	No	4	0	46.53 Å2	42.57 Å3	102.89 m3·mol-1	5	No	No	0.000617 mg/mL	5.78	-5.8	10.33	-5.4	P03372;!Q92731;!O75469;!P43681;!Q15596;!Q99527;!P00846;!Q14457;!P37059;!P62508	ESR1;!ESR2;!NR1I2;!CHRNA4;!NCOA2;!GPER1;!MT-ATP6;!BECN1;!HSD17B2;!ESRRG	1. Estrogen receptor alpha;!2. Estrogen receptor beta;!3. Nuclear receptor subfamily 1 group I member 2;!4. Neuronal acetylcholine receptor subunit alpha-4;!5. Nuclear receptor coactivator 2;!6. G-protein coupled estrogen receptor 1;!7. ATP synthase subunit a;!8. Beclin-1;!9. Estradiol 17-beta-dehydrogenase 2;!10. Estrogen-related receptor gamma
C27H32O4	Not Available	Not Available	420.549	[H]\C(=C(\[H])C1=C(C)CCCC1(C)C)\C(\C)=C(/[H])C([H])=C(\C(C)=C(\[H])C(O)=O)C1=CC(=CC=C1)C(O)=O	Solid	Not Available								4943196																	13-cis-12-(3'-Carboxyphenyl)retinoic acid	Experimental	DB14097	InChI=1S/C27H32O4/c1-18(12-14-24-19(2)8-7-15-27(24,4)5)11-13-23(20(3)16-25(28)29)21-9-6-10-22(17-21)26(30)31/h6,9-14,16-17H,7-8,15H2,1-5H3,(H,28,29)(H,30,31)/b14-12+,18-11+,20-16-,23-13-	XKKDQOHDTASHCE-PAZAWXFKSA-N			Not Available	Small Molecule																																			1	No	4	2	No	2	-2	74.6 Å2	47.45 Å3	129.42 m3·mol-1	7	No	No	0.000946 mg/mL	6.19	-5.6	3.74				
C40H56	Not Available	Not Available	536.888	C\C(\C=C\C=C(/C)\C=C\[C@H]1C(C)=CCCC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)CCCC1(C)C	Not Available	Not Available						35147		4925358														Alpha-Carotene	ZINC000008219947		alpha-Carotene	Experimental	DB15909	InChI=1S/C40H56/c1-31(19-13-21-33(3)25-27-37-35(5)23-15-29-39(37,7)8)17-11-12-18-32(2)20-14-22-34(4)26-28-38-36(6)24-16-30-40(38,9)10/h11-14,17-23,25-28,37H,15-16,24,29-30H2,1-10H3/b12-11+,19-13+,20-14+,27-25+,28-26+,31-17+,32-18+,33-21+,34-22+/t37-/m0/s1	ANVAOWXLWRTKGA-NTXLUARGSA-N			Not Available	Small Molecule																																			0	No	0	0	No	2	0	0 Å2	71.15 Å3	191.88 m3·mol-1	10	No	Yes	0.000307 mg/mL	11.17	-6.2					
C40H56O	Not Available	Not Available	552.887	C\C(\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)C[C@@H](O)CC1(C)C	Not Available	Not Available						10362		4444647				C08591		RRX								Cryptoxanthin	ZINC000004097702		Cryptoxanthin	Experimental	DB15914	InChI=1S/C40H56O/c1-30(18-13-20-32(3)23-25-37-34(5)22-15-27-39(37,7)8)16-11-12-17-31(2)19-14-21-33(4)24-26-38-35(6)28-36(41)29-40(38,9)10/h11-14,16-21,23-26,36,41H,15,22,27-29H2,1-10H3/b12-11+,18-13+,19-14+,25-23+,26-24+,30-16+,31-17+,32-20+,33-21+/t36-/m1/s1	DMASLKHVQRHNES-FKKUPVFPSA-N			Not Available	Small Molecule																																			0	No	1	1	No	2	0	20.23 Å2	72.68 Å3	193.28 m3·mol-1	10	No	Yes	0.000503 mg/mL	9.74	-6	18.91	-1.1			
C20H30O2	Not Available	Not Available	302.458	CC(C)=CCC\C(C)=C\CC\C(C)=C\C=C\C(\C)=C\C(O)=O	Not Available	Not Available								4942358															ZINC000030691356		Peretinoin	Investigational	DB16291	InChI=1S/C20H30O2/c1-16(2)9-6-10-17(3)11-7-12-18(4)13-8-14-19(5)15-20(21)22/h8-9,11,13-15H,6-7,10,12H2,1-5H3,(H,21,22)/b14-8+,17-11+,18-13+,19-15+	UUBHZHZSIKRVIV-KCXSXWJSSA-N	3		Not Available	Small Molecule																																			1	No	2	1	No	0	-1	37.3 Å2	37.93 Å3	99.77 m3·mol-1	9	No	Yes	0.00403 mg/mL	5.78	-4.9	4.81				
C40H56O2	Not Available	Not Available	568.886	C\C(\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)C[C@@H](O)CC1(C)C	Liquid	Not Available						28838	CHEMBL173929	4444655				C08601		LUT	PDRhealth Drug Page	PA164748318	5281243	46508835		11359		Xanthophyll	ZINC000008221225		Lutein	Approved, Investigational, Nutraceutical	DB00137	InChI=1S/C40H56O2/c1-29(17-13-19-31(3)21-23-37-33(5)25-35(41)27-39(37,7)8)15-11-12-16-30(2)18-14-20-32(4)22-24-38-34(6)26-36(42)28-40(38,9)10/h11-25,35-37,41-42H,26-28H2,1-10H3/b12-11+,17-13+,18-14+,23-21+,24-22+,29-15+,30-16+,31-19+,32-20+/t35-,36+,37-/m0/s1	KBPHJBAIARWVSC-RGZFRNHPSA-N	4		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.5006 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					7.9		196 °C		Insoluble	0	No	2	2	No	2	0	40.46 Å2	73.81 Å3	195.06 m3·mol-1	10	No	No	0.000732 mg/mL	8.55	-5.9	18.22	-0.91			
C20H30O	Not Available	1.9 hours	286.4516	C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C	Solid	Not Available	O43174	CYP26A1	1. Cytochrome P450 26A1		50092056	17336	CHEMBL986	393012	Drugs.com Drug Page		HMDB0000305	C17276	D00069	RTL	PDRhealth Drug Page	PA451884	445354	46508191	RxList Drug Page	11246	DNC001498	Vitamin_A	ZINC000003831417	Aquasol A, Infuvite, Infuvite Pediatric, Mvc-fluoride, Mvi Pediatric, Vitafol-one	Vitamin A	Approved, Nutraceutical, Vet approved	DB00162	InChI=1S/C20H30O/c1-16(8-6-9-17(2)13-15-21)11-12-19-18(3)10-7-14-20(19,4)5/h6,8-9,11-13,21H,7,10,14-15H2,1-5H3/b9-6+,12-11+,16-8+,17-13+	FPIPGXGPPPQFEQ-OVSJKPMPSA-N	4	Vitamin A is a vitamin important for retinal function that is used clinically to correct vitamin A deficiency.	Acute toxicity to vitamin A can occur when adults or children ingest >100x or >20x the RDA, respectively, over a period of hours or a few days.2 The RDA for vitamin A differs depending on age and sex and can range from 300 - 900 μg retinol activity equivalents (RAE) per day.4 Symptoms of acute systemic toxicity generally include mucocutaneous involvement (e.g. xerosis, cheilitis, skin peeling) and may involve mental status changes.3 Children are typically more susceptible to acute vitamin A toxicity - daily intakes of as little as 1500 IU/kg have been observed to result in toxicity.2Chronic vitamin A toxicity can develop following the long-term ingestion of high vitamin A doses. While there is a wide variation in the lowest toxic vitamin A dose, the ingestion of >25 000 IU daily for 6 years or 100,000 IU daily for 6 months is considered to be toxic.2 Chronic vitamin A toxicity can affect many organ systems and can lead to the development of osteoporosis and CNS effects (e.g. headaches).3	Small Molecule	http://smpdb.ca/view/SMP0000074?highlight[compounds][]=DB00162&highlight[proteins][]=DB00162;!http://smpdb.ca/view/SMP0000336?highlight[compounds][]=DB00162&highlight[proteins][]=DB00162	Retinol Metabolism;!Vitamin A Deficiency		AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.1249 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					5.68		63.5 °C		0.671 mg/L	1	Yes	1	1	No	1	0	20.23 Å2	36.54 Å3	97.92 m3·mol-1	5	Yes	Yes	0.00758 mg/mL	4.69	-4.6	16.44	-2.2	P05090;!P41222;!Q96NR8;!Q92781;!Q8NBN7;!O94788;!P00352;!O95237;!O75911;!P47895;!Q6NUM9;!Q8TC12;!Q9BTZ2;!Q9HBH5;!Q9NYR8	APOD;!PTGDS;!RDH12;!RDH5;!RDH13;!ALDH1A2;!ALDH1A1;!LRAT;!DHRS3;!ALDH1A3;!RETSAT;!RDH11;!DHRS4;!RDH14;!RDH8	1. Apolipoprotein D;!2. Prostaglandin-H2 D-isomerase;!3. Retinol dehydrogenase 12;!4. 11-cis retinol dehydrogenase;!5. Retinol dehydrogenase 13;!6. Retinal dehydrogenase 2;!7. Retinal dehydrogenase 1;!8. Lecithin retinol acyltransferase;!9. Short-chain dehydrogenase/reductase 3;!10. Aldehyde dehydrogenase family 1 member A3;!11. All-trans-retinol 13,14-reductase;!12. Retinol dehydrogenase 11;!13. Dehydrogenase/reductase SDR family member 4;!14. Retinol dehydrogenase 14;!15. Retinol dehydrogenase 8
C21H28O2	Not Available	Dydrogesterone: 5-7 hours, 20-dihydrodydrogesterone (DHD) metabolite: 14-17 hours	312.4458	[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]2([H])C=CC2=CC(=O)CC[C@@]12C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			31527	CHEMBL1200853	8699		GtP Drug Page	HMDB0014522		D01217			PA164745443	9051	46506195		3706	DAP001205	Dydrogesterone	ZINC000003875998		Dydrogesterone	Approved, Investigational, Withdrawn	DB00378	InChI=1S/C21H28O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h4-5,12,16-19H,6-11H2,1-3H3/t16-,17+,18-,19+,20+,21+/m0/s1	JGMOKGBVKVMRFX-HQZYFCCVSA-N	4	Dydrogesterone is a synthetic progesterone for menstrual cycle regulation, infertility treatment, prevention of miscarriage, and other conditions.	No serious or unexpected toxicity has been observed with dydrogesterone. In acute toxicity studies, the LD50 doses in rats exceeded 4,640mg/kg for the oral route.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	1.8041 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.4		168-169			1	Yes	2	0	No	4	0	34.14 Å2	36.39 Å3	93.82 m3·mol-1	1	Yes	Yes	0.00486 mg/mL	3.79	-4.8	19.4	-4.8	P06401	PGR	1. Progesterone receptor
C21H26O3	Not Available	49 hours (range 33 to 96 hours)	326.4293	COC1=C(C)C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1	Solid	Not Available					50088429	50173	CHEMBL1131	4447573	Drugs.com Drug Page		HMDB0014602		D02754		PDRhealth Drug Page	PA448039	5284513	46509178	RxList Drug Page	16818	DAP000743	Acitretin	ZINC000003798734	Soriatane	Acitretin	Approved	DB00459	InChI=1S/C21H26O3/c1-14(8-7-9-15(2)12-21(22)23)10-11-19-16(3)13-20(24-6)18(5)17(19)4/h7-13H,1-6H3,(H,22,23)/b9-7+,11-10+,14-8+,15-12+	IHUNBGSDBOWDMA-AQFIFDHZSA-N	4	Acitretin is an oral retinoid used in the treatment of severe psoriasis.	Oral, rat: LD50 = >4000 mg/kg. Symptoms of overdose include headache and vertigo.	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.8804 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					6.40		228-230 °C		0.0729 mg/L	1	Yes	3	1	No	1	-1	46.53 Å2	38.58 Å3	104.17 m3·mol-1	6	No	No	0.000478 mg/mL	5.59	-5.8	4.77	-4.8	P19793;!P10276;!P10826;!P13631;!P28702;!P48443;!P09455;!	RXRA;!RARA;!RARB;!RARG;!RXRB;!RXRG;!RBP1;!	1. Retinoic acid receptor RXR-alpha;!2. Retinoic acid receptor alpha;!3. Retinoic acid receptor beta;!4. Retinoic acid receptor gamma;!5. Retinoic acid receptor RXR-beta;!6. Retinoic acid receptor RXR-gamma;!7. Retinol-binding protein 1;!8. Retinoic acid receptor RXR
C20H28O2	Not Available	Not Available	300.4351	C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O	Solid	Not Available					31892	50648	CHEMBL705	395778	Drugs.com Drug Page		HMDB0002369	C15493	D02815	9CR		PA164746900	449171	46507356	RxList Drug Page	81864	DAP000275	Alitretinoin	ZINC000012661824	Panretin, Toctino	Alitretinoin	Approved, Investigational	DB00523	InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8-,16-14+	SHGAZHPCJJPHSC-ZVCIMWCZSA-N	3	Alitretinoin is a vitamin A derivative used to treat Kaposi's sarcoma and used off label to treat chronic hand eczema and psoriasis.	Not Available	Small Molecule	http://smpdb.ca/view/SMP0000074?highlight[compounds][]=DB00523&highlight[proteins][]=DB00523;!http://smpdb.ca/view/SMP0000336?highlight[compounds][]=DB00523&highlight[proteins][]=DB00523	Retinol Metabolism;!Vitamin A Deficiency		Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.1455 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					4.2		189-190 °C		0.6 mg/L	1	Yes	2	1	No	1	-1	37.3 Å2	35.89 Å3	97.79 m3·mol-1	5	No	Yes	0.00477 mg/mL	5.01	-4.8	4.76		P10276;!P19793;!P10826;!P28702;!P13631;!P48443;!P17936;!Q15238;!Q6V0L0	RARA;!RXRA;!RARB;!RXRB;!RARG;!RXRG;!IGFBP3;!PSG5;!CYP26C1	1. Retinoic acid receptor alpha;!2. Retinoic acid receptor RXR-alpha;!3. Retinoic acid receptor beta;!4. Retinoic acid receptor RXR-beta;!5. Retinoic acid receptor gamma;!6. Retinoic acid receptor RXR-gamma;!7. Insulin-like growth factor-binding protein 3;!8. Pregnancy-specific beta-1-glycoprotein 5;!9. Cytochrome P450 26C1
C20H28O2	Not Available	0.5-2 hours	300.442	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O	Solid	Not Available	P24462;!P20813;!P10632;!P11712;!P08684;!P20815;!P11509;!P33260;!P04798;!Q02928	CYP3A7;!CYP2B6;!CYP2C8;!CYP2C9;!CYP3A4;!CYP3A5;!CYP2A6;!CYP2C18;!CYP1A1;!CYP4A11	1. Cytochrome P450 3A7;!2. Cytochrome P450 2B6;!3. Cytochrome P450 2C8;!4. Cytochrome P450 2C9;!5. Cytochrome P450 3A4;!6. Cytochrome P450 3A5;!7. Cytochrome P450 2A6;!8. Cytochrome P450 2C18;!9. Cytochrome P450 1A1;!10. Cytochrome P450 4A11		31883	15367	CHEMBL38	392618	Drugs.com Drug Page		HMDB0001852	C00777	D00094	REA		PA164746900	5538	46504843	RxList Drug Page	10753	DNC000117	Tretinoin	ZINC000012358651	Altreno, Atralin, Avita, Biacna, Refissa, Renova, Retin-A, Stieva-A, Tri-luma, Twyneo, Veltin, Vesanoid, Ziana	Tretinoin	Approved, Investigational, Nutraceutical	DB00755	InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14+	SHGAZHPCJJPHSC-YCNIQYBTSA-N	4	Tretinoin is a vitamin A derivative used to treat acne vulgaris, certain types of promyelocytic leukemia, and fine wrinkles.	Not Available	Small Molecule	http://smpdb.ca/view/SMP0000074?highlight[compounds][]=DB00755&highlight[proteins][]=DB00755;!http://smpdb.ca/view/SMP0000336?highlight[compounds][]=DB00755&highlight[proteins][]=DB00755	Retinol Metabolism;!Vitamin A Deficiency		Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.1455 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					6.30		181 °C		<0.1 g/100 mL	1	Yes	2	1	No	1	-1	37.3 Å2	36.85 Å3	97.79 m3·mol-1	5	No	Yes	0.00477 mg/mL	5.01	-4.8	4.76				
C23H30O3	Not Available	In one study, the apparent terminal half-life of etretinate after 6 months of therapy was approximately 120 days. In another study of 47 patients who had undergone chronic therapy with etretinate, 5 patients had detectable serum drug concentrations (0.5 to 12 ng/mL) 2.1 to 2.9 years after therapy was completed.	354.4825	CCOC(=O)C=C(C)C=CC=C(C)C=CC1=C(C)C(C)=C(OC)C=C1C	Solid	Not Available	P11511	CYP19A1	1. Cytochrome P450 19A1		50248000	4913	CHEMBL464	4445538					D00316			PA449554	3312	46504486		4182		Etretinate	ZINC000003830820		Etretinate	Withdrawn	DB00926	InChI=1S/C23H30O3/c1-8-26-23(24)14-17(3)11-9-10-16(2)12-13-21-18(4)15-22(25-7)20(6)19(21)5/h9-15H,8H2,1-7H3/b11-9+,13-12+,16-10+,17-14+	HQMNCQVAMBCHCO-DJRRULDNSA-N			Symptoms of overdose include headache and vertigo.	Small Molecule				Non AMES toxic	Ready biodegradable	+	Inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Non-substrate	1.8763 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					6.5		104-105			1	No	2	0	No	1	0	35.53 Å2	42.98 Å3	113.68 m3·mol-1	8	No	Yes	0.000405 mg/mL	6.32	-5.9		-4.8	P10276;!P19793;!P10826;!P48443;!P28702;!P13631	RARA;!RXRA;!RARB;!RXRG;!RXRB;!RARG	1. Retinoic acid receptor alpha;!2. Retinoic acid receptor RXR-alpha;!3. Retinoic acid receptor beta;!4. Retinoic acid receptor RXR-gamma;!5. Retinoic acid receptor RXR-beta;!6. Retinoic acid receptor gamma
C20H28O2	The clearance of isotretinoin is 15.9L/h in pediatric patients with neuroblastoma.6 Clearance is also 21.3mL/min/kg in guinea pigs and 7.2mL/min/kg in obese rats.5	The half life ranges from 7-39 hours13 with a mean elimination half life of 20 hours.1 The half life of 4-oxo-13-cis-retinoic acid ranges from 17-50 hours with a mean elimination half life of 25 hours.13	300.4351	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O	Solid	The volume of distribution in humans is unknown because there is no intravenous preparation.13 In a study of pediatric patients with neuroblastoma the volume of distribution was found to be 85L.6 The volume of distribution was also found to be 2432mL/kg in guinea pigs and 1716mL/kg in obese rats.5	P08684	CYP3A4	1. Cytochrome P450 3A4		50031459	6067	CHEMBL547	4445539	Drugs.com Drug Page		HMDB0006219		D00348			PA450128	5282379	46508729	RxList Drug Page	6064	DAP000009	Isotretinoin	ZINC000003792789	Absorica, Accutane, Amnesteem, Claravis, Clarus, Epuris, Myorisan, Sotret, Zenatane	Isotretinoin	Approved	DB00982	InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14-	SHGAZHPCJJPHSC-XFYACQKRSA-N	4	Isotretinoin is a retinoid used to treat severe recalcitrant acne.	Patients experiencing an overdose may present with vomiting, facial flushing, cheilosis, abdominal pain, headache, dizziness, and ataxia.Label These symptoms may rapidly resolve.Label Generally no treatment is required for these overdoses.7The oral lowest dose causing toxic effect (TDLO) for children is 30mg/kg/21W, oral TDLO for men is 24mg/kg/4W, oral TDLO for women is 56mg/kg/8W.14 The intraperitoneal LD50 for rats is 901mg/kg, oral LD50 for mice is 3389mg/kg, oral LD50 for rats is >4000mg/kg.14Isotretinoin is associated with major congenital malformations, spontaneous abortion, and premature birth.Label It is unknown if isotretinoin is expressed in breast milk but due to the associated hazards a decision should be made to either stop nursing or stop taking isotretinoin.LabelIn animal studies, isotretinoin was associated with an increased risk of pheochromocytoma and adrenal medullary hyperplasia at doses above the recommended clinical dose.Label Isotretinoin was negative for the Ames test of mutagenicity once and weakly positive a second time.Label It has not been shown to be clastogenic.Label A study in dogs noted testicular atrophy after doses of 10-30 times the recommended clinical dose for 30 weeks.Label In trials with men there were no effects seen on sperm count, motility, morphology, ejaculate volume, and seminal plasma fructose.Label	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.1455 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				462.8	5.66		189-190	~4	0.00477mg/mL	1	Yes	2	1	No	1	-1	37.3 Å2	36.15 Å3	97.79 m3·mol-1	5	No	Yes	0.00477 mg/mL	5.01	-4.8	4.76		P13631;!P10276	RARG;!RARA	1. Retinoic acid receptor gamma;!2. Retinoic acid receptor alpha
C20H24O2	Not Available	24 hours	296.4034	[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC(=C)C2=CC(=O)C=C[C@]12C	Solid	Not Available	P11511;!P08684	CYP19A1;!CYP3A4	1. Cytochrome P450 19A1;!2. Cytochrome P450 3A4		50398447	4953	CHEMBL1200374	54278	Drugs.com Drug Page		HMDB0015125	C08162	D00963	EXM		PA449563	60198	46508243	RxList Drug Page	258494	DAP000625	Exemestane	ZINC000003973334	Aromasin	Exemestane	Approved, Investigational	DB00990	InChI=1S/C20H24O2/c1-12-10-14-15-4-5-18(22)20(15,3)9-7-16(14)19(2)8-6-13(21)11-17(12)19/h6,8,11,14-16H,1,4-5,7,9-10H2,2-3H3/t14-,15-,16-,19+,20-/m0/s1	BFYIZQONLCFLEV-DAELLWKTSA-N	4	Exemestane is an aromatase inhibitor used to treat breast cancer in postmenopausal women after treatment with tamoxifen.	Convulsions	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.7582 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.7		155.13 °C		Non-soluble	1	Yes	2	0	No	4	0	34.14 Å2	33.72 Å3	89.03 m3·mol-1	0	Yes	Yes	0.00683 mg/mL	3.87	-4.6		-5			
C30H42O2	Not Available	Not Available	434.6533	OC\C(C)=C\C=C\C(\C)=C/C=C/C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C[C@@H](O)CC1(C)C	Solid	Not Available						39930		4449866						3ON			5287502	46506703					ZINC000012501797		(1r)-4-[(1e,3e,5e,7z,9e,11z,13e,15e)-17-Hydroxy-3,7,12,16-Tetramethylheptadeca-1,3,5,7,9,11,13,15-Octaen-1-Yl]-3,5,5-Trimethylcyclohex-3-En-1-Ol	Experimental	DB02253	InChI=1S/C30H42O2/c1-23(12-8-9-13-24(2)15-11-17-26(4)22-31)14-10-16-25(3)18-19-29-27(5)20-28(32)21-30(29,6)7/h8-19,28,31-32H,20-22H2,1-7H3/b9-8+,14-10+,15-11+,19-18+,23-12-,24-13-,25-16+,26-17+/t28-/m1/s1	FNAJVVMDXCOSFY-VFGOXHQXSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.0310 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	2	2	No	1	0	40.46 Å2	55.26 Å3	149.43 m3·mol-1	9	No	No	0.00157 mg/mL	5.9	-5.4	16.76	-1.1	P74334	Not Available	1. Apocarotenoid-15,15'-oxygenase
C20H28O2	Not Available	Not Available	300.4351	C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)C(=O)CCC1(C)C	Solid	Not Available						44597		4451124			HMDB0012329	C16683		OXR			5289090	46506951					ZINC000012502479		4-Oxoretinol	Experimental	DB02699	InChI=1S/C20H28O2/c1-15(7-6-8-16(2)12-14-21)9-10-18-17(3)19(22)11-13-20(18,4)5/h6-10,12,21H,11,13-14H2,1-5H3/b8-6+,10-9+,15-7+,16-12+	PLIUCYCUYQIBDZ-RMWYGNQTSA-N			Not Available	Small Molecule	http://smpdb.ca/view/SMP0000074?highlight[compounds][]=DB02699&highlight[proteins][]=DB02699;!http://smpdb.ca/view/SMP0000336?highlight[compounds][]=DB02699&highlight[proteins][]=DB02699	Retinol Metabolism;!Vitamin A Deficiency		Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.7980 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	1	No	1	0	37.3 Å2	36.68 Å3	98.62 m3·mol-1	5	Yes	Yes	0.0121 mg/mL	4.03	-4.4	16.44	-2.2			
C20H28	Not Available	Not Available	268.4363	C\C(C=C)=C/C=C/C(/C)=C/C=C1/C(C)=CCCC1(C)C	Solid	Not Available								4449996			HMDB0062447			ANR			5287678	46507241					ZINC000049499553		Anhydrovitamin A	Experimental	DB02914	InChI=1S/C20H28/c1-7-16(2)10-8-11-17(3)13-14-19-18(4)12-9-15-20(19,5)6/h7-8,10-14H,1,9,15H2,2-6H3/b11-8+,16-10+,17-13+,19-14-	FWNRILWHNGFAIN-OYUWDNMLSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.5742 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	0	0	No	1	0	0 Å2	34.33 Å3	96.19 m3·mol-1	4	No	Yes	0.00223 mg/mL	5.67	-5.1					
C22H33NO	Not Available	Not Available	327.5035	CCNC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C	Solid	Not Available					50092057		CHEMBL418471	4450394						ETR			5288173	46506461					ZINC000012504028		N-Ethylretinamide	Experimental	DB03917	InChI=1S/C22H33NO/c1-7-23-21(24)16-18(3)11-8-10-17(2)13-14-20-19(4)12-9-15-22(20,5)6/h8,10-11,13-14,16H,7,9,12,15H2,1-6H3,(H,23,24)/b11-8+,14-13+,17-10+,18-16+	WKYDOCGICAMTKE-NBIQJRODSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Non-substrate	2.0384 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	1	1	No	1	0	29.1 Å2	41.35 Å3	109.26 m3·mol-1	6	Yes	Yes	0.00332 mg/mL	4.79	-5	16.31	-0.22			
C28H38O6	Not Available	Not Available	470.606	[H][C@]12C[C@]([H])(C(=O)C[C@@H]1C1=C(O)C=C(C=C1OC(=O)\C=C\C(O)=O)C(C)(C)CCCCCC)C2(C)C	Solid	Not Available					50006254		CHEMBL3234035	8349550									10174045	347827707					ZINC000034377258		Cannabinor	Investigational	DB05048	InChI=1S/C28H38O6/c1-6-7-8-9-12-27(2,3)17-13-22(30)26(23(14-17)34-25(33)11-10-24(31)32)18-15-21(29)20-16-19(18)28(20,4)5/h10-11,13-14,18-20,30H,6-9,12,15-16H2,1-5H3,(H,31,32)/b11-10+/t18-,19-,20+/m0/s1	GSTZHANFXAKPSE-MXTREEOPSA-N			Not Available	Small Molecule																																			0	No	5	2	Yes	3	-1	100.9 Å2	53.09 Å3	131.38 m3·mol-1	11	No	No	0.000675 mg/mL	6.91	-5.8	2.73	-6.1			
C26H33NO2	Not Available	Not Available	391.5457	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)NC1=CC=C(O)C=C1	Solid	Not Available					50092055	42588	CHEMBL7301	4450416					D04162	FEN			5288209	175426938				Fenretinide	ZINC000003871023		Fenretinide	Investigational	DB05076	InChI=1S/C26H33NO2/c1-19(11-16-24-21(3)10-7-17-26(24,4)5)8-6-9-20(2)18-25(29)27-22-12-14-23(28)15-13-22/h6,8-9,11-16,18,28H,7,10,17H2,1-5H3,(H,27,29)/b9-6+,16-11+,19-8+,20-18+	AKJHMTWEGVYYSE-FXILSDISSA-N	3		"Mechanism of fenretinide (4-HPR)-induced cell death"	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Non-substrate	2.1836 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	2	2	No	2	0	49.33 Å2	47.67 Å3	128.05 m3·mol-1	6	No	No	0.00119 mg/mL	6.15	-5.5	9.45	-1.2			
C20H28O5S	Not Available	Not Available	380.498	[H][C@@]12CCC3=CC(C(C)C)=C(C=C3[C@@]1(C)CCC[C@@]2(C)C(O)=O)S(O)(=O)=O	Solid	Not Available						135593	CHEMBL2104585	59201	Drugs.com Drug Page		HMDB0015613		D07885			PA165958350	65781	99443230					ZINC000003779720		Ecabet	Investigational	DB05265	InChI=1S/C20H28O5S/c1-12(2)14-10-13-6-7-17-19(3,8-5-9-20(17,4)18(21)22)15(13)11-16(14)26(23,24)25/h10-12,17H,5-9H2,1-4H3,(H,21,22)(H,23,24,25)/t17-,19-,20-/m1/s1	IWCWQNVIUXZOMJ-MISYRCLQSA-N	3		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3482 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	2	No	3	-2	91.67 Å2	41.24 Å3	100.07 m3·mol-1	3	Yes	No	0.00426 mg/mL	4.93	-5	-1.5		P18314;!Q8NFA2	ureC;!NOXO1	1. Urease subunit alpha;!2. NADPH oxidase organizer 1
C23H32O2	Not Available	Not Available	340.507	C\C(\C=C\C=C(/C)C1=CC(=CC(=C1)C(C)(C)C)C(C)(C)C)=C/C(O)=O	Solid	Not Available					50052033		CHEMBL89241	4450017						ARL				347910230							LGD-1550	Investigational	DB05785	InChI=1S/C23H32O2/c1-16(12-21(24)25)10-9-11-17(2)18-13-19(22(3,4)5)15-20(14-18)23(6,7)8/h9-15H,1-8H3,(H,24,25)/b10-9+,16-12+,17-11+	JMPZTWDLOGTBPM-OUQSKUGOSA-N			Not Available	Small Molecule																																			1	No	2	1	No	1	-1	37.3 Å2	41.93 Å3	109.59 m3·mol-1	6	No	Yes	0.000304 mg/mL	6.82	-6	4.57		P10276;!P10826;!P13631;!P05412	RARA;!RARB;!RARG;!JUN	1. Retinoic acid receptor alpha;!2. Retinoic acid receptor beta;!3. Retinoic acid receptor gamma;!4. Transcription factor AP-1
C20H24O4	Not Available	Not Available	328.408	C\C(\C=C\C=C(/C)C(O)=O)=C/C=C/C=C(\C)/C=C/C=C(\C)C(O)=O	Solid	Not Available					50269617	3918	CHEMBL464792	4444644				C08588										Crocetin	ZINC000004097701		Transcrocetinate	Investigational	DB05974	InChI=1S/C20H24O4/c1-15(11-7-13-17(3)19(21)22)9-5-6-10-16(2)12-8-14-18(4)20(23)24/h5-14H,1-4H3,(H,21,22)(H,23,24)/b6-5+,11-7+,12-8+,15-9+,16-10+,17-13+,18-14+	PANKHBYNKQNAHN-MQQNZMFNSA-N	2		Not Available	Small Molecule																																			1	Yes	4	2	No	0	-2	74.6 Å2	38.07 Å3	103.8 m3·mol-1	8	Yes	No	0.00558 mg/mL	4.4	-4.8	4.41				
C40H52O4	Not Available	Not Available	596.852	C\C(\C=C\C=C(/C)\C=C\C1=C(C)C(=O)[C@@H](O)CC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)C(=O)[C@@H](O)CC1(C)C	Solid	Not Available						40968	CHEMBL1255871	4444636			HMDB0002204	C08580		AXT			5281224	347827776		18451		Astaxanthin	ZINC000100042059		Astaxanthin	Investigational	DB06543	InChI=1S/C40H52O4/c1-27(17-13-19-29(3)21-23-33-31(5)37(43)35(41)25-39(33,7)8)15-11-12-16-28(2)18-14-20-30(4)22-24-34-32(6)38(44)36(42)26-40(34,9)10/h11-24,35-36,41-42H,25-26H2,1-10H3/b12-11+,17-13+,18-14+,23-21+,24-22+,27-15+,28-16+,29-19+,30-20+/t35-,36-/m0/s1	MQZIGYBFDRPAKN-UWFIBFSHSA-N	2		Not Available	Small Molecule																																			0	No	4	2	No	2	0	74.6 Å2	73.77 Å3	195.98 m3·mol-1	10	No	No	0.000667 mg/mL	8.05	-6	13.07	-3.5	P25963	NFKBIA	1. NF-kappa-B inhibitor alpha
C40H56	The clearance rate of beta-carotene administered orally is 0.68 nmol/L each hour.3	The apparent half-life of beta-carotene is of 6-11 days after initial administration.2	536.888	C\C(\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)CCCC1(C)C	Solid	No pharmacokinetic studies have been performed regarding the volume of distribution of beta-carotene.	Q9HAY6	BCO1	1. Beta,beta-carotene 15,15'-dioxygenase		54988	17579	CHEMBL1293	4444129			HMDB0000561	C02094	D03101	BCR			5280489	347827791		19143		Beta-Carotene	ZINC000006845076	Pregvit	Beta carotene	Approved, Nutraceutical	DB06755	InChI=1S/C40H56/c1-31(19-13-21-33(3)25-27-37-35(5)23-15-29-39(37,7)8)17-11-12-18-32(2)20-14-22-34(4)26-28-38-36(6)24-16-30-40(38,9)10/h11-14,17-22,25-28H,15-16,23-24,29-30H2,1-10H3/b12-11+,19-13+,20-14+,27-25+,28-26+,31-17+,32-18+,33-21+,34-22+	OENHQHLEOONYIE-JLTXGRSLSA-N	4	Beta carotene is a vitamin A precursor found in various nutritional supplements and health products.	Beta-carotene is not toxic but the high and constant administration of this substance can translate into skin yellow coloration.6 Some reports have indicated that administration of high and periodic doses of beta-carotene are correlated to the increase in cancer incidence. This risk seems to be very elevated in the case of smokers.15 The registered LD50 of beta-carotene is >5000 mg/kg.MSDS	Small Molecule																													633-577ºC	17.62		176-184ºC		0.0006 g/l at 25ºC	0	No	0	0	No	2	0	0 Å2	71.84 Å3	191.61 m3·mol-1	10	No	Yes	0.000391 mg/mL	11.12	-6.1					1. Free radicals
C15H24	Not Available	Not Available	204.3511	C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C	Solid	Not Available								25058473						LSR			15143646	99444598					ZINC000058639152		1,3,3-trimethyl-2-[(1E,3E)-3-methylpenta-1,3-dien-1-yl]cyclohexene	Experimental	DB08127	InChI=1S/C15H24/c1-6-12(2)9-10-14-13(3)8-7-11-15(14,4)5/h6,9-10H,7-8,11H2,1-5H3/b10-9+,12-6+	KUEVAPFABUUVHS-AYCKBHPDSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.4560 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	0	0	No	1	0	0 Å2	26.78 Å3	71.23 m3·mol-1	2	Yes	Yes	0.0267 mg/mL	4.68	-3.9					
C16H28O3	Not Available	Not Available	268.3917	COC(C)(C)CCC[C@@](C)([H])C\C=C\C(\C)=C\C(O)=O	Solid	Not Available								4450887						MEI			5288795	99444646					ZINC000002244163		(2E,4E)-11-METHOXY-3,7,11-TRIMETHYLDODECA-2,4-DIENOIC ACID	Experimental	DB08175	InChI=1S/C16H28O3/c1-13(10-7-11-16(3,4)19-5)8-6-9-14(2)12-15(17)18/h6,9,12-13H,7-8,10-11H2,1-5H3,(H,17,18)/b9-6+,14-12+/t13-/m1/s1	MNYBEULOKRVZKY-ATCPXPEISA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	1.3231 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	1	No	0	-1	46.53 Å2	32.11 Å3	80.86 m3·mol-1	9	Yes	No	0.00868 mg/mL	4.1	-4.5	4.82	-4.1	Q15596;!P28702;!Q13133	NCOA2;!RXRB;!NR1H3	1. Nuclear receptor coactivator 2;!2. Retinoic acid receptor RXR-beta;!3. Oxysterols receptor LXR-alpha
C27H32O4	Not Available	Not Available	420.5406	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC=C4C=C(CC[C@]4(C)[C@@]3([H])CC[C@]12C)C(O)=O)C(=O)C1=CC=C(O)C=C1	Solid	Not Available								8020773						MUF			9845059	99444691					ZINC000003803450		(8alpha,10alpha,13alpha,17beta)-17-[(4-hydroxyphenyl)carbonyl]androsta-3,5-diene-3-carboxylic acid	Experimental	DB08220	InChI=1S/C27H32O4/c1-26-13-11-17(25(30)31)15-18(26)5-8-20-21-9-10-23(27(21,2)14-12-22(20)26)24(29)16-3-6-19(28)7-4-16/h3-7,15,20-23,28H,8-14H2,1-2H3,(H,30,31)/t20-,21-,22-,23+,26-,27-/m0/s1	RPNNXCYIESWDSC-JRZBRKEGSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.6597 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	2	No	5	-1	74.6 Å2	47.84 Å3	121.45 m3·mol-1	3	No	No	0.00264 mg/mL	5.16	-5.2	4.35	-6.9	Q15788;!Q96RI1	NCOA1;!NR1H4	1. Nuclear receptor coactivator 1;!2. Bile acid receptor
C20H24O3	Not Available	Not Available	312.4028	[H]/C(=C(/[H])\C(\C)=C(/[H])C(O)=O)/C(/[H])=C(\C)/C(/[H])=C(\[H])C1=C(C)C=C(O)C(C)=C1C	Solid	Not Available								4943051						R12			6438583	99444926							Ro 12-7310	Experimental	DB08455	InChI=1S/C20H24O3/c1-13(7-6-8-14(2)11-20(22)23)9-10-18-15(3)12-19(21)17(5)16(18)4/h6-12,21H,1-5H3,(H,22,23)/b8-6+,10-9+,13-7+,14-11+	CAAFTBWHFUPDGX-OFCLTBKTSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1413 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	2	No	1	-1	57.53 Å2	36.52 Å3	99.68 m3·mol-1	5	No	No	0.00119 mg/mL	5.44	-5.4	4.77	-5.9			
C20H28O2	Not Available	Not Available	300.4351	O=C(O)\C=C(/C)\C=C\C[C@]1(C)CC2=C(CCCC2(C)C)C1=C	Solid	Not Available								4451273						RE9			5289278	99444938					ZINC000015475858		6-(2,3,4,5,6,7-HEXAHYDRO-2,4,4-TRIMETHYL-1-METYLENEINDEN-2-YL)-3-METHYLHEXA-2,4-DIENOIC ACID	Experimental	DB08467	InChI=1S/C20H28O2/c1-14(12-18(21)22)8-6-11-20(5)13-17-16(15(20)2)9-7-10-19(17,3)4/h6,8,12H,2,7,9-11,13H2,1,3-5H3,(H,21,22)/b8-6+,14-12+/t20-/m1/s1	HEVXQLBAMFMFKU-IAZPEVBMSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Non-substrate	2.1458 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	1	No	2	-1	37.3 Å2	34.61 Å3	93.62 m3·mol-1	4	Yes	Yes	0.00892 mg/mL	4.67	-4.5	4.54				
C22H30O4	Not Available	Not Available	358.478	[H][C@@]12CC[C@@](O)(CCC(O)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=CC2=CC(=O)CC[C@]12C	Solid	Not Available						50156	CHEMBL1616951	570976	Drugs.com Drug Page								656615	310264973		618970		Potassium_canrenoate	ZINC000003938750		Canrenoic acid	Approved, Withdrawn	DB09015	InChI=1S/C22H30O4/c1-20-9-5-15(23)13-14(20)3-4-16-17(20)6-10-21(2)18(16)7-11-22(21,26)12-8-19(24)25/h3-4,13,16-18,26H,5-12H2,1-2H3,(H,24,25)/t16-,17+,18+,20+,21+,22-/m1/s1	PBKZPPIHUVSDNM-WNHSNXHDSA-N	3	Canrenoic acid is an aldosterone antagonist used in primary hyperaldosteronism and other disorders related to aberrant aldosterone levels.	Not Available	Small Molecule																																165			1	Yes	4	2	No	4	-1	74.6 Å2	40.44 Å3	100.98 m3·mol-1	3	Yes	No	0.0442 mg/mL	2.93	-3.9	4.48	-3.1			
C23H32O2	Not Available	The half-life of medrogestone is reported to be of 4 hours.5	340.507	[H][C@@]12CC[C@](C)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			135446	CHEMBL2106825	8125459									9949848	310265040		6690		Medrogestone	ZINC000004216820		Medrogestone	Approved, Withdrawn	DB09124	InChI=1S/C23H32O2/c1-14-12-17-18(21(3)9-6-16(25)13-20(14)21)7-11-23(5)19(17)8-10-22(23,4)15(2)24/h12-13,17-19H,6-11H2,1-5H3/t17-,18+,19+,21-,22-,23+/m1/s1	HCFSGRMEEXUOSS-JXEXPEPMSA-N		Medrogestone is a progestin used as an adjunct to control secondary amenorrhea and dysfunctional bleeding in adolescent and adult females, and treat endometrial shedding in menopausal women.	There were reports of increased urinary flow rates and total micturition volumes as well as sexual dysfunction and hyperglycemia.4	Small Molecule																													467.17ºC at 760 mmHg	4.45		144-146ºC		5.34e-06 mol/L	1	Yes	2	0	No	4	0	34.14 Å2	40.37 Å3	102.6 m3·mol-1	1	Yes	Yes	0.00404 mg/mL	4.59	-4.9	19.18	-4.9	P06401	PGR	1. Progesterone receptor
C40H56O2	Not Available	Not Available	568.886	C\C(\C=C\C=C(/C)\C=C\C1=C(C)C[C@@H](O)CC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)C[C@@H](O)CC1(C)C	Not Available	Not Available						27547	CHEMBL2359248	4444421			HMDB0002789	C06098					5280899	347827933		39918		Zeaxanthin	ZINC000008220175		Zeaxanthin	Approved, Investigational	DB11176	InChI=1S/C40H56O2/c1-29(17-13-19-31(3)21-23-37-33(5)25-35(41)27-39(37,7)8)15-11-12-16-30(2)18-14-20-32(4)22-24-38-34(6)26-36(42)28-40(38,9)10/h11-24,35-36,41-42H,25-28H2,1-10H3/b12-11+,17-13+,18-14+,23-21+,24-22+,29-15+,30-16+,31-19+,32-20+/t35-,36-/m1/s1	JKQXZKUSFCKOGQ-QAYBQHTQSA-N	3		Not Available	Small Molecule																																			0	No	2	2	No	2	0	40.46 Å2	73.47 Å3	194.95 m3·mol-1	10	No	No	0.000649 mg/mL	8.35	-5.9	18.91	-0.79			
C18H22O	No pharmacokinetic data available.	The half life of enzacamene (4-MBC) and its main metabolite, 3-(4-carboxybenzylidene)camphor, displayed half-lives of approximately 15 h after reaching peak plasma concentrations after oral administration in rats 6.	254.373	CC1=CC=C(\C=C2/C3CCC(C)(C2=O)C3(C)C)C=C1	Solid	No pharmacokinetic data available.					50103609	135937	CHEMBL2104261	4939160									7019255	347827944		1311507		Enzacamene			Enzacamene	Approved	DB11219	InChI=1S/C18H22O/c1-12-5-7-13(8-6-12)11-14-15-9-10-18(4,16(14)19)17(15,2)3/h5-8,11,15H,9-10H2,1-4H3/b14-11+	HEOCBCNFKCOKBX-SDNWHVSQSA-N		Enzacamene is an ingredient used in sunscreen to block UVB radiation.	Oral LD50 and dermal LD50 in rat are reported to be 10,000 mg/kg 7. Oral TDLO in rat is 7 mg/kg MSDS. Oral and subcutaneous TDLO following continuous administration in rat are 476 mg/kg/4D and 4 mg/kg/2D, respectively MSDS. Cases of overdose have not been reported for enzacamene. Enzacamene is reported to be an endocrine disruptor that alters the reproductive axis.	Small Molecule																														5.14		66-69		Poorly soluble	1	Yes	1	0	No	3	0	17.07 Å2	30.58 Å3	79.68 m3·mol-1	1	No	Yes	0.0051 mg/mL	5.12	-4.7		-5.2	P06401;!P10275;!Q92731;!P03372	PGR;!AR;!ESR2;!ESR1	1. Progesterone receptor;!2. Androgen receptor;!3. Estrogen receptor beta;!4. Estrogen receptor alpha
C40H56	Not Available	Not Available	536.888	CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C	Not Available	Not Available						15948	CHEMBL501174	394156			HMDB0003000	C05432		LYC			446925	347827946		29008		Lycopene	ZINC000008214943		Lycopene	Approved, Investigational	DB11231	InChI=1S/C40H56/c1-33(2)19-13-23-37(7)27-17-31-39(9)29-15-25-35(5)21-11-12-22-36(6)26-16-30-40(10)32-18-28-38(8)24-14-20-34(3)4/h11-12,15-22,25-32H,13-14,23-24H2,1-10H3/b12-11+,25-15+,26-16+,31-17+,32-18+,35-21+,36-22+,37-27+,38-28+,39-29+,40-30+	OAIJSZIZWZSQBC-GYZMGTAESA-N	4	Lycopene is an ingredient found in a variety of supplements and vitamins.	Not Available	Small Molecule																																			0	No	0	0	No	0	0	0 Å2	73.69 Å3	197.81 m3·mol-1	16	No	No	0.000397 mg/mL	11.93	-6.1					
C19H34O3	Not Available	Not Available	310.478	[H]\C(C[C@@]([H])(C)CCCC(C)(C)OC)=C(\[H])/C(/C)=C(\[H])C(=O)OC(C)C	Not Available	Not Available						39255	CHEMBL1875086	1361490															ZINC000002005163		(S)-methoprene	Vet approved	DB11495	InChI=1S/C19H34O3/c1-15(2)22-18(20)14-17(4)11-8-10-16(3)12-9-13-19(5,6)21-7/h8,11,14-16H,9-10,12-13H2,1-7H3/b11-8+,17-14+/t16-/m1/s1	NFGXHKASABOEEW-GYMWBFJFSA-N			Not Available	Small Molecule																																			0	Yes	2	0	No	0	0	35.53 Å2	38.25 Å3	94.79 m3·mol-1	11	No	No	0.00307 mg/mL	5.26	-5		-4.1			
C24H32O2	Not Available	Not Available	352.518	C\C(\C=C\[C@@H]1C[C@]1(C)C1=CC=C2C(=C1)C(C)(C)CCC2(C)C)=C/C(O)=O	Not Available	Not Available					50101445		CHEMBL75133	8039037									9863341	347828153					ZINC000001550770		VTP-194204	Investigational	DB11806	InChI=1S/C24H32O2/c1-16(13-21(25)26)7-8-18-15-24(18,6)17-9-10-19-20(14-17)23(4,5)12-11-22(19,2)3/h7-10,13-14,18H,11-12,15H2,1-6H3,(H,25,26)/b8-7+,16-13+/t18-,24-/m1/s1	BOOOLEGQBVUTKC-NVQSDHBMSA-N	2		Not Available	Small Molecule																																			1	No	2	1	No	3	-1	37.3 Å2	41.37 Å3	109.56 m3·mol-1	4	No	Yes	0.000104 mg/mL	6.31	-6.5	4.83				
C22H32O2	Not Available	Not Available	328.4883	CC(=O)OC\C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C	Not Available	Not Available								8421459			HMDB0035185						10245972	347828413					ZINC000014685555		Zuretinol acetate	Investigational	DB12112	InChI=1S/C22H32O2/c1-17(9-7-10-18(2)14-16-24-20(4)23)12-13-21-19(3)11-8-15-22(21,5)6/h7,9-10,12-14H,8,11,15-16H2,1-6H3/b10-7+,13-12+,17-9-,18-14+	QGNJRVVDBSJHIZ-AQDFTDIISA-N	2		Not Available	Small Molecule																																			1	Yes	1	0	No	1	0	26.3 Å2	40.5 Å3	107.07 m3·mol-1	7	No	Yes	0.00238 mg/mL	5.14	-5.1		-7			
C25H36O4	Not Available	Not Available	400.5509	[H][C@@]12CC(=CC[C@@]1([H])C(C)(C)OC1=CC(=CC(O)=C21)C(C)(C)CCCCCC)C(O)=O	Not Available	Not Available					50005920		CHEMBL456341	2340729						AJA			3083542	347828478				Ajulemic_acid	ZINC000001905712		Ajulemic acid	Investigational	DB12193	InChI=1S/C25H36O4/c1-6-7-8-9-12-24(2,3)17-14-20(26)22-18-13-16(23(27)28)10-11-19(18)25(4,5)29-21(22)15-17/h10,14-15,18-19,26H,6-9,11-13H2,1-5H3,(H,27,28)/t18-,19-/m1/s1	YCHYFHOSGQABSW-RTBURBONSA-N	2		Not Available	Small Molecule																																			1	No	4	2	Yes	3	-1	66.76 Å2	47.46 Å3	116.68 m3·mol-1	7	No	No	0.00125 mg/mL	6.61	-5.5	3.88	-4.9			
C22H28O3	Not Available	Not Available	340.4559	[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=CC2=CC(=O)CC[C@]12C	Not Available	Not Available						135445	CHEMBL1463345	13192			HMDB0003033						13789	347828500		1982		Canrenone	ZINC000003881648		Canrenone	Investigational	DB12221	InChI=1S/C22H28O3/c1-20-9-5-15(23)13-14(20)3-4-16-17(20)6-10-21(2)18(16)7-11-22(21)12-8-19(24)25-22/h3-4,13,16-18H,5-12H2,1-2H3/t16-,17+,18+,20+,21+,22-/m1/s1	UJVLDDZCTMKXJK-WNHSNXHDSA-N	4	Canrenone is an antimineralocorticoid and active metabolite of spironolactone used in the treatment of primary hyperaldosteronism and edematous states caused by secondary hyperaldosteronism (e.g. heart failure).	Not Available	Small Molecule																																			1	Yes	2	0	No	5	0	43.37 Å2	38.67 Å3	97.48 m3·mol-1	0	Yes	No	0.0042 mg/mL	3.6	-4.9		-4.8			
C20H22O2	Not Available	Not Available	294.3875	[H]/C(=C(/[H])\C(\C)=C(/[H])C(O)=O)/C(/[H])=C(/C)\C(\[H])=C1/CCCC2=CC=CC=C12	Not Available	Not Available					50445062		CHEMBL3098771	8079857						1O8			9904203	347828580							9CUAB30	Investigational	DB12316	InChI=1S/C20H22O2/c1-15(7-5-8-16(2)14-20(21)22)13-18-11-6-10-17-9-3-4-12-19(17)18/h3-5,7-9,12-14H,6,10-11H2,1-2H3,(H,21,22)/b8-5+,15-7-,16-14+,18-13+	PPGNMFUMZSAZCW-VOYUZAMQSA-N	1		Not Available	Small Molecule																																			1	Yes	2	1	No	2	-1	37.3 Å2	33.81 Å3	94.7 m3·mol-1	4	Yes	Yes	0.00157 mg/mL	5	-5.3	4.54				
C26H38O2	Not Available	Not Available	382.5787	CC(C)=CCC\C(C)=C\CC\C(C)=C\CCC1(C)CCC2=CC(O)=CC=C2O1	Not Available	Not Available							CHEMBL120643	8105532			HMDB0036368						9929901	347828854		578285		Tocotrienol			Tocotrienol	Investigational	DB12647	InChI=1S/C26H38O2/c1-20(2)9-6-10-21(3)11-7-12-22(4)13-8-17-26(5)18-16-23-19-24(27)14-15-25(23)28-26/h9,11,13-15,19,27H,6-8,10,12,16-18H2,1-5H3/b21-11+,22-13+	GJJVAFUKOBZPCB-ZGRPYONQSA-N	2		Not Available	Small Molecule																																			1	No	2	1	No	2	0	29.46 Å2	48.17 Å3	122.8 m3·mol-1	9	No	Yes	0.000793 mg/mL	7.75	-5.7	10.01	-4.9			
C23H32O3	Not Available	Not Available	356.4984	[H][C@@]12CC[C@H](OC(=O)CCCC)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	Not Available	Not Available	P05177;!P22309;!P08684;!P20815;!P24462;!P04798;!Q16678;!P33261;!P10632;!P11712	CYP1A2;!UGT1A1;!CYP3A4;!CYP3A5;!CYP3A7;!CYP1A1;!CYP1B1;!CYP2C19;!CYP2C8;!CYP2C9	1. Cytochrome P450 1A2;!2. UDP-glucuronosyltransferase 1-1;!3. Cytochrome P450 3A4;!4. Cytochrome P450 3A5;!5. Cytochrome P450 3A7;!6. Cytochrome P450 1A1;!7. Cytochrome P450 1B1;!8. Cytochrome P450 2C19;!9. Cytochrome P450 2C8;!10. Cytochrome P450 2C9			31561	CHEMBL1511	13194				C12859					13791		RxList Drug Page			Estradiol_valerate	ZINC000003881556	Delestrogen, Natazia	Estradiol valerate	Approved, Investigational, Vet approved	DB13956	InChI=1S/C23H32O3/c1-3-4-5-22(25)26-21-11-10-20-19-8-6-15-14-16(24)7-9-17(15)18(19)12-13-23(20,21)2/h7,9,14,18-21,24H,3-6,8,10-13H2,1-2H3/t18-,19-,20+,21+,23+/m1/s1	RSEPBGGWRJCQGY-RBRWEJTLSA-N	4	Estradiol valerate is an estradiol prodrug used to treat some effects of menopause, hypoestrogenism, androgen dependant carcinoma of the prostate, and in combination products for endometriosis and contraception.	Not Available	Small Molecule																																			1	No	2	1	No	4	0	46.53 Å2	42.57 Å3	102.89 m3·mol-1	5	No	No	0.000617 mg/mL	5.78	-5.8	10.33	-5.4	P03372;!Q92731;!O75469;!P43681;!Q15596;!Q99527;!P00846;!Q14457;!P37059;!P62508	ESR1;!ESR2;!NR1I2;!CHRNA4;!NCOA2;!GPER1;!MT-ATP6;!BECN1;!HSD17B2;!ESRRG	1. Estrogen receptor alpha;!2. Estrogen receptor beta;!3. Nuclear receptor subfamily 1 group I member 2;!4. Neuronal acetylcholine receptor subunit alpha-4;!5. Nuclear receptor coactivator 2;!6. G-protein coupled estrogen receptor 1;!7. ATP synthase subunit a;!8. Beclin-1;!9. Estradiol 17-beta-dehydrogenase 2;!10. Estrogen-related receptor gamma
C27H32O4	Not Available	Not Available	420.549	[H]\C(=C(\[H])C1=C(C)CCCC1(C)C)\C(\C)=C(/[H])C([H])=C(\C(C)=C(\[H])C(O)=O)C1=CC(=CC=C1)C(O)=O	Solid	Not Available								4943196																	13-cis-12-(3'-Carboxyphenyl)retinoic acid	Experimental	DB14097	InChI=1S/C27H32O4/c1-18(12-14-24-19(2)8-7-15-27(24,4)5)11-13-23(20(3)16-25(28)29)21-9-6-10-22(17-21)26(30)31/h6,9-14,16-17H,7-8,15H2,1-5H3,(H,28,29)(H,30,31)/b14-12+,18-11+,20-16-,23-13-	XKKDQOHDTASHCE-PAZAWXFKSA-N			Not Available	Small Molecule																																			1	No	4	2	No	2	-2	74.6 Å2	47.45 Å3	129.42 m3·mol-1	7	No	No	0.000946 mg/mL	6.19	-5.6	3.74				
C40H56	Not Available	Not Available	536.888	C\C(\C=C\C=C(/C)\C=C\[C@H]1C(C)=CCCC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)CCCC1(C)C	Not Available	Not Available						35147		4925358														Alpha-Carotene	ZINC000008219947		alpha-Carotene	Experimental	DB15909	InChI=1S/C40H56/c1-31(19-13-21-33(3)25-27-37-35(5)23-15-29-39(37,7)8)17-11-12-18-32(2)20-14-22-34(4)26-28-38-36(6)24-16-30-40(38,9)10/h11-14,17-23,25-28,37H,15-16,24,29-30H2,1-10H3/b12-11+,19-13+,20-14+,27-25+,28-26+,31-17+,32-18+,33-21+,34-22+/t37-/m0/s1	ANVAOWXLWRTKGA-NTXLUARGSA-N			Not Available	Small Molecule																																			0	No	0	0	No	2	0	0 Å2	71.15 Å3	191.88 m3·mol-1	10	No	Yes	0.000307 mg/mL	11.17	-6.2					
C40H56O	Not Available	Not Available	552.887	C\C(\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)C[C@@H](O)CC1(C)C	Not Available	Not Available						10362		4444647				C08591		RRX								Cryptoxanthin	ZINC000004097702		Cryptoxanthin	Experimental	DB15914	InChI=1S/C40H56O/c1-30(18-13-20-32(3)23-25-37-34(5)22-15-27-39(37,7)8)16-11-12-17-31(2)19-14-21-33(4)24-26-38-35(6)28-36(41)29-40(38,9)10/h11-14,16-21,23-26,36,41H,15,22,27-29H2,1-10H3/b12-11+,18-13+,19-14+,25-23+,26-24+,30-16+,31-17+,32-20+,33-21+/t36-/m1/s1	DMASLKHVQRHNES-FKKUPVFPSA-N			Not Available	Small Molecule																																			0	No	1	1	No	2	0	20.23 Å2	72.68 Å3	193.28 m3·mol-1	10	No	Yes	0.000503 mg/mL	9.74	-6	18.91	-1.1			
C20H30O2	Not Available	Not Available	302.458	CC(C)=CCC\C(C)=C\CC\C(C)=C\C=C\C(\C)=C\C(O)=O	Not Available	Not Available								4942358															ZINC000030691356		Peretinoin	Investigational	DB16291	InChI=1S/C20H30O2/c1-16(2)9-6-10-17(3)11-7-12-18(4)13-8-14-19(5)15-20(21)22/h8-9,11,13-15H,6-7,10,12H2,1-5H3,(H,21,22)/b14-8+,17-11+,18-13+,19-15+	UUBHZHZSIKRVIV-KCXSXWJSSA-N	3		Not Available	Small Molecule																																			1	No	2	1	No	0	-1	37.3 Å2	37.93 Å3	99.77 m3·mol-1	9	No	Yes	0.00403 mg/mL	5.78	-4.9	4.81				
C40H56O2	Not Available	Not Available	568.886	C\C(\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)C[C@@H](O)CC1(C)C	Liquid	Not Available						28838	CHEMBL173929	4444655				C08601		LUT	PDRhealth Drug Page	PA164748318	5281243	46508835		11359		Xanthophyll	ZINC000008221225		Lutein	Approved, Investigational, Nutraceutical	DB00137	InChI=1S/C40H56O2/c1-29(17-13-19-31(3)21-23-37-33(5)25-35(41)27-39(37,7)8)15-11-12-16-30(2)18-14-20-32(4)22-24-38-34(6)26-36(42)28-40(38,9)10/h11-25,35-37,41-42H,26-28H2,1-10H3/b12-11+,17-13+,18-14+,23-21+,24-22+,29-15+,30-16+,31-19+,32-20+/t35-,36+,37-/m0/s1	KBPHJBAIARWVSC-RGZFRNHPSA-N	4		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.5006 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					7.9		196 °C		Insoluble	0	No	2	2	No	2	0	40.46 Å2	73.81 Å3	195.06 m3·mol-1	10	No	No	0.000732 mg/mL	8.55	-5.9	18.22	-0.91			
C20H30O	Not Available	1.9 hours	286.4516	C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C	Solid	Not Available	O43174	CYP26A1	1. Cytochrome P450 26A1		50092056	17336	CHEMBL986	393012	Drugs.com Drug Page		HMDB0000305	C17276	D00069	RTL	PDRhealth Drug Page	PA451884	445354	46508191	RxList Drug Page	11246	DNC001498	Vitamin_A	ZINC000003831417	Aquasol A, Infuvite, Infuvite Pediatric, Mvc-fluoride, Mvi Pediatric, Vitafol-one	Vitamin A	Approved, Nutraceutical, Vet approved	DB00162	InChI=1S/C20H30O/c1-16(8-6-9-17(2)13-15-21)11-12-19-18(3)10-7-14-20(19,4)5/h6,8-9,11-13,21H,7,10,14-15H2,1-5H3/b9-6+,12-11+,16-8+,17-13+	FPIPGXGPPPQFEQ-OVSJKPMPSA-N	4	Vitamin A is a vitamin important for retinal function that is used clinically to correct vitamin A deficiency.	Acute toxicity to vitamin A can occur when adults or children ingest >100x or >20x the RDA, respectively, over a period of hours or a few days.2 The RDA for vitamin A differs depending on age and sex and can range from 300 - 900 μg retinol activity equivalents (RAE) per day.4 Symptoms of acute systemic toxicity generally include mucocutaneous involvement (e.g. xerosis, cheilitis, skin peeling) and may involve mental status changes.3 Children are typically more susceptible to acute vitamin A toxicity - daily intakes of as little as 1500 IU/kg have been observed to result in toxicity.2Chronic vitamin A toxicity can develop following the long-term ingestion of high vitamin A doses. While there is a wide variation in the lowest toxic vitamin A dose, the ingestion of >25 000 IU daily for 6 years or 100,000 IU daily for 6 months is considered to be toxic.2 Chronic vitamin A toxicity can affect many organ systems and can lead to the development of osteoporosis and CNS effects (e.g. headaches).3	Small Molecule	http://smpdb.ca/view/SMP0000074?highlight[compounds][]=DB00162&highlight[proteins][]=DB00162;!http://smpdb.ca/view/SMP0000336?highlight[compounds][]=DB00162&highlight[proteins][]=DB00162	Retinol Metabolism;!Vitamin A Deficiency		AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.1249 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					5.68		63.5 °C		0.671 mg/L	1	Yes	1	1	No	1	0	20.23 Å2	36.54 Å3	97.92 m3·mol-1	5	Yes	Yes	0.00758 mg/mL	4.69	-4.6	16.44	-2.2	P05090;!P41222;!Q96NR8;!Q92781;!Q8NBN7;!O94788;!P00352;!O95237;!O75911;!P47895;!Q6NUM9;!Q8TC12;!Q9BTZ2;!Q9HBH5;!Q9NYR8	APOD;!PTGDS;!RDH12;!RDH5;!RDH13;!ALDH1A2;!ALDH1A1;!LRAT;!DHRS3;!ALDH1A3;!RETSAT;!RDH11;!DHRS4;!RDH14;!RDH8	1. Apolipoprotein D;!2. Prostaglandin-H2 D-isomerase;!3. Retinol dehydrogenase 12;!4. 11-cis retinol dehydrogenase;!5. Retinol dehydrogenase 13;!6. Retinal dehydrogenase 2;!7. Retinal dehydrogenase 1;!8. Lecithin retinol acyltransferase;!9. Short-chain dehydrogenase/reductase 3;!10. Aldehyde dehydrogenase family 1 member A3;!11. All-trans-retinol 13,14-reductase;!12. Retinol dehydrogenase 11;!13. Dehydrogenase/reductase SDR family member 4;!14. Retinol dehydrogenase 14;!15. Retinol dehydrogenase 8
C21H28O2	Not Available	Dydrogesterone: 5-7 hours, 20-dihydrodydrogesterone (DHD) metabolite: 14-17 hours	312.4458	[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]2([H])C=CC2=CC(=O)CC[C@@]12C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			31527	CHEMBL1200853	8699		GtP Drug Page	HMDB0014522		D01217			PA164745443	9051	46506195		3706	DAP001205	Dydrogesterone	ZINC000003875998		Dydrogesterone	Approved, Investigational, Withdrawn	DB00378	InChI=1S/C21H28O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h4-5,12,16-19H,6-11H2,1-3H3/t16-,17+,18-,19+,20+,21+/m0/s1	JGMOKGBVKVMRFX-HQZYFCCVSA-N	4	Dydrogesterone is a synthetic progesterone for menstrual cycle regulation, infertility treatment, prevention of miscarriage, and other conditions.	No serious or unexpected toxicity has been observed with dydrogesterone. In acute toxicity studies, the LD50 doses in rats exceeded 4,640mg/kg for the oral route.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	1.8041 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.4		168-169			1	Yes	2	0	No	4	0	34.14 Å2	36.39 Å3	93.82 m3·mol-1	1	Yes	Yes	0.00486 mg/mL	3.79	-4.8	19.4	-4.8	P06401	PGR	1. Progesterone receptor
C21H26O3	Not Available	49 hours (range 33 to 96 hours)	326.4293	COC1=C(C)C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1	Solid	Not Available					50088429	50173	CHEMBL1131	4447573	Drugs.com Drug Page		HMDB0014602		D02754		PDRhealth Drug Page	PA448039	5284513	46509178	RxList Drug Page	16818	DAP000743	Acitretin	ZINC000003798734	Soriatane	Acitretin	Approved	DB00459	InChI=1S/C21H26O3/c1-14(8-7-9-15(2)12-21(22)23)10-11-19-16(3)13-20(24-6)18(5)17(19)4/h7-13H,1-6H3,(H,22,23)/b9-7+,11-10+,14-8+,15-12+	IHUNBGSDBOWDMA-AQFIFDHZSA-N	4	Acitretin is an oral retinoid used in the treatment of severe psoriasis.	Oral, rat: LD50 = >4000 mg/kg. Symptoms of overdose include headache and vertigo.	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.8804 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					6.40		228-230 °C		0.0729 mg/L	1	Yes	3	1	No	1	-1	46.53 Å2	38.58 Å3	104.17 m3·mol-1	6	No	No	0.000478 mg/mL	5.59	-5.8	4.77	-4.8	P19793;!P10276;!P10826;!P13631;!P28702;!P48443;!P09455;!	RXRA;!RARA;!RARB;!RARG;!RXRB;!RXRG;!RBP1;!	1. Retinoic acid receptor RXR-alpha;!2. Retinoic acid receptor alpha;!3. Retinoic acid receptor beta;!4. Retinoic acid receptor gamma;!5. Retinoic acid receptor RXR-beta;!6. Retinoic acid receptor RXR-gamma;!7. Retinol-binding protein 1;!8. Retinoic acid receptor RXR
C20H28O2	Not Available	Not Available	300.4351	C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O	Solid	Not Available					31892	50648	CHEMBL705	395778	Drugs.com Drug Page		HMDB0002369	C15493	D02815	9CR		PA164746900	449171	46507356	RxList Drug Page	81864	DAP000275	Alitretinoin	ZINC000012661824	Panretin, Toctino	Alitretinoin	Approved, Investigational	DB00523	InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8-,16-14+	SHGAZHPCJJPHSC-ZVCIMWCZSA-N	3	Alitretinoin is a vitamin A derivative used to treat Kaposi's sarcoma and used off label to treat chronic hand eczema and psoriasis.	Not Available	Small Molecule	http://smpdb.ca/view/SMP0000074?highlight[compounds][]=DB00523&highlight[proteins][]=DB00523;!http://smpdb.ca/view/SMP0000336?highlight[compounds][]=DB00523&highlight[proteins][]=DB00523	Retinol Metabolism;!Vitamin A Deficiency		Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.1455 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					4.2		189-190 °C		0.6 mg/L	1	Yes	2	1	No	1	-1	37.3 Å2	35.89 Å3	97.79 m3·mol-1	5	No	Yes	0.00477 mg/mL	5.01	-4.8	4.76		P10276;!P19793;!P10826;!P28702;!P13631;!P48443;!P17936;!Q15238;!Q6V0L0	RARA;!RXRA;!RARB;!RXRB;!RARG;!RXRG;!IGFBP3;!PSG5;!CYP26C1	1. Retinoic acid receptor alpha;!2. Retinoic acid receptor RXR-alpha;!3. Retinoic acid receptor beta;!4. Retinoic acid receptor RXR-beta;!5. Retinoic acid receptor gamma;!6. Retinoic acid receptor RXR-gamma;!7. Insulin-like growth factor-binding protein 3;!8. Pregnancy-specific beta-1-glycoprotein 5;!9. Cytochrome P450 26C1
C20H28O2	Not Available	0.5-2 hours	300.442	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O	Solid	Not Available	P24462;!P20813;!P10632;!P11712;!P08684;!P20815;!P11509;!P33260;!P04798;!Q02928	CYP3A7;!CYP2B6;!CYP2C8;!CYP2C9;!CYP3A4;!CYP3A5;!CYP2A6;!CYP2C18;!CYP1A1;!CYP4A11	1. Cytochrome P450 3A7;!2. Cytochrome P450 2B6;!3. Cytochrome P450 2C8;!4. Cytochrome P450 2C9;!5. Cytochrome P450 3A4;!6. Cytochrome P450 3A5;!7. Cytochrome P450 2A6;!8. Cytochrome P450 2C18;!9. Cytochrome P450 1A1;!10. Cytochrome P450 4A11		31883	15367	CHEMBL38	392618	Drugs.com Drug Page		HMDB0001852	C00777	D00094	REA		PA164746900	5538	46504843	RxList Drug Page	10753	DNC000117	Tretinoin	ZINC000012358651	Altreno, Atralin, Avita, Biacna, Refissa, Renova, Retin-A, Stieva-A, Tri-luma, Twyneo, Veltin, Vesanoid, Ziana	Tretinoin	Approved, Investigational, Nutraceutical	DB00755	InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14+	SHGAZHPCJJPHSC-YCNIQYBTSA-N	4	Tretinoin is a vitamin A derivative used to treat acne vulgaris, certain types of promyelocytic leukemia, and fine wrinkles.	Not Available	Small Molecule	http://smpdb.ca/view/SMP0000074?highlight[compounds][]=DB00755&highlight[proteins][]=DB00755;!http://smpdb.ca/view/SMP0000336?highlight[compounds][]=DB00755&highlight[proteins][]=DB00755	Retinol Metabolism;!Vitamin A Deficiency		Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.1455 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					6.30		181 °C		<0.1 g/100 mL	1	Yes	2	1	No	1	-1	37.3 Å2	36.85 Å3	97.79 m3·mol-1	5	No	Yes	0.00477 mg/mL	5.01	-4.8	4.76				
C23H30O3	Not Available	In one study, the apparent terminal half-life of etretinate after 6 months of therapy was approximately 120 days. In another study of 47 patients who had undergone chronic therapy with etretinate, 5 patients had detectable serum drug concentrations (0.5 to 12 ng/mL) 2.1 to 2.9 years after therapy was completed.	354.4825	CCOC(=O)C=C(C)C=CC=C(C)C=CC1=C(C)C(C)=C(OC)C=C1C	Solid	Not Available	P11511	CYP19A1	1. Cytochrome P450 19A1		50248000	4913	CHEMBL464	4445538					D00316			PA449554	3312	46504486		4182		Etretinate	ZINC000003830820		Etretinate	Withdrawn	DB00926	InChI=1S/C23H30O3/c1-8-26-23(24)14-17(3)11-9-10-16(2)12-13-21-18(4)15-22(25-7)20(6)19(21)5/h9-15H,8H2,1-7H3/b11-9+,13-12+,16-10+,17-14+	HQMNCQVAMBCHCO-DJRRULDNSA-N			Symptoms of overdose include headache and vertigo.	Small Molecule				Non AMES toxic	Ready biodegradable	+	Inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Non-substrate	1.8763 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					6.5		104-105			1	No	2	0	No	1	0	35.53 Å2	42.98 Å3	113.68 m3·mol-1	8	No	Yes	0.000405 mg/mL	6.32	-5.9		-4.8	P10276;!P19793;!P10826;!P48443;!P28702;!P13631	RARA;!RXRA;!RARB;!RXRG;!RXRB;!RARG	1. Retinoic acid receptor alpha;!2. Retinoic acid receptor RXR-alpha;!3. Retinoic acid receptor beta;!4. Retinoic acid receptor RXR-gamma;!5. Retinoic acid receptor RXR-beta;!6. Retinoic acid receptor gamma
C20H28O2	The clearance of isotretinoin is 15.9L/h in pediatric patients with neuroblastoma.6 Clearance is also 21.3mL/min/kg in guinea pigs and 7.2mL/min/kg in obese rats.5	The half life ranges from 7-39 hours13 with a mean elimination half life of 20 hours.1 The half life of 4-oxo-13-cis-retinoic acid ranges from 17-50 hours with a mean elimination half life of 25 hours.13	300.4351	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O	Solid	The volume of distribution in humans is unknown because there is no intravenous preparation.13 In a study of pediatric patients with neuroblastoma the volume of distribution was found to be 85L.6 The volume of distribution was also found to be 2432mL/kg in guinea pigs and 1716mL/kg in obese rats.5	P08684	CYP3A4	1. Cytochrome P450 3A4		50031459	6067	CHEMBL547	4445539	Drugs.com Drug Page		HMDB0006219		D00348			PA450128	5282379	46508729	RxList Drug Page	6064	DAP000009	Isotretinoin	ZINC000003792789	Absorica, Accutane, Amnesteem, Claravis, Clarus, Epuris, Myorisan, Sotret, Zenatane	Isotretinoin	Approved	DB00982	InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14-	SHGAZHPCJJPHSC-XFYACQKRSA-N	4	Isotretinoin is a retinoid used to treat severe recalcitrant acne.	Patients experiencing an overdose may present with vomiting, facial flushing, cheilosis, abdominal pain, headache, dizziness, and ataxia.Label These symptoms may rapidly resolve.Label Generally no treatment is required for these overdoses.7The oral lowest dose causing toxic effect (TDLO) for children is 30mg/kg/21W, oral TDLO for men is 24mg/kg/4W, oral TDLO for women is 56mg/kg/8W.14 The intraperitoneal LD50 for rats is 901mg/kg, oral LD50 for mice is 3389mg/kg, oral LD50 for rats is >4000mg/kg.14Isotretinoin is associated with major congenital malformations, spontaneous abortion, and premature birth.Label It is unknown if isotretinoin is expressed in breast milk but due to the associated hazards a decision should be made to either stop nursing or stop taking isotretinoin.LabelIn animal studies, isotretinoin was associated with an increased risk of pheochromocytoma and adrenal medullary hyperplasia at doses above the recommended clinical dose.Label Isotretinoin was negative for the Ames test of mutagenicity once and weakly positive a second time.Label It has not been shown to be clastogenic.Label A study in dogs noted testicular atrophy after doses of 10-30 times the recommended clinical dose for 30 weeks.Label In trials with men there were no effects seen on sperm count, motility, morphology, ejaculate volume, and seminal plasma fructose.Label	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.1455 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				462.8	5.66		189-190	~4	0.00477mg/mL	1	Yes	2	1	No	1	-1	37.3 Å2	36.15 Å3	97.79 m3·mol-1	5	No	Yes	0.00477 mg/mL	5.01	-4.8	4.76		P13631;!P10276	RARG;!RARA	1. Retinoic acid receptor gamma;!2. Retinoic acid receptor alpha
C20H24O2	Not Available	24 hours	296.4034	[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC(=C)C2=CC(=O)C=C[C@]12C	Solid	Not Available	P11511;!P08684	CYP19A1;!CYP3A4	1. Cytochrome P450 19A1;!2. Cytochrome P450 3A4		50398447	4953	CHEMBL1200374	54278	Drugs.com Drug Page		HMDB0015125	C08162	D00963	EXM		PA449563	60198	46508243	RxList Drug Page	258494	DAP000625	Exemestane	ZINC000003973334	Aromasin	Exemestane	Approved, Investigational	DB00990	InChI=1S/C20H24O2/c1-12-10-14-15-4-5-18(22)20(15,3)9-7-16(14)19(2)8-6-13(21)11-17(12)19/h6,8,11,14-16H,1,4-5,7,9-10H2,2-3H3/t14-,15-,16-,19+,20-/m0/s1	BFYIZQONLCFLEV-DAELLWKTSA-N	4	Exemestane is an aromatase inhibitor used to treat breast cancer in postmenopausal women after treatment with tamoxifen.	Convulsions	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	1.7582 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.7		155.13 °C		Non-soluble	1	Yes	2	0	No	4	0	34.14 Å2	33.72 Å3	89.03 m3·mol-1	0	Yes	Yes	0.00683 mg/mL	3.87	-4.6		-5			
C30H42O2	Not Available	Not Available	434.6533	OC\C(C)=C\C=C\C(\C)=C/C=C/C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C[C@@H](O)CC1(C)C	Solid	Not Available						39930		4449866						3ON			5287502	46506703					ZINC000012501797		(1r)-4-[(1e,3e,5e,7z,9e,11z,13e,15e)-17-Hydroxy-3,7,12,16-Tetramethylheptadeca-1,3,5,7,9,11,13,15-Octaen-1-Yl]-3,5,5-Trimethylcyclohex-3-En-1-Ol	Experimental	DB02253	InChI=1S/C30H42O2/c1-23(12-8-9-13-24(2)15-11-17-26(4)22-31)14-10-16-25(3)18-19-29-27(5)20-28(32)21-30(29,6)7/h8-19,28,31-32H,20-22H2,1-7H3/b9-8+,14-10+,15-11+,19-18+,23-12-,24-13-,25-16+,26-17+/t28-/m1/s1	FNAJVVMDXCOSFY-VFGOXHQXSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.0310 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	2	2	No	1	0	40.46 Å2	55.26 Å3	149.43 m3·mol-1	9	No	No	0.00157 mg/mL	5.9	-5.4	16.76	-1.1	P74334	Not Available	1. Apocarotenoid-15,15'-oxygenase
C20H28O2	Not Available	Not Available	300.4351	C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)C(=O)CCC1(C)C	Solid	Not Available						44597		4451124			HMDB0012329	C16683		OXR			5289090	46506951					ZINC000012502479		4-Oxoretinol	Experimental	DB02699	InChI=1S/C20H28O2/c1-15(7-6-8-16(2)12-14-21)9-10-18-17(3)19(22)11-13-20(18,4)5/h6-10,12,21H,11,13-14H2,1-5H3/b8-6+,10-9+,15-7+,16-12+	PLIUCYCUYQIBDZ-RMWYGNQTSA-N			Not Available	Small Molecule	http://smpdb.ca/view/SMP0000074?highlight[compounds][]=DB02699&highlight[proteins][]=DB02699;!http://smpdb.ca/view/SMP0000336?highlight[compounds][]=DB02699&highlight[proteins][]=DB02699	Retinol Metabolism;!Vitamin A Deficiency		Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.7980 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	1	No	1	0	37.3 Å2	36.68 Å3	98.62 m3·mol-1	5	Yes	Yes	0.0121 mg/mL	4.03	-4.4	16.44	-2.2			
C20H28	Not Available	Not Available	268.4363	C\C(C=C)=C/C=C/C(/C)=C/C=C1/C(C)=CCCC1(C)C	Solid	Not Available								4449996			HMDB0062447			ANR			5287678	46507241					ZINC000049499553		Anhydrovitamin A	Experimental	DB02914	InChI=1S/C20H28/c1-7-16(2)10-8-11-17(3)13-14-19-18(4)12-9-15-20(19,5)6/h7-8,10-14H,1,9,15H2,2-6H3/b11-8+,16-10+,17-13+,19-14-	FWNRILWHNGFAIN-OYUWDNMLSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.5742 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	0	0	No	1	0	0 Å2	34.33 Å3	96.19 m3·mol-1	4	No	Yes	0.00223 mg/mL	5.67	-5.1					
C22H33NO	Not Available	Not Available	327.5035	CCNC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C	Solid	Not Available					50092057		CHEMBL418471	4450394						ETR			5288173	46506461					ZINC000012504028		N-Ethylretinamide	Experimental	DB03917	InChI=1S/C22H33NO/c1-7-23-21(24)16-18(3)11-8-10-17(2)13-14-20-19(4)12-9-15-22(20,5)6/h8,10-11,13-14,16H,7,9,12,15H2,1-6H3,(H,23,24)/b11-8+,14-13+,17-10+,18-16+	WKYDOCGICAMTKE-NBIQJRODSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Non-substrate	2.0384 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	1	1	No	1	0	29.1 Å2	41.35 Å3	109.26 m3·mol-1	6	Yes	Yes	0.00332 mg/mL	4.79	-5	16.31	-0.22			
C28H38O6	Not Available	Not Available	470.606	[H][C@]12C[C@]([H])(C(=O)C[C@@H]1C1=C(O)C=C(C=C1OC(=O)\C=C\C(O)=O)C(C)(C)CCCCCC)C2(C)C	Solid	Not Available					50006254		CHEMBL3234035	8349550									10174045	347827707					ZINC000034377258		Cannabinor	Investigational	DB05048	InChI=1S/C28H38O6/c1-6-7-8-9-12-27(2,3)17-13-22(30)26(23(14-17)34-25(33)11-10-24(31)32)18-15-21(29)20-16-19(18)28(20,4)5/h10-11,13-14,18-20,30H,6-9,12,15-16H2,1-5H3,(H,31,32)/b11-10+/t18-,19-,20+/m0/s1	GSTZHANFXAKPSE-MXTREEOPSA-N			Not Available	Small Molecule																																			0	No	5	2	Yes	3	-1	100.9 Å2	53.09 Å3	131.38 m3·mol-1	11	No	No	0.000675 mg/mL	6.91	-5.8	2.73	-6.1			
C26H33NO2	Not Available	Not Available	391.5457	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)NC1=CC=C(O)C=C1	Solid	Not Available					50092055	42588	CHEMBL7301	4450416					D04162	FEN			5288209	175426938				Fenretinide	ZINC000003871023		Fenretinide	Investigational	DB05076	InChI=1S/C26H33NO2/c1-19(11-16-24-21(3)10-7-17-26(24,4)5)8-6-9-20(2)18-25(29)27-22-12-14-23(28)15-13-22/h6,8-9,11-16,18,28H,7,10,17H2,1-5H3,(H,27,29)/b9-6+,16-11+,19-8+,20-18+	AKJHMTWEGVYYSE-FXILSDISSA-N	3		"Mechanism of fenretinide (4-HPR)-induced cell death"	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Non-substrate	2.1836 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	2	2	No	2	0	49.33 Å2	47.67 Å3	128.05 m3·mol-1	6	No	No	0.00119 mg/mL	6.15	-5.5	9.45	-1.2			
C20H28O5S	Not Available	Not Available	380.498	[H][C@@]12CCC3=CC(C(C)C)=C(C=C3[C@@]1(C)CCC[C@@]2(C)C(O)=O)S(O)(=O)=O	Solid	Not Available						135593	CHEMBL2104585	59201	Drugs.com Drug Page		HMDB0015613		D07885			PA165958350	65781	99443230					ZINC000003779720		Ecabet	Investigational	DB05265	InChI=1S/C20H28O5S/c1-12(2)14-10-13-6-7-17-19(3,8-5-9-20(17,4)18(21)22)15(13)11-16(14)26(23,24)25/h10-12,17H,5-9H2,1-4H3,(H,21,22)(H,23,24,25)/t17-,19-,20-/m1/s1	IWCWQNVIUXZOMJ-MISYRCLQSA-N	3		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3482 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	2	No	3	-2	91.67 Å2	41.24 Å3	100.07 m3·mol-1	3	Yes	No	0.00426 mg/mL	4.93	-5	-1.5		P18314;!Q8NFA2	ureC;!NOXO1	1. Urease subunit alpha;!2. NADPH oxidase organizer 1
C23H32O2	Not Available	Not Available	340.507	C\C(\C=C\C=C(/C)C1=CC(=CC(=C1)C(C)(C)C)C(C)(C)C)=C/C(O)=O	Solid	Not Available					50052033		CHEMBL89241	4450017						ARL				347910230							LGD-1550	Investigational	DB05785	InChI=1S/C23H32O2/c1-16(12-21(24)25)10-9-11-17(2)18-13-19(22(3,4)5)15-20(14-18)23(6,7)8/h9-15H,1-8H3,(H,24,25)/b10-9+,16-12+,17-11+	JMPZTWDLOGTBPM-OUQSKUGOSA-N			Not Available	Small Molecule																																			1	No	2	1	No	1	-1	37.3 Å2	41.93 Å3	109.59 m3·mol-1	6	No	Yes	0.000304 mg/mL	6.82	-6	4.57		P10276;!P10826;!P13631;!P05412	RARA;!RARB;!RARG;!JUN	1. Retinoic acid receptor alpha;!2. Retinoic acid receptor beta;!3. Retinoic acid receptor gamma;!4. Transcription factor AP-1
C20H24O4	Not Available	Not Available	328.408	C\C(\C=C\C=C(/C)C(O)=O)=C/C=C/C=C(\C)/C=C/C=C(\C)C(O)=O	Solid	Not Available					50269617	3918	CHEMBL464792	4444644				C08588										Crocetin	ZINC000004097701		Transcrocetinate	Investigational	DB05974	InChI=1S/C20H24O4/c1-15(11-7-13-17(3)19(21)22)9-5-6-10-16(2)12-8-14-18(4)20(23)24/h5-14H,1-4H3,(H,21,22)(H,23,24)/b6-5+,11-7+,12-8+,15-9+,16-10+,17-13+,18-14+	PANKHBYNKQNAHN-MQQNZMFNSA-N	2		Not Available	Small Molecule																																			1	Yes	4	2	No	0	-2	74.6 Å2	38.07 Å3	103.8 m3·mol-1	8	Yes	No	0.00558 mg/mL	4.4	-4.8	4.41				
C40H52O4	Not Available	Not Available	596.852	C\C(\C=C\C=C(/C)\C=C\C1=C(C)C(=O)[C@@H](O)CC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)C(=O)[C@@H](O)CC1(C)C	Solid	Not Available						40968	CHEMBL1255871	4444636			HMDB0002204	C08580		AXT			5281224	347827776		18451		Astaxanthin	ZINC000100042059		Astaxanthin	Investigational	DB06543	InChI=1S/C40H52O4/c1-27(17-13-19-29(3)21-23-33-31(5)37(43)35(41)25-39(33,7)8)15-11-12-16-28(2)18-14-20-30(4)22-24-34-32(6)38(44)36(42)26-40(34,9)10/h11-24,35-36,41-42H,25-26H2,1-10H3/b12-11+,17-13+,18-14+,23-21+,24-22+,27-15+,28-16+,29-19+,30-20+/t35-,36-/m0/s1	MQZIGYBFDRPAKN-UWFIBFSHSA-N	2		Not Available	Small Molecule																																			0	No	4	2	No	2	0	74.6 Å2	73.77 Å3	195.98 m3·mol-1	10	No	No	0.000667 mg/mL	8.05	-6	13.07	-3.5	P25963	NFKBIA	1. NF-kappa-B inhibitor alpha
C40H56	The clearance rate of beta-carotene administered orally is 0.68 nmol/L each hour.3	The apparent half-life of beta-carotene is of 6-11 days after initial administration.2	536.888	C\C(\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)CCCC1(C)C	Solid	No pharmacokinetic studies have been performed regarding the volume of distribution of beta-carotene.	Q9HAY6	BCO1	1. Beta,beta-carotene 15,15'-dioxygenase		54988	17579	CHEMBL1293	4444129			HMDB0000561	C02094	D03101	BCR			5280489	347827791		19143		Beta-Carotene	ZINC000006845076	Pregvit	Beta carotene	Approved, Nutraceutical	DB06755	InChI=1S/C40H56/c1-31(19-13-21-33(3)25-27-37-35(5)23-15-29-39(37,7)8)17-11-12-18-32(2)20-14-22-34(4)26-28-38-36(6)24-16-30-40(38,9)10/h11-14,17-22,25-28H,15-16,23-24,29-30H2,1-10H3/b12-11+,19-13+,20-14+,27-25+,28-26+,31-17+,32-18+,33-21+,34-22+	OENHQHLEOONYIE-JLTXGRSLSA-N	4	Beta carotene is a vitamin A precursor found in various nutritional supplements and health products.	Beta-carotene is not toxic but the high and constant administration of this substance can translate into skin yellow coloration.6 Some reports have indicated that administration of high and periodic doses of beta-carotene are correlated to the increase in cancer incidence. This risk seems to be very elevated in the case of smokers.15 The registered LD50 of beta-carotene is >5000 mg/kg.MSDS	Small Molecule																													633-577ºC	17.62		176-184ºC		0.0006 g/l at 25ºC	0	No	0	0	No	2	0	0 Å2	71.84 Å3	191.61 m3·mol-1	10	No	Yes	0.000391 mg/mL	11.12	-6.1					1. Free radicals
C15H24	Not Available	Not Available	204.3511	C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C	Solid	Not Available								25058473						LSR			15143646	99444598					ZINC000058639152		1,3,3-trimethyl-2-[(1E,3E)-3-methylpenta-1,3-dien-1-yl]cyclohexene	Experimental	DB08127	InChI=1S/C15H24/c1-6-12(2)9-10-14-13(3)8-7-11-15(14,4)5/h6,9-10H,7-8,11H2,1-5H3/b10-9+,12-6+	KUEVAPFABUUVHS-AYCKBHPDSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.4560 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	0	0	No	1	0	0 Å2	26.78 Å3	71.23 m3·mol-1	2	Yes	Yes	0.0267 mg/mL	4.68	-3.9					
C16H28O3	Not Available	Not Available	268.3917	COC(C)(C)CCC[C@@](C)([H])C\C=C\C(\C)=C\C(O)=O	Solid	Not Available								4450887						MEI			5288795	99444646					ZINC000002244163		(2E,4E)-11-METHOXY-3,7,11-TRIMETHYLDODECA-2,4-DIENOIC ACID	Experimental	DB08175	InChI=1S/C16H28O3/c1-13(10-7-11-16(3,4)19-5)8-6-9-14(2)12-15(17)18/h6,9,12-13H,7-8,10-11H2,1-5H3,(H,17,18)/b9-6+,14-12+/t13-/m1/s1	MNYBEULOKRVZKY-ATCPXPEISA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	1.3231 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	1	No	0	-1	46.53 Å2	32.11 Å3	80.86 m3·mol-1	9	Yes	No	0.00868 mg/mL	4.1	-4.5	4.82	-4.1	Q15596;!P28702;!Q13133	NCOA2;!RXRB;!NR1H3	1. Nuclear receptor coactivator 2;!2. Retinoic acid receptor RXR-beta;!3. Oxysterols receptor LXR-alpha
C27H32O4	Not Available	Not Available	420.5406	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC=C4C=C(CC[C@]4(C)[C@@]3([H])CC[C@]12C)C(O)=O)C(=O)C1=CC=C(O)C=C1	Solid	Not Available								8020773						MUF			9845059	99444691					ZINC000003803450		(8alpha,10alpha,13alpha,17beta)-17-[(4-hydroxyphenyl)carbonyl]androsta-3,5-diene-3-carboxylic acid	Experimental	DB08220	InChI=1S/C27H32O4/c1-26-13-11-17(25(30)31)15-18(26)5-8-20-21-9-10-23(27(21,2)14-12-22(20)26)24(29)16-3-6-19(28)7-4-16/h3-7,15,20-23,28H,8-14H2,1-2H3,(H,30,31)/t20-,21-,22-,23+,26-,27-/m0/s1	RPNNXCYIESWDSC-JRZBRKEGSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.6597 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	2	No	5	-1	74.6 Å2	47.84 Å3	121.45 m3·mol-1	3	No	No	0.00264 mg/mL	5.16	-5.2	4.35	-6.9	Q15788;!Q96RI1	NCOA1;!NR1H4	1. Nuclear receptor coactivator 1;!2. Bile acid receptor
C20H24O3	Not Available	Not Available	312.4028	[H]/C(=C(/[H])\C(\C)=C(/[H])C(O)=O)/C(/[H])=C(\C)/C(/[H])=C(\[H])C1=C(C)C=C(O)C(C)=C1C	Solid	Not Available								4943051						R12			6438583	99444926							Ro 12-7310	Experimental	DB08455	InChI=1S/C20H24O3/c1-13(7-6-8-14(2)11-20(22)23)9-10-18-15(3)12-19(21)17(5)16(18)4/h6-12,21H,1-5H3,(H,22,23)/b8-6+,10-9+,13-7+,14-11+	CAAFTBWHFUPDGX-OFCLTBKTSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1413 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	2	No	1	-1	57.53 Å2	36.52 Å3	99.68 m3·mol-1	5	No	No	0.00119 mg/mL	5.44	-5.4	4.77	-5.9			
C20H28O2	Not Available	Not Available	300.4351	O=C(O)\C=C(/C)\C=C\C[C@]1(C)CC2=C(CCCC2(C)C)C1=C	Solid	Not Available								4451273						RE9			5289278	99444938					ZINC000015475858		6-(2,3,4,5,6,7-HEXAHYDRO-2,4,4-TRIMETHYL-1-METYLENEINDEN-2-YL)-3-METHYLHEXA-2,4-DIENOIC ACID	Experimental	DB08467	InChI=1S/C20H28O2/c1-14(12-18(21)22)8-6-11-20(5)13-17-16(15(20)2)9-7-10-19(17,3)4/h6,8,12H,2,7,9-11,13H2,1,3-5H3,(H,21,22)/b8-6+,14-12+/t20-/m1/s1	HEVXQLBAMFMFKU-IAZPEVBMSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Inhibitor	Non-substrate	2.1458 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	1	No	2	-1	37.3 Å2	34.61 Å3	93.62 m3·mol-1	4	Yes	Yes	0.00892 mg/mL	4.67	-4.5	4.54				
C22H30O4	Not Available	Not Available	358.478	[H][C@@]12CC[C@@](O)(CCC(O)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=CC2=CC(=O)CC[C@]12C	Solid	Not Available						50156	CHEMBL1616951	570976	Drugs.com Drug Page								656615	310264973		618970		Potassium_canrenoate	ZINC000003938750		Canrenoic acid	Approved, Withdrawn	DB09015	InChI=1S/C22H30O4/c1-20-9-5-15(23)13-14(20)3-4-16-17(20)6-10-21(2)18(16)7-11-22(21,26)12-8-19(24)25/h3-4,13,16-18,26H,5-12H2,1-2H3,(H,24,25)/t16-,17+,18+,20+,21+,22-/m1/s1	PBKZPPIHUVSDNM-WNHSNXHDSA-N	3	Canrenoic acid is an aldosterone antagonist used in primary hyperaldosteronism and other disorders related to aberrant aldosterone levels.	Not Available	Small Molecule																																165			1	Yes	4	2	No	4	-1	74.6 Å2	40.44 Å3	100.98 m3·mol-1	3	Yes	No	0.0442 mg/mL	2.93	-3.9	4.48	-3.1			
C23H32O2	Not Available	The half-life of medrogestone is reported to be of 4 hours.5	340.507	[H][C@@]12CC[C@](C)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			135446	CHEMBL2106825	8125459									9949848	310265040		6690		Medrogestone	ZINC000004216820		Medrogestone	Approved, Withdrawn	DB09124	InChI=1S/C23H32O2/c1-14-12-17-18(21(3)9-6-16(25)13-20(14)21)7-11-23(5)19(17)8-10-22(23,4)15(2)24/h12-13,17-19H,6-11H2,1-5H3/t17-,18+,19+,21-,22-,23+/m1/s1	HCFSGRMEEXUOSS-JXEXPEPMSA-N		Medrogestone is a progestin used as an adjunct to control secondary amenorrhea and dysfunctional bleeding in adolescent and adult females, and treat endometrial shedding in menopausal women.	There were reports of increased urinary flow rates and total micturition volumes as well as sexual dysfunction and hyperglycemia.4	Small Molecule																													467.17ºC at 760 mmHg	4.45		144-146ºC		5.34e-06 mol/L	1	Yes	2	0	No	4	0	34.14 Å2	40.37 Å3	102.6 m3·mol-1	1	Yes	Yes	0.00404 mg/mL	4.59	-4.9	19.18	-4.9	P06401	PGR	1. Progesterone receptor
C40H56O2	Not Available	Not Available	568.886	C\C(\C=C\C=C(/C)\C=C\C1=C(C)C[C@@H](O)CC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)C[C@@H](O)CC1(C)C	Not Available	Not Available						27547	CHEMBL2359248	4444421			HMDB0002789	C06098					5280899	347827933		39918		Zeaxanthin	ZINC000008220175		Zeaxanthin	Approved, Investigational	DB11176	InChI=1S/C40H56O2/c1-29(17-13-19-31(3)21-23-37-33(5)25-35(41)27-39(37,7)8)15-11-12-16-30(2)18-14-20-32(4)22-24-38-34(6)26-36(42)28-40(38,9)10/h11-24,35-36,41-42H,25-28H2,1-10H3/b12-11+,17-13+,18-14+,23-21+,24-22+,29-15+,30-16+,31-19+,32-20+/t35-,36-/m1/s1	JKQXZKUSFCKOGQ-QAYBQHTQSA-N	3		Not Available	Small Molecule																																			0	No	2	2	No	2	0	40.46 Å2	73.47 Å3	194.95 m3·mol-1	10	No	No	0.000649 mg/mL	8.35	-5.9	18.91	-0.79			
C18H22O	No pharmacokinetic data available.	The half life of enzacamene (4-MBC) and its main metabolite, 3-(4-carboxybenzylidene)camphor, displayed half-lives of approximately 15 h after reaching peak plasma concentrations after oral administration in rats 6.	254.373	CC1=CC=C(\C=C2/C3CCC(C)(C2=O)C3(C)C)C=C1	Solid	No pharmacokinetic data available.					50103609	135937	CHEMBL2104261	4939160									7019255	347827944		1311507		Enzacamene			Enzacamene	Approved	DB11219	InChI=1S/C18H22O/c1-12-5-7-13(8-6-12)11-14-15-9-10-18(4,16(14)19)17(15,2)3/h5-8,11,15H,9-10H2,1-4H3/b14-11+	HEOCBCNFKCOKBX-SDNWHVSQSA-N		Enzacamene is an ingredient used in sunscreen to block UVB radiation.	Oral LD50 and dermal LD50 in rat are reported to be 10,000 mg/kg 7. Oral TDLO in rat is 7 mg/kg MSDS. Oral and subcutaneous TDLO following continuous administration in rat are 476 mg/kg/4D and 4 mg/kg/2D, respectively MSDS. Cases of overdose have not been reported for enzacamene. Enzacamene is reported to be an endocrine disruptor that alters the reproductive axis.	Small Molecule																														5.14		66-69		Poorly soluble	1	Yes	1	0	No	3	0	17.07 Å2	30.58 Å3	79.68 m3·mol-1	1	No	Yes	0.0051 mg/mL	5.12	-4.7		-5.2	P06401;!P10275;!Q92731;!P03372	PGR;!AR;!ESR2;!ESR1	1. Progesterone receptor;!2. Androgen receptor;!3. Estrogen receptor beta;!4. Estrogen receptor alpha
C40H56	Not Available	Not Available	536.888	CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C	Not Available	Not Available						15948	CHEMBL501174	394156			HMDB0003000	C05432		LYC			446925	347827946		29008		Lycopene	ZINC000008214943		Lycopene	Approved, Investigational	DB11231	InChI=1S/C40H56/c1-33(2)19-13-23-37(7)27-17-31-39(9)29-15-25-35(5)21-11-12-22-36(6)26-16-30-40(10)32-18-28-38(8)24-14-20-34(3)4/h11-12,15-22,25-32H,13-14,23-24H2,1-10H3/b12-11+,25-15+,26-16+,31-17+,32-18+,35-21+,36-22+,37-27+,38-28+,39-29+,40-30+	OAIJSZIZWZSQBC-GYZMGTAESA-N	4	Lycopene is an ingredient found in a variety of supplements and vitamins.	Not Available	Small Molecule																																			0	No	0	0	No	0	0	0 Å2	73.69 Å3	197.81 m3·mol-1	16	No	No	0.000397 mg/mL	11.93	-6.1					
C19H34O3	Not Available	Not Available	310.478	[H]\C(C[C@@]([H])(C)CCCC(C)(C)OC)=C(\[H])/C(/C)=C(\[H])C(=O)OC(C)C	Not Available	Not Available						39255	CHEMBL1875086	1361490															ZINC000002005163		(S)-methoprene	Vet approved	DB11495	InChI=1S/C19H34O3/c1-15(2)22-18(20)14-17(4)11-8-10-16(3)12-9-13-19(5,6)21-7/h8,11,14-16H,9-10,12-13H2,1-7H3/b11-8+,17-14+/t16-/m1/s1	NFGXHKASABOEEW-GYMWBFJFSA-N			Not Available	Small Molecule																																			0	Yes	2	0	No	0	0	35.53 Å2	38.25 Å3	94.79 m3·mol-1	11	No	No	0.00307 mg/mL	5.26	-5		-4.1			
C24H32O2	Not Available	Not Available	352.518	C\C(\C=C\[C@@H]1C[C@]1(C)C1=CC=C2C(=C1)C(C)(C)CCC2(C)C)=C/C(O)=O	Not Available	Not Available					50101445		CHEMBL75133	8039037									9863341	347828153					ZINC000001550770		VTP-194204	Investigational	DB11806	InChI=1S/C24H32O2/c1-16(13-21(25)26)7-8-18-15-24(18,6)17-9-10-19-20(14-17)23(4,5)12-11-22(19,2)3/h7-10,13-14,18H,11-12,15H2,1-6H3,(H,25,26)/b8-7+,16-13+/t18-,24-/m1/s1	BOOOLEGQBVUTKC-NVQSDHBMSA-N	2		Not Available	Small Molecule																																			1	No	2	1	No	3	-1	37.3 Å2	41.37 Å3	109.56 m3·mol-1	4	No	Yes	0.000104 mg/mL	6.31	-6.5	4.83				
C22H32O2	Not Available	Not Available	328.4883	CC(=O)OC\C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C	Not Available	Not Available								8421459			HMDB0035185						10245972	347828413					ZINC000014685555		Zuretinol acetate	Investigational	DB12112	InChI=1S/C22H32O2/c1-17(9-7-10-18(2)14-16-24-20(4)23)12-13-21-19(3)11-8-15-22(21,5)6/h7,9-10,12-14H,8,11,15-16H2,1-6H3/b10-7+,13-12+,17-9-,18-14+	QGNJRVVDBSJHIZ-AQDFTDIISA-N	2		Not Available	Small Molecule																																			1	Yes	1	0	No	1	0	26.3 Å2	40.5 Å3	107.07 m3·mol-1	7	No	Yes	0.00238 mg/mL	5.14	-5.1		-7			
C25H36O4	Not Available	Not Available	400.5509	[H][C@@]12CC(=CC[C@@]1([H])C(C)(C)OC1=CC(=CC(O)=C21)C(C)(C)CCCCCC)C(O)=O	Not Available	Not Available					50005920		CHEMBL456341	2340729						AJA			3083542	347828478				Ajulemic_acid	ZINC000001905712		Ajulemic acid	Investigational	DB12193	InChI=1S/C25H36O4/c1-6-7-8-9-12-24(2,3)17-14-20(26)22-18-13-16(23(27)28)10-11-19(18)25(4,5)29-21(22)15-17/h10,14-15,18-19,26H,6-9,11-13H2,1-5H3,(H,27,28)/t18-,19-/m1/s1	YCHYFHOSGQABSW-RTBURBONSA-N	2		Not Available	Small Molecule																																			1	No	4	2	Yes	3	-1	66.76 Å2	47.46 Å3	116.68 m3·mol-1	7	No	No	0.00125 mg/mL	6.61	-5.5	3.88	-4.9			
C22H28O3	Not Available	Not Available	340.4559	[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=CC2=CC(=O)CC[C@]12C	Not Available	Not Available						135445	CHEMBL1463345	13192			HMDB0003033						13789	347828500		1982		Canrenone	ZINC000003881648		Canrenone	Investigational	DB12221	InChI=1S/C22H28O3/c1-20-9-5-15(23)13-14(20)3-4-16-17(20)6-10-21(2)18(16)7-11-22(21)12-8-19(24)25-22/h3-4,13,16-18H,5-12H2,1-2H3/t16-,17+,18+,20+,21+,22-/m1/s1	UJVLDDZCTMKXJK-WNHSNXHDSA-N	4	Canrenone is an antimineralocorticoid and active metabolite of spironolactone used in the treatment of primary hyperaldosteronism and edematous states caused by secondary hyperaldosteronism (e.g. heart failure).	Not Available	Small Molecule																																			1	Yes	2	0	No	5	0	43.37 Å2	38.67 Å3	97.48 m3·mol-1	0	Yes	No	0.0042 mg/mL	3.6	-4.9		-4.8			
C20H22O2	Not Available	Not Available	294.3875	[H]/C(=C(/[H])\C(\C)=C(/[H])C(O)=O)/C(/[H])=C(/C)\C(\[H])=C1/CCCC2=CC=CC=C12	Not Available	Not Available					50445062		CHEMBL3098771	8079857						1O8			9904203	347828580							9CUAB30	Investigational	DB12316	InChI=1S/C20H22O2/c1-15(7-5-8-16(2)14-20(21)22)13-18-11-6-10-17-9-3-4-12-19(17)18/h3-5,7-9,12-14H,6,10-11H2,1-2H3,(H,21,22)/b8-5+,15-7-,16-14+,18-13+	PPGNMFUMZSAZCW-VOYUZAMQSA-N	1		Not Available	Small Molecule																																			1	Yes	2	1	No	2	-1	37.3 Å2	33.81 Å3	94.7 m3·mol-1	4	Yes	Yes	0.00157 mg/mL	5	-5.3	4.54				
C26H38O2	Not Available	Not Available	382.5787	CC(C)=CCC\C(C)=C\CC\C(C)=C\CCC1(C)CCC2=CC(O)=CC=C2O1	Not Available	Not Available							CHEMBL120643	8105532			HMDB0036368						9929901	347828854		578285		Tocotrienol			Tocotrienol	Investigational	DB12647	InChI=1S/C26H38O2/c1-20(2)9-6-10-21(3)11-7-12-22(4)13-8-17-26(5)18-16-23-19-24(27)14-15-25(23)28-26/h9,11,13-15,19,27H,6-8,10,12,16-18H2,1-5H3/b21-11+,22-13+	GJJVAFUKOBZPCB-ZGRPYONQSA-N	2		Not Available	Small Molecule																																			1	No	2	1	No	2	0	29.46 Å2	48.17 Å3	122.8 m3·mol-1	9	No	Yes	0.000793 mg/mL	7.75	-5.7	10.01	-4.9			
C23H32O3	Not Available	Not Available	356.4984	[H][C@@]12CC[C@H](OC(=O)CCCC)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	Not Available	Not Available	P05177;!P22309;!P08684;!P20815;!P24462;!P04798;!Q16678;!P33261;!P10632;!P11712	CYP1A2;!UGT1A1;!CYP3A4;!CYP3A5;!CYP3A7;!CYP1A1;!CYP1B1;!CYP2C19;!CYP2C8;!CYP2C9	1. Cytochrome P450 1A2;!2. UDP-glucuronosyltransferase 1-1;!3. Cytochrome P450 3A4;!4. Cytochrome P450 3A5;!5. Cytochrome P450 3A7;!6. Cytochrome P450 1A1;!7. Cytochrome P450 1B1;!8. Cytochrome P450 2C19;!9. Cytochrome P450 2C8;!10. Cytochrome P450 2C9			31561	CHEMBL1511	13194				C12859					13791		RxList Drug Page			Estradiol_valerate	ZINC000003881556	Delestrogen, Natazia	Estradiol valerate	Approved, Investigational, Vet approved	DB13956	InChI=1S/C23H32O3/c1-3-4-5-22(25)26-21-11-10-20-19-8-6-15-14-16(24)7-9-17(15)18(19)12-13-23(20,21)2/h7,9,14,18-21,24H,3-6,8,10-13H2,1-2H3/t18-,19-,20+,21+,23+/m1/s1	RSEPBGGWRJCQGY-RBRWEJTLSA-N	4	Estradiol valerate is an estradiol prodrug used to treat some effects of menopause, hypoestrogenism, androgen dependant carcinoma of the prostate, and in combination products for endometriosis and contraception.	Not Available	Small Molecule																																			1	No	2	1	No	4	0	46.53 Å2	42.57 Å3	102.89 m3·mol-1	5	No	No	0.000617 mg/mL	5.78	-5.8	10.33	-5.4	P03372;!Q92731;!O75469;!P43681;!Q15596;!Q99527;!P00846;!Q14457;!P37059;!P62508	ESR1;!ESR2;!NR1I2;!CHRNA4;!NCOA2;!GPER1;!MT-ATP6;!BECN1;!HSD17B2;!ESRRG	1. Estrogen receptor alpha;!2. Estrogen receptor beta;!3. Nuclear receptor subfamily 1 group I member 2;!4. Neuronal acetylcholine receptor subunit alpha-4;!5. Nuclear receptor coactivator 2;!6. G-protein coupled estrogen receptor 1;!7. ATP synthase subunit a;!8. Beclin-1;!9. Estradiol 17-beta-dehydrogenase 2;!10. Estrogen-related receptor gamma
C27H32O4	Not Available	Not Available	420.549	[H]\C(=C(\[H])C1=C(C)CCCC1(C)C)\C(\C)=C(/[H])C([H])=C(\C(C)=C(\[H])C(O)=O)C1=CC(=CC=C1)C(O)=O	Solid	Not Available								4943196																	13-cis-12-(3'-Carboxyphenyl)retinoic acid	Experimental	DB14097	InChI=1S/C27H32O4/c1-18(12-14-24-19(2)8-7-15-27(24,4)5)11-13-23(20(3)16-25(28)29)21-9-6-10-22(17-21)26(30)31/h6,9-14,16-17H,7-8,15H2,1-5H3,(H,28,29)(H,30,31)/b14-12+,18-11+,20-16-,23-13-	XKKDQOHDTASHCE-PAZAWXFKSA-N			Not Available	Small Molecule																																			1	No	4	2	No	2	-2	74.6 Å2	47.45 Å3	129.42 m3·mol-1	7	No	No	0.000946 mg/mL	6.19	-5.6	3.74				
C40H56	Not Available	Not Available	536.888	C\C(\C=C\C=C(/C)\C=C\[C@H]1C(C)=CCCC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)CCCC1(C)C	Not Available	Not Available						35147		4925358														Alpha-Carotene	ZINC000008219947		alpha-Carotene	Experimental	DB15909	InChI=1S/C40H56/c1-31(19-13-21-33(3)25-27-37-35(5)23-15-29-39(37,7)8)17-11-12-18-32(2)20-14-22-34(4)26-28-38-36(6)24-16-30-40(38,9)10/h11-14,17-23,25-28,37H,15-16,24,29-30H2,1-10H3/b12-11+,19-13+,20-14+,27-25+,28-26+,31-17+,32-18+,33-21+,34-22+/t37-/m0/s1	ANVAOWXLWRTKGA-NTXLUARGSA-N			Not Available	Small Molecule																																			0	No	0	0	No	2	0	0 Å2	71.15 Å3	191.88 m3·mol-1	10	No	Yes	0.000307 mg/mL	11.17	-6.2					
C40H56O	Not Available	Not Available	552.887	C\C(\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)C[C@@H](O)CC1(C)C	Not Available	Not Available						10362		4444647				C08591		RRX								Cryptoxanthin	ZINC000004097702		Cryptoxanthin	Experimental	DB15914	InChI=1S/C40H56O/c1-30(18-13-20-32(3)23-25-37-34(5)22-15-27-39(37,7)8)16-11-12-17-31(2)19-14-21-33(4)24-26-38-35(6)28-36(41)29-40(38,9)10/h11-14,16-21,23-26,36,41H,15,22,27-29H2,1-10H3/b12-11+,18-13+,19-14+,25-23+,26-24+,30-16+,31-17+,32-20+,33-21+/t36-/m1/s1	DMASLKHVQRHNES-FKKUPVFPSA-N			Not Available	Small Molecule																																			0	No	1	1	No	2	0	20.23 Å2	72.68 Å3	193.28 m3·mol-1	10	No	Yes	0.000503 mg/mL	9.74	-6	18.91	-1.1			
C20H30O2	Not Available	Not Available	302.458	CC(C)=CCC\C(C)=C\CC\C(C)=C\C=C\C(\C)=C\C(O)=O	Not Available	Not Available								4942358															ZINC000030691356		Peretinoin	Investigational	DB16291	InChI=1S/C20H30O2/c1-16(2)9-6-10-17(3)11-7-12-18(4)13-8-14-19(5)15-20(21)22/h8-9,11,13-15H,6-7,10,12H2,1-5H3,(H,21,22)/b14-8+,17-11+,18-13+,19-15+	UUBHZHZSIKRVIV-KCXSXWJSSA-N	3		Not Available	Small Molecule																																			1	No	2	1	No	0	-1	37.3 Å2	37.93 Å3	99.77 m3·mol-1	9	No	Yes	0.00403 mg/mL	5.78	-4.9	4.81				
C59H84N16O12	Leuprolide administered as a 1 mg intravenous bolus in healthy males has a mean systemic clearance between 7.6 and 8.3 L/h.5,6,7,8,9,10,12	Leuprolide has a terminal elimination half-life of approximately three hours.5,6,7,8,9,10,12	1209.3983	CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1	Solid	Leuprolide has an apparent steady-state volume of distribution of 27 L following intravenous bolus administration to healthy males. The volume of distribution for indicated routes of subcutaneous or intramuscular injection has not been reported.5,6,7,8,9,10,12					50369395	6427	CHEMBL1201199	571356	Drugs.com Drug Page		HMDB0041916	C07612	D08113			PA450203		46507635	RxList Drug Page	42375	DAP000020	Leuprorelin		Camcevi, Eligard, Fensolvi, Lupaneta Pack 1-month, Lupron, Lupron Depot-ped, Viadur, Zeulide Depot	Leuprolide	Approved, Investigational	DB00007	InChI=1S/C59H84N16O12/c1-6-63-57(86)48-14-10-22-75(48)58(87)41(13-9-21-64-59(60)61)68-51(80)42(23-32(2)3)69-52(81)43(24-33(4)5)70-53(82)44(25-34-15-17-37(77)18-16-34)71-56(85)47(30-76)74-54(83)45(26-35-28-65-39-12-8-7-11-38(35)39)72-55(84)46(27-36-29-62-31-66-36)73-50(79)40-19-20-49(78)67-40/h7-8,11-12,15-18,28-29,31-33,40-48,65,76-77H,6,9-10,13-14,19-27,30H2,1-5H3,(H,62,66)(H,63,86)(H,67,78)(H,68,80)(H,69,81)(H,70,82)(H,71,85)(H,72,84)(H,73,79)(H,74,83)(H4,60,61,64)/t40-,41-,42-,43+,44-,45-,46-,47-,48-/m0/s1	GFIJNRVAKGFPGQ-LIJARHBVSA-N	4	Leuprolide is a peptide-based GnRH receptor superagonist used for the palliative treatment of prostate cancer, uterine leiomyomata, endometriosis, and central precocious puberty.	Leuprolide is considered extremely safe, with low dose-related toxicity and comparatively mild adverse effects.1 Prostate cancer patients treated with leuprolide at doses as high as 20 mg/day for two years showed no additional adverse effects compared to those receiving 1 mg/day.10	Small Molecule																																150-155	9.6		0	No	16	16	Yes	6	1	429.04 Å2	125.24 Å3	327.24 m3·mol-1	32	No	No	0.0338 mg/mL	-2.4	-4.6	9.49	11.92	P30968	GNRHR	1. Gonadotropin-releasing hormone receptor
C59H84N18O14	121 +/- 42.4 mL/min [prostate cancer with 10.8 mg depot]	4-5 hours	1269.4105	CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O	Solid	44.1 ± 13.6 L [subcutaneous administration of 250 mcg]						5523	CHEMBL1201247	4470656	Drugs.com Drug Page		HMDB0014259		D00573			PA164747674	5311128	46507336	RxList Drug Page	50610	DAP000023	Goserelin		Zoladex	Goserelin	Approved	DB00014	InChI=1S/C59H84N18O14/c1-31(2)22-40(49(82)68-39(12-8-20-64-57(60)61)56(89)77-21-9-13-46(77)55(88)75-76-58(62)90)69-54(87)45(29-91-59(3,4)5)74-50(83)41(23-32-14-16-35(79)17-15-32)70-53(86)44(28-78)73-51(84)42(24-33-26-65-37-11-7-6-10-36(33)37)71-52(85)43(25-34-27-63-30-66-34)72-48(81)38-18-19-47(80)67-38/h6-7,10-11,14-17,26-27,30-31,38-46,65,78-79H,8-9,12-13,18-25,28-29H2,1-5H3,(H,63,66)(H,67,80)(H,68,82)(H,69,87)(H,70,86)(H,71,85)(H,72,81)(H,73,84)(H,74,83)(H,75,88)(H4,60,61,64)(H3,62,76,90)/t38-,39-,40-,41-,42-,43-,44-,45+,46-/m0/s1	BLCLNMBMMGCOAS-URPVMXJPSA-N	4	Goserelin is a synthetic analog of luteinizing hormone-releasing hormone used to treat breast cancer and prostate cancer by reducing secretion of gonadotropins from the pituitary.	No experience of overdosage from clinical trials.	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.6730 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor					-2				Soluble	0	No	18	17	Yes	6	1	495.89 Å2	130.74 Å3	325.84 m3·mol-1	33	No	No	0.0283 mg/mL	-5.1	-4.6	9.36	10.91	P22888;!P30968	LHCGR;!GNRHR	1. Lutropin-choriogonadotropic hormone receptor;!2. Gonadotropin-releasing hormone receptor
C46H64N14O12S2	Not Available	Following an intranasal dose of 1.66 mcg of desmopressin, the median apparent terminal half-life was 2.8 hours Label. Terminal half-life significantly increased from 3 hours in normal healthy patients to 9 hours in patients with severe renal impairment Label. The oral terminal half life of desmopressin ranges from 2 to 3.11 hours 9.	1069.22	NC(=O)CC[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O	Solid	The distribution volume of orally administered desmopressin is 0.2 – 0.32 l/kg 9. It is not reported to cross the blood-brain barrier.	P35354;!P23219	PTGS2;!PTGS1	1. Prostaglandin G/H synthase 2;!2. Prostaglandin G/H synthase 1		50205308	4450	CHEMBL1429	4470602	Drugs.com Drug Page		HMDB0014260	C06944	D00291			PA449237			RxList Drug Page	3251	DNC000526	Desmopressin		Ddavp, Nocdurna, Octostim, Stimate	Desmopressin	Approved	DB00035	InChI=1S/C46H64N14O12S2/c47-35(62)15-14-29-40(67)58-32(22-36(48)63)43(70)59-33(45(72)60-18-5-9-34(60)44(71)56-28(8-4-17-52-46(50)51)39(66)53-23-37(49)64)24-74-73-19-16-38(65)54-30(21-26-10-12-27(61)13-11-26)41(68)57-31(42(69)55-29)20-25-6-2-1-3-7-25/h1-3,6-7,10-13,28-34,61H,4-5,8-9,14-24H2,(H2,47,62)(H2,48,63)(H2,49,64)(H,53,66)(H,54,65)(H,55,69)(H,56,71)(H,57,68)(H,58,67)(H,59,70)(H4,50,51,52)/t28-,29+,30+,31+,32+,33+,34+/m1/s1	NFLWUMRGJYTJIN-PNIOQBSNSA-N	4	Desmopressin is a synthetic analog of vasopressin used to reduce renal excretion of water in central diabetes insipidus and nocturia.	Intravenous TDLo in humans is reported to be 0.3 µg/kg/10M MSDS. Desmopressin is associated with hyponatremia in case of overdose, which may require temporary or permanent discontinuation of the therapy depending on severity. The effects of hyponatremia include seizure, altered mental status (confusion, drowsiness or continuing headache), cardiac arrhythmias and worsening edema. Other signs of overdose may include oliguria and rapid weight gain due to fluid retention Label. In case of overdose, reduce the dose or frequency of drug administration, or discontinue use if appropriate. Assessment of serum sodium and initiation of appropriate medical treatment is recommended.	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.7183 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										0	No	15	14	Yes	4	1	435.41 Å2	104.78 Å3	279.78 m3·mol-1	19	No	No	0.11 mg/mL	-6.1	-4	9.5	11.77	P30518;!P37288;!P47901	AVPR2;!AVPR1A;!AVPR1B	1. Vasopressin V2 receptor;!2. Vasopressin V1a receptor;!3. Vasopressin V1b receptor
C49H66N10O10S2	The total body clearance of octreotide is 7-10 L/h.10 One pharmacokinetic study revealed a total body clearance of 11.4 L/h.2	After a subcutaneous dose, the plasma half-life is estimated to be 0.2 hours. The average elimination half-lives for subcutaneous and oral administration ranged from 2.3 - 2.7 hours and did not differ significantly.10 One pharmacokinetic study revealed a plasma half-life ranging from 72-113 minutes.2	1019.25	[H][C@]1(NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@H](CO)[C@@H](C)O)NC(=O)[C@H](N)CC1=CC=CC=C1)[C@@H](C)O	Solid	In a pharmacokinetic study, the volume of distribution was 13.6 L in healthy volunteers.10 One pharmacokinetic study revealed a volume of distribution ranging from 18.1-30.4L after intravenous administration in healthy volunteers.2	P05164;!P08684	MPO;!CYP3A4	1. Myeloperoxidase;!2. Cytochrome P450 3A4		50272772		CHEMBL1680	395352	Drugs.com Drug Page			C07306	D00442			PA450678	448601	46504600	RxList Drug Page	7617	DAP000397	Octreotide		Bynfezia, Mycapssa, Sandostatin	Octreotide	Approved, Investigational	DB00104	InChI=1S/C49H66N10O10S2/c1-28(61)39(25-60)56-48(68)41-27-71-70-26-40(57-43(63)34(51)21-30-13-5-3-6-14-30)47(67)54-37(22-31-15-7-4-8-16-31)45(65)55-38(23-32-24-52-35-18-10-9-17-33(32)35)46(66)53-36(19-11-12-20-50)44(64)59-42(29(2)62)49(69)58-41/h3-10,13-18,24,28-29,34,36-42,52,60-62H,11-12,19-23,25-27,50-51H2,1-2H3,(H,53,66)(H,54,67)(H,55,65)(H,56,68)(H,57,63)(H,58,69)(H,59,64)/t28-,29-,34-,36+,37+,38-,39-,40+,41+,42+/m1/s1	DEQANNDTNATYII-OULOTJBUSA-N	4	Octreotide is a peptide drug used to treat acromegaly as well as diarrhea associated with metastatic carcinoid tumors and vasoactive intestinal peptide secreting tumors.	There is limited information regarding cases of octreotide overdose aside from case reports of an overdose with injectable octreotide. The dose ranged from 2.4 mg/day to 6 mg/day administered by continuous infusion or subcutaneous administration of 1.5 mg three times daily. Effects of an overdose with octreotide may include hypotension, brain hypoxia, arrhythmia, cardiac arrest, lactic acidosis, pancreatitis, hepatomegaly, diarrhea, flushing, lethargy, and weakness.10	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.6174 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor				1447	-0.49		153-156	12.60		0	No	12	13	Yes	5	2	332.22 Å2	107.65 Å3	269.77 m3·mol-1	17	No	No	0.0122 mg/mL	-1.4	-4.9	11.4	10.17			1. Somatostatin receptor
C37H49N7O9S	Not Available	10 minutes or less	767.9	CSCC[C@H](NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O	Solid	Not Available	P06276	BCHE	1. Cholinesterase		50024321	31974	CHEMBL1328	8029364		GtP Drug Page			D01631			PA450849	9853654	46507747		7993	DNC001170	Pentagastrin	ZINC000008214644		Pentagastrin	Approved	DB00183	InChI=1S/C37H49N7O9S/c1-37(2,3)53-36(52)39-16-14-30(45)41-28(19-23-21-40-25-13-9-8-12-24(23)25)34(50)42-26(15-17-54-4)33(49)44-29(20-31(46)47)35(51)43-27(32(38)48)18-22-10-6-5-7-11-22/h5-13,21,26-29,40H,14-20H2,1-4H3,(H2,38,48)(H,39,52)(H,41,45)(H,42,50)(H,43,51)(H,44,49)(H,46,47)/t26-,27-,28-,29-/m0/s1	NEYNJQRKHLUJRU-DZUOILHNSA-N		Pentagastrin is a gastrin-like molecule used as a diagnostic aid for the evaluation of gastric acid secretory function, gastric hypersecretion, and Zollinger-Ellison tumors.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	3.2696 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor					1.6		229 dec °C			0	No	8	8	Yes	3	-1	250.91 Å2	78.01 Å3	200.04 m3·mol-1	22	No	No	0.00261 mg/mL	1.05	-5.5	4		P32239	CCKBR	1. Gastrin/cholecystokinin type B receptor
C37H48N6O5S2	The apparent oral clearance at steady-state is 8.8 ± 3.2 L/h.7 Renal clearance is minimal and estimated to be <0.1 L/h.7	The approximate half-life of ritonavir is 3-5 hours.7	720.944	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1	Solid	The estimated volume of distribution of ritonavir is 0.41 ± 0.25 L/kg.7					520	45409	CHEMBL163	347980	Drugs.com Drug Page		HMDB0014646	C07240	D00427	RIT		PA451260	392622	46505050	RxList Drug Page	85762	DAP000169	Ritonavir	ZINC000003944422	Kaletra, Norvir, Viekira Pak	Ritonavir	Approved, Investigational	DB00503	InChI=1S/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)/t28-,31-,32-,33-/m0/s1	NCDNCNXCDXHOMX-XGKFQTDJSA-N	4	Ritonavir is an HIV protease inhibitor used in combination with other antivirals in the treatment of HIV infection.	Human experience of acute overdose with ritonavir is limited. One patient in clinical trials took ritonavir 1500 mg/day for two days. The patient reported paresthesias which resolved after the dose was decreased. A post-marketing case of renal failure with eosinophilia has been reported with ritonavir overdose. The approximate lethal dose was found to be greater than 20 times the related human dose in rats and 10 times the related human dose in mice. Oral LD value in rats is >2500 mg/kg. Adverse effects of ritonavir may arise from drug-drug interactions. Other effects include hepatotoxicity, pancreatitis, and allergic reactions/hypersensitivity.	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Inhibitor	Non-inhibitor	Substrate	2.6154 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor					3.9				Practically insoluble	0	No	6	4	Yes	4	0	145.78 Å2	76.23 Å3	194.59 m3·mol-1	18	No	No	0.00126 mg/mL	5.22	-5.8	13.68	2.84	Q72874;!O75469	pol;!NR1I2	1. Human immunodeficiency virus type 1 protease;!2. Nuclear receptor subfamily 1 group I member 2
C52H88N10O15	12 mL/min [After single IV administration]	9-11 hours	1093.331	[H][C@@]12C[C@@H](O)CN1C(=O)[C@@H](NC(=O)[C@]([H])(C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]1[C@@H](O)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@@H](C)O	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4			474180	CHEMBL499808	17277006	Drugs.com Drug Page				D07626			PA164743013	3035406	46508288	RxList Drug Page	140108	DAP000547	Caspofungin		Cancidas	Caspofungin	Approved	DB00520	InChI=1S/C52H88N10O15/c1-5-28(2)24-29(3)12-10-8-6-7-9-11-13-39(69)56-34-26-38(68)46(55-22-21-54)60-50(75)43-37(67)19-23-61(43)52(77)41(36(66)18-20-53)58-49(74)42(45(71)44(70)31-14-16-32(64)17-15-31)59-48(73)35-25-33(65)27-62(35)51(76)40(30(4)63)57-47(34)72/h14-17,28-30,33-38,40-46,55,63-68,70-71H,5-13,18-27,53-54H2,1-4H3,(H,56,69)(H,57,72)(H,58,74)(H,59,73)(H,60,75)/t28-,29+,30+,33+,34-,35-,36+,37-,38+,40-,41-,42-,43-,44-,45-,46-/m0/s1	JYIKNQVWKBUSNH-WVDDFWQHSA-N	4	Caspofungin is an echinocandin used to treat a variety of fungal infections.	Side effects include rash, swelling, and nausea (rare)	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.9344 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					0					0	No	18	16	Yes	4	2	412.03 Å2	117.66 Å3	278.78 m3·mol-1	23	No	No	0.367 mg/mL	-4.8	-3.5	8.75	9.76	A2QLK4	fksA	1. 1,3-beta-glucan synthase component FKS1
C20H28N2O5	Following oral administration in healthy male volunteers, the renal clearance was approximately 158 ± 47 mL/min.8 It is reported that enalapril and enalaprilat are undetectable in the plasma by 4 hours post-dosing.3	The average terminal half life of enalaprilat is 35-38 hours. The effective half life following multiple doses is 11-14 hours. The prolonged terminal half-life is due to the binding of enalaprilat to ACE.5	376.4467	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O	Solid	The volume of distribution of enalapril has not been established. Enalaprilat is shown to penetrate into most tissuesm, in particular the kidneys and vascular tissuem, although penetration of the blood-brain barrier has not been demonstrated after administration at therapeutic doses.7 In dog studies, enalapril and enalaprilat cross the blood-brain barrier poorly.10 Minimal penetration occurs into breast milk but significant fetal transfer occurs.7 The drug crosses the placental barrier in rats and hamsters.10					50017129	4784	CHEMBL578	4534998	Drugs.com Drug Page		HMDB0014722	C06977	D07892		PDRhealth Drug Page	PA449456	5388962	46507920	RxList Drug Page	3827	DAP001374	Enalapril	ZINC000003791297	Epaned, Vaseretic, Vasotec	Enalapril	Approved, Vet approved	DB00584	InChI=1S/C20H28N2O5/c1-3-27-20(26)16(12-11-15-8-5-4-6-9-15)21-14(2)18(23)22-13-7-10-17(22)19(24)25/h4-6,8-9,14,16-17,21H,3,7,10-13H2,1-2H3,(H,24,25)/t14-,16-,17-/m0/s1	GBXSMTUPTTWBMN-XIRDDKMYSA-N	4	Enalapril is a prodrug of an ACE inhibitor used to treat hypertension and congestive heart failure.	LD50 and OverdoseOral LD50 in rats is 2973 mg/kg.MSDS Lethality was observed with single oral doses of enalapril above 1000 mg/kg in mice and greater than or equal to 1775 mg/kg in rats. Serum enalaprilat levels 100- and 200-fold higher than usually seen after therapeutic doses have been reported after ingestion of 300 mg and 440 mg of enalapril, respectively.10 While there is limited data about enalapril overdose in humans, overdosage may result in marked hypotension and stupor based on the pharmacological properties of the drug. Most common adverse effects of enalapril include cough, hypotension, stupor, headache, dizziness and fatigue. If hypotension is seen, usual treatment of intravenous infusion of normal saline solution is recommended. Enalaprilat may be removed from systemic circulation with the use of hemodialysis. It has been removed from neonatal circulation by peritoneal dialysis.LabelNonclinical toxicologyMaternal and fetal toxicity occudred in some rabbits treated with enalapril at doses of 1 mg/kg/day or more. There was no fetotoxicity, expressed as a decrease in average fetal weight, or teratogenicity in rats treated with enalapril at doses up to 200 mg/kg/day, which is about 333 times the maximum human dose.10 In mice and rats receiving enalapril at doses ranging from 90 to 180 mg/kg/day, there was no evidence of a tumorigenic effect. Neither enalapril or its active metabolite were shown to be mutagenic or genotoxic in in vitro and in vivo studies. There were no adverse effects on reproductive performance of male and female rats treated with up to 90 mg/kg/day of enalapril. LabelUse in special populationsCaution is warranted in patients who are concurrently using another ACE inhibitors with enalapril, as there have been incidences of agranulocytosis with the use of captopril, which is another ACE inhibitor. This adverse event may be particularly significant in patients with renal impairment or collagen vascular disease.Label As enalapril and enalaprilat were shown to be secreted in human milk in trace amounts, the use of enalaprilat in nursing women is not recommended.10 Significant fetal transfer occurs with enalapril and enalaprilat thus the use of the drug in pregnant women should be strongly avoided. Caution is advised when enalapril is used in patients who are elderly or with renal impairment, as dosage adjustments may be appropriate. The antihypertensive effect of angiotensin converting enzyme inhibitors is generally lower in individuals of African descent, usually a low-renin hypertensive population.Label	Small Molecule	http://smpdb.ca/view/SMP0000593?highlight[compounds][]=DB00584&highlight[proteins][]=DB00584;!http://smpdb.ca/view/SMP0000148?highlight[compounds][]=DB00584&highlight[proteins][]=DB00584	Enalapril Metabolism Pathway;!Enalapril Action Pathway		Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.8269 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor		-5.64			0.07		143-144.5		1.64E+004 mg/L	1	Yes	5	2	No	2	-1	95.94 Å2	40.41 Å3	99.57 m3·mol-1	10	Yes	No	0.213 mg/mL	0.59	-3.2	3.67	5.2			
C66H103N17O16S	Data regarding the clearance of bacitracin in humans has not been well studied.4 A study of 9 subjects in 1947 shows a renal clearance of 105-283mL/min with an average renal clearance of 159mL/min.6	Data regarding the half life of bacitracin in humans is not readily available.4	1422.693	CC[C@H](C)[C@H](N)C1=N[C@@H](CS1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H]1CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(O)=O)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@@H](CCCN)NC1=O)[C@@H](C)CC	Solid	Data regarding the volume of distribution of bacitracin in humans is not readily available.4						35862	CHEMBL1200558	9084687	Drugs.com Drug Page		HMDB0014764	C15482	D00128			PA448531	10909430	46504727	RxList Drug Page	1291	DAP000710	Bacitracin		Baciguent, Baciject, Cortisporin, Diosporin, Neo-polycin, Neo-polycin HC, Neosporin Ointment, Neosporin Plus Maximum Strength, Neosporin Solution, Polycin-B, Polysporin, Procomycin, Rash Relief Antibacterial, Triple Antibiotic	Bacitracin	Approved, Vet approved	DB00626	InChI=1S/C66H103N17O16S/c1-9-35(6)52(69)66-81-48(32-100-66)63(97)76-43(26-34(4)5)59(93)74-42(22-23-50(85)86)58(92)83-53(36(7)10-2)64(98)75-40-20-15-16-25-71-55(89)46(29-49(68)84)78-62(96)47(30-51(87)88)79-61(95)45(28-39-31-70-33-72-39)77-60(94)44(27-38-18-13-12-14-19-38)80-65(99)54(37(8)11-3)82-57(91)41(21-17-24-67)73-56(40)90/h12-14,18-19,31,33-37,40-48,52-54H,9-11,15-17,20-30,32,67,69H2,1-8H3,(H2,68,84)(H,70,72)(H,71,89)(H,73,90)(H,74,93)(H,75,98)(H,76,97)(H,77,94)(H,78,96)(H,79,95)(H,80,99)(H,82,91)(H,83,92)(H,85,86)(H,87,88)/t35-,36-,37-,40-,41+,42+,43-,44+,45-,46-,47+,48-,52-,53-,54-/m0/s1	CLKOFPXJLQSYAH-ABRJDSQDSA-N	4	Bacitracin is a cyclic polypeptide antibiotic used to prevent wound infections, treat pneumonia and empyema in infants, and to treat skin and eye infections.	The oral LD50 of bacitracin in rats is >2000mg/kg.12Specific data regarding bacitracin overdoses is not readily available.8 An overdose of bacitracin may lead to nephrotoxicity4 and patients should be treated with supportive measures.	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.8201 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor									Freely soluble	0	No	20	17	Yes	4	0	530.87 Å2	149.32 Å3	363.14 m3·mol-1	31	No	No	0.0245 mg/mL	-6.8	-4.8	3.19	9.63	BMOL0000024;!P14735;!P01023	;!IDE;!A2M	1. C55-isoprenyl pyrophosphate;!2. Insulin-degrading enzyme;!3. Alpha-2-macroglobulin
C55H75N17O13	Not Available	Very short, initial, 2 to 10 minutes; terminal, 10 to 40 minutes	1182.2901	CC(C)CC(NC(=O)CNC(=O)C(CC1=CC=C(O)C=C1)NC(=O)C(CO)NC(=O)C(CC1=CNC2=CC=CC=C12)NC(=O)C(CC1=CN=CN1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(N)=O	Liquid	Not Available							CHEMBL1981292	33562	Drugs.com Drug Page		HMDB0014782	C07607				PA449801	36523	46506144	RxList Drug Page	6384	DAP001052	Gonadorelin		Lutrepulse	Gonadorelin	Approved, Investigational, Vet approved	DB00644	InChI=1S/C55H75N17O13/c1-29(2)19-38(49(80)67-37(9-5-17-60-55(57)58)54(85)72-18-6-10-43(72)53(84)62-25-44(56)75)66-46(77)26-63-47(78)39(20-30-11-13-33(74)14-12-30)68-52(83)42(27-73)71-50(81)40(21-31-23-61-35-8-4-3-7-34(31)35)69-51(82)41(22-32-24-59-28-64-32)70-48(79)36-15-16-45(76)65-36/h3-4,7-8,11-14,23-24,28-29,36-43,61,73-74H,5-6,9-10,15-22,25-27H2,1-2H3,(H2,56,75)(H,59,64)(H,62,84)(H,63,78)(H,65,76)(H,66,77)(H,67,80)(H,68,83)(H,69,82)(H,70,79)(H,71,81)(H4,57,58,60)	XLXSAKCOAKORKW-UHFFFAOYSA-N	4	Gonadorelin is a synthetic GnRH used to test the function of gonadotropes and the pituitary.	LD50>3000 mg/kg (rat, oral)	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.6799 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					-3.6				1 mg/mL	0	No	17	16	Yes	6	1	474.63 Å2	120.21 Å3	302.51 m3·mol-1	31	No	No	0.0588 mg/mL	-6.3	-4.3	9.47	11.16	P30968;!Q96P88	GNRHR;!GNRHR2	1. Gonadotropin-releasing hormone receptor;!2. Putative gonadotropin-releasing hormone II receptor
C66H83N17O13	Not Available	3 hours	1322.496	CC(C)C[C@H](NC(=O)[C@@H](CC1=CC2=C(C=CC=C2)C=C1)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O	Solid	Not Available					84707	7445	CHEMBL1201309	10482014	Drugs.com Drug Page			C07613				PA164754805	25077405	46506496	RxList Drug Page	28656	DAP001051	Nafarelin		Synarel	Nafarelin	Approved	DB00666	InChI=1S/C66H83N17O13/c1-36(2)25-48(58(89)76-47(13-7-23-71-66(68)69)65(96)83-24-8-14-54(83)64(95)73-33-55(67)86)77-60(91)50(28-38-15-18-39-9-3-4-10-40(39)26-38)78-59(90)49(27-37-16-19-43(85)20-17-37)79-63(94)53(34-84)82-61(92)51(29-41-31-72-45-12-6-5-11-44(41)45)80-62(93)52(30-42-32-70-35-74-42)81-57(88)46-21-22-56(87)75-46/h3-6,9-12,15-20,26,31-32,35-36,46-54,72,84-85H,7-8,13-14,21-25,27-30,33-34H2,1-2H3,(H2,67,86)(H,70,74)(H,73,95)(H,75,87)(H,76,89)(H,77,91)(H,78,90)(H,79,94)(H,80,93)(H,81,88)(H,82,92)(H4,68,69,71)/t46-,47-,48-,49-,50+,51-,52-,53-,54-/m0/s1	RWHUEXWOYVBUCI-ITQXDASVSA-N	4	Nafarelin is a gonadotropin releasing hormone agonist used to treat central precocious puberty.	In experimental animals, a single subcutaneous administration of up to 60 times the recommended human dose (on a µg/kg basis, not adjusted for bioavailability) had no adverse effects. At present, there is no clinical evidence of adverse effects following overdosage of GnRH analogs.	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.6799 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	17	17	Yes	8	1	472.13 Å2	135.67 Å3	357.8 m3·mol-1	33	No	No	0.0166 mg/mL	-2.7	-4.9	9.49	11.92	P30968;!Q96P88	GNRHR;!GNRHR2	1. Gonadotropin-releasing hormone receptor;!2. Putative gonadotropin-releasing hormone II receptor
C27H34N2O7	441 mL/min	Moexipril elimination half-life is approximately 1 hour. Moexiprilat elimination half-life is 2 to 9 hours.	498.5681	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2=CC(OC)=C(OC)C=C2C[C@H]1C(O)=O	Solid	183 L					50084673	6960	CHEMBL1165	82418	Drugs.com Drug Page		HMDB0014829	C07704			PDRhealth Drug Page	PA164769059	91270	46508441	RxList Drug Page	30131	DAP000586	Moexipril	ZINC000003812306	Univasc	Moexipril	Approved	DB00691	InChI=1S/C27H34N2O7/c1-5-36-27(33)21(12-11-18-9-7-6-8-10-18)28-17(2)25(30)29-16-20-15-24(35-4)23(34-3)14-19(20)13-22(29)26(31)32/h6-10,14-15,17,21-22,28H,5,11-13,16H2,1-4H3,(H,31,32)/t17-,21-,22-/m0/s1	UWWDHYUMIORJTA-HSQYWUDLSA-N	4	Moexipril is an angiotensin converting enzyme inhibitor prodrug used to treat hypertension.	Human overdoses of moexipril have not been reported. In case reports of overdoses with other ACE inhibitors, hypotension has been the principal adverse effect noted. Single oral doses of 2 g/kg moexipril were associated with significant lethality in mice. Rats, however, tolerated single oral doses of up to 3 g/kg. Common adverse effects include cough, dizziness, diarrhea, flu syndrome, fatigue, pharyngitis, flushing, rash, and myalgia	Small Molecule	http://smpdb.ca/view/SMP0000151?highlight[compounds][]=DB00691&highlight[proteins][]=DB00691;!http://smpdb.ca/view/SMP0000595?highlight[compounds][]=DB00691&highlight[proteins][]=DB00691	Moexipril Action Pathway;!Moexipril Metabolism Pathway		Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Inhibitor	Inhibitor	Substrate	2.5131 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor					2.7				Soluble (about 10% weight-to-volume) in distilled water at room temperature as HCl salt.	1	No	7	2	Yes	3	-1	114.4 Å2	53.55 Å3	132.88 m3·mol-1	12	Yes	No	0.00585 mg/mL	1.5	-4.9	3.46	5.2			
C22H36N2O5S	213 - 314 mL/min [Healthy subjects]152 - 267 mL/min [patients with coronary artery disease]	2 hours	440.597	CCCCS(=O)(=O)N[C@@H](CC1=CC=C(OCCCCC2CCNCC2)C=C1)C(O)=O	Solid	22 to 42 L					50004058	9605	CHEMBL916	54912	Drugs.com Drug Page		HMDB0014913	C07965		AGG		PA451698	60947	46504678	RxList Drug Page	73137	DAP000696	Tirofiban	ZINC000003806104	Aggrastat	Tirofiban	Approved	DB00775	InChI=1S/C22H36N2O5S/c1-2-3-16-30(27,28)24-21(22(25)26)17-19-7-9-20(10-8-19)29-15-5-4-6-18-11-13-23-14-12-18/h7-10,18,21,23-24H,2-6,11-17H2,1H3,(H,25,26)/t21-/m0/s1	COKMIXFXJJXBQG-NRFANRHFSA-N	4	Tirofiban is a platelet aggregation inhibitor used to prevent thrombotic events in non-ST elevated acute coronary syndrome.	Not Available	Small Molecule	http://smpdb.ca/view/SMP0000267?highlight[compounds][]=DB00775&highlight[proteins][]=DB00775	Tirofiban Action Pathway		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3684 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor					1.4				Very slightly soluble	1	Yes	6	3	No	2	0	104.73 Å2	49.27 Å3	117.48 m3·mol-1	13	Yes	No	0.00317 mg/mL	0.6	-5.1	3.17	10.21			
C56H98N16O13	1 compartment models estimate clearance to be 2.37L/h to 2.5L/h1.	In one study the half life was 9 to 11.5 hours1. However, a Canadian monograph states the half life to be 6 hours, and 48-72 hours in patients with renal insufficiency8.	1203.499	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O	Solid	1 compartment models estimate the volume of distribution to be 34.3L to 47.2L1. However, the general consensus is that the volume of distribution is yet to be determined8.					50410807		CHEMBL1201283	25045120												8536		Polymyxin_B		Casporyn HC, Cortisporin, Dioptrol, Diosporin, Maxitrol, Neo-polycin, Neo-polycin HC, Neosporin Ointment, Neosporin Plus Maximum Strength, Neosporin Plus Maximum Strength Cream, Neosporin Solution, Polycin-B, Polysporin, Polytrim, Procomycin, Statrol, Triple Antibiotic	Polymyxin B	Approved, Vet approved	DB00781	InChI=1S/C56H98N16O13/c1-7-32(4)13-11-12-16-44(75)63-36(17-23-57)51(80)72-46(34(6)74)56(85)68-39(20-26-60)48(77)67-41-22-28-62-55(84)45(33(5)73)71-52(81)40(21-27-61)65-47(76)37(18-24-58)66-53(82)42(29-31(2)3)69-54(83)43(30-35-14-9-8-10-15-35)70-49(78)38(19-25-59)64-50(41)79/h8-10,14-15,31-34,36-43,45-46,73-74H,7,11-13,16-30,57-61H2,1-6H3,(H,62,84)(H,63,75)(H,64,79)(H,65,76)(H,66,82)(H,67,77)(H,68,85)(H,69,83)(H,70,78)(H,71,81)(H,72,80)/t32?,33-,34-,36+,37+,38-,39+,40+,41+,42+,43-,45+,46+/m1/s1	WQVJHHACXVLGBL-BPJDFBQWSA-N	4	Polymyxin B is a polymyxin antibiotic used to treat a wide variety of infections in the body.	Nephrotoxicity can occur in patients as polymyxin B is thought to accumulate in renal cells after renal tubular reabsorption1. This accumulation can lead to apoptosis of renal cells and decrease in renal function2. In recent studies, acute kidney injury (AKI) has been seen in 31.3% to 39.4% of patients receiving polymyxin B2.Overdose cases can cause neuromuscular block leading to apnea, muscular weakness, vertigo, transient facial parasthesia, slurred speed, vasomotor instability, visual disturbance, confusion, psychosis, and respiratory arrest8. Renal failure has also been seen through decreased urine output, and increased serum concentrations of blood urea nitrogen8.Overdose of polymyxin B is treated by stopping the drug and beginning symptomatic treatment8. Intravenous administration of mannitol may enhance renal clearance, and hemodialysis may manage renal complications8.Safety of polymyxin B has not been established in pregnancy, breast feeding, pediatrics, and geriatrics8. Polymyxin B should no be used in pregnancy unless the benefit outweighs the risk8. Nursing mothers should either stop nursing or stop polymyxin B treatment depending on the risks to both the mother and child8. Pediatric patients should be frequently monitored for renal function and no dosing information is available in children under 2 years of age8. Geriatric patients should have renal function assessed before and regularly during therapy8.	Small Molecule																																>203	8.9	Soluble	0	No	18	18	No	2	5	490.66 Å2	127.4 Å3	313.22 m3·mol-1	29	No	No	0.0744 mg/mL	-7.2	-4.2	11.57	10.23			1. Bacterial outer membrane
C25H30N2O5	The clearance of quinaprilat is 68mL/min.1	The active metabolite quinaprilat has an elimination half life of 2.3 hours.1,6	438.5161	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2=CC=CC=C2C[C@H]1C(O)=O	Solid	The mean volume of distribution of quinaprilat is 13.9L.1	P23141	CES1	1. Liver carboxylesterase 1		50368166	8713	CHEMBL1592	49565	Drugs.com Drug Page		HMDB0015019	C07398	D03752		PDRhealth Drug Page	PA451205	54892	46506309	RxList Drug Page	35208	DAP000588	Quinapril	ZINC000003801163	Accupril, Accuretic	Quinapril	Approved, Investigational	DB00881	InChI=1S/C25H30N2O5/c1-3-32-25(31)21(14-13-18-9-5-4-6-10-18)26-17(2)23(28)27-16-20-12-8-7-11-19(20)15-22(27)24(29)30/h4-12,17,21-22,26H,3,13-16H2,1-2H3,(H,29,30)/t17-,21-,22-/m0/s1	JSDRRTOADPPCHY-HSQYWUDLSA-N	4	Quinapril is an ACE inhibitor prodrug used to treat hypertension, congestive heart failure, and slow rate of progression of renal disease.	The oral LD50 in rats is 3541mg/kg and in mice is 1739mg/kg.8Patients experiencing an overdose may present with symptoms of severe hypotension.6,7 Due to the extensive protein binding of quinapril and the active metabolite quinaprilat, hemodialysis is not expected to remove the drug from circulation.6,7 Treat patients with symptomatic and supportive measures, including normal saline infusions to restore normal blood pressure.6,7	Small Molecule	http://smpdb.ca/view/SMP0000596?highlight[compounds][]=DB00881&highlight[proteins][]=DB00881;!http://smpdb.ca/view/SMP0000153?highlight[compounds][]=DB00881&highlight[proteins][]=DB00881	Quinapril Metabolism Pathway;!Quinapril Action Pathway		Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.2690 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor					0.86		120-130 °C	2.8		1	Yes	5	2	Yes	3	-1	95.94 Å2	47.36 Å3	119.96 m3·mol-1	10	Yes	No	0.0085 mg/mL	1.96	-4.7	3.7	5.2			
C28H46N6O8S	Not Available	Not Available	626.765		Solid	Not Available						59297	CHEMBL1201779	26331550			HMDB0015032					PA164754810	45266800	46505002		19079	DAP001314	Benzylpenicilloyl_polylysine		Pre-pen	Benzylpenicilloyl polylysine	Approved	DB00895	InChI=1S/C22H32N4O6S.C6H14N2O2/c1-22(2)17(21(31)32)26-19(33-22)16(25-15(27)12-13-8-4-3-5-9-13)18(28)24-11-7-6-10-14(23)20(29)30;7-4-2-1-3-5(8)6(9)10/h3-5,8-9,14,16-17,19,26H,6-7,10-12,23H2,1-2H3,(H,24,28)(H,25,27)(H,29,30)(H,31,32);5H,1-4,7-8H2,(H,9,10)/t14-,16?,17+,19-;5-/m11/s1	IMPVZRLKKKXMKQ-SGDOCVTFSA-N	3	Benzylpenicilloyl polylysine is a penicillin derivative used to determine penicillin allergies.	Symptoms of overdose include urticaria, generalized pruritus, local swelling, generalized flushing, anaphylaxis, bronchospasm, fainting and maculopapular eruption.	Small Molecule																														-0.8					0	No	8	6	No	2	0	170.85 Å2	50.31 Å3	122.22 m3·mol-1	17	No	No	0.0658 mg/mL	-3.8	-3.9	2.04	9.53	P30273;!P12319	FCER1G;!FCER1A	1. High affinity immunoglobulin epsilon receptor subunit gamma;!2. High affinity immunoglobulin epsilon receptor subunit alpha
C38H50N6O5	The systemic clearance of saquinavir is approximately 1.14 L/h/kg following intravenous administration.6	Not Available	670.8408	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C	Solid	The steady-state volume of distribution of saquinavir is approximately 700 L, suggesting extensive distribution into tissues.6					519	63621	CHEMBL114	390016	Drugs.com Drug Page				D00429	ROC		PA451305	441243	46508726	RxList Drug Page	83395	DAP000171	Saquinavir	ZINC000003914596	Invirase	Saquinavir	Approved, Investigational	DB01232	InChI=1S/C38H50N6O5/c1-38(2,3)43-37(49)32-20-26-14-7-8-15-27(26)22-44(32)23-33(45)30(19-24-11-5-4-6-12-24)41-36(48)31(21-34(39)46)42-35(47)29-18-17-25-13-9-10-16-28(25)40-29/h4-6,9-13,16-18,26-27,30-33,45H,7-8,14-15,19-23H2,1-3H3,(H2,39,46)(H,41,48)(H,42,47)(H,43,49)/t26-,27+,30-,31-,32-,33+/m0/s1	QWAXKHKRTORLEM-UGJKXSETSA-N	4	Saquinavir is an HIV protease inhibitor used in combination with other antiretroviral agents for the treatment of HIV-1 with advanced immunodeficiency.	The oral LD50 of saquinavir in both rats and mice is >5 g/kg.8 Data regarding overdose with saquinavir are limited.6 No acute toxicities or sequelae were noted in a patient ingesting 8 grams of saquinavir as a single dose, and a second subject ingesting 2.4 grams as a single dose experienced throat pain that lasted for 6 hours and subsequently resolved.6 Treatment of overdose should consist of symptomatic and supportive measures. Dialysis is unlikely to be of benefit given saquinavir's extensive protein-binding.6	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.6007 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor		-6.26			3.8		349.84 °C		Insoluble	0	No	7	5	Yes	5	1	166.75 Å2	73.76 Å3	186.67 m3·mol-1	13	No	No	0.00247 mg/mL	3.16	-5.4	13.61	8.47	Q72874	pol	1. Human immunodeficiency virus type 1 protease
C45H69N11O12S	Not Available	40 minutes	988.161	[H][C@]1(NC(=O)[C@H](CC2=CC=C(OC)C=C2)NC(=O)CCCSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)[C@@H](C)CC	Solid	Not Available					50044677	59204	CHEMBL3301668	16736854			HMDB0015402		D07229			PA164743086	16681432	46509009			DAP000269	Carbetocin	ZINC000150338703	Duratocin	Carbetocin	Approved, Investigational	DB01282	InChI=1S/C45H69N11O12S/c1-6-25(4)38-44(66)51-28(15-16-34(46)57)40(62)52-31(21-35(47)58)41(63)54-32(23-69-18-8-10-37(60)50-30(42(64)55-38)20-26-11-13-27(68-5)14-12-26)45(67)56-17-7-9-33(56)43(65)53-29(19-24(2)3)39(61)49-22-36(48)59/h11-14,24-25,28-33,38H,6-10,15-23H2,1-5H3,(H2,46,57)(H2,47,58)(H2,48,59)(H,49,61)(H,50,60)(H,51,66)(H,52,62)(H,53,65)(H,54,63)(H,55,64)/t25-,28-,29-,30-,31-,32-,33-,38-/m0/s1	NSTRIRCPWQHTIA-DTRKZRJBSA-N	4	Carbetocin is an oxytocin agent used to control postpartum hemorrhage and bleeding after giving birth.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	3.2094 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor					-2					0	No	12	10	Yes	3	0	362.51 Å2	101.2 Å3	250.18 m3·mol-1	18	No	No	0.0265 mg/mL	-3.6	-4.6	11.42		P30559	OXTR	1. Oxytocin receptor
C37H48N4O5	The estimated apparent clearance following oral administration is approximately 6-7 L/h.3,10	The elimination half-life of lopinavir is 6.9 ± 2.2 hours.7	628.8008	CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1	Solid	The volume of distribution of lopinavir following oral administration is approximately 16.9 L.7					50180655	31781	CHEMBL729	83706			HMDB0015539	C12871	D01425	AB1	PDRhealth Drug Page	PA450264	92727	46508588	RxList Drug Page	195088	DAP000708	Lopinavir	ZINC000003951740	Kaletra	Lopinavir	Approved	DB01601	InChI=1S/C37H48N4O5/c1-25(2)34(41-20-12-19-38-37(41)45)36(44)39-30(21-28-15-7-5-8-16-28)23-32(42)31(22-29-17-9-6-10-18-29)40-33(43)24-46-35-26(3)13-11-14-27(35)4/h5-11,13-18,25,30-32,34,42H,12,19-24H2,1-4H3,(H,38,45)(H,39,44)(H,40,43)/t30-,31-,32-,34-/m0/s1	KJHKTHWMRKYKJE-SUGCFTRWSA-N	4	Lopinavir is an HIV-1 protease inhibitor used in combination with ritonavir to treat human immunodeficiency virus (HIV) infection.	As lopinavir is only available in combination with ritonavir, experience with acute lopinavir overdose in isolation is limited. The risk related to overdose appears more pronounced in pediatric patients. One case report detailed a fatal cardiogenic shock in a 2.1kg infant following an approximately 10-fold overdose of Kaletra oral solution, while other reported reactions to overdose in infants include complete AV block, cardiomyopathy, lactic acidosis, and acute renal failure. The oral Kaletra solution is highly concentrated, posing a greater risk of overdose, and contains approximately 42% (v/v) ethanol, further increasing risk in children and infants.7There is no antidote for lopinavir overdose. Treatment of overdose should consist largely of supportive measures and close observation of vital signs and clinical status of the affected patient. Consideration should be given to the removal of unabsorbed drug using gastric lavage or activated charcoal, if clinically indicated. Dialysis is unlikely to be of benefit as lopinavir is highly protein-bound, but may help to remove ethanol and propylene glycol from the circulation in the case of overdose with Kaletra oral solution.7	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	-	Inhibitor	Inhibitor	Substrate	2.2503 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor									Practically insoluble	0	No	5	4	Yes	4	0	120 Å2	68.78 Å3	179.36 m3·mol-1	15	No	No	0.00192 mg/mL	4.69	-5.5	13.39	-1.5	Q72874	pol	1. Human immunodeficiency virus type 1 protease
C31H41N7O6	Not Available	Not Available	607.712	CC(C)C[C@H](NC(=O)[C@@H](NC(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O)C1CCNC(=N)N1)C(=O)N[C@@H](CC1=CC=CC=C1)C=O	Solid	Not Available					87059		CHEMBL247767	391398				C11308					5287931	46507872							Chymostatin	Experimental	DB01683	InChI=1S/C31H41N7O6/c1-19(2)15-24(27(40)34-22(18-39)16-20-9-5-3-6-10-20)35-28(41)26(23-13-14-33-30(32)36-23)38-31(44)37-25(29(42)43)17-21-11-7-4-8-12-21/h3-12,18-19,22-26H,13-17H2,1-2H3,(H,34,40)(H,35,41)(H,42,43)(H3,32,33,36)(H2,37,38,44)/t22-,23?,24-,25-,26-/m0/s1	MRXDGVXSWIXTQL-HYHFHBMOSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.5130 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	9	8	Yes	3	0	201.61 Å2	61.91 Å3	171.93 m3·mol-1	15	No	No	0.0182 mg/mL	-0.39	-4.5	3.41	10.99	Q8RJN5	pam	1. Peptide amidase
C25H38N3O10P	Not Available	Not Available	571.5571	CN(CCCC1CCCCC1)C(=O)[C@H](CCC(O)=O)NC(=O)N(CC(O)=O)CC1=CC=C(OP(O)(O)=O)C=C1	Solid	Not Available					50060737		CHEMBL420910	395343						UR2			448585	46504571					ZINC000014880066		4-[3-carboxymethyl-3-(4-phosphonooxy-benzyl)-ureido]-4-[(3-cyclohexyl-propyl)-methyl-carbamoyl]butyric acid	Experimental	DB01773	InChI=1S/C25H38N3O10P/c1-27(15-5-8-18-6-3-2-4-7-18)24(33)21(13-14-22(29)30)26-25(34)28(17-23(31)32)16-19-9-11-20(12-10-19)38-39(35,36)37/h9-12,18,21H,2-8,13-17H2,1H3,(H,26,34)(H,29,30)(H,31,32)(H2,35,36,37)/t21-/m0/s1	JSBQUMXQEBZYPW-NRFANRHFSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.4811 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										0	No	9	5	No	2	-4	194.01 Å2	57.06 Å3	139.39 m3·mol-1	15	No	No	0.00321 mg/mL	1.81	-5.2	1.78	-2.5	P63185	V-SRC	1. Tyrosine-protein kinase transforming protein Src
C30H41N3O10P2	Not Available	Not Available	665.6082	CC(=O)N[C@@H](CC1=CC=C(C(=C1)P(O)(O)=O)P(O)(O)=O)C(=O)N[C@H]1CCCCC2=CC(OCC3CCCCC3)=C(C=C12)C(N)=O	Solid	Not Available								393168						CC1			445561	46506466					ZINC000003976478		AP-22408	Experimental	DB01830	InChI=1S/C30H41N3O10P2/c1-18(34)32-25(13-20-11-12-27(44(37,38)39)28(14-20)45(40,41)42)30(36)33-24-10-6-5-9-21-15-26(23(29(31)35)16-22(21)24)43-17-19-7-3-2-4-8-19/h11-12,14-16,19,24-25H,2-10,13,17H2,1H3,(H2,31,35)(H,32,34)(H,33,36)(H2,37,38,39)(H2,40,41,42)/t24-,25-/m0/s1	SPSGYTWOIGAABK-DQEYMECFSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.5116 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										0	No	10	7	Yes	4	-3	225.58 Å2	66.63 Å3	166.34 m3·mol-1	11	No	No		0.54		1.27	-0.81	P06239	LCK	1. Tyrosine-protein kinase Lck
C24H27N3O7S	Not Available	Not Available	501.552	[H][C@](N)(CCC(=O)N[C@@]([H])(CS[C@]1([H])C2=CC=CC=C2C2=CC=CC=C2[C@@]1([H])O)C(=O)NCC(O)=O)C(O)=O	Solid	Not Available								395916						GPR			449366	46504778					ZINC000015685338		(9R,10R)-9-(S-glutathionyl)-10-hydroxy-9,10-dihydrophenanthrene	Experimental	DB01834	InChI=1S/C24H27N3O7S/c25-17(24(33)34)9-10-19(28)27-18(23(32)26-11-20(29)30)12-35-22-16-8-4-2-6-14(16)13-5-1-3-7-15(13)21(22)31/h1-8,17-18,21-22,31H,9-12,25H2,(H,26,32)(H,27,28)(H,29,30)(H,33,34)/t17-,18-,21+,22+/m0/s1	JNNIZILNBMPOAC-MOXQZVSFSA-N			Not Available	Small Molecule																																			0	No	8	6	Yes	3	-1	179.05 Å2	50.25 Å3	127.88 m3·mol-1	11	No	No	0.031 mg/mL	-2.2	-4.2	1.8	9.31	P09211;!P09488	GSTP1;!GSTM1	1. Glutathione S-transferase P;!2. Glutathione S-transferase Mu 1
C21H30N4O5S2	Not Available	Not Available	482.617	[H][C@@](CCSC)(NC(=O)[C@]1([H])CCCN1C(=O)[C@]([H])(CC1=CC=C(O)C=C1)NC(=O)CS)C(N)=O	Solid	Not Available								4451333						SD2			5289343	46506367					ZINC000033821516		N-(Sulfanylacetyl)Tyrosylprolylmethioninamide	Experimental	DB01883	InChI=1S/C21H30N4O5S2/c1-32-10-8-15(19(22)28)24-20(29)17-3-2-9-25(17)21(30)16(23-18(27)12-31)11-13-4-6-14(26)7-5-13/h4-7,15-17,26,31H,2-3,8-12H2,1H3,(H2,22,28)(H,23,27)(H,24,29)/t15-,16-,17-/m0/s1	LNLWXWOYQHAKTD-ULQDDVLXSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.4015 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	5	5	No	2	0	141.83 Å2	49.33 Å3	125.56 m3·mol-1	11	Yes	No	0.0197 mg/mL	-0.14	-4.4	9.17	-3.4	P15917	lef	1. Lethal factor
C25H33N3O5	Not Available	Not Available	455.5466	[H][C@@](CO)(CC1=CC=CC=C1)NC(=O)[C@@]([H])(NC(=O)[C@]([H])(C)NC(=O)OCC1=CC=CC=C1)C(C)C	Solid	Not Available								392362									444425	46508148					ZINC000015284458		Tl-3-093	Experimental	DB01891	InChI=1S/C25H33N3O5/c1-17(2)22(24(31)27-21(15-29)14-19-10-6-4-7-11-19)28-23(30)18(3)26-25(32)33-16-20-12-8-5-9-13-20/h4-13,17-18,21-22,29H,14-16H2,1-3H3,(H,26,32)(H,27,31)(H,28,30)/t18-,21-,22-/m0/s1	QLOIOASGERKBSU-NYVOZVTQSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1277 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	4	No	2	0	116.76 Å2	48.58 Å3	124.52 m3·mol-1	12	Yes	No	0.00941 mg/mL	2.73	-4.7	12.46	-2.8	P16088;!P03366	pol;!gag-pol	1. Pol polyprotein;!2. Gag-Pol polyprotein
C32H36N3O9P	Not Available	Not Available	637.6167	CC(=O)N[C@@H](CC1=CC=C(OCC(O)=O)C(=C1)P(O)(O)=O)C(=O)N[C@H]1CCCCN(CC2=CC=C(C=C2)C2=CC=CC=C2)C1=O	Solid	Not Available					14695		CHEMBL436462	4449878						493			5287515	46507938					ZINC000027559719		RU85493	Experimental	DB01908	InChI=1S/C32H36N3O9P/c1-21(36)33-27(17-23-12-15-28(44-20-30(37)38)29(18-23)45(41,42)43)31(39)34-26-9-5-6-16-35(32(26)40)19-22-10-13-25(14-11-22)24-7-3-2-4-8-24/h2-4,7-8,10-15,18,26-27H,5-6,9,16-17,19-20H2,1H3,(H,33,36)(H,34,39)(H,37,38)(H2,41,42,43)/t26-,27-/m0/s1	MWEWSHNGVWABKG-SVBPBHIXSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.5594 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										0	No	9	5	Yes	4	-3	182.57 Å2	65.46 Å3	164.35 m3·mol-1	12	No	No		1.63		1.61	-1.9	P12931	SRC	1. Proto-oncogene tyrosine-protein kinase Src
C42H60N6O11	Not Available	Not Available	824.973	CC(C)CCCCCCCCC(=O)N(C)[C@H](CO)C(=O)N[C@H](C)C(=O)NCC(=O)N(C)[C@H]1C2=CC(=C(O)C=C2)C2=CC(C[C@H](NC(=O)[C@H](C)NC1=O)C(O)=O)=CC=C2O	Solid	Not Available							CHEMBL1231055	8163609									9988024	46509042				Arylomycin_A2	ZINC000085740056		Arylomycin A2	Experimental	DB01934	InChI=1S/C42H60N6O11/c1-24(2)13-11-9-7-8-10-12-14-35(52)47(5)32(23-49)40(56)44-25(3)38(54)43-22-36(53)48(6)37-28-16-18-34(51)30(21-28)29-19-27(15-17-33(29)50)20-31(42(58)59)46-39(55)26(4)45-41(37)57/h15-19,21,24-26,31-32,37,49-51H,7-14,20,22-23H2,1-6H3,(H,43,54)(H,44,56)(H,45,57)(H,46,55)(H,58,59)/t25-,26+,31+,32-,37+/m1/s1	YFSXYWAZCKMYJN-JBBOGOJTSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.7802 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										0	No	11	8	Yes	3	-1	255.01 Å2	88.58 Å3	216.78 m3·mol-1	18	No	No	0.00815 mg/mL	2.02	-5	3.54	-2.8	P00803	lepB	1. Signal peptidase I
C38H57N7O10	Not Available	Not Available	771.9001	NC(N)=NCCC[C@H](NC(=O)C(=O)[C@@H](CC1CCCCC1)NC(=O)OCC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1CCCCC1)C(O)=O	Solid	Not Available								16743946						DKT			17753951	46507473					ZINC000098208801		(4S)-5-[[(1S)-1-Carboxy-2-cyclohexylethyl]amino]-4-[[(2S)-2-[[(3R)-4-cyclohexyl-2-oxo-3-(phenylmethoxycarbonylamino)butanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-oxopentanoic acid	Experimental	DB01984	InChI=1S/C38H57N7O10/c39-37(40)41-20-10-17-27(33(49)42-28(18-19-31(46)47)34(50)44-30(36(52)53)22-25-13-6-2-7-14-25)43-35(51)32(48)29(21-24-11-4-1-5-12-24)45-38(54)55-23-26-15-8-3-9-16-26/h3,8-9,15-16,24-25,27-30H,1-2,4-7,10-14,17-23H2,(H,42,49)(H,43,51)(H,44,50)(H,45,54)(H,46,47)(H,52,53)(H4,39,40,41)/t27-,28-,29+,30-/m0/s1	LKCWMWZIRUHWBW-ZXYZSCNASA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Inhibitor	Substrate	2.4223 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										0	No	12	8	Yes	3	-1	281.7 Å2	82.45 Å3	198.69 m3·mol-1	23	No	No	0.0106 mg/mL	1.2	-4.9	3.27	10.76			
C14H25N3O6S	Not Available	Not Available	363.43	CC(C)[C@@H](NC(=O)[C@H](CS)NC(=O)CCC[C@H](N)C(O)=O)C(O)=O	Solid	Not Available						28496	CHEMBL70421	395032				C05556		ACV			448130	46506598		1551571			ZINC000003873037		ACV tripeptide	Experimental	DB02025	InChI=1S/C14H25N3O6S/c1-7(2)11(14(22)23)17-12(19)9(6-24)16-10(18)5-3-4-8(15)13(20)21/h7-9,11,24H,3-6,15H2,1-2H3,(H,16,18)(H,17,19)(H,20,21)(H,22,23)/t8-,9-,11+/m0/s1	BYEIJZFKOAXBBV-ATZCPNFKSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.8780 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	7	6	No	0	-1	158.82 Å2	36.7 Å3	87.21 m3·mol-1	11	No	No	0.478 mg/mL	-3	-2.9	1.94	9.15			
C30H37N9O13	Not Available	Not Available	731.6673	[H]N([H])C1=NC(=O)C2=C(N([H])C[C@H](CN([H])C3=CC=C(C=C3)C(=O)N([H])[C@@H](CCC(=O)N([H])[C@@H](CCC(=O)N([H])[C@@H](CCC(O)=O)C(O)=O)C(O)=O)C(O)=O)N2C=O)N1[H]	Solid	Not Available							CHEMBL1236268	4883456						TGF			6323515	46506661					ZINC000055398661		Triglu-5-formyl-tetrahydrofolate	Experimental	DB02067	InChI=1S/C30H37N9O13/c31-30-37-24-23(26(46)38-30)39(13-40)16(12-33-24)11-32-15-3-1-14(2-4-15)25(45)36-19(29(51)52)6-9-21(42)34-17(27(47)48)5-8-20(41)35-18(28(49)50)7-10-22(43)44/h1-4,13,16-19,32H,5-12H2,(H,34,42)(H,35,41)(H,36,45)(H,43,44)(H,47,48)(H,49,50)(H,51,52)(H4,31,33,37,38,46)/t16-,17-,18-,19-/m0/s1	ZLOMJLIQXBKNHU-VJANTYMQSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.4031 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	18	11	Yes	3	-4	348.35 Å2	69.92 Å3	182.64 m3·mol-1	19	No	No	0.39 mg/mL	-5.8	-3.3	2.34	4.71	P34896	SHMT1	1. Serine hydroxymethyltransferase, cytosolic
C18H30N8O6S	Not Available	Not Available	486.546	CCNC1=NC(SC[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)NCC(O)=O)=NC(NC(C)C)=N1	Solid	Not Available								4450024						ATA			5287712	46506861					ZINC000012501645		Glutathione S-atrazine	Experimental	DB02146	InChI=1S/C18H30N8O6S/c1-4-20-16-24-17(22-9(2)3)26-18(25-16)33-8-11(14(30)21-7-13(28)29)23-12(27)6-5-10(19)15(31)32/h9-11H,4-8,19H2,1-3H3,(H,21,30)(H,23,27)(H,28,29)(H,31,32)(H2,20,22,24,25,26)/t10-,11-/m0/s1	WDLCRTLULMGVMR-QWRGUYRKSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.4883 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	12	7	No	1	-1	221.55 Å2	49.47 Å3	124.3 m3·mol-1	15	No	No	0.189 mg/mL	-6.6	-3.4	-6.9	9.31			
C35H42N8O15	Not Available	Not Available	814.7526	NC1=NC(=O)C2=C(NC=C2CCC2=CC=C(C=C2)C(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)NC(CCC(O)=O)C(O)=O)C(O)=O)C(O)=O)C(O)=O)N1	Solid	Not Available								64873357						LYB			131704196	46508632							LY231514 tetra glu	Experimental	DB02223	InChI=1S/C35H42N8O15/c36-35-42-28-27(30(50)43-35)18(15-37-28)6-3-16-1-4-17(5-2-16)29(49)41-22(34(57)58)9-13-25(46)39-20(32(53)54)7-11-23(44)38-19(31(51)52)8-12-24(45)40-21(33(55)56)10-14-26(47)48/h1-2,4-5,15,19-22H,3,6-14H2,(H,38,44)(H,39,46)(H,40,45)(H,41,49)(H,47,48)(H,51,52)(H,53,54)(H,55,56)(H,57,58)(H4,36,37,42,43,50)/t19-,20-,21?,22-/m0/s1	DICHBVJYDUDAIQ-QEGIFBSNSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.4984 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	18	12	Yes	3	-5	386.17 Å2	80.24 Å3	193.71 m3·mol-1	24	No	No	0.0492 mg/mL	-1.2	-4.2	2.81		P0A884	thyA	1. Thymidylate synthase
C23H27N3O6	Not Available	Not Available	441.477	[H]N([H])C(=O)[C@H](CC(O)=O)N([H])C(=O)[C@H](CC1=CC=CC=C1)N([H])[C@@H](CCC1=CC=CC=C1)C(O)=O	Solid	Not Available								395515						HPI			448836	46508508					ZINC000012501888		N-(1-carboxy-3-phenylpropyl)phenylalanyl-alpha-asparagine	Experimental	DB02307	InChI=1S/C23H27N3O6/c24-21(29)18(14-20(27)28)26-22(30)19(13-16-9-5-2-6-10-16)25-17(23(31)32)12-11-15-7-3-1-4-8-15/h1-10,17-19,25H,11-14H2,(H2,24,29)(H,26,30)(H,27,28)(H,31,32)/t17-,18-,19-/m0/s1	FOJUHLDAXGNCIP-FHWLQOOXSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.8533 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	5	No	2	-1	158.82 Å2	45.22 Å3	114.84 m3·mol-1	13	Yes	No	0.0139 mg/mL	-1.1	-4.5	3.1	7.81	P14756	lasB	1. Pseudolysin
C31H41FN4O7	Not Available	Not Available	600.688	[H]N([C@H](CCC(=O)OCC)C[C@@H]1CCN([H])C1=O)C(=O)[C@H](CC(=O)[C@@H](N([H])C(=O)C1=NOC(C)=C1)C(C)C)CC1=CC=C(F)C=C1	Solid	Not Available														AG7			6323208	46505563							Ethyl (4R)-4-{[(2R,5S)-2-(4-fluorobenzyl)-6-methyl-5-{[(5-methyl-1,2-oxazol-3-yl)carbonyl]amino}-4-oxoheptanoyl]amino}-5-[(3S)-2-oxo-3-pyrrolidinyl]pentanoate	Experimental	DB02313	InChI=1S/C31H41FN4O7/c1-5-42-27(38)11-10-24(16-21-12-13-33-29(21)39)34-30(40)22(15-20-6-8-23(32)9-7-20)17-26(37)28(18(2)3)35-31(41)25-14-19(4)43-36-25/h6-9,14,18,21-22,24,28H,5,10-13,15-17H2,1-4H3,(H,33,39)(H,34,40)(H,35,41)/t21-,22-,24+,28-/m0/s1	LMIUALQNZXJHOG-ROJPAJKQSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.6602 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	6	3	Yes	3	0	156.7 Å2	62.27 Å3	156.3 m3·mol-1	17	No	No	0.04 mg/mL	2.82	-4.2	12.5	-0.56	P04936	Not Available	1. Genome polyprotein
C28H43N5O23P2	Not Available	Not Available	879.6082	C[C@H](NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@H](OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)N2C=CC(=O)NC2=O)[C@@H]1NC(C)=O)C(=O)N[C@H](CCC(O)=O)C(O)=O	Solid	Not Available						46143		396037				C00692		UAG			449538	46505208					ZINC000096068408		Uridine-5'-Diphosphate-N-Acetylmuramoyl-L-Alanine-D-Glutamate	Experimental	DB02314	InChI=1S/C28H43N5O23P2/c1-10(23(42)31-13(26(44)45)4-5-17(37)38)29-24(43)11(2)52-22-18(30-12(3)35)27(54-14(8-34)20(22)40)55-58(49,50)56-57(47,48)51-9-15-19(39)21(41)25(53-15)33-7-6-16(36)32-28(33)46/h6-7,10-11,13-15,18-22,25,27,34,39-41H,4-5,8-9H2,1-3H3,(H,29,43)(H,30,35)(H,31,42)(H,37,38)(H,44,45)(H,47,48)(H,49,50)(H,32,36,46)/t10-,11+,13+,14+,15+,18+,19+,20+,21+,22+,25+,27+/m0/s1	OJZCATPXPWFLHF-HPUCEMLMSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.3272 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										0	No	20	12	Yes	3	-4	422.21 Å2	76.18 Å3	178.27 m3·mol-1	20	No	No	9.13 mg/mL	-6	-2	1.73		P22188;!P14900	murE;!murD	1. UDP-N-acetylmuramoyl-L-alanyl-D-glutamate--2,6-diaminopimelate ligase;!2. UDP-N-acetylmuramoylalanine--D-glutamate ligase
C38H62N6O8	Not Available	Not Available	730.9343	CC(C)C[C@H](NC(=O)[C@@H]1CC(=O)NCCCCCCOC(=O)N[C@@H](C(C)C)C(=O)N1)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)NCC1=CC=CC=C1	Solid	Not Available					16271		CHEMBL362592	395809						MMI			449218	46506044					ZINC000028353688		MMI-175	Experimental	DB02378	InChI=1S/C38H62N6O8/c1-23(2)19-28(30(45)20-26(7)34(47)43-32(24(3)4)36(49)40-22-27-15-11-10-12-16-27)41-35(48)29-21-31(46)39-17-13-8-9-14-18-52-38(51)44-33(25(5)6)37(50)42-29/h10-12,15-16,23-26,28-30,32-33,45H,8-9,13-14,17-22H2,1-7H3,(H,39,46)(H,40,49)(H,41,48)(H,42,50)(H,43,47)(H,44,51)/t26-,28+,29+,30+,32+,33+/m1/s1	QJAPFAZHNSZLJE-CWURXVSKSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.6249 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	7	7	No	2	0	204.06 Å2	79.71 Å3	195.87 m3·mol-1	14	No	No	0.0155 mg/mL	2.78	-4.7	11.17	-0.79	P56817	BACE1	1. Beta-secretase 1
C27H33N3O9	Not Available	Not Available	543.5656	CCCCCNC(=O)[C@H](CC1=CC=C(OC(C(O)=O)C(O)=O)C=C1)NC(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O	Solid	Not Available					13613			393320						INZ			445784	46506177					ZINC000003874712		{4-[(2S)-2-({[(1S)-1-Carboxy-2-phenylethyl]carbamoyl}amino)-3-oxo-3-(pentylamino)propyl]phenoxy}malonic acid	Experimental	DB02436	InChI=1S/C27H33N3O9/c1-2-3-7-14-28-23(31)20(15-18-10-12-19(13-11-18)39-22(25(34)35)26(36)37)29-27(38)30-21(24(32)33)16-17-8-5-4-6-9-17/h4-6,8-13,20-22H,2-3,7,14-16H2,1H3,(H,28,31)(H,32,33)(H,34,35)(H,36,37)(H2,29,30,38)/t20-,21-/m0/s1	BKONADSQADEJJP-SFTDATJTSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.4279 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	9	6	No	2	-3	191.36 Å2	55.78 Å3	137.05 m3·mol-1	16	No	No	0.00567 mg/mL	2.99	-5	2.32		P18031	PTPN1	1. Tyrosine-protein phosphatase non-receptor type 1
C33H52N6O4	Not Available	Not Available	596.8038	CC1=NC=CN1CCCCC1=CC=C(CC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)NCCC2CCCCC2)C=C1	Solid	Not Available					50034993		CHEMBL6269	393759						MIM			446385	46504453					ZINC000014880363		N-({4-[4-(2-Methyl-1H-imidazol-1-yl)butyl]phenyl}acetyl)-L-seryl-N-(2-cyclohexylethyl)-L-lysinamide	Experimental	DB02477	InChI=1S/C33H52N6O4/c1-25-35-20-22-39(25)21-8-6-11-27-13-15-28(16-14-27)23-31(41)37-30(24-40)33(43)38-29(12-5-7-18-34)32(42)36-19-17-26-9-3-2-4-10-26/h13-16,20,22,26,29-30,40H,2-12,17-19,21,23-24,34H2,1H3,(H,36,42)(H,37,41)(H,38,43)/t29-,30-/m0/s1	WHLPIOSHBKQGHA-KYJUHHDHSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3197 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										0	No	6	5	Yes	3	2	151.37 Å2	68.48 Å3	168.82 m3·mol-1	19	No	No	0.00299 mg/mL	2.39	-5.3	12.2	10.2	P30418	NMT1	1. Glycylpeptide N-tetradecanoyltransferase
C34H66N12O10S2	Not Available	Not Available	867.092	[H]N([H])CCCCN([H])CCCN([H])C(=O)CN([H])C(=O)[C@H](CSSC[C@H](N([H])C(=O)CC[C@@H](N([H])[H])C(O)=O)C(=O)N([H])CC(=O)N([H])CCCN([H])CCCCN([H])[H])N([H])C(=O)CC[C@@H](N([H])[H])C(O)=O	Solid	Not Available								396047						TS4			449555	46505065					ZINC000195757935		Glutathionylspermidine disulfide	Experimental	DB02553	InChI=1S/C34H66N12O10S2/c35-11-1-3-13-39-15-5-17-41-29(49)19-43-31(51)25(45-27(47)9-7-23(37)33(53)54)21-57-58-22-26(46-28(48)10-8-24(38)34(55)56)32(52)44-20-30(50)42-18-6-16-40-14-4-2-12-36/h23-26,39-40H,1-22,35-38H2,(H,41,49)(H,42,50)(H,43,51)(H,44,52)(H,45,47)(H,46,48)(H,53,54)(H,55,56)/t23-,24-,25+,26+/m1/s1	HCMZDPYSWPSKSP-XPGKHFPBSA-N			Not Available	Small Molecule				AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.1658 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	16	14	No	0	4	377.34 Å2	94.37 Å3	220.19 m3·mol-1	37	No	No		-13		1.44	10.99	P00390	GSR	1. Glutathione reductase, mitochondrial
C33H42Cl2N8O4	Not Available	Not Available	685.644	CC(C)C[C@@H](N=C(N)N)C(=O)NCC(=O)N1CCC(CC1)C1=CC(=NN1C)C1=C(Cl)C(Cl)=C(OCC2=CC=C(NC(C)=O)C=C2)C=C1	Solid	Not Available								571220						FRI			656989	46506770					ZINC000053683837		SP4160	Experimental	DB02555	InChI=1S/C33H42Cl2N8O4/c1-19(2)15-26(40-33(36)37)32(46)38-17-29(45)43-13-11-22(12-14-43)27-16-25(41-42(27)4)24-9-10-28(31(35)30(24)34)47-18-21-5-7-23(8-6-21)39-20(3)44/h5-10,16,19,22,26H,11-15,17-18H2,1-4H3,(H,38,46)(H,39,44)(H4,36,37,40)/t26-/m1/s1	VCXMTWSYQSVWRK-AREMUKBSSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.6710 LD50, mol/kg	Inhibitor	Weak inhibitor	Inhibitor										0	No	8	4	Yes	4	1	169.96 Å2	72.99 Å3	194.97 m3·mol-1	12	No	No	0.00616 mg/mL	3.41	-5	12.79	10.6	P60568	IL2	1. Interleukin-2
C15H26N4O7	Not Available	Not Available	374.3895	[H]N([H])CC(=O)N([H])[C@@H](CCCCC(=O)N([H])[C@H](C)C(=O)N([H])[C@H](C)C(O)=O)C(O)=O	Solid	Not Available								393699						REX			446306	46508348					ZINC000015599994		N-[(6S)-6-Carboxy-6-(glycylamino)hexanoyl]-D-alanyl-D-alanine	Experimental	DB02578	InChI=1S/C15H26N4O7/c1-8(13(22)18-9(2)14(23)24)17-11(20)6-4-3-5-10(15(25)26)19-12(21)7-16/h8-10H,3-7,16H2,1-2H3,(H,17,20)(H,18,22)(H,19,21)(H,23,24)(H,25,26)/t8-,9-,10+/m1/s1	RALBRZJHHGWNNU-BBBLOLIVSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	1.8059 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	8	6	No	0	-1	187.92 Å2	37.69 Å3	87.89 m3·mol-1	12	No	No	1.07 mg/mL	-4.9	-2.5	3.2	8.14	P15555	Not Available	1. D-alanyl-D-alanine carboxypeptidase
C19H28N2O4S	Not Available	Not Available	380.502	[H][C@@](C)(NC(=O)[C@]([H])(CC1=CC=CC=C1)NC(=O)[C@@]([H])(S)CCCCC)C(O)=O	Solid	Not Available								4451431						TI1			5289469	46505753			DNC001441		ZINC000006352218		[2(R,S)-2-Sulfanylheptanoyl]-Phe-Ala	Experimental	DB02597	InChI=1S/C19H28N2O4S/c1-3-4-6-11-16(26)18(23)21-15(12-14-9-7-5-8-10-14)17(22)20-13(2)19(24)25/h5,7-10,13,15-16,26H,3-4,6,11-12H2,1-2H3,(H,20,22)(H,21,23)(H,24,25)/t13-,15-,16-/m0/s1	GOIYKVXXGCPHQU-BPUTZDHNSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1308 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	4	No	1	-1	95.5 Å2	41.19 Å3	102.51 m3·mol-1	11	Yes	No	0.0104 mg/mL	3.01	-4.6	3.83	-3.4	P00800;!P43133;!P08473	npr;!nprS;!MME	1. Thermolysin;!2. Thermolysin;!3. Neprilysin
C52H74N16O15S2	Not Available	Not Available	1227.372	NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O	Solid	Not Available						135905	CHEMBL2135460	65067			HMDB0015569					PA164781020	72081	46504626		57048	DAP000058	Terlipressin			Terlipressin	Approved, Investigational	DB02638	InChI=1S/C52H74N16O15S2/c53-17-5-4-9-31(45(76)60-23-41(57)72)63-51(82)38-10-6-18-68(38)52(83)37-27-85-84-26-36(61-44(75)25-59-43(74)24-58-42(73)22-54)50(81)65-34(20-29-11-13-30(69)14-12-29)48(79)64-33(19-28-7-2-1-3-8-28)47(78)62-32(15-16-39(55)70)46(77)66-35(21-40(56)71)49(80)67-37/h1-3,7-8,11-14,31-38,69H,4-6,9-10,15-27,53-54H2,(H2,55,70)(H2,56,71)(H2,57,72)(H,58,73)(H,59,74)(H,60,76)(H,61,75)(H,62,78)(H,63,82)(H,64,79)(H,65,81)(H,66,77)(H,67,80)/t31-,32-,33-,34-,35-,36-,37-,38-/m0/s1	BENFXAYNYRLAIU-QSVFAHTRSA-N	4	Terlipressin is a drug used to treat bleeding caused by esophageal varices.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.9218 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										0	No	17	16	Yes	4	2	512.85 Å2	123.59 Å3	305.18 m3·mol-1	25	No	No	0.167 mg/mL	-10	-3.9	9.43	10.26	P30518;!P37288;!P47901	AVPR2;!AVPR1A;!AVPR1B	1. Vasopressin V2 receptor;!2. Vasopressin V1a receptor;!3. Vasopressin V1b receptor
C25H35N6O4	Not Available	Not Available	483.5832	[H]N([H])C(N([H])[H])=[N+]([H])CCC[C@H](N([H])C(=O)[C@H](CCC1=CC=CC=C1)N([H])[C@H](C)C(O)=O)C(=O)N([H])C1=CC=CC=C1	Solid	Not Available								4450760						8MI			5288637	46507423							Diamino-N-[(4S)-5-anilino-4-{[(2S)-2-{[(1R)-1-carboxyethyl]amino}-4-phenylbutanoyl]amino}-5-oxopentyl]methaniminium	Experimental	DB02747	InChI=1S/C25H34N6O4/c1-17(24(34)35)29-21(15-14-18-9-4-2-5-10-18)23(33)31-20(13-8-16-28-25(26)27)22(32)30-19-11-6-3-7-12-19/h2-7,9-12,17,20-21,29H,8,13-16H2,1H3,(H,30,32)(H,31,33)(H,34,35)(H4,26,27,28)/p+1/t17-,20+,21+/m1/s1	HDGWGGCPTVXRNA-QMMLZNLJSA-O			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.3141 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	7	7	No	2	1	173.54 Å2	51.92 Å3	144.99 m3·mol-1	14	No	No	0.00483 mg/mL	0.27	-5	7.46	10.87			
C18H23BrN4O7	Not Available	Not Available	487.302	[H]N(CCC(=O)N([H])[C@@]([H])(CO)C(=O)N([H])CCC1=CC=C(C=C1)N([H])C(=O)C(O)=O)C(=O)CBr	Solid	Not Available								25061011						FG1			49866981	46507801					ZINC000012502600		N-(Bromoacetyl)-beta-alanyl-N-(2-{4-[(carboxycarbonyl)amino]phenyl}ethyl)-L-serinamide	Experimental	DB02784	InChI=1S/C18H23BrN4O7/c19-9-15(26)20-8-6-14(25)23-13(10-24)16(27)21-7-5-11-1-3-12(4-2-11)22-17(28)18(29)30/h1-4,13,24H,5-10H2,(H,20,26)(H,21,27)(H,22,28)(H,23,25)(H,29,30)/t13-/m0/s1	IYAWTDCWUJJPHZ-ZDUSSCGKSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.1875 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	7	6	No	1	-1	173.93 Å2	44.1 Å3	109.47 m3·mol-1	12	No	No	0.0545 mg/mL	-1.3	-4	2.79	-2.4	P18031	PTPN1	1. Tyrosine-protein phosphatase non-receptor type 1
C30H37N6O15P	Not Available	Not Available	752.6197	[H]N([H])C1=NC(=O)C2=C(C=CC(CC(O)(CN([H])CC(=O)N([H])[C@@H]3O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]3O)C3=CC=C(C=C3)C(=O)N([H])[C@@H](CCC(O)=O)C(O)=O)=C2)N1[H]	Solid	Not Available								393847						138			446514	46508046					ZINC000098207915		(2S)-2-({4-[(2S)-1-(2-Amino-4-oxo-1,4-dihydro-6-quinazolinyl)-3-{[2-({(2R,3R,4S,5R)-3,4-dihydroxy-5-[(phosphonooxy)methyl]tetrahydro-2-furanyl}amino)-2-oxoethyl]amino}-2-hydroxy-2-propanyl]benzoyl}ami no)pentanedioic acid	Experimental	DB02794	InChI=1S/C30H37N6O15P/c31-29-34-18-6-1-14(9-17(18)26(43)36-29)10-30(46,16-4-2-15(3-5-16)25(42)33-19(28(44)45)7-8-22(38)39)13-32-11-21(37)35-27-24(41)23(40)20(51-27)12-50-52(47,48)49/h1-6,9,19-20,23-24,27,32,40-41,46H,7-8,10-13H2,(H,33,42)(H,35,37)(H,38,39)(H,44,45)(H2,47,48,49)(H3,31,34,36,43)/t19-,20+,23+,24+,27+,30+/m0/s1	QZUCAWXKEZPFBV-PRICPSHJSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.7383 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	18	12	Yes	4	-3	348.99 Å2	70.58 Å3	174.94 m3·mol-1	17	No	No	0.0905 mg/mL	-4.5	-3.9	1.21	8.14	P08179	purN	1. Phosphoribosylglycinamide formyltransferase
C20H26N6O4S	Not Available	Not Available	446.523	[H]N([H])C(=NCCC[C@H](N([H])C(=O)[C@@H]1C[C@@H](O)CN1C(C)=O)C(=O)C1=NC2=CC=CC=C2S1)N([H])[H]	Solid	Not Available					50228764		CHEMBL256892	4449928						ABB			5287596	46509114					ZINC000003916454		RWJ-56423	Experimental	DB02812	InChI=1S/C20H26N6O4S/c1-11(27)26-10-12(28)9-15(26)18(30)24-14(6-4-8-23-20(21)22)17(29)19-25-13-5-2-3-7-16(13)31-19/h2-3,5,7,12,14-15,28H,4,6,8-10H2,1H3,(H,24,30)(H4,21,22,23)/t12-,14+,15+/m1/s1	VXDAVYUFYPFGDX-SNPRPXQTSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.5098 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	8	4	Yes	3	1	164 Å2	46.34 Å3	113.74 m3·mol-1	8	Yes	No	0.144 mg/mL	-1.1	-3.5	12.27	11.05			
C18H31N3O6	Not Available	Not Available	385.4552	[H][C@](O)(CC(=O)N[C@]([H])(C(=O)N1CCC[C@@]1([H])C(O)=O)[C@@]([H])(C)CC)C(=O)NCCC	Solid	Not Available								4449798						074			5287408	46507264					ZINC000015894720		N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline	Experimental	DB02855	InChI=1S/C18H31N3O6/c1-4-8-19-16(24)13(22)10-14(23)20-15(11(3)5-2)17(25)21-9-6-7-12(21)18(26)27/h11-13,15,22H,4-10H2,1-3H3,(H,19,24)(H,20,23)(H,26,27)/t11-,12-,13-,15-/m0/s1	UDNIFTKCMDIXFC-ABHRYQDASA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.5003 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	6	4	No	1	-1	136.04 Å2	40.28 Å3	96.75 m3·mol-1	10	Yes	No	8.23 mg/mL	-0.29	-1.7	3.86	-2.3			
C17H25N3O5S	Not Available	Not Available	383.463	[H]N([H])CCCC(=O)N([H])[C@@H](CSCC1=CC=C(OC)C=C1)C(=O)N([H])CC(O)=O	Solid	Not Available	P08263	GSTA1	1. Glutathione S-transferase A1					394838						ABY			447867	46506921					ZINC000006484319		N-(4-Aminobutanoyl)-S-(4-methoxybenzyl)-L-cysteinylglycine	Experimental	DB02943	InChI=1S/C17H25N3O5S/c1-25-13-6-4-12(5-7-13)10-26-11-14(17(24)19-9-16(22)23)20-15(21)3-2-8-18/h4-7,14H,2-3,8-11,18H2,1H3,(H,19,24)(H,20,21)(H,22,23)/t14-/m0/s1	OMOPDEZZBQHMGS-AWEZNQCLSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1044 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	4	No	1	0	130.75 Å2	40.92 Å3	99.06 m3·mol-1	12	Yes	No		-2.6		3.36	9.99	P08263	GSTA1	1. Glutathione S-transferase A1
C18H33N3O6S	Not Available	Not Available	419.536	CCCCCCCCSC[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)NCC(O)=O	Solid	Not Available								391395				C11302		GTY			443115	46508495					ZINC000008234408		S-octylglutathione	Experimental	DB03032	InChI=1S/C18H33N3O6S/c1-2-3-4-5-6-7-10-28-12-14(17(25)20-11-16(23)24)21-15(22)9-8-13(19)18(26)27/h13-14H,2-12,19H2,1H3,(H,20,25)(H,21,22)(H,23,24)(H,26,27)/t13-,14-/m0/s1	MJWCZWAVSJZQNL-KBPBESRZSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1495 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	5	No	0	-1	158.82 Å2	45.91 Å3	106.09 m3·mol-1	17	Yes	No	0.0341 mg/mL	-1.5	-4.1	1.81	9.31	Q03013	GSTM4	1. Glutathione S-transferase Mu 4
C29H39N5O7S	Not Available	Not Available	601.714	COC1=C(C)C(C)=C(C(C)=C1)S(=O)(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](CC1=CC=C(C=C1)C(N)=N)C(=O)N1CCCCC1	Solid	Not Available							CHEMBL1231689	154815						CCR			177837	46508948					ZINC000003807259		[N-[N-(4-Methoxy-2,3,6-trimethylphenylsulfonyl)-L-aspartyl]-D-(4-amidino-phenylalanyl)]-piperidine	Experimental	DB03081	InChI=1S/C29H39N5O7S/c1-17-14-24(41-4)18(2)19(3)26(17)42(39,40)33-22(16-25(35)36)28(37)32-23(29(38)34-12-6-5-7-13-34)15-20-8-10-21(11-9-20)27(30)31/h8-11,14,22-23,33H,5-7,12-13,15-16H2,1-4H3,(H3,30,31)(H,32,37)(H,35,36)/t22-,23+/m0/s1	ZOXOKTJHZSUHRJ-XZOQPEGZSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.4430 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										0	No	9	5	Yes	3	0	191.98 Å2	60.38 Å3	168.66 m3·mol-1	11	No	No	0.0194 mg/mL	0.48	-4.5	3.42	11.47	P07477	PRSS1	1. Trypsin-1
C18H24N4O10S	Not Available	Not Available	488.469	[H]N([H])[C@@H](CCC(=O)N([H])[C@@H](CSC(O)OCC1=CC=C(C=C1)[N+]([O-])=O)C(=O)N([H])CC(O)=O)C(O)=O	Solid	Not Available								4450641						GNB			5288453	46508387							S-P-Nitrobenzyloxycarbonylglutathione	Experimental	DB03130	InChI=1S/C18H24N4O10S/c19-12(17(27)28)5-6-14(23)21-13(16(26)20-7-15(24)25)9-33-18(29)32-8-10-1-3-11(4-2-10)22(30)31/h1-4,12-13,18,29H,5-9,19H2,(H,20,26)(H,21,23)(H,24,25)(H,27,28)/t12-,13-,18?/m0/s1	QYFGPQQSJQOGEO-TVJRNMROSA-N			Not Available	Small Molecule				AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.5418 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	11	6	No	1	-1	231.42 Å2	46.28 Å3	112.39 m3·mol-1	15	No	No	0.286 mg/mL	-2.7	-3.2	1.76	9.31	Q04760	GLO1	1. Lactoylglutathione lyase
C32H33N3O6	Not Available	Not Available	555.6209	CC(=O)N[C@@H](CC1=CC(C=O)=C(C=C1)C(O)=O)C(=O)N[C@H]1CCCCN(CC2=CC=C(C=C2)C2=CC=CC=C2)C1=O	Solid	Not Available					14696		CHEMBL358866	4449823						197			5287443	46508717					ZINC000014880680		RU82197	Experimental	DB03268	InChI=1S/C32H33N3O6/c1-21(37)33-29(18-23-12-15-27(32(40)41)26(17-23)20-36)30(38)34-28-9-5-6-16-35(31(28)39)19-22-10-13-25(14-11-22)24-7-3-2-4-8-24/h2-4,7-8,10-15,17,20,28-29H,5-6,9,16,18-19H2,1H3,(H,33,37)(H,34,38)(H,40,41)/t28-,29-/m0/s1	WKTQBTSOHBKBRW-VMPREFPWSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3333 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	No	6	3	Yes	4	-1	132.88 Å2	60.24 Å3	154.46 m3·mol-1	10	No	No		3.24		4.15	-1.9	P12931	SRC	1. Proto-oncogene tyrosine-protein kinase Src
C17H34N6O5S	Not Available	Not Available	434.554	NCCCCNCCCNC(=O)CNC(=O)[C@H](CS)NC(=O)CC[C@H](N)C(O)=O	Solid	Not Available						16613		389641				C05730		TS5			440772	46505567					ZINC000003869959		Glutathionylspermidine	Experimental	DB03295	InChI=1S/C17H34N6O5S/c18-6-1-2-7-20-8-3-9-21-15(25)10-22-16(26)13(11-29)23-14(24)5-4-12(19)17(27)28/h12-13,20,29H,1-11,18-19H2,(H,21,25)(H,22,26)(H,23,24)(H,27,28)/t12-,13-/m0/s1	NEDQLXHBVHSKNV-STQMWFEESA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	1.9668 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	11	8	No	0	2	199.14 Å2	47.62 Å3	112.45 m3·mol-1	17	No	No		-8.3		1.87	10.89			
C20H32N6O12S2	Not Available	Not Available	612.631	N[C@@H](CCC(=O)N[C@@H](CSSC[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)NCC(O)=O)C(=O)NCC(O)=O)C(O)=O	Solid	Not Available					225231	17858	CHEMBL1372	58835				C00127	D00031	GDS			65359	46508372		25953		Glutathione_disulfide	ZINC000003870129	Bss Ophthalmic Solution	Glutathione disulfide	Approved, Experimental, Investigational	DB03310	InChI=1S/C20H32N6O12S2/c21-9(19(35)36)1-3-13(27)25-11(17(33)23-5-15(29)30)7-39-40-8-12(18(34)24-6-16(31)32)26-14(28)4-2-10(22)20(37)38/h9-12H,1-8,21-22H2,(H,23,33)(H,24,34)(H,25,27)(H,26,28)(H,29,30)(H,31,32)(H,35,36)(H,37,38)/t9-,10-,11-,12-/m0/s1	YPZRWBKMTBYPTK-BJDJZHNGSA-N	3	Glutathione disulfide is an ingredient of ophthalmic irrigation solutions used during ophthalmological procedures.	Not Available	Small Molecule				AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.0571 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	14	10	No	0	-2	317.64 Å2	58.47 Å3	136.65 m3·mol-1	21	No	No	0.406 mg/mL	-10	-3.2	1.44	9.61	BE0009997;!P10620;!BE0010006;!P28161;!P00390	;!MGST1;!;!GSTM2;!GSR	1. Glutathione peroxidase (Protein Group);!2. Microsomal glutathione S-transferase 1;!3. Glutathione S-transferases (Cytosolic) (Protein Group);!4. Glutathione S-transferase Mu 2;!5. Glutathione reductase, mitochondrial
C35H56N6O6	Not Available	Not Available	656.8557	COC1=CC=C(C[C@H](NC(=O)CC(C)(C)N)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC2CCCCC2)[C@@H](O)[C@@H](O)CC(C)C)C=C1	Solid	Not Available					50006202	4787	CHEMBL300337	54622				C07466	D03738				60594	46505948			DNC000604		ZINC000003920420		Enalkiren	Experimental	DB03395	InChI=1S/C35H56N6O6/c1-22(2)15-30(42)32(44)27(16-23-9-7-6-8-10-23)40-34(46)29(18-25-20-37-21-38-25)41-33(45)28(39-31(43)19-35(3,4)36)17-24-11-13-26(47-5)14-12-24/h11-14,20-23,27-30,32,42,44H,6-10,15-19,36H2,1-5H3,(H,37,38)(H,39,43)(H,40,46)(H,41,45)/t27-,28-,29-,30-,32+/m0/s1	KQXVERRYBYGQJZ-WRPDIKACSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.6931 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	8	7	Yes	3	1	191.69 Å2	72.63 Å3	180.16 m3·mol-1	18	No	No	0.0122 mg/mL	1.75	-4.7	12.03	9.58	P00797	REN	1. Renin
C32H42N4O7	Not Available	Not Available	594.6985	[H]N([C@@H](CC(C)C)C(=O)N([H])[C@@H]1CN(CC1=O)C(=O)[C@H](CC(C)C)N([H])C(=O)OCC1=CC=CC=C1)C(=O)OCC1=CC=CC=C1	Solid	Not Available								4451150						PCM			5289122	46506182					ZINC000014096696		N2-[(Benzyloxy)carbonyl]-N-[(3R)-1-{N-[(benzyloxy)carbonyl]-L-leucyl}-4-oxo-3-pyrrolidinyl]-L-leucinamide	Experimental	DB03405	InChI=1S/C32H42N4O7/c1-21(2)15-25(34-31(40)42-19-23-11-7-5-8-12-23)29(38)33-27-17-36(18-28(27)37)30(39)26(16-22(3)4)35-32(41)43-20-24-13-9-6-10-14-24/h5-14,21-22,25-27H,15-20H2,1-4H3,(H,33,38)(H,34,40)(H,35,41)/t25-,26-,27+/m0/s1	GXENQLUSOCKXDN-GMQQYTKMSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.7478 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										0	No	5	3	Yes	3	0	143.14 Å2	64.46 Å3	158.89 m3·mol-1	15	No	No	0.0045 mg/mL	4.28	-5.1	12.3	-3.4			
C18H33N7O5	Not Available	Not Available	427.4985	[H]N([H])C(=NCCC[C@@H](C=O)[C@H](N([H])C(=O)N1CCN(CC1)C(=O)N([H])C(C)(C)C)C(O)=O)N([H])[H]	Solid	Not Available								4883305						169			6323182	46509093					ZINC000012503583		(2S,3R)-2-[[4-(Tert-butylcarbamoyl)piperazine-1-carbonyl]amino]-6-(diaminomethylideneamino)-3-formylhexanoic acid	Experimental	DB03417	InChI=1S/C18H33N7O5/c1-18(2,3)23-17(30)25-9-7-24(8-10-25)16(29)22-13(14(27)28)12(11-26)5-4-6-21-15(19)20/h11-13H,4-10H2,1-3H3,(H,22,29)(H,23,30)(H,27,28)(H4,19,20,21)/t12-,13-/m0/s1	BVNQCAHTTOIOEK-STQMWFEESA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.5279 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	8	5	No	1	0	183.45 Å2	44.39 Å3	109.01 m3·mol-1	9	Yes	No		-3.6		3.43	11.57	P07477	PRSS1	1. Trypsin-1
C13H21N3O6S	Not Available	Not Available	347.387	[H]N([H])[C@@H](CCCC(=O)N([H])[C@@H](CS)C(=O)N([H])[C@H](C=C)C(O)=O)C(O)=O	Solid	Not Available								4911105						ASV			6398414	46508704					ZINC000006363128		delta-(L-alpha-Aminoadipoyl)-L-cysteinyl-D-vinylglycine	Experimental	DB03427	InChI=1S/C13H21N3O6S/c1-2-8(13(21)22)16-11(18)9(6-23)15-10(17)5-3-4-7(14)12(19)20/h2,7-9,23H,1,3-6,14H2,(H,15,17)(H,16,18)(H,19,20)(H,21,22)/t7-,8+,9-/m0/s1	JJJCGQKXGIRXKN-YIZRAAEISA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.9995 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	7	6	No	0	-1	158.82 Å2	33.47 Å3	82.62 m3·mol-1	11	No	No	0.905 mg/mL	-3.5	-2.6	1.94	9.15			
C27H49N9O10S2	Not Available	Not Available	723.862	N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(=O)NCCCCNCCCNC(=O)CNC(=O)[C@H](CS)NC(=O)CC[C@H](N)C(O)=O)C(O)=O	Solid	Not Available						17842		396023			HMDB0060520	C02090		GCG			449517	46505609				Trypanothione	ZINC000008217540		Trypanothione	Experimental	DB03470	InChI=1S/C27H49N9O10S2/c28-16(26(43)44)4-6-20(37)35-18(14-47)24(41)33-12-22(39)31-10-2-1-8-30-9-3-11-32-23(40)13-34-25(42)19(15-48)36-21(38)7-5-17(29)27(45)46/h16-19,30,47-48H,1-15,28-29H2,(H,31,39)(H,32,40)(H,33,41)(H,34,42)(H,35,37)(H,36,38)(H,43,44)(H,45,46)/t16-,17-,18-,19-/m0/s1	PHDOXVGRXXAYEB-VJANTYMQSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	1.9668 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	13	13	No	0	1	313.27 Å2	75.33 Å3	176.8 m3·mol-1	27	No	No	0.0121 mg/mL	-11	-4.8	1.64	10.57	P28593	TPR	1. Trypanothione reductase
C18H28FN5O4	Not Available	Not Available	397.4444	C[C@H](NC(=O)[C@H](CCCNC(N)N)NC(=O)OCC1=CC=CC=C1)C(=O)CF	Solid	Not Available								59051958						ZRA			131704251	46504937					ZINC000098209677		Benzyl N-[(2S)-5-(diaminomethylamino)-1-[[(2S)-4-fluoro-3-oxobutan-2-yl]amino]-1-oxopentan-2-yl]carbamate	Experimental	DB03536	InChI=1S/C18H28FN5O4/c1-12(15(25)10-19)23-16(26)14(8-5-9-22-17(20)21)24-18(27)28-11-13-6-3-2-4-7-13/h2-4,6-7,12,14,17,22H,5,8-11,20-21H2,1H3,(H,23,26)(H,24,27)/t12-,14-/m0/s1	FAAPWXRBXXSQNJ-JSGCOSHPSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1716 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	6	5	No	1	0	148.57 Å2	41.24 Å3	100.66 m3·mol-1	13	Yes	No	0.28 mg/mL	0.43	-3.2	12.73	6.71	Q9UBX1;!P25779	CTSF;!Not Available	1. Cathepsin F;!2. Cruzipain
C22H30F3N5O8	Not Available	Not Available	549.4975	[H][C@@](CCC(O)=O)(NC(=O)C1=CC=C(C=C1)[C@@]([H])(CCCC1C(O)=N[C@]([H])(N)N[C@]1([H])N)C(O)(O)C(F)(F)F)C(O)=O	Solid	Not Available								64873371						KEU			131704252	46505325							N-({4-[(1R)-4-[(2R,4S,5S)-2,4-diamino-6-oxohexahydropyrimidin-5-yl]-1-(2,2,2-trifluoro-1,1-dihydroxyethyl)butyl]phenyl}carbonyl)-L-glutamic acid	Experimental	DB03546	InChI=1S/C22H30F3N5O8/c23-22(24,25)21(37,38)13(3-1-2-12-16(26)29-20(27)30-18(12)34)10-4-6-11(7-5-10)17(33)28-14(19(35)36)8-9-15(31)32/h4-7,12-14,16,20,29,37-38H,1-3,8-9,26-27H2,(H,28,33)(H,30,34)(H,31,32)(H,35,36)/t12?,13-,14+,16+,20-/m1/s1	KOLDLUFBEMUZIM-YNPGLMGXSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.6180 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	12	9	No	2	-1	240.82 Å2	50.68 Å3	123.09 m3·mol-1	13	No	No	0.782 mg/mL	-2.3	-2.8	2.7	7.74	P22102	GART	1. Trifunctional purine biosynthetic protein adenosine-3
C32H41F4N5O13P2S	Not Available	Not Available	873.7	NC(=O)C(CS)NC(=O)CCCCCNC(=O)[C@H](CC1=CC=C(C=C1)C(F)(F)P(O)(O)=O)NC(=O)C(CC(O)=O)NC(=O)CC1=CC=C(C=C1)C(F)(F)P(O)(O)=O	Solid	Not Available								64873372						SNA			131704254	46505110							4-[[(2S)-1-[[6-[(1-Amino-1-oxo-3-sulfanylpropan-2-yl)amino]-6-oxohexyl]amino]-3-[4-[difluoro(phosphono)methyl]phenyl]-1-oxopropan-2-yl]amino]-3-[[2-[4-[difluoro(phosphono)methyl]phenyl]acetyl]amino]-4-oxobutanoic acid	Experimental	DB03557	InChI=1S/C32H41F4N5O13P2S/c33-31(34,55(49,50)51)20-9-5-18(6-10-20)14-22(29(47)38-13-3-1-2-4-25(42)40-24(17-57)28(37)46)41-30(48)23(16-27(44)45)39-26(43)15-19-7-11-21(12-8-19)32(35,36)56(52,53)54/h5-12,22-24,57H,1-4,13-17H2,(H2,37,46)(H,38,47)(H,39,43)(H,40,42)(H,41,48)(H,44,45)(H2,49,50,51)(H2,52,53,54)/t22-,23?,24?/m0/s1	JNKZDIBIDJQPGC-BOMBAVFCSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.4802 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										0	No	13	11	No	2	-5	311.85 Å2	77.99 Å3	194.36 m3·mol-1	23	No	No	0.011 mg/mL	-0.77	-4.9	0.19		P18031	PTPN1	1. Tyrosine-protein phosphatase non-receptor type 1
C19H28N2O5	Not Available	Not Available	364.436	[H][C@](O)(CC(O)=O)C(=O)N[C@]([H])(CCC1=CC=CC=C1)C(=O)NCCC(C)C	Solid	Not Available								4451259						R99			5289258	46505552					ZINC000012503755		WRR-99	Experimental	DB03573	InChI=1S/C19H28N2O5/c1-13(2)10-11-20-18(25)15(9-8-14-6-4-3-5-7-14)21-19(26)16(22)12-17(23)24/h3-7,13,15-16,22H,8-12H2,1-2H3,(H,20,25)(H,21,26)(H,23,24)/t15-,16+/m1/s1	KVZMXOVSHIMGNA-CVEARBPZSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.9502 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	4	No	1	-1	115.73 Å2	39.79 Å3	96.53 m3·mol-1	11	Yes	No	0.149 mg/mL	1.48	-3.4	4	-3.4	Q9UBX1;!P25779	CTSF;!Not Available	1. Cathepsin F;!2. Cruzipain
C17H22IN3O6S	Not Available	Not Available	523.343	[H]N([H])[C@@H](CCC(=O)N([H])[C@@H](CSCC1=CC=CC=C1I)C(=O)N([H])CC(O)=O)C(O)=O	Solid	Not Available								394293						IBG			447108	46508001					ZINC000014880825		gamma-Glutamyl[S-(2-iodobenzyl)cysteinyl]glycine	Experimental	DB03597	InChI=1S/C17H22IN3O6S/c18-11-4-2-1-3-10(11)8-28-9-13(16(25)20-7-15(23)24)21-14(22)6-5-12(19)17(26)27/h1-4,12-13H,5-9,19H2,(H,20,25)(H,21,22)(H,23,24)(H,26,27)/t12-,13-/m0/s1	QFYJAEOZTBVJQM-STQMWFEESA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.2538 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	7	5	No	1	-1	158.82 Å2	45.41 Å3	111.79 m3·mol-1	12	No	No	0.0301 mg/mL	-2	-4.2	1.81	9.31	O76074;!Q03013;!O76083	PDE5A;!GSTM4;!PDE9A	1. cGMP-specific 3',5'-cyclic phosphodiesterase;!2. Glutathione S-transferase Mu 4;!3. High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A
C17H23N3O6S	Not Available	Not Available	397.446	[H]N([H])[C@@H](CCC(=O)N([H])[C@@H](CSCC1=CC=CC=C1)C(=O)N([H])CC(O)=O)C(O)=O	Solid	Not Available	P08263	GSTA1	1. Glutathione S-transferase A1					393264						GSB			445707	46507389					ZINC000003874918		S-benzylglutathione	Experimental	DB03602	InChI=1S/C17H23N3O6S/c18-12(17(25)26)6-7-14(21)20-13(16(24)19-8-15(22)23)10-27-9-11-4-2-1-3-5-11/h1-5,12-13H,6-10,18H2,(H,19,24)(H,20,21)(H,22,23)(H,25,26)/t12-,13-/m0/s1	XYJWEQWNNKNSFU-STQMWFEESA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.8241 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	5	No	1	-1	158.82 Å2	40.51 Å3	98.43 m3·mol-1	12	Yes	No	0.116 mg/mL	-2.9	-3.5	1.81	9.31	Q04760;!P08263	GLO1;!GSTA1	1. Lactoylglutathione lyase;!2. Glutathione S-transferase A1
C29H41N9O10	Not Available	Not Available	675.7	CNC(=O)NC(=N)NCCC[C@@H]1NC(=O)[C@@H](C)NC(=O)C[C@H](NC(=O)C[C@H](NC(=O)[C@H](CC2=CC=CC=C2)N(C)C1=O)C(O)=O)C(O)=O	Solid	Not Available					10853		CHEMBL197199	395741									449124	46504954					ZINC000024693182		Argifin	Experimental	DB03632	InChI=1S/C29H41N9O10/c1-15-23(41)35-17(10-7-11-32-28(30)37-29(48)31-2)25(43)38(3)20(12-16-8-5-4-6-9-16)24(42)36-19(27(46)47)14-22(40)34-18(26(44)45)13-21(39)33-15/h4-6,8-9,15,17-20H,7,10-14H2,1-3H3,(H,33,39)(H,34,40)(H,35,41)(H,36,42)(H,44,45)(H,46,47)(H4,30,31,32,37,48)/t15-,17+,18+,19+,20+/m1/s1	UHBHXSDKGLPPGO-HTDHLNIYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.8913 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	12	10	No	2	-1	288.32 Å2	66.25 Å3	174.52 m3·mol-1	8	No	No	0.171 mg/mL	-5.1	-3.6	2.85	9.41			
C38H62N8O4	Not Available	Not Available	694.966	[H]N([H])CCCC[C@H](N([H])C(=O)[C@@H](CCCC)CN([H])N([H])C[C@@H](CCCC)C(=O)N([H])[C@@H](CCCCN([H])[H])C(=O)N([H])C1=CC=CC=C1)C(=O)N([H])C1=CC=CC=C1	Solid	Not Available														BL5			5496887	46507126							(2S,2'S)-2,2'-(1,2-Hydrazinediylbis{methylene[(2S)-1-oxo-2,1-hexanediyl]imino})bis(6-amino-N-phenylhexanamide)	Experimental	DB03648	InChI=1S/C38H62N8O4/c1-3-5-17-29(35(47)45-33(23-13-15-25-39)37(49)43-31-19-9-7-10-20-31)27-41-42-28-30(18-6-4-2)36(48)46-34(24-14-16-26-40)38(50)44-32-21-11-8-12-22-32/h7-12,19-22,29-30,33-34,41-42H,3-6,13-18,23-28,39-40H2,1-2H3,(H,43,49)(H,44,50)(H,45,47)(H,46,48)/t29-,30+,33-,34-/m0/s1	YFMXWONORHSZEM-DDOVKQMLSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3957 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	8	8	No	2	2	192.5 Å2	80.3 Å3	223.32 m3·mol-1	27	No	No	0.00414 mg/mL	4.13	-5.2	12.44	10.5	Q8I372	Not Available	1. Formylmethionine deformylase, putative
C17H22N4O8S	Not Available	Not Available	442.444	N[C@@H](CCC(=O)N[C@@H](CSCC1=CC=C(C=C1)[N+]([O-])=O)C(=O)NCC(O)=O)C(O)=O	Solid	Not Available						87407		88035						GTB			97538	46508527					ZINC000003874914		S-(4-nitrobenzyl)glutathione	Experimental	DB03686	InChI=1S/C17H22N4O8S/c18-12(17(26)27)5-6-14(22)20-13(16(25)19-7-15(23)24)9-30-8-10-1-3-11(4-2-10)21(28)29/h1-4,12-13H,5-9,18H2,(H,19,25)(H,20,22)(H,23,24)(H,26,27)/t12-,13-/m0/s1	OAWORKDPTSAMBZ-STQMWFEESA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.5268 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	9	5	No	1	-1	201.96 Å2	43 Å3	104.75 m3·mol-1	13	Yes	No		-3		1.81	9.31	P09211	GSTP1	1. Glutathione S-transferase P
C19H28N2O5	Not Available	Not Available	364.436	[H][C@](O)(CC(O)=O)C(=O)N[C@@]([H])(CCC1=CC=CC=C1)C(=O)NCCC(C)C	Solid	Not Available								4451288						RL2			5289294	46504442					ZINC000012503756		WRR-112	Experimental	DB03691	InChI=1S/C19H28N2O5/c1-13(2)10-11-20-18(25)15(9-8-14-6-4-3-5-7-14)21-19(26)16(22)12-17(23)24/h3-7,13,15-16,22H,8-12H2,1-2H3,(H,20,25)(H,21,26)(H,23,24)/t15-,16-/m0/s1	KVZMXOVSHIMGNA-HOTGVXAUSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.9502 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	4	No	1	-1	115.73 Å2	39.76 Å3	96.53 m3·mol-1	11	Yes	No	0.149 mg/mL	1.48	-3.4	4	-3.4	Q9UBX1;!P25779	CTSF;!Not Available	1. Cathepsin F;!2. Cruzipain
C26H33F3N4O7	Not Available	Not Available	570.558	[H]N(CC(O)=O)C(=O)C1=CC=C(C=C1)C(=O)N([H])[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N([H])[C@@H](C(C)C)C(=O)C(F)(F)F	Solid	Not Available								4450441						FR1			5288240	46508719					ZINC000003951728		N-{4-[(Carboxymethyl)carbamoyl]benzoyl}-L-valyl-N-[(3S)-1,1,1-trifluoro-4-methyl-2-oxo-3-pentanyl]-L-prolinamide	Experimental	DB03702	InChI=1S/C26H33F3N4O7/c1-13(2)19(21(36)26(27,28)29)31-24(39)17-6-5-11-33(17)25(40)20(14(3)4)32-23(38)16-9-7-15(8-10-16)22(37)30-12-18(34)35/h7-10,13-14,17,19-20H,5-6,11-12H2,1-4H3,(H,30,37)(H,31,39)(H,32,38)(H,34,35)/t17-,19-,20-/m0/s1	MRTSIBBMOWLRPY-IHPCNDPISA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.4914 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	7	4	No	2	-1	161.98 Å2	54.27 Å3	135.51 m3·mol-1	12	No	No	0.00627 mg/mL	2.08	-5	3.08	-1	Q9UNI1	CELA1	1. Chymotrypsin-like elastase family member 1
C19H26N4O10S	Not Available	Not Available	502.496	N[C@@H](CCC(=O)N[C@@H](CS[C@@H](CO)COC1=CC=C(C=C1)[N+]([O-])=O)C(=O)NCC(O)=O)C(O)=O	Solid	Not Available								16743963						EPY			17753973	46505823					ZINC000012503844		1-Hydroxy-2-S-glutathionyl-3-para-nitrophenoxy-propane	Experimental	DB03706	InChI=1S/C19H26N4O10S/c20-14(19(29)30)5-6-16(25)22-15(18(28)21-7-17(26)27)10-34-13(8-24)9-33-12-3-1-11(2-4-12)23(31)32/h1-4,13-15,24H,5-10,20H2,(H,21,28)(H,22,25)(H,26,27)(H,29,30)/t13-,14-,15-/m0/s1	YWXHXYSGHBAIBL-KKUMJFAQSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.5686 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	11	6	No	1	-1	231.42 Å2	48.93 Å3	116.83 m3·mol-1	16	No	No		-4		1.8	9.31	Q03013	GSTM4	1. Glutathione S-transferase Mu 4
C33H35N3O7	Not Available	Not Available	585.6469	CC(=O)N[C@@H](CC1=CC(C(O)=O)=C(CC(O)=O)C=C1)C(=O)N[C@H]1CCCCN(CC2=CC=C(C=C2)C2=CC=CC=C2)C1=O	Solid	Not Available					14694		CHEMBL432359	394587						853			447524	46505930					ZINC000014880878		RU85053	Experimental	DB03712	InChI=1S/C33H35N3O7/c1-21(37)34-29(18-23-12-15-26(19-30(38)39)27(17-23)33(42)43)31(40)35-28-9-5-6-16-36(32(28)41)20-22-10-13-25(14-11-22)24-7-3-2-4-8-24/h2-4,7-8,10-15,17,28-29H,5-6,9,16,18-20H2,1H3,(H,34,37)(H,35,40)(H,38,39)(H,42,43)/t28-,29-/m0/s1	CEKLBQMULVLLTD-VMPREFPWSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.3451 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										0	No	7	4	Yes	4	-2	153.11 Å2	62.6 Å3	159.18 m3·mol-1	11	No	No		3.16		3.41	-1.9			
C42H52N6O8	Not Available	Not Available	768.8977	CC(C)[C@H](NC(=O)[C@H](OCC1=CC=CC=C1)[C@H](O)[C@@H](O)[C@@H](OCC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)NCC1=NC=CC=C1)C(=O)NCC1=CC=CC=N1	Solid	Not Available					12222			392984						MS3			445309	46506501					ZINC000096210382		N,N-[2,5-O-dibenzyl-glucaryl]-DI-[valinyl-aminomethanyl-pyridine]	Experimental	DB03803	InChI=1S/C42H52N6O8/c1-27(2)33(39(51)45-23-31-19-11-13-21-43-31)47-41(53)37(55-25-29-15-7-5-8-16-29)35(49)36(50)38(56-26-30-17-9-6-10-18-30)42(54)48-34(28(3)4)40(52)46-24-32-20-12-14-22-44-32/h5-22,27-28,33-38,49-50H,23-26H2,1-4H3,(H,45,51)(H,46,52)(H,47,53)(H,48,54)/t33-,34-,35+,36+,37+,38+/m0/s1	SVFLQOLSPWURCD-CXPJILFNSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.1902 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	10	6	Yes	4	0	201.1 Å2	83 Å3	206.76 m3·mol-1	21	No	No	0.018 mg/mL	2.36	-4.6	11.55	4.44	P03366	gag-pol	1. Gag-Pol polyprotein
C21H25N3O6S	Not Available	Not Available	447.505	[H]N([H])[C@@H](CCC(=O)N([H])[C@@H](CSCC1=CC=CC2=CC=CC=C12)C(=O)N([H])CC(O)=O)C(O)=O	Solid	Not Available								395998						GGC			449471	46505686					ZINC000012504001		L-gamma-glutamyl-S-(naphthalen-1-ylmethyl)-L-cysteinylglycine	Experimental	DB03885	InChI=1S/C21H25N3O6S/c22-16(21(29)30)8-9-18(25)24-17(20(28)23-10-19(26)27)12-31-11-14-6-3-5-13-4-1-2-7-15(13)14/h1-7,16-17H,8-12,22H2,(H,23,28)(H,24,25)(H,26,27)(H,29,30)/t16-,17-/m0/s1	IHZCIRSQSFPOLH-IRXDYDNUSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.0967 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	5	No	2	-1	158.82 Å2	46.15 Å3	114.88 m3·mol-1	12	Yes	No		-1.9		1.81	9.31			
C34H50N4O8	Not Available	Not Available	642.7828	[H]N(C)C(=O)[C@@H](N([H])C(=O)[C@H](OCC1=CC=CC=C1)[C@H](O)[C@@H](O)[C@@H](OCC1=CC=CC=C1)C(=O)N([H])[C@@H]([C@@H](C)CC)C(=O)N([H])C)[C@@H](C)CC	Solid	Not Available								392978						BEI			445303	46506196					ZINC000024495494		N,N-[2,5-O-[Dibenzyl]-glucaryl]-DI-[isoleucyl-amido-methane]	Experimental	DB03908	InChI=1S/C34H50N4O8/c1-7-21(3)25(31(41)35-5)37-33(43)29(45-19-23-15-11-9-12-16-23)27(39)28(40)30(46-20-24-17-13-10-14-18-24)34(44)38-26(22(4)8-2)32(42)36-6/h9-18,21-22,25-30,39-40H,7-8,19-20H2,1-6H3,(H,35,41)(H,36,42)(H,37,43)(H,38,44)/t21-,22-,25-,26-,27+,28+,29+,30+/m0/s1	GLKONBHDVMFJNJ-XAOMMOPXSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.2411 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	8	6	No	2	0	175.32 Å2	70.1 Å3	172.09 m3·mol-1	19	No	No		2.07		11.69	-3.7	P03366	gag-pol	1. Gag-Pol polyprotein
C12H21N3O6	Not Available	Not Available	303.3116	[H]N([H])CC(=O)N([H])[C@@H](CCCCC(=O)N([H])[C@H](C)C(O)=O)C(O)=O	Solid	Not Available								393700						REY			446307	46506012					ZINC000003581164		Glycyl-L-alpha-amino-epsilon-pimelyl-D-alanine	Experimental	DB03927	InChI=1S/C12H21N3O6/c1-7(11(18)19)14-9(16)5-3-2-4-8(12(20)21)15-10(17)6-13/h7-8H,2-6,13H2,1H3,(H,14,16)(H,15,17)(H,18,19)(H,20,21)/t7-,8+/m1/s1	ZMQJQOKNTYQVHO-SFYZADRCSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	1.7329 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	5	No	0	-1	158.82 Å2	30.14 Å3	70.59 m3·mol-1	10	Yes	No		-4.3		3.28	8.14	P15555	Not Available	1. D-alanyl-D-alanine carboxypeptidase
C27H28N2O5S	Not Available	Not Available	492.587	[H]N([C@@H](CC1=CC=CC=C1)C(=O)N([H])[C@@H](CC1=CC=C(O)C=C1)C(O)=O)C(=O)[C@@H](S)CC1=CC=CC=C1	Solid	Not Available					50050160		CHEMBL277238	4451432						TI2			5289470	46505869					ZINC000012504054		N-[(2S)-3-Phenyl-2-sulfanylpropanoyl]-L-phenylalanyl-L-tyrosine	Experimental	DB03949	InChI=1S/C27H28N2O5S/c30-21-13-11-20(12-14-21)16-23(27(33)34)29-25(31)22(15-18-7-3-1-4-8-18)28-26(32)24(35)17-19-9-5-2-6-10-19/h1-14,22-24,30,35H,15-17H2,(H,28,32)(H,29,31)(H,33,34)/t22-,23-,24-/m0/s1	GIVBBFGMRNXKPE-HJOGWXRNSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.0580 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	5	5	Yes	3	-1	115.73 Å2	51.49 Å3	135.4 m3·mol-1	11	Yes	No	0.00135 mg/mL	4.16	-5.6	3.74	-4.1	P43133	nprS	1. Thermolysin
C29H38N3O10P	Not Available	Not Available	619.5999	[H]N([H])C(=O)C1=C(OCC2CCCCC2)C=CC(=C1)[C@H](C)N([H])C(=O)[C@H](CC1=CC(=C(OCC(O)=O)C=C1)P(O)(O)=O)N([H])C(C)=O	Solid	Not Available								393693						CC0			446300	46509016					ZINC000014880990		{4-[(2S)-2-Acetamido-3-({(1S)-1-[3-carbamoyl-4-(cyclohexylmethoxy)phenyl]ethyl}amino)-3-oxopropyl]-2-phosphonophenoxy}acetic acid	Experimental	DB04003	InChI=1S/C29H38N3O10P/c1-17(21-9-11-24(22(14-21)28(30)36)41-15-19-6-4-3-5-7-19)31-29(37)23(32-18(2)33)12-20-8-10-25(42-16-27(34)35)26(13-20)43(38,39)40/h8-11,13-14,17,19,23H,3-7,12,15-16H2,1-2H3,(H2,30,36)(H,31,37)(H,32,33)(H,34,35)(H2,38,39,40)/t17-,23-/m0/s1	FXUGQWABROMTDA-SBUREZEXSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.5499 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	10	6	Yes	3	-3	214.58 Å2	62.53 Å3	155.33 m3·mol-1	14	No	No	0.00145 mg/mL	0.57	-5.6	1.6	-0.89	P06239	LCK	1. Tyrosine-protein kinase Lck
C34H35N3O12	Not Available	Not Available	677.6546	[H]N(CCCCOC1=CC=CC(O)=C1C(=O)OC)C(=O)[C@H](CC1=CC=C(C=C1)N(C(=O)C(O)=O)C1=CC=CC=C1C(O)=O)N([H])C(=O)OCC=C	Solid	Not Available					50131545		CHEMBL325029	8480767						418			10305301	46506877			DNC000977		ZINC000027090034		2-[{4-[(2S)-2-{[(Allyloxy)carbonyl]amino}-3-({4-[3-hydroxy-2-(methoxycarbonyl)phenoxy]butyl}amino)-3-oxopropyl]phenyl}(carboxycarbonyl)amino]benzoic acid	Experimental	DB04088	InChI=1S/C34H35N3O12/c1-3-18-49-34(46)36-24(29(39)35-17-6-7-19-48-27-12-8-11-26(38)28(27)33(45)47-2)20-21-13-15-22(16-14-21)37(30(40)32(43)44)25-10-5-4-9-23(25)31(41)42/h3-5,8-16,24,38H,1,6-7,17-20H2,2H3,(H,35,39)(H,36,46)(H,41,42)(H,43,44)/t24-/m0/s1	JTJBRKLISQICDU-DEOSSOPVSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Inhibitor	Inhibitor	Substrate	2.3745 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										0	No	10	5	Yes	3	-2	218.1 Å2	67.77 Å3	172.94 m3·mol-1	19	No	No	0.0024 mg/mL	4.61	-5.4	2.31	-4			
C23H33N5O5	Not Available	Not Available	459.5386	C[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1)C(N)=O	Solid	Not Available					50078401		CHEMBL311875	394420									447280	46504972							Apstatin	Experimental	DB04092	InChI=1S/C23H33N5O5/c1-14(20(25)30)26-21(31)17-9-5-11-27(17)22(32)18-10-6-12-28(18)23(33)19(29)16(24)13-15-7-3-2-4-8-15/h2-4,7-8,14,16-19,29H,5-6,9-13,24H2,1H3,(H2,25,30)(H,26,31)/t14-,16+,17-,18-,19-/m0/s1	YVUUZAPYLPWFHE-HXFGRODQSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1807 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	4	Yes	3	1	159.06 Å2	47.91 Å3	120.17 m3·mol-1	8	Yes	No	1.92 mg/mL	-1.4	-2.4	12.11	8.35	P15034	pepP	1. Xaa-Pro aminopeptidase
C15H28N2O5	Not Available	Not Available	316.3932	[H][C@](O)(CC(O)=O)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCCC(C)C	Solid	Not Available								4450373						E6C			5288147	46505427					ZINC000003874327		N-[1-Hydroxycarboxyethyl-Carbonyl]Leucylamino-2-Methyl-Butane	Experimental	DB04126	InChI=1S/C15H28N2O5/c1-9(2)5-6-16-14(21)11(7-10(3)4)17-15(22)12(18)8-13(19)20/h9-12,18H,5-8H2,1-4H3,(H,16,21)(H,17,22)(H,19,20)/t11-,12-/m0/s1	KBIWEWPGBHKYML-RYUDHWBXSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.0096 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	4	No	0	-1	115.73 Å2	34.67 Å3	80.99 m3·mol-1	10	Yes	No	2.42 mg/mL	0.63	-2.1	4.25	-2.8	P07858;!P09668	CTSB;!CTSH	1. Cathepsin B;!2. Pro-cathepsin H
C16H29N3O6S	Not Available	Not Available	391.483	CCCCCCSC[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)NCC(O)=O	Solid	Not Available	P08263	GSTA1	1. Glutathione S-transferase A1		50095998	27704	CHEMBL345292	88033				C02886		LEE			97536	46505872			DNC001323		ZINC000003874923		S-Hexylglutathione	Experimental	DB04132	InChI=1S/C16H29N3O6S/c1-2-3-4-5-8-26-10-12(15(23)18-9-14(21)22)19-13(20)7-6-11(17)16(24)25/h11-12H,2-10,17H2,1H3,(H,18,23)(H,19,20)(H,21,22)(H,24,25)/t11-,12-/m0/s1	HXJDWCWJDCOHDG-RYUDHWBXSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.1333 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	5	No	0	-1	158.82 Å2	42.03 Å3	96.89 m3·mol-1	15	Yes	No	0.146 mg/mL	-2.4	-3.4	1.81	9.31	Q04760;!Q03013;!P09211;!Q8MU52;!P08263;!P0CG29	GLO1;!GSTM4;!GSTP1;!GST;!GSTA1;!GSTT2	1. Lactoylglutathione lyase;!2. Glutathione S-transferase Mu 4;!3. Glutathione S-transferase P;!4. Glutathione S-transferase;!5. Glutathione S-transferase A1;!6. Glutathione S-transferase theta-2
C15H18I2N2O6	Not Available	Not Available	576.1222	[H]N([C@@H](CC1=CC(I)=C(O)C(I)=C1)C(=O)N([H])[C@H]([C@@H](C)O)C(O)=O)C(C)=O	Solid	Not Available								4450770						IYT			5288651	46505151					ZINC000038377676		N-alpha-Acetyl-3,5-diiodotyrosyl-D-threonine	Experimental	DB04150	InChI=1S/C15H18I2N2O6/c1-6(20)12(15(24)25)19-14(23)11(18-7(2)21)5-8-3-9(16)13(22)10(17)4-8/h3-4,6,11-12,20,22H,5H2,1-2H3,(H,18,21)(H,19,23)(H,24,25)/t6-,11+,12-/m1/s1	TWMKRGDZEJLDDH-LKXWSVAYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.5639 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	5	No	1	-2	135.96 Å2	42.86 Å3	106.53 m3·mol-1	7	No	No	0.158 mg/mL	1.28	-3.6	2.57	-1.9	P19021	PAM	1. Peptidyl-glycine alpha-amidating monooxygenase
C24H27N3O7S	Not Available	Not Available	501.552	[H]N([H])[C@@H](CCC(=O)N([H])[C@@H](CS[C@]1([H])[C@@H](O)C2=CC=CC=C2C2=CC=CC=C12)C(=O)N([H])CC(O)=O)C(O)=O	Solid	Not Available								392389						GPS			444461	46506704					ZINC000012501153		(9S,10S)-9-(S-glutathionyl)-10-hydroxy-9,10-dihydrophenanthrene	Experimental	DB04187	InChI=1S/C24H27N3O7S/c25-17(24(33)34)9-10-19(28)27-18(23(32)26-11-20(29)30)12-35-22-16-8-4-2-6-14(16)13-5-1-3-7-15(13)21(22)31/h1-8,17-18,21-22,31H,9-12,25H2,(H,26,32)(H,27,28)(H,29,30)(H,33,34)/t17-,18-,21-,22-/m0/s1	JNNIZILNBMPOAC-GPHNJDIKSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.2178 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	8	6	Yes	3	-1	179.05 Å2	50.09 Å3	127.88 m3·mol-1	11	No	No	0.031 mg/mL	-2.2	-4.2	1.8	9.31	P09488	GSTM1	1. Glutathione S-transferase Mu 1
C29H47N5O7	Not Available	Not Available	577.7128	[H][C@@](C)(N)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC1=CC=CC=C1)[C@@]([H])(O)CCC(=O)N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(C(C)C)C(=O)OC	Solid	Not Available					903		CHEMBL49004	392186						PSI			444196	46508521					ZINC000003935186		Skf 107457	Experimental	DB04191	InChI=1S/C29H47N5O7/c1-16(2)24(28(39)34-25(17(3)4)29(40)41-7)33-23(36)14-13-22(35)21(15-20-11-9-8-10-12-20)32-27(38)19(6)31-26(37)18(5)30/h8-12,16-19,21-22,24-25,35H,13-15,30H2,1-7H3,(H,31,37)(H,32,38)(H,33,36)(H,34,39)/t18-,19-,21-,22-,24-,25-/m0/s1	IUDCAKKZLXFOQA-QJAPXLAMSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.2496 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	7	6	No	1	1	188.95 Å2	62.56 Å3	152.41 m3·mol-1	17	No	No	0.0237 mg/mL	0.6	-4.4	12.05	8.09	P05896	gag-pol	1. Gag-Pol polyprotein
C20H29BrN2O4	Not Available	Not Available	441.359	[H][C@@](CCCC)(NC(=O)[C@]([H])(CC(C)C)NC(=O)OCC1=CC=C(Br)C=C1)C=O	Solid	Not Available								4450929						MYE			5288867	46505737					ZINC000012504234		N2-({[(4-Bromophenyl)Methyl]Oxy}Carbonyl)-N1-[(1s)-1-Formylpentyl]-L-Leucinamide	Experimental	DB04234	InChI=1S/C20H29BrN2O4/c1-4-5-6-17(12-24)22-19(25)18(11-14(2)3)23-20(26)27-13-15-7-9-16(21)10-8-15/h7-10,12,14,17-18H,4-6,11,13H2,1-3H3,(H,22,25)(H,23,26)/t17-,18-/m0/s1	UEDKSAKLZBMNMA-ROUUACIJSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.4344 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	2	No	1	0	84.5 Å2	44.39 Å3	107.57 m3·mol-1	12	Yes	No	0.00246 mg/mL	4.32	-5.2	12.86	-3.6	P43235	CTSK	1. Cathepsin K
C35H43N3O8	Not Available	Not Available	633.7312	CNC(=O)[C@@H](NC(=O)[C@H](OCC1=CC=CC=C1)[C@H](O)[C@@H](O)[C@@H](OCC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12)C(C)C	Solid	Not Available					12216		CHEMBL573887	392980						BEC			445305	46505264					ZINC000024495650		Inhibitor BEA388	Experimental	DB04255	InChI=1S/C35H43N3O8/c1-21(2)27(33(42)36-3)37-34(43)31(45-19-22-12-6-4-7-13-22)29(40)30(41)32(46-20-23-14-8-5-9-15-23)35(44)38-28-25-17-11-10-16-24(25)18-26(28)39/h4-17,21,26-32,39-41H,18-20H2,1-3H3,(H,36,42)(H,37,43)(H,38,44)/t26-,27+,28+,29-,30-,31-,32-/m1/s1	VZNNJZGVQVNHCM-CDNLURBZSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.2983 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	8	6	Yes	4	0	166.45 Å2	67.86 Å3	170.15 m3·mol-1	15	No	No	0.0656 mg/mL	2.02	-4	11.75	-3.1	P03366	gag-pol	1. Gag-Pol polyprotein
C15H30N5O5	Not Available	Not Available	360.4292	CC(C)C[C@H](NC(=O)[C@@H](O)CC(O)=O)C(=O)NCCCC[NH+]=C(N)N	Solid	Not Available						30270		4450371						E64			5288145	46505123							4-[[(2S)-2-[[(2S)-3-Carboxy-2-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]butyl-(diaminomethylidene)azanium	Experimental	DB04276	InChI=1S/C15H29N5O5/c1-9(2)7-10(20-14(25)11(21)8-12(22)23)13(24)18-5-3-4-6-19-15(16)17/h9-11,21H,3-8H2,1-2H3,(H,18,24)(H,20,25)(H,22,23)(H4,16,17,19)/p+1/t10-,11-/m0/s1	QPQNJAXBPHVASB-QWRGUYRKSA-O			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.4411 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	7	7	No	0	0	181.74 Å2	38.57 Å3	101.66 m3·mol-1	12	No	No	0.52 mg/mL	-3.2	-2.9	3.95	11.28	A0A0H3JWX6;!P07384	srtB;!CAPN1	1. NPQTN specific sortase B;!2. Calpain-1 catalytic subunit
C17H32N6O3S	Not Available	Not Available	400.539	[H]N([H])C(=N[C@H](C1CCCCC1)C(=O)N([H])CC(=O)N([H])[C@@H](C)C(=O)N([H])CCCS)N([H])[H]	Solid	Not Available								4593463						NMP			5496715	46505946					ZINC000015677257		2-[2-(2-Cyclohexyl-2-guanidino-acetylamino)-acetylamino]-N-(3-mercapto-propyl)-propionamide	Experimental	DB04278	InChI=1S/C17H32N6O3S/c1-11(15(25)20-8-5-9-27)22-13(24)10-21-16(26)14(23-17(18)19)12-6-3-2-4-7-12/h11-12,14,27H,2-10H2,1H3,(H,20,25)(H,21,26)(H,22,24)(H4,18,19,23)/t11-,14+/m0/s1	YLLNYDDZOMCFDE-SMDDNHRTSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.2883 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	6	No	1	1	151.7 Å2	43.87 Å3	105.92 m3·mol-1	10	No	No	0.0543 mg/mL	-0.63	-3.9	10.05	10.76	P60568	IL2	1. Interleukin-2
C21H25N5O6	Not Available	Not Available	443.4531	[H]N([H])C1=NC(=O)C2=C(N([H])C[C@@H](CCC3=CC=C(C=C3)C(=O)N([H])[C@@H](CCC(O)=O)C(O)=O)C2)N1[H]	Solid	Not Available								392818						L24			445072	46505154					ZINC000001637602		LY249543	Experimental	DB04322	InChI=1S/C21H25N5O6/c22-21-25-17-14(19(30)26-21)9-12(10-23-17)2-1-11-3-5-13(6-4-11)18(29)24-15(20(31)32)7-8-16(27)28/h3-6,12,15H,1-2,7-10H2,(H,24,29)(H,27,28)(H,31,32)(H4,22,23,25,26,30)/t12-,15-/m0/s1	ZUQBAQVRAURMCL-WFASDCNBSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3887 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	10	6	Yes	3	-2	183.21 Å2	43.42 Å3	122 m3·mol-1	9	No	No	0.0911 mg/mL	-1	-3.7	3.03	4.75	P11586	MTHFD1	1. C-1-tetrahydrofolate synthase, cytoplasmic
C17H22IN3O6S	Not Available	Not Available	523.343	[H]N([H])[C@@H](CCC(=O)N([H])[C@@H](CSCC1=CC(I)=CC=C1)C(=O)N([H])CC(O)=O)C(O)=O	Solid	Not Available								395901						GBI			449342	46508698					ZINC000014881179		S-(3-Iodobenzyl)glutathione	Experimental	DB04341	InChI=1S/C17H22IN3O6S/c18-11-3-1-2-10(6-11)8-28-9-13(16(25)20-7-15(23)24)21-14(22)5-4-12(19)17(26)27/h1-3,6,12-13H,4-5,7-9,19H2,(H,20,25)(H,21,22)(H,23,24)(H,26,27)/t12-,13-/m0/s1	AHWSFXKKIDTZBI-STQMWFEESA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.2179 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	7	5	No	1	-1	158.82 Å2	46.1 Å3	111.79 m3·mol-1	12	No	No	0.03 mg/mL	-2	-4.2	1.81	9.31			
C38H47N5O7	Not Available	Not Available	685.822	[H]N([H])C(=O)CC[C@H](N([H])C(=O)[C@H](CC(=O)[C@H](CC1=CC=CC=C1)N([H])C(=O)OC(C)(C)C)CC1=CC=CC=C1)C(=O)N([H])[C@@H](CC1=CC=CC=C1)C(=O)N([H])[H]	Solid	Not Available														Q50			6323486	46507702							Tert-butyl N-[(2S,5R)-6-[[(2S)-5-amino-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-benzyl-3,6-dioxo-1-phenylhexan-2-yl]carbamate	Experimental	DB04353	InChI=1S/C38H47N5O7/c1-38(2,3)50-37(49)43-30(22-26-15-9-5-10-16-26)32(44)24-28(21-25-13-7-4-8-14-25)35(47)41-29(19-20-33(39)45)36(48)42-31(34(40)46)23-27-17-11-6-12-18-27/h4-18,28-31H,19-24H2,1-3H3,(H2,39,45)(H2,40,46)(H,41,47)(H,42,48)(H,43,49)/t28-,29-,30-,31-/m0/s1	DDOOHEYBNHOFCV-ORYMTKCHSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.5817 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	6	5	Yes	3	0	199.78 Å2	71.98 Å3	187.35 m3·mol-1	20	No	No	0.00138 mg/mL	3.46	-5.7	12.13	-1.1	P12499	gag-pol	1. Gag-Pol polyprotein
C32H41N3O4	Not Available	Not Available	531.6856	CC(C)C[C@@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)NC(=O)C1=CC=CC(N)=C1	Solid	Not Available								394146						R36			446912	46505068					ZINC000015658067		4-Amino-N-{4-[2-(2,6-Dimethyl-Phenoxy)-Acetylamino]-3-Hydroxy-1-Isobutyl-5-Phenyl-Pentyl}-Benzamide	Experimental	DB04373	InChI=1S/C32H41N3O4/c1-21(2)16-27(34-32(38)25-14-9-15-26(33)18-25)19-29(36)28(17-24-12-6-5-7-13-24)35-30(37)20-39-31-22(3)10-8-11-23(31)4/h5-15,18,21,27-29,36H,16-17,19-20,33H2,1-4H3,(H,34,38)(H,35,37)/t27-,28-,29-/m0/s1	WQUBEIMCFHCJCO-AWCRTANDSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	2.3747 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	5	4	Yes	3	0	113.68 Å2	59.66 Å3	156.13 m3·mol-1	13	No	No	0.000377 mg/mL	4.96	-6.2	13.5	3.26	P46925	Not Available	1. Plasmepsin-2
C32H41N3O4	Not Available	Not Available	531.6856	CC(C)C[C@@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)NC(=O)C1=CC=C(N)C=C1	Solid	Not Available								394151						R37			446917	46507593					ZINC000015658343		3-Amino-N-{4-[2-(2,6-Dimethyl-Phenoxy)-Acetylamino]-3-Hydroxy-1-Isobutyl-5-Phenyl-Pentyl}-Benzamide	Experimental	DB04378	InChI=1S/C32H41N3O4/c1-21(2)17-27(34-32(38)25-13-15-26(33)16-14-25)19-29(36)28(18-24-11-6-5-7-12-24)35-30(37)20-39-31-22(3)9-8-10-23(31)4/h5-16,21,27-29,36H,17-20,33H2,1-4H3,(H,34,38)(H,35,37)/t27-,28-,29-/m0/s1	APJAEXGNDLFGPD-AWCRTANDSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	2.3747 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	5	4	Yes	3	0	113.68 Å2	59.75 Å3	156.13 m3·mol-1	13	No	No	0.000377 mg/mL	4.96	-6.2	13.56	3.3	P46925	Not Available	1. Plasmepsin-2
C29H46N6O9S	Not Available	Not Available	654.78	[H]N([H])C(=NCCCCN([H])C(=O)[C@@H]1C[C@]2([H])CC[C@H](C[C@]2([H])N1C(=O)[C@H](N([H])C(=O)[C@H](O)CC1=CC=C(O)C=C1)[C@H](C)CC)OS(O)(=O)=O)N([H])[H]	Solid	Not Available								392303									444346	46509169					ZINC000024420133		Aeruginosin 98-B	Experimental	DB04391	InChI=1S/C29H46N6O9S/c1-3-17(2)25(34-27(39)24(37)14-18-6-9-20(36)10-7-18)28(40)35-22-16-21(44-45(41,42)43)11-8-19(22)15-23(35)26(38)32-12-4-5-13-33-29(30)31/h6-7,9-10,17,19,21-25,36-37H,3-5,8,11-16H2,1-2H3,(H,32,38)(H,34,39)(H4,30,31,33)(H,41,42,43)/t17-,19+,21-,22+,23+,24-,25-/m1/s1	WZVRXEOKWMIDDV-HTKJFTDNSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.5526 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										0	No	11	7	Yes	3	0	246.97 Å2	68.89 Å3	163.75 m3·mol-1	15	No	No	0.213 mg/mL	-0.29	-3.5	-11	11.23	P07477	PRSS1	1. Trypsin-1
C19H27N4O9S	Not Available	Not Available	487.504	[H][C@]12SC[C@@H](COC(C)=O)[C@H](N1C(=O)[C@H]2\N=C(/[O-])CCCC[C@H](NC(=O)CN)C(O)=O)C(O)=O	Solid	Not Available														H2A			131704283	46504718							(6S)-N-[(2S,3R,6R,7R)-3-(Acetyloxymethyl)-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]octan-7-yl]-6-[(2-aminoacetyl)amino]-7-hydroxy-7-oxoheptanimidate	Experimental	DB04488	InChI=1S/C19H28N4O9S/c1-9(24)32-7-10-8-33-17-14(16(27)23(17)15(10)19(30)31)22-12(25)5-3-2-4-11(18(28)29)21-13(26)6-20/h10-11,14-15,17H,2-8,20H2,1H3,(H,21,26)(H,22,25)(H,28,29)(H,30,31)/p-1/t10-,11+,14-,15+,17-/m1/s1	JDAREAJBQYNCGO-UPMYTKPLSA-M			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.1757 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	10	4	No	2	-1	211.75 Å2	47.24 Å3	122.37 m3·mol-1	13	Yes	No	0.392 mg/mL	-4.1	-3.1	3	8.14	P15555	Not Available	1. D-alanyl-D-alanine carboxypeptidase
C19H33N3O8S	Not Available	Not Available	463.546	[H]N([H])[C@@H](CCC(=O)N([H])[C@@H](CS[C@@]1([H])C[C@H](O)O[C@@H]1CCCCC)C(=O)N([H])CC(O)=O)C(O)=O	Solid	Not Available								392385						HAG			444455	46506521					ZINC000031976570		4-S-Glutathionyl-5-pentyl-tetrahydro-furan-2-ol	Experimental	DB04521	InChI=1S/C19H33N3O8S/c1-2-3-4-5-13-14(8-17(26)30-13)31-10-12(18(27)21-9-16(24)25)22-15(23)7-6-11(20)19(28)29/h11-14,17,26H,2-10,20H2,1H3,(H,21,27)(H,22,23)(H,24,25)(H,28,29)/t11-,12-,13+,14-,17+/m0/s1	ICRIFHIWWXQBPY-JEJJNBGPSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3527 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	9	6	No	1	-1	188.28 Å2	48.67 Å3	110.91 m3·mol-1	15	No	No	0.594 mg/mL	-2.8	-2.9	1.8	9.31	Q16772	GSTA3	1. Glutathione S-transferase A3
C30H37N3O10	Not Available	Not Available	599.6289	CCCCCNC(=O)[C@H](CC1=CC=C(OCC(O)=O)C(=C1)C(O)=O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CCC(O)=O	Solid	Not Available					13611		CHEMBL175198	393321						INX			445785	46506542					ZINC000003965850		N-(3-Carboxypropanoyl)-L-phenylalanyl-3-carboxy-O-(carboxymethyl)-N-pentyl-L-tyrosinamide	Experimental	DB04525	InChI=1S/C30H37N3O10/c1-2-3-7-14-31-28(39)22(17-20-10-11-24(43-18-27(37)38)21(15-20)30(41)42)33-29(40)23(16-19-8-5-4-6-9-19)32-25(34)12-13-26(35)36/h4-6,8-11,15,22-23H,2-3,7,12-14,16-18H2,1H3,(H,31,39)(H,32,34)(H,33,40)(H,35,36)(H,37,38)(H,41,42)/t22-,23-/m0/s1	PUAJYWYRZTYQKS-GOTSBHOMSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.4326 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										0	No	10	6	No	2	-3	208.43 Å2	62.15 Å3	152.37 m3·mol-1	19	No	No	0.0091 mg/mL	2	-4.8	2.99	-2.2			
C16H26N2O8	Not Available	Not Available	374.3862	CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O	Solid	Not Available								25060338						042			49866368	46504475					ZINC000014961482		N-{[(2S,3S)-3-(Ethoxycarbonyl)-2-oxiranyl]carbonyl}-L-threonyl-L-isoleucine	Experimental	DB04579	InChI=1S/C16H26N2O8/c1-5-7(3)9(15(22)23)17-13(20)10(8(4)19)18-14(21)11-12(26-11)16(24)25-6-2/h7-12,19H,5-6H2,1-4H3,(H,17,20)(H,18,21)(H,22,23)/t7-,8+,9-,10-,11-,12-/m0/s1	QMPAEYUADYAXIX-XFVKVHEMSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.3255 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	4	No	1	-1	154.56 Å2	36.93 Å3	86.37 m3·mol-1	11	Yes	No	10.6 mg/mL	-0.54	-1.6	3.75	-2.9	P07858	CTSB	1. Cathepsin B
C27H37N7O6S	Not Available	Not Available	587.691	CC[C@@H](C)[C@@H](NS(=O)(=O)CC1=CC(=CC=C1)C(O)=O)C(=O)N[C@@H](CCC(N)=N)C(=O)NCC1=CC=C(C=C1)C(N)=N	Solid	Not Available								4484168						3CB			5326876	46504568					ZINC000014881275		3-({1-[3-CARBAMIMIDOYL-1-(4-CARBAMIMIDOYL-BENZYLCARBAMOYL)-PROPYLCARBAMOYL]-2-METHYL-BUTYLSULFAMOYL}-METHYL)-BENZOIC ACID	Experimental	DB04593	InChI=1S/C27H37N7O6S/c1-3-16(2)23(34-41(39,40)15-18-5-4-6-20(13-18)27(37)38)26(36)33-21(11-12-22(28)29)25(35)32-14-17-7-9-19(10-8-17)24(30)31/h4-10,13,16,21,23,34H,3,11-12,14-15H2,1-2H3,(H3,28,29)(H3,30,31)(H,32,35)(H,33,36)(H,37,38)/t16-,21+,23-/m1/s1	UBGNMISWPGURDN-XORNHQRDSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.4649 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	10	8	No	2	1	241.41 Å2	61.4 Å3	174.64 m3·mol-1	15	No	No	0.0418 mg/mL	-3.7	-4.2	4.03	12.93	P08709	F7	1. Coagulation factor VII
C35H48N6O8	Not Available	Not Available	680.791	CC(C)C[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)C1=NOC(C)=C1)C(=O)N[C@H](\C=C\C(=O)OCC1=CC=CC=C1)C[C@@H]1CCNC1=O	Solid	Not Available								4883311									6323191	46506321					ZINC000053683585		(E)-(4S,6S)-8-METHYL-6-((S)-3-METHYL-2-{(S)-2-[(5-METHYL-ISOXAZOLE-3-CARBONYL)-AMINO]-PROPIONYLAMINO}-BUTYRYLAMINO)-5-OXO-4-((R)-2-OXO-PYRROLIDIN-3-YLMETHYL)-NON-2-ENOIC ACID BENZYL ESTER	Experimental	DB04595	InChI=1S/C35H48N6O8/c1-20(2)16-27(39-35(47)30(21(3)4)40-31(43)23(6)37-34(46)28-17-22(5)49-41-28)33(45)38-26(18-25-14-15-36-32(25)44)12-13-29(42)48-19-24-10-8-7-9-11-24/h7-13,17,20-21,23,25-27,30H,14-16,18-19H2,1-6H3,(H,36,44)(H,37,46)(H,38,45)(H,39,47)(H,40,43)/b13-12+/t23-,25-,26+,27-,30-/m0/s1	IDBWWEGDLCFCTD-VNEMRZQUSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.5188 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	7	5	Yes	3	0	197.83 Å2	72.41 Å3	181.45 m3·mol-1	18	No	No	0.0393 mg/mL	2.34	-4.2	11.71	-1.2			
C29H39N7O6S	Not Available	Not Available	613.728	CCCOC1=CC2=C(NC=C2C[C@@H](NS(=O)(=O)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC2=CC=C(C=C2)C(N)=N)C=C1	Solid	Not Available								4484180						5PI			5326888	46507880					ZINC000003989246		2-[2-ETHANESULFONYLAMINO-3-(5-PROPOXY-1H-INDOL-3-YL)-PROPIONYLAMINO]-PENTANEDIOIC ACID 5-AMIDE 1-(4-CARBAMIMIDOYL-BENZYLAMIDE)	Experimental	DB04606	InChI=1S/C29H39N7O6S/c1-3-13-42-21-9-10-23-22(15-21)20(17-33-23)14-25(36-43(40,41)4-2)29(39)35-24(11-12-26(30)37)28(38)34-16-18-5-7-19(8-6-18)27(31)32/h5-10,15,17,24-25,33,36H,3-4,11-14,16H2,1-2H3,(H2,30,37)(H3,31,32)(H,34,38)(H,35,39)/t24-,25+/m0/s1	UHMORXPPNXDKHY-LOSJGSFVSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.5330 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										0	No	8	7	Yes	3	1	222.35 Å2	64.89 Å3	172.77 m3·mol-1	16	No	No	0.0132 mg/mL	-0.34	-4.7	9.67	11.38	P08709	F7	1. Coagulation factor VII
C32H49N5O8	Not Available	Not Available	631.7602	CCOC(=O)\C=C\[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)C1=COC=C1	Solid	Not Available								4449909						9IN			5287569	46506597					ZINC000014881283		(E)-(4S,6S)-6-((S)-2-{(S)-2-[(FURAN-2-CARBONYL)-AMINO]-3-METHYL-BUTYRYLAMINO}-3-METHYL-BUTYRYLAMINO)-8-METHYL-5-OXO-4-((R)-2-OXO-PYRROLIDIN-3-YLMETHYL)-NON-2-ENOIC ACID ETHYL ESTER	Experimental	DB04613	InChI=1S/C32H49N5O8/c1-8-45-25(38)10-9-23(16-21-11-13-33-28(21)39)34-30(41)24(15-18(2)3)35-31(42)26(19(4)5)37-32(43)27(20(6)7)36-29(40)22-12-14-44-17-22/h9-10,12,14,17-21,23-24,26-27H,8,11,13,15-16H2,1-7H3,(H,33,39)(H,34,41)(H,35,42)(H,36,40)(H,37,43)/b10-9+/t21-,23+,24-,26-,27-/m0/s1	JQGYBVLTABWBOF-VTQXMFKGSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.4482 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	6	5	No	2	0	184.94 Å2	67.21 Å3	166.87 m3·mol-1	18	No	No	0.0496 mg/mL	2.05	-4.1	11.89	-1.2			
C26H41BN4O10	Not Available	Not Available	580.436	C[C@@H](NC(=O)[C@H](CCCCNC(=O)OCC1=CC=CC=C1)NC(=O)CC[C@H](NC(=O)OC(C)(C)C)C(O)=O)B(O)O	Solid	Not Available								4450121						BO9			5287824	46508422					ZINC000169748488		BOC-GAMMA-D-GLU-L-LYS(CBZ)-D-BOROALA	Experimental	DB04647	InChI=1S/C26H41BN4O10/c1-17(27(38)39)29-22(33)19(12-8-9-15-28-24(36)40-16-18-10-6-5-7-11-18)30-21(32)14-13-20(23(34)35)31-25(37)41-26(2,3)4/h5-7,10-11,17,19-20,38-39H,8-9,12-16H2,1-4H3,(H,28,36)(H,29,33)(H,30,32)(H,31,37)(H,34,35)/t17-,19+,20+/m1/s1	OTTYWVUOPWENAJ-HOJAQTOUSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.4749 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	8	7	No	1	-1	212.62 Å2	60.85 Å3	141.61 m3·mol-1	19	No	No	0.0237 mg/mL	1.69	-4.4	3.72	-5.4	P0AEB3;!P0AEB2	dacA;!dacA	1. D-alanyl-D-alanine carboxypeptidase DacA;!2. D-alanyl-D-alanine carboxypeptidase DacA
C30H40FN3O6	Not Available	Not Available	557.6535	[H]N([C@@H](CC(C)C)C(=O)N([H])[C@@H](CC(C)C)C(=O)N([H])[C@@H](CC1=CC=C(O)C=C1)C(=O)CF)C(=O)OCC1=CC=CC=C1	Solid	Not Available							CHEMBL72006	9679808						C1N			11505008	46507912					ZINC000026289134		N-[(benzyloxy)carbonyl]-L-leucyl-N-[(1S)-3-fluoro-1-(4-hydroxybenzyl)-2-oxopropyl]-L-leucinamide	Experimental	DB04653	InChI=1S/C30H40FN3O6/c1-19(2)14-25(28(37)32-24(27(36)17-31)16-21-10-12-23(35)13-11-21)33-29(38)26(15-20(3)4)34-30(39)40-18-22-8-6-5-7-9-22/h5-13,19-20,24-26,35H,14-18H2,1-4H3,(H,32,37)(H,33,38)(H,34,39)/t24-,25-,26-/m0/s1	JCRSHQCFRMCMOC-GSDHBNRESA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.5586 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	5	4	No	2	0	133.83 Å2	59.42 Å3	148.28 m3·mol-1	16	No	No	0.00384 mg/mL	4.78	-5.2	9.5	-3.1	P07384	CAPN1	1. Calpain-1 catalytic subunit
C29H42N4O7	Not Available	Not Available	558.6664	[H]N([C@@H](C(C)C)C(=O)N([H])[C@H](C(=O)N([H])C(C[C@@H]1CCN([H])C1=O)\C=C\C(=O)OCC)C1=CC=CC=C1)C(=O)OC(C)(C)C	Solid	Not Available								4883355						ENB			23304231	46508007							Ethyl (2E)-4-({(2S)-2-[(N-{[(2-methyl-2-propanyl)oxy]carbonyl}-L-valyl)amino]-2-phenylacetyl}amino)-5-[(3S)-2-oxo-3-pyrrolidinyl]-2-pentenoate	Experimental	DB04692	InChI=1S/C29H42N4O7/c1-7-39-22(34)14-13-21(17-20-15-16-30-25(20)35)31-27(37)24(19-11-9-8-10-12-19)32-26(36)23(18(2)3)33-28(38)40-29(4,5)6/h8-14,18,20-21,23-24H,7,15-17H2,1-6H3,(H,30,35)(H,31,37)(H,32,36)(H,33,38)/b14-13+/t20-,21?,23-,24-/m0/s1	NUDVEHBHDBJSMD-XBEUYHOESA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.7090 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	5	4	No	2	0	151.93 Å2	59.81 Å3	149.01 m3·mol-1	15	No	No	0.00719 mg/mL	2.49	-4.9	12	-1.3			
C38H61N11O6	Not Available	Not Available	767.961	NC(N)=NCCCC[C@H](NC(=O)[C@@H](CC1=CC=C(O)C=C1)NC(=O)[C@@H]1CCN1C(=O)[C@@H](CC1CCCCC1)NC(=O)[C@@H]1CC[C@H](CN=C(N)N)CC1)C(N)=O	Solid	Not Available														GAH			5288332	46507271							TRANS-4-(GUANIDINOMETHYL)-CYCLOHEXANE-L-YL-D-3-CYCLOHEXYLALANYL-L-AZETIDINE-2-YL-D-TYROSINYL-L-HOMOARGININAMIDE	Experimental	DB04697	InChI=1S/C38H61N11O6/c39-32(51)28(8-4-5-18-44-37(40)41)46-34(53)29(20-24-11-15-27(50)16-12-24)47-35(54)31-17-19-49(31)36(55)30(21-23-6-2-1-3-7-23)48-33(52)26-13-9-25(10-14-26)22-45-38(42)43/h11-12,15-16,23,25-26,28-31,50H,1-10,13-14,17-22H2,(H2,39,51)(H,46,53)(H,47,54)(H,48,52)(H4,40,41,44)(H4,42,43,45)/t25-,26+,28-,29+,30+,31-/m0/s1	PCCHJIAHIWBHDQ-CNXMXSPQSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3596 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	12	9	Yes	4	2	299.73 Å2	83.41 Å3	206.39 m3·mol-1	19	No	No	0.0147 mg/mL	-0.83	-4.7	9.5	11.79	P00734	F2	1. Prothrombin
C11H19N3O6S	Not Available	Not Available	321.35	CSC[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)NCC(O)=O	Solid	Not Available					225232	141473	CHEMBL1233129	103128				C11347		GSM			115260	46507560					ZINC000001532230		S-Methyl glutathione	Experimental	DB04701	InChI=1S/C11H19N3O6S/c1-21-5-7(10(18)13-4-9(16)17)14-8(15)3-2-6(12)11(19)20/h6-7H,2-5,12H2,1H3,(H,13,18)(H,14,15)(H,16,17)(H,19,20)/t6-,7-/m0/s1	QTQDDTSVRVWHMO-BQBZGAKWSA-N			Not Available	Small Molecule	http://smpdb.ca/view/SMP0000501?highlight[compounds][]=DB04701&highlight[proteins][]=DB04701;!http://smpdb.ca/view/SMP0000183?highlight[compounds][]=DB04701&highlight[proteins][]=DB04701;!http://smpdb.ca/view/SMP0000500?highlight[compounds][]=DB04701&highlight[proteins][]=DB04701;!http://smpdb.ca/view/SMP0000015?highlight[compounds][]=DB04701&highlight[proteins][]=DB04701;!http://smpdb.ca/view/SMP0000143?highlight[compounds][]=DB04701&highlight[proteins][]=DB04701;!http://smpdb.ca/view/SMP0000337?highlight[compounds][]=DB04701&highlight[proteins][]=DB04701	gamma-Glutamyltranspeptidase Deficiency;!gamma-Glutamyltransferase Deficiency;!5-Oxoprolinase Deficiency;!Glutathione Metabolism;!5-Oxoprolinuria;!Glutathione Synthetase Deficiency		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.7868 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	5	No	0	-1	158.82 Å2	31.25 Å3	73.77 m3·mol-1	10	Yes	No	2.61 mg/mL	-4.5	-2.1	1.81	9.31	P28161	GSTM2	1. Glutathione S-transferase Mu 2
C30H46N6O8	Not Available	Not Available	618.7216	CCOC(=O)\C=C\[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)C1=NOC(C)=C1	Solid	Not Available								4883391						I12			15959287	46505902					ZINC000014881295		(E)-(S)-4-[(S)-4-METHYL-2-((S)-3-METHYL-2{(S)-2-[(5-METHYL-ISOXAZOLE-3- CARBONYL)-AMINO]-PROPIONYLAMINO}-BUTYRYLAMINO)-PENTANOYLAMINO]-5-((S)-2- OXO-PYRROLIDIN-3-YL)-PENT-2-ENOIC ACID ETHYL ESTER	Experimental	DB04710	InChI=1S/C30H46N6O8/c1-8-43-24(37)10-9-21(15-20-11-12-31-27(20)39)33-28(40)22(13-16(2)3)34-30(42)25(17(4)5)35-26(38)19(7)32-29(41)23-14-18(6)44-36-23/h9-10,14,16-17,19-22,25H,8,11-13,15H2,1-7H3,(H,31,39)(H,32,41)(H,33,40)(H,34,42)(H,35,38)/b10-9+/t19-,20-,21+,22-,25-/m0/s1	LIVSSCDUYUOZEL-GLXPMXKMSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.5616 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	7	5	No	2	0	197.83 Å2	65.7 Å3	161.58 m3·mol-1	17	No	No	0.0744 mg/mL	0.97	-3.9	11.71	-1.2			
C37H59N7O20	Not Available	Not Available	921.8993	C[C@@H](NC(=O)[C@H](CCC[C@@H](N)C(O)=O)NC(=O)CC[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@@H]1[C@@H](NC(C)=O)[C@@H]2OC[C@@H](O2)[C@H]1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O)C(O)=O)C(O)=O	Solid	Not Available						46763		143523						MLD			163626	46508748					ZINC000096006131		2-ACETAMIDO-2-DEOXY-BETA-D-GLUCOPYRANOSE(BETA1-4)-2-ACETAMIDO-1,6-ANHYDRO-3-O-[(R)-1-CARBOXYETHYL]-2-DEOXY-BETA-D-GLUCOPYRANOSE-L-ALANYL-GAMMA-D-GLUTAMYL-MESO-DIAMINOPIMELYL-D-ALANINE	Experimental	DB04736	InChI=1S/C37H59N7O20/c1-13(30(51)44-20(35(58)59)9-10-23(48)43-19(8-6-7-18(38)34(56)57)32(53)40-14(2)33(54)55)39-31(52)15(3)61-29-25(42-17(5)47)36-60-12-22(63-36)28(29)64-37-24(41-16(4)46)27(50)26(49)21(11-45)62-37/h13-15,18-22,24-29,36-37,45,49-50H,6-12,38H2,1-5H3,(H,39,52)(H,40,53)(H,41,46)(H,42,47)(H,43,48)(H,44,51)(H,54,55)(H,56,57)(H,58,59)/t13-,14+,15+,18+,19-,20+,21+,22+,24+,25+,26+,27+,28+,29+,36+,37-/m0/s1	UPFMKPIBAIPLHT-RSJSDIDPSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.4244 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	21	13	Yes	3	-2	419.36 Å2	87.71 Å3	205.48 m3·mol-1	24	No	No	4.18 mg/mL	-8.8	-2.3	1.92	9.52	Q96LB9	PGLYRP3	1. Peptidoglycan recognition protein 3
C20H33N5O5S2	Not Available	Not Available	487.637	CCCS(=O)(=O)N[C@H]([C@H](C)O)C(=O)N[C@@H](CCSC)C(=O)NCC1=CC=C(C=C1)C(N)=N	Solid	Not Available								4451220						PSM			5289214	46505133					ZINC000012504502		N-[1-(4-CARBAMIMIDOYL-BENZYLCARBAMOYL)-3-METHYLSULFANYL-PROPYL]-3-HYDROXY-2-PROPOXYAMINO-BUTYRAMID	Experimental	DB04767	InChI=1S/C20H33N5O5S2/c1-4-11-32(29,30)25-17(13(2)26)20(28)24-16(9-10-31-3)19(27)23-12-14-5-7-15(8-6-14)18(21)22/h5-8,13,16-17,25-26H,4,9-12H2,1-3H3,(H3,21,22)(H,23,27)(H,24,28)/t13-,16-,17+/m0/s1	AIIJKVORRBMJHS-RRQGHBQHSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.5895 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	7	6	No	1	1	174.47 Å2	51.28 Å3	136.29 m3·mol-1	13	No	No	0.0589 mg/mL	-0.98	-3.9	8.59	11.37	P08709	F7	1. Coagulation factor VII
C23H35N7O5	Not Available	Not Available	489.5679	CC(C)C[C@H](NC(=O)C1=CC=C(C=C1)[N+]([O-])=O)C(=O)N1CCC[C@H]1C(=O)NCCCCN=C(N)N	Solid	Not Available								4591887						RA4			5494439	46506641					ZINC000016051710		1-GUANIDINO-4-(N-NITRO-BENZOYLAMINO-L-LEUCYL-L-PROLYLAMINO)BUTANE	Experimental	DB04771	InChI=1S/C23H35N7O5/c1-15(2)14-18(28-20(31)16-7-9-17(10-8-16)30(34)35)22(33)29-13-5-6-19(29)21(32)26-11-3-4-12-27-23(24)25/h7-10,15,18-19H,3-6,11-14H2,1-2H3,(H,26,32)(H,28,31)(H4,24,25,27)/t18-,19-/m0/s1	FIZYZWLGMGGGBJ-OALUTQOASA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.5775 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	8	4	No	2	1	186.05 Å2	51.32 Å3	130.19 m3·mol-1	12	Yes	No	0.0309 mg/mL	0.83	-4.2	13.73	11.28	P00734	F2	1. Prothrombin
C57H70N12O9S2	Not Available	30 minutes	1131.38	CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=CC=CC=C23)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(N)=O)NC(=O)[C@H](N)CC1=CC=CC=C1	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4				CHEMBL3349523	5293243					D06281			PA164743146	6918026	46506923			DAP001242	Vapreotide			Vapreotide	Experimental, Investigational	DB04894	InChI=1S/C57H70N12O9S2/c1-32(2)49-57(78)68-48(55(76)64-44(50(60)71)26-35-28-61-41-16-8-6-14-38(35)41)31-80-79-30-47(67-51(72)40(59)24-33-12-4-3-5-13-33)56(77)65-45(25-34-19-21-37(70)22-20-34)53(74)66-46(27-36-29-62-42-17-9-7-15-39(36)42)54(75)63-43(52(73)69-49)18-10-11-23-58/h3-9,12-17,19-22,28-29,32,40,43-49,61-62,70H,10-11,18,23-27,30-31,58-59H2,1-2H3,(H2,60,71)(H,63,75)(H,64,76)(H,65,77)(H,66,74)(H,67,72)(H,68,78)(H,69,73)/t40-,43+,44+,45+,46-,47+,48+,49+/m1/s1	SWXOGPJRIDTIRL-DOUNNPEJSA-N	3		Safety data are limited, however, headache, fatigue, diarrhea, nausea, vomiting, and abdominal pain have been reported commonly with the use of vapreotide.	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.7335 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										0	No	11	13	Yes	7	2	350.64 Å2	118.22 Å3	306.22 m3·mol-1	18	No	No	0.00401 mg/mL	1.07	-5.4	9.43	10.26	P30874;!P35346;!P25103	SSTR2;!SSTR5;!TACR1	1. Somatostatin receptor type 2;!2. Somatostatin receptor type 5;!3. Neurokinin 1 receptor
C24H35N5O5	Not Available	3-5 hours	473.5652	CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(C=C1)C(\N)=N\O)C1CCCCC1	Solid	Not Available	P11712	CYP2C9	1. Cytochrome P450 2C9			65172	CHEMBL522038	7848559			HMDB0015603					PA161748474	9574101	46509040			DAP001218	Ximelagatran	ZINC000012504524		Ximelagatran	Approved, Investigational, Withdrawn	DB04898	InChI=1S/C24H35N5O5/c1-2-34-20(30)15-26-21(17-6-4-3-5-7-17)24(32)29-13-12-19(29)23(31)27-14-16-8-10-18(11-9-16)22(25)28-33/h8-11,17,19,21,26,33H,2-7,12-15H2,1H3,(H2,25,28)(H,27,31)/t19-,21+/m0/s1	ZXIBCJHYVWYIKI-PZJWPPBQSA-N			Hepatotoxicity (liver damage) was reported during trials.	Small Molecule	http://smpdb.ca/view/SMP0000279?highlight[compounds][]=DB04898&highlight[proteins][]=DB04898	Ximelagatran Action Pathway		Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.4109 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	7	4	Yes	3	0	146.35 Å2	52.18 Å3	126.57 m3·mol-1	11	Yes	No	0.0845 mg/mL	0.87	-3.8	8.7	5.48	P00734	F2	1. Prothrombin
C78H111N21O19	Data regarding plasma clearance of afamelanotide are limited. Plasma drug levels are typically undetectable at day 10 following subcutaneous administration of the afamelanotide implant.4,3	The half-life of afamelanotide is approximately 30 minutes.4 The apparent half-life following administration of a slow-release subcutaneous implant is 15 hours.10	1646.8452	CCCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(N)=O	Solid	The apparent volume of distribution of afamelanotide following intravenous administration is approximately 0.54 L/kg.2					50017181	136034	CHEMBL441738	17310725									16197727	175426907		2262250		Melanotan		Scenesse	Afamelanotide	Approved, Investigational	DB04931	InChI=1S/C78H111N21O19/c1-5-6-19-52(91-75(116)61(41-101)97-72(113)57(34-46-24-26-49(103)27-25-46)94-74(115)60(40-100)88-44(4)102)68(109)92-54(28-29-64(105)106)70(111)96-59(36-48-38-83-42-87-48)73(114)93-56(33-45-16-8-7-9-17-45)71(112)90-53(22-14-31-84-78(81)82)69(110)95-58(35-47-37-85-51-20-11-10-18-50(47)51)67(108)86-39-63(104)89-55(21-12-13-30-79)77(118)99-32-15-23-62(99)76(117)98-65(43(2)3)66(80)107/h7-11,16-18,20,24-27,37-38,42-43,52-62,65,85,100-101,103H,5-6,12-15,19,21-23,28-36,39-41,79H2,1-4H3,(H2,80,107)(H,83,87)(H,86,108)(H,88,102)(H,89,104)(H,90,112)(H,91,116)(H,92,109)(H,93,114)(H,94,115)(H,95,110)(H,96,111)(H,97,113)(H,98,117)(H,105,106)(H4,81,82,84)/t52-,53-,54-,55-,56+,57-,58-,59-,60-,61-,62-,65-/m0/s1	UAHFGYDRQSXQEB-LEBBXHLNSA-N	3	Afamelanotide is an injectable subcutaneous implant used to mitigate phototoxicity secondary to erythropoietic protoporphyria (EPP).	Data regarding symptoms or treatment of afamelanotide overdose are currently unavailable.4	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	3.0321 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	24	23	Yes	6	2	642.98 Å2	171.61 Å3	434.35 m3·mol-1	50	No	No	0.023 mg/mL	-8.2	-4.9	3.46	11.58	Q01726	MC1R	1. Melanocyte-stimulating hormone receptor
C26H40Cl4N5O10PS	Not Available	18 min	787.46	N[C@@H](CCC(=O)N[C@@H](CS(=O)(=O)CCOP(=O)(N(CCCl)CCCl)N(CCCl)CCCl)C(=O)N[C@@H](C(O)=O)C1=CC=CC=C1)C(O)=O	Solid	Not Available						135883	CHEMBL2111086	4471543									5312109	175426923					ZINC000085537051		Canfosfamide	Investigational	DB04972	InChI=1S/C26H40Cl4N5O10PS/c27-8-12-34(13-9-28)46(42,35(14-10-29)15-11-30)45-16-17-47(43,44)18-21(32-22(36)7-6-20(31)25(38)39)24(37)33-23(26(40)41)19-4-2-1-3-5-19/h1-5,20-21,23H,6-18,31H2,(H,32,36)(H,33,37)(H,38,39)(H,40,41)/t20-,21-,23+/m0/s1	OJLHWPALWODJPQ-QNWVGRARSA-N	3		Canfosfamide-related toxicities included grade 1-2 nausea, vomiting, fatigue, transient microscopic hematuria, and anemia.	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.5940 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	10	5	No	1	-1	225.74 Å2	74.17 Å3	175.76 m3·mol-1	25	No	No	0.0385 mg/mL	-2.9	-4.3	1.37	9.26	P09211	GSTP1	1. Glutathione S-transferase P
C31H39FN4O7	Not Available	Not Available	598.6624	CCOC(=O)\C=C\[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@@H](CC(=O)[C@H](C(C)C)NC(=O)C1=NOC(C)=C1)CC1=CC=C(F)C=C1	Solid	Not Available					11243		CHEMBL20210	4944627									6440352	175426944					ZINC000003919807		Rupintrivir	Investigational	DB05102	InChI=1S/C31H39FN4O7/c1-5-42-27(38)11-10-24(16-21-12-13-33-29(21)39)34-30(40)22(15-20-6-8-23(32)9-7-20)17-26(37)28(18(2)3)35-31(41)25-14-19(4)43-36-25/h6-11,14,18,21-22,24,28H,5,12-13,15-17H2,1-4H3,(H,33,39)(H,34,40)(H,35,41)/b11-10+/t21-,22+,24+,28-/m0/s1	CAYJBRBGZBCZKO-BHGBQCOSSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.6484 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	6	3	Yes	3	0	156.7 Å2	62.56 Å3	157.24 m3·mol-1	16	No	No	0.0306 mg/mL	3.21	-4.3	12.5	-0.59	P03303	Not Available	1. Genome polyprotein
C56H79N9O14	Not Available	Not Available	1102.297	CCCCCCCCOC1=CC=C(C=C1)C1=CC=C(C=C1)C(=O)N[C@H]1CC(CNC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)CC1=CC=C(O)C=C1)NCCN	Solid	Not Available						84073		9854442									16072305	175426949				Aminocandin			Aminocandin	Investigational	DB05128	InChI=1S/C56H79N9O14/c1-4-5-6-7-8-9-24-79-41-20-16-36(17-21-41)35-12-14-37(15-13-35)50(72)60-42-26-38(58-23-22-57)28-59-54(76)48-49(71)32(2)29-65(48)55(77)43(31-66)61-53(75)47(45(70)25-34-10-18-39(68)19-11-34)63-52(74)44-27-40(69)30-64(44)56(78)46(33(3)67)62-51(42)73/h10-21,32-33,38,40,42-49,58,66-71H,4-9,22-31,57H2,1-3H3,(H,59,76)(H,60,72)(H,61,75)(H,62,73)(H,63,74)/t32-,33+,38?,40+,42-,43-,44-,45+,46-,47-,48-,49-/m0/s1	UMNFJRNUJIBDSK-NMVZEWDOSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	3.1232 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										0	No	16	13	Yes	6	2	354.78 Å2	117.73 Å3	288.69 m3·mol-1	19	No	No	0.0389 mg/mL	-2.1	-4.4	9.81	9.21			
C36H49N9O4	Not Available	Not Available	671.847	CCCC[C@@H](NC(=O)[C@@H](CC1=CC=CC=C1)NC(=O)[C@H](N)CC1=CC=CC=C1)C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC1=CC=NC=C1	Solid	Not Available								32702094									25030387	347827714				CR665			CR665	Investigational	DB05155	InChI=1S/C36H49N9O4/c1-2-3-15-30(34(48)43-29(16-10-19-41-36(38)39)33(47)42-24-27-17-20-40-21-18-27)44-35(49)31(23-26-13-8-5-9-14-26)45-32(46)28(37)22-25-11-6-4-7-12-25/h4-9,11-14,17-18,20-21,28-31H,2-3,10,15-16,19,22-24,37H2,1H3,(H,42,47)(H,43,48)(H,44,49)(H,45,46)(H4,38,39,41)/t28-,29-,30-,31-/m1/s1	DBOGGOVKHSCMNB-OMRVPHBLSA-N			Not Available	Small Molecule																																			0	No	9	8	Yes	3	2	217.21 Å2	74.14 Å3	197.95 m3·mol-1	20	No	No	0.00349 mg/mL	1.12	-5.3	12.18	11.69	P41145	OPRK1	1. Kappa-type opioid receptor
C46H83N13O11	Not Available	Not Available	994.2317	CCC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)CN(C)C(C)=O)C(C)C)[C@@H](C)CC)[C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC	Solid	Not Available					50165195		CHEMBL386115	5293759									6918562	175427003				ABT-510	ZINC000169362874		ABT-510	Investigational	DB05434	InChI=1S/C46H83N13O11/c1-12-18-30(39(64)55-36(26(7)13-2)42(67)53-31(19-16-21-50-46(47)48)45(70)59-22-17-20-32(59)40(65)49-15-4)52-44(69)38(28(9)60)57-43(68)37(27(8)14-3)56-41(66)35(25(5)6)54-33(62)23-51-34(63)24-58(11)29(10)61/h25-28,30-32,35-38,60H,12-24H2,1-11H3,(H,49,65)(H,51,63)(H,52,69)(H,53,67)(H,54,62)(H,55,64)(H,56,66)(H,57,68)(H4,47,48,50)/t26-,27-,28+,30-,31-,32-,35-,36-,37+,38-/m0/s1	RIWLPSIAFBLILR-WVNGMBSFSA-N	2		Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.7475 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	14	11	No	1	1	358.05 Å2	107.38 Å3	257.8 m3·mol-1	30	No	No	0.0426 mg/mL	-3.3	-4.4	10.73	11.56	P09038;!P14210;!P15692;!P10145	FGF2;!HGF;!VEGFA;!CXCL8	1. Fibroblast growth factor 2;!2. Hepatocyte growth factor;!3. Vascular endothelial growth factor A;!4. Interleukin-8
C27H35N3O6S	Not Available	Not Available	529.648	CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCC1=CC=CC=C1)C(=O)N[C@@H](C(=O)OCC)C1=CC=CC=C1	Solid	Not Available							CHEMBL2110585	4470493									5310939	175427010					ZINC000056898832		Ezatiostat	Investigational	DB05460	InChI=1S/C27H35N3O6S/c1-3-35-26(33)21(28)15-16-23(31)29-22(18-37-17-19-11-7-5-8-12-19)25(32)30-24(27(34)36-4-2)20-13-9-6-10-14-20/h5-14,21-22,24H,3-4,15-18,28H2,1-2H3,(H,29,31)(H,30,32)/t21-,22-,24+/m0/s1	GWEJFLVSOGNLSS-WPFOTENUSA-N	2		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.2434 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	5	3	No	2	1	136.82 Å2	57.51 Å3	141.82 m3·mol-1	17	No	No	0.00245 mg/mL	2.42	-5.3	11.75	7.18	P09211	GSTP1	1. Glutathione S-transferase P
C77H109N21O19S	Not Available	Not Available	1664.884	CSCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)NC(CC1=CN=CN1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(N)=O	Solid	Not Available								17286474									16129664	175427016							CZEN 002	Investigational	DB05479	InChI=1S/C77H109N21O19S/c1-42(2)64(65(79)106)97-75(116)61-20-13-30-98(61)76(117)54(18-10-11-28-78)88-62(103)38-85-66(107)57(34-46-36-84-50-17-9-8-16-49(46)50)94-67(108)51(19-12-29-83-77(80)81)89-70(111)55(32-44-14-6-5-7-15-44)92-72(113)58(35-47-37-82-41-86-47)95-68(109)52(25-26-63(104)105)90-69(110)53(27-31-118-4)91-74(115)60(40-100)96-71(112)56(33-45-21-23-48(102)24-22-45)93-73(114)59(39-99)87-43(3)101/h5-9,14-17,21-24,36-37,41-42,51-61,64,84,99-100,102H,10-13,18-20,25-35,38-40,78H2,1-4H3,(H2,79,106)(H,82,86)(H,85,107)(H,87,101)(H,88,103)(H,89,111)(H,90,110)(H,91,115)(H,92,113)(H,93,114)(H,94,108)(H,95,109)(H,96,112)(H,97,116)(H,104,105)(H4,80,81,83)/t51-,52-,53-,54-,55-,56-,57-,58?,59-,60-,61-,64-/m0/s1	WHNFPRLDDSXQCL-PDEGJNOBSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.9852 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										0	No	24	23	Yes	6	1	642.98 Å2	171.95 Å3	437.71 m3·mol-1	50	No	No	0.0261 mg/mL	-8.9	-4.8	3.47	11.57	Q01726	MC1R	1. Melanocyte-stimulating hormone receptor
C23H35N9O8S	Not Available	Not Available	597.65	CC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O	Solid	Not Available							CHEMBL4297456	8135892										347910170					ZINC000003924034		ATN-161	Investigational	DB05491	InChI=1S/C23H35N9O8S/c1-11(34)32-4-2-3-17(32)23(40)29-14(5-12-7-26-10-27-12)20(37)30-15(8-33)21(38)31-16(9-41)22(39)28-13(19(25)36)6-18(24)35/h7,10,13-17,33,41H,2-6,8-9H2,1H3,(H2,24,35)(H2,25,36)(H,26,27)(H,28,39)(H,29,40)(H,30,37)(H,31,38)/t13-,14-,15-,16-,17-/m0/s1	MMHDBUJXLOFTLC-WOYTXXSLSA-N	2		Not Available	Small Molecule																																			0	No	9	9	No	2	0	271.8 Å2	57.77 Å3	143.33 m3·mol-1	15	No	No	0.139 mg/mL	-6.7	-3.6	9.94	6.74			
C32H55N9O10	Not Available	Not Available	725.845	CC(C)C[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)CN)C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O	Solid	Not Available							CHEMBL2105646	7986288														Larazotide	ZINC000068009799		Larazotide	Investigational	DB05645	InChI=1S/C32H55N9O10/c1-16(2)12-20(38-30(49)26(17(3)4)39-24(44)14-35-23(43)13-33)28(47)40-27(18(5)6)31(50)37-19(9-10-22(34)42)32(51)41-11-7-8-21(41)29(48)36-15-25(45)46/h16-21,26-27H,7-15,33H2,1-6H3,(H2,34,42)(H,35,43)(H,36,48)(H,37,50)(H,38,49)(H,39,44)(H,40,47)(H,45,46)/t19-,20-,21-,26-,27-/m0/s1	ORFLZNAGUTZRLQ-ZMBVWFSWSA-N	2		Not Available	Small Molecule																																			0	No	11	9	No	1	0	301.32 Å2	75.32 Å3	180.06 m3·mol-1	21	No	No	0.218 mg/mL	-6.2	-3.5	3.43	7.84			
C27H53N7O7	Not Available	Not Available	587.763	CCOC(OCC)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)CCC(=O)N[C@H](CC([O-])=O)C[N+](C)(C)C	Solid	Not Available								32699207																	L-aminocarnityl-succinyl-leucyl-argininal-diethylacetal	Investigational	DB06124	InChI=1S/C27H53N7O7/c1-8-40-26(41-9-2)20(11-10-14-30-27(28)29)33-25(39)21(15-18(3)4)32-23(36)13-12-22(35)31-19(16-24(37)38)17-34(5,6)7/h18-21,26H,8-17H2,1-7H3,(H7-,28,29,30,31,32,33,35,36,37,38,39)/t19-,20+,21+/m1/s1	JOITUBWXBFATOR-HKBOAZHASA-N			Not Available	Small Molecule																																			0	No	10	6	No	0	1	207.79 Å2	65.49 Å3	187.34 m3·mol-1	22	No	No	0.0124 mg/mL	-6.4	-4.7	3.71	11.85	P20807	CAPN3	1. Calpain-3
C59H89N19O13S	Plasma clearance following subcutaneous administration was 245 ± 58 mL/min.	After subcutaneous administration, mean elimination half-life was 1.4 ± 0.4 hours.	1304.54	[H][C@]12C[C@]([H])(N(C(=O)[C@@]3([H])CC4=C(CN3C(=O)[C@H](CO)NC(=O)[C@H](CC3=CC=CS3)NC(=O)CNC(=O)[C@]3([H])C[C@@H](O)CN3C(=O)[C@@H]3CCCN3C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](N)CCCNC(N)=N)C=CC=C4)[C@@]1([H])CCCC2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O	Solid	Vdss, subcutaneous injection = 29.0 ± 8.7 L.					50406750	68556	CHEMBL2028850	5293384	Drugs.com Drug Page		HMDB0015624		D04492			PA164749185	71364	99443237	RxList Drug Page	1148138	DCL000131	Icatibant		Firazyr, Sajazir	Icatibant	Approved, Investigational	DB06196	InChI=1S/C59H89N19O13S/c60-37(14-5-19-67-57(61)62)48(82)72-38(15-6-20-68-58(63)64)52(86)75-22-8-18-43(75)54(88)77-30-35(80)26-44(77)50(84)70-28-47(81)71-40(27-36-13-9-23-92-36)49(83)74-41(31-79)53(87)76-29-34-12-2-1-10-32(34)24-46(76)55(89)78-42-17-4-3-11-33(42)25-45(78)51(85)73-39(56(90)91)16-7-21-69-59(65)66/h1-2,9-10,12-13,23,33,35,37-46,79-80H,3-8,11,14-22,24-31,60H2,(H,70,84)(H,71,81)(H,72,82)(H,73,85)(H,74,83)(H,90,91)(H4,61,62,67)(H4,63,64,68)(H4,65,66,69)/t33-,35+,37+,38-,39-,40-,41-,42-,43-,44-,45-,46+/m0/s1	QURWXBZNHXJZBE-SKXRKSCCSA-N	4	Icatibant is a bradykinin B2 receptor antagonist used to treat acute episodes of swelling and inflammation associated with hereditary angioedema (HAE).	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.4262 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor									1 mg/mL	0	No	23	18	Yes	7	3	516.22 Å2	135.1 Å3	363.79 m3·mol-1	30	No	No	0.0362 mg/mL	-7.7	-4.6	3.46	12.48	P30411;!P15144	BDKRB2;!ANPEP	1. B2 bradykinin receptor;!2. Aminopeptidase N
C25H32N2O4	402 ± 89 mL/min	10 to 17 hours (gut metabolite: 10 to 18 hours)	424.5326	C[C@H]1CN(C[C@H](CC2=CC=CC=C2)C(=O)NCC(O)=O)CC[C@@]1(C)C1=CC(O)=CC=C1	Solid	30±10 L					50088381	135686	CHEMBL270190	4589864	Drugs.com Drug Page		HMDB0015631		D02878			PA164754864	5488548	99443242	RxList Drug Page	480639	DAP001140	Alvimopan	ZINC000003802417	Entereg	Alvimopan	Approved, Investigational	DB06274	InChI=1S/C25H32N2O4/c1-18-16-27(12-11-25(18,2)21-9-6-10-22(28)14-21)17-20(24(31)26-15-23(29)30)13-19-7-4-3-5-8-19/h3-10,14,18,20,28H,11-13,15-17H2,1-2H3,(H,26,31)(H,29,30)/t18-,20-,25+/m0/s1	UPNUIXSCZBYVBB-JVFUWBCBSA-N	4	Alvimopan is an opioid antagonist used to reduce healing time of the upper and lower gastrointestinal tract following surgical procedures that involve bowel resection with primary anastomosis.	Not Available	Small Molecule	http://smpdb.ca/view/SMP0000685?highlight[compounds][]=DB06274&highlight[proteins][]=DB06274	Alvimopan Action Pathway		Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.6978 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor									<0.1 mg/mL	1	Yes	5	3	Yes	3	0	89.87 Å2	46.77 Å3	120.56 m3·mol-1	8	Yes	No	0.00834 mg/mL	0.82	-4.7	3.71	10.66	P35372;!P41145;!P41143	OPRM1;!OPRK1;!OPRD1	1. Mu-type opioid receptor;!2. Kappa-type opioid receptor;!3. Delta-type opioid receptor
C20H40N3O11P	Not Available	Not Available	529.524	COCCOC(=O)NCCCCC(NC(=O)OCCOC)C(=O)NCCCCCCOP(O)(O)=O	Solid	Not Available								52083501																	Pegnivacogin	Investigational	DB06293	InChI=1S/C20H40N3O11P/c1-30-13-15-32-19(25)22-11-7-5-9-17(23-20(26)33-16-14-31-2)18(24)21-10-6-3-4-8-12-34-35(27,28)29/h17H,3-16H2,1-2H3,(H,21,24)(H,22,25)(H,23,26)(H2,27,28,29)	QGVYYLZOAMMKAH-UHFFFAOYSA-N	1		Not Available	Small Molecule																																			0	No	8	5	No	0	-2	190.98 Å2	55.68 Å3	124.63 m3·mol-1	23	No	No	0.0854 mg/mL	0.14	-3.8	1.81	-3.3			
C31H40N4O8	Not Available	Not Available	596.681	CC(C)C[C@H](NC(=O)COC1=CC=CC=C1C)C(=O)N[C@@H](CC1=CC=C(OC(=O)N2CCC(CC2)C(N)=O)C=C1)C(O)=O	Solid	Not Available								7985272															ZINC000003976535		GW-559090	Investigational	DB06508	InChI=1S/C31H40N4O8/c1-19(2)16-24(33-27(36)18-42-26-7-5-4-6-20(26)3)29(38)34-25(30(39)40)17-21-8-10-23(11-9-21)43-31(41)35-14-12-22(13-15-35)28(32)37/h4-11,19,22,24-25H,12-18H2,1-3H3,(H2,32,37)(H,33,36)(H,34,38)(H,39,40)/t24-,25-/m0/s1	RZMCXMNNXGCFQG-DQEYMECFSA-N			Not Available	Small Molecule																																			0	No	7	4	Yes	3	-1	177.36 Å2	61.45 Å3	156.34 m3·mol-1	14	No	No	0.00604 mg/mL	2.63	-5	3.48	-1.5			
C49H75N15O12S	Not Available	Not Available	1098.29	COC1=CC=C(C[C@@H](CN[C@@H](CCCN=C(N)N)C(O)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CO)NC(=O)[C@H](CC2=CC=CS2)NC(=O)CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H]2CCCN2C(=O)[C@@H](N)CCCN=C(N)N)C=C1	Solid	Not Available							CHEMBL2105864	5293490																	Labradimil	Investigational	DB06549	InChI=1S/C49H75N15O12S/c1-76-31-14-12-28(13-15-31)21-29(24-57-34(47(74)75)9-3-17-56-49(53)54)59-43(70)37-10-4-18-62(37)45(72)36(27-65)61-41(68)35(23-32-7-6-20-77-32)60-40(67)25-58-42(69)39-22-30(66)26-64(39)46(73)38-11-5-19-63(38)44(71)33(50)8-2-16-55-48(51)52/h6-7,12-15,20,29-30,33-39,57,65-66H,2-5,8-11,16-19,21-27,50H2,1H3,(H,58,69)(H,59,70)(H,60,67)(H,61,68)(H,74,75)(H4,51,52,55)(H4,53,54,56)/t29-,30+,33-,34-,35-,36-,37-,38-,39-/m0/s1	IDXCXSCCZNCXCL-XMADEQCMSA-N	1		Not Available	Small Molecule																																			0	No	20	13	Yes	5	3	431.17 Å2	113.82 Å3	279.12 m3·mol-1	29	No	No	0.0428 mg/mL	-7.2	-4.4	1.65	11.48	P30411	BDKRB2	1. B2 bradykinin receptor
C60H86N16O13	Not Available	The elimination half-life is approximately 50 to 80 minutes following intravenous administration, 80 minutes after subcutaneous administration and approximately 1 to 2 hours after intranasal administration.	1239.447	CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1	Liquid	Buserelin circulates in serum predominantly in intact active form. Preferred accumulation is preferentially in the liver and kidneys as well as in the anterior pituitary lobe, the biological target organ.	P11511	CYP19A1	1. Cytochrome P450 19A1			135907	CHEMBL2110824	45545					D01831					347910362		1825		Buserelin		Suprefact	Buserelin	Approved, Investigational	DB06719	InChI=1S/C60H86N16O13/c1-7-64-57(87)48-15-11-23-76(48)58(88)41(14-10-22-65-59(61)62)69-51(81)42(24-33(2)3)70-56(86)47(31-89-60(4,5)6)75-52(82)43(25-34-16-18-37(78)19-17-34)71-55(85)46(30-77)74-53(83)44(26-35-28-66-39-13-9-8-12-38(35)39)72-54(84)45(27-36-29-63-32-67-36)73-50(80)40-20-21-49(79)68-40/h8-9,12-13,16-19,28-29,32-33,40-48,66,77-78H,7,10-11,14-15,20-27,30-31H2,1-6H3,(H,63,67)(H,64,87)(H,68,79)(H,69,81)(H,70,86)(H,71,85)(H,72,84)(H,73,80)(H,74,83)(H,75,82)(H4,61,62,65)/t40-,41-,42-,43-,44-,45-,46-,47+,48-/m0/s1	CUWODFFVMXJOKD-UVLQAERKSA-N	4	Buserelin is a LHRH agonist used for the palliative treatment of hormone-dependent advanced carcinoma of the prostate gland in males and treatment of endometriosis in females.	Buserelin may induce early, transient increase in serum testosterone or estradiol which can lead in the exacerbation of signs and symptoms of metastatic prostate cancer or endometriosis. Adverse reactions reported at more than 10% occurrence include headache, loss of libido in patients with prostate cancer, hot flashes, hypermenorrhea, decreased libido in prostate cancer and endometriosis, flatulence, impotence, vaginal dryness, back pain and nasal mucosa irritation.	Small Molecule																																			0	No	17	16	Yes	6	1	438.27 Å2	131.48 Å3	334.23 m3·mol-1	33	No	No		-3.3		9.49	11.85	P22888;!P30968	LHCGR;!GNRHR	1. Lutropin-choriogonadotropic hormone receptor;!2. Gonadotropin-releasing hormone receptor
C42H65N13O10	Not Available	Not Available	912.063	[H]N([H])C(=NCCC[C@H](N([H])C(=O)CN([H])C)C(=O)N([H])[C@@H](C(C)C)C(=O)N([H])[C@@H](CC1=CC=C(O)C=C1)C(=O)N([H])[C@@H](C(C)C)C(=O)N([H])[C@@H](CC1=CN=CN1[H])C(=O)N1CCC[C@H]1C(=O)N([H])[C@@H](C)C(O)=O)N([H])[H]	Solid	Not Available					50009338	135894	CHEMBL938	4884380												9556		Saralasin	ZINC000169289386		Saralasin	Investigational	DB06763	InChI=1S/C42H65N13O10/c1-22(2)33(53-35(58)28(50-32(57)20-45-6)9-7-15-47-42(43)44)38(61)51-29(17-25-11-13-27(56)14-12-25)36(59)54-34(23(3)4)39(62)52-30(18-26-19-46-21-48-26)40(63)55-16-8-10-31(55)37(60)49-24(5)41(64)65/h11-14,19,21-24,28-31,33-34,45,56H,7-10,15-18,20H2,1-6H3,(H,46,48)(H,49,60)(H,50,57)(H,51,61)(H,52,62)(H,53,58)(H,54,59)(H,64,65)(H4,43,44,47)/t24-,28-,29-,30-,31-,33-,34-/m0/s1	PFGWGEPQIUAZME-NXSMLHPHSA-N			Not Available	Small Molecule																																			0	No	15	12	Yes	3	2	357.55 Å2	94.21 Å3	234.83 m3·mol-1	25	No	No	0.0439 mg/mL	-4.7	-4.3	3.41	10.84			
C70H94N18O16	In prostate cancer patients (n=17) administered a histrelin implant (Vantas, Endo Pharmaceuticals) the apparent clearance was 174 ± 56.5 mL/min (mean ± SD).8	In healthy volunteers administered a subcutaneous bolus dose of histrelin, the terminal half-life was 3.92 ± 1.01 hr (mean ± SD).8	1443.632	CC(O)=O.CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC1=CN(CC2=CC=CC=C2)C=N1)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1	Solid	The apparent volume of distribution of histrelin following a subcutaneous bolus dose of histrelin (Vantas, Endo Pharmaceuticals, 500 mcg) in healthy volunteers was 58.4 ± 7.86 L.8						63530	CHEMBL1201255	26606349	Drugs.com Drug Page				D02369		PDRhealth Drug Page		56927879	347827797	RxList Drug Page	50975		Histrelin		Supprelin, Vantas	Histrelin	Approved, Withdrawn	DB06788	InChI=1S/C66H86N18O12.2C2H4O2/c1-4-70-64(95)55-17-11-25-84(55)65(96)48(16-10-24-71-66(67)68)76-58(89)49(26-38(2)3)77-62(93)53(30-43-34-83(37-74-43)33-40-12-6-5-7-13-40)81-59(90)50(27-39-18-20-44(86)21-19-39)78-63(94)54(35-85)82-60(91)51(28-41-31-72-46-15-9-8-14-45(41)46)79-61(92)52(29-42-32-69-36-73-42)80-57(88)47-22-23-56(87)75-47;2*1-2(3)4/h5-9,12-15,18-21,31-32,34,36-38,47-55,72,85-86H,4,10-11,16-17,22-30,33,35H2,1-3H3,(H,69,73)(H,70,95)(H,75,87)(H,76,89)(H,77,93)(H,78,94)(H,79,92)(H,80,88)(H,81,90)(H,82,91)(H4,67,68,71);2*1H3,(H,3,4)/t47-,48-,49-,50-,51-,52-,53+,54-,55-;;/m0../s1	BKEMVGVBBDMHKL-VYFXDUNUSA-N	3	Histrelin is a GnRH agonist found in subcutaneous implants used for the treatment of pediatric patients with central precocious puberty and the palliative treatment of advanced prostate cancer.	There were no signs of systemic toxicity in animals injected with up to 200 mcg/kg (rats, rabbits), or 2000 mcg/kg (mice) of histrelin acetate. These concentrations represent 20 to 200 times the maximal recommended human dose of 10 mcg/kg/day.8 Patients receiving one, two or four histrelin implants (Vantas, Endo Pharmaceuticals) had similar adverse event profiles.8 No overdose cases were reported in the clinical trials of the histrelin product Supprelin LA (Vantas, Endo Pharmaceuticals). The administration of high doses of histrelin in animal studies was associated with the expected pharmacological effects.6 Since both products of histrelin are administered using implants that deliver a constant dose, accidental or intentional overdose is unlikely.	Small Molecule																																	5.3 (His-base)	10 mg/mL	0	No	17	16	Yes	8	1	446.86 Å2	138.34 Å3	360.07 m3·mol-1	34	No	No		-2.1		9.49	11.59	P30968	GNRHR	1. Gonadotropin-releasing hormone receptor
C54H69N11O10S2	Estimated Clearance = 23.1 L/h	Half-life is approximately 22 days	1096.33	[H]N([H])CCCCC1N([H])C(=O)C(CC2=CN([H])C3=CC=CC=C23)N([H])C(=O)C(CC2=CC=C(O)C=C2)N([H])C(=O)C(CSSCC(N([H])C(=O)C(N([H])C1=O)C(C)C)C(=O)N([H])C(C(C)O)C(=O)N([H])[H])N([H])C(=O)C(CC1=CC2=CC=CC=C2C=C1)N([H])[H]	Solid	Estimated Volume of Distribution = 15.1 L	P08684	CYP3A4	1. Cytochrome P450 3A4				CHEMBL1201185	64450	Drugs.com Drug Page				D04666		PDRhealth Drug Page		71349	310264887	RxList Drug Page	68092		Lanreotide		Somatuline	Lanreotide	Approved	DB06791	InChI=1S/C54H69N11O10S2/c1-29(2)45-54(75)63-44(53(74)65-46(30(3)66)47(57)68)28-77-76-27-43(62-48(69)38(56)23-32-15-18-33-10-4-5-11-34(33)22-32)52(73)60-41(24-31-16-19-36(67)20-17-31)50(71)61-42(25-35-26-58-39-13-7-6-12-37(35)39)51(72)59-40(49(70)64-45)14-8-9-21-55/h4-7,10-13,15-20,22,26,29-30,38,40-46,58,66-67H,8-9,14,21,23-25,27-28,55-56H2,1-3H3,(H2,57,68)(H,59,72)(H,60,73)(H,61,71)(H,62,69)(H,63,75)(H,64,70)(H,65,74)	PUDHBTGHUJUUFI-UHFFFAOYSA-N	4	Lanreotide is a somatostatin analog used for the treatment of unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors and acromegaly.	The most common adverse events are GI related, occurring in 67-84% of patients, and are typically mild to moderate. GI related effects are often transient, improve with subsequent injections, and most frequently include diarrhea and abdominal pain. Other GI symptoms such as nausea, vomiting, and abdominal distension are less common. It is not clear whether or not GI effects are dose related.Adverse effects relating to site of injection occur in 43% of patients and are more common in patients who self-inject as opposed to those who had health-care professionals administer the injection.A small number of patients report newly impaired glucose tolerance, fasting glucose or diabetes mellitus. Patients being treated for diabetes mellitus may experience hypoglycemia. After 1 year, up to 30% of patients may experience gallstone formation and the presence of sludge within the gallbladder due to inhibition of gallbladder and GI motility. This may be influenced by previous exposure to somatostatin analogues. Other adverse effects include reduction in left ventricular end-diastolic and end-systolic volumes, bradycardia, nasopharyngitis, and alopecia. Lanreotide is classified as Pregnancy Category C.	Small Molecule																																			0	No	12	13	Yes	6	2	355.08 Å2	114.68 Å3	292.92 m3·mol-1	17	No	No	0.00496 mg/mL	-0.33	-5.3	9.43	10.26	P30874;!P35346	SSTR2;!SSTR5	1. Somatostatin receptor type 2;!2. Somatostatin receptor type 5
C64H82N18O13	In healthy male volunteers, total clearance of triptorelin was 211.9 mL/min.	The pharmacokinetics of triptorelin follows a 3 compartment model. The half lives are estimated to be 6 minutes, 45 minutes, and 3 hours respectively.	1311.473	CC(C)C[C@H](NC(=O)[C@@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O	Solid	After a single IV dose of 0.5mg, the volume of distribution of triptorelin peptide in healthy males was 30 - 33L.						63633	CHEMBL1201334	17290424	Drugs.com Drug Page				D06247				25074470	310264898	RxList Drug Page	38782		Triptorelin		Decapeptyl, Trelstar, Triptodur	Triptorelin	Approved, Vet approved	DB06825	InChI=1S/C64H82N18O13/c1-34(2)23-46(56(88)75-45(13-7-21-69-64(66)67)63(95)82-22-8-14-52(82)62(94)72-31-53(65)85)76-58(90)48(25-36-28-70-42-11-5-3-9-40(36)42)78-57(89)47(24-35-15-17-39(84)18-16-35)77-61(93)51(32-83)81-59(91)49(26-37-29-71-43-12-6-4-10-41(37)43)79-60(92)50(27-38-30-68-33-73-38)80-55(87)44-19-20-54(86)74-44/h3-6,9-12,15-18,28-30,33-34,44-52,70-71,83-84H,7-8,13-14,19-27,31-32H2,1-2H3,(H2,65,85)(H,68,73)(H,72,94)(H,74,86)(H,75,88)(H,76,90)(H,77,93)(H,78,89)(H,79,92)(H,80,87)(H,81,91)(H4,66,67,69)/t44-,45-,46-,47-,48+,49-,50-,51-,52-/m0/s1	VXKHXGOKWPXYNA-PGBVPBMZSA-N	4	Triptorelin is a GnRH agonist indicated for the palliative treatment of advanced prostate cancer.	Some of the most commonly reported adverse effects of triptorelin are hot flushes reported in 58.6% of patients, skeletal pain in 12.1%, impotence in 7.1%, and headache in 5.0%. Other reported adverse effects include injection site pain, general body pain, leg pain, fatigue, hypertension, dizziness, diarrhea, vomiting, insomnia, emotional lability, anemia, pruritus, urinary tract infections, and urinary retention. Triptorelin is classified as Pregnancy Category X and contraindicated in pregnant women or in women who may become pregnant. Hormonal changes caused by triptorelin increase the risk for pregnancy loss. Studies done on pregnant rats demonstrated maternal toxicity and embryo-fetal toxicities.	Small Molecule																																			0	No	17	18	Yes	8	1	487.92 Å2	135.23 Å3	352.43 m3·mol-1	33	No	No	0.0305 mg/mL	-3.6	-4.6	9.49	11.54	P30968	GNRHR	1. Gonadotropin-releasing hormone receptor
C21H34ClN6O3	Not Available	Not Available	453.986	NC(N)=NCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H]([NH3+])CC1=CC=CC=C1)[C@H](O)CCl	Solid	Not Available														0G6			131704300	99443312							[(2R)-1-[(2S)-2-[[(2S,3S)-1-Chloro-6-(diaminomethylideneamino)-2-hydroxyhexan-3-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]azanium	Experimental	DB06841	InChI=1S/C21H33ClN6O3/c22-13-18(29)16(8-4-10-26-21(24)25)27-19(30)17-9-5-11-28(17)20(31)15(23)12-14-6-2-1-3-7-14/h1-3,6-7,15-18,29H,4-5,8-13,23H2,(H,27,30)(H4,24,25,26)/p+1/t15-,16+,17+,18-/m1/s1	DVFLYEYCMMLBTQ-VSZNYVQBSA-O			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.5276 LD50, mol/kg	Inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	5	No	2	2	161.68 Å2	48.55 Å3	130.97 m3·mol-1	11	Yes	No		-0.28		13.56	11.16	P00734	F2	1. Prothrombin
C20H29N5O2	Not Available	Not Available	371.4766	[H][C@]1(CCCN1C(=O)CNC1CCCC1)C(=O)NCC1=CC=C(C=C1)C(N)=N	Solid	Not Available								25060166						10U			23629654	99443316					ZINC000013165429		(S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclopentylamino)ethanoyl)pyrrolidine-2-carboxamide	Experimental	DB06845	InChI=1S/C20H29N5O2/c21-19(22)15-9-7-14(8-10-15)12-24-20(27)17-6-3-11-25(17)18(26)13-23-16-4-1-2-5-16/h7-10,16-17,23H,1-6,11-13H2,(H3,21,22)(H,24,27)/t17-/m0/s1	WXYKSWZWRHMJTE-KRWDZBQOSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.4098 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	4	Yes	3	2	111.31 Å2	41.55 Å3	115.18 m3·mol-1	7	Yes	No	0.185 mg/mL	0.44	-3.3	14.46	11.48	P07477;!P00734	PRSS1;!F2	1. Trypsin-1;!2. Prothrombin
C26H33N3O5	Not Available	Not Available	467.5573	[H][C@](C)(O)[C@]([H])(CC1=CC=CC=C1)NC(=O)[C@]1([H])CCCN1C(=O)[C@]([H])(C)NC(=O)OCC1=CC=CC=C1	Solid	Not Available								4883307						1BH			6323185	99443357					ZINC000015289930		N-BENZYLOXYCARBONYL-ALA-PRO-3-AMINO-4-PHENYL-BUTAN-2-OL	Experimental	DB06886	InChI=1S/C26H33N3O5/c1-18(27-26(33)34-17-21-12-7-4-8-13-21)25(32)29-15-9-14-23(29)24(31)28-22(19(2)30)16-20-10-5-3-6-11-20/h3-8,10-13,18-19,22-23,30H,9,14-17H2,1-2H3,(H,27,33)(H,28,31)/t18-,19+,22-,23-/m0/s1	MACLRJNEKXUAJK-YDLSIGKMSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.4167 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	4	3	Yes	3	0	107.97 Å2	50.61 Å3	127.63 m3·mol-1	10	Yes	No	0.0149 mg/mL	2.54	-4.5	13.29	-2.8	P00781	apr	1. Subtilisin DY
C19H28N4O2	Not Available	Not Available	344.4512	[H][C@]1(CCCN1C(=O)CCC(C)C)C(=O)NCC1=CC=C(C=C1)C(N)=N	Solid	Not Available							CHEMBL1229851	25060244						26U			25113617	99443407					ZINC000039029983		N-(4-carbamimidoylbenzyl)-1-(4-methylpentanoyl)-L-prolinamide	Experimental	DB06936	InChI=1S/C19H28N4O2/c1-13(2)5-10-17(24)23-11-3-4-16(23)19(25)22-12-14-6-8-15(9-7-14)18(20)21/h6-9,13,16H,3-5,10-12H2,1-2H3,(H3,20,21)(H,22,25)/t16-/m0/s1	AEKJCSNKYXWOAQ-INIZCTEOSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.4277 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	3	No	2	1	99.28 Å2	39.26 Å3	109.01 m3·mol-1	7	Yes	No	0.163 mg/mL	1.45	-3.3	14.51	11.48	P00734	F2	1. Prothrombin
C17H25N5O2	Not Available	Not Available	331.4127	[H][C@@](N)(CC)C(=O)N1CCC[C@@]1([H])C(=O)NCC1=CC=C(C=C1)C(N)=N	Solid	Not Available					50307871		CHEMBL1198148	25046499						29U			25113128	99443418					ZINC000039024957		1-[(2R)-2-aminobutanoyl]-N-(4-carbamimidoylbenzyl)-L-prolinamide	Experimental	DB06947	InChI=1S/C17H25N5O2/c1-2-13(18)17(24)22-9-3-4-14(22)16(23)21-10-11-5-7-12(8-6-11)15(19)20/h5-8,13-14H,2-4,9-10,18H2,1H3,(H3,19,20)(H,21,23)/t13-,14+/m1/s1	YHAMQFKGUUSJMU-KGLIPLIRSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3608 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	4	No	2	2	125.3 Å2	36.51 Å3	103.01 m3·mol-1	6	Yes	No	0.114 mg/mL	-0.26	-3.5	14.43	11.48	P00734	F2	1. Prothrombin
C19H29N5O2	Not Available	Not Available	359.4659	[H][C@@](N)(CC(C)C)C(=O)N1CCC[C@@]1([H])C(=O)NCC1=CC=C(C=C1)C(N)=N	Solid	Not Available							CHEMBL1230016	25057486						31U			25220914	99443467					ZINC000039034766		D-leucyl-N-(4-carbamimidoylbenzyl)-L-prolinamide	Experimental	DB06996	InChI=1S/C19H29N5O2/c1-12(2)10-15(20)19(26)24-9-3-4-16(24)18(25)23-11-13-5-7-14(8-6-13)17(21)22/h5-8,12,15-16H,3-4,9-11,20H2,1-2H3,(H3,21,22)(H,23,25)/t15-,16+/m1/s1	XFNMDMGNNKIXBT-CVEARBPZSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.4005 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	4	No	2	2	125.3 Å2	40.41 Å3	112.16 m3·mol-1	7	Yes	No	0.128 mg/mL	0.47	-3.4	14.51	11.48	P00734	F2	1. Prothrombin
C25H35N3O6	Not Available	Not Available	473.5619	[H][C@](C)(CC)[C@]([H])(NC(=O)[C@@]1([H])O[C@]1([H])C(=O)NCCC)C(=O)N1CCC[C@@]1([H])C(=O)OCC1=CC=CC=C1	Solid	Not Available					16504			18741757						73V			22850133	99443690					ZINC000014961495		BENZYL N-({(2S,3S)-3-[(PROPYLAMINO)CARBONYL]OXIRAN-2-YL}CARBONYL)-L-ISOLEUCYL-L-PROLINATE	Experimental	DB07219	InChI=1S/C25H35N3O6/c1-4-13-26-22(29)20-21(34-20)23(30)27-19(16(3)5-2)24(31)28-14-9-12-18(28)25(32)33-15-17-10-7-6-8-11-17/h6-8,10-11,16,18-21H,4-5,9,12-15H2,1-3H3,(H,26,29)(H,27,30)/t16-,18-,19-,20-,21-/m0/s1	OMQNYWZURFTFHE-MQBSTWLZSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.3991 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	2	Yes	3	0	117.34 Å2	50.97 Å3	123.96 m3·mol-1	12	Yes	No	0.097 mg/mL	2.03	-3.7	12.15	-3.3	P07858	CTSB	1. Cathepsin B
C15H24N2O7	Not Available	Not Available	344.3603	[H][C@@](C)(NC(=O)[C@@]([H])(NC(=O)[C@@]1([H])O[C@]1([H])C(=O)OCC)[C@@]([H])(C)CC)C(O)=O	Solid	Not Available					16499			25056578						75V			23647358	99443695					ZINC000014961470		N-{[(2S,3S)-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL}-L-ISOLEUCYL-L-ALANINE	Experimental	DB07224	InChI=1S/C15H24N2O7/c1-5-7(3)9(12(18)16-8(4)14(20)21)17-13(19)10-11(24-10)15(22)23-6-2/h7-11H,5-6H2,1-4H3,(H,16,18)(H,17,19)(H,20,21)/t7-,8-,9-,10-,11-/m0/s1	FCCIQOJEDMDETP-QHZLYTNSSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.2711 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	6	3	No	1	-1	134.33 Å2	34.47 Å3	80.41 m3·mol-1	10	Yes	No	5.49 mg/mL	0.095	-1.8	3.8	-3.6	P07858	CTSB	1. Cathepsin B
C18H30N2O7	Not Available	Not Available	386.44	[H][C@](C)(CC)[C@]([H])(NC(=O)[C@@]([H])(NC(=O)[C@@]1([H])O[C@]1([H])C(=O)OCC)[C@@]([H])(C)CC)C(O)=O	Solid	Not Available								25060305						76V			46937062	99443696					ZINC000014961474		N-{[(2S,3S)-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL}-L-ISOLEUCYL-L-ISOLEUCINE	Experimental	DB07225	InChI=1S/C18H30N2O7/c1-6-9(4)11(15(21)20-12(17(23)24)10(5)7-2)19-16(22)13-14(27-13)18(25)26-8-3/h9-14H,6-8H2,1-5H3,(H,19,22)(H,20,21)(H,23,24)/t9-,10-,11-,12-,13-,14-/m0/s1	CFABOFMUPCWOPC-LHEWDLALSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.2711 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	6	3	No	1	-1	134.33 Å2	40.17 Å3	94.01 m3·mol-1	12	Yes	No	1.83 mg/mL	1.43	-2.3	3.97	-3.1	P07858	CTSB	1. Cathepsin B
C22H29N3O6	Not Available	Not Available	431.4822	[H][C@](C)(CC)[C@]([H])(NC(=O)[C@@]1([H])O[C@]1([H])C(=O)NCC1=CC=CC=C1)C(=O)N1CCC[C@@]1([H])C(O)=O	Solid	Not Available					16502			25056628						78A			23647361	99443702					ZINC000014961490		N-({(2S,3S)-3-[(BENZYLAMINO)CARBONYL]OXIRAN-2-YL}CARBONYL)-L-ISOLEUCYL-L-PROLINE	Experimental	DB07231	InChI=1S/C22H29N3O6/c1-3-13(2)16(21(28)25-11-7-10-15(25)22(29)30)24-20(27)18-17(31-18)19(26)23-12-14-8-5-4-6-9-14/h4-6,8-9,13,15-18H,3,7,10-12H2,1-2H3,(H,23,26)(H,24,27)(H,29,30)/t13-,15-,16-,17-,18-/m0/s1	MERYMLLGRCNRKE-HILJTLORSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3331 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	6	3	Yes	3	-1	128.34 Å2	44.54 Å3	109.92 m3·mol-1	9	Yes	No	0.484 mg/mL	1.01	-3	3.81	-3.3	P07858	CTSB	1. Cathepsin B
C20H36N6O3S	Not Available	Not Available	440.603	[H][C@@](CCCNC(N)N)(NC(=O)[C@@]([H])(NC(=O)CCC(C)C)C(C)C)C(=O)C1=NC=CS1	Solid	Not Available								5257036						995			6857702	99443770					ZINC000038190858		4-METHYL-PENTANOIC ACID {1-[4-GUANIDINO-1-(THIAZOLE-2-CARBONYL)-BUTYLCARBAMOYL]-2-METHYL-PROPYL}-AMIDE	Experimental	DB07299	InChI=1S/C20H36N6O3S/c1-12(2)7-8-15(27)26-16(13(3)4)18(29)25-14(6-5-9-24-20(21)22)17(28)19-23-10-11-30-19/h10-14,16,20,24H,5-9,21-22H2,1-4H3,(H,25,29)(H,26,27)/t14-,16-/m0/s1	ZXELQWLUDMEUHS-HOCLYGCPSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.5133 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	7	5	No	1	0	152.23 Å2	48.11 Å3	116.74 m3·mol-1	14	Yes	No	0.0248 mg/mL	1.23	-4.2	12.08	6.69	P03951	F11	1. Coagulation factor XI
C21H33N5O4	Not Available	Not Available	419.5178	[H][C@](CC1=CC=CC=C1)(NC(=O)OCC)C(=O)N1CCC[C@@]1([H])C(=O)NNCCCCN	Solid	Not Available								392213						AZL			444224	99443871					ZINC000003870519		1-ETHOXYCARBONYL-D-PHE-PRO-2(4-AMINOBUTYL)HYDRAZINE	Experimental	DB07400	InChI=1S/C21H33N5O4/c1-2-30-21(29)24-17(15-16-9-4-3-5-10-16)20(28)26-14-8-11-18(26)19(27)25-23-13-7-6-12-22/h3-5,9-10,17-18,23H,2,6-8,11-15,22H2,1H3,(H,24,29)(H,25,27)/t17-,18+/m1/s1	AEHSFPPTWRQOFS-MSOLQXFVSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3142 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	4	No	2	1	125.79 Å2	46.08 Å3	124.01 m3·mol-1	12	Yes	No	0.295 mg/mL	0.51	-3.2	12.27	10.2	P00734	F2	1. Prothrombin
C24H32N2O5	Not Available	Not Available	428.5213	[H][C@@](C)(O)[C@]([H])(CC1=CC=C(O)C=C1)NC(=O)[C@]([H])(CC(C)C)NC(=O)OCC1=CC=CC=C1	Solid	Not Available								5257044						CMQ			6857710	99444042					ZINC000024799667		N~2~-[(BENZYLOXY)CARBONYL]-N-[(1S,2S)-2-HYDROXY-1-(4-HYDROXYBENZYL)PROPYL]-L-LEUCINAMIDE	Experimental	DB07571	InChI=1S/C24H32N2O5/c1-16(2)13-22(26-24(30)31-15-19-7-5-4-6-8-19)23(29)25-21(17(3)27)14-18-9-11-20(28)12-10-18/h4-12,16-17,21-22,27-28H,13-15H2,1-3H3,(H,25,29)(H,26,30)/t17-,21-,22-/m0/s1	ZUWYQZGBCBSHFK-HSQYWUDLSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.5005 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	4	No	2	0	107.89 Å2	46.63 Å3	118.3 m3·mol-1	11	Yes	No	0.00846 mg/mL	3.75	-4.7	9.5	-2.8	P0A6G7	clpP	1. ATP-dependent Clp protease proteolytic subunit
C21H28FN3O7	Not Available	Not Available	453.467	CC(C)[C@H](NC(=O)OCC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)CF	Solid	Not Available							CHEMBL205821	4593739									5497171	99444215					ZINC000025668028		Z-Val-Ala-Asp fluoromethyl ketone	Experimental	DB07744	InChI=1S/C21H28FN3O7/c1-12(2)18(25-21(31)32-11-14-7-5-4-6-8-14)20(30)23-13(3)19(29)24-15(9-17(27)28)16(26)10-22/h4-8,12-13,15,18H,9-11H2,1-3H3,(H,23,30)(H,24,29)(H,25,31)(H,27,28)/t13-,15-,18-/m0/s1	SUUHZYLYARUNIA-YEWWUXTCSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.2208 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	6	4	No	1	-1	150.9 Å2	44.69 Å3	109.36 m3·mol-1	13	Yes	No	0.0358 mg/mL	1.16	-4.1	4.13	-4	P29466	CASP1	1. Caspase-1
C16H21ClN2O3	Not Available	Not Available	324.803	[H][C@@](C)(NC(C)=O)C(=O)N[C@@]([H])(CC1=CC=CC=C1)C(=O)CCCl	Solid	Not Available								25057340						HIN			46937104	99444370					ZINC000008239025		(2S) N-acetyl-L-alanyl-αL-phenylalanyl-chloroethylketone	Experimental	DB07899	InChI=1S/C16H21ClN2O3/c1-11(18-12(2)20)16(22)19-14(15(21)8-9-17)10-13-6-4-3-5-7-13/h3-7,11,14H,8-10H2,1-2H3,(H,18,20)(H,19,22)/t11-,14-/m0/s1	WABWAIGLGFELMI-FZMZJTMJSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1833 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	2	No	1	0	75.27 Å2	33.66 Å3	84.86 m3·mol-1	8	Yes	No	0.0374 mg/mL	1.46	-3.9	12.4	-1.9	P17538	CTRB1	1. Chymotrypsinogen B
C21H33NO4	Not Available	Not Available	363.491	[H][C@@](CC1=CC=C(O)C=C1)(NC(=O)CCCCCCCCCCC)C(O)=O	Solid	Not Available								5142256						NLT			6710104	99444746							N-DODECANOYL-L-TYROSINE	Experimental	DB08275	InChI=1S/C21H33NO4/c1-2-3-4-5-6-7-8-9-10-11-20(24)22-19(21(25)26)16-17-12-14-18(23)15-13-17/h12-15,19,23H,2-11,16H2,1H3,(H,22,24)(H,25,26)/t19-/m0/s1	SVQAZCRYIXURJT-IBGZPJMESA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.2586 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	Yes	4	3	No	1	-1	86.63 Å2	42.36 Å3	102.58 m3·mol-1	14	No	No	0.00427 mg/mL	5.29	-4.9	3.85	-1.5	Q8KNZ7	Not Available	1. Long-chain N-acyl amino acid synthase
C22H36N2O5	Not Available	Not Available	408.5316	[H][C@@](O)(COC)[C@]([H])(CC(C)C)NC(=O)[C@]([H])(CC(C)C)NC(=O)OCC1=CC=CC=C1	Solid	Not Available								4451322						SBA			5289332	99444997					ZINC000033821514		CARBOBENZYLOXY-(L)-LEUCINYL-(L)LEUCINYL METHOXYMETHYLKETONE	Experimental	DB08526	InChI=1S/C22H36N2O5/c1-15(2)11-18(20(25)14-28-5)23-21(26)19(12-16(3)4)24-22(27)29-13-17-9-7-6-8-10-17/h6-10,15-16,18-20,25H,11-14H2,1-5H3,(H,23,26)(H,24,27)/t18-,19-,20+/m0/s1	LHCNZPLAATYYPI-SLFFLAALSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.3224 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	3	No	1	0	96.89 Å2	46.19 Å3	111.67 m3·mol-1	13	Yes	No	0.0393 mg/mL	3.25	-4	13.38	-2.8	P09668	CTSH	1. Pro-cathepsin H
C24H31N3O4S	Not Available	Not Available	457.586	[H][C@@](CS)(NCC1=CC=C(C=C1)C1=CC=CC=C1)C(=O)NCC(=O)N[C@@]([H])(C(C)C)C(=O)OC	Solid	Not Available								3571842						TR1			4369141	99445114					ZINC000053683264		2-(2-{2-[(BIPHENYL-4-YLMETHYL)-AMINO]-3-MERCAPTO-PENTANOYLAMINO}-ACETYLAMINO)-3-METHYL-BUTYRIC ACID METHYL ESTER	Experimental	DB08643	InChI=1S/C24H31N3O4S/c1-16(2)22(24(30)31-3)27-21(28)14-26-23(29)20(15-32)25-13-17-9-11-19(12-10-17)18-7-5-4-6-8-18/h4-12,16,20,22,25,32H,13-15H2,1-3H3,(H,26,29)(H,27,28)/t20-,22-/m0/s1	QFAWBPLETHINFK-UNMCSNQZSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.4053 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	4	No	2	1	96.53 Å2	50.36 Å3	126.61 m3·mol-1	12	Yes	No	0.00165 mg/mL	2.67	-5.4	9.97	7.34	P08254	MMP3	1. Stromelysin-1
C20H31N3O5	Not Available	Not Available	393.4772	[H][C@@](C)(NC(=O)[C@@]([H])(O)[C@]([H])(N)C1=CC=C(C)C=C1)C(=O)N[C@]([H])(CC(C)C)C(=O)OC	Solid	Not Available								5290527						U15			6914647	99445140					ZINC000016052079		METHYL N-[(2S,3R)-3-AMINO-2-HYDROXY-3-(4-METHYLPHENYL)PROPANOYL]-D-ALANYL-D-LEUCINATE	Experimental	DB08669	InChI=1S/C20H31N3O5/c1-11(2)10-15(20(27)28-5)23-18(25)13(4)22-19(26)17(24)16(21)14-8-6-12(3)7-9-14/h6-9,11,13,15-17,24H,10,21H2,1-5H3,(H,22,26)(H,23,25)/t13-,15+,16+,17-/m0/s1	BMHZOSJVDHAFEE-SVGFKBNWSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.1672 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	4	No	1	1	130.75 Å2	41.53 Å3	104.4 m3·mol-1	10	Yes	No	0.164 mg/mL	1	-3.4	11.97	7.91	P0AE18	map	1. Methionine aminopeptidase
C22H35N3O5	Not Available	Not Available	421.5304	[H][C@@](C)(NC(=O)[C@@]([H])(O)[C@]([H])(N)C1=CC=C(C=C1)C(C)C)C(=O)N[C@]([H])(CC(C)C)C(=O)OC	Solid	Not Available								5290528						U16			6914648	99445141					ZINC000016052056		METHYL N-[(2S,3R)-3-AMINO-2-HYDROXY-3-(4-ISOPROPYLPHENYL)PROPANOYL]-D-ALANYL-D-LEUCINATE	Experimental	DB08670	InChI=1S/C22H35N3O5/c1-12(2)11-17(22(29)30-6)25-20(27)14(5)24-21(28)19(26)18(23)16-9-7-15(8-10-16)13(3)4/h7-10,12-14,17-19,26H,11,23H2,1-6H3,(H,24,28)(H,25,27)/t14-,17+,18+,19-/m0/s1	WIWZNHHLFMPGGO-PIKADFDJSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.1672 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	4	No	1	1	130.75 Å2	46.24 Å3	113.55 m3·mol-1	11	Yes	No	0.0308 mg/mL	1.73	-4.1	11.98	7.91	P0AE18	map	1. Methionine aminopeptidase
C22H26N2O5	Not Available	Not Available	398.4522	[H][C@](C)(NC(=O)[C@]([H])(CC1=CC=CC=C1)NC(=O)OCC1=CC=CC=C1)C(=O)CCO	Solid	Not Available								17347435						WR1			16220131	99445203					ZINC000016052314		NALPHA-[(BENZYLOXY)CARBONYL]-N-[(1R)-4-HYDROXY-1-METHYL-2-OXOBUTYL]-L-PHENYLALANINAMIDE	Experimental	DB08732	InChI=1S/C22H26N2O5/c1-16(20(26)12-13-25)23-21(27)19(14-17-8-4-2-5-9-17)24-22(28)29-15-18-10-6-3-7-11-18/h2-11,16,19,25H,12-15H2,1H3,(H,23,27)(H,24,28)/t16-,19+/m1/s1	UUOOAGBWJUGBMV-APWZRJJASA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1123 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	3	No	2	0	104.73 Å2	42.27 Å3	108.05 m3·mol-1	11	Yes	No	0.0146 mg/mL	2.45	-4.4	12.7	-2.4	P0C6X7;!P0C6U8	rep;!Not Available	1. Replicase polyprotein 1ab;!2. Replicase polyprotein 1a
C21H23FN2O5	Not Available	Not Available	402.4161	C[C@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)OCC1=CC=CC=C1)C(=O)CF	Solid	Not Available							CHEMBL68828	23161386						ZYA			15118984	99445246					ZINC000026272137		Benzoyl-tyrosine-alanine-fluoro-methyl ketone	Experimental	DB08775	InChI=1S/C21H23FN2O5/c1-14(19(26)12-22)23-20(27)18(11-15-7-9-17(25)10-8-15)24-21(28)29-13-16-5-3-2-4-6-16/h2-10,14,18,25H,11-13H2,1H3,(H,23,27)(H,24,28)/t14-,18-/m0/s1	RYABQRLJLIHDIP-KSSFIOAISA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.2664 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	3	No	2	0	104.73 Å2	40.51 Å3	103.64 m3·mol-1	10	Yes	No	0.0217 mg/mL	2.8	-4.3	9.5	-4.5	Q9UBX1	CTSF	1. Cathepsin F
C30H47N3O9S	Not Available	Not Available	625.774	CCCCC\C=C/C\C=C/C=C/C=C/[C@@H](SC[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)NCC(O)=O)[C@@H](O)CCCC(O)=O	Solid	Not Available						16978	CHEMBL451509	4444133			HMDB0001198	C02166		LTX								Leukotriene_C4	ZINC000004095814		Leukotriene C4	Experimental, Investigational	DB08855	InChI=1S/C30H47N3O9S/c1-2-3-4-5-6-7-8-9-10-11-12-13-16-25(24(34)15-14-17-27(36)37)43-21-23(29(40)32-20-28(38)39)33-26(35)19-18-22(31)30(41)42/h6-7,9-13,16,22-25,34H,2-5,8,14-15,17-21,31H2,1H3,(H,32,40)(H,33,35)(H,36,37)(H,38,39)(H,41,42)/b7-6-,10-9-,12-11+,16-13+/t22-,23-,24-,25+/m0/s1	GWNVDXQDILPJIG-NXOLIXFESA-N			Not Available	Small Molecule																																			0	No	10	7	No	0	-2	216.35 Å2	68.38 Å3	168.51 m3·mol-1	25	No	No	0.00254 mg/mL	-0.015	-5.4	1.8	9.31	Q9Y271;!Q9NS75;!P33527	CYSLTR1;!CYSLTR2;!ABCC1	1. Cysteinyl leukotriene receptor 1;!2. Cysteinyl leukotriene receptor 2;!3. Multidrug resistance-associated protein 1
C29H39N5O7	Not Available	Not Available	569.659	CC(C)C[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1)C(O)=O	Solid	Not Available					21025		CHEMBL340032	5292936														DADLE	ZINC000014952092		DADLE	Experimental	DB08856	InChI=1S/C29H39N5O7/c1-17(2)13-24(29(40)41)34-28(39)23(15-19-7-5-4-6-8-19)33-25(36)16-31-26(37)18(3)32-27(38)22(30)14-20-9-11-21(35)12-10-20/h4-12,17-18,22-24,35H,13-16,30H2,1-3H3,(H,31,37)(H,32,38)(H,33,36)(H,34,39)(H,40,41)/t18-,22+,23+,24-/m1/s1	ZHUJMSMQIPIPTF-IBURTVSXSA-N			Not Available	Small Molecule																																			0	No	8	7	No	2	0	199.95 Å2	59.13 Å3	150.09 m3·mol-1	15	No	No	0.00963 mg/mL	-1.3	-4.8	3.7	7.73			
C30H39N5O7S2	Not Available	Not Available	645.79	CC1(C)SSC(C)(C)[C@@H](NC(=O)[C@@H](N)CC2=CC=C(O)C=C2)C(=O)NCC(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@H]1C(O)=O	Solid	Not Available					21008	73356	CHEMBL31421	94592				C20164										DPDPE	ZINC000029206920		DPDPE	Experimental	DB08861	InChI=1S/C30H39N5O7S2/c1-29(2)23(34-25(38)20(31)14-18-10-12-19(36)13-11-18)27(40)32-16-22(37)33-21(15-17-8-6-5-7-9-17)26(39)35-24(28(41)42)30(3,4)44-43-29/h5-13,20-21,23-24,36H,14-16,31H2,1-4H3,(H,32,40)(H,33,37)(H,34,38)(H,35,39)(H,41,42)/t20-,21-,23-,24-/m0/s1	MCMMCRYPQBNCPH-WMIMKTLMSA-N			Not Available	Small Molecule																																			0	No	8	7	Yes	3	0	199.95 Å2	65.64 Å3	168.07 m3·mol-1	7	No	No	0.00632 mg/mL	-1	-5	3.39	7.73			
C30H53N3O6	Aliskiren is partially cleared in the kidneys, and safety data have not been established for patients with a creatinine clearance of less than 30 mL/min.9 One pharmacokinetic study revealed an average renal clearance of 1280 +/- 500 mL/hour in healthy volunteers.8	Plasma half-life for aliskiren can range from 30 to 40 hours 7 with an accumulation half-life of about 24 hours.7	551.7583	COCCCOC1=C(OC)C=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=C1	Solid	Unchanged aliskiren accounts for about 80% of the drug found in the plasma.7,9	P08684	CYP3A4	1. Cytochrome P450 3A4		17950	601027	CHEMBL1639	4591452	Drugs.com Drug Page		HMDB0015387		D03208	C41		PA143487910	5493444	310264980		325646		Aliskiren	ZINC000004393164	Rasilez, Tekturna, Tekturna Hct	Aliskiren	Approved, Investigational	DB09026	InChI=1S/C30H53N3O6/c1-19(2)22(14-21-10-11-26(38-8)27(15-21)39-13-9-12-37-7)16-24(31)25(34)17-23(20(3)4)28(35)33-18-30(5,6)29(32)36/h10-11,15,19-20,22-25,34H,9,12-14,16-18,31H2,1-8H3,(H2,32,36)(H,33,35)/t22-,23-,24-,25-/m0/s1	UXOWGYHJODZGMF-QORCZRPOSA-N	4	Aliskiren is a direct renin inhibitor used to manage hypertension.	The oral LD50 of aliskiren in rats is >2000 mg/kg.14 Overdose information is limited in the literature, however, an overdose with aliskiren is likely to result in hypotension. Supportive treatment should be initiated in the case of an overdose.9,15	Small Molecule																													748.4±60.0	2.45		>95	9.49	Highly soluble in water (as hemifumarate salt)	0	No	7	4	No	1	1	146.13 Å2	63.28 Å3	154.32 m3·mol-1	19	No	No	0.0021 mg/mL	3.12	-5.4	14.56	9.57			
C43H67N11O12S2	Atosiban has a mean clearance rate of 41.8 L/h 5.	Atosiban does not conform to either 1-compartment or 2-compartment kinetics. It has been determined to have an initial half life (tα) of 0.21 h and a terminal half life (tβ) of 1.7 h 5.	994.19	[H][C@]1(NC(=O)[C@@]([H])(NC(=O)[C@@H](CC2=CC=C(OCC)C=C2)NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)[C@@H](C)CC)[C@@H](C)O	Solid	Atosiban has a mean volume of distribution of 41.8 L. Atosiban crosses the placenta and, at a dose of 300 μg/min, was found to have a 0.12 maternal/fetal concentration ratio 5.					50177595	135899	CHEMBL382301	4470550	Drugs.com Drug Page				D03008							59639		Atosiban	ZINC000169362009		Atosiban	Approved, Investigational	DB09059	InChI=1S/C43H67N11O12S2/c1-5-23(3)35-41(63)53-36(24(4)55)42(64)50-29(20-32(45)56)38(60)51-30(43(65)54-17-8-10-31(54)40(62)49-27(9-7-16-44)37(59)47-21-33(46)57)22-68-67-18-15-34(58)48-28(39(61)52-35)19-25-11-13-26(14-12-25)66-6-2/h11-14,23-24,27-31,35-36,55H,5-10,15-22,44H2,1-4H3,(H2,45,56)(H2,46,57)(H,47,59)(H,48,58)(H,49,62)(H,50,64)(H,51,60)(H,52,61)(H,53,63)/t23-,24+,27-,28+,29-,30-,31-,35-,36-/m0/s1	VWXRQYYUEIYXCZ-OBIMUBPZSA-N	4	Atosiban is an inhibitor of oxytocin and vasopressin used to delay imminent preterm birth in pregnant adult women displaying specific clinical observations.	No systemic toxicities were found in rat and dog studies at dosages equivalent to 10 times normal human exposure 5. It is thought that the risk of toxicity is low due to the short duration of action and short half life of atosiban 1.	Small Molecule																																			0	No	13	11	Yes	3	1	365.67 Å2	101.49 Å3	250.62 m3·mol-1	18	No	No	0.0517 mg/mL	-4.6	-4.3	11.28	9.59	P30559;!P37288;!P47901;!P30518	OXTR;!AVPR1A;!AVPR1B;!AVPR2	1. Oxytocin receptor;!2. Vasopressin V1a receptor;!3. Vasopressin V1b receptor;!4. Vasopressin V2 receptor
C49H62N10O16S3	Not Available	Not Available	1143.27	CSCC[C@H](NC(=O)[C@H](CC1=CC=C(OS(O)(=O)=O)C=C1)NC(=O)[C@@H](N)CC(O)=O)C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O	Solid	Not Available					21147	135946	CHEMBL1121	8009168	Drugs.com Drug Page				D05845				9833444	310265055	RxList Drug Page	9800		Sincalide		Kinevac	Sincalide	Approved	DB09142	InChI=1S/C49H62N10O16S3/c1-76-18-16-34(55-47(69)37(58-44(66)32(50)23-41(61)62)21-28-12-14-30(15-13-28)75-78(72,73)74)45(67)53-26-40(60)54-38(22-29-25-52-33-11-7-6-10-31(29)33)48(70)56-35(17-19-77-2)46(68)59-39(24-42(63)64)49(71)57-36(43(51)65)20-27-8-4-3-5-9-27/h3-15,25,32,34-39,52H,16-24,26,50H2,1-2H3,(H2,51,65)(H,53,67)(H,54,60)(H,55,69)(H,56,70)(H,57,71)(H,58,66)(H,59,68)(H,61,62)(H,63,64)(H,72,73,74)/t32-,34-,35-,36-,37-,38-,39-/m0/s1	IZTQOLKUZKXIRV-YRVFCXMDSA-N	4	Sincalide is a diagnostic agent used to stimulate gallbladder contraction or pancreatic secretion during diagnostic tests, and accelerate fluoroscopy and x-ray examination of the intestinal tract.	Not Available	Small Molecule																																			0	No	16	13	Yes	4	-2	426.8 Å2	112.69 Å3	282.07 m3·mol-1	33	No	No	0.00441 mg/mL	-2.4	-5.4	-2	8.23			
C24H29NO5	Not Available	The half life of sacubitril is 1.1 to 3.6 hours, and the half life of it's metabolite LBQ657 is 9.9 to 11.1 hours.	411.498	CCOC(=O)[C@H](C)C[C@@H](CC1=CC=C(C=C1)C1=CC=CC=C1)NC(=O)CCC(O)=O	Solid	103 L						134714	CHEMBL3137301	7987587	Drugs.com Drug Page				D10225			PA166131580	9811834	310265184	RxList Drug Page	1656328		Sacubitril	ZINC000003792417	Entresto	Sacubitril	Approved	DB09292	InChI=1S/C24H29NO5/c1-3-30-24(29)17(2)15-21(25-22(26)13-14-23(27)28)16-18-9-11-20(12-10-18)19-7-5-4-6-8-19/h4-12,17,21H,3,13-16H2,1-2H3,(H,25,26)(H,27,28)/t17-,21+/m1/s1	PYNXFZCZUAOOQC-UTKZUKDTSA-N	4	Sacubitril is a neprilysin inhibitor used in combination with valsartan as an adjunct to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.	The most common adverse reactions (≥5%) are hypotension, hyperkalemia, cough, dizziness, and renal failure.	Small Molecule																																			1	Yes	4	2	No	2	-1	92.7 Å2	44.48 Å3	114.06 m3·mol-1	12	Yes	No	0.000942 mg/mL	3.79	-5.6	4.18	-1.6	P08473	MME	1. Neprilysin
C14H24N6O4	Not Available	Prezatide is rapidly eliminated within minutes 5.	340.384	NCCCC[C@H](NC(=O)[C@H](CC1=CNC=N1)NC(=O)CN)C(O)=O	Solid	Not Available					50350478	75430	CHEMBL1814493	66263									73587	347827962		1368533			ZINC000013507674		Prezatide	Experimental	DB11296	InChI=1S/C14H24N6O4/c15-4-2-1-3-10(14(23)24)20-13(22)11(19-12(21)6-16)5-9-7-17-8-18-9/h7-8,10-11H,1-6,15-16H2,(H,17,18)(H,19,21)(H,20,22)(H,23,24)/t10-,11-/m0/s1	MVORZMQFXBLMHM-QWRGUYRKSA-N			Not Available	Small Molecule																																			0	No	7	6	No	1	1	176.22 Å2	34.52 Å3	84.91 m3·mol-1	11	No	No	3.14 mg/mL	-5.1	-2	3.46	10.2			
C30H54N6O5	Not Available	Not Available	578.799	CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCCN)C(O)=O	Not Available	Not Available								8407354												1722914			ZINC000113569616		Palmitoyl oligopeptide	Experimental	DB11297	InChI=1S/C30H54N6O5/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-18-27(37)33-22-28(38)35-26(20-24-21-32-23-34-24)29(39)36-25(30(40)41)17-15-16-19-31/h21,23,25-26H,2-20,22,31H2,1H3,(H,32,34)(H,33,37)(H,35,38)(H,36,39)(H,40,41)/t25-,26-/m0/s1	BYUQATUKPXLFLZ-UIOOFZCWSA-N			Not Available	Small Molecule																																			0	No	7	6	No	1	0	179.3 Å2	68.63 Å3	158.79 m3·mol-1	26	No	No	0.00146 mg/mL	1.24	-5.6	3.49	10.2			
C64H83N17O12	Not Available	Not Available	1282.475	[H][C@]1(CCC(=O)N1)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC	Not Available	Not Available					84726		CHEMBL2365665	16736553												1311744		Deslorelin			Deslorelin	Investigational, Vet approved	DB11510	InChI=1S/C64H83N17O12/c1-4-68-62(92)53-16-10-24-81(53)63(93)46(15-9-23-69-64(65)66)74-56(86)47(25-35(2)3)75-58(88)49(27-37-30-70-43-13-7-5-11-41(37)43)77-57(87)48(26-36-17-19-40(83)20-18-36)76-61(91)52(33-82)80-59(89)50(28-38-31-71-44-14-8-6-12-42(38)44)78-60(90)51(29-39-32-67-34-72-39)79-55(85)45-21-22-54(84)73-45/h5-8,11-14,17-20,30-32,34-35,45-53,70-71,82-83H,4,9-10,15-16,21-29,33H2,1-3H3,(H,67,72)(H,68,92)(H,73,84)(H,74,86)(H,75,88)(H,76,91)(H,77,87)(H,78,90)(H,79,85)(H,80,89)(H4,65,66,69)/t45-,46-,47-,48-,49+,50-,51-,52-,53-/m0/s1	GJKXGJCSJWBJEZ-XRSSZCMZSA-N	2		Not Available	Small Molecule																																			0	No	16	17	Yes	8	1	444.83 Å2	132.52 Å3	349.27 m3·mol-1	32	No	No	0.0311 mg/mL	-1.9	-4.6	9.49	11.54			
C65H96N16O12S2	Not Available	Not Available	1357.7	CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=CC=CC=C23)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC2=CC=CC=C2)N(C)C(=O)[C@H](CCSCC(=O)NC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(N)=O)NC1=O	Not Available	Not Available						135908	CHEMBL1908335	8074277																	Depreotide	Withdrawn	DB11628	InChI=1S/C65H96N16O12S2/c1-38(2)55-64(92)76-49(26-30-95-37-54(83)72-35-44(69)57(85)74-47(20-10-13-28-67)58(86)79-52(36-94)62(90)73-46(56(70)84)19-9-12-27-66)65(93)81(3)53(32-39-15-5-4-6-16-39)63(91)78-50(31-40-22-24-42(82)25-23-40)60(88)77-51(33-41-34-71-45-18-8-7-17-43(41)45)61(89)75-48(59(87)80-55)21-11-14-29-68/h4-8,15-18,22-25,34,38,44,46-53,55,71,82,94H,9-14,19-21,26-33,35-37,66-69H2,1-3H3,(H2,70,84)(H,72,83)(H,73,90)(H,74,85)(H,75,89)(H,76,92)(H,77,88)(H,78,91)(H,79,86)(H,80,87)/t44-,46-,47-,48-,49-,50-,51+,52-,53-,55-/m0/s1	XXXSJQLZVNKRKX-YQRDHHIGSA-N			Not Available	Small Molecule																																			0	No	16	17	Yes	5	4	465.4 Å2	146.65 Å3	361.8 m3·mol-1	34	No	No	0.00502 mg/mL	-3.3	-5.4	9.67	10.63			
C50H68N14O10	The mean clearance of bremelanotide is 6.5±1.0L/hr.5	The half life of bremelanotide is 2.7 hours (1.9-4.0 hours).5	1025.182	CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@H](CC2=CNC3=CC=CC=C23)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CN=CN2)NC1=O)C(O)=O	Solid	The mean volume of distribution of bremelanotide is 25.0±5.8L.5					50389769		CHEMBL2070241	8116997									9941379	347828024		2176312		Bremelanotide		Vyleesi	Bremelanotide	Approved, Investigational	DB11653	InChI=1S/C50H68N14O10/c1-3-4-16-35(58-29(2)65)43(67)64-41-25-42(66)54-20-11-10-18-37(49(73)74)60-46(70)39(23-31-26-56-34-17-9-8-15-33(31)34)62-44(68)36(19-12-21-55-50(51)52)59-45(69)38(22-30-13-6-5-7-14-30)61-47(71)40(63-48(41)72)24-32-27-53-28-57-32/h5-9,13-15,17,26-28,35-41,56H,3-4,10-12,16,18-25H2,1-2H3,(H,53,57)(H,54,66)(H,58,65)(H,59,69)(H,60,70)(H,61,71)(H,62,68)(H,63,72)(H,64,67)(H,73,74)(H4,51,52,55)/t35-,36-,37-,38+,39-,40-,41-/m0/s1	FFHBJDQSGDNCIV-MFVUMRCOSA-N	3		Currently there are no reports of overdoses of bremelanotide.5 Patients taking higher doses are more likely to experience nausea, focal hyperpigmentation, and increases in blood pressure.5 In the event of an overdose, supportive measures should be used to address the associated symptoms.5	Small Molecule																													230						0	No	14	14	Yes	5	0	376.47 Å2	106.06 Å3	278.91 m3·mol-1	17	No	No	0.0251 mg/mL	-3.2	-4.6	3.45	11.96	Q01726;!P32245;!P41968;!P33032;!Q01718	MC1R;!MC4R;!MC3R;!MC5R;!MC2R	1. Melanocyte-stimulating hormone receptor;!2. Melanocortin receptor 4;!3. Melanocortin receptor 3;!4. Melanocortin receptor 5;!5. Adrenocorticotropic hormone receptor
C49H68N18O9S2	A 3mg subcutaneous dose of setmelanotide has an estimated clearance of 4.86 L/h.8	The elimination had life of setmelanotide is approximately 11 hours.8	1117.32	[H]N([H])C(=O)[C@@H]1CSSC[C@H](N([H])C(=O)[C@H](CCCN=C(N([H])[H])N([H])[H])N([H])C(C)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC2=CN=CN2[H])C(=O)N[C@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC2=CN([H])C3=CC=CC=C23)C(=O)N1	Liquid	The apparent volume of distribution of setmelanotide is 48.7 L.8							CHEMBL3301624	10166169									11993702	347828065		2469247		Setmelanotide		Imcivree	Setmelanotide	Approved, Investigational	DB11700	InChI=1S/C49H68N18O9S2/c1-26-41(70)63-37(20-30-22-55-25-59-30)46(75)64-35(18-28-10-4-3-5-11-28)44(73)62-34(15-9-17-57-49(53)54)43(72)65-36(19-29-21-58-32-13-7-6-12-31(29)32)45(74)66-38(40(50)69)23-77-78-24-39(47(76)60-26)67-42(71)33(61-27(2)68)14-8-16-56-48(51)52/h3-7,10-13,21-22,25-26,33-39,58H,8-9,14-20,23-24H2,1-2H3,(H2,50,69)(H,55,59)(H,60,76)(H,61,68)(H,62,73)(H,63,70)(H,64,75)(H,65,72)(H,66,74)(H,67,71)(H4,51,52,56)(H4,53,54,57)/t26-,33+,34+,35-,36+,37+,38+,39+/m1/s1	HDHDTKMUACZDAA-PHNIDTBTSA-N	3	Setmelanotide is setmelanotide is indicated to treat obesity caused by genetic POMC, PCSK1, or LEPR deficiencies.	Data regarding overdoses of setmelanotide are not readily available.8 In the event of an overdose, patients should be treated with symptomatic and supportive care.8	Small Molecule																																			0	No	16	15	Yes	5	2	449.16 Å2	113.93 Å3	290.87 m3·mol-1	18	No	No	0.0286 mg/mL	-5.3	-4.6	11.48	11	P32245	MC4R	1. Melanocortin receptor 4
C35H62N14O11S	Not Available	Not Available	887.03	CSCC[C@H](NC(=O)[C@H](CCC(O)=O)NC(=C)[C@H](CCC(O)=O)NC(C)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O	Not Available	Not Available								32700146									71587772	347828074		1314329		Acetyl_hexapeptide-3			Acetyl hexapeptide-3	Investigational	DB11709	InChI=1S/C35H62N14O11S/c1-18(20(45-19(2)50)9-12-27(52)53)44-23(10-13-28(54)55)31(58)49-25(14-17-61-3)33(60)48-24(8-11-26(36)51)32(59)47-22(7-5-16-43-35(40)41)30(57)46-21(29(37)56)6-4-15-42-34(38)39/h20-25,44H,1,4-17H2,2-3H3,(H2,36,51)(H2,37,56)(H,45,50)(H,46,57)(H,47,59)(H,48,60)(H,49,58)(H,52,53)(H,54,55)(H4,38,39,42)(H4,40,41,43)/t20-,21-,22-,23-,24-,25-/m0/s1	AJLNZWYOJAWBCR-OOPVGHQCSA-N	3		Not Available	Small Molecule																																			0	No	18	16	No	0	1	442.11 Å2	89.93 Å3	240.99 m3·mol-1	33	No	No	0.0981 mg/mL	-9.8	-4	3.55	12.09			
C41H62N12O11	Not Available	Not Available	899.02	[H][C@](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)([C@@H](C)CC)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N1CCC[C@H]1C(O)=O	Not Available	Not Available					85556	55438	CHEMBL3545347	110354									123805	347828083					ZINC000096077632		Angiotensin 1-7	Investigational	DB11720	InChI=1S/C41H62N12O11/c1-5-22(4)33(38(61)50-29(17-24-19-45-20-47-24)39(62)53-15-7-9-30(53)40(63)64)52-36(59)28(16-23-10-12-25(54)13-11-23)49-37(60)32(21(2)3)51-35(58)27(8-6-14-46-41(43)44)48-34(57)26(42)18-31(55)56/h10-13,19-22,26-30,32-33,54H,5-9,14-18,42H2,1-4H3,(H,45,47)(H,48,57)(H,49,60)(H,50,61)(H,51,58)(H,52,59)(H,55,56)(H,63,64)(H4,43,44,46)/t22-,26-,27-,28-,29-,30-,32-,33-/m0/s1	PVHLMTREZMEJCG-GDTLVBQBSA-N	2		Not Available	Small Molecule																																			0	No	16	13	Yes	3	1	377.24 Å2	92.45 Å3	238.19 m3·mol-1	25	No	No	0.0399 mg/mL	-6.3	-4.4	2.95	11.74			
C21H30N2O6	Not Available	Not Available	406.479	CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)C1=CC=CC=C1	Not Available	Not Available						95044	CHEMBL2103847	24606030									15547703	347828131					ZINC000013914293		Tosedostat	Investigational	DB11781	InChI=1S/C21H30N2O6/c1-13(2)12-16(18(24)20(26)23-28)19(25)22-17(14-8-4-3-5-9-14)21(27)29-15-10-6-7-11-15/h3-5,8-9,13,15-18,24,28H,6-7,10-12H2,1-2H3,(H,22,25)(H,23,26)/t16-,17+,18+/m1/s1	FWFGIHPGRQZWIW-SQNIBIBYSA-N	2		Not Available	Small Molecule																																			1	Yes	5	4	No	2	0	124.96 Å2	42.88 Å3	105.13 m3·mol-1	10	Yes	No	0.092 mg/mL	2.13	-3.6	8.61	-2.2	P55786;!P09960	NPEPPS;!LTA4H	1. Puromycin-sensitive aminopeptidase;!2. Leukotriene A-4 hydrolase
C20H27N3O6	Not Available	Not Available	405.4449	[H][C@@](C)(N[C@@]([H])(CCC1=CC=CC=C1)C(=O)OCC)C(=O)N1C(=O)N(C)C[C@@]1([H])C(O)=O	Not Available	Not Available					50020400	135654	CHEMBL317094	4576628			HMDB0041907					PA452640	5464343	347828133		60245		Imidapril	ZINC000003784427		Imidapril	Investigational	DB11783	InChI=1S/C20H27N3O6/c1-4-29-19(27)15(11-10-14-8-6-5-7-9-14)21-13(2)17(24)23-16(18(25)26)12-22(3)20(23)28/h5-9,13,15-16,21H,4,10-12H2,1-3H3,(H,25,26)/t13-,15-,16-/m0/s1	KLZWOWYOHUKJIG-BPUTZDHNSA-N		Imidapril is an ACE inhibitor used in the treatment of essential hypertension.	Not Available	Small Molecule																																			1	Yes	6	2	No	2	-1	116.25 Å2	42.36 Å3	103.2 m3·mol-1	10	Yes	No	0.447 mg/mL	-0.23	-3	3.49	5.22			
C25H37N5O6	Not Available	Not Available	503.6	C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@@]1(CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O	Not Available	Not Available							CHEMBL3989872	52085607									71249967	347828134				Apimostinel			NRX-1074	Investigational	DB11784	InChI=1S/C25H37N5O6/c1-15(31)19(26)23(35)29-12-6-10-18(29)22(34)30-13-7-11-25(30,14-17-8-4-3-5-9-17)24(36)28-20(16(2)32)21(27)33/h3-5,8-9,15-16,18-20,31-32H,6-7,10-14,26H2,1-2H3,(H2,27,33)(H,28,36)/t15-,16-,18+,19+,20+,25-/m1/s1	DVBUEXCIEIAXPM-PJUQSVSOSA-N	2		Not Available	Small Molecule																																			1	No	7	5	Yes	3	1	179.29 Å2	51.23 Å3	130.85 m3·mol-1	9	No	No	2.35 mg/mL	-1.6	-2.3	12.01	7.61			
C18H31N5O6	Not Available	Not Available	413.475	C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(N)=O	Not Available	Not Available							CHEMBL3544917	25069944									14539800	347828150				Rapastinel	ZINC000071773625		Rapastinel	Investigational	DB11801	InChI=1S/C18H31N5O6/c1-9(24)13(19)18(29)23-8-4-6-12(23)17(28)22-7-3-5-11(22)16(27)21-14(10(2)25)15(20)26/h9-14,24-25H,3-8,19H2,1-2H3,(H2,20,26)(H,21,27)/t9-,10-,11+,12+,13+,14+/m1/s1	GIBQQARAXHVEGD-BSOLPCOYSA-N	3		Not Available	Small Molecule																																			1	No	7	5	No	2	1	179.29 Å2	41.09 Å3	101.51 m3·mol-1	7	Yes	No	37.4 mg/mL	-3.7	-1	11.92	7.61			
C29H34N10O11S	Not Available	Not Available	730.71	N[C@@H](CNC(=O)CC[C@@H](NC(=O)C1=CC=C(NCC2=CNC3=NC=NC(=O)C3=N2)C=C1)C(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(O)=O	Not Available	Not Available								32702232									76958396	347828157				Technetium_(99mTc)_etarfolatide			Etarfolatide	Investigational	DB11810	InChI=1S/C29H34N10O11S/c30-16(25(44)38-18(7-21(41)42)26(45)39-19(11-51)29(49)50)10-32-20(40)6-5-17(28(47)48)37-24(43)13-1-3-14(4-2-13)31-8-15-9-33-23-22(36-15)27(46)35-12-34-23/h1-4,9,12,16-19,31,51H,5-8,10-11,30H2,(H,32,40)(H,37,43)(H,38,44)(H,39,45)(H,41,42)(H,47,48)(H,49,50)(H,33,34,35,46)/t16-,17+,18-,19-/m0/s1	YZSIZVRFVQKMJU-RDGPPVDQSA-N	2		Not Available	Small Molecule																																			0	No	17	11	Yes	3	-2	332.53 Å2	69.5 Å3	176.33 m3·mol-1	19	No	No	0.0697 mg/mL	-6.9	-4	2.87	7.1			
C55H99N13O9	Not Available	Not Available	1086.479	CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O	Not Available	Not Available								32699915									72187679	347828184							PZ-128	Investigational	DB11839	InChI=1S/C55H99N13O9/c1-5-6-7-8-9-10-11-12-13-14-15-16-20-31-47(70)63-41(28-21-23-32-56)51(74)64-42(29-22-24-33-57)52(75)68-46(37-69)54(77)65-43(30-25-34-61-55(59)60)50(73)62-39(4)49(72)67-45(35-38(2)3)53(76)66-44(48(58)71)36-40-26-18-17-19-27-40/h17-19,26-27,38-39,41-46,69H,5-16,20-25,28-37,56-57H2,1-4H3,(H2,58,71)(H,62,73)(H,63,70)(H,64,74)(H,65,77)(H,66,76)(H,67,72)(H,68,75)(H4,59,60,61)/t39-,41-,42-,43-,44-,45-,46-/m0/s1	VZRIKWNVDCTBTF-BKGFHLQYSA-N	2		Not Available	Small Molecule																																			0	No	14	14	No	1	3	380.96 Å2	124.63 Å3	307.87 m3·mol-1	45	No	No	0.00282 mg/mL	1.73	-5.6	11.51	11.9			
C50H71N13O12	The official prescribing information notes that the clearnace of angiotensin II is not dependent on hepatic function or renal function Label.	The plasma half-life of intravenously administered angiotensin II is less than one minute Label.	1046.1786	CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O	Liquid	The official prescribing information for angiotensin II notes that no specific studies have yet been conducted that examine the distribution of angiotensin II Label.					50236697	58506	CHEMBL408403	150504			HMDB0001035	C02135					172198	347828186		1999003		Angiotensin	ZINC000169676920	Giapreza	Angiotensin II	Approved, Investigational	DB11842	InChI=1S/C50H71N13O12/c1-5-28(4)41(47(72)59-36(23-31-25-54-26-56-31)48(73)63-20-10-14-38(63)45(70)60-37(49(74)75)22-29-11-7-6-8-12-29)62-44(69)35(21-30-15-17-32(64)18-16-30)58-46(71)40(27(2)3)61-43(68)34(13-9-19-55-50(52)53)57-42(67)33(51)24-39(65)66/h6-8,11-12,15-18,25-28,33-38,40-41,64H,5,9-10,13-14,19-24,51H2,1-4H3,(H,54,56)(H,57,67)(H,58,71)(H,59,72)(H,60,70)(H,61,68)(H,62,69)(H,65,66)(H,74,75)(H4,52,53,55)/t28-,33-,34-,35-,36-,37-,38-,40-,41-/m0/s1	CZGUSIXMZVURDU-JZXHSEFVSA-N	4	Angiotensin II is a peptide hormone of the RAAS system used to raise blood pressure in septic or other forms of shock.	Overdose with angiotensin II would be expected to result in hypertension, necessitating close monitoring and supportive care Label. Effects are also expected to be brief as the half-life of angiotensin II is less than one minute Label.In the ATHOS-3 clinical study there was a higher incidence of arterial and venous thrombotic and thromboembolic events in patients who received angiotensin II compared to placebo treated patients. The major imbalance was in deep venous thromboses - which prompts the potential need to use concurrent venous thromboembolism (VTE) prohphylaxis Label.Adverse effects of noticeable potential (>= 10%) include thromboembolic events (ie. like deep vein thrombosis) including arterial and venous thrombotic events, thrombocytopenia, tachycardia, and fungal infection. Effects whose potential are < 10% include delirium, acidosis, hyperglycemia, peripheral ischemia Label.Concomitant use of angiotensin converting enzymes (ACE) inhibitors may increase the response of angiotensin II Label.Concomitant use of angiotensin II blockers (ARBs) may decrease the response to angiotensin II Label.There are no formal data regarding the safe use of angiotensin II in pregnant women. However, septic or other distributive shock is a medical emergency that can be fatal if left untreated. Delaying treatment in pregnant women with hypotension associated with septic or otherdistributive shock is likely to increase the risk of maternal and fetal morbidity and mortality Label.There is no formal data regarding whether or not angiotensin II may become present in human milk and there is no data available on the effects of angiotensin II on the breastfed child or the effects on milk production Label.The safety and efficacy of angiotensin II in pediatric patients has not yet been established Label.There is no difference in the safety or efficacy between patients less than 65 years old and those 65 years or older when treated with angiotensin II Label.There is no difference in pharmacokinetics between male and female patients Label.The pharmacokinetics of angiotensin II are not expected to be influenced by renal impairment or hepatic impairment Label.	Small Molecule																																			0	No	17	13	Yes	4	0	408.84 Å2	107 Å3	269.81 m3·mol-1	29	No	No	0.0156 mg/mL	-5.3	-4.8	3.15	10.83	P30556	AGTR1	1. Type-1 angiotensin II receptor
C25H47N9O5	Not Available	Not Available	553.709	CC[C@H](C)C(NC(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(N)=O	Not Available	Not Available							CHEMBL3545314										71722017	347828216							Dusquetide	Investigational	DB11879	InChI=1S/C25H47N9O5/c1-6-14(4)19(33-21(36)16(26)9-7-11-30-25(28)29)23(38)32-18(13(2)3)24(39)34-12-8-10-17(34)22(37)31-15(5)20(27)35/h13-19H,6-12,26H2,1-5H3,(H2,27,35)(H,31,37)(H,32,38)(H,33,36)(H4,28,29,30)/t14-,15-,16-,17-,18-,19?/m0/s1	ZUJBBVJXXYRPFS-OUROWQTJSA-N	2		Not Available	Small Molecule																																			0	No	9	8	No	1	2	238.62 Å2	59.37 Å3	155.22 m3·mol-1	15	No	No	0.0992 mg/mL	-2.4	-3.8	12.21	11.74			
C27H40N8O7	Not Available	Not Available	588.666	CC(C)[C@@H]1N(C)C(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC1=O	Not Available	Not Available					50235980		CHEMBL429876	154046									176873	347828225				Cilengitide	ZINC000003952216		Cilengitide	Investigational	DB11890	InChI=1S/C27H40N8O7/c1-15(2)22-25(41)33-17(10-7-11-30-27(28)29)23(39)31-14-20(36)32-18(13-21(37)38)24(40)34-19(26(42)35(22)3)12-16-8-5-4-6-9-16/h4-6,8-9,15,17-19,22H,7,10-14H2,1-3H3,(H,31,39)(H,32,36)(H,33,41)(H,34,40)(H,37,38)(H4,28,29,30)/t17-,18-,19+,22-/m0/s1	AMLYAMJWYAIXIA-VWNVYAMZSA-N	3		Not Available	Small Molecule																																			0	No	10	8	No	2	0	235.91 Å2	59.8 Å3	159.97 m3·mol-1	9	No	No	0.144 mg/mL	-3.7	-3.6	3.59	12.02			
C36H53N7O6	One cycle of hemodialysis reduces difelikefalin plasma concentrations by 70-80% and no detectable drug remains after two cycles.4	The half-life of difelikefalin in hemodialysis patients prior to dialysis ranges between 23 and 31 hours.4	679.863	CC(C)C[C@@H](NC(=O)[C@@H](CC1=CC=CC=C1)NC(=O)[C@H](N)CC1=CC=CC=C1)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O	Solid	The mean volume of distribution of difelikefalin is approximately 238 mL/kg.4					235785		CHEMBL3989915	44208824									24794466	347828265		2569089		Difelikefalin		Korsuva	Difelikefalin	Approved, Investigational	DB11938	InChI=1S/C36H53N7O6/c1-24(2)21-29(32(45)40-28(15-9-10-18-37)34(47)43-19-16-36(39,17-20-43)35(48)49)42-33(46)30(23-26-13-7-4-8-14-26)41-31(44)27(38)22-25-11-5-3-6-12-25/h3-8,11-14,24,27-30H,9-10,15-23,37-39H2,1-2H3,(H,40,45)(H,41,44)(H,42,46)(H,48,49)/t27-,28-,29-,30-/m1/s1	FWMNVWWHGCHHJJ-SKKKGAJSSA-N	3	Difelikefalin is a kappa opioid receptor agonist used in the treatment of pruritus associated with chronic kidney disease in patients undergoing hemodialysis.	In clinical studies, single doses of up to 12 times (and multiple doses of up to 5 times) the recommended dosage of difelikefalin were administered in subjects undergoing hemodialysis.4 These patients experienced a dose-dependent increase in adverse reactions, including gastrointestinal effects and CNS depressant effects. In the event of overdosage, difelikefalin is dialyzable - 4 hours of high-flux hemodialysis effectively clears approximately 70-80% of the drug from plasma, and levels are likely to be undetectable following a second cycle.4	Small Molecule																																		Soluble	0	No	9	7	Yes	3	2	222.97 Å2	74.6 Å3	185.74 m3·mol-1	18	No	No	0.0103 mg/mL	-1.7	-4.8	1.92	10.26	P41145	OPRK1	1. Kappa-type opioid receptor
C58H80N16O14	Not Available	Not Available	1225.376	[H][C@]1(C[C@@H](O)CN1C(=O)[C@@H](CC1=CC=C(O)C=C1)NC(C)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NNC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)NC)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(N)=O	Not Available	Not Available					50196420		CHEMBL3924151	52083917									46700761	347828298							TAK-448	Investigational	DB11975	InChI=1S/C58H80N16O14/c1-30(2)22-42(51(82)66-40(16-11-21-63-57(61)62-5)50(81)67-41(49(60)80)25-35-28-64-39-15-10-9-14-38(35)39)70-58(88)73-72-53(84)43(23-33-12-7-6-8-13-33)69-55(86)48(31(3)75)71-52(83)44(27-47(59)79)68-54(85)46-26-37(78)29-74(46)56(87)45(65-32(4)76)24-34-17-19-36(77)20-18-34/h6-10,12-15,17-20,28,30-31,37,40-46,48,64,75,77-78H,11,16,21-27,29H2,1-5H3,(H2,59,79)(H2,60,80)(H,65,76)(H,66,82)(H,67,81)(H,68,85)(H,69,86)(H,71,83)(H,72,84)(H3,61,62,63)(H2,70,73,88)/t31-,37-,40+,41+,42+,43+,44+,45-,46+,48+/m1/s1	MWXWMWSUUYXMRA-GRKBUMBKSA-N			Not Available	Small Molecule																																			0	No	17	18	Yes	5	1	475.71 Å2	126.85 Å3	326.01 m3·mol-1	31	No	No	0.0182 mg/mL	-4.4	-4.8	9.4	12.08			
C32H49N9O5	Not Available	Not Available	639.802	CC1=CC(O)=CC(C)=C1C[C@H](NC(=O)[C@H](N)CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O	Not Available	Not Available							CHEMBL3833370	9939410									11764719	347828303				Elamipretide	ZINC000043130902		Elamipretide	Investigational	DB11981	InChI=1S/C32H49N9O5/c1-19-15-22(42)16-20(2)23(19)18-27(41-29(44)24(34)11-8-14-38-32(36)37)31(46)39-25(12-6-7-13-33)30(45)40-26(28(35)43)17-21-9-4-3-5-10-21/h3-5,9-10,15-16,24-27,42H,6-8,11-14,17-18,33-34H2,1-2H3,(H2,35,43)(H,39,46)(H,40,45)(H,41,44)(H4,36,37,38)/t24-,25+,26+,27+/m1/s1	SFVLTCAESLKEHH-WKAQUBQDSA-N	2		Not Available	Small Molecule																																			0	No	10	10	No	2	3	264.56 Å2	69.74 Å3	186.25 m3·mol-1	19	No	No	0.0155 mg/mL	-0.51	-4.6	9.62	11.84			
C30H49N9O9	Not Available	Not Available	679.776	CC(C)C(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O	Not Available	Not Available						135870	CHEMBL156025	26232604									451417	347828316		40230		Thymopentin			Thymopentin	Investigational	DB11996	InChI=1S/C30H49N9O9/c1-16(2)24(28(46)38-22(29(47)48)14-17-8-10-18(40)11-9-17)39-27(45)21(15-23(41)42)37-26(44)20(7-3-4-12-31)36-25(43)19(32)6-5-13-35-30(33)34/h8-11,16,19-22,24,40H,3-7,12-15,31-32H2,1-2H3,(H,36,43)(H,37,44)(H,38,46)(H,39,45)(H,41,42)(H,47,48)(H4,33,34,35)/t19-,20-,21-,22-,24?/m0/s1	PSWFFKRAVBDQEG-XXTQFKTOSA-N	3		Not Available	Small Molecule																																			0	No	14	11	No	1	1	327.67 Å2	70.84 Å3	171.76 m3·mol-1	22	No	No	0.0662 mg/mL	-6.3	-4	3.2	11.29			
C45H58N10O9S2	Not Available	Not Available	947.14	C[C@@H](O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@H](N)CC2=CC=CC=C2)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@H](CC2=CNC3=CC=CC=C23)C(=O)N[C@@H](CCCCN)C(=O)N1)C(N)=O	Not Available	Not Available							CHEMBL539934	5293471									6918265	347828394					ZINC000169289417		TT-232	Investigational	DB12088	InChI=1S/C45H58N10O9S2/c1-25(56)38(39(48)58)55-45(64)37-24-66-65-23-36(53-40(59)31(47)19-26-9-3-2-4-10-26)44(63)51-34(20-27-14-16-29(57)17-15-27)42(61)52-35(21-28-22-49-32-12-6-5-11-30(28)32)43(62)50-33(41(60)54-37)13-7-8-18-46/h2-6,9-12,14-17,22,25,31,33-38,49,56-57H,7-8,13,18-21,23-24,46-47H2,1H3,(H2,48,58)(H,50,62)(H,51,63)(H,52,61)(H,53,59)(H,54,60)(H,55,64)/t25-,31-,33+,34+,35-,36+,37+,38+/m1/s1	SNAJPQVDGYDQSW-DYCFWDQMSA-N	2		Not Available	Small Molecule																																			0	No	11	12	Yes	5	2	325.98 Å2	98.26 Å3	250.18 m3·mol-1	16	No	No	0.00927 mg/mL	-1.8	-5	7.7	10.61			
C50H73N15O11	Not Available	Not Available	1060.2085	N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O	Not Available	Not Available					50049949	3165	CHEMBL406291	388341			HMDB0004246	C00306				PA166109574	439201	347828425				Bradykinin			Bradykinin	Investigational	DB12126	InChI=1S/C50H73N15O11/c51-32(16-7-21-56-49(52)53)45(72)65-25-11-20-39(65)47(74)64-24-9-18-37(64)43(70)58-28-40(67)59-34(26-30-12-3-1-4-13-30)41(68)62-36(29-66)46(73)63-23-10-19-38(63)44(71)61-35(27-31-14-5-2-6-15-31)42(69)60-33(48(75)76)17-8-22-57-50(54)55/h1-6,12-15,32-39,66H,7-11,16-29,51H2,(H,58,70)(H,59,67)(H,60,69)(H,61,71)(H,62,68)(H,75,76)(H4,52,53,56)(H4,54,55,57)/t32-,33-,34-,35-,36-,37-,38-,39-/m0/s1	QXZGBUJJYSLZLT-FDISYFBBSA-N	1		Not Available	Small Molecule																																			0	No	18	14	Yes	5	2	413.78 Å2	111.38 Å3	295.08 m3·mol-1	27	No	No		-6.4		3.39	12.44			
C33H44N6O5	Not Available	Not Available	604.752	CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=CC=C2C=CC=CC2=N1)C(=O)NC(C)(C)C	Not Available	Not Available					483		CHEMBL322241	339331									382974	347828465							Telinavir	Investigational	DB12178	InChI=1S/C33H44N6O5/c1-21(2)19-39(32(44)38-33(3,4)5)20-28(40)26(17-22-11-7-6-8-12-22)36-31(43)27(18-29(34)41)37-30(42)25-16-15-23-13-9-10-14-24(23)35-25/h6-16,21,26-28,40H,17-20H2,1-5H3,(H2,34,41)(H,36,43)(H,37,42)(H,38,44)/t26-,27-,28+/m0/s1	ZILOOGIOHVCEKS-HZFUHODCSA-N	1		Not Available	Small Molecule																																			0	No	6	5	Yes	3	0	166.75 Å2	66.35 Å3	167.15 m3·mol-1	14	No	No	0.00427 mg/mL	2.48	-5.2	13.59	0.59			
C43H67N13O10	Not Available	Not Available	926.09	[H][C@](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC)C(C)C)([C@@H](C)CC)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(O)=O	Not Available	Not Available								32699929									3082475	347828484							TRV-120027	Investigational	DB12199	InChI=1S/C43H67N13O10/c1-7-24(4)35(40(63)53-31(19-27-20-47-22-49-27)41(64)56-17-9-11-32(56)38(61)50-25(5)42(65)66)55-37(60)30(18-26-12-14-28(57)15-13-26)52-39(62)34(23(2)3)54-36(59)29(51-33(58)21-46-6)10-8-16-48-43(44)45/h12-15,20,22-25,29-32,34-35,46,57H,7-11,16-19,21H2,1-6H3,(H,47,49)(H,50,61)(H,51,58)(H,52,62)(H,53,63)(H,54,59)(H,55,60)(H,65,66)(H4,44,45,48)/t24-,25+,29-,30-,31-,32-,34-,35-/m0/s1	XIEWFECSPPTVQN-KMIMAYJXSA-N	2		Not Available	Small Molecule																																			0	No	15	13	Yes	3	1	355.05 Å2	95.99 Å3	249.73 m3·mol-1	26	No	No		-4.2		3.4	11.75			
C40H63N9O8S	Not Available	Not Available	830.06	CC[C@H](C)[C@@H]1NC(=O)[C@@H](CC2=CNC3=CC=CC=C23)NC(=O)CCSCC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC1=O)[C@H](C)CC)C(=O)N(C)[C@H](CO)CCCN	Not Available	Not Available							CHEMBL2218898	8008159									9832431	347828560				Barusiban	ZINC000085537120		Barusiban	Investigational	DB12292	InChI=1S/C40H63N9O8S/c1-6-23(3)34-38(55)46-31(20-32(42)51)36(53)45-29(40(57)49(5)26(22-50)11-10-16-41)14-17-58-18-15-33(52)44-30(19-25-21-43-28-13-9-8-12-27(25)28)37(54)47-35(24(4)7-2)39(56)48-34/h8-9,12-13,21,23-24,26,29-31,34-35,43,50H,6-7,10-11,14-20,22,41H2,1-5H3,(H2,42,51)(H,44,52)(H,45,53)(H,46,55)(H,47,54)(H,48,56)/t23-,24+,26+,29+,30-,31+,34+,35+/m1/s1	UGNGRKKDUVKQDF-IHOMMZCZSA-N	2		Not Available	Small Molecule																																			0	No	9	9	Yes	3	1	270.94 Å2	86.06 Å3	220.2 m3·mol-1	14	No	No	0.0157 mg/mL	-0.66	-4.7	11.74	9.9			
C24H32N6O11	Not Available	Not Available	580.551	NCCCC[C@@H]1NC(=O)[C@H](CCC(O)=O)NC(=O)C2=C(OCC[C@H](NC1=O)C(=O)NCC(O)=O)C=CC(=C2)[N+]([O-])=O	Not Available	Not Available							CHEMBL3544981	7984131									9808372	347828682				Tavilermide	ZINC000136639443		Tavilermide	Investigational	DB12441	InChI=1S/C24H32N6O11/c25-9-2-1-3-15-23(37)29-17(22(36)26-12-20(33)34)8-10-41-18-6-4-13(30(39)40)11-14(18)21(35)27-16(24(38)28-15)5-7-19(31)32/h4,6,11,15-17H,1-3,5,7-10,12,25H2,(H,26,36)(H,27,35)(H,28,38)(H,29,37)(H,31,32)(H,33,34)/t15-,16-,17-/m0/s1	DVJXNXPFYJIACK-ULQDDVLXSA-N	3		Not Available	Small Molecule																																			0	No	12	7	No	2	-1	269.39 Å2	56.31 Å3	137.04 m3·mol-1	11	No	No	0.228 mg/mL	-4.8	-3.4	2.7	9.89			
C46H73N13O11S2	Not Available	Not Available	1048.29	CC[C@H](C)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(C)C)C(=O)NCC(N)=O	Not Available	Not Available					50350870		CHEMBL1817709	26609297									53330936	347828730				Selepressin			Selepressin	Investigational	DB12495	InChI=1S/C46H73N13O11S2/c1-5-26(4)38-45(69)54-30(14-9-17-35(48)60)41(65)56-32(21-36(49)61)42(66)57-33(24-72-71-23-28(47)39(63)55-31(43(67)58-38)20-27-12-7-6-8-13-27)46(70)59-19-11-16-34(59)44(68)53-29(15-10-18-51-25(2)3)40(64)52-22-37(50)62/h6-8,12-13,25-26,28-34,38,51H,5,9-11,14-24,47H2,1-4H3,(H2,48,60)(H2,49,61)(H2,50,62)(H,52,64)(H,53,68)(H,54,69)(H,55,63)(H,56,65)(H,57,66)(H,58,67)/t26-,28-,29-,30-,31-,32-,33-,34-,38-/m0/s1	JCVQBJTWWDYUFQ-MRUTUVJXSA-N	2		Not Available	Small Molecule																																			0	No	13	12	Yes	3	2	391.33 Å2	108.02 Å3	267.71 m3·mol-1	21	No	No	0.0249 mg/mL	-4.9	-4.6	11.4	10.08			
C36H60N10O12	Not Available	Not Available	824.934	CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O	Not Available	Not Available							CHEMBL2103826	8008132									9832404	347828827					ZINC000085540112		Davunetide	Investigational	DB12613	InChI=1S/C36H60N10O12/c1-6-18(4)28(35(56)46-14-8-9-23(46)31(52)41-21(36(57)58)11-12-25(38)48)44-30(51)22(16-47)42-33(54)27(17(2)3)43-32(53)24-10-7-13-45(24)34(55)19(5)40-29(50)20(37)15-26(39)49/h17-24,27-28,47H,6-16,37H2,1-5H3,(H2,38,48)(H2,39,49)(H,40,50)(H,41,52)(H,42,54)(H,43,53)(H,44,51)(H,57,58)/t18-,19-,20-,21-,22-,23-,24-,27-,28-/m0/s1	DWLTUUXCVGVRAV-XWRHUKJGSA-N	3		Not Available	Small Molecule																																			0	No	13	10	No	2	0	355.85 Å2	82.56 Å3	201.56 m3·mol-1	22	No	No	0.343 mg/mL	-7.5	-3.4	3.33	7.05			
C42H64N12O11	Not Available	Not Available	913.047	[H]N([C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N1CCC[C@H]1C(O)=O)C(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CCCC)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O	Not Available	Not Available								7987306									9811551	347828842							Aclerastide	Investigational	DB12631	InChI=1S/C42H64N12O11/c1-4-6-9-28(50-36(59)29(10-7-16-47-42(44)45)49-35(58)27(43)20-33(56)57)37(60)51-30(18-24-12-14-26(55)15-13-24)38(61)53-34(23(3)5-2)39(62)52-31(19-25-21-46-22-48-25)40(63)54-17-8-11-32(54)41(64)65/h12-15,21-23,27-32,34,55H,4-11,16-20,43H2,1-3H3,(H,46,48)(H,49,58)(H,50,59)(H,51,60)(H,52,62)(H,53,61)(H,56,57)(H,64,65)(H4,44,45,47)/t23-,27-,28-,29-,30-,31-,32-,34-/m0/s1	RUBMHAHMIJSMHA-LBWFYSSPSA-N	2		Not Available	Small Molecule																																			0	No	16	12	Yes	3	0	379.74 Å2	94.55 Å3	232.62 m3·mol-1	27	No	No	0.0352 mg/mL	-5.9	-4.4	2.95	10.84			
C27H35N5O7S	Not Available	The half life of metenkefalin is 4.2-39 minutes.7	573.67	CSCC[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1)C(O)=O	Not Available	Not Available	Q8N4T0	CPA6	1. Carboxypeptidase A6		50019056	6618	CHEMBL13786	391597				C11684					443363	347828872		1349278		Met-enkephalin	ZINC000004102171		Metenkefalin	Investigational	DB12668	InChI=1S/C27H35N5O7S/c1-40-12-11-21(27(38)39)32-26(37)22(14-17-5-3-2-4-6-17)31-24(35)16-29-23(34)15-30-25(36)20(28)13-18-7-9-19(33)10-8-18/h2-10,20-22,33H,11-16,28H2,1H3,(H,29,34)(H,30,36)(H,31,35)(H,32,37)(H,38,39)/t20-,21-,22-/m0/s1	YFGBQHOOROIVKG-FKBYEOEOSA-N	3	Metenkefalin is an investigational endogenous opioid being studied for the treatment of COVID-19.	Data regarding overdoses of metenkefalin are not readily available.7 Animal overdose studies have not determined an LD50.7	Small Molecule																																			0	No	8	7	No	2	0	199.95 Å2	58.85 Å3	149.01 m3·mol-1	16	No	No	0.0196 mg/mL	-2.5	-4.5	3.61	7.73	P41143;!P35372	OPRD1;!OPRM1	1. Delta-type opioid receptor;!2. Mu-type opioid receptor
C39H67N5O6	Not Available	Not Available	701.994	CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCC1=CC=CC=C1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C	Not Available	Not Available							CHEMBL3989512	5293519									6918315	347828881					ZINC000003951627		Soblidotin	Investigational	DB12677	InChI=1S/C39H67N5O6/c1-13-27(6)35(43(10)39(48)33(25(2)3)41-38(47)34(26(4)5)42(8)9)31(49-11)24-32(45)44-23-17-20-30(44)36(50-12)28(7)37(46)40-22-21-29-18-15-14-16-19-29/h14-16,18-19,25-28,30-31,33-36H,13,17,20-24H2,1-12H3,(H,40,46)(H,41,47)/t27-,28+,30-,31+,33-,34-,35-,36+/m0/s1	DZMVCVHATYROOS-ZBFGKEHZSA-N	2		Not Available	Small Molecule																																			0	No	7	2	No	2	1	120.52 Å2	80.46 Å3	197.97 m3·mol-1	20	No	No	0.00826 mg/mL	4.4	-4.9	12.7	8.03			
C43H69N11O3	Not Available	Not Available	788.099	CC(C)(C)C1=C(C[C@H](NC(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCCC2=CC=CC=C2)C2=C(N1)C(=CC(=C2)C(C)(C)C)C(C)(C)C	Not Available	Not Available						77752	CHEMBL1817968	26611002									25242323	347828909							LTX-109	Investigational	DB12711	InChI=1S/C43H69N11O3/c1-41(2,3)27-23-28-29(35(43(7,8)9)54-34(28)30(24-27)42(4,5)6)25-33(53-36(55)31(44)17-13-20-50-39(45)46)38(57)52-32(18-14-21-51-40(47)48)37(56)49-22-19-26-15-11-10-12-16-26/h10-12,15-16,23-24,31-33,54H,13-14,17-22,25,44H2,1-9H3,(H,49,56)(H,52,57)(H,53,55)(H4,45,46,50)(H4,47,48,51)/t31-,32-,33-/m0/s1	ZVOYWSKEBVVLGW-ZDCRTTOTSA-N	2		Not Available	Small Molecule																																			0	No	10	11	Yes	3	3	252.91 Å2	92.18 Å3	249.61 m3·mol-1	21	No	No	0.00105 mg/mL	3.67	-5.9	12.68	12.17			
C21H25N5O6	Not Available	Not Available	443.4531	NC1=NC(=O)C2=C(NC[C@H](CCC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C2)N1	Not Available	Not Available					22590		CHEMBL34412	130593						DDF			148138	347828954					ZINC000008577213		Lometrexol	Investigational	DB12769	InChI=1S/C21H25N5O6/c22-21-25-17-14(19(30)26-21)9-12(10-23-17)2-1-11-3-5-13(6-4-11)18(29)24-15(20(31)32)7-8-16(27)28/h3-6,12,15H,1-2,7-10H2,(H,24,29)(H,27,28)(H,31,32)(H4,22,23,25,26,30)/t12-,15+/m1/s1	ZUQBAQVRAURMCL-DOMZBBRYSA-N			Not Available	Small Molecule																																			1	No	10	6	Yes	3	-2	183.21 Å2	45.15 Å3	122 m3·mol-1	9	No	No	0.0911 mg/mL	-1	-3.7	3.03	4.75	P0ABQ4	folA	1. Dihydrofolate reductase
C38H73N21O10S2	7.66 L/hr	3 to 4 days	1048.26	C[C@@H](NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](C)NC(=O)[C@@H](CSSC[C@H](N)C(O)=O)NC(C)=O)C(=O)N[C@H](CCCNC(N)=N)C(N)=O	Not Available	796 L						134700	CHEMBL3545184	32697932					D10676				71511839	347829023		1876119		Etelcalcetide		Parsabiv	Etelcalcetide	Approved, Investigational	DB12865	InChI=1S/C38H73N21O10S2/c1-18(28(62)56-22(27(40)61)8-4-12-49-35(41)42)53-30(64)23(9-5-13-50-36(43)44)58-32(66)25(11-7-15-52-38(47)48)59-31(65)24(10-6-14-51-37(45)46)57-29(63)19(2)54-33(67)26(55-20(3)60)17-71-70-16-21(39)34(68)69/h18-19,21-26H,4-17,39H2,1-3H3,(H2,40,61)(H,53,64)(H,54,67)(H,55,60)(H,56,62)(H,57,63)(H,58,66)(H,59,65)(H,68,69)(H4,41,42,49)(H4,43,44,50)(H4,45,46,51)(H4,47,48,52)/t18-,19-,21+,22-,23-,24-,25-,26-/m1/s1	ANIAZGVDEUQPRI-ZJQCGQFWSA-N	3	Etelcalcetide is a calcium sensing receptor agonist used to treat secondary hyperparathyroidism in patients with chronic kidney disease who require hemodialysis.	Not Available	Small Molecule																																			0	No	23	22	No	0	4	557.71 Å2	108.23 Å3	303.63 m3·mol-1	36	No	No	0.132 mg/mL	-11	-3.9	-1.3	12.57	P41180	CASR	1. Extracellular calcium-sensing receptor
C48H68FN11O12S	Not Available	Not Available	1042.2	CC[C@H](C)[C@@H]1NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)CCCSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N(CC(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)CC1=CC=C(F)C=C1	Not Available	Not Available					50044686		CHEMBL3354594	34994563									76073634	347829077				Merotocin			Merotocin	Investigational	DB12932	InChI=1S/C48H68FN11O12S/c1-5-27(4)42-47(71)56-32(16-17-37(50)62)44(68)57-35(21-38(51)63)45(69)58-36(25-73-18-6-7-40(65)54-34(46(70)59-42)20-28-10-14-31(61)15-11-28)48(72)60(23-29-8-12-30(49)13-9-29)24-41(66)55-33(19-26(2)3)43(67)53-22-39(52)64/h8-15,26-27,32-36,42,61H,5-7,16-25H2,1-4H3,(H2,50,62)(H2,51,63)(H2,52,64)(H,53,67)(H,54,65)(H,55,66)(H,56,71)(H,57,68)(H,58,69)(H,59,70)/t27-,32-,33-,34-,35-,36-,42-/m0/s1	PVVHQWISMVJHFK-NIFJBHDKSA-N			Not Available	Small Molecule																																			0	No	12	11	Yes	3	0	373.51 Å2	104.41 Å3	263.25 m3·mol-1	20	No	No	0.0174 mg/mL	-2.5	-4.8	9.5	-6			
C26H42N6O12S2	Not Available	Not Available	694.77	CSCC[C@H](NC=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O	Not Available	Not Available						125492		34979857									44628955	347829167					ZINC000068077856		Foxy-5	Investigational	DB13034	InChI=1S/C26H42N6O12S2/c1-13(2)8-17(26(43)44)32-24(41)15(4-5-20(35)36)30-25(42)18(11-45)29-19(34)10-27-22(39)16(9-21(37)38)31-23(40)14(28-12-33)6-7-46-3/h12-18,45H,4-11H2,1-3H3,(H,27,39)(H,28,33)(H,29,34)(H,30,42)(H,31,40)(H,32,41)(H,35,36)(H,37,38)(H,43,44)/t14-,15-,16-,17-,18-/m0/s1	WFZPJYYCTSHDJI-ATIWLJMLSA-N	1		Not Available	Small Molecule																																			0	No	12	10	No	0	-3	286.5 Å2	67.64 Å3	162.76 m3·mol-1	23	No	No	0.033 mg/mL	-3.1	-4.3	3.39				
C28H39N7O9	Not Available	Not Available	617.66	C[C@@H](NC(=O)CNC(=O)[C@H]1C[C@H](O)CN1C(=O)[C@H]1CCCN1C(=O)[C@@H](CC1=CC=C(O)C=C1)NC(C)=O)C(=O)NCC(N)=O	Not Available	Not Available							CHEMBL450656	8114558									9938933	347829195				Rotigaptide	ZINC000014175498		Rotigaptide	Investigational	DB13067	InChI=1S/C28H39N7O9/c1-15(25(41)30-12-23(29)39)32-24(40)13-31-26(42)22-11-19(38)14-35(22)28(44)21-4-3-9-34(21)27(43)20(33-16(2)36)10-17-5-7-18(37)8-6-17/h5-8,15,19-22,37-38H,3-4,9-14H2,1-2H3,(H2,29,39)(H,30,41)(H,31,42)(H,32,40)(H,33,36)/t15-,19+,20-,21-,22-/m1/s1	GFJRASPBQLDRRY-TWTQBQJDSA-N	-Infinity		Not Available	Small Molecule																																			0	No	9	7	Yes	3	0	240.57 Å2	62.08 Å3	152.56 m3·mol-1	12	No	No	1.56 mg/mL	-4.6	-2.6	9.5	-1.9			
C45H63N13O12S2	Not Available	Not Available	1042.2	NCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O	Not Available	Not Available					50350865	136020	CHEMBL1819440	16736525												7703		Ornipressin			Ornipressin	Experimental	DB13464	InChI=1S/C45H63N13O12S2/c46-16-4-8-28(39(64)51-21-37(50)62)53-44(69)34-9-5-17-58(34)45(70)33-23-72-71-22-27(47)38(63)54-30(19-25-10-12-26(59)13-11-25)42(67)55-31(18-24-6-2-1-3-7-24)41(66)52-29(14-15-35(48)60)40(65)56-32(20-36(49)61)43(68)57-33/h1-3,6-7,10-13,27-34,59H,4-5,8-9,14-23,46-47H2,(H2,48,60)(H2,49,61)(H2,50,62)(H,51,64)(H,52,66)(H,53,69)(H,54,63)(H,55,67)(H,56,65)(H,57,68)/t27-,28-,29-,30-,31-,32-,33-,34-/m0/s1	MUNMIGOEDGHVLE-LGYYRGKSSA-N			Not Available	Small Molecule																																			0	No	14	13	Yes	4	2	425.55 Å2	103.78 Å3	262.17 m3·mol-1	18	No	No	0.064 mg/mL	-7.1	-4.2	9.25	9.85			
C49H70N14O11	Not Available	Not Available	1031.186	CC(C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O	Not Available	Not Available					50228199	135950	CHEMBL409803	8526544														Angiotensinamide			Angiotensinamide	Experimental	DB13517	InChI=1S/C49H70N14O11/c1-26(2)39(61-42(67)33(12-8-18-55-49(52)53)57-41(66)32(50)23-38(51)65)45(70)58-34(20-29-14-16-31(64)17-15-29)43(68)62-40(27(3)4)46(71)59-35(22-30-24-54-25-56-30)47(72)63-19-9-13-37(63)44(69)60-36(48(73)74)21-28-10-6-5-7-11-28/h5-7,10-11,14-17,24-27,32-37,39-40,64H,8-9,12-13,18-23,50H2,1-4H3,(H2,51,65)(H,54,56)(H,57,66)(H,58,70)(H,59,71)(H,60,69)(H,61,67)(H,62,68)(H,73,74)(H4,52,53,55)/t32-,33-,34-,35-,36-,37-,39-,40-/m0/s1	JYPVVOOBQVVUQV-CGHBYZBKSA-N			Not Available	Small Molecule																																			0	No	16	14	Yes	4	0	412.13 Å2	108.07 Å3	276.76 m3·mol-1	28	No	No	0.0169 mg/mL	-3.8	-4.8	3.42	11.7			
C22H31N5O4	Not Available	Not Available	429.5126	[H][C@]1(CCN1C(=O)[C@H](NCC(O)=O)C1CCCCC1)C(=O)NCC1=CC=C(C=C1)C(N)=N	Not Available	Not Available					29388	43966	CHEMBL266349	159822					D07143	MEL								Ximelagatran	ZINC000003809827		Melagatran	Experimental	DB13616	InChI=1S/C22H31N5O4/c23-20(24)16-8-6-14(7-9-16)12-26-21(30)17-10-11-27(17)22(31)19(25-13-18(28)29)15-4-2-1-3-5-15/h6-9,15,17,19,25H,1-5,10-13H2,(H3,23,24)(H,26,30)(H,28,29)/t17-,19+/m0/s1	DKWNMCUOEDMMIN-PKOBYXMFSA-N			Not Available	Small Molecule																																			1	No	7	5	Yes	3	1	148.61 Å2	46.84 Å3	125.7 m3·mol-1	9	Yes	No	0.117 mg/mL	-1.3	-3.6	3.2	11.48			
C43H65N11O12S2	Not Available	Not Available	992.18	CC[C@H](C)[C@@H]1NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O	Not Available	Not Available					50044676		CHEMBL439044	395815														Demoxytocin			Demoxytocin	Experimental	DB13798	InChI=1S/C43H65N11O12S2/c1-5-23(4)36-42(65)49-26(12-13-32(44)56)38(61)50-29(19-33(45)57)39(62)52-30(21-68-67-16-14-35(59)48-28(40(63)53-36)18-24-8-10-25(55)11-9-24)43(66)54-15-6-7-31(54)41(64)51-27(17-22(2)3)37(60)47-20-34(46)58/h8-11,22-23,26-31,36,55H,5-7,12-21H2,1-4H3,(H2,44,56)(H2,45,57)(H2,46,58)(H,47,60)(H,48,59)(H,49,65)(H,50,61)(H,51,64)(H,52,62)(H,53,63)/t23-,26-,27-,28-,29-,30-,31-,36-/m0/s1	GTYWGUNQAMYZPF-QPLNMOKZSA-N			Not Available	Small Molecule																																			0	No	12	11	Yes	3	0	373.51 Å2	100.81 Å3	249.01 m3·mol-1	17	No	No	0.0427 mg/mL	-3.8	-4.4	9.5	-6			
C65H87GaN14O19S2	The pharmacokinetics of dotatate gallium 68 is matched to the short half-life of the isotope gallium 68 thus, this pharmaceutical presents a very fast blood clearance.2	The half-life of gallium 68 is estimated to be of 68 min.2	1500.54	[68Ga+3].C[C@@H](O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)CN2CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC2)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(O)=O	Solid	The volume of distribution is registered in a range from 0.25-0.65 ml/cm3.6								58828606												676679					Dotatate gallium Ga-68	Approved, Investigational	DB13925	InChI=1S/C65H90N14O19S2.Ga/c1-38(80)56-64(96)73-51(63(95)75-57(39(2)81)65(97)98)37-100-99-36-50(72-59(91)47(28-40-10-4-3-5-11-40)68-52(83)32-76-20-22-77(33-53(84)85)24-26-79(35-55(88)89)27-25-78(23-21-76)34-54(86)87)62(94)70-48(29-41-15-17-43(82)18-16-41)60(92)71-49(30-42-31-67-45-13-7-6-12-44(42)45)61(93)69-46(58(90)74-56)14-8-9-19-66;/h3-7,10-13,15-18,31,38-39,46-51,56-57,67,80-82H,8-9,14,19-30,32-37,66H2,1-2H3,(H,68,83)(H,69,93)(H,70,94)(H,71,92)(H,72,91)(H,73,96)(H,74,90)(H,75,95)(H,84,85)(H,86,87)(H,88,89)(H,97,98);/q;+3/p-3/t38-,39-,46+,47-,48+,49-,50+,51+,56+,57+;/m1./s1/i;1-2	XBJPSVQFCQFGDC-WSCOIBMGSA-K	4		Studies on dotatate gallium 68 have not been studied but the comparative studies to other non-radioactivity compounds showed no mutation.Label	Small Molecule																												5		-3.69			2.6	At pH above 7 can be soluble	0	No	24	14	Yes	6	-2	505.95 Å2	144.31 Å3	397.34 m3·mol-1	26	No	No	0.068 mg/mL	-8.4	-4.4	0.47	10.28	P30874	SSTR2	1. Somatostatin receptor type 2
C65H87LuN14O19S2	The mean clearance (CL) is 4.5 L/h (CV 31%). Co-administration of amino acids with lutetium Lu 177 dotatate increased the mean beta-phase blood clearance of lutetium Lu 177 dotatate by 36% Label.	The mean (± standard deviation) effective blood elimination half-life is 3.5 (±1.4) hours and the mean terminal blood half-life is 71 (± 28) hours Label.	1609.55	[177Lu+3].C[C@@H](O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)CN2CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC2)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(O)=O	Solid	The mean volume of distribution is 460 L (CV 54%). Within 4 hours of administration, distribution in kidneys, tumor lesions, liver, spleen, and, in some patients, pituitary gland and thyroid was observed. High uptake of the radiolabeled peptide in the pancreas in animal biodistribution studies was observed due to high expression of SSTR2 Label. Co-administration of amino acids with lutetium Lu 177 dotatate may decrease the extent of drug distribution to the kidneys.								32699095												1999335				Lutathera	Lutetium Lu 177 dotatate	Approved, Investigational	DB13985	InChI=1S/C65H90N14O19S2.Lu/c1-38(80)56-64(96)73-51(63(95)75-57(39(2)81)65(97)98)37-100-99-36-50(72-59(91)47(28-40-10-4-3-5-11-40)68-52(83)32-76-20-22-77(33-53(84)85)24-26-79(35-55(88)89)27-25-78(23-21-76)34-54(86)87)62(94)70-48(29-41-15-17-43(82)18-16-41)60(92)71-49(30-42-31-67-45-13-7-6-12-44(42)45)61(93)69-46(58(90)74-56)14-8-9-19-66;/h3-7,10-13,15-18,31,38-39,46-51,56-57,67,80-82H,8-9,14,19-30,32-37,66H2,1-2H3,(H,68,83)(H,69,93)(H,70,94)(H,71,92)(H,72,91)(H,73,96)(H,74,90)(H,75,95)(H,84,85)(H,86,87)(H,88,89)(H,97,98);/q;+3/p-3/t38-,39-,46+,47-,48+,49-,50+,51+,56+,57+;/m1./s1/i;1+2	MXDPZUIOZWKRAA-PRDSJKGBSA-K	3	Lutetium Lu 177 dotatate is a radiolabeled somatostatin analog used to treat somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors.	While carcinogenicity and mutagenicity studies have not been conducted with lutetium 177 dotatate, radioisotope is considered a carcinogen and mutagen. No fertility studies have been performed Label. In repeat dose toxicity studies of rats, pancreatic acinar apoptosis occurred at lutetium Lu 175 dotatate doses ≥ 5 mg/kg. Pancreatic acinar cell atrophy also occurred in repeat dose toxicology studies in dogs at doses ≥ 500 mg/kg Label.	Small Molecule																																			0	No	24	14	Yes	6	-2	505.95 Å2	144.31 Å3	397.34 m3·mol-1	26	No	No	0.193 mg/mL	-8.4	-4	0.47	10.28	P30874;!P30872;!P32745;!P31391;!P35346	SSTR2;!SSTR1;!SSTR3;!SSTR4;!SSTR5	1. Somatostatin receptor type 2;!2. Somatostatin receptor type 1;!3. Somatostatin receptor type 3;!4. Somatostatin receptor type 4;!5. Somatostatin receptor type 5
C34H47N3O9	Not Available	Not Available	641.762	CC(C)(C)OC(=O)N[C@@H](CC(=O)OCC1=CC=CC=C1)C(=O)N[C@@H](CCCCNC(=O)OCC1=CC=CC=C1)C(=O)OC(C)(C)C	Solid	Not Available					50326927		CHEMBL221390	8114922															ZINC000043552569		Reversin 121	Experimental	DB14072	InChI=1S/C34H47N3O9/c1-33(2,3)45-30(40)26(19-13-14-20-35-31(41)44-23-25-17-11-8-12-18-25)36-29(39)27(37-32(42)46-34(4,5)6)21-28(38)43-22-24-15-9-7-10-16-24/h7-12,15-18,26-27H,13-14,19-23H2,1-6H3,(H,35,41)(H,36,39)(H,37,42)/t26-,27-/m0/s1	SVNKEDMVAQBLLN-SVBPBHIXSA-N			Not Available	Small Molecule																																			0	No	5	3	No	2	0	158.36 Å2	69.92 Å3	169.65 m3·mol-1	21	No	No	0.000514 mg/mL	4.84	-6.1	12.16	-5	P08183	ABCB1	1. P-glycoprotein 1
C34H62N8O7	Not Available	Not Available	694.919	[H]N([H])C(=O)CC[C@H](N([H])C(=O)CN([H])C(=O)CCCCCCCCCCCCCCC)C(=O)N1CCC[C@H]1C(=O)N([H])[C@@H](CCCN=C(N([H])[H])N([H])[H])C(O)=O	Not Available	Not Available								8253946												1314277			ZINC000163851498		Palmitoyl tetrapeptide-7	Experimental	DB14137	InChI=1S/C34H62N8O7/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-19-29(44)39-24-30(45)40-25(20-21-28(35)43)32(47)42-23-16-18-27(42)31(46)41-26(33(48)49)17-15-22-38-34(36)37/h25-27H,2-24H2,1H3,(H2,35,43)(H,39,44)(H,40,45)(H,41,46)(H,48,49)(H4,36,37,38)/t25-,26-,27-/m0/s1	IHRKJQSLKLYWBQ-QKDODKLFSA-N			Not Available	Small Molecule																																			0	No	10	7	No	1	0	252.4 Å2	79.54 Å3	185.21 m3·mol-1	28	No	No	0.00556 mg/mL	0.045	-5.1	3.54	11.23			
C65H90N14O19S2	Not Available	Not Available	1435.63	C[C@@H](O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)CN2CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC2)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(O)=O	Not Available	Not Available					50165166		CHEMBL441920	9345959												1797118					Dotatate	Approved, Experimental	DB14554	InChI=1S/C65H90N14O19S2/c1-38(80)56-64(96)73-51(63(95)75-57(39(2)81)65(97)98)37-100-99-36-50(72-59(91)47(28-40-10-4-3-5-11-40)68-52(83)32-76-20-22-77(33-53(84)85)24-26-79(35-55(88)89)27-25-78(23-21-76)34-54(86)87)62(94)70-48(29-41-15-17-43(82)18-16-41)60(92)71-49(30-42-31-67-45-13-7-6-12-44(42)45)61(93)69-46(58(90)74-56)14-8-9-19-66/h3-7,10-13,15-18,31,38-39,46-51,56-57,67,80-82H,8-9,14,19-30,32-37,66H2,1-2H3,(H,68,83)(H,69,93)(H,70,94)(H,71,92)(H,72,91)(H,73,96)(H,74,90)(H,75,95)(H,84,85)(H,86,87)(H,88,89)(H,97,98)/t38-,39-,46+,47-,48+,49-,50+,51+,56+,57+/m1/s1	QVFLVLMYXXNJDT-CSBVGUNJSA-N	2		Not Available	Small Molecule																																			0	No	24	17	Yes	6	-2	497.46 Å2	144.3 Å3	364.83 m3·mol-1	26	No	No	0.149 mg/mL	-8.4	-4	0.47	10.28			
C46H65N13O12S2	Not Available	Not Available	1056.23	[H]N([H])C(=O)C[C@]1([H])NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@@H](N)CSSC[C@H](NC1=O)C(=O)N1CCC[C@H]1C(=O)NC([H])(CCCCN)C(=O)NCC(N)=O	Not Available	Not Available						94802	CHEMBL1200690	559125														Vasopressin			Lypressin	Approved	DB14642	InChI=1S/C46H65N13O12S2/c47-17-5-4-9-29(40(65)52-22-38(51)63)54-45(70)35-10-6-18-59(35)46(71)34-24-73-72-23-28(48)39(64)55-31(20-26-11-13-27(60)14-12-26)43(68)56-32(19-25-7-2-1-3-8-25)42(67)53-30(15-16-36(49)61)41(66)57-33(21-37(50)62)44(69)58-34/h1-3,7-8,11-14,28-35,60H,4-6,9-10,15-24,47-48H2,(H2,49,61)(H2,50,62)(H2,51,63)(H,52,65)(H,53,67)(H,54,70)(H,55,64)(H,56,68)(H,57,66)(H,58,69)/t28-,29-,30-,31-,32-,33-,34-,35-/m0/s1	BJFIDCADFRDPIO-DZCXQCEKSA-N			Not Available	Small Molecule																																			0	No	24	16	Yes	4	2	452.95 Å2	106.45 Å3	303.23 m3·mol-1	19	No	No	0.0497 mg/mL	2.28	-4.3	2.86		P37288;!P30518;!P47901	AVPR1A;!AVPR2;!AVPR1B	1. Vasopressin V1a receptor;!2. Vasopressin V2 receptor;!3. Vasopressin V1b receptor
C14H23CuN6O4	Not Available	Prezatide is rapidly eliminated within minutes 5.	402.921	[Cu++].NCCCC[C@H](NC(=O)[C@H](CC1=CN=CN1)NC(=O)CN)C([O-])=O	Not Available	Not Available								32698045																	Prezatide copper	Experimental	DB14683	InChI=1S/C14H24N6O4.Cu/c15-4-2-1-3-10(14(23)24)20-13(22)11(19-12(21)6-16)5-9-7-17-8-18-9;/h7-8,10-11H,1-6,15-16H2,(H,17,18)(H,19,21)(H,20,22)(H,23,24);/q;+2/p-1/t10-,11-;/m0./s1	NZWIFMYRRCMYMN-ACMTZBLWSA-M			Not Available	Small Molecule																																			1	No	7	5	No	1	2	179.05 Å2	34.21 Å3	96.31 m3·mol-1	11	Yes	No	2.08 mg/mL	-5.4	-2.3	3.46	10.2			
C46H75N13O15	Not Available	Not Available	1050.182	C[C@@H](O)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)CNC(C)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O	Not Available	Not Available								9796945																	BIO-11006	Investigational	DB14886	InChI=1S/C46H75N13O15/c1-24(51-36(64)22-50-28(5)62)39(66)54-31(17-18-35(49)63)41(68)57-33(21-29-13-7-6-8-14-29)43(70)58-34(23-60)44(71)55-30(15-9-11-19-47)42(69)59-37(27(4)61)45(72)53-25(2)38(65)52-26(3)40(67)56-32(46(73)74)16-10-12-20-48/h6-8,13-14,24-27,30-34,37,60-61H,9-12,15-23,47-48H2,1-5H3,(H2,49,63)(H,50,62)(H,51,64)(H,52,65)(H,53,72)(H,54,66)(H,55,71)(H,56,67)(H,57,68)(H,58,70)(H,59,69)(H,73,74)/t24-,25-,26-,27+,30-,31-,32-,33-,34-,37-/m0/s1	KCSNGWMKFYVMKF-HGYIIGRXSA-N	2		Not Available	Small Molecule																																			0	No	17	16	No	1	1	463.89 Å2	107.51 Å3	260.49 m3·mol-1	35	No	No	0.0404 mg/mL	-10	-4.4	3.66	10.47			
C22H39N9O11S	Not Available	Not Available	637.67	C[C@@H](O)[C@H](NC(=O)[C@H](CS(O)(=O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)CN)C(=O)N1CCC[C@H]1C(O)=O	Not Available	Not Available								68057558																	Risuteganib	Investigational	DB14911	InChI=1S/C22H39N9O11S/c1-11(32)17(20(37)31-7-3-5-14(31)21(38)39)30-19(36)13(10-43(40,41)42)29-16(34)9-27-18(35)12(28-15(33)8-23)4-2-6-26-22(24)25/h11-14,17,32H,2-10,23H2,1H3,(H,27,35)(H,28,33)(H,29,34)(H,30,36)(H,38,39)(H4,24,25,26)(H,40,41,42)/t11-,12+,13+,14+,17+/m1/s1	MYZAXBZLEILEBR-RVFOSREFSA-N	2		Not Available	Small Molecule																																			0	No	15	11	No	1	0	336.53 Å2	61.64 Å3	155.01 m3·mol-1	17	No	No	0.643 mg/mL	-12	-3	-1.4	12.7			
C28H40FN4O14P	Not Available	Not Available	706.6078	OC(=O)CC[C@H](NP(O)(=O)OCCC[C@H](NC(=O)CC[C@H](NC(=O)CCCCCNC(=O)C1=CC=C(F)C=C1)C(O)=O)C(O)=O)C(O)=O	Not Available	Not Available					50088185		CHEMBL3427435	35034402						T57									ZINC000098209433		CTT-1057	Investigational	DB14965	InChI=1S/C28H40FN4O14P/c29-18-9-7-17(8-10-18)25(38)30-15-3-1-2-6-22(34)32-20(27(41)42)11-13-23(35)31-19(26(39)40)5-4-16-47-48(45,46)33-21(28(43)44)12-14-24(36)37/h7-10,19-21H,1-6,11-16H2,(H,30,38)(H,31,35)(H,32,34)(H,36,37)(H,39,40)(H,41,42)(H,43,44)(H2,33,45,46)/t19-,20-,21-/m0/s1	IZLOSIXADNUSCM-ACRUOGEOSA-N	1		Not Available	Small Molecule																																			0	No	13	9	No	1	-5	295.06 Å2	67.71 Å3	160.1 m3·mol-1	25	No	No	0.0209 mg/mL	-0.59	-4.5	2.77				
C27H44N10O6	Not Available	Not Available	604.713	CC(C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C=O	Not Available	Not Available							CHEMBL1230912	34678														Antipain	ZINC000008716755		Antipain	Experimental	DB15251	InChI=1S/C27H44N10O6/c1-16(2)21(23(40)34-18(15-38)10-6-12-32-25(28)29)37-22(39)19(11-7-13-33-26(30)31)35-27(43)36-20(24(41)42)14-17-8-4-3-5-9-17/h3-5,8-9,15-16,18-21H,6-7,10-14H2,1-2H3,(H,34,40)(H,37,39)(H,41,42)(H4,28,29,32)(H4,30,31,33)(H2,35,36,43)/t18-,19-,20-,21-/m0/s1	SDNYTAYICBFYFH-TUFLPTIASA-N			Not Available	Small Molecule																																			0	No	12	11	No	1	1	277.5 Å2	63.74 Å3	178.23 m3·mol-1	19	No	No	0.0835 mg/mL	-3.4	-3.9	3.42	12.05			
C47H65N9O17S	Not Available	Not Available	1060.14	N[C@@H](CNC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CCCCCCCNC(=O)CC[C@H](NC(=O)N[C@@H](CCC(O)=O)C(O)=O)C(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(O)=O	Not Available	Not Available								75531293																	EC-0652	Investigational	DB15340	InChI=1S/C47H65N9O17S/c48-29(40(63)52-34(24-39(61)62)43(66)54-35(26-74)46(71)72)25-50-41(64)32(22-27-12-6-4-7-13-27)53-42(65)33(23-28-14-8-5-9-15-28)51-37(58)16-10-2-1-3-11-21-49-36(57)19-17-30(44(67)68)55-47(73)56-31(45(69)70)18-20-38(59)60/h4-9,12-15,29-35,74H,1-3,10-11,16-26,48H2,(H,49,57)(H,50,64)(H,51,58)(H,52,63)(H,53,65)(H,54,66)(H,59,60)(H,61,62)(H,67,68)(H,69,70)(H,71,72)(H2,55,56,73)/t29-,30-,31-,32-,33-,34-,35-/m0/s1	VHRCAJFLDBPRPG-POFDKVPJSA-N			Not Available	Small Molecule																																			0	No	18	15	No	2	-3	428.25 Å2	107.71 Å3	259.02 m3·mol-1	36	No	No	0.00429 mg/mL	-4.1	-5.4	2.58	7.12			
C72H116N20O19	Not Available	Not Available	1565.841	CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O	Not Available	Not Available								64854333																	SOR-C13	Investigational	DB15366	InChI=1S/C72H116N20O19/c1-39(2)31-48(84-63(102)49(33-42-17-8-7-9-18-42)85-60(99)46(24-25-56(94)95)81-59(98)44(75)19-10-12-26-73)62(101)88-52(34-43-36-78-38-80-43)70(109)92-30-16-23-55(92)67(106)89-53(37-93)65(104)82-45(20-11-13-27-74)61(100)90-58(41(5)6)68(107)86-50(35-57(96)97)64(103)87-51(32-40(3)4)69(108)91-29-15-22-54(91)66(105)83-47(71(110)111)21-14-28-79-72(76)77/h7-9,17-18,36,38-41,44-55,58,93H,10-16,19-35,37,73-75H2,1-6H3,(H,78,80)(H,81,98)(H,82,104)(H,83,105)(H,84,102)(H,85,99)(H,86,107)(H,87,103)(H,88,101)(H,89,106)(H,90,100)(H,94,95)(H,96,97)(H,110,111)(H4,76,77,79)/t44-,45-,46-,47-,48-,49-,50-,51-,52-,53-,54-,55-,58-/m0/s1	LGANPTNILMNMES-TVNHODDRSA-N	1		Not Available	Small Molecule																																			0	No	26	21	Yes	4	2	632.39 Å2	162.6 Å3	408.39 m3·mol-1	50	No	No	0.0347 mg/mL	-12	-4.6	3.14	12.05			
C65H89GaN14O18S2	Data regarding the clearance of this medication is not readily available.7	Edotreotide gallium Ga-68 has a radioactive half life of 68 minutes.4,8 Edotreotide gallium Ga-68 has two half lives, 2.0±0.3min and 48±7min for its removal from blood.4,8	1486.55	[68Ga+3].C[C@@H](O)[C@@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)CN2CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC2)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1	Solid	Data regarding the volume of distribution of this medication is not readily available.7								52083916												2199391					Edotreotide gallium Ga-68	Approved	DB15494	InChI=1S/C65H92N14O18S2.Ga/c1-39(81)51(36-80)72-64(96)53-38-99-98-37-52(73-60(92)48(28-41-10-4-3-5-11-41)68-54(84)32-76-20-22-77(33-55(85)86)24-26-79(35-57(89)90)27-25-78(23-21-76)34-56(87)88)63(95)70-49(29-42-15-17-44(83)18-16-42)61(93)71-50(30-43-31-67-46-13-7-6-12-45(43)46)62(94)69-47(14-8-9-19-66)59(91)75-58(40(2)82)65(97)74-53;/h3-7,10-13,15-18,31,39-40,47-53,58,67,80-83H,8-9,14,19-30,32-38,66H2,1-2H3,(H,68,84)(H,69,94)(H,70,95)(H,71,93)(H,72,96)(H,73,92)(H,74,97)(H,75,91)(H,85,86)(H,87,88)(H,89,90);/q;+3/p-3/t39-,40-,47+,48-,49+,50-,51-,52+,53+,58+;/m1./s1/i;1-2	PZBPHYLKIMOZPR-FIYGWYQWSA-K	2	Edotreotide gallium Ga-68 is a radioactive diagnostic agent used in PET scans for somatostatin receptor positive neuroendocrine tumors in adult and pediatric patients.	The LD50 of this medication is not readily available.7In the event of an overdose, give patients plenty of fluids and diuretics if necessary to encourage frequent urination.7 If possible, an estimation of radioactive dose should be performed.7	Small Molecule																																			0	No	23	14	Yes	6	-1	488.88 Å2	143.64 Å3	397.48 m3·mol-1	26	No	No	0.0646 mg/mL	-9.6	-4.4	-0.48	10.28	P30874;!P35346;!P32745;!P30872	SSTR2;!SSTR5;!SSTR3;!SSTR1	1. Somatostatin receptor type 2;!2. Somatostatin receptor type 5;!3. Somatostatin receptor type 3;!4. Somatostatin receptor type 1
C75H106N20O19S	Not Available	Not Available	1623.85	CSCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O	Not Available	Not Available								17287850																	Tridecactide	Investigational	DB15687	InChI=1S/C75H106N20O19S/c1-41(2)62(74(113)114)94-72(111)59-19-12-29-95(59)73(112)53(17-9-10-27-76)85-60(99)37-83-64(103)56(33-44-35-82-49-16-8-7-15-47(44)49)91-65(104)50(18-11-28-81-75(78)79)86-68(107)55(31-42-13-5-4-6-14-42)90-70(109)57(34-45-36-80-40-84-45)92-66(105)51(24-25-61(100)101)87-67(106)52(26-30-115-3)88-71(110)58(39-97)93-69(108)54(89-63(102)48(77)38-96)32-43-20-22-46(98)23-21-43/h4-8,13-16,20-23,35-36,40-41,48,50-59,62,82,96-98H,9-12,17-19,24-34,37-39,76-77H2,1-3H3,(H,80,84)(H,83,103)(H,85,99)(H,86,107)(H,87,106)(H,88,110)(H,89,102)(H,90,109)(H,91,104)(H,92,105)(H,93,108)(H,94,111)(H,100,101)(H,113,114)(H4,78,79,81)/t48-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,62-/m0/s1	VGBVAARMQYYITG-DESRROFGSA-N	3	Tridecactide is an investigational modified alpha melanocyte stimulating hormone being studied for the treatment of COVID-19.	Not Available	Small Molecule																																			0	No	25	23	Yes	6	1	634.11 Å2	166.12 Å3	426.45 m3·mol-1	49	No	No	0.0266 mg/mL	-9.3	-4.8	3.17	11.91			
C21H31N3O8S	Not Available	Not Available	485.55	CC(C)C[C@H](NC(=O)OCC1=CC=CC=C1)C(=O)N[C@@H](CC1CCNC1=O)C(O)S(O)(=O)=O	Not Available	Not Available							CHEMBL2365410	29399539																	GC-376 free acidCommonly known or available as GC-376	Experimental	DB15796	InChI=1S/C21H31N3O8S/c1-13(2)10-16(24-21(28)32-12-14-6-4-3-5-7-14)19(26)23-17(20(27)33(29,30)31)11-15-8-9-22-18(15)25/h3-7,13,15-17,20,27H,8-12H2,1-2H3,(H,22,25)(H,23,26)(H,24,28)(H,29,30,31)/t15?,16-,17-,20?/m0/s1	BSPZFJDYQHDZNR-ASPXRTSYSA-N			Not Available	Small Molecule																																			1	No	7	5	No	2	-1	171.13 Å2	48.62 Å3	117.4 m3·mol-1	12	Yes	No	1.79 mg/mL	-0.55	-2.4	-0.88	-1.5	P0DTD1;!P0DTC1;!Q98VG9;!K9N638;!K9N7C7	rep;!Not Available;!rep;!Not Available;!rep	1. Replicase polyprotein 1ab;!2. Replicase polyprotein 1a;!3. Replicase polyprotein 1ab;!4. Replicase polyprotein 1a;!5. Replicase polyprotein 1ab
C21H29N3O5	Not Available	Not Available	403.479	CC(C)C[C@H](NC(=O)OCC1=CC=CC=C1)C(=O)N[C@@H](CC1CCNC1=O)C=O	Not Available	Not Available							CHEMBL1821850	26617691																	GC-373	Experimental	DB15797	InChI=1S/C21H29N3O5/c1-14(2)10-18(24-21(28)29-13-15-6-4-3-5-7-15)20(27)23-17(12-25)11-16-8-9-22-19(16)26/h3-7,12,14,16-18H,8-11,13H2,1-2H3,(H,22,26)(H,23,27)(H,24,28)/t16?,17-,18-/m0/s1	QYENXTYKACLCGO-FQECFTEESA-N			Not Available	Small Molecule																																			1	Yes	4	3	No	2	0	113.6 Å2	42.97 Å3	106.58 m3·mol-1	11	Yes	No	0.0386 mg/mL	1.28	-4	12.68	-1.6	K9N7C7;!K9N638;!P0DTD1;!P0DTC1;!Q98VG9	rep;!Not Available;!rep;!Not Available;!rep	1. Replicase polyprotein 1ab;!2. Replicase polyprotein 1a;!3. Replicase polyprotein 1ab;!4. Replicase polyprotein 1a;!5. Replicase polyprotein 1ab
C65H88CuN14O19S2	Not Available	The half-life of Copper Cu 64 is 12.7 hours.2	1497.55	[64Cu++].C[C@@H](O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)CN2CCN(CC(O)=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC2)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(O)=O	Not Available	Not Available								64854536												2396442					Copper oxodotreotide Cu-64	Approved	DB15873	InChI=1S/C65H90N14O19S2.Cu/c1-38(80)56-64(96)73-51(63(95)75-57(39(2)81)65(97)98)37-100-99-36-50(72-59(91)47(28-40-10-4-3-5-11-40)68-52(83)32-76-20-22-77(33-53(84)85)24-26-79(35-55(88)89)27-25-78(23-21-76)34-54(86)87)62(94)70-48(29-41-15-17-43(82)18-16-41)60(92)71-49(30-42-31-67-45-13-7-6-12-44(42)45)61(93)69-46(58(90)74-56)14-8-9-19-66;/h3-7,10-13,15-18,31,38-39,46-51,56-57,67,80-82H,8-9,14,19-30,32-37,66H2,1-2H3,(H,68,83)(H,69,93)(H,70,94)(H,71,92)(H,72,91)(H,73,96)(H,74,90)(H,75,95)(H,84,85)(H,86,87)(H,88,89)(H,97,98);/q;+2/p-2/t38-,39-,46+,47-,48+,49-,50+,51+,56+,57+;/m1./s1/i;1+0	IJRLLVFQGCCPPI-NVGRTJHCSA-L	3	Copper oxodotreotide Cu-64 is a Cu labeled somatostatin analog used in positron emission tomography to detect certain types of neuroendocrine tumors.	If radiation overdose occurs, patients should be advised to drink plenty of water and to void frequently to increase the rate of elimination of the radionuclide.2 In certain cases, it may be appropriate to administer a diuretic.2	Small Molecule																												1							0	No	24	15	Yes	6	-2	503.12 Å2	143.59 Å3	386.51 m3·mol-1	26	No	No	0.103 mg/mL	-8.4	-4.2	0.47	10.28	P30874	SSTR2	1. Somatostatin receptor type 2
C44H59GaN6O17	There is limited information on the clearance rate, but Ga-68 PSMA-11 shows fast blood clearance.6	Gallium-68 (Ga-68) decays with a half-life of 68 minutes.7	1011.909	[68Ga+3].OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)CCCCCNC(=O)CCC1=CC(CN(CCN(CC([O-])=O)CC2=C(O)C=CC(CCC([O-])=O)=C2)CC([O-])=O)=C(O)C=C1)C(O)=O)C(O)=O	Not Available	Ga-68 PSMA-11 accumulates in the liver (15%), kidneys (7%), spleen (2%), and salivary glands (0.5%).7 Ga-68 PSMA-11 accumulation increases at later acquisition times.4								52083842												2586016					Gallium Ga-68 gozetotideCommonly known or available as Ga 68 PSMA-11	Approved	DB16019	InChI=1S/C44H62N6O17.Ga/c51-34-13-8-28(22-30(34)24-49(26-40(59)60)20-21-50(27-41(61)62)25-31-23-29(9-14-35(31)52)11-16-38(55)56)10-15-37(54)46-18-4-1-2-7-36(53)45-19-5-3-6-32(42(63)64)47-44(67)48-33(43(65)66)12-17-39(57)58;/h8-9,13-14,22-23,32-33,51-52H,1-7,10-12,15-21,24-27H2,(H,45,53)(H,46,54)(H,55,56)(H,57,58)(H,59,60)(H,61,62)(H,63,64)(H,65,66)(H2,47,48,67);/q;+3/p-3/t32-,33-;/m0./s1/i;1-2	AEBYHKKMCWUMKX-LNTZDJBBSA-K	2	Ga 68 PSMA-11 is a radiopharmaceutical agent used in the diagnosis of prostate-specific membrane antigen (PSMA) positive lesions in male patients during positron emission tomography.	There is limited information on the LD50 value of Ga-68 PSMA-11. In the event of an overdose, it is recommended to enhance drug elimination by hydration, frequent bladder voiding, or the use of diuretics.7	Small Molecule																																			0	No	19	9	No	2	-5	378.56 Å2	95.33 Å3	268.15 m3·mol-1	35	No	No	0.0121 mg/mL	-3.2	-5	0.85	9.5	P07288	KLK3	1. Prostate-specific antigen
C30H42N4O8	Not Available	Not Available	586.686	COC1=CC=C(C=C1)[C@@H](O)[C@H](NC(=O)[C@H](C)NC(=O)CN1CCOCC1)C(=O)N[C@@H](CC1=CCCC1)C(=O)[C@@]1(C)CO1	Not Available	Not Available							CHEMBL4297468	78434307																	KZR-616	Investigational	DB16070	InChI=1S/C30H42N4O8/c1-19(31-24(35)17-34-12-14-41-15-13-34)28(38)33-25(26(36)21-8-10-22(40-3)11-9-21)29(39)32-23(16-20-6-4-5-7-20)27(37)30(2)18-42-30/h6,8-11,19,23,25-26,36H,4-5,7,12-18H2,1-3H3,(H,31,35)(H,32,39)(H,33,38)/t19-,23-,25-,26+,30+/m0/s1	GHYOCDFICYLMRF-UTIIJYGPSA-N			Not Available	Small Molecule																																			0	No	9	4	Yes	4	0	158.83 Å2	60.56 Å3	153.75 m3·mol-1	14	No	No	0.449 mg/mL	0.32	-3.1	11.62	5.04			
C47H76N16O13	Not Available	Not Available	1073.224	CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](N)CCCNC(N)=N)C(C)C)C(O)=O	Not Available	Not Available								30790862																	VEGFR2-169	Investigational	DB16152	InChI=1S/C47H76N16O13/c1-5-25(4)37(45(75)76)62-40(70)28(15-10-18-55-47(52)53)58-41(71)30(21-33(49)64)57-34(65)23-56-39(69)31(22-35(66)67)60-43(73)32-16-11-19-63(32)44(74)36(24(2)3)61-42(72)29(20-26-12-7-6-8-13-26)59-38(68)27(48)14-9-17-54-46(50)51/h6-8,12-13,24-25,27-32,36-37H,5,9-11,14-23,48H2,1-4H3,(H2,49,64)(H,56,69)(H,57,65)(H,58,71)(H,59,68)(H,60,73)(H,61,72)(H,62,70)(H,66,67)(H,75,76)(H4,50,51,54)(H4,52,53,55)/t25-,27-,28-,29-,30-,31-,32-,36-,37-/m0/s1	ZAJHBCDPAUKEPU-GIKXZWSFSA-N	2		Not Available	Small Molecule																																			0	No	20	17	No	2	1	491.52 Å2	108.81 Å3	290.03 m3·mol-1	33	No	No	0.0277 mg/mL	-8.5	-4.6	3.25	12.47			
C16H27N3O6	Not Available	Not Available	357.407	N[C@H](CC1CCCCC1)C(=O)N[C@H](CCC(O)=O)C(=O)NCC(O)=O	Not Available	Not Available								8301633															ZINC000034269848		AIM-102	Investigational	DB16176	InChI=1S/C16H27N3O6/c17-11(8-10-4-2-1-3-5-10)15(24)19-12(6-7-13(20)21)16(25)18-9-14(22)23/h10-12H,1-9,17H2,(H,18,25)(H,19,24)(H,20,21)(H,22,23)/t11-,12-/m1/s1	CNDMSQXUUIBFPE-VXGBXAGGSA-N	2		Not Available	Small Molecule																																			1	No	7	5	No	1	-1	158.82 Å2	36.94 Å3	87.06 m3·mol-1	10	Yes	No	0.812 mg/mL	-3.1	-2.6	3.16	8.13			
C35H56N10O15	Not Available	Not Available	856.888	C[C@@H](O)[C@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](C)N)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(N)=O	Not Available	Not Available							CHEMBL181276	160536															ZINC000169289402		DAPTA	Investigational	DB16290	InChI=1S/C35H56N10O15/c1-13(36)29(54)41-22(12-46)32(57)43-26(16(4)49)34(59)45-27(17(5)50)35(60)44-25(15(3)48)33(58)40-21(11-23(37)52)30(55)39-20(10-18-6-8-19(51)9-7-18)31(56)42-24(14(2)47)28(38)53/h6-9,13-17,20-22,24-27,46-51H,10-12,36H2,1-5H3,(H2,37,52)(H2,38,53)(H,39,55)(H,40,58)(H,41,54)(H,42,56)(H,43,57)(H,44,60)(H,45,59)/t13-,14-,15-,16-,17-,20+,21+,22+,24+,25+,26+,27+/m1/s1	AKWRNBWMGFUAMF-ZESMOPTKSA-N			Not Available	Small Molecule																																			0	No	16	16	No	1	1	437.28 Å2	83.66 Å3	203.25 m3·mol-1	24	No	No	0.419 mg/mL	-9	-3.3	9.51	8.07			
C44H62N6O17	Not Available	Not Available	947.005	OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)CCCCCNC(=O)CCC1=CC=C(O)C(CN(CCN(CC(O)=O)CC2=CC(CCC(O)=O)=CC=C2O)CC(O)=O)=C1)C(O)=O)C(O)=O	Not Available	Not Available							CHEMBL3578202	58827810															ZINC000203341463		Gallium-68 PSMA	Approved, Investigational	DB16303	InChI=1S/C44H62N6O17/c51-34-13-8-28(22-30(34)24-49(26-40(59)60)20-21-50(27-41(61)62)25-31-23-29(9-14-35(31)52)11-16-38(55)56)10-15-37(54)46-18-4-1-2-7-36(53)45-19-5-3-6-32(42(63)64)47-44(67)48-33(43(65)66)12-17-39(57)58/h8-9,13-14,22-23,32-33,51-52H,1-7,10-12,15-21,24-27H2,(H,45,53)(H,46,54)(H,55,56)(H,57,58)(H,59,60)(H,61,62)(H,63,64)(H,65,66)(H2,47,48,67)/t32-,33-/m0/s1	QJUIUFGOTBRHKP-LQJZCPKCSA-N	2		Not Available	Small Molecule																																			0	No	19	12	No	2	-5	370.07 Å2	98.3 Å3	235.64 m3·mol-1	35	No	No	0.059 mg/mL	-3.2	-4.2	0.85	9.5			
C24H33N4O9P	Not Available	Not Available	552.521	[H][C@@]1(C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)C2=CC3=C(N2)C=CC=C3OC)C(=O)COP(O)(O)=O)CCNC1=O	Not Available	Not Available																									PF-07304814	Investigational	DB16514	InChI=1S/C24H33N4O9P/c1-13(2)9-18(28-24(32)19-11-15-16(26-19)5-4-6-21(15)36-3)23(31)27-17(10-14-7-8-25-22(14)30)20(29)12-37-38(33,34)35/h4-6,11,13-14,17-18,26H,7-10,12H2,1-3H3,(H,25,30)(H,27,31)(H,28,32)(H2,33,34,35)/t14-,17-,18-/m0/s1	FQKALOFOWPDTED-WBAXXEDZSA-N	1		Not Available	Small Molecule																																			0	No	8	6	Yes	3	-2	196.15 Å2	54.41 Å3	135.49 m3·mol-1	13	No	No		0.19		1.21	-1.6	P0DTD1	rep	1. Replicase polyprotein 1ab
C46H72N10O15S	Not Available	Not Available	1037.2	CSCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@@H](C)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(O)=O	Not Available	Not Available							CHEMBL3989950	58828035																	Reltecimod	Investigational	DB16687	InChI=1S/C46H72N10O15S/c1-22(2)18-30(52-39(63)29(15-17-72-8)50-43(67)34-10-9-16-56(34)45(69)33(21-57)54-37(61)24(5)47)42(66)55-36(23(3)4)44(68)48-25(6)38(62)51-31(19-27-11-13-28(58)14-12-27)41(65)53-32(20-35(59)60)40(64)49-26(7)46(70)71/h11-14,22-26,29-34,36,57-58H,9-10,15-21,47H2,1-8H3,(H,48,68)(H,49,64)(H,50,67)(H,51,62)(H,52,63)(H,53,65)(H,54,61)(H,55,66)(H,59,60)(H,70,71)/t24-,25+,26-,29+,30+,31+,32+,33+,34+,36+/m1/s1	VRNHFZYMPDKTBS-WYUJEMNCSA-N	3		Not Available	Small Molecule																																			0	No	16	13	No	2	-1	394.19 Å2	104.23 Å3	257.8 m3·mol-1	29	No	No	0.0329 mg/mL	-5.2	-4.5	3.08	8.07			
C31H39N9O6S	Not Available	Not Available	665.77	CC(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)C1=NC2=CC=CC=C2S1	Not Available	Not Available																									MM3122	Experimental	DB16737	InChI=1S/C31H39N9O6S/c1-18(41)36-17-26(43)37-22(13-14-25(32)42)28(45)39-23(16-19-8-3-2-4-9-19)29(46)38-21(11-7-15-35-31(33)34)27(44)30-40-20-10-5-6-12-24(20)47-30/h2-6,8-10,12,21-23H,7,11,13-17H2,1H3,(H2,32,42)(H,36,41)(H,37,43)(H,38,46)(H,39,45)(H4,33,34,35)/t21-,22-,23-/m0/s1	ZEPMYXYJCBQSLH-VABKMULXSA-N			Not Available	Small Molecule																																			0	No	10	7	Yes	3	1	253.85 Å2	69.65 Å3	172.07 m3·mol-1	18	No	No	0.0092 mg/mL	-1.5	-4.9	11.69	10.99	O15393	TMPRSS2	1. Transmembrane protease serine 2
C10H17N3O6S	Not Available	Not Available	307.323	N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O	Solid	Not Available	P09210;!P08263	GSTA2;!GSTA1	1. Glutathione S-transferase A2;!2. Glutathione S-transferase A1		50422268	16856	CHEMBL1543	111188			HMDB0000125	C02471	D00014	GSH	PDRhealth Drug Page	PA449780	124886	46504598		4890		Glutathione	ZINC000003830891		Glutathione	Approved, Investigational, Nutraceutical	DB00143	InChI=1S/C10H17N3O6S/c11-5(10(18)19)1-2-7(14)13-6(4-20)9(17)12-3-8(15)16/h5-6,20H,1-4,11H2,(H,12,17)(H,13,14)(H,15,16)(H,18,19)/t5-,6-/m0/s1	RWSXRVCMGQZWBV-WDSKDSINSA-N	3		ORL-MUS LD50 5000 mg/kg, IPR-MUS LD50 4020 mg/kg, SCU-MUS LD50 5000 mg/kg, IVN-RBT LD50 > 2000 mg/kg, IMS-MUS LD50 4000 mg/kg	Small Molecule	http://smpdb.ca/view/SMP0000077?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000087?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000093?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000094?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000114?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000116?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000136?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000183?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000243?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000500?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000567?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000692?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000697?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000702?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000015?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000075?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000083?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000098?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000102?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000106?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000109?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000113?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000120?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000143?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000337?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000385?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000447?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000559?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000604?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000640?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143	Piroxicam Action Pathway;!Rofecoxib Action Pathway;!Diclofenac Action Pathway;!Sulindac Action Pathway;!Nabumetone Action Pathway;!Valdecoxib Action Pathway;!2-Hydroxyglutric Aciduria (D and L Form);!gamma-Glutamyltransferase Deficiency;!4-Hydroxybutyric Aciduria/Succinic Semialdehyde Dehydrogenase Deficiency;!5-Oxoprolinase Deficiency;!Succinic Semialdehyde Dehydrogenase Deficiency;!Antipyrine Action Pathway;!Flurbiprofen Action Pathway;!Nepafenac Action Pathway;!Glutathione Metabolism;!Arachidonic Acid Metabolism;!Acetylsalicylic Acid Action Pathway;!Ketorolac Action Pathway;!Bromfenac Action Pathway;!Meloxicam Action Pathway;!Mefenamic Acid Action Pathway;!Oxaprozin Action Pathway;!Naproxen Action Pathway;!5-Oxoprolinuria;!Glutathione Synthetase Deficiency;!Homocarnosinosis;!Cyclophosphamide Action Pathway;!Pyruvate Kinase Deficiency;!Cyclophosphamide Metabolism Pathway;!Acetaminophen Metabolism Pathway		AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.7842 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					-6.4		195 °C			1	No	7	6	No	0	-1	158.82 Å2	29.3 Å3	69.11 m3·mol-1	9	No	No		-4.9		1.94	9.22			
C23H32N2O5	The renal clearance of ramipril and ramiprilat was reported to be 7.2 and 77.4 mL/min/1.73m2. 4 The mean renal clearance of ramipril and ramiprilat is reported to be 10.7 and 126.8 mL/min in healthy elderly patients with normal renal function, additionally the Cmax of ramiprilat is approximately 20% higher in this population. While the pharmacokinetics of ramipril appear unaffected by reduced renal function, the plasma concentration and half-life of ramiprilat are increased. In patient's with hepatic failure the concentration of ramipril is initially increased while the tmax of ramiprilat is prolonged due to a reduced ability to metabolize the drug. However, steady state concentrations of ramiprilat are the same in hepatic failure as in healthy patients.	Plasma concentrations of ramiprilat decline in a triphasic manner.Label Initial rapid decline represents distribution into tissues and has a half life of 2-4 hours. The half life of the apparent elimination phase is 9-18 hours, which is thought to represent clearance of free drug. The half-life of the terminal elimination phase is > 50 hours and thought to represent clearance of drug bound to ACE due to its slow dissociation. The half life of ramiprilat after multiple daily doses (MDDs) is dose-dependent, ranging from 13-17 hours with 5-10 mg MDDs to 27-36 hours for 2.5 mg MDDs.	416.5106	[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC	Solid	Not Available	P06276	BCHE	1. Cholinesterase		50084681	8774	CHEMBL1168	4514937	Drugs.com Drug Page		HMDB0014324		D00421		PDRhealth Drug Page	PA451223	5362129	46506390	RxList Drug Page	35296	DAP000581	Ramipril	ZINC000003798757	Altace, Altace HCT	Ramipril	Approved	DB00178	InChI=1S/C23H32N2O5/c1-3-30-23(29)18(13-12-16-8-5-4-6-9-16)24-15(2)21(26)25-19-11-7-10-17(19)14-20(25)22(27)28/h4-6,8-9,15,17-20,24H,3,7,10-14H2,1-2H3,(H,27,28)/t15-,17-,18-,19-,20-/m0/s1	HDACQVRGBOVJII-JBDAPHQKSA-N	4	Ramipril is an ACE inhibitor used for the management of hypertension and the reduction of cardiovascular mortality following myocardial infarction in hemodynamically stable patients with clinical signs of congestive heart failure.	Symptoms of overdose may include excessive peripheral vasodilation (with marked hypotension and shock), bradycardia, electrolyte disturbances, and renal failure. Cases of ACE inhibitor induced hepatotoxicity have been reported in humans and presented as acute jaundice and elevated liver enzymes.3 Removal of the ACE inhbitor resulted in a decline in liver enzymes and re-challenge produced a subsequent increase. There were no observed tumerogenic effects at chronic doses up to 500mg/kg/day to rats for 24 months or at doses up to 1000mg/kg/day to mice for 18 months. For both species doses were administered by gavage and equivalent to 200 time the maximum recommended human exposure based on body surface area.No mutagenic activity was detected in the Ames test in bacteria, the micronucleus test in mice, unscheduled DNA synthesis in a human cell line, or a forward gene-mutation assay in a Chinese hamster ovary cell line. Several metabolites of ramipril also produced negative results in the Ames test.No effects on fertility were seen in rats at doses up to 500mg/kg/day. No teratogenicity was observed in rats and cynomolgus monkeys at doses 400 times the maximum recommended human exposure nor in rabbites at 2 times the maximum recommended human exposure.LD50 10 g/kg (rat).MSDSLD50 10.5 g/kg (mouse).MSDSLD50 1 g/kg (dog).MSDS	Small Molecule	http://smpdb.ca/view/SMP0000154?highlight[compounds][]=DB00178&highlight[proteins][]=DB00178;!http://smpdb.ca/view/SMP0000597?highlight[compounds][]=DB00178&highlight[proteins][]=DB00178	Ramipril Action Pathway;!Ramipril Metabolism Pathway		Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	1.6732 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.9		109 °C		3.5mg/L	1	Yes	5	2	Yes	3	-1	95.94 Å2	44.79 Å3	111.19 m3·mol-1	10	Yes	No	0.039 mg/mL	1.47	-4	3.75	5.2			
C23H27N5O7S	32 - 41 mL/min/1.73 m2124 - 160 mL/min/1.73 m2 [older pediatric patients]	36-72 minutes	517.555	[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=CC=C1)C(O)=O	Solid	101 mL/kg [intravenous administration of 50 mg/kg (5-minute infusion) in neonates]					50240426	8232	CHEMBL702	39798	Drugs.com Drug Page		HMDB0014464	C14034	D00466	WPP		PA450975	43672	46504757	RxList Drug Page	1546000	DAP001164	Piperacillin	ZINC000003913937	Pipracil, Zosyn	Piperacillin	Approved	DB00319	InChI=1S/C23H27N5O7S/c1-4-26-10-11-27(19(32)18(26)31)22(35)25-13(12-8-6-5-7-9-12)16(29)24-14-17(30)28-15(21(33)34)23(2,3)36-20(14)28/h5-9,13-15,20H,4,10-11H2,1-3H3,(H,24,29)(H,25,35)(H,33,34)/t13-,14-,15+,20-/m1/s1	IVBHGBMCVLDMKU-GXNBUGAJSA-N	4	Piperacillin is a penicillin antibiotic combined with tazobactam to treat piperacillin-resistant, piperacillin/tazobactam­ susceptible, β-lactamase generating strains of several bacteria.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.3925 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor					0.3					1	No	7	3	Yes	4	-1	156.43 Å2	51.77 Å3	126.3 m3·mol-1	6	No	No	0.119 mg/mL	-0.26	-3.6	3.49	-4.3	Q75Y35;!P0A3M6;!Q8DNB6;!Q7CRA4	pbp3;!penA;!pbp2a;!pbp1b	1. Penicillin-binding protein 3;!2. Penicillin-binding protein 2B;!3. Penicillin-binding protein 2a;!4. Penicillin-binding protein 1b
C30H46NO7P	26 - 39 mL/min [healthy]	12 hours	563.672	CCC(=O)O[C@@H](OP(=O)(CCCCC1=CC=CC=C1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C	Solid	Not Available						5163	CHEMBL3039598	23089342	Drugs.com Drug Page		HMDB0014635	C07016	D07992		PDRhealth Drug Page	PA449710	55891	46506495	RxList Drug Page	50166	DAP000582	Fosinopril	ZINC000003920355		Fosinopril	Approved	DB00492	InChI=1S/C30H46NO7P/c1-4-28(33)37-30(22(2)3)38-39(36,18-12-11-15-23-13-7-5-8-14-23)21-27(32)31-20-25(19-26(31)29(34)35)24-16-9-6-10-17-24/h5,7-8,13-14,22,24-26,30H,4,6,9-12,15-21H2,1-3H3,(H,34,35)/t25-,26+,30+,39+/m1/s1	BIDNLKIUORFRQP-FLODCBCLSA-N	4	Fosinopril is an ACE inhibitor used to treat mild to moderate hypertension, congestive heart failure, and to slow the progression of renal disease in hypertensive diabetics.	Human overdoses of fosinopril have not been reported, but the most common manifestation of human fosinopril overdosage is likely to be hypotension. Oral doses of fosinopril at 2600 mg/kg in rats were associated with significant lethality. The most common adverse effects include dizzines, cough, fatigue, and headache.	Small Molecule	http://smpdb.ca/view/SMP0000149?highlight[compounds][]=DB00492&highlight[proteins][]=DB00492;!http://smpdb.ca/view/SMP0000594?highlight[compounds][]=DB00492&highlight[proteins][]=DB00492	Fosinopril Action Pathway;!Fosinopril Metabolism Pathway		Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.8211 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					6.3		149-153 °C		Insoluble	0	No	5	1	Yes	3	-1	110.21 Å2	62.27 Å3	149.12 m3·mol-1	15	No	No	0.00101 mg/mL	5.62	-5.8	3.87	-4.4	P12821	ACE	1. Angiotensin-converting enzyme
C24H34N2O5	52 L/h [After approximately 2 mg IV doses]	The elimination half lives of trandolapril and trandolaprilat are about 6 and 10 hours, respectively, but, similar to all ACE inhibitors, trandolaprilat also has a prolonged terminal elimination phase that involves a small fraction of administered drug. This likely represents drug binding to plasma and tissue ACE. The effective half life of elimination for trandolaprilat is 16-24 hours.	430.5372	[H][C@@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC3=CC=CC=C3)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O	Solid	18 L	P23141	CES1	1. Liver carboxylesterase 1		50369775	9649	CHEMBL1519	4588590	Drugs.com Drug Page		HMDB0014660		D00383		PDRhealth Drug Page	PA451737	5484727	46508300	RxList Drug Page	38454	DAP000583	Trandolapril	ZINC000001853205	Mavik, Tarka	Trandolapril	Approved	DB00519	InChI=1S/C24H34N2O5/c1-3-31-24(30)19(14-13-17-9-5-4-6-10-17)25-16(2)22(27)26-20-12-8-7-11-18(20)15-21(26)23(28)29/h4-6,9-10,16,18-21,25H,3,7-8,11-15H2,1-2H3,(H,28,29)/t16-,18+,19-,20-,21-/m0/s1	VXFJYXUZANRPDJ-WTNASJBWSA-N	4	Trandolapril is a prodrug of an ACE inhibitor used to treat hypertension, congestive heart failure, and to improve survival following a myocardial infarction.	Most likely clinical manifestations of overdose are symptoms of severe hypotension. Most common adverse effects include cough, headache and dizziness. The oral LD50 of trandolapril in mice was 4875 mg/kg in males and 3990 mg/kg in females. In rats, an oral dose of 5000 mg/kg caused low mortality (1 male out of 5; 0 females). In dogs, an oral dose of 1000 mg/kg did not cause mortality and abnormal clinical signs were not observed.	Small Molecule	http://smpdb.ca/view/SMP0000157?highlight[compounds][]=DB00519&highlight[proteins][]=DB00519;!http://smpdb.ca/view/SMP0000599?highlight[compounds][]=DB00519&highlight[proteins][]=DB00519	Trandolapril Action Pathway;!Trandolapril Metabolism Pathway		Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.2048 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					3.5		119-123 °C			1	Yes	5	2	Yes	3	-1	95.94 Å2	46.96 Å3	115.79 m3·mol-1	10	Yes	No	0.0207 mg/mL	1.95	-4.3	3.8	5.21			
C20H28N2O5	Following oral administration in healthy male volunteers, the renal clearance was approximately 158 ± 47 mL/min.8 It is reported that enalapril and enalaprilat are undetectable in the plasma by 4 hours post-dosing.3	The average terminal half life of enalaprilat is 35-38 hours. The effective half life following multiple doses is 11-14 hours. The prolonged terminal half-life is due to the binding of enalaprilat to ACE.5	376.4467	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O	Solid	The volume of distribution of enalapril has not been established. Enalaprilat is shown to penetrate into most tissuesm, in particular the kidneys and vascular tissuem, although penetration of the blood-brain barrier has not been demonstrated after administration at therapeutic doses.7 In dog studies, enalapril and enalaprilat cross the blood-brain barrier poorly.10 Minimal penetration occurs into breast milk but significant fetal transfer occurs.7 The drug crosses the placental barrier in rats and hamsters.10					50017129	4784	CHEMBL578	4534998	Drugs.com Drug Page		HMDB0014722	C06977	D07892		PDRhealth Drug Page	PA449456	5388962	46507920	RxList Drug Page	3827	DAP001374	Enalapril	ZINC000003791297	Epaned, Vaseretic, Vasotec	Enalapril	Approved, Vet approved	DB00584	InChI=1S/C20H28N2O5/c1-3-27-20(26)16(12-11-15-8-5-4-6-9-15)21-14(2)18(23)22-13-7-10-17(22)19(24)25/h4-6,8-9,14,16-17,21H,3,7,10-13H2,1-2H3,(H,24,25)/t14-,16-,17-/m0/s1	GBXSMTUPTTWBMN-XIRDDKMYSA-N	4	Enalapril is a prodrug of an ACE inhibitor used to treat hypertension and congestive heart failure.	LD50 and OverdoseOral LD50 in rats is 2973 mg/kg.MSDS Lethality was observed with single oral doses of enalapril above 1000 mg/kg in mice and greater than or equal to 1775 mg/kg in rats. Serum enalaprilat levels 100- and 200-fold higher than usually seen after therapeutic doses have been reported after ingestion of 300 mg and 440 mg of enalapril, respectively.10 While there is limited data about enalapril overdose in humans, overdosage may result in marked hypotension and stupor based on the pharmacological properties of the drug. Most common adverse effects of enalapril include cough, hypotension, stupor, headache, dizziness and fatigue. If hypotension is seen, usual treatment of intravenous infusion of normal saline solution is recommended. Enalaprilat may be removed from systemic circulation with the use of hemodialysis. It has been removed from neonatal circulation by peritoneal dialysis.LabelNonclinical toxicologyMaternal and fetal toxicity occudred in some rabbits treated with enalapril at doses of 1 mg/kg/day or more. There was no fetotoxicity, expressed as a decrease in average fetal weight, or teratogenicity in rats treated with enalapril at doses up to 200 mg/kg/day, which is about 333 times the maximum human dose.10 In mice and rats receiving enalapril at doses ranging from 90 to 180 mg/kg/day, there was no evidence of a tumorigenic effect. Neither enalapril or its active metabolite were shown to be mutagenic or genotoxic in in vitro and in vivo studies. There were no adverse effects on reproductive performance of male and female rats treated with up to 90 mg/kg/day of enalapril. LabelUse in special populationsCaution is warranted in patients who are concurrently using another ACE inhibitors with enalapril, as there have been incidences of agranulocytosis with the use of captopril, which is another ACE inhibitor. This adverse event may be particularly significant in patients with renal impairment or collagen vascular disease.Label As enalapril and enalaprilat were shown to be secreted in human milk in trace amounts, the use of enalaprilat in nursing women is not recommended.10 Significant fetal transfer occurs with enalapril and enalaprilat thus the use of the drug in pregnant women should be strongly avoided. Caution is advised when enalapril is used in patients who are elderly or with renal impairment, as dosage adjustments may be appropriate. The antihypertensive effect of angiotensin converting enzyme inhibitors is generally lower in individuals of African descent, usually a low-renin hypertensive population.Label	Small Molecule	http://smpdb.ca/view/SMP0000593?highlight[compounds][]=DB00584&highlight[proteins][]=DB00584;!http://smpdb.ca/view/SMP0000148?highlight[compounds][]=DB00584&highlight[proteins][]=DB00584	Enalapril Metabolism Pathway;!Enalapril Action Pathway		Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.8269 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor		-5.64			0.07		143-144.5		1.64E+004 mg/L	1	Yes	5	2	No	2	-1	95.94 Å2	40.41 Å3	99.57 m3·mol-1	10	Yes	No	0.213 mg/mL	0.59	-3.2	3.67	5.2			
C21H31N3O5	A 30kg child has a typical clearance of 10L/h, which increases with renal function.8,9 The mean renal clearance of lisinopril in healthy adult males is 121mL/min.2	Lisinopril has an effective half life of accumulation of 12.6h2,8,9,10 and a terminal half life of 46.7h.2	405.4879	NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O	Solid	The apparent volume of distribution of lisinopril is 124L.3					66979	43755	CHEMBL1237	4514933	Drugs.com Drug Page		HMDB0001938		D00362	LPR	PDRhealth Drug Page	PA450242	5362119	46504893	RxList Drug Page	1546022	DAP000587	Lisinopril	ZINC000003812863	Prinivil, Qbrelis, Zestoretic, Zestril	Lisinopril	Approved, Investigational	DB00722	InChI=1S/C21H31N3O5/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29)/t16-,17-,18-/m0/s1	RLAWWYSOJDYHDC-BZSNNMDCSA-N	4	Lisinopril is an ACE inhibitor used to treat hypertension, heart failure, and acute myocardial infarction.	The oral and subcutaneous LD50 in rats is >8500mg/kg and in mice is >9100mg/kg.11 The oral LDLO in women is 1200µg/kg/16D and in men is 43mg/kg/43W.11Patients experiencing an overdose of lisinopril may present with hypotension.8,9,10 Patients should be treated with intravenous saline to restore blood pressure.8,9,10 Lisinopril can be removed from the blood by hemodialysis due to it not being protein bound.8,9,10	Small Molecule	http://smpdb.ca/view/SMP0000150?highlight[compounds][]=DB00722&highlight[proteins][]=DB00722	Lisinopril Action Pathway		Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.8723 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					-1.01		148	2.5 (at 25 °C)	9.7E+004 mg/L	1	No	7	4	No	2	0	132.96 Å2	43.64 Å3	107.37 m3·mol-1	12	Yes	No	0.216 mg/mL	-3.1	-3.3	3.17	10.21			
C19H27NO3	Not Available	1.5 hours	317.429	CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](CC1=CC=CC=C1)C(O)=O	Solid	10 liters in healthy subjects	P11712;!P08684;!P20815;!P24462;!P23219;!O60656;!P10635	CYP2C9;!CYP3A4;!CYP3A5;!CYP3A7;!PTGS1;!UGT1A9;!CYP2D6	1. Cytochrome P450 2C9;!2. Cytochrome P450 3A4;!3. Cytochrome P450 3A5;!4. Cytochrome P450 3A7;!5. Prostaglandin G/H synthase 1;!6. UDP-glucuronosyltransferase 1-9;!7. Cytochrome P450 2D6		50344967	31897	CHEMBL783	10482084	Drugs.com Drug Page		HMDB14869	C12508	D01111		PDRhealth Drug Page	PA450600	5311309	46504836	RxList Drug Page	274332	DAP000918	Nateglinide	ZINC000101489663	Starlix	Nateglinide	Approved, Investigational	DB00731	InChI=1S/C19H27NO3/c1-13(2)15-8-10-16(11-9-15)18(21)20-17(19(22)23)12-14-6-4-3-5-7-14/h3-7,13,15-17H,8-12H2,1-2H3,(H,20,21)(H,22,23)/t15-,16-,17-/m1/s1	OELFLUMRDSZNSF-BRWVUGGUSA-N	4	Nateglinide is a meglitinide used to treat non insulin dependent diabetes mellitus.	An overdose may result in an exaggerated glucose-lowering effect with the development of hypoglycemic symptoms.	Small Molecule	http://smpdb.ca/view/SMP0000453?highlight[compounds][]=DB00731&highlight[proteins][]=DB00731	Nateglinide Action Pathway		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.0362 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.4				Practically insoluble	1	Yes	3	2	No	2	-1	66.4 Å2	35.55 Å3	89.46 m3·mol-1	6	Yes	No	0.00848 mg/mL	4.03	-4.6	4	-1.1	Q09428;!P37231	ABCC8;!PPARG	1. ATP-binding cassette sub-family C member 8;!2. Peroxisome proliferator-activated receptor gamma
C17H25N3O5S	Not Available	Approximately 1 hour in adults and children 2 years of age and older with normal renal function. Approximately 1.5 hours in children 3 months to 2 years of age.	383.463	[H][C@]1([C@@H](C)O)C(=O)N2C(C(O)=O)=C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)[C@H](C)[C@]12[H]	Solid	Not Available	P14489;!P16444	bla;!DPEP1	1. Beta-lactamase OXA-10;!2. Dipeptidase 1		50129062	43968	CHEMBL127	389924	Drugs.com Drug Page		HMDB0014898		D02222	MEM		PA164764445	441130	46504928	RxList Drug Page	1546029	DAP000441	Meropenem	ZINC000003808779	Merrem, Vabomere	Meropenem	Approved, Investigational	DB00760	InChI=1S/C17H25N3O5S/c1-7-12-11(8(2)21)16(23)20(12)13(17(24)25)14(7)26-9-5-10(18-6-9)15(22)19(3)4/h7-12,18,21H,5-6H2,1-4H3,(H,24,25)/t7-,8-,9+,10+,11-,12-/m1/s1	DMJNNHOOLUXYBV-PQTSNVLCSA-N	4	Meropenem is a carbapenem antibiotic used to treat a wide variety of infections in the body.	In mice and rats, large intravenous doses of meropenem (2200-4000 mg/kg) have been associated with ataxia, dyspnea, convulsions, and mortalities.	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.9158 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					-0.6				Sparingly	1	No	6	3	No	3	0	110.18 Å2	39.32 Å3	97.89 m3·mol-1	5	Yes	No	5.63 mg/mL	-4.4	-1.8	3.28	9.39	P24228	dacB	1. D-alanyl-D-alanine carboxypeptidase DacB
C19H32N2O5	219 - 362 mL/min [oral administration]	Perindopril, 1.2 hours; Peridoprilat, 30-120 hours. The long half life of peridoprilat is due to its slow dissociation from ACE binding sites.	368.4678	[H][C@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O	Solid	Not Available	P06276	BCHE	1. Cholinesterase		50493988	8024	CHEMBL1581	96956	Drugs.com Drug Page		HMDB0014928	C07706	D03753		PDRhealth Drug Page	PA450877	107807	46508767	RxList Drug Page	54552	DNC001114	Perindopril	ZINC000003812867	Aceon, Coversyl, Prestalia, Viacoram	Perindopril	Approved	DB00790	InChI=1S/C19H32N2O5/c1-4-8-14(19(25)26-5-2)20-12(3)17(22)21-15-10-7-6-9-13(15)11-16(21)18(23)24/h12-16,20H,4-11H2,1-3H3,(H,23,24)/t12-,13-,14-,15-,16-/m0/s1	IPVQLZZIHOAWMC-QXKUPLGCSA-N	4	Perindopril is an ACE inhibitor prodrug used to treat hypertension, mild to moderate congestive heart failure, and to reduce cardiovascular risk in patients with hypertension or post-myocardial infarction.	The most likely symptom of overdose is severe hypotension. The most common adverse effects observed in controlled clinical trials include cough, digestive symptoms, fatigue, headache, and dizziness.	Small Molecule	http://smpdb.ca/view/SMP0000152?highlight[compounds][]=DB00790&highlight[proteins][]=DB00790	Perindopril Action Pathway		Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	1.9432 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.6					1	Yes	5	2	No	2	-1	95.94 Å2	39.99 Å3	95.69 m3·mol-1	9	Yes	No	1.22 mg/mL	0.63	-2.5	3.79	5.48	P12821;!Q6FHJ7	ACE;!SFRP4	1. Angiotensin-converting enzyme;!2. Secreted frizzled-related protein 4
C19H24N2O4S2	Not Available	Not Available	408.53	[H][C@]12CCC[C@H](N1C(=O)[C@H](CCS2)NC(=O)[C@@H](S)CC1=CC=CC=C1)C(O)=O	Solid	Not Available					50073120	135660	CHEMBL289556	570983					D01970	FT8			656629	175426852				Omapatrilat	ZINC000003809801		Omapatrilat	Investigational	DB00886	InChI=1S/C19H24N2O4S2/c22-17(15(26)11-12-5-2-1-3-6-12)20-13-9-10-27-16-8-4-7-14(19(24)25)21(16)18(13)23/h1-3,5-6,13-16,26H,4,7-11H2,(H,20,22)(H,24,25)/t13-,14-,15-,16-/m0/s1	LVRLSYPNFFBYCZ-VGWMRTNUSA-N			Side effects include hyperkalemia, cough, hypotension, increased SrCr, and dizziness. Dizziness, diarrhea, vision disturbance, hypotension and angioedema	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.0641 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.6					1	Yes	4	3	No	3	-1	86.71 Å2	41.8 Å3	106.68 m3·mol-1	5	Yes	No	0.0769 mg/mL	2.06	-3.7	3.77	-3.6			
C28H46N6O8S	Not Available	Not Available	626.765		Solid	Not Available						59297	CHEMBL1201779	26331550			HMDB0015032					PA164754810	45266800	46505002		19079	DAP001314	Benzylpenicilloyl_polylysine		Pre-pen	Benzylpenicilloyl polylysine	Approved	DB00895	InChI=1S/C22H32N4O6S.C6H14N2O2/c1-22(2)17(21(31)32)26-19(33-22)16(25-15(27)12-13-8-4-3-5-9-13)18(28)24-11-7-6-10-14(23)20(29)30;7-4-2-1-3-5(8)6(9)10/h3-5,8-9,14,16-17,19,26H,6-7,10-12,23H2,1-2H3,(H,24,28)(H,25,27)(H,29,30)(H,31,32);5H,1-4,7-8H2,(H,9,10)/t14-,16?,17+,19-;5-/m11/s1	IMPVZRLKKKXMKQ-SGDOCVTFSA-N	3	Benzylpenicilloyl polylysine is a penicillin derivative used to determine penicillin allergies.	Symptoms of overdose include urticaria, generalized pruritus, local swelling, generalized flushing, anaphylaxis, bronchospasm, fainting and maculopapular eruption.	Small Molecule																														-0.8					0	No	8	6	No	2	0	170.85 Å2	50.31 Å3	122.22 m3·mol-1	17	No	No	0.0658 mg/mL	-3.8	-3.9	2.04	9.53	P30273;!P12319	FCER1G;!FCER1A	1. High affinity immunoglobulin epsilon receptor subunit gamma;!2. High affinity immunoglobulin epsilon receptor subunit alpha
C15H23N3O4S	Not Available	Not Available	341.426	[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1(N)CCCCC1)C(O)=O	Solid	Not Available					50350474	31444	CHEMBL1200356	17941			HMDB0015135	C12766	D01334			PA164743456	19003	46508073		2968	DAP001159	Ciclacillin	ZINC000003830609		Cyclacillin	Approved	DB01000	InChI=1S/C15H23N3O4S/c1-14(2)9(12(20)21)18-10(19)8(11(18)23-14)17-13(22)15(16)6-4-3-5-7-15/h8-9,11H,3-7,16H2,1-2H3,(H,17,22)(H,20,21)/t8-,9+,11-/m1/s1	HGBLNBBNRORJKI-WCABBAIRSA-N			Symptoms of overdose include severe diarrhea, nausea and vomiting.	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	1.8643 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					1.31		182-183 °C			1	No	5	3	No	3	0	112.73 Å2	34.89 Å3	84.22 m3·mol-1	3	Yes	No	1.9 mg/mL	-1.9	-2.3	3.3	8.45	Q8DR59;!Q75Y35;!C1KC03;!BE0004840	pbpA;!pbp3;!mecA;!	1. Penicillin-binding protein 1A;!2. Penicillin-binding protein 3;!3. Penicillin binding protein 2a;!4. Penicillin-binding protein (Protein Group)
C20H23N5O6S	Not Available	Mean elimination half-life is 1.3 to 1.5 hours. Longer in neonates, and 2 to 6 hours in patients with renal impairment.	461.492	[H][C@](NC(=O)N1CCNC1=O)(C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@]12[H])C1=CC=CC=C1	Solid	Not Available						2956	CHEMBL1537	4980416			HMDB0015194	C06839	D02339			PA164749135	6479523	46506654		1266	DAP001169	Azlocillin	ZINC000003830261		Azlocillin	Approved	DB01061	InChI=1S/C20H23N5O6S/c1-20(2)13(17(28)29)25-15(27)12(16(25)32-20)22-14(26)11(10-6-4-3-5-7-10)23-19(31)24-9-8-21-18(24)30/h3-7,11-13,16H,8-9H2,1-2H3,(H,21,30)(H,22,26)(H,23,31)(H,28,29)/t11-,12-,13+,16-/m1/s1	JTWOMNBEOCYFNV-NFFDBFGFSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.1838 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					0.2				Sodium salt is soluble in water (50 mg/ml)	1	Yes	6	4	No	4	-1	148.15 Å2	44.97 Å3	111.71 m3·mol-1	5	Yes	No	0.233 mg/mL	-0.33	-3.3	3.49	-5.9	Q8XJ01	pbpA	1. Penicillin-binding protein 1A
C18H33ClN2O5S	The plasma clearance of clindamycin is estimated to be 12.3-17.4 L/h, and is reduced in patients with cirrhosis and altered in those with anemia.6,7	The elimination half-life of clindamycin is about 3 hours in adults and 2.5 hours in children.15,14 Half-life is increased to approximately 4 hours in the elderly.15,14	424.98	[H][C@@](NC(=O)[C@@H]1C[C@@H](CCC)CN1C)([C@H](C)Cl)[C@@]1([H])O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O	Solid	Clindamycin is widely distributed in the body, including into bone, but does not distribute into cerebrospinal fluid. The volume of distribution has been variably estimated between 43-74 L.7,6	P20815;!P08684	CYP3A5;!CYP3A4	1. Cytochrome P450 3A5;!2. Cytochrome P450 3A4			3745	CHEMBL1753	393915	Drugs.com Drug Page		HMDB0015321	C06914	D00277	CLY		PA449035	446598	46506073	RxList Drug Page	2582	DAP000409	Clindamycin	ZINC000004038341	Acanya, Benzaclin, Biacna, Cleocin, Cleocin-T, Clindacin, Clindagel, Clindesse, Clindoxyl, Dalacin, Dalacin C, Duac, Evoclin, Neuac, Onexton, Veltin, Xaciato, Ziana	Clindamycin	Approved, Vet approved	DB01190	InChI=1S/C18H33ClN2O5S/c1-5-6-10-7-11(21(3)8-10)17(25)20-12(9(2)19)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,22-24H,5-8H2,1-4H3,(H,20,25)/t9-,10+,11-,12+,13-,14+,15+,16+,18+/m0/s1	KDLRVYVGXIQJDK-AWPVFWJPSA-N	4	Clindamycin is a lincosamide antibiotic used to treat serious infections caused by susceptible anaerobic, streptococcal, staphylococcal, and pneumococcal bacteria.	The oral LD50 in mice and rats is 2540 mg/kg and 2190 mg/kg, respectively.19While no cases of overdose have been reported, symptoms are expected to be consistent with the adverse effect profile of clindamycin and may therefore include abdominal pain, nausea, vomiting, and diarrhea. During clinical trials, one 3-year-old child was given a dose of 100 mg/kg daily for 5 days and showed only mild abdominal pain and diarrhea.20 Activated charcoal may be of value to remove unabsorbed drug, but hemodialysis and peritoneal dialysis are ineffective.20 General supportive measures are recommended in cases of clindamycin overdose.20	Small Molecule	http://smpdb.ca/view/SMP0000249?highlight[compounds][]=DB01190&highlight[proteins][]=DB01190	Clindamycin Action Pathway		Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	2.3192 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.16		141-143C	7.6	Water soluble	1	Yes	6	4	No	2	1	102.26 Å2	44.82 Å3	105.72 m3·mol-1	7	Yes	No	3.1 mg/mL	1.04	-2.1	12.41	7.55	Q2G0P0	rplA	1. 50S ribosomal protein L1
C9H15NO3S	Not Available	2 hours	217.285	C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O	Solid	Not Available					21642	3380	CHEMBL1560	40130	Drugs.com Drug Page		HMDB0015328		D00251	X8Z	PDRhealth Drug Page	PA448780	44093	46506879	RxList Drug Page	1998	DAP000589	Captopril	ZINC000000057001		Captopril	Approved	DB01197	InChI=1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)/t6-,7+/m1/s1	FAKRSMQSSFJEIM-RQJHMYQMSA-N	4	Captopril is an ACE inhibitor used for the management of essential or renovascular hypertension, congestive heart failure, left ventricular dysfunction following myocardial infarction, and nephropathy.	Symptoms of overdose include emesis and decreased blood pressure. Side effects include dose-dependent rash (usually maculopapular), taste alterations, hypotension, gastric irritation, cough, and angioedema.	Small Molecule	http://smpdb.ca/view/SMP0000146?highlight[compounds][]=DB01197&highlight[proteins][]=DB01197	Captopril Action Pathway		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.7403 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					0.34		103-104		Freely soluble	1	Yes	3	2	No	1	-1	57.61 Å2	21.72 Å3	54.63 m3·mol-1	3	Yes	No	4.52 mg/mL	0.73	-1.7	4.02	-1.3			
C22H31N3O5	Total clearance is 12.3 L/h and renal clearance is 10.8 L/h. The total urinary recovery of cilazaprilat following the oral administration of 2.5 mg cilazapril is 52.6%.	Half-lives for the periods 1 to 4 hours and 1 to 7 days after the intravenous administration of 2.5 mg cilazaprilat are 0.90 and 46.2 hours respectively.	417.4986	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]1CCCN2CCC[C@H](N2C1=O)C(O)=O	Solid	Not Available						3698	CHEMBL515606	50831	Drugs.com Drug Page		HMDB0015433		D07699			PA164748302	56330	46505231		21102	DAP000912	Cilazapril	ZINC000003781951	Inhibace	Cilazapril	Approved	DB01340	InChI=1S/C22H31N3O5/c1-2-30-22(29)18(13-12-16-8-4-3-5-9-16)23-17-10-6-14-24-15-7-11-19(21(27)28)25(24)20(17)26/h3-5,8-9,17-19,23H,2,6-7,10-15H2,1H3,(H,27,28)/t17-,18-,19-/m0/s1	HHHKFGXWKKUNCY-FHWLQOOXSA-N		Cilazapril is an ACE inhibitor used for the management of hypertension and heart failure.	Limited data are available with regard to overdosage in humans. The most likely manifestations are hypotension, which may be severe, hyperkalaemia, hyponatraemia and renal impairment with metabolic acidosis. Treatment should be mainly symptomatic and supportive.	Small Molecule	http://smpdb.ca/view/SMP0000147?highlight[compounds][]=DB01340&highlight[proteins][]=DB01340;!http://smpdb.ca/view/SMP0000592?highlight[compounds][]=DB01340&highlight[proteins][]=DB01340	Cilazapril Action Pathway;!Cilazapril Metabolism Pathway		Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.3700 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor					0.8		98 ºC with decomposition		Water (25 ºC) 0.5 g/100 mL	1	Yes	6	2	Yes	3	-1	99.18 Å2	44.73 Å3	110.56 m3·mol-1	9	Yes	No	1.06 mg/mL	0.22	-2.6	3.4	5.06	P12821	ACE	1. Angiotensin-converting enzyme
C22H30N2O5S2	Not Available	30 to 35 hours	466.614	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2(C[C@H]1C(O)=O)SCCS2	Solid	Not Available					50017124	135756	CHEMBL431	4470933			HMDB0015438		D08529			PA164776913	5311447	46506126		36908	DAP000911	Spirapril	ZINC000004217459		Spirapril	Approved	DB01348	InChI=1S/C22H30N2O5S2/c1-3-29-21(28)17(10-9-16-7-5-4-6-8-16)23-15(2)19(25)24-14-22(30-11-12-31-22)13-18(24)20(26)27/h4-8,15,17-18,23H,3,9-14H2,1-2H3,(H,26,27)/t15-,17-,18-/m0/s1	HRWCVUIFMSZDJS-SZMVWBNQSA-N	4		Not Available	Small Molecule	http://smpdb.ca/view/SMP0000156?highlight[compounds][]=DB01348&highlight[proteins][]=DB01348;!http://smpdb.ca/view/SMP0000598?highlight[compounds][]=DB01348&highlight[proteins][]=DB01348	Spirapril Action Pathway;!Spirapril Metabolism Pathway		Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.2396 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	2	Yes	3	-1	95.94 Å2	48.74 Å3	121.94 m3·mol-1	10	Yes	No	0.0293 mg/mL	1.6	-4.2	3.62	5.2	P12821	ACE	1. Angiotensin-converting enzyme
C18H34N2O6S	Lincomycin administered intravenously to healthy adult males had a clearance of 9.9 ± 2.5, 10.0 ± 2.0, and 11.8 ± 2.4 L/h for 600, 1200, and 2400 mg doses, respectively.8	Lincomycin has a biological half-life of 5.4 ± 1.0 hours following intramuscular or intravenous administration, which is prolonged in patients with impaired hepatic or renal function.10	406.54	[H][C@]1(C[C@@H](CCC)CN1C)C(=O)N[C@H]([C@@H](C)O)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O	Solid	Lincomycin administered intravenously to healthy adult males had a steady-state volume of distribution of 63.8 ± 23.8, 78.8 ± 17.0, and 105.1 ± 43.1 L for 600, 1200, and 2400 mg doses, respectively.8					50335522	6472	CHEMBL1447	2272112	Drugs.com Drug Page			C06812	D00223	3QB		PA164749212	3000540	46506668	RxList Drug Page	6398	DAP000839	Lincomycin	ZINC000003982483	Lincocin	Lincomycin	Approved, Vet approved	DB01627	InChI=1S/C18H34N2O6S/c1-5-6-10-7-11(20(3)8-10)17(25)19-12(9(2)21)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,21-24H,5-8H2,1-4H3,(H,19,25)/t9-,10-,11+,12-,13+,14-,15-,16-,18-/m1/s1	OJMMVQQUTAEWLP-KIDUDLJLSA-N	1	Lincomycin is an antibiotic indicated only for the treatment of serious infections and is typically reserved for use in cases of penicillin allergy or where penicillin is inappropriate.	Toxicity information regarding lincomycin is not readily available. Patients experiencing an overdose are at an increased risk of severe adverse effects such as gastrointestinal effects including colitis, secondary infections, and severe hypersensitivity reactions. Symptomatic and supportive measures are recommended. It is important to note that hemodialysis and peritoneal dialysis do not appreciably affect lincomycin serum concentrations.10	Small Molecule	http://smpdb.ca/view/SMP0000728?highlight[compounds][]=DB01627&highlight[proteins][]=DB01627	Lincomycin Action Pathway		Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.5777 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					0.56		187-190		freely soluble	1	Yes	7	5	No	2	1	122.49 Å2	43.65 Å3	102.67 m3·mol-1	7	Yes	No	29.3 mg/mL	-0.32	-1.1	12.37	7.97	BSEQ0052173		1. 23S ribosomal RNA
C24H27N3O7S	Not Available	Not Available	501.552	[H][C@](N)(CCC(=O)N[C@@]([H])(CS[C@]1([H])C2=CC=CC=C2C2=CC=CC=C2[C@@]1([H])O)C(=O)NCC(O)=O)C(O)=O	Solid	Not Available								395916						GPR			449366	46504778					ZINC000015685338		(9R,10R)-9-(S-glutathionyl)-10-hydroxy-9,10-dihydrophenanthrene	Experimental	DB01834	InChI=1S/C24H27N3O7S/c25-17(24(33)34)9-10-19(28)27-18(23(32)26-11-20(29)30)12-35-22-16-8-4-2-6-14(16)13-5-1-3-7-15(13)21(22)31/h1-8,17-18,21-22,31H,9-12,25H2,(H,26,32)(H,27,28)(H,29,30)(H,33,34)/t17-,18-,21+,22+/m0/s1	JNNIZILNBMPOAC-MOXQZVSFSA-N			Not Available	Small Molecule																																			0	No	8	6	Yes	3	-1	179.05 Å2	50.25 Å3	127.88 m3·mol-1	11	No	No	0.031 mg/mL	-2.2	-4.2	1.8	9.31	P09211;!P09488	GSTP1;!GSTM1	1. Glutathione S-transferase P;!2. Glutathione S-transferase Mu 1
C21H30N4O5S2	Not Available	Not Available	482.617	[H][C@@](CCSC)(NC(=O)[C@]1([H])CCCN1C(=O)[C@]([H])(CC1=CC=C(O)C=C1)NC(=O)CS)C(N)=O	Solid	Not Available								4451333						SD2			5289343	46506367					ZINC000033821516		N-(Sulfanylacetyl)Tyrosylprolylmethioninamide	Experimental	DB01883	InChI=1S/C21H30N4O5S2/c1-32-10-8-15(19(22)28)24-20(29)17-3-2-9-25(17)21(30)16(23-18(27)12-31)11-13-4-6-14(26)7-5-13/h4-7,15-17,26,31H,2-3,8-12H2,1H3,(H2,22,28)(H,23,27)(H,24,29)/t15-,16-,17-/m0/s1	LNLWXWOYQHAKTD-ULQDDVLXSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.4015 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	5	5	No	2	0	141.83 Å2	49.33 Å3	125.56 m3·mol-1	11	Yes	No	0.0197 mg/mL	-0.14	-4.4	9.17	-3.4	P15917	lef	1. Lethal factor
C32H36N3O9P	Not Available	Not Available	637.6167	CC(=O)N[C@@H](CC1=CC=C(OCC(O)=O)C(=C1)P(O)(O)=O)C(=O)N[C@H]1CCCCN(CC2=CC=C(C=C2)C2=CC=CC=C2)C1=O	Solid	Not Available					14695		CHEMBL436462	4449878						493			5287515	46507938					ZINC000027559719		RU85493	Experimental	DB01908	InChI=1S/C32H36N3O9P/c1-21(36)33-27(17-23-12-15-28(44-20-30(37)38)29(18-23)45(41,42)43)31(39)34-26-9-5-6-16-35(32(26)40)19-22-10-13-25(14-11-22)24-7-3-2-4-8-24/h2-4,7-8,10-15,18,26-27H,5-6,9,16-17,19-20H2,1H3,(H,33,36)(H,34,39)(H,37,38)(H2,41,42,43)/t26-,27-/m0/s1	MWEWSHNGVWABKG-SVBPBHIXSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.5594 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										0	No	9	5	Yes	4	-3	182.57 Å2	65.46 Å3	164.35 m3·mol-1	12	No	No		1.63		1.61	-1.9	P12931	SRC	1. Proto-oncogene tyrosine-protein kinase Src
C36H52N6O9P	Not Available	Not Available	743.8066	[H]N([C@@H](CCCC[N+]([H])([H])[H])C(=O)N([H])[C@@H](CC1=CC=CC=C1)P(O)(=O)N([H])[C@@H](C)C(=O)N1CCC[C@H]1C(=O)OC)C(=O)[C@@H]1CCCN1C(=O)OCC1=CC=CC=C1	Solid	Not Available								20572427						PKF			16741116	46506751							Methyl N-{[(1R)-1-({1-[(benzyloxy)carbonyl]-L-prolyl-6-ammonio-L-norleucyl}amino)-2-phenylethyl](hydroxy)phosphoryl}-L-alanyl-L-prolinate	Experimental	DB01989	InChI=1S/C36H51N6O9P/c1-25(34(45)41-21-12-19-30(41)35(46)50-2)40-52(48,49)31(23-26-13-5-3-6-14-26)39-32(43)28(17-9-10-20-37)38-33(44)29-18-11-22-42(29)36(47)51-24-27-15-7-4-8-16-27/h3-8,13-16,25,28-31H,9-12,17-24,37H2,1-2H3,(H,38,44)(H,39,43)(H2,40,48,49)/p+1/t25-,28-,29-,30-,31+/m0/s1	JVJRALIDWYDPLY-HEPRJOMSSA-O			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.6005 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										0	No	7	5	Yes	4	0	211.32 Å2	76.48 Å3	203.14 m3·mol-1	19	No	No	0.00278 mg/mL	0.095	-5.4	3.02	10.2	Q9Y6L7	TLL2	1. Tolloid-like protein 2
C14H25N3O6S	Not Available	Not Available	363.43	CC(C)[C@@H](NC(=O)[C@H](CS)NC(=O)CCC[C@H](N)C(O)=O)C(O)=O	Solid	Not Available						28496	CHEMBL70421	395032				C05556		ACV			448130	46506598		1551571			ZINC000003873037		ACV tripeptide	Experimental	DB02025	InChI=1S/C14H25N3O6S/c1-7(2)11(14(22)23)17-12(19)9(6-24)16-10(18)5-3-4-8(15)13(20)21/h7-9,11,24H,3-6,15H2,1-2H3,(H,16,18)(H,17,19)(H,20,21)(H,22,23)/t8-,9-,11+/m0/s1	BYEIJZFKOAXBBV-ATZCPNFKSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.8780 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	7	6	No	0	-1	158.82 Å2	36.7 Å3	87.21 m3·mol-1	11	No	No	0.478 mg/mL	-3	-2.9	1.94	9.15			
C9H15NO3S	Not Available	Not Available	217.285	C[C@@H](CS)C(=O)N1CCC[C@H]1C(O)=O	Solid	Not Available					50140754		CHEMBL269634	599746						MCO			688267	46505775					ZINC000000057000		Epicaptopril	Experimental	DB02032	InChI=1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)/t6-,7-/m0/s1	FAKRSMQSSFJEIM-BQBZGAKWSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.7403 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	2	No	1	-1	57.61 Å2	21.96 Å3	54.63 m3·mol-1	3	Yes	No	4.52 mg/mL	0.73	-1.7	4.02	-1.3			
C20H37N3O6	Not Available	Not Available	415.5243	[H][C@@](CCCO)(C(=O)NO)[C@@]([H])(CC(C)C)C(=O)N[C@@]1([H])CCCCN(CCOC)C1=O	Solid	Not Available								16744190						S80			17754156	46508659					ZINC000033821511		A Disubstituted Succinyl Caprolactam Hydroxymate Mmp3inhibitor	Experimental	DB02090	InChI=1S/C20H37N3O6/c1-14(2)13-16(15(7-6-11-24)19(26)22-28)18(25)21-17-8-4-5-9-23(20(17)27)10-12-29-3/h14-17,24,28H,4-13H2,1-3H3,(H,21,25)(H,22,26)/t15-,16+,17-/m0/s1	JLEGVELHGVWFGG-BBWFWOEESA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.4682 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	6	4	No	1	0	128.2 Å2	44.53 Å3	108.5 m3·mol-1	12	Yes	No	4.58 mg/mL	0.056	-2	8.86	-0.39			
C22H26N4O4	Not Available	Not Available	410.4662	[H][C@@](CC1=CC=CC=C1)(NC(=O)C(=O)CC(=O)NCCC1=NC=CC=C1)C(=O)N(C)C	Solid	Not Available								4450156						C48			5287869	46507687					ZINC000003872096		N1-(1-Dimethylcarbamoyl-2-Phenyl-Ethyl)-2-Oxo-N4-(2-Pyridin-2-Yl-Ethyl)-Succinamide	Experimental	DB02140	InChI=1S/C22H26N4O4/c1-26(2)22(30)18(14-16-8-4-3-5-9-16)25-21(29)19(27)15-20(28)24-13-11-17-10-6-7-12-23-17/h3-10,12,18H,11,13-15H2,1-2H3,(H,24,28)(H,25,29)/t18-/m0/s1	ZPFPZRVOBBMZMP-SFHVURJKSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.3390 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	5	2	No	2	0	108.47 Å2	41.49 Å3	111.22 m3·mol-1	10	Yes	No	0.0475 mg/mL	0.96	-3.9	11.6	4.55	P09668	CTSH	1. Pro-cathepsin H
C18H30N8O6S	Not Available	Not Available	486.546	CCNC1=NC(SC[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)NCC(O)=O)=NC(NC(C)C)=N1	Solid	Not Available								4450024						ATA			5287712	46506861					ZINC000012501645		Glutathione S-atrazine	Experimental	DB02146	InChI=1S/C18H30N8O6S/c1-4-20-16-24-17(22-9(2)3)26-18(25-16)33-8-11(14(30)21-7-13(28)29)23-12(27)6-5-10(19)15(31)32/h9-11H,4-8,19H2,1-3H3,(H,21,30)(H,23,27)(H,28,29)(H,31,32)(H2,20,22,24,25,26)/t10-,11-/m0/s1	WDLCRTLULMGVMR-QWRGUYRKSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.4883 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	12	7	No	1	-1	221.55 Å2	49.47 Å3	124.3 m3·mol-1	15	No	No	0.189 mg/mL	-6.6	-3.4	-6.9	9.31			
C29H37F5N4O6	Not Available	Not Available	632.6193	CC(C)[C@@H](NC(=O)C1=CC=C(C=C1)C(=O)N1CCOCC1)C(=O)N1CCC[C@@H]1C(=O)N[C@H](C(C)C)C(=O)C(F)(F)C(F)(F)F	Solid	Not Available								26329702						SEI			46936357	46506771					ZINC000053683666		Mdl 101,146	Experimental	DB02341	InChI=1S/C29H37F5N4O6/c1-16(2)21(23(39)28(30,31)29(32,33)34)35-25(41)20-6-5-11-38(20)27(43)22(17(3)4)36-24(40)18-7-9-19(10-8-18)26(42)37-12-14-44-15-13-37/h7-10,16-17,20-22H,5-6,11-15H2,1-4H3,(H,35,41)(H,36,40)/t20-,21-,22-/m1/s1	XQAMVCHQGHAELT-YPAWHYETSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.6027 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										0	No	6	2	Yes	3	0	125.12 Å2	59.49 Å3	148.06 m3·mol-1	11	No	No	0.00809 mg/mL	3.31	-4.9	11.32	-0.98			
C8H15N3O4	Not Available	Not Available	217.2224	CC(=O)N[C@@H](CCCNC(N)=O)C(O)=O	Solid	Not Available						49002		571213				C15532		OLN			656979	46506512					ZINC000012494450		N-Acetyl-L-Citrulline	Experimental	DB02368	InChI=1S/C8H15N3O4/c1-5(12)11-6(7(13)14)3-2-4-10-8(9)15/h6H,2-4H2,1H3,(H,11,12)(H,13,14)(H3,9,10,15)/t6-/m0/s1	WMQMIOYQXNRROC-LURJTMIESA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.6137 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	4	No	0	-1	121.52 Å2	21.49 Å3	50.77 m3·mol-1	6	Yes	No	3.57 mg/mL	-1.9	-1.8	3.87	-1.5	Q8P8J2	argF'	1. N-acetylornithine carbamoyltransferase
C35H36FN3O9	Not Available	Not Available	661.6734	COC(=O)C1=C(C=CC(C[C@H](NC(C)=O)C(=O)N[C@H]2CCCCN(CC3=CC=C(C=C3)C3=CC=CC=C3)C2=O)=C1)C(F)(C(O)=O)C(O)=O	Solid	Not Available					14692		CHEMBL357488	394585						903			447522	46506689					ZINC000024662085		RU90395	Experimental	DB02432	InChI=1S/C35H36FN3O9/c1-21(40)37-29(19-23-13-16-27(26(18-23)32(43)48-2)35(36,33(44)45)34(46)47)30(41)38-28-10-6-7-17-39(31(28)42)20-22-11-14-25(15-12-22)24-8-4-3-5-9-24/h3-5,8-9,11-16,18,28-29H,6-7,10,17,19-20H2,1-2H3,(H,37,40)(H,38,41)(H,44,45)(H,46,47)/t28-,29-/m0/s1	RLLAUERCSKPFGD-VMPREFPWSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Inhibitor	Inhibitor	Substrate	2.6625 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										0	No	8	4	Yes	4	-2	179.41 Å2	65.9 Å3	169.79 m3·mol-1	13	No	No		3.54		2.25	-1.9	P12931	SRC	1. Proto-oncogene tyrosine-protein kinase Src
C16H19N5O10S	Not Available	Not Available	473.415	[H][C@](N)(CCC(=O)N[C@@]([H])(CSC1=C(C=C(C=C1)N(=O)=O)N(=O)=O)C(=O)NCC(O)=O)C(O)=O	Solid	Not Available					50391004	8927	CHEMBL1232997	88032			HMDB0062528	C11175		GDN			97535	46504887					ZINC000003870210		S-(2,4-dinitrophenyl)glutathione	Experimental	DB02458	InChI=1S/C16H19N5O10S/c17-9(16(26)27)2-4-13(22)19-10(15(25)18-6-14(23)24)7-32-12-3-1-8(20(28)29)5-11(12)21(30)31/h1,3,5,9-10H,2,4,6-7,17H2,(H,18,25)(H,19,22)(H,23,24)(H,26,27)/t9-,10-/m0/s1	FXEUKVKGTKDDIQ-UWVGGRQHSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.5332 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	11	5	No	1	-1	250.46 Å2	42.88 Å3	108.34 m3·mol-1	13	No	No	0.0319 mg/mL	-3.3	-4.2	1.59	9.31	P09488;!P28161	GSTM1;!GSTM2	1. Glutathione S-transferase Mu 1;!2. Glutathione S-transferase Mu 2
C15H26N4O7	Not Available	Not Available	374.3895	[H]N([H])CC(=O)N([H])[C@@H](CCCCC(=O)N([H])[C@H](C)C(=O)N([H])[C@H](C)C(O)=O)C(O)=O	Solid	Not Available								393699						REX			446306	46508348					ZINC000015599994		N-[(6S)-6-Carboxy-6-(glycylamino)hexanoyl]-D-alanyl-D-alanine	Experimental	DB02578	InChI=1S/C15H26N4O7/c1-8(13(22)18-9(2)14(23)24)17-11(20)6-4-3-5-10(15(25)26)19-12(21)7-16/h8-10H,3-7,16H2,1-2H3,(H,17,20)(H,18,22)(H,19,21)(H,23,24)(H,25,26)/t8-,9-,10+/m1/s1	RALBRZJHHGWNNU-BBBLOLIVSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	1.8059 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	8	6	No	0	-1	187.92 Å2	37.69 Å3	87.89 m3·mol-1	12	No	No	1.07 mg/mL	-4.9	-2.5	3.2	8.14	P15555	Not Available	1. D-alanyl-D-alanine carboxypeptidase
C19H28N2O4S	Not Available	Not Available	380.502	[H][C@@](C)(NC(=O)[C@]([H])(CC1=CC=CC=C1)NC(=O)[C@@]([H])(S)CCCCC)C(O)=O	Solid	Not Available								4451431						TI1			5289469	46505753			DNC001441		ZINC000006352218		[2(R,S)-2-Sulfanylheptanoyl]-Phe-Ala	Experimental	DB02597	InChI=1S/C19H28N2O4S/c1-3-4-6-11-16(26)18(23)21-15(12-14-9-7-5-8-10-14)17(22)20-13(2)19(24)25/h5,7-10,13,15-16,26H,3-4,6,11-12H2,1-2H3,(H,20,22)(H,21,23)(H,24,25)/t13-,15-,16-/m0/s1	GOIYKVXXGCPHQU-BPUTZDHNSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1308 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	4	No	1	-1	95.5 Å2	41.19 Å3	102.51 m3·mol-1	11	Yes	No	0.0104 mg/mL	3.01	-4.6	3.83	-3.4	P00800;!P43133;!P08473	npr;!nprS;!MME	1. Thermolysin;!2. Thermolysin;!3. Neprilysin
C13H14I2N2O5	Not Available	Not Available	532.0696	CC(=O)N[C@@H](CC1=CC(I)=C(O)C(I)=C1)C(=O)NCC(O)=O	Solid	Not Available								394720						IYG			447701	46507272					ZINC000014880426		N-Alpha-Acetyl-3,5-Diiodotyrosylglycine	Experimental	DB02598	InChI=1S/C13H14I2N2O5/c1-6(18)17-10(13(22)16-5-11(19)20)4-7-2-8(14)12(21)9(15)3-7/h2-3,10,21H,4-5H2,1H3,(H,16,22)(H,17,18)(H,19,20)/t10-/m0/s1	SXRYVFRVDCDPKH-JTQLQIEISA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.4777 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	5	4	No	1	-2	115.73 Å2	38.24 Å3	96.07 m3·mol-1	6	No	No	0.153 mg/mL	1.35	-3.5	2.54	-1.9	P19021	PAM	1. Peptidyl-glycine alpha-amidating monooxygenase
C25H38N4O3	Not Available	Not Available	442.5942	[H][C@@](C)(NC)C(=O)N[C@]([H])(C(=O)N1CCC[C@@]1([H])C(=O)N[C@]1([H])CCCC2=C1C=CC=C2)C(C)(C)C	Solid	Not Available					13166		CHEMBL1230662	3571936						998			4369343	46505788					ZINC000003960063		1-[3,3-Dimethyl-2-(2-Methylamino-Propionylamino)-Butyryl]-Pyrrolidine-2-Carboxylic Acid(1,2,3,4-Tetrahydro-Naphthalen-1-Yl)-Amide	Experimental	DB02628	InChI=1S/C25H38N4O3/c1-16(26-5)22(30)28-21(25(2,3)4)24(32)29-15-9-14-20(29)23(31)27-19-13-8-11-17-10-6-7-12-18(17)19/h6-7,10,12,16,19-21,26H,8-9,11,13-15H2,1-5H3,(H,27,31)(H,28,30)/t16-,19+,20-,21+/m0/s1	JUJIMRZGUBTJRV-NASSWSRMSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.5115 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	4	3	Yes	3	1	90.54 Å2	49.19 Å3	124.46 m3·mol-1	7	Yes	No	0.0362 mg/mL	2.45	-4.1	12.53	8.6			
C25H35N6O4	Not Available	Not Available	483.5832	[H]N([H])C(N([H])[H])=[N+]([H])CCC[C@H](N([H])C(=O)[C@H](CCC1=CC=CC=C1)N([H])[C@H](C)C(O)=O)C(=O)N([H])C1=CC=CC=C1	Solid	Not Available								4450760						8MI			5288637	46507423							Diamino-N-[(4S)-5-anilino-4-{[(2S)-2-{[(1R)-1-carboxyethyl]amino}-4-phenylbutanoyl]amino}-5-oxopentyl]methaniminium	Experimental	DB02747	InChI=1S/C25H34N6O4/c1-17(24(34)35)29-21(15-14-18-9-4-2-5-10-18)23(33)31-20(13-8-16-28-25(26)27)22(32)30-19-11-6-3-7-12-19/h2-7,9-12,17,20-21,29H,8,13-16H2,1H3,(H,30,32)(H,31,33)(H,34,35)(H4,26,27,28)/p+1/t17-,20+,21+/m1/s1	HDGWGGCPTVXRNA-QMMLZNLJSA-O			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.3141 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	7	7	No	2	1	173.54 Å2	51.92 Å3	144.99 m3·mol-1	14	No	No	0.00483 mg/mL	0.27	-5	7.46	10.87			
C20H26N6O4S	Not Available	Not Available	446.523	[H]N([H])C(=NCCC[C@H](N([H])C(=O)[C@@H]1C[C@@H](O)CN1C(C)=O)C(=O)C1=NC2=CC=CC=C2S1)N([H])[H]	Solid	Not Available					50228764		CHEMBL256892	4449928						ABB			5287596	46509114					ZINC000003916454		RWJ-56423	Experimental	DB02812	InChI=1S/C20H26N6O4S/c1-11(27)26-10-12(28)9-15(26)18(30)24-14(6-4-8-23-20(21)22)17(29)19-25-13-5-2-3-7-16(13)31-19/h2-3,5,7,12,14-15,28H,4,6,8-10H2,1H3,(H,24,30)(H4,21,22,23)/t12-,14+,15+/m1/s1	VXDAVYUFYPFGDX-SNPRPXQTSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.5098 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	8	4	Yes	3	1	164 Å2	46.34 Å3	113.74 m3·mol-1	8	Yes	No	0.144 mg/mL	-1.1	-3.5	12.27	11.05			
C18H31N3O6	Not Available	Not Available	385.4552	[H][C@](O)(CC(=O)N[C@]([H])(C(=O)N1CCC[C@@]1([H])C(O)=O)[C@@]([H])(C)CC)C(=O)NCCC	Solid	Not Available								4449798						074			5287408	46507264					ZINC000015894720		N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline	Experimental	DB02855	InChI=1S/C18H31N3O6/c1-4-8-19-16(24)13(22)10-14(23)20-15(11(3)5-2)17(25)21-9-6-7-12(21)18(26)27/h11-13,15,22H,4-10H2,1-3H3,(H,19,24)(H,20,23)(H,26,27)/t11-,12-,13-,15-/m0/s1	UDNIFTKCMDIXFC-ABHRYQDASA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.5003 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	6	4	No	1	-1	136.04 Å2	40.28 Å3	96.75 m3·mol-1	10	Yes	No	8.23 mg/mL	-0.29	-1.7	3.86	-2.3			
C17H25N3O5S	Not Available	Not Available	383.463	[H]N([H])CCCC(=O)N([H])[C@@H](CSCC1=CC=C(OC)C=C1)C(=O)N([H])CC(O)=O	Solid	Not Available	P08263	GSTA1	1. Glutathione S-transferase A1					394838						ABY			447867	46506921					ZINC000006484319		N-(4-Aminobutanoyl)-S-(4-methoxybenzyl)-L-cysteinylglycine	Experimental	DB02943	InChI=1S/C17H25N3O5S/c1-25-13-6-4-12(5-7-13)10-26-11-14(17(24)19-9-16(22)23)20-15(21)3-2-8-18/h4-7,14H,2-3,8-11,18H2,1H3,(H,19,24)(H,20,21)(H,22,23)/t14-/m0/s1	OMOPDEZZBQHMGS-AWEZNQCLSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1044 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	4	No	1	0	130.75 Å2	40.92 Å3	99.06 m3·mol-1	12	Yes	No		-2.6		3.36	9.99	P08263	GSTA1	1. Glutathione S-transferase A1
C13H21N3O7S2	Not Available	Not Available	395.452	[H]N([H])[C@@H](CCCC(=O)N([H])[C@@H]1C(=O)N([C@H](C[S@](C)=O)C(O)=O)[C@]1([H])S)C(O)=O	Solid	Not Available								7874544						ACS			9600398	46506055					ZINC000033774367		(2S)-2-amino-6-[[(3R,4R)-1-[(1S)-1-carboxy-2-[(S)-methylsulfinyl]ethyl]-2-oxo-4-sulfanylazetidin-3-yl]amino]-6-oxohexanoic acid	Experimental	DB03004	InChI=1S/C13H21N3O7S2/c1-25(23)5-7(13(21)22)16-10(18)9(11(16)24)15-8(17)4-2-3-6(14)12(19)20/h6-7,9,11,24H,2-5,14H2,1H3,(H,15,17)(H,19,20)(H,21,22)/t6-,7+,9+,11+,25-/m0/s1	UFLVUEXXBDLOEJ-QUNHDKFLSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.4253 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	8	5	No	1	-1	167.1 Å2	37.99 Å3	90 m3·mol-1	10	Yes	No	1.63 mg/mL	-5.5	-2.4	1.85	9.49			
C18H33N3O6S	Not Available	Not Available	419.536	CCCCCCCCSC[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)NCC(O)=O	Solid	Not Available								391395				C11302		GTY			443115	46508495					ZINC000008234408		S-octylglutathione	Experimental	DB03032	InChI=1S/C18H33N3O6S/c1-2-3-4-5-6-7-10-28-12-14(17(25)20-11-16(23)24)21-15(22)9-8-13(19)18(26)27/h13-14H,2-12,19H2,1H3,(H,20,25)(H,21,22)(H,23,24)(H,26,27)/t13-,14-/m0/s1	MJWCZWAVSJZQNL-KBPBESRZSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1495 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	5	No	0	-1	158.82 Å2	45.91 Å3	106.09 m3·mol-1	17	Yes	No	0.0341 mg/mL	-1.5	-4.1	1.81	9.31	Q03013	GSTM4	1. Glutathione S-transferase Mu 4
C33H33N3O6	Not Available	Not Available	567.6316	CC(=O)N\C(=C/C1=CC=C(CC(O)=O)C(C=O)=C1)C(=O)N[C@H]1CCCCN(CC2=CC=C(C=C2)C2=CC=CC=C2)C1=O	Solid	Not Available					14698		CHEMBL356002	4449905						821			5287555	46504640					ZINC000014880609		2-[4-[(Z)-2-Acetamido-3-oxo-3-[[(3S)-2-oxo-1-[(4-phenylphenyl)methyl]azepan-3-yl]amino]prop-1-enyl]-2-formylphenyl]acetic acid	Experimental	DB03104	InChI=1S/C33H33N3O6/c1-22(38)34-30(18-24-12-15-27(19-31(39)40)28(17-24)21-37)32(41)35-29-9-5-6-16-36(33(29)42)20-23-10-13-26(14-11-23)25-7-3-2-4-8-25/h2-4,7-8,10-15,17-18,21,29H,5-6,9,16,19-20H2,1H3,(H,34,38)(H,35,41)(H,39,40)/b30-18-/t29-/m0/s1	NKMPOVPTYDXGEC-MNRBYUMSSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.3759 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	No	6	3	Yes	4	-1	132.88 Å2	62.12 Å3	160.08 m3·mol-1	10	No	No	0.000515 mg/mL	3.12	-6	3.71	-0.78	P12931	SRC	1. Proto-oncogene tyrosine-protein kinase Src
C32H33N3O6	Not Available	Not Available	555.6209	CC(=O)N[C@@H](CC1=CC(C=O)=C(C=C1)C(O)=O)C(=O)N[C@H]1CCCCN(CC2=CC=C(C=C2)C2=CC=CC=C2)C1=O	Solid	Not Available					14696		CHEMBL358866	4449823						197			5287443	46508717					ZINC000014880680		RU82197	Experimental	DB03268	InChI=1S/C32H33N3O6/c1-21(37)33-29(18-23-12-15-27(32(40)41)26(17-23)20-36)30(38)34-28-9-5-6-16-35(31(28)39)19-22-10-13-25(14-11-22)24-7-3-2-4-8-24/h2-4,7-8,10-15,17,20,28-29H,5-6,9,16,18-19H2,1H3,(H,33,37)(H,34,38)(H,40,41)/t28-,29-/m0/s1	WKTQBTSOHBKBRW-VMPREFPWSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3333 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	No	6	3	Yes	4	-1	132.88 Å2	60.24 Å3	154.46 m3·mol-1	10	No	No		3.24		4.15	-1.9	P12931	SRC	1. Proto-oncogene tyrosine-protein kinase Src
C17H34N6O5S	Not Available	Not Available	434.554	NCCCCNCCCNC(=O)CNC(=O)[C@H](CS)NC(=O)CC[C@H](N)C(O)=O	Solid	Not Available						16613		389641				C05730		TS5			440772	46505567					ZINC000003869959		Glutathionylspermidine	Experimental	DB03295	InChI=1S/C17H34N6O5S/c18-6-1-2-7-20-8-3-9-21-15(25)10-22-16(26)13(11-29)23-14(24)5-4-12(19)17(27)28/h12-13,20,29H,1-11,18-19H2,(H,21,25)(H,22,26)(H,23,24)(H,27,28)/t12-,13-/m0/s1	NEDQLXHBVHSKNV-STQMWFEESA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	1.9668 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	11	8	No	0	2	199.14 Å2	47.62 Å3	112.45 m3·mol-1	17	No	No		-8.3		1.87	10.89			
C20H32N6O12S2	Not Available	Not Available	612.631	N[C@@H](CCC(=O)N[C@@H](CSSC[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)NCC(O)=O)C(=O)NCC(O)=O)C(O)=O	Solid	Not Available					225231	17858	CHEMBL1372	58835				C00127	D00031	GDS			65359	46508372		25953		Glutathione_disulfide	ZINC000003870129	Bss Ophthalmic Solution	Glutathione disulfide	Approved, Experimental, Investigational	DB03310	InChI=1S/C20H32N6O12S2/c21-9(19(35)36)1-3-13(27)25-11(17(33)23-5-15(29)30)7-39-40-8-12(18(34)24-6-16(31)32)26-14(28)4-2-10(22)20(37)38/h9-12H,1-8,21-22H2,(H,23,33)(H,24,34)(H,25,27)(H,26,28)(H,29,30)(H,31,32)(H,35,36)(H,37,38)/t9-,10-,11-,12-/m0/s1	YPZRWBKMTBYPTK-BJDJZHNGSA-N	3	Glutathione disulfide is an ingredient of ophthalmic irrigation solutions used during ophthalmological procedures.	Not Available	Small Molecule				AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.0571 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	14	10	No	0	-2	317.64 Å2	58.47 Å3	136.65 m3·mol-1	21	No	No	0.406 mg/mL	-10	-3.2	1.44	9.61	BE0009997;!P10620;!BE0010006;!P28161;!P00390	;!MGST1;!;!GSTM2;!GSR	1. Glutathione peroxidase (Protein Group);!2. Microsomal glutathione S-transferase 1;!3. Glutathione S-transferases (Cytosolic) (Protein Group);!4. Glutathione S-transferase Mu 2;!5. Glutathione reductase, mitochondrial
C16H21N3O8S	Not Available	Not Available	415.418	[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)CCC[C@@H](N)C(O)=O)C(O)=O	Solid	Not Available						15776	CHEMBL482858	58980			HMDB0060450	C00916		CSC			65536	46505733				Cephalosporin_C	ZINC000003977881		Cephalosporin C	Experimental	DB03313	InChI=1S/C16H21N3O8S/c1-7(20)27-5-8-6-28-14-11(13(22)19(14)12(8)16(25)26)18-10(21)4-2-3-9(17)15(23)24/h9,11,14H,2-6,17H2,1H3,(H,18,21)(H,23,24)(H,25,26)/t9-,11-,14-/m1/s1	HOKIDJSKDBPKTQ-GLXFQSAKSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	1.9527 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	8	4	No	2	-1	176.33 Å2	39.7 Å3	95.43 m3·mol-1	10	Yes	No		-4.4		1.83	9.22	Q7CRA4;!Q8DR59;!P0A3M6;!Q8DNB6;!Q75Y35;!P15555	pbp1b;!pbpA;!penA;!pbp2a;!pbp3;!Not Available	1. Penicillin-binding protein 1b;!2. Penicillin-binding protein 1A;!3. Penicillin-binding protein 2B;!4. Penicillin-binding protein 2a;!5. Penicillin-binding protein 3;!6. D-alanyl-D-alanine carboxypeptidase
C18H32N2O7	Not Available	Not Available	388.4559	[H]N([C@H]1CC[C@@H](O)CN([H])C1=O)C(=O)[C@H](OC)[C@H](O)[C@@H](O)[C@H](O)\C=C\C(C)(C)C	Solid	Not Available								395101						TDE			448235	46507692					ZINC000005884811		(2R,3R,4S,5R,6E)-3,4,5-Trihydroxy-N-[(3S,6R)-6-hydroxy-2-oxo-3-azepanyl]-2-methoxy-8,8-dimethyl-6-nonenamide	Experimental	DB03396	InChI=1S/C18H32N2O7/c1-18(2,3)8-7-12(22)13(23)14(24)15(27-4)17(26)20-11-6-5-10(21)9-19-16(11)25/h7-8,10-15,21-24H,5-6,9H2,1-4H3,(H,19,25)(H,20,26)/b8-7+/t10-,11+,12-,13+,14-,15-/m1/s1	FVBBTOIQETYGOA-SDNORSGYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.4992 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	6	No	1	0	148.35 Å2	41.34 Å3	97.96 m3·mol-1	8	No	No	10.9 mg/mL	-1.6	-1.6	12.15	-2.9	P50579	METAP2	1. Methionine aminopeptidase 2
C32H42N4O7	Not Available	Not Available	594.6985	[H]N([C@@H](CC(C)C)C(=O)N([H])[C@@H]1CN(CC1=O)C(=O)[C@H](CC(C)C)N([H])C(=O)OCC1=CC=CC=C1)C(=O)OCC1=CC=CC=C1	Solid	Not Available								4451150						PCM			5289122	46506182					ZINC000014096696		N2-[(Benzyloxy)carbonyl]-N-[(3R)-1-{N-[(benzyloxy)carbonyl]-L-leucyl}-4-oxo-3-pyrrolidinyl]-L-leucinamide	Experimental	DB03405	InChI=1S/C32H42N4O7/c1-21(2)15-25(34-31(40)42-19-23-11-7-5-8-12-23)29(38)33-27-17-36(18-28(27)37)30(39)26(16-22(3)4)35-32(41)43-20-24-13-9-6-10-14-24/h5-14,21-22,25-27H,15-20H2,1-4H3,(H,33,38)(H,34,40)(H,35,41)/t25-,26-,27+/m0/s1	GXENQLUSOCKXDN-GMQQYTKMSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.7478 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										0	No	5	3	Yes	3	0	143.14 Å2	64.46 Å3	158.89 m3·mol-1	15	No	No	0.0045 mg/mL	4.28	-5.1	12.3	-3.4			
C8H14N2O5S	Not Available	Not Available	250.272	N[C@@H](CCC(=O)N[C@@H](CS)C(O)=O)C(O)=O	Solid	Not Available						17515	CHEMBL460831	110467			HMDB0001049	C00669		3GC			123938	46506032				Gamma-Glutamylcysteine	ZINC000003870040		gamma-Glutamylcysteine	Experimental	DB03408	InChI=1S/C8H14N2O5S/c9-4(7(12)13)1-2-6(11)10-5(3-16)8(14)15/h4-5,16H,1-3,9H2,(H,10,11)(H,12,13)(H,14,15)/t4-,5-/m0/s1	RITKHVBHSGLULN-WHFBIAKZSA-N			Not Available	Small Molecule	http://smpdb.ca/view/SMP0000072?highlight[compounds][]=DB03408&highlight[proteins][]=DB03408;!http://smpdb.ca/view/SMP0000339?highlight[compounds][]=DB03408&highlight[proteins][]=DB03408;!http://smpdb.ca/view/SMP0000501?highlight[compounds][]=DB03408&highlight[proteins][]=DB03408;!http://smpdb.ca/view/SMP0000136?highlight[compounds][]=DB03408&highlight[proteins][]=DB03408;!http://smpdb.ca/view/SMP0000183?highlight[compounds][]=DB03408&highlight[proteins][]=DB03408;!http://smpdb.ca/view/SMP0000243?highlight[compounds][]=DB03408&highlight[proteins][]=DB03408;!http://smpdb.ca/view/SMP0000499?highlight[compounds][]=DB03408&highlight[proteins][]=DB03408;!http://smpdb.ca/view/SMP0000500?highlight[compounds][]=DB03408&highlight[proteins][]=DB03408;!http://smpdb.ca/view/SMP0000567?highlight[compounds][]=DB03408&highlight[proteins][]=DB03408;!http://smpdb.ca/view/SMP0000013?highlight[compounds][]=DB03408&highlight[proteins][]=DB03408;!http://smpdb.ca/view/SMP0000015?highlight[compounds][]=DB03408&highlight[proteins][]=DB03408;!http://smpdb.ca/view/SMP0000143?highlight[compounds][]=DB03408&highlight[proteins][]=DB03408;!http://smpdb.ca/view/SMP0000337?highlight[compounds][]=DB03408&highlight[proteins][]=DB03408;!http://smpdb.ca/view/SMP0000385?highlight[compounds][]=DB03408&highlight[proteins][]=DB03408;!http://smpdb.ca/view/SMP0000722?highlight[compounds][]=DB03408&highlight[proteins][]=DB03408	Glutamate Metabolism;!Hyperinsulinism-Hyperammonemia Syndrome;!gamma-Glutamyltranspeptidase Deficiency;!2-Hydroxyglutric Aciduria (D and L Form);!gamma-Glutamyltransferase Deficiency;!4-Hydroxybutyric Aciduria/Succinic Semialdehyde Dehydrogenase Deficiency;!beta-Mercaptolactate-Cysteine Disulfiduria;!5-Oxoprolinase Deficiency;!Succinic Semialdehyde Dehydrogenase Deficiency;!Cysteine Metabolism;!Glutathione Metabolism;!5-Oxoprolinuria;!Glutathione Synthetase Deficiency;!Homocarnosinosis;!Cystinosis, Ocular Nonnephropathic		AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.5829 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	5	No	0	-1	129.72 Å2	23.36 Å3	56.31 m3·mol-1	7	Yes	No	2.62 mg/mL	-3.8	-2	1.91	9.24	P48637	GSS	1. Glutathione synthetase
C18H33N7O5	Not Available	Not Available	427.4985	[H]N([H])C(=NCCC[C@@H](C=O)[C@H](N([H])C(=O)N1CCN(CC1)C(=O)N([H])C(C)(C)C)C(O)=O)N([H])[H]	Solid	Not Available								4883305						169			6323182	46509093					ZINC000012503583		(2S,3R)-2-[[4-(Tert-butylcarbamoyl)piperazine-1-carbonyl]amino]-6-(diaminomethylideneamino)-3-formylhexanoic acid	Experimental	DB03417	InChI=1S/C18H33N7O5/c1-18(2,3)23-17(30)25-9-7-24(8-10-25)16(29)22-13(14(27)28)12(11-26)5-4-6-21-15(19)20/h11-13H,4-10H2,1-3H3,(H,22,29)(H,23,30)(H,27,28)(H4,19,20,21)/t12-,13-/m0/s1	BVNQCAHTTOIOEK-STQMWFEESA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.5279 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	8	5	No	1	0	183.45 Å2	44.39 Å3	109.01 m3·mol-1	9	Yes	No		-3.6		3.43	11.57	P07477	PRSS1	1. Trypsin-1
C13H21N3O6S	Not Available	Not Available	347.387	[H]N([H])[C@@H](CCCC(=O)N([H])[C@@H](CS)C(=O)N([H])[C@H](C=C)C(O)=O)C(O)=O	Solid	Not Available								4911105						ASV			6398414	46508704					ZINC000006363128		delta-(L-alpha-Aminoadipoyl)-L-cysteinyl-D-vinylglycine	Experimental	DB03427	InChI=1S/C13H21N3O6S/c1-2-8(13(21)22)16-11(18)9(6-23)15-10(17)5-3-4-7(14)12(19)20/h2,7-9,23H,1,3-6,14H2,(H,15,17)(H,16,18)(H,19,20)(H,21,22)/t7-,8+,9-/m0/s1	JJJCGQKXGIRXKN-YIZRAAEISA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.9995 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	7	6	No	0	-1	158.82 Å2	33.47 Å3	82.62 m3·mol-1	11	No	No	0.905 mg/mL	-3.5	-2.6	1.94	9.15			
C19H26N4O3	Not Available	Not Available	358.4347	[H][C@@](CC(C)C)(NC(=O)OCC1=CC=CC=C1)C(=O)N[C@]1([H])CCN(C1)C#N	Solid	Not Available								4451045						NBL			5288988	46504451					ZINC000012503669		N2-[(benzyloxy)carbonyl]-n1-[(3S)-1-cyanopyrrolidin-3-yl]-l-leucinamide	Experimental	DB03456	InChI=1S/C19H26N4O3/c1-14(2)10-17(18(24)21-16-8-9-23(11-16)13-20)22-19(25)26-12-15-6-4-3-5-7-15/h3-7,14,16-17H,8-12H2,1-2H3,(H,21,24)(H,22,25)/t16-,17+/m1/s1	IMTUSTXBVIALBC-SJORKVTESA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.4411 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	2	No	2	0	94.46 Å2	38.51 Å3	98.11 m3·mol-1	8	Yes	No	0.137 mg/mL	2.2	-3.4	13.45	-3.1	P43235	CTSK	1. Cathepsin K
C18H22N2O4	Not Available	Not Available	330.3783	[H][C@]1(CCCN1C(=O)[C@]1([H])CCCN1C(=O)OCC1=CC=CC=C1)C=O	Solid	Not Available					50038879		CHEMBL79993	109328						ZPR			122623	46507956					ZINC000003803443		Z-Pro-Prolinal	Experimental	DB03535	InChI=1S/C18H22N2O4/c21-12-15-8-4-10-19(15)17(22)16-9-5-11-20(16)18(23)24-13-14-6-2-1-3-7-14/h1-3,6-7,12,15-16H,4-5,8-11,13H2/t15-,16-/m0/s1	ORZXYSPOAVJYRU-HOTGVXAUSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Non-substrate	2.2069 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	0	No	3	0	66.92 Å2	34.45 Å3	87.93 m3·mol-1	5	Yes	No	1.53 mg/mL	1.43	-2.3	17.96	-4			
C18H28FN5O4	Not Available	Not Available	397.4444	C[C@H](NC(=O)[C@H](CCCNC(N)N)NC(=O)OCC1=CC=CC=C1)C(=O)CF	Solid	Not Available								59051958						ZRA			131704251	46504937					ZINC000098209677		Benzyl N-[(2S)-5-(diaminomethylamino)-1-[[(2S)-4-fluoro-3-oxobutan-2-yl]amino]-1-oxopentan-2-yl]carbamate	Experimental	DB03536	InChI=1S/C18H28FN5O4/c1-12(15(25)10-19)23-16(26)14(8-5-9-22-17(20)21)24-18(27)28-11-13-6-3-2-4-7-13/h2-4,6-7,12,14,17,22H,5,8-11,20-21H2,1H3,(H,23,26)(H,24,27)/t12-,14-/m0/s1	FAAPWXRBXXSQNJ-JSGCOSHPSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1716 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	6	5	No	1	0	148.57 Å2	41.24 Å3	100.66 m3·mol-1	13	Yes	No	0.28 mg/mL	0.43	-3.2	12.73	6.71	Q9UBX1;!P25779	CTSF;!Not Available	1. Cathepsin F;!2. Cruzipain
C14H21N3O6S	Not Available	Not Available	359.398	[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CCC[C@H](N)C(O)=O)C(O)=O	Solid	Not Available						18165		389596				C05557		IP1			440723	46504620					ZINC000004096831		Isopenicillin N	Experimental	DB03550	InChI=1S/C14H21N3O6S/c1-14(2)9(13(22)23)17-10(19)8(11(17)24-14)16-7(18)5-3-4-6(15)12(20)21/h6,8-9,11H,3-5,15H2,1-2H3,(H,16,18)(H,20,21)(H,22,23)/t6-,8+,9-,11+/m0/s1	MIFYHUACUWQUKT-GTQWGBSQSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	1.9690 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	4	No	2	-1	150.03 Å2	35.64 Å3	83.05 m3·mol-1	7	Yes	No	8.96 mg/mL	-3.4	-1.6	1.83	9.23			
C20H25N3O10S	Not Available	Not Available	499.492	OC(=O)CCNC(=O)[C@H]1CCCN1S(=O)(=O)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O	Solid	Not Available					50149206		CHEMBL418875	393129						TP4			445506	46504915					ZINC000003874330		SP-876	Experimental	DB03558	InChI=1S/C20H25N3O10S/c24-16(25)8-7-14(20(30)31)22-18(28)12-3-5-13(6-4-12)34(32,33)23-11-1-2-15(23)19(29)21-10-9-17(26)27/h3-6,14-15H,1-2,7-11H2,(H,21,29)(H,22,28)(H,24,25)(H,26,27)(H,30,31)/t14-,15+/m0/s1	SRAHBOKVSSZEHQ-LSDHHAIUSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.2885 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	10	5	No	2	-3	207.48 Å2	48.09 Å3	114.23 m3·mol-1	11	Yes	No	0.353 mg/mL	-0.98	-3.2	2.58	-1.5	P0A884	thyA	1. Thymidylate synthase
C19H28N2O5	Not Available	Not Available	364.436	[H][C@](O)(CC(O)=O)C(=O)N[C@]([H])(CCC1=CC=CC=C1)C(=O)NCCC(C)C	Solid	Not Available								4451259						R99			5289258	46505552					ZINC000012503755		WRR-99	Experimental	DB03573	InChI=1S/C19H28N2O5/c1-13(2)10-11-20-18(25)15(9-8-14-6-4-3-5-7-14)21-19(26)16(22)12-17(23)24/h3-7,13,15-16,22H,8-12H2,1-2H3,(H,20,25)(H,21,26)(H,23,24)/t15-,16+/m1/s1	KVZMXOVSHIMGNA-CVEARBPZSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.9502 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	4	No	1	-1	115.73 Å2	39.79 Å3	96.53 m3·mol-1	11	Yes	No	0.149 mg/mL	1.48	-3.4	4	-3.4	Q9UBX1;!P25779	CTSF;!Not Available	1. Cathepsin F;!2. Cruzipain
C9H16N2O5	Not Available	Not Available	232.2337	NCCC[C@H](NC(=O)CCC(O)=O)C(O)=O	Solid	Not Available						27574		113025			HMDB0001199	C03415		SUO			127370	46507657							N~2~-Succinylornithine	Experimental	DB03582	InChI=1S/C9H16N2O5/c10-5-1-2-6(9(15)16)11-7(12)3-4-8(13)14/h6H,1-5,10H2,(H,11,12)(H,13,14)(H,15,16)/t6-/m0/s1	VWXQFHJBQHTHMK-LURJTMIESA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.2995 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	4	No	0	-1	129.72 Å2	22.77 Å3	53.55 m3·mol-1	8	Yes	No	19.3 mg/mL	-4.1	-1.1	3.32	9.9	P76216	astB	1. N-succinylarginine dihydrolase
C17H22IN3O6S	Not Available	Not Available	523.343	[H]N([H])[C@@H](CCC(=O)N([H])[C@@H](CSCC1=CC=CC=C1I)C(=O)N([H])CC(O)=O)C(O)=O	Solid	Not Available								394293						IBG			447108	46508001					ZINC000014880825		gamma-Glutamyl[S-(2-iodobenzyl)cysteinyl]glycine	Experimental	DB03597	InChI=1S/C17H22IN3O6S/c18-11-4-2-1-3-10(11)8-28-9-13(16(25)20-7-15(23)24)21-14(22)6-5-12(19)17(26)27/h1-4,12-13H,5-9,19H2,(H,20,25)(H,21,22)(H,23,24)(H,26,27)/t12-,13-/m0/s1	QFYJAEOZTBVJQM-STQMWFEESA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.2538 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	7	5	No	1	-1	158.82 Å2	45.41 Å3	111.79 m3·mol-1	12	No	No	0.0301 mg/mL	-2	-4.2	1.81	9.31	O76074;!Q03013;!O76083	PDE5A;!GSTM4;!PDE9A	1. cGMP-specific 3',5'-cyclic phosphodiesterase;!2. Glutathione S-transferase Mu 4;!3. High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A
C17H23N3O6S	Not Available	Not Available	397.446	[H]N([H])[C@@H](CCC(=O)N([H])[C@@H](CSCC1=CC=CC=C1)C(=O)N([H])CC(O)=O)C(O)=O	Solid	Not Available	P08263	GSTA1	1. Glutathione S-transferase A1					393264						GSB			445707	46507389					ZINC000003874918		S-benzylglutathione	Experimental	DB03602	InChI=1S/C17H23N3O6S/c18-12(17(25)26)6-7-14(21)20-13(16(24)19-8-15(22)23)10-27-9-11-4-2-1-3-5-11/h1-5,12-13H,6-10,18H2,(H,19,24)(H,20,21)(H,22,23)(H,25,26)/t12-,13-/m0/s1	XYJWEQWNNKNSFU-STQMWFEESA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.8241 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	5	No	1	-1	158.82 Å2	40.51 Å3	98.43 m3·mol-1	12	Yes	No	0.116 mg/mL	-2.9	-3.5	1.81	9.31	Q04760;!P08263	GLO1;!GSTA1	1. Lactoylglutathione lyase;!2. Glutathione S-transferase A1
C17H22N4O8S	Not Available	Not Available	442.444	N[C@@H](CCC(=O)N[C@@H](CSCC1=CC=C(C=C1)[N+]([O-])=O)C(=O)NCC(O)=O)C(O)=O	Solid	Not Available						87407		88035						GTB			97538	46508527					ZINC000003874914		S-(4-nitrobenzyl)glutathione	Experimental	DB03686	InChI=1S/C17H22N4O8S/c18-12(17(26)27)5-6-14(22)20-13(16(25)19-7-15(23)24)9-30-8-10-1-3-11(4-2-10)21(28)29/h1-4,12-13H,5-9,18H2,(H,19,25)(H,20,22)(H,23,24)(H,26,27)/t12-,13-/m0/s1	OAWORKDPTSAMBZ-STQMWFEESA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.5268 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	9	5	No	1	-1	201.96 Å2	43 Å3	104.75 m3·mol-1	13	Yes	No		-3		1.81	9.31	P09211	GSTP1	1. Glutathione S-transferase P
C19H28N2O5	Not Available	Not Available	364.436	[H][C@](O)(CC(O)=O)C(=O)N[C@@]([H])(CCC1=CC=CC=C1)C(=O)NCCC(C)C	Solid	Not Available								4451288						RL2			5289294	46504442					ZINC000012503756		WRR-112	Experimental	DB03691	InChI=1S/C19H28N2O5/c1-13(2)10-11-20-18(25)15(9-8-14-6-4-3-5-7-14)21-19(26)16(22)12-17(23)24/h3-7,13,15-16,22H,8-12H2,1-2H3,(H,20,25)(H,21,26)(H,23,24)/t15-,16-/m0/s1	KVZMXOVSHIMGNA-HOTGVXAUSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.9502 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	4	No	1	-1	115.73 Å2	39.76 Å3	96.53 m3·mol-1	11	Yes	No	0.149 mg/mL	1.48	-3.4	4	-3.4	Q9UBX1;!P25779	CTSF;!Not Available	1. Cathepsin F;!2. Cruzipain
C26H33F3N4O7	Not Available	Not Available	570.558	[H]N(CC(O)=O)C(=O)C1=CC=C(C=C1)C(=O)N([H])[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N([H])[C@@H](C(C)C)C(=O)C(F)(F)F	Solid	Not Available								4450441						FR1			5288240	46508719					ZINC000003951728		N-{4-[(Carboxymethyl)carbamoyl]benzoyl}-L-valyl-N-[(3S)-1,1,1-trifluoro-4-methyl-2-oxo-3-pentanyl]-L-prolinamide	Experimental	DB03702	InChI=1S/C26H33F3N4O7/c1-13(2)19(21(36)26(27,28)29)31-24(39)17-6-5-11-33(17)25(40)20(14(3)4)32-23(38)16-9-7-15(8-10-16)22(37)30-12-18(34)35/h7-10,13-14,17,19-20H,5-6,11-12H2,1-4H3,(H,30,37)(H,31,39)(H,32,38)(H,34,35)/t17-,19-,20-/m0/s1	MRTSIBBMOWLRPY-IHPCNDPISA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.4914 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	7	4	No	2	-1	161.98 Å2	54.27 Å3	135.51 m3·mol-1	12	No	No	0.00627 mg/mL	2.08	-5	3.08	-1	Q9UNI1	CELA1	1. Chymotrypsin-like elastase family member 1
C33H35N3O7	Not Available	Not Available	585.6469	CC(=O)N[C@@H](CC1=CC(C(O)=O)=C(CC(O)=O)C=C1)C(=O)N[C@H]1CCCCN(CC2=CC=C(C=C2)C2=CC=CC=C2)C1=O	Solid	Not Available					14694		CHEMBL432359	394587						853			447524	46505930					ZINC000014880878		RU85053	Experimental	DB03712	InChI=1S/C33H35N3O7/c1-21(37)34-29(18-23-12-15-26(19-30(38)39)27(17-23)33(42)43)31(40)35-28-9-5-6-16-36(32(28)41)20-22-10-13-25(14-11-22)24-7-3-2-4-8-24/h2-4,7-8,10-15,17,28-29H,5-6,9,16,18-20H2,1H3,(H,34,37)(H,35,40)(H,38,39)(H,42,43)/t28-,29-/m0/s1	CEKLBQMULVLLTD-VMPREFPWSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.3451 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										0	No	7	4	Yes	4	-2	153.11 Å2	62.6 Å3	159.18 m3·mol-1	11	No	No		3.16		3.41	-1.9			
C21H30N4O4	Not Available	Not Available	402.4873	[H][C@@](COCC1=CC=CC=C1)(NC(=O)[C@]([H])(CC(C)C)NC(=O)N1CCOCC1)C#N	Solid	Not Available					50121548		CHEMBL153813	4450096						BLN			5287799	46508762					ZINC000006616189		Morpholine-4-Carboxylic Acid [1s-(2-Benzyloxy-1r-Cyano-Ethylcarbamoyl)-3-Methyl-Butyl]Amide	Experimental	DB03767	InChI=1S/C21H30N4O4/c1-16(2)12-19(24-21(27)25-8-10-28-11-9-25)20(26)23-18(13-22)15-29-14-17-6-4-3-5-7-17/h3-7,16,18-19H,8-12,14-15H2,1-2H3,(H,23,26)(H,24,27)/t18-,19+/m1/s1	LXEDKIMJQBOMSU-MOPGFXCFSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.4503 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	5	2	No	2	0	103.69 Å2	42.5 Å3	108.34 m3·mol-1	9	Yes	No	0.126 mg/mL	1.23	-3.5	11.75	-1.7			
C14H20N2O3S2	Not Available	Not Available	328.45	[H][C@@]1(CCCN1S(=O)(=O)C1=CC=C(C)C=C1)C(=O)NCCS	Solid	Not Available								393126						TP2			445503	46507357					ZINC000005889105		N-[Tosyl-D-Prolinyl]Amino-Ethanethiol	Experimental	DB03818	InChI=1S/C14H20N2O3S2/c1-11-4-6-12(7-5-11)21(18,19)16-9-2-3-13(16)14(17)15-8-10-20/h4-7,13,20H,2-3,8-10H2,1H3,(H,15,17)/t13-/m1/s1	NWUYDTGYTUQMDG-CYBMUJFWSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.2554 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	2	No	2	0	66.48 Å2	34.27 Å3	85.62 m3·mol-1	4	Yes	No	0.218 mg/mL	1.46	-3.2	10.07	-4.3	P0A884	thyA	1. Thymidylate synthase
C17H25N4O7S	Not Available	Not Available	429.468	[H]N([C@@H](CCCCC(=O)N([H])[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@]12[H])C([O-])=O)C(=O)C[N+]([H])([H])[H]	Solid	Not Available								4450683						HEL			131704259	46504856							(2S,5R,6R)-6-({(6S)-6-[(Ammonioacetyl)amino]-6-carboxylatohexanoyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate	Experimental	DB03820	InChI=1S/C17H26N4O7S/c1-17(2)12(16(27)28)21-13(24)11(14(21)29-17)20-9(22)6-4-3-5-8(15(25)26)19-10(23)7-18/h8,11-12,14H,3-7,18H2,1-2H3,(H,19,23)(H,20,22)(H,25,26)(H,27,28)/p-1/t8-,11+,12-,14+/m0/s1	LDJWRKFRKCXUDO-RBQWDTSBSA-M			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.1677 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	3	No	2	-1	186.41 Å2	41.8 Å3	133.42 m3·mol-1	10	Yes	No	1.97 mg/mL	-4.2	-2.4	3.09	8.14	P15555	Not Available	1. D-alanyl-D-alanine carboxypeptidase
C21H25N3O6S	Not Available	Not Available	447.505	[H]N([H])[C@@H](CCC(=O)N([H])[C@@H](CSCC1=CC=CC2=CC=CC=C12)C(=O)N([H])CC(O)=O)C(O)=O	Solid	Not Available								395998						GGC			449471	46505686					ZINC000012504001		L-gamma-glutamyl-S-(naphthalen-1-ylmethyl)-L-cysteinylglycine	Experimental	DB03885	InChI=1S/C21H25N3O6S/c22-16(21(29)30)8-9-18(25)24-17(20(28)23-10-19(26)27)12-31-11-14-6-3-5-13-4-1-2-7-15(13)14/h1-7,16-17H,8-12,22H2,(H,23,28)(H,24,25)(H,26,27)(H,29,30)/t16-,17-/m0/s1	IHZCIRSQSFPOLH-IRXDYDNUSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.0967 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	5	No	2	-1	158.82 Å2	46.15 Å3	114.88 m3·mol-1	12	Yes	No		-1.9		1.81	9.31			
C12H21N3O6	Not Available	Not Available	303.3116	[H]N([H])CC(=O)N([H])[C@@H](CCCCC(=O)N([H])[C@H](C)C(O)=O)C(O)=O	Solid	Not Available								393700						REY			446307	46506012					ZINC000003581164		Glycyl-L-alpha-amino-epsilon-pimelyl-D-alanine	Experimental	DB03927	InChI=1S/C12H21N3O6/c1-7(11(18)19)14-9(16)5-3-2-4-8(12(20)21)15-10(17)6-13/h7-8H,2-6,13H2,1H3,(H,14,16)(H,15,17)(H,18,19)(H,20,21)/t7-,8+/m1/s1	ZMQJQOKNTYQVHO-SFYZADRCSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	1.7329 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	5	No	0	-1	158.82 Å2	30.14 Å3	70.59 m3·mol-1	10	Yes	No		-4.3		3.28	8.14	P15555	Not Available	1. D-alanyl-D-alanine carboxypeptidase
C14H19N3O6S	Not Available	Not Available	357.382	[H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)CCC[C@@H](N)C(O)=O)C(O)=O	Solid	Not Available						18229		140762				C06565		P1C			160139	46509194							Deacetoxycephalosporin C	Experimental	DB03938	InChI=1S/C14H19N3O6S/c1-6-5-24-12-9(11(19)17(12)10(6)14(22)23)16-8(18)4-2-3-7(15)13(20)21/h7,9,12H,2-5,15H2,1H3,(H,16,18)(H,20,21)(H,22,23)/t7-,9-,12-/m1/s1	NNQIJOYQWYKBOW-JWKOBGCHSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	1.8680 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	4	No	2	-1	150.03 Å2	34.95 Å3	84.5 m3·mol-1	7	Yes	No	2.51 mg/mL	-3.5	-2.2	1.84	9.23	P18548	cefE	1. Deacetoxycephalosporin C synthase
C18H26N2O5S2	Not Available	Not Available	414.539	[H][C@@](CC(C)C)(NC(=O)[C@]1([H])CSCCN1S(=O)(=O)C1=CC=C(C)C=C1)C(O)=O	Solid	Not Available								393777						TST			446411	46506052					ZINC000006522612		(3r)-4-(P-Toluenesulfonyl)-1,4-Thiazane-3-Carboxylicacid-L-Leucine	Experimental	DB04012	InChI=1S/C18H26N2O5S2/c1-12(2)10-15(18(22)23)19-17(21)16-11-26-9-8-20(16)27(24,25)14-6-4-13(3)5-7-14/h4-7,12,15-16H,8-11H2,1-3H3,(H,19,21)(H,22,23)/t15-,16-/m0/s1	GFEHACHKMVZGNQ-HOTGVXAUSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.4568 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	2	No	2	-1	103.78 Å2	41.18 Å3	105.21 m3·mol-1	6	Yes	No	0.0655 mg/mL	2.31	-3.8	3.37	-4.9	P62942	FKBP1A	1. Peptidyl-prolyl cis-trans isomerase FKBP1A
C16H20N2O5	Not Available	Not Available	320.3404	[H][C@@](C)(NC(=O)OCC1=CC=CC=C1)C(=O)N1CCC[C@@]1([H])C(O)=O	Solid	Not Available								4534974						ZAH			5388928	46508805					ZINC000001575977		Z-Ala Prolinal	Experimental	DB04033	InChI=1S/C16H20N2O5/c1-11(14(19)18-9-5-8-13(18)15(20)21)17-16(22)23-10-12-6-3-2-4-7-12/h2-4,6-7,11,13H,5,8-10H2,1H3,(H,17,22)(H,20,21)/t11-,13-/m0/s1	RSSOZTMMMIWOJB-AAEUAGOBSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	1.9366 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	2	No	2	-1	95.94 Å2	32.82 Å3	81.16 m3·mol-1	6	Yes	No	0.897 mg/mL	1.32	-2.6	3.63	-4.4	Q9X5N2	pep	1. Prolyl endopeptidase Pep
C23H33N5O5	Not Available	Not Available	459.5386	C[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1)C(N)=O	Solid	Not Available					50078401		CHEMBL311875	394420									447280	46504972							Apstatin	Experimental	DB04092	InChI=1S/C23H33N5O5/c1-14(20(25)30)26-21(31)17-9-5-11-27(17)22(32)18-10-6-12-28(18)23(33)19(29)16(24)13-15-7-3-2-4-8-15/h2-4,7-8,14,16-19,29H,5-6,9-13,24H2,1H3,(H2,25,30)(H,26,31)/t14-,16+,17-,18-,19-/m0/s1	YVUUZAPYLPWFHE-HXFGRODQSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1807 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	4	Yes	3	1	159.06 Å2	47.91 Å3	120.17 m3·mol-1	8	Yes	No	1.92 mg/mL	-1.4	-2.4	12.11	8.35	P15034	pepP	1. Xaa-Pro aminopeptidase
C15H28N2O5	Not Available	Not Available	316.3932	[H][C@](O)(CC(O)=O)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCCC(C)C	Solid	Not Available								4450373						E6C			5288147	46505427					ZINC000003874327		N-[1-Hydroxycarboxyethyl-Carbonyl]Leucylamino-2-Methyl-Butane	Experimental	DB04126	InChI=1S/C15H28N2O5/c1-9(2)5-6-16-14(21)11(7-10(3)4)17-15(22)12(18)8-13(19)20/h9-12,18H,5-8H2,1-4H3,(H,16,21)(H,17,22)(H,19,20)/t11-,12-/m0/s1	KBIWEWPGBHKYML-RYUDHWBXSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.0096 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	4	No	0	-1	115.73 Å2	34.67 Å3	80.99 m3·mol-1	10	Yes	No	2.42 mg/mL	0.63	-2.1	4.25	-2.8	P07858;!P09668	CTSB;!CTSH	1. Cathepsin B;!2. Pro-cathepsin H
C16H29N3O6S	Not Available	Not Available	391.483	CCCCCCSC[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)NCC(O)=O	Solid	Not Available	P08263	GSTA1	1. Glutathione S-transferase A1		50095998	27704	CHEMBL345292	88033				C02886		LEE			97536	46505872			DNC001323		ZINC000003874923		S-Hexylglutathione	Experimental	DB04132	InChI=1S/C16H29N3O6S/c1-2-3-4-5-8-26-10-12(15(23)18-9-14(21)22)19-13(20)7-6-11(17)16(24)25/h11-12H,2-10,17H2,1H3,(H,18,23)(H,19,20)(H,21,22)(H,24,25)/t11-,12-/m0/s1	HXJDWCWJDCOHDG-RYUDHWBXSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.1333 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	5	No	0	-1	158.82 Å2	42.03 Å3	96.89 m3·mol-1	15	Yes	No	0.146 mg/mL	-2.4	-3.4	1.81	9.31	Q04760;!Q03013;!P09211;!Q8MU52;!P08263;!P0CG29	GLO1;!GSTM4;!GSTP1;!GST;!GSTA1;!GSTT2	1. Lactoylglutathione lyase;!2. Glutathione S-transferase Mu 4;!3. Glutathione S-transferase P;!4. Glutathione S-transferase;!5. Glutathione S-transferase A1;!6. Glutathione S-transferase theta-2
C11H19N3O7S	Not Available	Not Available	337.349	N[C@@H](CCC(=O)N[C@@H](CSCO)C(=O)NCC(O)=O)C(O)=O	Solid	Not Available						48926		394301			HMDB0004662	C14180		AHE			447123	46507088					ZINC000003870218		S-Hydroxymethyl Glutathione	Experimental	DB04153	InChI=1S/C11H19N3O7S/c12-6(11(20)21)1-2-8(16)14-7(4-22-5-15)10(19)13-3-9(17)18/h6-7,15H,1-5,12H2,(H,13,19)(H,14,16)(H,17,18)(H,20,21)/t6-,7-/m0/s1	PIUSLWSYOYFRFR-BQBZGAKWSA-N			Not Available	Small Molecule				AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.9135 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	8	6	No	0	-1	179.05 Å2	32.23 Å3	75.2 m3·mol-1	11	No	No	5.27 mg/mL	-5.5	-1.8	1.79	9.31	P11766	ADH5	1. Alcohol dehydrogenase class-3
C7H12N2O4	Not Available	Not Available	188.1812	CC(=O)N[C@@H](CCC(N)=O)C(O)=O	Solid	Not Available						21553		158492						NLQ			182230	46508739		1426379		Aceglutamide	ZINC000002019886		Aceglutamide	Experimental	DB04167	InChI=1S/C7H12N2O4/c1-4(10)9-5(7(12)13)2-3-6(8)11/h5H,2-3H2,1H3,(H2,8,11)(H,9,10)(H,12,13)/t5-/m0/s1	KSMRODHGGIIXDV-YFKPBYRVSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.4053 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	3	No	0	-1	109.49 Å2	17.82 Å3	42.55 m3·mol-1	5	Yes	No	21.9 mg/mL	-1.9	-0.93	3.76	-1.4	Q9RYA6	menC	1. N-acylamino acid racemase
C24H27N3O7S	Not Available	Not Available	501.552	[H]N([H])[C@@H](CCC(=O)N([H])[C@@H](CS[C@]1([H])[C@@H](O)C2=CC=CC=C2C2=CC=CC=C12)C(=O)N([H])CC(O)=O)C(O)=O	Solid	Not Available								392389						GPS			444461	46506704					ZINC000012501153		(9S,10S)-9-(S-glutathionyl)-10-hydroxy-9,10-dihydrophenanthrene	Experimental	DB04187	InChI=1S/C24H27N3O7S/c25-17(24(33)34)9-10-19(28)27-18(23(32)26-11-20(29)30)12-35-22-16-8-4-2-6-14(16)13-5-1-3-7-15(13)21(22)31/h1-8,17-18,21-22,31H,9-12,25H2,(H,26,32)(H,27,28)(H,29,30)(H,33,34)/t17-,18-,21-,22-/m0/s1	JNNIZILNBMPOAC-GPHNJDIKSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.2178 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	8	6	Yes	3	-1	179.05 Å2	50.09 Å3	127.88 m3·mol-1	11	No	No	0.031 mg/mL	-2.2	-4.2	1.8	9.31	P09488	GSTM1	1. Glutathione S-transferase Mu 1
C29H47N5O7	Not Available	Not Available	577.7128	[H][C@@](C)(N)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC1=CC=CC=C1)[C@@]([H])(O)CCC(=O)N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(C(C)C)C(=O)OC	Solid	Not Available					903		CHEMBL49004	392186						PSI			444196	46508521					ZINC000003935186		Skf 107457	Experimental	DB04191	InChI=1S/C29H47N5O7/c1-16(2)24(28(39)34-25(17(3)4)29(40)41-7)33-23(36)14-13-22(35)21(15-20-11-9-8-10-12-20)32-27(38)19(6)31-26(37)18(5)30/h8-12,16-19,21-22,24-25,35H,13-15,30H2,1-7H3,(H,31,37)(H,32,38)(H,33,36)(H,34,39)/t18-,19-,21-,22-,24-,25-/m0/s1	IUDCAKKZLXFOQA-QJAPXLAMSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.2496 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	7	6	No	1	1	188.95 Å2	62.56 Å3	152.41 m3·mol-1	17	No	No	0.0237 mg/mL	0.6	-4.4	12.05	8.09	P05896	gag-pol	1. Gag-Pol polyprotein
C15H30N5O5	Not Available	Not Available	360.4292	CC(C)C[C@H](NC(=O)[C@@H](O)CC(O)=O)C(=O)NCCCC[NH+]=C(N)N	Solid	Not Available						30270		4450371						E64			5288145	46505123							4-[[(2S)-2-[[(2S)-3-Carboxy-2-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]butyl-(diaminomethylidene)azanium	Experimental	DB04276	InChI=1S/C15H29N5O5/c1-9(2)7-10(20-14(25)11(21)8-12(22)23)13(24)18-5-3-4-6-19-15(16)17/h9-11,21H,3-8H2,1-2H3,(H,18,24)(H,20,25)(H,22,23)(H4,16,17,19)/p+1/t10-,11-/m0/s1	QPQNJAXBPHVASB-QWRGUYRKSA-O			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.4411 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	7	7	No	0	0	181.74 Å2	38.57 Å3	101.66 m3·mol-1	12	No	No	0.52 mg/mL	-3.2	-2.9	3.95	11.28	A0A0H3JWX6;!P07384	srtB;!CAPN1	1. NPQTN specific sortase B;!2. Calpain-1 catalytic subunit
C17H32N6O3S	Not Available	Not Available	400.539	[H]N([H])C(=N[C@H](C1CCCCC1)C(=O)N([H])CC(=O)N([H])[C@@H](C)C(=O)N([H])CCCS)N([H])[H]	Solid	Not Available								4593463						NMP			5496715	46505946					ZINC000015677257		2-[2-(2-Cyclohexyl-2-guanidino-acetylamino)-acetylamino]-N-(3-mercapto-propyl)-propionamide	Experimental	DB04278	InChI=1S/C17H32N6O3S/c1-11(15(25)20-8-5-9-27)22-13(24)10-21-16(26)14(23-17(18)19)12-6-3-2-4-7-12/h11-12,14,27H,2-10H2,1H3,(H,20,25)(H,21,26)(H,22,24)(H4,18,19,23)/t11-,14+/m0/s1	YLLNYDDZOMCFDE-SMDDNHRTSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.2883 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	6	No	1	1	151.7 Å2	43.87 Å3	105.92 m3·mol-1	10	No	No	0.0543 mg/mL	-0.63	-3.9	10.05	10.76	P60568	IL2	1. Interleukin-2
C19H35N3O5	Not Available	Not Available	385.4983	[H][C@@](CCCCC)(CC(=O)NO)C(=O)N[C@@]([H])(C(C)C)C(=O)N1CCC[C@@]1([H])CO	Solid	Not Available					50089194		CHEMBL308333	391756				C12056		BB2			443600	46505294					ZINC000003979014		2-[(Formyl-Hydroxy-Amino)-Methyl]-Heptanoic Acid [1-(2-Hydroxymethyl-Pyrrolidine-1-Carbonyl)-2-Methyl-Propyl]-Amide	Experimental	DB04310	InChI=1S/C19H35N3O5/c1-4-5-6-8-14(11-16(24)21-27)18(25)20-17(13(2)3)19(26)22-10-7-9-15(22)12-23/h13-15,17,23,27H,4-12H2,1-3H3,(H,20,25)(H,21,24)/t14-,15+,17+/m1/s1	XJLATMLVMSFZBN-VYDXJSESSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3864 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	4	No	1	0	118.97 Å2	42.57 Å3	101.51 m3·mol-1	11	Yes	No	3.03 mg/mL	0.88	-2.1	8.9	-0.9			
C17H22IN3O6S	Not Available	Not Available	523.343	[H]N([H])[C@@H](CCC(=O)N([H])[C@@H](CSCC1=CC(I)=CC=C1)C(=O)N([H])CC(O)=O)C(O)=O	Solid	Not Available								395901						GBI			449342	46508698					ZINC000014881179		S-(3-Iodobenzyl)glutathione	Experimental	DB04341	InChI=1S/C17H22IN3O6S/c18-11-3-1-2-10(6-11)8-28-9-13(16(25)20-7-15(23)24)21-14(22)5-4-12(19)17(26)27/h1-3,6,12-13H,4-5,7-9,19H2,(H,20,25)(H,21,22)(H,23,24)(H,26,27)/t12-,13-/m0/s1	AHWSFXKKIDTZBI-STQMWFEESA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.2179 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	7	5	No	1	-1	158.82 Å2	46.1 Å3	111.79 m3·mol-1	12	No	No	0.03 mg/mL	-2	-4.2	1.81	9.31			
C29H42N10O9	Not Available	Not Available	674.7054	CC(=O)NC(=N)NCCC[C@@H]1NC(=O)[C@H](CCCC(O)=O)NC(=O)[C@H](CC2=CNC=N2)N2[C@H](O)C[C@H](NC(=O)[C@H]3CCCN3C1=O)C2=O	Solid	Not Available					10854		CHEMBL445236	395740									449123	46508598				Argadin	ZINC000024693311		Argadin	Experimental	DB04350	InChI=1S/C29H42N10O9/c1-15(40)34-29(30)32-9-3-6-18-27(47)38-10-4-7-20(38)25(45)37-19-12-22(41)39(28(19)48)21(11-16-13-31-14-33-16)26(46)35-17(24(44)36-18)5-2-8-23(42)43/h13-14,17-22,41H,2-12H2,1H3,(H,31,33)(H,35,46)(H,36,44)(H,37,45)(H,42,43)(H3,30,32,34,40)/t17-,18-,19-,20+,21-,22+/m0/s1	FOZYKTUSOWWQGR-KNPYFFGGSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.6480 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	12	9	Yes	4	0	279.11 Å2	67.01 Å3	173.09 m3·mol-1	10	No	No	0.945 mg/mL	-5.9	-2.8	3.63	8.67	Q13231;!Q873X9	CHIT1;!chiB1	1. Chitotriosidase-1;!2. Chitinase
C29H46N6O9S	Not Available	Not Available	654.78	[H]N([H])C(=NCCCCN([H])C(=O)[C@@H]1C[C@]2([H])CC[C@H](C[C@]2([H])N1C(=O)[C@H](N([H])C(=O)[C@H](O)CC1=CC=C(O)C=C1)[C@H](C)CC)OS(O)(=O)=O)N([H])[H]	Solid	Not Available								392303									444346	46509169					ZINC000024420133		Aeruginosin 98-B	Experimental	DB04391	InChI=1S/C29H46N6O9S/c1-3-17(2)25(34-27(39)24(37)14-18-6-9-20(36)10-7-18)28(40)35-22-16-21(44-45(41,42)43)11-8-19(22)15-23(35)26(38)32-12-4-5-13-33-29(30)31/h6-7,9-10,17,19,21-25,36-37H,3-5,8,11-16H2,1-2H3,(H,32,38)(H,34,39)(H4,30,31,33)(H,41,42,43)/t17-,19+,21-,22+,23+,24-,25-/m1/s1	WZVRXEOKWMIDDV-HTKJFTDNSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.5526 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										0	No	11	7	Yes	3	0	246.97 Å2	68.89 Å3	163.75 m3·mol-1	15	No	No	0.213 mg/mL	-0.29	-3.5	-11	11.23	P07477	PRSS1	1. Trypsin-1
C11H19N5O2	Not Available	Not Available	253.3009	[H][C@@]12CCCN1C(=O)[C@H](CCCNC(N)=N)NC2=O	Solid	Not Available								395718						ALJ			449095	46505787					ZINC000013584769		Verpacamide A	Experimental	DB04433	InChI=1S/C11H19N5O2/c12-11(13)14-5-1-3-7-10(18)16-6-2-4-8(16)9(17)15-7/h7-8H,1-6H2,(H,15,17)(H4,12,13,14)/t7-,8-/m0/s1	ZRJHYOXNWCMGMW-YUMQZZPRSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.5631 LD50, mol/kg	Inhibitor	Weak inhibitor	Non-inhibitor										1	No	5	4	No	2	1	111.31 Å2	26.68 Å3	75.71 m3·mol-1	4	Yes	No	1.6 mg/mL	-2.1	-2.2	11.27	12.17	P11797	chiB	1. Chitinase B
C19H27N4O9S	Not Available	Not Available	487.504	[H][C@]12SC[C@@H](COC(C)=O)[C@H](N1C(=O)[C@H]2\N=C(/[O-])CCCC[C@H](NC(=O)CN)C(O)=O)C(O)=O	Solid	Not Available														H2A			131704283	46504718							(6S)-N-[(2S,3R,6R,7R)-3-(Acetyloxymethyl)-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]octan-7-yl]-6-[(2-aminoacetyl)amino]-7-hydroxy-7-oxoheptanimidate	Experimental	DB04488	InChI=1S/C19H28N4O9S/c1-9(24)32-7-10-8-33-17-14(16(27)23(17)15(10)19(30)31)22-12(25)5-3-2-4-11(18(28)29)21-13(26)6-20/h10-11,14-15,17H,2-8,20H2,1H3,(H,21,26)(H,22,25)(H,28,29)(H,30,31)/p-1/t10-,11+,14-,15+,17-/m1/s1	JDAREAJBQYNCGO-UPMYTKPLSA-M			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.1757 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	10	4	No	2	-1	211.75 Å2	47.24 Å3	122.37 m3·mol-1	13	Yes	No	0.392 mg/mL	-4.1	-3.1	3	8.14	P15555	Not Available	1. D-alanyl-D-alanine carboxypeptidase
C19H33N3O8S	Not Available	Not Available	463.546	[H]N([H])[C@@H](CCC(=O)N([H])[C@@H](CS[C@@]1([H])C[C@H](O)O[C@@H]1CCCCC)C(=O)N([H])CC(O)=O)C(O)=O	Solid	Not Available								392385						HAG			444455	46506521					ZINC000031976570		4-S-Glutathionyl-5-pentyl-tetrahydro-furan-2-ol	Experimental	DB04521	InChI=1S/C19H33N3O8S/c1-2-3-4-5-13-14(8-17(26)30-13)31-10-12(18(27)21-9-16(24)25)22-15(23)7-6-11(20)19(28)29/h11-14,17,26H,2-10,20H2,1H3,(H,21,27)(H,22,23)(H,24,25)(H,28,29)/t11-,12-,13+,14-,17+/m0/s1	ICRIFHIWWXQBPY-JEJJNBGPSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3527 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	9	6	No	1	-1	188.28 Å2	48.67 Å3	110.91 m3·mol-1	15	No	No	0.594 mg/mL	-2.8	-2.9	1.8	9.31	Q16772	GSTA3	1. Glutathione S-transferase A3
C30H37N3O10	Not Available	Not Available	599.6289	CCCCCNC(=O)[C@H](CC1=CC=C(OCC(O)=O)C(=C1)C(O)=O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CCC(O)=O	Solid	Not Available					13611		CHEMBL175198	393321						INX			445785	46506542					ZINC000003965850		N-(3-Carboxypropanoyl)-L-phenylalanyl-3-carboxy-O-(carboxymethyl)-N-pentyl-L-tyrosinamide	Experimental	DB04525	InChI=1S/C30H37N3O10/c1-2-3-7-14-31-28(39)22(17-20-10-11-24(43-18-27(37)38)21(15-20)30(41)42)33-29(40)23(16-19-8-5-4-6-9-19)32-25(34)12-13-26(35)36/h4-6,8-11,15,22-23H,2-3,7,12-14,16-18H2,1H3,(H,31,39)(H,32,34)(H,33,40)(H,35,36)(H,37,38)(H,41,42)/t22-,23-/m0/s1	PUAJYWYRZTYQKS-GOTSBHOMSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.4326 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										0	No	10	6	No	2	-3	208.43 Å2	62.15 Å3	152.37 m3·mol-1	19	No	No	0.0091 mg/mL	2	-4.8	2.99	-2.2			
C31H42N4O4	Not Available	Not Available	534.6896	CN[C@@H](C)C(=O)N[C@H](C(=O)N1C[C@H](C[C@H]1C(=O)N[C@@H]1CCCC2=CC=CC=C12)OC1=CC=CC=C1)C(C)(C)C	Solid	Not Available					13174		CHEMBL1230661	4534975						997			5388929	46504945					ZINC000014881281		N-METHYLALANYL-3-METHYLVALYL-4-PHENOXY-N-(1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL)PROLINAMIDE	Experimental	DB04612	InChI=1S/C31H42N4O4/c1-20(32-5)28(36)34-27(31(2,3)4)30(38)35-19-23(39-22-14-7-6-8-15-22)18-26(35)29(37)33-25-17-11-13-21-12-9-10-16-24(21)25/h6-10,12,14-16,20,23,25-27,32H,11,13,17-19H2,1-5H3,(H,33,37)(H,34,36)/t20-,23-,25+,26-,27+/m0/s1	QKPXPZYQPBWDHS-MCJAPYMPSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.6274 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	No	5	3	Yes	4	1	99.77 Å2	59.09 Å3	150.04 m3·mol-1	9	No	No	0.00741 mg/mL	3.64	-4.9	12.38	8.6			
C32H49N5O8	Not Available	Not Available	631.7602	CCOC(=O)\C=C\[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)C1=COC=C1	Solid	Not Available								4449909						9IN			5287569	46506597					ZINC000014881283		(E)-(4S,6S)-6-((S)-2-{(S)-2-[(FURAN-2-CARBONYL)-AMINO]-3-METHYL-BUTYRYLAMINO}-3-METHYL-BUTYRYLAMINO)-8-METHYL-5-OXO-4-((R)-2-OXO-PYRROLIDIN-3-YLMETHYL)-NON-2-ENOIC ACID ETHYL ESTER	Experimental	DB04613	InChI=1S/C32H49N5O8/c1-8-45-25(38)10-9-23(16-21-11-13-33-28(21)39)34-30(41)24(15-18(2)3)35-31(42)26(19(4)5)37-32(43)27(20(6)7)36-29(40)22-12-14-44-17-22/h9-10,12,14,17-21,23-24,26-27H,8,11,13,15-16H2,1-7H3,(H,33,39)(H,34,41)(H,35,42)(H,36,40)(H,37,43)/b10-9+/t21-,23+,24-,26-,27-/m0/s1	JQGYBVLTABWBOF-VTQXMFKGSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.4482 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	6	5	No	2	0	184.94 Å2	67.21 Å3	166.87 m3·mol-1	18	No	No	0.0496 mg/mL	2.05	-4.1	11.89	-1.2			
C26H41BN4O10	Not Available	Not Available	580.436	C[C@@H](NC(=O)[C@H](CCCCNC(=O)OCC1=CC=CC=C1)NC(=O)CC[C@H](NC(=O)OC(C)(C)C)C(O)=O)B(O)O	Solid	Not Available								4450121						BO9			5287824	46508422					ZINC000169748488		BOC-GAMMA-D-GLU-L-LYS(CBZ)-D-BOROALA	Experimental	DB04647	InChI=1S/C26H41BN4O10/c1-17(27(38)39)29-22(33)19(12-8-9-15-28-24(36)40-16-18-10-6-5-7-11-18)30-21(32)14-13-20(23(34)35)31-25(37)41-26(2,3)4/h5-7,10-11,17,19-20,38-39H,8-9,12-16H2,1-4H3,(H,28,36)(H,29,33)(H,30,32)(H,31,37)(H,34,35)/t17-,19+,20+/m1/s1	OTTYWVUOPWENAJ-HOJAQTOUSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.4749 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	8	7	No	1	-1	212.62 Å2	60.85 Å3	141.61 m3·mol-1	19	No	No	0.0237 mg/mL	1.69	-4.4	3.72	-5.4	P0AEB3;!P0AEB2	dacA;!dacA	1. D-alanyl-D-alanine carboxypeptidase DacA;!2. D-alanyl-D-alanine carboxypeptidase DacA
C29H42N4O7	Not Available	Not Available	558.6664	[H]N([C@@H](C(C)C)C(=O)N([H])[C@H](C(=O)N([H])C(C[C@@H]1CCN([H])C1=O)\C=C\C(=O)OCC)C1=CC=CC=C1)C(=O)OC(C)(C)C	Solid	Not Available								4883355						ENB			23304231	46508007							Ethyl (2E)-4-({(2S)-2-[(N-{[(2-methyl-2-propanyl)oxy]carbonyl}-L-valyl)amino]-2-phenylacetyl}amino)-5-[(3S)-2-oxo-3-pyrrolidinyl]-2-pentenoate	Experimental	DB04692	InChI=1S/C29H42N4O7/c1-7-39-22(34)14-13-21(17-20-15-16-30-25(20)35)31-27(37)24(19-11-9-8-10-12-19)32-26(36)23(18(2)3)33-28(38)40-29(4,5)6/h8-14,18,20-21,23-24H,7,15-17H2,1-6H3,(H,30,35)(H,31,37)(H,32,36)(H,33,38)/b14-13+/t20-,21?,23-,24-/m0/s1	NUDVEHBHDBJSMD-XBEUYHOESA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.7090 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	5	4	No	2	0	151.93 Å2	59.81 Å3	149.01 m3·mol-1	15	No	No	0.00719 mg/mL	2.49	-4.9	12	-1.3			
C10H17N3O8S	Not Available	Not Available	339.322	N[C@@H](CCC(=O)N[C@@H](C[S@](O)=O)C(=O)NCC(O)=O)C(O)=O	Solid	Not Available								4484237						GSF			5326960	46506088					ZINC000012504471		GLUTATHIONE SULFINATE	Experimental	DB04700	InChI=1S/C10H17N3O8S/c11-5(10(18)19)1-2-7(14)13-6(4-22(20)21)9(17)12-3-8(15)16/h5-6H,1-4,11H2,(H,12,17)(H,13,14)(H,15,16)(H,18,19)(H,20,21)/t5-,6-/m0/s1	DMAPAHUEYHXRFI-WDSKDSINSA-N			Not Available	Small Molecule				AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.2108 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	9	6	No	0	-2	196.12 Å2	30.78 Å3	69.88 m3·mol-1	10	No	No	16.3 mg/mL	-5.9	-1.3	1.31	9.31	Q9Y2Q3	GSTK1	1. Glutathione S-transferase kappa 1
C11H19N3O6S	Not Available	Not Available	321.35	CSC[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)NCC(O)=O	Solid	Not Available					225232	141473	CHEMBL1233129	103128				C11347		GSM			115260	46507560					ZINC000001532230		S-Methyl glutathione	Experimental	DB04701	InChI=1S/C11H19N3O6S/c1-21-5-7(10(18)13-4-9(16)17)14-8(15)3-2-6(12)11(19)20/h6-7H,2-5,12H2,1H3,(H,13,18)(H,14,15)(H,16,17)(H,19,20)/t6-,7-/m0/s1	QTQDDTSVRVWHMO-BQBZGAKWSA-N			Not Available	Small Molecule	http://smpdb.ca/view/SMP0000501?highlight[compounds][]=DB04701&highlight[proteins][]=DB04701;!http://smpdb.ca/view/SMP0000183?highlight[compounds][]=DB04701&highlight[proteins][]=DB04701;!http://smpdb.ca/view/SMP0000500?highlight[compounds][]=DB04701&highlight[proteins][]=DB04701;!http://smpdb.ca/view/SMP0000015?highlight[compounds][]=DB04701&highlight[proteins][]=DB04701;!http://smpdb.ca/view/SMP0000143?highlight[compounds][]=DB04701&highlight[proteins][]=DB04701;!http://smpdb.ca/view/SMP0000337?highlight[compounds][]=DB04701&highlight[proteins][]=DB04701	gamma-Glutamyltranspeptidase Deficiency;!gamma-Glutamyltransferase Deficiency;!5-Oxoprolinase Deficiency;!Glutathione Metabolism;!5-Oxoprolinuria;!Glutathione Synthetase Deficiency		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.7868 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	5	No	0	-1	158.82 Å2	31.25 Å3	73.77 m3·mol-1	10	Yes	No	2.61 mg/mL	-4.5	-2.1	1.81	9.31	P28161	GSTM2	1. Glutathione S-transferase Mu 2
C30H46N6O8	Not Available	Not Available	618.7216	CCOC(=O)\C=C\[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)C1=NOC(C)=C1	Solid	Not Available								4883391						I12			15959287	46505902					ZINC000014881295		(E)-(S)-4-[(S)-4-METHYL-2-((S)-3-METHYL-2{(S)-2-[(5-METHYL-ISOXAZOLE-3- CARBONYL)-AMINO]-PROPIONYLAMINO}-BUTYRYLAMINO)-PENTANOYLAMINO]-5-((S)-2- OXO-PYRROLIDIN-3-YL)-PENT-2-ENOIC ACID ETHYL ESTER	Experimental	DB04710	InChI=1S/C30H46N6O8/c1-8-43-24(37)10-9-21(15-20-11-12-31-27(20)39)33-28(40)22(13-16(2)3)34-30(42)25(17(4)5)35-26(38)19(7)32-29(41)23-14-18(6)44-36-23/h9-10,14,16-17,19-22,25H,8,11-13,15H2,1-7H3,(H,31,39)(H,32,41)(H,33,40)(H,34,42)(H,35,38)/b10-9+/t19-,20-,21+,22-,25-/m0/s1	LIVSSCDUYUOZEL-GLXPMXKMSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.5616 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	7	5	No	2	0	197.83 Å2	65.7 Å3	161.58 m3·mol-1	17	No	No	0.0744 mg/mL	0.97	-3.9	11.71	-1.2			
C23H32BN3O5	Not Available	Not Available	441.328	[H][C@@](CC(C)C)(NC(=O)[C@@]([H])(CC1=C2C=CC=CC2=CC=C1)NC(=O)N1CCOCC1)B(O)O	Solid	Not Available							CHEMBL1234151	343397						M1N			387442	46505262					ZINC000169748489		N-(4-MORPHOLINE)CARBONYL-B-(1-NAPHTHYL)-L-ALANINE-L-LEUCINE BORONIC ACID	Experimental	DB04732	InChI=1S/C23H32BN3O5/c1-16(2)14-21(24(30)31)26-22(28)20(25-23(29)27-10-12-32-13-11-27)15-18-8-5-7-17-6-3-4-9-19(17)18/h3-9,16,20-21,30-31H,10-15H2,1-2H3,(H,25,29)(H,26,28)/t20-,21+/m1/s1	MQMHIOPMTAJOHV-RTWAWAEBSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Inhibitor	Non-inhibitor	Substrate	2.4890 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	5	4	Yes	3	0	111.13 Å2	46.91 Å3	117.38 m3·mol-1	8	Yes	No	0.0313 mg/mL	2.91	-4.2	8.64	-2	P9WHT9;!P9WHU1	prcB;!prcA	1. Proteasome subunit beta;!2. Proteasome subunit alpha
C23H35N7O5	Not Available	Not Available	489.5679	CC(C)C[C@H](NC(=O)C1=CC=C(C=C1)[N+]([O-])=O)C(=O)N1CCC[C@H]1C(=O)NCCCCN=C(N)N	Solid	Not Available								4591887						RA4			5494439	46506641					ZINC000016051710		1-GUANIDINO-4-(N-NITRO-BENZOYLAMINO-L-LEUCYL-L-PROLYLAMINO)BUTANE	Experimental	DB04771	InChI=1S/C23H35N7O5/c1-15(2)14-18(28-20(31)16-7-9-17(10-8-16)30(34)35)22(33)29-13-5-6-19(29)21(32)26-11-3-4-12-27-23(24)25/h7-10,15,18-19H,3-6,11-14H2,1-2H3,(H,26,32)(H,28,31)(H4,24,25,27)/t18-,19-/m0/s1	FIZYZWLGMGGGBJ-OALUTQOASA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.5775 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	8	4	No	2	1	186.05 Å2	51.32 Å3	130.19 m3·mol-1	12	Yes	No	0.0309 mg/mL	0.83	-4.2	13.73	11.28	P00734	F2	1. Prothrombin
C23H38N6O4S	Not Available	Not Available	494.651	CC(C)C[C@H](NS(=O)(=O)CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)NCCCCN=C(N)N	Solid	Not Available								4591888						RA8			5494440	46507293					ZINC000016051709		1-GUANIDINO-4-(N-PHENYLMETHANESULFONYL-L-LEUCYL-L-PROLYLAMINO)BUTANE	Experimental	DB04772	InChI=1S/C23H38N6O4S/c1-17(2)15-19(28-34(32,33)16-18-9-4-3-5-10-18)22(31)29-14-8-11-20(29)21(30)26-12-6-7-13-27-23(24)25/h3-5,9-10,17,19-20,28H,6-8,11-16H2,1-2H3,(H,26,30)(H4,24,25,27)/t19-,20-/m0/s1	DSVCYWOHJLRGMK-PMACEKPBSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.4174 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	4	No	2	1	159.98 Å2	52.68 Å3	131.54 m3·mol-1	12	Yes	No	0.099 mg/mL	0.08	-3.7	9.18	11.29	P00734	F2	1. Prothrombin
C26H29N5O7	Not Available	Not Available	523.5378	CCO[C@@H]1OC(=O)C[C@@H]1NC(=O)[C@@H]1CCCN2N1C(=O)[C@H](CCC2=O)NC(=O)C1=NC=CC2=CC=CC=C12	Solid	Not Available					50189360		CHEMBL437526	135089									153270	175426882							Pralnacasan	Investigational	DB04875	InChI=1S/C26H29N5O7/c1-2-37-26-18(14-21(33)38-26)29-23(34)19-8-5-13-30-20(32)10-9-17(25(36)31(19)30)28-24(35)22-16-7-4-3-6-15(16)11-12-27-22/h3-4,6-7,11-12,17-19,26H,2,5,8-10,13-14H2,1H3,(H,28,35)(H,29,34)/t17-,18-,19-,26+/m0/s1	CXAGHAZMQSCAKJ-WAHHBDPQSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.4106 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	2	Yes	5	0	147.24 Å2	52.38 Å3	131.03 m3·mol-1	6	No	No	0.387 mg/mL	0.07	-3.1	12.26	2.49			
C24H35N5O5	Not Available	3-5 hours	473.5652	CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(C=C1)C(\N)=N\O)C1CCCCC1	Solid	Not Available	P11712	CYP2C9	1. Cytochrome P450 2C9			65172	CHEMBL522038	7848559			HMDB0015603					PA161748474	9574101	46509040			DAP001218	Ximelagatran	ZINC000012504524		Ximelagatran	Approved, Investigational, Withdrawn	DB04898	InChI=1S/C24H35N5O5/c1-2-34-20(30)15-26-21(17-6-4-3-5-7-17)24(32)29-13-12-19(29)23(31)27-14-16-8-10-18(11-9-16)22(25)28-33/h8-11,17,19,21,26,33H,2-7,12-15H2,1H3,(H2,25,28)(H,27,31)/t19-,21+/m0/s1	ZXIBCJHYVWYIKI-PZJWPPBQSA-N			Hepatotoxicity (liver damage) was reported during trials.	Small Molecule	http://smpdb.ca/view/SMP0000279?highlight[compounds][]=DB04898&highlight[proteins][]=DB04898	Ximelagatran Action Pathway		Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.4109 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	7	4	Yes	3	0	146.35 Å2	52.18 Å3	126.57 m3·mol-1	11	Yes	No	0.0845 mg/mL	0.87	-3.8	8.7	5.48	P00734	F2	1. Prothrombin
C31H39FN4O7	Not Available	Not Available	598.6624	CCOC(=O)\C=C\[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@@H](CC(=O)[C@H](C(C)C)NC(=O)C1=NOC(C)=C1)CC1=CC=C(F)C=C1	Solid	Not Available					11243		CHEMBL20210	4944627									6440352	175426944					ZINC000003919807		Rupintrivir	Investigational	DB05102	InChI=1S/C31H39FN4O7/c1-5-42-27(38)11-10-24(16-21-12-13-33-29(21)39)34-30(40)22(15-20-6-8-23(32)9-7-20)17-26(37)28(18(2)3)35-31(41)25-14-19(4)43-36-25/h6-11,14,18,21-22,24,28H,5,12-13,15-17H2,1-4H3,(H,33,39)(H,34,40)(H,35,41)/b11-10+/t21-,22+,24+,28-/m0/s1	CAYJBRBGZBCZKO-BHGBQCOSSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.6484 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	6	3	Yes	3	0	156.7 Å2	62.56 Å3	157.24 m3·mol-1	16	No	No	0.0306 mg/mL	3.21	-4.3	12.5	-0.59	P03303	Not Available	1. Genome polyprotein
C11H19N3O7S	Not Available	Not Available	337.349	NC(CCC(=O)NC(CSCO)C(=O)NCC(O)=O)C(O)=O	Solid	Not Available								1052									1082	175427006							LJP 1082	Investigational	DB05446	InChI=1S/C11H19N3O7S/c12-6(11(20)21)1-2-8(16)14-7(4-22-5-15)10(19)13-3-9(17)18/h6-7,15H,1-5,12H2,(H,13,19)(H,14,16)(H,17,18)(H,20,21)	PIUSLWSYOYFRFR-UHFFFAOYSA-N			Not Available	Small Molecule				AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.9135 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	8	6	No	0	-1	179.05 Å2	32.24 Å3	75.2 m3·mol-1	11	No	No	5.27 mg/mL	-5.5	-1.8	1.79	9.31	P02749	APOH	1. Beta-2-glycoprotein 1
C23H35N9O8S	Not Available	Not Available	597.65	CC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O	Solid	Not Available							CHEMBL4297456	8135892										347910170					ZINC000003924034		ATN-161	Investigational	DB05491	InChI=1S/C23H35N9O8S/c1-11(34)32-4-2-3-17(32)23(40)29-14(5-12-7-26-10-27-12)20(37)30-15(8-33)21(38)31-16(9-41)22(39)28-13(19(25)36)6-18(24)35/h7,10,13-17,33,41H,2-6,8-9H2,1H3,(H2,24,35)(H2,25,36)(H,26,27)(H,28,39)(H,29,40)(H,30,37)(H,31,38)/t13-,14-,15-,16-,17-/m0/s1	MMHDBUJXLOFTLC-WOYTXXSLSA-N	2		Not Available	Small Molecule																																			0	No	9	9	No	2	0	271.8 Å2	57.77 Å3	143.33 m3·mol-1	15	No	No	0.139 mg/mL	-6.7	-3.6	9.94	6.74			
C36H53N7O6	Telaprevir has an estimated aparent total body clearance of 32.4 liters per hour with an interindividual variability of 27.2% Label.	Telaprevir has a half-life of elimination of 4.0-4.7 hours after a single dose and an effective half life of 9-11 hours at steady state Label.	679.8493	[H][C@@]12CCC[C@]1([H])[C@H](N(C2)C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1	Solid	The estimated apparent volume of distribution for Telapravir is 252 litres with an inter-individual variability of 72% Label.	P08684	CYP3A4	1. Cytochrome P450 3A4		50326056	68595	CHEMBL231813	2279948	Drugs.com Drug Page		HMDB0015616		D09012			PA165958354	3010818	175427024	RxList Drug Page	1102261		Telaprevir	ZINC000003992480		Telaprevir	Approved, Withdrawn	DB05521	InChI=1S/C36H53N7O6/c1-5-10-25(29(44)34(48)39-23-15-16-23)40-33(47)28-24-14-9-13-22(24)20-43(28)35(49)30(36(2,3)4)42-32(46)27(21-11-7-6-8-12-21)41-31(45)26-19-37-17-18-38-26/h17-19,21-25,27-28,30H,5-16,20H2,1-4H3,(H,39,48)(H,40,47)(H,41,45)(H,42,46)/t22-,24-,25-,27-,28-,30+/m0/s1	BBAWEDCPNXPBQM-GDEBMMAJSA-N	4	Telaprevir is an NS3/4A viral protease inhibitor used in combination with other antivirals for the curative treatment of chronic Hepatitis C Virus infections.	Serious skin reactions, including Stevens Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms, and Toxic Epidermal Necrolysis, have been reported in patients treated with telaprevir combination treatment. Use of Ribavirin, Peginterferon alfa-2a, Peginterferon alfa-2b and Telaprevir is associated with a further increase in anemia frequency than in Ribavirin, Peginterferon alfa-2a, and Peginterferon alfa-2b without telaprevir.	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.6980 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor									0.0047 mg/mL	0	No	8	4	Yes	5	0	179.56 Å2	73.79 Å3	180.04 m3·mol-1	14	No	No	0.0355 mg/mL	2.58	-4.3	11.86	-0.58	B0B3C9;!Q9Y6L6;!O94956	NS3/4A;!SLCO1B1;!SLCO2B1	1. NS3/4A protein;!2. Solute carrier organic anion transporter family member 1B1;!3. Solute carrier organic anion transporter family member 2B1
C12H19N3O6	Not Available	Not Available	301.299	[H]N([H])CC(=O)N1CCC[C@H]1C(=O)N([H])[C@@H](CCC(O)=O)C(O)=O	Solid	Not Available							CHEMBL371315	2338502															ZINC000003776571		Glypromate	Investigational	DB05633	InChI=1S/C12H19N3O6/c13-6-9(16)15-5-1-2-8(15)11(19)14-7(12(20)21)3-4-10(17)18/h7-8H,1-6,13H2,(H,14,19)(H,17,18)(H,20,21)/t7-,8-/m0/s1	JJGBXTYGTKWGAT-YUMQZZPRSA-N			Not Available	Small Molecule																																			1	No	7	4	No	1	-1	150.03 Å2	28.23 Å3	69.08 m3·mol-1	7	Yes	No	14.7 mg/mL	-4.9	-1.3	3.2	7.83			
C32H55N9O10	Not Available	Not Available	725.845	CC(C)C[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)CN)C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O	Solid	Not Available							CHEMBL2105646	7986288														Larazotide	ZINC000068009799		Larazotide	Investigational	DB05645	InChI=1S/C32H55N9O10/c1-16(2)12-20(38-30(49)26(17(3)4)39-24(44)14-35-23(43)13-33)28(47)40-27(18(5)6)31(50)37-19(9-10-22(34)42)32(51)41-11-7-8-21(41)29(48)36-15-25(45)46/h16-21,26-27H,7-15,33H2,1-6H3,(H2,34,42)(H,35,43)(H,36,48)(H,37,50)(H,38,49)(H,39,44)(H,40,47)(H,45,46)/t19-,20-,21-,26-,27-/m0/s1	ORFLZNAGUTZRLQ-ZMBVWFSWSA-N	2		Not Available	Small Molecule																																			0	No	11	9	No	1	0	301.32 Å2	75.32 Å3	180.06 m3·mol-1	21	No	No	0.218 mg/mL	-6.2	-3.5	3.43	7.84			
C27H36BN3O7	Not Available	Not Available	525.41	COCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](CC1=CC=CC=C1)NC(=O)OCC1=CC=CC=C1)B(O)O	Solid	Not Available								8047436															ZINC000169746723		Flovagatran	Investigational	DB05714	InChI=1S/C27H36BN3O7/c1-37-17-9-15-24(28(35)36)30-25(32)23-14-8-16-31(23)26(33)22(18-20-10-4-2-5-11-20)29-27(34)38-19-21-12-6-3-7-13-21/h2-7,10-13,22-24,35-36H,8-9,14-19H2,1H3,(H,29,34)(H,30,32)/t22-,23+,24+/m1/s1	PAOGOXGDGABPSC-SGNDLWITSA-N			Not Available	Small Molecule																																			0	No	6	4	Yes	3	0	137.43 Å2	56.32 Å3	136.74 m3·mol-1	14	No	No	0.0161 mg/mL	2.92	-4.5	8.64	-3.2	P00734	F2	1. Prothrombin
C31H38N2O6	Not Available	Not Available	534.6432	CCOC(=O)[C@H](CCC1=CC=CC=C1)CC1(CCCC1)C(=O)N[C@H]1CCC2=CC=CC=C2N(CC(O)=O)C1=O	Solid	Not Available								2302069									3038505	175427034					ZINC000003919685		Daglutril	Investigational	DB05796	InChI=1S/C31H38N2O6/c1-2-39-29(37)24(15-14-22-10-4-3-5-11-22)20-31(18-8-9-19-31)30(38)32-25-17-16-23-12-6-7-13-26(23)33(28(25)36)21-27(34)35/h3-7,10-13,24-25H,2,8-9,14-21H2,1H3,(H,32,38)(H,34,35)/t24-,25+/m1/s1	XMQODGUTLZXUGZ-RPBOFIJWSA-N	2		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.4160 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										0	No	5	2	Yes	4	-1	113.01 Å2	57.42 Å3	145.94 m3·mol-1	12	No	No	0.0015 mg/mL	5.01	-5.6	3.88	-0.055	P08473	MME	1. Neprilysin
C12H19NO4	Not Available	Not Available	241.287	CCC(C)(C)C(=O)C(=O)N1CCC[C@H]1C(O)=O	Solid	Not Available	P08684	CYP3A4	1. Cytochrome P450 3A4					8013376									9837656	347827745					ZINC000033979157		GPI-1485	Investigational	DB05814	InChI=1S/C12H19NO4/c1-4-12(2,3)9(14)10(15)13-7-5-6-8(13)11(16)17/h8H,4-7H2,1-3H3,(H,16,17)/t8-/m0/s1	FOPALECPEUVCTL-QMMMGPOBSA-N	2		Not Available	Small Molecule																																			1	Yes	4	1	No	1	-1	74.68 Å2	25.02 Å3	61.28 m3·mol-1	4	Yes	No	4.98 mg/mL	2.05	-1.7	3.99	-2.6	P62942	FKBP1A	1. Peptidyl-prolyl cis-trans isomerase FKBP1A
C13H21N3O6	Not Available	Not Available	315.326	C[C@]1(CCCN1C(=O)CN)C(=O)N[C@@H](CCC(O)=O)C(O)=O	Solid	Not Available							CHEMBL197084	9493869														Trofinetide			Trofinetide	Investigational	DB06045	InChI=1S/C13H21N3O6/c1-13(5-2-6-16(13)9(17)7-14)12(22)15-8(11(20)21)3-4-10(18)19/h8H,2-7,14H2,1H3,(H,15,22)(H,18,19)(H,20,21)/t8-,13-/m0/s1	BUSXWGRAOZQTEY-SDBXPKJASA-N	3		Not Available	Small Molecule																																			1	No	7	4	No	1	-1	150.03 Å2	30.95 Å3	73.79 m3·mol-1	7	Yes	No	10.4 mg/mL	-4.5	-1.5	3.27	7.83			
C27H53N7O7	Not Available	Not Available	587.763	CCOC(OCC)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)CCC(=O)N[C@H](CC([O-])=O)C[N+](C)(C)C	Solid	Not Available								32699207																	L-aminocarnityl-succinyl-leucyl-argininal-diethylacetal	Investigational	DB06124	InChI=1S/C27H53N7O7/c1-8-40-26(41-9-2)20(11-10-14-30-27(28)29)33-25(39)21(15-18(3)4)32-23(36)13-12-22(35)31-19(16-24(37)38)17-34(5,6)7/h18-21,26H,8-17H2,1-7H3,(H7-,28,29,30,31,32,33,35,36,37,38,39)/t19-,20+,21+/m1/s1	JOITUBWXBFATOR-HKBOAZHASA-N			Not Available	Small Molecule																																			0	No	10	6	No	0	1	207.79 Å2	65.49 Å3	187.34 m3·mol-1	22	No	No	0.0124 mg/mL	-6.4	-4.7	3.71	11.85	P20807	CAPN3	1. Calpain-3
C12H22AsN3O6S	Not Available	Not Available	411.3	C[As](C)SC[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)NCC(O)=O	Solid	Not Available						94295	CHEMBL3247378	9857733																	Darinaparsin	Investigational	DB06179	InChI=1S/C12H22AsN3O6S/c1-13(2)23-6-8(11(20)15-5-10(18)19)16-9(17)4-3-7(14)12(21)22/h7-8H,3-6,14H2,1-2H3,(H,15,20)(H,16,17)(H,18,19)(H,21,22)/t7-,8-/m0/s1	JGDXFQORBMPJGR-YUMQZZPRSA-N	2		Not Available	Small Molecule																																			1	No	7	5	No	0	-1	158.82 Å2	36.38 Å3	79.89 m3·mol-1	11	Yes	No	1.4 mg/mL	-4.4	-2.5	1.5	9.31			
C9H19BN2O3	Not Available	Not Available	214.07	CC(C)[C@H](N)C(=O)N1CCC[C@H]1B(O)O	Solid	Not Available					50050513		CHEMBL67279	5293769															ZINC000169746694		Talabostat	Investigational	DB06182	InChI=1S/C9H19BN2O3/c1-6(2)8(11)9(13)12-5-3-4-7(12)10(14)15/h6-8,14-15H,3-5,11H2,1-2H3/t7-,8-/m0/s1	FKCMADOPPWWGNZ-YUMQZZPRSA-N	2		Not Available	Small Molecule																																			1	Yes	4	3	No	1	1	86.79 Å2	23.37 Å3	52.34 m3·mol-1	3	Yes	No	59.2 mg/mL	-0.2	-0.56	8.88	8.27			
C25H32N2O4	402 ± 89 mL/min	10 to 17 hours (gut metabolite: 10 to 18 hours)	424.5326	C[C@H]1CN(C[C@H](CC2=CC=CC=C2)C(=O)NCC(O)=O)CC[C@@]1(C)C1=CC(O)=CC=C1	Solid	30±10 L					50088381	135686	CHEMBL270190	4589864	Drugs.com Drug Page		HMDB0015631		D02878			PA164754864	5488548	99443242	RxList Drug Page	480639	DAP001140	Alvimopan	ZINC000003802417	Entereg	Alvimopan	Approved, Investigational	DB06274	InChI=1S/C25H32N2O4/c1-18-16-27(12-11-25(18,2)21-9-6-10-22(28)14-21)17-20(24(31)26-15-23(29)30)13-19-7-4-3-5-8-19/h3-10,14,18,20,28H,11-13,15-17H2,1-2H3,(H,26,31)(H,29,30)/t18-,20-,25+/m0/s1	UPNUIXSCZBYVBB-JVFUWBCBSA-N	4	Alvimopan is an opioid antagonist used to reduce healing time of the upper and lower gastrointestinal tract following surgical procedures that involve bowel resection with primary anastomosis.	Not Available	Small Molecule	http://smpdb.ca/view/SMP0000685?highlight[compounds][]=DB06274&highlight[proteins][]=DB06274	Alvimopan Action Pathway		Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.6978 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor									<0.1 mg/mL	1	Yes	5	3	Yes	3	0	89.87 Å2	46.77 Å3	120.56 m3·mol-1	8	Yes	No	0.00834 mg/mL	0.82	-4.7	3.71	10.66	P35372;!P41145;!P41143	OPRM1;!OPRK1;!OPRD1	1. Mu-type opioid receptor;!2. Kappa-type opioid receptor;!3. Delta-type opioid receptor
C23H41N5O5S	Not Available	Not Available	499.67	CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](S)CCN1C(=O)N(C)C(C)(C)C1=O)C(C)(C)C	Solid	Not Available					50108168		CHEMBL76222	8089530															ZINC000003939175		Rebimastat	Investigational	DB06573	InChI=1S/C23H41N5O5S/c1-13(2)12-14(17(29)26-16(19(31)24-8)22(3,4)5)25-18(30)15(34)10-11-28-20(32)23(6,7)27(9)21(28)33/h13-16,34H,10-12H2,1-9H3,(H,24,31)(H,25,30)(H,26,29)/t14-,15-,16+/m0/s1	GTXSRFUZSLTDFX-HRCADAONSA-N	3		Not Available	Small Molecule																																			1	No	5	4	No	1	0	127.92 Å2	54.52 Å3	131.54 m3·mol-1	11	Yes	No	0.00618 mg/mL	0.97	-4.9	9.31	-2.6			
C22H28N2O5S	Not Available	Not Available	432.533	[H][C@]12CCC[C@H](N1C(=O)[C@H](CC1=C2C=CC=C1)NC(=O)[C@@H](SC(C)=O)C(C)C)C(O)=O	Solid	Not Available							CHEMBL3187812	7999878															ZINC000003928701		Ilepatril	Investigational	DB06604	InChI=1S/C22H28N2O5S/c1-12(2)19(30-13(3)25)20(26)23-16-11-14-7-4-5-8-15(14)17-9-6-10-18(22(28)29)24(17)21(16)27/h4-5,7-8,12,16-19H,6,9-11H2,1-3H3,(H,23,26)(H,28,29)/t16-,17+,18-,19-/m0/s1	FXKFFTMLFPWYFH-RDGPPVDQSA-N	3		Not Available	Small Molecule																																			1	Yes	5	2	Yes	3	-1	103.78 Å2	44.9 Å3	113.16 m3·mol-1	6	Yes	No	0.0589 mg/mL	2.41	-3.9	3.6	-3.5			
C31H42N6O3	Not Available	Not Available	546.716	CN(C)N(C)C(=O)[C@@]1(CC2=CC=CC=C2)CCCN(C1)C(=O)[C@@H](CC1=CNC2=CC=CC=C12)NC(=O)C(C)(C)N	Solid	Not Available							CHEMBL2110579	8004650														Anamorelin	ZINC000043130908		Anamorelin	Investigational	DB06645	InChI=1S/C31H42N6O3/c1-30(2,32)28(39)34-26(18-23-20-33-25-15-10-9-14-24(23)25)27(38)37-17-11-16-31(21-37,29(40)36(5)35(3)4)19-22-12-7-6-8-13-22/h6-10,12-15,20,26,33H,11,16-19,21,32H2,1-5H3,(H,34,39)/t26-,31-/m1/s1	VQPFSIRUEPQQPP-MXBOTTGLSA-N	3		Not Available	Small Molecule																																			1	No	5	3	Yes	4	1	114.77 Å2	61.1 Å3	157.07 m3·mol-1	9	No	No	0.0103 mg/mL	2.36	-4.7	12.7	8.34			
C10H20N2O2	Not Available	Not Available	200.282	CCCC(CCC)C(=O)NCC(N)=O	Solid	Not Available							CHEMBL471638	5293499															ZINC000001540787		Valrocemide	Investigational	DB06657	InChI=1S/C10H20N2O2/c1-3-5-8(6-4-2)10(14)12-7-9(11)13/h8H,3-7H2,1-2H3,(H2,11,13)(H,12,14)	RALGCAOVRLYSMA-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	Yes	2	2	No	0	0	72.19 Å2	22.73 Å3	54.87 m3·mol-1	7	Yes	No	2.39 mg/mL	0.89	-1.9	13.46	-0.99			
C42H65N13O10	Not Available	Not Available	912.063	[H]N([H])C(=NCCC[C@H](N([H])C(=O)CN([H])C)C(=O)N([H])[C@@H](C(C)C)C(=O)N([H])[C@@H](CC1=CC=C(O)C=C1)C(=O)N([H])[C@@H](C(C)C)C(=O)N([H])[C@@H](CC1=CN=CN1[H])C(=O)N1CCC[C@H]1C(=O)N([H])[C@@H](C)C(O)=O)N([H])[H]	Solid	Not Available					50009338	135894	CHEMBL938	4884380												9556		Saralasin	ZINC000169289386		Saralasin	Investigational	DB06763	InChI=1S/C42H65N13O10/c1-22(2)33(53-35(58)28(50-32(57)20-45-6)9-7-15-47-42(43)44)38(61)51-29(17-25-11-13-27(56)14-12-25)36(59)54-34(23(3)4)39(62)52-30(18-26-19-46-21-48-26)40(63)55-16-8-10-31(55)37(60)49-24(5)41(64)65/h11-14,19,21-24,28-31,33-34,45,56H,7-10,15-18,20H2,1-6H3,(H,46,48)(H,49,60)(H,50,57)(H,51,61)(H,52,62)(H,53,58)(H,54,59)(H,64,65)(H4,43,44,47)/t24-,28-,29-,30-,31-,33-,34-/m0/s1	PFGWGEPQIUAZME-NXSMLHPHSA-N			Not Available	Small Molecule																																			0	No	15	12	Yes	3	2	357.55 Å2	94.21 Å3	234.83 m3·mol-1	25	No	No	0.0439 mg/mL	-4.7	-4.3	3.41	10.84			
C21H34ClN6O3	Not Available	Not Available	453.986	NC(N)=NCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H]([NH3+])CC1=CC=CC=C1)[C@H](O)CCl	Solid	Not Available														0G6			131704300	99443312							[(2R)-1-[(2S)-2-[[(2S,3S)-1-Chloro-6-(diaminomethylideneamino)-2-hydroxyhexan-3-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]azanium	Experimental	DB06841	InChI=1S/C21H33ClN6O3/c22-13-18(29)16(8-4-10-26-21(24)25)27-19(30)17-9-5-11-28(17)20(31)15(23)12-14-6-2-1-3-7-14/h1-3,6-7,15-18,29H,4-5,8-13,23H2,(H,27,30)(H4,24,25,26)/p+1/t15-,16+,17+,18-/m1/s1	DVFLYEYCMMLBTQ-VSZNYVQBSA-O			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.5276 LD50, mol/kg	Inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	5	No	2	2	161.68 Å2	48.55 Å3	130.97 m3·mol-1	11	Yes	No		-0.28		13.56	11.16	P00734	F2	1. Prothrombin
C20H29N5O2	Not Available	Not Available	371.4766	[H][C@]1(CCCN1C(=O)CNC1CCCC1)C(=O)NCC1=CC=C(C=C1)C(N)=N	Solid	Not Available								25060166						10U			23629654	99443316					ZINC000013165429		(S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclopentylamino)ethanoyl)pyrrolidine-2-carboxamide	Experimental	DB06845	InChI=1S/C20H29N5O2/c21-19(22)15-9-7-14(8-10-15)12-24-20(27)17-6-3-11-25(17)18(26)13-23-16-4-1-2-5-16/h7-10,16-17,23H,1-6,11-13H2,(H3,21,22)(H,24,27)/t17-/m0/s1	WXYKSWZWRHMJTE-KRWDZBQOSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.4098 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	4	Yes	3	2	111.31 Å2	41.55 Å3	115.18 m3·mol-1	7	Yes	No	0.185 mg/mL	0.44	-3.3	14.46	11.48	P07477;!P00734	PRSS1;!F2	1. Trypsin-1;!2. Prothrombin
C21H31N5O2	Not Available	Not Available	385.5031	[H][C@]1(CCCN1C(=O)CNC1CCCCC1)C(=O)NCC1=CC=C(C=C1)C(N)=N	Solid	Not Available								25060602						11U			44141860	99443321					ZINC000039035255		(S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclohexylamino)ethanoyl)pyrrolidine-2-carboxamide	Experimental	DB06850	InChI=1S/C21H31N5O2/c22-20(23)16-10-8-15(9-11-16)13-25-21(28)18-7-4-12-26(18)19(27)14-24-17-5-2-1-3-6-17/h8-11,17-18,24H,1-7,12-14H2,(H3,22,23)(H,25,28)/t18-/m0/s1	RYKFVFFOIYLADT-SFHVURJKSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	2.4298 LD50, mol/kg	Inhibitor	Weak inhibitor	Inhibitor										1	Yes	5	4	Yes	3	2	111.31 Å2	43.07 Å3	119.78 m3·mol-1	7	Yes	No	0.137 mg/mL	0.88	-3.4	14.42	11.49	P07477;!P00734	PRSS1;!F2	1. Trypsin-1;!2. Prothrombin
C22H33N5O2	Not Available	Not Available	399.5297	[H][C@]1(CCCN1C(=O)CNC1CCCCCC1)C(=O)NCC1=CC=C(C=C1)C(N)=N	Solid	Not Available								25057147						12U			25113614	99443324					ZINC000039024438		N-cycloheptylglycyl-N-(4-carbamimidoylbenzyl)-L-prolinamide	Experimental	DB06853	InChI=1S/C22H33N5O2/c23-21(24)17-11-9-16(10-12-17)14-26-22(29)19-8-5-13-27(19)20(28)15-25-18-6-3-1-2-4-7-18/h9-12,18-19,25H,1-8,13-15H2,(H3,23,24)(H,26,29)/t19-/m0/s1	BYTJPDBCLWUEBU-IBGZPJMESA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.4115 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	4	Yes	3	2	111.31 Å2	45.48 Å3	124.38 m3·mol-1	7	Yes	No	0.0793 mg/mL	1.33	-3.7	14.37	11.49	P07477;!P00734	PRSS1;!F2	1. Trypsin-1;!2. Prothrombin
C23H35N5O2	Not Available	Not Available	413.5563	[H][C@]1(CCCN1C(=O)CNC1CCCCCCC1)C(=O)NCC1=CC=C(C=C1)C(N)=N	Solid	Not Available								25060816						13U			46937030	99443329					ZINC000039025304		N-cyclooctylglycyl-N-(4-carbamimidoylbenzyl)-L-prolinamide	Experimental	DB06858	InChI=1S/C23H35N5O2/c24-22(25)18-12-10-17(11-13-18)15-27-23(30)20-9-6-14-28(20)21(29)16-26-19-7-4-2-1-3-5-8-19/h10-13,19-20,26H,1-9,14-16H2,(H3,24,25)(H,27,30)/t20-/m0/s1	MMLOIDMSBRJZAE-FQEVSTJZSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	2.4249 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	4	Yes	3	2	111.31 Å2	48.09 Å3	128.98 m3·mol-1	7	Yes	No	0.046 mg/mL	1.77	-4	14.37	11.49	P00734;!P07477	F2;!PRSS1	1. Prothrombin;!2. Trypsin-1
C18H25ClN2O2	Not Available	Not Available	336.856	[H][C@]1(CCCN1C(=O)CCC(C)C)C(=O)NCC1=CC(Cl)=CC=C1	Solid	Not Available							CHEMBL1229677	25057569						16U			42615253	99443339					ZINC000039137935		N-(3-chlorobenzyl)-1-(4-methylpentanoyl)-L-prolinamide	Experimental	DB06868	InChI=1S/C18H25ClN2O2/c1-13(2)8-9-17(22)21-10-4-7-16(21)18(23)20-12-14-5-3-6-15(19)11-14/h3,5-6,11,13,16H,4,7-10,12H2,1-2H3,(H,20,23)/t16-/m0/s1	PQUULPKGCNPPBX-INIZCTEOSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.3494 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	2	1	No	2	0	49.41 Å2	36.47 Å3	92.14 m3·mol-1	6	Yes	No	0.0208 mg/mL	3.13	-4.2	14.27	-0.81	P00734	F2	1. Prothrombin
C24H35ClN4O4	Not Available	Not Available	479.012	[H][C@@](N)(C1CCCCC1)C(=O)N1CCC[C@@]1([H])C(=O)NCC1=C(OCC(=O)NCC)C=CC(Cl)=C1	Solid	Not Available					50066334		CHEMBL42039	395405						177			448677	99443340					ZINC000003831796		1-[2-AMINO-2-CYCLOHEXYL-ACETYL]-PYRROLIDINE-3-CARBOXYLIC ACID 5-CHLORO-2-(2-ETHYLCARBAMOYL-ETHOXY)-BENZYLAMIDE	Experimental	DB06869	InChI=1S/C24H35ClN4O4/c1-2-27-21(30)15-33-20-11-10-18(25)13-17(20)14-28-23(31)19-9-6-12-29(19)24(32)22(26)16-7-4-3-5-8-16/h10-11,13,16,19,22H,2-9,12,14-15,26H2,1H3,(H,27,30)(H,28,31)/t19-,22+/m0/s1	BMHVHOJXEQTIEA-SIKLNZKXSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.7122 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	5	3	Yes	3	1	113.76 Å2	51.3 Å3	126.63 m3·mol-1	9	Yes	No	0.0218 mg/mL	1.75	-4.3	13.91	8.19			
C16H22ClN3O2	Not Available	Not Available	323.818	[H][C@@](N)(CC)C(=O)N1CCC[C@@]1([H])C(=O)NCC1=CC=CC(Cl)=C1	Solid	Not Available					50307850		CHEMBL1198130	25048704						19U			25113126	99443349					ZINC000039024307		1-[(2R)-2-aminobutanoyl]-N-(3-chlorobenzyl)-L-prolinamide	Experimental	DB06878	InChI=1S/C16H22ClN3O2/c1-2-13(18)16(22)20-8-4-7-14(20)15(21)19-10-11-5-3-6-12(17)9-11/h3,5-6,9,13-14H,2,4,7-8,10,18H2,1H3,(H,19,21)/t13-,14+/m1/s1	OTYYXGRJXJFTCD-KGLIPLIRSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.4931 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	3	2	No	2	1	75.43 Å2	33.68 Å3	86.14 m3·mol-1	5	Yes	No	0.446 mg/mL	1.43	-2.9	14.17	8.14	P00734	F2	1. Prothrombin
C26H33N3O5	Not Available	Not Available	467.5573	[H][C@](C)(O)[C@]([H])(CC1=CC=CC=C1)NC(=O)[C@]1([H])CCCN1C(=O)[C@]([H])(C)NC(=O)OCC1=CC=CC=C1	Solid	Not Available								4883307						1BH			6323185	99443357					ZINC000015289930		N-BENZYLOXYCARBONYL-ALA-PRO-3-AMINO-4-PHENYL-BUTAN-2-OL	Experimental	DB06886	InChI=1S/C26H33N3O5/c1-18(27-26(33)34-17-21-12-7-4-8-13-21)25(32)29-15-9-14-23(29)24(31)28-22(19(2)30)16-20-10-5-3-6-11-20/h3-8,10-13,18-19,22-23,30H,9,14-17H2,1-2H3,(H,27,33)(H,28,31)/t18-,19+,22-,23-/m0/s1	MACLRJNEKXUAJK-YDLSIGKMSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.4167 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	4	3	Yes	3	0	107.97 Å2	50.61 Å3	127.63 m3·mol-1	10	Yes	No	0.0149 mg/mL	2.54	-4.5	13.29	-2.8	P00781	apr	1. Subtilisin DY
C18H26ClN3O2	Not Available	Not Available	351.871	[H][C@@](N)(CC(C)C)C(=O)N1CCC[C@@]1([H])C(=O)NCC1=CC(Cl)=CC=C1	Solid	Not Available							CHEMBL1229801	25057436						21U			25113127	99443382					ZINC000039024956		D-leucyl-N-(3-chlorobenzyl)-L-prolinamide	Experimental	DB06911	InChI=1S/C18H26ClN3O2/c1-12(2)9-15(20)18(24)22-8-4-7-16(22)17(23)21-11-13-5-3-6-14(19)10-13/h3,5-6,10,12,15-16H,4,7-9,11,20H2,1-2H3,(H,21,23)/t15-,16+/m1/s1	FHVBVJXZKNCSLP-CVEARBPZSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.4333 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	3	2	No	2	1	75.43 Å2	36.84 Å3	95.29 m3·mol-1	6	Yes	No	0.0718 mg/mL	2.16	-3.7	14.29	8.12	P00734	F2	1. Prothrombin
C21H24ClN3O2	Not Available	Not Available	385.887	[H][C@@](N)(CC1=CC=CC=C1)C(=O)N1CCC[C@@]1([H])C(=O)NCC1=CC(Cl)=CC=C1	Solid	Not Available					50133531		CHEMBL321130	23188426						22U			25011732	99443390							D-phenylalanyl-N-(3-chlorobenzyl)-L-prolinamide	Experimental	DB06919	InChI=1S/C21H24ClN3O2/c22-17-9-4-8-16(12-17)14-24-20(26)19-10-5-11-25(19)21(27)18(23)13-15-6-2-1-3-7-15/h1-4,6-9,12,18-19H,5,10-11,13-14,23H2,(H,24,26)/t18-,19+/m1/s1	CJHLRGCXPGIPCB-MOPGFXCFSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.5043 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	3	2	Yes	3	1	75.43 Å2	40.2 Å3	106.24 m3·mol-1	6	Yes	No	0.00916 mg/mL	2.56	-4.6	14.2	7.7			
C17H24N4O2	Not Available	Not Available	316.3981	[H][C@]1(CCCN1C(=O)CCC)C(=O)NCC1=CC=C(C=C1)C(N)=N	Solid	Not Available					50307861		CHEMBL1198191	25051355						24U			25113616	99443400					ZINC000039029982		1-butanoyl-N-(4-carbamimidoylbenzyl)-L-prolinamide	Experimental	DB06929	InChI=1S/C17H24N4O2/c1-2-4-15(22)21-10-3-5-14(21)17(23)20-11-12-6-8-13(9-7-12)16(18)19/h6-9,14H,2-5,10-11H2,1H3,(H3,18,19)(H,20,23)/t14-/m0/s1	RYAZZWWVNUWKNB-AWEZNQCLSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.4536 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	3	No	2	1	99.28 Å2	35.14 Å3	99.86 m3·mol-1	6	Yes	No	0.191 mg/mL	0.72	-3.2	14.42	11.48	P00734	F2	1. Prothrombin
C19H28N4O2	Not Available	Not Available	344.4512	[H][C@]1(CCCN1C(=O)CCC(C)C)C(=O)NCC1=CC=C(C=C1)C(N)=N	Solid	Not Available							CHEMBL1229851	25060244						26U			25113617	99443407					ZINC000039029983		N-(4-carbamimidoylbenzyl)-1-(4-methylpentanoyl)-L-prolinamide	Experimental	DB06936	InChI=1S/C19H28N4O2/c1-13(2)5-10-17(24)23-11-3-4-16(23)19(25)22-12-14-6-8-15(9-7-14)18(20)21/h6-9,13,16H,3-5,10-12H2,1-2H3,(H3,20,21)(H,22,25)/t16-/m0/s1	AEKJCSNKYXWOAQ-INIZCTEOSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.4277 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	3	No	2	1	99.28 Å2	39.26 Å3	109.01 m3·mol-1	7	Yes	No	0.163 mg/mL	1.45	-3.3	14.51	11.48	P00734	F2	1. Prothrombin
C17H30FN3O2	Not Available	Not Available	327.4374	[H][C@@](N)(C(=O)N1CC[C@]([H])(F)C1)[C@@]([H])(C)[C@@]1([H])CC[C@@]([H])(CC1)N(C)C(C)=O	Solid	Not Available							CHEMBL1229855	17279511						277			16122596	99443410							N-(TRANS-4-{(1S,2S)-2-AMINO-3-[(3S)-3-FLUOROPYRROLIDIN-1-YL]-1-METHYL-3-OXOPROPYL}CYCLOHEXYL)-N-METHYLACETAMIDE	Experimental	DB06939	InChI=1S/C17H30FN3O2/c1-11(16(19)17(23)21-9-8-14(18)10-21)13-4-6-15(7-5-13)20(3)12(2)22/h11,13-16H,4-10,19H2,1-3H3/t11-,13-,14-,15-,16-/m0/s1	BZFQBRSDORUYAB-YDMUCJKGSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.5082 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	3	1	No	2	1	66.64 Å2	36 Å3	87.09 m3·mol-1	4	Yes	No	0.722 mg/mL	0.25	-2.7		8.49			
C17H25N5O2	Not Available	Not Available	331.4127	[H][C@@](N)(CC)C(=O)N1CCC[C@@]1([H])C(=O)NCC1=CC=C(C=C1)C(N)=N	Solid	Not Available					50307871		CHEMBL1198148	25046499						29U			25113128	99443418					ZINC000039024957		1-[(2R)-2-aminobutanoyl]-N-(4-carbamimidoylbenzyl)-L-prolinamide	Experimental	DB06947	InChI=1S/C17H25N5O2/c1-2-13(18)17(24)22-9-3-4-14(22)16(23)21-10-11-5-7-12(8-6-11)15(19)20/h5-8,13-14H,2-4,9-10,18H2,1H3,(H3,19,20)(H,21,23)/t13-,14+/m1/s1	YHAMQFKGUUSJMU-KGLIPLIRSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3608 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	4	No	2	2	125.3 Å2	36.51 Å3	103.01 m3·mol-1	6	Yes	No	0.114 mg/mL	-0.26	-3.5	14.43	11.48	P00734	F2	1. Prothrombin
C19H29N5O2	Not Available	Not Available	359.4659	[H][C@@](N)(CC(C)C)C(=O)N1CCC[C@@]1([H])C(=O)NCC1=CC=C(C=C1)C(N)=N	Solid	Not Available							CHEMBL1230016	25057486						31U			25220914	99443467					ZINC000039034766		D-leucyl-N-(4-carbamimidoylbenzyl)-L-prolinamide	Experimental	DB06996	InChI=1S/C19H29N5O2/c1-12(2)10-15(20)19(26)24-9-3-4-16(24)18(25)23-11-13-5-7-14(8-6-13)17(21)22/h5-8,12,15-16H,3-4,9-11,20H2,1-2H3,(H3,21,22)(H,23,25)/t15-,16+/m1/s1	XFNMDMGNNKIXBT-CVEARBPZSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.4005 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	4	No	2	2	125.3 Å2	40.41 Å3	112.16 m3·mol-1	7	Yes	No	0.128 mg/mL	0.47	-3.4	14.51	11.48	P00734	F2	1. Prothrombin
C22H28N5O2	Not Available	Not Available	394.49	[H][C@@](N)(CC1=CC=CC=C1)C(=O)N1CCC[C@@]1([H])C(=O)NCC1=CC=C(C=C1)C(N)=[NH2+]	Solid	Not Available								25060596						32U			46937043	99443476							D-phenylalanyl-N-{4-[amino(iminio)methyl]benzyl}-L-prolinamide	Experimental	DB07005	InChI=1S/C22H27N5O2/c23-18(13-15-5-2-1-3-6-15)22(29)27-12-4-7-19(27)21(28)26-14-16-8-10-17(11-9-16)20(24)25/h1-3,5-6,8-11,18-19H,4,7,12-14,23H2,(H3,24,25)(H,26,28)/p+1/t18-,19+/m1/s1	VZFTWWJAUZOJDH-MOPGFXCFSA-O			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3841 LD50, mol/kg	Inhibitor	Weak inhibitor	Inhibitor										1	Yes	4	4	Yes	3	2	127.04 Å2	42.96 Å3	123.91 m3·mol-1	7	Yes	No	0.0132 mg/mL	0.88	-4.5	14.39	11.48	P00734	F2	1. Prothrombin
C21H24FN3O2	Not Available	Not Available	369.4326	[H][C@@](N)(CC1=CC=CC=C1)C(=O)N1CCC[C@@]1([H])C(=O)NCC1=CC=CC(F)=C1	Solid	Not Available								25058086						37U			25011733	99443498					ZINC000039020704		D-phenylalanyl-N-(3-fluorobenzyl)-L-prolinamide	Experimental	DB07027	InChI=1S/C21H24FN3O2/c22-17-9-4-8-16(12-17)14-24-20(26)19-10-5-11-25(19)21(27)18(23)13-15-6-2-1-3-7-15/h1-4,6-9,12,18-19H,5,10-11,13-14,23H2,(H,24,26)/t18-,19+/m1/s1	JGZSVYZIJHGHMA-MOPGFXCFSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.5272 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	3	2	Yes	3	1	75.43 Å2	38.92 Å3	101.65 m3·mol-1	6	Yes	No	0.0445 mg/mL	2.1	-3.9	14.21	7.7	P00734	F2	1. Prothrombin
C23H29N3O2	Not Available	Not Available	379.4953	[H][C@@](N)(C(C1=CC=CC=C1)C1=CC=CC=C1)C(=O)N1CCC[C@@]1([H])C(=O)NCCC	Solid	Not Available					29377		CHEMBL490730	23338407						44U			25271577	99443554					ZINC000039115027		beta-phenyl-D-phenylalanyl-N-propyl-L-prolinamide	Experimental	DB07083	InChI=1S/C23H29N3O2/c1-2-15-25-22(27)19-14-9-16-26(19)23(28)21(24)20(17-10-5-3-6-11-17)18-12-7-4-8-13-18/h3-8,10-13,19-21H,2,9,14-16,24H2,1H3,(H,25,27)/t19-,21+/m0/s1	HZKKJPDVZGOOPU-PZJWPPBQSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.4273 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	3	2	Yes	3	1	75.43 Å2	42.21 Å3	110.66 m3·mol-1	7	Yes	No	0.0127 mg/mL	2.61	-4.5	15.59	7.66	P00734	F2	1. Prothrombin
C20H28N4O3	Not Available	Not Available	372.4613	[H][C@]1(CCCN1C(=O)COC1CCCC1)C(=O)NCC1=CC=C(C=C1)C(N)=N	Solid	Not Available								25060647						45U			24963035	99443559					ZINC000039019414		(S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclopentyloxy)ethanoyl)pyrrolidine-2-carboxamide	Experimental	DB07088	InChI=1S/C20H28N4O3/c21-19(22)15-9-7-14(8-10-15)12-23-20(26)17-6-3-11-24(17)18(25)13-27-16-4-1-2-5-16/h7-10,16-17H,1-6,11-13H2,(H3,21,22)(H,23,26)/t17-/m0/s1	ZWXWAYUCJVQHOR-KRWDZBQOSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.2640 LD50, mol/kg	Inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	3	Yes	3	1	108.51 Å2	40.36 Å3	113.5 m3·mol-1	7	Yes	No	0.18 mg/mL	0.76	-3.3	14.36	11.48	P07477;!P00734	PRSS1;!F2	1. Trypsin-1;!2. Prothrombin
C21H30N4O3	Not Available	Not Available	386.4879	[H][C@]1(CCCN1C(=O)COC1CCCCC1)C(=O)NCC1=CC=C(C=C1)C(N)=N	Solid	Not Available								25060896						46U			24963036	99443562					ZINC000039019313		(S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclohexyloxy)ethanoyl)pyrrolidine-2-carboxamide	Experimental	DB07091	InChI=1S/C21H30N4O3/c22-20(23)16-10-8-15(9-11-16)13-24-21(27)18-7-4-12-25(18)19(26)14-28-17-5-2-1-3-6-17/h8-11,17-18H,1-7,12-14H2,(H3,22,23)(H,24,27)/t18-/m0/s1	IWPMQJKXKKKSEY-SFHVURJKSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	2.3086 LD50, mol/kg	Inhibitor	Weak inhibitor	Inhibitor										1	Yes	5	3	Yes	3	1	108.51 Å2	43.06 Å3	118.1 m3·mol-1	7	Yes	No	0.114 mg/mL	1.2	-3.5	14.32	11.48	P07477;!P00734	PRSS1;!F2	1. Trypsin-1;!2. Prothrombin
C21H30N4O2	Not Available	Not Available	370.4885	[H][C@]1(CCCN1C(=O)CCC1CCCC1)C(=O)NCC1=CC=C(C=C1)C(N)=N	Solid	Not Available					50307867		CHEMBL1198650	25052275						49U			24963037	99443566					ZINC000039019392		(S)-N-(4-carbamimidoylbenzyl)-1-(3-cyclopentylpropanoyl)pyrrolidine-2-carboxamide	Experimental	DB07095	InChI=1S/C21H30N4O2/c22-20(23)17-10-7-16(8-11-17)14-24-21(27)18-6-3-13-25(18)19(26)12-9-15-4-1-2-5-15/h7-8,10-11,15,18H,1-6,9,12-14H2,(H3,22,23)(H,24,27)/t18-/m0/s1	BNCHHUFGEOJCNH-SFHVURJKSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3571 LD50, mol/kg	Inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	3	Yes	3	1	99.28 Å2	42.03 Å3	116.41 m3·mol-1	7	Yes	No	0.0665 mg/mL	1.88	-3.8	14.5	11.48	P07477;!P00734	PRSS1;!F2	1. Trypsin-1;!2. Prothrombin
C22H32N4O2	Not Available	Not Available	384.5151	[H][C@]1(CCCN1C(=O)CCC1CCCCC1)C(=O)NCC1=CC=C(C=C1)C(N)=N	Solid	Not Available					50307868		CHEMBL1198138	25049922						50U			25134248	99443602					ZINC000039018741		(S)-N-(4-carbamimidoylbenzyl)-1-(3-cyclohexylpropanoyl)pyrrolidine-2-carboxamide	Experimental	DB07131	InChI=1S/C22H32N4O2/c23-21(24)18-11-8-17(9-12-18)15-25-22(28)19-7-4-14-26(19)20(27)13-10-16-5-2-1-3-6-16/h8-9,11-12,16,19H,1-7,10,13-15H2,(H3,23,24)(H,25,28)/t19-/m0/s1	DOTBZTLJSXFKCP-IBGZPJMESA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3983 LD50, mol/kg	Inhibitor	Weak inhibitor	Inhibitor										1	Yes	4	3	Yes	3	1	99.28 Å2	44.01 Å3	121.01 m3·mol-1	7	Yes	No	0.031 mg/mL	2.32	-4.1	14.45	11.48	P07477;!P00734	PRSS1;!F2	1. Trypsin-1;!2. Prothrombin
C22H27N3O2	Not Available	Not Available	365.4687	[H][C@@](N)(CC1=CC=CC=C1)C(=O)N1CCC[C@@]1([H])C(=O)NCC1=CC(C)=CC=C1	Solid	Not Available								25060226						51U			25021183	99443604					ZINC000039024292		D-phenylalanyl-N-(3-methylbenzyl)-L-prolinamide	Experimental	DB07133	InChI=1S/C22H27N3O2/c1-16-7-5-10-18(13-16)15-24-21(26)20-11-6-12-25(20)22(27)19(23)14-17-8-3-2-4-9-17/h2-5,7-10,13,19-20H,6,11-12,14-15,23H2,1H3,(H,24,26)/t19-,20+/m1/s1	CHKWABXWPATIIG-UXHICEINSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.2747 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	3	2	Yes	3	1	75.43 Å2	40.18 Å3	106.48 m3·mol-1	6	Yes	No	0.0119 mg/mL	2.47	-4.5	14.6	7.7	P00734	F2	1. Prothrombin
C21H25N3O2	Not Available	Not Available	351.4421	[H][C@@](N)(CC1=CC=CC=C1)C(=O)N1CCC[C@@]1([H])C(=O)NCC1=CC=CC=C1	Solid	Not Available					50133518		CHEMBL116597	23200354						53U			25113125	99443614					ZINC000053165085		D-phenylalanyl-N-benzyl-L-prolinamide	Experimental	DB07143	InChI=1S/C21H25N3O2/c22-18(14-16-8-3-1-4-9-16)21(26)24-13-7-12-19(24)20(25)23-15-17-10-5-2-6-11-17/h1-6,8-11,18-19H,7,12-15,22H2,(H,23,25)/t18-,19+/m1/s1	MEPJWLFTTFHOQO-MOPGFXCFSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.2824 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	3	2	Yes	3	1	75.43 Å2	37.95 Å3	101.43 m3·mol-1	6	Yes	No	0.0307 mg/mL	1.95	-4.1	14.55	7.7			
C16H20F3N3O2	Not Available	Not Available	343.3441	[H][C@](N)(CC(=O)N1CCCNC(=O)[C@@]1([H])C)CC1=C(F)C=C(F)C(F)=C1	Solid	Not Available					13519		CHEMBL385711	8625531						565			10450114	99443625					ZINC000003949268		(3R)-4-[(3R)-3-AMINO-4-(2,4,5-TRIFLUOROPHENYL)BUTANOYL]-3-METHYL-1,4-DIAZEPAN-2-ONE	Experimental	DB07154	InChI=1S/C16H20F3N3O2/c1-9-16(24)21-3-2-4-22(9)15(23)7-11(20)5-10-6-13(18)14(19)8-12(10)17/h6,8-9,11H,2-5,7,20H2,1H3,(H,21,24)/t9-,11-/m1/s1	SWKGZJAAGSVROJ-MWLCHTKSSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.4717 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	3	2	No	2	1	75.43 Å2	31.94 Å3	82.2 m3·mol-1	4	Yes	No	0.244 mg/mL	0.58	-3.2	13.62	8.78			
C21H30ClN3O2	Not Available	Not Available	391.935	[H][C@@](N)(CC1CCCCC1)C(=O)N1CCC[C@@]1([H])C(=O)NCC1=CC(Cl)=CC=C1	Solid	Not Available					50307857		CHEMBL1198500	25052858						64U			42615254	99443661					ZINC000039145543		3-cyclohexyl-D-alanyl-N-(3-chlorobenzyl)-L-prolinamide	Experimental	DB07190	InChI=1S/C21H30ClN3O2/c22-17-9-4-8-16(12-17)14-24-20(26)19-10-5-11-25(19)21(27)18(23)13-15-6-2-1-3-7-15/h4,8-9,12,15,18-19H,1-3,5-7,10-11,13-14,23H2,(H,24,26)/t18-,19+/m1/s1	JGFCNVHEEMBVJG-MOPGFXCFSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.5043 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	3	2	Yes	3	1	75.43 Å2	41.64 Å3	107.29 m3·mol-1	6	Yes	No	0.00961 mg/mL	3.03	-4.6	14.27	8.12	P00734	F2	1. Prothrombin
C25H35N3O6	Not Available	Not Available	473.5619	[H][C@](C)(CC)[C@]([H])(NC(=O)[C@@]1([H])O[C@]1([H])C(=O)NCCC)C(=O)N1CCC[C@@]1([H])C(=O)OCC1=CC=CC=C1	Solid	Not Available					16504			18741757						73V			22850133	99443690					ZINC000014961495		BENZYL N-({(2S,3S)-3-[(PROPYLAMINO)CARBONYL]OXIRAN-2-YL}CARBONYL)-L-ISOLEUCYL-L-PROLINATE	Experimental	DB07219	InChI=1S/C25H35N3O6/c1-4-13-26-22(29)20-21(34-20)23(30)27-19(16(3)5-2)24(31)28-14-9-12-18(28)25(32)33-15-17-10-7-6-8-11-17/h6-8,10-11,16,18-21H,4-5,9,12-15H2,1-3H3,(H,26,29)(H,27,30)/t16-,18-,19-,20-,21-/m0/s1	OMQNYWZURFTFHE-MQBSTWLZSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.3991 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	2	Yes	3	0	117.34 Å2	50.97 Å3	123.96 m3·mol-1	12	Yes	No	0.097 mg/mL	2.03	-3.7	12.15	-3.3	P07858	CTSB	1. Cathepsin B
C19H31N3O6	Not Available	Not Available	397.4659	[H][C@](C)(CC)[C@]([H])(NC(=O)[C@@]1([H])O[C@]1([H])C(=O)NCCC)C(=O)N1CCC[C@@]1([H])C(=O)OC	Solid	Not Available					16503		CHEMBL262103	5042571						74M			6610318	99443694					ZINC000004899858		METHYL N-({(2S,3S)-3-[(PROPYLAMINO)CARBONYL]OXIRAN-2-YL}CARBONYL)-L-ISOLEUCYL-L-PROLINATE	Experimental	DB07223	InChI=1S/C19H31N3O6/c1-5-9-20-16(23)14-15(28-14)17(24)21-13(11(3)6-2)18(25)22-10-7-8-12(22)19(26)27-4/h11-15H,5-10H2,1-4H3,(H,20,23)(H,21,24)/t11-,12-,13-,14-,15-/m0/s1	XGWSRLSPWIEMLQ-YTFOTSKYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.4300 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	2	No	2	0	117.34 Å2	41.92 Å3	99.34 m3·mol-1	10	Yes	No	2.9 mg/mL	0.31	-2.1	12.2	-3.3			
C22H29N3O6	Not Available	Not Available	431.4822	[H][C@](C)(CC)[C@]([H])(NC(=O)[C@@]1([H])O[C@]1([H])C(=O)NCC1=CC=CC=C1)C(=O)N1CCC[C@@]1([H])C(O)=O	Solid	Not Available					16502			25056628						78A			23647361	99443702					ZINC000014961490		N-({(2S,3S)-3-[(BENZYLAMINO)CARBONYL]OXIRAN-2-YL}CARBONYL)-L-ISOLEUCYL-L-PROLINE	Experimental	DB07231	InChI=1S/C22H29N3O6/c1-3-13(2)16(21(28)25-11-7-10-15(25)22(29)30)24-20(27)18-17(31-18)19(26)23-12-14-8-5-4-6-9-14/h4-6,8-9,13,15-18H,3,7,10-12H2,1-2H3,(H,23,26)(H,24,27)(H,29,30)/t13-,15-,16-,17-,18-/m0/s1	MERYMLLGRCNRKE-HILJTLORSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3331 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	6	3	Yes	3	-1	128.34 Å2	44.54 Å3	109.92 m3·mol-1	9	Yes	No	0.484 mg/mL	1.01	-3	3.81	-3.3	P07858	CTSB	1. Cathepsin B
C20H36N6O3S	Not Available	Not Available	440.603	[H][C@@](CCCNC(N)N)(NC(=O)[C@@]([H])(NC(=O)CCC(C)C)C(C)C)C(=O)C1=NC=CS1	Solid	Not Available								5257036						995			6857702	99443770					ZINC000038190858		4-METHYL-PENTANOIC ACID {1-[4-GUANIDINO-1-(THIAZOLE-2-CARBONYL)-BUTYLCARBAMOYL]-2-METHYL-PROPYL}-AMIDE	Experimental	DB07299	InChI=1S/C20H36N6O3S/c1-12(2)7-8-15(27)26-16(13(3)4)18(29)25-14(6-5-9-24-20(21)22)17(28)19-23-10-11-30-19/h10-14,16,20,24H,5-9,21-22H2,1-4H3,(H,25,29)(H,26,27)/t14-,16-/m0/s1	ZXELQWLUDMEUHS-HOCLYGCPSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.5133 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	7	5	No	1	0	152.23 Å2	48.11 Å3	116.74 m3·mol-1	14	Yes	No	0.0248 mg/mL	1.23	-4.2	12.08	6.69	P03951	F11	1. Coagulation factor XI
C20H29N5O4	Not Available	Not Available	403.4754	[H][C@]1(CNC(=O)NC2=CC=C(C=C2)C(=O)OC)CC[C@]([H])(N1)C(=O)N1CCC[C@@]1([H])CN	Solid	Not Available							CHEMBL1230763	10015418						AAF			11840913	99443799					ZINC000024803068		METHYL 4-{[({[(2R,5S)-5-{[(2S)-2-(AMINOMETHYL)PYRROLIDIN-1-YL]CARBONYL}PYRROLIDIN-2-YL]METHYL}AMINO)CARBONYL]AMINO}BENZOATE	Experimental	DB07328	InChI=1S/C20H29N5O4/c1-29-19(27)13-4-6-14(7-5-13)24-20(28)22-12-15-8-9-17(23-15)18(26)25-10-2-3-16(25)11-21/h4-7,15-17,23H,2-3,8-12,21H2,1H3,(H2,22,24,28)/t15-,16+,17+/m1/s1	USDCNOQKDUFKRD-IKGGRYGDSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.2583 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	4	Yes	3	2	125.79 Å2	43.47 Å3	109.06 m3·mol-1	7	Yes	No	0.317 mg/mL	0.2	-3.1	12.79	9.45	P27487	DPP4	1. Dipeptidyl peptidase 4
C17H26N4O3	Not Available	Not Available	334.4133	[H][C@]1(CCCN1C(=O)OCC1=CC=CC=C1)C(=O)NNCCCCN	Solid	Not Available								392226						ALZ			444238	99443837					ZINC000003874384		2-[N'-(4-AMINO-BUTYL)-HYDRAZINOCARBONYL]-PYRROLIDINE-1-CARBOXYLIC ACID BENZYL ESTER	Experimental	DB07366	InChI=1S/C17H26N4O3/c18-10-4-5-11-19-20-16(22)15-9-6-12-21(15)17(23)24-13-14-7-2-1-3-8-14/h1-3,7-8,15,19H,4-6,9-13,18H2,(H,20,22)/t15-/m0/s1	MOCIXHUQBOUBAK-HNNXBMFYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.2629 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	3	No	2	1	96.69 Å2	37.28 Å3	101.96 m3·mol-1	9	Yes	No	0.47 mg/mL	0.76	-2.8	12.4	10.2	P00734	F2	1. Prothrombin
C21H33N5O4	Not Available	Not Available	419.5178	[H][C@](CC1=CC=CC=C1)(NC(=O)OCC)C(=O)N1CCC[C@@]1([H])C(=O)NNCCCCN	Solid	Not Available								392213						AZL			444224	99443871					ZINC000003870519		1-ETHOXYCARBONYL-D-PHE-PRO-2(4-AMINOBUTYL)HYDRAZINE	Experimental	DB07400	InChI=1S/C21H33N5O4/c1-2-30-21(29)24-17(15-16-9-4-3-5-10-16)20(28)26-14-8-11-18(26)19(27)25-23-13-7-6-12-22/h3-5,9-10,17-18,23H,2,6-8,11-15,22H2,1H3,(H,24,29)(H,25,27)/t17-,18+/m1/s1	AEHSFPPTWRQOFS-MSOLQXFVSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3142 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	4	No	2	1	125.79 Å2	46.08 Å3	124.01 m3·mol-1	12	Yes	No	0.295 mg/mL	0.51	-3.2	12.27	10.2	P00734	F2	1. Prothrombin
C9H17BN2O3	Not Available	Not Available	212.054	[H][C@]1(CCCN1C(=O)[C@]1([H])CCCN1)B(O)O	Solid	Not Available					50050521	41285	CHEMBL63895	8373728						BPR			10198228	99443953					ZINC000169748497		(2R)-N-[(2R)-2-(DIHYDROXYBORYL)-1-L-PROLYLPYRROLIDIN-2-YL]-N-[(5R)-5-(DIHYDROXYBORYL)-1-L-PROLYLPYRROLIDIN-2-YL]-L-PROLINAMIDE	Experimental	DB07482	InChI=1S/C9H17BN2O3/c13-9(7-3-1-5-11-7)12-6-2-4-8(12)10(14)15/h7-8,11,14-15H,1-6H2/t7-,8-/m0/s1	XSBZZZGVAIXJLD-YUMQZZPRSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1213 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	3	No	2	1	72.8 Å2	22.52 Å3	50.91 m3·mol-1	2	Yes	No	30.2 mg/mL	-1.3	-0.85	8.61	9.85			
C20H37N3O4	Not Available	Not Available	383.5255	[H]C(=O)[C@H](CCCC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(C)=O	Solid	Not Available					50069792	2423	CHEMBL304784	391397				C11306		CIB			443118	99444029					ZINC000003826241		acetylleucyl-leucyl-norleucinal	Experimental	DB07558	InChI=1S/C20H37N3O4/c1-7-8-9-16(12-24)22-19(26)18(11-14(4)5)23-20(27)17(10-13(2)3)21-15(6)25/h12-14,16-18H,7-11H2,1-6H3,(H,21,25)(H,22,26)(H,23,27)/t16-,17-,18-/m0/s1	FMYKJLXRRQTBOR-BZSNNMDCSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3287 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	3	No	0	0	104.37 Å2	43.29 Å3	104.68 m3·mol-1	13	Yes	No	0.0596 mg/mL	1.93	-3.8	12.49	-1.7	O14818	PSMA7	1. Proteasome subunit alpha type-7
C24H38N4O4	Not Available	Not Available	446.5829	[H][C@](NC(=O)NC1CCCC1)(C(C)C)C(=O)N1CC[C@]([H])(NC(=O)C2CC2)[C@@]1([H])C1(CCC1)C=O	Solid	Not Available								4450228						CPX			5287977	99444053					ZINC000033821260		N-[(2R,3S)-1-((2S)-2-{[(CYCLOPENTYLAMINO)CARBONYL]AMINO}-3-METHYLBUTANOYL)-2-(1-FORMYL-1-CYCLOBUTYL)PYRROLIDINYL]CYCLOPROPANECARBOXAMIDE	Experimental	DB07582	InChI=1S/C24H38N4O4/c1-15(2)19(27-23(32)25-17-6-3-4-7-17)22(31)28-13-10-18(26-21(30)16-8-9-16)20(28)24(14-29)11-5-12-24/h14-20H,3-13H2,1-2H3,(H,26,30)(H2,25,27,32)/t18-,19-,20-/m0/s1	GCDRFILPPBOJLM-UFYCRDLUSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3639 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	3	Yes	4	0	107.61 Å2	49.2 Å3	119.3 m3·mol-1	8	Yes	No	0.352 mg/mL	1.46	-3.1	14.66	-0.57	P26664;!Q91RS4	Not Available;!Not Available	1. Genome polyprotein;!2. NS3 protease
C21H33BN4O5	Not Available	Not Available	432.322	CC(=O)N[C@H](CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)B(O)O	Solid	Not Available					50288414		CHEMBL100109	4450302						DI2			5288064	99444129					ZINC000169748501		AC-(D)Phe-pro-borolys-OH	Experimental	DB07658	InChI=1S/C21H33BN4O5/c1-15(27)24-17(14-16-8-3-2-4-9-16)21(29)26-13-7-10-18(26)20(28)25-19(22(30)31)11-5-6-12-23/h2-4,8-9,17-19,30-31H,5-7,10-14,23H2,1H3,(H,24,27)(H,25,28)/t17-,18+,19+/m1/s1	UCQIHCRMWNRFNP-QYZOEREBSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.2297 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	5	No	2	1	144.99 Å2	46.7 Å3	112.01 m3·mol-1	11	Yes	No	0.453 mg/mL	-1	-3	8.63	10.21			
C22H35BN4O5	Not Available	Not Available	446.348	[H][C@@](CCCCCN)(NC(=O)[C@]1([H])CCCN1C(=O)[C@@]([H])(CC1=CC=CC=C1)NC(C)=O)B(O)O	Solid	Not Available								4450304						DI4			5288066	99444130					ZINC000169748502		AC-(D)PHE-PRO-BOROHOMOLYS-OH	Experimental	DB07659	InChI=1S/C22H35BN4O5/c1-16(28)25-18(15-17-9-4-2-5-10-17)22(30)27-14-8-11-19(27)21(29)26-20(23(31)32)12-6-3-7-13-24/h2,4-5,9-10,18-20,31-32H,3,6-8,11-15,24H2,1H3,(H,25,28)(H,26,29)/t18-,19+,20+/m1/s1	AILSWIBFGYYZTK-AABGKKOBSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.2297 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	5	No	2	1	144.99 Å2	48.88 Å3	116.62 m3·mol-1	12	Yes	No	0.211 mg/mL	-0.62	-3.3	8.63	10.21	P00734	F2	1. Prothrombin
C20H31BN4O5	Not Available	Not Available	418.295	[H][C@@](CCCN)(NC(=O)[C@]1([H])CCCN1C(=O)[C@@]([H])(CC1=CC=CC=C1)NC(C)=O)B(O)O	Solid	Not Available								4450305						DI5			5288067	99444131					ZINC000169748503		AC-(D)PHE-PRO-BOROHOMOORNITHINE-OH	Experimental	DB07660	InChI=1S/C20H31BN4O5/c1-14(26)23-16(13-15-7-3-2-4-8-15)20(28)25-12-6-9-17(25)19(27)24-18(21(29)30)10-5-11-22/h2-4,7-8,16-18,29-30H,5-6,9-13,22H2,1H3,(H,23,26)(H,24,27)/t16-,17+,18+/m1/s1	YKWKWNKWBGQECF-SQNIBIBYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.2297 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	5	No	2	1	144.99 Å2	44.69 Å3	107.41 m3·mol-1	10	Yes	No	0.592 mg/mL	-1.3	-2.8	8.62	9.93	P00734	F2	1. Prothrombin
C21H28FN3O7	Not Available	Not Available	453.467	CC(C)[C@H](NC(=O)OCC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)CF	Solid	Not Available							CHEMBL205821	4593739									5497171	99444215					ZINC000025668028		Z-Val-Ala-Asp fluoromethyl ketone	Experimental	DB07744	InChI=1S/C21H28FN3O7/c1-12(2)18(25-21(31)32-11-14-7-5-4-6-8-14)20(30)23-13(3)19(29)24-15(9-17(27)28)16(26)10-22/h4-8,12-13,15,18H,9-11H2,1-3H3,(H,23,30)(H,24,29)(H,25,31)(H,27,28)/t13-,15-,18-/m0/s1	SUUHZYLYARUNIA-YEWWUXTCSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.2208 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	6	4	No	1	-1	150.9 Å2	44.69 Å3	109.36 m3·mol-1	13	Yes	No	0.0358 mg/mL	1.16	-4.1	4.13	-4	P29466	CASP1	1. Caspase-1
C20H24N4O3	Not Available	Not Available	368.4296	[H][C@@](C)(NC(=O)CN)C(=O)N1CCC[C@@]1([H])C(=O)NC1=CC=C2C=CC=CC2=C1	Solid	Not Available								25060358						GA0			46937094	99444284					ZINC000053683227		GLYCYLALANYL-N-2-NAPHTHYL-L-PROLINEAMIDE	Experimental	DB07813	InChI=1S/C20H24N4O3/c1-13(22-18(25)12-21)20(27)24-10-4-7-17(24)19(26)23-16-9-8-14-5-2-3-6-15(14)11-16/h2-3,5-6,8-9,11,13,17H,4,7,10,12,21H2,1H3,(H,22,25)(H,23,26)/t13-,17-/m0/s1	KCELZXZDIUJGNM-GUYCJALGSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.4335 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	4	3	No	3	1	104.53 Å2	39.46 Å3	103.01 m3·mol-1	5	Yes	No	0.0942 mg/mL	0.48	-3.6	12.49	7.84	Q7MUW6	ptpA	1. Prolyl tripeptidyl peptidase
C16H21ClN2O3	Not Available	Not Available	324.803	[H][C@@](C)(NC(C)=O)C(=O)N[C@@]([H])(CC1=CC=CC=C1)C(=O)CCCl	Solid	Not Available								25057340						HIN			46937104	99444370					ZINC000008239025		(2S) N-acetyl-L-alanyl-αL-phenylalanyl-chloroethylketone	Experimental	DB07899	InChI=1S/C16H21ClN2O3/c1-11(18-12(2)20)16(22)19-14(15(21)8-9-17)10-13-6-4-3-5-7-13/h3-7,11,14H,8-10H2,1-2H3,(H,18,20)(H,19,22)/t11-,14-/m0/s1	WABWAIGLGFELMI-FZMZJTMJSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1833 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	2	No	1	0	75.27 Å2	33.66 Å3	84.86 m3·mol-1	8	Yes	No	0.0374 mg/mL	1.46	-3.9	12.4	-1.9	P17538	CTRB1	1. Chymotrypsinogen B
C22H34N4O2	Not Available	Not Available	386.531	CN[C@H](CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)NC[C@H]1CC[C@H](N)CC1	Solid	Not Available					50366827		CHEMBL125181	18811687						MIN			448763	99444658					ZINC000100036469		N-Methylphenylalanyl-N-[(trans-4-aminocyclohexyl)methyl]-L-prolinamide	Experimental	DB08187	InChI=1S/C22H34N4O2/c1-24-19(14-16-6-3-2-4-7-16)22(28)26-13-5-8-20(26)21(27)25-15-17-9-11-18(23)12-10-17/h2-4,6-7,17-20,24H,5,8-15,23H2,1H3,(H,25,27)/t17-,18-,19-,20+/m1/s1	MDSVGJAUFNXYRR-WTGUMLROSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3327 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	4	3	Yes	3	2	87.46 Å2	44 Å3	110.67 m3·mol-1	7	Yes	No	0.0307 mg/mL	1.28	-4.1	15.7	10.46	P00734	F2	Details1. Prothrombin
C13H16N2O5S	Not Available	Not Available	312.342	[H][C@@](CS)(NC(=O)OCC1=CC=CC=C1)C(=O)NCC(O)=O	Solid	Not Available								13085330						MP2			15942661	99444670					ZINC000024777153		N-[(BENZYLOXY)CARBONYL]-L-CYSTEINYLGLYCINE	Experimental	DB08199	InChI=1S/C13H16N2O5S/c16-11(17)6-14-12(18)10(8-21)15-13(19)20-7-9-4-2-1-3-5-9/h1-5,10,21H,6-8H2,(H,14,18)(H,15,19)(H,16,17)/t10-/m0/s1	DHTSUHYTYUXMOL-JTQLQIEISA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.0503 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	4	No	1	-1	104.73 Å2	30.38 Å3	76.71 m3·mol-1	8	Yes	No	0.194 mg/mL	0.53	-3.2	3.54	-5.5	P52700	Not Available	1. Metallo-beta-lactamase L1
C23H27BN4O4	Not Available	Not Available	434.296	[H][C@@](N)(CC1=CC=CC=C1)C(=O)N1CCC[C@@]1([H])C(=O)N[C@@]([H])(CC1=CC(=CC=C1)C#N)B(O)O	Solid	Not Available								4451206						PPB			5289192	99444891					ZINC000169748507		1-{[1-(2-AMINO-3-PHENYL-PROPIONYL)-PYRROLIDINE-2-CARBONYL]-AMINO}-2-(3-CYANO-PHENYL)-ETHANEBORONIC ACID	Experimental	DB08420	InChI=1S/C23H27BN4O4/c25-15-18-9-4-8-17(12-18)14-21(24(31)32)27-22(29)20-10-5-11-28(20)23(30)19(26)13-16-6-2-1-3-7-16/h1-4,6-9,12,19-21,31-32H,5,10-11,13-14,26H2,(H,27,29)/t19-,20+,21+/m1/s1	UFOIPTZMXQILSG-HKBOAZHASA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.3326 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	6	4	Yes	3	1	139.68 Å2	45.35 Å3	115.6 m3·mol-1	8	Yes	No	0.0391 mg/mL	1.93	-4	8.69	7.65	P07477	PRSS1	1. Trypsin-1
C21H27N5O2	Not Available	Not Available	381.4714	[H][C@@](N)(CC1=CC=CC=C1)C(=O)N1CCC[C@@]1([H])C(=O)NCCNC1=CC=NC=C1	Solid	Not Available					50064655		CHEMBL65273							PPX			23586040	99444893					ZINC000003871334		[PHENYLALANINYL-PROLINYL]-[2-(PYRIDIN-4-YLAMINO)-ETHYL]-AMINE	Experimental	DB08422	InChI=1S/C21H27N5O2/c22-18(15-16-5-2-1-3-6-16)21(28)26-14-4-7-19(26)20(27)25-13-12-24-17-8-10-23-11-9-17/h1-3,5-6,8-11,18-19H,4,7,12-15,22H2,(H,23,24)(H,25,27)/t18-,19+/m1/s1	GEIDRYBJURDUSW-MOPGFXCFSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.4016 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	5	3	Yes	3	2	100.35 Å2	41.16 Å3	108.95 m3·mol-1	8	Yes	No	0.172 mg/mL	0.29	-3.4	15.29	8.86			
C23H28ClN3O4S	Not Available	Not Available	478.004	[H][C@](N)(CC(=O)N1CCC[C@@]1([H])CNC(=O)C1=CC=CC(=C1)S(C)(=O)=O)CC1=CC(Cl)=CC=C1	Solid	Not Available					50296131		CHEMBL564249	24629791						PS4			42608447	99444900					ZINC000039279922		N-({(2S)-1-[(3R)-3-amino-4-(3-chlorophenyl)butanoyl]pyrrolidin-2-yl}methyl)-3-(methylsulfonyl)benzamide	Experimental	DB08429	InChI=1S/C23H28ClN3O4S/c1-32(30,31)21-9-3-6-17(13-21)23(29)26-15-20-8-4-10-27(20)22(28)14-19(25)12-16-5-2-7-18(24)11-16/h2-3,5-7,9,11,13,19-20H,4,8,10,12,14-15,25H2,1H3,(H,26,29)/t19-,20+/m1/s1	QRGBOABBMKYMLG-UXHICEINSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.4702 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	5	2	Yes	3	1	109.57 Å2	49.35 Å3	125.44 m3·mol-1	8	Yes	No	0.0105 mg/mL	1.59	-4.7	14.03	8.92			
C25H36N4O4	Not Available	Not Available	456.5777	[H][C@@](CC(C)C)(CC(=O)NO)C(=O)N[C@@]1([H])CC2=CN(CCCCCCNC1=O)C1=C2C=CC=C1	Solid	Not Available					50086884		CHEMBL281795	419816						RRS			478379	99444960					ZINC000003811057		N4-HYDROXY-2-ISOBUTYL-N1-(9-OXO-1,8-DIAZA-TRICYCLO[10.6.1.013,18]NONADECA-12(19),13,15,17-TETRAEN-10-YL)-SUCCINAMIDE	Experimental	DB08489	InChI=1S/C25H36N4O4/c1-17(2)13-18(15-23(30)28-33)24(31)27-21-14-19-16-29(22-10-6-5-9-20(19)22)12-8-4-3-7-11-26-25(21)32/h5-6,9-10,16-18,21,33H,3-4,7-8,11-15H2,1-2H3,(H,26,32)(H,27,31)(H,28,30)/t18-,21+/m1/s1	GCBPAPVOMPJQHK-NQIIRXRSSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.5118 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	4	Yes	3	0	112.46 Å2	50.07 Å3	126.81 m3·mol-1	6	Yes	No	0.0139 mg/mL	2.66	-4.5	8.9	-1.2			
C25H35N3O4	Not Available	Not Available	441.5631	[H][C@@](CC(C)C)(CC(O)=O)C(=O)N[C@@]1([H])CC2=CN(CCCCCCNC1=O)C1=C2C=CC=C1	Solid	Not Available					50284756		CHEMBL282146	4451305						RSS			5289314	99444964					ZINC000003811056		5-METHYL-3-(9-OXO-1,8-DIAZA-TRICYCLO[10.6.1.013,18]NONADECA-12(19),13,15,17-TETRAEN-10-YLCARBAMOYL)-HEXANOIC ACID	Experimental	DB08493	InChI=1S/C25H35N3O4/c1-17(2)13-18(15-23(29)30)24(31)27-21-14-19-16-28(22-10-6-5-9-20(19)22)12-8-4-3-7-11-26-25(21)32/h5-6,9-10,16-18,21H,3-4,7-8,11-15H2,1-2H3,(H,26,32)(H,27,31)(H,29,30)/t18-,21+/m1/s1	AKWKBACKRMYPRV-NQIIRXRSSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.4057 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	3	Yes	3	-1	100.43 Å2	48.71 Å3	123.22 m3·mol-1	6	Yes	No	0.0113 mg/mL	3.47	-4.6	4.43	-1.2			
C9H15NO5	Not Available	Not Available	217.2191	[H][C@@](CCC)(NC(=O)CCC(O)=O)C(O)=O	Solid	Not Available								5254643						SN0			6852189	99445025							N-(3-carboxypropanoyl)-L-norvaline	Experimental	DB08554	InChI=1S/C9H15NO5/c1-2-3-6(9(14)15)10-7(11)4-5-8(12)13/h6H,2-5H2,1H3,(H,10,11)(H,12,13)(H,14,15)/t6-/m0/s1	HRAPDLBXHOBAKA-LURJTMIESA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.7519 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	3	No	0	-2	103.7 Å2	21.3 Å3	49.96 m3·mol-1	7	Yes	No	9.55 mg/mL	0.032	-1.4	3.64	-2	Q5LI27;!Q8P8J2	Not Available;!argF'	1. Putative ornithine carbamoyltransferase;!2. N-acetylornithine carbamoyltransferase
C19H35N3O6S	Not Available	Not Available	433.563	[H][C@@](CC)(C=O)[C@@]1([H])N(CC[C@]1([H])NS(C)(=O)=O)C(=O)[C@@]([H])(NC(=O)OC(C)(C)C)C(C)C	Solid	Not Available								4883464						TRL			6323528	99445115					ZINC000038321466		{1-[2-(1-FORMYL-PROPYL)-3-METHANESULFONYLAMINO-PYRROLIDINE-1-CARBONYL]-2-METHYL-PROPYL}-CARBAMIC ACID TERT-BUTYL ESTER	Experimental	DB08644	InChI=1S/C19H35N3O6S/c1-8-13(11-23)16-14(21-29(7,26)27)9-10-22(16)17(24)15(12(2)3)20-18(25)28-19(4,5)6/h11-16,21H,8-10H2,1-7H3,(H,20,25)/t13-,14+,15+,16-/m1/s1	NOWIRVOXJOWTSQ-FXUDXRNXSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Non-substrate	2.6872 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	2	No	1	0	121.88 Å2	46.01 Å3	108.25 m3·mol-1	9	Yes	No	0.826 mg/mL	0.51	-2.7	10.36	-3.1	P27958	Not Available	1. Genome polyprotein
C21H35N5O3	Not Available	Not Available	405.5343	[H][C@@](CC1CCCCC1)(NC(=O)N1CCOCC1)C(=O)NC1(CCN(C)CC1)C#N	Solid	Not Available					50401770		CHEMBL1236882	8063229						Y11			9887557	99445223					ZINC000013918552		N-[(1S)-2-[(4-cyano-1-methylpiperidin-4-yl)amino]-1-(cyclohexylmethyl)-2-oxoethyl]morpholine-4-carboxamide	Experimental	DB08752	InChI=1S/C21H35N5O3/c1-25-9-7-21(16-22,8-10-25)24-19(27)18(15-17-5-3-2-4-6-17)23-20(28)26-11-13-29-14-12-26/h17-18H,2-15H2,1H3,(H,23,28)(H,24,27)/t18-/m0/s1	IRSOCWQJNYLTDD-SFHVURJKSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.6378 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	5	2	No	3	1	97.7 Å2	44.73 Å3	110.43 m3·mol-1	5	Yes	No	0.678 mg/mL	0.47	-2.8	11.96	7.46			
C25H36N4O4	Not Available	Not Available	456.5777	[H][C@@](CC1CCCCC1)(NC(=O)N1CCOCC1)C(=O)N[C@@](C)(COCC1=CC=CC=C1)C#N	Solid	Not Available								25061202						Y15			46937176	99445226					ZINC000038970701		N-[(1S)-2-{[(1R)-2-(benzyloxy)-1-cyano-1-methylethyl]amino}-1-(cyclohexylmethyl)-2-oxoethyl]morpholine-4-carboxamide	Experimental	DB08755	InChI=1S/C25H36N4O4/c1-25(18-26,19-33-17-21-10-6-3-7-11-21)28-23(30)22(16-20-8-4-2-5-9-20)27-24(31)29-12-14-32-15-13-29/h3,6-7,10-11,20,22H,2,4-5,8-9,12-17,19H2,1H3,(H,27,31)(H,28,30)/t22-,25+/m0/s1	MQWUTQCRGGBPBT-WIOPSUGQSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.6242 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	5	2	Yes	3	0	103.69 Å2	48.97 Å3	125.06 m3·mol-1	9	Yes	No	0.03 mg/mL	2.53	-4.2	11.76	-1.7	P25774	CTSS	1. Cathepsin S
C11H16N2O8	Not Available	Not Available	304.255	CC(=O)N[C@@H](CC(=O)N[C@@H](CCC(O)=O)C(O)=O)C(O)=O	Solid	Not Available						135289	CHEMBL2105616	182277	Drugs.com Drug Page				D07374				210320	175427113				N-Acetylaspartylglutamic_acid	ZINC000002504638		Spaglumic acid	Experimental	DB08835	InChI=1S/C11H16N2O8/c1-5(14)12-7(11(20)21)4-8(15)13-6(10(18)19)2-3-9(16)17/h6-7H,2-4H2,1H3,(H,12,14)(H,13,15)(H,16,17)(H,18,19)(H,20,21)/t6-,7-/m0/s1	GUCKKCMJTSNWCU-BQBZGAKWSA-N	4	Spaglumic acid is the β-aspartyl isoform of N-Acetyl-l-aspartylglutamate, a naturally occurring neurotransmitter, used in allergic eye conditions due to its ability to stabilize mast cells.	Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.7395 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	8	5	No	0	-3	170.1 Å2	27.37 Å3	64.06 m3·mol-1	9	Yes	No	3.22 mg/mL	-2.3	-2	3.01	-2	Q04609	FOLH1	1. Glutamate carboxypeptidase 2
C29H39N5O7	Not Available	Not Available	569.659	CC(C)C[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1)C(O)=O	Solid	Not Available					21025		CHEMBL340032	5292936														DADLE	ZINC000014952092		DADLE	Experimental	DB08856	InChI=1S/C29H39N5O7/c1-17(2)13-24(29(40)41)34-28(39)23(15-19-7-5-4-6-8-19)33-25(36)16-31-26(37)18(3)32-27(38)22(30)14-20-9-11-21(35)12-10-20/h4-12,17-18,22-24,35H,13-16,30H2,1-3H3,(H,31,37)(H,32,38)(H,33,36)(H,34,39)(H,40,41)/t18-,22+,23+,24-/m1/s1	ZHUJMSMQIPIPTF-IBURTVSXSA-N			Not Available	Small Molecule																																			0	No	8	7	No	2	0	199.95 Å2	59.13 Å3	150.09 m3·mol-1	15	No	No	0.00963 mg/mL	-1.3	-4.8	3.7	7.73			
C27H45N5O5	Boceprevir has a mean total body clearance of 161 liters per hour Label.	Boceprevir has a mean half-life of elimination of 3.4 hours Label.	519.6767	[H][C@]12CN([C@H](C(=O)NC(CC3CCC3)C(=O)C(N)=O)[C@@]1([H])C2(C)C)C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C	Solid	The mean apparent volume of distribution for Bocepravir is 772 litres at steady state Label.	P08684;!P20815	CYP3A4;!CYP3A5	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5		12311	68621	CHEMBL218394	8499830	Drugs.com Drug Page				D08876	HU5		PA165948902	10324367	175427127	RxList Drug Page	1102129		Boceprevir			Boceprevir	Approved, Withdrawn	DB08873	InChI=1S/C27H45N5O5/c1-25(2,3)20(30-24(37)31-26(4,5)6)23(36)32-13-15-17(27(15,7)8)18(32)22(35)29-16(19(33)21(28)34)12-14-10-9-11-14/h14-18,20H,9-13H2,1-8H3,(H2,28,34)(H,29,35)(H2,30,31,37)/t15-,16?,17-,18-,20+/m0/s1	LHHCSNFAOIFYRV-DOVBMPENSA-N	4	Boceprevir is a hepatitis C virus NS3/4A protease inhibitor used in combination with other medications to treat chronic hepatitis C genotype 1 infection. Boceprevir is not indicated as monotherapy.	The most commonly reported adverse reactions in adult subjects were fatigue, anemia, nausea, headache, and dysgeusia when Boceprevir was used in combination with Ribavirin and Peginterferon alfa-2a/Peginterferon alfa-2b Label.	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.6263 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	5	4	Yes	3	0	150.7 Å2	56.79 Å3	138.2 m3·mol-1	10	No	No	0.0234 mg/mL	1.78	-4.4	12.44	-0.91	B0B3C9	NS3/4A	1. NS3/4A protein
C16H22N6O4	Not Available	Not Available	362.3837	[H][C@@](CC1=CN=CN1)(NC(=O)[C@]1([H])CCC(=O)N1)C(=O)N1CCC[C@@]1([H])C(N)=O	Not Available	Not Available					50072394	35940	CHEMBL1472	554166	Drugs.com Drug Page		HMDB0060080	C03958	D00176				638678	347827851	RxList Drug Page	10580		Protirelin	ZINC000004096261	Relefact Trh	Protirelin	Approved, Investigational	DB09421	InChI=1S/C16H22N6O4/c17-14(24)12-2-1-5-22(12)16(26)11(6-9-7-18-8-19-9)21-15(25)10-3-4-13(23)20-10/h7-8,10-12H,1-6H2,(H2,17,24)(H,18,19)(H,20,23)(H,21,25)/t10-,11-,12-/m0/s1	XNSAINXGIQZQOO-SRVKXCTJSA-N	3	Protirelin is a synthetic analogue of thyrotropin-releasing hormone that has been used during diagnostic tests to evaluate function of the thyroid gland.	Not Available	Small Molecule																																			1	No	5	4	Yes	3	0	150.28 Å2	35.03 Å3	89.76 m3·mol-1	6	Yes	No	4.18 mg/mL	-3.3	-1.9	11.15	6.74	P34981	TRHR	1. Thyrotropin Releasing Hormone Receptor
C18H24N2O5	The disposition of enalaprilat in patients with renal insufficiency is similar to that in patients with normal renal function until the glomerular filtration rate is 30 mL/min or less. Renal clearance was 158 ± 47 ml/min.	11 hr	348.3936	[H][C@@](C)(N[C@@]([H])(CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@@]1([H])C(O)=O	Not Available	Not Available					50367254	4786	CHEMBL577	4575429			HMDB0041886	C11720	D03769	EAL			5462501	347827859	RxList Drug Page	3829		Enalaprilat	ZINC000003812851		Enalaprilat	Approved	DB09477	InChI=1S/C18H24N2O5/c1-12(16(21)20-11-5-8-15(20)18(24)25)19-14(17(22)23)10-9-13-6-3-2-4-7-13/h2-4,6-7,12,14-15,19H,5,8-11H2,1H3,(H,22,23)(H,24,25)/t12-,14-,15-/m0/s1	LZFZMUMEGBBDTC-QEJZJMRPSA-N	4	Enalaprilat is an antihypertensive agent used for the management of hypertension when oral therapy is not practical.	Adverse experiences occurring in 0.5 to 1.0 percent of patients in controlled clinical trials included: myocardial infarction, fatigue, dizziness, fever, rash and constipation.Angioedema has also been reported in patients receiving enalaprilat, with an incidence higher in black than in non-black patients. Angioedema associated with laryngeal edema may be fatal. If angioedema of the face, extremities, lips, tongue, glottis and/or larynx occurs, treatment with enalaprilat should be discontinued and appropriate therapy instituted immediately . Rarer adverse effects that are less likely, but should be monitored for, include development of anaphylaxis, hypotension, agranulocytosis, hepatic failure, hyperkalemia, and persistent cough. Furthermore, ACE inhibitors should be avoided during pregnancy as they can cause fetal and neonatal morbidity and death. When pregnancy is detected, ACE inhibitors should be discontinued as soon as possible. Use during the second and third trimesters of pregnancy has been associated with fetal and neonatal injury, including hypotension, neonatal skull hypoplasia, anuria, reversible or irreversible renal failure, and death.	Small Molecule																																			1	No	6	3	No	2	-1	106.94 Å2	35.82 Å3	90.06 m3·mol-1	8	Yes	No	0.876 mg/mL	-1.1	-2.6	3.13	7.83	P12821;!P46663	ACE;!BDKRB1	1. Angiotensin-converting enzyme;!2. B1 bradykinin receptor
C31H41N5O5	No pharmacokinetic related to the clearance rate was found in current literature.	To know more about the pharmacokinetics please visit Ergoloid mesylate.	563.699	[H][C@@]12CCCN1C(=O)[C@H](C(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)(O[C@@]21O)C(C)C	Solid	To know more about the pharmacokinetics please visit Ergoloid mesylate.	P08684	CYP3A4	1. Cytochrome P450 3A4			59909	CHEMBL2365712	147720												3415		Dihydroergocornine	ZINC000004215648		Dihydroergocornine	Approved	DB11273	InChI=1S/C31H41N5O5/c1-16(2)26-28(38)35-11-7-10-24(35)31(40)36(26)29(39)30(41-31,17(3)4)33-27(37)19-12-21-20-8-6-9-22-25(20)18(14-32-22)13-23(21)34(5)15-19/h6,8-9,14,16-17,19,21,23-24,26,32,40H,7,10-13,15H2,1-5H3,(H,33,37)/t19-,21-,23-,24+,26+,30-,31+/m1/s1	SEALOBQTUQIVGU-QNIJNHAOSA-N		Dihydroergocornine is a nootropic with an unknown mechanism of action indicated in individuals over sixty who manifest signs and symptoms of an idiopathic decline in mental capacity.	Dihydroergocornine effect on fertility was tested in preclinical studies. The reported effect was a decreased weight gain in neonates.10 Overdosing has also been reported to present effects of fall of blood pressure and a decrease in heart rate to 13 beats per minute.4 To know more about the pharmacokinetics please visit Ergoloid mesylate.	Small Molecule																													Decomposes	2.33		187 ºC			1	No	6	3	No	7	1	118.21 Å2	62 Å3	152.66 m3·mol-1	4	No	No	0.402 mg/mL	3.06	-3.2	9.71	8.39	BE0004862;!BE0004872;!BE0004888	;!;!	1. Serotonin Receptors (Protein Group);!2. Beta adrenergic receptor (Protein Group);!3. Alpha adrenergic receptor (Protein Group)
C32H43N5O5	In preclinical studies, the clearance rate after intravenous or oral administration was registered to be 1.129 L/h and 25.98 L/h respectively.14 To know more about the ergoloid mesylate mixture please visit Ergoloid mesylate.	Alpha-dihydroergocryptine has been studied in Parkinson disease models and it has shown a half-life of 12-16 hours.5 To know more about the ergoloid mesylate mixture please visit Ergoloid mesylate.	577.726	[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)(O[C@@]21O)C(C)C	Solid	In preclinical studies, the volume of distribution after intravenous or oral administration was registered to be 11.054 L and 218.630 L respectively.14 To know more about the ergoloid mesylate mixture please visit Ergoloid mesylate.	P08684	CYP3A4	1. Cytochrome P450 3A4		81453	59919	CHEMBL1743263	102887												91170			ZINC000003929793		Dihydro-alpha-ergocryptine	Approved	DB11274	InChI=1S/C32H43N5O5/c1-17(2)12-25-29(39)36-11-7-10-26(36)32(41)37(25)30(40)31(42-32,18(3)4)34-28(38)20-13-22-21-8-6-9-23-27(21)19(15-33-23)14-24(22)35(5)16-20/h6,8-9,15,17-18,20,22,24-26,33,41H,7,10-14,16H2,1-5H3,(H,34,38)/t20-,22-,24-,25+,26+,31-,32+/m1/s1	PBUNVLRHZGSROC-VTIMJTGVSA-N		Dihydro-alpha-ergocryptine is a nootropic with an unknown mechanism of action indicated in individuals over sixty who manifest signs and symptoms of an idiopathic decline in mental capacity.	Alpha-dihydroergocryptine does not have effect in fertility and it does not present mutagenic potential.15 To know more about the ergoloid mesylate mixture please visit Ergoloid mesylate.	Small Molecule																													Decomposes	5.90		117 ºC			1	No	6	3	No	7	1	118.21 Å2	64.05 Å3	157.33 m3·mol-1	5	No	No	0.264 mg/mL	3.43	-3.3	9.71	8.39	P14416;!BE0004889;!P35462	DRD2;!;!DRD3	1. Dopamine D2 receptor;!2. D(1) dopamine receptor (Protein Group);!3. Dopamine D3 receptor
C32H43N5O5	Please refer to Ergoloid mesylate and to know more about the isomer please refer to Dihydro-alpha-ergocryptine.	Please refer to Ergoloid mesylate and to know more about the isomer please refer to Dihydro-alpha-ergocryptine.	577.726	[H][C@@]12CCCN1C(=O)[C@]([H])([C@H](C)CC)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)(O[C@@]21O)C(C)C	Solid	Please refer to Ergoloid mesylate and to know more about the isomer please refer to Dihydro-alpha-ergocryptine.						135927	CHEMBL2106411	59102												91171		Epicriptine	ZINC000004215812		Epicriptine	Approved	DB11275	InChI=1S/C32H43N5O5/c1-6-18(4)27-29(39)36-12-8-11-25(36)32(41)37(27)30(40)31(42-32,17(2)3)34-28(38)20-13-22-21-9-7-10-23-26(21)19(15-33-23)14-24(22)35(5)16-20/h7,9-10,15,17-18,20,22,24-25,27,33,41H,6,8,11-14,16H2,1-5H3,(H,34,38)/t18-,20-,22-,24-,25+,27+,31-,32+/m1/s1	SBFXHXZNBNFPHV-PXXBSISHSA-N		Epicriptine is a nootropic with an unknown mechanism of action indicated in individuals over sixty who manifest signs and symptoms of an idiopathic decline in mental capacity.	Please refer to Ergoloid mesylate and to know more about the isomer please refer to Dihydro-alpha-ergocryptine.	Small Molecule																													848 ºC at 760 mm Hg						1	No	6	3	No	7	1	118.21 Å2	63.58 Å3	157.26 m3·mol-1	5	No	No	0.276 mg/mL	3.5	-3.3	9.71	8.39	BE0009376		1. Dopamine receptor (Protein Group)
C14H24N6O4	Not Available	Prezatide is rapidly eliminated within minutes 5.	340.384	NCCCC[C@H](NC(=O)[C@H](CC1=CNC=N1)NC(=O)CN)C(O)=O	Solid	Not Available					50350478	75430	CHEMBL1814493	66263									73587	347827962		1368533			ZINC000013507674		Prezatide	Experimental	DB11296	InChI=1S/C14H24N6O4/c15-4-2-1-3-10(14(23)24)20-13(22)11(19-12(21)6-16)5-9-7-17-8-18-9/h7-8,10-11H,1-6,15-16H2,(H,17,18)(H,19,21)(H,20,22)(H,23,24)/t10-,11-/m0/s1	MVORZMQFXBLMHM-QWRGUYRKSA-N			Not Available	Small Molecule																																			0	No	7	6	No	1	1	176.22 Å2	34.52 Å3	84.91 m3·mol-1	11	No	No	3.14 mg/mL	-5.1	-2	3.46	10.2			
C30H54N6O5	Not Available	Not Available	578.799	CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCCN)C(O)=O	Not Available	Not Available								8407354												1722914			ZINC000113569616		Palmitoyl oligopeptide	Experimental	DB11297	InChI=1S/C30H54N6O5/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-18-27(37)33-22-28(38)35-26(20-24-21-32-23-34-24)29(39)36-25(30(40)41)17-15-16-19-31/h21,23,25-26H,2-20,22,31H2,1H3,(H,32,34)(H,33,37)(H,35,38)(H,36,39)(H,40,41)/t25-,26-/m0/s1	BYUQATUKPXLFLZ-UIOOFZCWSA-N			Not Available	Small Molecule																																			0	No	7	6	No	1	0	179.3 Å2	68.63 Å3	158.79 m3·mol-1	26	No	No	0.00146 mg/mL	1.24	-5.6	3.49	10.2			
C9H12N2O4S	Not Available	Half life of 4 h 5.	244.27	OC(=O)[C@@H]1CSCN1C(=O)[C@@H]1CCC(=O)N1	Solid	Not Available						94618	CHEMBL1488165	59348					D07261				65944	310265231		40450		Pidotimod	ZINC000003781245		Pidotimod	Experimental	DB11364	InChI=1S/C9H12N2O4S/c12-7-2-1-5(10-7)8(13)11-4-16-3-6(11)9(14)15/h5-6H,1-4H2,(H,10,12)(H,14,15)/t5-,6-/m0/s1	UUTKICFRNVKFRG-WDSKDSINSA-N	4	Pidotimod is a synthetic agent with immunomodulatory properties used in patients with documented cell-mediated immunosuppression to stimulate their immunity during lung and urinary tract infections.	Not Available	Small Molecule																																			1	No	4	2	No	2	-1	86.71 Å2	22.47 Å3	55.83 m3·mol-1	2	Yes	No	19.5 mg/mL	-1.3	-1.1	3.57	-2.2			
C19H27N3O6	Not Available	Not Available	393.44	OC(=O)CNC(=O)C1C(=O)N(C2CCCCC2)C(=O)N(C2CCCCC2)C1=O	Not Available	Not Available							CHEMBL3544988	33427356									91617630	347828049				Daprodustat	ZINC000231226004		Daprodustat	Investigational	DB11682	InChI=1S/C19H27N3O6/c23-14(24)11-20-16(25)15-17(26)21(12-7-3-1-4-8-12)19(28)22(18(15)27)13-9-5-2-6-10-13/h12-13,15H,1-11H2,(H,20,25)(H,23,24)	RUEYEZADQJCKGV-UHFFFAOYSA-N	3		Not Available	Small Molecule																																			1	Yes	6	2	No	3	-2	124.09 Å2	40.18 Å3	96.89 m3·mol-1	5	Yes	No	0.345 mg/mL	1.4	-3.1	0.35	-9.1			
C41H62N12O11	Not Available	Not Available	899.02	[H][C@](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)([C@@H](C)CC)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N1CCC[C@H]1C(O)=O	Not Available	Not Available					85556	55438	CHEMBL3545347	110354									123805	347828083					ZINC000096077632		Angiotensin 1-7	Investigational	DB11720	InChI=1S/C41H62N12O11/c1-5-22(4)33(38(61)50-29(17-24-19-45-20-47-24)39(62)53-15-7-9-30(53)40(63)64)52-36(59)28(16-23-10-12-25(54)13-11-23)49-37(60)32(21(2)3)51-35(58)27(8-6-14-46-41(43)44)48-34(57)26(42)18-31(55)56/h10-13,19-22,26-30,32-33,54H,5-9,14-18,42H2,1-4H3,(H,45,47)(H,48,57)(H,49,60)(H,50,61)(H,51,58)(H,52,59)(H,55,56)(H,63,64)(H4,43,44,46)/t22-,26-,27-,28-,29-,30-,32-,33-/m0/s1	PVHLMTREZMEJCG-GDTLVBQBSA-N	2		Not Available	Small Molecule																																			0	No	16	13	Yes	3	1	377.24 Å2	92.45 Å3	238.19 m3·mol-1	25	No	No	0.0399 mg/mL	-6.3	-4.4	2.95	11.74			
C10H20BN3O3	Not Available	10-13 hours	241.1	OB(O)[C@@H]1CCCN1C(=O)CN[C@@H]1CCNC1	Not Available	Not Available								9428517									11253490	347828085					ZINC000169746730		Dutogliptin	Investigational	DB11723	InChI=1S/C10H20BN3O3/c15-10(7-13-8-3-4-12-6-8)14-5-1-2-9(14)11(16)17/h8-9,12-13,16-17H,1-7H2/t8-,9+/m1/s1	DVJAMEIQRSHVKC-BDAKNGLRSA-N	3		Not Available	Small Molecule																																			1	No	5	4	No	2	1	84.83 Å2	25.94 Å3	58.91 m3·mol-1	4	Yes	No	6.93 mg/mL	-2.4	-1.5	8.63	10.1	P27487	DPP4	1. Dipeptidyl peptidase 4
C27H34N4O3	Not Available	Not Available	462.594	CN(C)C(=O)[C@@H]1CCCN1C(=O)NCC1=CC=C(C=C1C)C(=O)N1CCCCC2=C1C=CC=C2	Not Available	Not Available					50246575		CHEMBL518043	8473853									10298385	347828092					ZINC000038471398		Fedovapagon	Investigational	DB11734	InChI=1S/C27H34N4O3/c1-19-17-21(25(32)30-15-7-6-10-20-9-4-5-11-23(20)30)13-14-22(19)18-28-27(34)31-16-8-12-24(31)26(33)29(2)3/h4-5,9,11,13-14,17,24H,6-8,10,12,15-16,18H2,1-3H3,(H,28,34)/t24-/m0/s1	RUOLFWZIFNQQGH-DEOSSOPVSA-N	3		Not Available	Small Molecule																																			1	No	3	1	No	4	0	72.96 Å2	51.2 Å3	133.63 m3·mol-1	4	Yes	No	0.0762 mg/mL	3.17	-3.8	14.79	-1.8			
C20H27N3O6	Not Available	Not Available	405.4449	[H][C@@](C)(N[C@@]([H])(CCC1=CC=CC=C1)C(=O)OCC)C(=O)N1C(=O)N(C)C[C@@]1([H])C(O)=O	Not Available	Not Available					50020400	135654	CHEMBL317094	4576628			HMDB0041907					PA452640	5464343	347828133		60245		Imidapril	ZINC000003784427		Imidapril	Investigational	DB11783	InChI=1S/C20H27N3O6/c1-4-29-19(27)15(11-10-14-8-6-5-7-9-14)21-13(2)17(24)23-16(18(25)26)12-22(3)20(23)28/h5-9,13,15-16,21H,4,10-12H2,1-3H3,(H,25,26)/t13-,15-,16-/m0/s1	KLZWOWYOHUKJIG-BPUTZDHNSA-N		Imidapril is an ACE inhibitor used in the treatment of essential hypertension.	Not Available	Small Molecule																																			1	Yes	6	2	No	2	-1	116.25 Å2	42.36 Å3	103.2 m3·mol-1	10	Yes	No	0.447 mg/mL	-0.23	-3	3.49	5.22			
C25H37N5O6	Not Available	Not Available	503.6	C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@@]1(CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O	Not Available	Not Available							CHEMBL3989872	52085607									71249967	347828134				Apimostinel			NRX-1074	Investigational	DB11784	InChI=1S/C25H37N5O6/c1-15(31)19(26)23(35)29-12-6-10-18(29)22(34)30-13-7-11-25(30,14-17-8-4-3-5-9-17)24(36)28-20(16(2)32)21(27)33/h3-5,8-9,15-16,18-20,31-32H,6-7,10-14,26H2,1-2H3,(H2,27,33)(H,28,36)/t15-,16-,18+,19+,20+,25-/m1/s1	DVBUEXCIEIAXPM-PJUQSVSOSA-N	2		Not Available	Small Molecule																																			1	No	7	5	Yes	3	1	179.29 Å2	51.23 Å3	130.85 m3·mol-1	9	No	No	2.35 mg/mL	-1.6	-2.3	12.01	7.61			
C18H31N5O6	Not Available	Not Available	413.475	C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(N)=O	Not Available	Not Available							CHEMBL3544917	25069944									14539800	347828150				Rapastinel	ZINC000071773625		Rapastinel	Investigational	DB11801	InChI=1S/C18H31N5O6/c1-9(24)13(19)18(29)23-8-4-6-12(23)17(28)22-7-3-5-11(22)16(27)21-14(10(2)25)15(20)26/h9-14,24-25H,3-8,19H2,1-2H3,(H2,20,26)(H,21,27)/t9-,10-,11+,12+,13+,14+/m1/s1	GIBQQARAXHVEGD-BSOLPCOYSA-N	3		Not Available	Small Molecule																																			1	No	7	5	No	2	1	179.29 Å2	41.09 Å3	101.51 m3·mol-1	7	Yes	No	37.4 mg/mL	-3.7	-1	11.92	7.61			
C14H17N3O4	Not Available	Not Available	291.307	NCC(=O)N1C[C@@H](C[C@H]1C(O)=O)NC(=O)C1=CC=CC=C1	Not Available	Not Available							CHEMBL560592	17589967									16656685	347828168					ZINC000040836075		Danegaptide	Investigational	DB11821	InChI=1S/C14H17N3O4/c15-7-12(18)17-8-10(6-11(17)14(20)21)16-13(19)9-4-2-1-3-5-9/h1-5,10-11H,6-8,15H2,(H,16,19)(H,20,21)/t10-,11+/m1/s1	BIZKIHUJGMSVFD-MNOVXSKESA-N	2		Not Available	Small Molecule																																			1	No	5	3	No	2	0	112.73 Å2	29.07 Å3	74.08 m3·mol-1	4	Yes	No	1.91 mg/mL	-3.3	-2.2	3.32	8.13			
C8H15N3O4	Not Available	Not Available	217.225	C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(O)=O	Not Available	Not Available						74387	CHEMBL3707366	110464									123935	347828213		1359422			ZINC000002504612		Alanyl glutamine	Investigational	DB11876	InChI=1S/C8H15N3O4/c1-4(9)7(13)11-5(8(14)15)2-3-6(10)12/h4-5H,2-3,9H2,1H3,(H2,10,12)(H,11,13)(H,14,15)/t4-,5-/m0/s1	HJCMDXDYPOUFDY-WHFBIAKZSA-N	4	Alanyl glutamine is a dipeptide consisting of alanine and glutamine used for supplementation.	Not Available	Small Molecule																																			1	No	5	4	No	0	0	135.51 Å2	20.97 Å3	50.41 m3·mol-1	6	Yes	No	12.7 mg/mL	-4.5	-1.2	3.57	8.39			
C25H47N9O5	Not Available	Not Available	553.709	CC[C@H](C)C(NC(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(N)=O	Not Available	Not Available							CHEMBL3545314										71722017	347828216							Dusquetide	Investigational	DB11879	InChI=1S/C25H47N9O5/c1-6-14(4)19(33-21(36)16(26)9-7-11-30-25(28)29)23(38)32-18(13(2)3)24(39)34-12-8-10-17(34)22(37)31-15(5)20(27)35/h13-19H,6-12,26H2,1-5H3,(H2,27,35)(H,31,37)(H,32,38)(H,33,36)(H4,28,29,30)/t14-,15-,16-,17-,18-,19?/m0/s1	ZUJBBVJXXYRPFS-OUROWQTJSA-N	2		Not Available	Small Molecule																																			0	No	9	8	No	1	2	238.62 Å2	59.37 Å3	155.22 m3·mol-1	15	No	No	0.0992 mg/mL	-2.4	-3.8	12.21	11.74			
C27H40N8O7	Not Available	Not Available	588.666	CC(C)[C@@H]1N(C)C(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC1=O	Not Available	Not Available					50235980		CHEMBL429876	154046									176873	347828225				Cilengitide	ZINC000003952216		Cilengitide	Investigational	DB11890	InChI=1S/C27H40N8O7/c1-15(2)22-25(41)33-17(10-7-11-30-27(28)29)23(39)31-14-20(36)32-18(13-21(37)38)24(40)34-19(26(42)35(22)3)12-16-8-5-4-6-9-16/h4-6,8-9,15,17-19,22H,7,10-14H2,1-3H3,(H,31,39)(H,32,36)(H,33,41)(H,34,40)(H,37,38)(H4,28,29,30)/t17-,18-,19+,22-/m0/s1	AMLYAMJWYAIXIA-VWNVYAMZSA-N	3		Not Available	Small Molecule																																			0	No	10	8	No	2	0	235.91 Å2	59.8 Å3	159.97 m3·mol-1	9	No	No	0.144 mg/mL	-3.7	-3.6	3.59	12.02			
C36H53N7O6	One cycle of hemodialysis reduces difelikefalin plasma concentrations by 70-80% and no detectable drug remains after two cycles.4	The half-life of difelikefalin in hemodialysis patients prior to dialysis ranges between 23 and 31 hours.4	679.863	CC(C)C[C@@H](NC(=O)[C@@H](CC1=CC=CC=C1)NC(=O)[C@H](N)CC1=CC=CC=C1)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O	Solid	The mean volume of distribution of difelikefalin is approximately 238 mL/kg.4					235785		CHEMBL3989915	44208824									24794466	347828265		2569089		Difelikefalin		Korsuva	Difelikefalin	Approved, Investigational	DB11938	InChI=1S/C36H53N7O6/c1-24(2)21-29(32(45)40-28(15-9-10-18-37)34(47)43-19-16-36(39,17-20-43)35(48)49)42-33(46)30(23-26-13-7-4-8-14-26)41-31(44)27(38)22-25-11-5-3-6-12-25/h3-8,11-14,24,27-30H,9-10,15-23,37-39H2,1-2H3,(H,40,45)(H,41,44)(H,42,46)(H,48,49)/t27-,28-,29-,30-/m1/s1	FWMNVWWHGCHHJJ-SKKKGAJSSA-N	3	Difelikefalin is a kappa opioid receptor agonist used in the treatment of pruritus associated with chronic kidney disease in patients undergoing hemodialysis.	In clinical studies, single doses of up to 12 times (and multiple doses of up to 5 times) the recommended dosage of difelikefalin were administered in subjects undergoing hemodialysis.4 These patients experienced a dose-dependent increase in adverse reactions, including gastrointestinal effects and CNS depressant effects. In the event of overdosage, difelikefalin is dialyzable - 4 hours of high-flux hemodialysis effectively clears approximately 70-80% of the drug from plasma, and levels are likely to be undetectable following a second cycle.4	Small Molecule																																		Soluble	0	No	9	7	Yes	3	2	222.97 Å2	74.6 Å3	185.74 m3·mol-1	18	No	No	0.0103 mg/mL	-1.7	-4.8	1.92	10.26	P41145	OPRK1	1. Kappa-type opioid receptor
C30H49N9O9	Not Available	Not Available	679.776	CC(C)C(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O	Not Available	Not Available						135870	CHEMBL156025	26232604									451417	347828316		40230		Thymopentin			Thymopentin	Investigational	DB11996	InChI=1S/C30H49N9O9/c1-16(2)24(28(46)38-22(29(47)48)14-17-8-10-18(40)11-9-17)39-27(45)21(15-23(41)42)37-26(44)20(7-3-4-12-31)36-25(43)19(32)6-5-13-35-30(33)34/h8-11,16,19-22,24,40H,3-7,12-15,31-32H2,1-2H3,(H,36,43)(H,37,44)(H,38,46)(H,39,45)(H,41,42)(H,47,48)(H4,33,34,35)/t19-,20-,21-,22-,24?/m0/s1	PSWFFKRAVBDQEG-XXTQFKTOSA-N	3		Not Available	Small Molecule																																			0	No	14	11	No	1	1	327.67 Å2	70.84 Å3	171.76 m3·mol-1	22	No	No	0.0662 mg/mL	-6.3	-4	3.2	11.29			
C31H42N6O7	Not Available	Not Available	610.712	CC(C)C[C@@H]1NC(=O)[C@H](NC(=O)[C@@H]2CCCN2C(=O)[C@@H](CC(O)=O)NC(=O)[C@@H](CC2=CNC3=CC=CC=C23)NC1=O)C(C)C	Not Available	Not Available					50197954	2965	CHEMBL314691	391535				C11587					443289	347828364				BQ-123	ZINC000003926620		BQ-123	Investigational	DB12054	InChI=1S/C31H42N6O7/c1-16(2)12-21-27(40)33-22(13-18-15-32-20-9-6-5-8-19(18)20)28(41)35-23(14-25(38)39)31(44)37-11-7-10-24(37)29(42)36-26(17(3)4)30(43)34-21/h5-6,8-9,15-17,21-24,26,32H,7,10-14H2,1-4H3,(H,33,40)(H,34,43)(H,35,41)(H,36,42)(H,38,39)/t21-,22+,23+,24-,26+/m0/s1	VYCMAAOURFJIHD-PJNXIOHISA-N	2		Not Available	Small Molecule																																			0	No	7	6	Yes	4	-1	189.8 Å2	62.8 Å3	158.59 m3·mol-1	7	No	No	0.13 mg/mL	0.84	-3.7	4.04				
C26H33FN4O3S	Not Available	Not Available	500.63	CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C1=NC(=CS1)C(=O)C1=CC=C(F)C=C1	Not Available	Not Available					50441356		CHEMBL2431768	30687709									24737642	347828391					ZINC000095929260		LCL-161	Investigational	DB12085	InChI=1S/C26H33FN4O3S/c1-16(28-2)24(33)30-22(17-7-4-3-5-8-17)26(34)31-14-6-9-21(31)25-29-20(15-35-25)23(32)18-10-12-19(27)13-11-18/h10-13,15-17,21-22,28H,3-9,14H2,1-2H3,(H,30,33)/t16-,21-,22-/m0/s1	UFPFGVNKHCLJJO-SSKFGXFMSA-N	2		Not Available	Small Molecule																																			1	No	5	2	Yes	4	1	91.4 Å2	53 Å3	132.04 m3·mol-1	8	No	No	0.00313 mg/mL	3.78	-5.2	11.87	8.6			
C29H36N6O4S	Not Available	Not Available	564.71	CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)NC1=C(N=C(S1)C1=NC=CO1)C1=CC=CC=C1	Not Available	Not Available								35308299									71600094	347828595					ZINC000206792055		GDC-0917	Investigational	DB12336	InChI=1S/C29H36N6O4S/c1-18(30-2)24(36)32-23(20-12-7-4-8-13-20)29(38)35-16-9-14-21(35)25(37)34-27-22(19-10-5-3-6-11-19)33-28(40-27)26-31-15-17-39-26/h3,5-6,10-11,15,17-18,20-21,23,30H,4,7-9,12-14,16H2,1-2H3,(H,32,36)(H,34,37)/t18-,21-,23-/m0/s1	HSHPBORBOJIXSQ-HARLFGEKSA-N	1		Not Available	Small Molecule																																			1	No	6	3	Yes	5	1	129.46 Å2	61.29 Å3	171.74 m3·mol-1	9	No	No	0.0281 mg/mL	3.25	-4.3	9.92	8.58			
C19H27N3O4	Not Available	Not Available	361.442	CC(C)[C@H](O)C(=O)N[C@@H](C)C(=O)N[C@H]1C2=CC=CC=C2CCN(C)C1=O	Not Available	Not Available					28944	131158	CHEMBL520733	8019465						ESF			9843750	347828702				Semagacestat	ZINC000003989041		Semagacestat	Investigational	DB12463	InChI=1S/C19H27N3O4/c1-11(2)16(23)18(25)20-12(3)17(24)21-15-14-8-6-5-7-13(14)9-10-22(4)19(15)26/h5-8,11-12,15-16,23H,9-10H2,1-4H3,(H,20,25)(H,21,24)/t12-,15-,16-/m0/s1	PKXWXXPNHIWQHW-RCBQFDQVSA-N	3		Not Available	Small Molecule																																			1	Yes	4	3	No	2	0	98.74 Å2	38.39 Å3	97.22 m3·mol-1	5	Yes	No	1.16 mg/mL	0.39	-2.5	11.91	-3.7			
C36H60N10O12	Not Available	Not Available	824.934	CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O	Not Available	Not Available							CHEMBL2103826	8008132									9832404	347828827					ZINC000085540112		Davunetide	Investigational	DB12613	InChI=1S/C36H60N10O12/c1-6-18(4)28(35(56)46-14-8-9-23(46)31(52)41-21(36(57)58)11-12-25(38)48)44-30(51)22(16-47)42-33(54)27(17(2)3)43-32(53)24-10-7-13-45(24)34(55)19(5)40-29(50)20(37)15-26(39)49/h17-24,27-28,47H,6-16,37H2,1-5H3,(H2,38,48)(H2,39,49)(H,40,50)(H,41,52)(H,42,54)(H,43,53)(H,44,51)(H,57,58)/t18-,19-,20-,21-,22-,23-,24-,27-,28-/m0/s1	DWLTUUXCVGVRAV-XWRHUKJGSA-N	3		Not Available	Small Molecule																																			0	No	13	10	No	2	0	355.85 Å2	82.56 Å3	201.56 m3·mol-1	22	No	No	0.343 mg/mL	-7.5	-3.4	3.33	7.05			
C27H35N5O7S	Not Available	The half life of metenkefalin is 4.2-39 minutes.7	573.67	CSCC[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1)C(O)=O	Not Available	Not Available	Q8N4T0	CPA6	1. Carboxypeptidase A6		50019056	6618	CHEMBL13786	391597				C11684					443363	347828872		1349278		Met-enkephalin	ZINC000004102171		Metenkefalin	Investigational	DB12668	InChI=1S/C27H35N5O7S/c1-40-12-11-21(27(38)39)32-26(37)22(14-17-5-3-2-4-6-17)31-24(35)16-29-23(34)15-30-25(36)20(28)13-18-7-9-19(33)10-8-18/h2-10,20-22,33H,11-16,28H2,1H3,(H,29,34)(H,30,36)(H,31,35)(H,32,37)(H,38,39)/t20-,21-,22-/m0/s1	YFGBQHOOROIVKG-FKBYEOEOSA-N	3	Metenkefalin is an investigational endogenous opioid being studied for the treatment of COVID-19.	Data regarding overdoses of metenkefalin are not readily available.7 Animal overdose studies have not determined an LD50.7	Small Molecule																																			0	No	8	7	No	2	0	199.95 Å2	58.85 Å3	149.01 m3·mol-1	16	No	No	0.0196 mg/mL	-2.5	-4.5	3.61	7.73	P41143;!P35372	OPRD1;!OPRM1	1. Delta-type opioid receptor;!2. Mu-type opioid receptor
C39H67N5O6	Not Available	Not Available	701.994	CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCC1=CC=CC=C1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C	Not Available	Not Available							CHEMBL3989512	5293519									6918315	347828881					ZINC000003951627		Soblidotin	Investigational	DB12677	InChI=1S/C39H67N5O6/c1-13-27(6)35(43(10)39(48)33(25(2)3)41-38(47)34(26(4)5)42(8)9)31(49-11)24-32(45)44-23-17-20-30(44)36(50-12)28(7)37(46)40-22-21-29-18-15-14-16-19-29/h14-16,18-19,25-28,30-31,33-36H,13,17,20-24H2,1-12H3,(H,40,46)(H,41,47)/t27-,28+,30-,31+,33-,34-,35-,36+/m0/s1	DZMVCVHATYROOS-ZBFGKEHZSA-N	2		Not Available	Small Molecule																																			0	No	7	2	No	2	1	120.52 Å2	80.46 Å3	197.97 m3·mol-1	20	No	No	0.00826 mg/mL	4.4	-4.9	12.7	8.03			
C16H26N2O6S2	Not Available	Not Available	406.51	C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)CCCC[C@@H]1CCSS1)C(O)=O	Not Available	Not Available							CHEMBL3099551	31125664									49802864	347828972					ZINC000034636021		CMX-2043	Investigational	DB12795	InChI=1S/C16H26N2O6S2/c1-10(16(23)24)17-15(22)12(6-7-14(20)21)18-13(19)5-3-2-4-11-8-9-25-26-11/h10-12H,2-9H2,1H3,(H,17,22)(H,18,19)(H,20,21)(H,23,24)/t10-,11+,12-/m0/s1	MQXRTCVZPIHBLD-TUAOUCFPSA-N	2		Not Available	Small Molecule																																			1	Yes	6	4	No	1	-2	132.8 Å2	41.75 Å3	99.76 m3·mol-1	12	Yes	No	0.0852 mg/mL	0.69	-3.7	3.5	-1.3			
C26H42N6O12S2	Not Available	Not Available	694.77	CSCC[C@H](NC=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O	Not Available	Not Available						125492		34979857									44628955	347829167					ZINC000068077856		Foxy-5	Investigational	DB13034	InChI=1S/C26H42N6O12S2/c1-13(2)8-17(26(43)44)32-24(41)15(4-5-20(35)36)30-25(42)18(11-45)29-19(34)10-27-22(39)16(9-21(37)38)31-23(40)14(28-12-33)6-7-46-3/h12-18,45H,4-11H2,1-3H3,(H,27,39)(H,28,33)(H,29,34)(H,30,42)(H,31,40)(H,32,41)(H,35,36)(H,37,38)(H,43,44)/t14-,15-,16-,17-,18-/m0/s1	WFZPJYYCTSHDJI-ATIWLJMLSA-N	1		Not Available	Small Molecule																																			0	No	12	10	No	0	-3	286.5 Å2	67.64 Å3	162.76 m3·mol-1	23	No	No	0.033 mg/mL	-3.1	-4.3	3.39				
C28H39N7O9	Not Available	Not Available	617.66	C[C@@H](NC(=O)CNC(=O)[C@H]1C[C@H](O)CN1C(=O)[C@H]1CCCN1C(=O)[C@@H](CC1=CC=C(O)C=C1)NC(C)=O)C(=O)NCC(N)=O	Not Available	Not Available							CHEMBL450656	8114558									9938933	347829195				Rotigaptide	ZINC000014175498		Rotigaptide	Investigational	DB13067	InChI=1S/C28H39N7O9/c1-15(25(41)30-12-23(29)39)32-24(40)13-31-26(42)22-11-19(38)14-35(22)28(44)21-4-3-9-34(21)27(43)20(33-16(2)36)10-17-5-7-18(37)8-6-17/h5-8,15,19-22,37-38H,3-4,9-14H2,1-2H3,(H2,29,39)(H,30,41)(H,31,42)(H,32,40)(H,33,36)/t15-,19+,20-,21-,22-/m1/s1	GFJRASPBQLDRRY-TWTQBQJDSA-N	-Infinity		Not Available	Small Molecule																																			0	No	9	7	Yes	3	0	240.57 Å2	62.08 Å3	152.56 m3·mol-1	12	No	No	1.56 mg/mL	-4.6	-2.6	9.5	-1.9			
C16H24N2O6	Not Available	Not Available	340.376	OC(=O)[C@H]1CCCN1C(=O)CCCCC(=O)N1CCC[C@@H]1C(O)=O	Not Available	Not Available							CHEMBL25263	111662						GHE			125516	347829211					ZINC000003972138		Miridesap	Investigational	DB13087	InChI=1S/C16H24N2O6/c19-13(17-9-3-5-11(17)15(21)22)7-1-2-8-14(20)18-10-4-6-12(18)16(23)24/h11-12H,1-10H2,(H,21,22)(H,23,24)/t11-,12-/m1/s1	HZLAWYIBLZNRFZ-VXGBXAGGSA-N	2		Not Available	Small Molecule																																			1	Yes	6	2	No	2	-2	115.22 Å2	34.82 Å3	82.71 m3·mol-1	7	Yes	No	9.95 mg/mL	-0.037	-1.5	3.5	-0.77			
C14H27N3O2	Not Available	Not Available	269.389	CC(C)N(CCNC(=O)CN1CCCC1=O)C(C)C	Not Available	Not Available						135110	CHEMBL159776	46801														Pramiracetam	ZINC000001856108		Pramiracetam	Approved	DB13247	InChI=1S/C14H27N3O2/c1-11(2)17(12(3)4)9-7-15-13(18)10-16-8-5-6-14(16)19/h11-12H,5-10H2,1-4H3,(H,15,18)	ZULJGOSFKWFVRX-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	Yes	3	1	No	1	1	52.65 Å2	30.8 Å3	76.31 m3·mol-1	7	Yes	No	5.31 mg/mL	0.1	-1.7	15.85	9.61			
C18H26N2O4	Not Available	Not Available	334.416	CCCN(CCC)C(=O)C(CCC(O)=O)NC(=O)C1=CC=CC=C1	Not Available	Not Available					50014888	32058	CHEMBL316561	4753												8730		Proglumide			Proglumide	Experimental	DB13431	InChI=1S/C18H26N2O4/c1-3-12-20(13-4-2)18(24)15(10-11-16(21)22)19-17(23)14-8-6-5-7-9-14/h5-9,15H,3-4,10-13H2,1-2H3,(H,19,23)(H,21,22)	DGMKFQYCZXERLX-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	Yes	4	2	No	1	-1	86.71 Å2	36.7 Å3	91.56 m3·mol-1	10	Yes	No	0.145 mg/mL	2.14	-3.4	4.42	-1.2			
C22H31N5O4	Not Available	Not Available	429.5126	[H][C@]1(CCN1C(=O)[C@H](NCC(O)=O)C1CCCCC1)C(=O)NCC1=CC=C(C=C1)C(N)=N	Not Available	Not Available					29388	43966	CHEMBL266349	159822					D07143	MEL								Ximelagatran	ZINC000003809827		Melagatran	Experimental	DB13616	InChI=1S/C22H31N5O4/c23-20(24)16-8-6-14(7-9-16)12-26-21(30)17-10-11-27(17)22(31)19(25-13-18(28)29)15-4-2-1-3-5-15/h6-9,15,17,19,25H,1-5,10-13H2,(H3,23,24)(H,26,30)(H,28,29)/t17-,19+/m0/s1	DKWNMCUOEDMMIN-PKOBYXMFSA-N			Not Available	Small Molecule																																			1	No	7	5	Yes	3	1	148.61 Å2	46.84 Å3	125.7 m3·mol-1	9	Yes	No	0.117 mg/mL	-1.3	-3.6	3.2	11.48			
C34H62N8O7	Not Available	Not Available	694.919	[H]N([H])C(=O)CC[C@H](N([H])C(=O)CN([H])C(=O)CCCCCCCCCCCCCCC)C(=O)N1CCC[C@H]1C(=O)N([H])[C@@H](CCCN=C(N([H])[H])N([H])[H])C(O)=O	Not Available	Not Available								8253946												1314277			ZINC000163851498		Palmitoyl tetrapeptide-7	Experimental	DB14137	InChI=1S/C34H62N8O7/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-19-29(44)39-24-30(45)40-25(20-21-28(35)43)32(47)42-23-16-18-27(42)31(46)41-26(33(48)49)17-15-22-38-34(36)37/h25-27H,2-24H2,1H3,(H2,35,43)(H,39,44)(H,40,45)(H,41,46)(H,48,49)(H4,36,37,38)/t25-,26-,27-/m0/s1	IHRKJQSLKLYWBQ-QKDODKLFSA-N			Not Available	Small Molecule																																			0	No	10	7	No	1	0	252.4 Å2	79.54 Å3	185.21 m3·mol-1	28	No	No	0.00556 mg/mL	0.045	-5.1	3.54	11.23			
C21H28N2O5	Not Available	Not Available	388.4574	[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(O)=O	Not Available	Not Available						77363	CHEMBL1201365	4576531			HMDB0060579			X92						1546377			ZINC000004217399		Ramiprilat	Experimental	DB14208	InChI=1S/C21H28N2O5/c1-13(22-16(20(25)26)11-10-14-6-3-2-4-7-14)19(24)23-17-9-5-8-15(17)12-18(23)21(27)28/h2-4,6-7,13,15-18,22H,5,8-12H2,1H3,(H,25,26)(H,27,28)/t13-,15-,16-,17-,18-/m0/s1	KEDYTOTWMPBSLG-HILJTLORSA-N			Not Available	Small Molecule																																			1	Yes	6	3	Yes	3	-1	106.94 Å2	40.37 Å3	101.67 m3·mol-1	8	Yes	No	0.214 mg/mL	-0.18	-3.3	3.13	8.05			
C22H30N2O5	Not Available	Not Available	402.484	[H][C@@](C)(N[C@@]([H])(CCC1=CC=CC=C1)C(O)=O)C(=O)N1[C@@]([H])(C[C@@]2([H])CCCC[C@]12[H])C(O)=O	Not Available	Not Available						141521	CHEMBL1201387	4576532			HMDB0060583			X93						1546379			ZINC000003784432		Trandolaprilat	Experimental	DB14209	InChI=1S/C22H30N2O5/c1-14(23-17(21(26)27)12-11-15-7-3-2-4-8-15)20(25)24-18-10-6-5-9-16(18)13-19(24)22(28)29/h2-4,7-8,14,16-19,23H,5-6,9-13H2,1H3,(H,26,27)(H,28,29)/t14-,16+,17-,18-,19-/m0/s1	AHYHTSYNOHNUSH-HXFGRODQSA-N			Not Available	Small Molecule																																			1	Yes	6	3	Yes	3	-1	106.94 Å2	42.91 Å3	106.27 m3·mol-1	8	Yes	No	0.0834 mg/mL	0.19	-3.7	3.13	8.04			
C17H28N2O5	Not Available	Not Available	340.4146	[H][C@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC)C(O)=O)[C@@]1([H])CCCC2)C(O)=O	Not Available	Not Available						132041	CHEMBL1201368	65017			HMDB0060574			X94						1546400			ZINC000004217270		Perindoprilat	Experimental	DB14213	InChI=1S/C17H28N2O5/c1-3-6-12(16(21)22)18-10(2)15(20)19-13-8-5-4-7-11(13)9-14(19)17(23)24/h10-14,18H,3-9H2,1-2H3,(H,21,22)(H,23,24)/t10-,11-,12-,13-,14-/m0/s1	ODAIHABQVKJNIY-PEDHHIEDSA-N			Not Available	Small Molecule																																			1	No	6	3	No	2	-1	106.94 Å2	35.8 Å3	86.18 m3·mol-1	7	Yes	No	7.2 mg/mL	-0.85	-1.7	3.08	8.06			
C14H23CuN6O4	Not Available	Prezatide is rapidly eliminated within minutes 5.	402.921	[Cu++].NCCCC[C@H](NC(=O)[C@H](CC1=CN=CN1)NC(=O)CN)C([O-])=O	Not Available	Not Available								32698045																	Prezatide copper	Experimental	DB14683	InChI=1S/C14H24N6O4.Cu/c15-4-2-1-3-10(14(23)24)20-13(22)11(19-12(21)6-16)5-9-7-17-8-18-9;/h7-8,10-11H,1-6,15-16H2,(H,17,18)(H,19,21)(H,20,22)(H,23,24);/q;+2/p-1/t10-,11-;/m0./s1	NZWIFMYRRCMYMN-ACMTZBLWSA-M			Not Available	Small Molecule																																			1	No	7	5	No	1	2	179.05 Å2	34.21 Å3	96.31 m3·mol-1	11	Yes	No	2.08 mg/mL	-5.4	-2.3	3.46	10.2			
C36H61N5O7S	Not Available	Not Available	707.97	CCCCC(NC(=O)C1[C@@H]2[C@H](CN1C(=O)C(NC(=O)NC1(CS(=O)(=O)C(C)(C)C)CCCCC1)C(C)(C)C)C2(C)C)C(=O)C(=O)NC1CC1	Not Available	Not Available																						Narlaprevir			Narlaprevir	Experimental	DB14760	InChI=1S/C36H61N5O7S/c1-10-11-15-24(27(42)30(44)37-22-16-17-22)38-29(43)26-25-23(35(25,8)9)20-41(26)31(45)28(33(2,3)4)39-32(46)40-36(18-13-12-14-19-36)21-49(47,48)34(5,6)7/h22-26,28H,10-21H2,1-9H3,(H,37,44)(H,38,43)(H2,39,40,46)/t23-,24?,25-,26?,28?/m0/s1	RICZEKWVNZFTNZ-IOBYQIKSSA-N	3		Not Available	Small Molecule																																			0	No	7	4	Yes	4	0	170.85 Å2	76.76 Å3	186.29 m3·mol-1	15	No	No	0.00964 mg/mL	3.5	-4.9	12.32	-0.41			
C22H39N9O11S	Not Available	Not Available	637.67	C[C@@H](O)[C@H](NC(=O)[C@H](CS(O)(=O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)CN)C(=O)N1CCC[C@H]1C(O)=O	Not Available	Not Available								68057558																	Risuteganib	Investigational	DB14911	InChI=1S/C22H39N9O11S/c1-11(32)17(20(37)31-7-3-5-14(31)21(38)39)30-19(36)13(10-43(40,41)42)29-16(34)9-27-18(35)12(28-15(33)8-23)4-2-6-26-22(24)25/h11-14,17,32H,2-10,23H2,1H3,(H,27,35)(H,28,33)(H,29,34)(H,30,36)(H,38,39)(H4,24,25,26)(H,40,41,42)/t11-,12+,13+,14+,17+/m1/s1	MYZAXBZLEILEBR-RVFOSREFSA-N	2		Not Available	Small Molecule																																			0	No	15	11	No	1	0	336.53 Å2	61.64 Å3	155.01 m3·mol-1	17	No	No	0.643 mg/mL	-12	-3	-1.4	12.7			
C23H36ClN3O4	Not Available	Not Available	454.01	CC(C)[C@@H](NC(=O)NCC(C)(C)O)C(=O)N1CC[C@](O)(C2=CC=C(Cl)C=C2)C(C)(C)C1	Not Available	Not Available					50056504		CHEMBL3334824	58117293																	BMS-817399	Investigational	DB14941	InChI=1S/C23H36ClN3O4/c1-15(2)18(26-20(29)25-13-22(5,6)30)19(28)27-12-11-23(31,21(3,4)14-27)16-7-9-17(24)10-8-16/h7-10,15,18,30-31H,11-14H2,1-6H3,(H2,25,26,29)/t18-,23+/m1/s1	GTDPZONCGOCXOD-JPYJTQIMSA-N	2		Not Available	Small Molecule																																			1	Yes	4	4	No	2	0	101.9 Å2	49.51 Å3	121.27 m3·mol-1	6	Yes	No	0.128 mg/mL	2.21	-3.6	13.57	-1.1			
C27H44N10O6	Not Available	Not Available	604.713	CC(C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C=O	Not Available	Not Available							CHEMBL1230912	34678														Antipain	ZINC000008716755		Antipain	Experimental	DB15251	InChI=1S/C27H44N10O6/c1-16(2)21(23(40)34-18(15-38)10-6-12-32-25(28)29)37-22(39)19(11-7-13-33-26(30)31)35-27(43)36-20(24(41)42)14-17-8-4-3-5-9-17/h3-5,8-9,15-16,18-21H,6-7,10-14H2,1-2H3,(H,34,40)(H,37,39)(H,41,42)(H4,28,29,32)(H4,30,31,33)(H2,35,36,43)/t18-,19-,20-,21-/m0/s1	SDNYTAYICBFYFH-TUFLPTIASA-N			Not Available	Small Molecule																																			0	No	12	11	No	1	1	277.5 Å2	63.74 Å3	178.23 m3·mol-1	19	No	No	0.0835 mg/mL	-3.4	-3.9	3.42	12.05			
C11H22BN3O5	Not Available	Not Available	287.12	C[C@H](N)C(=O)N1C[C@H](CCCB(O)O)[C@@](N)(C1)C(O)=O	Not Available	Not Available								72379905																	CB-1158	Investigational	DB15286	InChI=1S/C11H22BN3O5/c1-7(13)9(16)15-5-8(3-2-4-12(19)20)11(14,6-15)10(17)18/h7-8,19-20H,2-6,13-14H2,1H3,(H,17,18)/t7-,8-,11-/m0/s1	ZZJLMZYUGLJBSO-LAEOZQHASA-N	2		Not Available	Small Molecule																																			1	No	7	5	No	1	1	150.11 Å2	29.93 Å3	66.88 m3·mol-1	6	Yes	No	6.82 mg/mL	-5.2	-1.6	1.99	8.69			
C16H22N4O4S	Not Available	Not Available	366.44	C[C@@H]1CCCN1C(=O)[C@H](CC1=CSC=N1)NC(=O)[C@H]1NC(=O)O[C@H]1C	Not Available	Not Available								8126670																	Rovatirelin	Investigational	DB15338	InChI=1S/C16H22N4O4S/c1-9-4-3-5-20(9)15(22)12(6-11-7-25-8-17-11)18-14(21)13-10(2)24-16(23)19-13/h7-10,12-13H,3-6H2,1-2H3,(H,18,21)(H,19,23)/t9-,10+,12+,13+/m1/s1	WTXWDXWZGJGIHV-URBCHYCLSA-N	3		Not Available	Small Molecule																																			1	Yes	4	2	No	3	0	100.63 Å2	36.28 Å3	89.39 m3·mol-1	5	Yes	No	0.161 mg/mL	0.019	-3.4	11.4	2.46			
C8H13N3O5S	Not Available	Not Available	263.27	OC(=O)CNC(=O)CNC(=O)CNC(=O)CS	Not Available	Not Available							CHEMBL1615778	54775															ZINC000004194756		Mertiatide	Experimental	DB15780	InChI=1S/C8H13N3O5S/c12-5(2-10-7(14)4-17)9-1-6(13)11-3-8(15)16/h17H,1-4H2,(H,9,12)(H,10,14)(H,11,13)(H,15,16)	RXACEEPNTRHYBQ-UHFFFAOYSA-N		Mertiatide is a radiopharmaceutical reconstituted with sodium pertechnetate for imaging of the kidney.	Not Available	Small Molecule																																			1	No	5	5	No	0	-1	124.6 Å2	24.44 Å3	58.88 m3·mol-1	7	Yes	No	0.29 mg/mL	-3.3	-3	3.64	-4.2			
C21H31N3O8S	Not Available	Not Available	485.55	CC(C)C[C@H](NC(=O)OCC1=CC=CC=C1)C(=O)N[C@@H](CC1CCNC1=O)C(O)S(O)(=O)=O	Not Available	Not Available							CHEMBL2365410	29399539																	GC-376 free acidCommonly known or available as GC-376	Experimental	DB15796	InChI=1S/C21H31N3O8S/c1-13(2)10-16(24-21(28)32-12-14-6-4-3-5-7-14)19(26)23-17(20(27)33(29,30)31)11-15-8-9-22-18(15)25/h3-7,13,15-17,20,27H,8-12H2,1-2H3,(H,22,25)(H,23,26)(H,24,28)(H,29,30,31)/t15?,16-,17-,20?/m0/s1	BSPZFJDYQHDZNR-ASPXRTSYSA-N			Not Available	Small Molecule																																			1	No	7	5	No	2	-1	171.13 Å2	48.62 Å3	117.4 m3·mol-1	12	Yes	No	1.79 mg/mL	-0.55	-2.4	-0.88	-1.5	P0DTD1;!P0DTC1;!Q98VG9;!K9N638;!K9N7C7	rep;!Not Available;!rep;!Not Available;!rep	1. Replicase polyprotein 1ab;!2. Replicase polyprotein 1a;!3. Replicase polyprotein 1ab;!4. Replicase polyprotein 1a;!5. Replicase polyprotein 1ab
C21H29N3O5	Not Available	Not Available	403.479	CC(C)C[C@H](NC(=O)OCC1=CC=CC=C1)C(=O)N[C@@H](CC1CCNC1=O)C=O	Not Available	Not Available							CHEMBL1821850	26617691																	GC-373	Experimental	DB15797	InChI=1S/C21H29N3O5/c1-14(2)10-18(24-21(28)29-13-15-6-4-3-5-7-15)20(27)23-17(12-25)11-16-8-9-22-19(16)26/h3-7,12,14,16-18H,8-11,13H2,1-2H3,(H,22,26)(H,23,27)(H,24,28)/t16?,17-,18-/m0/s1	QYENXTYKACLCGO-FQECFTEESA-N			Not Available	Small Molecule																																			1	Yes	4	3	No	2	0	113.6 Å2	42.97 Å3	106.58 m3·mol-1	11	Yes	No	0.0386 mg/mL	1.28	-4	12.68	-1.6	K9N7C7;!K9N638;!P0DTD1;!P0DTC1;!Q98VG9	rep;!Not Available;!rep;!Not Available;!rep	1. Replicase polyprotein 1ab;!2. Replicase polyprotein 1a;!3. Replicase polyprotein 1ab;!4. Replicase polyprotein 1a;!5. Replicase polyprotein 1ab
C7H13N3O4	Not Available	Not Available	203.198	NCC(=O)N[C@@H](CCC(N)=O)C(O)=O	Not Available	Not Available						74392	CHEMBL330038	110444															ZINC000002555108		Glycylglutamine	Experimental	DB15990	InChI=1S/C7H13N3O4/c8-3-6(12)10-4(7(13)14)1-2-5(9)11/h4H,1-3,8H2,(H2,9,11)(H,10,12)(H,13,14)/t4-/m0/s1	PNMUAGGSDZXTHX-BYPYZUCNSA-N		Glycylglutamine is an ingredient in amino acid solutions for parenteral nutrition.	Not Available	Small Molecule																																			1	No	5	4	No	0	0	135.51 Å2	19.22 Å3	45.91 m3·mol-1	6	Yes	No	17.4 mg/mL	-5.1	-1.1	3.48	8.14			
C11H21N5O5	Not Available	Not Available	303.319	OC(=O)[C@@H]1CCC(=O)N1.N[C@@H](CCCNC(N)=N)C(O)=O	Not Available	Not Available								171679												1482633					Arginine PCA	Experimental	DB16025	InChI=1S/C6H14N4O2.C5H7NO3/c7-4(5(11)12)2-1-3-10-6(8)9;7-4-2-1-3(6-4)5(8)9/h4H,1-3,7H2,(H,11,12)(H4,8,9,10);3H,1-2H2,(H,6,7)(H,8,9)/t4-;3-/m00/s1	UYCAGRPOUWSBIQ-WOYAITHZSA-N			Not Available	Small Molecule																																			1	No	6	5	No	1	1	125.22 Å2	18.04 Å3	53.92 m3·mol-1	6	Yes	No	2.28 mg/mL	-3.2	-1.9	2.41	12.41			
C16H27N3O6	Not Available	Not Available	357.407	N[C@H](CC1CCCCC1)C(=O)N[C@H](CCC(O)=O)C(=O)NCC(O)=O	Not Available	Not Available								8301633															ZINC000034269848		AIM-102	Investigational	DB16176	InChI=1S/C16H27N3O6/c17-11(8-10-4-2-1-3-5-10)15(24)19-12(6-7-13(20)21)16(25)18-9-14(22)23/h10-12H,1-9,17H2,(H,18,25)(H,19,24)(H,20,21)(H,22,23)/t11-,12-/m1/s1	CNDMSQXUUIBFPE-VXGBXAGGSA-N	2		Not Available	Small Molecule																																			1	No	7	5	No	1	-1	158.82 Å2	36.94 Å3	87.06 m3·mol-1	10	Yes	No	0.812 mg/mL	-3.1	-2.6	3.16	8.13			
C32H43N5O4	Not Available	Not Available	561.727	[H][C@]12CC[C@H](N1C(=O)[C@H](CN(CC2)C(=O)CC(C)C)NC(=O)[C@H](C)NC)C(=O)NC(C1=CC=CC=C1)C1=CC=CC=C1	Not Available	Not Available							CHEMBL2158051	28424114															ZINC000043208643		DEBIO-1143	Investigational	DB16305	InChI=1S/C32H43N5O4/c1-21(2)19-28(38)36-18-17-25-15-16-27(37(25)32(41)26(20-36)34-30(39)22(3)33-4)31(40)35-29(23-11-7-5-8-12-23)24-13-9-6-10-14-24/h5-14,21-22,25-27,29,33H,15-20H2,1-4H3,(H,34,39)(H,35,40)/t22-,25+,26-,27-/m0/s1	LSXUTRRVVSPWDZ-MKKUMYSQSA-N	2		Not Available	Small Molecule																																			1	No	5	3	Yes	4	1	110.85 Å2	61.95 Å3	157.05 m3·mol-1	9	No	No	0.0344 mg/mL	2.25	-4.2	12.18	8.6			
C24H33N4O9P	Not Available	Not Available	552.521	[H][C@@]1(C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)C2=CC3=C(N2)C=CC=C3OC)C(=O)COP(O)(O)=O)CCNC1=O	Not Available	Not Available																									PF-07304814	Investigational	DB16514	InChI=1S/C24H33N4O9P/c1-13(2)9-18(28-24(32)19-11-15-16(26-19)5-4-6-21(15)36-3)23(31)27-17(10-14-7-8-25-22(14)30)20(29)12-37-38(33,34)35/h4-6,11,13-14,17-18,26H,7-10,12H2,1-3H3,(H,25,30)(H,27,31)(H,28,32)(H2,33,34,35)/t14-,17-,18-/m0/s1	FQKALOFOWPDTED-WBAXXEDZSA-N	1		Not Available	Small Molecule																																			0	No	8	6	Yes	3	-2	196.15 Å2	54.41 Å3	135.49 m3·mol-1	13	No	No		0.19		1.21	-1.6	P0DTD1	rep	1. Replicase polyprotein 1ab
C23H32F3N5O4	The mean oral clearance of nirmatrelvir, administered with ritonavir, is 8.99 L/h.6	The mean half-life of nirmatrelvir, administered alongside ritonavir, is 6.05 hours.6	499.535	[H][C@]12CN([C@H](C(=O)N[C@@H](C[C@]3([H])CCNC3=O)C#N)[C@@]1([H])C2(C)C)C(=O)[C@@H](NC(=O)C(F)(F)F)C(C)(C)C	Solid	The mean volume of distribution of nirmatrelvir, when given with ritonavir, is 104.7 liters.6	P08684	CYP3A4	1. Cytochrome P450 3A4			170007	CHEMBL4802135	114826566												2587892		3C-like_protease			Nirmatrelvir	Approved, Investigational	DB16691	InChI=1S/C23H32F3N5O4/c1-21(2,3)16(30-20(35)23(24,25)26)19(34)31-10-13-14(22(13,4)5)15(31)18(33)29-12(9-27)8-11-6-7-28-17(11)32/h11-16H,6-8,10H2,1-5H3,(H,28,32)(H,29,33)(H,30,35)/t11-,12-,13-,14-,15-,16+/m0/s1	LIENCHBZNNMNKG-OJFNHCPVSA-N	1	Nirmatrelvir is an oral protease inhibitor with emergency use authorization for the treatment of mild-to-moderate COVID-19.	There are no data regarding overdosage with nirmatrelvir. Treatment of suspected overdose should consist of general supportive measures as clinically indicated.6	Small Molecule																																			1	No	5	3	Yes	3	-1	131.4 Å2	47.09 Å3	117.52 m3·mol-1	8	Yes	No	0.0277 mg/mL	0.44	-4.3	7.1	-1.6	P0DTD1	rep	1. Replicase polyprotein 1ab
C19H23N7O6	Not Available	Not Available	445.4292	NC1=NC(=O)C2=C(NCC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2)N1	Solid	Not Available					50022833	20506	CHEMBL2021342	82572				C00101				PA164745110	91443	46504756			DAP001308	Tetrahydrofolic_acid			Tetrahydrofolic acid	Nutraceutical	DB00116	InChI=1S/C19H23N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,11-12,21,23H,5-8H2,(H,24,29)(H,27,28)(H,31,32)(H4,20,22,25,26,30)/t11?,12-/m0/s1	MSTNYGQPCMXVAQ-KIYNQFGBSA-N			Not Available	Small Molecule	http://smpdb.ca/view/SMP0000033?highlight[compounds][]=DB00116&highlight[proteins][]=DB00116;!http://smpdb.ca/view/SMP0000144?highlight[compounds][]=DB00116&highlight[proteins][]=DB00116;!http://smpdb.ca/view/SMP0000168?highlight[compounds][]=DB00116&highlight[proteins][]=DB00116;!http://smpdb.ca/view/SMP0000203?highlight[compounds][]=DB00116&highlight[proteins][]=DB00116;!http://smpdb.ca/view/SMP0000221?highlight[compounds][]=DB00116&highlight[proteins][]=DB00116;!http://smpdb.ca/view/SMP0000223?highlight[compounds][]=DB00116&highlight[proteins][]=DB00116;!http://smpdb.ca/view/SMP0000244?highlight[compounds][]=DB00116&highlight[proteins][]=DB00116;!http://smpdb.ca/view/SMP0000427?highlight[compounds][]=DB00116&highlight[proteins][]=DB00116;!http://smpdb.ca/view/SMP0000430?highlight[compounds][]=DB00116&highlight[proteins][]=DB00116;!http://smpdb.ca/view/SMP0000432?highlight[compounds][]=DB00116&highlight[proteins][]=DB00116;!http://smpdb.ca/view/SMP0000513?highlight[compounds][]=DB00116&highlight[proteins][]=DB00116;!http://smpdb.ca/view/SMP0000724?highlight[compounds][]=DB00116&highlight[proteins][]=DB00116;!http://smpdb.ca/view/SMP0000004?highlight[compounds][]=DB00116&highlight[proteins][]=DB00116;!http://smpdb.ca/view/SMP0000009?highlight[compounds][]=DB00116&highlight[proteins][]=DB00116;!http://smpdb.ca/view/SMP0000044?highlight[compounds][]=DB00116&highlight[proteins][]=DB00116;!http://smpdb.ca/view/SMP0000050?highlight[compounds][]=DB00116&highlight[proteins][]=DB00116;!http://smpdb.ca/view/SMP0000123?highlight[compounds][]=DB00116&highlight[proteins][]=DB00116;!http://smpdb.ca/view/SMP0000177?highlight[compounds][]=DB00116&highlight[proteins][]=DB00116;!http://smpdb.ca/view/SMP0000191?highlight[compounds][]=DB00116&highlight[proteins][]=DB00116;!http://smpdb.ca/view/SMP0000210?highlight[compounds][]=DB00116&highlight[proteins][]=DB00116;!http://smpdb.ca/view/SMP0000364?highlight[compounds][]=DB00116&highlight[proteins][]=DB00116;!http://smpdb.ca/view/SMP0000365?highlight[compounds][]=DB00116&highlight[proteins][]=DB00116;!http://smpdb.ca/view/SMP0000428?highlight[compounds][]=DB00116&highlight[proteins][]=DB00116;!http://smpdb.ca/view/SMP0000535?highlight[compounds][]=DB00116&highlight[proteins][]=DB00116;!http://smpdb.ca/view/SMP0000543?highlight[compounds][]=DB00116&highlight[proteins][]=DB00116;!http://smpdb.ca/view/SMP0002313?highlight[compounds][]=DB00116&highlight[proteins][]=DB00116;!http://smpdb.ca/view/SMP0000053?highlight[compounds][]=DB00116&highlight[proteins][]=DB00116;!http://smpdb.ca/view/SMP0000167?highlight[compounds][]=DB00116&highlight[proteins][]=DB00116;!http://smpdb.ca/view/SMP0000179?highlight[compounds][]=DB00116&highlight[proteins][]=DB00116;!http://smpdb.ca/view/SMP0000214?highlight[compounds][]=DB00116&highlight[proteins][]=DB00116	Methionine Metabolism;!Adenosine Deaminase Deficiency;!AICA-Ribosiduria;!Molybdenum Cofactor Deficiency;!Methionine Adenosyltransferase Deficiency;!Non-Ketotic Hyperglycinemia;!Sarcosinemia;!Azathioprine Action Pathway;!Thioguanine Action Pathway;!Methotrexate Action Pathway;!Xanthinuria Type II;!Folate Malabsorption, Hereditary;!Glycine and Serine Metabolism;!Ammonia Recycling;!Histidine Metabolism;!Purine Metabolism;!Betaine Metabolism;!Cystathionine beta-Synthase Deficiency;!Histidinemia;!Purine Nucleoside Phosphorylase Deficiency;!Lesch-Nyhan Syndrome (LNS);!Gout or Kelley-Seegmiller Syndrome;!Mercaptopurine Action Pathway;!Adenine Phosphoribosyltransferase Deficiency (APRT);!Methylenetetrahydrofolate Reductase Deficiency (MTHFRD);!Sarcosine Oncometabolite Pathway;!Folate Metabolism;!Adenylosuccinate Lyase Deficiency;!Dihydropyrimidine Dehydrogenase Deficiency (DHPD);!S-Adenosylhomocysteine (SAH) Hydrolase Deficiency		Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.4563 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					-2.7					0	No	12	8	Yes	3	-2	207.27 Å2	42.95 Å3	121.39 m3·mol-1	9	No	No	0.269 mg/mL	-3.4	-3.2	3.21	5.33	P11586;!P13995;!P48728;!O75891;!Q99707;!O95954;!P31939;!P34896;!P34897;!P42898;!Q53ET4;!Q96DP5	MTHFD1;!MTHFD2;!AMT;!ALDH1L1;!MTR;!FTCD;!ATIC;!SHMT1;!SHMT2;!MTHFR;!Not Available;!MTFMT	1. C-1-tetrahydrofolate synthase, cytoplasmic;!2. Bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase, mitochondrial;!3. Aminomethyltransferase, mitochondrial;!4. Cytosolic 10-formyltetrahydrofolate dehydrogenase;!5. Methionine synthase;!6. Formimidoyltransferase-cyclodeaminase;!7. Bifunctional purine biosynthesis protein PURH;!8. Serine hydroxymethyltransferase, cytosolic;!9. Serine hydroxymethyltransferase, mitochondrial;!10. Methylenetetrahydrofolate reductase;!11. Serine hydroxymethyltransferase;!12. Methionyl-tRNA formyltransferase, mitochondrial
C10H17N3O6S	Not Available	Not Available	307.323	N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O	Solid	Not Available	P09210;!P08263	GSTA2;!GSTA1	1. Glutathione S-transferase A2;!2. Glutathione S-transferase A1		50422268	16856	CHEMBL1543	111188			HMDB0000125	C02471	D00014	GSH	PDRhealth Drug Page	PA449780	124886	46504598		4890		Glutathione	ZINC000003830891		Glutathione	Approved, Investigational, Nutraceutical	DB00143	InChI=1S/C10H17N3O6S/c11-5(10(18)19)1-2-7(14)13-6(4-20)9(17)12-3-8(15)16/h5-6,20H,1-4,11H2,(H,12,17)(H,13,14)(H,15,16)(H,18,19)/t5-,6-/m0/s1	RWSXRVCMGQZWBV-WDSKDSINSA-N	3		ORL-MUS LD50 5000 mg/kg, IPR-MUS LD50 4020 mg/kg, SCU-MUS LD50 5000 mg/kg, IVN-RBT LD50 > 2000 mg/kg, IMS-MUS LD50 4000 mg/kg	Small Molecule	http://smpdb.ca/view/SMP0000077?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000087?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000093?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000094?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000114?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000116?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000136?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000183?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000243?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000500?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000567?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000692?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000697?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000702?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000015?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000075?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000083?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000098?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000102?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000106?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000109?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000113?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000120?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000143?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000337?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000385?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000447?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000559?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000604?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143;!http://smpdb.ca/view/SMP0000640?highlight[compounds][]=DB00143&highlight[proteins][]=DB00143	Piroxicam Action Pathway;!Rofecoxib Action Pathway;!Diclofenac Action Pathway;!Sulindac Action Pathway;!Nabumetone Action Pathway;!Valdecoxib Action Pathway;!2-Hydroxyglutric Aciduria (D and L Form);!gamma-Glutamyltransferase Deficiency;!4-Hydroxybutyric Aciduria/Succinic Semialdehyde Dehydrogenase Deficiency;!5-Oxoprolinase Deficiency;!Succinic Semialdehyde Dehydrogenase Deficiency;!Antipyrine Action Pathway;!Flurbiprofen Action Pathway;!Nepafenac Action Pathway;!Glutathione Metabolism;!Arachidonic Acid Metabolism;!Acetylsalicylic Acid Action Pathway;!Ketorolac Action Pathway;!Bromfenac Action Pathway;!Meloxicam Action Pathway;!Mefenamic Acid Action Pathway;!Oxaprozin Action Pathway;!Naproxen Action Pathway;!5-Oxoprolinuria;!Glutathione Synthetase Deficiency;!Homocarnosinosis;!Cyclophosphamide Action Pathway;!Pyruvate Kinase Deficiency;!Cyclophosphamide Metabolism Pathway;!Acetaminophen Metabolism Pathway		AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.7842 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					-6.4		195 °C			1	No	7	6	No	0	-1	158.82 Å2	29.3 Å3	69.11 m3·mol-1	9	No	No		-4.9		1.94	9.22			
C19H19N7O6	Not Available	Not Available	441.3975	NC1=NC(=O)C2=NC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CN=C2N1	Solid	Tetrahydrofolic acid derivatives are distributed to all body tissues but are stored primarily in the liver.	Q92820;!P42898;!P00374	GGH;!MTHFR;!DHFR	1. Gamma-glutamyl hydrolase;!2. Methylenetetrahydrofolate reductase;!3. Dihydrofolate reductase		50237629	27470	CHEMBL1622	5815	Drugs.com Drug Page		HMDB0000121	C00504	D00070	FOL	PDRhealth Drug Page	PA449692	6037	46508092		4511	DAP001309	Folate	ZINC000008577218	Animi-3 With Vitamin D, Citranatal B-calm Kit, Citranatal Harmony, Concept Ob, EnBrace HR, EnLyte, Ferralet 90, Ferraplus, Folbic, Foltabs, Hematogen, Infuvite, Infuvite Pediatric, Irospan 24/6 Kit, Magnebind 400 Rx, Mvc-fluoride, Mvi Pediatric, Natafort, Nicomide, Pregvit, Tandem Plus, Vitafol-one	Folic acid	Approved, Nutraceutical, Vet approved	DB00158	InChI=1S/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s1	OVBPIULPVIDEAO-LBPRGKRZSA-N	4	Folic acid is a nutrient used to treat megaloblastic anemia and is found in many supplements.	IPR-MUS LD50 85 mg/kg,IVN-GPG LD50 120 mg/kg, IVN-MUS LD50 239 mg/kg, IVN-RAT LD50 500 mg/kg, IVN-RBT LD50 410 mg/kg	Small Molecule	http://smpdb.ca/view/SMP0000543?highlight[compounds][]=DB00158&highlight[proteins][]=DB00158;!http://smpdb.ca/view/SMP0000053?highlight[compounds][]=DB00158&highlight[proteins][]=DB00158;!http://smpdb.ca/view/SMP0000432?highlight[compounds][]=DB00158&highlight[proteins][]=DB00158;!http://smpdb.ca/view/SMP0000724?highlight[compounds][]=DB00158&highlight[proteins][]=DB00158	Methylenetetrahydrofolate Reductase Deficiency (MTHFRD);!Folate Metabolism;!Methotrexate Action Pathway;!Folate Malabsorption, Hereditary		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.4490 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					-2.5					0	No	12	6	Yes	3	-2	208.99 Å2	42.06 Å3	111.01 m3·mol-1	9	No	No	0.0761 mg/mL	-0.69	-3.8	3.38	2.12	P41439;!P14207;!P15328	FOLR3;!FOLR2;!FOLR1	1. Folate receptor gamma;!2. Folate receptor beta;!3. Folate receptor alpha
C14H18N2O5	Not Available	At room temperature, aspartame is most stable at pH 4.3, where its half-life is nearly 300 days. At pH 7, its half-life is shortened to only a few days.	294.3031	COC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](N)CC(O)=O	Solid	Not Available					50240005	2877	CHEMBL171679	118630			HMDB0001894	C11045	D02381	PME		PA448493	134601	46507278		1311524		Aspartame	ZINC000001532132		Aspartame	Investigational, Nutraceutical	DB00168	InChI=1S/C14H18N2O5/c1-21-14(20)11(7-9-5-3-2-4-6-9)16-13(19)10(15)8-12(17)18/h2-6,10-11H,7-8,15H2,1H3,(H,16,19)(H,17,18)/t10-,11-/m0/s1	IAOZJIPTCAWIRG-QWRGUYRKSA-N	3		Mild gastrointestinal side effects including diarrhea have been reported.	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	1.6896 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					-0.1		about 190 and 245-247		The solubility of aspartame in water is dependent on pH and temperature, the maximum solubility is reached at pH 2.2 (20 mg/mL at 25 °C) and the minimum solubility at pH 5.2 (pHi) is 13.5 mg/mL at 25 °C.	1	No	5	3	No	1	0	118.72 Å2	29.56 Å3	73.22 m3·mol-1	8	Yes	No	0.651 mg/mL	-2.2	-2.6	3.53	8.53	Q7RTX0;!Q8TE23;!Q8NER1	TAS1R3;!TAS1R2;!TRPV1	1. Taste receptor type 1 member 3;!2. Taste receptor type 1 member 2;!3. Transient receptor potential cation channel subfamily V member 1
C37H49N7O9S	Not Available	10 minutes or less	767.9	CSCC[C@H](NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O	Solid	Not Available	P06276	BCHE	1. Cholinesterase		50024321	31974	CHEMBL1328	8029364		GtP Drug Page			D01631			PA450849	9853654	46507747		7993	DNC001170	Pentagastrin	ZINC000008214644		Pentagastrin	Approved	DB00183	InChI=1S/C37H49N7O9S/c1-37(2,3)53-36(52)39-16-14-30(45)41-28(19-23-21-40-25-13-9-8-12-24(23)25)34(50)42-26(15-17-54-4)33(49)44-29(20-31(46)47)35(51)43-27(32(38)48)18-22-10-6-5-7-11-22/h5-13,21,26-29,40H,14-20H2,1-4H3,(H2,38,48)(H,39,52)(H,41,45)(H,42,50)(H,43,51)(H,44,49)(H,46,47)/t26-,27-,28-,29-/m0/s1	NEYNJQRKHLUJRU-DZUOILHNSA-N		Pentagastrin is a gastrin-like molecule used as a diagnostic aid for the evaluation of gastric acid secretory function, gastric hypersecretion, and Zollinger-Ellison tumors.	Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	3.2696 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor					1.6		229 dec °C			0	No	8	8	Yes	3	-1	250.91 Å2	78.01 Å3	200.04 m3·mol-1	22	No	No	0.00261 mg/mL	1.05	-5.5	4		P32239	CCKBR	1. Gastrin/cholecystokinin type B receptor
C20H28N2O5	Following oral administration in healthy male volunteers, the renal clearance was approximately 158 ± 47 mL/min.8 It is reported that enalapril and enalaprilat are undetectable in the plasma by 4 hours post-dosing.3	The average terminal half life of enalaprilat is 35-38 hours. The effective half life following multiple doses is 11-14 hours. The prolonged terminal half-life is due to the binding of enalaprilat to ACE.5	376.4467	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O	Solid	The volume of distribution of enalapril has not been established. Enalaprilat is shown to penetrate into most tissuesm, in particular the kidneys and vascular tissuem, although penetration of the blood-brain barrier has not been demonstrated after administration at therapeutic doses.7 In dog studies, enalapril and enalaprilat cross the blood-brain barrier poorly.10 Minimal penetration occurs into breast milk but significant fetal transfer occurs.7 The drug crosses the placental barrier in rats and hamsters.10					50017129	4784	CHEMBL578	4534998	Drugs.com Drug Page		HMDB0014722	C06977	D07892		PDRhealth Drug Page	PA449456	5388962	46507920	RxList Drug Page	3827	DAP001374	Enalapril	ZINC000003791297	Epaned, Vaseretic, Vasotec	Enalapril	Approved, Vet approved	DB00584	InChI=1S/C20H28N2O5/c1-3-27-20(26)16(12-11-15-8-5-4-6-9-15)21-14(2)18(23)22-13-7-10-17(22)19(24)25/h4-6,8-9,14,16-17,21H,3,7,10-13H2,1-2H3,(H,24,25)/t14-,16-,17-/m0/s1	GBXSMTUPTTWBMN-XIRDDKMYSA-N	4	Enalapril is a prodrug of an ACE inhibitor used to treat hypertension and congestive heart failure.	LD50 and OverdoseOral LD50 in rats is 2973 mg/kg.MSDS Lethality was observed with single oral doses of enalapril above 1000 mg/kg in mice and greater than or equal to 1775 mg/kg in rats. Serum enalaprilat levels 100- and 200-fold higher than usually seen after therapeutic doses have been reported after ingestion of 300 mg and 440 mg of enalapril, respectively.10 While there is limited data about enalapril overdose in humans, overdosage may result in marked hypotension and stupor based on the pharmacological properties of the drug. Most common adverse effects of enalapril include cough, hypotension, stupor, headache, dizziness and fatigue. If hypotension is seen, usual treatment of intravenous infusion of normal saline solution is recommended. Enalaprilat may be removed from systemic circulation with the use of hemodialysis. It has been removed from neonatal circulation by peritoneal dialysis.LabelNonclinical toxicologyMaternal and fetal toxicity occudred in some rabbits treated with enalapril at doses of 1 mg/kg/day or more. There was no fetotoxicity, expressed as a decrease in average fetal weight, or teratogenicity in rats treated with enalapril at doses up to 200 mg/kg/day, which is about 333 times the maximum human dose.10 In mice and rats receiving enalapril at doses ranging from 90 to 180 mg/kg/day, there was no evidence of a tumorigenic effect. Neither enalapril or its active metabolite were shown to be mutagenic or genotoxic in in vitro and in vivo studies. There were no adverse effects on reproductive performance of male and female rats treated with up to 90 mg/kg/day of enalapril. LabelUse in special populationsCaution is warranted in patients who are concurrently using another ACE inhibitors with enalapril, as there have been incidences of agranulocytosis with the use of captopril, which is another ACE inhibitor. This adverse event may be particularly significant in patients with renal impairment or collagen vascular disease.Label As enalapril and enalaprilat were shown to be secreted in human milk in trace amounts, the use of enalaprilat in nursing women is not recommended.10 Significant fetal transfer occurs with enalapril and enalaprilat thus the use of the drug in pregnant women should be strongly avoided. Caution is advised when enalapril is used in patients who are elderly or with renal impairment, as dosage adjustments may be appropriate. The antihypertensive effect of angiotensin converting enzyme inhibitors is generally lower in individuals of African descent, usually a low-renin hypertensive population.Label	Small Molecule	http://smpdb.ca/view/SMP0000593?highlight[compounds][]=DB00584&highlight[proteins][]=DB00584;!http://smpdb.ca/view/SMP0000148?highlight[compounds][]=DB00584&highlight[proteins][]=DB00584	Enalapril Metabolism Pathway;!Enalapril Action Pathway		Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.8269 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor		-5.64			0.07		143-144.5		1.64E+004 mg/L	1	Yes	5	2	No	2	-1	95.94 Å2	40.41 Å3	99.57 m3·mol-1	10	Yes	No	0.213 mg/mL	0.59	-3.2	3.67	5.2			
C21H31N3O5	A 30kg child has a typical clearance of 10L/h, which increases with renal function.8,9 The mean renal clearance of lisinopril in healthy adult males is 121mL/min.2	Lisinopril has an effective half life of accumulation of 12.6h2,8,9,10 and a terminal half life of 46.7h.2	405.4879	NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O	Solid	The apparent volume of distribution of lisinopril is 124L.3					66979	43755	CHEMBL1237	4514933	Drugs.com Drug Page		HMDB0001938		D00362	LPR	PDRhealth Drug Page	PA450242	5362119	46504893	RxList Drug Page	1546022	DAP000587	Lisinopril	ZINC000003812863	Prinivil, Qbrelis, Zestoretic, Zestril	Lisinopril	Approved, Investigational	DB00722	InChI=1S/C21H31N3O5/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29)/t16-,17-,18-/m0/s1	RLAWWYSOJDYHDC-BZSNNMDCSA-N	4	Lisinopril is an ACE inhibitor used to treat hypertension, heart failure, and acute myocardial infarction.	The oral and subcutaneous LD50 in rats is >8500mg/kg and in mice is >9100mg/kg.11 The oral LDLO in women is 1200µg/kg/16D and in men is 43mg/kg/43W.11Patients experiencing an overdose of lisinopril may present with hypotension.8,9,10 Patients should be treated with intravenous saline to restore blood pressure.8,9,10 Lisinopril can be removed from the blood by hemodialysis due to it not being protein bound.8,9,10	Small Molecule	http://smpdb.ca/view/SMP0000150?highlight[compounds][]=DB00722&highlight[proteins][]=DB00722	Lisinopril Action Pathway		Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.8723 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					-1.01		148	2.5 (at 25 °C)	9.7E+004 mg/L	1	No	7	4	No	2	0	132.96 Å2	43.64 Å3	107.37 m3·mol-1	12	Yes	No	0.216 mg/mL	-3.1	-3.3	3.17	10.21			
C19H32N2O5	219 - 362 mL/min [oral administration]	Perindopril, 1.2 hours; Peridoprilat, 30-120 hours. The long half life of peridoprilat is due to its slow dissociation from ACE binding sites.	368.4678	[H][C@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O	Solid	Not Available	P06276	BCHE	1. Cholinesterase		50493988	8024	CHEMBL1581	96956	Drugs.com Drug Page		HMDB0014928	C07706	D03753		PDRhealth Drug Page	PA450877	107807	46508767	RxList Drug Page	54552	DNC001114	Perindopril	ZINC000003812867	Aceon, Coversyl, Prestalia, Viacoram	Perindopril	Approved	DB00790	InChI=1S/C19H32N2O5/c1-4-8-14(19(25)26-5-2)20-12(3)17(22)21-15-10-7-6-9-13(15)11-16(21)18(23)24/h12-16,20H,4-11H2,1-3H3,(H,23,24)/t12-,13-,14-,15-,16-/m0/s1	IPVQLZZIHOAWMC-QXKUPLGCSA-N	4	Perindopril is an ACE inhibitor prodrug used to treat hypertension, mild to moderate congestive heart failure, and to reduce cardiovascular risk in patients with hypertension or post-myocardial infarction.	The most likely symptom of overdose is severe hypotension. The most common adverse effects observed in controlled clinical trials include cough, digestive symptoms, fatigue, headache, and dizziness.	Small Molecule	http://smpdb.ca/view/SMP0000152?highlight[compounds][]=DB00790&highlight[proteins][]=DB00790	Perindopril Action Pathway		Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	1.9432 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					2.6					1	Yes	5	2	No	2	-1	95.94 Å2	39.99 Å3	95.69 m3·mol-1	9	Yes	No	1.22 mg/mL	0.63	-2.5	3.79	5.48	P12821;!Q6FHJ7	ACE;!SFRP4	1. Angiotensin-converting enzyme;!2. Secreted frizzled-related protein 4
C28H46N6O8S	Not Available	Not Available	626.765		Solid	Not Available						59297	CHEMBL1201779	26331550			HMDB0015032					PA164754810	45266800	46505002		19079	DAP001314	Benzylpenicilloyl_polylysine		Pre-pen	Benzylpenicilloyl polylysine	Approved	DB00895	InChI=1S/C22H32N4O6S.C6H14N2O2/c1-22(2)17(21(31)32)26-19(33-22)16(25-15(27)12-13-8-4-3-5-9-13)18(28)24-11-7-6-10-14(23)20(29)30;7-4-2-1-3-5(8)6(9)10/h3-5,8-9,14,16-17,19,26H,6-7,10-12,23H2,1-2H3,(H,24,28)(H,25,27)(H,29,30)(H,31,32);5H,1-4,7-8H2,(H,9,10)/t14-,16?,17+,19-;5-/m11/s1	IMPVZRLKKKXMKQ-SGDOCVTFSA-N	3	Benzylpenicilloyl polylysine is a penicillin derivative used to determine penicillin allergies.	Symptoms of overdose include urticaria, generalized pruritus, local swelling, generalized flushing, anaphylaxis, bronchospasm, fainting and maculopapular eruption.	Small Molecule																														-0.8					0	No	8	6	No	2	0	170.85 Å2	50.31 Å3	122.22 m3·mol-1	17	No	No	0.0658 mg/mL	-3.8	-3.9	2.04	9.53	P30273;!P12319	FCER1G;!FCER1A	1. High affinity immunoglobulin epsilon receptor subunit gamma;!2. High affinity immunoglobulin epsilon receptor subunit alpha
C22H30N2O5S2	Not Available	30 to 35 hours	466.614	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2(C[C@H]1C(O)=O)SCCS2	Solid	Not Available					50017124	135756	CHEMBL431	4470933			HMDB0015438		D08529			PA164776913	5311447	46506126		36908	DAP000911	Spirapril	ZINC000004217459		Spirapril	Approved	DB01348	InChI=1S/C22H30N2O5S2/c1-3-29-21(28)17(10-9-16-7-5-4-6-8-16)23-15(2)19(25)24-14-22(30-11-12-31-22)13-18(24)20(26)27/h4-8,15,17-18,23H,3,9-14H2,1-2H3,(H,26,27)/t15-,17-,18-/m0/s1	HRWCVUIFMSZDJS-SZMVWBNQSA-N	4		Not Available	Small Molecule	http://smpdb.ca/view/SMP0000156?highlight[compounds][]=DB01348&highlight[proteins][]=DB01348;!http://smpdb.ca/view/SMP0000598?highlight[compounds][]=DB01348&highlight[proteins][]=DB01348	Spirapril Action Pathway;!Spirapril Metabolism Pathway		Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.2396 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	2	Yes	3	-1	95.94 Å2	48.74 Å3	121.94 m3·mol-1	10	Yes	No	0.0293 mg/mL	1.6	-4.2	3.62	5.2	P12821	ACE	1. Angiotensin-converting enzyme
C31H41N7O6	Not Available	Not Available	607.712	CC(C)C[C@H](NC(=O)[C@@H](NC(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O)C1CCNC(=N)N1)C(=O)N[C@@H](CC1=CC=CC=C1)C=O	Solid	Not Available					87059		CHEMBL247767	391398				C11308					5287931	46507872							Chymostatin	Experimental	DB01683	InChI=1S/C31H41N7O6/c1-19(2)15-24(27(40)34-22(18-39)16-20-9-5-3-6-10-20)35-28(41)26(23-13-14-33-30(32)36-23)38-31(44)37-25(29(42)43)17-21-11-7-4-8-12-21/h3-12,18-19,22-26H,13-17H2,1-2H3,(H,34,40)(H,35,41)(H,42,43)(H3,32,33,36)(H2,37,38,44)/t22-,23?,24-,25-,26-/m0/s1	MRXDGVXSWIXTQL-HYHFHBMOSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.5130 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	9	8	Yes	3	0	201.61 Å2	61.91 Å3	171.93 m3·mol-1	15	No	No	0.0182 mg/mL	-0.39	-4.5	3.41	10.99	Q8RJN5	pam	1. Peptide amidase
C9H17NO5	Not Available	Not Available	219.235	CC(C)(CO)[C@@H](O)C(=O)NCCC(O)=O	Solid	Not Available					50240040	46905	CHEMBL1594	6361			HMDB0000210	C00864	D07413	PAU			988	46505022		7891		Pantothenic_acid	ZINC000005356910	Concept Ob, Irospan 24/6 Kit, Pregvit, Tandem Plus	Pantothenic acid	Approved, Nutraceutical, Vet approved	DB01783	InChI=1S/C9H17NO5/c1-9(2,5-11)7(14)8(15)10-4-3-6(12)13/h7,11,14H,3-5H2,1-2H3,(H,10,15)(H,12,13)/t7-/m0/s1	GHOKWGTUZJEAQD-ZETCQYMHSA-N	4	Pantothenic acid is a vitamin B5 found in various nutritional supplements.	No Tolerable Upper Level Intake (UL) has been established for the vitamin.	Small Molecule	http://smpdb.ca/view/SMP0000493?highlight[compounds][]=DB01783&highlight[proteins][]=DB01783;!http://smpdb.ca/view/SMP0000007?highlight[compounds][]=DB01783&highlight[proteins][]=DB01783;!http://smpdb.ca/view/SMP0000027?highlight[compounds][]=DB01783&highlight[proteins][]=DB01783;!http://smpdb.ca/view/SMP0000351?highlight[compounds][]=DB01783&highlight[proteins][]=DB01783;!http://smpdb.ca/view/SMP0000492?highlight[compounds][]=DB01783&highlight[proteins][]=DB01783	Carnosinuria, Carnosinemia;!beta-Alanine Metabolism;!Pantothenate and CoA Biosynthesis;!GABA-Transaminase Deficiency;!Ureidopropionase Deficiency		Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	1.7394 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							195ºC (D-Calcium Pantothenate salt)		Soluble	1	No	5	4	No	0	-1	106.86 Å2	21.99 Å3	51.51 m3·mol-1	6	Yes	No	60.5 mg/mL	-1.4	-0.56	4.35	-2.8	P0A6I3	coaA	1. Pantothenate kinase
C23H24N2O5	Not Available	Not Available	408.4471	[H][C@@](C)(NC(=O)[C@@]([H])(CC1=CC=CC=C1)NC(=O)OCC1=CC=CC=C1)\C=C\C(=O)C=O	Solid	Not Available								4449820						186			5287438	46507094					ZINC000012501121		[1-(1-Methyl-4,5-Dioxo-Pent-2-Enylcarbamoyl)-2-Phenyl-Ethyl]-Carbamic Acid Benzyl Ester	Experimental	DB01810	InChI=1S/C23H24N2O5/c1-17(12-13-20(27)15-26)24-22(28)21(14-18-8-4-2-5-9-18)25-23(29)30-16-19-10-6-3-7-11-19/h2-13,15,17,21H,14,16H2,1H3,(H,24,28)(H,25,29)/b13-12+/t17-,21+/m0/s1	NOXVWFAAXREWMI-GURWAVDKSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.0880 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	2	No	2	0	101.57 Å2	42.65 Å3	112.82 m3·mol-1	11	Yes	No	0.0017 mg/mL	3.65	-5.4	13.43	-4	Q9UBX1;!P25779	CTSF;!Not Available	1. Cathepsin F;!2. Cruzipain
C9H16N2O6	Not Available	Not Available	248.2331	N[C@@H](CCCCNC(C(O)=O)C(O)=O)C(O)=O	Solid	Not Available								16744089						LLY			17754065	46504965					ZINC000006360448		Nz-(Dicarboxymethyl)Lysine	Experimental	DB01815	InChI=1S/C9H16N2O6/c10-5(7(12)13)3-1-2-4-11-6(8(14)15)9(16)17/h5-6,11H,1-4,10H2,(H,12,13)(H,14,15)(H,16,17)/t5-/m0/s1	XINFXVVRMYBFMI-YFKPBYRVSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.3212 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	8	5	No	0	-1	149.95 Å2	24.04 Å3	54.65 m3·mol-1	9	Yes	No	6.37 mg/mL	-5.6	-1.6	1.04	10.41	P0A872	talB	1. Transaldolase B
C29H31N3O7	Not Available	Not Available	533.5723	[H]N(CCCCC)C(=O)[C@H](CC1=CC=C(N(C(=O)C(O)=O)C2=CC=CC=C2C(O)=O)C2=CC=CC=C12)N([H])C(C)=O	Solid	Not Available							CHEMBL1230658	394510						989			447392	46507184					ZINC000014880083		2-{[4-(2-Acetylamino-2-pentylcarbamoyl-ethyl)-naphthalen-1-YL]-oxalyl-amino}-benzoic acid	Experimental	DB01820	InChI=1S/C29H31N3O7/c1-3-4-9-16-30-26(34)23(31-18(2)33)17-19-14-15-25(21-11-6-5-10-20(19)21)32(27(35)29(38)39)24-13-8-7-12-22(24)28(36)37/h5-8,10-15,23H,3-4,9,16-17H2,1-2H3,(H,30,34)(H,31,33)(H,36,37)(H,38,39)/t23-/m0/s1	UESXELNYBIOROE-QHCPKHFHSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1925 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	7	4	Yes	3	-2	153.11 Å2	54.96 Å3	143.01 m3·mol-1	12	No	No		3.45		2.53	-1.9			
C10H22N8O4	Not Available	Not Available	318.3329	NCC[C@H](NC(=O)[C@@H](N)CCCNC(=N)N[N+]([O-])=O)C(N)=O	Solid	Not Available					22030		CHEMBL44833	571159						DP1			656910	46509184					ZINC000012501145		L-N(omega)-Nitroarginine-2,4-L-diaminobutyric amide	Experimental	DB01821	InChI=1S/C10H22N8O4/c11-4-3-7(8(13)19)16-9(20)6(12)2-1-5-15-10(14)17-18(21)22/h6-7H,1-5,11-12H2,(H2,13,19)(H,16,20)(H3,14,15,17)/t6-,7-/m0/s1	KUZKVXUOMSVPOA-BQBZGAKWSA-N			Not Available	Small Molecule				AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.5862 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	9	7	No	0	3	215.28 Å2	31.28 Å3	87.09 m3·mol-1	10	No	No		-4		10.9	9.54			
C24H27N3O7S	Not Available	Not Available	501.552	[H][C@](N)(CCC(=O)N[C@@]([H])(CS[C@]1([H])C2=CC=CC=C2C2=CC=CC=C2[C@@]1([H])O)C(=O)NCC(O)=O)C(O)=O	Solid	Not Available								395916						GPR			449366	46504778					ZINC000015685338		(9R,10R)-9-(S-glutathionyl)-10-hydroxy-9,10-dihydrophenanthrene	Experimental	DB01834	InChI=1S/C24H27N3O7S/c25-17(24(33)34)9-10-19(28)27-18(23(32)26-11-20(29)30)12-35-22-16-8-4-2-6-14(16)13-5-1-3-7-15(13)21(22)31/h1-8,17-18,21-22,31H,9-12,25H2,(H,26,32)(H,27,28)(H,29,30)(H,33,34)/t17-,18-,21+,22+/m0/s1	JNNIZILNBMPOAC-MOXQZVSFSA-N			Not Available	Small Molecule																																			0	No	8	6	Yes	3	-1	179.05 Å2	50.25 Å3	127.88 m3·mol-1	11	No	No	0.031 mg/mL	-2.2	-4.2	1.8	9.31	P09211;!P09488	GSTP1;!GSTM1	1. Glutathione S-transferase P;!2. Glutathione S-transferase Mu 1
C21H30N4O5S2	Not Available	Not Available	482.617	[H][C@@](CCSC)(NC(=O)[C@]1([H])CCCN1C(=O)[C@]([H])(CC1=CC=C(O)C=C1)NC(=O)CS)C(N)=O	Solid	Not Available								4451333						SD2			5289343	46506367					ZINC000033821516		N-(Sulfanylacetyl)Tyrosylprolylmethioninamide	Experimental	DB01883	InChI=1S/C21H30N4O5S2/c1-32-10-8-15(19(22)28)24-20(29)17-3-2-9-25(17)21(30)16(23-18(27)12-31)11-13-4-6-14(26)7-5-13/h4-7,15-17,26,31H,2-3,8-12H2,1H3,(H2,22,28)(H,23,27)(H,24,29)/t15-,16-,17-/m0/s1	LNLWXWOYQHAKTD-ULQDDVLXSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.4015 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	5	5	No	2	0	141.83 Å2	49.33 Å3	125.56 m3·mol-1	11	Yes	No	0.0197 mg/mL	-0.14	-4.4	9.17	-3.4	P15917	lef	1. Lethal factor
C25H33N3O5	Not Available	Not Available	455.5466	[H][C@@](CO)(CC1=CC=CC=C1)NC(=O)[C@@]([H])(NC(=O)[C@]([H])(C)NC(=O)OCC1=CC=CC=C1)C(C)C	Solid	Not Available								392362									444425	46508148					ZINC000015284458		Tl-3-093	Experimental	DB01891	InChI=1S/C25H33N3O5/c1-17(2)22(24(31)27-21(15-29)14-19-10-6-4-7-11-19)28-23(30)18(3)26-25(32)33-16-20-12-8-5-9-13-20/h4-13,17-18,21-22,29H,14-16H2,1-3H3,(H,26,32)(H,27,31)(H,28,30)/t18-,21-,22-/m0/s1	QLOIOASGERKBSU-NYVOZVTQSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1277 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	4	No	2	0	116.76 Å2	48.58 Å3	124.52 m3·mol-1	12	Yes	No	0.00941 mg/mL	2.73	-4.7	12.46	-2.8	P16088;!P03366	pol;!gag-pol	1. Pol polyprotein;!2. Gag-Pol polyprotein
C42H60N6O11	Not Available	Not Available	824.973	CC(C)CCCCCCCCC(=O)N(C)[C@H](CO)C(=O)N[C@H](C)C(=O)NCC(=O)N(C)[C@H]1C2=CC(=C(O)C=C2)C2=CC(C[C@H](NC(=O)[C@H](C)NC1=O)C(O)=O)=CC=C2O	Solid	Not Available							CHEMBL1231055	8163609									9988024	46509042				Arylomycin_A2	ZINC000085740056		Arylomycin A2	Experimental	DB01934	InChI=1S/C42H60N6O11/c1-24(2)13-11-9-7-8-10-12-14-35(52)47(5)32(23-49)40(56)44-25(3)38(54)43-22-36(53)48(6)37-28-16-18-34(51)30(21-28)29-19-27(15-17-33(29)50)20-31(42(58)59)46-39(55)26(4)45-41(37)57/h15-19,21,24-26,31-32,37,49-51H,7-14,20,22-23H2,1-6H3,(H,43,54)(H,44,56)(H,45,57)(H,46,55)(H,58,59)/t25-,26+,31+,32-,37+/m1/s1	YFSXYWAZCKMYJN-JBBOGOJTSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.7802 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										0	No	11	8	Yes	3	-1	255.01 Å2	88.58 Å3	216.78 m3·mol-1	18	No	No	0.00815 mg/mL	2.02	-5	3.54	-2.8	P00803	lepB	1. Signal peptidase I
C38H57N7O10	Not Available	Not Available	771.9001	NC(N)=NCCC[C@H](NC(=O)C(=O)[C@@H](CC1CCCCC1)NC(=O)OCC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1CCCCC1)C(O)=O	Solid	Not Available								16743946						DKT			17753951	46507473					ZINC000098208801		(4S)-5-[[(1S)-1-Carboxy-2-cyclohexylethyl]amino]-4-[[(2S)-2-[[(3R)-4-cyclohexyl-2-oxo-3-(phenylmethoxycarbonylamino)butanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-oxopentanoic acid	Experimental	DB01984	InChI=1S/C38H57N7O10/c39-37(40)41-20-10-17-27(33(49)42-28(18-19-31(46)47)34(50)44-30(36(52)53)22-25-13-6-2-7-14-25)43-35(51)32(48)29(21-24-11-4-1-5-12-24)45-38(54)55-23-26-15-8-3-9-16-26/h3,8-9,15-16,24-25,27-30H,1-2,4-7,10-14,17-23H2,(H,42,49)(H,43,51)(H,44,50)(H,45,54)(H,46,47)(H,52,53)(H4,39,40,41)/t27-,28-,29+,30-/m0/s1	LKCWMWZIRUHWBW-ZXYZSCNASA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Inhibitor	Substrate	2.4223 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										0	No	12	8	Yes	3	-1	281.7 Å2	82.45 Å3	198.69 m3·mol-1	23	No	No	0.0106 mg/mL	1.2	-4.9	3.27	10.76			
C7H15N2O6P	Not Available	Not Available	254.1776	N[C@@H](CCCNC(=O)CP(O)(O)=O)C(O)=O	Solid	Not Available							CHEMBL1160567	111277						PAO			124992	46505486							N-(Phosphonoacetyl)-L-Ornithine	Experimental	DB02011	InChI=1S/C7H15N2O6P/c8-5(7(11)12)2-1-3-9-6(10)4-16(13,14)15/h5H,1-4,8H2,(H,9,10)(H,11,12)(H2,13,14,15)/t5-/m0/s1	FCIHAQFHXJOLIF-YFKPBYRVSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.9953 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	5	No	0	-1	149.95 Å2	22.61 Å3	53.64 m3·mol-1	7	Yes	No	5.85 mg/mL	-4.3	-1.6	1.48	9.28			
C14H25N3O6S	Not Available	Not Available	363.43	CC(C)[C@@H](NC(=O)[C@H](CS)NC(=O)CCC[C@H](N)C(O)=O)C(O)=O	Solid	Not Available						28496	CHEMBL70421	395032				C05556		ACV			448130	46506598		1551571			ZINC000003873037		ACV tripeptide	Experimental	DB02025	InChI=1S/C14H25N3O6S/c1-7(2)11(14(22)23)17-12(19)9(6-24)16-10(18)5-3-4-8(15)13(20)21/h7-9,11,24H,3-6,15H2,1-2H3,(H,16,18)(H,17,19)(H,20,21)(H,22,23)/t8-,9-,11+/m0/s1	BYEIJZFKOAXBBV-ATZCPNFKSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.8780 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	7	6	No	0	-1	158.82 Å2	36.7 Å3	87.21 m3·mol-1	11	No	No	0.478 mg/mL	-3	-2.9	1.94	9.15			
C19H23N7O6	Not Available	Not Available	445.4292	NC1=NC2=C(N[C@@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CN2)C(=O)N1	Solid	Not Available						15635		4573946						THG			5460413	46508587					ZINC000004228237		(6S)-5,6,7,8-tetrahydrofolic acid	Experimental	DB02031	InChI=1S/C19H23N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,11-12,21,23H,5-8H2,(H,24,29)(H,27,28)(H,31,32)(H4,20,22,25,26,30)/t11-,12-/m0/s1	MSTNYGQPCMXVAQ-RYUDHWBXSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.4563 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	11	8	Yes	3	-2	207.27 Å2	44.46 Å3	121.59 m3·mol-1	9	No	No	0.288 mg/mL	-1.9	-3.2	3.46	2.78	O34453;!P0A884	nos;!thyA	1. Nitric oxide synthase oxygenase;!2. Thymidylate synthase
C21H27N2O5P	Not Available	Not Available	418.4232	[H][C@@](C)(N)[P@](O)(=O)C[C@@]([H])(CC1=CC=C(C=C1)C1=CC=CC=C1)C(=O)N[C@@]([H])(C)C(O)=O	Solid	Not Available								4585985						BIR			5478838	46508788					ZINC000012080871		N-[3-[(1-Aminoethyl)(Hydroxy)Phosphoryl]-2-(1,1'-Biphenyl-4-Ylmethyl)Propanoyl]Alanine	Experimental	DB02062	InChI=1S/C21H27N2O5P/c1-14(21(25)26)23-20(24)19(13-29(27,28)15(2)22)12-16-8-10-18(11-9-16)17-6-4-3-5-7-17/h3-11,14-15,19H,12-13,22H2,1-2H3,(H,23,24)(H,25,26)(H,27,28)/t14-,15+,19+/m0/s1	CWJPVKSBGVPXRD-QMTMVMCOSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.2672 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	6	4	No	2	-1	129.72 Å2	42.61 Å3	110.95 m3·mol-1	9	Yes	No	0.00835 mg/mL	0.65	-4.7	-0.044	9.56			
C30H37N9O13	Not Available	Not Available	731.6673	[H]N([H])C1=NC(=O)C2=C(N([H])C[C@H](CN([H])C3=CC=C(C=C3)C(=O)N([H])[C@@H](CCC(=O)N([H])[C@@H](CCC(=O)N([H])[C@@H](CCC(O)=O)C(O)=O)C(O)=O)C(O)=O)N2C=O)N1[H]	Solid	Not Available							CHEMBL1236268	4883456						TGF			6323515	46506661					ZINC000055398661		Triglu-5-formyl-tetrahydrofolate	Experimental	DB02067	InChI=1S/C30H37N9O13/c31-30-37-24-23(26(46)38-30)39(13-40)16(12-33-24)11-32-15-3-1-14(2-4-15)25(45)36-19(29(51)52)6-9-21(42)34-17(27(47)48)5-8-20(41)35-18(28(49)50)7-10-22(43)44/h1-4,13,16-19,32H,5-12H2,(H,34,42)(H,35,41)(H,36,45)(H,43,44)(H,47,48)(H,49,50)(H,51,52)(H4,31,33,37,38,46)/t16-,17-,18-,19-/m0/s1	ZLOMJLIQXBKNHU-VJANTYMQSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.4031 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	18	11	Yes	3	-4	348.35 Å2	69.92 Å3	182.64 m3·mol-1	19	No	No	0.39 mg/mL	-5.8	-3.3	2.34	4.71	P34896	SHMT1	1. Serine hydroxymethyltransferase, cytosolic
C32H42N6O13S	Not Available	Not Available	750.773	[H][C@]1(NC(C(O)=O)=C(CC[C@H](NC(=O)CC[C@@H](NC(C)=O)C(O)=O)C(=O)N[C@H](C)C(=O)N[C@H](C)C(O)=O)CS1)[C@H](NC(=O)CC1=CC=CC=C1)C(O)=O	Solid	Not Available								16743898						CEH			17753890	46509008					ZINC000150342633		Cephalosporin analog	Experimental	DB02136	InChI=1S/C32H42N6O13S/c1-15(26(42)34-16(2)29(44)45)33-27(43)20(36-22(40)12-11-21(30(46)47)35-17(3)39)10-9-19-14-52-28(38-24(19)31(48)49)25(32(50)51)37-23(41)13-18-7-5-4-6-8-18/h4-8,15-16,20-21,25,28,38H,9-14H2,1-3H3,(H,33,43)(H,34,42)(H,35,39)(H,36,40)(H,37,41)(H,44,45)(H,46,47)(H,48,49)(H,50,51)/t15-,16-,20+,21-,25+,28-/m1/s1	PEUIVMLYMKXUBF-PULJXETJSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.4510 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	14	10	No	2	-3	306.73 Å2	74.16 Å3	179.8 m3·mol-1	20	No	No	0.0329 mg/mL	-2	-4.4	3.22		P15555	Not Available	1. D-alanyl-D-alanine carboxypeptidase
C18H30N8O6S	Not Available	Not Available	486.546	CCNC1=NC(SC[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)NCC(O)=O)=NC(NC(C)C)=N1	Solid	Not Available								4450024						ATA			5287712	46506861					ZINC000012501645		Glutathione S-atrazine	Experimental	DB02146	InChI=1S/C18H30N8O6S/c1-4-20-16-24-17(22-9(2)3)26-18(25-16)33-8-11(14(30)21-7-13(28)29)23-12(27)6-5-10(19)15(31)32/h9-11H,4-8,19H2,1-3H3,(H,21,30)(H,23,27)(H,28,29)(H,31,32)(H2,20,22,24,25,26)/t10-,11-/m0/s1	WDLCRTLULMGVMR-QWRGUYRKSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.4883 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	12	7	No	1	-1	221.55 Å2	49.47 Å3	124.3 m3·mol-1	15	No	No	0.189 mg/mL	-6.6	-3.4	-6.9	9.31			
C14H16N2O5S2	Not Available	Not Available	356.417	[H][C@@](NC(=O)CC1=CC=CS1)(C(O)=O)[C@@]1([H])NC(C(O)=O)=C(C)CS1	Solid	Not Available								4450777						KCP			5288660	46508343					ZINC000002043394		Hydrolyzed Cephalothin	Experimental	DB02247	InChI=1S/C14H16N2O5S2/c1-7-6-23-12(16-10(7)13(18)19)11(14(20)21)15-9(17)5-8-3-2-4-22-8/h2-4,11-12,16H,5-6H2,1H3,(H,15,17)(H,18,19)(H,20,21)/t11-,12-/m0/s1	JRYZEMHNDUZNMI-RYUDHWBXSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.3632 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	6	4	No	2	-1	115.73 Å2	33.68 Å3	85.95 m3·mol-1	6	Yes	No	0.0374 mg/mL	1.02	-4	4.05	-0.28	P00811	ampC	1. Beta-lactamase
C10H18N4O6	Not Available	Not Available	290.2731	N[C@@H](CCC\N=C(/N)N[C@H](CC(O)=O)C(O)=O)C(O)=O	Solid	Not Available								395433						AS1			448718	46504554				Argininosuccinic_acid			Argininosuccinate	Experimental	DB02267	InChI=1S/C10H18N4O6/c11-5(8(17)18)2-1-3-13-10(12)14-6(9(19)20)4-7(15)16/h5-6H,1-4,11H2,(H,15,16)(H,17,18)(H,19,20)(H3,12,13,14)/t5-,6+/m0/s1	KDZOASGQNOPSCU-NTSWFWBYSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.6366 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	10	6	No	0	-1	188.33 Å2	27.55 Å3	65.02 m3·mol-1	9	No	No	1.37 mg/mL	-5.9	-2.3	2.14	11.92	P04424;!P59846	ASL;!argG	1. Argininosuccinate lyase;!2. Argininosuccinate synthase
C23H27N3O6	Not Available	Not Available	441.477	[H]N([H])C(=O)[C@H](CC(O)=O)N([H])C(=O)[C@H](CC1=CC=CC=C1)N([H])[C@@H](CCC1=CC=CC=C1)C(O)=O	Solid	Not Available								395515						HPI			448836	46508508					ZINC000012501888		N-(1-carboxy-3-phenylpropyl)phenylalanyl-alpha-asparagine	Experimental	DB02307	InChI=1S/C23H27N3O6/c24-21(29)18(14-20(27)28)26-22(30)19(13-16-9-5-2-6-10-16)25-17(23(31)32)12-11-15-7-3-1-4-8-15/h1-10,17-19,25H,11-14H2,(H2,24,29)(H,26,30)(H,27,28)(H,31,32)/t17-,18-,19-/m0/s1	FOJUHLDAXGNCIP-FHWLQOOXSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.8533 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	5	No	2	-1	158.82 Å2	45.22 Å3	114.84 m3·mol-1	13	Yes	No	0.0139 mg/mL	-1.1	-4.5	3.1	7.81	P14756	lasB	1. Pseudolysin
C17H19N7O7	Not Available	Not Available	433.3755	[H]N([H])C1=NC(=O)C(N([H])[H])=C(N([H])C(=O)N([H])C2=CC=C(C=C2)C(=O)N([H])[C@@H](CCC(O)=O)C(O)=O)N1[H]	Solid	Not Available								392822						L37			445076	46505256							LY374571	Experimental	DB02358	InChI=1S/C17H19N7O7/c18-11-12(22-16(19)24-14(11)28)23-17(31)20-8-3-1-7(2-4-8)13(27)21-9(15(29)30)5-6-10(25)26/h1-4,9H,5-6,18H2,(H,21,27)(H,25,26)(H,29,30)(H5,19,20,22,23,24,28,31)/t9-/m0/s1	SZHRIPFGZWWRKW-VIFPVBQESA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.4119 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	11	8	No	2	-2	238.33 Å2	40.03 Å3	114.43 m3·mol-1	8	No	No	0.189 mg/mL	-2.7	-3.4	3.45	2.92	P11586	MTHFD1	1. C-1-tetrahydrofolate synthase, cytoplasmic
C8H15N3O4	Not Available	Not Available	217.2224	CC(=O)N[C@@H](CCCNC(N)=O)C(O)=O	Solid	Not Available						49002		571213				C15532		OLN			656979	46506512					ZINC000012494450		N-Acetyl-L-Citrulline	Experimental	DB02368	InChI=1S/C8H15N3O4/c1-5(12)11-6(7(13)14)3-2-4-10-8(9)15/h6H,2-4H2,1H3,(H,11,12)(H,13,14)(H3,9,10,15)/t6-/m0/s1	WMQMIOYQXNRROC-LURJTMIESA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.6137 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	4	No	0	-1	121.52 Å2	21.49 Å3	50.77 m3·mol-1	6	Yes	No	3.57 mg/mL	-1.9	-1.8	3.87	-1.5	Q8P8J2	argF'	1. N-acetylornithine carbamoyltransferase
C9H18N2O4	Not Available	Not Available	218.2502	C[C@@H](NCCCC[C@H](N)C(O)=O)C(O)=O	Solid	Not Available								16744100						RF9			17754073	46507581					ZINC000012501967		Nz-(1-Carboxyethyl)-Lysine	Experimental	DB02370	InChI=1S/C9H18N2O4/c1-6(8(12)13)11-5-3-2-4-7(10)9(14)15/h6-7,11H,2-5,10H2,1H3,(H,12,13)(H,14,15)/t6-,7+/m1/s1	XCYPSOHOIAZISD-RQJHMYQMSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.3371 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	4	No	0	0	112.65 Å2	23 Å3	53.16 m3·mol-1	8	Yes	No	14.3 mg/mL	-5	-1.2	1.66	10.68	Q9X1K9	dapA	1. 4-hydroxy-tetrahydrodipicolinate synthase
C38H62N6O8	Not Available	Not Available	730.9343	CC(C)C[C@H](NC(=O)[C@@H]1CC(=O)NCCCCCCOC(=O)N[C@@H](C(C)C)C(=O)N1)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)NCC1=CC=CC=C1	Solid	Not Available					16271		CHEMBL362592	395809						MMI			449218	46506044					ZINC000028353688		MMI-175	Experimental	DB02378	InChI=1S/C38H62N6O8/c1-23(2)19-28(30(45)20-26(7)34(47)43-32(24(3)4)36(49)40-22-27-15-11-10-12-16-27)41-35(48)29-21-31(46)39-17-13-8-9-14-18-52-38(51)44-33(25(5)6)37(50)42-29/h10-12,15-16,23-26,28-30,32-33,45H,8-9,13-14,17-22H2,1-7H3,(H,39,46)(H,40,49)(H,41,48)(H,42,50)(H,43,47)(H,44,51)/t26-,28+,29+,30+,32+,33+/m1/s1	QJAPFAZHNSZLJE-CWURXVSKSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.6249 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	7	7	No	2	0	204.06 Å2	79.71 Å3	195.87 m3·mol-1	14	No	No	0.0155 mg/mL	2.78	-4.7	11.17	-0.79	P56817	BACE1	1. Beta-secretase 1
C27H33N3O9	Not Available	Not Available	543.5656	CCCCCNC(=O)[C@H](CC1=CC=C(OC(C(O)=O)C(O)=O)C=C1)NC(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O	Solid	Not Available					13613			393320						INZ			445784	46506177					ZINC000003874712		{4-[(2S)-2-({[(1S)-1-Carboxy-2-phenylethyl]carbamoyl}amino)-3-oxo-3-(pentylamino)propyl]phenoxy}malonic acid	Experimental	DB02436	InChI=1S/C27H33N3O9/c1-2-3-7-14-28-23(31)20(15-18-10-12-19(13-11-18)39-22(25(34)35)26(36)37)29-27(38)30-21(24(32)33)16-17-8-5-4-6-9-17/h4-6,8-13,20-22H,2-3,7,14-16H2,1H3,(H,28,31)(H,32,33)(H,34,35)(H,36,37)(H2,29,30,38)/t20-,21-/m0/s1	BKONADSQADEJJP-SFTDATJTSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.4279 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	9	6	No	2	-3	191.36 Å2	55.78 Å3	137.05 m3·mol-1	16	No	No	0.00567 mg/mL	2.99	-5	2.32		P18031	PTPN1	1. Tyrosine-protein phosphatase non-receptor type 1
C16H19N5O10S	Not Available	Not Available	473.415	[H][C@](N)(CCC(=O)N[C@@]([H])(CSC1=C(C=C(C=C1)N(=O)=O)N(=O)=O)C(=O)NCC(O)=O)C(O)=O	Solid	Not Available					50391004	8927	CHEMBL1232997	88032			HMDB0062528	C11175		GDN			97535	46504887					ZINC000003870210		S-(2,4-dinitrophenyl)glutathione	Experimental	DB02458	InChI=1S/C16H19N5O10S/c17-9(16(26)27)2-4-13(22)19-10(15(25)18-6-14(23)24)7-32-12-3-1-8(20(28)29)5-11(12)21(30)31/h1,3,5,9-10H,2,4,6-7,17H2,(H,18,25)(H,19,22)(H,23,24)(H,26,27)/t9-,10-/m0/s1	FXEUKVKGTKDDIQ-UWVGGRQHSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.5332 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	11	5	No	1	-1	250.46 Å2	42.88 Å3	108.34 m3·mol-1	13	No	No	0.0319 mg/mL	-3.3	-4.2	1.59	9.31	P09488;!P28161	GSTM1;!GSTM2	1. Glutathione S-transferase Mu 1;!2. Glutathione S-transferase Mu 2
C33H52N6O4	Not Available	Not Available	596.8038	CC1=NC=CN1CCCCC1=CC=C(CC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)NCCC2CCCCC2)C=C1	Solid	Not Available					50034993		CHEMBL6269	393759						MIM			446385	46504453					ZINC000014880363		N-({4-[4-(2-Methyl-1H-imidazol-1-yl)butyl]phenyl}acetyl)-L-seryl-N-(2-cyclohexylethyl)-L-lysinamide	Experimental	DB02477	InChI=1S/C33H52N6O4/c1-25-35-20-22-39(25)21-8-6-11-27-13-15-28(16-14-27)23-31(41)37-30(24-40)33(43)38-29(12-5-7-18-34)32(42)36-19-17-26-9-3-2-4-10-26/h13-16,20,22,26,29-30,40H,2-12,17-19,21,23-24,34H2,1H3,(H,36,42)(H,37,41)(H,38,43)/t29-,30-/m0/s1	WHLPIOSHBKQGHA-KYJUHHDHSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3197 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										0	No	6	5	Yes	3	2	151.37 Å2	68.48 Å3	168.82 m3·mol-1	19	No	No	0.00299 mg/mL	2.39	-5.3	12.2	10.2	P30418	NMT1	1. Glycylpeptide N-tetradecanoyltransferase
C10H18N4O5	Not Available	Not Available	274.2737	NC(=N)NCCC[C@H](NC(=O)CCC(O)=O)C(O)=O	Solid	Not Available						17705		388993				C03296		SUG			439968	46507643					ZINC000001529628		N(2)-succinyl-L-arginine	Experimental	DB02501	InChI=1S/C10H18N4O5/c11-10(12)13-5-1-2-6(9(18)19)14-7(15)3-4-8(16)17/h6H,1-5H2,(H,14,15)(H,16,17)(H,18,19)(H4,11,12,13)/t6-/m0/s1	UMOXFSXIFQOWTD-LURJTMIESA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.8561 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	9	6	No	0	-1	169.09 Å2	26.29 Å3	74.78 m3·mol-1	9	No	No	0.41 mg/mL	-3	-2.8	3.23	12.16	P76216	astB	1. N-succinylarginine dihydrolase
C34H66N12O10S2	Not Available	Not Available	867.092	[H]N([H])CCCCN([H])CCCN([H])C(=O)CN([H])C(=O)[C@H](CSSC[C@H](N([H])C(=O)CC[C@@H](N([H])[H])C(O)=O)C(=O)N([H])CC(=O)N([H])CCCN([H])CCCCN([H])[H])N([H])C(=O)CC[C@@H](N([H])[H])C(O)=O	Solid	Not Available								396047						TS4			449555	46505065					ZINC000195757935		Glutathionylspermidine disulfide	Experimental	DB02553	InChI=1S/C34H66N12O10S2/c35-11-1-3-13-39-15-5-17-41-29(49)19-43-31(51)25(45-27(47)9-7-23(37)33(53)54)21-57-58-22-26(46-28(48)10-8-24(38)34(55)56)32(52)44-20-30(50)42-18-6-16-40-14-4-2-12-36/h23-26,39-40H,1-22,35-38H2,(H,41,49)(H,42,50)(H,43,51)(H,44,52)(H,45,47)(H,46,48)(H,53,54)(H,55,56)/t23-,24-,25+,26+/m1/s1	HCMZDPYSWPSKSP-XPGKHFPBSA-N			Not Available	Small Molecule				AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.1658 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	16	14	No	0	4	377.34 Å2	94.37 Å3	220.19 m3·mol-1	37	No	No		-13		1.44	10.99	P00390	GSR	1. Glutathione reductase, mitochondrial
C21H24N2O4S	Not Available	Not Available	400.491	[H][C@@](C)(NC(=O)[C@]([H])(CC1=CC=CC=C1)NC(=O)[C@]([H])(S)CC1=CC=CC=C1)C(O)=O	Solid	Not Available								395108						OIR			448249	46505323					ZINC000015894751		N-(3-Phenyl-2-Sulfanylpropanoyl)Phenylalanylalanine	Experimental	DB02558	InChI=1S/C21H24N2O4S/c1-14(21(26)27)22-19(24)17(12-15-8-4-2-5-9-15)23-20(25)18(28)13-16-10-6-3-7-11-16/h2-11,14,17-18,28H,12-13H2,1H3,(H,22,24)(H,23,25)(H,26,27)/t14-,17-,18+/m0/s1	CNILVMARPONFBX-JCGIZDLHSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.9103 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	4	No	2	-1	95.5 Å2	41.51 Å3	108.8 m3·mol-1	9	Yes	No	0.00712 mg/mL	2.81	-4.8	3.85	-3.9			
C15H26N4O7	Not Available	Not Available	374.3895	[H]N([H])CC(=O)N([H])[C@@H](CCCCC(=O)N([H])[C@H](C)C(=O)N([H])[C@H](C)C(O)=O)C(O)=O	Solid	Not Available								393699						REX			446306	46508348					ZINC000015599994		N-[(6S)-6-Carboxy-6-(glycylamino)hexanoyl]-D-alanyl-D-alanine	Experimental	DB02578	InChI=1S/C15H26N4O7/c1-8(13(22)18-9(2)14(23)24)17-11(20)6-4-3-5-10(15(25)26)19-12(21)7-16/h8-10H,3-7,16H2,1-2H3,(H,17,20)(H,18,22)(H,19,21)(H,23,24)(H,25,26)/t8-,9-,10+/m1/s1	RALBRZJHHGWNNU-BBBLOLIVSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	1.8059 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	8	6	No	0	-1	187.92 Å2	37.69 Å3	87.89 m3·mol-1	12	No	No	1.07 mg/mL	-4.9	-2.5	3.2	8.14	P15555	Not Available	1. D-alanyl-D-alanine carboxypeptidase
C19H28N2O4S	Not Available	Not Available	380.502	[H][C@@](C)(NC(=O)[C@]([H])(CC1=CC=CC=C1)NC(=O)[C@@]([H])(S)CCCCC)C(O)=O	Solid	Not Available								4451431						TI1			5289469	46505753			DNC001441		ZINC000006352218		[2(R,S)-2-Sulfanylheptanoyl]-Phe-Ala	Experimental	DB02597	InChI=1S/C19H28N2O4S/c1-3-4-6-11-16(26)18(23)21-15(12-14-9-7-5-8-10-14)17(22)20-13(2)19(24)25/h5,7-10,13,15-16,26H,3-4,6,11-12H2,1-2H3,(H,20,22)(H,21,23)(H,24,25)/t13-,15-,16-/m0/s1	GOIYKVXXGCPHQU-BPUTZDHNSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1308 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	4	No	1	-1	95.5 Å2	41.19 Å3	102.51 m3·mol-1	11	Yes	No	0.0104 mg/mL	3.01	-4.6	3.83	-3.4	P00800;!P43133;!P08473	npr;!nprS;!MME	1. Thermolysin;!2. Thermolysin;!3. Neprilysin
C13H14I2N2O5	Not Available	Not Available	532.0696	CC(=O)N[C@@H](CC1=CC(I)=C(O)C(I)=C1)C(=O)NCC(O)=O	Solid	Not Available								394720						IYG			447701	46507272					ZINC000014880426		N-Alpha-Acetyl-3,5-Diiodotyrosylglycine	Experimental	DB02598	InChI=1S/C13H14I2N2O5/c1-6(18)17-10(13(22)16-5-11(19)20)4-7-2-8(14)12(21)9(15)3-7/h2-3,10,21H,4-5H2,1H3,(H,16,22)(H,17,18)(H,19,20)/t10-/m0/s1	SXRYVFRVDCDPKH-JTQLQIEISA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.4777 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	5	4	No	1	-2	115.73 Å2	38.24 Å3	96.07 m3·mol-1	6	No	No	0.153 mg/mL	1.35	-3.5	2.54	-1.9	P19021	PAM	1. Peptidyl-glycine alpha-amidating monooxygenase
C25H35N6O4	Not Available	Not Available	483.5832	[H]N([H])C(N([H])[H])=[N+]([H])CCC[C@H](N([H])C(=O)[C@H](CCC1=CC=CC=C1)N([H])[C@H](C)C(O)=O)C(=O)N([H])C1=CC=CC=C1	Solid	Not Available								4450760						8MI			5288637	46507423							Diamino-N-[(4S)-5-anilino-4-{[(2S)-2-{[(1R)-1-carboxyethyl]amino}-4-phenylbutanoyl]amino}-5-oxopentyl]methaniminium	Experimental	DB02747	InChI=1S/C25H34N6O4/c1-17(24(34)35)29-21(15-14-18-9-4-2-5-10-18)23(33)31-20(13-8-16-28-25(26)27)22(32)30-19-11-6-3-7-12-19/h2-7,9-12,17,20-21,29H,8,13-16H2,1H3,(H,30,32)(H,31,33)(H,34,35)(H4,26,27,28)/p+1/t17-,20+,21+/m1/s1	HDGWGGCPTVXRNA-QMMLZNLJSA-O			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.3141 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	7	7	No	2	1	173.54 Å2	51.92 Å3	144.99 m3·mol-1	14	No	No	0.00483 mg/mL	0.27	-5	7.46	10.87			
C18H23BrN4O7	Not Available	Not Available	487.302	[H]N(CCC(=O)N([H])[C@@]([H])(CO)C(=O)N([H])CCC1=CC=C(C=C1)N([H])C(=O)C(O)=O)C(=O)CBr	Solid	Not Available								25061011						FG1			49866981	46507801					ZINC000012502600		N-(Bromoacetyl)-beta-alanyl-N-(2-{4-[(carboxycarbonyl)amino]phenyl}ethyl)-L-serinamide	Experimental	DB02784	InChI=1S/C18H23BrN4O7/c19-9-15(26)20-8-6-14(25)23-13(10-24)16(27)21-7-5-11-1-3-12(4-2-11)22-17(28)18(29)30/h1-4,13,24H,5-10H2,(H,20,26)(H,21,27)(H,22,28)(H,23,25)(H,29,30)/t13-/m0/s1	IYAWTDCWUJJPHZ-ZDUSSCGKSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.1875 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	7	6	No	1	-1	173.93 Å2	44.1 Å3	109.47 m3·mol-1	12	No	No	0.0545 mg/mL	-1.3	-4	2.79	-2.4	P18031	PTPN1	1. Tyrosine-protein phosphatase non-receptor type 1
C15H21NO6	Not Available	Not Available	311.3303	[H]\C(\C(\[H])=C(\C)[C@@]1([H])CN[C@]([H])(C(O)=O)[C@@]1([H])CC(O)=O)=C(\[H])[C@@]([H])(C)C(O)=O	Solid	Not Available						34727	CHEMBL1232313	4445428				C13732		DOQ			5282253	46505755				Domoic_acid	ZINC000003995581		Domoic Acid	Experimental	DB02852	InChI=1S/C15H21NO6/c1-8(4-3-5-9(2)14(19)20)11-7-16-13(15(21)22)10(11)6-12(17)18/h3-5,9-11,13,16H,6-7H2,1-2H3,(H,17,18)(H,19,20)(H,21,22)/b5-3+,8-4-/t9-,10+,11-,13+/m1/s1	VZFRNCSOCOPNDB-AOKDLOFSSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.4199 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	4	No	1	-2	123.93 Å2	31.25 Å3	79.03 m3·mol-1	7	Yes	No	0.759 mg/mL	-1.8	-2.6	1.68	11.59	Q13002	GRIK2	1. Glutamate receptor ionotropic, kainate 2
C18H31N3O6	Not Available	Not Available	385.4552	[H][C@](O)(CC(=O)N[C@]([H])(C(=O)N1CCC[C@@]1([H])C(O)=O)[C@@]([H])(C)CC)C(=O)NCCC	Solid	Not Available								4449798						074			5287408	46507264					ZINC000015894720		N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline	Experimental	DB02855	InChI=1S/C18H31N3O6/c1-4-8-19-16(24)13(22)10-14(23)20-15(11(3)5-2)17(25)21-9-6-7-12(21)18(26)27/h11-13,15,22H,4-10H2,1-3H3,(H,19,24)(H,20,23)(H,26,27)/t11-,12-,13-,15-/m0/s1	UDNIFTKCMDIXFC-ABHRYQDASA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.5003 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	6	4	No	1	-1	136.04 Å2	40.28 Å3	96.75 m3·mol-1	10	Yes	No	8.23 mg/mL	-0.29	-1.7	3.86	-2.3			
C10H21N2O7P	Not Available	Not Available	312.2567	C[C@H](N)[C@@H](CCCCCC(O)=O)NC(=O)OP(O)(O)=O	Solid	Not Available								392786						DPU			445026	46507124					ZINC000002046974		Mixed Carbamic Phosphoric Acid Anhydride of 7,8-Diaminononanic Acid	Experimental	DB02927	InChI=1S/C10H21N2O7P/c1-7(11)8(5-3-2-4-6-9(13)14)12-10(15)19-20(16,17)18/h7-8H,2-6,11H2,1H3,(H,12,15)(H,13,14)(H2,16,17,18)/t7-,8+/m0/s1	UJJZZEABROBUCE-JGVFFNPUSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.3147 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	5	No	0	-2	159.18 Å2	29.17 Å3	68.76 m3·mol-1	10	Yes	No	1.12 mg/mL	-1	-2.4	1.09	9.42	P13000	bioD1	1. ATP-dependent dethiobiotin synthetase BioD 1
C17H25N3O5S	Not Available	Not Available	383.463	[H]N([H])CCCC(=O)N([H])[C@@H](CSCC1=CC=C(OC)C=C1)C(=O)N([H])CC(O)=O	Solid	Not Available	P08263	GSTA1	1. Glutathione S-transferase A1					394838						ABY			447867	46506921					ZINC000006484319		N-(4-Aminobutanoyl)-S-(4-methoxybenzyl)-L-cysteinylglycine	Experimental	DB02943	InChI=1S/C17H25N3O5S/c1-25-13-6-4-12(5-7-13)10-26-11-14(17(24)19-9-16(22)23)20-15(21)3-2-8-18/h4-7,14H,2-3,8-11,18H2,1H3,(H,19,24)(H,20,21)(H,22,23)/t14-/m0/s1	OMOPDEZZBQHMGS-AWEZNQCLSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1044 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	4	No	1	0	130.75 Å2	40.92 Å3	99.06 m3·mol-1	12	Yes	No		-2.6		3.36	9.99	P08263	GSTA1	1. Glutathione S-transferase A1
C10H17N3O9S	Not Available	Not Available	355.322	[H]N([H])[C@@H](CCC(=O)N([H])[C@@H](CS(O)(=O)=O)C(=O)N([H])CC(O)=O)C(O)=O	Solid	Not Available								392112						GTS			444104	46504962					ZINC000001616624		Glutathione sulfonic acid	Experimental	DB03003	InChI=1S/C10H17N3O9S/c11-5(10(18)19)1-2-7(14)13-6(4-23(20,21)22)9(17)12-3-8(15)16/h5-6H,1-4,11H2,(H,12,17)(H,13,14)(H,15,16)(H,18,19)(H,20,21,22)/t5-,6-/m0/s1	QGWRMTHFAZVWAM-WDSKDSINSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.1180 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	10	6	No	0	-2	213.19 Å2	31.34 Å3	71.33 m3·mol-1	10	No	No	3.0 mg/mL	-5	-2.1	-1.2	9.31	Q03013;!P08263;!P09211;!P0A9D2	GSTM4;!GSTA1;!GSTP1;!gstA	1. Glutathione S-transferase Mu 4;!2. Glutathione S-transferase A1;!3. Glutathione S-transferase P;!4. Glutathione S-transferase GstA
C13H21N3O7S2	Not Available	Not Available	395.452	[H]N([H])[C@@H](CCCC(=O)N([H])[C@@H]1C(=O)N([C@H](C[S@](C)=O)C(O)=O)[C@]1([H])S)C(O)=O	Solid	Not Available								7874544						ACS			9600398	46506055					ZINC000033774367		(2S)-2-amino-6-[[(3R,4R)-1-[(1S)-1-carboxy-2-[(S)-methylsulfinyl]ethyl]-2-oxo-4-sulfanylazetidin-3-yl]amino]-6-oxohexanoic acid	Experimental	DB03004	InChI=1S/C13H21N3O7S2/c1-25(23)5-7(13(21)22)16-10(18)9(11(16)24)15-8(17)4-2-3-6(14)12(19)20/h6-7,9,11,24H,2-5,14H2,1H3,(H,15,17)(H,19,20)(H,21,22)/t6-,7+,9+,11+,25-/m0/s1	UFLVUEXXBDLOEJ-QUNHDKFLSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.4253 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	8	5	No	1	-1	167.1 Å2	37.99 Å3	90 m3·mol-1	10	Yes	No	1.63 mg/mL	-5.5	-2.4	1.85	9.49			
C18H33N3O6S	Not Available	Not Available	419.536	CCCCCCCCSC[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)NCC(O)=O	Solid	Not Available								391395				C11302		GTY			443115	46508495					ZINC000008234408		S-octylglutathione	Experimental	DB03032	InChI=1S/C18H33N3O6S/c1-2-3-4-5-6-7-10-28-12-14(17(25)20-11-16(23)24)21-15(22)9-8-13(19)18(26)27/h13-14H,2-12,19H2,1H3,(H,20,25)(H,21,22)(H,23,24)(H,26,27)/t13-,14-/m0/s1	MJWCZWAVSJZQNL-KBPBESRZSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1495 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	5	No	0	-1	158.82 Å2	45.91 Å3	106.09 m3·mol-1	17	Yes	No	0.0341 mg/mL	-1.5	-4.1	1.81	9.31	Q03013	GSTM4	1. Glutathione S-transferase Mu 4
C18H24N4O10S	Not Available	Not Available	488.469	[H]N([H])[C@@H](CCC(=O)N([H])[C@@H](CSC(O)OCC1=CC=C(C=C1)[N+]([O-])=O)C(=O)N([H])CC(O)=O)C(O)=O	Solid	Not Available								4450641						GNB			5288453	46508387							S-P-Nitrobenzyloxycarbonylglutathione	Experimental	DB03130	InChI=1S/C18H24N4O10S/c19-12(17(27)28)5-6-14(23)21-13(16(26)20-7-15(24)25)9-33-18(29)32-8-10-1-3-11(4-2-10)22(30)31/h1-4,12-13,18,29H,5-9,19H2,(H,20,26)(H,21,23)(H,24,25)(H,27,28)/t12-,13-,18?/m0/s1	QYFGPQQSJQOGEO-TVJRNMROSA-N			Not Available	Small Molecule				AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.5418 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	11	6	No	1	-1	231.42 Å2	46.28 Å3	112.39 m3·mol-1	15	No	No	0.286 mg/mL	-2.7	-3.2	1.76	9.31	Q04760	GLO1	1. Lactoylglutathione lyase
C16H27N3O4S	Not Available	Not Available	357.468	[H][C@@]1(CCCCC(=O)NCCCCCC(O)=O)SC[C@]2([H])NC(=O)N[C@]12[H]	Solid	Not Available								394140						BH7			446905	46507521					ZINC000005185702		6-[5-(2-Oxo-Hexahydro-Thieno[3,4-D]Imidazol-4-Yl)-Pentanoylamino]-Hexanoic Acid	Experimental	DB03139	InChI=1S/C16H27N3O4S/c20-13(17-9-5-1-2-8-14(21)22)7-4-3-6-12-15-11(10-24-12)18-16(23)19-15/h11-12,15H,1-10H2,(H,17,20)(H,21,22)(H2,18,19,23)/t11-,12-,15-/m0/s1	CMUGHZFPFWNUQT-HUBLWGQQSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.1398 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	4	No	2	-1	107.53 Å2	38.6 Å3	91.51 m3·mol-1	11	Yes	No	0.0693 mg/mL	0.63	-3.7	4.47	-1	P22629	Not Available	1. Streptavidin
C7H15N3O3	Not Available	Not Available	189.2123	NCCC(=O)NCC[C@H](N)C(O)=O	Solid	Not Available								25057781						193			46936619	46506230					ZINC000012503315		(2s)-4-(Beta-Alanylamino)-2-Aminobutanoic Acid	Experimental	DB03236	InChI=1S/C7H15N3O3/c8-3-1-6(11)10-4-2-5(9)7(12)13/h5H,1-4,8-9H2,(H,10,11)(H,12,13)/t5-/m0/s1	ZTTQHTAQUGLWNQ-YFKPBYRVSA-N			Not Available	Small Molecule				AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.6861 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	5	4	No	0	1	118.44 Å2	19.52 Å3	46.07 m3·mol-1	6	Yes	No	28.3 mg/mL	-5.1	-0.83	2.35	9.41			
C17H34N6O5S	Not Available	Not Available	434.554	NCCCCNCCCNC(=O)CNC(=O)[C@H](CS)NC(=O)CC[C@H](N)C(O)=O	Solid	Not Available						16613		389641				C05730		TS5			440772	46505567					ZINC000003869959		Glutathionylspermidine	Experimental	DB03295	InChI=1S/C17H34N6O5S/c18-6-1-2-7-20-8-3-9-21-15(25)10-22-16(26)13(11-29)23-14(24)5-4-12(19)17(27)28/h12-13,20,29H,1-11,18-19H2,(H,21,25)(H,22,26)(H,23,24)(H,27,28)/t12-,13-/m0/s1	NEDQLXHBVHSKNV-STQMWFEESA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	1.9668 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	11	8	No	0	2	199.14 Å2	47.62 Å3	112.45 m3·mol-1	17	No	No		-8.3		1.87	10.89			
C20H32N6O12S2	Not Available	Not Available	612.631	N[C@@H](CCC(=O)N[C@@H](CSSC[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)NCC(O)=O)C(=O)NCC(O)=O)C(O)=O	Solid	Not Available					225231	17858	CHEMBL1372	58835				C00127	D00031	GDS			65359	46508372		25953		Glutathione_disulfide	ZINC000003870129	Bss Ophthalmic Solution	Glutathione disulfide	Approved, Experimental, Investigational	DB03310	InChI=1S/C20H32N6O12S2/c21-9(19(35)36)1-3-13(27)25-11(17(33)23-5-15(29)30)7-39-40-8-12(18(34)24-6-16(31)32)26-14(28)4-2-10(22)20(37)38/h9-12H,1-8,21-22H2,(H,23,33)(H,24,34)(H,25,27)(H,26,28)(H,29,30)(H,31,32)(H,35,36)(H,37,38)/t9-,10-,11-,12-/m0/s1	YPZRWBKMTBYPTK-BJDJZHNGSA-N	3	Glutathione disulfide is an ingredient of ophthalmic irrigation solutions used during ophthalmological procedures.	Not Available	Small Molecule				AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.0571 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	14	10	No	0	-2	317.64 Å2	58.47 Å3	136.65 m3·mol-1	21	No	No	0.406 mg/mL	-10	-3.2	1.44	9.61	BE0009997;!P10620;!BE0010006;!P28161;!P00390	;!MGST1;!;!GSTM2;!GSR	1. Glutathione peroxidase (Protein Group);!2. Microsomal glutathione S-transferase 1;!3. Glutathione S-transferases (Cytosolic) (Protein Group);!4. Glutathione S-transferase Mu 2;!5. Glutathione reductase, mitochondrial
C16H21N3O8S	Not Available	Not Available	415.418	[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)CCC[C@@H](N)C(O)=O)C(O)=O	Solid	Not Available						15776	CHEMBL482858	58980			HMDB0060450	C00916		CSC			65536	46505733				Cephalosporin_C	ZINC000003977881		Cephalosporin C	Experimental	DB03313	InChI=1S/C16H21N3O8S/c1-7(20)27-5-8-6-28-14-11(13(22)19(14)12(8)16(25)26)18-10(21)4-2-3-9(17)15(23)24/h9,11,14H,2-6,17H2,1H3,(H,18,21)(H,23,24)(H,25,26)/t9-,11-,14-/m1/s1	HOKIDJSKDBPKTQ-GLXFQSAKSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	1.9527 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	8	4	No	2	-1	176.33 Å2	39.7 Å3	95.43 m3·mol-1	10	Yes	No		-4.4		1.83	9.22	Q7CRA4;!Q8DR59;!P0A3M6;!Q8DNB6;!Q75Y35;!P15555	pbp1b;!pbpA;!penA;!pbp2a;!pbp3;!Not Available	1. Penicillin-binding protein 1b;!2. Penicillin-binding protein 1A;!3. Penicillin-binding protein 2B;!4. Penicillin-binding protein 2a;!5. Penicillin-binding protein 3;!6. D-alanyl-D-alanine carboxypeptidase
C17H23IN4O8S	Not Available	Not Available	570.356	N[C@@H](CCC(=O)N[C@@H](CS[C@@H](O)N(O)C1=CC=C(I)C=C1)C(=O)NCC(O)=O)C(O)=O	Solid	Not Available								16743995						GIP			17753999	46505523					ZINC000014880713		S-(N-hydroxy-N-iodophenylcarbamoyl)glutathione	Experimental	DB03330	InChI=1S/C17H23IN4O8S/c18-9-1-3-10(4-2-9)22(30)17(29)31-8-12(15(26)20-7-14(24)25)21-13(23)6-5-11(19)16(27)28/h1-4,11-12,17,29-30H,5-8,19H2,(H,20,26)(H,21,23)(H,24,25)(H,27,28)/t11-,12-,17+/m0/s1	SCHAHXXLASZJCD-NVGCLXPQSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.5014 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	10	7	No	1	-1	202.52 Å2	48.57 Å3	128.66 m3·mol-1	13	No	No	0.163 mg/mL	-1.9	-3.5	1.77	9.31	Q04760	GLO1	1. Lactoylglutathione lyase
C8H14N2O5S	Not Available	Not Available	250.272	N[C@@H](CCC(=O)N[C@@H](CS)C(O)=O)C(O)=O	Solid	Not Available						17515	CHEMBL460831	110467			HMDB0001049	C00669		3GC			123938	46506032				Gamma-Glutamylcysteine	ZINC000003870040		gamma-Glutamylcysteine	Experimental	DB03408	InChI=1S/C8H14N2O5S/c9-4(7(12)13)1-2-6(11)10-5(3-16)8(14)15/h4-5,16H,1-3,9H2,(H,10,11)(H,12,13)(H,14,15)/t4-,5-/m0/s1	RITKHVBHSGLULN-WHFBIAKZSA-N			Not Available	Small Molecule	http://smpdb.ca/view/SMP0000072?highlight[compounds][]=DB03408&highlight[proteins][]=DB03408;!http://smpdb.ca/view/SMP0000339?highlight[compounds][]=DB03408&highlight[proteins][]=DB03408;!http://smpdb.ca/view/SMP0000501?highlight[compounds][]=DB03408&highlight[proteins][]=DB03408;!http://smpdb.ca/view/SMP0000136?highlight[compounds][]=DB03408&highlight[proteins][]=DB03408;!http://smpdb.ca/view/SMP0000183?highlight[compounds][]=DB03408&highlight[proteins][]=DB03408;!http://smpdb.ca/view/SMP0000243?highlight[compounds][]=DB03408&highlight[proteins][]=DB03408;!http://smpdb.ca/view/SMP0000499?highlight[compounds][]=DB03408&highlight[proteins][]=DB03408;!http://smpdb.ca/view/SMP0000500?highlight[compounds][]=DB03408&highlight[proteins][]=DB03408;!http://smpdb.ca/view/SMP0000567?highlight[compounds][]=DB03408&highlight[proteins][]=DB03408;!http://smpdb.ca/view/SMP0000013?highlight[compounds][]=DB03408&highlight[proteins][]=DB03408;!http://smpdb.ca/view/SMP0000015?highlight[compounds][]=DB03408&highlight[proteins][]=DB03408;!http://smpdb.ca/view/SMP0000143?highlight[compounds][]=DB03408&highlight[proteins][]=DB03408;!http://smpdb.ca/view/SMP0000337?highlight[compounds][]=DB03408&highlight[proteins][]=DB03408;!http://smpdb.ca/view/SMP0000385?highlight[compounds][]=DB03408&highlight[proteins][]=DB03408;!http://smpdb.ca/view/SMP0000722?highlight[compounds][]=DB03408&highlight[proteins][]=DB03408	Glutamate Metabolism;!Hyperinsulinism-Hyperammonemia Syndrome;!gamma-Glutamyltranspeptidase Deficiency;!2-Hydroxyglutric Aciduria (D and L Form);!gamma-Glutamyltransferase Deficiency;!4-Hydroxybutyric Aciduria/Succinic Semialdehyde Dehydrogenase Deficiency;!beta-Mercaptolactate-Cysteine Disulfiduria;!5-Oxoprolinase Deficiency;!Succinic Semialdehyde Dehydrogenase Deficiency;!Cysteine Metabolism;!Glutathione Metabolism;!5-Oxoprolinuria;!Glutathione Synthetase Deficiency;!Homocarnosinosis;!Cystinosis, Ocular Nonnephropathic		AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.5829 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	5	No	0	-1	129.72 Å2	23.36 Å3	56.31 m3·mol-1	7	Yes	No	2.62 mg/mL	-3.8	-2	1.91	9.24	P48637	GSS	1. Glutathione synthetase
C16H24N2O4	Not Available	Not Available	308.3728	CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1)C(O)=O	Solid	Not Available	P16444	DPEP1	1. Dipeptidase 1		50367209		CHEMBL29292	65145						BES			72172	46505598				Ubenimex	ZINC000001542895		Ubenimex	Investigational	DB03424	InChI=1S/C16H24N2O4/c1-10(2)8-13(16(21)22)18-15(20)14(19)12(17)9-11-6-4-3-5-7-11/h3-7,10,12-14,19H,8-9,17H2,1-2H3,(H,18,20)(H,21,22)/t12-,13+,14+/m1/s1	VGGGPCQERPFHOB-RDBSUJKOSA-N	3		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.8987 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	5	4	No	1	0	112.65 Å2	33.09 Å3	82.05 m3·mol-1	8	Yes	No	1.29 mg/mL	-1.1	-2.4	3.73	8.35			
C13H21N3O6S	Not Available	Not Available	347.387	[H]N([H])[C@@H](CCCC(=O)N([H])[C@@H](CS)C(=O)N([H])[C@H](C=C)C(O)=O)C(O)=O	Solid	Not Available								4911105						ASV			6398414	46508704					ZINC000006363128		delta-(L-alpha-Aminoadipoyl)-L-cysteinyl-D-vinylglycine	Experimental	DB03427	InChI=1S/C13H21N3O6S/c1-2-8(13(21)22)16-11(18)9(6-23)15-10(17)5-3-4-7(14)12(19)20/h2,7-9,23H,1,3-6,14H2,(H,15,17)(H,16,18)(H,19,20)(H,21,22)/t7-,8+,9-/m0/s1	JJJCGQKXGIRXKN-YIZRAAEISA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.9995 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	7	6	No	0	-1	158.82 Å2	33.47 Å3	82.62 m3·mol-1	11	No	No	0.905 mg/mL	-3.5	-2.6	1.94	9.15			
C18H35NO3	Not Available	Not Available	313.4754	CCCCCCCCCCCCCCCC(=O)NCC(O)=O	Solid	Not Available					212439	39540	CHEMBL226117	133100			HMDB0013034			140			151008	46505498					ZINC000008689962		N-hexadecanoylglycine	Experimental	DB03440	InChI=1S/C18H35NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-17(20)19-16-18(21)22/h2-16H2,1H3,(H,19,20)(H,21,22)	KVTFEOAKFFQCCX-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.6346 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	Yes	3	2	No	0	-1	66.4 Å2	39.94 Å3	89.89 m3·mol-1	16	No	No	0.000708 mg/mL	5.15	-5.6	4.05	-1.7	P14779	cyp102A1	1. Bifunctional P-450/NADPH-P450 reductase
C6H10NO8P	Not Available	Not Available	255.1193	[H]N([C@@H](CC(O)=O)C(O)=O)C(=O)CP(O)(O)=O	Solid	Not Available							CHEMBL504802	36554						PAL			39981	46507931			DNC000976		ZINC000001563934		Sparfosic acid	Experimental	DB03459	InChI=1S/C6H10NO8P/c8-4(2-16(13,14)15)7-3(6(11)12)1-5(9)10/h3H,1-2H2,(H,7,8)(H,9,10)(H,11,12)(H2,13,14,15)/t3-/m0/s1	ZZKNRXZVGOYGJT-VKHMYHEASA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.0339 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	8	5	No	0	-3	161.23 Å2	19.82 Å3	46.97 m3·mol-1	6	Yes	No	6.73 mg/mL	-2.7	-1.6	1.65		P0A789;!P27708	pyrB;!CAD	1. Aspartate carbamoyltransferase catalytic chain;!2. CAD protein
C27H49N9O10S2	Not Available	Not Available	723.862	N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(=O)NCCCCNCCCNC(=O)CNC(=O)[C@H](CS)NC(=O)CC[C@H](N)C(O)=O)C(O)=O	Solid	Not Available						17842		396023			HMDB0060520	C02090		GCG			449517	46505609				Trypanothione	ZINC000008217540		Trypanothione	Experimental	DB03470	InChI=1S/C27H49N9O10S2/c28-16(26(43)44)4-6-20(37)35-18(14-47)24(41)33-12-22(39)31-10-2-1-8-30-9-3-11-32-23(40)13-34-25(42)19(15-48)36-21(38)7-5-17(29)27(45)46/h16-19,30,47-48H,1-15,28-29H2,(H,31,39)(H,32,40)(H,33,41)(H,34,42)(H,35,37)(H,36,38)(H,43,44)(H,45,46)/t16-,17-,18-,19-/m0/s1	PHDOXVGRXXAYEB-VJANTYMQSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	1.9668 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	13	13	No	0	1	313.27 Å2	75.33 Å3	176.8 m3·mol-1	27	No	No	0.0121 mg/mL	-11	-4.8	1.64	10.57	P28593	TPR	1. Trypanothione reductase
C25H33NO3	Not Available	Not Available	395.5344	[H]N([C@@H](CCC(O)=O)CCC1=CC=CC=C1)C(=O)CCCCCCC1=CC=CC=C1	Solid	Not Available								394051						BR4			446783	46508085					ZINC000006579298		6-phenyl-4(R)-(7-phenyl-heptanoylamino)-hexanoic acid	Experimental	DB03471	InChI=1S/C25H33NO3/c27-24(16-10-2-1-5-11-21-12-6-3-7-13-21)26-23(19-20-25(28)29)18-17-22-14-8-4-9-15-22/h3-4,6-9,12-15,23H,1-2,5,10-11,16-20H2,(H,26,27)(H,28,29)/t23-/m1/s1	SMNHQYPORNSAQH-HSZRJFAPSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.6494 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	3	2	No	2	-1	66.4 Å2	46.79 Å3	116.27 m3·mol-1	14	No	No	0.000201 mg/mL	5.77	-6.3	4.6	-0.78	P14555	PLA2G2A	1. Phospholipase A2, membrane associated
C32H34F4N4O12P2	Not Available	Not Available	804.5731	[H]N([H])C(=O)[C@H](CC1=CC=C(C=C1)C(F)(F)P(O)(O)=O)N([H])C(=O)[C@H](CC1=CC=C(C=C1)C(F)(F)P(O)(O)=O)N([H])C(=O)[C@H](CCC(O)=O)N([H])C(=O)C1=CC=CC=C1	Solid	Not Available								394203						BGD			446986	46508067					ZINC000098208699		(4S)-5-[[(2S)-1-[[(2S)-1-Amino-3-[4-[difluoro(phosphono)methyl]phenyl]-1-oxopropan-2-yl]amino]-3-[4-[difluoro(phosphono)methyl]phenyl]-1-oxopropan-2-yl]amino]-4-benzamido-5-oxopentanoic acid	Experimental	DB03483	InChI=1S/C32H34F4N4O12P2/c33-31(34,53(47,48)49)21-10-6-18(7-11-21)16-24(27(37)43)39-30(46)25(17-19-8-12-22(13-9-19)32(35,36)54(50,51)52)40-29(45)23(14-15-26(41)42)38-28(44)20-4-2-1-3-5-20/h1-13,23-25H,14-17H2,(H2,37,43)(H,38,44)(H,39,46)(H,40,45)(H,41,42)(H2,47,48,49)(H2,50,51,52)/t23-,24-,25-/m0/s1	UJIWNECQGQOIKP-SDHOMARFSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.4530 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	12	9	Yes	3	-4	282.75 Å2	70.49 Å3	180.5 m3·mol-1	18	No	No	0.0267 mg/mL	0.83	-4.5	0.19		P18031	PTPN1	1. Tyrosine-protein phosphatase non-receptor type 1
C18H28FN5O4	Not Available	Not Available	397.4444	C[C@H](NC(=O)[C@H](CCCNC(N)N)NC(=O)OCC1=CC=CC=C1)C(=O)CF	Solid	Not Available								59051958						ZRA			131704251	46504937					ZINC000098209677		Benzyl N-[(2S)-5-(diaminomethylamino)-1-[[(2S)-4-fluoro-3-oxobutan-2-yl]amino]-1-oxopentan-2-yl]carbamate	Experimental	DB03536	InChI=1S/C18H28FN5O4/c1-12(15(25)10-19)23-16(26)14(8-5-9-22-17(20)21)24-18(27)28-11-13-6-3-2-4-7-13/h2-4,6-7,12,14,17,22H,5,8-11,20-21H2,1H3,(H,23,26)(H,24,27)/t12-,14-/m0/s1	FAAPWXRBXXSQNJ-JSGCOSHPSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1716 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	6	5	No	1	0	148.57 Å2	41.24 Å3	100.66 m3·mol-1	13	Yes	No	0.28 mg/mL	0.43	-3.2	12.73	6.71	Q9UBX1;!P25779	CTSF;!Not Available	1. Cathepsin F;!2. Cruzipain
C22H30F3N5O8	Not Available	Not Available	549.4975	[H][C@@](CCC(O)=O)(NC(=O)C1=CC=C(C=C1)[C@@]([H])(CCCC1C(O)=N[C@]([H])(N)N[C@]1([H])N)C(O)(O)C(F)(F)F)C(O)=O	Solid	Not Available								64873371						KEU			131704252	46505325							N-({4-[(1R)-4-[(2R,4S,5S)-2,4-diamino-6-oxohexahydropyrimidin-5-yl]-1-(2,2,2-trifluoro-1,1-dihydroxyethyl)butyl]phenyl}carbonyl)-L-glutamic acid	Experimental	DB03546	InChI=1S/C22H30F3N5O8/c23-22(24,25)21(37,38)13(3-1-2-12-16(26)29-20(27)30-18(12)34)10-4-6-11(7-5-10)17(33)28-14(19(35)36)8-9-15(31)32/h4-7,12-14,16,20,29,37-38H,1-3,8-9,26-27H2,(H,28,33)(H,30,34)(H,31,32)(H,35,36)/t12?,13-,14+,16+,20-/m1/s1	KOLDLUFBEMUZIM-YNPGLMGXSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.6180 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	12	9	No	2	-1	240.82 Å2	50.68 Å3	123.09 m3·mol-1	13	No	No	0.782 mg/mL	-2.3	-2.8	2.7	7.74	P22102	GART	1. Trifunctional purine biosynthetic protein adenosine-3
C14H21N3O6S	Not Available	Not Available	359.398	[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CCC[C@H](N)C(O)=O)C(O)=O	Solid	Not Available						18165		389596				C05557		IP1			440723	46504620					ZINC000004096831		Isopenicillin N	Experimental	DB03550	InChI=1S/C14H21N3O6S/c1-14(2)9(13(22)23)17-10(19)8(11(17)24-14)16-7(18)5-3-4-6(15)12(20)21/h6,8-9,11H,3-5,15H2,1-2H3,(H,16,18)(H,20,21)(H,22,23)/t6-,8+,9-,11+/m0/s1	MIFYHUACUWQUKT-GTQWGBSQSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	1.9690 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	4	No	2	-1	150.03 Å2	35.64 Å3	83.05 m3·mol-1	7	Yes	No	8.96 mg/mL	-3.4	-1.6	1.83	9.23			
C20H25N3O10S	Not Available	Not Available	499.492	OC(=O)CCNC(=O)[C@H]1CCCN1S(=O)(=O)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O	Solid	Not Available					50149206		CHEMBL418875	393129						TP4			445506	46504915					ZINC000003874330		SP-876	Experimental	DB03558	InChI=1S/C20H25N3O10S/c24-16(25)8-7-14(20(30)31)22-18(28)12-3-5-13(6-4-12)34(32,33)23-11-1-2-15(23)19(29)21-10-9-17(26)27/h3-6,14-15H,1-2,7-11H2,(H,21,29)(H,22,28)(H,24,25)(H,26,27)(H,30,31)/t14-,15+/m0/s1	SRAHBOKVSSZEHQ-LSDHHAIUSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.2885 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	10	5	No	2	-3	207.48 Å2	48.09 Å3	114.23 m3·mol-1	11	Yes	No	0.353 mg/mL	-0.98	-3.2	2.58	-1.5	P0A884	thyA	1. Thymidylate synthase
C19H28N2O5	Not Available	Not Available	364.436	[H][C@](O)(CC(O)=O)C(=O)N[C@]([H])(CCC1=CC=CC=C1)C(=O)NCCC(C)C	Solid	Not Available								4451259						R99			5289258	46505552					ZINC000012503755		WRR-99	Experimental	DB03573	InChI=1S/C19H28N2O5/c1-13(2)10-11-20-18(25)15(9-8-14-6-4-3-5-7-14)21-19(26)16(22)12-17(23)24/h3-7,13,15-16,22H,8-12H2,1-2H3,(H,20,25)(H,21,26)(H,23,24)/t15-,16+/m1/s1	KVZMXOVSHIMGNA-CVEARBPZSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.9502 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	4	No	1	-1	115.73 Å2	39.79 Å3	96.53 m3·mol-1	11	Yes	No	0.149 mg/mL	1.48	-3.4	4	-3.4	Q9UBX1;!P25779	CTSF;!Not Available	1. Cathepsin F;!2. Cruzipain
C9H16N2O5	Not Available	Not Available	232.2337	NCCC[C@H](NC(=O)CCC(O)=O)C(O)=O	Solid	Not Available						27574		113025			HMDB0001199	C03415		SUO			127370	46507657							N~2~-Succinylornithine	Experimental	DB03582	InChI=1S/C9H16N2O5/c10-5-1-2-6(9(15)16)11-7(12)3-4-8(13)14/h6H,1-5,10H2,(H,11,12)(H,13,14)(H,15,16)/t6-/m0/s1	VWXQFHJBQHTHMK-LURJTMIESA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.2995 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	4	No	0	-1	129.72 Å2	22.77 Å3	53.55 m3·mol-1	8	Yes	No	19.3 mg/mL	-4.1	-1.1	3.32	9.9	P76216	astB	1. N-succinylarginine dihydrolase
C17H22IN3O6S	Not Available	Not Available	523.343	[H]N([H])[C@@H](CCC(=O)N([H])[C@@H](CSCC1=CC=CC=C1I)C(=O)N([H])CC(O)=O)C(O)=O	Solid	Not Available								394293						IBG			447108	46508001					ZINC000014880825		gamma-Glutamyl[S-(2-iodobenzyl)cysteinyl]glycine	Experimental	DB03597	InChI=1S/C17H22IN3O6S/c18-11-4-2-1-3-10(11)8-28-9-13(16(25)20-7-15(23)24)21-14(22)6-5-12(19)17(26)27/h1-4,12-13H,5-9,19H2,(H,20,25)(H,21,22)(H,23,24)(H,26,27)/t12-,13-/m0/s1	QFYJAEOZTBVJQM-STQMWFEESA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.2538 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	7	5	No	1	-1	158.82 Å2	45.41 Å3	111.79 m3·mol-1	12	No	No	0.0301 mg/mL	-2	-4.2	1.81	9.31	O76074;!Q03013;!O76083	PDE5A;!GSTM4;!PDE9A	1. cGMP-specific 3',5'-cyclic phosphodiesterase;!2. Glutathione S-transferase Mu 4;!3. High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A
C17H23N3O6S	Not Available	Not Available	397.446	[H]N([H])[C@@H](CCC(=O)N([H])[C@@H](CSCC1=CC=CC=C1)C(=O)N([H])CC(O)=O)C(O)=O	Solid	Not Available	P08263	GSTA1	1. Glutathione S-transferase A1					393264						GSB			445707	46507389					ZINC000003874918		S-benzylglutathione	Experimental	DB03602	InChI=1S/C17H23N3O6S/c18-12(17(25)26)6-7-14(21)20-13(16(24)19-8-15(22)23)10-27-9-11-4-2-1-3-5-11/h1-5,12-13H,6-10,18H2,(H,19,24)(H,20,21)(H,22,23)(H,25,26)/t12-,13-/m0/s1	XYJWEQWNNKNSFU-STQMWFEESA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.8241 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	5	No	1	-1	158.82 Å2	40.51 Å3	98.43 m3·mol-1	12	Yes	No	0.116 mg/mL	-2.9	-3.5	1.81	9.31	Q04760;!P08263	GLO1;!GSTA1	1. Lactoylglutathione lyase;!2. Glutathione S-transferase A1
C10H20N2O4	Not Available	Not Available	232.2768	C[C@H](N)[C@@H](CCCCCC(O)=O)NC(O)=O	Solid	Not Available								392515						DSD			444640	46505130					ZINC000002046976		7-(Carboxyamino)-8-Amino-Nonanoic Acid	Experimental	DB03624	InChI=1S/C10H20N2O4/c1-7(11)8(12-10(15)16)5-3-2-4-6-9(13)14/h7-8,12H,2-6,11H2,1H3,(H,13,14)(H,15,16)/t7-,8+/m0/s1	OQNJZSIPDMTUAJ-JGVFFNPUSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	1.9406 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	5	4	No	0	-1	112.65 Å2	24.62 Å3	57.6 m3·mol-1	8	Yes	No	3.33 mg/mL	-1.8	-1.8	3.71	9.45	P13000	bioD1	1. ATP-dependent dethiobiotin synthetase BioD 1
C29H41N9O10	Not Available	Not Available	675.7	CNC(=O)NC(=N)NCCC[C@@H]1NC(=O)[C@@H](C)NC(=O)C[C@H](NC(=O)C[C@H](NC(=O)[C@H](CC2=CC=CC=C2)N(C)C1=O)C(O)=O)C(O)=O	Solid	Not Available					10853		CHEMBL197199	395741									449124	46504954					ZINC000024693182		Argifin	Experimental	DB03632	InChI=1S/C29H41N9O10/c1-15-23(41)35-17(10-7-11-32-28(30)37-29(48)31-2)25(43)38(3)20(12-16-8-5-4-6-9-16)24(42)36-19(27(46)47)14-22(40)34-18(26(44)45)13-21(39)33-15/h4-6,8-9,15,17-20H,7,10-14H2,1-3H3,(H,33,39)(H,34,40)(H,35,41)(H,36,42)(H,44,45)(H,46,47)(H4,30,31,32,37,48)/t15-,17+,18+,19+,20+/m1/s1	UHBHXSDKGLPPGO-HTDHLNIYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.8913 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	12	10	No	2	-1	288.32 Å2	66.25 Å3	174.52 m3·mol-1	8	No	No	0.171 mg/mL	-5.1	-3.6	2.85	9.41			
C17H22N4O8S	Not Available	Not Available	442.444	N[C@@H](CCC(=O)N[C@@H](CSCC1=CC=C(C=C1)[N+]([O-])=O)C(=O)NCC(O)=O)C(O)=O	Solid	Not Available						87407		88035						GTB			97538	46508527					ZINC000003874914		S-(4-nitrobenzyl)glutathione	Experimental	DB03686	InChI=1S/C17H22N4O8S/c18-12(17(26)27)5-6-14(22)20-13(16(25)19-7-15(23)24)9-30-8-10-1-3-11(4-2-10)21(28)29/h1-4,12-13H,5-9,18H2,(H,19,25)(H,20,22)(H,23,24)(H,26,27)/t12-,13-/m0/s1	OAWORKDPTSAMBZ-STQMWFEESA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.5268 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	9	5	No	1	-1	201.96 Å2	43 Å3	104.75 m3·mol-1	13	Yes	No		-3		1.81	9.31	P09211	GSTP1	1. Glutathione S-transferase P
C19H28N2O5	Not Available	Not Available	364.436	[H][C@](O)(CC(O)=O)C(=O)N[C@@]([H])(CCC1=CC=CC=C1)C(=O)NCCC(C)C	Solid	Not Available								4451288						RL2			5289294	46504442					ZINC000012503756		WRR-112	Experimental	DB03691	InChI=1S/C19H28N2O5/c1-13(2)10-11-20-18(25)15(9-8-14-6-4-3-5-7-14)21-19(26)16(22)12-17(23)24/h3-7,13,15-16,22H,8-12H2,1-2H3,(H,20,25)(H,21,26)(H,23,24)/t15-,16-/m0/s1	KVZMXOVSHIMGNA-HOTGVXAUSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.9502 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	4	No	1	-1	115.73 Å2	39.76 Å3	96.53 m3·mol-1	11	Yes	No	0.149 mg/mL	1.48	-3.4	4	-3.4	Q9UBX1;!P25779	CTSF;!Not Available	1. Cathepsin F;!2. Cruzipain
C26H33F3N4O7	Not Available	Not Available	570.558	[H]N(CC(O)=O)C(=O)C1=CC=C(C=C1)C(=O)N([H])[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N([H])[C@@H](C(C)C)C(=O)C(F)(F)F	Solid	Not Available								4450441						FR1			5288240	46508719					ZINC000003951728		N-{4-[(Carboxymethyl)carbamoyl]benzoyl}-L-valyl-N-[(3S)-1,1,1-trifluoro-4-methyl-2-oxo-3-pentanyl]-L-prolinamide	Experimental	DB03702	InChI=1S/C26H33F3N4O7/c1-13(2)19(21(36)26(27,28)29)31-24(39)17-6-5-11-33(17)25(40)20(14(3)4)32-23(38)16-9-7-15(8-10-16)22(37)30-12-18(34)35/h7-10,13-14,17,19-20H,5-6,11-12H2,1-4H3,(H,30,37)(H,31,39)(H,32,38)(H,34,35)/t17-,19-,20-/m0/s1	MRTSIBBMOWLRPY-IHPCNDPISA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.4914 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	7	4	No	2	-1	161.98 Å2	54.27 Å3	135.51 m3·mol-1	12	No	No	0.00627 mg/mL	2.08	-5	3.08	-1	Q9UNI1	CELA1	1. Chymotrypsin-like elastase family member 1
C19H26N4O10S	Not Available	Not Available	502.496	N[C@@H](CCC(=O)N[C@@H](CS[C@@H](CO)COC1=CC=C(C=C1)[N+]([O-])=O)C(=O)NCC(O)=O)C(O)=O	Solid	Not Available								16743963						EPY			17753973	46505823					ZINC000012503844		1-Hydroxy-2-S-glutathionyl-3-para-nitrophenoxy-propane	Experimental	DB03706	InChI=1S/C19H26N4O10S/c20-14(19(29)30)5-6-16(25)22-15(18(28)21-7-17(26)27)10-34-13(8-24)9-33-12-3-1-11(2-4-12)23(31)32/h1-4,13-15,24H,5-10,20H2,(H,21,28)(H,22,25)(H,26,27)(H,29,30)/t13-,14-,15-/m0/s1	YWXHXYSGHBAIBL-KKUMJFAQSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.5686 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	11	6	No	1	-1	231.42 Å2	48.93 Å3	116.83 m3·mol-1	16	No	No		-4		1.8	9.31	Q03013	GSTM4	1. Glutathione S-transferase Mu 4
C33H35N3O7	Not Available	Not Available	585.6469	CC(=O)N[C@@H](CC1=CC(C(O)=O)=C(CC(O)=O)C=C1)C(=O)N[C@H]1CCCCN(CC2=CC=C(C=C2)C2=CC=CC=C2)C1=O	Solid	Not Available					14694		CHEMBL432359	394587						853			447524	46505930					ZINC000014880878		RU85053	Experimental	DB03712	InChI=1S/C33H35N3O7/c1-21(37)34-29(18-23-12-15-26(19-30(38)39)27(17-23)33(42)43)31(40)35-28-9-5-6-16-36(32(28)41)20-22-10-13-25(14-11-22)24-7-3-2-4-8-24/h2-4,7-8,10-15,17,28-29H,5-6,9,16,18-20H2,1H3,(H,34,37)(H,35,40)(H,38,39)(H,42,43)/t28-,29-/m0/s1	CEKLBQMULVLLTD-VMPREFPWSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.3451 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										0	No	7	4	Yes	4	-2	153.11 Å2	62.6 Å3	159.18 m3·mol-1	11	No	No		3.16		3.41	-1.9			
C17H17F2N2O7P	Not Available	Not Available	430.2966	[H][C@@](CCC(O)=O)(NC(=O)C1=CC2=C(C=C1)C=C(C=C2)C(F)(F)P(O)(O)=O)C(N)=O	Solid	Not Available								392553						TPI			444695	46509105					ZINC000002047328		4-Carbamoyl-4-{[6-(Difluoro-Phosphono-Methyl)-Naphthalene-2-Carbonyl]-Amino}-Butyric Acid	Experimental	DB03714	InChI=1S/C17H17F2N2O7P/c18-17(19,29(26,27)28)12-4-3-9-7-11(2-1-10(9)8-12)16(25)21-13(15(20)24)5-6-14(22)23/h1-4,7-8,13H,5-6H2,(H2,20,24)(H,21,25)(H,22,23)(H2,26,27,28)/t13-/m0/s1	OWWCIKSGGKYNHT-ZDUSSCGKSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.4728 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	7	5	No	2	-3	167.02 Å2	37.73 Å3	96.4 m3·mol-1	8	Yes	No	0.0231 mg/mL	0.21	-4.3	0.5	-1.2			
C17H25N4O7S	Not Available	Not Available	429.468	[H]N([C@@H](CCCCC(=O)N([H])[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@]12[H])C([O-])=O)C(=O)C[N+]([H])([H])[H]	Solid	Not Available								4450683						HEL			131704259	46504856							(2S,5R,6R)-6-({(6S)-6-[(Ammonioacetyl)amino]-6-carboxylatohexanoyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate	Experimental	DB03820	InChI=1S/C17H26N4O7S/c1-17(2)12(16(27)28)21-13(24)11(14(21)29-17)20-9(22)6-4-3-5-8(15(25)26)19-10(23)7-18/h8,11-12,14H,3-7,18H2,1-2H3,(H,19,23)(H,20,22)(H,25,26)(H,27,28)/p-1/t8-,11+,12-,14+/m0/s1	LDJWRKFRKCXUDO-RBQWDTSBSA-M			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.1677 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	3	No	2	-1	186.41 Å2	41.8 Å3	133.42 m3·mol-1	10	Yes	No	1.97 mg/mL	-4.2	-2.4	3.09	8.14	P15555	Not Available	1. D-alanyl-D-alanine carboxypeptidase
C21H25N3O6S	Not Available	Not Available	447.505	[H]N([H])[C@@H](CCC(=O)N([H])[C@@H](CSCC1=CC=CC2=CC=CC=C12)C(=O)N([H])CC(O)=O)C(O)=O	Solid	Not Available								395998						GGC			449471	46505686					ZINC000012504001		L-gamma-glutamyl-S-(naphthalen-1-ylmethyl)-L-cysteinylglycine	Experimental	DB03885	InChI=1S/C21H25N3O6S/c22-16(21(29)30)8-9-18(25)24-17(20(28)23-10-19(26)27)12-31-11-14-6-3-5-13-4-1-2-7-15(13)14/h1-7,16-17H,8-12,22H2,(H,23,28)(H,24,25)(H,26,27)(H,29,30)/t16-,17-/m0/s1	IHZCIRSQSFPOLH-IRXDYDNUSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.0967 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	5	No	2	-1	158.82 Å2	46.15 Å3	114.88 m3·mol-1	12	Yes	No		-1.9		1.81	9.31			
C17H23BrN4O8S	Not Available	Not Available	523.356	N[C@@H](CCC(=O)N[C@@H](CS[C@H](O)N(O)C1=CC=C(Br)C=C1)C(=O)NCC(O)=O)C(O)=O	Solid	Not Available								25060414						GBP			17753992	46506985					ZINC000058660391		S-(N-hydroxy-N-bromophenylcarbamoyl)glutathione	Experimental	DB03889	InChI=1S/C17H23BrN4O8S/c18-9-1-3-10(4-2-9)22(30)17(29)31-8-12(15(26)20-7-14(24)25)21-13(23)6-5-11(19)16(27)28/h1-4,11-12,17,29-30H,5-8,19H2,(H,20,26)(H,21,23)(H,24,25)(H,27,28)/t11-,12-,17-/m0/s1	OGZMPQOWGQBWAV-PRXAMGSTSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.5080 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	10	7	No	1	-1	202.52 Å2	46.93 Å3	122.92 m3·mol-1	13	No	No		-2		1.77	9.31	Q16775	HAGH	1. Hydroxyacylglutathione hydrolase, mitochondrial
C34H50N4O8	Not Available	Not Available	642.7828	[H]N(C)C(=O)[C@@H](N([H])C(=O)[C@H](OCC1=CC=CC=C1)[C@H](O)[C@@H](O)[C@@H](OCC1=CC=CC=C1)C(=O)N([H])[C@@H]([C@@H](C)CC)C(=O)N([H])C)[C@@H](C)CC	Solid	Not Available								392978						BEI			445303	46506196					ZINC000024495494		N,N-[2,5-O-[Dibenzyl]-glucaryl]-DI-[isoleucyl-amido-methane]	Experimental	DB03908	InChI=1S/C34H50N4O8/c1-7-21(3)25(31(41)35-5)37-33(43)29(45-19-23-15-11-9-12-16-23)27(39)28(40)30(46-20-24-17-13-10-14-18-24)34(44)38-26(22(4)8-2)32(42)36-6/h9-18,21-22,25-30,39-40H,7-8,19-20H2,1-6H3,(H,35,41)(H,36,42)(H,37,43)(H,38,44)/t21-,22-,25-,26-,27+,28+,29+,30+/m0/s1	GLKONBHDVMFJNJ-XAOMMOPXSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.2411 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	8	6	No	2	0	175.32 Å2	70.1 Å3	172.09 m3·mol-1	19	No	No		2.07		11.69	-3.7	P03366	gag-pol	1. Gag-Pol polyprotein
C12H21N3O6	Not Available	Not Available	303.3116	[H]N([H])CC(=O)N([H])[C@@H](CCCCC(=O)N([H])[C@H](C)C(O)=O)C(O)=O	Solid	Not Available								393700						REY			446307	46506012					ZINC000003581164		Glycyl-L-alpha-amino-epsilon-pimelyl-D-alanine	Experimental	DB03927	InChI=1S/C12H21N3O6/c1-7(11(18)19)14-9(16)5-3-2-4-8(12(20)21)15-10(17)6-13/h7-8H,2-6,13H2,1H3,(H,14,16)(H,15,17)(H,18,19)(H,20,21)/t7-,8+/m1/s1	ZMQJQOKNTYQVHO-SFYZADRCSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	1.7329 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	5	No	0	-1	158.82 Å2	30.14 Å3	70.59 m3·mol-1	10	Yes	No		-4.3		3.28	8.14	P15555	Not Available	1. D-alanyl-D-alanine carboxypeptidase
C14H19N3O6S	Not Available	Not Available	357.382	[H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)CCC[C@@H](N)C(O)=O)C(O)=O	Solid	Not Available						18229		140762				C06565		P1C			160139	46509194							Deacetoxycephalosporin C	Experimental	DB03938	InChI=1S/C14H19N3O6S/c1-6-5-24-12-9(11(19)17(12)10(6)14(22)23)16-8(18)4-2-3-7(15)13(20)21/h7,9,12H,2-5,15H2,1H3,(H,16,18)(H,20,21)(H,22,23)/t7-,9-,12-/m1/s1	NNQIJOYQWYKBOW-JWKOBGCHSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	1.8680 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	4	No	2	-1	150.03 Å2	34.95 Å3	84.5 m3·mol-1	7	Yes	No	2.51 mg/mL	-3.5	-2.2	1.84	9.23	P18548	cefE	1. Deacetoxycephalosporin C synthase
C27H28N2O5S	Not Available	Not Available	492.587	[H]N([C@@H](CC1=CC=CC=C1)C(=O)N([H])[C@@H](CC1=CC=C(O)C=C1)C(O)=O)C(=O)[C@@H](S)CC1=CC=CC=C1	Solid	Not Available					50050160		CHEMBL277238	4451432						TI2			5289470	46505869					ZINC000012504054		N-[(2S)-3-Phenyl-2-sulfanylpropanoyl]-L-phenylalanyl-L-tyrosine	Experimental	DB03949	InChI=1S/C27H28N2O5S/c30-21-13-11-20(12-14-21)16-23(27(33)34)29-25(31)22(15-18-7-3-1-4-8-18)28-26(32)24(35)17-19-9-5-2-6-10-19/h1-14,22-24,30,35H,15-17H2,(H,28,32)(H,29,31)(H,33,34)/t22-,23-,24-/m0/s1	GIVBBFGMRNXKPE-HJOGWXRNSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.0580 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	5	5	Yes	3	-1	115.73 Å2	51.49 Å3	135.4 m3·mol-1	11	Yes	No	0.00135 mg/mL	4.16	-5.6	3.74	-4.1	P43133	nprS	1. Thermolysin
C29H38N3O10P	Not Available	Not Available	619.5999	[H]N([H])C(=O)C1=C(OCC2CCCCC2)C=CC(=C1)[C@H](C)N([H])C(=O)[C@H](CC1=CC(=C(OCC(O)=O)C=C1)P(O)(O)=O)N([H])C(C)=O	Solid	Not Available								393693						CC0			446300	46509016					ZINC000014880990		{4-[(2S)-2-Acetamido-3-({(1S)-1-[3-carbamoyl-4-(cyclohexylmethoxy)phenyl]ethyl}amino)-3-oxopropyl]-2-phosphonophenoxy}acetic acid	Experimental	DB04003	InChI=1S/C29H38N3O10P/c1-17(21-9-11-24(22(14-21)28(30)36)41-15-19-6-4-3-5-7-19)31-29(37)23(32-18(2)33)12-20-8-10-25(42-16-27(34)35)26(13-20)43(38,39)40/h8-11,13-14,17,19,23H,3-7,12,15-16H2,1-2H3,(H2,30,36)(H,31,37)(H,32,33)(H,34,35)(H2,38,39,40)/t17-,23-/m0/s1	FXUGQWABROMTDA-SBUREZEXSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.5499 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	10	6	Yes	3	-3	214.58 Å2	62.53 Å3	155.33 m3·mol-1	14	No	No	0.00145 mg/mL	0.57	-5.6	1.6	-0.89	P06239	LCK	1. Tyrosine-protein kinase Lck
C16H20N2O5	Not Available	Not Available	320.3404	[H][C@@](C)(NC(=O)OCC1=CC=CC=C1)C(=O)N1CCC[C@@]1([H])C(O)=O	Solid	Not Available								4534974						ZAH			5388928	46508805					ZINC000001575977		Z-Ala Prolinal	Experimental	DB04033	InChI=1S/C16H20N2O5/c1-11(14(19)18-9-5-8-13(18)15(20)21)17-16(22)23-10-12-6-3-2-4-7-12/h2-4,6-7,11,13H,5,8-10H2,1H3,(H,17,22)(H,20,21)/t11-,13-/m0/s1	RSSOZTMMMIWOJB-AAEUAGOBSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Inhibitor	Substrate	1.9366 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	2	No	2	-1	95.94 Å2	32.82 Å3	81.16 m3·mol-1	6	Yes	No	0.897 mg/mL	1.32	-2.6	3.63	-4.4	Q9X5N2	pep	1. Prolyl endopeptidase Pep
C7H11NO5	Not Available	Not Available	189.1659	CC(=O)N[C@@H](CCC(O)=O)C(O)=O	Solid	Not Available					50151383	17533	CHEMBL1234751	64077				C00624		NLG			70914	46507366					ZINC000001532704		N-Acetyl-L-Glutamate	Experimental	DB04075	InChI=1S/C7H11NO5/c1-4(9)8-5(7(12)13)2-3-6(10)11/h5H,2-3H2,1H3,(H,8,9)(H,10,11)(H,12,13)/t5-/m0/s1	RFMMMVDNIPUKGG-YFKPBYRVSA-N		N-Acetyl-L-Glutamate is a glutamate derivate used to prevent allergic conjunctivitis.	Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.4388 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor							199 °C			1	No	5	3	No	0	-2	103.7 Å2	17.44 Å3	40.73 m3·mol-1	5	Yes	No	18.6 mg/mL	-1.1	-1	3.43	-1.8	P0A6C8;!Q9HTN2	argB;!argB	1. Acetylglutamate kinase;!2. Acetylglutamate kinase
C23H33N5O5	Not Available	Not Available	459.5386	C[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1)C(N)=O	Solid	Not Available					50078401		CHEMBL311875	394420									447280	46504972							Apstatin	Experimental	DB04092	InChI=1S/C23H33N5O5/c1-14(20(25)30)26-21(31)17-9-5-11-27(17)22(32)18-10-6-12-28(18)23(33)19(29)16(24)13-15-7-3-2-4-8-15/h2-4,7-8,14,16-19,29H,5-6,9-13,24H2,1H3,(H2,25,30)(H,26,31)/t14-,16+,17-,18-,19-/m0/s1	YVUUZAPYLPWFHE-HXFGRODQSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1807 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	4	Yes	3	1	159.06 Å2	47.91 Å3	120.17 m3·mol-1	8	Yes	No	1.92 mg/mL	-1.4	-2.4	12.11	8.35	P15034	pepP	1. Xaa-Pro aminopeptidase
C15H28N2O5	Not Available	Not Available	316.3932	[H][C@](O)(CC(O)=O)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCCC(C)C	Solid	Not Available								4450373						E6C			5288147	46505427					ZINC000003874327		N-[1-Hydroxycarboxyethyl-Carbonyl]Leucylamino-2-Methyl-Butane	Experimental	DB04126	InChI=1S/C15H28N2O5/c1-9(2)5-6-16-14(21)11(7-10(3)4)17-15(22)12(18)8-13(19)20/h9-12,18H,5-8H2,1-4H3,(H,16,21)(H,17,22)(H,19,20)/t11-,12-/m0/s1	KBIWEWPGBHKYML-RYUDHWBXSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.0096 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	4	No	0	-1	115.73 Å2	34.67 Å3	80.99 m3·mol-1	10	Yes	No	2.42 mg/mL	0.63	-2.1	4.25	-2.8	P07858;!P09668	CTSB;!CTSH	1. Cathepsin B;!2. Pro-cathepsin H
C16H29N3O6S	Not Available	Not Available	391.483	CCCCCCSC[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)NCC(O)=O	Solid	Not Available	P08263	GSTA1	1. Glutathione S-transferase A1		50095998	27704	CHEMBL345292	88033				C02886		LEE			97536	46505872			DNC001323		ZINC000003874923		S-Hexylglutathione	Experimental	DB04132	InChI=1S/C16H29N3O6S/c1-2-3-4-5-8-26-10-12(15(23)18-9-14(21)22)19-13(20)7-6-11(17)16(24)25/h11-12H,2-10,17H2,1H3,(H,18,23)(H,19,20)(H,21,22)(H,24,25)/t11-,12-/m0/s1	HXJDWCWJDCOHDG-RYUDHWBXSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.1333 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	5	No	0	-1	158.82 Å2	42.03 Å3	96.89 m3·mol-1	15	Yes	No	0.146 mg/mL	-2.4	-3.4	1.81	9.31	Q04760;!Q03013;!P09211;!Q8MU52;!P08263;!P0CG29	GLO1;!GSTM4;!GSTP1;!GST;!GSTA1;!GSTT2	1. Lactoylglutathione lyase;!2. Glutathione S-transferase Mu 4;!3. Glutathione S-transferase P;!4. Glutathione S-transferase;!5. Glutathione S-transferase A1;!6. Glutathione S-transferase theta-2
C15H18I2N2O6	Not Available	Not Available	576.1222	[H]N([C@@H](CC1=CC(I)=C(O)C(I)=C1)C(=O)N([H])[C@H]([C@@H](C)O)C(O)=O)C(C)=O	Solid	Not Available								4450770						IYT			5288651	46505151					ZINC000038377676		N-alpha-Acetyl-3,5-diiodotyrosyl-D-threonine	Experimental	DB04150	InChI=1S/C15H18I2N2O6/c1-6(20)12(15(24)25)19-14(23)11(18-7(2)21)5-8-3-9(16)13(22)10(17)4-8/h3-4,6,11-12,20,22H,5H2,1-2H3,(H,18,21)(H,19,23)(H,24,25)/t6-,11+,12-/m1/s1	TWMKRGDZEJLDDH-LKXWSVAYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.5639 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	5	No	1	-2	135.96 Å2	42.86 Å3	106.53 m3·mol-1	7	No	No	0.158 mg/mL	1.28	-3.6	2.57	-1.9	P19021	PAM	1. Peptidyl-glycine alpha-amidating monooxygenase
C11H19N3O7S	Not Available	Not Available	337.349	N[C@@H](CCC(=O)N[C@@H](CSCO)C(=O)NCC(O)=O)C(O)=O	Solid	Not Available						48926		394301			HMDB0004662	C14180		AHE			447123	46507088					ZINC000003870218		S-Hydroxymethyl Glutathione	Experimental	DB04153	InChI=1S/C11H19N3O7S/c12-6(11(20)21)1-2-8(16)14-7(4-22-5-15)10(19)13-3-9(17)18/h6-7,15H,1-5,12H2,(H,13,19)(H,14,16)(H,17,18)(H,20,21)/t6-,7-/m0/s1	PIUSLWSYOYFRFR-BQBZGAKWSA-N			Not Available	Small Molecule				AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.9135 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	8	6	No	0	-1	179.05 Å2	32.23 Å3	75.2 m3·mol-1	11	No	No	5.27 mg/mL	-5.5	-1.8	1.79	9.31	P11766	ADH5	1. Alcohol dehydrogenase class-3
C7H12N2O4	Not Available	Not Available	188.1812	CC(=O)N[C@@H](CCC(N)=O)C(O)=O	Solid	Not Available						21553		158492						NLQ			182230	46508739		1426379		Aceglutamide	ZINC000002019886		Aceglutamide	Experimental	DB04167	InChI=1S/C7H12N2O4/c1-4(10)9-5(7(12)13)2-3-6(8)11/h5H,2-3H2,1H3,(H2,8,11)(H,9,10)(H,12,13)/t5-/m0/s1	KSMRODHGGIIXDV-YFKPBYRVSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.4053 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	4	3	No	0	-1	109.49 Å2	17.82 Å3	42.55 m3·mol-1	5	Yes	No	21.9 mg/mL	-1.9	-0.93	3.76	-1.4	Q9RYA6	menC	1. N-acylamino acid racemase
C24H27N3O7S	Not Available	Not Available	501.552	[H]N([H])[C@@H](CCC(=O)N([H])[C@@H](CS[C@]1([H])[C@@H](O)C2=CC=CC=C2C2=CC=CC=C12)C(=O)N([H])CC(O)=O)C(O)=O	Solid	Not Available								392389						GPS			444461	46506704					ZINC000012501153		(9S,10S)-9-(S-glutathionyl)-10-hydroxy-9,10-dihydrophenanthrene	Experimental	DB04187	InChI=1S/C24H27N3O7S/c25-17(24(33)34)9-10-19(28)27-18(23(32)26-11-20(29)30)12-35-22-16-8-4-2-6-14(16)13-5-1-3-7-15(13)21(22)31/h1-8,17-18,21-22,31H,9-12,25H2,(H,26,32)(H,27,28)(H,29,30)(H,33,34)/t17-,18-,21-,22-/m0/s1	JNNIZILNBMPOAC-GPHNJDIKSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.2178 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	8	6	Yes	3	-1	179.05 Å2	50.09 Å3	127.88 m3·mol-1	11	No	No	0.031 mg/mL	-2.2	-4.2	1.8	9.31	P09488	GSTM1	1. Glutathione S-transferase Mu 1
C9H18N4O4	Not Available	Not Available	246.2636	NC(=N)NCCC[C@H](NCCC(O)=O)C(O)=O	Solid	Not Available						57304		393816				C06655		CMA			446475	46505010					ZINC000001530510		N(2)-(2-carboxyethyl)-L-arginine	Experimental	DB04189	InChI=1S/C9H18N4O4/c10-9(11)13-4-1-2-6(8(16)17)12-5-3-7(14)15/h6,12H,1-5H2,(H,14,15)(H,16,17)(H4,10,11,13)/t6-/m0/s1	OHWCFZJEIHZWMN-LURJTMIESA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	1.8580 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	8	6	No	0	0	148.53 Å2	25.05 Å3	69.48 m3·mol-1	9	No	No	0.658 mg/mL	-5.5	-2.6	1.72	12.15			
C29H47N5O7	Not Available	Not Available	577.7128	[H][C@@](C)(N)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC1=CC=CC=C1)[C@@]([H])(O)CCC(=O)N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(C(C)C)C(=O)OC	Solid	Not Available					903		CHEMBL49004	392186						PSI			444196	46508521					ZINC000003935186		Skf 107457	Experimental	DB04191	InChI=1S/C29H47N5O7/c1-16(2)24(28(39)34-25(17(3)4)29(40)41-7)33-23(36)14-13-22(35)21(15-20-11-9-8-10-12-20)32-27(38)19(6)31-26(37)18(5)30/h8-12,16-19,21-22,24-25,35H,13-15,30H2,1-7H3,(H,31,37)(H,32,38)(H,33,36)(H,34,39)/t18-,19-,21-,22-,24-,25-/m0/s1	IUDCAKKZLXFOQA-QJAPXLAMSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.2496 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	7	6	No	1	1	188.95 Å2	62.56 Å3	152.41 m3·mol-1	17	No	No	0.0237 mg/mL	0.6	-4.4	12.05	8.09	P05896	gag-pol	1. Gag-Pol polyprotein
C11H20N2O6	Not Available	Not Available	276.2863	N[C@@H](CCCCN[C@@H](CCC(O)=O)C(O)=O)C(O)=O	Solid	Not Available						16927		141086			HMDB0000279	C00449		SHR			160556	46505056				Saccharopine	ZINC000001532666		L-Saccharopine	Experimental	DB04207	InChI=1S/C11H20N2O6/c12-7(10(16)17)3-1-2-6-13-8(11(18)19)4-5-9(14)15/h7-8,13H,1-6,12H2,(H,14,15)(H,16,17)(H,18,19)/t7-,8-/m0/s1	ZDGJAHTZVHVLOT-YUMQZZPRSA-N			Not Available	Small Molecule	http://smpdb.ca/view/SMP0000719?highlight[compounds][]=DB04207&highlight[proteins][]=DB04207;!http://smpdb.ca/view/SMP0000186?highlight[compounds][]=DB04207&highlight[proteins][]=DB04207;!http://smpdb.ca/view/SMP0000239?highlight[compounds][]=DB04207&highlight[proteins][]=DB04207;!http://smpdb.ca/view/SMP0000527?highlight[compounds][]=DB04207&highlight[proteins][]=DB04207;!http://smpdb.ca/view/SMP0000037?highlight[compounds][]=DB04207&highlight[proteins][]=DB04207;!http://smpdb.ca/view/SMP0000528?highlight[compounds][]=DB04207&highlight[proteins][]=DB04207;!http://smpdb.ca/view/SMP0000571?highlight[compounds][]=DB04207&highlight[proteins][]=DB04207	2-Aminoadipic 2-Oxoadipic Aciduria;!Glutaric Aciduria Type I;!Saccharopinuria/Hyperlysinemia II;!Hyperlysinemia I, Familial;!Lysine Degradation;!Hyperlysinemia II or Saccharopinuria;!Pyridoxine Dependency with Seizures		Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.1770 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	8	5	No	0	-1	149.95 Å2	28.14 Å3	63.95 m3·mol-1	11	Yes	No	5.25 mg/mL	-5.4	-1.7	1.44	10.89	Q9UDR5	AASS	1. Alpha-aminoadipic semialdehyde synthase, mitochondrial
C20H29BrN2O4	Not Available	Not Available	441.359	[H][C@@](CCCC)(NC(=O)[C@]([H])(CC(C)C)NC(=O)OCC1=CC=C(Br)C=C1)C=O	Solid	Not Available								4450929						MYE			5288867	46505737					ZINC000012504234		N2-({[(4-Bromophenyl)Methyl]Oxy}Carbonyl)-N1-[(1s)-1-Formylpentyl]-L-Leucinamide	Experimental	DB04234	InChI=1S/C20H29BrN2O4/c1-4-5-6-17(12-24)22-19(25)18(11-14(2)3)23-20(26)27-13-15-7-9-16(21)10-8-15/h7-10,12,14,17-18H,4-6,11,13H2,1-3H3,(H,22,25)(H,23,26)/t17-,18-/m0/s1	UEDKSAKLZBMNMA-ROUUACIJSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.4344 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	2	No	1	0	84.5 Å2	44.39 Å3	107.57 m3·mol-1	12	Yes	No	0.00246 mg/mL	4.32	-5.2	12.86	-3.6	P43235	CTSK	1. Cathepsin K
C15H30N5O5	Not Available	Not Available	360.4292	CC(C)C[C@H](NC(=O)[C@@H](O)CC(O)=O)C(=O)NCCCC[NH+]=C(N)N	Solid	Not Available						30270		4450371						E64			5288145	46505123							4-[[(2S)-2-[[(2S)-3-Carboxy-2-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]butyl-(diaminomethylidene)azanium	Experimental	DB04276	InChI=1S/C15H29N5O5/c1-9(2)7-10(20-14(25)11(21)8-12(22)23)13(24)18-5-3-4-6-19-15(16)17/h9-11,21H,3-8H2,1-2H3,(H,18,24)(H,20,25)(H,22,23)(H4,16,17,19)/p+1/t10-,11-/m0/s1	QPQNJAXBPHVASB-QWRGUYRKSA-O			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.4411 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	7	7	No	0	0	181.74 Å2	38.57 Å3	101.66 m3·mol-1	12	No	No	0.52 mg/mL	-3.2	-2.9	3.95	11.28	A0A0H3JWX6;!P07384	srtB;!CAPN1	1. NPQTN specific sortase B;!2. Calpain-1 catalytic subunit
C17H32N6O3S	Not Available	Not Available	400.539	[H]N([H])C(=N[C@H](C1CCCCC1)C(=O)N([H])CC(=O)N([H])[C@@H](C)C(=O)N([H])CCCS)N([H])[H]	Solid	Not Available								4593463						NMP			5496715	46505946					ZINC000015677257		2-[2-(2-Cyclohexyl-2-guanidino-acetylamino)-acetylamino]-N-(3-mercapto-propyl)-propionamide	Experimental	DB04278	InChI=1S/C17H32N6O3S/c1-11(15(25)20-8-5-9-27)22-13(24)10-21-16(26)14(23-17(18)19)12-6-3-2-4-7-12/h11-12,14,27H,2-10H2,1H3,(H,20,25)(H,21,26)(H,22,24)(H4,18,19,23)/t11-,14+/m0/s1	YLLNYDDZOMCFDE-SMDDNHRTSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.2883 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	6	No	1	1	151.7 Å2	43.87 Å3	105.92 m3·mol-1	10	No	No	0.0543 mg/mL	-0.63	-3.9	10.05	10.76	P60568	IL2	1. Interleukin-2
C19H35N3O5	Not Available	Not Available	385.4983	[H][C@@](CCCCC)(CC(=O)NO)C(=O)N[C@@]([H])(C(C)C)C(=O)N1CCC[C@@]1([H])CO	Solid	Not Available					50089194		CHEMBL308333	391756				C12056		BB2			443600	46505294					ZINC000003979014		2-[(Formyl-Hydroxy-Amino)-Methyl]-Heptanoic Acid [1-(2-Hydroxymethyl-Pyrrolidine-1-Carbonyl)-2-Methyl-Propyl]-Amide	Experimental	DB04310	InChI=1S/C19H35N3O5/c1-4-5-6-8-14(11-16(24)21-27)18(25)20-17(13(2)3)19(26)22-10-7-9-15(22)12-23/h13-15,17,23,27H,4-12H2,1-3H3,(H,20,25)(H,21,24)/t14-,15+,17+/m1/s1	XJLATMLVMSFZBN-VYDXJSESSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3864 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	4	No	1	0	118.97 Å2	42.57 Å3	101.51 m3·mol-1	11	Yes	No	3.03 mg/mL	0.88	-2.1	8.9	-0.9			
C21H25N5O6	Not Available	Not Available	443.4531	[H]N([H])C1=NC(=O)C2=C(N([H])C[C@@H](CCC3=CC=C(C=C3)C(=O)N([H])[C@@H](CCC(O)=O)C(O)=O)C2)N1[H]	Solid	Not Available								392818						L24			445072	46505154					ZINC000001637602		LY249543	Experimental	DB04322	InChI=1S/C21H25N5O6/c22-21-25-17-14(19(30)26-21)9-12(10-23-17)2-1-11-3-5-13(6-4-11)18(29)24-15(20(31)32)7-8-16(27)28/h3-6,12,15H,1-2,7-10H2,(H,24,29)(H,27,28)(H,31,32)(H4,22,23,25,26,30)/t12-,15-/m0/s1	ZUQBAQVRAURMCL-WFASDCNBSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3887 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	10	6	Yes	3	-2	183.21 Å2	43.42 Å3	122 m3·mol-1	9	No	No	0.0911 mg/mL	-1	-3.7	3.03	4.75	P11586	MTHFD1	1. C-1-tetrahydrofolate synthase, cytoplasmic
C17H22IN3O6S	Not Available	Not Available	523.343	[H]N([H])[C@@H](CCC(=O)N([H])[C@@H](CSCC1=CC(I)=CC=C1)C(=O)N([H])CC(O)=O)C(O)=O	Solid	Not Available								395901						GBI			449342	46508698					ZINC000014881179		S-(3-Iodobenzyl)glutathione	Experimental	DB04341	InChI=1S/C17H22IN3O6S/c18-11-3-1-2-10(6-11)8-28-9-13(16(25)20-7-15(23)24)21-14(22)5-4-12(19)17(26)27/h1-3,6,12-13H,4-5,7-9,19H2,(H,20,25)(H,21,22)(H,23,24)(H,26,27)/t12-,13-/m0/s1	AHWSFXKKIDTZBI-STQMWFEESA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.2179 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	7	5	No	1	-1	158.82 Å2	46.1 Å3	111.79 m3·mol-1	12	No	No	0.03 mg/mL	-2	-4.2	1.81	9.31			
C16H31N3O4	Not Available	Not Available	329.435	[H][C@@](CCCC)(CN(O)C=O)C(=O)N[C@]([H])(C(=O)N(C)C)C(C)(C)C	Solid	Not Available					50104501		CHEMBL431210	140323						BB1			159596	46504617			DNC000283				Bb-3497	Experimental	DB04368	InChI=1S/C16H31N3O4/c1-7-8-9-12(10-19(23)11-20)14(21)17-13(16(2,3)4)15(22)18(5)6/h11-13,23H,7-10H2,1-6H3,(H,17,21)/t12-,13-/m1/s1	AVDLWYHBABSSHC-CHWSQXEVSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.4539 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	2	No	0	0	89.95 Å2	36.42 Å3	88.1 m3·mol-1	9	Yes	No	1.5 mg/mL	1.1	-2.3	8.39	-0.72			
C19H27N4O9S	Not Available	Not Available	487.504	[H][C@]12SC[C@@H](COC(C)=O)[C@H](N1C(=O)[C@H]2\N=C(/[O-])CCCC[C@H](NC(=O)CN)C(O)=O)C(O)=O	Solid	Not Available														H2A			131704283	46504718							(6S)-N-[(2S,3R,6R,7R)-3-(Acetyloxymethyl)-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]octan-7-yl]-6-[(2-aminoacetyl)amino]-7-hydroxy-7-oxoheptanimidate	Experimental	DB04488	InChI=1S/C19H28N4O9S/c1-9(24)32-7-10-8-33-17-14(16(27)23(17)15(10)19(30)31)22-12(25)5-3-2-4-11(18(28)29)21-13(26)6-20/h10-11,14-15,17H,2-8,20H2,1H3,(H,21,26)(H,22,25)(H,28,29)(H,30,31)/p-1/t10-,11+,14-,15+,17-/m1/s1	JDAREAJBQYNCGO-UPMYTKPLSA-M			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.1757 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	10	4	No	2	-1	211.75 Å2	47.24 Å3	122.37 m3·mol-1	13	Yes	No	0.392 mg/mL	-4.1	-3.1	3	8.14	P15555	Not Available	1. D-alanyl-D-alanine carboxypeptidase
C9H15NO5S	Not Available	Not Available	249.284	[H][C@](CCSC)(NC(=O)CCC(O)=O)C(O)=O	Solid	Not Available								395339						SMG			448581	46504882					ZINC000002043758		N-Succinyl Methionine	Experimental	DB04511	InChI=1S/C9H15NO5S/c1-16-5-4-6(9(14)15)10-7(11)2-3-8(12)13/h6H,2-5H2,1H3,(H,10,11)(H,12,13)(H,14,15)/t6-/m1/s1	CZFFMUMOBDIXJU-ZCFIWIBFSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.6438 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	3	No	0	-2	103.7 Å2	24.65 Å3	57.92 m3·mol-1	8	Yes	No	2.31 mg/mL	-0.28	-2	3.54	-2	Q44244	Aaar	1. N-acylamino acid racemase
C19H33N3O8S	Not Available	Not Available	463.546	[H]N([H])[C@@H](CCC(=O)N([H])[C@@H](CS[C@@]1([H])C[C@H](O)O[C@@H]1CCCCC)C(=O)N([H])CC(O)=O)C(O)=O	Solid	Not Available								392385						HAG			444455	46506521					ZINC000031976570		4-S-Glutathionyl-5-pentyl-tetrahydro-furan-2-ol	Experimental	DB04521	InChI=1S/C19H33N3O8S/c1-2-3-4-5-13-14(8-17(26)30-13)31-10-12(18(27)21-9-16(24)25)22-15(23)7-6-11(20)19(28)29/h11-14,17,26H,2-10,20H2,1H3,(H,21,27)(H,22,23)(H,24,25)(H,28,29)/t11-,12-,13+,14-,17+/m0/s1	ICRIFHIWWXQBPY-JEJJNBGPSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3527 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	9	6	No	1	-1	188.28 Å2	48.67 Å3	110.91 m3·mol-1	15	No	No	0.594 mg/mL	-2.8	-2.9	1.8	9.31	Q16772	GSTA3	1. Glutathione S-transferase A3
C30H37N3O10	Not Available	Not Available	599.6289	CCCCCNC(=O)[C@H](CC1=CC=C(OCC(O)=O)C(=C1)C(O)=O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CCC(O)=O	Solid	Not Available					13611		CHEMBL175198	393321						INX			445785	46506542					ZINC000003965850		N-(3-Carboxypropanoyl)-L-phenylalanyl-3-carboxy-O-(carboxymethyl)-N-pentyl-L-tyrosinamide	Experimental	DB04525	InChI=1S/C30H37N3O10/c1-2-3-7-14-31-28(39)22(17-20-10-11-24(43-18-27(37)38)21(15-20)30(41)42)33-29(40)23(16-19-8-5-4-6-9-19)32-25(34)12-13-26(35)36/h4-6,8-11,15,22-23H,2-3,7,12-14,16-18H2,1H3,(H,31,39)(H,32,34)(H,33,40)(H,35,36)(H,37,38)(H,41,42)/t22-,23-/m0/s1	PUAJYWYRZTYQKS-GOTSBHOMSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.4326 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										0	No	10	6	No	2	-3	208.43 Å2	62.15 Å3	152.37 m3·mol-1	19	No	No	0.0091 mg/mL	2	-4.8	2.99	-2.2			
C16H26N2O8	Not Available	Not Available	374.3862	CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O	Solid	Not Available								25060338						042			49866368	46504475					ZINC000014961482		N-{[(2S,3S)-3-(Ethoxycarbonyl)-2-oxiranyl]carbonyl}-L-threonyl-L-isoleucine	Experimental	DB04579	InChI=1S/C16H26N2O8/c1-5-7(3)9(15(22)23)17-13(20)10(8(4)19)18-14(21)11-12(26-11)16(24)25-6-2/h7-12,19H,5-6H2,1-4H3,(H,17,20)(H,18,21)(H,22,23)/t7-,8+,9-,10-,11-,12-/m0/s1	QMPAEYUADYAXIX-XFVKVHEMSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.3255 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	4	No	1	-1	154.56 Å2	36.93 Å3	86.37 m3·mol-1	11	Yes	No	10.6 mg/mL	-0.54	-1.6	3.75	-2.9	P07858	CTSB	1. Cathepsin B
C27H37N7O6S	Not Available	Not Available	587.691	CC[C@@H](C)[C@@H](NS(=O)(=O)CC1=CC(=CC=C1)C(O)=O)C(=O)N[C@@H](CCC(N)=N)C(=O)NCC1=CC=C(C=C1)C(N)=N	Solid	Not Available								4484168						3CB			5326876	46504568					ZINC000014881275		3-({1-[3-CARBAMIMIDOYL-1-(4-CARBAMIMIDOYL-BENZYLCARBAMOYL)-PROPYLCARBAMOYL]-2-METHYL-BUTYLSULFAMOYL}-METHYL)-BENZOIC ACID	Experimental	DB04593	InChI=1S/C27H37N7O6S/c1-3-16(2)23(34-41(39,40)15-18-5-4-6-20(13-18)27(37)38)26(36)33-21(11-12-22(28)29)25(35)32-14-17-7-9-19(10-8-17)24(30)31/h4-10,13,16,21,23,34H,3,11-12,14-15H2,1-2H3,(H3,28,29)(H3,30,31)(H,32,35)(H,33,36)(H,37,38)/t16-,21+,23-/m1/s1	UBGNMISWPGURDN-XORNHQRDSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.4649 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	10	8	No	2	1	241.41 Å2	61.4 Å3	174.64 m3·mol-1	15	No	No	0.0418 mg/mL	-3.7	-4.2	4.03	12.93	P08709	F7	1. Coagulation factor VII
C35H48N6O8	Not Available	Not Available	680.791	CC(C)C[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)C1=NOC(C)=C1)C(=O)N[C@H](\C=C\C(=O)OCC1=CC=CC=C1)C[C@@H]1CCNC1=O	Solid	Not Available								4883311									6323191	46506321					ZINC000053683585		(E)-(4S,6S)-8-METHYL-6-((S)-3-METHYL-2-{(S)-2-[(5-METHYL-ISOXAZOLE-3-CARBONYL)-AMINO]-PROPIONYLAMINO}-BUTYRYLAMINO)-5-OXO-4-((R)-2-OXO-PYRROLIDIN-3-YLMETHYL)-NON-2-ENOIC ACID BENZYL ESTER	Experimental	DB04595	InChI=1S/C35H48N6O8/c1-20(2)16-27(39-35(47)30(21(3)4)40-31(43)23(6)37-34(46)28-17-22(5)49-41-28)33(45)38-26(18-25-14-15-36-32(25)44)12-13-29(42)48-19-24-10-8-7-9-11-24/h7-13,17,20-21,23,25-27,30H,14-16,18-19H2,1-6H3,(H,36,44)(H,37,46)(H,38,45)(H,39,47)(H,40,43)/b13-12+/t23-,25-,26+,27-,30-/m0/s1	IDBWWEGDLCFCTD-VNEMRZQUSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.5188 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	7	5	Yes	3	0	197.83 Å2	72.41 Å3	181.45 m3·mol-1	18	No	No	0.0393 mg/mL	2.34	-4.2	11.71	-1.2			
C32H49N5O8	Not Available	Not Available	631.7602	CCOC(=O)\C=C\[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)C1=COC=C1	Solid	Not Available								4449909						9IN			5287569	46506597					ZINC000014881283		(E)-(4S,6S)-6-((S)-2-{(S)-2-[(FURAN-2-CARBONYL)-AMINO]-3-METHYL-BUTYRYLAMINO}-3-METHYL-BUTYRYLAMINO)-8-METHYL-5-OXO-4-((R)-2-OXO-PYRROLIDIN-3-YLMETHYL)-NON-2-ENOIC ACID ETHYL ESTER	Experimental	DB04613	InChI=1S/C32H49N5O8/c1-8-45-25(38)10-9-23(16-21-11-13-33-28(21)39)34-30(41)24(15-18(2)3)35-31(42)26(19(4)5)37-32(43)27(20(6)7)36-29(40)22-12-14-44-17-22/h9-10,12,14,17-21,23-24,26-27H,8,11,13,15-16H2,1-7H3,(H,33,39)(H,34,41)(H,35,42)(H,36,40)(H,37,43)/b10-9+/t21-,23+,24-,26-,27-/m0/s1	JQGYBVLTABWBOF-VTQXMFKGSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.4482 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	6	5	No	2	0	184.94 Å2	67.21 Å3	166.87 m3·mol-1	18	No	No	0.0496 mg/mL	2.05	-4.1	11.89	-1.2			
C26H41BN4O10	Not Available	Not Available	580.436	C[C@@H](NC(=O)[C@H](CCCCNC(=O)OCC1=CC=CC=C1)NC(=O)CC[C@H](NC(=O)OC(C)(C)C)C(O)=O)B(O)O	Solid	Not Available								4450121						BO9			5287824	46508422					ZINC000169748488		BOC-GAMMA-D-GLU-L-LYS(CBZ)-D-BOROALA	Experimental	DB04647	InChI=1S/C26H41BN4O10/c1-17(27(38)39)29-22(33)19(12-8-9-15-28-24(36)40-16-18-10-6-5-7-11-18)30-21(32)14-13-20(23(34)35)31-25(37)41-26(2,3)4/h5-7,10-11,17,19-20,38-39H,8-9,12-16H2,1-4H3,(H,28,36)(H,29,33)(H,30,32)(H,31,37)(H,34,35)/t17-,19+,20+/m1/s1	OTTYWVUOPWENAJ-HOJAQTOUSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.4749 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	8	7	No	1	-1	212.62 Å2	60.85 Å3	141.61 m3·mol-1	19	No	No	0.0237 mg/mL	1.69	-4.4	3.72	-5.4	P0AEB3;!P0AEB2	dacA;!dacA	1. D-alanyl-D-alanine carboxypeptidase DacA;!2. D-alanyl-D-alanine carboxypeptidase DacA
C29H42N4O7	Not Available	Not Available	558.6664	[H]N([C@@H](C(C)C)C(=O)N([H])[C@H](C(=O)N([H])C(C[C@@H]1CCN([H])C1=O)\C=C\C(=O)OCC)C1=CC=CC=C1)C(=O)OC(C)(C)C	Solid	Not Available								4883355						ENB			23304231	46508007							Ethyl (2E)-4-({(2S)-2-[(N-{[(2-methyl-2-propanyl)oxy]carbonyl}-L-valyl)amino]-2-phenylacetyl}amino)-5-[(3S)-2-oxo-3-pyrrolidinyl]-2-pentenoate	Experimental	DB04692	InChI=1S/C29H42N4O7/c1-7-39-22(34)14-13-21(17-20-15-16-30-25(20)35)31-27(37)24(19-11-9-8-10-12-19)32-26(36)23(18(2)3)33-28(38)40-29(4,5)6/h8-14,18,20-21,23-24H,7,15-17H2,1-6H3,(H,30,35)(H,31,37)(H,32,36)(H,33,38)/b14-13+/t20-,21?,23-,24-/m0/s1	NUDVEHBHDBJSMD-XBEUYHOESA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.7090 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	5	4	No	2	0	151.93 Å2	59.81 Å3	149.01 m3·mol-1	15	No	No	0.00719 mg/mL	2.49	-4.9	12	-1.3			
C10H17N3O8S	Not Available	Not Available	339.322	N[C@@H](CCC(=O)N[C@@H](C[S@](O)=O)C(=O)NCC(O)=O)C(O)=O	Solid	Not Available								4484237						GSF			5326960	46506088					ZINC000012504471		GLUTATHIONE SULFINATE	Experimental	DB04700	InChI=1S/C10H17N3O8S/c11-5(10(18)19)1-2-7(14)13-6(4-22(20)21)9(17)12-3-8(15)16/h5-6H,1-4,11H2,(H,12,17)(H,13,14)(H,15,16)(H,18,19)(H,20,21)/t5-,6-/m0/s1	DMAPAHUEYHXRFI-WDSKDSINSA-N			Not Available	Small Molecule				AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.2108 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	9	6	No	0	-2	196.12 Å2	30.78 Å3	69.88 m3·mol-1	10	No	No	16.3 mg/mL	-5.9	-1.3	1.31	9.31	Q9Y2Q3	GSTK1	1. Glutathione S-transferase kappa 1
C11H19N3O6S	Not Available	Not Available	321.35	CSC[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)NCC(O)=O	Solid	Not Available					225232	141473	CHEMBL1233129	103128				C11347		GSM			115260	46507560					ZINC000001532230		S-Methyl glutathione	Experimental	DB04701	InChI=1S/C11H19N3O6S/c1-21-5-7(10(18)13-4-9(16)17)14-8(15)3-2-6(12)11(19)20/h6-7H,2-5,12H2,1H3,(H,13,18)(H,14,15)(H,16,17)(H,19,20)/t6-,7-/m0/s1	QTQDDTSVRVWHMO-BQBZGAKWSA-N			Not Available	Small Molecule	http://smpdb.ca/view/SMP0000501?highlight[compounds][]=DB04701&highlight[proteins][]=DB04701;!http://smpdb.ca/view/SMP0000183?highlight[compounds][]=DB04701&highlight[proteins][]=DB04701;!http://smpdb.ca/view/SMP0000500?highlight[compounds][]=DB04701&highlight[proteins][]=DB04701;!http://smpdb.ca/view/SMP0000015?highlight[compounds][]=DB04701&highlight[proteins][]=DB04701;!http://smpdb.ca/view/SMP0000143?highlight[compounds][]=DB04701&highlight[proteins][]=DB04701;!http://smpdb.ca/view/SMP0000337?highlight[compounds][]=DB04701&highlight[proteins][]=DB04701	gamma-Glutamyltranspeptidase Deficiency;!gamma-Glutamyltransferase Deficiency;!5-Oxoprolinase Deficiency;!Glutathione Metabolism;!5-Oxoprolinuria;!Glutathione Synthetase Deficiency		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.7868 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	7	5	No	0	-1	158.82 Å2	31.25 Å3	73.77 m3·mol-1	10	Yes	No	2.61 mg/mL	-4.5	-2.1	1.81	9.31	P28161	GSTM2	1. Glutathione S-transferase Mu 2
C30H46N6O8	Not Available	Not Available	618.7216	CCOC(=O)\C=C\[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)C1=NOC(C)=C1	Solid	Not Available								4883391						I12			15959287	46505902					ZINC000014881295		(E)-(S)-4-[(S)-4-METHYL-2-((S)-3-METHYL-2{(S)-2-[(5-METHYL-ISOXAZOLE-3- CARBONYL)-AMINO]-PROPIONYLAMINO}-BUTYRYLAMINO)-PENTANOYLAMINO]-5-((S)-2- OXO-PYRROLIDIN-3-YL)-PENT-2-ENOIC ACID ETHYL ESTER	Experimental	DB04710	InChI=1S/C30H46N6O8/c1-8-43-24(37)10-9-21(15-20-11-12-31-27(20)39)33-28(40)22(13-16(2)3)34-30(42)25(17(4)5)35-26(38)19(7)32-29(41)23-14-18(6)44-36-23/h9-10,14,16-17,19-22,25H,8,11-13,15H2,1-7H3,(H,31,39)(H,32,41)(H,33,40)(H,34,42)(H,35,38)/b10-9+/t19-,20-,21+,22-,25-/m0/s1	LIVSSCDUYUOZEL-GLXPMXKMSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.5616 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	7	5	No	2	0	197.83 Å2	65.7 Å3	161.58 m3·mol-1	17	No	No	0.0744 mg/mL	0.97	-3.9	11.71	-1.2			
C37H59N7O20	Not Available	Not Available	921.8993	C[C@@H](NC(=O)[C@H](CCC[C@@H](N)C(O)=O)NC(=O)CC[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@@H]1[C@@H](NC(C)=O)[C@@H]2OC[C@@H](O2)[C@H]1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O)C(O)=O)C(O)=O	Solid	Not Available						46763		143523						MLD			163626	46508748					ZINC000096006131		2-ACETAMIDO-2-DEOXY-BETA-D-GLUCOPYRANOSE(BETA1-4)-2-ACETAMIDO-1,6-ANHYDRO-3-O-[(R)-1-CARBOXYETHYL]-2-DEOXY-BETA-D-GLUCOPYRANOSE-L-ALANYL-GAMMA-D-GLUTAMYL-MESO-DIAMINOPIMELYL-D-ALANINE	Experimental	DB04736	InChI=1S/C37H59N7O20/c1-13(30(51)44-20(35(58)59)9-10-23(48)43-19(8-6-7-18(38)34(56)57)32(53)40-14(2)33(54)55)39-31(52)15(3)61-29-25(42-17(5)47)36-60-12-22(63-36)28(29)64-37-24(41-16(4)46)27(50)26(49)21(11-45)62-37/h13-15,18-22,24-29,36-37,45,49-50H,6-12,38H2,1-5H3,(H,39,52)(H,40,53)(H,41,46)(H,42,47)(H,43,48)(H,44,51)(H,54,55)(H,56,57)(H,58,59)/t13-,14+,15+,18+,19-,20+,21+,22+,24+,25+,26+,27+,28+,29+,36+,37-/m0/s1	UPFMKPIBAIPLHT-RSJSDIDPSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.4244 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	21	13	Yes	3	-2	419.36 Å2	87.71 Å3	205.48 m3·mol-1	24	No	No	4.18 mg/mL	-8.8	-2.3	1.92	9.52	Q96LB9	PGLYRP3	1. Peptidoglycan recognition protein 3
C20H33N5O5S2	Not Available	Not Available	487.637	CCCS(=O)(=O)N[C@H]([C@H](C)O)C(=O)N[C@@H](CCSC)C(=O)NCC1=CC=C(C=C1)C(N)=N	Solid	Not Available								4451220						PSM			5289214	46505133					ZINC000012504502		N-[1-(4-CARBAMIMIDOYL-BENZYLCARBAMOYL)-3-METHYLSULFANYL-PROPYL]-3-HYDROXY-2-PROPOXYAMINO-BUTYRAMID	Experimental	DB04767	InChI=1S/C20H33N5O5S2/c1-4-11-32(29,30)25-17(13(2)26)20(28)24-16(9-10-31-3)19(27)23-12-14-5-7-15(8-6-14)18(21)22/h5-8,13,16-17,25-26H,4,9-12H2,1-3H3,(H3,21,22)(H,23,27)(H,24,28)/t13-,16-,17+/m0/s1	AIIJKVORRBMJHS-RRQGHBQHSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.5895 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	7	6	No	1	1	174.47 Å2	51.28 Å3	136.29 m3·mol-1	13	No	No	0.0589 mg/mL	-0.98	-3.9	8.59	11.37	P08709	F7	1. Coagulation factor VII
C20H25N7O6	Not Available	Not Available	459.463	CN1C(CNC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNC2=C1C(=O)N=C(N)N2	Solid	Not Available							CHEMBL1221561	8001181									9825434	46505172		1313966		5-Methyltetrahydrofolate			5-methyltetrahydrofolic acid	Investigational, Nutraceutical	DB04789	InChI=1S/C20H25N7O6/c1-27-12(9-23-16-15(27)18(31)26-20(21)25-16)8-22-11-4-2-10(3-5-11)17(30)24-13(19(32)33)6-7-14(28)29/h2-5,12-13,22H,6-9H2,1H3,(H,24,30)(H,28,29)(H,32,33)(H4,21,23,25,26,31)/t12?,13-/m0/s1	ZNOVTXRBGFNYRX-ABLWVSNPSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.6188 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										0	No	12	7	Yes	3	-2	198.48 Å2	46.19 Å3	126.68 m3·mol-1	9	No	No	0.332 mg/mL	-3	-3.1	3.23	5.32	P48728	AMT	1. Aminomethyltransferase, mitochondrial
C21H30Cl2N2O5	Not Available	Not Available	461.379	CCCCCN(CCCOC)C(=O)[C@@H](CCC(O)=O)NC(=O)C1=CC(Cl)=C(Cl)C=C1	Solid	Not Available	P20813;!P05181;!P08684;!P11712;!P20815	CYP2B6;!CYP2E1;!CYP3A4;!CYP2C9;!CYP3A5	1. Cytochrome P450 2B6;!2. Cytochrome P450 2E1;!3. Cytochrome P450 3A4;!4. Cytochrome P450 2C9;!5. Cytochrome P450 3A5			135747	CHEMBL550781	59342									65937	175426866				Dexloxiglumide	ZINC000003801027		Dexloxiglumide	Investigational	DB04856	InChI=1S/C21H30Cl2N2O5/c1-3-4-5-11-25(12-6-13-30-2)21(29)18(9-10-19(26)27)24-20(28)15-7-8-16(22)17(23)14-15/h7-8,14,18H,3-6,9-13H2,1-2H3,(H,24,28)(H,26,27)/t18-/m1/s1	QNQZBKQEIFTHFZ-GOSISDBHSA-N	3		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1985 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	5	2	No	1	-1	95.94 Å2	47.86 Å3	117.01 m3·mol-1	14	Yes	No	0.00555 mg/mL	3.37	-4.9	4.05	-1.2	P32238	CCKAR	1. Cholecystokinin receptor type A
C26H40Cl4N5O10PS	Not Available	18 min	787.46	N[C@@H](CCC(=O)N[C@@H](CS(=O)(=O)CCOP(=O)(N(CCCl)CCCl)N(CCCl)CCCl)C(=O)N[C@@H](C(O)=O)C1=CC=CC=C1)C(O)=O	Solid	Not Available						135883	CHEMBL2111086	4471543									5312109	175426923					ZINC000085537051		Canfosfamide	Investigational	DB04972	InChI=1S/C26H40Cl4N5O10PS/c27-8-12-34(13-9-28)46(42,35(14-10-29)15-11-30)45-16-17-47(43,44)18-21(32-22(36)7-6-20(31)25(38)39)24(37)33-23(26(40)41)19-4-2-1-3-5-19/h1-5,20-21,23H,6-18,31H2,(H,32,36)(H,33,37)(H,38,39)(H,40,41)/t20-,21-,23+/m0/s1	OJLHWPALWODJPQ-QNWVGRARSA-N	3		Canfosfamide-related toxicities included grade 1-2 nausea, vomiting, fatigue, transient microscopic hematuria, and anemia.	Small Molecule				Non AMES toxic	Ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.5940 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	10	5	No	1	-1	225.74 Å2	74.17 Å3	175.76 m3·mol-1	25	No	No	0.0385 mg/mL	-2.9	-4.3	1.37	9.26	P09211	GSTP1	1. Glutathione S-transferase P
C36H49N9O4	Not Available	Not Available	671.847	CCCC[C@@H](NC(=O)[C@@H](CC1=CC=CC=C1)NC(=O)[C@H](N)CC1=CC=CC=C1)C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC1=CC=NC=C1	Solid	Not Available								32702094									25030387	347827714				CR665			CR665	Investigational	DB05155	InChI=1S/C36H49N9O4/c1-2-3-15-30(34(48)43-29(16-10-19-41-36(38)39)33(47)42-24-27-17-20-40-21-18-27)44-35(49)31(23-26-13-8-5-9-14-26)45-32(46)28(37)22-25-11-6-4-7-12-25/h4-9,11-14,17-18,20-21,28-31H,2-3,10,15-16,19,22-24,37H2,1H3,(H,42,47)(H,43,48)(H,44,49)(H,45,46)(H4,38,39,41)/t28-,29-,30-,31-/m1/s1	DBOGGOVKHSCMNB-OMRVPHBLSA-N			Not Available	Small Molecule																																			0	No	9	8	Yes	3	2	217.21 Å2	74.14 Å3	197.95 m3·mol-1	20	No	No	0.00349 mg/mL	1.12	-5.3	12.18	11.69	P41145	OPRK1	1. Kappa-type opioid receptor
C11H19N3O7S	Not Available	Not Available	337.349	NC(CCC(=O)NC(CSCO)C(=O)NCC(O)=O)C(O)=O	Solid	Not Available								1052									1082	175427006							LJP 1082	Investigational	DB05446	InChI=1S/C11H19N3O7S/c12-6(11(20)21)1-2-8(16)14-7(4-22-5-15)10(19)13-3-9(17)18/h6-7,15H,1-5,12H2,(H,13,19)(H,14,16)(H,17,18)(H,20,21)	PIUSLWSYOYFRFR-UHFFFAOYSA-N			Not Available	Small Molecule				AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.9135 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	8	6	No	0	-1	179.05 Å2	32.24 Å3	75.2 m3·mol-1	11	No	No	5.27 mg/mL	-5.5	-1.8	1.79	9.31	P02749	APOH	1. Beta-2-glycoprotein 1
C27H35N3O6S	Not Available	Not Available	529.648	CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCC1=CC=CC=C1)C(=O)N[C@@H](C(=O)OCC)C1=CC=CC=C1	Solid	Not Available							CHEMBL2110585	4470493									5310939	175427010					ZINC000056898832		Ezatiostat	Investigational	DB05460	InChI=1S/C27H35N3O6S/c1-3-35-26(33)21(28)15-16-23(31)29-22(18-37-17-19-11-7-5-8-12-19)25(32)30-24(27(34)36-4-2)20-13-9-6-10-14-20/h5-14,21-22,24H,3-4,15-18,28H2,1-2H3,(H,29,31)(H,30,32)/t21-,22-,24+/m0/s1	GWEJFLVSOGNLSS-WPFOTENUSA-N	2		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.2434 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	No	5	3	No	2	1	136.82 Å2	57.51 Å3	141.82 m3·mol-1	17	No	No	0.00245 mg/mL	2.42	-5.3	11.75	7.18	P09211	GSTP1	1. Glutathione S-transferase P
C16H19N3O5	Not Available	Not Available	333.3392	N[C@H](CCC(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(O)=O)C(O)=O	Solid	Not Available							CHEMBL2103812	5360288									6992140	175427014		2367440			ZINC000001549362		Golotimod	Investigational	DB05475	InChI=1S/C16H19N3O5/c17-11(15(21)22)5-6-14(20)19-13(16(23)24)7-9-8-18-12-4-2-1-3-10(9)12/h1-4,8,11,13,18H,5-7,17H2,(H,19,20)(H,21,22)(H,23,24)/t11-,13+/m1/s1	CATMPQFFVNKDEY-YPMHNXCESA-N	2		No adverse effects were observed in any patients participating in clinical trials.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.6624 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	5	No	2	-1	145.51 Å2	33.36 Å3	84.29 m3·mol-1	8	Yes	No	0.347 mg/mL	-2	-3	1.98	9.31	O60603;!O00206;!Q9NYK1;!Q9NR96	TLR2;!TLR4;!TLR7;!TLR9	1. Toll-like receptor 2;!2. Toll-like receptor 4;!3. Toll-like receptor 7;!4. Toll-like receptor 9
C23H35N9O8S	Not Available	Not Available	597.65	CC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O	Solid	Not Available							CHEMBL4297456	8135892										347910170					ZINC000003924034		ATN-161	Investigational	DB05491	InChI=1S/C23H35N9O8S/c1-11(34)32-4-2-3-17(32)23(40)29-14(5-12-7-26-10-27-12)20(37)30-15(8-33)21(38)31-16(9-41)22(39)28-13(19(25)36)6-18(24)35/h7,10,13-17,33,41H,2-6,8-9H2,1H3,(H2,24,35)(H2,25,36)(H,26,27)(H,28,39)(H,29,40)(H,30,37)(H,31,38)/t13-,14-,15-,16-,17-/m0/s1	MMHDBUJXLOFTLC-WOYTXXSLSA-N	2		Not Available	Small Molecule																																			0	No	9	9	No	2	0	271.8 Å2	57.77 Å3	143.33 m3·mol-1	15	No	No	0.139 mg/mL	-6.7	-3.6	9.94	6.74			
C12H19N3O6	Not Available	Not Available	301.299	[H]N([H])CC(=O)N1CCC[C@H]1C(=O)N([H])[C@@H](CCC(O)=O)C(O)=O	Solid	Not Available							CHEMBL371315	2338502															ZINC000003776571		Glypromate	Investigational	DB05633	InChI=1S/C12H19N3O6/c13-6-9(16)15-5-1-2-8(15)11(19)14-7(12(20)21)3-4-10(17)18/h7-8H,1-6,13H2,(H,14,19)(H,17,18)(H,20,21)/t7-,8-/m0/s1	JJGBXTYGTKWGAT-YUMQZZPRSA-N			Not Available	Small Molecule																																			1	No	7	4	No	1	-1	150.03 Å2	28.23 Å3	69.08 m3·mol-1	7	Yes	No	14.7 mg/mL	-4.9	-1.3	3.2	7.83			
C32H55N9O10	Not Available	Not Available	725.845	CC(C)C[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)CN)C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O	Solid	Not Available							CHEMBL2105646	7986288														Larazotide	ZINC000068009799		Larazotide	Investigational	DB05645	InChI=1S/C32H55N9O10/c1-16(2)12-20(38-30(49)26(17(3)4)39-24(44)14-35-23(43)13-33)28(47)40-27(18(5)6)31(50)37-19(9-10-22(34)42)32(51)41-11-7-8-21(41)29(48)36-15-25(45)46/h16-21,26-27H,7-15,33H2,1-6H3,(H2,34,42)(H,35,43)(H,36,48)(H,37,50)(H,38,49)(H,39,44)(H,40,47)(H,45,46)/t19-,20-,21-,26-,27-/m0/s1	ORFLZNAGUTZRLQ-ZMBVWFSWSA-N	2		Not Available	Small Molecule																																			0	No	11	9	No	1	0	301.32 Å2	75.32 Å3	180.06 m3·mol-1	21	No	No	0.218 mg/mL	-6.2	-3.5	3.43	7.84			
C16H19N3O5	Not Available	Not Available	333.344	N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O	Solid	Not Available						73512	CHEMBL2111029	90450			HMDB0028830						100094	347827743					ZINC000001576166		Oglufanide	Investigational	DB05779	InChI=1S/C16H19N3O5/c17-11(5-6-14(20)21)15(22)19-13(16(23)24)7-9-8-18-12-4-2-1-3-10(9)12/h1-4,8,11,13,18H,5-7,17H2,(H,19,22)(H,20,21)(H,23,24)/t11-,13-/m0/s1	LLEUXCDZPQOJMY-AAEUAGOBSA-N	3		Not Available	Small Molecule																																			1	No	6	5	No	2	-1	145.51 Å2	33.18 Å3	84.29 m3·mol-1	8	Yes	No	0.369 mg/mL	-2.2	-3	3.44	8.45			
C36H54N6O5	Not Available	Not Available	650.865	CN[C@H](CC(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC1=CC=CC=C1)C(=O)N[C@H](CC1=CC=CC=C1)C(=O)N[C@H](CC(C)C)C(N)=O	Solid	Not Available								8006703									9830969	347827746							PPI-1019	Investigational	DB05832	InChI=1S/C36H54N6O5/c1-22(2)18-27(32(37)43)39-34(45)29(20-25-14-10-8-11-15-25)40-35(46)30(21-26-16-12-9-13-17-26)41-36(47)31(24(5)6)42-33(44)28(38-7)19-23(3)4/h8-17,22-24,27-31,38H,18-21H2,1-7H3,(H2,37,43)(H,39,45)(H,40,46)(H,41,47)(H,42,44)/t27-,28-,29-,30-,31-/m1/s1	TUSUWHFYKZZRIG-JQWMYKLHSA-N	2		Not Available	Small Molecule																																			0	No	6	6	No	2	1	171.52 Å2	72.42 Å3	181.86 m3·mol-1	19	No	No	0.00303 mg/mL	3.61	-5.3	11.92	8.79			
C13H21N3O6	Not Available	Not Available	315.326	C[C@]1(CCCN1C(=O)CN)C(=O)N[C@@H](CCC(O)=O)C(O)=O	Solid	Not Available							CHEMBL197084	9493869														Trofinetide			Trofinetide	Investigational	DB06045	InChI=1S/C13H21N3O6/c1-13(5-2-6-16(13)9(17)7-14)12(22)15-8(11(20)21)3-4-10(18)19/h8H,2-7,14H2,1H3,(H,15,22)(H,18,19)(H,20,21)/t8-,13-/m0/s1	BUSXWGRAOZQTEY-SDBXPKJASA-N	3		Not Available	Small Molecule																																			1	No	7	4	No	1	-1	150.03 Å2	30.95 Å3	73.79 m3·mol-1	7	Yes	No	10.4 mg/mL	-4.5	-1.5	3.27	7.83			
C27H53N7O7	Not Available	Not Available	587.763	CCOC(OCC)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)CCC(=O)N[C@H](CC([O-])=O)C[N+](C)(C)C	Solid	Not Available								32699207																	L-aminocarnityl-succinyl-leucyl-argininal-diethylacetal	Investigational	DB06124	InChI=1S/C27H53N7O7/c1-8-40-26(41-9-2)20(11-10-14-30-27(28)29)33-25(39)21(15-18(3)4)32-23(36)13-12-22(35)31-19(16-24(37)38)17-34(5,6)7/h18-21,26H,8-17H2,1-7H3,(H7-,28,29,30,31,32,33,35,36,37,38,39)/t19-,20+,21+/m1/s1	JOITUBWXBFATOR-HKBOAZHASA-N			Not Available	Small Molecule																																			0	No	10	6	No	0	1	207.79 Å2	65.49 Å3	187.34 m3·mol-1	22	No	No	0.0124 mg/mL	-6.4	-4.7	3.71	11.85	P20807	CAPN3	1. Calpain-3
C12H22AsN3O6S	Not Available	Not Available	411.3	C[As](C)SC[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)NCC(O)=O	Solid	Not Available						94295	CHEMBL3247378	9857733																	Darinaparsin	Investigational	DB06179	InChI=1S/C12H22AsN3O6S/c1-13(2)23-6-8(11(20)15-5-10(18)19)16-9(17)4-3-7(14)12(21)22/h7-8H,3-6,14H2,1-2H3,(H,15,20)(H,16,17)(H,18,19)(H,21,22)/t7-,8-/m0/s1	JGDXFQORBMPJGR-YUMQZZPRSA-N	2		Not Available	Small Molecule																																			1	No	7	5	No	0	-1	158.82 Å2	36.38 Å3	79.89 m3·mol-1	11	Yes	No	1.4 mg/mL	-4.4	-2.5	1.5	9.31			
C20H40N3O11P	Not Available	Not Available	529.524	COCCOC(=O)NCCCCC(NC(=O)OCCOC)C(=O)NCCCCCCOP(O)(O)=O	Solid	Not Available								52083501																	Pegnivacogin	Investigational	DB06293	InChI=1S/C20H40N3O11P/c1-30-13-15-32-19(25)22-11-7-5-9-17(23-20(26)33-16-14-31-2)18(24)21-10-6-3-4-8-12-34-35(27,28)29/h17H,3-16H2,1-2H3,(H,21,24)(H,22,25)(H,23,26)(H2,27,28,29)	QGVYYLZOAMMKAH-UHFFFAOYSA-N	1		Not Available	Small Molecule																																			0	No	8	5	No	0	-2	190.98 Å2	55.68 Å3	124.63 m3·mol-1	23	No	No	0.0854 mg/mL	0.14	-3.8	1.81	-3.3			
C31H40N4O8	Not Available	Not Available	596.681	CC(C)C[C@H](NC(=O)COC1=CC=CC=C1C)C(=O)N[C@@H](CC1=CC=C(OC(=O)N2CCC(CC2)C(N)=O)C=C1)C(O)=O	Solid	Not Available								7985272															ZINC000003976535		GW-559090	Investigational	DB06508	InChI=1S/C31H40N4O8/c1-19(2)16-24(33-27(36)18-42-26-7-5-4-6-20(26)3)29(38)34-25(30(39)40)17-21-8-10-23(11-9-21)43-31(41)35-14-12-22(13-15-35)28(32)37/h4-11,19,22,24-25H,12-18H2,1-3H3,(H2,32,37)(H,33,36)(H,34,38)(H,39,40)/t24-,25-/m0/s1	RZMCXMNNXGCFQG-DQEYMECFSA-N			Not Available	Small Molecule																																			0	No	7	4	Yes	3	-1	177.36 Å2	61.45 Å3	156.34 m3·mol-1	14	No	No	0.00604 mg/mL	2.63	-5	3.48	-1.5			
C6H10N2O5	The apparent total clearance was 5.7 L/min (range 3.0-9.7), the renal clearance was 290 mL/min (range 204-445), and the 24-hour urinary excretion was 4.5 % of the dose (range 3.5-7.5).	Median values for the terminal half-life was 5.6 hours (range 4.3-9.5).	190.154	NC(=O)N[C@@H](CCC(O)=O)C(O)=O	Solid	The apparent volume of distribution was 2657 L (range: 1616-5797).						71028	CHEMBL1201780	108351	Drugs.com Drug Page		HMDB0015673	C05829	D07130			PA165958402	121396	99443290	RxList Drug Page	401713		Carglumic_acid	ZINC000001530283	Carbaglu	Carglumic acid	Approved	DB06775	InChI=1S/C6H10N2O5/c7-6(13)8-3(5(11)12)1-2-4(9)10/h3H,1-2H2,(H,9,10)(H,11,12)(H3,7,8,13)/t3-/m0/s1	LCQLHJZYVOQKHU-VKHMYHEASA-N	3	Carglumic acid is an analog of N-acetylglutamate (NAG) used for the treatment of acute and chronic hyperammonemia in patients with N-acetylglutamate synthase (NAGS) deficiency.	LD50, oral, mouse: >1000 mg/kg	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.3576 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					-1.097					1	No	5	4	No	0	-2	129.72 Å2	16.79 Å3	39.41 m3·mol-1	5	Yes	No	19.1 mg/mL	-1.4	-1	3.36	-2.3	P31327	CPS1	1. Carbamoyl-phosphate synthase [ammonia], mitochondrial
C25H35N3O6	Not Available	Not Available	473.5619	[H][C@](C)(CC)[C@]([H])(NC(=O)[C@@]1([H])O[C@]1([H])C(=O)NCCC)C(=O)N1CCC[C@@]1([H])C(=O)OCC1=CC=CC=C1	Solid	Not Available					16504			18741757						73V			22850133	99443690					ZINC000014961495		BENZYL N-({(2S,3S)-3-[(PROPYLAMINO)CARBONYL]OXIRAN-2-YL}CARBONYL)-L-ISOLEUCYL-L-PROLINATE	Experimental	DB07219	InChI=1S/C25H35N3O6/c1-4-13-26-22(29)20-21(34-20)23(30)27-19(16(3)5-2)24(31)28-14-9-12-18(28)25(32)33-15-17-10-7-6-8-11-17/h6-8,10-11,16,18-21H,4-5,9,12-15H2,1-3H3,(H,26,29)(H,27,30)/t16-,18-,19-,20-,21-/m0/s1	OMQNYWZURFTFHE-MQBSTWLZSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.3991 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	2	Yes	3	0	117.34 Å2	50.97 Å3	123.96 m3·mol-1	12	Yes	No	0.097 mg/mL	2.03	-3.7	12.15	-3.3	P07858	CTSB	1. Cathepsin B
C19H31N3O6	Not Available	Not Available	397.4659	[H][C@](C)(CC)[C@]([H])(NC(=O)[C@@]1([H])O[C@]1([H])C(=O)NCCC)C(=O)N1CCC[C@@]1([H])C(=O)OC	Solid	Not Available					16503		CHEMBL262103	5042571						74M			6610318	99443694					ZINC000004899858		METHYL N-({(2S,3S)-3-[(PROPYLAMINO)CARBONYL]OXIRAN-2-YL}CARBONYL)-L-ISOLEUCYL-L-PROLINATE	Experimental	DB07223	InChI=1S/C19H31N3O6/c1-5-9-20-16(23)14-15(28-14)17(24)21-13(11(3)6-2)18(25)22-10-7-8-12(22)19(26)27-4/h11-15H,5-10H2,1-4H3,(H,20,23)(H,21,24)/t11-,12-,13-,14-,15-/m0/s1	XGWSRLSPWIEMLQ-YTFOTSKYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.4300 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	2	No	2	0	117.34 Å2	41.92 Å3	99.34 m3·mol-1	10	Yes	No	2.9 mg/mL	0.31	-2.1	12.2	-3.3			
C15H24N2O7	Not Available	Not Available	344.3603	[H][C@@](C)(NC(=O)[C@@]([H])(NC(=O)[C@@]1([H])O[C@]1([H])C(=O)OCC)[C@@]([H])(C)CC)C(O)=O	Solid	Not Available					16499			25056578						75V			23647358	99443695					ZINC000014961470		N-{[(2S,3S)-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL}-L-ISOLEUCYL-L-ALANINE	Experimental	DB07224	InChI=1S/C15H24N2O7/c1-5-7(3)9(12(18)16-8(4)14(20)21)17-13(19)10-11(24-10)15(22)23-6-2/h7-11H,5-6H2,1-4H3,(H,16,18)(H,17,19)(H,20,21)/t7-,8-,9-,10-,11-/m0/s1	FCCIQOJEDMDETP-QHZLYTNSSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.2711 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	6	3	No	1	-1	134.33 Å2	34.47 Å3	80.41 m3·mol-1	10	Yes	No	5.49 mg/mL	0.095	-1.8	3.8	-3.6	P07858	CTSB	1. Cathepsin B
C18H30N2O7	Not Available	Not Available	386.44	[H][C@](C)(CC)[C@]([H])(NC(=O)[C@@]([H])(NC(=O)[C@@]1([H])O[C@]1([H])C(=O)OCC)[C@@]([H])(C)CC)C(O)=O	Solid	Not Available								25060305						76V			46937062	99443696					ZINC000014961474		N-{[(2S,3S)-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL}-L-ISOLEUCYL-L-ISOLEUCINE	Experimental	DB07225	InChI=1S/C18H30N2O7/c1-6-9(4)11(15(21)20-12(17(23)24)10(5)7-2)19-16(22)13-14(27-13)18(25)26-8-3/h9-14H,6-8H2,1-5H3,(H,19,22)(H,20,21)(H,23,24)/t9-,10-,11-,12-,13-,14-/m0/s1	CFABOFMUPCWOPC-LHEWDLALSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.2711 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	6	3	No	1	-1	134.33 Å2	40.17 Å3	94.01 m3·mol-1	12	Yes	No	1.83 mg/mL	1.43	-2.3	3.97	-3.1	P07858	CTSB	1. Cathepsin B
C22H29N3O6	Not Available	Not Available	431.4822	[H][C@](C)(CC)[C@]([H])(NC(=O)[C@@]1([H])O[C@]1([H])C(=O)NCC1=CC=CC=C1)C(=O)N1CCC[C@@]1([H])C(O)=O	Solid	Not Available					16502			25056628						78A			23647361	99443702					ZINC000014961490		N-({(2S,3S)-3-[(BENZYLAMINO)CARBONYL]OXIRAN-2-YL}CARBONYL)-L-ISOLEUCYL-L-PROLINE	Experimental	DB07231	InChI=1S/C22H29N3O6/c1-3-13(2)16(21(28)25-11-7-10-15(25)22(29)30)24-20(27)18-17(31-18)19(26)23-12-14-8-5-4-6-9-14/h4-6,8-9,13,15-18H,3,7,10-12H2,1-2H3,(H,23,26)(H,24,27)(H,29,30)/t13-,15-,16-,17-,18-/m0/s1	MERYMLLGRCNRKE-HILJTLORSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3331 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	6	3	Yes	3	-1	128.34 Å2	44.54 Å3	109.92 m3·mol-1	9	Yes	No	0.484 mg/mL	1.01	-3	3.81	-3.3	P07858	CTSB	1. Cathepsin B
C20H36N6O3S	Not Available	Not Available	440.603	[H][C@@](CCCNC(N)N)(NC(=O)[C@@]([H])(NC(=O)CCC(C)C)C(C)C)C(=O)C1=NC=CS1	Solid	Not Available								5257036						995			6857702	99443770					ZINC000038190858		4-METHYL-PENTANOIC ACID {1-[4-GUANIDINO-1-(THIAZOLE-2-CARBONYL)-BUTYLCARBAMOYL]-2-METHYL-PROPYL}-AMIDE	Experimental	DB07299	InChI=1S/C20H36N6O3S/c1-12(2)7-8-15(27)26-16(13(3)4)18(29)25-14(6-5-9-24-20(21)22)17(28)19-23-10-11-30-19/h10-14,16,20,24H,5-9,21-22H2,1-4H3,(H,25,29)(H,26,27)/t14-,16-/m0/s1	ZXELQWLUDMEUHS-HOCLYGCPSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.5133 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	7	5	No	1	0	152.23 Å2	48.11 Å3	116.74 m3·mol-1	14	Yes	No	0.0248 mg/mL	1.23	-4.2	12.08	6.69	P03951	F11	1. Coagulation factor XI
C21H23N5O7	Not Available	Not Available	457.4366	[H][C@@](C)(NC(=O)[C@]([H])(CC1=CC=CC=C1)C(=O)NO)C(=O)NCC(=O)NC1=CC=C(C=C1)[N+]([O-])=O	Solid	Not Available								26330350						BAN			46937074	99443905					ZINC000029342430		HONH-BENZYLMALONYL-L-ALANYLGLYCINE-P-NITROANILIDE	Experimental	DB07434	InChI=1S/C21H23N5O7/c1-13(23-20(29)17(21(30)25-31)11-14-5-3-2-4-6-14)19(28)22-12-18(27)24-15-7-9-16(10-8-15)26(32)33/h2-10,13,17,31H,11-12H2,1H3,(H,22,28)(H,23,29)(H,24,27)(H,25,30)/t13-,17-/m0/s1	TZWQPWGUQCSKDW-GUYCJALGSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.5171 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	7	5	No	2	0	179.77 Å2	44.12 Å3	116.54 m3·mol-1	10	Yes	No	0.0105 mg/mL	0.71	-4.6	8.78	-4.5	P00800	npr	1. Thermolysin
C10H19NO4	Not Available	Not Available	217.2622	[H][C@@](CCO)(NC(=O)CCCCC)C(O)=O	Solid	Not Available								24778570						C6L			24860535	99444003							N-hexanoyl-L-homoserine	Experimental	DB07532	InChI=1S/C10H19NO4/c1-2-3-4-5-9(13)11-8(6-7-12)10(14)15/h8,12H,2-7H2,1H3,(H,11,13)(H,14,15)/t8-/m0/s1	BJLILZXVIKTHKQ-QMMMGPOBSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.8852 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	3	No	0	-1	86.63 Å2	23.71 Å3	54.78 m3·mol-1	8	Yes	No	11.2 mg/mL	0.29	-1.3	4.14	-1.3			
C20H37N3O4	Not Available	Not Available	383.5255	[H]C(=O)[C@H](CCCC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(C)=O	Solid	Not Available					50069792	2423	CHEMBL304784	391397				C11306		CIB			443118	99444029					ZINC000003826241		acetylleucyl-leucyl-norleucinal	Experimental	DB07558	InChI=1S/C20H37N3O4/c1-7-8-9-16(12-24)22-19(26)18(11-14(4)5)23-20(27)17(10-13(2)3)21-15(6)25/h12-14,16-18H,7-11H2,1-6H3,(H,21,25)(H,22,26)(H,23,27)/t16-,17-,18-/m0/s1	FMYKJLXRRQTBOR-BZSNNMDCSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3287 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	3	No	0	0	104.37 Å2	43.29 Å3	104.68 m3·mol-1	13	Yes	No	0.0596 mg/mL	1.93	-3.8	12.49	-1.7	O14818	PSMA7	1. Proteasome subunit alpha type-7
C21H33BN4O5	Not Available	Not Available	432.322	CC(=O)N[C@H](CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)B(O)O	Solid	Not Available					50288414		CHEMBL100109	4450302						DI2			5288064	99444129					ZINC000169748501		AC-(D)Phe-pro-borolys-OH	Experimental	DB07658	InChI=1S/C21H33BN4O5/c1-15(27)24-17(14-16-8-3-2-4-9-16)21(29)26-13-7-10-18(26)20(28)25-19(22(30)31)11-5-6-12-23/h2-4,8-9,17-19,30-31H,5-7,10-14,23H2,1H3,(H,24,27)(H,25,28)/t17-,18+,19+/m1/s1	UCQIHCRMWNRFNP-QYZOEREBSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.2297 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	5	No	2	1	144.99 Å2	46.7 Å3	112.01 m3·mol-1	11	Yes	No	0.453 mg/mL	-1	-3	8.63	10.21			
C22H35BN4O5	Not Available	Not Available	446.348	[H][C@@](CCCCCN)(NC(=O)[C@]1([H])CCCN1C(=O)[C@@]([H])(CC1=CC=CC=C1)NC(C)=O)B(O)O	Solid	Not Available								4450304						DI4			5288066	99444130					ZINC000169748502		AC-(D)PHE-PRO-BOROHOMOLYS-OH	Experimental	DB07659	InChI=1S/C22H35BN4O5/c1-16(28)25-18(15-17-9-4-2-5-10-17)22(30)27-14-8-11-19(27)21(29)26-20(23(31)32)12-6-3-7-13-24/h2,4-5,9-10,18-20,31-32H,3,6-8,11-15,24H2,1H3,(H,25,28)(H,26,29)/t18-,19+,20+/m1/s1	AILSWIBFGYYZTK-AABGKKOBSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.2297 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	5	No	2	1	144.99 Å2	48.88 Å3	116.62 m3·mol-1	12	Yes	No	0.211 mg/mL	-0.62	-3.3	8.63	10.21	P00734	F2	1. Prothrombin
C20H31BN4O5	Not Available	Not Available	418.295	[H][C@@](CCCN)(NC(=O)[C@]1([H])CCCN1C(=O)[C@@]([H])(CC1=CC=CC=C1)NC(C)=O)B(O)O	Solid	Not Available								4450305						DI5			5288067	99444131					ZINC000169748503		AC-(D)PHE-PRO-BOROHOMOORNITHINE-OH	Experimental	DB07660	InChI=1S/C20H31BN4O5/c1-14(26)23-16(13-15-7-3-2-4-8-15)20(28)25-12-6-9-17(25)19(27)24-18(21(29)30)10-5-11-22/h2-4,7-8,16-18,29-30H,5-6,9-13,22H2,1H3,(H,23,26)(H,24,27)/t16-,17+,18+/m1/s1	YKWKWNKWBGQECF-SQNIBIBYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.2297 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	6	5	No	2	1	144.99 Å2	44.69 Å3	107.41 m3·mol-1	10	Yes	No	0.592 mg/mL	-1.3	-2.8	8.62	9.93	P00734	F2	1. Prothrombin
C21H28FN3O7	Not Available	Not Available	453.467	CC(C)[C@H](NC(=O)OCC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)CF	Solid	Not Available							CHEMBL205821	4593739									5497171	99444215					ZINC000025668028		Z-Val-Ala-Asp fluoromethyl ketone	Experimental	DB07744	InChI=1S/C21H28FN3O7/c1-12(2)18(25-21(31)32-11-14-7-5-4-6-8-14)20(30)23-13(3)19(29)24-15(9-17(27)28)16(26)10-22/h4-8,12-13,15,18H,9-11H2,1-3H3,(H,23,30)(H,24,29)(H,25,31)(H,27,28)/t13-,15-,18-/m0/s1	SUUHZYLYARUNIA-YEWWUXTCSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.2208 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	6	4	No	1	-1	150.9 Å2	44.69 Å3	109.36 m3·mol-1	13	Yes	No	0.0358 mg/mL	1.16	-4.1	4.13	-4	P29466	CASP1	1. Caspase-1
C16H19FN2O7S	Not Available	Not Available	402.395	OC(=O)CC[C@H](NC(=O)N[C@@H](CSCC1=CC=C(F)C=C1)C(O)=O)C(O)=O	Solid	Not Available								25059183						FBD			25113157	99444225					ZINC000039111997		DCFBC	Experimental	DB07754	InChI=1S/C16H19FN2O7S/c17-10-3-1-9(2-4-10)7-27-8-12(15(24)25)19-16(26)18-11(14(22)23)5-6-13(20)21/h1-4,11-12H,5-8H2,(H,20,21)(H,22,23)(H,24,25)(H2,18,19,26)/t11-,12-/m0/s1	IDTMSHGCAZPVLC-RYUDHWBXSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3503 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	7	5	No	1	-3	153.03 Å2	38.06 Å3	92.14 m3·mol-1	11	Yes	No	0.09 mg/mL	1.02	-3.6	3.11	-2.5	Q04609	FOLH1	1. Glutamate carboxypeptidase 2
C23H27N3O4S	Not Available	Not Available	441.543	[H][C@@](NC(=O)CC1=CC=CC=C1)(C(=O)NCC1=CC=CC=C1)[C@]1([H])N[C@@]([H])(C(O)=O)C(C)(C)S1	Solid	Not Available						42719		393571						G23			446136	99444277					ZINC000003809861		(2R,4S)-2-[(R)-BENZYLCARBAMOYL-PHENYLACETYL-METHYL]-5,5-DIMETHYL-THIAZOLIDINE-4-CARBOXYLIC ACID	Experimental	DB07806	InChI=1S/C23H27N3O4S/c1-23(2)19(22(29)30)26-21(31-23)18(20(28)24-14-16-11-7-4-8-12-16)25-17(27)13-15-9-5-3-6-10-15/h3-12,18-19,21,26H,13-14H2,1-2H3,(H,24,28)(H,25,27)(H,29,30)/t18-,19+,21-/m1/s1	UDMBRVGTYILYDX-SVFBPWRDSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.4535 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	4	Yes	3	0	107.53 Å2	46.01 Å3	118.94 m3·mol-1	8	Yes	No	0.00532 mg/mL	0.25	-4.9	2.89	6.19	P03366	gag-pol	1. Gag-Pol polyprotein
C20H24N4O3	Not Available	Not Available	368.4296	[H][C@@](C)(NC(=O)CN)C(=O)N1CCC[C@@]1([H])C(=O)NC1=CC=C2C=CC=CC2=C1	Solid	Not Available								25060358						GA0			46937094	99444284					ZINC000053683227		GLYCYLALANYL-N-2-NAPHTHYL-L-PROLINEAMIDE	Experimental	DB07813	InChI=1S/C20H24N4O3/c1-13(22-18(25)12-21)20(27)24-10-4-7-17(24)19(26)23-16-9-8-14-5-2-3-6-15(14)11-16/h2-3,5-6,8-9,11,13,17H,4,7,10,12,21H2,1H3,(H,22,25)(H,23,26)/t13-,17-/m0/s1	KCELZXZDIUJGNM-GUYCJALGSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.4335 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Inhibitor										1	Yes	4	3	No	3	1	104.53 Å2	39.46 Å3	103.01 m3·mol-1	5	Yes	No	0.0942 mg/mL	0.48	-3.6	12.49	7.84	Q7MUW6	ptpA	1. Prolyl tripeptidyl peptidase
C15H22NO6P	Not Available	Not Available	343.312	[H][C@@](CCCC)(NC(=O)CCC(O)=O)[P@](O)(=O)OC1=CC=CC=C1	Solid	Not Available						43012		392114						HEP			444107	99444364					ZINC000003874662		PHENYL[1-(N-SUCCINYLAMINO)PENTYL]PHOSPHONATE	Experimental	DB07893	InChI=1S/C15H22NO6P/c1-2-3-9-14(16-13(17)10-11-15(18)19)23(20,21)22-12-7-5-4-6-8-12/h4-8,14H,2-3,9-11H2,1H3,(H,16,17)(H,18,19)(H,20,21)/t14-/m1/s1	FJQWWGCHPFSERW-CQSZACIVSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.3495 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	3	No	1	-2	112.93 Å2	33.84 Å3	83.51 m3·mol-1	10	Yes	No	0.671 mg/mL	1.7	-2.7	1.51	-2.1	P01834	IGKC	1. Ig kappa chain C region
C16H21ClN2O3	Not Available	Not Available	324.803	[H][C@@](C)(NC(C)=O)C(=O)N[C@@]([H])(CC1=CC=CC=C1)C(=O)CCCl	Solid	Not Available								25057340						HIN			46937104	99444370					ZINC000008239025		(2S) N-acetyl-L-alanyl-αL-phenylalanyl-chloroethylketone	Experimental	DB07899	InChI=1S/C16H21ClN2O3/c1-11(18-12(2)20)16(22)19-14(15(21)8-9-17)10-13-6-4-3-5-7-13/h3-7,11,14H,8-10H2,1-2H3,(H,18,20)(H,19,22)/t11-,14-/m0/s1	WABWAIGLGFELMI-FZMZJTMJSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1833 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	2	No	1	0	75.27 Å2	33.66 Å3	84.86 m3·mol-1	8	Yes	No	0.0374 mg/mL	1.46	-3.9	12.4	-1.9	P17538	CTRB1	1. Chymotrypsinogen B
C14H14N2O5	Not Available	Not Available	290.2714	OC(=O)C[C@H](NC(=O)CC1=CNC2=CC=CC=C12)C(O)=O	Solid	Not Available						21484		393931						IAD			446620	99444422					ZINC000000056756		N-(indole-3-acetyl)-L-aspartic acid	Experimental	DB07951	InChI=1S/C14H14N2O5/c17-12(16-11(14(20)21)6-13(18)19)5-8-7-15-10-4-2-1-3-9(8)10/h1-4,7,11,15H,5-6H2,(H,16,17)(H,18,19)(H,20,21)/t11-/m0/s1	VAFNMNRKDDAKRM-NSHDSACASA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.7237 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	4	No	2	-2	119.49 Å2	27.68 Å3	71.78 m3·mol-1	6	Yes	No	0.228 mg/mL	0.53	-3.1	3.74	-2.8	P00929;!P0A2K1	trpA;!trpB	1. Tryptophan synthase alpha chain;!2. Tryptophan synthase beta chain
C16H25N3O3	Not Available	Not Available	307.388	[H][C@@](C)(N)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC1=CC=CC=C1)[C@@]([H])(C)O	Solid	Not Available								25058906						K7I			46937118	99444509					ZINC000053683343		L-alanyl-N-[(1S,2R)-1-benzyl-2-hydroxypropyl]-L-alaninamide	Experimental	DB08038	InChI=1S/C16H25N3O3/c1-10(17)15(21)18-11(2)16(22)19-14(12(3)20)9-13-7-5-4-6-8-13/h4-8,10-12,14,20H,9,17H2,1-3H3,(H,18,21)(H,19,22)/t10-,11-,12+,14-/m0/s1	CPAOOGAUUDSJCS-FMSGJZPZSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	1.9333 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	4	No	1	1	104.45 Å2	33.09 Å3	84.26 m3·mol-1	7	Yes	No	1.34 mg/mL	0.1	-2.4	12.78	8.09	P49862	KLK7	1. Kallikrein-7
C14H18N2O5	Not Available	Not Available	294.3031	C[C@H](NC(=O)[C@@H](CC(=O)NO)CC1=CC=CC=C1)C(O)=O	Solid	Not Available					92500		CHEMBL85320	110501						KEL			123982	99444511				Kelatorphan	ZINC000006020153		Kelatorphan	Experimental	DB08040	InChI=1S/C14H18N2O5/c1-9(14(19)20)15-13(18)11(8-12(17)16-21)7-10-5-3-2-4-6-10/h2-6,9,11,21H,7-8H2,1H3,(H,15,18)(H,16,17)(H,19,20)/t9-,11+/m0/s1	OJCFZTVYDSKXNM-GXSJLCMTSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.9556 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	4	No	1	-1	115.73 Å2	29.25 Å3	73.69 m3·mol-1	7	Yes	No	0.433 mg/mL	0.38	-2.8	3.8	-1.9			
C21H37N3O3	Not Available	Not Available	379.5368	[H][C@@](CC(C)C)(NC(=O)CCCCCCCCCCCN1C=CN=C1)C(O)=O	Solid	Not Available								25058832						LEH			46937122	99444557					ZINC000053683360		N-[12-(1H-imidazol-1-yl)dodecanoyl]-L-leucine	Experimental	DB08086	InChI=1S/C21H37N3O3/c1-18(2)16-19(21(26)27)23-20(25)12-10-8-6-4-3-5-7-9-11-14-24-15-13-22-17-24/h13,15,17-19H,3-12,14,16H2,1-2H3,(H,23,25)(H,26,27)/t19-/m0/s1	PSJOKLGFODYIHJ-IBGZPJMESA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1447 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	2	No	1	-1	84.22 Å2	45.12 Å3	107.23 m3·mol-1	16	Yes	No	0.00654 mg/mL	3.58	-4.8	4.26	6.54	P14779	cyp102A1	1. Bifunctional P-450/NADPH-P450 reductase
C11H20N2O3	Not Available	Not Available	228.2881	OC(=O)CCCNC(=O)NC1CCCCC1	Solid	Not Available					50192936		CHEMBL219695	4925684						NC4			6420119	99444728					ZINC000008754389		4-{[(CYCLOHEXYLAMINO)CARBONYL]AMINO}BUTANOIC ACID	Experimental	DB08257	InChI=1S/C11H20N2O3/c14-10(15)7-4-8-12-11(16)13-9-5-2-1-3-6-9/h9H,1-8H2,(H,14,15)(H2,12,13,16)	WSVFRGGLURJIMG-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.5478 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	3	No	1	-1	78.43 Å2	25.23 Å3	59.49 m3·mol-1	5	Yes	No	0.809 mg/mL	0.89	-2.4	4.32	-0.62			
C13H24N2O3	Not Available	Not Available	256.3413	OC(=O)CCCCCNC(=O)NC1CCCCC1	Solid	Not Available					50192966		CHEMBL434374	4925685						NC6			6420120	99444729					ZINC000013493677		6-{[(CYCLOHEXYLAMINO)CARBONYL]AMINO}HEXANOIC ACID	Experimental	DB08258	InChI=1S/C13H24N2O3/c16-12(17)9-5-2-6-10-14-13(18)15-11-7-3-1-4-8-11/h11H,1-10H2,(H,16,17)(H2,14,15,18)	KFTVEPYSUSWBRD-UHFFFAOYSA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.5478 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	3	3	No	1	-1	78.43 Å2	29.51 Å3	68.69 m3·mol-1	7	Yes	No	0.574 mg/mL	1.78	-2.6	4.39	-0.62			
C21H33NO4	Not Available	Not Available	363.491	[H][C@@](CC1=CC=C(O)C=C1)(NC(=O)CCCCCCCCCCC)C(O)=O	Solid	Not Available								5142256						NLT			6710104	99444746							N-DODECANOYL-L-TYROSINE	Experimental	DB08275	InChI=1S/C21H33NO4/c1-2-3-4-5-6-7-8-9-10-11-20(24)22-19(21(25)26)16-17-12-14-18(23)15-13-17/h12-15,19,23H,2-11,16H2,1H3,(H,22,24)(H,25,26)/t19-/m0/s1	SVQAZCRYIXURJT-IBGZPJMESA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.2586 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										0	Yes	4	3	No	1	-1	86.63 Å2	42.36 Å3	102.58 m3·mol-1	14	No	No	0.00427 mg/mL	5.29	-4.9	3.85	-1.5	Q8KNZ7	Not Available	1. Long-chain N-acyl amino acid synthase
C19H35N3O6	Not Available	Not Available	401.4977	[H][C@@](C)(NC(=O)[C@]([H])(CC(C)C)NC(=O)[C@]([H])(CC(C)C)CC(=O)NO)C(=O)OCC	Solid	Not Available					50146631		CHEMBL92608	4589311						RO4			5487313	99444953					ZINC000003801503		[[1-[N-HYDROXY-ACETAMIDYL]-3-METHYL-BUTYL]-CARBONYL-LEUCINYL]-ALANINE ETHYL ESTER	Experimental	DB08482	InChI=1S/C19H35N3O6/c1-7-28-19(26)13(6)20-18(25)15(9-12(4)5)21-17(24)14(8-11(2)3)10-16(23)22-27/h11-15,27H,7-10H2,1-6H3,(H,20,25)(H,21,24)(H,22,23)/t13-,14+,15-/m0/s1	XKRONJXEXGFBRZ-ZNMIVQPWSA-N			Not Available	Small Molecule				AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.4289 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	4	No	0	0	133.83 Å2	43.31 Å3	103.24 m3·mol-1	13	Yes	No	0.302 mg/mL	1.19	-3.1	8.9	-0.9			
C18H25BrN2O5	Not Available	Not Available	429.306	[H][C@@](CC1=CC=C(Br)C=C1)(NC(=O)CCCCCCC(=O)NO)C(=O)OC	Solid	Not Available					50375546		CHEMBL406734	23319843						S17			23640756	99444976					ZINC000016052595		methyl 4-bromo-N-[8-(hydroxyamino)-8-oxooctanoyl]-L-phenylalaninate	Experimental	DB08505	InChI=1S/C18H25BrN2O5/c1-26-18(24)15(12-13-8-10-14(19)11-9-13)20-16(22)6-4-2-3-5-7-17(23)21-25/h8-11,15,25H,2-7,12H2,1H3,(H,20,22)(H,21,23)/t15-/m0/s1	UPYGSQPRAHMDPD-HNNXBMFYSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.3391 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	3	No	1	0	104.73 Å2	40.87 Å3	99.84 m3·mol-1	12	Yes	No	0.00778 mg/mL	2.6	-4.7	8.91	-1.5	Q70I53	hdaH	1. Histone deacetylase-like amidohydrolase
C22H36N2O5	Not Available	Not Available	408.5316	[H][C@@](O)(COC)[C@]([H])(CC(C)C)NC(=O)[C@]([H])(CC(C)C)NC(=O)OCC1=CC=CC=C1	Solid	Not Available								4451322						SBA			5289332	99444997					ZINC000033821514		CARBOBENZYLOXY-(L)-LEUCINYL-(L)LEUCINYL METHOXYMETHYLKETONE	Experimental	DB08526	InChI=1S/C22H36N2O5/c1-15(2)11-18(20(25)14-28-5)23-21(26)19(12-16(3)4)24-22(27)29-13-17-9-7-6-8-10-17/h6-10,15-16,18-20,25H,11-14H2,1-5H3,(H,23,26)(H,24,27)/t18-,19-,20+/m0/s1	LHCNZPLAATYYPI-SLFFLAALSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.3224 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	3	No	1	0	96.89 Å2	46.19 Å3	111.67 m3·mol-1	13	Yes	No	0.0393 mg/mL	3.25	-4	13.38	-2.8	P09668	CTSH	1. Pro-cathepsin H
C9H15NO5	Not Available	Not Available	217.2191	[H][C@@](CCC)(NC(=O)CCC(O)=O)C(O)=O	Solid	Not Available								5254643						SN0			6852189	99445025							N-(3-carboxypropanoyl)-L-norvaline	Experimental	DB08554	InChI=1S/C9H15NO5/c1-2-3-6(9(14)15)10-7(11)4-5-8(12)13/h6H,2-5H2,1H3,(H,10,11)(H,12,13)(H,14,15)/t6-/m0/s1	HRAPDLBXHOBAKA-LURJTMIESA-N			Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.7519 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	3	No	0	-2	103.7 Å2	21.3 Å3	49.96 m3·mol-1	7	Yes	No	9.55 mg/mL	0.032	-1.4	3.64	-2	Q5LI27;!Q8P8J2	Not Available;!argF'	1. Putative ornithine carbamoyltransferase;!2. N-acetylornithine carbamoyltransferase
C24H31N3O4S	Not Available	Not Available	457.586	[H][C@@](CS)(NCC1=CC=C(C=C1)C1=CC=CC=C1)C(=O)NCC(=O)N[C@@]([H])(C(C)C)C(=O)OC	Solid	Not Available								3571842						TR1			4369141	99445114					ZINC000053683264		2-(2-{2-[(BIPHENYL-4-YLMETHYL)-AMINO]-3-MERCAPTO-PENTANOYLAMINO}-ACETYLAMINO)-3-METHYL-BUTYRIC ACID METHYL ESTER	Experimental	DB08643	InChI=1S/C24H31N3O4S/c1-16(2)22(24(30)31-3)27-21(28)14-26-23(29)20(15-32)25-13-17-9-11-19(12-10-17)18-7-5-4-6-8-18/h4-12,16,20,22,25,32H,13-15H2,1-3H3,(H,26,29)(H,27,28)/t20-,22-/m0/s1	QFAWBPLETHINFK-UNMCSNQZSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Non-inhibitor	Substrate	2.4053 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	4	No	2	1	96.53 Å2	50.36 Å3	126.61 m3·mol-1	12	Yes	No	0.00165 mg/mL	2.67	-5.4	9.97	7.34	P08254	MMP3	1. Stromelysin-1
C20H31N3O5	Not Available	Not Available	393.4772	[H][C@@](C)(NC(=O)[C@@]([H])(O)[C@]([H])(N)C1=CC=C(C)C=C1)C(=O)N[C@]([H])(CC(C)C)C(=O)OC	Solid	Not Available								5290527						U15			6914647	99445140					ZINC000016052079		METHYL N-[(2S,3R)-3-AMINO-2-HYDROXY-3-(4-METHYLPHENYL)PROPANOYL]-D-ALANYL-D-LEUCINATE	Experimental	DB08669	InChI=1S/C20H31N3O5/c1-11(2)10-15(20(27)28-5)23-18(25)13(4)22-19(26)17(24)16(21)14-8-6-12(3)7-9-14/h6-9,11,13,15-17,24H,10,21H2,1-5H3,(H,22,26)(H,23,25)/t13-,15+,16+,17-/m0/s1	BMHZOSJVDHAFEE-SVGFKBNWSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.1672 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	4	No	1	1	130.75 Å2	41.53 Å3	104.4 m3·mol-1	10	Yes	No	0.164 mg/mL	1	-3.4	11.97	7.91	P0AE18	map	1. Methionine aminopeptidase
C22H35N3O5	Not Available	Not Available	421.5304	[H][C@@](C)(NC(=O)[C@@]([H])(O)[C@]([H])(N)C1=CC=C(C=C1)C(C)C)C(=O)N[C@]([H])(CC(C)C)C(=O)OC	Solid	Not Available								5290528						U16			6914648	99445141					ZINC000016052056		METHYL N-[(2S,3R)-3-AMINO-2-HYDROXY-3-(4-ISOPROPYLPHENYL)PROPANOYL]-D-ALANYL-D-LEUCINATE	Experimental	DB08670	InChI=1S/C22H35N3O5/c1-12(2)11-17(22(29)30-6)25-20(27)14(5)24-21(28)19(26)18(23)16-9-7-15(8-10-16)13(3)4/h7-10,12-14,17-19,26H,11,23H2,1-6H3,(H,24,28)(H,25,27)/t14-,17+,18+,19-/m0/s1	WIWZNHHLFMPGGO-PIKADFDJSA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Substrate	2.1672 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	5	4	No	1	1	130.75 Å2	46.24 Å3	113.55 m3·mol-1	11	Yes	No	0.0308 mg/mL	1.73	-4.1	11.98	7.91	P0AE18	map	1. Methionine aminopeptidase
C22H26N2O5	Not Available	Not Available	398.4522	[H][C@](C)(NC(=O)[C@]([H])(CC1=CC=CC=C1)NC(=O)OCC1=CC=CC=C1)C(=O)CCO	Solid	Not Available								17347435						WR1			16220131	99445203					ZINC000016052314		NALPHA-[(BENZYLOXY)CARBONYL]-N-[(1R)-4-HYDROXY-1-METHYL-2-OXOBUTYL]-L-PHENYLALANINAMIDE	Experimental	DB08732	InChI=1S/C22H26N2O5/c1-16(20(26)12-13-25)23-21(27)19(14-17-8-4-2-5-9-17)24-22(28)29-15-18-10-6-3-7-11-18/h2-11,16,19,25H,12-15H2,1H3,(H,23,27)(H,24,28)/t16-,19+/m1/s1	UUOOAGBWJUGBMV-APWZRJJASA-N			Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Substrate	2.1123 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	Yes	4	3	No	2	0	104.73 Å2	42.27 Å3	108.05 m3·mol-1	11	Yes	No	0.0146 mg/mL	2.45	-4.4	12.7	-2.4	P0C6X7;!P0C6U8	rep;!Not Available	1. Replicase polyprotein 1ab;!2. Replicase polyprotein 1a
C11H16N2O8	Not Available	Not Available	304.255	CC(=O)N[C@@H](CC(=O)N[C@@H](CCC(O)=O)C(O)=O)C(O)=O	Solid	Not Available						135289	CHEMBL2105616	182277	Drugs.com Drug Page				D07374				210320	175427113				N-Acetylaspartylglutamic_acid	ZINC000002504638		Spaglumic acid	Experimental	DB08835	InChI=1S/C11H16N2O8/c1-5(14)12-7(11(20)21)4-8(15)13-6(10(18)19)2-3-9(16)17/h6-7H,2-4H2,1H3,(H,12,14)(H,13,15)(H,16,17)(H,18,19)(H,20,21)/t6-,7-/m0/s1	GUCKKCMJTSNWCU-BQBZGAKWSA-N	4	Spaglumic acid is the β-aspartyl isoform of N-Acetyl-l-aspartylglutamate, a naturally occurring neurotransmitter, used in allergic eye conditions due to its ability to stabilize mast cells.	Not Available	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	1.7395 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor										1	No	8	5	No	0	-3	170.1 Å2	27.37 Å3	64.06 m3·mol-1	9	Yes	No	3.22 mg/mL	-2.3	-2	3.01	-2	Q04609	FOLH1	1. Glutamate carboxypeptidase 2
C30H47N3O9S	Not Available	Not Available	625.774	CCCCC\C=C/C\C=C/C=C/C=C/[C@@H](SC[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)NCC(O)=O)[C@@H](O)CCCC(O)=O	Solid	Not Available						16978	CHEMBL451509	4444133			HMDB0001198	C02166		LTX								Leukotriene_C4	ZINC000004095814		Leukotriene C4	Experimental, Investigational	DB08855	InChI=1S/C30H47N3O9S/c1-2-3-4-5-6-7-8-9-10-11-12-13-16-25(24(34)15-14-17-27(36)37)43-21-23(29(40)32-20-28(38)39)33-26(35)19-18-22(31)30(41)42/h6-7,9-13,16,22-25,34H,2-5,8,14-15,17-21,31H2,1H3,(H,32,40)(H,33,35)(H,36,37)(H,38,39)(H,41,42)/b7-6-,10-9-,12-11+,16-13+/t22-,23-,24-,25+/m0/s1	GWNVDXQDILPJIG-NXOLIXFESA-N			Not Available	Small Molecule																																			0	No	10	7	No	0	-2	216.35 Å2	68.38 Å3	168.51 m3·mol-1	25	No	No	0.00254 mg/mL	-0.015	-5.4	1.8	9.31	Q9Y271;!Q9NS75;!P33527	CYSLTR1;!CYSLTR2;!ABCC1	1. Cysteinyl leukotriene receptor 1;!2. Cysteinyl leukotriene receptor 2;!3. Multidrug resistance-associated protein 1
C29H39N5O7	Not Available	Not Available	569.659	CC(C)C[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1)C(O)=O	Solid	Not Available					21025		CHEMBL340032	5292936														DADLE	ZINC000014952092		DADLE	Experimental	DB08856	InChI=1S/C29H39N5O7/c1-17(2)13-24(29(40)41)34-28(39)23(15-19-7-5-4-6-8-19)33-25(36)16-31-26(37)18(3)32-27(38)22(30)14-20-9-11-21(35)12-10-20/h4-12,17-18,22-24,35H,13-16,30H2,1-3H3,(H,31,37)(H,32,38)(H,33,36)(H,34,39)(H,40,41)/t18-,22+,23+,24-/m1/s1	ZHUJMSMQIPIPTF-IBURTVSXSA-N			Not Available	Small Molecule																																			0	No	8	7	No	2	0	199.95 Å2	59.13 Å3	150.09 m3·mol-1	15	No	No	0.00963 mg/mL	-1.3	-4.8	3.7	7.73			
C25H43N13O10	Not Available	Not Available	685.69	[H][C@@]1(CCN=C(N)N1)[C@]1([H])NC(=O)\C(NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CNC1=O)NC(=O)C[C@@H](N)[C@H](O)CCN)=C\NC(N)=O	Solid	Not Available							CHEMBL2146142	16736480	Drugs.com Drug Page				D07897				20055267	310264954				Enviomycin	ZINC000169291448		Enviomycin	Experimental	DB08993	InChI=1S/C25H43N13O10/c26-3-1-16(41)10(27)5-17(42)33-12-6-31-23(47)18(11-2-4-30-24(28)37-11)38-20(44)13(7-32-25(29)48)34-21(45)14(8-39)36-22(46)15(9-40)35-19(12)43/h7,10-12,14-16,18,39-41H,1-6,8-9,26-27H2,(H,31,47)(H,33,42)(H,34,45)(H,35,43)(H,36,46)(H,38,44)(H3,28,30,37)(H3,29,32,48)/b13-7-/t10-,11-,12+,14+,15+,16-,18+/m1/s1	HPWIIERXAFODPP-GHBBWTPBSA-N			Not Available	Small Molecule																																			0	No	15	15	No	2	3	392.86 Å2	65.92 Å3	161.87 m3·mol-1	10	No	No	2.56 mg/mL	-12	-2.4	8.71	10.52			
C24H29NO5	Not Available	The half life of sacubitril is 1.1 to 3.6 hours, and the half life of it's metabolite LBQ657 is 9.9 to 11.1 hours.	411.498	CCOC(=O)[C@H](C)C[C@@H](CC1=CC=C(C=C1)C1=CC=CC=C1)NC(=O)CCC(O)=O	Solid	103 L						134714	CHEMBL3137301	7987587	Drugs.com Drug Page				D10225			PA166131580	9811834	310265184	RxList Drug Page	1656328		Sacubitril	ZINC000003792417	Entresto	Sacubitril	Approved	DB09292	InChI=1S/C24H29NO5/c1-3-30-24(29)17(2)15-21(25-22(26)13-14-23(27)28)16-18-9-11-20(12-10-18)19-7-5-4-6-8-19/h4-12,17,21H,3,13-16H2,1-2H3,(H,25,26)(H,27,28)/t17-,21+/m1/s1	PYNXFZCZUAOOQC-UTKZUKDTSA-N	4	Sacubitril is a neprilysin inhibitor used in combination with valsartan as an adjunct to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.	The most common adverse reactions (≥5%) are hypotension, hyperkalemia, cough, dizziness, and renal failure.	Small Molecule																																			1	Yes	4	2	No	2	-1	92.7 Å2	44.48 Å3	114.06 m3·mol-1	12	Yes	No	0.000942 mg/mL	3.79	-5.6	4.18	-1.6	P08473	MME	1. Neprilysin
C18H24N2O5	The disposition of enalaprilat in patients with renal insufficiency is similar to that in patients with normal renal function until the glomerular filtration rate is 30 mL/min or less. Renal clearance was 158 ± 47 ml/min.	11 hr	348.3936	[H][C@@](C)(N[C@@]([H])(CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@@]1([H])C(O)=O	Not Available	Not Available					50367254	4786	CHEMBL577	4575429			HMDB0041886	C11720	D03769	EAL			5462501	347827859	RxList Drug Page	3829		Enalaprilat	ZINC000003812851		Enalaprilat	Approved	DB09477	InChI=1S/C18H24N2O5/c1-12(16(21)20-11-5-8-15(20)18(24)25)19-14(17(22)23)10-9-13-6-3-2-4-7-13/h2-4,6-7,12,14-15,19H,5,8-11H2,1H3,(H,22,23)(H,24,25)/t12-,14-,15-/m0/s1	LZFZMUMEGBBDTC-QEJZJMRPSA-N	4	Enalaprilat is an antihypertensive agent used for the management of hypertension when oral therapy is not practical.	Adverse experiences occurring in 0.5 to 1.0 percent of patients in controlled clinical trials included: myocardial infarction, fatigue, dizziness, fever, rash and constipation.Angioedema has also been reported in patients receiving enalaprilat, with an incidence higher in black than in non-black patients. Angioedema associated with laryngeal edema may be fatal. If angioedema of the face, extremities, lips, tongue, glottis and/or larynx occurs, treatment with enalaprilat should be discontinued and appropriate therapy instituted immediately . Rarer adverse effects that are less likely, but should be monitored for, include development of anaphylaxis, hypotension, agranulocytosis, hepatic failure, hyperkalemia, and persistent cough. Furthermore, ACE inhibitors should be avoided during pregnancy as they can cause fetal and neonatal morbidity and death. When pregnancy is detected, ACE inhibitors should be discontinued as soon as possible. Use during the second and third trimesters of pregnancy has been associated with fetal and neonatal injury, including hypotension, neonatal skull hypoplasia, anuria, reversible or irreversible renal failure, and death.	Small Molecule																																			1	No	6	3	No	2	-1	106.94 Å2	35.82 Å3	90.06 m3·mol-1	8	Yes	No	0.876 mg/mL	-1.1	-2.6	3.13	7.83	P12821;!P46663	ACE;!BDKRB1	1. Angiotensin-converting enzyme;!2. B1 bradykinin receptor
C20H25N7O6	Not Available	The mean elimination half-life is approximately 3 hours after 5mg of oral L-methylfolate, administered daily for 7 days [775].	459.4558	CN1[C@@H](CNC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNC2=C1C(=O)N=C(N)N2	Solid	Circulates in its free form or loosely bound to plasma proteins	Q99707	MTR	1. Methionine synthase		50391007	15641	CHEMBL1231574	392351	Drugs.com Drug Page			C00440		THH		PA166129561	444412	347827954		1025342		Levomefolic_acid	ZINC000002005305	Beyaz 28 Day, EnBrace HR, EnLyte, Safyral 28 Day, Yaz Plus	Levomefolic acid	Approved, Investigational	DB11256	InChI=1S/C20H25N7O6/c1-27-12(9-23-16-15(27)18(31)26-20(21)25-16)8-22-11-4-2-10(3-5-11)17(30)24-13(19(32)33)6-7-14(28)29/h2-5,12-13,22H,6-9H2,1H3,(H,24,30)(H,28,29)(H,32,33)(H4,21,23,25,26,31)/t12-,13-/m0/s1	ZNOVTXRBGFNYRX-STQMWFEESA-N	4	Levomefolic acid is a folate supplement used to prevent neural tube defects in pregnancy or folate deficiency.	Overdose of levomefolic acid is unlikely to cause clinically significant adverse events.	Small Molecule																													221					Approximately 0.3 mg/ml	0	No	12	7	Yes	3	-2	198.48 Å2	46.56 Å3	126.68 m3·mol-1	9	No	No	0.332 mg/mL	-3	-3.1	3.23	5.32			
C14H24N6O4	Not Available	Prezatide is rapidly eliminated within minutes 5.	340.384	NCCCC[C@H](NC(=O)[C@H](CC1=CNC=N1)NC(=O)CN)C(O)=O	Solid	Not Available					50350478	75430	CHEMBL1814493	66263									73587	347827962		1368533			ZINC000013507674		Prezatide	Experimental	DB11296	InChI=1S/C14H24N6O4/c15-4-2-1-3-10(14(23)24)20-13(22)11(19-12(21)6-16)5-9-7-17-8-18-9/h7-8,10-11H,1-6,15-16H2,(H,17,18)(H,19,21)(H,20,22)(H,23,24)/t10-,11-/m0/s1	MVORZMQFXBLMHM-QWRGUYRKSA-N			Not Available	Small Molecule																																			0	No	7	6	No	1	1	176.22 Å2	34.52 Å3	84.91 m3·mol-1	11	No	No	3.14 mg/mL	-5.1	-2	3.46	10.2			
C30H54N6O5	Not Available	Not Available	578.799	CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCCN)C(O)=O	Not Available	Not Available								8407354												1722914			ZINC000113569616		Palmitoyl oligopeptide	Experimental	DB11297	InChI=1S/C30H54N6O5/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-18-27(37)33-22-28(38)35-26(20-24-21-32-23-34-24)29(39)36-25(30(40)41)17-15-16-19-31/h21,23,25-26H,2-20,22,31H2,1H3,(H,32,34)(H,33,37)(H,35,38)(H,36,39)(H,40,41)/t25-,26-/m0/s1	BYUQATUKPXLFLZ-UIOOFZCWSA-N			Not Available	Small Molecule																																			0	No	7	6	No	1	0	179.3 Å2	68.63 Å3	158.79 m3·mol-1	26	No	No	0.00146 mg/mL	1.24	-5.6	3.49	10.2			
C20H33NO7	Not Available	Not Available	399.484	COCCOC[C@H](CC1(CCCC1)C(=O)N[C@H]1CC[C@H](CC1)C(O)=O)C(O)=O	Solid	Not Available					50281657	3354	CHEMBL434492	16736848				C11721	D03349				443380	347828015				Candoxatril			Candoxatrilat	Experimental	DB11623	InChI=1S/C20H33NO7/c1-27-10-11-28-13-15(18(24)25)12-20(8-2-3-9-20)19(26)21-16-6-4-14(5-7-16)17(22)23/h14-16H,2-13H2,1H3,(H,21,26)(H,22,23)(H,24,25)/t14-,15-,16+/m0/s1	ACZWIDANLCXHBM-HRCADAONSA-N			Not Available	Small Molecule																																			1	Yes	7	3	No	2	-2	122.16 Å2	42.2 Å3	100.73 m3·mol-1	11	Yes	No	0.766 mg/mL	1.87	-2.7	4.08	0.48	P08473	MME	1. Neprilysin
C35H62N14O11S	Not Available	Not Available	887.03	CSCC[C@H](NC(=O)[C@H](CCC(O)=O)NC(=C)[C@H](CCC(O)=O)NC(C)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O	Not Available	Not Available								32700146									71587772	347828074		1314329		Acetyl_hexapeptide-3			Acetyl hexapeptide-3	Investigational	DB11709	InChI=1S/C35H62N14O11S/c1-18(20(45-19(2)50)9-12-27(52)53)44-23(10-13-28(54)55)31(58)49-25(14-17-61-3)33(60)48-24(8-11-26(36)51)32(59)47-22(7-5-16-43-35(40)41)30(57)46-21(29(37)56)6-4-15-42-34(38)39/h20-25,44H,1,4-17H2,2-3H3,(H2,36,51)(H2,37,56)(H,45,50)(H,46,57)(H,47,59)(H,48,60)(H,49,58)(H,52,53)(H,54,55)(H4,38,39,42)(H4,40,41,43)/t20-,21-,22-,23-,24-,25-/m0/s1	AJLNZWYOJAWBCR-OOPVGHQCSA-N	3		Not Available	Small Molecule																																			0	No	18	16	No	0	1	442.11 Å2	89.93 Å3	240.99 m3·mol-1	33	No	No	0.0981 mg/mL	-9.8	-4	3.55	12.09			
C41H62N12O11	Not Available	Not Available	899.02	[H][C@](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)([C@@H](C)CC)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N1CCC[C@H]1C(O)=O	Not Available	Not Available					85556	55438	CHEMBL3545347	110354									123805	347828083					ZINC000096077632		Angiotensin 1-7	Investigational	DB11720	InChI=1S/C41H62N12O11/c1-5-22(4)33(38(61)50-29(17-24-19-45-20-47-24)39(62)53-15-7-9-30(53)40(63)64)52-36(59)28(16-23-10-12-25(54)13-11-23)49-37(60)32(21(2)3)51-35(58)27(8-6-14-46-41(43)44)48-34(57)26(42)18-31(55)56/h10-13,19-22,26-30,32-33,54H,5-9,14-18,42H2,1-4H3,(H,45,47)(H,48,57)(H,49,60)(H,50,61)(H,51,58)(H,52,59)(H,55,56)(H,63,64)(H4,43,44,46)/t22-,26-,27-,28-,29-,30-,32-,33-/m0/s1	PVHLMTREZMEJCG-GDTLVBQBSA-N	2		Not Available	Small Molecule																																			0	No	16	13	Yes	3	1	377.24 Å2	92.45 Å3	238.19 m3·mol-1	25	No	No	0.0399 mg/mL	-6.3	-4.4	2.95	11.74			
C18H31N5O6	Not Available	Not Available	413.475	C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(N)=O	Not Available	Not Available							CHEMBL3544917	25069944									14539800	347828150				Rapastinel	ZINC000071773625		Rapastinel	Investigational	DB11801	InChI=1S/C18H31N5O6/c1-9(24)13(19)18(29)23-8-4-6-12(23)17(28)22-7-3-5-11(22)16(27)21-14(10(2)25)15(20)26/h9-14,24-25H,3-8,19H2,1-2H3,(H2,20,26)(H,21,27)/t9-,10-,11+,12+,13+,14+/m1/s1	GIBQQARAXHVEGD-BSOLPCOYSA-N	3		Not Available	Small Molecule																																			1	No	7	5	No	2	1	179.29 Å2	41.09 Å3	101.51 m3·mol-1	7	Yes	No	37.4 mg/mL	-3.7	-1	11.92	7.61			
C29H34N10O11S	Not Available	Not Available	730.71	N[C@@H](CNC(=O)CC[C@@H](NC(=O)C1=CC=C(NCC2=CNC3=NC=NC(=O)C3=N2)C=C1)C(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(O)=O	Not Available	Not Available								32702232									76958396	347828157				Technetium_(99mTc)_etarfolatide			Etarfolatide	Investigational	DB11810	InChI=1S/C29H34N10O11S/c30-16(25(44)38-18(7-21(41)42)26(45)39-19(11-51)29(49)50)10-32-20(40)6-5-17(28(47)48)37-24(43)13-1-3-14(4-2-13)31-8-15-9-33-23-22(36-15)27(46)35-12-34-23/h1-4,9,12,16-19,31,51H,5-8,10-11,30H2,(H,32,40)(H,37,43)(H,38,44)(H,39,45)(H,41,42)(H,47,48)(H,49,50)(H,33,34,35,46)/t16-,17+,18-,19-/m0/s1	YZSIZVRFVQKMJU-RDGPPVDQSA-N	2		Not Available	Small Molecule																																			0	No	17	11	Yes	3	-2	332.53 Å2	69.5 Å3	176.33 m3·mol-1	19	No	No	0.0697 mg/mL	-6.9	-4	2.87	7.1			
C25H40N2O6S	Not Available	Not Available	496.66	CCCCC\C=C/C\C=C/C=C/C=C/[C@@H](SC[C@H](N)C(=O)NCC(O)=O)[C@@H](O)CCCC(O)=O	Not Available	Not Available					50292408	28666	CHEMBL288943	4444401			HMDB0003080	C05951		LTD			5280878	347828197				Leukotriene_D4	ZINC000004632133		Leukotriene D4	Investigational	DB11858	InChI=1S/C25H40N2O6S/c1-2-3-4-5-6-7-8-9-10-11-12-13-16-22(21(28)15-14-17-23(29)30)34-19-20(26)25(33)27-18-24(31)32/h6-7,9-13,16,20-22,28H,2-5,8,14-15,17-19,26H2,1H3,(H,27,33)(H,29,30)(H,31,32)/b7-6-,10-9-,12-11+,16-13+/t20-,21-,22+/m0/s1	YEESKJGWJFYOOK-IJHYULJSSA-N			Not Available	Small Molecule																																			1	No	7	5	No	0	-1	149.95 Å2	56.08 Å3	140.42 m3·mol-1	20	Yes	No	0.00258 mg/mL	0.76	-5.3	3.29	8.05	Q9Y271;!Q9NS75	CYSLTR1;!CYSLTR2	1. Cysteinyl leukotriene receptor 1;!2. Cysteinyl leukotriene receptor 2
C8H15N3O4	Not Available	Not Available	217.225	C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(O)=O	Not Available	Not Available						74387	CHEMBL3707366	110464									123935	347828213		1359422			ZINC000002504612		Alanyl glutamine	Investigational	DB11876	InChI=1S/C8H15N3O4/c1-4(9)7(13)11-5(8(14)15)2-3-6(10)12/h4-5H,2-3,9H2,1H3,(H2,10,12)(H,11,13)(H,14,15)/t4-,5-/m0/s1	HJCMDXDYPOUFDY-WHFBIAKZSA-N	4	Alanyl glutamine is a dipeptide consisting of alanine and glutamine used for supplementation.	Not Available	Small Molecule																																			1	No	5	4	No	0	0	135.51 Å2	20.97 Å3	50.41 m3·mol-1	6	Yes	No	12.7 mg/mL	-4.5	-1.2	3.57	8.39			
C25H47N9O5	Not Available	Not Available	553.709	CC[C@H](C)C(NC(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(N)=O	Not Available	Not Available							CHEMBL3545314										71722017	347828216							Dusquetide	Investigational	DB11879	InChI=1S/C25H47N9O5/c1-6-14(4)19(33-21(36)16(26)9-7-11-30-25(28)29)23(38)32-18(13(2)3)24(39)34-12-8-10-17(34)22(37)31-15(5)20(27)35/h13-19H,6-12,26H2,1-5H3,(H2,27,35)(H,31,37)(H,32,38)(H,33,36)(H4,28,29,30)/t14-,15-,16-,17-,18-,19?/m0/s1	ZUJBBVJXXYRPFS-OUROWQTJSA-N	2		Not Available	Small Molecule																																			0	No	9	8	No	1	2	238.62 Å2	59.37 Å3	155.22 m3·mol-1	15	No	No	0.0992 mg/mL	-2.4	-3.8	12.21	11.74			
C36H53N7O6	One cycle of hemodialysis reduces difelikefalin plasma concentrations by 70-80% and no detectable drug remains after two cycles.4	The half-life of difelikefalin in hemodialysis patients prior to dialysis ranges between 23 and 31 hours.4	679.863	CC(C)C[C@@H](NC(=O)[C@@H](CC1=CC=CC=C1)NC(=O)[C@H](N)CC1=CC=CC=C1)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O	Solid	The mean volume of distribution of difelikefalin is approximately 238 mL/kg.4					235785		CHEMBL3989915	44208824									24794466	347828265		2569089		Difelikefalin		Korsuva	Difelikefalin	Approved, Investigational	DB11938	InChI=1S/C36H53N7O6/c1-24(2)21-29(32(45)40-28(15-9-10-18-37)34(47)43-19-16-36(39,17-20-43)35(48)49)42-33(46)30(23-26-13-7-4-8-14-26)41-31(44)27(38)22-25-11-5-3-6-12-25/h3-8,11-14,24,27-30H,9-10,15-23,37-39H2,1-2H3,(H,40,45)(H,41,44)(H,42,46)(H,48,49)/t27-,28-,29-,30-/m1/s1	FWMNVWWHGCHHJJ-SKKKGAJSSA-N	3	Difelikefalin is a kappa opioid receptor agonist used in the treatment of pruritus associated with chronic kidney disease in patients undergoing hemodialysis.	In clinical studies, single doses of up to 12 times (and multiple doses of up to 5 times) the recommended dosage of difelikefalin were administered in subjects undergoing hemodialysis.4 These patients experienced a dose-dependent increase in adverse reactions, including gastrointestinal effects and CNS depressant effects. In the event of overdosage, difelikefalin is dialyzable - 4 hours of high-flux hemodialysis effectively clears approximately 70-80% of the drug from plasma, and levels are likely to be undetectable following a second cycle.4	Small Molecule																																		Soluble	0	No	9	7	Yes	3	2	222.97 Å2	74.6 Å3	185.74 m3·mol-1	18	No	No	0.0103 mg/mL	-1.7	-4.8	1.92	10.26	P41145	OPRK1	1. Kappa-type opioid receptor
C32H49N9O5	Not Available	Not Available	639.802	CC1=CC(O)=CC(C)=C1C[C@H](NC(=O)[C@H](N)CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O	Not Available	Not Available							CHEMBL3833370	9939410									11764719	347828303				Elamipretide	ZINC000043130902		Elamipretide	Investigational	DB11981	InChI=1S/C32H49N9O5/c1-19-15-22(42)16-20(2)23(19)18-27(41-29(44)24(34)11-8-14-38-32(36)37)31(46)39-25(12-6-7-13-33)30(45)40-26(28(35)43)17-21-9-4-3-5-10-21/h3-5,9-10,15-16,24-27,42H,6-8,11-14,17-18,33-34H2,1-2H3,(H2,35,43)(H,39,46)(H,40,45)(H,41,44)(H4,36,37,38)/t24-,25+,26+,27+/m1/s1	SFVLTCAESLKEHH-WKAQUBQDSA-N	2		Not Available	Small Molecule																																			0	No	10	10	No	2	3	264.56 Å2	69.74 Å3	186.25 m3·mol-1	19	No	No	0.0155 mg/mL	-0.51	-4.6	9.62	11.84			
C30H49N9O9	Not Available	Not Available	679.776	CC(C)C(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O	Not Available	Not Available						135870	CHEMBL156025	26232604									451417	347828316		40230		Thymopentin			Thymopentin	Investigational	DB11996	InChI=1S/C30H49N9O9/c1-16(2)24(28(46)38-22(29(47)48)14-17-8-10-18(40)11-9-17)39-27(45)21(15-23(41)42)37-26(44)20(7-3-4-12-31)36-25(43)19(32)6-5-13-35-30(33)34/h8-11,16,19-22,24,40H,3-7,12-15,31-32H2,1-2H3,(H,36,43)(H,37,44)(H,38,46)(H,39,45)(H,41,42)(H,47,48)(H4,33,34,35)/t19-,20-,21-,22-,24?/m0/s1	PSWFFKRAVBDQEG-XXTQFKTOSA-N	3		Not Available	Small Molecule																																			0	No	14	11	No	1	1	327.67 Å2	70.84 Å3	171.76 m3·mol-1	22	No	No	0.0662 mg/mL	-6.3	-4	3.2	11.29			
C24H32N6O11	Not Available	Not Available	580.551	NCCCC[C@@H]1NC(=O)[C@H](CCC(O)=O)NC(=O)C2=C(OCC[C@H](NC1=O)C(=O)NCC(O)=O)C=CC(=C2)[N+]([O-])=O	Not Available	Not Available							CHEMBL3544981	7984131									9808372	347828682				Tavilermide	ZINC000136639443		Tavilermide	Investigational	DB12441	InChI=1S/C24H32N6O11/c25-9-2-1-3-15-23(37)29-17(22(36)26-12-20(33)34)8-10-41-18-6-4-13(30(39)40)11-14(18)21(35)27-16(24(38)28-15)5-7-19(31)32/h4,6,11,15-17H,1-3,5,7-10,12,25H2,(H,26,36)(H,27,35)(H,28,38)(H,29,37)(H,31,32)(H,33,34)/t15-,16-,17-/m0/s1	DVJXNXPFYJIACK-ULQDDVLXSA-N	3		Not Available	Small Molecule																																			0	No	12	7	No	2	-1	269.39 Å2	56.31 Å3	137.04 m3·mol-1	11	No	No	0.228 mg/mL	-4.8	-3.4	2.7	9.89			
C19H26IN3O7	Not Available	Not Available	531.337	OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNCC1=CC=C([123I])C=C1)C(O)=O)C(O)=O	Not Available	Not Available							CHEMBL496978	24707633									25194767	347828745					ZINC000100529249		Iofolastat I-123	Investigational	DB12514	InChI=1S/C19H26IN3O7/c20-13-6-4-12(5-7-13)11-21-10-2-1-3-14(17(26)27)22-19(30)23-15(18(28)29)8-9-16(24)25/h4-7,14-15,21H,1-3,8-11H2,(H,24,25)(H,26,27)(H,28,29)(H2,22,23,30)/t14-,15-/m0/s1/i20-4	OXUUJYOSVPMNKP-ZANJDRPYSA-N	1		Not Available	Small Molecule																																			0	No	8	6	No	1	-2	165.06 Å2	46.59 Å3	114.95 m3·mol-1	14	No	No	0.0925 mg/mL	-0.97	-3.8	2.83	9.54			
C36H60N10O12	Not Available	Not Available	824.934	CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O	Not Available	Not Available							CHEMBL2103826	8008132									9832404	347828827					ZINC000085540112		Davunetide	Investigational	DB12613	InChI=1S/C36H60N10O12/c1-6-18(4)28(35(56)46-14-8-9-23(46)31(52)41-21(36(57)58)11-12-25(38)48)44-30(51)22(16-47)42-33(54)27(17(2)3)43-32(53)24-10-7-13-45(24)34(55)19(5)40-29(50)20(37)15-26(39)49/h17-24,27-28,47H,6-16,37H2,1-5H3,(H2,38,48)(H2,39,49)(H,40,50)(H,41,52)(H,42,54)(H,43,53)(H,44,51)(H,57,58)/t18-,19-,20-,21-,22-,23-,24-,27-,28-/m0/s1	DWLTUUXCVGVRAV-XWRHUKJGSA-N	3		Not Available	Small Molecule																																			0	No	13	10	No	2	0	355.85 Å2	82.56 Å3	201.56 m3·mol-1	22	No	No	0.343 mg/mL	-7.5	-3.4	3.33	7.05			
C42H64N12O11	Not Available	Not Available	913.047	[H]N([C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N1CCC[C@H]1C(O)=O)C(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CCCC)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O	Not Available	Not Available								7987306									9811551	347828842							Aclerastide	Investigational	DB12631	InChI=1S/C42H64N12O11/c1-4-6-9-28(50-36(59)29(10-7-16-47-42(44)45)49-35(58)27(43)20-33(56)57)37(60)51-30(18-24-12-14-26(55)15-13-24)38(61)53-34(23(3)5-2)39(62)52-31(19-25-21-46-22-48-25)40(63)54-17-8-11-32(54)41(64)65/h12-15,21-23,27-32,34,55H,4-11,16-20,43H2,1-3H3,(H,46,48)(H,49,58)(H,50,59)(H,51,60)(H,52,62)(H,53,61)(H,56,57)(H,64,65)(H4,44,45,47)/t23-,27-,28-,29-,30-,31-,32-,34-/m0/s1	RUBMHAHMIJSMHA-LBWFYSSPSA-N	2		Not Available	Small Molecule																																			0	No	16	12	Yes	3	0	379.74 Å2	94.55 Å3	232.62 m3·mol-1	27	No	No	0.0352 mg/mL	-5.9	-4.4	2.95	10.84			
C27H35N5O7S	Not Available	The half life of metenkefalin is 4.2-39 minutes.7	573.67	CSCC[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1)C(O)=O	Not Available	Not Available	Q8N4T0	CPA6	1. Carboxypeptidase A6		50019056	6618	CHEMBL13786	391597				C11684					443363	347828872		1349278		Met-enkephalin	ZINC000004102171		Metenkefalin	Investigational	DB12668	InChI=1S/C27H35N5O7S/c1-40-12-11-21(27(38)39)32-26(37)22(14-17-5-3-2-4-6-17)31-24(35)16-29-23(34)15-30-25(36)20(28)13-18-7-9-19(33)10-8-18/h2-10,20-22,33H,11-16,28H2,1H3,(H,29,34)(H,30,36)(H,31,35)(H,32,37)(H,38,39)/t20-,21-,22-/m0/s1	YFGBQHOOROIVKG-FKBYEOEOSA-N	3	Metenkefalin is an investigational endogenous opioid being studied for the treatment of COVID-19.	Data regarding overdoses of metenkefalin are not readily available.7 Animal overdose studies have not determined an LD50.7	Small Molecule																																			0	No	8	7	No	2	0	199.95 Å2	58.85 Å3	149.01 m3·mol-1	16	No	No	0.0196 mg/mL	-2.5	-4.5	3.61	7.73	P41143;!P35372	OPRD1;!OPRM1	1. Delta-type opioid receptor;!2. Mu-type opioid receptor
C17H37N7O3	Not Available	Not Available	387.529	NCCCNCCCCNC(=O)C(O)NC(=O)CCCCCCNC(N)=N	Not Available	Not Available						135609	CHEMBL406117	49995									55362	347828893				Gusperimus			Gusperimus	Investigational	DB12692	InChI=1S/C17H37N7O3/c18-9-7-11-21-10-5-6-12-22-15(26)16(27)24-14(25)8-3-1-2-4-13-23-17(19)20/h16,21,27H,1-13,18H2,(H,22,26)(H,24,25)(H4,19,20,23)	IDINUJSAMVOPCM-UHFFFAOYSA-N	2		Not Available	Small Molecule																																			0	No	8	8	No	0	3	178.38 Å2	44.43 Å3	115.75 m3·mol-1	17	No	No	0.129 mg/mL	-3.1	-3.5	11.37	12.28			
C21H25N5O6	Not Available	Not Available	443.4531	NC1=NC(=O)C2=C(NC[C@H](CCC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C2)N1	Not Available	Not Available					22590		CHEMBL34412	130593						DDF			148138	347828954					ZINC000008577213		Lometrexol	Investigational	DB12769	InChI=1S/C21H25N5O6/c22-21-25-17-14(19(30)26-21)9-12(10-23-17)2-1-11-3-5-13(6-4-11)18(29)24-15(20(31)32)7-8-16(27)28/h3-6,12,15H,1-2,7-10H2,(H,24,29)(H,27,28)(H,31,32)(H4,22,23,25,26,30)/t12-,15+/m1/s1	ZUQBAQVRAURMCL-DOMZBBRYSA-N			Not Available	Small Molecule																																			1	No	10	6	Yes	3	-2	183.21 Å2	45.15 Å3	122 m3·mol-1	9	No	No	0.0911 mg/mL	-1	-3.7	3.03	4.75	P0ABQ4	folA	1. Dihydrofolate reductase
C16H26N2O6S2	Not Available	Not Available	406.51	C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)CCCC[C@@H]1CCSS1)C(O)=O	Not Available	Not Available							CHEMBL3099551	31125664									49802864	347828972					ZINC000034636021		CMX-2043	Investigational	DB12795	InChI=1S/C16H26N2O6S2/c1-10(16(23)24)17-15(22)12(6-7-14(20)21)18-13(19)5-3-2-4-11-8-9-25-26-11/h10-12H,2-9H2,1H3,(H,17,22)(H,18,19)(H,20,21)(H,23,24)/t10-,11+,12-/m0/s1	MQXRTCVZPIHBLD-TUAOUCFPSA-N	2		Not Available	Small Molecule																																			1	Yes	6	4	No	1	-2	132.8 Å2	41.75 Å3	99.76 m3·mol-1	12	Yes	No	0.0852 mg/mL	0.69	-3.7	3.5	-1.3			
C15H30N2O5	At steady state following once-daily subcutaneous administration of 20 mg and 40 mg pegvaliase, the mean ± SD (range) apparent clearance was 0.39 ± 0.87 L/h and 1.25 ± 2.46 L/h, respectively Label.	Following once-daily subcutaneous administration of 20 mg and 40 mg pegvaliase, the mean ± SD (range) half-life at steady state was 47 ± 42 (14 to 132) hours and 60 ± 45 (14 to 127) hours, respectively Label.	318.414	COCCOCCCCCC(=O)NCCCC[C@H](N)C(O)=O	Solid	The mean ± SD (range) apparent volume of distribution at steady state was 26.4 ± 64.8 (1.8 to 241) L and 22.2 ± 19.7 (3.1 to 49.5) L after once-daily subcutaneous administration of 20 mg and 40 mg pegvaliase, respectively Label.								58172730									86278362	347829004		2046360		Pegvaliase		Palynziq	Pegvaliase	Approved, Investigational	DB12839	InChI=1S/C15H30N2O5/c1-21-11-12-22-10-6-2-3-8-14(18)17-9-5-4-7-13(16)15(19)20/h13H,2-12,16H2,1H3,(H,17,18)(H,19,20)/t13-/m0/s1	NPOCDVAOUKODSQ-ZDUSSCGKSA-N	3	Pegvaliase is an enzyme used to treat phenylketonuria in patients with phenylalanine levels that are too high on current treatment.	No LD50 value has been reported for pegvaliase. A subcutaneous dose of 20 mg/kg/day of pegvaliase-pqpz produced impaired fertility in female rats leading to decreases in corpora lutea, implantations, and litter size, in association with toxic effects including decreased weight, ovarian weight, and food consumption Label. The carcinogenic and genototoxic potential have not been studied.	Small Molecule																																			1	No	6	3	No	0	0	110.88 Å2	36.89 Å3	83.41 m3·mol-1	15	Yes	No	0.63 mg/mL	-2	-2.7	2.24	9.53			
C17H37N7O3	Not Available	Not Available	387.529	NCCCNCCCCNC(=O)[C@H](O)NC(=O)CCCCCCNC(N)=N	Not Available	Not Available							CHEMBL1172736	82420									91272	347829130					ZINC000004215557		Deoxyspergualin	Investigational	DB12991	InChI=1S/C17H37N7O3/c18-9-7-11-21-10-5-6-12-22-15(26)16(27)24-14(25)8-3-1-2-4-13-23-17(19)20/h16,21,27H,1-13,18H2,(H,22,26)(H,24,25)(H4,19,20,23)/t16-/m0/s1	IDINUJSAMVOPCM-INIZCTEOSA-N	2		Not Available	Small Molecule																																			0	No	8	8	No	0	3	178.38 Å2	44.84 Å3	115.75 m3·mol-1	17	No	No	0.129 mg/mL	-3.1	-3.5	11.37	12.28			
C19H25IN4O8	Not Available	Not Available	560.335	OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)NC1=CC=C([123I])C=C1)C(O)=O)C(O)=O	Not Available	Not Available							CHEMBL498623	24708821									25168442	347829132					ZINC000101669568		MIP-1095 I-123	Investigational	DB12994	InChI=1S/C19H25IN4O8/c20-11-4-6-12(7-5-11)22-18(31)21-10-2-1-3-13(16(27)28)23-19(32)24-14(17(29)30)8-9-15(25)26/h4-7,13-14H,1-3,8-10H2,(H,25,26)(H,27,28)(H,29,30)(H2,21,22,31)(H2,23,24,32)/t13-,14-/m0/s1/i20-4	LFEGKCKGGNXWDV-NKNRFTOXSA-N			Not Available	Small Molecule																																			0	No	8	7	No	1	-3	194.16 Å2	49.2 Å3	120.13 m3·mol-1	13	No	No	0.101 mg/mL	1.35	-3.8	3.09				
C51H84N16O21	Not Available	Not Available	1257.324	CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O	Not Available	Not Available							CHEMBL3545305	35013013									91810664	347829143							Cibinetide	Investigational	DB13006	InChI=1S/C51H84N16O21/c1-22(2)17-30(47(84)65-32(19-36(53)71)48(85)66-33(20-68)49(86)67-34(21-69)50(87)88)63-40(77)24(5)57-41(78)25(7-6-16-56-51(54)55)59-43(80)29(11-15-39(75)76)62-46(83)31(18-23(3)4)64-45(82)27(8-12-35(52)70)60-44(81)28(10-14-38(73)74)61-42(79)26-9-13-37(72)58-26/h22-34,68-69H,6-21H2,1-5H3,(H2,52,70)(H2,53,71)(H,57,78)(H,58,72)(H,59,80)(H,60,81)(H,61,79)(H,62,83)(H,63,77)(H,64,82)(H,65,84)(H,66,85)(H,67,86)(H,73,74)(H,75,76)(H,87,88)(H4,54,55,56)/t24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-/m0/s1	WZTIQQBMSJTRBR-WYKNNRPVSA-N	2		Not Available	Small Molecule																																			0	No	24	21	No	1	-2	620.54 Å2	124.09 Å3	306.97 m3·mol-1	42	No	No	0.232 mg/mL	-12	-3.7	2.91	11.67			
C26H42N6O12S2	Not Available	Not Available	694.77	CSCC[C@H](NC=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O	Not Available	Not Available						125492		34979857									44628955	347829167					ZINC000068077856		Foxy-5	Investigational	DB13034	InChI=1S/C26H42N6O12S2/c1-13(2)8-17(26(43)44)32-24(41)15(4-5-20(35)36)30-25(42)18(11-45)29-19(34)10-27-22(39)16(9-21(37)38)31-23(40)14(28-12-33)6-7-46-3/h12-18,45H,4-11H2,1-3H3,(H,27,39)(H,28,33)(H,29,34)(H,30,42)(H,31,40)(H,32,41)(H,35,36)(H,37,38)(H,43,44)/t14-,15-,16-,17-,18-/m0/s1	WFZPJYYCTSHDJI-ATIWLJMLSA-N	1		Not Available	Small Molecule																																			0	No	12	10	No	0	-3	286.5 Å2	67.64 Å3	162.76 m3·mol-1	23	No	No	0.033 mg/mL	-3.1	-4.3	3.39				
C28H39N7O9	Not Available	Not Available	617.66	C[C@@H](NC(=O)CNC(=O)[C@H]1C[C@H](O)CN1C(=O)[C@H]1CCCN1C(=O)[C@@H](CC1=CC=C(O)C=C1)NC(C)=O)C(=O)NCC(N)=O	Not Available	Not Available							CHEMBL450656	8114558									9938933	347829195				Rotigaptide	ZINC000014175498		Rotigaptide	Investigational	DB13067	InChI=1S/C28H39N7O9/c1-15(25(41)30-12-23(29)39)32-24(40)13-31-26(42)22-11-19(38)14-35(22)28(44)21-4-3-9-34(21)27(43)20(33-16(2)36)10-17-5-7-18(37)8-6-17/h5-8,15,19-22,37-38H,3-4,9-14H2,1-2H3,(H2,29,39)(H,30,41)(H,31,42)(H,32,40)(H,33,36)/t15-,19+,20-,21-,22-/m1/s1	GFJRASPBQLDRRY-TWTQBQJDSA-N	-Infinity		Not Available	Small Molecule																																			0	No	9	7	Yes	3	0	240.57 Å2	62.08 Å3	152.56 m3·mol-1	12	No	No	1.56 mg/mL	-4.6	-2.6	9.5	-1.9			
C65H104N18O26S4	No excretion studies have been conducted in humans.	half-life (t½) cannot be calculated due to negligible systemic absorbance	1681.89	[H][C@@]12CSSC[C@H](NC(=O)CNC(=O)[C@@]([H])(NC(=O)[C@]([H])(CSSC[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC2=O)C(C)C)C(C)C)[C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O	Solid	Concentrations of plecanatide and its active metabolite in plasma are below the limit of quantitation after an oral dose of 3 mg. Therefore, the volume of distribution can not be calculated.							CHEMBL2103867	28530494									70693500	347829276		1873752		Plecanatide		Trulance	Plecanatide	Approved, Investigational	DB13170	InChI=1S/C65H104N18O26S4/c1-25(2)15-34-55(98)80-41-24-113-110-21-38(58(101)77-37(65(108)109)16-26(3)4)71-44(87)20-69-62(105)50(30(10)84)83-61(104)40(78-51(94)29(9)70-63(106)48(27(5)6)81-57(100)35(18-43(68)86)76-64(107)49(28(7)8)82-60(41)103)23-112-111-22-39(59(102)73-32(53(96)75-34)11-13-45(88)89)79-54(97)33(12-14-46(90)91)72-56(99)36(19-47(92)93)74-52(95)31(66)17-42(67)85/h25-41,48-50,84H,11-24,66H2,1-10H3,(H2,67,85)(H2,68,86)(H,69,105)(H,70,106)(H,71,87)(H,72,99)(H,73,102)(H,74,95)(H,75,96)(H,76,107)(H,77,101)(H,78,94)(H,79,97)(H,80,98)(H,81,100)(H,82,103)(H,83,104)(H,88,89)(H,90,91)(H,92,93)(H,108,109)/t29-,30+,31-,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,48-,49-,50-/m0/s1	NSPHQWLKCGGCQR-DLJDZFDSSA-N	3	Plecanatide is a laxative used to treat chronic idiopathic constipation and IBS with constipation.	Single oral doses of plecanatide at 0.5 mg/kg and 10 mg/kg caused mortality in young juvenile mice on postnatal days 7 and 14, respectively (human age equivalent of approximately 1 month to less than 2 years).	Small Molecule																																			0	No	44	25	No	2	-8	772.46 Å2	164.58 Å3	427.55 m3·mol-1	28	No	No	0.25 mg/mL	3.71	-3.8	2.43		P33402	GUCY1A2	1. Guanylate cyclase soluble subunit alpha-2
C18H26N2O4	Not Available	Not Available	334.416	CCCN(CCC)C(=O)C(CCC(O)=O)NC(=O)C1=CC=CC=C1	Not Available	Not Available					50014888	32058	CHEMBL316561	4753												8730		Proglumide			Proglumide	Experimental	DB13431	InChI=1S/C18H26N2O4/c1-3-12-20(13-4-2)18(24)15(10-11-16(21)22)19-17(23)14-8-6-5-7-9-14/h5-9,15H,3-4,10-13H2,1-2H3,(H,19,23)(H,21,22)	DGMKFQYCZXERLX-UHFFFAOYSA-N			Not Available	Small Molecule																																			1	Yes	4	2	No	1	-1	86.71 Å2	36.7 Å3	91.56 m3·mol-1	10	Yes	No	0.145 mg/mL	2.14	-3.4	4.42	-1.2			
C10H19NO5	Not Available	Not Available	233.264	CC(C)(CO)[C@@H](O)C(=O)NCCCC(O)=O	Solid	Not Available						134949	CHEMBL2110783	26309					D08042									Hopantenic_acid	ZINC000002017228		Hopantenic acid	Experimental	DB14044	InChI=1S/C10H19NO5/c1-10(2,6-12)8(15)9(16)11-5-3-4-7(13)14/h8,12,15H,3-6H2,1-2H3,(H,11,16)(H,13,14)/t8-/m0/s1	SBBDHANTMHIRGW-QMMMGPOBSA-N			Not Available	Small Molecule																																			1	No	5	4	No	0	-1	106.86 Å2	23.92 Å3	56.27 m3·mol-1	7	Yes	No	40.1 mg/mL	-1.1	-0.77	4.37	-2.8			
C56H88N12O20	Not Available	Not Available	1249.384	CC(C)CC\C=C/C=C/C(=O)N[C@@H](C(C)C(O)=O)C(=O)N[C@H]1C(C)NC(=O)[C@@H]2C[C@@H](C)CN2C(=O)[C@@H](NC(=O)[C@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](NC1=O)C(C)C)C(O)C(O)=O)C(C)C(O)=O)C(C)C	Solid	Not Available						140173																Malacidin			Malacidin A	Experimental	DB14051	InChI=1S/C56H88N12O20/c1-25(2)17-13-11-12-14-19-35(69)62-40(29(8)54(83)84)50(79)66-42-31(10)59-47(76)34-21-28(7)24-68(34)53(82)39(27(5)6)65-49(78)41(30(9)55(85)86)63-36(70)23-58-45(74)33(22-37(71)72)61-52(81)43(44(73)56(87)88)67-46(75)32(18-15-16-20-57)60-48(77)38(26(3)4)64-51(42)80/h11-12,14,19,25-34,38-44,73H,13,15-18,20-24,57H2,1-10H3,(H,58,74)(H,59,76)(H,60,77)(H,61,81)(H,62,69)(H,63,70)(H,64,80)(H,65,78)(H,66,79)(H,67,75)(H,71,72)(H,83,84)(H,85,86)(H,87,88)/b12-11-,19-14+/t28-,29?,30?,31?,32+,33+,34+,38-,39+,40+,41-,42+,43+,44?/m1/s1	USNOUEMKNKRWQT-ORRWAHHJSA-N			Malacidin A has no observed toxicity or haemolytic effect on mammalian cells at concentrations of up to 100-250 μg/mL, over 100 times the MIC for affected pathogens 1.	Small Molecule																																			0	No	21	16	No	2	-3	506.76 Å2	127.11 Å3	306.63 m3·mol-1	22	No	No	0.0197 mg/mL	-6	-4.8	2.8	10.18			1. NAM/NAG peptide subunits of peptidoglycan
C57H90N12O20	Not Available	Not Available	1263.411	CCC(C)CC\C=C/C=C/C(=O)N[C@@H](C(C)C(O)=O)C(=O)N[C@H]1C(C)NC(=O)[C@@H]2C[C@@H](C)CN2C(=O)[C@@H](NC(=O)[C@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](NC1=O)C(C)C)C(O)C(O)=O)C(C)C(O)=O)C(C)C	Solid	Not Available						140174																			Malacidin B	Experimental	DB14052	InChI=1S/C57H90N12O20/c1-11-28(6)18-14-12-13-15-20-36(70)63-41(30(8)55(84)85)51(80)67-43-32(10)60-48(77)35-22-29(7)25-69(35)54(83)40(27(4)5)66-50(79)42(31(9)56(86)87)64-37(71)24-59-46(75)34(23-38(72)73)62-53(82)44(45(74)57(88)89)68-47(76)33(19-16-17-21-58)61-49(78)39(26(2)3)65-52(43)81/h12-13,15,20,26-35,39-45,74H,11,14,16-19,21-25,58H2,1-10H3,(H,59,75)(H,60,77)(H,61,78)(H,62,82)(H,63,70)(H,64,71)(H,65,81)(H,66,79)(H,67,80)(H,68,76)(H,72,73)(H,84,85)(H,86,87)(H,88,89)/b13-12-,20-15+/t28?,29-,30?,31?,32?,33+,34+,35+,39-,40+,41+,42-,43+,44+,45?/m1/s1	SMTCDPMWINUUKC-AVBBYWJWSA-N			Malacidin B has no observed toxicity or haemolytic effect on mammalian cells at concentrations of up to 100-250 μg/mL, over 100 times the MIC for affected pathogens 1.	Small Molecule																																			0	No	21	16	No	2	-3	506.76 Å2	129.37 Å3	311.23 m3·mol-1	23	No	No	0.0167 mg/mL	-5.6	-4.9	2.8	10.18			1. NAM/NAG peptide subunits of peptidoglycan
C22H24N2O5	Not Available	Not Available	396.4364	[H][C@@]1(CCC2=CC=CC=C2N(CC(O)=O)C1=O)N[C@@H](CCC1=CC=CC=C1)C(O)=O	Not Available	Not Available					50021127	88200	CHEMBL1192519	4576478			HMDB0060582		D03077							1546196		Benazepril	ZINC000003814184		Benazeprilat	Experimental	DB14125	InChI=1S/C22H24N2O5/c25-20(26)14-24-19-9-5-4-8-16(19)11-13-17(21(24)27)23-18(22(28)29)12-10-15-6-2-1-3-7-15/h1-9,17-18,23H,10-14H2,(H,25,26)(H,28,29)/t17-,18-/m0/s1	MADRIHWFJGRSBP-ROUUACIJSA-N			Not Available	Small Molecule																																			1	Yes	6	3	Yes	3	-1	106.94 Å2	41.41 Å3	105.71 m3·mol-1	8	Yes	No	0.0285 mg/mL	0.15	-4.1	3.08	7.96			
C22H25NO5	Not Available	Not Available	383.444	C[C@H](C[C@@H](CC1=CC=C(C=C1)C1=CC=CC=C1)NC(=O)CCC(O)=O)C(O)=O	Not Available	Not Available					50034842		CHEMBL417007	8605468						6LD						1860608		Sacubitrilat	ZINC000001536201		Sacubitrilat	Experimental	DB14127	InChI=1S/C22H25NO5/c1-15(22(27)28)13-19(23-20(24)11-12-21(25)26)14-16-7-9-18(10-8-16)17-5-3-2-4-6-17/h2-10,15,19H,11-14H2,1H3,(H,23,24)(H,25,26)(H,27,28)/t15-,19+/m1/s1	DOBNVUFHFMVMDB-BEFAXECRSA-N			Not Available	Small Molecule																																			1	Yes	5	3	No	2	-2	103.7 Å2	41.61 Å3	104.54 m3·mol-1	10	Yes	No	0.00358 mg/mL	3.29	-5	3.98	-1.6			
C34H62N8O7	Not Available	Not Available	694.919	[H]N([H])C(=O)CC[C@H](N([H])C(=O)CN([H])C(=O)CCCCCCCCCCCCCCC)C(=O)N1CCC[C@H]1C(=O)N([H])[C@@H](CCCN=C(N([H])[H])N([H])[H])C(O)=O	Not Available	Not Available								8253946												1314277			ZINC000163851498		Palmitoyl tetrapeptide-7	Experimental	DB14137	InChI=1S/C34H62N8O7/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-19-29(44)39-24-30(45)40-25(20-21-28(35)43)32(47)42-23-16-18-27(42)31(46)41-26(33(48)49)17-15-22-38-34(36)37/h25-27H,2-24H2,1H3,(H2,35,43)(H,39,44)(H,40,45)(H,41,46)(H,48,49)(H4,36,37,38)/t25-,26-,27-/m0/s1	IHRKJQSLKLYWBQ-QKDODKLFSA-N			Not Available	Small Molecule																																			0	No	10	7	No	1	0	252.4 Å2	79.54 Å3	185.21 m3·mol-1	28	No	No	0.00556 mg/mL	0.045	-5.1	3.54	11.23			
C21H28N2O5	Not Available	Not Available	388.4574	[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(O)=O	Not Available	Not Available						77363	CHEMBL1201365	4576531			HMDB0060579			X92						1546377			ZINC000004217399		Ramiprilat	Experimental	DB14208	InChI=1S/C21H28N2O5/c1-13(22-16(20(25)26)11-10-14-6-3-2-4-7-14)19(24)23-17-9-5-8-15(17)12-18(23)21(27)28/h2-4,6-7,13,15-18,22H,5,8-12H2,1H3,(H,25,26)(H,27,28)/t13-,15-,16-,17-,18-/m0/s1	KEDYTOTWMPBSLG-HILJTLORSA-N			Not Available	Small Molecule																																			1	Yes	6	3	Yes	3	-1	106.94 Å2	40.37 Å3	101.67 m3·mol-1	8	Yes	No	0.214 mg/mL	-0.18	-3.3	3.13	8.05			
C22H30N2O5	Not Available	Not Available	402.484	[H][C@@](C)(N[C@@]([H])(CCC1=CC=CC=C1)C(O)=O)C(=O)N1[C@@]([H])(C[C@@]2([H])CCCC[C@]12[H])C(O)=O	Not Available	Not Available						141521	CHEMBL1201387	4576532			HMDB0060583			X93						1546379			ZINC000003784432		Trandolaprilat	Experimental	DB14209	InChI=1S/C22H30N2O5/c1-14(23-17(21(26)27)12-11-15-7-3-2-4-8-15)20(25)24-18-10-6-5-9-16(18)13-19(24)22(28)29/h2-4,7-8,14,16-19,23H,5-6,9-13H2,1H3,(H,26,27)(H,28,29)/t14-,16+,17-,18-,19-/m0/s1	AHYHTSYNOHNUSH-HXFGRODQSA-N			Not Available	Small Molecule																																			1	Yes	6	3	Yes	3	-1	106.94 Å2	42.91 Å3	106.27 m3·mol-1	8	Yes	No	0.0834 mg/mL	0.19	-3.7	3.13	8.04			
C17H28N2O5	Not Available	Not Available	340.4146	[H][C@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC)C(O)=O)[C@@]1([H])CCCC2)C(O)=O	Not Available	Not Available						132041	CHEMBL1201368	65017			HMDB0060574			X94						1546400			ZINC000004217270		Perindoprilat	Experimental	DB14213	InChI=1S/C17H28N2O5/c1-3-6-12(16(21)22)18-10(2)15(20)19-13-8-5-4-7-11(13)9-14(19)17(23)24/h10-14,18H,3-9H2,1-2H3,(H,21,22)(H,23,24)/t10-,11-,12-,13-,14-/m0/s1	ODAIHABQVKJNIY-PEDHHIEDSA-N			Not Available	Small Molecule																																			1	No	6	3	No	2	-1	106.94 Å2	35.8 Å3	86.18 m3·mol-1	7	Yes	No	7.2 mg/mL	-0.85	-1.7	3.08	8.06			
C23H26N2O5	Not Available	Not Available	410.4629	C[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N1CC2=C(C[C@H]1C(O)=O)C=CC=C2	Not Available	Not Available					50367258	140296	CHEMBL1733	97106			HMDB0042005									1546359		Quinaprilat	ZINC000004217387		Quinaprilat	Experimental	DB14217	InChI=1S/C23H26N2O5/c1-15(24-19(22(27)28)12-11-16-7-3-2-4-8-16)21(26)25-14-18-10-6-5-9-17(18)13-20(25)23(29)30/h2-10,15,19-20,24H,11-14H2,1H3,(H,27,28)(H,29,30)/t15-,19-,20-/m0/s1	FLSLEGPOVLMJMN-YSSFQJQWSA-N			Not Available	Small Molecule																																			1	Yes	6	3	Yes	3	-1	106.94 Å2	42.76 Å3	110.44 m3·mol-1	8	Yes	No	0.0359 mg/mL	0.3	-4.1	3.07	7.8			
C14H23CuN6O4	Not Available	Prezatide is rapidly eliminated within minutes 5.	402.921	[Cu++].NCCCC[C@H](NC(=O)[C@H](CC1=CN=CN1)NC(=O)CN)C([O-])=O	Not Available	Not Available								32698045																	Prezatide copper	Experimental	DB14683	InChI=1S/C14H24N6O4.Cu/c15-4-2-1-3-10(14(23)24)20-13(22)11(19-12(21)6-16)5-9-7-17-8-18-9;/h7-8,10-11H,1-6,15-16H2,(H,17,18)(H,19,21)(H,20,22)(H,23,24);/q;+2/p-1/t10-,11-;/m0./s1	NZWIFMYRRCMYMN-ACMTZBLWSA-M			Not Available	Small Molecule																																			1	No	7	5	No	1	2	179.05 Å2	34.21 Å3	96.31 m3·mol-1	11	Yes	No	2.08 mg/mL	-5.4	-2.3	3.46	10.2			
C16H19FN2O7S	Not Available	Not Available	401.4	OC(=O)CC[C@H](NC(=O)N[C@@H](CSCC1=CC=C([18F])C=C1)C(O)=O)C(O)=O	Not Available	Not Available								32701129																	DCFBC F-18	Investigational	DB14772	InChI=1S/C16H19FN2O7S/c17-10-3-1-9(2-4-10)7-27-8-12(15(24)25)19-16(26)18-11(14(22)23)5-6-13(20)21/h1-4,11-12H,5-8H2,(H,20,21)(H,22,23)(H,24,25)(H2,18,19,26)/t11-,12-/m0/s1/i17-1	IDTMSHGCAZPVLC-STUNTBJNSA-N	2		Not Available	Small Molecule																																			1	Yes	7	5	No	1	-3	153.03 Å2	37.9 Å3	92.14 m3·mol-1	11	Yes	No	0.09 mg/mL	1.02	-3.6	3.11	-2.5			
C18H23FN4O8	Not Available	The half-life of distribution of piflufolastat F18 is 0.17 ± 0.044 hours and its elimination half-life is 3.47 ± 0.49 hours.3	441.403	OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)C1=CC=C([18F])N=C1)C(O)=O)C(O)=O	Liquid	Within 60 minutes of intravenous administration, piflufolastat F18 distributes to the kidneys, liver, and lungs.3							CHEMBL4297334	32702072												2556616				Pylarify	Piflufolastat F 18	Approved, Investigational	DB14805	InChI=1S/C18H23FN4O8/c19-13-6-4-10(9-21-13)15(26)20-8-2-1-3-11(16(27)28)22-18(31)23-12(17(29)30)5-7-14(24)25/h4,6,9,11-12H,1-3,5,7-8H2,(H,20,26)(H,24,25)(H,27,28)(H,29,30)(H2,22,23,31)/t11-,12-/m0/s1/i19-1	OLWVRJUNLXQDSP-MVBOSPHXSA-N	3	Piflufolastat F 18 is a radiopharmaceutical diagnostic agent used with PET to image PSMA-positive lesions for the diagnosis of metastatic or recurrent prostate cancer.	There are no data regarding the effects of overdosage with piflufolastat F18. In the event of overdose, the amount of absorbed radiation can be mitigated by administered fluids and encouraging frequent bladder voiding. The use of diuretics to encourage voiding may also be considered.3	Small Molecule																																			0	Yes	9	6	No	1	-3	195.02 Å2	42 Å3	101.38 m3·mol-1	13	No	No	0.191 mg/mL	-0.32	-3.4	2.99		Q04609	FOLH1	1. Glutamate carboxypeptidase 2
C46H75N13O15	Not Available	Not Available	1050.182	C[C@@H](O)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)CNC(C)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O	Not Available	Not Available								9796945																	BIO-11006	Investigational	DB14886	InChI=1S/C46H75N13O15/c1-24(51-36(64)22-50-28(5)62)39(66)54-31(17-18-35(49)63)41(68)57-33(21-29-13-7-6-8-14-29)43(70)58-34(23-60)44(71)55-30(15-9-11-19-47)42(69)59-37(27(4)61)45(72)53-25(2)38(65)52-26(3)40(67)56-32(46(73)74)16-10-12-20-48/h6-8,13-14,24-27,30-34,37,60-61H,9-12,15-23,47-48H2,1-5H3,(H2,49,63)(H,50,62)(H,51,64)(H,52,65)(H,53,72)(H,54,66)(H,55,71)(H,56,67)(H,57,68)(H,58,70)(H,59,69)(H,73,74)/t24-,25-,26-,27+,30-,31-,32-,33-,34-,37-/m0/s1	KCSNGWMKFYVMKF-HGYIIGRXSA-N	2		Not Available	Small Molecule																																			0	No	17	16	No	1	1	463.89 Å2	107.51 Å3	260.49 m3·mol-1	35	No	No	0.0404 mg/mL	-10	-4.4	3.66	10.47			
C22H39N9O11S	Not Available	Not Available	637.67	C[C@@H](O)[C@H](NC(=O)[C@H](CS(O)(=O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)CN)C(=O)N1CCC[C@H]1C(O)=O	Not Available	Not Available								68057558																	Risuteganib	Investigational	DB14911	InChI=1S/C22H39N9O11S/c1-11(32)17(20(37)31-7-3-5-14(31)21(38)39)30-19(36)13(10-43(40,41)42)29-16(34)9-27-18(35)12(28-15(33)8-23)4-2-6-26-22(24)25/h11-14,17,32H,2-10,23H2,1H3,(H,27,35)(H,28,33)(H,29,34)(H,30,36)(H,38,39)(H4,24,25,26)(H,40,41,42)/t11-,12+,13+,14+,17+/m1/s1	MYZAXBZLEILEBR-RVFOSREFSA-N	2		Not Available	Small Molecule																																			0	No	15	11	No	1	0	336.53 Å2	61.64 Å3	155.01 m3·mol-1	17	No	No	0.643 mg/mL	-12	-3	-1.4	12.7			
C28H40FN4O14P	Not Available	Not Available	706.6078	OC(=O)CC[C@H](NP(O)(=O)OCCC[C@H](NC(=O)CC[C@H](NC(=O)CCCCCNC(=O)C1=CC=C(F)C=C1)C(O)=O)C(O)=O)C(O)=O	Not Available	Not Available					50088185		CHEMBL3427435	35034402						T57									ZINC000098209433		CTT-1057	Investigational	DB14965	InChI=1S/C28H40FN4O14P/c29-18-9-7-17(8-10-18)25(38)30-15-3-1-2-6-22(34)32-20(27(41)42)11-13-23(35)31-19(26(39)40)5-4-16-47-48(45,46)33-21(28(43)44)12-14-24(36)37/h7-10,19-21H,1-6,11-16H2,(H,30,38)(H,31,35)(H,32,34)(H,36,37)(H,39,40)(H,41,42)(H,43,44)(H2,33,45,46)/t19-,20-,21-/m0/s1	IZLOSIXADNUSCM-ACRUOGEOSA-N	1		Not Available	Small Molecule																																			0	No	13	9	No	1	-5	295.06 Å2	67.71 Å3	160.1 m3·mol-1	25	No	No	0.0209 mg/mL	-0.59	-4.5	2.77				
C19H25IN4O8	Not Available	Not Available	568.335	OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)NC1=CC=C([131I])C=C1)C(O)=O)C(O)=O	Not Available	Not Available								64854190																	MIP-1095 I-131	Investigational	DB14978	InChI=1S/C19H25IN4O8/c20-11-4-6-12(7-5-11)22-18(31)21-10-2-1-3-13(16(27)28)23-19(32)24-14(17(29)30)8-9-15(25)26/h4-7,13-14H,1-3,8-10H2,(H,25,26)(H,27,28)(H,29,30)(H2,21,22,31)(H2,23,24,32)/t13-,14-/m0/s1/i20+4	LFEGKCKGGNXWDV-LUOJOMRDSA-N	1		Not Available	Small Molecule																																			0	No	8	7	No	1	-3	194.16 Å2	49.69 Å3	120.13 m3·mol-1	13	No	No	0.101 mg/mL	1.35	-3.8	3.09				
C27H44N10O6	Not Available	Not Available	604.713	CC(C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C=O	Not Available	Not Available							CHEMBL1230912	34678														Antipain	ZINC000008716755		Antipain	Experimental	DB15251	InChI=1S/C27H44N10O6/c1-16(2)21(23(40)34-18(15-38)10-6-12-32-25(28)29)37-22(39)19(11-7-13-33-26(30)31)35-27(43)36-20(24(41)42)14-17-8-4-3-5-9-17/h3-5,8-9,15-16,18-21H,6-7,10-14H2,1-2H3,(H,34,40)(H,37,39)(H,41,42)(H4,28,29,32)(H4,30,31,33)(H2,35,36,43)/t18-,19-,20-,21-/m0/s1	SDNYTAYICBFYFH-TUFLPTIASA-N			Not Available	Small Molecule																																			0	No	12	11	No	1	1	277.5 Å2	63.74 Å3	178.23 m3·mol-1	19	No	No	0.0835 mg/mL	-3.4	-3.9	3.42	12.05			
C28H29FN2O4	Not Available	Not Available	476.548	CC(C)(CC1=CC=C(F)C=C1)NC(=O)[C@H](CCC(O)=O)NC(=O)C1=CC=C(C=C1)C1=CC=CC=C1	Not Available	Not Available								13176829																	AGG-523	Investigational	DB15460	InChI=1S/C28H29FN2O4/c1-28(2,18-19-8-14-23(29)15-9-19)31-27(35)24(16-17-25(32)33)30-26(34)22-12-10-21(11-13-22)20-6-4-3-5-7-20/h3-15,24H,16-18H2,1-2H3,(H,30,34)(H,31,35)(H,32,33)/t24-/m0/s1	JWQMTWCFNZSLNR-DEOSSOPVSA-N	1		Not Available	Small Molecule																																			1	No	4	3	Yes	3	-1	95.5 Å2	50.96 Å3	131.9 m3·mol-1	10	Yes	No	0.000355 mg/mL	4.66	-6.1	4.25	-1.2			
C8H13N3O5S	Not Available	Not Available	263.27	OC(=O)CNC(=O)CNC(=O)CNC(=O)CS	Not Available	Not Available							CHEMBL1615778	54775															ZINC000004194756		Mertiatide	Experimental	DB15780	InChI=1S/C8H13N3O5S/c12-5(2-10-7(14)4-17)9-1-6(13)11-3-8(15)16/h17H,1-4H2,(H,9,12)(H,10,14)(H,11,13)(H,15,16)	RXACEEPNTRHYBQ-UHFFFAOYSA-N		Mertiatide is a radiopharmaceutical reconstituted with sodium pertechnetate for imaging of the kidney.	Not Available	Small Molecule																																			1	No	5	5	No	0	-1	124.6 Å2	24.44 Å3	58.88 m3·mol-1	7	Yes	No	0.29 mg/mL	-3.3	-3	3.64	-4.2			
C21H29N3O5	Not Available	Not Available	403.479	CC(C)C[C@H](NC(=O)OCC1=CC=CC=C1)C(=O)N[C@@H](CC1CCNC1=O)C=O	Not Available	Not Available							CHEMBL1821850	26617691																	GC-373	Experimental	DB15797	InChI=1S/C21H29N3O5/c1-14(2)10-18(24-21(28)29-13-15-6-4-3-5-7-15)20(27)23-17(12-25)11-16-8-9-22-19(16)26/h3-7,12,14,16-18H,8-11,13H2,1-2H3,(H,22,26)(H,23,27)(H,24,28)/t16?,17-,18-/m0/s1	QYENXTYKACLCGO-FQECFTEESA-N			Not Available	Small Molecule																																			1	Yes	4	3	No	2	0	113.6 Å2	42.97 Å3	106.58 m3·mol-1	11	Yes	No	0.0386 mg/mL	1.28	-4	12.68	-1.6	K9N7C7;!K9N638;!P0DTD1;!P0DTC1;!Q98VG9	rep;!Not Available;!rep;!Not Available;!rep	1. Replicase polyprotein 1ab;!2. Replicase polyprotein 1a;!3. Replicase polyprotein 1ab;!4. Replicase polyprotein 1a;!5. Replicase polyprotein 1ab
C7H13N3O4	Not Available	Not Available	203.198	NCC(=O)N[C@@H](CCC(N)=O)C(O)=O	Not Available	Not Available						74392	CHEMBL330038	110444															ZINC000002555108		Glycylglutamine	Experimental	DB15990	InChI=1S/C7H13N3O4/c8-3-6(12)10-4(7(13)14)1-2-5(9)11/h4H,1-3,8H2,(H2,9,11)(H,10,12)(H,13,14)/t4-/m0/s1	PNMUAGGSDZXTHX-BYPYZUCNSA-N		Glycylglutamine is an ingredient in amino acid solutions for parenteral nutrition.	Not Available	Small Molecule																																			1	No	5	4	No	0	0	135.51 Å2	19.22 Å3	45.91 m3·mol-1	6	Yes	No	17.4 mg/mL	-5.1	-1.1	3.48	8.14			
C16H27N3O6	Not Available	Not Available	357.407	N[C@H](CC1CCCCC1)C(=O)N[C@H](CCC(O)=O)C(=O)NCC(O)=O	Not Available	Not Available								8301633															ZINC000034269848		AIM-102	Investigational	DB16176	InChI=1S/C16H27N3O6/c17-11(8-10-4-2-1-3-5-10)15(24)19-12(6-7-13(20)21)16(25)18-9-14(22)23/h10-12H,1-9,17H2,(H,18,25)(H,19,24)(H,20,21)(H,22,23)/t11-,12-/m1/s1	CNDMSQXUUIBFPE-VXGBXAGGSA-N	2		Not Available	Small Molecule																																			1	No	7	5	No	1	-1	158.82 Å2	36.94 Å3	87.06 m3·mol-1	10	Yes	No	0.812 mg/mL	-3.1	-2.6	3.16	8.13			
C35H56N10O15	Not Available	Not Available	856.888	C[C@@H](O)[C@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](C)N)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(N)=O	Not Available	Not Available							CHEMBL181276	160536															ZINC000169289402		DAPTA	Investigational	DB16290	InChI=1S/C35H56N10O15/c1-13(36)29(54)41-22(12-46)32(57)43-26(16(4)49)34(59)45-27(17(5)50)35(60)44-25(15(3)48)33(58)40-21(11-23(37)52)30(55)39-20(10-18-6-8-19(51)9-7-18)31(56)42-24(14(2)47)28(38)53/h6-9,13-17,20-22,24-27,46-51H,10-12,36H2,1-5H3,(H2,37,52)(H2,38,53)(H,39,55)(H,40,58)(H,41,54)(H,42,56)(H,43,57)(H,44,60)(H,45,59)/t13-,14-,15-,16-,17-,20+,21+,22+,24+,25+,26+,27+/m1/s1	AKWRNBWMGFUAMF-ZESMOPTKSA-N			Not Available	Small Molecule																																			0	No	16	16	No	1	1	437.28 Å2	83.66 Å3	203.25 m3·mol-1	24	No	No	0.419 mg/mL	-9	-3.3	9.51	8.07			
C31H39N9O6S	Not Available	Not Available	665.77	CC(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)C1=NC2=CC=CC=C2S1	Not Available	Not Available																									MM3122	Experimental	DB16737	InChI=1S/C31H39N9O6S/c1-18(41)36-17-26(43)37-22(13-14-25(32)42)28(45)39-23(16-19-8-3-2-4-9-19)29(46)38-21(11-7-15-35-31(33)34)27(44)30-40-20-10-5-6-12-24(20)47-30/h2-6,8-10,12,21-23H,7,11,13-17H2,1H3,(H2,32,42)(H,36,41)(H,37,43)(H,38,46)(H,39,45)(H4,33,34,35)/t21-,22-,23-/m0/s1	ZEPMYXYJCBQSLH-VABKMULXSA-N			Not Available	Small Molecule																																			0	No	10	7	Yes	3	1	253.85 Å2	69.65 Å3	172.07 m3·mol-1	18	No	No	0.0092 mg/mL	-1.5	-4.9	11.69	10.99	O15393	TMPRSS2	1. Transmembrane protease serine 2
C22H23F3N4O4	Not Available	Not Available	464.445	C[C@H](NC(=O)CCC(F)(F)F)C(=O)N[C@H]1C2=CC=CC=C2C2=CC=CN=C2N(CCO)C1=O	Not Available	Not Available							CHEMBL2338397	29315056									71236992	347828361					ZINC000095586643		LY-3039478	Investigational	DB12050	InChI=1S/C22H23F3N4O4/c1-13(27-17(31)8-9-22(23,24)25)20(32)28-18-15-6-3-2-5-14(15)16-7-4-10-26-19(16)29(11-12-30)21(18)33/h2-7,10,13,18,30H,8-9,11-12H2,1H3,(H,27,31)(H,28,32)/t13-,18-/m0/s1	YCBAQKQAINQRFW-UGSOOPFHSA-N	2		Not Available	Small Molecule																																			1	Yes	5	3	Yes	3	0	111.63 Å2	43.07 Å3	112.03 m3·mol-1	8	Yes	No	0.0994 mg/mL	1.07	-3.7	11.41	2.24			
C16H20N6O	Not Available	~3 hours	312.3696	C[C@@H]1CCN(C[C@@H]1N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N	Solid	Vd= 87L after intravenous administration. Distribution is equal between red blood cells and plasma.					50193995	71200	CHEMBL221959	8102425	Drugs.com Drug Page				D09970	MI1	PDRhealth Drug Page		9926791	347827811	RxList Drug Page	1357536		Tofacitinib	ZINC000003818808	Xeljanz	Tofacitinib	Approved, Investigational	DB08895	InChI=1S/C16H20N6O/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20)/t11-,13+/m1/s1	UJLAWZDWDVHWOW-YPMHNXCESA-N	4	Tofacitinib is a Janus kinase (JAK) inhibitor used to treat rheumatic conditions, such as rheumatoid arthritis and ankylosing spondylitis, and ulcerative colitis.	Minimum lethal dose in rat: 500 mg/kg.Maximum asymptomatic dose in non human primate: 40 mg/kg. Lymphatic, immune system, bone marrow and erythroid cell toxicity was seen in animal studies involving rate and monkeys. Doses used in these studies ranged from 1mg/kg/day to 10mg/kg/day, over a duration of 6 weeks to 6 months. Lymphopenia, neutropenia, and anemia is seen in human subjects and may call for an interruption or discontinuation of therapy if severe. Reduced female fertility in rats was seen at exposures 17 times the maximum recommended human dose. Fertility may be impaired in human females and harm may be caused to unborn child.Carcinogenic potential is seen, however evidence for dose dependency is lacking.Because the janus kinase pathway plays a role in stimulating the production of red blood cells and is involved in immune cell function, inhibition of this pathway leads to increased risk of anemia, neutropenia, lymphopenia, cancer and infection. Lymphopenia, neutropenia, and anemia in human subjects may call for an interruption or discontinuation of therapy if severe. Role of JAK inhibition in the development of gastrointestinal perforation is not known.	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.7249 LD50, mol/kg	Inhibitor	Weak inhibitor	Inhibitor					1.808					1	Yes	5	1	No	3	1	88.91 Å2	32.38 Å3	87.8 m3·mol-1	3	Yes	No	0.299 mg/mL	1.24	-3	9.15	6.44			
C21H20O6	No pharmacokinetic data available.	No pharmacokinetic data available.	368.3799	COC1=CC(\C=C\C(=O)CC(=O)\C=C\C2=CC(OC)=C(O)C=C2)=CC=C1O	Solid	Following oral administration of radio-labelled curcumin to rats, radioactivity was detected in the liver and kidneys 3.	P11712;!P08684;!P20813;!P05177;!P10635;!P08263;!P09488;!P09211	CYP2C9;!CYP3A4;!CYP2B6;!CYP1A2;!CYP2D6;!GSTA1;!GSTM1;!GSTP1	1. Cytochrome P450 2C9;!2. Cytochrome P450 3A4;!3. Cytochrome P450 2B6;!4. Cytochrome P450 1A2;!5. Cytochrome P450 2D6;!6. Glutathione S-transferase A1;!7. Glutathione S-transferase Mu 1;!8. Glutathione S-transferase P		50140172	3962	CHEMBL140	839564			HMDB0002269			CC9			969516	347828040		2955		Curcumin	ZINC000000899824		Curcumin	Approved, Investigational	DB11672	InChI=1S/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-12,24-25H,13H2,1-2H3/b7-3+,8-4+	VFLDPWHFBUODDF-FCXRPNKRSA-N	4		In an acute oral toxicity study in mouse, LD50 was >2000 mg/kg MSDS. Single oral doses of curcumin at 1-5 g/kg bw induced no toxic effects in rats 3. There has been no cases of overdose reported 3.	Small Molecule																																183		Insoluble in cold water	1	Yes	6	2	No	2	0	93.06 Å2	38.12 Å3	103.81 m3·mol-1	8	Yes	No	0.00575 mg/mL	4.12	-4.8	9.08	-4.4	P37231;!P11473;!O15440;!P16152;!P09211	PPARG;!VDR;!ABCC5;!CBR1;!GSTP1	1. Peroxisome proliferator-activated receptor gamma;!2. Vitamin D3 receptor;!3. Multidrug resistance-associated protein 5;!4. Carbonyl reductase [NADPH] 1;!5. Glutathione S-transferase P
																																																																																														
C17H14F3N3O2S	Apparent clearance (CL/F), single oral 200 mg dose, healthy subjects = 27.7 L/hr.31 Clearance may be decreased by about 47% in patients with chronic renal insufficiency, according to a pharmacokinetic study. Studies have not been performed in patients with severe renal impairment.31	The effective half-life of celecoxib is approximately 11 hours when a single 200 mg dose is given to healthy subjects.25,31 The terminal half-life of celecoxib varies because of its low solubility, which prolongs absorption.31	381.372	CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F	Solid	The apparent volume of distribution of celecoxib at steady state (Vss/F) is about 429 L25, which suggests wide distribution into various tissues. Celecoxib is not preferentially bound to red blood cells.31 Another resource reports a volume of distribution of 455 ± 166L.12					11639	41423	CHEMBL118	2562	Drugs.com Drug Page		HMDB0005014	C07589	D00567	CEL		PA448871	2662	46505596	RxList Drug Page	140587	DAP000737	Celecoxib	ZINC000002570895	Celebrex, Consensi, Elyxyb, Seglentis	Celecoxib	Approved, Investigational	DB00482	InChI=1S/C17H14F3N3O2S/c1-11-2-4-12(5-3-11)15-10-16(17(18,19)20)22-23(15)13-6-8-14(9-7-13)26(21,24)25/h2-10H,1H3,(H2,21,24,25)	RZEKVGVHFLEQIL-UHFFFAOYSA-N	4	Celecoxib is an NSAID used to treat osteoarthritis, rheumatoid arthritis, acute pain, menstrual symptoms, and to reduce polyps is familial adenomatous polyposis.	The oral TDLo in humans 5.71 mg/kg.29It is not advisable to administer celecoxib in patients with renal impairment or advanced hepatic impairment, as this may lead to increased serum concentrations, causing toxicity.31 Symptoms of overdose may include breathing difficulties, coma, drowsiness, gastrointestinal bleeding, high blood pressure, kidney failure, nausea, sluggishness, stomach pain, and vomiting.23 Because serious gastrointestinal tract ulceration and bleeding can occur without preceding symptoms, patients should be monitored for signs/symptoms of gastrointestinal bleeding. Symptomatic and supportive measures should be taken in a celecoxib overdose. The induction of emesis or administration of active charcoal should take place if the patient is seen within 4 hours of celecoxib ingestion. Diuresis, urinary alkalinization, hemodialysis, or hemoperfusion may not be useful in a celecoxib overdose due to its high level of protein binding.31	Small Molecule	http://smpdb.ca/view/SMP0000096?highlight[compounds][]=DB00482&highlight[proteins][]=DB00482;!http://smpdb.ca/view/SMP0000644?highlight[compounds][]=DB00482&highlight[proteins][]=DB00482	Celecoxib Action Pathway;!Celecoxib Metabolism Pathway		Non AMES toxic	Not ready biodegradable	+	Inhibitor	Inhibitor	Inhibitor	Non-substrate	Non-inhibitor	Substrate	Inhibitor	Non-substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.3719 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor		13		529.0±60.0	3.53		157-159	11.1	Poorly soluble	1	Yes	3	1	No	3	0	77.98 Å2	35.2 Å3	92.23 m3·mol-1	4	Yes	No	0.00503 mg/mL	4.01	-4.9	10.6	-0.41			
C20H18NO4	Not Available	Not Available	336.3612	COC1=CC=C2C=C3C4=CC5=C(OCO5)C=C4CC[N+]3=CC2=C1OC	Solid	Not Available					50203126	16118	CHEMBL295124	2263			HMDB0003409	C00757	D00092	BER		PA165860812	2353	46506051		1437	DNC000385	Berberine	ZINC000003779067		Berberine	Approved, Investigational	DB04115	InChI=1S/C20H18NO4/c1-22-17-4-3-12-7-16-14-9-19-18(24-11-25-19)8-13(14)5-6-21(16)10-15(12)20(17)23-2/h3-4,7-10H,5-6,11H2,1-2H3/q+1	YBHILYKTIRIUTE-UHFFFAOYSA-N	4		Not Available	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	+	Non-carcinogens	-	Non-inhibitor	Non-inhibitor	Non-substrate	2.7834 LD50, mol/kg	Inhibitor	Weak inhibitor	Non-inhibitor							145 °C			1	No	4	0	No	5	1	40.8 Å2	36.92 Å3	93.52 m3·mol-1	2	Yes	No	0.000354 mg/mL	-1.3	-6		-4.4	O15392;!P0A0N5	BIRC5;!qacR	1. Baculoviral IAP repeat-containing protein 5;!2. HTH-type transcriptional regulator QacR
																																																																																														
C16H14O4	Not Available	Not Available	270.284	COC1=C(C(=O)\C=C\C2=CC=CC=C2)C(O)=CC(O)=C1	Not Available	Not Available					50185446		CHEMBL378104	557026			HMDB0132913											Cardamomin	ZINC000004716487		Dihydroxymethoxychalcone	Experimental	DB14122	InChI=1S/C16H14O4/c1-20-15-10-12(17)9-14(19)16(15)13(18)8-7-11-5-3-2-4-6-11/h2-10,17,19H,1H3/b8-7+	NYSZJNUIVUBQMM-BQYQJAHWSA-N			Not Available	Small Molecule																																			1	Yes	4	2	No	2	0	66.76 Å2	28.42 Å3	77.3 m3·mol-1	4	Yes	No	0.0777 mg/mL	3.78	-3.5	7.2	-4.9			
																																																																																														
C25H38O5	Not Available	4.85 hours19	418.5662	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC	Solid	Rat studies indicate that when radiolabeled simvastatin was administered, simvastatin-derived radioactivity crossed the blood-brain barrier.29	P08684;!P20815;!P10632;!P11712;!P10635;!P20813;!P22309;!P35503;!P16662;!P33261;!O00748;!P23141	CYP3A4;!CYP3A5;!CYP2C8;!CYP2C9;!CYP2D6;!CYP2B6;!UGT1A1;!UGT1A3;!UGT2B7;!CYP2C19;!CES2;!CES1	1. Cytochrome P450 3A4;!2. Cytochrome P450 3A5;!3. Cytochrome P450 2C8;!4. Cytochrome P450 2C9;!5. Cytochrome P450 2D6;!6. Cytochrome P450 2B6;!7. UDP-glucuronosyltransferase 1-1;!8. UDP-glucuronosyltransferase 1-3;!9. UDP-glucuronosyltransferase 2B7;!10. Cytochrome P450 2C19;!11. Cocaine esterase;!12. Liver carboxylesterase 1		50139181	9150	CHEMBL1064	49179	Drugs.com Drug Page		HMDB0005007		D00434		PDRhealth Drug Page	PA451363	54454	46508654	RxList Drug Page	36567	DAP001519	Simvastatin	ZINC000003780893	Cholib, FloLipid, Simcor, Vytorin, Zocor	Simvastatin	Approved	DB00641	InChI=1S/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1	RYMZZMVNJRMUDD-HGQWONQESA-N	4	Simvastatin is an HMG-CoA reductase inhibitor used to lower lipid levels and reduce the risk of cardiovascular events including myocardial infarction and stroke.	Not Available	Small Molecule	http://smpdb.ca/view/SMP0000082?highlight[compounds][]=DB00641&highlight[proteins][]=DB00641	Simvastatin Action Pathway		Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Inhibitor	Substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.0061 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					4.68		135-138 °C		Insoluble	1	Yes	3	1	Yes	3	0	72.83 Å2	47.88 Å3	117.68 m3·mol-1	7	Yes	No	0.0122 mg/mL	4.46	-4.5	14.91	-2.8			
																																																																																														
C6H14N4O2	Not Available	Not Available	174.201	N[C@@H](CCCNC(N)=N)C(O)=O	Solid	Not Available					21959	16467	CHEMBL1485	6082	Drugs.com Drug Page	GtP Drug Page	HMDB0000517	C00062	D02982	ARG	PDRhealth Drug Page	PA448478	6322	46507180		1091		Arginine	ZINC000001532525	Aminosyn II 7 %, Sulfite-free, Aminosyn-PF 7%, Clinimix 2.75/5, Clinimix E 2.75/5, Clinisol 15, Freamine 6.9, Freamine III 10, Hepatamine 8, Olimel, Periolimel, Plenamine, Premasol, Primene, Procalamine 3, Prosol, R-gene, Travasol 10, Trophamine 10 %	Arginine	Investigational, Nutraceutical	DB00125	InChI=1S/C6H14N4O2/c7-4(5(11)12)2-1-3-10-6(8)9/h4H,1-3,7H2,(H,11,12)(H4,8,9,10)/t4-/m0/s1	ODKSFYDXXFIFQN-BYPYZUCNSA-N	4	Arginine is an amino acid commonly found as a component of total parenteral nutrition.	Oral supplementation with L-arginine at doses up to 15 grams daily are generally well tolerated. The most common adverse reactions of higher doses from 15 to 30 grams daily are nausea, abdominal cramps and diarrhea. Some may experience these symptoms at lower doses.	Small Molecule	http://smpdb.ca/view/SMP0000002?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000003?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000004?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000020?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000188?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000360?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000361?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000507?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000179?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000242?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000362?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000484?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000485?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000504?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000505?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000721?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000001?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000059?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000067?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000175?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000192?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000205?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000207?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000208?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000223?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000244?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000357?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000363?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0000506?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125;!http://smpdb.ca/view/SMP0063777?highlight[compounds][]=DB00125&highlight[proteins][]=DB00125	Carbamoyl Phosphate Synthetase Deficiency;!Argininosuccinic Aciduria;!Glycine and Serine Metabolism;!Arginine and Proline Metabolism;!Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency);!Hyperprolinemia Type II;!Hyperprolinemia Type I;!L-Arginine:Glycine Amidinotransferase Deficiency;!Dihydropyrimidine Dehydrogenase Deficiency (DHPD);!Dimethylglycine Dehydrogenase Deficiency;!Arginine: Glycine Amidinotransferase Deficiency (AGAT Deficiency);!Dimethylglycine Dehydrogenase Deficiency;!Hyperglycinemia, Non-Ketotic;!Creatine Deficiency, Guanidinoacetate Methyltransferase Deficiency;!Hyperornithinemia with Gyrate Atrophy (HOGA);!3-Phosphoglycerate Dehydrogenase Deficiency;!Citrullinemia Type I;!Urea Cycle;!Aspartate Metabolism;!Canavan Disease;!Hypoacetylaspartia;!Ornithine Transcarbamylase Deficiency (OTC Deficiency);!Prolidase Deficiency (PD);!Prolinemia Type II;!Non-Ketotic Hyperglycinemia;!Sarcosinemia;!Argininemia;!Ornithine Aminotransferase Deficiency (OAT Deficiency);!Hyperornithinemia-Hyperammonemia-Homocitrullinuria [HHH-syndrome];!Nitric Oxide Signaling Pathway		AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.4851 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					-4.20		244 dec °C	2.24 (at 0 °C)	1.82E+005 mg/L (at 25 °C)	1	No	6	5	No	0	1	125.22 Å2	17.8 Å3	53.92 m3·mol-1	5	Yes	No	2.28 mg/mL	-3.2	-1.9	2.41	12.41			
C20H30O5	Not Available	Not Available	350.455	[H][C@]12CCC(=C)[C@@H](C\C=C3/[C@H](O)COC3=O)[C@]1(C)CC[C@@H](O)[C@@]2(C)CO	Solid	Not Available					50084419	65408	CHEMBL186141	4477067									5318517	347827741				Andrographolide	ZINC000003881797		Andrographolide	Investigational	DB05767	InChI=1S/C20H30O5/c1-12-4-7-16-19(2,9-8-17(23)20(16,3)11-21)14(12)6-5-13-15(22)10-25-18(13)24/h5,14-17,21-23H,1,4,6-11H2,2-3H3/b13-5+/t14-,15-,16+,17-,19+,20+/m1/s1	BOJKULTULYSRAS-OTESTREVSA-N	2		Not Available	Small Molecule																																			1	Yes	4	3	No	3	0	86.99 Å2	38.27 Å3	94.93 m3·mol-1	3	Yes	No	0.284 mg/mL	1.66	-3.1	13.48	-2.8	P01375;!P01584;!P05231;!Q00653;!P19838	TNF;!IL1B;!IL6;!NFKB2;!NFKB1	1. Tumor necrosis factor;!2. Interleukin-1 beta;!3. Interleukin-6;!4. Nuclear factor NF-kappa-B p100 subunit;!5. Nuclear factor NF-kappa-B p105 subunit
																																																																																														
C33H35FN2O5	The registered total plasma clearance of atorvastatin is of 625 ml/min.5	The half-life of atorvastatin is 14 hours while the half-life of its metabolites can reach up to 30 hours.41,42	558.6398	CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1	Solid	The reported volume of distribution of atorvastatin is of 380 L.41,42					22164	39548	CHEMBL1487	54810	Drugs.com Drug Page		HMDB0005006	C06834	D07474	117	PDRhealth Drug Page	PA448500	60823	46506188	RxList Drug Page	1483793	DAP000553	Atorvastatin	ZINC000003920719	Caduet, Lipitor	Atorvastatin	Approved	DB01076	InChI=1S/C33H35FN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40)/t26-,27-/m1/s1	XUKUURHRXDUEBC-KAYWLYCHSA-N	4	Atorvastatin is an HMG-CoA reductase inhibitor used to lower lipid levels and reduce the risk of cardiovascular disease including myocardial infarction and stroke.	The reported LD50 of oral atorvastatin in mice is higher than 5000 mg/kg.MSDS In cases of overdose with atorvastatin, there is reported symptoms of complicated breathing, jaundice, liver damage, dark urine, muscle pain, and seizures.38 In case of overdose, symptomatic treatment is recommended and due to the high plasma protein binding, hemodialysis is not expected to generate significant improvement.LabelIn carcinogenic studies with high doses of atorvastatin, evidence of rhabdomyosarcoma, fibrosarcoma, liver adenoma, and liver carcinoma were observed.LabelIn fertility studies with high doses of atorvastatin, there were events of aplasia, aspermia, low testis and epididymal weight, decreased sperm motility, decreased spermatid head concentration and increased abnormal sperm.LabelAtorvastatin was shown to not be mutagenic in diverse mutagenic assays.Label	Small Molecule				Non AMES toxic	Not ready biodegradable	-	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	High CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Inhibitor	Inhibitor	Substrate	2.5686 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				722 ºC at 760 mmHg	6.36		176 °C	4.46	Practically insoluble	0	No	5	4	Yes	4	-1	111.79 Å2	59.45 Å3	158.2 m3·mol-1	12	No	No	0.00063 mg/mL	5.39	-6	4.31	-2.7			
																																																																																														
																																																																																														
C4H11N5	Renal clearance is about 3.5 times greater than creatinine clearance, which indicates that tubular secretion is the major route of metformin elimination. Following oral administration, approximately 90% of the absorbed drug is eliminated via the renal route within the first 24 hours.24	The plasma elimination half-life of metformin is 6.2 hours in the plasma.24 The elimination half-life in the blood is approximately 17.6 hours, suggesting that the erythrocyte mass may be a compartment of distribution.24	129.1636	CN(C)C(=N)NC(N)=N	Solid	The apparent volume of distribution (V/F) of metformin after one oral dose of metformin 850 mg averaged at 654 ± 358 L.24					50229665	6801	CHEMBL1431	3949	Drugs.com Drug Page		HMDB0001921	C07151	D04966	MF8		PA450395	4091	46507752	RxList Drug Page	6809	DAP000205	Metformin	ZINC000012859773	Actoplus Met, Avandamet, Fortamet, Glubrava, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo	Metformin	Approved	DB00331	InChI=1S/C4H11N5/c1-9(2)4(7)8-3(5)6/h1-2H3,(H5,5,6,7,8)	XZWYZXLIPXDOLR-UHFFFAOYSA-N	4	Metformin is a biguanide antihyperglycemic used in conjunction with diet and exercise for glycemic control in type 2 diabetes mellitus. It is also used off-label for insulin resistance in polycystic ovary syndrome (PCOS).	Metformin (hydrochloride) toxicity data: Oral LD50 (rat): 1 g/kg; Intraperitoneal LD50 (rat): 500 mg/kg; Subcutaneous LD50 (rat): 300 mg/kg; Oral LD50 (mouse): 1450 mg/kg; Intraperitoneal LD50 (mouse): 420 mg/kg; Subcutaneous LD50 (mouse): 225 mg/kg.34A note on lactic acidosisMetformin decreases liver uptake of lactate, thereby increasing lactate blood levels which may increase the risk of lactic acidosis.24 There have been reported postmarketing cases of metformin-associated lactic acidosis, including some fatal cases. Such cases had a subtle onset and were accompanied by nonspecific symptoms including malaise, myalgias, abdominal pain, respiratory distress, or increased somnolence. In certain cases, hypotension and resistant bradyarrhythmias have occurred with severe lactic acidosis.24 Metformin-associated lactic acidosis was characterized by elevated blood lactate concentrations (>5 mmol/L), anion gap acidosis (without evidence of ketonuria or ketonemia), as well as an increased lactate:pyruvate ratio; metformin plasma levels were generally >5 mcg/mL.24Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g. carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, and hepatic impairment.24A note on renal functionIn patients with decreased renal function, the plasma and blood half-life of metformin is prolonged and the renal clearance is decreased.24Metformin should be avoided in those with severely compromised renal function (creatinine clearance < 30 ml/min), acute/decompensated heart failure, severe liver disease and for 48 hours after the use of iodinated contrast dyes due to the risk of lactic acidosis.24 Lower doses should be used in the elderly and those with decreased renal function. Metformin decreases fasting plasma glucose, postprandial blood glucose and glycosolated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control. Metformin may also have a positive effect on lipid levels. A note on hypoglycemiaWhen used alone, metformin does not cause hypoglycemia, however, it may potentiate the hypoglycemic effects of sulfonylureas and insulin when they are used together.24Use in pregnancy Available data from post-marketing studies have not indicated a clear association of metformin with major birth defects, miscarriage, or adverse maternal or fetal outcomes when metformin was ingested during pregnancy. Despite this, the abovementioned studies cannot definitively establish the absence of any metformin-associated risk due to methodological limitations, including small sample size and inconsistent study groups.24Use in nursingA limited number of published studies indicate that metformin is present in human milk. There is insufficient information to confirm the effects of metformin on the nursing infant and no available data on the effects of metformin on the production of milk. The developmental and health benefits of breastfeeding should be considered as well as the mother’s clinical need for metformin and any possible adverse effects on the nursing child.24	Small Molecule				Non AMES toxic	Not ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Low CYP Inhibitory Promiscuity	-	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	1.7407 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				224.1ºC at 760 mmHg	-2.6		223-226 °C	12.4	Freely soluble	1	No	5	4	No	0	2	88.99 Å2	13.43 Å3	56.64 m3·mol-1	0	Yes	No	1.38 mg/mL	-0.92	-2		12.33	Q16134;!Q9Y478;!P21695	ETFDH;!PRKAB1;!GPD1	1. Electron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial;!2. 5'-AMP-activated protein kinase subunit beta-1;!3. Glycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic
C20H30O5	Not Available	Not Available	350.455	[H][C@]12CCC(=C)[C@@H](C\C=C3/[C@H](O)COC3=O)[C@]1(C)CC[C@@H](O)[C@@]2(C)CO	Solid	Not Available					50084419	65408	CHEMBL186141	4477067									5318517	347827741				Andrographolide	ZINC000003881797		Andrographolide	Investigational	DB05767	InChI=1S/C20H30O5/c1-12-4-7-16-19(2,9-8-17(23)20(16,3)11-21)14(12)6-5-13-15(22)10-25-18(13)24/h5,14-17,21-23H,1,4,6-11H2,2-3H3/b13-5+/t14-,15-,16+,17-,19+,20+/m1/s1	BOJKULTULYSRAS-OTESTREVSA-N	2		Not Available	Small Molecule																																			1	Yes	4	3	No	3	0	86.99 Å2	38.27 Å3	94.93 m3·mol-1	3	Yes	No	0.284 mg/mL	1.66	-3.1	13.48	-2.8	P01375;!P01584;!P05231;!Q00653;!P19838	TNF;!IL1B;!IL6;!NFKB2;!NFKB1	1. Tumor necrosis factor;!2. Interleukin-1 beta;!3. Interleukin-6;!4. Nuclear factor NF-kappa-B p100 subunit;!5. Nuclear factor NF-kappa-B p105 subunit
																																																																																														
C20H30O2	Not Available	Not Available	302.458	CC(C)=CCC\C(C)=C\CC\C(C)=C\C=C\C(\C)=C\C(O)=O	Not Available	Not Available								4942358															ZINC000030691356		Peretinoin	Investigational	DB16291	InChI=1S/C20H30O2/c1-16(2)9-6-10-17(3)11-7-12-18(4)13-8-14-19(5)15-20(21)22/h8-9,11,13-15H,6-7,10,12H2,1-5H3,(H,21,22)/b14-8+,17-11+,18-13+,19-15+	UUBHZHZSIKRVIV-KCXSXWJSSA-N	3		Not Available	Small Molecule																																			1	No	2	1	No	0	-1	37.3 Å2	37.93 Å3	99.77 m3·mol-1	9	No	Yes	0.00403 mg/mL	5.78	-4.9	4.81				
C20H28O2	Not Available	0.5-2 hours	300.442	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O	Solid	Not Available	P24462;!P20813;!P10632;!P11712;!P08684;!P20815;!P11509;!P33260;!P04798;!Q02928	CYP3A7;!CYP2B6;!CYP2C8;!CYP2C9;!CYP3A4;!CYP3A5;!CYP2A6;!CYP2C18;!CYP1A1;!CYP4A11	1. Cytochrome P450 3A7;!2. Cytochrome P450 2B6;!3. Cytochrome P450 2C8;!4. Cytochrome P450 2C9;!5. Cytochrome P450 3A4;!6. Cytochrome P450 3A5;!7. Cytochrome P450 2A6;!8. Cytochrome P450 2C18;!9. Cytochrome P450 1A1;!10. Cytochrome P450 4A11		31883	15367	CHEMBL38	392618	Drugs.com Drug Page		HMDB0001852	C00777	D00094	REA		PA164746900	5538	46504843	RxList Drug Page	10753	DNC000117	Tretinoin	ZINC000012358651	Altreno, Atralin, Avita, Biacna, Refissa, Renova, Retin-A, Stieva-A, Tri-luma, Twyneo, Veltin, Vesanoid, Ziana	Tretinoin	Approved, Investigational, Nutraceutical	DB00755	InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14+	SHGAZHPCJJPHSC-YCNIQYBTSA-N	4	Tretinoin is a vitamin A derivative used to treat acne vulgaris, certain types of promyelocytic leukemia, and fine wrinkles.	Not Available	Small Molecule	http://smpdb.ca/view/SMP0000074?highlight[compounds][]=DB00755&highlight[proteins][]=DB00755;!http://smpdb.ca/view/SMP0000336?highlight[compounds][]=DB00755&highlight[proteins][]=DB00755	Retinol Metabolism;!Vitamin A Deficiency		Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.1455 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					6.30		181 °C		<0.1 g/100 mL	1	Yes	2	1	No	1	-1	37.3 Å2	36.85 Å3	97.79 m3·mol-1	5	No	Yes	0.00477 mg/mL	5.01	-4.8	4.76				
C20H28O2	Not Available	Not Available	300.4351	C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O	Solid	Not Available					31892	50648	CHEMBL705	395778	Drugs.com Drug Page		HMDB0002369	C15493	D02815	9CR		PA164746900	449171	46507356	RxList Drug Page	81864	DAP000275	Alitretinoin	ZINC000012661824	Panretin, Toctino	Alitretinoin	Approved, Investigational	DB00523	InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8-,16-14+	SHGAZHPCJJPHSC-ZVCIMWCZSA-N	3	Alitretinoin is a vitamin A derivative used to treat Kaposi's sarcoma and used off label to treat chronic hand eczema and psoriasis.	Not Available	Small Molecule	http://smpdb.ca/view/SMP0000074?highlight[compounds][]=DB00523&highlight[proteins][]=DB00523;!http://smpdb.ca/view/SMP0000336?highlight[compounds][]=DB00523&highlight[proteins][]=DB00523	Retinol Metabolism;!Vitamin A Deficiency		Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.1455 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor					4.2		189-190 °C		0.6 mg/L	1	Yes	2	1	No	1	-1	37.3 Å2	35.89 Å3	97.79 m3·mol-1	5	No	Yes	0.00477 mg/mL	5.01	-4.8	4.76		P10276;!P19793;!P10826;!P28702;!P13631;!P48443;!P17936;!Q15238;!Q6V0L0	RARA;!RXRA;!RARB;!RXRB;!RARG;!RXRG;!IGFBP3;!PSG5;!CYP26C1	1. Retinoic acid receptor alpha;!2. Retinoic acid receptor RXR-alpha;!3. Retinoic acid receptor beta;!4. Retinoic acid receptor RXR-beta;!5. Retinoic acid receptor gamma;!6. Retinoic acid receptor RXR-gamma;!7. Insulin-like growth factor-binding protein 3;!8. Pregnancy-specific beta-1-glycoprotein 5;!9. Cytochrome P450 26C1
C20H28O2	The clearance of isotretinoin is 15.9L/h in pediatric patients with neuroblastoma.6 Clearance is also 21.3mL/min/kg in guinea pigs and 7.2mL/min/kg in obese rats.5	The half life ranges from 7-39 hours13 with a mean elimination half life of 20 hours.1 The half life of 4-oxo-13-cis-retinoic acid ranges from 17-50 hours with a mean elimination half life of 25 hours.13	300.4351	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O	Solid	The volume of distribution in humans is unknown because there is no intravenous preparation.13 In a study of pediatric patients with neuroblastoma the volume of distribution was found to be 85L.6 The volume of distribution was also found to be 2432mL/kg in guinea pigs and 1716mL/kg in obese rats.5	P08684	CYP3A4	1. Cytochrome P450 3A4		50031459	6067	CHEMBL547	4445539	Drugs.com Drug Page		HMDB0006219		D00348			PA450128	5282379	46508729	RxList Drug Page	6064	DAP000009	Isotretinoin	ZINC000003792789	Absorica, Accutane, Amnesteem, Claravis, Clarus, Epuris, Myorisan, Sotret, Zenatane	Isotretinoin	Approved	DB00982	InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14-	SHGAZHPCJJPHSC-XFYACQKRSA-N	4	Isotretinoin is a retinoid used to treat severe recalcitrant acne.	Patients experiencing an overdose may present with vomiting, facial flushing, cheilosis, abdominal pain, headache, dizziness, and ataxia.Label These symptoms may rapidly resolve.Label Generally no treatment is required for these overdoses.7The oral lowest dose causing toxic effect (TDLO) for children is 30mg/kg/21W, oral TDLO for men is 24mg/kg/4W, oral TDLO for women is 56mg/kg/8W.14 The intraperitoneal LD50 for rats is 901mg/kg, oral LD50 for mice is 3389mg/kg, oral LD50 for rats is >4000mg/kg.14Isotretinoin is associated with major congenital malformations, spontaneous abortion, and premature birth.Label It is unknown if isotretinoin is expressed in breast milk but due to the associated hazards a decision should be made to either stop nursing or stop taking isotretinoin.LabelIn animal studies, isotretinoin was associated with an increased risk of pheochromocytoma and adrenal medullary hyperplasia at doses above the recommended clinical dose.Label Isotretinoin was negative for the Ames test of mutagenicity once and weakly positive a second time.Label It has not been shown to be clastogenic.Label A study in dogs noted testicular atrophy after doses of 10-30 times the recommended clinical dose for 30 weeks.Label In trials with men there were no effects seen on sperm count, motility, morphology, ejaculate volume, and seminal plasma fructose.Label	Small Molecule				Non AMES toxic	Ready biodegradable	+	Non-inhibitor	Non-inhibitor	Non-inhibitor	Non-substrate	Non-inhibitor	Non-substrate	Non-inhibitor	Substrate	Low CYP Inhibitory Promiscuity	+	Non-carcinogens	+	Non-inhibitor	Non-inhibitor	Non-substrate	2.1455 LD50, mol/kg	Non-inhibitor	Weak inhibitor	Non-inhibitor				462.8	5.66		189-190	~4	0.00477mg/mL	1	Yes	2	1	No	1	-1	37.3 Å2	36.15 Å3	97.79 m3·mol-1	5	No	Yes	0.00477 mg/mL	5.01	-4.8	4.76		P13631;!P10276	RARG;!RARA	1. Retinoic acid receptor gamma;!2. Retinoic acid receptor alpha
																																																																																														
																																																																																														
																																																																																														